,updated,ID,name,absorption,protein_binding,half_life,strength,route,state,experimental_water_solubility,experimental_logP,predicted_water_solubility,pKa_strongest_acidic,pKa_strongest_basic,SMILES,pb_low,pb_high,half_life_low,half_life_high,total_charge,strength_norm,molecular_weight,n_rings,aromatic_rings,n_heterocycles,n_aromatic_heterocycles,n_saturated_heterocycles,n_aliphatic_heterocycles
0,02/07/2019 00:00,DB00006,Bivalirudin,"Following intravenous administration, bivalirudin exhibits linear pharmacokinetics.  The mean steady state concentration is 12.3 +/- 1.7mcg/mL after administration of an intravenous bolus of 1mg/kg followd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.",,"* Normal renal function: 25 min (in normal conditions)
* Creatinine clearance 10-29mL/min: 57min
* Dialysis-dependant patients: 3.5h",250 mg/1,Intracavernous,solid,,,0.0464,2.79,11.88,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O,,,,,0,,2178.985813,6,3,3,0,3,3
1,02/07/2019 00:00,DB00014,Goserelin,"Inactive orally, rapidly absorbed following subcutaneous administration.",0.273,4-5 hours,10.8 mg/1,Subcutaneous,solid,Soluble,-2,0.0283,9.27,10.82,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,0.273,0.273,4,5,0,,1268.641439,6,4,4,2,2,2
2,04/06/2019 00:00,DB00027,Gramicidin D,,,,,Auricular (otic); Ophthalmic,liquid,,,0.0039,11.56,,CC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCCO,,,,,0,,1810.033419,8,8,4,4,0,0
3,02/07/2019 00:00,DB00035,Desmopressin,"Following nasal spray administration of 0.83 mcg and 1.66 mcg, median time to peak plasma concentrations (Tmax) was 0.25 and 0.75 hour, respectively [FDA Label]. The peak plasma concentration was approximately 4.00 (Â± 3.85) pg/mL and 9.11 (Â± 6.90) pg/mL, respectively [FDA Label]. The bioavailability of 1.5 mg/mL desmopressin administered by the intranasal route was between 3.3 and 4.1% [L1183].

The absolute bioavailability of orally administered desmopressin varies between 0.08% and 0.16% where the mean maximum plasma concentration is reached within 2 hours [L1184].",0.015,"Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours [FDA Label]. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment [FDA Label]. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours [L1184].",4 ug/1mL,Intravenous,solid,,,0.11,9.5,11.77,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O,0.015,0.015,,,0,,1068.426955,4,2,2,0,2,2
4,02/07/2019 00:00,DB00050,Cetrorelix,Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%.,0.86,~62.8 hours,0.25 mg,Subcutaneous,solid,,,0.00694,9.49,11.11,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,0.86,0.86,62.8,62.8,0,,1429.669818,6,5,2,1,1,1
5,02/07/2019 00:00,DB00080,Daptomycin,Generally exhibits linear and time-independent pharmacokinetics at a dosage of 4â€“12 mg/kg IV once every 24 hours. Steady-state trough serum concentrations are achieved by the third daily dose.,,Half-life elimination: 8-9 hours (up to 28 hours in renal impairment) ,350 mg/350mg,Intravenous,solid,,,0.0173,2.98,9.59,CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O,,,,,0,,1619.710366,4,3,2,1,1,1
6,04/06/2019 00:00,DB00093,Felypressin,,,,,,solid,,,0.0453,11.39,10.18,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,,,,,0,,1039.436792,4,2,2,0,2,2
7,02/07/2019 00:00,DB00104,Octreotide,,,,1000 ug/1mL,Intravenous,liquid,,1,0.0122,11.4,10.17,[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O,,,,,0,,1018.44048,5,4,2,1,1,1
8,04/06/2019 00:00,DB00106,Abarelix,"Following IM administration of 100 mg, abarelix is absorbed slowly with a mean peak concentration of 43.4 ng/mL observed approximately 3 days after the injection.",96-99%,13.2 &plusmn; 3.2 days,,,solid,,,0.00371,9.47,10.66,CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,0.96,0.99,,,0,,1414.684071,6,5,2,1,1,1
9,04/06/2019 00:00,DB00114,Pyridoxal phosphate,,,,15 mg/1,Oral,solid,Appreciable,-1.2,5.7,1.68,4.11,CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O,,,,,0,15,247.0245737,1,1,1,1,0,0
10,04/06/2019 00:00,DB00116,Tetrahydrofolic acid,,,,,,solid,,-2.7,0.269,3.51,3.58,NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2)N1,,,,,0,,445.1709815,3,2,2,1,0,1
11,04/06/2019 00:00,DB00117,Histidine,Absorbed from the small intestine via an active transport mechanism requiring the presence of sodium.,,,0.5 g/100g,Intravenous,solid,4.56E+004 mg/L (at 25 Â°C),-3.32,62,1.85,9.44,N[C@@H](CC1=CN=CN1)C(O)=O,,,,,0,,155.0694765,1,1,1,1,0,0
12,04/06/2019 00:00,DB00118,Ademetionine,"S-Adenosylmethionine is absorbed from the small intestine following oral intake. As absorption is affected by food, it is best to take on an empty stomach. Bioavailability is low following oral intake.",,,,,solid,,,1.62,1.7,9.41,[H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O,,,,,0,,398.1372388,3,2,3,2,1,1
13,04/06/2019 00:00,DB00119,Pyruvic acid,Pyruvate is absorbed from the gastrointestinal tract from whence it is transported to the liver via the portal circulation.,,,,Extracorporeal,liquid,1E+006 mg/L (at 20 Â°C),-0.5,134,2.93,-9.6,CC(=O)C(O)=O,,,,,0,,88.01604399,0,0,0,0,0,0
14,04/06/2019 00:00,DB00120,L-Phenylalanine,Absorbed from the small intestine by a sodium dependent active transport process.,,,,Intravenous,solid,2.69E+004 mg/L (at 25 Â°C),-1.38,4.14,2.47,9.45,N[C@@H](CC1=CC=CC=C1)C(O)=O,,,,,0,,165.0789786,1,1,0,0,0,0
15,02/07/2019 00:00,DB00121,Biotin,Systemic - approximately 50%,,,300 mcg,Oral,solid,220 mg/L (at 25 Â°C),0.5,1.22,4.4,-1.9,[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2,,,,,0,0.3,244.0881634,2,0,2,0,2,2
16,02/07/2019 00:00,DB00122,Choline,,,,250 mg,Oral,liquid,Soluble,,3.61,13.97,-3.2,C[N+](C)(C)CCO,,,,,1,250,104.1069905,0,0,0,0,0,0
17,04/06/2019 00:00,DB00123,L-Lysine,Absorbed from the lumen of the small intestine into the enterocytes by an active transport process,,,,Intravenous,solid,1E+006 mg/L (at 20 Â°C),-3.05,105,2.74,10.29,NCCCC[C@H](N)C(O)=O,,,,,0,,146.1055277,0,0,0,0,0,0
18,02/07/2019 00:00,DB00125,L-Arginine,Absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism.,,,1 kg/1kg,Intravenous,solid,1.82E+005 mg/L (at 25 Â°C),-4.2,2.28,2.41,12.41,N[C@@H](CCCNC(N)=N)C(O)=O,,,,,0,,174.1116757,0,0,0,0,0,0
19,02/07/2019 00:00,DB00126,Ascorbic acid,70% to 90%,0.25,16 days (3.4 hours in people who have excess levels of vitamin C),250 mg/1,Oral,solid,4E+005 mg/L (at 40 Â°C),-1.85,245,4.36,-3,[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO,0.25,0.25,,,0,250,176.032088,1,0,1,0,0,1
20,04/06/2019 00:00,DB00127,Spermine,,,,,,solid,> 100 mg/mL,-0.7,2.19,,11.1,NCCCNCCCCNCCCN,,,,,0,,202.2157468,0,0,0,0,0,0
21,04/06/2019 00:00,DB00128,Aspartic acid,Absorbed from the small intestine by an active transport process,,,,Intravenous,solid,5390 mg/L (at 25 Â°C),-3.89,142,1.7,9.61,N[C@@H](CC(O)=O)C(O)=O,,,,,0,,133.0375077,0,0,0,0,0,0
22,04/06/2019 00:00,DB00129,Ornithine,Absorbed from the small intestine via a sodium-dependent active transport process,,,,Intravenous,solid,Appreciable,-4.22,172,2.67,10.29,NCCC[C@H](N)C(O)=O,,,,,0,,132.0898776,0,0,0,0,0,0
23,04/06/2019 00:00,DB00130,L-Glutamine,Absorption is efficient and occurs by an active transport mechanism. Tmax is 30 minutes after a single dose [FDA Label]. Absorption kinetics following multiple doses has not yet been determined.,,The half life of elimination is 1 h [FDA Label].,5 g/1,Oral,solid,4.13E+004 mg/L (at 25 Â°C),-3.64,97.8,2.15,9.31,N[C@@H](CCC(N)=O)C(O)=O,,,,,0,,146.0691422,0,0,0,0,0,0
24,04/06/2019 00:00,DB00131,Adenosine phosphate,,,,,,solid,1E+004 mg/L (at 20 Â°C),-3.1,3.31,1.23,4.97,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1,,,,,0,,347.0630844,3,2,3,2,1,1
25,04/06/2019 00:00,DB00132,Alpha-Linolenic Acid,,,,,Oral,liquid,0.000124 mg/mL at 25 Â°C,6.46,0.000266,4.99,,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O,,,,,0,,278.2245802,0,0,0,0,0,0
26,04/06/2019 00:00,DB00133,Serine,,,,,Intravenous,solid,4.25E+005 mg/L (at 25 Â°C),-3.07,480,2.03,8.93,N[C@@H](CO)C(O)=O,,,,,0,,105.0425931,0,0,0,0,0,0
27,04/06/2019 00:00,DB00134,Methionine,Absorbed from the lumen of the small intestine into the enterocytes by an active transport process.,,,,Intravenous,solid,5.66E+004 mg/L (at 25 Â°C),-1.87,23.9,2.53,9.5,CSCC[C@H](N)C(O)=O,,,,,0,,149.0510496,0,0,0,0,0,0
28,04/06/2019 00:00,DB00135,Tyrosine,L-tyrosine is absorbed from the small intestine by a sodium-dependent active transport process.,,,,Intravenous,solid,479 mg/L (at 25 Â°C),-2.26,7.67,2,9.19,N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,,,,,0,,181.0738932,1,1,0,0,0,0
29,02/07/2019 00:00,DB00136,Calcitriol,"Upon administration, calcitriol is rapidly absorbed from the intestines. When a single oral dose of 0.5 mcg of calcitriol was administered, the mean serum concentrations of calcitriol rose from a baseline value of 40.0Â±4.4 (SD) pg/mL to 60.0Â±4.4 pg/mL at 2 hours, and declined to 53.0Â±6.9 at 4 hours, 50Â±7.0 at 8 hours, 44Â±4.6 at 12 hours and 41.5Â±5.1 at 24 hours [FDA Label]. Following administration of single doses of 0.25 to 1.0 mcg of calcitriol, the peak plasma concentrations were reached within 3 to 6 hours [FDA Label]. In a pharmacokinetic study, the oral bioavailability was 70.6Â±5.8% in healthy male volunteers and 72.2Â±4.8% in male patients with uraemia [A175726]. ",0.999,"After administration of single oral doses, the elimination half life was 5-8 hours [FDA Label]. ",2 mcg,Intravenous,solid,Insoluble,5,0.00667,14.39,-1.3,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,0.999,0.999,,,0,,416.3290453,3,0,0,0,0,0
30,04/06/2019 00:00,DB00137,Lutein,,,,20 g/100g,Oral,liquid,Insoluble,7.9,0.000732,18.22,-0.91,C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,,,,,0,,568.428031,2,0,0,0,0,0
31,04/06/2019 00:00,DB00138,Cystine,,,,,Vaginal,solid,190 mg/L (at 20 Â°C),-5.08,16.8,1.56,9.34,N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O,,,,,0,,240.0238489,0,0,0,0,0,0
32,04/06/2019 00:00,DB00139,Succinic acid,,,,,Oral,solid,8.32E+004 mg/L (at 25 Â°C),-0.59,211,3.55,,OC(=O)CCC(O)=O,,,,,0,,118.0266087,0,0,0,0,0,0
33,02/07/2019 00:00,DB00140,Riboflavin,Vitamin B2 is readily absorbed from the upper gastrointestinal tract.,0.6,66-84 minutes,50 mg,Oral,solid,84.7 mg/L (at 25 Â°C),-1.46,0.657,6.97,0.76,CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1,0.6,0.6,1.1,1.4,0,50,376.1382844,3,1,2,0,0,2
34,14/06/2019 00:00,DB00141,N-Acetylglucosamine,Approximately 90% of orally administered glucosamine (salt form) gets absorbed from the small intestine.,,,,Oral,solid,,-2.1,148,11.56,-1.2,[H]C(=O)[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@H](O)CO,,,,,0,,221.0899372,0,0,0,0,0,0
35,02/07/2019 00:00,DB00142,Glutamic Acid,Absorbed from the lumen of the small intestine into the enterocytes.Absorption is efficient and occurs by an active transport mechanism.,,,325 mg,Intravenous,solid,8570 mg/L (at 25 Â°C),-3.69,80.6,1.88,9.54,N[C@@H](CCC(O)=O)C(O)=O,,,,,0,,147.0531578,0,0,0,0,0,0
36,04/06/2019 00:00,DB00143,Glutathione,"Research suggests that glutathione is not orally bioactive, and that very little of oral glutathione tablets or capsules is actually absorbed by the body.",,,,Oral,solid,,-6.4,0.879,1.94,9.22,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,,,,,0,,307.0838063,0,0,0,0,0,0
37,04/06/2019 00:00,DB00144,Phosphatidyl serine,Absorbed in the small intestine.,,,,Oral,solid,,-3.5,3.7,1.47,9.38,CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O,,,,,0,,385.1137826,0,0,0,0,0,0
38,02/07/2019 00:00,DB00145,Glycine,Absorbed from the small intestine via an active transport mechanism.,,,0.5 g/100g,Topical,solid,2.49E+005 mg/L (at 25 Â°C),-3.21,552,2.31,9.24,NCC(O)=O,,,,,0,,75.0320284,0,0,0,0,0,0
39,04/06/2019 00:00,DB00146,Calcifediol,Readily absorbed.,,288 hours,30 mcg,Oral,solid,Insoluble,6,0.0022,18.38,-0.98,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,,,288,288,0,0.03,400.3341306,3,0,0,0,0,0
40,04/06/2019 00:00,DB00147,Pyridoxal,,,,,,solid,5E+005 mg/L,0,11.7,7.97,4.11,CC1=NC=C(CO)C(C=O)=C1O,,,,,0,,167.0582431,1,1,1,1,0,0
41,04/06/2019 00:00,DB00148,Creatine,,,3 hours,,Oral,solid,1.33E+004 mg/L (at 18 Â°C),-0.2,4.11,3.5,12.43,CN(CC(O)=O)C(N)=N,,,3,3,0,,131.0694765,0,0,0,0,0,0
42,04/06/2019 00:00,DB00149,L-Leucine,,,,,Intravenous,solid,2.15E+004 mg/L (at 25 Â°C),-1.52,69.8,2.79,9.52,CC(C)C[C@H](N)C(O)=O,,,,,0,,131.0946287,0,0,0,0,0,0
43,02/07/2019 00:00,DB00150,L-Tryptophan,,,,500 mg,Intravenous,solid,1.34E+004 mg/L (at 25 Â°C),-1.06,1.36,2.54,9.4,N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,,,,,0,,204.0898776,2,2,1,1,0,0
44,02/07/2019 00:00,DB00151,L-Cysteine,,,,0.5 g/10mL,Topical,solid,2.77E+005 mg/L (at 25 Â°C),-2.49,23.1,2.35,9.05,N[C@@H](CS)C(O)=O,,,,,0,,121.0197495,0,0,0,0,0,0
45,02/07/2019 00:00,DB00152,Thiamine,"Absorbed mainly from duodenum, by both active and passive processes",90-94%,,100 mg,Oral,solid,5E+005 mg/L,,0.0153,15.5,5.54,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N,0.9,0.94,,,1,100,265.1117586,2,2,2,2,0,0
46,02/07/2019 00:00,DB00153,Ergocalciferol,"Ergocalciferol is absorbed in the intestine and carried to the liver in chylomicrons. Its intestinal absorption does not present limitations unless the presence of conditions related to fat malabsorption.[T577] However, for absorption to take place, the presence of bile is required.[L6088]",70-90%,Ergocalciferol can be found circulation for 1-2 days. This quick turnover is presented due to hepatic conversion and uptake by fat and muscle cells where it is transformed to the active form.[T577],1.25 mg/1,Oral,solid,Insoluble,8.89,0.000433,18.38,-1.3,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,0.7,0.9,,,0,1.25,396.339216,3,0,0,0,0,0
47,04/06/2019 00:00,DB00154,Dihomo-gamma-linolenic acid,,,,,,solid,,6.8,7.71E-05,4.89,,CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O,,,,,0,,306.2558803,0,0,0,0,0,0
48,04/06/2019 00:00,DB00155,L-Citrulline,,,,,Intramuscular,solid,200 g/L (at 20 Â°C),-3.19,21.8,2.27,9.23,N[C@@H](CCCNC(N)=O)C(O)=O,,,,,0,,175.0956913,0,0,0,0,0,0
49,04/06/2019 00:00,DB00156,L-Threonine,,,,,Topical,solid,9.7E+004 mg/L (at 25 Â°C),-2.94,477,2.21,9,C[C@@H](O)[C@H](N)C(O)=O,,,,,0,,119.0582431,0,0,0,0,0,0
50,04/06/2019 00:00,DB00157,NADH,Unclear how much of an administered dose is absorbed.,,,,Oral,solid,,-5.1,2.95,-7,5,NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O,,,,,0,,665.1247719,5,2,5,2,2,3
51,02/07/2019 00:00,DB00158,Folic acid,"Folic acid is absorbed rapidly from the small intestine, primarily from the proximal portion. Naturally occurring conjugated folates are reduced enzymatically to folic acid in the gastrointestinal tract prior to absorption. Folic acid appears in the plasma approximately 15 to 30 minutes after an oral dose; peak levels are generally reached within 1 hour. [FDA Label]",,,5 mg,Oral,solid,,-2.5,0.0761,3.37,2.09,NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1,,,,,0,5,441.1396813,3,3,2,2,0,0
52,04/06/2019 00:00,DB00159,Icosapent,,,,,Oral,liquid,,6.1,0.000289,4.82,,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,,,,,0,,302.2245802,0,0,0,0,0,0
53,04/06/2019 00:00,DB00160,L-Alanine,,,,,Intravenous,solid,1.64E+005 mg/L (at 25 Â°C),-2.85,447,2.47,9.48,C[C@H](N)C(O)=O,,,,,0,,89.04767846,0,0,0,0,0,0
54,04/06/2019 00:00,DB00161,L-Valine,Absorbed from the small intestine by a sodium-dependent active-transport process.,,,,Intravenous,solid,5.85E+004 mg/L (at 25 Â°C),-2.26,214,2.72,9.6,CC(C)[C@H](N)C(O)=O,,,,,0,,117.0789786,0,0,0,0,0,0
55,02/07/2019 00:00,DB00162,Vitamin A,Readily absorbed from the normal gastrointestinal tract,<5%,1.9 hours,10000 unit,Oral,solid,0.671 mg/L,5.68,0.00758,16.44,-2.2,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C,0,0.05,1.9,1.9,0,,286.2296656,1,0,0,0,0,0
56,02/07/2019 00:00,DB00163,Vitamin E,"10-33% of deuterium labelled vitamin E is absorbed in the small intestine[A176110,L3063]. Absorption of Vitamin E is dependant upon absorption of the fat in which it is dissolved[L3063,A176104]. For patients with poor fat absorption, a water soluble form of vitamin E may need to be substituted such as tocopheryl polyethylene glycol-1000 succinate[L3063].

In other studies the oral bioavailability of alpha-tocopherol was 36%, gamma-tocotrienol was 9%[A32447]. The time to maximum concentration was 9.7 hours for alpha-tocopherol and 2.4 hours for gamma-tocotrienol[A32447].",,44 hours in premature neonates given a 20mg/kg intramuscular injection[A176113]. 12 minutes in intravenous injection of intestinal lymph[A176363].,0.06 g/2g,Topical,solid,"Insoluble in water, but water-dispersible.",,7.04E-06,10.8,-4.9,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C,,,,,0,,430.3810808,2,1,1,0,0,1
57,02/07/2019 00:00,DB00165,Pyridoxine,"The B vitamins are readily absorbed from the gastrointestinal tract, except in malabsorption syndromes. Pyridoxine is absorbed mainly in the jejunum. The Cmax of pyridoxine is achieved within 5.5 hours.",0.6,The total adult body pool consists of 16 to 25 mg of pyridoxine.  Its half-life appears to be 15 to 20 days. ,500 mg,Oral,solid,2.2E+005 mg/L,-0.77,16.1,9.4,5.58,CC1=C(O)C(CO)=C(CO)C=N1,0.6,0.6,,,0,500,169.0738932,1,1,1,1,0,0
58,04/06/2019 00:00,DB00166,Lipoic Acid,,,,,Oral,solid,Insoluble,2.1,0.224,4.52,,OC(=O)CCCC[C@@H]1CCSS1,,,,,0,,206.0435217,1,0,1,0,1,1
59,04/06/2019 00:00,DB00167,Isoleucine,Absorbed from the small intestine by a sodium-dependent active-transport process,,,,Intravenous,solid,3.44E+004 mg/L (at 25 Â°C),-1.7,114,2.79,9.59,CC[C@H](C)[C@H](N)C(O)=O,,,,,0,,131.0946287,0,0,0,0,0,0
60,04/06/2019 00:00,DB00168,Aspartame,"Absorbed in the small intestine, aspartame is metabolized and absorbed very quickly.",,"At room temperature, aspartame is most stable at pH 4.3, where its half-life is nearly 300 days. At pH 7, its half-life is shortened to only a few days.",,,solid,"The solubility of aspartame in water is dependent on pH and temperature, the maximum solubility is reached at pH 2.2 (20 mg/mL at 25 Â°C) and the minimum solubility at pH 5.2 (pHi) is 13.5 mg/mL at 25 Â°C.",-0.1,0.652,3.53,8.53,COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CC(O)=O,,,,,0,,294.1215717,1,1,0,0,0,0
61,02/07/2019 00:00,DB00169,Cholecalciferol,"Cholecalciferol is readily absorbed from the small intestine if fat absorption is normal [F4027, F4042, F4048]. Moreover, bile is necessary for absorption as well [F4027, F4042, F4048].

In particular, recent studies have determined aspects about the absorption of vitamin D, like the fact that a) the 25-hydroxyvitamin D metabolite of cholecalciferol is absorbed to a greater extent than the nonhydroxy form of cholecalciferol, b) the quantity of fat with which cholecalciferol is ingested does not appear to largely affect its bioavailability, and c) age does not apparently effect vitamin D cholecalciferol [A176447].",0.8,"At this time, there have been resources that document the half-life of cholecalciferol as being about 50 days [T527] while other sources have noted that the half-life of calcitriol (1,25-dihydroxyvitamin D3) is approximately 15 hours while that of calcidiol (25-hydroxyvitamin D3) is about 15 days [L1782].

Moreover, it appears that the half-lives of any particular administration of vitamin d can vary due to variations in vitamin d binding protein concentrations and genotype in particular individuals [A32185].",1000 [iU]/1,Topical,solid,Insoluble,7.5,0.00038,18.38,-1.3,CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,0.8,0.8,,,0,,384.339216,3,0,0,0,0,0
62,04/06/2019 00:00,DB00170,Menadione,Variable and ranges from 10% to 80%,,,,,solid,160 mg/L (at 30 Â°C),2.2,0.504,12.94,-7.2,CC1=CC(=O)C2=CC=CC=C2C1=O,,,,,0,,172.0524295,2,1,0,0,0,0
63,02/07/2019 00:00,DB00171,ATP,,,,,,solid,1E+006 mg/L,-5.5,4.49,0.9,5,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,,,,,0,,506.9957455,3,2,3,2,1,1
64,04/06/2019 00:00,DB00172,Proline,,,,,Intravenous,solid,1.62E+005 mg/L (at 25 Â°C),-2.54,365,1.94,11.33,OC(=O)[C@@H]1CCCN1,,,,,0,,115.0633285,1,0,1,0,1,1
65,04/06/2019 00:00,DB00173,Adenine,,,,,Intravenous,solid,1030 mg/L (at 25 Â°C),-0.09,11.5,10.29,5.32,NC1=C2NC=NC2=NC=N1,,,,,0,,135.0544952,2,2,2,2,0,0
66,04/06/2019 00:00,DB00174,Asparagine,,,,,,solid,2.94E+004 mg/L (at 25 Â°C),-3.82,168,2,8.43,N[C@@H](CC(N)=O)C(O)=O,,,,,0,,132.0534921,0,0,0,0,0,0
67,02/07/2019 00:00,DB00175,Pravastatin,"Pravastatin is absorbed 60-90 min after oral administration and it presents a low bioavailability of 17%.[A34502] This low bioavailability can be presented due to the polar nature of pravastatin which produces a high range of first-pass metabolism and incomplete absorption.[T239]

Pravastatin is rapidly absorbed from the upper part of the small intestine via proton-coupled carrier-mediated transport to be later taken up in the livery by the sodium-independent bile acid transporter.[A39676] The reported time to reach the peak serum concentration in the range of 30-55 mcg/L is of 1-1.5 hours with an AUC ranging from 60-90 mcg.h/L.[A177907]",43-48%,The reported elimination half-life of pravastatin is reported to be of 1.8 hours.[A34502],10 mg,Oral,solid,10 mg/ml,0.59,0.242,4.21,-2.7,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC,0.43,0.48,,,0,10,424.2461035,2,0,0,0,0,0
68,02/07/2019 00:00,DB00176,Fluvoxamine,"Well absorbed, bioavailability of fluvoxamine maleate is 53% [FDA Label].",~77-80%,15.6 hours [FDA Label].,100 mg,Oral,solid,,3.2,0.00734,,8.86,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F,0.77,0.8,,,0,100,318.1555126,1,1,0,0,0,0
69,02/07/2019 00:00,DB00177,Valsartan,"Absolute bioavailability for valsartan is approximately 25% (ranges between 10%-35%). The bioavailability of the suspension is 1.6 times higher than that of the oral tablet. With the tablet, food decreases the exposure to valsartan by approximately 40% and peak plasma concentration by approximately 50%. AUC and Cmax values of valsartan genereally increase linearly with increasing dose over the therapeutic dose range. Valsartan does not accumulate appreciably in plasma following repetitive administration [FDA label].

After one oral dose, the antihypertensive activity of valsartan begins within approximately 2 hours and peaks within 4-6 hours in most patients [F3139].",0.97,"After intravenous (IV) administration, valsartan demonstrates bi-exponential decay kinetics (t1/2Î± <1 hour and t1/2Î² between 5-9 hours) [F3139].",160 mg/1,Oral,solid,"soluble in ethanol, DMSO, and dimethyl formamide at 30 mg/mL",1.499,0.0234,4.37,-0.11,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O,0.97,0.97,,,0,160,435.2270398,3,3,1,1,0,0
70,02/07/2019 00:00,DB00178,Ramipril,"The extent of absorption is at least 50-60%.[FDA Label]. Food decreases the rate of absorption from the GI tract without affecting the extent of absorption. The absolute bioavailabilities of ramipril and ramiprilat were 28% and 44%, respectively, when oral administration was compared to intravenous administration. The serum concentration of ramiprilat was unchanged when capsules were opened and the contents dissolved in water, dissolved in apple juice, or suspended in apple sauce.",0.73,"Plasma concentrations of ramiprilat decline in a triphasic manner.[FDA Label] Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours, which is thought to represent clearance of free drug. The half-life of the terminal elimination phase is > 50 hours and thought to represent clearance of drug bound to ACE due to its slow dissociation. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs. ",1.25 mg/1,Oral,solid,3.5mg/L,2.9,0.039,3.75,5.2,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,0.73,0.73,,,0,1.25,416.2311221,3,1,1,0,1,1
71,04/06/2019 00:00,DB00179,Masoprocol,Less than 1%-2% is absorbed through the skin over a 4-day period following application.,,,,,solid,,5.8,0.0136,9.21,-6.3,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1,,,,,0,,302.1518092,2,2,0,0,0,0
72,02/07/2019 00:00,DB00180,Flunisolide,Absorbed rapidly,0.4,1.8 hours,250 ug/1,Respiratory (inhalation),solid,Practically insoluble,1.1,0.0374,13.73,-2.9,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,0.4,0.4,1.8,1.8,0,,434.2104669,5,0,1,0,1,1
73,02/07/2019 00:00,DB00181,Baclofen,"Rapidly and almost completely absorbed from the gastrointestinal tract.  Absorption may be dose-dependent, being reduced with increased doses [FDA label].

Baclofen, when introduced directly into the intrathecal space, allows for effective CSF concentrations to be achieved with resulting plasma concentrations 100 times less than concentrations occurring with oral administration [F2983], [FDA label].",0.3,Elimination half-life: Approximately 5.5 hours [FDA label].,0.05 mg/1mL,Intrathecal,solid,slightly soluble,1.3,0.712,3.89,9.79,NCC(CC(O)=O)C1=CC=C(Cl)C=C1,0.3,0.3,,,0,,213.0556563,1,1,0,0,0,0
74,02/07/2019 00:00,DB00182,Amphetamine,Amphetamine is well absorbed in the gut and as it is a weak base hence the more basic the environment the more of the drug is found in a lipid-soluble form and the absorption through lipid-rich cell membranes is highly favored.[A174292] The peak response of amphetamine occurs 1-3 hours after oral administration and approximately 15 minutes after injection and it presents a bioavailability of over 75%.[L5206] Complete amphetamine absorption is usually done after 4-6 hours.[L5209],,"The half-life of amphetamine highly depends on the isomer. For d-amphetamine, the reported half-life is of approximately 9-11 hours while for l-amphetamine the half-life is reported to be of 11-14 hours. The urine pH can modify this pharmacokinetic parameter which can vary from 7 hours in acid urine to 34 hours for alkaline urine.[A174292]",1.25 mg/1mL,Oral,liquid,Moderate solubility ,1.76,1.74,,10.01,CC(N)CC1=CC=CC=C1,,,,,0,,135.1047994,1,1,0,0,0,0
75,04/06/2019 00:00,DB00183,Pentagastrin,Rapidly absorbed after parenteral administration.,,10 minutes or less,250 ug/1.6mL,Intravenous,solid,,1.6,0.00261,4,,CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,,,,,0,,767.3312471,3,3,1,1,0,0
76,02/07/2019 00:00,DB00184,Nicotine,Absorption of nicotine through the buccal mucosa is relatively slow and the high and rapid rise followed by the decline in nicotine arterial plasma concentrations seen with cigarette smoking are not achieved with the inhaler. About 10% of absorbed nicotine is excreted unchanged in urine.,0.05,"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours",14 mg/1,Transdermal,liquid,1E+006 mg/L,1.17,93.3,,8.86,CN1CCC[C@H]1C1=CN=CC=C1,0.05,0.05,,,0,,162.1156984,2,1,2,1,1,1
77,04/06/2019 00:00,DB00185,Cevimeline,Rapidly absorbed with peak concentration after 1.5 to 2 hours,0.2,5 &plusmn; 1 hours,30 mg/1,Oral,solid,Very soluble,1.3,2.41,,8.59,CC1O[C@@]2(CS1)CN1CCC2CC1,0.2,0.2,,,0,30,199.1030852,4,0,4,0,4,4
78,02/07/2019 00:00,DB00186,Lorazepam,"Readily absorbed with an absolute bioavailability of 90% when given orally. When intramuscularly administered a dose of 4 mg, lorazepam is completely and rapidly absorbed and achieves a maximal serum concentration of 48 ng/ml in 15-30 minutes. When administered orally, the time to attained maximum concentration is observed to be of 2 hours.[T385]",0.85,"When administered parentally, the registered half-life of lorazepam is of 14 hours.[T385]",4.0 mg/1mL,Intramuscular; Intravenous,solid,80 mg/L,2.39,0.0176,10.61,-2.2,OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2,0.85,0.85,,,0,,320.0119329,3,2,1,0,0,1
79,02/07/2019 00:00,DB00187,Esmolol,"Rapidly absorbed, steady-state blood levels for dosages from 50-300 &micro;g/kg/min (0.05-0.3 mg/kg/mm) are obtained within five minutes.",0.55,Rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. The acid metabolite has an elimination half-life of about 3.7 hours.,20 mg/1mL,Intravenous,solid,Very soluble as hydrochloride salt,1.7,0.144,14.09,9.67,COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1,0.55,0.55,,,0,,295.1783583,1,1,0,0,0,0
80,02/07/2019 00:00,DB00188,Bortezomib,,0.83,The mean elimination half-life of bortezomib after first dose ranged from 9 to 15 hours at doses ranging from 1.45 to 2.00 mg/m2 in patients with advanced malignancies.,1 mg/1mL,Intravenous,solid,"The solubility of bortezomib, as the monomeric boronic acid, is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5.",,0.0532,13.04,-0.7,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,0.83,0.83,,,0,,384.1968857,2,2,1,1,0,0
81,02/07/2019 00:00,DB00189,Ethchlorvynol,Rapidly absorbed from gastrointestinal tract.,35-50%,"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.",200 mg,Oral,liquid,,1.8,0.143,12.88,-3.7,CCC(O)(\C=C\Cl)C#C,0.35,0.5,,,0,200,144.0341926,0,0,0,0,0,0
82,04/06/2019 00:00,DB00190,Carbidopa,"When [levodopa]/carbidopa is administered orally, 40-70% of the administered dose is absorbed.[L5116] Once absorbed, carbidopa shows bioavailability of 58%.[A173941] A maximum concentration of 0.085 mcg/ml was achieved after 143 min with an AUC of 19.28 mcg.min/ml.[A173944]",,The reported half-life of carbidopa is of approximately 107 minutes.[A173944],1 kg/1kg,Oral,solid,3.8 mg/L,-1.9,3.73,2.35,5.66,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O,,,,,0,,226.0953569,1,1,0,0,0,0
83,04/06/2019 00:00,DB00191,Phentermine,"Phentermine shows a dose-dependent pharmacokinetic profile. After oral administration of a dose of 15 mg, the maximal concentration was achieved after 6 hours and its bioavailability was not affected by the consumption of high-fat meals.[A174370] The reported plasma concentration at steady-state is of around 200 ng/ml as observed in clinical trials.[T49]",,"The mean terminal half-life of phentermine is reported to be of approximately 20 hours.[A174370] In conditions where there is acidic urine (pH <5), the elimination half-life is of 7-8 hours.[T49]",30 mg,Oral,solid,18.6 g/L,1.9,0.757,,10.25,CC(C)(N)CC1=CC=CC=C1,,,,,0,30,149.1204495,1,1,0,0,0,0
84,04/06/2019 00:00,DB00192,Indecainide,Nearly complete following oral administration.,,,,,solid,1.88 mg/L,3.11,0.000896,16.51,10.4,CC(C)NCCCC1(C(N)=O)C2=CC=CC=C2C2=CC=CC=C12,,,,,0,,308.1888634,3,2,0,0,0,0
85,02/07/2019 00:00,DB00193,Tramadol,Oral administration of a dose of 100 mg of racemic tramadol has been shown to present a very rapid absorption and distribution. The reported peak concentration of 0.31 mg/L is reached after only 2 hours of the administration.[A173980] The bioavailability of tramadol has ranged from 75 to 90% depending on the tested individual and this bioavailability does not change according to any diet.[A173989],0.2,Tramadol reported a half-life of 5-6 hours while the M1 metabolite presents a half-life of 8 hours.[A173980],100 mg/1,Oral,solid,Soluble ,1.34,0.75,13.8,9.23,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C,0.2,0.2,,,0,100,263.188529,2,1,0,0,0,0
86,04/06/2019 00:00,DB00194,Vidarabine,Systemetic absorption of vidarabine should not be expected to occur following ocular administration and swallowing lacrimal secretions. ,24-38%,,30 mg/1g,Topical,solid,,-2.115,14,12.45,4.99,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0.24,0.38,,,0,,267.0967539,3,2,3,2,1,1
87,02/07/2019 00:00,DB00195,Betaxolol,Absorption of an oral dose is complete. There is a small and consistent first-pass effect resulting in an absolute bioavailability of 89% &plusmn; 5% that is unaffected by the concomitant ingestion of food or alcohol.,0.5,14-22 hours,5 mg/1mL,Ophthalmic,solid,451 mg/L,2.81,0.0298,14.09,9.67,CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1,0.5,0.5,14,22,0,,307.2147438,2,1,0,0,0,0
88,02/07/2019 00:00,DB00196,Fluconazole,"The pharmacokinetic properties of fluconazole are comparable after administration by the intravenous (IV) and oral (PO) routes. In healthy volunteers, the bioavailability of orally administered fluconazole is measured to be above 90%.[FDA label] It is extensively absorbed in the gastrointestinal tract when an oral dose is taken.[A178813] Oral absorption is not affected by food intake with fluconazole but may increase the time until the maximum concentration is reached.[L6496,A178792]

Tmax (or the time taken to achieve the maximum concentration) in one clinical study of healthy patients receiving 50 mg/kg of fluconazole was 3 hours.[A178792] 

Peak plasma concentrations (Cmax) in fasting and healthy volunteers occur between 1-2 hours post-dose.[FDA label] Steady-state concentrations are achieved within 5 to 10 days after oral doses of 50-400 mg administered once daily. Administration of a loading dose on the first day of fluconazole treatment,  or twice the usual daily dose, leads to plasma concentrations close to steady-state by the second day.[FDA label] Mean AUC (area under the curve) was 20.3 in healthy volunteers receiving 25 mg of fluconazole.[A178792]

**A note on the capsule and powder form and malabsorption syndromes**

The capsule forms of fluconazole often contain lactose and should not be administered with hereditary galactose intolerance, _Lapp lactase enzyme_ deficiency, or malabsorption of glucose/galactose.[FDA label] The powder form, used for the oral suspension, lists sucrose as an ingredient and should not be used in patients who have been diagnosed with fructose, glucose/galactose malabsorption, and _sucrase-isomaltase_ enzyme deficiency.[FDA label]",,"The terminal elimination half-life in the plasma is approximately 30 hours (range: 20-50 hours) after oral administration.[FDA label]
The long plasma elimination half-life supports a single dose therapy for vaginal candidiasis, once daily and once weekly dosing for other indications.[L6496]. Patients with renal failure may require dosage adjustment, and half-life can be significantly increased in these patients.[A178792]
",200 mg,Oral,solid,slightly soluble in water,0.5,1.39,12.71,2.56,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,,,,,0,200,306.1040654,3,3,2,2,0,0
89,04/06/2019 00:00,DB00197,Troglitazone,Absorbed rapidly. Food increases the extent of absorption by 30% to 85%.,0.99,16-34 hours,,,solid,,3.6,0.00121,6.61,-4.6,CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O,0.99,0.99,16,34,0,,441.160994,4,2,2,0,1,2
90,02/07/2019 00:00,DB00198,Oseltamivir,"Oseltamivir is readily absorbed from the gastrointestinal tract after oral administration of oseltamivir phosphate (pro-drug) and is extensively converted by predominantly hepatic esterases to the active metabolite (oseltamivir carboxylate) [F3094, F3097, L5161, F3115]. At least 75 % of an oral dose reaches the systemic circulation as the active metabolite [F3094, F3097, L5161, F3115]. Exposure to the pro-drug is less than 5 % relative to the active metabolite [F3094, F3097, L5161, F3115]. Plasma concentrations of both pro-drug and active metabolite are proportional to dose and are unaffected by co-administration with food [F3094, F3097, L5161, F3115].",%,"Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration, although plasma concentrations of oseltamivir carboxylate declined with a half-life of 6 to 10 hours in most subjects after oral administration [F3094, F3097].",30 mg/1,Oral,solid,Soluble,1,0.686,14.03,9.31,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,,,,,0,30,312.2049074,1,0,0,0,0,0
91,02/07/2019 00:00,DB00199,Erythromycin,"Orally administered erythromycin stearate is readily and reliably absorbed. Optimal serum levels of erythromycin are reached when it is taken in the fasting state or immediately before meals [F3322].

Erythromycin is well known for its highly variable bioavailability (18-45%) [A174451] after oral ingestion and its susceptibility to be degraded under acidic conditions [A174448]. ",0.93,"3.5 h [A174451] 

In patients with liver disease, the half-life has been shown to be significantly increased, however, this is of little clinical significance [F3322]. ",20 mg/1g,Topical,solid,Soluble in water at 2mg/ml,2.6,0.459,12.44,8.38,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,0.93,0.93,,,0,,733.4612412,3,0,3,0,3,3
92,02/07/2019 00:00,DB00201,Caffeine,Readily absorbed after oral or parenteral administration. The peak plasma level for caffeine range from 6-10mg/L and the mean time to reach peak concentration ranged from 30 minutes to 2 hours.,,"3 to 7 hours in adults, 65 to 130 hours in neonates",201,Oral,solid,2.16E+004 mg/L (at 25 Â°C),-0.07,11,,-0.92,CN1C=NC2=C1C(=O)N(C)C(=O)N2C,,,,,0,,194.0803756,2,2,2,2,0,0
93,02/07/2019 00:00,DB00202,Succinylcholine,,,,20 mg/1mL,Intramuscular; Intravenous; Parenteral,solid,,,0.000757,,-6.8,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,,,,,2,,290.2194603,0,0,0,0,0,0
94,02/07/2019 00:00,DB00203,Sildenafil,"Sildenafil is known to be quickly absorbed, with maximum plasma concentrations being observed within 30-120 minutes (with a median of 60 minutes) of oral administration in a fasting patient [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Moreover, the mean absolute bioavailability observed for sildenafil is about 41% (from a range of 25-63%) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. In particular, after oral three times a day dosing of sildenafil, the AUC and Cmax increase in proportion with dose over the recommended dosage range of 25-100 mg [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].

When used in pulmonary arterial hypertension patients, however, the oral bioavailability of sildenafil after a dosing regimen of 80 mg three times a day, was on average 43% greater than compared to the lower doses [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].

Finally, if sildenafil is administered orally with food, the rate of absorption is observed to be decreased with a mean delay in Tmax of about 60 minutes and a mean decrease in Cmax of approximately 29% [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Regardless, the extent of absorption is not observed to be significantly affected as the recorded AUC decreased by only about 11 % [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].",0.96,"The terminal phase half-life observed for sildenafil is approximately 3 to 5 hours [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. ",100 mg,Oral,solid,3.5 mg/mL,1.9,0.433,7.27,5.97,CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1,0.96,0.96,,,0,100,474.2049244,4,3,3,2,1,1
95,04/06/2019 00:00,DB00204,Dofetilide,>90%,0.6,10 hours,125 ug/1,Oral,solid,,2.1,0.0198,10.15,8.99,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,0.6,0.6,10,10,0,0.125,441.139213,2,2,0,0,0,0
96,04/06/2019 00:00,DB00205,Pyrimethamine,Well absorbed with peak levels occurring between 2 to 6 hours following administration,0.87,96 hours,25 mg/1,Oral,solid,121 mg/L,2.69,0.179,17.22,7.77,CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1,0.87,0.87,96,96,0,25,248.0828741,2,2,1,1,0,0
97,04/06/2019 00:00,DB00206,Reserpine,,0.62,,.25 mg,Oral,solid,73 mg/L (at 30 Â°C),3.2,0.0113,16.29,7.39,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,0.62,0.62,,,0,0.25,608.2733809,6,3,3,1,1,2
98,02/07/2019 00:00,DB00207,Azithromycin,"Bioavailability of azithromycin is 37% following oral administration. Absorption is not affected by food.  Macrolide absorption in the intestines is believed to be mediated by P-glycoprotein (ABCB1) efflux transporters, which are known to be encoded by the _ABCB1_ gene [A174175]. ",0.51,Terminal elimination half-life: 68 hours [FDA label],250 mg,Oral,solid,"soluble in ethanol and DSMO, minimally soluble in water",3.03,0.514,12.43,9.57,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,0.51,0.51,,,0,250,748.5085257,3,0,3,0,3,3
99,02/07/2019 00:00,DB00208,Ticlopidine,Absorption is greater than 80%. Food increases absorption by approximately 20%.,0.15,"Half-life following a single 250-mg dose is approximately 7.9 hours in subjects 20 to 43 years of age and 12.6 hours in subjects 65 to 76 years of age. With repeated dosing (250 mg twice a day), half-life is about 4 days in subjects 20 to 43 years of age and about 5 days in subjects 65 to 76 years of age.",250 mg,Oral,solid,Freely soluble,2.9,0.0219,,7.31,ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2,0.15,0.15,,,0,250,263.0535481,3,2,2,1,0,1
100,02/07/2019 00:00,DB00209,Trospium,0.096,50-85%,20 hours,60 mg,Oral,solid,,,6.68E-05,11.05,-4.5,[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1,0.5,0.85,20,20,1,60,392.2220202,5,2,3,0,3,3
101,02/07/2019 00:00,DB00210,Adapalene,Adapalene displays a limited absorption potential across the human skin. Only trace amounts (<0.25 ng/mL) of parent substance have been found in the plasma of acne patients following chronic topical application of adapalene in controlled clinical trials,,,0.1 g/100g,Topical,solid,Practically Insoluble,8.6,4.01E-06,3.99,-4.8,COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2,,,,,0,,412.2038448,7,3,0,0,0,0
102,02/07/2019 00:00,DB00211,Midodrine,"Rapidly absorbed following oral administration. The peak plasma concentrations of the prodrug, desglymidodrine, is reached about half an hour following drug administration. The metabolites reach their peak plasma concentrations at about 1 to 2 hours following drug administration. The absolute bioavailability of midodrine (measured as desglymidodrine) is 93% and is not affected by food. As desglymidodrine displays poor diffusibility across the blood-brain barrier, it is expected to have minimal effects on the central nervous system. ",,The metabolites display a half-life of about 3 to 4 hours.,5 mg,Oral,solid,Soluble,-0.5,4.45,13.77,8.14,COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1,,,,,0,5,254.1266571,1,1,0,0,0,0
103,04/06/2019 00:00,DB00212,Remikiren,Absorbed following oral administration.,0.83,,,,solid,,3.9,0.0128,5.47,6.49,[H][C@@](CC1=CC=CC=C1)(CS(=O)(=O)C(C)(C)C)C(O)=N[C@@]([H])(CC1=CN=CN1)C(O)=N[C@@]([H])(CC1CCCCC1)[C@@]([H])(O)[C@@]([H])(O)C1CC1,0.83,0.83,,,0,,630.3451063,4,2,1,1,0,0
104,02/07/2019 00:00,DB00213,Pantoprazole,"Pantoprazole is absorbed after oral administration as an enteric-coated tablet with maximum plasma concentrations attained within 2 â€“ 3 hours and a bioavailability of 77% that does not change with multiple dosing [A174247]. Following an oral dose of 40mg, the Cmax is approximately 2.5 Î¼g/mL with a tmax of 2 to 3 hours. The AUC is approximately 5 Î¼g.h/mL. There is no food effect on AUC (bioavailability) and Cmax[F4486].

Delayed-release tablets are prepared as enteric-coated tablets so that absorption of pantoprazole begins only after the tablet leaves the stomach.",0.98,About 1 hour [F3202].,20 mg,Oral,solid,Freely soluble in water.,2.05,0.495,9.15,3.55,COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1,0.98,0.98,,,0,20,383.0751334,3,3,2,2,0,0
105,04/06/2019 00:00,DB00214,Torasemide,Torasemide is the diuretic with the highest oral bioavailability even in advanced stages of chronic kidney disease.[A174463] This bioavailability tends to be higher than 80% regardless of the patient condition. The maximal serum concentration is reported to be of 1 hour and the absorption parameters are not affected by its use concomitantly with food.[A174472],0.99,The average half-life of torasemide is 3.5 hours.[A174472],10 mg/1mL,Intravenous,solid,Soluble,3.356,0.0596,5.92,4.2,CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1,0.99,0.99,,,0,,348.1256115,2,2,1,1,0,0
106,02/07/2019 00:00,DB00215,Citalopram,Rapidly and well absorbed from the GI tract. Peak plasma concentrations occur within 4 hours of a single orally administered dose. Bioavailability is 80% following oral administration. Food does not affect absorption [FDA label].,0.8,"About 35 hours [FDA label]. 

",20 mg,Oral,solid,Sparingly soluble ,3.76,0.00588,,9.78,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,0.8,0.8,,,0,20,324.1637915,3,2,1,0,0,1
107,02/07/2019 00:00,DB00216,Eletriptan,Well absorbed after oral administration with a mean absolute bioavailability of approximately 50%.,,The terminal elimination half-life of eletriptan is approximately 4 hours.,20 mg/1,Oral,solid,Readily soluble as hydrobromide formulation,3.9,0.00118,16.56,8.37,CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2,,,,,0,20,382.1714991,4,3,2,1,1,1
108,04/06/2019 00:00,DB00217,Bethanidine,Absorbed rapidly in the gastrointestinal tract following oral administration.,,9 hours (range 7 to 11 hours),,,solid,,0.49,1.58,,12.41,CN\C(NCC1=CC=CC=C1)=N/C,,,,,0,,177.1265975,1,1,0,0,0,0
109,02/07/2019 00:00,DB00218,Moxifloxacin,Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption.,0.5,"11.5-15.6 hours (single dose, oral)",0.005,Ophthalmic,solid,,2.9,0.168,5.69,9.42,[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O,0.5,0.5,,,0,,401.1750845,5,2,3,1,2,2
110,04/06/2019 00:00,DB00219,Oxyphenonium,,0.93,,,,solid,,0.17,0.000136,11.53,-4.3,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,0.93,0.93,,,1,,348.2533204,2,1,0,0,0,0
111,02/07/2019 00:00,DB00220,Nelfinavir,Well absorbed following oral administration.,&gt;98%,3.5 - 5 hours,50 mg/1g,Oral,solid,Slightly soluble,6,0.00191,9.32,8.18,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,0.98,0.98,,,0,,567.3130779,4,2,1,0,1,1
112,04/06/2019 00:00,DB00221,Isoetarine,,,,,,solid,Appreciable,2.2,3.18,10.01,9.01,CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1,,,,,0,,239.1521435,1,1,0,0,0,0
113,02/07/2019 00:00,DB00222,Glimepiride,"Glimepiride is completely absorbed after oral administration within 1 hour of administration with a linear pharmacokinetics profile [A177703]. Following administration of a single oral dose of glimepiride in healthy subjects and with multiple oral doses with type 2 diabetes, the peak plasma concentrations (Cmax) were reached after 2 to 3 hours post-dose [FDA Label]. Accumulation does not occur after multiple doses [A177703]. When glimepiride was given with meals, the time to reach Cmax was increased by 12% while the mean and AUC (area under the curve) were decreased by 8 to 9%, respectively [F4540]. In a pharmacokinetic study of Japanese patients with T2DM, Cmax value in once-daily dose was higher than those in twice-daily doses [A177724]. The absolute bioavailability of glimepiride is reported to be complete following oral administration [A177721]. ",0.995,"The elimination half-life of glimepiride is approximately 5 to 8 hours [A177715], which can increase up to 9 hours following multiple doses [A177709]. ",1 mg,Oral,solid,Partly miscible,,0.0347,2.23,-0.36,[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1,0.995,0.995,,,0,1,490.2249912,3,1,1,0,0,1
114,04/06/2019 00:00,DB00223,Diflorasone,"Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.",,,0.5 mg/1g,Topical,solid,,2.1,0.0853,12.42,-3.3,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,410.1904804,4,0,0,0,0,0
115,02/07/2019 00:00,DB00224,Indinavir,Rapidly absorbed,0.6,1.8 (&plusmn; 0.4) hours,100 mg/1,Oral,solid,0.015 mg/ml,2.9,0.0482,13.19,7.37,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,0.6,0.6,,,0,100,613.362805,5,3,2,1,1,1
116,04/06/2019 00:00,DB00226,Guanadrel,Rapidly and readily absorbed from the gastrointestinal tract.,0.2,10 hours,,,solid,,0.6,1.93,19.85,12.56,NC(N)=NCC1COC2(CCCCC2)O1,0.2,0.2,10,10,0,,213.1477268,2,0,1,0,1,1
117,02/07/2019 00:00,DB00227,Lovastatin,"Studies suggest that less than 5% of the oral dose reaches the general circulation as active inhibitors and the time to peak serum concentration is 2-4 hours. Lovastatin undergoes extensive first-pass metabolism so the availability of the drug in the system is low and variable.[L5284]

The peak concentrations of lovastatin when a dose of 10-40 mg is administered are reported to range from 1.04-4.03 ng/ml and an AUC of 14-53 ng.h/ml. This indicates that lovastatin presents a dose-dependent pharmacokinetic profile.[A174586]",0.9,Lovastatin half-life is reported to be of 4.5 hours.[L5284] The elimination half-life of the hydroxy acid form of lovastatin is reported to be of 0.7-3 hours.[A174583],20 mg/1,Oral,solid,0.0004 mg/mL,4.08,0.0243,14.91,-2.8,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,0.9,0.9,,,0,20,404.2562743,3,0,1,0,1,1
118,04/06/2019 00:00,DB00228,Enflurane,Rapidly absorbed into the circulation via the lungs.,0.97,,1 mL/1mL,Respiratory (inhalation),liquid,5620 mg/L (at 37 Â°C),2.1,3.9,,-5,FC(F)OC(F)(F)C(F)Cl,0.97,0.97,,,0,,183.9714335,0,0,0,0,0,0
119,04/06/2019 00:00,DB00229,Cefotiam,Rapidly absorbed following intramuscular injection. Bioavailability is 60% following intramuscular injection.,0.4,Approximately 1 hour.,,,solid,Soluble,-2.1,1.29,2.79,8.36,[H][C@]12SCC(CSC3=NN=NN3CCN(C)C)=C(N1C(=O)[C@H]2NC(=O)CC1=CSC(N)=N1)C(O)=O,0.4,0.4,,,0,,525.1035132,4,2,4,2,1,2
120,02/07/2019 00:00,DB00230,Pregabalin,Absorption of pregabalin is rapid and extensive reflecting it's relatively quick onset of efficacy.  Maximal plasma concentration occurs ~1 hour after administration and steady state occurs within 24-48 hours. [A31165],,The elimination half life of pregabalin is roughly 6 hours [FDA Label].,100 mg/1,Oral,solid,Freely soluble ,-1.35,11.3,4.8,10.23,CC(C)C[C@H](CN)CC(O)=O,,,,,0,100,159.1259288,0,0,0,0,0,0
121,02/07/2019 00:00,DB00231,Temazepam,"Studies demonstrate that between 90 to 100% of an orally administered temazepam dose is absorbed, making the medication very well absorbed [F3718, L5539]. The oral administration of 15 to 45 mg temazepam resulted in rapid absorption with significant blood levels achieved in 30 minutes and peak levels at 2-3 hours [F3718, L5539]. In particular, direct studies following the oral ingestion of 30 mg of temazepam revealed measurable plasma concentrations were obtained 10-20 minutes after dosing with peak plasma levels ranging between 666-982 ng/mL (with a mean of 865 ng/mL) presenting approximately 1.2-1.6 hours (with a mean of 1.5 hours) after the dosing [FDA Label]. Finally, a dose-proportional relationship was established for the area under the plasma concentration/time curve over the 15 to 30 mg dose range [FDA Label]. ",0.96,"The terminal half-life determined for temazepam is recorded as being between 3.5-18 hours, with a mean of 9 hours [F3718, L5539].",15 mg,Oral,solid,164 mg/L,2.19,0.0534,10.68,-1.4,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,0.96,0.96,,,0,15,300.0665553,3,2,1,0,0,1
122,04/06/2019 00:00,DB00232,Methyclothiazide,Rapidly absorbed following oral administration.,,,5 mg,Oral,solid,11.2 mg/L,1.42,0.824,9.29,-3.4,CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O,,,,,0,5,358.9568032,2,1,1,0,0,1
123,04/06/2019 00:00,DB00233,Aminosalicylic Acid,,50-60%,,4 g,Oral,solid,1690 mg/L (at 23 Â°C),0.89,11.8,3.68,2.19,NC1=CC(O)=C(C=C1)C(O)=O,0.5,0.6,,,0,,153.0425931,1,1,0,0,0,0
124,04/06/2019 00:00,DB00234,Reboxetine,Reboxetine is rapidly and extensively absorbed following oral administration.,0.98,12.5 hours,,,solid,8 mg/mL (Mesylate salt),3.1,0.0223,,7.91,[H][C@@](OC1=CC=CC=C1OCC)(C1=CC=CC=C1)[C@@]1([H])CNCCO1,0.98,0.98,12.5,12.5,0,,313.1677936,3,2,1,0,1,1
125,02/07/2019 00:00,DB00235,Milrinone,Milrinone is rapidly and almost completely absorbed after oral administration. Bioavailability is 92% (in healthy volunteers).,0.8,2.3 hours,1 mg/1mL,Intravenous,solid,Slightly soluble,0.4,0.209,7.54,4.82,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1,0.8,0.8,2.3,2.3,0,,211.0745619,2,2,2,2,0,0
126,04/06/2019 00:00,DB00236,Pipobroman,Well absorbed from the GI tract.,,,,,solid,2490 mg/L,0.42,2.24,,-0.72,BrCCC(=O)N1CCN(CC1)C(=O)CCBr,,,,,0,,353.957852,1,0,1,0,1,1
127,04/06/2019 00:00,DB00237,Butabarbital,,,,30 mg/5mL,Oral,solid,1360 mg/L,1.65,1.39,8.48,,CCC(C)C1(CC)C(=O)NC(=O)NC1=O,,,,,0,,212.1160924,1,0,1,0,1,1
128,02/07/2019 00:00,DB00238,Nevirapine,"Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy subjects and adults with HIV-1 infection. The absolute bioavailability in healthy adults following a single dose administration is 93 Â± 9% (mean Â± SD) for a 50 mg tablet and 91 Â± 8% for an oral solution. Peak plasma nevirapine concentrations of 2 Â± 0.4 mcg/mL (7.5 micromolar) were attained by 4 hours following a single 200 mg dose. Nevirapine tablets and suspension have been shown to be comparably bioavailable and interchangeable at doses up to 200 mg. When the oral tablet is given with a high-fat meal, the extent of absorption is compared to that of the fasted-state. ",0.6,45 hours,200 mg/1,Oral,solid,0.7046 mg/L,2.5,0.105,10.37,5.06,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,0.6,0.6,45,45,0,200,266.1167611,4,2,3,2,0,1
129,04/06/2019 00:00,DB00239,Oxiconazole,Systemic absorption of oxiconazole is low.,,,10 mg/1g,Topical,solid,,,0.00191,,6.74,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1,,,,,0,,426.9812728,3,3,1,1,0,0
130,04/06/2019 00:00,DB00240,Alclometasone,Topical corticosteroids can be absorbed from normal intact skin. Studies have shown that approximately 3% of steroid is absorbed during 8 hours of contact with intact skin of normal volunteers.,,,0.5 mg/1g,Topical,solid,Insoluble,2.7,0.137,12.45,-2.9,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C,,,,,0,,408.1703517,4,0,0,0,0,0
131,04/06/2019 00:00,DB00241,Butalbital,Butalbital gets readily and rapidly absorbed from the gastrointestinal tract [F4561]. The time to reach the peak plasma concentrations is reported to be approximately 2 hours [A177754]. Typical blood concentrations of butalbital peaked at 2.1 mg/L and declined to 1.5 mg/L at 24 hr [A177838]. Plasma concentrations of 10 to 20 Î¼g/mL have been associated with toxicity; coma and fatalities have occurred with concentrations of 25 to 30 Î¼g/mL [A177754]. ,0.45,"The plasma half-life is about 35 hours. In a study of 5 healthy volunteers receiving 100 mg butalbital in combination with aspirin and caffeine, the mean plasma elimination half-life of butalbital was 61 hours, with the range of 35 to 88 hours [A177838, T598]. ",,Oral,solid,1700 mg/L (at 25 Â°C),1.87,2.23,8.48,,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,0.45,0.45,,,0,,224.1160924,1,0,1,0,1,1
132,02/07/2019 00:00,DB00242,Cladribine,Oral bioavailability is 34 to 48%.,0.2,5.4 hours,1 mg/1mL,Intravenous,solid,,-0.1,6.35,13.89,1.33,NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1,0.2,0.2,5.4,5.4,0,,285.0628669,3,2,3,2,1,1
133,04/06/2019 00:00,DB00243,Ranolazine,"The time to reach peak serum concentration is very variable but it has been suggested to be of 2-6 hours and to reach steady-state within 3 days.[A174898] The absorption of ranolazine is not modified by food consumption.[A174940] The bioavailability of ranolazine is reported to be of about 73% counting both the unchanged form and the metabolites. After multiple administration of a dose of 500 mg, the reported Cmax and AUC were 1770 ng/ml and 13700 ng.h/ml respectively.[L5473]",0.62,"Due to the short half-life of the immediate release formulation of ranolazine (1.4-1.9 hours), it was required the generation of an extended-release formulation which presented an approximate steady-state half-life of 7-9 hours.[A174898]",1000 mg/1,Oral,solid,<1 mg/ml,2.07,0.11,13.6,7.17,COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1,0.62,0.62,,,0,1000,427.2471065,3,2,1,0,1,1
134,02/07/2019 00:00,DB00244,Mesalazine,"Depending on the formulation administered, prescribing information for orally administered delayed-released tablets of 2.4g or 4.8g of mesalazine given once daily for 14 days to healthy volunteers was to found to be about 21% to 22% of the administered dose [FDA Label] while prescribing information for an orally administered controlled-release capsule formulation suggests 20% to 30% of the mesalazine in the formulation is absorbed [F3001]. In contrast, when mesalamine is administered orally as an unformulated 1-g aqueous suspension, mesalazine is approximately 80% absorbed [F3001]. ",0.43,The apparent elimination half-life documented for oral delayed-release mesalazine tablets is 7 to 12 hours [L5122]. The elimination half-life recorded for the active N-acetyl-5-aminosalicylic acid metabolite generated from the administration of oral delayed-release mesalazine tablets is 12 to 23 hours [L5122].,400 mg,Oral,solid,0.84 g/L at 20Â°C,1.2,12.2,2.02,5.87,NC1=CC(C(O)=O)=C(O)C=C1,0.43,0.43,,,0,400,153.0425931,1,1,0,0,0,0
135,02/07/2019 00:00,DB00245,Benzatropine,Oral administration of 1.5 mg of benztropine is slowly absorbed in the gastrointestinal tract and it reaches a peak concentration of 2.5 ng/ml in about 7 hours.[A175087] It has an approximate oral bioavailability of 29%.[T445],0.95,The elimination half-life of benztropine is very variable and it is reported to be of around 36 hours.[F3682],1 mg/1mL,Intramuscular; Intravenous,solid,81 mg/ml,4.27,0.00121,,9.54,[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C,0.95,0.95,,,0,,307.1936144,4,2,2,0,2,2
136,02/07/2019 00:00,DB00246,Ziprasidone,"In the absence of food, ziprasidone's oral bioavailability is 60%, while absorption may reach up to 100% if ziprasidone is taken with a meal equal or greater than 500 kcal.  The difference in bioavailability has little to do with the fat content of the food and appears to be related to the bulk of the meal since more absorption occurs the longer ziprasidone remains in the stomach. [A174562]",0.99,The half life of ziprasidone is 6-7 hours. [A174562],20 mg,Oral,solid,,3.8,0.00718,13.18,7.09,ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1,0.99,0.99,,,0,20,412.11246,5,3,3,1,1,2
137,04/06/2019 00:00,DB00247,Methysergide,Rapid,,,2 mg,Oral,solid,,1.5,0.224,15.01,7.85,[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO,,,,,0,2,353.2103271,4,2,2,1,0,1
138,02/07/2019 00:00,DB00248,Cabergoline,"First-pass effect is seen, however the absolute bioavailability is unknown.",(40%,The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.,0.5 mg/1,Oral,solid,Insoluble,2.6,0.064,15.25,9.32,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,0.4,0.4,,,0,0.5,451.2947254,4,2,2,1,1,1
139,02/07/2019 00:00,DB00249,Idoxuridine,"Systemic absorption is unlikely following ocular administration even when nasolacrimal secretions are swallowed, since vidarabine is rapidly deaminated in the gastrointestinal tract.",,,1 mg/1mL,Ophthalmic,solid,2000 mg/L (at 25 Â°C),-0.96,23.4,8.46,-3,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O,,,,,0,,353.9712695,2,1,2,1,1,1
140,02/07/2019 00:00,DB00250,Dapsone,Bioavailability is 70 to 80% following oral administration.,0.9,28 hours (range 10-50 hours),0.05,Topical,solid,380 mg/L (at 37 Â°C),0.97,0.284,,2.39,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,0.9,0.9,,,0,,248.0619486,2,2,0,0,0,0
141,02/07/2019 00:00,DB00251,Terconazole,"Following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations",0.949,6.9 hours (range 4.0-11.3),0.004,Vaginal,solid,,4.5,0.0116,,8.41,CC(C)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1,0.949,0.949,,,0,,531.1803952,5,3,3,1,2,2
142,02/07/2019 00:00,DB00252,Phenytoin,"Bioavailability 70-100% oral, 24.4% rectal. Rapid rate of absorption with peak blood concentration expected in 1&frac12; to 3 hours.",,22 hours (range of 7 to 42 hours),30 mg,Oral,solid,32 mg/L (at 22 Â°C),2.47,0.0711,9.47,-9,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,30,252.0898776,3,2,1,0,1,1
143,04/06/2019 00:00,DB00253,Medrysone,Rapidly absorbed following oral administration.,,,0.01,Ophthalmic,solid,,3.2,0.0337,19.14,-0.26,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,,,,,0,,344.2351449,4,0,0,0,0,0
144,02/07/2019 00:00,DB00254,Doxycycline,"Tetracyclines, such as doxycycline, are readily absorbed and are bound to plasma proteins by varying degrees. Doxycycline is almost completely absorbed after oral administration. This drug is highly lipid soluble and has a low affinity for calcium binding [FDA label]. Absorption is not significantly affected by the concomitant ingestion of food or milk [F3052]. Peak serum levels of approximately 2.6 mcg/ml are reached at 2 hours following a 200 mg tablet oral dose [F3052].",>90%,16.33 hr (Â± 4.53 sd) [FDA label].,150 mg/1,Oral,solid,50 mg/mL,0.63,0.63,2.93,7.46,[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O,0.9,1,,,0,150,444.1532657,4,1,0,0,0,0
145,04/06/2019 00:00,DB00255,Diethylstilbestrol,,,,250 mg,Intravenous,solid,12 mg/L (at 25 Â°C),5.07,0.0109,8.63,-6.5,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,,,,,0,,268.1463299,2,2,0,0,0,0
146,04/06/2019 00:00,DB00256,Lymecycline,Absorption is fast and efficient. Bioavailability is 100% following oral administration.,,,,,solid,Soluble (at all physiological pH values),0.3,1.31,0.4,9.5,[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C,,,,,0,,602.2587934,4,1,0,0,0,0
147,02/07/2019 00:00,DB00257,Clotrimazole,"Because clotrimazole is generally not significantly absorbed, drug interactions are not a major issue with its use [A174094].",0.98,,10 mg/1g,Topical,solid,0.49 mg/L,0.5,0.00147,,6.62,ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,0.98,0.98,,,0,,344.1080262,4,4,1,1,0,0
148,02/07/2019 00:00,DB00258,Calcium acetate,40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.,,,667 mg/667mg,Topical,solid,,,147,4.54,,[Ca++].CC([O-])=O.CC([O-])=O,,,,,0,,157.9891997,0,0,0,0,0,0
149,04/06/2019 00:00,DB00259,Sulfanilamide,Sulfonamides are absorbed through the vaginal mucosa. There are no pharmacokinetic data available describing how much of an intravaginal dose reaches the systemic circulation.,,,0.15,Vaginal,solid,7500 mg/L (at 25 Â°C),-0.62,10.4,10.99,2.27,NC1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,172.0306485,1,1,0,0,0,0
150,04/06/2019 00:00,DB00260,Cycloserine,Rapidly and almost completely absorbed (70 to 90%) from the gastrointestinal tract following oral administration.,,"Half-life in patients with normal renal function is 10 hours, and is prolonged in patients with impaired renal function.",251,Oral,solid,Soluble,-0.9,877,4.21,8.36,N[C@@H]1CONC1=O,,,,,0,,102.0429274,1,0,1,0,1,1
151,02/07/2019 00:00,DB00261,Anagrelide,,,"At fasting and at a dose of 0.5 mg of anagrelide, the plasma half-life is 1.3 hours.",1 mg/1,Oral,solid,Very slightly soluble,2.4,0.279,12.55,3.62,ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl,,,,,0,1,254.9966172,3,1,2,0,1,2
152,02/07/2019 00:00,DB00262,Carmustine,5 to 28% bioavailability,0.8,15-30 minutes,100 mg/30mL,Intravenous,solid,4000 mg/L (at 25 Â°C),1.53,1.53,11.96,-5.3,ClCCNC(=O)N(CCCl)N=O,0.8,0.8,0.25,0.5,0,,213.0071819,0,0,0,0,0,0
153,02/07/2019 00:00,DB00263,Sulfisoxazole,,,,500 mg,Oral,solid,300 mg/L (at 37 Â°C),1.01,0.313,5.8,2.17,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C,,,,,0,500,267.0677623,2,2,1,1,0,0
154,02/07/2019 00:00,DB00264,Metoprolol,"When metoprolol is administered orally, it is almost completely absorbed in the gastrointestinal tract.[A175141] The maximum serum concentration is achieved 20 min after intravenous administration and 1-2 hours after oral administration. The bioavailability of metoprolol is of 100% when administered intravenously and when administered orally it presents about 50% for the tartrate derivative and 40% for the succinate derivative.[T274]

The absorption of metoprolol in the form of the tartrate derivative is increased by the concomitant administration of food.[T274]",0.11,The immediate release formulations of metoprolol present a half-life of about 3-7 hours.[A175141],25 mg,Oral,solid,Soluble (tartrate form),2.15,0.402,14.09,9.67,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,0.11,0.11,,,0,25,267.1834437,1,1,0,0,0,0
155,02/07/2019 00:00,DB00265,Crotamiton,10 % absorbed when applied locally.,,,100 mg/1g,Topical,liquid,,2.9,0.353,,-0.6,CCN(C(=O)C=CC)C1=CC=CC=C1C,,,,,0,,203.1310142,1,1,0,0,0,0
156,04/06/2019 00:00,DB00266,Dicoumarol,,,,,,solid,128 mg/L,2.07,0.0662,-12,-3.1,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,,,,,0,,336.0633881,4,4,2,2,0,0
157,04/06/2019 00:00,DB00267,Cefmenoxime,Bioavailability is approximately 100% following intramuscular injection.,50-70%,1 hour,,,solid,,-1.3,0.446,3.04,4.14,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,0.5,0.7,1,1,0,,511.0514776,4,2,4,2,1,2
158,02/07/2019 00:00,DB00268,Ropinirole,"Ropinirole is rapidly absorbed after oral administration, reaching peak concentration in approximately 1 to 2 hours [FDA label], [A37840].

Absolute bioavailability was 45% to 55%, suggesting approximately 50% hepatic first-pass effect [FDA label]. The bioavailability of ropinirole prolonged release compared to the immediate release tablets is about 100% [A38215].

Ingestion of food does not affect the absorption of ropinirole, although its Tmax was increased by 2.5 hours and its Cmax was reduced by approximately 25% when the drug is taken with a high-fat meal [FDA label].",0.4,"Approximately 6 hours [FDA label], [A37840].",1 mg,Oral,solid,133 mg/mL,3.06,0.353,13.24,10.17,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,0.4,0.4,,,0,1,260.1888634,2,1,1,0,0,1
159,04/06/2019 00:00,DB00269,Chlorotrianisene,Absorption following oral administration is rapid.,50-80%,,,,solid,,6.4,0.000199,,-4.4,COC1=CC=C(C=C1)C(Cl)=C(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1,0.5,0.8,,,0,,380.1179222,3,3,0,0,0,0
160,04/06/2019 00:00,DB00270,Isradipine,"Isradipine is 90%-95% absorbed and is subject to extensive first-pass metabolism, resulting in a bioavailability of about 15%-24%.",0.95,8 hours,2.5 mg/1,Oral,solid,Practically insoluble (< 10 mg/L at 37 Â°C),4.28,0.228,,5.33,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,0.95,0.95,8,8,0,2.5,371.1481208,3,2,2,1,0,1
161,02/07/2019 00:00,DB00271,Diatrizoate,,,,180 mg/1mL,Intravesical,solid,,3.3,0.107,2.17,-4.2,CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,,,,,0,,613.7696508,1,1,0,0,0,0
162,04/06/2019 00:00,DB00272,Betazole,Rapid and complete.,0.99,,,,liquid,,0.1,156,14.52,9.79,NCCC1=CC=NN1,0.99,0.99,,,0,,111.0796473,1,1,1,1,0,0
163,02/07/2019 00:00,DB00273,Topiramate,"Topiramate has good oral bioavailability of 81-95% and it presents a linear kinetic profile.[A175237] It reaches a maximal concentration of 1.73-28.7 mcg/ml after 2-4 hours of initial administration.[A175243, A175246] The plasma steady-state after multiple dosing is achieved after 4 days.[A175246]

The concomitant administration of food produces changes in the absorption rate but not in the absorption extent.[A175246]",0.15,"The elimination half-life is reported to be in the range of 19-23 hours.[A175243] If coadministered with enzyme-inducers, the half-life can be changed to 12-15 hours.[A175246]",50 mg,Oral,solid,9.8 mg/mL at 23 ÂºC,-0.5,6.8,11.09,-3.7,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,0.15,0.15,,,0,50,339.0987876,3,0,3,0,3,3
164,04/06/2019 00:00,DB00274,Cefmetazole,Bioavailability is approximately 100% following intramuscular injection.,,1.50 &plusmn;0.14 hours,,,solid,94.2 mg/L,-0.6,2.16,3.38,-1.7,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O,,,,,0,,471.0453296,3,1,3,1,1,2
165,02/07/2019 00:00,DB00275,Olmesartan,"Olmesartan, in the form of olmesartan medoxomil is rapidly absorbed in the gastrointestinal tract and metabolized to olmesartan. The esterification with medoxomil was created with the intention of increasing olmesartan bioavailability from 4.5% to 28.6%.[A175330]

Oral administration of 10-160 mg of olmesartan has been shown to reach peak plasma concentration of 0.22-2.1 mg/L after 1-3 hours with an AUC of 1.6-19.9mgh/L.[A175342] The pharmacokinetic profile of olmesartan has been observed to be nearly linear and dose-dependent under the therapeutic range.[A175330] The steady-state level of olmesartan is achieved after once a day dosing during 3 to 5 days.[L5566]",0.99,The mean plasma olmesartan half-life is reported to be from 10-15 hours after multiple oral administration.[A175330],10 mg,Oral,solid,Insoluble,0.73,0.0105,0.91,5.57,CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O,0.99,0.99,,,0,10,446.2066387,4,4,2,2,0,0
166,02/07/2019 00:00,DB00276,Amsacrine,Poorly absorbed,96-98%,8-9 hours,50 mg,Intravenous,solid,<1 mg/mL,3.8,0.00317,10.82,8.44,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1,0.96,0.98,8,9,0,,393.1147125,4,4,1,1,0,0
167,02/07/2019 00:00,DB00277,Theophylline,Theophylline is rapidly and completely absorbed after oral administration in solution or immediate-release solid oral dosage form.,,8 hours,100 mg,Oral,solid,7360 mg/L (at 25 Â°C),-0.02,22.9,7.82,-0.78,CN1C2=C(NC=N2)C(=O)N(C)C1=O,,,8,8,0,100,180.0647255,2,2,2,2,0,0
168,02/07/2019 00:00,DB00278,Argatroban,Bioavailability is 100% (intravenous).,0.54,39 and 51 minutes,1 mg/1mL,Intravenous,solid,,1,0.168,3.06,11.8,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2,0.54,0.54,,,0,,508.2467893,3,1,2,0,1,2
169,02/07/2019 00:00,DB00279,Liothyronine,"Thyroid hormones are well absorbed orally. From these hormones, liothyronine is almost completely absorbed and it does not present changes in the absorption rate due to concomitant administration of food.[T322]liothyronin Multiple administration of 50 mcg of liothyronine provided a maximal plasma concentration of total T3 of 346 ng/dL in about 2.5 hours with an AUC of 4740 ng.h/dL.[A175435]",0.997,The half-life of liothyronine is reported to be between 1 and 2 days.[T460],25 mcg,Oral,solid,Very slightly soluble,3,0.0195,0.3,9.48,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O,0.997,0.997,,,0,0.025,650.7900519,2,2,0,0,0,0
170,02/07/2019 00:00,DB00280,Disopyramide,Nearly complete,50%-65%,6.7 hours (range 4-10 hours),100 mg/1,Oral,solid,44.9 mg/L,2.58,0.0493,16.19,10.42,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C,0.5,0.65,,,0,100,339.2310625,2,2,1,1,0,0
171,02/07/2019 00:00,DB00281,Lidocaine,"In general, lidocaine is readily absorbed across mucous membranes and damaged skin but poorly through intact skin [F4468]. The agent is quickly absorbed from the upper airway, tracheobronchial tree, and alveoli into the bloodstream [F4468]. And although lidocaine is also well absorbed across the gastrointestinal tract the oral bioavailability is only about 35% as a result of a high degree of first-pass metabolism [F4468]. After injection into tissues, lidocaine is also rapidly absorbed and the absorption rate is affected by both vascularity and the presence of tissue and fat capable of binding lidocaine in the particular tissues [F4468].

The concentration of lidocaine in the blood is subsequently affected by a variety of aspects, including its rate of absorption from the site of injection, the rate of tissue distribution, and the rate of metabolism and excretion [F4349, L5930, L5948]. Subsequently, the systemic absorption of lidocaine is determined by the site of injection, the dosage given, and its pharmacological profile [F4349, L5930, L5948]. The maximum blood concentration occurs following intercostal nerve blockade followed in order of decreasing concentration, the lumbar epidural space, brachial plexus site, and subcutaneous tissue [F4349, L5930, L5948]. The total dose injected regardless of the site is the primary determinant of the absorption rate and blood levels achieved [F4349, L5930, L5948]. There is a linear relationship between the amount of lidocaine injected and the resultant peak anesthetic blood levels [F4349, L5930, L5948].

Nevertheless, it has been observed that lidocaine hydrochloride is completely absorbed following parenteral administration, its rate of absorption depending also on lipid solubility and the presence or absence of a vasoconstrictor agent [F4349, L5930, L5948]. Except for intravascular administration, the highest blood levels are obtained following intercostal nerve block and the lowest after subcutaneous administration [F4349, L5930, L5948].

Additionally, lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion [F4349].",0.8,"The elimination half-life of lidocaine hydrochloride following an intravenous bolus injection is typically 1.5 to 2.0 hours [F4349]. Because of the rapid rate at which lidocaine hydrochloride is metabolized, any condition that affects liver function may alter lidocaine HCl kinetics [F4349]. The half-life may be prolonged two-fold or more in patients with liver dysfunction [F4349].",20 mg,Intravenous,solid,4100 mg/L (at 30 Â°C),2.44,0.593,13.78,7.75,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C,0.8,0.8,,,0,,234.1732133,1,1,0,0,0,0
172,02/07/2019 00:00,DB00282,Pamidronic acid,Plasma concentration rises rapidly upon IV administration. ,0.54,The mean &plusmn; SD elimination half-life is 28 &plusmn; 7 hours,30 mg/10mL,Intravenous,solid,,-4.7,15.8,0.67,9.86,NCCC(O)(P(O)(O)=O)P(O)(O)=O,0.54,0.54,,,0,,235.001075,0,0,0,0,0,0
173,04/06/2019 00:00,DB00283,Clemastine,Rapidly absorbed from the gastrointestinal tract.,,,0.5 mg/1mL,Oral,solid,Soluble (hydrogen fumarate formulation),5.2,0.000405,,9.55,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,,,,,0,,343.1702921,3,2,1,0,1,1
174,02/07/2019 00:00,DB00284,Acarbose,Extremely low bioavailability. Less than 2% of an oral dose of acarbose was absorbed as active drug. Peak plasma concentrations of the active drug were achieved 1 hour after dosing. Drug accumulation does not occur with multiple doses. ,,Healthy volunteers = 2 hours,100 mg/1,Oral,solid,,-6.8,108,11.83,7.03,[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O,,,,,0,100,645.2480135,3,0,2,0,2,2
175,02/07/2019 00:00,DB00285,Venlafaxine,"Venlafaxine is well absorbed, with at least 92% of a single dose absorbed on the basis of mass balance studies [FDA Label]. Food does not affect the absorption of venlafaxine or its subsequent metabolism into ODV. Bioavailability is 45% following oral administration.
Time to steady state = 3 days. ",0.27,5 hours,150.0 mg,Oral,solid,572 mg/ml (Hydrochloride salt),,0.23,14.42,8.91,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,0.27,0.27,5,5,0,150,277.2041791,2,1,0,0,0,0
176,02/07/2019 00:00,DB00287,Travoprost,"Travoprost is systemically absorbed through the cornea [F3061, F3064, L5146]. In humans, peak plasma concentrations of travoprost free acid were low (25 pg/mL or less) and occurred within 30 minutes following topical ocular administration of one drop of 0.004% travoprost ophthalmic solution [F3061, F3064, L5146].",0.8,"The terminal elimination half-life of travoprost free acid is determined to be approximately 45 minutes, although studies demonstrated half-life values that ranged from 17 to 86 minutes [F3061, F3064].",0.00003,Ophthalmic,liquid,>16 mg/ml at 25.0Â°C,4.6,0.00759,13.95,-2.9,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F,0.8,0.8,,,0,,500.2385735,2,1,0,0,0,0
177,02/07/2019 00:00,DB00288,Amcinonide,Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.,,,1 mg/1g,Topical,solid,,2.3,0.00774,13.63,-3.4,[H][C@@]12C[C@H]3OC4(CCCC4)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,502.2366817,6,0,1,0,1,1
178,02/07/2019 00:00,DB00289,Atomoxetine,"The pharmacokinetic profile of atomoxetine is highly dependent on cytochrome P450 2D6 genetic polymorphisms of the individual [A175669]. A large fraction of the population (up to 10% of Caucasians and 2% of people of African descent and 1% of Asians) are poor metabolizers (PMs) of CYP2D6 metabolized drugs. These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of 21.6 hours) of atomoxetine compared with people with normal CYP2D6 activity.

Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in extensive metabolizers (EMs) and 94% in poor metabolizers (PMs). Mean maximal plasma concentrations (Cmax) are reached approximately 1 to 2 hours after dosing with a maximal concentration of 350 ng/ml with an AUC of 2 mcg.h/ml[A175669].
",0.987,The reported half-life depends on the CYP2D6 genetic polymorphisms of the individual and can range from 3 to 5.6 hours.[A175669],10 mg/1,Oral,solid,27.8 mg/mL,0.676,0.0039,,9.8,CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1,0.987,0.987,,,0,10,255.1623143,2,2,0,0,0,0
179,02/07/2019 00:00,DB00290,Bleomycin,Systemic absorption is approximately 45%.,0.01,115 minutes,15 [USP'U]/1,Intramuscular; Intrapleural; Intravenous; Subcutaneous,solid,Soluble,,0.0282,11.34,7.67,C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C,0.01,0.01,1.916666667,1.916666667,1,,1414.518432,6,4,6,4,2,2
180,02/07/2019 00:00,DB00291,Chlorambucil,,0.99,1.5 hours,2 mg,Oral,solid,1.24E+004 mg/L,1.7,0.0773,4.46,1.72,OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl,0.99,0.99,1.5,1.5,0,2,303.0792842,1,1,0,0,0,0
181,04/06/2019 00:00,DB00292,Etomidate,,,75 minutes.,2 mg/1mL,Intravenous,solid,63.2 mg/L,3.05,0.477,,4.54,CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1,,,1.25,1.25,0,,244.1211778,2,2,1,1,0,0
182,02/07/2019 00:00,DB00293,Raltitrexed,,>93%,198 hours,2 mg,Intravenous,solid,soluble,-1.2,0.0181,3.72,-0.46,CN(CC1=CC2=C(NC(C)=NC2=O)C=C1)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,0.93,1,198,198,0,,458.1260054,3,3,2,2,0,0
183,04/06/2019 00:00,DB00294,Etonogestrel,"Vaginal administration of etonogestrel is known to be significantly absorbed through the vaginal epithelium but it does not increase the levels of etonogestrel in the urine. On the other hand, oral administration is absorbed in the GI tract and it goes through the first-pass metabolism.[A37184]

When etonogestrel is administered subdermally it is absorbed rapidly into the bloodstream and it presents a bioavailability of 82%.[T55] It is reported that the implant releases around 60 mcg per day in the first 3 months and then decreases steady reaching a concentration of 30 mcg at the end of year 2.[A175993]",96-99%,The elimination half-life of etonogestrel is reported to be of 25 hours which indicates a reversible contraceptive effect.[L5695],68 mg/1,Subcutaneous,solid,Insoluble,3.32,0.00737,17.99,-1.5,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],0.96,0.99,,,0,,324.2089301,4,0,0,0,0,0
184,02/07/2019 00:00,DB00295,Morphine,"Morphine presents an almost complete absorption mainly done in an alkaline environment in the upper intestine as well as in the rectal mucosa.[A176119] Morphine presents significant first-pass metabolism and thus, oral doses are required to be six times bigger than parenteral administration in order to achieve the same analgesic effect. The steady-state concentration of morphine is achieved after 24-48 hours of initial administration,[A176035] and a peak plasma concentration of 283 nmol/L can range from 15 min when administered parentally to 90 min when administered orally.[A176122, A176164] The AUC of morphine is reported to be in the range of 225-290 nmol.h/L with a bioavailability that can range from 80-100% depending on the route of administration.[A176164]",0.1,Morphine presents an equilibrated half-life of 2-3 hours.[A176116],0.5 mg/1mL,Epidural; Intrathecal; Intravenous,solid,149 mg/L (at 20 Â°C),0.87,10.2,10.26,9.12,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,0.1,0.1,,,0,,285.1364935,5,1,2,0,1,2
185,02/07/2019 00:00,DB00296,Ropivacaine,Bioavailability is 87%â€“98% following epidural administration.,,Approximately 4.2 hours.,2 mg/1mL,Epidural; Infiltration,solid,57.6 mg/L,2.9,0.253,13.62,7.82,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,,,,,0,,274.2045135,2,1,1,0,1,1
186,02/07/2019 00:00,DB00297,Bupivacaine,"Systemic absorption of local anesthetics is dose- and concentration-dependendent on the total drug administered. Other factors that affect the rate of systemic absorption include the route of administration, blood flow at the administration site, and the presence or absence of epinephrine in the anesthetic solution.",0.95,2.7 hours in adults and 8.1 hours in neonates,1.25 mg/1mL,Epidural,solid,2400 mg/L (at 25 Â°C),3.41,0.0977,13.62,8,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C,0.95,0.95,,,0,,288.2201635,2,1,1,0,1,1
187,04/06/2019 00:00,DB00298,Dapiprazole,Systemic absorption is negligible.,,,,,solid,Soluble,2.3,0.751,,7.67,CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1,,,,,0,,325.2266459,4,2,3,1,1,2
188,04/06/2019 00:00,DB00299,Penciclovir,Measurable penciclovir concentrations were not detected in plasma or urine of healthy male volunteers (n= 12) following single or repeat application of the 1% cream at a dose of 180 mg penciclovir daily.,,2 hours,0.01,Topical,solid,1.7mg/ml,-1.1,7.45,8.01,2.84,NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2,,,2,2,0,,253.1174893,2,2,2,2,0,0
189,02/07/2019 00:00,DB00300,Tenofovir disoproxil,"After oral administration of tenofovir disoproxil to patients with HIV infection, tenofovir disoproxil is quickly absorbed and metabolized to tenofovir [F3442].

Administration of tenofovir disoproxil 300 mg tablets after a high-fat meal increases the oral bioavailability of this drug, as demonstrated by an increase in tenofovir AUC0-âˆž of about 40% as well as an increase in Cmax of about 14%.  On the contrary, the administration of tenofovir disoproxil with a light meal did not exert a relevant effect on the pharmacokinetics of tenofovir when compared to administration under fasting conditions.  The presence of ingested food slows the time to tenofovir Cmax by approximately  1 hour. Cmax and AUC of tenofovir are 0.33 Â± 0.12 Î¼g/mL and 3.32 Â± 1.37 Î¼gâ€¢hr/mL after several doses of tenofovir disoproxil 300 mg once daily in the fed state when meal content is not controlled [FDA label].",,"When a single oral dose is given, the terminal elimination half-life is approximately 17 hours [FDA label].",1 kg/1kg,Not applicable,solid,13.4 mg/mL in distilled water at 25 Â°C (disoproxil fumarate salt),1.25,0.712,18.59,4.13,[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C,,,,,0,,519.1730288,2,2,2,2,0,0
190,04/06/2019 00:00,DB00301,Flucloxacillin,Bioavailability is 50â€“70% following oral administration.,,0.75â€“1 hour,250 mg,Oral,solid,,2.58,0.0545,3.75,-0.93,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O,,,0.75,1,0,250,453.0561475,4,2,3,1,2,2
191,02/07/2019 00:00,DB00302,Tranexamic acid,Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.,0.03,Biological half-life in the joint fluid is about 3 hours.,500 mg/1,Oral,solid,1.67E+005 mg/L,0.3,18.2,4.56,10.22,NC[C@H]1CC[C@@H](CC1)C(O)=O,0.03,0.03,,,0,500,157.1102787,1,0,0,0,0,0
192,02/07/2019 00:00,DB00303,Ertapenem,"Ertapenem is almost completely absorbed following intramuscular administration. The bioavailability of a 1 g intramuscular dose approximated 92% in 26 healthy subjects [77% male; median (range) age, 29 (22â€“41) years]. Plasma concentrations of total ertapenem were similar whether given intramuscularly or intravenously.",0.95,The mean plasma half-life is approximately 4 hours.,1 g/1,Intramuscular; Intravenous,solid,Soluble as sodium salt,0.3,0.286,3.22,9.03,[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,0.95,0.95,,,0,,475.1413211,4,1,3,0,2,3
193,04/06/2019 00:00,DB00304,Desogestrel,"After oral administration, desogestrel is rapidly absorbed and it reaches a peak concentration of 2 ng/ml after 1.5 hours. The bioavailability of desogestrel is reported to be in the range of 60-80% and the reported AUC is of 3000 ng.h/ml.[F4127] Almost all the administered dose is modified to the active metabolite, [etonogestrel].[A176423]",96-98%,The terminal half-life of desogestrel is determined to be of 30 hours.[F4127],,Oral,solid,<1 mg/ml,5.65,0.00301,17.99,-1.5,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],0.96,0.98,,,0,,310.2296656,4,0,0,0,0,0
194,02/07/2019 00:00,DB00305,Mitomycin,Erratic.,,8-48 min,0.5 mg/1mL,Intravenous,solid,Soluble (8430 mg/L),-0.4,10.1,-0.3,6.8,CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,,,0.133333333,0.8,0,,334.1277197,4,0,3,0,2,3
195,04/06/2019 00:00,DB00306,Talbutal,,,,,,solid,1810 mg/L at 25 Â°C,1.47,2.46,8.48,,CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O,,,,,0,,224.1160924,1,0,1,0,1,1
196,04/06/2019 00:00,DB00307,Bexarotene,,>99%,7 hours,75 mg/1,Oral,solid,,6.9,0.000149,4.07,,CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C,0.99,1,7,7,0,75,348.2089301,3,2,0,0,0,0
197,02/07/2019 00:00,DB00308,Ibutilide,Rapid after intravenous injection,0.4,6 hours (ranges from 2-12 hours),0.1 mg,Intravenous,solid,100 mg/mL,4.6,0.00473,9.72,10.4,CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1,0.4,0.4,,,0,,384.244664,1,1,0,0,0,0
198,04/06/2019 00:00,DB00309,Vindesine,,65-75%,24 hours.,5 mg,Intravenous,solid,,2.9,0.07,11.34,8.68,[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@@H]5C[N@@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O,0.65,0.75,24,24,0,,753.4101491,9,3,6,1,2,5
199,02/07/2019 00:00,DB00310,Chlorthalidone,,,"40-50 hours [FDA Label, A176327].",25 mg/1,Oral,solid,120 mg/L (at 20 Â°C),0.85,0.0528,8.76,-2.6,NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12,,,,,0,25,338.0128055,3,2,1,0,0,1
200,04/06/2019 00:00,DB00311,Ethoxzolamide,Rapidly absorbed with 65% bioavailability,~89%,2.5-5.5 hours,,,solid,40 mg/L,2.01,0.688,7.51,-1.9,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O,0.89,0.89,2.5,5.5,0,,258.0132842,2,2,1,1,0,0
201,04/06/2019 00:00,DB00312,Pentobarbital,"Barbiturates are absorbed in varying degrees following oral, rectal, or parenteral administration.",,5 to 50 hours (dose dependent),50 mg/1mL,Rectal,solid,679 mg/L (at 25 Â°C),2.1,0.864,8.48,,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,,,,,0,,226.1317424,1,0,1,0,1,1
202,02/07/2019 00:00,DB00313,Valproic Acid,"The intravenous and oral forms of valproic acid are expected to produce the same AUC, Cmax, and Cmin at steady-state.[label] The oral delayed-release tablet formulation has a Tmax of 4 hours. Differences in absorption rate are expected from other formulations but are not considered to be clinically important in the context of chronic therapy beyond impacting frequency of dosing. Differences in absorption may create earlier Tmax or higher Cmax values on initiation of therapy and may be affected differently by meals.[L6196] The extended release tablet formulation had Tmax increase from 4 hours to 8 hours when taken with food. In comparison, the sprinkle capsule formulation had Tmax increase from 3.3 hours to 4.8 hours. Bioavailability is reported to be approximately 90% with all oral formulations with enteric-coated forms possibly reaching 100%.[A178066]",0.1,"13-19 hours.[label]

The half-life in neonates ranges from 10-67 hours while the half-life in pediatric patients under 2 months of age ranges from 7-13 hours.",125 mg,Oral,solid,1.3 mg/mL,2.75,2.36,5.14,,CCCC(CCC)C(O)=O,0.1,0.1,,,0,125,144.1150298,0,0,0,0,0,0
203,02/07/2019 00:00,DB00315,Zolmitriptan,Mean absolute oral bioavailability is approximately 40%. Food has no affect on the rate and extent of absorption.,0.25,The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.,2.5 mg,Oral,solid,,1.6,0.19,13,9.55,CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12,0.25,0.25,,,0,2.5,287.1633769,3,2,2,1,1,1
204,02/07/2019 00:00,DB00316,Acetaminophen,"Acetaminophen has 88% oral bioavailability and reaches its highest plasma concentration 90 minutes after ingestion [A35815].
Peak blood levels of free acetaminophen are not reached until 3 hours after rectal administration of the suppository form of acetaminophen and the peak blood concentration is approximately 50% of the observed concentration after the ingestion of an equivalent oral dose (10-20 mcg/mL) [F4124].

The percentage of a systemically absorbed rectal dose of acetaminophen is inconsistent, demonstrated by major differences in the bioavailability of acetaminophen after a dose administered rectally. Higher rectal doses or an increased frequency of administration may be used to attain blood concentrations of acetaminophen similar to those attained after oral acetaminophen administration [FDA label]. ",0.1,"The half-life for adults is 2.5 h after an intravenous dose of 15 mg/kg [FDA label].   After an overdose, the half-life can range from 4 to 8 hours depending on the severity of injury to the liver, as it heavily metabolizes acetaminophen [A35815].  More information on half-life for neonates and other populations may be found on the acetaminophen FDA label [FDA label]. ",325 mg/1,Ophthalmic; Oral; Topical,solid,very slightly soluble in cold water but greater solubility in hot water,0.91,4.15,9.46,-4.4,CC(=O)NC1=CC=C(O)C=C1,0.1,0.1,,,0,325,151.0633285,1,1,0,0,0,0
205,02/07/2019 00:00,DB00317,Gefitinib,Absorbed slowly after oral administration with a mean bioavailability of 60%. Peak plasma levels occurs 3-7 hours post-administration. Food does not affect the bioavailability of gefitinib. ,0.9,48 hours [IV administration] ,250 mg,Oral,solid,Sparingly soluble (<pH4),3.2,0.027,16.11,6.85,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,0.9,0.9,,,0,250,446.1520965,4,3,2,1,1,1
206,02/07/2019 00:00,DB00318,Codeine,"**Absorption**

Codeine is absorbed from the gastrointestinal tract. The maximum plasma concentration occurs 60 minutes after administration [FDA label]. 

**Food Effects**

When 60 mg codeine sulfate was given 30 minutes post-ingestion of a high high-calorie meal, there was no significant change in the absorption of codeine [FDA label].

**Steady-state concentration**

The administration of 15 mg codeine sulfate every 4 hours for 5 days lead to steady-state concentrations of codeine, morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) within 48 hours [FDA label]. 
",7-25%,Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours [FDA label]. ,100 mg,Oral,solid,soluble in water,1.39,0.577,13.78,9.19,[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC,0.07,0.25,,,0,100,299.1521435,5,1,2,0,1,2
207,02/07/2019 00:00,DB00319,Piperacillin,Not absorbed following oral administration.,,36-72 minutes,2 g/1,Intravenous,solid,,0.3,0.119,3.49,-4.3,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O,,,0.6,1.2,0,,517.1631192,4,1,3,0,3,3
208,02/07/2019 00:00,DB00320,Dihydroergotamine,Interpatient variable and may be dependent on the administration technique,0.93,9 hours,1 mg/1mL,Intramuscular; Intravenous; Subcutaneous,solid,,2,0.229,9.71,8.39,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,0.93,0.93,9,9,0,,583.2794693,8,3,5,1,4,4
209,02/07/2019 00:00,DB00321,Amitriptyline,Rapidly absorbed following oral administration (bioavailability is 30-60% due to first pass metabolism). Peak plasma concentrations are reached 2-12 hours after oral or intramuscular administration [FDA label].  Steady-state plasma concentrations vary greatly and this variation may be due to genetic differences [F3454]. ,,The elimination half-life (t1â„2 Î²) amitriptyline after peroral administration is about 25 hours (24.65 Â± 6.31 hours; range 16.49-40.36 hours) [FDA Label].,10 mg/1,Oral,solid,freely soluble in water,4.92,0.0045,,9.76,CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,,,,,0,10,277.1830497,3,2,0,0,0,0
210,04/06/2019 00:00,DB00322,Floxuridine,,,,500 mg/5mL,Intra-arterial,solid,1.19E+004 mg/L,-1.16,40.8,7.68,-3,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O,,,,,0,,246.0651997,2,1,2,1,1,1
211,04/06/2019 00:00,DB00323,Tolcapone,Rapidly absorbed (absolute bioavailability is about 65%),0.999,2-3.5 hours,100 mg,Oral,solid,,4,0.0569,5.17,-6.4,CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O,0.999,0.999,2,3.5,0,100,273.0637225,2,2,0,0,0,0
212,02/07/2019 00:00,DB00324,Fluorometholone,,,,0.1 mL/100mL,Ophthalmic,solid,30 mg/L (at 25 Â°C),2,0.0166,12.65,-3.4,[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,,,,,0,,376.2049876,4,0,0,0,0,0
213,04/06/2019 00:00,DB00326,Calcium glucoheptonate,Rapidly absorbed following oral administration.,,,125 mg,Oral,solid,Soluble,,39.8,3.38,-3,[Ca++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O,,,,,0,125,490.0846757,0,0,0,0,0,0
214,02/07/2019 00:00,DB00327,Hydromorphone,"The immediate release version of hydromorphone reaches its peak concentration after 30-60 minutes while the extended-release version reaches the peak concentration after 9 hours.[A176468] When administered orally, hydromorphone is absorbed mainly in the upper small intestine with a bioavailability of 60% due to intensive first-pass metabolism. In the controlled-release version of hydromorphone, the absorption follows a biphasic pharmacokinetic profile. However, even though there are clear distinctions in the absorption pathway of hydromorphone, the AUC of both versions is reported to be of 34 ng.h/ml which indicates an equivalence.[A176471]

The parenteral administration of hydromorphone, which is the most common pathway, presents an almost immediate absorption as observed by the presence of peak plasma concentration almost immediately. This peak plasma concentration declines rapidly due to fast redistribution into liver, spleen, kidney and skeletal muscle. In the parenteral route, the pharmacokinetic profile is log-linear and dose-dependent and to present a higher bioavailability of 78%.[A176471]

Other administration routes such as rectal, nasal, intraspinal and transdermal present lower bioavailability and changes in their pharmacokinetic profile.[A176471]",8-19%,The half-life of hydromorphone immediate-release is of 2-3 hour while the extended release can range from 8-15 hours.[A176468],9 mg,Oral,solid,Highly soluble,1.06,4.39,10.11,8.59,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,0.08,0.19,,,0,9,285.1364935,5,1,2,0,1,2
215,02/07/2019 00:00,DB00328,Indometacin,"Indometacin displays a linear pharmacokinetics profile where the plasma concentrations and area under the curve (AUC) are dose-proportional, whereas half-life (T1/2) and plasma and renal clearance are dose-dependent.[A177871] Indometacin is readily and rapidly absorbed from the gastrointestinal tract. The bioavailability is virtually 100% following oral administration [A177871] and about 90% of the dose is absorbed within 4 hours.[L6778] The bioavailability is about 80-90% following rectal administration.[A177901]

The peak plasma concentrations following a single oral dose were achieved between 0.9 Â± 0.4 and 1.5 Â± 0.8 hours in a fasting state.[A177901] Despite large intersubject variation as well using the same preparation, peak plasma concentrations are dose-proportional and averaged 1.54 Â± 0.76 Î¼g/mL, 2.65 Â± 1.03 Î¼g/mL, and 4.92 Â± 1.88 Î¼g/mL following 25 mg, 50 mg, and 75 mg single doses in fasting subjects, respectively.[A177901] With a typical therapeutic regimen of 25 or 50 mg t.i.d., the steady-state plasma concentrations of indomethacin are an average 1.4 times those following the first dose.[L6778]",90-99%,"Indometacin disposition from the plasma is reported to be biphasic, with a half-life of 1 hour during the initial phase and 2.6â€“11.2 hours during the second phase.[A177949] Interindividual and intraindividual variations are possible due to the extensive and sporadic nature of the enterohepatic recycling and biliary discharge of the drug.[A177874,A177949]

The mean half-life of oral indomethacin is estimated to be about 4.5 hours.[L6778] The disposition of intravenous indometacin in preterm neonates was shown to vary across premature infants. In neonates older than 7 days, the mean plasma half-life of intravenous indometacin was approximately 20 hours, ranging from 15 hours in infants weighing more than 1000 g and 21 hours in infants weighing less than 1000 g.[F4600]",75 mg,Oral,solid,0.937 mg/L (at 25 Â°C),4.27,0.0024,3.79,-2.9,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,0.9,0.99,,,0,75,357.0767857,3,3,1,1,0,0
216,02/07/2019 00:00,DB00330,Ethambutol,About 75% to 80% of an orally administered dose of ethambutol is absorbed from the gastrointestinal tract.,20-30%,"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.",400 mg/1,Oral,solid,,-0.3,7.58,14.82,9.55,CC[C@@H](CO)NCCN[C@@H](CC)CO,0.2,0.3,,,0,400,204.183778,0,0,0,0,0,0
217,02/07/2019 00:00,DB00331,Metformin,"
**Regular tablet absorption**

The absolute bioavailability of a metformin 500 mg tablet administered in the fasting state is about 50%-60%. Single-dose clinical studies using oral doses of metformin 500 to 1500 mg and 850 to 2550 mg show that there is a lack of dose proportionality with an increase in metformin dose, attributed to decreased absorption rather than changes in elimination [FDA label]. 

At usual clinical doses and dosing schedules of metformin, steady-state plasma concentrations of metformin are achieved within 24-48 hours and are normally measured at <1 Î¼g/mL [FDA label].

**Extended-release tablet absorption**

After a single oral dose of metformin extended-release, Cmax is reached with a median value of 7 hours and a range of between 4 and 8 hours. Peak plasma levels are measured to be about 20% lower compared to the same dose of regular metformin, however, the extent of absorption of both forms (as measured by area under the curve - AUC), are similar [FDA label].

**Effect of food**

Food reduces the absorption of metformin, as demonstrated by about a 40% lower mean peak plasma concentration (Cmax), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute increase in time to peak plasma concentration (Tmax) after ingestion of an 850 mg tablet of metformin taken with food, compared to the same dose administered during fasting [FDA label].

Though the extent of metformin absorption (measured by the area under the curve - AUC) from the metformin extended-release tablet is increased by about 50% when given with food, no effect of food on Cmax and Tmax of metformin is observed. High and low-fat meals exert similar effects on the pharmacokinetics of extended-release metformin [FDA label]. ",0.9,"Approximately 6.2 hours in the plasma [FDA label] and in the blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution [FDA label].",500 mg/1,Oral,solid,2g of metformin hydrochloride is soluble in 10mL of  water,-2.6,1.38,,12.33,CN(C)C(=N)NC(N)=N,0.9,0.9,,,0,500,129.1014454,0,0,0,0,0,0
218,02/07/2019 00:00,DB00332,Ipratropium,"Ipratropium is a topically active but poorly absorbed agent.[T539] The lack of absorption potential in the mucosal surfaces is associated with the presence of a charge in the 5-valent nitrogen. The molecule itself presents very large topic effectiveness however, it does not produce detectable blood levels nor systemic effects.[T542]

Serum levels of ipratropium after oral or inhaled administration are very low, corresponding to only 1-2% of the administered dose. These low levels peak after 1-2 hours and it presents a low bioavailability of 2%.[T542]",0-9%,Ipratropium presents a short half-life of about 1.6 hours.[A176945],250 mcg,Respiratory (inhalation),solid,Freely soluble,0.038,0.00122,15.15,-2.7,[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C,0.009,0.009,,,1,,332.2220202,3,1,2,0,2,2
219,02/07/2019 00:00,DB00333,Methadone,Well absorbed following oral administration. The bioavailability of methadone ranges between 36 to 100%.,(85%,24-36 hours,1 mg,Oral,solid,,3.93,0.0059,19.79,9.12,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,0.85,0.85,24,36,0,1,309.2092645,2,2,0,0,0,0
220,02/07/2019 00:00,DB00334,Olanzapine,"Olanzapine presents a linear pharmacokinetic profile and, after daily administration, it reaches steady-state in about a week.[A177014] Under the administration of a normal dosage of olanzapine, the steady-state plasma concentration does not seem to exceed 150 ng/ml with an AUC of 333 ng/h/ml.[A177059, T554]

The absorption of olanzapine is not affected by the concomitant administration of food. The pharmacokinetic profile of olanzapine is characterized by reaching peak plasma concentration of 156.9 ng/ml approximately 6 hours after oral administration.[T548]",0.93,Olanzapine presents a half-life ranging between 21 to 54 hours with an average half-life of 30 hours.[A177014],10.0 mg,Oral,solid,Partly miscible ,4.094,0.0942,14.17,7.24,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,0.93,0.93,,,0,10,312.1408676,4,2,3,1,1,2
221,02/07/2019 00:00,DB00335,Atenolol,"Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, with the remainder being excreted unchanged in the feces.[label] Administering atenolol with food can decrease the AUC by about 20%.[A178180] While atenolol can cross the blood-brain barrier, it does so slowly and to a small extent.",6-16%,6-7 hrs.[label],100 mg/1,Oral,solid,1.33E+004 mg/L (at 25 Â°C),0.16,0.429,14.08,9.67,CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1,0.06,0.16,6,7,0,100,266.1630426,1,1,0,0,0,0
222,04/06/2019 00:00,DB00336,Nitrofural,Well absorbed.,,5 hours,,,solid,210 mg/L (at 25 Â°C),0.23,0.268,11.79,-2,NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O,,,5,5,0,,198.0389047,1,1,1,1,0,0
223,02/07/2019 00:00,DB00337,Pimecrolimus,"Because of the low systemic absorption of pimecrolimus following topical application the calculation of standard pharmacokinetic measures such as AUC, C<sub>max</sub>, half-life, etc. cannot be reliably done.",74%-87%,,0.01,Topical,solid,,4.4,0.00152,9.96,-2.9,[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC,0.74,0.87,,,0,,809.4480897,4,0,3,0,2,3
224,02/07/2019 00:00,DB00338,Omeprazole,"Omeprazole delayed-release capsules contain an enteric-coated granule formulation of omeprazole (because omeprazole is acid-labile), so that absorption of omeprazole begins only after the granules exit the stomach [FDA label]. 

Absorption of omeprazole occurs rapidly, with peak plasma concentrations of omeprazole achieved within 0.5-3.5 hours [FDA label]. 

Absolute bioavailability (compared with intravenous administration) is approximately 30-40% at doses of 20-40 mg, largely due to pre-systemic metabolism. The bioavailability of omeprazole increases slightly upon repeated administration of omeprazole delayed-release capsules [FDA label].",0.95,"0.5-1 hour (healthy subjects, delayed-release capsule) [FDA label]  
Approximately 3 hours (hepatic impairment) [FDA label] ",20 mg,Oral,solid,0.359 mg/ml,2.23,0.359,9.29,4.77,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C,0.95,0.95,,,0,20,345.1147125,3,3,2,2,0,0
225,02/07/2019 00:00,DB00339,Pyrazinamide,Rapidly and well absorbed from the gastrointestinal tract.,~10%,9-10 hours (normal conditions),500 mg,Oral,solid,1.5E+004 mg/L (at 25 Â°C),-0.6,93.7,13.06,-0.68,NC(=O)C1=NC=CN=C1,0.1,0.1,,,0,500,123.0432618,1,1,1,1,0,0
226,04/06/2019 00:00,DB00340,Metixene,"Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.",,,,,liquid,Soluble as HCl salt,4.7,0.000102,,9.34,CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1,,,,,0,,309.1551207,4,2,2,0,1,2
227,02/07/2019 00:00,DB00341,Cetirizine,"Cetirizine was rapidly absorbed with a time to maximum concentration (Tmax) of about 1 hour after oral administration of tablets or syrup formulation in adult volunteers [FDA label]. Bioavailability was found to be similar between the tablet and syrup dosage forms. When healthy study volunteers were given several doses of cetirizine (10 mg tablets once daily for 10 days), a mean peak plasma concentration (Cmax) of 311 ng/mL was measured [FDA label]. 

**Effect of food on absorption**

Food had no effect on cetirizine exposure (AUC), however, Tmax was delayed by 1.7 hours and Cmax was decreased by 23% in the fed state [FDA label]. ",0.93,Plasma elimination half-life is 8.3 hours [FDA label]. ,10 mg/1,Oral,solid,101 mg/L,2.8,0.0658,3.6,7.79,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,0.93,0.93,,,0,10,388.1553703,3,2,1,0,1,1
228,04/06/2019 00:00,DB00342,Terfenadine,On the basis of a mass balance study using 14C labeled terfenadine the oral absorption of terfenadine was estimated to be at least 70%,0.7,3.5 hours,120 mg,Oral,solid,0.0963 mg/L (at 25 Â°C),7.1,0.000458,13.2,9.02,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,0.7,0.7,3.5,3.5,0,120,471.3137296,4,3,1,0,1,1
229,02/07/2019 00:00,DB00343,Diltiazem,"Diltiazem is readily absorbed from the gastrointestinal tract. Minimum therapeutic plasma diltiazem concentrations appear to be in the range of 50 to 200 ng/mL.[label] Following oral administration of extended formulations of 360 mg diltiazem, the drug in plasma was detectable within 3 to 4 hours and the peak plasma concentrations were reached between 11 and 18 hours post-dose. Diltiazem peak and systemic exposures were not affected by concurrent food intake.[label] Due to hepatic first-pass metabolism, the absolute bioavailability following oral administration is about 40%[label], with the value ranging from 24 to 74% due to high interindividual variation in the first pass effect.[A178420] The bioavailability may increase in patients with hepatic impairment.[label] ",70-80%,The plasma elimination half-life is approximately 3.0 - 4.5 hours following single and multiple oral doses. The half-life may slightly increase with dose and the extent of hepatic impairment.[label] The apparent elimination half-life for diltiazem as extended-release tablets after single or multiple dosing is 6 to 9 hours.[label] The plasma elimination half-life is approximately 3.4 hours following administration of a single intravenous injection.[L6292],120 mg,Oral,solid,465 mg/L,2.8,0.0168,12.86,8.18,COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,0.7,0.8,,,0,120,414.1613283,3,2,1,0,0,1
230,04/06/2019 00:00,DB00344,Protriptyline,,,,10 mg/1,Oral,solid,1.04 mg/L,4.7,0.000231,,10.54,CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12,,,,,0,10,263.1673997,3,2,0,0,0,0
231,04/06/2019 00:00,DB00345,Aminohippuric acid,,,,0.2,Intravenous,solid,Slightly soluble,-2.2,3.13,2.7,4.24,NC1=CC=C(C=C1)C(=O)NCC(O)=O,,,,,0,,194.0691422,1,1,0,0,0,0
232,02/07/2019 00:00,DB00346,Alfuzosin,Absorption is 50% lower under fasting conditions,82%-90%,10 hours,10 mg/1,Oral,solid,,1.4,0.282,14.64,7.3,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1,0.82,0.9,10,10,0,10,389.2063043,3,2,2,1,1,1
233,04/06/2019 00:00,DB00347,Trimethadione,,0.9,,150 mg/1,Oral,solid,5E+004 mg/L,0,212,,,CN1C(=O)OC(C)(C)C1=O,0.9,0.9,,,0,150,143.0582431,1,0,1,0,1,1
234,02/07/2019 00:00,DB00348,Nitisinone,The capsule and liquid formulations are bioequivalent in both the plasma concentration-time curve and maximum plasma concentration (Cmax).,,~54 hours,10 mg,Oral,solid,,1.6,0.00811,2.71,-7.3,[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O,,,54,54,0,10,329.0511071,2,1,0,0,0,0
235,02/07/2019 00:00,DB00349,Clobazam,"After oral administration of clobazam, it is almost completely absorbed (87% of dose). Bioavailability relative to solution was almost at 100%. Food does not affect absorption. 
Tmax = 1-3 hours.",,"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy. ",2.5 mg/1mL,Oral,solid,188 mg/L,2.12,0.164,4.07,-6.7,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,,,,,0,,300.0665553,3,2,1,0,0,1
236,02/07/2019 00:00,DB00350,Minoxidil,Minoxidil is at least 90% absorbed from the GI tract in experimental animals and man.,,4.2 hours,0.02,Topical,solid,2200 mg/L,1.24,19.9,14.22,4.34,NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1,,,4.2,4.2,0,,209.1276601,2,1,2,1,1,1
237,02/07/2019 00:00,DB00351,Megestrol acetate,"Variable, but well absorbed orally.",,34 hours,20 mg/1,Oral,solid,2 Âµg/mL (at 37 Â°C for the acetate salt),3.2,0.00336,17.83,-4.9,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,,,34,34,0,20,384.2300595,4,0,0,0,0,0
238,02/07/2019 00:00,DB00352,Tioguanine,"Absorption of an oral dose is incomplete and variable, averaging approximately 30% of the administered dose (range: 14% to 46%)",,"When the compound was given in singles doses of 65 to 300 mg/m^2, the median plasma half-disappearance time was 80 minutes (range 25-240 minutes)",40 mg,Oral,solid,36.3 mg/mL,-0.07,0.834,10.53,3.7,NC1=NC(=S)C2=C(N1)N=CN2,,,,,0,40,167.0265662,2,2,2,2,0,0
239,04/06/2019 00:00,DB00353,Methylergometrine,Absorption is rapid after oral (60% bioavailability) and intramuscular (78% bioavailability) administration.,,3.39 hours,0.2 mg/1mL,Intramuscular; Intravenous,solid,25 mg/mL,1.2,0.204,15,7.93,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,,,3.39,3.39,0,,339.194677,4,2,2,1,0,1
240,04/06/2019 00:00,DB00354,Buclizine,Rapidly absorbed following oral administration.,,,,,liquid,,7.1,0.000246,,8.04,CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1,,,,,0,,432.2332267,4,3,1,0,1,1
241,02/07/2019 00:00,DB00355,Aztreonam,Less than 1% absorbed from the gastrointestinal tract following oral administration. Completely absorbed following intramuscular administration.,0.56,"The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2.0) in subjects with normal renal function, independent of the dose. In elderly patients and in patients with impaired renal function, the mean serum half-life of aztreonam increased (4.7 to 6 hours and 2.1 hours, respectively).",1 g/1,Intramuscular; Intravenous,solid,Insoluble,,0.0429,-1.9,4.14,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O,0.56,0.56,,,0,,435.0518545,2,1,2,1,1,1
242,04/06/2019 00:00,DB00356,Chlorzoxazone,,13-18%,,500 mg/1,Oral,solid,1000 mg/L,1.6,2.96,9.39,-2.2,ClC1=CC2=C(OC(=O)N2)C=C1,0.13,0.18,,,0,500,168.993056,2,2,1,1,0,0
243,04/06/2019 00:00,DB00357,Aminoglutethimide,Rapidly and completely absorbed from gastrointestinal tract. The bioavailability of tablets is equivalent to equal doses given as a solution.,21-25%,12.5 &plusmn; 1.6 hours,250 mg/1,Oral,solid,Practically insoluble in water,1.3,0.371,11.69,4.28,CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1,0.21,0.25,,,0,250,232.1211778,2,1,1,0,1,1
244,02/07/2019 00:00,DB00358,Mefloquine,Well absorbed from the gastrointestinal tract. The presence of food significantly enhances the rate and extent of absorption.,0.98,2 to 4 weeks,250 mg/1,Oral,solid,5000 mg/L (HCl salt),3.9,0.038,13.79,9.46,OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F,0.98,0.98,,,0,250,378.1166825,3,2,2,1,1,1
245,04/06/2019 00:00,DB00359,Sulfadiazine,,,,1 g/1g,Oral,solid,77 mg/L (at 25 Â°C),-0.09,0.601,6.99,2.01,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1,,,,,0,,250.0524466,2,2,1,1,0,0
246,02/07/2019 00:00,DB00360,Sapropterin,,,,100 mg,Oral,solid,>20 mg/mL (dichloride salt),-1.7,2.03,11.12,4.61,[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O,,,,,0,100,241.1174893,2,1,2,1,0,1
247,02/07/2019 00:00,DB00361,Vinorelbine,"Vinorelbine is rapidly absorbed with peak serum concentration reached within 2 hours [L1998].

Vinorelbine is highly bound to platelets and lymphocytes and is also bound to alpha 1-acid glycoprotein, albumin, and lipoproteins [A32354].",80-90%,The terminal phase half-life averaged 27.7 to 43.6 hours; the mean plasma clearances ranged from 0.97 to 1.26 L/hr/kg [A32354]. ,10 mg/1mL,Intravenous,solid,10 mg/mL in water,4,0.0122,10.87,8.66,[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC,0.8,0.9,,,0,,778.3941647,9,3,6,1,1,5
248,02/07/2019 00:00,DB00362,Anidulafungin,,0.84,40-50 hours,100 mg/30mL,Intravenous,solid,Practically insoluble,2.9,0.0564,9.46,-3.5,[H][C@]1(NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C1=O)NC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,0.84,0.84,40,50,0,,1139.506294,7,4,3,0,3,3
249,02/07/2019 00:00,DB00363,Clozapine,Rapid and almost complete,0.97,8 hours (range 4-12 hours),200 mg/1,Oral,solid,11.8 mg/L,3.23,0.186,15.9,7.35,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,0.97,0.97,,,0,200,326.1298243,4,2,2,0,1,2
250,02/07/2019 00:00,DB00364,Sucralfate,"This drug is absorbed from the gastrointestinal tract in very minimal quantities [FDA label]. The adsorbed sulfated disaccharide is excreted in the urine [F4519]. This drug contains aluminum and after the administration of 1 g of sucralfate 4 times per day, about 0.001% to 0.017% of this aluminum content is absorbed in patients with normal renal function [F4519]. This number is expected to increase in those with impaired renal function [F4519]. ",,"The half-life is not known. In animals, the elimination half-life of the sucrose component of this drug is from 6-20 h [F4537].",1000 mg,Oral,solid,Insoluble,-7.087,0.714,13.53,-3,O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O,,,,,0,1000,1447.588624,2,0,2,0,2,2
251,04/06/2019 00:00,DB00365,Grepafloxacin,Rapidly and extensively absorbed following oral administration. The absolute bioavailability is approximately 70%.,0.5,15 &plusmn; 3 hours,200 mg,Oral,solid,,2.9,0.632,5.88,8.77,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,0.5,0.5,,,0,200,359.1645198,4,2,2,1,1,1
252,02/07/2019 00:00,DB00366,Doxylamine,Readily absorbed via the gastrointestinal tract.,,10 hours,5 mg/1,Oral,liquid,1 g/ml (succinate salt),2.5,0.541,,8.87,CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1,,,10,10,0,5,270.1732133,2,2,1,1,0,0
253,02/07/2019 00:00,DB00367,Levonorgestrel,"Levonorgestrel is not subjected to a ""first-pass"" effect and is virtually 100% bioavailable.",0.55,,13.5 mg,Transdermal,solid,2.05 mg/L,3.8,0.00583,17.91,-1.5,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],0.55,0.55,,,0,,312.2089301,4,0,0,0,0,0
254,02/07/2019 00:00,DB00368,Norepinephrine,,,,1 mg,Intravenous,solid,,-1.24,12.5,9.5,8.85,NC[C@H](O)C1=CC(O)=C(O)C=C1,,,,,0,,169.0738932,1,1,0,0,0,0
255,02/07/2019 00:00,DB00369,Cidofovir,1,0.06,2.4 to 3.2 hours,75 mg/1mL,Intravenous,solid,,-3.9,11.5,1.19,2.15,NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1,0.06,0.06,,,0,,279.0620218,1,1,1,1,0,0
256,02/07/2019 00:00,DB00370,Mirtazapine,"The absorption of this drug is rapid and complete.[A177826, FDA label] Due to first pass metabolism in the liver and metabolism in the gut wall, absolute bioavailability is about 50%.[FDA label,A177826] Peak blood concentrations are attained within about 2 hours after an oral dose. Food has little effect on the absorption of mirtazapine, and no dose adjustment is required if it is taken with food.[FDA label] Steady-state levels are achieved by about 5 days after the initial dose.[FDA label, A177826] Mirtazapine pharmacokinetics vary across gender and age range. Females and the elderly population have been shown to have higher blood concentrations in comparison to males and younger adults.[A177826]",0.85,"20-40 hours [FDA label, A177826]",1 kg/1kg,Not applicable,solid,slightly soluble in water,2.9,1.1,,6.67,CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1,0.85,0.85,,,0,,265.1578976,4,2,3,1,1,2
257,04/06/2019 00:00,DB00371,Meprobamate,Well absorbed from the gastrointestinal tract.,,Plasma half-life is about 10 hours.,400 mg,Oral,solid,4700 mg/L (at 25 Â°C),0.7,2.47,15.17,,CCCC(C)(COC(N)=O)COC(N)=O,,,,,0,400,218.1266571,0,0,0,0,0,0
258,04/06/2019 00:00,DB00372,Thiethylperazine,,0.6,,10 mg/2mL,Intramuscular,liquid,0.0584 mg/L,5.41,0.00487,,8.4,CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1,0.6,0.6,,,0,,399.1802899,4,2,2,0,1,2
259,02/07/2019 00:00,DB00373,Timolol,"The systemic bioavailability of the ophthalmic eyedrop in one study of healthy volunteers was 78.0 Â± 24.5% [A179539], indicating that caution must be observed when this drug is administered, as it may be significantly absorbed and have various systemic effects. Another study measured the bioavailability of timolol eyedrops to be 60% in healthy volunteers.[A179548]

The peak concentration of ophthalmic timolol in plasma, Cmax was about 1.14 ng/ml in most subjects within 15 minutes following the administration of timolol by the ophthalmic route. The mean area under the curve (AUC) was about 6.46 ng/ml per hour after intravenous injection and about 4.78 ng/ml per hour following eyedrop administration.[A179539]",,Timolol half-life was measured at 2.9 Â± 0.3 h hours in a clinical study of healthy volunteers.[A179560] ,0.0025,Ophthalmic,solid,soluble in water,1.8,0.269,14.08,9.76,[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1,,,,,0,,316.1569116,2,1,2,1,1,1
260,02/07/2019 00:00,DB00374,Treprostinil,"Relatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng per kg of body weight per min for 150 mins the AUC 0-&infin; was increased 3-fold and 5-fold respectively.",0.91,"Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.",0.125 mg/1,Oral,solid,Insoluble at 25Â°C,4.1,0.00731,3.76,-1.3,[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1,0.91,0.91,,,0,0.125,390.2406242,3,1,0,0,0,0
261,02/07/2019 00:00,DB00376,Trihexyphenidyl,Trihexyphenidyl is rapidly absorbed from the gastrointestinal tract.,,3.3-4.1 hours,2 mg,Oral,solid,,4.49,0.00314,13.84,9.32,OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1,,,3.3,4.1,0,2,301.2405646,3,1,1,0,1,1
262,02/07/2019 00:00,DB00377,Palonosetron,Low oral bioavailability.,0.62,Approximately 40 hours,0.5 mg,Oral,solid,,2.7,0.464,,7.97,[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2,0.62,0.62,,,0,0.5,296.1888634,6,1,4,0,3,4
263,04/06/2019 00:00,DB00378,Dydrogesterone,Rapidly absorbed in the gastrointestinal tract with a bioavailability of 28%.,,"Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours",,,solid,,3.4,0.00486,19.29,-4.8,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C,,,,,0,,312.2089301,4,0,0,0,0,0
264,02/07/2019 00:00,DB00379,Mexiletine,Well absorbed (bioavailability 90%) from the gastrointenstinal tract.,50-60%,10-12 hours,100 mg,Oral,solid,8.25 mg/mL,2.15,0.538,,9.52,CC(N)COC1=C(C)C=CC=C1C,0.5,0.6,10,12,0,100,179.1310142,1,1,0,0,0,0
265,02/07/2019 00:00,DB00380,Dexrazoxane,IV administration results in complete bioavailability.,,2.5 hours,500 mg/1,Intravenous,solid,Sparingly soluble,-2.6,10.4,11.2,3.6,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,,,2.5,2.5,0,,268.117155,2,0,2,0,2,2
266,02/07/2019 00:00,DB00381,Amlodipine,Amlodipine absorbed slowly and almost completely from the gastrointestinal tract. Peak plasma concentrations are achieved 6-12 hours after oral administration. The estimated bioavailability of amlodipine is 64-90%. Steady-state plasma amlodipine levels are achieved after 7-8 days of consecutive daily dosing. Absorption is not affected by food [FDA label]. ,0.98,"The terminal elimination half-life of about 30â€“50 hours [FDA label].

Plasma elimination half-life is 56 hours in patients with impaired hepatic function, titrate slowly when administering this drug to patients with severe hepatic impairment [FDA label].
",10 mg/1,Oral,solid,slightly soluble in water,3,0.0074,19.12,9.45,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,0.98,0.98,,,0,10,408.1451996,2,1,1,0,0,1
267,04/06/2019 00:00,DB00382,Tacrine,Tacrine is rapidly absorbed. Absolute bioavailability of tacrine is approximately 17%.,0.55,2 to 4 hours,10 mg/1,Oral,solid,217 mg/L,2.71,0.136,,8.95,NC1=C2CCCCC2=NC2=CC=CC=C12,0.55,0.55,,,0,10,198.1156984,3,2,1,1,0,0
268,04/06/2019 00:00,DB00383,Oxyphencyclimine,,,,,,solid,6.61 mg/L at 25 Â°C,3.7,0.0567,11.53,8.37,CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,,,,,0,,344.2099928,3,1,1,0,0,1
269,02/07/2019 00:00,DB00384,Triamterene,"Triamterene is shown to be rapidly absorbed in the gastrointestinal tract [T28] [Label] Its onset of action achiveved within 2 to 4 hours after oral ingestion [Label] and its duration of action is 12-16 hours.[T28] It is reported that the diuretic effect of triamterene may not be observed for several days after administration.[Label] In a pharmacokinetic study, the oral bioavailability of triamterene was determined to be 52%.[A178012] Following administration of a single oral dose to fasted healthy male volunteers, the mean AUC of triamterene was about 148.7 ng*hr/mL [L6169] and the mean peak plasma concentrations (Cmax) were 46.4 ng/mL reached at 1.1 hour after administration.[L6169] In a limited study, administration of triamterene in combination with hydrochlorothiazide resulted in an increased bioavailability of triamterene by about 67% and a delay of up to 2 hours in the absorption of the drug.[L6169] It is advised that triamterene is administered after meals; in a limited study, combination use of triamterene and hydrochlorothiazide with the consumption of a high-fat meal resulted in an increase in the mean bioavailability and peak serum concentrations of triamterene and its active sulfate metabolite, as well as a delay of up to 2 hours in the absorption of the active constituents.[L6169]",0.67,"The half-life of the drug in plasma ranges from 1.5 to 2 hours.[L6193] In a pharmacokinetic study involving healthy volunteers, the terminal half-lives for triamterene and 4â€²-hydroxytriamterene sulfate were 255 Â± 42 and 188 Â± 70 minutes, respectively, after intravenous infusion of the parent drug.[A577,L6163] ",100 mg/1,Oral,solid,Very slightly soluble in water (<0.1%),0.98,0.963,15.88,3.11,NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1,0.67,0.67,,,0,100,253.1075934,3,3,2,2,0,0
270,02/07/2019 00:00,DB00385,Valrubicin,,>99%,,40 mg/1mL,Intravesical,solid,insoluble,2.2,0.0325,8,-3.4,[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1,0.99,1,,,0,,723.2138749,5,2,1,0,1,1
271,02/07/2019 00:00,DB00387,Procyclidine,,1,,5 mg/1,Oral,solid,"Moderately soluble in water, ~ 30 mg/ml",4.2,0.00984,13.84,9.45,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1,1,1,,,0,5,287.2249145,3,1,1,0,1,1
272,02/07/2019 00:00,DB00388,Phenylephrine,"Completely absorbed after oral administration. It has a reduced bioavailability (compared to pseudoephedrine) following oral administration due to significant first-pass metabolism in the intestinal wall. Compared to IV administration, bioavailability is approximately 38%. Peak serum concentrations are achieved approximately 0.75-2 hours following oral administration. Phenylephrine should be administered parenterally to achieve cardiovascular effects. Occasionally, systemic effects are observed following oral inhalation. ",0.95,2.1 to 3.4 hours,10 mg,Not applicable,solid,Freely soluble in water,-0.31,22,9.07,9.69,CNC[C@H](O)C1=CC(O)=CC=C1,0.95,0.95,,,0,,167.0946287,1,1,0,0,0,0
273,04/06/2019 00:00,DB00389,Carbimazole,,0.85,,,,solid,,0.4,3.14,,-3,CCOC(=O)N1C=CN(C)C1=S,0.85,0.85,,,0,,186.0462986,1,1,1,1,0,0
274,02/07/2019 00:00,DB00390,Digoxin,"Digoxin is approximately 70-80% absorbed in the first part of the small bowel.[A178228]  The bioavailability of an oral dose varies from 50-90%, however, oral gelatinized capsules of digoxin are reported to have a bioavailability of 100%.[A178252] Tmax, or the time to reach the maximum concentration of digoxin was measured to be 1.0 h in one clinical study of healthy patients taking 0.25 mg of digoxin with a placebo.[A178369] Cmax, or maximum concentration, was 1.32 Â± 0.18 ng/mlâˆ’1 in the same study, and AUC (area under the curve) was 12.5 Â± 2.38 ng/mlâˆ’1.[A178369]
If digoxin is ingested after a meal, absorption is slowed but this does not change the total amount of absorbed drug. If digoxin is taken with meals that are in fiber, absorption may be decreased.[L6274]

**A note on gut bacteria**

An oral dose of digoxin may be transformed into pharmacologically inactive products by bacteria in the colon. Studies have indicated that 10% of patients receiving digoxin tablets will experience the degradation of at least 40% of an ingested dose of digoxin by gut bacteria. Several antibiotics may increase the absorption of digoxin in these patients, due to the elimination of gut bacteria, which normally cause digoxin degradation.[L6775] 

**A note on malabsorption**

Patients with malabsorption due to a variety of causes may have a decreased ability to absorb digoxin.[L6775] P-glycoprotein, located on cells in the intestine, may interfere with digoxin pharmacokinetics, as it is a substrate of this efflux transporter. P-glycoprotein can be induced by other drugs, therefore reducing the effects of digoxin by increasing its efflux in the intestine.[L6775] ",,"Digoxin has a half-life of 1.5-2 days in healthy subjects.[L6775] The half-life in patients who do not pass urine, usually due to renal failure, is prolonged to 3.5-5 days.  Since most of the drug is distributed extravascularly, dialysis and exchange transfusion are not optimal methods for the removal of digoxin.[L6775]",0.25 mg/1mL,Intramuscular; Intravenous,solid,64.8 mg/L (at 25 Â°C),2.37,0.127,7.15,-3,[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1,,,,,0,,780.4296067,8,0,4,0,3,4
275,04/06/2019 00:00,DB00391,Sulpiride,Sulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences. ,,6 to 8 hours,,,solid,2280 mg/L,0.57,0.537,10.24,8.39,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O,,,,,0,,341.1409272,2,1,1,0,1,1
276,02/07/2019 00:00,DB00392,Profenamine,Well-absorbed from the gastrointestinal tract.,0.93,1 to 2 hours,50 mg,Oral,solid,0.693 mg/L,5.2,0.00524,,9.6,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12,0.93,0.93,,,0,50,312.1660198,3,2,1,0,0,1
277,02/07/2019 00:00,DB00393,Nimodipine,"In humans, nimodipine is rapidly absorbed after oral administration, and peak concentrations are generally attained within one hour. Bioavailability is 100% following intravenous administration and 3-30% following oral administration due to extensive first-pass metabolism. ",0.95,1.7-9 hours,30 mg/1,Oral,solid,,3.05,0.012,,5.41,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C,0.95,0.95,1.7,9,0,30,418.1740012,2,1,1,0,0,1
278,02/07/2019 00:00,DB00394,Beclomethasone dipropionate,"Following oral inhalation of 320 mcg of beclomethasone dipropionate, the Cmax was 88 pg/mL and it was reached after 0.5 at post-administration. The mean Cmax of the major and most active metabolite, beclomethasone-17-monopropionate (17-BMP), was 1419 pg/mL at 0.7 hour post-dosing.[L6871]",94-96%,2.8 hours,100 mcg,Respiratory (inhalation),solid,,3.49,0.00208,13.85,-3.3,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,0.94,0.96,2.8,2.8,0,,520.2227812,4,0,0,0,0,0
279,04/06/2019 00:00,DB00395,Carisoprodol,The absolute bioavailability of carisoprodol has not yet been established. The mean time to peak plasma concentrations (Tmax) of this drug was about 1.5-2 hours in clinical studies [FDA label]. Co-administration of a fatty meal with carisoprodol (350 mg tablet) had no impact on carisoprodol pharmacokinetics [FDA label]. ,0.6,The terminal half-life is approximately 2 hours [FDA label]. ,350 mg/1,Oral,solid,slightly soluble,2.1,0.792,15.06,,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,0.6,0.6,,,0,350,260.1736072,0,0,0,0,0,0
280,02/07/2019 00:00,DB00396,Progesterone,"**Oral micronized capsules**

Following oral administration of progesterone in the micronized soft-gelatin capsule formulation, peak serum concentration was achieved in the first 3 hours. The absolute bioavailability of micronized progesterone is unknown at this time.  In postmenopausal women, serum progesterone concentration increased in a dose-proportional and linear fashion after multiple doses of progesterone capsules, ranging from 100 mg/day to 300 mg/day [FDA label]. 

**IM administration**

After intramuscular (IM) administration of 10 mg of progesterone in oil, the maximum plasma concentrations were achieved in about 8 hours post-injection and plasma concentrations stayed above baseline for approximately 24 hours post-injection. Injections of 10, 25, and 50 mg lead to geometric mean values for maximum plasma concentration (CMAX) of 7, 28, and 50 ng/mL, respectively [F3916]. Progesterone administered by the intramuscular (IM) route avoids significant first-pass hepatic metabolism. As a result, endometrial tissue concentrations of progesterone achieved with IM administration are higher when compared with oral administration. Despite this, the highest concentrations of progesterone in endometrial tissue are reached with vaginal administration [A175657]. 

**Note on oral contraceptive tablet absorption**

Serum progestin levels peak about 2 hours after oral administration of progesterone-only contraceptive tablets, followed by rapid distribution and elimination. By 24 hours after drug administration, serum levels remain near the baseline, making efficacy dependent upon strict adherence to the dosing schedule. Large variations in serum progesterone levels occur among individuals. Progestin-only administration leads to lower steady-state serum progestin levels and a shorter elimination half-life than concurrent administration with estrogens [F3904].   ",96%-99%,"Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes (progesterone gel) [F3898].  

Progesterone, administered orally, has a short serum half-life (approximately 5 minutes). It is rapidly metabolized to _17-hydroxyprogesterone_ during its first pass through the liver [A175657]. 

",50 mg,Intramuscular,solid,<0.1 g/100 mL at 19 ÂºC,3.87,0.00546,18.47,-4.8,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.96,0.99,,,0,,314.2245802,4,0,0,0,0,0
281,04/06/2019 00:00,DB00397,Phenylpropanolamine,Reduced bioavailability (about 38%) from gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver.,,2.1 to 3.4 hours.,,Oral,solid,Freely soluble,0.67,20.6,13.9,9.37,[H][C@@](C)(N)[C@]([H])(O)C1=CC=CC=C1,,,,,0,,151.099714,1,1,0,0,0,0
282,02/07/2019 00:00,DB00398,Sorafenib,"The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. Sorafenib reached peak plasma levels in 3 hours following oral administration. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state.",0.995,25-48 hours,200 mg,Oral,solid,Insoluble,3.8,0.00171,11.55,2.03,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,0.995,0.995,25,48,0,200,464.0863027,3,3,1,1,0,0
283,02/07/2019 00:00,DB00399,Zoledronic acid,Poorly absorbed (oral absorption is about 1% of what intravenous absorption is).,0.22,146 hours,5 mg/100ml,Intravenous,solid,Sparingly soluble,-4.2,3.27,0.66,6.67,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O,0.22,0.22,146,146,0,,271.9963239,1,1,1,1,0,0
284,04/06/2019 00:00,DB00400,Griseofulvin,Poorly absorbed from GI ranging from 25 to 70% of an oral dose. Absorption is significantly enhanced by administration with or after a fatty meal.,,9-21 hours,330 mg,Oral,solid,8.64 mg/L (at 25 Â°C),2.18,0.0504,17.69,-4.3,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,,,9,21,0,330,352.0713659,3,1,1,0,0,1
285,04/06/2019 00:00,DB00401,Nisoldipine,Relatively well absorbed into the systemic circulation with 87% of the radiolabeled drug recovered in urine and feces. The absolute bioavailability of nisoldipine is about 5%.,0.99,7-12 hours,17 mg/1,Oral,solid,,3.26,0.00577,,5.32,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C,0.99,0.99,7,12,0,17,388.1634365,2,1,1,0,0,1
286,02/07/2019 00:00,DB00402,Eszopiclone,"Eszopiclone is rapidly absorbed and the peak concentration is reached within about 1 hour after oral administration.[A179659,L6769] The mean AUC after a 3 mg dose of eszopiclone was 278 ng/mL Ã— h.[A179638] The consumption of a high-fat has been shown to slow absorption.  Steady-state concentrations of eszopiclone are reached within 24-48 hours.[A179662]",52-59%,"The half-life is 6.1 hours in healthy patients but is prolonged in various patients, including those with hepatic impairment, elderly patients, in addition to those taking CYP3A enzyme inhibiting drugs.[A179638,L6769]",1 mg/1,Oral,solid,soluble in water,0.81,0.885,13.04,6.89,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1,0.52,0.59,,,0,1,388.1050661,4,2,4,2,1,2
287,04/06/2019 00:00,DB00403,Ceruletide,Absorbed following intravenous administration.,,,,,solid,,-0.9,0.0116,-2,,[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,,,,,0,,1351.448538,5,4,2,1,1,1
288,02/07/2019 00:00,DB00404,Alprazolam,"Oral bioavailability of a standard release tablet of alprazolam is 84-91% with a time to maximum concentration of 1.8 hours.[A177925] A 1mg oral dose of alprazolam leads to a maximum plasma concentration of 12-22mcg/L.[A177925] Alprazolam is rapidly absorbed in the gastrointestinal tract.[A177925]

Data for the area under the curve and the effect of taking alprazolam with food are not readily available.[Label]",0.8,"11.2 hours in healthy patients.[Label] The half life is 16.3h in the elderly, 5.8-65.3h in patients with alcoholic liver disease, 9.9-40.4h in obese patients.[Label] The half life is 25% higher in Asian patients compared to Caucasians.[Label] Other studies have shown the half life to be 9-16h.[A177925]",1 mg/1mL,Oral,solid,,,0.0324,18.3,5.08,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,0.8,0.8,,,0,,308.0828741,4,3,2,1,0,1
289,04/06/2019 00:00,DB00405,Dexbrompheniramine,Antihistamines are well absorbed from the gastrointestinal tract after oral administration.,,25 hours,2 mg/1,Oral,solid,,3.4,0.0127,,9.48,CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1,,,25,25,0,2,318.0731607,2,2,1,1,0,0
290,02/07/2019 00:00,DB00406,Gentian violet cation,,,,1 g/100mL,Topical,solid,4 mg/mL,3.18,0.00193,,4.83,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C,,,,,1,,372.2434244,3,2,0,0,0,0
291,02/07/2019 00:00,DB00408,Loxapine,Systemic bioavailability of the parent drug was only about one third that after an equivalent intramuscular dose (25 mg base) in male volunteers,,Oral-4 hours,10 mg/1,Respiratory (inhalation),solid,,3.6,0.103,,7.18,CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2,,,4,4,0,,327.1138399,4,2,2,0,1,2
292,04/06/2019 00:00,DB00409,Remoxipride,Rapidly absorbed. Absolute bioavailability is 90%.,89-98%,4-7 hours,,,solid,74 mg/L,2.1,0.127,13.06,8.4,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC,0.89,0.98,4,7,0,,370.0892047,2,1,1,0,1,1
293,02/07/2019 00:00,DB00410,Mupirocin,"Systemic or percutaneous absorption of mupirocin following dermal application is expected to be minimal in adults and children.[label] Occlusive dressings do not significantly enhance drug absorption, but damaged skin may allow enhanced penetration of the drug across the skin barrier.[A178552]",,"In healthy male volunteers, the elimination half-life of mupirocin was about 20 to 40 minutes following intravenous administration. The elimination half-life of monic acid was about 30 to 80 minutes.[L6349]",20 mg/1g,Topical,solid,,,0.0265,4.83,-2.7,C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O,,,,,0,,500.298533,2,0,2,0,2,2
294,02/07/2019 00:00,DB00411,Carbamoylcholine,Carbachol displays limited absorption from the gastrointestinal tract and it is not reported to cross the blood-brain barrier.,,,.25 mg,Subcutaneous,solid,1 g/ml,-3.78,0.706,15.23,,C[N+](C)(C)CCOC(N)=O,,,,,1,,147.1128041,0,0,0,0,0,0
295,02/07/2019 00:00,DB00412,Rosiglitazone,"The absolute bioavailability of rosiglitazone is 99%. Peak plasma concentrations are observed about 1 hour after dosing. Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in C<sub>max</sub> and a delay in T<sub>max</sub> (1.75 hours). These changes are not likely to be clinically significant; therefore, rosiglitazone may be administered with or without food. Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range. ",0.998,"3-4 hours (single oral dose, independent of dose) ",2 mg,Oral,solid,,2.4,0.038,6.84,6.23,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1,0.998,0.998,,,0,2,357.1147125,3,2,2,1,1,1
296,02/07/2019 00:00,DB00413,Pramipexole,"The bioavailability of pramipexole is higher than 90%, indicating a high level of absorption [FDA label]. ",0.15,About 8.5-12 hours [FDA label]. ,0.75 mg,Oral,solid,freely soluble in water,1.42,0.14,17.66,10.31,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,0.15,0.15,,,0,0.75,211.1143185,2,1,1,1,0,0
297,04/06/2019 00:00,DB00414,Acetohexamide,Rapidly absorbed from the GI tract.,0.9,Elimination half-life of the parent compound is 1.3 hours and the elimination half-life of the active metabolite is approximately 5-6 hours.,500 mg,Oral,solid,3430 mg/L (at 37 Â°C),2.44,0.0483,4.31,-7.4,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,0.9,0.9,,,0,500,324.1143781,2,1,0,0,0,0
298,02/07/2019 00:00,DB00415,Ampicillin,,,,250 mg/1,Oral,solid,1.01E+004 mg/L (at 21 Â°C),1.35,0.605,3.24,7.44,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,,,,,0,250,349.1096271,3,1,2,0,2,2
299,04/06/2019 00:00,DB00416,Metocurine Iodide,,0.35,3 to 4 hours,2 mg,Intravenous,solid,,,0.000123,12.99,-4.3,[I-].[I-].[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,0.35,0.35,,,0,,906.1601833,8,4,4,0,0,4
300,02/07/2019 00:00,DB00417,Phenoxymethylpenicillin,"Upon oral administration, phenoxymethylpenicillin is rapidly but incompletely absorbed.[A178612] The bioavailability of phenoxymethylpenicillin ranges from 25 to 60%.[A178618] Compared to the free acid form of the drug, the calcium or potassium salts of phenoxymethylpenicillin displays better absorption profiles. It is reported that fasting state enhances the drug absorption. The peak plasma concentrations of 200 to 700 ng/mL are achieved in 2 hours following an oral dose of 125 mg. Following an oral dose of 500 mg, the peak plasma concentrations of 3 to 5 Î¼g/mL are reached in 30 to 60 minutes post-dose.[L6412]",50-80%,"Upon oral administration, the half-life is about 30 minutes. It can last up to 4 hours in patients with renal impairment.[L6412]",125 mg,Oral,solid,<0.1 g/100mL,2.09,0.454,3.39,-4.9,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O,0.5,0.8,,,0,125,350.0936427,3,1,2,0,2,2
301,02/07/2019 00:00,DB00418,Secobarbital,,,,100 mg,Oral,solid,550 mg/L,1.97,1.21,8.48,,CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O,,,,,0,100,238.1317424,1,0,1,0,1,1
302,02/07/2019 00:00,DB00419,Miglustat,Mean oral bioavailability is 97%.,,The effective half-life of miglustat is approximately 6 to 7 hours.,100 mg/1,Oral,solid,Highly soluble in water (>1000 mg/mL as a free base).,-0.6,331,12.9,8.49,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,,,,,0,100,219.1470582,1,0,1,0,1,1
303,04/06/2019 00:00,DB00420,Promazine,Absorption may be erratic and peak plasma concentrations show large interindividual differences.,0.94,,50 mg,Intramuscular; Intravenous,liquid,14.2 mg/L (at 24 Â°C),4.55,0.0207,,9.2,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12,0.94,0.94,,,0,,284.1347196,3,2,1,0,0,1
304,02/07/2019 00:00,DB00421,Spironolactone,"Spironolactone reaches a maximum concentration in 2.6 hours and an active metabolite (canrenone) reaches a maximum concentration in 4.3 hours.[Label] When taken with food, the bioavailability of spironolactone increases to 95.4%.[Label]

Giving spironolactone with food increases the maximum concentration from 209ng/mL to 301ng/mL.[A178165] The time to maximum concentration also increases from 2.28 hours to 3.05 hours.[A178165] The area under the curve varies from 2103ng/mL\*hr to 4544ng/mL*hr.[A178165]",0.98,"1.4 hours.[Label,A178192]

Canrenone has a half life of 16.5 hours, 7-Î±-thiomethylspirolactone has a half life of 13.8 hours, and 6-ÃŸ-hydroxy-7-Î±-thiomethylspirolactone has a half life of 15 hours.[Label,A178192]",100 mg,Oral,solid,,2.78,0.00198,18.01,-4.9,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O,0.98,0.98,,,0,100,416.2021305,5,0,1,0,1,1
305,02/07/2019 00:00,DB00422,Methylphenidate,"ConcertaÂ®: Methylphenidate is readily absorbed. Following oral administration of Concerta, plasma methylhphenidate concentrations reach an initial maximum at about 1 hour followed by gradual ascending concentrations over the next 5-9 hours. Mean times to reach peak plasma concentrations across all doses of Concerta occurred between 6-10 hours. Once daily dosing minimizes the fluctuations between peak and trough concentrations associated with multiple doses of immediate-release methylphenidate treatments[F4474]. Depending on the doses provided, Cmax was found to range from 6.0-15.0ng/mL, Tmax ranged from 8.1-9.4h, and AUC ranged from 50.4-121.5 ngÂ·h/mL in children[F4474].

When provided as ConcertaÂ®, methylphenidate is released through the patented Osmotic Controlled-Release Oral Delivery (OROS) system where 22% of the dose is provided as an immediate release and 78% is provided through a gradual release[A631]. OROS is comprised of an osmotically active trilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat. Within an aqueous environment, such as the stomach, the drug overcoat, which consists of 22% of the dose, dissolves within one hour, providing an initial immediate-release formulation of methylphenidate. Water then permeates through the membrane into the tablet core where the osmotically active polymer excipients expand, allowing methylphenidate to release slowly through the orifice over a period of 6-7 hours. Concerta also provides a sustained 10-12 hour effect, allowing for once-daily dosing.


BiphentinÂ®: Methylphenidate is rapidly and extensively absorbed following oral administration, with peak blood levels obtained in 1-3 hours[F4480].

When provided as BiphentinÂ®, methylphenidate is released through a multi-layer release delivery system (MLRTM) where 40% of the dose is provided as an immediate release and 60% is provided through a gradual release. Biphentin was designed to be an alternative to separate doses of immediate-release (IR) methylphenidate by providing a biphasic concentration-time profile when given as a single dose. The MLRTM release system allows for a sustained effect for 10-12 hours, allowing for once-daily dosing that covers the major times that ADHD impairment might occur (such as school, homework periods, during the work day, etc).


Methylphenidate (immediate release): Methylphenidate hydrochloride is rapidly and extensively absorbed from the tablets following oral administration; however, owing to extensive first-pass metabolism, bioavailability is low (approx. 30%) and large individual differences exist (11-52%). In one study, the administration of methylphenidate hydrochloride with food accelerated absorption, but had no effect on the amount absorbed. Peak plasma concentrations of 10.8 and 7.8 ng/mL were observed, on average, 2 hours after administration of 0.30 mg/kg in children and adults, respectively. Peak plasma concentrations showed marked variability between subjects. Both the area under the concentration-time curve (AUC), and the peak plasma concentrations (Cmax) showed dose-proportionality [F4483].",0.05,"Concerta: The half-life of methylphenidate in adults following oral administration of ConcertaÂ® was approximately 3.5 h[F4474].

Biphentin: Methylphenidate is eliminated from plasma with a mean half-life of 2.4 hours in children and 2.1 hours in adults[F4480].

Methylphenidate (immediate release): Methylphenidate is eliminated from the plasma with a mean half-life of 2.4 hours in children and 2.1 hours in adults[F4483].
",25 mg/1,Oral,solid,1255mg/L,,0.182,,9.09,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,0.05,0.05,,,0,25,233.1415788,2,1,1,0,1,1
306,02/07/2019 00:00,DB00423,Methocarbamol,"The time to maximum concentration is 1.1 hours for both healthy patients and those on hemodialysis.[A636] The maximum plasma concentration is 21.3mg/L for healthy patients and 28.7mg/L in hemodialysis patients.[A636] The area under the curve for healthy patients is 52.5mg/L\*hr and 87.1mg/L*hr in hemodialysis patients.[A636] AUC% based on terminal elimination half life is 2% for healthy patients and 4% for hemodialysis patients.[A636]

Older studies report maximum plasma concentrations in 0.5 hours.[A178366]",46-50%,The elimination half life is 1.14 hours in healthy subjects and 1.24 hours in subjects with renal insufficiency.[A636] Older studies report half lives of 1.6-2.15 hours.[A178366],500 mg/1,Intramuscular; Intravenous,solid,2.5g/100mL,0.61,4.21,13.6,-3.4,COC1=C(OCC(O)COC(N)=O)C=CC=C1,0.46,0.5,,,0,,241.0950226,1,1,0,0,0,0
307,02/07/2019 00:00,DB00424,Hyoscyamine,Absorbed totally and completely by sublingual administration as well as oral administration.,0.5,2-3.5 hours,0.125 mg/1,Oral; Sublingual,solid,3560 mg/L (at 20 Â°C),1.8,2.52,15.15,9.39,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1,0.5,0.5,2,3.5,0,0.125,289.1677936,3,1,2,0,2,2
308,02/07/2019 00:00,DB00425,Zolpidem,"Zolpidem is rapidly absorbed from the gastrointestinal tract. In a single-dose crossover study in 45 healthy subjects given 5 and 10 mg zolpidem tartrate tablets, the average peak zolpidem concentrations (Cmax) were 59 and 121 ng/mL, respectively, occurring at a mean time (Tmax) of 1.6 hours for both doses [FDA label]. ",0.001,"The average zolpidem elimination half-life was 2.6 and 2.5 hours, for the 5 and 10 mg tablets, respectively [FDA label]. ",12.5 mg/1,Oral,solid,23 mg/mL at 20 C,3.02,0.0313,,5.65,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1,0.001,0.001,,,0,12.5,307.1684623,3,3,2,2,0,0
309,02/07/2019 00:00,DB00426,Famciclovir,0.77,20-25%,10 hours,125 mg/1,Oral,solid,,0.6,1.32,16.7,5.05,CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O,0.2,0.25,10,10,0,125,321.1437041,2,2,2,2,0,0
310,02/07/2019 00:00,DB00427,Triprolidine,Rapidly absorbed in the intestinal tract.,,4 to 6 hours.,2.5 mg/5mL,Oral,solid,74.9 mg/L,3.92,0.0537,,8.64,CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1,,,,,0,,278.1782987,3,2,2,1,1,1
311,02/07/2019 00:00,DB00428,Streptozocin,Poor oral absorption (17-25%),,5-15 minutes,100 mg/1mL,Intravenous,solid,5070 mg/L,-1.45,33.5,11.43,-3,CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,,,0.083333333,0.25,0,,265.0909998,1,0,1,0,1,1
312,02/07/2019 00:00,DB00429,Carboprost tromethamine,,,,250 ug/1mL,Intramuscular,solid,Carboprost tromethamine dissolves readily in water at room temperature at a concentration greater than 75 mg/mL.,3.3,0.0622,4.36,-1.3,OCC([NH3+])(CO)CO.CCCCC[C@@](O)(C)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)[O-],,,,,0,,489.3301675,1,0,0,0,0,0
313,04/06/2019 00:00,DB00430,Cefpiramide,Rapidly absorbed following intramuscular injection.,,4.44 hours,,,solid,,-0.9,0.0668,3.47,2.66,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O,,,4.44,4.44,0,,612.1209371,5,3,4,2,1,2
314,04/06/2019 00:00,DB00431,Lindane,Lindane is absorbed significantly through the skin. A mean peak blood concentration of 28 nanograms per mL occurred in infants and children 6 hours after total body application of lindane lotion for scabies.,0.91,18 hours,0.01,Topical,liquid,7.3 mg/L (at 25 Â°C),3.72,0.00547,,,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,0.91,0.91,18,18,0,,287.8600663,1,0,0,0,0,0
315,02/07/2019 00:00,DB00432,Trifluridine,"Systemic absorption of trifluridine following therapeutic dosing with ophthalmic trifluridine appears to be negligible [F658]. 

At least 57% of the orally-administered trifluridine is absorbed [F649]. Following twice daily oral dosing of trifluridine in combination with tipiracil, systemic exposure of trifluridine increased more than dose-proportionally over the dose range of 15 to 35 mg/m^2. Trifluridine accumulation was 3-fold for AUC0-last and 2-fold for peak plasma concentration (Cmax) at steady state [FDA Label]. The time to reach the peak plasma concentrations (Cmax) was 2 hours [FDA Label]. Tipiracil increases the AUC and Cmax of trifluridine. Food intake was shown to decrease the Cmax and AUC compared to those in a fasting state [F649].",,"The half life is 12 to 18 minutes following ophthalmic administration [F658].

After administration of trifluridine with tipiracil at oral doses 35 mg/m^2 twice daily, the mean elimination half-life (t1/2) of trifluridine was 1.4 hours following a single dose [FDA Label]. At steady state, the mean elimination half-life was 2.1 hours [FDA Label].",10 mg/1mL,Oral,solid,Soluble,-0.46,6.69,7.6,-3,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F,,,,,0,,296.0620061,2,1,2,1,1,1
316,02/07/2019 00:00,DB00433,Prochlorperazine,"Following oral administration, prochlorperazine is reported to be well absorbed from the gastrointestinal tract. The onset of pharmacological action is about 30 to 40 minutes following oral administration and 10 to 20 minutes following intramuscular administration. The duration of action for all routes is about 3 to 4 hours.[L6646] Following oral administration in healthy volunteers, the mean oral bioavailability was about 12.5%. In these patients, the time to reach the peak plasma concentrations was about 5 hours. Repeated oral dosing resulted in an accumulation of prochlorperazine and its metabolite. Following multiple twice daily dosing, the steady state of prochlorperazine was reached by 7 days.[A179173]",,"Following intravenous and single oral dose administration, the terminal elimination half live were 9 and 8 hours, respectively.[A179173]",10 mg/1,Oral,solid,15 mg/L (at 24 Â°C),4.88,0.011,,8.39,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,,,,,0,10,373.1379464,4,2,2,0,1,2
317,02/07/2019 00:00,DB00434,Cyproheptadine,Well absorbed after oral administration.,0.99,,2 mg/5mL,Oral,solid,Soluble,4.69,0.0136,,8.05,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12,0.99,0.99,,,0,,287.1673997,4,2,1,0,1,1
318,04/06/2019 00:00,DB00436,Bendroflumethiazide,Absorbed relatively rapidly after oral administration,0.96,8.5 hours,5 mg/1,Oral,solid,108 mg/L (at 25 Â°C),1.89,0.214,9.04,-3.1,NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F,0.96,0.96,8.5,8.5,0,5,421.0377826,3,2,1,0,0,1
319,02/07/2019 00:00,DB00437,Allopurinol,"This drug is about 90% absorbed from the gastrointestinal tract. Peak plasma levels normally occur at 1.5 hours and 4.5 hours post-dose for allopurinol and oxipurinol respectively. Following one oral dose of 300 mg of allopurinol, maximum plasma levels of about 3 mcg/mL of allopurinol and 6.5 mcg/mL of oxipurinol were measured [FDA label].",,"The plasma half-life of allopurinol is 1-2 hours, due to its rapid renal clearance [FDA label]. ",100 mg/1,Oral,solid,solubility in water at 37Â°C is 80.0 mg/dL and is greater in an alkaline solution,-1.8,5.88,7.83,2.57,O=C1N=CN=C2NNC=C12,,,,,0,100,136.0385107,2,0,2,0,0,2
320,02/07/2019 00:00,DB00438,Ceftazidime,The absorption of ceftazidime is directly proportional to the size of the dose.,0.1,"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.",1 g/20mL,Intravenous,solid,396 mg/L,-1.6,0.00573,2.77,4.26,[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1,0.1,0.1,,,0,,546.099139,4,2,4,2,1,2
321,04/06/2019 00:00,DB00439,Cerivastatin,The mean absolute oral bioavailability 60% (range 39 - 101%).,0.99,2-3 hours,0.4 mg,Oral,solid,Highly solubility,3.4,0.00419,4.05,5.58,COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C,0.99,0.99,2,3,0,0.4,459.2421014,2,2,1,1,0,0
322,02/07/2019 00:00,DB00440,Trimethoprim,"Readily and almost completely absorbed in the GI tract with peak serum concentrations attained 1-4 hours after oral administration. Widely distributed to tissues and fluids including kidney, lung, seminal fluid, aqueous humour, middle ear fluid, sputum, vaginal secretions, bile, bone and CSF. ",42-46%,8-11 hours in adults with normal renal function,50 mg/5mL,Oral,solid,400 mg/L (at 25 Â°C),0.91,0.615,17.33,7.16,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC,0.42,0.46,,,0,,290.1378904,2,2,1,1,0,0
323,02/07/2019 00:00,DB00441,Gemcitabine,The pharmacokinetics of gemcitabine are described by a 2-compartment model. ,,"Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.",38 mg,Intravenous,solid,Soluble,-1.4,22.3,11.52,-1.3,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,,,,,0,,263.0717623,2,1,2,1,1,1
324,02/07/2019 00:00,DB00442,Entecavir,"Absorption Following oral administration in healthy subjects, entecavir peak plasma concentrations occurred between 0.5 and 1.5 hours. In healthy subjects, the bioavailability of the tablet is 100% relative to the oral solution.",,"After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128-149 hours. The phosphorylated metabolite has a half-life of 15 hours.",0.05 mg/ml,Oral,solid,"Slightly soluble (2.4 mg/mL at pH 7.9, 25 Â°C)",-0.8,6.59,8,2.77,NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C,,,,,0,,277.1174893,3,2,2,2,0,0
325,02/07/2019 00:00,DB00443,Betamethasone,,,,0.00025,Topical,solid,66.5 mg/L (at 25 Â°C),1.94,0.0505,12.42,-3.3,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,392.1999022,4,0,0,0,0,0
326,02/07/2019 00:00,DB00444,Teniposide,,,5 hours,10 mg/1mL,Intravenous,solid,,1.24,0.0598,9.33,-3.7,[H][C@]12COC(=O)[C@]1([H])[C@]([H])(C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@]2([H])O[C@]1([H])O[C@]2([H])CO[C@]([H])(O[C@@]2([H])[C@]([H])(O)[C@@]1([H])O)C1=CC=CS1,,,5,5,0,,656.1563621,8,3,5,1,3,4
327,02/07/2019 00:00,DB00445,Epirubicin,1,0.77,"Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively",2 mg/1mL,Intravenous,solid,0.093 mg/ml,-0.5,1.18,9.53,8.94,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,0.77,0.77,,,0,,543.1740607,5,2,1,0,1,1
328,02/07/2019 00:00,DB00446,Chloramphenicol,Rapidly and completely absorbed from gastrointestinal tract following oral administration (bioavailability 80%). Well absorbed following intramuscular administration (bioavailability 70%). Intraocular and some systemic absorption also occurs after topical application to the eye.,50-60%,"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.",0.004,Topical,solid,2500 mg/L (at 25 Â°C),1.14,0.461,7.49,-2.8,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,0.5,0.6,,,0,,322.0123268,1,1,0,0,0,0
329,04/06/2019 00:00,DB00447,Loracarbef,Well absorbed with approximately 90% absorbed from the gastrointestinal tract after oral ingestion.,0.25,1 hour. In subjects with moderate impairment of renal function the plasma half-life was prolonged to approximately 5.6 hours.,200 mg/1,Oral,solid,,0.5,0.325,3.13,7.44,N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1,0.25,0.25,,,0,200,349.0829337,3,1,2,0,1,2
330,02/07/2019 00:00,DB00448,Lansoprazole,"The oral bioavailability of lansoprazole is reported to be 80-90%[A177053] and the peak plasma concentration(Cmax) is achieved about 1.7 hours after oral dosing.[FDA Label] Food reduces the absorption of lansoprazole (both Cmax and AUC are reduced by 50-70%); therefore, patients should be instructed to take lansoprazole before meals.[FDA Label]",0.97,"One source reports the half life of lansoprazole to be 0.9 - 1.6 hours[A177053], while another source cites 0.9 - 2.1 hours[A174244]. The general consensus is that lansoprazole has a short half life and is approximately 2 hours or less. [FDA Label]  These numbers may be misleading since it suggests that lansoprazole has a short duration of action when in practice, lansoprazole can effectively inhibit acid secretion for ~24 hours due to it's mechanism of action. [FDA Label]",0.9 g/0.9g,Oral,solid,0.97 mg/L,,0.25,9.35,4.16,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,0.97,0.97,,,0,,369.0758823,3,3,2,2,0,0
331,02/07/2019 00:00,DB00449,Dipivefrin,Well absorbed following occular administration.,,,0.001,Ophthalmic,solid,Freely soluble as HCl salt,1.7,0.0582,14,9.33,CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1,,,,,0,,351.204573,1,1,0,0,0,0
332,02/07/2019 00:00,DB00450,Droperidol,Completely absorbed following intramuscular administration.,,"Biphasic distribution. The rapid distribution phase is 1.4 &plusmn; 0.5 minutes and the slower distribution phase is 14.3 &plusmn; 6.5 minutes. Elimination half-life in adults is 134 &plusmn; 13 minutes and may be increased in geriatric patients. In children, it is 101.5 &plusmn; 26.4 minutes.",2.5 mg/1mL,Intramuscular; Intravenous,solid,4.21 mg/L,3.5,0.0966,12.72,6.75,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12,,,,,0,,379.1696052,4,3,2,1,0,1
333,02/07/2019 00:00,DB00451,Levothyroxine,"Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the levothyroxine sodium tablets dose is absorbed from the jejunum and upper ileum. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans, milk, and dietary fiber. Absorption may also decrease with age. In addition, many drugs affect T4 absorption including bile acide sequestrants, sucralfate, proton pump inhibitors, and minerals such as calcium (including in yogurt and milk products)[A179617], magnesium, iron, and aluminum supplements. To prevent the formation of insoluble chelates, levothyroxine should generally be taken on an empty stomach at least 2 hours before a meal and separated by at least 4 hours from any interacting agents. ",0.99,"T<sub>4</sub>, 6 to 7 days. T<sub>3</sub>, 1 to 2 days.",.1 mg,Oral,solid,0.105 mg/mL,4,0.00898,0.27,9.43,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,0.99,0.99,,,0,0.1,776.6866998,2,2,0,0,0,0
334,02/07/2019 00:00,DB00452,Framycetin,,,,0.01,Rectal,solid,,-7.8,64.7,12.29,9.97,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,,,,,0,,614.3122855,4,0,3,0,3,3
335,04/06/2019 00:00,DB00453,Clomocycline,,,,,,solid,,0.2,1.77,0.013,8.23,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(=O)NCO)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC(Cl)=C1[C@@]3(C)O,,,,,0,,508.1248581,4,1,0,0,0,0
336,02/07/2019 00:00,DB00454,Meperidine,"The oral bioavailability of meperidine in patients with normal hepatic function is 50-60% due to extensive first-pass metabolism. Bioavailability increases to 80-90% in patients with hepatic impairment (e.g. liver cirrhosis). Meperidine is less than half as effective when administered orally compared to parenteral administration. One study reported that 80-85% of the drug administered intramuscularly was absorbed within 6 hours of intragluteal injection in health adults; however, inter-individual variation and patient-specific variable appear to cause considerable variations in absorption upon IM injection. ",60-80%,Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.,100 mg/1mL,Intramuscular; Intravenous; Subcutaneous,solid,3220 mg/L (at 30 Â°C),2.72,1.11,,8.16,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,0.6,0.8,,,0,,247.1572289,2,1,1,0,1,1
337,02/07/2019 00:00,DB00455,Loratadine,"Loratadine is rapidly absorbed and achieves peak plasma concentration in 1-2 hours, while it's main metabolite achieves peak plasma concentration in 3-4 hours.[A176438]",0.99,The elimination half life is approximately 10 hours for loratadine and 20 hours for descarbethoxyloratadine.[A176438],10 mg,Oral,solid,0.000011 mg/ml,5.2,0.0134,,4.33,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,0.99,0.99,,,0,10,382.1448057,4,2,2,1,1,1
338,04/06/2019 00:00,DB00456,Cefalotin,,65-80%,30 minutes,1 g,Intravenous,solid,158 mg/L,0,0.0521,3.63,-3.3,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O,0.65,0.8,0.5,0.5,0,,396.0449782,3,1,3,1,1,2
339,02/07/2019 00:00,DB00457,Prazosin,"After administration of an oral dose, peak plasma concentrations are attained at approximately 3 hours [FDA label].  There is a linear association between the prazosin dose given and plasma concentration at steady state [A176657]. ",0.97,The plasma half-life is about 2-3 hours [FDA label]. ,1 mg,Oral,solid,1.4 mg/mL,1.3,0.693,,7.24,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1,0.97,0.97,,,0,1,383.1593542,4,3,3,2,1,1
340,02/07/2019 00:00,DB00458,Imipramine,"Rapidly and well absorbed (>95%) after oral administration [A31907]. The primary site of absorption is the small intestine as the basic amine groups are ionized in the acidic environment of the stomach, preventing movement across tissues. Bioavailability ranges from 29-77% due to high inter-individual variability. Peak plasma concentration is usually attained 2-6 hours following oral administration. Absorption is unaffected by food. ",60-96%,"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].",10 mg,Oral,solid,18.2 mg/L (at 24 Â°C),4.8,0.0664,,9.2,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,0.6,0.96,,,0,10,280.1939488,3,2,1,0,0,1
341,02/07/2019 00:00,DB00459,Acitretin,"Oral absorption of acitretin is optimal when given with food, and is linear and proportional with increasing doses from 25 to 100 mg. Approximately 72% (range 47% to 109%) of the administered dose was absorbed after a single 50 mg dose of acitretin was given to 12 healthy subjects.",0.999,49 hours (range 33 to 96 hours),17.5 mg/1,Oral,solid,0.0729 mg/L,6.4,0.000478,5.01,-4.8,COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1,0.999,0.999,,,0,17.5,326.1881947,1,1,0,0,0,0
342,02/07/2019 00:00,DB00460,Verteporfin,,,"Following intravenous infusion, verteporfin exhibits a bi-exponential elimination with a terminal elimination half-life of approximately 5-6 hours. Mild hepatic insufficiency increases half-life by approximately 20%.",15 mg/1,Intravenous,solid,,2.1,0.0136,4.12,4.78,COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C,,,,,0,,718.3002643,6,3,5,3,0,2
343,02/07/2019 00:00,DB00461,Nabumetone,"Nabumetone is well-absorbed from the GI tract and undergoes significant first pass metabolism resulting in approximately 35% being converted to the active metabolite, 6-MNA.[label,A178903] Tmax for 6-MNA varies widely with a mean values of 3 and 11 hours reported in official product monographs, and described as 9-12 hours in published literature [label,L6466,A178903] Administration with food increases Cmax by 33% and increases absorption rate.[label,A178903] If formulated as a suspension the Cmax increases and the Tmax is reduced by 0.8 hours while the all other pharmacokinetic parameters remain unchanged.[A178903]",0.99,6-MNA has a mean half-life of 24 hours with a range of 19-36 hours.[label],500 mg/1,Oral,solid,Practically insoluble,2400,0.00193,19.59,-4.8,COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2,0.99,0.99,,,0,500,228.1150298,2,2,0,0,0,0
344,04/06/2019 00:00,DB00462,Methscopolamine bromide,"Poorly and unreliably absorbed, total absorption is 10-25%.",,,2.5 mg/1,Oral,solid,Freely soluble,-2.58,0.0132,15.15,-2.7,[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,,,,,0,2.5,397.0888703,4,1,3,0,3,3
345,04/06/2019 00:00,DB00463,Metharbital,,,,,,solid,1980 mg/L (at 25 Â°C),1.15,19.5,8.75,,CCC1(CC)C(=O)NC(=O)N(C)C1=O,,,,,0,,198.1004423,1,0,1,0,1,1
346,02/07/2019 00:00,DB00464,Sodium Tetradecyl Sulfate,,,,10 mg,Intravenous,solid,,,0.00798,-1.1,,[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O,,,,,0,,316.1684247,0,0,0,0,0,0
347,02/07/2019 00:00,DB00465,Ketorolac,"Ketorolac is rapidly, and completely absorbed after oral administration with a bioavailability of 80% after oral administration.[L6526][A176143] Cmax is attained 20-60 minutes after administration, and after intramuscular administration, the area under the plasma concentration-time curve (AUC) is proportional to the dose administered.[A175966] 

After intramuscular administration, ketorolac demonstrates a time to maximal plasma concentration (tmax) of approximately 45-50 minutes, and a tmax of 30-40 minutes after oral administration.[A176143] The rate of absorption may be reduced by food; however, the extent of absorption remains unaffected.[A176143]",>99%,"Ketorolac tromethamine is administered as a racemic mixture, therefore the half-life of each enantiomer must be considered.  The half life of the S-enantiomer is ~2.5 hours, while the half life of the R-enantiomer is ~5 hours.  Based on this data, the S enantiomer is cleared about twice as fast as the R enantiomer. [L6526]",5 mg/1mL,Ophthalmic,solid,200 g/l (tromethamine salt),2.1,0.513,3.84,-7.8,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,0.99,1,,,0,,255.0895433,3,2,2,1,0,1
348,04/06/2019 00:00,DB00467,Enoxacin,"Rapidly absorbed following oral administration, with an absolute oral bioavailability of approximately 90%.",0.4,Plasma half-life is 3 to 6 hours.,,,solid,3.43 g/L,-0.2,1.09,5.5,8.59,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,0.4,0.4,,,0,,320.1284686,3,2,3,2,1,1
349,02/07/2019 00:00,DB00468,Quinine,76 - 88%,0.7,Approximately 18 hours,324 mg/1,Oral,solid,500 mg/L (at 15 Â°C),3.44,0.334,13.89,9.05,[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12,0.7,0.7,,,0,324,324.183778,5,2,4,1,3,3
350,02/07/2019 00:00,DB00469,Tenoxicam,Oral absorption of tenoxicam is rapid and complete (absolute bioavailability 100%).,0.99,72 hours (range 59 to 74 hours),20 mg,Oral,solid,14.1 mg/L,1.9,0.257,2.21,4.26,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O,0.99,0.99,,,0,20,337.0190978,3,2,3,2,0,1
351,02/07/2019 00:00,DB00470,Dronabinol,"Dronabinol capsules are almost completely absorbed (90 to 95%) after single oral doses. Due to the combined effects of first pass hepatic metabolism and high lipid solubility, only 10 to 20% of the administered dose reaches the systemic circulation. After oral administration, dronabinol has an onset of action of approximately 0.5 to 1 hours and peak effect at 2 to 4 hours. Following BID dosing of 2.5mg of dronabinol, Cmax was found to be 1.32ng/mL with a median Tmax of 1.00 hr. ",,The elimination phase of dronabinol can be described using a two compartment model with an initial (alpha) half-life of about 4 hours and a terminal (beta) half-life of 25 to 36 hours. ,10 mg/1,Oral,solid,2800 mg/L (at 23 Â°C),5.648,0.00263,9.34,-4.9,[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1,,,,,0,10,314.2245802,3,1,1,0,0,1
352,02/07/2019 00:00,DB00471,Montelukast,"It has been observed that montelukast is quickly absorbed following administration by the oral route.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] The oral bioavailability documented for the drug is 64%.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Furthermore, it seems that having a regular meal in the morning or even a high fat snack in the evening does not affect the absorption of montelukast.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] ",,"Studies have demonstrated that the mean plasma half-life of montelukast varies from 2.7 to 5.5 hours when observed in healthy young adults.[L6301,L6304,L6307,L6325,L6328,L6331]",4 mg/1,Oral,solid,"mixes with water (>100 mg/ml, 25 C)",7.9,8.20E-06,4.4,3.12,OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1,,,,,0,4,585.2104427,5,4,1,1,0,0
353,02/07/2019 00:00,DB00472,Fluoxetine,"Well absorbed from the GI tract following oral administration. Oral bioavailability is estimated to be at least 60-80%. Peak plasma concentrations occur within 6-8 hours following a single oral administration of a 40 mg dose. The oral solution and delayed-release capsule are bioequivalent. Food does not affect the systemic bioavailability of fluoxetine but it delays the absorption by 1-2 hours (not clinically significant). Prozac Weekly capsules, a delayedâ€“release formulation, contain entericâ€“coated pellets that resist dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. The enteric coating delays the onset of absorption of fluoxetine 1 to 2 hours relative to the immediateâ€“release formulations.",0.945,"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].  ",20 mg/1,Not applicable,solid,50 mg/mL at 25 Â°C,4.05,0.0017,,9.8,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,0.945,0.945,,,0,,309.1340489,2,2,0,0,0,0
354,04/06/2019 00:00,DB00473,Hexylcaine,,,<10 minutes,,,solid,,3.9,0.00971,,9.87,CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1,,,0.166666667,0.166666667,0,,261.172879,2,1,0,0,0,0
355,04/06/2019 00:00,DB00474,Methohexital,The absolute bioavailability following rectal administration of methohexital is 17%.,0.73,5.6 &plusmn; 2.7 minutes,2.5 g/1,Intramuscular; Rectal,solid,,1.8,0.0524,8.73,,CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O,0.73,0.73,,,0,,262.1317424,1,0,1,0,1,1
356,02/07/2019 00:00,DB00475,Chlordiazepoxide,,,24-48 hours,10 mg,Oral,solid,2000 mg/L,2.44,0.0199,-2.7,7.06,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,,,24,48,0,10,299.0825397,3,2,1,0,0,1
357,02/07/2019 00:00,DB00476,Duloxetine,"Duloxetine is incompletely absorbed with a mean bioavailability of 50% although there is wide variability in the range of 30-80%.[A14807] The population absorption constant (ka) is 0.168 h<sup>-1</sup>.The molecule is susceptible to hydrolysis in acidic environments necessitating the use of an enteric coating to protect it during transit through the stomach. This creates a 2 hour lag time from administration to the start of absorption. The Tmax is 6 hours including the lag time.[label] Administering duloxetine with food 3 hour delay in Tmax along with an 10% decrease in AUC. Similarly, administering the dose at bedtime produces a 4 hour delay and 18% decrease in AUC with a 29% reduction in Cmax.[A14807] These are attributed to delayed gastric emptying in both cases but are not expected to impact therapy to a clinically significant degree.",0.9,"Mean of 12 h with a range of 8-17.[label,A14807]",30 mg,Oral,solid,,4,0.00296,,9.7,CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,0.9,0.9,,,0,30,297.1187352,3,3,1,1,0,0
358,02/07/2019 00:00,DB00477,Chlorpromazine,Readily absorbed from the GI tract. Bioavailability varies due to first-pass metabolism by the liver. ,0.9,~ 30 hours,111.4 mg,Oral,liquid,2.55 mg/L (at 24 Â°C),5.41,0.00417,,9.2,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,0.9,0.9,,,0,111.4,318.0957473,3,2,1,0,0,1
359,04/06/2019 00:00,DB00478,Rimantadine,"Well absorbed, with the tablet and syrup formulations being equally absorbed after oral administration.",0.4,25 to 30 hours in young adults (22 to 44 years old). Approximately 32 hours in elderly (71 to 79 years old) and in patients with chronic liver disease. Approximately 13 to 38 hours in children (4 to 8 years old).,50 mg/5mL,Oral,solid,Hydrochloride salt freely soluble (50 mg/ml at 20 Â°C),3.6,0.00915,,10.14,CC(N)C12CC3CC(CC(C3)C1)C2,0.4,0.4,,,0,,179.1673997,4,0,0,0,0,0
360,02/07/2019 00:00,DB00479,Amikacin,"Rapidly absorbed after intramuscular administration. Rapid absorption occurs from the peritoneum and pleura. Poor oral and topical absorption. Poorly absorbed from bladder irrigations and intrathecal administration.[F1954,Label]

The bioavailability of this drug is expected to vary primarily from individual differences in nebulizer efficiency and airway pathology.[Label]

Following IM administration of a single dose of amikacin of 7.5 mg/kg in adults with normal renal function, peak plasma amikacin concentrations of 17-25 micrograms/mL are attained within 45 minutes to 2 hours.[F1949]

Following IV infusion of the same dose given over 1 hour peak plasma concentrations of the drug average 38 micrograms/mL immediately following the infusion, 5.5 micrograms/mL at 4 hours, and 1.3 micrograms/mL at 8 hours.[F1949]",,The plasma elimination half-life of amikacin is usually 2-3 hours in adults with normal renal function and is reported to range from 30-86 hours in adults with severe renal impairment.[Label],250 mg/1mL,Intramuscular; Intravenous,solid,50 mg/ml,,49.7,12.1,9.79,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,,,,,0,,585.2857364,3,0,2,0,2,2
361,02/07/2019 00:00,DB00480,Lenalidomide,"Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (C<sub>max</sub>) by 36%. The pharmacokinetic disposition of lenalidomide is linear. Accumulation does not occur following multiple doses. ",0.3,"Healthy subjects = 3 hours;
Multiple myeloma or MDS patients = 3 - 5 hours. ",10 mg,Oral,solid,"Soluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL.",-0.4,2.33,11.61,2.31,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,0.3,0.3,,,0,10,259.0956913,3,1,2,0,1,2
362,02/07/2019 00:00,DB00481,Raloxifene,"Raloxifene is well absorbed from the gastrointestinal tract, with approximately 60% fo the drug being absorbed following oral administration.[T28] Due to the extensive first-pass hepatic metabolism that involves glucuronide conjugation, the absolute oral bioavailability of raloxifene is about 2%.[T28] Following oral ingestion of a single dose or multiple dose of raloxifen in healthy postmenopausal women, the mean peak plasma concentrations (Cmax) were 0.50 and 1.36 ng/mL, respectively, and the AUC values were 27.2 and 24.2 ngxhr/mL, respectively. The time to reach Cmax following a single or multiple oral doses were 27.7 and 32.5 hours, respectively.[label] Although not clinically significant, oral ingestion of raloxifene with high-fat meals is thought to increase the systemic bioavailability of the drug[A4977] by increasnig the peak plasma concentrations (Cmax) and AUC by 28% and 16%, respectively.[label]",0.95,"The average plasma elimination half-life of raloxifene ranges from 27 to 32 hours.[A4977,T28] The prolonged half-life has been attributed to the drug's reversible systemic metabolism and significant enterohepatic cycling.[A4977]",60 mg/1,Oral,solid,Insoluble,5.2,0.000512,8.89,7.95,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,0.95,0.95,,,0,60,473.1660793,5,4,2,1,1,1
363,02/07/2019 00:00,DB00482,Celecoxib,"Easily absorbed in the gastrointestinal tract. When a single dose of 200 mg is given to healthy subjects, peak plasma levels occur 3 hours after an oral dose. The peak plasma level is 705 ng/mL. Absolute bioavailability studies have not been conducted. When multiple doses are given, steady-state is reached on or before Day 5. When taken with a high-fat meal, peak plasma levels are delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20% [FDA label].

A meta-analysis of pharmacokinetic studies has suggested an approximately 40% higher AUC (area under the curve) of celecoxib in black patients compared to Caucasians for unknown reasons [L3296].",,The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption [FDA label].,100 mg/1,Oral; Topical,solid,Poorly soluble,3.53,0.00503,10.7,-0.42,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,,,,,0,100,381.0758823,3,3,1,1,0,0
364,04/06/2019 00:00,DB00483,Gallamine Triethiodide,,,,20 mg,Intravenous,solid,Soluble,3.5,4.65E-06,,-4.5,[I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC,,,,,0,,891.1768868,1,1,0,0,0,0
365,02/07/2019 00:00,DB00484,Brimonidine,"Brimonidine readily penetrates the cornea following ocular administration [A178951] to reach pharmacologically active concentrations in the aqueous humor and ciliary body, the putative sites of its IOP-lowering activity.[A36674] Following ocular administration of 0.2% brimonidine solution, the peak plasma concentrations were achieved within 1 to 4 hours.[label]

In a clinical study of adult subjects with facial erythema of rosacea, brimonidine was cutaneously applied on facial skin in a repeated manner. While there was no drug accumulation in plasma, the highest peak plasma concentrations (Cmax) and AUC were 46 Â± 62 pg/mL and 417 Â± 264 pgxhr/mL, respectively.[L6544]",,"Following ocular administration of 0.2% brimonidine solution, the systemic half-life was approximately 3 hours.[label]",0.002,Ophthalmic,solid,34 mg/mL,,0.154,,8.32,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12,,,,,0,,291.0119574,3,2,2,1,0,1
366,02/07/2019 00:00,DB00485,Dicloxacillin,"Absorption of the isoxazolyl penicillins after oral administration is rapid but incomplete: peak blood levels are achieved in 1-1.5 hours. Oral absorption of cloxacillin, dicloxacillin, oxacillin and nafcillin is delayed when the drugs are administered after meals.",,The elimination half-life for dicloxacillin is about 0.7 hour.,250 mg/1,Oral,solid,3.63 mg/L,2.91,0.0296,3.75,-0.71,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O,,,,,0,250,469.026597,4,2,3,1,2,2
367,02/07/2019 00:00,DB00486,Nabilone,"Nabilone appears to be completely absorbed from the human gastrointestinal tract when administered orally. Following oral administration of a 2 mg dose of radiolabeled nabilone, peak plasma concentrations of approximately 2 ng/mL nabilone and 10 ng equivalents/mL total radioactivity are achieved within 2.0 hours. ",,"The plasma half-life (T1/2) values for nabilone and total radioactivity of identified and unidentified metabolites are about 2 and 35 hours, respectively.",0.25 mg,Oral,solid,,6.8,0.000493,9.33,-4.9,[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC,,,,,0,0.25,372.266445,3,1,1,0,0,1
368,02/07/2019 00:00,DB00487,Pefloxacin,Well absorbed by the oral route.,20-30%,8.6 hours,,,solid,11.4 mg/mL at 25 Â°C,0.27,1.23,5.66,6.47,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1,0.2,0.3,8.6,8.6,0,,333.1488697,3,2,2,1,1,1
369,04/06/2019 00:00,DB00488,Altretamine,,0.94,4.7-10.2 hours,50 mg/1,Oral,solid,91 mg/L (at 25 Â°C),2.73,3.1,,7.75,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,0.94,0.94,4.7,10.2,0,50,210.1592946,1,1,1,1,0,0
370,02/07/2019 00:00,DB00489,Sotalol,"Sotalol is 90-100% bioavailable.[Label,A178483] When taken with a meal, adsorption is lowered by 18%.[Label,A178483]
In patients with a creatinine clearance >80mL/min, the maximum concentration is 6.25Â±2.19.[A178483]",,"The terminal elimination half life is 10-20 hours in healthy patients.[Label,A178483] In patients with a creatinine clearance >80mL/min, the half life is 17.5Â±0.97h.[A178483] In patients with a creatinine clearance 30-80mL/min, the half life is 22.7Â±6.4h.[A178483] In patients with a creatinine clearance 10-30mL/min, the half life is 64Â±27.2h.[A178483] In patients with a creatinine clearance <10mL/min, the half life is 97.9Â±57.3h.[A178483]",160 mg,Oral,solid,,,0.782,10.07,9.43,CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1,,,,,0,160,272.1194635,1,1,0,0,0,0
371,02/07/2019 00:00,DB00490,Buspirone,Rapidly absorbed in man. Bioavailability is low and variable (approximately 5%) due to extensive first pass metabolism.,0.95,2-3 hours (although the action of a single dose is much longer than the short halflife indicates).,10 mg,Oral,solid,21.4 mg/L,2.63,0.588,,7.62,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1,0.95,0.95,,,0,10,385.2477752,4,1,3,1,2,2
372,04/06/2019 00:00,DB00491,Miglitol,Absorption of miglitol is saturable at high doses with 25 mg being completely absorbed while a 100-mg dose is only 50-70% absorbed. No evidence exists to show that systemic absorption of miglitol adds to its therapeutic effect.,,The elimination half-life of miglitol from plasma is approximately 2 hours.,100 mg/1,Oral,solid,Soluble,-2.7,610,12.9,7.6,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,,,,,0,100,207.1106726,1,0,1,0,1,1
373,02/07/2019 00:00,DB00492,Fosinopril,Average absolute absorption is 36%. The primary site of absorption is the proximal small intestine (duodenum/jejunum). Food slows the rate of absorption with no effect on the extent of absorption. ,&ge;95%,12 hours,10 mg/1,Oral,solid,Insoluble,6.3,0.00101,3.87,-4.4,CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C,0.95,0.95,12,12,0,10,563.3011894,3,1,1,0,1,1
374,02/07/2019 00:00,DB00493,Cefotaxime,Rapidly absorbed following intramuscular injection.,,Approximately 1 hour.,10 g/1,Intravenous,solid,Soluble,-0.5,0.146,3.18,4.15,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,,,,,0,,455.0569399,3,1,3,1,1,2
375,02/07/2019 00:00,DB00494,Entacapone,Entacapone is rapidly absorbed (approximately 1 hour). The absolute bioavailability following oral administration is 35%.,0.98,0.4-0.7 hour,200 mg,Oral,solid,,2.8,0.0797,5.68,-0.036,CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N,0.98,0.98,0.4,0.7,0,200,305.1011706,1,1,0,0,0,0
376,02/07/2019 00:00,DB00495,Zidovudine,"Rapid and nearly complete absorption from the gastrointestinal tract following oral administration; however, because of first-pass metabolism, systemic bioavailability of zidovudine capsules and solution is approximately 65% (range, 52 to 75%). Bioavailability in neonates up to 14 days of age is approximately 89%, and it decreases to approximately 61% and 65% in neonates over 14 days of age and children 3 months to 12 years, respectively. Administration with a high-fat meal may decrease the rate and extent of absorption.",30-38%,"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours) ",100 mg/1,Oral,solid,2.01E+004 mg/L (at 25 Â°C),0.05,16.3,9.96,-3,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,0.3,0.38,,,0,100,267.0967539,2,1,2,1,1,1
377,02/07/2019 00:00,DB00496,Darifenacin,"The mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.",0.98,The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.,15 mg/1,Oral,solid,,4.5,0.000298,16.21,10.11,NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1,0.98,0.98,,,0,15,426.2307282,5,3,2,0,1,2
378,02/07/2019 00:00,DB00497,Oxycodone,"Oxycodone has an oral bioavailability of 60% to 87% that is unaffected by food.[Label]

The area under the curve is 135ng/mL\*hr, maximum plasma concentration is 11.5ng/mL, and time to maximum concentration is 5.11hr in patients given a 10mg oral immediate release dose of oxycodone.[Label]",,"The apparent elimination half life of oxycodone is 3.2 hours for immediate release formulations and 4.5 hours for extended release formulations.[Label] Noroxycodone has a half life of 5.8 hours, oxymorphone has a half life of 8.8 hours, noroxymorphone has a half life of 9 hours.[A178639]",5 mg,Oral,solid,166mg/mL,0.7,5.59,13.56,8.21,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O,,,,,0,5,315.1470582,5,1,2,0,1,2
379,04/06/2019 00:00,DB00498,Phenindione,Absorbed slowly from the gastrointestinal tract.,0.88,5-10 hours,,,solid,27 mg/L (at 20 Â°C),2.9,0.023,4.88,-7.5,O=C1C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1,0.88,0.88,5,10,0,,222.0680796,3,2,0,0,0,0
380,02/07/2019 00:00,DB00499,Flutamide,Rapidly and completely absorbed.,94-96%,The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.,125 mg/1,Oral,solid,9.45 mg/L,3.35,0.00566,13.17,-3.7,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,0.94,0.96,,,0,125,276.0721769,1,1,0,0,0,0
381,04/06/2019 00:00,DB00500,Tolmetin,Rapidly and almost completely absorbed with peak plasma levels being reached within 30-60 minutes after an oral therapeutic dose.,,Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.,400 mg,Oral,solid,222 mg/L,2.79,0.131,3.96,-7.8,CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1,,,,,0,400,257.1051933,2,2,1,1,0,0
382,02/07/2019 00:00,DB00501,Cimetidine,Rapid 60-70%,15-20%,2 hours,200 mg,Oral,solid,9380 mg/L (at 25 Â°C),0.4,0.176,13.38,6.91,CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,0.15,0.2,2,2,0,200,252.1157155,1,1,1,1,0,0
383,02/07/2019 00:00,DB00502,Haloperidol,"
Haloperidol is well-absorbed from the gastrointestinal tract when ingested orally,  however, the first-pass hepatic metabolism decreases its oral bioavailability to 40 - 75% [L1996]. 

Administration of haloperidol decanoate (the depot form of haloperidol for long-term treatment) in sesame oil results in slow release of the drug for long-term effects. The plasma concentrations of haloperidol gradually rise, reaching its peak concentration at about 6 days after the injection, with an apparent half-life of about 21 days. Steady-state plasma concentrations are achieved after the third or fourth dose [FDA label].

Serum concentration peaks 0.5 to 4 hours after an oral dose [L1996].",,"
For the non-decanoate formulations, the haloperidol half-life is on average 24 hours after oral administration and 21 hours after intramuscular administration [L2028].",100 mg/1mL,Intramuscular,solid,14 mg/L (at 25 Â°C),4.3,0.00446,13.96,8.05,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,,,,,0,,375.1401349,3,2,1,0,1,1
384,02/07/2019 00:00,DB00503,Ritonavir,The absolute bioavailability of ritonavir has not been determined.,98-99%,3-5 hours [A19647].,100 mg/1,Oral,solid,Practically insoluble,3.9,0.00126,13.68,2.84,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,0.98,0.99,,,0,100,720.3127606,4,4,2,2,0,0
385,04/06/2019 00:00,DB00504,Levallorphan,Rapidly absorbed.,,1 hour,,,solid,633 mg/L,3.48,0.0252,10.36,9.41,[H][C@@]12CCCC[C@@]11CCN(CC=C)[C@@H]2CC2=C1C=C(O)C=C2,,,1,1,0,,283.1936144,4,1,1,0,1,1
386,04/06/2019 00:00,DB00505,Tridihexethyl,,,,,,solid,11 mg/mL,1.17,1.68E-05,13.69,-3.4,CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1,,,,,1,,318.2791412,2,1,0,0,0,0
387,04/06/2019 00:00,DB00507,Nitazoxanide,"The relative bioavailability of the suspension compared to the tablet was 70%. When administered with food the AUC and C<sub>max</sub> increased by two-fold and 50%, respectively, for the tablet and 45 to 50% and &le; 10%, respectively, for the oral suspension [FDA label].",,7.3h [L1422],100 mg/5mL,Oral,solid,0.000189,1.63,0.00755,8.3,-4.2,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,,,7.3,7.3,0,,307.0262914,2,2,1,1,0,0
388,04/06/2019 00:00,DB00508,Triflupromazine,Absorption may be erratic and peak plasma concentrations show large interindividual differences.,(90%,,,,solid,,5.54,0.0018,,9.2,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,0.9,0.9,,,0,,352.1221043,3,2,1,0,0,1
389,04/06/2019 00:00,DB00509,Dextrothyroxine,,,,2 mg,Oral,solid,,4,0.00898,0.27,9.43,N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,,,,,0,2,776.6866998,2,2,0,0,0,0
390,04/06/2019 00:00,DB00511,Acetyldigitoxin,Bioavailability is 60 to 80% following oral administration.,,,,,solid,0.0274 mg/L at 25 Â°C,3.7,0.0123,7.18,0.24,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,,,,,0,,806.4452568,8,0,4,0,3,4
391,02/07/2019 00:00,DB00512,Vancomycin,"Poorly absorbed from gastrointestinal tract, however systemic absorption (up to 60%) may occur following intraperitoneal administration [FDA Label].",0.5,"Half-life in normal renal patients is approximately 6 hours (range 4 to 11 hours). In anephric patients, the average half-life of elimination is 7.5 days [FDA Label].",1 g/1g,Oral,solid,,-3.1,0.225,2.99,9.93,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,0.5,0.5,,,0,,1447.4302,12,5,7,0,2,7
392,04/06/2019 00:00,DB00513,Aminocaproic Acid,"Absorbed rapidly following oral administration. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1).",,The terminal elimination half-life is approximately 2 hours.,0.25 g/1mL,Oral,solid,5.05E+005 mg/L (at 25 Â°C),-2.95,45.2,4.73,10.21,NCCCCCC(O)=O,,,,,0,,131.0946287,0,0,0,0,0,0
393,02/07/2019 00:00,DB00514,Dextromethorphan,Rapidly absorbed from the gastrointestinal tract.,,3-6 hours,20 mg,Oral,solid,74.7 mg/L,3.6,0.00851,,9.85,[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,,,3,6,0,20,271.1936144,4,1,1,0,1,1
394,04/06/2019 00:00,DB00517,Anisotropine methylbromide,Gastrointestinal absorption is poor and irregular. Total absorption after an oral dose is about 10 to 25%.,,Not Known,,,solid,1600 mg/L,0.6,9.67E-05,,-7.1,[Br-].CCCC(CCC)C(=O)O[C@H]1CC2CCC(C1)[N+]2(C)C,,,,,0,,361.1616414,2,0,2,0,2,2
395,04/06/2019 00:00,DB00518,Albendazole,Poorly absorbed from the gastrointestinal tract due to its low aqueous solubility. Oral bioavailability appears to be enhanced when coadministered with a fatty meal (estimated fat content 40 g),0.7,"Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).",200 mg/1,Oral,solid,Practically insoluble,2.7,0.0228,9.51,4.27,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,0.7,0.7,,,0,200,265.0884977,2,2,1,1,0,0
396,02/07/2019 00:00,DB00519,Trandolapril,~ 40-60% absorbed; extensive first pass metabolism results in a low bioavailability of 4-14%,0.8,"The elimination half lives of trandolapril and trandolaprilat are about 6 and 10 hours, respectively, but, similar to all ACE inhibitors, trandolaprilat also has a prolonged terminal elimination phase that involves a small fraction of administered drug. This likely represents drug binding to plasma and tissue ACE. The effective half life of elimination for trandolaprilat is 16-24 hours. ",0.5 mg,Oral,solid,,3.5,0.0207,3.8,5.21,[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O,0.8,0.8,,,0,0.5,430.2467722,3,1,1,0,1,1
397,02/07/2019 00:00,DB00520,Caspofungin,92% tissue distribution within 36-48 hours after intravenous infusion,0.97,9-11 hours,50 mg,Intravenous,solid,,0,0.367,8.75,9.76,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,0.97,0.97,9,11,0,,1092.643062,4,1,3,0,3,3
398,04/06/2019 00:00,DB00521,Carteolol,,,,10 mg/1mL,Ophthalmic,solid,,1.1,0.421,13.41,9.76,CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2,,,,,0,,292.1786926,2,1,1,0,0,1
399,04/06/2019 00:00,DB00522,Bentiromide,,,,,,solid,,3.3,0.00412,4.16,-1.3,OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1,,,,,0,,404.1372217,3,3,0,0,0,0
400,02/07/2019 00:00,DB00523,Alitretinoin,,,,0.001,Topical,solid,0.6 mg/L,4.2,0.00477,5,,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O,,,,,0,,300.2089301,1,0,0,0,0,0
401,02/07/2019 00:00,DB00524,Metolazone,Peak blood levels are obtained within 2 to 4 hours of oral administration. The rate and extent of absorption are formulation dependent. ,50-70%,Approximately 14 hours.,10 mg/1,Oral,solid,60.3 mg/L (at 25 Â°C),2.5,0.0407,9.54,-1.6,CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O,0.5,0.7,,,0,10,365.0600901,3,2,1,0,0,1
402,02/07/2019 00:00,DB00525,Tolnaftate,,,,.45 g/45g,Topical,solid,7.02e-05 mg/mL at 25 Â°C,5.1,0.000546,,0.075,CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC=CC(C)=C1,,,,,0,,307.1030852,3,3,0,0,0,0
403,02/07/2019 00:00,DB00526,Oxaliplatin,"Bioavailability is complete following intravenous administration. When a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m^2 is given, the peak serum concentration was 0.814 mcg/mL. ",,"The decline of ultrafilterable platinum levels following oxaliplatin administartion is triphasic, with two distribution phases: t1/2Î±; 0.43 hours and t1/2Î²; 16.8 hours. This is followed by a long terminal elimination phase that lasts 391 hours (t1/2Î³). ",5 mg/1mL,Intravenous,solid,,,27.5,,,[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1,,,,,,,,,,,,,
404,02/07/2019 00:00,DB00527,Cinchocaine,"In general, ionized forms (salts) of local anesthetics are not readily absorbed through intact skin. However, both nonionized (bases) and ionized forms of local anesthetics are readily absorbed through traumatized or abraded skin into the systemic circulation.",,,10 mg/1g,Topical,solid,42 mg/L (at 21 Â°C),4.4,0.0389,14.57,9.04,CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC,,,,,0,,343.2259772,2,2,1,1,0,0
405,04/06/2019 00:00,DB00528,Lercanidipine,,,,,,solid,,6.4,0.000156,,9.36,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,611.299536,4,3,1,0,0,1
406,04/06/2019 00:00,DB00529,Foscarnet,Poorly absorbed after oral administration (bioavailability from 12 to 22%).,14-17%,3.3-6.8 hours,24 mg/1mL,Intravenous,solid,Complete,-2.1,16.8,-0.096,,OC(=O)P(O)(O)=O,0.14,0.17,3.3,6.8,0,,125.9718098,0,0,0,0,0,0
407,02/07/2019 00:00,DB00530,Erlotinib,Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%. Peak plasma levels occur 4 hours after dosing. The solubility of erlotinib is pH dependent. Solubility decreases pH increases. Smoking also decrease the exposure of erlotinib. ,0.93,Median half-life of 36.2 hours.,100 mg/1,Oral,solid,Very slightly soluble (hydrochloride salt - maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2),2.7,0.00891,16.14,4.62,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,0.93,0.93,,,0,100,393.1688562,3,3,1,1,0,0
408,02/07/2019 00:00,DB00531,Cyclophosphamide,"After oral administration, peak concentrations occur at one hour. ",0.2,3-12 hours,25 mg/1,Oral,solid,Soluble. 1-5 g/100 mL at 23 Â°C,0.8,15.1,12.78,-0.57,ClCCN(CCCl)P1(=O)NCCCO1,0.2,0.2,3,12,0,25,260.0248197,1,0,1,0,1,1
409,04/06/2019 00:00,DB00532,Mephenytoin,,,Approximately 7 hours,100 mg/1,Oral,solid,1270 mg/L,1.69,0.97,11.18,-8.1,CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1,,,,,0,100,218.1055277,2,1,1,0,1,1
410,04/06/2019 00:00,DB00533,Rofecoxib,"The mean oral bioavailability of rofecoxib at therapeutically recommended doses of 12.5, 25, and 50 mg is approximately 93%.",0.87,17 hours,12.5 mg,Oral,solid,Insoluble,3.2,0.0106,14.84,-7,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,0.87,0.87,17,17,0,12.5,314.0612799,3,2,1,0,0,1
411,04/06/2019 00:00,DB00534,Chlormerodrin,,,,,,solid,1.1E+004 mg/L (at 25 Â°C),-0.8,29.2,14.05,-1.8,COC(CNC(N)=O)C[Hg]Cl,,,,,0,,368.0215483,0,0,0,0,0,0
412,04/06/2019 00:00,DB00535,Cefdinir,"Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%. Absorption is reduced by approximately 15% when administered with a high fat meal.",,1.7 &plusmn; 0.6 hours,300 mg/1,Oral,solid,,-0.2,0.0878,1.74,7.45,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,,,,,0,300,395.0358105,3,1,3,1,1,2
413,04/06/2019 00:00,DB00536,Guanidine,Rapidly absorbed and distributed,,7-8 hours,125 mg/1,Oral,solid,1840 mg/L (at 20 Â°C),-0.6,11.5,,12.55,NC(N)=N,,,7,8,0,125,59.04834716,0,0,0,0,0,0
414,02/07/2019 00:00,DB00537,Ciprofloxacin,"A 250mg oral dose of ciprofloxacin reaches an average maximum concentration of 0.94mg/L in 0.81 hours with an average area under the curve of 1.013L/h\*kg.[A178858] The FDA reports an oral bioavailability of 70-80%[Label,A820] while other studies report it to be approximately 60%.[A178858] An early review of ciprofloxacin reported an oral bioavailability of 64-85% but recommends 70% for all practical uses.[A178876]",,"The average half life following a 250mg oral dose was 4.71 hours and 3.65 hours following a 100mg intravenous dose.[A178858] Generally the half life is reported as 4 hours.[Label,A178858]",0.003,Ophthalmic,solid,<1mg/mL,0.28,1.35,5.76,8.68,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O,,,,,0,,331.1332197,4,2,2,1,1,1
415,02/07/2019 00:00,DB00538,Gadoversetamide,,,"Distribution 13.3 &plusmn; 6.8 (mean) minutes, elimination 103.6 &plusmn; 19.5 (mean) minutes.",0.5 mmol/1mL,Intravenous,solid,,,2.98,2.32,8.97,[Gd+3].COCCNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NCCOC)CC([O-])=O)CC([O-])=O,,,,,0,,662.1546712,0,0,0,0,0,0
416,04/06/2019 00:00,DB00539,Toremifene,Well absorbed,0.02,5 days,60 mg/1,Oral,solid,,6.8,0.000409,,8.76,CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,0.02,0.02,120,120,0,60,405.1859422,3,3,0,0,0,0
417,02/07/2019 00:00,DB00540,Nortriptyline,"As with other TCAs, notriptyline is well absorbed from the GI tract. Peak plasma concentrations occur within 4-8.8 hours following oral administration, with the mean time of 5.5 hours [L1354]. The mean oral bioavailability is 51% [L1354].",0.93,The elimination half-life (t 1â„2Î²) after oral nortriptyline administration is approximately 26 hours (25.5 Â± 7.9 hours; range 16-38 hours) [L1354].,10 mg,Oral,solid,,4.51,0.000874,,10.47,CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,0.93,0.93,,,0,10,263.1673997,3,2,0,0,0,0
418,02/07/2019 00:00,DB00541,Vincristine,,~75%,"When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours. ",5 mg/5mL,Intravenous,solid,,2.82,0.03,10.85,8.66,CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1,0.75,0.75,,,0,,824.399644,9,3,6,1,2,5
419,02/07/2019 00:00,DB00542,Benazepril,Bioavailability of oral dosing is 3% to 4% in horses[A176450]. In humans at least 37% of oral benazepril is absorbed and reaches peak plasma concentration in 0.5 hours to 1 hour[A176453]. Other studies have shown a peak plasma concentration at a median of 1.5 hours[A836].,0.967,"The half life of the prodrug benazepril is 2.7Â±8.5h[A836].
The half life of the active metabolite benazeprilat is 22.3Â±9.2h[A836]
The accumulation half life of benazepril is 10 to 11 hours[FDA Label][A836].",10 mg,Oral,solid,19mg/mL,,0.0105,3.53,5.36,[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,0.967,0.967,,,0,10,424.199822,3,2,1,0,0,1
420,04/06/2019 00:00,DB00543,Amoxapine,Rapidly and almost completely absorbed from the GI tract. Peak plasma concentrations occur within 1-2 hours of oral administration of a single dose. ,,8 hours,100 mg/1,Oral,solid,,3.4,0.171,,8.83,ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1,,,8,8,0,100,313.0981898,4,2,2,0,1,2
421,02/07/2019 00:00,DB00544,Fluorouracil,28-100%,8-12%,10-20 minutes,2.5 g/50mL,Topical,solid,1.11E+004 mg/L (at 22 Â°C),-0.89,5.86,7.76,-8,FC1=CNC(=O)NC1=O,0.08,0.12,0.166666667,0.333333333,0,,130.0178556,1,1,1,1,0,0
422,02/07/2019 00:00,DB00545,Pyridostigmine,Poorly absorbed from the GI tract with an oral bioavailability of 7.6 +/- 2.4%.,,3 hours following oral administration.,60 mg,Oral,solid,,1.554,1.04,19.53,,CN(C)C(=O)OC1=C[N+](C)=CC=C1,,,,,1,60,181.0971541,1,1,1,1,0,0
423,04/06/2019 00:00,DB00546,Adinazolam,,,Less than 3 hours.,,,solid,,4.4,0.0672,18.38,6.66,CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,,,,,0,,351.1250733,4,3,2,1,0,1
424,02/07/2019 00:00,DB00547,Desoximetasone,"Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.",,The half-life of the material was 15 &plusmn; 2 hours (for urine) and 17 &plusmn; 2 hours (for feces) between the third and fifth trial day.,2.5 mg/1g,Topical,solid,42.1 mg/L,2.35,0.031,13.44,-3.3,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,376.2049876,4,0,0,0,0,0
425,02/07/2019 00:00,DB00548,Azelaic acid,Approximately 4% of the topically applied azelaic acid is systemically absorbed.,,"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.",0.2 g/1g,Topical,solid,2400 mg/L (at 20 Â°C),1.57,2.28,4.15,,OC(=O)CCCCCCCC(O)=O,,,,,0,,188.104859,0,0,0,0,0,0
426,02/07/2019 00:00,DB00549,Zafirlukast,"Rapidly absorbed following oral administration, reduced following a high-fat or high-protein meal.",0.99,10 hours,20 mg/1,Oral,solid,,5.4,0.000962,4.29,-1.1,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,0.99,0.99,10,10,0,20,575.2090068,5,4,1,1,0,0
427,02/07/2019 00:00,DB00550,Propylthiouracil,Well absorbed following oral administration.,0.82,2 hours,100 mg,Oral,solid,1200 mg/L (at 25 Â°C),0.4,0.466,8.09,-2.7,CCCC1=CC(=O)NC(=S)N1,0.82,0.82,2,2,0,100,170.0513839,1,1,1,1,0,0
428,04/06/2019 00:00,DB00551,Acetohydroxamic acid,Well absorbed from the GI tract following oral administration.,,5-10 hours in patients with normal renal function,250 mg/1,Oral,solid,1E+006 mg/L,-1.59,509,8.94,-5.4,CC(=O)NO,,,,,0,250,75.0320284,0,0,0,0,0,0
429,04/06/2019 00:00,DB00552,Pentostatin,"Not absorbed orally, crosses blood brain barrier.",0.04,5.7 hours (with a range between 2.6 and 16 hrs),2 mg/1mL,Intravenous,solid,30 mg/mL,-1.1,10.7,13.06,8.33,OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O,0.04,0.04,,,0,,268.117155,3,1,3,1,1,2
430,02/07/2019 00:00,DB00553,Methoxsalen,,,Approximately 2 hours,10 mg/1,Oral,solid,47.6 mg/L (at 30 Â°C),1.7,0.164,,-2.9,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,,,,,0,10,216.0422587,3,3,2,2,0,0
431,02/07/2019 00:00,DB00554,Piroxicam,Well absorbed following oral administration.,,30 to 86 hours,10 mg,Oral,solid,23 mg/L (at 22 Â°C),3.06,0.143,4.76,3.79,CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O,,,,,0,10,331.0626769,3,2,2,1,0,1
432,02/07/2019 00:00,DB00555,Lamotrigine,"Lamotrigine is rapidly and completely absorbed with negligible first-pass metabolism. Its oral absolute bioavailability is 98% which is not affected by food intake.  Peak plasma concentrations is reached anywhere from 1.4 to 4.8 hours following drug administration, which varies depending on the dosing regimen of lamotrigine, concomitant medications, and epileptic states [FDA Label].  ",0.55,"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual. ",100 mg,Oral,solid,,2.5,0.488,14.98,5.87,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,0.55,0.55,,,0,100,255.0078506,2,2,1,1,0,0
433,02/07/2019 00:00,DB00556,Perflutren,,,The mean half-life of OFP in blood 1.9 minutes,6.52 mg/1mL,Intravenous,liquid,5.7 mg/L (at 15 Â°C),3,0.146,,,FC(F)(F)C(F)(F)C(F)(F)F,,,,,0,,187.9872258,0,0,0,0,0,0
434,02/07/2019 00:00,DB00557,Hydroxyzine,Rapidly absorbed from the gastrointestinal tract,0.93,20 to 25 hours,10 mg,Oral,solid,< 700 mg/mL,2.7,0.0914,15.12,7.82,OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,0.93,0.93,,,0,10,374.1761058,3,2,1,0,1,1
435,02/07/2019 00:00,DB00558,Zanamivir,"Absolute bioavailability is very low following oral administration (2%).  Following oral inhalation, bioavailability is 4% to 17%.",,2.5-5.1 hours,5 mg,Oral; Respiratory (inhalation),solid,,-3,7.31,3.25,11.93,[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,,,2.5,5.1,0,5,332.133199,1,0,1,0,0,1
436,02/07/2019 00:00,DB00559,Bosentan,Absolute bioavailability is approximately 50% and food does not affect absorption.,0.98,Terminal elimination half-life is about 5 hours in healthy adult subjects.,125 mg/1,Oral,solid,Poorly soluble in water (1.0 mg/100 ml) and in aqueous solutions at low pH (0.1 mg/100 ml at pH 1.1 and 4.0; 0.2 mg/100 ml at pH 5.0). Solubility increases at higher pH values (43 mg/100 ml at pH 7.5).,3.7,0.00904,5.8,-0.43,COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1,0.98,0.98,,,0,125,551.1838546,4,4,2,2,0,0
437,02/07/2019 00:00,DB00560,Tigecycline,,0.71,27-43 hours,50 mg/10mL,Intravenous,solid,,0.8,0.45,0.25,8.76,[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C,0.71,0.71,27,43,0,,585.2798632,4,1,0,0,0,0
438,04/06/2019 00:00,DB00561,Doxapram,,,,20 mg,Intravenous,solid,Sparingly soluble,3.6,0.0343,,7.23,CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,378.2307282,4,2,2,0,2,2
439,04/06/2019 00:00,DB00562,Benzthiazide,Absorbed in the digestive tract.,0.3,,,,solid,8.91 mg/L,1.73,0.0121,9.18,-4.7,NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O,0.3,0.3,,,0,,430.9834966,3,2,1,0,0,1
440,02/07/2019 00:00,DB00563,Methotrexate,"Oral absorption is dose dependent in adults and leukemic pediatric patients. In adults, peak serum levels are reached within one to two hours. At doses of 30 mg/m^2 or less, methotrexate is generally well absorbed with a mean bioavailability of 60%. At doses greater than 80 mg/m^2, the absorption of the doses is significantly less due to a saturation effect. ",0.5,Low doses (less than 30 mg/m^2): 3 to 10 hours; High doses: 8 to 15 hours.,25 mg/1mL,Intra-arterial; Intramuscular; Intrathecal; Intravenous,solid,2600 mg/L,-1.85,0.171,3.41,2.81,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,0.5,0.5,,,0,,454.1713158,3,3,2,2,0,0
441,02/07/2019 00:00,DB00564,Carbamazepine,"In clinical studies, carbamazepine suspension, conventional tablets, and extended-release tablets delivered equivalent amounts of drug to the systemic circulation. However, it has been observed that the suspension is somewhat faster absorbed. Furthermore, the extended-release tablet is slightly slower than the conventional tablet. The bioavailability of the extended-release tablet is 89%, compared to the suspension. Plasma levels of carbamazepine are variable. The time to peak concentration for the different formulations are as follows:
Suspension = 1.5 hours;
Conventional tablets = 4-5 hours;
Extended-release tablets = 3-12 hours. ",0.76,"Initial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses. ",1 g/1g,Not applicable,solid,17.7 mg/L,2.45,0.152,15.96,-3.8,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,0.76,0.76,,,0,,236.094963,3,2,1,0,0,1
442,02/07/2019 00:00,DB00565,Cisatracurium,,,Elimination half-life of 22 minutes.,10 mg/1mL,Intravenous,solid,,,2.32E-05,19.02,-4.1,COC1=CC2=C(C=C1OC)[C@@H](CC1=CC(OC)=C(OC)C=C1)[N@@+](C)(CCC(=O)OCCCCCOC(=O)CC[N@@+]1(C)CCC3=C(C=C(OC)C(OC)=C3)[C@H]1CC1=CC(OC)=C(OC)C=C1)CC2,,,,,2,,928.5074286,6,4,2,0,0,2
443,04/06/2019 00:00,DB00566,Succimer,Rapid but variable.,,48 hours,100 mg/1,Oral,solid,,-0.3,2.43,3.37,,OC(=O)[C@@H](S)[C@@H](S)C(O)=O,,,48,48,0,100,181.9707507,0,0,0,0,0,0
444,02/07/2019 00:00,DB00567,Cephalexin,"Well absorbed from the upper gastrointestinal tract with nearly 100% oral bioavailability.[A179032,A179035] Cephalexin is not absorbed in the stomach but is absorbed in the upper intestine.[A179065]

Patients taking 250mg of cephalexin reach a maximum plasma concentration of 7.7mcg/mL and patients taking 500mg reach 12.3mcg/mL.[A179026]",10-15%,The half life of cephalexin is 49.5 minutes in a fasted state and 76.5 minutes with food though these times were not significantly different in the study.[A179032],125 mg/5mL,Oral,solid,10mg/mL,0.65,0.297,3.45,7.44,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,0.1,0.15,,,0,,347.093977,3,1,2,0,1,2
445,04/06/2019 00:00,DB00568,Cinnarizine,,,,,,solid,750 mg/L (at 25 Â°C),5.77,0.00172,,8.4,C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,368.2252489,4,3,1,0,1,1
446,02/07/2019 00:00,DB00569,Fondaparinux,100% bioavailability when administered subcutaneously,0.94,17-21 hours,2.5 mg/0.5ml,Intravenous; Subcutaneous,solid,,0.4,7.91,-3,,CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O,0.94,0.94,17,21,0,,1506.951333,5,0,5,0,5,5
447,02/07/2019 00:00,DB00570,Vinblastine,,98-99%,"Triphasic: 35 min, 53 min, and 19 hours",10 mg,Intravenous,solid,Negligible,3.7,0.0169,10.87,8.86,[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC,0.98,0.99,,,0,,810.4203794,9,3,6,1,2,5
448,02/07/2019 00:00,DB00571,Propranolol,"Propranolol is almost completely absorbed from the GI tract; however, plasma concentrations attained are quite variable among individuals.",0.9,4 hours,4.28 mg/1mL,Oral,solid,61.7 mg/L (at 25 Â°C),3.48,0.0794,14.09,9.67,CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2,0.9,0.9,4,4,0,,259.1572289,2,2,0,0,0,0
449,02/07/2019 00:00,DB00572,Atropine,Atropine is rapidly and well absorbed after intramuscular administration. Atropine disappears rapidly from the blood and is distributed throughout the various body tissues and fluids.,0.22,3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.,0.25 mg/0.3mL,Intramuscular,solid,2200 mg/L (at 25 Â°C),1.83,2.52,15.15,9.39,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1,0.22,0.22,,,0,,289.1677936,3,1,2,0,2,2
450,04/06/2019 00:00,DB00573,Fenoprofen,"Rapidly absorbed under fasting conditions, and peak plasma levels of 50 &micro;g/mL are achieved within 2 hours after oral administration of 600 mg doses.",0.99,Plasma half-life is approximately 3 hours.,400 mg/1,Oral,solid,Slight (calcium salt),3.1,0.0811,3.96,-8.7,CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1,0.99,0.99,,,0,400,242.0942943,2,2,0,0,0,0
451,04/06/2019 00:00,DB00574,Fenfluramine,"Fenfluramine is well-absorbed from the gastrointestinal tract, and a maximal anorectic effect is generally seen after 2 to 4 hours.",,20 hours,20 mg,Oral,liquid,412 mg/L,3.36,0.0215,,10.22,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F,,,20,20,0,20,231.1234842,1,1,0,0,0,0
452,02/07/2019 00:00,DB00575,Clonidine,Well absorbed following oral administration. Bioavailability following chronic administration is approximately 65%.,,"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine. ",0.1 mg/24h,Transdermal,solid,Appreciable,1.59,0.48,,8.16,ClC1=CC=CC(Cl)=C1NC1=NCCN1,,,,,0,,229.0173526,2,1,1,0,0,1
453,04/06/2019 00:00,DB00576,Sulfamethizole,Rapidly absorbed.,98-99%,3-8 hours,,Oral,solid,1050 mg/L (at 37 Â°C),0.54,0.611,6.71,1.95,CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1,0.98,0.99,3,8,0,,270.0245176,2,2,1,1,0,0
454,02/07/2019 00:00,DB00577,Valaciclovir,"After oral administration, valacyclovir hydrochloride is rapidly absorbed from the gastrointestinal (GI) tract and converted to acyclovir and L-valine. The absolute bioavailability of acyclovir after administration of valacyclovir was measured at 54.5% Â± 9.1% after the administration of a 1 gram oral dose of valacyclovir and a 350 mg intravenous (IV) acyclovir dose to 12 healthy subjects. Acyclovir (a metabolite of valacyclovir) bioavailability from the administration of this drug is not affected by the administration with food [FDA label]. ",0.135,The plasma elimination half-life of acyclovir typically averaged 2.5 to 3.3 hours in several studies of valacyclovir in volunteers with normal renal function [FDA label]. ,1000 mg,Oral,solid,174 mg/mL at 25 degrees Celsius,-0.3,3.55,8.1,7.36,CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1NC(N)=NC2=O,0.135,0.135,,,0,1000,324.1546031,2,2,2,2,0,0
455,04/06/2019 00:00,DB00578,Carbenicillin,Rapidly absorbed from the small intestine following oral administration. Oral bioavailability is 30 to 40%.,0.6,1 hour,,,solid,451 mg/L,1.13,0.39,3.11,-6.3,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(O)=O)C1=CC=CC=C1)C(O)=O,0.6,0.6,1,1,0,,378.0885573,3,1,2,0,2,2
456,02/07/2019 00:00,DB00579,Mazindol,,,10-13 hours,1 mg,Oral,solid,,3.7,0.139,11.61,3.86,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1,,,10,13,0,1,284.0716407,4,2,2,0,0,2
457,04/06/2019 00:00,DB00580,Valdecoxib,Oral bioavailability is 83%.,0.98,8-11 hours,10 mg/1,Oral,solid,,3.2,0.0348,10.06,0.42,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,0.98,0.98,8,11,0,10,314.0725133,3,3,1,1,0,0
458,02/07/2019 00:00,DB00581,Lactulose,"After administration by the oral route, less than 3% of the given dose of lactulose solution is absorbed by the small intestine.[L6199] The remaining unabsorbed lactulose reaches the large intestine where it is metabolized - but even then, negligible quantities of unchanged lactulose or its metabolites are absorbed across the colon.[L6199,L6202]",,The data regarding the half-life of lactulose is not readily available or accessible.,667 mg,Oral,solid,"Soluble in cold water, hot water. Solubility in water: 76.4% @ 30 deg. C",-4.3,792,10.28,-3,OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,,,,,0,667,342.1162115,2,0,2,0,2,2
459,02/07/2019 00:00,DB00582,Voriconazole,The oral bioavailability is estimated to be 96% (CV 13%).,0.58,,200 mg,Intravenous,solid,Low,1,0.0978,12.71,2.27,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,0.58,0.58,,,0,,349.1150447,3,3,2,2,0,0
460,02/07/2019 00:00,DB00583,Levocarnitine,"Absolute bioavailability is 15% (tablets or solution).
Time to maximum plasma concentration was found to be 3.3 hours. ",,"17.4 hours (elimination) following a single intravenous dose.
",1 g/5mL,Oral,solid,2500 mg/mL,,5.33,4.2,-3.6,C[N+](C)(C)C[C@H](O)CC([O-])=O,,,,,0,,161.1051933,0,0,0,0,0,0
461,02/07/2019 00:00,DB00584,Enalapril,"Following oral administration, the peak plasma concentrations (Cmax) of enalapril is achieved within 1 hour post dosing while the Cmax of enalaprilat occurs at three to four hours post dosing.[label] The steady-state is achieved by the fourth daily dose and there is no accumulation with repeated dosing.[A179134] However, accumulation of enalaprilat may occur in patients with creatinine clearance less than 30 mL/min.[A179131] Food intake is reported to have a minimal effect on drug absorption.[A179119] Following oral administration, about 60% of enalapril was absorbed.[label] Bioavailability of enalapril averaged about 40% when intravenous enalaprilat was used as a reference standard.[A18459]",0.5,The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours. The prolonged terminal half-life is due to the binding of enalaprilat to ACE.[A179134],10 mg,Oral,solid,1.64E+004 mg/L,0.07,0.213,3.67,5.2,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,0.5,0.5,,,0,10,376.199822,2,1,1,0,1,1
462,02/07/2019 00:00,DB00585,Nizatidine,Rapid (bioavailability of nizatidine exceeds 70%),0.35,1-2 hours,150 mg/1,Oral,solid,10-33mg/mL,1.1,0.0386,,6.54,CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O,0.35,0.35,1,2,0,150,331.1136669,1,1,1,1,0,0
463,02/07/2019 00:00,DB00586,Diclofenac,Completely absorbed from the gastrointestinal tract.,0.99,2 hours,1 g/10mL,Oral,solid,2.37 mg/L (at 25 Â°C),4.51,0.00447,4,-2.1,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,0.99,0.99,2,2,0,,295.016684,2,2,0,0,0,0
464,04/06/2019 00:00,DB00587,Cinalukast,,,,,,solid,,4,0.000872,4.36,2.44,CCC(CC)(CC(=O)NC1=CC(\C=C\C2=NC(=CS2)C2CCC2)=CC=C1)C(O)=O,,,,,0,,412.1820638,3,2,1,1,0,0
465,02/07/2019 00:00,DB00588,Fluticasone propionate,"Intranasal bioavailability of fluticasone propionate is <2%, and oral bioavailability is <1%[F4358][FDA Label]. Intranasal exposure results in the majority of the dose being swallowed[A177118]. Topical absorption of fluticasone propionate is very low but can change depending on a number of factors including integrity of the skin and the presence of inflammation or disease[F4355]. A study of 24 healthy Caucasian males showed an inhaled bioavailability of 9.0%[A7490].",0.99,7.8 hours for intravenous fluticasone propionate[F4358][FDA Label]. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation[A7490].,113 mcg,Respiratory (inhalation),solid,Insoluble,2.78,0.0114,13.56,-3.4,[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,0.99,0.99,,,0,,500.1844298,4,0,0,0,0,0
466,04/06/2019 00:00,DB00589,Lisuride,,0.15,,,,solid,,2.2,0.14,15.36,6.88,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC,0.15,0.15,,,0,,338.2106615,4,2,2,1,0,1
467,02/07/2019 00:00,DB00590,Doxazosin,0.65,0.98,22 hours,4 mg/1,Oral,solid,24 mg/L,2.1,0.79,12.67,7.24,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1,0.98,0.98,22,22,0,4,451.1855689,5,3,3,1,1,2
468,02/07/2019 00:00,DB00591,Fluocinolone acetonide,"When administered as an eye implant, fluocinolone acetonide presents a sustained delivery for even 12 months in which there can be observed a sustained release.[L4686] The concentration of fluocinolone acetonide are generally higher in the vitreous and retina with a little dispersion to the aqueous humor.[T359]

There are reports indicating that topical administration of fluocinolone acetonide produces a percutaneous absorption which is determined by the vehicle, integrity of the epidermal barrier and the use of occlusive dressing.[F1956]

Independently of the route of administration, the systemic absorption of fluocinolone acetonide is below 0.1 ng/ml which indicates that the systemic distribution is very minimal and the effect of fluocinolone is mainly local.[A39533]",,The reported half-life of fluocinolone acetonide ranges between 1.3-1.7 hours.[A39536],1 mg/1mg,Topical,solid,Insoluble,2.48,0.0547,13.38,-3.3,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,,,,,0,,452.2010451,5,0,1,0,1,1
469,02/07/2019 00:00,DB00592,Piperazine,Rapidly absorbed from the gastrointestinal tract,60-70%,,2 g,Oral,solid,1E+006 mg/L (at 25 Â°C),-1.5,371,,9.56,C1CNCCN1,0.6,0.7,,,0,,86.08439832,1,0,1,0,1,1
470,02/07/2019 00:00,DB00593,Ethosuximide,Bioavailability following oral administration is 93%.,,53 hours,251,Oral,solid,39.2 g/L,0.38,101,10.73,-6.6,CCC1(C)CC(=O)NC1=O,,,53,53,0,,141.0789786,1,0,1,0,1,1
471,02/07/2019 00:00,DB00594,Amiloride,Readily absorbed following oral administration.,,Plasma half-life varies from 6 to 9 hours.,5 mg/1,Oral,solid,Slightly soluble,-0.3,1.22,16.46,3.29,NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1,,,,,0,5,229.0478856,1,1,1,1,0,0
472,04/06/2019 00:00,DB00595,Oxytetracycline,Readily absorbed following oral administration.,,,250 mg/1,Ophthalmic,solid,313 mg/L (at 25 Â°C),-0.9,1.4,2.84,7.41,[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,,,,,0,,460.1481803,4,1,0,0,0,0
473,02/07/2019 00:00,DB00596,Ulobetasol,The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.,,,0.1 mg/1g,Topical,solid,Mostly insoluble,2.9,0.022,12.46,-3.4,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,428.1565935,4,0,0,0,0,0
474,02/07/2019 00:00,DB00597,Gadoteridol,,,"Distribution 12 minutes (mean), elimination 100 minutes (mean).",279.3 mg/1mL,Intravenous,solid,,,11.2,0.76,10,[Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,,,,,0,,559.1277282,1,0,1,0,1,1
475,02/07/2019 00:00,DB00598,Labetalol,Completely absorbed (100%) from the gastrointestinal tract with peak plasma levels occurring 1 to 2 hours after oral administration. The absolute bioavailability of labetalol is increased when administered with food.,0.5,6-8 hours,1 kg/1kg,Not applicable,solid,117 mg/L (at 25 Â°C),3.09,0.00578,8.05,9.8,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1,0.5,0.5,6,8,0,,328.1786926,2,2,0,0,0,0
476,02/07/2019 00:00,DB00599,Thiopental,Rapidly absorbed.,0.8,3-8 hours,25 mg,Intravenous,solid,,2.85,0.0398,7.2,-3,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,0.8,0.8,3,8,0,,242.1088988,1,0,1,0,1,1
477,04/06/2019 00:00,DB00600,Monobenzone,,,,200 mg/1g,Topical,solid,251 mg/L,3.2,0.0392,9.91,-4.8,OC1=CC=C(OCC2=CC=CC=C2)C=C1,,,,,0,,200.0837296,2,2,0,0,0,0
478,02/07/2019 00:00,DB00601,Linezolid,"Linezolid is rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.",0.31,4.5-5.5 hours,2 mg/1mL,Intravenous,solid,3 mg/mL,0.9,1.44,14.45,-0.66,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,0.31,0.31,4.5,5.5,0,,337.1437843,3,1,2,0,2,2
479,02/07/2019 00:00,DB00603,Medroxyprogesterone acetate,Rapidly absorbed from GI tract,0.9,50 days,100 mg,Oral,solid,22.2mg/L,3.5,0.00221,17.82,-4.9,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,0.9,0.9,1200,1200,0,100,386.2457096,4,0,0,0,0,0
480,04/06/2019 00:00,DB00604,Cisapride,"Cisapride is rapidly absorbed after oral administration, with an absolute bioavailability of 35-40%.",0.975,6-12 hours,1 mg,Oral,solid,2.71 mg/L,3.3,0.012,14.58,8.24,CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC,0.975,0.975,6,12,0,1,465.1830623,3,2,1,0,1,1
481,02/07/2019 00:00,DB00605,Sulindac,Approximately 90% absorbed in humans following oral administration.,0.93,The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.,150 mg/1,Oral,solid,3000 mg/L,3.42,0.0251,4.09,-6.7,CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O,0.93,0.93,,,0,150,356.0882436,3,2,0,0,0,0
482,04/06/2019 00:00,DB00606,Cyclothiazide,,,,,,solid,,1.95,0.279,9.06,-2.5,NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2,,,,,0,,389.0270757,4,1,1,0,0,1
483,04/06/2019 00:00,DB00607,Nafcillin,"Following intravenous administration of 500mg nafcillin, the mean plasma concentration was approximately 30 Âµg/mL. This value was reached after 5 minutes of injection [FDA Label]. ",,The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.,1 g/1,Intramuscular; Intravenous,solid,Soluble,3.3,0.0172,3.31,-1.6,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O,,,,,0,,414.1249428,4,2,2,0,2,2
484,02/07/2019 00:00,DB00608,Chloroquine,Completely absorbed from gastrointestinal tract,~55%,1-2 months,250 mg/1,Oral,solid,10.6 mg/L,4.63,0.0175,,10.32,CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1,0.55,0.55,730,1460,0,250,319.1815255,2,2,1,1,0,0
485,04/06/2019 00:00,DB00609,Ethionamide,Essentially completely absorbed following oral administration and not subjected to any appreciable first pass metabolism. Bioavailability approximately 100%.,0.3,2 to 3 hours,250 mg/1,Oral,solid,Practically insoluble,0.5,0.839,11.89,5,CCC1=NC=CC(=C1)C(N)=S,0.3,0.3,,,0,250,166.0564693,1,1,1,1,0,0
486,04/06/2019 00:00,DB00610,Metaraminol,"The effect starts 1-2 min after IV injection, 10 min after IM injection, 5-20 min after subcutaneous injection.",0.45,,,,solid,1000 g/L,-0.27,12.8,9.03,9.68,C[C@H](N)[C@H](O)C1=CC(O)=CC=C1,0.45,0.45,,,0,,167.0946287,1,1,0,0,0,0
487,02/07/2019 00:00,DB00611,Butorphanol,"Rapidly absorbed after intramuscular injection and peak plasma levels are reached in 20-40 minutes. The absolute bioavailability is 60-70% and is unchanged in patients with allergic rhinitis. In patients using a nasal vasoconstrictor (oxymetazoline) the fraction of the dose absorbed was unchanged, but the rate of absorption was slowed. Oral bioavailability is only 5-17% because of extensive first-pass metabolism.",,"The elimination half-life of butorphanol is about 18 hours. In renally impaired patients with creatinine clearances &lt;30 mL/min the elimination half-life is approximately doubled. After intravenous administration to patients with hepatic impairment, the elimination half-life of butorphanol was approximately tripled.",10 mg,Nasal,solid,Moderate,3.3,0.16,9.86,10.7,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,,,,,0,,327.2198292,5,1,1,0,1,1
488,02/07/2019 00:00,DB00612,Bisoprolol,Well absorbed. Bioavailability > 80%. Absorption is not affected by food. Peak plasma concentrations occur within 2-4 hours. ,0.3,9-12 hours; prolonged in the elderly and those with decreased renal function,10 mg/1,Oral,solid,2240 mg/L,1.87,0.0707,14.09,9.67,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1,0.3,0.3,,,0,10,325.2253085,1,1,0,0,0,0
489,04/06/2019 00:00,DB00613,Amodiaquine,Rapidly absorbed following oral administration.,,5.2 &plusmn; 1.7 (range 0.4 to 5.5) minutes,,,solid,,3.7,0.0088,9.12,10.23,CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1,,,,,0,,355.14514,3,3,1,1,0,0
490,04/06/2019 00:00,DB00614,Furazolidone,Radiolabeled drug studies indicate that furazolidone is well absorbed following oral administration,,10 minutes,,,solid,40 mg/L (at 25 Â°C),-0.04,0.364,,-2.4,[H]C(=NN1CCOC1=O)C1=CC=C(O1)[N+]([O-])=O,,,0.166666667,0.166666667,0,,225.0385703,2,1,2,1,1,1
491,02/07/2019 00:00,DB00615,Rifabutin,"Rifabutin is readily absorbed from the gastrointestinal tract, with an absolute bioavailability averaging 20%.",0.85,45 (&plusmn; 17) hours,150 mg/1,Oral,solid,Minimally soluble (0.19 mg/mL),4.1,0.017,7.93,8.62,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21,0.85,0.85,,,0,150,846.4415088,6,1,4,0,1,4
492,04/06/2019 00:00,DB00616,Candoxatril,,,,,,solid,,3.7,0.00225,4.29,1.32,COCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1,,,,,0,,515.2883027,4,1,0,0,0,0
493,04/06/2019 00:00,DB00617,Paramethadione,Rapid via the digestive tract.,,12 to 24 hours (however the half-life for the active metabolite is not known),,,liquid,8.4 mg/mL,0.3,135,,,CCC1(C)OC(=O)N(C)C1=O,,,,,0,,157.0738932,1,0,1,0,1,1
494,04/06/2019 00:00,DB00618,Demeclocycline,Tetracyclines are readily absorbed.,41-50%,10-17 hours,300 mg,Oral,solid,1520 mg/L (at 21 Â°C),0.2,0.53,-2.6,8.23,[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O,0.41,0.5,10,17,0,300,464.0986433,4,1,0,0,0,0
495,02/07/2019 00:00,DB00619,Imatinib,The pharmacokinetics in CML and GIST patients are similar. Imatinib is well absorbed with mean absolute bioavailability is 98% and maximum plasma levels achieved within 2-4 hours of dosing,0.95,"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively. ",100 mg,Oral,solid,Very soluble in water at pH < 5.5 (mesylate salt),3,0.0146,12.45,8.27,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,0.95,0.95,,,0,100,493.2590086,5,4,3,2,1,1
496,02/07/2019 00:00,DB00620,Triamcinolone,Rapid absorption following oral administration,0.68,88 minutes,0.5 mg/1mL,Nasal,solid,80 mg/L (at 25 Â°C),1.16,0.847,11.75,-3.3,[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,0.68,0.68,1.466666667,1.466666667,0,,394.1791668,4,0,0,0,0,0
497,04/06/2019 00:00,DB00621,Oxandrolone,,,"0.55 hours (1st phage), 9 hours (2nd phase)",10 mg/1,Oral,solid,,4.2,0.014,,-0.53,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C,,,,,0,10,306.2194948,4,0,1,0,1,1
498,04/06/2019 00:00,DB00622,Nicardipine,"While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.",>95%,8.6 hours,30 mg/1,Oral,solid,2.2 mg/L,3.82,0.00247,,8.18,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1,0.95,1,8.6,8.6,0,30,479.2056356,3,2,1,0,0,1
499,02/07/2019 00:00,DB00623,Fluphenazine,,,,2.5 mg,Oral,liquid,31.1 mg/L (at 37 Â°C),4.36,0.019,15.59,8.21,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,,,,,0,2.5,437.1748681,4,2,2,0,1,2
500,02/07/2019 00:00,DB00624,Testosterone,Approximately 10% of the testosterone dose applied on the skin surface is absorbed into systemic circulation,0.4,10-100 minutes,12.2 mg/1,Transdermal,solid,23.4 mg/L (at 25 Â°C),3.32,0.0333,18.52,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.4,0.4,0.166666667,1.666666667,0,,288.2089301,4,0,0,0,0,0
501,02/07/2019 00:00,DB00625,Efavirenz,,99.5-99.75%,40-55 hours,100 mg/1,Oral,solid,,4.6,0.00855,12.52,-1.5,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,0.995,0.9975,40,55,0,100,315.0273909,3,1,1,0,0,1
502,02/07/2019 00:00,DB00626,Bacitracin,Absorption of bacitracin following intramuscular injection is rapid and complete. Absorption from the gastrointestinal tract following oral administration is not appreciable. Absorption following topical application is negligible.,,,500 1/1g,Topical,solid,Freely soluble,-0.8,0.0245,3.19,9.63,CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC,,,,,0,,1421.748941,4,2,3,1,1,2
503,02/07/2019 00:00,DB00627,Niacin,Both nicotinic acid and nicotinamide are efficiently absorbed from the stomach and small intestine.,,20-45 minutes.,50 mg,Oral,solid,1.8E+004 mg/L (at 25 Â°C),0.36,83.1,2.79,4.19,OC(=O)C1=CN=CC=C1,,,0.333333333,0.75,0,50,123.0320284,1,1,1,1,0,0
504,02/07/2019 00:00,DB00628,Clorazepic acid,Rapidly absorbed following oral administration (bioavailability is 91%).,,"The serum half-life is about 2 days. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.",15 mg,Oral,solid,Very soluble,3,0.0248,3.32,-0.64,OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,,,,,0,15,314.0458199,3,2,1,0,0,1
505,04/06/2019 00:00,DB00629,Guanabenz,Approximately 75% absorbed from gastrointestinal tract,0.9,6 hours.,4 mg/1,Oral,solid,,3.2,0.0889,,6.82,NC(N)=NN=CC1=C(Cl)C=CC=C1Cl,0.9,0.9,6,6,0,4,230.0126016,1,1,0,0,0,0
506,02/07/2019 00:00,DB00630,Alendronic acid,Mean oral bioavailability of alendronic acid in women is 0.64% and in men is 0.59%[FDA Label][A176750]. Bioavailability of alendronic acid decreases by up to 40% if it is taken within an hour of a meal[FDA Label].,,"Due to alendronic acid being incorporated into the skeleton, the terminal half life is estimated to be over 10 years[FDA Label].",70 mg/75mL,Oral,solid,,,16.9,0.69,9.91,NCCCC(O)(P(O)(O)=O)P(O)(O)=O,,,,,0,,249.016725,0,0,0,0,0,0
507,02/07/2019 00:00,DB00631,Clofarabine,,0.47,The terminal half-life is estimated to be 5.2 hours.,1 mg/1mL,Intravenous,solid,,0,4.89,12.71,1.3,[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12,0.47,0.47,,,0,,303.0534451,3,2,3,2,1,1
508,02/07/2019 00:00,DB00632,Docosanol,Topical absorption has been shown to be minimal under conditions reflecting normal clinical use.,,,0.1,Topical,solid,,9,1.96E-05,16.84,-2,CCCCCCCCCCCCCCCCCCCCCCO,,,,,0,,326.3548661,0,0,0,0,0,0
509,02/07/2019 00:00,DB00633,Dexmedetomidine,,0.94,2 hours,100 ug/1mL,Intravenous,solid,Freely soluble in water,2.8,0.174,14.09,6.54,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1,0.94,0.94,2,2,0,,200.1313485,2,2,1,1,0,0
510,02/07/2019 00:00,DB00634,Sulfacetamide,,,7-12.8 hours,100 mg,Ophthalmic,solid,1.25E+004 mg/L (at 37 Â°C),-0.96,4.21,4.3,2.14,CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1,,,7,12.8,0,,214.0412132,1,1,0,0,0,0
511,02/07/2019 00:00,DB00635,Prednisone,"Readily absorbed from the gastrointestinal tract. Rayos, the delayed-release formulation, has a 4-hour release time. To compare, the delayed-release formulation has a Tmax of 6.0 - 6.5 hours in healthy male subjects, whereas the immediate-release formulation has a Tmax of 2.0 hours. The rate of absorption, Cmax, and exposure is comparable between formulations. ",,Half life of both the immediate- and delayed- release formulation is 2 to 3 hours. ,50 mg,Oral,solid,Very slightly soluble,1.46,0.111,12.58,-3.3,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,50,358.1780239,4,0,0,0,0,0
512,04/06/2019 00:00,DB00636,Clofibrate,"Completely but slowly absorbed from the intestine. Between 95% and 99% of an oral dose of clofibrate is excreted in the urine as free and conjugated clofibric acid; thus, the absorption of clofibrate is virtually complete.",(95%,Half-life in normal volunteers averages 18 to 22 hours (range 14 to 35 hours) but can vary by up to 7 hours in the same subject at different times.,1 g,Oral,liquid,Insoluble,3.3,0.029,,-4.9,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,0.95,0.95,,,0,,242.070972,1,1,0,0,0,0
513,04/06/2019 00:00,DB00637,Astemizole,Rapidly absorbed from the gastrointestinal tract.,0.967,1 day,10 mg,Oral,solid,432 mg/L,5.8,0.0012,,8.75,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,0.967,0.967,24,24,0,10,458.2481898,5,4,2,1,1,1
514,04/06/2019 00:00,DB00639,Butoconazole,"Following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1.7% (range 1.3-2.2%) of the dose was absorbed on average.",,,100 mg/5g,Vaginal,solid,Nitrate salt: 0.26 mg/ml (practically insoluble),6.7,0.000818,,6.78,ClC1=CC=C(CCC(CN2C=CN=C2)SC2=C(Cl)C=CC=C2Cl)C=C1,,,,,0,,410.0178026,3,3,1,1,0,0
515,02/07/2019 00:00,DB00640,Adenosine,,,Less than 10 secs,0.12 mg/30mL,Topical,solid,8230 mg/L,-1.05,14,12.45,3.94,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,,,,,0,,267.0967539,3,2,3,2,1,1
516,02/07/2019 00:00,DB00641,Simvastatin,"Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues. However, because simvastatin undergoes extensive first-pass metabolism, the availability of the drug in the systemic is low. Peak plasma concentration occurs 1.3 - 2.4 hours after administration. ",,3 hours,20 mg/5mL,Oral,solid,Insoluble ,4.68,0.0122,14.91,-2.8,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,,,3,3,0,,418.2719243,3,0,1,0,1,1
517,02/07/2019 00:00,DB00642,Pemetrexed,,0.81,3.5 hours,100 mg/4mL,Intravenous,solid,,-1.5,0.0905,2.72,20.82,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O,0.81,0.81,3.5,3.5,0,,427.1491834,3,3,2,2,0,0
518,02/07/2019 00:00,DB00643,Mebendazole,Poorly absorbed (approximately 5 to 10%) from gastrointestinal tract. Fatty food increases absorption.,90-95%,2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).,100 mg/1,Oral,solid,71.3 mg/L (at 25 Â°C),2.83,0.0387,8.44,3.93,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1,0.9,0.95,,,0,100,295.0956913,3,3,1,1,0,0
519,02/07/2019 00:00,DB00644,Gonadorelin,Rapidly absorbed when injected,,"Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes",.5 mg,Intravenous; Subcutaneous,liquid,1 mg/mL,-3.6,0.0588,9.47,11.16,CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,,,,,0,,1181.573025,6,4,4,2,2,2
520,02/07/2019 00:00,DB00645,Dyclonine,"Readily absorbed through mucous membranes into the systemic circulation. The rate of absorption is influenced by the vascularity or rate of blood flow at the site of application, the total dosage (concentration and volume) administered, and the duration of exposure. Absorption from mucous membranes of the throat or respiratory tract may be especially rapid.",,Approximately 30 to 60 minutes.,0.001,Topical,solid,Soluble (HCl salt),3.7,0.046,15.88,8.36,CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1,,,,,0,,289.2041791,2,1,1,0,1,1
521,02/07/2019 00:00,DB00646,Nystatin,Nystatin is not absorbed from intact skin or mucous membrane.,,,100000 unit,Oral,solid,360 mg/L (at 24 Â°C),0.5,0.066,3.62,9.11,C[C@H]1OC(OC2CC(O)C(C(O)CC(=O)CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)OC(C)C(C)C(O)C(C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)C(O)=O)[C@@H](O)[C@@H](N)[C@@H]1O,,,,,0,,925.5034999,2,0,2,0,1,2
522,04/06/2019 00:00,DB00647,Dextropropoxyphene,,,6-12 hours,65 mg,Oral,solid,3.32 mg/L (at 25 Â°C),4.18,0.00419,,9.52,CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1,,,6,12,0,65,339.2198292,2,2,0,0,0,0
523,02/07/2019 00:00,DB00648,Mitotane,About 40% oral Lysodren is absorbed,0.06,18-159 days,500 mg/1,Oral,solid,0.1 mg/L (at 25 Â°C),6,9.42E-06,,,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl,0.06,0.06,432,3816,0,500,317.953661,2,2,0,0,0,0
524,02/07/2019 00:00,DB00649,Stavudine,"Following oral administration, stavudine is rapidly absorbed (bioavailability is 68-104%).",,0.8-1.5 hours (in adults),15 mg/1,Oral,solid,5-10 g/100 mL at 21 Â°C,-0.72,40.5,9.95,-3,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O,,,,,0,15,224.0797069,2,1,2,1,0,1
525,02/07/2019 00:00,DB00650,Leucovorin,"Following oral administration, leucovorin is rapidly absorbed. The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.",~15%,6.2 hours,5 mg,Oral,solid,Complete,-3.2,0.297,3.47,2.81,[H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2,0.15,0.15,6.2,6.2,0,5,473.1658961,3,2,2,1,0,1
526,04/06/2019 00:00,DB00651,Dyphylline,,0.84,2 hours (range 1.8 - 2.1 hours),200 mg/1,Oral,solid,3.33E+005 mg/L (at 25 Â°C),-1.9,14.3,13.91,-0.97,CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O,0.84,0.84,,,0,200,254.1015049,2,2,2,2,0,0
527,02/07/2019 00:00,DB00652,Pentazocine,Well absorbed from the gastro-intestinal tract.,,2 to 3 hours,30 mg/1mL,Oral,solid,,4.64,0.122,7.59,12.4,C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C,,,,,0,,285.2092645,3,1,1,0,1,1
528,02/07/2019 00:00,DB00654,Latanoprost,Latanoprost is well absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form. Peak concentration is reached 2 hrs after topical administration.,,17 minutes,50 ug/1mL,Ophthalmic,liquid,8 mg/mL,4.4,0.0129,14.47,-2.7,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1,,,0.283333333,0.283333333,0,,432.2875744,2,1,0,0,0,0
529,02/07/2019 00:00,DB00655,Estrone,0.43,0.95,19 hours,0.001,Vaginal,solid,0.76 g/L at 20 ÂºC,2.6,0.00394,10.33,-5.4,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,0.95,0.95,19,19,0,,270.1619799,4,1,0,0,0,0
530,02/07/2019 00:00,DB00656,Trazodone,Rapidly and almost completely absorbed following oral administration. Food may decrease the rate and extent of absorption. ,89-95%,Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.,150 mg,Oral,solid,Sparigly soluble,2.9,0.29,,7.09,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,0.89,0.95,,,0,150,371.151288,4,3,3,2,1,1
531,04/06/2019 00:00,DB00657,Mecamylamine,Mecamylamine is almost completely absorbed from the gastrointestinal tract,0.4,,2.5 mg/1,Oral,liquid,,2.7,0.124,,10.88,CNC1(C)C2CCC(C2)C1(C)C,0.4,0.4,,,0,2.5,167.1673997,2,0,0,0,0,0
532,02/07/2019 00:00,DB00659,Acamprosate,The absolute bioavailability of acamprosate after oral administration is about 11%. The food effect on absorption is not clinically significant and no adjustment of dose is necessary.,,20 - 33 hours,333 mg/1,Oral,solid,,-1.1,18.8,-1.1,-0.47,CC(=O)NCCCS(O)(=O)=O,,,,,0,333,181.0408788,0,0,0,0,0,0
533,04/06/2019 00:00,DB00660,Metaxalone,The absolute bioavailability of metaxalone from Skelaxin tablets is not known.,,9.2 (+/- 4.8) hours,640 mg/1,Oral,solid,,2.3,1.28,13.14,-4.9,CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1,,,,,0,640,221.1051933,2,1,1,0,1,1
534,02/07/2019 00:00,DB00661,Verapamil,0.9,0.9,2.8-7.4 hours,80 mg,Oral,liquid,4.47 mg/L,3.79,0.00394,,9.68,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1,0.9,0.9,2.8,7.4,0,80,454.2831577,2,2,0,0,0,0
535,04/06/2019 00:00,DB00662,Trimethobenzamide,The relative bioavailability of the capsule formulation compared to the solution is 100%.,,The mean elimination half-life of trimethobenzamide is 7 to 9 hours.,100 mg/1mL,Intramuscular,solid,40 mg/L,2.29,0.0398,14.36,8.77,COC1=CC(=CC(OC)=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1,,,,,0,,388.199822,2,2,0,0,0,0
536,02/07/2019 00:00,DB00663,Flumethasone,Minimal if applied topically,,,0.0003,Topical,solid,0.392 mg/L,3.86,0.0853,12.42,-3.3,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,410.1904804,4,0,0,0,0,0
537,04/06/2019 00:00,DB00664,Sulfametopyrazine,,,,,,solid,4030 mg/L,0.7,0.406,5.91,1.98,COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1,,,,,0,,280.0630112,2,2,1,1,0,0
538,02/07/2019 00:00,DB00665,Nilutamide,"Rapidly and completely absorbed, yielding high and persistent plasma concentrations.",,38.0-59.1 hours,50 mg,Oral,solid,,1.8,0.00419,15.01,-4.4,CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,,,38,59.1,0,50,317.0623405,2,1,1,0,1,1
539,02/07/2019 00:00,DB00666,Nafarelin,Rapidly absorbed into the systemic circulation after intranasal administration. Bioavailability from a 400 &micro;g dose averaged 2.8% (range 1.2 to 5.6%). Not absorbed after oral administration.,,3 hours,2 mg,Nasal,solid,,,0.0144,9.47,11.16,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,,,3,3,0,,1321.635626,8,6,4,2,2,2
540,02/07/2019 00:00,DB00668,Epinephrine,"Following I.V. (intravenous) injection, epinephrine disappears rapidly from the blood stream. Subcutaneously or I.M. (intramuscular) administered epinephrine has a rapid onset and short duration of action. Subcutaneous (SC) administration during asthmatic attacks may produce bronchodilation within 5 to 10 minutes, and maximal effects may occur within 20 minutes. The drug becomes fixed in the tissues rapidly [F1247], [FDA label].",,"The plasma half-life is approximately 2-3 minutes. However, when administered by subcutaneous or intramuscular injection, local vasoconstriction may delay absorption so that epinephrine's effects may last longer than the half-life suggests [L4361].",1 mg/1mL,Intramuscular; Subcutaneous,solid,less than 0.1 mg/mL at 64Â° F,-1.37,18.6,9.69,8.91,CNC[C@H](O)C1=CC(O)=C(O)C=C1,,,,,0,,183.0895433,1,1,0,0,0,0
541,02/07/2019 00:00,DB00669,Sumatriptan,"A 6mg subcutaneous injection of sumatriptan reaches a C<sub>max</sub> of 69.5ng/mL (95% CI  of 62.8-76.9ng/mL) with a T<sub>max</sub> of 0.17h (95% CI  of 0.08-0.33h), an AUC of 9.0h\*ng/mL (95% CI of 7.5-10.9h\*ng/mL), and a bioavailability of 100%.[A179737]

A 25mg oral dose of sumatriptan reaches a C<sub>max</sub> of 16.5ng/mL (95% CI  of 13.5-20.1ng/mL) with a T<sub>max</sub> of 1.50h (95% CI  of 0.50-2.00h), an AUC of 8.7h\*ng/mL (95% CI of 6.1-12.5h\*ng/mL), and a bioavailability of 14.3% (95% CI of 11.4-17.9%).[A179737]

A 20mg intranasal dose of sumatriptan reaches a C<sub>max</sub> of 12.9ng/mL (95% CI  of 10.5-15.9ng/mL) with a T<sub>max</sub> of 1.50h (95% CI  of 0.25-3.00h), an AUC of 7.4h\*ng/mL (95% CI of 5.0-10.8h\*ng/mL), and a bioavailability of 15.8% (95% CI of 12.6-19.8%).[A179737]

A 25mg rectal dose of sumatriptan reaches a C<sub>max</sub> of 22.9ng/mL (95% CI  of 18.4-28.6ng/mL) with a T<sub>max</sub> of 1.00h (95% CI  of 0.75-3.00h), an AUC of 14.6h\*ng/mL (95% CI of 11.3-18.8h\*ng/mL), and a bioavailability of 19.2% (95% CI of 15.3-24.1%).[A179737]",14%-21%,Subcutaneous sumatriptan has a half life of 1.9h (95% CI  of 1.7-2.0h).[A179737] Oral sumatriptan has a half life of 1.7h (95% CI  of 1.4-1.9h).[A179737] Rectal sumatriptan has a half life of 1.8h (95% CI  of 1.6-2.2h).[A179737] Intrsnasal sumatriptan has a half life of 1.8h (95% CI  of 1.7-2.0h).[A179737],20 mg,Nasal,solid,54mg/mL,0.93,0.127,11.24,9.54,CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1,0.14,0.21,,,0,,295.1354479,2,2,1,1,0,0
542,04/06/2019 00:00,DB00670,Pirenzepine,,,,50 mg,Oral,solid,,0.6,0.682,9.57,7.59,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,,,,,0,50,351.1695249,4,2,3,1,1,2
543,02/07/2019 00:00,DB00671,Cefixime,"About 40%-50% absorbed orally whether administered with or without food, however, time to maximal absorption is increased approximately 0.8 hours when administered with food.",0.65,"3-4 hours (may range up to 9 hours). In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours.",400 mg,Oral,solid,55.11 mg/L,-0.4,0.104,3.45,2.92,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O,0.65,0.65,,,0,400,453.0412898,3,1,3,1,1,2
544,02/07/2019 00:00,DB00672,Chlorpropamide,Readily absorbed from the GI tract. Peak plasma concentrations occur within 2-4 hours and the onset of action occurs within one hour. The maximal effect of chlorpropamide is seen 3-6 hours following oral administration. ,,Approximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours. ,100 mg,Oral,solid,258 mg/L (at 37 Â°C),2.27,0.157,4.33,,CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1,,,,,0,100,276.033541,1,1,0,0,0,0
545,02/07/2019 00:00,DB00673,Aprepitant,The mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.,,9-13 hours,125 mg/1,Oral,solid,Practically insoluble,4.5,0.0194,9.65,3.51,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,,,9,13,0,125,534.1501881,4,3,2,1,1,1
546,02/07/2019 00:00,DB00674,Galantamine,,0.18,7 hours,12 mg/1,Oral,solid,10 mg/mL (HBr salt),1.8,1.7,14.81,8.91,[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3,0.18,0.18,7,7,0,12,287.1521435,4,1,2,0,0,2
547,02/07/2019 00:00,DB00675,Tamoxifen,"When a single oral dose of 20 mg is given, the average peak plasma concentration (Cmax) is 40 ng/mL which occurred approximately 5 hours after dosing (Tmax). The Cmax of N-desmethyl tamoxifen is 15 ng/mL. Steady-state concentrations for tamoxifen is achieved in 4 weeks, while steady-state concentrations for N-desmethyl tamoxifen is achieved in 8 weeks. ",,The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days. ,10 mg,Oral,solid,0.000167 mg/mL at 25 Â°C,7.1,0.00102,,8.76,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,,,,,0,10,371.2249145,3,3,0,0,0,0
548,04/06/2019 00:00,DB00676,Benzyl benzoate,"No data are available on percutaneous absorption of benzyl benzoate. Some older studies have suggested some percutaneous absorption, however the amount was not quantified.",,,,,liquid,15.4 mg/L,3.97,0.0198,,-6.9,O=C(OCC1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,212.0837296,2,2,0,0,0,0
549,04/06/2019 00:00,DB00677,Isoflurophate,,,,,,liquid,1.54E+004 mg/L (at 25 Â°C),1.17,6.78,,-9.6,CC(C)OP(F)(=O)OC(C)C,,,,,0,,184.0664592,0,0,0,0,0,0
550,02/07/2019 00:00,DB00678,Losartan,"Losartan is well absorbed and undergoes substantial first-pass metabolism; the systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. While maximum plasma concentrations of losartan and its active metabolite are approximately equal, the AUC of the metabolite is about 4 times as great as that of losartan. When given with a meal, absorption is slows down and Cmax decreases. ",0.997,The terminal t<sub>1/2</sub> of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours. ,100.0 mg,Oral,solid,0.82 mg/L,6.1,0.0047,7.4,4.12,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,0.997,0.997,,,0,100,422.162187,4,4,2,2,0,0
551,04/06/2019 00:00,DB00679,Thioridazine,0.6,0.95,21-25 hours,30 mg,Oral,solid,0.0336 mg/L,5.9,0.000855,,8.93,CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1,0.95,0.95,21,25,0,30,370.1537408,4,2,2,0,1,2
552,04/06/2019 00:00,DB00680,Moricizine,"Well absorbed, absorption is complete within 2 to 3 hours. Significant first-pass metabolism results in an absolute bioavailability of approximately 38%. Administration within 30 minutes after a meal slows the rate, but does not affect the extent of absorption, although peak plasma concentrations are reduced.",,2 hours (range 1.5-3.5 hours).,200 mg/1,Oral,solid,0.457 mg/L,2.98,0.0339,12.9,6.73,CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN2CCOCC2)C=C1,,,,,0,200,427.1565773,4,2,2,0,1,2
553,02/07/2019 00:00,DB00681,Amphotericin B,Bioavailability is 100% for intravenous infusion.,,An elimination half-life of approximately 15 days follows an initial plasma half-life of about 24 hours.,5 mg,Intravenous,solid,750 mg/L (at 28 Â°C),0.8,0.0819,3.58,9.11,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,,,,,0,,923.4878499,3,0,3,0,2,3
554,02/07/2019 00:00,DB00682,Warfarin,"Completely absorbed from the GI tract. The mean Tmax for warfarin sodium tablets is 4 hours.[label,L6616,A2460]",0.99,"R-warfarin is cleared more slowly than S-warfarin, at about half the rate.[label] T<sub>1/2</sub> for R-warfarin is 37-89 hours. T<sub>1/2</sub> for S-warfarin is 21-43 hours.",2 mg/1mL,Intravenous,solid,17 mg/L (at 20 Â°C),2.7,0.0472,6.33,-6.6,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,0.99,0.99,,,0,,308.104859,3,3,1,1,0,0
555,02/07/2019 00:00,DB00683,Midazolam,"**Oral Absorption**: Rapidly absorbed after oral administration.  The absolute bioavailability, if given intramuscularly (IM), is greater than 90% [FDA label]. Due to first pass metabolism, only 40-50% of the administered oral dose reaches the circulation.[A173842] The absolute bioavailability of the midazolam syrup in pediatric patients is about 36%.[L5092]

**Intramuscular Absorption**:  The mean peak concentration (Cmax) and time to peak (Tmax) following the IM dose was 90 ng/mL (20% CV) and 0.5 hour (50% CV).[FDA label]

**Rectal administration**: After rectal administration midazolam is absorbed rapidly. Maximum plasma concentration is reached within 30 minutes. The absolute bioavailability is approximately 50%.[F2977]


**Intranasal Administration**: Midazolam is absorbed rapidly after intranasal administration. Mean peak plasma concentrations are reached within 10.2 to 12.6 minutes. The bioavailability is between 55 and 57%.[F2977]
",0.97,"**Intravenous**: healthy adults = 1.8 to 6.4 hours (mean of 3 hours).[F2434]

**Intramuscular**: Following IM administration of 10 mg midazolam, mean (Â±SD) elimination half-life was 4.2 (Â±1.87) hours.[FDA label]",1 mg,Intramuscular; Intravenous,solid,soluble,,0.00987,,6.57,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,0.97,0.97,,,0,,325.0782033,4,3,2,1,0,1
556,02/07/2019 00:00,DB00684,Tobramycin,The bioavailability of tobramycin may vary because of individual differences in nebulizer performance and airway pathology.,,The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration.,300 mg/4mL,Respiratory (inhalation),solid,1E+003 mg/ml,-5.8,53.7,12.54,9.83,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,,,,,0,,467.2591278,3,0,2,0,2,2
557,04/06/2019 00:00,DB00685,Trovafloxacin,Well-absorbed from the gastrointestinal tract after oral administration and does not depend on concomitant food intake. The absolute bioavailability is approximately 88%.,,"Following oral administration, half-life ranged from 9.1 hours to 12.2 hours over the dosage range of 100 to 200 mg tablets. Following intravenous infusion, half-life ranged from 9.4 to 12.7 hours over a dosage range of 100 to 300 mg.",5 mg/1mL,Intravenous,solid,12.3 mg/L (at 25 Â°C),0.31,0.0704,5.41,9.44,[H][C@@]12CN(C[C@]1([H])[C@H]2N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=C(F)C=C(F)C=C1)C(O)=O,,,,,0,,416.109625,5,3,3,2,1,1
558,02/07/2019 00:00,DB00686,Pentosan Polysulfate,Slow,,4.8 hours,100 mg/1,Oral,solid,,-8,3.49,-2.9,-3.6,O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O,,,4.8,4.8,0,100,601.9223416,2,0,2,0,2,2
559,02/07/2019 00:00,DB00687,Fludrocortisone,,,3.5 hours,0.1 mg,Oral,solid,140 mg/L (at 25 Â°C),1.67,0.224,12.55,-3.3,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,3.5,3.5,0,0.1,380.1999022,4,0,0,0,0,0
560,02/07/2019 00:00,DB00688,Mycophenolate mofetil,"Rapidly absorbed following oral administration. In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. The absolute bioavailability of the delayed release tablet in stable renal transplant patients on cyclosporin is 72%. Food (27 g fat, 650 calories) has no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil.",0.98,"The mean elimination half-life for mycophenolic acid (the active metabolite) ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.",250 mg,Oral,solid,Slightly soluble (43 Î¼g/mL at pH 7.4); 4.27 mg/mL at pH 3.6,2.5,0.095,9.76,6.19,COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C,0.98,0.98,,,0,250,433.2100523,3,1,2,0,1,2
561,02/07/2019 00:00,DB00689,Cephaloglycin,Well absorbed following oral administration.,,,,,solid,154 mg/L,-0.3,0.148,3.34,7.44,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,,,,,0,,405.0994563,3,1,2,0,1,2
562,02/07/2019 00:00,DB00690,Flurazepam,Flurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract,0.83,The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours,15 mg/1,Oral,solid,500 mg/mL (HCl salt),3.8,0.01,,8.71,CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F,0.83,0.83,,,0,15,387.1513683,3,2,1,0,0,1
563,04/06/2019 00:00,DB00691,Moexipril,"Moexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces C<sub>max</sub> and AUC by about 70% and 40%, respectively, after the ingestion of a low-fat breakfast or by 80% and 50%, respectively, after the ingestion of a high-fat breakfast.",0.5,Moexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.,15 mg/1,Oral,solid,Soluble (about 10% weight-to-volume) in distilled water at room temperature as HCl salt.,2.7,0.00585,3.46,5.2,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O,0.5,0.5,,,0,15,498.2366014,3,2,1,0,0,1
564,02/07/2019 00:00,DB00692,Phentolamine,,,19 minutes,0.235 mg/1mL,Submucosal,solid,,3.3,0.272,9.78,9.02,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1,,,0.316666667,0.316666667,0,0.01175,281.1528122,3,2,1,0,0,1
565,02/07/2019 00:00,DB00693,Fluorescein,Rapidly distributed,0.85,,100 mg/1mL,Intravenous,solid,600 mg/mL (sodium salt),3.4,0.0255,8.72,-3.7,OC1=CC=C2C(OC3=CC(O)=CC=C3C22OC(=O)C3=C2C=CC=C3)=C1,0.85,0.85,,,0,,332.0684735,5,3,2,0,0,2
566,02/07/2019 00:00,DB00694,Daunorubicin,,0.97,18.5 hours,20 mg/4mL,Intravenous,solid,39.2 mg/L,1.83,0.627,9.53,8.94,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O,0.97,0.97,18.5,18.5,0,,527.1791461,5,2,1,0,1,1
567,02/07/2019 00:00,DB00695,Furosemide,60% absorbed in patients with normal renal function,0.95,2 hours,20 mg,Oral,solid,73.1 mg/L (at 30 Â°C),2.03,0.118,4.25,-1.5,NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O,0.95,0.95,2,2,0,20,330.0077201,2,2,1,1,0,0
568,02/07/2019 00:00,DB00696,Ergotamine,The bioavailability of sublingually administered ergotamine has not been determined.,,2 hours,2 mg/1,Oral,solid,Slight,2,0.223,9.7,7.78,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O,,,2,2,0,2,581.2638192,8,3,5,1,3,4
569,02/07/2019 00:00,DB00697,Tizanidine,"This drug undergoes significant first-pass metabolism. After the administration of an oral dose, tizanidine is mostly absorbed. The absolute oral bioavailability of tizanidine is measured to be about 40% [FDA label]. 

**Effect of food on absorption**

Food has been shown to increase absorption for both the tablets and capsules. The increase in absorption with the tablet (about 30%) was noticeably higher than the capsule (~10%). When the capsule and tablet were administered with food, the amount absorbed from the capsule was about 80% of the amount absorbed from the tablet [FDA label]. It is therefore advisable to take this drug with food for increased absorption, especially in tablet form.",0.3,Approximately 2.5 hours [FDA label].,4 mg/1,Oral,solid,slightly soluble,1.72,0.133,,7.49,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,0.3,0.3,,,0,4,253.0188939,3,2,2,1,0,1
570,02/07/2019 00:00,DB00698,Nitrofurantoin,Nitrofurantoin reaches a C<sub>max</sub> of 0.875-0.963mg/L with an AUC of 2.21-2.42mg\*h/L.[A179830] It is 38.8-44.3% bioavailable.[A179830] Taking nitrofurantoin with food increases the absorption and duration of therapeutic concentrations in the urine.[A179854],0.9,The half life of nitrofurantoin is 0.72-0.78h.[A179830],25 mg/5mL,Oral,solid,79.5 mg/L (at 24 Â°C),-0.47,0.415,8.23,-2.2,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,0.9,0.9,,,0,,238.0338193,2,1,2,1,1,1
571,04/06/2019 00:00,DB00699,Nicergoline,,,,,,solid,,3.3,0.0127,,8.12,[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@]1(C[C@@H](COC(=O)C1=CN=CC(Br)=C1)CN2C)OC,,,,,0,,483.1157538,5,3,3,2,1,1
572,02/07/2019 00:00,DB00700,Eplerenone,The absolute bioavailability of eplerenone is unknown.,0.5,4-6 hours,50 mg/1,Oral,solid,Slightly soluble,1.3,0.00903,15.11,-4.2,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,0.5,0.5,4,6,0,50,414.2042387,6,0,2,0,2,2
573,04/06/2019 00:00,DB00701,Amprenavir,Rapidly absorbed after oral administration in HIV-1-infected patients with a time to peak concentration (T<sub>max</sub>) typically between 1 and 2 hours after a single oral dose. The absolute oral bioavailability of amprenavir in humans has not been established. ,,7.1-10.6 hours,150 mg,Oral,solid,,,0.0491,13.61,2.39,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,,,7.1,10.6,0,150,505.2246568,3,2,1,0,1,1
574,02/07/2019 00:00,DB00703,Methazolamide,Methazolamide is well absorbed from the gastrointestinal tract.,0.55,14 hours,25 mg/1,Oral,solid,3500 mg/L,0.13,1.74,7.21,-3.6,CN1N=C(SC1=NC(C)=O)S(N)(=O)=O,0.55,0.55,14,14,0,25,236.0037821,1,1,1,1,0,0
575,02/07/2019 00:00,DB00704,Naltrexone,"Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.",0.21,4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.,1000 mg/1,Subcutaneous,solid,100 mg/mL (as hydrochloride salt),1.92,3.07,7.39,11.54,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O,0.21,0.21,,,0,,341.1627082,6,1,2,0,1,2
576,02/07/2019 00:00,DB00705,Delavirdine,Rapidly absorbed,0.98,5.8 hours,100 mg/1,Oral,solid,,2.8,0.086,9.39,6.82,CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2,0.98,0.98,5.8,5.8,0,100,456.1943598,4,3,3,2,1,1
577,02/07/2019 00:00,DB00706,Tamsulosin,Oral tamsulosin is 90% absorbed in fasted patients.[Label] The area under the curve is 151-199ng/mL\*hr for a 0.4mg oral dose and 440-557ng/mL*hr for a 0.8mg oral dose.[Label] The maximum plasma concentration is 3.1-5.3ng/mL for a 0.4mg oral dose and 2.5-3.6ng/mL for a 0.8mg oral dose.[Label] Taking tamsulosin with food increases the time to maximum concentration from 4-5 hours to 6-7 hours but increases bioavailability by 30% and maximum plasma concentration by 40-70%.[Label],94%-99%,"The half life in fasted patients is 14.9Â±3.9 hours.[Label] The elimination half life is 5-7 hours and the apparent half life is 9 to 13 hours in healthy subjects.[Label] In patients who require tamsulosin, the apparent half life is 14-15 hours.[Label]",0.4 mg/1,Oral,solid,Sparingly soluble in water,,0.00655,9.93,9.28,CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O,0.94,0.99,,,0,0.4,408.171893,2,2,0,0,0,0
578,02/07/2019 00:00,DB00708,Sufentanil,"Bioavailability of a single sublingual tablet was 52%, decreasing to 35% with repeat dosing [A39629].

After epidural administration of incremental doses totaling 5 to 40 mcg sufentanil during labor and delivery, maternal and neonatal sufentanil plasma concentrations were at or near the 0.05 to 0.1 ng/mL limit of detection, and were slightly higher in mothers than in their infants [FDA label].
",0.93,"The elimination half-life is 164 minutes in adults when administered intravenously (IV). The elimination half-life of sufentanil is shorter (e.g. 97 +/- 42 minutes) in infants and children, and longer in neonates (e.g. 434 +/- 160 minutes) compared to that of adolescents and adults [FDA label].

After a single administration of a 15 microgram sufentanil sublingual tablet, mean terminal phase half-lives in the range of 6-10 hours have been observed. After multiple administrations, a longer average terminal half-life of up to 18 hours was measured, owing to the higher plasma concentrations of sufentanil achieved after repeated dosing and due to the possibility to quantify these concentrations over a longer time period [F2009].

",30 ug/1,Sublingual,solid,Soluble,3.95,0.012,,8.86,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1,0.93,0.93,,,0,0.03,386.2027992,3,2,2,1,1,1
579,02/07/2019 00:00,DB00709,Lamivudine,"Lamivudine was rapidly absorbed after oral administration in HIV-infected patients. Absolute bioavailability in 12 adult patients was 86% Â± 16% (mean Â± SD) for the 150-mg tablet and 87% Â± 13% for the oral solution. The peak serum lamivudine concentration (Cmax) was 1.5 Â± 0.5 mcg/mL when an oral dose of 2 mg/kg twice a day was given to HIV-1 patients. When given with food, absorption is slower, compared to the fasted state. ",<36%,5 to 7 hours (healthy or HBV-infected patients) ,10 mg,Oral,solid,70 mg/ml,-1.4,2.76,14.29,-0.16,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,0,0.36,,,0,10,229.0521122,2,1,2,1,1,1
580,04/06/2019 00:00,DB00710,Ibandronate,Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.,0.995,10-60 hours,3 mg,Intravenous,solid,Freely soluble,-2.1,13.4,0.66,9.93,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O,0.995,0.995,10,60,0,,319.0949753,0,0,0,0,0,0
581,04/06/2019 00:00,DB00711,Diethylcarbamazine,Readily absorbed following oral administration.,,Approximately 8 hours.,50 mg,Oral,solid,63.7 mg/mL at 25 Â°C,0.1,236,,6.9,CCN(CC)C(=O)N1CCN(C)CC1,,,,,0,50,199.1684623,1,0,1,0,1,1
582,02/07/2019 00:00,DB00712,Flurbiprofen,Fluribiprofen is rapidly and almost completely absorbed following oral administration. Peak plasma concentrations are reached 0.5 - 4 hours after oral administration. ,0.99,"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours",50 mg/1,Oral,solid,8 mg/L (at 22 Â°C),4.16,0.0249,4.42,,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,0.99,0.99,,,0,50,244.0899579,2,2,0,0,0,0
583,02/07/2019 00:00,DB00713,Oxacillin,,0.021,20 to 30 minutes,1 g/1,Intramuscular; Intravenous,solid,13.9 mg/L,2.38,0.0862,3.75,-0.12,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O,0.021,0.021,,,0,,401.1045417,4,2,3,1,2,2
584,02/07/2019 00:00,DB00714,Apomorphine,100% following subcutaneous administration,,40 minutes (range 30 - 60 minutes),30 mg/3mL,Subcutaneous,solid,1.66E+004 mg/L,3.1,0.51,6.58,13.25,[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23,,,,,0,,267.1259288,4,2,1,0,0,1
585,02/07/2019 00:00,DB00715,Paroxetine,"Paroxetine hydrochloride is slowly, but completely absorbed following oral administration. Paroxetine mesylate salt is also completely absorbed after oral dosing. The oral bioavailability appears to be low due to extensive first-pass metabolism. Paroxetine hydrochloride oral tablets and suspension are reportedly bioequivalent. Absorption of either salt form is not substantially affected by food. Peak concentrations of Brisbelle (mesylate salt) were reached at 6 hours (3 to 8 hours range). Steady state Cmax was 13.10 ng/mL. The steady state AUC (0-last) was 237 hr*ng/mL. Paroxetine mesylate generally follows non-linear pharmacokinetics because CYP2D6, the enzyme that is part responisible for paroxetine metabolism, is readily saturable. ",0.95,21-24 hours,7.5 mg/1,Oral,solid,>1 g/mL (mesylate salt) ,3.6,0.00853,,9.77,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1,0.95,0.95,21,24,0,7.5,329.1427217,4,2,2,0,1,2
586,02/07/2019 00:00,DB00716,Nedocromil,Low,0.89,~3.3 hours,0.02,Ophthalmic,solid,145 mg/L,2.22,0.0459,2.28,-4.2,CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O,0.89,0.89,3.3,3.3,0,,371.1005019,3,3,2,2,0,0
587,02/07/2019 00:00,DB00717,Norethisterone,"Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone is rapidly absorbed from norethindrone acetate, in which maximum plasma concentration occur 2 hours post-dose (Tmax). When a single dose is given to healthy women, the Cmax is 26.19 Â± 6.19 hours. The AUC (0-inf) is 166.90 Â± 56.28 ng/mL*h. Absolute oral bioavailability is approximately 64%. The effect of food on the pharmacokinetics of norethindrone acetate is unknown. ",0.36,8.51 Â± 2.19 (when a single dose is given to healthy women) ,0.35 mg/1,Oral,solid,7.04 mg/L (at 25 Â°C),2.97,0.00668,17.59,-1.7,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],0.36,0.36,,,0,0.35,298.1932801,4,0,0,0,0,0
588,02/07/2019 00:00,DB00718,Adefovir dipivoxil,"The approximate oral bioavailability of adefovir from HEPSERA is 59%. When a single oral 10 mg dose is given to chronic hepatitis B patients, the peak plasma concentration (Cmax) of adefovir was 18.4 Â± 6.26 ng/mL. This occurred between 0.58 - 4 hours post dose (Tmax). The adefovir area under the plasma concentration-time curve (AUC0â€“âˆž) was 220 Â± 70.0 ngâˆ™h/mL. Food does not affect the exposure of adeforvir. ",&le;4%,Plasma adefovir concentrations declined in a biexponential manner with a terminal elimination half-life of 7.48 Â± 1.65 hours.,10 mg/1,Oral,solid,19 mg/mL at pH 2.0 and 0.4 mg/mL at pH 7.2.,1.91,0.633,18.59,5.13,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C,0.04,0.04,,,0,10,501.1988496,2,2,2,2,0,0
589,04/06/2019 00:00,DB00719,Azatadine,Well absorbed after oral administration.,,,1 mg,Oral,solid,Very soluble,3.59,0.113,,7.91,CN1CCC(CC1)=C1C2=CC=CC=C2CCC2=C1N=CC=C2,,,,,0,1,290.1782987,4,2,2,1,1,1
590,02/07/2019 00:00,DB00720,Clodronic acid,"After oral administration, absorption is estimated at 1&ndash;3% of the ingested dose because of the low uptake from the gastrointestinal tract.",2%-36%,Approximately 13 hours.,60 mg,Intravenous,solid,395 mg/L,-2.4,7.47,0.62,,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O,0.02,0.36,,,0,,243.8860165,0,0,0,0,0,0
591,04/06/2019 00:00,DB00721,Procaine,,,7.7 minutes,10 mg/1mL,Infiltration,solid,9450 mg/L (at 30 Â°C),2.14,6.81,,8.96,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1,,,0.128333333,0.128333333,0,,236.1524779,1,1,0,0,0,0
592,02/07/2019 00:00,DB00722,Lisinopril,"Approximately 25%, but widely variable between individuals (6 to 60%) in all doses tested (5-80 mg); absorption is unaffected by food",,Effective half life of accumulation following multiple dosing is 12 hours. ,40 mg,Oral,solid,9.7E+004 mg/L,-1.01,0.216,3.17,10.21,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,,,,,0,40,405.2263711,2,1,1,0,1,1
593,04/06/2019 00:00,DB00723,Methoxamine,,,,20 mg,Intramuscular; Intravenous,solid,Soluble (185 g/L),0.8,9.21,13.61,9.28,COC1=CC(C(O)C(C)N)=C(OC)C=C1,,,,,0,,211.1208434,1,1,0,0,0,0
594,02/07/2019 00:00,DB00724,Imiquimod,Well absorbed through skin (as a cream),,"20 hours (topical dose), 2 hours (subcutaneous dose)",50 mg/1000mg,Topical,solid,Poorly soluble,2.7,0.247,,5.4,CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N,,,,,0,,240.1374965,3,3,2,2,0,0
595,04/06/2019 00:00,DB00725,Homatropine methylbromide,,,,,Oral,solid,,3.421,0.0052,11.99,-4.1,[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1,,,,,0,,369.0939557,3,1,2,0,2,2
596,02/07/2019 00:00,DB00726,Trimipramine,Rapid absorption,93%-96%,11-18 hrs,75 mg,Oral,solid,Slightly soluble,4.2,0.026,,9.42,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12,0.93,0.96,11,18,0,75,294.2095988,3,2,1,0,0,1
597,02/07/2019 00:00,DB00727,Nitroglycerin,,,3 minutes,400 ug/1,Sublingual,liquid,1380 mg/L (at 20 Â°C),1.62,0.204,,-5.6,[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O,,,0.05,0.05,0,0.4,227.0025787,0,0,0,0,0,0
598,02/07/2019 00:00,DB00728,Rocuronium,Poorly absorbed from the GI tract.,0.3,"The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.",10 mg/1mL,Intravenous,solid,Complete,,2.84E-05,14.59,7.96,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1,0.3,0.3,,,1,,529.3999846,6,0,2,0,2,2
599,04/06/2019 00:00,DB00730,Thiabendazole,Rapidly absorbed and peak plasma concentration is reached within 1 to 2 hours after the oral administration of a suspension. Some systemic absorption may occur from topical preparations applied to the skin.,,The half-life for thiabendazole in both normal and anephric patients is 1.2 hours (range 0.9 to 2 hours). The half-life for the 5-hydroxythiabendazole metabolite in both normal and anephric patients is 1.7 hours (range 1.4 to 2 hours).,500 mg/5mL,Oral,solid,50 mg/L (at 25 Â°C),2.47,0.138,10.28,4.08,N1C2=CC=CC=C2N=C1C1=CSC=N1,,,,,0,,201.0360682,3,3,2,2,0,0
600,04/06/2019 00:00,DB00731,Nateglinide,"Rapidly absorbed following oral administration prior to a meal, absolute bioavailability is estimated to be approximately 73%. Peak plasma concentrations generally occur within 1 hour of oral administration. Onset of action is <20 minutes and the duration of action is approximately 4 hours. ",0.98,1.5 hours,120 mg/1,Oral,solid,Practically insoluble,2.4,0.00688,4.06,1.53,[H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O,0.98,0.98,1.5,1.5,0,120,317.1990937,2,1,0,0,0,0
601,02/07/2019 00:00,DB00732,Atracurium besylate,,,The elimination half-life is approximately 20 minutes.,10 mg/1mL,Intravenous,solid,Miscible,,4.17E-05,19.02,-4.1,[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2,,,,,0,,1242.500406,8,6,2,0,0,2
602,04/06/2019 00:00,DB00733,Pralidoxime,,,74-77 minutes,600 mg/2mL,Intramuscular,solid,,1.564,0.149,5.78,-1.1,C[N+]1=C(\C=N\O)C=CC=C1,,,1.233333333,1.283333333,1,,137.0709393,1,1,1,1,0,0
603,02/07/2019 00:00,DB00734,Risperidone,Well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.,~88%,"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]
",0.50 mg,Oral,solid,2.33 mg/mL,,0.171,,8.76,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,0.88,0.88,,,0,0.5,410.2118043,5,3,4,2,1,2
604,04/06/2019 00:00,DB00735,Naftifine,"Following single topical applications of 3H-labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed.",,Approximately 2 to 3 days following topical administration.,1 mg/1g,Topical,solid,,5.4,0.000229,,9.08,CN(CC=CC1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12,,,,,0,,287.1673997,3,3,0,0,0,0
605,02/07/2019 00:00,DB00736,Esomeprazole,"After oral administration, peak plasma levels (Cmax) occur at approximately 1.5 hours (Tmax). The Cmax increases proportionally when the dose is increased, and there is a three-fold increase in the area under the plasma concentration-time curve (AUC) from 20 to 40 mg. At repeated once-daily dosing with 40 mg, the systemic bioavailability is approximately 90% compared to 64% after a single dose of 40 mg. The mean exposure (AUC) to esomeprazole increases from 4.32 Î¼mol*hr/L on Day 1 to 11.2 Î¼mol*hr/L on Day 5 after 40 mg once daily dosing. The AUC after administration of a single 40 mg dose of Esomeprazole is decreased by 43% to 53% after food intake compared to fasting conditions. Esomeprazole should be taken at least one hour before meals[FDA Label].

_Combination Therapy with Antimicrobials:_

Esomeprazole magnesium 40 mg once daily was given in combination with [DB01211] 500 mg twice daily and [DB01060] 1000 mg twice daily for 7 days to 17 healthy male and female subjects. The mean steady state AUC and Cmax of esomeprazole increased by 70% and 18%, respectively during triple combination therapy compared to treatment with esomeprazole alone. The observed increase in esomeprazole exposure during co-administration with clarithromycin and amoxicillin is not expected to produce significant safety concerns.

",0.97,1-1.5 hours,20 mg/1,Oral,solid,Very slightly soluble in water,0.6,0.353,9.68,4.77,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,0.97,0.97,1,1.5,0,20,345.1147125,3,3,2,2,0,0
606,02/07/2019 00:00,DB00737,Meclizine,"Most histamine H1 antagonists are reported to be readily absorbed following oral administration.[L6760] Upon oral administration, the time to reach peak plasma concentrations (Cmax) of meclizine is about 3 hours post-dose, with the value ranging from 1.5 to 6 hours.[L6772] ",,Meclizine has a plasma elimination half-life of about 5-6 hours in humans.[L6772],50 mg/1,Oral,solid,0.1g/100mL,,0.00103,,8.16,CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1,,,,,0,50,390.1862765,4,3,1,0,1,1
607,02/07/2019 00:00,DB00738,Pentamidine,Absorbed poorly through the gastrointestinal tract and is usually administered parenterally.,0.69,9.1-13.2 hours,300 mg/6mL,Respiratory (inhalation),solid,Complete,4,0.0236,,12.13,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1,0.69,0.69,9.1,13.2,0,,340.189926,2,2,0,0,0,0
608,04/06/2019 00:00,DB00739,Hetacillin,,,,,,solid,,1.3,0.512,3.63,5.47,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O,,,,,0,,389.1409272,4,1,3,0,3,3
609,02/07/2019 00:00,DB00740,Riluzole,"Riluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%.",0.96,The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.,50 mg/1,Oral,solid,,2.3,0.0395,16.44,4.57,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2,0.96,0.96,,,0,50,234.0074684,2,2,1,1,0,0
610,02/07/2019 00:00,DB00741,Hydrocortisone,Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.,0.95,6-8 hours,0.01 g/1g,Topical,solid,320 mg/L (at 25 Â°C),1.61,0.199,12.59,-2.8,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.95,0.95,6,8,0,,362.2093241,4,0,0,0,0,0
611,02/07/2019 00:00,DB00742,Mannitol,Approximately 7% of ingested mannitol is absorbed during gastrointestinal perfusion in uremic patients.,,100 minutes,40 mg,Respiratory (inhalation),solid,2.16E+005 mg/L (at 25 Â°C),-3.1,229,12.59,-3,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,,,1.666666667,1.666666667,0,,182.0790382,0,0,0,0,0,0
612,02/07/2019 00:00,DB00743,Gadobenic acid,,,1 hour,529 mg/1mL,Intravenous,solid,,,0.768,0.085,9.58,[Gd+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)C(COCC1=CC=CC=C1)C(O)=O,,,1,1,0,,668.0964876,1,1,0,0,0,0
613,04/06/2019 00:00,DB00744,Zileuton,Rapidly and almost completely absorbed. The absolute bioavailability is unknown.,0.93,2.5 hours,1 kg/1kg,Not applicable,solid,Practically insoluble (0.5 mg/ml),0.9,0.0539,8.84,-5.5,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,0.93,0.93,2.5,2.5,0,,236.0619486,2,2,1,1,0,0
614,02/07/2019 00:00,DB00745,Modafinil,Rapid following oral administration.,0.6,23-215 hours,100 mg,Oral,solid,Slightly soluble,0.6,0.622,8.84,-4.4,NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,0.6,0.6,23,215,0,100,273.0823497,2,2,0,0,0,0
615,02/07/2019 00:00,DB00746,Deferoxamine,"Deferoxamine is rapidly absorbed after intramuscular or subcutaneous administration, but only poorly absorbed from the gastrointestinal tract in the presence of intact mucosa.",0.1,Biphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.,95 mg/1mL,Intramuscular; Intravenous; Subcutaneous,solid,1.2E+004 mg/L (at 20 Â°C),-2.2,0.099,7.92,10.23,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,0.1,0.1,,,0,,560.3533625,0,0,0,0,0,0
616,02/07/2019 00:00,DB00747,Scopolamine,Bioavailability is 10 - 50%,,4.5 hours,2.5 mg/1mL,Buccal; Oral; Sublingual,solid,1E+005 mg/L,0.98,6.61,15.15,6.95,CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,,,4.5,4.5,0,0.125,303.1470582,4,1,3,0,3,3
617,04/06/2019 00:00,DB00748,Carbinoxamine,,,10 to 20 hours,0.8 mg/1mL,Oral,liquid,,2.6,0.228,,8.87,CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,,,,,0,,290.1185909,2,2,1,1,0,0
618,02/07/2019 00:00,DB00749,Etodolac,"Based on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%.",0.99,"Terminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours",200 mg,Oral,solid,16 mg/L,2.5,0.0392,4.73,-4.2,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,0.99,0.99,,,0,200,287.1521435,3,2,2,1,0,1
619,02/07/2019 00:00,DB00750,Prilocaine,,0.98,,40 mg,Infiltration,solid,541 mg/L,2.11,0.326,13.51,8.82,CCCNC(C)C(=O)NC1=CC=CC=C1C,0.98,0.98,,,0,,220.1575633,1,1,0,0,0,0
620,04/06/2019 00:00,DB00751,Epinastine,The absolute bioavailability of epinastine is about 40%.,0.64,12 hours,0.5 mg/1mL,Ophthalmic,solid,,3.51,0.163,,8.77,NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21,0.64,0.64,12,12,0,,249.1265975,4,2,2,0,0,2
621,02/07/2019 00:00,DB00752,Tranylcypromine,"Interindividual variability in absorption. May be biphasic in some individuals. Peak plasma concentrations occur in one hour following oral administration with a secondary peak occurring within 2-3 hours. Biphasic absorption may represent different rates of absorption of the stereoisomers of the drug, though additional studies are required to confirm this. ",,1.5-3.2 hours in patients with normal renal and hepatic function,10 mg,Oral,solid,4.86E+004 mg/L,1.58,1.49,,9.62,NC1CC1C1=CC=CC=C1,,,,,0,10,133.0891494,2,1,0,0,0,0
622,02/07/2019 00:00,DB00753,Isoflurane,,,,1 mL/1mL,Respiratory (inhalation),liquid,4470 mg/L (at 37 Â°C),2.06,3.56,,-4.7,FC(F)OC(Cl)C(F)(F)F,,,,,0,,183.9714335,0,0,0,0,0,0
623,04/06/2019 00:00,DB00754,Ethotoin,"Fairly rapidly absorbed, however, the extent of oral absorption is not known.",,3 to 9 hours,250 mg/1,Oral,solid,5280 mg/L,1.05,2.38,11.29,-8.4,CCN1C(=O)NC(C1=O)C1=CC=CC=C1,,,,,0,250,204.0898776,2,1,1,0,1,1
624,02/07/2019 00:00,DB00755,Tretinoin,1-31% (topical),0.95,0.5-2 hours,0.5 mg/1g,Topical,solid,<0.1 g/100 mL,6.3,0.00477,4.76,,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O,0.95,0.95,0.5,2,0,,300.2089301,1,0,0,0,0,0
625,04/06/2019 00:00,DB00756,Hexachlorophene,Detectable blood levels of hexachlorophene following absorption through intact skin have been found in subjects who regularly scrubbed with hexachlorophene.,0.92,,0.03,Topical,liquid,140 mg/L (at 25 Â°C),7.54,0.000433,5.15,-7.4,OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl,0.92,0.92,,,0,,403.8498955,2,2,0,0,0,0
626,02/07/2019 00:00,DB00757,Dolasetron,Orally-administered dolasetron is well absorbed,69-77%,8.1 hours,100 mg/5mL,Intravenous,solid,Freely soluble in water,2.1,0.261,12.18,5.68,[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2,0.69,0.77,8.1,8.1,0,,324.1473925,6,2,5,1,4,4
627,02/07/2019 00:00,DB00758,Clopidogrel,Absorption is at least 50% based on urinary excretion of clopidogrel-related metabolites. Bioavailability has not been found to be affected by food.,0.98,Carboxylic acid derivative: 8 hours (after single and multiple doses). Covalent binding to platelets has accounted for 2% of radiolabeled clopidogrel with a half-life of 11 days.,300 mg/1,Oral,solid,50.78 mg/L,2.5,0.0118,,5.14,[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl,0.98,0.98,,,0,300,321.0590274,3,2,2,1,0,1
628,02/07/2019 00:00,DB00759,Tetracycline,"Bioavailability is less than 40% when administered via intramuscular injection, 100% intravenously, and 60-80% orally (fasting adults). Food and/or milk reduce GI absorption of oral preparations of tetracycline by 50% or more.",0.67,6-12 hours,0.01,Ophthalmic,solid,231 mg/L (at 25 Â°C),-1.3,1.33,-2.2,8.24,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,0.67,0.67,6,12,0,,444.1532657,4,1,0,0,0,0
629,02/07/2019 00:00,DB00760,Meropenem,,,Approximately 1 hour in adults and children 2 years of age and older with normal renal function. Approximately 1.5 hours in children 3 months to 2 years of age.,1 g/30mL,Intravenous,solid,Sparingly,-0.6,5.63,3.47,9.39,[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)[C@H](C)[C@]12[H],,,,,0,,383.1514919,3,0,3,0,2,3
630,02/07/2019 00:00,DB00762,Irinotecan,"The maximum plasma concentration (Cmax) when a dose of 125 mg/m^2 is given to patients with solid tumours is 1660 ng/mL. The AUC (0-24) is 10,200 ngÂ·h/mL. The Cmax when a dose of 340 mg/m^2 is given to patients with solid tumours is 3392 ng/mL. The AUC (0-24) is 20,604 ngÂ·h/mL.",30%-68%,"The half life of irinotecan is about 6 - 12 hours. The terminal elimination half-life of the active metabolite, SN-38 is 10 - 20 hours. ",100 mg/5mL,Intravenous,solid,Soluble,3.2,0.107,11.71,9.47,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12,0.3,0.68,,,0,,586.2791349,7,3,6,2,2,4
631,02/07/2019 00:00,DB00763,Methimazole,Rapid with an oral bioavailability of 93%.,,5-6 hours,10 mg/1,Oral,solid,275 g/L,-0.34,11.3,10.41,-3,CN1C=CNC1=S,,,5,6,0,10,114.0251692,1,1,1,1,0,0
632,02/07/2019 00:00,DB00764,Mometasone,Nasal spray is virtually undetectable in plasma,0.98,5.8 hours,50 ug/1,Nasal,solid,Practically insoluble.,2.1,0.00523,12.49,-3.3,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,0.98,0.98,5.8,5.8,0,,426.1364647,4,0,0,0,0,0
633,04/06/2019 00:00,DB00765,Metyrosine,Well absorbed from the gastrointestinal tract.,,3.4 to 3.7 hours,250 mg/1,Oral,solid,Very slightly soluble,-1.7,2.48,2.06,9.93,C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O,,,,,0,250,195.0895433,1,1,0,0,0,0
634,04/06/2019 00:00,DB00766,Clavulanic acid,0.75,,1.0 hour,,Oral,solid,300 mg/mL (potassium salt),-1.5,337,3.32,-2.6,[H][C@@]12CC(=O)N1[C@@H](C(O)=O)\C(O2)=C\CO,,,1,1,0,,199.0480724,2,0,2,0,2,2
635,04/06/2019 00:00,DB00767,Benzquinamide,"Incomplete, with 33&ndash;39% bioavailability via the capsule and suppository routes, relative to the intramuscular route.",,1-1.6 hours (for all formulations),,,solid,153 mg/L,1.7,0.49,19.61,7.5,CCN(CC)C(=O)C1CN2CCC3=CC(OC)=C(OC)C=C3C2CC1OC(C)=O,,,,,0,,404.2311221,3,1,2,0,1,2
636,02/07/2019 00:00,DB00768,Olopatadine,"Ocular administration of olopatadine in healthy subjects resulted in the Cmax of 1.6 Â± 0.9 ng/mL, which was reached after about 2.0 hours. The AUC was 9.7 Â± 4.4 ngxh/mL.[L6781] 

The average absolute bioavaiability of intranasal olopatadine is about 57%. Following intranasal administration in healthy subjects, the Cmax of 6.0 Â± 8.99 ng/mL at steady-state was reached between 30 minutes to 1 hour after twice daily intranasal administration. The average AUC was 66.0 Â± 26.8 ngÂ·h/mL. In patients with seasonal allergic rhinitis, the Cmax of 23.3 Â± 6.2 ng/mL at steady-state was reached between 15 minutes and 2 hours post-dosing and the average AUC was 78.0 Â± 13.9 ngÂ·h/mL.[L6784]",0.55,"Following ocular administration, the elimination half-life of olopatadine was 3.4 Â± 1.2 hours. In oral pharmacokinetics study, the elimination half-life was reported to be 8 to 12 hours.[L6787]",0.001,Ophthalmic,solid,,,0.0313,3.78,9.76,CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2,0.55,0.55,,,0,,337.1677936,3,2,1,0,0,1
637,04/06/2019 00:00,DB00769,Hydrocortamate,,,,,,solid,,1.2,0.0855,12.61,6.43,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,475.293388,4,0,0,0,0,0
638,02/07/2019 00:00,DB00770,Alprostadil,The absolute bioavailability of alprostadil has not been determined.,(81%,"5 to 10 minutes (after a single dose), in healthy adults and neonates.",500 ug/1mL,Intravascular; Intravenous,solid,26.7 mg/L,3.2,0.0788,4.35,-1.6,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,0.81,0.81,,,0,,354.2406242,1,0,0,0,0,0
639,04/06/2019 00:00,DB00771,Clidinium,,,,,Oral,solid,,,0.000377,11.05,-4.5,C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,352.1907201,5,2,3,0,3,3
640,04/06/2019 00:00,DB00772,Malathion,"Malathion in an acetone vehicle has been reported to be absorbed through normal human skin only to the extent of 8% of the applied dose. Absorption may be increased when malathion is applied to damaged skin. Malathion is rapidly and effectively absorbed by practically all routes including the gastrointestinal tract, skin, mucous membranes, and lungs. However, it is readily excreted in the urine, and does not accumulate in organs or tissues.",,8-24 hours,0.0005 g/1mL,Topical,liquid,143 mg/L (at 20 Â°C),2.36,0.165,,-6.8,CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC,,,8,24,0,,330.036067,0,0,0,0,0,0
641,02/07/2019 00:00,DB00773,Etoposide,"Absorbed well, time to peak plasma concentration is 1-1.5 hrs. Mean bioavailability is 50% (range of 25% - 75%). Cmax and AUC values for orally administered etoposide capsules display intra- and inter-subject variability. There is no evidence of first-pass effect for etoposide. ",0.97,4-11 hours,100 mg/1,Intravenous,solid,Sparingly soluble ,0.6,0.978,9.33,-3.7,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O,0.97,0.97,4,11,0,,588.1842911,7,2,4,0,3,4
642,04/06/2019 00:00,DB00774,Hydroflumethiazide,Hydroflumethiazide is incompletely but fairly rapidly absorbed from the gastrointestinal tract,0.74,It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours,50 mg/1,Oral,solid,300 mg/L (at 25 Â°C),0.36,0.858,9.07,-2.7,NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F,0.74,0.74,,,0,50,330.9908324,2,1,1,0,0,1
643,02/07/2019 00:00,DB00775,Tirofiban,,0.65,2 hours,3.75 mg/15mL,Intravenous,solid,Very slightly soluble,1.4,0.00317,3.17,10.21,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O,0.65,0.65,2,2,0,,440.2344933,2,1,1,0,1,1
644,02/07/2019 00:00,DB00776,Oxcarbazepine,"Completely absorbed following oral administration. Food has no effect on the rate and extent of absorption of oxcarbazepine. After single-dose administration of Trileptal tablets to healthy male volunteers under fasted conditions, the median tmax was 4.5 (range 3 to 13) hours. After single-dose administration of Trileptal oral suspension to healthy male volunteers under fasted conditions, the median tmax was six hours. Steady-state plasma concentrations of MHD are reached within 2-3 days in patients when Trileptal is given twice a day.",0.4,"The half-life of the parent is about 2 hours, while the half-life of MHD is about 9 hours, so that MHD is responsible for most anti-epileptic activity.",300 mg/5mL,Oral,solid,"308 mg/L at 25 Â°C (SRC PhysProp estimated -- MEYLAN,WM et al. (1996))",1.5,0.16,13.18,-4.3,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,0.4,0.4,,,0,,252.0898776,3,2,1,0,0,1
645,04/06/2019 00:00,DB00777,Propiomazine,,0.81,,,,solid,0.454 mg/L,4.79,0.00703,16.64,8.32,CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1,0.81,0.81,,,0,,340.1609344,3,2,1,0,0,1
646,04/06/2019 00:00,DB00778,Roxithromycin,Very rapidly absorbed and diffused into most tissues and phagocytes.,,12 hours,,,solid,"0.0189 mg/L at 25 Â°C (SRC PhysProp estimated -- MEYLAN,WM et al. (1996))",1.7,0.187,12.45,9.08,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,,,12,12,0,,836.5245697,3,0,3,0,3,3
647,04/06/2019 00:00,DB00779,Nalidixic acid,"Following oral administration, nalidixic acid is rapidly absorbed from the gastrointestinal tract. Bioavailability is approximately 96%. Absorption may be delayed if taken with antacids.",0.93,"1.1 to 2.5 hours in healthy adult patients, and up to 21 hours in patients with impaired renal function.",500 mg/1,Oral,solid,100 mg/L (at 23 Â°C),1.59,2.3,5.95,4.68,CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2,0.93,0.93,,,0,500,232.0847922,2,2,2,2,0,0
648,02/07/2019 00:00,DB00780,Phenelzine,Phenelzine is rapidly absorbed from the gastrointestinal tract. The decay of the drug action is not dependent on the pharmacokinetic parameters but on the rate of protein synthesis which restores the functional levels of monoamine oxidase.[L1365] The mean Cmax is 19.8 ng/ml and it occurs after 43 minutes of dose administration.[FDA label],,After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365],15 mg,Oral,liquid,29.1 g/L,,11.1,,5.55,NNCCC1=CC=CC=C1,,,,,0,15,136.1000484,1,1,0,0,0,0
649,04/06/2019 00:00,DB00782,Propantheline,,,,15 mg/1,Oral,solid,,,7.22E-05,18.1,-7.2,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C,,,,,1,15,368.2220202,3,2,1,0,0,1
650,02/07/2019 00:00,DB00783,Estradiol,0.43,>95%,36 hours,0.025 mg/1d,Oral,solid,3.6 mg/L (at 27 Â°C),4.01,0.0213,10.33,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,0.95,1,36,36,0,,272.17763,4,1,0,0,0,0
651,02/07/2019 00:00,DB00784,Mefenamic acid,Mefenamic acid is rapidly absorbed after oral administration.,0.9,2 hours,250 mg,Oral,solid,20 mg/L (at 30 Â°C),5.12,0.0137,3.89,-1.6,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,0.9,0.9,2,2,0,250,241.1102787,2,2,0,0,0,0
652,04/06/2019 00:00,DB00786,Marimastat,,,,,,solid,,0.4,3.38,8.61,-1,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,,,,,0,,331.210721,0,0,0,0,0,0
653,02/07/2019 00:00,DB00787,Acyclovir,"The oral bioavailability is 10% to 20%, and decreases with increasing dose. Food does not affect the absorption of acyclovir. The following are the pharmacokinetic parameters for 50 mg buccal tablet, Sitavig, in the saliva:
AUC 0 - 24 hours = 2900Â±2400 mcg.h/mL;
Cmax = 440Â±241 mcg/mL;
Tmax = 7.95 Â± 4.08 hours. ",9%-33%,2.5-3.3 hours,200 mg/1,Oral,solid,2.5 mg/mL at 37Â°C,-1.56,9.08,7.99,2.63,NC1=NC(=O)C2=C(N1)N(COCCO)C=N2,0.09,0.33,2.5,3.3,0,200,225.0861892,2,2,2,2,0,0
654,02/07/2019 00:00,DB00788,Naproxen,"Naproxen is available as a free acid and sodium salt.[A179098] At comparable doses, (naproxen 500 mg = naproxen sodium 550 mg) they differ slightly in their rates of absorption, but otherwise they are therapeutically and pharmacologically equivalent.[A179098] Naproxen sodium achieves a peak plasma concentration after 1 hour, while peak plasma concentration is observed after 2 hours with naproxen (free acid).[A179098] There are no differences between the 2 forms in the post-absorption phase pharmacokinetics.[A179098] The difference in initial absorption should be considered when treating acute pain, since naproxen sodium may offer a quicker onset of action.[A179098]

Overall, naproxen is rapidly and completely absorbed when administered orally and rectally.[A179110][A179098] Food may contribute to a delay in the absorption of orally administered naproxen, but will not affect the extent of absorption.[A179098]",>99%,The half-life of naproxen is reported to be 12-17 hours.[A178975],125 mg,Oral,solid,15.9 mg/L (at 25 Â°C),3.18,0.0511,4.19,-4.8,COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O,0.99,1,,,0,125,230.0942943,2,2,0,0,0,0
655,02/07/2019 00:00,DB00789,Gadopentetic acid,,,"Distribution half life 12 minutes, elimination half 100 minutes",469.01 mg/1mL,Intravenous,solid,,,7.86,1.95,8.82,[Gd+3].OC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O,,,,,0,,548.0389727,0,0,0,0,0,0
656,02/07/2019 00:00,DB00790,Perindopril,"Rapidly absorbed with peak plasma concentrations occurring approximately 1 hour after oral administration. Bioavailability is 65-75%. Following absorption, perindopril is hydrolyzed to perindoprilat, which has an average bioavailability of 20%. The rate and extent of absorption is unaffected by food. However, food decreases the extent of biotransformation to peridoprilat and reduces its bioavailability by 35%. ",10-20%,"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites. ",10 mg,Oral,solid,,2.6,1.22,3.79,5.48,[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O,0.1,0.2,,,0,10,368.2311221,2,0,1,0,1,1
657,04/06/2019 00:00,DB00791,Uracil mustard,,0.05,,,,solid,1070 mg/L,1.2,1.32,9.05,1.61,ClCCN(CCCl)C1=CNC(=O)NC1=O,0.05,0.05,,,0,,251.022832,1,1,1,1,0,0
658,02/07/2019 00:00,DB00792,Tripelennamine,Well absorbed in the digestive tract.,,,0.01,Topical,solid,587 mg/L (at 30 Â°C),3.3,2.84,,8.76,CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1,,,,,0,,255.1735477,2,2,1,1,0,0
659,04/06/2019 00:00,DB00793,Haloprogin,,,,,,solid,,5.3,0.00601,,-5,ClC1=CC(Cl)=C(Cl)C=C1OCC#CI,,,,,0,,359.8372458,1,1,0,0,0,0
660,02/07/2019 00:00,DB00794,Primidone,90 to 100%,0.7,3-23 hours,125 mg,Oral,solid,500 mg/L (at 22 Â°C),0.91,1.04,11.5,-6.2,CCC1(C(=O)NCNC1=O)C1=CC=CC=C1,0.7,0.7,3,23,0,125,218.1055277,2,1,1,0,1,1
661,02/07/2019 00:00,DB00795,Sulfasalazine,,,5-10 hours,500 mg,Oral,solid,,2.5,0.0464,3.23,0.55,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1,,,5,10,0,500,398.0684905,3,3,1,1,0,0
662,02/07/2019 00:00,DB00796,Candesartan cilexetil,"Following administration of the candesartan cilexetil prodrug, the absolute bioavailability of candesartan was estimated to be 15%. Food with a high fat content has no effect on the bioavailability of candesartan from candesartan cilexetil.",,Approximately 9 hours.,16 mg/1,Oral,solid,,6.1,0.00204,4.23,1.45,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1,,,,,0,16,610.2539828,6,5,2,2,0,0
663,04/06/2019 00:00,DB00797,Tolazoline,,,,25 mg/1mL,Intravenous,solid,373 mg/L,2.65,1.36,,10.25,C(C1=NCCN1)C1=CC=CC=C1,,,,,0,,160.1000484,2,1,1,0,0,1
664,02/07/2019 00:00,DB00798,Gentamicin,"Injections lead to peak serum concentrations in 30-60 minutes. Topical gentamicin is readily absorbed from large burned, denuded, or granulating areas but not through intact skin. Absorption of gentamicin is faster and greater with the cream compared to the ointment. Gentamicin is absorbed in small quantities following topical application to the eye. Gentamicin is also absorbed in small amounts following topical application to the ear (especially if the eardrum is perforated or if tissue damage is present). Gentamicin is very poorly absorbed orally. ",,3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.,40 mg,Intramuscular; Intravenous,solid,100 mg/mL,-3.1,12.6,12.55,10.18,CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,,,,,0,,477.3162487,3,0,2,0,2,2
665,02/07/2019 00:00,DB00799,Tazarotene,"Minimal systemic absorption of tazarotene occurs due to its rapid metabolism in the skin to the active metabolite, tazarotenic acid, which can be systemically absorbed and further metabolized. Gender had no influence on the systemic bioavailability of tazarotenic acid.",,"The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients.",1 mg/1g,Cutaneous,solid,Soluble,5.6,0.00075,,1.23,CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1,,,,,0,,351.1292999,3,2,2,1,0,1
666,04/06/2019 00:00,DB00800,Fenoldopam,,,"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.",10 mg/1mL,Intravenous,solid,4000 mg/L,2,0.272,8.12,10.4,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12,,,,,0,,305.0818711,3,2,1,0,0,1
667,04/06/2019 00:00,DB00801,Halazepam,,,,,,solid,,3.97,0.0017,18.88,2.33,FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,,,,,0,,352.0590253,3,2,1,0,0,1
668,02/07/2019 00:00,DB00802,Alfentanil,For intravenous injection or infusion only. ,0.92,90-111 minutes,500 ug/1mL,Intravenous,solid,34.6 mg/L,2.16,0.252,,7.5,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O,0.92,0.92,1.5,1.85,0,,416.2535889,3,2,2,1,1,1
669,02/07/2019 00:00,DB00803,Colistin,Very poor absorption from gastrointestinal tract.,,5 hours,,Auricular (otic),solid,5.64E+005 mg/L,-2.4,0.0799,2.69,,[H]C(C)(CC)CCCC(O)=N[C@@]([H])(CCN)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CCN)C(O)=N[C@@]1([H])CCN=C(O)C([H])(N=C(O)[C@@]([H])(CCN)N=C(O)[C@]([H])(CCN)N=C(O)[C@@]([H])(CC(C)C)N=C(O)C([H])(CC(C)C)N=C(O)[C@]([H])(CCN)N=C1O)[C@@]([H])(C)O)[C@@]([H])(C)O,,,5,5,0,,1154.749927,1,0,1,0,0,1
670,02/07/2019 00:00,DB00804,Dicyclomine,,>99%,,10 mg/5mL,Oral,solid,,5.5,0.00327,,8.96,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1,0.99,1,,,0,,309.2667794,2,0,0,0,0,0
671,04/06/2019 00:00,DB00805,Minaprine,,,,,,solid,2360 mg/L,2.03,0.0701,19.25,6.28,CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1,,,,,0,,298.1793613,3,2,2,1,1,1
672,02/07/2019 00:00,DB00806,Pentoxifylline,,0.7,0.4-0.8 hours,1 g/1g,Topical,solid,7.7E+004 mg/L (at 25 Â°C),0.29,5.17,19.64,-0.93,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,0.7,0.7,0.4,0.8,0,,278.1378904,2,2,2,2,0,0
673,02/07/2019 00:00,DB00807,Proparacaine,,,,0.005,Ophthalmic,solid,Soluble,2.5,1.39,,8.96,CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC,,,,,0,,294.1943427,1,1,0,0,0,0
674,02/07/2019 00:00,DB00808,Indapamide,Rapidly absorbed from gastrointestinal tract.,71-79%,14 hours (biphasic),1.25 mg/1,Oral,solid,75 mg/L,2.2,0.0342,8.85,0.097,CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O,0.71,0.79,,,0,1.25,365.0600901,3,2,1,0,0,1
675,02/07/2019 00:00,DB00809,Tropicamide,,0.45,,0.005,Ophthalmic,solid,,1.3,0.375,15.18,5.02,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1,0.45,0.45,,,0,,284.1524779,2,2,1,1,0,0
676,04/06/2019 00:00,DB00810,Biperiden,87% bioavailability,0.6,,2 mg/1,Oral,solid,25.1 mg/L,4.25,0.00426,13.82,9.3,OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1,0.6,0.6,,,0,2,311.2249145,4,1,1,0,1,1
677,02/07/2019 00:00,DB00811,Ribavirin,Ribavirin is reported to be rapidly and extensively absorbed following oral administration. The average time to reach Cmax was 2 hours after oral administration of 1200 mg ribavirin [FDA Label]. The oral bioavailability is 64% following a single oral dose administration of 600mg ribavirin [L864]. ,,The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].,200 mg,Oral,solid,Soluble,-1.85,33.2,11.88,-1.2,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,,,,,0,200,244.0807695,2,1,2,1,1,1
678,04/06/2019 00:00,DB00812,Phenylbutazone,,,,100 mg,Oral,solid,47.5 mg/L (at 30 Â°C),3.16,0.144,5.13,,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,100,308.1524779,3,2,1,0,1,1
679,02/07/2019 00:00,DB00813,Fentanyl,"Fentanyl sublingual tablets are 54% bioavailable[L6598], transmucosal lozenges are 50% bioavailable[L6601], buccal tablets are 65% bioavailable[L6604], sublingual spray is 76% bioavailable[L6607], and nasal spray is 20% more bioavailable than transmucosal[L6610] (or approximately 64% bioavailable).

Fentanyl transmucosal lozenges reach a C<sub>max</sub> of 0.4Â±0.1ng/mL for a 200Âµg dose and 2.5Â±0.6ng/mL for a 1600Âµg dose with a T<sub>max</sub> of 20-40 minutes.[A179644] The AUC was 172Â±96ng\*min/mL for a 200Âµg dose and 1508Â±1360ng\*min/mL for a 1600Âµg dose.[A179644]

Fentanyl sublingual spray reached a C<sub>max</sub> of 0.20Â±0.06ng/mL for a 100Âµg dose and 1.61Â±0.60ng/mL for an 800Âµg dose with a T<sub>max</sub> of 0.69-1.25 hours, decreasing as the dose increased.[A179647] The AUC was 1.25Â±0.67ng\*h/mL for a 100Âµg dose and 10.38Â±3.70ng\*h/mL for a 800Âµg dose.[A179647]

Fentanyl transdermal systems reached a C<sub>max</sub> of 0.24Â±0.20ng/mL with a T<sub>max</sub> of 3.6Â±1.3h for a 25Âµg/h dose.[A179653] The AUC was 0.42Â±0.35ng/mL\*h.[A179653]

Fentanyl nasal spray reaches a C<sub>max</sub> of 815Â±301pg/mL with a T<sub>max</sub> of less than 1 hour for a 200Âµg/100ÂµL dose.[A179656] The AUC was 3772pg\*h/mL.[A179656]",80-85%,The half life of fentanyl is 7  hours.[L6601] The half life of fentanyl sublingual spray is 5-12 hours.[L6607],100 ug/1,Sublingual,solid,0.74mg/mL,4.05,0.024,,8.77,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,0.8,0.85,,,0,0.1,336.2201635,3,2,1,0,1,1
680,02/07/2019 00:00,DB00814,Meloxicam,Absolute bioavailability = 89%,0.994,15-20 hours,15.0 mg,Oral,solid,7.15 mg/L,3.43,0.154,4.47,0.47,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,0.994,0.994,15,20,0,15,351.0347479,3,2,2,1,0,1
681,04/06/2019 00:00,DB00815,Sodium lauryl sulfate,,,,0.7675 g/100g,Oral,solid,1E+005 mg/L,1.6,0.0121,-1.5,,[Na+].CCCCCCCCCCCCOS([O-])(=O)=O,,,,,0,,288.1371246,0,0,0,0,0,0
682,02/07/2019 00:00,DB00816,Orciprenaline,3% (oral bioavailability of 40%),,6 hours,0.650 mg/1,Respiratory (inhalation),solid,9.7mg/L,1,6.92,8.84,9.7,CC(C)NCC(O)C1=CC(O)=CC(O)=C1,,,6,6,0,,211.1208434,1,1,0,0,0,0
683,04/06/2019 00:00,DB00817,Rosoxacin,,,,,,solid,0.0209 mg/mL at 25 Â°C,3,0.102,6.18,4.9,CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1,,,,,0,,294.1004423,3,3,2,2,0,0
684,02/07/2019 00:00,DB00818,Propofol,"Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes. ",,Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours. ,0.01,Intravenous,liquid,124 mg/L,3.79,0.158,10.98,-5,CC(C)C1=CC=CC(C(C)C)=C1O,,,,,0,,178.1357652,1,1,0,0,0,0
685,02/07/2019 00:00,DB00819,Acetazolamide,,0.98,3 to 9 hours,500 mg/1,Oral,solid,980 mg/L (at 30 Â°C),-0.26,2.79,6.93,-3.3,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,0.98,0.98,,,0,500,221.9881321,1,1,1,1,0,0
686,02/07/2019 00:00,DB00820,Tadalafil,"After single oral-dose administration, the maximum observed plasma concentration (Cmax) of tadalafil is achieved between 30 minutes and 6 hours (median time of 2 hours). Absolute bioavailability of tadalafil following oral dosing has not been determined.",0.94,17.5 hours,20 mg/1,Oral,solid,Practically insoluble in water,1.7,0.25,15.17,-4.2,[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1,0.94,0.94,17.5,17.5,0,20,389.1375561,6,3,4,1,1,3
687,04/06/2019 00:00,DB00821,Carprofen,Rapidly and nearly completely absorbed (more than 90% bioavailable) when administered orally.,,Approximately 8 hours (range 4.5&ndash;9.8 hours) in dogs.,,,solid,Practically insoluble at 25 Â°C,3.8,0.00379,4.42,,CC(C(O)=O)C1=CC2=C(C=C1)C1=C(N2)C=CC(Cl)=C1,,,,,0,,273.0556563,3,3,1,1,0,0
688,04/06/2019 00:00,DB00822,Disulfiram,Disulfiram is absorbed slowly from the gastrointestinal tract (80 to 90% of oral dose).,,,250 mg/1,Oral,solid,4.09 mg/L (at 25 Â°C),3.88,0.0126,,,CCN(CC)C(=S)SSC(=S)N(CC)CC,,,,,0,250,296.0509326,0,0,0,0,0,0
689,04/06/2019 00:00,DB00823,Ethynodiol diacetate,,50-85%,,,Oral,solid,,5,0.00397,,-6.7,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H],0.5,0.85,,,0,,384.2300595,4,0,0,0,0,0
690,04/06/2019 00:00,DB00824,Enprofylline,Rapidly absorbed from the digestive tract,0.49,1.9 hours,,,solid,1200 mg/L,0.33,5.68,7.83,-0.77,CCCN1C2=C(NC=N2)C(=O)NC1=O,0.49,0.49,1.9,1.9,0,,194.0803756,2,2,2,2,0,0
691,04/06/2019 00:00,DB00825,Levomenthol,,,,0.3 g/100mL,Topical,solid,490 mg/L (at 25 Â°C),3.4,0.558,19.55,-0.81,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,,,,,0,,156.1514153,1,0,0,0,0,0
692,04/06/2019 00:00,DB00826,Natamycin,"Systemic absorption should not be expected following topical administration, and as with other polyene antibiotics, absorption from the gastrointestinal tract is very poor.",,,50 mg/1mL,Ophthalmic,solid,4100 mg/L (at 21 Â°C),1.1,0.278,3.58,9.11,[H][C@@]12C[C@H](O)C[C@]3(O)C[C@H](O)[C@@H](C(O)=O)[C@]([H])(C[C@@H](O[C@]4([H])O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O)\C=C\C=C\C=C\C=C\C[C@@H](C)OC(=O)\C=C\[C@@]1([H])O2)O3,,,,,0,,665.3047406,4,0,4,0,3,4
693,04/06/2019 00:00,DB00827,Cinoxacin,"Rapidly absorbed after oral administration. While concurrent food intake may delay the drug absorption, the total drug absorption is not affected. ",0.8,"While the mean serum half-life is 1.5 hours, the half-life may exceed 10 hours in case of renal impairment. ",,,solid,,1.5,0.961,4.93,-4.6,CCN1N=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12,0.8,0.8,,,0,,262.0589714,3,2,2,1,0,1
694,02/07/2019 00:00,DB00828,Fosfomycin,"Fosfomycin tromethamine is rapidly absorbed following oral administration and converted to fosfomycin. Oral bioavailability under fasting conditions is 37%. When given with food, oral bioavailability is reduced to 30%",0,5.7 (&plusmn; 2.8) hours. The elimination half-life is 40 hours in anuric patients undergoing hemodialysis.,2 g,Intravenous,solid,50 mg/mL (Sodium salt),-1.6,46.9,1.25,-4.3,C[C@@H]1O[C@@H]1P(O)(O)=O,0,0,,,0,,138.0081953,1,0,1,0,1,1
695,02/07/2019 00:00,DB00829,Diazepam,"After oral administration, it is considered that diazepam is rapidly and completely absorbed from the gastrointestinal tract as  >90% of diazepam is absorbed and the average time to achieve peak plasma concentrations is 1 â€“ 1.5 hours with a range of 0.25 to 2.5 hours [F3157, F3160, L5188].

Absorption is delayed and decreased when administered with a moderate fat meal [F3157]. In the presence of food mean lag times are approximately 45 minutes as compared with 15 minutes when fasting [F3157]. There is also an increase in the average time to achieve peak concentrations to about 2.5 hours in the presence of food as compared with 1.25 hours when fasting [F3157]. This results in an average decrease in Cmax of 20% in addition to a 27% decrease in AUC (range 15% to 50%) when administered with food [F3157].",,"Diazepam has a biphasic half-life with an initial rapid distribution phase followed by a prolonged terminal elimination phase of 1 or 2 days; its action is further prolonged by the even longer half-life of 2-5 days of its principal active metabolite, desmethyldiazepam (nordiazepam), the relative proportion of which increases in the body on long-term administration [L5188]. The plasma half-life of diazepam is prolonged in neonates, in the elderly, and in patients with kidney or liver disease [L5188].",10 mg,Oral,solid,50 mg/L (at 25 Â°C),2.82,0.0122,,2.92,CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,,,,,0,10,284.0716407,3,2,1,0,0,1
696,04/06/2019 00:00,DB00830,Phenmetrazine,Readily absorbed from the gastro-intestinal tract and buccal mucosa.,,16 to 31 hours,,,solid,>5 mg/L,1.7,2.44,,8.22,CC1NCCOC1C1=CC=CC=C1,,,,,0,,177.1153641,2,1,1,0,1,1
697,02/07/2019 00:00,DB00831,Trifluoperazine,,,10-20 hours,1.18 mg,Oral,solid,12.2 mg/L (at 24 Â°C),5.03,0.00876,,8.39,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,,,10,20,0,1.18,407.1643034,4,2,2,0,1,2
698,04/06/2019 00:00,DB00832,Phensuximide,Rapid and complete.,0.21,,,,solid,7020 mg/L,0.7,2.21,19.4,-7.4,CN1C(=O)CC(C1=O)C1=CC=CC=C1,0.21,0.21,,,0,,189.0789786,2,1,1,0,1,1
699,02/07/2019 00:00,DB00833,Cefaclor,"Well absorbed after oral administration, independent of food intake.",0.235,0.6-0.9 hour,250 mg/1,Oral,solid,1E+004 mg/L,0.4,0.21,3.03,7.44,[H][C@]12SCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,0.235,0.235,0.6,0.9,0,250,367.0393546,3,1,2,0,1,2
700,04/06/2019 00:00,DB00834,Mifepristone,The absolute bioavailability of a 20 mg oral dose is 69%,0.98,18 hours,300 mg/1,Oral,solid,Poorly soluble,4.5,0.00336,12.87,4.89,[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H],0.98,0.98,18,18,0,300,429.2667794,5,1,0,0,0,0
701,02/07/2019 00:00,DB00835,Brompheniramine,Antihistamines are well absorbed from the gastrointestinal tract after oral administration.,,,11 mg/1,Oral,liquid,Freely soluble (maleate salt),3.4,0.0127,,9.48,CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1,,,,,0,11,318.0731607,2,2,1,1,0,0
702,02/07/2019 00:00,DB00836,Loperamide,Not significantly absorbed from the gut,0.97,9.1 to 14.4 hours (average 10.8 hours),1 mg/5mL,Oral,solid,Slight,5.5,0.00086,13.96,9.41,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,0.97,0.97,,,0,,476.223056,4,3,1,0,1,1
703,04/06/2019 00:00,DB00837,Progabide,Well absorbed with a bioavailability of 60%,0.95,4 hours,,,solid,70.9 mg/L,3.06,0.00552,-1.1,12,OC(=N)CCC\N=C(\C1=CC=C(Cl)C=C1)C1=C(O)C=CC(F)=C1,0.95,0.95,4,4,0,,334.0884337,2,2,0,0,0,0
704,04/06/2019 00:00,DB00838,Clocortolone,"Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.",,,0.001 g/1g,Topical,solid,,3.8,0.015,13.53,-3.3,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,410.1660153,4,0,0,0,0,0
705,04/06/2019 00:00,DB00839,Tolazamide,Rapidly and well absorbed from the gastrointestinal tract.,,The average biological half-life of the drug is 7 hours.,100 mg/1,Oral,solid,65.4 mg/L (at 30 Â°C),2.69,0.308,4.07,1.61,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1,,,,,0,100,311.1303625,2,1,1,0,1,1
706,02/07/2019 00:00,DB00841,Dobutamine,,,2 minutes,12.5 mg/1mL,Intravenous,solid,,3.6,0.0137,10.14,9.27,CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1,,,0.033333333,0.033333333,0,,301.1677936,2,2,0,0,0,0
707,02/07/2019 00:00,DB00842,Oxazepam,"Well absorbed from the gastrointestinal tract following oral administration however is absorbed at a slower rate compared to other benzodiazepines like diazepam or flurazepam. Time to peak concentration = 2-4 hours. Onset of action is slow, > 3 hours, following oral administration. ",80-99%,Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours) ,10 mg,Oral,solid,179 mg/L,2.24,0.0881,10.61,-1.5,OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,0.8,0.99,,,0,10,286.0509053,3,2,1,0,0,1
708,02/07/2019 00:00,DB00843,Donepezil,Donepezil is well absorbed with a relative oral bioavailability of 100% and reaches peak plasma concentrations in 3 to 4 hours.,0.96,70 hours,1 mg/1mL,Oral,solid,2.931 mg/L,3.6,0.0045,17.02,8.62,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1,0.96,0.96,70,70,0,,379.2147438,4,2,1,0,1,1
709,02/07/2019 00:00,DB00844,Nalbuphine,"The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine. Clinical studies show that the duration of analgesic activity of the drug can range from 3 to 6 hours. ",,The plasma half-life of nalbuphine is about 5 hours. ,10 mg/1mL,Intramuscular; Intravenous; Subcutaneous,solid,35.5 mg/mL at 25 Â°C as HCl salt,1.4,2.09,7.45,13.75,O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5,,,,,0,,357.1940083,6,1,2,0,1,2
710,04/06/2019 00:00,DB00845,Clofazimine,Absorption varies from 45 to 62% following oral administration in leprosy patients. Bioavailability is approximately 70%. Food increases bioavailability and rate of absorption.,,"10 days following a single dose, 70 days after long-term, high-dose therapy.",50 mg/1,Oral,solid,0.225 mg/L (virtually insoluble),7.66,0.00151,16.15,9.29,CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1,,,,,0,50,472.1221521,5,3,1,0,0,1
711,02/07/2019 00:00,DB00846,Flurandrenolide,"Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to those of systemically administered corticosteroids",,,0.5 mg/1g,Topical,solid,Insoluble,0.6,0.0578,13.74,-2.8,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,,,,,0,,436.226117,5,0,1,0,1,1
712,02/07/2019 00:00,DB00847,Cysteamine,"CystagonÂ® reaches its maximum plasma concentration in about 1.4 hours.

 ",0.52,,0.0037,Ophthalmic,solid,Freely soluble in water.,0.1,23.5,9.42,10.4,NCCS,0.52,0.52,,,0,,77.02992022,0,0,0,0,0,0
713,04/06/2019 00:00,DB00848,Levamisole,Levamisole is rapidly absorbed (2 hours) from the gastrointestinal tract.,20-25%,4.4-5.6 hours (biphasic),50 mg,Oral,solid,210 mg/mL,1.84,1.44,,6.98,C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1,0.2,0.25,,,0,50,204.0721194,3,1,2,0,1,2
714,04/06/2019 00:00,DB00849,Methylphenobarbital,Approximately 50% of an oral dose of mephobarbital is absorbed from the gastrointestinal tract.,70-76%,34 (range 11-67) hours,32 mg/1,Oral,solid,Slightly soluble,1.84,0.71,8.4,,CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1,0.7,0.76,,,0,32,246.1004423,2,1,1,0,1,1
715,02/07/2019 00:00,DB00850,Perphenazine,Absolute bioavailability is 40% following oral administration.,,"8-12 hours, but ranges up to 20 hours.",16 mg,Oral,solid,28.3 mg/L (at 24 Â°C),4.2,0.0237,15.59,8.21,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,,,,,0,16,403.1485111,4,2,2,0,1,2
716,02/07/2019 00:00,DB00851,Dacarbazine,"Erratic, slow and incomplete.",0.05,5 hours,10 mg/1mL,Intravenous,solid,4220 mg/L,-0.24,1.36,6.64,1.72,CN(C)\N=N\C1=C(N=CN1)C(N)=O,0.05,0.05,5,5,0,,182.0916089,1,1,1,1,0,0
717,02/07/2019 00:00,DB00852,Pseudoephedrine,Pseudoephedrine is readily and almost completely absorbed from the GI tract and there is no evidence of first-pass metabolism.,,9-16 hours,7.5 mg,Oral,solid,7 mg/L,0.89,8.26,13.89,9.52,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,,,9,16,0,7.5,165.1153641,1,1,0,0,0,0
718,02/07/2019 00:00,DB00853,Temozolomide,Rapid and complete absorption in the gastrointestinal tract,0.15,Approximately 1.8 hours.,180 mg,Oral,solid,,-2.8,5.09,10.51,-3.6,CN1N=NC2=C(N=CN2C1=O)C(N)=O,0.15,0.15,,,0,180,194.0552234,2,2,2,2,0,0
719,04/06/2019 00:00,DB00854,Levorphanol,Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing.,0.4,11-16 hours,2 mg/1mL,Parenteral,solid,1840 mg/L,3.11,0.173,10.46,9.66,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,0.4,0.4,11,16,0,,257.1779644,4,1,1,0,1,1
720,02/07/2019 00:00,DB00855,Aminolevulinic acid,Oral bioavailability is 50-60%.,,Mean half-life is 0.70 &plusmn; 0.18 h after the oral dose and 0.83 &plusmn; 0.05 h after the intravenous dose.,78 mg/g,Cutaneous,solid,Very soluble,-1.5,173,4.05,7.84,NCC(=O)CCC(O)=O,,,,,0,,131.0582431,0,0,0,0,0,0
721,04/06/2019 00:00,DB00856,Chlorphenesin,Rapid and complete.,,2.3-5 hours,10 mg,Topical,solid,1E+004 mg/L,1.2,10.4,13.62,-3,OCC(O)COC1=CC=C(Cl)C=C1,,,2.3,5,0,,202.0396719,1,1,0,0,0,0
722,02/07/2019 00:00,DB00857,Terbinafine,Readily absorbed from gastrointestinal tract.,>99%,36 hours,125 mg,Oral,solid,Slightly soluble,5.9,0.000738,,8.86,CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12,0.99,1,36,36,0,125,291.1986998,2,2,0,0,0,0
723,04/06/2019 00:00,DB00858,Drostanolone,,,,,,solid,,3.99,0.00605,19.38,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C,,,,,0,,304.2402303,4,0,0,0,0,0
724,02/07/2019 00:00,DB00859,Penicillamine,rapidly but incompletely,>80%,1 hour,125 mg,Oral,solid,1.11E+005 mg/L (at 20 Â°C),-1.78,4.65,2.56,9.09,[H][C@](N)(C(O)=O)C(C)(C)S,0.8,1,1,1,0,125,149.0510496,0,0,0,0,0,0
725,02/07/2019 00:00,DB00860,Prednisolone,"Readily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.",,2-3 hours,1.25 mg/1mL,Ophthalmic,solid,223 mg/L (at 25 Â°C),1.62,0.239,12.59,-2.9,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,2,3,0,,360.193674,4,0,0,0,0,0
726,02/07/2019 00:00,DB00861,Diflunisal,"Rapidly and completely absorbed following oral administration, with a bioavailability of 80-90%. Peak plasma concentrations are achieved 2 - 3 hours following oral administration. ",0.99,8 to 12 hours,250 mg,Oral,solid,Practically insoluble (14.5 mg/L) at neutral or acidic pH.,4.44,0.0711,2.69,-6.3,OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1,0.99,0.99,,,0,250,250.0441506,2,2,0,0,0,0
727,02/07/2019 00:00,DB00862,Vardenafil,Vardenafil is rapidly absorbed with absolute bioavailability of approximately 15%.,0.95,4-5 hours,10 mg,Oral,solid,0.11 mg/mL (HCl salt),1.4,0.325,8.01,6.21,CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1,0.95,0.95,4,5,0,10,488.2205745,4,3,3,2,1,1
728,02/07/2019 00:00,DB00863,Ranitidine,"Ranitidine is 50% absorbed after an oral tablet and both the syrup and effervescent tablet formulations are found to be bioequivalent to the tablet form. After an intravenous (IV) injection, average peak levels of 440 to 545 ng/mL are attained about 2-3 hours after a single 150 mg dose. Food or antacids have limited effects on absorption. One clinical study found that the administration of a potent antacid (150 mmol) in subjects in the fasted state showed decreased absorption of ranitidine [FDA label].",0.15,"2.5-3 hours [FDA label]. The plasma half-life is longer for elderly patients population due to a decrease in renal function, and is measured at 3-4 hours [FDA label]. ",75.0 mg,Oral,solid,soluble in water,0.2,0.0795,,7.8,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O,0.15,0.15,,,0,75,314.1412616,1,1,1,1,0,0
729,02/07/2019 00:00,DB00864,Tacrolimus,"Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17Â±10%; in adults liver transplant patients is 22Â±6%; in healthy subjects is 18Â±5%. The absolute bioavailability in pediatric liver transplant patients was 31Â±24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition.",~99%,"The elimination half life in adult healthy volunteers, kidney transplant patients, liver transplants patients, and heart transplant patients are approximately 35, 19, 12, 24 hours, respectively. The elimination half life in pediatric liver transplant patients was 11.5Â±3.8 hours, in pediatric kidney transplant patients was 10.2Â±5.0 (range 3.4-25) hours. ",0.5 mg,Oral,solid,Insoluble,3.3,0.00402,9.96,-2.9,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC,0.99,0.99,,,0,0.5,803.4819766,4,0,3,0,2,3
730,04/06/2019 00:00,DB00865,Benzphetamine,Readily absorbed from the gastro-intestinal tract and buccal mucosa. It Is resistant to metabolism by monoamine oxidase.,75-99%,16 to 31 hours,50 mg/1,Oral,solid,Readily soluble,4.1,0.0233,,9.8,C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1,0.75,0.99,,,0,50,239.1673997,2,2,0,0,0,0
731,04/06/2019 00:00,DB00866,Alprenolol,,80-90%,2-3 hours,,,solid,547 mg/L,3.1,0.188,14.09,9.67,CC(C)NCC(O)COC1=CC=CC=C1CC=C,0.8,0.9,2,3,0,,249.172879,1,1,0,0,0,0
732,04/06/2019 00:00,DB00867,Ritodrine,,~56%,1.7-2.6 hours,10 mg,Intravenous,solid,Complete,2.4,0.179,9.15,9.81,C[C@H](NCCC1=CC=C(O)C=C1)[C@H](O)C1=CC=C(O)C=C1,0.56,0.56,1.7,2.6,0,,287.1521435,2,2,0,0,0,0
733,04/06/2019 00:00,DB00868,Benzonatate,,,3-8 hours,100 mg/1,Oral,liquid,Soluble in most organic solvents except aliphatic hydrocarbons,2.45,0.00159,,3.47,CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,,,3,8,0,100,603.3618615,1,1,0,0,0,0
734,02/07/2019 00:00,DB00869,Dorzolamide,,~33%,4 months,0.02,Ophthalmic,solid,,-1,0.699,8.18,7.14,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,0.33,0.33,2920,2920,0,,324.02722,2,1,2,1,0,1
735,04/06/2019 00:00,DB00870,Suprofen,,0.2,,10 mg/1mL,Ophthalmic,solid,limited solubility,2.2,0.0422,4.01,-7.8,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1,0.2,0.2,,,0,,260.0507152,2,2,1,1,0,0
736,02/07/2019 00:00,DB00871,Terbutaline,Approximately 30-50% if administered orally and well absorbed subcutaneously.,,5.5-5.9 hours,2.5 mg,Oral,solid,213 mg/mL,0.9,5.84,8.86,9.76,CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1,,,5.5,5.9,0,2.5,225.1364935,1,1,0,0,0,0
737,04/06/2019 00:00,DB00872,Conivaptan,,0.99,5 hours,5 mg/1mL,Conjunctival; Intravenous,solid,Very slightly soluble (0.15 mg/mL at 23 Â°C),6.3,0.00175,11.14,6.23,CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1,0.99,0.99,5,5,0,,498.2055761,6,5,2,1,0,1
738,02/07/2019 00:00,DB14596,Loteprednol etabonate,"Loteprednol etabonate (LE) demonstrates good ocular permeation properties as it is lipid soluble, allowing the agent to penetrate into cells with relative ease [FDA Label, A1312].

Results from the ocular administration of loteprednol in normal, healthy volunteers have shown that there are low or undetectable concentrations of either unchanged material or its metabolite [L4539]. Following twice-daily unilateral topical ocular dosing of LE for 14 days in healthy subjects, the plasma concentrations of loteprednol etabonate were below the limit of quantitation (1 ng/mL) at all time points [FDA Label]. These finds suggest that limited, if any, systemic absorption of LE occurs [L4539].",0.98,The terminal half-life of loteprednol etabonate as determined when administered intravenously at a dose of 5 mg/kg in the dog animal model is 2.8 hours [A38682].,0.002,Ophthalmic,solid,5 mg/mL,3.4,0.00693,14.88,-2.9,[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,0.98,0.98,,,0,,466.175831,4,0,0,0,0,0
739,02/07/2019 00:00,DB00874,Guaifenesin,"Studies have shown that guaifenesin is well absorbed from and along the gastrointestinal tract after oral administration [A177634, F4522, L6100]. ",,"The half-life in plasma observed for guaifenesin is approximately one hour [A177676, L6079, L6100, F4522, F4525]. ",200 mg,Oral,solid,5E+004 mg/L (at 25 Â°C),1.39,14.9,13.62,-3,COC1=CC=CC=C1OCC(O)CO,,,,,0,200,198.0892089,1,1,0,0,0,0
740,02/07/2019 00:00,DB00875,Flupentixol,Fairly slow and incomplete after oral administration,,19 to 39 hours,0.5 mg,Oral,solid,0.000346 mg/ml,4.51,0.00399,15.59,8.43,[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,,,,,0,0.5,434.1639691,4,2,2,0,1,2
741,02/07/2019 00:00,DB00876,Eprosartan,Absolute bioavailability following a single 300 mg oral dose of eprosartan is approximately 13%. Administering eprosartan with food delays absorption.,,The terminal elimination half-life of eprosartan following oral administration is typically 5 to 9 hours.,400 mg/1,Oral,solid,Insoluble (mesylate form),3.9,0.00866,3.63,6.93,CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O,,,,,0,400,424.1456782,3,3,2,2,0,0
742,02/07/2019 00:00,DB00877,Sirolimus,,0.92,57-63 hours,1 mg/ml,Oral,solid,,4.3,0.00173,9.96,-3,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC,0.92,0.92,57,63,0,,913.5551416,4,0,3,0,2,3
743,02/07/2019 00:00,DB00878,Chlorhexidine,"Absorption of chlorhexidine from the gastrointestinal tract is very poor. Additionally, an in vivo study in 18 adult patients found no detectable plasma or urine chlorhexidine concentrations following insertion of four periodontal implants under clinical conditions.",0.87,,.0045 g/.9g,Topical,solid,800 mg/L (at 20 Â°C),0.08,0.0261,,10.52,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1,0.87,0.87,,,0,,504.2031963,2,2,0,0,0,0
744,02/07/2019 00:00,DB00879,Emtricitabine,"Rapidly absorbed (mean absolute bioavailability of 93% for capsules, and 75% for solution). Food does not effect absorption.",,10 hours,200 mg/1,Oral,solid,112 mg/mL,-1.4,2,14.29,-3.1,NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1,,,10,10,0,200,247.0426904,2,1,2,1,1,1
745,04/06/2019 00:00,DB00880,Chlorothiazide,Rapidly absorbed following oral administration.,0.4,45-120 minutes,250 mg/1,Oral,solid,266 mg/L (at 30 Â°C),-0.24,0.398,9.1,1.15,NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1,0.4,0.4,0.75,2,0,250,294.9488254,2,1,1,0,0,1
746,02/07/2019 00:00,DB00881,Quinapril,Peak plasma concentrations of quinapril occur within one hour following oral administration. The extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25-30%) when ACCUPRIL tablets are administered during a high-fat meal.,0.97,Elimination half life is 2 hours with a prolonged terminal phase of 25 hours. ,5 mg,Oral,solid,1 mg/L,3.2,0.0085,3.7,5.2,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O,0.97,0.97,,,0,5,438.2154721,3,2,1,0,0,1
747,02/07/2019 00:00,DB00882,Clomifene,"Based on early studies with 14 C-labeled clomifene, the drug was shown to be readily absorbed orally in humans.",,5-7 days,50 mg,Oral,solid,Slightly soluble,7.2,0.000414,,9.31,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1,,,120,168,0,50,405.1859422,3,3,0,0,0,0
748,02/07/2019 00:00,DB00883,Isosorbide dinitrate,"Absorption of isosorbide dinitrate after oral dosing is nearly complete, but bioavailability is highly variable (10% to 90%), with extensive first-pass metabolism in the liver. The average bioavailability of isosorbide dinitrate is about 25%.",,1 hour,20 mg,Oral,solid,550 mg/L (at 25 Â°C),1.31,0.938,,-4.2,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,,,1,1,0,20,236.0280652,2,0,2,0,2,2
749,02/07/2019 00:00,DB00884,Risedronic acid,Oral bioavailability is 0.63% and maximum absorption is approximately 1 hour after dosing[FDA Label]. Administration half and hour before a meal reduces bioavailability by 55% compared to fasting and dosing 1 hour before a meal reduces bioavailability by 30%[FDA Label].,,"The initial half life of risedronic acid is approximately 1.5 hours[T536], with a terminal half life of 561 hours[FDA Label].",75 mg,Oral,solid,,,10.4,0.68,4.91,OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O,,,,,0,75,283.001075,1,1,1,1,0,0
750,04/06/2019 00:00,DB00885,Pemirolast,,,4.5 hours (Ophthalmic),1 mg/1mL,Ophthalmic,solid,,0,0.462,5.8,-1.4,CC1=CC=CN2C(=O)C(=CN=C12)C1=NNN=N1,,,,,0,,228.0759589,3,3,3,3,0,0
751,14/06/2019 00:00,DB00886,Omapatrilat,The absolute oral bioavailability of omapatrilat is 20% to 30% and the absorption is not affected by food intake.,,,,,solid,,2.6,0.0769,3.77,-3.6,[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)CC1=CC=CC=C1)C(O)=O,,,,,0,,408.1177492,3,1,2,0,2,2
752,02/07/2019 00:00,DB00887,Bumetanide,"Bumetanide is completely absorbed (80%), and the absorption is not altered when taken with food. Bioavailability is almost complete.",0.97,60-90 minutes,0.25 mg/1mL,Intramuscular; Intravenous,solid,>20 mg/mL (in base),2.6,0.0257,4.69,2.7,CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O,0.97,0.97,1,1.5,0,,364.1092927,2,2,0,0,0,0
753,04/06/2019 00:00,DB00888,Mechlorethamine,"Partially absorbed following intracavitary administration, most likely due to rapid deactivation by body fluids. When it is topically administered, systemic exposure was undetectable. ",,15 minutes,10 mg/10mL,Intracavitary; Intravenous,solid,Very soluble,0.91,33.4,,6.08,CN(CCCl)CCCl,,,0.25,0.25,0,,155.0268547,0,0,0,0,0,0
754,02/07/2019 00:00,DB00889,Granisetron,"Absorption of is rapid and complete, though oral bioavailability is reduced to about 60% as a result of first pass metabolism.",0.65,"4-6 hours in healthy patients, 9-12 hours in cancer patients",0.1 mg/1mL,Intravenous,solid,,2.6,0.434,14.75,9,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2,0.65,0.65,,,0,,312.1950114,4,2,3,1,2,2
755,14/06/2019 00:00,DB00890,Dienestrol,"Systemic absorption and mode of action of dienestrol are undetermined.Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).",0.8,,0.0001,Vaginal,solid,3 mg/L (at 37 Â°C),5.9,0.0123,9.1,-6,[H]\C(C)=C(/C(=C(\[H])C)/C1=CC=C(O)C=C1)\C1=CC=C(O)C=C1,0.8,0.8,,,0,,266.1306798,2,2,0,0,0,0
756,04/06/2019 00:00,DB00891,Sulfapyridine,Approximately 60-80%,0.5,6-14 hours.,500 mg,Oral,solid,268 mg/L (at 25 Â°C),0.35,0.235,6.24,2.63,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,0.5,0.5,6,14,0,500,249.0571976,2,2,1,1,0,0
757,02/07/2019 00:00,DB00892,Oxybuprocaine,,,,0.004,Ophthalmic,solid,Very soluble (hydrochloride salt),3.1,0.544,19.76,8.96,CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC,,,,,0,,308.2099928,1,1,0,0,0,0
758,04/06/2019 00:00,DB00894,Testolactone,Testolactone is well absorbed from the gastrointestinal tract.,~85%,,50 mg/1,Oral,solid,Slightly soluble (27.4 mg/L),3.7,0.023,18.84,-5,[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)OC(=O)CC[C@@]21[H],0.85,0.85,,,0,50,300.1725446,4,0,1,0,1,1
759,04/06/2019 00:00,DB00896,Rimexolone,Systemically absorbed.,,"The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours).",10 mg/1mL,Ophthalmic,solid,Insoluble,4.2,0.0121,18.76,-0.21,[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,370.2507949,4,0,0,0,0,0
760,02/07/2019 00:00,DB00897,Triazolam,Bioavailability is 44% (oral) and 53% (sublingual).,,1.5-5.5 hours,.125 mg/1,Oral,solid,4.53 mg/L,2.42,0.0183,18.08,4.32,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12,,,1.5,5.5,0,0.125,342.0439017,4,3,2,1,0,1
761,02/07/2019 00:00,DB00898,Ethanol,Rapidly absorbed.,,,62 mL/1,Topical,liquid,1E+006 mg/L (at 25 Â°C),-0.31,579,16.47,-2.2,CCO,,,,,0,,46.04186481,0,0,0,0,0,0
762,02/07/2019 00:00,DB00899,Remifentanil,,0.7,1-20 minutes,1 mg,Intravenous,solid,,1.4,0.591,,7.51,CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC,0.7,0.7,0.016666667,0.333333333,0,,376.199822,2,1,1,0,1,1
763,02/07/2019 00:00,DB00900,Didanosine,Rapidly absorbed (bioavailability 30-40%) with peak plasma concentrations appearing within 0.5 and 1.5 hrs.,,30 minutes in plasma and more than 12 hours in intracellular environment.,125 mg/1,Oral,solid,15.8 mg/mL,-1.24,6.58,6.94,2.75,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O,,,,,0,125,236.0909402,3,2,3,2,1,1
764,04/06/2019 00:00,DB00901,Bitolterol,,,,,,solid,,5.8,0.00048,14,9.59,CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C,,,,,0,,461.2202231,3,3,0,0,0,0
765,04/06/2019 00:00,DB00902,Methdilazine,Well absorbed in the digestive tract.,,,,,solid,0.348 mg/L,5.23,0.0147,,8.81,CN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1,,,,,0,,296.1347196,4,2,2,0,1,2
766,02/07/2019 00:00,DB00903,Etacrynic acid,"Onset of action is rapid, usually within 30 minutes after an oral dose of ethacrynic acid or within 5 minutes after an intravenous injection of ethacrynic acid.",0.98,,25 mg/1,Oral,solid,,3.3,0.0194,2.8,-5,CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1,0.98,0.98,,,0,25,302.0112642,1,1,0,0,0,0
767,02/07/2019 00:00,DB00904,Ondansetron,"Ondansetron is absorbed from the gastrointestinal tract and undergoes some limited first-pass metabolism [F3178]. Mean bioavailability in healthy subjects, following administration of a single 8-mg tablet, was recorded as being approximately 56% to 60% [F3178, F3181, F3184]. Bioavailability is also slightly enhanced by the presence of food [F3178].

Ondansetron systemic exposure does not increase proportionately to dose [F3178]. The AUC from a 16-mg tablet was 24% greater than predicted from an 8-mg tablet dose [F3178]. This may reflect some reduction of first-pass metabolism at higher oral doses [F3178].",0.73,"The half-life of ondansetron after either an 8 mg oral dose or intravenous dose was approximately 3-4 hours and could be extended to 6-8 hours in the elderly [F3181, F3184]. ",2 mg/1mL,Sublingual,solid,,2.4,0.248,15.39,7.34,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2,0.73,0.73,,,0,0.1,293.1528122,4,3,2,2,0,0
768,02/07/2019 00:00,DB00905,Bimatoprost,"This drug is absorbed systemically when administered to the eye. A study was performed on 15 healthy volunteers and bimatoprost ophthalmic solution 0.03% was administered once daily for 14 days. The mean Cmax was approximately 0.08 ng/mL and AUC0-24hr was approximately 0.09 on days 7 and 14 of the study.[L6877] By 10 minutes, peak blood concentration was achieved. Bimatoprost was not detectable at 1.5 hours after administration in most subjects. The maximum blood concentration in a study of 6 healthy volunteers was determined to be 12.2 ng/mL. Steady state was reached in the first week of dosing.[L6877]

One drug label mentions that onset of decreased intraocular pressure occurs approximately 4 hours after the first administration and the peak effect occurs in the range of 8-12 hours. Bimatoprost effects may last up to 24 hours.[L6898]",88%-90%,"The elimination half-life of bimatoprost is approximately 45 minutes.[L6877,L6892]",0.0003,Ophthalmic,solid,soluble in water,3.2,0.0187,14.35,-1.3,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1,0.88,0.9,,,0,,415.2722587,2,1,0,0,0,0
769,04/06/2019 00:00,DB00906,Tiagabine,Tiagabine is nearly completely absorbed (>95%).,0.96,7-9 hours,12 mg/1,Oral,solid,,2.6,0.0211,4.14,9.26,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1,0.96,0.96,7,9,0,12,375.132671,3,2,3,2,1,1
770,02/07/2019 00:00,DB00907,Cocaine,"Cocaine is absorbed from all sites of application, including mucous membranes and gastrointestinal mucosa. By oral or intra-nasal route, 60 to 80% of cocaine is absorbed.",,1 hour,100 mg/1mL,Topical,solid,1800 mg/L (at 22 Â°C),2.3,5.03,,8.85,[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C,,,1,1,0,,303.1470582,3,1,2,0,2,2
771,02/07/2019 00:00,DB00908,Quinidine,,80-88%,6-8 hours,275 mg,Oral,solid,140 mg/L (at 25 Â°C),3.44,0.334,13.89,9.05,[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,0.8,0.88,6,8,0,275,324.183778,5,2,4,1,3,3
772,04/06/2019 00:00,DB00909,Zonisamide,The absorption is rapid with a time to peak concentration of 2.8-3.9 hours. Food has not effect on bioavailability.,0.4,63 hours,100 mg,Oral,solid,0.8 mg/mL,0.5,2.09,9.84,-1.8,NS(=O)(=O)CC1=NOC2=CC=CC=C12,0.4,0.4,63,63,0,100,212.0255631,2,2,1,1,0,0
773,04/06/2019 00:00,DB00910,Paricalcitol,Well absorbed,0.998,4 to 6 hours,1 ug/1,Oral,solid,,4.5,0.0068,14.81,-1,[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)O,0.998,0.998,,,0,0.001,416.3290453,3,0,0,0,0,0
774,04/06/2019 00:00,DB00911,Tinidazole,Rapidly and completely absorbed under fasting conditions. Administration with food results in a delay in T<sub>max</sub> of approximately 2 hours and a decline in C<sub>max</sub> of approximately 10% and an AUC of 901.6 &plusmn; 126.5 mcg hr/mL.,,The elimination half-life is 13.2Â±1.4 hours and the plasma half-life is 12 to 14 hours.,500 mg/1,Oral,solid,1.99E+004 mg/L,-0.35,3.03,,3.1,CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O,,,,,0,500,247.0626769,1,1,1,1,0,0
775,02/07/2019 00:00,DB00912,Repaglinide,"Rapidly and completely absorbed following oral administration. Peak plasma concentrations are observed within 1 hour (range 0.5-1.4 hours). The absolute bioavailability is approximately 56%. Maximal biological effect is observed within 3-3.5 hours and plasma insulin levels remain elevated for 4-6 hours. When a single 2 mg dose of repaglinide is given to healthy subjects, the area under the curve (AUC) is 18.0 - 18.7 (ng/mL/h)^3. ",>98%,1 hour,1 mg,Oral,solid,,5.9,0.00294,3.68,4.82,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O,0.98,1,1,1,0,1,452.2675076,3,2,1,0,1,1
776,04/06/2019 00:00,DB00913,Anileridine,Anileridine is absorbed by all routes of administration.,0.95,,25 mg,Intramuscular; Intravenous; Subcutaneous,solid,,3.7,0.0124,,8.88,CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1,0.95,0.95,,,0,,352.2150781,3,2,1,0,1,1
777,04/06/2019 00:00,DB00914,Phenformin,,,,,,solid,210 mg/mL,-0.83,0.232,,11.97,NC(=N)NC(=N)NCCC1=CC=CC=C1,,,,,0,,205.1327455,1,1,0,0,0,0
778,02/07/2019 00:00,DB00915,Amantadine,Amantadine is well absorbed orally from the gastrointestinal tract.,0.67,"Mean half-lives ranged from 10 to 14 hours, however renal function impairment causes a severe increase in half life to 7 to 10 days.",100 mg/1,Oral,solid,6290 mg/L (freely soluble),2.44,0.0846,,10.71,NC12CC3CC(CC(C3)C1)C2,0.67,0.67,,,0,100,151.1360995,4,0,0,0,0,0
779,02/07/2019 00:00,DB00916,Metronidazole,Well absorbed (at least 80%) with peak plasma concentrations achieved in 1-3 hours following oral administration of therapeutic doses of immediate release formulation. ,0.2,6-8 hours,375 mg/1,Oral,solid,9500 mg/L (at 25 Â°C),-0.02,5.92,15.44,3.09,CC1=NC=C(N1CCO)[N+]([O-])=O,0.2,0.2,6,8,0,375,171.0643911,1,1,1,1,0,0
780,02/07/2019 00:00,DB00917,Dinoprostone,Absorbed at a rate of 0.3 mg per hour over 12 hours while the vaginal system is in place.,,Less than 5 minutes.,10 mg,Vaginal,solid,58.1 mg/L,2.82,0.044,4.3,-1.6,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,,,,,0,,352.2249741,1,0,0,0,0,0
781,02/07/2019 00:00,DB00918,Almotriptan,,0.35,3-4 hours,12.5 mg/1,Oral,solid,,1.6,0.121,17.14,9.55,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2,0.35,0.35,3,4,0,12.5,335.166748,3,2,2,1,1,1
782,02/07/2019 00:00,DB00919,Spectinomycin,Rapidly and almost completely absorbed after intramuscular injection.,,1 to 3 hours in patients with normal renal function and 10 to 30 hours in patients with impaired renal function with a creatinine clearance &lt; 20 mL per minute.,400 mg/1mL,Intramuscular,solid,Easily soluble in cold water,-2.3,150,8.58,9.4,[H][C@@]12O[C@H](C)CC(=O)[C@]1(O)O[C@]1([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]1([H])O2,,,,,0,,332.1583511,3,0,2,0,2,2
783,02/07/2019 00:00,DB00920,Ketotifen,Following oral administration absorption is at least 60%,0.75,21 hours (for elimination),0.35 mg/1mL,Ophthalmic,solid,,2.2,0.00787,12.3,7.15,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=CC=CC=C12,0.75,0.75,,,0,,309.1187352,4,2,2,1,1,1
784,02/07/2019 00:00,DB00921,Buprenorphine,"31% bioavailability (sublingual). Sublingual absorption is also dependent on pH. The length of time the tablet is under the tongue has little effect on absorption. Although buprenorphine is rapidly absorbed from the oral mucosa, the absorption into the systemic is slower. The time to reach peak plasma concentration (Tmax) varies between individuals (range of 40 minutes to 3.5 hours). How buprenorphine is formulated does not affect this pharmacokinetic parameter. It also undergoes extensive first-pass metabolism and as a consequence, has very low oral bioavailability. Coadministration with naloxone does not effect the pharmacokinetics of buprenorphine.",0.96,"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours. ",150 ug/1,Buccal,solid,,4.98,0.0168,7.5,12.54,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,0.96,0.96,,,0,0.15,467.3035588,8,1,2,0,1,2
785,04/06/2019 00:00,DB00922,Levosimendan,The bioavailability of oral levosimendan is 85 &plusmn; 6% in healthy volunteers and 84 &plusmn; 4% in patients.,0.98,Eliminination half-life is approximately 1 hour.,,,solid,,,0.0881,10.53,4.91,C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1,0.98,0.98,,,0,,280.107259,2,1,1,0,0,1
786,04/06/2019 00:00,DB00923,Ceforanide,Rapidly absorbed following intramuscular injection.,0.806,2.6 to 2.98 hours,,,solid,,-3.7,0.197,2.55,9.14,[H][C@]12SCC(CSC3=NN=NN3CC(O)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1CN)C(O)=O,0.806,0.806,,,0,,519.0994734,4,2,3,1,1,2
787,02/07/2019 00:00,DB00924,Cyclobenzaprine,Slowly but well absorbed after oral administration,,18 hours (range 8-37 hours),15 mg/1,Oral,solid,Freely Soluble,5.2,0.00689,,9.76,CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12,,,,,0,15,275.1673997,3,2,0,0,0,0
788,04/06/2019 00:00,DB00925,Phenoxybenzamine,Twenty to 30 percent of orally administered phenoxybenzamine appears to be absorbed in the active form.,,24 hours,10 mg/1,Oral,solid,,4.7,0.0103,,7.97,CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1,,,24,24,0,10,303.138992,2,2,0,0,0,0
789,04/06/2019 00:00,DB00926,Etretinate,Absorbed in the small intestine. Studies in normal volunteers indicate that the absorption of etretinate is greater in patients consuming whole milk or a high-fat diet than in patients in a fasting state.,0.99,"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.",,,solid,,6.5,0.000405,,-4.8,CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C,0.99,0.99,,,0,,354.2194948,1,1,0,0,0,0
790,02/07/2019 00:00,DB00927,Famotidine,The bioavailability of oral doses is 40-45%.,15-20%,2.5-3.5 hours,10 mg/1,Oral,solid,1000 mg/L (at 20 Â°C),-0.64,0.271,9.29,8.38,NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1,0.15,0.2,2.5,3.5,0,10,337.0449357,1,1,1,1,0,0
791,02/07/2019 00:00,DB00928,Azacitidine,"Azacitidine is rapidly absorbed after subcutaneous administration. The bioavailability of subcutaneous azacitidine relative to IV azacitidine is approximately 89%, based on area under the curve.",,Mean elimination half-life is approximately 4 hours.,100 mg/30mL,Intravenous; Subcutaneous,solid,8.9E+004 mg/L,-3.5,12.1,12.55,-0.38,NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,,,,,0,,244.0807695,2,1,2,1,1,1
792,02/07/2019 00:00,DB00929,Misoprostol,Misoprostol is extensively absorbed.,0.85,20-40 minutes,100 ug/1,Oral,liquid,>1.6 mg/mL at 25.0 Â°C,3.6,0.0164,14.68,-0.95,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,0.85,0.85,0.333333333,0.666666667,0,0.1,382.2719243,1,0,0,0,0,0
793,04/06/2019 00:00,DB00931,Metacycline,58% absorbed,75-78%,14 hours,,,solid,7550 mg/L (at 21 Â°C),-0.3,1.14,2.88,7.44,[H][C@@]12[C@@H](O)[C@]3([H])C(=C)C4=C(C(O)=CC=C4)C(=O)C3=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,0.75,0.78,14,14,0,,442.1376157,4,1,0,0,0,0
794,02/07/2019 00:00,DB00932,Tipranavir,"Absorption is limited, although no absolute quantification of absorption is available.",,5-6 hours,250 mg,Oral,solid,Insoluble,6.9,0.000205,5.92,-3.3,[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O,,,5,6,0,250,602.2062278,4,3,2,1,0,1
795,04/06/2019 00:00,DB00933,Mesoridazine,Well absorbed from the gastrointestinal tract.,0.04,24 to 48 hours,25 mg/1mL,Intramuscular,solid,,3.9,0.0767,15.86,8.19,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,0.04,0.04,,,0,,386.1486555,4,2,2,0,1,2
796,02/07/2019 00:00,DB00934,Maprotiline,"Slowly, but completely absorbed from the GI tract following oral administration. ",0.88,Average ~ 51 hours (range: 27-58 hours),25 mg/1,Oral,solid,Slightly soluble,5.1,0.00015,,10.54,CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21,0.88,0.88,,,0,25,277.1830497,5,2,0,0,0,0
797,02/07/2019 00:00,DB00935,Oxymetazoline,,,,50 mg/100mL,Nasal,solid,,3.4,0.0515,10.91,10.15,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C,,,,,0,,260.1888634,2,1,1,0,0,1
798,02/07/2019 00:00,DB00936,Salicylic acid,,,,2 g/100mL,Topical,solid,2240 mg/L (at 25 Â°C),2.26,11.3,2.79,-6.3,OC(=O)C1=CC=CC=C1O,,,,,0,,138.0316941,1,1,0,0,0,0
799,04/06/2019 00:00,DB00937,Diethylpropion,Diethylpropion is rapidly absorbed from the GI tract after oral administration.,,"Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours.",75 mg/1,Oral,solid,,2.8,1.22,17.43,7.44,CCN(CC)C(C)C(=O)C1=CC=CC=C1,,,,,0,75,205.1466642,1,1,0,0,0,0
800,02/07/2019 00:00,DB00938,Salmeterol,"Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses.",0.96,5.5 hours,21 ug/1,Respiratory (inhalation),solid,Sparingly soluble,4.2,0.00226,10.12,9.4,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1,0.96,0.96,5.5,5.5,0,,415.2722587,2,2,0,0,0,0
801,04/06/2019 00:00,DB00939,Meclofenamic acid,"Rapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamic acid. Unlike most NSAIDs, which when administered with food have a decrease in rate but not in extent of absorption, meclofenamic acid is decreased in both. It has been reported that following the administration of meclofenamic acid capsules one-half hour after a meal, the average extent of bioavailability decreased by 26%, the average peak concentration (C<sub>max</sub>) decreased fourfold and the time to C<sub>max</sub> was delayed by 3 hours.",0.99,In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.,100 mg/1,Oral,solid,30 mg/L,5,0.00366,3.79,-3.6,CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1,0.99,0.99,,,0,100,295.016684,2,2,0,0,0,0
802,04/06/2019 00:00,DB00940,Methantheline,Rapidly absorbed.,,,,,solid,,,0.000132,18.1,-7.2,CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12,,,,,1,,340.1907201,3,2,1,0,0,1
803,04/06/2019 00:00,DB00941,Hexafluronium,,,,,,solid,,-0.06,2.09E-07,16.64,,C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C2=C1C=CC=C2)C1C2=C(C=CC=C2)C2=C1C=CC=C2,,,,,2,,502.3337022,6,4,0,0,0,0
804,04/06/2019 00:00,DB00942,Cycrimine,,14-21%,,,,solid,,4,0.00909,13.84,9.32,OC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1,0.14,0.21,,,0,,287.2249145,3,1,1,0,1,1
805,04/06/2019 00:00,DB00943,Zalcitabine,Bioavailability is over 80% following oral administration.,0.04,2 hours,0.375 mg/1,Oral,solid,7.64E+004 mg/L (at 25 Â°C),-1.3,7.05,14.67,0.18,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,0.04,0.04,2,2,0,0.375,211.0956913,2,1,2,1,1,1
806,04/06/2019 00:00,DB00944,Demecarium,,,,,,solid,,-1.75,1.69E-05,,,CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,,,,,2,,556.397759,2,2,0,0,0,0
807,02/07/2019 00:00,DB00945,Acetylsalicylic acid,"
Absorption is generally rapid and complete following oral administration but absorption may be variable depending on the route, dosage form, and other factors including but not limited to the rate of tablet dissolution, gastric contents, gastric emptying time, and gastric pH [FDA label].

**Detailed absorption information**

When ingested orally, acetylsalicylic acid is rapidly absorbed in both the stomach and proximal small intestine. The non-ionized acetylsalicylic acid passes through the stomach lining by passive diffusion. Ideal absorption of salicylate in the stomach occurs in the pH range of 2.15 - 4.10. Intestinal absorption of acetylsalicylic acid occurs at a much faster rate.  At least half of the ingested dose is hydrolyzed to salicylic acid in the first-hour post-ingestion by esterases found in the gastrointestinal tract. Peak plasma salicylate concentrations occur between 1-2  hours post-administration [FDA label].",0.5,The half-life of ASA in the circulation ranges from 13 - 19 minutes. Blood concentrations drop rapidly after complete absorption. The half-life of the salicylate ranges between 3.5 and 4.5 hours  [FDA label].,500 mg,Ophthalmic; Oral; Topical,solid,10 mg/mL,1.18,1.46,3.41,-7.1,CC(=O)OC1=CC=CC=C1C(O)=O,0.5,0.5,,,0,500,180.0422587,1,1,0,0,0,0
808,04/06/2019 00:00,DB00946,Phenprocoumon,Bioavailability is close to 100%,0.99,5-6 days,,,solid,12.9 mg/L,3.62,0.0486,6.44,-6.5,CCC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,0.99,0.99,120,144,0,,280.1099444,3,3,1,1,0,0
809,02/07/2019 00:00,DB00947,Fulvestrant,,0.99,40 days,50 mg/1mL,Intramuscular,solid,,8.9,0.00672,10.32,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H],0.99,0.99,960,960,0,,606.3166075,4,1,0,0,0,0
810,02/07/2019 00:00,DB00948,Mezlocillin,,16-59%,1.3 to 4.4 hours,,,solid,,0,0.471,3.49,-5.9,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O,0.16,0.59,,,0,,539.1144548,4,1,3,0,3,3
811,04/06/2019 00:00,DB00949,Felbamate,>90%,20-36%,20-23 hours,600 mg/5mL,Oral,solid,Slightly soluble in water,0.3,0.742,14.98,,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,0.2,0.36,20,23,0,,238.0953569,1,1,0,0,0,0
812,02/07/2019 00:00,DB00950,Fexofenadine,0.33,60%-70%,14.4 hours,60 mg/1,Oral,solid,Slightly soluble,5.6,0.00266,4.04,9.01,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,0.6,0.7,14.4,14.4,0,60,501.2879087,4,3,1,0,1,1
813,02/07/2019 00:00,DB00951,Isoniazid,"Readily absorbed following oral administration; however, may undergo significant first pass metabolism. Absorption and bioavailability are reduced when isoniazid is administered with food.",,Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.,50 mg/5mL,Oral,solid,1.4E+005 mg/L (at 25 Â°C),-0.7,34.9,13.61,3.35,NNC(=O)C1=CC=NC=C1,,,,,0,,137.0589118,1,1,1,1,0,0
814,02/07/2019 00:00,DB00952,Naratriptan,"Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.",28%-31%,5-8 hours,1 mg,Oral,solid,35 mg/mL,1.6,0.114,11.55,9.18,CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1,0.28,0.31,5,8,0,1,335.166748,3,2,2,1,1,1
815,02/07/2019 00:00,DB00953,Rizatriptan,"Rapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack.",0.14,2-3 hours,5 mg,Oral,solid,42 mg/mL (for free base),1.4,0.338,17.24,9.56,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2,0.14,0.14,2,3,0,5,269.1640456,3,3,2,2,0,0
816,04/06/2019 00:00,DB00954,Dirithromycin,"Oral dirithromycin is rapidly absorbed, with an absolute bioavailability of approximately 10%. Dietary fat has little or no effect on the bioavailability of dirithromycin.",0.3,"The mean plasma half-life of erythromycylamine was estimated to be about 8 h (2 to 36 h), with a mean urinary terminal elimination half-life of about 44 h (16 to 65 h) in patients with normal renal function.",,,solid,Poor,1.6,0.23,12.49,9.13,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,0.3,0.3,,,0,,834.5453052,4,0,4,0,4,4
817,04/06/2019 00:00,DB00955,Netilmicin,"Rapidly and completely absorbed after IM administration, peak serum levels were achieved within 30-60 minutes. Aminoglycosides are poorly absorbed orally. Topical absorption is also poor unless severe skin damage is present. ",,2.5 hours,100 mg,Intramuscular; Intravenous,solid,100 mg/mL,-3,9.2,12.55,9.8,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O,,,2.5,2.5,0,,475.3005987,3,0,2,0,1,2
818,02/07/2019 00:00,DB00956,Hydrocodone,Well absorbed from the gastrointestinal tract.,0.19,1.25-3 hours,5 mg,Oral,solid,Insoluble,1.2,0.797,18,8.61,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,0.19,0.19,1.25,3,0,5,299.1521435,5,1,2,0,1,2
819,04/06/2019 00:00,DB00957,Norgestimate,,,12-30 hours,,Oral,solid,,4.8,0.00531,11.47,3.11,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O,,,12,30,0,,369.2303939,4,0,0,0,0,0
820,02/07/2019 00:00,DB00958,Carboplatin,"The Cmax values and areas under the plasma concentration versus time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin exhibits linear pharmacokinetics. ",,"Initial plasma half-life (alpha) = 1.1 to 2 hours;
Post distribution plasma half-life (beta) = 2.6 - 5.9 hours. ",10 mg/1mL,Intravenous,solid,,,79.8,,,[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H],,,,,,,,,,,,,
821,02/07/2019 00:00,DB00959,Methylprednisolone,Oral bioavailability 80-99%,0.78,1-3 hours,20 mg/1mL,Intralesional; Intramuscular; Intrasynovial; Soft tissue,solid,120 mg/L (at 25 Â°C),1.5,0.109,12.59,-2.9,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,0.78,0.78,1,3,0,,374.2093241,4,0,0,0,0,0
822,02/07/2019 00:00,DB00960,Pindolol,Rapidly and reproducibly absorbed (bioavailability greater than 95%).,0.4,3 to 4 hours,10 mg,Oral,solid,7880 mg/L,1.75,0.861,14.09,9.67,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2,0.4,0.4,,,0,10,248.1524779,2,2,1,1,0,0
823,02/07/2019 00:00,DB00961,Mepivacaine,"Absorbed locally. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.",0.75,The half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.,0.01,Epidural; Intracaudal,solid,7000 mg/L (at 23 Â°C),1.95,0.621,13.62,7.25,CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C,0.75,0.75,,,0,,246.1732133,2,1,1,0,1,1
824,02/07/2019 00:00,DB00962,Zaleplon,Absorption Zaleplon is rapidly and almost completely absorbed following oral administration.,0.6,Approximately 1 hour,10 mg,Oral,solid,,0.9,0.0403,,0.3,CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N,0.6,0.6,,,0,10,305.1276601,3,3,2,2,0,0
825,02/07/2019 00:00,DB00963,Bromfenac,The plasma concentration of bromfenac following ocular administration in humans is unknown.,,,0.9 mg/1mL,Ophthalmic,solid,,3.4,0.0126,3.81,1.59,NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1,,,,,0,,333.0000553,2,2,0,0,0,0
826,02/07/2019 00:00,DB00964,Apraclonidine,"Topical use of apraclonidine ophthalmic solution leads to systemic absorption. Studies of apraclonidine (0.5% ophthalmic solution) dosed one drop three times a day in both eyes for 10 days in normal volunteers yielded mean peak and trough concentrations of 0.9 ng/mL and 0.5 ng/mL, respectively.",0.987,8 hours,5.75 mg/1mL,Ophthalmic,solid,,1.4,0.409,,8.48,NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1,0.987,0.987,8,8,0,,244.0282517,2,1,1,0,0,1
827,02/07/2019 00:00,DB00966,Telmisartan,Absolute bioavailability depends on dosage. Food slightly decreases the bioavailability (a decrease of about 6% is seen when the 40-mg dose is administered with food).,,Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.,20 mg,Oral,solid,Practically insoluble,7.7,0.0035,3.65,6.13,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O,,,,,0,20,514.2368762,6,6,2,2,0,0
828,02/07/2019 00:00,DB00967,Desloratadine,,82-87%,50 hours,0.5 mg,Oral,solid,,3.2,0.00395,,9.73,ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1,0.82,0.87,50,50,0,0.5,310.1236763,4,2,2,1,1,1
829,02/07/2019 00:00,DB00968,Methyldopa,Absorption from the gastrointestinal tract is variable but averages approximately 50%.,,The plasma half-life of methyldopa is 105 minutes.,250 mg,Intravenous,solid,1E+004 mg/L (at 25 Â°C),-1.7,2.26,1.73,9.85,C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O,,,,,0,,211.0844579,1,1,0,0,0,0
830,04/06/2019 00:00,DB00969,Alosetron,50-60 %,0.82,1.5 hours,0.5 mg/1,Oral,solid,,2,0.438,13.32,6.81,CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2,0.82,0.82,1.5,1.5,0,0.5,294.1480612,4,3,3,2,0,1
831,02/07/2019 00:00,DB00970,Dactinomycin,poorly absorbed from gastrointestinal tract,0.05,36 hours,0.5 mg/1mL,Intravenous,solid,Soluble at 10 Â°C,1.6,0.02,10.52,-0.13,[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C,0.05,0.05,36,36,0,,1254.628475,7,1,5,0,4,5
832,04/06/2019 00:00,DB00972,Azelastine,Absorption of azelastine following ocular administration was relatively low. Systemic bioavailability is approximately 40% after nasal administration.,0.88,"Elimination half-life (based on intravenous and oral administration) is 22 hours. Elimination half-life of the active metabolite, desmethylazelastine, is 54 hours (after oral administration of azelastine).",137 ug/1,Nasal,solid,Sparingly soluble (hydrochloride salt),4.9,0.0092,,8.88,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O,0.88,0.88,,,0,,381.1607901,4,3,2,1,1,1
833,02/07/2019 00:00,DB00973,Ezetimibe,"Administration of a single 10-mg dose of ezetimibe in fasted adults resulted in a peak plasma concentrations (Cmax) of 3.4 to 5.5 ng/mL were achieved within 4 to 12 hours (Tmax) [FDA Label]. The Cmax of the major pharmacologically-active metabolite, ezetimibe-glucuronide, was 45 to 71 ng/mL and the Tmax was between 1 and 2 hours [FDA Label]. Food consumption had minimal effect on ezetimibe absorption, but the Cmax was increased by 38% with consumption of high-fat meals [FDA Label]. The absolute bioavailability of ezetimibe cannot be determined, as the compound is virtually insoluble in aqueous media suitable for injection [FDA Label].",>90%,Both ezetimibe and ezetimibe-glucuronide display an approximate half-life of 22 hours [FDA Label]. ,10 mg,Oral,solid,Insoluble ,,0.00846,9.48,-3,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1,0.9,1,,,0,10,409.14895,4,3,1,0,1,1
834,02/07/2019 00:00,DB00974,Edetic Acid,Poorly absorbed from the gastrointestinal tract. Well absorbed following intramuscular injection.,,The half life of edetate calcium disodium is 20 to 60 minutes.,,Topical,solid,1000000 mg/L at 25 Â°C,-2.6,9.26,2.35,7.73,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O,,,,,0,,292.0906655,0,0,0,0,0,0
835,02/07/2019 00:00,DB00975,Dipyridamole,0.7,0.99,40 minutes,50 mg,Oral,solid,Slightly,1.5,0.922,14.97,6.59,OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1,0.99,0.99,0.666666667,0.666666667,0,50,504.3172518,4,2,4,2,2,2
836,04/06/2019 00:00,DB00976,Telithromycin,Absolute bioavailability is approximately 57%. Maximal concentrations are reached 0.5 - 4 hours following oral administration. Food intake does not affected absorption. ,0.7,Main elimination half-life is 2-3 hours; terminal elimination half-life is 10 hours,400 mg,Oral,solid,300 mg/L,3,0.0283,8.84,7.65,[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1,0.7,0.7,,,0,400,811.4731433,5,2,5,2,3,3
837,02/07/2019 00:00,DB00977,Ethinylestradiol,Rapid and complete absorption follows oral intake of ethinyl estradiol (bioavailability 43%).,0.97,36 +/- 13 hours,.05 mg,Oral,solid,11.3 mg/L (at 27 Â°C),3.67,0.00677,10.33,-1.7,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,0.97,0.97,,,0,0.05,296.17763,4,1,0,0,0,0
838,04/06/2019 00:00,DB00978,Lomefloxacin,Rapid and nearly complete with approximately 95% to 98% of a single oral dose being absorbed.,0.1,8 hours,400 mg/1,Oral,solid,27.2 mg/mL,-0.3,0.106,5.64,8.7,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12,0.1,0.1,8,8,0,400,351.1394479,3,2,2,1,1,1
839,02/07/2019 00:00,DB00979,Cyclopentolate,Absorbed following ophthalmic administration.,,,10 mg/1mL,Ophthalmic,solid,,2.4,1.5,14.19,8.42,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,,,,,0,,291.1834437,2,1,0,0,0,0
840,04/06/2019 00:00,DB00980,Ramelteon,"Rapid, total absorption is at least 84%.",~82%,~1-2.6 hours,8 mg/1,Oral,solid,,2.4,0.0164,15.82,-0.4,CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2,0.82,0.82,1,2.6,0,8,259.1572289,3,1,1,0,0,1
841,04/06/2019 00:00,DB00981,Physostigmine,,,,1 mg,Intramuscular; Intravenous,solid,7760 mg/L,1.58,0.992,14.77,6.59,[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C,,,,,0,,275.1633769,3,1,2,0,1,2
842,02/07/2019 00:00,DB00982,Isotretinoin,"Patients reach a maximum concentration of 74-511ng/mL after 1-4 hours following a 100mg oral dose.[A179089] Isotretinoin is better absorbed with a high fat meal and bioavailability may change from one brand to another.[Label]

Following a 40mg oral dose, fasted subjects reached a maximum concentration of 314ng/mL in 2.9 hours with an area under the curve of 4055ng/mL\*hr.[Label] Subjects given a high fat meal and a 40mg oral doses reached a maximum concentration of 395ng/mL in 6.4 hours with an area under the curve of 6095ng/mL\*mL.[Label]",>99.9%,The half life ranges from 7-39 hours[L6589] with a mean elimination half life of 20 hours.[A179089] The half life of 4-oxo-13-cis-retinoic acid ranges from 17-50 hours with a mean elimination half life of 25 hours.[L6589],25 mg/1,Oral,solid,0.00477mg/mL,5.66,0.00477,5,,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O,0.99,1,,,0,25,300.2089301,1,0,0,0,0,0
843,02/07/2019 00:00,DB00983,Formoterol,Rapidly absorbed into plasma following administration by oral inhalation. It is likely that the majority of the inhaled formoterol delivered is swallowed and then absorbed from the gastrointestinal tract.,61%-64%,10 hours,12 ug/1,Respiratory (inhalation),solid,Slightly (as fumarate salt),2.2,0.0416,8.61,9.81,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1,0.61,0.64,10,10,0,,344.1736072,2,2,0,0,0,0
844,04/06/2019 00:00,DB00984,Nandrolone phenpropionate,"The absorption after oral dosing is rapid for testosterone and probably for other anabolic steroids, but there is extensive first-pass hepatic metabolism for all anabolic steroids except those that are substituted at the 17-alpha position. The rate of absorption from subcutaneous or intramuscular depots depends on the product and its formulation. Absorption is slow for the lipid-soluble esters such as the cypionate or enanthate, and for oily suspensions.",0.58,The elimination half-life from plasma is very short.,,,solid,3090 mg/L (at 25 Â°C),2.62,0.000458,19.28,-4.7,[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],0.58,0.58,,,0,,406.2507949,5,1,0,0,0,0
845,02/07/2019 00:00,DB00985,Dimenhydrinate,Well absorbed after oral administration.,,1 to 4 hours,25 mg/1,Oral,solid,3000 mg/L,-0.39,0.00125,,8.87,CN1C2=C([N-]C(Cl)=N2)C(=O)N(C)C1=O.C[NH+](C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,25,469.1880674,4,4,2,2,0,0
846,02/07/2019 00:00,DB00986,Glycopyrronium,Rapidly absorbed (1-2 minutes) after intravenous injection,,0.6-1.2 hours,1 mg/5mL,Respiratory (inhalation),solid,,-0.99,0.000944,11.53,-4.3,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1,,,0.6,1.2,1,,318.2063702,3,1,1,0,1,1
847,02/07/2019 00:00,DB00987,Cytarabine,Less than 20% of the orally administered dose is absorbed from the gastrointestinal tract.,0.13,10 minutes,100 mg/5mL,Intrathecal; Intravenous; Subcutaneous,solid,Freely soluble,-2.8,43.8,12.55,-0.55,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0.13,0.13,0.166666667,0.166666667,0,,243.0855205,2,1,2,1,1,1
848,02/07/2019 00:00,DB00988,Dopamine,Dopamine is rapidly absorbed from the small intestine.,,2 minutes,160 mg/1mL,Intravenous,solid,600 g/L,-0.98,7.43,10.01,9.27,NCCC1=CC(O)=C(O)C=C1,,,0.033333333,0.033333333,0,,153.0789786,1,1,0,0,0,0
849,02/07/2019 00:00,DB00989,Rivastigmine,,0.4,1.5 hours,18 mg,Transdermal,solid,,2.3,2.04,,8.89,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,0.4,0.4,1.5,1.5,0,,250.1681279,1,1,0,0,0,0
850,02/07/2019 00:00,DB00990,Exemestane,0.42,0.9,24 hours,25 mg/1,Oral,solid,Non-soluble,3.7,0.00683,19.96,-5,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C,0.9,0.9,24,24,0,25,296.17763,4,0,0,0,0,0
851,02/07/2019 00:00,DB00991,Oxaprozin,"Oxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.",>99.5%,54.9 hours,600 mg,Oral,solid,Insoluble,4.19,0.0325,4.95,-0.59,OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1,0.99,1,54.9,54.9,0,600,293.1051933,3,3,1,1,0,0
852,02/07/2019 00:00,DB00992,Methyl aminolevulinate,"In vitro, after 24 hours the mean cumulative absorption through human skin was 0.26% of the administered dose.",,,168 mg,Topical,solid,Freely soluble,-1.2,220,16.12,7.83,COC(=O)CCC(=O)CN,,,,,0,,145.0738932,0,0,0,0,0,0
853,02/07/2019 00:00,DB00993,Azathioprine,Well absorbed following oral administration.,,,100 mg/1,Oral,solid,Insoluble ,0.1,1.07,8.65,4,CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O,,,,,0,100,277.0381935,3,3,3,3,0,0
854,02/07/2019 00:00,DB00995,Auranofin,,,,3 mg/1,Oral,solid,,,0.151,,-4.3,CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O,,,,,0,3,678.132684,1,0,1,0,1,1
855,02/07/2019 00:00,DB00996,Gabapentin,"Rapid. Absorbed in part by the L-amino acid transport system, which is a carrier-mediated, saturable transport system; as the dose increases, bioavailability decreases. Bioavailability ranges from approximately 60% for a 900 mg dose per day to approximately 27% for a 4800 milligram dose per day. Food has a slight effect on the rate and extent of absorption of gabapentin (14% increase in AUC).",0.03,5-7 hours,10.5 g/10.5g,Oral,solid,4490 mg/L,-1.1,4.34,4.63,9.91,NCC1(CC(O)=O)CCCCC1,0.03,0.03,5,7,0,,171.1259288,1,0,0,0,0,0
856,02/07/2019 00:00,DB00997,Doxorubicin,,74-76%,Terminal half life = 20 - 48 hours. ,2 mg/1mL,Intravenous,solid,Soluble,1.27,1.18,9.53,8.94,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,0.74,0.76,,,0,,543.1740607,5,2,1,0,1,1
857,02/07/2019 00:00,DB00998,Frovatriptan,"Frovatriptan is rapidly absorbed from the duodenum, but has low oral bioavailability.",,26 hours,2.5 mg,Oral,solid,Soluble,0.9,0.123,14.54,10.42,CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O,,,26,26,0,2.5,243.1371622,3,2,1,1,0,0
858,02/07/2019 00:00,DB00999,Hydrochlorothiazide,50-60%,0.679,5.6 and 14.8 hours,50 mg,Oral,solid,722 mg/L (at 25 Â°C),-0.07,2.24,9.09,-2.7,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,0.679,0.679,,,0,50,296.9644754,2,1,1,0,0,1
859,04/06/2019 00:00,DB01000,Cyclacillin,Moderately absorbed.,,,,,solid,,1.31,1.9,3.3,8.45,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O,,,,,0,,341.1409272,3,0,2,0,2,2
860,02/07/2019 00:00,DB01001,Salbutamol,"Following inhalation, salbutamol acts topically on bronchial smooth muscle and the drug is initially undetectable in the blood.[F3265] After 2 to 3 hours low concentrations are seen, due presumably to the portion of the dose which is swallowed and absorbed in the gut.[F3265]

In particular, the systemic levels of salbutamol are low after inhalation of recommended doses.[Label] A trial conducted in 12 healthy male and female subjects using a higher dose (1,080 mcg of albuterol base) showed that mean peak plasma concentrations of approximately 3 ng/mL occurred after dosing when salbutamol was delivered using propellant HFA-134a.[Label] The mean time to peak concentrations (Tmax) was delayed after administration of VENTOLIN (salbutamol) HFA (Tmax = 0.42 hours) as compared with CFC-propelled salbutamol inhaler (Tmax = 0.17 hours).[Label] ",,"The elimination half-life of inhaled or oral salbutamol has been recorded as being between 2.7 and 5 hours while the apparent terminal plasma half-life of albuterol has been documented as being approximately 4.6 hours.[F3265,Label]",0.63 mg/3mL,Respiratory (inhalation),solid,1.41E+004 mg/L,1.4,2.15,10.12,9.4,CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1,,,,,0,,239.1521435,1,1,0,0,0,0
861,04/06/2019 00:00,DB01002,Levobupivacaine,"The plasma concentration of levobupivacaine following therapeutic administration depends on dose and also on route of administration, because absorption from the site of administration is affected by the vascularity of the tissue. Peak levels in blood were reached approximately 30 minutes after epidural administration, and doses up to 150 mg resulted in mean C<sub>max</sub> levels of up to 1.2 Âµg/mL.",>97%,3.3 hours,,,solid,,3.6,0.0977,13.62,8,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,0.97,1,3.3,3.3,0,,288.2201635,2,1,1,0,1,1
862,02/07/2019 00:00,DB01003,Cromoglicic acid,0.01,,1.3 hours,0.02,Nasal,solid,210 mg/L,1.92,0.0358,1.77,-3.4,OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O,,,1.3,1.3,0,,468.0692613,4,4,2,2,0,0
863,02/07/2019 00:00,DB01004,Ganciclovir,"Poorly absorbed systemically following oral administration. Bioavailability under fasting conditions is approximately 5%, and when administered with food, 6 to 9% (about 30% with a fatty meal).",0.02,"2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally).",250 mg,Oral,solid,4300 mg/L (at 25 Â°C),-1.66,11.5,10.16,1.76,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,0.02,0.02,,,0,250,255.0967539,2,2,2,2,0,0
864,02/07/2019 00:00,DB01005,Hydroxyurea,Well absorbed from the gastrointestinal tract.,,3-4 hours,200 mg/1,Oral,solid,1E+006 mg/L (at 25 Â°C),-1.8,269,10.14,-4.9,NC(=O)NO,,,3,4,0,200,76.02727737,0,0,0,0,0,0
865,02/07/2019 00:00,DB01006,Letrozole,Rapidly and completely absorbed. Absorption is not affected by food.,,2 days,2.5 mg,Oral,solid,,2.5,0.0799,,2.17,N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N,,,48,48,0,2.5,285.1014454,3,3,1,1,0,0
866,02/07/2019 00:00,DB01007,Tioconazole,Systemic absorption following a single intravaginal application of tioconazole in nonpregnant patients is negligible.,,,0.065,Topical; Vaginal,solid,,4.4,0.0165,,6.77,ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1,,,,,0,,385.9814171,3,3,2,2,0,0
867,02/07/2019 00:00,DB01008,Busulfan,"Completely absorbed from the gastrointestinal tract. Busulfan is a small, highly lipophilic molecule that crosses the blood-brain-barrier. The absolute bioavailability, if a single 2 mg IV bolus injection is given to adult patients, is 80% Â± 20%. In children (1.5 - 6 years old), the absolute bioavailability was 68% Â± 31%. When a single oral dose is given to patients, the area under the curve (AUC) was 130 ngâ€¢hr/mL. The peak plasma concentration when given orally is 30 ng/mL (after dose normalization to 2 mg). It takes 0.9 hours to reach peak plasma concentration after dose normalization to 4 mg. ",0.32,2.6 hours,6 mg/1mL,Intravenous,solid,6.9E+004 mg/L,-0.52,5.16,,,CS(=O)(=O)OCCCCOS(C)(=O)=O,0.32,0.32,2.6,2.6,0,,246.0231802,0,0,0,0,0,0
868,02/07/2019 00:00,DB01009,Ketoprofen,"Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.",0.99,"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>",33.5 g/33.5g,Oral,solid,51 mg/L (at 22 Â°C),3.12,0.0213,3.88,-7.5,CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,0.99,0.99,,,0,,254.0942943,2,2,0,0,0,0
869,04/06/2019 00:00,DB01010,Edrophonium,Rapidly absorbed.,,Distribution half-life is 7 to 12 minutes. Elimination half-life is 33 to 110 minutes.,10 mg/1mL,Intramuscular; Intravenous,liquid,Appreciable as liquid hydrochloride salt,-2.95,0.0486,8.59,-6.1,CC[N+](C)(C)C1=CC(O)=CC=C1,,,,,1,,166.1226406,1,1,0,0,0,0
870,04/06/2019 00:00,DB01011,Metyrapone,Absorbed rapidly and well when administered orally. Peak plasma concentrations are usually reached 1 hour after administration.,,1.9 &plusmn;0.7 hours.,250 mg/1,Oral,solid,Sparingly soluble,1.8,0.427,,4.87,CC(C)(C(=O)C1=CN=CC=C1)C1=CC=CN=C1,,,,,0,250,226.1106131,2,2,2,2,0,0
871,02/07/2019 00:00,DB01012,Cinacalcet,Rapidly absorbed following oral administration.,0.97,"Terminal half-life is 30 to 40 hours. The mean half-life of cinacalcet is prolonged by 33% and 70% in patients with moderate and severe hepatic impairment, respectively.",30 mg/1,Oral,solid,Slightly soluble (in HCl salt form),6.5,5.59E-05,,10.3,C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12,0.97,0.97,,,0,30,357.1704344,3,3,0,0,0,0
872,02/07/2019 00:00,DB01013,Clobetasol propionate,"Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.",,,0.0005,Topical,solid,3.86 mg/L,3.5,0.00413,13.63,-3.4,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,466.19223,4,0,0,0,0,0
873,04/06/2019 00:00,DB01014,Balsalazide,"Low and variable, intact balsalazide is poorly absorbed systemically.",&ge;99%,Half-life could not be determined.,750 mg/1,Oral,solid,Freely soluble as disodium salt,1.3,0.0621,3.06,-0.033,OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O,0.99,0.99,,,0,750,357.0960852,2,2,0,0,0,0
874,02/07/2019 00:00,DB01015,Sulfamethoxazole,Rapidly absorbed following oral administration. Also well-absorbed topically. ,0.7,10 hours,1 g/1g,Oral,solid,610 mg/L (at 37 Â°C),0.89,0.459,6.16,1.97,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,0.7,0.7,10,10,0,,253.0521122,2,2,1,1,0,0
875,02/07/2019 00:00,DB01016,Glyburide,Significant absorption within 1 hour and peak plasma levels are reached in 2 to 4 hours. Onset of action occurs within one hour. ,~99%,1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.,2.5 mg,Oral,solid,4 mg/L (at 27 Â°C),4.7,0.00206,4.32,-1.2,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,0.99,0.99,,,0,2.5,493.1438197,3,2,0,0,0,0
876,02/07/2019 00:00,DB01017,Minocycline,Rapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.,0.55,11-22 hours,100 mg,Oral,solid,5.2E+004 mg/L (at 25 Â°C),0.05,3.07,-2.3,8.25,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,0.55,0.55,11,22,0,100,457.1849002,4,1,0,0,0,0
877,02/07/2019 00:00,DB01018,Guanfacine,"Rapid and complete, with an oral bioavailability of approximately 80%.",0.7,17 hours (range 10-30 hours),3 mg/1,Oral,solid,1892 mg/L,1.7,0.139,12.94,6.65,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl,0.7,0.7,,,0,3,245.0122673,1,1,0,0,0,0
878,02/07/2019 00:00,DB01019,Bethanechol,,,,10 mg/1,Oral,solid,10 mg/mL (chloride salt),,0.311,15.34,,CC(C[N+](C)(C)C)OC(N)=O,,,,,1,10,161.1284542,0,0,0,0,0,0
879,02/07/2019 00:00,DB01020,Isosorbide Mononitrate,1,0.05,5 hours,120 mg/1,Oral,solid,1.07E+005 mg/L,-0.15,57,13.34,-3.5,[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O,0.05,0.05,5,5,0,120,191.042987,2,0,2,0,2,2
880,04/06/2019 00:00,DB01021,Trichlormethiazide,,,,,,solid,800 mg/L (at 25 Â°C),0.62,0.415,8.32,-4.1,NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl,,,,,0,,378.9021808,2,1,1,0,0,1
881,02/07/2019 00:00,DB01022,Phylloquinone,"Oral phylloquinone is adequately absorbed from the gastrointestinal tract only if bile salts are present. After absorption, phylloquinone is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues.",,,5 mg/1,Intravenous,liquid,Insoluble in water,9.3,5.92E-05,,-7.2,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O,,,,,0,,450.3497807,2,1,0,0,0,0
882,02/07/2019 00:00,DB01023,Felodipine,"Is completely absorbed from the gastrointestinal tract; however, extensive first-pass metabolism through the portal circulation results in a low systemic availability of 15%. Bioavailability is unaffected by food. ",,17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.,2.5 mg/1,Oral,solid,19.7 mg/L,3.86,0.00715,19.46,-6.6,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC,,,,,0,2.5,383.0691134,2,1,1,0,0,1
883,02/07/2019 00:00,DB01024,Mycophenolic acid,Bioavailability following oral administration of Myfortic delayed-release tablet ranges from 70-95%,>98%,"The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.",180 mg,Oral,solid,Insoluble,2.8,0.0355,3.57,-4.1,COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C,0.98,1,,,0,180,320.1259884,2,1,1,0,0,1
884,04/06/2019 00:00,DB01025,Amlexanox,No significant absorption directly through the active ulcer. Most of the systemic absorption is via the gastrointestinal tract.,,Elimination half-life is 3.5 &plusmn; 1.1 hours.,0.05,Oral,solid,,4.1,0.146,4.3,0.87,CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1,,,,,0,,298.0953569,3,3,2,2,0,0
885,02/07/2019 00:00,DB01026,Ketoconazole,Moderate,0.99,2 hours,20 mg/1g,Topical,solid,0.0866 mg/L,4.35,0.00931,,6.75,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,0.99,0.99,2,2,0,,530.1487607,5,3,3,1,2,2
886,02/07/2019 00:00,DB01028,Methoxyflurane,,,,0.999,Respiratory (inhalation),liquid,2.83E+004 mg/L (at 37 Â°C),2.21,6.46,,-4.5,COC(F)(F)C(Cl)Cl,,,,,0,,163.9607265,0,0,0,0,0,0
887,02/07/2019 00:00,DB01029,Irbesartan,Rapid and complete with an average absolute bioavailability of 60-80%. Food has no affect on bioavailability.,0.9,11-15 hours,150 mg,Oral,solid,,6,0.00884,7.4,4.12,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,0.9,0.9,11,15,0,150,428.2324595,5,3,2,1,0,1
888,02/07/2019 00:00,DB01030,Topotecan,,0.35,2-3 hours,.25 mg/1,Oral,solid,1 mg/ml,0.8,0.861,8,9.83,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O,0.35,0.35,2,3,0,0.25,421.1637708,5,3,4,2,0,2
889,04/06/2019 00:00,DB01031,Ethinamate,Rapidly absorbed following oral administration.,,2.5 hours,,,solid,2500 mg/L (at 25 Â°C),1.2,0.106,15.37,,NC(=O)OC1(CCCCC1)C#C,,,2.5,2.5,0,,167.0946287,1,0,0,0,0,0
890,04/06/2019 00:00,DB01032,Probenecid,,75-95%,6-12 hours,500 mg,Oral,solid,27.1 mg/L,3.21,0.425,3.53,,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O,0.75,0.95,6,12,0,500,285.1034791,1,1,0,0,0,0
891,02/07/2019 00:00,DB01033,Mercaptopurine,"Clinical studies have shown that the absorption of an oral dose of mercaptopurine in humans is incomplete and variable, averaging approximately 50% of the administered dose. The factors influencing absorption are unknown.",0.19,"Triphasic: 45 minutes, 2.5 hours, and 10 hours.",50 mg/1,Oral,solid,6.85E+004 mg/L,0.01,0.735,9.5,2.99,S=C1N=CNC2=C1NC=N2,0.19,0.19,,,0,50,152.0156671,2,2,2,2,0,0
892,04/06/2019 00:00,DB01034,Cerulenin,,,,,,solid,Slightly soluble,1.2,1.6,-3.4,12.56,[H][C@]1(O[C@]1([H])C(=O)CC\C=C\C\C=C\C)C(N)=O,,,,,0,,223.1208434,1,0,1,0,1,1
893,02/07/2019 00:00,DB01035,Procainamide,75 to 95%,0.2,~2.5-4.5 hours,375 g,Oral,solid,5050 mg/L,0.88,3.02,15.75,9.04,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1,0.2,0.2,2.5,4.5,0,,235.1684623,1,1,0,0,0,0
894,02/07/2019 00:00,DB01036,Tolterodine,,,1.9-3.7 hours,1 mg,Oral,solid,,5.6,0.00534,10.28,11.01,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C,,,1.9,3.7,0,1,325.2405646,2,2,0,0,0,0
895,02/07/2019 00:00,DB01037,Selegiline,Rapidly absorbed from the gastrointestinal tract.,0.995,1.2-2 hours,5 mg,Oral,solid,,2.7,0.0254,,8.67,C[C@H](CC1=CC=CC=C1)N(C)CC#C,0.995,0.995,1.2,2,0,5,187.1360995,1,1,0,0,0,0
896,04/06/2019 00:00,DB01038,Carphenazine,,,,,,solid,,3.3,0.0366,15.56,7.67,CCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,,,,,0,,425.2136982,4,2,2,0,1,2
897,02/07/2019 00:00,DB01039,Fenofibrate,"Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide",0.99,20 hours,130 mg/1,Oral,solid,0.25mg/ml at 25 Â°C,5.3,0.000707,,-4.9,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,0.99,0.99,20,20,0,130,360.1128368,2,2,0,0,0,0
898,02/07/2019 00:00,DB01041,Thalidomide,"The absolute bioavailability has not yet been characterized in human subjects due to its poor aqueous solubility. In studies of both healthy volunteers and subjects with Hansen&rsquo;s disease, the mean time to peak plasma concentrations (Tmax) ranged from 2.9 to 5.7 hours indicating that thalidomide is slowly absorbed from the gastrointestinal tract.",0.55,The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.,100 mg,Oral,solid,545 mg/L (at 25 Â°C),0.33,2.55,11.59,-6.4,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12,0.55,0.55,,,0,100,258.0640568,3,1,2,0,1,2
899,02/07/2019 00:00,DB01042,Melphalan,"Incomplete, variable, 25-89% post oral dose",0.3,1.5 (&plusmn;0.83) hours,2 mg/1,Oral,solid,< 0.1 g/100 mL at 22 Â°C,-0.52,0.358,1.29,9.51,N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O,0.3,0.3,,,0,2,304.0745332,1,1,0,0,0,0
900,02/07/2019 00:00,DB01043,Memantine,"After an oral dose, memantine is well absorbed. Its peak drug concentrations are attained in about 3-7 hours. Memantine shows linear pharmacokinetics when given at normal therapeutic doses. This drug can be taken without regard to food, as there is no effect of food on memantine absorption [FDA label]. ",0.45,"Within the range of 60-100 hours [FDA label].

The terminal elimination half-life was significantly increased in patients with moderate to severe renal impairment, in comparison with patients with normal renal function [FDA label]. Exercise caution when this drug is administered to patients with renal dysfunction.",5 mg,Oral,solid,soluble in water,3.28,0.0455,,10.7,CC12CC3CC(C)(C1)CC(N)(C3)C2,0.45,0.45,,,0,5,179.1673997,4,0,0,0,0,0
901,02/07/2019 00:00,DB01044,Gatifloxacin,Well absorbed from the gastrointestinal tract after oral administration with absolute bioavailability of gatifloxacin is 96%,0.2,7-14 hours,3 mg/1mL,Ophthalmic,solid,60 mg/mL (at pH 4),2.6,0.631,5.69,8.73,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1,0.2,0.2,7,14,0,,375.1594344,4,2,2,1,1,1
902,02/07/2019 00:00,DB01045,Rifampicin,Well absorbed from gastrointestinal tract.,0.89,3.35 (+/- 0.66) hours,50 mg/5mL,Oral,solid,1400 mg/L (at 25 Â°C),2.7,0.0413,6.9,7.53,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C,0.89,0.89,,,0,,822.4051233,6,2,4,0,1,4
903,02/07/2019 00:00,DB01046,Lubiprostone,Lubiprostone has low systemic availability following oral administration and concentrations of lubiprostone in plasma are below the level of quantitation (10 pg/mL).,0.94,0.9 to 1.4 hours,24 mcg,Oral,solid,Practically insoluble,4.3,0.0256,4.3,-4.4,[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC,0.94,0.94,,,0,0.024,390.2217806,2,0,1,0,1,1
904,02/07/2019 00:00,DB01047,Fluocinonide,"The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. In general, percutaneous absorption is minimal. ",,,0.5 mg/1mL,Topical,solid,4.74 mg/L,3.19,0.0168,13.55,-3.4,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O,,,,,0,,494.2116098,5,0,1,0,1,1
905,02/07/2019 00:00,DB01048,Abacavir,"Rapid and extensive after oral administration (83% bioavailability, tablet). When a 300 mg tablet is given twice daily to subjects, the peak plasma concentration (Cmax) was 3.0 Â± 0.89 mcg/mL and the area under the curve (AUC 0-12 hours) was 6.02 Â± 1.73 mcgâ€¢hr/mL. ",,1.54 Â± 0.63 hours,301,Oral,solid,77 mg/mL (sulfate salt),1.2,1.21,15.41,5.77,NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1,,,,,0,,286.1542092,4,2,2,2,0,0
906,02/07/2019 00:00,DB01050,Ibuprofen,"It is very well absorbed orally and the peak serum concentration can be attained in 1 to 2 hours after extravascular administration. When ibuprofen is administered immediately after a meal there is a slight reduction in the absorption rate but there is no change in the extent of the absorption.[A39092] 

When orally administered, the absorption of ibuprofen in adults is very rapidly done in the upper GI tract.[A39190] The average Cmax, Tmax and AUC ranges around 20 mcg/ml, 2 h and 70 mcg.h/ml. These parameters can vary depending on the enantiomer form, route, and dose of administration.[A39190]",0.99,"The serum half-life of ibuprofen is 1.2-2 hours.[A39092] In patients with a compromised liver function, the half-life can be prolonged to 3.1-3.4 hours.[A39190]",600 mg,Topical,solid,21 mg/L (at 25 Â°C),3.97,0.0684,4.85,,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,0.99,0.99,,,0,,206.1306798,1,1,0,0,0,0
907,04/06/2019 00:00,DB01051,Novobiocin,Oral bioavailability is negligible.,0.95,6 hours,,,solid,Insoluble,4.1,0.00966,6.96,-3.9,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=C(C)C3=C(C=C2)C(O)=C(NC(=O)C2=CC=C(O)C(CC=C(C)C)=C2)C(=O)O3)OC1(C)C,0.95,0.95,6,6,0,,612.23191,4,3,2,1,1,1
908,02/07/2019 00:00,DB01053,Benzylpenicillin,"Rapidly absorbed following both intramuscular and subcutaneous injection. Initial blood levels following parenteral administration are high but transient. Oral absorption in fasting, healthy humans is only about 15-30% as it is very susceptible to acid-catalyzed hydrolysis.",,In adults with normal renal function is reportedly 0.4â€“0.9 hours,1200000 [iU]/2mL,Intramuscular,solid,Slightly soluble (210 mg/L),1.83,0.285,3.53,-2.6,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,,,,,0,,334.0987281,3,1,2,0,2,2
909,04/06/2019 00:00,DB01054,Nitrendipine,,0.99,,,,solid,Insoluble,2.88,0.0142,,5.43,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC,0.99,0.99,,,0,,360.1321364,2,1,1,0,0,1
910,04/06/2019 00:00,DB01055,Mimosine,,>99.5%,,,,solid,,-2.5,13.1,1.94,8.88,N[C@@H](CN1C=CC(=O)C(O)=C1)C(O)=O,0.99,1,,,0,,198.0640568,1,1,1,1,0,0
911,04/06/2019 00:00,DB01056,Tocainide,"Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.",,The average plasma half-life in patients is approximately 15 hours. May be prolonged up to 35 hours in patients with severe renal function impairment (creatinine clearance less than 30 mL per min per 1.73 square meters of body surface area.,400 mg,Oral,solid,1.07E+004 mg/L,0.76,1.6,13.65,8.23,CC(N)C(=O)NC1=C(C)C=CC=C1C,,,,,0,400,192.1262631,1,1,0,0,0,0
912,04/06/2019 00:00,DB01057,Echothiophate,This ophthalmic medication may be systemically absorbed.,,,6.25 mg/5mL,Ophthalmic,solid,Soluble,-2.25,0.297,,-8.2,CCOP(=O)(OCC)SCC[N+](C)(C)C,,,,,1,,256.1130776,0,0,0,0,0,0
913,02/07/2019 00:00,DB01058,Praziquantel,Rapidly absorbed (80%),0.85,0.8-1.5 hours (in serum),600 mg,Oral,solid,400 mg/L,2.5,0.381,19.38,-0.22,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,0.85,0.85,,,0,600,312.183778,4,1,2,0,1,2
914,02/07/2019 00:00,DB01059,Norfloxacin,Rapid,0.15,3-4 hours,400 mg,Oral,solid,1.78E+005 mg/L,-1.03,1.01,5.77,8.68,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1,0.15,0.15,3,4,0,400,319.1332197,3,2,2,1,1,1
915,02/07/2019 00:00,DB01060,Amoxicillin,Rapidly absorbed after oral administration.,0.2,61.3 minutes,500 mg/1,Oral,solid,3430 mg/L,0.87,0.958,3.23,7.43,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,0.2,0.2,1.021666667,1.021666667,0,500,365.1045417,3,1,2,0,2,2
916,04/06/2019 00:00,DB01061,Azlocillin,Not significantly absorbed from the gastrointestinal tract.,0.46,"Mean elimination half-life is 1.3 to 1.5 hours. Longer in neonates, and 2 to 6 hours in patients with renal impairment.",,,solid,Sodium salt is soluble in water (50 mg/ml),0.2,0.233,3.49,-5.9,[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1,0.46,0.46,,,0,,461.1369045,4,1,3,0,3,3
917,02/07/2019 00:00,DB01062,Oxybutynin,Rapidly absorbed from gastrointestinal tract.,91%-93%,12.4-13.2 hours,5 mg,Oral,solid,,4.3,0.01,11.53,8.77,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,0.91,0.93,12.4,13.2,0,5,357.2303939,2,1,0,0,0,0
918,04/06/2019 00:00,DB01063,Acetophenazine,,,,,,solid,,2.62,0.0601,15.46,8.07,CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,,,,,0,,411.1980482,4,2,2,0,1,2
919,02/07/2019 00:00,DB01064,Isoprenaline,,,,.2 mg,Respiratory (inhalation),solid,,1.4,5.86,9.81,8.96,CC(C)NCC(O)C1=CC(O)=C(O)C=C1,,,,,0,,211.1208434,1,1,0,0,0,0
920,04/06/2019 00:00,DB01065,Melatonin,The absorption and bioavailability of melatonin varies widely.,,35 to 50 minutes,2.5 mg/1,Oral; Sublingual,solid,,1.6,0.143,15.8,-1.6,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1,,,,,0,2.5,232.1211778,2,2,1,1,0,0
921,04/06/2019 00:00,DB01066,Cefditoren,"Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases. Under fasting conditions, the estimated absolute bioavailability of cefditoren pivoxil is approximately 14%. The absolute bioavailability of cefditoren pivoxil administered with a low fat meal (693 cal, 14 g fat, 122 g carb, 23 g protein) is 16.1 &plusmn; 3.0%.",0.88,Mean terminal elimination half-life is 1.6 &plusmn; 0.4 hours in young healthy adults.,200 mg/1,Oral,solid,Soluble at levels equal to < 0.1 mg/mL.,,0.0441,3.4,4.22,[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,0.88,0.88,,,0,200,506.0500807,4,2,4,2,1,2
922,26/06/2019 00:00,DB01067,Glipizide,"Gastrointestinal absorption of glipizide is uniform, rapid, and essentially complete.[A179485] The absolute bioavailability of glipizide in patients with type 2 diabetes receiving a single oral dose was 100%. The maximum plasma concentrations are expected to be reached within 6 to 12 hours following initial dosing. The steady-state plasma concentrations of glipizide from extended-release oral formulations are maintained over the 24-hour dosing interval.[label] In healthy volunteers, the absorption of glipizide was delayed by the presence of food but the total absorption was unaffected.[L6745]",98-99%,The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.[label],10 mg/1,Oral,solid,37.2 mg/L,1.91,0.0164,4.32,0.061,CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,0.98,0.99,,,0,10,445.1783753,3,2,1,1,0,0
923,02/07/2019 00:00,DB01068,Clonazepam,"Clonazepam is rapidly and almost entirely absorbed after oral administration as tablets [FDA Label] [F3763, F3796]. Peak plasma concentrations of clonazepam administered by the oral route are reached within 1-4 hours and the associated absorption half-life is about 25 minutes [FDA Label] [F3763, F3796]. The absolute bioavailability is approximately 90% - but with substantially large differences between individuals [FDA Label] [F3763, F3796]. ",82â€“86%,"The mean elimination half-life determined for clonazepam is independent of the dose given and has been documented as being about 30-40 hours [F3763, F3796].",1.0 mg,Oral,solid,100 mg/L (at 25 Â°C),2.41,0.0106,11.89,1.86,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0.82,0.86,,,0,1,315.0410689,3,2,1,0,0,1
924,02/07/2019 00:00,DB01069,Promethazine,"On average, 88% of a promethazine dose is absorbed after oral administration; however, the absolute bioavailability is only 25% because of first-pass clearance.",0.93,16-19 hours,50 mg/1mL,Oral,solid,15.6 mg/L (at 24 Â°C),4.81,0.0245,,9.05,CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C,0.93,0.93,16,19,0,,284.1347196,3,2,1,0,0,1
925,04/06/2019 00:00,DB01070,Dihydrotachysterol,,>99%,,.125 mg,Oral,solid,,7.5,0.000125,18.3,-1.4,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C,0.99,1,,,0,0.125,398.3548661,3,0,0,0,0,0
926,04/06/2019 00:00,DB01071,Mequitazine,,,,,,solid,,4.7,0.00401,,8.61,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12,,,,,0,,322.1503697,6,2,4,0,3,4
927,02/07/2019 00:00,DB01072,Atazanavir,Atazanavir is rapidly absorbed with a T<sub>max</sub> of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability. Oral bioavailability is 60-68%.,0.86,Elimination half-life in adults (healthy and HIV infected) is approximately 7 hours (following a 400 mg daily dose with a light meal). Elimination half-life in hepatically impaired is 12.1 hours (following a single 400 mg dose).,100 mg/1,Oral,solid,Free base slightly soluble (4-5 mg/mL),4.5,0.00327,11.92,4.42,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,0.86,0.86,,,0,100,704.389748,3,3,1,1,0,0
928,02/07/2019 00:00,DB01073,Fludarabine,Bioavailability is 55% following oral administration.,19-29%,20 hours,25.0 mg,Intravenous,solid,3.53 mg/ml,-2.8,12.1,12.45,0.71,NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0.19,0.29,20,20,0,,285.0873321,3,2,3,2,1,1
929,04/06/2019 00:00,DB01074,Perhexiline,Well absorbed (>80%) from the gastrointestinal tract following oral administration.,,"Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.",,,solid,0.0608 mg/L,6.2,2.72E-05,,10.58,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1,,,,,0,,277.2769501,3,0,1,0,1,1
930,02/07/2019 00:00,DB01075,Diphenhydramine,"Diphenhydramine is quickly absorbed after oral administration with maximum activity occurring in approximately one hour [A644, L5287]. The oral bioavailability of diphenhydramine has been documented in the range of 40% to 60%, and peak plasma concentration occurs about 2 to 3 hours after administration [A644, L5287].",0.78,"The elimination half-life ranges from 2.4-9.3 hours in healthy adults [F3394, L5287]. The terminal elimination half-life is prolonged in liver cirrhosis [L5287].",20 mg/1mL,Topical,solid,3060 mg/L (at 37 Â°C),3.27,0.0752,,8.87,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,0.78,0.78,,,0,,255.1623143,2,2,0,0,0,0
931,02/07/2019 00:00,DB01076,Atorvastatin,"Atorvastatin presents a dose-dependent and non-linear pharmacokinetic profile.[A177436] It is very rapidly absorbed after oral administration. After the administration of a dose of 40 mg, its peak plasma concentration of 28 ng/ml is reached 1-2 hours after initial administration with an AUC of about 200 ng.h/ml.[A177478] It does present a very large first-pass metabolism and hence, its bioavailability is of only 14%.[A177397]

Administration of atorvastatin with food results in prolonged Tmax and a reduction in Cmax and AUC.[A177415]",0.98,The half-life of atorvastatin is of about 14 hours while the half-life of its metabolites can reach up to 30 hours.[A177397],1 kg/1kg,Not applicable,solid,Practically insoluble,6.36,0.00063,4.33,-2.7,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,0.98,0.98,,,0,,558.2530004,4,4,1,1,0,0
932,02/07/2019 00:00,DB01077,Etidronic acid,The amount of drug absorbed after an oral dose is approximately 3%.,,"In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.",200 mg,Oral,solid,,-3.8,11.5,0.7,-5.1,CC(O)(P(O)(O)=O)P(O)(O)=O,,,,,0,200,205.9745259,0,0,0,0,0,0
933,04/06/2019 00:00,DB01078,Deslanoside,Little absorption from the gastrointestinal tract (40%).,0.2,36 hours,,,solid,,0.2,0.468,7.15,-3.2,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,0.2,0.2,36,36,0,,942.4824301,9,0,5,0,4,5
934,04/06/2019 00:00,DB01079,Tegaserod,"The absolute bioavailability of tegaserod is approximately 10% when administered to fasting subjects. The median time of peak tegaserod plasma concentration (Tmax) is approximately one hour (range 0.7 to 2 hours) [F4223].

Nevertheless, when tegaserod was given to individuals thirty minutes before a meal of high-fat and high-calorie content (about 150 calories from protein, 250 calories from carbohydrates, and 500 calories from fat), the AUC was reduced by 40% to 65%, the Cmax was reduced by approximately 20% to 40%, and the median Tmax was 0.7 hours [F4223]. Additionally, plasma concentrations were similar when tegaserod was administered within thirty minutes before a meal or even two and a half hours after a meal [F4223].",0.98,The mean terminal elimination half-life documented for tegaserod ranges from 4.6 to 8.1 hours following oral administration [F4223].,2 mg/1,Oral,solid,,2.6,0.0288,15.24,8.5,CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2,0.98,0.98,,,0,2,301.1902604,2,2,1,1,0,0
935,02/07/2019 00:00,DB01080,Vigabatrin,"Rapidly absorbed following oral administration, absorption is comparable between neonates, infants, and children. 
Cmax, 50 mg/kg dose, neonates= 14 mg/L;
Tmax, 50 mg/kg dose, neonates = 2.1 hours;
However, extent of absorption is higher and elimination half life is longer in neonates compared to children and infants. This is because neonates have reduced renal function compared to the aforementioned population groups. 
AUC, 50 mg/kg dose, neonates = 142.6 Â± 44.0 mg/L/hr; 
Food may slightly decrease the rate (Cmax decreased by 33%, Tmax increased to 2 hours), but not the extent of absorption. Furthermore, vigabatrin does not cross the blood-brain-barrier well, thus high doses are needed. 
",,"Neonates, 50 mg/kg = 7.5 Â± 2.1 hours (due to reduced renal function); 
Infants = 5.7 hours;
Adults = 7.5 hours;
Elderly = 12 - 13 hours


",500 mg,Oral,solid,55.1 mg/mL,-2.16,96.6,4.61,9.91,NC(CCC(O)=O)C=C,,,,,0,500,129.0789786,0,0,0,0,0,0
936,04/06/2019 00:00,DB01081,Diphenoxylate,0.9,74-95%,12-14 hours,,Oral,solid,800 mg/L (at 25 Â°C),6.3,0.00146,,8.5,CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1,0.74,0.95,12,14,0,,452.2463783,4,3,1,0,1,1
937,02/07/2019 00:00,DB01082,Streptomycin,Rapidly absorbed after intramuscular injection with peak serum concentrations attained after 1 - 2 hours. Not absorbed in the GI tract. ,,5 - 6 hours in adults with normal renal function,1 g/1,Intramuscular,solid,,-6.4,12.8,10.88,11.9,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O,,,,,0,,581.2656697,3,0,2,0,2,2
938,02/07/2019 00:00,DB01083,Orlistat,"Systemic absorption of orlistat is minimal, however systemic absorption of the drug is not needed for activity.",>99%,1 to 2 hours.,60 mg/1,Oral,solid,Practically insoluble,8.6,9.19E-05,12.74,-0.91,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,0.99,1,,,0,60,495.3923738,1,0,1,0,1,1
939,04/06/2019 00:00,DB01084,Emedastine,Ophthalmic use of emedastine usually does not produce measurable plasma concentrations.,,The elimination half-life in the plasma is 3-4 hours following oral administration.,0.0005,Ophthalmic,solid,Soluble (difumarate formulation),2.6,1.44,,8.68,CCOCCN1C(=NC2=CC=CC=C12)N1CCCN(C)CC1,,,,,0,,302.2106615,3,2,2,1,1,1
940,02/07/2019 00:00,DB01085,Pilocarpine,There was a decrease in the rate of absorption of pilocarpine from SALAGEN Tablets when taken with a high fat meal by 12 healthy male volunteers,,0.76 hours,10 mg,Ophthalmic,solid,1E+006 mg/L (at 25 Â°C),1.1,2.07,,6.61,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O,,,0.76,0.76,0,,208.1211778,2,1,2,1,1,1
941,02/07/2019 00:00,DB01086,Benzocaine,,,,10 mg/1,Dental,solid,1310 mg/L (at 30 Â°C),1.86,2.85,,2.78,CCOC(=O)C1=CC=C(N)C=C1,,,,,0,,165.0789786,1,1,0,0,0,0
942,02/07/2019 00:00,DB01087,Primaquine,,,3.7-7.4 hours,26.3 mg,Oral,solid,,2.1,0.0564,17.11,10.2,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1,,,3.7,7.4,0,26.3,259.1684623,2,2,1,1,0,0
943,04/06/2019 00:00,DB01088,Iloprost,Rapidly absorbed with bioavailability of 63%,0.6,20-30 minutes,0.01 mg/1mL,Respiratory (inhalation),solid,Very slightly soluble,4.8,0.00874,4.66,-0.87,[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O,0.6,0.6,0.333333333,0.5,0,,360.2300595,2,0,0,0,0,0
944,04/06/2019 00:00,DB01089,Deserpidine,,,,,Oral,solid,,3.3,0.0111,16.37,7.57,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2,,,,,0,,578.2628162,6,3,3,1,1,2
945,04/06/2019 00:00,DB01090,Pentolinium,,,,,,solid,,,1.16E-05,,,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,,,,,2,,240.2554519,2,0,2,0,2,2
946,02/07/2019 00:00,DB01091,Butenafine,The total amount absorbed through the skin into the systemic circulation has not been quantified.,,"Following topical application, a biphasic decline of plasma butenafine concentrations was observed with the half-lives estimated to be 35 hours initial and over 150 hours terminal.",0.01,Topical,solid,Slightly soluble (HCl salt),6.6,7.56E-05,,9.23,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12,,,,,0,,317.2143499,3,3,0,0,0,0
947,04/06/2019 00:00,DB01092,Ouabain,,0.6,,,,solid,1.03E+004 mg/L,-2,4.61,7.18,-2.9,[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,0.6,0.6,,,0,,584.2832768,6,0,2,0,1,2
948,02/07/2019 00:00,DB01093,Dimethyl sulfoxide,Readily and rapidly absorbed following administration by all routes and distributed throughout the body.,,,0.7,Topical,liquid,1E+006 mg/L,-1.35,65.7,,-6.2,CS(C)=O,,,,,0,,78.01393581,0,0,0,0,0,0
949,04/06/2019 00:00,DB01094,Hesperetin,,,,,,solid,273 mg/L,2.6,0.138,7.92,-3.9,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1,,,,,0,,302.0790382,3,2,1,0,0,1
950,02/07/2019 00:00,DB01095,Fluvastatin,"Rapidly and almost completely absorbed (> 90%), but undergoes extensive first pass metabolism. Bioavailability is 24% (range 9-50%) when a 10 mg dose is given. The mean relative bioavailability of the extended-release tablet is 29% (range: 9% to 66%) compared to an immediate-release capsule administered under fasting conditions. When given orally, fluvastatin reaches peak concentrations (Tmax) in less than one hour.  Taking the extended release tablet with a high-fat meal will delay absorption (Tmax = 6 hours) and increase bioavailability by approximately 50%. However, the maximum concentration of fluvastatin sodium extended-release tablets seen after a high fat meal is less than the peak concentration following a single dose or twice daily dose of the 40 mg fluvastatin capsule.",0.98,3 hours ,80 mg/1,Oral,solid,0.46 mg/L,4.5,0.00441,4.56,-2.8,CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12,0.98,0.98,3,3,0,80,411.1845865,3,3,1,1,0,0
951,04/06/2019 00:00,DB01096,Oxamniquine,Well absorbed orally,,1-2.5 hours,,,solid,820 mg/L,2.24,0.124,14.55,9.9,CC(C)NCC1CCC2=CC(CO)=C(C=C2N1)[N+]([O-])=O,,,1,2.5,0,,279.1582915,2,1,1,0,0,1
952,02/07/2019 00:00,DB01097,Leflunomide,"Well absorbed, peak plasma concentrations appear 6-12 hours after dosing",>99.3%,2 weeks,10 mg,Oral,solid,21 mg/L (poorly soluble),2.8,0.0844,10.41,-0.45,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,0.99,1,336,336,0,10,270.0616122,2,2,1,1,0,0
953,02/07/2019 00:00,DB01098,Rosuvastatin,Bioavailability is approximately 20%. Peak plasma concentrations were reached 3 to 5 hours following oral dosing. Both Cmax and AUC increased in approximate proportion to CRESTOR dose. Food has no effect on the AUC of rosuvastatin. ,0.88,19 hours,10 mg/1,Oral,solid,Sparingly soluble in water,0.13,0.0886,4,-2.8,CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O,0.88,0.88,19,19,0,10,481.1682848,2,2,1,1,0,0
954,04/06/2019 00:00,DB01099,Flucytosine,Rapidly and virtually completely absorbed following oral administration. Bioavailability 78% to 89%.,28-31%,2.4 to 4.8 hours.,250 mg/1,Oral,solid,1.5E+004 mg/L (at 25 Â°C),-1.1,1.92,8.16,1.06,NC1=C(F)C=NC(=O)N1,0.28,0.31,,,0,250,129.03384,1,1,1,1,0,0
955,02/07/2019 00:00,DB01100,Pimozide,Greater than 50% absorption after oral administration. Serum peak appears 6-8 hours post ingestion.,,29 &plusmn; 10 hours (single-dose study of healthy volunteers).,2 mg/1,Oral,solid,10 mg/L (at 25 Â°C),6.3,0.00173,12.9,8.38,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1,,,,,0,2,461.227869,5,4,2,1,1,1
956,02/07/2019 00:00,DB01101,Capecitabine,Readily absorbed through the GI tract (~70%),0.6,45-60 minutes for capecitabine and its metabolites.,150 mg/1,Oral,solid,26 mg/mL,0.4,0.248,8.23,-3.6,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,0.6,0.6,,,0,150,359.1492636,2,1,2,1,1,1
957,04/06/2019 00:00,DB01102,Arbutamine,,0.58,Elimination half-life is approximately 8 minutes.,,,solid,,2.9,0.0842,8.97,9.76,O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1,0.58,0.58,,,0,,317.1627082,2,2,0,0,0,0
958,02/07/2019 00:00,DB01103,Quinacrine,Absorbed rapidly from the gastrointestinal tract following oral administration.,80-90%,5 to 14 days,,,solid,Slight,5.5,0.00239,,10.33,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=C1C=CC(Cl)=C2,0.8,0.9,,,0,,399.2077403,3,3,1,1,0,0
959,02/07/2019 00:00,DB01104,Sertraline,"Following once-daily administration over the range of 50 to 200 mg for 14 days, mean peak plasma concentrations (Cmax) of sertraline occurred between 4.5 to 8.4 hours post-administration [FDA Label]. The steady-state concentrations are reached after 1 week following once-daily administration, and approximately two-fold accumulation up to steady-state concentrations is observed [FDA Label]. The single dose bioavailability of sertraline tablets is approximately equal to an equivalent dose of sertraline oral solution [FDA Label].

The effects of food on the bioavailability of the sertraline tablet and oral concentrate were studied in subjects administered a single dose with and without food. For the tablet, AUC was slightly increased when drug was administered with food but the Cmax was 25% greater, while the time to reach peak plasma concentration (Tmax) decreased from 8 hours post-dosing to 5.5 hours. For the oral concentrate, Tmax was slightly prolonged from 5.9 hours to 7.0 hours with food. ",,The elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours [FDA Label].,20 mg/1mL,Oral,solid,3.5mg/L,5.1,0.000145,,9.85,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12,,,,,0,,305.0738049,3,2,0,0,0,0
960,04/06/2019 00:00,DB01105,Sibutramine,"Rapid absorption following oral administration. Absolute bioavailability is not known, but at least 77% of a single oral dose of sibutramine is absorbed.",0.97,1.1 hours,10 mg/1,Oral,solid,2.9 mg/mL (in pH 5.2 water),5.2,0.00094,,9.77,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1,0.97,0.97,1.1,1.1,0,10,279.1753775,2,1,0,0,0,0
961,02/07/2019 00:00,DB01106,Levocabastine,"After instillation in the eye, levocabastine is systemically absorbed, albeit at low levels.",,36 hours (after oral administration),0.5 mg/1mL,Ophthalmic,solid,>0.5 mg/mL,5,0.00347,3.71,10.32,C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1,,,,,0,,420.2213064,4,2,1,0,1,1
962,04/06/2019 00:00,DB01107,Methyprylon,,0.6,6-16 hours,,,solid,1.15E+004 mg/L,0.78,11.3,14.53,-3.1,CCC1(CC)C(=O)NCC(C)C1=O,0.6,0.6,6,16,0,,183.1259288,1,0,1,0,1,1
963,04/06/2019 00:00,DB01108,Trilostane,,,8 hours.,,,solid,,3,0.0592,5.23,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,,,8,8,0,,329.1990937,5,0,1,0,1,1
964,02/07/2019 00:00,DB01110,Miconazole,,,,20 mg/1g,Topical,solid,1g/100mL (20 Â°C),6.1,0.000763,,6.77,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,,,,,0,,413.9860238,3,3,1,1,0,0
965,02/07/2019 00:00,DB01111,Colistimethate,Very poor absorption from gastrointestinal tract.,,"2-3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.",150 mg/2mL,Intramuscular; Intravenous,solid,Appreciable,,4.17,-4.3,6.46,CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O,,,,,-5,,1633.59152,1,0,1,0,1,1
966,02/07/2019 00:00,DB01112,Cefuroxime,Absorbed from the gastrointestinal tract. Absorption is greater when taken after food (absolute bioavailability increases from 37% to 52%).,0.5,Approximately 80 minutes following intramuscular or intravenous injection.,125 mg/5mL,Oral,solid,Freely soluble as sodium salt (145 mg/L),-0.16,0.284,3.15,-1.1,[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O,0.5,0.5,,,0,,424.0688845,3,1,3,1,1,2
967,02/07/2019 00:00,DB01113,Papaverine,,~90%,0.5-2 hours,30 mg/1mL,Intramuscular; Intravenous,solid,,3,0.0129,,6.03,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1,0.9,0.9,0.5,2,0,,339.1470582,3,3,1,1,0,0
968,02/07/2019 00:00,DB01114,Chlorphenamine,Well absorbed in the gastrointestinal tract.,0.72,21-27 hours,2 mg/5mL,Oral,liquid,5500 mg/L (at 37 Â°C),3.38,0.0519,,9.47,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,0.72,0.72,21,27,0,,274.1236763,2,2,1,1,0,0
969,02/07/2019 00:00,DB01115,Nifedipine,Rapidly and fully absorbed following oral administration.,92-98%,2 hours,30 mg/1,Oral,solid,Insoluble,2.2,0.0177,,5.33,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC,0.92,0.98,2,2,0,30,346.1164863,2,1,1,0,0,1
970,04/06/2019 00:00,DB01116,Trimethaphan,,,,,,solid,,3.473,0.00665,,-2,O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1,,,,,1,,365.1682108,5,2,3,0,3,3
971,02/07/2019 00:00,DB01117,Atovaquone,"The bioavailability of atovaquone is low and variable and is highly dependent on formulation and diet. Bioavailability of the suspension increases two-fold when administered with meals. When administered with food, bioavailability is approximately 47%. Without food, the bioavailability is 23%.",,2.2 to 3.2 days,750 mg/5mL,Oral,solid,Practically insoluble,5.8,0.000796,8.23,-4.1,OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O,,,,,0,,366.1022721,4,2,0,0,0,0
972,02/07/2019 00:00,DB01118,Amiodarone,Slow and variable (about 20 to 55% of an oral dose is absorbed).,>96%,58 days (range 15-142 days),1.8 mg/1mL,Intravenous,solid,Low,7.57,0.00476,,8.47,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,0.96,1,,,0,,645.0236898,3,3,1,1,0,0
973,02/07/2019 00:00,DB01119,Diazoxide,Readily absorbed following oral administration.,,28 &plusmn;8.3 hours in normal adults.,1 g/1g,Not applicable,solid,2850 mg/L,1.2,0.552,10.48,1.33,CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2,,,,,0,,229.9916761,2,1,1,0,0,1
974,02/07/2019 00:00,DB01120,Gliclazide,Rapidly and well absorbed but may have wide inter- and intra-individual variability. Peak plasma concentrations occur within 4-6 hours of oral administration. ,,10.4 hours. Duration of action is 10-24 hours. ,60 mg,Oral,solid,,2.6,0.19,4.07,1.38,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1,,,,,0,60,323.1303625,3,1,1,0,1,1
975,04/06/2019 00:00,DB01121,Phenacemide,Almost completely absorbed.,,22-25 hours.,,,solid,10.2 g/L,0.87,1.06,11.75,-7.8,NC(=O)NC(=O)CC1=CC=CC=C1,,,22,25,0,,178.0742276,1,1,0,0,0,0
976,04/06/2019 00:00,DB01122,Ambenonium,Oral - poorly absorbed from the gastrointestinal tract.,,,10 mg/1,Oral,solid,Soluble,,9.42E-07,10.78,-3.6,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1Cl,,,,,2,10,536.2673848,2,2,0,0,0,0
977,04/06/2019 00:00,DB01123,Proflavine,,,,,Topical,solid,5E+005 mg/L (at 20 Â°C),1.83,0.104,,8.32,NC1=CC2=NC3=C(C=CC(N)=C3)C=C2C=C1,,,,,0,,209.0952974,3,3,1,1,0,0
978,02/07/2019 00:00,DB01124,Tolbutamide,"Readily absorbed following oral administration. Tolbutamide is detectable in plasma 30-60 minutes following oral administration of a single dose with peak plasma concentrations occurring within 3-5 hours. 

Absorption is unaltered if taken with food but is increased with high pH.",0.95,"Approximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.",1 g,Oral,solid,109 mg/L (at 37 Â°C),2.34,0.202,4.33,,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1,0.95,0.95,,,0,,270.1038134,1,1,0,0,0,0
979,04/06/2019 00:00,DB01125,Anisindione,Accumulation does not occur with repeated dosing.,,Not Known,,,solid,79.8 mg/L,2.88,0.0128,4.5,-4.8,COC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O,,,,,0,,252.0786442,3,2,0,0,0,0
980,02/07/2019 00:00,DB01126,Dutasteride,"Following oral administration of a single dose of 0.5 mg dutasteride, the peak serum concentrations were reached within 2 to 3 hours. Following daily oral administration of 0.5 mg dutasteride, the steady-state concentration of 40 ng/mL is expected to be achieved at 6 months following initial administration. In healthy subjects, the absolute bioavailability was 60%, ranging from 40% to 94%. While food intake reduced the maximum serum concentrations by 10 to 15%, food intake is reported to have a negligible effect on the bioavailability of the drug.[label]",0.99,The terminal elimination half-life of dutasteride is approximately 5 weeks at steady state. This long half-life accounts for the serum concentrations remaining detectable for up to 4 to 6 months after discontinuation of treatment.[label],0.5 mg,Oral,solid,Insoluble,6.8,0.000908,12.56,2.17,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F,0.99,0.99,,,0,0.5,528.2211475,5,1,1,0,0,1
981,04/06/2019 00:00,DB01127,Econazole,"After topical application to the skin of normal subjects, systemic absorption of econazole nitrate is extremely low. Although most of the applied drug remains on the skin surface, drug concentrations were found in the stratum corneum which, by far, exceeded the minimum inhibitory concentration for dermatophytes.",,,10 mg/1,Topical,solid,,5.5,0.00148,,6.77,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,,,,,0,,380.0249961,3,3,1,1,0,0
982,02/07/2019 00:00,DB01128,Bicalutamide,"Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.",0.96,5.9 days,50 mg/1,Oral,solid,5 mg/L,2.5,0.00928,11.95,-4,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F,0.96,0.96,141.6,141.6,0,50,430.0610408,2,2,0,0,0,0
983,02/07/2019 00:00,DB01129,Rabeprazole,Absolute bioavailability is approximately 52%.,0.963,1-2 hours (in plasma),20 mg/1,Oral,solid,,0.6,0.336,9.35,4.24,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1,0.963,0.963,,,0,20,359.1303625,3,3,2,2,0,0
984,02/07/2019 00:00,DB01130,Prednicarbate,Absorbed systemically across the stratum corneum.,,,1 mg/1g,Topical,solid,,2.9,0.00562,14.83,-2.9,[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,488.2410181,4,0,0,0,0,0
985,02/07/2019 00:00,DB01131,Proguanil,Rapidly and well absorbed in humans following oral doses ranging from 50 to 500 mg.,0.75,Approximately 20 hours,100 mg,Oral,solid,156 mg/L,2.53,0.116,,10.4,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1,0.75,0.75,,,0,100,253.1094232,1,1,0,0,0,0
986,02/07/2019 00:00,DB01132,Pioglitazone,"Following oral administration of pioglitazone, peak concentrations of pioglitazone were observed within 2 hours. Food slightly delays the time to peak serum concentration (T max) to 3 to 4 hours, but does not alter the extent of absorption (AUC). Steady state concentrations are achieved after 7 days of once daily administration of pioglitazone [FDA Label].",,"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].",15 mg/1,Oral,solid,mg/mL,2.3,0.00442,6.66,5.6,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,,,,,0,15,356.1194635,3,2,2,1,1,1
987,04/06/2019 00:00,DB01133,Tiludronic acid,"The mean oral bioavailability in healthy male subjects is 6% after an oral dose equivalent to 400 mg tiludronic acid administered after an overnight fast and 4 hours before a standard breakfast. In single-dose studies, bioavailability was reduced by 90% when an oral dose equivalent to 400 mg tiludronic acid was administered with, or 2 hours after, a standard breakfast compared to the same dose administered after an overnight fast and 4 hours before a standard breakfast.",0.9,"Half-life in healthy subjects is 50 hours following administration of a 400 mg single oral dose. Half-life in pagetic patients is about 150 hours following administration of 400 mg tiludronate a day for 12 days. In patients with renal insufficiency (creatinine clearance between 11 and 18 mL per minute [mL/min]), half-life is 205 hours from plasma after administration of a single, oral dose equivalent to 400 mg tiludronate.",200 mg/1,Oral,solid,,-0.6,6.97,1.03,,OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O,0.9,0.9,,,0,200,317.9283599,1,1,0,0,0,0
988,04/06/2019 00:00,DB01134,Desoxycorticosterone pivalate,,0.9,,,,solid,Insoluble,4,0.00141,17.19,-4.8,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)COC(=O)C(C)(C)C,0.9,0.9,,,0,,414.2770097,4,0,0,0,0,0
989,04/06/2019 00:00,DB01135,Doxacurium,,,99 minutes in normal healthy adults.,1 mg/1mL,Intravenous,solid,,,9.02E-05,18.41,-4.1,COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC,,,,,2,,1034.534037,6,4,2,0,0,2
990,02/07/2019 00:00,DB01136,Carvedilol,"Carvedilol is rapidly and extensively absorbed following oral administration, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.",0.98,7-10 hours,12.5 mg/1,Oral,solid,Practically insoluble (0.583 mg/L),4.19,0.00444,14.03,8.74,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,0.98,0.98,7,10,0,12.5,406.1892573,4,4,1,1,0,0
991,02/07/2019 00:00,DB01137,Levofloxacin,"Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.",24-38%,6-8 hours,15 mg/1mL,Ophthalmic,solid,Insoluble,2.1,1.44,5.45,6.2,C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,0.24,0.38,6,8,0,,361.1437843,4,2,3,1,1,2
992,02/07/2019 00:00,DB01138,Sulfinpyrazone,,98-99%,Approximately 4-6 hours,100 mg,Oral,solid,31.2 mg/L,2.3,0.323,3.41,-6.7,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1,0.98,0.99,,,0,100,404.1194635,4,3,1,0,1,1
993,04/06/2019 00:00,DB01139,Cefapirin,,,,,,solid,1030 mg/L,-1.15,0.151,3.54,5,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O,,,,,0,,423.0558773,3,1,3,1,1,2
994,02/07/2019 00:00,DB01140,Cefadroxil,Cefadroxil is well absorbed on oral administration; food does not interfere with its absorption.,0.281,1.5 hours,500 mg/1,Oral,solid,1110 mg/L,-0.4,0.399,3.45,7.43,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,0.281,0.281,1.5,1.5,0,500,363.0888916,3,1,2,0,1,2
995,02/07/2019 00:00,DB01141,Micafungin,Not absorbed orally,,14-17 hours,10 mg/1mL,Intravenous,solid,Freely soluble as sodium salt (> 200mg/mL),-1.5,0.218,-2.2,-3.6,CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O,,,14,17,0,,1269.438351,7,4,4,1,3,3
996,02/07/2019 00:00,DB01142,Doxepin,Doxepin is moderately absorbed following oral ingestion with a bioavailability of 30%.[T388] The median peak concentration of doxepin ranges from 8.8-45.8 ng/ml and it is achieved 3.5 hours after initial administration. Its absorption is increased with concomitant administration of a high-fat meal.[L5995],0.755,The mean elimination half-life is reported to be of 15 hours.[T388],10 mg/1,Oral,solid,31.6 mg/L (at 25 Â°C),4.29,0.0319,,9.76,[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12,0.755,0.755,,,0,10,279.1623143,3,2,1,0,0,1
997,04/06/2019 00:00,DB01143,Amifostine,,,8 minutes,50 mg/1mL,Intravenous,solid,1000 mg/mL,-1.9,18.7,2.06,10.71,NCCCNCCSP(O)(O)=O,,,0.133333333,0.133333333,0,,214.0541,0,0,0,0,0,0
998,04/06/2019 00:00,DB01144,Diclofenamide,,0.55,,50 mg/1,Oral,solid,,0.2,0.398,7.94,,NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O,0.55,0.55,,,0,50,303.914604,1,1,0,0,0,0
999,04/06/2019 00:00,DB01145,Sulfoxone,Rapidly absorbed.,0.69,3-8 hours,,,solid,,-2.8,2.63,-1.5,-0.056,OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1,0.69,0.69,3,8,0,,404.0170492,2,2,0,0,0,0
1000,04/06/2019 00:00,DB01146,Diphenylpyraline,Well absorbed after oral administration.,0.99,,,Oral,solid,,3.7,0.0188,,8.87,CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1,0.99,0.99,,,0,,281.1779644,3,2,1,0,1,1
1001,02/07/2019 00:00,DB01147,Cloxacillin,Well absorbed from the gastrointestinal tract.,0.95,,500 mg,Intramuscular; Intravenous,solid,13.9 mg/L,2.48,0.0532,3.75,-0.41,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O,0.95,0.95,,,0,,435.0655694,4,2,3,1,2,2
1002,02/07/2019 00:00,DB01148,Flavoxate,Well absorbed from gastrointestinal tract.,,,100 mg/1,Oral,solid,10 mg/L (at 37 Â°C),4.4,0.0154,,7.29,CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1,,,,,0,100,391.1783583,4,3,2,1,1,1
1003,04/06/2019 00:00,DB01149,Nefazodone,Nefazodone is rapidly and completely absorbed. Its absolute bioavailability is low (about 20%).,0.99,2-4 hours,100 mg/1,Oral,solid,,4.7,0.0698,,7.09,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1,0.99,0.99,2,4,0,100,469.2244529,4,3,2,1,1,1
1004,02/07/2019 00:00,DB01150,Cefprozil,Oral bioavailability is approximately 95%.,0.36,1.3 hours,500 mg,Oral,solid,55 mg/L,0.6,0.149,3.53,7.43,[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,0.36,0.36,1.3,1.3,0,500,389.1045417,3,1,2,0,1,2
1005,02/07/2019 00:00,DB01151,Desipramine,Desipramine hydrochloride is rapidly and almost completely absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism. Peak plasma concentrations are attained 4 - 6 hours following oral administration.  ,73-92%,7-60+ hours; 70% eliminated renally,10 mg,Oral,solid,58.6 mg/L (at 24 Â°C),4.9,0.0396,,10.02,CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12,0.73,0.92,,,0,10,266.1782987,3,2,1,0,0,1
1006,04/06/2019 00:00,DB01153,Sertaconazole,Bioavailability is negligible.,>99%,,20 mg/1g,Topical,solid,Practically insoluble,6.2,0.00637,,6.77,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl,0.99,1,,,0,,435.9970671,4,4,2,2,0,0
1007,04/06/2019 00:00,DB01154,Thiamylal,Rapidly absorbed (high lipid solubility).,,"Although no studies have been performed on humans, the half-life in cats is 14.3 hours.",,,solid,49.4 mg/L (at 25 Â°C),3.23,0.0506,7.2,-3,CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O,,,,,0,,254.1088988,1,0,1,0,1,1
1008,04/06/2019 00:00,DB01155,Gemifloxacin,Rapidly absorbed from the gastrointestinal tract. The absolute bioavailability averages approximately 71%.,60-70%,7 (&plusmn; 2) hours,320 mg/1,Oral,solid,"Freely soluble at neutral pH (350 mg/mL at 37 Â°C, pH 7.0).",2.3,0.21,5.53,9.53,CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O,0.6,0.7,,,0,320,389.1499323,4,2,3,2,1,1
1009,02/07/2019 00:00,DB01156,Bupropion,"Bupropion is currently available in 3 distinct, but bioequivalent formulations: immediate release (IR), sustained-release (SR), and extended-release (XL). 

**Immediate Release Formulation**
In humans, following oral administration of bupropion hydrochloride tablets, peak plasma bupropion concentrations are usually achieved within 2 hours. IR formulations provide a short duration of action and are therefore generally dosed three times per day. 

**Sustained Release Formulation**
In humans, following oral administration of bupropion hydrochloride sustained-release tablets (SR), peak plasma concentration (Cmax) of bupropion is usually achieved within 3 hours. SR formulations provide a 12-hour extended release of medication and are therefore generally dosed twice per day. 

**Extended Release Formulation**
Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours. The presence of food did not affect the peak concentration or area under the curve of bupropion. XL formulations provide a 24-hour extended release of medication and are therefore generally dosed once per day/ 

In a trial comparing chronic dosing with bupropion hydrochloride extended-release tablets (SR) 150 mg twice daily to bupropion immediate-release formulation 100 mg 3 times daily, the steady state Cmax for bupropion after bupropion hydrochloride sustained-release tablets (SR) administration was approximately 85% of those achieved after bupropion immediate-release formulation administration. Exposure (AUC) to bupropion was equivalent for both formulations. Bioequivalence was also demonstrated for all three major active metabolites (i.e., hydroxybupropion, threohydrobupropion and erythrohydrobupropion) for both Cmax and AUC. Thus, at steady state, bupropion hydrochloride sustained-release tablets (SR) given twice daily, and the immediate-release formulation of bupropion given 3 times daily, are essentially bioequivalent for both bupropion and the 3 quantitatively important metabolites.[FDA Label]

Furthermore, in a study comparing 14-day dosing with bupropion hydrochloride extended-release tablets (XL), 300 mg once-daily to the immediate-release formulation of bupropion at 100 mg 3 times daily, equivalence was demonstrated for peak plasma concentration and area under the curve for bupropion and the three metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion). Additionally, in a study comparing 14-day dosing with bupropion hydrochloride extended-release tablets (XL) 300 mg once daily to the sustained-release formulation of bupropion at 150 mg 2 times daily, equivalence was demonstrated for peak plasma concentration and area under the curve for bupropion and the three metabolites.[FDA Label]

Bupropion hydrochloride extended-release tablets (SR) can be taken with or without food. Bupropion Cmax and AUC were increased by 11% to 35% and 16% to 19%, respectively, when bupropion hydrochloride extended-release tablets (SR) was administered with food to healthy volunteers in three trials. The food effect is not considered clinically significant.[FDA Label]

Following a single-dose administration of bupropion hydrochloride extended-release tablets (SR) in humans, Cmax of bupropion's metabolite hydroxybupropion occurs approximately 6 hours post-dose and is approximately 10 times the peak level of the parent drug at steady state. The elimination half-life of hydroxybupropion is approximately 20 (Â±5) hours and its AUC at steady state is about 17 times that of bupropion. The times to peak concentrations for the erythrohydrobupropion and threohydrobupropion metabolites are similar to that of the hydroxybupropion metabolite. However, their elimination half-lives are longer, 33(Â±10) and 37 (Â±13) hours, respectively, and steady-state AUCs are 1.5 and 7 times that of bupropion, respectively.[FDA Label]",0.84,24 hours,174 mg/1,Oral,solid,312 mg/ml,3.6,0.0693,18.29,8.22,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,0.84,0.84,24,24,0,174,239.1076919,1,1,0,0,0,0
1010,04/06/2019 00:00,DB01157,Trimetrexate,,0.95,11 to 20 hours,200 mg/16mL,Intravenous,solid,31.4 mg/L,2.55,0.0309,17.04,7.54,COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC,0.95,0.95,,,0,,369.1800896,3,3,1,1,0,0
1011,02/07/2019 00:00,DB01158,Bretylium,,,"The terminal half-life in four normal volunteers averaged 7.8&plusmn;0.6 hours (range 6.9-8.1). During hemodialysis, this patient's arterial and venous bretylium concentrations declined rapidly, resulting in a half-life of 13 hours.",50 mg,Intramuscular; Intravenous,solid,Freely soluble,,0.000154,17.58,,CC[N+](C)(C)CC1=CC=CC=C1Br,,,,,1,,242.0538881,1,1,0,0,0,0
1012,02/07/2019 00:00,DB01159,Halothane,,,,1 g,Respiratory (inhalation),liquid,4070 mg/L (at 25 Â°C),2.3,3.81,,,[H]C(Cl)(Br)C(F)(F)F,,,,,0,,195.8902245,0,0,0,0,0,0
1013,02/07/2019 00:00,DB01160,Dinoprost tromethamine,Slowly absorbed from the amniotic fluid into systemic circulation.,,The half-life of dinoprost in amniotic fluid is 3 to 6 hours. The plasma half-life of dinoprost after intravenous administration is reported to be less than 1 minute.,,,solid,0.2 g/mL,-0.12,0.117,4.36,-1.6,NC(CO)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,,,,,0,,475.3145174,1,0,0,0,0,0
1014,04/06/2019 00:00,DB01161,Chloroprocaine,"The rate of systemic absorption of local anesthetic drugs is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic injection.",,21 +/- 2 seconds,20 mg/1mL,Epidural; Infiltration,solid,0.665 mg/mL,2.86,1.3,,8.96,CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1,,,,,0,,270.1135055,1,1,0,0,0,0
1015,02/07/2019 00:00,DB01162,Terazosin,Approximately 90%[A176831].,,Terazosin has a mean half life 12 hours though this can be as high as 14 hours in patients over 70 years and as low as 11.4 hours in patients 20 to 39 years old[FDA Label][A176831].,10 mg,Oral,solid,,,1.5,19.93,7.24,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1,,,,,0,10,387.1906543,4,2,3,1,2,2
1016,04/06/2019 00:00,DB01163,Amdinocillin,Poorly absorbed if given orally.,,Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.,,,solid,0.0103 mg/mL at 25 Â°C,1.3,0.979,3.3,7.92,[H]C(=N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])N1CCCCCC1,,,,,0,,325.1460126,3,0,3,0,3,3
1017,02/07/2019 00:00,DB01165,Ofloxacin,Bioavailability of ofloxacin in the tablet formulation is approximately 98%,0.32,9 hours,200 mg/1,Oral,solid,28.3 mg/mL,-0.39,1.44,5.45,6.2,CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,0.32,0.32,9,9,0,200,361.1437843,4,2,3,1,1,2
1018,04/06/2019 00:00,DB01166,Cilostazol,"Cilostazol is absorbed after oral administration. A high fat meal increases absorption, with an approximately 90% increase in C<sub>max</sub> and a 25% increase in AUC. Absolute bioavailability is not known.",95-98%,11-13 hours.,100 mg/1,Conjunctival; Oral,solid,,2.3,0.0324,14.42,-0.51,O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2,0.95,0.98,11,13,0,100,369.2164751,4,2,2,1,0,1
1019,02/07/2019 00:00,DB01167,Itraconazole,"The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.",0.998,21 hours,100 mg/1,Topical,solid,Insoluble,5.66,0.00964,,3.91,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,0.998,0.998,21,21,0,,704.2393071,7,5,4,2,2,2
1020,02/07/2019 00:00,DB01168,Procarbazine,Procarbazine is rapidly and completely absorbed.,,10 minutes,50 mg/1,Oral,solid,1420 mg/L,0.06,0.228,15.03,5.6,CNNCC1=CC=C(C=C1)C(=O)NC(C)C,,,0.166666667,0.166666667,0,50,221.1528122,1,1,0,0,0,0
1021,04/06/2019 00:00,DB01170,Guanethidine,3-30% of oral dose (poor and highly variable),,1.5 days,10 mg,Oral,solid,Very soluble,0.8,2.25,,11.77,NC(N)=NCCN1CCCCCCC1,,,36,36,0,10,198.1844467,1,0,1,0,1,1
1022,02/07/2019 00:00,DB01171,Moclobemide,"Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first-pass metabolism reduces bioavailability to about 56% following administration of one dose, but increases to 90% with steady-state dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 0.3 - 1 hours following oral administration with a terminal half-life of 1.6h [L1350].",0.5,1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted,100 mg,Oral,solid,0.000352,10.6,1.12,14.73,6.02,ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1,0.5,0.5,,,0,100,268.0978555,2,1,1,0,1,1
1023,04/06/2019 00:00,DB01172,Kanamycin,Kanamycin is rapidly absorbed after intramuscular injection and peak serum levels are generally reached within approximately one hour. Poor oral and topical absorption except with severe skin damage. ,,2.5 hours,333 mg/1mL,Intramuscular; Intravenous,solid,,-6.3,92.3,12.11,9.75,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,,,2.5,2.5,0,,484.238058,3,0,2,0,2,2
1024,02/07/2019 00:00,DB01173,Orphenadrine,Orphenadrine is almost completely absorbed in the gastrointestinal tract.,0.95,13-20 hours,50 mg,Oral,solid,Sparingly soluble in water,3.77,0.03,,8.87,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C,0.95,0.95,13,20,0,50,269.1779644,2,2,0,0,0,0
1025,02/07/2019 00:00,DB01174,Phenobarbital,"Absorbed in varying degrees following oral, rectal or parenteral administration. The salts are more rapidly absorbed than are the acids. The rate of absorption is increased if the sodium salt is ingested as a dilute solution or taken on an empty stomach.",0.45,53 to 118 hours (mean 79 hours),4 mg,Oral,solid,1110 mg/L (at 25 Â°C),1.47,0.276,8.14,,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1,0.45,0.45,,,0,4,232.0847922,2,1,1,0,1,1
1026,02/07/2019 00:00,DB01175,Escitalopram,The absolute bioavailability of citalopram is about 80% relative to an intravenous dose.,~56%,27-32 hours,10 mg,Oral,solid,,3.5,0.00588,,9.78,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,0.56,0.56,27,32,0,10,324.1637915,3,2,1,0,0,1
1027,04/06/2019 00:00,DB01176,Cyclizine,,,20 hours,25 mg/25mg,Oral,solid,1000 mg/L (at 25 Â°C),3,0.0752,,8.51,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,,,20,20,0,,266.1782987,3,2,1,0,1,1
1028,02/07/2019 00:00,DB01177,Idarubicin,,0.97,22 hours,1 mg/1mL,Intravenous,solid,,0.2,0.772,9.55,8.95,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O,0.97,0.97,22,22,0,,497.1685814,5,2,1,0,1,1
1029,04/06/2019 00:00,DB01178,Chlormezanone,,,,,,solid,2500 mg/L (at 25 Â°C),1.3,1.61,19.07,-2.5,CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O,,,,,0,,273.0226419,2,1,1,0,1,1
1030,02/07/2019 00:00,DB01179,Podofilox,Topical application of 0.05 mL of 0.5% podofilox solution to external genitalia did not result in detectable serum levels. Applications of 0.1 to 1.5 mL resulted in peak serum levels of 1 to 17 ng/mL one to two hours after application.,,1.0 to 4.5 hours.,0.005,Topical,solid,100 mg/L (at 25 Â°C),1.5,0.114,14.02,-3.2,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OC)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@H]2O,,,,,0,,414.1314677,5,2,2,0,1,2
1031,04/06/2019 00:00,DB01180,Rescinnamine,,,,,,solid,,3.5,0.00349,16.29,7.56,[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,,,,,0,,634.2890309,6,3,3,1,1,2
1032,02/07/2019 00:00,DB01181,Ifosfamide,,,7-15 hours. The elimination half-life increase appeared to be related to the increase in ifosfamide volume of distribution with age.,1 g/20mL,Intravenous,solid,3780 mg/L,0.86,15,13.24,0.12,ClCCNP1(=O)OCCCN1CCCl,,,,,0,,260.0248197,1,0,1,0,1,1
1033,02/07/2019 00:00,DB01182,Propafenone,"Nearly completely absorbed following oral administration (90%). Systemic bioavailability ranges from 5 to 50%, due to significant first-pass metabolism. This wide range in systemic bioavailability is related to two factors: presence of food (food increases bioavailability) and dosage (bioavailability is 3.4% for a 150-mg tablet compared to 10.6% for a 300-mg tablet).",0.97,2-10 hours,150 mg,Oral,solid,Slightly soluble,3.2,0.00758,14.09,9.63,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1,0.97,0.97,2,10,0,150,341.1990937,2,2,0,0,0,0
1034,02/07/2019 00:00,DB01183,Naloxone,"Tmax:
0.4mg IM injection = 0.38 hr
Nasal spray (one 2mg spray) = 0.33 hr
Nasal spray (one 4mg spray) = 0.50 hr 

Cmax:
0.4mg IM injection = 0.88 ng/mL
Nasal spray (one 2mg spray) = 2.91 ng/mL
Nasal spray (one 4mg spray) = 4.83 ng/mL",,"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr
",0.4 mg/1,Buccal,solid,Soluble,2.09,5.64,10.07,7.84,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,,,,,0,0.4,327.1470582,5,1,2,0,1,2
1035,02/07/2019 00:00,DB01184,Domperidone,,91%-93%,7 hours,10 mg,Oral,solid,0.986 mg/L,3.9,0.0925,12.52,7.03,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2,0.91,0.93,7,7,0,10,425.1618527,5,4,3,2,1,1
1036,04/06/2019 00:00,DB01185,Fluoxymesterone,Oral absorption is less than 44%.,0.8,9.2 hours,10 mg/1,Oral,solid,67.5 mg/L,2.38,0.0452,13.6,-3,[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.8,0.8,9.2,9.2,0,10,336.210073,4,0,0,0,0,0
1037,04/06/2019 00:00,DB01186,Pergolide,Significant amount may be absorbed (evidence on bioavailability still lacking).,0.9,27 hours,0.05 mg/1,Oral,solid,,4,0.000584,17.35,9.49,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC,0.9,0.9,27,27,0,0.05,314.1816698,4,2,2,1,1,1
1038,04/06/2019 00:00,DB01187,Iophendylate,,,,,,liquid,,7.7,2.52E-05,,-7,CCOC(=O)CCCCCCCCC(C)C1=CC=CC=C1I,,,,,0,,416.1212282,1,1,0,0,0,0
1039,02/07/2019 00:00,DB01188,Ciclopirox,Rapidly absorbed after oral administration. Mean absorption of ciclopirox after application to nails of all twenty digits and adjacent 5 millimeters of skin once daily for 6 months in patients with dermatophytic onychomycoses was less than 5% of the applied dose. Ciclopirox olamine also penetrates into hair and through the epidermis and hair follicles into sebaceous glands and dermis.,94-97%,1.7 hours for 1% topical solution.,7.7 mg/1g,Topical,solid,,2.3,1.41,6.84,-6.2,CC1=CC(=O)N(O)C(=C1)C1CCCCC1,0.94,0.97,,,0,,207.1259288,2,1,1,1,0,0
1040,02/07/2019 00:00,DB01189,Desflurane,Rapidly absorbed into the circulation via the lungs following inhalation.,,,1.5 g/1mL,Respiratory (inhalation),liquid,Negligible,1.9,3.54,18.87,-4.8,FC(F)OC(F)C(F)(F)F,,,,,0,,168.000984,0,0,0,0,0,0
1041,02/07/2019 00:00,DB01190,Clindamycin,Rapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Absorption of an oral dose is virtually complete (90%) and the concomitant intake of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Clindamycin does not penetrate the blood brain barrier.,92-94%,2.4 hours,75 mg/5mL,Topical,solid,30.6 mg/L,2.16,3.1,12.41,7.55,CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,0.92,0.94,2.4,2.4,0,,424.1798708,2,0,2,0,2,2
1042,04/06/2019 00:00,DB01191,Dexfenfluramine,Well-absorbed from the gastrointestinal tract.,0.36,17-20 hours,,,solid,,3.5,0.0215,,10.22,CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F,0.36,0.36,17,20,0,,231.1234842,1,1,0,0,0,0
1043,02/07/2019 00:00,DB01192,Oxymorphone,,,1.3 (+/-0.7) hours,1 mg/1mL,Parenteral,solid,2.4E+004 mg/L,0.83,25.6,10.07,8.21,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O,,,,,0,,301.1314081,5,1,2,0,1,2
1044,02/07/2019 00:00,DB01193,Acebutolol,Well absorbed from the Gl tract with an absolute bioavailability of approximately 40% for the parent compound. In,0.26,"The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.",200 mg/1,Oral,solid,259 mg/L,1.71,0.172,13.91,9.57,CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1,0.26,0.26,,,0,200,336.2049074,1,1,0,0,0,0
1045,02/07/2019 00:00,DB01194,Brinzolamide,Absorbed into systemic circulation following topical ocular application,,111 days,10 mg/1mL,Ophthalmic,solid,,-1.8,0.713,8.19,6.78,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,,,2664,2664,0,,383.0643338,2,1,2,1,0,1
1046,02/07/2019 00:00,DB01195,Flecainide,Nearly complete following oral administration.,0.4,20 hours (range 12-27 hours),100 mg,Oral,solid,48.4 mg/mL at 37 Â°C (acetate form),3.78,0.0324,13.68,9.62,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1,0.4,0.4,,,0,100,414.1378118,2,1,1,0,1,1
1047,02/07/2019 00:00,DB01196,Estramustine,,,20 hours,140 mg/1,Oral,solid,,5.7,0.000385,19.38,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H],,,20,20,0,140,439.1680992,4,1,0,0,0,0
1048,02/07/2019 00:00,DB01197,Captopril,60-75% in fasting individuals; food decreases absorption by 25-40% (some evidence indicates that this is not clinically significant),25-30%,2 hours,100 mg,Oral,solid,Freely soluble,0.34,4.52,4.02,-1.2,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,0.25,0.3,2,2,0,100,217.0772643,1,0,1,0,1,1
1049,02/07/2019 00:00,DB01198,Zopiclone,Rapidly absorbed following oral administration.,0.45,Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.,5 mg,Oral,solid,0.151 mg/mL at 25 Â°C,0.8,0.885,13.04,6.89,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1,0.45,0.45,,,0,5,388.1050661,4,2,4,2,1,2
1050,04/06/2019 00:00,DB01199,Tubocurarine,,,1-2 hours,3 mg,Intravenous,solid,,,0.000323,6.45,8.12,[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3,,,1,2,1,,609.2959135,8,4,4,0,0,4
1051,02/07/2019 00:00,DB01200,Bromocriptine,"Approximately 28% of the oral dose is absorbed; however due to a substantial first pass effect, only 6% of the oral dose reaches the systemic circulation unchanged. Bromocriptine and its metabolites appear in the blood as early as 10 minutes following oral administration and peak plasma concentration are reached within 1-1.5 hours. Serum prolactin may be decreased within 2 hours or oral administration with a maximal effect achieved after 8 hours. Growth hormone concentrations in patients with acromegaly is reduced within 1-2 hours with a single oral dose of 2.5 mg and decreased growth hormone concentrations persist for at least 4-5 hours. ",90-96%,2-8 hours,5 mg,Oral,solid,,3.5,0.0858,9.68,6.71,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C,0.9,0.96,2,8,0,5,653.2212815,7,2,5,1,3,4
1052,04/06/2019 00:00,DB01201,Rifapentine,Rapidly and well absorbed from the gastrointestinal tract.,0.977,,150 mg/1,Oral,solid,,4,0.0213,7.01,7.98,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O,0.977,0.977,,,0,150,876.4520735,7,2,4,0,1,4
1053,02/07/2019 00:00,DB01202,Levetiracetam,Rapidly and almost completely absorbed after oral administration (99%). Peak plasma concentrations occurring in about an hour following oral administration in fasted subjects.,,6-8 hours,1000 mg/1,Oral,solid,,-0.6,298,16.09,-1.6,CC[C@H](N1CCCC1=O)C(N)=O,,,6,8,0,1000,170.1055277,1,0,1,0,1,1
1054,02/07/2019 00:00,DB01203,Nadolol,"Absorption of nadolol after oral dosing is variable, averaging about 30 percent.",0.3,14-24 hours,120 mg/1,Oral,solid,8330 mg/L (at 25 Â°C),0.81,2.25,13.59,9.76,CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2,0.3,0.3,14,24,0,120,309.1940083,2,1,0,0,0,0
1055,02/07/2019 00:00,DB01204,Mitoxantrone,Poorly absorbed following oral administration,0.78,75 hours,2 mg/1mL,Intravenous,liquid,,-3.1,0.734,8.27,9.36,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O,0.78,0.78,75,75,0,,444.2008846,3,2,0,0,0,0
1056,02/07/2019 00:00,DB01205,Flumazenil,,,"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).",0.1 mg/1mL,Intravenous,solid,128 mg/L,1,1.04,,3.27,CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1,,,,,0,,303.1019195,3,2,2,1,0,1
1057,02/07/2019 00:00,DB01206,Lomustine,Well and rapidly absorbed from the gastrointestinal tract.,0.5,"Approximately 94 minutes, however the metabolites have a serum half-life of 16 to 48 hours.",10 mg,Oral,solid,111 mg/L,2.83,0.755,13.3,-5.3,ClCCN(N=O)C(=O)NC1CCCCC1,0.5,0.5,,,0,10,233.0931044,1,0,0,0,0,0
1058,04/06/2019 00:00,DB01207,Ridogrel,Rapidly absorbed after oral administration (30-60 min),0.6,,,,solid,,4.3,0.00839,3.5,4.26,OC(=O)CCCCO\N=C(\C1=CN=CC=C1)C1=CC(=CC=C1)C(F)(F)F,0.6,0.6,,,0,,366.1191271,2,2,1,1,0,0
1059,04/06/2019 00:00,DB01208,Sparfloxacin,"Well absorbed following oral administration with an absolute oral bioavailability of 92%. Unaffected by administration with milk or food, however concurrent administration of antacids containing magnesium hydroxide and aluminum hydroxide reduces the oral bioavailability of sparfloxacin by as much as 50%.",,Mean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance &lt;50 mL/min).,,,solid,Practically insoluble,2.5,0.113,5.75,8.79,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O,,,,,0,,392.165997,4,2,2,1,1,1
1060,04/06/2019 00:00,DB01209,Dezocine,Rapid and complete following intramuscular administration.,,"Elimination half-life following intramuscular administration averages 2.2 hours. Elimination half-life following a 5mg intravenous dose averages 1.7 to 2.6 hours (range 0.6 to 4.4 hours) while a 10mg dose averages 2.4 to 2.6 hours (range 1.2 to 7.4 hours). In patients with hepatic cirrhosis, the half-life is increased by 30 to 50%.",,,solid,,3.3,0.014,10.43,9.67,[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N,,,,,0,,245.1779644,3,1,0,0,0,0
1061,02/07/2019 00:00,DB01210,Levobunolol,0.8,,20 hours,5 mg,Ophthalmic,solid,,2.4,0.251,14.09,9.66,CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O,,,20,20,0,,291.1834437,2,1,0,0,0,0
1062,02/07/2019 00:00,DB01211,Clarithromycin,"Clarithromycin is well-absorbed, acid stable and may be taken with food. ",0.7,3-4 hours,500 mg,Oral,solid,0.33 mg/L,3.16,0.217,12.46,8.38,[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC,0.7,0.7,3,4,0,500,747.4768913,3,0,3,0,3,3
1063,02/07/2019 00:00,DB01212,Ceftriaxone,,0.95,5.8-8.7 hours,1 g/1,Intramuscular,solid,,-1.7,0.105,2.7,3.36,[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,0.95,0.95,5.8,8.7,0,,554.0460579,4,2,4,2,1,2
1064,02/07/2019 00:00,DB01213,Fomepizole,Rapid and complete,,"The plasma half-life of Antizol varies with dose, even in patients with normal renal function, and has not been calculated.",1 g/1mL,Intravenous,liquid,,0.9,559,15.82,2.13,CC1=CNN=C1,,,,,0,,82.05309819,1,1,1,1,0,0
1065,04/06/2019 00:00,DB01214,Metipranolol,,,,3 mg/1mL,Ophthalmic,solid,589 mg/L,2.66,0.173,14.09,9.67,CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1,,,,,0,,309.1940083,1,1,0,0,0,0
1066,04/06/2019 00:00,DB01215,Estazolam,"Tablets have been found to be equivalent in absorption to an orally administered solution of estazolam. In healthy subjects who received up to three times the recommended dose, peak estazolam plasma concentrations occurred within two hours after dosing (range 0.5 to 6.0 hours) and were proportional to the administered dose, suggesting linear pharmacokinetics over the dosage range tested.",0.93,The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.,1 mg/1,Oral,solid,Practically insoluble (1.5 mg/L),4.7,0.0423,18.4,4.97,ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1,0.93,0.93,,,0,1,294.067224,4,3,2,1,0,1
1067,02/07/2019 00:00,DB01216,Finasteride,"Finasteride is well absorbed following oral administration [T28] and displays a slow accumulation phase after multiple dosing.[lablel] In healthy male subjects receiving oral finasteride, the mean oral bioavailability was 65% for 1 mg finasteride and 63% for 5 mg finasteride, and the values ranged from 26 to 170% for 1 mg dose and from 34 to 108% for 5 mg dose, respectively.[L6235,Label] It is reported that food intake does not affect the oral bioavailability of the drug.[A178195] The peak plasma concentrations (Cmax) averaged 37 ng/mL (range, 27-49 ng/mL) and was reached 1-2 hours post administration.[label] The AUC(0-24 hr) was 53 ngxhr/mL (range, 20-154 ngxhr/mL).[L6235] The plasma concentrations and AUC are reported to be higher in elderly male patients aged 70 years or older.[L6235]",0.9,"In healthy young subjects receiving finasteride, the mean elimination half-life in plasma was 6 hours ranging from 3 to 16 hours.[label] In elderly patients over the age of 70 years, the half-life is prolonged to 8 hours.",1 mg/1,Oral,solid,Slightly soluble,3.03,0.00198,14.53,2.22,[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C,0.9,0.9,,,0,1,372.2776784,4,0,1,0,0,1
1068,02/07/2019 00:00,DB01217,Anastrozole,"Rapidly absorbed into the systemic cirulation following oral administration. Peak plasma concentrations are usually attained within 2 hours under fasting conditions, with steady-state plasma concentrations attained in approximately 7 days.",0.4,50 hours,1 mg/1,Oral,solid,0.5 mg/mL,2.4,0.0661,,2,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N,0.4,0.4,50,50,0,1,293.1640456,2,2,1,1,0,0
1069,04/06/2019 00:00,DB01218,Halofantrine,,,6-10 days,250 mg/1,Oral,solid,,8.9,0.000111,14.47,10.05,CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F,,,144,240,0,250,499.1656546,3,3,0,0,0,0
1070,02/07/2019 00:00,DB01219,Dantrolene,Bioavailability is 70%.,,"The mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.",100 mg/1,Oral,solid,Low (146 mg/L),1.7,0.0805,9.23,-1.4,[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O,,,,,0,100,314.0651194,3,2,2,1,1,1
1071,02/07/2019 00:00,DB01220,Rifaximin,Low absorption in both the fasting state and when administered within 30 minutes of a high-fat breakfast.,,Approximately 6 hours.,200 mg/1,Oral,solid,,2.6,0.00738,3.66,11.87,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O,,,,,0,200,785.3523595,6,4,4,2,0,2
1072,02/07/2019 00:00,DB01221,Ketamine,"Ketamine absorption is very rapid and the bioavailability is around 93%. After the first pass metabolism, only 17% of the administered dose is absorbed.[A31883] It distributes very rapidly and presents a distribution half-life of 1.95 min.[A31887] The Cmax levels at peak reach 0.75 mcg/ml in plasma and 0.2 mcg/ml in cerebrospinal fluid.[L1336]",0.535,The reported half-life in preclinical studies for ketamine is 186 min.[A31883],10 mg/1mL,Intramuscular; Intravenous,solid,Soluble,3.12,0.0464,18.78,7.45,CNC1(CCCCC1=O)C1=CC=CC=C1Cl,0.535,0.535,,,0,,237.0920418,2,1,0,0,0,0
1073,02/07/2019 00:00,DB01222,Budesonide,"Absorption is complete following oral administration. The pharmacokinetic parameters of the inhaled powder formulation are as follows: 
Tmax = 30 minutes; 
Absolute systemic availability = 39%.
When a single oral administration of 9 mg of Uceris are given, the pharmacokinetic parameters are as follows:
Tmax = 13.3 Â± 5.9 hours;
Cmax = 1.35 Â± 0.96 ng/mL;
AUC = 16.43 Â± 10.52 ngÂ·hr/mL.
It is important to note that the parameters have a high degree of variability. 
When a single oral administration of Entocort EC are given, the pharmacokinetic parameters are as follows:
Tmax = 3- 600 minutes; 
Cmax = 5 nmol/L;
AUC = 30 nmolâ€¢hr/L. 
",85-90%,"Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohnâ€™s disease. ",3 mg/1,Oral,solid,insoluble,1.9,0.0457,13.74,-2.9,[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,0.85,0.9,,,0,3,430.2355388,5,0,1,0,1,1
1074,02/07/2019 00:00,DB01224,Quetiapine,Rapidly and well absorbed.,0.83,6 hours,100 mg,Oral,solid,Moderate,2.8,0.0403,15.12,7.06,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,0.83,0.83,6,6,0,100,383.166748,4,2,2,0,1,2
1075,04/06/2019 00:00,DB01226,Mivacurium,,,"The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.",2 mg/1mL,Intravenous,liquid,,,3.26E-05,18.59,-4.1,COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC,,,,,2,,1028.559858,6,4,2,0,0,2
1076,04/06/2019 00:00,DB01227,Levacetylmethadol,Levomethadyl acetate is rapidly absorbed from an oral solution.,0.8,2.6 days,,,solid,>15 mg/mL,5.4,0.00179,,9.87,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,0.8,0.8,62.4,62.4,0,,353.2354792,2,2,0,0,0,0
1077,04/06/2019 00:00,DB01228,Encainide,,,1-2 hours,25 mg/1,Oral,solid,,4,0.00401,12.37,9.48,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C,,,1,2,0,25,352.2150781,3,2,1,0,1,1
1078,02/07/2019 00:00,DB01229,Paclitaxel,"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the maximum plasma concentration (Cmax) is 195 ng/mL, while the AUC is 6300 ngâ€¢h/mL. ",89%-98%,"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours. ",5 mg/ml,Intravenous,solid,Insoluble,3,0.00556,10.36,-1,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,0.89,0.98,,,0,,853.3309553,7,3,1,0,1,1
1079,04/06/2019 00:00,DB01230,Pemoline,Pemoline is rapidly absorbed from the gastrointestinal tract,0.5,The serum half-life of pemoline is approximately 12 hours.,18.75 mg/1,Oral,solid,,0.7,0.979,14.95,0.99,NC1=NC(=O)C(O1)C1=CC=CC=C1,0.5,0.5,,,0,18.75,176.0585775,2,1,1,0,0,1
1080,04/06/2019 00:00,DB01231,Diphenidol,Well absorbed from gastrointestinal tract following oral administration.,,4 hours,25 mg/1,Oral,solid,,4.3,0.00587,13.4,9.23,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,,,4,4,0,25,309.2092645,3,2,1,0,1,1
1081,02/07/2019 00:00,DB01232,Saquinavir,Absolute bioavailability averages 4%,0.98,,200 mg/1,Oral,solid,Insoluble,3.8,0.00247,13.61,8.47,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,0.98,0.98,,,0,200,670.3842687,5,3,2,1,1,1
1082,02/07/2019 00:00,DB01233,Metoclopramide,Rapidly and well absorbed (oral bioavailability 80&plusmn;15.5%).,0.3,5-6 hr,1 mg,Oral,solid,200 mg/L (at 25 Â°C),2.62,0.31,14.49,9.04,CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC,0.3,0.3,5,6,0,1,299.1400546,1,1,0,0,0,0
1083,02/07/2019 00:00,DB01234,Dexamethasone,80-90%,0.7,36-54 hours,.7 mg,Intracardiac,solid,89 mg/L (at 25 Â°C),1.83,0.0505,12.42,-3.3,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,0.7,0.7,36,54,0,,392.1999022,4,0,0,0,0,0
1084,04/06/2019 00:00,DB01235,Levodopa,"Orally inhaled levodopa reaches a peak concentration in 0.5 hours with a bioavailability than is 70% that of the immediate release levodopa tablets with a peripheral dopa decarboxylase inhibitor like carbidopa or benserazide[Label,A177781].",,"2.3 hours for orally inhaled levodopa[FDA Label]. Oral levodopa has a half life of 50 minutes but when combined with a peripheral dopa decarboxylase inhibitor, the half life is increased to 1.5 hours[F4579].",42 mg/1,Oral,solid,5mM,0.05,3.3,1.65,9.06,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O,,,,,0,42,197.0688078,1,1,0,0,0,0
1085,02/07/2019 00:00,DB01236,Sevoflurane,"Rapidly absorbed into circulation via the lungs, however solubility in the blood is low.",,15-23 hours,1 mL/1mL,Respiratory (inhalation),liquid,Very slightly soluble,2.4,1.48,15.07,-4.5,FCOC(C(F)(F)F)C(F)(F)F,,,15,23,0,,200.0072123,0,0,0,0,0,0
1086,04/06/2019 00:00,DB01237,Bromodiphenhydramine,Well absorbed in the digestive tract.,0.96,1 to 4 hours,,Topical,solid,,4,0.00345,,8.87,CN(C)CCOC(C1=CC=CC=C1)C1=CC=C(Br)C=C1,0.96,0.96,,,0,,333.0728264,2,2,0,0,0,0
1087,02/07/2019 00:00,DB01238,Aripiprazole,"Aripiprazole tablets are 87% bioavailable and reach peak plasma concentrations in 3 to 5 hours[Label]. These tablets can be taken with or without food, but a high fat meal can delay the time to max concentration by 3 hours and up to 12 hours for the active metabolite[Label].",,"The half life of aripiprazole is 75 hours while the half life of the active metabolite is 94 hours[Label]. For populations that are poor CYP2D6 metabolizers, the half life of aripiprazole is 146 hours and these patients should be treated with half the normal dose[Label]. Other studies have reported a half life of 61.03Â±19.59 hours for aripiprazole and 279Â±299 hours for the active metabolite[A177904].",9.75 mg/1.3mL,Intramuscular,solid,0.0000001,,0.00777,13.51,7.46,ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl,,,,,0,,447.1480325,4,2,2,0,1,2
1088,04/06/2019 00:00,DB01239,Chlorprothixene,Incomplete bioavailability.,,8 to 12 hours,,,solid,0.295 mg/L,5.18,0.000366,,9.76,CN(C)CC\C=C1\C2=CC=CC=C2SC2=CC=C(Cl)C=C12,,,,,0,,315.0848483,3,2,1,0,0,1
1089,02/07/2019 00:00,DB01240,Epoprostenol,,,The in vitro half-life of epoprostenol in human blood at 37&deg;C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.,1.5 mg/5mL,Intravenous,solid,,3,0.136,4.43,-1.6,[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O,,,,,0,,352.2249741,2,0,1,0,1,1
1090,02/07/2019 00:00,DB01241,Gemfibrozil,Well absorbed from gastrointestinal tract (within 1-2 hours).,0.95,1.5 hours,600 mg/1,Oral,solid,10 mg/mL (in base),3.4,0.0278,4.42,-4.8,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,0.95,0.95,1.5,1.5,0,600,250.1568946,1,1,0,0,0,0
1091,02/07/2019 00:00,DB01242,Clomipramine,"Well absorbed from the GI tract following oral administration. Bioavailability is approximately 50% orally due to extensive first-pass metabolism. Bioavailability is not affected by food. Peak plasma concentrations occurred 2-6 hours following oral administration of a single 50 mg dose. The peak plasma concentration ranged from 56 ng/mL to 154 mg/mL (mean, 92 ng/mL).  There are large interindividual variations in plasma concentrations occur, partly due to genetic differences in clomipramine metabolism. On average, steady state plasma concentrations are achieved in 1-2 weeks following multiple dose oral administration. Smoking appears to lower the steady-state plasma concentration of clomipramine, but not its active metabolite desmethylclomipramine. ",97-98%,"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).  ",25 mg/1,Oral,solid,0.294 mg/L,5.19,0.0144,,9.2,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2,0.97,0.98,,,0,25,314.1549764,3,2,1,0,0,1
1092,04/06/2019 00:00,DB01243,Chloroxine,,,,20 mg/1g,Topical,solid,,3,0.138,6.95,3.4,OC1=C(Cl)C=C(Cl)C2=C1N=CC=C2,,,,,0,,212.9748191,2,2,1,1,0,0
1093,04/06/2019 00:00,DB01244,Bepridil,Rapidly and completely absorbed after oral administration.,0.99,24-50 hours,,,solid,Slightly soluble,5.2,0.00655,,9.16,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,0.99,0.99,24,50,0,,366.2671137,3,2,1,0,1,1
1094,04/06/2019 00:00,DB01245,Decamethonium,Rapidly absorbed.,,,,,solid,Substantial,,7.04E-06,,,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,,,,,2,,258.3024021,0,0,0,0,0,0
1095,02/07/2019 00:00,DB01246,Alimemazine,Well absorbed in the digestive tract.,,,2.5 mg,Oral,solid,0.942 mg/L,4.71,0.00835,,9.42,CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=CC=C12,,,,,0,2.5,298.1503697,3,2,1,0,0,1
1096,04/06/2019 00:00,DB01247,Isocarboxazid,"The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are readily absorbed by the GI tract, present a low bioavailability and reach peak concentrations in 1-2 hours.[T114]",,The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor.[T117] These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.[T114],10 mg/1,Oral,solid,Very slightly soluble in hot water,1.49,0.224,12.02,3.12,CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1,,,,,0,10,231.1007767,2,2,1,1,0,0
1097,02/07/2019 00:00,DB01248,Docetaxel,The pharmacokinetic profile is consistent with a three-compartment model.  The area under the curve (AUC) was dose proportional following doses of 70 mg/m2 to 115 mg/m2 with infusion times of 1 to 2 hours.,0.94,"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively. ",20 mg/0.8mL,Intravenous,solid,Insoluble ,2.4,0.0127,10.96,-3,[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,0.94,0.94,,,0,,807.3466054,6,2,1,0,1,1
1098,02/07/2019 00:00,DB01249,Iodixanol,,,"2.1 hours. In patients with significantly impaired renal function (mean creatinine clearance rate, 9.91 [&plusmn; 3.58] mL per minute), the plasma half-life is increased to 23 hours.",270 mg/1mL,Intravascular,solid,,0.5,0.185,11.43,-3.2,CC(=O)N(CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,,,,,0,,1549.713303,2,2,0,0,0,0
1099,02/07/2019 00:00,DB01250,Olsalazine,"After oral administration, olsalazine, has limited systemic bioavailability.  98-99% of the dose is converted to mesalamine (5-ASA) in the colon, which is absorbed slowly resulting in very high local concentrations in the colon.",0.99,"Olsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.",250 mg/1,Oral,solid,,2.3,0.0781,2.93,-0.019,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O,0.99,0.99,,,0,250,302.053886,2,2,0,0,0,0
1100,04/06/2019 00:00,DB01251,Gliquidone,,,The mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours),,,solid,,4.5,0.0022,4.32,-4.8,COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O,,,,,0,,527.2090068,4,2,1,0,0,1
1101,04/06/2019 00:00,DB01252,Mitiglinide,,,,,,solid,,2.9,0.0708,4.62,-0.83,[H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O,,,,,0,,315.1834437,3,1,1,0,1,1
1102,02/07/2019 00:00,DB01253,Ergometrine,Absorption is rapid and complete after oral or intramuscular administration.,,t<sub>1/2 &alpha;</sub>=10 minutes; t<sub>1/2 &beta;</sub>=2 hours,0.2 mg/1,Oral,solid,2.68 mg/mL at 25 Â°C,0.9,0.321,15,7.93,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO,,,,,0,0.2,325.179027,4,2,2,1,0,1
1103,02/07/2019 00:00,DB01254,Dasatinib,,0.96,The overall mean terminal half-life of dasatinib is 3-5 hours.,100 mg,Oral,solid,,1.8,0.0128,8.49,7.22,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,0.96,0.96,,,0,100,487.1557218,4,3,3,2,1,1
1104,02/07/2019 00:00,DB01255,Lisdexamfetamine,"After oral administration, lisdexamfetamine is rapidly absorbed from the gastrointestinal tract [FDA label], [F2355].

**Chewable tablet form:** After a single dose of 60 mg a chewable tablet in healthy subjects under fasted conditions, the Tmax of lisdexamfetamine and dextroamphetamine was reached at about 1 hour and 4.4 hour post administration, respectively [FDA label].

**Capsule form:** Following single-dose oral (30 mg, 50 mg, or 70 mg) in patients ages 6 to 12 years with ADHD under fasted conditions, Tmax of lisdexamfetamine and dextroamphetamine was reached at about 1 hour and 3.5 hours post administration, respectively [FDA label].",,"The mean plasma elimination half-life of dextroamphetamine was about 12 hours after oral administration of lisdexamfetamine dimesylate [FDA label]. 

The plasma elimination half-life of lisdexamfetamine alone averaged less than one hour in studies of lisdexamfetamine dimesylate administered in volunteer subjects [FDA label].",10 mg,Oral,liquid,792 mg/mL (dimesylate salt),-1.76,0.0877,15.89,10.21,C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN,,,,,0,10,263.1997624,1,1,0,0,0,0
1105,02/07/2019 00:00,DB01256,Retapamulin,,0.94,,10 mg/1g,Topical,solid,,5,0.000394,14.43,9.69,[H][C@]12CC[C@]([H])(C[C@]([H])(C1)SCC(=O)O[C@]1([H])C[C@@](C)(C=C)[C@@]([H])(O)[C@]([H])(C)[C@]34CCC(=O)[C@@]3([H])[C@@]1(C)[C@]([H])(C)CC4)N2C,0.94,0.94,,,0,,517.32258,5,0,2,0,2,2
1106,02/07/2019 00:00,DB01259,Lapatinib,Absorption following oral administration of lapatinib is incomplete and variable.,,"Single-dose terminal half life: 14.2 hours
Effective multiple-dose half life: 24 hours",250 mg/1,Oral,solid,,5.4,0.0223,15.99,7.2,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,,,,,0,250,580.1347322,5,5,2,2,0,0
1107,02/07/2019 00:00,DB01260,Desonide,"Topical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption.",,,0.0005,Topical,solid,Practically insoluble,1.4,0.0594,13.75,-2.9,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,416.2198887,5,0,1,0,1,1
1108,02/07/2019 00:00,DB01261,Sitagliptin,"Sitagliptin is 87% orally bioavailable and taking it with or without food does not affect its pharmacokinetics[Label,A2260]. Sitagliptin reaches maximum plasma concentration in 2 hours[A2260].",,Approximately 12.4 hours[Label]. Other studies have reported a half life of approximately 11 hours[A2260].,100 mg,Oral,solid,,1.5,0.034,,8.78,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F,,,,,0,100,407.1180794,3,2,2,1,0,1
1109,04/06/2019 00:00,DB01262,Decitabine,,,The terminal phase elimination half-life is 0.51 &plusmn; 0.31 hours.,50 mg,Intravenous,solid,Sparingly soluble,,5.5,13.89,-0.25,NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1,,,,,0,,228.0858549,2,1,2,1,1,1
1110,02/07/2019 00:00,DB01263,Posaconazole,Posaconazole is absorbed with a median Tmax of approximately 3 to 5 hours.,,Posaconazole is eliminated with a mean half-life (t&frac12;) of 35 hours (range 20 to 66 hours).,300 mg,Intravenous,solid,Insoluble,5.5,0.012,14.83,3.93,[H][C@@](C)(O)[C@]([H])(CC)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@]2([H])CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1,,,,,0,,700.3297083,7,5,4,2,2,2
1111,02/07/2019 00:00,DB01264,Darunavir,"The absolute oral bioavailability of a single 600 mg dose of darunavir alone and after co-administration with 100 mg ritonavir twice daily was 37% and 82%, respectively.",0.95,The terminal elimination half-life of darunavir was approximately 15 hours when combined with ritonavir.,1 kg/1kg,Not applicable,solid,Approximately 0.15 mg/mL at 20 Â°C as ethanolate salt,1.8,0.0668,13.59,2.39,[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,0.95,0.95,,,0,,547.2352215,4,2,2,0,2,2
1112,02/07/2019 00:00,DB01265,Telbivudine,"Absorbed following oral administration. Telbivudine absorption and exposure were unaffected when a single 600â€“mg dose was administered with a highâ€“fat (~55 g), highâ€“calorie (~950 kcal) meal.",,Approximately 15 hours.,20 mg/ml,Oral,solid,Sparingly soluble in water (>20 mg/mL),-1.4,66.8,9.96,-3,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O,,,,,0,,242.0902715,2,1,2,1,1,1
1113,02/07/2019 00:00,DB01267,Paliperidone,The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.,,The terminal elimination half-life of paliperidone is approximately 23 hours.,1.5 mg,Oral,solid,Practically insoluble in water,1.8,0.297,13.74,8.76,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1,,,,,0,1.5,426.2067189,5,3,4,2,1,2
1114,02/07/2019 00:00,DB01268,Sunitinib,"Maximum plasma concentrations (Cmax) of sunitinib are generally observed between 6 and 12 hours (Tmax) following oral administration. Food has no effect on the bioavailability of sunitinib. Sunitinib may be taken with or without food. The pharmacokinetics were similar in healthy volunteers and in the solid tumor patient populations tested, including patients with GIST and RCC.",0.95,"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.",12.5 mg/1,Oral,solid,>25 mg/mL over pH of 1.2 to 6.8,5.2,0.0308,11.46,9.04,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,0.95,0.95,,,0,12.5,398.2118043,3,2,2,1,0,1
1115,02/07/2019 00:00,DB01273,Varenicline,,,The elimination half-life of varenicline is approximately 24 hours,0.5 mg,Oral,solid,,0.9,0.0877,,9.73,[H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21,,,,,0,0.5,211.1109474,4,2,2,1,1,1
1116,04/06/2019 00:00,DB01274,Arformoterol,,52-65%,"In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.",15 ug/2mL,Respiratory (inhalation),solid,,2.2,0.0416,8.61,9.81,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1,0.52,0.65,,,0,,344.1736072,2,2,0,0,0,0
1117,02/07/2019 00:00,DB01275,Hydralazine,Hydralazine is rapidly and extensively absorbed (up to 90%) from the gastrointestinal tract and undergoes extensive first-pass metabolism by genetic polymorphic acetylation. Oral bioavailability of hydralazine is dependent upon acetylator phenotype. Bioavailability is approximately 31% in slow acetylators and 10% in fast acetylators.,0.87,3 to 7 hours,20 mg,Intravenous,solid,,1,2.61,17.69,6.4,NNC1=NN=CC2=CC=CC=C12,0.87,0.87,,,0,,160.0748963,2,2,1,1,0,0
1118,02/07/2019 00:00,DB01280,Nelarabine,,,Nelarabine and ara-G are rapidly eliminated from plasma with a half-life of approximately 30 minutes and 3 hours.,5 mg/1mL,Intravenous,solid,Slightly soluble to soluble in water,-1,13.9,12.45,3.47,COC1=NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,,,,,0,,297.1073186,3,2,3,2,1,1
1119,02/07/2019 00:00,DB01282,Carbetocin,Bioavailability is 80% following intramuscular injection.,,40 minutes,100 mcg,Intravenous,solid,,-2,0.0265,11.42,,[H][C@]1(NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC,,,0.666666667,0.666666667,0,,987.4847876,3,1,2,0,2,2
1120,04/06/2019 00:00,DB01283,Lumiracoxib,"Rapidly absorbed following oral administration, with an absolute oral bioavailablity of 74%.",,Terminal half-life is approximately 4 hours.,,,solid,,3.9,0.00549,4.11,-1.9,CC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1,,,,,0,,293.0618846,2,2,0,0,0,0
1121,02/07/2019 00:00,DB01284,Tetracosactide,Rapidly absorbed following intramuscular administration.,,About 15 minutes following intravenous administration.,0.25 mg/1mL,Intramuscular; Intravenous; Parenteral,solid,,,0.0481,3.03,12.38,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O,,,,,0,,2931.580641,9,6,5,2,3,3
1122,04/06/2019 00:00,DB01288,Fenoterol,,,,1 mg,Respiratory (inhalation),solid,,,0.162,8.85,9.63,CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1,,,,,0,,303.1470582,2,2,0,0,0,0
1123,04/06/2019 00:00,DB01289,Glisoxepide,,,,,,solid,,,0.103,4.07,1.59,CC1=CC(=NO1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1,,,,,0,,449.17329,3,2,2,1,1,1
1124,04/06/2019 00:00,DB01291,Pirbuterol,,,2 hours.,200 ug/1,Respiratory (inhalation),solid,,,6.22,8.79,9.59,CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1,,,2,2,0,,240.1473925,1,1,1,1,0,0
1125,02/07/2019 00:00,DB01294,Bismuth subsalicylate,"Following oral administration, absorption of the salicylate component from the small intestine is generally rapid and complete (>90%). ",,,17.66 mg,Oral,solid,,,59.7,14.3,-3.1,O[Bi]1OC(=O)C2=CC=CC=C2O1,,,,,0,17.66,361.9991823,2,1,1,0,0,1
1126,04/06/2019 00:00,DB01295,Bevantolol,,,,,,solid,,3,0.0137,14.09,9.31,COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1,,,,,0,,345.1940083,2,2,0,0,0,0
1127,04/06/2019 00:00,DB01296,Glucosamine,,,,,Oral,solid,,,551,11.73,8.23,N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,,,,,0,,179.0793725,1,0,1,0,1,1
1128,04/06/2019 00:00,DB01297,Practolol,,,,,,solid,,0.79,0.49,14.03,9.67,CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1,,,,,0,,266.1630426,1,1,0,0,0,0
1129,04/06/2019 00:00,DB01298,Sulfacytine,Well absorbed following oral administration.,,,,,solid,1750 mg/L (at 37 Â°C),,0.468,10.55,2.17,CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O,,,,,0,,294.0786613,2,2,1,1,0,0
1130,04/06/2019 00:00,DB01299,Sulfadoxine,,,,,Oral,solid,,0.7,0.296,6.12,2.55,COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC,,,,,0,,310.0735759,2,2,1,1,0,0
1131,04/06/2019 00:00,DB01301,Rolitetracycline,,,,275 mg,Intra-articular; Intraperitoneal; Intrapleural; Intrathecal; Intravenous,solid,5.55E+005 mg/L,,1.81,0.31,8.24,[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCN1CCCC1)=C(O)[C@H]2N(C)C,,,,,0,,527.226765,5,1,1,0,1,1
1132,02/07/2019 00:00,DB01303,Oxtriphylline,"After ingestion, theophylline is released from oxytriphylline in the acidic environment of the stomach. ",0.56,"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5â€“9.5 hours, and for for premature infants is 15â€“58 hours.",100 mg,Oral,solid,Soluble in alcohol and water.,,3.84,7.82,-0.78,C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O,0.56,0.56,,,0,100,283.1644395,2,2,2,2,0,0
1133,02/07/2019 00:00,DB01319,Fosamprenavir,"The absolute oral bioavailability of amprenavir after administration of fosamprenavir in humans has not been established. After administration of a single 1,400 mg dose in the fasted state, fosamprenavir oral suspension (50 mg/mL) and fosamprenavir tablets (700 mg) provided similar amprenavir exposures (AUC), however, the C<sub>max</sub> of amprenavir after administration of the suspension formulation was 14.5 % higher compared with the tablet.",,The plasma elimination half-life of amprenavir (the active metabolite) is approximately 7.7 hours.,50 mg/1mL,Oral,solid,,,0.685,1.22,2.45,CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,,,,,0,,585.1909874,3,2,1,0,1,1
1134,02/07/2019 00:00,DB01320,Fosphenytoin,Fosphenytoin is completely bioavailable following lM administration.,(95%,Fosphenytoin has a half-life of approximately 15 minutes.,75 mg,Intramuscular; Intravenous,solid,,,0.145,1.46,-9.7,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,0.95,0.95,,,0,,362.0667728,3,2,1,0,1,1
1135,04/06/2019 00:00,DB01321,Josamycin,,,,,,solid,,,0.0535,12.71,7.9,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,,,,,0,,827.4667205,3,0,3,0,2,3
1136,04/06/2019 00:00,DB01322,Kava,,,,,,solid,,,0.0632,16.55,-4.8,COC1=CC(=O)OC(C1)\C=C\C1=CCCC=C1,,,,,0,,232.1099444,2,0,1,0,0,1
1137,04/06/2019 00:00,DB01324,Polythiazide,,,,1 mg/1,Oral,solid,,1.9,0.264,9.31,-3.1,CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O,,,,,0,1,438.9708812,2,1,1,0,0,1
1138,04/06/2019 00:00,DB01325,Quinethazone,,,,,,solid,150 mg/L (at 25 Â°C),,2.51,9.56,-0.97,CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O,,,,,0,,289.0287899,2,1,1,0,0,1
1139,04/06/2019 00:00,DB01326,Cefamandole,,0.75,"The half-life after an intravenous dose is 32 minutes; after intramuscular administration, the half-life is 60 minutes.",1 g,Intravenous,solid,,0.5,0.581,3.32,-1.7,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O,0.75,0.75,,,0,,462.0780097,4,2,3,1,1,2
1140,02/07/2019 00:00,DB01327,Cefazolin,Not absorbed from GI tract. Must be administered parenterally. Peak serum concentrations attained 1-2 hours post intramuscular injection. ,74-86%,The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.,1 g/1,Intramuscular,solid,,-0.58,0.487,3.03,0.26,[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O,0.74,0.86,,,0,,454.0300139,4,2,4,2,1,2
1141,04/06/2019 00:00,DB01328,Cefonicid,,0.98,4.5 hours,,,solid,,,0.895,-1.4,-2.1,[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O,0.98,0.98,4.5,4.5,0,,542.0348245,4,2,3,1,1,2
1142,04/06/2019 00:00,DB01329,Cefoperazone,,0.93,"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.",1 g/1,Intravenous,solid,,-0.74,0.286,3.19,-1.7,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O,0.93,0.93,,,0,,645.1424008,5,2,4,1,2,3
1143,04/06/2019 00:00,DB01330,Cefotetan,,0.88,"In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged",1 g/1,Intramuscular; Intravenous,solid,,,0.521,3.23,-1.3,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O,0.88,0.88,,,0,,575.0021445,4,1,4,1,2,3
1144,02/07/2019 00:00,DB01331,Cefoxitin,,,The half-life after an intravenous dose is 41 to 59 minutes. ,1 g/10mL,Intravenous,solid,,-0.02,0.195,3.59,-3.8,[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O,,,,,0,,427.0507919,3,1,3,1,1,2
1145,04/06/2019 00:00,DB01332,Ceftizoxime,,0.3,,1 g/1,Intramuscular; Intravenous,solid,,,0.229,3.13,4.16,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,0.3,0.3,,,0,,383.0358105,3,1,3,1,1,2
1146,04/06/2019 00:00,DB01333,Cefradine,,,,250 mg/1,Oral,solid,2.13E+004 mg/L,,0.778,3.46,7.6,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CCC=CC1)C(O)=O,,,,,0,250,349.1096271,3,0,2,0,1,2
1147,04/06/2019 00:00,DB01336,Metocurine,,,,,,solid,,,6.42E-06,12.99,-3.4,[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,,,,,2,,652.3501401,8,4,4,0,0,4
1148,02/07/2019 00:00,DB01337,Pancuronium,,0.91,1.5 to 2.7 hours.,1 mg/1mL,Intravenous,solid,5E+005 mg/L,,3.08E-06,,-6.7,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1,0.91,0.91,,,2,,572.4542112,6,0,2,0,2,2
1149,04/06/2019 00:00,DB01338,Pipecuronium,,,"Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]",10 mg/1,Intravenous,solid,,,9.50E-05,,5.31,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1,,,,,2,,602.4760093,6,0,2,0,2,2
1150,02/07/2019 00:00,DB01339,Vecuronium,,,51â€“80 minutes,10 mg/10mL,Intravenous,solid,,,1.86E-05,,9.65,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1,,,0.85,1.333333333,1,,557.4312847,6,0,2,0,2,2
1151,02/07/2019 00:00,DB01340,Cilazapril,"Maximum plasma concentrations of cilazaprilat are reached within two hours after
administration of cilazapril. ",0.9,Half-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively. ,5 mg,Oral,solid,Water (25 ÂºC) 0.5 g/100 mL ,0.8,1.06,3.41,5.35,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O,0.9,0.9,,,0,5,417.2263711,3,1,2,0,2,2
1152,04/06/2019 00:00,DB01342,Forasartan,,,,,,solid,,,0.00667,7.35,3.99,CCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N1,,,,,0,,416.2436929,4,4,3,3,0,0
1153,04/06/2019 00:00,DB01347,Saprisartan,,,,,,solid,,,0.0151,2.27,5.18,CCC1=NC(C2CC2)=C(N1CC1=CC2=C(OC(=C2Br)C2=CC=CC=C2NS(=O)(=O)C(F)(F)F)C=C1)C(N)=O,,,,,0,,610.0497229,5,4,2,2,0,0
1154,04/06/2019 00:00,DB01348,Spirapril,Bioavailability is 50% following oral administration.,,30 to 35 hours,,,solid,,,0.0293,3.62,5.2,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2,,,,,0,,466.1596141,3,1,2,0,2,2
1155,04/06/2019 00:00,DB01349,Tasosartan,,,,,,solid,,,0.0325,7.4,2.79,CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=CC=CC=C3C3=NNN=N3)C2=N1,,,,,0,,411.1807583,5,4,3,2,0,1
1156,04/06/2019 00:00,DB01351,Amobarbital,,,,0.5 g/5mL,Intramuscular; Intravenous,solid,603 mg/L (at 25 Â°C),2.07,0.897,8.48,,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O,,,,,0,,226.1317424,1,0,1,0,1,1
1157,04/06/2019 00:00,DB01352,Aprobarbital,,,,,,solid,4080 mg/L (at 25 Â°C),1.15,5.17,8.48,,CC(C)C1(CC=C)C(=O)NC(=O)NC1=O,,,,,0,,210.1004423,1,0,1,0,1,1
1158,04/06/2019 00:00,DB01353,Butobarbital,Rapidly absorbed following oral administration.,,37 hours,,,solid,4880 mg/L (at 25 Â°C),1.73,1.27,8.48,,CCCCC1(CC)C(=O)NC(=O)NC1=O,,,37,37,0,,212.1160924,1,0,1,0,1,1
1159,04/06/2019 00:00,DB01354,Heptabarbital,,,,,,solid,250 mg/L (at 25 Â°C),2.03,0.324,8.14,,CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1,,,,,0,,250.1317424,2,0,1,0,1,1
1160,04/06/2019 00:00,DB01355,Hexobarbital,,0.25,,,,solid,435 mg/L (at 25 Â°C),1.98,1.51,8.41,,CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1,0.25,0.25,,,0,,236.1160924,2,0,1,0,1,1
1161,04/06/2019 00:00,DB01357,Mestranol,,,,,Oral,solid,,,0.00377,17.59,-1.7,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3,,,,,0,,310.1932801,4,1,0,0,0,0
1162,04/06/2019 00:00,DB01359,Penbutolol,>90%.,80-98%,"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis. ",20 mg/1,Oral,solid,,4.15,0.0212,14.09,9.76,CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1,0.8,0.98,,,0,20,291.2198292,2,1,0,0,0,0
1163,02/07/2019 00:00,DB01362,Iohexol,"Small amounts are absorbed through the bladder via intravesical instillation. Following intrauterine instillation, the majority of the medium within the uterine cavity is discharged into the vagina immediately upon termination of procedure. However, any medium retained in the uterine or peritoneal cavity is absorbed systemically within 60 minutes. May not be absorbed for up to 24 hours if tubes are obstructed and dilated.",,Intrathecal half-life is 3.4 hours (mean). Intravascular is approximately 2 hours (with normal renal function).,140 mg/1mL,Intravenous,solid,,-3.05,0.796,11.73,-3,CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,,,,,0,,820.8803234,1,1,0,0,0,0
1164,02/07/2019 00:00,DB01364,Ephedrine,0.85,,3-6 hours,10 mg/1mL,Nasal,solid,6.36E+004 mg/L (at 30 Â°C),1.13,8.26,13.89,9.52,CN[C@@H](C)[C@H](O)C1=CC=CC=C1,,,3,6,0,,165.1153641,1,1,0,0,0,0
1165,04/06/2019 00:00,DB01365,Mephentermine,,,17 to 18 hours.,30 mg,Intramuscular; Intravenous,liquid,,,0.457,,10.3,CNC(C)(C)CC1=CC=CC=C1,,,,,0,,163.1360995,1,1,0,0,0,0
1166,04/06/2019 00:00,DB01366,Procaterol,"Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses.",,,10 mcg,Respiratory (inhalation),solid,,,0.329,8.52,9.88,CC[C@H](NC(C)C)[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1,,,,,0,,290.1630426,2,2,1,1,0,0
1167,02/07/2019 00:00,DB01367,Rasagiline,Rasagiline is rapidly absorbed following oral administration.  The absolute bioavailability of rasagiline is about 36%.,88-94%,Rasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.,1 mg,Oral,solid,,,0.0249,,8.69,C#CCN[C@@H]1CCC2=CC=CC=C12,0.88,0.94,,,0,1,171.1047994,2,1,0,0,0,0
1168,04/06/2019 00:00,DB01369,Quinupristin,,,3.1 hours,,Intravenous,solid,,,0.0445,7.45,8.28,[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1,,,3.1,3.1,0,,1021.47316,9,3,7,1,6,6
1169,02/07/2019 00:00,DB01373,Calcium,,,,0.99 1/1,Oral,solid,,,0,,,[Ca],,,,,0,,39.96259098,0,0,0,0,0,0
1170,04/06/2019 00:00,DB01375,Aluminium monostearate,,,,,,solid,,-1.85,0.000685,14.62,-2.8,CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O,,,,,0,,344.2507233,0,0,0,0,0,0
1171,02/07/2019 00:00,DB01380,Cortisone acetate,,,,10 mg/1,Oral,solid,20 mg/L (at 25 Â°C),2.1,0.0278,12.6,-3.8,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,10,402.2042387,4,0,0,0,0,0
1172,04/06/2019 00:00,DB01382,Glymidine,Rapidly and completely absorbed following oral administration.,0.9,4 hours.,,,solid,,,0.124,6.92,-1.4,COCCOC1=CN=C(NS(=O)(=O)C2=CC=CC=C2)N=C1,0.9,0.9,4,4,0,,309.078327,2,2,1,1,0,0
1173,04/06/2019 00:00,DB01384,Paramethasone,,0.8,,,,solid,,,0.145,12.45,-2.9,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,0.8,0.8,,,0,,392.1999022,4,0,0,0,0,0
1174,04/06/2019 00:00,DB01388,Mibefradil,"Bioavailability after a single dose is 70%. After multiple dosing, the proportion of mibefradil undergoing first-pass metabolism is reduced, resulting in a steady state bioavailability of approximately 90%. Food does not affect the rate or extent of absorption of mibefradil.",,17 to 25 hours at steady state.,,,solid,,,0.00104,12.54,9.82,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,,,,,0,,495.2897203,4,3,1,1,0,0
1175,02/07/2019 00:00,DB01390,Sodium bicarbonate,,,,50 mg/1mL,Topical,solid,1E+005 mg/L (at 25 Â°C),,764,6.05,,[Na+].OC([O-])=O,,,,,0,,83.98233817,0,0,0,0,0,0
1176,02/07/2019 00:00,DB01392,Yohimbine,"Rapidly absorbed following oral administration. Bioavailability is highly variable, ranging from 7 to 87% (mean 33%).",,Elimination half-life is approximately 36 minutes.,2 mg,Oral,solid,,2.73,0.348,14.68,7.65,[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2,,,,,0,2,354.1943427,5,2,3,1,1,2
1177,02/07/2019 00:00,DB01393,Bezafibrate,Bezafibrate is almost completely absorbed after oral administration. The relative bioavailability of bezafibrate retard compared to the standard form is about 70%.,94-96%,1-2 hours,400 mg,Oral,solid,,,0.00155,3.83,-0.84,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O,0.94,0.96,1,2,0,400,361.1080858,2,2,0,0,0,0
1178,02/07/2019 00:00,DB01394,Colchicine,"Colchicine is rapidly absorbed after oral administration, probably from the jejunum and ileum. However, the rate and extent of absorption are variable, depending on the tablet dissolution rate; variability in gastric emptying, intestinal motility, and pH at the absorption site; and the extent to which colchicine is bound to microtubules in gastrointestinal mucosal cells.",,"Elimination half-life is approximately 1 hour in healthy subjects, although a study with an extended sampling time reported mean terminal elimination half-life values of approximately 9 to 10.5 hours. Other studies have reported half-life values of approximately 2 hours in patients with alcoholic cirrhosis and approximately 2.5 hours in patients with familial Mediterranean fever.",0.6 mg/1,Oral,solid,4.5E+004 mg/L (at 25 Â°C),1.3,0.0276,15.06,-0.038,COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O,,,,,0,0.6,399.1681875,3,2,0,0,0,0
1179,04/06/2019 00:00,DB01395,Drospirenone,Oral bioavailability is approximately 76%.,95-97%,30 hours,4 mg/1,Oral,solid,,,0.00225,,-5,[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21,0.95,0.97,30,30,0,4,366.2194948,7,0,1,0,1,1
1180,04/06/2019 00:00,DB01396,Digitoxin,,,,.1 mg,Oral,solid,3.9 mg/L (at 25 Â°C),1.85,0.0289,7.18,0.24,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,,,,,0,0.1,764.4346921,8,0,4,0,3,4
1181,04/06/2019 00:00,DB01397,Magnesium salicylate,,,,325 mg,Oral,solid,,,0.0686,2.79,-6.3,[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O,,,,,0,325,298.0327797,2,2,0,0,0,0
1182,04/06/2019 00:00,DB01399,Salsalate,"Salsalate is insoluble in acid gastric fluids (< 0.1 mg/ml at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged. The amount of salicylic acid available from salsalate is about 15% less than from aspirin, when the two drugs are administered on a salicylic acid molar equivalent basis (3.6 g salsalate/5 g aspirin). Food slows the absorption of all salicylates including salsalate.",90-95%,The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.,500 mg,Oral,solid,,,0.246,3.4,-4.3,OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O,0.9,0.95,,,0,500,258.0528234,2,2,0,0,0,0
1183,02/07/2019 00:00,DB01400,Neostigmine,Neostigmine bromide is poorly absorbed from the gastrointestinal tract following oral administration,,The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.,0.5 mg/1mL,Intramuscular; Intravenous; Subcutaneous,solid,,,0.0677,,,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C,,,,,1,,223.1441043,1,1,0,0,0,0
1184,02/07/2019 00:00,DB01403,Methotrimeprazine,"Methotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver. Oral bioavailability is approximately 50 to 60%.",,Approximately 20 hours.,2 mg,Oral,solid,20 mg/L (at 25 Â°C),4.68,0.00525,,9.42,COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1,,,,,0,2,328.1609344,3,2,1,0,0,1
1185,04/06/2019 00:00,DB01405,Temafloxacin,"Studies in healthy volunteers indicate that the average bioavailability of temafloxacin exceeds 90%, with little intersubject variability.",,Approximately 8 hours in patients with normal renal function.,,,solid,,-0.2,0.0144,5.6,8.76,CC1CN(CCN1)C1=C(F)C=C2C(=O)C(=CN(C2=C1)C1=C(F)C=C(F)C=C1)C(O)=O,,,,,0,,417.1300261,4,3,2,1,1,1
1186,02/07/2019 00:00,DB01406,Danazol,,,Approximately 24 hours.,100 mg,Oral,solid,,0.51,0.0176,17.59,0.25,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3,,,,,0,100,337.2041791,5,1,1,1,0,0
1187,04/06/2019 00:00,DB01407,Clenbuterol,89-98% orally,,36-39 hours,,,solid,,,0.112,14.06,9.63,CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1,,,36,39,0,,276.0796186,1,1,0,0,0,0
1188,04/06/2019 00:00,DB01408,Bambuterol,Bioavailability is 20% following oral administration.,,13 hours for bambuterol and 21 hours for the primary active metabolite terbutaline.,,,solid,,,0.469,13.91,9.52,CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C,,,,,0,,367.210721,1,1,0,0,0,0
1189,02/07/2019 00:00,DB01409,Tiotropium,Bioavailability is 19.5% following administration by inhalation. Oral solutions of tiotropium have an absolute bioavailability of 2-3%. ,0.72,5-6 days,18 ug/1,Respiratory (inhalation),solid,,,0.0156,10.35,-4.3,[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1,0.72,0.72,120,144,1,,392.0984766,5,2,5,2,3,3
1190,02/07/2019 00:00,DB01410,Ciclesonide,Ciclesonide and des-ciclesonide have negligible oral bioavailability (both less than 1%) due to low gastrointestinal absorption and high first-pass metabolism. The intranasal administration of ciclesonide at recommended doses results in negligible serum concentrations of ciclesonide.,0.99,,100 mcg,Respiratory (inhalation),solid,,,0.00157,14.78,-2.9,[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C,0.99,0.99,,,0,,540.3087037,6,0,1,0,1,1
1191,04/06/2019 00:00,DB01411,Pranlukast,,,,,,solid,,,0.0032,6.86,-1.7,O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1,,,,,0,,481.1750042,5,5,2,2,0,0
1192,04/06/2019 00:00,DB01412,Theobromine,,,,,,solid,330 mg/L (at 25 Â°C),-0.78,9.74,9.28,-0.91,CN1C=NC2=C1C(=O)NC(=O)N2C,,,,,0,,180.0647255,2,2,2,2,0,0
1193,02/07/2019 00:00,DB01413,Cefepime,The absolute bioavailability of cefepime after an IM dose of 50 mg/kg was 82.3 (&plusmn;15)% in eight patients.,0.2,2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.,1 g/1,Intramuscular; Intravenous,solid,,,0.0173,3.25,4.06,CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1,0.2,0.2,,,0,,480.1249599,4,1,4,1,2,3
1194,04/06/2019 00:00,DB01414,Cefacetrile,,0.38,1.2 hours,,,solid,,-0.45,2.43,3.31,-6.2,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC#N)C(O)=O,0.38,0.38,1.2,1.2,0,,339.0525061,2,0,2,0,1,2
1195,04/06/2019 00:00,DB01415,Ceftibuten,Rapidly absorbed following oral administration.,0.65,,400 mg/1,Oral,solid,,,0.0705,2.99,4.69,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O,0.65,0.65,,,0,400,410.0354762,3,1,3,1,1,2
1196,02/07/2019 00:00,DB01416,Cefpodoxime,"Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically.",0.33,2.09 to 2.84 hours,100 mg/5mL,Oral,solid,,,0.185,3.22,4.16,[H][C@]12SCC(COC)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,0.33,0.33,,,0,,427.0620253,3,1,3,1,1,2
1197,02/07/2019 00:00,DB01418,Acenocoumarol,Rapidly absorbed orally with greater than 60% bioavailability. Peak plasma levels are attained 1 to 3 hours following oral administration. ,0.987,8 to 11 hours.,1 mg,Oral,solid,practically insoluble,1.98,0.0106,5.79,-6.8,CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O,0.987,0.987,,,0,1,353.0899372,3,3,1,1,0,0
1198,04/06/2019 00:00,DB01419,Antrafenine,,,,,,solid,,,0.00284,16.69,7.04,FC(F)(F)C1=CC(=CC=C1)N1CCN(CCOC(=O)C2=CC=CC=C2NC2=C3C=CC(=CC3=NC=C2)C(F)(F)F)CC1,,,,,0,,588.1959954,5,4,2,1,1,1
1199,02/07/2019 00:00,DB01420,Testosterone propionate,"Testosterone propionate presents a slow absorption from the intramuscular site of administration. This slow absorption is due to the presence of the less polar ester group.[L1162] The absorption rate of testosterone propionate generates a frequent injection requirement when compared with testosterone enanthate or testosterone cypionate. It presents absorption parameters of AUC and residence time of 180-210 ng h/ml and 40-60 h, respectively.[A31625]",0.98,"Testosterone propionate presents a the shortest half life of all testosterone esters, being of 4.5 days. This characteristic produces a higher administration requirement.[L1159]",100 mg,Intramuscular,solid,1.48 mg/L (at 25ÂºC),,0.00502,19.09,-4.8,[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.98,0.98,,,0,,344.2351449,4,0,0,0,0,0
1200,02/07/2019 00:00,DB01421,Paromomycin,"Poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.",,,250 mg/1,Oral,solid,,,79.7,12.23,9.94,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,,,,,0,250,615.2963011,4,0,3,0,3,3
1201,04/06/2019 00:00,DB01422,Nitroxoline,,,,,,solid,,1.99,2.73,6.88,2.08,OC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O,,,,,0,,190.0378421,2,2,1,1,0,0
1202,04/06/2019 00:00,DB01423,Stepronin,,,,,,solid,,,0.211,3.56,-4.6,CC(SC(=O)C1=CC=CS1)C(=O)NCC(O)=O,,,,,0,,273.0129498,1,1,1,1,0,0
1203,04/06/2019 00:00,DB01424,Aminophenazone,,,,,,solid,5.44E+004 mg/L (at 30 Â°C),1,22.5,,3.47,CN(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1,,,,,0,,231.1371622,2,2,1,1,0,0
1204,04/06/2019 00:00,DB01425,Alizapride,,,3 hours,,,solid,,1.79,0.495,8.86,7.77,COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C,,,3,3,0,,315.1695249,3,2,2,1,1,1
1205,04/06/2019 00:00,DB01426,Ajmaline,,,,,,solid,490 mg/L (at 30 Â°C),1.81,4.09,13.28,7.2,CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=CC=CC=C5[C@]44C[C@@H](C2[C@H]4O)N3[C@@H]1O,,,,,0,,326.1994281,7,1,5,0,4,5
1206,04/06/2019 00:00,DB01427,Amrinone,,0.49,5 to 8 hours,5 mg/1mL,Intravenous,solid,,,5.6,11.01,4.87,NC1=CC(=CNC1=O)C1=CC=NC=C1,0.49,0.49,,,0,,187.0745619,2,2,2,2,0,0
1207,04/06/2019 00:00,DB01428,Oxybenzone,,,,0.05 g/100g,Topical,solid,,3.79,0.128,8.07,-4.8,COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1,,,,,0,,228.0786442,2,2,0,0,0,0
1208,04/06/2019 00:00,DB01429,Aprindine,,,,,,solid,,4.86,0.00782,,9.94,CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C1=CC=CC=C1,,,,,0,,322.240899,3,2,0,0,0,0
1209,04/06/2019 00:00,DB01430,Almitrine,,,,,,solid,,,0.0144,14.27,7.49,FC1=CC=C(C=C1)C(N1CCN(CC1)C1=NC(NCC=C)=NC(NCC=C)=N1)C1=CC=C(F)C=C1,,,,,0,,477.2452504,4,3,2,1,1,1
1210,04/06/2019 00:00,DB01431,Allylestrenol,,,,,,solid,,,0.000558,,-0.17,[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],,,,,0,,300.2453156,4,0,0,0,0,0
1211,04/06/2019 00:00,DB01433,Methadyl acetate,,,,,,solid,,4.27,0.00179,,9.87,CCC(OC(C)=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,353.2354792,2,2,0,0,0,0
1212,04/06/2019 00:00,DB01434,19-norandrostenedione,"Absorption appears variable, but some absorption does occur.",,,,,solid,,,0.0454,19.19,-4.7,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],,,,,0,,272.17763,4,0,0,0,0,0
1213,04/06/2019 00:00,DB01435,Antipyrine,,,,,Topical,solid,5.19E+004 mg/L (at 25 Â°C),0.38,47.4,,0.49,CN1N(C(=O)C=C1C)C1=CC=CC=C1,,,,,0,,188.094963,2,2,1,1,0,0
1214,02/07/2019 00:00,DB01436,Alfacalcidol,,,,0.25 mcg,Oral,solid,,,0.00163,14.39,-2.8,CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,,,,,0,0.00025,400.3341306,3,0,0,0,0,0
1215,04/06/2019 00:00,DB01437,Glutethimide,Variable,,10-12 hours,,,solid,999 mg/L (at 30 Â°C),1.9,0.327,11.69,-6.7,CCC1(CCC(=O)NC1=O)C1=CC=CC=C1,,,10,12,0,,217.1102787,2,1,1,0,1,1
1216,02/07/2019 00:00,DB01438,Phenazopyridine,,,7.35 hours,95 mg/1,Oral,solid,,,0.202,18.85,6.86,NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1,,,7.35,7.35,0,95,213.1014454,2,2,1,1,0,0
1217,04/06/2019 00:00,DB01439,3-Methylthiofentanyl,,,,,,solid,,,0.018,,9.07,CCC(=O)N(C1CCN(CCC2=CC=CS2)CC1C)C1=CC=CC=C1,,,,,0,,356.1922345,3,2,2,1,1,1
1218,04/06/2019 00:00,DB01440,gamma-Hydroxybutyric acid,,,30 to 60 minutes,,,solid,,,494,4.44,-2.4,OCCCC(O)=O,,,,,0,,104.0473441,0,0,0,0,0,0
1219,04/06/2019 00:00,DB01441,"5-Methoxy-N,N-diisopropyltryptamine",5-MeO-DIPT produces effects with an onset of 20 to 30 minutes and with peak effects occurring between 1 to 1.5 hours after administration. ,,,,,solid,,,0.0673,17.44,10.68,COC1=CC2=C(NC=C2CCN(C(C)C)C(C)C)C=C1,,,,,0,,274.2045135,2,2,1,1,0,0
1220,04/06/2019 00:00,DB01442,MMDA,,,,,,solid,,,2.71,,9.99,COC1=CC(CC(C)N)=CC2=C1OCO2,,,,,0,,209.1051933,2,1,1,0,0,1
1221,04/06/2019 00:00,DB01443,19-Nor-5-androstenedione,,,,,,solid,,,0.0621,16.25,-7.2,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)CC3=CC[C@@]21[H],,,,,0,,272.17763,4,0,0,0,0,0
1222,04/06/2019 00:00,DB01444,Dimethylthiambutene,,,,,,liquid,,,0.0839,,8.67,CC(C=C(C1=CC=CS1)C1=CC=CS1)N(C)C,,,,,0,,263.0802415,2,2,2,2,0,0
1223,04/06/2019 00:00,DB01445,Bufotenine,Rapidly absorbed following intravenous administration.,,,,,solid,,,3.2,9.23,9.91,CN(C)CCC1=CNC2=C1C=C(O)C=C2,,,,,0,,204.1262631,2,2,1,1,0,0
1224,04/06/2019 00:00,DB01446,Indopan,,,,,,solid,,,1.15,17.14,9.96,CC(N)CC1=CNC2=CC=CC=C12,,,,,0,,174.1156984,2,2,1,1,0,0
1225,04/06/2019 00:00,DB01447,4-Methylaminorex,,,,,,solid,,,0.468,,7.24,CC1N=C(N)OC1C1=CC=CC=C1,,,,,0,,176.094963,2,1,1,0,0,1
1226,04/06/2019 00:00,DB01450,Dihydroetorphine,,,,,,solid,,,0.114,7.5,11.87,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)CCC,,,,,0,,413.2566086,7,1,2,0,1,2
1227,04/06/2019 00:00,DB01451,1-Androstenedione,,,,,,solid,,,0.0051,19.96,-4.9,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)C=C[C@]34C)[C@@H]1CCC2=O,,,,,0,,286.1932801,4,0,0,0,0,0
1228,04/06/2019 00:00,DB01452,Diamorphine,"Bioavailability is less than 35% when orally administered [A173668]. In particular, some studies have determined that the bioavailability of orally administered diamorphine could be as low as 22.9% (16.4-29.4%) on average in opioid-naive subjects [A173683].

Nevertheless, diamorphine administered by any many medically indicated routes of administration leads to a rapid absorption [L4996]. Peak serum levels are achieved five to ten minutes subcutaneously, three to five minutes intranasally and intramuscularly, and less than one minute intravenously [L4996].",0.35,"In man, administered diamorphine has a half-life of approximately two to three minutes [L4999]. ",100 mg,Intramuscular; Intravenous; Subcutaneous,solid,600 mg/L (at 25 Â°C),1.58,0.266,,9.1,[H][C@@]12C=C[C@H](OC(C)=O)[C@@H]3OC4=C(OC(C)=O)C=CC5=C4[C@]13CCN(C)[C@@H]2C5,0.35,0.35,,,0,,369.1576228,5,1,2,0,1,2
1229,04/06/2019 00:00,DB01453,Beta-hydroxyfentanyl,,,,,,solid,,,0.114,14.11,8.28,CCC(=O)N(C1CCN(CC(O)C2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,352.2150781,3,2,1,0,1,1
1230,04/06/2019 00:00,DB01454,Midomafetamine,,,6â€“10 (though duration of effects is typically actually 3â€“5 hours),,,solid,,,3.22,,10.14,CNC(C)CC1=CC2=C(OCO2)C=C1,,,,,0,,193.1102787,2,1,1,0,0,1
1231,04/06/2019 00:00,DB01455,19-Nor-5-androstenediol,,,,,,solid,,,0.0645,18.23,-0.77,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](O)CC3=CC[C@@]21[H],,,,,0,,276.2089301,4,0,0,0,0,0
1232,04/06/2019 00:00,DB01456,5-androstenedione,,,,,,solid,,,0.0366,16.23,-7.2,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2CC(=O)CC[C@]12C,,,,,0,,286.1932801,4,0,0,0,0,0
1233,04/06/2019 00:00,DB01458,"2,5-Dimethoxy-4-(n)-propylthiophenethylamine",,,,,,solid,,,0.101,,9.69,CCCSC1=CC(OC)=C(CCN)C=C1OC,,,,,0,,255.1292999,1,1,0,0,0,0
1234,04/06/2019 00:00,DB01459,Bezitramide,"Bezitramide has poor water solubility, thus administration is restricted to the oral route. [A14383]",,11-24h. [A14383],,,solid,Poor water solubility ,4.8,0.0067,,8.32,CCC(=O)N1C(=O)N(C2CCN(CCC(C#N)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C2=CC=CC=C12,,,11,24,0,,492.2525263,5,4,2,1,1,1
1235,04/06/2019 00:00,DB01460,Diethyltryptamine,,,,,,solid,,,0.353,17.16,10.08,CCN(CC)CCC1=CNC2=CC=CC=C12,,,,,0,,216.1626486,2,2,1,1,0,0
1236,04/06/2019 00:00,DB01461,Dimenoxadol,,,,,,solid,,,0.0304,,8.42,CCOC(C(=O)OCCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,327.1834437,2,2,0,0,0,0
1237,04/06/2019 00:00,DB01462,Etonitazene,,,,,,solid,,,0.0121,,9.63,CCOC1=CC=C(CC2=NC3=C(C=CC(=C3)[N+]([O-])=O)N2CCN(CC)CC)C=C1,,,,,0,,396.2161408,3,3,1,1,0,0
1238,04/06/2019 00:00,DB01463,Fencamfamin,,,,,,solid,,3.2,0.00295,,10.56,CCNC1C2CCC(C2)C1C1=CC=CC=C1,,,,,0,,215.1673997,3,1,0,0,0,0
1239,04/06/2019 00:00,DB01464,Furethidine,,,,,,solid,,,0.0485,,7.98,CCOC(=O)C1(CCN(CCOCC2CCCO2)CC1)C1=CC=CC=C1,,,,,0,,361.2253085,3,1,2,0,2,2
1240,04/06/2019 00:00,DB01465,"2,5-Dimethoxyamphetamine",,,,,,solid,,1.72,1.25,,9.91,COC1=CC(CC(C)N)=C(OC)C=C1,,,,,0,,195.1259288,1,1,0,0,0,0
1241,04/06/2019 00:00,DB01466,Ethylmorphine,,,,,,solid,2610 mg/L (at 20 Â°C),,0.835,13.78,9.19,[H][C@@]12OC3=C(OCC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,,,,,0,,313.1677936,5,1,2,0,1,2
1242,04/06/2019 00:00,DB01467,"2,5-Dimethoxy-4-ethylamphetamine",,,,,,solid,,2.81,0.413,,9.93,CCC1=CC(OC)=C(CC(C)N)C=C1OC,,,,,0,,223.1572289,1,1,0,0,0,0
1243,04/06/2019 00:00,DB01468,Ethylmethylthiambutene,,,,,,solid,,,0.0676,,8.94,CCN(C)C(C)C=C(C1=CC=CS1)C1=CC=CS1,,,,,0,,277.0958916,2,2,2,2,0,0
1244,04/06/2019 00:00,DB01469,Acetorphine,,,,,,solid,,,0.0197,14.68,8.97,[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@@]11C[C@]([H])([C@](C)(O)CCC)[C@]2(OC)C=C1,,,,,0,,453.2515232,7,1,2,0,1,2
1245,04/06/2019 00:00,DB01470,Î±-methylthiofentanyl,,,,,,solid,,,0.0186,,8.98,CCC(=O)N(C1CCN(CC1)C(C)CC1=CC=CS1)C1=CC=CC=C1,,,,,0,,356.1922345,3,2,2,1,1,1
1246,04/06/2019 00:00,DB01471,Bolasterone,,,,,,solid,,,0.0112,19.56,-0.53,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](C)CC2=CC(=O)CC[C@]12C,,,,,0,,316.2402303,4,0,0,0,0,0
1247,04/06/2019 00:00,DB01472,4-Methoxyamphetamine,,,,,,solid,,,0.928,,10.04,COC1=CC=C(CC(C)N)C=C1,,,,,0,,165.1153641,1,1,0,0,0,0
1248,04/06/2019 00:00,DB01473,Betaprodine,,,,,,solid,,,0.475,,8.9,[H][C@@]1(C)CN(C)CC[C@]1(OC(=O)CC)C1=CC=CC=C1,,,,,0,,261.172879,2,1,1,0,1,1
1249,04/06/2019 00:00,DB01474,"17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene",,,,,,solid,,,0.0339,17.5,-0.5,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,,,,,0,,304.2402303,4,0,0,0,0,0
1250,04/06/2019 00:00,DB01475,Dioxaphetyl butyrate,,,,,,solid,,,0.0154,,6.88,CCOC(=O)C(CCN1CCOCC1)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,353.1990937,3,2,1,0,1,1
1251,04/06/2019 00:00,DB01476,Haloxazolam,,,,,,solid,,,0.0308,12.68,2.22,FC1=CC=CC=C1C12OCCN1CC(=O)NC1=C2C=C(Br)C=C1,,,,,0,,376.022268,4,2,2,0,1,2
1252,04/06/2019 00:00,DB01477,Codeine methylbromide,,,,,,solid,2.6E+005 mg/L,,0.000959,13.78,-3.3,[Br-].[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CC[N+](C)(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,,,,,0,,393.0939557,5,1,2,0,1,2
1253,04/06/2019 00:00,DB01478,Desmethylprodine,,,,,,solid,,,1.22,,8.58,CCC(=O)OC1(CCN(C)CC1)C1=CC=CC=C1,,,,,0,,247.1572289,2,1,1,0,1,1
1254,04/06/2019 00:00,DB01479,BA-2664,,,,,,solid,,,0.00469,18.3,-0.47,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,,,,,0,,306.2558803,4,0,0,0,0,0
1255,04/06/2019 00:00,DB01480,Cyprenorphine,,,,,,solid,,,0.0582,10.35,9.54,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@@]11C[C@]([H])(C(C)(C)O)[C@]2(OC)C=C1,,,,,0,,423.2409585,8,1,2,0,1,2
1256,04/06/2019 00:00,DB01481,1-Testosterone,,,,,,solid,,,0.0128,19.38,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C,,,,,0,,288.2089301,4,0,0,0,0,0
1257,04/06/2019 00:00,DB01483,Barbital,,,,,,solid,7460 mg/L (at 25 Â°C),0.65,3.23,8.48,,CCC1(CC)C(=O)NC(=O)NC1=O,,,,,0,,184.0847922,1,0,1,0,1,1
1258,04/06/2019 00:00,DB01484,"4-Bromo-2,5-dimethoxyamphetamine",,,,,,solid,,2.58,0.0948,,9.9,COC1=CC(Br)=C(OC)C=C1CC(C)N,,,,,0,,273.0364409,1,1,0,0,0,0
1259,04/06/2019 00:00,DB01485,4-Hydroxytestosterone,,,"

",,,solid,,,0.068,9.28,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C,,,,,0,,304.2038448,4,0,0,0,0,0
1260,04/06/2019 00:00,DB01486,Cathine,"The mucosa of the oral cavity is considered to be the first absorption segment, where the major proportion of the alkaloids is absorbed (mean +/- SD: 84 +/- 6% for cathine). [PMID: 12848785]",,5.2 +/- 3.4 hours,,,solid,2E+004 mg/L (at 25 Â°C),0.83,20.6,13.9,9.37,C[C@H](N)[C@@H](O)C1=CC=CC=C1,,,,,0,,151.099714,1,1,0,0,0,0
1261,04/06/2019 00:00,DB01487,Embutramide,,,,,,solid,,,0.0417,15.63,-0.062,CCC(CC)(CNC(=O)CCCO)C1=CC(OC)=CC=C1,,,,,0,,293.1990937,1,1,0,0,0,0
1262,04/06/2019 00:00,DB01488,Dimethyltryptamine,,,,,,solid,,,1.69,17.16,9.55,CN(C)CCC1=CNC2=CC=CC=C12,,,,,0,,188.1313485,2,2,1,1,0,0
1263,04/06/2019 00:00,DB01489,Camazepam,Almost completely absorbed into the bloodstream after oral administration. 90% bioavailability can be achieved in humans. ,,,,,solid,,,0.0182,,-1.7,CN(C)C(=O)OC1N=C(C2=CC=CC=C2)C2=C(C=CC(Cl)=C2)N(C)C1=O,,,,,0,,371.1036691,3,2,1,0,0,1
1264,04/06/2019 00:00,DB01490,Aminorex,,,,,,solid,,,0.792,19.48,7.49,NC1=NCC(O1)C1=CC=CC=C1,,,,,0,,162.0793129,2,1,1,0,0,1
1265,04/06/2019 00:00,DB01491,Dipipanone,,,,,,solid,,,0.000757,18.77,9.3,CCC(=O)C(CC(C)N1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,349.2405646,3,2,1,0,1,1
1266,04/06/2019 00:00,DB01493,Ethylestrenol,,,,,,solid,,,0.00086,,-0.27,[H][C@@]12CC[C@@](O)(CC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],,,,,0,,288.2453156,4,0,0,0,0,0
1267,04/06/2019 00:00,DB01495,Dichloralphenazone,,,,,Oral,solid,,,47.4,,0.49,OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1,,,,,0,,515.9346878,2,2,1,1,0,0
1268,04/06/2019 00:00,DB01496,Barbituric acid derivative,,,,,,solid,,,0.0206,3.41,-2.8,FC(F)(F)C1=CC=CC=C1C1=CC=C(CC2C(=O)NC(=S)NC2=O)O1,,,,,0,,368.0442479,3,2,2,1,1,1
1269,04/06/2019 00:00,DB01497,Etorphine,,,,,,solid,,2.79,0.112,7.48,11.72,[H][C@]12CC3=C4C(OC5[C@@]4(CCN1C)[C@]21CC(C(C)(O)CCC)C5(OC)C=C1)=C(O)C=C3,,,,,0,,411.2409585,7,1,2,0,1,2
1270,04/06/2019 00:00,DB01498,Alphamethadol,,,,,,solid,,,0.0128,14.52,9.57,CC[C@@H](O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,311.2249145,2,2,0,0,0,0
1271,04/06/2019 00:00,DB01499,Alphameprodine,,,,,,solid,,,0.211,,9.1,CC[C@H]1CN(C)CC[C@]1(OC(=O)CC)C1=CC=CC=C1,,,,,0,,275.188529,2,1,1,0,1,1
1272,04/06/2019 00:00,DB01500,Oxabolone,,,,,,solid,,,0.0883,9.3,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C(O)=C3CC[C@@]21[H],,,,,0,,290.1881947,4,0,0,0,0,0
1273,04/06/2019 00:00,DB01501,Difenoxin,"A high percentage of Motofen(R) is absorbed, and absorption occurs rapidly.
Peak plasma concentrations are achieved within 40-60 minutes. [Lexicomp, 2013]  ",,The elimination half life was calculated to be 7.24 hours. The appearance half life was calculated to be 0.82h. [3] ,,Oral,solid,,,0.00208,3.38,9.41,OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,424.2150781,4,3,1,0,1,1
1274,04/06/2019 00:00,DB01502,Diampromide,,,,,,solid,,,0.0276,,8.74,CCC(=O)N(CC(C)N(C)CCC1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,324.2201635,2,2,0,0,0,0
1275,04/06/2019 00:00,DB01503,1-Androstenediol,,,,,,solid,,,0.0348,17.5,-0.82,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)C=C[C@]34C)[C@@H]1CC[C@@H]2O,,,,,0,,290.2245802,4,0,0,0,0,0
1276,04/06/2019 00:00,DB01505,Etoxeridine,,,,,,solid,,,1.37,15.12,8.02,CCOC(=O)C1(CCN(CCOCCO)CC1)C1=CC=CC=C1,,,,,0,,321.1940083,2,1,1,0,1,1
1277,04/06/2019 00:00,DB01506,1-Phenylcyclohexylamine,,,,,,solid,,,0.0573,,10.05,NC1(CCCCC1)C1=CC=CC=C1,,,,,0,,175.1360995,2,1,0,0,0,0
1278,04/06/2019 00:00,DB01509,Tenamfetamine,,,,,,solid,,1.64,2.83,,10.01,CC(N)CC1=CC2=C(OCO2)C=C1,,,,,0,,179.0946287,2,1,1,0,0,1
1279,04/06/2019 00:00,DB01511,Delorazepam,"77-87% oral bioavailability, with a relatively slow absorption rate. [5] Reaches peak plasma levels within 1-2 hours of administration. Food may slow absorption, however other pharmacokinetic variables remain unchanged. After multiple doses delorazepam accumulates, however accumulation is slower in younger patients.[1]",>90%,"Very long elimination half life of 80-115 hours, varying with age. Elimination is slower as age increases. [1] Liver disease also impacts elimination half life, with impairment resulting in half lives up to 395 hours. [2] ",,,solid,,3.15,0.00642,12.29,2.05,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,0.9,1,,,0,,304.0170183,3,2,1,0,0,1
1280,04/06/2019 00:00,DB01512,Hydromorphinol,,,,,,solid,,,20.6,7.44,11.56,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CC[C@@H]2O,,,,,0,,303.1470582,5,1,2,0,1,2
1281,04/06/2019 00:00,DB01513,"17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane",,,,,,solid,,,0.00469,18.3,-0.47,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,,,,,0,,306.2558803,4,0,0,0,0,0
1282,04/06/2019 00:00,DB01514,Furazabol,,,,,,solid,,,0.0277,,-0.51,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NON=C3C[C@]12C,,,,,0,,330.2307282,5,1,1,1,0,0
1283,04/06/2019 00:00,DB01515,Benzoylecgonine,,,,,,solid,,,3.82,3.15,9.54,[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(O)=O)N2C,,,,,0,,289.1314081,3,1,2,0,2,2
1284,04/06/2019 00:00,DB01516,"3,4,5-Trimethoxyamphetamine",,,,,,solid,,1.21,0.479,,10,COC1=CC(CC(C)N)=CC(OC)=C1OC,,,,,0,,225.1364935,1,1,0,0,0,0
1285,04/06/2019 00:00,DB01518,Benzethidine,,,,,,solid,,,0.00673,,8.11,CCOC(=O)C1(CCN(CCOCC2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,367.2147438,3,2,1,0,1,1
1286,04/06/2019 00:00,DB01520,Tenocyclidine,,,,,,solid,,,0.0313,,10.44,C1CCN(CC1)C1(CCCCC1)C1=CC=CS1,,,,,0,,249.1551207,3,1,2,1,1,1
1287,04/06/2019 00:00,DB01521,Clostebol,,,,,,solid,,,0.0153,19.31,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C,,,,,0,,322.1699578,4,0,0,0,0,0
1288,04/06/2019 00:00,DB01522,Betacetylmethadol,,,,,,solid,,,0.00179,,9.87,CC[C@H](OC(C)=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,353.2354792,2,2,0,0,0,0
1289,04/06/2019 00:00,DB01523,Clonitazene,,,,,,solid,,,0.0111,,9.63,CCN(CC)CCN1C(CC2=CC=C(Cl)C=C2)=NC2=C1C=CC(=C2)[N+]([O-])=O,,,,,0,,386.1509537,3,3,1,1,0,0
1290,04/06/2019 00:00,DB01524,Androstenediol,,,,,,solid,,,0.055,18.2,-0.77,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C,,,,,0,,290.2245802,4,0,0,0,0,0
1291,04/06/2019 00:00,DB01525,Ecgonine,,,,,,solid,1.78E+005 mg/L,,1050,3.48,9.69,[H][C@]12CC[C@]([H])([C@H]([C@@H](O)C1)C(O)=O)N2C,,,,,0,,185.1051933,2,0,2,0,2,2
1292,04/06/2019 00:00,DB01526,4-Androstenediol,,,,,,solid,,,0.0481,17.5,-0.82,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C[C@@H](O)CC[C@]12C,,,,,0,,290.2245802,4,0,0,0,0,0
1293,04/06/2019 00:00,DB01527,Clortermine,,,,,,solid,,,0.104,,10.16,CC(C)(N)CC1=CC=CC=C1Cl,,,,,0,,183.0814771,1,1,0,0,0,0
1294,04/06/2019 00:00,DB01528,"4-Methyl-2,5-dimethoxyamphetamine",,,,,,solid,,2.24,0.969,,9.94,COC1=CC(CC(C)N)=C(OC)C=C1C,,,,,0,,209.1415788,1,1,0,0,0,0
1295,04/06/2019 00:00,DB01529,Dextromoramide,,,,,,solid,,3.61,0.0175,,7.77,C[C@H](CN1CCOCC1)C(C(=O)N1CCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,392.2463783,4,2,2,0,2,2
1296,04/06/2019 00:00,DB01530,"5alpha-androstane-3alpha,17beta-diol",,,,,,solid,,,0.0193,18.3,-0.76,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)CC[C@]12C,,,,,0,,292.2402303,4,0,0,0,0,0
1297,04/06/2019 00:00,DB01531,Desomorphine,,,,,,solid,,,0.86,10.35,9.38,[H][C@@]12CCC[C@@]3([H])[C@@]4([H])CC5=CC=C(O)C(O1)=C5[C@@]23CCN4C,,,,,0,,271.1572289,5,1,2,0,1,2
1298,04/06/2019 00:00,DB01532,Î±-Methylacetylfentanyl,,,,,,solid,,,0.022,,9.01,CC(CC1=CC=CC=C1)N1CCC(CC1)N(C(C)=O)C1=CC=CC=C1,,,,,0,,336.2201635,3,2,1,0,1,1
1299,04/06/2019 00:00,DB01533,Diethylthiambutene,,,,,,solid,,,0.0539,,9.22,CCN(CC)C(C)C=C(C1=CC=CS1)C1=CC=CS1,,,,,0,,291.1115417,2,2,2,2,0,0
1300,04/06/2019 00:00,DB01534,Chlorhexadol,,,,,,solid,,,1.24,9.67,-2.7,CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl,,,,,0,,264.0086774,0,0,0,0,0,0
1301,04/06/2019 00:00,DB01535,Carfentanil,,,,,,solid,,,0.0259,,8.05,CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC2=CC=CC=C2)CC1)C(=O)OC,,,,,0,,394.2256428,3,2,1,0,1,1
1302,04/06/2019 00:00,DB01536,Androstenedione,,,,,,solid,57.8 mg/L (at 25 Â°C),2.75,0.027,19.03,-4.8,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,286.1932801,4,0,0,0,0,0
1303,04/06/2019 00:00,DB01537,"4-Bromo-2,5-dimethoxyphenethylamine",,,,,,solid,,,0.199,,9.68,COC1=CC(Br)=C(OC)C=C1CCN,,,,,0,,259.0207908,1,1,0,0,0,0
1304,04/06/2019 00:00,DB01538,Acetyldihydrocodeine,,,,,,solid,,,0.134,,9.3,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC[C@@H]2OC(C)=O,,,,,0,,343.1783583,5,1,2,0,1,2
1305,04/06/2019 00:00,DB01539,1-Piperidinocyclohexanecarbonitrile,,,,,,solid,,,0.522,,6.98,N#CC1(CCCCC1)N1CCCCC1,,,,,0,,192.1626486,2,0,1,0,1,1
1306,04/06/2019 00:00,DB01540,17alpha-methyl-4-hydroxynandrolone,,,,,,solid,,,0.0575,9.33,-0.53,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C(O)=C3CC[C@@]21[H],,,,,0,,304.2038448,4,0,0,0,0,0
1307,04/06/2019 00:00,DB01541,Boldenone,,,14 days,,,solid,,,0.0259,18.86,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,336,336,0,,286.1932801,4,0,0,0,0,0
1308,04/06/2019 00:00,DB01542,Allylprodine,,,,,,solid,,2.97,0.0462,,9.19,CCC(=O)OC1(CCN(C)CC1CC=C)C1=CC=CC=C1,,,,,0,,287.188529,2,1,1,0,1,1
1309,04/06/2019 00:00,DB01543,18-methyl-19-nortestosterone,,,,,,solid,,,0.0302,19.28,-0.75,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O,,,,,0,,288.2089301,4,0,0,0,0,0
1310,04/06/2019 00:00,DB01544,Flunitrazepam,50% (suppository) and 64-77% (oral),,18-26 hours,,,solid,,2.06,0.00858,,1.7,CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F,,,18,26,0,,313.0862695,3,2,1,0,0,1
1311,04/06/2019 00:00,DB01545,Ethyl loflazepate,,,,,,solid,,,0.00525,9.51,-1.4,CCOC(=O)C1N=C(C2=CC=CC=C2F)C2=C(NC1=O)C=CC(Cl)=C2,,,,,0,,360.0676982,3,2,1,0,0,1
1312,04/06/2019 00:00,DB01546,Etryptamine,,,,,,solid,510 mg/L,,0.481,17.13,9.99,CCC(N)CC1=CNC2=CC=CC=C12,,,,,0,,188.1313485,2,2,1,1,0,0
1313,04/06/2019 00:00,DB01547,Drotebanol,,,,,,solid,,,2.15,13.64,8.9,[H][C@]12CC3=C(C(OC)=C(OC)C=C3)[C@@]3(CCN1C)C[C@H](O)CC[C@@]23O,,,,,0,,333.1940083,4,1,1,0,1,1
1314,04/06/2019 00:00,DB01548,Diprenorphine,,,,,,solid,,,0.104,10.42,9.63,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@H](C1)C(C)(C)O,,,,,0,,425.2566086,8,1,2,0,1,2
1315,04/06/2019 00:00,DB01549,Rolicyclidine,,,,,,solid,,,0.0239,,10.78,C1CCN(C1)C1(CCCCC1)C1=CC=CC=C1,,,,,0,,229.1830497,3,1,1,0,1,1
1316,04/06/2019 00:00,DB01550,Fenproporex,,,,,,solid,,,0.184,,7.88,CC(CC1=CC=CC=C1)NCCC#N,,,,,0,,188.1313485,1,1,0,0,0,0
1317,04/06/2019 00:00,DB01551,Dihydrocodeine,"Bioavailability is low (approximately 20%) if administered orally. This may be due to poor gastrointestinal absorption. It is also likely due to pre-systemic metabolism by the liver and intestinal wall. [2] 

The AUCs after oral and intravenous administration are similar (3203ug/l/h and 3401ug/l/h, respectively). [2]


Time to peak values are 1.6 and 1.8hours for a 30mg and 60mg dose, respectively. The concentrations achieved were 71.8 ug/1 and 146 ug/1, respectively. [2]",,4h,,Oral,solid,,,2.38,14.15,9.33,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC[C@@H]2O,,,,,0,,301.1677936,5,1,2,0,1,2
1318,04/06/2019 00:00,DB01552,Betameprodine,,,,,,solid,1.43 mg/L at 25Â°C,3.61,0.211,,9.1,CC[C@@H]1CN(C)CC[C@]1(OC(=O)CC)C1=CC=CC=C1,,,,,0,,275.188529,2,1,1,0,1,1
1319,04/06/2019 00:00,DB01553,Cloxazolam,,,65 hours,,,solid,,,0.0266,12.69,2.6,ClC1=CC2=C(NC(=O)CN3CCOC23C2=CC=CC=C2Cl)C=C1,,,65,65,0,,348.043233,4,2,2,0,1,2
1320,04/06/2019 00:00,DB01554,Bolandiol,,,,,,solid,,,0.0566,17.52,-0.82,C[C@]12CC[C@H]3[C@@H](CCC4=C[C@@H](O)CC[C@H]34)[C@@H]1CC[C@@H]2O,,,,,0,,276.2089301,4,0,0,0,0,0
1321,04/06/2019 00:00,DB01555,Alphacetylmethadol,,,,,,solid,,,0.00179,,9.87,CC[C@@H](OC(C)=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,353.2354792,2,2,0,0,0,0
1322,04/06/2019 00:00,DB01556,Chlorphentermine,Well absorbed following oral administration.,,40 hours,,,solid,,2.6,0.105,,10.24,CC(C)(N)CC1=CC=C(Cl)C=C1,,,40,40,0,,183.0814771,1,1,0,0,0,0
1323,04/06/2019 00:00,DB01557,Î±-Methylfentanyl,,,,,,solid,,,0.014,,9,CCC(=O)N(C1CCN(CC1)C(C)CC1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,350.2358136,3,2,1,0,1,1
1324,02/07/2019 00:00,DB01558,Bromazepam,Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration. ,0.7,10-20 hours,1.5 mg,Oral,solid,,2.05,0.0399,12.24,2.68,BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1,0.7,0.7,10,20,0,1.5,315.000724,3,2,2,1,0,1
1325,04/06/2019 00:00,DB01559,Clotiazepam,,0.99,4 hours,,,solid,,3.18,0.00537,,2.39,CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl,0.99,0.99,4,4,0,,318.0593618,3,2,2,1,0,1
1326,04/06/2019 00:00,DB01560,Cathinone,,,,,,solid,,,2.46,18.65,7.55,C[C@H](N)C(=O)C1=CC=CC=C1,,,,,0,,149.084064,1,1,0,0,0,0
1327,04/06/2019 00:00,DB01561,Androstanedione,,,,,,solid,,,0.00739,19.78,-7.1,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C,,,,,0,,288.2089301,4,0,0,0,0,0
1328,04/06/2019 00:00,DB01562,1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine,,,,,,solid,,,0.00592,,9.24,CC(=O)OC1(CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,323.188529,3,2,1,0,1,1
1329,02/07/2019 00:00,DB01563,Chloral hydrate,"Rapidly absorbed in the GI tract following oral or rectal administration. Chloral hydrate and its active metabolite, trichloroethanol, have been detected in CSF, umbilical cord blood, fetal blood, and amniotic fluid. ",,,100 mg,Oral,solid,7.93E+005 mg/L (at 25 Â°C),0.99,43.4,9.51,-5.1,OC(O)C(Cl)(Cl)Cl,,,,,0,100,163.9198624,0,0,0,0,0,0
1330,04/06/2019 00:00,DB01564,Calusterone,,,,,,solid,,,0.0112,19.56,-0.53,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](C)CC2=CC(=O)CC[C@]12C,,,,,0,,316.2402303,4,0,0,0,0,0
1331,04/06/2019 00:00,DB01565,Dihydromorphine,,,,,,solid,,,1.82,10.29,9.24,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC[C@@H]2O,,,,,0,,287.1521435,5,1,2,0,1,2
1332,04/06/2019 00:00,DB01566,Methylenedioxyethamphetamine,,,,,,solid,,,1.46,,10.22,CCNC(C)CC1=CC2=C(OCO2)C=C1,,,,,0,,207.1259288,2,1,1,0,0,1
1333,04/06/2019 00:00,DB01567,Fludiazepam,,,,,,solid,,2.75,0.0144,,1.89,CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F,,,,,0,,302.0622189,3,2,1,0,0,1
1334,04/06/2019 00:00,DB01568,Codeine-N-oxide,,,,,,solid,,,0.138,13.78,2.75,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CC[N@+](C)([O-])[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,,,,,0,,315.1470582,5,1,2,0,1,2
1335,04/06/2019 00:00,DB01569,Formebolone,,,,,,solid,,,0.0605,14.39,-2.9,[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C(C=O)=C[C@]12C,,,,,0,,344.1987594,4,0,0,0,0,0
1336,04/06/2019 00:00,DB01570,Ohmefentanyl,,,,,,solid,,,0.0865,14.11,8.59,CCC(=O)N(C1CCN(CC(O)C2=CC=CC=C2)CC1C)C1=CC=CC=C1,,,,,0,,366.2307282,3,2,1,0,1,1
1337,04/06/2019 00:00,DB01571,3-Methylfentanyl,,,,,,solid,,,0.015,,9.08,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1C)C1=CC=CC=C1,,,,,0,,350.2358136,3,2,1,0,1,1
1338,04/06/2019 00:00,DB01572,Methyl-1-testosterone,,,,,,solid,,,0.00401,,-0.53,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C,,,,,0,,302.2245802,4,0,0,0,0,0
1339,04/06/2019 00:00,DB01573,Benzylmorphine,,,,,,solid,400 mg/L,,0.0456,13.78,9.19,[H][C@@]12OC3=C(OCC4=CC=CC=C4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,,,,,0,,375.1834437,6,2,2,0,1,2
1340,02/07/2019 00:00,DB01576,Dextroamphetamine,"Bioavailability data of dextroamphetamine is not readily available, however there is no difference in bioavailability when taken with or without a meal[Label].",,11.75 hours[Label]. In a study of post-stroke patients the half life was 16.0 hours in females and 12.4 hours in males[A2505]. Studies in healthy populations show a half life of 7.9 hours[A177247].,10 mg/1,Oral,liquid,Moderately Soluble,,1.74,,10.01,C[C@H](N)CC1=CC=CC=C1,,,,,0,10,135.1047994,1,1,0,0,0,0
1341,04/06/2019 00:00,DB01577,Metamfetamine,"Methamphetamine is rapidly absorbed from the gastrointestinal tract with peak methamphetamine concentrations occurring in 3.13 to 6.3 hours post ingestion. Moreover, when administered intranasally or as an inhalation, methamphetamine also demonstrates a high degree of absorption. It is distributed to most parts of the body. Because methamphetamine has a high lipophilicity it is distributed across the blood brain barrier and crosses the placenta.",,The biological half-life has been reported in the range of 4 to 5 hours.,5 mg/1,Oral,solid,,2.07,0.928,,10.21,CN[C@@H](C)CC1=CC=CC=C1,,,,,0,5,149.1204495,1,1,0,0,0,0
1342,04/06/2019 00:00,DB01578,Metrizamide,Absorption from gastrointestinal tract is negligible following oral or rectal administration.,,,,,solid,5E+005 mg/L (at 25 Â°C),-1.89,0.335,11.75,-2,CN(C(C)=O)C1=C(I)C(C(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO)=C(I)C(NC(C)=O)=C1I,,,,,0,,788.8541087,1,1,0,0,0,0
1343,04/06/2019 00:00,DB01579,Phendimetrazine,Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours.,,19-24 hours,105 mg/1,Oral,solid,,,2.43,,7.28,C[C@H]1[C@@H](OCCN1C)C1=CC=CC=C1,,,19,24,0,105,191.1310142,2,1,1,0,1,1
1344,04/06/2019 00:00,DB01580,Oxprenolol,Oral bioavailability is 20-70%.,,1-2 hours,160 mg,Oral,solid,,2.1,0.68,14.09,9.67,CC(C)NCC(O)COC1=CC=CC=C1OCC=C,,,1,2,0,160,265.1677936,1,1,0,0,0,0
1345,04/06/2019 00:00,DB01581,Sulfamerazine,Rapidly absorbed following oral administration.,,,,Oral,solid,202 mg/L (at 20 Â°C),0.14,0.304,6.99,2.01,CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1,,,,,0,,264.0680966,2,2,1,1,0,0
1346,04/06/2019 00:00,DB01582,Sulfamethazine,Rapidly absorbed following oral administration.,,,,Oral,solid,1500 mg/L (at 29 Â°C),0.89,0.23,6.99,2.04,CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1,,,,,0,,278.0837467,2,2,1,1,0,0
1347,02/07/2019 00:00,DB01586,Ursodeoxycholic acid,,,,250 mg,Dental,solid,20 mg/L (at 20 Â°C),3,0.0197,4.6,-0.54,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,,,,,0,,392.2926598,4,0,0,0,0,0
1348,04/06/2019 00:00,DB01587,Ketazolam,,,26-200 hours,30 mg,Oral,solid,,,0.0839,14.2,-0.89,CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1,,,26,200,0,30,368.0927701,4,2,2,0,0,2
1349,04/06/2019 00:00,DB01588,Prazepam,,,36-200 hours,,,solid,,3.73,0.00399,,3.06,ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1,,,36,200,0,,324.1029408,4,2,1,0,0,1
1350,04/06/2019 00:00,DB01589,Quazepam,Bioavailability is 29-35% following oral administration.,,39 hours,15 mg/1,Oral,solid,,4.03,0.00231,18.93,2.59,FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2,,,39,39,0,15,386.0267599,3,2,1,0,0,1
1351,02/07/2019 00:00,DB01590,Everolimus,"In patients with advanced solid tumors, peak everolimus concentrations are reached 1 to 2 hours after administration of oral doses ranging from 5 mg to 70 mg. Following single doses, Cmax is dose-proportional between 5 mg and 10 mg. At doses of 20 mg and higher, the increase in Cmax is less than dose-proportional, however AUC shows dose-proportionality over the 5 mg to 70 mg dose range. Steady-state was achieved within 2 weeks following once-daily dosing.
Dose Proportionality in Patients with SEGA (subependymal giant-cell astrocytomas) and TSC (tuberous sclerosis complex): In patients with SEGA and TSC, everolimus Cmin was approximately dose-proportional within the dose range from 1.35 mg/m2 to 14.4 mg/m2.",0.74,~30 hours.,10 mg,Oral,solid,,,0.00163,9.96,-2.7,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,0.74,0.74,30,30,0,10,957.5813563,4,0,3,0,2,3
1352,02/07/2019 00:00,DB01591,Solifenacin,"The absolute bioavailability of solifenacin is approximately 90%, and plasma concentrations of solifenacin are proportional to the dose administered.",0.98,The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.,10 mg/1,Oral,solid,,,0.0729,,8.88,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1,0.98,0.98,,,0,10,362.1994281,6,2,4,0,3,4
1353,04/06/2019 00:00,DB01594,Cinolazepam,Bioavailability following oral administration is 90-100%.,,9 hours,,,solid,,,0.012,10.68,-2.5,OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O,,,9,9,0,,357.0680326,3,2,1,0,0,1
1354,02/07/2019 00:00,DB01595,Nitrazepam,Bioavailability is 53-94% following oral administration.,,15-38 hours (mean elimination half life 26 hours).,10 mg,Oral,solid,,2.25,0.0299,11.9,2.61,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1,,,,,0,10,281.0800412,3,2,1,0,0,1
1355,04/06/2019 00:00,DB01597,Cilastatin,,,,1 kg/1kg,Not applicable,solid,,,0.1,2.53,9.14,CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O,,,,,0,,358.1562429,1,0,0,0,0,0
1356,04/06/2019 00:00,DB01598,Imipenem,Imipenem is not effectively absorbed from the gastrointestinal tract and therefore must be administered parenterally.,0.2,1 hour,1 kg/1kg,Not applicable,solid,1E+004 mg/L,,0.776,3.63,10.88,[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,0.2,0.2,1,1,0,,299.093977,2,0,2,0,1,2
1357,04/06/2019 00:00,DB01599,Probucol,Absorption from the gastrointestinal tract is limited and variable (about 7%).,,"Ranges from 12 hours to more than 500 hours, the longest half-life probably being in adipose tissue.",250 mg,Oral,solid,,,4.18E-05,10.29,-5.1,CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C,,,,,0,250,516.3095728,2,2,0,0,0,0
1358,02/07/2019 00:00,DB01600,Tiaprofenic acid,Bioavailability is 90% following oral administration.,,1.5-2.5 hours,300 mg,Oral,solid,,,0.0324,4.03,-7.8,CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1,,,1.5,2.5,0,300,260.0507152,2,2,1,1,0,0
1359,04/06/2019 00:00,DB01601,Lopinavir,"Administered alone, lopinavir has insufficient bioavailability; however, like several HIV protease inhibitors, its blood levels are greatly increased by low doses of ritonavir, a potent inhibitor of cytochrome P450 3A4.",98-99%,,,Oral,solid,,,0.00192,13.39,-1.5,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,0.98,0.99,,,0,,628.3624706,4,3,1,0,1,1
1360,04/06/2019 00:00,DB01602,Bacampicillin,Absorbed following oral administration.,,,400 mg,Oral,solid,,,0.123,11.72,7.44,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OC(C)OC(=O)OCC,,,,,0,400,465.1569712,3,1,2,0,2,2
1361,04/06/2019 00:00,DB01603,Meticillin,Not absorbed following oral administration.,,25-60 minutes,,,solid,,1.22,0.31,2.96,-1.8,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O,,,0.416666667,1,0,,380.1042074,3,1,2,0,2,2
1362,04/06/2019 00:00,DB01604,Pivampicillin,Absorbed following oral administration.,,Approximately 1 hour.,175 mg,Oral,solid,,,0.0354,11.71,7.44,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)C(C)(C)C,,,,,0,175,463.1777066,3,1,2,0,2,2
1363,02/07/2019 00:00,DB01605,Pivmecillinam,Well absorbed following oral administration.,,,200 mg,Oral,solid,,,0.0526,13.66,7.91,[H]C(=N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@]12[H])N1CCCCCC1,,,,,0,200,439.2140922,3,0,3,0,3,3
1364,14/06/2019 00:00,DB01606,Tazobactam,"Tazobactam is coadministered with piperacillin or ceftolozane, pharmacokinetic information will be provided for these combinations.

**Piperacillin-tazobactam**

Peak plasma concentrations occur immediately after the completion of intravenous infusion.  Following several doses of piperacillin-tazobactam infusions every 6 hours, peak concentrations were similar to those that were measured after the initial dose.[L4417]

**Ceftolozane-piperacillin**

AUC: 24.4-25 mcgâ€¢h/mL

Peak concentrations are reached on day 1 after the first dose and range from 18 to 18.4 mcg/mL.[FDA label]
 ",0.3,"Piperacillin-tazobactam

After a single dose in healthy volunteers, the plasma half-life of piperacillin and tazobactam was in the range of 0.7 to 1.2 hours.[L4417]

Ceftolozane-tazobactam

0.91-1.03 hours [FDA label]",,Intravenous,solid,50 mg/mL,,9.59,2.86,0.73,[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O,0.3,0.3,,,0,,300.0528405,3,1,3,1,2,2
1365,04/06/2019 00:00,DB01607,Ticarcillin,,0.45,1.1 hours,3 g/1,Intravenous,solid,,,0.0716,3.09,-6.3,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C(O)=O)C1=CSC=C1)C(O)=O,0.45,0.45,1.1,1.1,0,,384.0449782,3,1,3,1,2,2
1366,02/07/2019 00:00,DB01608,Periciazine,,,,10 mg,Oral,solid,38 mg/L (at 37 Â°C),3.52,0.059,15.18,8.37,OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1,,,,,0,10,365.1561834,4,2,2,0,1,2
1367,02/07/2019 00:00,DB01609,Deferasirox,The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.,,The mean elimination half-life ranged from 8 to 16 hours following oral administration.,125 mg/1,Oral,solid,0.038 mg/mL at 37 Â°C,3.52,0.0343,4.55,0.19,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,,,,,0,125,373.106256,4,4,1,1,0,0
1368,02/07/2019 00:00,DB01610,Valganciclovir,Valganciclovir is well absorbed from the gastrointestinal tract and the absolute bioavailability from valganciclovir tablets (following administration with food) is approximately 60%.,0.01,Approximately 4.08 hours. Increased in patients with renal function impairment.,50 mg/1mL,Oral,solid,,,4.79,8.1,7.36,CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O,0.01,0.01,,,0,,354.1651678,2,2,2,2,0,0
1369,02/07/2019 00:00,DB01611,Hydroxychloroquine,Very rapidly and completely absorbed following oral administration.,,Terminal elimination half-life In blood is approximately 50 days. In plasma it is approximately 32 days.,200 mg/1,Enteral,solid,,,0.0261,15.59,9.76,CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1,,,,,0,,335.1764401,2,2,1,1,0,0
1370,04/06/2019 00:00,DB01612,Amyl Nitrite,"Amyl nitrite vapors are absorbed rapidly through the pulmonary alveoli, manifesting therapeutic effects within one minute after inhalation.",,,0.3 g/0.3mL,Respiratory (inhalation),liquid,,,3.97,,-1.8,CCCCCON=O,,,,,0,,117.0789786,0,0,0,0,0,0
1371,04/06/2019 00:00,DB01613,Erythrityl tetranitrate,,,,,,solid,,,0.195,,-5.5,[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O,,,,,0,,301.9982216,0,0,0,0,0,0
1372,04/06/2019 00:00,DB01614,Acepromazine,,,3 hours in horses.,,,liquid,,,0.0098,16.06,8.5,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O,,,,,0,,326.1452843,3,2,1,0,0,1
1373,04/06/2019 00:00,DB01615,Aceprometazine,Rapidly absorbed following oral administration.,,,,,solid,,,0.0122,16.06,8.32,CC(CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O)N(C)C,,,,,0,,326.1452843,3,2,1,0,0,1
1374,04/06/2019 00:00,DB01616,Alverine,,,The plasma half-life averages 0.8 hours for alverine and 5.7 hours for the active primary metabolite.,,,solid,,,0.00096,,10.44,CCN(CCCC1=CC=CC=C1)CCCC1=CC=CC=C1,,,,,0,,281.2143499,2,2,0,0,0,0
1375,04/06/2019 00:00,DB01618,Molindone,Rapidly absorbed from the gastrointestinal tract following oral administration.,,,10 mg/1,Oral,solid,,,0.474,15.34,6.65,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2,,,,,0,10,276.183778,3,1,2,1,1,1
1376,04/06/2019 00:00,DB01619,Phenindamine,,,,,,solid,,,0.0277,18.01,9,CN1CCC2=C(C1)C(C1=CC=CC=C21)C1=CC=CC=C1,,,,,0,,261.1517496,4,2,1,0,0,1
1377,04/06/2019 00:00,DB01620,Pheniramine,,,,,Oral,liquid,,,0.377,,9.48,CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1,,,,,0,,240.1626486,2,2,1,1,0,0
1378,04/06/2019 00:00,DB01621,Pipotiazine,,,,25 mg,Intramuscular,solid,,,0.0127,17.09,8.86,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1,,,,,0,,475.1963339,4,2,2,0,1,2
1379,02/07/2019 00:00,DB01622,Thioproperazine,,,,10 mg,Oral,solid,,,0.0569,,8.36,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1,,,,,0,10,446.1810182,4,2,2,0,1,2
1380,02/07/2019 00:00,DB01623,Thiothixene,,,10-20 hours,20 mg/1,Oral,solid,,,0.0139,,8.56,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1,,,10,20,0,20,443.1701192,4,2,2,0,1,2
1381,02/07/2019 00:00,DB01624,Zuclopenthixol,"Upon reaching the body water phase, the decanoate ester is slowly released from the oil depot, which is resultantly hydrolyzed to the active substance, zuclopenthixol. The decanoate ester provides a means of slow release since zuclopenthixol itself is a short-acting drug. ",98-99%,"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.",40 mg,Oral,liquid,slight,,0.0026,15.59,8.43,OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,0.98,0.99,,,0,40,400.1376121,4,2,2,0,1,2
1382,04/06/2019 00:00,DB01625,Isopropamide,,,,,Oral,solid,,,4.24E-05,16.31,-3.3,CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C,,,,,1,,353.2587401,2,2,0,0,0,0
1383,04/06/2019 00:00,DB01626,Pargyline,,,,,,solid,,,0.0998,,8.13,CN(CC#C)CC1=CC=CC=C1,,,,,0,,159.1047994,1,1,0,0,0,0
1384,04/06/2019 00:00,DB01627,Lincomycin,Rapidly absorbed from the gastrointestinal tract following oral administration. Approximately 20 to 30% absorbed orally in fasting state; absorption decreased when taken with food.,0.86,The biological half-life after intramuscular or intravenous administration is 5.4 Â± 1.0 hours. The serum half-life may be prolonged in patients with severe impairment of renal function. Half life may be extended up to 2-fold in patients with hepatic impairment.,500 mg,Oral,solid,,0.56,3.02,3.24,8.41,[H][C@](C)(O)[C@@]([H])(N=C(O)[C@]1([H])C[C@@]([H])(CCC)CN1C)[C@@]1([H])O[C@]([H])(SC)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,0.86,0.86,,,0,500,406.2137578,2,0,2,0,2,2
1385,04/06/2019 00:00,DB01628,Etoricoxib,Bioavailability is 100% following oral administration.,0.92,22 hours,,,solid,,,0.00328,19.69,4.96,CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O,0.92,0.92,22,22,0,,358.0542764,3,3,2,2,0,0
1386,04/06/2019 00:00,DB01629,5-fluorouridine,,,,,,solid,,,60.7,7.67,-3,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=C(F)C(=O)NC1=O,,,,,0,,262.0601143,2,1,2,1,1,1
1387,04/06/2019 00:00,DB01630,SC-74020,,,,,,solid,,,0.0101,8.71,5.11,CCCCCC1=CC=C(C=C1)C(=O)NC1=CC=C(C=C1)S(=O)(=O)N(CCN1CCOCC1)[C@H](C(C)C)C(=O)NO,,,,,0,,574.2825061,3,2,1,0,1,1
1388,04/06/2019 00:00,DB01631,Methyl Nonanoate (Ester),,,,,,solid,,,0.0455,,-7,CCCCCCCCC(=O)OC,,,,,0,,172.1463299,0,0,0,0,0,0
1389,04/06/2019 00:00,DB01632,5-O-phosphono-alpha-D-ribofuranosyl diphosphate,,,,,,solid,,,11.6,1.09,-3.7,O[C@H]1[C@@H](O)[C@@H](OP(O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O,,,,,0,,389.951815,1,0,1,0,1,1
1390,04/06/2019 00:00,DB01633,Deoxy-2-fluoro-beta-D-cellotrioside,,,,,,solid,,,258,10.98,-3,[H][C@]1(F)[C@@H](O)O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H]1O,,,,,0,,506.1646985,3,0,3,0,3,3
1391,04/06/2019 00:00,DB01634,2-Oxy-4-Hydroxy-5-(2-Hydrazinopyridine)Phenylalanine,,,,,,solid,,,1.12,1.63,9.65,[H][C@](N)(C[C@]1([H])C=C(NNC2=CC=CC=N2)C(O)=CC1=O)C(O)=O,,,,,0,,304.117155,2,1,1,1,0,0
1392,04/06/2019 00:00,DB01635,"2,2-Dimethylthiazolidine-4-Carboxylic Acid;(Dmt)Thiazolidine",,,,,,solid,,,31.9,2.97,7.75,CC1(C)N[C@@H](CS1)C(O)=O,,,,,0,,161.0510496,1,0,1,0,1,1
1393,04/06/2019 00:00,DB01636,Clorocruoro Hem,,,,,,solid,,,0.542,3.69,-7.3,CC1=C(CCC(O)=O)C2=CC3=C(CCC(O)=O)C(C)=C4C=C5N6C(=CC7=C(C=O)C(C)=C8C=C1N2[Fe]6(N34)N78)C(C)=C5C=C,,,,,0,,618.1565576,8,4,8,4,0,4
1394,04/06/2019 00:00,DB01637,"3,7,11,15-tetramethyl-hexadecan-1-ol",,,,,,solid,,,2.31E-05,17.11,-1.9,CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@H](C)CCO,,,,,0,,298.323566,0,0,0,0,0,0
1395,02/07/2019 00:00,DB01638,Sorbitol,,,,3.3 g/100mL,Oral,solid,2.75E+006 mg/L (at 30 Â°C),-2.2,229,12.59,-3,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,,,,,0,,182.0790382,0,0,0,0,0,0
1396,04/06/2019 00:00,DB01639,N-Methyl-Pyridoxal-5'-Phosphate,,,,,,solid,,,0.499,1.59,-6.6,CC1=C(O)C(C=O)=C(COP(O)(O)=O)C=[N+]1C,,,,,1,,262.0475002,1,1,1,1,0,0
1397,04/06/2019 00:00,DB01640,"(5r)-6-(4-{[2-(3-Iodobenzyl)-3-Oxocyclohex-1-En-1-Yl]Amino}Phenyl)-5-Methyl-4,5-Dihydropyridazin-3(2h)-One",,,,,,solid,,,0.00226,6.61,1.34,[H][C@@]1(C)CC(O)=NN=C1C1=CC=C(NC2=C(CC3=CC(I)=CC=C3)C(=O)CCC2)C=C1,,,,,0,,513.091325,4,2,1,0,0,1
1398,04/06/2019 00:00,DB01641,"(5z)-2-[(1s,2r)-1-Amino-2-Hydroxypropyl]-5-[(4-Amino-1h-Indol-3-Yl)Methylene]-3-(2-Hydroxyethyl)-3,5-Dihydro-4h-Imidazol-4-One",,,,,,solid,,,0.211,3.76,7.56,C[C@@H](O)[C@H](N)C1=N\C(=C/C2=CNC3=C2C(N)=CC=C3)C(=O)N1CC(O)=O,,,,,0,,357.1437041,3,2,2,1,0,1
1399,04/06/2019 00:00,DB01642,methyl beta-D-glucopyranoside,,,,,,solid,,,862,12.21,-3,CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,194.0790382,1,0,1,0,1,1
1400,04/06/2019 00:00,DB01643,Thymidine monophosphate,,,,,,solid,,,6.78,1.23,-3.2,CC1=CN([C@H]2C[C@H](O)[C@@H](COP(O)(O)=O)O2)C(=O)NC1=O,,,,,0,,322.0566021,2,1,2,1,1,1
1401,04/06/2019 00:00,DB01644,"3,6-dihydroxy-xanthene-9-propionic acid",,,,,,solid,,,0.0589,3.6,-6,OC(=O)CCC1C2=CC=C(O)C=C2OC2=C1C=CC(O)=C2,,,,,0,,286.0841235,3,2,1,0,0,1
1402,04/06/2019 00:00,DB01645,Genistein,,,,,,solid,,,0.123,6.55,-5.3,OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O,,,,,0,,270.0528234,3,3,1,1,0,0
1403,04/06/2019 00:00,DB01646,N-Acetylmethionine,,,,,,solid,3.07E+005 mg/L (at 25 Â°C),,6.84,4.02,-1.8,CSCC[C@H](NC(C)=O)C(O)=O,,,,,0,,191.0616143,0,0,0,0,0,0
1404,04/06/2019 00:00,DB01647,Daxalipram,,,,,,solid,,,0.313,12.73,-4.6,CCCOC1=CC(=CC=C1OC)[C@]1(C)CNC(=O)O1,,,,,0,,265.1314081,2,1,1,0,1,1
1405,04/06/2019 00:00,DB01648,Methyl 4-thio-beta-D-glucopyranoside,,,,,,solid,,,40.6,9.5,-3,CO[C@@H]1O[C@H](CO)[C@@H](S)[C@H](O)[C@H]1O,,,,,0,,210.0561945,1,0,1,0,1,1
1406,04/06/2019 00:00,DB01649,7-methyl-GpppA,,,,,,solid,,,2.89,0.9,5,CN1C=[N+]([C@@H]2O[C@H](CO[P@](O)(=O)O[P@](O)(=O)O[P@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)N3C=NC4=C(N)N=CN=C34)[C@@H](O)[C@H]2O)C2=C1C(=O)N=C(N)N2,,,,,1,,787.0997758,6,4,6,4,2,2
1407,04/06/2019 00:00,DB01650,trans-2-hydroxycinnamic acid,,,,,,solid,,,1.15,4.04,-6,OC(=O)\C=C\C1=CC=CC=C1O,,,,,0,,164.0473441,1,1,0,0,0,0
1408,04/06/2019 00:00,DB01651,"Methyl 4,6-O-[(1R)-1-carboxyethylidene]-beta-D-galactopyranoside",,,,,,solid,,,264,2.96,-3.7,[H][C@@]12CO[C@](C)(O[C@]1([H])[C@H](O)[C@@H](O)[C@H](OC)O2)C(O)=O,,,,,0,,264.0845175,2,0,2,0,2,2
1409,04/06/2019 00:00,DB01652,4-hydroxybenzoyl-CoA,,,,,,solid,,,3.28,0.83,4.89,CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C1=CC=C(O)C=C1,,,,,0,,887.1363383,4,3,3,2,1,1
1410,04/06/2019 00:00,DB01655,L-gulonic acid 6-phosphate,,,,,,solid,,,20.7,1.49,-3.5,O[C@@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O,,,,,0,,276.0246332,0,0,0,0,0,0
1411,02/07/2019 00:00,DB01656,Roflumilast,"After a 500mcg dose, the bioavailability of roflumilast is about 80%. In the fasted state, maximum plasma concentrations are reached in 0.5 to 2 hours. While in the fed state, Cmax is reduced by 40%, Tmax is increased by one hour, and total absorption is unchanged.",0.99,Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose). ,250 ug/1,Oral,solid,insoluble (0.52-0.56 mg/L at 22Â°C),,0.0062,8.18,2.4,FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl,0.99,0.99,,,0,0.25,402.0349541,3,2,1,1,0,0
1412,04/06/2019 00:00,DB01657,"2-Amino-3-[4-Hydroxy-6-Oxo-3-(2-Phenyl-Cyclopropylimino)-Cyclohexa-1,4-Dienyl]-Propionic Acid",,,,,,solid,,,0.166,1.88,9.32,NC(CC1C\C(=N/C2CC2C2=CC=CC=C2)C(O)=CC1=O)C(O)=O,,,,,0,,328.1423071,3,1,0,0,0,0
1413,04/06/2019 00:00,DB01658,1'-Deazo-Thiamin Diphosphate,,,,,,solid,,,0.157,1.78,6.98,CC1=C(CCO[P@](O)(=O)O[P@](O)([O-])=O)SC=[N+]1CC1=CC=C(C)N=C1N,,,,,0,,423.0418942,2,2,2,2,0,0
1414,04/06/2019 00:00,DB01659,"3-(1,10-Phenanthrol-2-Yl)-L-Alanine",,,,,,solid,,,0.121,2.14,9.28,N[C@@H](CC1=CC=C2C=CC3=C(N=CC=C3)C2=N1)C(O)=O,,,,,0,,267.1007767,3,3,2,2,0,0
1415,04/06/2019 00:00,DB01661,1-(5-phospho-D-ribosyl)-ATP,,,,,,solid,,,9.92,1.1,0.6,O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=NC2=C1N=CN(C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O)C2=N,,,,,0,,719.0043347,4,2,4,2,2,2
1416,04/06/2019 00:00,DB01662,Trans-O-Hydroxy-Alpha-Methyl Cinnamate,,,,,,solid,,,1.97,4.28,-6,[H][C@@](C)(CC1=CC=CC=C1O)C(O)=O,,,,,0,,180.0786442,1,1,0,0,0,0
1417,04/06/2019 00:00,DB01664,(S)-DES-ME-AMPA,,,,,,solid,,,48.9,1.77,9.36,N[C@@H](CC1=CONC1=O)C(O)=O,,,,,0,,172.0484067,1,1,1,1,0,0
1418,04/06/2019 00:00,DB01665,2H-Benzimidazol-2-amine,,,,,,solid,,,1.95,14.86,3.29,NC1N=C2C=CC=CC2=N1,,,,,0,,133.0639972,2,1,1,0,0,1
1419,04/06/2019 00:00,DB01666,D-Myo-Inositol-Hexasulphate,,,,,,solid,,,0.394,-3.5,,[H][C@]1(OS(O)(=O)=O)[C@]([H])(OS(O)(=O)=O)[C@@]([H])(OS(O)(=O)=O)[C@]([H])(OS(O)(=O)=O)[C@]([H])(OS(O)(=O)=O)[C@]1([H])OS(O)(=O)=O,,,,,0,,659.8042773,1,0,0,0,0,0
1420,04/06/2019 00:00,DB01667,8-azaguanine,,,,,,solid,Insoluble,-0.71,5.66,7.89,0.05,NC1=NC2=C(NN=N2)C(O)=N1,,,,,0,,152.0446587,2,2,2,2,0,0
1421,04/06/2019 00:00,DB01668,Nanaomycin D,,,,,,solid,,,1.95,9.41,-4.2,[H][C@]12CC(=O)O[C@]1([H])C1=C(C(=O)C3=C(C=CC=C3O)C1=O)[C@]([H])(C)O2,,,,,0,,300.0633881,4,1,2,0,1,2
1422,04/06/2019 00:00,DB01669,Virginiamycin M1,,,,,,solid,Poorly soluble in water,,0.0601,11.38,2.19,CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)C2=COC(=N2)CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C,,,,,0,,525.2475005,3,1,3,1,0,2
1423,04/06/2019 00:00,DB01670,Propyl acetate,,,,,,solid,1.89E+004 mg/L (at 20 Â°C),1.24,28.2,,-7,CCCOC(C)=O,,,,,0,,102.0680796,0,0,0,0,0,0
1424,04/06/2019 00:00,DB01671,4-(Hydroxymercury)Benzoic Acid,,,,,,solid,,,52.2,3.86,-2.4,O[Hg]C1=CC=C(C=C1)C(O)=O,,,,,0,,340.0023371,1,1,0,0,0,0
1425,04/06/2019 00:00,DB01672,"2,3-Dihydroxy-Benzoic Acid",,,,,,solid,,1.2,6.88,2.56,-6.3,OC(=O)C1=CC=CC(O)=C1O,,,,,0,,154.0266087,1,1,0,0,0,0
1426,04/06/2019 00:00,DB01673,Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine,,,,,,solid,,,9.58,1.73,-3.7,C[C@H](NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)NC2=O)[C@@H]1NC(C)=O)C(O)=O,,,,,0,,750.1398128,3,1,3,1,2,2
1427,04/06/2019 00:00,DB01674,[2-(1-Amino-2-Hydroxy-Propyl)-4-(4-Fluoro-1h-Indol-3-Ylmethyl)-5-Hydroxy-Imidazol-1-Yl]-Acetic Acid,,,,,,solid,,,0.316,3.81,7.55,[H][C@@](C)(O)[C@]([H])(N)C1=NC(CC2=CNC3=CC=CC(F)=C23)=C(O)N1CC(O)=O,,,,,0,,362.1390333,3,3,2,2,0,0
1428,04/06/2019 00:00,DB01675,Methacrylyl-Coenzyme A,,,,,,solid,,,4.11,0.83,4.95,CC(=C)C(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N,,,,,0,,835.1414237,3,2,3,2,1,1
1429,04/06/2019 00:00,DB01676,Trinitrotoluene,,,,,,solid,115 mg/L (at 23 Â°C),1.6,0.0778,16.99,,CC1=C(C=C(C=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O,,,,,0,,227.0178349,1,1,0,0,0,0
1430,04/06/2019 00:00,DB01677,Fumaric Acid,,,,,,solid,7000 mg/L (at 25 Â°C),0.46,24.1,3.55,,OC(=O)\C=C\C(O)=O,,,,,0,,116.0109586,0,0,0,0,0,0
1431,04/06/2019 00:00,DB01678,RU84687,,,,,,solid,,,0.000744,1.75,-1.9,CC(=O)N[C@@H](CC1=CC=C(OP(O)(O)=O)C(C=O)=C1)C(=O)N[C@H]1CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O,,,,,0,,607.2083517,4,3,1,0,1,1
1432,04/06/2019 00:00,DB01679,Propyl Trihydrogen Diphosphate,,,,,,solid,,,11.9,1.78,,CCCO[P@](O)(=O)OP(O)(O)=O,,,,,0,,219.9901759,0,0,0,0,0,0
1433,04/06/2019 00:00,DB01681,Benzene Hexacarboxylic Acid,,,,,,solid,,1.5,0.204,0.77,,OC(=O)C1=C(C(O)=O)C(C(O)=O)=C(C(O)=O)C(C(O)=O)=C1C(O)=O,,,,,0,,341.9859256,1,1,0,0,0,0
1434,04/06/2019 00:00,DB01682,6'-Methyl-Thiamin Diphosphate,,,,,,solid,,,0.259,1.78,6.3,CC1=C(CCO[P@](O)(=O)O[P@](O)([O-])=O)SC=[N+]1CC1=C(C)N=C(C)N=C1N,,,,,0,,438.0527932,2,2,2,2,0,0
1435,04/06/2019 00:00,DB01683,Chymostatin,,,,,,solid,,,0.0368,3.6,11.48,[H][C@](CC1=CC=CC=C1)(C=O)N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@@]([H])(NC(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=O)[C@]1([H])CCNC(=N)N1,,,,,0,,607.311832,3,2,1,0,1,1
1436,04/06/2019 00:00,DB01684,1-Hydroxy-1-Thio-Glycerol,,,,,,solid,,,607,13.63,-2.9,OC[C@@H](O)CSO,,,,,0,,124.0194151,0,0,0,0,0,0
1437,04/06/2019 00:00,DB01685,Topiroxostat,The time to reach peak plasma concentration of 229.9 ng/mL was 0.67 hour following a single oral dose of 20mg topiroxostat [L867]. The oral bioavailability in male rats was 69.6% after oral administration of a single dose of 1mg/kg [L867].,>97.5%,The mean half life of topiroxostat after a single oral dose of 20mg topiroxostat is 5 hours under fasting condition. The complex of molybdenum (IV)- topiroxostat has an approximate half life of 20.4 hours [L867].,,,solid,,,0.0779,11.06,3.91,N#CC1=NC=CC(=C1)C1=NNC(=N1)C1=CC=NC=C1,0.97,1,,,0,,248.0810443,3,3,3,3,0,0
1438,04/06/2019 00:00,DB01686,"N,N-dimethylarginine",,,,,,solid,,,6.77,2.54,12.34,N[C@@H](CCC\N=C(/N)N(C)C)C(O)=O,,,,,0,,202.1429758,0,0,0,0,0,0
1439,04/06/2019 00:00,DB01687,beta-Mannobiose,,,,,,solid,,,586,11.25,-3,OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@H](O)O[C@@H]2CO)[C@@H](O)[C@@H](O)[C@@H]1O,,,,,0,,342.1162115,2,0,2,0,2,2
1440,04/06/2019 00:00,DB01688,P-Cresol,,,,,,solid,2.15E+004 mg/L (at 25 Â°C),1.94,23.1,10.36,-5.4,CC1=CC=C(O)C=C1,,,,,0,,108.0575149,1,1,0,0,0,0
1441,04/06/2019 00:00,DB01689,Inhibitor Idd 384,,,,,,solid,,,0.0134,3.12,-4.8,CC1=CC=CC=C1CC(=O)NC1=CC(C)=C(C(C)=C1)S(=O)(=O)NCC(O)=O,,,,,0,,390.1249428,2,2,0,0,0,0
1442,04/06/2019 00:00,DB01690,Bis(Adenosine)-5'-Triphosphate,,,,,,solid,,,4.39,0.9,5.29,[H][C@]1(COP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,756.0819347,6,4,6,4,2,2
1443,04/06/2019 00:00,DB01691,Indole Naphthyridinone,,,,,,solid,,,0.0196,12.03,3.57,CN(CC1=CN(C)C2=CC=CC=C12)C(=O)\C=C\C1=CN=C2NC(=O)CCC2=C1,,,,,0,,374.1742759,4,3,3,2,0,1
1444,04/06/2019 00:00,DB01692,Dithioerythritol,,,,,,solid,,,5.14,9.62,-3.3,[H][C@](O)(CS)[C@]([H])(O)CS,,,,,0,,154.0122216,0,0,0,0,0,0
1445,04/06/2019 00:00,DB01694,D-tartaric acid,,,,,,solid,1E+006 mg/L (at 25 Â°C),,161,2.72,-4.3,O[C@@H]([C@H](O)C(O)=O)C(O)=O,,,,,0,,150.0164379,0,0,0,0,0,0
1446,04/06/2019 00:00,DB01695,N-Hydroxy-4-Phosphono-Butanamide,,,,,,solid,,,46.4,1.81,-5.5,ONC(=O)CCCP([O-])([O-])=O,,,,,-2,,181.0151061,0,0,0,0,0,0
1447,04/06/2019 00:00,DB01697,beta-cellotriose,,,,,,solid,,,554,11.22,-3.6,[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O[C@]3([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,504.1690349,3,0,3,0,3,3
1448,04/06/2019 00:00,DB01698,Rutin,,,,,Oral,solid,125 mg/L,,3.54,6.43,-3.7,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,,,,,0,,610.1533849,5,3,3,1,2,2
1449,04/06/2019 00:00,DB01699,(4e)-4-Aminohex-4-Enoic Acid,,,,,,solid,,,52.4,4.6,7.06,[H]\C(C)=C(/N)CCC(O)=O,,,,,0,,129.0789786,0,0,0,0,0,0
1450,04/06/2019 00:00,DB01700,AICA ribonucleotide,,,,,,solid,,,2.79,1.22,4.8,NC(=O)C1=C(N)N(C=N1)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,,,,,0,,338.0627501,2,1,2,1,1,1
1451,04/06/2019 00:00,DB01701,"1,2-Dichloro-Propane",,,,,,solid,2800 mg/L (at 25 Â°C),1.98,2.11,,,C[C@@H](Cl)CCl,,,,,0,,111.9846556,0,0,0,0,0,0
1452,04/06/2019 00:00,DB01702,"2-(3,4-Dihydroxyphenyl)Acetic Acid",,,,,,solid,,0.98,7.23,3.61,-6.3,OC(=O)CC1=CC(O)=C(O)C=C1,,,,,0,,168.0422587,1,1,0,0,0,0
1453,04/06/2019 00:00,DB01704,"2,4-Dihydroxy-Trans Cinnamic Acid",,,,,,solid,,,1.59,3.64,-5.6,OC(=O)\C=C\C1=C(O)C=C(O)C=C1,,,,,0,,180.0422587,1,1,0,0,0,0
1454,04/06/2019 00:00,DB01705,Bis(5-Amidino-Benzimidazolyl)Methane,,,,,,solid,,,0.00536,10.94,11.3,NC(=[NH2+])C1=CC2=C(C=C1)N=C(CC1=NC3=C(N1)C=C(C=C3)C([NH3+])=[NH2+])N2,,,,,3,,335.1716219,4,4,2,2,0,0
1455,04/06/2019 00:00,DB01706,2-Bromo-6-Chloro-Purine,,,,,,solid,,,0.285,2.4,-1.9,ClC1=C2N=CN=C2NC(Br)=N1,,,,,0,,231.9151358,2,0,2,0,0,2
1456,04/06/2019 00:00,DB01707,"L-Alfa-Lysophosphatidylcholine, Lauroyl",,,,,,solid,,,0.00134,1.86,-3.4,CCCCCCCCCCCC(=O)OCC(O)COP(O)(=O)OCC[N+](C)(C)C,,,,,1,,440.2771658,0,0,0,0,0,0
1457,04/06/2019 00:00,DB01708,Prasterone,"Following a 50-mg DHEA PO dose in cynomolgus monkeys, systemic availability was only 3.1 +/- 0.4%. [PMID: 12970301]",,12 hours,6.5 mg/1,Vaginal,solid,63.5 mg/L (at 25 Â°C),3.23,0.0438,18.2,-1.4,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C,,,12,12,0,,288.2089301,4,0,0,0,0,0
1458,04/06/2019 00:00,DB01709,2-phospho-D-glyceric acid,,,,,,solid,,,20.3,0.81,-3.1,OC[C@@H](OP(O)(O)=O)C(O)=O,,,,,0,,185.9929392,0,0,0,0,0,0
1459,04/06/2019 00:00,DB01710,Porphyrin Fe(III),,,,,,solid,,,2.72,,,C1=CC2=CC3=CC=C4C=C5C=CC6=CC7=CC=C8C=C1N2[Fe](N78)(N34)N56,,,,,0,,364.0411339,8,4,8,4,0,4
1460,04/06/2019 00:00,DB01711,"2,3,4,5,6-Pentafluorobenzyl Alcohol",,,,,,solid,,,0.481,13.68,-3.4,OCC1=C(F)C(F)=C(F)C(F)=C1F,,,,,0,,198.0104058,1,1,0,0,0,0
1461,04/06/2019 00:00,DB01712,"(3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Phenylalanine Ethyl Ester",,,,,,solid,,,0.00348,11.85,-5.2,[H][C@@](CC1=CC=CC=C1)(NC(=O)[C@]1([H])CSCCN1S(=O)(=O)C1=CC=C(C)C=C1)C(=O)OCC,,,,,0,,476.143964,3,2,1,0,1,1
1462,04/06/2019 00:00,DB01713,Udp-Alpha-D-Xylopyranose,,,,,,solid,,,21.8,1.73,-3.5,[H][C@]1(COP(O)(=O)OP(O)(=O)O[C@@]2([H])OC[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,536.0444559,3,1,3,1,2,2
1463,04/06/2019 00:00,DB01714,N-Methyl-Lysine,,,,,,solid,,,51.5,2.8,10.58,CNCCCC[C@H](N)C(O)=O,,,,,0,,160.1211778,0,0,0,0,0,0
1464,04/06/2019 00:00,DB01715,"7,8-Diamino-Nonanoic Acid",,,,,,solid,,,4.94,4.73,9.97,C[C@H](N)[C@H](N)CCCCCC(O)=O,,,,,0,,188.1524779,0,0,0,0,0,0
1465,04/06/2019 00:00,DB01716,2-Propenyl-N-Acetyl-Neuramic Acid,,,,,,solid,,,43.6,3.68,2.38,[H][C@@](O)(CO)[C@@]([H])(O)[C@]1([H])O[C@](CC=C)(C[C@]([H])(O)[C@@]1([H])N=C(C)O)C(O)=O,,,,,0,,333.1423667,1,0,1,0,1,1
1466,04/06/2019 00:00,DB01717,Bis(Adenosine)-5'-Pentaphosphate,,,,,,solid,,,6.92,0.41,5.3,[H][C@]1(COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,916.0145957,6,4,6,4,2,2
1467,02/07/2019 00:00,DB01718,Cetrimonium,,,,0.01,Topical,solid,1E+005 mg/L,,5.24E-06,,,CCCCCCCCCCCCCCCC[N+](C)(C)C,,,,,1,,284.3311768,0,0,0,0,0,0
1468,04/06/2019 00:00,DB01719,Thio-Maltopentaose,,,,,,solid,,,95.9,8.64,-3.7,[H][C@]1(S)O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(S[C@@]3([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]4([H])O[C@]([H])(CO)[C@@]([H])(S[C@@]5([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]5([H])O)[C@]([H])(O)[C@@]4([H])O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,876.2061509,5,0,5,0,5,5
1469,04/06/2019 00:00,DB01720,(2z)-2-(Benzoylamino)-3-[4-(2-Bromophenoxy)Phenyl]-2-Propenoic Acid,,,,,,solid,,,0.000356,3.24,-7,OC(=O)C(\NC(=O)C1=CC=CC=C1)=C\C1=CC=C(OC2=CC=CC=C2Br)C=C1,,,,,0,,437.0262701,3,3,0,0,0,0
1470,04/06/2019 00:00,DB01721,Analogue of Indinavir Drug,,,,,,solid,,,0.00605,5.57,7.73,[H][C@@](O)(CN1CCN(CC2=CC3=C(OCO3)C=C2)C[C@@]1([H])C(O)=NC(C)(C)C)C[C@]([H])(C(O)=N[C@@]1([H])C2=CC=CC=C2C[C@@]1([H])O)[C@]([H])(C)C1=CC=CC=C1,,,,,0,,670.3730353,6,3,2,0,1,2
1471,04/06/2019 00:00,DB01723,"{3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid",,,,,,solid,,,0.00094,3.44,-1.5,[H][C@](CCC1=CC(OC)=C(OC)C=C1)(OC(=O)[C@]1([H])CCCCN1C(=O)[C@@]([H])(CC)C1=CC(OC)=C(OC)C(OC)=C1)C1=CC(OCC(O)=O)=CC=C1,,,,,0,,693.3149113,4,3,1,0,1,1
1472,04/06/2019 00:00,DB01724,Reduced Threonine,,,,,,solid,,,805,14.64,9.3,[H][C@](C)(O)[C@]([H])(N)CO,,,,,0,,105.0789786,0,0,0,0,0,0
1473,04/06/2019 00:00,DB01725,"2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide",,,,,,solid,,,0.00599,8.85,10.61,NC(=N)C1=CC2=C(NC(=N2)C2=CC=CC(C3=CC=CC=C3)=C2O)C=C1,,,,,0,,328.1324111,4,4,1,1,0,0
1474,04/06/2019 00:00,DB01726,2-Aminophenol,,,,,,solid,2E+004 mg/L (at 20 Â°C),0.62,116,10.35,4.52,NC1=CC=CC=C1O,,,,,0,,109.0527638,1,1,0,0,0,0
1475,04/06/2019 00:00,DB01727,Isocitric Acid,,,,,,solid,,,52.5,3.07,-4,O[C@@H]([C@H](CC(O)=O)C(O)=O)C(O)=O,,,,,0,,192.0270026,0,0,0,0,0,0
1476,04/06/2019 00:00,DB01728,"3-[Aminoethylphosphoryl]-[1,2-Di-Palmitoyl]-Sn-Glycerol",,,,,,solid,,,9.45E-05,1.87,10,[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC,,,,,0,,691.515205,0,0,0,0,0,0
1477,04/06/2019 00:00,DB01729,"(1s,3s,4s)-1,3,4-Triphospho-Myo-Inositol",,,,,,solid,,,14.8,0.54,-3.7,O[C@@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@@H](O)[C@H]1OP(O)(O)=O,,,,,0,,419.9623797,1,0,0,0,0,0
1478,04/06/2019 00:00,DB01731,(S)-wiskostatin,,,,,,solid,,,0.0162,14.43,9.09,[H][C@](O)(CN(C)C)CN1C2=CC=C(Br)C=C2C2=C1C=CC(Br)=C2,,,,,0,,423.9785874,3,3,1,1,0,0
1479,04/06/2019 00:00,DB01732,"(4r,5s,6s,7r)-1,3-Dibenzyl-4,7-Bis(Phenoxymethyl)-5,6-Dihydroxy-1,3 Diazepan-2-One",,,,,,solid,,,0.0305,13.16,-1.6,[H][C@]1(COC2=CC=CC=C2)N(CC2=CC=CC=C2)C(=O)N(CC2=CC=CC=C2)[C@]([H])(COC2=CC=CC=C2)[C@]([H])(O)[C@@]1([H])O,,,,,0,,538.2467722,5,4,1,0,1,1
1480,04/06/2019 00:00,DB01733,L-Phospholactate,,,,,,solid,,,21,1.13,,C[C@@H](OP(O)(O)=O)C(O)=O,,,,,0,,169.9980246,0,0,0,0,0,0
1481,04/06/2019 00:00,DB01734,3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid,,,,,,solid,,,0.0778,2.48,-6.9,OC(=O)C(=O)NC1=CC2=C(C=CC=C2)C=C1C(O)=O,,,,,0,,259.0480724,2,2,0,0,0,0
1482,04/06/2019 00:00,DB01735,3-Chloroalaninate,,,,,,solid,,,16.6,1.7,8.52,[NH3+][C@H](CCl)C([O-])=O,,,,,0,,123.0087061,0,0,0,0,0,0
1483,04/06/2019 00:00,DB01736,[3-(Dodecanoylamino)Propyl](Hydroxy)Dimethylammonium,,,,,,solid,,,0.0019,15.85,4.13,CCCCCCCCCCCC(=O)NCCC[N+](C)(C)[O-],,,,,0,,300.2776784,0,0,0,0,0,0
1484,04/06/2019 00:00,DB01737,"Nalpha-(2-Naphthylsulfonylglycyl)-3-Amidino-D,L-Phenylalanine-Isopropylester",,,,,,solid,,,0.0392,10.32,11.31,[H][C@@](CC1=CC=CC(=C1)C(N)=N)(NC(=O)CNS(=O)(=O)C1=CC=C(C)C=C1)C(=O)OC,,,,,0,,432.1467409,2,2,0,0,0,0
1485,04/06/2019 00:00,DB01738,Phosphorylcolamine,,,,,,solid,,,25.8,1.54,10.02,NCCOP(O)(O)=O,,,,,0,,141.0190944,0,0,0,0,0,0
1486,04/06/2019 00:00,DB01739,Allo-Isoleucine,,,,,,solid,,,114,2.79,9.59,CC[C@@H](C)[C@H](N)C(O)=O,,,,,0,,131.0946287,0,0,0,0,0,0
1487,04/06/2019 00:00,DB01740,2-Amino-4-Butyl-5-Propylselenazole,,,,,,solid,,,1.77,,7.21,CCCCC1=C(CCC)[Se]C(=N)N1,,,,,0,,246.0635199,1,1,1,1,0,0
1488,04/06/2019 00:00,DB01741,CRA_17693,,,,,,solid,,,0.00623,4.39,10.6,NC(=[NH2+])C1=CC=C2NC(=NC2=C1)C1=CC(=CC(=C1[O-])C1=C(F)C=CC=C1)[C@@H](CC([O-])=O)C([O-])=O,,,,,-2,,460.119395,4,4,1,1,0,0
1489,04/06/2019 00:00,DB01742,(3r)-1-Acetyl-3-Methylpiperidine,,,,,,solid,,,139,,0.018,C[C@@H]1CCCN(C1)C(C)=O,,,,,0,,141.1153641,1,0,1,0,1,1
1490,02/07/2019 00:00,DB01744,Camphor,,,,0.0578 g/4.25g,Topical,solid,1600 mg/L (at 25 Â°C),2.38,0.88,,-7.5,[H][C@@]12CC[C@@](C)(C(=O)C1)C2(C)C,,,,,0,,152.1201151,2,0,0,0,0,0
1491,04/06/2019 00:00,DB01745,N-Alpha-(2-Naphthylsulfonyl)-N(3-Amidino-L-Phenylalaninyl)Isopipecolinic Acid Methyl Ester,,,,,,solid,,,0.0097,10.02,11.47,COC(=O)C1CCN(CC1)C(=O)[C@H](CC1=CC=CC(=C1)C(N)=N)NS(=O)(=O)C1=CC=C2C=CC=CC2=C1,,,,,0,,522.1936911,4,3,1,0,1,1
1492,04/06/2019 00:00,DB01746,D-Leucine,,,,,,solid,,,69.8,2.79,9.52,CC(C)C[C@@H](N)C(O)=O,,,,,0,,131.0946287,0,0,0,0,0,0
1493,04/06/2019 00:00,DB01747,Coprogen,,,,,,solid,,,0.0285,4.14,2.2,[Fe+3].[H]\C(=C(\C)CCO)C(=O)N([O-])CCC[C@]([H])(N=C(C)O)C(=O)OCC\C(C)=C(/[H])C(=O)N([O-])CCC[C@]1([H])N=C(O)[C@]([H])(CCCN([O-])C(=O)C(\[H])=C(/C)CCO)N=C1O,,,,,0,,821.3019983,1,0,1,0,0,1
1494,04/06/2019 00:00,DB01748,N-Benzyl-4-Sulfamoyl-Benzamide,,,,,,solid,,,0.0451,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=CC=CC=C1,,,,,0,,290.0725133,2,2,0,0,0,0
1495,04/06/2019 00:00,DB01749,"1,2-Dimethoxyethane",,,,,,solid,1E+006 mg/L (at 20 Â°C),-0.21,181,,-3.8,COCCOC,,,,,0,,90.06807956,0,0,0,0,0,0
1496,04/06/2019 00:00,DB01750,1-naphthaleneacetic acid,,,,,,solid,420 mg/L (at 20 Â°C),2.24,0.11,4.75,,OC(=O)CC1=C2C=CC=CC2=CC=C1,,,,,0,,186.0680796,2,2,0,0,0,0
1497,04/06/2019 00:00,DB01751,"3,3',5,5'-Tetraiodothyroacetic Acid",,,,,,solid,,,0.00489,2.25,-6.9,OC(=O)CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1,,,,,0,,747.6601507,2,2,0,0,0,0
1498,04/06/2019 00:00,DB01752,S-adenosyl-L-homocysteine,,,,,,solid,,,4.08,1.81,9.5,N[C@@H](CCSC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(N)N=CN=C12)C(O)=O,,,,,0,,384.1215887,3,2,3,2,1,1
1499,04/06/2019 00:00,DB01753,4-Oxo-Nicotinamide-Adenine Dinucleotide Phosphate,,,,,,solid,,,6.1,-1.6,12.47,[H][C@]1(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(OP(O)(O)=O)[C@]2([H])O)O[C@@]([H])([N+]2=C[C@]([H])(C(O)=N)C(=O)C=C2)[C@]([H])(O)[C@]1([H])O,,,,,1,,760.0776434,5,2,5,2,2,3
1500,04/06/2019 00:00,DB01754,"3,4-Dihydroxy-1-Methylquinolin-2(1h)-One",,,,,,solid,,,13.6,6.09,-3,CN1C(=O)C(O)=C(O)C2=CC=CC=C12,,,,,0,,191.0582431,2,2,1,1,0,0
1501,04/06/2019 00:00,DB01755,N-[Isoleucinyl]-N'-[Adenosyl]-Diaminosufone,,,,,,solid,,,1.81,4.25,8.7,[H][C@](C)(CC)[C@]([H])(N)C(O)=NS(=O)(=O)NC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,458.1696016,3,2,3,2,1,1
1502,04/06/2019 00:00,DB01756,4-phospho-L-threonic acid,,,,,,solid,,,19.6,1.47,-3.6,O[C@@H](COP(O)(O)=O)[C@@H](O)C(O)=O,,,,,0,,216.0035039,0,0,0,0,0,0
1503,04/06/2019 00:00,DB01758,3-Iodo-Tyrosine,,,,,,solid,,,0.937,0.99,9.5,N[C@@H](CC1=CC=C(O)C(I)=C1)C(O)=O,,,,,0,,306.9705412,1,1,0,0,0,0
1504,04/06/2019 00:00,DB01759,Kojic acid,,,,,,solid,,-0.64,92.3,9.3,-3.1,OCC1=CC(=O)C(O)=CO1,,,,,0,,142.0266087,1,1,1,1,0,0
1505,04/06/2019 00:00,DB01760,2-Methoxy-3-Isopropylpyrazine,,,,,,solid,,,61.4,,0.88,COC1=NC=CN=C1C(C)C,,,,,0,,152.094963,1,1,1,1,0,0
1506,04/06/2019 00:00,DB01761,4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine,,,,,,solid,,,0.00438,14.11,10.02,C[C@H](NC1=NC=CC(=N1)C1=C(N=C(C2CCNCC2)N1C)C1=CC(=CC=C1)C(F)(F)F)C1=CC=CC=C1,,,,,0,,506.2405796,5,4,3,2,1,1
1507,04/06/2019 00:00,DB01762,Acetoacetic Acid,,,,,,solid,1E+006 mg/L (at 20 Â°C),,240,4.02,-7.5,CC(=O)CC(O)=O,,,,,0,,102.0316941,0,0,0,0,0,0
1508,04/06/2019 00:00,DB01763,7-thionicotinamide-adenine-dinucleotide phosphate,,,,,,solid,,,7.49,0.66,6.14,[H][C@]1(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(=C3)C([S-])=N)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(OP(O)(O)=O)[C@]1([H])O,,,,,0,,759.0526087,5,3,5,3,2,2
1509,04/06/2019 00:00,DB01764,Dalfopristin,,,The elimination half-life is approximately 0.70 hours.,,Intravenous,solid,,,0.0716,11.38,7.09,[H]\C1=C(\[H])/C(/C)=C([H])/[C@@]([H])(O)CC(=O)CC2=NC(=CO2)C(=O)N2CC[C@]([H])([C@]2([H])C(=O)O[C@]([H])(C(C)C)[C@]([H])(C)\C([H])=C([H])\C(O)=NC1)S(=O)(=O)CCN(CC)CC,,,,,0,,690.3298502,3,1,3,1,1,2
1510,04/06/2019 00:00,DB01765,"(5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid",,,,,,solid,,,0.13,4.22,-4.1,OC(=O)CC1=C2NC(=O)C3=CC=CC=C3N2C2=C1C=CC=C2,,,,,0,,292.0847922,4,4,2,2,0,0
1511,04/06/2019 00:00,DB01766,Beta-(2-Naphthyl)-Alanine,,,,,,solid,,,0.201,2.61,9.44,[H][C@](N)(CC1=CC=C2C=CC=CC2=C1)C(O)=O,,,,,0,,215.0946287,2,2,0,0,0,0
1512,04/06/2019 00:00,DB01767,Hemi-Babim,,,,,,solid,,,0.0274,11.47,10.71,NC(=N)C1=CC2=C(NC(CC3=NC4=C(N3)C=CC=C4)=N2)C=C1,,,,,0,,290.1279944,4,4,2,2,0,0
1513,04/06/2019 00:00,DB01768,Methylumbelliferyl Sialic Acid,,,,,,solid,,,1.46,2.85,1.87,[H][C@@](O)(CO)[C@@]([H])(O)[C@]1([H])O[C@@](C[C@]([H])(O)[C@@]1([H])N=C(C)O)(OC1=CC2=C(C=C1)C(C)=CC(=O)O2)C(O)=O,,,,,0,,467.1427606,3,2,2,1,1,1
1514,04/06/2019 00:00,DB01771,CRA_10991,,,,,,solid,,,0.000264,9.49,10.14,NC(=[NH2+])C1=C(Cl)C=C2NC(=CC2=C1)C1=CC=CC(OC2CCCC2)=C1[O-],,,,,0,,369.1244046,4,3,1,1,0,0
1515,04/06/2019 00:00,DB01772,"3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione",,,,,,solid,,,0.0455,9.47,3.7,[H][C@@](O)(CO)CNC1=CC=CC(=C1)C1=C(C(=O)NC1=O)C1=CN(C)C2=CC=C(F)C=C12,,,,,0,,409.1437843,4,3,2,1,0,1
1516,04/06/2019 00:00,DB01773,4-[3-Carboxymethyl-3-(4-Phosphonooxy-Benzyl)-Ureido]-4-[(3-Cyclohexyl-Propyl)-Methyl-Carbamoyl]Butyric Acid,,,,,,solid,,,0.00581,1.74,2.79,[H][C@@](CCC(O)=O)(N=C(O)N(CC(O)=O)CC1=CC=C(OP(O)(O)=O)C=C1)C(=O)N(C)CCCC1CCCCC1,,,,,0,,571.229481,2,1,0,0,0,0
1517,04/06/2019 00:00,DB01774,Adenosine-5'-Monophosphate Glucopyranosyl-Monophosphate Ester,,,,,,solid,,,4.84,1.73,5,NC1=C2N=CN([C@@H]3O[C@H](CO[P@](O)(=O)O[P@](O)(=O)O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](O)[C@H]3O)C2=NC=N1,,,,,0,,589.0822384,4,2,4,2,2,2
1518,04/06/2019 00:00,DB01775,Dihydroxyacetone,,,,,,solid,,,838,13.49,-3.3,OCC(=O)CO,,,,,0,,90.03169405,0,0,0,0,0,0
1519,04/06/2019 00:00,DB01776,M-Cresol,,,,,,solid,2.27E+004 mg/L (at 25 Â°C),1.96,25.1,10.13,-5.5,CC1=CC=CC(O)=C1,,,,,0,,108.0575149,1,1,0,0,0,0
1520,04/06/2019 00:00,DB01777,Coa-S-Trimethylene-Acetyl-Tryptamine,,,,,,solid,,,3.5,0.82,4.8,[H][C@](O)(C(O)=NCCC(O)=NCCSCCCCC(O)=NCCC1=CNC2=CC=CC=C12)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,1009.257122,5,4,4,3,1,1
1521,04/06/2019 00:00,DB01778,"8-Amino-1,3-Dimethyl-3,7-Dihydropurine-2,6-Dione",,,,,,solid,,,3.68,11.27,8.74,CN1C2=C(NC(=N)N2)C(=O)N(C)C1=O,,,,,0,,195.0756245,2,2,2,2,0,0
1522,04/06/2019 00:00,DB01779,Glycerol-2-Phosphate,,,,,,solid,,,30.7,1.13,-3,OCC(CO)OP(O)(O)=O,,,,,0,,172.0136746,0,0,0,0,0,0
1523,04/06/2019 00:00,DB01780,Fusicoccin,,,,,,solid,,,0.0849,12.24,-3,[H]\C1=C2/[C@@]([H])(COC)CC[C@@]2([H])[C@@]([H])(C)[C@@]([H])(O)[C@]([H])(O[C@@]2([H])O[C@]([H])(COC(C)(C)C=C)[C@@]([H])(O)[C@]([H])(OC(C)=O)[C@@]2([H])O)C2=C(C[C@]([H])(O)[C@]12C)[C@]([H])(C)COC(C)=O,,,,,0,,680.3771772,4,0,1,0,1,1
1524,04/06/2019 00:00,DB01782,"2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One",,,,,,solid,,,0.186,12.77,0.46,O=C1C2=CC=CC3=C2C(=NN3)C2=C1C=CC=C2,,,,,0,,220.0636629,4,3,1,1,0,0
1525,02/07/2019 00:00,DB01783,Pantothenic acid,"Dietary pantothenic acid is primarily in the form of CoA or ACP and must be converted into free pantothenic acid for absorption. CoA and ACP are hydrolyzed into 4'-phosphopantetheine which is then dephosphorylated into pantetheine and subsequently hydrolyzed again to free pantothenic acid by Pantetheinase in the intestinal lumen.  Free pantothenic acid is absorbed into intestinal cells via a saturable, sodium-dependent active transport system with passive diffusion acting as a secondary pathway. As intake increases  up to 10-fold absorption rate can decrease to as low as 10% due to transporter saturation.",,,1 g,Oral,solid,Soluble,,60.5,4.35,-2.8,CC(C)(CO)C(O)C(=O)NCCC(O)=O,,,,,0,,219.1106726,0,0,0,0,0,0
1526,04/06/2019 00:00,DB01784,4-Flourobenzenesulfonamide,,,,,,solid,,,2.16,9.81,,NS(=O)(=O)C1=CC=C(F)C=C1,,,,,0,,175.0103277,1,1,0,0,0,0
1527,04/06/2019 00:00,DB01785,Dimethylallyl Diphosphate,,,,,,solid,,,6.54,1.77,,CC(C)=CCO[P@](O)(=O)OP(O)(O)=O,,,,,0,,246.005826,0,0,0,0,0,0
1528,04/06/2019 00:00,DB01786,D-Alanine,,,,,,solid,1.65E+005 mg/L (at 25 Â°C),,447,2.47,9.48,C[C@@H](N)C(O)=O,,,,,0,,89.04767846,0,0,0,0,0,0
1529,04/06/2019 00:00,DB01788,4-Imino-5-Methidyl-2-Methylpyrimidine,,,,,,solid,,,0.157,,5.41,CC1=NC(=N)C(=C)C=N1,,,,,0,,121.0639972,1,0,1,0,0,1
1530,04/06/2019 00:00,DB01789,"1-Amino-2,3-Dihydroxy-5-Hydroxymethyl Cyclohex-5-Ene",,,,,,solid,,,293,13.43,8.61,[H][C@]1(N)C=C(CO)C[C@]([H])(O)[C@@]1([H])O,,,,,0,,159.0895433,1,0,0,0,0,0
1531,04/06/2019 00:00,DB01790,"Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate",,,,,,solid,,,1.84,1.89,4.99,[H][C@@]12CO[P@@](O)(=S)O[C@@]1([H])[C@@]([H])(O)[C@@]([H])(O2)N1C=NC2=C(N)N=CN=C12,,,,,0,,345.0296761,4,2,4,2,2,2
1532,04/06/2019 00:00,DB01791,Piclamilast,,,,,,solid,,,0.0061,8.25,2.4,COC1=CC=C(C=C1OC1CCCC1)C(=O)NC1=C(Cl)C=NC=C1Cl,,,,,0,,380.0694478,3,2,1,1,0,0
1533,04/06/2019 00:00,DB01792,Adenylyl-3'-5'-Phospho-Uridine-3'-Monophosphate,,,,,,solid,,,5.5,0.83,4.94,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,653.0883864,5,3,5,3,2,2
1534,04/06/2019 00:00,DB01793,SB-409513,,,,,,solid,,,0.00214,3.73,-5.3,OC(=O)C1=CC(NC2=C(C(=O)NC2=O)C2=CC(Cl)=CC=C2)=CC=C1Cl,,,,,0,,376.0017622,3,2,1,0,0,1
1535,04/06/2019 00:00,DB01794,bis(molybdopterin)tungsten cofactor,,,,,,solid,,,15.2,3.94,1.25,NC1=NC2=C(NC3C(N2)OC2COP([O-])(=O)O[Mg]OP([O-])(=O)OCC4OC5NC6=C(NC5C5=C4S[W]4(SC2=C3S4)S5)C(=O)NC(N)=N6)C(=O)N1,,,,,-2,,989.8990934,9,2,9,2,1,7
1536,04/06/2019 00:00,DB01795,Phenyl Boronic Acid,,,,,,solid,,,10.1,8.76,-5.4,OB(O)C1=CC=CC=C1,,,,,0,,122.0539099,1,1,0,0,0,0
1537,04/06/2019 00:00,DB01796,Quinolinic Acid,,,,,,solid,1.1E+004 mg/L (at 25 Â°C),,4.07,0.29,5.26,OC(=O)C1=CC=CN=C1C(O)=O,,,,,0,,167.0218576,1,1,1,1,0,0
1538,04/06/2019 00:00,DB01797,"(2R)-2-(aminomethyl)-2,4-dihydroxy-5-oxo-3-(2-oxoethyl)-2,5-dihydro-1h-imidazol-3-ium",,,,,,solid,,,3.71,3.11,7.47,[NH3+]C[C@@]1(O)[N-]C(=O)C(=O)[NH+]1CC(O)=O,,,,,1,,204.0614968,1,0,1,0,1,1
1539,04/06/2019 00:00,DB01798,Ethyl Dihydrogen Diphosphate,,,,,,solid,,,13,1.78,,CCO[P@](O)(=O)OP(O)(O)=O,,,,,0,,205.9745259,0,0,0,0,0,0
1540,04/06/2019 00:00,DB01799,4-Hydroxy-3-Methyl Butyl Diphosphate,,,,,,solid,,,10.5,1.78,-2.6,C[C@H](CO)CCO[P@](O)(=O)OP(O)(O)=O,,,,,0,,264.0163907,0,0,0,0,0,0
1541,04/06/2019 00:00,DB01800,"N,4-Dihydroxy-N-Oxo-3-(Sulfooxy)Benzenaminium",,,,,,solid,,,1.14,-3,-5.5,OC1=CC=C(C=C1OS(O)(=O)=O)[N+]([O-])=O,,,,,0,,234.9786725,1,1,0,0,0,0
1542,04/06/2019 00:00,DB01802,"(4r)-7aza-7,8-Dihydrolimonene",,,,,,solid,,,74.4,,10.16,CN(C)[C@@H]1CCC(C)=CC1,,,,,0,,139.1360995,1,0,0,0,0,0
1543,04/06/2019 00:00,DB01803,2-(Trimethylammonium)Ethyl Thiol,,,,,,solid,,,0.0511,9.7,-9.8,C[N+](C)(C)CCS,,,,,1,,120.0841469,0,0,0,0,0,0
1544,04/06/2019 00:00,DB01804,"2-Ammoniobut-3-Enoate, 2-Amino-3-Butenoate",,,,,,solid,,,7.71,2.42,8.95,[NH3+][C@H](C=C)C([O-])=O,,,,,0,,101.0476785,0,0,0,0,0,0
1545,04/06/2019 00:00,DB01805,Monoisopropylphosphorylserine,,,,,,solid,,,26.8,1.67,9.38,[H][C@](N)(COP(O)(=O)OC(C)C)C(O)=O,,,,,0,,227.0558738,0,0,0,0,0,0
1546,04/06/2019 00:00,DB01806,"10-{4-Dimethylamino-5-[4-Hydroxy-6-Methyl-5-(6-Methyl-5-Oxo-Tetrahydro-Pyran-2-Yloxy)-Tetrahydro-Pyrane-2-Yloxy]-6-Methyl-Tetrahydro-Pyran-2-Yloxy}-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene-5,12-Dione",,,,,,solid,,,0.134,8.94,8.22,[H][C@]1(O)C[C@@]([H])(O[C@]2([H])[C@]([H])(C)O[C@]([H])(C[C@]2([H])N(C)C)O[C@@]2([H])C[C@](O)(CC)CC3=CC4=C(C(O)=C23)C(=O)C2=C(C=CC=C2O)C4=O)O[C@@]([H])(C)[C@]1([H])O[C@@]1([H])CCC(=O)[C@@]([H])(C)O1,,,,,0,,753.3360407,7,2,3,0,3,3
1547,04/06/2019 00:00,DB01807,"N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea",,,,,,solid,,,0.0123,7.15,7.78,CC(C)(C)C1=C\C(=N/C(=O)NC2=CC=C(Cl)C=C2)N(N1)C1=CC=CC=C1,,,,,0,,368.140389,3,3,1,1,0,0
1548,04/06/2019 00:00,DB01808,Thiarsahydroxy-Cysteine,,,,,,solid,,,33.7,1.47,8.79,N[C@@H](CS[AsH]O)C(O)=O,,,,,0,,212.9440856,0,0,0,0,0,0
1549,04/06/2019 00:00,DB01809,"1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",,,,,,solid,,,0.0953,19.69,6.57,CC1=CC=C(C=C1)C1=NN(C2=C1C(N)=NC=N2)C(C)(C)C,,,,,0,,281.1640456,3,3,2,2,0,0
1550,04/06/2019 00:00,DB01810,"[1-(1-Methyl-4,5-Dioxo-Pent-2-Enylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester",,,,,,solid,,,0.0017,13.43,-4,[H][C@@](C)(NC(=O)[C@@]([H])(CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)\C=C\C(=O)C=O,,,,,0,,408.1685219,2,2,0,0,0,0
1551,04/06/2019 00:00,DB01811,"3h-Indole-5,6-Diol",,,,,,solid,,,5.78,8.72,-6.3,OC1=C(O)C=C2C=CNC2=C1,,,,,0,,149.0476785,2,2,1,1,0,0
1552,04/06/2019 00:00,DB01812,Adenosine-3'-5'-Diphosphate,,,,,,solid,,,3.33,0.71,4.92,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O,,,,,0,,427.0294149,3,2,3,2,1,1
1553,04/06/2019 00:00,DB01813,Pyridoxyl-Glutamic Acid-5'-Monophosphate,,,,,,solid,,,0.257,0.98,10.12,[H][C@@](CCC(O)=O)(NCC1=C(COP(O)(O)=O)C=[NH+]C(C)=C1O)C(O)=O,,,,,1,,379.0900933,1,1,1,1,0,0
1554,04/06/2019 00:00,DB01814,2-Tridecanoyloxy-Pentadecanoic Acid,,,,,,solid,,,2.97E-05,4.52,-7,[H][C@](CCCCCCCCCCCC)(CC(O)=O)OC(=O)CCCCCCCCCCCC,,,,,0,,454.4022102,0,0,0,0,0,0
1555,04/06/2019 00:00,DB01815,Nz-(Dicarboxymethyl)Lysine,,,,,,solid,,,6.37,0.082,11.58,N[C@@H](CCCCNC(C(O)=O)C(O)=O)C(O)=O,,,,,0,,248.1008362,0,0,0,0,0,0
1556,04/06/2019 00:00,DB01816,Castanospermine,,,,,,solid,,,1110,12.89,8.96,[H][C@]1(O)CCN2C[C@]([H])(O)[C@@]([H])(O)[C@]([H])(O)[C@@]12[H],,,,,0,,189.100108,2,0,2,0,2,2
1557,04/06/2019 00:00,DB01817,Threonine-Aspartic Ester,,,,,,solid,,,28.1,1.62,9.2,[H][C@](N)(C[C@]([H])(O)O[C@]([H])(C)[C@]([H])(N)C(O)=O)C(O)=O,,,,,0,,236.1008362,0,0,0,0,0,0
1558,04/06/2019 00:00,DB01818,O3-Sulfonylgalactose,,,,,,solid,,,104,-2,-3,[H][C@@]1(O)O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(OS(O)(=O)=O)[C@@]1([H])O,,,,,0,,260.020203,1,0,1,0,1,1
1559,04/06/2019 00:00,DB01819,Phosphoenolpyruvate,,,,,,solid,,,13.2,0.76,,OC(=O)C(=C)OP(O)(O)=O,,,,,0,,167.9823745,0,0,0,0,0,0
1560,04/06/2019 00:00,DB01820,"Compound 12, N-Acetyl-4-[(Carboxycarbonyl)(2-Carboxyphenyl)Amino]-N-Pentyl-1-Napthylalaniamide",,,,,,solid,,,0.0016,2.47,4.01,[H][C@@](CC1=CC=C(N(C(=O)C(O)=O)C2=CC=CC=C2C(O)=O)C2=CC=CC=C12)(N=C(C)O)C(O)=NCCCCC,,,,,0,,533.2162003,3,3,0,0,0,0
1561,04/06/2019 00:00,DB01821,"L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide",,,,,,solid,,,0.249,-1.3,12.9,[H][C@](N)(CCCNC(=N)NN(=O)=O)C(O)=N[C@@]([H])(CCN)C(O)=N,,,,,0,,318.1764012,0,0,0,0,0,0
1562,04/06/2019 00:00,DB01822,"(4R,5R)-1,2-dithiane-4,5-diol",,,,,,solid,,,70.5,13.48,-3.3,O[C@H]1CSSC[C@@H]1O,,,,,0,,151.9965715,1,0,1,0,1,1
1563,04/06/2019 00:00,DB01823,Beta-D-Glucopyranose Spirohydantoin,,,,,,solid,,,230,9.09,-3,OC[C@H]1O[C@]2(NC(=O)NC2=O)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,248.0644507,2,0,2,0,2,2
1564,04/06/2019 00:00,DB01824,"(3s)-Tetrahydrofuran-3-Yl (1r,2s)-3-[4-((1r)-2-{[(S)-Amino(Hydroxy)Methyl]Oxy}-2,3-Dihydro-1h-Inden-1-Yl)-2-Benzyl-3-Oxopyrrolidin-2-Yl]-1-Benzyl-2-Hydroxypropylcarbamate",,,,,,solid,,,0.0136,8.28,7.67,[H][C@](N)(O)O[C@]1([H])CC2=CC=CC=C2[C@]1([H])[C@]1([H])CN[C@@](CC2=CC=CC=C2)(C[C@]([H])(O)[C@]([H])(CC2=CC=CC=C2)N=C(O)O[C@@]2([H])CCOC2)C1=O,,,,,0,,629.3101007,6,3,2,0,2,2
1565,04/06/2019 00:00,DB01825,2-Amino-8-Methylquinazolin-4(3h)-One,,,,,,solid,,,1.12,10,1.55,CC1=CC=CC2=C1NC(N)=NC2=O,,,,,0,,175.0745619,2,2,1,1,0,0
1566,04/06/2019 00:00,DB01826,N-Butyl Isocyanide,,,,,,solid,,,0.5,16.22,,CCCC[N+]#[C-],,,,,0,,83.07349929,0,0,0,0,0,0
1567,04/06/2019 00:00,DB01827,"2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide",,,,,,solid,,,0.309,10.49,-3,COC1=C(F)C(F)=C(C(N)=O)C(F)=C1F,,,,,0,,223.0256413,1,1,0,0,0,0
1568,04/06/2019 00:00,DB01828,Methylamine,,,,,,solid,1.08E+006 mg/L (at 25 Â°C),-0.57,367,,10.08,CN,,,,,0,,31.04219916,0,0,0,0,0,0
1569,04/06/2019 00:00,DB01829,Desulfo-Coenzyme A,,,,,,solid,,,6.44,0.82,5.14,[H][C@](O)(C(O)=NCCC(O)=NCC)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,735.143138,3,2,3,2,1,1
1570,04/06/2019 00:00,DB01830,"{4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid",,,,,,solid,,,0.0165,1.21,6.72,[H][C@@](CC1=CC(=C(C=C1)P(O)(O)=O)P(O)(O)=O)(N=C(C)O)C(O)=N[C@@]1([H])CCCCC2=CC(OCC3CCCCC3)=C(C=C12)C(O)=N,,,,,0,,665.2267178,4,2,0,0,0,0
1571,04/06/2019 00:00,DB01831,Tryptophanyl-5'amp,,,,,,solid,,,1.11,0.77,6.92,N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(N)N=CN=C12,,,,,0,,533.1423974,5,4,4,3,1,1
1572,04/06/2019 00:00,DB01832,4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid,,,,,,solid,,,29.9,1.85,-7.8,C[P@@](O)(=O)CC(=O)CC(O)=O,,,,,0,,180.01876,0,0,0,0,0,0
1573,04/06/2019 00:00,DB01833,L-2-Amino-4-(Guanidinooxy)Butyric Acid,,,,,,solid,,,2.77,2.1,10.34,N[C@@H](CCONC(N)=N)C(O)=O,,,,,0,,176.0909402,0,0,0,0,0,0
1574,04/06/2019 00:00,DB01834,"(9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene",,,,,,solid,,,0.031,1.8,9.31,[H][C@](N)(CCC(=O)N[C@@]([H])(CS[C@]1([H])C2=CC=CC=C2C2=CC=CC=C2[C@@]1([H])O)C(=O)NCC(O)=O)C(O)=O,,,,,0,,501.1569712,3,2,0,0,0,0
1575,04/06/2019 00:00,DB01835,4r-Fluoro-N6-Ethanimidoyl-L-Lysine,,,,,,solid,,,0.442,2.54,12.76,CC(=N)NCC[C@@H](F)C[C@H](N)C(O)=O,,,,,0,,205.122655,0,0,0,0,0,0
1576,04/06/2019 00:00,DB01836,"[4-(6-Chloro-Naphthalene-2-Sulfonyl)-Piperazin-1-Yl]-(3,4,5,6-Tetrahydro-2h-[1,4']Bipyridinyl-4-Yl)-Methanone",,,,,,solid,,,0.0343,,8.72,ClC1=CC=C2C=C(C=CC2=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1CCN(CC1)C1=CC=NC=C1,,,,,0,,498.1492394,5,3,3,1,2,2
1577,04/06/2019 00:00,DB01837,O-acetyl-L-serine,,,,,,solid,,,174,1.86,8.6,CC(=O)OC[C@H](N)C(O)=O,,,,,0,,147.0531578,0,0,0,0,0,0
1578,04/06/2019 00:00,DB01838,"6,4'-Dihydroxy-3-Methyl-3',5'-Dibromoflavone",,,,,,solid,,,0.0196,6.01,-5.4,CC1=C(OC2=CC=C(O)C=C2C1=O)C1=CC(Br)=C(O)C(Br)=C1,,,,,0,,423.894583,3,3,1,1,0,0
1579,04/06/2019 00:00,DB01839,Propylene glycol,,,,9.5 mg/1mL,Ophthalmic,solid,1E+006 mg/L (at 20 Â°C),-0.92,952,14.47,-2.9,CC(O)CO,,,,,0,,76.0524295,0,0,0,0,0,0
1580,04/06/2019 00:00,DB01840,2-Deoxy-D-Glucitol 6-(E)-Vinylhomophosphonate,,,,,,solid,,,21,3.54,-2.4,OCC[C@@H](O)[C@H](O)[C@H](O)\C=C\P(O)(O)=O,,,,,0,,242.0555395,0,0,0,0,0,0
1581,04/06/2019 00:00,DB01841,"4,6-Dideoxyglucose",,,,,,solid,,,904,11.33,-3.3,[H][C@@]1(C)C[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(O)O1,,,,,0,,148.0735589,1,0,1,0,1,1
1582,04/06/2019 00:00,DB01842,3'-Phosphate-Adenosine-5'-Diphosphate,,,,,,solid,,,4.61,0.81,4.94,[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,506.9957455,3,2,3,2,1,1
1583,04/06/2019 00:00,DB01843,"3-Amino-8,9,10-Trihydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione",,,,,,solid,,,116,5.62,2.09,[H][C@]1(CO)O[C@@]2(N=C(O)N(N)C2=O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,263.0753498,2,0,2,0,1,2
1584,04/06/2019 00:00,DB01844,"N,N-dimethylformamide",,,,,,solid,1E+006 mg/L (at 25 Â°C),-1.01,725,,-0.65,CN(C)C=O,,,,,0,,73.05276384,0,0,0,0,0,0
1585,04/06/2019 00:00,DB01846,Oxidized Coenzyme A,,,,,,solid,,,6.8,0.82,4.78,[H][C@](O)(C(O)=NCCC(O)=NCCSO)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,783.1101236,3,2,3,2,1,1
1586,04/06/2019 00:00,DB01847,N-Carbamyl-D-Valine,,,,,,solid,,,21.4,4.02,-2,CC(C)[C@@H](NC(N)=O)C(O)=O,,,,,0,,160.0847922,0,0,0,0,0,0
1587,04/06/2019 00:00,DB01849,"3,4-Dihydrouracil",,,,,,solid,,,25.9,11.73,-7.6,O=C1CCNC(=O)N1,,,,,0,,114.0429274,1,0,1,0,1,1
1588,04/06/2019 00:00,DB01850,"(2s,3s,8s,9s)-3-Amino-9-Methoxy-2,6,8-Trimethyl-10-Phenyldeca-4,6-Dienoic Acid",,,,,,solid,,,0.00813,4.01,10.01,[H]\C(=C(\[H])[C@]([H])(N)[C@]([H])(C)C(O)=O)\C(\C)=C(/[H])[C@@]([H])(C)[C@@]([H])(CC1=CC=CC=C1)OC,,,,,0,,331.2147438,1,1,0,0,0,0
1589,04/06/2019 00:00,DB01851,Tetrabutylammonium Ion,,,,,,solid,,,1.14E-05,,,CCCC[N+](CCCC)(CCCC)CCCC,,,,,1,,242.2842266,0,0,0,0,0,0
1590,04/06/2019 00:00,DB01852,Kaempherol,,,,,,solid,,,0.178,6.44,-3.9,OC1=CC=C(C=C1)C1=C(O)C(=O)C2=C(O1)C=C(O)C=C2O,,,,,0,,286.047738,3,3,1,1,0,0
1591,04/06/2019 00:00,DB01853,Bacteriochlorophyll A,,,,,,solid,,,0.000187,3.84,7.45,[H][C@]1(CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)\C2=C\C3=C(C)C(C(C)=O)=C4\C=C5/N=C(/C=C6\N([Mg]N34)C3=C([C@@H](C(=O)OC)C(=O)C3=C6C)C1=N2)[C@H](CC)[C@H]5C,,,,,0,,910.5458778,7,2,6,2,0,4
1592,04/06/2019 00:00,DB01854,5-Bromonicotinamide,,,,,,solid,,,16.7,13.07,1.97,NC(=O)C1=CN=CC(Br)=C1,,,,,0,,199.9585249,1,1,1,1,0,0
1593,04/06/2019 00:00,DB01855,5-(Hydroxy-Methyl-Amino)-3-Methyl-Pyrrolidine-2-Carboxylic Acid,,,,,,solid,,,170,3.11,7.43,[H][C@@]1(C)C[C@]([H])(N[C@@]1([H])C(O)=O)N(C)O,,,,,0,,174.1004423,1,0,1,0,1,1
1594,04/06/2019 00:00,DB01856,Pimelic Acid,,,,,,solid,5E+004 mg/L (at 20 Â°C),0.61,13.3,4.05,,OC(=O)CCCCCC(O)=O,,,,,0,,160.0735589,0,0,0,0,0,0
1595,04/06/2019 00:00,DB01857,Phosphoaspartate,,,,,,solid,,,13.2,1.08,8.6,N[C@@H](CC(=O)OP(O)(O)=O)C(O)=O,,,,,0,,213.0038382,0,0,0,0,0,0
1596,04/06/2019 00:00,DB01858,[1-(4-Fluorobenzyl)Cyclobutyl]Methyl (1s)-1-[Oxo(1h-Pyrazol-5-Ylamino)Acetyl]Pentylcarbamate,,,,,,solid,,,0.00446,11.9,1.86,[H][C@@](CCCC)(NC(=O)OCC1(CC2=CC=C(F)C=C2)CCC1)C(=O)C(=O)NC1=CC=NN1,,,,,0,,444.2172836,3,2,1,1,0,0
1597,04/06/2019 00:00,DB01859,4-Diphosphocytidyl-2-C-Methyl-D-Erythritol 2-Phosphate,,,,,,solid,,,9.98,1.05,1.85,[H][C@@](O)(COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=CC(=N)N=C2O)[C@]([H])(O)[C@]1([H])O)[C@](C)(CO)OP(O)(O)=O,,,,,0,,601.0475063,2,1,2,1,1,1
1598,04/06/2019 00:00,DB01860,Cordycepin Triphosphate,,,,,,solid,,,3.83,0.9,5,[H][C@@]1(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C[C@@]([H])(O)[C@@]([H])(O1)N1C=NC2=C(N)N=CN=C12,,,,,0,,491.0008308,3,2,3,2,1,1
1599,04/06/2019 00:00,DB01861,Uridine diphosphate glucose,,,,,,solid,,,15,1.73,-3.6,OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)NC2=O)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,566.0550206,3,1,3,1,2,2
1600,04/06/2019 00:00,DB01862,Isopropyl beta-D-thiogalactopyranoside,,,,,,solid,,-1.26,128,12.48,-3,[H][C@]1(CO)O[C@@]([H])(SC(C)C)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,238.0874947,1,0,1,0,1,1
1601,04/06/2019 00:00,DB01863,"Inositol 1,3,4,5-Tetrakisphosphate",,,,,,solid,,,11.5,0.33,,O[C@H]1[C@@H](OP(O)(O)=O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1OP(O)(O)=O,,,,,0,,499.9287102,1,0,0,0,0,0
1602,04/06/2019 00:00,DB01864,5'-Guanosine-Diphosphate-Monothiophosphate,,,,,,solid,,,5.15,1.08,4.91,[H][C@]1(COP(O)(=O)OP(O)(=O)OP(O)(O)=S)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,538.9678165,3,2,3,2,1,1
1603,04/06/2019 00:00,DB01865,3-(6-Aminopyridin-3-Yl)-N-Methyl-N-[(1-Methyl-1h-Indol-2-Yl)Methyl]Acrylamide,,,,,,solid,,,0.0321,,6.45,CN(CC1=CC2=C(C=CC=C2)N1C)C(=O)\C=C\C1=CN=C(N)C=C1,,,,,0,,320.1637113,3,3,2,2,0,0
1604,04/06/2019 00:00,DB01866,RU79256,,,,,,solid,,,2.41,-1.3,,[H][C@](C(O)=O)(C1=CC=CC=C1)S(O)(=O)=O,,,,,0,,216.0092444,1,1,0,0,0,0
1605,04/06/2019 00:00,DB01868,Glycyl-L-a-Aminopimelyl-E-(D-2-Aminoethyl)Phosphonate,,,,,,solid,,,5.52,1.58,9.36,[H][C@](C)(N=C([O-])CCCC[C@]([H])(N=C(O)CN)C(O)=O)P(O)(O)=O,,,,,-1,,338.1122602,0,0,0,0,0,0
1606,04/06/2019 00:00,DB01870,"1,4-dithio-alpha-D-glucopyranose",,,,,,solid,,,8.09,8.59,-3,[H][C@@]1(O)[C@@]([H])(O)[C@]([H])(S)[C@@]([H])(CO)O[C@]1([H])S,,,,,0,,212.0177009,1,0,1,0,1,1
1607,04/06/2019 00:00,DB01871,[1-(1-Benzyl-3-Hydroxy-2-Oxo-Propylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester,,,,,,solid,,,0.00155,12.54,-3.3,[H][C@@](CC1=CC=CC=C1)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)C(=O)CO,,,,,0,,460.199822,3,3,0,0,0,0
1608,04/06/2019 00:00,DB01872,2-deoxy-2-acetamido-beta-D-galactose-4-sulfate,,,,,,solid,,,42.9,-1.9,-0.75,CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O,,,,,0,,301.0467521,1,0,1,0,1,1
1609,04/06/2019 00:00,DB01873,Epothilone D,,,,,,solid,,,0.00246,14.09,2.73,[H]\C(=C(\C)[C@]1([H])C\C([H])=C(C)/CCC[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)C(C)(C)[C@@]([H])(O)CC(=O)O1)C1=CSC(C)=N1,,,,,0,,491.2705444,2,1,2,1,0,1
1610,04/06/2019 00:00,DB01874,Tropinone,,,,,,solid,,,541,18.02,8.88,CN1[C@H]2CC[C@@H]1CC(=O)C2,,,,,0,,139.099714,2,0,2,0,2,2
1611,04/06/2019 00:00,DB01875,8-Azaxanthine,,,,,,solid,,,6.79,5.8,-0.18,OC1=NC2=C(N=NN2)C(O)=N1,,,,,0,,153.0286743,2,2,2,2,0,0
1612,04/06/2019 00:00,DB01876,Bis(5-Amidino-2-Benzimidazolyl)Methanone,,,,,,solid,,,0.0263,7.47,11.5,NC(=N)C1=CC2=C(C=C1)N=C(N2)C(=O)C1=NC2=C(N1)C=CC(=C2)C(N)=N,,,,,0,,346.1290571,4,4,2,2,0,0
1613,04/06/2019 00:00,DB01877,"N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide",,,,,,solid,,,2.32,8.71,3.92,CON[C@H]1C[C@@H](N(C1)S(=O)(=O)C1=CC=C(OC)C=C1)C(=O)NO,,,,,0,,345.0994563,2,1,1,0,1,1
1614,04/06/2019 00:00,DB01878,Benzophenone,,,,,Topical,solid,137 mg/L (at 25 Â°C),3.18,0.0401,,-7.5,O=C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,182.0731649,2,2,0,0,0,0
1615,04/06/2019 00:00,DB01879,(S)-2-{Methyl-[2-(Naphthalene-2-Sulfonylamino)-5-(Naphthalene-2-Sulfonyloxy)-Benzoyl]-Amino}-Succinicacid,,,,,,solid,,,0.000444,2.38,-1.5,[H][C@@](CC(O)=O)(N(C)C(=O)C1=C(NS(=O)(=O)C2=CC3=CC=CC=C3C=C2)C=CC(OS(=O)(=O)C2=CC3=CC=CC=C3C=C2)=C1)C(O)=O,,,,,0,,662.102887,5,5,0,0,0,0
1616,04/06/2019 00:00,DB01880,"3,4-Dihydroxycinnamic Acid",,,,,,solid,,1.15,1.61,3.64,-6.3,OC(=O)\C=C\C1=CC(O)=C(O)C=C1,,,,,0,,180.0422587,1,1,0,0,0,0
1617,04/06/2019 00:00,DB01881,"2-Methylpentane-1,2,4-Triol",,,,,,solid,,,440,13.98,-2.6,[H][C@@](C)(O)C[C@](C)(O)CO,,,,,0,,134.0942943,0,0,0,0,0,0
1618,04/06/2019 00:00,DB01882,"(2s)-2-Amino-4-(Methylsulfanyl)-1-Pyridin-2-Ylbutane-1,1-Diol",,,,,,solid,,,9.28,10.24,8.39,[H][C@](N)(CCSC)C(O)(O)C1=CC=CC=N1,,,,,0,,228.0932488,1,1,1,1,0,0
1619,04/06/2019 00:00,DB01883,N-(Sulfanylacetyl)Tyrosylprolylmethioninamide,,,,,,solid,,,0.0197,9.17,-3.4,[H][C@@](CCSC)(NC(=O)[C@]1([H])CCCN1C(=O)[C@]([H])(CC1=CC=C(O)C=C1)NC(=O)CS)C(N)=O,,,,,0,,482.1657621,2,1,1,0,1,1
1620,04/06/2019 00:00,DB01884,2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One,,,,,,solid,,,244,,8.51,[H][C@](N)(C(C)C)C(=O)N1CCCC1,,,,,0,,170.1419132,1,0,1,0,1,1
1621,04/06/2019 00:00,DB01885,D-Galctopyranosyl-1-On,,,,,,solid,,,586,11.62,-3,[H][C@]1(O)C(=O)O[C@]([H])(CO)[C@]([H])(O)[C@]1([H])O,,,,,0,,178.047738,1,0,1,0,1,1
1622,04/06/2019 00:00,DB01887,Inhibitor BEA369,,,,,,solid,,,0.0402,4.54,2.32,[H][C@@](O)([C@@]([H])(O)[C@@]([H])(OCC1=CC=CC=C1)C(O)=N[C@@]1([H])C2=CC=CC=C2C[C@@]1([H])O)[C@@]([H])(OCC1=CC=CC=C1)C(O)=N[C@]1([H])CO[C@]([H])(CO)C1,,,,,0,,620.2733809,5,3,1,0,1,1
1623,04/06/2019 00:00,DB01888,"4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide",,,,,,solid,,,0.00934,17.55,10.45,CC(C)C1=C2N=C(N[C@H]3CC[C@H](N)CC3)C=C(NC3=CC=C(C=C3)S(=O)(=O)N(C)C)N2N=C1,,,,,0,,471.2416443,4,3,2,2,0,0
1624,04/06/2019 00:00,DB01889,"16,17-Androstene-3-Ol",,,,,,solid,,,0.000355,18.3,-1.4,[H][C@@]12CC=C[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@]([H])(O)CC[C@]12C,,,,,0,,274.2296656,4,0,0,0,0,0
1625,04/06/2019 00:00,DB01890,"N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide",,,,,,solid,,,0.0736,5.13,3.66,[H][C@@](C)(CCC(=O)N(CCCN=C(O)[C@]([H])(O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)CO)CCCN=C(O)[C@]([H])(O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)CO)[C@@]1([H])CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C,,,,,0,,861.5198187,4,0,0,0,0,0
1626,04/06/2019 00:00,DB01891,Tl-3-093,,,,,,solid,,,0.00941,12.46,-2.8,[H][C@@](CO)(CC1=CC=CC=C1)NC(=O)[C@@]([H])(NC(=O)[C@]([H])(C)NC(=O)OCC1=CC=CC=C1)C(C)C,,,,,0,,455.2420212,2,2,0,0,0,0
1627,04/06/2019 00:00,DB01892,Hyperforin,,,9 hours,,,solid,,,0.000632,3.82,-7.3,CC(C)C(=O)[C@@]12C(O)=C(CC=C(C)C)C(=O)[C@@](CC=C(C)C)(C[C@H](CC=C(C)C)[C@@]1(C)CCC=C(C)C)C2=O,,,9,9,0,,536.3865601,2,0,0,0,0,0
1628,04/06/2019 00:00,DB01893,N6-Benzyl Adenosine-5'-Diphosphate,,,,,,solid,,,2.23,1.77,4.85,[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(NCC4=CC=CC=C4)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,517.0763651,4,3,3,2,1,1
1629,04/06/2019 00:00,DB01895,Aspartyl-Adenosine-5'-Monophosphate,,,,,,solid,,,2.59,0.76,7.49,[H][C@](N)(CC(O)=O)C(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,462.0900274,3,2,3,2,1,1
1630,04/06/2019 00:00,DB01896,M-Aminophenylboronic Acid,,,,,,solid,,,2.53,8.79,3.12,NC1=CC=CC(=C1)B(O)O,,,,,0,,137.0648089,1,1,0,0,0,0
1631,04/06/2019 00:00,DB01897,2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride,,,,,,solid,,,0.00281,10.01,-0.54,O=C1NNC(=O)C2=CC(=CC=C12)[N+]1=NC(\C=C\C2=CC=CC=C2)=NN1C1=NC2=C(S1)C=CC=C2,,,,,1,,466.1080702,6,6,3,3,0,0
1632,04/06/2019 00:00,DB01898,"(2S,3S)-2-azanyl-3-methyl-pentanedioic acid",,,,,,solid,,,38.1,2.02,9.6,[H][C@](C)(CC(O)=O)[C@]([H])(N)C(O)=O,,,,,0,,161.0688078,0,0,0,0,0,0
1633,04/06/2019 00:00,DB01899,Nd1-Phosphonohistidine,,,,,,solid,,,1.79,0.56,8.98,N[C@@H](CC1=C[NH+]=CN1P(O)(O)=O)C(O)=O,,,,,1,,236.0430835,1,1,1,1,0,0
1634,04/06/2019 00:00,DB01901,Sucrosofate,,,,,,solid,,,1.45,-3.4,,OS(=O)(=O)OC[C@H]1O[C@@](COS(O)(=O)=O)(O[C@H]2O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1OS(O)(=O)=O,,,,,0,,981.7707304,2,0,2,0,2,2
1635,04/06/2019 00:00,DB01902,"1-Ethyl-Pyrrolidine-2,5-Dione",,,,,,solid,,,615,,-6.7,CCN1C(=O)CCC1=O,,,,,0,,127.0633285,1,0,1,0,1,1
1636,04/06/2019 00:00,DB01903,5-Bromo-2'-Deoxyuridine-5'-Monophosphate,,,,,,solid,,,13,1.23,-3.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C(Br)C(O)=NC1=O,,,,,0,,385.9514641,2,1,2,1,1,1
1637,04/06/2019 00:00,DB01905,2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine,,,,,,solid,,,0.0802,9.08,10.59,COC1=CC=C(O)C(=C1)C1=NC2=C(N1)C=CC(=C2)C(N)=[NH2+],,,,,1,,283.1189521,3,3,1,1,0,0
1638,04/06/2019 00:00,DB01906,"3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-Benzoic Acid",,,,,,solid,,,2.83,3.9,-1.5,NC1=NC2=NN(N=C2C(O)=N1)C1=CC(=CC=C1)C(O)=O,,,,,0,,272.0657881,3,3,2,2,0,0
1639,04/06/2019 00:00,DB01908,RU85493,,,,,,solid,,,0.00449,1.93,1.38,[H][C@@](CC1=CC(=C(OCC(O)=O)C=C1)P(O)(O)=O)(N=C(C)O)C(O)=N[C@@]1([H])CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O,,,,,0,,637.2189164,4,3,1,0,1,1
1640,04/06/2019 00:00,DB01909,Alpha-Cyclodextrin (Cyclohexa-Amylose),,,,,,solid,,,792,11.56,-3.7,[H][C@]1(CO)O[C@]2([H])O[C@]3([H])[C@@]([H])(CO)O[C@]([H])(O[C@]4([H])[C@@]([H])(CO)O[C@]([H])(O[C@]5([H])[C@@]([H])(CO)O[C@]([H])(O[C@]6([H])[C@@]([H])(CO)O[C@]([H])(O[C@]7([H])[C@@]([H])(CO)O[C@]([H])(O[C@@]1([H])[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]7([H])O)[C@]([H])(O)[C@@]6([H])O)[C@]([H])(O)[C@@]5([H])O)[C@]([H])(O)[C@@]4([H])O)[C@]([H])(O)[C@@]3([H])O,,,,,0,,972.3169405,22,0,22,0,22,22
1641,04/06/2019 00:00,DB01910,Sinefungin,,,,,,solid,,,4.63,1.95,10.18,[H][C@](N)(CC[C@]([H])(N)C(O)=O)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,381.1760668,3,2,3,2,1,1
1642,04/06/2019 00:00,DB01911,N-Methylmesoporphyrin,,,,,,solid,,,0.0383,3.71,5.03,CCC1=C(C)C2=CC3=C(CC)C(C)=C(C=C4N=C(C=C5N\C(=C/C1=N2)C(C)=C5CCC(O)=O)C(CCC(O)=O)=C4C)N3C,,,,,0,,580.3049558,5,3,5,3,0,2
1643,04/06/2019 00:00,DB01912,"2,2':6',2''-Terpyridine Platinum(Ii)",,,,,,solid,,,0.129,,3.26,[Cl-].[Pt++].C1=CC=C(N=C1)C1=CC=CC(=N1)C1=CC=CC=N1,,,,,1,,463.0283926,3,3,3,3,0,0
1644,04/06/2019 00:00,DB01914,D-glucose,"Polysaccharides can be broken down into smaller units by pancreatic and intestinal glycosidases or intestinal flora. Sodium-dependent glucose transporter SGLT1 and GLUT2 (SLC2A2) play predominant roles in intestinal transport of glucose into the circulation.[A19395] SGLT1 is located in the apical membrane of the intestinal wall while GLUT2 is located in the basolateral membrane, but it was proposed that GLUT2 can be recruited into the apical membrane after a high luminal glucose bolus allowing bulk absorption of glucose by facilitated diffusion.[A19400] Oral preparation of glucose reaches the peak concentration within 40 minutes and the intravenous infusions display 100% bioavailability.[A19406]",,"The approximate half-life is 14.3 minutes following intravenous infusion. Gut glucose half-life was markedly higher in females (79 Â± 2 min) than in males (65 Â± 3 min, P < 0.0001) and negatively related to body height (r = -0.481; P < 0.0001).[A19407]",5000 mg/100mL,Intravenous,solid,Soluble,,261,11.8,-3,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O,,,,,0,,180.0633881,0,0,0,0,0,0
1645,04/06/2019 00:00,DB01915,S-Hydroxycysteine,,,,,,solid,,,342,1.87,8.69,N[C@@H](CSO)C(O)=O,,,,,0,,137.0146641,0,0,0,0,0,0
1646,04/06/2019 00:00,DB01917,Putrescine,,,,,,solid,,-0.7,236,,10.51,NCCCCN,,,,,0,,88.10004838,0,0,0,0,0,0
1647,04/06/2019 00:00,DB01918,[Methyltelluro]Acetate,,,,,,solid,,,116,3.8,,C[Te]CC([O-])=O,,,,,-1,,202.9357274,0,0,0,0,0,0
1648,04/06/2019 00:00,DB01919,Pentanal,,,,,,solid,1.17E+004 mg/L (at 25 Â°C),,14.8,15.59,-6.9,CCCCC=O,,,,,0,,86.07316494,0,0,0,0,0,0
1649,04/06/2019 00:00,DB01920,1-O-[O-Nitrophenyl]-Beta-D-Galactopyranose,,,,,,solid,,,20.6,12.2,-3,[H][C@]1(CO)O[C@@]([H])(OC2=CC=CC=C2N(=O)=O)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,301.0797664,2,1,1,0,1,1
1650,04/06/2019 00:00,DB01921,Xylose-Derived Lactam Oxime,,,,,,solid,,,76.7,9.74,1.48,O\N=C1/NC[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,162.0640568,1,0,1,0,1,1
1651,04/06/2019 00:00,DB01922,"Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam",,,,,,solid,,,198,11.84,5.36,[H][C@]1(CO)O[C@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@]([H])(O[C@]3([H])[C@@]([H])(CO)N=C(NO)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,516.1802683,3,0,3,0,2,3
1652,04/06/2019 00:00,DB01923,L-Xylulose 5-Phosphate,,,,,,solid,,,26.1,1.48,-3.3,[H][C@](O)(COP(O)(O)=O)[C@@]([H])(O)C(=O)CO,,,,,0,,230.0191539,0,0,0,0,0,0
1653,04/06/2019 00:00,DB01924,Benzhydroxamic Acid,,,,,,solid,,0.26,4.57,9.65,-5.1,ONC(=O)C1=CC=CC=C1,,,,,0,,137.0476785,1,1,0,0,0,0
1654,04/06/2019 00:00,DB01925,"2'-Chloro-Biphenyl-2,3-Diol",,,,,,solid,,,0.105,9.03,-6.3,OC1=CC=CC(=C1O)C1=C(Cl)C=CC=C1,,,,,0,,220.0291072,2,2,0,0,0,0
1655,04/06/2019 00:00,DB01926,Carboxymycobactin S,,,,,,solid,,,0.103,4.88,7.08,C[C@H]1C[C@H](O)N[C@@H]2CCCCN(O[Fe@@]34O[C@@H](\C=C\CCCCCCC(O)=O)[N@](CCCC[C@H](NC(=O)[C@H]5COC(=N5)C5=CC=CC=C5O3)C(=O)O1)O4)C2=O,,,,,0,,801.2883596,6,1,5,0,3,5
1656,04/06/2019 00:00,DB01927,Duroquinone,,,,,,solid,,2.23,1.69,,-7.4,CC1=C(C)C(=O)C(C)=C(C)C1=O,,,,,0,,164.0837296,1,0,0,0,0,0
1657,04/06/2019 00:00,DB01929,"5-Chloryl-2,4,6-Quinazolinetriamine",,,,,,solid,,,1.37,17.16,4.98,NC1=C(C2=C(N)N=C(N)N=C2C=C1)[Cl](=O)=O,,,,,,,,,,,,,
1658,04/06/2019 00:00,DB01930,"2,4-Dihydroxy-3,3-Dimethyl-Butyrate",,,,,,solid,,,473,3.96,-2.8,CC(C)(CO)[C@@H](O)C([O-])=O,,,,,-1,,147.0662824,0,0,0,0,0,0
1659,04/06/2019 00:00,DB01931,"Dcka, 5,7-Dichlorokynurenic Acid",,,,,,solid,,,0.156,3.82,0.59,OC(=O)C1=NC2=CC(Cl)=CC(Cl)=C2C(O)=C1,,,,,0,,256.9646484,2,2,1,1,0,0
1660,04/06/2019 00:00,DB01932,5-Methylpyrrole,,,,,,solid,,,276,18.08,,CC1=CNC=C1,,,,,0,,81.05784922,1,1,1,1,0,0
1661,04/06/2019 00:00,DB01933,7-Hydroxystaurosporine,,,,,,solid,,,0.0592,7.42,9.56,[H][C@]1(O)N=C(O)C2=C3C4=CC=CC=C4N4C3=C3N(C5=CC=CC=C5C3=C12)[C@@]1(C)O[C@]4([H])C[C@@]([H])(NC)[C@@]1([H])OC,,,,,0,,482.1954053,8,5,5,2,1,3
1662,04/06/2019 00:00,DB01934,"N-Methyl-N-(10-Methylundecanoyl)-D-Seryl-L-Alanyl-N~1~-[(7s,10s,13s)-13-Carboxy-3,18-Dihydroxy-10-Methyl-8,11-Dioxo-9,12-Diazatricyclo[13.3.1.1~2,6~]Icosa-1(19),2(20),3,5,15,17-Hexaen-7-Yl]-N~1~-Methylglycinamide",,,,,,solid,,,0.00718,-6.5,15,[H][C@](C)(N=C(O)[C@@]([H])(CO)N(C)C(=O)CCCCCCCCC(C)C)C(O)=NCC(=O)N(C)[C@@]1([H])C2=CC(=C(O)C=C2)C2=C(O)C=CC(C[C@]([H])(N=C(O)[C@]([H])(C)N=C1O)C(O)=O)=C2,,,,,0,,824.4320067,3,2,1,0,0,1
1663,04/06/2019 00:00,DB01935,3-{[(1r)-1-Benzyl-2-Sulfanylethyl]Amino}-3-Oxopropanoic Acid,,,,,,solid,,,0.412,4.11,-5.4,[H][C@](CS)(CC1=CC=CC=C1)NC(=O)CC(O)=O,,,,,0,,253.0772643,1,1,0,0,0,0
1664,04/06/2019 00:00,DB01936,alpha-D-arabinofuranose,,,,,,solid,,-2.32,1070,11.31,-3,OC[C@H]1O[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,150.0528234,1,0,1,0,1,1
1665,04/06/2019 00:00,DB01937,Guanosine-2'-Monophosphate,,,,,,solid,,,2.92,0.81,4.86,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(OP(O)(O)=O)[C@]1([H])O,,,,,0,,363.057999,3,2,3,2,1,1
1666,04/06/2019 00:00,DB01938,L-Histidine Beta Naphthylamide,,,,,,solid,,,0.104,12.75,8.01,[H][C@@](N)(CC1=CN=CN1)C(=O)NC1=CC=C2C=CC=CC2=C1,,,,,0,,280.1324111,3,3,1,1,0,0
1667,04/06/2019 00:00,DB01939,5-Amidino-Benzimidazole,,,,,,solid,,,1.86,11.77,10.92,NC(=[NH2+])C1=CC2=C(C=C1)N=CN2,,,,,1,,161.0821727,2,2,1,1,0,0
1668,04/06/2019 00:00,DB01940,Balanol Analog 2,,,,,,solid,,,0.00395,7.98,9.65,[H][C@]1(CNCCC[C@@]1([H])OC(=O)C1=CC=C(C=C1)C(=O)C1=CC=CC=C1O)NC(=O)C1=CC=C(O)C=C1,,,,,0,,474.1790866,4,3,1,0,1,1
1669,04/06/2019 00:00,DB01941,"6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-Tetrahydronaphthalen-2-Yl)Cyclopropyl]Pyridine-3-Carboxylic Acid",,,,,,solid,,,0.000302,3.93,2.53,CC1=CC2=C(C=C1C1(CC1)C1=CC=C(C=N1)C(O)=O)C(C)(C)CCC2(C)C,,,,,0,,363.2198292,4,2,1,1,0,0
1670,04/06/2019 00:00,DB01942,Formic acid,Formic acid is readily metabolized and eliminated by the body.,,,,Oral,liquid,1E+006 mg/L (at 25 Â°C),-0.54,477,4.27,,OC=O,,,,,0,,46.0054793,0,0,0,0,0,0
1671,04/06/2019 00:00,DB01944,(S)-blebbistatin,,,,,,solid,,,0.198,11.54,2.73,CC1=CC=C2N=C3N(CC[C@@]3(O)C(=O)C2=C1)C1=CC=CC=C1,,,,,0,,292.1211778,4,2,2,0,1,2
1672,04/06/2019 00:00,DB01945,4-Carbamoyl-1-Beta-D-Ribofuranosyl-Imidazolium-5-Olate-5'-Phosphate,,,,,,solid,,,4.66,1.21,2.78,[H][C@]1(COP(O)([O-])=O)O[C@@]([H])(N2C=NC(C(N)=O)=C2[O-])[C@]([H])(O)[C@]1([H])O,,,,,-2,,337.0322128,2,1,2,1,1,1
1673,04/06/2019 00:00,DB01946,"3-[1-(3-Aminopropyl)-1h-Indol-3-Yl]-4-(1-Methyl-1h-Indol-3-Yl)-1h-Pyrrole-2,5-Dione",,,,,,solid,,,0.0318,9.61,10.41,CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(CCCN)C2=C1C=CC=C2,,,,,0,,398.1742759,5,4,3,2,0,1
1674,04/06/2019 00:00,DB01947,RU78262,,,,,,solid,,,4.44,1.75,-7.3,OP(O)(=O)OC1=C(C=O)C=CC=C1,,,,,0,,202.00311,1,1,0,0,0,0
1675,04/06/2019 00:00,DB01948,"1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One",,,,,,solid,,,0.000122,19.58,10.04,FC1=CC=C(C(F)=C1)C1=CC(=CC2=C1CCC(=O)N2C1=C(Cl)C=CC=C1Cl)C1CCNCC1,,,,,0,,486.1077251,5,3,2,0,1,2
1676,04/06/2019 00:00,DB01949,"2-Amino-N,3,3-Trimethylbutanamide",,,,,,solid,,,73.3,16.28,8.24,CNC(=O)[C@@H](N)C(C)(C)C,,,,,0,,144.1262631,0,0,0,0,0,0
1677,04/06/2019 00:00,DB01950,"N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thiazol-2-Yl)Urea",,,,,,solid,,,0.0119,10.45,-4.2,COC1=CC=C(CNC(=O)NC2=NC=C(S2)[N+]([O-])=O)C=C1,,,,,0,,308.0579259,2,2,1,1,0,0
1678,04/06/2019 00:00,DB01951,Gpi-1046,,,,,,solid,,,0.332,,4.93,[H][C@]1(CCCN1C(=O)C(=O)C(C)(C)CC)C(=O)OCCCC1=CN=CC=C1,,,,,0,,360.2049074,2,1,2,1,1,1
1679,04/06/2019 00:00,DB01952,"1,N6-Ethenoadenine",,,,,,solid,,,23.4,9.05,4.97,N1C=NC2=C1N=CN1C=CN=C21,,,,,0,,159.0544952,3,3,3,3,0,0
1680,04/06/2019 00:00,DB01953,Inhibitor of P38 Kinase,,,,,,solid,,,0.00869,17.28,5.67,C(CC1=CC=NC=C1)C1=CNC2=CC=CC=C12,,,,,0,,222.1156984,3,3,2,2,0,0
1681,04/06/2019 00:00,DB01954,Rolipram,,,,,,solid,,,0.0239,3.83,6.08,COC1=C(OC2CCCC2)C=C(C=C1)C1CN=C(O)C1,,,,,0,,275.1521435,3,1,1,0,0,1
1682,04/06/2019 00:00,DB01955,"1,4-Butanediol",,,,,,solid,1E+006 mg/L (at 20 Â°C),-0.83,675,15.67,-2.4,OCCCCO,,,,,0,,90.06807956,0,0,0,0,0,0
1683,04/06/2019 00:00,DB01956,Taurine,"Oral administration of taurine was studied and it reported dose-dependent values of AUC, Cmax and tmax wherein a dose of 1-30 mg/kg ranged from 89-3452 mcg min/L, 2-15.7 mcg min/ml and 15 min respectively.[A31399] Further studies in healthy individuals gave an AUC, Cmax and tmax in the range of 116-284.5 mg h/L, 59-112.6 mg/L and 1-2.5 h.[A31400]",,Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.[A31400],1 g/100g,Intravenous,solid,65 g/L in cold water,,105,-1.5,9.34,NCCS(O)(=O)=O,,,,,0,,125.0146641,0,0,0,0,0,0
1684,04/06/2019 00:00,DB01957,3-Chlorophenol,,,,,,solid,2.6E+004 mg/L (at 20 Â°C),2.5,14.6,8.79,-6.3,OC1=CC=CC(Cl)=C1,,,,,0,,128.0028925,1,1,0,0,0,0
1685,04/06/2019 00:00,DB01958,"5-[4-Tert-Butylphenylsulfanyl]-2,4-Quinazolinediamine",,,,,,solid,,,0.00278,16.67,6.58,CC(C)(C)C1=CC=C(SC2=CC=CC3=C2C(N)=NC(N)=N3)C=C1,,,,,0,,324.1408676,3,3,1,1,0,0
1686,04/06/2019 00:00,DB01959,"3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,,,,,solid,,,0.106,,1.99,CCOC(=O)C1=C(C)N(N=C1C)C1=CC(=CC=C1)[N+]([O-])=O,,,,,0,,289.106256,2,2,1,1,0,0
1687,04/06/2019 00:00,DB01960,7n-Methyl-8-Hydroguanosine-5'-Diphosphate,,,,,,solid,,,7.68,1.77,15,[H][C@]1(O)[C@@]([H])(O)[C@@]([H])(O[C@]1([H])COP(O)(=O)OP(O)(O)=O)N1CN(C)C2=C1NC(=N)N=C2O,,,,,0,,459.0556297,3,1,3,1,1,2
1688,04/06/2019 00:00,DB01961,Cytidine 3'-monophosphate,,,,,,solid,,,5.57,0.74,2.39,[H][C@]1(CO)O[C@@]([H])(N2C=CC(=N)N=C2O)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,323.051851,2,1,2,1,1,1
1689,04/06/2019 00:00,DB01962,Phosphonotyrosine,,,,,,solid,,,1.93,1.38,9.46,N[C@@H](CC1=CC=C(OP(O)(O)=O)C=C1)C(O)=O,,,,,0,,261.0402237,1,1,0,0,0,0
1690,04/06/2019 00:00,DB01963,Phenylethane Boronic Acid,,,,,,solid,,,1.82,,,OB(O)CCC1=CC=CC=C1,,,,,0,,150.08521,1,1,0,0,0,0
1691,04/06/2019 00:00,DB01964,AL5424,,,,,,solid,,,0.519,8.14,-3.6,[H][C@]1(O)CN(C2=CC=C(OC)C=C2)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,,,,,0,,390.0013992,3,2,2,1,0,1
1692,04/06/2019 00:00,DB01965,"2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate",,,,,,solid,,,10.6,0.58,-3.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(=O)NP(O)(=O)OP(O)(O)=O)N1C=CC(O)=NC1=O,,,,,0,,466.9895975,2,1,2,1,1,1
1693,04/06/2019 00:00,DB01966,Di-Stearoyl-3-Sn-Phosphatidylethanolamine,,,,,,solid,,,5.43E-05,1.87,10,CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](CO[P@](O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCCCC,,,,,0,,747.5778052,0,0,0,0,0,0
1694,04/06/2019 00:00,DB01967,"N-{3-[(7ar,12as,12bs)-7-Oxo-1,3,4,6,7,7a,12a,12b-Octahydroindolo[2,3-a]Quinolizin-12(2h)-Yl]Propyl}Propane-2-Sulfonamide",,,,,,solid,,,0.288,11.91,3.76,[H][C@@]12CCCC[N@]1CC(=O)C1=C2N(CCCNS(=O)(=O)C(C)C)C2=C1C=CC=C2,,,,,0,,403.1929628,4,2,3,1,1,2
1695,04/06/2019 00:00,DB01968,2-Thioethenamine,,,,,,solid,,,17.7,9.69,5.7,[H]\C(N)=C(/[H])S,,,,,0,,75.01427016,0,0,0,0,0,0
1696,04/06/2019 00:00,DB01969,Trifluoroacetonyl Coenzyme A,,,,,,solid,,,6.61,0.82,4.8,[H][C@](O)(C(O)=NCCC(O)=NCCSCC(=O)C(F)(F)F)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,877.1131583,3,2,3,2,1,1
1697,04/06/2019 00:00,DB01970,"Hg9a-9, Nonanoyl-N-Hydroxyethylglucamide",,,,,,solid,,,9.98,12.65,0.22,[H][C@](O)(CO)[C@]([H])(O)[C@]([H])(O)[C@]([H])(O)CN(CCO)C(=O)CCCCCCCC,,,,,0,,365.2413525,0,0,0,0,0,0
1698,04/06/2019 00:00,DB01971,trans-urocanic acid,,,,,,solid,1500 mg/L (at 17 Â°C),,42.5,3.85,6.13,OC(=O)\C=C\C1=CNC=N1,,,,,0,,138.0429274,1,1,1,1,0,0
1699,04/06/2019 00:00,DB01972,Guanosine-5'-Monophosphate,,,,,,solid,,,3.56,1.05,1.73,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]2O)C(=O)N1,,,,,0,,363.057999,3,2,3,2,1,1
1700,04/06/2019 00:00,DB01973,O-Benzylsulfonyl-Serine,,,,,,solid,,,2.3,1.53,8.57,N[C@@H](COS(=O)(=O)CC1=CC=CC=C1)C(O)=O,,,,,0,,259.0514435,1,1,0,0,0,0
1701,04/06/2019 00:00,DB01974,"2-Amino-3-[5-(Amino-Carboxy-Methyl)-2,3-Dihydro-Isoxazol-3-Ylsulfanyl]-Propionic Acid",,,,,,solid,,,11.2,1.02,9.16,[H][C@](N)(CS[C@@]1([H])NOC(=C1)[C@]([H])(N)C(O)=O)C(O)=O,,,,,0,,263.0575915,1,0,1,0,0,1
1702,04/06/2019 00:00,DB01975,AMPCPR,,,,,,solid,,,4.24,0.81,4.99,[H][C@]1(O)O[C@]([H])(COP(O)(=O)CP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,557.0924091,4,2,4,2,2,2
1703,04/06/2019 00:00,DB01976,Aminoanthracene,,,,,,solid,,,0.00545,,4.07,NC1=CC=CC2=C1C=C1C=CC=CC1=C2,,,,,0,,193.0891494,3,3,0,0,0,0
1704,04/06/2019 00:00,DB01977,6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine,,,,,,solid,,,0.0129,12.14,11.22,NC(=N)C1=CC=C2C=C(C=CC2=C1)C(=O)NC1=CC=CC=C1,,,,,0,,289.1215121,3,3,0,0,0,0
1705,04/06/2019 00:00,DB01978,"7,9-Dimethylguanine",,,,,,solid,,,3.14,11.09,5.41,[H][C@@]1(N)NC2=C([N+](C)=CN2C)[C@]([H])(O)N1,,,,,1,,184.1192865,2,1,2,1,0,1
1706,04/06/2019 00:00,DB01979,Methyl alpha-D-mannoside,,,,,,solid,,,862,12.21,-3,CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O,,,,,0,,194.0790382,1,0,1,0,1,1
1707,04/06/2019 00:00,DB01980,Para-Iodo-D-Phenylalanine Hydroxamic Acid,,,,,,solid,,,0.256,8.8,7.56,[H][C@@](N)(CC1=CC=C(I)C=C1)C(=O)NO,,,,,0,,305.9865256,1,1,0,0,0,0
1708,04/06/2019 00:00,DB01981,"3,6-Anhydro-D-Galactose-2-Sulfate",,,,,,solid,,,105,-2.1,-3.7,[H][C@]1(O)[C@@]2([H])CO[C@]1([H])[C@@]([H])(OS(O)(=O)=O)[C@@]([H])(O)O2,,,,,0,,242.0096383,2,0,2,0,2,2
1709,04/06/2019 00:00,DB01982,D-Mannuronic Acid,,,,,,solid,,,295,3.21,-3.7,[H][C@]1(O)O[C@]([H])(C(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@]1([H])O,,,,,0,,194.0426527,1,0,1,0,1,1
1710,04/06/2019 00:00,DB01983,2(S)-Amino-6-Boronohexanoic Acid,,,,,,solid,,,2.83,1.9,9.53,N[C@@H](CCCC[B-](O)(O)O)C(O)=O,,,,,-1,,192.1048766,0,0,0,0,0,0
1711,04/06/2019 00:00,DB01984,4-[2-(3-Benzyloxycarbonylamino-4-Cyclohexyl-1-Hydroxy-2-Oxo-Butylamino)-5-Guanidino-Pentanoylamino]-4-(1-Carboxy-2-Cyclohexyl-Ethylcarbamoyl)-Butyric Acid,,,,,,solid,,,0.00938,3.28,11.7,[H][C@@](CCCNC(N)=N)(NC(=O)C(=O)[C@@]([H])(CC1CCCCC1)N=C(O)OCC1=CC=CC=C1)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC1CCCCC1)C(O)=O,,,,,0,,771.416691,3,1,0,0,0,0
1712,04/06/2019 00:00,DB01985,N-Alpha-L-Acetyl-Arginine,,,,,,solid,,,0.767,3.68,12.24,CC(=O)N[C@@H](CCCNC(N)=N)C(O)=O,,,,,0,,216.1222404,0,0,0,0,0,0
1713,04/06/2019 00:00,DB01986,3-Fluoro-2-Methyl-Aniline,,,,,,solid,,,11.7,,3.29,CC1=C(N)C=CC=C1F,,,,,0,,125.0640775,1,1,0,0,0,0
1714,04/06/2019 00:00,DB01987,Cocarboxylase,,,,,Oral,solid,,,0.372,1.78,5.53,CC1=C(CCO[P@](O)(=O)O[P@](O)([O-])=O)SC=[N+]1CC1=CN=C(C)N=C1N,,,,,0,,424.0371432,2,2,2,2,0,0
1715,04/06/2019 00:00,DB01988,6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine,,,,,,solid,,,0.00157,,8.87,C([C@H]1CN(CCN1)C1=NN=C(C2=CC3=CC=CC=C3C=C2)C(=C1)C1=CC=NC=C1)C1=CC=CC=C1,,,,,0,,457.2266459,6,5,3,2,1,1
1716,04/06/2019 00:00,DB01989,Carbobenzoxy-Pro-Lys-Phe-Y(Po2)-Ala-Pro-Ome,,,,,,solid,,,0.0078,2.95,10.21,[H][C@@](C)(NP(O)(=O)[C@]([H])(CC1=CC=CC=C1)N=C(O)[C@]([H])(CCCC[NH3+])N=C(O)[C@]1([H])CCCN1C(=O)OCC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)OC,,,,,1,,743.3527903,4,2,2,0,2,2
1717,04/06/2019 00:00,DB01990,Cholesterol sulfate,,,,,,solid,,,7.48E-05,-1.4,,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OS(O)(=O)=O)[C@H](C)CCCC(C)C,,,,,0,,466.311681,4,0,0,0,0,0
1718,04/06/2019 00:00,DB01991,Tu-514,,,,,,solid,,,0.0615,6.45,0.46,[H][C@]1(CC(O)=NO)CO[C@]([H])(CO)[C@@]([H])(O)[C@]1([H])OC(=O)CCCCCCCCCCCCC,,,,,0,,431.2883027,1,0,1,0,1,1
1719,04/06/2019 00:00,DB01992,Coenzyme A,,,,,,solid,,,4.64,0.83,4.95,CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N)[C@@H](O)C(=O)NCCC(=O)NCCS,,,,,0,,767.115209,3,2,3,2,1,1
1720,04/06/2019 00:00,DB01993,N-(5'-Phosphopyridoxyl)-D-Alanine,,,,,,solid,,,1.48,1.03,9.86,C[C@@H](NCC1=C(O)C(C)=NC=C1COP(O)(O)=O)C(O)=O,,,,,0,,320.0773375,1,1,1,1,0,0
1721,04/06/2019 00:00,DB01994,"2-(Pyrido[1,2-E]Purin-4-Yl)Amino-Ethanol",,,,,,solid,,,0.199,15.33,0.59,OCCNC1=NC=NC2=C1N=C1C=CC=CN21,,,,,0,,229.09636,3,3,3,3,0,0
1722,04/06/2019 00:00,DB01995,5-Methylcytidine-5'-Monophosphate,,,,,,solid,,,4.15,1.2,2.49,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=C(C)C(=N)N=C2O)[C@]([H])(O)[C@]1([H])O,,,,,0,,337.0675011,2,1,2,1,1,1
1723,04/06/2019 00:00,DB01996,3-Methylpyridine,,,,,,solid,1E+006 mg/L (at 25 Â°C),1.2,197,,5.63,CC1=CC=CN=C1,,,,,0,,93.05784922,1,1,1,1,0,0
1724,04/06/2019 00:00,DB01997,3-Bromo-7-Nitroindazole,,,,,,solid,,,0.757,9.64,-1.3,BrC1=NNC2=C1C=CC=C2N(=O)=O,,,,,0,,240.9486885,2,2,1,1,0,0
1725,04/06/2019 00:00,DB01998,"2-[3,4-Dihydroxy-2-Hydroxymethyl-5-(2-Hydroxy-Nonyl)-Tetrahydro-Furan-2-Yloxy]-6-Hydroxymethyl-Tetra Hydro-Pyran-3,4,5-Triol",,,,,,solid,,,15,11.85,-2.7,[H][C@@](O)(CCCCCCC)C[C@@]1([H])O[C@@](CO)(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,454.241412,2,0,2,0,2,2
1726,04/06/2019 00:00,DB02001,"5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine",,,,,,solid,,,0.0675,16.67,6.59,NC1=NC2=C(C(N)=N1)C(SC1=CC=C(C=C1)N1CCOCC1)=CC=C2,,,,,0,,353.1310312,4,3,2,1,1,1
1727,04/06/2019 00:00,DB02002,2-Aminoprop-2-Enamide,,,,,,solid,,,243,16.27,3.2,NC(=C)C(N)=O,,,,,0,,86.04801281,0,0,0,0,0,0
1728,04/06/2019 00:00,DB02004,"5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine",,,,,,solid,,,0.0123,19.77,8.8,COC1=CC(=CC(OC)=C1)C1=NC(=C(CN)C(N)=N1)C1=CC=C(Cl)C=C1Cl,,,,,0,,404.0806812,3,3,1,1,0,0
1729,04/06/2019 00:00,DB02005,2-Oxo-3-Pentenoic Acid,,,,,,solid,,,19.8,3.22,-9.7,[H]\C(C)=C(/[H])C(=O)C(O)=O,,,,,0,,114.0316941,0,0,0,0,0,0
1730,04/06/2019 00:00,DB02006,Br-Coeleneterazine,,,,,,solid,,,0.00962,9.5,4.21,[H][C@@]1(CC2=CC=CC=C2)NC(=CN2C(=O)[C@](CC3=CC=C(Br)C=C3)(OO)N=C12)C1=CC=C(O)C=C1,,,,,0,,519.0793683,5,3,2,0,0,2
1731,04/06/2019 00:00,DB02007,alpha-D-glucose 6-phosphate,,,,,,solid,,,31.4,1.22,-3.6,O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,260.0297186,1,0,1,0,1,1
1732,04/06/2019 00:00,DB02008,1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine,,,,,,solid,,,0.0277,7.86,-0.69,CCCCN1C2=C(NC(CC3=CC=C(NC(C)=O)C=C3)=N2)C(=O)N(CC2=CC=CC=C2F)C1=O,,,,,0,,463.2019679,4,4,2,2,0,0
1733,04/06/2019 00:00,DB02009,"L-756,423",,,,,,solid,,,0.0321,5.66,8.33,[H][C@@](O)(CN1CCN(CC2=CC3=CC=CC=C3O2)C[C@@]1([H])C(O)=NC(C)(C)C)C[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@@]1([H])C2=CC=CC=C2C[C@@]1([H])O,,,,,0,,652.3624706,6,4,2,1,1,1
1734,04/06/2019 00:00,DB02010,Staurosporine,,,,,,solid,,,0.0439,14.14,9.55,[H][C@]1(C[C@@]2([H])O[C@](C)(N3C4=CC=CC=C4C4=C5CNC(=O)C5=C5C6=CC=CC=C6N2C5=C34)[C@]1([H])OC)NC,,,,,0,,466.2004907,8,5,5,2,1,3
1735,04/06/2019 00:00,DB02011,N-(Phosphonoacetyl)-L-Ornithine,,,,,,solid,,,5.85,1.48,9.28,N[C@@H](CCCNC(=O)CP(O)(O)=O)C(O)=O,,,,,0,,254.0667728,0,0,0,0,0,0
1736,04/06/2019 00:00,DB02014,"5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid",,,,,,solid,,,0.0337,3.9,-3.6,COC(=O)C1=C(O)C=CC=C1OC\C=C\C1=CC(C2=CC(=NO2)C(O)=O)=C(F)C=C1,,,,,0,,413.0910801,3,3,1,1,0,0
1737,04/06/2019 00:00,DB02015,Dihydrofolic Acid,,,,,,solid,,,0.125,3.16,3.68,NC1=NC2=C(N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CN2)C(=O)N1,,,,,0,,443.1553314,3,2,2,1,0,1
1738,04/06/2019 00:00,DB02016,R048-8071,,,,,,solid,,,0.000155,,9.42,CN(CCCCCCOC1=CC=C(C(=O)C2=CC=C(Br)C=C2)C(F)=C1)CC=C,,,,,0,,447.1209194,2,2,0,0,0,0
1739,04/06/2019 00:00,DB02017,Imidazole-Derived Cellobiose,,,,,,solid,,,38.6,11.98,5.56,[H][C@]1(CO)O[C@@]([H])(O[C@]2([H])[C@@]([H])(CO)N3C=CN=C3[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,362.1325303,3,1,3,1,1,2
1740,04/06/2019 00:00,DB02018,Amido Phenyl Pyruvic Acid,,,,,,solid,,,0.309,3.11,11.49,NC(=N)C1=CC=C(CC(=O)C(O)=O)C=C1,,,,,0,,206.0691422,1,1,0,0,0,0
1741,04/06/2019 00:00,DB02019,Acetyl Dithranol,,,,,,solid,,,0.0948,3.41,-4.4,OC(=O)CC1=C(O)C2=C(CC3=C(C(O)=CC=C3)C2=O)C=C1,,,,,0,,284.0684735,3,2,0,0,0,0
1742,04/06/2019 00:00,DB02020,Alrestatin,,,,,,solid,,,0.0614,3.45,-6.6,OC(=O)CN1C(=O)C2=CC=CC3=CC=CC(C1=O)=C23,,,,,0,,255.0531578,3,2,1,0,0,1
1743,04/06/2019 00:00,DB02021,Fidarestat,,,,,,solid,,,0.0698,-2.3,11.48,[H][C@]1(C[C@]2(N=C(O)N=C2O)C2=C(O1)C=CC(F)=C2)C(O)=N,,,,,0,,279.065534,3,1,2,0,0,2
1744,04/06/2019 00:00,DB02022,4-Amino-5-Hydroxymethyl-2-Methylpyrimidine,,,,,,solid,,,12,14.41,6.17,CC1=NC=C(CO)C(N)=N1,,,,,0,,139.0745619,1,1,1,1,0,0
1745,04/06/2019 00:00,DB02023,8-Oxo-2'-Deoxy-Guanosine-5'-Monophosphate,,,,,,solid,,,2.33,1.23,5.31,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C(O)=NC2=C1NC(=N)N=C2O,,,,,0,,363.057999,3,2,3,2,1,1
1746,04/06/2019 00:00,DB02024,3-phenylpropionic acid,,,,,,solid,5900 mg/L (at 20 Â°C),1.84,1.7,4.73,,OC(=O)CCC1=CC=CC=C1,,,,,0,,150.0680796,1,1,0,0,0,0
1747,04/06/2019 00:00,DB02025,L-D-(a-Aminoadipoyl)-L-Cysteinyl-D-Valine,,,,,,solid,,,0.478,1.94,9.15,CC(C)[C@@H](NC(=O)[C@H](CS)NC(=O)CCC[C@H](N)C(O)=O)C(O)=O,,,,,0,,363.1464065,0,0,0,0,0,0
1748,04/06/2019 00:00,DB02026,"Furo[2,3d]Pyrimidine Antifolate",,,,,,solid,,,0.425,3.22,4.48,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)N(C)CC1=COC2=NC(N)=NC(N)=C12)C(O)=O,,,,,0,,442.1600824,3,3,2,2,0,0
1749,04/06/2019 00:00,DB02027,N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine,,,,,,solid,,,0.338,10.3,9.72,NCCNC[C@@H](N)CCCNC(=N)N[N+]([O-])=O,,,,,0,,247.1756729,0,0,0,0,0,0
1750,04/06/2019 00:00,DB02028,"(1R,2R,3S,4R,6S)-3,4,6-Trihydroxy-5-{[(S)-hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-1,2-cyclohexanediyl bis[dihydrogen (phosphate)]",,,,,,solid,,,14.3,0.62,-3.7,OCC(=O)COP(O)(=O)OC1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O,,,,,0,,491.983509,1,0,0,0,0,0
1751,04/06/2019 00:00,DB02029,N-Cyclohexyl-N'-(4-Iodophenyl)Urea,,,,,,solid,,,0.0214,13.51,-2.4,IC1=CC=C(NC(=O)NC2CCCCC2)C=C1,,,,,0,,344.0385612,2,1,0,0,0,0
1752,04/06/2019 00:00,DB02030,Alpha-Ribazole-5'-Phosphate,,,,,,solid,,,1.53,1.22,5.81,CC1=CC2=C(C=C1C)N(C=N2)[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,,,,,0,,358.0929876,3,2,2,1,1,1
1753,04/06/2019 00:00,DB02031,"(6S)-5,6,7,8-tetrahydrofolate",,,,,,solid,,,0.215,-13,15,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(NC[C@@]2([H])CNC3=C(N2)C(O)=NC(=N)N3)C=C1)C(O)=O,,,,,0,,445.1709815,3,2,2,1,0,1
1754,04/06/2019 00:00,DB02032,1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid,,,,,,solid,,,4.52,4.02,-1.2,[H][C@](C)(CS)C(=O)N1CCC[C@@]1([H])C(O)=O,,,,,0,,217.0772643,1,0,1,0,1,1
1755,04/06/2019 00:00,DB02033,"N-(3-Cyclopropyl(5,6,7,8,9,10-Hexahydro-2-Oxo-2h-Cycloocta[B]Pyran-3-Yl)Methyl)Phenylbenzensulfonamide",,,,,,solid,,,0.00173,6.89,-6.3,OC1=C([C@@H](C2CC2)C2=CC=CC(NS(=O)(=O)C3=CC=CC=C3)=C2)C(=O)OC2=C1CCCCCC2,,,,,0,,479.176644,5,3,1,1,0,0
1756,04/06/2019 00:00,DB02034,Tridolgosir,,,,,,solid,,,1320,13.28,9.47,[H][C@@]1(O)CN2CCC[C@@]([H])(O)[C@]2([H])[C@]1([H])O,,,,,0,,173.1051933,2,0,2,0,2,2
1757,04/06/2019 00:00,DB02035,1-Hexadecylsulfonyl Fluoride,,,,,,solid,,,0.000316,,,CCCCCCCCCCCCCCCCS(F)(=O)=O,,,,,0,,308.2185295,0,0,0,0,0,0
1758,04/06/2019 00:00,DB02036,"2-(3,4-Dihydro-3-Oxo-2h-Benzo[B][1,4]Thiazin-2-Yl)-N-Hydroxyacetamide",,,,,,solid,,,0.623,8.89,-5.5,[H][C@]1(CC(=O)NO)SC2=CC=CC=C2NC1=O,,,,,0,,238.0412132,2,1,1,0,0,1
1759,04/06/2019 00:00,DB02037,"2,4-Diamino-4,6-Dihydroxypyrimidine",,,,,,solid,,,37.8,12.91,0.41,NC1=NC(O)=C(N)C(O)=N1,,,,,0,,142.0490754,1,1,1,1,0,0
1760,04/06/2019 00:00,DB02038,"D-[3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-N,O-cycloserylamide",,,,,,solid,,,2.21,1.74,7.99,CC1=NC=C(COP(O)(O)=O)C(CN[C@@H]2CONC2=O)=C1O,,,,,0,,333.0725865,2,1,2,1,1,1
1761,04/06/2019 00:00,DB02039,S-Acetyl-Cysteine,,,,,,solid,,,23.2,1.89,8.29,[H][C@](N)(CSC(C)=O)C(O)=O,,,,,0,,163.0303141,0,0,0,0,0,0
1762,04/06/2019 00:00,DB02041,Isoluminol,,,,,,solid,,,2.43,13.75,2.15,NC1=CC=C2C(=O)NNC(=O)C2=C1,,,,,0,,177.0538265,2,2,1,1,0,0
1763,04/06/2019 00:00,DB02042,2-(2-{2-[2-(2-Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol,,,,,,solid,,,4.22,15.12,-2.7,COCCOCCOCCOCCOCCO,,,,,0,,252.1572885,0,0,0,0,0,0
1764,04/06/2019 00:00,DB02043,"1,2-Dipalmitoyl-Phosphatidyl-Glycerole",,,,,,solid,,,0.000141,1.89,-3,CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC,,,,,0,,722.5097852,0,0,0,0,0,0
1765,04/06/2019 00:00,DB02044,N-(3-(Aminomethyl)Benzyl)Acetamidine,,,,,,solid,,,0.724,,12.16,CC(=N)NCC1=CC=CC(CN)=C1,,,,,0,,177.1265975,1,1,0,0,0,0
1766,04/06/2019 00:00,DB02045,Amylamine,,,,,,solid,1E+006 mg/L (at 20 Â°C),1.49,18,,10.21,CCCCCN,,,,,0,,87.10479942,0,0,0,0,0,0
1767,04/06/2019 00:00,DB02046,N-[(Furan-2-Yl)Carbonyl]-(S)-Leucyl-(R)-[1-Amino-2(1h-Indol-3-Yl)Ethyl]-Phosphonic Acid,,,,,,solid,,,0.0688,1.49,-3.4,[H][C@@](CC(C)C)(NC(=O)C1=CC=CO1)C(=O)N[C@@]([H])(CC1=CNC2=C1C=CC=C2)P(O)(O)=O,,,,,0,,447.1559222,3,3,2,2,0,0
1768,04/06/2019 00:00,DB02047,"2-(1,1'-Biphenyl-4-Yl)Propanoic Acid",,,,,,solid,,,0.0285,4.71,,[H][C@@](C)(C(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,226.0993797,2,2,0,0,0,0
1769,04/06/2019 00:00,DB02048,"1,2,4-Triazole-Carboxamidine",,,,,,solid,,,13.5,,8.93,NC(=[NH2+])N1C=NC=N1,,,,,1,,112.0617716,1,1,1,1,0,0
1770,04/06/2019 00:00,DB02049,2-{4-[4-(4-Chloro-Phenoxy)-Benzenesulfonyl]-Tetrahydro-Pyran-4-Yl}-N-Hydroxy-Acetamide,,,,,,solid,,,0.0124,8.89,-4.1,ONC(=O)CC1(CCOCC1)S(=O)(=O)C1=CC=C(OC2=CC=C(Cl)C=C2)C=C1,,,,,0,,425.069986,3,2,1,0,1,1
1771,04/06/2019 00:00,DB02051,3-[N-[Benzyloxycarbonyl]-Phenylalaninyl-Amino]-5-Phenyl-Pentane-1-Sulfonic Acid 4-Nitro-Phenyl Ester,,,,,,solid,,,0.000263,5.3,3.08,[H][C@](CCC1=CC=CC=C1)(CCS(=O)(=O)OC1=CC=C(C=C1)N(=O)=O)N=C(O)[C@]([H])(CC1=CC=CC=C1)N=C(O)OCC1=CC=CC=C1,,,,,0,,645.2144861,4,4,0,0,0,0
1772,04/06/2019 00:00,DB02052,Indirubin-3'-Monoxime,,,,,,solid,,,0.117,8.31,1.51,O\N=C1\C(\NC2=C\1C=CC=C2)=C1\C(=O)NC2=C1C=CC=C2,,,,,0,,277.0851266,4,2,2,0,0,2
1773,04/06/2019 00:00,DB02053,Ribose-5-phosphate,,,,,,solid,,,19.3,1.49,-3.5,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@@]([H])(O)C=O,,,,,0,,230.0191539,0,0,0,0,0,0
1774,04/06/2019 00:00,DB02054,Gabaculine,,,,,,solid,,,6.36,4.81,3.27,NC1=CC=CC(=C1)C(O)=O,,,,,0,,137.0476785,1,1,0,0,0,0
1775,04/06/2019 00:00,DB02055,N-Butyl-Benzenesulfonamide,,,,,,solid,,,0.46,10.19,,CCCCNS(=O)(=O)C1=CC=CC=C1,,,,,0,,213.0823497,1,1,0,0,0,0
1776,04/06/2019 00:00,DB02056,Prostaglandin D2,,,,,,solid,,,0.086,4.4,-1.6,[H][C@](O)(CCCCC)\C=C\[C@@]1([H])C(=O)C[C@]([H])(O)[C@]1([H])C\C=C/CCCC(O)=O,,,,,0,,352.2249741,1,0,0,0,0,0
1777,04/06/2019 00:00,DB02057,(S)-AMPA,,,,,,solid,,,24.5,1.56,8.9,CC1=C(C[C@H](N)C(O)=O)C(O)=NO1,,,,,0,,186.0640568,1,1,1,1,0,0
1778,04/06/2019 00:00,DB02058,SU4984,,,,,,solid,,,0.167,6.51,3.33,OC1=NC2=CC=CC=C2C1CC1=CC=C(C=C1)N1CCN(CC1)C=O,,,,,0,,335.1633769,4,2,2,0,1,2
1779,04/06/2019 00:00,DB02059,Adenosine-5-Diphosphoribose,,,,,,solid,,,3.61,1.86,5,NC1=C2N=CN([C@@H]3O[C@H](CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]4O[C@H](O)[C@H](O)[C@@H]4O)[C@@H](O)[C@H]3O)C2=NC=N1,,,,,0,,559.0716737,4,2,4,2,2,2
1780,04/06/2019 00:00,DB02060,Cyclohexanone,,,,,,liquid,2.5E+004 mg/L (at 25 Â°C),0.81,19.6,,-7.3,O=C1CCCCC1,,,,,0,,98.07316494,1,0,0,0,0,0
1781,04/06/2019 00:00,DB02061,Cellobiose,,,,,,solid,,,586,11.25,-3,OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,342.1162115,2,0,2,0,2,2
1782,04/06/2019 00:00,DB02062,"N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine",,,,,,solid,,,0.00835,-0.036,9.56,[H][C@@](C)(N)[P@](O)(=O)C[C@@]([H])(CC1=CC=C(C=C1)C1=CC=CC=C1)C(=O)N[C@@]([H])(C)C(O)=O,,,,,0,,418.1657586,2,2,0,0,0,0
1783,04/06/2019 00:00,DB02063,CRA_16847,,,,,,solid,,,0.0421,3.16,11.53,[H][C@](CC([O-])=O)(C(O)=O)C1=CC(C2=NC3=C(N2)C=C(C=C3)C(N)=N)=C([O-])C(Br)=C1,,,,,-2,,444.0080288,3,3,1,1,0,0
1784,04/06/2019 00:00,DB02065,4-Deoxylactose,,,,,,solid,,,550,11.27,-2.9,[H][C@@]1(CO)C[C@]([H])(O)[C@@]([H])(O)[C@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)O1,,,,,0,,326.1212969,2,0,2,0,2,2
1785,04/06/2019 00:00,DB02066,N7-Methyl-Formycin A,,,,,,solid,,,6.14,11.87,3.32,[H][C@]1(CO)O[C@@]([H])(C2=C3N=CN=C(NC)C3=NN2)[C@]([H])(O)[C@]1([H])O,,,,,0,,281.112404,3,2,3,2,1,1
1786,04/06/2019 00:00,DB02067,Triglu-5-Formyl-Tetrahydrofolate,,,,,,solid,,,0.0981,2.52,15,[H][C@@](CCC(O)=N[C@@]([H])(CCC(O)=N[C@@]([H])(CCC(O)=O)C(O)=O)C(O)=O)(NC(=O)C1=CC=C(NC[C@@]2([H])CNC3=C(N2C=O)C(O)=NC(=N)N3)C=C1)C(O)=O,,,,,0,,731.2510822,3,2,2,1,0,1
1787,04/06/2019 00:00,DB02068,Delta-Amino Valeric Acid,,,,,,solid,,,10.3,4.65,10.21,[NH3+]CCCCC(O)=O,,,,,1,,118.086255,0,0,0,0,0,0
1788,04/06/2019 00:00,DB02069,N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide,,,,,,solid,,,0.0278,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=CC=CC=C1F,,,,,0,,308.0630915,2,2,0,0,0,0
1789,04/06/2019 00:00,DB02070,L-2-Amino-4-[2-Aminophenyl]-4-Oxobutanoic Acid,,,,,,solid,,,1.67,1.19,8.96,N[C@@H](CC(=O)C1=CC=CC=C1N)C(O)=O,,,,,0,,208.0847922,1,1,0,0,0,0
1790,04/06/2019 00:00,DB02071,WAY-151693,,,,,,solid,,,0.0124,9.5,4.81,COC1=CC=C(C=C1)S(=O)(=O)N(CC1=CC=CN=C1)C1=C(C=CC=C1C)C(=O)NO,,,,,0,,427.1201918,3,3,1,1,0,0
1791,04/06/2019 00:00,DB02072,"2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid",,,,,,solid,,,0.053,1.98,-7.4,OC(=O)C(=O)NC1=C(C(O)=O)C2=C(CSCC2)S1,,,,,0,,286.9922144,2,1,2,1,0,1
1792,04/06/2019 00:00,DB02073,Biliverdine IX Alpha,,,,,,solid,,,0.0129,3.87,5.86,CC1=C(C=C)\C(NC1=O)=C\C1=C(C)C(CCC(O)=O)=C(N1)\C=C1/N=C(/C=C2\NC(=O)C(C=C)=C2C)C(C)=C1CCC(O)=O,,,,,0,,582.2478348,4,1,4,1,0,3
1793,04/06/2019 00:00,DB02074,Butenoic Acid,,,,,,solid,9.4E+004 mg/L (at 25 Â°C),,101,4.9,,C\C=C\C(O)=O,,,,,0,,86.03677943,0,0,0,0,0,0
1794,04/06/2019 00:00,DB02075,"(1s)-1(9-Deazahypoxanthin-9yl)1,4-Dideoxy-1,4-Imino-D-Ribitol-5-Phosphate",,,,,,solid,,,6.99,0.9,9.14,[H][C@]1(COP(O)(O)=O)N[C@@]([H])(C2=CNC3=C2N=CN=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,346.0678355,3,2,3,2,1,1
1795,04/06/2019 00:00,DB02076,6-phospho-D-gluconic acid,,,,,,solid,,,20.7,1.49,-3.5,O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O,,,,,0,,276.0246332,0,0,0,0,0,0
1796,04/06/2019 00:00,DB02077,L-N(omega)-Nitroarginine-(4R)-Amino-L-Proline Amide,,,,,,solid,,,0.297,10.06,8.96,N[C@@H](CCCNC(=N)N[N+]([O-])=O)C(=O)N[C@H]1CN[C@@H](C1)C(N)=O,,,,,0,,330.1764012,1,0,1,0,1,1
1797,04/06/2019 00:00,DB02078,Triglyme,,,,,,solid,,,16.7,,-3.5,COCCOCCOCCOC,,,,,0,,178.1205091,0,0,0,0,0,0
1798,04/06/2019 00:00,DB02079,Aminooxyacetic acid,,,,,,solid,,,526,3.16,4.52,NOCC(O)=O,,,,,0,,91.02694302,0,0,0,0,0,0
1799,04/06/2019 00:00,DB02080,"1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene",,,,,,solid,,,0.000207,,-3.6,COCCOCCOCCOC1=CC=C(C=C1)C(C)(C)CC(C)(C)C,,,,,0,,352.2613596,1,1,0,0,0,0
1800,04/06/2019 00:00,DB02081,Bis-Benzamidine,,,,,,solid,,,0.0058,,11.8,[H][C@@]1(CC2=CC=C(C=C2)C(N)=N)CCCC[C@@]([H])(CC2=CC=C(C=C2)C(N)=N)C1=O,,,,,0,,376.2263115,3,2,0,0,0,0
1801,04/06/2019 00:00,DB02082,Phosphoaminophosphonic Acid Guanylate Ester,,,,,,solid,,,7,0.34,3.58,[H][C@]1(COP(O)(=O)OP(O)(=O)NP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,522.0066445,3,2,3,2,1,1
1802,04/06/2019 00:00,DB02083,"N,N-dimethylglycine",,,,,,solid,,-2.91,939,1.88,9.69,CN(C)CC(O)=O,,,,,0,,103.0633285,0,0,0,0,0,0
1803,04/06/2019 00:00,DB02084,CRA_17312,,,,,,solid,,,0.0118,3.86,11.53,[H][C@](CC([O-])=O)(C(O)=O)C1=CC(=C([O-])C(=C1)C1=NC2=C(N1)C=C(C=C2)C(N)=N)C1=CC=CC=C1OC,,,,,-2,,472.1393815,4,4,1,1,0,0
1804,04/06/2019 00:00,DB02085,1-Aminocyclopropanecarboxylic Acid,,,,,,solid,,-2.78,437,2.2,9.35,NC1(CC1)C(O)=O,,,,,0,,101.0476785,1,0,0,0,0,0
1805,04/06/2019 00:00,DB02086,"(3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium",,,,,,solid,,,0.000287,8.04,-6.4,OC1=CC=C(C=C1O)[As+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,415.0673778,4,4,0,0,0,0
1806,04/06/2019 00:00,DB02087,"3,5-Difluorobenzenesulfonamide",,,,,,solid,,,2.18,8.59,,NS(=O)(=O)C1=CC(F)=CC(F)=C1,,,,,0,,193.0009058,1,1,0,0,0,0
1807,04/06/2019 00:00,DB02088,Norleucine Phosphonate,,,,,,solid,,,31.7,-0.24,10.24,CCCC[C@H](N)P(O)(O)=O,,,,,0,,167.0711299,0,0,0,0,0,0
1808,04/06/2019 00:00,DB02089,CP-526423,,,,,,solid,,,0.00263,11.95,-1.3,ClC1=CC2=C(NC(=C2)C(=O)NCCOCCOCCNC(=O)C2=CC3=C(N2)C=CC(Cl)=C3)C=C1,,,,,0,,502.1174606,4,4,2,2,0,0
1809,04/06/2019 00:00,DB02090,A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor,,,,,,solid,,,4.58,8.86,0.079,[H][C@@](CCCO)(C(=O)NO)[C@@]([H])(CC(C)C)C(=O)N[C@@]1([H])CCCCN(CCOC)C1=O,,,,,0,,415.2682359,1,0,1,0,1,1
1810,04/06/2019 00:00,DB02091,"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine",,,,,,solid,,,0.259,16.36,3.26,CC1=NC(C)=C(S1)C1=NC(N)=NC=C1,,,,,0,,206.0626173,2,2,2,2,0,0
1811,04/06/2019 00:00,DB02092,Cholesteryl Linoleate,,,,,,solid,,,5.79E-06,,-7,CCCCC\C=C/C\C=C/CCCCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@]3([H])[C@]4([H])CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@]23[H])C1,,,,,0,,648.5845317,4,0,0,0,0,0
1812,04/06/2019 00:00,DB02093,5-Phospho-D-Arabinohydroxamic Acid,,,,,,solid,,,12,1.49,-0.59,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)C(O)=NO,,,,,0,,261.0249676,0,0,0,0,0,0
1813,04/06/2019 00:00,DB02094,N-2-Thiophen-2-Yl-Acetamide Boronic Acid,,,,,,solid,,,0.221,15.07,-2.9,OB(O)CNC(=O)CC1=CC=CS1,,,,,0,,199.0474446,1,1,1,1,0,0
1814,04/06/2019 00:00,DB02095,Isatin,,,,,,solid,,0.83,2.77,8.93,-5.6,O=C1NC2=CC=CC=C2C1=O,,,,,0,,147.0320284,2,1,1,0,0,1
1815,04/06/2019 00:00,DB02096,FR221647,,,,,,solid,,,0.644,13.9,3.53,[H][C@](CO)(CCC1=CC=CC=C1)N1C=NC(=C1)C(N)=O,,,,,0,,259.1320768,2,2,1,1,0,0
1816,04/06/2019 00:00,DB02097,Cytidine,,,,,,solid,,,43.8,12.55,-2.6,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,,,,,0,,243.0855205,2,1,2,1,1,1
1817,04/06/2019 00:00,DB02098,Adenosine-2'-5'-Diphosphate,,,,,,solid,,,3.29,0.57,4.89,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(OP(O)(O)=O)[C@]1([H])O,,,,,0,,427.0294149,3,2,3,2,1,1
1818,04/06/2019 00:00,DB02099,S-azabisabolene,,,,,,solid,,,0.00228,,10.62,C[N@H+](CCC=C(C)C)[C@@H]1CCC(C)=CC1,,,,,1,,208.2059763,1,0,0,0,0,0
1819,04/06/2019 00:00,DB02100,Methyl alpha-galactoside,,,,,,solid,,,862,12.21,-3,CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,,,,,0,,194.0790382,1,0,1,0,1,1
1820,04/06/2019 00:00,DB02101,"(S,R)-fidarestat",,,,,,solid,,,0.0698,-2.3,11.48,[H][C@]1(C[C@@]2(N=C(O)N=C2O)C2=C(O1)C=CC(F)=C2)C(O)=N,,,,,0,,279.065534,3,1,2,0,0,2
1821,04/06/2019 00:00,DB02102,DMP450,,,,,,solid,,,0.0207,13.23,4.44,[H][C@]1(CC2=CC=CC=C2)N(CC2=CC(N)=CC=C2)C(=O)N(CC2=CC(N)=CC=C2)[C@]([H])(CC2=CC=CC=C2)[C@]([H])(O)[C@@]1([H])O,,,,,0,,536.278741,5,4,1,0,1,1
1822,04/06/2019 00:00,DB02103,2-Chlorodideoxyadenosine,,,,,,solid,,,3.69,14.67,1.33,[H][C@@]1(CO)CC[C@@]([H])(O1)N1C=NC2=C1N=C(Cl)N=C2N,,,,,0,,269.0679523,3,2,3,2,1,1
1823,04/06/2019 00:00,DB02104,"2,4-Diamino-5-Methyl-6-[(3,4,5-Trimethoxy-N-Methylanilino)Methyl]Pyrido[2,3-D]Pyrimidine",,,,,,solid,,,0.188,16.06,3.89,COC1=CC(=CC(OC)=C1OC)N(C)CC1=C(C)C2=C(N)N=C(N)N=C2N=C1,,,,,0,,384.1909886,3,3,2,2,0,0
1824,04/06/2019 00:00,DB02105,"3,5-Dinitrocatechol",,,,,,solid,,,0.605,4.38,-6.5,OC1=CC(=CC(=C1O)[N+]([O-])=O)[N+]([O-])=O,,,,,0,,200.0069358,1,1,0,0,0,0
1825,04/06/2019 00:00,DB02106,"[3,5-Dibromo-4-(4-Hydroxy-3-Phenethylcarbamoyl-Phenoxy)-Phenyl]-Acetic Acid",,,,,,solid,,,0.00816,8.69,9.73,OC(O)CC1=CC(Br)=C(OC2=CC(C(O)NCCC3=CC=CC=C3)=C(O)C=C2)C(Br)=C1,,,,,0,,550.994297,3,3,0,0,0,0
1826,04/06/2019 00:00,DB02107,Leucine - Reduced Carbonyl,,,,,,solid,,,9.83,,10.42,CC(C)C[C@@H](C)N,,,,,0,,101.1204495,0,0,0,0,0,0
1827,04/06/2019 00:00,DB02108,2-Aminoethanimidic Acid,,,,,,solid,,,11.4,,10.13,[H]N=C([H])CN,,,,,0,,58.05309819,0,0,0,0,0,0
1828,04/06/2019 00:00,DB02109,Hadacidin,,,,,,solid,,,50,3.28,-5.9,ON(CC(O)=O)C=O,,,,,0,,119.0218576,0,0,0,0,0,0
1829,04/06/2019 00:00,DB02110,Protoporphyrin Ix Containing Co,,,,,,solid,,,0.369,3.72,,CC1=C(CCC(O)=O)C2=CC3=C(CCC(O)=O)C(C)=C4C=C5N6C(=CC7=C(C=C)C(C)=C8C=C1N2[Co]6(N34)N78)C(C)=C5C=C,,,,,0,,619.1755505,8,4,8,4,0,4
1830,04/06/2019 00:00,DB02111,3-Hydroxyisoxazole-4-Carboxylic Acid,,,,,,solid,,,43.9,3.82,-3,OC(=O)C1=CON=C1O,,,,,0,,129.0062076,1,1,1,1,0,0
1831,04/06/2019 00:00,DB02112,Zk-806450,,,,,,solid,,,0.0121,,12.45,CC(=N)N1CCC(CC1)OC1=CC=C2C(=C1)N(CC1=CC=C3C=CC(=CC3=C1)C(N)=N)C1=C2C=CC=C1,,,,,0,,489.2528606,6,5,2,1,1,1
1832,04/06/2019 00:00,DB02113,6-Methylpurine,,,,,,solid,2E+005 mg/L (at 20 Â°C),,29.3,9.84,4.55,CC1=C2NC=NC2=NC=N1,,,,,0,,134.0592462,2,2,2,2,0,0
1833,04/06/2019 00:00,DB02114,Para-Isopropylaniline,,,,,,solid,,,1.74,,4.87,CC(C)C1=CC=C(N)C=C1,,,,,0,,135.1047994,1,1,0,0,0,0
1834,04/06/2019 00:00,DB02115,Daidzin,,,,,,solid,,,0.661,8.96,-3,[H][C@]1(CO)O[C@@]([H])(OC2=CC=C3C(=O)C(=COC3=C2)C2=CC=C(O)C=C2)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,416.1107322,4,3,2,1,1,1
1835,04/06/2019 00:00,DB02116,Olomoucine,,,,,,solid,,,0.509,14.85,5.63,CN1C=NC2=C1N=C(NCCO)N=C2NCC1=CC=CC=C1,,,,,0,,298.1542092,3,3,2,2,0,0
1836,04/06/2019 00:00,DB02118,CP-271485,,,,,,solid,,,0.0892,12.86,-4.2,[H][C@@]1(CN(CC2=CC=CC=C2)C(=O)CO1)C1=CC2=C(C=C1)N(C)S(=O)(=O)C2,,,,,0,,372.1143781,4,2,2,0,1,2
1837,04/06/2019 00:00,DB02119,"6-Hydroxymethyl-7,8-Dihydropterin",,,,,,solid,,,2.47,10.91,3.9,NC1=NC2=C(N=C(CO)CN2)C(=O)N1,,,,,0,,195.0756245,2,1,2,1,0,1
1838,04/06/2019 00:00,DB02120,"6-Amino-4-Hydroxymethyl-Cyclohex-4-Ene-1,2,3-Triol",,,,,,solid,,,342,12.83,8.3,[H][C@]1(N)C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,175.0844579,1,0,0,0,0,0
1839,04/06/2019 00:00,DB02121,Butyramide,,,,,,solid,1.63E+005 mg/L (at 15 Â°C),-0.21,216,16.96,-0.87,CCCC(N)=O,,,,,0,,87.06841391,0,0,0,0,0,0
1840,04/06/2019 00:00,DB02122,4-iodo-acetamido phenylboronic acid,,,,,,solid,,,0.179,8.68,-5.4,OB(O)C1=CC=CC(NC(=O)CI)=C1,,,,,0,,304.9720215,1,1,0,0,0,0
1841,04/06/2019 00:00,DB02123,Glycochenodeoxycholic Acid,,,,,,solid,3.15 mg/L (at 20 Â°C),2.12,0.00793,3.77,-0.29,C[C@H](CCC(=O)NCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,,,,,0,,449.3141235,4,0,0,0,0,0
1842,04/06/2019 00:00,DB02124,"(2s,3s)-Trans-2,3-Dihydro-3-Hydroxyanthranilic Acid",,,,,,solid,,,65.4,3.77,9.38,[H][C@]1(O)C=CC=C(C(O)=O)[C@]1([H])N,,,,,0,,155.0582431,1,0,0,0,0,0
1843,04/06/2019 00:00,DB02125,Adamantanone,,,,,,solid,,,0.335,,-7.5,O=C1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2,,,,,0,,150.1044651,4,0,0,0,0,0
1844,04/06/2019 00:00,DB02126,4-Carboxycinnamic Acid,,,,,,solid,,,0.224,3.52,,OC(=O)\C=C\C1=CC=C(C=C1)C(O)=O,,,,,0,,192.0422587,1,1,0,0,0,0
1845,04/06/2019 00:00,DB02127,Methylphosphonic Acid Diisopropyl Ester,,,,,,solid,,,12.8,,-7.9,CC(C)OP(C)(=O)OC(C)C,,,,,0,,180.091531,0,0,0,0,0,0
1846,04/06/2019 00:00,DB02128,[1-(3-Hydroxy-2-Oxo-1-Phenethyl-Propylcarbamoyl)2-Phenyl-Ethyl]-Carbamic Acid Pyridin-4-Ylmethyl Ester,,,,,,solid,,,0.00714,5.49,4.59,[H][C@@](CCC1=CC=CC=C1)(N=C(O)[C@]([H])(CC1=CC=CC=C1)N=C(O)OCC1=CN=CC=C1)C(=O)CO,,,,,0,,475.210721,3,3,1,1,0,0
1847,04/06/2019 00:00,DB02129,Dihydroorotic Acid,,,,,,solid,,,12.7,3.28,-8.2,OC(=O)[C@@H]1CC(=O)NC(=O)N1,,,,,0,,158.0327567,1,0,1,0,1,1
1848,04/06/2019 00:00,DB02130,Vanillic acid,,,,,,solid,1500 mg/L (at 14 Â°C),1.43,18.6,4.16,-4.9,COC1=CC(=CC=C1O)C([O-])=O,,,,,-1,,167.0349823,1,1,0,0,0,0
1849,04/06/2019 00:00,DB02131,N-1-Methylheptylformamide,,,,,,solid,,,0.0961,8.58,5.96,[H][C@@](C)(CCCCCC)N=CO,,,,,0,,157.1466642,0,0,0,0,0,0
1850,04/06/2019 00:00,DB02132,Zenarestat,,,,,,solid,,,0.0101,3.41,-7.4,OC(=O)CN1C(=O)N(CC2=C(F)C=C(Br)C=C2)C(=O)C2=C1C=C(Cl)C=C2,,,,,0,,439.9574748,3,3,1,1,0,0
1851,04/06/2019 00:00,DB02133,Chlorophyll A,,,,,,solid,,,0.000231,3.89,7.36,CCC1=C(C)\C2=C\C3=C(C=C)C(C)=C4\C=C5/N=C([C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@@H]5C)C5=C6N([Mg]N34)\C(=C/C1=N2)C(C)=C6C(=O)[C@@H]5C(=O)OC,,,,,0,,892.5353131,7,2,6,2,0,4
1852,04/06/2019 00:00,DB02134,Xanthine,,,,,,solid,69 mg/L (at 16 Â°C),-0.73,4.91,7.95,-0.7,O=C1NC2=C(NC=N2)C(=O)N1,,,,,0,,152.0334254,2,2,2,2,0,0
1853,04/06/2019 00:00,DB02135,"4-{2,6,8-Trioxo-9-[(2R,3S,4R)-2,3,4,5-Tetrahydroxypentyl]-1,2,3,6,8,9-Hexahydro-7h-Purin-7-Yl}Butyl Dihydrogen Phosphate",,,,,,solid,,,7.68,1.81,-3,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)CN1C(=O)N(CCCCOP(O)(O)=O)C2=C1N=C(O)N=C2O,,,,,0,,454.1100942,2,2,2,2,0,0
1854,04/06/2019 00:00,DB02136,Cephalosporin Analog,,,,,,solid,,,0.043,3.08,,[H][C@](C)(N=C(O)[C@@]([H])(C)N=C(O)[C@]([H])(CCC1=C(N[C@]([H])(SC1)[C@]([H])(N=C(O)CC1=CC=CC=C1)C(O)=O)C(O)=O)N=C(O)CC[C@@]([H])(N=C(C)O)C(O)=O)C(O)=O,,,,,0,,750.2530564,2,1,1,0,0,1
1855,04/06/2019 00:00,DB02137,Molybdenum cofactor,,,,,,solid,,,15.3,1.26,0.3,O=[Mo++]=O.NC1=NC2=C(N[C@@H]3[C@H](N2)O[C@H](COP([O-])([O-])=O)C([S-])=C3[S-])C(=O)N1,,,,,-2,,520.8773463,3,1,3,1,0,2
1856,04/06/2019 00:00,DB02138,Diethyl 4-Methylbenzylphosphonate,,,,,,solid,,,1.48,,-8,CCOP(=O)(CC1=CC=C(C)C=C1)OCC,,,,,0,,242.1071811,1,1,0,0,0,0
1857,04/06/2019 00:00,DB02139,(2e)-N-Allyl-4-{[3-(4-Bromophenyl)-5-Fluoro-1-Methyl-1h-Indazol-6-Yl]Oxy}-N-Methyl-2-Buten-1-Amine,,,,,,solid,,,0.00241,,8.56,CN(CC=C)C\C=C\COC1=CC2=C(C=C1F)C(=NN2C)C1=CC=C(Br)C=C1,,,,,0,,443.1008527,3,3,1,1,0,0
1858,04/06/2019 00:00,DB02140,N1-(1-Dimethylcarbamoyl-2-Phenyl-Ethyl)-2-Oxo-N4-(2-Pyridin-2-Yl-Ethyl)-Succinamide,,,,,,solid,,,0.0475,6.96,4.54,[H][C@@](CC1=CC=CC=C1)(NC(=O)C(=O)CC(=O)NCCC1=NC=CC=C1)C(=O)N(C)C,,,,,0,,410.1954053,2,2,1,1,0,0
1859,04/06/2019 00:00,DB02141,"S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea",,,,,,solid,,,0.0203,,10.89,NC(=N)SCCC1=CC=C(CCSC(N)=N)C=C1,,,,,0,,282.0972886,1,1,0,0,0,0
1860,04/06/2019 00:00,DB02142,Pyridoxamine-5'-Phosphate,,,,,,solid,,,6.61,1.74,10.11,CC1=NC=C(COP(O)(O)=O)C(CN)=C1O,,,,,0,,248.0562081,1,1,1,1,0,0
1861,04/06/2019 00:00,DB02143,N-Isopropyl-N'-Hydroxyguanidine,,,,,,solid,,,4.64,14.82,10.77,CC(C)NC(=N)NO,,,,,0,,117.090212,0,0,0,0,0,0
1862,04/06/2019 00:00,DB02144,"1,2-diacyl-sn-glycero-3-phosphoinositol",,,,,,solid,,,0.000801,1.83,-3.6,[H]\C(CCCCCCCC)=C(\[H])CCCCCCCC(=O)O[C@]([H])(COC(=O)CCCCCCCCCCCCCCC)COP([O-])(=O)O[C@@]1([H])[C@]([H])(O)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,-1,,835.5342028,1,0,0,0,0,0
1863,04/06/2019 00:00,DB02145,Butyl alcohol,,,,,,solid,6.32E+004 mg/L (at 25 Â°C),0.88,158,16.95,-1.9,CCCCO,,,,,0,,74.07316494,0,0,0,0,0,0
1864,04/06/2019 00:00,DB02146,Atrazine Glutathione Conjugate,,,,,,solid,,,0.182,-0.17,13.56,[H][C@](N)(CCC(O)=N[C@@]([H])(CSC1=NC(NC(N1)=NC(C)C)=NCC)C(O)=NCC(O)=O)C(O)=O,,,,,0,,486.2009017,1,1,1,1,0,0
1865,04/06/2019 00:00,DB02148,3-Amino-4-Oxybenzyl-2-Butanone,,,,,,solid,,,1.65,16.32,7.44,CC(=O)[C@@H](N)COCC1=CC=CC=C1,,,,,0,,193.1102787,1,1,0,0,0,0
1866,04/06/2019 00:00,DB02151,Methionine Phosphonate,,,,,,solid,,,30.9,-0.24,10.21,CSCC[C@H](N)P(O)(O)=O,,,,,0,,185.0275509,0,0,0,0,0,0
1867,04/06/2019 00:00,DB02152,K-252a,,,,,,solid,,,0.0597,10.71,-1.6,[H][C@]12C[C@](O)(C(=O)OC)[C@](C)(O1)N1C3=C(C=CC=C3)C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13,,,,,0,,467.1481208,8,5,5,2,1,3
1868,04/06/2019 00:00,DB02153,3-sulfino-L-alanine,,,,,,solid,,,30.2,-0.78,9.09,N[C@@H](C[S@@](O)=O)C(O)=O,,,,,0,,153.0095787,0,0,0,0,0,0
1869,04/06/2019 00:00,DB02154,"2,3-Bis-Benzo[1,3]Dioxol-5-Ylmethyl-Succinic Acid",,,,,,solid,,,0.117,3.24,-4.4,[H][C@@](CC1=CC=C2OCOC2=C1)(C(O)=O)[C@]([H])(CC1=CC=C2OCOC2=C1)C(O)=O,,,,,0,,386.1001675,4,2,2,0,0,2
1870,04/06/2019 00:00,DB02155,Balanol Analog 8,,,,,,solid,,,0.00242,7.89,9.77,[H][C@](C)(CC)C1=C(O)C=CC(=C1)C(O)=N[C@]1([H])CNCCC[C@@]1([H])OC(=O)C1=CC=C(C=C1)C(=O)C1=C(O)C=CC(OC)=C1,,,,,0,,560.2522515,4,3,1,0,1,1
1871,04/06/2019 00:00,DB02156,Sulfopyruvate,,,,,,solid,,,12.9,-1.8,,OC(=O)C(=O)CS(O)(=O)=O,,,,,0,,167.9728588,0,0,0,0,0,0
1872,04/06/2019 00:00,DB02158,"(1s)-1-(9-Deazaadenin-9-Yl)-1,4,5-Trideoxy-1,4-Imino-5-Methylthio-D-Ribitol",,,,,,solid,,,0.876,12.93,8.38,[H][C@]1(CSC)N[C@@]([H])(C2=CNC3=C2N=CNC3([H])N)[C@]([H])(O)[C@]1([H])O,,,,,0,,297.1259458,3,1,3,1,1,2
1873,04/06/2019 00:00,DB02159,(R)-Propylene glycol,,,,,,solid,,,952,14.47,-2.9,C[C@@H](O)CO,,,,,0,,76.0524295,0,0,0,0,0,0
1874,04/06/2019 00:00,DB02160,S-Butyryl-Cystein,,,,,,solid,,,12.1,2.13,8.28,[H][C@](N)(CSC(=O)CCC)C(O)=O,,,,,0,,191.0616143,0,0,0,0,0,0
1875,04/06/2019 00:00,DB02161,Hydroxy-Phenyl-Acetic Acid 8-Methyl-8-Aza-Bicyclo[3.2.1]Oct-3-Yl Ester,,,,,,solid,,,5.57,11.99,9.38,[H][C@](O)(C(=O)O[C@@]1([H])C[C@]2([H])CC[C@]([H])(C1)N2C)C1=CC=CC=C1,,,,,0,,275.1521435,3,1,2,0,2,2
1876,04/06/2019 00:00,DB02162,5'-O-(N-Ethyl-Sulfamoyl)Adenosine,,,,,,solid,,,5.29,11.74,4.99,[H][C@]1(COS(=O)(=O)NCC)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,374.1008533,3,2,3,2,1,1
1877,04/06/2019 00:00,DB02163,"2,5-Xylidine",,,,,,solid,5600 mg/L (at 12 Â°C),1.83,5.07,,4.65,CC1=CC=C(C)C(N)=C1,,,,,0,,121.0891494,1,1,0,0,0,0
1878,04/06/2019 00:00,DB02164,N-Sulfo-Flavin Mononucleotide,,,,,,solid,,,0.286,-2.5,-3.2,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@@]([H])(O)CN1C2=C(C=C(C)C(C)=C2)[N+](=C2C(O)=NC(=O)N=C12)S([O-])(=O)=O,,,,,0,,536.0614297,3,1,2,0,0,2
1879,04/06/2019 00:00,DB02166,Propidium,,,,,,solid,,,7.13E-07,,3.48,CC[N+](C)(CC)CCC[N+]1=C(C2=CC=CC=C2)C2=C(C=CC(N)=C2)C2=C1C=C(N)C=C2,,,,,2,,414.2772499,4,4,1,1,0,0
1880,04/06/2019 00:00,DB02167,"N,N-Dimethyl-L-Alanine",,,,,,solid,,,774,1.96,9.97,[H][C@@](C)(N(C)C)C(O)=O,,,,,0,,117.0789786,0,0,0,0,0,0
1881,04/06/2019 00:00,DB02168,Bromopurine,,,,,,solid,,,1.08,4.3,-1.1,BrC1=C2N=CN=C2NC=N1,,,,,0,,197.9541082,2,0,2,0,0,2
1882,04/06/2019 00:00,DB02169,"9,10-Deepithio-9,10-Didehydroacanthifolicin",,,,,,solid,,,0.00442,3.76,-3.2,[H]\C(=C(\[H])[C@@]1([H])CC[C@@]2(CC[C@@]3([H])O[C@@]([H])(C(=C)[C@@]([H])(O)[C@]3([H])O2)[C@@]([H])(O)C[C@]([H])(C)[C@@]2([H])O[C@@]3(CCCCO3)CC[C@@]2([H])C)O1)[C@@]([H])(C)[C@]1([H])CC(C)=C[C@@]2(O[C@]([H])(C[C@@](C)(O)C(O)=O)CC[C@@]2([H])O)O1,,,,,0,,804.4659922,7,0,7,0,6,7
1883,04/06/2019 00:00,DB02170,"1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One",,,,,,solid,,,0.325,7.26,-5.2,OC1=CC=C(C2=C1C(=O)C1=C(O)C=CC=C1O2)[N+]([O-])=O,,,,,0,,273.0273369,3,3,1,1,0,0
1884,04/06/2019 00:00,DB02172,"2,5-Dideoxy-2,5-Imino-D-Glucitol",,,,,,solid,,,323,13.18,8.88,OC[C@@H]1N[C@@H](CO)[C@H](O)[C@H]1O,,,,,0,,163.0844579,1,0,1,0,1,1
1885,04/06/2019 00:00,DB02174,D-Glutamine,,,,,,solid,,,97.8,2.15,9.31,N[C@H](CCC(N)=O)C(O)=O,,,,,0,,146.0691422,0,0,0,0,0,0
1886,04/06/2019 00:00,DB02175,Malonic acid,,,,,,solid,7.63E+005 mg/L (at 25 Â°C),-0.81,197,2.43,,OC(=O)CC(O)=O,,,,,0,,104.0109586,0,0,0,0,0,0
1887,04/06/2019 00:00,DB02176,Mercury Acetate Ion,,,,,,solid,,,81.5,,-7.2,CC(=O)O[Hg+],,,,,1,,260.9833988,0,0,0,0,0,0
1888,04/06/2019 00:00,DB02177,1-Acetyl-4-(4-{4-[(2-Ethoxyphenyl)Thio]-3-Nitrophenyl}Pyridin-2-Yl)Piperazine,,,,,,solid,,,0.00468,,6.26,CCOC1=CC=CC=C1SC1=C(C=C(C=C1)C1=CC(=NC=C1)N1CCN(CC1)C(C)=O)N(=O)=O,,,,,0,,478.1674763,4,3,2,1,1,1
1889,04/06/2019 00:00,DB02178,Phenylacetaldehyde,,,,,,solid,,1.78,2.08,14.98,-7,O=CCC1=CC=CC=C1,,,,,0,,120.0575149,1,1,0,0,0,0
1890,04/06/2019 00:00,DB02179,O-Trifluoromethylphenyl Anthranilic Acid,,,,,,solid,,,0.0116,3.84,-3.6,OC(=O)C1=CC=CC=C1NC1=C(C=CC=C1)C(F)(F)F,,,,,0,,281.0663632,2,2,0,0,0,0
1891,04/06/2019 00:00,DB02180,Myristoyl-Coa,,,,,,solid,,,2.21,0.83,4.95,CCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N,,,,,0,,977.3135744,3,2,3,2,1,1
1892,04/06/2019 00:00,DB02181,2'-Deoxyguanosine-5'-Triphosphate,,,,,,solid,,,5.59,0.82,1.61,NC1=NC2=C(N=CN2[C@H]2C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O2)C(=O)N1,,,,,0,,506.9957455,3,2,3,2,1,1
1893,04/06/2019 00:00,DB02182,Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe),,,,,,solid,,,0.418,3.74,,CCC1=C2C=C3N4C(=CC5=C(C)C(CCC(O)=O)=C6C=C7N8C(=CC(N2[Fe]48N56)=C1C)C(C)=C7CCC(O)=O)C(C=C)=C3C,,,,,0,,618.1929431,8,4,8,4,0,4
1894,04/06/2019 00:00,DB02183,Adenosine-5'-Ditungstate,,,,,,solid,,,10.4,2.2,4.93,[H]N([H])C1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO[W](O)(=O)O[W](O)(O)=O)[C@@H](O)[C@H]1O,,,,,0,,732.9837541,3,2,3,2,1,1
1895,04/06/2019 00:00,DB02184,"D-1,4-dithiothreitol",,,,,,solid,,,5.14,9.62,-3.3,O[C@H](CS)[C@H](O)CS,,,,,0,,154.0122216,0,0,0,0,0,0
1896,04/06/2019 00:00,DB02185,"2,4-Dihydroxy-7-(Methyloxy)-2h-1,4-Benzoxazin-3(4h)-One",,,,,,solid,,,24.6,7.85,-4.6,[H][C@@]1(O)OC2=C(C=CC(OC)=C2)N(O)C1=O,,,,,0,,211.0480724,2,1,1,0,0,1
1897,04/06/2019 00:00,DB02186,N-Acetyl-D-Galactosamine 6-Sulfate,,,,,,solid,,,44.5,-2,-0.76,CC(=O)N[C@H]1[C@H](O)O[C@H](COS(O)(=O)=O)[C@H](O)[C@@H]1O,,,,,0,,301.0467521,1,0,1,0,1,1
1898,04/06/2019 00:00,DB02187,Equilin,Well absorbed.,0.9,,,,solid,1.41 mg/L (at 25 Â°C),,0.0133,9.41,-6,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC=C21)C=C(O)C=C3,0.9,0.9,,,0,,268.1463299,4,1,0,0,0,0
1899,04/06/2019 00:00,DB02188,N-Methylmesoporphyrin Containing Copper,,,,,,solid,,,0.138,3.15,8.18,CCC1=C2C=C3N4C(=CC5=[N+]6C(=CC7=[N]8(C)C(=CC(N2[Cu-]468)=C1C)C(CC)=C7C)C(C)=C5CCC(O)=O)C(CCC(O)=O)=C3C,,,,,,,,,,,,,
1900,04/06/2019 00:00,DB02189,"2',3'-Dideoxyadenosine-5'-Triphosphate",,,,,,solid,,,3.05,0.9,5.01,NC1=NC=NC2=C1N=CN2[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1,,,,,0,,475.0059162,3,2,3,2,1,1
1901,04/06/2019 00:00,DB02190,(S)-oxalosuccinic acid,,,,,,solid,,,7.47,2.38,-10,[H][C@@](CC(O)=O)(C(O)=O)C(=O)C(O)=O,,,,,0,,190.0113525,0,0,0,0,0,0
1902,04/06/2019 00:00,DB02191,"(7as,12ar,12bs)-1,2,3,4,7a,12,12a,12b-Octahydroindolo[2,3-a]Quinolizin-7(6h)-One",,,,,,solid,,,1.07,12.44,3.68,[H][C@@]12CCCC[N@]1CC(=O)C1=C2NC2=C1C=CC=C2,,,,,0,,240.1262631,4,2,3,1,1,2
1903,04/06/2019 00:00,DB02192,Phenylethyl alcohol,,,,,,solid,2.22E+004 mg/L (at 25 Â°C),1.36,11.3,15.88,-2.4,OCCC1=CC=CC=C1,,,,,0,,122.0731649,1,1,0,0,0,0
1904,04/06/2019 00:00,DB02194,"8-Benzyl-2-Hydroxy-2-(4-Hydroxy-Benzyl)-6-(4-Hydroxy-Phenyl)-2h-Imidazo[1,2-a]Pyrazin-3-One",,,,,,solid,,,0.0147,8.93,1.1,OC1=CC=C(C[C@@]2(O)N=C3N(C=C(N=C3CC3=CC=CC=C3)C3=CC=C(O)C=C3)C2=O)C=C1,,,,,0,,439.1532062,5,3,2,0,0,2
1905,04/06/2019 00:00,DB02195,"3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine",,,,,,solid,,,0.00865,11.26,4.7,ON1C2=CC=CN=C2C(=C1C1=CC=NC=C1)C1=CC=C(F)C=C1,,,,,0,,305.0964402,4,4,3,3,0,0
1906,04/06/2019 00:00,DB02196,Uridine-Diphosphate-N-Acetylgalactosamine,,,,,,solid,,,11.4,1.74,-3.5,CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[P@](O)(=O)O[P@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O,,,,,0,,607.0815697,3,1,3,1,2,2
1907,04/06/2019 00:00,DB02197,"4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide",,,,,,solid,,,0.0248,10.67,5.54,NS(=O)(=O)C1=CC=C(NC2=NC(=CC=N2)C2=CN=C3C=CC=CN23)C=C1,,,,,0,,366.0898947,4,4,3,3,0,0
1908,04/06/2019 00:00,DB02198,2-Bromoacetyl Group,,,,,,solid,1.75E+006 mg/L (at 25 Â°C),0.41,107,2.64,,OC(=O)CBr,,,,,0,,137.9316414,0,0,0,0,0,0
1909,04/06/2019 00:00,DB02199,"1,3-Dedimethyl-1,3-Divinyl Heme",,,,,,solid,,,0.136,3.7,,CC1=C(CCC(O)=O)C2=CC3=C(CCC(O)=O)C(C)=C4C=C5N6C(=CC7=C(C=C)C(C=C)=C8C=C1N2[Fe]6(N34)N78)C(C=C)=C5C=C,,,,,0,,640.177293,8,4,8,4,0,4
1910,04/06/2019 00:00,DB02200,3-[N-[Benzyloxycarbonyl]-Phenylalaninyl-Amino]-5-Phenyl-Pentane-1-Sulfonylmethylbenzene,,,,,,solid,,,0.000358,5.61,3.48,[H][C@](CCC1=CC=CC=C1)(CCS(=O)(=O)CC1=CC=CC=C1)N=C(O)[C@]([H])(CC1=CC=CC=C1)N=C(O)OCC1=CC=CC=C1,,,,,0,,598.2501433,4,4,0,0,0,0
1911,04/06/2019 00:00,DB02201,Malonate Ion,,,,,,solid,7.63E+005 mg/L (at 25 Â°C),-0.81,467,2.43,,[O-]C(=O)CC([O-])=O,,,,,-2,,101.9964057,0,0,0,0,0,0
1912,04/06/2019 00:00,DB02202,"(S)-butane-1,3-diol",,,,,,solid,1E+006 mg/L (at 25 Â°C),,742,15.41,-2.4,C[C@H](O)CCO,,,,,0,,90.06807956,0,0,0,0,0,0
1913,04/06/2019 00:00,DB02203,Acetone Cyanohydrin,,,,,,solid,1E+006 mg/L,,26,12.76,-3.8,CC(C)(O)C#N,,,,,0,,85.05276384,0,0,0,0,0,0
1914,04/06/2019 00:00,DB02205,"6-(1,1-Dimethylallyl)-2-(1-Hydroxy-1-Methylethyl)-2,3-Dihydro-7h-Furo[3,2-G]Chromen-7-One",,,,,,solid,,,0.022,14.3,-3.1,[H][C@]1(CC2=C(O1)C=C1OC(=O)C(=CC1=C2)C(C)(C)C=C)C(C)(C)O,,,,,0,,314.1518092,3,2,2,1,0,1
1915,04/06/2019 00:00,DB02207,7-Nitroindazole,,,,,,solid,,,4.23,10.22,-0.39,O=N(=O)C1=CC=CC2=CNN=C12,,,,,0,,163.0381764,2,2,1,1,0,0
1916,04/06/2019 00:00,DB02209,Pyridoxine phosphate,,,,,,solid,,,9.41,1.74,5.55,CC1=NC=C(COP(O)(O)=O)C(CO)=C1O,,,,,0,,249.0402237,1,1,1,1,0,0
1917,04/06/2019 00:00,DB02210,"Hexane-1,6-Diol",,,,,,solid,,,84.4,16.84,-1.7,OCCCCCCO,,,,,0,,118.0993797,0,0,0,0,0,0
1918,04/06/2019 00:00,DB02211,N-Methyl-N-Propargyl-1(R)-Aminoindan,,,,,,solid,,,0.0365,,8.54,[H][C@]1(CCC2=C1C=CC=C2)N(C)CC#C,,,,,0,,185.1204495,2,1,0,0,0,0
1919,04/06/2019 00:00,DB02213,Metanitrophenyl-Alpha-D-Galactoside,,,,,,solid,,,16.9,12.2,-3,[H][C@]1(CO)O[C@]([H])(OC2=CC=CC(=C2)N(=O)=O)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,301.0797664,2,1,1,0,1,1
1920,04/06/2019 00:00,DB02214,"6,7-Dioxo-5h-8-Ribitylaminolumazine",,,,,,solid,,,18.7,9.17,-3,[H][C@@](O)(CO)[C@@]([H])(O)[C@@]([H])(O)CN1C(=O)C(=O)NC2=C1N=C(O)N=C2O,,,,,0,,330.0811634,2,2,2,2,0,0
1921,04/06/2019 00:00,DB02215,Furoyl-Leucine,,,,,,solid,,,0.32,3.9,-3.4,[H][C@@](CC(C)C)(NC(=O)C1=CC=CO1)C(O)=O,,,,,0,,225.100108,1,1,1,1,0,0
1922,04/06/2019 00:00,DB02216,S-Methylcysteine,,,,,,solid,,,65.8,2.44,9.15,CSC[C@H](N)C(O)=O,,,,,0,,135.0353995,0,0,0,0,0,0
1923,04/06/2019 00:00,DB02217,Dpb-T,,,,,,solid,,,4.43,0.65,-3.9,[H][C@]1(C[C@]2([H])O[C@@](OC[C@]2([H])O1)(C1=CC=CC=C1)P(O)(O)=O)N1C=C(C)C(=O)NC1=O,,,,,0,,410.0879022,4,2,3,1,2,2
1924,04/06/2019 00:00,DB02218,"N-[4-hydroxymethyl-cyclohexan-6-yl-1,2,3-triol]-4,6-dideoxy-4-aminoglucopyranoside",,,,,,solid,,,168,11.31,6.73,[H][C@]1(C)O[C@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])N[C@@]1([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,321.1423667,2,0,1,0,1,1
1925,04/06/2019 00:00,DB02219,3-Cyclohexyl-1-Propylsulfonic Acid,,,,,,solid,,,1.51,-0.53,10.45,OS(=O)(=O)CCCNC1CCCCC1,,,,,0,,221.1085645,1,0,0,0,0,0
1926,04/06/2019 00:00,DB02220,AL7089A,,,,,,solid,,,0.263,8.17,6.44,CN[C@H]1CN(C2=CC(OC)=CC=C2)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,,,,,0,,403.0330336,3,2,2,1,0,1
1927,04/06/2019 00:00,DB02221,"4-(Aminosulfonyl)-N-[(2,4,6-Trifluorophenyl)Methyl]-Benzamide",,,,,,solid,,,0.0123,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=C(F)C=C(F)C=C1F,,,,,0,,344.0442479,2,2,0,0,0,0
1928,04/06/2019 00:00,DB02222,"2,6-Diamino-(S)-9-[2-(Phosphonomethoxy)Propyl]Purine",,,,,,solid,,,2.72,1.36,6.01,C[C@@H](CN1C=NC2=C1N=C(N)N=C2N)OCP([O-])([O-])=O,,,,,-2,,300.0746867,2,2,2,2,0,0
1929,04/06/2019 00:00,DB02223,LY231514 Tetra Glu,,,,,,solid,,,0.0506,2.81,,[H][C@@](CCC(O)=N[C@@]([H])(CCC(O)=N[C@@]([H])(CCC(O)=NC([H])(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O,,,,,0,,814.2769626,3,3,2,2,0,0
1930,04/06/2019 00:00,DB02224,Taxifolin,,,,,,solid,,0.95,1.16,7.8,-3.9,O[C@@H]1[C@H](OC2=CC(O)=CC(O)=C2C1=O)C1=CC=C(O)C(O)=C1,,,,,0,,304.0583027,3,2,1,0,0,1
1931,04/06/2019 00:00,DB02225,"1,2-Di-N-Pentanoyl-Sn-Glycero-3-Dithiophosphocholine",,,,,,solid,,,0.000175,1.35,-6.7,CCCCC(=O)OC[C@H](CO[P@@]([S-])(=S)OCC[N+](C)(C)C)OC(=O)CCCC,,,,,0,,457.1721665,0,0,0,0,0,0
1932,04/06/2019 00:00,DB02226,"3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium",,,,,,solid,,,0.000297,,8.89,NC1=CC2=C(C=C1)C1=CC=C(N)C=C1C(C1=CC=CC=C1)=[N+]2CCCCCCC1=CN(CCNC2=C3CCCCC3=NC3=C2C=CC=C3)N=N1,,,,,1,,661.3761699,8,7,3,3,0,0
1933,04/06/2019 00:00,DB02227,"4,5-Dihydroxy-Tetrahydro-Pyran-2-Carboxylic Acid",,,,,,solid,,,692,3.53,-3.2,O[C@H]1CO[C@@H](C[C@@H]1O)C(O)=O,,,,,0,,162.0528234,1,0,1,0,1,1
1934,04/06/2019 00:00,DB02228,2-deoxy-2-fluoro-Î²-D-galactose,,,,,,solid,,,257,11.02,-3,[H][C@@]1(O)O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]1([H])F,,,,,0,,182.0590517,1,0,1,0,1,1
1935,04/06/2019 00:00,DB02229,5'-O-[(L-methionyl)-sulphamoyl]adenosine,,,,,,solid,,,2.29,5.71,9,[H][C@](N)(CCSC)C(O)=NS(=O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CNC23[H])[C@]([H])(O)[C@]1([H])O,,,,,0,,479.1256881,3,0,3,0,1,3
1936,04/06/2019 00:00,DB02230,Immucillin-G,,,,,,solid,,,1.46,8.25,9.17,[H][C@]1(CO)N[C@@]([H])(C2=CNC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,281.112404,3,2,3,2,1,1
1937,04/06/2019 00:00,DB02232,"1,2-Dihydroxybenzene",,,,,,solid,4.61E+005 mg/L (at 25 Â°C),0.88,75,9.34,-6.3,OC1=CC=CC=C1O,,,,,0,,110.0367794,1,1,0,0,0,0
1938,04/06/2019 00:00,DB02233,6-hydroxy-D-norleucine,,,,,,solid,,,101,2.46,9.53,[H][C@@](N)(CCCCO)C(O)=O,,,,,0,,147.0895433,0,0,0,0,0,0
1939,04/06/2019 00:00,DB02234,S-Ethylisothiourea,,,,,,solid,,,4.77,,10.59,CCSC(N)=N,,,,,0,,104.0408193,0,0,0,0,0,0
1940,04/06/2019 00:00,DB02235,L-methionine (R)-S-oxide,,,,,,solid,,,54,1.74,9.11,C[S@@](=O)CC[C@H](N)C(O)=O,,,,,0,,165.0459642,0,0,0,0,0,0
1941,04/06/2019 00:00,DB02236,Glycinamide Ribonucleotide,,,,,,solid,,,14.6,1.23,8.14,NCC(=O)NC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,,,,,0,,286.0566021,1,0,1,0,1,1
1942,04/06/2019 00:00,DB02237,Maltotetraose,,,,,,solid,,,221,11.7,-3.7,OC[C@@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C=O,,,,,0,,666.2218584,3,0,3,0,3,3
1943,04/06/2019 00:00,DB02238,4-(Methylsulfanyl)-2-Oxobutanoic Acid,,,,,,solid,,,7.44,3.3,-9.7,CSCCC(=O)C(O)=O,,,,,0,,148.0194151,0,0,0,0,0,0
1944,04/06/2019 00:00,DB02239,Laevulinic Acid,,,,,,solid,,-0.49,139,4.32,-7.3,CC(=O)CCC(O)=O,,,,,0,,116.0473441,0,0,0,0,0,0
1945,04/06/2019 00:00,DB02240,Quinacrine mustard,,,,,,solid,,,0.000967,,8.38,COC1=CC2=C(NC(C)CCCN(CCCl)CCCl)C3=CC=C(Cl)C=C3N=C2C=C1,,,,,0,,467.1297956,3,3,1,1,0,0
1946,04/06/2019 00:00,DB02241,"8-Benzyl-2-Hydroperoxy-2-(4-Hydroxy-Benzyl)-6-(4-Hydroxy-Phenyl)-2h-Imidazo[1,2-a]Pyrazin-3-One",,,,,,solid,,,0.016,8.95,1.04,OO[C@]1(CC2=CC=C(O)C=C2)N=C2N(C=C(N=C2CC2=CC=CC=C2)C2=CC=C(O)C=C2)C1=O,,,,,0,,455.1481208,5,3,2,0,0,2
1947,04/06/2019 00:00,DB02242,Cyclohexane Propionic Acid,,,,,,solid,,,0.508,5,,OC(=O)CCC1CCCCC1,,,,,0,,156.1150298,1,0,0,0,0,0
1948,04/06/2019 00:00,DB02243,4-Morpholin-4-Yl-Piperidine-1-Carboxylic Acid [1-(3-Benzenesulfonyl-1-Propyl-Allylcarbamoyl)-2-Phenylethyl]-Amide,,,,,,solid,,,0.0144,4.55,7.75,[H][C@](CCC)(C=CS(=O)(=O)C1=CC=CC=C1)N=C(O)[C@]([H])(CC1=CC=CC=C1)N=C(O)N1CCC(CC1)N1CCOCC1,,,,,0,,582.2875914,4,2,2,0,2,2
1949,04/06/2019 00:00,DB02245,7-Deazaguanine,,,,,,solid,,,2.76,9.21,3.44,NC1=NC2=C(CC=N2)C(=O)N1,,,,,0,,150.0541608,2,1,2,1,0,1
1950,04/06/2019 00:00,DB02247,Hydrolyzed Cephalothin,,,,,,solid,,,0.0374,3.62,-0.87,[H][C@@](NC(=O)CC1=CC=CS1)(C(O)=O)[C@@]1([H])NC(C(O)=O)=C(C)CS1,,,,,0,,356.0500636,2,1,2,1,0,1
1951,04/06/2019 00:00,DB02248,3-Methyl-5-Sulfo-Pyrrolidine-2-Carboxylic Acid,,,,,,solid,,,31.1,-3.9,5.91,[H][C@@]1(C)C[C@@]([H])(N[C@@]1([H])C(O)=O)S(O)(=O)=O,,,,,0,,209.0357935,1,0,1,0,1,1
1952,04/06/2019 00:00,DB02249,2-Ethoxyethanol,,,,,,solid,1E+006 mg/L,-0.32,585,15.12,-2.7,CCOCCO,,,,,0,,90.06807956,0,0,0,0,0,0
1953,04/06/2019 00:00,DB02251,O-Succinylbenzoate,,,,,,solid,,,0.557,3.42,-7.6,OC(=O)CCC(=O)C1=C(C=CC=C1)C(O)=O,,,,,0,,222.0528234,1,1,0,0,0,0
1954,04/06/2019 00:00,DB02252,Iodophenyl,,,,,,solid,,,0.145,,,IC1=CC=CC=C1,,,,,0,,203.9435982,1,1,0,0,0,0
1955,04/06/2019 00:00,DB02253,"(1r)-4-[(1e,3e,5e,7z,9e,11z,13e,15e)-17-Hydroxy-3,7,12,16-Tetramethylheptadeca-1,3,5,7,9,11,13,15-Octaen-1-Yl]-3,5,5-Trimethylcyclohex-3-En-1-Ol",,,,,,solid,,,0.00157,16.76,-1.1,OC\C(C)=C\C=C\C(\C)=C/C=C/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C,,,,,0,,434.3184806,1,0,0,0,0,0
1956,04/06/2019 00:00,DB02254,Trifluoro-thiamin phosphate,,,,,,solid,,,0.0178,1.71,0.71,CC1=C(CCOP([O-])([O-])=O)SC=[N+]1CC1=CN=C(N=C1N)C(F)(F)F,,,,,-1,,397.0352708,2,2,2,2,0,0
1957,04/06/2019 00:00,DB02255,GM6001,,,,,,solid,,,0.0408,8.9,-0.71,[H][C@@](CC(C)C)(CC(=O)NO)C(=O)N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(=O)NC,,,,,0,,388.2110554,2,2,1,1,0,0
1958,04/06/2019 00:00,DB02256,2'-Deoxyuridine,,,,,,solid,,-1.51,90.6,9.71,-3,OC[C@H]1O[C@H](C[C@@H]1O)N1C=CC(=O)NC1=O,,,,,0,,228.0746215,2,1,2,1,1,1
1959,04/06/2019 00:00,DB02257,N-Bromoacetyl-Aminoethyl Phosphate,,,,,,solid,,,16.7,1.49,-4.6,CC(=O)N(Br)CCOP(O)(O)=O,,,,,0,,260.9401711,0,0,0,0,0,0
1960,04/06/2019 00:00,DB02258,SR11254,,,,,,solid,,,9.86E-05,4.03,2.93,CC1(C)CCC(C)(C)C2=CC(=CC=C12)C(=N/O)\C1=CC=C2C=C(C=CC2=C1)C(O)=O,,,,,0,,401.1990937,4,3,0,0,0,0
1961,04/06/2019 00:00,DB02259,"3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide",,,,,,solid,,,0.0137,5.11,-4.5,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=C(C=C2)S(=O)(=O)NC1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,655.8922171,4,4,1,1,0,0
1962,04/06/2019 00:00,DB02260,4-Oxosebacic Acid,,,,,,solid,,,2.23,4.31,-7.4,OC(=O)CCCCCC(=O)CCC(O)=O,,,,,0,,216.0997736,0,0,0,0,0,0
1963,04/06/2019 00:00,DB02261,Platelet Activating Factor,,,,,,solid,,,0.000225,1.86,-4.1,CCCCCCCCCCCCCCCCOC[C@H](CO[P@@]([O-])(=O)OCC[N+](C)(C)C)OC(C)=O,,,,,0,,523.3637897,0,0,0,0,0,0
1964,04/06/2019 00:00,DB02262,Orotic Acid,,,,,,solid,1820 mg/L (at 18 Â°C),-0.83,4.51,2.83,-6,OC(=O)C1=CC(=O)NC(=O)N1,,,,,0,,156.0171066,1,1,1,1,0,0
1965,04/06/2019 00:00,DB02263,Glyceraldehyde-3-Phosphate,,,,,,solid,,,20.5,1.4,-3.8,O[C@H](COP(O)(O)=O)C=O,,,,,0,,169.9980246,0,0,0,0,0,0
1966,04/06/2019 00:00,DB02264,O2-Sulfo-Glucuronic Acid,,,,,,solid,,,78.2,-2.1,-3.7,[H][C@@]1(O)O[C@@]([H])(C(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])OS(O)(=O)=O,,,,,0,,273.9994675,1,0,1,0,1,1
1967,04/06/2019 00:00,DB02265,Ethyl-Trimethyl-Silane,,,,,,solid,,,0.228,,,CC[Si](C)(C)C,,,,,0,,102.086477,0,0,0,0,0,0
1968,04/06/2019 00:00,DB02266,Flufenamic Acid,,,,,,solid,9.09 mg/L (at 25 Â°C),5.25,0.008,3.88,-2.1,OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F,,,,,0,,281.0663632,2,2,0,0,0,0
1969,04/06/2019 00:00,DB02267,Argininosuccinate,,,,,,solid,,,0.456,2.14,12.39,N[C@@H](CCCNC(=N)N[C@H](CC(O)=O)C(O)=O)C(O)=O,,,,,0,,290.1226343,0,0,0,0,0,0
1970,04/06/2019 00:00,DB02268,4-(Acetylamino)-3-Amino Benzoic Acid,,,,,,solid,,,2.29,4.86,2.43,CC(=O)NC1=C(N)C=C(C=C1)C(O)=O,,,,,0,,194.0691422,1,1,0,0,0,0
1971,04/06/2019 00:00,DB02269,[4-({[5-Benzyloxy-1-(3-Carbamimidoyl-Benzyl)-1h-Indole-2-Carbonyl]-Amino}-Methyl)-Phenyl]-Trimethyl-Ammonium,,,,,,solid,,,0.0002,14.73,11.49,C[N+](C)(C)C1=CC=C(CNC(=O)C2=CC3=C(C=CC(OCC4=CC=CC=C4)=C3)N2CC2=CC=CC(=C2)C(N)=N)C=C1,,,,,1,,546.2863518,5,5,1,1,0,0
1972,04/06/2019 00:00,DB02270,Dimethylallyl S-Thiolodiphosphate,,,,,,solid,,,13.2,2.04,,CC(C)CCS[P@](O)(=O)OP(O)(O)=O,,,,,0,,263.9986324,0,0,0,0,0,0
1973,04/06/2019 00:00,DB02271,S-(2-Oxo)Pentadecylcoa,,,,,,solid,,,3.08,0.82,4.96,[H][C@@](O)(C(O)=NCCC(O)=NCCSCC(=O)CCCCCCCCCCCCC)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,991.3292245,3,2,3,2,1,1
1974,04/06/2019 00:00,DB02272,Porphobilinogen,,,,,,solid,,,2.72,3.66,8.99,NCC1=C(CC(O)=O)C(CCC(O)=O)=CN1,,,,,0,,226.0953569,1,1,1,1,0,0
1975,04/06/2019 00:00,DB02273,"2,6-Dimethyl-7-Octen-2-Ol",,,,,,solid,,,0.102,18.53,-1.3,C[C@@H](CCCC(C)(C)O)C=C,,,,,0,,156.1514153,0,0,0,0,0,0
1976,04/06/2019 00:00,DB02274,7-Keto-8-Aminopelargonic Acid,,,,,,solid,,,3.84,4.45,8.08,[H][C@@](C)(N)C(=O)CCCCCC(O)=O,,,,,0,,187.1208434,0,0,0,0,0,0
1977,04/06/2019 00:00,DB02275,"[2-Aminomethyl-5-Oxo-4-(4-Oxo-Cyclohexa-2,5-Dienylmethyl)-4,5-Dihydro-Imidazol-1-Yl] -Acetaldehyde",,,,,,solid,,,0.758,8.2,7.34,[H][C@@]1(CC2C=CC(=O)C=C2)N=C(CN)N(CC=O)C1=O,,,,,0,,261.1113413,2,0,1,0,0,1
1978,04/06/2019 00:00,DB02276,(S)-2-(Phosphonoxy)Caproyl-L-Leucyl-P-Nitroanilide,,,,,,solid,,,0.0181,1.42,-5.4,[H][C@@](CC(C)C)(NC(=O)[C@]([H])(CCCC)OP(O)(O)=O)C(=O)NC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,445.1614015,1,1,0,0,0,0
1979,04/06/2019 00:00,DB02277,1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea,,,,,,solid,,,0.0631,11.61,2.3,CN1N=C(C=C1NC(=O)NC1=CC=C(Cl)C=C1)C(C)(C)C,,,,,0,,306.1247389,2,2,1,1,0,0
1980,04/06/2019 00:00,DB02278,"7,8-Dihydro-7,7-Dimethyl-6-Hydroxypterin",,,,,,solid,,,1.57,5.8,3.77,CC1(C)NC2=C(N=C1O)C(=O)NC(N)=N2,,,,,0,,209.0912746,2,1,2,1,0,1
1981,04/06/2019 00:00,DB02279,Benzoylformic Acid,,,,,,solid,9.2E+005 mg/L (at 0 Â°C),,2.42,2.69,-9.5,OC(=O)C(=O)C1=CC=CC=C1,,,,,0,,150.0316941,1,1,0,0,0,0
1982,04/06/2019 00:00,DB02280,(R)-Mandelic acid,,,,,,solid,1.1E+005 mg/L (at 25 Â°C),,16.8,3.75,-4.1,O[C@@H](C(O)=O)C1=CC=CC=C1,,,,,0,,152.0473441,1,1,0,0,0,0
1983,04/06/2019 00:00,DB02281,Formycin,,,,,,solid,,,10.3,11.89,3.38,[H][C@]1(CO)O[C@@]([H])(C2=C3N=CN=C(N)C3=NN2)[C@]([H])(O)[C@]1([H])O,,,,,0,,267.0967539,3,2,3,2,1,1
1984,04/06/2019 00:00,DB02282,5'-Deoxy-5'-Methylthioadenosine,,,,,,solid,,,6.5,12.47,4.99,CSC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N,,,,,0,,297.0895603,3,2,3,2,1,1
1985,04/06/2019 00:00,DB02283,2-Phenylamino-Ethanesulfonic Acid,,,,,,solid,,,4.39,-1.1,4.66,OS(=O)(=O)CCNC1=CC=CC=C1,,,,,0,,201.0459642,1,1,0,0,0,0
1986,04/06/2019 00:00,DB02285,Protoporphyrin,,,,,,solid,169 mg/L (at 25 Â°C),,0.0217,3.68,4.96,CC1=C(CCC(O)=O)/C2=C/C3=N/C(=C\C4=C(C)C(C=C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C=C)=C4C)/C(C)=C3CCC(O)=O,,,,,0,,562.2580056,5,3,5,3,0,2
1987,04/06/2019 00:00,DB02286,2-Amino-3-(4-Amino-1h-Indol-3-Yl)Propanoic Acid,,,,,,solid,,,4.17,1.84,9.4,[H][C@](N)(CC1=CNC2=CC=CC(N)=C12)C(O)=O,,,,,0,,219.1007767,2,2,1,1,0,0
1988,04/06/2019 00:00,DB02287,2-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-Carboxamidine,,,,,,solid,,,0.0814,9.09,11.55,NC(=[NH2+])C1=CC2=C(C=C1)N=C(N2)C1=CC=CC=C1O,,,,,1,,253.1083875,3,3,1,1,0,0
1989,04/06/2019 00:00,DB02288,CRA_9334,,,,,,solid,,,0.0116,7.68,10.6,CC1=CC(Br)=C([O-])C(=C1)C1=NC2=CC(=CC=C2N1)C(N)=[NH2+],,,,,0,,344.0272731,3,3,1,1,0,0
1990,04/06/2019 00:00,DB02289,2-Aminopropanedioic Acid,,,,,,solid,,,126,0.45,8.5,NC(C(O)=O)C(O)=O,,,,,0,,119.0218576,0,0,0,0,0,0
1991,04/06/2019 00:00,DB02290,"3-{2,6,8-trioxo-9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate",,,,,,solid,,,8.49,1.76,-3,[H][C@@](O)(CO)[C@@]([H])(O)[C@@]([H])(O)CN1C(=O)N(CCCOP(O)(O)=O)C2=C1N=C(O)N=C2O,,,,,0,,440.0944441,2,2,2,2,0,0
1992,04/06/2019 00:00,DB02292,Irosustat,,,,,,solid,,,0.0967,10.65,-6,NS(=O)(=O)OC1=CC=C2C3=C(CCCCC3)C(=O)OC2=C1,,,,,0,,309.0670936,3,2,1,1,0,0
1993,04/06/2019 00:00,DB02293,"(2S)-2,3-bis{[(3R,7R)-3,7,11,15-tetramethylhexadecyl]oxy}propyl (2R)-2-hydroxy-3-[(hydroxyphosphinato)oxy]propyl phosphate",,,,,,solid,,,0.000277,1.35,-3.4,[H]C(C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@@]([H])(C)CCOC[C@@]([H])(COP(O)(=O)OC[C@]([H])(O)COP([O-])([O-])=O)OCC[C@]([H])(C)CCC[C@]([H])(C)CCCC([H])(C)CCCC(C)C,,,,,-2,,884.6282342,0,0,0,0,0,0
1994,04/06/2019 00:00,DB02294,"(5R,6S,7S,8S)-5-hydroxymethyl-6,7,8-trihydroxy-tetrazolo[1,5-A]piperidine",,,,,,solid,,,47.8,12.05,-1.9,[H][C@]1(O)C2=NN=NN2[C@]([H])(CO)[C@]([H])(O)[C@]1([H])O,,,,,0,,202.0702048,2,1,2,1,0,1
1995,04/06/2019 00:00,DB02295,"N-[3-(Dimethylamino)Propyl]-2-({[4-({[4-(Formylamino)-1-Methyl-1h-Pyrrol-2-Yl]Carbonyl}Amino)-1-Methyl-1h-Pyrrol-2-Yl]Carbonyl}Amino)-5-Isopropyl-1,3-Thiazole-4-Carboxamide",,,,,,solid,,,0.086,10.12,9.23,CC(C)C1=C(N=C(NC(=O)C2=CC(NC(=O)C3=CC(NC=O)=CN3C)=CN2C)S1)C(=O)NCCCN(C)C,,,,,0,,542.2423726,3,3,3,3,0,0
1996,04/06/2019 00:00,DB02296,Isoamyl alcohol,,,,,,solid,,,38,17.17,-1.9,CC(C)CCO,,,,,0,,88.088815,0,0,0,0,0,0
1997,04/06/2019 00:00,DB02297,2-Amino-6-Chloropyrazine,,,,,,solid,,,55.9,19.58,-0.049,NC1=CN=CC(Cl)=N1,,,,,0,,129.0093748,1,1,1,1,0,0
1998,04/06/2019 00:00,DB02298,5-Hydroxyamino-3-Methyl-Pyrrolidine-2-Carboxylic Acid,,,,,,solid,,,30.4,3.1,7.32,[H][C@@]1(C)C[C@@]([H])(NO)N[C@@]1([H])C(O)=O,,,,,0,,160.0847922,1,0,1,0,1,1
1999,04/06/2019 00:00,DB02299,Arginineamide,,,,,,solid,,,24.1,16.31,12.4,N[C@@H](CCCNC(N)=[NH2+])C(N)=O,,,,,1,,174.1349366,0,0,0,0,0,0
2000,02/07/2019 00:00,DB02300,Calcipotriol,"Clinical studies with radiolabeled ointment indicate that approximately 6% (+3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques or 5% (+2.6%, SO) when applied to normal skin.",,,0.05 mg/1g,Topical,solid,,,0.0135,14.39,-1.6,O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1,,,,,0,,412.2977451,4,0,0,0,0,0
2001,04/06/2019 00:00,DB02301,"5,10-Methylene-6-Hydrofolic Acid",,,,,,solid,,,0.335,3.24,5.19,NC1=NC(=O)C2=C(N1)N=C[C@@H]1CN(CN21)C1=CC=C(C=C1)C(=O)N[C@H](CCC(O)=O)C(O)=O,,,,,0,,455.1553314,4,2,3,1,1,2
2002,04/06/2019 00:00,DB02302,"N3, N4-Dimethylarginine",,,,,,solid,,,1.56,2.54,12.4,CN\C(NCCC[C@H](N)C(O)=O)=N/C,,,,,0,,202.1429758,0,0,0,0,0,0
2003,04/06/2019 00:00,DB02303,"(5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione",,,,,,solid,,,1.01,4.72,2.41,[H][C@]1(I)CN=C(O)N=C1O,,,,,0,,239.9395754,1,0,1,0,0,1
2004,04/06/2019 00:00,DB02304,Prostaglandin B2,,,,,,solid,,,0.0299,4.25,-1.6,CCCCC[C@H](O)\C=C\C1=C(C\C=C/CCCC(O)=O)C(=O)CC1,,,,,0,,334.2144094,1,0,0,0,0,0
2005,04/06/2019 00:00,DB02305,"4,5-Dehydro-D-Glucuronic Acid",,,,,,solid,,,208,3.27,-3.5,[H][C@@]1(O)OC(=C[C@]([H])(O)[C@@]1([H])O)C(O)=O,,,,,0,,176.032088,1,0,1,0,0,1
2006,04/06/2019 00:00,DB02306,Palmitoyl-Linoleoyl Phosphatidylcholine,,,,,,solid,,,2.53E-05,1.86,-6.7,CCCCCCCCCCCCCCCC(=O)OC[C@]([H])(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC,,,,,0,,757.5621551,0,0,0,0,0,0
2007,04/06/2019 00:00,DB02307,N-(1-Carboxy-3-Phenylpropyl)Phenylalanyl-Alpha-Asparagine,,,,,,solid,,,0.0386,-1.9,12.51,[H][C@@](CCC1=CC=CC=C1)(N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@@]([H])(CC(O)=O)C(O)=N)C(O)=O,,,,,0,,441.1899856,2,2,0,0,0,0
2008,04/06/2019 00:00,DB02308,"4-(1,3,2-Dioxaborolan-2-Yloxy)Butan-1-Aminium",,,,,,solid,,,9.14,,10.2,[NH3+]CCCCOB1OCCO1,,,,,1,,160.1139502,1,0,1,0,1,1
2009,04/06/2019 00:00,DB02309,5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine,,,,,,solid,,,2.65,1.25,0.048,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=[NH+]C3=C2N=C(O)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,1,,365.0492911,3,2,3,2,1,1
2010,04/06/2019 00:00,DB02310,"3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium",,,,,,solid,,,0.000205,,3.53,CC1=CN=C2C(=C1)C(C)=C(C)C1=C2[N+](C)=CC(C)=C1,,,,,1,,251.154275,3,3,2,2,0,0
2011,04/06/2019 00:00,DB02311,Methyl Methylsulfinylmethyl Sulfide,,,,,,solid,,,46.9,,-6.6,CSC[S@](C)=O,,,,,0,,124.0016569,0,0,0,0,0,0
2012,04/06/2019 00:00,DB02312,beta-D-galactose 6-phosphate,,,,,,solid,,,31.4,1.22,-3.6,O[C@@H]1O[C@H](COP(O)(O)=O)[C@H](O)[C@H](O)[C@H]1O,,,,,0,,260.0297186,1,0,1,0,1,1
2013,04/06/2019 00:00,DB02313,4-{2-(4-Fluoro-Benzyl)-6-Methyl-5-[(5-Methyl-Isoxazole-3-Carbonyl)-Amino]-4-Oxo-Heptanoylamino}-5-(2-Oxo-Pyrrolidin-3-Yl)-Pentanoic Acid Ethyl Ester,,,,,,solid,,,0.0433,6.48,4.48,[H][C@@](CCC(=O)OCC)(C[C@]1([H])CCN=C1O)N=C(O)[C@@]([H])(CC(=O)[C@@]([H])(NC(=O)C1=NOC(C)=C1)C(C)C)CC1=CC=C(F)C=C1,,,,,0,,600.2959279,3,2,2,1,0,1
2014,04/06/2019 00:00,DB02314,Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine-D-Glutamate,,,,,,solid,,,9.13,1.73,,C[C@H](NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)NC2=O)[C@@H]1NC(C)=O)C(=O)N[C@H](CCC(O)=O)C(O)=O,,,,,0,,879.1824059,3,1,3,1,2,2
2015,04/06/2019 00:00,DB02315,Cyclic GMP,,,,,,solid,,,3.79,2.05,1.41,NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(O)(=O)O[C@H]3[C@H]2O)C(=O)N1,,,,,0,,345.0474344,4,2,4,2,2,2
2016,04/06/2019 00:00,DB02316,"1-(5-Carboxypentyl)-5-[(2,6-Dichlorobenzyl)Oxy]-1 H-Indole-2-Carboxylic Acid",,,,,,solid,,,0.000823,3.31,-4.9,OC(=O)CCCCCN1C(=CC2=C1C=CC(OCC1=C(Cl)C=CC=C1Cl)=C2)C(O)=O,,,,,0,,449.0796781,3,3,1,1,0,0
2017,04/06/2019 00:00,DB02317,Alpha-D-Galactose-1-Phosphate,,,,,,solid,,,32.3,1.16,-3,OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H]1O,,,,,0,,260.0297186,1,0,1,0,1,1
2018,04/06/2019 00:00,DB02318,2-deoxy-2-fluoro-alpha-D-mannosyl fluoride,,,,,,solid,,,129,12.52,-3,[H][C@]1(O)[C@]([H])(O)[C@@]([H])(CO)OC([H])(F)[C@@]1([H])F,,,,,0,,184.0547152,1,0,1,0,1,1
2019,04/06/2019 00:00,DB02319,"5,6-Dihydroxy-Nadp",,,,,,solid,,,8.22,0.66,8.02,[H][C@]1(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(OP(O)(O)=O)[C@]2([H])O)O[C@@]([H])(N2C=C(C[C@]([H])(O)[C@]2([H])O)C(O)=N)[C@]([H])(O)[C@]1([H])O,,,,,0,,779.0965817,5,2,5,2,2,3
2020,04/06/2019 00:00,DB02320,1-N-Acetyl-Beta-D-Glucosamine,,,,,,solid,,,82.5,7.28,-0.78,[H][C@]1(CO)O[C@@]([H])(N=C(C)O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,221.0899372,1,0,1,0,1,1
2021,04/06/2019 00:00,DB02321,"5-(3-Amino-4,4-Dihyroxy-Butylsulfanylmethyl)-Tetrahydro-Furan-2,3,4-Triol",,,,,,solid,,,41,1.8,9.5,N[C@@H](CCSC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O)C(O)=O,,,,,0,,267.0776583,1,0,1,0,1,1
2022,04/06/2019 00:00,DB02322,Heparin Disaccharide I-S,,,,,,solid,,,12,-2.5,-3.5,[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,,,,,-4,,572.9422346,2,0,2,0,1,2
2023,04/06/2019 00:00,DB02323,EM-1745,,,,,,solid,,,0.00559,10.32,4.99,[H][C@]1(CCCCCCCCC(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)C[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]2(C)[C@@]1([H])O,,,,,0,,677.378849,7,3,3,2,1,1
2024,04/06/2019 00:00,DB02324,5-Iodo-2'-Deoxyuridine-5'-Monophosphate,,,,,,solid,,,7.24,1.23,-3.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C(I)C(=O)NC1=O,,,,,0,,433.9376,2,1,2,1,1,1
2025,02/07/2019 00:00,DB02325,Isopropyl alcohol,,,,0.7 mL/1mL,Topical,solid,1E+006 mg/L (at 25 Â°C),0.05,378,17.26,-1.8,CC(C)O,,,,,0,,60.05751488,0,0,0,0,0,0
2026,04/06/2019 00:00,DB02326,1-Hydroxyamine-2-Isobutylmalonic Acid,,,,,,solid,,,22.8,3.99,-5.5,CC(C)C[C@@H](C(O)=O)C(=O)NO,,,,,0,,175.0844579,0,0,0,0,0,0
2027,04/06/2019 00:00,DB02327,Triethylene glycol,,,,,,solid,,,336,14.82,-2.7,OCCOCCOCCO,,,,,0,,150.0892089,0,0,0,0,0,0
2028,04/06/2019 00:00,DB02328,2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Imino]-5-Phosphono-Pent-3-Enoic Acid,,,,,,solid,,,1.52,1.6,5.57,[H]\C(CP(O)(O)=O)=C(\[H])/C(=N\CC1=C(COP(O)(O)=O)C=NC(C)=C1O)/C(O)=O,,,,,0,,424.043668,1,1,1,1,0,0
2029,04/06/2019 00:00,DB02329,Carbenoxolone,,,,,,solid,,,0.000738,4.04,-5.1,[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O,,,,,0,,570.3556539,5,0,0,0,0,0
2030,04/06/2019 00:00,DB02331,"(2s)-2-[(5-Benzofuran-2-Yl-Thiophen-2-Ylmethyl)-(2,4-Dichloro-Benzoyl)-Amino]-3-Phenyl-Propionic Acid",,,,,,solid,,,0.00255,4.42,-1.7,[H][C@@](CC1=CC=CC=C1)(N(CC1=CC=C(S1)C1=CC2=CC=CC=C2O1)C(=O)C1=C(Cl)C=C(Cl)C=C1)C(O)=O,,,,,0,,549.0568345,5,5,2,2,0,0
2031,04/06/2019 00:00,DB02332,Flavin-N7 Protonated-Adenine Dinucleotide,,,,,,solid,,,2.18,1.86,4.96,[H][C@@](O)(COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C([NH3+])N=CN=C23)[C@]([H])(O)[C@]1([H])O)[C@@]([H])(O)[C@@]([H])(O)CN1C2=C(C=C(C)C(C)=C2)N=C2C(O)=NC(=O)N=C12,,,,,1,,786.1644111,6,3,5,2,1,3
2032,04/06/2019 00:00,DB02333,Deoxyuridine-5'-Triphosphate,,,,,,solid,,,8.63,0.9,-3.2,O[C@H]1C[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O,,,,,0,,467.973613,2,1,2,1,1,1
2033,04/06/2019 00:00,DB02334,(R)-2-Hydroxy-3-Sulfopropanoic Acid,,,,,,solid,,,78.9,-1.6,-4.2,O[C@@H](CS(O)(=O)=O)C(O)=O,,,,,0,,169.9885089,0,0,0,0,0,0
2034,04/06/2019 00:00,DB02335,2-Aminothiazoline,,,,,,solid,,,12.2,,9.3,NC1=NCCS1,,,,,0,,102.0251692,1,0,1,0,0,1
2035,04/06/2019 00:00,DB02336,RU83876,,,,,,solid,,,0.0116,1.65,1.16,[H][C@@](CC1=CC(=C(C=C1)P(O)(O)=O)P(O)(O)=O)(N=C(C)O)C(O)=N[C@@]1([H])CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O,,,,,0,,643.184853,4,3,1,0,1,1
2036,04/06/2019 00:00,DB02337,S-(D-Carboxybutyl)-L-Homocysteine,,,,,,solid,,,1.98,2.55,9.5,N[C@@H](CCSCCCCC(O)=O)C(O)=O,,,,,0,,235.087829,0,0,0,0,0,0
2037,04/06/2019 00:00,DB02338,Nadph Dihydro-Nicotinamide-Adenine-Dinucleotidephosphate,,,,,,solid,,,5.45,0.66,4.92,NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)N2C=NC3=C2N=CN=C3N)[C@@H](O)[C@H]1O,,,,,0,,745.0911024,5,2,5,2,2,3
2038,04/06/2019 00:00,DB02339,Allyl-{6-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-Hexyl-}-Methyl-Amin,,,,,,solid,,,0.00293,,9.42,CN(CCCCCCOC1=CC=C2C(OC=C2C2=CC=C(Br)C=C2)=C1)CC=C,,,,,0,,441.1303412,3,3,1,1,0,0
2039,04/06/2019 00:00,DB02340,N-Acetyl-Serine,,,,,,solid,,,84.6,3.61,-1.5,CC(=O)N[C@@H](CO)C(O)=O,,,,,0,,147.0531578,0,0,0,0,0,0
2040,04/06/2019 00:00,DB02341,"Mdl 101,146",,,,,,solid,,,0.00809,10.32,-0.48,CC(C)[C@@H](NC(=O)C1=CC=C(C=C1)C(=O)N1CCOCC1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](C(C)C)C(=O)C(F)(F)C(F)(F)F,,,,,0,,632.263326,3,1,2,0,2,2
2041,04/06/2019 00:00,DB02342,2-Methoxyestradiol,,,,,,solid,,,0.00968,10.29,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C(OC)=C3,,,,,0,,302.1881947,4,1,0,0,0,0
2042,04/06/2019 00:00,DB02343,"3,6,9,12,15-Pentaoxaheptadecane",,,,,,solid,,,1.35,,-3.4,CCOCCOCCOCCOCCOCC,,,,,0,,250.1780239,0,0,0,0,0,0
2043,04/06/2019 00:00,DB02345,Selenocysteine,,,,,Oral,solid,3.92E+005 mg/L (at 0 Â°C),,325,1.27,8.42,N[C@@H](C[SeH])C(O)=O,,,,,0,,168.9641998,0,0,0,0,0,0
2044,04/06/2019 00:00,DB02346,3'-O-N-Octanoyl-a-D-Glucopyranosyl-B-D-Fructofuranoside,,,,,,solid,,,16.9,11.86,-3,[H][C@]1(CO)O[C@@](CO)(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(OC(=O)CCCCCCC)[C@@]2([H])O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,468.2206766,2,0,2,0,2,2
2045,04/06/2019 00:00,DB02347,2-Amino-3-(5-Tert-Butyl-3-(Phosphonomethoxy)-4-Isoxazolyl)Propionic Acid,,,,,,solid,,,0.657,1.27,9.15,CC(C)(C)C1=C(C[C@H](N)C(O)=O)C(OCP(O)(O)=O)=NO1,,,,,0,,322.0929876,1,1,1,1,0,0
2046,04/06/2019 00:00,DB02349,Nicotinamide-Adenine-Dinucleotide-5-Hydroxy-4-Oxonorvaline,,,,,,solid,,,4.92,0.75,8.67,[H][C@](N)(CC(=O)[C@@]([H])(O)C1=CC=[N+](C=C1C(O)=N)[C@]1([H])O[C@]([H])(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O)C(O)=O,,,,,1,,809.153906,5,3,5,3,2,2
2047,04/06/2019 00:00,DB02350,"N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide",,,,,,solid,,,0.224,8.7,-4.8,[H][C@@]1(N(CCCSC1(C)C)S(=O)(=O)C1=CC=C(OC)C=C1)C(=O)NO,,,,,0,,374.0970138,2,1,1,0,1,1
2048,04/06/2019 00:00,DB02352,3-(Benzyloxy)Pyridin-2-Amine,,,,,,solid,,,6.29,,6.53,NC1=NC=CC=C1OCC1=CC=CC=C1,,,,,0,,200.094963,2,2,1,1,0,0
2049,04/06/2019 00:00,DB02353,Heparin Disaccharide Iii-S,,,,,,solid,,,37.5,-2.1,-3,[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O,,,,,-3,,493.9926962,2,0,2,0,1,2
2050,04/06/2019 00:00,DB02354,4-{[1-Methyl-5-(2-Methyl-Benzoimidazol-1-Ylmethyl)-1h-Benzoimidazol-2-Ylmethyl]-Amino}-Benzamidine,,,,,,solid,,,0.0447,18.16,12.52,CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(CN1C(C)=NC3=C1C=CC=C3)=C2,,,,,0,,423.2171438,5,5,2,2,0,0
2051,04/06/2019 00:00,DB02355,Adenosine-5'-Rp-Alpha-Thio-Triphosphate,,,,,,solid,,,2.03,1.07,4.99,[H][C@]1(CO[P@@](O)(=S)OP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,522.9729018,3,2,3,2,1,1
2052,04/06/2019 00:00,DB02356,4-Imidazolmethylene-5-Imidazolone Chromophore,,,,,,solid,,,2.57,3.24,8.12,[H][C@](N)(CO)[C@@]1([H])N=C(CC2=CN=CN2)C(=O)N1CC(O)=O,,,,,0,,281.112404,2,1,2,1,0,1
2053,04/06/2019 00:00,DB02357,Methyl-O3-(Alpha-D-Mannose)-Alpha-D-Mannose,,,,,,solid,,,570,11.94,-3,[H][C@]1(O)[C@]([H])(O)[C@@]([H])(CO)O[C@]([H])(O[C@@]2([H])[C@]([H])(O)[C@@]([H])(CO)O[C@]([H])(OC)[C@@]2([H])O)[C@@]1([H])O,,,,,0,,356.1318616,2,0,2,0,2,2
2054,04/06/2019 00:00,DB02358,LY374571,,,,,,solid,,,0.0855,-4,13.01,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(NC(O)=NC2=C(N)C(O)=NC(=N)N2)C=C1)C(O)=O,,,,,0,,433.1345959,2,2,1,1,0,0
2055,04/06/2019 00:00,DB02359,"9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine",,,,,,solid,,,0.0618,18.59,5.06,CCCCN1C(CC2=CC(OC)=CC=C2OC)=NC2=C(N)N=CN=C12,,,,,0,,341.185175,3,3,2,2,0,0
2056,04/06/2019 00:00,DB02360,Bis-Napthyl Beta-Ketophosphonic Acid,,,,,,solid,,,0.0016,1.54,-7.8,[H][C@](C(=O)C1=CC2=CC=CC=C2C=C1)(C1=CC=CC2=CC=CC=C12)P(O)(O)=O,,,,,0,,376.0864457,4,4,0,0,0,0
2057,04/06/2019 00:00,DB02361,S-Methyl Thiocysteine Group,,,,,,solid,,,19.3,2.15,9.04,[H][C@](N)(CSSC)C(O)=O,,,,,0,,167.0074705,0,0,0,0,0,0
2058,04/06/2019 00:00,DB02362,Aminobenzoic acid,,,,500 mg,Oral,solid,6110 mg/L (at 30 Â°C),0.83,4.41,4.77,2.69,NC1=CC=C(C=C1)C(O)=O,,,,,0,500,137.0476785,1,1,0,0,0,0
2059,04/06/2019 00:00,DB02363,2'-Monophosphoadenosine-5'-Diphosphate,,,,,,solid,,,4.78,0.65,4.92,[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(OP(O)(O)=O)[C@]1([H])O,,,,,0,,506.9957455,3,2,3,2,1,1
2060,04/06/2019 00:00,DB02364,2-Amino-3-(Diethoxy-Phosphoryloxy)-Propionic Acid,,,,,,solid,,,35,2.19,9.34,[H][C@](N)(COP(=O)(OCC)OCC)C(O)=O,,,,,0,,241.0715239,0,0,0,0,0,0
2061,04/06/2019 00:00,DB02365,"1,10-Phenanthroline",,,,,,solid,2690 mg/L (at 25 Â°C),1.78,0.132,,4.8,C1=CC2=CC=C3C=CC=NC3=C2N=C1,,,,,0,,180.0687483,3,3,2,2,0,0
2062,04/06/2019 00:00,DB02366,CRA_10762,,,,,,solid,,,0.00305,8.77,9.61,NC(=N)C1=CC2=C(NC(=N2)C2=CC=CC(C3=CC=CC=C3)=C2O)C=C1Cl,,,,,0,,362.0934388,4,4,1,1,0,0
2063,04/06/2019 00:00,DB02367,(1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine,,,,,,solid,,,0.459,8.71,-4.9,CCCCOC1=CC=C(C=C1)S(=O)(=O)N1C[C@H](C[C@@H]1C(=O)NO)NS(C)(=O)=O,,,,,0,,435.1133921,2,1,1,0,1,1
2064,04/06/2019 00:00,DB02368,N-Acetyl-L-Citrulline,,,,,,solid,,,3.57,3.87,-1.1,CC(=O)N[C@@H](CCCNC(N)=O)C(O)=O,,,,,0,,217.106256,0,0,0,0,0,0
2065,04/06/2019 00:00,DB02369,"3-Aza-2,3-Dihydrogeranyl Diphosphate",,,,,,solid,,,27.9,1.76,9.6,CN(CCO[P@]([O-])(=O)OP([O-])([O-])=O)CCC=C(C)C,,,,,-3,,314.0574959,0,0,0,0,0,0
2066,04/06/2019 00:00,DB02370,Nz-(1-Carboxyethyl)-Lysine,,,,,,solid,,,14.3,1.66,10.68,C[C@@H](NCCCC[C@H](N)C(O)=O)C(O)=O,,,,,0,,218.1266571,0,0,0,0,0,0
2067,04/06/2019 00:00,DB02371,"2-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Ethanesulfonic Acid",,,,,,solid,,,24,-1.5,8.06,OCC(CO)(CO)NCCS(O)(=O)=O,,,,,0,,229.0620082,0,0,0,0,0,0
2068,04/06/2019 00:00,DB02372,"2,5-Dimethylpyrimidin-4-Amine",,,,,,solid,,,44.4,,6.35,CC1=CN=C(C)N=C1N,,,,,0,,123.0796473,1,1,1,1,0,0
2069,04/06/2019 00:00,DB02373,Adenosine Monotungstate,,,,,,solid,,,15.8,12.3,4.99,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H](CO[W](O)(O)=O)[C@H](O)[C@H]1O,,,,,0,,500.040254,3,2,3,2,1,1
2070,04/06/2019 00:00,DB02374,Xylose-Derived Imidazole,,,,,,solid,,,25.1,12.36,5.61,[H][C@@]1(O)CN2C=CN=C2[C@]([H])(O)[C@@]1([H])O,,,,,0,,170.0691422,2,1,2,1,0,1
2071,04/06/2019 00:00,DB02375,Myricetin,,,,,,solid,,,0.301,6.43,-4.1,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC(O)=C(O)C(O)=C2)=C1,,,,,0,,318.0375673,3,3,1,1,0,0
2072,04/06/2019 00:00,DB02376,"D-gluconhydroximo-1,5-lactam",,,,,,solid,,,67.3,12.42,5.37,[H][C@]1(O)C(NO)=N[C@]([H])(CO)[C@@]([H])(O)[C@]1([H])O,,,,,0,,192.0746215,1,0,1,0,0,1
2073,04/06/2019 00:00,DB02377,Guanine,,,,,,solid,2080 mg/L (at 37 Â°C),-0.91,2.31,8.95,2.22,NC1=NC(=O)C2=C(N1)N=CN2,,,,,0,,151.0494098,2,2,2,2,0,0
2074,04/06/2019 00:00,DB02378,MMI-175,,,,,,solid,,,0.0138,-1.2,15,[H][C@@](C)(C[C@]([H])(O)[C@]([H])(CC(C)C)N=C(O)[C@]1([H])CC(O)=NCCCCCCOC(O)=N[C@@]([H])(C(C)C)C(O)=N1)C(O)=N[C@@]([H])(C(C)C)C(O)=NCC1=CC=CC=C1,,,,,0,,730.4629129,2,1,1,0,0,1
2075,04/06/2019 00:00,DB02379,Beta-D-Glucose,,,,,,solid,1.2E+006 mg/L (at 30 Â°C),-3.24,782,11.3,-3,OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,180.0633881,1,0,1,0,1,1
2076,04/06/2019 00:00,DB02380,2'-Deoxyinosine,,,,,,solid,,-1.71,10.1,11.68,-0.1,OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CN=C2O,,,,,0,,252.0858549,3,2,3,2,1,1
2077,04/06/2019 00:00,DB02381,nor-NOHA,,,,,,solid,,,2.24,2.08,10.57,N[C@@H](CCNC(=N)NO)C(O)=O,,,,,0,,176.0909402,0,0,0,0,0,0
2078,04/06/2019 00:00,DB02382,Namn,,,,,,solid,,,4.61,1.2,-3.7,[H][C@]1(COP(O)([O-])=O)O[C@@]([H])([N+]2=CC=CC(=C2)C(O)=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,335.0406177,2,1,2,1,1,1
2079,04/06/2019 00:00,DB02383,Tolrestat,,,,,,solid,,,0.0076,3.95,-3,COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F,,,,,0,,357.064649,2,2,0,0,0,0
2080,04/06/2019 00:00,DB02384,(E)-2-Fluoro-P-Hydroxycinnamate,,,,,,solid,,,0.415,2.47,-6,[H]\C(=C(/F)C(O)=O)C1=CC=C([O-])C=C1,,,,,-1,,181.0306459,1,1,0,0,0,0
2081,04/06/2019 00:00,DB02385,D-threo-neopterin,,,,,,solid,,,6.26,9.99,0.98,NC1=NC2=NC=C(N=C2C(=O)N1)[C@@H](O)[C@H](O)CO,,,,,0,,253.0811038,2,2,2,2,0,0
2082,04/06/2019 00:00,DB02386,Leucine Phosphonic Acid,,,,,,solid,,,33.1,-0.24,10.23,CC(C)C[C@H](N)P(O)(O)=O,,,,,0,,167.0711299,0,0,0,0,0,0
2083,04/06/2019 00:00,DB02388,"Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine",,,,,,solid,,,0.00223,15.07,10.02,CCCN1C(=NC(=C1C1=CC=NC(NC2CCCCC2)=N1)C1=CC=C(Cl)C(Cl)=C1)C1CCNCC1,,,,,0,,512.2222004,5,3,3,2,1,1
2084,04/06/2019 00:00,DB02390,5-Bromo-N[2-(Dimethylamino)Ethyl]-9-Aminoacridine-4-Carboxamide,,,,,,solid,,,3.82E-05,14.71,8.52,C[NH+](C)CCNC(=O)C1=CC=CC2=C(N)C3=C([NH+]=C12)C(Br)=CC=C3,,,,,2,,388.0887762,3,3,1,1,0,0
2085,04/06/2019 00:00,DB02391,"2-Amino-7-[2-(2-Hydroxy-1-Hydroxymethyl-Ethylamino)-Ethyl]-1,7-Dihydro-Purin-6-One",,,,,,solid,,,8.59,10.72,8.77,NC1=NC2=C(N(CCNC(CO)CO)C=N2)C(=O)N1,,,,,0,,268.1283884,2,2,2,2,0,0
2086,04/06/2019 00:00,DB02393,"D-Gluco-2,5-Anhydro-1-Deoxy-1-Phosphonohexitol-6-Phosphate",,,,,,solid,,,21.8,1.12,-3.6,[H][C@]1(O)[C@]([H])(O)[C@]([H])(CP(O)(O)=O)O[C@]1([H])COP(O)(O)=O,,,,,0,,308.0062199,1,0,1,0,1,1
2087,04/06/2019 00:00,DB02394,Oxiranpseudoglucose,,,,,,solid,,,1160,12.63,-3.1,[H][C@@]12C[C@]([H])(O)[C@@]([H])(O)[C@]([H])(O)[C@]1(CO)O2,,,,,0,,176.0684735,2,0,1,0,1,1
2088,04/06/2019 00:00,DB02395,"3-Hydroxymethyl-5-Aziridinyl-1methyl-2-[1h-Indole-4,7-Dione]-Propanol",,,,,,solid,,,5.38,13.6,-1.6,CN1C(CCCO)=C(CO)C2=C1C(=O)C=C(N1CC1)C2=O,,,,,0,,290.1266571,3,1,2,1,1,1
2089,04/06/2019 00:00,DB02396,Methylethylamine,,,,,,solid,,0.15,418,,10.54,CCNC,,,,,0,,59.07349929,0,0,0,0,0,0
2090,04/06/2019 00:00,DB02397,O-(2-Acetamido-2-Deoxy-Alpha-D-Galactopyranosyl)-L-Serine,,,,,,solid,,,40.6,1.91,9.04,[H][C@](N)(CO[C@@]1([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]1([H])N=C(C)O)C(O)=O,,,,,0,,308.1219656,1,0,1,0,1,1
2091,04/06/2019 00:00,DB02398,6-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-Naphthalenecarboxamidine,,,,,,solid,,,0.0135,12.05,11.21,NCC1=CC=C(NC(=O)C2=CC=C3C=C(C=CC3=C2)C(N)=N)C=C1,,,,,0,,318.1480612,3,3,0,0,0,0
2092,04/06/2019 00:00,DB02399,L-Rhamnitol,,,,,,solid,,,476,12.7,-3,[H][C@@](C)(O)[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(O)CO,,,,,0,,166.0841235,0,0,0,0,0,0
2093,04/06/2019 00:00,DB02400,"5-Methoxy-1,2-Dimethyl-3-(4-Nitrophenoxymethyl)Indole-4,7-Dione",,,,,,solid,,,0.0273,12.61,-4.6,COC1=CC(=O)C2=C(C(COC3=CC=C(C=C3)[N+]([O-])=O)=C(C)N2C)C1=O,,,,,0,,356.1008362,3,2,1,1,0,0
2094,04/06/2019 00:00,DB02401,"4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid",,,,,,solid,,,46.5,3.4,-5.7,OC(=O)C1=NON=C1O,,,,,0,,130.0014565,1,1,1,1,0,0
2095,04/06/2019 00:00,DB02402,"5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine",,,,,,solid,,,0.347,16.48,7.28,COC1=CC=C(OC2=CC=CC3=NC(N)=NC(N)=C23)C=C1,,,,,0,,282.1116757,3,3,1,1,0,0
2096,04/06/2019 00:00,DB02403,2-Fluoroaniline,,,,,,solid,,1.26,12.7,19.26,2.43,NC1=CC=CC=C1F,,,,,0,,111.0484274,1,1,0,0,0,0
2097,04/06/2019 00:00,DB02404,1-Deoxy-1-Thio-Heptaethylene Glycol,,,,,,solid,,,0.172,9.97,-2.7,OCCOCCOCCOCCOCCOCCOCCS,,,,,0,,342.1712243,0,0,0,0,0,0
2098,04/06/2019 00:00,DB02405,12-Bromododecanoic Acid,,,,,,solid,,,0.00138,4.95,,OC(=O)CCCCCCCCCCCBr,,,,,0,,278.0881421,0,0,0,0,0,0
2099,04/06/2019 00:00,DB02406,N-Valeric Acid,,,,,,solid,2.4E+004 mg/L (at 25 Â°C),1.39,40.3,5.01,,CCCCC(O)=O,,,,,0,,102.0680796,0,0,0,0,0,0
2100,04/06/2019 00:00,DB02407,6-O-Cyclohexylmethyl Guanine,,,,,,solid,,,0.829,8.98,3.77,NC1=NC(OCC2CCCCC2)=C2N=CNC2=N1,,,,,0,,247.1433102,3,2,2,2,0,0
2101,04/06/2019 00:00,DB02408,"(3s)-3-Amino-1-(Cyclopropylamino)Heptane-2,2-Diol",,,,,,solid,,,46.8,11.2,9.33,[H][C@](N)(CCCC)C(O)(O)CNC1CC1,,,,,0,,202.1681279,1,0,0,0,0,0
2102,04/06/2019 00:00,DB02409,"(1r,4s)-2-Azabornane",,,,,,solid,,,4.38,,11.35,[H][C@@]12CC[C@@](C)(NC1)C2(C)C,,,,,0,,139.1360995,2,0,1,0,1,1
2103,04/06/2019 00:00,DB02410,"2-Acetyl-3-[(4-Amino-2-Methyl-5-Pyrimidinyl)Methyl]-4-Methyl-5-(4,6,6-Trihydroxy-3,5-Dioxa-4,6-Diphosphahex-1-Yl)Thiazolium Inner Salt P,P'-Dioxide",,,,,,solid,,,0.0596,1.78,5.53,CC(=O)C1=[N+](CC2=CN=C(C)N=C2N)C(C)=C(CCOP(O)(=O)OP(O)(O)=O)S1,,,,,1,,467.0549843,2,2,2,2,0,0
2104,04/06/2019 00:00,DB02411,"2-(11-{2-[Benzenesulfonyl-(3-Methyl-Butyl)-Amino]-1-Hydroxy-Ethyl}-6,9-Dioxo-2-Oxa-7,10-Diaza-Bicyclo[11.2.2]Heptadeca-1(16),13(17),14-Trien-8-Yl)-Acetamide, Inhibitor 2",,,,,,solid,,,0.0814,10.74,-1.1,CC(C)CCN(C[C@@H](O)[C@@H]1CC2=CC=C(OCCCC(=O)N[C@@H](CC(N)=O)C(=O)N1)C=C2)S(=O)(=O)C1=CC=CC=C1,,,,,0,,588.2617706,4,2,2,0,0,2
2105,04/06/2019 00:00,DB02412,Tetrahydropyran,,,,,,solid,8.02E+004 mg/L (at 25 Â°C),0.95,38.1,,-4.1,C1CCOCC1,,,,,0,,86.07316494,1,0,1,0,1,1
2106,04/06/2019 00:00,DB02413,Hydroxyethylcysteine,,,,,,solid,,,38.3,2.26,9.14,N[C@@H](CSCCO)C(O)=O,,,,,0,,165.0459642,0,0,0,0,0,0
2107,04/06/2019 00:00,DB02414,"(3s,8ar)-3-(1h-Imidazol-5-Ylmethyl)Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione",,,,,,solid,,,3.58,5.92,6.82,[H][C@@]12CCCN1C(=O)[C@]([H])(CC1=CN=CN1)N=C2O,,,,,0,,234.1116757,3,1,3,1,1,2
2108,04/06/2019 00:00,DB02415,N-Octyl-2-Hydroxyethyl Sulfoxide,,,,,,solid,,,2.3,15.18,-2.7,CCCCCCCC[S@@](=O)CCO,,,,,0,,206.1340509,0,0,0,0,0,0
2109,04/06/2019 00:00,DB02416,"2-Ribofuranosyl-3-Iodo-2,3-Dihydro-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",,,,,,solid,,,4.86,12.54,7.83,[H][C@]1(I)NN(C2=NC=NC(N)=C12)[C@]1([H])O[C@]([H])(CO)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,395.0090519,3,1,3,1,1,2
2110,04/06/2019 00:00,DB02417,"2,4,6-Tribromophenol",,,,,,solid,70 mg/L (at 15 Â°C),4.13,0.0545,6.34,-7.7,OC1=C(Br)C=C(Br)C=C1Br,,,,,0,,327.773401,1,1,0,0,0,0
2111,04/06/2019 00:00,DB02418,"(R,R)-2,3-Butanediol",,,,,,solid,,,603,14.22,-3,C[C@@H](O)[C@H](C)O,,,,,0,,90.06807956,0,0,0,0,0,0
2112,04/06/2019 00:00,DB02419,Ethyl Oxo(Piperidin-1-Yl)Acetate,,,,,,solid,,,31,,-4.5,CCOC(=O)C(=O)N1CCCCC1,,,,,0,,185.1051933,1,0,1,0,1,1
2113,04/06/2019 00:00,DB02420,"[[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,",,,,,,solid,,,0.77,2.52,9.47,NCC1=CC=C(NC(=O)C(O)=O)C=C1,,,,,0,,194.0691422,1,1,0,0,0,0
2114,04/06/2019 00:00,DB02421,Uridine-5'-Diphosphate-Mannose,,,,,,solid,,,26,1.73,-3.6,[H][C@]1(COP(O)(=O)OP(O)(=O)O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,566.0550206,3,1,3,1,2,2
2115,04/06/2019 00:00,DB02422,Methyl-2-S-(Alpha-D-Mannopyranosyl)-2-Thio-Alpha-D-Mannopyranoside,,,,,,solid,,,369,12.34,-3,[H][C@]1(CO)O[C@]([H])(OC)[C@@]([H])(S[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,372.109018,2,0,2,0,2,2
2116,04/06/2019 00:00,DB02424,Geldanamycin,,,,,,solid,,,0.00618,7.24,4.54,[H]/C1=C([H])/[C@]([H])(OC)[C@@]([H])(OC(O)=N)\C(C)=C([H])\[C@]([H])(C)[C@@]([H])(O)[C@]([H])(C[C@]([H])(C)CC2=C(OC)C(=O)C=C(N=C(O)\C(C)=C\1/[H])C2=O)OC,,,,,0,,560.2733809,2,0,1,0,0,1
2117,04/06/2019 00:00,DB02425,Hexadecyl Octanoate,,,,,,solid,,,1.82E-05,,-7,CCCCCCCCCCCCCCCOC(=O)CCCCCCC,,,,,0,,354.3497807,0,0,0,0,0,0
2118,04/06/2019 00:00,DB02426,Carboxyatractyloside,,,,,,solid,,,2.17,-2.3,-0.69,CC(C)CC(=O)O[C@H]1[C@@H](O[C@@H]2C[C@]3(C)[C@H]4CC[C@@H]5C[C@@]4(CC[C@H]3C(C2)(C(O)=O)C(O)=O)[C@@H](O)C5=C)O[C@@H](COO)[C@H](OS(O)(=O)=O)[C@@H]1OS(O)(=O)=O,,,,,0,,786.2074713,5,0,1,0,1,1
2119,04/06/2019 00:00,DB02427,"2,4-Diamino-6-[N-(2',5'-Dimethoxybenzyl)-N-Methylamino]Quinazoline",,,,,,solid,,,0.213,18.54,7.4,COC1=CC(CN(C)C2=CC=C3N=C(N)N=C(N)C3=C2)=C(OC)C=C1,,,,,0,,339.1695249,3,3,1,1,0,0
2120,04/06/2019 00:00,DB02428,Quinaldic Acid,,,,,,solid,1.4E+004 mg/L (at 25 Â°C),,0.76,1.07,4.89,OC(=O)C1=NC2=C(C=CC=C2)C=C1,,,,,0,,173.0476785,2,2,1,1,0,0
2121,04/06/2019 00:00,DB02429,4-(Aminosulfonyl)-N-[(4-Fluorophenyl)Methyl]-Benzamide,,,,,,solid,,,0.0335,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=CC=C(F)C=C1,,,,,0,,308.0630915,2,2,0,0,0,0
2122,04/06/2019 00:00,DB02430,Trehalose-6-Phosphate,,,,,,solid,,,40.6,1.22,-3.6,OC[C@H]1O[C@H](O[C@H]2O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,422.082542,2,0,2,0,2,2
2123,04/06/2019 00:00,DB02431,Cytidine-5'-Triphosphate,,,,,,solid,,,11.2,0.91,-0.54,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,,,,,0,,482.9845121,2,1,2,1,1,1
2124,04/06/2019 00:00,DB02432,RU90395,,,,,,solid,,,0.00127,2.28,1.48,[H][C@@](CC1=CC(C(=O)OC)=C(C=C1)C(F)(C(O)=O)C(O)=O)(N=C(C)O)C(O)=N[C@@]1([H])CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O,,,,,0,,661.243558,4,3,1,0,1,1
2125,04/06/2019 00:00,DB02433,"{[(2,2-Dihydroxy-Ethyl)-(2,3,4,5-Tetrahydroxy-6-Phosphonooxy-Hexyl)-Amino]-Methyl}-Phosphonic Acid",,,,,,solid,,,17.8,-0.8,5.55,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)CN(CC(O)O)CP(O)(O)=O,,,,,0,,415.0644631,0,0,0,0,0,0
2126,04/06/2019 00:00,DB02434,4-(2-Thienyl)Butyric Acid,,,,,,solid,,,0.38,4.94,-8,OC(=O)CCCC1=CC=CS1,,,,,0,,170.0401506,1,1,1,1,0,0
2127,04/06/2019 00:00,DB02435,Aminomethylcyclohexane,,,,,,solid,,,0.0152,,10.22,[NH3+]CC1CCCCC1,,,,,1,,114.1277259,1,0,0,0,0,0
2128,04/06/2019 00:00,DB02436,2-{4-[(2s)-2-[({[(1s)-1-Carboxy-2-Phenylethyl]Amino}Carbonyl)Amino]-3-Oxo-3-(Pentylamino)Propyl]Phenoxy}Malonic Acid,,,,,,solid,,,0.0108,2.08,5.91,[H][C@@](CC1=CC=CC=C1)(NC(O)=N[C@@]([H])(CC1=CC=C(OC(C(O)=O)C(O)=O)C=C1)C(O)=NCCCCC)C(O)=O,,,,,0,,543.2216796,2,2,0,0,0,0
2129,04/06/2019 00:00,DB02437,(5r)-5-Amino-6-Hydroxyhexylcarbamic Acid,,,,,,solid,,,26.3,4.13,9.83,N[C@H](CO)CCCCNC(O)=O,,,,,0,,176.1160924,0,0,0,0,0,0
2130,04/06/2019 00:00,DB02438,3-O-Methylfructose in Linear Form,,,,,,solid,,,507,12.48,-3,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(OC)C(=O)CO,,,,,0,,194.0790382,0,0,0,0,0,0
2131,04/06/2019 00:00,DB02441,"2-Butyl-5,6-Dihydro-1h-Imidazo[4,5-D]Pyridazine-4,7-Dione",,,,,,solid,,,0.47,7.42,0.046,CCCCC1=NC2=C(N1)C(=O)NNC2=O,,,,,0,,208.0960256,2,2,2,2,0,0
2132,04/06/2019 00:00,DB02442,Dioxyselenocysteine,,,,,,solid,,,215,1.15,7.54,[H][C@](N)(C[SeH](=O)=O)C(O)=O,,,,,0,,200.954029,0,0,0,0,0,0
2133,04/06/2019 00:00,DB02443,Methicillin Acyl-Serine,,,,,,solid,,,0.103,1.02,8.74,[H][C@](N)(COC(=O)[C@@]([H])(N=C([O-])C1=C(OC)C=CC=C1OC)[C@]1([H])N[C@@]([H])(C(O)=O)C(C)(C)S1)C([O-])=O,,,,,-2,,483.1322475,2,1,1,0,1,1
2134,04/06/2019 00:00,DB02445,2-Deoxy-2-Amino Glucitol-6-Phosphate,,,,,,solid,,,25.5,1.49,8.61,[H][C@](N)(CO)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)COP(O)(O)=O,,,,,0,,261.0613531,0,0,0,0,0,0
2135,04/06/2019 00:00,DB02446,Glutamine hydroxamate,,,,,,solid,,,55,1.93,9.46,N[C@@H](CCC(=O)NO)C(O)=O,,,,,0,,162.0640568,0,0,0,0,0,0
2136,04/06/2019 00:00,DB02447,"3,8,9,10-Tetrahydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione",,,,,,solid,,,98.1,5.16,-3,[H][C@]1(CO)O[C@@]2(N=C(O)N(O)C2=O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,264.0593653,2,0,2,0,1,2
2137,04/06/2019 00:00,DB02448,N-Tridecanoic Acid,,,,,,solid,33 mg/L (at 20 Â°C),,0.00391,4.95,,CCCCCCCCCCCCC(O)=O,,,,,0,,214.1932801,0,0,0,0,0,0
2138,04/06/2019 00:00,DB02449,3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid,,,,,,solid,,,0.00114,2.67,3.69,[H][C@@](CC1=CNC2=CC=CC=C12)(NS(=O)(=O)C1=CC=C(C=C1)N1CCC(CC1)C1=CC=CC=C1)C(O)=O,,,,,0,,503.1878774,5,4,2,1,1,1
2139,04/06/2019 00:00,DB02450,"2-Benzo[1,3]Dioxol-5-Ylmethyl-3-Benzyl-Succinic Acid",,,,,,solid,,,0.156,3.62,-4.7,[H][C@@](CC1=CC=CC=C1)(C(O)=O)[C@]([H])(CC1=CC2=C(OCO2)C=C1)C(O)=O,,,,,0,,342.1103383,3,2,1,0,0,1
2140,04/06/2019 00:00,DB02451,B-nonylglucoside,,,,,,solid,,,8.64,12.21,-3,CCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,306.2042387,1,0,1,0,1,1
2141,04/06/2019 00:00,DB02452,Thymidine-5'-Triphosphate,,,,,,solid,,,7.78,0.9,-3.2,CC1=CN([C@H]2C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O2)C(=O)NC1=O,,,,,0,,481.9892631,2,1,2,1,1,1
2142,04/06/2019 00:00,DB02454,5-(6-Amino-9h-Purin-9-Yl)-4-Hydroxytetrahydrofuran-3-Yl Dihydrogen Phosphate,,,,,,solid,,,3.25,0.83,4.93,[H][C@@]1(CO[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]1([H])O)OP(O)(O)=O,,,,,0,,317.0525197,3,2,3,2,1,1
2143,04/06/2019 00:00,DB02455,Fluoresceinylthioureido,,,,,,solid,,,0.015,3.89,7.2,CCN=C(S)NC1=CC(C(O)=O)=C(C=C1)C1=C2C=CC(=O)C=C2OC2=C1C=CC(O)=C2,,,,,0,,434.0936427,4,2,1,0,0,1
2144,04/06/2019 00:00,DB02456,Aracytidine 5'-monophosphate,,,,,,solid,,,4.89,1.21,2.56,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=CC(=N)N=C2O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,323.051851,2,1,2,1,1,1
2145,04/06/2019 00:00,DB02457,Undecyl-Phosphinic Acid Butyl Ester,,,,,,solid,,,0.000183,,-6.6,[H][P@@](=O)(CCCCCCCCCCC)OCCCC,,,,,0,,276.2218169,0,0,0,0,0,0
2146,04/06/2019 00:00,DB02458,"S-(2,4-dinitrophenyl)glutathione",,,,,,solid,,,0.0319,1.6,9.31,[H][C@](N)(CCC(=O)N[C@@]([H])(CSC1=C(C=C(C=C1)N(=O)=O)N(=O)=O)C(=O)NCC(O)=O)C(O)=O,,,,,0,,473.0852628,1,1,0,0,0,0
2147,04/06/2019 00:00,DB02459,4-Guanidinobenzoic Acid,,,,,,solid,,,0.92,4.02,10.26,NC(=N)NC1=CC=C(C=C1)C(O)=O,,,,,0,,179.0694765,1,1,0,0,0,0
2148,04/06/2019 00:00,DB02460,Hydrogenobyrinic Acid,,,,,,solid,,,0.0143,3.39,8.71,[H][C@]12N=C(\C(C)=C3/N=C(/C=C4\N=C(\C(\C)=C5/N[C@]1(C)[C@@](C)(CC(O)=O)[C@@H]5CCC(O)=O)[C@@](C)(CC(O)=O)[C@@H]4CCC(O)=O)C(C)(C)[C@@H]3CCC(O)=O)[C@](C)(CCC(O)=O)[C@H]2CC(O)=O,,,,,0,,880.4106026,5,0,5,0,1,5
2149,04/06/2019 00:00,DB02461,S-Methyl Phosphocysteine,,,,,,solid,,,27.6,1.49,9.2,N[C@@H](CSCP(O)(O)=O)C(O)=O,,,,,0,,215.0017301,0,0,0,0,0,0
2150,04/06/2019 00:00,DB02462,Thiocoumarin,,,,,,solid,,,0.295,,9.46,CN(C)CCCOC1=CC(=O)SC2=CC=CC=C12,,,,,0,,263.0979998,2,2,1,1,0,0
2151,04/06/2019 00:00,DB02463,2-(2-Hydroxy-Phenyl)-1h-Indole-5-Carboxamidine,,,,,,solid,,,0.0225,9.64,11.23,NC(=[NH2+])C1=CC2=C(NC(=C2)C2=CC=CC=C2O)C=C1,,,,,1,,252.1131385,3,3,1,1,0,0
2152,04/06/2019 00:00,DB02464,Benzylamine,,,,,,solid,1E+006 mg/L (at 20 Â°C),1.09,9.71,,9.51,NCC1=CC=CC=C1,,,,,0,,107.0734993,1,1,0,0,0,0
2153,04/06/2019 00:00,DB02465,Methoxy arachidonyl fluorophosphonate,,,,,,solid,,,0.00038,,-8.5,[H]\C(CCCCC)=C(/[H])C\C([H])=C(\[H])C\C([H])=C(\[H])C\C([H])=C(\[H])CCCC[P@](F)(=O)OC,,,,,0,,370.2436952,0,0,0,0,0,0
2154,04/06/2019 00:00,DB02466,"4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid",,,,,,solid,,,0.000112,4.11,-7.3,CC1(C)CCC(C)(C)C2=CC(=CC=C12)C(=O)\C=C\C1=CC=C(C=C1)C(O)=O,,,,,0,,362.1881947,3,2,0,0,0,0
2155,04/06/2019 00:00,DB02467,L-methionine (S)-S-oxide,,,,,,solid,,,54,1.74,9.11,[H]C([H])([H])[S@](=O)C([H])([H])C([H])([H])[C@@]([H])(C([O-])=O)[N+]([H])([H])[H],,,,,0,,165.0459642,0,0,0,0,0,0
2156,04/06/2019 00:00,DB02468,12-Phenylheme,,,,,,solid,,,0.00274,3.6,,CC1C(C=C)C2=CC3=C(C)C(CCC(O)=O)=C4C=C5N6C(=CC7=C(C)C(C=C)=C8N7[Fe++]6(N34)N2C1=C8C1=CC=CC=C1)C(C)=C5CCC(O)=O,,,,,2,,694.223146,9,4,8,3,1,5
2157,04/06/2019 00:00,DB02469,"4,6-dideoxy-4-amino-beta-D-glucopyranoside",,,,,,solid,,,722,11.32,8.56,[H][C@]1(C)O[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])N,,,,,0,,163.0844579,1,0,1,0,1,1
2158,04/06/2019 00:00,DB02470,D-Glycero-D-Mannopyranose-7-Phosphate,,,,,,solid,,,34.6,1.49,-3.5,[H][C@@](O)(COP(O)(O)=O)[C@@]1([H])O[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,290.0402833,1,0,1,0,1,1
2159,04/06/2019 00:00,DB02471,Nojirimycine Tetrazole,,,,,,solid,,,47.8,12.05,-1.9,[H][C@]1(O)C2=NN=NN2[C@]([H])(CO)[C@@]([H])(O)[C@]1([H])O,,,,,0,,202.0702048,2,1,2,1,0,1
2160,04/06/2019 00:00,DB02472,"6-Hydroxy-7,8-Dihydro Purine Nucleoside",,,,,,solid,,,31.4,12.39,1.79,[H][C@]1(CO)O[C@@]([H])(N2CNC3=C2N=CN=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,270.0964195,3,1,3,1,1,2
2161,04/06/2019 00:00,DB02473,"6-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine",,,,,,solid,,,0.00423,11.76,11.11,CC(C)C1=NCCC2=C1C=C(NC(=O)C1=CC=C3C=C(C=CC3=C1)C(N)=N)C=C2,,,,,0,,384.1950114,4,3,1,0,0,1
2162,04/06/2019 00:00,DB02474,Bmsc-0013,,,,,,solid,,,1.83,7.02,2.56,[H][C@]1(CO)O[C@@]([H])(N=C(O)CCCCCN=C(O)OC)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,350.1689158,1,0,1,0,1,1
2163,04/06/2019 00:00,DB02475,Deoxyguanidinoproclavaminic acid,,,,,,solid,,,1.38,3.6,12.23,[H][C@@](CCCNC(N)=N)(N1CCC1=O)C(O)=O,,,,,0,,228.1222404,1,0,1,0,1,1
2164,04/06/2019 00:00,DB02477,[Cyclohexylethyl]-[[[[4-[2-Methyl-1-Imidazolyl-Butyl]Phenyl]Acetyl]-Seryl]-Lysinyl]-Amine,,,,,,solid,,,0.00816,5.34,10.21,[H][C@@](CO)(N=C(O)CC1=CC=C(CCCCN2C=CN=C2C)C=C1)C(O)=N[C@@]([H])(CCCCN)C(O)=NCCC1CCCCC1,,,,,0,,596.4050041,3,2,1,1,0,0
2165,04/06/2019 00:00,DB02479,(R)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide,,,,,,solid,,,0.0411,9.95,-0.91,[H]N([H])S(=O)(=O)C1=CC=C(C=C1)C(=O)N([H])C[C@@H](C)CN1C=CC2=CC=CC=C12,,,,,0,,371.1303625,3,3,1,1,0,0
2166,04/06/2019 00:00,DB02480,(S)-4-bromo-3-hydroxy-3-methylbutyl diphosphate,,,,,,solid,,,10.1,1.78,-3.2,C[C@@](O)(CBr)CCOP(O)(=O)OP(O)(O)=O,,,,,0,,341.9269027,0,0,0,0,0,0
2167,04/06/2019 00:00,DB02481,N-Benzylformamide,,,,,,solid,,,3.97,16.11,-0.96,O=CNCC1=CC=CC=C1,,,,,0,,135.0684139,1,1,0,0,0,0
2168,04/06/2019 00:00,DB02482,Phosphonothreonine,,,,,,solid,,,23.5,1.21,9.47,C[C@H](OP(O)(O)=O)[C@@H](N)C(O)=O,,,,,0,,199.0245737,0,0,0,0,0,0
2169,04/06/2019 00:00,DB02483,Etheno-Nad,,,,,,solid,,,3.69,1.86,6.4,[H][C@]1(COP([O-])(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(=C3)C(O)=N)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C2N=CN2C=CN=C32)[C@]([H])(O)[C@]1([H])O,,,,,0,,687.1091218,6,4,6,4,2,2
2170,04/06/2019 00:00,DB02484,Cytidine 5'-Diphosphoglycerol,,,,,,solid,,,8.98,1.77,3.34,[H][C@](O)(CO)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=CC(=N)N=C2O)[C@]([H])(O)[C@]1([H])O,,,,,0,,477.054961,2,1,2,1,1,1
2171,04/06/2019 00:00,DB02485,Cytidine-5'-Monophosphate-5-N-Acetylneuraminic Acid,,,,,,solid,,,36.3,1.48,-0.77,[H][C@]1(O[C@](C[C@H](O)[C@H]1NC(C)=O)(OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(N)=NC1=O)C(O)=O)[C@H](O)[C@H](O)CO,,,,,0,,614.1472675,3,1,3,1,2,2
2172,04/06/2019 00:00,DB02486,2-Hydroxyethyl Disulfide,,,,,,solid,,,36.5,15.14,-2.6,OCCSSCCO,,,,,0,,154.0122216,0,0,0,0,0,0
2173,04/06/2019 00:00,DB02488,1-(2-Ethanone)-2-Hydroxy-2-(1-Amino-2-Methyl-2-Ethanol)-4-(2-Dimethyl)Ethane-Imidazoline-5-One;Chromophore (Thr-Leu-Gly),,,,,,solid,,,4.87,10.08,7.36,[H][C@](C)(O)[C@]([H])(N)[C@@]1(O)N=C(CC(C)C)C(=O)N1CC=O,,,,,0,,271.1532062,1,0,1,0,0,1
2174,04/06/2019 00:00,DB02489,9-Methylguanine,,,,,,solid,,,8.33,11.62,1.22,CN1C=NC2=C1N=C(N)N=C2O,,,,,0,,165.0650598,2,2,2,2,0,0
2175,04/06/2019 00:00,DB02490,(Diaminomethyl-Methyl-Amino)-Acetic Acid,,,,,,solid,,,412,4.74,6.76,CN(CC(O)=O)C(N)N,,,,,0,,133.0851266,0,0,0,0,0,0
2176,04/06/2019 00:00,DB02491,4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine,,,,,,solid,,,0.00603,13.61,9.88,CC(C)(N)C1=CC=C(C=C1)C1=NC(NC2=CC=C(CCN3CCOCC3)C=C2)=NC=C1Cl,,,,,0,,451.2138883,4,3,2,1,1,1
2177,04/06/2019 00:00,DB02492,Ghavamiol,,,,,,solid,,,89.4,13.14,6.98,[H][C@@](O)(CN1C[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])CO)C([H])(CO)OS([O-])([O-])[O-],,,,,-3,,316.0718729,1,0,1,0,1,1
2178,04/06/2019 00:00,DB02493,Hydantocidin-5'-Phosphate,,,,,,solid,,,16.8,1.17,-2.5,[H][C@]1(COP(O)(O)=O)O[C@@]2(N=C(O)N=C2O)[C@]([H])(O)[C@]1([H])O,,,,,0,,298.0202166,2,0,2,0,1,2
2179,04/06/2019 00:00,DB02494,Alpha-Hydroxy-Beta-Phenyl-Propionic Acid,,,,,,solid,,,9.8,4.02,-3.8,[H][C@](O)(CC1=CC=CC=C1)C(O)=O,,,,,0,,166.0629942,1,1,0,0,0,0
2180,04/06/2019 00:00,DB02495,9-(4-hydroxybutyl)-N2-phenylguanine,,,,,,solid,,,0.775,9.43,0.8,OCCCCN1C=NC2=C1N=C(NC1=CC=CC=C1)NC2=O,,,,,0,,299.1382248,3,3,2,2,0,0
2181,04/06/2019 00:00,DB02496,1-Deoxy-D-xylulose 5-phosphate,,,,,,solid,,,27.6,1.48,-3.6,CC(=O)[C@@H](O)[C@H](O)COP(O)(O)=O,,,,,0,,214.0242393,0,0,0,0,0,0
2182,04/06/2019 00:00,DB02497,L-Alpha-Glycerophosphorylserine,,,,,,solid,,,19.6,1.51,9.38,[H][C@@](O)(CO)COP(O)(=O)OC[C@]([H])(N)C(O)=O,,,,,0,,259.045703,0,0,0,0,0,0
2183,04/06/2019 00:00,DB02498,Carba-Nicotinamide-Adenine-Dinucleotide,,,,,,solid,,,2.73,1.86,5.42,[H][C@]1(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)C[C@@]([H])([N+]2=CC=CC(=C2)C(O)=N)[C@]([H])(O)[C@]1([H])O,,,,,1,,662.1371337,5,3,4,3,1,1
2184,04/06/2019 00:00,DB02499,Dinor-N(Omega)-Hydroxy-L-Arginine,,,,,,solid,,,11.7,1.82,10.05,N[C@@H](C\N=C(/N)NO)C(O)=O,,,,,0,,162.0752902,0,0,0,0,0,0
2185,04/06/2019 00:00,DB02500,6-(Dihydroxy-Isobutyl)-Thymine,,,,,,solid,,,8.62,10,-2.6,CC1=C(CC(CO)CO)NC(=O)NC1=O,,,,,0,,214.0953569,1,1,1,1,0,0
2186,04/06/2019 00:00,DB02501,N~2~-Succinylarginine,,,,,,solid,,,0.297,3.32,12.16,[H][C@@](CCCNC(N)=N)(N=C(O)CCC(O)=O)C(O)=O,,,,,0,,274.1277197,0,0,0,0,0,0
2187,04/06/2019 00:00,DB02502,8-Hydroxy-2'-Deoxyguanosine,,,,,,solid,,,14.8,10.09,1.59,NC1=NC2=C(N=C(O)N2[C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)N1,,,,,0,,283.0916685,3,2,3,2,1,1
2188,04/06/2019 00:00,DB02503,4-(Carboxyvin-2-Yl)Phenylboronic Acid,,,,,,solid,,,0.208,3.66,-5.4,OB(O)C1=CC=C(\C=C\C(O)=O)C=C1,,,,,0,,192.0593892,1,1,0,0,0,0
2189,04/06/2019 00:00,DB02504,[3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic Acid,,,,,,solid,,,0.0338,1.81,-2.2,CC1=C(CC(N)=O)C2=C(C=CC(OCCCP(O)(O)=O)=C2)N1CC1=CC=CC=C1,,,,,0,,416.1501085,3,3,1,1,0,0
2190,04/06/2019 00:00,DB02505,N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl),,,,,,solid,,,0.000426,12.62,6.77,CCCCCC1=CC=C(C=C1)C(=O)N(CC1=CC=C(C=C1)C1=CC=C(CC(=O)OC)C=C1)C1CCN(CC2=NC=CN2)CC1,,,,,0,,592.3413413,5,4,2,1,1,1
2191,04/06/2019 00:00,DB02506,"2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid",,,,,,solid,,,0.0042,4.1,10.59,[H][C@@](C)(CC[C@]([H])(N)[C@]([H])(C)C(O)=O)C[C@]([H])(C)[C@]([H])(CC1=CC=CC=C1)OC,,,,,0,,335.2460439,1,1,0,0,0,0
2192,04/06/2019 00:00,DB02507,4-Hydroxy-3-[(1s)-3-Oxo-1-Phenylbutyl]-2h-Chromen-2-One,,,,,,solid,,,0.0472,5.56,-6.9,[H][C@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,,,,,0,,308.104859,3,3,1,1,0,0
2193,04/06/2019 00:00,DB02508,Isopentyl Pyrophosphate,,,,,,solid,,,9.07,1.78,,CC(C)CCO[P@](O)(=O)OP(O)(O)=O,,,,,0,,248.021476,0,0,0,0,0,0
2194,04/06/2019 00:00,DB02509,Farnesol,,,,,,solid,,,0.0587,16.33,-2.2,CC(C)=CCC\C(C)=C/CC\C(C)=C/CO,,,,,0,,222.1983655,0,0,0,0,0,0
2195,04/06/2019 00:00,DB02510,'5'-O-(N-(L-Prolyl)-Sulfamoyl)Adenosine,,,,,,solid,,,4.79,5.46,8.5,[H][C@]1(CCCN1)C(O)=NS(=O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,443.122317,4,2,4,2,2,2
2196,04/06/2019 00:00,DB02511,2-Hydroxy-5-({1-[(2-Naphthyloxy)Methyl]-3-Oxoprop-1-Enyl}Amino)Tyrosine,,,,,,solid,,,0.00714,1.69,8.84,[H][C@](N)(CC1=C(O)C=C(O)C(N\C(COC2=CC=C3C=CC=CC3=C2)=C\C=O)=C1)C(O)=O,,,,,0,,422.1477864,3,3,0,0,0,0
2197,04/06/2019 00:00,DB02512,"1,6-Fructose Diphosphate (Linear Form)",,,,,,solid,,,13.6,1.01,-3.5,O[C@H](COP(O)(O)=O)[C@H](O)[C@H](O)C(=O)COP(O)(O)=O,,,,,0,,339.9960491,0,0,0,0,0,0
2198,04/06/2019 00:00,DB02513,Thymol,,,,0.7 g/50g,Topical,solid,900 mg/L (at 20 Â°C),3.3,0.643,10.59,-5.2,CC(C)C1=CC=C(C)C=C1O,,,,,0,,150.1044651,1,1,0,0,0,0
2199,04/06/2019 00:00,DB02514,(2Z)-3-{[Oxido(oxo)phosphoranyl]oxy}-2-phenylacrylate,,,,,,solid,,,0.21,2.51,,[O-]C(=O)C(=C/OP(=O)=O)\C1=CC=CC=C1,,,,,-1,,224.9958335,1,1,0,0,0,0
2200,04/06/2019 00:00,DB02515,3-Phosphoglycerol,,,,,,solid,,,30.6,1.51,-3,OC[C@@H](O)COP(O)(O)=O,,,,,0,,172.0136746,0,0,0,0,0,0
2201,04/06/2019 00:00,DB02516,"O5'-(4-(3-{2-[2-((R)-3-Hydroxy-4-(Trimethylammonio)-1-Oxo-Butyl)Sulfanyl-Ethylcarbamoyl]-Ethylcarbamoyl}-(R)-3-Hydroxy-2,2-Dimethyl-Propyl)-1-Hydroxy-3-Oxido-1,3-Dioxo-2,4-Dioxa-1,3-Diphosphabut-1-Yl) 3'-Phospho-Adenosine",,,,,,solid,,,6.17,0.82,4.79,[H][C@@](O)(CC(=O)SCCN=C(O)CCN=C(O)[C@]([H])(O)C(C)(C)COP([O-])(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O)C[N+](C)(C)C,,,,,0,,910.2098376,3,2,3,2,1,1
2202,04/06/2019 00:00,DB02517,D-Glutamic Acid,,,,,,solid,8880 mg/L (at 25 Â°C),,80.6,1.88,9.54,N[C@H](CCC(O)=O)C(O)=O,,,,,0,,147.0531578,0,0,0,0,0,0
2203,04/06/2019 00:00,DB02518,N-Acetylalanine,,,,,,solid,,,43.6,3.89,-1.5,C[C@H](NC(C)=O)C(O)=O,,,,,0,,131.0582431,0,0,0,0,0,0
2204,04/06/2019 00:00,DB02519,Indirubin-5-Sulphonate,,,,,,solid,,,0.0639,-2.1,-2.8,OS(=O)(=O)C1=CC=C2NC(=O)\C(=C3/NC4=CC=CC=C4C3=O)C2=C1,,,,,0,,342.0310424,4,2,2,0,0,2
2205,04/06/2019 00:00,DB02520,Ditiocarb,,,,,,solid,,,0.186,2,,CCN(CC)C(S)=S,,,,,0,,149.0332914,0,0,0,0,0,0
2206,04/06/2019 00:00,DB02521,"2,5,7-Trihydroxynaphthoquinone",,,,,,solid,,,2.4,7.12,-4.5,OC1=CC2=C(C(O)=C1)C(=O)C=C(O)C2=O,,,,,0,,206.0215233,2,1,0,0,0,0
2207,04/06/2019 00:00,DB02522,Phosphonopyruvate,,,,,,solid,,,18.8,1.64,-10,OC(=O)C(=O)CP(O)(O)=O,,,,,0,,167.9823745,0,0,0,0,0,0
2208,04/06/2019 00:00,DB02523,"2-aminooxyethyl-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl]-methyl-sulfonium",,,,,,solid,,,1.96,12.44,4.5,[H][C@@]1(C[S+](C)CCON)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,1,,357.1339506,3,2,3,2,1,1
2209,04/06/2019 00:00,DB02524,"2',3'-O-{4-[Hydroxy(oxido)-Î»5-azanylidene]-2,6-dinitro-2,5-cyclohexadiene-1,1-diyl}adenosine 5'-(tetrahydrogen triphosphate)",,,,,,solid,,,2.15,-0.5,4.93,[H]N([H])C1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@]4([H])OC5(O[C@@]34[H])C(=CC(C=C5[N+]([O-])=O)=[N+](O)[O-])[N+]([O-])=O)C2=NC=N1,,,,,0,,717.9822802,5,2,4,2,2,2
2210,04/06/2019 00:00,DB02525,"D-galactohydroximo-1,5-lactam",,,,,,solid,,,67.3,12.42,5.37,[H][C@]1(O)C(NO)=N[C@]([H])(CO)[C@]([H])(O)[C@]1([H])O,,,,,0,,192.0746215,1,0,1,0,0,1
2211,04/06/2019 00:00,DB02526,CRA_10655,,,,,,solid,,,0.00488,9.14,10.6,NC(=[NH2+])C1=CC=C2NC(=NC2=C1)C1=CC=CC(OC2CCCC2)=C1[O-],,,,,0,,336.1586259,4,3,1,1,0,0
2212,04/06/2019 00:00,DB02527,Cyclic adenosine monophosphate,,,,,,solid,,-2.96,3.58,1.83,3.94,NC1=C2N=CN([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)C2=NC=N1,,,,,0,,329.0525197,4,2,4,2,2,2
2213,04/06/2019 00:00,DB02528,Tetrazolyl Histidine,,,,,,solid,,,5.13,8.34,7.44,[H][C@](N)(CC1=CN(C=N1)C1=NNN=N1)C=O,,,,,0,,207.0868579,2,2,2,2,0,0
2214,04/06/2019 00:00,DB02529,"5-N-Acetyl-4-Amino-6-Diethylcarboxamide-4,5-Dihydro-2h-Pyran-2-Carboxylic Acid",,,,,,solid,,,8.1,3.61,9.75,[H][C@]1(N)C[C@@]([H])(O[C@@]([H])(C(=O)N(CC)CC)[C@]1([H])N=C(C)O)C(O)=O,,,,,0,,301.1637708,1,0,1,0,1,1
2215,04/06/2019 00:00,DB02530,gamma-Aminobutyric acid,,,,0.022 mL/100mL,Topical,solid,,,365,4.53,10.22,NCCCC(O)=O,,,,,0,,103.0633285,0,0,0,0,0,0
2216,04/06/2019 00:00,DB02531,Isobutyric acid,,,,,,solid,1.67E+005 mg/L (at 20 Â°C),0.94,197,4.87,,CC(C)C(O)=O,,,,,0,,88.0524295,0,0,0,0,0,0
2217,04/06/2019 00:00,DB02532,"2,4,6-Triaminoquinazoline",,,,,,solid,,,5.51,18.65,7.43,NC1=CC=C2N=C(N)N=C(N)C2=C1,,,,,0,,175.0857953,2,2,1,1,0,0
2218,04/06/2019 00:00,DB02534,2-Allylphenol,,,,,,solid,,,3.06,9.33,-6,OC1=CC=CC=C1CC=C,,,,,0,,134.0731649,1,1,0,0,0,0
2219,04/06/2019 00:00,DB02535,Aminodi(Ethyloxy)Ethylaminocarbonylbenzenesulfonamide,,,,,,solid,,,1.15,10.07,9.33,NCCOCCOCCNC(=O)C1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,331.1201918,1,1,0,0,0,0
2220,04/06/2019 00:00,DB02536,D-glyceraldehyde,,,,,,solid,,,814,12.8,-3,OC[C@@H](O)C=O,,,,,0,,90.03169405,0,0,0,0,0,0
2221,04/06/2019 00:00,DB02537,2-Hydroxy-5-({1-[(4-Methylphenoxy)Methyl]-3-Oxoprop-1-Enyl}Amino)-L-Tyrosine,,,,,,solid,,,0.0342,1.69,8.84,[H]\C(C=O)=C(\COC1=CC=C(C)C=C1)NC1=C(O)C=C(O)C(C[C@]([H])(N)C(O)=O)=C1,,,,,0,,386.1477864,2,2,0,0,0,0
2222,04/06/2019 00:00,DB02538,"N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide",,,,,,solid,,,0.0371,12.02,5.39,CC(=O)NC1=NC(=CC=N1)C1=C(C)N=C2C=CC=CN12,,,,,0,,267.11201,3,3,3,3,0,0
2223,04/06/2019 00:00,DB02540,"(10S)-10-Formyl-5,8,10-Trideazafolic Acid",,,,,,solid,,,0.0597,3.11,6.39,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)[C@]([H])(CC1=CC2=C(NC(=N)N=C2O)C=C1)C(O)=O)C(O)=O,,,,,0,,482.1437637,3,3,1,1,0,0
2224,04/06/2019 00:00,DB02541,4-Hydroxybutan-1-Aminium,,,,,,solid,,,24.1,15.97,9.9,[NH3+]CCCCO,,,,,1,,90.09134042,0,0,0,0,0,0
2225,04/06/2019 00:00,DB02542,(4s)-5-Fluoro-L-Leucine,,,,,,solid,,,62,2.52,9.52,C[C@H](CF)C[C@H](N)C(O)=O,,,,,0,,149.0852068,0,0,0,0,0,0
2226,04/06/2019 00:00,DB02543,Pyrrole-2-Carboxylate,,,,,,solid,,,164,3.62,,OC(=O)C1=CC=CN1,,,,,0,,111.0320284,1,1,1,1,0,0
2227,04/06/2019 00:00,DB02544,"N-(6-{[3-(4-Bromophenyl)-1,2-Benzisothiazol-6-Yl]Oxy}Hexyl)-N-Methylprop-2-En-1-Amine",,,,,,solid,,,0.000602,,9.42,CN(CCCCCCOC1=CC=C2C(SN=C2C2=CC=C(Br)C=C2)=C1)CC=C,,,,,0,,458.1027466,3,3,1,1,0,0
2228,04/06/2019 00:00,DB02545,Fexaramine,,,,,,solid,,,0.000233,,4.82,COC(=O)\C=C\C1=CC(=CC=C1)N(CC1=CC=C(C=C1)C1=CC=C(C=C1)N(C)C)C(=O)C1CCCCC1,,,,,0,,496.272593,4,3,0,0,0,0
2229,02/07/2019 00:00,DB02546,Vorinostat,,0.71,2 hours,100 mg/1,Oral,solid,,,0.0716,8.91,-3.5,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,0.71,0.71,2,2,0,100,264.1473925,1,1,0,0,0,0
2230,04/06/2019 00:00,DB02547,Guanosine-5'-Diphosphate-Rhamnose,,,,,,solid,,,6.96,1.73,-2.7,C[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C2NC(N)=NC3=O)[C@@H](O)[C@@H](O)[C@@H]1O,,,,,0,,589.0822384,4,2,4,2,2,2
2231,04/06/2019 00:00,DB02548,D-glucitol 6-phosphate,,,,,,solid,,,26.6,1.49,-3,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(O)(O)=O,,,,,0,,262.0453687,0,0,0,0,0,0
2232,04/06/2019 00:00,DB02549,3'-O-Acetylthymidine-5'-Diphosphate,,,,,,solid,,,7.6,1.77,-4,[H][C@@]1(C[C@]([H])(OC(C)=O)[C@@]([H])(COP(O)(=O)OP(O)(O)=O)O1)N1C=C(C)C(O)=NC1=O,,,,,0,,444.0334973,2,1,2,1,1,1
2233,04/06/2019 00:00,DB02550,"8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine",,,,,,solid,,,0.02,17.67,0.99,COC1=C(OC)C(OC)=C(Cl)C(CC2=NC3=C(N)N=C(F)N=C3N2CCCC#C)=C1,,,,,0,,433.1316954,3,3,2,2,0,0
2234,04/06/2019 00:00,DB02551,"6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine",,,,,,solid,,,0.00538,12.15,11.23,[H][C@]1(CC)CNCC2=C1C=C(NC(=O)C1=CC=C3C=C(C=CC3=C1)C(N)=N)C=C2,,,,,0,,372.1950114,4,3,1,0,0,1
2235,04/06/2019 00:00,DB02552,Geranyl Diphosphate,,,,,,solid,,,0.902,1.77,,CC(C)=CCC\C(C)=C\CO[P@@](=O)(O)OP(=O)(O)O,,,,,0,,314.0684262,0,0,0,0,0,0
2236,04/06/2019 00:00,DB02553,Glutathionylspermidine Disulfide,,,,,,solid,,,0.0623,3.34,11.05,[H][C@@](N)(CCC(O)=N[C@@]([H])(CSSC[C@]([H])(N=C(O)CC[C@@]([H])(N)C(O)=O)C(O)=NCC(O)=NCCCNCCCCN)C(O)=NCC(O)=NCCCNCCCCN)C(O)=O,,,,,0,,866.4466283,0,0,0,0,0,0
2237,04/06/2019 00:00,DB02554,"Sulfoquinovose-Uridine-C1,5'-Diphosphate",,,,,,solid,,,35.1,-1.3,-3.7,[H][C@]1(COP(O)(=O)OP(O)(=O)O[C@@]2([H])O[C@]([H])(CS(O)(=O)=O)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,630.0169208,3,1,3,1,2,2
2238,04/06/2019 00:00,DB02555,SP4160,,,,,,solid,,,0.00616,12.8,10.6,CC(C)C[C@@H](N=C(N)N)C(=O)NCC(=O)N1CCC(CC1)C1=CC(=NN1C)C1=C(Cl)C(Cl)=C(OCC2=CC=C(NC(C)=O)C=C2)C=C1,,,,,0,,684.2706072,4,3,2,1,1,1
2239,04/06/2019 00:00,DB02556,D-Phenylalanine,,,,,,solid,2.82E+004 mg/L (at 16 Â°C),,4.14,2.47,9.45,N[C@H](CC1=CC=CC=C1)C(O)=O,,,,,0,,165.0789786,1,1,0,0,0,0
2240,04/06/2019 00:00,DB02557,Phosphoramidon,,,,,,solid,,,0.752,2.49,-3.6,[H][C@@](CC(C)C)(NP(O)(=O)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O)C(O)=N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(O)=O,,,,,0,,543.1981809,3,2,2,1,1,1
2241,04/06/2019 00:00,DB02558,N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine,,,,,,solid,,,0.00712,3.85,-3.9,[H][C@@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)[C@]([H])(S)CC1=CC=CC=C1)C(O)=O,,,,,0,,400.1456782,2,2,0,0,0,0
2242,04/06/2019 00:00,DB02559,"6-(Octahydro-1h-Indol-1-Ylmethyl)Decahydroquinazoline-2,4-Diamine",,,,,,solid,,,0.415,,11.12,[H][C@@]12CCN(C[C@@]3([H])CC[C@]4([H])N[C@@]([H])(N)N[C@@]([H])(N)[C@]4([H])C3)[C@@]1([H])CCCC2,,,,,0,,307.2735961,4,0,2,0,2,2
2243,04/06/2019 00:00,DB02560,[(1S)-1-acetamido-2-(4-chlorophenyl)ethyl]-[(2S)-2-amino-3-hydroxy-3-oxo-propoxy]-dihydroxy-boron,,,,,,solid,,,0.258,1.69,8.34,CC(=O)N[C@H](CC1=CC=C(Cl)C=C1)[B-](O)(O)OC[C@H](N)C(O)=O,,,,,-1,,345.103018,1,1,0,0,0,0
2244,04/06/2019 00:00,DB02561,Beta-D-Fructopyranose,,,,,,solid,,,1190,10.29,-3.5,OC[C@]1(O)OC[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,180.0633881,1,0,1,0,1,1
2245,04/06/2019 00:00,DB02562,"Quinonoid 7,8-Tetrahydrobiopterin",,,,,,solid,,,1.45,7.69,1.82,[H][C@@]1(CN=C2NC(N)=NC(=O)C2=N1)[C@@H](O)[C@H](C)O,,,,,0,,239.1018393,2,1,2,1,0,1
2246,04/06/2019 00:00,DB02563,Hexanoyl-CoA,,,,,,solid,,,3.67,0.83,4.95,CCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N,,,,,0,,865.1883739,3,2,3,2,1,1
2247,04/06/2019 00:00,DB02565,4-Dimethylamino-N-(6-Hydroxycarbamoyethyl)Benzamide-N-Hydroxy-7-(4-Dimethyla Minobenzoyl)Aminoheptanamide,,,,,,solid,,,0.183,6.89,3.49,CN(C)C1=CC=C(C=C1)C(=O)NCCCCCCC(O)=NO,,,,,0,,307.1895917,1,1,0,0,0,0
2248,04/06/2019 00:00,DB02566,8-Hydroxy-4-(1-Hydroxyethyl)Quinoline-2-Carboxylic Acid,,,,,,solid,,,2.99,0.99,4.63,[H][C@@](C)(O)C1=CC(=NC2=C1C=CC[C@]2([H])O)C(O)=O,,,,,0,,235.0844579,2,1,1,1,0,0
2249,04/06/2019 00:00,DB02567,PD173955,,,,,,solid,,,0.000616,12.99,1.51,CSC1=CC=CC(NC2=NC=C3C=C(C(=O)N(C)C3=N2)C2=C(Cl)C=CC=C2Cl)=C1,,,,,0,,442.0421875,4,4,2,2,0,0
2250,04/06/2019 00:00,DB02568,Peldesine,,,,,,solid,,,0.121,10.49,5.39,NC1=NC(=O)C2=C(N1)C(CC1=CN=CC=C1)=CN2,,,,,0,,241.09636,3,3,3,3,0,0
2251,04/06/2019 00:00,DB02569,"2',3'-Dehydro-2',3'-Deoxy-Thymidine 5'-Diphosphate",,,,,,solid,,,4.53,1.77,-4.2,CC1=CN([C@@H]2O[C@H](CO[P@@](O)(=O)OP(O)(O)=O)C=C2)C(=O)NC1=O,,,,,0,,384.0123679,2,1,2,1,0,1
2252,04/06/2019 00:00,DB02570,PD150606,,,,,,solid,,,0.0448,3.32,,[H][C@](S)(CC1=CC=C(I)C=C1)C(O)=O,,,,,0,,307.9367985,1,1,0,0,0,0
2253,04/06/2019 00:00,DB02571,2-Amino-6-Oxo-Hexanoic Acid,,,,,,solid,,,49.4,2.25,9.33,N[C@@H](CCCC=O)C(O)=O,,,,,0,,145.0738932,0,0,0,0,0,0
2254,04/06/2019 00:00,DB02572,BV4,,,,,,solid,,,0.0723,3.58,9.05,[H]C(N)(COC(O)=NCCCOCCOCCOCCCNC1=C(NCCCN2CCN(CCCN=C(O)C3=CC(=CC(OC4([H])OC([H])(CO)C([H])(O)C([H])(O)C4([H])O)=C3)N(=O)=O)CC2)C(=O)C1=O)COC(O)=NCCCOCCOCCOCCCNC1=C(NCCCN2CCN(CCCN=C(O)C3=CC(=CC(O[C@@]4([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]4([H])O)=C3)N(=O)=O)CC2)C(=O)C1=O,,,,,0,,1793.845857,8,4,4,0,4,4
2255,04/06/2019 00:00,DB02573,"2'-Deoxycytidine-2'-Deoxyadenosine-3',5'-Monophosphate",,,,,,solid,,,2.26,1.64,5,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])CO)N1C=CC(=N)N=C1O)N1C=NC2=C(N)N=CN=C12,,,,,0,,540.148211,5,3,5,3,2,2
2256,04/06/2019 00:00,DB02574,BV2,,,,,,solid,,,0.0734,1.83,9.12,[H]C(N)(COC(O)=NCCCN1CCN(CCCN=C(O)C2=CC(=CC(OC3([H])OC([H])(CO)C([H])(O)C([H])(O)C3([H])O)=C2)N(=O)=O)CC1)COC(O)=NCCCN1CCN(CCCN=C(O)C2=CC(=CC(O[C@@]3([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]3([H])O)=C2)N(=O)=O)CC1,,,,,0,,1197.540113,6,2,4,0,4,4
2257,04/06/2019 00:00,DB02576,F-Loop of Vitamin B12,,,,,,solid,1E+006 mg/L,-0.96,99.9,15.3,9.6,C[C@H](O)C[NH3+],,,,,1,,76.07569036,0,0,0,0,0,0
2258,04/06/2019 00:00,DB02577,Mesoheme,,,,,,solid,,,0.00841,3.64,,CC1=C(CCC(O)=O)C2=CC3=C(CCC(O)=O)C(C)=C4C=C5N6C(=CC7=C(C=C)C(C)=C8C=C1N2[Fe++]6(N34)N78)C(C)=C5C=C,,,,,2,,616.1761958,8,4,8,4,0,4
2259,04/06/2019 00:00,DB02578,Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanyl-D-Alanine,,,,,,solid,,,0.169,3.52,9.34,[H][C@](C)(N=C(O)[C@@]([H])(C)N=C(O)CCCC[C@]([H])(N=C(O)CN)C(O)=O)C(O)=O,,,,,0,,374.1801492,0,0,0,0,0,0
2260,04/06/2019 00:00,DB02579,Acrylic Acid,,,,,,solid,1E+006 mg/L,0.35,123,4.72,,OC(=O)C=C,,,,,0,,72.02112937,0,0,0,0,0,0
2261,04/06/2019 00:00,DB02580,Pentaglyme,,,,,,solid,,,2.13,,-3.4,COCCOCCOCCOCCOCCOC,,,,,0,,266.1729386,0,0,0,0,0,0
2262,04/06/2019 00:00,DB02581,"5-[2,3-Dichloro-4-(5-{1-[2-(2-Guanidino-4-Methyl-Pentanoylamino)-Acetyl]-Piperidin-4-Yl}-1-Methyl-1h-Pyrazol-3-Yl)-Phenoxymethyl]-Furan-2-Carboxylic Acid",,,,,,solid,,,0.0718,3.13,11.36,CC(C)C[C@@H](NC(N)=N)C(=O)NCC(=O)N1CCC(CC1)C1=CC(=NN1C)C1=CC=C(OCC2=CC=C(O2)C(O)=O)C(Cl)=C1Cl,,,,,0,,661.2182373,4,3,3,2,1,1
2263,04/06/2019 00:00,DB02582,D-(L-a-Aminoadipoyl)-L-Cysteinyl-D-Isodehydrovaline,,,,,,solid,,,0.075,2.06,9.42,[H]C(N)(CCCC(O)=NC([H])(CS)C(O)=N[C@]([H])(C(C)=C)C(O)=O)C(O)=O,,,,,0,,361.1307565,0,0,0,0,0,0
2264,04/06/2019 00:00,DB02583,"N6-(2,5-Dimethoxy-Benzyl)-N6-Methyl-Pyrido[2,3-D]Pyrimidine-2,4,6-Triamine",,,,,,solid,,,0.353,16.08,4.3,COC1=CC(CN(C)C2=CC3=C(N=C2)N=C(N)N=C3N)=C(OC)C=C1,,,,,0,,340.1647739,3,3,2,2,0,0
2265,04/06/2019 00:00,DB02585,4-(Hydroxymethyl)Benzamidine,,,,,,solid,,,1.18,14.97,11.47,NC(=N)C1=CC=C(CO)C=C1,,,,,0,,150.0793129,1,1,0,0,0,0
2266,04/06/2019 00:00,DB02586,"4,7-Dimethyl-[1,10]Phenanthroline",,,,,,solid,22.4 mg/L (at 25 Â°C),,0.0248,,5.59,CC1=CC=NC2=C3N=CC=C(C)C3=CC=C12,,,,,0,,208.1000484,3,3,2,2,0,0
2267,04/06/2019 00:00,DB02587,Colforsin,,,,,,solid,,,1.1,11.57,-3,[H][C@]1(O)CCC(C)(C)[C@]2([H])[C@]([H])(O)[C@]([H])(OC(C)=O)[C@@]3(C)O[C@](C)(CC(=O)[C@]3(O)[C@@]12C)C=C,,,,,0,,410.2304534,3,0,1,0,1,1
2268,04/06/2019 00:00,DB02588,Moxalactam Derivative,,,,,,solid,,,0.141,3,-3.8,[H][C@@](C(O)=O)(C(O)=N[C@](OC)(C=O)[C@@]1([H])OCC(=C)C(=N1)C(O)=O)C1=CC=C(O)C=C1,,,,,0,,406.1012302,2,1,1,0,0,1
2269,04/06/2019 00:00,DB02589,Se-Ethyl-Isoselenourea,,,,,,solid,,,6.6,,9.71,CC[Se]C(N)=N,,,,,0,,151.9852696,0,0,0,0,0,0
2270,04/06/2019 00:00,DB02590,Abequose,,,,,,solid,,,848,11.43,-3.2,[H][C@@]1(O)C[C@@]([H])(O)[C@@]([H])(O)O[C@]1([H])C,,,,,0,,148.0735589,1,0,1,0,1,1
2271,04/06/2019 00:00,DB02591,"5,6-Dimethylbenzimidazole",,,,,,solid,,2.35,2.08,12.73,6.43,CC1=CC2=C(C=C1C)N=CN2,,,,,0,,146.0843983,2,2,1,1,0,0
2272,04/06/2019 00:00,DB02592,Carbaphosphonate,,,,,,solid,,,42.1,1.8,-3.2,[H][C@@]1(O)C[C@@](O)(C[C@]([H])(CP(O)(O)=O)[C@@]1([H])O)C(O)=O,,,,,0,,270.0504541,1,0,0,0,0,0
2273,04/06/2019 00:00,DB02593,"7,8-Dihydroxy-1-Methoxy-3-Methyl-10-Oxo-4,10-Dihydro-1h,3h-Pyrano[4,3-B]Chromene-9-Carboxylic Acid",,,,,,solid,,,1.27,2.25,-4,[H][C@]1(C)CC2=C(C(=O)C3=C(O2)C=C(O)C(O)=C3C(O)=O)[C@]([H])(OC)O1,,,,,0,,322.0688674,3,2,2,1,0,1
2274,04/06/2019 00:00,DB02594,2'-Deoxycytidine,,,,,,solid,,-1.77,15.9,13.89,-0.0012,NC1=NC(=O)N(C=C1)[C@H]1C[C@H](O)[C@@H](CO)O1,,,,,0,,227.0906059,2,1,2,1,1,1
2275,04/06/2019 00:00,DB02595,Bulgecin A,,,,,,solid,,,7.72,-2,7.59,[H][C@]1(C[C@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@@]([H])(OS(O)(=O)=O)[C@]([H])(O)[C@@]2([H])N=C(C)O)[C@@]([H])(CO)N1)C(O)=[NH+]CCS(O)(=O)=O,,,,,1,,552.1163711,2,0,2,0,2,2
2276,04/06/2019 00:00,DB02596,"Alpha,Beta-Methyleneadenosine-5'-Triphosphate",,,,,,solid,,,4.29,1.03,4.99,[H][C@]1(COP(O)(=O)CP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,505.0164809,3,2,3,2,1,1
2277,04/06/2019 00:00,DB02597,"[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala",,,,,,solid,,,0.0104,3.83,-3.4,[H][C@@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)[C@@]([H])(S)CCCCC)C(O)=O,,,,,0,,380.1769784,1,1,0,0,0,0
2278,04/06/2019 00:00,DB02598,"N-Alpha-Acetyl-3,5-Diiodotyrosylglycine",,,,,,solid,,,0.153,2.54,-1.4,CC(=O)N[C@@H](CC1=CC(I)=C(O)C(I)=C1)C(=O)NCC(O)=O,,,,,0,,531.8992175,1,1,0,0,0,0
2279,04/06/2019 00:00,DB02599,"2,6-Diamino-8-Propylsulfanylmethyl-3h-Quinazoline-4-One",,,,,,solid,,,0.435,11.4,5.87,CCCSCC1=CC(N)=CC2=C1N=C(N)NC2=O,,,,,0,,264.1044821,2,2,1,1,0,0
2280,04/06/2019 00:00,DB02600,Oseltamivir acid,,,,,,solid,,,3.15,4.19,9.33,CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O,,,,,0,,284.1736072,1,0,0,0,0,0
2281,04/06/2019 00:00,DB02601,4-Hydroxyphenylglycine,,,,,,solid,,,7.44,1.74,8.57,NC(C(O)=O)C1=CC=C(O)C=C1,,,,,0,,167.0582431,1,1,0,0,0,0
2282,04/06/2019 00:00,DB02602,AL7182,,,,,,solid,,,0.206,8.18,-4.8,COC1=CC(=CC=C1)N1CCC2=C(SC(=C2)S(N)(=O)=O)S1(=O)=O,,,,,0,,374.0064845,3,2,2,1,0,1
2283,04/06/2019 00:00,DB02603,1-Amino-6-Cyclohex-3-Enylmethyloxypurine,,,,,,solid,,,0.288,9.23,5.45,NC1=NC(OCC2CCCCC2)=C2N=CNC2=C1,,,,,0,,246.1480612,3,2,2,2,0,0
2284,04/06/2019 00:00,DB02604,2-Deoxy-Glucose-6-Phosphate,,,,,,solid,,,33.4,1.22,-3.3,O[C@H]1C[C@@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1,,,,,0,,244.034804,1,0,1,0,1,1
2285,04/06/2019 00:00,DB02606,2-Butanol,,,,,,solid,1.81E+005 mg/L (at 25 Â°C),0.61,195,17.69,-1.6,CC[C@@H](C)O,,,,,0,,74.07316494,0,0,0,0,0,0
2286,04/06/2019 00:00,DB02607,Adenosine Phosphonoacetic Acid,,,,,,solid,,,2.97,1.64,4.99,[H][C@]1(COC(=O)CP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,389.0736491,3,2,3,2,1,1
2287,04/06/2019 00:00,DB02608,N-Acetyl-P-Nitrophenylserinol,,,,,,solid,,,0.919,6.92,1.8,[H][C@@](O)(C1=CC=C(C=C1)N(=O)=O)[C@@]([H])(CO)N=C(C)O,,,,,0,,254.0902715,1,1,0,0,0,0
2288,04/06/2019 00:00,DB02609,4-Hydroxy-L-Threonine-5-Monophosphate,,,,,,solid,,,22.7,1.31,8.93,N[C@@H]([C@H](O)COP(O)(O)=O)C(O)=O,,,,,0,,215.0194883,0,0,0,0,0,0
2289,04/06/2019 00:00,DB02610,"N-(2,3,4,5,6-Pentaflouro-Benzyl)-4-Sulfamoyl-Benzamide",,,,,,solid,,,0.0142,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=C(F)C(F)=C(F)C(F)=C1F,,,,,0,,380.0254042,2,2,0,0,0,0
2290,04/06/2019 00:00,DB02611,Balanol Analog 1,,,,,,solid,,,0.104,8.17,9.67,[H][C@]1(CNCCC[C@@]1([H])OC(=O)C1=CC=C(O)C=C1)NC(=O)C1=CC=C(O)C=C1,,,,,0,,370.1528718,3,2,1,0,1,1
2291,04/06/2019 00:00,DB02613,"Decylamine-N,N-Dimethyl-N-Oxide",,,,,,solid,,,0.000663,,4.17,CCCCCCCCCC[N+](C)(C)[O-],,,,,0,,201.2092645,0,0,0,0,0,0
2292,04/06/2019 00:00,DB02614,1(R)-1-Acetamido-2-(3-Carboxyphenyl)Ethyl Boronic Acid,,,,,,solid,,,0.491,4.04,-0.97,[H][C@@](CC1=CC=CC(=C1)C(O)=O)(NC(C)=O)B(O)O,,,,,0,,251.0965029,1,1,0,0,0,0
2293,04/06/2019 00:00,DB02615,Compound 19,,,,,,solid,,,0.00178,9.55,9,[H][C@@](C)(COC1=CC=C(C=C1)[C@]1([H])OC2=C(S[C@]1([H])C1=CC=C(O)C=C1)C=C(O)C=C2)N1CCCC1,,,,,0,,463.1817294,5,3,2,0,1,2
2294,04/06/2019 00:00,DB02616,FR117016,,,,,,solid,,,0.0578,12.4,7.93,NC(N)=NC1=NC(=CS1)C1=CC=C(CNC2=NC3=C(N2)C=CC=C3)S1,,,,,0,,369.0830355,4,4,3,3,0,0
2295,04/06/2019 00:00,DB02617,"1-(N-Imidazolyl)-2-Hydroxy-2-(2,3-Dichlorophenyl)Octane",,,,,,solid,,,0.00472,13.42,6.77,CCCCCC[C@](O)(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl,,,,,0,,340.1109187,2,2,1,1,0,0
2296,04/06/2019 00:00,DB02618,Ethyl Dimethyl Ammonio Propane Sulfonate,,,,,,solid,,,0.254,-0.87,,CC[N+](C)(C)CCCS([O-])(=O)=O,,,,,0,,195.0929144,0,0,0,0,0,0
2297,04/06/2019 00:00,DB02619,Bromo-Dodecanol,,,,,,solid,,,0.000623,16.84,-2,OCCCCCCCCCCCCBr,,,,,0,,264.1088775,0,0,0,0,0,0
2298,04/06/2019 00:00,DB02620,Sp7343-Sp7964,,,,,,solid,,,0.0447,3.01,4.55,[H][C@@]1(CC[C@]([H])(CC1)C(O)=NCCSSCCN=C(C)O)N=C(O)C1=C(N=CC=N1)C(O)=O,,,,,0,,469.145361,2,1,1,1,0,0
2299,04/06/2019 00:00,DB02621,Latrunculin A,,,,,,solid,,,0.0195,7.37,1.17,[H]\C1=C(\[H])/C(/[H])=C([H])\[C@@]([H])(C)CC[C@]2([H])C[C@]([H])(C[C@@](O)(O2)[C@]2([H])CSC(O)=N2)OC(=O)\C([H])=C(C)/CC1,,,,,0,,421.1922941,3,0,3,0,1,3
2300,04/06/2019 00:00,DB02622,2-(Oxalyl-Amino)-Benzoic Acid,,,,,,solid,,,0.922,2.11,-6.9,OC(=O)C(=O)NC1=C(C=CC=C1)C(O)=O,,,,,0,,209.0324223,1,1,0,0,0,0
2301,04/06/2019 00:00,DB02623,Aminophosphonic Acid-Guanylate Ester,,,,,,solid,,,4.55,0.64,5,[H][C@]1(COP(O)(=O)OP(N)(O)=O)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,442.040314,3,2,3,2,1,1
2302,04/06/2019 00:00,DB02624,Homoserine Lactone,,,,,,solid,,,695,,7.33,N[C@@H]1CCOC1=O,,,,,0,,101.0476785,1,0,1,0,1,1
2303,04/06/2019 00:00,DB02625,(2r)-2-{[Formyl(Hydroxy)Amino]Methyl}Hexanoic Acid,,,,,,solid,,,16.4,4.4,-5.7,[H][C@@](CCCC)(CN(O)C=O)C(O)=O,,,,,0,,189.100108,0,0,0,0,0,0
2304,04/06/2019 00:00,DB02627,"4,4'-Biphenyldiboronic Acid",,,,,,solid,,,0.0418,8.44,-5.4,OB(O)C1=CC=C(C=C1)C1=CC=C(C=C1)B(O)O,,,,,0,,242.0921697,2,2,0,0,0,0
2305,04/06/2019 00:00,DB02628,"1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide",,,,,,solid,,,0.0362,12.54,8.6,[H][C@@](C)(NC)C(=O)N[C@]([H])(C(=O)N1CCC[C@@]1([H])C(=O)N[C@]1([H])CCCC2=C1C=CC=C2)C(C)(C)C,,,,,0,,442.2943911,3,1,1,0,1,1
2306,04/06/2019 00:00,DB02629,Inhibitor Bea403,,,,,,solid,,,0.0127,4.07,1.19,[H][C@@](O)([C@@]([H])(O)[C@@]([H])(OCC1=CC=CC=C1F)C(O)=N[C@@]1([H])C2=CC=CC=C2C[C@@]1([H])O)[C@@]([H])(OCC1=CC=CC=C1F)C(O)=N[C@@]1([H])C2=CC=CC=C2C[C@@]1([H])O,,,,,0,,688.2596226,6,4,0,0,0,0
2307,04/06/2019 00:00,DB02630,L-xylitol 5-phosphate,,,,,,solid,,,28.5,1.49,-3,OC[C@@H](O)[C@H](O)[C@@H](O)COP(O)(O)=O,,,,,0,,232.034804,0,0,0,0,0,0
2308,04/06/2019 00:00,DB02632,4-nitrophenyl-beta-D-galactoside,,,,,,solid,,,14.4,12.2,-3,[H][C@]1(CO)O[C@@]([H])(OC2=CC=C(C=C2)N(=O)=O)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,301.0797664,2,1,1,0,1,1
2309,04/06/2019 00:00,DB02633,Cibacron Blue,,,,,,solid,,,0.0168,-5.6,0.78,NC1=C(C=C(NC2=CC=C(NC3=NC(Cl)=NC(NC4=CC=CC=C4S(O)(=O)=O)=N3)C(=C2)S(O)(=O)=O)C2=C1C(=O)C1=CC=CC=C1C2=O)S(O)(=O)=O,,,,,0,,773.0071451,6,5,1,1,0,0
2310,04/06/2019 00:00,DB02635,N-[O-Phosphono-Pyridoxyl]-Isoleucine,,,,,,solid,,,0.691,1.19,10.25,[H][C@](C)(CC)[C@@]([H])(NCC1=C(COP(O)(O)=O)C=NC(C)=C1O)C(O)=O,,,,,0,,362.1242877,1,1,1,1,0,0
2311,04/06/2019 00:00,DB02636,"9-Hydroxy-8-Methoxy-6-Nitro-Phenanthrol[3,4-D][1,3]Dioxole-5-Carboxylic Acid",,,,,,solid,,,0.0747,3.32,-4.5,COC1=C(O)C=CC2=C1C=C(C1=C2C2=C(OCO2)C=C1C(O)=O)[N+]([O-])=O,,,,,0,,357.0484663,4,3,1,0,0,1
2312,04/06/2019 00:00,DB02637,Oxaloacetate Ion,,,,,,solid,,,54.2,2.41,-9.9,OC(=O)C(=O)CC([O-])=O,,,,,-1,,130.9985968,0,0,0,0,0,0
2313,04/06/2019 00:00,DB02638,Terlipressin,,0.3,,,,solid,,,0.167,9.43,10.26,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,0.3,0.3,,,0,,1226.496098,4,2,2,0,2,2
2314,04/06/2019 00:00,DB02639,4-methylumbelliferyl Î±-D-glucoside,,,,,,solid,,,5.11,12.2,-3,[H][C@]1(CO)O[C@]([H])(OC2=CC3=C(C=C2)C(C)=CC(=O)O3)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,338.1001675,3,2,2,1,1,1
2315,04/06/2019 00:00,DB02640,Fumagillin,,,,,,solid,,,0.0033,4.88,-3.7,CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O,,,,,0,,458.2304534,3,0,2,0,2,2
2316,04/06/2019 00:00,DB02641,Heptanamide,,,,,,solid,,,3.79,17.12,-0.58,CCCCCCC(N)=O,,,,,0,,129.1153641,0,0,0,0,0,0
2317,04/06/2019 00:00,DB02642,[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate,,,,,,solid,,,2.87,1.55,,OP(O)(=O)CNC(=O)OCC1=CC=CC=C1,,,,,0,,245.0453091,1,1,0,0,0,0
2318,04/06/2019 00:00,DB02643,"N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate",,,,,,solid,,,0.000189,-0.8,,CCCCCCCCCCCC[N+](C)(C)CCCS(O)(=O)=O,,,,,1,,336.2566915,0,0,0,0,0,0
2319,04/06/2019 00:00,DB02644,N-Omega-Propyl-L-Arginine,,,,,,solid,,,4.99,2.29,12.73,CCCNC(=[NH2+])NCCC[C@H](N)C(O)=O,,,,,1,,217.1659023,0,0,0,0,0,0
2320,04/06/2019 00:00,DB02645,"3,4-Epoxybutyl-Alpha-D-Glucopyranoside",,,,,,solid,,,421,12.21,-3,[H][C@]1(CCO[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)CO1,,,,,0,,250.1052529,2,0,2,0,2,2
2321,04/06/2019 00:00,DB02646,Nitrosoethane,,,,,,solid,,,43.3,17.84,-1.6,CCN=O,,,,,0,,59.03711378,0,0,0,0,0,0
2322,04/06/2019 00:00,DB02647,N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide,,,,,,solid,,,0.166,11.65,2.55,O=C(NC1=CC(=NN1)C1CC1)C1=CC=CC=C1,,,,,0,,227.105862,3,2,1,1,0,0
2323,04/06/2019 00:00,DB02648,(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium,,,,,,solid,,,6.58,4.2,-3.6,C[N+](C)(C)C[C@H](O)CC(O)=O,,,,,1,,162.1124698,0,0,0,0,0,0
2324,04/06/2019 00:00,DB02649,3-Amino-3-Oxopropanoic Acid,,,,,,solid,,,229,3.66,-5.9,NC(=O)CC(O)=O,,,,,0,,103.026943,0,0,0,0,0,0
2325,04/06/2019 00:00,DB02650,Trichloroacetaldehyde,,,,,,solid,,,3.15,,-8,[H]C(=O)C(Cl)(Cl)Cl,,,,,0,,145.9092977,0,0,0,0,0,0
2326,04/06/2019 00:00,DB02651,"{[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)",,,,,,solid,,,0.0202,-0.0069,0.47,OP(O)(=O)C(F)(F)C1=CC=C(CC(CC2=CC=C(C=C2)C(F)(F)P(O)(O)=O)(N2N=NC3=C2C=CC=C3)C2=CC=C(F)C(F)=C2)C=C1,,,,,0,,685.096628,5,5,1,1,0,0
2327,04/06/2019 00:00,DB02652,L-[(N-Hydroxyamino)Carbonyl]Phenylalanine,,,,,,solid,,,1.32,3.8,-4.9,[H]N(O)C(=O)N([H])[C@@H](CC1=CC=CC=C1)C(O)=O,,,,,0,,224.0797069,1,1,0,0,0,0
2328,04/06/2019 00:00,DB02654,6-Hydroxy-Flavin-Adenine Dinucleotide,,,,,,solid,,,4.66,1.86,4.99,CC1=C(C)C(O)=C2N=C3C(=O)NC(=O)N=C3N(C[C@H](O)[C@H](O)[C@H](O)COP(O)(=O)OP(O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)N3C=NC4=C(N)N=CN=C34)C2=C1,,,,,0,,801.1520492,6,3,5,2,1,3
2329,04/06/2019 00:00,DB02655,D-Aspartic Acid,,,,,,solid,,,142,1.7,9.61,N[C@H](CC(O)=O)C(O)=O,,,,,0,,133.0375077,0,0,0,0,0,0
2330,04/06/2019 00:00,DB02656,LY-294002,,,,,,solid,,,0.127,15.95,3.47,O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1,,,,,0,,307.1208434,4,3,2,1,1,1
2331,04/06/2019 00:00,DB02657,Glucosamine 6-Phosphate,,,,,,solid,,,34.8,1.22,8.23,N[C@H]1[C@@H](O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O,,,,,0,,259.045703,1,0,1,0,1,1
2332,04/06/2019 00:00,DB02658,"2,4-Dinitrophenyl 2-Deoxy-2-Fluoro-Beta-D-Allopyranoside",,,,,,solid,,,1.48,12.53,-3,[H][C@]1(CO)O[C@@]([H])(OC2=C(C=C(C=C2)[N+]([O-])=O)[N+]([O-])=O)[C@]([H])(F)[C@@]([H])(O)[C@]1([H])O,,,,,0,,348.0605082,2,1,1,0,1,1
2333,04/06/2019 00:00,DB02659,Cholic Acid,,,,250 mg/1,Oral,solid,175 mg/L (at 20 Â°C),2.02,0.0738,4.48,-0.16,[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C,,,,,0,250,408.2875744,4,0,0,0,0,0
2334,04/06/2019 00:00,DB02660,Filaminast,,,,,,solid,,,0.0192,13.29,1.5,COC1=CC=C(C=C1OC1CCCC1)C(\C)=N\OC(N)=O,,,,,0,,292.1423071,2,1,0,0,0,0
2335,04/06/2019 00:00,DB02661,"Adenosine-5'-Diphosphate-2',3'-Vanadate",,,,,,solid,,,2.91,1.77,4.99,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H](CO[P@](O)(=O)OP(O)(O)=O)[C@H]2O[V](=O)(=O)O[C@H]12,,,,,0,,506.9507526,4,2,4,2,2,2
2336,04/06/2019 00:00,DB02662,Novo Nordisk a/S Compound,,,,,,solid,,,0.166,1.47,-6.9,OC(=O)C(=O)NC1=C(C=C(I)C=C1)C(O)=O,,,,,0,,334.9290703,1,1,0,0,0,0
2337,04/06/2019 00:00,DB02663,2-Amino-4-(Hydroxymethyl-Phosphinyl)Butanoic Acid,,,,,,solid,,,46.3,1.86,9.53,C[P@@](O)(=O)CC[C@@H](N)C(O)=O,,,,,0,,181.0503945,0,0,0,0,0,0
2338,04/06/2019 00:00,DB02664,1-Butane Boronic Acid,,,,,,solid,,,126,,,CCCCB(O)O,,,,,0,,102.08521,0,0,0,0,0,0
2339,04/06/2019 00:00,DB02665,"(1R,2S)-2-Phenylcyclopropanaminium",,,,,,solid,,,0.0104,,9.62,[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1,,,,,1,,134.0964258,2,1,0,0,0,0
2340,04/06/2019 00:00,DB02666,(C8-R)-Hydantocidin 5'-Phosphate,,,,,,solid,,,11.1,1.22,-2.8,[H][C@](CCCN1C(O)=N[C@@]2(O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@@]2([H])O)C1=O)(N(O)CO)C(O)=O,,,,,0,,459.0890244,2,0,2,0,1,2
2341,04/06/2019 00:00,DB02667,Factor IIIm,,,,,,solid,,,0.00172,-0.45,5.82,COC1=CC=C2N(C=NC2=C1)[C@H]1O[C@H](CO)[C@@H](O[P@]([OH-])(=O)O[C@H](C)CNC(=O)CC[C@]2(C)[C@@H](CC(N)=O)C3=[N+]4C2=C(C)C2=[N+]5C(=CC6=[N+]7C(=C(C)C8=[N+]([C@]3(C)[C@@](C)(CC(N)=O)[C@@H]8CCC(N)=O)[Co]457)[C@@](C)(CC(N)=O)[C@@H]6CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O)[C@H]1O,,,,,,,,,,,,,
2342,04/06/2019 00:00,DB02668,"Je-2147, Ag1776, Kni-764",,,,,,solid,,,0.00278,5.91,3.53,[H][C@@](O)(C(=O)N1CSC(C)(C)[C@@]1([H])C(O)=NCC1=CC=CC=C1C)[C@]([H])(CC1=CC=CC=C1)N=C(O)C1=C(C)C(O)=CC=C1,,,,,0,,575.2453923,4,3,1,0,1,1
2343,04/06/2019 00:00,DB02669,RB106,,,,,,solid,,,0.0105,3.83,-4,[H][C@](S)(CC1=CC=CC=C1)C(=O)NCC(=O)N1[C@@]([H])(CC[C@]1([H])C1=CC=CC=C1)C(O)=O,,,,,0,,412.1456782,3,2,1,0,1,1
2344,04/06/2019 00:00,DB02670,4-Deoxy-Alpha-D-Glucose,,,,,,solid,,,1020,11.33,-2.9,[H][C@]1(O)C[C@@]([H])(CO)O[C@]([H])(O)[C@]1([H])O,,,,,0,,164.0684735,1,0,1,0,1,1
2345,04/06/2019 00:00,DB02671,1-Methylimidazole,,,,,,solid,1E+006 mg/L (at 20 Â°C),-0.06,2.26,,6.82,CN1C=C[NH+]=C1,,,,,1,,83.06037464,1,1,1,1,0,0
2346,04/06/2019 00:00,DB02673,"(4ar,6s,8ar)-11-[8-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Octyl]-6-Hydroxy-3-Methoxy-5,6,9,10-Tetrahydro-4ah-[1]Benzofuro[3a,3,2-Ef][2]Benzazepin-11-Ium",,,,,,solid,,,0.00831,14.79,7.85,[H][C@]12C[C@@]([H])(O)C=C[C@]11CCN(CCCCCCCCN3C(=O)C4=CC=CC=C4C3=O)C=C3C=CC(=[O+]C)C(O2)=C13,,,,,1,,529.2696987,6,1,3,0,0,3
2347,04/06/2019 00:00,DB02674,"4-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Butyricacid",,,,,,solid,,,2.22,4.33,-1.9,[H][C@]12CS[C@@]([H])(CCCC(O)=O)[C@@]1([H])NC(=O)N2,,,,,0,,230.0725133,2,0,2,0,2,2
2348,04/06/2019 00:00,DB02675,(4-Hydroxymaltosephenyl)Glycine,,,,,,solid,,,31.7,1.38,8.83,[H][C@@](N)(C(O)=O)C1=CC=C(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]2([H])O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]2([H])O)C=C1,,,,,0,,491.16389,3,1,2,0,2,2
2349,04/06/2019 00:00,DB02676,"2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol",,,,,,solid,,,14.2,13.86,9.28,OCC(CO)(CO)NCCCNC(CO)(CO)CO,,,,,0,,282.1790866,0,0,0,0,0,0
2350,04/06/2019 00:00,DB02677,D-naphthyl-1-acetamido boronic acid alanine,,,,,,solid,,,0.0374,1.89,8.34,CC(=O)N[C@H](CC1=CC=CC2=C1C=CC=C2)[B-](O)(O)OC[C@H](N)C(O)=O,,,,,-1,,361.1576404,2,2,0,0,0,0
2351,04/06/2019 00:00,DB02678,2-Deoxy-2-Aminogalactose,,,,,,solid,,,551,11.73,8.23,N[C@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1O,,,,,0,,179.0793725,1,0,1,0,1,1
2352,04/06/2019 00:00,DB02679,Cyanamide,,,,,,solid,5E+005 mg/L (at 25 Â°C),-0.82,27.4,10.87,,NC#N,,,,,0,,42.02179806,0,0,0,0,0,0
2353,04/06/2019 00:00,DB02680,Dinitrophenylene,,,,,,solid,,,0.147,,,[O-][N+](=O)C1=CC(=CC=C1)[N+]([O-])=O,,,,,0,,168.0171066,1,1,0,0,0,0
2354,04/06/2019 00:00,DB02683,Inhibitor Bea428,,,,,,solid,,,0.00922,3.33,5.86,[H][C@@](O)([C@@]([H])(O)[C@@]([H])(OCC1=CC=C(C=C1)C1=CN=CC=C1)C(O)=N[C@@]([H])(C(C)C)C(O)=NC)[C@@]([H])(OCC1=CC=C(C=C1)C1=CN=CC=C1)C(O)=N[C@@]([H])(C(C)C)C(O)=NC,,,,,0,,768.3846626,4,4,2,2,0,0
2355,04/06/2019 00:00,DB02684,5'-O-(N-(L-Cysteinyl)-Sulfamoyl)Adenosine,,,,,,solid,,,2.39,5.45,8.6,[H][C@](N)(CS)C(O)=NS(=O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,449.0787379,3,2,3,2,1,1
2356,04/06/2019 00:00,DB02685,3-Methylphenylalanine,,,,,,solid,,,1.99,2.58,9.45,CC1=CC=CC(C[C@H](N)C(O)=O)=C1,,,,,0,,179.0946287,1,1,0,0,0,0
2357,04/06/2019 00:00,DB02686,Undecyl-Beta-D-Maltopyranoside,,,,,,solid,,,3.84,11.94,-3,[H][C@]1(O)[C@]([H])(O)[C@@]([H])(CO)O[C@]([H])(O[C@@]2([H])[C@]([H])(O)[C@@]([H])(O)[C@]([H])(OCCCCCCCCCCC)O[C@]2([H])CO)[C@]1([H])O,,,,,0,,496.2883622,2,0,2,0,2,2
2358,04/06/2019 00:00,DB02688,"2,3-Didehydroalanine",,,,,,solid,,,233,2.58,8.64,NC(=C)C(O)=O,,,,,0,,87.0320284,0,0,0,0,0,0
2359,04/06/2019 00:00,DB02689,S-{2-[Amino(Dihydroxy)-Lambda~4~-Sulfanyl]Ethyl}-D-Cysteine,,,,,,solid,,,28.7,1.64,9.14,[H][C@](N)(CSCCS(N)(=O)=O)C(O)=O,,,,,0,,228.0238489,0,0,0,0,0,0
2360,04/06/2019 00:00,DB02690,NU1025,,,,,,solid,,,1.04,7.65,1.72,CC1=NC2=C(C=CC=C2O)C(=O)N1,,,,,0,,176.0585775,2,2,1,1,0,0
2361,04/06/2019 00:00,DB02691,Glycocholic acid,,,,,,solid,3.3 mg/L (at 20 Â°C),1.65,0.0214,3.77,-0.14,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC([O-])=O,,,,,-1,,464.3017616,4,0,0,0,0,0
2362,04/06/2019 00:00,DB02693,"(4S,5S)-1,2-dithiane-4,5-diol",,,,,,solid,,,70.5,13.48,-3.3,[H][C@@]1(O)CSSC[C@@]1([H])O,,,,,0,,151.9965715,1,0,1,0,1,1
2363,04/06/2019 00:00,DB02694,Pantoyl Adenylate,,,,,,solid,,,2.93,0.76,4.99,[H][C@](O)(C(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C(C)(C)CO,,,,,0,,477.1260786,3,2,3,2,1,1
2364,04/06/2019 00:00,DB02695,O1-Pentyl-Mannose,,,,,,solid,,,112,12.21,-3,[H][C@]1(O)[C@]([H])(O)[C@@]([H])(CO)O[C@]([H])(OCCCCC)[C@@]1([H])O,,,,,0,,250.1416384,1,0,1,0,1,1
2365,04/06/2019 00:00,DB02696,"6-Aminohexyl-Uridine-C1,5'-Diphosphate",,,,,,solid,,,10.4,1.87,10.21,[H][C@]1(COP(O)(=O)OP(O)(=O)OCCCCCCN)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,503.1069966,2,1,2,1,1,1
2366,04/06/2019 00:00,DB02697,Hydroxyaminovaline,,,,,,solid,,,179,8.93,7.94,CC(C)[C@@H](N)C(=O)NO,,,,,0,,132.0898776,0,0,0,0,0,0
2367,04/06/2019 00:00,DB02698,"N-(M-Trifluoromethylphenyl) Phenoxazine-4,6-Dicarboxylic Acid",,,,,,solid,,,0.00817,3.95,-9.5,OC(=O)C1=CC=CC2=C1OC1=C(C=CC=C1C(O)=O)N2C1=CC(=CC=C1)C(F)(F)F,,,,,0,,415.0667571,4,3,1,0,0,1
2368,04/06/2019 00:00,DB02699,4-Oxoretinol,,,,,,solid,,,0.0121,16.44,-2.2,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C,,,,,0,,300.2089301,1,0,0,0,0,0
2369,04/06/2019 00:00,DB02700,3-Deoxy-D-Glucosamine,,,,,,solid,,,849,11.84,8.74,[H][C@@]1(N)C[C@]([H])(O)[C@@]([H])(CO)O[C@]1([H])O,,,,,0,,163.0844579,1,0,1,0,1,1
2370,02/07/2019 00:00,DB02701,Nicotinamide,,,,1 g/50mL,Topical,solid,5E+005 mg/L (at 25 Â°C),-0.37,50.1,13.39,3.63,NC(=O)C1=CC=CN=C1,,,,,0,,122.0480128,1,1,1,1,0,0
2371,04/06/2019 00:00,DB02702,XV638,,,,,,solid,,,0.0019,9.15,0.2,[H][C@]1(CC2=CC=CC=C2)N(CC2=CC(=CC=C2)C(=O)NC2=NC=CS2)C(=O)N(CC2=CC(=CC=C2)C(=O)NC2=NC=CS2)[C@]([H])(CC2=CC=CC=C2)[C@]([H])(O)[C@@]1([H])O,,,,,0,,758.2345103,7,6,3,2,1,1
2372,02/07/2019 00:00,DB02703,Fusidic acid,"Sodium fusidic acid tablets have a 91% oral bioavailability. Absorption of the film-coated tablets is complete when compared to a solution, however oral absorption is variable. Oral fusidic acid hemihydrate (suspension) achieved a 22.5% bioavailability in pediatric patients following a 20 milligram/kilogram dose.",0.99,Approximately 5 to 6 hours in adults.,20 mg/1g,Topical,solid,,,0.00521,4.66,-0.2,O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C,0.99,0.99,,,0,,516.3450893,4,0,0,0,0,0
2373,04/06/2019 00:00,DB02704,"(2r,3r,4r,5r)-3,4-Dihydroxy-N,N'-Bis[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-2,5-Bis(2-Phenylethyl)Hexanediamide",,,,,,solid,,,0.00562,6.36,2.61,[H][C@](CCC1=CC=CC=C1)(C(O)=N[C@@]1([H])C2=CC=CC=C2C[C@@]1([H])O)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(CCC1=CC=CC=C1)C(O)=N[C@@]1([H])C2=CC=CC=C2C[C@@]1([H])O,,,,,0,,648.3199371,6,4,0,0,0,0
2374,04/06/2019 00:00,DB02705,"6-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine",,,,,,solid,,,0.00361,12.05,11.21,[H][C@]1(NCCC2=C1C=C(NC(=O)C1=CC=C3C=C(C=CC3=C1)C(N)=N)C=C2)C(C)C,,,,,0,,386.2106615,4,3,1,0,0,1
2375,04/06/2019 00:00,DB02706,Mercaptocarboxylate Inhibitor,,,,,,solid,,,0.022,2.07,-1.1,[H][C@](CS)(CCC1=CC=CC=C1)C(=O)N=C(C(O)=O)C1=CC=C(CN2C=NN=N2)S1,,,,,0,,429.0929315,3,3,2,2,0,0
2376,04/06/2019 00:00,DB02707,Pentyl Trihydrogen Diphosphate,,,,,,solid,,,9.04,1.78,,CCCCCO[P@](O)(=O)OP(O)(O)=O,,,,,0,,248.021476,0,0,0,0,0,0
2377,04/06/2019 00:00,DB02709,Resveratrol,High absorption but very low bioavailability.,,,,Oral,solid,,,0.0688,8.49,-6.2,OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1,,,,,0,,228.0786442,2,2,0,0,0,0
2378,04/06/2019 00:00,DB02710,"2,3,-Dihydroxybenzoylserine",,,,,,solid,,,5.76,2.98,-2,[H][C@@](CO)(NC(=O)C1=C(O)C(O)=CC=C1)C(O)=O,,,,,0,,241.0586371,1,1,0,0,0,0
2379,04/06/2019 00:00,DB02711,"4-{2,6,8-Trioxo-9-[(2S,3R,4R)-2,3,4,5-Tetrahydroxypentyl]-1,2,3,6,8,9-Hexahydro-7h-Purin-7-Yl}Butyl Dihydrogen Phosphate",,,,,,solid,,,3.41,1.81,-3,OC[C@@H](O)[C@H](O)[C@@H](O)CN1C(=O)N(CCCCOP(O)(O)=O)C2=C1NC(=O)NC2=O,,,,,0,,454.1100942,2,2,2,2,0,0
2380,04/06/2019 00:00,DB02712,Sorbinil,,,,,,solid,,0.78,2.63,8.67,-4.9,FC1=CC=C2OCC[C@]3(NC(=O)NC3=O)C2=C1,,,,,0,,236.0597204,3,1,2,0,1,2
2381,04/06/2019 00:00,DB02713,Acetylamino-Acetic Acid,,,,,,solid,2.63E+004 mg/L (at 15 Â°C),,51.3,3.77,-1.6,CC(=O)NCC(O)=O,,,,,0,,117.0425931,0,0,0,0,0,0
2382,04/06/2019 00:00,DB02714,3'-Uridinemonophosphate,,,,,,solid,,,15.8,0.87,-3,[H][C@]1(CO)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,324.0358666,2,1,2,1,1,1
2383,04/06/2019 00:00,DB02715,Compound 18,,,,,,solid,,,0.00178,9.55,9,[H][C@](C)(COC1=CC=C(C=C1)[C@]1([H])OC2=C(S[C@]1([H])C1=CC=C(O)C=C1)C=C(O)C=C2)N1CCCC1,,,,,0,,463.1817294,5,3,2,0,1,2
2384,04/06/2019 00:00,DB02716,7-Methyl-Guanosine-5'-Triphosphate,,,,,,solid,,,6.13,0.88,2.12,[H][C@]1(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=[N+](C)C3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,1,,538.0135866,3,2,3,2,1,1
2385,04/06/2019 00:00,DB02717,Cellotetraose,,,,,,solid,,,350,11.19,-3.7,[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O[C@]3([H])O[C@]([H])(CO)[C@@]([H])(O[C@]4([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]4([H])O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,666.2218584,4,0,4,0,4,4
2386,04/06/2019 00:00,DB02719,C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide,,,,,,solid,,,35.4,-6.4,12.83,[H][C@]1(O)[C@]([H])(O)[C@@]([H])(O)[C@@](O)(O[C@]1([H])CO)C(O)=N,,,,,0,,223.0692018,1,0,1,0,1,1
2387,04/06/2019 00:00,DB02720,Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide,,,,,,solid,,,24.6,-2,12.05,[H][C@]1(O)[C@]([H])(O)[C@@]([H])(CO)O[C@]([H])(C(O)=N)[C@]1([H])O,,,,,0,,207.0742871,1,0,1,0,1,1
2388,04/06/2019 00:00,DB02721,4-Iodopyrazole,,,,,,solid,,1.7,11.8,13.51,1.45,IC1=CNN=C1,,,,,0,,193.9340961,1,1,1,1,0,0
2389,04/06/2019 00:00,DB02722,4-O-methyl-beta-D-glucuronic acid,,,,,,solid,,,334,3.34,-3.7,CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O,,,,,0,,208.0583027,1,0,1,0,1,1
2390,04/06/2019 00:00,DB02723,"4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide",,,,,,solid,,,1.06,13.15,7.29,O\N=C(/N)N1CCC(CC1)CNC(=O)[C@@H]1CC[C@H]2CN(CC(=O)N12)S(=O)(=O)CC1=CC=CC=C1,,,,,0,,492.2154891,4,1,3,0,3,3
2391,04/06/2019 00:00,DB02725,"2-Amino-4-(4-Amino-Cyclohexa-2,5-Dienyl)-Butyric Acid",,,,,,solid,,,4,2.63,9.74,[H][C@](N)(CC[C@@]1([H])C=CC([H])(N)C=C1)C(O)=O,,,,,0,,196.1211778,1,0,0,0,0,0
2392,04/06/2019 00:00,DB02726,2-Phosphoglycolic Acid,,,,,,solid,,,18.4,1.14,,OC(=O)COP(O)(O)=O,,,,,0,,155.9823745,0,0,0,0,0,0
2393,04/06/2019 00:00,DB02727,N-Butyl-N'-Hydroxyguanidine,,,,,,solid,,,2.9,14.82,10.72,CCCCNC(=N)NO,,,,,0,,131.105862,0,0,0,0,0,0
2394,04/06/2019 00:00,DB02728,7-Hydroxy-2-Oxo-Chromene-3-Carboxylic Acid Ethyl Ester,,,,,,solid,,,0.806,7.67,-7,CCOC(=O)C1=CC2=CC=C(O)C=C2OC1=O,,,,,0,,234.0528234,2,2,1,1,0,0
2395,04/06/2019 00:00,DB02729,SD146,,,,,,solid,,,0.00278,6.55,2.8,[H][C@]1(CC2=CC=CC=C2)N(CC2=CC(=CC=C2)C(O)=NC2=NC3=CC=CC=C3N2)C(=O)N(CC2=CC(=CC=C2)C(O)=NC2=NC3=CC=CC=C3N2)[C@]([H])(CC2=CC=CC=C2)[C@]([H])(O)[C@@]1([H])O,,,,,0,,824.3434665,9,8,3,2,1,1
2396,04/06/2019 00:00,DB02730,4-Methylthio-Alpha-D-Mannose,,,,,,solid,,,269,11.32,-3,[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(SC)[C@]([H])(O)[C@@]1([H])O,,,,,0,,210.0561945,1,0,1,0,1,1
2397,04/06/2019 00:00,DB02731,Ethylmercurithiosalicylic acid,,,,,,solid,,,4.63,3.62,,CC[Hg]SC1=CC=CC=C1C(O)=O,,,,,0,,384.0107936,1,1,0,0,0,0
2398,04/06/2019 00:00,DB02732,Nicotinamide Adenine Dinucleotide Acetone Adduct,,,,,,solid,,,4.03,1.86,6.41,[H][C@]1(COP([O-])(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=C(CC(C)=O)C(=C3)C(O)=N)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,719.1353366,5,3,5,3,2,2
2399,04/06/2019 00:00,DB02733,Purvalanol,,,,,,solid,,,0.0662,3.54,4.46,[H][C@@](CO)(NC1=NC2=C(N=CN2C(C)C)C(NC2=CC=C(C(O)=O)C(Cl)=C2)=N1)C(C)C,,,,,0,,432.1676663,3,3,2,2,0,0
2400,04/06/2019 00:00,DB02734,4-Deoxy-D-Mannuronic Acid,,,,,,solid,,,208,3.27,-3.5,[H][C@@]1(O)OC(=C[C@]([H])(O)[C@]1([H])O)C(O)=O,,,,,0,,176.032088,1,0,1,0,0,1
2401,04/06/2019 00:00,DB02735,2-Amino-3-Oxo-4-Sulfo-Butyric Acid,,,,,,solid,,,24,-2.2,8.03,[H][C@@](N)(C(O)=O)[C@@]([H])(O)OS(O)(=O)=O,,,,,0,,200.9943226,0,0,0,0,0,0
2402,04/06/2019 00:00,DB02736,Acetamide,,,,,,solid,2.25E+006 mg/L (at 25 Â°C),-1.26,369,16.75,-1.3,CC(N)=O,,,,,0,,59.03711378,0,0,0,0,0,0
2403,04/06/2019 00:00,DB02738,Adenosine-5'-Pentaphosphate,,,,,,solid,,,5.58,0.42,5,NC1=C2N=CN([C@@H]3O[C@H](CO[P@@](O)(=O)O[P@](O)(=O)O[P@@](O)(=O)O[P@@](O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1,,,,,0,,666.9284065,3,2,3,2,1,1
2404,04/06/2019 00:00,DB02740,3-Indolebutyric Acid,,,,,,solid,250 mg/L (at 20 Â°C),2.3,0.356,4.86,,OC(=O)CCCC1=CNC2=C1C=CC=C2,,,,,0,,203.0946287,2,2,1,1,0,0
2405,04/06/2019 00:00,DB02741,CD564,,,,,,solid,,,4.81E-05,3.99,-7.5,CC1(C)CCC(C)(C)C2=C1C=CC(=C2)C(=O)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O,,,,,0,,386.1881947,4,3,0,0,0,0
2406,04/06/2019 00:00,DB02742,Kifunensine,,,,,,solid,,,190,9.94,-2.8,[H][C@]12NC(=O)C(=O)N1[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]2([H])O,,,,,0,,232.0695361,2,0,2,0,2,2
2407,04/06/2019 00:00,DB02743,beta-D-galactopyranosyl-(1->4)-beta-D-galactopyranose,,,,,,solid,,,586,11.25,-3,[H][C@@]1(O)O[C@]([H])(CO)[C@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,342.1162115,2,0,2,0,2,2
2408,04/06/2019 00:00,DB02744,RPR131247,,,,,,solid,,,0.0743,7.55,12.74,NC(=N)C1=CC=C(O)C(CN2CC[C@H](NS(=O)(=O)C3=CC4=C(S3)C=CC=N4)C2=O)=C1,,,,,0,,445.0878461,4,3,3,2,1,1
2409,04/06/2019 00:00,DB02745,Uridine,,,,,,solid,,-1.98,135,9.7,-3,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O,,,,,0,,244.0695361,2,1,2,1,1,1
2410,04/06/2019 00:00,DB02746,Phthalic Acid,,,,,,solid,7010 mg/L (at 25 Â°C),0.73,3.12,2.94,,OC(=O)C1=CC=CC=C1C(O)=O,,,,,0,,166.0266087,1,1,0,0,0,0
2411,04/06/2019 00:00,DB02747,N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl)Glycyl-L-Arginine-N-Phenylamide,,,,,,solid,,,0.0101,1.66,11.96,[H][C@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=N[C@@]([H])(CCCNC(N)=[NH2+])C(O)=NC1=CC=CC=C1)C(O)=O,,,,,1,,483.27143,2,2,0,0,0,0
2412,04/06/2019 00:00,DB02749,Pyromellitic Acid,,,,,,solid,1.4E+004 mg/L (at 16 Â°C),,0.653,1.97,,OC(=O)C1=CC(C(O)=O)=C(C=C1C(O)=O)C(O)=O,,,,,0,,254.0062672,1,1,0,0,0,0
2413,04/06/2019 00:00,DB02750,S-(Methylmercury)-L-Cysteine,,,,,,solid,,,20.2,1.76,9.21,C[Hg]SC[C@@H](N)C(O)=O,,,,,0,,337.0060425,0,0,0,0,0,0
2414,04/06/2019 00:00,DB02751,Glycocyamine,,,,,,solid,,,4.19,3.37,12.24,NC(=N)NCC(O)=O,,,,,0,,117.0538265,0,0,0,0,0,0
2415,04/06/2019 00:00,DB02752,Tosyl-D-Proline,,,,,,solid,,,2.91,3.21,,[H][C@@]1(CCCN1S(=O)(=O)C1=CC=C(C)C=C1)C(O)=O,,,,,0,,269.072179,2,1,1,0,1,1
2416,04/06/2019 00:00,DB02753,Selenoinosine,,,,,,solid,,,39.6,12.45,3.04,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C2N=CN=C3[SeH])[C@]([H])(O)[C@]1([H])O,,,,,0,,332.0023762,3,2,3,2,1,1
2417,04/06/2019 00:00,DB02754,"9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine",,,,,,solid,,,0.0544,18.6,5.07,CCCCN1C(CC2=CC(OC)=C(OC)C(OC)=C2)=NC2=C(N)N=CN=C12,,,,,0,,371.1957397,3,3,2,2,0,0
2418,04/06/2019 00:00,DB02755,1-3 Sugar Ring of Pentamannosyl 6-Phosphate,,,,,,solid,,,50.8,1.22,-3.7,[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O[C@@]3([H])O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@]3([H])O)[C@]2([H])O)[C@]1([H])O,,,,,0,,584.1353655,3,0,3,0,3,3
2419,04/06/2019 00:00,DB02756,Pyroquilon,,,,,,solid,,,11.3,,-3.5,O=C1CCC2=CC=CC3=C2N1CC3,,,,,0,,173.084064,3,1,2,0,0,2
2420,04/06/2019 00:00,DB02757,Pyrazole,,,,,,solid,1.94E+004 mg/L (at 25 Â°C),0.26,484,14.63,2.17,N1C=CC=N1,,,,,0,,68.03744813,1,1,1,1,0,0
2421,04/06/2019 00:00,DB02758,Indolylpropionic Acid,,,,,,solid,,,0.727,4.8,,OC(=O)CCC1=CNC2=CC=CC=C12,,,,,0,,189.0789786,2,2,1,1,0,0
2422,04/06/2019 00:00,DB02759,4-Methylumbelliferyl Chitobiose,,,,,,solid,,,1.04,6.81,1.53,[H][C@]1(CO)O[C@@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@@]([H])(OC3=CC4=C(C=C3)C(C)=CC(=O)O4)[C@]([H])(N=C(C)O)[C@@]2([H])O)[C@]([H])(N=C(C)O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,582.2060891,4,2,3,1,2,2
2423,04/06/2019 00:00,DB02760,"1,6-Di-O-Phosphono-D-Allitol",,,,,,solid,,,16.2,1.19,-3.5,[H][C@](O)(COP(O)(O)=O)[C@]([H])(O)[C@]([H])(O)[C@]([H])(O)COP(O)(O)=O,,,,,0,,342.0116992,0,0,0,0,0,0
2424,04/06/2019 00:00,DB02761,S-Mercaptocysteine,,,,,,solid,,,14.3,2.04,8.9,N[C@@H](CSS)C(O)=O,,,,,0,,152.9918205,0,0,0,0,0,0
2425,04/06/2019 00:00,DB02762,RU79072,,,,,,solid,,,0.552,1.72,-1.7,OP(O)(=O)OC1=CC=CC2=CC=C(N=C12)C#N,,,,,0,,250.0143433,2,2,1,1,0,0
2426,04/06/2019 00:00,DB02763,5-Mercapto-2-Nitro-Benzoic Acid,,,,,,solid,,,0.116,2.19,,OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O,,,,,0,,198.9939286,1,1,0,0,0,0
2427,04/06/2019 00:00,DB02765,R-9-(2-hydroxypropyl)adenine,,,,,,solid,,,5.45,15.17,5.12,C[C@@H](O)CN1C=NC2=C1N=CN=C2N,,,,,0,,193.09636,2,2,2,2,0,0
2428,04/06/2019 00:00,DB02766,(3r)-3-{[(Benzyloxy)Carbonyl]Amino}-2-Oxo-4-Phenylbutane-1-Diazonium,,,,,,solid,,,0.0127,7.73,-9,[H][C@](CC1=CC=CC=C1)([N-]C(=O)OCC1=CC=CC=C1)C(=[OH+])C[N+]#N,,,,,1,,324.1342679,2,2,0,0,0,0
2429,04/06/2019 00:00,DB02767,3-Hydroxy-Myristic Acid,,,,,,solid,,,0.0299,4.67,-2.8,[H][C@@](O)(CCCCCCCCCCC)CC(O)=O,,,,,0,,244.2038448,0,0,0,0,0,0
2430,04/06/2019 00:00,DB02768,Tert-Butyloxycarbonyl Group,,,,,,solid,,,25,,-6.8,CC(C)(C)OC=O,,,,,0,,102.0680796,0,0,0,0,0,0
2431,04/06/2019 00:00,DB02770,7-Alpha-D-Ribofuranosyl-2-Aminopurine-5'-Phosphate,,,,,,solid,,,2,1.23,12,[H][C@]1(COP(O)(O)=O)O[C@]([H])(N2C=NC3=NC(=N)NC=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,347.0630844,3,2,3,2,1,1
2432,04/06/2019 00:00,DB02772,Sucrose,,,,,Oral,solid,2.1E+006 mg/L (at 25 Â°C),-3.7,824,11.84,-3,OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,,,,,0,,342.1162115,2,0,2,0,2,2
2433,04/06/2019 00:00,DB02773,(3-Chloro-4-Propoxy-Phenyl)-Acetic Acid,,,,,,solid,,,0.227,3.69,-4.9,CCCOC1=CC=C(CC(O)=O)C=C1Cl,,,,,0,,228.055322,1,1,0,0,0,0
2434,04/06/2019 00:00,DB02774,"1,3-Propandiol",,,,,,solid,,,859,15.6,-2.4,OCCCO,,,,,0,,76.0524295,0,0,0,0,0,0
2435,04/06/2019 00:00,DB02776,1-Hexadecanosulfonic Acid,,,,,,solid,,,0.000857,-0.59,,CCCCCCCCCCCCCCCCS(O)(=O)=O,,,,,0,,306.2228659,0,0,0,0,0,0
2436,04/06/2019 00:00,DB02777,Diundecyl Phosphatidyl Choline,,,,,,solid,,,9.31E-05,1.86,-6.7,[H][C@@](COC(=O)CCCCCCCCCCC)(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC,,,,,1,,622.4442311,0,0,0,0,0,0
2437,04/06/2019 00:00,DB02778,"2,5-Anhydroglucitol-1,6-Biphosphate",,,,,,solid,,,16,0.93,-3.6,[H][C@]1(O)[C@]([H])(O)[C@]([H])(COP(O)(O)=O)O[C@]1([H])COP(O)(O)=O,,,,,0,,324.0011345,1,0,1,0,1,1
2438,04/06/2019 00:00,DB02779,Dodecane-Trimethylamine,,,,,,solid,,,1.17E-05,,,CCCCCCCCCCCC[N+](C)(C)C,,,,,1,,228.2685765,0,0,0,0,0,0
2439,04/06/2019 00:00,DB02780,Beta-3-Cysteine,,,,,,solid,,,13.5,4.06,10.63,[H][C@](N)(CS)CC(O)=O,,,,,0,,135.0353995,0,0,0,0,0,0
2440,04/06/2019 00:00,DB02781,"4-{(Z)-[2-[3-(Methylsulfanyl)Propanoyl]-5-Oxo-1-(2-Oxoethyl)-1,5-Dihydro-4h-Imidazol-4-Ylidene]Methyl}Benzenolate",,,,,,solid,,,0.0417,8.83,-4.3,[H]\C(=C1/N=C(N(CC=O)C1=O)C(=O)CCSC)C1=CC=C([O-])C=C1,,,,,-1,,331.0758015,2,1,1,0,0,1
2441,04/06/2019 00:00,DB02783,4'-Deoxy-4'-Acetylyamino-Pyridoxal-5'-Phosphate,,,,,,solid,,,1.91,1.71,4.99,CC1=NC=C(COP(O)(O)=O)C(CNOCC(O)=O)=C1O,,,,,0,,322.0566021,1,1,1,1,0,0
2442,04/06/2019 00:00,DB02784,N-[4-(2-{2-[3-(2-Bromo-Acetylamino)-Propionylamino]-3-Hydroxy-Propionylamino}-Ethyl)-Phenyl]-Oxalamic Acid,,,,,,solid,,,0.0829,3.19,3.83,[H][C@@](CO)(N=C(O)CCN=C(O)CBr)C(O)=NCCC1=CC=C(C=C1)N=C(O)C(O)=O,,,,,0,,486.0750112,1,1,0,0,0,0
2443,04/06/2019 00:00,DB02785,N-[2(S)-Cyclopentyl-1(R)-Hydroxy-3(R)Methyl]-5-[(2(S)-Tertiary-Butylamino-Carbonyl)-4-(N1-(2)-(N-Methylpiperazinyl)-3-Chloro-Pyrazinyl-5-Carbonyl)-Piperazino]-4(S)-Hydroxy-2(R)-Phenylmethyl-Pentanamide,,,,,,solid,,,0.09,5.54,6.39,[H][C@@](O)(CN1CCN(C[C@@]1([H])C(O)=NC(C)(C)C)C(=O)C1=NC(Cl)=C(N=C1)N1CCN(C)CC1)C[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@@]1([H])[C@@]([H])(C)CC[C@@]1([H])O,,,,,0,,726.3983945,5,2,3,1,2,2
2444,04/06/2019 00:00,DB02786,2-Anhydro-3-Fluoro-Quinic Acid,,,,,,solid,,,109,3.39,-3.3,[H][C@@]1(O)C[C@@](O)(C=C(F)[C@@]1([H])O)C(O)=O,,,,,0,,192.0434016,1,0,0,0,0,0
2445,04/06/2019 00:00,DB02787,N-Acetylmannosaminitol,,,,,,solid,,,148,12.78,7.75,[H][C@@](C)(O)N[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)CO,,,,,0,,225.1212373,0,0,0,0,0,0
2446,04/06/2019 00:00,DB02788,(S)-acetoin,,,,,,solid,1E+006 mg/L (at 20 Â°C),,473,13.72,-3.4,C[C@H](O)C(C)=O,,,,,0,,88.0524295,0,0,0,0,0,0
2447,04/06/2019 00:00,DB02789,Pregnenolone,,,,1 kg/1kg,,solid,,,0.0136,18.2,-1.4,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C,,,,,0,,316.2402303,4,0,0,0,0,0
2448,04/06/2019 00:00,DB02790,Phenyl-Uridine-5'-Diphosphate,,,,,,solid,,,6.61,1.63,-3.7,[H][C@]1(COP(O)(=O)OP(O)(=O)OC2=CC=CC=C2)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,480.0334973,3,2,2,1,1,1
2449,04/06/2019 00:00,DB02792,Deglucobalhimycin,,,,,,solid,,,0.0467,1.99,,[H][C@](CC(C)C)(NC)C(O)=N[C@@]1([H])C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@]2([H])C3=CC(OC4=C(Cl)C=C(C=C4)[C@@]1([H])O)=C(O)C(OC1=C(Cl)C=C(C=C1)[C@@]([H])(O[C@@]1([H])C[C@](C)(N)C(O)(O)[C@]([H])(C)O1)[C@]1([H])N=C(O)[C@]([H])(N=C2O)C2=CC(=C(O)C=C2)C2=C(C=C(O)C=C2O)[C@]([H])(N=C1O)C(O)=O)=C3,,,,,0,,1301.372291,11,5,6,0,1,6
2450,04/06/2019 00:00,DB02793,Isochorismic Acid,,,,,,solid,,,13.9,3.39,-3.6,[H][C@]1(O)C(=CC=C[C@]1([H])OC(=C)C([O-])=O)C([O-])=O,,,,,-2,,224.0331851,1,0,0,0,0,0
2451,04/06/2019 00:00,DB02794,N-[5'-O-Phosphono-Ribofuranosyl]-2-[2-Hydroxy-2-[4-[Glutamic Acid]-N-Carbonylphenyl]-3-[2-Amino-4-Hydroxy-Quinazolin-6-Yl]-Propanylamino]-Acetamide,,,,,,solid,,,0.12,1.22,8.69,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)[C@](O)(CNCC(O)=N[C@]1([H])O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@@]1([H])O)CC1=CC2=C(NC(=N)N=C2O)C=C1)C(O)=O,,,,,0,,752.2054511,4,3,2,1,1,1
2452,04/06/2019 00:00,DB02795,P-Anisic Acid,,,,,,solid,530 mg/L (at 37 Â°C),1.96,2,4.37,-4.8,COC1=CC=C(C=C1)C(O)=O,,,,,0,,152.0473441,1,1,0,0,0,0
2453,04/06/2019 00:00,DB02796,9-Deazainosine,,,,,,solid,,,15.7,11.62,2.24,[H][C@]1(CO)O[C@@]([H])(C2=CNC3=C2N=CN=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,267.0855205,3,2,3,2,1,1
2454,04/06/2019 00:00,DB02797,3-Nitrophenylboronic Acid,,,,,,solid,,,1.4,8.49,-5.5,OB(O)C1=CC=CC(=C1)[N+]([O-])=O,,,,,0,,167.0389881,1,1,0,0,0,0
2455,04/06/2019 00:00,DB02798,Alpha-Methylene Adenosine Monophosphate,,,,,,solid,,,3.16,1.41,4.99,[H][C@]1(COP(C)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,345.0838199,3,2,3,2,1,1
2456,04/06/2019 00:00,DB02799,N-[2-(1-Maleimidyl)Ethyl]-7-Diethylaminocoumarin-3-Carboxamide,,,,,,solid,,,0.0984,13.66,4.16,CCN(CC)C1=CC2=C(C=C1)C=C(C(=O)N\C=C/N1C(=O)CCC1=O)C(=O)O2,,,,,0,,383.1481208,3,2,2,1,1,1
2457,04/06/2019 00:00,DB02800,5-Hydroxymethylene-6-Hydrofolic Acid,,,,,,solid,,,0.103,1.85,6.63,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(NC[C@@]2([H])C=NC3=C(N2CO)C(O)=NC(=N)N3)C=C1)C(O)=O,,,,,0,,473.1658961,3,2,2,1,0,1
2458,04/06/2019 00:00,DB02801,"2,3-Anhydro-quinic acid",,,,,,solid,,,303,3.49,-3.2,[H][C@@]1(O)C[C@@](O)(C=C[C@@]1([H])O)C(O)=O,,,,,0,,174.0528234,1,0,0,0,0,0
2459,04/06/2019 00:00,DB02802,5-Aminocarbonyl-3-Nitrophenyl-Alpha-D-Galactopyranose,,,,,,solid,,,1,6.98,5.32,[H][C@]1(CO)O[C@]([H])(OC2=CC(=CC(=C2)N(=O)=O)C(O)=N)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,344.0855801,2,1,1,0,1,1
2460,04/06/2019 00:00,DB02803,"3-Phenyl-1,2-Propandiol",,,,,,solid,,,27.1,14.2,-2.9,OC[C@@H](O)CC1=CC=CC=C1,,,,,0,,152.0837296,1,1,0,0,0,0
2461,04/06/2019 00:00,DB02804,A-98881,,,,,,solid,,,0.0176,9.63,2.9,[H][C@@]1(O)CN(CC2=CC=CC=C2)N(CC2=CC(OC)=C(O)C=C2)C(=O)N(CC2=CC(OC)=C(O)C=C2)[C@]1([H])CC1=CC=CC=C1,,,,,0,,583.2682359,5,4,1,0,1,1
2462,04/06/2019 00:00,DB02805,Uracil arabinose-3'-phosphate,,,,,,solid,,,15.8,0.87,-3,[H][C@]1(CO)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,324.0358666,2,1,2,1,1,1
2463,04/06/2019 00:00,DB02806,2-Methoxyethanol,,,,,,solid,1E+006 mg/L (at 25 Â°C),-0.77,812,15.12,-2.7,COCCO,,,,,0,,76.0524295,0,0,0,0,0,0
2464,04/06/2019 00:00,DB02807,3-deoxy-D-lyxo-hexonic acid,,,,,,solid,,,255,3.57,-3,[H][C@](O)(C[C@@]([H])(O)[C@]([H])(O)CO)C(O)=O,,,,,0,,180.0633881,0,0,0,0,0,0
2465,04/06/2019 00:00,DB02808,Trifluorofurnesyl Diphosphate,,,,,,solid,,,0.0896,1.77,,CC(C)=CCC\C(C)=C\CC\C(=C\CO[P@@](=O)(O)OP(O)(O)=O)C(F)(F)F,,,,,0,,436.1027611,0,0,0,0,0,0
2466,04/06/2019 00:00,DB02809,"Brodimoprim-4,6-Dicarboxylate",,,,,,solid,,,0.00803,3.05,7.16,COC1=CC(CC2=C[NH+]=C(N)N=C2N)=CC(OCCC[C@@H](CCC([O-])=O)C([O-])=O)=C1Br,,,,,-1,,495.0884702,2,2,1,1,0,0
2467,04/06/2019 00:00,DB02810,N-(2-Acetamido)Iminodiacetic Acid,,,,,,solid,,,49.1,2.31,5.96,NC(=O)CN(CC(O)=O)CC(O)=O,,,,,0,,190.0589714,0,0,0,0,0,0
2468,04/06/2019 00:00,DB02811,Diethylphosphono Group,,,,,,solid,,,63.8,,-7.8,CCOP(=O)OCC,,,,,0,,138.0445808,0,0,0,0,0,0
2469,04/06/2019 00:00,DB02812,"(2s,4r)-1-Acetyl-N-[(1s)-4-[(Aminoiminomethyl)Amino]-1-(2-Benzothiazolylcarbonyl)Butyl]-4-Hydroxy-2-Pyrrolidinecarboxamide",,,,,,solid,,,0.14,5.89,11.85,[H][C@@](CCCNC(N)=N)(N=C(O)[C@]1([H])C[C@@]([H])(O)CN1C(C)=O)C(=O)C1=NC2=CC=CC=C2S1,,,,,0,,446.1736243,3,2,2,1,1,1
2470,04/06/2019 00:00,DB02813,"2-Acetamido-2-Deoxy-D-Glucono-1,5-Lactone",,,,,,solid,,,233,11.6,-1.3,CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=O,,,,,0,,219.0742871,1,0,1,0,1,1
2471,04/06/2019 00:00,DB02814,3'-Deazo-Thiamin Diphosphate,,,,,,solid,,,0.138,1.78,9.07,CC1=C(CCO[P@](O)(=O)O[P@](O)([O-])=O)SC=[N+]1CC1=C(N)C=C(C)N=C1,,,,,0,,423.0418942,2,2,2,2,0,0
2472,04/06/2019 00:00,DB02816,"7-(1-Methyl-1,2,3-Triazol-4-Yl)-6-Formyl-2,7-Dihydro-[1,4]Thiazepine-3-Carboxylic Acid, Brl42715, C6-(N1-Methyl-1,2,3-Triazolylmethylene)Penem",,,,,,solid,,,1.99,3.88,0.16,[H][C@@]1(SC=C(NC=C1C=O)C(O)=O)C1=CN(C)N=N1,,,,,0,,266.0473612,2,1,2,1,0,1
2473,04/06/2019 00:00,DB02817,5-Exo-Hydroxycamphor,,,,,,solid,,,12.4,14.88,-2.9,[H][C@@]1(O)C[C@@]2(C)C(=O)C[C@]1([H])C2(C)C,,,,,0,,168.1150298,2,0,0,0,0,0
2474,04/06/2019 00:00,DB02818,Iodo-Willardiine,,,,,,solid,,,6.5,0.99,8.64,N[C@@H](CN1C=C(I)C(=O)NC1=O)C(O)=O,,,,,0,,324.9559537,1,1,1,1,0,0
2475,04/06/2019 00:00,DB02819,"Mono-[3,4-Dihydroxy-5-(5-Methyl-Benzoimidazol-1-Yl)-Tetrahydor-Furan-2-Ylmethyl] Ester",,,,,,solid,,,1.82,1.22,5.66,[H][C@]1(COP(O)(O)=O)O[C@]([H])(N2C=NC3=C2C=CC(C)=C3)[C@]([H])(O)[C@]1([H])O,,,,,0,,344.0773375,3,2,2,1,1,1
2476,04/06/2019 00:00,DB02820,"1-Azepan-1-Yl-2-Phenyl-2-(4-Thioxo-1,4-Dihydro-Pyrazolo[3,4-D]Pyrimidin-5-Yl)Ethanone Adduct",,,,,,solid,,,0.349,1.86,7.56,[H][C@@](N1C=NC2=NN(C=C2C1=S)[C@@]1([H])C=CN(C=C1C([O-])=N)[C@]1([H])O[C@]([H])(COP([O-])(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])([O-])[C@]2([H])[O-])[C@@]([H])(O)[C@@]1([H])O)(C(=O)N1CCCCCC1)C1=CC=CC=C1,,,,,-4,,1026.226697,9,5,8,4,3,4
2477,04/06/2019 00:00,DB02821,Canaline,,,,,,solid,,,308,2.24,9.46,NOCC[C@H](N)C(O)=O,,,,,0,,134.0691422,0,0,0,0,0,0
2478,04/06/2019 00:00,DB02822,Para-Bromobenzyl Alcohol,,,,,,solid,2200 mg/L (at 20 Â°C),,3.01,14.98,-2.8,OCC1=CC=C(Br)C=C1,,,,,0,,185.9680269,1,1,0,0,0,0
2479,04/06/2019 00:00,DB02823,Phosphonoacetic Acid,,,,,,solid,3.92E+005 mg/L (at 0 Â°C),,25.1,1.64,,OC(=O)CP(O)(O)=O,,,,,0,,139.9874599,0,0,0,0,0,0
2480,04/06/2019 00:00,DB02824,N-Pyridoxyl-Glycine-5-Monophosphate,,,,,,solid,,,1.97,0.99,9.79,CC1=NC=C(COP(O)(O)=O)C(CNCC(O)=O)=C1O,,,,,0,,306.0616875,1,1,1,1,0,0
2481,04/06/2019 00:00,DB02825,Methylphosphonic Acid Ester Group,,,,,,solid,,,394,2.31,,CP([O-])=O,,,,,-1,,78.99543958,0,0,0,0,0,0
2482,04/06/2019 00:00,DB02827,"7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid",,,,,,solid,,,0.0226,1.88,-0.33,[H][C@@]1(COC2=NS(=O)(=O)C3=C2C=CC=C3)OCCC2=C1SC(NC(=O)C(O)=O)=C2C(O)=O,,,,,0,,466.014072,4,2,3,1,0,2
2483,04/06/2019 00:00,DB02828,5-Fluorolevulinic Acid,,,,,,solid,,,36.9,4.08,-8,OC(=O)CCC(=O)CF,,,,,0,,134.0379223,0,0,0,0,0,0
2484,04/06/2019 00:00,DB02829,4-(Acetylamino)-3-[(Aminoacetyl)Amino]Benzoic Acid,,,,,,solid,,,0.229,4.02,7.98,CC(=O)NC1=CC=C(C=C1NC(=O)C[NH3+])C(O)=O,,,,,1,,252.0978823,1,1,0,0,0,0
2485,04/06/2019 00:00,DB02830,FR236913,,,,,,solid,,,0.0616,13.08,3.53,[H][C@](CO)(CCN1C=CC2=C1C=C(NC(=O)NCC1=CC=CC=C1)C=C2)N1C=NC(=C1)C(N)=O,,,,,0,,446.2066387,4,4,2,2,0,0
2486,04/06/2019 00:00,DB02832,Siroheme,,,,,,solid,,,0.296,2.65,,C[C@@]1(CC(O)=O)C2=CC3=C(CC(O)=O)C(CCC(O)=O)=C4C=C5N6C(=CC7=C(CCC(O)=O)[C@](C)(CC(O)=O)C8=CC(N2[Fe@]6(N34)N78)=C1CCC(O)=O)C(CC(O)=O)=C5CCC(O)=O,,,,,0,,914.1945188,8,2,8,2,0,6
2487,04/06/2019 00:00,DB02833,[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine,,,,,,solid,,,0.0159,12.01,4.07,CC1=C(SC(N)=N1)C1=NC(NC2=CC=CC(=C2)[N+]([O-])=O)=NC=C1,,,,,0,,328.0742446,3,3,2,2,0,0
2488,04/06/2019 00:00,DB02834,IDD552,,,,,,solid,,,0.00367,3.39,0.54,OC(=O)COC1=CC(F)=CC=C1C(=O)NCC1=NC2=C(S1)C(F)=CC(F)=C2F,,,,,0,,414.0297407,3,3,1,1,0,0
2489,04/06/2019 00:00,DB02835,"Alpha-D-Glucose 1,6-Bisphosphate",,,,,,solid,,,16,0.89,-3.6,O[C@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H](OP(O)(O)=O)[C@@H]1O,,,,,0,,339.9960491,1,0,1,0,1,1
2490,04/06/2019 00:00,DB02836,Guanosine 5'-Diphosphate 2':3'-Cyclic Monophosphate,,,,,,solid,,,6.67,1.48,4.94,[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]2([H])OP(O)(=O)O[C@]12[H],,,,,0,,504.9800954,4,2,4,2,2,2
2491,04/06/2019 00:00,DB02837,O4-Sulfonylgalactose,,,,,,solid,,,107,-2,-3,[H][C@@]1(O)O[C@]([H])(CO)[C@]([H])(OS(O)(=O)=O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,260.020203,1,0,1,0,1,1
2492,04/06/2019 00:00,DB02838,"3,4-Dihydro-2h-Pyrrolium-5-Carboxylate",,,,,,solid,,,23.6,3.93,1.72,[O-]C(=O)C1=[NH+]CCC1,,,,,0,,113.0476785,1,0,1,0,0,1
2493,04/06/2019 00:00,DB02839,"2,4-Dihydroxybenzoic Acid",,,,,,solid,5780 mg/L (at 25 Â°C),1.63,12.4,3.1,-5.8,OC(=O)C1=CC=C(O)C=C1O,,,,,0,,154.0266087,1,1,0,0,0,0
2494,04/06/2019 00:00,DB02840,"4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid",,,,,,solid,,,0.16,3.47,0.28,CCC1=C(O)C=C(O)C(=C1)C1=NNC(C(O)=O)=C1C1=CC=C2OCOC2=C1,,,,,0,,368.1008362,4,3,2,1,0,1
2495,04/06/2019 00:00,DB02841,[(2-Ethoxy-1-Naphthoyl)Amino]Methylboronic Acid,,,,,,solid,,,0.0815,14.35,-1.3,CCOC1=C(C(=O)NCB(O)O)C2=C(C=CC=C2)C=C1,,,,,0,,273.1172384,2,2,0,0,0,0
2496,04/06/2019 00:00,DB02842,9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide,,,,,,solid,,,0.0776,14.74,9.33,CN(C)CCCNC(=O)C1=CC=CC2=C(N)C3=C(C=CC=C3)N=C12,,,,,0,,322.1793613,3,3,1,1,0,0
2497,04/06/2019 00:00,DB02843,alpha-D-glucose-1-phosphate,,,,,,solid,1E+006 mg/L,,32.3,1.16,-3,OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,260.0297186,1,0,1,0,1,1
2498,04/06/2019 00:00,DB02844,"S-Adenosyl-1,8-Diamino-3-Thiooctane",,,,,,solid,,,0.674,12.47,10.3,[H][C@]1(CSC(CCCCCN)=CCN)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,423.2052588,3,2,3,2,1,1
2499,04/06/2019 00:00,DB02845,Methylphosphinic Acid,,,,,,solid,,,691,2.31,,CP(O)=O,,,,,0,,80.00271603,0,0,0,0,0,0
2500,04/06/2019 00:00,DB02846,L-thioproline,,,,,,solid,,,84,2.59,7.7,[H][C@]1(CSCN1)C(O)=O,,,,,0,,133.0197495,1,0,1,0,1,1
2501,04/06/2019 00:00,DB02847,"(2s,3r)-1-Amino-2-Methylbutane-2,3-Diol",,,,,,solid,,,585,13.61,9.27,[H][C@](C)(O)[C@@](C)(O)CN,,,,,0,,119.0946287,0,0,0,0,0,0
2502,04/06/2019 00:00,DB02848,"{4-[3-(6,7-Diethoxy-Quinazolin-4-Ylamino)-Phenyl]-Thiazol-2-Yl}-Methanol",,,,,,solid,,,0.00312,13.63,4.61,CCOC1=C(OCC)C=C2C(NC3=CC=CC(=C3)C3=CSC(CO)=N3)=NC=NC2=C1,,,,,0,,422.1412616,4,4,2,2,0,0
2503,04/06/2019 00:00,DB02849,N-Pyridoxyl-1-Amino-Cyclopropanecarboxylic Acid-5-Monophosphate,,,,,,solid,,,2.09,0.97,9.55,CC1=NC=C(COP(O)(O)=O)C(CNC2(CC2)C(O)=O)=C1O,,,,,0,,332.0773375,2,1,1,1,0,0
2504,04/06/2019 00:00,DB02850,(1-Tert-Butyl-5-Hydroxy-1h-Pyrazol-4-Yl)-(6-Methanesulfonyl-4'-Methoxy-2-Methyl-Biphenyl-3-Yl)-Methanone,,,,,,solid,,,0.007,5.89,1.24,COC1=CC=C(C=C1)C1=C(C=CC(C(=O)C2=C(O)N(N=C2)C(C)(C)C)=C1C)S(C)(=O)=O,,,,,0,,442.1562429,3,3,1,1,0,0
2505,04/06/2019 00:00,DB02851,Thiocamphor,,,,,,solid,,,0.00847,19.87,,[H][C@@]12CC[C@@](C)(C(=S)C1)C2(C)C,,,,,0,,168.0972715,2,0,0,0,0,0
2506,04/06/2019 00:00,DB02852,Domoic Acid,,,,,,solid,,,0.759,1.68,11.59,[H]\C(\C(\[H])=C(\C)[C@@]1([H])CN[C@]([H])(C(O)=O)[C@@]1([H])CC(O)=O)=C(\[H])[C@@]([H])(C)C(O)=O,,,,,0,,311.1368874,1,0,1,0,1,1
2507,04/06/2019 00:00,DB02853,D-Proline,,,,,,solid,,,365,1.94,11.33,OC(=O)[C@H]1CCCN1,,,,,0,,115.0633285,1,0,1,0,1,1
2508,04/06/2019 00:00,DB02854,Aetiocholanolone,,,,,,solid,,,0.00634,18.3,-1.4,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@]([H])(O)CC[C@]12C,,,,,0,,290.2245802,4,0,0,0,0,0
2509,04/06/2019 00:00,DB02855,N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline,,,,,,solid,,,8.23,3.86,-2.3,[H][C@](O)(CC(=O)N[C@]([H])(C(=O)N1CCC[C@@]1([H])C(O)=O)[C@@]([H])(C)CC)C(=O)NCCC,,,,,0,,385.2212857,1,0,1,0,1,1
2510,04/06/2019 00:00,DB02856,Methyl-Carbamic Acid Ethyl Ester,,,,,,solid,,,321,15.22,,CCOC(=O)NC,,,,,0,,103.0633285,0,0,0,0,0,0
2511,04/06/2019 00:00,DB02857,Guanosine,,,,,,solid,700 mg/L (at 18 Â°C),-1.9,15.3,10.16,1.79,NC1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(=O)N1,,,,,0,,283.0916685,3,2,3,2,1,1
2512,04/06/2019 00:00,DB02858,3-(4-Benzenesulfonyl-Thiophene-2-Sulfonylamino)-Phenylboronic Acid,,,,,,solid,,,0.014,6.11,-5.4,OB(O)C1=CC(NS(=O)(=O)C2=CC(=CS2)S(=O)(=O)C2=CC=CC=C2)=CC=C1,,,,,0,,423.0076306,3,3,1,1,0,0
2513,04/06/2019 00:00,DB02859,Soraphen A,,,,,,solid,,,0.00916,10.6,-3.4,[H]\C1=C([H])/[C@@]([H])(OC)[C@]([H])(CCCC[C@]([H])(OC(=O)[C@@]([H])(C)[C@@]2(O)O[C@]([H])([C@@]([H])(C)[C@]([H])(O)[C@@]2([H])OC)[C@@]1([H])C)C1=CC=CC=C1)OC,,,,,0,,520.3036184,3,1,2,0,1,2
2514,04/06/2019 00:00,DB02860,Calyculin A,,,,,,solid,,,0.249,1.15,8.22,[H][C@@]1(O[C@]2(C[C@@H](O)[C@H](C)[C@H](C\C=C\C3=COC(=N3)[C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)O2)C(C)(C)[C@H]1OP(O)(O)=O)[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC,,,,,0,,1008.543605,3,1,3,1,2,2
2515,04/06/2019 00:00,DB02861,"4-(Aminosulfonyl)-N-[(3,4,5-Trifluorophenyl)Methyl]-Benzamide",,,,,,solid,,,0.0118,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=CC(F)=C(F)C(F)=C1,,,,,0,,344.0442479,2,2,0,0,0,0
2516,04/06/2019 00:00,DB02862,Gluco-Phenylimidazole,,,,,,solid,,,9.89,12.32,4.53,[H][C@]1(CO)N2C=C(N=C2[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O)C1=CC=CC=C1,,,,,0,,276.111007,3,2,2,1,0,1
2517,04/06/2019 00:00,DB02864,Biliverdin Ix Gamma Chromophore,,,,,,solid,,,0.0147,3.46,6.69,[H]\C(=C1\N\C(=C(\[H])C2=NC(=O)C(CCC(O)=O)=C2C)C(C=C)=C1C)C1=C(C=C)C(C)=C(N1)C(\[H])=C1/N=C(O)C(CCC(O)=O)=C1C,,,,,0,,582.2478348,4,2,4,2,0,2
2518,04/06/2019 00:00,DB02865,Glucosamine 4-Phosphate,,,,,,solid,,,38.6,0.93,8.53,N[C@H]1[C@H](O)O[C@H](CO)[C@@H](OP(O)(O)=O)[C@@H]1O,,,,,0,,259.045703,1,0,1,0,1,1
2519,04/06/2019 00:00,DB02866,Dansylamide,,,,,,solid,,,0.212,9.97,4.63,CN(C)C1=C2C=CC=C(C2=CC=C1)S(N)(=O)=O,,,,,0,,250.0775987,2,2,0,0,0,0
2520,04/06/2019 00:00,DB02867,D-Mannose 1-Phosphate,,,,,,solid,,,32.3,1.16,-3,OC[C@H]1OC(OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O,,,,,0,,260.0297186,1,0,1,0,1,1
2521,04/06/2019 00:00,DB02868,"3''-(Beta-Chloroethyl)-2'',4''-Dioxo-3, 5''-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine",,,,,,solid,,,0.00934,14.41,8.97,[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)(C[C@@]22OC(=O)N(CCCl)C2=O)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC,,,,,0,,825.3868268,10,3,7,1,3,6
2522,04/06/2019 00:00,DB02869,3-amino-5-phenylpentane,,,,,,solid,,,0.00252,19.34,8.89,[H][C@](N)(CCC1=CC=CC=C1)C=CS(=O)(=O)C1=CC=CC=C1,,,,,0,,301.1136498,2,2,0,0,0,0
2523,04/06/2019 00:00,DB02870,N-Allyl-Aniline,,,,,,solid,,,7.31,,4.54,C=CCNC1=CC=CC=C1,,,,,0,,133.0891494,1,1,0,0,0,0
2524,04/06/2019 00:00,DB02871,3-Butylthiolane 1-Oxide,,,,,,solid,,,4.03,,-6.4,[H][C@]1(CCCC)CC[S@](=O)C1,,,,,0,,160.0921861,1,0,1,0,1,1
2525,04/06/2019 00:00,DB02872,"Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone",,,,,,solid,,,0.00547,15.59,6.77,[H][C@]1(N=C(N(C(=O)N2CCN(CCO)CC2)[C@]1([H])C1=CC=C(Br)C=C1)C1=C(OCC)C=C(OC)C=C1)C1=CC=C(Br)C=C1,,,,,0,,684.0946798,5,3,2,0,1,2
2526,04/06/2019 00:00,DB02873,"1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One",,,,,,solid,,,0.00592,15.38,8.86,FC1=CC=C(C(F)=C1)C1=C2CNC(=O)N(C2=CC(=C1)N1CCNCC1)C1=C(Cl)C=CC=C1Cl,,,,,0,,488.0982231,5,3,2,0,1,2
2527,04/06/2019 00:00,DB02875,CRA_1802,,,,,,solid,,,0.0402,8.4,10.58,NC(=[NH2+])C1=CC=C2NC(=NC2=C1)C1=CC(F)=CC=C1[O-],,,,,0,,270.0916892,3,3,1,1,0,0
2528,04/06/2019 00:00,DB02876,"3-(4-Carbamoyl-1-Carboxy-2-Methylsulfonyl-Buta-1,3-Dienylamino)-Indolizine-2-Carboxylic Acid",,,,,,solid,,,0.0409,3.68,8.08,[H]\C(=C(\[H])/C(/CS(=O)=O)=C(/NC1=C(C=O)C=C2C=CC=CN12)C(O)=O)C(O)=N,,,,,0,,377.0681562,2,2,2,2,0,0
2529,04/06/2019 00:00,DB02877,Arotinoid acid,,,,,,solid,,,0.000144,4.12,,C\C(=C/C1=CC=C(C=C1)C(O)=O)C1=CC=C2C(=C1)C(C)(C)CCC2(C)C,,,,,0,,348.2089301,3,2,0,0,0,0
2530,04/06/2019 00:00,DB02878,3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid,,,,,,solid,,,3.23,3.92,10.51,[H][C@](CN)(CCC(O)=O)[C@]([H])(CCN)CC(O)=O,,,,,0,,232.1423071,0,0,0,0,0,0
2531,04/06/2019 00:00,DB02879,"2,3-Di-O-Sulfo-Alpha-D-Glucopyranose",,,,,,solid,,,10.3,-2.6,-3,[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(OS(O)(=O)=O)[C@@]1([H])OS(O)(=O)=O,,,,,0,,339.9770178,1,0,1,0,1,1
2532,04/06/2019 00:00,DB02880,N-[1-(4-Bromophenyl)Ethyl]-5-Fluoro Salicylamide,,,,,,solid,,,0.0103,6.54,2.16,[H][C@](C)(N=C(O)C1=C(O)C=CC(F)=C1)C1=CC=C(Br)C=C1,,,,,0,,337.011369,2,2,0,0,0,0
2533,04/06/2019 00:00,DB02881,4-(4-Hydroxy-3-Isopropylphenylthio)-2-Isopropylphenol,,,,,,solid,,,0.00573,9.46,-5.7,CC(C)C1=CC(SC2=CC=C(O)C(=C2)C(C)C)=CC=C1O,,,,,0,,302.1340509,2,2,0,0,0,0
2534,04/06/2019 00:00,DB02882,Cyanocinnoline,,,,,,solid,,,0.000233,,7.49,NCC1=C(N=CC=C(C2=CC=CC=C2)C2=CC=CC=C2)C2=CC=CC=C2N=N1,,,,,0,,364.1687966,4,4,1,1,0,0
2535,04/06/2019 00:00,DB02883,"2',3'-Dideoxycytidine-5'-Monophosphate",,,,,,solid,,,11.2,1.34,0.011,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](COP(O)(O)=O)O1,,,,,0,,291.0620218,2,1,2,1,1,1
2536,04/06/2019 00:00,DB02884,Beta-Cyclohexyl-Alanine,,,,,,solid,,,2.52,2.73,9.52,N[C@@H](CC1CCCCC1)C(O)=O,,,,,0,,171.1259288,1,0,0,0,0,0
2537,04/06/2019 00:00,DB02885,4-Imino-5-Methidyl-2-Trifluoromethylpyrimidine,,,,,,solid,,,0.0245,,3.43,FC(F)(F)C1=NC(=N)C(=C)C=N1,,,,,0,,175.0357318,1,0,1,0,0,1
2538,04/06/2019 00:00,DB02887,"2',3'-Dehydro-2',3'-Deoxy-Thymidine 5'-Triphosphate",,,,,,solid,,,5.45,0.9,-4.2,CC1=CN([C@@H]2O[C@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)C=C2)C(=O)NC1=O,,,,,0,,463.9786984,2,1,2,1,0,1
2539,04/06/2019 00:00,DB02888,FKB-001,,,,,,solid,,,0.000295,,5.56,COC1=CC(=CC(OC)=C1OC)C(F)(F)C(=O)N1CCCC[C@H]1C(=O)O[C@@H](CCCC1=CC=CC=C1)CCCC1=CN=CC=C1,,,,,0,,624.3010935,4,3,2,1,1,1
2540,04/06/2019 00:00,DB02889,"4-O-(4,6-Dideoxy-4-{[4,5,6-Trihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}-Beta-D-Lyxo-Hexopyranosyl)-Alpha-D-Erythro-Hexopyranose",,,,,,solid,,,159,11.26,7.03,[H][C@]1(C)O[C@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])N[C@@]1([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,483.1951901,3,0,2,0,2,2
2541,04/06/2019 00:00,DB02890,6-Hydroxyuridine-5'-Phosphate,,,,,,solid,,,12.8,1.23,-3.7,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C(O)=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,340.0307812,2,1,2,1,1,1
2542,04/06/2019 00:00,DB02891,Tricyclazole,,,,,,solid,,,1.6,,0.84,CC1=C2N3C=NN=C3SC2=CC=C1,,,,,0,,189.0360682,3,3,2,2,0,0
2543,04/06/2019 00:00,DB02892,L-2-Amino-6-Methylene-Pimelic Acid,,,,,,solid,,,22,2.16,9.53,N[C@@H](CCCC(=C)C(O)=O)C(O)=O,,,,,0,,187.0844579,0,0,0,0,0,0
2544,04/06/2019 00:00,DB02893,D-Methionine,,,,,Intravenous,solid,,,23.9,2.53,9.5,CSCC[C@@H](N)C(O)=O,,,,,0,,149.0510496,0,0,0,0,0,0
2545,04/06/2019 00:00,DB02894,"Sulfamic Acid 2,3-O-(1-Methylethylidene)-4,5-O-Sulfonyl-Beta-Fructopyranose Ester",,,,,,solid,,,10.1,11.09,-4,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OS(=O)(=O)O2,,,,,0,,361.0137377,3,0,3,0,3,3
2546,04/06/2019 00:00,DB02895,3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol,,,,,,solid,,,5.26,8.36,-6.6,S\C=C\C[S@](=O)CC=C,,,,,0,,162.0173069,0,0,0,0,0,0
2547,04/06/2019 00:00,DB02896,Methylthioinosine,,,,,,solid,,0.09,8.21,12.45,4.5,CSC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,,,,,0,,298.0735759,3,2,3,2,1,1
2548,04/06/2019 00:00,DB02897,Acetylphosphate,,,,,,solid,,,17.8,1.24,-7.4,CC(=O)OP(O)(O)=O,,,,,0,,139.9874599,0,0,0,0,0,0
2549,04/06/2019 00:00,DB02898,5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone,,,,,,solid,,,0.17,6.97,5.22,[H][C@]1(COC2=NC(=N)NC3=C2N=CN3)CCC(O)=N1,,,,,0,,248.1021736,3,2,3,2,0,1
2550,04/06/2019 00:00,DB02899,N-Carboxymethionine,,,,,,solid,,,7.08,3.48,,[H][C@@](CCSC)(NC(O)=O)C(O)=O,,,,,0,,193.0408788,0,0,0,0,0,0
2551,04/06/2019 00:00,DB02900,alpha-D-mannose 6-phosphate,,,,,,solid,,,31.4,1.22,-3.6,[H][C@]1(O)O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@]1([H])O,,,,,0,,260.0297186,1,0,1,0,1,1
2552,04/06/2019 00:00,DB02901,Stanolone,Bioavailability is very low (0-2%) following oral administration.,,,,,solid,525 mg/mL (at 25 Â°C),3.55,0.00998,19.38,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C,,,,,0,,290.2245802,4,0,0,0,0,0
2553,04/06/2019 00:00,DB02902,3'-Phosphate-Adenosine-5'-Phosphate Sulfate,,,,,,solid,,,5.05,-2.1,4.94,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](OP(O)(O)=O)[C@H]1O,,,,,0,,506.9862298,3,2,3,2,1,1
2554,04/06/2019 00:00,DB02903,BV3,,,,,,solid,,,0.164,3.47,9.05,[H]C(N)(COC(O)=NCCNC1=C(NCCCN2CCN(CCCN=C(O)C3=CC(=CC(OC4([H])OC([H])(CO)C([H])(O)C([H])(O)C4([H])O)=C3)N(=O)=O)CC2)C(=O)C1=O)COC(O)=NCCNC1=C(NCCCN2CCN(CCCN=C(O)C3=CC(=CC(O[C@@]4([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]4([H])O)=C3)N(=O)=O)CC2)C(=O)C1=O,,,,,0,,1473.625968,8,4,4,0,4,4
2555,04/06/2019 00:00,DB02904,Beta-3-Serine,,,,,,solid,,,465,3.75,9.95,[H][C@](CN)(CO)C(O)=O,,,,,0,,119.0582431,0,0,0,0,0,0
2556,04/06/2019 00:00,DB02905,"Phosphoric Acid Mono-[3,4-Dihydroxy-5-(5-Hydroxy-Benzoimidazol-1-Yl)Tetrahydro-Furan-2-Ylmethyl] Ester",,,,,,solid,,,3.39,1.2,2.54,[H][C@]1(COP(O)(O)=O)O[C@]([H])(N2C=NC3=NC(O)=NC=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,348.0471,3,2,3,2,1,1
2557,04/06/2019 00:00,DB02906,"(2s,4s)-Alpha-Campholinic Acid",,,,,,solid,,,39.9,12.55,-3.7,[H][C@@]1(C)C(=O)C[C@@]([H])(CC(O)O)C1(C)C,,,,,0,,186.1255944,1,0,0,0,0,0
2558,04/06/2019 00:00,DB02907,2-Amino-Vinyl-Phosphate,,,,,,solid,,,18.8,1.4,5.25,N\C=C\OP(O)(O)=O,,,,,0,,139.0034443,0,0,0,0,0,0
2559,04/06/2019 00:00,DB02908,RU78783,,,,,,solid,,,8.42,1.13,,OP(O)(=O)C(C1=CC=CC=C1)P(O)(O)=O,,,,,0,,251.9952613,1,1,0,0,0,0
2560,04/06/2019 00:00,DB02909,5-(2-Chlorophenyl)Furan-2-Carboxylic Acid,,,,,,solid,,,0.064,3.13,-4.7,OC(=O)C1=CC=C(O1)C1=CC=CC=C1Cl,,,,,0,,222.0083718,2,2,1,1,0,0
2561,04/06/2019 00:00,DB02910,Octanoyl-Coenzyme A,,,,,,solid,,,3.47,0.83,4.95,CCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N,,,,,0,,893.219674,3,2,3,2,1,1
2562,04/06/2019 00:00,DB02911,"2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine",,,,,,solid,,,0.311,19.3,6.98,[H][C@]1(CNC2=C(N1)C(N)=NC(N)=N2)C1=CC=CC=C1,,,,,0,,242.1279944,3,2,2,1,0,1
2563,04/06/2019 00:00,DB02912,Propanoyl-CoA,,,,,,solid,,,4.27,0.83,4.95,CCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N,,,,,0,,823.1414237,3,2,3,2,1,1
2564,04/06/2019 00:00,DB02914,"(6e)-6-[(2e,4e,6e)-3,7-Dimethylnona-2,4,6,8-Tetraenylidene]-1,5,5-Trimethylcyclohexene",,,,,,solid,,,0.00223,,,[H]/C(=C(/[H])\C(\C)=C(/[H])\C(\[H])=C1\C(C)=CCCC1(C)C)/C(/[H])=C(\C)C=C,,,,,0,,268.2191009,1,0,0,0,0,0
2565,04/06/2019 00:00,DB02915,"4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine",,,,,,solid,,,0.00224,13.07,2.65,CC1=NC(C)=C(S1)C1=CC=NC(NC2=CC=C(C=C2)C(F)(F)F)=N1,,,,,0,,350.0813021,3,3,2,2,0,0
2566,04/06/2019 00:00,DB02916,"[(2r,3s,4r,5r)-5-(6-Amino-9h-Purin-9-Yl)-3,4-Dihydroxytetrahydro-2-Furanyl]Methyl Sulfamate",,,,,,solid,,,5.93,11.3,4.99,[H][C@]1(COS(N)(=O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,346.0695532,3,2,3,2,1,1
2567,04/06/2019 00:00,DB02917,N-Hydroxy-4-(Methyl{[5-(2-Pyridinyl)-2-Thienyl]Sulfonyl}Amino)Benzamide,,,,,,solid,,,0.0194,9.82,3.07,CN(C1=CC=C(C=C1)C(=O)NO)S(=O)(=O)C1=CC=C(S1)C1=NC=CC=C1,,,,,0,,389.050398,3,3,2,2,0,0
2568,04/06/2019 00:00,DB02918,Zardaverine,,,,,,solid,,,0.0993,10.34,-1.7,COC1=CC(=CC=C1OC(F)F)C1=NNC(=O)C=C1,,,,,0,,268.0659486,2,2,1,1,0,0
2569,04/06/2019 00:00,DB02919,"2,4-Diamino-6-[N-(3',4',5'-Trimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine",,,,,,solid,,,0.351,16.08,4.3,COC1=CC(CN(C)C2=CN=C3N=C(N)N=C(N)C3=C2)=CC(OC)=C1OC,,,,,0,,370.1753386,3,3,2,2,0,0
2570,04/06/2019 00:00,DB02920,Zn(Ii)-(20-Oxo-Protoporphyrin Ix),,,,,,solid,,,0.519,3.62,-6.4,CC1=C(CCC(O)=O)C2=CC3=C(CCC(O)=O)C(C)=C4N3[Zn]35N2C1=CC1=C(C=C)C(C)=C(C=C2N3C(C(C)=C2C=C)=C4O)N51,,,,,0,,640.1664123,8,4,8,4,0,4
2571,04/06/2019 00:00,DB02921,(South)-Methanocarba-Thymidine,,,,,,solid,,,38.7,10.3,-2.6,CC1=CN(C(=O)NC1=O)[C@]12C[C@H]1[C@H](CO)[C@@H](O)C2,,,,,0,,252.111007,3,1,1,1,0,0
2572,04/06/2019 00:00,DB02922,Hexafluoroacetone Hydrate,,,,,,solid,,,0.669,4.99,-7,OC(O)(C(F)(F)F)C(F)(F)F,,,,,0,,183.9958986,0,0,0,0,0,0
2573,04/06/2019 00:00,DB02923,"Biphenyl-2,3-Diol",,,,,,solid,,,0.552,9.15,-6.3,OC1=C(O)C(=CC=C1)C1=CC=CC=C1,,,,,0,,186.0680796,2,2,0,0,0,0
2574,04/06/2019 00:00,DB02924,"(4R)-limonene 1Î±,2Î±-epoxide",,,,,,solid,,,0.351,,-4.2,CC(=C)[C@@H]1CC[C@@]2(C)O[C@H]2C1,,,,,0,,152.1201151,2,0,1,0,1,1
2575,04/06/2019 00:00,DB02925,Piretanide,,,,,,solid,,3.92,0.0914,4.68,-0.62,NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O,,,,,0,,362.0936427,3,2,1,0,1,1
2576,04/06/2019 00:00,DB02927,"Mixed Carbamic Phosphoric Acid Anhydride of 7,8-Diaminononanic Acid",,,,,,solid,,,1.12,1.09,9.42,C[C@H](N)[C@@H](CCCCCC(O)=O)NC(=O)OP(O)(O)=O,,,,,0,,312.1086376,0,0,0,0,0,0
2577,04/06/2019 00:00,DB02928,3-Amino-6-Hydroxy-Tyrosine,,,,,,solid,,,3.21,0.99,9.05,N[C@@H](CC1=CC(N)=C(O)C=C1O)C(O)=O,,,,,0,,212.0797069,1,1,0,0,0,0
2578,04/06/2019 00:00,DB02929,K201,,,,,,solid,,,0.00037,,9.44,COC1=CC2=C(SCCN(C2)C(=O)CCN2CCC(CC3=CC=CC=C3)CC2)C=C1,,,,,0,,424.2184493,4,2,2,0,1,2
2579,04/06/2019 00:00,DB02930,Adenosine 5'-[Î³-thio]triphosphate,,,,,,solid,,,2.26,1.03,4.96,[H][C@]1(COP(O)(=O)OP(O)(=O)OP(O)(O)=S)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,522.9729018,3,2,3,2,1,1
2580,04/06/2019 00:00,DB02931,Coa-S-Acetyl Tryptamine,,,,,,solid,,,6.03,0.82,4.8,[H][C@](O)(C(O)=NCCC(O)=NCCSCC(O)=NCCC1=CNC2=CC=CC=C12)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,967.210172,5,4,4,3,1,1
2581,04/06/2019 00:00,DB02932,(R)-Bicalutamide,,,,,,solid,,,0.00928,11.95,-4,C[C@](O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F,,,,,0,,430.0610408,2,2,0,0,0,0
2582,04/06/2019 00:00,DB02933,5'-Deoxy-5'-(Methylthio)-Tubercidin,,,,,,solid,,,4.64,12.47,7.2,[H][C@]1(CSC)O[C@@]([H])(N2C=CC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,296.0943114,3,2,3,2,1,1
2583,04/06/2019 00:00,DB02934,9-(6-deoxy-alpha-L-talofuranosyl)-6-methylpurine,,,,,,solid,,,8.73,12.45,4.22,[H][C@@](C)(O)[C@@]1([H])O[C@@]([H])(N2C=NC3=C(C)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,280.117155,3,2,3,2,1,1
2584,04/06/2019 00:00,DB02935,Diglyme,,,,,,solid,,,60.9,,-3.7,COCCOCCOC,,,,,0,,134.0942943,0,0,0,0,0,0
2585,04/06/2019 00:00,DB02936,4-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric Acid,,,,,,solid,,,0.00529,4.16,-2.2,CC1=C(CC(N)=O)C2=C(C=CC(OCCCC(O)=O)=C2)N1CC1=CC=CC=C1,,,,,0,,380.1736072,3,3,1,1,0,0
2586,04/06/2019 00:00,DB02937,"Gamma-Arsono-Beta, Gamma-Methyleneadenosine-5'-Diphosphate",,,,,,solid,,,3.62,1.85,5.04,[H][C@]1(COP(O)(=O)OP(O)(=O)C[As](O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,548.9643158,3,2,3,2,1,1
2587,04/06/2019 00:00,DB02938,Heptanoic Acid,,,,,,solid,,,2.98,5.15,,CCCCCCC(O)=O,,,,,0,,130.0993797,0,0,0,0,0,0
2588,04/06/2019 00:00,DB02940,"(4s)-2-[(1e)-1-Aminoprop-1-Enyl]-4,5-Dihydro-1,3-Thiazole-4-Carboxylic Acid",,,,,,solid,,,1.65,3.6,4.23,[H][C@@]1(CSC(=N1)C(\N)=C\C)C(O)=O,,,,,0,,186.0462986,1,0,1,0,0,1
2589,04/06/2019 00:00,DB02941,3-(1-Aminoethyl)Nonanedioic Acid,,,,,,solid,,,1.27,3.98,10.46,[H][C@@](C)(N)[C@@]([H])(CCCCCC(O)=O)CC(O)=O,,,,,0,,231.1470582,0,0,0,0,0,0
2590,04/06/2019 00:00,DB02942,"Inositol 1,3-Bisphosphate",,,,,,solid,,,23.9,0.86,-3.6,O[C@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](O)[C@@H](OP(O)(O)=O)[C@@H]1O,,,,,0,,339.9960491,1,0,0,0,0,0
2591,04/06/2019 00:00,DB02943,N-(4-Aminobutanoyl)-S-(4-Methoxybenzyl)-L-Cysteinylglycine,,,,,,solid,,,0.112,3.4,10.22,[H][C@@](CSCC1=CC=C(OC)C=C1)(N=C(O)CCCN)C(O)=NCC(O)=O,,,,,0,,383.1514919,1,1,0,0,0,0
2592,04/06/2019 00:00,DB02945,alpha-L-iduronic acid,,,,,,solid,,,295,3.21,-3.7,[H][C@@]1(O)O[C@@]([H])(C(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,194.0426527,1,0,1,0,1,1
2593,04/06/2019 00:00,DB02946,Carpropamide,,,,,,solid,,,0.000173,5.64,2.38,[H][C@](C)(N=C(O)[C@]1(CC)[C@@]([H])(C)C1(Cl)Cl)C1=CC=C(Cl)C=C1,,,,,0,,333.0453972,2,1,0,0,0,0
2594,04/06/2019 00:00,DB02947,2-Fluoro-2'-Deoxyadenosine,,,,,,solid,,,9.17,13.89,0.73,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO)N1C=NC2=C(N)N=C(F)N=C12,,,,,0,,269.0924175,3,2,3,2,1,1
2595,04/06/2019 00:00,DB02948,Fosmidomycin,,,,,,solid,,,21.9,1.81,-5.6,ON(CCCP(O)(O)=O)C=O,,,,,0,,183.0296591,0,0,0,0,0,0
2596,04/06/2019 00:00,DB02949,2-Acetyl-Protoporphyrin Ix,,,,,,solid,,,1.05,3.14,10.31,CC1=C2C=C3[C@@H](C(O)=C)C(C)=C4C=C5N6C(=CC7=C(CCC(O)=O)C(C)=C8C=C([C@@H]1C=C)N2[Fe@@]6(N34)N78)C(CCC(O)=O)=C5C,,,,,0,,634.1878577,8,2,8,2,0,6
2597,04/06/2019 00:00,DB02950,Hymenialdisine,,,,,,solid,,,0.163,7.12,0.32,[H][C@@]12C=C(Br)N=C1C(=O)NCC[C@]2([H])C1=NC(N)=NC1=O,,,,,0,,323.0017867,3,0,3,0,1,3
2598,04/06/2019 00:00,DB02951,3-Hydroxypyruvic Acid,,,,,,solid,,,209,2.57,-3.4,OCC(=O)C(O)=O,,,,,0,,104.0109586,0,0,0,0,0,0
2599,04/06/2019 00:00,DB02952,Alpha-Aminoisobutyric Acid,,,,,,solid,,,337,2.58,9.72,CC(C)(N)C(O)=O,,,,,0,,103.0633285,0,0,0,0,0,0
2600,04/06/2019 00:00,DB02953,2-Thiomethyl-3-Phenylpropanoic Acid,,,,,,solid,,,0.28,4.63,-9.6,[H][C@](CS)(CC1=CC=CC=C1)C(O)=O,,,,,0,,196.0558006,1,1,0,0,0,0
2601,04/06/2019 00:00,DB02954,(Carboxyhydroxyamino)Ethanoic Acid,,,,,,solid,,,22.6,2.48,-6,ON(CC(O)=O)C(O)=O,,,,,0,,135.0167723,0,0,0,0,0,0
2602,04/06/2019 00:00,DB02955,Ricinoleic Acid,,,,,,solid,3460 mg/L (at 25 Â°C),,0.00254,4.99,-1.3,[H]\C(CCCCCCCC(O)=O)=C(/[H])C[C@]([H])(O)CCCCCC,,,,,0,,298.2507949,0,0,0,0,0,0
2603,04/06/2019 00:00,DB02957,Orotidine-5'-Monophosphate,,,,,,solid,,,8.61,1.21,-3.7,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(O)=O)N1C(=O)NC(=O)C=C1C(O)=O,,,,,0,,368.0256959,2,1,2,1,1,1
2604,04/06/2019 00:00,DB02958,Selenomethionine Selenoxide,,,,,,solid,,,105,1.6,9.11,[H][C@](N)(CC[Se](C)=O)C(O)=O,,,,,0,,212.9904145,0,0,0,0,0,0
2605,04/06/2019 00:00,DB02959,Oxitriptan,,,,,Oral,solid,,,3.63,2.15,9.18,N[C@@H](CC1=CNC2=C1C=C(O)C=C2)C(O)=O,,,,,0,,220.0847922,2,2,1,1,0,0
2606,04/06/2019 00:00,DB02960,1-Carboxyethylaminomethyl-4-Aminomethylbenzene,,,,,,solid,,,0.151,3.5,9.9,[NH3+]CC1=CC=C(CNCCC(O)=O)C=C1,,,,,1,,209.1284542,1,1,0,0,0,0
2607,04/06/2019 00:00,DB02961,Rhamnose,,,,,,solid,,,258,11.84,-3,[H][C@@](C)(O)[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(O)C=O,,,,,0,,164.0684735,0,0,0,0,0,0
2608,04/06/2019 00:00,DB02962,Benzimidazole,,,,,,solid,2010 mg/L (at 20 Â°C),1.32,17,12.25,5.79,N1C=NC2=CC=CC=C12,,,,,0,,118.0530982,2,2,1,1,0,0
2609,04/06/2019 00:00,DB02963,"(5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine",,,,,,solid,,,0.0314,16.96,1.35,CS(=O)(=O)C1=CC=C(NC2=CC(Cl)=NC3=CC=NN23)C=C1,,,,,0,,322.0291243,3,3,2,2,0,0
2610,04/06/2019 00:00,DB02964,"8,9,10-Trihydroxy-7-Hydroxymethyl-2-Thioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Decan-4-One",,,,,,solid,,,11.3,2.3,-1.4,[H][C@]1(CO)O[C@@]2(N=C(S)N=C2O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,264.0416071,2,0,2,0,1,2
2611,04/06/2019 00:00,DB02965,Ndelta-(N'-Sulphodiaminophosphinyl)-L-Ornithine,,,,,,solid,,,5.55,-1,9.33,[H][C@](N)(CCCN[P@@](N)(=O)NS(O)(=O)=O)C(O)=O,,,,,0,,290.0449918,0,0,0,0,0,0
2612,04/06/2019 00:00,DB02966,Fluoro-Willardiine,,,,,,solid,,,3.83,1.72,8.56,N[C@@H](CN1C=C(F)C(=O)NC1=O)C(O)=O,,,,,0,,217.049884,1,1,1,1,0,0
2613,04/06/2019 00:00,DB02967,N-Ethylmaleimide,,,,,,solid,,,254,,-4.3,CCN1C(=O)C=CC1=O,,,,,0,,125.0476785,1,0,1,0,0,1
2614,04/06/2019 00:00,DB02968,Penicillin G Acyl-Serine,,,,,,solid,,,0.106,1.32,8.76,[H][C@](N)(COC(=O)[C@@]([H])(N=C([O-])CC1=CC=CC=C1)[C@]1([H])N[C@@]([H])(C(O)=O)C(C)(C)S1)C([O-])=O,,,,,-2,,437.1267682,2,1,1,0,1,1
2615,04/06/2019 00:00,DB02969,4-Methyl-5-Hydroxyethylthiazole,,,,,,solid,,,2.26,15.62,3.12,CC1=C(CCO)SC=N1,,,,,0,,143.0404849,1,1,1,1,0,0
2616,04/06/2019 00:00,DB02970,2-Propyl-Aniline,,,,,,solid,,,1.75,,4.38,CCCC1=CC=CC=C1N,,,,,0,,135.1047994,1,1,0,0,0,0
2617,04/06/2019 00:00,DB02971,2-Amino-4-(2-Amino-Ethoxy)-Butyric Acid,,,,,,solid,,,159,2.45,9.75,[H][C@](N)(CCOCCN)C(O)=O,,,,,0,,162.1004423,0,0,0,0,0,0
2618,04/06/2019 00:00,DB02972,1-Benzyl-(R)-Propylamine,,,,,,solid,,,0.78,,10.04,CC[C@H](N)CC1=CC=CC=C1,,,,,0,,149.1204495,1,1,0,0,0,0
2619,04/06/2019 00:00,DB02973,4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide,,,,,,solid,,,0.024,10.03,-1,NS(=O)(=O)C1=CC=C(C=C1)\N=N\C1=C2C=C(Br)C=CC2=NC1=O,,,,,0,,391.9578732,3,2,1,0,0,1
2620,04/06/2019 00:00,DB02974,4-(4-Chlorophenyl)Imidazole,,,,,,solid,,,4.78,12.32,6.62,ClC1=CC=C(C=C1)C1=CN=CN1,,,,,0,,178.0297759,2,2,1,1,0,0
2621,04/06/2019 00:00,DB02975,GE-2270A,,,,,,solid,,,0.00897,-2.4,12.01,[H][C@](O)(C1=CC=CC=C1)[C@]1([H])N=C(O)CN=C(O)C2=C(COC)SC(=N2)[C@@]([H])(N=C(O)C2=C(C)SC(=N2)[C@]([H])(CC(O)=NC)N=C(O)C2=CSC(=N2)C2=C(N=C(C=C2)C2=NC(=CS2)C2=N[C@@]([H])(CO2)C(=O)N2CCC[C@@]2([H])C(O)=N)C2=CSC(=N2)C2=CSC1=N2)C(C)C,,,,,0,,1289.258059,11,8,10,7,1,3
2622,04/06/2019 00:00,DB02976,Uridine-5'-monophosphate 2-deoxy-2-fluoro-galactopyranosyl-monophosphate ester,,,,,,solid,,,43,1.73,-3,[H][C@]1(COP(O)(=O)OP(O)(=O)O[C@@]2([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]2([H])F)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,568.0506841,3,1,3,1,2,2
2623,04/06/2019 00:00,DB02977,PNU177836,,,,,,solid,,,0.101,2.74,8.39,[H][C@@](O)(N[C@@]([H])(CC1=CC=CC=C1)[C@]([H])(O)N[C@@]([H])(CC1=CC(C(O)=O)=C(OCC(O)=O)C=C1)[C@@]([H])(O)NCCCCC)OC(C)(C)C,,,,,0,,605.3312301,2,2,0,0,0,0
2624,04/06/2019 00:00,DB02978,Beta-Hydroxyleucine,,,,,,solid,,,217,2.44,8.99,CC(C)[C@H](O)[C@H](N)C(O)=O,,,,,0,,147.0895433,0,0,0,0,0,0
2625,04/06/2019 00:00,DB02979,"N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane",,,,,,solid,,,0.000307,,9.88,CS\C(N)=N\CCCCCCCCCCCCCC\N=C(/N)SC,,,,,0,,374.2537892,0,0,0,0,0,0
2626,04/06/2019 00:00,DB02980,Thymidine-5'-(Dithio)Phosphate,,,,,,solid,,,0.215,1.32,-3.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(S)=S)N1C=C(C)C(O)=NC1=O,,,,,0,,354.0109148,2,1,2,1,1,1
2627,04/06/2019 00:00,DB02981,Vitamin B6 Complexed with 2-Amino-Hexanoic Acid,,,,,,solid,,,0.687,1.19,10.08,[H][C@@](CCCC)(NCC1=C(COP(O)(O)=O)C=NC(C)=C1O)C(O)=O,,,,,0,,362.1242877,1,1,1,1,0,0
2628,04/06/2019 00:00,DB02982,Bombykol,,,,,,solid,,,0.00021,16.84,-2,[H]\C(CCC)=C(/[H])\C(\[H])=C(/[H])CCCCCCCCCO,,,,,0,,238.2296656,0,0,0,0,0,0
2629,04/06/2019 00:00,DB02983,Para-Mercury-Benzenesulfonic Acid,,,,,,solid,,,9.7,-2.5,,OS(=O)(=O)C1=CC=C([Hg])C=C1,,,,,0,,358.966583,1,1,0,0,0,0
2630,04/06/2019 00:00,DB02984,"4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline",,,,,,solid,,,0.00455,16.13,4.62,COC1=CC2=NC=NC(NC3=CC(SC)=CC=C3)=C2C=C1OC,,,,,0,,327.1041478,3,3,1,1,0,0
2631,04/06/2019 00:00,DB02985,8-Iodo-Guanine,,,,,,solid,,,0.357,-8.7,32.78,OC1=NC(=N)NC2=C1N=C(I)N2,,,,,0,,276.9460577,2,2,2,2,0,0
2632,04/06/2019 00:00,DB02986,"N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide",,,,,,solid,,,0.463,7.9,-8.2,NS(=O)(=O)C1=CC=C(S1)S(=O)(=O)NCC1=CC=CS1,,,,,0,,337.9523408,2,2,2,2,0,0
2633,04/06/2019 00:00,DB02987,Cysteine-S-Acetamide,,,,,,solid,,,21.5,2.07,8.83,N[C@@H](CSCC(N)=O)C(O)=O,,,,,0,,178.0412132,0,0,0,0,0,0
2634,04/06/2019 00:00,DB02988,Imino-Tryptophan,,,,,,solid,,,0.122,4.5,3.48,[H]N=C(CC1=CNC2=CC=CC=C12)C(O)=O,,,,,0,,202.0742276,2,2,1,1,0,0
2635,04/06/2019 00:00,DB02989,CRA_10972,,,,,,solid,,,0.00956,9.01,9.68,CC(C)COC1=CC=CC(C2=NC3=C(N2)C=C(Cl)C(=C3)C(N)=N)=C1O,,,,,0,,358.1196535,3,3,1,1,0,0
2636,04/06/2019 00:00,DB02990,C16-Fatty-Acyl-Substrate-Mimic,,,,,,solid,,,0.000217,15.78,-0.96,CCCCCCCCCCCCCCCC(=O)SCCNC(C)=O,,,,,0,,357.2701505,0,0,0,0,0,0
2637,04/06/2019 00:00,DB02991,S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea,,,,,,solid,,,0.0353,,6.11,CCS\C(N)=N\C1=CC=C(C=C1)C(F)(F)F,,,,,0,,248.059504,1,1,0,0,0,0
2638,04/06/2019 00:00,DB02992,1-Deoxy-6-O-Phosphono-1-[(Phosphonomethyl)Amino]-L-Threo-Hexitol,,,,,,solid,,,14.9,-0.58,6.77,[H][C@@](O)(CNCP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)COP(O)(O)=O,,,,,0,,355.0433337,0,0,0,0,0,0
2639,04/06/2019 00:00,DB02993,8-Methyl-9-Oxoguanine,,,,,,solid,,,7.71,9.81,-0.54,CC1=NC2=C(O1)N=C(N)NC2=O,,,,,0,,166.0490754,2,2,2,2,0,0
2640,04/06/2019 00:00,DB02994,Cacodylic acid,,,,,,solid,,,255,6.22,,C[As](C)(O)=O,,,,,0,,137.966201,0,0,0,0,0,0
2641,04/06/2019 00:00,DB02995,Cyclohexylammonium Ion,,,,,,solid,,,0.074,,10.45,[NH3+]C1CCCCC1,,,,,1,,100.1120759,1,0,0,0,0,0
2642,04/06/2019 00:00,DB02996,2-(Thiomethylene)-4-Methylpentanoic Acid,,,,,,solid,,,1.8,4.91,-9.6,[H][C@](CS)(CC(C)C)C(O)=O,,,,,0,,162.0714507,0,0,0,0,0,0
2643,04/06/2019 00:00,DB02998,Metribolone,,,,,,solid,,,0.0332,18.9,-0.53,[H][C@@]12CC[C@](C)(O)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H],,,,,0,,284.17763,4,0,0,0,0,0
2644,04/06/2019 00:00,DB02999,Quisqualate,,,,,,solid,,,53.6,1.46,8.56,N[C@@H](CN1OC(=O)NC1=O)C(O)=O,,,,,0,,189.0385703,1,1,1,1,0,0
2645,04/06/2019 00:00,DB03000,S-9-(2-hydroxypropyl)adenine,,,,,,solid,,,5.45,15.17,5.12,[H][C@@](C)(O)CN1C=NC2=C(N)N=CN=C12,,,,,0,,193.09636,2,2,2,2,0,0
2646,04/06/2019 00:00,DB03001,Peridinin,,,,,,solid,,,0.00088,14.04,-2.7,CC(=O)O[C@H]1CC(C)(C)C(=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C2/OC(=O)C(\C=C\[C@@]34O[C@]3(C)C[C@@H](O)CC4(C)C)=C2)[C@](C)(O)C1,,,,,0,,630.3556539,4,0,2,0,1,2
2647,04/06/2019 00:00,DB03002,p-Iodophenol,,,,,,solid,,,0.977,9.1,-6.3,OC1=CC=C(I)C=C1,,,,,0,,219.9385128,1,1,0,0,0,0
2648,04/06/2019 00:00,DB03003,Glutathione Sulfonic Acid,,,,,,solid,,,2.16,-1.7,9.54,[H][C@](N)(CCC(O)=N[C@@]([H])(CS(O)(=O)=O)C(O)=NCC(O)=O)C(O)=O,,,,,0,,355.0685501,0,0,0,0,0,0
2649,04/06/2019 00:00,DB03004,1-[(1s)-Carboxy-2-(Methylsulfinyl)Ethyl]-(3r)-[(5s)-5-Amino-5-Carboxypentanamido]-(4r)-Sulfanylazetidin-2-One,,,,,,solid,,,0.619,1.83,9.7,[H][C@](N)(CCCC(O)=N[C@]1([H])C(=O)N([C@]([H])(C[S@](C)=O)C(O)=O)[C@]1([H])S)C(O)=O,,,,,0,,395.082092,1,0,1,0,1,1
2650,04/06/2019 00:00,DB03005,"3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium",,,,,,solid,,,0.000296,,8.89,NC1=CC2=C(C=C1)C1=CC=C(N)C=C1C(C1=CC=CC=C1)=[N+]2CCCCCCC1=CN=NN1CCNC1=C2CCCCC2=NC2=C1C=CC=C2,,,,,1,,661.3761699,8,7,3,3,0,0
2651,04/06/2019 00:00,DB03006,Arsanilic acid,,,,,,solid,,,11,3.95,2.73,NC1=CC=C(C=C1)[As](O)(O)=O,,,,,0,,216.9720146,1,1,0,0,0,0
2652,04/06/2019 00:00,DB03007,"9r,13r-Opda",,,,,,solid,,,0.00322,4.78,-4.9,[H][C@@]1(CCCCCCCC(O)=O)C=CC(=O)[C@]1([H])CC=CCC,,,,,0,,292.2038448,1,0,0,0,0,0
2653,04/06/2019 00:00,DB03008,5-fluoro-beta-L-gulosyl fluoride,,,,,,solid,,,256,11.61,-3.6,[H][C@]1(O)[C@@]([H])(O)[C@]([H])(O)[C@](F)(CO)OC1([H])F,,,,,0,,200.0496299,1,0,1,0,1,1
2654,04/06/2019 00:00,DB03009,2-[(2-Oxo-2-Piperidin-1-Ylethyl)Thio]-6-(Trifluoromethyl)Pyrimidin-4(1h)-One,,,,,,solid,,,0.518,11.59,-1.1,OC1=CC(=NC(SCC(=O)N2CCCCC2)=N1)C(F)(F)F,,,,,0,,321.0758823,2,1,2,1,1,1
2655,04/06/2019 00:00,DB03010,Patupilone,,,,,,solid,,,0.00342,14.09,2.73,[H]\C(=C(\C)[C@]1([H])C[C@]2([H])O[C@]2(C)CCC[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)C(C)(C)[C@@]([H])(O)CC(=O)O1)C1=CSC(C)=N1,,,,,0,,507.265459,3,1,3,1,2,2
2656,04/06/2019 00:00,DB03011,Adenosine-5'-(Dithio)Phosphate,,,,,,solid,,,0.7,1.31,3.92,[H][C@]1(COP(O)(S)=S)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)C([H])(O)[C@]1([H])O,,,,,0,,379.0173972,3,2,3,2,1,1
2657,04/06/2019 00:00,DB03012,Phenylalanine-N-Sulfonamide,,,,,,solid,,,3.71,3.44,-1.4,[H][C@@](CC1=CC=CC=C1)(NS(N)(=O)=O)C(O)=O,,,,,0,,244.0517779,1,1,0,0,0,0
2658,04/06/2019 00:00,DB03013,Di(N-Acetyl-D-Glucosamine),,,,,,solid,,,24.7,6.89,1.7,[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])N=C(C)O)[C@]([H])(O)[C@@]1([H])N=C(C)O,,,,,0,,424.1693097,2,0,2,0,2,2
2659,04/06/2019 00:00,DB03015,"6-Hydroxy-1,6-Dihydro Purine Nucleoside",,,,,,solid,,,13,11.92,6.39,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C2[NH+]=CN[C@@]3([H])O)[C@]([H])(O)[C@]1([H])O,,,,,1,,271.103696,3,1,3,1,1,2
2660,04/06/2019 00:00,DB03016,CRA_1801,,,,,,solid,,,0.0834,8.47,11.39,NC(=N)C1=CC2=C(C=C1)N=C(N2)C1=C(O)C=CC=N1,,,,,0,,253.09636,3,3,2,2,0,0
2661,04/06/2019 00:00,DB03017,Lauric acid,,,,,Topical,solid,4.81 mg/L (at 25 Â°C),4.6,0.00997,4.95,,CCCCCCCCCCCC(O)=O,,,,,0,,200.17763,0,0,0,0,0,0
2662,04/06/2019 00:00,DB03018,"3,4-Dimethylaniline",,,,,,solid,,,4.48,,5.18,CC1=CC=C(N)C=C1C,,,,,0,,121.0891494,1,1,0,0,0,0
2663,04/06/2019 00:00,DB03019,"4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine",,,,,,solid,,,0.0358,16.46,3.45,NC1=NC=CC(=N1)C1=C(Cl)SC(Cl)=C1,,,,,0,,244.9581235,2,2,2,2,0,0
2664,04/06/2019 00:00,DB03020,5-Beta-D-Ribofuranosylnicotinamide Adenine Dinucleotide,,,,,,solid,,,3.64,2.58,5.87,[H][C@]1(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(C3=CC(=CN=C3)C(O)=N)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,663.1091218,5,3,5,3,2,2
2665,04/06/2019 00:00,DB03021,Ulapualide A,,,,,,solid,,,0.0132,14.03,4.36,[H]C(=C([H])C([H])(C)C([H])(OC(C)=O)[C@]([H])(C)C(=O)CC[C@]([H])(C)[C@]([H])(C[C@]1([H])OC(=O)C[C@@]([H])(O)CCCC(=O)C[C@]([H])(C)C2=COC(=N2)C2=COC(=N2)C2=COC(=N2)\C([H])=C([H])\C[C@]([H])(OC)[C@@]1([H])C)OC)N(C)CO,,,,,0,,882.4626382,4,3,4,3,0,1
2666,04/06/2019 00:00,DB03022,"3-{2,6,8-trioxo-9-[(2R,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate",,,,,,solid,,,8.49,1.76,-3,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)CN1C(=O)N(CCCOP(O)(O)=O)C2=C1N=C(O)N=C2O,,,,,0,,440.0944441,2,2,2,2,0,0
2667,04/06/2019 00:00,DB03023,"1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",,,,,,solid,,,0.0203,19.69,6.57,CC(C)(C)N1[NH+]=C(C2=C1N=CN=C2N)C1=CC=C(Cl)C=C1,,,,,1,,302.1166996,3,3,2,2,0,0
2668,04/06/2019 00:00,DB03024,2-Methyl-3-(2-Aminothiazolo)Propanal,,,,,,solid,,,2.37,14.42,4.69,[H][C@](C)(CC1=CSC(N)=N1)C=O,,,,,0,,170.0513839,1,1,1,1,0,0
2669,04/06/2019 00:00,DB03025,(S)-oct-1-en-3-ol,,,,,,solid,,,1.31,17.49,-1.7,CCCCC[C@H](O)C=C,,,,,0,,128.1201151,0,0,0,0,0,0
2670,04/06/2019 00:00,DB03026,Phosphoglycolohydroxamic Acid,,,,,,solid,,,13.8,1.32,-5.6,ONC(=O)COP(O)(O)=O,,,,,0,,170.9932735,0,0,0,0,0,0
2671,04/06/2019 00:00,DB03028,1h-Benoximidazole-2-Carboxylic Acid,,,,,,solid,,,3.12,1.83,3.64,OC(=O)C1=NC2=CC=CC=C2N1,,,,,0,,162.0429274,2,2,1,1,0,0
2672,04/06/2019 00:00,DB03030,4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole,,,,,,solid,,,0.0798,,5.43,CC1=CC=C(CN2C=NC(=C2)C2=CC=CS2)C=C1,,,,,0,,254.0877694,3,3,2,2,0,0
2673,04/06/2019 00:00,DB03031,Adamantane-1-Carboxylic Acid-5-Dimethylamino-Naphthalene-1-Sulfonylamino-Octyl-Amide,,,,,,solid,,,0.000133,9.91,4.63,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCCCCCCNC(=O)C12CC3CC(CC(C3)C1)C2,,,,,0,,539.3181633,6,2,0,0,0,0
2674,04/06/2019 00:00,DB03032,S-Octylglutathione,,,,,,solid,,,0.0322,2.03,9.54,[H][C@](N)(CCC(O)=N[C@@]([H])(CSCCCCCCCC)C(O)=NCC(O)=O)C(O)=O,,,,,0,,419.2090068,0,0,0,0,0,0
2675,04/06/2019 00:00,DB03033,1-Methyloxy-4-Sulfone-Benzene,,,,,,solid,,,0.959,5.26,-4.8,COC1=CC=C(C=C1)S(=O)=O,,,,,0,,172.0194151,1,1,0,0,0,0
2676,04/06/2019 00:00,DB03034,D-Levofloxacin,,,,,,solid,,,1.44,5.45,6.2,C[C@@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,,,,,0,,361.1437843,4,2,3,1,1,2
2677,04/06/2019 00:00,DB03035,"1,8-Di-Hydroxy-4-Nitro-Anthraquinone",,,,,,solid,,,0.19,7.11,-5.2,OC1=CC=CC2=C1C(=O)C1=C(O)C=CC(=C1C2=O)[N+]([O-])=O,,,,,0,,285.0273369,3,2,0,0,0,0
2678,04/06/2019 00:00,DB03037,Oxidized Acetyl Dithranol,,,,,,solid,,,0.147,2.95,-4.4,OC(=O)CC1=C(O)C2=C(C=C1)C(=O)C1=C(C(O)=CC=C1)C2=O,,,,,0,,298.047738,3,2,0,0,0,0
2679,04/06/2019 00:00,DB03038,LY341770,,,,,,solid,,,0.0542,3.2,7.19,[H][C@@](CCC1=NNN=N1)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O,,,,,0,,451.1716502,4,4,3,3,0,0
2680,04/06/2019 00:00,DB03039,"4-(Aminosulfonyl)-N-[(2,5-Difluorophenyl)Methyl]-Benzamide",,,,,,solid,,,0.0198,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=CC(F)=CC=C1F,,,,,0,,326.0536697,2,2,0,0,0,0
2681,04/06/2019 00:00,DB03040,Nitrilotriacetic Acid,,,,,,solid,,,31.7,1.78,5.58,OC(=O)CN(CC(O)=O)CC(O)=O,,,,,0,,191.042987,0,0,0,0,0,0
2682,04/06/2019 00:00,DB03041,UDP-alpha-D-glucuronic acid,,,,,,solid,,,18.1,1.72,-3.7,O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)O[C@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)C(O)=O)O[C@H]([C@@H]1O)N1C=CC(=O)NC1=O,,,,,0,,580.0342851,3,1,3,1,2,2
2683,04/06/2019 00:00,DB03042,5-Phosphoarabinonic Acid,,,,,,solid,,,20,1.48,-3.5,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)C(O)=O,,,,,0,,246.0140686,0,0,0,0,0,0
2684,04/06/2019 00:00,DB03043,"(S)-2-Amino-3-(6h-Selenolo[2,3-B]-Pyrrol-4-Yl)-Propionic Acid",,,,,,solid,,,10.8,1.84,9.38,[H][C@](N)(CC1=CNC2=C1C=C[Se]2)C(O)=O,,,,,0,,257.9907489,2,2,2,2,0,0
2685,04/06/2019 00:00,DB03044,1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea,,,,,,solid,,,0.00375,11.46,6.78,CC1=CC=C(C=C1)N1N=C(C=C1NC(=O)NC1=CC=C(OCCN2CCOCC2)C2=C1C=CC=C2)C(C)(C)C,,,,,0,,527.28964,5,4,2,1,1,1
2686,04/06/2019 00:00,DB03045,Pantothenyl-Aminoethanol-Acetate Pivalic Acid,,,,,,solid,,,0.624,12.69,-1.5,CC(=O)OCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COC(=O)C(C)(C)C,,,,,0,,388.2209514,0,0,0,0,0,0
2687,04/06/2019 00:00,DB03046,7-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-Carboximidamide,,,,,,solid,,,0.0945,,11.26,COC1=CC=C2C=CC(=CC2=C1C1=CN(N=C1)S(C)(=O)=O)C(N)=N,,,,,0,,344.0943114,3,3,1,1,0,0
2688,04/06/2019 00:00,DB03047,L-Alpha-Phosphatidyl-Beta-Oleoyl-Gamma-Palmitoyl-Phosphatidylethanolamine,,,,,,solid,,,0.000107,1.87,10,[H]\C(C)=C(\[H])CCC([H])=C([H])CC\C([H])=C(/[H])CCCCCCC(=O)OC[C@]([H])(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C([H])=C(/[H])C\C([H])=C(/[H])CCC,,,,,0,,709.4682548,0,0,0,0,0,0
2689,04/06/2019 00:00,DB03048,6-Carboxymethyluracil,,,,,,solid,,,4,3.77,-5.3,OC(=O)CC1=CC(=O)NC(=O)N1,,,,,0,,170.0327567,1,1,1,1,0,0
2690,04/06/2019 00:00,DB03049,S-Selanyl Cysteine,,,,,,solid,,,57.5,1.17,9.05,N[C@@H](CS[SeH])C(O)=O,,,,,0,,200.9362708,0,0,0,0,0,0
2691,04/06/2019 00:00,DB03051,Tetrahydrofuran-2-Carboxylic Acid,,,,,,solid,,,364,3.83,-4.2,OC(=O)[C@H]1CCCO1,,,,,0,,116.0473441,1,0,1,0,1,1
2692,04/06/2019 00:00,DB03052,Dazoxiben,,,,,,solid,,,1.28,4.36,6.77,OC(=O)C1=CC=C(OCCN2C=CN=C2)C=C1,,,,,0,,232.0847922,2,2,1,1,0,0
2693,04/06/2019 00:00,DB03053,1-Aminocyclopropylphosphonate,,,,,,solid,,,54.5,-0.29,10.06,NC1(CC1)[P@](O)([O-])=O,,,,,-1,,136.0169033,1,0,0,0,0,0
2694,04/06/2019 00:00,DB03054,Bromoform,,,,,,solid,,,1.88,,,BrC(Br)Br,,,,,0,,249.7628363,0,0,0,0,0,0
2695,04/06/2019 00:00,DB03056,4-Piperidino-Piperidine,,,,,,solid,,,14.8,,10.75,C1CCN(CC1)C1CCNCC1,,,,,0,,168.1626486,2,0,2,0,2,2
2696,04/06/2019 00:00,DB03057,Malonaldehyde,,,,,,solid,,,241,6.68,-6.8,O=CCC=O,,,,,0,,72.02112937,0,0,0,0,0,0
2697,04/06/2019 00:00,DB03058,2-Aminobenzyl alcohol,,,,,,solid,,,46.2,14.99,3.55,NC1=CC=CC=C1CO,,,,,0,,123.0684139,1,1,0,0,0,0
2698,04/06/2019 00:00,DB03059,Acetoacetyl-CoA,,,,,,solid,,,3.83,0.83,4.95,CC(=O)CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N,,,,,0,,851.1363383,3,2,3,2,1,1
2699,04/06/2019 00:00,DB03060,Sri-9662,,,,,,solid,,,0.0273,16.06,3.89,COC1=CC(\C=C/C2=C(C)C3=C(N)N=C(N)N=C3N=C2)=C(OC)C=C1,,,,,0,,337.1538748,3,3,2,2,0,0
2700,04/06/2019 00:00,DB03061,(R)-N-(1-Methyl-Hexyl)-Formamide,,,,,,solid,,,2.49,16.77,-0.2,CCCCC[C@H](C)NC=O,,,,,0,,143.1310142,0,0,0,0,0,0
2701,04/06/2019 00:00,DB03062,(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone,,,,,,solid,,,0.0425,,8.99,CN1C=CN=C1C(=O)C1=C(C)C2=C(O1)C=CC=C2OCCCNCC1=CN=CC=C1,,,,,0,,404.1848406,4,4,3,3,0,0
2702,04/06/2019 00:00,DB03063,"N-(1-Benzyl-3-{[3-(1,3-Dioxo-1,3-Dihydro-Isoindol-2-Yl)-Propionyl]-[2-(Hexahydro-Benzo[1,3]Dioxol-5-Yl)-Ethyl]-Amino}-2-Hydroxy-Propyl)-4-Benzyloxy-3,5-Dimethoxy-Benzamide",,,,,,solid,,,0.002,8.1,3.22,[H][C@](O)(CN(CC[C@]1([H])CCC2([H])OCOC2([H])C1)C(=O)CCN1C(=O)C2=CC=CC=C2C1=O)[C@]([H])(CC1=CC=CC=C1)N=C(O)C1=CC(OC)=C(OCC2=CC=CC=C2)C(OC)=C1,,,,,0,,805.3574448,7,4,2,0,1,2
2703,04/06/2019 00:00,DB03064,"3-Decyl-2,5-Dioxo-4-Hydroxy-3-Pyrroline",,,,,,solid,,,0.0538,6.66,-5.3,CCCCCCCCCCC1=C(O)C(=O)NC1=O,,,,,0,,253.1677936,1,0,1,0,0,1
2704,04/06/2019 00:00,DB03065,7-Nitroindazole-2-Carboxamidine,,,,,,solid,,,0.622,,8.66,NC(=N)N1C=C2C=CC=C(C2=N1)[N+]([O-])=O,,,,,0,,205.0599745,2,2,1,1,0,0
2705,04/06/2019 00:00,DB03066,D-Lactic acid,,,,,,solid,,,562,3.78,-3.7,C[C@@H](O)C(O)=O,,,,,0,,90.03169405,0,0,0,0,0,0
2706,04/06/2019 00:00,DB03067,"4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid",,,,,,solid,,,0.000419,2.84,-3.8,OC(=O)C1=C(C=C(OC2=C(NC(=O)C3=CC(=CC=C3)[N+]([O-])=O)C=C(NC(=O)C3=CC(=CC=C3)[N+]([O-])=O)C=C2)C=C1)C(O)=O,,,,,0,,586.0972074,4,4,0,0,0,0
2707,04/06/2019 00:00,DB03068,Zebularine,,,,,,solid,,,58.2,12.55,-3,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC=NC1=O,,,,,0,,228.0746215,2,1,2,1,1,1
2708,04/06/2019 00:00,DB03069,Cytidine-5'-Diphospho-Beta-D-Xylose,,,,,,solid,,,12.3,1.67,3.26,[H][C@]1(COP(O)(=O)OP(O)(=O)O[C@@]2([H])OC[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)O[C@@]([H])(N2C=CC(=N)N=C2O)[C@]([H])(O)[C@]1([H])O,,,,,0,,535.0604403,3,1,3,1,2,2
2709,04/06/2019 00:00,DB03070,Selenazole-4-Carboxyamide-Adenine Dinucleotide,,,,,,solid,,,7.19,1.85,5.05,[H][C@]1(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(C3=NC(=C[Se]3)C(O)=N)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,717.009993,5,3,5,3,2,2
2710,04/06/2019 00:00,DB03071,4-Methylidene-5-One,,,,,,solid,,,10.4,3.14,8.09,C[C@H](N)C1=NC(C)=C(O)N1CC(O)=O,,,,,0,,199.0956913,1,1,1,1,0,0
2711,04/06/2019 00:00,DB03072,"2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone",,,,,,solid,,,0.0126,9.95,8.78,CC1=CC=CC2=C1N=C(CCCN1CCC(=CC1)C1=CC=C(F)C=C1)NC2=O,,,,,0,,377.1903406,4,3,2,1,0,1
2712,04/06/2019 00:00,DB03073,3-Methoxybenzamide,,,,,,solid,,,4.58,14.16,-1.3,COC1=CC=CC(=C1)C(N)=O,,,,,0,,151.0633285,1,1,0,0,0,0
2713,04/06/2019 00:00,DB03074,7-Deaza-7-Cyano-Guanine,,,,,,solid,,,2.21,-1.9,18.64,OC1=NC(=N)NC2=C1C(=CN2)C#N,,,,,0,,175.0494098,2,2,2,2,0,0
2714,04/06/2019 00:00,DB03076,AHA047,,,,,,solid,,,0.0384,7.9,4.95,[H][C@@]1(O)[C@@]([H])(O)[C@@]([H])(COC2=CC=CC=C2)N(CC2=CC(=CC=C2)C(O)=NC)S(=O)(=O)N(CC2=CC=CC=C2)[C@]1([H])COC1=CC=CC=C1,,,,,0,,631.2352215,5,4,1,0,1,1
2715,04/06/2019 00:00,DB03077,"3-Amino-4-{3-[2-(2-Propoxy-Ethoxy)-Ethoxy]-Propylamino}-Cyclobut-3-Ene-1,2-Dione",,,,,,solid,,,0.71,,-1,CCCOCCOCCOCCCNC1=C(N)C(=O)C1=O,,,,,0,,300.1685219,1,1,0,0,0,0
2716,04/06/2019 00:00,DB03078,PASBN,,,,,,solid,,,0.441,1.33,-7.3,O[P@@](=O)(OCC1=CC=CC=C1)OC1=C(C=O)C=CC=C1,,,,,0,,292.0500601,2,2,0,0,0,0
2717,04/06/2019 00:00,DB03079,Alpha-Ribazole-5'-Phosphate Derivative,,,,,,solid,,,2.41,1.22,5.31,[H][C@]1(COP(O)(O)=O)O[C@]([H])(N2C=NC3=CC=CC=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,330.0616875,3,2,2,1,1,1
2718,04/06/2019 00:00,DB03081,Crc200 (Chiron-Behring),,,,,,solid,,,0.0262,3.7,11.6,[H][C@@](CC(O)=O)(NS(=O)(=O)C1=C(C)C=C(OC)C(C)=C1C)C(O)=N[C@]([H])(CC1=CC=C(C=C1)C(N)=N)C(=O)N1CCCCC1,,,,,0,,601.2570196,3,2,1,0,1,1
2719,04/06/2019 00:00,DB03082,6-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-Naphthamide,,,,,,solid,,,0.0116,11.79,11.12,NCC1=CC=C(NC(=O)C2=CC(NC3=NC=CC=N3)=C3C=C(C=CC3=C2)C(N)=N)C=C1,,,,,0,,411.1807583,4,4,1,1,0,0
2720,04/06/2019 00:00,DB03083,IC261,,,,,,solid,,,0.0104,11.31,-2,COC1=CC(OC)=C(\C=C2\C(=O)NC3=CC=CC=C23)C(OC)=C1,,,,,0,,311.115758,3,2,1,0,0,1
2721,04/06/2019 00:00,DB03084,"Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine",,,,,,solid,,,0.0081,15.07,8.89,CCCN1C(=NC(=C1C1=CC=NC(NC2CC2)=N1)C1=CC=C(Cl)C(Cl)=C1)C1CCN(C)CC1,,,,,0,,484.1909003,5,3,3,2,1,1
2722,04/06/2019 00:00,DB03085,Glycolic acid,,,,3 g/30mL,Topical,solid,,-1.11,608,3.53,-3.6,OCC(O)=O,,,,,0,,76.01604399,0,0,0,0,0,0
2723,04/06/2019 00:00,DB03086,"N'-(2s,3r)-3-Amino-4-Cyclohexyl-2-Hydroxy-Butano-N-(4-Methylphenyl)Hydrazide",,,,,,solid,,,0.0952,12.45,8.77,[H][C@@](N)(CC1CCCCC1)[C@]([H])(O)C(=O)NNC1=CC=C(C)C=C1,,,,,0,,305.2103271,2,1,0,0,0,0
2724,04/06/2019 00:00,DB03087,2-(Sec-Butyl)Thiazole,,,,,,solid,,,0.667,,3.34,CC[C@@H](C)C1=NC=CS1,,,,,0,,141.0612204,1,1,1,1,0,0
2725,04/06/2019 00:00,DB03088,Pidolic Acid,"In skin conditioning agents, it has been observed that the percutaneous absorption of 5, 10, and 20% sodium pidolic acid through human skin was 5.97, 6.78, and 5.89%, respectively [F53].",,Some studies have determined that the specific half-life of the N-terminal glutamic acid is about 9 months in a pH 4.1 buffer at 45 degrees Celsius [A33004].,1.5 g,Topical,solid,4.76E+005 mg/L (at 13 Â°C),,151,3.61,-1.8,OC(=O)[C@@H]1CCC(=O)N1,,,,,0,,129.0425931,1,0,1,0,1,1
2726,04/06/2019 00:00,DB03090,Ethylaminobenzylmethylcarbonyl Group,,,,,,solid,,,0.781,3.86,6.89,[H][C@@](CCCC)(N1CCN[C@]([H])(CC2=CC=CC=C2)C1=O)C(O)=O,,,,,0,,304.1786926,2,1,1,0,1,1
2727,04/06/2019 00:00,DB03091,4-Amido-4-Carbamoyl-Butyric Acid,,,,,,solid,,,79.7,4.06,8.46,N[C@@H](CCC(O)=O)C(N)=O,,,,,0,,146.0691422,0,0,0,0,0,0
2728,04/06/2019 00:00,DB03092,5-Hydroxymethyl-Chonduritol,,,,,,solid,,,412,12.65,-2.8,[H][C@]1(O)C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,176.0684735,1,0,0,0,0,0
2729,04/06/2019 00:00,DB03093,"8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine",,,,,,solid,,,0.173,10.3,1.93,COC1=CC(CC2=NC3=NC(F)=NC(N)=C3N2)=C(OC)C=C1,,,,,0,,303.1131529,3,3,2,2,0,0
2730,04/06/2019 00:00,DB03094,"3,5-Dihydro-5-Methylidene-4h-Imidazol-4-On",,,,,,solid,,,59.5,3.68,8.76,[H][C@@](C)(N)[C@@]1([H])N[C@@]([H])(CN)C(=O)N1CC(O)=O,,,,,0,,216.1222404,1,0,1,0,1,1
2731,04/06/2019 00:00,DB03095,Tetramethylammonium Ion,,,,,,solid,,,0.133,,,C[N+](C)(C)C,,,,,1,,74.0964258,0,0,0,0,0,0
2732,04/06/2019 00:00,DB03096,N-Aminoethylmorpholine,,,,,,solid,,,984,,9.37,NCCN1CCOCC1,,,,,0,,130.1106131,1,0,1,0,1,1
2733,04/06/2019 00:00,DB03097,"Pmp-Hydroxyisoxazole, Pyridoxamine-5-Phosphate-Hydroxyisoxazole",,,,,,solid,,,2.35,1.75,5.74,CC1=NC=C(COP(O)(O)=O)C(CNC2=CON=C2O)=C1O,,,,,0,,331.0569364,2,2,2,2,0,0
2734,04/06/2019 00:00,DB03098,[Methylseleno]Acetate,,,,,,solid,,,107,3.11,,C[Se]CC([O-])=O,,,,,-1,,152.9460243,0,0,0,0,0,0
2735,04/06/2019 00:00,DB03099,5-Amino 6-Nitro Uracil,,,,,,solid,,,1.97,6.07,-4.3,NC1=C(NC(=O)NC1=O)[N+]([O-])=O,,,,,0,,172.0232546,1,1,1,1,0,0
2736,04/06/2019 00:00,DB03100,6-Nitroindazole,,,,,,solid,,,4.58,13.61,0.11,O=N(=O)C1=CC2=NNC=C2C=C1,,,,,0,,163.0381764,2,2,1,1,0,0
2737,04/06/2019 00:00,DB03101,Ribose-1-Phosphate,,,,,,solid,,,35.2,1.16,-3,OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H]1O,,,,,0,,230.0191539,1,0,1,0,1,1
2738,04/06/2019 00:00,DB03102,"2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid",,,,,,solid,,,0.184,1.84,-4.2,OC(=O)C(=O)NC1=C(C(O)=O)C2=C(COCC2)S1,,,,,0,,271.015058,2,1,2,1,0,1
2739,04/06/2019 00:00,DB03103,Thymidine-5'- Diphosphate,,,,,,solid,,,6.94,1.77,-3.2,CC1=CN([C@H]2C[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O2)C(=O)NC1=O,,,,,0,,402.0229326,2,1,2,1,1,1
2740,04/06/2019 00:00,DB03104,RU82129,,,,,,solid,,,0.00137,3.58,2.05,[H]\C(=C(\N=C(C)O)C(O)=N[C@@]1([H])CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O)C1=CC(C=O)=C(CC(O)=O)C=C1,,,,,0,,567.2369358,4,3,1,0,1,1
2741,04/06/2019 00:00,DB03105,5-Hydroxy Norvaline,,,,,,solid,,,268,2.36,9.22,N[C@@H](CCCO)C(O)=O,,,,,0,,133.0738932,0,0,0,0,0,0
2742,04/06/2019 00:00,DB03106,scyllo-inositol,,,,,,solid,,,485,12.29,-3.6,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,180.0633881,1,0,0,0,0,0
2743,04/06/2019 00:00,DB03107,Beta-Alanine,,,,,,solid,5.45E+005 mg/L (at 25 Â°C),-3.05,494,4.08,10.31,NCCC(O)=O,,,,,0,,89.04767846,0,0,0,0,0,0
2744,04/06/2019 00:00,DB03108,4-phospho-D-erythronic acid,,,,,,solid,,,19.6,1.47,-3.6,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)C(O)=O,,,,,0,,216.0035039,0,0,0,0,0,0
2745,04/06/2019 00:00,DB03109,N-Acetyl-D-Allosamine,,,,,,solid,,,82.5,7.38,1.46,[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(O)[C@@]([H])(O)[C@@]1([H])N=C(C)O,,,,,0,,221.0899372,1,0,1,0,1,1
2746,04/06/2019 00:00,DB03110,2-Chlorophenol,,,,,,solid,,,14.8,7.97,-6.7,OC1=CC=CC=C1Cl,,,,,0,,128.0028925,1,1,0,0,0,0
2747,04/06/2019 00:00,DB03111,Glucosamine 1-Phosphate,,,,,,solid,,,35.1,1.18,8.69,N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(O)=O,,,,,0,,259.045703,1,0,1,0,1,1
2748,04/06/2019 00:00,DB03112,"6-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Hexanoic Acid",,,,,,solid,,,0.776,4.58,-1.9,[H][C@]12CS[C@@]([H])(CCCCCC(O)=O)[C@@]1([H])NC(=O)N2,,,,,0,,258.1038134,2,0,2,0,2,2
2749,04/06/2019 00:00,DB03113,3-Fluoro-2-(Phosphonooxy)Propanoic Acid,,,,,,solid,,,9.02,0.5,,[H][C@@](CF)(OP(O)(O)=O)C(O)=O,,,,,0,,187.9886028,0,0,0,0,0,0
2750,04/06/2019 00:00,DB03114,PAS219,,,,,,solid,,,0.65,1.37,-7.3,O[P@@](=O)(OCC1CCCCC1)OC1=C(C=O)C=CC=C1,,,,,0,,298.0970103,2,1,0,0,0,0
2751,04/06/2019 00:00,DB03115,"5-Bromo-N-(2,3-Dihydroxypropoxy)-3,4-Difluoro-2-[(2-Fluoro-4-Iodophenyl)Amino]Benzamide",,,,,,solid,,,0.0116,6.21,4.29,[H][C@](O)(CO)CON=C(O)C1=CC(Br)=C(F)C(F)=C1NC1=C(F)C=C(I)C=C1,,,,,0,,559.9055517,2,2,0,0,0,0
2752,04/06/2019 00:00,DB03116,5-(1-Carboxy-1-Phosphonooxy-Ethoxyl)-Shikimate-3-Phosphate,,,,,,solid,,,7.87,0.72,-3.6,[H][C@]1(CC(=C[C@@]([H])(OP(O)(O)=O)[C@@]1([H])O)C(O)=O)O[C@@](C)(OP(O)(O)=O)C(O)=O,,,,,0,,422.0015285,1,0,0,0,0,0
2753,04/06/2019 00:00,DB03117,2-Carboxypropyl-Coenzyme A,,,,,,solid,,,5.37,0.82,4.89,[H][C@](C)(CSCCN=C(O)CCN=C(O)[C@]([H])(O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O)C(O)=O,,,,,0,,853.1519884,3,2,3,2,1,1
2754,04/06/2019 00:00,DB03118,1-(5-Chloroindol-3-Yl)-3-Hydroxy-3-(2h-Tetrazol-5-Yl)-Propenone,,,,,,solid,,,0.226,6.68,-2.2,[H]\C(=C(\O)C1=NNN=N1)C(=O)C1=CNC2=C1C=C(Cl)C=C2,,,,,0,,289.0366522,3,3,2,2,0,0
2755,04/06/2019 00:00,DB03120,Para-Toluene Sulfonate,,,,,,solid,,,2.3,-2.1,,CC1=CC=C(C=C1)S(O)(=O)=O,,,,,0,,172.0194151,1,1,0,0,0,0
2756,04/06/2019 00:00,DB03121,(1-Benzyl-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid,,,,,,solid,,,0.0101,4.43,-4.8,COC1=CC2=C(C=C1)N(CC1=CC=CC=C1)C(C)=C2CC(O)=O,,,,,0,,309.1364935,3,3,1,1,0,0
2757,04/06/2019 00:00,DB03124,5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid,,,,,,solid,,,0.0278,2.42,-0.96,[H][C@@](CC(O)=O)(NC(=O)C1=CC=C(CNS(=O)(=O)C2=CC(C(O)=O)=C(O)C=C2)C=C1)C(C)=O,,,,,0,,464.0889512,2,2,0,0,0,0
2758,04/06/2019 00:00,DB03125,"2,4-Diamino-5-(3,4,5-Trimethoxy-Benzyl)-Pyrimidin-1-Ium",,,,,,solid,,,0.283,17.33,7.16,COC1=CC(CC2=C[NH+]=C(N)N=C2N)=CC(OC)=C1OC,,,,,1,,291.1451669,2,2,1,1,0,0
2759,04/06/2019 00:00,DB03126,Mant-Adp,,,,,,solid,,,1.91,2.25,5.01,[H][C@@]1(C[C@]([H])(OC(=O)C2=CC=CC=C2NC)[C@@]([H])(COP(O)(=O)OP(O)(O)=O)O1)N1C=NC2=C(N)N=CN=C12,,,,,0,,544.0872642,4,3,3,2,1,1
2760,04/06/2019 00:00,DB03127,Benzamidine,,,,,,solid,,,3.57,,11.53,NC(=[NH2+])C1=CC=CC=C1,,,,,1,,121.0760247,1,1,0,0,0,0
2761,02/07/2019 00:00,DB03128,Acetylcholine,,,,20 mg/2mL,Ophthalmic,solid,,,0.136,,-7,CC(=O)OCC[N+](C)(C)C,,,,,1,,146.1175552,0,0,0,0,0,0
2762,04/06/2019 00:00,DB03129,"[3-(1,3,2-Dioxaborolan-2-Yloxy)Propyl]Guanidine",,,,,,solid,,,37.3,,12.17,NC(=[NH2+])NCCCOB1OCCO1,,,,,1,,188.1200982,1,0,1,0,1,1
2763,04/06/2019 00:00,DB03130,S-P-Nitrobenzyloxycarbonylglutathione,,,,,,solid,,,0.286,1.76,9.31,[H]N([H])[C@@H](CCC(=O)N([H])[C@@H](CSC(O)OCC1=CC=C(C=C1)[N+]([O-])=O)C(=O)N([H])CC(O)=O)C(O)=O,,,,,0,,488.121314,1,1,0,0,0,0
2764,04/06/2019 00:00,DB03132,3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid,,,,,,solid,,,0.101,-1.3,1.11,OS(=O)(=O)CCCSC1=NC2=C(S1)C=CC=C2,,,,,0,,288.9901062,2,2,1,1,0,0
2765,04/06/2019 00:00,DB03133,"2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole",,,,,,solid,,,20.4,11.23,4.85,[H][C@]1(CO)O[C@@]([H])(C2=NC3=C(N2)C=C(C)C=C3)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,294.1215717,3,2,2,1,1,1
2766,04/06/2019 00:00,DB03134,2-Aminopimelic Acid,,,,,,solid,,,12.6,2.13,9.53,N[C@@H](CCCCC(O)=O)C(O)=O,,,,,0,,175.0844579,0,0,0,0,0,0
2767,04/06/2019 00:00,DB03135,[2(Formyl-Hydroxy-Amino)-Ethyl]-Phosphonic Acid,,,,,,solid,,,21.5,1.79,-5.7,ON(CCP(O)(O)=O)C=O,,,,,0,,169.014009,0,0,0,0,0,0
2768,04/06/2019 00:00,DB03136,4-Iodobenzo[B]Thiophene-2-Carboxamidine,,,,,,solid,,,0.0148,,8.59,NC(=[NH2+])C1=CC2=C(S1)C=CC=C2I,,,,,1,,302.9447437,2,2,1,1,0,0
2769,04/06/2019 00:00,DB03137,"8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine",,,,,,solid,,,0.0274,17.67,0.97,COC1=CC(CC2=NC3=C(N)N=C(F)N=C3N2CCCC#C)=C(OC)C=C1,,,,,0,,369.1601031,3,3,2,2,0,0
2770,04/06/2019 00:00,DB03139,"6-[5-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Pentanoylamino]-Hexanoic Acid",,,,,,solid,,,0.0693,4.47,0.074,[H][C@@]1(CCCCC(=O)NCCCCCC(O)=O)SC[C@]2([H])NC(=O)N[C@]12[H],,,,,0,,357.1722273,2,0,2,0,2,2
2771,04/06/2019 00:00,DB03140,4-Carboxyphenylboronic Acid,,,,,,solid,,,1.17,3.59,-5.5,OB(O)C1=CC=C(C=C1)C(O)=O,,,,,0,,166.0437391,1,1,0,0,0,0
2772,04/06/2019 00:00,DB03141,"3-{[(5R,6R)-5-Benzyl-6-hydroxy-2,4-bis(4-hydroxybenzyl)-3-oxo-1,2,4-triazepan-1-yl]sulfonyl}benzonitril",,,,,,solid,,,0.0141,9.19,-3.2,O[C@@H]1CN(N(CC2=CC=C(O)C=C2)C(=O)N(CC2=CC=C(O)C=C2)[C@@H]1CC1=CC=CC=C1)S(=O)(=O)C1=CC(=CC=C1)C#N,,,,,0,,598.1886057,5,4,1,0,1,1
2773,04/06/2019 00:00,DB03142,Alpha-L-Arabinose,,,,,,solid,,,1070,11.31,-3,OC[C@@H]1O[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,150.0528234,1,0,1,0,1,1
2774,04/06/2019 00:00,DB03143,Nonan-1-Ol,,,,,,solid,,,0.15,16.84,-2,CCCCCCCCCO,,,,,0,,144.1514153,0,0,0,0,0,0
2775,04/06/2019 00:00,DB03144,N-Omega-Hydroxy-L-Arginine,,,,,,solid,,,1.49,2.2,10.48,N[C@@H](CCCNC(=N)NO)C(O)=O,,,,,0,,190.1065903,0,0,0,0,0,0
2776,04/06/2019 00:00,DB03145,4-Methyl-5-Hydroxyethylthiazole Phosphate,,,,,,solid,,,2.73,1.61,2.58,CC1=C(CCOP(O)(O)=O)SC=N1,,,,,0,,223.0068154,1,1,1,1,0,0
2777,04/06/2019 00:00,DB03146,2-deazo-6-thiophosphate guanosine-5'-monophosphate,,,,,,solid,,,2.73,0.88,4.68,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2[NH+]=CN=C3SP(O)(O)=O)[C@]([H])(O)[C@]1([H])O,,,,,1,,444.9978634,3,2,3,2,1,1
2778,04/06/2019 00:00,DB03147,Flavin adenine dinucleotide,,,,,Oral,solid,,,4.25,1.86,4.99,CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO[P@](O)(=O)O[P@@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC3=C1N=CN=C3N)C1=NC(=O)NC(=O)C1=N2,,,,,0,,785.1571346,6,3,5,2,1,3
2779,04/06/2019 00:00,DB03148,Phosphomethylphosphonic Acid Adenosyl Ester,,,,,,solid,,,3.36,0.98,4.99,[H][C@]1(COP(O)(=O)CP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,425.0501504,3,2,3,2,1,1
2780,04/06/2019 00:00,DB03150,"2',3'-Dideoxythymidine-5'-Monophosphate",,,,,,solid,,,6.52,1.31,-4.2,CC1=CN([C@H]2CC[C@@H](COP(O)(O)=O)O2)C(=O)NC1=O,,,,,0,,306.0616875,2,1,2,1,1,1
2781,04/06/2019 00:00,DB03152,B-2-Octylglucoside,,,,,,solid,,,15.2,11.33,-3,[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])OCCCCCCCC,,,,,0,,292.1885886,1,0,1,0,1,1
2782,04/06/2019 00:00,DB03153,"3h-Pyrazolo[4,3-D]Pyrimidin-7-Ol",,,,,,solid,,,1.55,10.2,0.38,OC1=NC=NC2=C1N=NC2,,,,,0,,136.0385107,2,1,2,1,0,1
2783,04/06/2019 00:00,DB03154,{[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid,,,,,,solid,,,0.828,0.19,,OP(O)(=O)C(F)(F)C1=CC2=CC(=CC=C2C=C1)C(F)(F)P(O)(O)=O,,,,,0,,387.9888742,2,2,0,0,0,0
2784,04/06/2019 00:00,DB03155,"1-(2-Deoxy-2-Fluoro-3-O-Phosphono-Beta-L-Ribofuranosyl)Pyrimidine-2,4(1h,3h)-Dione",,,,,,solid,,,15.9,0.58,-3,[H][C@]1(CO)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(F)[C@]1([H])OP(O)(O)=O,,,,,0,,326.0315302,2,1,2,1,1,1
2785,04/06/2019 00:00,DB03156,beta-D-glucuronic acid,,,,,,solid,485 mg/mL,-2.57,295,3.21,-3.7,O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O,,,,,0,,194.0426527,1,0,1,0,1,1
2786,04/06/2019 00:00,DB03157,"N,O-Didansyl-L-Tyrosine",,,,,,solid,,,0.000995,2.89,4.9,[H][C@@](CC1=CC=C(OS(=O)(=O)C2=CC=CC3=C2C=CC=C3N(C)C)C=C1)(NS(=O)(=O)C1=CC=CC2=C1C=CC=C2N(C)C)C(O)=O,,,,,0,,647.1759924,5,5,0,0,0,0
2787,04/06/2019 00:00,DB03158,"D-Myo-Inositol-1,4-Bisphosphate",,,,,,solid,,,24.4,0.86,-3.7,O[C@H]1[C@@H](O)[C@@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1OP(O)(O)=O,,,,,0,,339.9960491,1,0,0,0,0,0
2788,04/06/2019 00:00,DB03159,CRA_8696,,,,,,solid,,,0.000198,9.36,11.22,NC(=[NH2+])C1=CC=C2NC(=CC2=C1)C1=CC=CC(=C1[O-])C1=CC=CC=C1,,,,,0,,327.1371622,4,4,1,1,0,0
2789,04/06/2019 00:00,DB03160,N-Pyridoxyl-7-Keto-8-Aminopelargonic Acid-5'-Monophosphate,,,,,,solid,,,0.239,1.74,7.99,[H][C@@](C)(NCC1=C(COP(O)(O)=O)C=NC(C)=C1O)C(=O)CCCCCC(O)=O,,,,,0,,418.1505025,1,1,1,1,0,0
2790,04/06/2019 00:00,DB03161,Thymidine-5'-Diphospho-Beta-D-Xylose,,,,,,solid,,,15,1.73,-3.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(=O)OP(O)(=O)O[C@@]1([H])OC[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O)N1C=C(C)C(O)=NC1=O,,,,,0,,534.0651913,3,1,3,1,2,2
2791,04/06/2019 00:00,DB03162,"4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid",,,,,,solid,,,5.27,2.68,-3.1,OC(=O)C1=NSN=C1O,,,,,0,,145.9786129,1,1,1,1,0,0
2792,04/06/2019 00:00,DB03163,2-oxopropyl-CoM,,,,,,solid,,,23.9,-1,-7.5,CC(=O)CSCCS(O)(=O)=O,,,,,0,,198.0020508,0,0,0,0,0,0
2793,04/06/2019 00:00,DB03164,6-Amino-1-Methylpurine,,,,,,solid,,,1.02,4.27,-0.75,C[N+]1=CNC2=NC=NC2=C1N,,,,,1,,150.0774217,2,0,2,0,0,2
2794,04/06/2019 00:00,DB03165,2-Dimethylamino-Ethyl-Diphosphate,,,,,,solid,,,14.6,1.76,9.1,CN(C)CCO[P@](O)(=O)OP(O)(O)=O,,,,,0,,249.016725,0,0,0,0,0,0
2795,04/06/2019 00:00,DB03166,Acetic acid,,,,0.25 g/100mL,Irrigation,solid,1E+006 mg/L (at 25 Â°C),-0.17,323,4.54,,CC(O)=O,,,,,0,,60.02112937,0,0,0,0,0,0
2796,04/06/2019 00:00,DB03167,Pentabromophenol,,,,,,solid,,,0.00206,5.01,-8.4,OC1=C(Br)C(Br)=C(Br)C(Br)=C1Br,,,,,0,,483.5944252,1,1,0,0,0,0
2797,04/06/2019 00:00,DB03168,Nicotinamide Adenine Dinucleotide Cyclohexanone,,,,,,solid,,,4.52,1.86,6.53,[H][C@]1(COP([O-])(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=C(C(=C3)C(O)=N)[C@]3([H])CCCCC3=O)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,759.1666367,6,3,5,3,2,2
2798,04/06/2019 00:00,DB03169,(S)-Hmg-Coa,,,,,,solid,,,9,0.82,4.84,[H][C@](O)(C([O-])=NCCC([O-])=NCCSC(=O)C[C@@](C)(O)CC([O-])=O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP([O-])([O-])=O,,,,,-5,,906.1210854,3,2,3,2,1,1
2799,04/06/2019 00:00,DB03170,Dephospho Coenzyme A,,,,,,solid,,,2.56,1.86,5,CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N)[C@@H](O)C(=O)NCCC(=O)NCCS,,,,,0,,687.1488784,3,2,3,2,1,1
2800,04/06/2019 00:00,DB03171,Indole-3-Propanol Phosphate,,,,,,solid,,,1.59,1.8,,OP(O)(=O)OCCCC1=CNC2=C1C=CC=C2,,,,,0,,255.0660446,2,2,1,1,0,0
2801,04/06/2019 00:00,DB03172,Tubercidin,,,,,,solid,3000 mg/L,-0.8,16.6,12.46,6.51,NC1=NC=NC2=C1C=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,,,,,0,,266.1015049,3,2,3,2,1,1
2802,04/06/2019 00:00,DB03173,CRA_10433,,,,,,solid,,,0.001,9.66,11.23,NC(=[NH2+])C1=CC=C2NC(=CC2=C1)C1=CC=CC(OC2CCCC2)=C1[O-],,,,,0,,335.1633769,4,3,1,1,0,0
2803,04/06/2019 00:00,DB03174,Phosphonoacetaldehyde,,,,,,solid,,,23.2,1.69,-7.3,OP(O)(=O)CC=O,,,,,0,,123.9925453,0,0,0,0,0,0
2804,04/06/2019 00:00,DB03175,Propyl alcohol,,,,,Topical,solid,1E+006 mg/L (at 25 Â°C),0.25,391,16.85,-2,CCCO,,,,,0,,60.05751488,0,0,0,0,0,0
2805,04/06/2019 00:00,DB03176,KB-141,,,,,,solid,,,0.00319,3.27,-3.7,CC(C)C1=CC(OC2=C(Cl)C=C(CC(O)=O)C=C2Cl)=CC=C1O,,,,,0,,354.0425644,2,2,0,0,0,0
2806,04/06/2019 00:00,DB03177,5-methylbenzimidazole,,,,,,solid,,,6.8,12.46,6,CC1=CC2=C(C=C1)N=CN2,,,,,0,,132.0687483,2,2,1,1,0,0
2807,04/06/2019 00:00,DB03178,"Guanosine-2',3'-Cyclophosphorothioate",,,,,,solid,,,0.934,1.85,4.95,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]2([H])O[P@@](O)(=S)O[C@]12[H],,,,,0,,361.0245907,4,2,4,2,2,2
2808,04/06/2019 00:00,DB03179,Sinapoyl Coenzyme A,,,,,,solid,,,6.05,0.81,4.04,[H]\C(=C(\[H])C1=CC(OC)=C(O)C(OC)=C1)C(=O)SCCN=C(O)CCN=C(O)C1(O)[C@]([H])(OP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@@]([H])(O)[C@]2([H])OP(O)(O)=O)C1(C)C,,,,,0,,971.1574677,5,3,3,2,1,1
2809,04/06/2019 00:00,DB03180,"4,5-Dimethyl-1,2-Phenylenediamine",,,,,,solid,,,13.1,,5.23,CC1=CC(N)=C(N)C=C1C,,,,,0,,136.1000484,1,1,0,0,0,0
2810,04/06/2019 00:00,DB03181,"2-[4-(4-Hydroxy-3-Isopropyl-Phenoxy)-3,5-Dimethyl-Phenyl]-2h-[1,2,4]Triazine-3,5-Dione",,,,,,solid,,,0.0101,7.33,-5.7,CC(C)C1=CC(OC2=C(C)C=C(C=C2C)N2N=CC(=O)NC2=O)=CC=C1O,,,,,0,,367.1532062,3,3,1,1,0,0
2811,04/06/2019 00:00,DB03182,Alpha-Fluoro-Carboxymethyldethia Coenzyme a Complex,,,,,,solid,,,6,0.82,4.81,[H][C@](F)(CCN=C(O)CCN=C(O)[C@]([H])(O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O)C(O)=O,,,,,0,,811.1391955,3,2,3,2,1,1
2812,04/06/2019 00:00,DB03183,"1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,,,,,solid,,,0.448,,4.66,CCOC(=O)C1=C(C)N(N=C1C)C1=CC=C(N)C=C1,,,,,0,,259.1320768,2,2,1,1,0,0
2813,04/06/2019 00:00,DB03184,5-Amino-3-Methyl-Pyrrolidine-2-Carboxylic Acid,,,,,,solid,,,193,3.13,8.62,[H][C@]1(N)C[C@@]([H])(C)[C@@]([H])(N1)C(O)=O,,,,,0,,144.0898776,1,0,1,0,1,1
2814,04/06/2019 00:00,DB03185,"1-Beta-Ribofuranosyl-1,3-Diazepinone",,,,,,solid,,,183,10.29,-3,[H][C@]1(CO)O[C@@]([H])(N2C=CC=CNC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,242.0902715,2,0,2,0,1,2
2815,04/06/2019 00:00,DB03186,U-Pi-a-Pi,,,,,,solid,,,14.6,0.68,4.92,[H][C@@]1(C[C@]([H])(OP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])OP(O)(O)=O)[C@@]([H])(COP(O)(O)=O)O1)N1C=CC(O)=NC1=O,,,,,0,,797.0261328,5,3,5,3,2,2
2816,04/06/2019 00:00,DB03187,6-(Hydroxyethyldithio)-8-(Aminomethylthio)Octanoic Acid,,,,,,solid,,,0.0505,4.06,8.33,[H][C@](CCCCC(O)=O)(CCSCN)SSCCO,,,,,0,,313.0840066,0,0,0,0,0,0
2817,04/06/2019 00:00,DB03189,Cu-Cyclam,,,,,,solid,,,0.294,,10.3,[Cu].C1CNCCNCCCNCCNC1,,,,,0,,263.1296943,1,0,1,0,1,1
2818,04/06/2019 00:00,DB03190,"N-Octanoyl-B-D-Fructofuranosyl-a-D-Glucopyranoside,Sucrose Monocaproylate",,,,,,solid,,,12.9,11.84,-3,[H][C@]1(COC(=O)CCCCCCC)O[C@@](CO)(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,468.2206766,2,0,2,0,2,2
2819,04/06/2019 00:00,DB03191,3-Oxiran-2ylalanine,,,,,,solid,,,457,2.08,9.45,[H][C@](N)(C[C@@]1([H])CO1)C(O)=O,,,,,0,,131.0582431,1,0,1,0,1,1
2820,04/06/2019 00:00,DB03192,3r-Hydroxydecanoyl-Coa,,,,,,solid,,,6.05,0.82,4.79,[H][C@@](O)(CCCCCCC)CC(=O)SCCN=C(O)CCN=C(O)[C@]([H])(O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,937.2458888,3,2,3,2,1,1
2821,04/06/2019 00:00,DB03193,Stearic acid,,,,16 g/100mL,Topical,solid,0.597 mg/L (at 25 Â°C),8.23,6.61E-05,4.95,,CCCCCCCCCCCCCCCCCC(O)=O,,,,,0,,284.2715304,0,0,0,0,0,0
2822,04/06/2019 00:00,DB03194,beta-L-methyl-fucose,,,,,,solid,,,812,12.23,-3.6,[H][C@@]1(C)O[C@]([H])(OC)[C@@]([H])(O)[C@]([H])(O)[C@]1([H])O,,,,,0,,178.0841235,1,0,1,0,1,1
2823,04/06/2019 00:00,DB03195,"Phosphoric Acid Mono-[3-Fluoro-5-(5-Methyl-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Tetrahyro-Furan-2-Ylmethyl] Ester",,,,,,solid,,,6.05,1.22,-4.2,[H][C@]1(F)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C(C)C(=O)NC1=O,,,,,0,,324.0522656,2,1,2,1,1,1
2824,04/06/2019 00:00,DB03196,4-Nitrophenyl-Ara,,,,,,solid,,,15.8,12.26,-3,[H][C@@]1(CO)O[C@@]([H])(OC2=CC=C(C=C2)[N+]([O-])=O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,271.0692018,2,1,1,0,1,1
2825,04/06/2019 00:00,DB03197,6-Hydroxymethylpterin,,,,,,solid,,,1.8,9.99,1.2,NC1=NC2=NC=C(CO)N=C2C(=O)N1,,,,,0,,193.0599745,2,2,2,2,0,0
2826,04/06/2019 00:00,DB03198,Thio-Maltohexaose,,,,,,solid,,,243,11.22,-3.7,[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(S[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]3([H])O[C@]([H])(CO)[C@@]([H])(S[C@@]4([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]5([H])O[C@]([H])(CO)[C@@]([H])(S[C@@]6([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]6([H])O)[C@]([H])(O)[C@@]5([H])O)[C@]([H])(O)[C@@]4([H])O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,1038.258974,6,0,6,0,6,6
2827,04/06/2019 00:00,DB03199,4-Methoxy-E-Rhodomycin T,,,,,,solid,,,0.431,9.22,8.32,[H][C@@]1(C[C@]([H])(N(C)C)[C@]([H])(O)[C@]([H])(C)O1)O[C@@]1([H])C[C@](O)(CC)[C@]([H])(C(=O)OC)C2=C(O)C3=C(C(O)=C12)C(=O)C1=C(C=CC=C1OC)C3=O,,,,,0,,599.236661,5,2,1,0,1,1
2828,04/06/2019 00:00,DB03200,7-Alpha-D-Ribofuranosyl-Purine-5'-Phosphate,,,,,,solid,,,3.28,4.14,1.22,[H][C@]1(COP(O)(O)=O)O[C@]([H])(N2C=NC3=NC=NC=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,332.0521854,3,2,3,2,1,1
2829,04/06/2019 00:00,DB03201,D-Cysteine,,,,,,solid,,,23.1,2.35,9.05,N[C@H](CS)C(O)=O,,,,,0,,121.0197495,0,0,0,0,0,0
2830,04/06/2019 00:00,DB03202,"2-[5-Methanesulfonylamino-2-(4-Aminophenyl)-6-Oxo-1,6-Dihydro-1-Pyrimidinyl]-N-(3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl)Acetamide",,,,,,solid,,,0.00422,6.87,3.58,[H][C@](NC(=O)CN1C(=O)C(NS(C)(=O)=O)=CN=C1C1=CC=C(N)C=C1)(C(C)C)C(=O)C(F)(F)F,,,,,0,,489.1293745,2,2,1,1,0,0
2831,04/06/2019 00:00,DB03203,Sphingosine,,,,,,solid,,,0.0039,14.12,9.23,[H]\C(CCCCCCCCCCCCC)=C(\[H])[C@@]([H])(O)[C@@]([H])(N)CO,,,,,0,,299.2824294,0,0,0,0,0,0
2832,04/06/2019 00:00,DB03204,5-(Aminomethyl)-2-Methylpyrimidin-4-Amine,,,,,,solid,,,19.5,,8.5,CC1=NC=C(CN)C(N)=N1,,,,,0,,138.0905463,1,1,1,1,0,0
2833,04/06/2019 00:00,DB03205,Pyrroloquinoline Quinone,,,,,,solid,,,0.0966,3.05,-3.3,OC(=O)C1=CC2=C(N1)C1=C(N=C(C=C1C(O)=O)C(O)=O)C(=O)C2=O,,,,,0,,330.0124152,3,2,2,2,0,0
2834,04/06/2019 00:00,DB03206,Duvoglustat,,,,,,solid,,-1.8,511,12.91,8.06,OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,163.0844579,1,0,1,0,1,1
2835,04/06/2019 00:00,DB03207,"2-(Biphenyl-4-Sulfonyl)-1,2,3,4-Tetrahydro-Isoquinoline-3-Carboxylic Acid",,,,,,solid,,,0.00214,3.35,,[H][C@@]1(CC2=C(CN1S(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1)C=CC=C2)C(O)=O,,,,,0,,393.1034791,4,3,1,0,0,1
2836,04/06/2019 00:00,DB03208,"Beta-1,2,3,4,6-Penta-O-Galloyl-D-Glucopyranose",,,,,,solid,,,0.679,7.43,-5.5,[H][C@@]1(COC(=O)C2=CC(O)=C(O)C(O)=C2)O[C@@]([H])(OC(=O)C2=CC(O)=C(O)C(O)=C2)[C@@]([H])(OC(=O)C2=CC(O)=C(O)C(O)=C2)[C@@]([H])(OC(=O)C2=CC(O)=C(O)C(O)=C2)[C@]1([H])OC(=O)C1=CC(O)=C(O)C(O)=C1,,,,,0,,940.1181811,6,5,1,0,1,1
2837,04/06/2019 00:00,DB03209,Oteracil,"After administration of a single dose of 50 mg Teysuno (expressed as tegafur content), median Tmax for Teysuno components tegafur, gimeracil, and oteracil was 0.5, 1.0, and 2.0 hours, respectively [L933].",0.523,"Following a single dose of Teysuno, T1/2 values ranged from 6.7 to 11.3 hours for tegafur, from 3.1 to 4.1 hours for gimeracil, and from 1.8 to 9.5 hours for oteracil [L933].",,Oral,solid,,,7.15,2.14,,OC(=O)C1=NC(=O)NC(=O)N1,0.523,0.523,,,0,,157.0123556,1,1,1,1,0,0
2838,04/06/2019 00:00,DB03210,4-Aminohydrocinnamic Acid,,,,,,solid,,,2.04,3.61,5.5,NC1=CC=C(CCC(O)=O)C=C1,,,,,0,,165.0789786,1,1,0,0,0,0
2839,04/06/2019 00:00,DB03211,(3-Formyl-but-3-Enyl)-Phosphonic Acid,,,,,,solid,,,15.4,1.8,-4.5,OP(O)(=O)CCC(=C)C=O,,,,,0,,164.0238454,0,0,0,0,0,0
2840,04/06/2019 00:00,DB03212,4-Deoxyglucarate,,,,,,solid,,,560,2.96,-3.3,[H][C@](O)(C[C@]([H])(O)[C@@]([H])(O)C([O-])=O)C([O-])=O,,,,,-2,,192.0280998,0,0,0,0,0,0
2841,04/06/2019 00:00,DB03213,Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone,,,,,,solid,,,0.00839,7.47,11.5,NC(=N)C1=CC2=C(C=C1)N=C(N2)C(=O)C1=NC2=C(N1)C=CC(=C2)C([NH3+])=[NH2+],,,,,2,,348.14361,4,4,2,2,0,0
2842,04/06/2019 00:00,DB03214,Vinylglycine,,,,,,solid,,,250,2.42,8.95,N[C@@H](C=C)C(O)=O,,,,,0,,101.0476785,0,0,0,0,0,0
2843,04/06/2019 00:00,DB03215,"(2s,5s)-5-Carboxymethylproline",,,,,,solid,,,43.9,1.51,11.33,[H][C@@]1(CC(O)=O)CC[C@]([H])(N1)C(O)=O,,,,,0,,173.0688078,1,0,1,0,1,1
2844,04/06/2019 00:00,DB03216,"(1'R,2'S)-9-(2-Hydroxy-3'-Keto-Cyclopenten-1-yl)Adenine",,,,,,solid,,,6.86,13.19,5.09,NC1=NC=NC2=C1N=CN2[C@@H]1C=C[C@H](O)[C@H]1O,,,,,0,,233.0912746,3,2,2,2,0,0
2845,04/06/2019 00:00,DB03217,DPI59,,,,,,solid,,,1.83,1.22,-4.2,[H][C@@](O)(C1=CC=CC2=CC=CC=C12)P(O)(O)=O,,,,,0,,238.0394955,2,2,0,0,0,0
2846,04/06/2019 00:00,DB03218,N-Acetyl-N'-Beta-D-Glucopyranosyl Urea,,,,,,solid,,,11.9,6.59,-0.38,[H][C@]1(CO)O[C@@]([H])(N=C(O)N=C(C)O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,264.0957509,1,0,1,0,1,1
2847,04/06/2019 00:00,DB03219,11-Deoxy-Beta-Rhodomycin,,,,,,solid,,,0.292,8.82,8.17,[H][C@]1(O)C[C@]([H])(O[C@]2([H])[C@]([H])(C)O[C@]([H])(C[C@]2([H])N(C)C)O[C@@]2([H])C[C@](O)(CC)[C@]([H])(O)C3=C2C(O)=C2C(=O)C4=C(C=CC=C4O)C(=O)C2=C3)O[C@@]([H])(C)[C@]1([H])O[C@@]1([H])CCC(=O)[C@@]([H])(C)O1,,,,,0,,769.3309553,7,2,3,0,3,3
2848,04/06/2019 00:00,DB03220,FR233623,,,,,,solid,,,0.0202,13.88,3.53,[H][C@@](C)(O)[C@@]([H])(CCC1=CC=CC2=C1C=CC=C2)N1C=NC(=C1)C(N)=O,,,,,0,,323.1633769,3,3,1,1,0,0
2849,04/06/2019 00:00,DB03221,AL7099A,,,,,,solid,,,0.263,8.17,6.44,CN[C@@H]1CN(C2=CC(OC)=CC=C2)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,,,,,0,,403.0330336,3,2,2,1,0,1
2850,04/06/2019 00:00,DB03222,dATP,,,,,,solid,,,3.83,0.9,5.01,NC1=NC=NC2=C1N=CN2[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1,,,,,0,,491.0008308,3,2,3,2,1,1
2851,04/06/2019 00:00,DB03223,Diphthamide,,,,,,solid,,,0.124,1.5,9.25,C[N+](C)(C)[C@@H](CCC1=NC(C[C@H](N)C(O)=O)=CN1)C(N)=O,,,,,1,,298.187366,1,1,1,1,0,0
2852,04/06/2019 00:00,DB03224,2-Formyl-Protoporphryn Ix,,,,,,solid,,,0.00611,1.76,11.76,[Fe+4].[H]\C(O)=C1/C(C)=C2[N-]/C/1=C([H])\C1=C(C)[C@@]([H])(C=C)\C([N-]1)=C([H])\C1=C(C)C(CCC(O)=O)=C([N-]1)\C([H])=C1/[N-]/C(=C\2/[H])C(C)=C1CCC(O)=O,,,,,0,,620.1722076,5,3,5,3,0,2
2853,04/06/2019 00:00,DB03225,D-Tryptophan,,,,,,solid,,,1.36,2.54,9.4,N[C@H](CC1=CNC2=CC=CC=C12)C(O)=O,,,,,0,,204.0898776,2,2,1,1,0,0
2854,04/06/2019 00:00,DB03226,Trifluoroethanol,,,,,,solid,,,55.8,11.49,-4.3,OCC(F)(F)F,,,,,0,,100.0135994,0,0,0,0,0,0
2855,04/06/2019 00:00,DB03227,Nicotinamide Mononucleotide,,,,,,solid,,,1.8,1.21,-2.2,NC(=O)C1=CC=C[N+](=C1)[C@@H]1O[C@@H](COP(O)(O)=O)[C@H](O)[C@H]1O,,,,,1,,335.0638785,2,1,2,1,1,1
2856,04/06/2019 00:00,DB03228,"5-[Bis-2(Chloro-Ethyl)-Amino]-2,4-Dintro-Benzamide",,,,,,solid,,,0.00931,11.29,-2.5,NC(=O)C1=C(C=C(C(=C1)N(CCCl)CCCl)[N+]([O-])=O)[N+]([O-])=O,,,,,0,,350.0184748,1,1,0,0,0,0
2857,04/06/2019 00:00,DB03229,2-Oxo-4-Methylpentanoic Acid,,,,,,solid,,,6.76,3.53,-9.7,CC(C)CC(=O)C(O)=O,,,,,0,,130.0629942,0,0,0,0,0,0
2858,04/06/2019 00:00,DB03230,Adenosine-5'-Propylphosphate,,,,,,solid,,,2.98,1.92,4.99,[H][C@]1(COP(O)(=O)OCCC)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,389.1100346,3,2,3,2,1,1
2859,04/06/2019 00:00,DB03231,"3-(5-Amino-7-oxo-3,7-dihydro-2H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(2-{[2-(hydroxymethyl)phenyl]sulfanyl}benzyl)benzamide",,,,,,solid,,,0.0321,4.62,-1.1,[H]N([H])C1=NC(=O)C2=NN(N([H])C2=N1)C1=CC=CC(=C1)C(=O)N([H])CC1=CC=CC=C1SC1=CC=CC=C1CO,,,,,0,,499.1426585,5,3,2,0,0,2
2860,04/06/2019 00:00,DB03232,"2-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-Octamethyldotriaconta-2,6,10,14,18,22,26,30-Octaenyl]Phenol",,,,,,solid,,,0.000226,9.33,-6,CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=CC=CC=C1O,,,,,0,,638.5426669,1,1,0,0,0,0
2861,04/06/2019 00:00,DB03233,"Phosphoric Acid Mono-[3-Amino-5-(5-Methyl-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Tetrahydro-Furan-2-Ylmethyl] Ester",,,,,,solid,,,9.03,1.26,9.21,[H][C@]1(N)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C(C)C(O)=NC1=O,,,,,0,,321.0725865,2,1,2,1,1,1
2862,04/06/2019 00:00,DB03234,"(4'-{[Allyl(Methyl)Amino]Methyl}-1,1'-Biphenyl-4-Yl)(4-Bromophenyl)Methanone",,,,,,solid,,,8.61E-05,,8.53,CN(CC=C)CC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)C1=CC=C(Br)C=C1,,,,,0,,419.0884764,3,3,0,0,0,0
2863,04/06/2019 00:00,DB03235,N-{3-[4-(3-aminopropyl)piperazin-1-yl]propyl}-3-(alpha-D-galactopyranosyloxy)-5-nitrobenzamide,,,,,,solid,,,1.59,6.91,10.18,[H][C@]1(CO)O[C@]([H])(OC2=CC(=CC(=C2)N(=O)=O)C(O)=NCCCN2CCN(CCCN)CC2)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,527.2591278,3,1,2,0,2,2
2864,04/06/2019 00:00,DB03236,(2s)-4-(Beta-Alanylamino)-2-Aminobutanoic Acid,,,,,,solid,,,28.3,2.35,9.41,NCCC(=O)NCC[C@H](N)C(O)=O,,,,,0,,189.1113413,0,0,0,0,0,0
2865,04/06/2019 00:00,DB03237,"2,3-Dihydroxy-5-Oxo-Hexanedioate",,,,,,solid,,,262,2.5,-3.3,O[C@@H](CC(=O)C([O-])=O)[C@@H](O)C([O-])=O,,,,,-2,,190.0124497,0,0,0,0,0,0
2866,04/06/2019 00:00,DB03238,"3,5-Difluoroaniline",,,,,,solid,,,8.24,,2.05,NC1=CC(F)=CC(F)=C1,,,,,0,,129.0390056,1,1,0,0,0,0
2867,04/06/2019 00:00,DB03239,"3',5'-Dinitro-N-Acetyl-L-Thyronine",,,,,,solid,,,0.00894,2.96,-1.5,[H][C@@](CC1=CC=C(OC2=CC(=C(O)C(=C2)[N+]([O-])=O)[N+]([O-])=O)C=C1)(NC(C)=O)C(O)=O,,,,,0,,405.0808291,2,2,0,0,0,0
2868,04/06/2019 00:00,DB03240,"(S)-2-Amino-3-(1,3,5,7-Pentahydro-2,4-Dioxo-Cyclopenta[E]Pyrimidin-1-Yl) Proionic Acid",,,,,,solid,,,25.4,1.92,8.47,N[C@@H](CN1C2=C(CCC2)C(=O)NC1=O)C(O)=O,,,,,0,,239.0906059,2,1,1,1,0,0
2869,04/06/2019 00:00,DB03241,1-Amino-1-Carbonyl Pentane,,,,,,solid,,,43.6,17.46,8.09,[H][C@](N)(CCCC)C=O,,,,,0,,115.099714,0,0,0,0,0,0
2870,04/06/2019 00:00,DB03242,P-Aminophenyl-Alpha-D-Galactopyranoside,,,,,,solid,,,32.9,12.2,4.74,[H][C@]1(CO)O[C@]([H])(OC2=CC=C(N)C=C2)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,271.1055873,2,1,1,0,1,1
2871,04/06/2019 00:00,DB03243,4-Fluorobenzylamine,,,,,,solid,,,0.184,,9.44,[NH3+]CC1=CC=C(F)C=C1,,,,,1,,126.0713539,1,1,0,0,0,0
2872,04/06/2019 00:00,DB03244,"(S)-2-[4-(Aminomethyl)-1h-1,2,3-Triazol-1-Yl]-4-Methylpentanoic Acid",,,,,,solid,,,5.75,3.49,8.24,[H][C@@](CC(C)C)(N1C=C(CN)N=N1)C(O)=O,,,,,0,,212.1273258,1,1,1,1,0,0
2873,04/06/2019 00:00,DB03245,S-4-Nitrobutyryl-Coa,,,,,,solid,,,6.39,0.82,4.79,[H][C@](O)(C(O)=NCCC(O)=NCCSC(=O)CCCN(=O)=O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,882.142152,3,2,3,2,1,1
2874,04/06/2019 00:00,DB03246,Beta-L-Arabinose,,,,,,solid,,,1070,11.31,-3,OC[C@@H]1O[C@H](O)[C@H](O)[C@H]1O,,,,,0,,150.0528234,1,0,1,0,1,1
2875,02/07/2019 00:00,DB03247,Flavin mononucleotide,,,,1.46 mg/1mL,Oral,solid,,,0.668,1.57,0.68,CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)C1=NC(=O)NC(=O)C1=N2,,,,,0,,456.1046149,3,1,2,0,0,2
2876,04/06/2019 00:00,DB03248,2-(Phosphonooxy)Butanoic Acid,,,,,,solid,,,22.1,1.14,,CC[C@@H](OP(O)(O)=O)C(O)=O,,,,,0,,184.0136746,0,0,0,0,0,0
2877,04/06/2019 00:00,DB03249,2'-O-Methyl-3'-Methyl-3'-Deoxy-Arabinofuranosyl-Thymine-5'-Phosphate,,,,,,solid,,,4.89,1.3,-3.9,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=C(C)C(=O)NC2=O)[C@]([H])(OC)[C@]1([H])C,,,,,0,,350.0879022,2,1,2,1,1,1
2878,04/06/2019 00:00,DB03250,"2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole",,,,,,solid,,,1.39,12.46,1.64,[H][C@]1(CO)O[C@@]([H])(C2=NC3=CC(C)=CC=C3S2)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,311.0827436,3,2,2,1,1,1
2879,04/06/2019 00:00,DB03251,RWJ-51084,,,,,,solid,,,0.0487,12.68,11.8,[H][C@@](CCCNC(N)=N)(NC(=O)C1CCCC1)C(=O)C1=NC2=C(S1)C=CC=C2,,,,,0,,387.172896,3,2,1,1,0,0
2880,04/06/2019 00:00,DB03252,D-Lysine,,,,,,solid,,,105,2.74,10.29,[H][C@@](N)(CCCCN)C(O)=O,,,,,0,,146.1055277,0,0,0,0,0,0
2881,04/06/2019 00:00,DB03253,(2s)-Pyrrolidin-2-Ylmethylamine,,,,,,solid,,,427,,10.97,NC[C@@H]1CCCN1,,,,,0,,100.1000484,1,0,1,0,1,1
2882,04/06/2019 00:00,DB03254,4-Phenyl-1h-Imidazole,,,,,,solid,,,28.9,12.32,6.62,N1C=NC=C1C1=CC=CC=C1,,,,,0,,144.0687483,2,2,1,1,0,0
2883,02/07/2019 00:00,DB03255,Phenol,Phenol is rapidly absorbed through the skin and into the lungs. ,,,1 mg/1mL,Oral,solid,8.28E+004 mg/L (at 25 Â°C),1.46,46.6,10.02,-5.5,OC1=CC=CC=C1,,,,,0,,94.04186481,1,1,0,0,0,0
2884,04/06/2019 00:00,DB03256,(6R)-Folinic acid,,,,,,solid,,,0.176,-3.2,15,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(NC[C@]2([H])CNC3=C(N2C=O)C(O)=NC(=N)N3)C=C1)C(O)=O,,,,,0,,473.1658961,3,2,2,1,0,1
2885,04/06/2019 00:00,DB03257,"5-[1-(Acetylamino)-3-Methylbutyl]-2,5-Anhydro-3,4-Dideoxy-4-(Methoxycarbonyl)Pentonic Acid",,,,,,solid,,,9.29,3.89,-0.27,[H][C@@](CC(C)C)(NC(C)=O)[C@]1([H])O[C@]([H])(C[C@@]1([H])C(=O)OC)C(O)=O,,,,,0,,301.1525375,1,0,1,0,1,1
2886,04/06/2019 00:00,DB03258,2'-Deoxycytidine 5'-triphosphate,,,,,,solid,,,11.8,0.95,-0.05,NC1=NC(=O)N(C=C1)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1,,,,,0,,466.9895975,2,1,2,1,1,1
2887,04/06/2019 00:00,DB03259,"2',6'-Dichloro-Biphenyl-2,6-Diol",,,,,,solid,,,0.0784,8.92,-6.3,OC1=CC=CC(=C1O)C1=C(Cl)C=CC=C1Cl,,,,,0,,253.9901349,2,2,0,0,0,0
2888,04/06/2019 00:00,DB03260,"1,6-Diaminohexane",,,,,,solid,,,23.4,,10.51,NCCCCCCN,,,,,0,,116.1313485,0,0,0,0,0,0
2889,04/06/2019 00:00,DB03262,"Al-6619, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Hydroxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]",,,,,,solid,,,0.146,8.12,4.31,NS(=O)(=O)C1=CC2=C(S1)S(=O)(=O)N(C(CN1CCOCC1)=C2)C1=CC(O)=CC=C1,,,,,0,,457.0435983,4,2,3,1,1,2
2890,04/06/2019 00:00,DB03263,Thiocellobiose,,,,,,solid,,,431,11.29,-3,[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(S[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,358.0933679,2,0,2,0,2,2
2891,04/06/2019 00:00,DB03264,Dodecyl-Coa,,,,,,solid,,,2.59,0.83,4.95,CCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C(N)N=CN=C12,,,,,0,,949.2822743,3,2,3,2,1,1
2892,04/06/2019 00:00,DB03266,Glutaral,,,,,,solid,,,64,14.48,-6.6,O=CCCCC=O,,,,,0,,100.0524295,0,0,0,0,0,0
2893,04/06/2019 00:00,DB03267,1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine,,,,,,solid,,,0.16,7.86,-0.69,CCCCN1C2=C(NC(CC3=CC=C(NC(C)=O)C=C3)=N2)C(=O)N(CC=C)C1=O,,,,,0,,395.1957397,3,3,2,2,0,0
2894,04/06/2019 00:00,DB03268,RU82197,,,,,,solid,,,0.00271,4.12,1.73,[H][C@@](CC1=CC(C=O)=C(C=C1)C(O)=O)(N=C(C)O)C(O)=N[C@@]1([H])CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O,,,,,0,,555.2369358,4,3,1,0,1,1
2895,04/06/2019 00:00,DB03269,"4,6-Dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino}hexopyranose",,,,,,solid,,,168,11.31,6.73,[H][C@]1(C)O[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])N[C@@]1([H])C=C(CO)C([H])(O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,321.1423667,2,0,1,0,1,1
2896,04/06/2019 00:00,DB03270,"2,6-Difluorobenzenesulfonamide",,,,,,solid,,,1.62,7.36,,NS(=O)(=O)C1=C(F)C=CC=C1F,,,,,0,,193.0009058,1,1,0,0,0,0
2897,04/06/2019 00:00,DB03272,4-Bromo-3-(5'-Carboxy-4'-Chloro-2'-Fluorophenyl)-1-Methyl-5-Trifluoromethyl-Pyrazol,,,,,,solid,,,0.0104,3.11,0.44,CN1N=C(C(Br)=C1C(F)(F)F)C1=CC(C(O)=O)=C(Cl)C=C1F,,,,,0,,399.9237301,2,2,1,1,0,0
2898,04/06/2019 00:00,DB03273,3'-Oxo-Adenosine,,,,,,solid,,,13.6,11.71,4.99,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)C1=O,,,,,0,,265.0811038,3,2,3,2,1,1
2899,04/06/2019 00:00,DB03274,2'-5'dideoxyuridine,,,,,,solid,,,12.5,7.94,-3.2,[H][C@]1(C)O[C@]([H])(C[C@]1([H])O)N1C=CC(O)=NC1=O,,,,,0,,212.0797069,2,1,2,1,1,1
2900,04/06/2019 00:00,DB03275,2-Amino-3-Mercapto-Propionamide,,,,,,solid,,,3.59,4.2,9.13,[H][C@](N)(CS)C(O)=N,,,,,0,,120.0357339,0,0,0,0,0,0
2901,04/06/2019 00:00,DB03276,"4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid",,,,,,solid,,,0.000825,1.74,-0.21,NC(=O)C[C@@H]1NC(=O)C2(CCCCC2)NC(=O)C[C@H](\C=C\C[C@H](CNC1=O)CC1=CC=CC2=CC=CC=C12)C1=CC=C(C=C1)CP(O)(O)=O,,,,,0,,688.3025864,5,3,1,0,0,1
2902,04/06/2019 00:00,DB03277,alpha-maltotriose,,,,,,solid,,,554,11.22,-3.6,[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]3([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,504.1690349,3,0,3,0,3,3
2903,04/06/2019 00:00,DB03278,D-Treitol,,,,,,solid,,,1160,13.04,-3,OC[C@H](O)[C@@H](O)CO,,,,,0,,122.0579088,0,0,0,0,0,0
2904,04/06/2019 00:00,DB03279,Dodecyl-Alpha-D-Maltoside,,,,,,solid,,,2.28,11.94,-3,[H][C@]1(O)[C@]([H])(O)[C@@]([H])(CO)O[C@]([H])(O[C@@]2([H])[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(OCCCCCCCCCCCC)O[C@]2([H])CO)[C@]1([H])O,,,,,0,,510.3040123,2,0,2,0,2,2
2905,04/06/2019 00:00,DB03280,P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate,,,,,,solid,,,9.73,0.41,5,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)N1C=C(C)C(O)=NC1=O,,,,,0,,891.0081134,5,3,5,3,2,2
2906,04/06/2019 00:00,DB03281,2'-Deoxymaltose,,,,,,solid,,,545,11.98,-3,[H][C@@]1(O)C[C@@]([H])(O)[C@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@@]([H])(CO)O1,,,,,0,,326.1212969,2,0,2,0,2,2
2907,04/06/2019 00:00,DB03283,beta-L-fucose,,,,,,solid,,,827,11.3,-3.6,C[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@@H]1O,,,,,0,,164.0684735,1,0,1,0,1,1
2908,04/06/2019 00:00,DB03284,"2,6-Anhydro-3-Deoxy-D-Erythro-Hex-2-Enonic Acid",,,,,,solid,,,274,3.43,-3.4,[H][C@]1(O)COC(=C[C@]1([H])O)C(O)=O,,,,,0,,160.0371734,1,0,1,0,0,1
2909,04/06/2019 00:00,DB03285,"2',4,4'-Trihydroxychalcone",,,,,,solid,,,0.0551,7.75,-5.9,OC1=CC=C(\C=C\C(=O)C2=CC=C(O)C=C2O)C=C1,,,,,0,,256.0735589,2,2,0,0,0,0
2910,04/06/2019 00:00,DB03286,C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide,,,,,,solid,,,54.6,11.92,7.51,[H]C(N)(O)[C@]1(O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O)N=[N+]=[N-],,,,,0,,250.0913342,1,0,1,0,1,1
2911,04/06/2019 00:00,DB03287,4-(2-Amino-Ethoxy)-2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-but-3-Enoic Acid,,,,,,solid,,,0.378,1.79,9.5,[H]\C(OCCN)=C(\[H])/C(=N\CC1=C(COP(O)(O)=O)C=NC(C)=C1O)/C(O)=O,,,,,0,,389.0988012,1,1,1,1,0,0
2912,04/06/2019 00:00,DB03288,5-Chloro-1h-Indole-2-Carboxylic Acid{[Cyclopentyl-(2-Hydroxy-Ethyl)-Carbamoyl]-Methyl}-Amide,,,,,,solid,,,0.287,12.21,7.75,[H][C@@](O)(CNC(=O)C1=CC2=CC(Cl)=CC=C2N1)N(CCO)C1CCCC1,,,,,0,,365.1506193,3,2,1,1,0,0
2913,04/06/2019 00:00,DB03289,Thiarsa Dihydroxy Cysteine,,,,,,solid,,,37.5,1.29,8.56,[H][C@](N)(CS[As](O)O)C(O)=O,,,,,0,,228.9390002,0,0,0,0,0,0
2914,04/06/2019 00:00,DB03290,L-naphthyl-1-acetamido boronic acid alanine,,,,,,solid,,,0.0583,2.14,8.59,[H][C@](N)(CO[B-](O)(O)[C@]([H])(CC1=CC=CC2=CC=CC=C12)N=C(C)O)C(O)=O,,,,,-1,,361.1576404,2,2,0,0,0,0
2915,04/06/2019 00:00,DB03291,4-Deoxy-4-Amino-Beta-D-Glucose,,,,,,solid,,,537,11.32,8.18,[H][C@]1(N)[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(O)O[C@]1([H])CO,,,,,0,,179.0793725,1,0,1,0,1,1
2916,04/06/2019 00:00,DB03292,3-Phosphono-D-alanine,,,,,,solid,,,34.7,1.4,9.83,[H][C@@](N)(CP(O)(O)=O)C(O)=O,,,,,0,,169.014009,0,0,0,0,0,0
2917,04/06/2019 00:00,DB03293,9-Methyl Uric Acid,,,,,,solid,,,3.6,7.63,-6.2,CN1C(=O)NC2=C1NC(=O)NC2=O,,,,,0,,182.0439901,2,2,2,2,0,0
2918,04/06/2019 00:00,DB03294,"1-Methyl-3-Oxo-1,3-Dihydro-Benzo[C]Isothiazole-5-Sulfonic Acid Amide",,,,,,solid,,,3.96,10.07,-5.2,CN1SC(=O)C2=CC(=CC=C12)S(N)(=O)=O,,,,,0,,243.9976341,2,2,1,1,0,0
2919,04/06/2019 00:00,DB03295,Glutathionylspermidine,,,,,,solid,,,0.101,1.88,10.89,[H][C@](N)(CCC(O)=N[C@@]([H])(CS)C(O)=NCC(O)=NCCCNCCCCN)C(O)=O,,,,,0,,434.2311392,0,0,0,0,0,0
2920,04/06/2019 00:00,DB03296,3'-beta-Sialyl-beta-lactose,,,,,,solid,,,117,2.84,-3.6,[H]N([C@@H]1[C@@H](O)C[C@@](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](CO)O[C@H](O)[C@H](O)[C@H]3O)[C@@H]2O)(O[C@@]1([H])[C@H](O)[C@H](O)CO)C(O)=O)C(C)=O,,,,,0,,633.211628,3,0,3,0,3,3
2921,04/06/2019 00:00,DB03297,Benzylsulfinic Acid,,,,,,solid,,,4.35,-0.98,,OS(=O)(=O)CC1=CC=CC=C1,,,,,0,,172.0194151,1,1,0,0,0,0
2922,04/06/2019 00:00,DB03298,Phenylphosphate,,,,,,solid,,,7.64,1.79,,OP(O)(=O)OC1=CC=CC=C1,,,,,0,,174.0081953,1,1,0,0,0,0
2923,04/06/2019 00:00,DB03299,N-Succinyl Phenylglycine,,,,,,solid,,,1.19,3.46,-2,[H][C@](NC(=O)CCC(O)=O)(C(O)=O)C1=CC=CC=C1,,,,,0,,251.0793725,1,1,0,0,0,0
2924,04/06/2019 00:00,DB03300,Pterin Cytosine Dinucleotide,,,,,,solid,,,0.765,1.86,-0.032,[H][C@]12NC3=C(N[C@@]1([H])C(S)=C(S)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(N)=NC1=O)O2)C(=O)NC(N)=N3,,,,,0,,700.0535982,5,2,5,2,1,3
2925,04/06/2019 00:00,DB03301,2-Allyl-6-Methyl-Phenol,,,,,,solid,,,1.35,9.7,-6,CC1=CC=CC(CC=C)=C1O,,,,,0,,148.088815,1,1,0,0,0,0
2926,04/06/2019 00:00,DB03302,"4,5,6,7-Tetrachloro-3h-Isobenzofuran-1-One",,,,,,solid,,,0.00502,14.27,-7,ClC1=C2COC(=O)C2=C(Cl)C(Cl)=C1Cl,,,,,0,,269.88089,2,1,1,0,0,1
2927,04/06/2019 00:00,DB03303,3-deoxy-D-arabino-hexonic acid,,,,,,solid,,,255,3.57,-3,OC[C@@H](O)[C@@H](O)C[C@H](O)C(O)=O,,,,,0,,180.0633881,0,0,0,0,0,0
2928,04/06/2019 00:00,DB03304,7-Deaza-7-Aminomethyl-Guanine,,,,,,solid,,,2.93,11.04,8.6,NCC1=CNC2=C1C(=O)NC(N)=N2,,,,,0,,179.0807099,2,2,2,2,0,0
2929,04/06/2019 00:00,DB03305,N5-Iminoethyl-L-Ornithine,,,,,,solid,,,1.86,2.53,12.82,[H][C@](N)(CCCNC(C)=N)C(O)=O,,,,,0,,173.1164267,0,0,0,0,0,0
2930,04/06/2019 00:00,DB03306,RU78300,,,,,,solid,,,3.87,1.59,-4.9,COC1=CC=CC(C=O)=C1OP(O)(O)=O,,,,,0,,232.0136746,1,1,0,0,0,0
2931,04/06/2019 00:00,DB03307,4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide,,,,,,solid,,,0.439,10.75,6.38,NC1=NC=NC(NC2=CC=C(C=C2)S(N)(=O)=O)=C1,,,,,0,,265.0633456,2,2,1,1,0,0
2932,04/06/2019 00:00,DB03308,L-Leucyl-Hydroxylamine,,,,,,solid,,,58.6,8.9,7.89,CC(C)C[C@H](N)C(=O)NO,,,,,0,,146.1055277,0,0,0,0,0,0
2933,04/06/2019 00:00,DB03309,N-cyclohexyltaurine,,,,,,solid,,,3.97,-1.1,9.88,OS(=O)(=O)CCNC1CCCCC1,,,,,0,,207.0929144,1,0,0,0,0,0
2934,04/06/2019 00:00,DB03310,Glutathione disulfide,,,,,Intraocular,solid,,,0.406,1.44,9.61,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O,,,,,0,,612.1519625,0,0,0,0,0,0
2935,04/06/2019 00:00,DB03311,"3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide",,,,,,solid,,,0.00655,5.1,0.59,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=C(C=C2)S(=O)(=O)NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1,,,,,0,,738.8751871,5,5,2,2,0,0
2936,04/06/2019 00:00,DB03312,Brivudine,,,,,,solid,,,1.48,7.54,-3,[H]\C(Br)=C(\[H])C1=CN(C(=O)N=C1O)[C@@]1([H])C[C@]([H])(O)[C@@]([H])(CO)O1,,,,,0,,332.0007836,2,1,2,1,1,1
2937,04/06/2019 00:00,DB03313,Cephalosporin C,,,,,,solid,,,0.389,1.82,9.53,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N=C(O)CCC[C@@H](N)C(O)=O)C2=O)C(O)=O,,,,,0,,415.1049356,2,0,2,0,1,2
2938,04/06/2019 00:00,DB03314,5-fluorotryptophan,,,,,,solid,,,1.21,2.12,9.4,N[C@@H](CC1=CNC2=C1C=C(F)C=C2)C(O)=O,,,,,0,,222.0804558,2,2,1,1,0,0
2939,04/06/2019 00:00,DB03315,Guanosine 3'-monophosphate,,,,,,solid,,,3.51,0.78,1.67,NC1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]2O)C(=O)N1,,,,,0,,363.057999,3,2,3,2,1,1
2940,04/06/2019 00:00,DB03316,"1,4-Diethylene Dioxide",,,,,,solid,,,283,,-3.9,C1COCCO1,,,,,0,,88.0524295,1,0,1,0,1,1
2941,04/06/2019 00:00,DB03317,Heme C,,,,,,solid,,,0.00697,3.35,,CC(S)C1=C2C=C3C(C)=C(C(C)S)C4=[N+]3[Fe--]35N6C(=C4)C(C)=C(CCC(O)=O)C6=CC4=[N+]3C(=CC(N25)=C1C)C(C)=C4CCC(O)=O,,,,,0,,684.1527351,8,2,8,2,0,6
2942,04/06/2019 00:00,DB03318,6-Hydro-1-Methyladenosine-5'-Monophosphate,,,,,,solid,,,2.62,1.03,3.76,[H]N=C1N(C)C=NC2=C1N=CN2[C@]1([H])O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,361.0787345,3,2,3,2,1,1
2943,04/06/2019 00:00,DB03319,"(2S)-2-Ammonio-3-[5-(2-methyl-2-propanyl)-3-oxido-1,2-oxazol-4-yl]propanoate",,,,,,solid,,,4.29,1.98,8.89,[H][C@](N)(CC1=C(ON=C1[O-])C(C)(C)C)C(O)=O,,,,,-1,,227.1037305,1,1,1,1,0,0
2944,04/06/2019 00:00,DB03320,3-Amino-Alanine,,,,,,solid,,,177,2.1,9.57,N[C@@H](C[NH3+])C(O)=O,,,,,1,,105.0658539,0,0,0,0,0,0
2945,04/06/2019 00:00,DB03321,"4-Amino-2-Deoxy-2,3-Dehydro-N-Neuraminic Acid",,,,,,solid,,,19.5,3.25,9.09,[H][C@@](O)(CO)[C@@]([H])(O)[C@]1([H])OC(=C[C@]([H])(N)[C@@]1([H])N=C(C)O)C(O)=O,,,,,0,,290.1114009,1,0,1,0,0,1
2946,04/06/2019 00:00,DB03322,Dexpropranolol,,,,,,solid,,,0.0794,14.09,9.67,CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2,,,,,0,,259.1572289,2,2,0,0,0,0
2947,04/06/2019 00:00,DB03323,Maltose,,,,,,solid,7.8E+005 mg/L (at 20 Â°C),,586,11.25,-3,OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,342.1162115,2,0,2,0,2,2
2948,04/06/2019 00:00,DB03325,Tyrosyladenylate,,,,,,solid,,,1.52,5.47,8.85,[H][C@](N)(CC1=CC=C(O)C=C1)C(O)=NS(=O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,509.1328817,4,3,3,2,1,1
2949,04/06/2019 00:00,DB03326,"deoxycytidylyl-3',5'-guanosine",,,,,,solid,,,1.29,-5.7,20.4,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(=O)OC1([H])CC([H])(OC1([H])CO)N1C=CC(=N)N=C1O)N1C=NC2=C1NC(=N)N=C2O,,,,,0,,556.1431256,5,3,5,3,2,2
2950,04/06/2019 00:00,DB03327,{1-[(3-Hydroxy-Methyl-5-Phosphonooxy-Methyl-Pyridin-4-Ylmethyl)-Amino]-Ethyl}-Phosphonic Acid,,,,,,solid,,,3.98,-0.6,8.79,[H][C@@](C)(NCC1=C(COP(O)(O)=O)C=NC(C)=C1O)P(O)(O)=O,,,,,0,,356.0538388,1,1,1,1,0,0
2951,04/06/2019 00:00,DB03329,2-Pyridinethiol,,,,,,solid,,,3.37,7.64,0.5,SC1=CC=CC=N1,,,,,0,,111.0142702,1,1,1,1,0,0
2952,04/06/2019 00:00,DB03330,S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione,,,,,,solid,,,0.0767,1.82,9.53,[H][C@](N)(CCC(O)=N[C@@]([H])(CS[C@@]([H])(O)N(O)C1=CC=C(I)C=C1)C(O)=NCC(O)=O)C(O)=O,,,,,0,,570.0281327,1,1,0,0,0,0
2953,04/06/2019 00:00,DB03331,"N-Naphthalen-1-Ylmethyl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine",,,,,,solid,,,0.0408,7.5,4.84,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(NCC4=CC=CC5=CC=CC=C45)N=CN=C23)[C@]([H])(N=C(O)C2=CC(OC)=CC(OC)=C2)[C@]1([H])O,,,,,0,,570.2226827,6,5,3,2,1,1
2954,04/06/2019 00:00,DB03332,"5,6-Cyclic-Tetrahydropteridine",,,,,,solid,,,4.26,11.08,4.19,NC1=NC2=C(N3[C@@H](COC3=O)CN2)C(=O)N1,,,,,0,,223.0705391,3,1,3,1,1,2
2955,04/06/2019 00:00,DB03333,(4-sulfamoyl-phenyl)-thiocarbamic acid O-(2-thiophen-3-yl-ethyl) ester,,,,,,solid,,,0.00512,10.16,-2.2,NS(=O)(=O)C1=CC=C(NC(=S)OCCC2=CSC=C2)C=C1,,,,,0,,342.0166553,2,2,1,1,0,0
2956,04/06/2019 00:00,DB03335,1-Bromopropane-2-Ol,,,,,,solid,,,61.8,14.73,-2.9,C[C@H](O)CBr,,,,,0,,137.9680269,0,0,0,0,0,0
2957,04/06/2019 00:00,DB03336,BIA,,,,,,solid,,,0.0434,4.92,7.04,OC1=CC(=CC(=C1O)[N+]([O-])=O)C(=O)CCN1CCN(CC1)C1=CC(=CC=C1)C(F)(F)F,,,,,0,,439.1355054,3,2,1,0,1,1
2958,04/06/2019 00:00,DB03337,1-(2-Amidinophenyl)-3-(Phenoxyphenyl)Urea,,,,,,solid,,,0.021,11.81,11.19,NC(=N)C1=CC=C(NC(=O)NC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1,,,,,0,,346.1429758,3,3,0,0,0,0
2959,04/06/2019 00:00,DB03338,Heptyl-Beta-D-Glucopyranoside,,,,,,solid,,,32.1,12.21,-3,[H][C@]1(O)[C@]([H])(O)[C@@]([H])(CO)O[C@@]([H])(OCCCCCCC)[C@]1([H])O,,,,,0,,278.1729386,1,0,1,0,1,1
2960,04/06/2019 00:00,DB03339,3-Iodo-Benzyl Alcohol,,,,,,solid,,,0.329,14.93,-2.8,OCC1=CC=CC(I)=C1,,,,,0,,233.9541628,1,1,0,0,0,0
2961,04/06/2019 00:00,DB03340,3-[(1-Amino-2-Carboxy-Ethyl)-Hydroxy-Phosphinoyl]-2-Methyl-Propionic Acid,,,,,,solid,,,29,-0.07,10.01,[H][C@@](C)(CP(O)(=O)[C@@]([H])(N)CC(O)=O)C(O)=O,,,,,0,,239.0558738,0,0,0,0,0,0
2962,04/06/2019 00:00,DB03341,Coa-S-Acetyl 5-Bromotryptamine,,,,,,solid,,,3.96,0.82,4.79,[H][C@](O)(C(O)=NCCC(O)=NCCSCC(O)=NCCC1=CNC2=C1C=C(Br)C=C2)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,1045.120684,5,4,4,3,1,1
2963,04/06/2019 00:00,DB03342,4-(Acetylamino)-3-Guanidinobenzoic Acid,,,,,,solid,,,1.28,4.78,5.91,CC(=O)NC1=CC=C(C=C1NC(N)N)C(O)=O,,,,,0,,238.1065903,1,1,0,0,0,0
2964,04/06/2019 00:00,DB03343,Malate Like Intermediate,,,,,,solid,,,691,3.1,-4,O[C@H](\C=C(/O)[O-])C([O-])=O,,,,,-2,,132.0069704,0,0,0,0,0,0
2965,04/06/2019 00:00,DB03344,"Inositol-(1,3,4,5,6)-Pentakisphosphate",,,,,,solid,,,13.4,0.19,,[H][C@]1(O)[C@]([H])(OP(O)(O)=O)[C@@]([H])(OP(O)(O)=O)[C@@]([H])(OP(O)(O)=O)[C@]([H])(OP(O)(O)=O)[C@@]1([H])OP(O)(O)=O,,,,,0,,579.8950407,1,0,0,0,0,0
2966,04/06/2019 00:00,DB03345,Mercaptoethanol,,,,,,solid,1E+006 mg/L,,29.2,9.97,-2.5,OCCS,,,,,0,,78.01393581,0,0,0,0,0,0
2967,04/06/2019 00:00,DB03346,"3,5,3',5'-Tetrachloro-Biphenyl-4,4'-Diol",,,,,,solid,,,0.00359,6.11,-7.5,OC1=C(Cl)C=C(C=C1Cl)C1=CC(Cl)=C(O)C(Cl)=C1,,,,,0,,321.9121902,2,2,0,0,0,0
2968,04/06/2019 00:00,DB03347,Triethyl Phosphate,,,,,,solid,,,15.9,,-9.1,CCOP(=O)(OCC)OCC,,,,,0,,182.0707956,0,0,0,0,0,0
2969,04/06/2019 00:00,DB03348,Huperzine B,,,,,,solid,,,0.16,11.34,9.56,[H][C@@]12CC3=C(C=CC(O)=N3)[C@]3(CC(C)=C1)NCCC[C@]23[H],,,,,0,,256.1575633,4,1,2,1,1,1
2970,04/06/2019 00:00,DB03349,8-Bromo-Adenosine-5'-Monophosphate,,,,,,solid,,,3.26,1.22,4,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C(Br)=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,424.9735965,3,2,3,2,1,1
2971,04/06/2019 00:00,DB03351,Sri-9439,,,,,,solid,,,0.0267,16.06,5.14,CC1=C(CNC2=CC=CC3=NC=CC=C23)C=NC2=NC(N)=NC(N)=C12,,,,,0,,331.1545435,4,4,3,3,0,0
2972,04/06/2019 00:00,DB03352,S-Arsonocysteine,,,,,,solid,,,40.4,1.1,9.22,N[C@@H](CS[As](O)(O)=O)C(O)=O,,,,,0,,244.9339149,0,0,0,0,0,0
2973,04/06/2019 00:00,DB03353,2-Iminobiotin,,,,,,solid,,,1.17,4.43,11.41,[H][C@]12CS[C@@]([H])(CCCCC(O)=O)[C@@]1([H])NC(=N)N2,,,,,0,,243.1041478,2,0,2,0,2,2
2974,04/06/2019 00:00,DB03354,"2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole",,,,,,solid,,,48.7,12.4,-1.7,[H][C@]1(CO)O[C@@]([H])(C2=NN=C(C)O2)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,246.0851862,2,1,2,1,1,1
2975,04/06/2019 00:00,DB03355,5'-O-(N-(L-Threonyl)-Sulfamoyl)Adenosine,,,,,,solid,,,5.97,5.37,8.49,[H][C@](C)(O)[C@]([H])(N)C(O)=NS(=O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,447.1172316,3,2,3,2,1,1
2976,04/06/2019 00:00,DB03357,(S)-Mandelic acid,,,,,,solid,1.81E+005 mg/L (at 25 Â°C),0.62,16.8,3.75,-4.1,O[C@H](C(O)=O)C1=CC=CC=C1,,,,,0,,152.0473441,1,1,0,0,0,0
2977,04/06/2019 00:00,DB03358,7n-Methyl-8-Hydroguanosine-5'-Triphosphate,,,,,,solid,,,8.2,0.89,15,[H][C@]1(O)[C@@]([H])(O)[C@@]([H])(O[C@]1([H])COP(O)(=O)OP(O)(=O)OP(O)(O)=O)N1CN(C)C2=C1NC(=N)N=C2O,,,,,0,,539.0219602,3,1,3,1,1,2
2978,04/06/2019 00:00,DB03359,"M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene",,,,,,solid,,,0.00872,7.53,-5.9,C[N+](C)(C)C1=CC=CC(=C1)C(O)(O)C(F)(F)F,,,,,1,,250.1049398,1,1,0,0,0,0
2979,04/06/2019 00:00,DB03360,N-Acetylproline,,,,,,solid,,,517,3.89,-1.1,[H][C@]1(CCCN1C(C)=O)C(O)=O,,,,,0,,157.0738932,1,0,1,0,1,1
2980,04/06/2019 00:00,DB03361,"2-{(9as)-9a-[(1s)-1-Hydroxyethyl]-2,7-Dimethyl-9a,10-Dihydro-5h-Pyrimido[4,5-D][1,3]Thiazolo[3,2-a]Pyrimidin-8-Yl}Ethyl Trihydrogen Diphosphate",,,,,,solid,,,2.87,2.06,4.89,[H][C@@](C)(O)[C@]12NC3=NC(C)=NC=C3CN1C(C)=C(CCOP(O)(=O)OP(O)(O)=O)S2,,,,,0,,468.0633579,3,1,3,1,0,2
2981,04/06/2019 00:00,DB03362,N-Dimethyl-Lysine,,,,,,solid,,,170,2.84,9.98,[H][C@](N)(CCCCN(C)C)C(O)=O,,,,,0,,174.1368278,0,0,0,0,0,0
2982,04/06/2019 00:00,DB03363,3-Acetylpyridine Adenine Dinucleotide,,,,,,solid,,,2.12,1.86,5,[H][C@]1(COP([O-])(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(=C3)C(C)=O)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,662.1138728,5,3,5,3,2,2
2983,04/06/2019 00:00,DB03364,N-Carbamyl-D-Methionine,,,,,,solid,,,12.8,3.94,-2.3,CSCC[C@@H](NC(N)=O)C(O)=O,,,,,0,,192.0568632,0,0,0,0,0,0
2984,04/06/2019 00:00,DB03365,"4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline",,,,,,solid,,,0.133,9.67,4.62,COC1=CC2=NC=NC(NC3=CC(O)=CC=C3)=C2C=C1OC,,,,,0,,297.1113413,3,3,1,1,0,0
2985,04/06/2019 00:00,DB03366,Imidazole,,,,,,solid,,-0.08,538,13.4,6.97,N1C=CN=C1,,,,,0,,68.03744813,1,1,1,1,0,0
2986,04/06/2019 00:00,DB03367,PF-00356231,,,,,,solid,,,0.000488,4.46,5.19,[H][C@](CC(O)=O)(NC(=O)C1=CC(=CS1)C1=CC=C(C=C1)C1=CC=NC=C1)C1=CC=CC=C1,,,,,0,,428.1194635,4,4,2,2,0,0
2987,04/06/2019 00:00,DB03368,"5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione",,,,,,solid,,,0.0139,8.14,-8.7,CC1(C(=O)NC(=O)NC1=O)C1=CC=C(OC2=CC=CC=C2)C=C1,,,,,0,,310.0953569,3,2,1,0,1,1
2988,04/06/2019 00:00,DB03369,9-Aminophenanthrene,,,,,,solid,,,0.00581,,3.8,NC1=CC2=C(C=CC=C2)C2=C1C=CC=C2,,,,,0,,193.0891494,3,3,0,0,0,0
2989,04/06/2019 00:00,DB03370,FR239087,,,,,,solid,,,0.0377,13.88,3.53,[H][C@@](C)(O)[C@@]([H])(CCC1=CC=CC(Cl)=C1Cl)N1C=NC(=C1)C(N)=O,,,,,0,,341.0697821,2,2,1,1,0,0
2990,04/06/2019 00:00,DB03371,Modified Ribosylated Glutamyl Ester,,,,,,solid,,,182,1.69,9.54,[H][C@](N)(CCC(=O)O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]1(O)F)C(O)=O,,,,,0,,297.0859947,1,0,1,0,1,1
2991,04/06/2019 00:00,DB03372,"3-Mercapto-1-(1,3,4,9-Tetrahydro-B-Carbolin-2-Yl)-Propan-1-One",,,,,,solid,,,0.014,10.12,-1.2,SCCC(=O)N1CCC2=C(C1)NC1=C2C=CC=C1,,,,,0,,260.0983341,3,2,2,1,0,1
2992,04/06/2019 00:00,DB03373,ZK-806711,,,,,,solid,,,0.0152,,12.45,[H]N=C(C)N1CCC(CC1)OC1=CC2=C(C=C1)N=C(C)N2CC1=CC2=C(C=C1)C=CC(=C2)C(N)=[NH2+],,,,,1,,455.255386,5,4,2,1,1,1
2993,04/06/2019 00:00,DB03374,"3,5-Diiodotyrosine",,,,,,solid,617 mg/L (at 25 Â°C),,0.519,0.48,9.45,[H][C@](N)(CC1=CC(I)=C(O)C(I)=C1)C(O)=O,,,,,0,,432.8671891,1,1,0,0,0,0
2994,04/06/2019 00:00,DB03376,'5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine,,,,,,solid,,,3.95,5.46,8.98,[H][C@@](C)(N)C(O)=NS(=O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,417.1066669,3,2,3,2,1,1
2995,04/06/2019 00:00,DB03379,2-Carboxyethylphosphonic Acid,,,,,,solid,,,27.4,1.8,,OC(=O)CCP(O)(O)=O,,,,,0,,154.00311,0,0,0,0,0,0
2996,04/06/2019 00:00,DB03380,L-tyrosinamide,,,,,,solid,,,2.98,9.52,8.03,[H][C@](N)(CC1=CC=C(O)C=C1)C(N)=O,,,,,0,,180.0898776,1,1,0,0,0,0
2997,04/06/2019 00:00,DB03381,Hexadecanal,,,,,,solid,,,5.88E-05,15.56,-6.9,CCCCCCCCCCCCCCCC=O,,,,,0,,240.2453156,0,0,0,0,0,0
2998,04/06/2019 00:00,DB03382,S-oxy-L-cysteine,,,,,,solid,,,470,1.4,8.82,[H][C@](N)(CS=O)C(O)=O,,,,,0,,137.0146641,0,0,0,0,0,0
2999,04/06/2019 00:00,DB03383,5-Chloro-1h-Indole-2-Carboxylic Acid [1-(4-Fluorobenzyl)-2-(4-Hydroxypiperidin-1yl)-2-Oxoethyl]Amide,,,,,,solid,,,0.0223,12.24,-2,[H][C@@](CC1=CC=C(F)C=C1)(NC(=O)C1=CC2=C(N1)C=CC(Cl)=C2)C(=O)N1CCC(O)CC1,,,,,0,,443.1411975,4,3,2,1,1,1
3000,04/06/2019 00:00,DB03384,Fica,,,,,,solid,,,0.0262,10.07,-1.5,FC1=CC2=C(NC(=C2)C(=O)NCCS)C=C1,,,,,0,,238.0576122,2,2,1,1,0,0
3001,04/06/2019 00:00,DB03385,4-Methylimidazole,,,,,,solid,,,578,13.78,7.49,CC1=CN=CN1,,,,,0,,82.05309819,1,1,1,1,0,0
3002,04/06/2019 00:00,DB03386,4-Fluorotryptophane,,,,,,solid,,,1.59,2.18,9.36,N[C@@H](CC1=CNC2=C1C(F)=CC=C2)C(O)=O,,,,,0,,222.0804558,2,2,1,1,0,0
3003,04/06/2019 00:00,DB03387,N-Hydroxy-N-Isopropyloxamic Acid,,,,,,solid,,,23.5,2.79,-6,CC(C)N(O)C(=O)C(O)=O,,,,,0,,147.0531578,0,0,0,0,0,0
3004,04/06/2019 00:00,DB03388,"3-[(2,4-Dichlorobenzoyl)(Isopropyl)Amino]-5-Phenylthiophene-2-Carboxylic Acid",,,,,,solid,,,0.000276,3.56,-3.2,CC(C)N(C(=O)C1=C(Cl)C=C(Cl)C=C1)C1=C(SC(=C1)C1=CC=CC=C1)C(O)=O,,,,,0,,433.0306198,3,3,1,1,0,0
3005,04/06/2019 00:00,DB03389,alpha-D-Xylopyranose,,,,,,solid,,,1220,11.31,-3.5,O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O,,,,,0,,150.0528234,1,0,1,0,1,1
3006,04/06/2019 00:00,DB03390,N-Propyl-Tartramic Acid,,,,,,solid,,,21.6,3.05,3.91,[H][C@](O)(C(O)=O)[C@@]([H])(O)C(O)=NCCC,,,,,0,,191.0793725,0,0,0,0,0,0
3007,04/06/2019 00:00,DB03391,Chromophore (Met-Tyr-Gly),,,,,,solid,,,0.133,3.48,8.04,[H]\C(=C1\N=C(N(CC(O)=O)C1=O)[C@@]([H])(N)CCSC)C1=CC=C(O)C=C1,,,,,0,,349.1096271,2,1,1,0,0,1
3008,04/06/2019 00:00,DB03392,"(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester",,,,,,solid,,,32.6,12.33,-3,[H][C@]1(O)[C@]([H])(O)[C@@]([H])(CO)O[C@@]([H])(NP(=O)(OC)OC)[C@]1([H])O,,,,,0,,287.0770032,1,0,1,0,1,1
3009,04/06/2019 00:00,DB03393,"(3s,6s,9r,10r,11s,12s,13e,15e,18s,21s)-18-{(1e,3e,7s,8s)-9-[(2s,3r,4s,5s,6r,9s,11s)-9-Ethyl-4-Hydroxy-3,5,11-Trimethyl-8-Oxo-1-Oxa-7-Azaspiro[5.5]Undec-2-Yl]-8-Hydroxy-1,7-Dimethylnona-1,3-Dienyl}-10,12-Dihydroxy-3-(3-Hydroxybenzyl)-6-Isopropyl-11-Methyl-",,,,,,solid,,,0.00673,5.42,1.93,[H]\C(CC[C@]([H])(C)[C@@]([H])(O)C[C@]1([H])O[C@@]2(N=C(O)[C@@]([H])(CC)C[C@]2([H])C)[C@@]([H])(C)[C@@]([H])(O)[C@@]1([H])C)=C(\[H])/C(/[H])=C(\C)[C@]1([H])C\C([H])=C(/[H])\C(\[H])=C([H])\[C@]([H])(O)[C@]([H])(C)[C@@]([H])(O)[C@@]([H])(CCC(C)=O)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CC2=CC(O)=CC=C2)C(=O)N2CCC[C@]([H])(N2)C(=O)O1,,,,,0,,1089.661338,5,1,4,0,2,4
3010,04/06/2019 00:00,DB03394,Heptaethylene glycol,,,,,,solid,,,1.55,14.82,-2.7,OCCOCCOCCOCCOCCOCCOCCO,,,,,0,,326.1940679,0,0,0,0,0,0
3011,04/06/2019 00:00,DB03395,Enalkiren,,,,,,solid,,,0.0122,12.03,9.58,COC1=CC=C(C[C@H](NC(=O)CC(C)(C)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC2CCCCC2)[C@@H](O)[C@@H](O)CC(C)C)C=C1,,,,,0,,656.4261335,3,2,1,1,0,0
3012,04/06/2019 00:00,DB03396,"(E)-(2r,3r,4s,5r)-3,4,5-Trihydroxy-2-Methoxy-8,8-Dimethyl-Non-6-Enoic Acid ((3s,6r)-6-Hydroxy-2-Oxo-Azepan-3-Yl)-Amide",,,,,,solid,,,0.313,4.95,2.99,[H]\C(=C(\[H])C(C)(C)C)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(OC)C(O)=N[C@@]1([H])CC[C@@]([H])(O)CN=C1O,,,,,0,,388.2209514,1,0,1,0,0,1
3013,04/06/2019 00:00,DB03397,Uridine-Diphosphate-N-Acetylglucosamine,,,,,,solid,,,11.4,1.74,-3.5,CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O,,,,,0,,607.0815697,3,1,3,1,2,2
3014,04/06/2019 00:00,DB03399,Ethyl Isocyanide,,,,,,solid,,,1.08,16.27,,CC[N+]#C,,,,,1,,56.04947561,0,0,0,0,0,0
3015,04/06/2019 00:00,DB03400,3-(P-Tolyl)Propionic Acid,,,,,,solid,,,0.493,4.85,,CC1=CC=C(CCC(O)=O)C=C1,,,,,0,,164.0837296,1,1,0,0,0,0
3016,04/06/2019 00:00,DB03401,"1D-myo-inositol 1,4,5-trisphosphate",,,,,,solid,,,14.8,0.54,-3.7,O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O,,,,,0,,419.9623797,1,0,0,0,0,0
3017,04/06/2019 00:00,DB03402,"1,2-Di-1-(3,7,11,15-Tetramethyl-Hexadecane)-Sn-Glycero-3-Phosphate",,,,,,solid,,,5.11E-05,1.25,-3.9,[H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@@]([H])(C)CCOC[C@@]([H])(COP(O)(O)=O)OCC[C@]([H])(C)CCC[C@]([H])(C)CCC[C@]([H])(C)CCCC(C)C,,,,,0,,732.6396772,0,0,0,0,0,0
3018,04/06/2019 00:00,DB03403,Cytidine-5'-Monophosphate,,,,,,solid,,,16.3,1.23,-0.62,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,,,,,0,,323.051851,2,1,2,1,1,1
3019,04/06/2019 00:00,DB03405,N2-[(Benzyloxy)carbonyl]-N-[(3R)-1-{N-[(benzyloxy)carbonyl]-L-leucyl}-4-oxo-3-pyrrolidinyl]-L-leucinamide,,,,,,solid,,,0.0045,12.3,-3.4,[H]N([C@@H](CC(C)C)C(=O)N([H])[C@@H]1CN(CC1=O)C(=O)[C@H](CC(C)C)N([H])C(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1,,,,,0,,594.3053497,3,2,1,0,1,1
3020,04/06/2019 00:00,DB03406,O1-Methyl-4-Deoxy-4-Thio-Alpha-D-Glucose,,,,,,solid,,,40.6,9.5,-3,[H][C@@]1(O)[C@@]([H])(O)[C@@]([H])(OC)O[C@]([H])(CO)[C@@]1([H])S,,,,,0,,210.0561945,1,0,1,0,1,1
3021,04/06/2019 00:00,DB03407,4-Nitrocatechol,,,,,,solid,,1.66,7.76,7.17,-6.4,OC1=CC=C(C=C1O)[N+]([O-])=O,,,,,0,,155.0218576,1,1,0,0,0,0
3022,04/06/2019 00:00,DB03408,gamma-Glutamylcysteine,,,,,,solid,,,2.62,1.91,9.24,N[C@@H](CCC(=O)N[C@@H](CS)C(O)=O)C(O)=O,,,,,0,,250.0623425,0,0,0,0,0,0
3023,04/06/2019 00:00,DB03409,Octahydroindole-2-Carboxylic Acid,,,,,,solid,,,10.9,2.09,11.64,[H][C@]1(C[C@]2([H])CCCC[C@]2([H])N1)C(O)=O,,,,,0,,169.1102787,2,0,1,0,1,1
3024,04/06/2019 00:00,DB03410,4-hydroxycoumarin,,,,,,solid,,,2.78,5.3,-7,OC1=CC(=O)OC2=CC=CC=C12,,,,,0,,162.0316941,2,2,1,1,0,0
3025,04/06/2019 00:00,DB03411,"2-Hydroxymethyl-Pyrrolidine-3,4-Diol",,,,,,solid,,,659,13.32,9.36,OC[C@@H]1NC[C@H](O)[C@H]1O,,,,,0,,133.0738932,1,0,1,0,1,1
3026,04/06/2019 00:00,DB03412,6-hydroxy-L-norleucine,,,,,,solid,,,101,2.46,9.53,N[C@@H](CCCCO)C(O)=O,,,,,0,,147.0895433,0,0,0,0,0,0
3027,04/06/2019 00:00,DB03413,Deoxyuridine-5'-Diphosphate,,,,,,solid,,,8.03,1.77,-3.2,O[C@H]1C[C@@H](O[C@@H]1COP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O,,,,,0,,388.0072825,2,1,2,1,1,1
3028,04/06/2019 00:00,DB03414,5-Thio-a/B-D-Mannopyranosylamine,,,,,,solid,,,235,12.77,7.1,[H][C@]1(N)S[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]1([H])O,,,,,0,,195.0565289,1,0,1,0,1,1
3029,04/06/2019 00:00,DB03415,3-Thiaoctanoyl-Coenzyme A,,,,,,solid,,,5.2,0.82,4.79,[H][C@](O)(C(O)=NCCC(O)=NCCSC(=O)CSCCCCC)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,911.176095,3,2,3,2,1,1
3030,04/06/2019 00:00,DB03416,Thiamine(1+) monophosphate,,,,,,solid,,,0.089,1.66,5.51,CC1=C(CCO[P@](O)([O-])=O)SC=[N+]1CC1=CN=C(C)N=C1N,,,,,0,,344.0708127,2,2,2,2,0,0
3031,04/06/2019 00:00,DB03417,1-(4-Tert-Butylcarbamoyl-Piperazine-1-Carbonyl)-3-(3-Guanidino-Propyl)-4-Oxo-Azetidine-2-Carboxylic Acid,,,,,,solid,,,0.105,2.48,12.05,[H][C@](CCCNC(N)=N)(C=O)[C@]([H])(N=C(O)N1CCN(CC1)C(O)=NC(C)(C)C)C(O)=O,,,,,0,,427.2543172,1,0,1,0,1,1
3032,04/06/2019 00:00,DB03418,Diacetyldeuteroheme,,,,,,solid,,,0.601,3.67,-5,CC(=O)C1=C(C)C2=CC3=C(C(O)=C)C(C)=C4C=C5N6C(=CC7=C(CCC(O)=O)C(C)=C8C=C1N2[Fe]6(N78)N34)C(CCC(O)=O)=C5C,,,,,0,,648.1671222,8,4,8,4,0,4
3033,04/06/2019 00:00,DB03419,Uracil,,,,,,solid,3600 mg/L (at 25 Â°C),-1.07,26.5,9.77,-5.5,O=C1NC=CC(=O)N1,,,,,0,,112.0272774,1,1,1,1,0,0
3034,04/06/2019 00:00,DB03420,"2,4-Deoxy-4-Guanidino-5-N-Acetyl-Neuraminic Acid",,,,,,solid,,,2.03,3.65,12.19,[H][C@@](O)(CO)[C@@]([H])(O)[C@]1([H])O[C@]([H])(C[C@]([H])(NC(N)=N)[C@@]1([H])N=C(C)O)C(O)=O,,,,,0,,334.148849,1,0,1,0,1,1
3035,04/06/2019 00:00,DB03421,"2-Phenethyl-2,3-Dihydro-Phthalazine-1,4-Dione",,,,,,solid,,,0.0337,13.78,-4.5,O=C1NN(CCC2=CC=CC=C2)C(=O)C2=C1C=CC=C2,,,,,0,,266.1055277,3,3,1,1,0,0
3036,04/06/2019 00:00,DB03422,"1,3-Thiazole-4-Carboxylic Acid",,,,,,solid,,,3.39,3.18,0.059,OC(=O)C1=CSC=N1,,,,,0,,128.9884493,1,1,1,1,0,0
3037,04/06/2019 00:00,DB03423,S-Adenosyl-L-Homoselenocysteine,,,,,,solid,,,8.42,1.31,9.5,[H][C@](N)(CC[Se]C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C(O)=O,,,,,0,,432.066039,3,2,3,2,1,1
3038,04/06/2019 00:00,DB03424,Ubenimex,,,,,,solid,,,0.841,3.77,9.54,[H][C@@](N)(CC1=CC=CC=C1)[C@]([H])(O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O,,,,,0,,308.1736072,1,1,0,0,0,0
3039,04/06/2019 00:00,DB03425,"2s,4r-4-Methylglutamate",,,,,,solid,,,267,2.01,9.53,[H][C@@](C)(C[C@]([H])(N)C(O)=O)C([O-])=O,,,,,-1,,160.0615314,0,0,0,0,0,0
3040,04/06/2019 00:00,DB03426,Digalactosyl Diacyl Glycerol (Dgdg),,,,,,solid,,,0.00208,11.91,-3,[H][C@@](COC(=O)CCCCCCCCCCCCCCCCC)(CO[C@]1([H])O[C@]([H])(CO[C@@]2([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@]([H])(O)[C@@]1([H])O)OC(=O)CCCCCCCCCCCCCCCCC,,,,,0,,948.6749224,2,0,2,0,2,2
3041,04/06/2019 00:00,DB03427,Delta-(L-Alpha-Aminoadipoyl)-L-Cysteinyl-D-Vinylglycine,,,,,,solid,,,0.109,2.04,9.43,[H][C@](N)(CCCC(O)=N[C@@]([H])(CS)C(O)=N[C@]([H])(C=C)C(O)=O)C(O)=O,,,,,0,,347.1151064,0,0,0,0,0,0
3042,04/06/2019 00:00,DB03428,SU9516,,,,,,solid,,,0.323,11.59,6.64,COC1=CC=C2NC(=O)\C(=C/C3=CN=CN3)C2=C1,,,,,0,,241.0851266,3,2,2,1,0,1
3043,04/06/2019 00:00,DB03429,Tetrastearoyl cardiolipin,,,,,,solid,,,6.62E-05,1.59,-3.4,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)COP(O)(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC,,,,,0,,1465.097427,0,0,0,0,0,0
3044,04/06/2019 00:00,DB03430,(2s)-Hydroxy(4-Hydroxyphenyl)Ethanenitrile,,,,,,solid,,,8.37,9.46,-4.2,O[C@H](C#N)C1=CC=C(O)C=C1,,,,,0,,149.0476785,1,1,0,0,0,0
3045,04/06/2019 00:00,DB03432,Beta-Amino Isobutyrate,,,,,,solid,,,567,4.17,10.32,C[C@H](CN)C([O-])=O,,,,,-1,,102.0560521,0,0,0,0,0,0
3046,04/06/2019 00:00,DB03433,{3-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-2-Methyl-Propyl}-Phosphonic Acid,,,,,,solid,,,2.62,1.3,9.81,C[C@H](CNCC1=C(O)C(C)=NC=C1COP(O)(O)=O)OP(O)(O)=O,,,,,0,,386.0644035,1,1,1,1,0,0
3047,04/06/2019 00:00,DB03434,3[N-Morpholino]Propane Sulfonic Acid,,,,,,solid,,,37.2,-0.96,6.88,OS(=O)(=O)CCCN1CCOCC1,,,,,0,,209.072179,1,0,1,0,1,1
3048,04/06/2019 00:00,DB03435,Uridine-5'-Diphosphate,,,,,,solid,,,8.89,1.77,-3.7,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O,,,,,0,,404.0021971,2,1,2,1,1,1
3049,04/06/2019 00:00,DB03436,Gallichrome,,,,,,solid,,,30.8,,,CC1=[O][Ga]2345ON1CCC[C@H]1NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCCN(O2)C(C)=[O]3)NC(=O)C(CCCN(O4)C(C)=[O]5)NC1=O,,,,,,,,,,,,,
3050,04/06/2019 00:00,DB03437,"2-{1-[2-(2-Amino-Thiazol-4-Yl)-2-Methoxyimino-Acetylamino]-2-Oxo-Ethyl}-5,5-Dimethyl-Thiazolidine-4-Carboxylic Acid",,,,,,solid,,,0.214,2.63,6.96,[H][C@](C=O)(N=C(O)C(=N/OC)\C1=CSC(=N)N1)[C@]1([H])N[C@@]([H])(C(O)=O)C(C)(C)S1,,,,,0,,401.0827607,2,1,2,1,1,1
3051,04/06/2019 00:00,DB03438,Lysophosphatidylglycerol,,,,,,solid,,,0.00329,1.89,-3,[H][C@](O)(CO)COP([O-])(=O)OC[C@@]([H])(O)COC(=O)CCCCCCCCCCCCCCC,,,,,-1,,483.2728432,0,0,0,0,0,0
3052,04/06/2019 00:00,DB03439,"4,6-dideoxy-4-amino-alpha-D-glucose",,,,,,solid,,,722,11.32,8.56,[H][C@]1(C)O[C@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])N,,,,,0,,163.0844579,1,0,1,0,1,1
3053,04/06/2019 00:00,DB03440,N-Hexadecanoylglycine,,,,,,solid,,,0.000708,4.05,-0.95,CCCCCCCCCCCCCCCC(=O)NCC(O)=O,,,,,0,,313.261694,0,0,0,0,0,0
3054,04/06/2019 00:00,DB03441,2-Benzyl-3-Iodopropanoic Acid,,,,,,solid,,,0.0576,3.76,,[H][C@@](CI)(CC1=CC=CC=C1)C(O)=O,,,,,0,,289.9803776,1,1,0,0,0,0
3055,04/06/2019 00:00,DB03442,2-[5-Hydroxy-3-Methyl-1-(2-Methyl-4-Sulfo-Phenyl)-1h-Pyrazol-4-Ylazo]-4-Sulfo-Benzoic Acid,,,,,,solid,,,0.156,-2.8,1.49,CC1=NN(C(O)=C1\N=N\C1=CC(=CC=C1C(O)=O)S(O)(=O)=O)C1=CC=C(C=C1C)S(O)(=O)=O,,,,,0,,496.0358701,3,3,1,1,0,0
3056,04/06/2019 00:00,DB03443,Bis(5-Amidino-Benzimidazolyl)Methanone Zinc,,,,,,solid,,,0.0112,3.92,7.97,NC(N)C1=CC2=C(C=C1)[N+]1=C(N2)C(=O)C2=[N+]([Zn]1)C1=C(N2)C=C(C=C1)C(N)N,,,,,2,,414.0884022,5,4,3,2,0,1
3057,04/06/2019 00:00,DB03444,"(3e)-6'-Bromo-2,3'-Biindole-2',3(1h,1'h)-Dione 3-Oxime",,,,,,solid,,,0.0341,7.84,0.96,O\N=C1\C(\NC2=C\1C=CC=C2)=C1\C(=O)NC2=C1C=CC(Br)=C2,,,,,0,,354.9956387,4,2,2,0,0,2
3058,04/06/2019 00:00,DB03445,"(3S)-3-(dioxidosulfanyl)-N-[(1E)-3-oxoprop-1-en-1-yl]-4-(1H-1,2,3-triazol-1-yl)-D-valine",,,,,,solid,,,2.14,3.3,1.51,[H]\C(N[C@@]([H])(C(O)=O)[C@](C)(CN1C=CN=N1)S(=O)=O)=C(\[H])C=O,,,,,0,,302.0684905,1,1,1,1,0,0
3059,04/06/2019 00:00,DB03446,N-Benzyl-3-(alpha-D-galactopyranosyloxy)benzamide,,,,,,solid,,,2.49,12.2,-1.2,[H][C@]1(CO)O[C@]([H])(OC2=CC=CC(=C2)C(=O)NCC2=CC=CC=C2)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,389.1474521,3,2,1,0,1,1
3060,04/06/2019 00:00,DB03447,Uridylyl-2'-5'-Phospho-Adenosine,,,,,,solid,,,3.36,1.82,4.99,[H][C@]1(CO)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@]1([H])O,,,,,0,,573.1220558,5,3,5,3,2,2
3061,04/06/2019 00:00,DB03448,2'-Deoxyuridine 3'-Monophosphate,,,,,,solid,,,8.41,1.09,-3,OC[C@H]1O[C@H](C[C@@H]1OP(O)(O)=O)N1C=CC(=O)NC1=O,,,,,0,,308.040952,2,1,2,1,1,1
3062,04/06/2019 00:00,DB03449,N-(4-(2-((3-Chlorophenylmethyl)Amino)Ethyl)Phenyl)-2-Thiophecarboxamidine,,,,,,solid,,,0.00167,,9.74,ClC1=CC=CC(CNCCC2=CC=C(NC(=N)C3=CC=CS3)C=C2)=C1,,,,,0,,369.1066463,3,3,1,1,0,0
3063,04/06/2019 00:00,DB03450,Cephalothin Group,,,,,,solid,,,0.0279,3.76,-2.5,[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(CC(=O)OC)CS1,,,,,0,,398.0606283,2,1,2,1,0,1
3064,04/06/2019 00:00,DB03451,"1-alpha, 25-dihydroxyl-20-epi-22-oxa-24, 26 ,27-trihomovitamin D3",,,,,,solid,,,0.00632,14.25,-2.8,[H]\C(\C(\[H])=C1/CCC[C@@]2(C)[C@@]1([H])CC[C@]2([H])[C@@]([H])(C)OCCCC(O)(CC)CC)=C1/C[C@@]([H])(O)C[C@]([H])(O)C1=C,,,,,0,,460.35526,3,0,0,0,0,0
3065,04/06/2019 00:00,DB03452,3-Trimethylsilylsuccinic Acid,,,,,,solid,,,5.95,4.09,,C[Si](C)(C)C(CC(O)=O)C(O)=O,,,,,0,,190.0661355,0,0,0,0,0,0
3066,04/06/2019 00:00,DB03453,(R)â€”N[2-[1-(aminoiminomethyl)-3-piperidinyl]-1-oxoethyl]-4-(phenylethynyl)-l-phenylalanine methylester,,,,,,solid,,,0.00896,7.2,12.15,[H][C@@](CC1=CC=C(C=C1)C#CC1=CC=CC=C1)(N=C(O)C[C@@]1([H])CCCN(C1)C(N)=N)C(=O)OC,,,,,0,,446.2317908,3,2,1,0,1,1
3067,04/06/2019 00:00,DB03454,"3-methyl-benzene-1,2-diol",,,,,,solid,,,36.7,9.59,-6.3,CC1=CC=CC(O)=C1O,,,,,0,,124.0524295,1,1,0,0,0,0
3068,04/06/2019 00:00,DB03455,(1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid,,,,,,solid,,,0.106,4.38,2.65,[H][C@](NOCCS)(C(O)=O)C1=CNC2=C1C=CC=C2,,,,,0,,266.0725133,2,2,1,1,0,0
3069,04/06/2019 00:00,DB03456,N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide,,,,,,solid,,,0.137,12.87,-3.1,[H][C@@](CC(C)C)(NC(=O)OCC1=CC=CC=C1)C(=O)N[C@]1([H])CCN(C1)C#N,,,,,0,,358.2004907,2,1,1,0,1,1
3070,04/06/2019 00:00,DB03458,"N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acid",,,,,,solid,,,6.81,1.91,9.54,CN(CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(N)N=CN=C12,,,,,0,,381.1760668,3,2,3,2,1,1
3071,04/06/2019 00:00,DB03459,Sparfosic acid,,,,,,solid,,,8.45,1.68,0.14,[H][C@@](CC(O)=O)(N=C(O)CP(O)(O)=O)C(O)=O,,,,,0,,255.0144029,0,0,0,0,0,0
3072,04/06/2019 00:00,DB03460,Violaxanthin,,,,,,solid,,,0.000568,14.84,-2.7,C\C(\C=C\C=C(/C)\C=C\[C@@]12O[C@]1(C)C[C@@H](O)CC2(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@@]12O[C@]1(C)C[C@@H](O)CC2(C)C,,,,,0,,600.4178603,4,0,2,0,2,2
3073,04/06/2019 00:00,DB03461,2'-Monophosphoadenosine 5'-Diphosphoribose,,,,,,solid,,,6.96,0.66,6.48,[H][C@]1(COP([O-])(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(=C3)C(O)=N)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(OP(O)(O)=O)[C@]1([H])O,,,,,0,,743.0754523,5,3,5,3,2,2
3074,04/06/2019 00:00,DB03462,Thymine,,,,,,solid,3820 mg/L (at 25 Â°C),-0.62,10.8,10.02,-5,CC1=CNC(=O)NC1=O,,,,,0,,126.0429274,1,1,1,1,0,0
3075,04/06/2019 00:00,DB03464,Formycin-5'-Monophosphate,,,,,,solid,,,13.3,1.23,3.38,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(C2=C3N=CN=C(N)C3=NN2)[C@]([H])(O)[C@]1([H])O,,,,,0,,347.0630844,3,2,3,2,1,1
3076,04/06/2019 00:00,DB03466,BMS184394,,,,,,solid,,,0.000149,3.99,-3.4,CC1(C)CCC(C)(C)C2=C1C=CC(=C2)[C@@H](O)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O,,,,,0,,388.2038448,4,3,0,0,0,0
3077,04/06/2019 00:00,DB03467,Naringenin,,,,,,solid,,2.52,0.214,7.91,-3.9,[H][C@]1(CC(=O)C2=C(O1)C=C(O)C=C2O)C1=CC=C(O)C=C1,,,,,0,,272.0684735,3,2,1,0,0,1
3078,04/06/2019 00:00,DB03468,"1,2,3,4-Tetrahydro-Isoquinoline-7-Sulfonic Acid Amide",,,,,,solid,,,2.08,10.37,8.62,NS(=O)(=O)C1=CC2=C(CCNC2)C=C1,,,,,0,,212.0619486,2,1,1,0,0,1
3079,04/06/2019 00:00,DB03469,Heme D,,,,,,solid,,,0.0492,3.32,2.46,CC1=C(CCC(O)=O)C2=CC3=C(CCC(O)=O)C(C)=C4C=C5[N+]6=C(C=C7N8C(C=C1N2[Fe]68N34)=C([O-])[C@]7(C)CC(O)=O)C(=O)[C@]5(C)CC(O)=O,,,,,0,,712.1467807,8,2,8,2,0,6
3080,04/06/2019 00:00,DB03470,Trypanothione,,,,,,solid,,,0.0121,1.64,10.57,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)NCCCCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O)C(O)=O,,,,,0,,723.3043808,0,0,0,0,0,0
3081,04/06/2019 00:00,DB03471,6-Phenyl-4(R)-(7-Phenyl-Heptanoylamino)-Hexanoic Acid,,,,,,solid,,,0.000328,4.28,5.01,[H][C@](CCC(O)=O)(CCC1=CC=CC=C1)N=C(O)CCCCCCC1=CC=CC=C1,,,,,0,,395.2460439,2,2,0,0,0,0
3082,04/06/2019 00:00,DB03472,Cyclohexyl-Hexyl-Beta-D-Maltoside,,,,,,solid,,,2.89,11.94,-3,[H][C@]1(CO)O[C@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@@]([H])(OCCCCCCC3CCCCC3)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,508.2883622,3,0,2,0,2,2
3083,04/06/2019 00:00,DB03473,N5-Methylglutamine,,,,,,solid,,,56.5,2.26,9.31,CNC(=O)CC[C@H](N)C(O)=O,,,,,0,,160.0847922,0,0,0,0,0,0
3084,04/06/2019 00:00,DB03474,Reactive Red 1 Dye,,,,,,solid,,,0.131,-3.3,7.32,NC1=NC(NC2=CC(=CC3=C2C(O)=C(\N=N\C2=CC=CC=C2S(O)(=O)=O)C(=C3)S(O)(=O)=O)S(O)(=O)=O)=NC(N)=N1,,,,,0,,612.0151517,4,4,1,1,0,0
3085,04/06/2019 00:00,DB03475,"1-[4-Carboxy-2-(3-Pentylamino)Phenyl]-5,5'-Di(Hydroxymethyl)Pyrrolidin-2-One",,,,,,solid,,,1.47,4.94,3.75,CCC(CC)NC1=CC(=CC=C1N1C(=O)CCC1(CO)CO)C(O)=O,,,,,0,,350.1841719,2,1,1,0,1,1
3086,04/06/2019 00:00,DB03476,Trans-6-(2-Phenylcyclopropyl)-Naphthalene-2-Carboxamidine,,,,,,solid,,,0.000395,,11.32,[H][C@]1(C[C@@]1([H])C1=CC2=CC=C(C=C2C=C1)C(N)=N)C1=CC=CC=C1,,,,,0,,286.1469986,4,3,0,0,0,0
3087,04/06/2019 00:00,DB03477,1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole,,,,,,solid,,,0.00251,10.7,-0.45,NS(=O)(=O)C1=CC=C(C=C1)N1N=C(C=C1C1=CC=C(Br)C=C1)C(F)(F)F,,,,,0,,444.9707444,3,3,1,1,0,0
3088,04/06/2019 00:00,DB03478,2'-O-Acetyl Adenosine-5-Diphosphoribose,,,,,,solid,,,3.54,1.86,5,[H][C@]1(O)O[C@]([H])(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])OC(C)=O,,,,,0,,601.0822384,4,2,4,2,2,2
3089,04/06/2019 00:00,DB03479,"8,9,10-Trihydroxy-7-Hydroxymethyl-3-Methyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione",,,,,,solid,,,127,5.76,-3,[H][C@]1(CO)O[C@@]2(N=C(O)N(C)C2=O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,262.0801008,2,0,2,0,1,2
3090,04/06/2019 00:00,DB03480,Brequinar Analog,,,,,,solid,,,0.000464,3.38,0.77,CC1=C(N=C2C=CC(F)=CC2=C1C(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,357.116507,4,4,1,1,0,0
3091,04/06/2019 00:00,DB03481,"5,10-Dimethylene Tetrahydromethanopterin",,,,,,solid,,,1.48,1.75,4.62,C[C@H]1[C@@H]2[C@@H](C)NC3=C(N2CN1C1=CC=C(C[C@@H](O)[C@@H](O)[C@H](O)CO[C@H]2O[C@H](CO[P@@](O)(=O)O[C@@H](CCC(O)=O)C(O)=O)[C@@H](O)[C@@H]2O)C=C1)C(=O)NC(N)=N3,,,,,0,,788.262966,5,2,4,1,2,3
3092,04/06/2019 00:00,DB03482,8-Demethyl-8-Dimethylamino-Flavin-Adenine-Dinucleotide,,,,,,solid,,,4.15,1.85,5.02,[H][C@@](O)(COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)[C@@]([H])(O)[C@@]([H])(O)CN1C2=C(C=C(C)C(=C2)N(C)C)N=C2C(O)=NC(=O)N=C12,,,,,0,,814.1836837,6,3,5,2,1,3
3093,04/06/2019 00:00,DB03483,4-Benzoylamino-4-{1-{1-Carbamoyl-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-Butyric Acid,,,,,,solid,,,0.0341,0.19,,[H][C@@](CCC(O)=O)(N=C(O)C1=CC=CC=C1)C(O)=N[C@@]([H])(CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)C(O)=N[C@@]([H])(CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)C(O)=N,,,,,0,,804.1584587,3,3,0,0,0,0
3094,04/06/2019 00:00,DB03484,L-Alpha-Glycerophosphorylethanolamine,,,,,,solid,,,36.5,1.87,10,NCCO[P@@](O)(=O)OC[C@@H](O)CO,,,,,0,,215.0558738,0,0,0,0,0,0
3095,04/06/2019 00:00,DB03485,Alpha-D-Fucose,,,,,,solid,,,827,11.3,-3.6,C[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O,,,,,0,,164.0684735,1,0,1,0,1,1
3096,04/06/2019 00:00,DB03486,Phosphomethylphosphonic Acid Guanosyl Ester,,,,,,solid,,,5.45,1.04,4.93,[H][C@]1(COP(O)(=O)CP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,441.045065,3,2,3,2,1,1
3097,04/06/2019 00:00,DB03487,3-Aminosuccinimide,,,,,,solid,,,30.3,6.15,8.03,[H][C@]1(N)CC(O)=NC1=O,,,,,0,,114.0429274,1,0,1,0,0,1
3098,04/06/2019 00:00,DB03488,Uridine-5'-diphosphate-2-deoxy-2-fluoro-alpha-D-galactose,,,,,,solid,,,43,1.73,-3,[H][C@]1(COP(O)(=O)OP(O)(=O)O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])F)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,568.0506841,3,1,3,1,2,2
3099,04/06/2019 00:00,DB03489,2-Keto-3-Deoxygluconate,,,,,,solid,,,134,2.91,-3,OC[C@H](O)[C@@H](O)CC(=O)C(O)=O,,,,,0,,178.047738,0,0,0,0,0,0
3100,04/06/2019 00:00,DB03490,"3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole",,,,,,solid,,,0.0949,8.81,4.91,C1C2=C(C=CC=C2)C2=NNC(=C12)C1=CC=NC=C1,,,,,0,,233.0952974,4,3,2,2,0,0
3101,04/06/2019 00:00,DB03491,2'-Deoxyguanosine-5'-Diphosphate,,,,,,solid,,,3.6,1.97,1.36,NC1=NC2=C(N=CN2[C@H]2C[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O2)C(=O)N1,,,,,0,,427.0294149,3,2,3,2,1,1
3102,04/06/2019 00:00,DB03493,7-Methylguanosine,,,,,,solid,,,5.61,8.16,-2.1,CN1C=[N+]([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C2=C1C(=O)N=C(N)N2,,,,,1,,298.114595,3,2,3,2,1,1
3103,04/06/2019 00:00,DB03495,"4,6-Dideoxy-4-{[4,5,6-Trihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}-Alpha-D-Lyxo-Hexopyranosyl-(1->4)-Alpha-D-Threo-Hexopyranosyl-(1->6)-Alpha-L-Threo-Hexopyranose",,,,,,solid,,,138,11.23,7.03,[H][C@]1(C)O[C@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@]([H])(OC[C@@]3([H])O[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])N[C@@]1([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,645.2480135,4,0,3,0,3,3
3104,04/06/2019 00:00,DB03496,Alvocidib,,,,,,solid,,,0.094,6.71,7.36,CN1CC[C@@H]([C@H](O)C1)C1=C(O)C=C(O)C2=C1OC(=CC2=O)C1=CC=CC=C1Cl,,,,,0,,401.1030004,4,3,2,1,1,1
3105,04/06/2019 00:00,DB03497,O-Sulfo-L-Serine,,,,,,solid,,,40.7,-2.1,8.59,[H][C@](N)(COS(O)(=O)=O)C(O)=O,,,,,0,,184.9994079,0,0,0,0,0,0
3106,04/06/2019 00:00,DB03498,Mercaptomethyl Phosphonate,,,,,,solid,,,13.2,1.64,,[O-]P([O-])(=O)CS,,,,,-2,,125.9551487,0,0,0,0,0,0
3107,04/06/2019 00:00,DB03499,Malate Ion,,,,,,solid,,,218,3.2,-3.9,O[C@H](CC(O)=O)C(O)=O,,,,,0,,134.0215233,0,0,0,0,0,0
3108,04/06/2019 00:00,DB03500,Tricosanoic Acid,,,,,,solid,,,2.57E-05,4.95,,CCCCCCCCCCCCCCCCCCCCCCC(O)=O,,,,,0,,354.3497807,0,0,0,0,0,0
3109,04/06/2019 00:00,DB03501,Galactose-uridine-5'-diphosphate,,,,,,solid,,,15,1.73,-3.6,OC[C@H]1O[C@H](O[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)NC2=O)[C@H](O)[C@@H](O)[C@H]1O,,,,,0,,566.0550206,3,1,3,1,2,2
3110,04/06/2019 00:00,DB03502,(4s)-4-{[(2s)-2-Amino-3-Oxopropyl]Sulfanyl}-L-Homoserinate,,,,,,solid,,,24.1,1.62,9.29,[H][C@](O)(C[C@]([H])(N)C(O)=O)SC[C@]([H])(N)C(O)=O,,,,,0,,238.0623425,0,0,0,0,0,0
3111,04/06/2019 00:00,DB03503,"4-Acetyl-4-Guanidino-6-Methyl(Propyl)Carboxamide-4,5-Dihydro-2h-Pyran-2-Carboxylic Acid",,,,,,solid,,,0.503,3.8,11.93,CCCN(C)C(=O)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O,,,,,0,,341.1699188,1,0,1,0,0,1
3112,04/06/2019 00:00,DB03504,"9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine",,,,,,solid,,,0.0283,18.59,5.06,CCCCN1C(CC2=CC(OC)=C(OC)C(OC)=C2Cl)=NC2=C(N)N=CN=C12,,,,,0,,405.1567673,3,3,2,2,0,0
3113,04/06/2019 00:00,DB03505,"2,6-Diaminoquinazolin-4(3h)-One",,,,,,solid,,,14.5,13.35,2.86,NC1=CC2=C(C=C1)N=C(N)N=C2O,,,,,0,,176.0698109,2,2,1,1,0,0
3114,04/06/2019 00:00,DB03506,9-Deazaadenine,,,,,,solid,,,1.2,7.46,12.54,N=C1NC=NC2=C1NC=C2,,,,,0,,134.0592462,2,2,2,2,0,0
3115,04/06/2019 00:00,DB03507,"6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One",,,,,,solid,,,0.0214,,6.54,[O-][N+](=O)C1=CC(=CC=C1)C1=CC2=C(S1)C=C1N2C(=S)N(CCCN2CCOCC2)C1=O,,,,,0,,456.0925971,5,3,4,2,1,2
3116,04/06/2019 00:00,DB03508,1-Ethoxy-2-(2-Methoxyethoxy)Ethane,,,,,,solid,,,25.3,,-3.7,CCOCCOCCOC,,,,,0,,148.1099444,0,0,0,0,0,0
3117,04/06/2019 00:00,DB03509,2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide,,,,,,solid,,,0.0119,14.1,0.22,NC(=O)C1=CC=CC2=NC=C(N=C12)C1=CC=C(Cl)C=C1,,,,,0,,283.0512396,3,3,1,1,0,0
3118,04/06/2019 00:00,DB03510,6-O-Phosphoryl Inosine Monophosphate,,,,,,solid,,,3.37,0.69,2.12,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2N=CN=C3OP(O)(O)=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,428.0134305,3,2,3,2,1,1
3119,04/06/2019 00:00,DB03511,alpha-D-galacturonic acid,,,,,,solid,,,295,3.21,-3.7,O[C@H]1O[C@@H]([C@H](O)[C@H](O)[C@H]1O)C(O)=O,,,,,0,,194.0426527,1,0,1,0,1,1
3120,04/06/2019 00:00,DB03512,"Uridine-2',3'-Vanadate",,,,,,solid,,,13.7,9.7,-3,OC[C@@H]1O[C@H]([C@H]2O[V](O)(O)(=O)O[C@H]12)N1C=CC(=O)NC1=O,,,,,0,,342.0014385,3,1,3,1,2,2
3121,04/06/2019 00:00,DB03513,"(S)-2-Amino-3-(4h-Selenolo[3,2-B]-Pyrrol-6-Yl)-Propionic Acid",,,,,,solid,,,11.6,1.67,9.39,[H][C@](N)(CC1=CNC2=C1[Se]C=C2)C(O)=O,,,,,0,,257.9907489,2,2,2,2,0,0
3122,04/06/2019 00:00,DB03514,2-Methoxy-4-Vinyl-Phenol,,,,,,solid,,,7.42,10.03,-4.9,COC1=CC(C=C)=CC=C1O,,,,,0,,150.0680796,1,1,0,0,0,0
3123,04/06/2019 00:00,DB03515,Equilenin,,,,,,solid,,,0.0052,9.78,-5.5,[H][C@@]12CCC(=O)[C@@]1(C)CCC1=C2C=CC2=C1C=CC(O)=C2,,,,,0,,266.1306798,4,2,0,0,0,0
3124,04/06/2019 00:00,DB03516,Eniluracil,,,,,,solid,,,0.254,9.5,-6.4,O=C1NC=C(C#C)C(=O)N1,,,,,0,,136.0272774,1,1,1,1,0,0
3125,04/06/2019 00:00,DB03517,[Methylthio]Acetate,,,,,,solid,,,67.9,4.36,,CSCC([O-])=O,,,,,-1,,105.001574,0,0,0,0,0,0
3126,04/06/2019 00:00,DB03518,Mevalonic acid,,,,,,solid,,,414,4.38,-2.4,C[C@@](O)(CCO)CC(O)=O,,,,,0,,148.0735589,0,0,0,0,0,0
3127,04/06/2019 00:00,DB03520,6-Chloro-2-Fluoropurine,,,,,,solid,,,0.0646,0.042,-1.8,FC1=NC(Cl)=C2N=CN=C2N1,,,,,0,,171.995202,2,0,2,0,0,2
3128,04/06/2019 00:00,DB03522,Aspartic Acid-4-Carboxymethyl Ester,,,,,,solid,,,20.9,1.51,8.6,N[C@@H](CC(=O)OCC(O)=O)C(O)=O,,,,,0,,191.042987,0,0,0,0,0,0
3129,04/06/2019 00:00,DB03523,Brequinar,,,,,,solid,,,0.000539,3.38,0.75,CC1=C(N=C2C=CC(F)=CC2=C1C(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1F,,,,,0,,375.1070852,4,4,1,1,0,0
3130,04/06/2019 00:00,DB03524,"N-{3-[4-(3-Amino-Propyl)-Piperazin-1-Yl]-Propyl}-3-(2-Thiophen-2-Yl-Acetylamino)-5-(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yloxy)-Benzamide",,,,,,solid,,,0.109,6.04,10.18,[H][C@]1(CO)O[C@]([H])(OC2=CC(=CC(=C2)N=C(O)CC2=CC=CS2)C(O)=NCCCN2CCN(CCCN)CC2)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,621.2832343,4,2,3,1,2,2
3131,04/06/2019 00:00,DB03525,RU79073,,,,,,solid,,,2.94,1.19,4.01,OP(O)(=O)OC1=C2NCCCC2=CC=C1,,,,,0,,229.0503945,2,1,1,0,0,1
3132,04/06/2019 00:00,DB03526,AL5927,,,,,,solid,,,0.119,8.17,-4.8,COC1=CC=C(CNS(=O)(=O)C2=CC=C(S2)S(N)(=O)=O)C=C1,,,,,0,,362.0064845,2,2,1,1,0,0
3133,04/06/2019 00:00,DB03528,9-Beta-D-Xylofuranosyl-Adenine,,,,,,solid,,,14,12.45,4.99,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@@]1([H])O,,,,,0,,267.0967539,3,2,3,2,1,1
3134,04/06/2019 00:00,DB03530,Acylated Ceftazidime,,,,,,solid,,,0.0771,2.98,6.85,[H][C@](C=O)(N=C(O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(=N)N1)[C@@]1([H])SCC(=C)C(=N1)C(O)=O,,,,,0,,469.0725899,2,1,2,1,0,1
3135,04/06/2019 00:00,DB03531,Flavin-Adenine Dinucleotide-N5-Isobutyl Ketone,,,,,,solid,,,0.141,1.8,3.38,[H][C@@](O)(COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])([N+]2=CN=C3C2=NC=NC3=N)[C@]([H])(O)[C@]1([H])O)[C@@]([H])(O)[C@@]([H])(O)CN1C2=C(C=C(C)C(C)=C2)N(C(=O)C(C)C)C2=C1N=C(O)N=C2[O-],,,,,0,,855.1989994,6,2,5,1,1,4
3136,04/06/2019 00:00,DB03532,Phosphomethylphosphonic Acid Guanylate Ester,,,,,,solid,,,8.61,1.08,4.94,[H][C@]1(COP(O)(=O)CP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,521.0113955,3,2,3,2,1,1
3137,04/06/2019 00:00,DB03533,Glycoluril,,,,,,solid,,,6.2,11.69,-3.6,O=C1N[C@@H]2NC(=O)N[C@@H]2N1,,,,,0,,142.0490754,2,0,2,0,2,2
3138,04/06/2019 00:00,DB03534,3-[(Acetyl-Methyl-Amino)-Methyl]-4-Amino-N-Methyl-N-(1-Methyl-1h-Indol-2-Ylmethyl)-Benzamide,,,,,,solid,,,0.0346,,2.58,CN(CC1=C(N)C=CC(=C1)C(=O)N(C)CC1=CC2=C(C=CC=C2)N1C)C(C)=O,,,,,0,,378.2055761,3,3,1,1,0,0
3139,04/06/2019 00:00,DB03535,Z-Pro-Prolinal,,,,,,solid,,,1.53,15.37,-4,[H][C@]1(CCCN1C(=O)[C@]1([H])CCCN1C(=O)OCC1=CC=CC=C1)C=O,,,,,0,,330.1579572,3,1,2,0,2,2
3140,04/06/2019 00:00,DB03536,Benzoyl-Arginine-Alanine-Methyl Ketone,,,,,,solid,,,0.0904,5.49,6.73,[H][C@@](C)(N=C(O)[C@]([H])(CCCNC(N)N)N=C(O)OCC1=CC=CC=C1)C(=O)CF,,,,,0,,397.2125326,1,1,0,0,0,0
3141,04/06/2019 00:00,DB03537,[4-(4-Hydroxy-Benzyl)-2-(2-Hydroxy-1-Methyl-Ethyl)-5-Oxo-Imidazolidin-1-Yl]-Acetic Acid,,,,,,solid,,,0.457,3.28,7.49,[H]\C(=C1\N=C(N(CC(O)=O)C1=O)[C@@]([H])(N)CO)C1=CC=C(O)C=C1,,,,,0,,305.1011706,2,1,1,0,0,1
3142,04/06/2019 00:00,DB03539,2-(Acetylamino)-2-Deoxy-6-O-Methyl-Alpha-D-Allopyranose,,,,,,solid,,,11.8,13.12,2.66,[H][C@]1(O)[C@]([H])(O)[C@@]2([H])N=C(O[C@@]2([H])[C@]1([H])CO)N=C,,,,,0,,200.0797069,2,0,1,0,0,1
3143,04/06/2019 00:00,DB03540,Norcamphor,,,,,,solid,,,8.51,,-7.4,[H][C@]12CC[C@]([H])(C1)C(=O)C2,,,,,0,,110.0731649,2,0,0,0,0,0
3144,04/06/2019 00:00,DB03541,"10-Propargyl-5,8-Dideazafolic Acid",,,,,,solid,,,0.0204,3.24,1.02,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)N(CC#C)CC1=CC=C2NC(N)=NC(=O)C2=C1)C(O)=O,,,,,0,,477.1648335,3,3,1,1,0,0
3145,04/06/2019 00:00,DB03542,L-Myo-Inositol-1-Phosphate,,,,,,solid,,,85.9,1.16,-3.6,[H][C@]1(O)[C@]([H])(O)[C@]([H])(O)[C@]([H])(OP([O-])([O-])=O)[C@@]([H])(O)[C@]1([H])O,,,,,-2,,258.0151657,1,0,0,0,0,0
3146,04/06/2019 00:00,DB03543,1-(O-Carboxy-Phenylamino)-1-Deoxy-D-Ribulose-5-Phosphate,,,,,,solid,,,2.29,1.75,1.14,[H][C@@](O)(CNC1=CC=CC=C1C(O)=O)[C@]([H])(O)[C@]([H])(O)COP(O)(O)=O,,,,,0,,351.0719178,1,1,0,0,0,0
3147,04/06/2019 00:00,DB03544,S-Phosphocysteine,,,,,,solid,,,42.9,1.5,9.9,N[C@@H](CSP(O)(O)=O)C(O)=O,,,,,0,,200.98608,0,0,0,0,0,0
3148,04/06/2019 00:00,DB03546,"N-({4-[(1R)-4-[(2R,4S,5S)-2,4-diamino-6-oxohexahydropyrimidin-5-yl]-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl}carbonyl)-L-glutamic acid",,,,,,solid,,,0.782,2.7,7.74,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)[C@@]([H])(CCCC1([H])C(O)=N[C@]([H])(N)N[C@]1([H])N)C(O)(O)C(F)(F)F)C(O)=O,,,,,0,,549.2046476,2,1,1,0,0,1
3149,04/06/2019 00:00,DB03548,3-deoxy-Î±-D-manno-oct-2-ulopyranosonic acid,,,,,,solid,,,612,2.89,-3,[H][C@@](O)(CO)[C@@]1([H])O[C@](O)(C[C@@]([H])(O)[C@@]1([H])O)C(O)=O,,,,,0,,238.0688674,1,0,1,0,1,1
3150,04/06/2019 00:00,DB03549,Biotinyl P-Nitroaniline,,,,,,solid,,,0.0286,13.07,-1.9,[H][C@@]1(CCCCC(=O)NC2=CC=C(C=C2)[N+]([O-])=O)SC[C@]2([H])NC(=O)N[C@]12[H],,,,,0,,364.1205261,3,1,2,0,2,2
3151,04/06/2019 00:00,DB03550,Isopenicillin N,,,,,,solid,,,0.791,1.83,9.53,[H][C@](N)(CCCC(O)=N[C@]1([H])C(=O)N2[C@]1([H])SC(C)(C)[C@]2([H])C(O)=O)C(O)=O,,,,,0,,359.1151064,2,0,2,0,2,2
3152,04/06/2019 00:00,DB03551,"(3R,4R)-3-Hydroxy-4-(hydroxymethyl)-1-[(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]pyrrolidinium",,,,,,solid,,,0.648,11.49,7.94,[H]N1C=C(C[N+]2([H])C[C@H](O)[C@@H](CO)C2)C2N=CN([H])C(=O)C12,,,,,1,,267.1451669,3,0,3,0,1,3
3153,04/06/2019 00:00,DB03552,3-Tyrosine,,,,,,solid,,,5.13,2,9.14,N[C@@H](CC1=CC=CC(O)=C1)C(O)=O,,,,,0,,181.0738932,1,1,0,0,0,0
3154,04/06/2019 00:00,DB03553,Glutaric Acid,,,,,,solid,1.6E+006 mg/L (at 28 Â°C),-0.29,56,3.76,,OC(=O)CCCC(O)=O,,,,,0,,132.0422587,0,0,0,0,0,0
3155,04/06/2019 00:00,DB03554,5-Iodouracil,,,,,,solid,,,8.12,8.14,-6.6,IC1=CNC(=O)NC1=O,,,,,0,,237.9239253,1,1,1,1,0,0
3156,04/06/2019 00:00,DB03555,CRA_11092,,,,,,solid,,,0.00637,9.28,8.58,[H][C@]1(C)CCCC[C@]1([H])OC1=CC=CC(C2=NC3=C(N2)C=C(F)C(=C3)C(N)=N)=C1O,,,,,0,,382.1805042,4,3,1,1,0,0
3157,04/06/2019 00:00,DB03556,"2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400",,,,,,solid,,,0.232,15.12,-2.7,CCOCCOCCOCCOCCOCCOCCOCCOCCO,,,,,0,,398.2515828,0,0,0,0,0,0
3158,04/06/2019 00:00,DB03557,N-{1-[5-(1-Carbamoyl-2-Mercapto-Ethylcarbamoyl)-Pentylcarbamoyl]-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethyl}-3-{2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Acetylamino}-Succinamic Acid,,,,,,solid,,,0.0372,0.19,,[H]C(CS)(N=C(O)CCCCCN=C(O)[C@]([H])(CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)N=C(O)C([H])(CC(O)=O)N=C(O)CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)C(O)=N,,,,,0,,873.1832935,2,2,0,0,0,0
3159,04/06/2019 00:00,DB03558,Sp-876,,,,,,solid,,,0.187,2.45,2.97,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)S(=O)(=O)N1CCC[C@]1([H])C(O)=NCCC(O)=O)C(O)=O,,,,,0,,499.126065,2,1,1,0,1,1
3160,04/06/2019 00:00,DB03559,Cyclohexylformamide,,,,,,solid,,,18.8,16.45,0.093,O=CNC1CCCCC1,,,,,0,,127.099714,1,0,0,0,0,0
3161,04/06/2019 00:00,DB03560,P-Hydroxybenzaldehyde,,,,,,solid,8450 mg/L (at 25 Â°C),1.35,9.51,7.32,-7.1,OC1=CC=C(C=O)C=C1,,,,,0,,122.0367794,1,1,0,0,0,0
3162,04/06/2019 00:00,DB03562,Tetrahydrodeoxyuridine,,,,,,solid,,,115,11.64,-3,[H]N1C(=O)CCN(C2C[C@H](O)[C@@H](CO)O2)C1=O,,,,,0,,230.0902715,2,0,2,0,2,2
3163,04/06/2019 00:00,DB03564,"(4r)-2-Methylpentane-2,4-Diol",,,,,,solid,,,162,15.12,-2.5,C[C@H](O)CC(C)(C)O,,,,,0,,118.0993797,0,0,0,0,0,0
3164,04/06/2019 00:00,DB03565,1-O-Octyl-2-Heptylphosphonyl-Sn-Glycero-3-Phosphoethanolamine,,,,,,solid,,,0.806,0.75,10,[H][C@@](COCCCCCCCC)(COP(O)(=O)OCCN)OP(O)(=O)CCCCCCC,,,,,0,,489.2620407,0,0,0,0,0,0
3165,04/06/2019 00:00,DB03566,Spermidine,,,,,,solid,,,32.7,,10.9,NCCCCNCCCN,,,,,0,,145.1578976,0,0,0,0,0,0
3166,04/06/2019 00:00,DB03567,alpha-N-Acetyl-D-galactosamine,,,,,,solid,,,254,11.6,-0.78,CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O,,,,,0,,221.0899372,1,0,1,0,1,1
3167,30/06/2019 00:00,DB03568,Butyric Acid,,,,1 g/1g,Not applicable,solid,6E+004 mg/L (at 25 Â°C),0.79,239,4.91,,CCCC(O)=O,,,,,0,,88.0524295,0,0,0,0,0,0
3168,04/06/2019 00:00,DB03569,"4,5-Dehydro-L-Iduronic Acid",,,,,,solid,,,145,2.89,-3.8,[H][C@@]1(O)OC(C(O)=O)=C(O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,192.0270026,1,0,1,0,0,1
3169,04/06/2019 00:00,DB03570,Tris-Hydroxymethyl-Methyl-Ammonium,,,,,,solid,,,29.7,11.84,-4,C[N+](CO)(CO)CO,,,,,1,,122.0811697,0,0,0,0,0,0
3170,04/06/2019 00:00,DB03571,"3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-N-(3,5-Dichlorobenzyl)-Benzamide",,,,,,solid,,,0.019,10.59,-1,NC1=NC2=NN(N=C2C(O)=N1)C1=CC(=CC=C1)C(=O)NCC1=CC(Cl)=CC(Cl)=C1,,,,,0,,429.050778,4,4,2,2,0,0
3171,04/06/2019 00:00,DB03572,FR230513,,,,,,solid,,,0.025,13.9,3.53,[H][C@](CO)(CCC1=CC=CC2=C1C=CC=C2)N1C=NC(=C1)C(N)=O,,,,,0,,309.1477268,3,3,1,1,0,0
3172,04/06/2019 00:00,DB03573,WRR-99,,,,,,solid,,,0.149,4,-3.4,[H][C@](O)(CC(O)=O)C(=O)N[C@]([H])(CCC1=CC=CC=C1)C(=O)NCCC(C)C,,,,,0,,364.199822,1,1,0,0,0,0
3173,04/06/2019 00:00,DB03575,Phencyclidine,,,,,,solid,,4.69,0.00325,,10.56,C1CCN(CC1)C1(CCCCC1)C1=CC=CC=C1,,,,,0,,243.1986998,3,1,1,0,1,1
3174,04/06/2019 00:00,DB03576,N-Pyridoxyl-Threonine-5-Monophosphate,,,,,,solid,,,1.52,1,9.51,CC(O)C(NCC1=C(COP(O)(O)=O)C=NC(C)=C1O)C(O)=O,,,,,0,,350.0879022,1,1,1,1,0,0
3175,04/06/2019 00:00,DB03577,Alpha-Benzyl-Aminobenzyl-Phosphonic Acid,,,,,,solid,,,0.524,-0.72,6.36,[H][C@](NCC1=CC=CC=C1)(C1=CC=CC=C1)P(O)(O)=O,,,,,0,,277.08678,2,2,0,0,0,0
3176,04/06/2019 00:00,DB03578,Pyruvamide,,,,,,solid,,,165,13.78,-4,CC(=O)C(N)=O,,,,,0,,87.0320284,0,0,0,0,0,0
3177,04/06/2019 00:00,DB03581,Glucose-6-Phosphate,,,,,,solid,,,21.7,1.49,-3.5,O[C@H](COP(O)(O)=O)[C@H](O)[C@H](O)[C@@H](O)C=O,,,,,0,,260.0297186,0,0,0,0,0,0
3178,04/06/2019 00:00,DB03582,N~2~-Succinylornithine,,,,,,solid,,,19.3,3.32,9.9,NCCC[C@H](NC(=O)CCC(O)=O)C(O)=O,,,,,0,,232.1059216,0,0,0,0,0,0
3179,04/06/2019 00:00,DB03583,"(2e,3s)-3-Hydroxy-5'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3'-Biindol-2'(1'h)-One",,,,,,solid,,,0.176,10.55,-1.9,OC1CCN(CC1)S(=O)(=O)C1=CC2=C(C=C1)NC(=O)\C2=C1/NC2=C(C=CC=C2)[C@]1(C)O,,,,,0,,441.1358418,5,2,3,0,1,3
3180,04/06/2019 00:00,DB03584,4-Thio-beta-D-glucopyranose,,,,,,solid,,,53,9.49,-3,[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(S)[C@]([H])(O)[C@@]1([H])O,,,,,0,,196.0405445,1,0,1,0,1,1
3181,02/07/2019 00:00,DB03585,Oxyphenbutazone,,,,100 mg,Oral,solid,60 mg/L (at 30 Â°C),2.72,0.256,4.87,-6,CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1,,,,,0,100,324.1473925,3,2,1,0,1,1
3182,04/06/2019 00:00,DB03586,"(3R,4R,5S,6R)-6-Fluoro-3,4,5-trihydroxytetrahydro-2H-pyran-2-olate",,,,,,solid,,,441,11.18,-3.7,[H][C@]1(F)OC([O-])[C@H](O)[C@@H](O)[C@@H]1O,,,,,-1,,167.0361252,1,0,1,0,1,1
3183,04/06/2019 00:00,DB03587,Pyruvaldehyde,,,,,,solid,,,180,16.38,-8,CC(=O)C=O,,,,,0,,72.02112937,0,0,0,0,0,0
3184,04/06/2019 00:00,DB03588,Diphenylacetic Acid,,,,,,solid,,,0.102,4.43,,OC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,212.0837296,2,2,0,0,0,0
3185,04/06/2019 00:00,DB03589,Alpha-Ketomalonic Acid,,,,,,solid,,,14.5,1.56,,OC(=O)C(=O)C(O)=O,,,,,0,,117.9902232,0,0,0,0,0,0
3186,04/06/2019 00:00,DB03590,"2,6-Diaminopimelic Acid",,,,,,solid,,,14.1,1.85,9.83,N[C@@H](CCC[C@H](N)C(O)=O)C(O)=O,,,,,0,,190.0953569,0,0,0,0,0,0
3187,04/06/2019 00:00,DB03591,RU82209,,,,,,solid,,,0.00158,0.48,1.81,[H][C@@](CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)(N=C(C)O)C(O)=N[C@@]1([H])CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O,,,,,0,,613.2153289,4,3,1,0,1,1
3188,04/06/2019 00:00,DB03592,Pterin-6-Yl-Methyl-Monophosphate,,,,,,solid,,,6.53,1.63,0.8,NC1=NC2=NC=C(COP(O)(O)=O)N=C2C(=O)N1,,,,,0,,273.026305,2,2,2,2,0,0
3189,04/06/2019 00:00,DB03593,N7-Methyl-Guanosine-5'-Monophosphate,,,,,,solid,,,1.29,1.19,2.34,C[N+]1=CN([C@@H]2O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]2O)C2=C1C(O)=NC(=N)N2,,,,,1,,378.0809256,3,2,3,2,1,1
3190,04/06/2019 00:00,DB03594,"1,2,4-Triazole",,,,,,solid,,,569,9,2.47,N1C=NC=N1,,,,,0,,69.0326971,1,1,1,1,0,0
3191,04/06/2019 00:00,DB03595,CRA_9785,,,,,,solid,,,0.0176,8.77,10.59,NC(=[NH2+])C1=CC=C2NC(=NC2=C1)C1=CC(OC(F)(F)F)=CC=C1[O-],,,,,0,,336.0834103,3,3,1,1,0,0
3192,04/06/2019 00:00,DB03596,N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide,,,,,,solid,,,0.00324,9.95,-0.78,[H][C@@](CC)(CNC(=O)C1=CC=C(C=C1)S(N)(=O)=O)C1=CC2=C(NC=C2)C=C1,,,,,0,,371.1303625,3,3,1,1,0,0
3193,04/06/2019 00:00,DB03597,Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine,,,,,,solid,,,0.00601,1.85,9.54,[H][C@](N)(CCC(O)=N[C@@]([H])(CSCC1=CC=CC=C1I)C(O)=NCC(O)=O)C(O)=O,,,,,0,,523.0274044,1,1,0,0,0,0
3194,04/06/2019 00:00,DB03598,"Al-6629, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Methoxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]",,,,,,solid,,,0.0734,8.14,4.31,COC1=CC=CC(=C1)N1C(CN2CCOCC2)=CC2=C(SC(=C2)S(N)(=O)=O)S1(=O)=O,,,,,0,,471.0592484,4,2,3,1,1,2
3195,04/06/2019 00:00,DB03600,Capric acid,,,,,,solid,61.8 mg/L (at 25 Â°C),4.09,0.0946,4.95,,CCCCCCCCCC(O)=O,,,,,0,,172.1463299,0,0,0,0,0,0
3196,04/06/2019 00:00,DB03601,5-deoxyflavanone,,,,,,solid,,,0.133,7.79,-4.9,OC1=CC=C(C=C1)[C@@H]1CC(=O)C2=CC=C(O)C=C2O1,,,,,0,,256.0735589,3,2,1,0,0,1
3197,04/06/2019 00:00,DB03602,S-Benzyl-Glutathione,,,,,,solid,,,0.0801,2,9.54,[H][C@](N)(CCC(O)=N[C@@]([H])(CSCC1=CC=CC=C1)C(O)=NCC(O)=O)C(O)=O,,,,,0,,397.1307565,1,1,0,0,0,0
3198,04/06/2019 00:00,DB03603,Glucaric acid,,,,,,solid,,,63.1,2.83,-3.7,O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O,,,,,0,,210.0375673,0,0,0,0,0,0
3199,04/06/2019 00:00,DB03604,Tiratricol,,,,,,solid,,,0.00539,2.31,-6.4,OC(=O)CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1,,,,,0,,621.7635028,2,2,0,0,0,0
3200,04/06/2019 00:00,DB03605,"(2s)-2-[(2,4-Dichloro-Benzoyl)-(3-Trifluoromethyl-Benzyl)-Amino]-3-Phenyl-Propionic Acid",,,,,,solid,,,0.000379,3.59,-1.6,[H][C@@](CC1=CC=CC=C1)(N(CC1=CC(=CC=C1)C(F)(F)F)C(=O)C1=C(Cl)C=C(Cl)C=C1)C(O)=O,,,,,0,,495.0615835,3,3,0,0,0,0
3201,04/06/2019 00:00,DB03606,(S)-Rolipram,,,,,,solid,,,0.0672,14.28,-1.9,[H][C@@]1(CNC(=O)C1)C1=CC=C(OC)C(OC2CCCC2)=C1,,,,,0,,275.1521435,3,1,1,0,1,1
3202,04/06/2019 00:00,DB03607,[(1R)-1-acetamido-2-(4-chlorophenyl)ethyl]-[(2S)-2-amino-3-hydroxy-3-oxo-propoxy]-dihydroxy-boron,,,,,,solid,,,0.143,1.78,8.54,[H][C@](N)(CO[B-](O)(O)[C@]([H])(CC1=CC=C(Cl)C=C1)N=C(C)O)C(O)=O,,,,,-1,,345.103018,1,1,0,0,0,0
3203,04/06/2019 00:00,DB03608,Diminazene,,,,,,solid,,,0.102,18.96,12.07,NC(=N)C1=CC=C(N\N=N\C2=CC=C(C=C2)C(N)=N)C=C1,,,,,0,,281.1388935,2,2,0,0,0,0
3204,04/06/2019 00:00,DB03609,3-Deoxyguanosine,,,,,,solid,,,9.05,6.09,4.93,[H][C@@]1(CO)C[C@@]([H])(O)[C@@]([H])(O1)N1C=NC2=C1NC(=N)N=C2O,,,,,0,,267.0967539,3,2,3,2,1,1
3205,04/06/2019 00:00,DB03610,4-(trifluoromethyl)phenol,,,,,,solid,,,5.06,9.39,-6,OC1=CC=C(C=C1)C(F)(F)F,,,,,0,,162.0292494,1,1,0,0,0,0
3206,04/06/2019 00:00,DB03611,L-2-amino-4-methoxy-cis-but-3-enoic acid,,,,,,solid,,,242,2.19,8.88,[H]\C(OC)=C(/[H])[C@]([H])(N)C(O)=O,,,,,0,,131.0582431,0,0,0,0,0,0
3207,04/06/2019 00:00,DB03612,3-Hydroxybutyryl-Coenzyme A,,,,,,solid,,,4.07,0.82,4.95,CC(O)CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N,,,,,0,,853.1519884,3,2,3,2,1,1
3208,04/06/2019 00:00,DB03613,4-Hydroxyphenacyl Coenzyme A,,,,,,solid,,,5.58,0.82,4.8,[H][C@](O)(C(O)=NCCC(O)=NCCSCC(=O)C1=CC=C(O)C=C1)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,901.1519884,4,3,3,2,1,1
3209,04/06/2019 00:00,DB03615,Ribostamycin,,,,,,solid,,,88.7,12.19,9.67,[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2N)O[C@H](CO)[C@@H](O)[C@H]1O,,,,,0,,454.2274933,3,0,2,0,2,2
3210,04/06/2019 00:00,DB03616,Kabiramide C,,,,,,solid,,,0.0231,11.4,7.6,[H]\C(=C(\[H])[C@@]([H])(C)[C@@]([H])(OC)[C@@]([H])(C)C(=O)CC[C@]([H])(C)[C@]([H])(C[C@]1([H])OC(=O)C[C@]([H])(C[C@]([H])(C)C[C@]([H])(O)[C@]([H])(C)[C@@]([H])(OC)C2=COC(=N2)C2=COC(=N2)C2=COC(=N2)\C([H])=C([H])\C[C@]([H])(OC)[C@@]1([H])C)O[C@]([H])(N)O)OC)N(C)CO,,,,,0,,945.5310521,4,3,4,3,0,1
3211,04/06/2019 00:00,DB03617,Modified Acarbose Hexasaccharide,,,,,,solid,,,71.1,11.18,7.33,[H][C@]1(C)O[C@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@]([H])(O[C@]3([H])C(CO)=C[C@]([H])(N[C@]4([H])[C@@]([H])(C)O[C@]([H])(O[C@]5([H])[C@@]([H])(CO)O[C@]([H])(O[C@]6([H])[C@@]([H])(C)O[C@@]([H])(O)[C@]([H])(O)[C@@]6([H])O)[C@]([H])(O)[C@@]5([H])O)[C@]([H])(O)[C@@]4([H])O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,937.3638311,6,0,5,0,5,5
3212,04/06/2019 00:00,DB03618,2-(Acetylamino)-2-Deoxy-4-O-Beta-D-Galactopyranosyl-Alpha-D-Glucopyranose,,,,,,solid,,,157,7.18,1.36,[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])N=C(C)O,,,,,0,,383.1427606,2,0,2,0,2,2
3213,02/07/2019 00:00,DB03619,Deoxycholic Acid,"Deoxycholic acid is rapidly absorbed after subcutaneous administration. After maximum recommended single treatment dose, 100mg, the post-treatment plasma levels returned to endogenous levels within 24 hours. With the proposed treatment guideline, no accumulation is expected. ",0.98,,10 mg,Subcutaneous,solid,43.6 mg/L (at 20 Â°C),3.5,0.0173,4.65,-0.35,[H][C@@]12CC[C@H]([C@H](C)CCC(O)=O)[C@@]1(C)[C@@H](O)C[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C,0.98,0.98,,,0,,392.2926598,4,0,0,0,0,0
3214,04/06/2019 00:00,DB03621,"L-709,587",,,,,,solid,,,0.00455,9.96,-2.9,[H]\C(=C(\C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@]([H])(C[C@@]2([H])C)OC)[C@]([H])(C[C@@]([H])(C)[C@]([H])(O)\C(C)=C([H])\[C@@]([H])(CC)C(=O)C[C@]([H])(O)[C@@]1([H])C)OC)[C@]1([H])CC[C@@]([H])(OC2=CC=C3N(C)C=CC3=C2)[C@@]([H])(C1)OC,,,,,0,,936.5347405,6,2,4,1,2,3
3215,04/06/2019 00:00,DB03622,"2-Hydroxy-5-[4-(2-Hydroxy-Ethyl)-Piperidin-1-Yl]-5-Phenyl-1h-Pyrimidine-4,6-Dione",,,,,,solid,,,0.518,6.6,4.66,OCCC1CCN(CC1)[C@@]1(C(=O)NC(O)=NC1=O)C1=CC=CC=C1,,,,,0,,331.1532062,3,1,2,0,1,2
3216,04/06/2019 00:00,DB03623,"9-(4-Hydroxyphenyl)-2,7-Phenanthroline",,,,,,solid,,,0.00439,9.77,4.95,OC1=CC=C(C=C1)C1=CC2=C(C=CC3=C2C=NC=C3)N=C1,,,,,0,,272.094963,4,4,2,2,0,0
3217,04/06/2019 00:00,DB03624,7-(Carboxyamino)-8-Amino-Nonanoic Acid,,,,,,solid,,,3.33,3.71,9.45,C[C@H](N)[C@@H](CCCCCC(O)=O)NC(O)=O,,,,,0,,232.1423071,0,0,0,0,0,0
3218,04/06/2019 00:00,DB03626,"5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione",,,,,,solid,,,0.0646,12.61,-4.6,COC1=CC(=O)C2=C(C(COC3=CC=CC=C3)=C(C)N2C)C1=O,,,,,0,,311.115758,3,2,1,1,0,0
3219,04/06/2019 00:00,DB03627,Adamantane,,,,,,solid,,,0.00491,,,C1C2CC3CC1CC(C2)C3,,,,,0,,136.1252005,4,0,0,0,0,0
3220,04/06/2019 00:00,DB03628,ISO24,,,,,,solid,,,1.32,0.34,-7.1,CCC1=CC=C(NC(=O)P(O)(O)=O)C=C1,,,,,0,,229.0503945,1,1,0,0,0,0
3221,04/06/2019 00:00,DB03629,Pyridoxal-5'-Phosphate-N-Oxide,,,,,,solid,,,2.66,1.66,0.029,CC1=C(O)C(C=O)=C(COP(O)(O)=O)C=[N+]1[O-],,,,,0,,263.0194883,1,1,1,1,0,0
3222,04/06/2019 00:00,DB03630,2-Iodobenzylthio Group,,,,,,solid,,,0.028,9.92,-9.7,SCC1=CC=CC=C1I,,,,,0,,249.9313192,1,1,0,0,0,0
3223,04/06/2019 00:00,DB03631,"3-(4-Hydroxy-3-Imino-6-Oxo-Cyclohexa-1,4-Dienyl)-Alanine",,,,,,solid,,,0.82,1.75,9.45,[H]N=C1C=C(C[C@]([H])(N)C(O)=O)C(=O)C=C1O,,,,,0,,210.0640568,1,0,0,0,0,0
3224,04/06/2019 00:00,DB03632,Argifin,,,,,,solid,,,0.16,2.34,12.12,[H][C@]1(C)N=C(O)C[C@]([H])(N=C(O)C[C@]([H])(N=C(O)[C@]([H])(CC2=CC=CC=C2)N(C)C(=O)[C@]([H])(CCCNC(=N)NC(O)=NC)N=C1O)C(O)=O)C(O)=O,,,,,0,,675.2976385,2,1,1,0,0,1
3225,04/06/2019 00:00,DB03633,Lpc-Ether,,,,,,solid,,,0.000391,1.86,-3.4,CCCCCCCCCCCCCCCCCCOC[C@@H](O)CO[P@@](O)(=O)OCC[N+](C)(C)C,,,,,1,,510.3918016,0,0,0,0,0,0
3226,04/06/2019 00:00,DB03634,"1,3-Di(N-Propyloxy-a-Mannopyranosyl)-Carbomyl 5-Methyazido-Benzene",,,,,,solid,,,3.38,7.4,4.83,[H][C@]1(CO)O[C@]([H])(OCCCN=C(O)C2=CC(=CC(CN=[N+]=[N-])=C2)C(O)=NCCCO[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,659.265001,3,1,2,0,2,2
3227,04/06/2019 00:00,DB03635,Ethanesulfonic Acid,,,,,,solid,,,52.4,-1.3,,CCS(O)(=O)=O,,,,,0,,110.0037651,0,0,0,0,0,0
3228,04/06/2019 00:00,DB03636,Glycinamid,,,,,,solid,,,544,16.37,8.15,NCC(N)=O,,,,,0,,74.04801281,0,0,0,0,0,0
3229,04/06/2019 00:00,DB03637,Guanidine-3-Propanol,,,,,,solid,,,219,15.93,12.6,NC(=[NH2+])NCCCO,,,,,1,,118.0974884,0,0,0,0,0,0
3230,04/06/2019 00:00,DB03638,Cytidyl-2'-5'-Phospho-Guanosine,,,,,,solid,,,2.59,1.65,4.94,[H][C@]1(CO)O[C@@]([H])(N2C=CC(=N)N=C2O)[C@]([H])(OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C3NC(=N)N=C4O)[C@]([H])(O)[C@]2([H])O)[C@]1([H])O,,,,,0,,588.1329549,5,3,5,3,2,2
3231,04/06/2019 00:00,DB03639,1-Guanidinium-7-Aminoheptane,,,,,,solid,,,24.1,,10.21,NCCCCCCCNC(N)N,,,,,0,,174.1844467,0,0,0,0,0,0
3232,04/06/2019 00:00,DB03640,Beta-Hydroxyaspartic Acid,,,,,,solid,,,111,2.57,9.08,N[C@@H]([C@@H](O)C(O)=O)C(O)=O,,,,,0,,149.0324223,0,0,0,0,0,0
3233,04/06/2019 00:00,DB03641,"2'-deoxyuridine 5'-alpha,beta-imido-diphosphate",,,,,,solid,,,11,1.06,-3.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(=O)NP(O)(O)=O)N1C=CC(O)=NC1=O,,,,,0,,387.0232669,2,1,2,1,1,1
3234,04/06/2019 00:00,DB03642,Benzofuran-2-Carboxylic Acid {(S)-3-Methyl-1-[3-Oxo-1-(Pyridin-2-Ylsulfonyl)Azepan-4-Ylcarbamoyl]Butyl}Amide,,,,,,solid,,,0.0593,4.99,1.03,[H][C@@](CC(C)C)(N=C(O)C1=CC2=CC=CC=C2O1)C(O)=N[C@@]1([H])CCCN(CC1=O)S(=O)(=O)C1=CC=CC=N1,,,,,0,,526.1886057,4,3,3,2,1,1
3235,04/06/2019 00:00,DB03643,CRA_1144,,,,,,solid,,,0.0691,9.12,10.62,NC(=[NH2+])C1=CC=C2NC(=NC2=C1)C1=CC=CC=C1[O-],,,,,0,,252.101111,3,3,1,1,0,0
3236,04/06/2019 00:00,DB03644,3-hydroxyanthranilic acid,,,,,,solid,,,10.5,1.94,4.82,NC1=C(O)C=CC=C1C(O)=O,,,,,0,,153.0425931,1,1,0,0,0,0
3237,04/06/2019 00:00,DB03645,Phosphonoacetohydroxamic Acid,,,,,,solid,,,19,1.66,-5.5,ONC(=O)CP(O)(O)=O,,,,,0,,154.9983589,0,0,0,0,0,0
3238,04/06/2019 00:00,DB03646,"2,3-di-O-phytanyl-sn-glycerol",,,,,,solid,,,6.11E-06,14.6,-3,[H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@@]([H])(C)CCOC[C@@]([H])(CO)OCC[C@]([H])(C)CCC[C@]([H])(C)CCC[C@]([H])(C)CCCC(C)C,,,,,0,,652.6733467,0,0,0,0,0,0
3239,04/06/2019 00:00,DB03647,3-[Isopropyl(4-Methylbenzoyl)Amino]-5-Phenylthiophene-2-Carboxylic Acid,,,,,,solid,,,0.00109,3.56,-2.9,CC(C)N(C(=O)C1=CC=C(C)C=C1)C1=C(SC(=C1)C1=CC=CC=C1)C(O)=O,,,,,0,,379.1242145,3,3,1,1,0,0
3240,04/06/2019 00:00,DB03648,2-{N'-[2-(5-Amino-1-Phenylcarbamoyl-Pentylcarbamoyl)-Hexyl]-Hydrazinomethyl}-Hexanoic Acid(5-Amino-1-Phenylcarbamoyl-Pentyl)-Amide,,,,,,solid,,,0.00298,5.28,10.51,[H][C@](CCCC)(CNNC[C@]([H])(CCCC)C(O)=N[C@@]([H])(CCCCN)C(O)=NC1=CC=CC=C1)C(O)=N[C@@]([H])(CCCCN)C(O)=NC1=CC=CC=C1,,,,,0,,694.4894025,2,2,0,0,0,0
3241,04/06/2019 00:00,DB03649,"[{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate",,,,,,solid,,,6.05,0.87,4.49,OP(O)(=O)C(NC1=CC=C(Cl)C=N1)P(O)(O)=O,,,,,0,,301.9624369,1,1,1,1,0,0
3242,04/06/2019 00:00,DB03650,(3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One,,,,,,solid,,,0.222,8.64,-0.45,OC1=CC=C(C=C1)\N=C1/C(=O)NC2=CC=CC=C12,,,,,0,,238.0742276,3,2,1,0,0,1
3243,04/06/2019 00:00,DB03651,Picric acid,,,,13 g/100g,Topical,solid,,,0.194,1.35,-8.5,OC1=C(C=C(C=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O,,,,,0,,228.9970994,1,1,0,0,0,0
3244,04/06/2019 00:00,DB03652,beta-D-Galactopyranuronic acid,,,,,,solid,,,295,3.21,-3.7,O[C@@H]1O[C@@H]([C@H](O)[C@H](O)[C@H]1O)C(O)=O,,,,,0,,194.0426527,1,0,1,0,1,1
3245,04/06/2019 00:00,DB03653,"5-{[Ethyl(Methyl)Amino]Methyl}-2-Methyl-5,6-Dihydropyrimidin-4-Amine",,,,,,solid,,,5.86,,7.78,CCN(C)CC1=CN=C(C)N=C1N,,,,,0,,180.1374965,1,1,1,1,0,0
3246,04/06/2019 00:00,DB03654,"S,S-Propylthiocysteine",,,,,,solid,,,1.6,15.99,7.58,[H][C@](N)(CSSCCC)C=O,,,,,0,,179.043856,0,0,0,0,0,0
3247,04/06/2019 00:00,DB03656,Tribenuron Methyl,,,,,,solid,,,0.0238,3.41,-1,COC(=O)C1=CC=CC=C1S(=O)(=O)NC(=O)N(C)C1=NC(C)=NC(OC)=N1,,,,,0,,395.0899543,2,2,1,1,0,0
3248,04/06/2019 00:00,DB03657,1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose,,,,,,solid,,,90.4,7.61,-2.9,[H][C@]1(CO)O[C@@]([H])(N=C(O)OC)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,237.0848518,1,0,1,0,1,1
3249,04/06/2019 00:00,DB03658,"2-{1-[2-Amino-2-(4-Hydroxy-Phenyl)-Acetylamino]-2-Oxo-Ethyl}-5,5-Dimethyl-Thiazolidine-4-Carboxylic Acid",,,,,,solid,,,0.347,2.82,8.65,[H][C@](N)(C(O)=N[C@]([H])(C=O)[C@]1([H])N[C@@]([H])(C(O)=O)C(C)(C)S1)C1=CC=C(O)C=C1,,,,,0,,367.1201918,2,1,1,0,1,1
3250,04/06/2019 00:00,DB03659,Butylamine,,,,,,liquid,1E+006 mg/L (at 20 Â°C),0.97,80.7,,10.21,CCCCN,,,,,0,,73.08914935,0,0,0,0,0,0
3251,04/06/2019 00:00,DB03660,4-Iodo-L-phenylalanine,,,,,,solid,,,0.274,1.27,9.44,[H][C@](N)(CC1=CC=C(I)C=C1)C(O)=O,,,,,0,,290.9756266,1,1,0,0,0,0
3252,04/06/2019 00:00,DB03661,Cysteinesulfonic Acid,,,,,,solid,,,73.6,-1.7,8.79,N[C@@H](CS(O)(=O)=O)C(O)=O,,,,,0,,169.0044933,0,0,0,0,0,0
3253,04/06/2019 00:00,DB03662,Vitamin B6 Complexed with 2-Amino-Pentanoic Acid,,,,,,solid,,,1,1.14,10.08,CCC[C@H](NCC1=C(O)C(C)=NC=C1COP(O)(O)=O)C(O)=O,,,,,0,,348.1086376,1,1,1,1,0,0
3254,04/06/2019 00:00,DB03663,"1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol",,,,,,solid,,,1.58,10.19,3.08,CC(C)C(=O)COC1=NC(N)=NC2=C1NC=N2,,,,,0,,235.1069247,2,2,2,2,0,0
3255,04/06/2019 00:00,DB03664,UP5,,,,,,solid,,,6.52,0.23,4.93,[H]N([H])C1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)N4C=CC(=O)N([H])C4=O)[C@@H](O)[C@H]3O)C2=NC=N1,,,,,0,,892.9873779,5,3,5,3,2,2
3256,04/06/2019 00:00,DB03666,3'-Azido-3'-Deoxythymidine-5'-Monophosphate,,,,,,solid,,,3.56,1.26,-4.1,[H][C@@]1(C[C@]([H])(N=[N+]=[N-])[C@@]([H])(COP(O)(O)=O)O1)N1C=C(C)C(O)=NC1=O,,,,,0,,347.0630844,2,1,2,1,1,1
3257,04/06/2019 00:00,DB03667,Acetic Acid Salicyloyl-Amino-Ester,,,,,,solid,,,2.28,8.01,-6.2,CC(=O)ONC(=O)C1=C(O)C=CC=C1,,,,,0,,195.0531578,1,1,0,0,0,0
3258,04/06/2019 00:00,DB03668,1-(5'-Phospho-Beta-D-Ribofuranosyl)Barbituric Acid,,,,,,solid,,,18.9,1.23,-3.4,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C(=O)CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,340.0307812,2,0,2,0,1,2
3259,04/06/2019 00:00,DB03669,4-Fluorophenethyl Alcohol,,,,,,solid,,,3.1,15.89,-2.4,OCCC1=CC=C(F)C=C1,,,,,0,,140.0637431,1,1,0,0,0,0
3260,04/06/2019 00:00,DB03670,"2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid",,,,,,solid,,,0.128,1.67,8.48,OC(=O)C(=O)NC1=C(C(O)=O)C2=C(CNCC2)S1,,,,,0,,270.0310424,2,1,2,1,0,1
3261,04/06/2019 00:00,DB03671,"4-(3,12,14-Trihydroxy-10,13-Dimethyl-Hexadecahydro-Cyclopenta[a]Phenanthren-17-Yl)-5h-Furan-2-One",,,,,,solid,,,0.0632,7.15,-1.4,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@@]([H])(O)[C@]12C)C1=CC(=O)OC1,,,,,0,,390.2406242,5,0,1,0,0,1
3262,04/06/2019 00:00,DB03672,9-N-Phenylmethylamino-Tacrine,,,,,,solid,,,0.00109,,8.87,C(NC1=C2C=CC=CC2=NC2=C1CCCC2)C1=CC=CC=C1,,,,,0,,288.1626486,4,3,1,1,0,0
3263,04/06/2019 00:00,DB03673,Beta(2-Thienyl)Alanine,,,,,,solid,,,1.61,2.6,9.27,N[C@@H](CC1=CC=CS1)C(O)=O,,,,,0,,171.0353995,1,1,1,1,0,0
3264,04/06/2019 00:00,DB03675,"2,3-Dihydroxy-Valerianic Acid",,,,,,solid,,,486,3.93,-3.3,CC[C@@](C)(O)[C@@H](O)C(O)=O,,,,,0,,148.0735589,0,0,0,0,0,0
3265,04/06/2019 00:00,DB03676,Cystein-S-Yl Cacodylate,,,,,,solid,,,6.46,1.67,9.05,[H][C@](N)(CS[As](C)(C)=O)C(O)=O,,,,,0,,240.9753857,0,0,0,0,0,0
3266,04/06/2019 00:00,DB03677,N-Cyclohexyl-N'-Decylurea,,,,,,solid,,,0.00489,15.55,-0.62,CCCCCCCCCCNC(=O)NC1CCCCC1,,,,,0,,282.2671137,1,0,0,0,0,0
3267,04/06/2019 00:00,DB03678,"(6,7-Difluoro-Quinazolin-4-Yl)-(1-Methyl-2,2-Diphenyl-Ethyl)-Amine",,,,,,solid,,,0.000344,19.07,3.71,C[C@H](NC1=NC=NC2=C1C=C(F)C(F)=C2)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,375.154704,4,4,1,1,0,0
3268,04/06/2019 00:00,DB03679,2-Hydroxy-Tryptophan,,,,,,solid,,,4.5,2.2,8.64,[H][C@](N)(CC1=C(O)NC2=CC=CC=C12)C(O)=O,,,,,0,,220.0847922,2,2,1,1,0,0
3269,04/06/2019 00:00,DB03680,Tartronate,,,,,,solid,,,542,2.16,-4.9,OC(C([O-])=O)C([O-])=O,,,,,-2,,117.9913203,0,0,0,0,0,0
3270,04/06/2019 00:00,DB03682,"Dibenzofuran-4,6-Dicarboxylic Acid",,,,,,solid,,,0.0727,2.87,-4.5,OC(=O)C1=CC=CC2=C1OC1=C2C=CC=C1C(O)=O,,,,,0,,256.0371734,3,3,1,1,0,0
3271,04/06/2019 00:00,DB03683,2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid,,,,,,solid,,,15.5,4.39,-5.7,[H][C@@](CC(C)C)(CN(O)C=O)C(O)=O,,,,,0,,189.100108,0,0,0,0,0,0
3272,04/06/2019 00:00,DB03685,Uridine monophosphate,,,,,,solid,,,12,1.23,-3.7,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(O)=O)N1C=CC(=O)NC1=O,,,,,0,,324.0358666,2,1,2,1,1,1
3273,04/06/2019 00:00,DB03686,S-(P-Nitrobenzyl)Glutathione,,,,,,solid,,,0.049,1.84,9.54,[H][C@](N)(CCC(O)=N[C@@]([H])(CSCC1=CC=C(C=C1)N(=O)=O)C(O)=NCC(O)=O)C(O)=O,,,,,0,,442.1158347,1,1,0,0,0,0
3274,04/06/2019 00:00,DB03687,4-Diphosphocytidyl-2-C-Methyl-D-Erythritol,,,,,,solid,,,10.8,1.77,3.34,[H][C@@](O)(COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=CC(=N)N=C2O)[C@]([H])(O)[C@]1([H])O)[C@@](C)(O)CO,,,,,0,,521.0811757,2,1,2,1,1,1
3275,04/06/2019 00:00,DB03688,3-Hydroxy-Propanoic Acid,,,,,,solid,,,647,4.2,-2.5,OCCC(O)=O,,,,,0,,90.03169405,0,0,0,0,0,0
3276,04/06/2019 00:00,DB03690,"(Z,Z)-4-Hydroxy-N,N,N-Trimethyl-10-Oxo-7-[(1-Oxo-9-Octadecenyl)Oxy]-3,5,9-Trioxa-4-Phosphaheptacos-18-En-1-Aminium-4-Oxide",,,,,,solid,,,3.14E-05,1.86,-6.7,CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC,,,,,1,,786.6007317,0,0,0,0,0,0
3277,04/06/2019 00:00,DB03691,WRR-112,,,,,,solid,,,0.149,4,-3.4,[H][C@](O)(CC(O)=O)C(=O)N[C@@]([H])(CCC1=CC=CC=C1)C(=O)NCCC(C)C,,,,,0,,364.199822,1,1,0,0,0,0
3278,04/06/2019 00:00,DB03692,1-Hexadecanosulfonyl-O-L-Serine,,,,,,solid,,,0.000448,1.54,8.57,[H][C@](N)(COS(=O)(=O)CCCCCCCCCCCCCCCC)C(O)=O,,,,,0,,393.2548943,0,0,0,0,0,0
3279,04/06/2019 00:00,DB03693,N-(2-Aminoethyl)-5-Chloroisoquinoline-8-Sulfonamide,,,,,,solid,,,0.184,9.56,8.92,NCCNS(=O)(=O)C1=CC=C(Cl)C2=C1C=NC=C2,,,,,0,,285.0338753,2,2,1,1,0,0
3280,04/06/2019 00:00,DB03694,N-Phenylthiourea,,,,,,solid,,,0.904,9.62,-3,NC(=S)NC1=CC=CC=C1,,,,,0,,152.0408193,1,1,0,0,0,0
3281,04/06/2019 00:00,DB03695,Piritrexim,,,,,,solid,,,0.064,16.06,3.91,COC1=CC(CC2=C(C)C3=C(N=C2)N=C(N)N=C3N)=C(OC)C=C1,,,,,0,,325.1538748,3,3,2,2,0,0
3282,04/06/2019 00:00,DB03696,Lanosterol,,,,,,solid,,,0.000376,19.55,-0.81,[H][C@@]1(CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@]1([H])CC3)[C@H](C)CCC=C(C)C,,,,,0,,426.3861662,4,0,0,0,0,0
3283,04/06/2019 00:00,DB03697,4-Sulfonamide-[1-(4-Aminobutane)]Benzamide,,,,,,solid,,,1.67,10.23,9.63,NCCCCNC(=O)C1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,271.0990624,1,1,0,0,0,0
3284,04/06/2019 00:00,DB03698,5-Mercaptoethanol-2-Decenoyl-Coenzyme A,,,,,,solid,,,0.525,0.71,4.51,[H]\C(C[C@]([H])(CCCCC)SCC=O)=C(\[H])C(=O)SCCN=C(O)CCN[C@]([H])(O)C(=O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])([N+]2=CNC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,1,,994.2252362,3,2,3,2,1,1
3285,04/06/2019 00:00,DB03699,Succinyl-Coenzyme A,,,,,,solid,,,3.84,0.82,4.98,CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O,,,,,0,,867.131253,3,2,3,2,1,1
3286,04/06/2019 00:00,DB03700,D-Threonine,,,,,,solid,,,477,2.21,9,C[C@@H](O)[C@@H](N)C(O)=O,,,,,0,,119.0582431,0,0,0,0,0,0
3287,04/06/2019 00:00,DB03701,Vanoxerine,,,,,,solid,,,0.00139,,8.58,FC1=CC=C(C=C1)C(OCCN1CCN(CCCC2=CC=CC=C2)CC1)C1=CC=C(F)C=C1,,,,,0,,450.2482701,4,3,1,0,1,1
3288,04/06/2019 00:00,DB03702,"2-[4-[[(S)-1-[[(S)-2-[[(Rs)-3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl]Aminocarbonyl]Pyrrolidin-1-Yl-]Carbonyl]-2-Methylpropyl]Aminocarbonyl]Benzoylamino]Acetic Acid",,,,,,solid,,,0.00635,3.08,0.75,[H][C@](NC(=O)C1=CC=C(C=C1)C(=O)NCC(O)=O)(C(C)C)C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(C(C)C)C(=O)C(F)(F)F,,,,,0,,570.2301341,2,1,1,0,1,1
3289,04/06/2019 00:00,DB03703,Cyclohexanol,,,,,,solid,4.2E+004 mg/L (at 10 Â°C),1.23,17.2,18.18,-1.4,OC1CCCCC1,,,,,0,,100.088815,1,0,0,0,0,0
3290,04/06/2019 00:00,DB03704,12-Hydroxydodecanoic Acid,,,,,,solid,,,0.214,4.95,-2,OCCCCCCCCCCCC(O)=O,,,,,0,,216.1725446,0,0,0,0,0,0
3291,04/06/2019 00:00,DB03705,6-Methylamino-5-Nitroisocytosine,,,,,,solid,,,2.27,10.73,3.01,CNC1=C(C(=O)NC(N)=N1)[N+]([O-])=O,,,,,0,,185.0548891,1,1,1,1,0,0
3292,04/06/2019 00:00,DB03706,1-Hydroxy-2-S-Glutathionyl-3-Para-Nitrophenoxy-Propane,,,,,,solid,,,0.0572,1.86,9.54,[H][C@](CO)(COC1=CC=C(C=C1)N(=O)=O)SC[C@]([H])(N=C(O)CC[C@]([H])(N)C(O)=O)C(O)=NCC(O)=O,,,,,0,,502.136964,1,1,0,0,0,0
3293,04/06/2019 00:00,DB03707,S-Ethyl-N-Phenyl-Isothiourea,,,,,,solid,,,0.401,,6.41,CCS\C(N)=N\C1=CC=CC=C1,,,,,0,,180.0721194,1,1,0,0,0,0
3294,04/06/2019 00:00,DB03708,Adenosine 5'-phosphosulfate,,,,,,solid,,,3.29,-2.1,4.99,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O,,,,,0,,427.0198993,3,2,3,2,1,1
3295,04/06/2019 00:00,DB03709,Bicine,,,,,,solid,,,182,3.01,7.66,OCCN(CCO)CC(O)=O,,,,,0,,163.0844579,0,0,0,0,0,0
3296,04/06/2019 00:00,DB03710,N5-(1-Imino-3-Butenyl)-L-Ornithine,,,,,,solid,,,0.434,2.39,12.73,[H][C@]([NH3+])(CCCNC(=N)CCC)C(O)=O,,,,,1,,202.1550033,0,0,0,0,0,0
3297,04/06/2019 00:00,DB03711,6-Hydroxy-6-Methyl-Heptan-3-One,,,,,,solid,,,13.5,15.38,-2.6,CCC(=O)CCC(C)(C)O,,,,,0,,144.1150298,0,0,0,0,0,0
3298,04/06/2019 00:00,DB03712,RU85053,,,,,,solid,,,0.0031,3.34,1.78,[H][C@@](CC1=CC(C(O)=O)=C(CC(O)=O)C=C1)(N=C(C)O)C(O)=N[C@@]1([H])CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O,,,,,0,,585.2475005,4,3,1,0,1,1
3299,04/06/2019 00:00,DB03714,4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid,,,,,,solid,,,0.0231,0.5,-1,[H][C@@](CCC(O)=O)(NC(=O)C1=CC2=C(C=C1)C=C(C=C2)C(F)(F)P(O)(O)=O)C(N)=O,,,,,0,,430.074144,2,2,0,0,0,0
3300,04/06/2019 00:00,DB03716,5'-Fluoro-5'-Deoxyadenosine,,,,,,solid,,,9.47,12.45,3.92,NC1=C2N=CN([C@@H]3O[C@H](CF)[C@@H](O)[C@H]3O)C2=NC=N1,,,,,0,,269.0924175,3,2,3,2,1,1
3301,04/06/2019 00:00,DB03717,"3-Hydroxy-4-(3,4,5-Trihydroxy-Tetrahydro-Pyran-2-Yloxy)-Piperidin-2-One",,,,,,solid,,,112,3.16,5.18,[H][C@@]1(O)CO[C@@]([H])(O[C@]2([H])CCN=C(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,263.1005019,2,0,2,0,1,2
3302,04/06/2019 00:00,DB03718,6-Aza-Ump,,,,,,solid,,,15.8,1.23,-3.7,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2N=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,325.0311156,2,1,2,1,1,1
3303,04/06/2019 00:00,DB03719,N-Ethyl-5'-Carboxamido Adenosine,,,,,,solid,,,7.34,12.39,4.99,CCNC(=O)[C@@H]1O[C@H]([C@H](O)[C@H]1O)N1C=NC2=C1N=CN=C2N,,,,,0,,308.123303,3,2,3,2,1,1
3304,04/06/2019 00:00,DB03720,Z-Dehydrobutyrine,,,,,,solid,,,188,2.88,8.46,C\C=C(/N)C(O)=O,,,,,0,,101.0476785,0,0,0,0,0,0
3305,04/06/2019 00:00,DB03721,N-acetyl-alpha-neuraminic acid,,,,,,solid,,,227,3,-1.3,[H][C@]1(O[C@](O)(C[C@H](O)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,,,,,0,,309.1059812,1,0,1,0,1,1
3306,04/06/2019 00:00,DB03722,"3,4-Dihydro-5-Methyl-Isoquinolinone",,,,,,solid,,,0.753,14.85,-0.61,CC1=CC=CC2=C1CCNC2=O,,,,,0,,161.084064,2,1,1,0,0,1
3307,04/06/2019 00:00,DB03723,2'-Deoxy-Thymidine-Beta-L-Rhamnose,,,,,,solid,,,11.6,1.73,-3.2,C[C@@H]1O[C@H](OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2O)N2C=C(C)C(=O)NC2=O)[C@H](O)[C@H](O)[C@H]1O,,,,,0,,548.0808414,3,1,3,1,2,2
3308,04/06/2019 00:00,DB03724,"(1s,2s)-1-Amino-1-(1,3-Thiazol-2-Yl)Propan-2-Ol",,,,,,solid,,,5.67,14.54,7.67,[H][C@](C)(O)[C@]([H])(N)C1=NC=CS1,,,,,0,,158.0513839,1,1,1,1,0,0
3309,04/06/2019 00:00,DB03725,Phosphomethylphosphonic Acid-Guanylate Ester,,,,,,solid,,,8.75,1.4,4.94,[H][C@]1(COP(O)(=O)OP(O)(=O)CP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,521.0113955,3,2,3,2,1,1
3310,04/06/2019 00:00,DB03726,Purine Riboside-5'-Monophosphate,,,,,,solid,,,3.29,-2.3,6.25,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=NC3=CN=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,332.0521854,3,2,3,2,1,1
3311,04/06/2019 00:00,DB03727,Coproporphyrin I,,,,,,solid,,,0.0309,3.56,5.18,CC1=C(CCC(O)=O)/C2=C/C3=N/C(=C\C4=C(C)C(CCC(O)=O)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(CCC(O)=O)=C4C)/C(CCC(O)=O)=C3C,,,,,0,,654.2689642,5,3,5,3,0,2
3312,04/06/2019 00:00,DB03728,p-Chlorobenzoic acid,,,,,,solid,72 mg/L (at 25 Â°C),2.65,1.1,4.07,,OC(=O)C1=CC=C(Cl)C=C1,,,,,0,,155.9978071,1,1,0,0,0,0
3313,04/06/2019 00:00,DB03729,2-Amino-5-Hydroxy-Benzimidazole,,,,,,solid,,,2.23,10.04,9.09,OC1=CC2=C(NC(=N)N2)C=C1,,,,,0,,149.0589118,2,2,1,1,0,0
3314,04/06/2019 00:00,DB03730,"3,9-Dimethyladenine",,,,,,solid,,,1.35,18.49,0.094,CN1C=NC2=C1[N+](C)=CN=C2N,,,,,1,,164.0930717,2,2,2,2,0,0
3315,04/06/2019 00:00,DB03731,S-2-(Boronoethyl)-L-Cysteine,,,,,,solid,,,1.46,1.78,9.14,[H][C@](N)(CSCC[B-](O)(O)O)C(O)=O,,,,,-1,,210.0612975,0,0,0,0,0,0
3316,04/06/2019 00:00,DB03732,Etheno-Nadp,,,,,,solid,,,5.63,0.72,4.9,[H][C@@]1(O)O[C@]([H])(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C3N=CN3C=CN=C43)[C@]([H])(OP(O)(O)=O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,663.0380042,5,3,5,3,2,2
3317,04/06/2019 00:00,DB03733,Ethylene Dichloride,,,,,,solid,8600 mg/L (at 25 Â°C),1.48,5.94,,,ClCCCl,,,,,0,,97.96900549,0,0,0,0,0,0
3318,04/06/2019 00:00,DB03734,Xylarohydroxamate,,,,,,solid,,,125,3.17,-3.8,ONC(=O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,,,,,-1,,194.0306252,0,0,0,0,0,0
3319,04/06/2019 00:00,DB03735,9-(2-Deoxy-Beta-D-Ribofuranosyl)-6-Methylpurine,,,,,,solid,,,7.78,13.89,4.24,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO)N1C=NC2=C(C)N=CN=C12,,,,,0,,250.1065903,3,2,3,2,1,1
3320,04/06/2019 00:00,DB03736,2-Cyclopropylmethylenepropanal,,,,,,solid,,,1.98,15.89,-7,[H][C@](C)(CC1CC1)C=O,,,,,0,,112.088815,1,0,0,0,0,0
3321,04/06/2019 00:00,DB03737,"4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One",,,,,,solid,,,0.0201,11.32,8.9,[H][C@](C)(O)[C@]([H])(N)[C@]([H])(O)C#CC1=C(F)C=CC2=C1\C(=C\C1=C(OC)C=CN1)C(=O)N2,,,,,0,,385.1437843,3,2,2,1,0,1
3322,04/06/2019 00:00,DB03738,Pantothenoylaminoethenethiol,,,,,,solid,,,0.22,5.73,4.62,[H]\C(S)=C(/[H])N=C(O)CCN=C(O)[C@]([H])(O)C(C)(C)CO,,,,,0,,276.1143781,0,0,0,0,0,0
3323,04/06/2019 00:00,DB03739,3-Hydroxyimino Quinic Acid,,,,,,solid,,,95.6,3.33,-3.2,[H][C@@]1(O)C[C@@](O)(C\C(=N/O)[C@@]1([H])O)C(O)=O,,,,,0,,205.0586371,1,0,0,0,0,0
3324,04/06/2019 00:00,DB03740,N-acetyl-alpha-D-glucosamine,,,,,,solid,,,82.5,7.38,1.46,[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])N=C(C)O,,,,,0,,221.0899372,1,0,1,0,1,1
3325,04/06/2019 00:00,DB03741,2-Methylbutanoic Acid,,,,,,solid,,,57.2,4.97,,CC[C@@H](C)C(O)=O,,,,,0,,102.0680796,0,0,0,0,0,0
3326,04/06/2019 00:00,DB03742,Compound 4-D,,,,,,solid,,,0.00162,9.45,8.73,[H][C@]1(OC2=C(S[C@]1([H])C1=CC=C(O)C=C1)C=C(O)C=C2)C1=CC=C(OCCN2CCCCC2)C=C1,,,,,0,,463.1817294,5,3,2,0,1,2
3327,04/06/2019 00:00,DB03744,"Cp403700, (S)-1-{2-[(5-Chloro-1h-Indole-2-Carbonyl)-Amino]-3-Phenyl-Propionyl}-Azetidine-3-Carboxylate",,,,,,solid,,,0.0215,3.85,-2,[H][C@@](CC1=CC=CC=C1)(NC(=O)C1=CC2=C(N1)C=CC(Cl)=C2)C(=O)N1CC(C1)C(O)=O,,,,,0,,425.1142338,4,3,2,1,1,1
3328,04/06/2019 00:00,DB03745,Arabinose-5-phosphate,,,,,,solid,,,28.5,1.49,-3,[H][C@@](O)(CO)[C@]([H])(O)[C@]([H])(O)COP(O)(O)=O,,,,,0,,232.034804,0,0,0,0,0,0
3329,04/06/2019 00:00,DB03746,"3-Amino-4,5-Dihydroxy-Cyclohex-1-Enecarboxylate",,,,,,solid,,,381,4,8.92,N[C@H]1C=C(C[C@@H](O)[C@@H]1O)C([O-])=O,,,,,-1,,172.0615314,1,0,0,0,0,0
3330,04/06/2019 00:00,DB03747,"3ar,5r,6s,7r,7ar-5-Hydroxymethyl-2-Methyl-5,6,7,7a-Tetrahydro-3ah-Pyrano[3,2-D]Thiazole-6,7-Diol",,,,,,solid,,,18.6,12.81,2.29,[H][C@]12O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])N=C(C)S2,,,,,0,,219.0565289,2,0,2,0,1,2
3331,04/06/2019 00:00,DB03748,Methyl-[4-(4-Piperidine-1-Ylmethyl-Phenyl)-Cyclohexyl]-Carbaminic Acid-(4-Chlorophenyl)-Ester,,,,,,solid,,,0.000347,,9.34,CN([C@H]1CC[C@@H](CC1)C1=CC=C(CN2CCCCC2)C=C1)C(=O)OC1=CC=C(Cl)C=C1,,,,,0,,440.223056,4,2,1,0,1,1
3332,04/06/2019 00:00,DB03749,"4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole",,,,,,solid,,,0.436,8.74,5.79,CCC1=C(O)C=C(O)C(=C1)C1=NNC=C1C1=CNC=N1,,,,,0,,270.1116757,3,3,2,2,0,0
3333,04/06/2019 00:00,DB03750,Isovaleric Acid,,,,,,solid,4.07E+004 mg/L (at 20 Â°C),1.16,64.9,5.01,,CC(C)CC(O)=O,,,,,0,,102.0680796,0,0,0,0,0,0
3334,04/06/2019 00:00,DB03751,2'deoxy-Thymidine-5'-Diphospho-Alpha-D-Glucose,,,,,,solid,,,11.2,1.73,-3,CC1=CN([C@H]2C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O2)C(=O)NC1=O,,,,,0,,564.075756,3,1,3,1,2,2
3335,04/06/2019 00:00,DB03752,P-(2'-Iodo-5'-Thenoyl)Hydrotropic Acid,,,,,,solid,,,0.00368,3.8,-7.8,[H][C@@](C)(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=C(I)S1,,,,,0,,385.9473632,2,2,1,1,0,0
3336,04/06/2019 00:00,DB03753,Flurbiprofen Methyl Ester,,,,,,solid,,,0.00471,,-7.1,COC(=O)[C@@H](C)C1=CC=C(C(F)=C1)C1=CC=CC=C1,,,,,0,,258.1056079,2,2,0,0,0,0
3337,02/07/2019 00:00,DB03754,Tromethamine,,,,3.6 g/100mL,Topical,solid,,,695,14.16,8.95,NC(CO)(CO)CO,,,,,0,,121.0738932,0,0,0,0,0,0
3338,04/06/2019 00:00,DB03755,"Adenosine-5'-[Beta, Gamma-Methylene]Tetraphosphate",,,,,,solid,,,4.81,1.5,5,[H][C@]1(COP(O)(=O)OP(O)(=O)CP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,584.9828114,3,2,3,2,1,1
3339,04/06/2019 00:00,DB03756,Doconexent,"Like other omega-3 fatty acids, DHA is hydrolyzed from the intestines and delivered through the lymphatic circulation. Plasma DHA concentrations increase in a dose-dependent and saturable manner. ",,Approximately 20 hours [A19370].,,Oral,liquid,,,0.000186,4.89,,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O,,,,,0,,328.2402303,0,0,0,0,0,0
3340,04/06/2019 00:00,DB03757,(Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine,,,,,,solid,,,0.153,-1.6,11.98,[H][C@@](C)(N=C(O)[C@]([H])(C)N=C(O)OC(C)(C)C)C(O)=N,,,,,0,,259.1532062,0,0,0,0,0,0
3341,04/06/2019 00:00,DB03758,Radicicol,,,,,,solid,,,0.188,7.02,-4.1,[H]/C1=C([H])\C(=O)CC2=C(C(O)=CC(O)=C2Cl)C(=O)O[C@]([H])(C)C[C@@]2([H])O[C@]2([H])/C([H])=C\1/[H],,,,,0,,364.0713659,3,1,2,0,1,2
3342,04/06/2019 00:00,DB03759,FG-9041,,,,,,solid,,,0.0912,9.53,-6.2,[O-][N+](=O)C1=C(C=C2NC(=O)C(=O)NC2=C1)[N+]([O-])=O,,,,,0,,252.0130838,2,2,1,1,0,0
3343,04/06/2019 00:00,DB03760,Dihydrolipoic Acid,,,,,,solid,,,0.103,4.91,-9.6,[H][C@](S)(CCS)CCCCC(O)=O,,,,,0,,208.0591718,0,0,0,0,0,0
3344,04/06/2019 00:00,DB03761,5-Fluoro-2'-Deoxyuridine-5'-Monophosphate,,,,,,solid,,,8.91,1.23,-3.2,O[C@H]1C[C@@H](O[C@@H]1COP(O)(O)=O)N1C=C(F)C(O)=NC1=O,,,,,0,,326.0315302,2,1,2,1,1,1
3345,04/06/2019 00:00,DB03763,5-Methyl-2'-Deoxypseudouridine,,,,,,solid,,,18.7,7.49,-3,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO)C1=CN(C)C(=O)N=C1O,,,,,0,,242.0902715,2,1,2,1,1,1
3346,04/06/2019 00:00,DB03764,4-Hydroperoxy-2-Methoxy-Phenol,,,,,,solid,,,13.4,9.9,-4.3,COC1=CC(OO)=CC=C1O,,,,,0,,156.0422587,1,1,0,0,0,0
3347,04/06/2019 00:00,DB03765,2'-cytidylic acid,,,,,,solid,,,5.46,0.65,2.43,[H][C@]1(CO)O[C@@]([H])(N2C=CC(=N)N=C2O)[C@]([H])(OP(O)(O)=O)[C@]1([H])O,,,,,0,,323.051851,2,1,2,1,1,1
3348,04/06/2019 00:00,DB03766,Propanoic acid,"Some propionic acid is oxidized to lactic acid during absorption, but most passes to the liver, which removes nearly all of it from the portal blood [L2725]. Propionic acid represents 20-25% of absorbed volatile fatty acids [L2725].

Propionic acid is rapidly absorbed through the gastrointestinal tract [L2725].",,The half-life of iv sodium propionate administered in the sheep animal model is about 6.9 +/- 0.4 minutes [L2725].,,Vaginal,solid,1E+006 mg/L (at 25 Â°C),0.33,352,4.75,,CCC(O)=O,,,,,0,,74.03677943,0,0,0,0,0,0
3349,04/06/2019 00:00,DB03767,Morpholine-4-Carboxylic Acid [1s-(2-Benzyloxy-1r-Cyano-Ethylcarbamoyl)-3-Methyl-Butyl]Amide,,,,,,solid,,,0.126,8.2,-1.7,[H][C@@](COCC1=CC=CC=C1)(NC(=O)[C@]([H])(CC(C)C)NC(=O)N1CCOCC1)C#N,,,,,0,,402.2267054,2,1,1,0,1,1
3350,04/06/2019 00:00,DB03768,"N-[2-Hydroxy-2-(8-Isopropyl-6,9-Dioxo-2-Oxa-7,10-Diaza-Bicyclo[11.2.2]Heptadeca-1(16),13(17),14-Trien-11-Yl)-Ethyl]-N-(3-Methyl-Butyl)-Benzenesulfonamide,Inhibitor 3",,,,,,solid,,,0.0148,10.96,-0.53,CC(C)CCN(C[C@@H](O)[C@@H]1CC2=CC=C(OCCCC(=O)N[C@@H](C(C)C)C(=O)N1)C=C2)S(=O)(=O)C1=CC=CC=C1,,,,,0,,573.2872571,4,2,2,0,0,2
3351,04/06/2019 00:00,DB03769,D-Eritadenine,,,,,,solid,,,9.78,3.26,5.13,[H][C@@](O)(CN1C=NC2=C(N)N=CN=C12)[C@@]([H])(O)C(O)=O,,,,,0,,253.0811038,2,2,2,2,0,0
3352,04/06/2019 00:00,DB03770,N-Hydroxyguanidine,,,,,,solid,,,6.83,14.82,10.51,NC(=N)NO,,,,,0,,75.04326178,0,0,0,0,0,0
3353,04/06/2019 00:00,DB03771,Allyl-{4-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-but-2-Enyl}-Methyl-Amine,,,,,,solid,,,0.00559,,8.56,CN(CC=C)C\C=C\COC1=CC2=C(C=C1)C(=CO2)C1=CC=C(Br)C=C1,,,,,0,,411.083391,3,3,1,1,0,0
3354,04/06/2019 00:00,DB03772,"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,5-Diol",,,,,,solid,,,39,13.23,-3,[H][C@@]1(O)C[C@@]([H])(O)[C@]([H])(OCCCCCC)O[C@]1([H])CO,,,,,0,,248.1623739,1,0,1,0,1,1
3355,04/06/2019 00:00,DB03773,alpha-D-quinovopyranose,,,,,,solid,,,827,11.3,-3.6,[H][C@]1(C)O[C@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,164.0684735,1,0,1,0,1,1
3356,04/06/2019 00:00,DB03774,Glutamyl Group,,,,,,solid,,,23.7,2.12,9.11,[NH3+][C@@H](CCC=O)C(O)=O,,,,,1,,132.0655196,0,0,0,0,0,0
3357,04/06/2019 00:00,DB03775,D-Dethiobiotin,,,,,,solid,,,1.27,4.63,-1.8,[H][C@@]1(C)NC(=O)N[C@]1([H])CCCCCC(O)=O,,,,,0,,214.1317424,1,0,1,0,1,1
3358,04/06/2019 00:00,DB03776,Lactaldehyde,,,,,,solid,,,658,14.01,-3.2,[H]C(=O)[C@H](C)O,,,,,0,,74.03677943,0,0,0,0,0,0
3359,04/06/2019 00:00,DB03777,Rbt205 Inhibitor,,,,,,solid,,,0.00824,9.99,9.39,CN(C)CCCN1C=C(C2=C1C=CC=C2)C1=C(C(=O)NC1=O)C1=CNC2=C1C=CC=C2,,,,,0,,412.189926,5,4,3,2,0,1
3360,04/06/2019 00:00,DB03779,Glucosaminyl-(Alpha-6)-D-Myo-Inositol,,,,,,solid,,,387,12.25,8.13,N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@H]1O,,,,,0,,341.1321959,2,0,1,0,1,1
3361,04/06/2019 00:00,DB03780,2-Aminoquinazolin-4(3h)-One,,,,,,solid,,,1.67,11.42,5.79,NC1=NC2=CC=CC=C2C(=O)N1,,,,,0,,161.0589118,2,2,1,1,0,0
3362,04/06/2019 00:00,DB03781,"2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid",,,,,,solid,,,0.00556,2.92,-4.9,[H][C@](C)(OC1=CC=C(OC2=CC=C(Cl)C=C2Cl)C=C1)C(O)=O,,,,,0,,326.0112642,2,2,0,0,0,0
3363,04/06/2019 00:00,DB03782,N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea,,,,,,solid,,,0.0461,14.94,10.34,[H]C12CC3([H])CC([H])(C1)CC(C2)(C3)NC(=O)NCC1=CC=C(NC(N)=N)C=C1,,,,,0,,341.2215605,5,1,0,0,0,0
3364,04/06/2019 00:00,DB03783,Phenacetin,,,,,,solid,766 mg/L (at 25 Â°C),1.58,1.78,14.98,-4.2,CCOC1=CC=C(NC(C)=O)C=C1,,,,,0,,179.0946287,1,1,0,0,0,0
3365,04/06/2019 00:00,DB03784,Elaidoylamide,,,,,,solid,,,7.31E-05,16.92,-0.58,CCCCCCCC\C=C\CCCCCCCC(N)=O,,,,,0,,281.2718647,0,0,0,0,0,0
3366,04/06/2019 00:00,DB03785,"(3r,5r)-7-((1r,2r,6s,8r,8as)-2,6-Dimethyl-8-{[(2r)-2-Methylbutanoyl]Oxy}-1,2,6,7,8,8a-Hexahydronaphthalen-1-Yl)-3,5-Dihydroxyheptanoic Acid",,,,,,solid,,,0.0641,4.21,-2.7,[H][C@@](O)(CC[C@@]1([H])[C@@]([H])(C)C=CC2=C[C@]([H])(C)C[C@]([H])(OC(=O)[C@@]([H])(C)CC)[C@]12[H])C[C@@]([H])(O)CC(O)=O,,,,,0,,422.2668389,2,0,0,0,0,0
3367,04/06/2019 00:00,DB03787,"[5-hydroxy-6-methyl-4-({[(4E)-3-oxo-1,2-oxazolidin-4-ylidene]amino}methyl)pyridin-3-yl]methyl dihydrogen phosphate",,,,,,solid,,,2.25,1.85,5.66,CC1=C(O)C(C\N=C2/CON=C2O)=C(COP(O)(O)=O)C=N1,,,,,0,,331.0569364,2,1,2,1,0,1
3368,04/06/2019 00:00,DB03788,GC-24,,,,,,solid,,,0.000404,3.92,-4.9,CC1=CC(OCC(O)=O)=CC(C)=C1CC1=CC=C(O)C(CC2=CC=CC=C2)=C1,,,,,0,,376.1674592,3,3,0,0,0,0
3369,04/06/2019 00:00,DB03789,"2,3-Dimethylimidazolium Ion",,,,,,solid,,,1.99,,7.38,CN1C=C[NH+]=C1C,,,,,1,,97.07602471,1,1,1,1,0,0
3370,04/06/2019 00:00,DB03790,S-Dioxymethionine,,,,,,solid,,,43.9,1.55,8.69,CS(=O)(=O)CC[C@H](N)C(O)=O,,,,,0,,181.0408788,0,0,0,0,0,0
3371,04/06/2019 00:00,DB03791,"(3-{3-[[2-Chloro-3-(Trifluoromethyl)Benzyl](2,2-Diphenylethyl)Amino]Propoxy}Phenyl)Acetic Acid",,,,,,solid,,,7.90E-05,3.88,8.63,OC(=O)CC1=CC(OCCCN(CC(C2=CC=CC=C2)C2=CC=CC=C2)CC2=C(Cl)C(=CC=C2)C(F)(F)F)=CC=C1,,,,,0,,581.1944562,4,4,0,0,0,0
3372,04/06/2019 00:00,DB03792,"5-Amino-1h-Pyrimidine-2,4-Dione",,,,,,solid,,,11.3,9.54,-1.4,NC1=CNC(=O)NC1=O,,,,,0,,127.0381764,1,1,1,1,0,0
3373,04/06/2019 00:00,DB03793,Benzoic Acid,,,,,Intravenous,solid,3400 mg/L (at 25 Â°C),1.87,7.08,4.08,,OC(=O)C1=CC=CC=C1,,,,,0,,122.0367794,1,1,0,0,0,0
3374,04/06/2019 00:00,DB03794,Trifluoroalanine,,,,,,solid,,,17.6,1.02,4.73,[H][C@](N)(C(O)=O)C(F)(F)F,,,,,0,,143.019413,0,0,0,0,0,0
3375,04/06/2019 00:00,DB03795,2-Dehydropantoate,,,,,,solid,,,109,3.25,-2.8,CC(C)(CO)C(=O)C(O)=O,,,,,0,,146.0579088,0,0,0,0,0,0
3376,04/06/2019 00:00,DB03796,Palmitic Acid,,,,,Oral,solid,0.04 mg/L (at 25 Â°C),7.17,0.000407,4.95,,CCCCCCCCCCCCCCCC(O)=O,,,,,0,,256.2402303,0,0,0,0,0,0
3377,04/06/2019 00:00,DB03797,3-Aminomethyl-Pyridinium-Adenine-Dinucleotide,,,,,,solid,,,2.21,1.86,8.49,[H][C@]1(COP([O-])(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(CN)=C3)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,649.1298572,5,3,5,3,2,2
3378,04/06/2019 00:00,DB03798,2'-Deoxycytidine-5'-Monophosphate,,,,,,solid,,,10.9,1.26,-0.12,NC1=NC(=O)N(C=C1)[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1,,,,,0,,307.0569364,2,1,2,1,1,1
3379,04/06/2019 00:00,DB03799,Trifluoromethionine,,,,,,solid,,,12.8,1.59,9.5,N[C@@H](CCSC(F)(F)F)C(O)=O,,,,,0,,203.0227842,0,0,0,0,0,0
3380,04/06/2019 00:00,DB03800,Deoxyuridine monophosphate,,,,,,solid,,,7.97,1.23,-3.2,O[C@H]1C[C@@H](O[C@@H]1COP(O)(O)=O)N1C=CC(=O)NC1=O,,,,,0,,308.040952,2,1,2,1,1,1
3381,04/06/2019 00:00,DB03801,Lysine Nz-Carboxylic Acid,,,,,,solid,,,13.5,2.14,9.53,N[C@@H](CCCCNC(O)=O)C(O)=O,,,,,0,,190.0953569,0,0,0,0,0,0
3382,04/06/2019 00:00,DB03802,"1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol",,,,,,solid,,,0.0269,9.58,8.41,[H][C@@]12CCCCN1CCN(C2)C1=CC=C(C=C1)[C@@]1([H])N(CCC2=CC(O)=CC=C12)C1=CC=CC=C1,,,,,0,,439.2623627,6,3,3,0,2,3
3383,04/06/2019 00:00,DB03803,Inhibitor Msa367,,,,,,solid,,,0.0154,4.49,4.01,[H][C@@](O)([C@@]([H])(O)[C@@]([H])(OCC1=CC=CC=C1)C(O)=N[C@@]([H])(C(C)C)C(O)=NCC1=CC=CC=N1)[C@@]([H])(OCC1=CC=CC=C1)C(O)=N[C@@]([H])(C(C)C)C(O)=NCC1=CC=CC=N1,,,,,0,,768.3846626,4,4,2,2,0,0
3384,04/06/2019 00:00,DB03804,5-Bromothienyldeoxyuridine,,,,,,solid,,,0.14,9.29,-3,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO)N1C=C(C2=CC=C(Br)S2)C(=O)NC1=O,,,,,0,,387.9728546,3,2,3,2,1,1
3385,04/06/2019 00:00,DB03807,"1-(2-Chlorophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,,,,,solid,,,0.0454,,1.97,CCOC(=O)C1=C(C)N(N=C1C)C1=C(Cl)C=CC=C1,,,,,0,,278.0822054,2,2,1,1,0,0
3386,04/06/2019 00:00,DB03808,Hexamidine,,,,,,solid,,,0.0142,,12.13,NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1,,,,,0,,354.2055761,2,2,0,0,0,0
3387,04/06/2019 00:00,DB03809,9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine,,,,,,solid,,,0.0724,18.6,5.07,CCCCN1C(CC2=CC=CC(OC)=C2)=NC2=C(N)N=CN=C12,,,,,0,,311.1746103,3,3,2,2,0,0
3388,04/06/2019 00:00,DB03810,3-Methylglutamic acid,,,,,,solid,,,38.1,2.02,9.6,[H][C@@](C)(CC(O)=O)[C@]([H])(N)C(O)=O,,,,,0,,161.0688078,0,0,0,0,0,0
3389,04/06/2019 00:00,DB03811,Histidinol,,,,,,solid,,,136,13.45,9.41,[H][C@@]([NH3+])(CO)CC1=CN=CN1,,,,,1,,142.0974884,1,1,1,1,0,0
3390,04/06/2019 00:00,DB03812,"3-{2,6,8-trioxo-9-[(2S,3R,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate",,,,,,solid,,,4.2,1.76,-3,OC[C@@H](O)[C@H](O)[C@@H](O)CN1C(=O)N(CCCOP(O)(O)=O)C2=C1NC(=O)NC2=O,,,,,0,,440.0944441,2,2,2,2,0,0
3391,04/06/2019 00:00,DB03813,2-Decenoyl N-Acetyl Cysteamine,,,,,,solid,,,0.00717,15.73,-0.96,CCCCCCC\C=C/C(=O)SCCNC(C)=O,,,,,0,,271.1606,0,0,0,0,0,0
3392,04/06/2019 00:00,DB03814,2-(N-Morpholino)-Ethanesulfonic Acid,,,,,,solid,,,4.58,-1.5,6.51,[O-]S(=O)(=O)CC[NH+]1CCOCC1,,,,,0,,195.0565289,1,0,1,0,1,1
3393,04/06/2019 00:00,DB03815,Fucitol,,,,,,solid,,,476,12.7,-3,[H][C@@](C)(O)[C@@]([H])(O)[C@@]([H])(O)[C@]([H])(O)CO,,,,,0,,166.0841235,0,0,0,0,0,0
3394,04/06/2019 00:00,DB03816,Difluoromethionine,,,,,,solid,,,21.6,1.95,9.5,N[C@@H](CCSC(F)F)C(O)=O,,,,,0,,185.032206,0,0,0,0,0,0
3395,04/06/2019 00:00,DB03817,"L-2,4-diaminobutyric acid",,,,,,solid,,,270,2.55,10.25,NCC[C@H](N)C(O)=O,,,,,0,,118.0742276,0,0,0,0,0,0
3396,04/06/2019 00:00,DB03818,N-[Tosyl-D-Prolinyl]Amino-Ethanethiol,,,,,,solid,,,0.218,10.07,-4.3,[H][C@@]1(CCCN1S(=O)(=O)C1=CC=C(C)C=C1)C(=O)NCCS,,,,,0,,328.0915345,2,1,1,0,1,1
3397,04/06/2019 00:00,DB03819,Salicylhydroxamic Acid,,,,,,solid,,,8.03,8.01,-5.3,ONC(=O)C1=CC=CC=C1O,,,,,0,,153.0425931,1,1,0,0,0,0
3398,04/06/2019 00:00,DB03820,"(2s,5r,6r)-6-{[(6r)-6-(Glycylamino)-7-Oxido-7-Oxoheptanoyl]Amino}-3,3-Dimethyl-7-Oxo-4-Thia-1-Azabicyclo[3.2.0]Heptane-2-Carboxylate",,,,,,solid,,,0.244,3.38,9.34,[H][C@@](CCCCC([O-])=N[C@]1([H])C(=O)N2[C@]1([H])SC(C)(C)[C@]2([H])C(O)=O)(N=C(O)CN)C(O)=O,,,,,-1,,429.1449437,2,0,2,0,2,2
3399,04/06/2019 00:00,DB03821,2-Amino-3-Hydroxy-3-Phosphonooxy-Propionic Acid,,,,,,solid,,,24.1,0.91,8.82,[H][C@@](N)(C(O)=O)[C@@]([H])(O)OP(O)(O)=O,,,,,0,,201.0038382,0,0,0,0,0,0
3400,04/06/2019 00:00,DB03822,Ethyl Dihydrogen Phosphate,,,,,,solid,,,29,1.8,,CCOP(O)(O)=O,,,,,0,,126.0081953,0,0,0,0,0,0
3401,04/06/2019 00:00,DB03823,Epigallocatechin,,,,,,solid,,,0.871,8.73,-3.3,O[C@@H]1CC2=C(O[C@@H]1C1=CC(O)=C(O)C(O)=C1)C=C(O)C=C2O,,,,,0,,306.0739528,3,2,1,0,0,1
3402,04/06/2019 00:00,DB03824,"7-Iodo-1,2,3,4-Tetrahydro-Isoquinoline",,,,,,solid,,,0.0981,,9.21,IC1=CC2=C(CCNC2)C=C1,,,,,0,,258.9857973,2,1,1,0,0,1
3403,04/06/2019 00:00,DB03825,Rhodamine 6G,,,,,,solid,2E+004 mg/L,,0.000496,18.72,2.34,[Cl-].CCNC1=CC2=[O+]C3=C(C=C(C)C(NCC)=C3)C(C3=CC=CC=C3C(=O)OCC)=C2C=C1C,,,,,0,,478.2023205,4,4,1,1,0,0
3404,04/06/2019 00:00,DB03826,"5,6-Diaminouracil",,,,,,solid,,,13.8,9.42,2.52,NC1=C(N)C(=O)NC(=O)N1,,,,,0,,142.0490754,1,1,1,1,0,0
3405,04/06/2019 00:00,DB03827,"(3s)-3,4-Di-N-Hexanoyloxybutyl-1-Phosphocholine",,,,,,solid,,,0.00116,1.27,-6.7,[H][C@](CCP([O-])(=O)OCC[N+](C)(C)C)(COC(=O)CCCCC)OC(=O)CCCCC,,,,,0,,451.2698893,0,0,0,0,0,0
3406,04/06/2019 00:00,DB03828,RU78299,,,,,,solid,,,1.17,1.73,-7,CC1=CC(C=O)=C(OP(O)(O)=O)C(C=O)=C1,,,,,0,,244.0136746,1,1,0,0,0,0
3407,04/06/2019 00:00,DB03829,Pseudouridine-5'-Monophosphate,,,,,,solid,,,7.51,1.23,-3.6,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(O)=O)C1=CNC(=O)NC1=O,,,,,0,,324.0358666,2,1,2,1,1,1
3408,04/06/2019 00:00,DB03830,Phosphorylated Dihydropteroate,,,,,,solid,,,0.516,1.16,1.83,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)OP(O)(O)=O)N=C2C(=O)N1,,,,,0,,392.0634188,3,3,2,2,0,0
3409,04/06/2019 00:00,DB03831,"[(Z)-octadec-9-enyl] (2R)-2,3-bis(oxidanyl)propanoate",,,,,,solid,,,0.00105,11.94,-3,[H]\C(CCCCCCCC)=C(/[H])CCCCCCCCOC(=O)[C@]([H])(O)CO,,,,,0,,356.2926598,0,0,0,0,0,0
3410,04/06/2019 00:00,DB03832,"3-Carboxy-N,N,N-Trimethyl-2-(Octanoyloxy)Propan-1-Aminium",,,,,,solid,,,0.00634,4.22,-7.1,[H][C@@](CC(O)=O)(C[N+](C)(C)C)OC(=O)CCCCCCC,,,,,1,,288.2169349,0,0,0,0,0,0
3411,04/06/2019 00:00,DB03833,"2-Prolyl-5-Tert-Butyl-[1,3,4]Oxadiazole",,,,,,solid,,,0.524,15.34,8.34,[H][C@]1(CCCN1)C(=O)C1=NN=C(O1)C(C)(C)C,,,,,0,,223.1320768,2,1,2,1,1,1
3412,04/06/2019 00:00,DB03834,"(3S)-3-(dioxidosulfanyl)-N-[(1Z)-3-oxoprop-1-en-1-yl]-4-(1H-1,2,3-triazol-1-yl)-D-valine",,,,,,solid,,,2.14,3.3,1.51,[H]\C(N[C@@]([H])(C(O)=O)[C@](C)(CN1C=CN=N1)S(=O)=O)=C(/[H])C=O,,,,,0,,302.0684905,1,1,1,1,0,0
3413,04/06/2019 00:00,DB03835,"N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide",,,,,,solid,,,99.8,9.17,-3,CC(=O)NN1C(=O)N[C@@]2(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O,,,,,0,,305.0859144,2,0,2,0,2,2
3414,04/06/2019 00:00,DB03836,"1,3,5-Trichloro-Benzene",,,,,,solid,,,0.031,,,ClC1=CC(Cl)=CC(Cl)=C1,,,,,0,,179.9300331,1,1,0,0,0,0
3415,04/06/2019 00:00,DB03837,Morpholine-4-Carboxylic Acid (1-(3-Benzenesulfonyl-1-Phenethylallylcarbamoyl)-3-Methylbutyl)-Amide,,,,,,solid,,,0.00418,13.94,-1.7,C(C)(C)C[C@H](C(=O)N[C@H](CCC1=CC=CC=C1)\C=C\S(=O)(=O)C1=CC=CC=C1)NC(=O)N1CCOCC1,,,,,0,,527.2453923,3,2,1,0,1,1
3416,04/06/2019 00:00,DB03839,D-Tyrosine,,,,,,solid,453 mg/L (at 25 Â°C),,7.67,2,9.19,N[C@H](CC1=CC=C(O)C=C1)C(O)=O,,,,,0,,181.0738932,1,1,0,0,0,0
3417,04/06/2019 00:00,DB03840,Tetra(Imidazole)Diaquacopper (Ii),,,,,,solid,,,2.12,13.4,6.97,O.O.[Cu+4].[N-]1C=CN=C1.[N-]1C=CN=C1.[N-]1C=CN=C1.[N-]1C=CN=C1,,,,,0,,367.0692193,4,4,4,4,0,0
3418,04/06/2019 00:00,DB03841,Y-700,,,,,,solid,,,0.0931,3.42,0.4,CC(C)(C)COC1=C(C=C(C=C1)N1C=C(C=N1)C(O)=O)C#N,,,,,0,,299.1269914,2,2,1,1,0,0
3419,04/06/2019 00:00,DB03842,2-Chloro-6-Methyl-Aniline,,,,,,solid,,,10.7,,9.33,CC1=CC=CC(=C)[C@H]1N,,,,,0,,121.0891494,1,0,0,0,0,0
3420,04/06/2019 00:00,DB03843,Formaldehyde,,,,.2 mL/59mL,Topical,gas,4E+005 mg/L (at 20 Â°C),0.35,198,,-8.1,[H]C([H])=O,,,,,0,,30.01056468,0,0,0,0,0,0
3421,04/06/2019 00:00,DB03844,"N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide",,,,,,solid,,,0.021,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=C(F)C=CC=C1F,,,,,0,,326.0536697,2,2,0,0,0,0
3422,04/06/2019 00:00,DB03845,P1-(5'-Adenosyl)P5-(5'-(3'azido-3'-Deoxythymidyl))Pentaphosphate,,,,,,solid,,,40.9,0.41,5,[H][C@@]1(C[C@]([H])(N=[N+]=[N-])[C@@]([H])(COP([O-])(=O)OP([O-])(=O)OP(O)(=O)OP([O-])(=O)OP([O-])(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)O1)N1C=C(C)C([O-])=NC1=O,,,,,-5,,910.9782135,5,3,5,3,2,2
3423,04/06/2019 00:00,DB03846,5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate,,,,,,solid,,,12.8,1.23,-2.8,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C(CO)C(O)=NC1=O,,,,,0,,338.0515167,2,1,2,1,1,1
3424,04/06/2019 00:00,DB03847,Gamma-Carboxy-Glutamic Acid,,,,,,solid,,,22.5,1.48,9.54,N[C@@H](CC(C(O)=O)C(O)=O)C(O)=O,,,,,0,,191.042987,0,0,0,0,0,0
3425,04/06/2019 00:00,DB03848,Benzenesulfinic acid,,,,,,solid,,,9.55,1.36,,O[S@@](=O)C1=CC=CC=C1,,,,,0,,142.0088504,1,1,0,0,0,0
3426,04/06/2019 00:00,DB03849,Cilomilast,,,,,,solid,,,0.0155,2.33,-4.6,[H][C@@]1(CC[C@](CC1)(C#N)C1=CC(OC2CCCC2)=C(OC)C=C1)C(O)=O,,,,,0,,343.1783583,3,1,0,0,0,0
3427,04/06/2019 00:00,DB03850,Jaspisamide A,,,,,,solid,,,0.0213,13.97,4.42,[H]\C(C[C@@]([H])(OC)[C@@]([H])(C)C(=O)CC[C@]([H])(C)[C@]([H])(C[C@]1([H])OC(=O)C[C@@]([H])(O)C[C@]([H])(O)CC(=O)[C@]([H])(C)[C@]([H])(OC)C2=COC(=N2)C2=COC(=N2)C2=COC(=N2)\C([H])=C([H])\CC[C@@]1([H])C)OC)=C(\[H])N(C)CO,,,,,0,,856.4469881,4,3,4,3,0,1
3428,04/06/2019 00:00,DB03851,Carbazole Butanoic Acid,,,,,,solid,,,0.0315,4.94,,OC(=O)CCCN1C2=CC=CC=C2C2=C1C=CC=C2,,,,,0,,253.1102787,3,3,1,1,0,0
3429,04/06/2019 00:00,DB03852,Eucalyptol,,,,0.7 g/50g,Oral,liquid,3500 mg/L (at 21 Â°C),2.74,0.0225,,-4.2,C[C@@]12CC[C@@H](CC1)C(C)(C)O2,,,,,0,,154.1357652,3,0,2,0,2,2
3430,04/06/2019 00:00,DB03853,Reactive Red 6 hapten,,,,,,solid,,,0.148,-3.7,-6.5,OC1=C(C=C(C=C1)S(O)(=O)=O)\N=N\C1=C(C=C2C(C=CC(NC3=NC(NC4=C(C5=CC(=C(\N=N\C6=C(O)C=CC(=C6)S(O)(=O)=O)C(O)=C5C=C4)S(O)(=O)=O)S(O)(=O)=O)=NC=N3)=C2S(O)(=O)=O)=C1O)S(O)(=O)=O,,,,,0,,1114.943839,7,7,1,1,0,0
3431,04/06/2019 00:00,DB03854,"Pentane-1,5-Diamine",,,,,,solid,,,89.1,,10.51,NCCCCCN,,,,,0,,102.1156984,0,0,0,0,0,0
3432,04/06/2019 00:00,DB03855,L-Threonohydroxamate 4-Phosphate,,,,,,solid,,,15.6,3.4,1.47,[H][C@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)NO,,,,,0,,233.030053,0,0,0,0,0,0
3433,04/06/2019 00:00,DB03856,L-Eflornithine,,,,,,solid,,,50,2.19,10.2,NCCC[C@@](N)(C(F)F)C(O)=O,,,,,0,,182.0866841,0,0,0,0,0,0
3434,04/06/2019 00:00,DB03857,"1,4-dithio-beta-D-glucopyranose",,,,,,solid,,,8.09,8.59,-3,OC[C@H]1O[C@@H](S)[C@H](O)[C@@H](O)[C@@H]1S,,,,,0,,212.0177009,1,0,1,0,1,1
3435,04/06/2019 00:00,DB03858,S-Acetonylcysteine,,,,,,solid,,,14.9,2.16,8.93,CC(=O)CSC[C@H](N)C(O)=O,,,,,0,,177.0459642,0,0,0,0,0,0
3436,04/06/2019 00:00,DB03859,1-Thio-Beta-D-Glucopyranose,,,,,,solid,,,62.6,8.64,-3,OC[C@H]1O[C@@H](S)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,196.0405445,1,0,1,0,1,1
3437,04/06/2019 00:00,DB03860,"N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide",,,,,,solid,,,0.000143,10.32,0.29,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])[C@]([H])(CCCCCCCCCCC(=O)N(C)CCCC)CC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C,,,,,0,,525.4181946,4,1,0,0,0,0
3438,04/06/2019 00:00,DB03861,"(2r,3r,4s,5r)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium",,,,,,solid,,,27.1,7.6,4.4,[H][C@]1(CO)CN[C@]([H])(N=C(C)O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,204.111007,1,0,1,0,1,1
3439,04/06/2019 00:00,DB03862,Tetrahydrooxazine,,,,,,solid,,,783,12.94,4.06,OC[C@H]1ONC[C@@H](O)[C@@H]1O,,,,,0,,149.0688078,1,0,1,0,1,1
3440,04/06/2019 00:00,DB03863,2-O-methyl fucose,,,,,,solid,,,723,11.33,-3.6,[H][C@@]1(C)O[C@]([H])(O)[C@@]([H])(OC)[C@]([H])(O)[C@]1([H])O,,,,,0,,178.0841235,1,0,1,0,1,1
3441,04/06/2019 00:00,DB03864,Monothioglycerol,,,,,,solid,,,40.5,9.92,-2.9,OC[C@@H](O)CS,,,,,0,,108.0245005,0,0,0,0,0,0
3442,04/06/2019 00:00,DB03865,6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine,,,,,,solid,,,0.000297,9.27,10.06,NC(=[NH2+])C1=CC2=C(NC(=C2)C2=CC=CC(=C2O)C2=CC=CC=C2)C=C1Cl,,,,,1,,362.1054663,4,4,1,1,0,0
3443,04/06/2019 00:00,DB03866,Prostaglandin G2,,,,,,solid,,,0.0264,4.36,-4.2,[H][C@@](CCCCC)(OO)\C=C\[C@@]1([H])[C@@]2([H])C[C@]([H])(OO2)[C@]1([H])C\C=C/CCCC(O)=O,,,,,0,,368.2198887,2,0,1,0,1,1
3444,04/06/2019 00:00,DB03867,Meta-Nitro-Tyrosine,,,,,,solid,,,1.49,0.96,9.48,N[C@@H](CC1=CC=C(O)C(=C1)[N+]([O-])=O)C(O)=O,,,,,0,,226.0589714,1,1,0,0,0,0
3445,04/06/2019 00:00,DB03868,3-Dehydroquinic Acid,,,,,,solid,,,702,3.3,-3.3,O[C@@H]1C[C@@](O)(CC(=O)[C@H]1O)C(O)=O,,,,,0,,190.047738,1,0,0,0,0,0
3446,04/06/2019 00:00,DB03869,5'-O-(N-(L-Seryl)-Sulfamoyl)Adenosine,,,,,,solid,,,6.98,5.34,8.42,[H][C@](N)(CO)C(O)=NS(=O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,433.1015816,3,2,3,2,1,1
3447,04/06/2019 00:00,DB03870,"Ara-Alpha(1,3)-Xyl",,,,,,solid,,,643,11.27,-3,[H][C@@]1(CO)O[C@@]([H])(O[C@@]2([H])[C@]([H])(O)CO[C@@]([H])(O)[C@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,282.0950822,2,0,2,0,2,2
3448,04/06/2019 00:00,DB03872,"2,3-Dideoxyfucose",,,,,,solid,,,707,12.45,-3.2,[H][C@]1(O)CC[C@]([H])(O)[C@@]([H])(C)O1,,,,,0,,132.0786442,1,0,1,0,1,1
3449,04/06/2019 00:00,DB03874,"(4e,8e,12z,16z)-N,N,4,8,13,17,21-Heptamethyldocosa-4,8,12,16,20-Pentaen-1-Amine",,,,,,solid,,,0.000891,,9.86,CN(C)CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C,,,,,0,,413.4021506,0,0,0,0,0,0
3450,04/06/2019 00:00,DB03876,"Thieno[2,3-B]Pyridine-2-Carboxamidine",,,,,,solid,,,0.328,,8.48,NC(=[NH2+])C1=CC2=C(S1)N=CC=C2,,,,,1,,178.0433447,2,2,2,2,0,0
3451,04/06/2019 00:00,DB03877,AL4623,,,,,,solid,,,1.1,8.19,6.78,[H][C@@]1(CN(CCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O)NCC,,,,,0,,369.0486837,2,1,2,1,0,1
3452,04/06/2019 00:00,DB03878,N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide,,,,,,solid,,,0.00873,12.01,4.34,CC1=CC=C(NC(=O)C2=CC=CN=C2)C=C1NC1=NC=CC(=N1)C1=CC=CN=C1,,,,,0,,382.1542092,4,4,3,3,0,0
3453,04/06/2019 00:00,DB03879,alpha-L-methyl-fucose,,,,,,solid,,,812,12.23,-3.6,[H][C@@]1(C)O[C@@]([H])(OC)[C@@]([H])(O)[C@]([H])(O)[C@]1([H])O,,,,,0,,178.0841235,1,0,1,0,1,1
3454,04/06/2019 00:00,DB03880,Batimastat,,,,,,solid,,,0.00173,8.86,-0.57,[H][C@@](CC1=CC=CC=C1)(NC(=O)[C@]([H])(CC(C)C)[C@]([H])(CSC1=CC=CS1)C(=O)NO)C(=O)NC,,,,,0,,477.1755985,2,2,1,1,0,0
3455,04/06/2019 00:00,DB03881,"(2S,3R,4S,5S)-3,4-Dihydroxy-2-[(methylsulfanyl)methyl]-5-(4-oxo-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidinium",,,,,,solid,,,1.13,11.25,8.58,[H][C@]1(CSC)N[C@@]([H])(C2=C[NH2+]C3=C2N=CN=C3O)[C@]([H])(O)[C@]1([H])O,,,,,1,,297.1015878,3,1,3,1,1,2
3456,04/06/2019 00:00,DB03882,"5-Alpha-Androstane-3-Beta,17beta-Diol",,,,,,solid,,,0.0193,18.3,-0.76,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C,,,,,0,,292.2402303,4,0,0,0,0,0
3457,04/06/2019 00:00,DB03883,Carboxyethyllumazine,,,,,,solid,,,3.35,3.73,-3,[H]N1C(=O)N([H])C2=C(N=C(CCC(O)=O)C(=O)N2C[C@H](O)[C@H](O)[C@H](O)CO)C1=O,,,,,0,,386.1073782,2,2,2,2,0,0
3458,04/06/2019 00:00,DB03884,Phenylpyruvic acid,,,,,,solid,,,0.932,3.33,-9.8,OC(=O)C(=O)CC1=CC=CC=C1,,,,,0,,164.0473441,1,1,0,0,0,0
3459,04/06/2019 00:00,DB03885,1-Menaphthyl Glutathione Conjugate,,,,,,solid,,,0.0114,2.05,9.54,[H][C@](N)(CCC(O)=N[C@@]([H])(CSCC1=CC=CC2=CC=CC=C12)C(O)=NCC(O)=O)C(O)=O,,,,,0,,447.1464065,2,2,0,0,0,0
3460,04/06/2019 00:00,DB03886,Biopterin,,,,,,solid,,,3.71,9.99,1.05,C[C@@H](O)[C@@H](O)C1=CN=C2N=C(N)NC(=O)C2=N1,,,,,0,,237.0861892,2,2,2,2,0,0
3461,04/06/2019 00:00,DB03887,Alpha-Adenosine Monophosphate,,,,,,solid,,,3.34,1.22,5.21,[H][C@]1(COP(O)(O)=O)O[C@]([H])(N2C=NC3=NC=NC(N)=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,347.0630844,3,2,3,2,1,1
3462,04/06/2019 00:00,DB03888,N-Allyl-6-{[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yl]oxy}-N-methyl-1-hexanamine,,,,,,solid,,,0.00182,,9.42,CN(CCCCCCOC1=CC2=C(C=C1)C(=NN2C)C1=CC=C(Br)C=C1)CC=C,,,,,0,,455.1572247,3,3,1,1,0,0
3463,04/06/2019 00:00,DB03889,S-(N-Hydroxy-N-Bromophenylcarbamoyl)Glutathione,,,,,,solid,,,0.148,1.82,9.53,[H][C@](N)(CCC(O)=N[C@@]([H])(CS[C@]([H])(O)N(O)C1=CC=C(Br)C=C1)C(O)=NCC(O)=O)C(O)=O,,,,,0,,522.0419968,1,1,0,0,0,0
3464,04/06/2019 00:00,DB03890,N-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-Methanesulfonamide,,,,,,solid,,,0.407,10.36,7.78,O=C[C@@]([H])(C(C)C)[C@]1([H])N(CC[C@@]1([H])NS(=O)(=O)C)C(=O)\C=C\CN1CCCCC1,,,,,0,,399.2191775,2,0,2,0,2,2
3465,04/06/2019 00:00,DB03891,"1,5-Bis(N-Benzyloxycarbonyl-L-Leucinyl)Carbohydrazide",,,,,,solid,,,0.00706,4.53,0.22,[H][C@@](CC(C)C)(N=C(O)OCC1=CC=CC=C1)C(O)=NNC(O)=NN=C(O)[C@]([H])(CC(C)C)N=C(O)OCC1=CC=CC=C1,,,,,0,,584.2958476,2,2,0,0,0,0
3466,04/06/2019 00:00,DB03892,5-N-Allyl-Arginine,,,,,,solid,,,8.62,2.34,12.01,N[C@@H](CCCN\C(N)=[NH+]\CC=C)C(O)=O,,,,,1,,215.1502523,0,0,0,0,0,0
3467,04/06/2019 00:00,DB03893,Thionicotinamide-Adenine-Dinucleotide,,,,,,solid,,,4.7,1.86,5.93,[H][C@]1(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(=C3)C([S-])=N)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,679.0862782,5,3,5,3,2,2
3468,04/06/2019 00:00,DB03894,N-Propargyl-1(S)-Aminoindan,,,,,,solid,,,0.0249,,8.69,[H][C@@]1(CCC2=C1C=CC=C2)NCC#C,,,,,0,,171.1047994,2,1,0,0,0,0
3469,04/06/2019 00:00,DB03895,Malachite Green,,,,,,solid,,,0.00138,,4.52,CN(C)C1=CC=C(C=C1)C(C1=CC=CC=C1)=C1C=CC(C=C1)=[N+](C)C,,,,,1,,329.2012252,3,2,0,0,0,0
3470,04/06/2019 00:00,DB03897,Hydroxyphenyl Propionic Acid,,,,,,solid,,,2.71,4.21,-6,OC(=O)CCC1=CC=C(O)C=C1,,,,,0,,166.0629942,1,1,0,0,0,0
3471,04/06/2019 00:00,DB03898,3-Chloro-4-Hydroxyphenylglycine,,,,,,solid,,,2.01,1.28,8.85,N[C@H](C(O)=O)C1=CC(Cl)=C(O)C=C1,,,,,0,,201.0192708,1,1,0,0,0,0
3472,04/06/2019 00:00,DB03899,9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine,,,,,,solid,,,0.0706,18.6,5.07,CCCCN1C(CC2=CC=C(OC)C=C2)=NC2=C(N)N=CN=C12,,,,,0,,311.1746103,3,3,2,2,0,0
3473,04/06/2019 00:00,DB03900,2-Methyl-2-Propanol,,,,,,solid,,,154,18.09,-1.4,CC(C)(C)O,,,,,0,,74.07316494,0,0,0,0,0,0
3474,04/06/2019 00:00,DB03901,5-Oxo-Pyrrolidine-2-Carbaldehyde,,,,,,solid,,,13.3,7.31,2.28,[H][C@]1(CCC(O)=N1)C=O,,,,,0,,113.0476785,1,0,1,0,0,1
3475,04/06/2019 00:00,DB03902,Oxalic Acid,,,,,,solid,2.2E+005 mg/L (at 25 Â°C),,65.7,1.36,,OC(=O)C(O)=O,,,,,0,,89.99530854,0,0,0,0,0,0
3476,04/06/2019 00:00,DB03903,Tmr,,,,,,solid,,,0.0199,3.72,7.42,CN(C)C1=CCC2=C(C3=CC=C(C=C3OC2=C1)N(C)C)C1=CC=C(C=C1C(O)=O)N1C(=O)C=CC1=O,,,,,0,,483.1794209,5,2,2,0,0,2
3477,02/07/2019 00:00,DB03904,Urea,,,,39 g/100g,Topical,solid,5.45E+005 mg/L (at 25 Â°C),-2.11,412,15.73,-2.4,NC(N)=O,,,,,0,,60.03236275,0,0,0,0,0,0
3478,04/06/2019 00:00,DB03905,Succinamide-Coa,,,,,,solid,,,9.58,0.82,,[H][C@](O)(C(O)=NCCC(O)=NCCN=C(O)CCC(O)=O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,850.170081,3,2,3,2,1,1
3479,04/06/2019 00:00,DB03906,2-Phenylheme,,,,,,solid,,,0.000717,3.53,,CC1=C(C=C)C2=CC3=[N+]4C(=CC5=C(C)C(CCC(O)=O)=C6N5[Fe]44N2C1=CC1=[N+]4C(C(CCC(O)=O)=C1C)=C6C1=CC=CC=C1)C(C=C)=C3C,,,,,2,,692.207496,9,3,8,2,0,6
3480,04/06/2019 00:00,DB03907,"N-{3-[5-(6-Amino-Purin-9-Yl)-3,4-Dihydroxy-Tetrahydro-Furan-2-Yl]-Allyl}-2,3-Dihydroxy-5-Nitro-Benzamide",,,,,,solid,,,0.602,6.01,4.95,[H]\C(CN=C(O)C1=C(O)C(O)=CC(=C1)N(=O)=O)=C(\[H])[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,473.1295106,4,3,3,2,1,1
3481,04/06/2019 00:00,DB03908,Inhibitor Bea322,,,,,,solid,,,0.0149,4.02,5.88,[H][C@](C)(CC)[C@]([H])(N=C(O)[C@]([H])(OCC1=CC=CC=C1)[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(OCC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=NC)[C@@]([H])(C)CC)C(O)=NC,,,,,0,,642.3628646,2,2,0,0,0,0
3482,04/06/2019 00:00,DB03909,"Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate",,,,,,solid,,,4.45,1.38,5,[H][C@]1(COP(O)(=O)OP(O)(=O)CP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,505.0164809,3,2,3,2,1,1
3483,04/06/2019 00:00,DB03910,"S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea",,,,,,solid,,,0.0207,,10.89,NC(=N)SCCC1=CC(CCSC(N)=N)=CC=C1,,,,,0,,282.0972886,1,1,0,0,0,0
3484,04/06/2019 00:00,DB03911,L-Xylopyranose,,,,,,solid,,,1220,11.31,-3.5,O[C@H]1COC(O)[C@@H](O)[C@@H]1O,,,,,0,,150.0528234,1,0,1,0,1,1
3485,04/06/2019 00:00,DB03912,4'-Phosphopantetheine,,,,,,solid,,,0.375,1.79,-1.5,CC(C)(COP(O)(O)=O)[C@@H](O)C(=O)NCCC(=O)NCCS,,,,,0,,358.0963587,0,0,0,0,0,0
3486,04/06/2019 00:00,DB03913,Coenzyme F420,,,,,,solid,,,0.165,1.78,-6.4,[H][C@@](C)(OP(O)(=O)OC[C@@]([H])(O)[C@@]([H])(O)[C@@]([H])(O)CN1C2=C(C=CC(O)=C2)C=C2C(O)=NC(=O)N=C12)C(O)=N[C@@]([H])(CCC(O)=N[C@@]([H])(CCC(O)=O)C(O)=O)C(O)=O,,,,,0,,773.1792959,3,1,2,0,0,2
3487,04/06/2019 00:00,DB03914,"[2-(1-amino-2-hydroxy-propyl)-4-(1H-indol-3-ylmethylene)-5-oxo-4,5-dihydro-imidazol-1-yl]-acetaldehyde",,,,,,solid,,,0.141,3.54,7.56,[H]\C(C1=CNC2=CC=CC=C12)=C1\N=C(N(CC(O)=O)C1=O)[C@@]([H])(N)[C@@]([H])(C)O,,,,,0,,342.1328051,3,2,2,1,0,1
3488,04/06/2019 00:00,DB03915,2-Amino-3-Ketobutyric Acid,,,,,,solid,,,206,1.87,7.25,CC(=O)[C@H](N)C(O)=O,,,,,0,,117.0425931,0,0,0,0,0,0
3489,04/06/2019 00:00,DB03916,4-{2-[4-(2-Aminoethyl)Piperazin-1-Yl]Pyridin-4-Yl}-N-(3-Chloro-4-Methylphenyl)Pyrimidin-2-Amine,,,,,,solid,,,0.0447,13.29,9.38,CC1=C(Cl)C=C(NC2=NC(=CC=N2)C2=CC(=NC=C2)N2CCN(CCN)CC2)C=C1,,,,,0,,423.1938215,4,3,3,2,1,1
3490,04/06/2019 00:00,DB03917,N-Ethyl Retinamide,,,,,,solid,,,0.00332,16.31,1.9,CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C,,,,,0,,327.2562147,1,0,0,0,0,0
3491,04/06/2019 00:00,DB03918,"6S-5,6,7,8-Tetrahydrobiopterin",,,,,,solid,,,2.83,-1.5,14.86,[H][C@](C)(O)[C@@]([H])(O)[C@@]1([H])CNC2=C(N1)C(O)=NC(=N)N2,,,,,0,,241.1174893,2,1,2,1,0,1
3492,04/06/2019 00:00,DB03919,Ethyl-Carbamic Acid Methyl Ester,,,,,,solid,,,279,15.12,,CCNC(=O)OC,,,,,0,,103.0633285,0,0,0,0,0,0
3493,04/06/2019 00:00,DB03920,N-Methyl-Alpha-Beta-Dehydroalanine,,,,,,solid,,,99.9,4.7,2.36,CNC(=C)C(O)=O,,,,,0,,101.0476785,0,0,0,0,0,0
3494,04/06/2019 00:00,DB03921,4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline,,,,,,solid,,,0.0273,14.33,3.71,N1C=C(C(=N1)C1=NC=CC=C1)C1=C2C=CC=CC2=NC=C1,,,,,0,,272.1061964,4,4,3,3,0,0
3495,04/06/2019 00:00,DB03923,Feruloyl Coenzyme A,,,,,,solid,,,2.83,0.83,4.95,COC1=CC(\C=C\C(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO[P@@](=O)(O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2OP(O)(O)=O)N2C=NC3=C(N)N=CN=C23)=CC(O)=C1O,,,,,0,,959.1574677,4,3,3,2,1,1
3496,04/06/2019 00:00,DB03924,"5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone",,,,,,solid,,,0.371,9.65,3.33,NC1=CC=C(N)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O,,,,,0,,270.0640568,3,2,0,0,0,0
3497,04/06/2019 00:00,DB03925,Freselestat,,,,,,solid,,,0.113,12.1,0.3,CC(C)[C@@H](NC(=O)CN1C(=O)C(N)=CN=C1C1=CC=CC=C1)[C@@H](O)C1=NN=C(O1)C(C)(C)C,,,,,0,,454.2328534,3,3,2,2,0,0
3498,04/06/2019 00:00,DB03926,"5-Alpha-Androstane-3-Beta,17-Alpha-Diol",,,,,,solid,,,0.0193,18.3,-0.76,[H][C@@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C,,,,,0,,292.2402303,4,0,0,0,0,0
3499,04/06/2019 00:00,DB03927,Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanine,,,,,,solid,,,0.332,3.58,9.34,[H][C@](C)(N=C(O)CCCC[C@]([H])(N=C(O)CN)C(O)=O)C(O)=O,,,,,0,,303.1430354,0,0,0,0,0,0
3500,04/06/2019 00:00,DB03928,"Carboxymethylthio-3-(3-Chlorophenyl)-1,2,4-Oxadiazol",,,,,,solid,,,0.267,3.83,-2,OC(=O)CSC1=NC(=NO1)C1=CC=CC(Cl)=C1,,,,,0,,269.9865908,2,2,1,1,0,0
3501,04/06/2019 00:00,DB03929,D-Serine,,,,,,solid,3.64E+005 mg/L (at 20 Â°C),,480,2.03,8.93,N[C@H](CO)C(O)=O,,,,,0,,105.0425931,0,0,0,0,0,0
3502,04/06/2019 00:00,DB03930,4-Methyl-Pyrroline-5-Carboxylic Acid,,,,,,solid,,,132,1.8,10.33,[H][C@@]1(C)C=CN[C@@]1([H])C(O)=O,,,,,0,,127.0633285,1,0,1,0,0,1
3503,04/06/2019 00:00,DB03931,Diguanosine-5'-Triphosphate,,,,,,solid,,,4.77,0.9,-2.7,NC1=NC(=O)C2=C(N1)N(C=N2)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C2NC(N)=NC3=O)[C@@H](O)[C@H]1O,,,,,0,,788.0717639,6,4,6,4,2,2
3504,04/06/2019 00:00,DB03932,LFA703,,,,,,solid,,,0.00152,14.62,-1.5,[H][C@](C)(CC)C(=O)O[C@@]1([H])C[C@@]([H])(C)C=C2C=C[C@]([H])(C)[C@]([H])(CC[C@@]3([H])C[C@@]([H])(O)CC(=O)N3CC3=CC4=C(C=C3)C(CO)=C(OC)C=C4)[C@@]12[H],,,,,0,,603.3559883,5,2,1,0,1,1
3505,04/06/2019 00:00,DB03933,C-1027 Aromatized Chromophore,,,,,,solid,,,0.0113,6.2,8.63,[H][C@@]12OC3=C(Cl)C=C(C=C3O)[C@@]([H])([NH3+])CC(=O)OC[C@]([H])(OC(=O)C3=C4N=C(O)C(=C)OC4=CC(OC)=C3)C3=CC(=C1C=C3)C1=CC=C[C@]21O[C@]1([H])OC(C)(C)[C@@]([H])(N(C)C)[C@@]([H])(O)[C@@]1([H])O,,,,,1,,846.2635426,11,3,6,0,1,6
3506,04/06/2019 00:00,DB03934,Protoporphyrin Ix Containing Zn,,,,,,solid,,,0.0526,,,CC1=C(CCC(O)=O)C2=CC3=[N]4C(=CC5=C(C)C(C=C)=C6C=C7C(C)=C(C=C)C8=[N]7[Zn]4(N2C1=C8)N56)C(C)=C3CCC(O)=O,,,,,,,,,,,,,
3507,04/06/2019 00:00,DB03935,"1,4-Dideoxy-O2-Sulfo-Glucuronic Acid",,,,,,solid,,,78.2,-2.1,-3.7,[H][C@]1(O)O[C@@]([H])(C(O)=O)[C@]([H])(O)[C@]([H])(O)[C@@]1([H])OS(O)(=O)=O,,,,,0,,273.9994675,1,0,1,0,1,1
3508,04/06/2019 00:00,DB03936,1-Deoxy-Ribofuranose-5'-Phosphate,,,,,,solid,,,38.6,1.23,-3.5,[H][C@]1(O)CO[C@]([H])(COP(O)(O)=O)[C@]1([H])O,,,,,0,,214.0242393,1,0,1,0,1,1
3509,04/06/2019 00:00,DB03937,Erythose-4-Phosphate,,,,,,solid,,,23.7,1.48,-3.6,O[C@H](COP(O)(O)=O)[C@@H](O)C=O,,,,,0,,200.0085893,0,0,0,0,0,0
3510,04/06/2019 00:00,DB03938,Deacetoxycephalosporin-C,,,,,,solid,,,0.716,1.83,9.53,[H][C@@](N)(CCCC(O)=N[C@]1([H])C(=O)N2C(C(O)=O)=C(C)CS[C@]12[H])C(O)=O,,,,,0,,357.0994563,2,0,2,0,1,2
3511,04/06/2019 00:00,DB03939,"4-Hydroxy-3,4-Dihydro-1h-Pyrimidin-2-One",,,,,,solid,,,58,8.78,4.13,[H][C@@]1(O)NC(O)=NC=C1,,,,,0,,114.0429274,1,0,1,0,0,1
3512,04/06/2019 00:00,DB03940,Oxamic Acid,,,,,,solid,,,108,2.49,-6.2,NC(=O)C(O)=O,,,,,0,,89.01129296,0,0,0,0,0,0
3513,04/06/2019 00:00,DB03941,Heptanyl-P-Phenol,,,,,,solid,,,0.0114,10.31,-5.4,CCCCCCCC1=CC=C(O)C=C1,,,,,0,,192.1514153,1,1,0,0,0,0
3514,04/06/2019 00:00,DB03942,Carboxylic PRPP,,,,,,solid,,,13.1,1.45,-3.3,[H][C@]1(O)[C@@]([H])(O)[C@]([H])(C[C@]1([H])COP(O)(O)=O)OP(O)(=O)OP(O)(O)=O,,,,,0,,387.9725504,1,0,0,0,0,0
3515,04/06/2019 00:00,DB03943,D-Asparagine,,,,,,solid,,,168,2,8.43,N[C@H](CC(N)=O)C(O)=O,,,,,0,,132.0534921,0,0,0,0,0,0
3516,04/06/2019 00:00,DB03944,"5-[1-(3,4-Dimethoxy-Benzoyl)-1,2,3,4-Tetrahydro-Quinolin-6-Yl]-6-Methyl-3,6-Dihydro-[1,3,4]Thiadiazin-2-One",,,,,,solid,,,0.0197,11.36,0.62,[H][C@]1(C)SC(=O)NN=C1C1=CC2=C(C=C1)N(CCC2)C(=O)C1=CC(OC)=C(OC)C=C1,,,,,0,,425.1409272,4,2,2,0,0,2
3517,04/06/2019 00:00,DB03945,"N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium",,,,,,solid,,,4.36,1.15,,C[N+](C)(C)CCOP(O)(O)=O,,,,,1,,184.073321,0,0,0,0,0,0
3518,04/06/2019 00:00,DB03946,"3,4-Dihydroxybenzoic Acid",,,,,,solid,1.82E+004 mg/L (at 14 Â°C),0.86,12.4,4.16,-6.3,OC(=O)C1=CC=C(O)C(O)=C1,,,,,0,,154.0266087,1,1,0,0,0,0
3519,04/06/2019 00:00,DB03947,D-Xylulose,,,,,,solid,,,678,10.57,-3,OC[C@H](O)[C@H](O)C(=O)CO,,,,,0,,150.0528234,0,0,0,0,0,0
3520,04/06/2019 00:00,DB03948,"6-Chloropurine Riboside, 5'-Monophosphate",,,,,,solid,,,1.87,1.16,2.09,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(Cl)[NH+]=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,1,,367.0204895,3,2,3,2,1,1
3521,04/06/2019 00:00,DB03949,(2-Sulfanyl-3-Phenylpropanoyl)-Phe-Tyr,,,,,,solid,,,0.000655,3.79,1.6,[H][C@](S)(CC1=CC=CC=C1)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(O)=O,,,,,0,,492.171893,3,3,0,0,0,0
3522,04/06/2019 00:00,DB03950,(S)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide,,,,,,solid,,,0.0411,9.95,-0.91,[H]N([H])S(=O)(=O)C1=CC=C(C=C1)C(=O)N([H])C[C@H](C)CN1C=CC2=CC=CC=C12,,,,,0,,371.1303625,3,3,1,1,0,0
3523,04/06/2019 00:00,DB03951,N-acetyl-D-glucosamine-6-phosphate,,,,,,solid,,,17.6,1.23,-0.79,CC(=O)N[C@H]1C(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O,,,,,0,,301.0562677,1,0,1,0,1,1
3524,04/06/2019 00:00,DB03952,9-(6-deoxy-beta-D-allofuranosyl)-6-methylpurine,,,,,,solid,,,8.73,12.45,4.22,[H][C@](C)(O)[C@@]1([H])O[C@@]([H])(N2C=NC3=C(C)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,280.117155,3,2,3,2,1,1
3525,04/06/2019 00:00,DB03953,L-Thiocitrulline,,,,,,solid,,,2,1.59,15,N[C@@H](CCC\N=C(/N)S)C(O)=O,,,,,0,,191.0728477,0,0,0,0,0,0
3526,04/06/2019 00:00,DB03955,1-deoxymannojirimycin,,,,,,solid,,,511,12.91,8.06,[H][C@@]1(O)CN[C@]([H])(CO)[C@@]([H])(O)[C@]1([H])O,,,,,0,,163.0844579,1,0,1,0,1,1
3527,04/06/2019 00:00,DB03956,"Inositol 2,4,5-trisphosphate",,,,,,solid,,,14.8,0.54,-3.7,O[C@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1OP(O)(O)=O,,,,,0,,419.9623797,1,0,0,0,0,0
3528,04/06/2019 00:00,DB03957,SP2456,,,,,,solid,,,0.00846,5.88,11.97,[H][C@@](NC(N)=N)(C1CCCCC1)C(O)=NCC(=O)N1CCC(CC1)C1=CC(=NN1)C1=C(Cl)C(Cl)=CC=C1,,,,,0,,533.2072787,4,2,2,1,1,1
3529,04/06/2019 00:00,DB03958,7-methyl-guanosine-5'-triphosphate-5'-guanosine,,,,,,solid,,,6.06,0.88,4.95,[H][C@]1(COP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=[N+](C)C4=C3NC(=N)N=C4O)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,1,,803.0946904,6,4,6,4,2,2
3530,04/06/2019 00:00,DB03959,"N,O6-Disulfo-Glucosamine",,,,,,solid,,,11,-2.3,-3.5,[H][C@]1(O)O[C@]([H])(COS(O)(=O)=O)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])NS(O)(=O)=O,,,,,0,,338.9930022,1,0,1,0,1,1
3531,04/06/2019 00:00,DB03960,Cp-Coeleneterazine,,,,,,solid,,,0.0573,9.2,4.3,[H][C@@]1(CC2CCCC2)NC(=CN2C(=O)[C@](CC3=CC=C(O)C=C3)(OO)N=C12)C1=CC=C(O)C=C1,,,,,0,,449.195071,5,2,2,0,0,2
3532,04/06/2019 00:00,DB03961,"2c-Methyl-D-Erythritol 2,4-Cyclodiphosphate",,,,,,solid,,,21.4,1.83,-3.1,[H][C@@]1(O)COP(O)(=O)OP(O)(=O)O[C@@]1(C)CO,,,,,0,,277.9956552,1,0,1,0,1,1
3533,04/06/2019 00:00,DB03962,Nicotinamide 8-Bromo-Adenine Dinucleotide Phosphate,,,,,,solid,,,7.87,0.65,6.47,[H][C@]1(COP([O-])(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])([N+]3=CC=CC(=C3)C(O)=N)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C(Br)=NC3=C(N)N=CN=C23)[C@]([H])(OP(O)(O)=O)[C@]1([H])O,,,,,0,,820.9859644,5,3,5,3,2,2
3534,04/06/2019 00:00,DB03963,S-(Dimethylarsenic)Cysteine,,,,,,solid,,,7.58,1.95,9.14,[H][C@](N)(CS[As](C)C)C(O)=O,,,,,0,,224.9804711,0,0,0,0,0,0
3535,04/06/2019 00:00,DB03964,4-Hydroxy-Aconitate Ion,,,,,,solid,,,39.5,2.78,-4.2,[H]\C(C([O-])=O)=C(/C([O-])=O)[C@@]([H])(O)C([O-])=O,,,,,-3,,186.9895232,0,0,0,0,0,0
3536,04/06/2019 00:00,DB03966,Clorobiocin,,,,,,solid,,,0.00328,5.15,-3.9,CO[C@@H]1[C@@H](OC(=O)C2=CC=C(C)N2)[C@@H](O)[C@H](OC2=C(Cl)C3=C(C=C2)C(O)=C(NC(=O)C2=CC(CC=C(C)C)=C(O)C=C2)C(=O)O3)OC1(C)C,,,,,0,,696.2085877,5,4,3,2,1,1
3537,04/06/2019 00:00,DB03967,Dodecyl sulfate,,,,,,solid,,,0.0113,-1.5,,CCCCCCCCCCCCOS(O)(=O)=O,,,,,0,,266.1551803,0,0,0,0,0,0
3538,04/06/2019 00:00,DB03968,"1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine",,,,,,solid,,,317,,-0.66,CN1C(=O)CCC1(C)C,,,,,0,,127.099714,1,0,1,0,1,1
3539,04/06/2019 00:00,DB03970,"(7R)-7-(6,7-Dihydro-5H-cyclopenta[d]imidazo[2,1-b][1,3]thiazol-2-yl)-2,7-dihydro-1,4-thiazepine-3,6-dicarboxylic acid",,,,,,solid,,,0.81,2.59,5.14,[H][C@]1(SCC(=NC=C1C(O)=O)C(O)=O)C1=CN2C(SC3=C2CCC3)=N1,,,,,0,,363.0347479,4,2,3,2,0,1
3540,04/06/2019 00:00,DB03971,Acarbose Derived Hexasaccharide,,,,,,solid,,,101,11.18,7.33,[H][C@]1(C)O[C@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@]([H])(OC[C@@]3([H])O[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])N[C@@]1([H])C=C(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]3([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,969.3536604,6,0,5,0,5,5
3541,04/06/2019 00:00,DB03972,"2-Amino-4h-1,3-Benzoxathiin-4-Ol",,,,,,solid,,,12.5,12.87,5.98,[H][C@]1(N)OC2=CC=CC=C2[C@]([H])(O)S1,,,,,0,,183.0353995,2,1,1,0,0,1
3542,04/06/2019 00:00,DB03973,"3-{2,6,8-trioxo-9-[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate",,,,,,solid,,,8.49,1.76,-3,[H][C@@](O)(CO)[C@]([H])(O)[C@]([H])(O)CN1C(=O)N(CCCOP(O)(O)=O)C2=C1N=C(O)N=C2O,,,,,0,,440.0944441,2,2,2,2,0,0
3543,04/06/2019 00:00,DB03974,L-Homoarginine,,,,,,solid,,,1.58,2.49,12.3,N[C@@H](CCCCNC(N)=N)C(O)=O,,,,,0,,188.1273258,0,0,0,0,0,0
3544,04/06/2019 00:00,DB03975,Mercuribenzoic Acid,,,,,,solid,,,47.7,4.02,,OC(=O)C1=CC=C([Hg])C=C1,,,,,0,,322.9995974,1,1,0,0,0,0
3545,04/06/2019 00:00,DB03976,Phosphorylisopropane,,,,,,solid,,,29.6,1.78,,CC(C)OP(O)(O)=O,,,,,0,,140.0238454,0,0,0,0,0,0
3546,04/06/2019 00:00,DB03977,N-Trimethyllysine,,,,,,solid,,,0.233,2.41,9.53,[H][C@](N)(CCCC[N+](C)(C)C)C(O)=O,,,,,1,,189.1597543,0,0,0,0,0,0
3547,04/06/2019 00:00,DB03978,Tyrosinal,,,,,,solid,,,2.77,9.51,7.68,[H][C@](N)(CC1=CC=C(O)C=C1)C=O,,,,,0,,165.0789786,1,1,0,0,0,0
3548,04/06/2019 00:00,DB03979,1-[Glycerolylphosphonyl]-2-[8-(2-Hexyl-Cyclopropyl)-Octanal-1-Yl]-3-[Hexadecanal-1-Yl]-Glycerol,,,,,,solid,,,0.000127,1.89,-3,[H]C(O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC[C@@]1([H])C[C@@]1([H])CCCCCC,,,,,0,,734.5097852,1,0,0,0,0,0
3549,04/06/2019 00:00,DB03980,4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole,,,,,,solid,,,0.0618,16.38,4.8,NC1=NC(=CC=N1)C1=C(N=CN1CC1CC1)C1=CC=C(F)C=C1,,,,,0,,309.1389737,4,3,2,2,0,0
3550,04/06/2019 00:00,DB03981,"1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid",,,,,,solid,,,35.2,-2.1,-3.5,[H][C@@]1(O)OC(=C[C@]([H])(O)[C@@]1([H])OS(O)(=O)=O)C(O)=O,,,,,0,,255.9889028,1,0,1,0,0,1
3551,04/06/2019 00:00,DB03982,"Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid",,,,,,solid,,,0.00842,2.52,-6.7,OC(=O)C(=O)N(C1=CC=CC=C1C(O)=O)C1=CC=CC2=C1C=CC=C2,,,,,0,,335.0793725,3,3,0,0,0,0
3552,04/06/2019 00:00,DB03983,"(Molybdopterin-S,S)-Dioxo-Thio-Molybdenum(V)",,,,,,solid,,,3.93,1.2,3.84,NC1=NC2=C(N[C@@H]3[C@H](N2)O[C@@H](COP(O)(O)=O)C2=C3S[Mo](S)(=O)(=O)S2)C(=O)N1,,,,,0,,555.8717952,4,1,4,1,0,3
3553,04/06/2019 00:00,DB03984,Morpholine-4-Carboxylic Acid [1-(2-Benzylsulfanyl-1-Formyl-Ethylcarbamoyl)-2-Phenyl-Ethyl]-Amide,,,,,,solid,,,0.00494,12.68,-2,[H][C@@](CSCC1=CC=CC=C1)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)N1CCOCC1)C=O,,,,,0,,455.1878774,3,2,1,0,1,1
3554,04/06/2019 00:00,DB03985,R-azabisabolene,,,,,,solid,,,0.00228,,10.62,C[N@@H+](CCC=C(C)C)[C@H]1CCC(C)=CC1,,,,,1,,208.2059763,1,0,0,0,0,0
3555,04/06/2019 00:00,DB03986,6-Methyl-Formycin A,,,,,,solid,,,0.751,2.77,-0.66,[H][C@]1(CO)O[C@@]([H])(C2=C3NC=[N+](C)C(N)=C3N=N2)[C@]([H])(O)[C@]1([H])O,,,,,1,,282.1196804,3,0,3,0,1,3
3556,04/06/2019 00:00,DB03987,"2,4-Diamino-6-[N-(3',5'-Dimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine",,,,,,solid,,,0.338,16.08,4.3,COC1=CC(OC)=CC(CN(C)C2=CN=C3N=C(N)N=C(N)C3=C2)=C1,,,,,0,,340.1647739,3,3,2,2,0,0
3557,04/06/2019 00:00,DB03988,"2,6-Diamino-Hexanoic Acid Amide",,,,,,solid,,,10.4,16.63,10.21,N[C@@H](CCCC[NH3+])C(N)=O,,,,,1,,146.1287886,0,0,0,0,0,0
3558,04/06/2019 00:00,DB03989,D-Allopyranose,,,,,,solid,,,782,11.3,-3,OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O,,,,,0,,180.0633881,1,0,1,0,1,1
3559,04/06/2019 00:00,DB03990,4'-nitrophenyl-3i-thiolaminaritrioside,,,,,,solid,,,48.3,11.97,-3,[H][C@]1(CO)O[C@@]([H])(S[C@@]2([H])[C@]([H])(O)[C@@]([H])(CO)O[C@@]([H])(OC3([H])C([H])(O)C([H])(CO)OC([H])(OC4=CC=C(C=C4)N(=O)=O)C3([H])O)[C@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,641.1625697,4,1,3,0,3,3
3560,04/06/2019 00:00,DB03991,"2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid",,,,,,solid,,,24,3.46,2.04,[H][C@@](O)(CO)[C@@]([H])(O)[C@]1([H])OC(=C[C@]([H])(O)[C@@]1([H])N=C(C)O)C(O)=O,,,,,0,,291.0954165,1,0,1,0,0,1
3561,04/06/2019 00:00,DB03992,3-(Benzoylamino)-L-Alanine,,,,,,solid,,,2.95,1.91,8.5,N[C@@H](CNC(=O)C1=CC=CC=C1)C(O)=O,,,,,0,,208.0847922,1,1,0,0,0,0
3562,04/06/2019 00:00,DB03993,4-Methyl Valeric Acid,,,,,,solid,,,12.9,5.09,,CC(C)CCC(O)=O,,,,,0,,116.0837296,0,0,0,0,0,0
3563,04/06/2019 00:00,DB03994,Ethanolamine,,,,,,solid,1E+006 mg/L,-1.31,849,15.61,9.55,NCCO,,,,,0,,61.05276384,0,0,0,0,0,0
3564,04/06/2019 00:00,DB03995,Betadex,,,,,,solid,,,910,11.51,-3.7,[H][C@]1(CO)O[C@]2([H])O[C@]3([H])[C@@]([H])(CO)O[C@]([H])(O[C@]4([H])[C@@]([H])(CO)O[C@]([H])(O[C@]5([H])[C@@]([H])(CO)O[C@]([H])(O[C@]6([H])[C@@]([H])(CO)O[C@]([H])(O[C@]7([H])[C@@]([H])(CO)O[C@]([H])(O[C@]8([H])[C@@]([H])(CO)O[C@]([H])(O[C@@]1([H])[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]8([H])O)[C@]([H])(O)[C@@]7([H])O)[C@]([H])(O)[C@@]6([H])O)[C@]([H])(O)[C@@]5([H])O)[C@]([H])(O)[C@@]4([H])O)[C@]([H])(O)[C@@]3([H])O,,,,,0,,1134.369764,21,0,21,0,21,21
3565,04/06/2019 00:00,DB03996,"3-[(5s)-1-Acetyl-3-(2-Chlorophenyl)-4,5-Dihydro-1h-Pyrazol-5-Yl]Phenol",,,,,,solid,,,0.0322,9.4,0.35,[H][C@]1(CC(=NN1C(C)=O)C1=C(Cl)C=CC=C1)C1=CC=CC(O)=C1,,,,,0,,314.0822054,3,2,1,0,0,1
3566,04/06/2019 00:00,DB03997,L-histidinol phosphate,,,,,,solid,,,28.3,1.59,9.67,N[C@H](COP(O)(O)=O)CC1=CNC=N1,,,,,0,,221.0565425,1,1,1,1,0,0
3567,04/06/2019 00:00,DB03998,"[2-(Methyleneamine)-4-(4-Hydroxy-Benzylidine)-5-Oxo-4,5-Dihydro-Imidazol-1-Yl]-Acetaldehyde",,,,,,solid,,,0.328,3.31,7.79,[H]\C(=C1\N=C(CN)N(CC(O)=O)C1=O)C1=CC=C(O)C=C1,,,,,0,,275.0906059,2,1,1,0,0,1
3568,04/06/2019 00:00,DB03999,Butylphosphonate,,,,,,solid,,,33.4,1.81,,CCCCP(O)(O)=O,,,,,0,,138.0445808,0,0,0,0,0,0
3569,04/06/2019 00:00,DB04000,Bromo-Willardiine,,,,,,solid,,,3.41,1.01,8.64,N[C@@H](CN1C=C(Br)C(=O)NC1=O)C(O)=O,,,,,0,,276.9698178,1,1,1,1,0,0
3570,04/06/2019 00:00,DB04001,6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid,,,,,,solid,,,0.16,2.39,-6.9,OC(=O)C(=O)NC1=CC2=C(C=CN2)C=C1C(O)=O,,,,,0,,248.0433214,2,2,1,1,0,0
3571,04/06/2019 00:00,DB04002,4-Sulfonamide-[4-(Thiomethylaminobutane)]Benzamide,,,,,,solid,,,0.0604,9.48,8.02,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCCCCNCS,,,,,0,,317.0867835,1,1,0,0,0,0
3572,04/06/2019 00:00,DB04003,{4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid,,,,,,solid,,,0.00145,1.6,-0.89,[H]N([H])C(=O)C1=C(OCC2CCCCC2)C=CC(=C1)[C@H](C)N([H])C(=O)[C@H](CC1=CC(=C(OCC(O)=O)C=C1)P(O)(O)=O)N([H])C(C)=O,,,,,0,,619.229481,3,2,0,0,0,0
3573,04/06/2019 00:00,DB04004,"2,6-Diamino-8-(2-Dimethylaminoethylsulfanylmethyl)-3h-Quinazolin-4-One",,,,,,solid,,,0.475,11.4,8.96,CN(C)CCSCC1=C2N=C(N)NC(=O)C2=CC(N)=C1,,,,,0,,293.1310312,2,2,1,1,0,0
3574,04/06/2019 00:00,DB04005,Uridine 5'-triphosphate,,,,,,solid,,,8.37,0.9,-3.7,O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O,,,,,0,,483.9685277,2,1,2,1,1,1
3575,04/06/2019 00:00,DB04006,"[2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone",,,,,,solid,,,0.00214,18.86,4.64,NC1=C(N2C=C(C=CC2=N1)C(=O)C1=C(F)C=CC=C1F)C(=O)C1=CC=CC=C1,,,,,0,,377.0975831,4,4,2,2,0,0
3576,04/06/2019 00:00,DB04007,Bromo-WR99210,,,,,,solid,,,0.0412,20,7.63,CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC=C(Br)C=C1,,,,,0,,369.080037,2,1,1,0,0,1
3577,04/06/2019 00:00,DB04008,Bis(5-Amidino-Benzimidazolyl)Methane Zinc,,,,,,solid,,,0.112,11.69,11.02,[H]N=C(N)C1=CC2=C(C=C1)N1[Zn]N3C(CC1=[NH+]2)=[NH+]C1=C3C=CC(=C1)C(N)=N[H],,,,,2,,396.0778376,5,4,3,2,0,1
3578,04/06/2019 00:00,DB04009,Dimethyl Propionate Ester Heme,,,,,,solid,,,0.235,,-6.7,COC(=O)CCC1=C(C)C2=CC3=C(C=C)C(C)=C4C=C5N6C(=CC7=C(C)C(CCC(=O)OC)=C8C=C1N2[Fe@@]6(N78)N34)C(C)=C5C=C,,,,,0,,644.2085931,8,4,8,4,0,4
3579,04/06/2019 00:00,DB04010,2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide,,,,,,solid,,,0.1,10.33,4.07,COC1=CC=CC(=C1)C1=NC2=C(N1)C=CC=C2C(N)=O,,,,,0,,267.1007767,3,3,1,1,0,0
3580,04/06/2019 00:00,DB04011,"2'-(4-Dimethylaminophenyl)-5-(4-Methyl-1-Piperazinyl)-2,5'-Bi-Benzimidazole",,,,,,solid,,,0.025,11.3,7.87,CN(C)C1=CC=C(C=C1)C1=NC2=C(N1)C=CC(=C2)C1=NC2=C(N1)C=C(C=C2)N1CCN(C)CC1,,,,,0,,451.2484439,6,5,3,2,1,1
3581,04/06/2019 00:00,DB04012,"(3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine",,,,,,solid,,,0.0655,3.37,-4.9,[H][C@@](CC(C)C)(NC(=O)[C@]1([H])CSCCN1S(=O)(=O)C1=CC=C(C)C=C1)C(O)=O,,,,,0,,414.1283139,2,1,1,0,1,1
3582,04/06/2019 00:00,DB04013,1-Deoxy-1-Methoxycarbamido-Beta-D-Gluco-2-Heptulopyranosonamide,,,,,,solid,,,6.83,-4.2,11.64,[H][C@]1(CO)O[C@](N=C(O)OC)(C(O)=N)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,280.0906655,1,0,1,0,1,1
3583,04/06/2019 00:00,DB04014,Alsterpaullone,,,,,,solid,,,0.0237,12.45,-5.1,[O-][N+](=O)C1=CC2=C(NC3=C2CC(=O)NC2=C3C=CC=C2)C=C1,,,,,0,,293.0800412,4,3,2,1,0,1
3584,04/06/2019 00:00,DB04015,Methionine Phosphinate,,,,,,solid,,,29.7,0.25,9.84,CSCC[C@H](N)P(O)=O,,,,,0,,169.0326363,0,0,0,0,0,0
3585,04/06/2019 00:00,DB04016,2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid,,,,,,solid,,,0.000133,1.56,0.22,CN(C1CCN(CC1)C(=O)C1=CC2=CC=CC=C2C=C1)C(=O)C1=CC2=CC=CC=C2C=C1C(=O)[C@@H](C1=CC=CC2=CC=CC=C12)P(O)(O)=O,,,,,0,,670.2232735,7,6,1,0,1,1
3586,04/06/2019 00:00,DB04017,Clorgiline,,,,,,solid,,,0.014,,8.4,CN(CCCOC1=CC=C(Cl)C=C1Cl)CC#C,,,,,0,,271.0530695,1,1,0,0,0,0
3587,04/06/2019 00:00,DB04018,S-Isopropyl-Isothiourea,,,,,,solid,,,3.18,,10.56,CC(C)SC(N)=N,,,,,0,,118.0564693,0,0,0,0,0,0
3588,04/06/2019 00:00,DB04020,"4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol",,,,,,solid,,,0.00471,10.26,8.66,OC1=CC=C(CCNC2=NC(SCCCC3=CC=C(Cl)C=C3)=NC(=N2)N2CCNCC2)C=C1,,,,,0,,484.1812082,4,3,2,1,1,1
3589,04/06/2019 00:00,DB04021,MF268,,,,,,solid,,,0.185,16.36,8.36,[H][C@]1(C)CN(CCCCCCCCNC=O)C[C@@]([H])(C)O1,,,,,0,,270.2307282,1,0,1,0,1,1
3590,04/06/2019 00:00,DB04022,"Guanosine-5',3'-Tetraphosphate",,,,,,solid,,,10.3,1.46,7.15,[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])OP(O)(=O)OP(O)(O)=O,,,,,0,,602.9569906,3,2,3,2,1,1
3591,04/06/2019 00:00,DB04023,"Guanosine 5'-(Trihydrogen Diphosphate), P'-D-Mannopyranosyl Ester",,,,,,solid,,,6.73,1.72,4.95,[H][C@]1(COP(O)(=O)OP(O)(=O)O[C@@]2([H])O[C@]([H])(C(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])O,,,,,0,,619.0564175,4,2,4,2,2,2
3592,04/06/2019 00:00,DB04024,N'-L-Seryl-3'-Amino-(3'-Deoxy)-Adenosine,,,,,,solid,,,7.91,4.24,9.01,[H][C@](N)(CO)C(O)=N[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]1([H])O,,,,,0,,353.1447667,3,2,3,2,1,1
3593,04/06/2019 00:00,DB04026,Pseudotropine,,,,,,solid,,,645,15.16,9.7,[H][C@]12CC[C@]([H])(C[C@@]([H])(O)C1)N2C,,,,,0,,141.1153641,2,0,2,0,2,2
3594,04/06/2019 00:00,DB04027,D-Arginine,,,,,,solid,,,2.28,2.41,12.41,N[C@H](CCCNC(N)=N)C(O)=O,,,,,0,,174.1116757,0,0,0,0,0,0
3595,04/06/2019 00:00,DB04028,Tyvelose,,,,,,solid,,,848,11.43,-3.2,[H][C@]1(O)C[C@]([H])(O)[C@@]([H])(O)O[C@]1([H])C,,,,,0,,148.0735589,1,0,1,0,1,1
3596,04/06/2019 00:00,DB04029,Phenylalanine Amide,,,,,,solid,,,2.77,16.34,8.02,[H][C@](N)(CC1=CC=CC=C1)C(N)=O,,,,,0,,164.094963,1,1,0,0,0,0
3597,04/06/2019 00:00,DB04030,"1,3,4,9-Tetrahydro-2-(Hydroxybenzoyl)-9-[(4-Hydroxyphenyl)Methyl]-6-Methoxy-2h-Pyrido[3,4-B]Indole",,,,,,solid,,,0.00982,8.45,-0.61,OC1=CC=C(CN2C3=C(CCN(C3)C(=O)C3=CC=C(O)C=C3)C3=CC=CC=C23)C=C1,,,,,0,,398.1630426,5,4,2,1,0,1
3598,04/06/2019 00:00,DB04031,Serine vanadate,,,,,,solid,,,32.5,1.25,7.68,N[C@@H](CO[V](O)([O-])([O-])[O-])C(O)=O,,,,,-3,,218.9710558,0,0,0,0,0,0
3599,04/06/2019 00:00,DB04032,Adamantane-1-Carboxylic Acid-5-Dimethylamino-Naphthalene-1-Sulfonylamino-Butyl-Amide,,,,,,solid,,,0.00143,9.91,4.63,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCCNC(=O)C12CC3CC(CC(C3)C1)C2,,,,,0,,483.255563,6,2,0,0,0,0
3600,04/06/2019 00:00,DB04033,Z-Ala Prolinal,,,,,,solid,,,0.897,3.63,-4.4,[H][C@@](C)(NC(=O)OCC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(O)=O,,,,,0,,320.1372217,2,1,1,0,1,1
3601,04/06/2019 00:00,DB04034,Ribulose-5-Phosphate,,,,,,solid,,,26.1,1.48,-3.3,OCC(=O)[C@@H](O)[C@H](O)COP(O)(O)=O,,,,,0,,230.0191539,0,0,0,0,0,0
3602,04/06/2019 00:00,DB04035,Pinacol[[2-Amino-Alpha-(1-Carboxy-1-Methylethoxyimino)-4-Thiazoleacetyl]Amino]Methaneboronate,,,,,,solid,,,0.115,3.07,4.13,CC(C)(O\N=C(/C(=O)NCB(O)O)C1=CSC(N)=N1)C(O)=O,,,,,0,,330.0805356,1,1,1,1,0,0
3603,04/06/2019 00:00,DB04036,Coenzyme a Persulfide,,,,,,solid,,,5.85,0.82,4.79,[H][C@](O)(C(O)=NCCC(O)=NCCSS)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,799.08728,3,2,3,2,1,1
3604,04/06/2019 00:00,DB04037,"N,N-Bis(4-Chlorobenzyl)-1h-1,2,3,4-Tetraazol-5-Amine",,,,,,solid,,,0.0563,8.5,-1.3,ClC1=CC=C(CN(CC2=CC=C(Cl)C=C2)C2=NNN=N2)C=C1,,,,,0,,333.0548008,3,3,1,1,0,0
3605,04/06/2019 00:00,DB04038,Ergosterol,,,,,Oral,solid,,,0.000156,18.27,-1.4,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,,,,,0,,396.339216,4,0,0,0,0,0
3606,04/06/2019 00:00,DB04039,3-Oxo-Pentadecanoic Acid,,,,,,solid,,,0.00211,4.44,-7.5,CCCCCCCCCCCCC(=O)CC(O)=O,,,,,0,,256.2038448,0,0,0,0,0,0
3607,04/06/2019 00:00,DB04040,"N-(2-Morpholin-4-Yl-1-Morpholin-4-Ylmethyl-Ethyl)-3-Nitro-5-(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yloxy)-Benzamide",,,,,,solid,,,1.82,7.23,6.15,[H][C@]1(CO)O[C@]([H])(OC2=CC(=CC(=C2)N(=O)=O)C(O)=NC(CN2CCOCC2)CN2CCOCC2)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,556.238058,4,1,3,0,3,3
3608,04/06/2019 00:00,DB04041,Nitrocefin Acyl-Serine,,,,,,solid,,,0.00434,1.68,8.61,[H]\C(=C(\[H])C1=C(C=C(C=C1)N(=O)=O)N(=O)=O)C1=C(N[C@]([H])(SC1)[C@]([H])(N=C([O-])CC1=CC=CS1)C(=O)OC[C@]([H])(N)C([O-])=O)C(O)=O,,,,,-2,,619.0689957,3,2,2,1,0,1
3609,04/06/2019 00:00,DB04042,"2-[4-(Hydroxy-Methoxy-Methyl)-Benzyl]-7-(4-Hydroxymethyl-Benzyl)-1,1-Dioxo-3,6-Bis-Phenoxymethyl-1lambda6-[1,2,7]Thiadiazepane-4,5-Diol",,,,,,solid,,,0.0873,11.66,-2.8,[H][C@](O)(OC)C1=CC=C(CN2[C@]([H])(COC3=CC=CC=C3)[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(COC3=CC=CC=C3)N(CC3=CC=C(CO)C=C3)S2(=O)=O)C=C1,,,,,0,,664.2454519,5,4,1,0,1,1
3610,04/06/2019 00:00,DB04043,Carboxymycobactin T,,,,,,solid,,,0.24,4.86,6.12,OC(=O)CCCCCC\C=C/[C@@H]1O[Fe@]23ON1CCCC[C@@H](NC(=O)[C@@H]1CO[C@H](N1)C1=CC=CC=C1O2)C(=O)OCCC(=O)N[C@@H]1CCCCN(O3)C1=O,,,,,0,,787.2727095,6,1,5,0,4,5
3611,04/06/2019 00:00,DB04044,4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid,,,,,,solid,,,0.00235,2.84,-4.1,OC(=O)C1=C(C=C(OC2=C(NC(=O)C3=CC(=CC=C3)[N+]([O-])=O)C=CC=C2)C=C1)C(O)=O,,,,,0,,422.0750154,3,3,0,0,0,0
3612,04/06/2019 00:00,DB04045,Methylmalonyl-Coenzyme A,,,,,,solid,,,5.49,0.82,4.82,[H][C@@](C)(C(O)=O)C(=O)SCCN=C(O)CCN=C(O)[C@]([H])(O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,867.1312529,3,2,3,2,1,1
3613,04/06/2019 00:00,DB04046,Methyl beta-galactoside,,,,,,solid,,,862,12.21,-3,CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,,,,,0,,194.0790382,1,0,1,0,1,1
3614,04/06/2019 00:00,DB04047,[Pterin-6-Yl Methanyl]-Phosphonophosphate,,,,,,solid,,,5.52,1.81,0.77,NC1=NC2=NC=C(CO[P@](O)(=O)OP(O)(O)=O)N=C2C(=O)N1,,,,,0,,352.9926355,2,2,2,2,0,0
3615,04/06/2019 00:00,DB04048,N-Carbamoyl-Alanine,,,,,,solid,,,59,3.77,-2.6,C[C@@H](NC(N)=O)C(O)=O,,,,,0,,132.0534921,0,0,0,0,0,0
3616,04/06/2019 00:00,DB04049,Coelenteramide,,,,,,solid,,,0.00277,9.18,-0.26,OC1=CC=C(CC(=O)NC2=NC=C(N=C2CC2=CC=CC=C2)C2=CC=C(O)C=C2)C=C1,,,,,0,,411.1582915,4,4,1,1,0,0
3617,04/06/2019 00:00,DB04050,N-Propyl Isocyanide,,,,,,solid,,,1.24,16.22,,CCC[N+]#[C-],,,,,0,,69.05784922,0,0,0,0,0,0
3618,04/06/2019 00:00,DB04051,5-Phenylvaleric Acid,,,,,,solid,,,0.204,4.94,,OC(=O)CCCCC1=CC=CC=C1,,,,,0,,178.0993797,1,1,0,0,0,0
3619,04/06/2019 00:00,DB04052,"3,4-Dimethylphenol",,,,,,solid,,,5.45,10.47,-5.4,CC1=CC=C(O)C=C1C,,,,,0,,122.0731649,1,1,0,0,0,0
3620,04/06/2019 00:00,DB04054,"9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine",,,,,,solid,,,0.0383,17.67,0.97,CCCCN1C(CC2=C(OC)C=CC(OC)=C2)=NC2=C(N)N=C(F)N=C12,,,,,0,,359.1757532,3,3,2,2,0,0
3621,04/06/2019 00:00,DB04055,"2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium",,,,,,solid,,,0.00119,2.24,-7.1,CC[N+]1=C(C)C(C(=O)OC(C)C)=C(C2=CC=CC=C2Cl)C(C(O)=O)=C1C(O)=O,,,,,1,,406.1051915,2,2,1,1,0,0
3622,04/06/2019 00:00,DB04057,"Beta-Dadf, Msa, Multisubstrate Adduct Inhibitor",,,,,,solid,,,0.119,1.22,4.9,[H]\C(=C(\[H])C1=C(N=CN1[C@]1([H])O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@@]1([H])O)C(O)=N)C(=O)N(CC1=NC2=C(NC(=N)N=C2O)C=C1)C1=CC=C(C=C1)C(=O)N[C@@]([H])(CCC(O)=O)C(O)=O,,,,,0,,815.191198,5,4,4,3,1,1
3623,04/06/2019 00:00,DB04058,D-[(Amino)Carbonyl]Phenylalanine,,,,,,solid,,,1.84,3.96,-2.6,[H][C@@](CC1=CC=CC=C1)(NC(N)=O)C(O)=O,,,,,0,,208.0847922,1,1,0,0,0,0
3624,04/06/2019 00:00,DB04059,8-(Pyrimidin-2-Ylamino)Naphthalene-2-Carboximidamide,,,,,,solid,,,0.04,12.72,11.25,NC(=N)C1=CC2=C(C=CC=C2NC2=NC=CC=N2)C=C1,,,,,0,,263.1170954,3,3,1,1,0,0
3625,04/06/2019 00:00,DB04060,"(5-Methyl-6-Oxo-1,6-Dihydro-Pyridin-3-Yl)-1,2-Dideoxy-Ribofuranose-5-Monophosphate",,,,,,solid,,,7.94,1.21,2.53,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)C1=CN=C(O)C(C)=C1,,,,,0,,305.0664385,2,1,2,1,1,1
3626,04/06/2019 00:00,DB04061,Alpha-Amino-2-Indanacetic Acid,,,,,,solid,,,1.9,2.4,9.56,[H][C@@](N)(C1CC2=CC=CC=C2C1)C(O)=O,,,,,0,,191.0946287,2,1,0,0,0,0
3627,04/06/2019 00:00,DB04062,Beta-D-Fucose,,,,,,solid,,,827,11.3,-3.6,C[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O,,,,,0,,164.0684735,1,0,1,0,1,1
3628,04/06/2019 00:00,DB04063,2-Methylleucine,,,,,,solid,,,29.8,2.81,9.76,CC(C)C[C@](C)(N)C(O)=O,,,,,0,,145.1102787,0,0,0,0,0,0
3629,04/06/2019 00:00,DB04064,Nogalaviketone,,,,,,solid,,,0.0233,6.3,-2.9,COC(=O)C1=C(C)CC(=O)C2=C(O)C3=C(C=C12)C(=O)C1=CC=CC(O)=C1C3=O,,,,,0,,378.0739528,4,2,0,0,0,0
3630,04/06/2019 00:00,DB04065,N-Cyclopentyl-N-Cyclobutylformamide,,,,,,solid,,,6.45,,0.93,O=CN(C1CCC1)C1CCCC1,,,,,0,,167.1310142,2,0,0,0,0,0
3631,04/06/2019 00:00,DB04066,para-Coumaric Acid,,,,,,solid,,,1.02,4,-6,OC(=O)\C=C\C1=CC=C(O)C=C1,,,,,0,,164.0473441,1,1,0,0,0,0
3632,04/06/2019 00:00,DB04067,4-Hydroxybenzyl Coenzyme A,,,,,,solid,,,5.74,0.82,4.8,[H][C@](O)(C(O)=NCCC(O)=NCCSCC1=CC=C(O)C=C1)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,873.1570738,4,3,3,2,1,1
3633,04/06/2019 00:00,DB04068,Fudp,,,,,,solid,,,11.7,1.77,-4.1,[H][C@]1(F)C[C@@]([H])(O[C@]1([H])COP(O)(=O)OP(O)(O)=O)N1C=CC(O)=NC1=O,,,,,0,,390.0029461,2,1,2,1,1,1
3634,04/06/2019 00:00,DB04069,"5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine",,,,,,solid,,,1.8,,4.88,NC1=NN=C2C(CCC3=CC=CC=C23)=C1,,,,,0,,197.0952974,3,2,1,1,0,0
3635,04/06/2019 00:00,DB04070,6-Deoxyerythronolide B,,,,,,solid,,,1.12,14,-3,[H][C@@]1(C)C[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)O[C@]([H])(CC)[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C1=O,,,,,0,,386.2668389,1,0,1,0,1,1
3636,04/06/2019 00:00,DB04071,Cpad,,,,,,solid,,,3.15,1.86,5,NC(=O)C1=NC(=CC=C1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C2N=CN=C3N)[C@@H](O)[C@H]1O,,,,,0,,663.1091218,5,3,5,3,2,2
3637,04/06/2019 00:00,DB04072,Alpha-Methylisocitric Acid,,,,,,solid,,,149,3.17,-4.1,C[C@@](O)([C@H](CC(O)=O)C(O)=O)C(O)=O,,,,,0,,206.0426527,0,0,0,0,0,0
3638,04/06/2019 00:00,DB04073,N-{3-[4-(3-aminopropyl)piperazin-1-yl]propyl}-3-(beta-D-galactopyranosyloxy)-5-nitrobenzamide,,,,,,solid,,,1.59,6.91,10.18,[H][C@]1(CO)O[C@@]([H])(OC2=CC(=CC(=C2)N(=O)=O)C(O)=NCCCN2CCN(CCCN)CC2)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,527.2591278,3,1,2,0,2,2
3639,04/06/2019 00:00,DB04074,alpha-Ketoisovalerate,,,,,,solid,,,30.2,3.37,-9.7,CC(C)C(=O)C(O)=O,,,,,0,,116.0473441,0,0,0,0,0,0
3640,04/06/2019 00:00,DB04075,N-Acetyl-L-Glutamate,,,,,,solid,,,18.6,3.43,-1.2,CC(=O)N[C@@H](CCC(O)=O)C(O)=O,,,,,0,,189.0637225,0,0,0,0,0,0
3641,04/06/2019 00:00,DB04076,Hypoxanthine,,,,,,solid,700 mg/L (at 23 Â°C),-1.11,13,8.72,2.66,OC1=NC=NC2=C1NC=N2,,,,,0,,136.0385107,2,2,2,2,0,0
3642,04/06/2019 00:00,DB04079,"Heptane-1,2,3-Triol",,,,,,solid,,,210,13.34,-3,[H][C@@](O)(CO)[C@]([H])(O)CCCC,,,,,0,,148.1099444,0,0,0,0,0,0
3643,04/06/2019 00:00,DB04080,RU78191,,,,,,solid,,,4.84,2.49,,OC(=O)C(C(O)=O)C1=CC=CC=C1,,,,,0,,180.0422587,1,1,0,0,0,0
3644,04/06/2019 00:00,DB04081,"(4s-Trans)-4-(Methylamino)-5,6-Dihydro-6-Methyl-4h-Thieno(2,3-B)Thiopyran-2-Sulfonamide-7,7-Dioxide",,,,,,solid,,,1.08,8.18,7.13,[H][C@]1(C)C[C@]([H])(NC)C2=C(SC(=C2)S(N)(=O)=O)S1(=O)=O,,,,,0,,310.0115699,2,1,2,1,0,1
3645,04/06/2019 00:00,DB04082,Decyloxy-Methanol,,,,,,solid,,,0.0547,13.06,-3.6,CCCCCCCCCCOCO,,,,,0,,188.17763,0,0,0,0,0,0
3646,04/06/2019 00:00,DB04083,N'-Pyridoxyl-Lysine-5'-Monophosphate,,,,,,solid,,,0.451,1.38,9.95,[H]\C(=N/CCCC[C@]([H])(N)C(O)=O)C1=C(COP(O)(O)=O)C=NC(C)=C1O,,,,,0,,375.1195367,1,1,1,1,0,0
3647,04/06/2019 00:00,DB04084,2-deoxy-2-fluoro-Î±-D-mannose,,,,,,solid,,,257,11.02,-3,OC[C@H]1O[C@H](O)[C@@H](F)[C@@H](O)[C@@H]1O,,,,,0,,182.0590517,1,0,1,0,1,1
3648,04/06/2019 00:00,DB04085,"1-[Pyrrol-1-Yl-2,5-Dione-Methoxymethyl]-Pyrrole-2,5-Dione",,,,,,solid,,,10.4,,-4.2,O=C1C=CC(=O)N1COCN1C(=O)C=CC1=O,,,,,0,,236.0433214,2,0,2,0,0,2
3649,04/06/2019 00:00,DB04086,"2',4'-Dinitrophenyl-2deoxy-2-Fluro-B-D-Cellobioside",,,,,,solid,,,5.5,12.08,-3,[H][C@]1(CO)O[C@@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@@]([H])(OC3=C(C=C(C=C3)N(=O)=O)N(=O)=O)[C@]([H])(F)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,510.1133316,3,1,2,0,2,2
3650,04/06/2019 00:00,DB04087,Open Form of 2'-Deoxy-Ribofuranose-5'-Phosphate,,,,,,solid,,,33,1.5,-2.4,[H][C@](O)(CCO)[C@]([H])(O)COP(O)(O)=O,,,,,0,,216.0398894,0,0,0,0,0,0
3651,04/06/2019 00:00,DB04088,2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid,,,,,,solid,,,0.0024,2.31,-4,[H]N(CCCCOC1=CC=CC(O)=C1C(=O)OC)C(=O)[C@H](CC1=CC=C(C=C1)N(C(=O)C(O)=O)C1=CC=CC=C1C(O)=O)N([H])C(=O)OCC=C,,,,,0,,677.2220736,3,3,0,0,0,0
3652,04/06/2019 00:00,DB04089,AL5300,,,,,,solid,,,0.929,8.16,-3.6,[H][C@]1(O)CN(CC2=CC=CS2)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,,,,,0,,379.9629055,3,2,3,2,0,1
3653,04/06/2019 00:00,DB04090,RH-1,,,,,,solid,,,44.2,14.87,-0.56,CC1=C(N2CC2)C(=O)C(CO)=C(N2CC2)C1=O,,,,,0,,234.1004423,3,0,2,0,2,2
3654,04/06/2019 00:00,DB04092,Apstatin,,,,,,solid,,,1.92,12.11,8.35,C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(N)=O,,,,,0,,459.2481692,3,1,2,0,2,2
3655,04/06/2019 00:00,DB04093,Undecanal,,,,,,solid,,,0.00201,15.56,-6.9,CCCCCCCCCCC=O,,,,,0,,170.1670653,0,0,0,0,0,0
3656,04/06/2019 00:00,DB04094,4-Hydroxy-2-Butanone,,,,,,solid,,,632,15.8,-2.4,CC(=O)CCO,,,,,0,,88.0524295,0,0,0,0,0,0
3657,04/06/2019 00:00,DB04095,9-Deazahypoxanthine,,,,,,solid,,,9.59,12.35,2.45,OC1=NC=NC2=C1NC=C2,,,,,0,,135.0432618,2,2,2,2,0,0
3658,04/06/2019 00:00,DB04096,"5-Amino-5-Deoxy-Cellobiono-1,5-Lactam",,,,,,solid,,,176,4.61,1.24,[H][C@]1(CO)O[C@@]([H])(O[C@]2([H])[C@@]([H])(CO)N=C(O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,339.1165459,2,0,2,0,1,2
3659,04/06/2019 00:00,DB04097,Uridine-5'-Diphosphate-4-Deoxy-4-Fluoro-Alpha-D-Galactose,,,,,,solid,,,43.6,1.73,-3,[H][C@]1(COP(O)(=O)OP(O)(=O)O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(F)[C@]([H])(O)[C@@]2([H])O)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,568.0506841,3,1,3,1,2,2
3660,04/06/2019 00:00,DB04098,Balanol,,,,,,solid,,,0.0157,2.98,9.74,OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C=C1O)C(=O)O[C@@H]1CCCNC[C@@H]1NC(=O)C1=CC=C(O)C=C1,,,,,0,,550.158745,4,3,1,0,1,1
3661,04/06/2019 00:00,DB04099,Deamido-Nad+,,,,,,solid,,,1.88,1.81,5,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)[N+]4=CC=CC(=C4)C(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1,,,,,1,,665.1004138,5,3,5,3,2,2
3662,04/06/2019 00:00,DB04100,"(1,10 Phenanthroline)-(Tri-Carbon Monoxide) Rhenium (I)",,,,,,solid,,,2.03,,,[O]#C[Re+]1(C#[O])(C#[O])[N]2=CC=CC3=C2C2=C(C=CC=[N]12)C=C3,,,,,,,,,,,,,
3663,04/06/2019 00:00,DB04101,"N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N'-Hydroxyimidoformamide",,,,,,solid,,,0.109,10.44,2.64,CC1=NC(C)=C(S1)C1=CC=NC(N\C=N/O)=N1,,,,,0,,249.068431,2,2,2,2,0,0
3664,04/06/2019 00:00,DB04102,2-Amino-Adenosine,,,,,,solid,,,10,13.38,8.35,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(N)[C@]1([H])O,,,,,0,,266.1127383,3,2,3,2,1,1
3665,04/06/2019 00:00,DB04103,3-Methylcytosine,,,,,,solid,,,11.5,8.52,-4.8,C[N+]1=C(N)C=CNC1=O,,,,,1,,126.0661883,1,1,1,1,0,0
3666,04/06/2019 00:00,DB04104,3-Methyladenine,,,,,,solid,,,1.81,17.3,3.03,CN1C=NC(N)=C2N=CN=C12,,,,,0,,149.0701452,2,0,2,0,0,2
3667,04/06/2019 00:00,DB04105,N-Heptylformamide,,,,,,solid,,,1.73,16.88,-0.38,CCCCCCCNC=O,,,,,0,,143.1310142,0,0,0,0,0,0
3668,04/06/2019 00:00,DB04106,Fotemustine,,,,,,solid,,,4.11,11.06,-5.4,CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)N=O,,,,,0,,315.075085,0,0,0,0,0,0
3669,04/06/2019 00:00,DB04107,[(1-{2[(4-Carbamimidoyl-Phenylamino)-Methyl]-1-Methyl-1h-Benzoimidazol-5-Yl}-Cyclopropyl)-Pyridin-2-Yl-Methyleneaminooxy]-Acetic Acid Ethyl Ester,,,,,,solid,,,0.0289,18.16,12.52,CCOC(=O)CO\N=C(\C1=CC=CC=N1)C1(CC1)C1=CC=C2N(C)C(CNC3=CC=C(C=C3)C(N)=N)=NC2=C1,,,,,0,,525.2488379,5,4,2,2,0,0
3670,04/06/2019 00:00,DB04108,"(2s,3r)-3-Amino-2-Hydroxy-5-(Ethylsulfanyl)Pentanoyl-((S)-(-)-(1-Naphthyl)Ethyl)Amide",,,,,,solid,,,0.00918,12.59,8.75,[H][C@](N)(CCSCC)[C@]([H])(O)C(=O)N[C@@]([H])(C)C1=C2C=CC=CC2=CC=C1,,,,,0,,346.1714991,2,2,0,0,0,0
3671,04/06/2019 00:00,DB04109,"[4-(1,3,2-Dioxaborolan-2-Yloxy)Methyl]Benzamidine",,,,,,solid,,,0.4,,11.47,NC(=[NH2+])C1=CC=C(COB2OCCO2)C=C1,,,,,1,,221.1091991,2,1,1,0,1,1
3672,04/06/2019 00:00,DB04110,2-Nitro-P-Cresol,,,,,,solid,,,2.26,6.8,-6.6,CC1=CC=C(O)C(=C1)[N+]([O-])=O,,,,,0,,153.0425931,1,1,0,0,0,0
3673,04/06/2019 00:00,DB04111,Balhimycin,,,,,,solid,,,0.126,1.98,,[H][C@](CC(C)C)(NC)C(O)=N[C@@]1([H])C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@]2([H])C3=CC(OC4=C(Cl)C=C(C=C4)[C@@]1([H])O)=C(O[C@]1([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O)C(OC1=C(Cl)C=C(C=C1)[C@@]([H])(O[C@@]1([H])C[C@](C)(N)C(O)(O)[C@]([H])(C)O1)[C@]1([H])N=C(O)[C@]([H])(N=C2O)C2=CC(=C(O)C=C2)C2=C(C=C(O)C=C2O)[C@]([H])(N=C1O)C(O)=O)=C3,,,,,0,,1463.425114,12,5,7,0,2,7
3674,04/06/2019 00:00,DB04112,1-Octadecyl-2-Acetamido-2-Deoxy-Sn-Glycerol-3-Phosphoethylmethyl Sulfide,,,,,,solid,,,0.000806,1.79,3.19,[H][C@@](COCCCCCCCCCCCCCCCCCC)(COP(O)(=O)OCCSC)N=C(C)O,,,,,0,,539.3409461,0,0,0,0,0,0
3675,04/06/2019 00:00,DB04113,N-Formylpiperidine,,,,,,solid,,,282,,-0.01,O=CN1CCCCC1,,,,,0,,113.084064,1,0,1,0,1,1
3676,04/06/2019 00:00,DB04114,"3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine",,,,,,solid,,,0.00163,,8.07,[H][C@]12CC3=C(C(N)=C4C=CC(Cl)=CC4=N3)[C@]([H])(CC(CC)=C1)C2,,,,,0,,298.1236763,4,2,1,1,0,0
3677,04/06/2019 00:00,DB04115,Berberine,,,,,,solid,,,0.000354,,-4.4,COC1=CC=C2C=C3C4=CC5=C(OCO5)C=C4CC[N+]3=CC2=C1OC,,,,,1,,336.1230345,5,3,3,1,0,2
3678,04/06/2019 00:00,DB04116,Allolactose,,,,,,solid,,,511,11.25,-3,OC[C@H]1O[C@@H](OC[C@H]2OC(O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1O,,,,,0,,342.1162115,2,0,2,0,2,2
3679,04/06/2019 00:00,DB04117,"4-(N,N-Dimethylamino)Cinnamoyl-Coa",,,,,,solid,,,5.44,0.82,4.97,[H]\C(=C(\[H])C1=CC=C(C=C1)N(C)C)C(=O)SCCN=C(O)CCN=C(O)[C@]([H])(O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,940.1992729,4,3,3,2,1,1
3680,04/06/2019 00:00,DB04118,N-Coeleneterazine,,,,,,solid,,,0.00404,9.5,4.21,[H][C@@]1(CC2=CC=CC=C2)NC(=CN2C(=O)[C@](CC3=CC4=CC=CC=C4C=C3)(OO)N=C12)C1=CC=C(O)C=C1,,,,,0,,491.1845063,6,4,2,0,0,2
3681,04/06/2019 00:00,DB04120,"4-Methyl-1,2-Benzenediol",,,,,,solid,,1.37,37.9,9.55,-6.2,CC1=CC=C(O)C(O)=C1,,,,,0,,124.0524295,1,1,0,0,0,0
3682,04/06/2019 00:00,DB04121,Guanosine-3'-Monophosphate-5'-Diphosphate,,,,,,solid,,,7.23,0.81,4.89,[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2NC(=N)N=C3O)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,522.9906601,3,2,3,2,1,1
3683,04/06/2019 00:00,DB04122,beta-D-glucose 6-phosphate,,,,,,solid,,,31.4,1.22,-3.6,O[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,260.0297186,1,0,1,0,1,1
3684,04/06/2019 00:00,DB04123,(P-Iodophenylacetylamino)Methylphosphinic Acid,,,,,,solid,,,0.0948,1.93,-2.8,[H][P@](O)(=O)CNC(=O)CC1=CC=C(I)C=C1,,,,,0,,338.9521278,1,1,0,0,0,0
3685,04/06/2019 00:00,DB04124,Aurodox,,,,,,solid,,,0.00636,6.37,3.92,[H]\C(C)=C(/[H])\C(\[H])=C(/[H])[C@]1([H])O[C@](O)([C@]([H])(CC)C(O)=NC\C([H])=C(/[H])\C(\[H])=C(/C)[C@@]([H])(OC)[C@@]([H])(C)[C@]2([H])O[C@]([H])(C(\[H])=C(/[H])\C(\[H])=C(/[H])\C(\[H])=C(/C)C(=O)C3=C(O)C=CN(C)C3=O)[C@]([H])(O)[C@]2([H])O)[C@]([H])(O)[C@]([H])(O)C1(C)C,,,,,0,,810.4302754,3,1,3,1,2,2
3686,04/06/2019 00:00,DB04125,N-Alpha-(2-Naphthylsulfonyl)-N(3-Amidino-L-Phenylalaninyl)-4-Acetyl-Piperazine,,,,,,solid,,,0.0295,10.02,11.47,CC(=O)N1CCN(CC1)C(=O)[C@H](CC1=CC=CC(=C1)C(N)=N)NS(=O)(=O)C1=CC=C2C=CC=CC2=C1,,,,,0,,507.1940254,4,3,1,0,1,1
3687,04/06/2019 00:00,DB04126,N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane,,,,,,solid,,,2.42,4.25,-2.8,[H][C@](O)(CC(O)=O)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCCC(C)C,,,,,0,,316.199822,0,0,0,0,0,0
3688,04/06/2019 00:00,DB04127,beta-D-arabinofuranose 5-phosphate,,,,,,solid,,,33.6,1.22,-3.7,[H][C@@]1(O)O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,230.0191539,1,0,1,0,1,1
3689,04/06/2019 00:00,DB04128,"5-Nitroso-6-Ribityl-Amino-2,4(1h,3h)-Pyrimidinedione",,,,,,solid,,,11.4,10.7,-1.4,[H][C@@](O)(CO)[C@@]([H])(O)[C@@]([H])(O)CNC1=C(N=O)C(O)=NC(O)=N1,,,,,0,,290.0862488,1,1,1,1,0,0
3690,04/06/2019 00:00,DB04129,Willardiine,,,,,,solid,,,21.7,1.78,8.46,N[C@@H](CN1C=CC(=O)NC1=O)C(O)=O,,,,,0,,199.0593058,1,1,1,1,0,0
3691,04/06/2019 00:00,DB04130,5-Methoxybenzimidazole,,,,,,solid,,,5.6,12.18,6.08,COC1=CC2=C(C=C1)N=CN2,,,,,0,,148.0636629,2,2,1,1,0,0
3692,04/06/2019 00:00,DB04131,"10-(4-Dimethylamino-5-Hydroxy-6-Methyl-Tetrahydro-Pyran-2-Yloxy)-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene-5,12-Dione",,,,,,solid,,,0.244,8.95,8.26,[H][C@@]1(C[C@]([H])(N(C)C)[C@]([H])(O)[C@]([H])(C)O1)O[C@@]1([H])C[C@](O)(CC)CC2=CC3=C(C(O)=C12)C(=O)C1=C(C=CC=C1O)C3=O,,,,,0,,511.220617,5,2,1,0,1,1
3693,04/06/2019 00:00,DB04132,S-Hexylglutathione,,,,,,solid,,,0.0915,2.07,9.54,[H][C@](N)(CCC(O)=N[C@@]([H])(CSCCCCCC)C(O)=NCC(O)=O)C(O)=O,,,,,0,,391.1777066,0,0,0,0,0,0
3694,04/06/2019 00:00,DB04133,Degraded Cephaloridine,,,,,,solid,,,0.0411,3.89,-0.82,[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@]1([H])NC(C(O)=O)=C(C)CS1,,,,,0,,340.055149,2,1,2,1,0,1
3695,04/06/2019 00:00,DB04135,"5-Fluoro-4-(S)-Hydroxy-3,4-Dihydropyrimidine",,,,,,solid,,,7.55,8.05,1.42,[H][C@@]1(O)NC(O)=NC=C1F,,,,,0,,132.0335056,1,0,1,0,0,1
3696,04/06/2019 00:00,DB04136,Lysophosphotidylserine,,,,,,solid,,,0.00707,1.51,9.38,[H][C@@](O)(CO[C@@]([H])(O)CCCCCCCCCCCCCC)COP(O)(=O)OC[C@]([H])(N)C(O)=O,,,,,0,,485.2753686,0,0,0,0,0,0
3697,04/06/2019 00:00,DB04137,Guanosine-5'-Triphosphate,,,,,,solid,,,10.4,0.8,1.57,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]2O)C(=O)N1,,,,,0,,522.9906601,3,2,3,2,1,1
3698,04/06/2019 00:00,DB04138,"2,4-Dinitro,5-[Bis(2-Bromoethyl)Amino]-N-(2',3'-Dioxopropyl)Benzamide",,,,,,solid,,,0.00479,4.92,0.34,OC(=NCC(=O)C=O)C1=CC(N(CCBr)CCBr)=C(C=C1N(=O)=O)N(=O)=O,,,,,0,,507.922923,1,1,0,0,0,0
3699,04/06/2019 00:00,DB04139,6-Hydroxypropylthymine,,,,,,solid,,,6.2,10.29,-2.4,CC1=C(CCCO)NC(=O)NC1=O,,,,,0,,184.0847922,1,1,1,1,0,0
3700,04/06/2019 00:00,DB04140,1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide,,,,,,solid,,,0.195,8.71,-2.8,[H][C@@]1(CC(=O)N(CC2=CC=CC=C2)CN1S(=O)(=O)C1=CC=C(OC)C=C1)C(=O)NO,,,,,0,,419.1151064,3,2,1,0,1,1
3701,04/06/2019 00:00,DB04141,"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,,,,,solid,,,57,12.21,-3,[H][C@]1(O)[C@@]([H])(O)[C@@]([H])(CO)O[C@@]([H])(OCCCCCC)[C@]1([H])O,,,,,0,,264.1572885,1,0,1,0,1,1
3702,04/06/2019 00:00,DB04142,"3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide",,,,,,solid,,,0.0129,5.11,-4.4,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=C(C=C2)S(=O)(=O)N(C)C,,,,,0,,528.9194178,3,3,1,1,0,0
3703,04/06/2019 00:00,DB04143,Indole-3-Glycerol Phosphate,,,,,,solid,,,3.87,1.49,-3.4,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)C1=CNC2=C1C=CC=C2,,,,,0,,287.0558738,2,2,1,1,0,0
3704,04/06/2019 00:00,DB04144,"Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone",,,,,,solid,,,0.000943,,7.82,[H][C@]1(N=C(N(C(=O)N2CCNCC2)[C@]1([H])C1=CC=C(Cl)C=C1)C1=C(OC(C)C)C=C(OC)C=C1)C1=CC=C(Cl)C=C1,,,,,0,,566.1851462,5,3,2,0,1,2
3705,04/06/2019 00:00,DB04145,Nicotinyl alcohol,,,,,,solid,,,312,14.69,4.73,OCC1=CC=CN=C1,,,,,0,,109.0527638,1,1,1,1,0,0
3706,04/06/2019 00:00,DB04146,I-Coeleneterazine,,,,,,solid,,,0.00352,9.5,4.21,[H][C@]1(CC2=CC=CC=C2)NC(=CN2C(=O)[C@](CC3=CC=C(I)C=C3)(OO)N=C12)C1=CC=C(O)C=C1,,,,,0,,567.0655042,5,3,2,0,0,2
3707,04/06/2019 00:00,DB04147,Lauryl Dimethylamine-N-Oxide,,,,,,solid,,,0.00015,,4.17,CCCCCCCCCCCC[N+](C)(C)[O-],,,,,0,,229.2405646,0,0,0,0,0,0
3708,04/06/2019 00:00,DB04149,(R)-Rolipram,,,,,,solid,,,0.0672,14.28,-1.3,[H][C@]1(CNC(=O)C1)C1=CC(OC2CCCC2)=C(OC)C=C1,,,,,0,,275.1521435,3,1,1,0,1,1
3709,04/06/2019 00:00,DB04150,Threonine Derivative,,,,,,solid,,,0.0686,2.63,0.99,[H][C@](C)(O)[C@@]([H])(N=C(O)[C@]([H])(CC1=CC(I)=C(O)C(I)=C1)N=C(C)O)C(O)=O,,,,,0,,575.9254323,1,1,0,0,0,0
3710,04/06/2019 00:00,DB04151,4-Methyl-Histidine,,,,,,solid,,,6.93,1.96,9.25,CN1C=NC(C[C@H](N)C(O)=O)=C1,,,,,0,,169.0851266,1,1,1,1,0,0
3711,04/06/2019 00:00,DB04152,"2-Amino-3-(3-Hydroxy-7,8-Dihydro-6h-Cyclohepta[D]-4-Isoxazolyl)Propionic Acid",,,,,,solid,,,4.36,2.05,9.48,N[C@@H](CC1=CCCCC2=C1C(=O)NO2)C(O)=O,,,,,0,,238.0953569,2,1,1,1,0,0
3712,04/06/2019 00:00,DB04153,S-Hydroxymethyl Glutathione,,,,,,solid,,,5.27,1.79,9.31,N[C@@H](CCC(=O)N[C@@H](CSCO)C(=O)NCC(O)=O)C(O)=O,,,,,0,,337.0943709,0,0,0,0,0,0
3713,04/06/2019 00:00,DB04154,"N-Methyl-N-[3-(6-Phenyl[1,2,4]Triazolo[4,3-B]Pyridazin-3-Yl)Phenyl]Acetamide",,,,,,solid,,,0.0245,,1.36,CN(C(C)=O)C1=CC=CC(=C1)C1=NN=C2C=CC(=NN12)C1=CC=CC=C1,,,,,0,,343.1433102,4,4,2,2,0,0
3714,04/06/2019 00:00,DB04155,2-Fluoro-2-Deoxy-Beta-D-Galactopyranosyl-Beta-D-Glucopyranose,,,,,,solid,,,290,11.28,-3,[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]2([H])F)[C@]([H])(O)[C@@]1([H])O,,,,,0,,344.1118751,2,0,2,0,2,2
3715,04/06/2019 00:00,DB04156,Aspartate Beryllium Trifluoride,,,,,,solid,,,0.272,1.29,9.08,N[C@@H](C[C@H](O)O[Be](F)(F)F)C(O)=O,,,,,,,,,,,,,
3716,04/06/2019 00:00,DB04157,N-[(Aminooxy)Carbonyl]Aniline,,,,,,solid,,,5.6,12.65,2.6,NOC(=O)NC1=CC=CC=C1,,,,,0,,152.0585775,1,1,0,0,0,0
3717,04/06/2019 00:00,DB04158,"6-(Adenosine Tetraphosphate-Methyl)-7,8-Dihydropterin",,,,,,solid,,,14.2,0.13,15,[H][C@]1(COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OCC2=NC3=C(NC2)NC(=N)N=C3O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,764.0271358,5,3,5,3,1,2
3718,04/06/2019 00:00,DB04159,Beta-Hydroxytryptophane,,,,,,solid,,,9.39,2.3,8.83,[H][C@@](N)(C(O)=O)[C@@]([H])(O)C1=CNC2=CC=CC=C12,,,,,0,,220.0847922,2,2,1,1,0,0
3719,04/06/2019 00:00,DB04161,Propionamide,,,,,,solid,,,364,16.86,-1,CCC(N)=O,,,,,0,,73.05276384,0,0,0,0,0,0
3720,04/06/2019 00:00,DB04162,"5-Nitro-6-Ribityl-Amino-2,4(1h,3h)-Pyrimidinedione",,,,,,solid,,,7.98,9.51,-2.9,[H][C@@](O)(CO)[C@@]([H])(O)[C@@]([H])(O)CNC1=C(C(O)=NC(O)=N1)N(=O)=O,,,,,0,,306.0811634,1,1,1,1,0,0
3721,04/06/2019 00:00,DB04163,"5-Phenylsulfanyl-2,4-Quinazolinediamine",,,,,,solid,,,0.023,16.67,6.58,NC1=NC2=C(C(N)=N1)C(SC1=CC=CC=C1)=CC=C2,,,,,0,,268.0782674,3,3,1,1,0,0
3722,04/06/2019 00:00,DB04164,"1,4-Deoxy-4-((5-Hydroxymethyl-2,3,4-Trihydroxycyclohex-5-Enyl)Amino)Fructose",,,,,,solid,,,85,11.2,5.84,[H][C@]1(O)OC(=C)[C@@]([H])(N[C@@]2([H])C=C(C=O)C(=O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,315.0954165,2,0,1,0,1,1
3723,04/06/2019 00:00,DB04165,Valpromide,,,,,,solid,,,3.52,17.09,0.13,CCCC(CCC)C(N)=O,,,,,0,,143.1310142,0,0,0,0,0,0
3724,04/06/2019 00:00,DB04166,Anthranilic acid,,,,,,solid,,,6.81,4.89,1.95,NC1=CC=CC=C1C(O)=O,,,,,0,,137.0476785,1,1,0,0,0,0
3725,04/06/2019 00:00,DB04167,Aceglutamide,,,,,,solid,,,21.9,3.76,-1.4,CC(=O)N[C@@H](CCC(N)=O)C(O)=O,,,,,0,,188.0797069,0,0,0,0,0,0
3726,04/06/2019 00:00,DB04168,2-Amino-5-Bromo-6-Phenylpyrimidin-4-Ol,,,,,,solid,,,1.56,10.96,1.49,NC1=NC(=C(Br)C(O)=N1)C1=CC=CC=C1,,,,,0,,264.985074,2,2,1,1,0,0
3727,04/06/2019 00:00,DB04169,"3,5-Diaminophthalhydrazide",,,,,,solid,,,4.04,13.95,2.8,NC1=CC(N)=C2C(=O)NNC(=O)C2=C1,,,,,0,,192.0647255,2,2,1,1,0,0
3728,04/06/2019 00:00,DB04170,4-bromo-3-hydroxy-3-methyl butyl diphosphate,,,,,,solid,,,10.1,1.78,-3.2,C[C@](O)(CBr)CCO[P@](O)(=O)OP(O)(O)=O,,,,,0,,341.9269027,0,0,0,0,0,0
3729,04/06/2019 00:00,DB04171,D-Isovaline,,,,,,solid,,,238,2.68,9.78,CC[C@@](C)(N)C(O)=O,,,,,0,,117.0789786,0,0,0,0,0,0
3730,04/06/2019 00:00,DB04172,"[2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta-Alanine",,,,,,solid,,,0.00871,10.56,11.51,[H][C@@](CC1=CC(=CC=C1)C(N)=N)(NS(=O)(=O)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C)C(=O)N1CCN(CC1)C(=O)CCN,,,,,0,,612.345775,3,2,1,0,1,1
3731,04/06/2019 00:00,DB04173,Fructose,,,,750 mg/1,Oral,solid,,,1110,10.28,-3,OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,,,,,0,750,180.0633881,1,0,1,0,1,1
3732,04/06/2019 00:00,DB04174,3'-1-Carboxy-1-Phosphonooxy-Ethoxy-Uridine-Diphosphate-N-Acetylglucosamine,,,,,,solid,,,15.4,0.8,-3.8,[H][C@]1(COP(O)(=O)OP(O)(=O)O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O[C@@](C)(OP(O)(O)=O)C(O)=O)[C@@]2([H])N=C(C)O)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,775.0639442,3,1,3,1,2,2
3733,04/06/2019 00:00,DB04175,Mdl-29951,,,,,,solid,,,0.0424,3.37,,OC(=O)CCC1=C(NC2=C1C(Cl)=CC(Cl)=C2)C(O)=O,,,,,0,,300.9908631,2,2,1,1,0,0
3734,04/06/2019 00:00,DB04176,"Phosporic Acid Mono-[3,4-Dihydroxy-5-(5-Methoxy-Benzoimidazol-1-Yl)-Tetrahydro-Furan-2-Ylmethyl] Ester",,,,,,solid,,,1.9,1.22,5.68,[H][C@]1(COP(O)(O)=O)O[C@]([H])(N2C=NC3=C2C=CC(OC)=C3)[C@]([H])(O)[C@]1([H])O,,,,,0,,360.0722521,3,2,2,1,1,1
3735,04/06/2019 00:00,DB04177,"4-(3,14-Dihydroxy-10,13-Dimethyl-Hexadecahydro-Cyclopenta[a]Phenanthren-17-Yl)-5h-Furan-2-One",,,,,,solid,,,0.0244,7.18,0.25,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C1=CC(=O)OC1,,,,,0,,374.2457096,5,0,1,0,0,1
3736,04/06/2019 00:00,DB04178,Di-Stearoyl-3-Sn-Phosphatidylcholine,,,,,,solid,,,2.96E-05,1.86,-6.7,[H][C@@](COC(=O)CCCCCCCCCCCCCCCCC)(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,,,,,1,,790.6320319,0,0,0,0,0,0
3737,04/06/2019 00:00,DB04179,Benzofuran,,,,,,solid,,,0.815,,-3.4,O1C=CC2=C1C=CC=C2,,,,,0,,118.0418648,2,2,1,1,0,0
3738,04/06/2019 00:00,DB04180,"4-(Aminosulfonyl)-N-[(2,4-Difluorophenyl)Methyl]-Benzamide",,,,,,solid,,,0.0189,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=C(F)C=C(F)C=C1,,,,,0,,326.0536697,2,2,0,0,0,0
3739,04/06/2019 00:00,DB04182,"(S)-2-Amino-4-[(2s,3r)-2,3,5-Trihydroxy-4-Oxo-Pentyl]Mercapto-Butyric Acid",,,,,,solid,,,21.3,1.87,9.3,[H][C@](N)(CCSC[C@@]([H])(O)[C@@]([H])(O)C(=O)CO)C(O)=O,,,,,0,,267.0776583,0,0,0,0,0,0
3740,04/06/2019 00:00,DB04183,Methylmalonic Acid,,,,,,solid,6.79E+005 mg/L (at 25 Â°C),,149,2.48,,CC(C(O)=O)C(O)=O,,,,,0,,118.0266087,0,0,0,0,0,0
3741,04/06/2019 00:00,DB04185,Norvaline,,,,,,solid,,,212,2.71,9.53,CCC[C@H](N)C(O)=O,,,,,0,,117.0789786,0,0,0,0,0,0
3742,04/06/2019 00:00,DB04186,"N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea",,,,,,solid,,,0.101,10.86,3.84,[H][C@]12CCCN1C(=O)C1=C2C(NC(=O)NC2=CC=CC=N2)=CC=C1,,,,,0,,308.1273258,4,2,3,1,1,2
3743,04/06/2019 00:00,DB04187,"(9S,10S)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene",,,,,,solid,,,0.0224,2.01,9.54,[H][C@](N)(CCC(O)=N[C@@]([H])(CS[C@@]1([H])C2=CC=CC=C2C2=CC=CC=C2[C@]1([H])O)C(O)=NCC(O)=O)C(O)=O,,,,,0,,501.1569712,3,2,0,0,0,0
3744,04/06/2019 00:00,DB04188,MDL72527,,,,,,solid,,,0.304,,9.81,C=C=CCNCCCCNCC=C=C,,,,,0,,192.1626486,0,0,0,0,0,0
3745,04/06/2019 00:00,DB04189,N2-(Carboxyethyl)-L-Arginine,,,,,,solid,,,0.658,1.72,12.13,[H][C@@](CCCNC(N)=N)(NCCC(O)=O)C(O)=O,,,,,0,,246.1328051,0,0,0,0,0,0
3746,04/06/2019 00:00,DB04190,Inhibitor Bea425,,,,,,solid,,,0.00555,4.71,1.75,[H][C@](C[C@@]([H])(O)[C@@]([H])(OCC1=CC=CC=C1)C(O)=N[C@@]1([H])C2=CC=CC=C2C[C@@]1([H])O)(OCC1=CC=CC=C1)C(O)=N[C@@]1([H])C2=CC=CC=C2C[C@@]1([H])O,,,,,0,,636.2835516,6,4,0,0,0,0
3747,04/06/2019 00:00,DB04191,Skf 107457,,,,,,solid,,,0.0237,12.05,8.09,[H][C@@](C)(N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CC=CC=C1)[C@@]([H])(O)CCC(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(C(C)C)C(=O)OC,,,,,0,,577.3475488,1,1,0,0,0,0
3748,04/06/2019 00:00,DB04193,L-Homoserine,,,,,,solid,1E+006 mg/L (at 30 Â°C),,423,2.22,9.16,N[C@@H](CCO)C(O)=O,,,,,0,,119.0582431,0,0,0,0,0,0
3749,04/06/2019 00:00,DB04194,Chitotriose,,,,,,solid,,,18.3,6.69,-3.6,[H][C@@]1(O)O[C@]([H])(CO)[C@@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O[C@]3([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])N=C(C)O)[C@]([H])(O)[C@@]2([H])N=C(C)O)[C@]([H])(O)[C@@]1([H])N=C(C)O,,,,,0,,627.2486822,3,0,3,0,3,3
3750,04/06/2019 00:00,DB04195,Heptulose-2-Phosphate,,,,,,solid,,,31.8,1.15,-3,C[C@]1(OP(O)(O)=O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,274.0453687,1,0,1,0,1,1
3751,04/06/2019 00:00,DB04196,Pteroic Acid,,,,,,solid,,,0.253,4.73,2.67,NC1=NC2=C(N=C(CNC3=CC=C(C=C3)C(O)=O)C=N2)C(O)=N1,,,,,0,,312.0970882,3,3,2,2,0,0
3752,04/06/2019 00:00,DB04197,Descarboxy-nor-N(Omega)-Hydroxy-L-Arginine,,,,,,solid,,,4.52,14.82,10.31,N\C(NO)=N/CCC[NH3+],,,,,1,,133.1083875,0,0,0,0,0,0
3753,04/06/2019 00:00,DB04198,Formycin B,,,,,,solid,,,10,8.63,-1.2,[H][C@]1(CO)O[C@@]([H])(C2=C3N=CNC(=O)C3=NN2)[C@]([H])(O)[C@]1([H])O,,,,,0,,268.0807695,3,2,3,2,1,1
3754,04/06/2019 00:00,DB04199,1-Monohexanoyl-2-Hydroxy-Sn-Glycero-3-Phosphate,,,,,,solid,,,8.94,1.51,-3.4,[H][C@](O)(COC(=O)CCCCC)COP(O)(O)=O,,,,,0,,270.0868396,0,0,0,0,0,0
3755,04/06/2019 00:00,DB04200,Matairesinol,,,,,,solid,,,0.0121,9.64,-4.6,[H][C@]1(CC2=CC=C(O)C(OC)=C2)COC(=O)[C@]1([H])CC1=CC=C(O)C(OC)=C1,,,,,0,,358.1416384,3,2,1,0,1,1
3756,04/06/2019 00:00,DB04201,Histidyl-Adenosine Monophosphate,,,,,,solid,,,2.05,0.76,7.17,[H][C@](N)(CC1=CN=CN1)C(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,484.1219963,4,3,4,3,1,1
3757,04/06/2019 00:00,DB04202,Isoformononetin,,,,,,solid,,,0.0396,8.96,-4.7,COC1=CC=C2C(=O)C(=COC2=C1)C1=CC=C(O)C=C1,,,,,0,,268.0735589,3,3,1,1,0,0
3758,04/06/2019 00:00,DB04203,3-Mercuri-4-Aminobenzenesulfonamide,,,,,,solid,,,5.75,11.06,2.49,NC1=CC=C(C=C1[Hg])S(N)(=O)=O,,,,,0,,372.9934665,1,1,0,0,0,0
3759,04/06/2019 00:00,DB04204,[(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid,,,,,,solid,,,0.0769,0.19,,OP(O)(=O)C(F)(F)C1=CC=C(CCCCC2=CC=C(C=C2)C(F)(F)P(O)(O)=O)C=C1,,,,,0,,470.0671245,2,2,0,0,0,0
3760,04/06/2019 00:00,DB04205,"Thymidine-3',5'-Diphosphate",,,,,,solid,,,7.73,0.85,-4.2,[H][C@@]1(C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C(C)C(=O)NC1=O)OP(O)(O)=O,,,,,0,,402.0229326,2,1,2,1,1,1
3761,04/06/2019 00:00,DB04206,Nz2-Tryptophan,,,,,,solid,,,5.2,2.29,9.38,[H][C@](N)(CC1=CNC2=C1C=CC=N2)C(O)=O,,,,,0,,205.0851266,2,2,2,2,0,0
3762,04/06/2019 00:00,DB04207,N-(5-Amino-5-Carboxypentyl)Glutamic Acid,,,,,,solid,,,5.25,1.44,10.89,N[C@@H](CCCCN[C@@H](CCC(O)=O)C(O)=O)C(O)=O,,,,,0,,276.1321364,0,0,0,0,0,0
3763,04/06/2019 00:00,DB04208,"3-(3,4-Dimethoxyphenyl)Propionic Acid",,,,,,solid,,,0.682,4.05,-4.6,COC1=C(OC)C=C(CCC(O)=O)C=C1,,,,,0,,210.0892089,1,1,0,0,0,0
3764,02/07/2019 00:00,DB04209,Dequalinium,The degree of absorption is minimal in case of topical or vaginal administration thus systemic exposure is negligible. <0.1 % is absorbed systemically after oral administration. ,,,0.25 mg,Oral,solid,,,4.77E-07,,-0.34,CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2,,,,,2,0.25,456.3242001,4,4,2,2,0,0
3765,04/06/2019 00:00,DB04210,BV1,,,,,,solid,,,0.183,7.3,6.88,[H]C1(CO)OC([H])(OC2=CC(=CC(=C2)N(=O)=O)C(O)=NCCCN2CCN(CCCNC3=C(NCCCN4CCN(CCCN=C(O)C5=CC(=CC(O[C@@]6([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]6([H])O)=C5)N(=O)=O)CC4)C(=O)C3=O)CC2)C([H])(O)C([H])(O)C1([H])O,,,,,0,,1132.492435,7,3,4,0,4,4
3766,04/06/2019 00:00,DB04211,"(2R,3R,4R,5R,6R)-3-fluoro-2,4-dihydroxy-5-[(1-hydroxyethylidene)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid",,,,,,solid,,,72.7,3.12,1.82,[H][C@@](O)(CO)[C@@]([H])(O)[C@]1([H])O[C@](O)(C(O)=O)[C@]([H])(F)[C@]([H])(O)[C@@]1([H])N=C(C)O,,,,,0,,327.0965594,1,0,1,0,1,1
3767,04/06/2019 00:00,DB04212,2-Iminiopropanoate,,,,,,solid,,,83.5,4.1,3.32,CC(=[NH2+])C([O-])=O,,,,,0,,87.0320284,0,0,0,0,0,0
3768,04/06/2019 00:00,DB04213,N-Cyclohexyl-N'-(Propyl)Phenyl Urea,,,,,,solid,,,0.0242,15.47,-0.62,O=C(NCCCC1=CC=CC=C1)NC1CCCCC1,,,,,0,,260.1888634,2,1,0,0,0,0
3769,04/06/2019 00:00,DB04214,4-Nitrophenyl Phosphate,,,,,,solid,,,1.03,1.78,,OP(O)(=O)OC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,218.9932735,1,1,0,0,0,0
3770,04/06/2019 00:00,DB04215,CRA_9076,,,,,,solid,,,0.00141,8.19,11.21,CC1=CC(Br)=C([O-])C(=C1)C1=CC2=CC(=CC=C2N1)C(N)=[NH2+],,,,,0,,343.0320242,3,3,1,1,0,0
3771,04/06/2019 00:00,DB04216,Quercetin,,,,,,solid,60 mg/L (at 16 Â°C),,0.261,6.44,-4,OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1,,,,,0,,302.0426527,3,3,1,1,0,0
3772,04/06/2019 00:00,DB04217,L-2-amino-3-butynoic acid,,,,,,solid,,,1.5,1.66,8.3,N[C@@H](C#C)C(O)=O,,,,,0,,99.0320284,0,0,0,0,0,0
3773,04/06/2019 00:00,DB04218,1-Deaza-Adenosine,,,,,,solid,,,12.9,12.45,3.18,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(N)C=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,266.1015049,3,2,3,2,1,1
3774,04/06/2019 00:00,DB04220,CGP 4832,,,,,,solid,,,0.016,6.78,9.13,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)CC(=O)OCC3CCCN(C)C3)[C@@H]1C)=C(N1CCOCC1)C2=O,,,,,0,,935.4415684,7,1,5,0,2,5
3775,04/06/2019 00:00,DB04221,Didecyldimethylammonium,,,,,Topical,solid,,,3.91E-06,,,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC,,,,,1,,326.378127,0,0,0,0,0,0
3776,04/06/2019 00:00,DB04222,Sparsomycin,,,,,,solid,,,1.59,9.93,1.66,CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O,,,,,0,,361.0766127,1,1,1,1,0,0
3777,04/06/2019 00:00,DB04223,Nitroarginine,,,,,,solid,,,0.874,1.83,9.16,N[C@@H](CCCNC(=N)N[N+]([O-])=O)C(O)=O,,,,,0,,219.0967539,0,0,0,0,0,0
3778,04/06/2019 00:00,DB04224,Oleic Acid,"Fatty acid uptake by different tissues may be mediated via passive diffusion to facilitated diffusion or a combination of both [L2896]. Fatty acids taken up by tissues are then stored in the form of triglycerides or oxidized [L2896]. Oleic acid was shown to penetrate rat skin [L2896]. Following oral administration of Brucea javanica oil emulsion in rats, the time of oleic acid to reach peak plasma concentration was approximately 15.6 hours [A33178]. ",,No pharmacokinetic data available. ,,Oral,solid,,,0.000121,4.99,,CCCCCCCC\C=C\CCCCCCCC(O)=O,,,,,0,,282.2558803,0,0,0,0,0,0
3779,04/06/2019 00:00,DB04225,N-Methyldehydrobutyrine,,,,,,solid,,,26,4.85,2.67,CN\C(=C/C)C(O)=O,,,,,0,,115.0633285,0,0,0,0,0,0
3780,04/06/2019 00:00,DB04226,Dihydro-Acarbose,,,,,,solid,,,187,11.23,7.88,[H][C@]1(CO)C[C@]([H])(N[C@]2([H])[C@@]([H])(C)O[C@]([H])(O[C@@]3([H])[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(O[C@@]4([H])[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(O)O[C@]4([H])CO)O[C@]3([H])CO)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,647.2636636,4,0,3,0,3,3
3781,04/06/2019 00:00,DB04227,"9-Amino-2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid",,,,,,solid,,,21.1,3.29,9.22,[H][C@@](O)(CN)[C@@]([H])(O)[C@]1([H])OC(=C[C@]([H])(O)[C@@]1([H])N=C(C)O)C(O)=O,,,,,0,,290.1114009,1,0,1,0,0,1
3782,04/06/2019 00:00,DB04228,"(2r)-Amino(3,5-Dihydroxyphenyl)Acetic Acid",,,,,,solid,,,8.09,1.37,8.07,N[C@H](C(O)=O)C1=CC(O)=CC(O)=C1,,,,,0,,183.0531578,1,1,0,0,0,0
3783,04/06/2019 00:00,DB04229,"7,10,13-Tri(Carboxymethyl)-5,15-Dioxo-4,7,10,13,16-Pentaaza-1,19-Dithianonadecane",,,,,,solid,,,0.391,2.42,8.9,OC(=O)CN(CCN(CC(O)=O)CC(=O)NCCS)CCN(CC(O)=O)CC(=O)NCCS,,,,,0,,511.177055,0,0,0,0,0,0
3784,04/06/2019 00:00,DB04230,Nitromethyldethia Coenzyme A,,,,,,solid,,,7.01,0.82,4.8,[H][C@](O)(C(O)=NCCC(O)=NCCCN(=O)=O)C(C)(C)COP(O)(=O)OP(O)(=O)OC[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])OP(O)(O)=O,,,,,0,,794.1438662,3,2,3,2,1,1
3785,04/06/2019 00:00,DB04232,N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide,,,,,,solid,,,0.145,8.7,-4.8,[H][C@@]1(CN(CCN1S(=O)(=O)C1=CC=C(OC)C=C1)C(=O)OCC1=CC=CC=C1)C(=O)NO,,,,,0,,449.1256711,3,2,1,0,1,1
3786,04/06/2019 00:00,DB04233,(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,,,,,solid,,,0.0256,15.12,-2.7,CCCCCCCCOCCOCCOCCOCCO,,,,,0,,306.2406242,0,0,0,0,0,0
3787,04/06/2019 00:00,DB04234,N2-({[(4-Bromophenyl)Methyl]Oxy}Carbonyl)-N1-[(1s)-1-Formylpentyl]-L-Leucinamide,,,,,,solid,,,0.00246,12.46,-3.6,[H][C@@](CCCC)(NC(=O)[C@]([H])(CC(C)C)NC(=O)OCC1=CC=C(Br)C=C1)C=O,,,,,0,,440.1310695,1,1,0,0,0,0
3788,04/06/2019 00:00,DB04235,4-Amino Hexanoic Acid,,,,,,solid,,,105,4.7,10.47,[H][C@@](N)(CC)CCC(O)=O,,,,,0,,131.0946287,0,0,0,0,0,0
3789,04/06/2019 00:00,DB04236,2-Amino-3-(1h-Indol-3-Yl)-Propan-1-Ol,,,,,,solid,,,2.13,15.11,9.36,[H][C@@](N)(CO)CC1=CNC2=CC=CC=C12,,,,,0,,190.1106131,2,2,1,1,0,0
3790,04/06/2019 00:00,DB04237,Tris(Hydroxyethyl)Aminomethane,,,,,,solid,,,291,15.44,9.63,NC(CCO)(CCO)CCO,,,,,0,,163.1208434,0,0,0,0,0,0
3791,04/06/2019 00:00,DB04238,N-Alpha-(2-Naphthylsulfonyl)-N-(3-Amidino-L-Phenylalaninyl)-D-Pipecolinic Acid,,,,,,solid,,,0.0137,3.31,11.47,[H][C@@](CC1=CC(=CC=C1)C(N)=N)(NS(=O)(=O)C1=CC2=CC=CC=C2C=C1)C(=O)N1CCCC[C@]1([H])C(O)=O,,,,,0,,508.178041,4,3,1,0,1,1
3792,04/06/2019 00:00,DB04239,2-Amino-6-Aminomethyl-8-Phenylsulfanylmethyl-3h-Quinazolin-4-One,,,,,,solid,,,0.0462,11.39,9.21,NCC1=CC(CSC2=CC=CC=C2)=C2N=C(N)NC(=O)C2=C1,,,,,0,,312.1044821,3,3,1,1,0,0
3793,04/06/2019 00:00,DB04240,"(1S)-1-C-{(2R)-6-[(2R)-2-Butanyl]-5,10-dihydroxy-4-oxo-1,2,3,4-tetrahydro-2-anthracenyl}-5-deoxy-1-O-methyl-D-xylulose",,,,,,solid,,,0.127,8.87,-3.1,CC[C@@H](C)C1=C(O)C2=C(O)C3=C(C[C@H](CC3=O)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)C=C2C=C1,,,,,0,,430.1991533,3,2,0,0,0,0
3794,04/06/2019 00:00,DB04241,N-Pyridoxyl-2-Methylalanine-5-Phosphate,,,,,,solid,,,0.992,1.06,9.94,CC1=NC=C(COP(O)(O)=O)C(CNC(C)(C)C(O)=O)=C1O,,,,,0,,334.0929876,1,1,1,1,0,0
3795,04/06/2019 00:00,DB04242,P-Hydroxybenzoic Acid,,,,,,solid,,,11.9,4.38,-6.1,OC(=O)C1=CC=C(O)C=C1,,,,,0,,138.0316941,1,1,0,0,0,0
3796,04/06/2019 00:00,DB04243,5-Methyluridine 5'-Monophosphate,,,,,,solid,,,16.4,1.23,-3.7,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=C(C)C(O)=NC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,338.0515167,2,1,2,1,1,1
3797,04/06/2019 00:00,DB04244,(2R)-2-(3-Biphenylyl)-N-{(2R)-2-hydroxy-3-[(2-pyridinylsulfonyl)amino]propyl}-4-methylpentanamide,,,,,,solid,,,0.00252,8.86,-0.73,[H]N(C[C@@H](O)CN([H])S(=O)(=O)C1=CC=CC=N1)C(=O)[C@H](CC(C)C)C1=CC=CC(=C1)C1=CC=CC=C1,,,,,0,,481.2035275,3,3,1,1,0,0
3798,04/06/2019 00:00,DB04246,CRA_23653,,,,,,solid,,,0.00146,8.94,11.56,NC(=N)C1=CC2=C(C=C1)N=C(N2)C1=CC(CC[NH3+])=CC(=C1O)C1=CC=CC=C1,,,,,1,,372.1818867,4,4,1,1,0,0
3799,04/06/2019 00:00,DB04248,beta-(1->4)-galactotriose,,,,,,solid,,,554,11.22,-3.6,[H][C@@]1(O)O[C@]([H])(CO)[C@]([H])(O[C@]2([H])O[C@]([H])(CO)[C@]([H])(O[C@]3([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,504.1690349,3,0,3,0,3,3
3800,04/06/2019 00:00,DB04249,Zinc Substituted Heme C,,,,,,solid,,,0.00449,3.56,9.12,[Zn+4].[H]\C(C)=C1\C(C)=C2[N-]\C\1=C([H])/C1=C(C)C(=C([H])C)\C([N-]1)=C([H])\C1=C(C)C(CCC(O)=O)=C([N-]1)\C([H])=C1/[N-]\C(=C/2\[H])C(C)=C1CCC(O)=O,,,,,0,,626.1871478,5,4,5,4,0,1
3801,04/06/2019 00:00,DB04250,Butyrylthiocholine,,,,,,solid,,,0.00606,,-6.1,CCCC(=O)SCC[N+](C)(C)C,,,,,1,,190.1260117,0,0,0,0,0,0
3802,04/06/2019 00:00,DB04252,N-Carbamoyl-L-Aspartate,,,,,,solid,,,21.3,3.33,-2.6,NC(=O)N[C@@H](CC(O)=O)C(O)=O,,,,,0,,176.0433214,0,0,0,0,0,0
3803,04/06/2019 00:00,DB04253,Tretazicar,,,,,,solid,,,0.904,11.29,-2.5,NC(=O)C1=CC(N2CC2)=C(C=C1[N+]([O-])=O)[N+]([O-])=O,,,,,0,,252.0494694,2,1,1,0,1,1
3804,04/06/2019 00:00,DB04254,"8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine",,,,,,solid,,,0.162,17.68,1.03,CCCCN1C(CC2=CC3=C(OCO3)C=C2)=NC2=C(N)N=C(F)N=C12,,,,,0,,343.144453,4,3,3,2,0,1
3805,04/06/2019 00:00,DB04255,Inhibitor Bea388,,,,,,solid,,,0.0175,3.69,6.09,[H][C@@](O)([C@@]([H])(O)[C@@]([H])(OCC1=CC=CC=C1)C(O)=N[C@@]1([H])C2=CC=CC=C2C[C@@]1([H])O)[C@@]([H])(OCC1=CC=CC=C1)C(O)=N[C@@]([H])(C(C)C)C(O)=NC,,,,,0,,633.3050153,4,3,0,0,0,0
3806,04/06/2019 00:00,DB04256,4-(1-Amino-1-Carboxy-Ethyl)-Benzoic Acid,,,,,,solid,,,1.77,1.46,9.1,C[C@@](N)(C(O)=O)C1=CC=C(C=C1)C(O)=O,,,,,0,,209.0688078,1,1,0,0,0,0
3807,04/06/2019 00:00,DB04257,Palmitoleic Acid,,,,,,solid,,,0.000447,4.99,,CCCCCC\C=C/CCCCCCCC(O)=O,,,,,0,,254.2245802,0,0,0,0,0,0
3808,04/06/2019 00:00,DB04258,Seocalcitol,,,,,,solid,,,0.00382,14.39,-1,[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\C=C\C(O)(CC)CC,,,,,0,,454.3446953,3,0,0,0,0,0
3809,04/06/2019 00:00,DB04259,7n-Methyl-8-Hydroguanosine-5'-Monophosphate,,,,,,solid,,,8.76,1.22,15.04,[H][C@]1(O)[C@@]([H])(O)[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1CN(C)C2=C1NC(=N)N=C2O,,,,,0,,379.0892992,3,1,3,1,1,2
3810,04/06/2019 00:00,DB04260,"9-(5,5-Difluoro-5-Phosphonopentyl)Guanine",,,,,,solid,,,1.2,0.53,1.54,NC1=NC2=C(N=CN2CCCCC(F)(F)P(O)(O)=O)C(=O)N1,,,,,0,,337.075147,2,2,2,2,0,0
3811,04/06/2019 00:00,DB04261,Carbamic Acid,,,,,,solid,,,379,3.92,,NC(O)=O,,,,,0,,61.01637834,0,0,0,0,0,0
3812,04/06/2019 00:00,DB04262,3-(7-hydroxy-8-ribityllumazine-6-yl) propionic acid,,,,,,solid,,,0.749,3.57,-3,[H][C@@](O)(CO)[C@@]([H])(O)[C@@]([H])(O)CN1C(O)=C(CCC(O)=O)N=C2C(O)=NC(=O)N=C12,,,,,0,,386.1073782,2,0,2,0,0,2
3813,04/06/2019 00:00,DB04263,Geneticin,,,,,,solid,,,58.3,12.42,9.79,[H][C@](C)(O)[C@@]1([H])O[C@]([H])(O[C@]2([H])[C@@]([H])(N)C[C@@]([H])(N)[C@]([H])(O[C@@]3([H])OC[C@](C)(O)[C@]([H])(NC)[C@@]3([H])O)[C@@]2([H])O)[C@]([H])(N)[C@@]([H])(O)[C@]1([H])O,,,,,0,,496.2744435,3,0,2,0,2,2
3814,04/06/2019 00:00,DB04264,"(10R)-10-Formyl-5,8,10-Trideazafolic Acid",,,,,,solid,,,0.0716,3.11,2.03,NC1=NC(O)=C2C=C(C[C@@H](C(O)=O)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=CC2=N1,,,,,0,,482.1437637,3,3,1,1,0,0
3815,04/06/2019 00:00,DB04265,N-acetyl-beta-neuraminic acid,,,,,,solid,,,227,3,-0.38,CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O,,,,,0,,309.1059812,1,0,1,0,1,1
3816,04/06/2019 00:00,DB04266,"5-(6-D-Ribitylamino-2,4-Dihydroxypyrimidin-5-Yl)-1-Pentyl-Phosphonic Acid",,,,,,solid,,,3.14,1.81,-0.27,[H][C@@](O)(CO)[C@@]([H])(O)[C@@]([H])(O)CNC1=C(CCCCCP(O)(O)=O)C(O)=NC(O)=N1,,,,,0,,411.140666,1,1,1,1,0,0
3817,04/06/2019 00:00,DB04267,Dipicolinic Acid,,,,,,solid,,,3.46,3.24,-2.5,OC(=O)C1=CC=CC(=N1)C(O)=O,,,,,0,,167.0218576,1,1,1,1,0,0
3818,04/06/2019 00:00,DB04268,Methylumbelliferyl Chitotriose,,,,,,solid,,,1.12,6.64,1.33,[H][C@]1(CO)O[C@@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@@]([H])(O[C@]3([H])[C@@]([H])(CO)O[C@]([H])(OC4=CC5=C(C=C4)C(C)=CC(=O)O5)[C@]([H])(N=C(C)O)[C@@]3([H])O)[C@]([H])(N=C(C)O)[C@@]2([H])O)[C@]([H])(N=C(C)O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,785.2854617,5,2,4,1,3,3
3819,04/06/2019 00:00,DB04269,Cyclotheonamide A,,,,,,solid,,,0.0398,5.67,11.92,[H]\C1=C([H])/[C@]([H])(CC2=CC=C(O)C=C2)N=C(O)[C@@]([H])(CC2=CC=CC=C2)NC(=O)C(=O)[C@]([H])(CCCNC(N)=N)N=C(O)[C@]2([H])CCCN2C(=O)[C@]([H])(CN=C1O)N=CO,,,,,0,,731.3391094,4,2,2,0,1,2
3820,04/06/2019 00:00,DB04270,(S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid,,,,,,solid,,,0.00185,3.73,-4.1,[H][C@@](CC1=CC=C(OCCN2C3=C(C=CC=C3)C3=C2C=CC=C3)C=C1)(OCC)C(O)=O,,,,,0,,403.1783583,4,4,1,1,0,0
3821,04/06/2019 00:00,DB04271,"3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,,,,,solid,,,37.6,12.08,2.52,CCOC(=O)C1=C(C)NN=C1C,,,,,0,,168.0898776,1,1,1,1,0,0
3822,22/06/2019 00:00,DB04272,Citric acid,,,,8 mg/1mL,Intravenous,solid,5.92E+005 mg/L (at 20 Â°C),-1.64,106,3.05,-4.2,OC(=O)CC(O)(CC(O)=O)C(O)=O,,,,,0,,192.0270026,0,0,0,0,0,0
3823,04/06/2019 00:00,DB04273,"8,9-Dichloro-2,3,4,5-Tetrahydro-1h-Benzo[C]Azepine",,,,,,solid,,,0.0515,,8.84,ClC1=CC=C2CCCNCC2=C1Cl,,,,,0,,215.0268547,2,1,1,0,0,1
3824,04/06/2019 00:00,DB04274,"5,4'-Dideoxyflavanone",,,,,,solid,,,0.111,7.8,-4.9,OC1=CC=C2C(=O)C[C@H](OC2=C1)C1=CC=CC=C1,,,,,0,,240.0786442,3,2,1,0,0,1
3825,04/06/2019 00:00,DB04275,N-acetylserotonin,,,,,,solid,,,0.569,9.56,-0.94,CC(=O)NCCC1=CNC2=C1C=C(O)C=C2,,,,,0,,218.1055277,2,2,1,1,0,0
3826,04/06/2019 00:00,DB04276,N-[N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-Butyl]-Guanidine,,,,,,solid,,,1.1,3.95,11.88,CC(C)C[C@H](NC(=O)[C@@H](O)CC(O)=O)C(=O)NCCCCNC(N)=[NH2+],,,,,1,,360.2241455,0,0,0,0,0,0
3827,04/06/2019 00:00,DB04277,Fructose -6-Phosphate,,,,,,solid,,,23.2,1.49,-3.3,OCC(=O)[C@@H](O)[C@@H](O)[C@H](O)COP(O)(O)=O,,,,,0,,260.0297186,0,0,0,0,0,0
3828,04/06/2019 00:00,DB04278,2-[2-(2-Cyclohexyl-2-Guanidino-Acetylamino)-Acetylamino]-N-(3-Mercapto-Propyl)-Propionamide,,,,,,solid,,,0.113,5.42,11.97,[H][C@@](C)(N=C(O)CN=C(O)[C@]([H])(NC(N)=N)C1CCCCC1)C(O)=NCCCS,,,,,0,,400.2256599,1,0,0,0,0,0
3829,04/06/2019 00:00,DB04279,3-Isopropylmalic Acid,,,,,,solid,,,83.3,3.68,-4,CC(C)C(C(O)C(O)=O)C(O)=O,,,,,0,,176.0684735,0,0,0,0,0,0
3830,04/06/2019 00:00,DB04280,"((2r,3s,5r)-3-Hydroxy-5-(4-Hydroxy-2-Oxo-3,4-Dihydropyrimidin-1(2h)-Yl)-Tetrahydrofuran-2-Yl)Methyldihydrogen Phosphate",,,,,,solid,,,13.4,1.26,0.067,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C[C@@]([H])(O)N=C1O,,,,,0,,310.0566021,2,0,2,0,1,2
3831,04/06/2019 00:00,DB04281,"2-[4-(4-Chlorophenyl)Cyclohexylidene]-3,4-Dihydroxy-1(2h)-Naphthalenone",,,,,,solid,,,0.00227,7.37,-5.8,[H]C1(CCC(CC1)=C1C(O)=C(O)C2=CC=CC=C2C1=O)C1=CC=C(Cl)C=C1,,,,,0,,366.1022721,4,2,0,0,0,0
3832,04/06/2019 00:00,DB04282,2-deoxy-2-fluoro-Î±-D-glucose,,,,,,solid,,,257,11.02,-3,[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])F,,,,,0,,182.0590517,1,0,1,0,1,1
3833,04/06/2019 00:00,DB04283,2-Bromo-6-Hydroxy-Purine,,,,,,solid,,,1.53,8.91,-0.16,OC1=NC(Br)=NC2=C1N=CN2,,,,,0,,213.9490228,2,2,2,2,0,0
3834,04/06/2019 00:00,DB04284,L-proline betaine,,,,,,solid,,,0.666,2.26,,C[N+]1(C)CCC[C@H]1C([O-])=O,,,,,0,,143.0946287,1,0,1,0,1,1
3835,04/06/2019 00:00,DB04285,"{4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid",,,,,,solid,,,0.0041,0.72,2.02,[H]\C(C[C@](CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)(N1N=NC2=CC=CC=C12)C1=NC2=CC=CC=C2S1)=C(\[H])C1=CC=CC=C1,,,,,0,,602.1353047,6,6,2,2,0,0
3836,04/06/2019 00:00,DB04286,beta-D-Ribopyranose,,,,,,solid,,,1220,11.31,-3.5,O[C@@H]1CO[C@@H](O)[C@H](O)[C@@H]1O,,,,,0,,150.0528234,1,0,1,0,1,1
3837,04/06/2019 00:00,DB04287,(S)-5-(4-Benzyloxy-Phenyl)-4-(7-Phenyl-Heptanoylamino)-Pentanoic Acid,,,,,,solid,,,0.00014,3.91,4.6,[H][C@](CCC(O)=O)(CC1=CC=C(OCC2=CC=CC=C2)C=C1)N=C(O)CCCCCCC1=CC=CC=C1,,,,,0,,487.2722587,3,3,0,0,0,0
3838,04/06/2019 00:00,DB04288,2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine,,,,,,solid,,,0.0337,15.39,10.45,[H][C@]1(N)CC[C@@]([H])(CC1)NC1=NC(NCC2=CC=CC=C2)=C2N=CN(C3CCCC3)C2=N1,,,,,0,,405.264094,5,3,2,2,0,0
3839,04/06/2019 00:00,DB04289,Genz-10850,,,,,,solid,,,0.00805,15.91,7.1,O=C(N1CCN(CC1)C1C2=CC=CC=C2C2=CC=CC=C12)C1=CC2=C(NC=C2)C=C1,,,,,0,,393.1841124,6,4,2,1,1,1
3840,04/06/2019 00:00,DB04291,Oxfenicine,,,,,,solid,,,7.44,1.74,8.75,N[C@H](C(O)=O)C1=CC=C(O)C=C1,,,,,0,,167.0582431,1,1,0,0,0,0
3841,04/06/2019 00:00,DB04292,4-[(Isopropylamino)Methyl]Phenylalanine,,,,,,solid,,,0.192,2.27,9.99,CC(C)NCC1=CC=C(C[C@H](N)C(O)=O)C=C1,,,,,0,,236.1524779,1,1,0,0,0,0
3842,04/06/2019 00:00,DB04293,7-(2-Amino-2-Phenyl-Acetylamino)-3-Chloro-8-Oxo-1-Aza-Bicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid,,,,,,solid,,,0.325,3.13,7.44,N[C@@H](C(=O)N[C@@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1,,,,,0,,349.0829337,3,1,2,0,1,2
3843,04/06/2019 00:00,DB04294,5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate,,,,,,solid,,,18.3,0.74,-3.7,[H][C@]1(O)[C@@]([H])(O)[C@@]([H])(OP(O)(=O)CP(O)(O)=O)O[C@]1([H])COP(O)(O)=O,,,,,0,,387.9725504,1,0,1,0,1,1
3844,04/06/2019 00:00,DB04295,N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea,,,,,,solid,,,1.35,6.87,0.11,[H][C@]1(CO)O[C@@]([H])(N=C(O)N=C(O)C2=CC=CC=C2)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,326.1114009,2,1,1,0,1,1
3845,04/06/2019 00:00,DB04296,5-Oxo-L-Norleucine,,,,,,solid,,,91.6,2.25,9.11,[H][C@](N)(CCC(C)=O)C(O)=O,,,,,0,,145.0738932,0,0,0,0,0,0
3846,04/06/2019 00:00,DB04297,"7-[4-(Dimethylamino)Phenyl]-N-Hydroxy-4,6-Dimethyl-7-Oxo-2,4-Heptadienamide",,,,,,solid,,,0.0425,9.57,3.36,ONC(=O)\C=C\C(\C)=C\[C@](C)([H])C(=O)C1=CC=C(N(C)C)C=C1,,,,,0,,302.1630426,1,1,0,0,0,0
3847,04/06/2019 00:00,DB04298,"3-(4-Amino-2-Tert-Butyl-5-Methyl-Phenylsulfanyl)-6-Cyclopentyl-4-Hydroxy-6-[2-(4-Hydroxy-Phenyl)-Ethyl]-5,6-Dihydro-Pyran-2-One",,,,,,solid,,,0.000414,7.15,3.86,CC1=CC(SC2=C(O)C[C@](CCC3=CC=C(O)C=C3)(OC2=O)C2CCCC2)=C(C=C1N)C(C)(C)C,,,,,0,,495.2443297,4,2,1,0,0,1
3848,04/06/2019 00:00,DB04299,Maleic Acid,,,,,,solid,4.41E+005 mg/L (at 25 Â°C),-0.48,24.1,3.05,,OC(=O)\C=C/C(O)=O,,,,,0,,116.0109586,0,0,0,0,0,0
3849,04/06/2019 00:00,DB04300,"(1s,3r,4r,6s)-1,3,4,6-Tetrapkisphosphate",,,,,,solid,,,11.5,0.35,,O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@@H](O)[C@@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O,,,,,0,,499.9287102,1,0,0,0,0,0
3850,04/06/2019 00:00,DB04301,Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone Hydrate,,,,,,solid,,,0.0357,8.55,12.46,NC(=N)C1=CC2=C(C=C1)N=C(N2)C(O)(O)C1=NC2=C(N1)C=C(C=C2)C([NH3+])=[NH2+],,,,,2,,366.1541747,4,4,2,2,0,0
3851,04/06/2019 00:00,DB04302,"4-Hydroxy-3,5-Dimethyl-5-(2-Methyl-Buta-1,3-Dienyl)-5h-Thiophen-2-One",,,,,,solid,,,0.499,6.82,-6.1,C\C(C=C)=C/[C@@]1(C)SC(=O)C(C)=C1O,,,,,0,,210.0714507,1,0,1,0,0,1
3852,04/06/2019 00:00,DB04303,4-O-methyl-alpha-D-glucuronic acid,,,,,,solid,,,334,3.34,-3.7,[H][C@]1(O)O[C@]([H])(C(O)=O)[C@@]([H])(OC)[C@]([H])(O)[C@@]1([H])O,,,,,0,,208.0583027,1,0,1,0,1,1
3853,04/06/2019 00:00,DB04304,L-Gluconic Acid,,,,,,solid,,,159,3.39,-3,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O,,,,,0,,196.0583027,0,0,0,0,0,0
3854,04/06/2019 00:00,DB04306,"5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine",,,,,,solid,,,0.01,16.67,6.59,CC1=CC=C(SC2=CC=CC3=C2C(N)=NC(N)=N3)C=C1,,,,,0,,282.0939174,3,3,1,1,0,0
3855,04/06/2019 00:00,DB04307,5-Hydroxy-N-Propargyl-1(R)-Aminoindan,,,,,,solid,,,0.0679,9.73,8.21,[H][C@]1(CCC2=CC=C(O)C=C12)NCC#C,,,,,0,,187.099714,2,1,0,0,0,0
3856,04/06/2019 00:00,DB04308,D-4-hydroxyphenylglycine,,,,,,solid,,,7.44,1.74,8.75,[H][C@](N)(C(O)=O)C1=CC=C(O)C=C1,,,,,0,,167.0582431,1,1,0,0,0,0
3857,04/06/2019 00:00,DB04310,2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide,,,,,,solid,,,3.03,8.9,-0.4,[H][C@@](CCCCC)(CC(=O)NO)C(=O)N[C@@]([H])(C(C)C)C(=O)N1CCC[C@@]1([H])CO,,,,,0,,385.2576712,1,0,1,0,1,1
3858,04/06/2019 00:00,DB04311,4-Phenylbutylamine,,,,,,solid,,,0.432,,10.21,NCCCCC1=CC=CC=C1,,,,,0,,149.1204495,1,1,0,0,0,0
3859,04/06/2019 00:00,DB04312,"2,3-Difluorobenzyl Alcohol",,,,,,solid,,,2.39,14.39,-3.1,OCC1=CC=CC(F)=C1F,,,,,0,,144.0386713,1,1,0,0,0,0
3860,04/06/2019 00:00,DB04313,(3S)-3-methyl-D-aspartic acid,,,,,,solid,,,97.4,1.87,9.68,C[C@@H]([C@@H](N)C(O)=O)C(O)=O,,,,,0,,147.0531578,0,0,0,0,0,0
3861,04/06/2019 00:00,DB04314,1-Methylcytosine,,,,,,solid,,,29.1,,3.07,CN1C=CC(N)=NC1=O,,,,,0,,125.0589118,1,1,1,1,0,0
3862,04/06/2019 00:00,DB04315,Guanosine-5'-Diphosphate,,,,,,solid,,,4.44,1.97,1.35,NC1=NC2=C(N=CN2[C@@H]2O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]2O)C(=O)N1,,,,,0,,443.0243296,3,2,3,2,1,1
3863,04/06/2019 00:00,DB04316,D-[(N-Hydroxyamino)Carbonyl]Phenylalanine,,,,,,solid,,,1.32,4.03,3.06,[H]N(O)C(=O)N([H])[C@H](CC1=CC=CC=C1)C(O)=O,,,,,0,,224.0797069,1,1,0,0,0,0
3864,04/06/2019 00:00,DB04317,"3,3-Dichloro-2-Phosphonomethyl-Acrylic Acid",,,,,,solid,,,5.36,1.72,,OC(=O)C(CP(O)(O)=O)=C(Cl)Cl,,,,,0,,233.9251653,0,0,0,0,0,0
3865,04/06/2019 00:00,DB04318,NÎ±-[(2S)-2-{[(S)-[(1S)-1-{[(Benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl]methyl}-5-phenylpentanoyl]-L-tryptophanamide,,,,,,solid,,,0.000359,1.54,-1.2,[H]N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CCCC1=CC=CC=C1)CP(O)(=O)[C@@H](CC1=CC=CC=C1)N([H])C(=O)OCC1=CC=CC=C1,,,,,0,,694.2920217,5,5,1,1,0,0
3866,04/06/2019 00:00,DB04320,2-Bromo-2-Propene-1-Ol,,,,,,solid,,,66.8,14.09,-3.2,OCC(Br)=C,,,,,0,,135.9523769,0,0,0,0,0,0
3867,04/06/2019 00:00,DB04321,N-Hexylphosphonate Ethyl Ester,,,,,,solid,,,8.53,1.93,,CCCCCC[P@@](O)(=O)OCC,,,,,0,,194.1071811,0,0,0,0,0,0
3868,04/06/2019 00:00,DB04322,LY249543,,,,,,solid,,,0.131,-2.6,14.85,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CC[C@]2([H])CNC3=C(C2)C(O)=NC(=N)N3)C=C1)C(O)=O,,,,,0,,443.1804835,3,2,2,1,0,1
3869,04/06/2019 00:00,DB04323,2-Amino-3-(Cystein-S-Yl)-Isoxazolidin-5-Yl-Acetic Acid,,,,,,solid,,,18.5,1.13,9.29,[H][C@](N)(CS[C@]1([H])C[C@@]([H])(ON1)[C@]([H])(N)C(O)=O)C(O)=O,,,,,0,,265.0732416,1,0,1,0,1,1
3870,04/06/2019 00:00,DB04324,Ovalicin,,,,,,solid,,,2.27,11.59,-3.4,[H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1(O)[C@]([H])(OC)C(=O)CC[C@@]1(C)O,,,,,0,,298.1780239,2,0,1,0,1,1
3871,04/06/2019 00:00,DB04325,Phenethylamine,,,,,,solid,,1.41,2.19,,9.79,NCCC1=CC=CC=C1,,,,,0,,121.0891494,1,1,0,0,0,0
3872,04/06/2019 00:00,DB04326,Dihydroxyacetone phosphate,,,,,,solid,,,21.9,1.19,-3.3,OCC(=O)COP(O)(O)=O,,,,,0,,169.9980246,0,0,0,0,0,0
3873,04/06/2019 00:00,DB04327,Phosphatidylethanolamine,,,,,,solid,,,4.03E-05,1.87,10,CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](CO[P@](O)(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC,,,,,1,,748.5850817,0,0,0,0,0,0
3874,04/06/2019 00:00,DB04328,Shikimate-3-Phosphate,,,,,,solid,,,21,1.32,-3.2,O[C@@H]1CC(=C[C@@H](OP(O)(O)=O)[C@H]1O)C(O)=O,,,,,0,,254.0191539,1,0,0,0,0,0
3875,04/06/2019 00:00,DB04329,Isoquinoline,,,,,,solid,4520 mg/L (at 25 Â°C),2.08,2.81,,5.26,C1=CC=C2C=NC=CC2=C1,,,,,0,,129.0578492,2,2,1,1,0,0
3876,04/06/2019 00:00,DB04330,Bilh 434,,,,,,solid,,,0.000742,3.92,-0.45,[H][C@]1(O[C@@]2(C(=O)C3=C(C=C(C)C=C3)C2=O)[C@]([H])(C(O)=O)[C@]1([H])C(=O)NC1=CC=C(C=C1)C1=CSN=N1)C1=CC(Cl)=C(Cl)C=C1,,,,,0,,607.0371617,6,4,2,1,1,1
3877,04/06/2019 00:00,DB04331,Monastrol,,,,,,solid,,,0.0603,9.37,-3,[H][C@]1(NC(=S)NC(C)=C1C(=O)OCC)C1=CC=CC(O)=C1,,,,,0,,292.0881634,2,1,1,0,0,1
3878,04/06/2019 00:00,DB04332,2-{2-[2-2-(Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethanol,,,,,,solid,,,31.8,15.12,-2.7,COCCOCCOCCOCCO,,,,,0,,208.1310737,0,0,0,0,0,0
3879,04/06/2019 00:00,DB04333,Octamethylenediamine,,,,,,solid,,,2.43,,10.51,NCCCCCCCCN,,,,,0,,144.1626486,0,0,0,0,0,0
3880,04/06/2019 00:00,DB04334,6-hydroxydopa quinone,,,,,,solid,,,2.01,1.73,9.04,N[C@@H](CC1=CC(=O)C(O)=CC1=O)C(O)=O,,,,,0,,211.0480724,1,0,0,0,0,0
3881,04/06/2019 00:00,DB04335,Inosine,Ingested inosine is absorbed from the small intestine.,,,,Extracorporeal,solid,1.58E+004 mg/L (at 20 Â°C),-2.1,14.3,6.94,2.74,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O,,,,,0,,268.0807695,3,2,3,2,1,1
3882,04/06/2019 00:00,DB04336,1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea,,,,,,solid,,,0.0931,11.76,11.14,NC(=N)C1=CC=C(NC(=O)NC2=CC=C(Cl)C=C2)C=C1,,,,,0,,288.0777887,2,2,0,0,0,0
3883,04/06/2019 00:00,DB04337,Methyl Isocyanide,,,,,,solid,,,3.72,16.35,,C[N+]#[C-],,,,,0,,41.0265491,0,0,0,0,0,0
3884,04/06/2019 00:00,DB04338,SB220025,,,,,,solid,,,0.154,16.38,10.13,NC1=NC=CC(=N1)C1=C(N=CN1C1CCNCC1)C1=CC=C(F)C=C1,,,,,0,,338.1655228,4,3,3,2,1,1
3885,04/06/2019 00:00,DB04339,Carbocisteine,,,,,,solid,,,21.6,1.84,9.14,N[C@@H](CSCC(O)=O)C(O)=O,,,,,0,,179.0252288,0,0,0,0,0,0
3886,04/06/2019 00:00,DB04340,2-[(Dioxidophosphoranyl)oxy]benzoate,,,,,,solid,,,13.7,2.02,,[O-]C(=O)C1=CC=CC=C1OP([O-])=O,,,,,-2,,199.988557,1,1,0,0,0,0
3887,04/06/2019 00:00,DB04341,S-(3-Iodobenzyl)Glutathione,,,,,,solid,,,0.00611,1.85,9.54,[H][C@](N)(CCC(O)=N[C@@]([H])(CSCC1=CC(I)=CC=C1)C(O)=NCC(O)=O)C(O)=O,,,,,0,,523.0274044,1,1,0,0,0,0
3888,04/06/2019 00:00,DB04342,7-((Carboxy(4-Hydroxyphenyl)Acetyl)Amino)-7-Methoxy-(3-((1-Methyl-1h-Tetrazol-5-Yl)Thio)Methyl)-8-Oxo-5-Oxa-1-Azabicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid,,,,,,solid,,,0.751,2.92,-1.7,CO[C@]1(NC(=O)[C@H](C(O)=O)C2=CC=C(O)C=C2)[C@H]2OCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O,,,,,0,,520.1012472,4,2,3,1,1,2
3889,04/06/2019 00:00,DB04343,Glyoxylic acid,,,,,,solid,,,224,2.61,-9.2,OC(=O)C=O,,,,,0,,74.00039392,0,0,0,0,0,0
3890,04/06/2019 00:00,DB04345,Lumichrome,,,,,,solid,,,0.0511,8.85,-0.15,CC1=CC2=NC3=C(N=C2C=C1C)C(=O)NC(=O)N3,,,,,0,,242.0803756,3,3,2,2,0,0
3891,04/06/2019 00:00,DB04346,"(2r,4s)-2-Methyl-2,3,3,4-Tetrahydroxytetrahydrofuran",,,,,,solid,,,766,9.16,-4,[H][C@]1(O)CO[C@@](C)(O)C1(O)O,,,,,0,,150.0528234,1,0,1,0,1,1
3892,04/06/2019 00:00,DB04347,3-Dehydroshikimate,,,,,,solid,,,137,3.21,-3.3,O[C@@H]1CC(=CC(=O)[C@H]1O)C(O)=O,,,,,0,,172.0371734,1,0,0,0,0,0
3893,04/06/2019 00:00,DB04348,Taurocholic Acid,,,,,,solid,,,0.0771,-1.1,0.28,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCCS(O)(=O)=O,,,,,0,,515.2916738,4,0,0,0,0,0
3894,04/06/2019 00:00,DB04349,"(S)-propane-1,2-diol",,,,,,solid,,,952,14.47,-2.9,C[C@H](O)CO,,,,,0,,76.0524295,0,0,0,0,0,0
3895,04/06/2019 00:00,DB04350,Argadin,,,,,,solid,,,0.945,3.63,8.67,CC(=O)NC(=N)NCCC[C@@H]1NC(=O)[C@H](CCCC(O)=O)NC(=O)[C@H](CC2=CNC=N2)N2[C@H](O)C[C@H](NC(=O)[C@H]3CCCN3C1=O)C2=O,,,,,0,,674.3136229,4,1,4,1,3,3
3896,04/06/2019 00:00,DB04351,Aconitate Ion,,,,,,solid,,,21.1,2.11,,[O-]C(=O)C\C(=C\C([O-])=O)C([O-])=O,,,,,-3,,170.9946086,0,0,0,0,0,0
3897,04/06/2019 00:00,DB04352,beta-D-Ribose-5-phosphate,,,,,,solid,,,33.6,1.22,-3.7,[H][C@@]1(O)O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,230.0191539,1,0,1,0,1,1
3898,04/06/2019 00:00,DB04353,{(1s)-1-Benzyl-4-[3-Carbamoyl-1-(1-Carbamoyl-2-Phenyl-Ethylcarbamoyl)-(S)-Propylcarbamoyl]-2-Oxo-5-Phenyl-Pentyl}-Carbamic Acid Tert-Butyl Ester,,,,,,solid,,,0.0104,-1,12.67,[H][C@](CC(=O)[C@]([H])(CC1=CC=CC=C1)N=C(O)OC(C)(C)C)(CC1=CC=CC=C1)C(O)=N[C@@]([H])(CCC(O)=N)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N,,,,,0,,685.3475488,3,3,0,0,0,0
3899,04/06/2019 00:00,DB04356,9-Deazaguanine,,,,,,solid,,,1.01,8.95,5.99,OC1=NC(=N)NC2=C1NC=C2,,,,,0,,150.0541608,2,2,2,2,0,0
3900,04/06/2019 00:00,DB04357,Pteric Acid,,,,,,solid,,,0.184,4.73,2.67,NC1=NC(O)=C2N=C(CNC3=CC=C(C=C3)C(O)=O)C=NC2=[NH+]1,,,,,1,,313.1043647,3,3,2,2,0,0
3901,04/06/2019 00:00,DB04359,Vinylsulphonic Acid,,,,,,solid,,,20.2,-1.3,,OS(=O)(=O)C=C,,,,,0,,107.988115,0,0,0,0,0,0
3902,04/06/2019 00:00,DB04360,Benzo[B]Thiophene-2-Boronic Acid,,,,,,solid,,,0.194,7.91,-5.8,OB(O)C1=CC2=C(S1)C=CC=C2,,,,,0,,178.0259809,2,2,1,1,0,0
3903,04/06/2019 00:00,DB04361,Methyldiazene,,,,,,solid,,,3.97,,1.08,[H]N=NC,,,,,0,,44.03744813,0,0,0,0,0,0
3904,04/06/2019 00:00,DB04362,Adenosine Diphosphate 5-(Beta-Ethyl)-4-Methyl-Thiazole-2-Carboxylic Acid,,,,,,solid,,,1.05,1.83,5,[H][C@]1(COP([O-])(=O)OP([O-])(=O)OCCC2=C(C)N=C(S2)C([O-])=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,-3,,593.027335,4,3,4,3,1,1
3905,04/06/2019 00:00,DB04363,Mesobiliverdin Iv Alpha,,,,,,solid,,,0.018,3.41,5.67,[H]\C(C1=C(C)C(CCC(O)=O)=C(N1)C(\[H])=C1/N=C(O)C(C)=C1CC)=C1\N=C(\C(\[H])=C2/N=C(O)C(C)=C2CC)C(CCC(O)=O)=C1C,,,,,0,,586.2791349,4,1,4,1,0,3
3906,04/06/2019 00:00,DB04364,(R)-acetoin,,,,,,solid,,,473,13.72,-3.4,C[C@@H](O)C(C)=O,,,,,0,,88.0524295,0,0,0,0,0,0
3907,04/06/2019 00:00,DB04365,Arecoline,,,,,,solid,1E+006 mg/L (at 25 Â°C),0.35,446,,8.23,COC(=O)C1=CCCN(C)C1,,,,,0,,155.0946287,1,0,1,0,0,1
3908,04/06/2019 00:00,DB04366,3'-Deoxy 3'-Amino Adenosine-5'-Diphosphate,,,,,,solid,,,2.87,1.77,9.19,[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])N,,,,,0,,426.0453994,3,2,3,2,1,1
3909,04/06/2019 00:00,DB04367,Debromohymenialdisine,,,,,,solid,,,0.146,7.45,5.98,OC1=NC(=N)N\C1=C1\CCN=C(O)C2=C1C=CN2,,,,,0,,245.0912746,3,1,3,1,0,2
3910,04/06/2019 00:00,DB04368,Bb-3497,,,,,,solid,,,1.5,8.39,-0.44,[H][C@@](CCCC)(CN(O)C=O)C(=O)N[C@]([H])(C(=O)N(C)C)C(C)(C)C,,,,,0,,329.2314565,0,0,0,0,0,0
3911,04/06/2019 00:00,DB04369,"1,3,2-Dioxaborolan-2-Ol",,,,,,solid,,,675,8.98,-4.8,OB1OCCO1,,,,,0,,88.03317442,1,0,1,0,1,1
3912,04/06/2019 00:00,DB04370,S-sulphocysteine,,,,,,solid,,,53.8,-1.9,8.99,N[C@@H](CSS(O)(=O)=O)C(O)=O,,,,,0,,200.9765643,0,0,0,0,0,0
3913,04/06/2019 00:00,DB04371,AL6528,,,,,,solid,,,0.0739,8.14,-4.8,COC1=CC(=CC=C1)N1C=CC2=C(SC(=C2)S(N)(=O)=O)S1(=O)=O,,,,,0,,371.9908345,3,2,2,1,0,1
3914,04/06/2019 00:00,DB04372,Di-Linoleoyl-3-Sn-Phosphatidylcholine,,,,,,solid,,,3.16E-05,1.86,-6.7,CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@]([H])(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC,,,,,0,,781.5621551,0,0,0,0,0,0
3915,04/06/2019 00:00,DB04373,"4-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide",,,,,,solid,,,0.000377,13.5,3.27,CC(C)C[C@@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)NC(=O)C1=CC=CC(N)=C1,,,,,0,,531.3097068,3,3,0,0,0,0
3916,04/06/2019 00:00,DB04374,"4-Carboxy-5-(1-Pentyl)Hexylsulfanyl-1,2,3-Triazole",,,,,,solid,,,0.00662,2.96,-1.1,CCCCCC(CCCCC)SC1=C(N=NN1)C(O)=O,,,,,0,,299.166748,1,1,1,1,0,0
3917,04/06/2019 00:00,DB04376,13-Acetylphorbol,,,,,,solid,,,1.44,12.54,-2.7,[H][C@]12[C@]3([H])C=C(CO)C[C@]4(O)C(=O)C(C)=C[C@@]4([H])[C@@]3(O)[C@]([H])(C)[C@@]([H])(O)[C@@]1(OC(C)=O)C2(C)C,,,,,0,,406.1991533,4,0,0,0,0,0
3918,04/06/2019 00:00,DB04377,Meglutol,,,,,,solid,,,275,3.68,-3,CC(O)(CC(O)=O)CC(O)=O,,,,,0,,162.0528234,0,0,0,0,0,0
3919,04/06/2019 00:00,DB04378,"3-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide",,,,,,solid,,,0.000377,13.56,3.3,CC(C)C[C@@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)NC(=O)C1=CC=C(N)C=C1,,,,,0,,531.3097068,3,3,0,0,0,0
3920,04/06/2019 00:00,DB04379,N-Methyl-N-(Methylbenzyl)Formamide,,,,,,solid,,,1.56,,-0.58,[H][C@@](C)(N(C)C=O)C1=CC=CC=C1,,,,,0,,163.099714,1,1,0,0,0,0
3921,04/06/2019 00:00,DB04380,Allantoate,,,,,,solid,,,27.2,3.24,-3.1,NC(=O)NC(NC(N)=O)C([O-])=O,,,,,-1,,175.0472783,0,0,0,0,0,0
3922,04/06/2019 00:00,DB04381,Crotonaldehyde,,,,,,solid,,,66.5,,-4.1,C\C=C\C=O,,,,,0,,70.04186481,0,0,0,0,0,0
3923,04/06/2019 00:00,DB04382,2-Deoxy-Beta-D-Galactose,,,,,,solid,,,984,12.29,-3,[H][C@@]1(O)C[C@@]([H])(O)[C@@]([H])(O)[C@@]([H])(CO)O1,,,,,0,,164.0684735,1,0,1,0,1,1
3924,04/06/2019 00:00,DB04383,L-valinol,,,,,,solid,,,286,15.12,9.9,CC(C)[C@H](N)CO,,,,,0,,103.099714,0,0,0,0,0,0
3925,04/06/2019 00:00,DB04385,3-Deazacytidine,,,,,,solid,,,208,12.55,1.79,[H][C@]1(CO)O[C@@]([H])(N2C=CC(N)=CC2=O)[C@]([H])(O)[C@]1([H])O,,,,,0,,242.0902715,2,1,2,1,1,1
3926,04/06/2019 00:00,DB04386,"4,6-O-(1-Carboxyethylidene)-Beta-D-Glucose",,,,,,solid,,,476,2.86,-3.7,C[C@]1(OC[C@H]2O[C@@H](O)[C@H](O)[C@@H](O)[C@H]2O1)C(O)=O,,,,,0,,250.0688674,2,0,2,0,2,2
3927,04/06/2019 00:00,DB04387,1-Hydroxy-2-Amino-3-Cyclohexylpropane,,,,,,solid,,,2.96,15.13,9.83,N[C@H](CO)CC1CCCCC1,,,,,0,,157.1466642,1,0,0,0,0,0
3928,04/06/2019 00:00,DB04388,4-Carboxy-4-Aminobutanal,,,,,,solid,,,144,2.12,9.11,N[C@@H](CCC=O)C(O)=O,,,,,0,,131.0582431,0,0,0,0,0,0
3929,04/06/2019 00:00,DB04389,Ado-P-Ch2-P-Ps-Ado,,,,,,solid,,,2.98,1,5.29,[H][C@]1(COP(O)(=O)CP(O)(=O)O[P@](O)(=S)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,770.0798265,6,4,6,4,2,2
3930,04/06/2019 00:00,DB04391,Aeruginosin 98-B,,,,,,solid,,,0.139,-1.8,12.06,[H][C@@](O)(CC1=CC=C(O)C=C1)C(O)=N[C@@]([H])(C(=O)N1[C@@]([H])(C[C@]2([H])CC[C@]([H])(C[C@]12[H])OS(O)(=O)=O)C(O)=NCCCCNC(N)=N)[C@]([H])(C)CC,,,,,0,,654.3046981,3,1,1,0,1,1
3931,04/06/2019 00:00,DB04392,"Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]",,,,,,solid,,,0.0673,2.06,-6.9,[H][C@@]1(C[C@@]2([H])C(=O)OC3=C(C=CC=C3)C2=O)C(=O)OC2=CC=CC=C2C1=O,,,,,0,,336.0633881,4,2,2,0,0,2
3932,04/06/2019 00:00,DB04393,Soneclosan,,,,,,solid,,,0.0327,7.7,-6.7,OC1=C(OC2=CC=C(Cl)C=C2)C=CC(Cl)=C1,,,,,0,,253.9901349,2,2,0,0,0,0
3933,04/06/2019 00:00,DB04394,3-Nitro-4-(2-Oxo-Pyrrolidin-1-Yl)-Benzenesulfonamide,,,,,,solid,,,0.634,9.78,-3.9,NS(=O)(=O)C1=CC=C(N2CCCC2=O)C(=C1)[N+]([O-])=O,,,,,0,,285.0419415,2,1,1,0,1,1
3934,04/06/2019 00:00,DB04395,Phosphoaminophosphonic Acid-Adenylate Ester,,,,,,solid,,,4.17,-7,3.58,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H](CO[P@](O)(=O)O[P@@](O)(=O)NP(O)(O)=O)[C@H](O)[C@H]1O,,,,,0,,506.0117299,3,2,3,2,1,1
3935,04/06/2019 00:00,DB04396,Thiodigalactoside,,,,,,solid,,,452,12.17,-3,[H][C@]1(CO)O[C@@]([H])(S[C@]2([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,358.0933679,2,0,2,0,2,2
3936,04/06/2019 00:00,DB04397,Alpha-D-Glucose-1-Phosphate-6-Vanadate,,,,,,solid,,,9.16,1.16,-3.6,O[C@@H]1[C@@H](O)[C@H](CO[V](O)(=O)=O)O[C@H](OP(O)(O)=O)[C@H]1O,,,,,0,,357.961621,1,0,1,0,1,1
3937,02/07/2019 00:00,DB04398,Lactic acid,,,,0.001 g/1g,Oral,solid,1E+006 mg/L,-0.72,562,3.78,-3.7,CC(O)C(O)=O,,,,,0,,90.03169405,0,0,0,0,0,0
3938,04/06/2019 00:00,DB04400,"L-erythro-7,8-dihydrobiopterin",,,,,,solid,,,0.826,-2.4,14.7,[H][C@@](C)(O)[C@]([H])(O)C1=NC2=C(NC1)NC(=N)N=C2O,,,,,0,,239.1018393,2,1,2,1,0,1
3939,04/06/2019 00:00,DB04401,"[Formylmethyl]Trimethyl-Ammonium, N,N,N-Trimethylammonium Acetaldehyde",,,,,,solid,,,0.932,,-8.2,C[N+](C)(C)CC=O,,,,,1,,102.0913404,0,0,0,0,0,0
3940,04/06/2019 00:00,DB04404,Allosamizoline,,,,,,solid,,,49.9,13.12,6.81,[H][C@]1(O)[C@]([H])(O)[C@@]2([H])N=C(O[C@@]2([H])[C@]1([H])CO)N(C)C,,,,,0,,216.111007,2,0,1,0,0,1
3941,04/06/2019 00:00,DB04405,"2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid",,,,,,solid,,,0.000986,3.8,-4.8,[H][C@](CCN1C(=O)C2=CC=CC=C2C1=O)(CC(=O)C1=CC=C(C=C1)C1=CC=C(OCC)C=C1)C(O)=O,,,,,0,,471.1681875,4,3,1,0,0,1
3942,04/06/2019 00:00,DB04406,3-(Phosphonomethyl)Pyridine-2-Carboxylic Acid,,,,,,solid,,,11.9,0.8,5.33,OC(=O)C1=NC=CC=C1CP(O)(O)=O,,,,,0,,217.014009,1,1,1,1,0,0
3943,04/06/2019 00:00,DB04407,4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol,,,,,,solid,,,0.02,10.23,3.01,CNC1=NC(C)=C(S1)C1=CC=NC(NC2=CC=C(O)C=C2)=N1,,,,,0,,313.0997311,3,3,2,2,0,0
3944,04/06/2019 00:00,DB04408,Ncs-Chromophore,,,,,,solid,,,0.0267,9.52,8.1,[H]\C1=C2\C(=C[C@@]([H])(OC(=O)C3=C(O)C=CC4=C3C=C(OC)C=C4C)[C@]2([H])O[C@@]2([H])O[C@]([H])(C)[C@]([H])(O)[C@]([H])(O)[C@@]2([H])NC)C#C[C@@]2(O[C@]2([H])C#C1)[C@@]1([H])COC(=O)O1,,,,,0,,659.2002755,7,2,3,0,3,3
3945,04/06/2019 00:00,DB04409,Naphthalene Trisulfonate,,,,,,solid,,,0.356,-3.3,,[O-]S(=O)(=O)C1=CC2=C(C=C1)C(=CC(=C2)S([O-])(=O)=O)S([O-])(=O)=O,,,,,-3,,364.9112155,2,2,0,0,0,0
3946,04/06/2019 00:00,DB04410,3-Phenylpropylamine,,,,,,solid,,,1.22,,10.05,NCCCC1=CC=CC=C1,,,,,0,,135.1047994,1,1,0,0,0,0
3947,04/06/2019 00:00,DB04411,Alpha-N-Dichloroacetyl-P-Aminophenylserinol,,,,,,solid,,,4.97,8.23,3.95,[H][C@](CO)(NC(=O)C(Cl)Cl)[C@]([H])(O)C1=CC=C(N)C=C1,,,,,0,,292.0381477,1,1,0,0,0,0
3948,04/06/2019 00:00,DB04415,3-Amino-1-Chloro-4-Phenyl-Butanol-2-Yl,,,,,,solid,,,3.08,13.77,9.42,N[C@@H](CC1=CC=CC=C1)[C@@H](O)CCl,,,,,0,,199.0763917,1,1,0,0,0,0
3949,04/06/2019 00:00,DB04416,"R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid",,,,,,solid,,,0.0043,3.18,-4.1,[H][C@](CC#CCOC)(NS(=O)(=O)C1=CC=C(C=C1)C1=CC=C(OC)C=C1)C(O)=O,,,,,0,,403.1089584,2,2,0,0,0,0
3950,04/06/2019 00:00,DB04417,P-Nitrophenol,,,,,,solid,1.16E+004 mg/L (at 20 Â°C),1.91,3.6,7.04,-7.1,OC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,139.026943,1,1,0,0,0,0
3951,04/06/2019 00:00,DB04418,Adenylosuccinic acid,,,,,,solid,,,2.38,1.22,4.58,O[C@@H]1[C@@H](COP(O)(O)=O)O[C@H]([C@@H]1O)N1C=NC2=C(N[C@@H](CC(O)=O)C(O)=O)N=CN=C12,,,,,0,,463.074043,3,2,3,2,1,1
3952,04/06/2019 00:00,DB04419,D-norleucine,,,,,,solid,,,89.2,2.79,9.53,CCCC[C@@H](N)C(O)=O,,,,,0,,131.0946287,0,0,0,0,0,0
3953,04/06/2019 00:00,DB04421,Nicotinamide Adenine Dinucleotide 3-Pentanone Adduct,,,,,,solid,,,4.13,1.86,6.54,[H][C@@](C)(C(=O)CC)C1=CC=[N+](C=C1C(O)=N)[C@]1([H])O[C@]([H])(COP(O)(=O)OP([O-])(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C(N)N=CN=C34)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,747.1666367,5,3,5,3,2,2
3954,04/06/2019 00:00,DB04422,2-Amino-4-Mercapto-Butyric Acid,,,,,,solid,,,14.8,2.46,9.41,N[C@@H](CCS)C(O)=O,,,,,0,,135.0353995,0,0,0,0,0,0
3955,04/06/2019 00:00,DB04423,Coproporphyrin I Containing Co(Iii),,,,,,solid,,,0.807,3.48,,CC1=C(CCC(O)=O)C2=CC3=C(C)C(CCC(O)=O)=C4C=C5N6C(=CC7=C(C)C(CCC(O)=O)=C8C=C1N2[Co]6(N78)N34)C(CCC(O)=O)=C5C,,,,,0,,711.1865091,8,4,8,4,0,4
3956,04/06/2019 00:00,DB04424,RPR128515,,,,,,solid,,,0.00158,15,11.46,COC(=O)[C@H](CC1=CC=CC(=C1)C(N)=N)[C@@H](C)NC(=O)C1=CC=C(C=C1)C1=CC=CC(CN)=C1,,,,,0,,458.2317908,3,3,0,0,0,0
3957,04/06/2019 00:00,DB04425,"7,8-Dihydroneopterin",,,,,,solid,,,1.98,10.61,3.58,NC1=NC2=C(N=C(CN2)[C@H](O)[C@H](O)CO)C(=O)N1,,,,,0,,255.0967539,2,1,2,1,0,1
3958,04/06/2019 00:00,DB04426,Alpha-Methyl-N-Acetyl-D-Glucosamine,,,,,,solid,,,237,12.27,-0.78,[H][C@]1(CO)O[C@@]([H])(OC)[C@]([H])(NC(C)=O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,235.1055873,1,0,1,0,1,1
3959,04/06/2019 00:00,DB04427,3-[[N-[4-Methyl-Piperazinyl]Carbonyl]-Phenylalaninyl-Amino]-5-Phenyl-Pentane-1-Sulfonic Acid Benzyloxy-Amide,,,,,,solid,,,0.00915,5.73,7.19,[H][C@](CCC1=CC=CC=C1)(CCS(=O)(=O)NOCC1=CC=CC=C1)N=C(O)[C@]([H])(CC1=CC=CC=C1)N=C(O)N1CCN(C)CC1,,,,,0,,621.2984905,4,3,1,0,1,1
3960,04/06/2019 00:00,DB04429,4'-Hydroxyflavanone,,,,,,solid,,,0.0992,9.47,-4.9,OC1=CC=C(C=C1)[C@@H]1CC(=O)C2=CC=CC=C2O1,,,,,0,,240.0786442,3,2,1,0,0,1
3961,04/06/2019 00:00,DB04430,3-(4-Phenylamino-Phenylamino)-2-(1h-Tetrazol-5-Yl)-Acrylonitrile,,,,,,solid,,,0.0377,6.75,2.15,N#C\C(=C\NC1=CC=C(NC2=CC=CC=C2)C=C1)C1=NNN=N1,,,,,0,,303.1232434,3,3,1,1,0,0
3962,04/06/2019 00:00,DB04431,4-Epi-Vancosaminyl Derivative of Vancomycin,,,,,,solid,,,0.0531,1.98,,[H][C@](CC(C)C)(NC)C(O)=N[C@@]1([H])C(O)=N[C@@]([H])(CC(O)=[NH2+])C(O)=N[C@]2([H])C3=CC(OC4=C(Cl)C=C(C=C4)[C@@]1([H])O)=C(O[C@]1([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O[C@@]1([H])C[C@](C)([NH3+])[C@@]([H])(O)[C@]([H])(C)O1)C(OC1=C(Cl)C=C(C=C1)[C@@]([H])(O[C@@]1([H])C[C@](C)([NH3+])[C@@]([H])(O)[C@]([H])(C)O1)[C@]1([H])N=C(O)[C@]([H])(N=C2O)C2=CC(=C(O)C=C2)C2=C(C=C(O)C=C2O)[C@]([H])(N=C1O)C(O)=O)=C3,,,,,3,,1593.546658,13,5,8,0,3,8
3963,04/06/2019 00:00,DB04432,ZK-805623,,,,,,solid,,,0.00315,,11.34,CC1=C(F)C(OC2=CC(=CC=C2)C(N)=N)=[NH+]C(OC2=CC=CC(=C2)C(N)=N)=C1F,,,,,1,,398.1423077,3,3,1,1,0,0
3964,04/06/2019 00:00,DB04433,"N''-{3-[(3s,8ar)-1,4-Dioxooctahydropyrrolo[1,2-a]Pyrazin-3-Yl]Propyl}Guanidine",,,,,,solid,,,0.881,6.29,12.12,[H][C@@]12CCCN1C(=O)[C@]([H])(CCCNC(N)=N)N=C2O,,,,,0,,253.1538748,2,0,2,0,1,2
3965,04/06/2019 00:00,DB04434,Naphthyridine Inhibitor,,,,,,solid,,,0.0374,,4.45,CC1=CC=CC(=N1)C1=C(CNN1)C1=CC=C2N=CC=CC2=N1,,,,,0,,289.1327455,4,3,4,3,0,1
3966,04/06/2019 00:00,DB04436,3-Fluoro-L-tyrosine,,,,,,solid,,,2.19,1.57,9.48,N[C@@H](CC1=CC(F)=C(O)C=C1)C(O)=O,,,,,0,,199.0644714,1,1,0,0,0,0
3967,04/06/2019 00:00,DB04437,"Cysteine-Methylene-Carbamoyl-1,10-Phenanthroline",,,,,,solid,,,0.0343,2.12,8.83,N[C@@H](CSCC(=O)NC1=CC2=C(N=CC=C2)C2=C1C=CC=N2)C(O)=O,,,,,0,,356.0943114,3,3,2,2,0,0
3968,04/06/2019 00:00,DB04438,Brivudine monophosphate,,,,,,solid,,,3.97,1.23,-3.2,O[C@H]1C[C@@H](O[C@@H]1COP(O)(O)=O)N1C=C(\C=C\Br)C(=O)NC1=O,,,,,0,,411.9671141,2,1,2,1,1,1
3969,04/06/2019 00:00,DB04439,Modified Acarbose Pentasaccharide,,,,,,solid,,,89.9,11.2,7.33,[H][C@]1(C)O[C@]([H])(O[C@]2([H])C(CO)=C[C@]([H])(N[C@]3([H])[C@@]([H])(C)O[C@]([H])(O[C@]4([H])[C@@]([H])(CO)O[C@]([H])(O[C@]5([H])[C@@]([H])(CO)O[C@]([H])(O)[C@]([H])(O)[C@@]5([H])O)[C@]([H])(O)[C@@]4([H])O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,791.3059223,5,0,4,0,4,4
3970,04/06/2019 00:00,DB04440,Nebularine,,,,,,solid,1E+005 mg/L,,16.8,12.45,3.77,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=CN=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,252.0858549,3,2,3,2,1,1
3971,04/06/2019 00:00,DB04441,2-Fluoroadenosine,,,,,,solid,,,12.1,12.45,0.71,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(N)N=C(F)N=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,285.0873321,3,2,3,2,1,1
3972,04/06/2019 00:00,DB04442,"2-(2-Oxo-1,2-Dihydro-Pyridin-3-Yl)-1h-Benzoimidazole-5-Carboxamidine",,,,,,solid,,,0.224,10.3,11,NC(=[NH2+])C1=CC2=C(NC(=N2)C2=C(O)N=CC=C2)C=C1,,,,,1,,254.1036364,3,3,2,2,0,0
3973,04/06/2019 00:00,DB04446,Benzo[B]Thiophene-2-Carboxamidine,,,,,,solid,,,0.0648,,8.66,NC(=[NH2+])C1=CC2=C(S1)C=CC=C2,,,,,1,,177.0480957,2,2,1,1,0,0
3974,04/06/2019 00:00,DB04447,"1,4-Dithiothreitol",,,,,,solid,,,5.14,9.62,-3.3,O[C@@H](CS)[C@@H](O)CS,,,,,0,,154.0122216,0,0,0,0,0,0
3975,04/06/2019 00:00,DB04448,"2,4-Difluorobenzyl Alcohol 2,4-Difluoro-1-(Hydroxymethyl)Benzene",,,,,,solid,,,2.54,14.49,-3,OCC1=CC=C(F)C=C1F,,,,,0,,144.0386713,1,1,0,0,0,0
3976,04/06/2019 00:00,DB04449,"5-(3,3-Dihydroxypropeny)-3-Methoxy-Benzene-1,2-Diol",,,,,,solid,,,2.54,9.46,-3.9,COC1=CC(\C=C\C(O)O)=CC(O)=C1O,,,,,0,,212.0684735,1,1,0,0,0,0
3977,04/06/2019 00:00,DB04450,Heptyl 1-Thiohexopyranoside,,,,,,solid,,,10.1,12.48,-3,[H][C@]1(CO)O[C@@]([H])(SCCCCCCC)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,294.1500949,1,0,1,0,1,1
3978,04/06/2019 00:00,DB04451,4-Methylpiperazin-1-Yl Carbonyl Group,,,,,,solid,,,646,3.77,7.29,CN1CCN(CC1)C(O)=O,,,,,0,,144.0898776,1,0,1,0,1,1
3979,04/06/2019 00:00,DB04452,Aminoquinuride,,,,,,solid,,,0.0111,11.52,9.07,CC1=NC2=CC=C(NC(=O)NC3=CC4=C(C=C3)N=C(C)C=C4N)C=C2C(N)=C1,,,,,0,,372.1698593,4,4,2,2,0,0
3980,04/06/2019 00:00,DB04453,"4-O-(4,6-Dideoxy-4-{[4-[(4-O-Hexopyranosylhexopyranosyl)Oxy]-5,6-Dihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}Hexopyranosyl)Hexopyranose",,,,,,solid,,,126,11.2,7.33,[H][C@]1(C)O[C@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])N[C@@]1([H])C=C(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]3([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O,,,,,0,,807.300837,5,0,4,0,4,4
3981,04/06/2019 00:00,DB04454,Alpha-Aminobutyric Acid,,,,,,solid,,,358,2.62,9.53,CC[C@@H](N)C(O)=O,,,,,0,,103.0633285,0,0,0,0,0,0
3982,04/06/2019 00:00,DB04455,"N,N,N-trimethylglycinium",,,,,,solid,,,1.75,2.26,,C[N+](C)(C)CC(O)=O,,,,,1,,118.086255,0,0,0,0,0,0
3983,04/06/2019 00:00,DB04457,2'-Deoxyguanosine-5'-Monophosphate,,,,,,solid,,,2.67,1.21,2.62,NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1,,,,,0,,347.0630844,3,2,3,2,1,1
3984,04/06/2019 00:00,DB04458,"2,2-Dichloro-1-Methanesulfinyl-3-Methyl-Cyclopropanecarboxylic Acid [1-(4-Bromo-Phenyl)-Ethyl]-Amide",,,,,,solid,,,0.0404,4.44,1.87,[H][C@](C)(N=C(O)[C@]1([S@](C)=O)[C@@]([H])(C)C1(Cl)Cl)C1=CC=C(Br)C=C1,,,,,0,,410.9462172,2,1,0,0,0,0
3985,04/06/2019 00:00,DB04459,"3,4-Dichloroisocoumarin",,,,,,solid,,,0.0697,,-7.1,ClC1=C(Cl)C2=CC=CC=C2C(=O)O1,,,,,0,,213.9588347,2,2,1,1,0,0
3986,04/06/2019 00:00,DB04460,(C8-S)-Hydantocidin 5'-Phosphate,,,,,,solid,,,11.1,1.22,-2.8,[H][C@@](CCCN1C(O)=N[C@@]2(O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@@]2([H])O)C1=O)(N(O)CO)C(O)=O,,,,,0,,459.0890244,2,0,2,0,1,2
3987,04/06/2019 00:00,DB04461,Coproporphyrinogen III,,,,,,solid,,,0.0112,3.8,,CC1=C2CC3=C(C)C(CCC(O)=O)=C(CC4=C(CCC(O)=O)C(C)=C(CC5=C(CCC(O)=O)C(C)=C(CC(N2)=C1CCC(O)=O)N5)N4)N3,,,,,0,,660.3159144,5,4,5,4,0,1
3988,04/06/2019 00:00,DB04462,Tetrabromo-2-Benzotriazole,,,,,,solid,,,0.01,8.62,-1.2,[H]N1N=C2C(=N1)C(Br)=C(Br)C(Br)=C2Br,,,,,0,,430.6903954,2,2,1,1,0,0
3989,04/06/2019 00:00,DB04463,"3-(4-Amino-1-Tert-Butyl-1h-Pyrazolo[3,4-D]Pyrimidin-3-Yl)Phenol",,,,,,solid,,,0.325,9.54,6.57,CC(C)(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=CC(O)=C1,,,,,0,,283.1433102,3,3,2,2,0,0
3990,04/06/2019 00:00,DB04464,N-Formylmethionine,,,,,,solid,,,9.75,3.93,-0.91,[H][C@@](CCSC)(NC=O)C(O)=O,,,,,0,,177.0459642,0,0,0,0,0,0
3991,04/06/2019 00:00,DB04465,Lactose,,,,50 g,Oral,solid,1.95E+005 mg/L (at 20 Â°C),,586,11.25,-3,OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O,,,,,0,,342.1162115,2,0,2,0,2,2
3992,04/06/2019 00:00,DB04466,SR12813,,,,,,solid,,,0.0581,10.42,-5.1,CCOP(=O)(OCC)C(=CC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)P(=O)(OCC)OCC,,,,,0,,504.2405769,1,1,0,0,0,0
3993,04/06/2019 00:00,DB04467,N-(5'-phosphopyridoxyl)-L-alanine,,,,,,solid,,,1.48,1.03,9.86,[H][C@@](C)(NCC1=C(COP(O)(O)=O)C=NC(C)=C1O)C(O)=O,,,,,0,,320.0773375,1,1,1,1,0,0
3994,04/06/2019 00:00,DB04468,Afimoxifene,Absorbed following topical application.,,,,,solid,,,0.00303,9.45,8.66,CC\C(=C(/C1=CC=C(O)C=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,,,,,0,,387.2198292,3,3,0,0,0,0
3995,04/06/2019 00:00,DB04469,"1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,,,,,solid,,,0.231,,1.99,CCOC(=O)C1=C(C)N(N=C1C)C1=CC=C(OC)C=C1,,,,,0,,274.1317424,2,2,1,1,0,0
3996,04/06/2019 00:00,DB04470,CRA_10656,,,,,,solid,,,0.00757,9.16,10.6,CC(C)COC1=C([O-])C(=CC=C1)C1=NC2=CC(=CC=C2N1)C(N)=[NH2+],,,,,0,,324.1586259,3,3,1,1,0,0
3997,04/06/2019 00:00,DB04471,"2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol",,,,,,solid,,,0.0122,9.63,8.77,OC1=CC=C2[C@H](N(CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCCC2)C=C1,,,,,0,,428.2463783,5,3,2,0,1,2
3998,04/06/2019 00:00,DB04472,(R)-1-Para-Nitro-Phenyl-2-Azido-Ethanol,,,,,,solid,,,2.7,13.73,-3.5,[H][C@](O)(CN=[N+]=[N-])C1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,208.0596401,1,1,0,0,0,0
3999,04/06/2019 00:00,DB04473,Alpha-L-Fucose,,,,,,solid,,,827,11.3,-3.6,C[C@@H]1O[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O,,,,,0,,164.0684735,1,0,1,0,1,1
4000,04/06/2019 00:00,DB04474,1-Anilino-8-Naphthalene Sulfonate,,,,,,solid,,,0.0151,-2,-0.083,OS(=O)(=O)C1=C2C(NC3=CC=CC=C3)=CC=CC2=CC=C1,,,,,0,,299.0616143,3,3,0,0,0,0
4001,04/06/2019 00:00,DB04476,"Trencam-3,2-Hopo",,,,,,solid,,,6.71,8.32,-1.9,NC(=O)C1=CC=CC(O)=C1O,,,,,0,,153.0425931,1,1,0,0,0,0
4002,04/06/2019 00:00,DB04477,"N-1,2,3,4-Tetrahydronaphth-1-Yl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine",,,,,,solid,,,0.069,7.5,4.82,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(N[C@]4([H])CCCC5=CC=CC=C45)N=CN=C23)[C@]([H])(N=C(O)C2=CC(OC)=CC(OC)=C2)[C@]1([H])O,,,,,0,,560.2383327,6,4,3,2,1,1
4003,04/06/2019 00:00,DB04478,"Cp-166572, 2-Hydroxymethyl-4-(4-N,N-Dimethylaminosulfonyl-1-Piperazino)-Pyrimidine",,,,,,solid,,,8.78,13.55,4.82,CN(C)S(=O)(=O)N1CCN(CC1)C1=CC=NC(CO)=N1,,,,,0,,301.1208605,2,1,2,1,1,1
4004,04/06/2019 00:00,DB04479,4-Nitro-Inden-1-One,,,,,,solid,,,0.402,14.49,-7.4,[O-][N+](=O)C1=CC=CC2=C1C=CC2=O,,,,,0,,175.026943,2,1,0,0,0,0
4005,04/06/2019 00:00,DB04480,"3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole",,,,,,solid,,,0.00869,,1.81,CC1=NC(=CC=C1)C1=NN2CCCC2=C1C1=CC=C(F)C=C1,,,,,0,,293.1328257,4,3,3,2,0,1
4006,04/06/2019 00:00,DB04481,Meso-Erythritol,,,,,,solid,,,1160,13.04,-3,OC[C@H](O)[C@H](O)CO,,,,,0,,122.0579088,0,0,0,0,0,0
4007,04/06/2019 00:00,DB04482,Cmp-2-Keto-3-Deoxy-Octulosonic Acid,,,,,,solid,,,49.6,1.47,-0.77,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](COP(O)(=O)O[C@]2(C[C@@H](O)[C@@H](O)[C@H](O2)[C@H](O)CO)C(O)=O)[C@@H](O)[C@H]1O,,,,,0,,543.1101538,3,1,3,1,2,2
4008,04/06/2019 00:00,DB04483,2-deoxy-2-fluoro-Î²-D-mannose,,,,,,solid,,,257,11.02,-3,OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O,,,,,0,,182.0590517,1,0,1,0,1,1
4009,04/06/2019 00:00,DB04484,L-phenylalaninol,,,,,,solid,,,10.3,15.12,9.41,N[C@H](CO)CC1=CC=CC=C1,,,,,0,,151.099714,1,1,0,0,0,0
4010,04/06/2019 00:00,DB04485,Thymidine,,,,,,solid,,-0.93,66.8,9.96,-3,CC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O,,,,,0,,242.0902715,2,1,2,1,1,1
4011,04/06/2019 00:00,DB04486,"(2s)-2,8-Diaminooctanoic Acid",,,,,,solid,,,11,2.84,10.29,NCCCCCC[C@H](N)C(O)=O,,,,,0,,174.1368278,0,0,0,0,0,0
4012,04/06/2019 00:00,DB04487,N-Methylleucine,,,,,,solid,,,35,2.42,10.58,CN[C@H](CC(C)C)C(O)=O,,,,,0,,145.1102787,0,0,0,0,0,0
4013,04/06/2019 00:00,DB04488,"(6r,7r)-3-[(Acetyloxy)Methyl]-7-{[(6s)-6-(Glycylamino)-7-Oxido-7-Oxoheptanoyl]Amino}-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]Octane-2-Carboxylate",,,,,,solid,,,0.212,3.31,9.34,[H][C@@](CCCCC([O-])=N[C@]1([H])C(=O)N2[C@]1([H])SC[C@@]([H])(COC(C)=O)[C@@]2([H])C(O)=O)(N=C(O)CN)C(O)=O,,,,,-1,,487.150423,2,0,2,0,2,2
4014,04/06/2019 00:00,DB04489,Guanidinoethylmercaptosuccinic acid,,,,,,solid,,,1.93,3.91,12.11,NC(=N)NCCS[C@@H](CC(O)=O)C(O)=O,,,,,0,,235.0626769,0,0,0,0,0,0
4015,04/06/2019 00:00,DB04490,3-(Mercaptomethylene)Pyridine,,,,,,solid,,,1.62,9.92,4.86,SCC1=CC=CN=C1,,,,,0,,125.0299202,1,1,1,1,0,0
4016,04/06/2019 00:00,DB04491,Diisopropylphosphono Group,,,,,,solid,,,7.09,,-7.8,CC(C)OP(=O)OC(C)C,,,,,0,,166.075881,0,0,0,0,0,0
4017,04/06/2019 00:00,DB04492,2-(acetylamino)-2-deoxy-4-O-sulfo-alpha-D-galactopyranose,,,,,,solid,,,38.1,-1.9,0.99,[H][C@]1(O)O[C@]([H])(CO)[C@]([H])(OS(O)(=O)=O)[C@]([H])(O)[C@@]1([H])N=C(C)O,,,,,0,,301.0467521,1,0,1,0,1,1
4018,04/06/2019 00:00,DB04493,Fructose-6-Phosphate,,,,,,solid,,,23.2,1.49,-3.3,OCC(=O)[C@@H](O)[C@H](O)[C@H](O)COP(O)(O)=O,,,,,0,,260.0297186,0,0,0,0,0,0
4019,04/06/2019 00:00,DB04495,RU81843,,,,,,solid,,,0.0027,2.16,1.55,[H][C@@](CC1=CC=C(OP(O)(O)=O)C=C1)(N=C(C)O)C(O)=N[C@@]1([H])CCCCN(CC2=CC=C(C=C2)C2=CC=CC=C2)C1=O,,,,,0,,579.2134371,4,3,1,0,1,1
4020,04/06/2019 00:00,DB04496,4-Phospho-D-Erythronohydroxamic Acid,,,,,,solid,,,12,1.48,-0.6,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)C(O)=NO,,,,,0,,231.0144029,0,0,0,0,0,0
4021,04/06/2019 00:00,DB04497,2'-Monophosphoadenosine-5'-Diphosphoribose,,,,,,solid,,,6.36,0.82,6.9,[H][C@@]1(O)O[C@]([H])(COP(O)(=O)OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C3NCN[C@@]4([H])[NH3+])[C@]([H])(OP(O)(O)=O)[C@]2([H])O)[C@@]([H])(O)[C@@]1([H])O,,,,,1,,644.0765808,4,1,4,1,2,3
4022,04/06/2019 00:00,DB04498,Aspartate Semialdehyde,,,,,,solid,,,225,1.95,8.98,[H][C@@](N)(CC=O)C(O)=O,,,,,0,,117.0425931,0,0,0,0,0,0
4023,04/06/2019 00:00,DB04499,R-Styrene Oxide,,,,,,solid,,,1.26,,-4.2,C1O[C@@H]1C1=CC=CC=C1,,,,,0,,120.0575149,2,1,1,0,1,1
4024,04/06/2019 00:00,DB04500,Acedoben,,,,,,solid,,1.31,1.36,4.16,-4.4,CC(=O)NC1=CC=C(C=C1)C(O)=O,,,,,0,,179.0582431,1,1,0,0,0,0
4025,04/06/2019 00:00,DB04501,Camphane,,,,,,solid,,,0.00437,,,[H][C@]12CC[C@](C)(CC1)C2(C)C,,,,,0,,138.1408506,2,0,0,0,0,0
4026,04/06/2019 00:00,DB04502,WRR-204,,,,,,solid,,,0.00038,5.46,3.31,[H][C@](CCC1=CC=CC=C1)(CCS(=O)(=O)OC1=CC=CC=C1)N=C(O)[C@]([H])(CC1=CC=CC=C1)N=C(O)OCC1=CC=CC=C1,,,,,0,,600.2294079,4,4,0,0,0,0
4027,04/06/2019 00:00,DB04503,Sp-722,,,,,,solid,,,0.611,2.4,-1.3,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)S(=O)(=O)N1CCC[C@]1([H])C(O)=O)C(O)=O,,,,,0,,428.0889512,2,1,1,0,1,1
4028,04/06/2019 00:00,DB04504,"(3s)-2,3,4,5-Tetrahydropyridin-3-Amine",,,,,,solid,,,14.8,,9.71,[H][C@@]1(N)CCC=NC1,,,,,0,,98.08439832,1,0,1,0,0,1
4029,04/06/2019 00:00,DB04505,"8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine",,,,,,solid,,,0.0241,18.59,5.06,COC1=C(OC)C(OC)=C(Cl)C(CC2=NC3=C(N)N=CN=C3N2CCCC#C)=C1,,,,,0,,415.1411172,3,3,2,2,0,0
4030,04/06/2019 00:00,DB04506,Chlorophyll B,,,,,,solid,,,0.000131,11.71,4.65,[Mg++].CCC1=C(C=O)C2=N\C\1=C/C1=C(C)C3=C([N-]1)\C([C@@H](C(=O)OC)C3=O)=C1/N=C(/C=C3\[N-]/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C,,,,,0,,906.5145777,6,3,5,3,0,2
4031,04/06/2019 00:00,DB04508,"Methyl(6s)-1-Thio-L-Manno-Hexodialdo-6,2-Pyranoside",,,,,,solid,,,21.6,11.65,-3.7,[H][C@@]1(O)[C@@]([H])(O)[C@]([H])(OC)O[C@]([H])(C=S)[C@]1([H])O,,,,,0,,208.0405445,1,0,1,0,1,1
4032,04/06/2019 00:00,DB04509,N-Methylnaloxonium,,,,,,solid,,,0.0208,7.4,-3.9,C[N@@+]1(CC=C)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35,,,,,1,,342.1699847,5,1,2,0,1,2
4033,04/06/2019 00:00,DB04510,3-phospho-D-glyceric acid,,,,,,solid,,,21,1.3,-4.2,O[C@H](COP(O)(O)=O)C(O)=O,,,,,0,,185.9929392,0,0,0,0,0,0
4034,04/06/2019 00:00,DB04511,N-Succinyl Methionine,,,,,,solid,,,2.31,3.54,-1.5,[H][C@](CCSC)(NC(=O)CCC(O)=O)C(O)=O,,,,,0,,249.0670936,0,0,0,0,0,0
4035,04/06/2019 00:00,DB04512,2-Isobutyl-3-Methoxypyrazine,,,,,,solid,,,20.9,,0.98,COC1=NC=CN=C1CC(C)C,,,,,0,,166.1106131,1,1,1,1,0,0
4036,04/06/2019 00:00,DB04513,N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide,,,,,,solid,,,0.00172,9.72,10.38,NCCCCCCNS(=O)(=O)C1=CC=CC2=C1C=CC=C2Cl,,,,,0,,340.1012266,2,2,0,0,0,0
4037,04/06/2019 00:00,DB04514,Phosphoric Acid-2'-[2'-Deoxy-Uridine]Ester-5'-Guanosine Ester,,,,,,solid,,,2.97,1.83,4.93,[H][C@]1(CO)O[C@@]([H])(N2C=CC(O)=NC2=O)[C@]([H])(OP(O)(=O)OC[C@@]2([H])O[C@@]([H])(N3C=NC4=C3NC(=N)N=C4O)[C@]([H])(O)[C@]2([H])O)[C@]1([H])O,,,,,0,,589.1169705,5,3,5,3,2,2
4038,04/06/2019 00:00,DB04515,6-deoxy-2-O-methyl-alpha-L-galactopyranose,,,,,,solid,,,723,11.33,-3.6,[H][C@@]1(C)O[C@@]([H])(O)[C@@]([H])(OC)[C@]([H])(O)[C@]1([H])O,,,,,0,,178.0841235,1,0,1,0,1,1
4039,04/06/2019 00:00,DB04516,2-Deoxy-Glucitol-6-Phosphate,,,,,,solid,,,28.2,1.49,-2.4,[H][C@@](O)(CCO)[C@]([H])(O)[C@]([H])(O)COP(O)(O)=O,,,,,0,,246.0504541,0,0,0,0,0,0
4040,04/06/2019 00:00,DB04517,Dipyrromethane Cofactor,,,,,,solid,,,0.114,3.68,,CC1=C(CC(O)=O)C(CCC(O)=O)=C(CC2=C(CC(O)=O)C(CCC(O)=O)=CN2)N1,,,,,0,,420.1532657,2,2,2,2,0,0
4041,04/06/2019 00:00,DB04518,"3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol",,,,,,solid,,,0.0158,9.63,2.69,CC1=NC(C)=C(S1)C1=NC(NC2=CC=CC(O)=C2)=NC=C1,,,,,0,,298.0888321,3,3,2,2,0,0
4042,04/06/2019 00:00,DB04519,Caprylic acid,,,,,,liquid,789 mg/L (at 30 Â°C),3.05,0.907,5.19,,CCCCCCCC(O)=O,,,,,0,,144.1150298,0,0,0,0,0,0
4043,04/06/2019 00:00,DB04520,"(3s,8ar)-3-(4-Hydroxybenzyl)Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione",,,,,,solid,,,11.2,9.49,-4,[H][C@@]12CCCN1C(=O)[C@]([H])(CC1=CC=C(O)C=C1)NC2=O,,,,,0,,260.1160924,3,1,2,0,2,2
4044,04/06/2019 00:00,DB04521,GSHNA,,,,,,solid,,,0.111,1.97,9.54,[H][C@](N)(CCC(O)=N[C@@]([H])(CS[C@@]1([H])C[C@]([H])(O)O[C@]1([H])CCCCC)C(O)=NCC(O)=O)C(O)=O,,,,,0,,463.198836,1,0,1,0,1,1
4045,04/06/2019 00:00,DB04522,Dexfosfoserine,,,,,,solid,,,19.9,1.2,9.39,N[C@@H](COP(O)(O)=O)C(O)=O,,,,,0,,185.0089236,0,0,0,0,0,0
4046,04/06/2019 00:00,DB04523,Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate,,,,,,solid,,,0.336,13.95,-7.4,[H][C@@](NC(=O)OC(C)(C)C)(C=O)C1CCCCC1,,,,,0,,241.1677936,1,0,0,0,0,0
4047,04/06/2019 00:00,DB04524,Malonyl-CoA,,,,,,solid,,,3.8,0.82,4.97,CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O,,,,,0,,853.1156029,3,2,3,2,1,1
4048,04/06/2019 00:00,DB04525,2-(Carboxymethoxy)-5-[(2s)-2-({(2s)-2-[(3-Carboxypropanoyl)Amino] -3-Phenylpropanoyl}Amino)-3-Oxo-3-(Pentylamino)Propyl]Benzoic Acid,,,,,,solid,,,0.00686,2.85,4.44,[H][C@@](CC1=CC=CC=C1)(N=C(O)CCC(O)=O)C(O)=N[C@@]([H])(CC1=CC(C(O)=O)=C(OCC(O)=O)C=C1)C(O)=NCCCCC,,,,,0,,599.2478944,2,2,0,0,0,0
4049,04/06/2019 00:00,DB04526,L-Glycero-D-Manno-Heptopyranose,,,,,,solid,,,485,11.29,-3,[H][C@](O)(CO)[C@@]1([H])O[C@]([H])(O)[C@@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,210.0739528,1,0,1,0,1,1
4050,04/06/2019 00:00,DB04527,beta-Hydroxyasparagine,,,,,,solid,,,97.1,1.76,7.89,N[C@@H]([C@H](O)C(N)=O)C(O)=O,,,,,0,,148.0484067,0,0,0,0,0,0
4051,04/06/2019 00:00,DB04528,"2,4-Dinitrophenol",,,,,,solid,2790 mg/L (at 20 Â°C),1.67,0.376,4.04,-7.8,OC1=CC=C(C=C1[N+]([O-])=O)[N+]([O-])=O,,,,,0,,184.0120212,1,1,0,0,0,0
4052,04/06/2019 00:00,DB04529,Desvancosaminyl Vancomycin,,,,,,solid,,,0.0812,1.94,,[H][C@](CC(C)C)(NC)C(O)=N[C@@]1([H])C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@]2([H])C3=CC(OC4=C(Cl)C=C(C=C4)[C@@]1([H])O)=C(O[C@]1([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O)C(OC1=C(Cl)C=C(C=C1)[C@@]([H])(O)[C@]1([H])N=C(O)[C@]([H])(N=C2O)C2=CC(=C(O)C=C2)C2=C(C=C(O)C=C2O)[C@]([H])(N=C1O)C(O)=O)=C3,,,,,0,,1304.335571,11,5,6,0,1,6
4053,04/06/2019 00:00,DB04530,"S,S-(2-Hydroxyethyl)Thiocysteine",,,,,,solid,,,36,2.04,9.04,N[C@@H](CSSCCO)C(O)=O,,,,,0,,197.0180352,0,0,0,0,0,0
4054,04/06/2019 00:00,DB04531,Benzylcysteine,,,,,,solid,,,1.07,2.42,9.14,N[C@@H](CSCC1=CC=CC=C1)C(O)=O,,,,,0,,211.0666997,1,1,0,0,0,0
4055,04/06/2019 00:00,DB04532,Indole,,,,,,solid,3560 mg/L (at 25 Â°C),2.14,5.31,16.44,,N1C=CC2=C1C=CC=C2,,,,,0,,117.0578492,2,2,1,1,0,0
4056,04/06/2019 00:00,DB04533,2-Amino-P-Cresol,,,,,,solid,,,38.4,10.69,4.74,CC1=CC=C(O)C(N)=C1,,,,,0,,123.0684139,1,1,0,0,0,0
4057,04/06/2019 00:00,DB04534,5-Nitroindazole,,,,,,solid,,,4.6,12.7,0.69,O=N(=O)C1=CC=C2NN=CC2=C1,,,,,0,,163.0381764,2,2,1,1,0,0
4058,04/06/2019 00:00,DB04537,L-Tryptophanamide,,,,,,solid,,,2.63,15.95,7.97,[H][C@](N)(CC1=CNC2=C1C=CC=C2)C(N)=O,,,,,0,,203.105862,2,2,1,1,0,0
4059,04/06/2019 00:00,DB04538,threo-3-methyl-L-aspartic acid,,,,,,solid,,,97.4,1.87,9.68,[H][C@@](C)(C(O)=O)[C@]([H])(N)C(O)=O,,,,,0,,147.0531578,0,0,0,0,0,0
4060,04/06/2019 00:00,DB04539,Glyphosate,,,,,,solid,1.2E+004 mg/L (at 25 Â°C),-4,10.7,-0.58,6.34,OC(=O)C[NH2+]CP(O)(O)=O,,,,,1,,170.0212854,0,0,0,0,0,0
4061,04/06/2019 00:00,DB04540,Cholesterol,,,,,,solid,0.095 mg/L (at 30 Â°C),,2.79E-05,18.2,-1.4,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C,,,,,0,,386.3548661,4,0,0,0,0,0
4062,04/06/2019 00:00,DB04541,"(8ar)-Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione",,,,,,solid,,,197,11.35,-4.2,O=C1CNC(=O)[C@@H]2CCCN12,,,,,0,,154.0742276,2,0,2,0,2,2
4063,04/06/2019 00:00,DB04542,3'-Azido-3'-Deoxythymidine-5'-Diphosphate,,,,,,solid,,,9.47,1.77,-4,[H][C@@]1(C[C@]([H])(N=[N+]=[N-])[C@@]([H])(COP(O)(=O)OP(O)(O)=O)O1)N1C=C(C)C(O)=NC1=O,,,,,0,,427.0294149,2,1,2,1,1,1
4064,04/06/2019 00:00,DB04543,"2,6-Diamino-8-(1h-Imidazol-2-Ylsulfanylmethyl)-3h-Quinazoline-4-One",,,,,,solid,,,0.22,11.18,5.91,NC1=NC2=C(C=C(N)C=C2CSC2=NC=CN2)C(=O)N1,,,,,0,,288.07933,3,3,2,2,0,0
4065,04/06/2019 00:00,DB04544,1-Deoxy-1-Acetylamino-Beta-D-Gluco-2-Heptulopyranosonamide,,,,,,solid,,,6.07,-5.1,11.71,[H][C@]1(CO)O[C@](N=C(C)O)(C(O)=N)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,264.0957509,1,0,1,0,1,1
4066,04/06/2019 00:00,DB04545,Afegostat,,,,,,solid,,,538,13.52,8.8,OC[C@H]1CNC[C@@H](O)[C@@H]1O,,,,,0,,147.0895433,1,0,1,0,1,1
4067,04/06/2019 00:00,DB04546,3-Deaza-Adenosine,,,,,,solid,,,8.2,11.64,6.99,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C2C=CNC3=N)[C@]([H])(O)[C@]1([H])O,,,,,0,,266.1015049,3,2,3,2,1,1
4068,04/06/2019 00:00,DB04547,Inhibitor Bea409,,,,,,solid,,,0.00121,3.95,5.8,[H][C@@](O)([C@@]([H])(O)[C@@]([H])(OCC1=CC=C(C=C1)C1=CSC=C1)C(O)=N[C@@]([H])(C(C)C)C(O)=NC)[C@@]([H])(OCC1=CC=C(C=C1)C1=CSC=C1)C(O)=N[C@@]([H])(C(C)C)C(O)=NC,,,,,0,,778.3070066,4,4,2,2,0,0
4069,04/06/2019 00:00,DB04548,4-Deoxy-D-Glucuronic Acid,,,,,,solid,,,472,3.37,-3.3,O[C@H]1C[C@H](O[C@@H](O)[C@@H]1O)C(O)=O,,,,,0,,178.047738,1,0,1,0,1,1
4070,04/06/2019 00:00,DB04549,"4-(Aminosulfonyl)-N-[(2,3,4-Trifluorophenyl)Methyl]-Benzamide",,,,,,solid,,,0.0127,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=C(F)C(F)=C(F)C=C1,,,,,0,,344.0442479,2,2,0,0,0,0
4071,04/06/2019 00:00,DB04551,"beta-D-fructofuranose 1,6-bisphosphate",,,,,,solid,,,16.1,0.89,-3.7,O[C@H]1[C@H](O)[C@@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O,,,,,0,,339.9960491,1,0,1,0,1,1
4072,04/06/2019 00:00,DB04552,Niflumic acid,Well absorbed following oral administration.,0.9,2.5 hours,,,solid,19 mg/L (at 25 Â°C),4.43,0.0883,1.88,5.51,OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1,0.9,0.9,2.5,2.5,0,,282.0616122,2,2,1,1,0,0
4073,04/06/2019 00:00,DB04553,2-Oxobutanoic Acid,,,,,,solid,,,79.2,3.19,-9.7,CCC(=O)C(O)=O,,,,,0,,102.0316941,0,0,0,0,0,0
4074,04/06/2019 00:00,DB04554,8-Bromoadenosine-5'-Diphosphate,,,,,,solid,,,2.76,1.77,4.07,[H][C@]1(COP(O)(=O)OP(O)(O)=O)O[C@@]([H])(N2C(Br)=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,504.939927,3,2,3,2,1,1
4075,04/06/2019 00:00,DB04555,Cytidine-5'-Diphosphate,,,,,,solid,,,10.1,1.77,-0.52,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,,,,,0,,403.0181816,2,1,2,1,1,1
4076,04/06/2019 00:00,DB04556,3-[(1s)-1-(Dimethylamino)Ethyl]Phenol,,,,,,solid,,,37.9,9.52,8.6,[H][C@@](C)(N(C)C)C1=CC(O)=CC=C1,,,,,0,,165.1153641,1,1,0,0,0,0
4077,04/06/2019 00:00,DB04557,Arachidonic Acid,,,,,,solid,,6.98,0.000151,4.82,,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,,,,,0,,304.2402303,0,0,0,0,0,0
4078,04/06/2019 00:00,DB04559,N-(Chlorophenyl)-N'-Hydroxyguanidine,,,,,,solid,,,0.635,14.81,8.3,ONC(=N)NC1=CC=C(Cl)C=C1,,,,,0,,185.0355896,1,1,0,0,0,0
4079,04/06/2019 00:00,DB04560,"4,7-Dioxosebacic Acid",,,,,,solid,,,2.94,3.97,-7.1,OC(=O)CCC(=O)CCC(=O)CCC(O)=O,,,,,0,,230.0790382,0,0,0,0,0,0
4080,04/06/2019 00:00,DB04561,"4-Acetamido-2,4-Didexoy-D-Glycero-Beta-D-Galacto-Octopyranosylphosphonic Acid",,,,,,solid,,,28.1,1.19,2.47,[H][C@@](O)(CO)[C@@]([H])(O)[C@]1([H])O[C@]([H])(C[C@]([H])(O)[C@@]1([H])N=C(C)O)P(O)(O)=O,,,,,0,,329.0875678,1,0,1,0,1,1
4081,04/06/2019 00:00,DB04562,Tricarballylic Acid,,,,,,solid,,,37.8,3.59,,OC(=O)CC(CC(O)=O)C(O)=O,,,,,0,,176.032088,0,0,0,0,0,0
4082,04/06/2019 00:00,DB04563,CRA_9678,,,,,,solid,,,0.0252,3.44,11.21,NC(=N)C1=CC2=C(NC(=C2)C2=C(O)C(Br)=CC(CC([O-])=O)=C2)C=C1,,,,,-1,,386.014577,3,3,1,1,0,0
4083,04/06/2019 00:00,DB04564,Gluconolactone,,,,,Irrigation,solid,5.9E+005 mg/L (at 25 Â°C),,586,11.62,-3,OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,178.047738,1,0,1,0,1,1
4084,04/06/2019 00:00,DB04565,4-(Acetylamino)-3-[(Hydroxyacetyl)Amino]Benzoic Acid,,,,,,solid,,,0.788,4.02,-3.4,CC(=O)NC1=CC=C(C=C1NC(=O)CO)C(O)=O,,,,,0,,252.0746215,1,1,0,0,0,0
4085,04/06/2019 00:00,DB04566,Inosinic Acid,,,,,,solid,,,3.05,1.32,0.51,O[C@@H]1[C@@H](COP(O)(O)=O)O[C@H]([C@@H]1O)N1C=NC2=C1N=CNC2=O,,,,,0,,348.0471,3,2,3,2,1,1
4086,04/06/2019 00:00,DB04567,Chromophore (Gly-Tyr-Gly),,,,,,solid,,,0.392,3.36,7.55,[H]\C(=C1\N=C(N(CC(O)=O)C1=O)[C@@]([H])(N)[C@@]([H])(C)O)C1=CC=C(O)C=C1,,,,,0,,319.1168206,2,1,1,0,0,1
4087,04/06/2019 00:00,DB04568,5-Aminoimidazole Ribonucleoside,,,,,,solid,,,30.7,12.45,7.91,[H][C@]1(CO)O[C@@]([H])(N2C=NC=C2N)[C@]([H])(O)[C@]1([H])O,,,,,0,,215.0906059,2,1,2,1,1,1
4088,04/06/2019 00:00,DB04569,Formic Acid Benzyl Ester,,,,,,solid,,,2.2,,-6.8,O=COCC1=CC=CC=C1,,,,,0,,136.0524295,1,1,0,0,0,0
4089,04/06/2019 00:00,DB04570,Latamoxef,Rapidly absorbed after oral administration.,0.4,1.6 hours,,,solid,,-0.58,0.751,2.81,-1.7,[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O,0.4,0.4,1.6,1.6,0,,520.1012472,4,2,3,1,1,2
4090,04/06/2019 00:00,DB04571,Trioxsalen,,,,5 mg,Oral,solid,,,0.0627,,-2.7,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1,,,,,0,5,228.0786442,3,3,2,2,0,0
4091,02/07/2019 00:00,DB04572,Thiotepa,,,1.5 to 4.1 hours,100 mg/1,Intracavitary; Intravenous; Intravesical,solid,1.9E+005 mg/L (at 25 Â°C),0.53,9.27,,-0.3,S=P(N1CC1)(N1CC1)N1CC1,,,,,0,,189.048955,3,0,3,0,3,3
4092,04/06/2019 00:00,DB04573,Estriol,,,,,,solid,,2.45,0.119,10.33,-3.2,[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,,,,,0,,288.1725446,4,1,0,0,0,0
4093,04/06/2019 00:00,DB04574,Estrone sulfate,"Estropipate is well absorbed through the skin and gastrointestinal tract. When applied for a local action, absorption is usually sufficient to cause systemic effects.",,,0.75 mg/1,Oral,solid,,,0.0059,-1.7,-7.5,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O,,,,,0,0.75,350.1187948,4,1,0,0,0,0
4094,04/06/2019 00:00,DB04575,Quinestrol,Absorbed following oral administration.,,,,,solid,,,0.00157,17.59,-1.7,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC1CCCC1)C=C3,,,,,0,,364.2402303,5,1,0,0,0,0
4095,04/06/2019 00:00,DB04576,Fleroxacin,Rapidly and well absorbed from the gastrointestinal tract after oral administration.,,,,,solid,,0.24,0.284,5.44,6.06,CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN(CCF)C2=C1F)C(O)=O,,,,,0,,369.1300261,3,2,2,1,1,1
4096,04/06/2019 00:00,DB04577,1-(1-phenylcyclopentyl)methylamine,,,,,,solid,,,0.06,,9.47,NCC1(CCCC1)C1=CC=CC=C1,,,,,0,,175.1360995,2,1,0,0,0,0
4097,04/06/2019 00:00,DB04578,"(S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide",,,,,,solid,,,0.052,15.25,8.81,[H][C@](N)(CC(=O)N1CC2=CC=CC=C2C[C@@]1([H])C(N)=O)CC1=CC=CC=C1F,,,,,0,,355.1696052,3,2,1,0,0,1
4098,04/06/2019 00:00,DB04579,"N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-",,,,,,solid,,,0.29,3.71,0.46,[H][C@](C)(O)[C@]([H])(N=C(O)[C@@]1([H])O[C@]1([H])C(=O)OCC)C(O)=N[C@]([H])(C(O)=O)[C@@]([H])(C)CC,,,,,0,,374.1689158,1,0,1,0,1,1
4099,04/06/2019 00:00,DB04580,1-Methyl-2-quinolone,,,,,,solid,1.43E+004 mg/L (at 25 Â°C),1.45,12.1,,-1.6,CN1C(=O)C=CC2=CC=CC=C12,,,,,0,,159.0684139,2,2,1,1,0,0
4100,04/06/2019 00:00,DB04581,1-benzylimidazole,,,,,,solid,,1.6,1.47,,6.75,C(N1C=CN=C1)C1=CC=CC=C1,,,,,0,,158.0843983,2,2,1,1,0,0
4101,04/06/2019 00:00,DB04582,IMAZAQUIN,,,,,,solid,,,0.0604,3.67,1.77,CC(C)[C@@]1(C)N=C(NC1=O)C1=NC2=CC=CC=C2C=C1C(O)=O,,,,,0,,311.1269914,3,2,2,1,0,1
4102,04/06/2019 00:00,DB04583,"5-Carbamoyl-1,1':4',1''-terphenyl-3-carboxylic acid",,,,,,solid,,,0.000915,3.81,-1.4,NC(=O)C1=CC(=CC(=C1)C1=CC=C(C=C1)C1=CC=CC=C1)C(O)=O,,,,,0,,317.1051933,3,3,0,0,0,0
4103,04/06/2019 00:00,DB04584,Phenyldehydroalanine,,,,,,solid,,,0.5,2.83,7.73,N\C(=C/C1=CC=CC=C1)C(O)=O,,,,,0,,163.0633285,1,1,0,0,0,0
4104,04/06/2019 00:00,DB04585,DEHYDRO-2(S)-AMINO-6-BORONOHEXANOIC ACID,,,,,,solid,,,1.17,1.84,9.52,N[C@@H](CC\C=C\[B-](O)(O)O)C(O)=O,,,,,-1,,190.0892265,0,0,0,0,0,0
4105,04/06/2019 00:00,DB04586,o-Bromophenol,,,,,,liquid,,2.35,7.6,8.16,-6.7,OC1=CC=CC=C1Br,,,,,0,,171.9523769,1,1,0,0,0,0
4106,04/06/2019 00:00,DB04587,2'-O-BUTYL-5-METHYLURIDINE,,,,,,solid,,,7.25,1.23,-3.7,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=C(C)C(O)=NC2=O)[C@]([H])(OCCCC)[C@]1([H])O,,,,,0,,394.1141169,2,1,2,1,1,1
4107,04/06/2019 00:00,DB04588,"N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE",,,,,,solid,,,0.0473,7.54,1.04,NS(=O)(=O)C1=CC=C(CNC(=O)C2=C(NN=C2)C2=CC(Cl)=C(O)C=C2O)C=C1,,,,,0,,422.0451683,3,3,1,1,0,0
4108,04/06/2019 00:00,DB04590,(2R)-({4-[AMINO(IMINO)METHYL]PHENYL}AMINO){5-ETHOXY-2-FLUORO-3-[(3R)-TETRAHYDROFURAN-3-YLOXY]PHENYL}ACETICACID,,,,,,solid,,,0.0296,3.78,12.52,CCOC1=CC([C@@H](NC2=CC=C(C=C2)C(N)=N)C(O)=O)=C(F)C(O[C@@H]2CCOC2)=C1,,,,,0,,417.1699991,3,2,1,0,1,1
4109,04/06/2019 00:00,DB04591,"N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE",,,,,,solid,,,0.103,14.35,7.06,[H][C@@]1(CCCCN1)C(F)(F)CNC1=NC=CC2=C1N=C(CC1=CC=CC=C1N1C=NC=N1)O2,,,,,0,,439.1932148,5,4,4,3,1,1
4110,04/06/2019 00:00,DB04592,3-Bromo-3-buten-1-ol,,,,,,solid,,,29.4,15.9,-2.4,OCCC(Br)=C,,,,,0,,149.9680269,0,0,0,0,0,0
4111,04/06/2019 00:00,DB04593,3-({1-[3-CARBAMIMIDOYL-1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-PROPYLCARBAMOYL]-2-METHYL-BUTYLSULFAMOYL}-METHYL)-BENZOIC ACID,,,,,,solid,,,0.0418,4.03,12.93,CC[C@@H](C)[C@@H](NS(=O)(=O)CC1=CC(=CC=C1)C(O)=O)C(=O)N[C@@H](CCC(N)=N)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,587.2526029,2,2,0,0,0,0
4112,04/06/2019 00:00,DB04594,3-hydroxyglutaric acid,,,,,,solid,,,172,3.52,-2.9,OC(CC(O)=O)CC(O)=O,,,,,0,,148.0371734,0,0,0,0,0,0
4113,04/06/2019 00:00,DB04595,"(E)-(4S,6S)-8-METHYL-6-((S)-3-METHYL-2-{(S)-2-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID BENZYL ESTER",,,,,,solid,,,0.0393,11.71,-0.54,CC(C)C[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)C1=NOC(C)=C1)C(=O)N[C@H](\C=C\C(=O)OCC1=CC=CC=C1)C[C@@H]1CCNC1=O,,,,,0,,680.3533625,3,2,2,1,1,1
4114,04/06/2019 00:00,DB04596,"4-O-{4,6-O-[(1S)-1-Carboxyethylidene]-Î²-D-mannopyranosyl}-D-glucopyranuronic acid",,,,,,solid,,,94.1,2.63,-3.7,[H][C@@]12CO[C@@](C)(O[C@@]1([H])[C@H](O)[C@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1C(O)=O)O2)C(O)=O,,,,,0,,426.1009554,3,0,3,0,3,3
4115,04/06/2019 00:00,DB04597,"[4,6-O-(1-CARBOXYETHYLIDENE)-BETA-D-MANNOSE]",,,,,,solid,,,476,2.86,-3.7,C[C@@]1(OC[C@H]2O[C@@H](O)[C@@H](O)[C@@H](O)[C@@H]2O1)C(O)=O,,,,,0,,250.0688674,2,0,2,0,2,2
4116,04/06/2019 00:00,DB04598,2-AMINO-4-CHLORO-3-HYDROXYBENZOIC ACID,,,,,,solid,,,1.86,4.56,1.53,NC1=C(C=CC(Cl)=C1O)C(O)=O,,,,,0,,187.0036207,1,1,0,0,0,0
4117,04/06/2019 00:00,DB04599,Aniracetam,,,1-2.5 hours,,,solid,,,2.47,,-4.8,COC1=CC=C(C=C1)C(=O)N1CCCC1=O,,,1,2.5,0,,219.0895433,2,1,1,0,1,1
4118,04/06/2019 00:00,DB04600,"4-[(3-BROMO-4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE",,,,,,solid,,,0.144,10.2,1.8,NS(=O)(=O)OC1=CC=C(CN(N2C=NN=C2)C2=CC=C(C=C2)C#N)C=C1Br,,,,,0,,447.9953214,3,3,1,1,0,0
4119,04/06/2019 00:00,DB04601,"4-[(4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE",,,,,,solid,,,0.239,10.79,1.81,NS(=O)(=O)OC1=CC=C(CN(N2C=NN=C2)C2=CC=C(C=C2)C#N)C=C1,,,,,0,,370.0848093,3,3,1,1,0,0
4120,04/06/2019 00:00,DB04602,PUROMYCIN AMINONUCLEOSIDE-5'-MONOPHOSPHATE,,,,,,solid,,,2.83,1.26,9.19,CN(C)C1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](N)[C@H]1O,,,,,0,,374.110369,3,2,3,2,1,1
4121,04/06/2019 00:00,DB04603,2'-DEOXY-5-FORMYLCYTIDINE-5'-MONOPHOSPHATE,,,,,,solid,,,2.17,1.06,1.72,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C(C=O)C(=N)N=C1O,,,,,0,,335.051851,2,1,2,1,1,1
4122,04/06/2019 00:00,DB04604,5-iodotubercidin,,,,,,solid,,,3.61,12.46,6.56,[H][C@]1(CO)O[C@@]([H])(N2C=C(I)C3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,391.9981529,3,2,3,2,1,1
4123,04/06/2019 00:00,DB04605,5-Aminoisoquinoline,,,,,,solid,,,3.03,,5.48,NC1=CC=CC2=C1C=CN=C2,,,,,0,,144.0687483,2,2,1,1,0,0
4124,04/06/2019 00:00,DB04606,2-[2-ETHANESULFONYLAMINO-3-(5-PROPOXY-1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE),,,,,,solid,,,0.0132,9.67,11.38,CCCOC1=CC2=C(NC=C2C[C@@H](NS(=O)(=O)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC2=CC=C(C=C2)C(N)=N)C=C1,,,,,0,,613.268253,3,3,1,1,0,0
4125,04/06/2019 00:00,DB04607,"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE",,,,,,solid,,,0.000996,10.75,5.15,NS(=O)(=O)C1=CC=C(NC2=CN3C=C(C=CC3=N2)C(=O)C2=C(Cl)C=CC=C2Cl)C=C1,,,,,0,,460.0163667,4,4,2,2,0,0
4126,04/06/2019 00:00,DB04608,"9-HYDROXY-4-PHENYL-6H-PYRROLO[3,4-C]CARBAZOLE-1,3-DIONE",,,,,,solid,,,0.00468,8.13,-5.6,OC1=CC2=C(NC3=CC(=C4C(=O)NC(=O)C4=C23)C2=CC=CC=C2)C=C1,,,,,0,,328.0847922,5,4,2,1,0,1
4127,04/06/2019 00:00,DB04609,INHIBITOR Q8467 OF DUPONT MERCK,,,,,,solid,,,0.00281,9.46,0.014,O[C@@H]1[C@@H](O)[C@@H](CC2=CC=CC=C2)N(CC2=CC(=CC=C2)C(=O)NC2=NC=CS2)C(=O)N(CC2CC2)[C@@H]1CC1=CC=CC=C1,,,,,0,,596.2457266,6,4,2,1,1,1
4128,04/06/2019 00:00,DB04610,"7,8-dihydro-6-hydroxymethyl-7-methyl-7-[2-phenylethyl]-pterin",,,,,,solid,,,0.176,10.92,3.65,C[C@@]1(CCC2=CC=CC=C2)NC2=C(N=C1CO)C(=O)NC(N)=N2,,,,,0,,313.1538748,3,2,2,1,0,1
4129,04/06/2019 00:00,DB04612,"N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE",,,,,,solid,,,0.00741,12.39,8.6,CN[C@@H](C)C(=O)N[C@H](C(=O)N1C[C@H](C[C@H]1C(=O)N[C@@H]1CCCC2=CC=CC=C12)OC1=CC=CC=C1)C(C)(C)C,,,,,0,,534.3206058,4,2,1,0,1,1
4130,04/06/2019 00:00,DB04613,"(E)-(4S,6S)-6-((S)-2-{(S)-2-[(FURAN-2-CARBONYL)-AMINO]-3-METHYL-BUTYRYLAMINO}-3-METHYL-BUTYRYLAMINO)-8-METHYL-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID ETHYL ESTER",,,,,,solid,,,0.0496,11.89,-0.51,CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)C1=COC=C1,,,,,0,,631.3581135,2,1,2,1,1,1
4131,04/06/2019 00:00,DB04614,(R)-tacrine(10)-hupyridone,,,,,,solid,,,0.000751,11.33,9.94,O=C1NC2=C(C=C1)[C@@H](CCC2)NCCCCCCCCCCNC1=C2CCCCC2=NC2=CC=CC=C12,,,,,0,,500.351512,5,3,2,2,0,0
4132,04/06/2019 00:00,DB04615,(S)-tacrine(10)-hupyridone,,,,,,solid,,,0.000751,11.33,9.94,O=C1NC2=C(C=C1)[C@H](CCC2)NCCCCCCCCCCNC1=C2CCCCC2=NC2=CC=CC=C12,,,,,0,,500.351512,5,3,2,2,0,0
4133,04/06/2019 00:00,DB04616,TACRINE(8)-4-AMINOQUINOLINE,,,,,,solid,,,0.000597,,8.97,C(CCCCNC1=C2CCCCC2=NC2=CC=CC=C12)CCCNC1=CC=NC2=CC=CC=C12,,,,,0,,452.2939972,5,4,2,2,0,0
4134,04/06/2019 00:00,DB04617,"(9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM",,,,,,solid,,,1.95E-06,,10.23,[NH3+]CCCCCCCCNC1=C2CCCCC2=[NH+]C2=CC=CC=C12,,,,,2,,327.2663509,3,2,1,1,0,0
4135,04/06/2019 00:00,DB04618,"4,6-DIDEOXY-4-{[4-[(4-O-HEXOPYRANOSYLHEXOPYRANOSYL)OXY]-5,6-DIHYDROXY-3-(HYDROXYMETHYL)CYCLOHEX-2-EN-1-YL]AMINO}HEXOPYRANOSYL-(1->4)HEXOPYRANOSYL-(1->4)HEXOPYRANOSE",,,,,,solid,,,105,11.18,7.33,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O,,,,,0,,969.3536604,6,0,5,0,5,5
4136,04/06/2019 00:00,DB04619,ACETOPHENONE,,,,,,solid,,,1.36,16.1,-7.4,CC(=O)C1=CC=CC=C1,,,,,0,,120.0575149,1,1,0,0,0,0
4137,04/06/2019 00:00,DB04620,Cycloleucine,,,,,,solid,5E+004 mg/L (at 25 Â°C),-2.28,171,2.48,9.83,NC1(CCCC1)C(O)=O,,,,,0,,129.0789786,1,0,0,0,0,0
4138,04/06/2019 00:00,DB04622,N-ACETYLHISTAMINE,,,,,,solid,,,2.83,12.94,6.75,CC(=O)NCCC1=CN=CN1,,,,,0,,153.090212,1,1,1,1,0,0
4139,04/06/2019 00:00,DB04623,"2-ETHOXYETHYL (2S,3S)-4-((S)-2-BENZYL-3-OXO-4-((3AR,8R,8AS)-2-OXO-3,3A,8,8A-TETRAHYDRO-2H-INDENO[1,2-D]OXAZOL-8-YL)-2,3-DIHYDRO-1H-PYRROL-2-YL)-3-HYDROXY-1-PHENYLBUTAN-2-YLCARBAMATE",,,,,,solid,,,0.00245,12.23,1.62,CCOCCOC(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)C[C@]1(CC2=CC=CC=C2)NC=C([C@@H]2[C@@H]3OC(=O)N[C@@H]3C3=CC=CC=C23)C1=O,,,,,0,,625.2788006,6,3,2,0,1,2
4140,04/06/2019 00:00,DB04624,DERIVATIVE OF AKLANONIC ACID METHYL ESTER (AAME),,,,,,solid,,,0.159,9.21,-2.7,[H][C@](O)(CC)C[C@@]([H])(O)C1=C(O)C2=C(C=C1CC(=O)OC)C(=O)C1=CC=CC(O)=C1C2=O,,,,,0,,414.1314677,3,2,0,0,0,0
4141,04/06/2019 00:00,DB04626,Apramycin,,,,,,solid,,,53.3,12.29,9.73,CN[C@H]1[C@@H](O)[C@H]2O[C@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O,,,,,0,,539.2802571,4,0,3,0,3,3
4142,04/06/2019 00:00,DB04627,Cyclouridine,,,,,,solid,,,56.2,12.98,-3,OC[C@H]1O[C@@H]2[C@@H](OC3=NC(=O)C=CN23)[C@@H]1O,,,,,0,,226.0589714,3,1,3,1,1,2
4143,04/06/2019 00:00,DB04628,Allosamidin,,,,,,solid,,,39.4,11.81,6.81,CN(C)C1=N[C@@H]2[C@@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@H]4NC(C)=O)[C@@H](O)[C@H]3NC(C)=O)[C@@H](CO)[C@@H]2O1,,,,,0,,622.269752,4,0,3,0,2,3
4144,04/06/2019 00:00,DB04629,Aplyronine A,,,,,,solid,,,0.0016,14.33,6.99,COC[C@H](N(C)C)C(=O)O[C@@H]1C\C=C\C=C\C(=O)O[C@@H](C\C=C\[C@H](OC)C[C@H](C)C\C=C(C)\[C@@H](OC)CC[C@@H](C)[C@@H](O)[C@@H]1C)[C@@H](C)[C@@H](O)[C@@H](C)CC[C@@H](OC(=O)[C@H](C)N(C)C)[C@H](C)[C@H](OC(C)=O)[C@H](C)\C=C\N(C)C=O,,,,,0,,1075.728355,1,0,1,0,0,1
4145,04/06/2019 00:00,DB04630,Aldosterone,,,,,,solid,51.2 mg/L (at 37 Â°C),1.08,0.148,13.82,-2.9,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@H](O)C[C@]12C=O)C(=O)CO,,,,,0,,360.193674,4,0,0,0,0,0
4146,04/06/2019 00:00,DB04631,Atpenin A5,,,,,,solid,,,0.0303,6.08,-4.7,[H][C@](C)(C[C@]([H])(C)[C@@]([H])(Cl)CCl)C(=O)C1=C(O)C(OC)=C(NC1=O)OC,,,,,0,,365.0796781,1,1,1,1,0,0
4147,04/06/2019 00:00,DB04632,4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE,,,,,,solid,,,0.028,8.1,11,OC1=C(CNC2CCN(CC2)S(=O)(=O)NC2=CC(OC3=CC=C(F)C=C3)=CC=C2)C=CC=C1,,,,,0,,471.1628055,4,3,1,0,1,1
4148,04/06/2019 00:00,DB04633,"N-ethyl-N-[3-(propylamino)propyl]propane-1,3-diamine",,,,,,solid,,,0.881,,11.1,CCCNCCCNCCCNCC,,,,,0,,201.2204979,0,0,0,0,0,0
4149,04/06/2019 00:00,DB04634,N-BENZYLOXYCARBONYL-L-SERINE-BETALACTONE,,,,,,solid,,,1.28,3.75,,[H][C@@](C)(NC(=O)OCC1=CC=CC=C1)C(O)=O,,,,,0,,223.0844579,1,1,0,0,0,0
4150,04/06/2019 00:00,DB04636,Glutamine t-butyl ester,,,,,,solid,,,14.4,16.46,7.18,CC(C)(C)OC(=O)[C@@H](N)CCC(N)=O,,,,,0,,202.1317424,0,0,0,0,0,0
4151,04/06/2019 00:00,DB04637,6-Bromo-1-hexanol,,,,,,solid,,,1.14,16.84,-2,OCCCCCCBr,,,,,0,,180.0149771,0,0,0,0,0,0
4152,04/06/2019 00:00,DB04638,"2,5-DI-(TERT-BUTYL)-1,4,BENZOHYDROQUINONE",,,,,,solid,,,0.25,10.36,-5.5,CC(C)(C)C1=CC(O)=C(C=C1O)C(C)(C)C,,,,,0,,222.1619799,1,1,0,0,0,0
4153,04/06/2019 00:00,DB04639,Biphenylalanine,,,,,,solid,,,0.0587,2.49,9.44,[H][C@](N)(CC1=CC=C(C=C1)C1=CC=CC=C1)C(O)=O,,,,,0,,241.1102787,2,2,0,0,0,0
4154,04/06/2019 00:00,DB04640,"Naphthalene-2,6-disulfonic acid",,,,,,solid,,,0.341,-2.8,,OS(=O)(=O)C1=CC2=CC=C(C=C2C=C1)S(O)(=O)=O,,,,,0,,287.97623,2,2,0,0,0,0
4155,04/06/2019 00:00,DB04641,"3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID",,,,,,solid,,,0.49,2.69,-5.5,OC(=O)C1=C(O)C=C2C=CC(O)=CC2=C1,,,,,0,,204.0422587,2,2,0,0,0,0
4156,04/06/2019 00:00,DB04642,"7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID",,,,,,solid,,,0.000162,3.94,-4.9,OC(=O)CCCCCCOC1=C(Cl)C=C(NC(=O)NC(=O)C2=CC=CC=C2Cl)C=C1Cl,,,,,0,,486.0516048,2,2,0,0,0,0
4157,04/06/2019 00:00,DB04643,"4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID",,,,,,solid,,,0.000714,3.66,-4.8,OC(=O)CCCOC1=CC=C(NC(=O)NC(=O)C2=CC=C(Cl)C=C2Cl)C(Cl)=C1,,,,,0,,444.0046546,2,2,0,0,0,0
4158,04/06/2019 00:00,DB04644,"4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID",,,,,,solid,,,0.00192,4.28,-4.8,CC1=C(C)C(OCCCC(O)=O)=CC=C1NC(=O)NC(=O)C1=CC=C(Cl)C=C1Cl,,,,,0,,438.0749271,2,2,0,0,0,0
4159,04/06/2019 00:00,DB04645,"5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID",,,,,,solid,,,0.000836,4.19,-4.8,CC1=C(NC(=O)NC(=O)C2=CC=C(Cl)C=C2Cl)C=CC=C1OCCCCC(O)=O,,,,,0,,438.0749271,2,2,0,0,0,0
4160,04/06/2019 00:00,DB04646,Dibromothymoquinone,,,,,,solid,,,0.132,,,CC(C)C1=C(Br)C(=O)C(C)=C(Br)C1=O,,,,,0,,319.9047538,1,0,0,0,0,0
4161,04/06/2019 00:00,DB04647,BOC-GAMMA-D-GLU-L-LYS(CBZ)-D-BOROALA,,,,,,solid,,,0.0237,3.72,-0.81,C[C@@H](NC(=O)[C@H](CCCCNC(=O)OCC1=CC=CC=C1)NC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(O)=O)B(O)O,,,,,0,,580.2915739,1,1,0,0,0,0
4162,04/06/2019 00:00,DB04648,S-propylamine-L-cysteine,,,,,,solid,,,31.1,15.1,10.25,NCCCSC[C@H](N)CO,,,,,0,,164.0983341,0,0,0,0,0,0
4163,04/06/2019 00:00,DB04649,TETRAHEDRAL INTERMEDIATE OF BLASTICIDIN S,,,,,,solid,,,0.659,3.33,12.25,CN(CC[C@H](N)CC(=O)N[C@H]1C=C[C@@H](O[C@@H]1C(O)=O)N1C=C[C@@](N)(O)NC1=O)C(N)=N,,,,,0,,440.2131806,2,0,2,0,0,2
4164,04/06/2019 00:00,DB04650,"5-[(3AS,4R,6AR)-2-OXOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-4-YL]PENTANOIC ACID",,,,,,solid,,,1.22,4.4,-1.9,[H][C@]12CS[C@]([H])(CCCCC(O)=O)[C@@]1([H])NC(=O)N2,,,,,0,,244.0881634,2,0,2,0,2,2
4165,04/06/2019 00:00,DB04651,BIOTINOL-5-AMP,,,,,,solid,,,1.9,1.92,4.99,NC1=C2N=CN([C@@H]3O[C@H](CO[P@@](O)(=O)OCCCCC[C@@H]4SC[C@@H]5NC(=O)N[C@H]45)[C@@H](O)[C@H]3O)C2=NC=N1,,,,,0,,559.1614186,5,2,5,2,3,3
4166,04/06/2019 00:00,DB04652,Corticosterone,,,,,,solid,,,0.046,13.86,-0.26,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]12C)C(=O)CO,,,,,0,,346.2144094,4,0,0,0,0,0
4167,04/06/2019 00:00,DB04653,CBZ-LEU-LEU-TYR-CH2F,,,,,,solid,,,0.00358,5.17,1.59,[H][C@@](CC(C)C)(N=C(O)OCC1=CC=CC=C1)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(=O)CF,,,,,0,,557.2901142,2,2,0,0,0,0
4168,04/06/2019 00:00,DB04654,4-PIPERIDIN-4-YLBUTANAL,,,,,,solid,,,1.98,15.52,10.26,O=CCCCC1CCNCC1,,,,,0,,155.1310142,1,0,1,0,1,1
4169,04/06/2019 00:00,DB04655,Metoprine,,,,,,solid,,,0.0758,17.21,7.93,CC1=C(C(N)=NC(N)=N1)C1=CC(Cl)=C(Cl)C=C1,,,,,0,,268.0282517,2,2,1,1,0,0
4170,04/06/2019 00:00,DB04656,"1,3,4-TRIHYDROXY-5-(3-PHENOXYPROPYL)-CYCLOHEXANE-1-CARBOXYLIC A CID",,,,,,solid,,,4.11,3.51,-3.2,[H][C@@]1(O)C[C@@](O)(C[C@]([H])(CCCOC2=CC=CC=C2)[C@@]1([H])O)C(O)=O,,,,,0,,310.1416384,2,1,0,0,0,0
4171,04/06/2019 00:00,DB04657,Carboxin,,,,,,solid,147 mg/L (at 20 Â°C),2.14,0.536,13.24,-2.1,CC1=C(SCCO1)C(=O)NC1=CC=CC=C1,,,,,0,,235.0666997,2,1,1,0,0,1
4172,04/06/2019 00:00,DB04658,"(1S,2R,3S,4R,5S)-8-AZABICYCLO[3.2.1]OCTANE-1,2,3,4-TETROL",,,,,,solid,,,733,12.13,8.57,O[C@H]1[C@H]2CC[C@](O)(N2)[C@@H](O)[C@@H]1O,,,,,0,,175.0844579,2,0,2,0,2,2
4173,04/06/2019 00:00,DB04659,"(1S,2S,3R,4S,5S)-2,3,4-TRIHYDROXY-5-(HYDROXYMETHYL)CYCLOHEXYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE",,,,,,solid,,,1.9,-3.4,0.072,OC[C@H]1C[C@@H](S\C(=N/OS(O)(=O)=O)CC2=CC=CC=C2)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,407.0708586,2,1,0,0,0,0
4174,04/06/2019 00:00,DB04660,Choline alfoscerate,,,,,,solid,,,8.96,1.86,-3,[H][C@@](O)(CO)COP([O-])(=O)OCC[N+](C)(C)C,,,,,0,,257.102824,0,0,0,0,0,0
4175,04/06/2019 00:00,DB04661,cis-tetracosenoyl sulfatide,,,,,,solid,,,0.000272,-1.9,-0.99,CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](OS(O)(=O)=O)[C@H]1O)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC,,,,,0,,889.6312837,1,0,1,0,1,1
4176,04/06/2019 00:00,DB04662,OLOMOUCINE II,,,,,,solid,,,0.268,9.23,5.55,[H][C@@](CC)(CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2O)=N1,,,,,0,,370.2117241,3,3,2,2,0,0
4177,04/06/2019 00:00,DB04663,"2-KETO-6-PHOSPHATE-D-GLUCONIC ACID, ALPHA-FURANOSE FORM",,,,,,solid,,,26.4,1.21,-3.7,O[C@@H]1[C@@H](COP(O)(O)=O)O[C@](O)([C@@H]1O)C(O)=O,,,,,0,,274.0089832,1,0,1,0,1,1
4178,04/06/2019 00:00,DB04664,Cyclohexyl-pentyl-maltoside,,,,,,solid,,,4.92,11.94,-3,OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](OCCCCCC3CCCCC3)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,494.2727122,3,0,2,0,2,2
4179,04/06/2019 00:00,DB04665,Coumarin,,,,,,solid,,,1,,-6.9,O=C1OC2=CC=CC=C2C=C1,,,,,0,,146.0367794,2,2,1,1,0,0
4180,04/06/2019 00:00,DB04666,CHROMOPHORE (LYS-TYR-GLY),,,,,,solid,,,0.228,3.4,10.25,[H]\C(=C1\N=C(N(CC(O)=O)C1=O)[C@@]([H])(N)CCCCN)C1=CC=C(O)C=C1,,,,,0,,346.1641052,2,1,1,0,0,1
4181,04/06/2019 00:00,DB04667,CHROMOPHORE (HIS-TYR-GLY),,,,,,solid,,,0.797,3.56,7.93,[H][C@](N)(CC1=CN=CN1)C1=NC(C=C2C=CC(=O)C=C2)=C(O)N1CC([O-])=O,,,,,-1,,354.1207776,3,2,2,2,0,0
4182,04/06/2019 00:00,DB04668,CHROMOPHORE (GLU-TYR-GLY),,,,,,solid,,,0.0952,3.04,3.6,[H]N=C(CCC(O)=O)C1=N\C(=C(/[H])C2=CC=C(O)C=C2)C(=O)N1CC(O)=O,,,,,0,,345.0960852,2,1,1,0,0,1
4183,04/06/2019 00:00,DB04669,TRIAZOLOPYRIMIDINE,,,,,,solid,,,0.00529,8.77,5.02,BrC1=CC=CC(=C1)C1=NC2=[N+](NC=N2)C(NCC2=CC=NC=C2)=C1,,,,,1,,381.045783,4,4,3,3,0,0
4184,04/06/2019 00:00,DB04671,L-CYSTEIN-S-1-(IMINOMETHYL)-L-ORNITHINE,,,,,,solid,,,0.242,1.86,10.48,[H][C@](N)(CSC(=N)NCCC[C@]([H])([NH3+])C(O)=O)C(O)=O,,,,,1,,279.1121525,0,0,0,0,0,0
4185,04/06/2019 00:00,DB04672,"Cyclic 3',5'-thymidine monophosphate",,,,,,solid,,,4.64,1.24,-4.2,[H][C@]1(COP(O)(O)=O)O[C@]([H])(C=C1)N1C=C(C)C(=O)NC1=O,,,,,0,,304.0460374,2,1,2,1,0,1
4186,04/06/2019 00:00,DB04673,4-[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE,,,,,,solid,,,0.0203,9.63,4.34,[H][C@@]1(CC(C)C)CN(CCN1C(=O)C1=NC=C(C=N1)C1=CC=NC=C1)S(=O)(=O)C1=CC2=CC(Cl)=CC=C2N1,,,,,0,,538.1553874,5,4,4,3,1,1
4187,04/06/2019 00:00,DB04674,"2-HYDROXY-3,5-DIIODOBENZOIC ACID",,,,,,solid,,,0.155,2.51,-7.1,OC(=O)C1=C(O)C(I)=CC(I)=C1,,,,,0,,389.82499,1,1,0,0,0,0
4188,04/06/2019 00:00,DB04676,Dansyllysine,,,,,,solid,,,0.0782,1.54,9.38,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCC[C@H](N)C(O)=O,,,,,0,,379.1565773,2,2,0,0,0,0
4189,04/06/2019 00:00,DB04677,N-METHYL-N-[(1R)-1-METHYL-2-PHENYLETHYL]PROP-2-EN-1-AMINE,,,,,,solid,,,0.13,,9.18,[H][C@@](C)(CC1=CC=CC=C1)N(C)CC=C,,,,,0,,189.1517496,1,1,0,0,0,0
4190,04/06/2019 00:00,DB04678,H TYPE II TRISACCHARIDE,,,,,,solid,,,186,11.44,-3.5,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@H]2[C@H](O)[C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)[C@@H](O)[C@H](O)[C@@H]1O,,,,,0,,529.2006694,3,0,3,0,3,3
4191,04/06/2019 00:00,DB04679,H TYPE I TRISACCHARIDE,,,,,,solid,,,217,7.13,-3.6,[H][C@@]1(C)O[C@@]([H])(O[C@@]2([H])[C@]([H])(O[C@@]3([H])[C@]([H])(O)[C@@]([H])(CO)O[C@@]([H])(O)[C@]3([H])N=C(C)O)O[C@]([H])(CO)[C@]([H])(O)[C@]2([H])O)[C@@]([H])(O)[C@]([H])(O)[C@]1([H])O,,,,,0,,529.2006694,3,0,3,0,3,3
4192,04/06/2019 00:00,DB04680,GALACTOSE GREASE,,,,,,solid,,,6.89,12.21,-3,[H][C@]1(O)[C@@]([H])(O)[C@@]([H])(CO)O[C@@]([H])(OCCCCCCCCC(=O)OC)[C@]1([H])O,,,,,0,,350.1940679,1,0,1,0,1,1
4193,04/06/2019 00:00,DB04681,BETA-METHYLLACTOSIDE,,,,,,solid,,,569,11.94,-3,CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O,,,,,0,,356.1318616,2,0,2,0,2,2
4194,04/06/2019 00:00,DB04682,Octylphenoxy polyethoxyethanol,,,,,,solid,,,0.000553,15.12,-2.7,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1,,,,,0,,1526.953508,1,1,0,0,0,0
4195,04/06/2019 00:00,DB04683,"(2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E)-OCTADEC-9-ENOATE",,,,,,solid,,,0.000105,1.89,-3,CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OC[C@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCC,,,,,0,,746.5097852,0,0,0,0,0,0
4196,04/06/2019 00:00,DB04684,BIS(HEXAMETHYLENE)TRIAMINE,,,,,,solid,,,0.21,,10.95,NCCCCCCNCCCCCCN,,,,,0,,215.2361479,0,0,0,0,0,0
4197,04/06/2019 00:00,DB04685,"1-{(2S,5S)-4-FLUORO-5-[(TRITYLOXY)METHYL]TETRAHYDROFURAN-2-YL}PYRIMIDINE-2,4(1H,3H)-DIONE",,,,,,solid,,,0.00117,9.46,-4,[H][C@]1(F)C[C@@]([H])(O[C@]1([H])COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)N1C=CC(=O)NC1=O,,,,,0,,472.1798355,5,4,2,1,1,1
4198,04/06/2019 00:00,DB04686,CHROMOPHORE (ASP-TYR-GLY),,,,,,solid,,,0.254,2.91,8.14,[H]\C(=C1\N=C(N(CC(O)=O)C1=O)[C@@]([H])(N)CC(O)=O)C1=CC=C(O)C=C1,,,,,0,,333.0960852,2,1,1,0,0,1
4199,04/06/2019 00:00,DB04687,DIMETHYL THIOPHOSPHATE,,,,,,solid,,,9.93,2.86,,COP(O)(=S)OC,,,,,0,,141.9853517,0,0,0,0,0,0
4200,04/06/2019 00:00,DB04688,Methylecgonine,,,,,,solid,,,587,14.6,9.04,[H][C@@]12CC[C@@]([H])(N1C)[C@@]([H])(C(=O)OC)[C@@]([H])(O)C2,,,,,0,,199.1208434,2,0,2,0,2,2
4201,04/06/2019 00:00,DB04689,2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID,,,,,,solid,,,4.69E-05,3.96,-4.5,CCCC1=C(OCCCOC2=CC3=C(C=C2)N(CC(O)=O)C=C3)C=CC2=C1C=CC(=C2)C(=O)C1=CC=CC=C1,,,,,0,,521.2202231,5,5,1,1,0,0
4202,04/06/2019 00:00,DB04690,Camptothecin,,,,,,solid,,1.74,0.511,11.71,3.07,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O,,,,,0,,348.111007,5,3,4,2,0,2
4203,04/06/2019 00:00,DB04691,2'-O-[1-ETHYL-1H-IMIDAZOL)] THYMIDINE-5'-MONOPHOSPHATE,,,,,,solid,,,1.83,1.23,6.84,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=C(C)C(O)=NC2=O)[C@]([H])(OCCN2C=CN=C2)[C@]1([H])O,,,,,0,,432.1046149,3,2,3,2,1,1
4204,04/06/2019 00:00,DB04692,Ethyl (2E)-4-({(2S)-2-[(N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-valyl)amino]-2-phenylacetyl}amino)-5-[(3S)-2-oxo-3-pyrrolidinyl]-2-pentenoate,,,,,,solid,,,0.00719,12,-1.3,[H]N([C@@H](C(C)C)C(=O)N([H])[C@H](C(=O)N([H])C(C[C@@H]1CCN([H])C1=O)\C=C\C(=O)OCC)C1=CC=CC=C1)C(=O)OC(C)(C)C,,,,,0,,558.3053497,2,1,1,0,1,1
4205,04/06/2019 00:00,DB04693,"(13S)-13-METHYLDODECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE-3,17(2H,4H)-DIONE",,,,,,solid,,,0.00879,19.96,-7.1,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@H]34)[C@@H]1CCC2=O,,,,,0,,274.1932801,4,0,0,0,0,0
4206,04/06/2019 00:00,DB04694,"2,6-anhydro-3-deoxy-3-fluoronononic acid",,,,,,solid,,,207,3,-3,[H][C@]1(O[C@](O)(C(O)=O)[C@]([H])(F)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CO,,,,,0,,286.0700103,1,0,1,0,1,1
4207,04/06/2019 00:00,DB04695,Farnesyl thiopyrophosphate,,,,,,solid,,,0.138,2.03,,[H]\C(CC\C(C)=C(/[H])CSP(O)(=O)OP(O)(O)=O)=C(\C)CCC=C(C)C,,,,,0,,398.1081829,0,0,0,0,0,0
4208,04/06/2019 00:00,DB04696,"4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN",,,,,,solid,,,0.000323,7.78,-6.7,OC1=C(Br)C=C(C=C1)C1(OC(=O)C2=C3C(C=CC=C13)=C(Cl)C=C2)C1=CC(Br)=C(O)C=C1,,,,,0,,557.8869108,5,4,1,0,0,1
4209,04/06/2019 00:00,DB04697,TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE,,,,,,solid,,,0.0147,9.5,11.79,NC(N)=NCCCC[C@H](NC(=O)[C@@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H]1CCN1C(=O)[C@@H](CC1CCCCC1)NC(=O)[C@@H]1CC[C@H](CN=C(N)N)CC1)C(N)=O,,,,,0,,767.4806287,4,1,1,0,1,1
4210,04/06/2019 00:00,DB04698,"N-(1,4-DIHYDRO-5H-TETRAZOL-5-YLIDENE)-9-OXO-9H-XANTHENE-2-SULFONAMIDE",,,,,,solid,,,0.112,6.37,-1.9,O=C1C2=CC=CC=C2OC2=C1C=C(C=C2)S(=O)(=O)N=C1NN=NN1,,,,,0,,343.0375248,4,4,2,2,0,0
4211,04/06/2019 00:00,DB04699,gamma-butyrolactone,,,,,,solid,,,238,,-7,O=C1CCCO1,,,,,0,,86.03677943,1,0,1,0,1,1
4212,04/06/2019 00:00,DB04700,GLUTATHIONE SULFINATE,,,,,,solid,,,16.3,-0.22,9.31,N[C@@H](CCC(=O)N[C@@H](C[S@](O)=O)C(=O)NCC(O)=O)C(O)=O,,,,,0,,339.0736355,0,0,0,0,0,0
4213,04/06/2019 00:00,DB04701,S-METHYL-GLUTATHIONE,,,,,,solid,,,2.61,1.82,9.31,CSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O,,,,,0,,321.0994563,0,0,0,0,0,0
4214,04/06/2019 00:00,DB04702,"S-[(2E)-3,7-DIMETHYLOCTA-2,6-DIENYL] TRIHYDROGENTHIODIPHOSPHATE",,,,,,solid,,,1.4,2.03,,[H]\C(CSP(O)(=O)OP(O)(O)=O)=C(\C)CCC=C(C)C,,,,,0,,330.0455826,0,0,0,0,0,0
4215,04/06/2019 00:00,DB04703,Hesperidin,,,,,Oral,solid,,,2.69,9.51,-3.6,COC1=CC=C(C=C1O)[C@@H]1CC(=O)C2=C(O1)C=C(O[C@@H]1O[C@H](CO[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]1O)C=C2O,,,,,0,,610.1897704,5,2,3,0,2,3
4216,04/06/2019 00:00,DB04704,20-hydroxycholesterol,,,,,,solid,,,0.000571,18.2,-0.26,CC(C)CCC[C@@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,,,,,0,,402.3497807,4,0,0,0,0,0
4217,04/06/2019 00:00,DB04705,"(3BETA)-CHOLEST-5-ENE-3,25-DIOL",,,,,,solid,,,0.000244,18.2,-1,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,,,,,0,,402.3497807,4,0,0,0,0,0
4218,04/06/2019 00:00,DB04706,"(3BETA,7BETA)-CHOLEST-5-ENE-3,7-DIOL",,,,,,solid,,,0.000476,18.2,-0.83,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,,,,,0,,402.3497807,4,0,0,0,0,0
4219,04/06/2019 00:00,DB04707,Hydroxyfasudil,,,,,,solid,,,0.659,11.09,8.04,OC1=C2C=CC=C(C2=CC=N1)S(=O)(=O)N1CCCNCC1,,,,,0,,307.0990624,3,2,2,1,1,1
4220,04/06/2019 00:00,DB04708,"(S)-TETRAHYDROFURAN-3-YL (2S,3S)-4-((S)-4-((1R,3R)-3-(2-AMINO-2-OXOETHYL)-2,3-DIHYDRO-1H-INDEN-1-YL)-2-BENZYL-3-OXO-2,3-DIHYDRO-1H-PYRROL-2-YL)-3-HYDROXY-1-PHENYLBUTAN-2-YLCARBAMATE",,,,,,solid,,,0.000727,13.94,1.95,NC(=O)C[C@H]1C[C@@H](C2=CN[C@](C[C@H](O)[C@H](CC3=CC=CC=C3)NC(=O)O[C@H]3CCOC3)(CC3=CC=CC=C3)C2=O)C2=CC=CC=C12,,,,,0,,623.299536,6,3,2,0,1,2
4221,04/06/2019 00:00,DB04709,"(3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE",,,,,,solid,,,0.00903,16.91,-1,[H][C@]12C(=O)N(C(=O)[C@@]1([H])[C@]1([H])CC[C@@]2([H])CC1)C1=CC=C(C2=CC=CC=C12)[N+]([O-])=O,,,,,0,,350.1266571,6,2,1,0,1,1
4222,04/06/2019 00:00,DB04710,(E)-(S)-4-[(S)-4-METHYL-2-((S)-3-METHYL-2{(S)-2-[(5-METHYL-ISOXAZOLE-3- CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-PENTANOYLAMINO]-5-((S)-2- OXO-PYRROLIDIN-3-YL)-PENT-2-ENOIC ACID ETHYL ESTER,,,,,,solid,,,0.0744,11.71,-0.54,CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)C1=NOC(C)=C1,,,,,0,,618.3377124,2,1,2,1,1,1
4223,02/07/2019 00:00,DB04711,Iodipamide,,,,520 mg/1mL,Intravenous,solid,460 mg/L (at 20 Â°C),,0.00306,2.03,-3.4,OC(=O)C1=C(I)C(NC(=O)CCCCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C(I)C=C1I,,,,,0,,1139.512024,2,2,0,0,0,0
4224,04/06/2019 00:00,DB04712,ANILINOMETHYL GLUCO-PHENYLIMIDAZOLE,,,,,,solid,,,6.65,12.33,4.86,OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C2=NC(CNC3=CC=CC=C3)=CN12,,,,,0,,305.1375561,3,2,2,1,0,1
4225,04/06/2019 00:00,DB04713,4-Iodo-D-phenylalanine,,,,,,solid,,,0.274,1.27,9.44,[H][C@@](N)(CC1=CC=C(I)C=C1)C(O)=O,,,,,0,,290.9756266,1,1,0,0,0,0
4226,04/06/2019 00:00,DB04714,ISOPENTENYL PYROPHOSPHATE,,,,,,solid,,,6.69,1.78,,CC(=C)CCO[P@](O)(=O)OP(O)(O)=O,,,,,0,,246.005826,0,0,0,0,0,0
4227,04/06/2019 00:00,DB04715,IMIDAZOPYRIDAZIN 1,,,,,,solid,,,0.0165,15.98,4.3,CC(=O)C1=CC=CC(=C1)C1=CN=C2C=CC(NCC3CC3)=NN12,,,,,0,,306.1480612,4,3,2,2,0,0
4228,04/06/2019 00:00,DB04716,"2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE",,,,,,solid,,,0.00747,10.28,3.91,CC(C)(C)C1=NC2=C3C=CC(F)=CC3=C3C(=O)NC=CC3=C2N1,,,,,0,,309.1277404,4,4,2,2,0,0
4229,04/06/2019 00:00,DB04717,2''-O-[N-(3-(aminopropyl)2-aminoethyl]paromomycin,,,,,,solid,,,29.2,13.09,10.48,NCCCNCCO[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2N)O[C@H](CO)[C@H]1O[C@H]1O[C@@H](CN)[C@@H](O)[C@H](O)[C@H]1N,,,,,0,,715.3963495,4,0,3,0,3,3
4230,04/06/2019 00:00,DB04718,"(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-2-O-{2-[(piperidin-3-ylmethyl)amino]ethyl}-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside",,,,,,solid,,,27.7,13.09,10.37,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2OCCNCC2CCCNC2)[C@H](N)[C@@H](O)[C@@H]1O,,,,,0,,755.4276496,5,0,4,0,4,4
4231,04/06/2019 00:00,DB04719,"DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE",,,,,,solid,,,0.00565,10.77,5,CN(C)C1=NC2=C(Br)C(Br)=C(Br)C(Br)=C2N1,,,,,0,,472.7373456,2,2,1,1,0,0
4232,04/06/2019 00:00,DB04720,"S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE",,,,,,solid,,,0.00131,8.94,3.1,CSC1=NC2=C(N1)C(Br)=C(Br)C(Br)=C2Br,,,,,0,,475.6828675,2,2,1,1,0,0
4233,04/06/2019 00:00,DB04721,"N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE",,,,,,solid,,,0.0464,,4.79,CN1CCN2C1=NC1=C(Br)C(Br)=C(Br)C(Br)=C21,,,,,0,,484.7373456,3,2,2,1,0,1
4234,04/06/2019 00:00,DB04722,"2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE",,,,,,solid,,,0.00033,12.33,-0.21,[H][C@](C)(NC(=O)CC1=[N+]([O-])C(NCC(F)(F)C2=[N+]([O-])C=CC=C2)=CC=C1Cl)C1=CC=CC(Cl)=C1,,,,,0,,496.0880523,3,3,2,2,0,0
4235,04/06/2019 00:00,DB04723,2-(3-GUANIDINOPHENYL)-3-MERCAPTOPROPANOIC ACID,,,,,,solid,,,0.201,3.74,11.16,NC(N)=NC1=CC=CC(=C1)[C@@H](CS)C(O)=O,,,,,0,,239.0728477,1,1,0,0,0,0
4236,04/06/2019 00:00,DB04724,"(S)-2-((S)-3-ISOBUTYL-2,5-DIOXO-4-QUINOLIN-3-YLMETHYL-[1,4]DIAZEPAN-1YL)-N-METHYL-3-NAPHTALEN-2-YL-PROPIONAMIDE",,,,,,solid,,,0.00194,4.79,6.73,[H][C@@](CC1=CC2=CC=CC=C2C=C1)(N1CCC(=O)N(CC2=CC3=CC=CC=C3N=C2)[C@@]([H])(CC(C)C)C1=O)C(O)=NC,,,,,0,,536.278741,5,4,2,1,1,1
4237,04/06/2019 00:00,DB04725,Licofelone,,,,,,solid,,,0.00111,4.83,,CC1(C)CN2C(CC(O)=O)=C(C(=C2C1)C1=CC=CC=C1)C1=CC=C(Cl)C=C1,,,,,0,,379.1339066,4,3,2,1,0,1
4238,04/06/2019 00:00,DB04726,"7,8,10-TRIMETHYLBENZO[G]PTERIDINE-2,4(3H,10H)-DIONE",,,,,,solid,,,0.218,6.97,0.77,CN1C2=C(C=C(C)C(C)=C2)N=C2C(=O)NC(=O)N=C12,,,,,0,,256.0960256,3,1,2,0,0,2
4239,04/06/2019 00:00,DB04727,"N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA",,,,,,solid,,,0.0182,7.52,2.46,COC1=CC=C(C=C1)C1=C(C2=C(N)N=CN=C2O1)C1=CC=C(NC(O)=NC2=C(F)C=CC(=C2)C(F)(F)F)C=C1,,,,,0,,537.1424023,5,5,2,2,0,0
4240,04/06/2019 00:00,DB04728,Lividomycin A,,,,,,solid,,,66.1,12.02,9.99,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)C[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O,,,,,0,,761.3542099,5,0,4,0,4,4
4241,04/06/2019 00:00,DB04729,Gentamicin C1a,,,,,,solid,,,20.5,12.55,9.9,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O,,,,,0,,449.2849486,3,0,2,0,2,2
4242,04/06/2019 00:00,DB04731,1-ACETYL-2-LYSO-SN-GLYCERO-3-PHOSPHOETHANOLAMINE,,,,,,solid,,,16.7,1.87,10,CC(=O)OC[C@H](O)CO[P@](O)(=O)OCC[NH3+],,,,,1,,258.0737149,0,0,0,0,0,0
4243,04/06/2019 00:00,DB04732,N-(4-MORPHOLINE)CARBONYL-B-(1-NAPHTHYL)-L-ALANINE-L-LEUCINE BORONIC ACID,,,,,,solid,,,0.0313,13.77,-2,[H][C@@](CC(C)C)(NC(=O)[C@@]([H])(CC1=C2C=CC=CC2=CC=C1)NC(=O)N1CCOCC1)B(O)O,,,,,0,,441.2435015,3,2,1,0,1,1
4244,04/06/2019 00:00,DB04733,"1,6-DI-O-PHOSPHONO-D-MANNITOL",,,,,,solid,,,16.2,1.19,-3.5,O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H](O)COP(O)(O)=O,,,,,0,,342.0116992,0,0,0,0,0,0
4245,04/06/2019 00:00,DB04734,Citraconic acid,,,,,,solid,7.83E+005 mg/L (at 25 Â°C),,15.9,2.31,,C\C(=C\C(O)=O)C(O)=O,,,,,0,,130.0266087,0,0,0,0,0,0
4246,04/06/2019 00:00,DB04735,MONOGALACTOSYL-DIACYLGLYCEROL,,,,,,solid,,,0.000905,12.21,-3,CCCCCCCCCCCCCCCC(=O)O[C@@H](CO[C@@H]1O[C@@H](CO)[C@H](O)[C@H](O)[C@@H]1O)COC(=O)CCCCCCCCCCCC,,,,,0,,688.5125485,1,0,1,0,1,1
4247,04/06/2019 00:00,DB04736,"2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE",,,,,,solid,,,4.18,1.92,9.52,C[C@@H](NC(=O)[C@H](CCC[C@@H](N)C(O)=O)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@@H]2OC[C@@H](O2)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)C(O)=O)C(O)=O,,,,,0,,921.3814873,3,0,3,0,3,3
4248,04/06/2019 00:00,DB04737,(S)-HYDROXY(PHENYL)ACETONITRILE,,,,,,solid,,,5.89,11.8,-4.2,O[C@H](C#N)C1=CC=CC=C1,,,,,0,,133.0527638,1,1,0,0,0,0
4249,04/06/2019 00:00,DB04738,Motuporin,,,,,,solid,,,0.00543,3.43,-0.6,[H]N1[C@H](CCC(=O)N(C)\C(=C/C)C(=O)N([H])[C@H]([C@H](C)C(=O)N([H])[C@@H](C(C)C)C(=O)N([H])[C@@H](\C=C\C(\C)=C\[C@H](C)[C@H](CC2=CC=CC=C2)OC)[C@H](C)C1=O)C(O)=O)C(O)=O,,,,,0,,767.410543,2,1,1,0,1,1
4250,04/06/2019 00:00,DB04739,4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE,,,,,,solid,,,0.0209,12.27,8.27,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1,,,,,0,,479.2433585,5,4,3,2,1,1
4251,04/06/2019 00:00,DB04740,MOXALACTAM (HYDROLYZED),,,,,,solid,,,0.362,2.48,-3.9,CO[C@](NC(=O)[C@H](C(O)=O)C1=CC=C(O)C=C1)([C@H]1OCC(=C)C(=N1)C(O)=O)C(O)=O,,,,,0,,422.0961448,2,1,1,0,0,1
4252,04/06/2019 00:00,DB04741,Myxothiazol,,,,,,solid,,,0.00149,15.91,1.42,CO[C@@H](\C=C\C1=CSC(=N1)C1=CSC(=N1)[C@@H](C)\C=C\C=C\C(C)C)[C@@H](C)C(\OC)=C/C(N)=O,,,,,0,,487.1963339,2,2,2,2,0,0
4253,04/06/2019 00:00,DB04742,"(2R)-2-{(1R)-2-oxo-1-[(2-thienylacetyl)amino]ethyl}-5,6-dihydro-2h-1,3-thiazine-4-carboxylic acid",,,,,,solid,,,0.0551,3.57,-1.5,[H][C@@](NC(=O)CC1=CC=CS1)(C=O)[C@@]1([H])SCCC(=N1)C(O)=O,,,,,0,,326.0394989,2,1,2,1,0,1
4254,04/06/2019 00:00,DB04743,Nimesulide,Rapidly absorbed following oral administration.,>97.5%,1.8â€“4.7 hours,,,solid,,2.6,0.0182,6.86,-8.9,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O,0.97,1,1.8,4.7,0,,308.0466925,2,2,0,0,0,0
4255,04/06/2019 00:00,DB04744,Lawsone,,,,,,solid,,,1.8,8.02,-4.2,OC1=CC(=O)C2=CC=CC=C2C1=O,,,,,0,,174.0316941,2,1,0,0,0,0
4256,04/06/2019 00:00,DB04745,2-OXOQUINOLINE,,,,,,solid,,,2.45,13.95,-2.2,O=C1NC2=CC=CC=C2C=C1,,,,,0,,145.0527638,2,2,1,1,0,0
4257,04/06/2019 00:00,DB04746,"(10E,12Z)-octadecadienoic acid",,,,,,solid,,,0.000149,5.02,,CCCCC\C=C/C=C/CCCCCCCCC(O)=O,,,,,0,,280.2402303,0,0,0,0,0,0
4258,04/06/2019 00:00,DB04747,11-TRANS-13-TRANS-15-CIS-OCTADECATRIENOIC ACID,,,,,,solid,,,0.000233,4.95,,CC\C=C/C=C/C=C/CCCCCCCCCC(O)=O,,,,,0,,278.2245802,0,0,0,0,0,0
4259,04/06/2019 00:00,DB04748,OXIMINOARYLSULFONAMIDE,,,,,,solid,,,0.00941,7.05,2.89,C(C)(C)CN(C[C@@H](O)[C@@H](NC(=O)[C@H](C(C)C)N1CCN(CC2=CSC(C)=N2)C1=O)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(C=C1)\C=N\O,,,,,0,,698.2920252,4,3,2,1,1,1
4260,04/06/2019 00:00,DB04749,2-(3-OXO-PROPYLSULFANYLCARBONYL)-ETHANETHIOLATE,,,,,,solid,,,1.51,10.13,-6,[S-]CCC(=O)SCCC=O,,,,,-1,,177.0049451,0,0,0,0,0,0
4261,04/06/2019 00:00,DB04750,OREGON GREEN 488 CARBOXYLATE,,,,,,solid,,,0.0069,3.28,1.87,OC(=O)C1=CC(C(O)=O)=C(C=C1)C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C12,,,,,0,,412.0394591,4,2,1,0,0,1
4262,04/06/2019 00:00,DB04751,Purvalanol A,,,,,,solid,,,0.0557,13.92,4.39,[H][C@@](CO)(NC1=NC(NC2=CC=CC(Cl)=C2)=C2N=CN(C(C)C)C2=N1)C(C)C,,,,,0,,388.1778371,3,3,2,2,0,0
4263,04/06/2019 00:00,DB04752,Phosphatidyl ethanol,,,,,,solid,,,7.64E-05,1.89,-2.8,[H]\C(CCCCCC)=C(/[H])CCCCCCCC(=O)O[C@@]([H])(COC(=O)CCCCCCC\C([H])=C(\[H])CCCCCCCC)COP(O)(=O)OCCO,,,,,0,,716.4992205,0,0,0,0,0,0
4264,04/06/2019 00:00,DB04753,"9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE",,,,,,solid,,,12.6,1.73,-0.34,OC[C@H]1O[C@H]([C@@H]2O[C@H](CP(O)(O)=O)O[C@H]12)C1=CNC2=C1NC=NC2=O,,,,,0,,373.0675011,4,2,4,2,2,2
4265,04/06/2019 00:00,DB04754,"GUANOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE",,,,,,solid,,,3.45,1.67,2.64,NC1=NC(=O)C2=C(N1)N(C=N2)[C@@H]1O[C@H](CO)[C@H]2O[C@@H](CP(O)(O)=O)O[C@@H]12,,,,,0,,389.0736491,4,2,4,2,2,2
4266,04/06/2019 00:00,DB04755,PROPYL-1-PHOSPHATE,,,,,,solid,,,155,15.9,-2.4,[O-]CCCOP(=O)=O,,,,,-1,,137.0009189,0,0,0,0,0,0
4267,04/06/2019 00:00,DB04756,"2-[(3,5-Dichloro-4-trioxidanylphenyl)amino]benzoic acid",,,,,,solid,,,0.0205,3.87,-2.2,OOOC1=C(Cl)C=C(NC2=CC=CC=C2C(O)=O)C=C1Cl,,,,,0,,328.9857777,2,2,0,0,0,0
4268,04/06/2019 00:00,DB04757,"GUANOSINE-2',3'-O-METHYLIDENEPHOSPHONATE",,,,,,solid,,,3.53,0.8,2.59,NC1=NC(=O)C2=C(N1)N(C=N2)[C@@H]1O[C@H](CO)[C@H]2O[C@@H](O[C@@H]12)P(O)(O)=O,,,,,0,,375.057999,4,2,4,2,2,2
4269,04/06/2019 00:00,DB04758,2-[2-ETHANESULFONYLAMINO-3-(1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIM IDOYL-BENZYLAMIDE),,,,,,solid,,,0.0212,9.65,11.4,CCS(=O)(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,555.2263882,3,3,1,1,0,0
4270,04/06/2019 00:00,DB04759,"PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(3-METHYL-BENZYLAMIDE)",,,,,,solid,,,0.00751,13.34,-2.8,CC1=CC(CNC(=O)C2=CC(=NC=N2)C(=O)NCC2=CC=CC(C)=C2)=CC=C1,,,,,0,,374.1742759,3,3,1,1,0,0
4271,04/06/2019 00:00,DB04760,"PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(4-FLUORO-3-METHYL-BENZYLAMIDE)",,,,,,solid,,,0.00301,13.14,-2.8,CC1=C(F)C=CC(CNC(=O)C2=CC(=NC=N2)C(=O)NCC2=CC(C)=C(F)C=C2)=C1,,,,,0,,410.1554323,3,3,1,1,0,0
4272,04/06/2019 00:00,DB04761,"PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-[(PYRIDIN-3-YLMETHYL)-AMIDE]",,,,,,solid,,,0.0199,13.03,5.12,O=C(NCC1=CC=CN=C1)C1=CC(=NC=N1)C(=O)NCC1=CN=CC=C1,,,,,0,,348.1334738,3,3,3,3,0,0
4273,04/06/2019 00:00,DB04762,N-PYRIDOXYL-D-GLUTAMIC ACID-5'-MONOPHOSPHATE,,,,,,solid,,,0.819,0.98,10.12,CC1=NC=C(COP(O)(O)=O)C(CN[C@H](CCC(O)=O)C(O)=O)=C1O,,,,,0,,378.0828168,1,1,1,1,0,0
4274,04/06/2019 00:00,DB04763,"1-N-(4-SULFAMOYLPHENYL-ETHYL)-2,4,6-TRIMETHYLPYRIDINIUM",,,,,,solid,,,0.000152,10.3,,CC1=CC(C)=[N+](CCC2=CC=C(C=C2)S(N)(=O)=O)C(C)=C1,,,,,1,,305.1318253,2,2,1,1,0,0
4275,04/06/2019 00:00,DB04764,[4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE,,,,,,solid,,,0.000803,,9.48,NCC1=CC=CC(=C1)C1CCN(CC1)C(=O)C1=CC(CCC2=CC=CC=C2)=CN=C1,,,,,0,,399.2310625,4,3,2,1,1,1
4276,04/06/2019 00:00,DB04765,N-PYRIDOXYL-2-METHYL-L-GLUTAMIC ACID-5'-MONOPHOSPHATE,,,,,,solid,,,0.77,1,10.2,CC1=NC=C(COP(O)(O)=O)C(CN[C@@](C)(CCC(O)=O)C(O)=O)=C1O,,,,,0,,392.0984669,1,1,1,1,0,0
4277,04/06/2019 00:00,DB04767,N-[1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-3-METHYLSULFANYL-PROPYL]-3-HYDROXY-2-PROPOXYAMINO-BUTYRAMID,,,,,,solid,,,0.0589,8.59,11.37,CCCS(=O)(=O)N[C@H]([C@H](C)O)C(=O)N[C@@H](CCSC)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,487.1923112,1,1,0,0,0,0
4278,04/06/2019 00:00,DB04768,Pyrithiamine Pyrophosphate,,,,,,solid,,,0.611,1.78,5.54,CC1=NC=C(C[N+]2=CC=CC(CCO[P@](O)(=O)OP(O)(O)=O)=C2C)C(N)=N1,,,,,1,,419.0879987,2,2,2,2,0,0
4279,04/06/2019 00:00,DB04769,"5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE",,,,,,solid,,,0.111,7.9,1.63,O=C1NC(=O)\C(S1)=C\C1=CC2=C(C=C1)N=CC=N2,,,,,0,,257.0258975,3,2,2,1,1,1
4280,04/06/2019 00:00,DB04770,"O6-(R)-ROSCOVITINE, R-2-(6-BENZYLOXY-9-ISOPROPYL-9H-PURIN-2-YLAMINO)-BUTAN-1-OL",,,,,,solid,,,0.17,14,3.35,[H][C@@](CC)(CO)NC1=NC2=C(N=CN2C(C)C)C(OCC2=CC=CC=C2)=N1,,,,,0,,355.200825,3,3,2,2,0,0
4281,04/06/2019 00:00,DB04771,1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE,,,,,,solid,,,0.0309,13.89,11.28,CC(C)C[C@H](NC(=O)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)N1CCC[C@H]1C(=O)NCCCCN=C(N)N,,,,,0,,489.2699672,2,1,1,0,1,1
4282,04/06/2019 00:00,DB04772,1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE,,,,,,solid,,,0.099,9.18,11.29,CC(C)C[C@H](NS(=O)(=O)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)NCCCCN=C(N)N,,,,,0,,494.2675247,2,1,1,0,1,1
4283,04/06/2019 00:00,DB04773,METHYL (3R)-3-{[(3R)-3-{[(3R)-3-HYDROXYBUTANOYL]OXY}BUTANOYL]OXY}BUTANOATE,,,,,,solid,,,7.82,15.41,-2.6,[H][C@](C)(O)CC(=O)O[C@]([H])(C)CC(=O)O[C@]([H])(C)CC(=O)OC,,,,,0,,290.136553,0,0,0,0,0,0
4284,04/06/2019 00:00,DB04774,Reidispongiolide A,,,,,,solid,,,0.000436,16.57,-3.4,CO[C@H](C\C=C\N(C)C=O)[C@@H](C)C(=O)CC[C@H](C)[C@H](OC)[C@H](C)[C@H]1OC(=O)\C=C\C=C(C)\C[C@H](CC2=CC(=O)O[C@H](C2)[C@H](C)[C@H](C[C@H](OC)\C=C\[C@H](C)[C@H](C[C@@H](OC)\C=C\[C@@H]1C)OC)OC)OC,,,,,0,,957.6177418,2,0,2,0,0,2
4285,04/06/2019 00:00,DB04775,Reidispongiolide C,,,,,,solid,,,0.000431,4.37,-3.4,[H]/C1=C([H])\C(=O)O[C@]([H])([C@@]([H])(C)[C@@]([H])(OC)[C@@]([H])(C)CCC(=O)[C@]([H])(C)[C@@]([H])(CCC(O)=O)OC)[C@@]([H])(C)\C([H])=C([H])\[C@@]([H])(C[C@]([H])(OC)[C@@]([H])(C)\C([H])=C([H])\[C@]([H])(C[C@]([H])(OC)[C@@]([H])(C)[C@@]2([H])CC(C[C@@]([H])(C\C(C)=C\1/[H])OC)=CC(=O)O2)OC)OC,,,,,0,,932.5861074,2,0,2,0,0,2
4286,04/06/2019 00:00,DB04776,(2R)-2-({6-[benzyl(methyl)amino]-9-isopropyl-9H-purin-2-yl}amino)butan-1-ol,,,,,,solid,,,0.24,14.33,5.4,[H][C@@](CC)(CO)NC1=NC2=C(N=CN2C(C)C)C(=N1)N(C)CC1=CC=CC=C1,,,,,0,,368.2324595,3,3,2,2,0,0
4287,04/06/2019 00:00,DB04777,(R)-4-Nitrostyrene oxide,,,,,,solid,,,0.885,,-4.2,[O-][N+](=O)C1=CC=C(C=C1)[C@@H]1CO1,,,,,0,,165.0425931,2,1,1,0,1,1
4288,04/06/2019 00:00,DB04778,SC45647,,,,,,solid,,,0.274,12.19,9.62,C[C@@H](N[C@@H](NCC(O)O)NC1=CC=C(CN)C=C1)C1=CC=CC=C1,,,,,0,,330.2055761,2,2,0,0,0,0
4289,04/06/2019 00:00,DB04779,ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE,,,,,,solid,,,0.0452,-3.4,0.2,CCS\C(CC1=CC=CC=C1)=N/OS(O)(=O)=O,,,,,0,,275.0285999,1,1,0,0,0,0
4290,04/06/2019 00:00,DB04780,Sulfatide,,,,,,solid,,,0.000599,-1.8,-3,CCCCCCCCCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](OS(O)(=O)=O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC,,,,,0,,907.6418484,1,0,1,0,1,1
4291,04/06/2019 00:00,DB04781,5-hydroxyvaleric acid,,,,,,solid,,,243,4.59,-2,OCCCCC(O)=O,,,,,0,,118.0629942,0,0,0,0,0,0
4292,04/06/2019 00:00,DB04782,(S)-4-Nitrostyrene oxide,,,,,,solid,,,0.885,,-4.2,[O-][N+](=O)C1=CC=C(C=C1)[C@H]1CO1,,,,,0,,165.0425931,2,1,1,0,1,1
4293,04/06/2019 00:00,DB04783,Sphinxolide B,,,,,,solid,,,0.00146,13.49,-2.9,CO[C@H](C\C=C\N(C)C=O)[C@@H](C)C(=O)CC[C@H](C)[C@H](OC)[C@H](C)[C@H]1OC(=O)\C=C\C=C(C)/C[C@H](CC2=CC(=O)O[C@H]([C@H]2O)[C@H](C)[C@H](C[C@H](OC)\C=C\[C@H](C)[C@@H](O)C[C@@H](OC)\C=C\[C@@H]1C)OC)OC,,,,,0,,959.5970064,2,0,2,0,0,2
4294,04/06/2019 00:00,DB04784,(R)-1-phenylethanol,,,,,,solid,1.47E+004 mg/L (at 25 Â°C),1.42,15.5,14.81,-2.9,C[C@@H](O)C1=CC=CC=C1,,,,,0,,122.0731649,1,1,0,0,0,0
4295,04/06/2019 00:00,DB04785,Streptolydigin,,,,,,solid,,,0.0165,3.79,4.96,[H]/C(=C(/[H])\C(\O)=C1/C(=O)N([C@]([H])(C1=O)[C@]([H])(C)C(O)=NC)[C@]1([H])CC[C@]([H])(O)[C@]([H])(C)O1)/C(/C)=C(\[H])[C@@]([H])(C)[C@@]1([H])O[C@@]2(C)O[C@]([H])(C=C[C@@]22CO2)[C@]1([H])C,,,,,0,,600.304681,5,0,5,0,4,5
4296,04/06/2019 00:00,DB04786,Suramin,Poorly absorbed from the gastrointestinal tract.,0.997,Approximately 36 to 60 days,,,solid,,,0.00872,-3.5,,CC1=C(NC(=O)C2=CC(NC(=O)NC3=CC=CC(=C3)C(=O)NC3=C(C)C=CC(=C3)C(=O)NC3=C4C(C=C(C=C4S(O)(=O)=O)S(O)(=O)=O)=C(C=C3)S(O)(=O)=O)=CC=C2)C=C(C=C1)C(=O)NC1=C2C(C=C(C=C2S(O)(=O)=O)S(O)(=O)=O)=C(C=C1)S(O)(=O)=O,0.997,0.997,,,0,,1296.046908,8,8,0,0,0,0
4297,04/06/2019 00:00,DB04787,Tanaproget,,,,,,solid,,,0.0311,10.79,-2.1,CN1C(=CC=C1C1=CC=C2NC(=S)OC(C)(C)C2=C1)C#N,,,,,0,,297.0935831,3,2,2,1,0,1
4298,04/06/2019 00:00,DB04788,Tagetitoxin,,,,,,solid,,,37.5,0.85,8.72,[H]N([H])[C@H]1[C@@H](OC(C)=O)[C@@]2([H])O[C@](CS[C@@]2(O)C(=O)N([H])[H])([C@@H]1OP(O)(O)=O)C(O)=O,,,,,0,,416.029067,2,0,2,0,2,2
4299,04/06/2019 00:00,DB04789,5-methyltetrahydrofolic acid,,,,,Oral,solid,,,0.332,3.23,5.32,CN1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2,,,,,0,,459.1866315,3,2,2,1,0,1
4300,04/06/2019 00:00,DB04790,"2,5-bis-O-{3-[amino(imino)methyl]phenyl}-1,4:3,6-dianhydro-D-glucitol",,,,,,solid,,,0.0539,,11.45,[H][C@]1(CO[C@]2([H])[C@]([H])(CO[C@]12[H])OC1=CC=CC(=C1)C(N)=N)OC1=CC(=CC=C1)C(N)=N,,,,,0,,382.1641052,4,2,2,0,2,2
4301,04/06/2019 00:00,DB04791,"2-O-(4'-AMIDINOPHENYL)-5-O-(3''-AMIDINOPHENYL)-1,4:3,6-DIANHYDRO-D-SORBITOL",,,,,,solid,,,0.0524,,11.89,[H][C@@]1(CO[C@]2([H])[C@@]([H])(CO[C@]12[H])OC1=CC=CC(=C1)C(N)=N)OC1=CC=C(C=C1)C(N)=N,,,,,0,,382.1641052,4,2,2,0,2,2
4302,04/06/2019 00:00,DB04792,"2,5-O,O-BIS-{4',4''-AMIDINOPHENYL}-1,4:3,6-DIANHYDRO-D-SORBITOL",,,,,,solid,,,0.0509,,12.11,[H][C@]1(CO[C@]2([H])[C@]([H])(CO[C@]12[H])OC1=CC=C(C=C1)C(N)=N)OC1=CC=C(C=C1)C(N)=N,,,,,0,,382.1641052,4,2,2,0,2,2
4303,04/06/2019 00:00,DB04793,"1,4:3,6-Dianhydro-2-O-(3-carbamimidoylphenyl)-5-O-(4-carbamimidoylphenyl)-D-glucitol",,,,,,solid,,,0.0524,,11.89,[H]N=C(N([H])[H])C1=CC=C(O[C@@H]2CO[C@]3([H])[C@H](CO[C@]23[H])OC2=CC=CC(=C2)C(=N[H])N([H])[H])C=C1,,,,,0,,382.1641052,4,2,2,0,2,2
4304,04/06/2019 00:00,DB04794,Bifonazole,Very low absorption following topical administration (0.6% of an applied dose).  In cases of skin lesions absorption is increased (2.5%).,,1-2 hours,,,solid,,4.77,0.00245,,6.69,C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1,,,1,2,0,,310.1469986,4,4,1,1,0,0
4305,04/06/2019 00:00,DB04795,Thenoyltrifluoroacetone,,,,,,solid,,1.46,0.0752,7.17,-8,FC(F)(F)C(=O)CC(=O)C1=CC=CS1,,,,,0,,221.9962351,1,1,1,1,0,0
4306,04/06/2019 00:00,DB04796,Inecalcitol,,,,,,solid,,,0.00221,14.67,-2.7,[H][C@@]1(CC[C@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)CC#CC(C)(C)O,,,,,0,,400.2977451,3,0,0,0,0,0
4307,04/06/2019 00:00,DB04797,Triazolopyridine,,,,,,solid,,,0.0705,,2.86,CC(C)C1=NN=C2C=CC(=CN12)C1=C(N=CO1)C1=CC=C(F)C=C1,,,,,0,,322.1229893,4,4,3,3,0,0
4308,04/06/2019 00:00,DB04798,THIO-ATPA,,,,,,solid,,,0.0394,2.29,8.96,[H][C@]([NH3+])(CC1=C(SN=C1[O-])C(C)(C)C)C(O)=O,,,,,0,,244.0881634,1,1,1,1,0,0
4309,04/06/2019 00:00,DB04799,"6-Hydroxy-5-undecyl-4,7-benzothiazoledione",,,,,,solid,,,0.00186,6.88,-0.81,CCCCCCCCCCCC1=C(O)C(=O)C2=C(N=CS2)C1=O,,,,,0,,335.1555147,2,1,1,1,0,0
4310,04/06/2019 00:00,DB04800,1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID,,,,,,solid,,,1.08,-1.8,3.08,CN1N=C(C=C1NS(O)(=O)=O)C1=CC=CC=C1,,,,,0,,253.0521122,2,2,1,1,0,0
4311,04/06/2019 00:00,DB04801,cis-Vaccenic acid,,,,,,solid,,,0.000123,4.95,,CCCCCC\C=C/CCCCCCCCCC(O)=O,,,,,0,,282.2558803,0,0,0,0,0,0
4312,04/06/2019 00:00,DB04802,"D-ERITHRO-2,3-DIAMINO-BUTYRIC ACID",,,,,,solid,,,289,2.22,9.78,[H][C@](C)(N)[C@@]([H])(N)C(O)=O,,,,,0,,118.0742276,0,0,0,0,0,0
4313,04/06/2019 00:00,DB04803,Verdoheme,,,,,,solid,,,0.0326,4.32,-3.6,CC1=CC2=CC3=[N+]4C(=CC5=C(C=C)C(C)=C6OC7=C(C=C)C(C)=C8C=C1N2[Fe]4(N56)N78)C(C)=C3CCC(O)=O,,,,,1,,547.1427046,8,3,8,3,0,5
4314,04/06/2019 00:00,DB04804,"L-threo-2,3-diamino-butyric acid",,,,,,solid,,,289,2.22,9.78,[H][C@](C)(N)[C@]([H])(N)C(O)=O,,,,,0,,118.0742276,0,0,0,0,0,0
4315,04/06/2019 00:00,DB04805,Virginiamycin S1,,,,,,solid,,,0.139,7.53,1.57,[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)CCN1C(=O)[C@]([H])(CC1=CC=CC=C1)N(C)C2=O)C1=CC=CC=C1,,,,,0,,823.3540908,6,3,4,1,3,3
4316,04/06/2019 00:00,DB04806,(5-BROMO-4-CHLORO-3-INDOLYL)-A-D-MANNOSE,,,,,,solid,,,1.72,12.2,-3,OC[C@H]1O[C@H](OC2=CNC3=C2C(Cl)=C(Br)C=C3)[C@@H](O)[C@@H](O)[C@@H]1O,,,,,0,,406.977127,3,2,2,1,1,1
4317,04/06/2019 00:00,DB04807,4-NITROPHENYL-(6-S-ALPHA-D-XYLOPYRANOSYL)-BETA-D-GLUCOPYRANOSIDE,,,,,,solid,,,14,12.04,-3.5,O[C@@H]1CO[C@H](SC[C@H]2O[C@@H](OC3=CC=C(C=C3)[N+]([O-])=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H]1O,,,,,0,,449.0991816,3,1,2,0,2,2
4318,04/06/2019 00:00,DB04808,Neamine,,,,,,solid,,,101,12.66,9.67,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,,,,,0,,322.1852346,2,0,1,0,1,1
4319,04/06/2019 00:00,DB04809,SALOPHEN-10-PROPIONATE IRON CHELATE,,,,,,solid,,,8.22E-05,3.57,0.54,[Fe+4].[H]\C(=N/C1=C(C=C(CCC(O)=O)C=C1)/N=C(\[H])C1=CC=CC=C1[O-])C1=CC=CC=C1[O-],,,,,2,,442.0604974,3,3,0,0,0,0
4320,04/06/2019 00:00,DB04810,Salophen-10-carboxylate iron chelate,,,,,,solid,,,9.22E-05,4.67,-0.21,[Fe+4].[H]\C(=N/C1=C(C=C(C=C1)C(O)=O)/N=C(\[H])C1=CC=CC=C1[O-])C1=CC=CC=C1[O-],,,,,2,,414.0291973,3,3,0,0,0,0
4321,04/06/2019 00:00,DB04811,Salophen iron chelate,,,,,,solid,,,3.36E-05,8.03,0.58,[Fe+4].[H]\C(=N/C1=CC=CC=C1\N=C(/[H])C1=CC=CC=C1[O-])C1=CC=CC=C1[O-],,,,,2,,370.039368,3,3,0,0,0,0
4322,04/06/2019 00:00,DB04812,Benoxaprofen,,,,,,solid,,3.23,0.0317,4.66,0.091,CC(C(O)=O)C1=CC2=C(OC(=N2)C2=CC=C(Cl)C=C2)C=C1,,,,,0,,301.0505709,3,3,1,1,0,0
4323,04/06/2019 00:00,DB04813,Bithionol,,,,,,solid,4 mg/L (at 25 Â°C),,0.00166,4.89,-7.2,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl,,,,,0,,353.8842612,2,2,0,0,0,0
4324,04/06/2019 00:00,DB04814,Bunamiodyl,,,,,,solid,,,0.0023,2.37,-3.9,CCCC(=O)NC1=C(I)C=C(I)C(\C=C(/CC)C(O)=O)=C1I,,,,,0,,638.8264374,1,1,0,0,0,0
4325,02/07/2019 00:00,DB04815,Clioquinol,"Topical absorption is rapid and extensive, especially when the skin is covered with an occlusive dressing or if the medication is applied to extensive or eroded areas of the skin. Clioquinol is absorbed through the skin in sufficient amounts to affect thyroid function tests. ",,,0.03,Topical,solid,,,0.264,7.34,3.28,OC1=C(I)C=C(Cl)C2=C1N=CC=C2,,,,,0,,304.9104395,2,2,1,1,0,0
4326,04/06/2019 00:00,DB04816,Dantron,,,,,Oral,solid,,,0.305,9.09,-4.4,OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O,,,,,0,,240.0422587,3,2,0,0,0,0
4327,02/07/2019 00:00,DB04817,Metamizole,,,,,,solid,,,2.53,-1.4,-0.54,CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1,,,,,0,,311.093977,2,2,1,1,0,0
4328,04/06/2019 00:00,DB04818,Iproniazid,,,,,,solid,,0.37,0.674,13.66,3.82,CC(C)NNC(=O)C1=CC=NC=C1,,,,,0,,179.105862,1,1,1,1,0,0
4329,04/06/2019 00:00,DB04819,Methapyrilene,,,,,,solid,601 mg/L (at 30 Â°C),2.87,0.287,,8.76,CN(C)CCN(CC1=CC=CS1)C1=NC=CC=C1,,,,,0,,261.1299686,2,2,2,2,0,0
4330,04/06/2019 00:00,DB04820,Nialamide,,,,,,solid,,0.87,0.0873,13.65,3.41,O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1,,,,,0,,298.1429758,2,2,1,1,0,0
4331,04/06/2019 00:00,DB04821,Nomifensine,,,,,,solid,,,0.318,,8.88,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2,,,,,0,,238.1469986,3,2,1,0,0,1
4332,04/06/2019 00:00,DB04822,Oxeladin,,,,,,solid,,,0.0158,,9.41,CCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1,,,,,0,,335.2460439,1,1,0,0,0,0
4333,04/06/2019 00:00,DB04823,Oxyphenisatin,,,,,,solid,,,0.0125,9.18,-6,OC1=CC=C(C=C1)C1(C(=O)NC2=CC=CC=C12)C1=CC=C(O)C=C1,,,,,0,,317.1051933,4,3,1,0,0,1
4334,04/06/2019 00:00,DB04824,Phenolphthalein,,,,60 mg,Oral,solid,400 mg/L,2.41,0.00992,9.16,-6,OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1,,,,,0,60,318.0892089,4,3,1,0,0,1
4335,04/06/2019 00:00,DB04825,Prenylamine,,,,,,solid,50 mg/L (at 37 Â°C),,3.54E-05,,10.48,CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,329.2143499,3,3,0,0,0,0
4336,04/06/2019 00:00,DB04826,Thenalidine,,,,,,solid,,,0.0883,,8.69,CN1CCC(CC1)N(CC1=CC=CS1)C1=CC=CC=C1,,,,,0,,286.1503697,3,2,2,1,1,1
4337,04/06/2019 00:00,DB04827,Urethane,,,,,,solid,4.8E+005 mg/L (at 15 Â°C),-0.15,371,15.47,,CCOC(N)=O,,,,,0,,89.04767846,0,0,0,0,0,0
4338,04/06/2019 00:00,DB04828,Zomepirac,,,,,,solid,,,0.026,3.86,-7.8,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1,,,,,0,,291.066221,2,2,1,1,0,0
4339,04/06/2019 00:00,DB04829,Lysergic acid diethylamide,Rapidly absorbed.,,3 hours,,,solid,,2.95,0.27,17.02,7.98,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N(CC)CC,,,3,3,0,,323.1997624,4,2,2,1,0,1
4340,04/06/2019 00:00,DB04830,Buformin,,,,,,solid,,-1.2,1.41,,11.52,CCCC\N=C(/N)N=C(N)N,,,,,0,,157.1327455,0,0,0,0,0,0
4341,04/06/2019 00:00,DB04831,Tienilic acid,,,,,,solid,,,0.00254,3.22,-5,OC(=O)COC1=C(Cl)C(Cl)=C(C=C1)C(=O)C1=CC=CS1,,,,,0,,329.9520351,2,2,1,1,0,0
4342,04/06/2019 00:00,DB04832,Zimelidine,,,8.4 +/- 2.0 hours for the parent compound and 19.4 +/- 3.6 hours for norzimelidine.,,,solid,,,0.0239,,8.62,CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CC=CN=C1,,,,,0,,316.0575106,2,2,1,1,0,0
4343,04/06/2019 00:00,DB04833,Methaqualone,,,,,,solid,,,0.0407,,-1.2,CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O,,,,,0,,250.1106131,3,3,1,1,0,0
4344,04/06/2019 00:00,DB04834,Rapacuronium,,0.5,141 minutes (mean),100 mg/1,Intravenous,solid,,,4.64E-06,,9.65,[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1,0.5,0.5,,,1,,597.4625849,6,0,2,0,2,2
4345,02/07/2019 00:00,DB04835,Maraviroc,The absolute oral bioavailability of a 100 mg dose is 23% and is predicted to be 33% at 300 mg. Coadministration of a 300mg tablet with a high fat breakfast reduced maraviroc Cmax and AUC by 33% in healthy volunteers.,0.76,14-18 hours,150 mg,Oral,solid,,,0.0106,13.98,9.65,CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1,0.76,0.76,14,18,0,150,513.3279174,5,2,3,1,2,2
4346,04/06/2019 00:00,DB04836,Amineptine,,,48 minutes for the parent drug and 2.5 hours for the metabolites.,,,solid,,,0.000305,4.41,9.17,OC(=O)CCCCCCNC1C2=CC=CC=C2CCC2=CC=CC=C12,,,,,0,,337.2041791,3,2,0,0,0,0
4347,02/07/2019 00:00,DB04837,Clofedanol,,,,25 mg,Oral,solid,,,0.0621,13.18,8.87,CN(C)CCC(O)(C1=CC=CC=C1)C1=CC=CC=C1Cl,,,,,0,25,289.1233419,2,2,0,0,0,0
4348,04/06/2019 00:00,DB04838,Cyclandelate,Well absorbed following oral administration.,,,200 mg,Oral,solid,,,0.0997,11.99,-4.1,CC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1,,,,,0,200,276.1725446,2,1,0,0,0,0
4349,02/07/2019 00:00,DB04839,Cyproterone acetate,Completely absorbed following oral administration.,,"Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.",100 mg,Intramuscular,solid,,,0.00152,17.83,-5.6,[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H],,,,,0,,416.1754371,5,0,0,0,0,0
4350,04/06/2019 00:00,DB04840,Debrisoquine,,,,,,solid,,0.75,0.842,,12.47,NC(=N)N1CCC2=CC=CC=C2C1,,,,,0,,175.1109474,2,1,1,0,0,1
4351,02/07/2019 00:00,DB04841,Flunarizine,85% following oral administration.,0.99,18 days,5 mg,Oral,solid,,5.78,0.00168,,7.6,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1,0.99,0.99,432,432,0,5,404.2064053,4,3,1,0,1,1
4352,04/06/2019 00:00,DB04842,Fluspirilene,,,,10 mg,Intramuscular,solid,10 mg/L (at 25 Â°C),5.86,0.00167,11.99,9.31,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1,,,,,0,,475.2435191,5,3,2,0,2,2
4353,04/06/2019 00:00,DB04843,Mepenzolate,"Between 3 and 22% of an orally administered dose is excreted in the urine over a 5-day period, with the majority of the radioactivity appearing on Day 1. The remainder appears in the next 5 days in the feces and presumably has not been absorbed.
",,,25 mg/1,Oral,solid,,,0.000627,11.05,-4.5,C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,25,340.1907201,3,2,1,0,1,1
4354,02/07/2019 00:00,DB04844,Tetrabenazine,"Following oral administration of tetrabenazine, the extent of absorption is at least 75%.  After single oral doses ranging from 12.5 to 50 mg, plasma concentrations of tetrabenazine are generally below the limit of detection because of the rapid and extensive hepatic metabolism of tetrabenazine. Food does not affect the absorption of tetrabenazine. 
Cmax, oral = 4.8 ng/mL in HD or tardive dyskinesia patients;  
Tmax, oral = 69 min in HD or tardive dyskinesia patients",,"Î±-HTBZ = 7 hours; 
Î²-HTBZ = 5 hours;
9-desmethyl-Î²-DHTBZ = 12 hours. ",25 mg,Oral,solid,Sparingly soluble,,0.361,18.24,7.41,COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1,,,,,0,25,317.1990937,3,1,2,0,1,2
4355,04/06/2019 00:00,DB04845,Ixabepilone,,67-77%,52 hours,15 mg/15mg,Intravenous,solid,,,0.00352,13.85,2.73,[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1,0.67,0.77,52,52,0,,506.2814434,3,1,3,1,2,2
4356,04/06/2019 00:00,DB04846,Celiprolol,"Absorption of an oral dose is rapid and consistent but incomplete (55% for 200 mg dose and 74% for 400 mg dose) from the gastrointestinal tract. The bioavailability of celiprolol has been shown to be markedly affected by food and one should avoid administration of celiprolol with food. Coadministration of chlorthalidone, hydrochlorothiazide and theophylline also reduces the bioavailability of celiprolol. Following oral dosing, maximal blood concentrations are reached between 2 and 3 hours.",,5 hours,,,solid,,,0.174,13.55,9.66,CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O,,,5,5,0,,379.2471065,1,1,0,0,0,0
4357,04/06/2019 00:00,DB04847,Roxadustat,Orally active,,,,,solid,,,0.0115,3.35,2.24,CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12,,,,,0,,352.1059216,3,3,1,1,0,0
4358,04/06/2019 00:00,DB04849,Cediranib,Available following oral administration.,,12 to 35 hours,,,solid,,,0.0155,16.59,9.14,COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1,,,,,0,,450.2067189,5,4,3,2,1,1
4359,04/06/2019 00:00,DB04850,Posizolid,,,,,,solid,,,0.71,12.4,-1.8,OC[C@H](O)C(=O)N1CCC(=CC1)C1=C(F)C=C(C=C1F)N1C[C@H](COC2=NOC=C2)OC1=O,,,,,0,,465.1347565,4,2,3,1,1,2
4360,04/06/2019 00:00,DB04851,Biricodar,,,,,,solid,,,0.00129,,5.86,COC1=CC(=CC(OC)=C1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)OC(CCCC1=CN=CC=C1)CCCC1=CN=CC=C1,,,,,0,,603.2944507,4,3,3,2,1,1
4361,04/06/2019 00:00,DB04852,Implitapide,,,,,,solid,,,0.000202,13.4,4.35,CC1=NC2=C(C3=CC=CC=C3N2CC2=CC(=CC=C2)[C@H](C2CCCC2)C(=O)N[C@@H](CO)C2=CC=CC=C2)C(C)=C1,,,,,0,,531.2885774,6,5,2,2,0,0
4362,04/06/2019 00:00,DB04853,Binodenoson,,,10 &plusmn; 4 minutes,,,solid,,,1.14,10.99,4.34,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(N)N=C(N\N=C\C3CCCCC3)N=C12,,,,,0,,391.1968023,4,2,3,2,1,1
4363,02/07/2019 00:00,DB04854,Febuxostat,>49%,0.992,~5-8 hours. ,120 mg,Oral,solid,,,0.0183,3.08,0.39,CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N,0.992,0.992,5,8,0,120,316.0881634,2,2,1,1,0,0
4364,02/07/2019 00:00,DB04855,Dronedarone,"Because of presystemic first pass metabolism the absolute bioavailability of dronedarone without food is low, about 4%. It increases to approximately 15% when dronedarone is administered with a high fat meal. After oral administration in fed conditions, peak plasma concentrations of dronedarone and the main circulating active metabolite (N-debutyl metabolite) are reached within 3 to 6 hours. After repeated administration of 400 mg twice daily, steady state is reached within 4 to 8 days of treatment. The steady state Cmax and exposure of the main N-debutyl metabolite is similar to that of the parent compound. ",>98%,Elimination half-life: 13-19 hours ,400 mg,Oral,solid,Insoluble ,7.346,0.00201,9.08,9.79,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2,0.98,1,,,0,400,556.2970935,3,3,1,1,0,0
4365,04/06/2019 00:00,DB04856,Dexloxiglumide,Rapidly and extensively absorbed after single oral administration in humans with an absolute bioavailability of 48%. The incomplete bioavailability is due to both incomplete absorption and hepatic first-pass effect.,94-98%,,,,solid,,,0.00555,4.05,-1,CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1,0.94,0.98,,,0,,460.1531774,1,1,0,0,0,0
4366,04/06/2019 00:00,DB04857,Brasofensine,"Brasofensine is rapidly absorbed after oral administration in rats and monkeys, with peak plasma concentrations occurring 0.5-1 hr, but 3-8 hr for brasofensine in humans.",,"Plasma terminal elimination half-lives were ~2 hr in rats, ~4 hr in monkeys, but ~24 hr in humans.",,,solid,,,0.00111,,9.45,[H][C@@]12CC[C@@]([H])(N1C)[C@]([H])(\C=N\OC)[C@H](C2)C1=CC(Cl)=C(Cl)C=C1,,,,,0,,326.0952686,3,1,2,0,2,2
4367,04/06/2019 00:00,DB04858,Tirapazamine,,,,,,solid,,,3.93,12.97,2.18,NC1=[N+]([O-])C2=C(C=CC=C2)[N+]([O-])=N1,,,,,0,,178.0490754,2,2,1,1,0,0
4368,04/06/2019 00:00,DB04859,Zanapezil,,,,,,solid,,,0.000615,17.1,8.74,O=C(CCC1CCN(CC2=CC=CC=C2)CC1)C1=CC2=C(CCCCN2)C=C1,,,,,0,,376.2514636,4,2,2,0,1,2
4369,04/06/2019 00:00,DB04860,Isatoribine,,,,,,solid,,,34.8,7.54,1.03,NC1=NC(=O)C2=C(N1)N([C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O)C(=O)S2,,,,,0,,316.0477551,3,2,3,2,1,1
4370,02/07/2019 00:00,DB04861,Nebivolol,The absorption of nebivolol is rapid and not affected by food.,0.98,10 hours,10 mg/1,Oral,solid,,,0.0403,13.52,8.9,OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2,0.98,0.98,10,10,0,10,405.1751647,4,2,2,0,0,2
4371,04/06/2019 00:00,DB04862,Merimepodib,,,,,,solid,,,0.11,11.22,0.57,COC1=C(C=CC(NC(=O)NC2=CC=CC(CNC(=O)O[C@H]3CCOC3)=C2)=C1)C1=CN=CO1,,,,,0,,452.1695845,4,3,2,1,1,1
4372,04/06/2019 00:00,DB04863,Lefradafiban,,,,,,solid,,,0.0088,14,0.71,COC(=O)C[C@@H]1C[C@@H](COC2=CC=C(C=C2)C2=CC=C(C=C2)C(\N)=N\C(=O)OC)NC1=O,,,,,0,,439.1743355,3,2,1,0,1,1
4373,04/06/2019 00:00,DB04864,Huperzine A,,,,,,solid,,,0.166,11.11,9.09,[H][C@@]12CC3=C(C=CC(=O)N3)[C@@](N)(CC(C)=C1)\C2=C\C,,,,,0,,242.1419132,3,1,1,1,0,0
4374,04/06/2019 00:00,DB04865,Omacetaxine mepesuccinate,"Homoharringtonine absorption was not quantified, but maximum concentration is reached after about 30 mins. ",,Homoharringtonine has a half life of about 6 hours after subcutaneous administration.,3.5 mg/1mL,Subcutaneous,solid,,,0.108,12.09,9.42,[H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H],,,,,0,,545.2624818,5,1,3,0,1,3
4375,04/06/2019 00:00,DB04866,Halofuginone,Readily bioavailable and rapidly absorbed following oral administration.,,23.8 to 72.1 hours,,,solid,,,0.114,14.48,9.28,[H][C@]1(O)CCCN[C@]1([H])CC(=O)CN1C=NC2=C(C=C(Cl)C(Br)=C2)C1=O,,,,,0,,413.0141812,3,2,2,1,1,1
4376,04/06/2019 00:00,DB04867,Lintitript,,,,,,solid,,,0.00854,4.19,-1.2,OC(=O)CN1C(=CC2=CC=CC=C12)C(=O)NC1=NC(=CS1)C1=CC=CC=C1Cl,,,,,0,,411.04444,4,4,2,2,0,0
4377,02/07/2019 00:00,DB04868,Nilotinib,Orally available,,15 hours,150 mg/1,Oral,solid,,,0.00201,12.38,5.92,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F,,,15,15,0,150,529.183793,5,5,3,3,0,0
4378,04/06/2019 00:00,DB04869,Olcegepant,,,,,,solid,,,0.0316,4.17,10.24,[H][C@@](CCCCN)(N=C(O)[C@@]([H])(CC1=CC(Br)=C(O)C(Br)=C1)N=C(O)N1CCC(CC1)N1CC2=CC=CC=C2N=C1O)C(=O)N1CCN(CC1)C1=CC=NC=C1,,,,,0,,867.2066898,6,3,4,1,2,3
4379,04/06/2019 00:00,DB04870,Oleoyl-estrone,Orally available,,,,,solid,,,4.87E-06,19.96,-7,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC(=O)CCCCCCC\C=C/CCCCCCCC)C=C3,,,,,0,,534.4072956,4,1,0,0,0,0
4380,02/07/2019 00:00,DB04871,Lorcaserin,"Lorcaserin has a peak plasma concentration of about 1.5 - 2 hours, but the bioavailability was not determined.",,The plasma half life is approximately 11 hours.,10 mg/1,Oral,solid,Water solubility is greater than 400  mg/mL.,,0.0709,,10.12,C[C@H]1CNCCC2=CC=C(Cl)C=C12,,,,,0,10,195.0814771,2,1,1,0,0,1
4381,04/06/2019 00:00,DB04872,Osanetant,,,,,,solid,,,0.000154,,9.3,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C2=CC=CC=C2)C2=CC(Cl)=C(Cl)C=C2)CC1)C1=CC=CC=C1,,,,,0,,605.2575829,5,3,2,0,2,2
4382,04/06/2019 00:00,DB04873,Piboserod,,,,,,solid,,,0.0287,14.3,9.8,CCCCN1CCC(CNC(=O)C2=C3OCCCN3C3=CC=CC=C23)CC1,,,,,0,,369.2416272,4,2,3,1,1,2
4383,04/06/2019 00:00,DB04875,Pralnacasan,Orally bioavailable,,,,,solid,,,0.387,12.26,1.49,CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2N1C(=O)[C@H](CCC2=O)NC(=O)C1=NC=CC2=CC=CC=C12,,,,,0,,523.2066983,5,2,4,1,3,3
4384,04/06/2019 00:00,DB04876,Vildagliptin,Rapidly absorbed following oral administration with an oral bioavailability of greater than 90%.,0.093,The elimination half-life is approximately 90 minutes.,50 mg,Oral,solid,,,1.75,14.71,9.03,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N,0.093,0.093,,,0,50,303.194677,5,0,1,0,1,1
4385,04/06/2019 00:00,DB04877,Voacamine,,,,,,solid,,,0.00323,15.56,8.53,[H][C@@]12C[C@H](CC)[C@]3([H])N(C1)CCC1=C(NC4=CC(=C(OC)C=C14)[C@@]1([H])C[C@]4([H])C(C(=O)OC)[C@@]([H])(CC5=C1NC1=CC=CC=C51)N(C)C\C4=C\C)[C@@]3(C2)C(=O)OC,,,,,0,,704.3937708,10,4,6,2,3,4
4386,04/06/2019 00:00,DB04878,Voglibose,Slowly and poorly absorbed. The reported pharmacokinetic parameters of voglibose with metformin are Cmax corresponds to 1.38 mcg/ml while AUC is 8.17 mcg.h/ml and tmax is of 2.5 hours.[A38919],,The half-life of voglibose is very similar to the one found for metformin and it is reported to be of 4.08 hours.[A38919],,,solid,,,190,12.46,7.66,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,267.131802,1,0,0,0,0,0
4387,04/06/2019 00:00,DB04879,Vatalanib,Rapid onset of absorption,,Approximately 6 hours.,,,solid,,,0.00179,15.17,4.95,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=CC=CC=C23)C=C1,,,,,0,,346.0985242,4,4,2,2,0,0
4388,04/06/2019 00:00,DB04880,Enoximone,Bioavailabvility is 50% following oral administration.,0.85,4-10 hours,,,solid,,,0.0682,9.68,-7.8,CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1,0.85,0.85,4,10,0,,248.0619486,2,2,1,1,0,0
4389,04/06/2019 00:00,DB04881,Elacridar,,,,,,solid,,,0.00281,12.06,8.35,COC1=CC=CC2=C1NC1=C(C=CC=C1C(=O)NC1=CC=C(CCN3CCC4=CC(OC)=C(OC)C=C4C3)C=C1)C2=O,,,,,0,,563.2420212,6,5,2,1,0,1
4390,04/06/2019 00:00,DB04882,Edotecarin,,,20 to 25 hours,,,solid,,,1.58,8.82,2.44,OCC(CO)NN1C(=O)C2=C3C(NC4=C3C=CC(O)=C4)=C3N([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C4=C(C=CC(O)=C4)C3=C2C1=O,,,,,0,,608.1754577,7,5,4,2,1,2
4391,04/06/2019 00:00,DB04883,Darusentan,,,,,,solid,,,0.0994,3.2,-0.17,COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1,,,,,0,,410.1477864,3,3,1,1,0,0
4392,04/06/2019 00:00,DB04884,Dapoxetine,Rapidly absorbed.,,Initial half-life of 1-2 hours.,,,solid,,,0.000837,,9.04,CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1,,,,,0,,305.1779644,3,3,0,0,0,0
4393,04/06/2019 00:00,DB04885,Cilansetron,Rapidly absorbed orally with a bioavailability of greater than 80% in rats.,,The elimination half-life after 4- and 8-mg oral doses administered 3 times daily for 6 days was reported to be 1.6 to 1.9 hours.,,,solid,,,0.115,15.48,7.34,CC1=NC=CN1C[C@H]1CCC2=C(C3=CC=CC4=C3N2CCC4)C1=O,,,,,0,,319.1684623,5,3,3,2,0,1
4394,04/06/2019 00:00,DB04886,Calanolide A,,,20 hours for 800mg,,,solid,,,0.0178,13.63,-3.4,CCCC1=CC(=O)OC2=C1C1=C(C=CC(C)(C)O1)C1=C2[C@@H](O)[C@H](C)[C@@H](C)O1,,,,,0,,370.1780239,4,2,3,1,0,2
4395,04/06/2019 00:00,DB04887,Brecanavir,"Brecanavir, a CYP3A4 substrate, demonstrated low oral bioavailability in animals (0 to 30%), which increased to 60 to 100% following coadministration with oral ritonavir (a potent CYP3A inhibitor).",0.98,,,,solid,,,0.0177,13.18,2.6,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=C(OCC2=CSC(C)=N2)C=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC2=C(OCO2)C=C1,0.98,0.98,,,0,,703.2233365,6,3,4,1,2,3
4396,04/06/2019 00:00,DB04888,Bifeprunox,,,,,,solid,,,0.0197,9.47,7.83,O=C1NC2=C(O1)C(=CC=C2)N1CCN(CC2=CC(=CC=C2)C2=CC=CC=C2)CC1,,,,,0,,385.179027,5,4,2,1,1,1
4397,04/06/2019 00:00,DB04889,Bicifadine,,,,,,solid,,,0.172,,10.6,CC1=CC=C(C=C1)C12CC1CNC2,,,,,0,,173.1204495,3,1,1,0,1,1
4398,02/07/2019 00:00,DB04890,Bepotastine,"Tmax, after single dose, opthalmic = 1.2 hours;
Cmax, 1.5%, opthalmic dose = 7.3 Â±1.9  ng/mL;
After 24 hours post-installation, levels of bepotastine are below quantifiable limit of 2 ng/mL. Minimal systemic absorption with opthalmic dosage form. ",0.554,Elimination half life = 2.5 hours ,0.015,Ophthalmic,liquid,,,0.0503,4.1,9.39,OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,0.554,0.554,,,0,,388.1553703,3,2,2,1,1,1
4399,04/06/2019 00:00,DB04891,Becocalcidiol,,,,,,solid,,,0.0097,14.19,-3,CC[C@@](C)([H])[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@](O)([H])C(=C)[C@]([H])(O)C1,,,,,0,,344.2715304,3,0,0,0,0,0
4400,04/06/2019 00:00,DB04892,Phenserine,Rapidly absorbed and cleared from the body.,,8 to 10 hours,,,solid,,,0.0509,12.86,6.58,[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC3=CC=CC=C3)=C1)N2C,,,,,0,,337.179027,4,2,2,0,1,2
4401,04/06/2019 00:00,DB04894,Vapreotide,,,30 minutes,,,solid,,,0.0103,2.82,,[H][C@@](N)(CC1=CC=CC=C1)C(O)=N[C@@]1([H])CSSC[C@]([H])(N=C(O)[C@@]([H])(N=C(O)[C@]([H])(CCCCN)N=C(O)[C@@]([H])(CC2=CNC3=CC=CC=C23)N=C(O)[C@]([H])(CC2=CC=C(O)C=C2)N=C1O)C(C)C)C(O)=N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(O)=N,,,0.5,0.5,0,,1130.483014,7,6,3,2,0,1
4402,19/06/2019 00:00,DB04896,Milnacipran,"Racemic milnacipram demonstrates an absolute bioavailability of about 85-90% following oral administration [F3925]. Maximum concentrations of the racemic agent are reached within 2-4 hours after oral dosing, and steady-state levels are obtained by 36-48 hours [F3925].

Conversely, the relative bioavailability of levomilnacipram has been documented as 92% [F3919, F3922]. The median time to peak concentration Tmax for levomilnacipram is about 6-8 hours after oral administration [F3919, F3922]. After daily dosing of levomilnacipram 120 mg, the mean Cmax value is 341 ng/mL, and the mean steady-state AUC value is 5196 ng.h/mL.

In general, the administration of either racemic milnacipram or levomilnacipram with food does not affect the medication's oral bioavailability [F3925, F3919, F3922]. ",0.13,"The terminal elimination half-life documented for racemic milnacipran is approximately 6-8 hours, where d-milnacipran has a longer elimination half-life of 8-10 hours compared to that of the l-enantionmer at 4-6 hours [F3925]. Alternatively, the terminal elimination half-life determined specifically for levomilnacipran formulations is about 12 hours [F3919, F3922].",100 mg/1,Oral,solid,19 mg/mL,,1.23,,9.83,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1,0.13,0.13,,,0,100,246.1732133,2,1,0,0,0,0
4403,04/06/2019 00:00,DB04898,Ximelagatran,Rapidly absorbed by the small intestine with an oral bioavailability of 20%.,,3-5 hours,,,solid,,,0.0845,9.64,5.48,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1,,,3,5,0,,473.2638192,3,1,1,0,1,1
4404,04/06/2019 00:00,DB04903,Pagoclone,,,,,,solid,,,0.00655,13.39,-2.6,CC(C)CCC(=O)CC1N(C(=O)C2=CC=CC=C12)C1=NC2=C(C=CC(Cl)=N2)C=C1,,,,,0,,407.1400546,4,3,3,2,0,1
4405,04/06/2019 00:00,DB04905,Tesmilifene,,,,,,solid,,,0.00905,,9.33,CCN(CC)CCOC1=CC=C(CC2=CC=CC=C2)C=C1,,,,,0,,283.1936144,2,2,0,0,0,0
4406,02/07/2019 00:00,DB04908,Flibanserin,"Flibanserin has an absolute oral availability of 33%.
",,â‰ˆ11 hours,100 mg,Oral,solid,,,0.178,12.91,7.03,FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1,,,11,11,0,100,390.166746,4,3,2,1,1,1
4407,04/06/2019 00:00,DB04909,Sitamaquine,,,,,,solid,,,0.0134,17.89,10.33,CCN(CC)CCCCCCNC1=CC(OC)=CC2=C(C)C=CN=C12,,,,,0,,343.2623627,2,2,1,1,0,0
4408,04/06/2019 00:00,DB04910,Oxibendazole,,,,,,solid,,,0.347,9.64,4.56,CCCOC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,,,,,0,,249.1113413,2,2,1,1,0,0
4409,19/06/2019 00:00,DB04911,Oritavancin,,,The mean (range) plasma terminal half-life of oritavancin is 195.4 (135.8-273.8) hours across all dose levels from 0.05-0.5 mg/kg.,400 mg/1,Intravenous,solid,,,0.0588,2.98,9.96,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,,,,,0,,1790.564106,15,7,8,0,3,8
4410,04/06/2019 00:00,DB04912,Stannsoporfin,Not absorbed orally,,3.8 hours following i.v. administration of 1 mumole per kg body weight,,,solid,,,0.0106,3.73,5.04,[Cl-].[Cl-].[Sn+4].CCC1=C2[N-]C(\C=C3/N=C(/C=C4\[N-]\C(=C/C5=N/C(=C\2)/C(C)=C5CC)C(C)=C4CCC(O)=O)C(CCC(O)=O)=C3C)=C1C,,,,,0,,754.1135557,5,3,5,3,0,2
4411,04/06/2019 00:00,DB04915,Idronoxil,,,,,,solid,,,0.0693,9.13,-4.9,OC1=CC=C(C=C1)C1=CC2=C(OC1)C=C(O)C=C2,,,,,0,,240.0786442,3,2,1,0,0,1
4412,04/06/2019 00:00,DB04917,Renzapride,,,,,,solid,,,0.195,14.68,8.8,COC1=C(C=CC(N)=C1Cl)C(=O)NC1CCN2CCCC1C2,,,,,0,,323.1400546,3,1,2,0,2,2
4413,02/07/2019 00:00,DB04918,Ceftobiprole,,,,500 mg,Intravenous,solid,,,0.159,2.89,10.4,[H][C@@]1(NC(=O)C(=N/O)\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\C=C1/CCN(C1=O)[C@]1([H])CCNC1,,,,,0,,534.1103724,5,1,5,1,3,4
4414,02/07/2019 00:00,DB04920,Clevidipine,,>99.5%,1 minute,0.5 mg/1mL,Intravenous,solid,,,0.00267,,5.31,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,0.99,1,0.016666667,0.016666667,0,,455.0902428,2,1,1,0,0,1
4415,04/06/2019 00:00,DB04924,Itopride,,,,,,solid,,,0.0261,14.71,8.77,COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1,,,,,0,,358.1892573,2,2,0,0,0,0
4416,04/06/2019 00:00,DB04926,Neramexane,,,,,,solid,,,0.0629,,10.66,CC1(C)CC(C)(C)CC(C)(N)C1,,,,,0,,169.1830497,1,0,0,0,0,0
4417,02/07/2019 00:00,DB04930,Permethrin,Poorly absorbed through the skin.,,,50 mg/1g,Cutaneous,solid,0.006 mg/L (at 20 Â°C),6.5,6.91E-05,,-3.7,CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1,,,,,0,,390.0789499,3,2,0,0,0,0
4418,04/06/2019 00:00,DB04931,Afamelanotide,Absorbed through the skin and distributed throughout the body (systemically).,,The plasma half-lives following SC dosing (0.08 to 0.21 mg/kg) ranged from 0.07 to 0.79 h for the absorption phase and from 0.8 to 1.7 h for the beta-phase.,,,solid,,,0.023,3.47,11.58,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O,,,,,0,,1645.83651,6,5,3,2,1,1
4419,04/06/2019 00:00,DB04933,Eritoran,,,50.4 to 62.7 hours,,,solid,,,0.00368,0.5,-3.6,[H]\C(CCCCCC)=C(/[H])CCCCCCCCCC(O)=N[C@@]1([H])[C@]([H])(OC[C@@]2([H])O[C@]([H])(OP(O)(O)=O)[C@]([H])(N=C(O)CC(=O)CCCCCCCCCCC)[C@@]([H])(OCCCCCCCCCC)[C@]2([H])O)O[C@]([H])(COC)[C@@]([H])(OP(O)(O)=O)[C@]1([H])OCC[C@@]([H])(CCCCCCC)OC,,,,,0,,1312.843003,2,0,2,0,2,2
4420,04/06/2019 00:00,DB04934,Rifalazil,,,,,,solid,,,0.0116,4.52,8.63,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1OC5=C(N=C1C4=C3C2=O)C(O)=CC(=C5)N1CCN(CC(C)C)CC1,,,,,0,,940.4469881,7,2,4,0,1,4
4421,04/06/2019 00:00,DB04936,Tagatose,Only 15-20 percent of tagatose is absorbed in the small intestine.,,,,,solid,,,399,9.48,-3,OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO,,,,,0,,180.0633881,0,0,0,0,0,0
4422,04/06/2019 00:00,DB04938,Ospemifene,"When a single oral dose of ospemifene 60 mg is given to postmenopausal women under fasted conditions, the pharmacokinetic parameters are as follows:
Tmax = 2 hours (range of 1 - 8 hours);
Cmax = 533 ng/mL;
AUC (0-inf) = 4165 ngâ€¢hr/mL. 
When the same aforementioned dose is given to postmenopausal women under fed conditions, the pharmacokinetic parameters are as follows:
Tmax = 2.5 hours (1 - 6 hours); 
Cmax = 1198 ng/mL;
AUC (0-inf) = 7521 ngâ€¢hr/mL. 
Accumulation occurs following repeated doses. 
Time to steady state = 9 days.   
Although the bioavailability of ospemifene has not been formally evaluated, it is expected to have a low bioavailability because of its lipophilic nature. ",>99%,Terminal half-life = 26 hours . ,60 mg/1,Oral,solid,Insoluble ,,0.000526,15.1,-2.8,OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,0.99,1,,,0,60,378.1386577,3,3,0,0,0,0
4423,04/06/2019 00:00,DB04942,Tamibarotene,,,,,,solid,,,0.000575,3.69,-4,CC1(C)CCC(C)(C)C2=C1C=CC(NC(=O)C1=CC=C(C=C1)C(O)=O)=C2,,,,,0,,351.1834437,3,2,0,0,0,0
4424,04/06/2019 00:00,DB04944,Acadesine,,,1 week,,,solid,,,25,12.45,4.82,[H][C@]1(CO)O[C@]([H])([C@H](O)[C@@H]1O)N1C=NC(C(N)=O)=C1N,,,168,168,0,,258.0964195,2,1,2,1,1,1
4425,04/06/2019 00:00,DB04946,Iloperidone,"Well absorbed from the GI tract and Cmax is reached within 2-4 hours.
Steady-state concentration is achieved in 3-4 days post-administration of iloperidone. Relative bioavailability of the tablet formulation compared to oral solution is 96%. Accumulation occurs in a predictable fashion. ",0.95,"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively. ",1 mg/1,Oral,solid,Insoluble ,,0.0304,16.14,7.91,COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O,0.95,0.95,,,0,1,426.1954856,4,3,2,1,1,1
4426,04/06/2019 00:00,DB04947,Altropane,,,,,,solid,,,0.0081,,7.59,[H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C(F)C=C1)C(=O)OC)N2C\C=C\I,,,,,0,,429.0601051,3,1,2,0,2,2
4427,04/06/2019 00:00,DB04948,Lofexidine,"Lofexidine has a good oral bioavailability and the peak plasma concentration occurs after 2-5 hours of oral administration.[T210] The bioavailability is registered to be even higher than 72%.[T55] About 30% of the administered dose of lofexidine is lost during first-pass metabolism. The absorption is registered to be very rapidly recirculated in the gut. After oral administration of 0.8 mg of lofexidine, a maximal dose of 1.26 ng/ml is achieved after 3 hours.[L2801]",0.55,The reported elimination half-life of lofexidine is 11 hours.[T55],0.2 mg/1,Oral,solid,Soluble,5.37,0.147,,7.67,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1,0.55,0.55,,,0,0.2,258.0326684,2,1,1,0,0,1
4428,02/07/2019 00:00,DB04951,Pirfenidone,Rapidly absorbed following oral administration.,,2-2.5 hours,267 mg/1,Oral,solid,,,2.89,,-1.2,CC1=CN(C(=O)C=C1)C1=CC=CC=C1,,,2,2.5,0,267,185.084064,2,2,1,1,0,0
4429,04/06/2019 00:00,DB04952,Ramoplanin,No/limited absorption.,,,,,solid,,,0.0503,7.85,10.28,NCCC[C@H]1NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H]([C@@H](O)C)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H]([C@@H](C)O)NC(=O)[C@@H](CCCN)NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(N)=O)NC(=O)\C=C/C=C\CC(C)C)[C@@H](OC(=O)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]([C@@H](C)O)NC(=O)[C@@H](NC1=O)C1=CC=C(C=C1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)C1=CC=C(O)C=C1)C1=CC(Cl)=C(O)C=C1)C(N)=O)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,,,,,0,,2552.035046,10,7,3,0,3,3
4430,04/06/2019 00:00,DB04953,Ezogabine,"Rapidly absorbed and distributed, with an absolute oral bioavailability of 60%. Pharmacokinetics of ezogabine suggest first-order kinetics. 
Tmax, single oral dose = 30-120 minutes; 
Time to steady state = 3 days ",0.8,Terminal half-life = 7.5 hours ,200 mg/1,Oral,solid,,,0.0307,13.6,3.99,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,0.8,0.8,,,0,200,303.138305,2,2,0,0,0,0
4431,04/06/2019 00:00,DB04954,Tecadenoson,,,,,,solid,,,8.22,12.45,4.84,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(N[C@@H]3CCOC3)N=CN=C12,,,,,0,,337.1386187,4,2,4,2,2,2
4432,04/06/2019 00:00,DB04957,Azimilide,Excellent oral absorption.,,,,,solid,,,0.0861,11.95,8.7,CN1CCN(CCCCN2C(=O)CN(N=CC3=CC=C(O3)C3=CC=C(Cl)C=C3)C2=O)CC1,,,,,0,,457.1880674,4,2,3,1,2,2
4433,04/06/2019 00:00,DB04960,Tipifarnib,,,,,,solid,,,0.000478,,7.74,CN1C=NC=C1[C@@](N)(C1=CC=C(Cl)C=C1)C1=CC2=C(C=C1)N(C)C(=O)C=C2C1=CC(Cl)=CC=C1,,,,,0,,488.1170667,5,5,2,2,0,0
4434,04/06/2019 00:00,DB04961,Troxacitabine,,,,,,solid,,,1.83,9.15,2.43,[H][C@]1(CO)OC[C@]([H])(O1)N1C=CC(=N)N=C1O,,,,,0,,213.0749558,2,1,2,1,1,1
4435,04/06/2019 00:00,DB04967,Lucanthone,Orally available,,,,,solid,,,0.00315,18.84,8.69,CCN(CC)CCNC1=C2C(=O)C3=CC=CC=C3SC2=C(C)C=C1,,,,,0,,340.1609344,3,3,1,1,0,0
4436,04/06/2019 00:00,DB04970,Lesopitron,"Rapidly absorbed in patients, having a time to maximum concentration (Tmax) ranging from 0.5 to 1 hour. The absolute bioavailability of lesopitron in rats was about 10%, suggesting an important first-pass effect.",,1.1 to 5.6 hours,,,solid,,,1.25,,7.75,ClC1=CN(CCCCN2CCN(CC2)C2=NC=CC=N2)N=C1,,,,,0,,320.1516224,3,2,3,2,1,1
4437,04/06/2019 00:00,DB04971,Reglitazar,,,,,,solid,,,0.0244,9.65,0.93,CC1=C(CCOC2=CC=C(CC3C(=O)NOC3=O)C=C2)N=C(O1)C1=CC=CC=C1,,,,,0,,392.1372217,4,3,2,1,1,1
4438,04/06/2019 00:00,DB04972,Canfosfamide,,,18 min,,,solid,,,0.0358,1.53,9.14,[H][C@](N)(CCC(O)=N[C@@]([H])(CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)C(O)=N[C@@]([H])(C(O)=O)C1=CC=CC=C1)C(O)=O,,,0.3,0.3,0,,785.0987608,1,1,0,0,0,0
4439,04/06/2019 00:00,DB04975,Banoxantrone,,,0.64 to 0.83 hours,,,solid,,,0.0151,8.45,4.6,C[N+](C)([O-])CCNC1=CC=C(NCC[N+](C)(C)[O-])C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O,,,,,0,,444.2008846,3,2,0,0,0,0
4440,04/06/2019 00:00,DB04977,Plitidepsin,,,,,,solid,,,0.0201,10.91,-3.1,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@@H](OC(=O)C[C@H](O)[C@]([H])(NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]1CCCN1C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](CC1=CC=C(OC)C=C1)N(C)C2=O)[C@@H](C)CC)C(C)C,,,,,0,,1109.626015,4,1,3,0,3,3
4441,04/06/2019 00:00,DB04982,Talampanel,"Rapidly absorbed, with maximal plasma concentrations achieved within 1-3 hours.",,3-6 hours,,,solid,,,0.126,,3.38,C[C@@H]1CC2=CC3=C(OCO3)C=C2C(=NN1C(C)=O)C1=CC=C(N)C=C1,,,3,6,0,,337.1426415,4,2,2,0,0,2
4442,04/06/2019 00:00,DB04983,Denufosol,,,,,,solid,,,22.3,0.76,0.13,[H]N([H])C1=NC(=O)N(C=C1)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)N([H])C2=O)O1,,,,,0,,773.0148994,4,2,4,2,2,2
4443,04/06/2019 00:00,DB05003,Imexon,,,,,,solid,,,71.4,,3.63,NC1=NC(=O)N2CC12,,,,,0,,111.0432618,2,0,2,0,1,2
4444,04/06/2019 00:00,DB05009,Apadenoson,,,,,,solid,,,0.116,12.39,1.09,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=C(N=C2N)C#CC[C@H]1CC[C@@H](CC1)C(=O)OC,,,,,0,,486.2226827,4,2,3,2,1,1
4445,04/06/2019 00:00,DB05010,SGS-742,,,4 hours,,,solid,,,21.2,1.92,10.21,CCCCP(O)(=O)CCCN,,,4,4,0,,179.1075154,0,0,0,0,0,0
4446,02/07/2019 00:00,DB05013,Ingenol mebutate,"Since ingenol mebutate is a topical treatment, the systemic absorption is less than 0.1 ng/mL.",,There is no half-life quantity since ingenol mebutate is a topical treatment.,150 micrograms/g,Cutaneous,solid,,,0.279,12.13,-2.8,[H][C@@]12C[C@@H](C)[C@]34C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@H](O)C(CO)=C[C@@]([H])(C4=O)[C@]1([H])C2(C)C,,,,,0,,430.2355388,4,0,0,0,0,0
4447,04/06/2019 00:00,DB05015,Belinostat,,0.929,Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours,500 mg/10mL,Intravenous,solid,0.14 mg/mL,,0.0285,7.82,-5.1,ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1,0.929,0.929,,,0,,318.0674279,2,2,0,0,0,0
4448,04/06/2019 00:00,DB05016,Ataluren,Peak plasma levels of ataluren are attained approximately 1.5 hours after dosing in subjects who received medicinal product within 30 minutes of a meal [L925].,0.996,Ataluren plasma half-life ranges from 2-6 hours and is unaffected either by dose or repeated administration [L925].,1000 mg,Oral,solid,,,0.117,3.9,-1.6,OC(=O)C1=CC=CC(=C1)C1=NOC(=N1)C1=CC=CC=C1F,0.996,0.996,,,0,1000,284.0597204,3,3,1,1,0,0
4449,02/07/2019 00:00,DB05018,Migalastat,"With absorption occurring largely in the gut [L4263], the absolute bioavailability (AUC) for a single oral 150 mg migalastat hydrochloride dose or a single 2-hour 150 mg intravenous infusion was approximately 75% [FDA Label, F1107]. Following a single oral dose of 150 mg migalastat hydrochloride solution, the time to peak plasma concentration was approximately 3 hours [FDA Label, F1107]. Plasma migalastat exposure (AUC0-âˆž) and Cmax demonstrated dose-proportional increases at migalastat hydrochloride oral doses from 50 mg to 1,250 mg [FDA Label, F1107].

Migalastat administered with a high-fat meal, or 1 hour before a high-fat or light meal, or 1 hour after a light meal, resulted in significant reductions of 37% to 42% in mean total migalastat exposure (AUC0-âˆž) and reductions of 15% to 40% in mean peak migalastat exposure (Cmax) compared with the fasting state [FDA Label, F1107].",,"The mean elimination half-life (t1/2) of migalastat ranges from approximately 3 to 5 hours [FDA Label, F1107].",123 mg/1,Oral,solid,,,511,12.91,8.06,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O,,,,,0,123,163.0844579,1,0,1,0,1,1
4450,04/06/2019 00:00,DB05022,Amonafide,,,,,,solid,,,0.764,,8.52,CN(C)CCN1C(=O)C2=CC=CC3=CC(N)=CC(C1=O)=C23,,,,,0,,283.1320768,3,2,1,0,0,1
4451,04/06/2019 00:00,DB05025,Arimoclomol,,,,,,solid,,,0.237,14,9.14,O[C@@H](CON=C(Cl)C1=C[N+]([O-])=CC=C1)CN1CCCCC1,,,,,0,,313.1193192,2,1,2,1,1,1
4452,04/06/2019 00:00,DB05034,Ularitide,,,,,,solid,,,0.15,3.13,12.68,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O,,,,,0,,3503.683362,5,3,2,0,2,2
4453,04/06/2019 00:00,DB05035,Eprotirome,,,,,,solid,,,0.00201,2.21,-3.7,CC(C)C1=CC(OC2=C(Br)C=C(NC(=O)CC(O)=O)C=C2Br)=CC=C1O,,,,,0,,484.9473468,2,2,0,0,0,0
4454,04/06/2019 00:00,DB05038,Anatibant,,>97.7%,,,,solid,,,0.000654,14.12,10.94,CC1=CC(C)=C2C=CC=C(OCC3=C(Cl)C=CC(=C3Cl)S(=O)(=O)N3CCC[C@H]3C(=O)NCCCNC(=O)C3=CC=C(C=C3)C(N)=N)C2=N1,0.97,1,,,0,,710.1844946,5,4,2,1,1,1
4455,02/07/2019 00:00,DB05039,Indacaterol,The median time to reach peak serum concentrations of indacaterol was approximately 15 minutes after single or repeated inhaled doses. Absolute bioavailability of indacaterol after an inhaled dose was on average 43-45%.,94.1-95.3%,"Indacaterol serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing with once daily doses between 75 mcg and 600 mcg ranged from 40 to 56 hours which is consistent with the observed time-to-steady state of approximately 12-15 days.",75 ug/1,Oral; Respiratory (inhalation),solid,,,0.00798,8.51,9.71,CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1,0.941,0.953,,,0,0.075,392.2099928,4,3,1,1,0,0
4456,04/06/2019 00:00,DB05047,CX717,,,,,,solid,,,9.23,,-1.3,O=C(N1CCOCC1)C1=CC2=NON=C2C=C1,,,,,0,,233.0800412,3,2,2,1,1,1
4457,04/06/2019 00:00,DB05048,Cannabinor,,,,,,solid,,,0.000675,2.92,-6.1,CCCCCCC(C)(C)C1=CC(O)=C([C@H]2CC(=O)[C@H]3C[C@@H]2C3(C)C)C(OC(=O)\C=C\C(O)=O)=C1,,,,,0,,470.2668389,4,1,0,0,0,0
4458,04/06/2019 00:00,DB05053,MB-07803,,,,,,solid,,,0.0379,15.41,1.91,CCOC(=O)C(C)(C)NP(=O)(NC(C)(C)C(=O)OCC)C1=CC=C(O1)C1=C(SC(N)=N1)C(=O)C(C)(C)C,,,,,0,,556.2120572,2,2,2,2,0,0
4459,04/06/2019 00:00,DB05057,Erdosteine,,,,,,solid,,,4.85,3.79,-3.7,OC(=O)CSCC(=O)NC1CCSC1=O,,,,,0,,249.0129498,1,0,1,0,1,1
4460,04/06/2019 00:00,DB05075,TG-100801,,,,,,solid,,,0.00167,13.33,9.03,CC1=C2N=C(NC3=CC=C(OCCN4CCCC4)C=C3)N=NC2=CC(=C1)C1=CC(OC(=O)C2=CC=CC=C2)=CC=C1Cl,,,,,0,,579.2037175,6,5,2,1,1,1
4461,04/06/2019 00:00,DB05076,Fenretinide,,,,,,solid,,,0.00119,9.45,-1.2,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1,,,,,0,,391.2511293,2,1,0,0,0,0
4462,04/06/2019 00:00,DB05087,Ganaxolone,,>99%,1.3-1.9 hours,,,solid,,,0.000712,19.1,-1,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C,0.99,1,1.3,1.9,0,,332.2715304,4,0,0,0,0,0
4463,04/06/2019 00:00,DB05095,Cimicoxib,,,,,,solid,,,0.018,10.8,3.69,COC1=C(F)C=C(C=C1)C1=C(Cl)N=CN1C1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,381.0350182,3,3,1,1,0,0
4464,04/06/2019 00:00,DB05100,Prinomastat,,,2-5 hours,,,solid,,,0.0464,4.42,5.95,[H][C@]1(N(CCSC1(C)C)S(=O)(=O)C1=CC=C(OC2=CC=NC=C2)C=C1)C(O)=NO,,,2,5,0,,423.0922628,3,2,2,1,1,1
4465,04/06/2019 00:00,DB05102,Rupintrivir,,,,,,solid,,,0.0306,12.49,0.035,CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@H](C(C)C)NC(=O)C1=NOC(C)=C1)CC1=CC=C(F)C=C1,,,,,0,,598.2802778,3,2,2,1,1,1
4466,04/06/2019 00:00,DB05103,AN-9,,,,,,solid,,,1.46,,-6.8,CCCC(=O)OCOC(=O)C(C)(C)C,,,,,0,,202.1205091,0,0,0,0,0,0
4467,04/06/2019 00:00,DB05104,Asimadoline,,,,,,solid,,,0.0112,14.85,8.17,CN([C@H](CN1CC[C@H](O)C1)C1=CC=CC=C1)C(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,414.2307282,4,3,1,0,1,1
4468,04/06/2019 00:00,DB05105,Pleconaril,70% (oral),&gt;99%,,,,solid,,,0.0219,,1.64,CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C2=NOC(=N2)C(F)(F)F)=C1,0.99,0.99,,,0,,381.1300261,3,3,2,2,0,0
4469,04/06/2019 00:00,DB05107,16-Bromoepiandrosterone,,,,,,solid,,,0.00209,17.86,-1.4,[H][C@@]12C[C@@H](Br)C(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C,,,,,0,,368.1350923,4,0,0,0,0,0
4470,02/07/2019 00:00,DB05109,Trabectedin,Administered intravenously. ,0.98,33-50 hours,0.05 mg/1mL,Intravenous,solid,,,0.328,9.27,7.66,[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31,0.98,0.98,33,50,0,,761.2618302,10,3,7,0,2,7
4471,04/06/2019 00:00,DB05116,Thymectacin,,,,,,solid,,,0.0809,9.62,-3.2,COC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O)OC1=CC=CC=C1,,,,,0,,573.0511781,3,2,2,1,1,1
4472,04/06/2019 00:00,DB05119,Rilapladib,,,,,,solid,,,0.000509,13.77,8.4,COCCN1CCC(CC1)N(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C(SCC2=C(F)C(F)=CC=C2)=CC(=O)C2=C1C=CC=C2,,,,,0,,735.2554042,6,5,2,1,1,1
4473,04/06/2019 00:00,DB05123,Gemcabene,,,,,,solid,,,0.0608,4.38,-4.1,CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O,,,,,0,,302.2093241,0,0,0,0,0,0
4474,04/06/2019 00:00,DB05128,Aminocandin,,,,,,solid,,,0.0389,9.81,9.21,CCCCCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1CC(CNC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)CC1=CC=C(O)C=C1)NCCN,,,,,0,,1101.574648,6,3,3,0,3,3
4475,04/06/2019 00:00,DB05129,Elsamitrucin,,,36â€“60 h,,,solid,,,0.379,9.1,7.98,CO[C@@H]1[C@@H](N)[C@@H](O[C@H]2[C@H](OC3=CC=CC4=C3C3=C5C(C(=O)OC6=C5C(=C(C)C=C6)C(=O)O3)=C4O)O[C@H](C)[C@H](O)[C@]2(C)O)O[C@H](C)[C@@H]1O,,,36,60,0,,653.2108402,7,5,4,2,2,2
4476,04/06/2019 00:00,DB05134,Tanespimycin,,,,,,solid,,,0.00715,-2.9,11.59,[H]/C1=C([H])/[C@]([H])(OC)[C@@]([H])(OC(O)=N)C(C)=C([H])[C@]([H])(C)[C@@]([H])(O)[C@]([H])(C[C@]([H])(C)CC2=C(NCC=C)C(=O)C=C(N=C(O)\C(C)=C\1/[H])C2=O)OC,,,,,0,,585.3050153,2,0,1,0,0,1
4477,04/06/2019 00:00,DB05137,Lobeline,,,,,,solid,,,0.0298,14.42,8.77,CN1[C@H](C[C@H](O)C2=CC=CC=C2)CCC[C@@H]1CC(=O)C1=CC=CC=C1,,,,,0,,337.2041791,3,2,1,0,1,1
4478,04/06/2019 00:00,DB05143,OXI-4503,,,,,,solid,,,0.0268,1.31,-4.3,[H]\C(=C(/[H])C1=C(OP(O)(O)=O)C(OP(O)(O)=O)=C(OC)C=C1)C1=CC(OC)=C(OC)C(OC)=C1,,,,,0,,492.0586494,2,2,0,0,0,0
4479,04/06/2019 00:00,DB05154,Pretomanid,,,,,,solid,,,0.0117,,-3,[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC1=CC=C(OC(F)(F)F)C=C1,,,,,0,,359.0729051,3,2,2,1,0,1
4480,04/06/2019 00:00,DB05155,CR665,,,,,,solid,,,0.00349,12.18,11.69,CCCC[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC1=CC=NC=C1,,,,,0,,671.390751,3,3,1,1,0,0
4481,04/06/2019 00:00,DB05168,Vintafolide,,,,,,solid,,,0.0133,2.47,11.9,[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC,,,,,0,,1915.729405,12,4,8,1,2,7
4482,04/06/2019 00:00,DB05171,E-2012,,,,,,solid,,,0.00165,,6.27,[H]\C(C1=CC(OC)=C(C=C1)N1C=NC(C)=C1)=C1\CCCN(C1=O)[C@@]([H])(C)C1=CC=C(F)C=C1,,,,,0,,419.2009053,4,3,2,1,1,1
4483,04/06/2019 00:00,DB05186,SQ-109,,,,,,solid,,,0.00171,,10.24,CC(C)=CCC\C(C)=C\CNCCNC1C2CC3CC(C2)CC1C3,,,,,0,,330.3034992,4,0,0,0,0,0
4484,04/06/2019 00:00,DB05187,Elafibranor,,,,,,solid,,,0.000228,4,-4.9,CSC1=CC=C(C=C1)C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1,,,,,0,,384.1395302,2,2,0,0,0,0
4485,04/06/2019 00:00,DB05197,Sofalcone,,,,,,solid,,,0.000674,3.22,-4.4,CC(C)=CCOC1=CC=C(\C=C\C(=O)C2=C(OCC(O)=O)C=C(OCC=C(C)C)C=C2)C=C1,,,,,0,,450.2042387,2,2,0,0,0,0
4486,04/06/2019 00:00,DB05212,HE3286,Up to 25% oral bioavailability in mice.,,,,,solid,,,0.017,17.59,-0.77,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]2(O)C#C)[C@@H](O)C=C1C[C@@H](O)CC[C@]31C,,,,,0,,330.2194948,4,0,0,0,0,0
4487,02/07/2019 00:00,DB05219,Crisaborole,Systemic concentrations of crisaborole were reached by 8 days of twice-daily topical administration. It has low systemic absorption thus poses less risk for developing systemic side effects. ,0.97,,0.02,Topical,solid,Insoluble,,0.0234,8.95,-3.7,OB1OCC2=C1C=CC(OC1=CC=C(C=C1)C#N)=C2,0.97,0.97,,,0,,251.0753736,3,2,1,0,0,1
4488,04/06/2019 00:00,DB05220,Alisertib,,,,,,solid,,,0.00149,4.28,3.01,COC1=CC(NC2=NC=C3CN=C(C4=C(C=CC(Cl)=C4)C3=N2)C2=C(F)C=CC=C2OC)=CC=C1C(O)=O,,,,,0,,518.115711,5,4,2,1,0,1
4489,04/06/2019 00:00,DB05223,Pracinostat,Oral bioavailability in mice is 34%.,,,,,solid,,,0.0306,9.3,9.9,CCCCC1=NC2=CC(\C=C\C(=O)NO)=CC=C2N1CCN(CC)CC,,,,,0,,358.2368762,2,2,1,1,0,0
4490,04/06/2019 00:00,DB05229,Beraprost,Oral bioavailability is 50â€“70%.,,35â€“40 minutes,,,solid,,,0.00811,4.2,-1.4,[Na+].[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C1=CC=CC(CCCC([O-])=O)=C1O2,,,0.583333333,0.666666667,0,,420.1912683,3,1,1,0,0,1
4491,04/06/2019 00:00,DB05232,Tetrodotoxin,,,,,,solid,,,117,10.4,9.62,[H][C@]12OC3([O-])OC(C4C(O)[NH+]=C(N)NC4(C1O)[C@@H]3O)C2(O)CO,,,,,0,,319.1015645,5,0,4,0,3,4
4492,04/06/2019 00:00,DB05234,LGD2941,Orally-available,,,,,solid,,,0.0344,10.91,0.46,C[C@@H]1CC[C@H]([C@@H](O)C(F)(F)F)N1C1=CC2=C(NC(=O)C=C2C(F)(F)F)C=C1,,,,,0,,394.1115971,3,2,2,1,1,1
4493,02/07/2019 00:00,DB05239,Cobimetinib,"The bioavailability of cobimetinib is 46%, the AUC and Cmax is unaffected by food. ",0.95,Average half life was 44 hours. ,20 mg,Oral,solid,,,0.0422,13.37,9.76,OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1,0.95,0.95,,,0,20,531.0630596,4,2,2,0,2,2
4494,02/07/2019 00:00,DB05245,Silver sulfadiazine,Very limited penetration through the skin. Only when applied to very large area burns is absorption into the body generally an issue.,,,0.01,Topical,solid,,,7.87,6.99,2.01,[Ag+].NC1=CC=C(C=C1)S(=O)(=O)[N-]C1=NC=CC=N1,,,,,0,,355.9497185,2,2,1,1,0,0
4495,04/06/2019 00:00,DB05246,Methsuximide,,,1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.,150 mg/1,Oral,solid,,,2.13,19.03,-7.2,CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1,,,,,0,150,203.0946287,2,1,1,0,1,1
4496,04/06/2019 00:00,DB05252,Fenoxaprop-ethyl,,,,,,solid,,,0.0273,,-2.9,CCOC(=O)C(C)OC1=CC=C(OC2=NC3=C(O2)C=C(Cl)C=C3)C=C1,,,,,0,,361.0717003,3,3,1,1,0,0
4497,04/06/2019 00:00,DB05255,Ronacaleret,,,,,,solid,,,0.00145,3.23,9.96,CC(C)(CC1CC2=C(C1)C=CC=C2)NC[C@@H](O)COC1=CC(CCC(O)=O)=CC(F)=C1F,,,,,0,,447.2221149,3,2,0,0,0,0
4498,04/06/2019 00:00,DB05262,Oxypurinol,,,23.3 +/- 6.0 hours,,,solid,,,2.32,7.19,-3.7,O=C1NC(=O)C2=CNNC2=N1,,,,,0,,152.0334254,2,0,2,0,0,2
4499,04/06/2019 00:00,DB05263,Caprospinol,,,,,,solid,,,1.55E-05,,-4,CCCCCC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C[C@@H]5O[C@]6(CC[C@@H](C)CO6)[C@@H](C)[C@H]45)[C@@H]3CC=C2C1,,,,,0,,512.3865601,6,0,2,0,2,2
4500,04/06/2019 00:00,DB05265,Ecabet,,,,,,solid,,,0.00426,-1.5,,[H][C@@]12CCC3=CC(C(C)C)=C(C=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)S(O)(=O)=O,,,,,0,,380.165745,3,1,0,0,0,0
4501,04/06/2019 00:00,DB05266,Ibudilast,,,19 hours,,,solid,,,0.179,16.12,1.86,CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C,,,19,19,0,,230.1419132,2,2,2,2,0,0
4502,02/07/2019 00:00,DB05271,Rotigotine,"Bioavailability varies depending on the application site. Differences in bioavailability were very small between the abdomen and hip (<1%). In contrast, the shoulder and thigh had a very large different in measured bioavailability (46%), with the shoulder showing the higher value. 
Tmax, 8 mg dose = 15 - 18 hours (it take approximately 3 hours until rotigotine reaches detectable levels in the plasma). The peak concentration cannot be observered. Steady state is reached in 2-3 days. ",0.92,"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.",1 mg,Transdermal,solid,,4.7,0.00904,10.03,10.97,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1,0.92,0.92,,,0,,315.1656854,3,2,1,1,0,0
4503,04/06/2019 00:00,DB05273,Samarium (153Sm) lexidronam,,,,50 mCi/1mL,Intravenous,solid,,,20,0.96,,[153Sm+3].OP(O)(=O)CN(CCN(CP(O)([O-])=O)CP(O)([O-])=O)CP(O)([O-])=O,,,,,0,,585.8952929,0,0,0,0,0,0
4504,04/06/2019 00:00,DB05284,CA4P,,,,,,solid,,,0.0545,9.99,-3.1,COC1=CC(=CC(OC)=C1OC)[C@@H](O)CC1=CC(O)=C(OC)C=C1,,,,,0,,334.1416384,2,2,0,0,0,0
4505,04/06/2019 00:00,DB05288,Anecortave acetate,,,,,,solid,,,0.0113,12.61,-3.8,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,386.2093241,4,0,0,0,0,0
4506,04/06/2019 00:00,DB05289,Tarenflurbil,,,,,,solid,,,0.0249,4.42,,C[C@@H](C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,,,,,0,,244.0899579,2,2,0,0,0,0
4507,02/07/2019 00:00,DB05294,Vandetanib,"Slow- peak plasma concentrations reached at a median 6 hours. On multiple dosing, Vandetanib accumulates about 8 fold with steady state reached after around 3 months. ",,Median half life of 19 days.,100 mg,Oral,solid,0.008 mg/mL at 25Â°C (77Â°F ),,0.0102,13.8,9.13,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1,,,,,0,100,474.1066663,4,3,2,1,1,1
4508,04/06/2019 00:00,DB05295,Eldecalcitol,,,,,,solid,,,0.0105,13.38,-1.3,[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C)[C@H](C)CCCC(C)(C)O,,,,,0,,490.3658247,3,0,0,0,0,0
4509,04/06/2019 00:00,DB05296,Motexafin lutetium,,,,,,solid,,,0.00532,15.62,2.45,[Lu+3].CC([O-])=O.CC([O-])=O.CCC1=C2[N-]C(\C=C3/N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4\N=C\C4=N\C(=C/2)\C(CCCO)=C4C)C(C)=C3CCCO)=C1CC,,,,,0,,1165.448349,5,3,4,2,0,2
4510,04/06/2019 00:00,DB05297,Paclitaxel docosahexaenoic acid,,,,,,solid,,,7.67E-05,10.37,-1,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@@]3([H])[C@@](C)([C@@H](O)C[C@@]4([H])OC[C@@]34OC(=O)C)C(=O)[C@H](OC(=O)C)C(=C1C)C2(C)C)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,1163.560621,7,3,1,0,1,1
4511,04/06/2019 00:00,DB05298,Tetomilast,,,,,,solid,,,0.00301,3.62,-0.68,CCOC1=C(OCC)C=C(C=C1)C1=NC(=CS1)C1=NC(=CC=C1)C(O)=O,,,,,0,,370.0987281,3,3,2,2,0,0
4512,04/06/2019 00:00,DB05316,Pimavanserin,,,,34 mg/1,Oral,solid,,,0.00748,15.06,8.44,CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1,,,,,0,34,427.2635055,3,2,1,0,1,1
4513,04/06/2019 00:00,DB05327,Ranirestat,,,,,,solid,,,0.0295,8.52,-6.9,FC1=C(CN2C(=O)C3=CC=CN3[C@@]3(CC(=O)NC3=O)C2=O)C=CC(Br)=C1,,,,,0,,418.9916962,4,2,3,1,1,2
4514,04/06/2019 00:00,DB05340,ATL-2502,,,,,,solid,,,0.0249,-2.5,-2.9,[Na+].CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)COC(=O)C1=CC(=CC=C1)S([O-])(=O)=O,,,,,0,,566.1586479,5,1,0,0,0,0
4515,04/06/2019 00:00,DB05343,Arundic acid,,,,,,solid,,,0.0919,5.24,,CCCCCC[C@@H](CCC)C(O)=O,,,,,0,,186.1619799,0,0,0,0,0,0
4516,02/07/2019 00:00,DB05351,Dexlansoprazole,"After oral administration, the peak plasma concentration increases approximately dose proportionally. The dual delayed release formulation achieves two plasma concentration peaks, where the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. The delivery technology of dexlansoprazole MR is designed to release the drug in two separate pH-dependent phases, the first in the proximal duodenum (25% of total drug dose) and the second (75% of total drug dose) in the more distal small intestine. The median time (Tmax) to peak plasma concentrations (Cmax) of 30 mg dexlansoprazole was 4 hours and ranged from 1 to 6 hours with the Cmax value of 688 ng/mL. AUC was found to be 3275 (ngâˆ™h/mL)[FDA Label].",0.96,Dexlansoprazole is eliminated with a half-life of approximately one to two hours in healthy subjects and in patients with symptomatic GERD. ,30 mg,Oral,solid,0.21mg/mL at pH7.0,2.38,0.25,9.35,4.16,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,0.96,0.96,,,0,30,369.0758823,3,3,2,2,0,0
4517,04/06/2019 00:00,DB05377,Chlorfenson,,,,,,solid,,,0.0079,,,ClC1=CC=C(OS(=O)(=O)C2=CC=C(Cl)C=C2)C=C1,,,,,0,,301.9571205,2,2,0,0,0,0
4518,04/06/2019 00:00,DB05380,DOTMP HO-166,,,,,,solid,,,32.1,0.96,,[166Ho++].OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP([O-])([O-])=O)CCN(CP(O)(O)=O)CC1,,,,,0,,712.0133531,1,0,1,0,1,1
4519,02/07/2019 00:00,DB05381,Histamine,Readily absorbed after parenteral administration.,,,0.05 g/100g,Topical,solid,,,169,14.46,9.58,NCCC1=CNC=N1,,,,,0,,111.0796473,1,1,1,1,0,0
4520,04/06/2019 00:00,DB05383,Pimagedine,,,,,,solid,,,8.36,,12.01,NNC(N)=N,,,,,0,,74.05924619,0,0,0,0,0,0
4521,04/06/2019 00:00,DB05395,Amibegron,,,,,,solid,,,0.00179,14.03,9.7,CCOC(=O)COC1=CC=C2CC[C@@H](CC2=C1)NC[C@H](O)C1=CC=CC(Cl)=C1,,,,,0,,403.155036,3,2,0,0,0,0
4522,04/06/2019 00:00,DB05399,Succinobucol,,,,,,solid,,,3.09E-05,4.33,-5.1,CC(C)(C)C1=CC(SC(C)(C)SC2=CC(=C(OC(=O)CCC(O)=O)C(=C2)C(C)(C)C)C(C)(C)C)=CC(=C1O)C(C)(C)C,,,,,0,,616.3256168,2,2,0,0,0,0
4523,04/06/2019 00:00,DB05403,CEP-1347,,,,,,solid,,,0.0111,13.91,-1.6,[H][C@@]12C[C@H](C(=O)OOC)[C@](C)(O1)N1C3=C(C=C(CSCC)C=C3)C3=C4CNC(=O)C4=C4C5=C(C=CC(CSCC)=C5)N2C4=C13,,,,,0,,615.1861632,8,5,5,2,1,3
4524,04/06/2019 00:00,DB05408,Emricasan,,,,,,solid,,,0.00213,3.51,-4.3,C[C@H](NC(=O)C(=O)NC1=CC=CC=C1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F,,,,,0,,569.1785131,2,2,0,0,0,0
4525,04/06/2019 00:00,DB05409,NCX 701,,,,,,solid,,,0.0468,14.68,-4.4,CC(=O)NC1=CC=C(OC(=O)CCCO[N+]([O-])=O)C=C1,,,,,0,,282.0851862,1,1,0,0,0,0
4526,04/06/2019 00:00,DB05410,NCX 1022,,,,,,solid,,,0.00244,12.61,-2.8,CC12CC(O)C3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C(=O)COC(=O)C1=CC=CC(CON(=O)=O)=C1,,,,,0,,541.2311817,5,1,0,0,0,0
4527,04/06/2019 00:00,DB05412,Talmapimod,,,,,,solid,,,0.00586,,5.95,[H][C@]1(C)CN(C(=O)C2=C(Cl)C=C3N(C)C=C(C(=O)C(=O)N(C)C)C3=C2)[C@]([H])(C)CN1CC1=CC=C(F)C=C1,,,,,0,,512.1990467,4,3,2,1,1,1
4528,04/06/2019 00:00,DB05414,Pipendoxifene,,,,,,solid,,,0.000933,9.51,8.77,CC1=C(N(CC2=CC=C(OCCN3CCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1,,,,,0,,456.2412929,5,4,2,1,1,1
4529,04/06/2019 00:00,DB05416,Cardarine,,,,,,solid,,,0.000325,3.51,2.14,CC1=C(CSC2=CC(C)=C(OCC(O)=O)C=C2)SC(=N1)C1=CC=C(C=C1)C(F)(F)F,,,,,0,,453.0680201,3,3,1,1,0,0
4530,04/06/2019 00:00,DB05420,Gallium maltolate,,,,,,solid,,,0.0149,9.45,-3.6,[Ga+3].CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1,,,,,0,,443.9971807,3,3,3,3,0,0
4531,04/06/2019 00:00,DB05421,CP-122721,,,,,,solid,,,0.00152,,9.04,COC1=CC=C(OC(F)(F)F)C=C1CN[C@H]1CCCN[C@H]1C1=CC=CC=C1,,,,,0,,380.1711626,3,2,1,0,1,1
4532,04/06/2019 00:00,DB05422,OPC-14523,,,,,,solid,,,0.0296,,7.67,COC1=CC=CC2=C1CCC(=O)N2CCCN1CCN(CC1)C1=CC=CC(Cl)=C1,,,,,0,,413.1870048,4,2,2,0,1,2
4533,04/06/2019 00:00,DB05423,ORG-34517,,,,,,solid,,,0.00337,12.87,-3.7,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1=CC=C2OCOC2=C1,,,,,0,,430.2144094,6,1,1,0,0,1
4534,04/06/2019 00:00,DB05424,Canertinib,,,,,,solid,,,0.0155,12.54,6.87,FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1,,,,,0,,485.1629956,4,3,2,1,1,1
4535,04/06/2019 00:00,DB05426,talactoferrin alpha,,,,,,solid,,,0.0537,9.21,7.72,COC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1,,,,,0,,672.3118916,2,2,0,0,0,0
4536,04/06/2019 00:00,DB05428,motexafin gadolinium,,,,,,solid,,,0.0122,15.62,2.19,[Gd+3].CC([O-])=O.CC([O-])=O.CCC1=C(CC)/C2=C/C3=N/C(=C\N=C4/C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=C/C/4=N\C=C4/N=C(/C=C\1\[N-]\2)C(CCCO)=C4C)/C(C)=C3CCCO,,,,,0,,1148.431681,5,3,4,2,0,2
4537,04/06/2019 00:00,DB05431,MLN-977,,,,,,solid,,,0.00919,4.22,6.8,[H][C@@]1(COC2=CC=C(F)C=C2)CC[C@]([H])(O1)C#CCCN(O)C(O)=N,,,,,0,,322.1328853,2,1,1,0,1,1
4538,04/06/2019 00:00,DB05434,ABT-510,,,,,,solid,,,0.0426,10.73,11.56,CCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN(C)C(C)=O)C(C)C)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC,,,,,0,,993.6335005,1,0,1,0,1,1
4539,04/06/2019 00:00,DB05442,Etiprednol dicloacetate,,,,,,solid,,,0.00235,14.88,-2.9,[H][C@@]12CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,484.141944,4,0,0,0,0,0
4540,04/06/2019 00:00,DB05444,Iroxanadine,,,,,,solid,,,0.908,18.8,8.68,C(C1CONC(=N1)C1=CN=CC=C1)N1CCCCC1,,,,,0,,260.1637113,3,1,3,1,1,2
4541,04/06/2019 00:00,DB05446,LJP 1082,,,,,,solid,,,5.27,1.79,9.31,NC(CCC(=O)NC(CSCO)C(=O)NCC(O)=O)C(O)=O,,,,,0,,337.0943709,0,0,0,0,0,0
4542,04/06/2019 00:00,DB05448,PX-12,the optimum PD dose was identified as 96 mg/m2 as a 3-hr infusion,,,,,solid,,,0.783,10.93,4.81,CCC(C)SSC1=NC=CN1,,,,,0,,188.0441904,1,1,1,1,0,0
4543,04/06/2019 00:00,DB05450,Smilagenin,,,,,,solid,,,3.28E-05,18.3,-1.4,[H][C@]12C[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@@H](O)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2,,,,,0,,416.3290453,6,0,2,0,2,2
4544,04/06/2019 00:00,DB05454,Paliroden,,,,,,solid,,,0.000158,,8.92,FC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC=C(C=C2)C2=CC=CC=C2)CC1,,,,,0,,407.1860844,4,3,1,0,0,1
4545,04/06/2019 00:00,DB05456,ETC-588,,,,,,solid,,,2.06E-05,1.86,-6.7,CCCCCCCCCCCCCCCC(=O)OC(COC(=O)CCCCCCC\C=C/CCCCCCCC)COP([O-])(=O)OCC[N+](C)(C)C,,,,,0,,759.5778052,0,0,0,0,0,0
4546,04/06/2019 00:00,DB05458,Pozanicline,,,,,,solid,,,13.1,,10.47,CC1=C(OC[C@@H]2CCCN2)C=CC=N1,,,,,0,,192.1262631,2,1,2,1,1,1
4547,04/06/2019 00:00,DB05460,Ezatiostat,,,,,,solid,,,0.00245,11.8,7.18,CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@@H](C(=O)OCC)C1=CC=CC=C1,,,,,0,,529.2246568,2,2,0,0,0,0
4548,04/06/2019 00:00,DB05462,Chlorotoxin I-131,,,,,,solid,,,6.91E-05,,8.78,CCC(C(C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,,,,,0,,373.2405646,3,3,0,0,0,0
4549,04/06/2019 00:00,DB05465,Tandutinib,,,,,,solid,,,0.0753,14.01,9.03,COC1=C(OCCCN2CCCCC2)C=C2N=CN=C(N3CCN(CC3)C(=O)NC3=CC=C(OC(C)C)C=C3)C2=C1,,,,,0,,562.3267538,5,3,3,1,2,2
4550,04/06/2019 00:00,DB05470,VX-702,,,,,,solid,,,0.00245,13.95,-0.73,NC(=O)N(C1=CC=C(C(N)=O)C(=N1)C1=CC=C(F)C=C1F)C1=C(F)C=CC=C1F,,,,,0,,404.0896385,3,3,1,1,0,0
4551,04/06/2019 00:00,DB05475,Golotimod,,,,,,solid,,,0.347,1.98,9.31,N[C@H](CCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O)C(O)=O,,,,,0,,333.1324707,2,2,1,1,0,0
4552,04/06/2019 00:00,DB05476,WX-UK1,,,,,,solid,,,0.00462,10.55,11.51,Cl.CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC1=CC=CC(=C1)C(N)=N)NS(=O)(=O)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C,,,,,0,,649.3064683,3,2,1,0,1,1
4553,04/06/2019 00:00,DB05479,CZEN 002,,,,,,solid,,,0.0261,3.48,11.57,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NC(CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O,,,,,0,,1663.792931,6,5,3,2,1,1
4554,04/06/2019 00:00,DB05482,7-ethyl-10-hydroxycamptothecin,,,,,,solid,,,0.29,9.68,3.91,CCC1=C2C=C(O)C=CC2=NC2=C1CN1C2=CC2=C(COC(=O)[C@]2(O)CC)C1=O,,,,,0,,392.1372217,5,3,4,2,0,2
4555,04/06/2019 00:00,DB05490,AMG-131,,,,,,solid,,,6.99E-05,7.11,3.75,ClC1=CC=C(C(Cl)=C1)S(=O)(=O)NC1=CC(Cl)=C(OC2=CN=C3C=CC=CC3=C2)C(Cl)=C1,,,,,0,,511.932274,4,4,1,1,0,0
4556,04/06/2019 00:00,DB05492,Epicept NP-1,,,,,,solid,,,0.472,13.99,9.82,CC1=CC(=C(NCCCN)C=C1)[N+]([O-])=O,,,,,0,,209.1164267,1,1,0,0,0,0
4557,04/06/2019 00:00,DB05494,Elacytarabine,,,,,,solid,,,0.00304,5.72,2.37,[H]\C(CCCCCCCC)=C(\[H])CCCCCCCC(=O)OC[C@@]1([H])O[C@@]([H])(N2C=CC(=N)N=C2O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,507.3308362,2,1,2,1,1,1
4558,04/06/2019 00:00,DB05498,KW-7158,,,,,,solid,,,0.0795,9.45,-5.2,C[C@](O)(C(=O)NC1=CC=CC2=C1C(=O)C1=C(CS2(=O)=O)C=CS1)C(F)(F)F,,,,,0,,419.0108991,3,2,2,1,0,1
4559,04/06/2019 00:00,DB05501,AMD-070,,,,,,solid,,,0.0284,11.5,10.18,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@H]1CCCC2=C1N=CC=C2,,,,,0,,349.2266459,4,3,2,2,0,0
4560,04/06/2019 00:00,DB05511,Piclidenoson,,,,,,solid,,,0.192,12.39,4.84,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(NCC3=CC(I)=CC=C3)N=CN=C12,,,,,0,,510.0512511,4,3,3,2,1,1
4561,04/06/2019 00:00,DB05513,Atiprimod,,,,,,solid,,,0.000701,,10.2,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,,,,,0,,336.3504494,2,0,1,0,1,1
4562,04/06/2019 00:00,DB05514,Cobiprostone,,,,,,solid,,,0.0158,4.3,-4.4,CC[C@H](C)CC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(O)=O)O1,,,,,0,,404.2374306,2,0,1,0,1,1
4563,04/06/2019 00:00,DB05518,Managlinat dialanetil,,,,,,solid,,,0.244,8.26,8.87,[H][C@@](C)(NP(=O)(N[C@@]([H])(C)C(=O)OCC)C1=CC=C(O1)C1=C(CC(C)C)SC(=N)N1)C(=O)OCC,,,,,0,,500.1858424,2,2,2,2,0,0
4564,04/06/2019 00:00,DB05519,Budiodarone,,,,,,solid,,,0.00553,18.08,8.47,CC[C@H](C)OC(=O)CC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,,,,,0,,703.0291691,3,3,1,1,0,0
4565,04/06/2019 00:00,DB05520,Mimopezil,,,,,,solid,,,0.00521,8.86,3.02,[H]\C(C)=C1\[C@]2([H])CC3=C(C=CC(O)=N3)[C@]1(CC(C)=C2)\N=C(/[H])C1=CC(Cl)=CC(OC)=C1O,,,,,0,,410.1397203,4,2,1,1,0,0
4566,04/06/2019 00:00,DB05521,Telaprevir,"Telaprevir reaches peak plasma concentration 4-5hours after administration [FDA Label]. Absolute bioavailability has not been determined. When taken with a normal fat meal (21g of fat), exposure increases by 235% compared to fasting conditions. With low (3.6g of fat) and high fat (56g of fat) meals, exposure increased 117% and 330% respectively.",59-76%,Telaprevir has a half-life of elimination of 4.0-4.7 hours after a single dose and an effective half life of 9-11 hours at steady state [FDA Label].,375 mg,Oral,solid,0.0047 mg/mL,,0.0355,11.86,-0.69,[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,0.59,0.76,,,0,375,679.4057324,5,1,2,1,1,1
4567,04/06/2019 00:00,DB05524,Pelitinib,,,,,,solid,,,0.0078,12.55,8.81,CCOC1=CC2=C(C=C1NC(=O)\C=C\CN(C)C)C(NC1=CC(Cl)=C(F)C=C1)=C(C=N2)C#N,,,,,0,,467.1524309,3,3,1,1,0,0
4568,04/06/2019 00:00,DB05531,alpha-Pyrrolidinononanophenone,,,,,,solid,,,0.00492,17.87,7.81,CCCCCCCC(N1CCCC1)C(=O)C1=CC=CC=C1,,,,,0,,287.2249145,2,1,1,0,1,1
4569,04/06/2019 00:00,DB05532,BMS-488043,,,,,,solid,,,0.0992,8.6,2.35,COC1=C2C(NC=C2C(=O)C(=O)N2CCN(CC2)C(=O)C2=CC=CC=C2)=C(OC)N=C1,,,,,0,,422.1590198,4,3,3,2,1,1
4570,04/06/2019 00:00,DB05540,Alanosine,,,,,,solid,,,20.7,1.5,8.67,N[C@@H](CN(O)N=O)C(O)=O,,,,,0,,149.0436557,0,0,0,0,0,0
4571,02/07/2019 00:00,DB05541,Brivaracetam,Nearly 100% oral bioavailability [A19180].,<20%,7-8h [A19180].,10 mg/ml,Intravenous,solid,,,46.8,16.29,-0.57,CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1,0,0.2,7,8,0,,212.1524779,1,0,1,0,1,1
4572,04/06/2019 00:00,DB05542,Naronapride,,,,,,solid,,,0.0658,14.58,9.26,CO[C@H]1CN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)CC[C@H]1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1,,,,,0,,536.2765481,5,1,4,0,4,4
4573,04/06/2019 00:00,DB05549,INO-1001,,,,,,solid,,,0.0764,9.93,6.14,CS(O)(=O)=O.OC1=NC2=C(CC3=CC(=CC=C23)S(=O)(=O)NCCCN2CCOCC2)C2=CC=CC=C12,,,,,0,,535.1446923,5,3,2,1,1,1
4574,04/06/2019 00:00,DB05552,TG100-115,,,,,,solid,,,0.182,9.25,1.8,NC1=NC(N)=C2N=C(C3=CC=CC(O)=C3)C(=NC2=N1)C1=CC(O)=CC=C1,,,,,0,,346.1178237,4,4,2,2,0,0
4575,04/06/2019 00:00,DB05553,Regrelor,,,,,,solid,,,0.556,1.18,2.23,[H][C@]12O[C@@H](O[C@@]1([H])[C@@H](O[C@@H]2COP(O)(O)=O)N1C=NC2=C1N=CN=C2NC(=O)NCC)\C=C\C1=CC=CC=C1,,,,,0,,532.1471484,5,3,4,2,2,2
4576,04/06/2019 00:00,DB05560,Delcasertib,,,,,,solid,,,0.117,2.92,12.69,[H][C@](N)(CSSC[C@]([H])(N)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(O)=NCC(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CCC(O)=N)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=O)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=NCC(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC(C)C)C(O)=O,,,,,0,,2878.46675,3,3,0,0,0,0
4577,04/06/2019 00:00,DB05562,Naluzotan,,,,,,solid,,,0.0489,11.08,7.64,CC(=O)NC1=CC=CC(=C1)N1CCN(CCCCNS(=O)(=O)CC2CCCCC2)CC1,,,,,0,,450.2664621,3,1,1,0,1,1
4578,04/06/2019 00:00,DB05565,PBT-1033,,,,,,solid,,,0.355,6.77,8.34,CN(C)CC1=CC=C2C(Cl)=CC(Cl)=C(O)C2=N1,,,,,0,,270.0326684,2,2,1,1,0,0
4579,04/06/2019 00:00,DB05575,Motesanib,,,,,,solid,,,0.00844,5.45,7.02,CC1(C)CNC2=C1C=CC(=C2)N=C(O)C1=C(NCC2=CC=NC=C2)N=CC=C1,,,,,0,,373.1902604,4,3,3,2,0,1
4580,04/06/2019 00:00,DB05585,Verubulin,,,,,,solid,,,0.0641,,4.94,COC1=CC=C(C=C1)N(C)C1=NC(C)=NC2=C1C=CC=C2,,,,,0,,279.1371622,3,3,1,1,0,0
4581,04/06/2019 00:00,DB05586,Facinicline,,,,,,solid,,,0.107,9.97,7.85,[H]N([C@@H]1CN2CCC1CC2)C(=O)C1=NN([H])C2=CC=CC=C12,,,,,0,,270.1480612,5,2,4,1,3,3
4582,04/06/2019 00:00,DB05590,Bedoradrine,,,,,,solid,,,0.0626,9.34,10.07,CN(C)C(=O)COC1=CC=C2CC[C@@H](CC2=C1)NC[C@H](O)C1=CC=C(O)C(CCO)=C1,,,,,0,,428.2311221,3,2,0,0,0,0
4583,04/06/2019 00:00,DB05592,Blarcamesine,,,,,,solid,,,0.0197,,9.54,CN(C)CC1CCOC1(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,281.1779644,3,2,1,0,1,1
4584,04/06/2019 00:00,DB05596,PRX-03140,,,,,,solid,,,0.0434,5.25,9.24,CC(C)N1C2=C(C=CS2)C(O)=C(C(=O)NCCCN2CCCCC2)C1=O,,,,,0,,377.1773127,3,2,3,2,1,1
4585,04/06/2019 00:00,DB05607,PRX-08066,,,,,,solid,,,0.00421,18.39,7.34,OC(=O)\C=C\C(O)=O.FC1=C(C=C(CN2CCC(CC2)NC2=C3C=C(Cl)SC3=NC=N2)C=C1)C#N,,,,,0,,517.0986811,4,3,3,2,1,1
4586,04/06/2019 00:00,DB05608,MKC-1,,,,,,solid,,,0.0373,9.71,-4.9,CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C)C2=CC(=CC=C12)[N+]([O-])=O,,,,,0,,400.117155,5,4,3,2,0,1
4587,04/06/2019 00:00,DB05611,Apilimod,,,,,,solid,,,0.0278,14.42,5.89,CC1=CC=CC(\C=N\NC2=CC(=NC(OCCC3=CC=CC=N3)=N2)N2CCOCC2)=C1,,,,,0,,418.2117241,4,3,3,2,1,1
4588,04/06/2019 00:00,DB05616,"4'-Methylene-5,8,10-trideazaaminopterin",,,,,,solid,,,0.0392,2.92,14.19,OC(=O)C(CC(=C)C(O)=O)NC(=O)C1=CC=C(CCC2=CC3=C(NC(=N)NC3=N)C=C2)C=C1,,,,,0,,449.1699188,3,3,1,1,0,0
4589,04/06/2019 00:00,DB05624,Teverelix,,,,,,solid,,,0.00393,9.47,10.66,CC(C)C[C@H](NC(=O)[C@@H](CCCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,,,,,0,,1457.726271,6,5,2,1,1,1
4590,04/06/2019 00:00,DB05626,Retaspimycin,,,,,,solid,,,0.0174,9.62,4.55,CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(O)=CC(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)=C2O,,,,,0,,587.3206654,2,1,1,0,0,1
4591,04/06/2019 00:00,DB05631,ALT-2074,,,2.08 (+/-0.17) hours. ,,,solid,,,5.81,,5.12,CC1(C)CN[Se]C2=CC=CC=C12,,,,,0,,227.0213207,2,1,1,0,0,1
4592,04/06/2019 00:00,DB05633,Glypromate,,,,,,solid,,,4.11,3.2,8.13,[H][C@@](CCC(O)=O)(N=C(O)[C@]1([H])CCCN1C(=O)CN)C(O)=O,,,,,0,,301.1273853,1,0,1,0,1,1
4593,04/06/2019 00:00,DB05642,DDP-225,,,,,,solid,,,0.014,,8.68,O.Cl.CC1=CC2=C(N=C(N=C2S1)N1CCNCC1)C1=CC=CC=C1F,,,,,0,,382.1030382,4,3,3,2,1,1
4594,04/06/2019 00:00,DB05644,KP-1461,,,,,,solid,,,1.03,5.9,2.42,CCCCCCCOC(=O)NC1=NC(=O)N(CN1)[C@H]1C[C@H](O)[C@@H](CO)O1,,,,,0,,372.2008846,2,0,2,0,1,2
4595,04/06/2019 00:00,DB05645,Larazotide,,,,,,solid,,,0.218,3.43,7.84,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O,,,,,0,,725.407189,1,0,1,0,1,1
4596,04/06/2019 00:00,DB05650,OT-551,,,,,,solid,,,10.4,14.74,2.88,CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1,,,,,0,,241.1677936,2,0,1,0,1,1
4597,04/06/2019 00:00,DB05653,IRX-5183,,,,,,solid,,,0.00087,2.62,-4,CC1(C)CCC(C)(C)C2=C1C=C(C(=O)NC1=CC(F)=C(C(O)=O)C(F)=C1)C(O)=C2Cl,,,,,0,,437.1205423,3,2,0,0,0,0
4598,04/06/2019 00:00,DB05659,Faropenem medoxomil,,,,,,solid,,,1.18,14.85,-2.8,[H][C@]12SC(=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(=O)OCC1=C(C)OC(=O)O1)[C@@]1([H])CCCO1,,,,,0,,397.0831376,4,1,4,1,2,3
4599,04/06/2019 00:00,DB05667,Levoketoconazole,,,,,,solid,,,0.00931,,6.75,CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,,,,,0,,530.1487607,5,3,3,1,2,2
4600,04/06/2019 00:00,DB05668,Palifosfamide,,,,,,solid,,,8.86,5.43,-0.54,OP(=O)(NCCCl)NCCCl,,,,,0,,219.9935196,0,0,0,0,0,0
4601,02/07/2019 00:00,DB05676,Apremilast,"When taken orally, apremilast is absorbed with an absolute bioavailability of ~73%. Co-administration with food does not alter the extent of absorption.",,6-9 hours.,30 mg,Oral,solid,,,0.0503,4.83,-0.25,[H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1,,,6,9,0,30,460.1304221,3,2,1,0,0,1
4602,04/06/2019 00:00,DB05678,SLx-4090,,,,,,solid,,,0.000311,4.71,0.84,COC1=CC=CC(C(O)=NC2=CC=C3CN(CCC3=C2)C(=O)OC2=CC=CC=C2)=C1C1=CC=C(C=C1)C(F)(F)F,,,,,0,,546.1766419,5,4,1,0,0,1
4603,04/06/2019 00:00,DB05680,Sotirimod,,,,,,solid,,,0.287,19.18,3.69,CC(C)CN1C(C)=NC2=C1C1=NC=CC=C1N=C2N,,,,,0,,255.1483955,3,3,3,3,0,0
4604,04/06/2019 00:00,DB05683,Iodofiltic acid I-123,,,,,,solid,,,6.82E-06,5,,CC(CCCCCCCCCCCCC1=CC=C([123I])C=C1)CC(O)=O,,,,,0,,454.1692944,1,1,0,0,0,0
4605,04/06/2019 00:00,DB05686,Sivifene,,,,,,solid,,,0.00461,8.77,3.94,OC1=CC=C(C=C1)C(=NNC1=CC=C(C=C1[N+]([O-])=O)[N+]([O-])=O)C1=CC=C(O)C=C1,,,,,0,,394.0913342,3,3,0,0,0,0
4606,04/06/2019 00:00,DB05695,NPS-2143,,,,,,solid,,,0.00116,14.09,9.5,CC(C)(CC1=CC=C2C=CC=CC2=C1)NC[C@@H](O)COC1=CC=CC(Cl)=C1C#N,,,,,0,,408.1604557,3,3,0,0,0,0
4607,04/06/2019 00:00,DB05706,13-deoxydoxorubicin,,,,,,solid,,,0.656,8.21,9.39,COC1=C2C(=O)C3=C(O)C4=C(C[C@@](O)(CCO)C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(O)=C3C(=O)C2=CC=C1,,,,,0,,529.1947962,5,2,1,0,1,1
4608,04/06/2019 00:00,DB05708,GTS-21,"Rapidly and extensively absorbed after oral administration.  In rat, GTS-21 showed linear pharmacokinetics over doses ranging from 1 to 10 mg/kg with an absolute bioavailability of 23%. In dog, the absolute bioavailability was 27% at an oral dose of 3 mg/kg.",,,,,solid,,,0.00683,,5.89,[H]\C(=C1\CCCN=C1C1=CN=CC=C1)C1=C(OC)C=C(OC)C=C1,,,,,0,,308.1524779,3,2,2,1,0,1
4609,04/06/2019 00:00,DB05710,Gantacurium,,,3.09Â±0.21 minutes,,,solid,,,3.11E-05,17.91,-4.1,COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N@@+]2(C)CCCOC(=O)C(\Cl)=C\C(=O)OCCC[N@@+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@@H]2C2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC,,,0.0465,0.0535,2,,992.4426354,6,4,2,0,0,2
4610,04/06/2019 00:00,DB05713,LY-517717,,,,,,solid,,,0.0694,12.54,8.81,CN1CCC(CC1)N1CCN(CC1)C(=O)[C@H](NC(=O)C1=CC=C2C=CNC2=C1)C1=CC=CC=C1,,,,,0,,459.2634253,5,3,3,1,2,2
4611,04/06/2019 00:00,DB05714,Flovagatran,,,,,,solid,,,0.0161,8.64,-3.2,COCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)B(O)O,,,,,0,,525.2646309,3,2,1,0,1,1
4612,04/06/2019 00:00,DB05719,Elesclomol,,,,,,solid,,,0.00282,10.45,-2.7,CN(NC(=O)CC(=O)NN(C)C(=S)C1=CC=CC=C1)C(=S)C1=CC=CC=C1,,,,,0,,400.1027679,2,2,0,0,0,0
4613,04/06/2019 00:00,DB05724,alpha-Conotoxin VC 1.1,,,,,,solid,,,0.939,3.04,11.84,[H]NCC(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(N)=O)NC2=O)[C@@H](C)CC)C(N)=O)NC1=O,,,,,0,,1805.63783,6,2,5,1,4,4
4614,04/06/2019 00:00,DB05737,Varespladib methyl,,,,,,solid,,,0.00343,13.81,-3.7,CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)C=CC=C2N1CC1=CC=CC=C1,,,,,0,,394.1528718,3,3,1,1,0,0
4615,04/06/2019 00:00,DB05738,Vapitadine,,,,,,solid,,,0.193,8.62,10.05,OC(=N)C1=CN=C2N1CCC1=CC=CC=C1C21CCNCC1,,,,,0,,296.1637113,4,2,3,1,1,2
4616,04/06/2019 00:00,DB05767,Andrographolide,,,,,,solid,,,0.284,13.48,-2.8,[H]\C(C[C@]1([H])C(=C)CC[C@]2([H])[C@](C)(CO)[C@]([H])(O)CC[C@@]12C)=C1/C(=O)OC[C@@]1([H])O,,,,,0,,350.2093241,3,0,1,0,1,1
4617,04/06/2019 00:00,DB05772,Rabeximod,,,,,,solid,,,0.0191,15.34,8.51,CN(C)CCNC(=O)CN1C2=C(C=C(Cl)C=C2)C2=C1N=C1C=C(C)C(C)=CC1=N2,,,,,0,,409.1669381,4,4,2,2,0,0
4618,04/06/2019 00:00,DB05779,Oglufanide,,,,,,solid,,,0.184,3.3,9.62,N[C@@H](CCC(O)=O)C(O)=N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O,,,,,0,,333.1324707,2,2,1,1,0,0
4619,04/06/2019 00:00,DB05786,Irofulven,,,,,,solid,,,0.52,12.77,-1.7,CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1,,,,,0,,246.1255944,3,0,0,0,0,0
4620,04/06/2019 00:00,DB05790,SR 140333,,,,,,solid,,,4.87E-07,,-1.1,[Cl-].CC(C)OC1=CC=CC(CC(=O)N2CCC[C@](CC[N+]34CCC(CC3)(CC4)C3=CC=CC=C3)(C2)C2=CC(Cl)=C(Cl)C=C2)=C1,,,,,0,,654.2546617,7,3,4,0,4,4
4621,04/06/2019 00:00,DB05791,Perflubron,,,,,,solid,,,0.0314,,,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br,,,,,0,,497.8911918,0,0,0,0,0,0
4622,04/06/2019 00:00,DB05796,Daglutril,,,,,,solid,,,0.0015,3.88,0.36,CCOC(=O)[C@H](CCC1=CC=CC=C1)CC1(CCCC1)C(=O)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O,,,,,0,,534.2729869,4,2,1,0,0,1
4623,04/06/2019 00:00,DB05800,Alethine,,,,,,solid,,,1.64,15.3,9.43,NCCC(=O)NCCSSCCNC(=O)CCN,,,,,0,,294.1184179,0,0,0,0,0,0
4624,04/06/2019 00:00,DB05804,Prasterone sulfate,,,,,,solid,,,0.00806,-1.4,-7.5,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OS(O)(=O)=O,,,,,0,,368.165745,4,0,0,0,0,0
4625,04/06/2019 00:00,DB05805,NS-2359,,,,,,solid,,,0.00223,,9.76,COC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C1=CC=C(Cl)C(Cl)=C1)N2C,,,,,0,,313.1000197,3,1,2,0,2,2
4626,04/06/2019 00:00,DB05806,Cositecan,,,,,,solid,,,0.0194,11.71,3.86,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C(CC[Si](C)(C)C)C4=CC=CC=C4N=C13)C2=O,,,,,0,,448.1818339,5,3,4,2,0,2
4627,02/07/2019 00:00,DB05812,Abiraterone,"Abiraterone itself is poorly absorbed and is susceptible to hydrolysis by esterases. The salt form, abiraterone acetate, is a prodrug which has a much higher oral bioavailability and is also esterase resistant. Peak drug concentrations of abiraterone were reached in 1.5 - 4 hours. Abiraterone acetate was rapidly and completely deacetylated into abiraterone-the parent salt form was not detectable in early pharmacokinetic studies. Food and high fat meals increases absorption 4.4-fold. ",>99%,Terminal elimination half-life = 5-14 hours ,250 mg/1,Oral,solid,,,0.00305,18.2,4.81,[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C,0.99,1,,,0,250,349.2405646,5,1,1,1,0,0
4628,04/06/2019 00:00,DB05814,GPI-1485,,,,,,solid,,,4.98,3.99,-2.6,CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O,,,,,0,,241.1314081,1,0,1,0,1,1
4629,04/06/2019 00:00,DB05817,Laromustine,,,,,,solid,,,0.736,12.87,,CNC(=O)N(N(CCCl)S(C)(=O)=O)S(C)(=O)=O,,,,,0,,307.0063402,0,0,0,0,0,0
4630,04/06/2019 00:00,DB05824,CNS-5161,,,,,,solid,,,0.00076,,8.51,CSC1=CC(\N=C(/N)N(C)C2=CC(SC)=CC=C2)=C(Cl)C=C1,,,,,0,,351.0630673,2,2,0,0,0,0
4631,04/06/2019 00:00,DB05830,Trestolone,,,,,,solid,,,0.0391,18.34,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H],,,,,0,,288.2089301,4,0,0,0,0,0
4632,04/06/2019 00:00,DB05832,PPI-1019,,,,,,solid,,,0.00303,11.92,8.79,CN[C@H](CC(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@H](CC(C)C)C(N)=O,,,,,0,,650.4155688,2,2,0,0,0,0
4633,04/06/2019 00:00,DB05835,NS-3728,,,,,,solid,,,0.0136,8.22,-1.5,FC(F)(F)C1=CC(=CC(NC(=O)NC2=C(C=CC(Br)=C2)C2=NNN=N2)=C1)C(F)(F)F,,,,,0,,493.9925403,3,3,1,1,0,0
4634,04/06/2019 00:00,DB05838,OPC-51803,,,,,,solid,,,0.00385,14.81,1.57,CC(C)NC(=O)C[C@H]1CCCN(C(=O)C2=C(Cl)C=C(C=C2)N2CCCC2)C2=CC=CC=C12,,,,,0,,453.2183049,4,2,2,0,1,2
4635,04/06/2019 00:00,DB05855,Rivanicline,,,,,,solid,,,4.74,,10.47,CNCC\C=C\C1=CN=CC=C1,,,,,0,,162.1156984,1,1,1,1,0,0
4636,04/06/2019 00:00,DB05861,Tasquinimod,,,,,,solid,,,0.00911,4.73,-2.4,COC1=CC=CC2=C1C(O)=C(C(=O)N(C)C1=CC=C(C=C1)C(F)(F)F)C(=O)N2C,,,,,0,,406.1140417,3,3,1,1,0,0
4637,04/06/2019 00:00,DB05864,PPI-2458,,,,,,solid,,,0.0439,13.45,-3.6,[H][C@@]1([C@H](OC)[C@@H](CC[C@]11CO1)OC(=O)N[C@H](C(C)C)C(N)=O)[C@@]1(C)O[C@@H]1CC=C(C)C,,,,,0,,424.2573369,3,0,2,0,2,2
4638,04/06/2019 00:00,DB05868,Ciluprevir,,,,,,solid,,,0.00288,3.73,2.37,COC1=CC2=C(C=C1)C(O[C@H]1CN3C(=O)[C@H](CCCCC\C=C/[C@]4([H])C[C@@]4(C(O)=O)NC(=O)[C@]3([H])C1)NC(=O)OC1CCCC1)=CC(=N2)C1=CSC(NC(C)C)=N1,,,,,0,,774.3410836,7,3,4,2,1,2
4639,04/06/2019 00:00,DB05869,Ethyl pyruvate,,,,,,solid,,,31.3,16.9,-7.7,CCOC(=O)C(C)=O,,,,,0,,116.0473441,0,0,0,0,0,0
4640,04/06/2019 00:00,DB05871,UC-781,,,,,,solid,,,0.0123,10.85,-2.8,CC(C)=CCOC1=C(Cl)C=CC(NC(=S)C2=C(C)OC=C2)=C1,,,,,0,,335.0746775,2,2,1,1,0,0
4641,04/06/2019 00:00,DB05875,"Sar9, Met (O2)11-Substance P",,,,,,solid,,,0.04,11.48,11.87,CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O,,,,,0,,1392.733625,4,2,2,0,2,2
4642,04/06/2019 00:00,DB05884,HCV-086,,,,,,solid,,,0.0357,7.05,-1.7,CNC(=O)C1=C(OC2=CC(NS(C)(=O)=O)=C(OC(C)C)C=C12)C1=CC=C(F)C=C1,,,,,0,,420.115521,3,3,1,1,0,0
4643,04/06/2019 00:00,DB05885,Seletracetam,"Seletracetam is rapidly absorbed following oral administration, reaching the Cmax within 1 hour and displaying oral bioavailability of >90%. ",,Approximately 8 hours in healthy young male subjects. ,,,solid,,,1.02,14.66,-0.75,CC[C@H](N1C[C@@H](CC1=O)C=C(F)F)C(N)=O,,,,,0,,232.1023341,1,0,1,0,1,1
4644,04/06/2019 00:00,DB05903,KOS-1584,,,,,,solid,,,0.00256,14.06,2.73,C[C@H]1\C=C\C\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1=CSC(C)=N1,,,,,0,,489.2548943,2,1,2,1,0,1
4645,04/06/2019 00:00,DB05913,OSI-930,,,,,,solid,,,0.000411,12.71,4.4,FC(F)(F)OC1=CC=C(NC(=O)C2=C(NCC3=CC=NC4=CC=CC=C34)C=CS2)C=C1,,,,,0,,443.0915324,4,4,2,2,0,0
4646,04/06/2019 00:00,DB05928,Dovitinib,,,,,,solid,,,0.137,8.56,7.87,CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F,,,,,0,,392.1760875,5,4,3,2,1,1
4647,04/06/2019 00:00,DB05932,Denibulin,,,,,,solid,,,0.0105,3.33,14.71,[H][C@@](C)(N)C(=O)NC1=CC=C(SC2=CC3=C(C=C2)N=C(N3)N=C(O)OC)C=C1,,,,,0,,385.1208605,3,3,1,1,0,0
4648,04/06/2019 00:00,DB05936,CVT-6883,,,,,,solid,,,0.014,6.65,1.69,CCCN1C(=O)N(CC)C2=C(NC(=N2)C2=CN(CC3=CC=CC(=C3)C(F)(F)F)N=C2)C1=O,,,,,0,,446.1678086,4,4,3,3,0,0
4649,04/06/2019 00:00,DB05938,Edonerpic,,,,,,solid,,,0.0404,14.79,7.24,OC1CN(CCCOCCC2=CC3=C(SC=C3)C=C2)C1,,,,,0,,291.1292999,3,2,2,1,1,1
4650,04/06/2019 00:00,DB05939,MK-0354,,,,,,solid,,,7.21,5.26,0.82,C1CC2=C(C1)C(=NN2)C1=NNN=N1,,,,,0,,176.0810443,3,2,2,2,0,0
4651,04/06/2019 00:00,DB05943,Resatorvid,,,,,,solid,,,0.0192,8.8,-6.9,[H][C@]1(CCCC=C1C(=O)OCC)S(=O)(=O)NC1=C(Cl)C=C(F)C=C1,,,,,0,,361.0550849,2,1,0,0,0,0
4652,04/06/2019 00:00,DB05944,Varlitinib,,,,,,solid,,,0.0047,17.09,4.64,C[C@@H]1COC(NC2=CC=C3N=CN=C(NC4=CC=C(OCC5=NC=CS5)C(Cl)=C4)C3=C2)=N1,,,,,0,,466.0978725,5,4,3,2,0,1
4653,04/06/2019 00:00,DB05956,EVT-101,,,,,,solid,,,0.0285,,7.3,Cl.Cl.CC1=NC=CN1CC1=CC(=CN=N1)C1=CC=C(F)C(=C1)C(F)F,,,,,0,,390.0625865,3,3,2,2,0,0
4654,04/06/2019 00:00,DB05959,ENMD-1198,,,,,,solid,,,0.00021,13.89,-0.8,COC1=C(C=C2CC[C@H]3[C@@H]4CC=C[C@@]4(C)CC[C@@H]3C2=C1)C(N)=O,,,,,0,,311.188529,4,1,0,0,0,0
4655,04/06/2019 00:00,DB05961,PPL-100,,,,,,solid,,,0.0019,13.3,2.43,COC(=O)N[C@@H](C(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)NCCCC[C@@H](CO)N(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,,,,,0,,624.2981561,3,3,0,0,0,0
4656,04/06/2019 00:00,DB05964,Amitifadine,,,,,,solid,,,0.0162,,10.48,[H][C@]12C[C@]1(CNC2)C1=CC(Cl)=C(Cl)C=C1,,,,,0,,227.0268547,3,1,1,0,1,1
4657,04/06/2019 00:00,DB05966,TAS-108,,,,,,solid,,,3.66E-05,10.34,9.03,OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CC1=CC=C(OCC[C@H]2CC[C@H]3[C@@H]4[C@H](C)CC5=C(C=CC(O)=C5)[C@H]4CC[C@]23C)C(OC)=C1,,,,,0,,697.382597,5,2,0,0,0,0
4658,04/06/2019 00:00,DB05968,PR-104,,,,,,solid,,,0.0342,1.54,-1.3,CS(=O)(=O)OCCN(CCBr)C1=C(C=C(C=C1[N+]([O-])=O)[N+]([O-])=O)C(=O)NCCOP(O)(O)=O,,,,,0,,577.9719418,1,1,0,0,0,0
4659,04/06/2019 00:00,DB05969,SNS-032,,,,,,solid,,,0.0252,10.85,10.06,CC(C)(C)C1=CN=C(CSC2=CN=C(NC(=O)C3CCNCC3)S2)O1,,,,,0,,380.134068,3,2,3,2,1,1
4660,04/06/2019 00:00,DB05973,Inosine 5'-sulfate,,,,,,solid,,,10.7,-2.2,0.58,O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]1O)N1C=NC2=C1N=CNC2=O,,,,,0,,348.0375843,3,2,3,2,1,1
4661,04/06/2019 00:00,DB05974,Transcrocetinate,,,,,,solid,,,0.00558,4.41,,C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O,,,,,0,,328.1674592,0,0,0,0,0,0
4662,04/06/2019 00:00,DB05983,Bardoxolone methyl,,,,,,solid,,,0.00294,,-5.3,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,,,,,0,,505.3192089,5,0,0,0,0,0
4663,04/06/2019 00:00,DB05984,RAF-265,,,,,,solid,,,0.00285,9.28,7.21,CN1C(NC2=CC=C(C=C2)C(F)(F)F)=NC2=CC(OC3=CC=NC(=C3)C3=NC=C(N3)C(F)(F)F)=CC=C12,,,,,0,,518.1289785,5,5,3,3,0,0
4664,02/07/2019 00:00,DB05990,Obeticholic acid,"Peak plasma concentrations (Cmax) of obeticholic acid occurred at a median time (Tmax) of approximately 1.5 hours.
Coadministration with food did not alter the extent of absorption of obeticholic acid.",0.99,Steady state half life: ~4 days,10 mg,Oral,solid,,,0.011,4.6,-0.16,[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)[C@]([H])(CC)[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C,0.99,0.99,,,0,10,420.3239599,4,0,0,0,0,0
4665,04/06/2019 00:00,DB05992,Plinabulin,,,,,,solid,,,0.0218,7.05,6.23,CC(C)(C)C1=C(\C=C2/NC(=O)\C(NC2=O)=C\C2=CC=CC=C2)N=CN1,,,,,0,,336.1586259,3,3,2,2,0,0
4666,04/06/2019 00:00,DB05993,PRX-07034,,,,,,solid,,,0.0431,14.33,8.63,Cl.COC1=C(OC)C(=CC(Cl)=C1)C(C)NC1=CC(=CC=C1S(C)(=O)=O)N1CCNCC1,,,,,0,,489.1255828,3,2,1,0,1,1
4667,04/06/2019 00:00,DB06011,AMG-222,,,,,,solid,,,0.0336,6.44,7.77,[H][C@](C)(CC1(C2=NNN=N2)C2=CC=C(C=C2CCC2=CC(=CC=C12)C(=O)N(C)C)C(=O)N(C)C)NCC(=O)N1CCC[C@@]1([H])C#N,,,,,0,,597.3175861,5,3,2,1,1,1
4668,04/06/2019 00:00,DB06013,Aldoxorubicin,,,,,,solid,,,0.151,8.2,9.39,COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1,,,,,0,,750.2748374,6,2,2,0,1,2
4669,04/06/2019 00:00,DB06016,Cariprazine,,,~1 week for the combined drug. ,1.5 mg/1,Oral,solid,,,0.0279,15.68,7.91,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1,,,,,0,1.5,426.195317,3,1,1,0,1,1
4670,04/06/2019 00:00,DB06021,AV-412,,,,,,solid,,,0.00607,13.25,7.65,CC1=CC=C(C=C1)S(O)(=O)=O.CC1=CC=C(C=C1)S(O)(=O)=O.CN1CCN(CC1)C(C)(C)C#CC1=C(NC(=O)C=C)C=C2C(NC3=CC=C(F)C(Cl)=C3)=NC=NC2=C1,,,,,0,,850.2385456,6,5,2,1,1,1
4671,04/06/2019 00:00,DB06040,Filanesib,,,,,,solid,,,0.0045,,9.9,CON(C)C(=O)N1N=C(S[C@@]1(CCCN)C1=CC=CC=C1)C1=CC(F)=CC=C1F,,,,,0,,420.1431534,3,2,1,0,0,1
4672,11/06/2019 00:00,DB06045,Trofinetide,,,,,,solid,,,10.4,3.27,7.83,C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(O)=O)C(O)=O,,,,,0,,315.1430354,1,0,1,0,1,1
4673,04/06/2019 00:00,DB06061,AZD-8330,,,,,,solid,,,0.0887,8.29,-2.8,CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F,,,,,0,,461.0247822,2,2,1,1,0,0
4674,04/06/2019 00:00,DB06070,SNX-5422,,,,,,solid,,,0.00924,15.17,7.09,CC1(C)CC2=C(C(=NN2C2=CC(N[C@H]3CC[C@@H](CC3)OC(=O)CN)=C(C=C2)C(N)=O)C(F)(F)F)C(=O)C1,,,,,0,,521.2249891,4,2,1,1,0,0
4675,04/06/2019 00:00,DB06075,Linsitinib,,,,,,solid,,,0.0027,15.23,5.66,C[C@@]1(O)C[C@@H](C1)C1=NC(=C2N1C=CN=C2N)C1=CC=C2C=CC(=NC2=C1)C1=CC=CC=C1,,,,,0,,421.1902604,6,5,3,3,0,0
4676,04/06/2019 00:00,DB06077,Lumateperone,,,,,,solid,,,0.0805,16.4,8.47,[H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C,,,,,0,,393.2216407,5,2,3,0,1,3
4677,04/06/2019 00:00,DB06082,PX-478,,,,,,solid,,,0.017,1.54,9.42,Cl.Cl.N[C@@H](CC1=CC=C(C=C1)[N+]([O-])(CCCl)CCCl)C(O)=O,,,,,0,,392.0228032,1,1,0,0,0,0
4678,04/06/2019 00:00,DB06083,Tapinarof,,,,,,solid,,,0.0339,9.19,-5.9,CC(C)C1=C(O)C=C(\C=C\C2=CC=CC=C2)C=C1O,,,,,0,,254.1306798,2,2,0,0,0,0
4679,04/06/2019 00:00,DB06087,Friulimicin B,,,,,,solid,,,0.0161,3.08,8.33,CC(C)CCCCCCC\C=C/CC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]1[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H]2CCCCN2C1=O)[C@H](C)C(O)=O)[C@@H](C)N)C(C)C,,,,,0,,1302.681967,3,0,3,0,3,3
4680,04/06/2019 00:00,DB06090,Bradanicline,,,,,,solid,,,0.0559,14.57,7.44,[H][C@@]1(CC2=CC=CN=C2)N2CCC(CC2)[C@@]1([H])NC(=O)C1=CC2=C(O1)C=CC=C2,,,,,0,,361.179027,6,3,5,2,3,3
4681,04/06/2019 00:00,DB06091,Evofosfamide,,,,,,solid,,,0.292,13.89,-0.14,CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N+]([O-])=O,,,,,0,,446.9306648,1,1,1,1,0,0
4682,04/06/2019 00:00,DB06106,AIT-034,,,,,,solid,,,2.8,10.96,2.99,O=C(CCN1C=NC2=C1NC=NC2=O)NCCCN1CCCC1=O,,,,,0,,332.1596885,3,2,3,2,1,1
4683,04/06/2019 00:00,DB06112,"3,4-Methylenedioxy-N-isopropylamphetamine",,,,,,solid,,,0.772,,10.31,CC(C)NC(C)CC1=CC2=C(OCO2)C=C1,,,,,0,,221.1415788,2,1,1,0,0,1
4684,04/06/2019 00:00,DB06117,"1alpha,24S-Dihydroxyvitamin D2",,,,,,solid,,,0.00726,14.39,-1.1,CC(C)[C@](C)(O)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,,,,,0,,428.3290453,3,0,0,0,0,0
4685,04/06/2019 00:00,DB06119,Cenobamate,,,,,,solid,,,0.936,14.28,-1.7,NC(=O)O[C@@H](CN1N=CN=N1)C1=CC=CC=C1Cl,,,,,0,,267.0523022,2,2,1,1,0,0
4686,04/06/2019 00:00,DB06124,L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal,,,,,,solid,,,0.0124,3.71,11.85,CCOC(OCC)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)CCC(=O)N[C@H](CC([O-])=O)C[N+](C)(C)C,,,,,0,,587.400647,0,0,0,0,0,0
4687,04/06/2019 00:00,DB06127,Bisegliptin,,,,,,solid,,,0.294,,9.46,[H][C@@]1(F)CN(C(=O)CNC23CCC(CC2)(CC3)C(=O)OCC)[C@@]([H])(C1)C#N,,,,,0,,351.1958199,4,0,1,0,1,1
4688,04/06/2019 00:00,DB06133,Dimethylcurcumin,,,,,,solid,,,0.00141,9.04,-4.3,COC1=CC=C(\C=C\C(\O)=C\C(=O)\C=C\C2=CC(OC)=C(OC)C=C2)C=C1OC,,,,,0,,396.1572885,2,2,0,0,0,0
4689,04/06/2019 00:00,DB06134,SNS-314,,,,,,solid,,,0.00971,7.38,3.86,ClC1=CC=CC(NC(=O)NC2=NC=C(CCNC3=C4SC=CC4=NC=N3)S2)=C1,,,,,0,,430.0437288,4,4,3,3,0,0
4690,04/06/2019 00:00,DB06137,KX-01,,,,,,solid,,,0.0248,15.36,6.63,O=C(CC1=CC=C(C=N1)C1=CC=C(OCCN2CCOCC2)C=C1)NCC1=CC=CC=C1,,,,,0,,431.2208918,4,3,2,1,1,1
4691,02/07/2019 00:00,DB06140,SUVN-502,,,,,,solid,,,0.0544,,7.79,COC1=CC=C2N(C=C(CN3CCN(C)CC3)C2=C1)S(=O)(=O)C1=CC=CC=C1Br,,,,,0,,477.0721747,4,3,2,1,1,1
4692,04/06/2019 00:00,DB06144,Sertindole,Orally available.,,3 days,,,solid,,,0.00963,14.36,8.59,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2,,,72,72,0,,440.1779174,5,3,3,1,2,2
4693,02/07/2019 00:00,DB06145,Spiramycin,"The extent of absorption of Spiramycin was shown to be incomplete. Oral bioavailability ranges from 30-39%. 
Spiramycin has slower rate of absorption than Erythromycin. It has a high pKa (7.9) which could be a result of high degree of ionization in acidic medium of the stomach.",,"Intravenous:
Young persons (18 to 32 years of age): Approximately 4.5 to 6.2 hours.
Elderly persons (73 to 85 years of age): Approximately 9.8 to 13.5 hours. 

Oral: 5.5-8 hours, Rectal in children: 8 hours
",750000 unit,Oral,solid,,,0.196,12.53,9.28,[H]\C1=C(\[H])/C(/[H])=C([H])/[C@]([H])(O[C@@]2([H])CC[C@]([H])(N(C)C)[C@]([H])(C)O2)[C@]([H])(C)C[C@]([H])(CC=O)[C@]([H])(O[C@]2([H])O[C@]([H])(C)[C@@]([H])(O[C@@]3([H])C[C@@](C)(O)[C@@]([H])(O)[C@]([H])(C)O3)[C@]([H])(N(C)C)[C@@]2([H])O)[C@@]([H])(OC)[C@]([H])(O)CC(=O)O[C@]([H])(C)C1,,,,,0,,842.514005,4,0,4,0,3,4
4694,04/06/2019 00:00,DB06147,Sulfathiazole,,,,,Vaginal,solid,373 mg/L (at 25 Â°C),0.05,0.921,6.93,2.04,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1,,,,,0,,255.0136185,2,2,1,1,0,0
4695,04/06/2019 00:00,DB06148,Mianserin,Absorbed following oral administration.,0.9,10-17 hours,,,solid,,,0.232,,6.92,CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21,0.9,0.9,10,17,0,,264.1626486,4,2,2,0,1,2
4696,04/06/2019 00:00,DB06150,Sulfadimethoxine,,,,,,solid,343 mg/L,1.63,0.278,6.91,1.95,COC1=NC(OC)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1,,,,,0,,310.0735759,2,2,1,1,0,0
4697,02/07/2019 00:00,DB06151,Acetylcysteine,Bioavailability is 6â€“10% following oral administration and less than 3% following topical administration.,0.83,"5.6 hours (adults), 11 hours (neonates)",200 mg/1mL,Intravenous,solid,,,5.09,3.82,-1.5,CC(=O)N[C@@H](CS)C(O)=O,0.83,0.83,,,0,,163.0303141,0,0,0,0,0,0
4698,02/07/2019 00:00,DB06152,Nylidrin,Readily absorbed from the gastrointestinal tract [L2279].,,Duration of action is 10h [L2286].,12 mg,Oral,solid,,,0.0204,9.25,10.11,CC(CCC1=CC=CC=C1)NC(C)C(O)C1=CC=C(O)C=C1,,,,,0,12,299.188529,2,2,0,0,0,0
4699,02/07/2019 00:00,DB06153,Pizotifen,The absorption half-life of pizotifen following oral administration is 0.5 to 0.8 hours in an adult male with nearly complete absorption rate of 80%. Maximum blood levels are reached 5 hours post-administration and the absolute bioavailability is 78% [L2292].,0.9,The elimination half-life for pizotifen and N-glucuronide conjugate is about 23 hours [L2292].,0.50 mg,Oral,solid,Partly miscible,,0.00706,,7.98,CN1CCC(CC1)=C1C2=C(CCC3=CC=CC=C13)SC=C2,0.9,0.9,,,0,0.5,295.1394707,4,2,2,1,1,1
4700,04/06/2019 00:00,DB06154,Pentaerythritol tetranitrate,,,The elimination half-life in plasma from male volunteers given an oral 100-mg dose of the tetranitrate was reported to be 4-5 hours [L2395].,80 mg,Oral,solid,0.133 mg/mL,,0.133,,-5.5,[O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O,,,,,0,80,316.0138717,0,0,0,0,0,0
4701,04/06/2019 00:00,DB06155,Rimonabant,Undetermined,1,6 to 9 days with normal BMI and 16 days if BMI is greater than 30,20 mg,Oral,solid,,,0.002,12.42,1.68,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1,1,1,,,0,20,462.0780943,4,3,2,1,1,1
4702,04/06/2019 00:00,DB06156,Tesofensine,,,,,,solid,,,0.000882,,9.67,CCOC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C1=CC(Cl)=C(Cl)C=C1)N2C,,,,,0,,327.1156697,3,1,2,0,2,2
4703,04/06/2019 00:00,DB06157,Istaroxime,,,,,,solid,,,0.0174,,8.84,C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O,,,,,0,,360.2412929,4,0,0,0,0,0
4704,04/06/2019 00:00,DB06159,Rubitecan,,,,,,solid,,,0.239,11.71,0.29,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=C(C1=C3)[N+]([O-])=O)C2=O,,,,,0,,393.0960852,5,3,4,2,0,2
4705,04/06/2019 00:00,DB06160,Garenoxacin,,,,,,solid,,,0.0232,6.05,8.88,C[C@H]1NCC2=CC(=CC=C12)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1OC(F)F)C(O)=O,,,,,0,,426.1391136,5,3,2,1,0,1
4706,04/06/2019 00:00,DB06163,Plevitrexed,,,,,,solid,,,0.00901,3.13,-0.58,CC1=NC(=O)C2=CC(CN(CC#C)C3=CC=C(C(=O)N[C@@H](CCC4=NN=NN4)C(O)=O)C(F)=C3)=C(C)C=C2N1,,,,,0,,532.1982795,4,4,2,2,0,0
4707,04/06/2019 00:00,DB06166,Fosdevirine,,,,,,solid,,,0.00943,10.8,-1.6,CO[P@](=O)(C1=C(NC2=CC=C(Cl)C=C12)C(N)=O)C1=CC(C)=CC(\C=C\C#N)=C1,,,,,0,,413.0696057,3,3,1,1,0,0
4708,04/06/2019 00:00,DB06169,Indibulin,,,,,,solid,,,0.00151,11.22,5.51,ClC1=CC=C(CN2C=C(C(=O)C(=O)NC3=CC=NC=C3)C3=CC=CC=C23)C=C1,,,,,0,,389.0931044,4,4,2,2,0,0
4709,04/06/2019 00:00,DB06174,Noscapine,,,,,,solid,,,0.181,14.59,6.44,[H][C@@]1(OC(=O)C2=C1C=CC(OC)=C2OC)[C@]1([H])N(C)CCC2=CC3=C(OCO3)C(OC)=C12,,,,,0,,413.1474521,5,2,3,0,0,3
4710,02/07/2019 00:00,DB06176,Romidepsin,Romidepsin exhibited linear pharmacokinetics at standard doses. ,,Approximately 3 hours,10 mg/2mL,Intravenous,solid,,,0.0209,10.67,-0.54,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,,,,,0,,540.2076269,2,0,2,0,1,2
4711,04/06/2019 00:00,DB06177,Glufosfamide,,,,,,solid,,,9.05,12.17,-0.94,OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,382.046343,1,0,1,0,1,1
4712,04/06/2019 00:00,DB06178,Talotrexin,,,,,,solid,,,0.0326,3.23,2.25,NC1=NC(N)=C2N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCCNC(=O)C3=CC=CC=C3C(O)=O)C(O)=O)C=NC2=N1,,,,,0,,573.2084296,4,4,2,2,0,0
4713,04/06/2019 00:00,DB06179,Darinaparsin,,,,,,solid,,,1.4,1.5,9.31,C[As](C)SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O,,,,,0,,411.0445279,0,0,0,0,0,0
4714,04/06/2019 00:00,DB06182,Talabostat,,,,,,solid,,,59.2,8.88,8.27,CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O,,,,,0,,214.1488729,1,0,1,0,1,1
4715,04/06/2019 00:00,DB06185,Forodesine,,,,,,solid,,,4.11,10.03,8.22,OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C1=CNC2=C1N=CNC2=O,,,,,0,,266.1015049,3,2,3,2,1,1
4716,04/06/2019 00:00,DB06187,Valtorcitabine,,,,,,solid,,,6.19,14.59,7.48,CC(C)[C@H](N)C(=O)O[C@@H]1C[C@H](O[C@H]1CO)N1C=CC(N)=NC1=O,,,,,0,,326.1590198,2,1,2,1,1,1
4717,04/06/2019 00:00,DB06188,Ispinesib,,,,,,solid,,,0.00122,,9.77,CC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C1=NC2=CC(Cl)=CC=C2C(=O)N1CC1=CC=CC=C1,,,,,0,,516.229204,4,4,1,1,0,0
4718,04/06/2019 00:00,DB06190,Solabegron,,,,,,solid,,,0.00167,4.01,9.02,[H][C@](O)(CNCCNC1=CC(=CC=C1)C1=CC(=CC=C1)C(O)=O)C1=CC=CC(Cl)=C1,,,,,0,,410.1397203,3,3,0,0,0,0
4719,04/06/2019 00:00,DB06191,Zosuquidar,,,,,,solid,,,0.00974,14.08,7.63,[H][C@]12C3=CC=CC=C3[C@H](N3CCN(C[C@@H](O)COC4=CC=CC5=C4C=CC=N5)CC3)C3=CC=CC=C3[C@@]1([H])C2(F)F,,,,,0,,527.2384337,7,4,2,1,1,1
4720,04/06/2019 00:00,DB06193,Pixantrone,"Intravenous administration results in a rapid distribution followed by a slow elimination. [2] In ex vivo myocardial strips, pixantrone is taken up to a higher degree than mitoxantrone. In myocardial strips which are doxorubicin naive pixantrone displays higher uptake than in DOX-loaded myocardial strips. DOX clearance causes membrane effects which may be responsible for this observation. DOX clearance involves rapid passive diffusion through one side of the membrane followed by ""flip flop"" reorientation of the lipid bilayer. This disorganization of lipids is believed to impair membrane penetration by pixantrone. [3] ",,Half life is 12 hours. [2] ,29 mg,Intravenous,solid,,,0.494,,9.52,NCCNC1=CC=C(NCCN)C2=C1C(=O)C1=C(C=NC=C1)C2=O,,,,,0,,325.1538748,3,2,1,1,0,0
4721,04/06/2019 00:00,DB06194,Elocalcitol,,,,,,solid,,,0.00185,15.08,-1.1,CCC(O)(CC)\C=C\C[C@H](C)C1=CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@@](F)([H])C1=C,,,,,0,,442.3247088,3,0,0,0,0,0
4722,04/06/2019 00:00,DB06195,Seliciclib,,,,,,solid,,,0.163,14.34,5.55,CC[C@H](CO)NC1=NC(NCC2=CC=CC=C2)=C2N=CN(C(C)C)C2=N1,,,,,0,,354.2168095,3,3,2,2,0,0
4723,02/07/2019 00:00,DB06196,Icatibant,The absolute bioavailability of icatibant following a 30 mg subcutaneous dose is approximately 97%. Maximum plasma concentrations (Cmax) of 974 Â± 280 ng/mL was reached when a single subcutaneous dose of 30 mg was administered. The AUC was 2165 Â± 568 ngâˆ™hr/mL. Icatibant did not accumulate following multiple doses. ,,"After subcutaneous administration, mean elimination half-life was 1.4 Â± 0.4 hours. ",30.0 mg/3mL,Subcutaneous,solid,1 mg/mL ,,0.057,3.46,11.45,[H][C@]12CC(N(C(=O)C3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)C3C[C@@H](O)CN3C(=O)C3CCCN3C(=O)C(CCCN=C(N)N)NC(=O)[C@H](N)CCCN=C(N)N)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O,,,,,0,,1303.660795,7,2,5,1,3,4
4724,04/06/2019 00:00,DB06197,Bimosiamose,,,,,,solid,,,0.0166,3.85,-3.6,[H][C@]1(CO)O[C@]([H])(OC2=C(C=C(CCCCCCC3=CC(=C(O[C@@]4([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]4([H])O)C=C3)C3=CC=CC(CC(O)=O)=C3)C=C2)C2=CC=CC(CC(O)=O)=C2)[C@@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,862.3411856,6,4,2,0,2,2
4725,04/06/2019 00:00,DB06198,Alovudine,,,,,,solid,,,79.2,10.11,-3,CC1=CN([C@H]2C[C@H](F)[C@@H](CO)O2)C(=O)NC1=O,,,,,0,,244.0859351,2,1,2,1,1,1
4726,04/06/2019 00:00,DB06199,Atrasentan,,,,,,solid,,,0.0321,3.02,8.25,CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C1=CC=C(OC)C=C1)C(O)=O)C1=CC2=C(OCO2)C=C1,,,,,0,,510.2729869,4,2,2,0,1,2
4727,04/06/2019 00:00,DB06200,Tedisamil,,,,,,solid,,,0.0214,,9.56,C(C1CC1)N1CC2CN(CC3CC3)CC(C1)C21CCCC1,,,,,0,,288.256549,5,0,2,0,2,2
4728,02/07/2019 00:00,DB06201,Rufinamide,"The oral suspension and tablet are bioequivalent on a mg per mg basis. Rufinamide is well absorbed but the rate is slow and the extent of absorption decreases as dose is increases. Based on urinary excretion, the extent of absorption was at least 85% following oral administration of a single dose of 600 mg rufinamide tablet under fed conditions.
Bioavailability= 70%-85% (decreases with increasing doses); 
Tmax, fed and fasted states= 4-6 hours; 
Cmax, 10 mg/kg/day= 4.01 ÂµL/mL; 
Cmax, 30mg/kg/day= 8.68 ÂµL/mL;
AUC (0h-12h), 10mg/kg/day= 37.8Â±47 ÂµgÂ·h/mL; 
AUC (0h-12h), 30mg/kg/day= 89.3Â±59 ÂµgÂ·h/mL.  ",0.263,"Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.  ",40 mg,Oral,solid,Insoluble ,0.835,0.642,12.69,-1.1,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1,0.263,0.263,,,0,40,238.0666173,2,2,1,1,0,0
4729,04/06/2019 00:00,DB06202,Lasofoxifene,"Peak plasma concentrations (Cmax) were reached in about 6.0 to 7.3 hours [A19181]. Displays higher oral bioavailability compared to other SERMs with increased resistance to intestinal glucuronidation due to  nonpolar tetrahydronaphthalene structure [A4024]. In a comparative study in the rat, lasofoxifene showed bioavailability of 62%  [A19178].",,Elimination half-life is approximately 6 days [A19178].,500 Î¼g,Oral,solid,,,0.000398,10.21,8.98,[H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1,,,,,0,,413.2354792,5,3,1,0,1,1
4730,02/07/2019 00:00,DB06203,Alogliptin,"The pharmacokinetics of NESINA was also shown to be similar in healthy subjects and in patients with type 2 diabetes. When single, oral doses up to 800 mg in healthy subjects and type 2 diabetes patients are given, the peak plasma alogliptin concentration (median Tmax) occurred 1 to 2 hours after dosing. Accumulation of aloglipin is minimal. The absolute bioavailability of NESINA is approximately 100%. Food does not affect the absorption of alogliptin. 
",0.2,Terminal half-life = 21 hours ,12.5 mg/1,Oral,solid,Sparingly soluble ,,0.58,,9.47,CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O,0.2,0.2,,,0,12.5,339.1695249,3,2,2,1,1,1
4731,02/07/2019 00:00,DB06204,Tapentadol,"Bioavailability, immediate release (IR), 86 mg: 32%; 
Bioavailability, extended release (ER), 86 mg: 32%; 
Cmax, IR: 64.2 ng/mL;
Cmax, ER: 22.5 ng/mL; 
T max, IR: 1.5 hours;
T max, ER: 5.0 hours;
Tapentadol accumulates following multiple repeat doses.  

",~20%,"Elimination half-life, IV: 4 hours. ",20 mg/1mL,Oral,solid,,2.87,0.78,10.28,9.6,CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1,0.2,0.2,,,0,,221.1779644,1,1,0,0,0,0
4732,02/07/2019 00:00,DB06206,Sugammadex,Sugammadex is administered intravenously.,,About 2 hours,100 mg/1mL,Intravenous,solid,,,26.6,2.82,,O[C@@H]1[C@@H](O)[C@@H]2O[C@H]3O[C@H](CSCCC(O)=O)[C@@H](O[C@H]4O[C@H](CSCCC(O)=O)[C@@H](O[C@H]5O[C@H](CSCCC(O)=O)[C@@H](O[C@H]6O[C@H](CSCCC(O)=O)[C@@H](O[C@H]7O[C@H](CSCCC(O)=O)[C@@H](O[C@H]8O[C@H](CSCCC(O)=O)[C@@H](O[C@H]9O[C@H](CSCCC(O)=O)[C@@H](O[C@H]1O[C@@H]2CSCCC(O)=O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,,,,,0,,2000.408873,30,0,30,0,30,30
4733,02/07/2019 00:00,DB06207,Silodosin,"Quickly absorbed and has a bioavailability of 32% at 8mg/day (therapeutic dose).
When 8 mg of silodosin is taken once daily with food, the pharmacokinetic parameters are as follows: 
Cmax = 61.6 Â± 27.54 ng/mL;
Tmax = 2.6 Â± 0.90 hours;  
AUC (0h-24h) = 373 ngâ€¢hr/ml. 
The AUC of its metabolite, KMD3213G, is four times greater than silodosin.  ",0.97,"Silodosin = 13.3 Â± 8.07 hours;
KMD-3213G = 24 hours;  ",4 mg/1,Oral,solid,Very slightly soluble ,,0.0111,14.87,9.66,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F,0.97,0.97,,,0,4,495.2344912,3,2,1,0,0,1
4734,02/07/2019 00:00,DB06209,Prasugrel,"79% or greater of the dose is absorbed after oral administration. Absorption and metabolism occur rapidly and peak plasma concentrations (C<sub>max</sub>) are reached approximately 30 minutes following oral administration. Administration with a high fat, high calorie meal did not affect the AUC of the active metabolite in healthy individuals, but the C<sub>max</sub> was decreased by ~49% and the T<sub>max</sub> was increased to 0.5 to 1.5 hours. Prasugrel may be administered with or without food. ",0.98,The active metabolite has an elimination half-life of about 7.4 hours (range 2-15 hours). ,10 mg,Oral,solid,,3.536,0.00237,14.25,5.48,CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1,0.98,0.98,,,0,10,373.1147927,4,2,2,1,0,1
4735,02/07/2019 00:00,DB06210,Eltrombopag,"Peak absorption of Eltrombopag occurs around 2-6 hours following oral administration, and the total oral absorption of drug-related material following a 75 mg dose was estimated to be at least 52%. ",,"About 21-32 hours in healthy patients.
About 26-35 hours in patients with idiopathic thrombocytopenic purpura.",12.5 mg/1,Oral,solid,"Eltrombopag olamine is practically insoluble in aqueous buffer across a pH range of 1 to 7.4, and is sparingly soluble in water.",,0.0103,3.99,0.17,CC1=NN(C(=O)\C1=N/NC1=C(O)C(=CC=C1)C1=CC=CC(=C1)C(O)=O)C1=CC=C(C)C(C)=C1,,,,,0,12.5,442.1641052,4,3,1,0,0,1
4736,04/06/2019 00:00,DB06211,Doripenem,Doripenem is administered intravenously as an infusion. There was no accumulation of doripenem following mulitiple infusions of either 500mg or 1g administered every 8 hours for 7-10 days in subjects with normal renal function. ,0.081,"1 hour, in healthy non-elderly adults. ",250 mg,Intravenous,solid,,,3.13,3.54,9.51,[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,0.081,0.081,,,0,,420.1137265,3,0,3,0,2,3
4737,02/07/2019 00:00,DB06212,Tolvaptan,"Tmax, Healthy subjects: 2 - 4 hours;
Cmax, Healthy subjects, 30 mg: 374 ng/mL;
Cmax, Healthy subjects, 90 mg: 418 ng/mL;
Cmax, heart failure patients, 30 mg: 460 ng/mL;
Cmax, heart failure patients, 90 mg: 723 ng/mL;
AUC(0-24 hours), 60 mg: 3.71 Î¼gÂ·h/mL;
AUC(âˆž), 60 mg: 4.55 Î¼gÂ·h/mL;
The pharmacokinetic properties of tolvaptan are stereospecific, with a steady-state ratio of the S-(-) to the R-(+) enantiomer of about 3. The absolute bioavailability of tolvaptan is unknown. At least 40% of the dose is absorbed as tolvaptan or metabolites. Food does not impact the bioavailability of tolvaptan. ",0.99,"Terminal half life, oral dose = 12 hours. ",15 mg/1,Oral,solid,,,0.00124,11.76,-2.1,CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2,0.99,0.99,,,0,15,448.1553703,4,3,1,0,0,1
4738,04/06/2019 00:00,DB06213,Regadenoson,"The pharmacokinetic profile of regadenoson is best described by a 3-compartment model. 
T max, injection = 1 to 3 minutes;
Onset of pharmacodynamic response = 1 to 3 minutes;  
E max 12.3 ng/mL 
",,"Initial phase: 2-4 minutes;
Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); 
Terminal phase: 2 hours ",0.08 mg/1mL,Intravenous,liquid,,,4.85,12.37,1.63,CNC(=O)C1=CN(N=C1)C1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(N)=N1,,,,,0,,390.1400157,4,3,4,3,1,1
4739,02/07/2019 00:00,DB06217,Vernakalant,"In patients, average peak plasma concentrations of vernakalant were 3.9 Î¼g/ml following a single 10 minute infusion of 3 mg/kg vernakalant hydrochloride, and 4.3 Î¼g/ml following a second infusion of 2 mg/kg with a 15 minute interval between doses [L765]. ",53-63%,Elimination half life in CYP2D6 extensive metabolizers is 3 hours and 5.5 hours in poor metabolizers. ,20 mg,Intravenous,solid,,,0.156,14.85,9.65,COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1,0.53,0.63,,,0,,349.2253085,3,1,1,0,1,1
4740,02/07/2019 00:00,DB06218,Lacosamide,"Lacosamide has a negligible first pass effect with bioavailability of about 100%. The maximum Lacosamide plasma concentrations occur about 1-4 hours after oral administration, and the pharmacokinetics of Lacosamide are dose proportional. Food does not affect absorption. ",<15%,13 Hours,10 mg/1mL,Oral,solid,Lacosamide is a white to light yellow powder. It is sparingly soluble in water and slightly soluble in acetonitrile and ethanol.,0.728,0.465,12.47,-1.5,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,0,0.15,13,13,0,,250.1317424,1,1,0,0,0,0
4741,02/07/2019 00:00,DB06228,Rivaroxaban,"Following oral administration, rivaroxaban is rapidly absorbed and reaches peak plasma concentration in 2-4 hours. Bioavailability of the 10 mg dose is >80%. However, the 15-20 mg dose have a lower bioavailability if taken in the fasted state and consequently should be taken with food. 
",0.92,The terminal half life is 5-9 hours in adults and 11-13 hours in the elderly.,10 mg,Oral,solid,,,0.01,13.6,-1.6,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,0.92,0.92,,,0,10,435.0655694,4,2,3,1,2,2
4742,04/06/2019 00:00,DB06229,Ocaperidone,,,,,,solid,,,0.126,,8.79,CC1=CC=CN2C(=O)C(CCN3CCC(CC3)C3=NOC4=CC(F)=CC=C34)=C(C)N=C12,,,,,0,,420.1961543,5,4,4,3,1,1
4743,02/07/2019 00:00,DB06230,Nalmefene,"Following a single oral administration of 18.06 mg, nalmefene is rapidly absorbed with a peak plasma concentration (Cmax) of 16.5 ng/ml with the time to reach the peak concentration (Tmax) of approxmately 1.5 hours and the exposure (AUC) of 131 ng x h/ml. Although there is little association to clinical relevance, the AUC and Cmax values are expected to increase by 30 to 50%, respectively, and the Tmax is delayed by 30 minutes after consumption of high-fat food. The absolute oral bioavailability of nalmefene is 41% [L1024]. 

Nalmefene exhibits dose-proportional pharmacokinetics following intravenous injection. The Tmax following intramuscular or subcutaneous injection is approximately 1.5-2.3 hours. In an emergency setting, however, therapeutic plasma concentrations are likely to be reached within 5-15 minutes after a 1 mg dose given intravenously where the plasma concentration is approximately 3.7 ng/mL at 5 minutes in young adult males [FDA Label]. ",30-45%,"The terminal half-life is approximately 12.5 hours following oral administration [L1024]. After intravenous administration of 1 mg in adult males, the terminal half life was 10.8 Â± 5.2 hours [FDA Label]. ",0.1 mg/1mL,Intravenous,solid,Freely soluble in water up to 130 mg/mL,,0.839,10.35,9.57,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C,0.3,0.45,,,0,,339.1834437,6,1,2,0,1,2
4744,04/06/2019 00:00,DB06231,Caldaret,,,,,,solid,,,1.9,-1.7,8.84,CC1=CC=C(N2CCNCC2)C(=C1)S(O)(=O)=O,,,,,0,,256.0881634,2,1,1,0,1,1
4745,04/06/2019 00:00,DB06233,Ridaforolimus,,,,,,solid,,,0.000805,9.96,-3,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O,,,,,0,,989.562943,4,0,3,0,2,3
4746,04/06/2019 00:00,DB06234,Maribavir,,,,,,solid,,,0.72,12.45,6.38,CC(C)NC1=NC2=CC(Cl)=C(Cl)C=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O,,,,,0,,375.0752614,3,2,2,1,1,1
4747,04/06/2019 00:00,DB06235,Vadimezan,,,,,,solid,,,0.0225,3.6,-7.7,CC1=C(C)C2=C(C=C1)C(=O)C1=CC=CC(CC(O)=O)=C1O2,,,,,0,,282.0892089,3,3,1,1,0,0
4748,04/06/2019 00:00,DB06236,Elvucitabine,,,,,,solid,,,1.04,14.63,-3,NC1=NC(=O)N(C=C1F)[C@H]1O[C@@H](CO)C=C1,,,,,0,,227.0706194,2,1,2,1,0,1
4749,04/06/2019 00:00,DB06237,Avanafil,"Avanafil is rapidly absorbed and does not accumulate following multiple doses. 
Tmax = 30 - 45 minutes;
Time to peak response = 10 minutes (20 minutes shorter than sildenafil) ",0.99,Mean elimination half-life = 5.36 - 10.66 hours ,100 mg,Oral,solid,,,0.0297,12.53,5.54,COC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N2CCC[C@H]2CO)C(=O)NCC2=NC=CC=N2)C=C1,0.99,0.99,,,0,100,483.1785654,4,3,3,2,1,1
4750,04/06/2019 00:00,DB06240,Tariquidar,,,,,,solid,,,0.00202,11.45,8.36,COC1=CC2=C(CN(CCC3=CC=C(NC(=O)C4=CC(OC)=C(OC)C=C4NC(=O)C4=CN=C5C=CC=CC5=C4)C=C3)CC2)C=C1OC,,,,,0,,646.2791349,6,5,2,1,0,1
4751,02/07/2019 00:00,DB06243,Eflornithine,,,8 hours,0.139,Topical,solid,,,50,2.19,10.2,NCCCC(N)(C(F)F)C(O)=O,,,8,8,0,,182.0866841,0,0,0,0,0,0
4752,04/06/2019 00:00,DB06246,Exisulind,,,,,,solid,,,0.00155,3.94,,CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)(=O)=O,,,,,0,,372.0831582,3,2,0,0,0,0
4753,04/06/2019 00:00,DB06247,CX516,,,,,,solid,,,0.831,,1.15,O=C(N1CCCCC1)C1=CC2=C(C=C1)N=CC=N2,,,,,0,,241.1215121,3,2,2,1,1,1
4754,04/06/2019 00:00,DB06248,Amelubant,,,,,,solid,,,0.000101,8.16,2.62,CCOC(=O)NC(=N)C1=CC=C(OCC2=CC=CC(COC3=CC=C(C=C3)C(C)(C)C3=CC=C(O)C=C3)=C2)C=C1,,,,,0,,538.2467722,4,4,0,0,0,0
4755,04/06/2019 00:00,DB06249,Arzoxifene,,,,,,solid,,,0.000496,9.47,8.68,COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,,,,,0,,475.1817294,5,4,2,1,1,1
4756,04/06/2019 00:00,DB06250,Fluasterone,,,,,,solid,,,0.00261,16.48,-8.2,C[C@]12CC[C@H]3[C@@H](CC=C4CCCC[C@]34C)[C@@H]1C[C@@H](F)C2=O,,,,,0,,290.2045937,4,0,0,0,0,0
4757,04/06/2019 00:00,DB06251,Dersalazine,,,,,,solid,,,0.00415,3.23,5.56,CC1=NC2=CN=CC=C2N1CC1CCN(CC1)C(=O)\C=C(\C1=CC=CC=C1)C1=CC=C(C=C1)\N=N\C1=CC(C(O)=O)=C(O)C=C1,,,,,0,,600.2485035,6,5,3,2,1,1
4758,04/06/2019 00:00,DB06253,Thioctic acid tromethamine,,,,,,solid,,,0.224,4.52,,NC(CO)(CO)CO.OC(=O)CCCC[C@@H]1CCSS1,,,,,0,,327.1174149,1,0,1,0,1,1
4759,04/06/2019 00:00,DB06255,Incadronic acid,"Pharmacokinetic studies in patients with MAH have indicated linear pharmacokinetics with intravenous administration. [8]

In studies comparing absorption of incadronate in healthy volunteers verses volunteers with MAH plasma levels have been similar at 2 h, however at 8 h the plasma levels are three times higher in patients with MAH. This can be explained by the decrease in renal function experienced by patients with MAH. Notably, however, the plasma levels of incadronate are not as high as expected based on the reduction in renal clearance. This indicates that patients with hypercalcemia may experience enhanced bone uptake of the drug. [8]",,0.26-0.40 h (t1/2 alpha) and 1.58 - 1.98 h (t1/2 beta). [8],,,solid,,,12.5,-1.1,5.57,OP(O)(=O)C(NC1CCCCCC1)P(O)(O)=O,,,,,0,,287.0687606,1,0,0,0,0,0
4760,04/06/2019 00:00,DB06257,HE-2200,,,,,,solid,,,0.223,18.2,-0.55,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C=C2C[C@@H](O)CC[C@]12C,,,,,0,,306.2194948,4,0,0,0,0,0
4761,04/06/2019 00:00,DB06258,Bimoclomol,,,,,,solid,,,0.488,14,9.14,OC(CO\N=C(/Cl)C1=CN=CC=C1)CN1CCCCC1,,,,,0,,297.1244046,2,1,2,1,1,1
4762,04/06/2019 00:00,DB06260,Aviptadil,,,,,,solid,,,0.0536,2.94,11.9,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1)C(C)C)[C@@H](C)O)[C@H](O)CC)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O,,,,,0,,3253.691767,4,4,1,1,0,0
4763,02/07/2019 00:00,DB06261,Hexaminolevulinate,Absolute bioavailability 7% (90% confidence interval [CI]: 5%-10%),,"Biphasic elimination, with an initial elimination half-life of 39 minutes, followed by a terminal half-life of approximately 76 hours.",100 mg/50mL,Intravesical,solid,,,0.511,16.11,7.83,[H]N([H])CC(=O)CCC(=O)OCCCCCC,,,,,0,,215.1521435,0,0,0,0,0,0
4764,04/06/2019 00:00,DB06262,Droxidopa,Oral bioavailability is 90%.,,2-3 hours.,100 mg/1,Oral,solid,,,15.3,1.46,8.72,N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O,,,2,3,0,100,213.0637225,1,1,0,0,0,0
4765,04/06/2019 00:00,DB06263,Amrubicin,"Peak plasma concentrations of the active metabolite _amrubicinol_ were observed from immediately after administration of amrubicin to 1h after administration. Plasma concentrations of amrubicinol were low compared with amrubicin plasma concentrations. The plasma amrubicinol AUC (area under the curve) was approximately 10-fold lower than the amrubicin plasma AUC. Concentrations of amrubicinol were higher in RBCs as compared with plasma. Amrubicinol AUCs ranged from 2.5-fold to 57.9-fold higher in red blood cells (RBCs) compared to plasma. Because amrubicinol distributes itself into RBCs more than amrubicin, the concentrations of amrubicinol and amrubicin in RBCs were quite similar. The AUC of amrubicinol in RBCs was approximately twofold lower than the amrubicin RBC AUC [L1713].

In one study,  after repeated daily amrubicin administration, amrubicinol accumulation was observed in plasma and RBCs. On day 3, the amrubicinol plasma AUC was 1.2-fold to 6-fold higher than day 1 values; the RBC AUC was 1.2-fold to 1.7-fold higher than day 1 values. After 5 consecutive daily doses, plasma and RBC amrubicinol AUCs were 1.2-fold to 2.0-fold higher than day 1 values [L1713].",91.3â€“97.1%,"20-30 h [A32143]

In a study of dogs, Amrubicin plasma concentrations followed a biphasic pattern with peak concentrations observed immediately after dosing followed by Î± and Î² half-lives (t1/2) Â± SD of 0.06 Â± 0.01 and 2.0 Â± 0.3 hours, respectively [L1710].",,,solid,"not soluble in water, but soluble in DMSO",2.64,1.14,8.1,7.02,[H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1,0.913,0.971,,,0,,483.1529314,5,2,1,0,1,1
4766,04/06/2019 00:00,DB06264,Tolperisone,,,,,,solid,,,0.167,16.51,8.78,CC(CN1CCCCC1)C(=O)C1=CC=C(C)C=C1,,,,,0,,245.1779644,2,1,1,0,1,1
4767,04/06/2019 00:00,DB06266,Lonidamine,,,,,,solid,,,0.00904,3.12,-1.5,OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C2=C1C=CC=C2,,,,,0,,320.0119329,3,3,1,1,0,0
4768,04/06/2019 00:00,DB06267,Udenafil,,,,,,solid,,,0.0798,7.21,8.48,CCCOC1=C(C=C(C=C1)S(=O)(=O)NCCC1CCCN1C)C1=NC(=O)C2=C(N1)C(CCC)=NN2C,,,,,0,,516.2518746,4,3,3,2,1,1
4769,04/06/2019 00:00,DB06268,Sitaxentan,70-100%,0.99,10 hours,100 mg,Oral,solid,,,0.0181,6.89,0.75,CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl,0.99,0.99,10,10,0,100,454.0060059,4,3,3,2,0,1
4770,04/06/2019 00:00,DB06272,Maxacalcitol,,,,,,solid,,,0.015,14.34,-2.7,[H]\C(\C(\[H])=C1/CCC[C@@]2(C)[C@@]1([H])CC[C@]2([H])[C@]([H])(C)OCCC(C)(C)O)=C1/C[C@@]([H])(O)C[C@]([H])(O)C1=C,,,,,0,,418.3083098,3,0,0,0,0,0
4771,04/06/2019 00:00,DB06274,Alvimopan,Alvimopan's high affinity for the peripheral mu-receptor leads to slower absorption dependent on dissociation from the receptor and subsequently low oral bioavailability of less than 7%.,0.8,10 to 17 hours (gut metabolite: 10 to 18 hours) ,12 mg/1,Oral,solid,<0.1 mg/mL,,0.00834,3.71,10.66,C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1,0.8,0.8,,,0,12,424.2362075,3,2,1,0,1,1
4772,04/06/2019 00:00,DB06276,Tanomastat,,,,,,solid,,,0.000108,4.18,-7.5,OC(=O)[C@@H](CSC1=CC=CC=C1)CC(=O)C1=CC=C(C=C1)C1=CC=C(Cl)C=C1,,,,,0,,410.0743431,3,3,0,0,0,0
4773,04/06/2019 00:00,DB06280,Senicapoc,,,,,,solid,,,0.000975,15.27,-4.6,NC(=O)C(C1=CC=CC=C1)(C1=CC=C(F)C=C1)C1=CC=C(F)C=C1,,,,,0,,323.1121705,3,3,0,0,0,0
4774,04/06/2019 00:00,DB06281,Torcetrapib,,,,,,solid,,,0.00589,,-1.7,CCOC(=O)N1[C@H](CC)C[C@H](N(CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C(=O)OC)C2=C1C=CC(=C2)C(F)(F)F,,,,,0,,600.1670613,3,2,1,0,0,1
4775,04/06/2019 00:00,DB06282,Levocetirizine,"Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, peak plasma concentrations are achieved 0.9 hour after administration of the oral tablet. The accumulation ratio following daily oral administration is 1.12 with steady state achieved after 2 days. Peak concentrations are typically 270 ng/mL and 308 ng/mL following a single and a repeated 5 mg once daily dose, respectively. Food had no effect on the extent of exposure (AUC) of the levocetirizine tablet, but Tmax was delayed by about 1.25 hours and Cmax was decreased by about 36% after administration with a high fat meal; therefore, levocetirizine can be administered with or without food. ",,8-9 hours.,2.5 mg/5mL,Topical,solid,,,0.0658,3.59,7.42,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1,,,8,9,0,,388.1553703,3,2,1,0,1,1
4776,02/07/2019 00:00,DB06287,Temsirolimus,Infused intravenous over 30 - 60 minutes. C<sub>max</sub> is typically observed at the end of infusion,0.87,"Temsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.",25 mg,Intravenous,solid,,,0.00235,9.96,-2.9,OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC,0.87,0.87,,,0,,1029.602486,4,0,3,0,2,3
4777,04/06/2019 00:00,DB06288,Amisulpride,Bioavailability is 48% following oral administration.,,Approximately 12 hours,,,solid,,1.06,0.293,14.03,7.05,CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC,,,,,0,,369.1722273,2,1,1,0,1,1
4778,02/07/2019 00:00,DB06290,Simeprevir,"The mean absolute bioavailability of simeprevir following a single oral 150 mg dose of simeprevir capsule in fed conditions is 62%. Maximum plasma concentrations (Cmax) are typically
achieved between 4 to 6 hours following the oral administration. ",,The elimination half-life of simeprevir following 200mg dose administration is about 41 hours in HCV-positive patients and 10 to 13 hours in individuals without HCV infection.,150 mg/1,Oral,solid,Insoluble,,0.00458,5.87,1.7,[H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1,,,,,0,150,749.2916908,7,3,3,2,0,1
4779,02/07/2019 00:00,DB06292,Dapagliflozin,"Oral dapagliflozin reaches a maximum concentration within 1 hour of administration when patients have been fasting[A6757]. When patients have consumed a high fat meal, the time to maximum concentration increases to 2 hours and the maximum concentration decreases by half though a dose adjustment is not necessary[Label]. Oral dapagliflozin is 78% bioavailable[Label].",,13.8h[A6757]. ,10 mg,Oral,solid,,2.7,0.173,12.57,-3,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1,,,,,0,10,408.1339662,3,2,1,0,1,1
4780,04/06/2019 00:00,DB06293,Pegnivacogin,,,,,,solid,,,0.0854,1.81,-3.3,COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O,,,,,0,,529.2400457,0,0,0,0,0,0
4781,04/06/2019 00:00,DB06295,Pramiconazole,,,,,,solid,,,0.0214,,3.94,CC(C)N1CCN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2OC[C@@](CN3C=NC=N3)(O2)C2=CC=C(F)C=C2F)C=C1,,,,,0,,659.3031592,7,4,4,1,3,3
4782,04/06/2019 00:00,DB06297,LX-2931,,,,,,solid,,,14.8,9.73,4.65,C\C(=N/O)C1=NC=C(N1)[C@@H](O)[C@H](O)[C@H](O)CO,,,,,0,,245.1011706,1,1,1,1,0,0
4783,04/06/2019 00:00,DB06299,Hydronidone,,,,,,solid,,,3.15,9.3,-1.2,CC1=CN(C(=O)C=C1)C1=CC=C(O)C=C1,,,,,0,,201.0789786,2,2,1,1,0,0
4784,04/06/2019 00:00,DB06302,Glesatinib,,,,,,solid,,,8.10E-05,9.27,8.28,COCCNCC1=CC=C(N=C1)C1=CC2=NC=CC(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=C2S1,,,,,0,,619.1523382,5,5,3,3,0,0
4785,04/06/2019 00:00,DB06306,Onalespib,,,,,,solid,,,0.301,8.51,7.78,CC(C)C1=CC(C(=O)N2CC3=CC=C(CN4CCN(C)CC4)C=C3C2)=C(O)C=C1O,,,,,0,,409.2365419,4,2,2,0,1,2
4786,04/06/2019 00:00,DB06307,Apoptone,,,,,,solid,,,0.00398,17.59,-1.2,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C,,,,,0,,316.2402303,4,0,0,0,0,0
4787,04/06/2019 00:00,DB06309,Refametinib,,,,,,solid,,,0.0818,7.21,-2.9,[H][C@@](O)(CO)CC1(CC1)S(=O)(=O)NC1=C(OC)C=C(F)C(F)=C1NC1=C(F)C=C(I)C=C1,,,,,0,,572.0089754,3,2,0,0,0,0
4788,04/06/2019 00:00,DB06311,Darapladib,,,,,,solid,,,0.000692,16.27,8.31,CCN(CC)CCN(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C2=C(CCC2)C(=O)N=C1SCC1=CC=C(F)C=C1,,,,,0,,666.2651603,5,4,1,1,0,0
4789,04/06/2019 00:00,DB06313,BNC105,,,,,,solid,,,0.0853,1.54,-3,COC1=CC(=CC(OC)=C1OC)C(=O)C1=C(C)OC2=C1C=CC(OC)=C2OP(O)(O)=O,,,,,0,,452.0872335,3,3,1,1,0,0
4790,15/09/2018 00:00,DB06314,SGX-523,,,,,,solid,,,0.0177,,4.26,CN1C=C(C=N1)C1=NN2C(SC3=CC=C4N=CC=CC4=C3)=NN=C2C=C1,,,,,0,,359.0953144,5,5,4,4,0,0
4791,04/06/2019 00:00,DB06321,R-348,,,,,,solid,,,0.00263,4.24,1.9,CCC(=O)NS(=O)(=O)C1=CC(NC2=NC=C(F)C(NC3=CC=C(OCC#C)C=C3)=N2)=CC=C1C,,,,,0,,483.1376534,3,3,1,1,0,0
4792,04/06/2019 00:00,DB06328,Methoxyamine,,,,,,solid,,,600,,4.32,CON,,,,,0,,47.03711378,0,0,0,0,0,0
4793,04/06/2019 00:00,DB06331,4-O-Demethylpenclomedine,,,,,,solid,,,0.15,7.07,-2.4,COC1=C(Cl)C(O)=C(Cl)C(=N1)C(Cl)(Cl)Cl,,,,,0,,308.8684668,1,1,1,1,0,0
4794,04/06/2019 00:00,DB06333,Trodusquemine,,,,,,solid,,,0.000255,-1.3,10.97,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCNCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C,,,,,0,,684.5223424,4,0,0,0,0,0
4795,04/06/2019 00:00,DB06334,Tucidinostat,,,,,,solid,,,0.00236,13.67,4.84,NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CN=CC=C2)C=C1,,,,,0,,390.1492041,3,3,1,1,0,0
4796,02/07/2019 00:00,DB06335,Saxagliptin,"Following a 5 mg single oral dose of saxagliptin to healthy subjects, the mean plasma AUC values for saxagliptin and its active metabolite were 78 ngâ€¢h/mL and 214 ngâ€¢h/mL, respectively. The corresponding plasma Cmax values were 24 ng/mL and 47 ng/mL, respectively. Saxagliptin did not accumulate following repeated doses. The median time to maximum concentration (Tmax) following the 5 mg once daily dose was 2 hours for saxagliptin and 4 hours for its active metabolite.
Bioavailability, 2.5 - 50 mg dose = 67% ",,"Saxagliptin = 2.5 hours;
5-hydroxy saxagliptin = 3.1 hours; ",2.5 mg,Oral,solid,Sparingly soluble,,2.26,14.74,7.9,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,,,,,0,2.5,315.194677,6,0,1,0,1,1
4797,04/06/2019 00:00,DB06345,AR-9281,,,,,,solid,,,0.148,15.08,0.33,CC(=O)N1CCC(CC1)NC(=O)NC12CC3CC(CC(C3)C1)C2,,,,,0,,319.2259772,5,0,1,0,1,1
4798,04/06/2019 00:00,DB06346,Fiboflapon,,,,,,solid,,,0.000146,4.67,4.06,CCOC1=CC=C(C=N1)C1=CC=C(CN2C(CC(C)(C)C(O)=O)=C(SC(C)(C)C)C3=CC(OCC4=CC=C(C)C=N4)=CC=C23)C=C1,,,,,0,,637.2974279,5,5,3,3,0,0
4799,04/06/2019 00:00,DB06347,Cenisertib,,,,,,solid,,,0.0752,14.79,7.86,[H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O,,,,,0,,451.2495868,5,2,2,1,1,1
4800,04/06/2019 00:00,DB06350,Elinogrel,,,,,,solid,,,0.00327,4.69,2.01,CNC1=C(F)C=C2C(NC(=O)N(C2=O)C2=CC=C(NC(=O)NS(=O)(=O)C3=CC=C(Cl)S3)C=C2)=C1,,,,,0,,523.0187165,4,4,2,2,0,0
4801,04/06/2019 00:00,DB06354,Tezampanel,,,,,,solid,,,0.224,1.72,10.55,[H][C@]1(CCC2=NN=NN2)CC[C@@]2([H])CN[C@@]([H])(C[C@@]2([H])C1)C(O)=O,,,,,0,,279.1695249,3,1,2,1,1,1
4802,04/06/2019 00:00,DB06358,Iclaprim,,,,,,solid,,,0.142,17.32,7.15,COC1=CC(CC2=CN=C(N)N=C2N)=C2C=CC(OC2=C1OC)C1CC1,,,,,0,,354.1691906,4,2,2,1,0,1
4803,04/06/2019 00:00,DB06362,Becatecarin,,,,,,solid,,,0.0132,11.86,9.07,CCN(CC)CCN1C(=O)C2=C(C1=O)C1=C(N([C@@H]3O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]3O)C3=C(Cl)C=CC=C13)C1=C2C2=C(N1)C(Cl)=CC=C2,,,,,0,,668.1804548,7,5,4,2,1,2
4804,04/06/2019 00:00,DB06364,XR5944,,,,,,solid,,,0.0012,7.19,9.01,CC1=CC=CC2=NC3=CC=CC(C(O)=NCCNCCNCCN=C(O)C4=C5N=C6C(C)=CC=CC6=NC5=CC=C4)=C3N=C12,,,,,0,,586.2804723,6,6,2,2,0,0
4805,04/06/2019 00:00,DB06365,Sapacitabine,,,,,,solid,,,0.00915,11.14,-1.9,CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1C#N,,,,,0,,490.3155204,2,1,2,1,1,1
4806,04/06/2019 00:00,DB06367,Relacatib,,,,,,solid,,,0.0302,12.07,-2,CC(C)C[C@H](NC(=O)C1=CC2=CC=CC=C2O1)C(=O)N[C@H]1CC[C@@H](C)N(CC1=O)S(=O)(=O)C1=CC=CC=N1,,,,,0,,540.2042557,4,3,3,2,1,1
4807,04/06/2019 00:00,DB06368,Alamifovir,,,,,,solid,,,0.164,16.4,4.26,COC1=CC=C(SC2=C3N=CN(CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F)C3=NC(N)=N2)C=C1,,,,,0,,575.0826957,3,3,2,2,0,0
4808,04/06/2019 00:00,DB06370,Indisulam,,,,,,solid,,,0.0213,6.85,,NS(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl,,,,,0,,384.9957755,3,3,1,1,0,0
4809,04/06/2019 00:00,DB06374,Elacestrant,,,,,,solid,,,0.00035,10.58,9.96,CCNCCC1=CC=C(CN(CC)C2=C(C=CC(OC)=C2)[C@@H]2CCC3=CC(O)=CC=C3C2)C=C1,,,,,0,,458.2933285,4,3,0,0,0,0
4810,04/06/2019 00:00,DB06393,Xaliproden,,,,,,solid,,,0.000229,,8.96,FC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC3=CC=CC=C3C=C2)CC1,,,,,0,,381.1704344,4,3,1,0,0,1
4811,04/06/2019 00:00,DB06395,Abafungin,,,,,,solid,,,0.00354,,6.54,CC1=CC=C(OC2=CC=CC=C2C2=CSC(N=C3NCCCN3)=N2)C(C)=C1,,,,,0,,378.1514323,4,3,2,1,1,1
4812,04/06/2019 00:00,DB06397,Nicaraven,,,,,,solid,,,0.0706,13.58,3.92,CC(CNC(=O)C1=CC=CN=C1)NC(=O)C1=CC=CN=C1,,,,,0,,284.1273258,2,2,2,2,0,0
4813,14/06/2019 00:00,DB06401,Bazedoxifene,Bazedoxifene is rapidly absorbed with a tmax of approximately 2 hours and exhibits a linear increase in plasma concentrations for single doses from 0.5 mg up to 120 mg and multiple daily doses from 1 mg to 80 mg. The absolute bioavailability of bazedoxifene is approximately 6%.,,~30 hours.,,Oral,solid,,,0.000564,9.63,9.09,CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1,,,30,30,0,,470.2569429,5,4,2,1,1,1
4814,02/07/2019 00:00,DB06402,Telavancin,"Telavancin demonstrates linear pharmacokinetics at doses between 1 and 12.5 mg/kg. Furthermore, 24 hours post-infusion of a dose of 7.5 to 15 mg/kg, activity against MRSA and penicillin-resistant Streptococcus pneumonia can still be observed. The trough concentration at this point of time is approximately 10
Î¼g/mL. Telavancin also has poor bioavailability and must be administered over 30-120 minutes IV. 
Cmax, healthy subjects, 10 mg/kg = 93.6 Â± 14.2 Î¼g/mL;
AUC (0- âˆž), healthy subjects, 10 mg/kg = 747 Â± 129 Î¼g Â· h/mL;
AUC (0-24h), healthy subjects, 10 mg/kg = 666Â± 107 Î¼g Â· h/mL;
Time to steady state = 3 days;",>90%,Terminal elimination half-life = 8 Â± 1.5 hours (with normal renal function) ,15 mg/1mL,Intravenous,solid,,,0.0148,1.55,9.99,CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=C(Cl)C=C(C=C2)[C@@H](O)[C@@H]2NC(=O)[C@H](NC4=O)C4=CC(=C(O)C=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[C@H](NC2=O)C(O)=O)=C3)O[C@@H](C)[C@H]1O,0.9,1,,,0,,1753.637429,12,5,7,0,2,7
4815,02/07/2019 00:00,DB06403,Ambrisentan,Ambrisentan is rapidly absorbed with peak plasma concentrations occuring around 2 hours after oral administration. Cmax and AUC increase proportionally with dose across the therapeutic dosing range. Absolute oral bioavailability of ambrisentan is unknown. Absorption is not affected by food.,0.99,Ambrisentan has a terminal half-life of 15 hours. It is thought that steady state is achieved after around 4 days of repeat-dosing.,1 kg/1kg,Not applicable,solid,Ambrisentan is practically insoluble in aqueous solutions at low pH. Solubility increases at higher pH.,,0.05,3.59,2.48,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1,0.99,0.99,,,0,,378.1579572,3,3,1,1,0,0
4816,04/06/2019 00:00,DB06405,Eprodisate,,,,,,solid,,,14.2,-2,,OS(=O)(=O)CCCS(O)(=O)=O,,,,,0,,203.97623,0,0,0,0,0,0
4817,04/06/2019 00:00,DB06408,Taribavirin,,,,,,solid,,,11.2,12.42,5.34,NC(=N)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,,,,,0,,243.0967539,2,1,2,1,1,1
4818,04/06/2019 00:00,DB06409,Morphine glucuronide,,,,,,solid,,,9.19,2.87,9.12,[H][C@]12C=C[C@H](O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4O,,,,,0,,461.1685814,6,1,3,0,2,3
4819,04/06/2019 00:00,DB06410,Doxercalciferol,,,32 to 37 hours. ,0.5 ug/1,Oral,solid,Relatively insoluble,,0.00168,14.39,-2.8,[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\[C@H](C)C(C)C,,,,,0,0.0005,412.3341306,3,0,0,0,0,0
4820,04/06/2019 00:00,DB06412,Oxymetholone,,,,50 mg/1,Oral,solid,5.21 mg/L,,0.0349,8.87,-0.53,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O,,,,,0,50,332.2351449,4,0,0,0,0,0
4821,04/06/2019 00:00,DB06413,Armodafinil,"Tmax is 2 hours when fasted and can be delayed approximately 2-4 hours by food, potentially affecting the onset of action.",,Terminal half-life is approximately 15 hours.,100 mg/1,Oral,solid,,,0.622,8.84,-4.4,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,100,273.0823497,2,2,0,0,0,0
4822,02/07/2019 00:00,DB06414,Etravirine,"Maximum oral absorption is achieved in 2.5-4 hours. 

Absorption is unaffected by the concomitant use of oral ranitidine or omeprazole, which decrease gastric acidity.  

Administration under fasting conditions resulted in a near 50% decrease in systemic exposure (AUC) when compared to administration after a meal.  ",0.999,Half life of 9.05-41 hours.  ,100 mg/1,Oral,solid,,,0.0169,12.49,4.13,CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N,0.999,0.999,,,0,100,434.0490712,3,3,1,1,0,0
4823,04/06/2019 00:00,DB06419,Cethromycin,,,,,,solid,,,0.00672,3.69,7.68,[H][C@]12N=C(O)O[C@]1(C)[C@@]([H])(CC)OC(=O)[C@]([H])(C)C(=O)[C@]([H])(C)[C@@]([H])(O[C@]1([H])O[C@]([H])(C)C[C@]([H])(N(C)C)[C@@]1([H])O)[C@@](C)(C[C@@]([H])(C)C(=O)[C@]2([H])C)OCC=CC1=CC2=CC=CC=C2N=C1,,,,,0,,765.4200451,5,2,4,1,2,3
4824,04/06/2019 00:00,DB06420,Annamycin,,,,,,solid,,,0.527,8.05,-3.3,C[C@@H]1O[C@@H](O[C@H]2C[C@@](O)(CC3=C2C(O)=C2C(=O)C4=CC=CC=C4C(=O)C2=C3O)C(=O)CO)[C@H](I)[C@H](O)[C@H]1O,,,,,0,,640.0441596,5,2,1,0,1,1
4825,04/06/2019 00:00,DB06421,Declopramide,,,,,,solid,,,0.768,15.34,9.04,CCN(CC)CCNC(=O)C1=CC=C(N)C(Cl)=C1,,,,,0,,269.1294899,1,1,0,0,0,0
4826,04/06/2019 00:00,DB06422,Ticalopride,,,,,,solid,,,0.299,14.58,9.32,CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC,,,,,0,,313.1193192,2,1,1,0,1,1
4827,04/06/2019 00:00,DB06429,Talnetant,,,,,,solid,,,0.00127,8.03,2.73,CCC(NC(=O)C1=C(O)C(=NC2=CC=CC=C12)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,382.1681279,4,4,1,1,0,0
4828,04/06/2019 00:00,DB06433,Tezacitabine,,,,,,solid,,,3.27,13.28,-0.73,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)\C1=C/F,,,,,0,,257.0811841,2,1,2,1,1,1
4829,04/06/2019 00:00,DB06435,Tarazepide,,,,,,solid,,,0.00486,15.75,0.96,CN1C2=CC=CC=C2C(=N[C@H](NC(=O)C2=CC3=CC=CC4=C3N2CCC4)C1=O)C1=CC=CC=C1,,,,,0,,448.189926,6,4,3,1,0,2
4830,04/06/2019 00:00,DB06436,Semaxanib,,,,,,solid,,,0.104,11.29,-2.1,CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12,,,,,0,,238.1106131,3,2,2,1,0,1
4831,04/06/2019 00:00,DB06440,Ravuconazole,,,,,,solid,,,0.0158,12.68,2.46,C[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,,,,,0,,437.1121876,4,4,2,2,0,0
4832,04/06/2019 00:00,DB06441,Cangrelor,,,The average elimination half-life of cangrelor is about 3-6 minutes. ,50 mg/1,Intravenous,solid,,,4.33,0.8,2.61,CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1,,,,,0,,774.9483131,3,2,3,2,1,1
4833,04/06/2019 00:00,DB06442,Avasimibe,,,,,,solid,,,1.63E-05,2.9,-6,CC(C)C1=CC(C(C)C)=C(CC(=O)NS(=O)(=O)OC2=C(C=CC=C2C(C)C)C(C)C)C(=C1)C(C)C,,,,,0,,501.2912799,2,2,0,0,0,0
4834,04/06/2019 00:00,DB06444,Dexanabinol,,,,,,solid,,,0.00148,9.98,-2.7,CCCCCCC(C)(C)C1=CC(O)=C2[C@H]3CC(CO)=CC[C@@H]3C(C)(C)OC2=C1,,,,,0,,386.2820951,3,1,1,0,0,1
4835,04/06/2019 00:00,DB06445,Diethylnorspermine,,,,,,solid,,,0.239,,10.75,CCNCCCNCCCNCCCNCC,,,,,0,,244.262697,0,0,0,0,0,0
4836,04/06/2019 00:00,DB06446,Dotarizine,,,,,,solid,,,0.00339,,8.62,C(CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1)CC1(OCCO1)C1=CC=CC=C1,,,,,0,,442.2620283,5,3,2,0,2,2
4837,04/06/2019 00:00,DB06447,E5531,,,,,,solid,,,0.00493,0.5,-3.6,[H]\C(CCCCCC)=C(/[H])CCCC(=O)O[C@]([H])(CCCCCCC)CCO[C@@]1([H])[C@]([H])(OP(O)(O)=O)[C@@]([H])(COC)O[C@@]([H])(OC[C@@]2([H])O[C@]([H])(OP(O)(O)=O)[C@]([H])(N=C(O)CC(=O)CCCCCCCCCCC)[C@@]([H])(OCC[C@]([H])(O)CCCCCCC)[C@]2([H])O)[C@]1([H])N=C(O)CC(=O)CCCCCCCCCCC,,,,,0,,1454.905997,2,0,2,0,2,2
4838,04/06/2019 00:00,DB06448,Lonafarnib,,,,,,solid,,,0.000829,15.75,3.28,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2C3=C(CCC4=C2C(Br)=CC(Cl)=C4)C=C(Br)C=N3)CC1,,,,,0,,636.0502281,5,2,3,1,2,2
4839,04/06/2019 00:00,DB06454,Sarizotan,,,,,,solid,,,0.000894,,8.86,FC1=CC=C(C=C1)C1=CN=CC(CNC[C@H]2CCC3=CC=CC=C3O2)=C1,,,,,0,,348.1637915,4,3,2,1,0,1
4840,04/06/2019 00:00,DB06455,Meclinertant,,,,,,solid,,,0.00164,3.4,5.77,COC1=CC=CC(OC)=C1C1=CC(=NN1C1=C2C=CC(Cl)=CC2=NC=C1)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O,,,,,0,,586.1982978,8,4,2,2,0,0
4841,04/06/2019 00:00,DB06457,Tecastemizole,,,,,,solid,,,0.0776,,10.12,FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1,,,,,0,,324.1750249,4,3,2,1,1,1
4842,04/06/2019 00:00,DB06458,Remacemide,,,,,,solid,,,0.00895,13.61,8.14,CC(CC1=CC=CC=C1)(NC(=O)CN)C1=CC=CC=C1,,,,,0,,268.1575633,2,2,0,0,0,0
4843,04/06/2019 00:00,DB06460,Enrasentan,,,,,,solid,,,0.00434,3.71,-2.8,CCCOC1=CC=C2[C@@H]([C@H]([C@@H](C2=C1)C1=CC=C(OC)C=C1OCCO)C(O)=O)C1=CC=C2OCOC2=C1,,,,,0,,506.1940679,5,3,1,0,0,1
4844,04/06/2019 00:00,DB06461,Squalamine,,,,,,solid,,,0.000169,-1.3,10.89,CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(O)(=O)=O,,,,,0,,627.4644932,4,0,0,0,0,0
4845,04/06/2019 00:00,DB06465,FK-960,,,,,,solid,,,4.11,14.31,-0.31,CC(=O)N1CCN(CC1)NC(=O)C1=CC=C(F)C=C1,,,,,0,,265.122655,2,1,1,0,1,1
4846,04/06/2019 00:00,DB06468,Cariporide,,,,,,solid,,,0.15,10.27,7.62,CC(C)C1=CC=C(C=C1S(C)(=O)=O)C(=O)NC(N)=N,,,,,0,,283.0990624,1,1,0,0,0,0
4847,04/06/2019 00:00,DB06469,Lestaurtinib,,,,,,solid,,,0.105,12.26,-1.5,C[C@]12O[C@H](C[C@]1(O)CO)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C3C(=O)NC4)C3=CC=CC=C3N21,,,,,0,,439.1532062,8,5,5,2,1,3
4848,04/06/2019 00:00,DB06470,Clomethiazole,,,,,,solid,,,0.674,,3.18,CC1=C(CCCl)SC=N1,,,,,0,,161.0065979,1,1,1,1,0,0
4849,04/06/2019 00:00,DB06471,Naxifylline,,,,,,solid,,,0.5,7.79,2.58,[H][C@]12O[C@@]1([H])[C@@]1([H])C[C@]2([H])C[C@@H]1C1=NC2=C(N1)N(CCC)C(=O)C(CCC)C2=O,,,,,0,,343.1895917,5,1,3,1,1,2
4850,04/06/2019 00:00,DB06472,Fradafiban,,,,,,solid,,,0.0484,3.62,11.49,NC(=N)C1=CC=C(C=C1)C1=CC=C(OC[C@@H]2C[C@@H](CC(O)=O)C(=O)N2)C=C1,,,,,0,,367.1532062,3,2,1,0,1,1
4851,04/06/2019 00:00,DB06477,Sumanirole,,,,,,solid,,,1.25,12.88,9.11,CN[C@H]1CN2C(=O)NC3=CC=CC(C1)=C23,,,,,0,,203.105862,3,2,2,1,0,1
4852,04/06/2019 00:00,DB06478,Porfiromycin,,,,,,solid,,,23.3,0.9,4.15,CO[C@]12[C@@H]3[C@H](CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O)N3C,,,,,0,,348.1433697,4,0,3,0,2,3
4853,04/06/2019 00:00,DB06479,Propentofylline,,,,,,solid,,,2.72,19.64,-0.96,CCCN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,,,,,0,,306.1691906,2,2,2,2,0,0
4854,02/07/2019 00:00,DB06480,Prucalopride,Prucalopride is well absorbed and it reaches maximum plasma concentration of 3.79ng/ml with a tmax of 2.77 hours after initial administration. It presents an AUC of 96.5 mn.h/ml.[A40255] The bioavailability of prucalopride is of over 90% and this bioavailability does not get influenced by the ingestion of food.[F2384],,The reported half-life of prucalopride is of around 18-20 hours.[A40255],1 mg/1,Oral,solid,<1 mg/mL ,2.56,0.129,14.64,8.98,COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1,,,,,0,1,367.1662694,3,1,2,0,1,2
4855,04/06/2019 00:00,DB06481,Manitimus,,,,,,solid,,,0.012,5.22,-2.9,O\C(CCC#C)=C(\C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,,,,,0,,308.0772623,1,1,0,0,0,0
4856,04/06/2019 00:00,DB06485,Ropidoxuridine,,,,,,solid,,,3.13,13.89,-3,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C=NC1=O,,,,,0,,337.9763548,2,1,2,1,1,1
4857,04/06/2019 00:00,DB06486,Enzastaurin,,,,,,solid,,,0.00903,9.71,7.56,CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12,,,,,0,,515.2321252,7,5,5,3,1,2
4858,04/06/2019 00:00,DB06494,Sufugolix,,,,,,solid,,,0.000282,9.07,7.57,CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)CC2=CC=CC=C2)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=CC=C1,,,,,0,,667.2064819,6,6,2,2,0,0
4859,04/06/2019 00:00,DB06497,Aplaviroc,,,,,,solid,,,0.0233,4.3,7.94,[H][C@@]1(NC(=O)C2(CCN(CC3=CC=C(OC4=CC=C(C=C4)C(O)=O)C=C3)CC2)N(CCCC)C1=O)[C@H](O)C1CCCCC1,,,,,0,,577.3151861,5,2,2,0,2,2
4860,04/06/2019 00:00,DB06499,Furaprofen,,,,,,solid,,,0.0154,5.03,-2.9,CC(C(O)=O)C1=CC=CC2=C1OC=C2C1=CC=CC=C1,,,,,0,,266.0942943,3,3,1,1,0,0
4861,04/06/2019 00:00,DB06504,S-8510,,,,,,solid,,,0.977,8.75,4.68,C1CC2=C(CO1)C1=C(NC(=N1)C1=NOC=C1)C=N2,,,,,0,,242.0803756,4,3,4,3,0,1
4862,04/06/2019 00:00,DB06506,Repinotan,,,,,,solid,,,0.0059,,9.63,O=C1N(CCCCNC[C@H]2CCC3=CC=CC=C3O2)S(=O)(=O)C2=CC=CC=C12,,,,,0,,400.1456782,4,2,2,0,0,2
4863,04/06/2019 00:00,DB06508,GW-559090,,,,,,solid,,,0.00604,3.48,-1.5,CC(C)C[C@H](NC(=O)COC1=CC=CC=C1C)C(=O)N[C@@H](CC1=CC=C(OC(=O)N2CCC(CC2)C(N)=O)C=C1)C(O)=O,,,,,0,,596.2846142,3,2,1,0,1,1
4864,04/06/2019 00:00,DB06510,Muraglitazar,,,,,,solid,,,0.0129,3.19,0.93,COC1=CC=C(OC(=O)N(CC(O)=O)CC2=CC=C(OCCC3=C(C)OC(=N3)C3=CC=CC=C3)C=C2)C=C1,,,,,0,,516.1896512,4,4,1,1,0,0
4865,04/06/2019 00:00,DB06512,Deramciclane,,,,,,solid,,,0.00103,,8.87,[H][C@]12CC[C@](C)(C1(C)C)[C@@](C2)(OCCN(C)C)C1=CC=CC=C1,,,,,0,,301.2405646,3,1,0,0,0,0
4866,04/06/2019 00:00,DB06515,Resiniferatoxin,,,,,,solid,,,0.00082,9.94,-3.9,[H][C@]12O[C@]3(CC4=CC=CC=C4)O[C@]1(C[C@@]([H])(C)[C@]1(O3)[C@]3([H])C=C(C)C(=O)[C@@]3(O)CC(COC(=O)CC3=CC(OC)=C(O)C=C3)=C[C@@]21[H])C(C)=C,,,,,0,,628.2672329,7,2,2,0,2,2
4867,04/06/2019 00:00,DB06518,R-1487,,,,,,solid,,,0.0618,14.77,2.56,CN1C(=O)C(OC2=CC=C(F)C=C2F)=CC2=C1N=C(NC1CCOCC1)N=C2,,,,,0,,388.1346969,4,3,3,2,1,1
4868,04/06/2019 00:00,DB06519,Edaglitazone,,,,,,solid,,,0.00855,4.36,0.93,CC1=C(CCOC2=C3C=CSC3=C(CC3SC(=O)N=C3O)C=C2)N=C(O1)C1=CC=CC=C1,,,,,0,,464.0864491,5,4,3,2,0,1
4869,04/06/2019 00:00,DB06521,Ertiprotafib,,,,,,solid,,,3.29E-05,4.31,-4.9,CC1=C(C)C2=C(C3=CC(C)=C(O[C@H](CC4=CC=CC=C4)C(O)=O)C(C)=C3)C3=CC=CC=C3C(Br)=C2S1,,,,,0,,558.0864278,5,5,1,1,0,0
4870,04/06/2019 00:00,DB06523,Levovirin,,,,,,solid,,,33.2,11.88,-1.2,NC(=O)C1=NN(C=N1)[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O,,,,,0,,244.0807695,2,1,2,1,1,1
4871,04/06/2019 00:00,DB06525,Ganstigmine,,,,,,solid,,,0.14,12.9,2.06,CCC1=C(NC(=O)OC2=CC3=C(C=C2)N(C)[C@H]2ON(C)CC[C@@]32C)C=CC=C1,,,,,0,,381.2052417,4,2,2,0,1,2
4872,04/06/2019 00:00,DB06527,Tramiprosate,,,,,,solid,,,73.9,-0.99,10.19,NCCCS(O)(=O)=O,,,,,0,,139.0303141,0,0,0,0,0,0
4873,04/06/2019 00:00,DB06529,Ocinaplon,,,,,,solid,,,0.0833,,4.5,O=C(C1=C2N=CC=C(N2N=C1)C1=CC=NC=C1)C1=CC=CC=N1,,,,,0,,301.09636,4,4,4,4,0,0
4874,04/06/2019 00:00,DB06530,Resiquimod,,,,,,solid,,,0.312,14.93,4.64,CCOCC1=NC2=C(N1CC(C)(C)O)C1=CC=CC=C1NC2=N,,,,,0,,314.1742759,3,3,2,2,0,0
4875,04/06/2019 00:00,DB06532,Pafuramidine,,,,,,solid,,,0.0663,,8.83,CONC(=N)C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(=N)NOC,,,,,0,,364.1535405,3,3,1,1,0,0
4876,04/06/2019 00:00,DB06533,Ragaglitazar,,,,,,solid,,,0.00985,3.73,-3.6,CCO[C@H](CC1=CC=C(OCCN2C3=CC=CC=C3OC3=C2C=CC=C3)C=C1)C(O)=O,,,,,0,,419.1732729,4,3,1,0,0,1
4877,04/06/2019 00:00,DB06535,Etilevodopa,,,,,,solid,,,1.78,9.29,6.97,CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1,,,,,0,,225.100108,1,1,0,0,0,0
4878,04/06/2019 00:00,DB06536,Tesaglitazar,,,,,,solid,,,0.00351,3.73,-4.1,CCO[C@@H](CC1=CC=C(OCCC2=CC=C(OS(C)(=O)=O)C=C2)C=C1)C(O)=O,,,,,0,,408.1242741,2,2,0,0,0,0
4879,04/06/2019 00:00,DB06538,Robalzotan,,,,,,solid,,,0.122,14.23,8.8,NC(=O)C1=C2C[C@H](COC2=C(F)C=C1)N(C1CCC1)C1CCC1,,,,,0,,318.1743562,4,1,1,0,0,1
4880,04/06/2019 00:00,DB06543,Astaxanthin,,,,1 kg/1kg,Not applicable,solid,,,0.000667,13.07,-3.5,C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C,,,,,0,,596.3865601,2,0,0,0,0,0
4881,04/06/2019 00:00,DB06548,Minodronic acid,,,,,,solid,,,8.68,0.68,6.32,OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O,,,,,0,,322.011974,2,2,2,2,0,0
4882,04/06/2019 00:00,DB06549,Labradimil,,,,,,solid,,,0.036,1.65,12.48,COC1=CC=C(C[C@@H](CN[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CS2)NC(=O)CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CCCNC(N)=N)C=C1,,,,,0,,1097.544034,5,2,4,1,3,3
4883,04/06/2019 00:00,DB06554,Gaboxadol,,,,,,solid,,,16.6,5.12,8.85,O=C1NOC2=C1CCNC2,,,,,0,,140.0585775,2,1,2,1,0,1
4884,04/06/2019 00:00,DB06555,Siramesine,,,,,,solid,,,0.000176,,9.58,FC1=CC=C(C=C1)N1C=C(CCCCN2CCC3(CC2)OCC2=CC=CC=C32)C2=CC=CC=C12,,,,,0,,454.2420418,6,4,3,1,1,2
4885,04/06/2019 00:00,DB06558,Tezosentan,,,"A pronounced and rapid disposition phase (half-life 6 min), accounting for the major part of the elimination, was followed by a slower phase (half-life 3 h), probably caused by distribution from tissues.",,,solid,,,0.0298,5.2,2.11,COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=NC=C(C=C2)C(C)C)N=C(N=C1OCCO)C1=CC(=NC=C1)C1=NNN=N1,,,,,0,,605.1805006,5,5,4,4,0,0
4886,04/06/2019 00:00,DB06569,P-57AS3,,,,,,solid,,,0.00769,12.29,-3.2,[H][C@@]12CC=C3C[C@H](CC[C@]3(C)[C@@]1([H])C[C@@H](OC(=O)C(\C)=C\C)[C@]1(C)[C@H](CC[C@]21O)C(C)=O)O[C@H]1C[C@H](OC)[C@H](O[C@H]2C[C@H](OC)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](OC)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1,,,,,0,,878.5027717,7,0,3,0,3,3
4887,04/06/2019 00:00,DB06573,Rebimastat,,,,,,solid,,,0.00618,9.31,-2.6,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,,,,,0,,499.2828404,1,0,1,0,1,1
4888,04/06/2019 00:00,DB06575,Valomaciclovir,,,,,,solid,,,3.03,10.17,7.48,CC(C)[C@H](N)C(=O)OCC[C@@H](CO)CN1C=NC2=C1N=C(N)NC2=O,,,,,0,,352.1859032,2,2,2,2,0,0
4889,04/06/2019 00:00,DB06578,Tonabersat,,,,,,solid,,,0.00892,12.39,-1.1,CC(=O)C1=CC=C2OC(C)(C)[C@@H](O)[C@@H](NC(=O)C3=CC=C(F)C(Cl)=C3)C2=C1,,,,,0,,391.098664,3,2,1,0,0,1
4890,04/06/2019 00:00,DB06579,Adipiplon,,,,,,solid,,,0.031,,2.96,CCCC1=C(CN2C=CN=C2C2=C(F)C=CC=N2)N=CN2N=C(C)N=C12,,,,,0,,351.1607718,4,4,4,4,0,0
4891,04/06/2019 00:00,DB06580,Celgosivir,,,,,,solid,,,344,12.93,8.19,CCCC(=O)O[C@H]1CN2CC[C@H](O)[C@@H]2[C@@H](O)[C@@H]1O,,,,,0,,259.1419728,2,0,2,0,2,2
4892,04/06/2019 00:00,DB06581,Bevirimat,,,56.3 to 69.5 hours,,,solid,,,0.000135,4.16,-7.1,[H][C@]12[C@@H](CC[C@@]1(CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O)C(C)=C,,,,,0,,584.4076895,5,0,0,0,0,0
4893,04/06/2019 00:00,DB06582,Dextofisopam,,,,,,solid,,,0.00239,,-2.2,CC[C@@H]1C2=CC(OC)=C(OC)C=C2C(=NN=C1C)C1=CC=C(OC)C(OC)=C1,,,,,0,,382.1892573,3,2,1,0,0,1
4894,04/06/2019 00:00,DB06585,Fipamezole,,,,,,solid,,,0.139,14.35,6.57,CCC1(CC2=CC=C(F)C=C2C1)C1=CNC=N1,,,,,0,,230.1219267,3,2,1,1,0,0
4895,04/06/2019 00:00,DB06586,Cetilistat,,,,,,solid,,,1.25E-05,,-4.4,CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C)C=C2)C(=O)O1,,,,,0,,401.2929941,2,2,1,1,0,0
4896,04/06/2019 00:00,DB06587,Mitemcinal,,,,,,solid,,,0.038,12.63,9.63,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C(C)C)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC,,,,,0,,755.4819766,4,0,4,0,3,4
4897,04/06/2019 00:00,DB06588,Triphendiol,,,,,,solid,,,0.0071,9.5,-4.5,COC1=CC=C(C=C1)[C@@H]1[C@@H](COC2=CC(O)=CC=C12)C1=CC=C(O)C=C1,,,,,0,,348.1361591,4,3,1,0,0,1
4898,02/07/2019 00:00,DB06589,Pazopanib,"Absorption of pazopanib in cancer patients is slow and incomplete. In patients with solid tumour, over a dose range of 50-2000 mg, absorption is nonlinear. Significant accumulation of pazopanib can also be observed in patients receiving 800 mg once daily for 22 days. Crushing tablets may increase exposure (increase in Cmax and AUC, while Tmax decreases by 2 hours). 
Bioavailability, oral tablet 800 mg, cancer patient = 21%;
Bioavailability may be low due to incomplete absorption from the gastrointestinal tract. The major circulating component of the drug in the systemic is pazopanib, and not its metabolites. 
Mean maximum plasma concentration= 58.1 Âµg/mL;
Mean AUC= 1037 Âµg Â· h/mL; ",>99%,35 hours. Oral absorption is not the rate limiting step of elimination from the plasma. ,200 mg,Oral,solid,,,0.0433,10.41,5.07,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1,0.99,1,,,0,200,437.163394,4,4,2,2,0,0
4899,02/07/2019 00:00,DB06590,Ceftaroline fosamil,,,1.60 hours (600 mg dose).,400 mg/20mL,Intravenous,solid,>100 mg/ml,,0.0245,1.8,0.39,[H][C@]12SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC)\C1=NSC(NP(O)(O)=O)=N1)C([O-])=O,,,,,0,,684.0102803,5,3,5,3,1,2
4900,04/06/2019 00:00,DB06594,Agomelatine,Bioavailability is less than 5%.,0.95,<2 hours,,,solid,"~0.5 mg/ml in 1:1 EtOH:PBS (pH 7.2); ~30 mg/ml in EtOH, DMF & DMSO",,0.00776,15.96,-0.94,COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1,0.95,0.95,2,2,0,,243.1259288,2,2,0,0,0,0
4901,02/07/2019 00:00,DB06595,Midostaurin,The time to reach maximum concentration ranges from 1-3 hrs in fasting patients. The maximum concentration and the time it takes to reach this concentration is reduced up to 20% in presence of a standard meal. ,>99.8%,"Elimination half life is approximately 21 hrs for midostaurin, 32 hrs for CGP62221 and 482 hrs  for CGP52421. ",25 mg,Oral,solid,<1mg/mL,5.89,0.0157,13.45,-0.83,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1,0.99,1,,,0,25,570.2267054,9,6,5,2,1,3
4902,04/06/2019 00:00,DB06597,Estradiol sulfamate,,,,,,solid,,,0.00725,10.85,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OS(N)(=O)=O)C=C3CC[C@@]21[H],,,,,0,,351.1504293,4,1,0,0,0,0
4903,04/06/2019 00:00,DB06598,Brostallicin,,,,,,solid,,,0.106,12.42,11.57,CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC(=O)C4=CC(NC(=O)C(Br)=C)=CN4C)=CN3C)=CN2C)C=C1C(=O)NCCNC(N)=N,,,,,0,,722.2036743,4,4,4,4,0,0
4904,04/06/2019 00:00,DB06600,Nemonoxacin,,,,,,solid,,,0.453,5.73,9.66,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC=C1N1C[C@@H](C)C[C@H](N)C1)C1CC1,,,,,0,,371.1845063,4,2,2,1,1,1
4905,04/06/2019 00:00,DB06603,Panobinostat,"After a 20 mg dose, panobinostat was quickly absorbed with a time to maximum absorption of 2 hours. ",,30 hours,10 mg/1,Oral,solid,,,0.000834,5.45,10.01,[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO,,,30,30,0,10,349.179027,3,3,1,1,0,0
4906,04/06/2019 00:00,DB06604,Ilepatril,,,,,,solid,,,0.0589,3.6,-3.5,[H][C@]12CCC[C@H](N1C(=O)[C@H](CC1=C2C=CC=C1)NC(=O)[C@@H](SC(C)=O)C(C)C)C(O)=O,,,,,0,,432.171893,3,1,2,0,1,2
4907,02/07/2019 00:00,DB06605,Apixaban,Apixaban is approximately 50% bioavailable[Label] though other studies report 43-46% oral bioavailability[A177565].,,"12.7Â±8.55h[Label,A177565,A6897].",2.5 mg,Oral,solid,0.11mg/mL,2.71,0.0679,13.12,-1.6,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O,,,,,0,2.5,459.1906543,5,3,3,1,1,2
4908,04/06/2019 00:00,DB06608,Tafenoquine,"The first-in-human pharmacokinetic study showed a tmax of 13.8 hours and this study suggested that the prolonged absorption from the gut can be due to absorption in the distal gastrointestinal tract combined with a slow clearance. The AUC and Cmax demonstrated an intersubject variability. The bioavailability of tafenoquine is increased in the presence of a high-fat meal by modifying the amount of drug absorbed rather than the rate of absorption. Once absorbed, the concentration of tafenoquine in the whole body is two-fold higher than the corresponding concentration in plasma and it seems to be highly distributed in the liver showing an AUC of approximately 80 times more than what is found in the plasma.[A35677]",,Tafenoquine presents a long half-life of approximately 14 days.[A35693],100 mg/1,Oral,solid,Insoluble,,0.00137,17.14,10.2,COC1=CC(C)=C2C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C(NC(C)CCCN)C2=N1,,,,,0,100,463.2082764,3,3,1,1,0,0
4909,04/06/2019 00:00,DB06609,Odiparcil,,,,,,solid,,,1.82,12.6,-3.3,[H][C@@]1(O)CS[C@@]([H])(OC2=CC3=C(C=C2)C(C)=CC(=O)O3)[C@]([H])(O)[C@@]1([H])O,,,,,0,,324.0667592,3,2,2,1,1,1
4910,04/06/2019 00:00,DB06610,Omiganan,,,,,,solid,,,0.0111,,12.38,[H]N=C(N([H])[H])N([H])CCC[C@H](N([H])C(=O)[C@H](CCCN([H])C(=N[H])N([H])[H])N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CCCN([H])C(=N[H])N([H])[H])N([H])C(=O)[C@H](CC(C)C)N([H])C(=O)[C@@H](N([H])[H])[C@@H](C)CC)C(=O)N([H])[C@@H](CCCCN([H])[H])C(=O)N([H])[H],,,,,0,,1778.015753,10,8,6,4,2,2
4911,02/07/2019 00:00,DB06614,Peramivir,,,,10 mg,Intravenous,solid,,,0.38,4.09,12.46,[H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O,,,,,0,,328.2110554,1,0,0,0,0,0
4912,02/07/2019 00:00,DB06616,Bosutinib,"Food increase the exposure of bosutinib. 
Tmax, single dose, cancer patients, fed-state = 4-6 hours;
After 15 daily doses of bosutinib 500 mg with food in CML patients, the pharmacokinetic parameters are as follows:
Cmax = 200 ng/mL; 
AUC = 3650 ngâˆ™h/mL
",0.94,"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours ",100 mg,Oral,solid,,,0.0095,15.48,8.43,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,0.94,0.94,,,0,100,529.1647451,4,3,2,1,1,1
4913,04/06/2019 00:00,DB06618,Cutamesine,,,,,,solid,,,0.0432,,8.33,COC1=C(OC)C=C(CCN2CCN(CCCC3=CC=CC=C3)CC2)C=C1,,,,,0,,368.2463783,3,2,1,0,1,1
4914,04/06/2019 00:00,DB06619,Amdoxovir,,,,,,solid,,,9.68,13.85,5.81,NC1=NC(N)=C2N=CN([C@H]3CO[C@@H](CO)O3)C2=N1,,,,,0,,252.0970882,3,2,3,2,1,1
4915,04/06/2019 00:00,DB06620,Aplindore,,,,,,solid,,,0.139,11.88,8.69,O=C1CC2=C3O[C@@H](CNCC4=CC=CC=C4)COC3=CC=C2N1,,,,,0,,310.1317424,4,2,2,0,0,2
4916,04/06/2019 00:00,DB06622,7-beta-Hydroxyepiandrosterone,,,,,,solid,,,0.102,18.3,-0.51,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C[C@@]2([H])C[C@@H](O)CC[C@]12C,,,,,0,,306.2194948,4,0,0,0,0,0
4917,04/06/2019 00:00,DB06623,Flupirtine,"Bioavailability: 90% (oral), 70% (rectal)",,"6.5 hrs (average), 11.2-16.8 hrs (average 14 hrs) (elderly), 8.7-10.9 hrs (average 9.8 hrs) (in those with moderate-level renal impairment).",,,solid,,,0.0732,12.9,7.5,CCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1,,,,,0,,304.133554,2,2,1,1,0,0
4918,04/06/2019 00:00,DB06624,Taranabant,,,,,,solid,,,0.000596,13.74,1.59,C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N,,,,,0,,515.1587394,3,3,1,1,0,0
4919,04/06/2019 00:00,DB06625,Vipadenant,,,,,,solid,,,0.212,15.78,4.16,CC1=CC(CN2N=NC3=C(N=C(N)N=C23)C2=CC=CO2)=CC=C1N,,,,,0,,321.1338081,4,4,3,3,0,0
4920,02/07/2019 00:00,DB06626,Axitinib,"After one 5 mg dose of axitinib, it takes about 2.5 to 4.1 hours to reach maximum plasma concentration.

",0.99,Axitinib has a half life of 2.5 to 6.1 hours.,1 mg,Oral,solid,"In aqueous media with a pH between 1.1 to 7.8, axitinib has a solubility of over 0.2 Î¼g/mL. ",,0.000551,13.07,4.59,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1,0.99,0.99,,,0,1,386.1201322,4,4,2,2,0,0
4921,04/06/2019 00:00,DB06629,Zibotentan,,,,,,solid,,,0.177,5.46,0.92,COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=C1)C1=NN=CO1,,,,,0,,424.095374,4,4,3,3,0,0
4922,04/06/2019 00:00,DB06630,Anacetrapib,,,,,,solid,,,0.00192,,-4.9,COC1=CC(F)=C(C=C1C1=CC=C(C=C1CN1[C@@H](C)[C@H](OC1=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C,,,,,0,,637.1674759,4,3,1,0,1,1
4923,04/06/2019 00:00,DB06633,N-chlorotaurine,,,,,,solid,,,28.3,-2.2,3.07,OS(=O)(=O)CCNCl,,,,,0,,158.9756917,0,0,0,0,0,0
4924,04/06/2019 00:00,DB06634,Casopitant,,,,,,solid,,,0.00445,,7.31,C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,,,,,0,,616.2648239,4,2,2,0,2,2
4925,04/06/2019 00:00,DB06635,Otamixaban,,,,,,solid,,,0.00202,14.94,11.46,COC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C1=CC=C(C=C1)C1=CC=[N+]([O-])C=C1,,,,,0,,446.1954053,3,3,1,1,0,0
4926,04/06/2019 00:00,DB06636,Isavuconazonium,"When administered intravenously as isavuconazonium, >99% of the prodrug is quickly converted to active isavuconazole (catalyzed by plasma esterases). Oral administration of isavuconazonium shows 98% oral bioavailability, however administration with food results in a 20% decrease in AUC (area under concentration-time curve) as well as decreasing maximum serum concentration (Cmax) by 50% and increasing time to Cmax by 1.5 hours. ",>99%,80 to 130 hours.,100 mg,Oral,solid,,,0.00516,12.57,6.45,[H]C(C)(OC(=O)N(C)C1=C(COC(=O)CNC)C=CC=N1)[N+]1=CN(C[C@](O)(C2=C(F)C=CC(F)=C2)[C@@]([H])(C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)N=C1,0.99,1,,,1,100,717.2413701,5,5,3,3,0,0
4927,02/07/2019 00:00,DB06637,Dalfampridine,"Orally-administered dalfampridine is rapidly and completely absorbed from the gastrointestinal tract. 
Tmax, immediate release form = 1 hour;
Tmax, extended release form = 3.5 hours;
Cmax, 10 mg extended release = 17.3 - 21.6 ng/mL; 
Relative bioavailability of 10 mg extended-release tablets compared to aqueous oral solution = 96%",1-3%,"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;  ",10 mg/1,Oral,solid,74 g/L,,6.73,16.04,12.18,NC1=CC=NC=C1,0.01,0.03,,,0,10,94.05309819,1,1,1,1,0,0
4928,04/06/2019 00:00,DB06638,Quarfloxin,,,,,,solid,,,0.0157,2.77,9.16,[H][C@@]1(CCN=C(O)C2=CN3C4=CC5=CC=CC=C5C=C4OC4=C3C(=CC(F)=C4N3CCC([H])(C3)C3=CN=CC=N3)C2=O)CCCN1C,,,,,0,,604.2598171,8,5,5,2,2,3
4929,04/06/2019 00:00,DB06640,Fispemifene,,,,,,solid,,,0.000461,15.12,-2.7,OCCOCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,,,,,0,,422.1648724,3,3,0,0,0,0
4930,04/06/2019 00:00,DB06641,Perifosine,,,,,,solid,,,0.000101,1.9,,CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1,,,,,0,,461.3633958,1,0,1,0,1,1
4931,04/06/2019 00:00,DB06645,Anamorelin,,,,,,solid,,,0.0103,12.7,8.34,CN(C)N(C)C(=O)[C@@]1(CC2=CC=CC=C2)CCCN(C1)C(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)C(C)(C)N,,,,,0,,546.3318392,4,3,2,1,1,1
4932,04/06/2019 00:00,DB06649,Priralfinamide,,,,,,solid,,,0.0115,15.76,7.93,C[C@H](NCC1=CC=C(OCC2=CC=CC=C2F)C=C1)C(N)=O,,,,,0,,302.1430561,2,2,0,0,0,0
4933,04/06/2019 00:00,DB06651,DiaPep 277,,,,,,solid,,,0.0386,2.48,11.86,[H][C@](C)(O)[C@]([H])(N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(CO)N=C(O)[C@]([H])(CC(O)=O)N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(C)N=C(O)[C@]1([H])CCCN1C(=O)[C@@]([H])(N=C(O)[C@@]([H])(N=C(O)[C@]([H])(CCCNC(N)=N)N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(CC(C)C)N=C(O)[C@]([H])(C)N=C(O)[C@@]([H])(N=C(O)CN=C(O)CN=C(O)CN=C(O)[C@]([H])(CC(C)C)N=C(O)[C@@]([H])(N)C(C)C)C(C)C)C(C)C)[C@@]([H])(C)CC)C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(O)=O)C(O)=O,,,,,0,,2389.321675,2,0,2,0,2,2
4934,04/06/2019 00:00,DB06652,Vicriviroc,,,,,,solid,,,0.0362,,8.85,COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1=C(C)N=CN=C1C)C1=CC=C(C=C1)C(F)(F)F,,,,,0,,533.2977601,4,2,3,1,2,2
4935,04/06/2019 00:00,DB06654,Safinamide,"Rapid with peak plasma concentrations ranging from 2 to 4 h, total bioavailability is 95%. Food prolonged the rate and did not affect the extent of absorption of safinamide.",88â€“90%,22 h,100 mg,Oral,solid,,,0.00989,15.76,7.93,C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O,0.88,0.9,22,22,0,100,302.1430561,2,2,0,0,0,0
4936,04/06/2019 00:00,DB06656,TAS-106,,,,,,solid,,,1.47,11.21,-2.7,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@](O)(C#C)[C@H]1O,,,,,0,,267.0855205,2,1,2,1,1,1
4937,04/06/2019 00:00,DB06657,Valrocemide,,,,,,solid,,,2.39,13.46,-0.99,CCCC(CCC)C(=O)NCC(N)=O,,,,,0,,200.1524779,0,0,0,0,0,0
4938,04/06/2019 00:00,DB06659,Rostaporfin,,,,,,solid,,,0.00394,12.37,5.15,[Cl-].[Sn+4].CCOC(=O)C1=CC2=C3[N-]\C(=C/C4=N/C(=C\C5=C(CC)C(C)=C([N-]5)\C=C5/N=C2C(C)=C5CC)/C(C)=C4CC)[C@@H](C)[C@]13CC,,,,,1,,729.2012754,6,2,5,2,0,3
4939,04/06/2019 00:00,DB06660,Saredutant,,,,,,solid,,,0.000115,13.69,9.03,CN(C[C@@H](CCN1CCC(CC1)(NC(C)=O)C1=CC=CC=C1)C1=CC=C(Cl)C(Cl)=C1)C(=O)C1=CC=CC=C1,,,,,0,,551.2106327,4,3,1,0,1,1
4940,02/07/2019 00:00,DB06663,Pasireotide,"The peak plasma concentration of pasireotide occurs in 0.25-0.5 hours. After administration of single and multiple doses, there is  dose-proportionoal increases in Cmax and AUC.",,The half-life is 12 hours.,0.3 mg/1mL,Subcutaneous,solid,Soluble in water.,,0.00203,9.09,10.43,NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1,,,,,0,,1046.501424,8,6,3,1,2,2
4941,04/06/2019 00:00,DB06666,Lixivaptan,,,,,,solid,,,0.000467,12.37,-3.1,CC1=CC=C(F)C=C1C(=O)NC1=CC=C(C(=O)N2CC3=CC=CN3CC3=C2C=CC=C3)C(Cl)=C1,,,,,0,,473.1306328,5,4,2,1,0,1
4942,04/06/2019 00:00,DB06669,Arverapamil,,,,,,solid,,,0.00293,,10.29,COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,,,,,0,,440.2675076,2,2,0,0,0,0
4943,04/06/2019 00:00,DB06670,Odanacatib,Tmax of 2-6h [A19389]. The absolute bioavailabilities observed with 30mg and 50 mg doses are 70% and 30% respectively. When taken with high fat meals the 50mg dose's bioavailability increases to 49% and tmax increases to 10.5h [A19391].,0.975,Apparent half life observed to be 87.3-94.7h [A19389].,,,solid,,,0.00666,11.12,3.25,CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,0.975,0.975,,,0,,525.1709256,3,2,0,0,0,0
4944,04/06/2019 00:00,DB06673,Almorexant,,,,,,solid,,,0.000309,15.25,7.06,CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,,,,,0,,512.2286775,4,3,1,0,0,1
4945,04/06/2019 00:00,DB06677,Clazosentan,,,,,,solid,,,0.0428,3.53,2.11,COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C)C=N2)N=C(N=C1OCCO)C1=CC=NC(=C1)C1=NN=NN1,,,,,0,,577.1492005,5,5,4,4,0,0
4946,04/06/2019 00:00,DB06678,Esmirtazapine,,,10 hours,,,solid,Soluble in methanol and chloroform mg/mL (20 Â°C),,1.1,,6.67,[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1,,,10,10,0,,265.1578976,4,2,3,1,1,2
4947,04/06/2019 00:00,DB06680,Asoprisnil,,,,,,solid,,,0.00211,8.34,2.56,[H]\C(=N/O)C1=CC=C(C=C1)[C@@]1([H])C[C@@]2(C)[C@@]([H])(CC[C@]2(COC)OC)[C@]2([H])CCC3=CC(=O)CCC3=C12,,,,,0,,449.2566086,5,1,0,0,0,0
4948,04/06/2019 00:00,DB06682,Naproxcinod,,,,,,solid,,,0.000281,,-4.8,COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(=O)OCCCCO[N+]([O-])=O,,,,,0,,347.1368874,2,2,0,0,0,0
4949,04/06/2019 00:00,DB06683,Clevudine,,,,,,solid,,,87.7,10.1,-3,CC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)C(=O)NC1=O,,,,,0,,260.0808497,2,1,2,1,1,1
4950,02/07/2019 00:00,DB06684,Vilazodone,"Vilazodone's bioavailability is 72% when taken with food[Label,A38477].",,"25 hours[Label,A38477]. Other studies show a half life of 24Â±5.2h with a single 40mg dose and 28.9Â±3.2h with repeated doses[A177628].",10 mg,Oral,solid,,,0.123,14.19,8.6,NC(=O)C1=CC2=CC(=CC=C2O1)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1,,,,,0,10,441.2164751,5,4,3,2,1,1
4951,04/06/2019 00:00,DB06685,Laquinimod,,,,,,solid,,,0.0438,5.02,-2.2,CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1,,,,,0,,356.0927701,3,3,1,1,0,0
4952,14/06/2019 00:00,DB06691,Mepyramine,,,,25 kg/25kg,Oral,solid,,3.27,0.781,,8.76,COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1,,,,,0,,285.1841124,2,2,1,1,0,0
4953,04/06/2019 00:00,DB06693,Mevastatin,,,,,,solid,,3.95,0.0321,14.91,-2.8,[H][C@]12[C@H](CCC=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,,,,,0,,390.2406242,3,0,1,0,1,1
4954,02/07/2019 00:00,DB06694,Xylometazoline,,,,1 mg/1mL,Nasal,solid,,3.2,0.00893,,10.29,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C,,,,,0,,244.1939488,2,1,1,0,0,1
4955,02/07/2019 00:00,DB06695,Dabigatran etexilate,"Oral dabigatran is 3-7% bioavailable, reaching a maximum concentration 1 hour after administration in fasted subjects[Label]. When taken with a meal that is high in fat, the time to maximum concentration increases to 2 hours, though this does not affect dosing[Label,A177463]. Dabigatran etexilate's bioavailability increases to 75% when taken without the capsule shell and so patients should not chew or crush the capsules[Label].",0.35,"12 to 17 hours[Label,A177463].",110 mg,Oral,solid,"1.8mg/ml, partly soluble ",3.8,0.00466,17.89,4.48,CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1,0.35,0.35,,,0,110,627.3169174,4,4,2,2,0,0
4956,04/06/2019 00:00,DB06696,Arbekacin,Aminoglycosides are not well absorbed from the gastrointestinal tract. Their absorption is markedly improved by parenteral administration.,3-12%,3 hours,,,solid,,,41,12.49,9.99,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,0.03,0.12,3,3,0,,552.3118916,3,0,2,0,2,2
4957,04/06/2019 00:00,DB06697,Artemether,Food increases absorption. ,(95.4%,"Artemether, 1.6 +/- 0.7 and 2.2 +/- 1.9 hr; Dihydroartemisinin, 1.6 +/- 0.6 and 2.2 +/- 1.5 hr",,Oral,solid,Insoluble ,3.53,0.457,,-3.9,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OC)[C@@H]2C)O4,0.95,0.04,,,0,,298.1780239,5,0,4,0,4,4
4958,02/07/2019 00:00,DB06698,Betahistine,"When given orally, betahistine is rapidly absorbed from the gastrointestinal tract.",,3-4 hours,16 mg,Oral,solid,,0.68,49.3,,9.77,CNCCC1=CC=CC=N1,,,3,4,0,16,136.1000484,1,1,1,1,0,0
4959,02/07/2019 00:00,DB06699,Degarelix,"Degarelix forms a depot at the site of injection after subcutaneous administration from which the drug slowly released into circulation. After a single bolus dose of 2mg/kg, peak plasma concentrations of degarelix occured within 6 hours at a concentration of 330 ng/mL. 
Ki = 0.082 ng/mL and 93% of receptors were fully suppressed; 
MRT = 4.5 days. ",0.9,"Terminal half-life: 41.5 - 70.2 days; 
Absorption half-life: 32.9 hours; 
Half-life from injection site: 1.17 days. ",120 mg,Subcutaneous,solid,,,0.0041,10.55,11.16,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,0.9,0.9,,,0,,1630.748797,8,6,3,1,2,2
4960,02/07/2019 00:00,DB06700,Desvenlafaxine,"Oral bioavailability is approximately 80%[A6997,A6991,A6996] and is unaffected by food. Peak plasma concentration is reached in 7.5 hours[A6996].",0.3,The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment[A6991].,25 mg/1,Oral,solid,,,1.4,10.11,8.87,CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1,0.3,0.3,,,0,25,263.188529,2,1,0,0,0,0
4961,04/06/2019 00:00,DB06701,Dexmethylphenidate,"Taking dexmethylphenidate with or without food does not affect patients in a clinically relevant way[A177187]. 90% of an oral dose is absorbed[Label] but as a result of hepatic first pass metabolism, oral bioavailability of dexmethylphenidate is 23% compared to l-methylphenidate with an oral bioavailability of 5% [A177187]. Maximum concentration is generally reached in 1-1.5 hours[Label].",12-15%,"The mean terminal half life is approximately 2.2 hours[Label]. However other studies have shown 3.8-3.9 hours[A177184], or 5.96 hours after intravenous administration and 5.69 hours following an oral dose[A177187].",10 mg/1,Oral,solid,,,0.182,,9.09,[H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1,0.12,0.15,,,0,10,233.1415788,2,1,1,0,1,1
4962,02/07/2019 00:00,DB06702,Fesoterodine,"Tmax (5-HMT): 5 hours post-adminitration of fesoterodine. 
AUC (0,âˆž)= 49.5 ngÂ·h/ ml  
Bioavailability, 5-HMT = 52% ",0.5,7-8 hours for the active metabolite 5-hydroxymethyl tolterodine ,4 mg,Oral,solid,Highly soluble ,,0.00205,14.98,10.64,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C,0.5,0.5,,,0,4,411.277344,2,2,0,0,0,0
4963,02/07/2019 00:00,DB06703,Gadobutrol,"With normal renal function, the AUC is 1.1 Â± 0.1 mmolÂ·h/L. ",,1.81 hours (1.33-2.13 hours). ,604.72 mg/1mL,Intravenous,liquid,,,0.0496,0.99,-3,OC[C@H](O)[C@H](CO)[N+]12CC[N+]3(CC([O-])=O)CC[N+]4(CC([O-])=O)CC[N+](CC([O-])=O)(CC1)[Gd-]234,,,,,0,,605.1332075,4,0,4,0,4,4
4964,04/06/2019 00:00,DB06704,Iobenguane,Iobenguane rapidly clears from the blood and is highly retained in adrenergic tissues. ,,Physical half life = 13.2 hours ,2 mCi/1mL,Intravenous,liquid,Soluble ,,0.0878,,11.27,NC(N)=NCC1=CC(I)=CC=C1,,,,,0,,274.9919453,1,1,0,0,0,0
4965,04/06/2019 00:00,DB06705,Gadofosveset trisodium,,80-90%,18.5 hours,0.25 mmol/ml,Intravenous,solid,,,0.169,0.78,9.67,[Na+].[Na+].[Na+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC(COP([O-])(=O)OC1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1)N(CC([O-])=O)CC([O-])=O,0.8,0.9,18.5,18.5,0,,958.1025513,3,2,0,0,0,0
4966,04/06/2019 00:00,DB06706,Isometheptene,,,,,Oral,solid,,,3.06,,10.67,CNC(C)CCC=C(C)C,,,,,0,,141.1517496,0,0,0,0,0,0
4967,04/06/2019 00:00,DB06707,Levonordefrin,,,,,Subcutaneous,solid,,,14.6,9.63,8.96,C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1,,,,,0,,183.0895433,1,1,0,0,0,0
4968,04/06/2019 00:00,DB06708,Lumefantrine,Food increases absorption. ,0.997,~ 4.5 days,,Oral,solid,,,3.09E-05,14.1,9.78,CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1,0.997,0.997,,,0,,527.1549477,4,3,0,0,0,0
4969,02/07/2019 00:00,DB06709,Methacholine,,,,1600 mg,Respiratory (inhalation),solid,,,0.0678,,-7,CC(C[N+](C)(C)C)OC(C)=O,,,,,1,,160.1332052,0,0,0,0,0,0
4970,04/06/2019 00:00,DB06710,Methyltestosterone,The methyl group aids to increase oral bioavailability.,0.4,6-8 hours,10 mg,Oral,solid,33.9 mg/L (at 25 Â°C),3.36,0.0139,19.09,-0.53,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.4,0.4,6,8,0,10,302.2245802,4,0,0,0,0,0
4971,02/07/2019 00:00,DB06711,Naphazoline,"Absorption data for naphazoline are scarce but imidazoline compounds in general are weakly basic and lipophilic, with high bioavailability from the gastrointestinal tract[T530].",,Half life has not been determined but effects last for 4 to 8 hours[L5807]. Other imidazoline compounds have half lives varying from 2 to 12 hours[T530].,0.00012,Ophthalmic,solid,,3.881,0.0381,,10.19,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12,,,,,0,,210.1156984,3,2,1,0,0,1
4972,04/06/2019 00:00,DB06712,Nilvadipine,,,,,,solid,,,0.0124,,-0.57,COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N,,,,,0,,385.1273853,2,1,1,0,0,1
4973,04/06/2019 00:00,DB06713,Norelgestromin,,,,,Transdermal,solid,,,0.00605,11.47,3.12,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO,,,,,0,,327.2198292,4,0,0,0,0,0
4974,04/06/2019 00:00,DB06714,Propylhexedrine,,,,250 mg/1,Nasal,solid,,,0.0904,,10.61,CNC(C)CC1CCCCC1,,,,,0,,155.1673997,1,0,0,0,0,0
4975,04/06/2019 00:00,DB06716,Fospropofol,"Adequate sedation achieved after 7 minutes with a IV bolus dose of 10mg/kg. It takes 21-45 minutes for patients to recover for fospropopol-induced sedation. Following an intravenous bolus administration of 6 mg/kg in a healthy subject, the pharmacokinetic parameters of fospropofol are as follows: 
Cmax = 78.7 Î¼g/mL;
Tmax = 4 minutes; 
AUC(0-âˆž) = 19.0 Î¼g â‹… h/mL; 
",,"When given to a patient, the half-lives are as follows: 
Fospropofol = 0.81 hours; 
Propofol metabolite = 1.13 hours 
",35 mg/1mL,Intravenous,solid,,,0.302,1.44,-5,CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O,,,,,0,,288.1126604,1,1,0,0,0,0
4976,02/07/2019 00:00,DB06717,Fosaprepitant,,0.95,9-13 hours,115 mg/5mL,Intravenous,solid,,,0.00632,1.02,5.69,C[C@@H](O[C@H]1OCCN(CC2=NC(=O)N(N2)P(O)(O)=O)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,0.95,0.95,9,13,0,,614.1165186,4,3,2,1,1,1
4977,04/06/2019 00:00,DB06718,Stanozolol,,,24 hours,,,solid,,,0.00173,16.23,2.86,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C,,,24,24,0,,328.2514636,5,1,1,1,0,0
4978,04/06/2019 00:00,DB06721,Gimatecan,,,,,,solid,,,0.0427,11.71,3.06,[H]\C(=N/OC(C)(C)C)C1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=CC=C12,,,,,0,,447.1794209,5,3,4,2,0,2
4979,02/07/2019 00:00,DB06724,Calcium Carbonate,"Maximal absorption occurs at doses of 500 mg or less taken with food. Oral bioavailability depends on intestinal pH, the presence of food and dosage.",,,1000 mg/1,Oral,solid,,,128,6.05,,[Ca++].[O-]C([O-])=O,,,,,0,1000,99.94733484,0,0,0,0,0,0
4980,04/06/2019 00:00,DB06725,Lornoxicam,Lornoxicam is absorbed rapidly and almost completely from the GI tract (90-100%).,0.99,3-5 hours,,,solid,,2.62,0.0437,1.82,4.22,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O,0.99,0.99,3,5,0,,370.9801255,3,2,3,2,0,1
4981,04/06/2019 00:00,DB06726,Bufuralol,,,,,,solid,,3.5,0.0356,13.06,9.24,CCC1=CC=CC2=C1OC(=C2)C(O)CNC(C)(C)C,,,,,0,,261.172879,2,2,1,1,0,0
4982,04/06/2019 00:00,DB06727,Sparteine,,,,,,solid,3040 mg/L (at 22 Â°C),,0.931,,9.16,[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2CCCC[C@]12[H],,,,,0,,234.2095988,4,0,4,0,4,4
4983,04/06/2019 00:00,DB06728,Aniline,,,,,,liquid,3.6E+004 mg/L (at 25 Â°C),0.9,18,,4.64,NC1=CC=CC=C1,,,,,0,,93.05784922,1,1,0,0,0,0
4984,04/06/2019 00:00,DB06729,Sulfaphenazole,,,,,,solid,1500 mg/L (at 25 Â°C),1.52,0.278,6.82,2.44,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1,,,,,0,,314.0837467,3,3,1,1,0,0
4985,04/06/2019 00:00,DB06730,Gestodene,in vitro 99% using 3H=R5020 / in vivo similar to progesterone,,16 to 18 hrs.,,Oral,solid,,,0.00581,17.08,-1.9,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C,,,,,0,,310.1932801,4,0,0,0,0,0
4986,04/06/2019 00:00,DB06731,Seproxetine,,,4-16 days,,,solid,,,0.00915,,9.77,NCC[C@H](OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,,,96,384,0,,295.1183988,2,2,0,0,0,0
4987,04/06/2019 00:00,DB06732,beta-Naphthoflavone,,,,,,solid,,,0.00101,15.42,-5.4,O=C1C=C(OC2=C1C1=CC=CC=C1C=C2)C1=CC=CC=C1,,,,,0,,272.0837296,4,4,1,1,0,0
4988,04/06/2019 00:00,DB06733,Bafilomycin A1,,,,,,solid,,,0.0155,11.69,-0.73,CO[C@H]1\C=C\C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(OC)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C,,,,,0,,622.4080834,2,0,2,0,1,2
4989,04/06/2019 00:00,DB06735,Enclomiphene,,,,,,solid,,,0.000414,,9.31,CCN(CC)CCOC1=CC=C(C=C1)C(=C(\Cl)C1=CC=CC=C1)\C1=CC=CC=C1,,,,,0,,405.1859422,3,3,0,0,0,0
4990,04/06/2019 00:00,DB06736,Aceclofenac,"Aceclofenac is rapidly and completely absorbed from the gastrointestinal tract and circulates mainly as unchanged drug following oral administration. Peak plasma concentrations are reached around 1.25 to 3 hours post-ingestion, and the drug penetrates into the synovial fluid where the concentration may reach up to 60% of that in the plasma [L868]. There is no accumulation in regular dosing, with similar maximum plasma concentration (Cmax) and time to reach peak plasma concentration (Tmax) after single and multiple doses [A19667]. ",,The mean plasma elimination half-life is approximately 4 hours [L868].,200 mg/1,Oral,solid,Insoluble ,2.17,0.00199,3.44,-2.1,OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,,,,,0,200,353.0221633,2,2,0,0,0,0
4991,04/06/2019 00:00,DB06737,Zaltoprofen,,,,,,solid,,,0.0139,3.67,-7.6,CC(C(O)=O)C1=CC=C2SC3=C(C=CC=C3)C(=O)CC2=C1,,,,,0,,298.0663653,3,2,1,0,0,1
4992,04/06/2019 00:00,DB06738,Ketobemidone,"34% (oral), 44% (rectal)",,"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h",,,solid,,,3.01,9.44,8.09,CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1,,,,,0,,247.1572289,2,1,1,0,1,1
4993,04/06/2019 00:00,DB06739,Seratrodast,,,,,,solid,,,0.00359,4.3,-7.9,CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O,,,,,0,,354.1831093,2,1,0,0,0,0
4994,04/06/2019 00:00,DB06740,BW-A 58C,,,,,,solid,,,0.0115,5.95,-5.1,CC(C)(C)C1CCC(CC1)C1=C(O)C(=O)C2=CC=CC=C2C1=O,,,,,0,,312.1725446,3,1,0,0,0,0
4995,04/06/2019 00:00,DB06741,Gavestinel,,,,,,solid,,,0.0012,5.04,-2,OC(=O)C1=C(\C=C\C(=O)NC2=CC=CC=C2)C2=C(Cl)C=C(Cl)C=C2N1,,,,,0,,374.0224976,3,3,1,1,0,0
4996,04/06/2019 00:00,DB06742,Ambroxol,Rapid and almost complete.,0.9,7-12 hours,,,solid,,,0.0185,15.26,9.01,NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1,0.9,0.9,7,12,0,,375.9785874,2,1,0,0,0,0
4997,04/06/2019 00:00,DB06743,Ginkgolide A,,,,,,solid,,,3.05,11.77,-4.1,C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,,,,,0,,408.1420323,6,0,4,0,4,4
4998,04/06/2019 00:00,DB06744,ginkgolide-B,,,,,,solid,,,5.21,11.71,-3.5,C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,,,,,0,,424.136947,6,0,4,0,4,4
4999,04/06/2019 00:00,DB06745,ginkgolide-C,,,,,,solid,,,8.99,11.7,-3.3,C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@]34[C@@H]5OC(=O)[C@]3(O[C@@H]3OC(=O)[C@H](O)[C@]43[C@@H]([C@H]5O)C(C)(C)C)[C@@]12O,,,,,0,,440.1318616,6,0,4,0,4,4
5000,04/06/2019 00:00,DB06746,ginkgolide-J,,,,,,solid,,,6.96,11.76,-3.3,C[C@@H]1C(=O)O[C@H]2C[C@]34[C@@H]5OC(=O)[C@]3(O[C@@H]3OC(=O)[C@H](O)[C@]43[C@@H]([C@H]5O)C(C)(C)C)[C@@]12O,,,,,0,,424.136947,6,0,4,0,4,4
5001,04/06/2019 00:00,DB06747,ginkgolide-M,,,,,,solid,,,7.96,12.05,-3.3,C[C@H]1C2[C@@H](OC1=O)[C@H](O)[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H]([C@H]4O)C(C)(C)C,,,,,0,,424.136947,6,0,4,0,4,4
5002,04/06/2019 00:00,DB06748,Ginsenoside C,,,,,,solid,,,0.784,11.75,-3.6,[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@]3([H])CC[C@@]21C)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO[C@@H]2OC[C@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,1078.592375,8,0,4,0,4,4
5003,04/06/2019 00:00,DB06750,Ginsenoside Rg1,,,,,,solid,,,0.304,11.91,-3,CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,800.492207,6,0,2,0,2,2
5004,04/06/2019 00:00,DB06751,Drotaverine,Bioavailability is highly variable,0.95,7 to 12 hours,,,solid,,,0.002,,7.4,CCOC1=C(OCC)C=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1,0.95,0.95,,,0,,397.2253085,3,2,1,0,0,1
5005,04/06/2019 00:00,DB06753,Triclofos,,,,,,solid,,,7.86,1.17,,OP(O)(=O)OCC(Cl)(Cl)Cl,,,,,0,,227.8912783,0,0,0,0,0,0
5006,02/07/2019 00:00,DB06755,Beta carotene,"After administration of beta-carotene, some of the administered dose is absorbed into the circulatory system unchanged and stored in the fat tissue. The coadministration of beta-carotene and a high-fat content diet is correlated to a better absorption of beta-carotene. The absorption is also dependent on the isomeric form of the molecule where the cis conformation seems to present a higher bioavailability. The absorption of beta-carotene is thought to be performed in 6-7 hours.[L2202]

The reported AUC of beta-carotene when administered orally from 0 to 440 hours after initial administration was reported to be 26.3 mcg.h/L. The maximal concentration of beta-carotene is attained in a dual pharmacokinetic profile after 6 hours and again after 32 hours with a concentration of 0.58 micromol/L.[A32488]",,The apparent half-life of beta-carotene is of 6-11 days after initial administration.[A32487],10000 unit,Oral,solid,0.0006 g/l at 25ÂºC,17.62,0.000391,,,C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C,,,,,0,,536.4382018,2,0,0,0,0,0
5007,02/07/2019 00:00,DB06756,Glycine betaine,"After a single oral dose of betaine (50 mg/kg), absorption was rapid (tmax = 0.9 Â± 0.3 hours and a Cmax = 0.9 Â± 0.2 mM).",,14 hours,0.2 g/100g,Oral,solid,,,1.86,2.26,,C[N+](C)(C)CC([O-])=O,,,14,14,0,,117.0789786,0,0,0,0,0,0
5008,04/06/2019 00:00,DB06762,Pinacidil,,,,,,solid,,,0.126,14.27,5.61,CC(N\C(NC1=CC=NC=C1)=N/C#N)C(C)(C)C,,,,,0,,245.1640456,1,1,1,1,0,0
5009,04/06/2019 00:00,DB06763,Saralasin,,,,,,solid,,,0.0584,3.31,11.74,CNCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O,,,,,0,,911.4977353,3,2,2,1,1,1
5010,02/07/2019 00:00,DB06764,Tetryzoline,,,,0.05 mg/1mL,Ophthalmic,solid,,,0.239,,10.17,C1CN=C(N1)C1CCCC2=CC=CC=C12,,,,,0,,200.1313485,3,1,1,0,0,1
5011,04/06/2019 00:00,DB06766,Alcaftadine,,0.392,The elimination half-life of the carboxylic acid metabolite is approximately 2 hours following topical ocular administration.,2.5 mg/1mL,Ophthalmic,solid,slightly solubility,3.202,0.333,,7.16,CN1CCC(CC1)=C1C2=NC=C(C=O)N2CCC2=CC=CC=C12,0.392,0.392,,,0,,307.1684623,4,2,3,1,1,2
5012,02/07/2019 00:00,DB06767,Ammonium chloride,"Completely absorbed within 3â€“6 h.  In healthy persons, absorption of ammonium chloride given by mouth was practically complete. Only 1 to 3% of the dose was recovered in the feces.",,Unknown ,0.009,Intravenous,solid,,,124,-7,,[NH4+].[Cl-],,,,,0,,53.00322681,0,0,0,0,0,0
5013,04/06/2019 00:00,DB06768,Ammonium lactate,"In vitro study of percutaneous absorption of ammonium lactate lotion, 12% using human cadaver skin indicates that approximately 5.8% of the material was absorbed after 68 hours.
",,,12 g/100g,Topical,solid,,,866,3.78,-3.7,[NH4+].CC(O)C([O-])=O,,,,,0,,107.0582431,0,0,0,0,0,0
5014,02/07/2019 00:00,DB06769,Bendamustine,Following a single IV dose of bendamustine hydrochloride Cmax typically occurred at the end of infusion. The dose proportionality of bendamustine has not been studied.,94-96%,40 minutes,100 mg/1,Intravenous,solid,,,0.0618,4.38,6.65,CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl,0.94,0.96,0.666666667,0.666666667,0,,357.1010823,2,2,1,1,0,0
5015,04/06/2019 00:00,DB06770,Benzyl alcohol,,,,10 mg/1g,Topical,liquid,"33 mg/mL, clear, colorless",1.1,26.8,15.02,-2.8,OCC1=CC=CC=C1,,,,,0,,108.0575149,1,1,0,0,0,0
5016,02/07/2019 00:00,DB06771,Besifloxacin,"Although ocular surface concentrations are high, average systemic concentrtions after three-times daily dosing was less than 0.5 ng/mL. This indicates that besifloxacin is not appreciably absorbed into the systemic and has a very low risk of systemic side effects. ",,The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.,0.006,Ophthalmic,liquid,Not soluble in water ,,0.143,5.64,9.67,N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O,,,,,0,,393.1255474,4,2,2,1,1,1
5017,02/07/2019 00:00,DB06772,Cabazitaxel,"After an intravenous dose of cabazitaxel 25 mg/m2 every three weeks to a population of 170 patients with solid tumors, the mean Cmax in patients with metastatic prostate cancer was 226 ng/mL (CV 107%) and was reached at the end of the one-hour infusion (Tmax). The mean AUC in patients with metastatic prostate cancer was 991 ng.h/mL (CV 34%). Administration with prednisone or prednisolone do not effect the pharmacokinetic profile of cabazitaxel. ",(88%,"Following a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with Î±-, Î²-, and Î³- half-lives of 4 minutes, 2 hours, and 95 hours, respectively.",60 mg/1.5mL,Intravenous,solid,,,0.00413,11.96,-3.6,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C,0.88,0.88,,,0,,835.3779055,6,2,1,0,1,1
5018,02/07/2019 00:00,DB06774,Capsaicin,"**Oral**: Following oral administration, capsaicin may be absorbed by a nonactive process from the stomach and whole intestine with an extent of absorption ranging between 50 and 90%, depending on the animal [A32319]. The peak blood concentration can be reached within 1 hour following administration [A32319]. Capsaicin may undergo minor metabolism in the small intestine epithelial cells post-absorption from the stomach into the small intestines. While oral pharmacokinetics information in humans is limited, ingestion of equipotent dose of 26.6 mg of pure capsaicin, capsaicin was detected in the plasma after 10 minutes and the peak plasma concentration of 2.47 Â± 0.13 ng/ml was reached at 47.1 Â± 2.0 minutes [A32319].

**Systemic**: Following intravenous or subcutaneous administration in animals, the concentrations in the brain and spinal cord were approximately 5-fold higher than that in blood and the concentration in the liver was approximately 3-fold higher than that in blood [A32319]. 

**Topical**: Topical capsaicin in humans is rapidly and well absorbed through the skin, however systemic absorption following topical or transdermal administration is unlikely [A32319]. For patients receiving the topical patch containing 179 mg of capsaicin, a population analysis was performed and plasma concentrations of capsaicin were fitted using a one-compartment model with first-order absorption and linear elimination. The mean peak plasma concentration was 1.86 ng/mL but the maximum value observed in any patient was 17.8 ng/mL [A32319].",,"Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 Â± 5.0 min [A32319]. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h [A32319]. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin [A32319].",0.025 g/100g,Topical,solid,Insoluble in cold water,,0.00841,9.93,-0.52,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1,,,,,0,,305.1990937,1,1,0,0,0,0
5019,02/07/2019 00:00,DB06775,Carglumic acid,"30% bioavailability;
Cmax, mean, 100 mg/kg dose = 2.6 Î¼g/mL (range of 1.9 - 4.8)  
Carglumic acid is not subject to to intracellular degradation. ",,Median values for the terminal half-life was 5.6 hours (range 4.3-9.5).,200 mg/1,Oral,solid,,-1.097,19.1,3.36,-2.3,NC(=O)N[C@@H](CCC(O)=O)C(O)=O,,,,,0,200,190.0589714,0,0,0,0,0,0
5020,04/06/2019 00:00,DB06777,Chenodeoxycholic acid,Chenodiol is well absorbed from the small intestine.,,,250 mg/1,Oral,solid,89.9 mg/L (at 20 Â°C),4.15,0.0197,4.6,-0.54,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,,,,,0,250,392.2926598,4,0,0,0,0,0
5021,04/06/2019 00:00,DB06780,Desoxycorticosterone acetate,,,,,,solid,,,0.00502,17.17,-4.8,[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,372.2300595,4,0,0,0,0,0
5022,02/07/2019 00:00,DB06781,Difluprednate,Difluprednate penetrates the corneal epithelium rapidly and effectively. Low systemic absorption. ,,,0.0005,Ophthalmic,solid,,,0.0097,13.55,-3.4,[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,508.2272599,4,0,0,0,0,0
5023,02/07/2019 00:00,DB06782,Dimercaprol,After intra-muscular injection.,,The drug has a short half life.,100 mg/1mL,Intramuscular,solid,8.7E+004 mg/L,,2.76,9.58,-2.8,OCC(S)CS,,,,,0,,124.0016569,0,0,0,0,0,0
5024,04/06/2019 00:00,DB06784,Gallium citrate Ga 67,"The body generally handles Ga3+ as though it were ferric iron (Fe-III). However, gallium can not be reduced in vivo. Therefore, ferric ion is easily reduced and interacts with protoporphyrin IX to form heme, gallium remains bound to iron-transport proteins and carrier molecules.",,78.26 hours,2.0 mCi/1mL,Intravenous,solid,,,3.21,3.05,-4.2,[67Ga+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,,78.26,78.26,0,,255.9317292,0,0,0,0,0,0
5025,02/07/2019 00:00,DB06785,Ganirelix,Ganirelix is rapidly absorbed following subcutaneous injection with maximum serum concentrations reached approximately one hour after dosing.,,16.2 hours.,250 ug/0.5mL,Subcutaneous,solid,,,0.00531,9.5,12.14,CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,,,16.2,16.2,0,,1568.842303,6,5,2,1,1,1
5026,04/06/2019 00:00,DB06786,Halcinonide,,,,1 mg/1g,Topical,liquid,,,0.0112,13.63,-3.4,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,454.19223,5,0,1,0,1,1
5027,04/06/2019 00:00,DB06787,Hexocyclium,,,,,,solid,,,0.000576,13.51,4.95,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,,,,,1,,317.2587401,3,1,1,0,1,1
5028,04/06/2019 00:00,DB06788,Histrelin," Following subcutaneous insertion of one histrelin implant as the product Vantas in advanced prostate cancer patients (n = 17), peak serum concentrations of 1.10 Ã‚Â± 0.375 ng/mL (mean Ã‚Â± SD) occurred at a median of 12 hours. Continuous subcutaneous release was evident, as serum levels were sustained throughout the 52 week dosing period (see Figure 1). The mean serum histrelin concentration at the end of the 52 week treatment duration was 0.13 Ã‚Â± 0.065 ng/mL.",0.295,,50 mg/1,Subcutaneous,solid,,,0.162,2.71,11.9,CC(O)=O.CC(O)=O.[H][C@@](CO)(N=C(O)[C@]([H])(CC1=CNC2=CC=CC=C12)N=C(O)[C@]([H])(CC1=CN=CN1)N=C(O)[C@]1([H])CCC(O)=N1)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(O)=N[C@]([H])(CC1=CN(CC2=CC=CC=C2)C=N1)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCNC(N)=N)C(=O)N1CCC[C@@]1([H])C(O)=NCC,0.295,0.295,,,0,,1442.709519,8,6,5,3,1,2
5029,04/06/2019 00:00,DB06789,Hydroxyprogesterone caproate,"Absorption of 17-hydroxyprogesteron caproate is slow, occurring over a long period of time. (3)",,Half-life = 16 days (Â±6 days). (3),1250 mg/5mL,Intramuscular,solid,,,0.000866,17.75,-4.8,[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,428.2926598,4,0,0,0,0,0
5030,02/07/2019 00:00,DB06791,Lanreotide,"Lanreotide forms a drug depot at the site of injection (4); therefore, there are 2 phases that describe the absorption of Lanreotide:
1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed.   
2. Slow release of drug from the depot via passive diffusion. (1)
Absorption is independent of body weight, gender, and dosage. (5)",,Half-life is approximately 22 days (5),1 g/1g,Not applicable,solid,,,0.00496,9.43,10.26,[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H],,,,,0,,1095.467029,6,5,2,1,1,1
5031,02/07/2019 00:00,DB06792,Lanthanum carbonate,Bioavailability very low (<0.002%) following single or multiple dose oral administration.,,Elimination half-life of 53 hours.,1000 mg/1,Oral,solid,Practically insoluble.,,31,6.05,,[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O,,,,,0,1000,457.7669382,0,0,0,0,0,0
5032,04/06/2019 00:00,DB06793,Levopropoxyphene,,,,,,solid,3.32 mg/L at 25ÂºC,4.11,0.00419,,9.52,[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1,,,,,0,,339.2198292,2,2,0,0,0,0
5033,02/07/2019 00:00,DB06794,Lodoxamide,"In a study of twelve healthy adult volunteers, topical administration of lodoxamide tromethamine ophthalmic solution 0.1%, one drop in each eye four times per day for ten days, did not result in any measurable lodoxamide plasma levels at a detection limit of 2.5 ng/mL. ",,Elimination half-life was 8.5 hours in urine.,0.001,Ophthalmic,solid,,,0.0361,-6.7,0.73,OC(=O)C(=O)NC1=CC(=CC(NC(=O)C(O)=O)=C1Cl)C#N,,,,,0,,310.9945126,1,1,0,0,0,0
5034,14/06/2019 00:00,DB06795,Mafenide,Mafenide is absorbed through devascularized areas into the systemic circulation following topical administration.,,,50 g/1,Topical,solid,,,5.18,10.27,9.24,NCC1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,186.0462986,1,1,0,0,0,0
5035,04/06/2019 00:00,DB06796,Mangafodipir,Mangafodipir is taken up by the liver and pancreas where the contrast enhancement effect is mediated. ,0.27,"The mean initial plasma half-life of manganese metals is approximately 20 minutes and 50 minutes for fodipir (dipyridoxyl diphosphate, DPDP) [L874]. ",0.01 mmol/ml,Intravenous,solid,,,1.06,1.38,-6.4,[Mn++].CC1=C(O)C(CN(CCN(CC([O-])=O)CC2=CC(COP(O)(O)=O)=NC(C)=C2O)CC([O-])=O)=CC(COP(O)(O)=O)=N1,0.27,0.27,,,0,,691.06142,2,2,2,2,0,0
5036,04/06/2019 00:00,DB06797,Mebutamate,,,,,,solid,1000 mg/L,,1.22,15.24,,CCC(C)C(C)(COC(N)=O)COC(N)=O,,,,,0,,232.1423071,0,0,0,0,0,0
5037,02/07/2019 00:00,DB06799,Methenamine,"After oral administration, rapid absorption of methenamine occurs. (1)",,Elimination half-life = 3-4 hours assuming normal renal function. (1),1 g,Oral,solid,,,766,,5.88,C1N2CN3CN1CN(C2)C3,,,,,0,,140.1061964,4,0,4,0,4,4
5038,02/07/2019 00:00,DB06800,Methylnaltrexone,"Methylnaltrexone is rapidly absorbed. 
Tmax (SubQ): 30 minutes (regardless of dose);
Cmax, 0.15 mg/kg SubQ dose = 117 ng/mL; 
AUC24, 0.15 mg/kg SubQ dose = 175 ngÂ·hr/mL; ",0.11,"terminal: 8.89 Â± 2.59 h (intravenous) 
terminal: 6.14- 8.83 h (subcutaneous) ",12 mg/0.6ml,Subcutaneous,solid,â‰¥5 mg/mL ,2.2,0.00729,9.9,-3.9,C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35,0.11,0.11,,,1,,356.1856347,6,1,2,0,1,2
5039,04/06/2019 00:00,DB06801,Monoctanoin,,,,,,solid,,,4.36,13.62,-3,CCCCCCCC(=O)OCC(O)CO,,,,,0,,218.1518092,0,0,0,0,0,0
5040,02/07/2019 00:00,DB06802,Nepafenac,Nepafenac rapidly cross the cornea (6 times faster than diclofenac in vitro).,0.954,,0.003,Ophthalmic,solid,,,0.0197,15.82,1.83,NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N,0.954,0.954,,,0,,254.1055277,2,2,0,0,0,0
5041,04/06/2019 00:00,DB06803,Niclosamide,Niclosamide appears to be minimally absorbed from the gastrointestinal tractâ€”neither the drug nor its metabolites have been recovered from the blood or urine.,,,,,solid,1.6 mg/L (at 20 Â°C),,0.00799,6.89,-4.4,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O,,,,,0,,325.9861121,2,2,0,0,0,0
5042,04/06/2019 00:00,DB06804,Nonoxynol-9,,,,4.0 g/100g,Vaginal,solid,,,0.000214,15.12,-2.7,CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1,,,,,0,,616.4186481,1,1,0,0,0,0
5043,04/06/2019 00:00,DB06807,Phenyl aminosalicylate,,,,,,solid,,,0.173,9.87,2.32,NC1=CC(O)=C(C=C1)C(=O)OC1=CC=CC=C1,,,,,0,,229.0738932,2,2,0,0,0,0
5044,02/07/2019 00:00,DB06809,Plerixafor,"Pharmacokinetic profile follows a two-compartment model with first-order absorption. A median peak plasma concentration of 0.24 mg/kg of plerixafor occurred 30-60 minutes after subcutaneous dose. 
",0.58,"Terminal elimination half-life, NHL patients: 4.4 hours;
Terminal elimination half-life, MM patients: 5.6 hours;
Terminal elimination half-life, Hodgkin's lymphoma patients: 3.5 hours; 
Distribution half-life: 0.3 hours ",20 mg,Subcutaneous,liquid,Soluble,,0.0472,,10.54,C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1,0.58,0.58,,,0,,502.4471437,3,1,2,0,2,2
5045,04/06/2019 00:00,DB06810,Plicamycin,,,,,,solid,,,1.3,8.49,-3.6,CO[C@@H]([C@@H]1CC2=CC3=CC(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)=C(C)C(O)=C3C(O)=C2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O,,,,,0,,1084.472653,8,2,5,0,5,5
5046,02/07/2019 00:00,DB06811,Polidocanol,"When given intravenously, the maximum blood concentrations were reached in 15 mins.",,The half-life is approximately 1.5 h. ,0.00500 g/1mL,Intravenous,liquid,miscible ,3.94,0.000403,15.12,-2.7,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,,,,,0,,582.4342982,0,0,0,0,0,0
5047,02/07/2019 00:00,DB06813,Pralatrexate,"Pralatrexate demonstrates linear pharmacokinetics with a multiphasic decline with both diasteromers over dose range of 30-325 mg/m^2. 
Bioavailability, nonformulated preparation = 13 - 20%
",0.86,12-18 hours ,20 mg/1mL,Intravenous,solid,,,0.0178,3.44,2.86,NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1,0.86,0.86,12,18,0,,477.1760668,3,3,2,2,0,0
5048,04/06/2019 00:00,DB06814,Protokylol,,,,,,solid,,,0.236,9.86,8.98,CC(CC1=CC=C2OCOC2=C1)NCC(O)C1=CC=C(O)C(O)=C1,,,,,0,,331.1419728,3,2,1,0,0,1
5049,02/07/2019 00:00,DB06815,Pyrithione,"Following oral ingestion, only the pyrithione moiety is absorbed. Less than 1% of administered zinc pyrithione is absorbed from the skin [L1758]. Radioabeled Zn pyrithione administered to rats, rabbits and monkeys, either orally or via intraperitoneal injection were absorbed into circulatin to extent of 80-90% [L1758].",,,0.012,Topical,solid,Soluble in cold water (Zinc salt),,3,6.84,0.66,[O-][N+]1=C(S)C=CC=C1,,,,,0,,127.0091848,1,1,1,1,0,0
5050,04/06/2019 00:00,DB06816,Pyrvinium,Pyrvinium is not significantly absorbed from the gastrointestinal tract [L789].,,,50 mg,Oral,solid,,,0.000288,,1.48,CN(C)C1=CC2=C(C=C1)[N+](C)=C(\C=C\C1=C(C)N(C(C)=C1)C1=CC=CC=C1)C=C2,,,,,1,50,382.2277743,4,4,2,2,0,0
5051,04/06/2019 00:00,DB06819,Phenylbutyric acid,"Under fasting condition the Cmax of a single orally ingested 5g tablet and 5g powder after 1 hour are respectively 218mcg/ml and 195mcg/ml. 
The effect of food on phenylbutyrate absorption is still unknown.",,For sodium phenylbutyrate the half life  is 0.77 hours. For phenylacetate the half life is 1.15 hours. ,940 mg/g,Oral,solid,100mM,,0.513,4.81,,OC(=O)CCCC1=CC=CC=C1,,,,,0,,164.0837296,1,1,0,0,0,0
5052,04/06/2019 00:00,DB06820,Sulconazole,Total sulconazole systemic absorption after topical administration was ~8.71% of the dose. ,,,10 mg/1g,Topical,solid,,,0.00129,,6.78,ClC1=CC=C(CSC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,,,,,0,,396.0021525,3,3,1,1,0,0
5053,04/06/2019 00:00,DB06821,Sulfameter,,,,,,solid,,,0.313,7.06,1.98,COC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1,,,,,0,,280.0630112,2,2,1,1,0,0
5054,04/06/2019 00:00,DB06823,Tiopronin,"Tiopronin undergoes slow absorption, reaching peak plasma concentration 3-6 hours after ingestion. In a study of healthy subjects, the bioavailability of total and unbound tiopronin was found to be 63% and 40%, respectively.",,"Tiopronin has a long terminal half life of 53 hours in healthy subjects. However, the unbound drug fraction of tiopronin is eliminated much more rapidly from plasma with a calculated half life of 1.8 hours.",100 mg/1,Oral,solid,,,2.71,3.84,1.32,CC(S)C(O)=NCC(O)=O,,,,,0,100,163.0303141,0,0,0,0,0,0
5055,04/06/2019 00:00,DB06824,Triethylenetetramine,It is poorly absorbed from the gastrointestinal tract with a bioavailability of 8 to 30% and and what is absorbed is metabolized and inactivated. 5% to 18% that is systemically absorbed in humans is reported to be extensively metabolized [A18804]. The time to reach peak concentration (Tmax) for humans occur between 0.8 to 4 hours [A19333]. ,,The plasma elimination half life of TETA in healthy volunteers and Wilson's disease patients ranges from 1.3 to 4 hours. The metabolites are expected to be longer than the parent drug. ,250 mg/1,Oral,liquid,Soluble,,27.5,,9.77,NCCNCCNCCN,,,,,0,250,146.1531466,0,0,0,0,0,0
5056,02/07/2019 00:00,DB06825,Triptorelin,"Following IV administration of triptorelin, triptorelin is completely absorbed.",,"The pharmacokinetics of triptorelin follows a 3 compartment model.  The half lives are estimated to be 6 minutes, 45 minutes, and 3 hours respectively.",0.1 mg,Subcutaneous,solid,,,0.0305,9.49,11.54,CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,,,,,0,,1310.630875,8,6,5,3,2,2
5057,04/06/2019 00:00,DB06826,Unoprostone,"After application to the eye, unoprostone isopropyl is absorbed through the cornea and conjunctival epithelium where it is hydrolyzed by esterases to unoprostone free acid. mean peak unoprostone free acid plasma concentration was <1.5 ng/mL and dro pped below the lower limit of quantitation (<0.250 ng/mL) 1 hour following instillation, indicating low systemic absorption and rapid plasma excretion.",,Half-life of  Unoprostone is 14 minutes.,0.0015,Ophthalmic,liquid,,,0.0306,4.31,-2.9,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,,,,,0,,382.2719243,1,0,0,0,0,0
5058,04/06/2019 00:00,DB06827,Viomycin,,,,,,solid,,,1.04,10.5,10.14,[H][C@@]1(C[C@H](O)NC(=N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC1=O)NC(=O)C[C@@H](N)CCCN)=C\NC(N)=O,,,,,0,,685.3255846,2,0,2,0,2,2
5059,04/06/2019 00:00,DB06828,5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole,,,,,,solid,,,0.288,16.76,-4.9,C(CN1C=CC=C1)OC1=CC2=C(NC=C2)C=C1,,,,,0,,226.1106131,3,3,2,2,0,0
5060,04/06/2019 00:00,DB06829,4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID,,,,,,solid,,,0.000901,3.07,4.88,OC(=O)COC1=C(SC(=C1Br)C1=CC=CC(NC2CCCCC2)=C1)C(O)=O,,,,,0,,453.0245558,3,2,1,1,0,0
5061,04/06/2019 00:00,DB06830,"(1-HYDROXYHEPTANE-1,1-DIYL)BIS(PHOSPHONIC ACID)",,,,,,solid,,,11,0.69,-5.2,CCCCCCC(O)(P(O)(O)=O)P(O)(O)=O,,,,,0,,276.0527762,0,0,0,0,0,0
5062,04/06/2019 00:00,DB06831,2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE,,,,,,solid,,,0.00641,9.91,3.88,COC1=CC=CC=C1N1C(=O)C2=C(Cl)C=CC=C2N=C1CSC1=C2N=CNC2=NC=N1,,,,,0,,450.0665724,5,5,3,3,0,0
5063,04/06/2019 00:00,DB06832,"2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL",,,,,,solid,,,0.103,7.53,1,OC1=CC2=C(OC(=N2)C2=CC=C(O)C(F)=C2)C(C=C)=C1,,,,,0,,271.0644714,3,3,1,1,0,0
5064,04/06/2019 00:00,DB06833,1-CYCLOHEXYL-N-{[1-(4-METHYLPHENYL)-1H-INDOL-3-YL]METHYL}METHANAMINE,,,,,,solid,,,0.00116,,10.25,CC1=CC=C(C=C1)N1C=C(CNCC2CCCCC2)C2=CC=CC=C12,,,,,0,,332.2252489,4,3,1,1,0,0
5065,04/06/2019 00:00,DB06834,"N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide",,,,,,solid,,,0.0203,13.91,4.38,CN1C=C(C2=CC3=CC=CN=C3N2)C2=CC(=CC=C12)C(=O)NC(C)(C)CO,,,,,0,,362.1742759,4,4,3,3,0,0
5066,04/06/2019 00:00,DB06835,(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(S)-HYDROXY[(1R)-2-METHYL-1-{[(2-PHENYLETHYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID,,,,,,solid,,,0.298,1.52,9.42,[H][C@@](C[P@@](O)(=O)[C@@]([H])(NS(=O)(=O)CCC1=CC=CC=C1)C(C)C)(C(O)=O)C1=CC=CC(CN)=C1,,,,,0,,482.1640443,2,2,0,0,0,0
5067,04/06/2019 00:00,DB06836,"N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide",,,,,,solid,,,0.0315,8,-0.38,[H]N(CCO)S(=O)(=O)C1=C(Cl)C=CC(=C1)C1=C(C)N=C(S1)N([H])C(C)=O,,,,,0,,389.0270757,2,2,1,1,0,0
5068,04/06/2019 00:00,DB06837,"(2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide",,,,,,solid,,,0.162,8.79,-0.99,[H][C@](CC(=O)NO)(CC1=CC(O)=CC=C1)C(=O)N[C@@]1([H])C2=C(C[C@@]1([H])O)C=CC=C2,,,,,0,,370.1528718,3,2,0,0,0,0
5069,04/06/2019 00:00,DB06838,methyl L-phenylalaninate,,,,,,solid,,,3.11,,6.97,[H][C@](N)(CC1=CC=CC=C1)C(=O)OC,,,,,0,,179.0946287,1,1,0,0,0,0
5070,04/06/2019 00:00,DB06839,N-(ethoxycarbonyl)-L-leucine,,,,,,solid,,,12.6,4.07,,[H][C@@](CC(C)C)(NC(=O)OCC)C(O)=O,,,,,0,,203.115758,0,0,0,0,0,0
5071,04/06/2019 00:00,DB06840,"diethyl [(1R)-1,5-diaminopentyl]boronate",,,,,,solid,,,6.26,,10.26,[H][C@](N)(CCCCN)B(OCC)OCC,,,,,0,,202.1852584,0,0,0,0,0,0
5072,04/06/2019 00:00,DB06841,D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide,,,,,,solid,,,0.0513,6.2,11.93,[H][C@@]([NH3+])(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CCCNC(N)=N)[C@]([H])(O)CCl,,,,,1,,453.237543,2,1,1,0,1,1
5073,04/06/2019 00:00,DB06842,(4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one,,,,,,solid,,,0.288,13.35,-2.2,[H][C@@]1(CC2=CC(OCCCC)=C(OC)C=C2)CNC(=O)N1,,,,,0,,278.1630426,2,1,1,0,1,1
5074,04/06/2019 00:00,DB06843,"2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE",,,,,,solid,,,2.35,1.16,4.97,[H][C@]1(C)O[C@]([H])(C[C@]1([H])OP(O)(O)=O)N1C=NC2=C1N=CN=C2N,,,,,0,,315.0732552,3,2,3,2,1,1
5075,04/06/2019 00:00,DB06844,"4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE",,,,,,solid,,,0.0316,6.23,2.55,O=C1N=C2C=CC3=C(SC=N3)C2=C1CNC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,,,,,0,,449.0616313,5,4,3,2,0,1
5076,04/06/2019 00:00,DB06845,(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide,,,,,,solid,,,0.185,15.31,11.49,[H][C@]1(CCCN1C(=O)CNC1CCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,371.2321252,3,1,1,0,1,1
5077,04/06/2019 00:00,DB06847,"5-[(3S)-3-(2-methoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,,,,,solid,,,0.00385,17.61,7.29,[H][C@@](C)(C#CC1=C(N)N=C(N)N=C1C)C1=CC(OC)=C(C=C1)C1=CC=CC=C1,,,,,0,,358.1793613,3,3,1,1,0,0
5078,04/06/2019 00:00,DB06848,"1-(1'-{[3-(methylsulfanyl)-2-benzothiophen-1-yl]carbonyl}spiro[1-benzofuran-3,4'-piperidin]-5-yl)methanamine",,,,,,solid,,,0.00184,,9.47,CSC1=C2C=CC=CC2=C(S1)C(=O)N1CCC2(COC3=C2C=C(CN)C=C3)CC1,,,,,0,,424.12792,5,3,3,1,1,2
5079,04/06/2019 00:00,DB06849,"1-[1'-(3-phenylacryloyl)spiro[1-benzofuran-3,4'-piperidin]-5-yl]methanamine",,,,,,solid,,,0.0138,,9.47,NCC1=CC2=C(OCC22CCN(CC2)C(=O)\C=C\C2=CC=CC=C2)C=C1,,,,,0,,348.183778,4,2,2,0,1,2
5080,04/06/2019 00:00,DB06850,(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide,,,,,,solid,,,0.137,15.26,11.49,[H][C@]1(CCCN1C(=O)CNC1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,385.2477752,3,1,1,0,1,1
5081,04/06/2019 00:00,DB06851,N-(pyridin-3-ylmethyl)aniline,,,,,,solid,,,2.1,,4.86,C(NC1=CC=CC=C1)C1=CC=CN=C1,,,,,0,,184.1000484,2,2,1,1,0,0
5082,04/06/2019 00:00,DB06852,4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE,,,,,,solid,,,0.0266,7.95,7.88,[H][C@@]12CC[N@@](CC1)C[C@@]2([H])NC1=C(C2=NC3=CC=CC=C3N2)C(=O)NC2=C1C=C(Cl)C=C2,,,,,0,,419.151288,7,4,5,2,3,3
5083,04/06/2019 00:00,DB06853,N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide,,,,,,solid,,,0.0793,15.22,11.49,[H][C@]1(CCCN1C(=O)CNC1CCCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,399.2634253,3,1,1,0,1,1
5084,04/06/2019 00:00,DB06855,6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine,,,,,,solid,,,0.00657,9.29,8.59,CC(C)COC1=C(O)C(=CC=C1)C1=NC2=CC(C(N)=N)=C(F)C=C2N1,,,,,0,,342.1492041,3,3,1,1,0,0
5085,04/06/2019 00:00,DB06856,6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE,,,,,,solid,,,0.00219,9.78,9.02,[H][C@]1(C)CCCC[C@]1([H])OC1=C(O)C(=CC=C1)C1=CC2=CC(C(N)=N)=C(F)C=C2N1,,,,,0,,381.1852552,4,3,1,1,0,0
5086,04/06/2019 00:00,DB06857,N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDE,,,,,,solid,,,0.0063,7.21,10.23,CC1=CC(I)=C(O)C(=C1)C(=O)NC1=CC(Cl)=C(C=C1)C(N)=N,,,,,0,,428.9741023,2,2,0,0,0,0
5087,04/06/2019 00:00,DB06858,N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide,,,,,,solid,,,0.046,15.22,11.49,[H][C@]1(CCCN1C(=O)CNC1CCCCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,413.2790754,3,1,1,0,1,1
5088,04/06/2019 00:00,DB06859,N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE,,,,,,solid,,,0.00957,,9.85,NC(=N)NOCCCOC1=CC(Cl)=CC(=C1)C(=O)N(CC=C)C1CCCC1,,,,,0,,394.1771684,2,1,0,0,0,0
5089,04/06/2019 00:00,DB06860,"2-(2-chloropyridin-4-yl)-4-methyl-1H-isoindole-1,3(2H)-dione",,,,,,solid,,,0.737,,-0.24,CC1=C2C(=O)N(C(=O)C2=CC=C1)C1=CC=NC(Cl)=C1,,,,,0,,272.0352552,3,2,2,1,0,1
5090,04/06/2019 00:00,DB06861,6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE,,,,,,solid,,,0.437,14.75,12.87,[H][C@](CCCCC(N)=N)(C=O)[C@@]1([H])CCC[C@]1([H])O,,,,,0,,226.1681279,1,0,0,0,0,0
5091,04/06/2019 00:00,DB06862,2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID,,,,,,solid,,,0.659,2.44,-6.4,OC(=O)C1=C(O)C=CC(=C1)S(=O)(=O)NCCS,,,,,0,,277.0078645,1,1,0,0,0,0
5092,04/06/2019 00:00,DB06864,"2-(3-CARBOXYPROPIONYL)-6-HYDROXY-CYCLOHEXA-2,4-DIENE CARBOXYLIC ACID",,,,,,solid,,,2.73,3.63,-3.1,[H][C@@]1(O)C=CC=C(C(=O)CCC(O)=O)[C@@]1([H])C(O)=O,,,,,0,,240.0633881,1,0,0,0,0,0
5093,04/06/2019 00:00,DB06865,6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID,,,,,,solid,,,0.0332,4.52,12.88,[H][C@](CCCCC(N)=N)(C(O)=O)[C@@]1([H])C2=C(C[C@]1([H])O)C=CC(=C2)C1=CC=C(O)C=C1,,,,,0,,382.1892573,3,2,0,0,0,0
5094,04/06/2019 00:00,DB06866,6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID,,,,,,solid,,,0.0106,4.5,12.87,[H][C@](CCCCC(N)=N)(C(O)=O)[C@@]1([H])C2=C(C[C@]1([H])O)C=C(C=C2)C1=CC(OC)=CC=C1,,,,,0,,396.2049074,3,2,0,0,0,0
5095,04/06/2019 00:00,DB06867,"3,6,9,12,15,18-HEXAOXAICOSANE",,,,,,solid,,,0.62,,-3.4,CCOCCOCCOCCOCCOCCOCC,,,,,0,,294.2042387,0,0,0,0,0,0
5096,04/06/2019 00:00,DB06868,N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide,,,,,,solid,,,0.0208,14.72,-0.086,[H][C@]1(CCCN1C(=O)CCC(C)C)C(=O)NCC1=CC(Cl)=CC=C1,,,,,0,,336.1604557,2,1,1,0,1,1
5097,04/06/2019 00:00,DB06869,1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE,,,,,,solid,,,0.0218,14.01,8.19,[H][C@@](N)(C1CCCCC1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=C(OCC(=O)NCC)C=CC(Cl)=C1,,,,,0,,478.2346833,3,1,1,0,1,1
5098,04/06/2019 00:00,DB06870,"17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE",,,,,,solid,,,0.0199,18.9,-0.14,[H][C@@]12CC[C@@](O)(CC)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H],,,,,0,,312.2089301,4,0,0,0,0,0
5099,04/06/2019 00:00,DB06871,17-METHYL-17-ALPHA-DIHYDROEQUILENIN,,,,,,solid,,,0.00218,9.79,-3,[H][C@@]12CC[C@@](C)(O)[C@@]1(C)CCC1=C2C=CC2=CC(O)=CC=C12,,,,,0,,282.1619799,4,2,0,0,0,0
5100,04/06/2019 00:00,DB06872,"1-((2-HYDROXYETHOXY)METHYL)-5-(PHENYLTHIO)PYRIMIDINE-2,4(1H,3H)-DIONE",,,,,,solid,,,0.322,9.47,-2.7,OCCOCN1C=C(SC2=CC=CC=C2)C(=O)NC1=O,,,,,0,,294.0674279,2,2,1,1,0,0
5101,04/06/2019 00:00,DB06873,"1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)PYRIMIDINE-2,4(1H,3H)-DIONE",,,,,,solid,,,0.00609,9.95,-2.7,OCCOCN1C=C(CC2=CC=CC(OCC3=CC=CC=C3)=C2)C(=O)NC1=O,,,,,0,,382.1528718,3,3,1,1,0,0
5102,04/06/2019 00:00,DB06874,"(6-[4-(AMINOMETHYL)-2,6-DIMETHYLPHENOXY]-2-{[4-(AMINOMETHYL)PHENYL]AMINO}-5-BROMOPYRIMIDIN-4-YL)METHANOL",,,,,,solid,,,0.0232,12.15,1.72,CC1=CC(=CC(C)=C1OC1=C(Br)C(CO)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N,,,,,0,,449.0487369,3,3,1,1,0,0
5103,04/06/2019 00:00,DB06875,3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE,,,,,,solid,,,0.00547,7.93,-6.2,OC1=CC=C2C=C(C=C(C#N)C2=C1)C1=CC=C(O)C(F)=C1,,,,,0,,279.0695568,3,3,0,0,0,0
5104,04/06/2019 00:00,DB06876,"N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE",,,,,,solid,,,0.0439,12.44,7.88,CN1CCN(CC1)C1=CC=C(C=C1)C1=CC2=C(NC=C2NC(=O)C2=CN=CC=C2)N=C1,,,,,0,,412.2011594,5,4,4,3,1,1
5105,04/06/2019 00:00,DB06877,"N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE",,,,,,solid,,,0.126,11.59,1.64,CN(C)C(=O)C1=CC(=CN1)C1=NNC=C1C1=CC=CC=C1,,,,,0,,280.1324111,3,3,2,2,0,0
5106,04/06/2019 00:00,DB06878,1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide,,,,,,solid,,,0.446,14.62,8.14,[H][C@@](N)(CC)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=CC(Cl)=C1,,,,,0,,323.1400546,2,1,1,0,1,1
5107,04/06/2019 00:00,DB06879,"5-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILE",,,,,,solid,,,0.0733,,5.63,CCN1C2=C(F)C=CC(F)=C2C(N)=NC11CCN(CC1)C(=O)C1=CN=C(CC1)C#N,,,,,0,,412.1823158,4,1,3,0,1,3
5108,04/06/2019 00:00,DB06880,"(1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE",,,,,,solid,,,0.193,,9.26,[H][C@](N)(C1CCCC1)C(=O)N1[C@]([H])(CN)CC[C@]1([H])C#CC,,,,,0,,263.1997624,2,0,1,0,1,1
5109,04/06/2019 00:00,DB06881,(1Z)-2-HYDROXY-3-OXOHEX-1-EN-1-YL DIHYDROGEN PHOSPHATE,,,,,,solid,,,8.11,1.36,-4.5,CCCC(=O)C(\O)=C\OP(O)(O)=O,,,,,0,,210.0293247,0,0,0,0,0,0
5110,04/06/2019 00:00,DB06882,1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea,,,,,,solid,,,0.00528,11.23,4.33,CC(C)(C)C1=NN(C(NC(=O)NC2=C3C=CC=CC3=CC=C2)=C1)C1=CC=CC(N)=C1,,,,,0,,399.2059104,4,4,1,1,0,0
5111,04/06/2019 00:00,DB06883,1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea,,,,,,solid,,,0.0198,11.55,4.3,CC(C)(C)C1=NN(C(NC(=O)NC2=CC=CC=C2)=C1)C1=CC=CC(N)=C1,,,,,0,,349.1902604,3,3,1,1,0,0
5112,04/06/2019 00:00,DB06884,4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE,,,,,,solid,,,0.0169,8.4,3.51,CC(C)C1=CC=C(CNNC(=O)C2=CC=C(O)C=C2)C=C1,,,,,0,,284.1524779,2,2,0,0,0,0
5113,04/06/2019 00:00,DB06885,3-[({(1E)-[2-(trifluoromethyl)phenyl]methylidene}amino)oxy]propanoic acid,,,,,,solid,,,0.0791,3.87,2.07,OC(=O)CCO\N=C\C1=C(C=CC=C1)C(F)(F)F,,,,,0,,261.0612778,1,1,0,0,0,0
5114,04/06/2019 00:00,DB06886,N-BENZYLOXYCARBONYL-ALA-PRO-3-AMINO-4-PHENYL-BUTAN-2-OL,,,,,,solid,,,0.0149,13.29,-2.8,[H][C@](C)(O)[C@]([H])(CC1=CC=CC=C1)NC(=O)[C@]1([H])CCCN1C(=O)[C@]([H])(C)NC(=O)OCC1=CC=CC=C1,,,,,0,,467.2420212,3,2,1,0,1,1
5115,04/06/2019 00:00,DB06887,"[(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid",,,,,,solid,,,0.11,-1.4,-4.4,CNC(=O)[C@@H]1CC2=CC=C(NS(O)(=O)=O)C=C2CN1C(=O)OC(C)(C)C,,,,,0,,385.1307565,2,1,1,0,0,1
5116,04/06/2019 00:00,DB06888,"(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE",,,,,,solid,,,0.335,8.26,7.01,[H][C@]12CN(CCN3NC4=C(C=CC=C4C3=O)C3=NC4=C(NC3=O)C=CC=C4O1)[C@]([H])(C)C2,,,,,0,,403.1644395,6,4,4,2,1,2
5117,04/06/2019 00:00,DB06889,"3-(1H-tetrazol-5-ylmethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one",,,,,,solid,,,0.122,4.1,1.83,O=C1N(CC2=NN=NN2)C=NC2=C1C1=C(CCCC1)S2,,,,,0,,288.07933,4,3,3,3,0,0
5118,04/06/2019 00:00,DB06890,(2R)-2-PHENYL-N-PYRIDIN-4-YLBUTANAMIDE,,,,,,solid,,,0.175,13.25,5.65,[H][C@](CC)(C(=O)NC1=CC=NC=C1)C1=CC=CC=C1,,,,,0,,240.1262631,2,2,1,1,0,0
5119,04/06/2019 00:00,DB06891,"5-{[(4-AMINO-3-CHLORO-5-FLUOROPHENYL)SULFONYL]AMINO}-1,3,4-THIADIAZOLE-2-SULFONAMIDE",,,,,,solid,,,0.218,6.42,-0.78,NC1=C(F)C=C(C=C1Cl)S(=O)(=O)NC1=NN=C(S1)S(N)(=O)=O,,,,,0,,386.9332726,2,2,1,1,0,0
5120,04/06/2019 00:00,DB06892,"(5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide",,,,,,solid,,,0.0156,8.13,-2.8,[H][C@@]1(F)C(F)=CC=C(C(=O)NOCCO)\C1=N\C1=C(F)C=C(I)C=C1,,,,,0,,451.9844749,2,1,0,0,0,0
5121,04/06/2019 00:00,DB06893,1-DECANE-SULFONIC-ACID,,,,,,solid,,,0.0727,-0.59,,CCCCCCCCCCS(O)(=O)=O,,,,,0,,222.1289656,0,0,0,0,0,0
5122,04/06/2019 00:00,DB06894,1-DODECANOL,,,,,,solid,,,0.0026,16.84,-2,CCCCCCCCCCCCO,,,,,0,,186.1983655,0,0,0,0,0,0
5123,04/06/2019 00:00,DB06896,"1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide",,,,,,solid,,,0.00173,13.1,5.02,FC1=CC=C(C=C1)N1C=CC=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)C1=O,,,,,0,,458.1190468,5,5,3,3,0,0
5124,04/06/2019 00:00,DB06897,"3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol",,,,,,solid,,,0.0221,15.96,3.67,[H][C@@](C)(NC1=CC2=C(ON=C2C2=CC(Cl)=CC(CCCO)=C2)C=N1)C1=CC=CC=C1,,,,,0,,407.1400546,4,4,2,2,0,0
5125,04/06/2019 00:00,DB06898,"4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol",,,,,,solid,,,0.726,9.76,5.46,CN1C(N)=NC2=C1C=C(C=N2)C1=CC=C(O)C=C1,,,,,0,,240.101111,3,3,2,2,0,0
5126,04/06/2019 00:00,DB06899,"N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE",,,,,,solid,,,0.0588,15.24,7.77,CCC1=NC(N)=NC(N)=C1C1=CC=C2SC(C)(C)C(=O)N(CCNC(C)=O)C2=C1,,,,,0,,414.1837951,3,2,2,1,0,1
5127,04/06/2019 00:00,DB06900,1-[4-(hydroxymethyl)phenyl]guanidine,,,,,,solid,,,0.858,15.1,10.64,NC(=N)NC1=CC=C(CO)C=C1,,,,,0,,165.090212,1,1,0,0,0,0
5128,04/06/2019 00:00,DB06901,2-(2-HYDROXY-CYCLOPENTYL)-PENT-4-ENAL,,,,,,solid,,,4.22,14.82,-2.8,[H][C@](CC=C)(C=O)[C@@]1([H])CCC[C@]1([H])O,,,,,0,,168.1150298,1,0,0,0,0,0
5129,04/06/2019 00:00,DB06902,4-(1-methyl-1-phenylethyl)phenol,,,,,,solid,,,0.0209,10.08,-5.5,CC(C)(C1=CC=CC=C1)C1=CC=C(O)C=C1,,,,,0,,212.1201151,2,2,0,0,0,0
5130,04/06/2019 00:00,DB06903,"(1S,3aS,5aR,8aS)-1,7,7-trimethyl-1,2,3,3a,5a,6,7,8-octahydrocyclopenta[c]pentalene-4-carboxylic acid",,,,,,solid,,,0.0415,4.94,,[H][C@]1(C)CC[C@]2([H])C(=C[C@@]3([H])CC(C)(C)C[C@@]123)C(O)=O,,,,,0,,234.1619799,3,0,0,0,0,0
5131,04/06/2019 00:00,DB06904,"(5S,6S)-6-[(R)ACETOXYETH-2-YL]-PENEM-3-CARBOXYLATEPROPANE",,,,,,solid,,,0.428,12.11,-1.1,[H][C@](C)(OC(C)=O)[C@@]([H])(C=O)[C@@]1([H])NC(=CS1)C(=O)OCC=C,,,,,0,,299.0827436,1,0,1,0,0,1
5132,04/06/2019 00:00,DB06905,"(2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid",,,,,,solid,,,0.00813,4.01,10.01,[H][C@](C)(\C=C(/C)\C=C\[C@]([H])(N)[C@]([H])(C)C(O)=O)[C@]([H])(CC1=CC=CC=C1)OC,,,,,0,,331.2147438,1,1,0,0,0,0
5133,04/06/2019 00:00,DB06906,2-AMINO-4-HYDROXYPYRIMIDINE-5-CARBOXYLIC ACID ETHYL ESTER,,,,,,solid,,,16.2,12.6,0.91,CCOC(=O)C1=C(O)N=C(N)N=C1,,,,,0,,183.0643911,1,1,1,1,0,0
5134,04/06/2019 00:00,DB06907,"2-(2,6-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID",,,,,,solid,,,0.0287,3.73,-0.76,OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=C(Cl)C=CC=C1Cl,,,,,0,,306.9802984,3,3,1,1,0,0
5135,04/06/2019 00:00,DB06908,"(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID",,,,,,solid,,,0.0148,4.02,0.37,[H][C@@](CC1=CC2=C(C=C1)N(CC1=C(C)OC(=N1)C1=C(Cl)C=CC=C1)C=C2)(OCC)C(O)=O,,,,,0,,438.1346349,4,4,2,2,0,0
5136,04/06/2019 00:00,DB06909,"1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide",,,,,,solid,,,0.0473,14.78,5.16,CCN1N=CC2=C1N=CC(C(=O)NCC1=CC=CC=C1)=C2NC1CCOCC1,,,,,0,,379.200825,4,3,3,2,1,1
5137,04/06/2019 00:00,DB06910,"[4-R-(4-ALPHA,6-BETA,7-BETA]-HEXAHYDRO-5,6-DI(HYDROXY)-1,3-DI(ALLYL)-4,7-BISPHENYLMETHYL)-2H-1,3-DIAZEPINONE",,,,,,solid,,,0.25,13.23,-0.62,[H][C@]1(CC2=CC=CC=C2)N(CC=C)C(=O)N(CC=C)[C@]([H])(CC2=CC=CC=C2)[C@]([H])(O)[C@@]1([H])O,,,,,0,,406.2256428,3,2,1,0,1,1
5138,04/06/2019 00:00,DB06911,D-leucyl-N-(3-chlorobenzyl)-L-prolinamide,,,,,,solid,,,0.0718,14.74,8.12,[H][C@@](N)(CC(C)C)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(Cl)=CC=C1,,,,,0,,351.1713548,2,1,1,0,1,1
5139,04/06/2019 00:00,DB06912,"UNDECA-3,7-DIENE-1,3,7,11-TETRACARBALDEHYDE",,,,,,solid,,,0.0166,14.25,-4,O=CCCCC=C(CCC=C(CCC=O)C=O)C=O,,,,,0,,264.1361591,0,0,0,0,0,0
5140,04/06/2019 00:00,DB06913,"(2R,3R)-3-{[3,5-BIS(TRIFLUOROMETHYL)PHENYL]AMINO}-2-CYANO-3-THIOXOPROPANAMIDE",,,,,,solid,,,0.0192,-5.3,10.72,[H][C@](S)(NC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C([H])(C#N)C(O)=N,,,,,0,,357.0370522,1,1,0,0,0,0
5141,04/06/2019 00:00,DB06914,"1-({2-[2-(4-CHLOROPHENYL)ETHYL]-1,3-DIOXOLAN-2-YL}METHYL)-1H-IMIDAZOLE",,,,,,solid,,,0.183,,6.75,ClC1=CC=C(CCC2(CN3C=CN=C3)OCCO2)C=C1,,,,,0,,292.0978555,3,2,2,1,1,1
5142,04/06/2019 00:00,DB06915,"naphthalene-1,2,4,5,7-pentol",,,,,,solid,,,1.65,8.48,-5.7,OC1=CC(O)=C2C(O)=CC(O)=C(O)C2=C1,,,,,0,,208.0371734,2,2,0,0,0,0
5143,04/06/2019 00:00,DB06916,"N-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-1-[2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDIN-4-YL]-D-PROLINAMIDE",,,,,,solid,,,0.321,14.84,6.25,[H][C@@]1(CCCN1C1=NC(=NC(C)=C1)N1C=CN=C1)C(=O)NCCC1=CC2=C(OCO2)C=C1,,,,,0,,420.1909886,5,3,4,2,1,2
5144,04/06/2019 00:00,DB06917,(4-fluorophenyl)(pyridin-4-yl)methanone,,,,,,solid,,,0.547,,3.18,FC1=CC=C(C=C1)C(=O)C1=CC=NC=C1,,,,,0,,201.0589921,2,2,1,1,0,0
5145,04/06/2019 00:00,DB06918,2-(2-METHYLPHENYL)-1H-INDOLE-6-CARBOXIMIDAMIDE,,,,,,solid,,,0.00584,14.55,11.17,CC1=CC=CC=C1C1=CC2=C(N1)C=C(C=C2)C(N)=N,,,,,0,,249.1265975,3,3,1,1,0,0
5146,04/06/2019 00:00,DB06919,D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide,,,,,,solid,,,0.00916,14.65,7.7,[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(Cl)=CC=C1,,,,,0,,385.1557047,3,2,1,0,1,1
5147,04/06/2019 00:00,DB06920,Eribaxaban,,,,,,solid,,,0.00717,11.46,-1.5,[H][C@@]1(CN(C(=O)NC2=CC=C(Cl)C=C2)[C@]([H])(C1)C(=O)NC1=CC=C(C=C1F)N1C=CC=CC1=O)OC,,,,,0,,484.1313611,4,3,2,1,1,1
5148,04/06/2019 00:00,DB06921,(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-HYDROXY{(1R)-2-METHYL-1-[(PHENYLSULFONYL)AMINO]PROPYL}PHOSPHORYL]PROPANOIC ACID,,,,,,solid,,,0.939,1.51,9.4,[H][C@@](C[P@](O)(=O)[C@@]([H])(NS(=O)(=O)C1=CC=CC=C1)C(C)C)(C(O)=O)C1=CC(CN)=CC=C1,,,,,0,,454.1327442,2,2,0,0,0,0
5149,04/06/2019 00:00,DB06922,"2-[(1R)-1-carboxy-2-naphthalen-1-ylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid",,,,,,solid,,,0.00674,3.07,-7,[H][C@](CC1=CC=CC2=CC=CC=C12)(N1C(=O)C2=CC=C(C=C2C1=O)C(O)=O)C(O)=O,,,,,0,,389.0899372,4,3,1,0,0,1
5150,04/06/2019 00:00,DB06923,2-(3-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE,,,,,,solid,,,0.00586,14.95,11.21,CC1=CC=CC(=C1)C1=CC2=C(N1)C=CC(=C2)C(N)=N,,,,,0,,249.1265975,3,3,1,1,0,0
5151,04/06/2019 00:00,DB06924,(2R)-2-benzyl-3-nitropropanoic acid,,,,,,solid,,,0.445,3.94,,[H][C@@](CC1=CC=CC=C1)(C[N+]([O-])=O)C(O)=O,,,,,0,,209.0688078,1,1,0,0,0,0
5152,04/06/2019 00:00,DB06925,3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE,,,,,,solid,,,0.000988,11.49,4.04,CC1=CC=C(C=C1C1=CC=C2N=C(N)N=CC2=C1)C(=O)NC1=CC=CC(=C1)C(F)(F)F,,,,,0,,422.1354458,4,4,1,1,0,0
5153,04/06/2019 00:00,DB06926,"(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid",,,,,,solid,,,0.00298,4.99,-1.6,[H][C@](O)(CCCCC)\C=C\C=C/CCCCCCCC(O)=O,,,,,0,,296.2351449,0,0,0,0,0,0
5154,04/06/2019 00:00,DB06927,[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE,,,,,,solid,,,0.242,8.75,-3.4,OC1=CC=C(C=C1)C1=CC2=C(O1)C(CC#N)=CC(O)=C2,,,,,0,,265.0738932,3,3,1,1,0,0
5155,04/06/2019 00:00,DB06928,(2S)-2-{[HYDROXY(4-IODOBENZYL)PHOSPHORYL]METHYL}PENTANEDIOIC ACID,,,,,,solid,,,0.827,1.82,,[H][C@@](CCC(O)=O)(C[P@](O)(=O)CC1=CC=C(I)C=C1)C(O)=O,,,,,0,,425.9729229,1,1,0,0,0,0
5156,04/06/2019 00:00,DB06929,1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide,,,,,,solid,,,0.191,15.27,11.48,[H][C@]1(CCCN1C(=O)CCC)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,316.189926,2,1,1,0,1,1
5157,04/06/2019 00:00,DB06930,"N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide",,,,,,solid,,,0.0228,13.3,6.79,NC(=N)NC(=O)CN1C(=CC=C1C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,318.1480612,3,3,1,1,0,0
5158,04/06/2019 00:00,DB06931,"(1-HYDROXYNONANE-1,1-DIYL)BIS(PHOSPHONIC ACID)",,,,,,solid,,,8.2,0.69,-5.2,CCCCCCCCC(O)(P(O)(O)=O)P(O)(O)=O,,,,,0,,304.0840763,0,0,0,0,0,0
5159,04/06/2019 00:00,DB06932,"10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine",,,,,,solid,,,0.0109,,5.96,COC1=CC2=NC=C3C(N)=NC4=C(C)C(N)=CC=C4C3=C2C=C1OC,,,,,0,,334.1429758,4,4,2,2,0,0
5160,04/06/2019 00:00,DB06933,N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide,,,,,,solid,,,0.00112,10.14,5.65,CC(C)(C)NS(=O)(=O)C1=CC=C(C=C1)C1=CN=C2C=CC=C(NC3=CC=CC=N3)C2=C1,,,,,0,,432.161997,4,4,2,2,0,0
5161,04/06/2019 00:00,DB06934,(1R)-3-chloro-1-phenylpropan-1-ol,,,,,,solid,,,2.12,14.44,-3,[H][C@@](O)(CCCl)C1=CC=CC=C1,,,,,0,,170.0498427,1,1,0,0,0,0
5162,04/06/2019 00:00,DB06935,"2',6'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID",,,,,,solid,,,0.0288,3.92,,OC(=O)C1=CC=C(C=C1)C1=C(F)C=CC=C1F,,,,,0,,234.0492359,2,2,0,0,0,0
5163,04/06/2019 00:00,DB06936,N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide,,,,,,solid,,,0.163,15.36,11.48,[H][C@]1(CCCN1C(=O)CCC(C)C)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,344.2212261,2,1,1,0,1,1
5164,04/06/2019 00:00,DB06937,"4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL",,,,,,solid,,,0.856,8.2,-0.92,OC1=CC2=C(C=C1)C(=NO2)C1=C(O)C=C(O)C=C1,,,,,0,,243.0531578,3,3,1,1,0,0
5165,04/06/2019 00:00,DB06938,4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide,,,,,,solid,,,0.00348,11.64,6.56,CNC(=O)C1=NC=CC(OC2=CC3=C(C=C2)N=C(NC2=CC(=C(Cl)C=C2)C(F)(F)F)N3)=C1,,,,,0,,461.0866371,4,4,2,2,0,0
5166,04/06/2019 00:00,DB06939,"N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE",,,,,,solid,,,0.722,,8.49,[H][C@@](N)(C(=O)N1CC[C@]([H])(F)C1)[C@@]([H])(C)[C@@]1([H])CC[C@@]([H])(CC1)N(C)C(C)=O,,,,,0,,327.2322054,2,0,1,0,1,1
5167,04/06/2019 00:00,DB06940,"N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide",,,,,,solid,,,0.02,12.86,2.69,CCNC(=O)C1=CN2N=CN=C(NC3=CC(=CC=C3C)C(=O)NOC)C2=C1C,,,,,0,,382.1753386,3,3,2,2,0,0
5168,04/06/2019 00:00,DB06941,(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide,,,,,,solid,,,0.118,11.82,7.77,CN1CCN(CC1)C1=C(C\N=N/C(N)=S)C=CC=C1,,,,,0,,277.1361166,2,1,1,0,1,1
5169,04/06/2019 00:00,DB06942,N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide,,,,,,solid,,,0.0462,15.24,11.48,[H][C@]1(CCCN1C(=O)CCC1=CC=CC=C1)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,378.2055761,3,2,1,0,1,1
5170,04/06/2019 00:00,DB06943,(3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol,,,,,,solid,,,0.0177,9.92,-4.9,[H][C@]1(S)CCN(C1)S(=O)(=O)C1=CC=C(OCC#CC)C=C1,,,,,0,,311.0649854,2,1,1,0,1,1
5171,04/06/2019 00:00,DB06944,N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide,,,,,,solid,,,0.0065,12.91,2.58,O=C(CC1=CC2=C(C=CC=C2)C=C1)NC1=CC(=NN1)C1CC1,,,,,0,,291.1371622,4,3,1,1,0,0
5172,04/06/2019 00:00,DB06945,N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide,,,,,,solid,,,0.0441,8.66,-4.1,ONC(=O)C1(CCOCC1)S(=O)(=O)C1=CC=C(OC2=CC=C(C=C2)C(F)(F)F)C=C1,,,,,0,,445.080693,3,2,1,0,1,1
5173,04/06/2019 00:00,DB06946,"(2S,3S)-3-(4-fluorophenyl)-2,3-dihydroxypropanoic acid",,,,,,solid,,,7.39,3.27,-3.6,[H][C@@](O)(C(O)=O)[C@@]([H])(O)C1=CC=C(F)C=C1,,,,,0,,200.048487,1,1,0,0,0,0
5174,04/06/2019 00:00,DB06947,1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide,,,,,,solid,,,0.114,15.28,11.48,[H][C@@](N)(CC)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,331.200825,2,1,1,0,1,1
5175,04/06/2019 00:00,DB06948,2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE,,,,,,solid,,,0.0205,9.88,2,C(OC1=C2NC=NC2=NC(NC2=CC=CC=C2)=N1)C1CCCCC1,,,,,0,,323.1746103,4,3,2,2,0,0
5176,04/06/2019 00:00,DB06949,"N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]naphthalene-2-carbohydrazide",,,,,,solid,,,0.00463,6.44,0.33,OC1=C(Br)C=C(\C=N\NC(=O)C2=CC=C3C=CC=CC3=C2)C(O)=C1Br,,,,,0,,461.9214664,3,3,0,0,0,0
5177,04/06/2019 00:00,DB06950,"4-chloro-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,,,,,solid,,,0.0102,6.44,-0.26,OC1=C(Br)C=C(\C=N\NC(=O)C2=CC=C(Cl)C=C2)C(O)=C1Br,,,,,0,,445.866844,2,2,0,0,0,0
5178,04/06/2019 00:00,DB06951,(3R)-3-ethyl-N-[(4-methylphenyl)sulfonyl]-L-aspartic acid,,,,,,solid,,,0.519,3.15,,[H][C@](CC)(C(O)=O)[C@]([H])(NS(=O)(=O)C1=CC=C(C)C=C1)C(O)=O,,,,,0,,315.0776583,1,1,0,0,0,0
5179,04/06/2019 00:00,DB06952,(2S)-2-HYDROXY-2H-CHROMENE-2-CARBOXYLIC ACID,,,,,,solid,,,8.8,2.85,-5.1,OC(=O)[C@@]1(O)OC2=CC=CC=C2C=C1,,,,,0,,192.0422587,2,1,1,0,0,1
5180,04/06/2019 00:00,DB06953,2-CHLORO-5-(3-CHLORO-PHENYL)-6-[(4-CYANO-PHENYL)-(3-METHYL-3H-IMIDAZOL-4-YL)- METHOXYMETHYL]-NICOTINONITRILE,,,,,,solid,,,0.0102,,6.26,[H][C@](OCC1=NC(Cl)=C(C=C1C1=CC(Cl)=CC=C1)C#N)(C1=CN=CN1C)C1=CC=C(C=C1)C#N,,,,,0,,473.0810155,4,4,2,2,0,0
5181,04/06/2019 00:00,DB06954,"2-(cycloheptylmethyl)-1,1-dioxido-1-benzothiophen-6-yl sulfamate",,,,,,solid,,,0.0268,10.53,-6,NS(=O)(=O)OC1=CC=C2C=C(CC3CCCCCC3)S(=O)(=O)C2=C1,,,,,0,,371.0861148,3,1,1,0,0,1
5182,04/06/2019 00:00,DB06955,"3,4-bis(7-chloro-1H-indol-3-yl)-1H-pyrrole-2,5-dicarboxylic acid",,,,,,solid,,,0.000674,3.21,,OC(=O)C1=C(C2=CNC3=C(Cl)C=CC=C23)C(=C(N1)C(O)=O)C1=CNC2=C(Cl)C=CC=C12,,,,,0,,453.0283113,5,5,3,3,0,0
5183,04/06/2019 00:00,DB06956,"N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE",,,,,,solid,,,0.0286,7.53,1.01,CC(=O)C1=CC=C(NC(=O)C2=C(NN=C2)C2=CC(Cl)=C(O)C=C2O)C=C1,,,,,0,,371.0672836,3,3,1,1,0,0
5184,04/06/2019 00:00,DB06957,"4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL",,,,,,solid,,,0.178,8.01,5.39,CS(=O)(=O)C1=CC=C(CN2CCN(CC2)C2=C(NN=C2)C2=CC(Cl)=C(O)C=C2O)C=C1,,,,,0,,462.1128539,4,3,2,1,1,1
5185,04/06/2019 00:00,DB06958,"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE",,,,,,solid,,,0.404,7.91,8.72,CCNC(=O)C1=NNC(=C1N1CCNCC1)C1=CC(Cl)=C(O)C=C1O,,,,,0,,365.1254672,3,2,2,1,1,1
5186,04/06/2019 00:00,DB06959,(2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine,,,,,,solid,,,0.00032,14.15,9.53,[H]N([H])[C@H](COC1=CN=CC(=C1)C1=CC2=C(C=C1)C=NC=C2)CC1C=NC2=CC=CC=C12,,,,,0,,394.1793613,5,4,3,2,0,1
5187,04/06/2019 00:00,DB06960,"N-[(1R,2R,3E)-2-hydroxy-1-(hydroxymethyl)heptadec-3-en-1-yl]acetamide",,,,,,solid,,,0.00296,13.59,-0.68,[H][C@@](O)(\C=C\CCCCCCCCCCCCC)[C@@]([H])(CO)NC(C)=O,,,,,0,,341.2929941,0,0,0,0,0,0
5188,04/06/2019 00:00,DB06961,"5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide",,,,,,solid,,,0.113,7.44,6.86,CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=C(O)C=C(O)C(Cl)=C1,,,,,0,,457.1404485,4,3,2,1,1,1
5189,04/06/2019 00:00,DB06962,"(5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-yl)(5-(phenylethynyl)furan-2-yl)methanone",,,,,,solid,,,0.0204,,9.47,NCC1=CC=C2OCC3(CCN(CC3)C(=O)C3=CC=C(O3)C#CC3=CC=CC=C3)C2=C1,,,,,0,,412.1786926,5,3,3,1,1,2
5190,04/06/2019 00:00,DB06963,"3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide",,,,,,solid,,,0.00462,16,8.17,[H][C@@](C)(NC1=CC2=C(C=N1)C(C)=NN2C1=CC=CC(CCC(N)=O)=C1)C1=CC=CC=C1,,,,,0,,399.2059104,4,4,2,2,0,0
5191,04/06/2019 00:00,DB06964,"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE",,,,,,solid,,,0.0795,7.17,-2.7,CCNC(=O)C1=NOC(=C1C1=CC=C(OC)C=C1)C1=C(O)C=C(O)C(Cl)=C1,,,,,0,,388.0825993,3,3,1,1,0,0
5192,04/06/2019 00:00,DB06965,Hexylphosphonic acid (R)-2-methyl-3-phenylpropyl ester,,,,,,solid,,,0.0373,1.96,,CCCCCCP(O)(=O)OC[C@H](C)CC1=CC=CC=C1,,,,,0,,298.1697814,1,1,0,0,0,0
5193,04/06/2019 00:00,DB06966,Hexylphosphonic acid (S)-2-methyl-3-phenylpropyl ester,,,,,,solid,,,0.0373,1.96,,CCCCCCP(O)(=O)OC[C@@H](C)CC1=CC=CC=C1,,,,,0,,298.1697814,1,1,0,0,0,0
5194,04/06/2019 00:00,DB06967,"6-ETHYL-5-[9-(3-METHOXYPROPYL)-9H-CARBAZOL-2-YL]PYRIMIDINE-2,4-DIAMINE",,,,,,solid,,,0.0158,17.18,7.76,CCC1=NC(N)=NC(N)=C1C1=CC2=C(C=C1)C1=CC=CC=C1N2CCCOC,,,,,0,,375.2059104,4,4,2,2,0,0
5195,04/06/2019 00:00,DB06968,"1,1'-HEXANE-1,6-DIYLBIS(1H-IMIDAZOLE)",,,,,,solid,,,0.973,,7.09,C(CCCN1C=CN=C1)CCN1C=CN=C1,,,,,0,,218.1531466,2,2,2,2,0,0
5196,04/06/2019 00:00,DB06969,"2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide",,,,,,solid,,,0.00249,13.9,8.03,CCNC(=O)C1=CC2=C(N=C(N)N=C2S1)C1=C(Cl)C=C(Cl)C(OCCN2CCCC2)=C1,,,,,0,,479.0949513,4,3,3,2,1,1
5197,04/06/2019 00:00,DB06970,"2-CHLORO-N-(3-CYANO-5,6-DIHYDRO-4H-CYCLOPENTA[B]THIOPHEN-2-YL)-5-DIETHYLSULFAMOYL-BENZAMIDE",,,,,,solid,,,0.00587,7.71,-4.8,CCN(CC)S(=O)(=O)C1=CC=C(Cl)C(=C1)C(=O)NC1=C(C#N)C2=C(CCC2)S1,,,,,0,,437.0634612,3,2,1,1,0,0
5198,04/06/2019 00:00,DB06971,"N-{2-[(4'-CYANO-1,1'-BIPHENYL-4-YL)OXY]ETHYL}-N'-HYDROXY-N-METHYLUREA",,,,,,solid,,,0.0193,10.06,-4.8,CN(CCOC1=CC=C(C=C1)C1=CC=C(C=C1)C#N)C(=O)NO,,,,,0,,311.1269914,2,2,0,0,0,0
5199,04/06/2019 00:00,DB06972,"7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile",,,,,,solid,,,0.00705,,1.06,ClC1=CC(=CC(Cl)=C1)C1=C(C#N)[C@@]2(CC3=CC=C(C=C3)C#N)CCCN2C1=O,,,,,0,,407.0592175,4,2,2,0,1,2
5200,04/06/2019 00:00,DB06973,"4,4'-PROPANE-2,2-DIYLDIPHENOL",,,,,,solid,,,0.0865,9.78,-5.5,CC(C)(C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,,,,,0,,228.1150298,2,2,0,0,0,0
5201,04/06/2019 00:00,DB06974,"5-hydroxy-4-(7-methoxy-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-(3-methylbutyl)-6-phenylpyridazin-3(2H)-one",,,,,,solid,,,0.0237,6.28,-3.2,COC1=CC=C2N=C(NS(=O)(=O)C2=C1)C1=C(O)C(=NN(CCC(C)C)C1=O)C1=CC=CC=C1,,,,,0,,468.1467409,4,3,2,1,0,1
5202,04/06/2019 00:00,DB06976,"1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA",,,,,,solid,,,0.0395,10.63,9.17,[H][C@]1(CCCN1)C1=CC(NC(=O)NC2=CC=CC3=C2[C@]2([H])CCCN2C3=O)=NN1,,,,,0,,366.1804239,5,2,4,1,2,3
5203,04/06/2019 00:00,DB06977,(2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine,,,,,,solid,,,0.0101,12.99,9.5,[H][C@@](N)(COC1=CN=CC(=C1)C1=CC2=CNN=C2C=C1)CC1=C2C=CC=CC2([H])N=C1,,,,,0,,383.1746103,5,3,3,2,0,1
5204,04/06/2019 00:00,DB06978,"N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]-4-methoxybenzohydrazide",,,,,,solid,,,0.0251,6.44,0.011,COC1=CC=C(C=C1)C(=O)N\N=C\C1=CC(Br)=C(O)C(Br)=C1O,,,,,0,,441.9163811,2,2,0,0,0,0
5205,04/06/2019 00:00,DB06979,"5-(dodecylthio)-1H-1,2,3-triazole-4-carboxylic acid",,,,,,solid,,,0.0027,2.96,-1.1,CCCCCCCCCCCCSC1=C(N=NN1)C(O)=O,,,,,0,,313.1823981,1,1,1,1,0,0
5206,04/06/2019 00:00,DB06980,(2S)-2-(1H-indol-3-yl)hexanoic acid,,,,,,solid,,,0.106,4.82,,[H][C@@](CCCC)(C(O)=O)C1=CNC2=C1C=CC=C2,,,,,0,,231.1259288,2,2,1,1,0,0
5207,04/06/2019 00:00,DB06981,(2S)-2-(1H-indol-3-yl)pentanoic acid,,,,,,solid,,,0.381,4.77,,[H][C@@](CCC)(C(O)=O)C1=CNC2=CC=CC=C12,,,,,0,,217.1102787,2,2,1,1,0,0
5208,04/06/2019 00:00,DB06982,(2S)-8-[(tert-butoxycarbonyl)amino]-2-(1H-indol-3-yl)octanoic acid,,,,,,solid,,,0.00303,4.76,,[H][C@@](CCCCCCNC(=O)OC(C)(C)C)(C(O)=O)C1=CNC2=C1C=CC=C2,,,,,0,,374.2205574,2,2,1,1,0,0
5209,04/06/2019 00:00,DB06983,"(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol",,,,,,solid,,,0.0308,14.54,4.82,OCC1=C2N=C(C=C(NCC3=CN=CC=C3)N2N=C1)C1=CC=CC=C1,,,,,0,,331.1433102,4,4,3,3,0,0
5210,04/06/2019 00:00,DB06984,"(1R,2R,3R,4S,5R)-4-(BENZYLAMINO)-5-(METHYLTHIO)CYCLOPENTANE-1,2,3-TRIOL",,,,,,solid,,,5.64,12.88,8.25,[H][C@@]1(O)[C@]([H])(O)[C@]([H])(NCC2=CC=CC=C2)[C@@]([H])(SC)[C@]1([H])O,,,,,0,,269.1085645,2,1,0,0,0,0
5211,04/06/2019 00:00,DB06985,2-[({4-[2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)amino]benzoic acid,,,,,,solid,,,0.0101,3.53,-3,OC(=O)C1=C(NC(=O)N2CCC(CC2)C2=C(C=CC=C2)C(F)(F)F)C=CC=C1,,,,,0,,392.1347771,3,2,1,0,1,1
5212,04/06/2019 00:00,DB06986,"2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE",,,,,,solid,,,0.00646,9.3,-1.5,[H][C@]1(CC2=C(C=CC=C2)[C@@]1([H])O)NC(=O)C1=CC2=C(N1)SC(Cl)=C2,,,,,0,,332.0386263,4,3,2,2,0,0
5213,04/06/2019 00:00,DB06987,(R)-Atenolol,,,,,,solid,,,0.429,14.08,9.67,CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1,,,,,0,,266.1630426,1,1,0,0,0,0
5214,04/06/2019 00:00,DB06988,2-HYDROXY-5-{[(1E)-2-PHENYLETHYLIDENE]AMINO}-L-TYROSINE,,,,,,solid,,,0.0792,1.46,9.09,[H][C@](N)(CC1=CC(\N=C\CC2=CC=CC=C2)=C(O)C=C1O)C(O)=O,,,,,0,,314.1266571,2,2,0,0,0,0
5215,04/06/2019 00:00,DB06989,{4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID,,,,,,solid,,,0.00657,-1.4,-6.9,COC(=O)C(CC1=CC=CC=C1)(CC1=CC=C(NS(O)(=O)=O)C=C1)C(=O)OC,,,,,0,,407.103873,2,2,0,0,0,0
5216,04/06/2019 00:00,DB06990,"4-[(1E,7E)-8-(2,6-DIOXO-1,2,3,6-TETRAHYDROPYRIMIDIN-4-YL)-3,6-DIOXA-2,7-DIAZAOCTA-1,7-DIEN-1-YL]BENZOIC ACID",,,,,,solid,,,0.105,3.98,2.93,OC(=O)C1=CC=C(\C=N\OCCO\N=C\C2=CC(=O)NC(=O)N2)C=C1,,,,,0,,346.0913342,2,2,1,1,0,0
5217,04/06/2019 00:00,DB06991,"N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide",,,,,,solid,,,0.00582,9.97,2.02,[H][C@@](C)(CC)NC1=NC=C(S1)C(=O)NC1=C(C)C=CC(=C1)C(=O)NC,,,,,0,,346.1463469,2,2,1,1,0,0
5218,04/06/2019 00:00,DB06992,"(3,3-dimethylpiperidin-1-yl)(6-(3-fluoro-4-methylphenyl)pyridin-2-yl)methanone",,,,,,solid,,,0.02,,0.4,CC1=CC=C(C=C1F)C1=NC(=CC=C1)C(=O)N1CCCC(C)(C)C1,,,,,0,,326.1794416,3,2,2,1,1,1
5219,04/06/2019 00:00,DB06993,"(2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine",,,,,,solid,,,0.654,16.17,8.07,[H][C@@](N)(C(=O)N1CC[C@]([H])(F)C1)[C@]([H])(CC1CC1)C1([H])N[C@]([H])(NO1)C1=C(F)C=C(C=C1)S(C)(=O)=O,,,,,0,,458.1799328,4,1,2,0,2,2
5220,04/06/2019 00:00,DB06994,"(2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine",,,,,,solid,,,0.0262,19.65,7.55,[H][C@@](N)(C(F)=C1CCCC1)[C@]([H])(CC1CC1)C1=NC(=NO1)C1=CC=C(C=C1Cl)S(C)(=O)=O,,,,,0,,453.1289186,4,2,1,1,0,0
5221,04/06/2019 00:00,DB06995,N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide,,,,,,solid,,,0.00366,10.63,7.54,NC1=NC=CC(OC2=C(F)C=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C2)=C1,,,,,0,,398.1190468,3,3,1,1,0,0
5222,04/06/2019 00:00,DB06996,D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide,,,,,,solid,,,0.128,15.36,11.48,[H][C@@](N)(CC(C)C)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,359.2321252,2,1,1,0,1,1
5223,04/06/2019 00:00,DB06997,"2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide",,,,,,solid,,,0.0021,10.63,5.02,FC1=CC=C(CC(=O)NC(=O)NC2=CC(F)=C(OC3=CC=NC4=C3C=CN4)C=C2)C=C1,,,,,0,,422.1190468,4,4,2,2,0,0
5224,04/06/2019 00:00,DB06998,"[(5R)-5-(2,3-dibromo-5-ethoxy-4-hydroxybenzyl)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid",,,,,,solid,,,0.00671,2.3,-4.9,[H][C@]1(CC2=C(Br)C(Br)=C(O)C(OCC)=C2)SC(=S)N(CC(O)=O)C1=O,,,,,0,,496.8601887,2,1,1,0,1,1
5225,04/06/2019 00:00,DB06999,"N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide",,,,,,solid,,,0.00422,7.17,1.65,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(Cl)C=C23)=C(F)C=C1,,,,,0,,413.0412464,3,3,2,2,0,0
5226,04/06/2019 00:00,DB07000,"N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide",,,,,,solid,,,0.00359,7.28,4.67,CCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CN=CC=C2)=C1F,,,,,0,,442.0911178,4,4,3,3,0,0
5227,04/06/2019 00:00,DB07001,"(3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine",,,,,,solid,,,0.059,,7.4,[H][C@]1(CCC)COC2=C(SC=C2)C(=N)N1,,,,,0,,210.0826841,2,1,2,1,0,1
5228,04/06/2019 00:00,DB07002,4-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrile,,,,,,solid,,,0.0646,,7.97,COC1=CC=NC(NC2CCN(CC2)C(=O)C2=CC=C(C=C2)C#N)=C1,,,,,0,,336.1586259,3,2,2,1,1,1
5229,04/06/2019 00:00,DB07003,"(2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine",,,,,,solid,,,0.465,,6.71,[H][C@]1(C)CN=C(N)C2=C(O1)C=CS2,,,,,0,,182.0513839,2,1,2,1,0,1
5230,04/06/2019 00:00,DB07004,2-[(5-hex-1-yn-1-ylfuran-2-yl)carbonyl]-N-methylhydrazinecarbothioamide,,,,,,solid,,,0.0237,11.8,-3,CCCCC#CC1=CC=C(O1)C(=O)NNC(=S)NC,,,,,0,,279.1041478,1,1,1,1,0,0
5231,04/06/2019 00:00,DB07005,D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide,,,,,,solid,,,0.0132,15.24,11.48,[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=[NH2+],,,,,1,,394.2237516,3,2,1,0,1,1
5232,04/06/2019 00:00,DB07006,"9-HYDROXY-6-(3-HYDROXYPROPYL)-4-(2-METHOXYPHENYL)PYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE",,,,,,solid,,,0.019,8.1,-2.4,COC1=CC=CC=C1C1=CC2=C(C3=C(C=CC(O)=C3)N2CCCO)C2=C1C(=O)NC2=O,,,,,0,,416.1372217,5,4,2,1,0,1
5233,04/06/2019 00:00,DB07007,"(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine",,,,,,solid,,,0.0186,17.21,9.18,[H][C@@]1(COC2=CC=C3CCNCC3=C2)COC2=C(SC=C2)C(N)=N1,,,,,0,,329.1197978,4,2,3,1,0,2
5234,04/06/2019 00:00,DB07008,"4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PYRIMIDINE",,,,,,solid,,,0.0727,,6.43,C1OC2=C(O1)C=C(OC1=CC=NC(OC3=CC=C(C=C3)N3C=CN=C3)=N1)C=C2,,,,,0,,374.1015049,5,4,3,2,0,1
5235,04/06/2019 00:00,DB07009,"2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL",,,,,,solid,,,0.0821,8.84,0.32,OC1=CC2=C(C=C1)N=C(O2)C1=C2C=CC=C(O)C2=CC=C1,,,,,0,,277.0738932,4,4,1,1,0,0
5236,04/06/2019 00:00,DB07010,N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE,,,,,,solid,,,0.0026,11.61,1.63,ClC1=CC(=CC=C1)C1=CNN=C1C1=CNC(=C1)C(=O)NCC1=CC=CC=C1,,,,,0,,376.1090888,4,4,2,2,0,0
5237,04/06/2019 00:00,DB07011,"(3S)-1-(1,3-BENZODIOXOL-5-YLMETHYL)-3-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PIPERIDINE",,,,,,solid,,,0.0737,,8.16,[H][C@@]1(CCCN(CC2=CC3=C(OCO3)C=C2)C1)OC1=CC=C(C=C1)N1C=CN=C1,,,,,0,,377.1739416,5,3,3,1,1,2
5238,04/06/2019 00:00,DB07012,"6-AMINO-3,7-DIHYDRO-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE",,,,,,solid,,,0.42,11.06,5.13,NC1=NC2=CC3=C(C=C2C(=O)N1)N=CN3,,,,,0,,201.0650598,3,3,2,2,0,0
5239,04/06/2019 00:00,DB07013,TERT-BUTYL 4-({[4-(BUT-2-YN-1-YLAMINO)PHENYL]SULFONYL}METHYL)-4-[(HYDROXYAMINO)CARBONYL]PIPERIDINE-1-CARBOXYLATE,,,,,,solid,,,0.0132,8.83,0.91,CC#CCNC1=CC=C(C=C1)S(=O)(=O)CC1(CCN(CC1)C(=O)OC(C)(C)C)C(=O)NO,,,,,0,,465.1933567,2,1,1,0,1,1
5240,04/06/2019 00:00,DB07014,"2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole",,,,,,solid,,,0.0952,,-2.1,COC1=C(F)C=C(CSC2=NN=C(O2)C2=CC3=C(OCO3)C=C2)C=C1,,,,,0,,360.0580061,4,3,2,1,0,1
5241,04/06/2019 00:00,DB07015,"(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine",,,,,,solid,,,1.27,,8.32,[H][C@]1(N)CN(C[C@@]1([H])C(=O)N1CCCC1)C(=O)C1=CN=C2C=CC=CC2=N1,,,,,0,,339.1695249,4,2,3,1,2,2
5242,04/06/2019 00:00,DB07016,"(3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline",,,,,,solid,,,0.506,5.83,2.71,[H][C@]1(C)CNC2=C(C1)C=CC=C2S(=O)=O,,,,,0,,211.0666997,2,1,1,0,0,1
5243,04/06/2019 00:00,DB07017,"(5S)-2-{[(1S)-1-(4-fluorophenyl)ethyl]amino}-5-(1-hydroxy-1-methylethyl)-5-methyl-1,3-thiazol-4(5H)-one",,,,,,solid,,,0.0622,14.19,-0.78,[H][C@@](C)(NC1=NC(=O)[C@@](C)(S1)C(C)(C)O)C1=CC=C(F)C=C1,,,,,0,,310.1151271,2,1,1,0,0,1
5244,04/06/2019 00:00,DB07018,5-ETHYL-3-[(2-METHOXYETHYL)METHYLAMINO]-6-METHYL-4-(3-METHYLBENZYL)PYRIDIN-2(1H)-ONE,,,,,,solid,,,0.0812,11.82,4.42,CCC1=C(C)NC(=O)C(N(C)CCOC)=C1CC1=CC=CC(C)=C1,,,,,0,,328.2150781,2,2,1,1,0,0
5245,04/06/2019 00:00,DB07019,"N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE",,,,,,solid,,,0.0017,,7.22,[H][C@@]1(C)CCC2=CC(C[C@@](C)(N)C(=O)OCC3=CC(CC1)=NC(=C3)N(C)S(C)(=O)=O)=CC=C2,,,,,0,,459.2191775,3,2,2,1,0,1
5246,04/06/2019 00:00,DB07020,"N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide",,,,,,solid,,,0.0941,9.75,1.67,O=C(NC1=CC(=CC=C1)C1=NNC2=CC=C(C=C12)C1=NNC=N1)C1=CC=CO1,,,,,0,,370.1178237,5,5,3,3,0,0
5247,04/06/2019 00:00,DB07021,"(7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine",,,,,,solid,,,0.0975,,9.26,[H][C@]1(N)CN2C(C[C@]1([H])C1=CC(F)=C(F)C=C1F)=NC1=C2C=CN=C1,,,,,0,,318.1092311,4,3,3,2,0,1
5248,04/06/2019 00:00,DB07022,3-Hydroxypropyl 3-[(7-carbamimidoyl-1-naphthyl)carbamoyl]benzenesulfonate,,,,,,solid,,,0.0198,10.86,11.5,NC(=N)C1=CC2=C(NC(=O)C3=CC=CC(=C3)S(=O)(=O)OCCCO)C=CC=C2C=C1,,,,,0,,427.1201918,3,3,0,0,0,0
5249,04/06/2019 00:00,DB07023,"(1R)-2-{[AMINO(IMINO)METHYL]AMINO}-1-{4-[(4R)-4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL]PHENYL}ETHYL NICOTINATE",,,,,,solid,,,0.152,14.65,11.7,[H][C@@](CNC(N)=N)(OC(=O)C1=CC=CN=C1)C1=CC=C(C=C1)B1OC[C@@]([H])(CO)O1,,,,,0,,384.1605002,3,2,2,1,1,1
5250,04/06/2019 00:00,DB07024,"2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE",,,,,,solid,,,0.481,8.4,-3.8,CC1=CC(N2CCCS2(=O)=O)=C2OC(=C(O)C(=O)C2=C1)C1=CC=C(O)C(O)=C1,,,,,0,,403.0725729,4,3,2,1,1,1
5251,04/06/2019 00:00,DB07025,3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE,,,,,,solid,,,0.00709,11.76,10.27,NCC1CCN(CC2=CC3=C(NC(=C3)C3=CC4=CC=CC=C4NC3=O)C=C2)CC1,,,,,0,,386.2106615,5,4,3,2,1,1
5252,04/06/2019 00:00,DB07026,"(1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE",,,,,,solid,,,0.458,10.04,-4.1,[H][C@]12CN(C[C@]([H])(O1)[C@@]([H])(O2)C(=O)NCC1=CC=C(C=C1)C1=CC=CC=C1)C(=O)NO,,,,,0,,383.1481208,4,2,2,0,2,2
5253,04/06/2019 00:00,DB07027,D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide,,,,,,solid,,,0.0445,14.67,7.7,[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=CC(F)=C1,,,,,0,,369.1852552,3,2,1,0,1,1
5254,04/06/2019 00:00,DB07028,(2-{[(4-BROMO-2-FLUOROBENZYL)AMINO]CARBONYL}-5-CHLOROPHENOXY)ACETIC ACID,,,,,,solid,,,0.00355,2.97,-1.4,OC(=O)COC1=CC(Cl)=CC=C1C(=O)NCC1=C(F)C=C(Br)C=C1,,,,,0,,414.9622259,2,2,0,0,0,0
5255,04/06/2019 00:00,DB07029,"4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]-6-METHYLPYRIMIDINE",,,,,,solid,,,0.037,,6.43,CC1=NC(OC2=CC=C(C=C2)N2C=CN=C2)=NC(OC2=CC3=C(OCO3)C=C2)=C1,,,,,0,,388.117155,5,4,3,2,0,1
5256,04/06/2019 00:00,DB07030,(5-CHLORO-2-{[(3-NITROBENZYL)AMINO]CARBONYL}PHENOXY)ACETIC ACID,,,,,,solid,,,0.00755,3,-1.3,OC(=O)COC1=CC(Cl)=CC=C1C(=O)NCC1=CC(=CC=C1)[N+]([O-])=O,,,,,0,,364.0462138,2,2,0,0,0,0
5257,04/06/2019 00:00,DB07031,"3-Fluoro-4-{[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic acid",,,,,,solid,,,0.00116,3.87,-3.9,CC1(C)CCC(C)(C)C2=C1C=CC(=C2)[C@@H](O)C(=O)NC1=C(F)C=C(C=C1)C(O)=O,,,,,0,,399.1845865,3,2,0,0,0,0
5258,04/06/2019 00:00,DB07032,2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL,,,,,,solid,,,0.112,9.13,-3.3,OC1=CC=C(C=C1)C1=CC2=C(O1)C=CC(O)=C2,,,,,0,,226.0629942,3,3,1,1,0,0
5259,04/06/2019 00:00,DB07033,5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE,,,,,,solid,,,0.148,9.41,0.45,[H][C@](C)(C1=CC=CN1)C1=C2C=C(O)C=CC2=NC1=O,,,,,0,,240.0898776,3,2,2,1,0,1
5260,04/06/2019 00:00,DB07034,"2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID",,,,,,solid,,,0.0829,2.96,1.56,ON=C1C2=CC(OCC(O)=O)=CC=C2C2=C1C=C(OCC(O)=O)C=C2,,,,,0,,343.0692018,3,2,0,0,0,0
5261,04/06/2019 00:00,DB07035,"(2E)-3-{3-[(5-ETHYL-3-IODO-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-4-YL)OXY]PHENYL}ACRYLONITRILE",,,,,,solid,,,0.0174,10.34,-4.7,CCC1=C(C)NC(=O)C(I)=C1OC1=CC=CC(\C=C\C#N)=C1,,,,,0,,406.0178257,2,2,1,1,0,0
5262,04/06/2019 00:00,DB07036,"(3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol",,,,,,solid,,,0.0413,9.31,-4.1,[H][C@@]12CC(F)(F)C[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1COC)C1=CC=C(O)C=C1,,,,,0,,362.1329656,4,2,1,0,0,1
5263,04/06/2019 00:00,DB07037,(2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL,,,,,,solid,,,1.19,12.44,9.2,[H][C@](O)(CN)CNC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O,,,,,0,,262.1065903,2,2,1,1,0,0
5264,04/06/2019 00:00,DB07038,2-(cyclohexylamino)benzoic acid,,,,,,solid,,,0.211,2.17,5.02,OC(=O)C1=CC=CC=C1NC1CCCCC1,,,,,0,,219.1259288,2,1,0,0,0,0
5265,04/06/2019 00:00,DB07039,(2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide,,,,,,solid,,,0.0224,11.95,-4,C[C@](O)(COC1=CC=C(C=C1)C#N)C(=O)NC1=CC=C(C#N)C(I)=C1,,,,,0,,447.0079893,2,2,0,0,0,0
5266,04/06/2019 00:00,DB07040,"2-amino-7-fluoro-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxamide",,,,,,solid,,,0.489,13.45,1.19,NC(=O)C1=C(N)N=C2OC3=C(C=C(F)C=C3)C(=O)C2=C1,,,,,0,,273.0549693,3,3,2,2,0,0
5267,04/06/2019 00:00,DB07041,"N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide",,,,,,solid,,,0.00579,14.89,4.11,CC(C)(CNC(=O)C1=CC=C(OC2=CC=CC=C2)C=C1)C1=NC2=NC(N)=NC(N)=C2C=C1,,,,,0,,428.196074,4,4,2,2,0,0
5268,04/06/2019 00:00,DB07042,"7-amino-2-tert-butyl-4-{[2-(1H-imidazol-4-yl)ethyl]amino}pyrido[2,3-d]pyrimidine-6-carboxamide",,,,,,solid,,,0.0466,13.58,6.7,CC(C)(C)C1=NC2=NC(N)=C(C=C2C(NCCC2=CNC=N2)=N1)C(N)=O,,,,,0,,354.1916573,3,3,3,3,0,0
5269,04/06/2019 00:00,DB07043,"7-amino-2-tert-butyl-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrido[2,3-d]pyrimidine-6-carboxamide",,,,,,solid,,,0.105,13.64,3.25,CC(C)(C)C1=NC(N2CCN(CC2)C2=NC=CC=N2)=C2C=C(C(N)=O)C(N)=NC2=N1,,,,,0,,407.2182064,4,3,4,3,1,1
5270,04/06/2019 00:00,DB07044,"3-bromo-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,,,,,solid,,,0.00844,6.44,-0.21,OC1=C(Br)C=C(\C=N\NC(=O)C2=CC=CC(Br)=C2)C(O)=C1Br,,,,,0,,489.8163284,2,2,0,0,0,0
5271,04/06/2019 00:00,DB07045,"(2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol",,,,,,solid,,,0.511,12.45,4.7,[H][C@]1(CO)O[C@@]([H])(N2C(NCC3=CC=C(Cl)C(Cl)=C3)=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,440.0766584,4,3,3,2,1,1
5272,04/06/2019 00:00,DB07046,"2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide",,,,,,solid,,,0.0103,11.97,-3,[H][C@@](O)(CO)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1Cl,,,,,0,,497.965489,2,2,0,0,0,0
5273,04/06/2019 00:00,DB07047,"2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID",,,,,,solid,,,0.0242,2.7,-6.3,OC(=O)C1=CC(=CC=C1O)C1=C(Cl)C=C(Cl)C=C1,,,,,0,,281.9850495,2,2,0,0,0,0
5274,04/06/2019 00:00,DB07048,"N-[(2R)-5-(aminosulfonyl)-2,3-dihydro-1H-inden-2-yl]-2-propylpentanamide",,,,,,solid,,,0.0237,10.19,0.61,[H][C@]1(CC2=C(C1)C=C(C=C2)S(N)(=O)=O)NC(=O)C(CCC)CCC,,,,,0,,338.1664137,2,1,0,0,0,0
5275,04/06/2019 00:00,DB07049,(2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(4-nitrophenyl)piperazine,,,,,,solid,,,0.00784,,-1.5,[H][C@@]1(C)CN(CCN1S(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,417.1722273,3,2,1,0,1,1
5276,04/06/2019 00:00,DB07050,"5-[(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide",,,,,,solid,,,0.438,6.4,-2.8,NS(=O)(=O)C1=NN=C(NS(=O)(=O)C2=CC=CC=C2)S1,,,,,0,,319.9707677,2,2,1,1,0,0
5277,04/06/2019 00:00,DB07051,"3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER",,,,,,solid,,,0.0355,,1.99,CCOC(=O)C1=C(C)N([NH+]=C1C)C1=CC=CC=C1,,,,,1,,245.1284542,2,2,1,1,0,0
5278,04/06/2019 00:00,DB07052,5'-S-ethyl-5'-thioadenosine,,,,,,solid,,,5,12.47,4.99,[H][C@]1(CSCC)O[C@@]([H])(N2C=NC3=C2N=CN=C3N)[C@]([H])(O)[C@]1([H])O,,,,,0,,311.1052104,3,2,3,2,1,1
5279,04/06/2019 00:00,DB07053,2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID,,,,,,solid,,,0.0122,3.96,-2.7,CCCC1=C2ON=C(C2=CC=C1OCCCOC1=CC2=C(C=C1)N(CC(O)=O)C=C2)C(F)(F)F,,,,,0,,476.1559065,4,4,2,2,0,0
5280,04/06/2019 00:00,DB07054,(2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL,,,,,,solid,,,0.0255,13.22,8.7,[H][C@](O)(COC1=CC=C(NC2=NC=NC(NC3=C(F)C=CC(=C3)C(F)(F)F)=C2)C=C1)CN(C)C,,,,,0,,465.1787879,3,3,1,1,0,0
5281,04/06/2019 00:00,DB07055,"2-[2-(1H-tetrazol-5-yl)ethyl]-1H-isoindole-1,3(2H)-dione",,,,,,solid,,,1.38,4.42,-1.2,O=C1N(CCC2=NN=NN2)C(=O)C2=CC=CC=C12,,,,,0,,243.0756245,3,2,2,1,0,1
5282,04/06/2019 00:00,DB07056,"2-(6-{[(3-chloro-2-methylphenyl)sulfonyl]amino}pyridin-2-yl)-N,N-diethylacetamide",,,,,,solid,,,0.0837,6.8,1.68,CCN(CC)C(=O)CC1=CC=CC(NS(=O)(=O)C2=C(C)C(Cl)=CC=C2)=N1,,,,,0,,395.1070402,2,2,1,1,0,0
5283,04/06/2019 00:00,DB07057,(3S)-1-(2-hydroxyphenyl)-5-oxopyrrolidine-3-carboxylic acid,,,,,,solid,,,15.8,3.82,-4.2,[H][C@]1(CN(C(=O)C1)C1=C(O)C=CC=C1)C(O)=O,,,,,0,,221.0688078,2,1,1,0,1,1
5284,04/06/2019 00:00,DB07058,"5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione",,,,,,solid,,,0.0196,6.47,4.94,COC1=CC=C(C=C1)N1C=NC2=C1C=C(C=C2)C1=NNC(=S)O1,,,,,0,,324.0680966,4,4,2,2,0,0
5285,04/06/2019 00:00,DB07059,"N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOXAZIN-4-YL]ETHYL}ACETAMIDE",,,,,,solid,,,0.232,15.18,7.77,CCC1=NC(N)=NC(N)=C1C1=CC2=C(OC(C)(C)C(=O)N2CCNC(C)=O)C=C1,,,,,0,,398.2066387,3,2,2,1,0,1
5286,04/06/2019 00:00,DB07060,3-(INDOL-3-YL) LACTATE,,,,,,solid,,,2.12,4.14,-3.9,[H][C@](O)(CC1=CNC2=C1C=CC=C2)C(O)=O,,,,,0,,205.0738932,2,2,1,1,0,0
5287,04/06/2019 00:00,DB07061,"1-(CYCLOHEXYLAMINO)-3-(6-METHYL-3,4-DIHYDRO-1H-CARBAZOL-9(2H)-YL)PROPAN-2-OL",,,,,,solid,,,0.00361,14.44,10.21,[H][C@](O)(CNC1CCCCC1)CN1C2=C(CCCC2)C2=C1C=CC(C)=C2,,,,,0,,340.2514636,4,2,1,1,0,0
5288,04/06/2019 00:00,DB07062,"N-{3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide",,,,,,solid,,,0.333,6.82,-3.1,CC(C)CCN1N2C=CC=C2C(O)=C(C1=O)C1=NC2=C(C=C(NS(C)(=O)=O)C=C2)S(=O)(=O)N1,,,,,0,,493.1089755,4,3,3,2,0,1
5289,04/06/2019 00:00,DB07063,"{3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID",,,,,,solid,,,0.011,4.22,1.45,OC(=O)CN1C=C(CC2=NC3=C(S2)C(F)=CC(F)=C3F)C2=C1C=CC=C2,,,,,0,,376.0493333,4,4,2,2,0,0
5290,04/06/2019 00:00,DB07064,"(4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE",,,,,,solid,,,0.101,9.44,-1.6,[H][C@@]1(CN(CC2=C1C=CC(C)=C2C)C(=O)N(C)C)C1=CC(O)=CC=C1,,,,,0,,324.183778,3,2,1,0,0,1
5291,04/06/2019 00:00,DB07065,"5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine",,,,,,solid,,,0.0076,,5.02,ClC1=C(Cl)C(=CC=C1)C1=NC2=C(SC#N)C=NN2C(NCC2=CC=NC=C2)=C1,,,,,0,,426.0221207,4,4,3,3,0,0
5292,04/06/2019 00:00,DB07066,"2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE",,,,,,solid,,,0.0056,9.29,-2,[H][C@]1(CC2=C(NC1=O)C=CC=C2)NC(=O)C1=CC2=C(N1)SC(Cl)=C2,,,,,0,,345.0338753,4,3,3,2,0,1
5293,04/06/2019 00:00,DB07067,"(2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE",,,,,,solid,,,0.271,19.22,7.53,[H][C@@](N)(C(=O)N1CCCC1)[C@]([H])(C)C1=NC(=NO1)C1=CC=C(C=C1)S(C)(=O)=O,,,,,0,,378.1361762,3,2,2,1,1,1
5294,04/06/2019 00:00,DB07068,"(4-{4-[(TERT-BUTOXYCARBONYL)AMINO]-2,2-BIS(ETHOXYCARBONYL)BUTYL}PHENYL)SULFAMIC ACID",,,,,,solid,,,0.0431,-1.4,-6.9,CCOC(=O)C(CCNC(=O)OC(C)(C)C)(CC1=CC=C(NS(O)(=O)=O)C=C1)C(=O)OCC,,,,,0,,488.1828516,1,1,0,0,0,0
5295,04/06/2019 00:00,DB07069,3-Hydroxyhippuric acid,,,,,,solid,,,2.91,3.25,-1.4,OC(=O)CNC(=O)C1=CC(O)=CC=C1,,,,,0,,195.0531578,1,1,0,0,0,0
5296,04/06/2019 00:00,DB07070,(2S)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid,,,,,,solid,,,0.00213,4.08,-1.9,[H][C@](CC)(CC1=CC(CNC(=O)C2=C(F)C=C(C=C2)C(F)(F)F)=C(OC)C=C1)C(O)=O,,,,,0,,427.140671,2,2,0,0,0,0
5297,04/06/2019 00:00,DB07071,"(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE",,,,,,solid,,,0.417,14.65,12.1,[H][C@@]1(CO)COB(O1)C1=CC=C(CCNC(N)=N)C=C1,,,,,0,,263.1441218,2,1,1,0,1,1
5298,04/06/2019 00:00,DB07072,"(1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE",,,,,,solid,,,0.0274,,9.87,[H][C@@]1(CC[C@]([H])(C2=C(F)C=C(F)C(F)=C2)[C@@]([H])(N)C1)N1CCN2C(C1)=NN=C2C(F)(F)F,,,,,0,,419.1544649,4,2,2,1,0,1
5299,04/06/2019 00:00,DB07073,"5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one",,,,,,solid,,,0.557,16.31,1.18,CC1(C)CC2=C(SC(=N2)N2CCOCC2)C(=O)C1,,,,,0,,266.1088988,3,1,2,1,1,1
5300,04/06/2019 00:00,DB07074,6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER,,,,,,solid,,,0.0174,9.16,11.28,COC(=O)C1=CC2=CC=C(C=C2C(NC(=O)C2=CC=CC(O)=C2C)=C1)C(N)=N,,,,,0,,377.1375561,3,3,0,0,0,0
5301,04/06/2019 00:00,DB07075,3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE,,,,,,solid,,,0.0116,13.02,10.28,NCC1CCN(CC2=CC3=C(NC(=C3)C3=NNC4=C3C=CC(=C4)C#N)C=C2)CC1,,,,,0,,384.2062448,5,4,3,2,1,1
5302,04/06/2019 00:00,DB07076,6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE,,,,,,solid,,,0.00168,11.79,11.12,NC(=N)C1=CC2=CC=C(C=C2C=C1)C(=O)NC1=CC=CC(OC2CCCC2)=C1,,,,,0,,373.179027,4,3,0,0,0,0
5303,04/06/2019 00:00,DB07077,"(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE",,,,,,solid,,,0.677,14.65,9.44,[H][C@@]1(CO)COB(O1)C1=CC=C(NC(N)=N)C=C1,,,,,0,,235.1128217,2,1,1,0,1,1
5304,04/06/2019 00:00,DB07078,"(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE",,,,,,solid,,,0.0458,9.82,-2.1,COC1=CC(=CC=C1O)C1=CC2=C(C=C1)\C(=C\C1=CC=CN1)C(=O)N2,,,,,0,,332.1160924,4,3,2,1,0,1
5305,04/06/2019 00:00,DB07079,3-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}propane-1-thiol,,,,,,solid,,,0.00897,10.19,-4.9,CC#CCOC1=CC=C(C=C1)S(=O)(=O)CCCS,,,,,0,,284.0540864,1,1,0,0,0,0
5306,04/06/2019 00:00,DB07080,"N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE",,,,,,solid,,,0.00867,7.45,-6.1,OC(C1=CC=C(C=C1)N(CC(F)(F)F)S(=O)(=O)C1=CC=CC=C1)(C(F)(F)F)C(F)(F)F,,,,,0,,481.0394182,2,2,0,0,0,0
5307,04/06/2019 00:00,DB07081,"(2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE",,,,,,solid,,,0.0279,,8.78,[H][C@](N)(CC(=O)N1CCN2N=C(N=C2[C@@]1([H])C)C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1,,,,,0,,421.1337295,3,2,2,1,0,1
5308,04/06/2019 00:00,DB07082,"1,1,1,3,3,3-HEXAFLUORO-2-{4-[(2,2,2-TRIFLUOROETHYL)AMINO]PHENYL}PROPAN-2-OL",,,,,,solid,,,0.0449,7.51,1.23,OC(C1=CC=C(NCC(F)(F)F)C=C1)(C(F)(F)F)C(F)(F)F,,,,,0,,341.0462179,1,1,0,0,0,0
5309,04/06/2019 00:00,DB07083,beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide,,,,,,solid,,,0.0127,15.59,7.66,[H][C@@](N)(C(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCCC,,,,,0,,379.2259772,3,2,1,0,1,1
5310,04/06/2019 00:00,DB07084,"N-(6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2-yl)acetamide",,,,,,solid,,,0.0188,14.48,-3.6,CC(=O)NC1=CC=C2OCCOCCOC3=C(OCCOCCOC2=C1)C=CC=C3,,,,,0,,417.1787522,3,2,1,0,0,1
5311,04/06/2019 00:00,DB07085,2-{[N-(2-ACETYL-5-CHLORO-4-FLUOROPHENYL)GLYCYL]AMINO}BENZOIC ACID,,,,,,solid,,,0.00543,3.56,0.28,CC(=O)C1=CC(F)=C(Cl)C=C1NCC(=O)NC1=CC=CC=C1C(O)=O,,,,,0,,364.0626128,2,2,0,0,0,0
5312,04/06/2019 00:00,DB07086,"4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,,,,,solid,,,0.113,9.47,-2.8,[H][C@@]12C[C@@](CO)(CO[C@]1([H])C1=CC=C(O)C=C1)CC=C2C,,,,,0,,260.1412445,3,1,1,0,1,1
5313,04/06/2019 00:00,DB07087,"4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,,,,,solid,,,0.0558,9.47,-2.8,[H][C@]1(C)CC[C@]2(CO)CO[C@]([H])(C3=CC=C(O)C=C3)[C@@]1([H])[C@@]2([H])C,,,,,0,,276.1725446,3,1,1,0,1,1
5314,04/06/2019 00:00,DB07088,(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide,,,,,,solid,,,0.18,15.21,11.48,[H][C@]1(CCCN1C(=O)COC1CCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,372.2161408,3,1,1,0,1,1
5315,04/06/2019 00:00,DB07089,N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide,,,,,,solid,,,0.000783,13.19,6.7,CCCOC1=CC=C(C=C1)C1=CSC(=C1CC(=O)NC(N)=N)C1=CC=CC=C1Cl,,,,,0,,427.1121256,3,3,1,1,0,0
5316,04/06/2019 00:00,DB07090,(3S)-N-(3-CHLORO-2-METHYLPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE,,,,,,solid,,,0.0406,13.81,-0.59,[H][C@]1(CN(C2CCCCC2)C(=O)C1)C(=O)NC1=C(C)C(Cl)=CC=C1,,,,,0,,334.1448057,3,1,1,0,1,1
5317,04/06/2019 00:00,DB07091,(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide,,,,,,solid,,,0.114,15.17,11.48,[H][C@]1(CCCN1C(=O)COC1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,386.2317908,3,1,1,0,1,1
5318,04/06/2019 00:00,DB07092,"(2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE",,,,,,solid,,,0.23,18.91,7.39,[H][C@@](N)(C(=O)N1CCC(F)(F)C1)[C@@]([H])(C(=O)N(C)C)[C@@]1([H])CC[C@@]([H])(CC1)C1=CN2N=CN=C2C=C1,,,,,0,,448.2398306,4,2,3,2,1,1
5319,04/06/2019 00:00,DB07093,"{3-[(5-CHLORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL}ACETIC ACID",,,,,,solid,,,0.0118,3.74,2.3,OC(=O)CN1C=CC(=O)N(CC2=NC3=CC(Cl)=CC=C3S2)C1=O,,,,,0,,351.0080545,3,3,2,2,0,0
5320,04/06/2019 00:00,DB07094,"1-(2,2'-bithiophen-5-yl)methanamine",,,,,,solid,,,0.137,,8.77,NCC1=CC=C(S1)C1=CC=CS1,,,,,0,,195.0176413,2,2,2,2,0,0
5321,04/06/2019 00:00,DB07095,(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide,,,,,,solid,,,0.0665,15.35,11.48,[H][C@]1(CCCN1C(=O)CCC1CCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,370.2368762,3,1,1,0,1,1
5322,04/06/2019 00:00,DB07096,"6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE",,,,,,solid,,,0.397,9.01,2.64,NC1=CC=C2C(=O)NC(=O)C3=CC=CC1=C23,,,,,0,,212.0585775,3,2,1,0,0,1
5323,04/06/2019 00:00,DB07097,"4-tert-butyl-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,,,,,solid,,,0.00228,6.44,0.38,CC(C)(C)C1=CC=C(C=C1)C(=O)N\N=C\C1=CC(Br)=C(O)C(Br)=C1O,,,,,0,,467.9684166,2,2,0,0,0,0
5324,04/06/2019 00:00,DB07098,"4-bromo-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,,,,,solid,,,0.00912,6.44,-0.21,OC1=C(Br)C=C(\C=N\NC(=O)C2=CC=C(Br)C=C2)C(O)=C1Br,,,,,0,,489.8163284,2,2,0,0,0,0
5325,04/06/2019 00:00,DB07099,N-[4-(benzyloxy)phenyl]glycinamide,,,,,,solid,,,0.0583,13.99,7.98,NCC(=O)NC1=CC=C(OCC2=CC=CC=C2)C=C1,,,,,0,,256.1211778,2,2,0,0,0,0
5326,04/06/2019 00:00,DB07100,"4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL",,,,,,solid,,,0.82,7.94,8.76,OC1=CC(O)=C(Cl)C=C1C1=C(C=NN1)N1CCNCC1,,,,,0,,294.0883534,3,2,2,1,1,1
5327,04/06/2019 00:00,DB07101,PD-0325901,,,,,,solid,,,0.0313,11.88,-3,[H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1,,,,,0,,481.9950396,2,2,0,0,0,0
5328,04/06/2019 00:00,DB07102,(2S)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acid,,,,,,solid,,,0.0094,1.86,9.31,[H][C@](N)(CCC(=O)NC1=CC=C(OCC2=CC=CC=C2)C=C1)C(O)=O,,,,,0,,328.1423071,2,2,0,0,0,0
5329,04/06/2019 00:00,DB07103,2-(4-METHYLPHENOXY)ETHYLPHOSPHINATE,,,,,,solid,,,1.67,2.2,-4.8,[H][P@]([O-])(=O)CCOC1=CC=C(C)C=C1,,,,,-1,,199.0529545,1,1,0,0,0,0
5330,04/06/2019 00:00,DB07104,4-amino-N-[4-(benzyloxy)phenyl]butanamide,,,,,,solid,,,0.0152,14.76,9.99,NCCCC(=O)NC1=CC=C(OCC2=CC=CC=C2)C=C1,,,,,0,,284.1524779,2,2,0,0,0,0
5331,04/06/2019 00:00,DB07105,2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE,,,,,,solid,,,0.019,11.79,10.18,[H][C@@](CC1=CC=C(NC(N)=N)C=C1)(NC(=O)CSC1=CC=C(Cl)C=C1)C(N)=O,,,,,0,,405.1026236,2,2,0,0,0,0
5332,04/06/2019 00:00,DB07106,4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE,,,,,,solid,,,1.5,,10.65,CN(C)CCCCSC(N)=N,,,,,0,,175.1143185,0,0,0,0,0,0
5333,04/06/2019 00:00,DB07107,(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE,,,,,,solid,,,0.000753,17.11,9.24,[H][C@@](N)(COC1=CN=CC(\C=C\C2=CC=NC=C2)=C1)CC1=CNC2=C1C=CC=C2,,,,,0,,370.1793613,4,4,3,3,0,0
5334,04/06/2019 00:00,DB07108,"4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID",,,,,,solid,,,0.0302,4.08,,OC(=O)C1=CC=C(C=C1)C1=CC=C(F)C=C1,,,,,0,,216.0586577,2,2,0,0,0,0
5335,04/06/2019 00:00,DB07109,(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid,,,,,,solid,,,0.871,3.77,-4.9,COC1=C(O)C=C(\C=C\C(O)=O)C=C1,,,,,0,,194.0579088,1,1,0,0,0,0
5336,04/06/2019 00:00,DB07110,4-(4-FLUOROBENZYL)PIPERIDINE,,,,,,solid,,,0.0256,,10.35,FC1=CC=C(CC2CCNCC2)C=C1,,,,,0,,193.1266777,2,1,1,0,1,1
5337,04/06/2019 00:00,DB07111,"(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid",,,,,,solid,,,0.00124,4.64,-2.9,[H][C@](O)(CCC(O)=O)\C=C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC,,,,,0,,344.2351449,0,0,0,0,0,0
5338,04/06/2019 00:00,DB07112,N-[(4-HYDROXY-8-IODOISOQUINOLIN-3-YL)CARBONYL]GLYCINE,,,,,,solid,,,0.132,2.67,0.99,OC(=O)CNC(=O)C1=C(O)C2=CC=CC(I)=C2C=N1,,,,,0,,371.9607048,2,2,1,1,0,0
5339,04/06/2019 00:00,DB07113,"(2S)-6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2-(3,5-DIFLUOROPHENYL)-4-(3-METHOXYPROPYL)-2H-1,4-BENZOXAZIN-3(4H)-ONE",,,,,,solid,,,0.0176,17.25,7.77,[H][C@]1(OC2=C(C=C(C=C2)C2=C(N)N=C(N)N=C2CC)N(CCCOC)C1=O)C1=CC(F)=CC(F)=C1,,,,,0,,469.1925461,4,3,2,1,0,1
5340,04/06/2019 00:00,DB07114,4-[(METHYLSULFONYL)AMINO]BENZOIC ACID,,,,,,solid,,,4.8,4.5,,CS(=O)(=O)NC1=CC=C(C=C1)C(O)=O,,,,,0,,215.0252288,1,1,0,0,0,0
5341,04/06/2019 00:00,DB07115,"N-(4-chlorobenzyl)-N-methylbenzene-1,4-disulfonamide",,,,,,solid,,,0.0437,9.7,,CN(CC1=CC=C(Cl)C=C1)S(=O)(=O)C1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,374.0161766,2,2,0,0,0,0
5342,04/06/2019 00:00,DB07116,1-(2-DEOXY-5-O-PHOSPHONO-BETA-D-ERYTHRO-PENTOFURANOSYL)-4-METHYL-1H-INDOLE,,,,,,solid,,,1.15,1.23,-3.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=CC2=C(C)C=CC=C12,,,,,0,,327.0871739,3,2,2,1,1,1
5343,04/06/2019 00:00,DB07117,"5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE",,,,,,solid,,,0.031,7.67,2.95,O=C1NC(=O)C(N2CCN(CC2)C2=NC=CC=N2)(C(=O)N1)C1=CC=C(OC2=CC=CC=C2)C=C1,,,,,0,,458.1702532,5,3,3,1,2,2
5344,04/06/2019 00:00,DB07118,Hymecromone,,,,,,solid,,,1.99,7.8,-7,CC1=CC(=O)OC2=C1C=CC(O)=C2,,,,,0,,176.0473441,2,2,1,1,0,0
5345,04/06/2019 00:00,DB07119,1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL,,,,,,solid,,,0.0063,7.78,-5.5,OC1=CC=C(C=C1)C1=CC=C2C(C=CC(O)=C2Cl)=C1,,,,,0,,270.0447573,3,3,0,0,0,0
5346,04/06/2019 00:00,DB07120,"N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE",,,,,,solid,,,0.292,15.36,9.01,NC(=N)NNC(=O)N(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,269.1276601,2,2,0,0,0,0
5347,04/06/2019 00:00,DB07121,"4-({4-[(4-AMINOBUT-2-YNYL)OXY]PHENYL}SULFONYL)-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE",,,,,,solid,,,0.035,8.45,9.06,[H][C@]1(N(CCSC1(C)C)S(=O)(=O)C1=CC=C(OCC#CCN)C=C1)C(=O)NO,,,,,0,,413.1079128,2,1,1,0,1,1
5348,04/06/2019 00:00,DB07122,1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine,,,,,,solid,,,0.095,16.49,10.27,NC(=N)NC1=CC=C(CC(=O)C2=CC=CC=C2)C=C1,,,,,0,,253.1215121,2,2,0,0,0,0
5349,04/06/2019 00:00,DB07123,N-(4-METHYLBENZOYL)-4-BENZYLPIPERIDINE,,,,,,solid,,,0.00314,,-0.024,CC1=CC=C(C=C1)C(=O)N1CCC(CC2=CC=CC=C2)CC1,,,,,0,,293.1779644,3,2,1,0,1,1
5350,04/06/2019 00:00,DB07124,"(2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE",,,,,,solid,,,0.0384,14.34,9.5,[H][C@@](N)(COC1=CN=CC(=C1)C1=NCC2=NN=CC2=C1)CC1=C2C=CCC=C2N=C1,,,,,0,,384.1698593,5,1,4,1,0,3
5351,04/06/2019 00:00,DB07125,"4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid",,,,,,solid,,,0.073,3.71,4.48,[H][C@@](CC)(CO)NC1=NN2C(C=C1)=NC=C2C1=CC=C(C=C1)C(O)=O,,,,,0,,326.1378904,3,3,2,2,0,0
5352,04/06/2019 00:00,DB07126,O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE,,,,,,solid,,,0.0189,8.94,2.37,NS(=O)(=O)C1=CC=C(NC2=NC(OCC3CCCCC3)=C3N=CNC3=N2)C=C1,,,,,0,,402.1474096,4,3,2,2,0,0
5353,04/06/2019 00:00,DB07127,"{4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID",,,,,,solid,,,0.0537,-1.6,-1,CC1=NC(=NO1)C(CC1=CC=CC=C1)(CC1=CC=C(NS(O)(=O)=O)C=C1)C1=NOC(C)=N1,,,,,0,,455.1263398,4,4,2,2,0,0
5354,04/06/2019 00:00,DB07128,"N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE",,,,,,solid,,,0.00648,10.59,0.97,CCCCNC1=CC(C)=NC2=NC(NC3=CC(Cl)=CC=C3C)=NN12,,,,,0,,344.1516224,3,3,2,2,0,0
5355,04/06/2019 00:00,DB07129,"(2R)-1-(2,6-dimethylphenoxy)propan-2-amine",,,,,,solid,,,0.538,,9.52,[H][C@](C)(N)COC1=C(C)C=CC=C1C,,,,,0,,179.1310142,1,1,0,0,0,0
5356,04/06/2019 00:00,DB07130,4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID,,,,,,solid,,,0.00606,3.09,-5,OC(=O)COC1=C(SC(=C1Br)C1=CC=CC=C1)C(O)=O,,,,,0,,355.9354065,2,2,1,1,0,0
5357,04/06/2019 00:00,DB07131,(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide,,,,,,solid,,,0.031,15.3,11.48,[H][C@]1(CCCN1C(=O)CCC1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N,,,,,0,,384.2525263,3,1,1,0,1,1
5358,04/06/2019 00:00,DB07132,1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA,,,,,,solid,,,0.0911,13.66,0.49,[H][C@](C)(C1=CC=CN1)C1=C2C=C(NC(N)=O)C=CC2=NC1=O,,,,,0,,282.1116757,3,2,2,1,0,1
5359,04/06/2019 00:00,DB07133,D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide,,,,,,solid,,,0.0119,15.45,7.7,[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(C)=CC=C1,,,,,0,,365.2103271,3,2,1,0,1,1
5360,04/06/2019 00:00,DB07134,"5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE",,,,,,solid,,,0.0309,3.78,-4.6,ClC1=C(SC=C1N1CC(=O)NS1(=O)=O)C1=CC=CC=C1,,,,,0,,327.9743118,3,2,2,1,1,1
5361,04/06/2019 00:00,DB07135,"(2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE",,,,,,solid,,,0.152,18.94,7.39,[H][C@@](N)(C(=O)N1CC[C@]([H])(F)C1)[C@@]([H])(C(=O)N(C)C)[C@@]1([H])CC[C@@]([H])(CC1)C1=CC=CC2=NC=NN12,,,,,0,,430.2492525,4,2,3,2,1,1
5362,04/06/2019 00:00,DB07136,(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(R)-HYDROXY[(1R)-2-METHYL-1-{[(3-PHENYLPROPYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID,,,,,,solid,,,0.122,1.52,9.43,[H][C@@](C[P@](O)(=O)[C@@]([H])(NS(=O)(=O)CCCC1=CC=CC=C1)C(C)C)(C(O)=O)C1=CC(CN)=CC=C1,,,,,0,,496.1796944,2,2,0,0,0,0
5363,04/06/2019 00:00,DB07137,(2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE,,,,,,solid,,,0.0387,8.56,4.31,[H][C@@](C)(C(=O)\N=C1/C=C(N=N1)C1CC1)C1=CC=C(C=C1)N1CCN=C1O,,,,,0,,337.1538748,4,1,2,0,0,2
5364,04/06/2019 00:00,DB07138,Neflamapimod,,,,,,solid,,,0.000559,,-3.2,FC1=CC(F)=C(SC2=NN3C=NC(=O)C(=C3C=C2)C2=C(Cl)C=CC=C2Cl)C=C1,,,,,0,,434.9811447,4,4,2,2,0,0
5365,04/06/2019 00:00,DB07139,3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid,,,,,,solid,,,0.00483,4.41,-8.3,OC(=O)CCC1=CC=C(S1)C1=CC(=CC=C1)[N+]([O-])=O,,,,,0,,277.0408788,2,2,1,1,0,0
5366,04/06/2019 00:00,DB07140,"5-[(3R)-3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,,,,,solid,,,0.00385,17.61,7.29,[H][C@](C)(C#CC1=C(C)N=C(N)N=C1N)C1=CC(OC)=CC(=C1)C1=CC=CC=C1,,,,,0,,358.1793613,3,3,1,1,0,0
5367,04/06/2019 00:00,DB07141,"5-[(3R)-3-(5-methoxy-4'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,,,,,solid,,,0.00269,17.61,7.29,[H][C@](C)(C#CC1=C(C)N=C(N)N=C1N)C1=CC(OC)=CC(=C1)C1=CC=C(C)C=C1,,,,,0,,372.1950114,3,3,1,1,0,0
5368,04/06/2019 00:00,DB07142,"5-[(3R)-3-(5-methoxy-3',5'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,,,,,solid,,,0.00213,17.61,7.29,[H][C@](C)(C#CC1=C(C)N=C(N)N=C1N)C1=CC(OC)=CC(=C1)C1=CC(C)=CC(C)=C1,,,,,0,,386.2106615,3,3,1,1,0,0
5369,04/06/2019 00:00,DB07143,D-phenylalanyl-N-benzyl-L-prolinamide,,,,,,solid,,,0.0307,15.39,7.7,[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=CC=C1,,,,,0,,351.194677,3,2,1,0,1,1
5370,04/06/2019 00:00,DB07144,"5-[(3R)-3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine",,,,,,solid,,,0.00217,17.61,7.29,[H][C@](C)(C#CC1=C(N)N=C(N)N=C1C)C1=CC(OC)=CC(=C1)C1=C(C)C=CC=C1C,,,,,0,,386.2106615,3,3,1,1,0,0
5371,04/06/2019 00:00,DB07145,(2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE,,,,,,solid,,,0.00414,8.72,5.02,[H][C@](C)(N1CC[C@](C)(C1=O)C1=CC=C(OCC2=CC(C)=NC3=CC=CC=C23)C=C1)C(=O)NO,,,,,0,,433.2001563,4,3,2,1,1,1
5372,04/06/2019 00:00,DB07146,"2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE",,,,,,solid,,,0.0341,,9.28,C(CN1CCNCC1)NC1=CC=NC2=C1C(=C(O2)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,398.2106615,5,4,3,2,1,1
5373,04/06/2019 00:00,DB07147,"methyl (1R,2S)-2-(hydroxycarbamoyl)-1-{4-[(2-methylquinolin-4-yl)methoxy]benzyl}cyclopropanecarboxylate",,,,,,solid,,,0.0023,8.86,5.02,[H][C@@]1(C[C@]1(CC1=CC=C(OCC2=CC(C)=NC3=C2C=CC=C3)C=C1)C(=O)OC)C(=O)NO,,,,,0,,420.1685219,4,3,1,1,0,0
5374,04/06/2019 00:00,DB07148,"(6S)-1-chloro-3-[(4-fluorobenzyl)oxy]-6-(pyrrolidin-1-ylcarbonyl)pyrrolo[1,2-a]pyrazin-4(6H)-one",,,,,,solid,,,0.0289,14.85,-4.3,[H][C@]1(C=CC2=C(Cl)N=C(OCC3=CC=C(F)C=C3)C(=O)N12)C(=O)N1CCCC1,,,,,0,,389.0942473,4,2,3,1,1,2
5375,04/06/2019 00:00,DB07149,"(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one",,,,,,solid,,,0.444,10.76,4.16,[H][C@]1(CCF)CNC(=O)C2=C1NC(=C2)C1=NC(N)=NC=C1,,,,,0,,275.1182383,3,2,3,2,0,1
5376,04/06/2019 00:00,DB07150,4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME,,,,,,solid,,,0.00429,8.59,2.9,O\N=C\C1=C2C=CC=CC2=C(C=C1)C1=CC=C(O)C=C1,,,,,0,,263.0946287,3,3,0,0,0,0
5377,04/06/2019 00:00,DB07151,4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one,,,,,,solid,,,0.0129,9,-2.1,CC1=CC(=CC=C1O)C1=NC(=O)N=C(C1)C1=CC=CC=C1,,,,,0,,278.1055277,3,2,1,0,0,1
5378,04/06/2019 00:00,DB07152,N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide,,,,,,solid,,,0.0211,9.48,1.67,CC(=O)NC1=NC(=C(N1)C1=CC=C2N=CC=NC2=C1)C1=NC(C)=C(F)C=C1,,,,,0,,362.1291373,4,4,3,3,0,0
5379,04/06/2019 00:00,DB07153,"6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine",,,,,,solid,,,0.0115,17.61,7.29,COC1=CC(=CC(OC)=C1OC)C(C)(C)C#CC1=C(C)N=C(N)N=C1N,,,,,0,,356.1848406,2,2,1,1,0,0
5380,04/06/2019 00:00,DB07154,"(3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE",,,,,,solid,,,0.244,12.92,8.78,[H][C@](N)(CC(=O)N1CCCNC(=O)[C@@]1([H])C)CC1=C(F)C=C(F)C(F)=C1,,,,,0,,343.1507615,2,1,1,0,1,1
5381,04/06/2019 00:00,DB07155,(3S)-1-CYCLOHEXYL-5-OXO-N-PHENYLPYRROLIDINE-3-CARBOXAMIDE,,,,,,solid,,,0.31,13.96,-0.59,[H][C@]1(CN(C2CCCCC2)C(=O)C1)C(=O)NC1=CC=CC=C1,,,,,0,,286.1681279,3,1,1,0,1,1
5382,04/06/2019 00:00,DB07156,"(4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione",,,,,,solid,,,0.00482,8.32,9.5,BrC1=CC=C2C(=O)NC(=O)\C(=C/NC3=CC=C(CN4CCCC4)C=C3)C2=C1,,,,,0,,425.073889,4,2,2,0,1,2
5383,04/06/2019 00:00,DB07157,"(5R,6S,8S)-8-[3-(AMINOMETHYL)PHENYL]-6-HYDROXY-5-ISOPROPYL-3-OXO-1-PHENYL-2,7-DIOXA-4-AZA-6-PHOSPHANONAN-9-OIC ACID 6-OXIDE",,,,,,solid,,,0.0552,1,9.46,[H][C@](NC(=O)OCC1=CC=CC=C1)(C(C)C)[P@@](O)(=O)O[C@]([H])(C(O)=O)C1=CC(CN)=CC=C1,,,,,0,,450.1555878,2,2,0,0,0,0
5384,04/06/2019 00:00,DB07158,"5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE",,,,,,solid,,,0.783,8.49,-0.35,CCN1C(=O)C2=C(NN=C2C)C2=C1C=CC=C2,,,,,0,,227.105862,3,3,2,2,0,0
5385,04/06/2019 00:00,DB07159,Tamatinib,,,,,,solid,,,0.0291,10.9,2.77,COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)NC4=N3)=N2)=CC(OC)=C1OC,,,,,0,,470.1713961,4,3,3,2,0,1
5386,04/06/2019 00:00,DB07160,"N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE",,,,,,solid,,,27.6,3.55,-4.3,[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)OCC)C(O)=O,,,,,0,,273.1212373,1,0,1,0,1,1
5387,04/06/2019 00:00,DB07161,5-phenyl-1H-indazol-3-amine,,,,,,solid,,,0.134,15.28,2.93,NC1=NNC2=CC=C(C=C12)C1=CC=CC=C1,,,,,0,,209.0952974,3,3,1,1,0,0
5388,04/06/2019 00:00,DB07162,4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide,,,,,,solid,,,0.00696,10.16,2.93,CC(C)(C)NS(=O)(=O)C1=CC=C(C=C1)C1=CC2=C(NN=C2N)C=C1,,,,,0,,344.1306969,3,3,1,1,0,0
5389,04/06/2019 00:00,DB07163,5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE,,,,,,solid,,,0.092,10.44,9.54,NCCNC1=CC(C2=CC=CN2)=C2C(=O)NC3=CC=C(F)C1=C23,,,,,0,,310.1229893,4,3,2,1,0,1
5390,04/06/2019 00:00,DB07164,"N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine",,,,,,solid,,,0.0402,15.1,3.06,C1CC1NC1=NC(=CC=N1)C1=C2C=CC=NN2N=C1,,,,,0,,252.1123444,4,3,3,3,0,0
5391,04/06/2019 00:00,DB07165,N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE,,,,,,solid,,,0.00589,12.18,6.17,[H][C@@]1(Cl)CN=C(NCCC2=NC=CC=C2)[C@]([H])(O)N1CC(=O)NCC1=CSC2=CC=C(Cl)C=C12,,,,,0,,491.0949513,4,3,3,2,0,1
5392,04/06/2019 00:00,DB07167,5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE,,,,,,solid,,,0.374,10.01,3.99,CC1CCN(CC1)C1=CC=C(CO)C=C1NC(=O)C1=CC=C(O1)C#N,,,,,0,,339.1582915,3,2,2,1,1,1
5393,04/06/2019 00:00,DB07168,[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile,,,,,,solid,,,0.0565,12.29,4.47,CNC1=NC(NC2=CC=C(CC#N)C=C2)=NC(NC2=NNC(=C2)C2CC2)=C1,,,,,0,,360.1810926,4,3,2,2,0,0
5394,04/06/2019 00:00,DB07169,"5R-(3,4-DICHLOROPHENYLMETHYL)-3-(2-THIOPHENESULFONYLAMINO)-4-OXO-2-THIONOTHIAZOLIDINE",,,,,,solid,,,0.00118,3.87,,[H][C@]1(CC2=CC=C(Cl)C(Cl)=C2)SC(=S)N(NS(=O)(=O)C2=CC=CS2)C1=O,,,,,0,,451.8951315,3,2,2,1,1,1
5395,04/06/2019 00:00,DB07170,"5'-FLUORO-2',5'-DIDEOXYADENOSINE",,,,,,solid,,,6.99,13.97,5,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CF)N1C=NC2=C1N=CN=C2N,,,,,0,,253.0975028,3,2,3,2,1,1
5396,04/06/2019 00:00,DB07171,"5-(2-hydroxyethyl)nonane-1,9-diol",,,,,,solid,,,1.99,16.84,-1.5,OCCCCC(CCO)CCCCO,,,,,0,,204.1725446,0,0,0,0,0,0
5397,04/06/2019 00:00,DB07172,"(5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid",,,,,,solid,,,0.00286,4.58,-1.5,[H][C@@](O)(CCCC(O)=O)\C=C\C=C/C\C=C/C\C=C/C\C=C/CC,,,,,0,,318.2194948,0,0,0,0,0,0
5398,04/06/2019 00:00,DB07173,"7-(5-DEOXY-BETA-D-RIBOFURANOSYL)-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE",,,,,,solid,,,2.55,12.48,6.56,[H][C@]1(C)O[C@@]([H])(N2C=C(I)C3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,376.0032383,3,2,3,2,1,1
5399,04/06/2019 00:00,DB07174,"6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-4-(3-METHOXYPROPYL)-2,2-DIMETHYL-2H-1,4-BENZOXAZIN-3(4H)-ONE",,,,,,solid,,,0.371,17.25,7.77,CCC1=C(C(N)=NC(N)=N1)C1=CC=C2OC(C)(C)C(=O)N(CCCOC)C2=C1,,,,,0,,385.2113897,3,2,2,1,0,1
5400,04/06/2019 00:00,DB07175,N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide,,,,,,solid,,,0.00762,10.21,4.02,CC1=CC=C(NC2=CC(=NC=N2)C2=CC=CC=C2)C=C1NS(C)(=O)=O,,,,,0,,354.1150468,3,3,1,1,0,0
5401,04/06/2019 00:00,DB07176,5-aminonaphthalene-1-sulfonic acid,,,,,,solid,,,1.14,-1.9,3.62,NC1=C2C=CC=C(C2=CC=C1)S(O)(=O)=O,,,,,0,,223.0303141,2,2,0,0,0,0
5402,04/06/2019 00:00,DB07177,"(5E,13E)-11-HYDROXY-9,15-DIOXOPROSTA-5,13-DIEN-1-OIC ACID",,,,,,solid,,,0.0583,4.3,-2.9,[H]C(CCCC(O)=O)=C([H])CC1C(\C([H])=C(/[H])C(=O)CCCCC)C(O)CC1=O,,,,,0,,350.2093241,1,0,0,0,0,0
5403,04/06/2019 00:00,DB07178,5-PENTYL-2-PHENOXYPHENOL,,,,,,solid,,,0.0109,8.53,-6.3,CCCCCC1=CC(O)=C(OC2=CC=CC=C2)C=C1,,,,,0,,256.1463299,2,2,0,0,0,0
5404,04/06/2019 00:00,DB07179,"3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide",,,,,,solid,,,0.00318,,1.91,CC1=C(C=CC=C1)C1=NC2=C(Br)C=NN2C(NCC2=C[N+]([O-])=CC=C2)=C1,,,,,0,,409.0538222,4,4,3,3,0,0
5405,04/06/2019 00:00,DB07180,"5-[(Z)-(5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-1H-pyrrole-3-carboxamide",,,,,,solid,,,0.022,11.27,-0.88,[H]N(C)C(=O)C1=C(C)N([H])C(\C=C2/C(=O)N([H])C3=C2C=C(Cl)C=C3)=C1C,,,,,0,,329.0931044,3,2,2,1,0,1
5406,04/06/2019 00:00,DB07181,"4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide",,,,,,solid,,,0.00117,14.64,9.51,[H][C@@](N)(CC1=CC(F)=CC=C1F)C1=CC=C(C=C1)C1=CC=CC(=C1)C(N)=O,,,,,0,,352.1387196,3,3,0,0,0,0
5407,04/06/2019 00:00,DB07182,(2S)-2-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-3-[(S)-HYDROXY(3-PHENYLPROPYL)PHOSPHORYL]PROPANOIC ACID,,,,,,solid,,,0.0166,1.9,10.28,[H][C@@](C[P@](O)(=O)CCCC1=CC=CC=C1)(C(O)=O)C1=CC(NC(N)=N)=CC=C1,,,,,0,,389.1504429,2,2,0,0,0,0
5408,04/06/2019 00:00,DB07183,N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide,,,,,,solid,,,0.00364,11.49,5.41,O=C(NC1=CC=C(OC2=CC=CC=C2)C=C1)C1=C(NCC2=CC=NC=C2)N=CC=C1,,,,,0,,396.1586259,4,4,2,2,0,0
5409,04/06/2019 00:00,DB07184,"6-(cyclohexylsulfanyl)-1-(ethoxymethyl)-5-(1-methylethyl)pyrimidine-2,4(1H,3H)-dione",,,,,,solid,,,0.137,9.88,-4,CCOCN1C(=O)NC(=O)C(C(C)C)=C1SC1CCCCC1,,,,,0,,326.1664137,2,1,1,1,0,0
5410,04/06/2019 00:00,DB07185,2-{[(4-CHLOROPHENOXY)ACETYL]AMINO}BENZOIC ACID,,,,,,solid,,,0.0137,3.56,-4.9,OC(=O)C1=C(NC(=O)COC2=CC=C(Cl)C=C2)C=CC=C1,,,,,0,,305.0454855,2,2,0,0,0,0
5411,04/06/2019 00:00,DB07186,"4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE",,,,,,solid,,,0.101,10.41,7.74,CN1CCN(CC1)C1=CC=C(C=C1)C(=O)NC1=NNC2=CN(C=C12)C(=O)CC1=CC=CS1,,,,,0,,448.168145,5,4,4,3,1,1
5412,04/06/2019 00:00,DB07187,6-[(5-CHLORO-3-METHYL-1-BENZOFURAN-2-YL)SULFONYL]PYRIDAZIN-3(2H)-ONE,,,,,,solid,,,0.0516,8.5,-4.7,CC1=C(OC2=CC=C(Cl)C=C12)S(=O)(=O)C1=NNC(=O)C=C1,,,,,0,,323.9971554,3,3,2,2,0,0
5413,04/06/2019 00:00,DB07188,"(3S)-1-CYCLOHEXYL-N-(3,5-DICHLOROPHENYL)-5-OXOPYRROLIDINE-3-CARBOXAMIDE",,,,,,solid,,,0.0178,13.36,-0.59,[H][C@]1(CN(C2CCCCC2)C(=O)C1)C(=O)NC1=CC(Cl)=CC(Cl)=C1,,,,,0,,354.0901832,3,1,1,0,1,1
5414,04/06/2019 00:00,DB07189,"(1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid",,,,,,solid,,,0.000513,4.09,3.46,[H][C@@]1(C[C@@]11C[C@]([H])(NC1=O)C1=CC=C(OCC2=CC(=NC3=C2C=CC=C3)C2=CC=CC=C2)C=C1)C(O)=O,,,,,0,,464.1736072,6,4,2,1,1,1
5415,04/06/2019 00:00,DB07190,3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide,,,,,,solid,,,0.00961,14.72,8.12,[H][C@@](N)(CC1CCCCC1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(Cl)=CC=C1,,,,,0,,391.2026549,3,1,1,0,1,1
5416,04/06/2019 00:00,DB07192,(3S)-N-(3-BROMOPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE,,,,,,solid,,,0.0539,13.69,-0.59,[H][C@]1(CN(C2CCCCC2)C(=O)C1)C(=O)NC1=CC=CC(Br)=C1,,,,,0,,364.07864,3,1,1,0,1,1
5417,04/06/2019 00:00,DB07193,"(2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine",,,,,,solid,,,0.0389,19.67,8.86,[H][C@]1(N)CN2C(C[C@]1([H])C1=C(F)C=C(F)C(F)=C1)=NC1=CC(=CC=C21)S(C)(=O)=O,,,,,0,,395.0915324,4,3,2,1,0,1
5418,04/06/2019 00:00,DB07194,"2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide",,,,,,solid,,,0.0037,13.12,0.86,[H][C@](C)(CO)NC(=O)C1=C(C)N=C(S1)C1=NC(NC2=CC(C)=CC(C)=C2)=NC=C1,,,,,0,,397.157246,3,3,2,2,0,0
5419,04/06/2019 00:00,DB07195,"4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,,,,,solid,,,0.0503,9.47,-2.8,[H][C@]1(C)C=C(C)[C@]2([H])[C@]([H])(C)[C@@]1(CO)CO[C@]2([H])C1=CC=C(O)C=C1,,,,,0,,288.1725446,3,1,1,0,1,1
5420,04/06/2019 00:00,DB07196,N-methyl-1-(2-thiophen-2-ylphenyl)methanamine,,,,,,solid,,,0.0322,,9.92,CNCC1=CC=CC=C1C1=CC=CS1,,,,,0,,203.0768704,2,2,1,1,0,0
5421,04/06/2019 00:00,DB07197,4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID,,,,,,solid,,,0.0124,2.98,-5,OC(=O)COC1=C(SC(=C1Br)C1=CC=C(O)C=C1)C(O)=O,,,,,0,,371.9303211,2,2,1,1,0,0
5422,04/06/2019 00:00,DB07198,5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE,,,,,,solid,,,0.263,7.9,-3.6,OC1=CC=C(C=C1)C1=CC2=C(O1)C(=CC(O)=C2)C#N,,,,,0,,251.0582431,3,3,1,1,0,0
5423,04/06/2019 00:00,DB07199,"(2S,4S,5R)-1-(4-TERT-BUTYLBENZOYL)-2-ISOBUTYL-5-(1,3-THIAZOL-2-YL)PYRROLIDINE-2,4-DICARBOXYLIC ACID",,,,,,solid,,,0.00345,3.61,2.07,[H][C@@]1(C[C@](CC(C)C)(N(C(=O)C2=CC=C(C=C2)C(C)(C)C)[C@@]1([H])C1=NC=CS1)C(O)=O)C(O)=O,,,,,0,,458.1875431,3,2,2,1,1,1
5424,04/06/2019 00:00,DB07200,"(2S,4S,5R)-2-ISOBUTYL-5-(2-THIENYL)-1-[4-(TRIFLUOROMETHYL)BENZOYL]PYRROLIDINE-2,4-DICARBOXYLIC ACID",,,,,,solid,,,0.00317,4.1,-0.6,[H][C@@]1(C[C@](CC(C)C)(N(C(=O)C2=CC=C(C=C2)C(F)(F)F)[C@@]1([H])C1=CC=CS1)C(O)=O)C(O)=O,,,,,0,,469.1170785,3,2,2,1,1,1
5425,04/06/2019 00:00,DB07201,(2S)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methylpropanoic acid,,,,,,solid,,,0.0145,4.25,3.39,[H][C@](C)(CON=C1C2=C(C=CC=C2)C2=C1C=CC=C2)C(O)=O,,,,,0,,281.1051933,3,2,0,0,0,0
5426,04/06/2019 00:00,DB07202,6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE,,,,,,solid,,,0.0291,12.77,0.55,CC1=NOC(=C1)C1=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,,,,,0,,336.0665553,4,4,2,2,0,0
5427,04/06/2019 00:00,DB07203,6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE,,,,,,solid,,,0.0096,9.88,2,ClC1=CC=CC(NC2=NC(OCC3CCCCC3)=C3NC=NC3=N2)=C1,,,,,0,,357.1356379,4,3,2,2,0,0
5428,04/06/2019 00:00,DB07204,"(1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE",,,,,,solid,,,0.00297,17.11,9.24,[H][C@@](N)(COC1=C2C=CC(=NC2=CN=C1)C1=CC=NC=C1)CC1=CNC2=C1C=CC=C2,,,,,0,,395.1746103,5,5,4,4,0,0
5429,04/06/2019 00:00,DB07205,N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,,,,,solid,,,1.74,1.23,4.85,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2N=CN=C3NCCC(C)C)[C@]([H])(O)[C@]1([H])O,,,,,0,,417.1413347,3,2,3,2,1,1
5430,04/06/2019 00:00,DB07206,6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE,,,,,,solid,,,0.0182,16.58,7.38,NC1=NC(CCC2=CC=C3C=CNC3=C2)=CC=C1,,,,,0,,237.1265975,3,3,2,2,0,0
5431,04/06/2019 00:00,DB07207,2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE,,,,,,solid,,,0.0324,6.85,11,NC(=N)C1=CC=C2NC(=NC2=C1)C1=NNC(=C1O)C1=CC=CC=C1,,,,,0,,318.1229091,4,4,2,2,0,0
5432,04/06/2019 00:00,DB07208,"(8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid",,,,,,solid,,,0.0273,4.49,-1.6,[H][C@](O)(C\C=C/CCCCC)\C=C\CC(=O)CCCCC(O)=O,,,,,0,,310.2144094,0,0,0,0,0,0
5433,04/06/2019 00:00,DB07209,"(8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid",,,,,,solid,,,0.0308,4.39,-2.9,[H][C@@](O)(CC(=O)CCCCC(O)=O)\C=C/C\C=C/CCCCC,,,,,0,,310.2144094,0,0,0,0,0,0
5434,04/06/2019 00:00,DB07210,"3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,,,,,solid,,,0.00781,,5.02,BrC1=C2N=C(C=C(NCC3=CC=NC=C3)N2N=C1)C1=CC=CC=C1,,,,,0,,379.0432575,4,4,3,3,0,0
5435,04/06/2019 00:00,DB07211,(2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE,,,,,,solid,,,0.0804,9.05,-3.1,C\C(=C/S(=O)(=O)N[C@@]1([H])CCN([C@](C)([H])C(=O)N2CCOCC2)C1=O)C1=CC=C(Cl)S1,,,,,0,,461.0845905,3,1,3,1,2,2
5436,04/06/2019 00:00,DB07212,N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE,,,,,,solid,,,0.0227,9.23,11.12,CC1=C(O)C=CC=C1C(=O)NC1=C2C=C(C=CC2=CC=C1)C(N)=N,,,,,0,,319.1320768,3,3,0,0,0,0
5437,04/06/2019 00:00,DB07213,"(5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL",,,,,,solid,,,0.018,9.7,9.07,OCC1=NNN=C1C1=CC2=C(C=C1)C(=NN2)C1=CC2=C(N1)C=CC(CN1CCCCC1)=C2,,,,,0,,427.2120584,6,5,4,3,1,1
5438,04/06/2019 00:00,DB07215,"2-METHYL-2-(4-{[({4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL}CARBONYL)AMINO]METHYL}PHENOXY)PROPANOIC ACID",,,,,,solid,,,0.000582,3.78,0.93,CC1=C(SC(=N1)C1=CC=C(C=C1)C(F)(F)F)C(=O)NCC1=CC=C(OC(C)(C)C(O)=O)C=C1,,,,,0,,478.1174128,3,3,1,1,0,0
5439,04/06/2019 00:00,DB07216,"(11S)-8-CHLORO-11-[1-(METHYLSULFONYL)PIPERIDIN-4-YL]-6-PIPERAZIN-1-YL-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE",,,,,,solid,,,0.0472,,9.23,[H][C@]1(C2CCN(CC2)S(C)(=O)=O)C2=C(C=C(Cl)C=C2)C(=CC2=C1N=CC=C2)N1CCNCC1,,,,,0,,472.1699748,5,2,3,1,2,2
5440,04/06/2019 00:00,DB07217,"N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide",,,,,,solid,,,0.00309,7.76,-5,FC1=CC=CC=C1C(=O)NC1=C(C#N)C2=C(CCCC2)S1,,,,,0,,300.0732623,3,2,1,1,0,0
5441,04/06/2019 00:00,DB07218,"6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE",,,,,,solid,,,1.48,13.37,0.21,CN1N=C(C)C2=C1N(O)C1=C(C=C(Cl)C=C1)C2=O,,,,,0,,263.0461542,3,3,2,2,0,0
5442,04/06/2019 00:00,DB07219,"BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE",,,,,,solid,,,0.1,12.15,-3.3,[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCCC)C(=O)N1CCC[C@@]1([H])C(=O)OCC1=CC=CC=C1,,,,,0,,473.2525858,3,1,2,0,2,2
5443,04/06/2019 00:00,DB07220,"N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE",,,,,,solid,,,0.0987,11.5,5.43,O=C(CC1=CC=C(C=C1)N1CCCCC1)NC1=NNC2=C1C=C(C=C2)N1CCCS1(=O)=O,,,,,0,,453.1834607,5,3,3,1,2,2
5444,04/06/2019 00:00,DB07221,"(2,2-DIPHOSPHONOETHYL)(DODECYL)DIMETHYLPHOSPHONIUM",,,,,,solid,,,0.114,1.15,,CCCCCCCCCCCC[P+](C)(C)CC(P(O)(O)=O)P(O)(O)=O,,,,,1,,419.1875752,0,0,0,0,0,0
5445,04/06/2019 00:00,DB07222,(3S)-N-(5-CHLORO-2-METHYLPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE,,,,,,solid,,,0.0441,13.75,-0.59,[H][C@]1(CN(C2CCCCC2)C(=O)C1)C(=O)NC1=C(C)C=CC(Cl)=C1,,,,,0,,334.1448057,3,1,1,0,1,1
5446,04/06/2019 00:00,DB07223,"METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE",,,,,,solid,,,2.9,12.2,-3.3,[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCCC)C(=O)N1CCC[C@@]1([H])C(=O)OC,,,,,0,,397.2212857,2,0,2,0,2,2
5447,04/06/2019 00:00,DB07224,"N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE",,,,,,solid,,,5.49,3.8,-3.6,[H][C@@](C)(NC(=O)[C@@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)OCC)[C@@]([H])(C)CC)C(O)=O,,,,,0,,344.1583511,1,0,1,0,1,1
5448,04/06/2019 00:00,DB07225,"N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE",,,,,,solid,,,1.83,3.97,-3.1,[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)OCC)[C@@]([H])(C)CC)C(O)=O,,,,,0,,386.2053013,1,0,1,0,1,1
5449,04/06/2019 00:00,DB07226,"N-[4-(2-CHLOROPHENYL)-1,3-DIOXO-1,2,3,6-TETRAHYDROPYRROLO[3,4-C]CARBAZOL-9-YL]FORMAMIDE",,,,,,solid,,,0.00665,8.11,-4.5,ClC1=CC=CC=C1C1=CC2=C(C3=C(N2)C=CC(NC=O)=C3)C2=C1C(=O)NC2=O,,,,,0,,389.0567189,5,4,2,1,0,1
5450,04/06/2019 00:00,DB07227,4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE,,,,,,solid,,,0.17,17.53,6.42,ClC1=CC=CC(=C1)N1CCN(CC2=CN=CN2CC2=CC=C(C=C2)C#N)CC1=O,,,,,0,,405.1356379,4,3,2,1,1,1
5451,04/06/2019 00:00,DB07228,1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA,,,,,,solid,,,0.0166,10.31,8.77,[H][C@](C)(CN(C)C)OC1=CN=CC(NC(=O)NC2=C(OC)C=CC(Cl)=C2)=N1,,,,,0,,379.1411172,2,2,1,1,0,0
5452,04/06/2019 00:00,DB07229,"3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-5-METHOXY-1,1'-BIPHENYL-2-OLATE",,,,,,solid,,,0.000278,9.35,11.22,COC1=CC(=C([O-])C(=C1)C1=CC2=CC(=CC=C2N1)C(N)=[NH2+])C1=CC=CC=C1,,,,,0,,357.1477268,4,4,1,1,0,0
5453,04/06/2019 00:00,DB07230,3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE,,,,,,solid,,,0.0266,8.45,-6,OC1=CC=C(C=C1)C1=C(Br)C2=C(C=C(O)C=C2)C1=O,,,,,0,,315.9735062,3,2,0,0,0,0
5454,04/06/2019 00:00,DB07231,"N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE",,,,,,solid,,,0.484,3.81,-3.3,[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(O)=O,,,,,0,,431.2056356,3,1,2,0,2,2
5455,04/06/2019 00:00,DB07232,Veliparib,,,,,,solid,,,0.275,9.21,8.97,C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1,,,,,0,,244.1324111,3,2,2,1,1,1
5456,04/06/2019 00:00,DB07233,N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan,,,,,,solid,,,0.00229,3.27,-4.9,[H][C@](CC1=CNC2=C1C=C(C)C=C2)(NS(=O)(=O)C1=CC=C(OCC#CC)C=C1)C(O)=O,,,,,0,,426.1249428,3,3,1,1,0,0
5457,04/06/2019 00:00,DB07234,"3-{[(1R)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione",,,,,,solid,,,0.0669,10.93,5.88,[H][C@](C)(NC1=C(NC2=CC=NC=C2)C(=O)C1=O)C1=CC=CC=C1,,,,,0,,293.1164267,3,3,1,1,0,0
5458,04/06/2019 00:00,DB07235,"N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE",,,,,,solid,,,0.00129,14.17,9.02,[H][C@@](CN)(CC1=C(Cl)C=C(Cl)C=C1)NC(=O)C1=CC=C(S1)C1=CC=NC(NC)=N1,,,,,0,,435.0687366,3,3,2,2,0,0
5459,04/06/2019 00:00,DB07236,3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL,,,,,,solid,,,0.0689,8.9,-0.67,OC1=CC2=C(C=C1)C(=NO2)C1=CC2=C(C=C1)C=C(O)C=C2,,,,,0,,277.0738932,4,4,1,1,0,0
5460,04/06/2019 00:00,DB07237,{4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanone,,,,,,solid,,,0.00064,,10.38,[H][C@]1(COC2=CC=C(C=C2)C(=O)C2=CC=C(C=C2)C2=CSC=C2)CCCN1,,,,,0,,363.1292999,4,3,2,1,1,1
5461,04/06/2019 00:00,DB07238,Nesbuvir,,,,,,solid,,,0.0631,15.34,-1.7,CNC(=O)C1=C(OC2=CC(N(CCO)S(C)(=O)=O)=C(C=C12)C1CC1)C1=CC=C(F)C=C1,,,,,0,,446.1311711,4,3,1,1,0,0
5462,04/06/2019 00:00,DB07239,7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile,,,,,,solid,,,0.0716,,9.73,CN1C=NC2=CC(C#N)=C(C(CN)=C12)C1=C(Cl)C=CC=C1,,,,,0,,296.0828741,3,3,1,1,0,0
5463,04/06/2019 00:00,DB07240,3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid,,,,,,solid,,,0.0197,4.23,3.34,OC(=O)CCON=C1C2=C(C=CC=C2)C2=C1C=CC=C2,,,,,0,,267.0895433,3,2,0,0,0,0
5464,04/06/2019 00:00,DB07241,"7-carboxy-5-hydroxy-12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazole",,,,,,solid,,,0.00959,3.59,-8.8,OC(=O)C1=C2C(=C(O)N1)C1=C(NC3=C1C=CC=C3)C1=C2C2=C(N1)C=CC=C2,,,,,0,,355.0956913,6,6,3,3,0,0
5465,04/06/2019 00:00,DB07242,"(4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile",,,,,,solid,,,0.107,11.74,8.35,[H][C@@]1(C#N)C2=C(N(C)C3=C(Cl)C(Cl)=CC=C23)C(=O)NC11CCN(C)CC1,,,,,0,,376.0857666,4,2,3,1,1,2
5466,04/06/2019 00:00,DB07243,"(3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE",,,,,,solid,,,0.983,11.64,9.33,[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C1=CNC3=C1C=CC=N3)N2C,,,,,0,,285.1477268,4,2,4,2,2,2
5467,04/06/2019 00:00,DB07244,"5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE",,,,,,solid,,,0.0074,17.36,7.79,CCC1=C(C(N)=NC(N)=N1)C1=CC=C(NCC2=CC(F)=CC(F)=C2)C=C1,,,,,0,,355.160852,3,3,1,1,0,0
5468,04/06/2019 00:00,DB07245,6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE,,,,,,solid,,,0.00205,,7.38,COC1=CC=CC(=C1)C1=CC(CCC2=CC=CC(N)=N2)=CC=C1,,,,,0,,304.1575633,3,3,1,1,0,0
5469,04/06/2019 00:00,DB07246,"(2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE",,,,,,solid,,,0.0258,8.6,1.86,N[C@](CS(=O)(=O)C1=CC=C(OC2=CC=CC=C2)C=C1)(C(=O)NO)C(F)(F)F,,,,,0,,404.0653772,2,2,0,0,0,0
5470,04/06/2019 00:00,DB07247,"[2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA",,,,,,solid,,,0.0056,9.42,8.22,NC(=O)NCC1=CC(=CC=C1)C1=C(O)C(=CC=C1)C1=CC2=C(N1)C=CN=C2,,,,,0,,358.1429758,4,4,2,2,0,0
5471,04/06/2019 00:00,DB07248,"7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE",,,,,,solid,,,0.0488,13.24,6.22,COC1=CC(NC2=NC=C3C=CN(C3=N2)C2=CC=CC=N2)=CC(OC)=C1OC,,,,,0,,377.1487895,4,4,3,3,0,0
5472,04/06/2019 00:00,DB07249,"N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine",,,,,,solid,,,0.0199,12.85,9.03,COC1=C(OCCCN2CCCCC2)C=C2N=CN=C(NC3=C(Cl)C=CC4=C3OCO4)C2=C1,,,,,0,,470.172083,5,3,3,1,1,2
5473,04/06/2019 00:00,DB07250,"N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE",,,,,,solid,,,0.0529,12.63,5.03,COC1=CC(NC2=NC(NC3=C(Cl)C=CC4=C3OCO4)=CC=N2)=CC(OC)=C1OC,,,,,0,,430.1043974,4,3,2,1,0,1
5474,04/06/2019 00:00,DB07251,"N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE",,,,,,solid,,,0.026,12.28,3.3,COC1=CC(NC2=NC=NC(NC3=CC(Cl)=C(OC)C=C3)=N2)=CC(OC)=C1OC,,,,,0,,417.1203818,3,3,1,1,0,0
5475,04/06/2019 00:00,DB07252,"3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide",,,,,,solid,,,0.0267,10.23,5.03,NS(=O)(=O)C1=CC(NC2=NC(NC3=C(Cl)C=CC4=C3OCO4)=CC=N2)=CC=C1,,,,,0,,419.0455026,4,3,2,1,0,1
5476,04/06/2019 00:00,DB07253,"N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine",,,,,,solid,,,0.0222,12.3,5.03,CS(=O)(=O)C1=CC(NC2=NC(NC3=C(Cl)C=CC4=C3OCO4)=CC=N2)=CC=C1,,,,,0,,418.0502536,4,3,2,1,0,1
5477,04/06/2019 00:00,DB07254,"N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE",,,,,,solid,,,0.0402,9.9,5.03,CS(=O)(=O)NC1=CC(NC2=NC(NC3=C(Cl)C=CC4=C3OCO4)=CC=N2)=CC=C1,,,,,0,,433.0611527,4,3,2,1,0,1
5478,04/06/2019 00:00,DB07255,"N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE",,,,,,solid,,,0.0377,12.71,5.03,ClC1=C(NC2=NC(NC3=CC(=CC=C3)N3CCOCC3)=NC=C2)C2=C(OCO2)C=C1,,,,,0,,425.1254672,5,3,3,1,1,2
5479,04/06/2019 00:00,DB07256,"3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE",,,,,,solid,,,0.0297,12.5,5.03,NC(=O)C1=CC(NC2=NC(NC3=C(Cl)C=CC4=C3OCO4)=CC=N2)=CC=C1,,,,,0,,383.078517,4,3,2,1,0,1
5480,04/06/2019 00:00,DB07257,"4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2H,6H)-dione",,,,,,solid,,,0.0168,8.06,-2.5,CN1C=C(CCO)C2=C1C=C(C1=C2C(=O)NC1=O)C1=CC=CC=C1Cl,,,,,0,,354.07712,4,3,2,1,0,1
5481,04/06/2019 00:00,DB07258,(R)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol,,,,,,solid,,,0.682,13.6,8.97,[H][C@](O)(C1=CC=NC=C1)C1=CC=C(OCCN2CCCC2)C=C1,,,,,0,,298.1681279,3,2,2,1,1,1
5482,04/06/2019 00:00,DB07259,1-(4-thiophen-2-ylphenyl)methanamine,,,,,,solid,,,0.0882,,9.44,NCC1=CC=C(C=C1)C1=CC=CS1,,,,,0,,189.0612204,2,2,1,1,0,0
5483,04/06/2019 00:00,DB07260,N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline,,,,,,solid,,,0.0126,,10.56,[H][C@]1(COC2=CC=C(NCC3=CC=CC=C3)C=C2)CCCN1,,,,,0,,282.1732133,3,2,1,0,1,1
5484,04/06/2019 00:00,DB07261,"THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [1-(1-AMINO-ISOQUINOLIN-7-YLMETHYL)-2-OXO-PYRROLDIN-3-YL]-AMIDE",,,,,,solid,,,0.0293,8.65,7.08,[H][C@@]1(CCN(CC2=CC3=C(C=CN=C3N)C=C2)C1=O)NS(=O)(=O)C1=CC2=C(S1)C=CC=N2,,,,,0,,453.0929315,5,4,4,3,1,1
5485,04/06/2019 00:00,DB07262,1-{[N-(1-IMINO-GUANIDINO-METHYL)]SULFANYLMETHYL}-3-TRIFLUOROMETHYL-BENZENE,,,,,,solid,,,0.0226,,10.03,NC(=N)NC(=N)SCC1=CC=CC(=C1)C(F)(F)F,,,,,0,,276.065652,1,1,0,0,0,0
5486,04/06/2019 00:00,DB07263,"[{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid",,,,,,solid,,,0.000507,0.49,-7.6,[H][C@](CC1=CC(Br)=C(C=C1)C(F)(F)P(O)(O)=O)(C(=O)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,494.0094142,3,3,0,0,0,0
5487,04/06/2019 00:00,DB07264,(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE,,,,,,solid,,,0.00208,11.54,1.63,[H][C@](CO)(NC(=O)C1=CC(=CN1)C1=NNC=C1C1=CC=CC(Cl)=C1)C1=CC(Cl)=C(F)C=C1,,,,,0,,458.0712594,4,4,2,2,0,0
5488,04/06/2019 00:00,DB07265,"3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID",,,,,,solid,,,0.0172,4.07,-5.6,OC(=O)CCN1C2=C(C=C(O)C=C2)C2=C1C=C(C1=C2C(=O)NC1=O)C1=CC=CC=C1,,,,,0,,400.1059216,5,4,2,1,0,1
5489,04/06/2019 00:00,DB07266,"8-ethyl-3,10,10-trimethyl-4,5,6,8,10,12-hexahydropyrazolo[4',3':6,7]cyclohepta[1,2-b]pyrrolo[2,3-f]indol-9(1H)-one",,,,,,solid,,,0.0275,14.98,2.87,CCN1C(=O)C(C)(C)C2=CC3=C(C=C12)C1=C(N3)C2=C(CCC1)C(C)=NN2,,,,,0,,348.1950114,5,3,3,2,0,1
5490,04/06/2019 00:00,DB07267,2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine,,,,,,solid,,,0.0129,15.03,7.68,CC1=CC=CC(=N1)C1=NC(NC2=CC=NC=C2)=C2C=CC=CC2=N1,,,,,0,,313.1327455,4,4,3,3,0,0
5491,04/06/2019 00:00,DB07268,2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE,,,,,,solid,,,0.0726,9.63,5.12,NC(=O)C1=CC=CC=C1NC1=NC(NC2=CC(O)=CC=C2)=NC=C1,,,,,0,,321.1225747,3,3,1,1,0,0
5492,04/06/2019 00:00,DB07269,(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-[(1R)-1-{[(BENZYLOXY)CARBONYL]AMINO}-2-METHYLPROPYL](HYDROXY)PHOSPHORYL]PROPANOIC ACID,,,,,,solid,,,0.0227,1.53,9.49,[H][C@@](C[P@](O)(=O)[C@@]([H])(NC(=O)OCC1=CC=CC=C1)C(C)C)(C(O)=O)C1=CC(CN)=CC=C1,,,,,0,,448.1763233,2,2,0,0,0,0
5493,04/06/2019 00:00,DB07270,"N-[7-(3-AMINOPHENYL)-5-METHOXY-1,3-BENZOXAZOL-2-YL]-2,5-DICHLOROBENZENESULFONAMIDE",,,,,,solid,,,0.0124,6.58,3.64,COC1=CC2=C(OC(NS(=O)(=O)C3=CC(Cl)=CC=C3Cl)=N2)C(=C1)C1=CC(N)=CC=C1,,,,,0,,463.0160323,4,4,1,1,0,0
5494,04/06/2019 00:00,DB07271,"4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one",,,,,,solid,,,0.0485,12.58,8.78,N[C@@H](CC(=O)N1CCCNC(=O)C1CC(F)(F)F)CC1=C(F)C=C(F)C(F)=C1,,,,,0,,411.1381462,2,1,1,0,1,1
5495,04/06/2019 00:00,DB07272,"N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE",,,,,,solid,,,0.02,11.85,2.41,CCOC1=NC(NC(=O)CC2=CC(OC)=C(Br)C=C2OC)=CC(N)=C1C#N,,,,,0,,434.0589672,2,2,1,1,0,0
5496,04/06/2019 00:00,DB07273,1-[(2-AMINO-4-CHLORO-5-METHYLPHENYL)SULFONYL]-L-PROLINE,,,,,,solid,,,1.51,3.22,1.13,[H][C@]1(CCCN1S(=O)(=O)C1=C(N)C=C(Cl)C(C)=C1)C(O)=O,,,,,0,,318.0441056,2,1,1,0,1,1
5497,04/06/2019 00:00,DB07274,"N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide",,,,,,solid,,,0.0018,15.5,5.89,COC1=C(OC)C=C2C(OC3=CC4=CC=CC(C(=O)NC5CC5)=C4C=C3)=CC=NC2=C1,,,,,0,,414.1579572,5,4,1,1,0,0
5498,04/06/2019 00:00,DB07275,"3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)quinolin-2(1H)-one",,,,,,solid,,,0.0392,6.46,0.84,CC(C)CCN1C(=O)C(C2=NS(=O)(=O)C3=CC=CC=C3N2)=C(O)C2=CC=CC=C12,,,,,0,,411.1252772,4,3,2,1,0,1
5499,04/06/2019 00:00,DB07276,"5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE",,,,,,solid,,,0.0265,13.95,-3.1,CCOC1=NC(=CC=C1C#N)C(=O)NCC1=CC(OC)=CC=C1OC,,,,,0,,341.1375561,2,2,1,1,0,0
5500,04/06/2019 00:00,DB07277,2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE,,,,,,solid,,,0.291,9.22,-3.1,[H][C@@](C)(N1CC[C@]([H])(NS(=O)(=O)CCC2=CC=C(Cl)S2)C1=O)C(=O)N1CCOCC1,,,,,0,,449.0845905,3,1,3,1,2,2
5501,04/06/2019 00:00,DB07278,2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE,,,,,,solid,,,0.122,9.18,-3.1,O=C([C@@](C)([H])N1CC[C@]([H])(NS(=O)(=O)\C=C\C2=CC=C(Cl)S2)C1=O)N1CCOCC1,,,,,0,,447.0689405,3,1,3,1,2,2
5502,04/06/2019 00:00,DB07279,N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE,,,,,,solid,,,0.0664,,8.79,[H][C@](C)(COC1=CC(=CC(C)=C1)C(=O)N(CC)C(C)C)NC1=CC=NC=C1,,,,,0,,355.2259772,2,2,1,1,0,0
5503,04/06/2019 00:00,DB07280,5-[4-(DIMETHYLAMINO)PHENYL]-6-[(6-MORPHOLIN-4-YLPYRIDIN-3-YL)ETHYNYL]PYRIMIDIN-4-AMINE,,,,,,solid,,,0.0176,,4.56,CN(C)C1=CC=C(C=C1)C1=C(N=CN=C1N)C#CC1=CC=C(N=C1)N1CCOCC1,,,,,0,,400.2011594,4,3,3,2,1,1
5504,04/06/2019 00:00,DB07281,"N~3~-BENZYLPYRIDINE-2,3-DIAMINE",,,,,,solid,,,0.656,,7.12,NC1=NC=CC=C1NCC1=CC=CC=C1,,,,,0,,199.1109474,2,2,1,1,0,0
5505,04/06/2019 00:00,DB07282,3-({[(1Z)-(2-methoxyphenyl)methylidene]amino}oxy)propanoic acid,,,,,,solid,,,0.256,3.73,2.8,COC1=CC=CC=C1\C=N/OCCC(O)=O,,,,,0,,223.0844579,1,1,0,0,0,0
5506,04/06/2019 00:00,DB07283,"9-benzyl-2,3,4,9-tetrahydro-1H-carbazole-8-carboxylic acid",,,,,,solid,,,0.00529,3.09,,OC(=O)C1=C2N(CC3=CC=CC=C3)C3=C(CCCC3)C2=CC=C1,,,,,0,,305.1415788,4,3,1,1,0,0
5507,04/06/2019 00:00,DB07284,"N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE",,,,,,solid,,,0.028,,7.12,NC1=NC=CC=C1NCC1=CC=CC(=C1)C1=CN=CC=C1,,,,,0,,276.1374965,3,3,2,2,0,0
5508,04/06/2019 00:00,DB07285,"(3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID",,,,,,solid,,,1.47,3.46,-4.8,[H][C@@](CC(O)=O)(C(F)F)S(=O)(=O)C1=CC=C(OC)C=C1,,,,,0,,294.0373509,1,1,0,0,0,0
5509,04/06/2019 00:00,DB07286,BMS-564929,,,,,,solid,,,1.09,12.27,-3.1,[H][C@@]1(O)CCN2C(=O)N(C(=O)[C@]12[H])C1=C(C)C(Cl)=C(C=C1)C#N,,,,,0,,305.0567189,3,1,2,0,2,2
5510,04/06/2019 00:00,DB07287,"2-(2,4-DICHLOROPHENOXY)-5-(PYRIDIN-2-YLMETHYL)PHENOL",,,,,,solid,,,0.00524,8.41,4.86,OC1=CC(CC2=CC=CC=N2)=CC=C1OC1=CC=C(Cl)C=C1Cl,,,,,0,,345.032334,3,3,1,1,0,0
5511,04/06/2019 00:00,DB07288,N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide,,,,,,solid,,,0.00491,11.88,5.02,ClC1=CC=C(NC(=O)C2=C(NCC3=CC=NC=C3)C=CC=C2)C=C1,,,,,0,,337.0981898,3,3,1,1,0,0
5512,04/06/2019 00:00,DB07289,5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID,,,,,,solid,,,0.000868,2.93,3.58,OC(=O)COC1=C(SC(=C1Br)C1=CC=CC(NCC2=CC=CC=C2)=C1)C(O)=O,,,,,0,,460.9932557,3,3,1,1,0,0
5513,04/06/2019 00:00,DB07290,(2R)-2-{[(4-FLUORO-3-METHYLPHENYL)SULFONYL]AMINO}-N-HYDROXY-2-TETRAHYDRO-2H-PYRAN-4-YLACETAMIDE,,,,,,solid,,,1.16,8.68,-4.1,[H][C@@](NS(=O)(=O)C1=CC(C)=C(F)C=C1)(C1CCOCC1)C(=O)NO,,,,,0,,346.0998709,2,1,1,0,1,1
5514,04/06/2019 00:00,DB07291,5-amino-1-(4-chlorophenyl)-1H-pyrazole-4-carbonitrile,,,,,,solid,,,0.363,,2.03,NC1=C(C=NN1C1=CC=C(Cl)C=C1)C#N,,,,,0,,218.0359239,2,2,1,1,0,0
5515,04/06/2019 00:00,DB07292,"4-(2-amino-1,3-thiazol-4-yl)phenol",,,,,,solid,,,1.36,9.46,4.08,NC1=NC(=CS1)C1=CC=C(O)C=C1,,,,,0,,192.0357339,2,2,1,1,0,0
5516,04/06/2019 00:00,DB07293,benzyl (2-oxopropyl)carbamate,,,,,,solid,,,0.398,13.78,-7.6,CC(=O)CNC(=O)OCC1=CC=CC=C1,,,,,0,,207.0895433,1,1,0,0,0,0
5517,04/06/2019 00:00,DB07294,"3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid",,,,,,solid,,,0.00116,3.87,-3.9,CC1(C)CCC(C)(C)C2=C1C=CC(=C2)[C@H](O)C(=O)NC1=C(F)C=C(C=C1)C(O)=O,,,,,0,,399.1845865,3,2,0,0,0,0
5518,04/06/2019 00:00,DB07295,2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID,,,,,,solid,,,0.0439,2.36,-5.5,OC(=O)C(=O)N(C1=CC=CC=C1C(O)=O)C1=CC=CC2=CC=C(O)C=C12,,,,,0,,351.0742871,3,3,0,0,0,0
5519,04/06/2019 00:00,DB07296,(5Z)-3-(4-CHLOROPHENYL)-4-HYDROXY-5-(1-NAPHTHYLMETHYLENE)FURAN-2(5H)-ONE,,,,,,solid,,,0.000348,6.76,-6.4,OC1=C(C(=O)O\C1=C/C1=CC=CC2=CC=CC=C12)C1=CC=C(Cl)C=C1,,,,,0,,348.055322,4,3,1,0,0,1
5520,04/06/2019 00:00,DB07297,"5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE",,,,,,solid,,,0.0636,17.79,9.25,C(CN1CCNCC1)NC1=C2C(OC(=C2C2=CC=CC=C2)C2=CC=CC=C2)=NC=N1,,,,,0,,399.2059104,5,4,3,2,1,1
5521,04/06/2019 00:00,DB07298,"3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID",,,,,,solid,,,0.182,3.36,0.89,OC(=O)COC1=C(SC2=NC=CC=C12)C(O)=O,,,,,0,,253.0044933,2,2,2,2,0,0
5522,04/06/2019 00:00,DB07299,4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE,,,,,,solid,,,0.0248,12.08,6.52,[H][C@@](CCCNC(N)N)(NC(=O)[C@@]([H])(NC(=O)CCC(C)C)C(C)C)C(=O)C1=NC=CS1,,,,,0,,440.25696,1,1,1,1,0,0
5523,04/06/2019 00:00,DB07300,"2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine",,,,,,solid,,,0.0562,,6.77,COCCOC1=C(OC)C=C2C(=C1)N=CC1=C(N)N=C(C=C21)N1C=CN=C1,,,,,0,,365.1487895,4,4,3,3,0,0
5524,04/06/2019 00:00,DB07301,9H-CARBAZOLE,,,,,,solid,,,0.0669,14.97,,N1C2=CC=CC=C2C2=CC=CC=C12,,,,,0,,167.0734993,3,3,1,1,0,0
5525,04/06/2019 00:00,DB07302,"(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid",,,,,,solid,,,0.00322,4.68,-1.6,[H][C@](O)(CCCCCCCC(O)=O)\C=C\C=C/CCCCC,,,,,0,,296.2351449,0,0,0,0,0,0
5526,04/06/2019 00:00,DB07303,"N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE",,,,,,solid,,,0.0246,,7.12,COC1=CN=CC(=C1)C1=CC(CNC2=CC=CN=C2N)=CC=C1,,,,,0,,306.1480612,3,3,2,2,0,0
5527,04/06/2019 00:00,DB07304,5-[2-(TRIFLUOROMETHOXY)PHENYL]-2-FUROIC ACID,,,,,,solid,,,0.0436,3.13,-4.7,OC(=O)C1=CC=C(O1)C1=C(OC(F)(F)F)C=CC=C1,,,,,0,,272.0296434,2,2,1,1,0,0
5528,04/06/2019 00:00,DB07305,5-(2-CHLORO-4-NITROPHENYL)-2-FUROIC ACID,,,,,,solid,,,0.0396,3.13,-4.8,OC(=O)C1=CC=C(O1)C1=CC=C(C=C1Cl)[N+]([O-])=O,,,,,0,,266.99345,2,2,1,1,0,0
5529,04/06/2019 00:00,DB07306,ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE,,,,,,solid,,,0.137,,5.45,CCOC(=O)N1CCC(CC1)NC1=NC=CC(Cl)=C1,,,,,0,,283.1087545,2,1,2,1,1,1
5530,04/06/2019 00:00,DB07307,N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide,,,,,,solid,,,0.000686,15.4,2.54,CC1=CC=CC=C1C1=NN=CC2=C1C=CC(=C2)C1=C(C)C=CC(=C1)C(=O)NC1CC1,,,,,0,,393.1841124,5,4,1,1,0,0
5531,04/06/2019 00:00,DB07308,5-(2-CHLOROBENZYL)-2-FUROIC ACID,,,,,,solid,,,0.0433,3.15,-4.4,OC(=O)C1=CC=C(CC2=CC=CC=C2Cl)O1,,,,,0,,236.0240218,2,2,1,1,0,0
5532,04/06/2019 00:00,DB07309,5-BROMO-2-{[(4-CHLOROPHENYL)SULFONYL]AMINO}BENZOIC ACID,,,,,,solid,,,0.0075,3.87,,OC(=O)C1=C(NS(=O)(=O)C2=CC=C(Cl)C=C2)C=CC(Br)=C1,,,,,0,,388.9124185,2,2,0,0,0,0
5533,04/06/2019 00:00,DB07310,"(5S)-2-{[(1S)-1-(2-fluorophenyl)ethyl]amino}-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4(5H)-one",,,,,,solid,,,0.0131,,-1.8,[H][C@@](C)(NC1=NC(=O)[C@](C)(S1)C(F)(F)F)C1=C(F)C=CC=C1,,,,,0,,320.0606469,2,1,1,0,0,1
5534,04/06/2019 00:00,DB07311,"18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE",,,,,,solid,,,0.0573,10.29,-0.42,ClC1=CC2=C(OCCCCCOC3=CN=CC(NC(=O)N2)=N3)C=C1,,,,,0,,348.0989181,3,2,2,1,0,1
5535,04/06/2019 00:00,DB07312,"2,5-DICHLORO-N-(5-CHLORO-1,3-BENZOXAZOL-2-YL)BENZENESULFONAMIDE",,,,,,solid,,,0.0188,6.58,-2.4,ClC1=CC=C2OC(NS(=O)(=O)C3=CC(Cl)=CC=C3Cl)=NC2=C1,,,,,0,,375.9242961,3,3,1,1,0,0
5536,04/06/2019 00:00,DB07313,5-METHYL-2-[(PHENYLSULFONYL)AMINO]BENZOIC ACID,,,,,,solid,,,0.0721,4.03,,CC1=CC=C(NS(=O)(=O)C2=CC=CC=C2)C(=C1)C(O)=O,,,,,0,,291.0565289,2,2,0,0,0,0
5537,04/06/2019 00:00,DB07314,"1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA",,,,,,solid,,,0.0612,10.44,-3.8,COC1=CC(OC)=C(NC(=O)NC2=NC=C(N=C2)C#N)C=C1Cl,,,,,0,,333.0628669,2,2,1,1,0,0
5538,04/06/2019 00:00,DB07315,"5-chloro-N-{4-[(1R)-1,2-dihydroxyethyl]phenyl}-1H-indole-2-carboxamide",,,,,,solid,,,0.0347,11.71,-3,[H][C@](O)(CO)C1=CC=C(NC(=O)C2=CC3=CC(Cl)=CC=C3N2)C=C1,,,,,0,,330.07712,3,3,1,1,0,0
5539,04/06/2019 00:00,DB07316,"N-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide",,,,,,solid,,,0.0442,10.7,9.12,C[C@](O)(C1=CC=C(C=C1)C(=O)N(C1CC1)C1CCN(CC2(CC2)C(N)=O)CC1)C(F)(F)F,,,,,0,,453.2239265,4,1,1,0,1,1
5540,04/06/2019 00:00,DB07317,(3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one,,,,,,solid,,,1.35,15.65,-0.84,O=C1OCC\C1=C/NC1=CC=CC=C1,,,,,0,,189.0789786,2,1,1,0,1,1
5541,04/06/2019 00:00,DB07318,"N-[2-(4-AMINO-5,8-DIFLUORO-1,2-DIHYDROQUINAZOLIN-2-YL)ETHYL]-3-FURAMIDE",,,,,,solid,,,0.164,10.15,6.1,[H][C@@]1(CCNC(=O)C2=COC=C2)NC2=C(F)C=CC(F)=C2C(N)=N1,,,,,0,,320.1084821,3,2,2,1,0,1
5542,04/06/2019 00:00,DB07319,"6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE",,,,,,solid,,,0.0564,15.59,5.43,NC1=NC(=NC(N)=N1)C1=CC2=CC=CC=C2C=C1Br,,,,,0,,315.0119574,3,3,1,1,0,0
5543,04/06/2019 00:00,DB07320,"4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID",,,,,,solid,,,0.00281,3.89,10.43,[H][C@]1(C)CC[C@]([H])(CC1)NCC1=CC2=C(C=C1)C1=C(C2)C(=NN1)C1=CC=C(C=C1)C(O)=O,,,,,0,,401.2103271,5,3,1,1,0,0
5544,04/06/2019 00:00,DB07321,"2,5-DICHLORO-N-[5-METHOXY-7-(6-METHOXYPYRIDIN-3-YL)-1,3-BENZOXAZOL-2-YL]BENZENESULFONAMIDE",,,,,,solid,,,0.0237,6.58,2.29,COC1=CC2=C(OC(NS(=O)(=O)C3=CC(Cl)=CC=C3Cl)=N2)C(=C1)C1=CN=C(OC)C=C1,,,,,0,,479.0109469,4,4,2,2,0,0
5545,04/06/2019 00:00,DB07322,"2-[(PHENYLSULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID",,,,,,solid,,,0.0282,4.07,,OC(=O)C1=C2CCCCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1,,,,,0,,331.087829,3,2,0,0,0,0
5546,04/06/2019 00:00,DB07323,"2-[({2-[(1Z)-3-(DIMETHYLAMINO)PROP-1-ENYL]-4-FLUOROPHENYL}SULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID",,,,,,solid,,,0.00456,4.07,8.67,CN(C)C\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C2CCCCC2=C1C(O)=O,,,,,0,,432.1519065,3,2,0,0,0,0
5547,04/06/2019 00:00,DB07324,"3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE",,,,,,solid,,,0.0241,16.61,4.09,CC1=CC(=NC(N)=N1)C#CC1=C(CNN2C=COC2=O)C=CC=C1,,,,,0,,321.1225747,3,3,2,2,0,0
5548,04/06/2019 00:00,DB07325,N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE,,,,,,solid,,,0.15,9.69,4.02,CC1=NC(N)=NC(CNS(=O)(=O)C2=CC(N\C=C3/CCOC3=O)=CC=C2)=C1,,,,,0,,389.1157751,3,2,2,1,1,1
5549,04/06/2019 00:00,DB07326,"6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide",,,,,,solid,,,0.044,8.75,0.83,FC(F)(F)C1=CC(NC2=NOC3=C(C(=O)NC4=CN=CN=C4)C(Cl)=CC=C23)=CC=C1,,,,,0,,433.0553369,4,4,2,2,0,0
5550,04/06/2019 00:00,DB07327,"(2-ACETYL-5-METHYLANILINO)(2,6-DIBROMOPHENYL)ACETAMIDE",,,,,,solid,,,0.00104,12.16,-0.67,[H][C@@](NC1=CC(C)=CC=C1C(C)=O)(C(N)=O)C1=C(Br)C=CC=C1Br,,,,,0,,437.957852,2,2,0,0,0,0
5551,04/06/2019 00:00,DB07328,"METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE",,,,,,solid,,,0.317,12.79,9.45,[H][C@]1(CNC(=O)NC2=CC=C(C=C2)C(=O)OC)CC[C@]([H])(N1)C(=O)N1CCC[C@@]1([H])CN,,,,,0,,403.2219544,3,1,2,0,2,2
5552,04/06/2019 00:00,DB07329,1-[N-4'-NITROBENZYL-N-4'-CARBOXYBUTYLAMINO]METHYLPHOSPHONIC ACID,,,,,,solid,,,0.343,-0.81,8.57,OC(=O)CCCCN(CC1=CC=C(C=C1)[N+]([O-])=O)CP(O)(O)=O,,,,,0,,346.0929876,1,1,0,0,0,0
5553,04/06/2019 00:00,DB07330,trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium,,,,,,solid,,,0.339,9.95,9.56,CCCN1CCC(CC1)C1=NC2=C(N1)C(=CC=C2)C(N)=O,,,,,0,,286.1793613,3,2,2,1,1,1
5554,04/06/2019 00:00,DB07331,2-(4-NITROPHENYL)ACETIC ACID,,,,,,solid,,,0.791,3.07,-9.7,OC(=O)CC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,181.0375077,1,1,0,0,0,0
5555,04/06/2019 00:00,DB07332,"ALPHA-(2,6-DICHLOROPHENYL)-ALPHA-(2-ACETYL-5-METHYLANILINO)ACETAMIDE",,,,,,solid,,,0.00119,12.13,-0.69,[H][C@@](NC1=C(C=CC(C)=C1)C(C)=O)(C(N)=O)C1=C(Cl)C=CC=C1Cl,,,,,0,,350.0588831,2,2,0,0,0,0
5556,04/06/2019 00:00,DB07333,"N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE",,,,,,solid,,,0.0262,9.2,4.72,COC1=CC=C(C=C1NC1=NC=C(O1)C1=CC(=CC=C1)C1=CN=CC=C1)S(=O)(=O)NCC1CC1,,,,,0,,476.1518262,5,4,2,2,0,0
5557,04/06/2019 00:00,DB07334,"N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE",,,,,,solid,,,0.0269,9.29,4.38,CCS(=O)(=O)C1=CC=C(OC)C(NC2=NC=C(O2)C2=CC=CC(=C2)C2=CC=CC=N2)=C1,,,,,0,,435.1252772,4,4,2,2,0,0
5558,04/06/2019 00:00,DB07335,"3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL",,,,,,solid,,,0.537,9.54,6.58,CC(C)N1N=C(C2=C1N=CN=C2N)C1=CC=CC(O)=C1,,,,,0,,269.1276601,3,3,2,2,0,0
5559,04/06/2019 00:00,DB07336,4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL,,,,,,solid,,,0.00965,9.66,3.94,COC1=CC(=CC=C1O)C1=CC2=C(C=C1)C(=NN2)C1=NC2=CC=CC=C2N1,,,,,0,,356.1273258,5,5,2,2,0,0
5560,04/06/2019 00:00,DB07337,"4-[4-AMINO-6-(5-CHLORO-1H-INDOL-4-YLMETHYL)-[1,3,5]TRIAZIN-2-YLAMINO]-BENZONITRILE",,,,,,solid,,,0.0137,12.39,5.08,NC1=NC(CC2=C3C=CNC3=CC=C2Cl)=NC(NC2=CC=C(C=C2)C#N)=N1,,,,,0,,375.0999211,4,4,2,2,0,0
5561,04/06/2019 00:00,DB07338,Acifluorfen,,,,,,solid,,,0.000852,0.86,-3.8,OC(=O)C1=C(C=CC(OC2=CC=C(C=C2Cl)C(F)(F)F)=C1)[N+]([O-])=O,,,,,0,,360.9964847,2,2,0,0,0,0
5562,04/06/2019 00:00,DB07339,"(3S)-3-hydroxy-1-methyl-2,3-dihydro-1H-indole-5,6-dione",,,,,,solid,,,68,14.09,3.88,[H][C@@]1(O)CN(C)C2=CC(=O)C(=O)C=C12,,,,,0,,179.0582431,2,0,1,0,1,1
5563,04/06/2019 00:00,DB07340,"N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamine",,,,,,solid,,,0.0355,9.71,4.55,C1CCC(CC1)NC1=C2N=CNC2=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1,,,,,0,,393.2277085,5,3,3,2,1,1
5564,04/06/2019 00:00,DB07341,"octyl 3-amino-3-deoxy-2-O-(2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)-beta-D-galactopyranoside",,,,,,solid,,,4.43,12.96,8.7,[H][C@]1(O)C[C@]([H])(O[C@]2([H])[C@@]([H])(N)[C@@]([H])(O)[C@@]([H])(CO)O[C@@]2([H])OCCCCCCCC)O[C@@]([H])(C)[C@@]1([H])O,,,,,0,,421.2675672,2,0,2,0,2,2
5565,04/06/2019 00:00,DB07342,1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone,,,,,,solid,,,0.262,17.92,6.73,[H]C12CC3([H])CC([H])(C1)CC(C2)(C3)C(=O)CN1C=CN=C1,,,,,0,,244.1575633,5,1,1,1,0,0
5566,04/06/2019 00:00,DB07343,"4-[4-AMINO-6-(2,6-DICHLORO-PHENOXY)-[1,3,5]TRIAZIN-2-YLAMINO]-BENZONITRILE",,,,,,solid,,,0.0198,11.9,3.22,NC1=NC(OC2=C(Cl)C=CC=C2Cl)=NC(NC2=CC=C(C=C2)C#N)=N1,,,,,0,,372.0293143,3,3,1,1,0,0
5567,04/06/2019 00:00,DB07344,"3,6,9,12,15-PENTAOXAHEPTADECAN-1-OL",,,,,,solid,,,2.4,15.12,-2.7,CCOCCOCCOCCOCCOCCO,,,,,0,,266.1729386,0,0,0,0,0,0
5568,04/06/2019 00:00,DB07345,4-(2-aminoethyl)-2-cyclohexylphenol,,,,,,solid,,,0.0451,10.77,9.76,NCCC1=CC=C(O)C(=C1)C1CCCCC1,,,,,0,,219.1623143,2,1,0,0,0,0
5569,04/06/2019 00:00,DB07346,4-(2-aminoethyl)-2-ethylphenol,,,,,,solid,,,2.12,10.64,9.74,CCC1=CC(CCN)=CC=C1O,,,,,0,,165.1153641,1,1,0,0,0,0
5570,04/06/2019 00:00,DB07347,4-(2-Aminoethyl)Benzenesulfonyl Fluoride,,,,,,solid,,,0.385,,9.28,NCCC1=CC=C(C=C1)S(F)(=O)=O,,,,,0,,203.0416278,1,1,0,0,0,0
5571,04/06/2019 00:00,DB07348,Brefeldin A,,,,,,solid,,,0.812,14.42,-2.7,[H][C@]1(O)C[C@@]2([H])\C=C\CCC[C@]([H])(C)OC(=O)\C=C\[C@@]([H])(O)[C@]2([H])C1,,,,,0,,280.1674592,2,0,1,0,0,1
5572,04/06/2019 00:00,DB07349,"(1S)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PENTANOYLOXY)METHYL]ETHYL OCTANOATE",,,,,,solid,,,1.59,1.89,-3,[H][C@](O)(CO)CO[P@@]([O-])(=O)OC[C@@]([H])(COC(=O)CCCC)OC(=O)CCCCCCC,,,,,-1,,455.2051576,0,0,0,0,0,0
5573,04/06/2019 00:00,DB07350,(2E)-N-hydroxy-3-[1-methyl-4-(phenylacetyl)-1H-pyrrol-2-yl]prop-2-enamide,,,,,,solid,,,0.0539,9.52,-5.2,CN1C=C(C=C1\C=C\C(=O)NO)C(=O)CC1=CC=CC=C1,,,,,0,,284.1160924,2,2,1,1,0,0
5574,04/06/2019 00:00,DB07351,O-(((1R)-((N-(PHENYL-METHOXY-CARBONYL)-ALANYL)-AMINO)METHYL)HYDROXYPHOSPHINYL)3-L-PHENYLLACTATE,,,,,,solid,,,0.0213,0.9,-5.1,[H][C@@](C)(NC(=O)OCC1=CC=CC=C1)C(=O)NC[P@](O)(=O)O[C@@]([H])(CC1=CC=CC=C1)C(O)=O,,,,,0,,464.1348524,2,2,0,0,0,0
5575,04/06/2019 00:00,DB07352,Apigenin,,,,,,solid,,,0.118,6.63,-5.2,OC1=CC=C(C=C1)C1=CC(=O)C2=C(O1)C=C(O)C=C2O,,,,,0,,270.0528234,3,3,1,1,0,0
5576,04/06/2019 00:00,DB07353,"4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL",,,,,,solid,,,2.17,10.42,9.78,[H][C@](N)(O)CC[C@@]([H])(N)CC1=CC=C(O)C=C1,,,,,0,,210.1368278,1,1,0,0,0,0
5577,04/06/2019 00:00,DB07354,"2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM",,,,,,solid,,,0.00126,11.52,5.44,COC1=C(OC)C=C2C3=C([NH+]=CC2=C1)C1=C(C3)C=C2OCOC2=C1,,,,,1,,322.1073844,5,3,2,1,0,1
5578,04/06/2019 00:00,DB07355,3-(heptyloxy)benzoic acid,,,,,,solid,,,0.0174,3.84,-4.9,CCCCCCCOC1=CC=CC(=C1)C(O)=O,,,,,0,,236.1412445,1,1,0,0,0,0
5579,04/06/2019 00:00,DB07356,"(1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE",,,,,,solid,,,0.166,,9.26,[H][C@](N)(C1CCCC1)C(=O)N1[C@]([H])(CN)CC[C@]1([H])C#C,,,,,0,,249.1841124,2,0,1,0,1,1
5580,04/06/2019 00:00,DB07357,"4-AMINO-2-HEXYLOXY-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,5-DIOL",,,,,,solid,,,36.1,12.67,8.81,[H][C@]1(N)[C@@]([H])(O)[C@@]([H])(CO)O[C@@]([H])(OCCCCCC)[C@]1([H])O,,,,,0,,263.1732729,1,0,1,0,1,1
5581,04/06/2019 00:00,DB07358,"2-amino-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide",,,,,,solid,,,0.172,9.57,1.98,CN1C=NN=C1SC1=CC=C(N)C(=C1)C(=O)NC1=NC(C)=CS1,,,,,0,,346.0670511,3,3,2,2,0,0
5582,04/06/2019 00:00,DB07359,"3-[(4-fluorophenyl)sulfanyl]-N-(4-methyl-1,3-thiazol-2-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide",,,,,,solid,,,0.0219,8.2,1.73,CN1C=NN=C1SC1=NC(C(=O)NC2=NC(C)=CS2)=C(SC2=CC=C(F)C=C2)C=C1,,,,,0,,458.0453503,4,4,3,3,0,0
5583,04/06/2019 00:00,DB07360,"1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea",,,,,,solid,,,0.00349,10.17,3.86,FC(F)(F)C1=CC=CC(NC(=O)NC2=NC=C(CCNC3=NC=NC4=C3SC=C4)S2)=C1,,,,,0,,464.0700858,4,4,3,3,0,0
5584,04/06/2019 00:00,DB07362,"1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea",,,,,,solid,,,0.011,10.17,2.74,CN1N=CC2=C1C(NCCC1=CN=C(NC(=O)NC3=CC=CC(=C3)C(F)(F)F)S1)=NC=N2,,,,,0,,462.1198128,4,4,3,3,0,0
5585,04/06/2019 00:00,DB07363,"THIOPHENE-2,5-DISULFONIC ACID 2-AMIDE-5-(4-METHYL-BENZYLAMIDE)",,,,,,solid,,,0.0775,8.17,,CC1=CC=C(CNS(=O)(=O)C2=CC=C(S2)S(N)(=O)=O)C=C1,,,,,0,,346.0115699,2,2,1,1,0,0
5586,04/06/2019 00:00,DB07364,"6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE",,,,,,solid,,,0.0361,10.03,2.82,CCCCC1=C(NC2=NC=CN=C12)C1=CC=C(O)C=C1,,,,,0,,267.1371622,3,3,2,2,0,0
5587,04/06/2019 00:00,DB07365,NAPHTHALEN-2-YL-3-ALANINE,,,,,,solid,,,0.221,2.61,9.42,[H][C@](N)(CC1=CC=CC2=C1C=CC=C2)C(O)=O,,,,,0,,215.0946287,2,2,0,0,0,0
5588,04/06/2019 00:00,DB07366,2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER,,,,,,solid,,,0.47,12.4,10.2,[H][C@]1(CCCN1C(=O)OCC1=CC=CC=C1)C(=O)NNCCCCN,,,,,0,,334.2004907,2,1,1,0,1,1
5589,04/06/2019 00:00,DB07367,"(3Z,5S,6R,7S,8S,8aR)-3-(octylimino)hexahydro[1,3]oxazolo[3,4-a]pyridine-5,6,7,8-tetrol",,,,,,solid,,,3.71,12.16,2.52,[H][C@]12CO\C(=N/CCCCCCCC)N1[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@@]2([H])O,,,,,0,,316.199822,2,0,2,0,2,2
5590,04/06/2019 00:00,DB07368,4-(METHYLSULFONYL)BENZENECARBOXIMIDAMIDE,,,,,,solid,,,0.767,19.69,10.39,CS(=O)(=O)C1=CC=C(C=C1)C(N)=N,,,,,0,,198.0462986,1,1,0,0,0,0
5591,04/06/2019 00:00,DB07369,"N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide",,,,,,solid,,,0.00114,18.21,-0.061,CN(C1=CC(Cl)=CC=C1)S(=O)(=O)C1=CC2=C(CC3=C(C)C(C)=C(C)N3)C(=O)N=C2C=C1,,,,,0,,455.1070402,4,3,2,1,0,1
5592,04/06/2019 00:00,DB07370,"(3Z,5S,6R,7S,8R,8aS)-3-(octylimino)hexahydro[1,3]thiazolo[3,4-a]pyridine-5,6,7,8-tetrol",,,,,,solid,,,1.18,12.18,4.18,[H][C@]12CS\C(=N/CCCCCCCC)N1[C@@H](O)[C@H](O)[C@@H](O)[C@@H]2O,,,,,0,,332.1769784,2,0,2,0,2,2
5593,04/06/2019 00:00,DB07371,3-(10-methyl-9-anthryl)propanoic acid,,,,,,solid,,,0.000216,5.03,,CC1=C2C=CC=CC2=C(CCC(O)=O)C2=C1C=CC=C2,,,,,0,,264.1150298,3,3,0,0,0,0
5594,04/06/2019 00:00,DB07373,"ANDROSTA-1,4-DIENE-3,17-DIONE",,,,,,solid,,,0.0169,18.83,-5,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,284.17763,4,0,0,0,0,0
5595,04/06/2019 00:00,DB07374,Anisomycin,,,,,,solid,,,2.07,13.77,9.22,[H][C@]1(O)CN[C@]([H])(CC2=CC=C(OC)C=C2)[C@]1([H])OC(C)=O,,,,,0,,265.1314081,2,1,1,0,1,1
5596,04/06/2019 00:00,DB07375,"5-BETA-ANDROSTANE-3,17-DIONE",,,,,,solid,,,0.00739,19.78,-7.1,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])CC(=O)CC[C@]12C,,,,,0,,288.2089301,4,0,0,0,0,0
5597,04/06/2019 00:00,DB07376,5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID),,,,,,solid,,,0.545,-1.9,4.89,CN(C)C1=C2C=CC=C(C2=CC=C1)S(O)(=O)=O,,,,,0,,251.0616143,2,2,0,0,0,0
5598,04/06/2019 00:00,DB07377,"N'-((2S,3R)-3-AMINO-2-HYDROXY-5-(ISOPROPYLSULFANYL)PENTANOYL)-N-3-CHLOROBENZOYL HYDRAZIDE",,,,,,solid,,,0.0455,9.49,8.37,[H][C@@](N)(CCSC(C)C)[C@]([H])(O)C(=O)NNC(=O)C1=CC(Cl)=CC=C1,,,,,0,,359.1070402,1,1,0,0,0,0
5599,04/06/2019 00:00,DB07378,"4-AMINO-2-OCTYLOXY-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,5-DIOL",,,,,,solid,,,10,12.67,8.81,[H][C@]1(N)[C@@]([H])(O)[C@@]([H])(CO)O[C@@]([H])(OCCCCCCCC)[C@]1([H])O,,,,,0,,291.204573,1,0,1,0,1,1
5600,04/06/2019 00:00,DB07379,(2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol,,,,,,solid,,,0.0822,13.99,4.47,[H][C@](CO)(NC1=NC2=C(N=CN2C(C)C)C(NC2=CC(Cl)=CC(N)=C2)=N1)C(C)C,,,,,0,,403.1887361,3,3,2,2,0,0
5601,04/06/2019 00:00,DB07380,"1,1,1-TRIFLUORO-3-ACETAMIDO-4-PHENYL BUTAN-2-ONE(N-ACETYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)",,,,,,solid,,,0.027,11.1,-1.1,[H][C@@](CC1=CC=CC=C1)(NC(C)=O)C(=O)C(F)(F)F,,,,,0,,259.0820133,1,1,0,0,0,0
5602,04/06/2019 00:00,DB07381,(S)-atrolactic acid,,,,,,solid,,,19.7,3.81,-4.2,CC(O)(C(O)=O)C1=CC=CC=C1,,,,,0,,166.0629942,1,1,0,0,0,0
5603,04/06/2019 00:00,DB07382,"N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine",,,,,,solid,,,0.0213,12.38,6.69,C1CC1C1=NNC(NC2=CC=NC(NC3=CC4=C(NC=N4)C=C3)=N2)=C1,,,,,0,,332.1497925,5,4,3,3,0,0
5604,04/06/2019 00:00,DB07383,"N-(1-BENZYL-3,3,3-TRIFLUORO-2,2-DIHYDROXY-PROPYL)-ACETAMIDE",,,,,,solid,,,1.56,7.86,-0.71,[H][C@@](CC1=CC=CC=C1)(NC(C)=O)C(O)(O)C(F)(F)F,,,,,0,,277.092578,1,1,0,0,0,0
5605,04/06/2019 00:00,DB07384,1-ACETYL-2-CARBOXYPIPERIDINE,,,,,,solid,,,303,4,-0.82,[H][C@]1(CCCCN1C(C)=O)C(O)=O,,,,,0,,171.0895433,1,0,1,0,1,1
5606,04/06/2019 00:00,DB07385,"3-(HYDROXYMETHYL)-1-METHYL-5-(2-METHYLAZIRIDIN-1-YL)-2-PHENYL-1H-INDOLE-4,7-DIONE",,,,,,solid,,,0.744,13.44,-1.3,[H][C@@]1(C)C[N@@]1C1=CC(=O)C2=C(C(CO)=C(N2C)C2=CC=CC=C2)C1=O,,,,,0,,322.1317424,4,2,2,1,1,1
5607,04/06/2019 00:00,DB07387,3-(BUTYLSULPHONYL)-PROPANOIC ACID,,,,,,solid,,,13.8,3.98,,CCCCS(=O)(=O)CCC(O)=O,,,,,0,,194.0612799,0,0,0,0,0,0
5608,04/06/2019 00:00,DB07388,ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE,,,,,,solid,,,0.222,,7.39,CCOC(=O)N1CCC(CC1)NC1=NC=CC(C)=C1,,,,,0,,263.1633769,2,1,2,1,1,1
5609,04/06/2019 00:00,DB07389,N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE,,,,,,solid,,,0.0369,14.54,7.07,CC1=CC(N)=NC(CCNC(=O)C2=CC=C(C=C2)C#N)=C1,,,,,0,,280.1324111,2,2,1,1,0,0
5610,04/06/2019 00:00,DB07390,"2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE",,,,,,solid,,,0.0148,6.76,-1.4,[H][C@@](CC1=CC=CC=C1)(NC(=O)NC1=NN=C(S)S1)C(=O)NC,,,,,0,,337.0667167,2,2,1,1,0,0
5611,04/06/2019 00:00,DB07391,"(2S)-2-AMINO-1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)PROPAN-1-ONE",,,,,,solid,,,2.18,15.23,7.04,[H][C@@](C)(N)C(=O)C1=NN=C(O1)C(C)(C)C,,,,,0,,197.1164267,1,1,1,1,0,0
5612,04/06/2019 00:00,DB07392,"2-CHLORO-4-ISOPROPYLAMINO-6-ETHYLAMINO -1,3,5-TRIAZINE",,,,,,solid,,,0.0275,14.48,3.2,CCNC1=NC(NC(C)C)=NC(Cl)=N1,,,,,0,,215.0937731,1,1,1,1,0,0
5613,04/06/2019 00:00,DB07393,"2-(2-PHENYL-3-PYRIDIN-2-YL-4,5,6,7-TETRAHYDRO-2H-ISOPHOSPHINDOL-1-YL)PYRIDINE",,,,,,solid,,,0.00464,,4.14,C1CCC2=C(P(C(=C2C1)C1=NC=CC=C1)C1=CC=CC=C1)C1=NC=CC=C1,,,,,0,,368.1442353,5,4,3,3,0,0
5614,04/06/2019 00:00,DB07394,AUROVERTIN B,,,,,,solid,,,0.011,12.91,-3.7,[H][C@]1(CC)O[C@]2(C)[C@]([H])(OC(C)=O)[C@@]1(C)O[C@@]([H])(\C=C\C=C\C=C\C1=C(C)C(OC)=CC(=O)O1)[C@]2([H])O,,,,,0,,460.209718,3,1,3,1,2,2
5615,04/06/2019 00:00,DB07395,"4-[3-(2-Chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid",,,,,,solid,,,0.00118,3.9,-5.3,OC(=O)C1=CC=C(NC(=O)NC(=O)C2=CC(F)=C(F)C=C2Cl)C(OC(F)(F)F)=C1,,,,,0,,438.0041901,2,2,0,0,0,0
5616,04/06/2019 00:00,DB07396,"1-{2-[3-(2-Chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid",,,,,,solid,,,0.00635,3.25,4.41,OC(=O)C1CCN(CC1)C1=C(NC(=O)NC(=O)C2=CC(F)=C(F)C=C2Cl)C=C(F)C=C1,,,,,0,,455.0859684,3,2,1,0,1,1
5617,04/06/2019 00:00,DB07397,"(5S)-5-(2-amino-2-oxoethyl)-4-oxo-N-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidine-2-carboxamide",,,,,,solid,,,0.0202,7.43,0.67,[H][C@@]1(CC(N)=O)CCCC2=C1C1=C(S2)N=C(NC1=O)C(=O)NCC1=CC=C2OCC(=O)NC2=C1,,,,,0,,467.1263398,5,3,3,2,0,1
5618,04/06/2019 00:00,DB07398,"2-[(CYCLOPROPYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE",,,,,,solid,,,0.0547,10.4,-1.3,NC(=O)C1=C(NC(=O)C2CC2)SC2=C1CCCC2,,,,,0,,264.0932488,3,1,1,1,0,0
5619,04/06/2019 00:00,DB07400,1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE,,,,,,solid,,,0.295,12.27,10.2,[H][C@](CC1=CC=CC=C1)(NC(=O)OCC)C(=O)N1CCC[C@@]1([H])C(=O)NNCCCCN,,,,,0,,419.2532545,2,1,1,0,1,1
5620,04/06/2019 00:00,DB07401,METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,,,,,solid,,,0.00618,,0.94,CO\C=C(\C(=O)OC)C1=CC=CC=C1OC1=NC=NC(OC2=CC=CC=C2C#N)=C1,,,,,0,,403.1168206,3,3,1,1,0,0
5621,04/06/2019 00:00,DB07402,Azapropazone,,,,,,solid,,,0.641,0.52,7.58,[H][C@@]1(CC=C)C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C,,,,,0,,298.1429758,3,1,2,0,1,2
5622,04/06/2019 00:00,DB07403,"4-[(3-CHLORO-4-{[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]AMINO}PHENYL)SULFONYL]-N,N-DIMETHYLBENZAMIDE",,,,,,solid,,,0.00392,9.44,-0.99,CN(C)C(=O)C1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NC(=O)[C@@](C)(O)C(F)(F)F)C(Cl)=C1,,,,,0,,478.057705,2,2,0,0,0,0
5623,04/06/2019 00:00,DB07404,"(1-HYDROXY-1-PHOSPHONO-2-[1,1';3',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID",,,,,,solid,,,0.117,0.69,-5.2,OC(CC1=CC=CC(=C1)C1=CC(=CC=C1)C1=CC=CC=C1)(P(O)(O)=O)P(O)(O)=O,,,,,0,,434.0684262,3,3,0,0,0,0
5624,04/06/2019 00:00,DB07405,"1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE",,,,,,solid,,,0.0478,9.88,5.75,NC1=NC2(CCN(CC2)C(=O)C2=CC=C(N=C2)C#N)NC2=C(F)C=CC(F)=C12,,,,,0,,382.1353656,4,2,3,1,1,2
5625,04/06/2019 00:00,DB07406,"(4R)-N-[4-({[2-(DIMETHYLAMINO)ETHYL]AMINO}CARBONYL)-1,3-THIAZOL-2-YL]-4-METHYL-1-OXO-2,3,4,9-TETRAHYDRO-1H-BETA-CARBOLINE-6-CARBOXAMIDE",,,,,,solid,,,0.00961,9.31,8.43,[H][C@]1(C)CNC(=O)C2=C1C1=CC(=CC=C1N2)C(=O)NC1=NC(=CS1)C(=O)NCCN(C)C,,,,,0,,440.1630596,4,3,3,2,0,1
5626,04/06/2019 00:00,DB07407,5-(2-METHOXYPHENYL)-2-FUROIC ACID,,,,,,solid,,,0.123,3.13,-4.5,COC1=C(C=CC=C1)C1=CC=C(O1)C(O)=O,,,,,0,,218.0579088,2,2,1,1,0,0
5627,04/06/2019 00:00,DB07408,5-(2-NITROPHENYL)-2-FUROIC ACID,,,,,,solid,,,0.0793,3.13,-4.9,OC(=O)C1=CC=C(O1)C1=C(C=CC=C1)[N+]([O-])=O,,,,,0,,233.0324223,2,2,1,1,0,0
5628,04/06/2019 00:00,DB07409,"(1-HYDROXY-1-PHOSPHONO-2-[1,1';4',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID",,,,,,solid,,,0.104,0.69,-5.2,OC(CC1=CC=CC(=C1)C1=CC=C(C=C1)C1=CC=CC=C1)(P(O)(O)=O)P(O)(O)=O,,,,,0,,434.0684262,3,3,0,0,0,0
5629,04/06/2019 00:00,DB07410,[2-(3-DIBENZOFURAN-4-YL-PHENYL)-1-HYDROXY-1-PHOSPHONO-ETHYL]-PHOSPHONIC ACID,,,,,,solid,,,0.0714,0.69,-3.8,OC(CC1=CC(=CC=C1)C1=CC=CC2=C1OC1=C2C=CC=C1)(P(O)(O)=O)P(O)(O)=O,,,,,0,,448.0476908,4,4,1,1,0,0
5630,04/06/2019 00:00,DB07411,PHENYLALANINE BORONIC ACID,,,,,,solid,,,1.84,,9.08,[H][C@](N)(CC1=CC=CC=C1)B(O)O,,,,,0,,165.096109,1,1,0,0,0,0
5631,04/06/2019 00:00,DB07412,1-biphenyl-2-ylmethanamine,,,,,,solid,,,0.0765,,9.67,NCC1=C(C=CC=C1)C1=CC=CC=C1,,,,,0,,183.1047994,2,2,0,0,0,0
5632,04/06/2019 00:00,DB07413,5'-S-[2-(decylamino)ethyl]-5'-thioadenosine,,,,,,solid,,,0.0385,12.47,10.16,[H][C@]1(CSCCNCCCCCCCCCC)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,466.2726101,3,2,3,2,1,1
5633,04/06/2019 00:00,DB07414,"(5S)-1-benzyl-3-(1,1-dioxido-1,2-benzisothiazol-3-yl)-4-hydroxy-5-(1-methylethyl)-1,5-dihydro-2H-pyrrol-2-one",,,,,,solid,,,0.0289,6.08,0.095,[H][C@@]1(C(C)C)N(CC2=CC=CC=C2)C(=O)C(=C1O)C1=NS(=O)(=O)C2=C1C=CC=C2,,,,,0,,396.1143781,4,2,2,0,0,2
5634,04/06/2019 00:00,DB07415,4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine,,,,,,solid,,,0.0123,14.64,8.92,[H][C@@](CC1=CC(=CC=C1OC)[N+]([O-])=O)(C1=CNC(N)=N1)C1=CC=C(OC)C(F)=C1,,,,,0,,386.1390333,3,3,1,1,0,0
5635,04/06/2019 00:00,DB07416,(2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE,,,,,,solid,,,0.0721,14.58,-3,[H][C@](CO)(COC(=O)CCCCCCCC)OC(=O)CCC,,,,,0,,302.2093241,0,0,0,0,0,0
5636,04/06/2019 00:00,DB07418,bis(4-nitrophenyl) hydrogen phosphate,,,,,,solid,,,0.0116,0.85,,OP(=O)(OC1=CC=C(C=C1)[N+]([O-])=O)OC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,340.0096519,2,2,0,0,0,0
5637,04/06/2019 00:00,DB07419,S-23,,,,,,solid,,,0.00426,11.95,-4,C[C@](O)(COC1=CC=C(Cl)C(F)=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F,,,,,0,,416.0550828,2,2,0,0,0,0
5638,04/06/2019 00:00,DB07420,(1R)-4-(3-phenoxyphenyl)-1-phosphonobutane-1-sulfonic acid,,,,,,solid,,,0.535,-1.1,-8.7,[H][C@@](CCCC1=CC=CC(OC2=CC=CC=C2)=C1)(P(O)(O)=O)S(O)(=O)=O,,,,,0,,386.0589106,2,2,0,0,0,0
5639,04/06/2019 00:00,DB07421,"4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile",,,,,,solid,,,0.0107,11.57,-2,[H][C@](O)(NC1=CC(=C(C=C1)C#N)C(F)(F)F)[C@@](C)(O)COC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,411.1042053,2,2,0,0,0,0
5640,04/06/2019 00:00,DB07422,(2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide,,,,,,solid,,,0.00848,11.77,-4,C[C@](O)(COC1=C(F)C(F)=C(F)C(F)=C1F)C(=O)NC1=CC=C(C(=C1)C(F)(F)F)[N+]([O-])=O,,,,,0,,474.0461972,2,2,0,0,0,0
5641,04/06/2019 00:00,DB07423,(2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide,,,,,,solid,,,0.00109,11.77,-4,CC(=O)NC1=CC=C(OC[C@](C)(O)C(=O)NC2=CC(=C(C=C2)[N+]([O-])=O)C(F)(F)F)C=C1,,,,,0,,441.11477,2,2,0,0,0,0
5642,04/06/2019 00:00,DB07424,tripotassium (1R)-4-biphenyl-4-yl-1-phosphonatobutane-1-sulfonate,,,,,,solid,,,1.42,,-7.5,[H][C@@](CCCC1=CC=C(C=C1)C1=CC=CC=C1)(P(=O)(O[K])O[K])S(=O)(=O)O[K],,,,,0,,483.9316409,2,2,0,0,0,0
5643,04/06/2019 00:00,DB07425,Sobetirome,,,,,,solid,,,0.00261,3.93,-4.9,CC(C)C1=C(O)C=CC(CC2=C(C)C=C(OCC(O)=O)C=C2C)=C1,,,,,0,,328.1674592,2,2,0,0,0,0
5644,04/06/2019 00:00,DB07426,"[1-HYDROXY-2-(1,1':3',1''-TERPHENYL-3-YLOXY)ETHANE-1,1-DIYL]BIS(PHOSPHONIC ACID)",,,,,,solid,,,0.0526,0.65,-4.9,OC(COC1=CC=CC(=C1)C1=CC=CC(=C1)C1=CC=CC=C1)(P(O)(O)=O)P(O)(O)=O,,,,,0,,450.0633409,3,3,0,0,0,0
5645,04/06/2019 00:00,DB07427,2-[(2-methoxy-5-methylphenoxy)methyl]pyridine,,,,,,solid,,,0.892,,3.78,COC1=C(OCC2=NC=CC=C2)C=C(C)C=C1,,,,,0,,229.1102787,2,2,1,1,0,0
5646,04/06/2019 00:00,DB07428,4-[(5-methoxy-2-methylphenoxy)methyl]pyridine,,,,,,solid,,,0.69,,4.99,COC1=CC(OCC2=CC=NC=C2)=C(C)C=C1,,,,,0,,229.1102787,2,2,1,1,0,0
5647,04/06/2019 00:00,DB07429,2-({[4-bromo-3-(diethylsulfamoyl)phenyl]carbonyl}amino)benzoic acid,,,,,,solid,,,0.00664,3.55,-4.1,CCN(CC)S(=O)(=O)C1=CC(=CC=C1Br)C(=O)NC1=CC=CC=C1C(O)=O,,,,,0,,454.0198048,2,2,0,0,0,0
5648,04/06/2019 00:00,DB07430,"(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one",,,,,,solid,,,0.00153,15.79,5,[H][C@@]1(C)CNC2=C(SC3=C2C2=C(C=C3)N=C(C=C2)C2=CN=C(C)C=C2)C(=O)N1,,,,,0,,374.1201322,5,4,4,3,0,1
5649,04/06/2019 00:00,DB07431,"(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one",,,,,,solid,,,0.051,15.86,8.8,[H][C@@]1(CN)CNC2=C(SC3=C2C=C(OC)C=C3)C(=O)N1,,,,,0,,277.0884977,3,2,2,1,0,1
5650,04/06/2019 00:00,DB07432,"[[(3R,4R,5S,6R)-3-(butanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] N-phenylcarbamate",,,,,,solid,,,1.04,11.77,-0.64,[H][C@]1(CO)O\C(=N/OC(=O)NC2=CC=CC=C2)[C@]([H])(NC(=O)CCC)[C@@]([H])(O)[C@]1([H])O,,,,,0,,381.1536001,2,1,1,0,1,1
5651,04/06/2019 00:00,DB07433,(TERT-BUTYLOXYCARBONYL)-ALANYL-AMINO ETHYL-FORMAMIDE,,,,,,solid,,,0.716,12.68,-1.4,[H][C@](C)(NC=O)NC(=O)[C@]([H])(C)NC(=O)OC(C)(C)C,,,,,0,,259.1532062,0,0,0,0,0,0
5652,04/06/2019 00:00,DB07434,HONH-BENZYLMALONYL-L-ALANYLGLYCINE-P-NITROANILIDE,,,,,,solid,,,0.0105,8.78,-4.5,[H][C@@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)C(=O)NO)C(=O)NCC(=O)NC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,457.1597481,2,2,0,0,0,0
5653,04/06/2019 00:00,DB07435,"1,2,3-TRIHYDROXY-1,2,3,4-TETRAHYDROBENZO[A]PYRENE",,,,,,solid,,,0.0218,12.87,-3.3,[H][C@@]1(O)CC2=C3C=CC4=CC=CC5=CC=C(C=C2[C@@]([H])(O)[C@]1([H])O)C3=C45,,,,,0,,304.1099444,5,4,0,0,0,0
5654,04/06/2019 00:00,DB07436,N-(1-PHENYL-PROPYL)-FORMAMIDE,,,,,,solid,,,0.792,16.14,-0.48,[H][C@](CC)(NC=O)C1=CC=CC=C1,,,,,0,,163.099714,1,1,0,0,0,0
5655,04/06/2019 00:00,DB07437,"1-((2-HYDROXYETHOXY)METHYL)-5-BENZYLPYRIMIDINE-2,4(1H,3H)-DIONE",,,,,,solid,,,0.818,9.95,-2.7,OCCOCN1C=C(CC2=CC=CC=C2)C(=O)NC1=O,,,,,0,,276.111007,2,2,1,1,0,0
5656,04/06/2019 00:00,DB07439,"1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE",,,,,,solid,,,0.0122,6.64,-2.7,OCCOCN1C(=O)NC(=O)C(CC2=CC=CC(OCC3=CC=CC=C3)=C2)=C1O,,,,,0,,398.1477864,3,3,1,1,0,0
5657,04/06/2019 00:00,DB07440,4-TERT-BUTYLBENZENESULFONIC ACID,,,,,,solid,,,0.26,-1.8,,CC(C)(C)C1=CC=C(C=C1)S(O)(=O)=O,,,,,0,,214.0663653,1,1,0,0,0,0
5658,04/06/2019 00:00,DB07441,"3-{[(9-CYANO-9,10-DIHYDRO-10-METHYLACRIDIN-9-YL)CARBONYL]AMINO}PROPANOIC ACID",,,,,,solid,,,0.0514,2.97,-1.7,CN1C2=CC=CC=C2C(C#N)(C(=O)NCCC(O)=O)C2=C1C=CC=C2,,,,,0,,335.1269914,3,2,1,0,0,1
5659,04/06/2019 00:00,DB07443,(2Z)-N-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide,,,,,,solid,,,0.00936,6.41,-3.2,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,278.1055277,2,2,0,0,0,0
5660,04/06/2019 00:00,DB07444,"6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE",,,,,,solid,,,0.0287,8.29,10.31,CC1=CC2=C(C=C1)N(CCCN)C1=C2C2=C(C(=O)NC2=O)C(C)=C1,,,,,0,,321.1477268,4,3,2,1,0,1
5661,04/06/2019 00:00,DB07445,"N'-[(1E)-(3,5-DIBROMO-2,4-DIHYDROXYPHENYL)METHYLENE]NICOTINOHYDRAZIDE",,,,,,solid,,,0.077,6.44,3.51,OC1=C(Br)C=C(\C=N\NC(=O)C2=CN=CC=C2)C(O)=C1Br,,,,,0,,412.9010653,2,2,1,1,0,0
5662,04/06/2019 00:00,DB07446,N-(biphenyl-4-ylsulfonyl)-D-leucine,,,,,,solid,,,0.00551,3.43,,[H][C@](CC(C)C)(NS(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(O)=O,,,,,0,,347.1191292,2,2,0,0,0,0
5663,04/06/2019 00:00,DB07447,5beta-dihydrotestosterone,,,,,,solid,,,0.00998,19.38,-0.88,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C,,,,,0,,290.2245802,4,0,0,0,0,0
5664,04/06/2019 00:00,DB07448,(2S)-3-[(R)-[(1S)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid,,,,,,solid,,,0.0709,-0.057,9.92,[H][C@@](CC1=CC=CC=C1)(C[P@](O)(=O)[C@]([H])(N)CCC1=CC=CC=C1)C(O)=O,,,,,0,,361.1442949,2,2,0,0,0,0
5665,04/06/2019 00:00,DB07449,N-[(1S)-1-(AMINOCARBONYL)-4-(ETHANIMIDOYLAMINO)BUTYL]BENZAMIDE,,,,,,solid,,,0.34,14.99,12.82,[H][C@@](CCCNC(C)=N)(NC(=O)C1=CC=CC=C1)C(N)=O,,,,,0,,276.1586259,1,1,0,0,0,0
5666,04/06/2019 00:00,DB07450,(R)-minalrestat,,,,,,solid,,,0.012,9.33,-6.2,[H]N1C(=O)C[C@@]2(C1=O)C(=O)N(CC1=C(F)C=C(Br)C=C1)C(=O)C1=C2C=C(F)C=C1,,,,,0,,447.9870254,4,2,2,0,1,2
5667,04/06/2019 00:00,DB07451,1-(5-BROMO-PYRIDIN-2-YL)-3-[2-(6-FLUORO-2-HYDROXY-3-PROPIONYL-PHENYL)-CYCLOPROPYL]-UREA,,,,,,solid,,,0.0294,8.94,2.13,[H][C@@]1(C[C@@]1([H])C1=C(F)C=CC(C(=O)CC)=C1O)NC(=O)NC1=NC=C(Br)C=C1,,,,,0,,421.0437317,3,2,1,1,0,0
5668,04/06/2019 00:00,DB07452,"2,6-diamino-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,,,,,solid,,,0.613,11.01,5.75,NC1=NC2=C(N1)C=C1C(=O)NC(N)=NC1=C2,,,,,0,,216.0759589,3,3,2,2,0,0
5669,04/06/2019 00:00,DB07453,2-PHENYL-4H-BENZO[H]CHROMEN-4-ONE,,,,,,solid,,,0.000871,15.56,-5.4,O=C1C=C(OC2=C1C=CC1=CC=CC=C21)C1=CC=CC=C1,,,,,0,,272.0837296,4,4,1,1,0,0
5670,04/06/2019 00:00,DB07454,(R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE,,,,,,solid,,,0.0041,11.83,-4,C[C@](O)(CBr)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,,,,,0,,369.9776036,1,1,0,0,0,0
5671,04/06/2019 00:00,DB07455,"N,N'-[biphenyl-4,4'-diyldi(2R)propane-2,1-diyl]dimethanesulfonamide",,,,,,solid,,,0.0021,10.95,,[H][C@](C)(CNS(C)(=O)=O)C1=CC=C(C=C1)C1=CC=C(C=C1)[C@@]([H])(C)CNS(C)(=O)=O,,,,,0,,424.1490494,2,2,0,0,0,0
5672,04/06/2019 00:00,DB07456,"3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione",,,,,,solid,,,0.00428,9.55,10.21,[H]N1C=C(C2=CC=CC=C12)C1=C(C(=O)N([H])C1=O)C1=CN(CC[C@H]2CCCN2C)C2=CC=CC=C12,,,,,0,,438.2055761,6,4,4,2,1,2
5673,04/06/2019 00:00,DB07457,"3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE",,,,,,solid,,,0.00842,9.61,10.41,NCCCN1C=C(C2=C1C=CC=C2)C1=C(C(=O)NC1=O)C1=CNC2=C1C=CC=C2,,,,,0,,384.1586259,5,4,3,2,0,1
5674,04/06/2019 00:00,DB07458,"3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione",,,,,,solid,,,0.00428,5.34,9.36,[H]N1C=C(C2=CC=CC=C12)C1=C(C(=O)N([H])C1=O)C1=CN(CC[C@@H]2CCCN2C)C2=CC=CC=C12,,,,,0,,438.2055761,6,4,4,2,1,2
5675,04/06/2019 00:00,DB07459,4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE,,,,,,solid,,,0.011,14.77,4.14,O=C(NCC1=NC=CC=C1)C1=CC=C(OC2=CC=CC=C2)C=C1,,,,,0,,304.1211778,3,3,1,1,0,0
5676,04/06/2019 00:00,DB07460,2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE,,,,,,solid,,,0.0211,12.79,4.02,CNC(=O)C1=C(NC2=NC(NC3=CC=C(C=C3OC)N3CCOCC3)=NC=C2Cl)C=CC=C1,,,,,0,,468.1676663,4,3,2,1,1,1
5677,04/06/2019 00:00,DB07461,"3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE",,,,,,solid,,,13.3,14.21,8.03,[H][C@]1(CCN2CC[C@@](N)(CC3=CC=CC=C3)C(=O)N12)C=O,,,,,0,,273.1477268,3,1,2,0,2,2
5678,04/06/2019 00:00,DB07462,"(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE",,,,,,solid,,,0.122,6.2,-7,OC1=CC=C(C(=O)C2=CC=CC=C2)C(=C1O)[N+]([O-])=O,,,,,0,,259.0480724,2,2,0,0,0,0
5679,04/06/2019 00:00,DB07463,"(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(butylsulfanyl)methyl]pyrrolidin-3-ol",,,,,,solid,,,0.0861,13.47,8.66,[H][C@]1(O)CN(CC2=CNC3=C2N=CN=C3N)C[C@]1([H])CSCCCC,,,,,0,,335.1779814,3,2,3,2,1,1
5680,04/06/2019 00:00,DB07464,1(R)-1-ACETAMIDO-2-(3-CARBOXY-2-HYDROXYPHENYL)ETHYL BORONIC ACID,,,,,,solid,,,0.68,2.76,-0.97,[H][C@@](CC1=CC=CC(C(O)=O)=C1O)(NC(C)=O)B(O)O,,,,,0,,267.0914176,1,1,0,0,0,0
5681,04/06/2019 00:00,DB07465,"(1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile",,,,,,solid,,,2.26,14.74,7.9,[H][C@@](N)(C(=O)N1[C@@]2([H])C[C@@]2([H])C[C@@]1([H])C#N)[C@]12C[C@@]3([H])C[C@]([H])(C[C@](O)(C3)C1)C2,,,,,0,,315.194677,6,0,1,0,1,1
5682,04/06/2019 00:00,DB07466,(1R)-2-PHENYLACETAMIDO-2-(3-CARBOXYPHENYL)ETHYL BORONIC ACID,,,,,,solid,,,0.0211,4.04,-2.1,[H][C@@](CC1=CC=CC(=C1)C(O)=O)(NC(=O)CC1=CC=CC=C1)B(O)O,,,,,0,,327.1278031,2,2,0,0,0,0
5683,04/06/2019 00:00,DB07467,"4-chloro-N-[(2S)-2-methyl-2,3-dihydro-1H-indol-1-yl]-3-sulfamoylbenzamide",,,,,,solid,,,0.0342,8.85,0.097,[H][C@]1(C)CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(=C1)S(N)(=O)=O,,,,,0,,365.0600901,3,2,1,0,0,1
5684,04/06/2019 00:00,DB07468,"(3aS)-3a-hydroxy-5-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one",,,,,,solid,,,0.206,11.55,2.38,CC1=C2C(=CC=C1)N=C1N(CC[C@@]1(O)C2=O)C1=CC=CC=C1,,,,,0,,292.1211778,4,2,2,0,1,2
5685,04/06/2019 00:00,DB07469,"(3aS)-3a-hydroxy-7-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one",,,,,,solid,,,0.194,11.55,2.35,CC1=CC=C2C(=C1)N=C1N(CC[C@@]1(O)C2=O)C1=CC=CC=C1,,,,,0,,292.1211778,4,2,2,0,1,2
5686,04/06/2019 00:00,DB07470,"(3aS)-3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one",,,,,,solid,,,0.257,11.54,2.25,O[C@@]12CCN(C1=NC1=C(C=CC=C1)C2=O)C1=CC=CC=C1,,,,,0,,278.1055277,4,2,2,0,1,2
5687,04/06/2019 00:00,DB07471,"5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE",,,,,,solid,,,0.0104,14.13,6,[H][C@](C)(OC1=C(SC(=C1)N1C=NC2=CC(OC)=C(OC)C=C12)C(N)=O)C1=CC=CC=C1Cl,,,,,0,,457.0863048,4,4,2,2,0,0
5688,04/06/2019 00:00,DB07472,"(R)-(+)9B-(3-METHYL)PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-5(9BH)-ONE",,,,,,solid,,,0.00615,,-1.7,CC1=CC(=CC=C1)[C@]12SCCN1C(=O)C1=CC=CC=C21,,,,,0,,281.0874351,4,2,2,0,1,2
5689,04/06/2019 00:00,DB07473,"(R)-(+) 5(9BH)-OXO-9B-PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-3-CARBOXYLIC ACID METHYL ESTER",,,,,,solid,,,0.0147,,-2.2,COC(=O)[C@@H]1CS[C@]2(N1C(=O)C1=CC=CC=C21)C1=CC=CC=C1,,,,,0,,325.0772643,4,2,2,0,1,2
5690,04/06/2019 00:00,DB07474,3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE,,,,,,solid,,,0.0302,9,6.43,CC1=CC(=CC2=C1N=C(N2)C1=C(NCC2=NC=CC=C2)C=CNC1=O)N1C=CN=C1,,,,,0,,397.1651082,5,5,4,4,0,0
5691,04/06/2019 00:00,DB07476,N-[4-(AMINOSULFONYL)PHENYL]-2-MERCAPTOBENZAMIDE,,,,,,solid,,,0.0191,5.35,-4.1,NS(=O)(=O)C1=CC=C(NC(=O)C2=CC=CC=C2S)C=C1,,,,,0,,308.0289342,2,2,0,0,0,0
5692,04/06/2019 00:00,DB07477,Felbinac,,,,,,solid,,,0.0372,4.71,,OC(=O)CC1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,212.0837296,2,2,0,0,0,0
5693,04/06/2019 00:00,DB07478,"1,1'-BIPHENYL-3,4-DIOL",,,,,,solid,,,0.426,9.19,-6.3,OC1=C(O)C=C(C=C1)C1=CC=CC=C1,,,,,0,,186.0680796,2,2,0,0,0,0
5694,04/06/2019 00:00,DB07479,"(1S)-1,2,3,4-TETRAHYDRO-BENZO[C]PHENANTHRENE-2,3,4-TRIOL",,,,,,solid,,,0.0674,12.88,-3.3,[H][C@@]1(O)CC2=C(C=CC3=C2C2=C(C=CC=C2)C=C3)[C@@]([H])(O)[C@]1([H])O,,,,,0,,280.1099444,4,3,0,0,0,0
5695,04/06/2019 00:00,DB07480,4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN,,,,,,solid,,,0.207,1.49,,OP(O)(=O)OC1=CC=C(CC2=CC=C(OP(O)(O)=O)C=C2)C=C1,,,,,0,,360.0163907,2,2,0,0,0,0
5696,04/06/2019 00:00,DB07481,"tert-butyl [(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl]carbamate",,,,,,solid,,,0.253,11.03,5.45,CC(C)(C)OC(=O)NCC1=CNC2=C1C(=O)NC(N)=N2,,,,,0,,279.1331394,2,2,2,2,0,0
5697,04/06/2019 00:00,DB07482,(2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE,,,,,,solid,,,30.2,,9.82,[H][C@]1(CCCN1C(=O)[C@]1([H])CCCN1)B(O)O,,,,,0,,212.1332228,2,0,2,0,2,2
5698,04/06/2019 00:00,DB07483,"1,1'-BIPHENYL-2-SULFINIC ACID",,,,,,solid,,,1.69,0.96,,O[S@@](=O)C1=CC=CC=C1C1=CC=CC=C1,,,,,0,,218.0401506,2,2,0,0,0,0
5699,04/06/2019 00:00,DB07484,"(2R)-4,4-dihydroxy-5-nitro-2-(phenylmethyl)pentanoic acid",,,,,,solid,,,0.974,3.9,-4.4,[H][C@@](CC1=CC=CC=C1)(CC(O)(O)C[N+]([O-])=O)C(O)=O,,,,,0,,269.0899372,1,1,0,0,0,0
5700,04/06/2019 00:00,DB07485,"4,4'-cyclohexane-1,1-diyldiphenol",,,,,,solid,,,0.0141,9.76,-5.5,OC1=CC=C(C=C1)C1(CCCCC1)C1=CC=C(O)C=C1,,,,,0,,268.1463299,3,2,0,0,0,0
5701,04/06/2019 00:00,DB07486,"3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline",,,,,,solid,,,0.00891,,3.3,NC1=CC=CC(SC2=CC=C(\C=C\C(=O)N3CCOCC3)C(=C2C(F)(F)F)C(F)(F)F)=C1,,,,,0,,476.0993181,3,2,1,0,1,1
5702,04/06/2019 00:00,DB07487,"(6-METHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL)METHYLPHOSPHINATE",,,,,,solid,,,0.645,2.19,-4.9,[H][C@@]1(C[P@@]([H])([O-])=O)CCC2=CC(C)=CC=C2O1,,,,,-1,,225.0686045,2,1,1,0,0,1
5703,04/06/2019 00:00,DB07488,"{(2Z)-4-AMINO-2-[(4-METHOXYPHENYL)IMINO]-2,3-DIHYDRO-1,3-THIAZOL-5-YL}(4-METHOXYPHENYL)METHANONE",,,,,,solid,,,0.0485,10.84,3.78,COC1=CC=C(C=C1)\N=C1\NC(N)=C(S1)C(=O)C1=CC=C(OC)C=C1,,,,,0,,355.0990624,3,3,1,1,0,0
5704,04/06/2019 00:00,DB07489,"4-Amino-2-[(3-chlorophenyl)amino]-5-(4-fluorobenzoyl)-1,3-thiazol-3-ium",,,,,,solid,,,0.000674,12.12,1.4,[H]N([H])C1=C(SC(N([H])C2=CC(Cl)=CC=C2)=[N+]1[H])C(=O)C1=CC=C(F)C=C1,,,,,1,,348.0368153,3,3,1,1,0,0
5705,04/06/2019 00:00,DB07490,"2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL",,,,,,solid,,,0.0028,4.39,-7.6,[H][C@@](C)(C1=CC=C(Cl)C=C1)C1=CC(=CC(=C1O)[N+]([O-])=O)[N+]([O-])=O,,,,,0,,322.0356491,2,2,0,0,0,0
5706,04/06/2019 00:00,DB07491,"5-amino-2,4,6-tribromobenzene-1,3-dicarboxylic acid",,,,,,solid,,,0.0206,2.55,0.16,NC1=C(Br)C(C(O)=O)=C(Br)C(C(O)=O)=C1Br,,,,,0,,414.7690439,1,1,0,0,0,0
5707,04/06/2019 00:00,DB07492,Bromamphenicol,,,,,,solid,,,0.344,7.67,-2.8,[H][C@](CO)(NC(=O)C(Br)Br)[C@]([H])(O)C1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,409.9112957,1,1,0,0,0,0
5708,04/06/2019 00:00,DB07493,"(2Z)-5'-BROMO-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE AMMONIATE",,,,,,solid,,,0.0189,7.25,-2.6,BrC1=CC2=C(NC(=O)\C2=C2/NC3=C(C=CC=C3)C2=O)C=C1,,,,,0,,339.9847396,4,2,2,0,0,2
5709,04/06/2019 00:00,DB07494,"(3-EXO)-3-(10,11-DIHYDRO-5H-DIBENZO[A,D][7]ANNULEN-5-YLOXY)-8,8-DIMETHYL-8-AZONIABICYCLO[3.2.1]OCTANE",,,,,,solid,,,2.76E-06,,-4.2,[H][C@]12CC[C@]([H])(C[C@]([H])(C1)OC1C3=CC=CC=C3CCC3=C1C=CC=C3)[N+]2(C)C,,,,,1,,348.232191,5,2,2,0,2,2
5710,04/06/2019 00:00,DB07495,"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE",,,,,,solid,,,0.0324,7.84,-0.32,CCNC(=O)C1=NNC(=C1C1=CC=C(OC)C=C1)C1=CC(Cl)=C(O)C=C1O,,,,,0,,387.0985837,3,3,1,1,0,0
5711,04/06/2019 00:00,DB07496,"1,3-DIPHENYLUREA",,,,,,solid,,,0.0912,11.53,-4.5,O=C(NC1=CC=CC=C1)NC1=CC=CC=C1,,,,,0,,212.094963,2,2,0,0,0,0
5712,04/06/2019 00:00,DB07497,"5-(HEXAHYDRO-2-OXO-1H-THIENO[3,4-D]IMIDAZOL-6-YL)PENTANAL",,,,,,solid,,,0.897,13.59,-1.9,[H][C@@]1(CCCCC=O)SC[C@]2([H])NC(=O)N[C@]12[H],,,,,0,,228.0932488,2,0,2,0,2,2
5713,04/06/2019 00:00,DB07498,"4-[3-(3-NITROPHENYL)-1,2,4-OXADIAZOL-5-YL]BUTANOIC ACID",,,,,,solid,,,0.199,4.06,-2.6,OC(=O)CCCC1=NC(=NO1)C1=CC(=CC=C1)[N+]([O-])=O,,,,,0,,277.0698705,2,2,1,1,0,0
5714,04/06/2019 00:00,DB07499,"N-(4-{[amino(imino)methyl]amino}butyl)-2,4'-bi-1,3-thiazole-4-carboxamide",,,,,,solid,,,0.165,14.62,11.97,NC(=N)NCCCCNC(=O)C1=CSC(=N1)C1=CSC=N1,,,,,0,,324.0827011,2,2,2,2,0,0
5715,04/06/2019 00:00,DB07500,(2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one,,,,,,solid,,,0.00322,8.03,-4.9,COC1=CC(O)=C(C=C1CC=C(C)C)C(=O)\C=C\C1=CC=C(O)C=C1,,,,,0,,338.1518092,2,2,0,0,0,0
5716,04/06/2019 00:00,DB07501,(2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol,,,,,,solid,,,0.035,13.85,8.7,[H]N(C1=CC=C(OC[C@@H](O)CN(C)C)C=C1)C1=NC=C(Br)C(=N1)N([H])C1=CC=CC=C1,,,,,0,,457.1113371,3,3,1,1,0,0
5717,04/06/2019 00:00,DB07502,"4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol",,,,,,solid,,,0.453,7.44,-0.96,OC1=CC2=C(C=C1)C(=NO2)C1=CC(Br)=C(O)C=C1O,,,,,0,,320.9636698,3,3,1,1,0,0
5718,04/06/2019 00:00,DB07503,"(5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE",,,,,,solid,,,0.133,7.4,-5,FC1(F)OC2=C(O1)C=C(\C=C1/SC(=O)NC1=O)C=C2,,,,,0,,284.9907351,3,1,2,0,1,2
5719,04/06/2019 00:00,DB07504,(2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol,,,,,,solid,,,0.035,9.13,8.65,[H]N(C1=CC=C(OC[C@H](O)CN(C)C)C=C1)C1=NC=C(Br)C(=N1)N([H])C1=CC=CC=C1,,,,,0,,457.1113371,3,3,1,1,0,0
5720,04/06/2019 00:00,DB07505,"N-({(3R,4R)-4-[(benzyloxy)methyl]pyrrolidin-3-yl}methyl)-N-(2-methylpropyl)benzenesulfonamide",,,,,,solid,,,0.00161,,11.06,[H][C@]1(COCC2=CC=CC=C2)CNC[C@]1([H])CN(CC(C)C)S(=O)(=O)C1=CC=CC=C1,,,,,0,,416.2133639,3,2,1,0,1,1
5721,04/06/2019 00:00,DB07506,L-BENZYLSUCCINIC ACID,,,,,,solid,,,1.47,4.25,,[H][C@](CC(O)=O)(CC1=CC=CC=C1)C(O)=O,,,,,0,,208.0735589,1,1,0,0,0,0
5722,04/06/2019 00:00,DB07507,"2-(4-hydroxybiphenyl-3-yl)-4-methyl-1H-isoindole-1,3(2H)-dione",,,,,,solid,,,0.00599,8.15,-1.9,CC1=C2C(=O)N(C(=O)C2=CC=C1)C1=CC(=CC=C1O)C1=CC=CC=C1,,,,,0,,329.1051933,4,3,1,0,0,1
5723,04/06/2019 00:00,DB07508,4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE,,,,,,solid,,,0.0372,7.69,11.51,CN1C(CC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(NS(=O)(=O)C1=CC=CC=C1)=C2,,,,,0,,419.1415959,4,4,1,1,0,0
5724,04/06/2019 00:00,DB07509,difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron,,,,,,solid,,,0.000689,4.53,,CCCCCCCCC1=CC=C2C=C3C=CC(CCCCC(O)=O)=[N+]3[B-](F)(F)N12,,,,,0,,404.2446651,3,1,3,1,0,2
5725,04/06/2019 00:00,DB07510,"3-fluoro-6-(4-fluorophenyl)-2-hydroxy-6-oxohexa-2,4-dienoic acid",,,,,,solid,,,0.0155,3.04,-7.2,OC(=O)C(\O)=C(\F)/C=C/C(=O)C1=CC=C(F)C=C1,,,,,0,,254.0390652,1,1,0,0,0,0
5726,04/06/2019 00:00,DB07511,"4-(4-methyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzonitrile",,,,,,solid,,,0.0269,,-1.8,CC1=C2C(=O)N(C(=O)C2=CC=C1)C1=CC=C(C=C1)C#N,,,,,0,,262.0742276,3,2,1,0,0,1
5727,04/06/2019 00:00,DB07512,7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE,,,,,,solid,,,0.00346,,-4.9,ClC1=CC=CC(COC2=CC=C3C(OC(=O)C=C3C=O)=C2)=C1,,,,,0,,314.0345865,3,3,1,1,0,0
5728,04/06/2019 00:00,DB07513,7-[(3-CHLOROBENZYL)OXY]-4-[(METHYLAMINO)METHYL]-2H-CHROMEN-2-ONE,,,,,,solid,,,0.0037,,8.82,CNCC1=CC(=O)OC2=C1C=CC(OCC1=CC=CC(Cl)=C1)=C2,,,,,0,,329.0818711,3,3,1,1,0,0
5729,04/06/2019 00:00,DB07514,"3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one",,,,,,solid,,,0.0112,16.46,4.27,CC1=C(C(=O)N(C=C1)C1=CC=C2C(NCC2(C)C)=C1)C1=CC2=CN=C(N)N=C2C=C1,,,,,0,,397.1902604,5,4,3,2,0,1
5730,04/06/2019 00:00,DB07515,"1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL",,,,,,solid,,,0.078,12.14,9.18,[H][C@]1(N)CCC([H])(CNCCN2C(Cl)=CN=C(NCC(F)(F)C3=CC=CC=N3)C2([H])O)C([H])(C)N1,,,,,0,,457.2168427,3,1,3,1,1,2
5731,04/06/2019 00:00,DB07516,"(2Z,4E)-3-chloro-2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid",,,,,,solid,,,0.0692,3.28,-6.8,OC(=O)C(\O)=C(\Cl)/C=C/C(=O)C1=CC=CC=C1,,,,,0,,252.0189364,1,1,0,0,0,0
5732,04/06/2019 00:00,DB07517,3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPIONIC,,,,,,solid,,,0.217,3.87,-2.9,CCCC1=C(C)C(C(O)=O)=C(CCC(O)=O)O1,,,,,0,,240.0997736,1,1,1,1,0,0
5733,04/06/2019 00:00,DB07518,(2R)-2-ETHYL-1-HEXANESULFONIC ACID,,,,,,solid,,,0.721,-1.2,,[H][C@@](CC)(CCCC)COS(O)(=O)=O,,,,,0,,210.0925801,0,0,0,0,0,0
5734,04/06/2019 00:00,DB07519,"(6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one",,,,,,solid,,,0.00384,19.17,6.79,COC1=CC(=CC=C1)C1=CC(CC[C@]2(C)CC(=O)N(C)C(N)=N2)=CC=C1,,,,,0,,351.194677,3,2,1,0,0,1
5735,04/06/2019 00:00,DB07520,"N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(MORPHOLIN-4-YLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE",,,,,,solid,,,0.569,11.96,9.2,[H][C@@](CS(=O)(=O)N1CCOCC1)(N[C@@]([H])(C1=CC=C(F)C=C1)C(F)(F)F)C(=O)NC1(CN)CC1,,,,,0,,482.1610892,3,1,1,0,1,1
5736,04/06/2019 00:00,DB07521,"6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL",,,,,,solid,,,0.00386,12.21,10.42,[H][C@]1(CCN=C2NC[C@]([H])(Cl)N(CCNCC3=CSC4=C3C=C(Cl)C=C4)C2([H])O)CCCCN1,,,,,0,,483.162637,4,2,3,1,2,2
5737,04/06/2019 00:00,DB07522,"N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE",,,,,,solid,,,0.0115,10.11,8.98,[H][C@](N)(CC1=CC=CC=C1)[C@]([H])(O)CNS(=O)(=O)C1=CC=C2C=CC=CC2=C1,,,,,0,,370.1351136,3,3,0,0,0,0
5738,04/06/2019 00:00,DB07524,"N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine",,,,,,solid,,,0.0877,17.41,4.13,N(C1=CNC2=NC=CC=C12)C1=CC=CC=C1,,,,,0,,209.0952974,3,3,2,2,0,0
5739,04/06/2019 00:00,DB07525,"3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine",,,,,,solid,,,0.0233,16.08,4.29,COC1=CC=CC(CC2=CNC3=C2C=CC=N3)=C1,,,,,0,,238.1106131,3,3,2,2,0,0
5740,04/06/2019 00:00,DB07526,N-[4-({[5-(DIMETHYLAMINO)-1-NAPHTHYL]SULFONYL}AMINO)BUTYL]-3-SULFANYLPROPANAMIDE,,,,,,solid,,,0.00755,9.7,4.63,CN(C)C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)NCCCCNC(=O)CCS,,,,,0,,409.1493837,2,2,0,0,0,0
5741,04/06/2019 00:00,DB07527,"N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE",,,,,,solid,,,0.0236,10.91,9.01,[H][C@](N)(CC1=CC=CC=C1)[C@]([H])(O)CNS(=O)(=O)C1=C(C)C=C(OC)C(C)=C1C,,,,,0,,392.1769784,2,2,0,0,0,0
5742,04/06/2019 00:00,DB07528,3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one,,,,,,solid,,,0.00584,16.46,3.93,CC1=C(C2=CC3=C(C=C2)N=C(N)N=C3)C(=O)N(C=C1)C1=CC(=CC=C1)C(F)(F)F,,,,,0,,396.1197958,4,4,2,2,0,0
5743,04/06/2019 00:00,DB07529,"2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE",,,,,,solid,,,0.458,10.85,4.16,N=C1NC(=O)\C(S1)=C/C1=CC=CC=N1,,,,,0,,205.0309828,2,1,2,1,1,1
5744,04/06/2019 00:00,DB07530,"(1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol",,,,,,solid,,,0.00107,6.43,-2.7,[H][C@]1(CC[C@](C)(CCC#CC(O)(C(F)(F)F)C(F)(F)F)C1(C)C)\C=C\C=C1C[C@](O)([H])C[C@@](O)([H])C1,,,,,0,,482.2255642,2,0,0,0,0,0
5745,04/06/2019 00:00,DB07531,"4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE",,,,,,solid,,,0.0571,7.89,-3.3,NS(=O)(=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=C1/SC(=O)NC1=O,,,,,0,,350.0031134,3,2,2,1,1,1
5746,04/06/2019 00:00,DB07532,N-hexanoyl-L-homoserine,,,,,,solid,,,11.2,4.14,-0.47,[H][C@@](CCO)(NC(=O)CCCCC)C(O)=O,,,,,0,,217.1314081,0,0,0,0,0,0
5747,04/06/2019 00:00,DB07533,"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE",,,,,,solid,,,0.0964,9.94,1.47,CNS(=O)(=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=C1/SC(=N)NC1=O,,,,,0,,363.0347479,3,2,2,1,1,1
5748,04/06/2019 00:00,DB07534,"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE",,,,,,solid,,,0.105,9.97,1.47,NS(=O)(=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=C1/SC(=N)NC1=O,,,,,0,,349.0190978,3,2,2,1,1,1
5749,04/06/2019 00:00,DB07535,2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one,,,,,,solid,,,0.129,11.45,4.42,NC1=NC(CCC2=CC3=C(C=CN3)C=C2)=CC(=O)N1,,,,,0,,254.1167611,3,3,2,2,0,0
5750,04/06/2019 00:00,DB07536,"N-{(1S,2R)-2-hydroxy-1-[(hydroxyamino)carbonyl]propyl}-4-{[4-(morpholin-4-ylmethyl)phenyl]ethynyl}benzamide",,,,,,solid,,,0.0159,8.71,6.85,[H][C@](C)(O)[C@]([H])(NC(=O)C1=CC=C(C=C1)C#CC1=CC=C(CN2CCOCC2)C=C1)C(=O)NO,,,,,0,,437.195071,3,2,1,0,1,1
5751,04/06/2019 00:00,DB07537,"N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide",,,,,,solid,,,0.00662,11.75,5.88,CC1=CC=C(C=C1C(=O)NC1=CN=C(N)C=C1)C(=O)NCCC1CCCC1,,,,,0,,366.2055761,3,2,1,1,0,0
5752,04/06/2019 00:00,DB07538,"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE",,,,,,solid,,,0.0546,8.76,1.47,NS(=O)(=O)C1=CC=C(C=C1C(F)(F)F)C1=CC=C(O1)\C=C1/SC(=N)NC1=O,,,,,0,,417.0064825,3,2,2,1,1,1
5753,04/06/2019 00:00,DB07539,"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID",,,,,,solid,,,0.0808,3.9,1.47,OC(=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=C1/SC(=N)NC1=O,,,,,0,,314.0361278,3,2,2,1,1,1
5754,04/06/2019 00:00,DB07540,"4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE",,,,,,solid,,,0.115,9.97,1.43,C\C(C1=CC=C(O1)C1=CC=C(C=C1)S(N)(=O)=O)=C1\SC(=N)NC1=O,,,,,0,,363.0347479,3,2,2,1,1,1
5755,04/06/2019 00:00,DB07541,4-(dihydroxyboranyl)-2-({[4-(phenylsulfonyl)thiophen-2-yl]sulfonyl}amino)benzoic acid,,,,,,solid,,,0.0112,3.55,-5.5,OB(O)C1=CC(NS(=O)(=O)C2=CC(=CS2)S(=O)(=O)C2=CC=CC=C2)=C(C=C1)C(O)=O,,,,,0,,466.9974598,3,3,1,1,0,0
5756,04/06/2019 00:00,DB07542,5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOBUTYL-HEXANOIC ACID,,,,,,solid,,,0.198,4.56,9.87,[H][C@](N)(CC1CCCCC1)[C@@]([H])(O)C[C@@]([H])(CC(C)C)C(O)=O,,,,,0,,285.2303939,1,0,0,0,0,0
5757,04/06/2019 00:00,DB07543,(2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol,,,,,,solid,,,0.031,14.03,9.67,[H][C@](O)(CNC(C)C)COC1=CC=CC2=C1C1=C(N2)C=CC=C1,,,,,0,,298.1681279,3,3,1,1,0,0
5758,04/06/2019 00:00,DB07544,N'-(5-CHLOROBENZOFURAN-2-CARBONYL)-2-(TRIFLUOROMETHYL)BENZENESULFONOHYDRAZIDE,,,,,,solid,,,0.0152,4.04,-4.6,FC(F)(F)C1=CC=CC=C1S(=O)(=O)NNC(=O)C1=CC2=CC(Cl)=CC=C2O1,,,,,0,,418.0001901,3,3,1,1,0,0
5759,04/06/2019 00:00,DB07545,N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE,,,,,,solid,,,0.00711,13.09,5.16,FC(F)(F)C1=CC=CC(NC2=NC(NC3=CC(NC(=O)C4CC4)=CC=C3)=NC=C2)=C1,,,,,0,,413.1463449,4,3,1,1,0,0
5760,04/06/2019 00:00,DB07546,[1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid,,,,,,solid,,,0.167,3.85,4.48,CC(C)NC1=CC2=C(C=NN2C2=NC(=CN=C2)N2C=CC(CC(O)=O)=C2)C=C1,,,,,0,,376.1647739,4,4,3,3,0,0
5761,04/06/2019 00:00,DB07547,5-(4-CYANOPHENYL)-3-{[(2-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID,,,,,,solid,,,0.00406,3.82,-9,CC1=CC=CC=C1S(=O)(=O)NC1=C(SC(=C1)C1=CC=C(C=C1)C#N)C(O)=O,,,,,0,,398.0394989,3,3,1,1,0,0
5762,04/06/2019 00:00,DB07548,"2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE",,,,,,solid,,,0.0246,11.66,3.12,CC1=CN=C(NCC(F)(F)C2=CC=CC=N2)C(=O)N1CC(=O)NCC1=C(F)C=CC=N1,,,,,0,,432.1521585,3,3,3,3,0,0
5763,04/06/2019 00:00,DB07549,"2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE",,,,,,solid,,,0.00123,11.75,3.27,CC1=C[NH+]=C(NCC(F)(F)C2=[NH+]C=CC=C2)C(=O)N1CC(=O)NCC1=C(F)C(C)=CC=N1,,,,,2,,448.1823615,3,3,3,3,0,0
5764,04/06/2019 00:00,DB07550,"2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE",,,,,,solid,,,0.00314,12.46,2.02,[O-][N+]1=CC=CC=C1C(F)(F)CNC1=NC=C(Cl)N(CC(=O)NCC2=C(F)C=CC=C2)C1=O,,,,,0,,467.0972017,3,3,2,2,0,0
5765,04/06/2019 00:00,DB07551,"(2S)-2-{[4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino}-2-methylbutanenitrile",,,,,,solid,,,0.296,14.4,0.57,CCNC1=NC(Cl)=NC(NC(C)(CC)C#N)=N1,,,,,0,,254.1046722,1,1,1,1,0,0
5766,04/06/2019 00:00,DB07552,"(2R)-2-{[4-chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino}-2-methylbutanenitrile",,,,,,solid,,,0.296,9.15,7.38,CCNC1=NC(Cl)=NC(NC(C)(CC)C#N)=N1,,,,,0,,254.1046722,1,1,1,1,0,0
5767,04/06/2019 00:00,DB07553,"9,9,9-TRIFLUORO-8-OXO-N-PHENYLNONANAMIDE",,,,,,solid,,,0.00313,13.96,-3.5,FC(F)(F)C(=O)CCCCCCC(=O)NC1=CC=CC=C1,,,,,0,,301.1289635,1,1,0,0,0,0
5768,04/06/2019 00:00,DB07555,"Hydroxy(oxo)(2-{(1S)-2,2,2-trifluoro-1-[2-(trimethylarsonio)ethoxy]ethyl}phenyl)ammonium",,,,,,solid,,,0.00211,-11,-4.3,[H][C@](OCC[As+](C)(C)C)(C1=CC=CC=C1[N+](O)=O)C(F)(F)F,,,,,2,,369.0522025,1,1,0,0,0,0
5769,04/06/2019 00:00,DB07556,N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE,,,,,,solid,,,0.0525,8.71,4.81,[H][C@](C(C)C)(N(CC1=CC=CN=C1)S(=O)(=O)C1=CC=C(OC)C=C1)C(=O)NO,,,,,0,,393.1358418,2,2,1,1,0,0
5770,04/06/2019 00:00,DB07557,"(5BETA)-PREGNANE-3,20-DIONE",,,,,,solid,,,0.00129,19.34,-7.1,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O,,,,,0,,316.2402303,4,0,0,0,0,0
5771,04/06/2019 00:00,DB07558,acetylleucyl-leucyl-norleucinal,,,,,,solid,,,0.0596,12.49,-1.7,[H]C(=O)[C@H](CCCC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O,,,,,0,,383.2784067,0,0,0,0,0,0
5772,04/06/2019 00:00,DB07559,"(2Z)-2-cyano-N-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide",,,,,,solid,,,0.00266,5.87,-3.2,C\C(O)=C(/C#N)C(=O)NC1=CC(Cl)=C(C=C1)C1=CC=CC=C1Cl,,,,,0,,346.027583,2,2,0,0,0,0
5773,04/06/2019 00:00,DB07560,N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide,,,,,,solid,,,0.207,12.36,5.63,[H][C@](NC(=O)C1CCCCC1)(C(C)C)C(=O)NC1=CC=NC=C1,,,,,0,,303.194677,2,1,1,1,0,0
5774,04/06/2019 00:00,DB07561,(2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide,,,,,,solid,,,0.00543,6.39,-3.2,CCOC1=CC(=CC=C1)C1=CC=C(NC(=O)C(\C#N)=C(\C)O)C=C1,,,,,0,,322.1317424,2,2,0,0,0,0
5775,04/06/2019 00:00,DB07562,"N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE",,,,,,solid,,,0.0141,14.57,5.85,CN(C)C1=CC=C(NC2=NC(=CC=N2)C2=C(C)N=C(C)S2)C=C1,,,,,0,,325.1361166,3,3,2,2,0,0
5776,04/06/2019 00:00,DB07563,"1-{7-cyclohexyl-6-[4-(4-methylpiperazin-1-yl)benzyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}methanamine",,,,,,solid,,,0.0442,,8.15,CN1CCN(CC1)C1=CC=C(CC2=CC3=CN=C(CN)N=C3N2C2CCCCC2)C=C1,,,,,0,,418.2844951,5,3,3,2,1,1
5777,04/06/2019 00:00,DB07564,"6-amino-2-[(2-morpholin-4-ylethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,,,,,solid,,,0.231,11.13,6.76,NC1=NC2=C(C=C3N=C(NCCN4CCOCC4)NC3=C2)C(=O)N1,,,,,0,,329.1600228,4,3,3,2,1,1
5778,04/06/2019 00:00,DB07565,Chloramphenicol succinate,,,,1 g/10mL,Intravenous,solid,,,0.112,3.65,-3.4,O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,422.0283708,1,1,0,0,0,0
5779,04/06/2019 00:00,DB07567,"(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL",,,,,,solid,,,0.00444,9.78,8.9,[H][C@@]1(C)C2=CC(O)=CC=C2O[C@@]([H])(C2=CC=C(OCCN3CCCC3)C=C2)[C@@]1([H])C1=CC=C(O)C=C1,,,,,0,,445.2253085,5,3,2,0,1,2
5780,04/06/2019 00:00,DB07568,"(2S)-2-[(2,1,3-BENZOTHIADIAZOL-4-YLSULFONYL)AMINO]-2-PHENYL-N-PYRIDIN-4-YLACETAMIDE",,,,,,solid,,,0.0226,7.64,5.62,[H][C@@](NS(=O)(=O)C1=CC=CC2=NSN=C12)(C(=O)NC1=CC=NC=C1)C1=CC=CC=C1,,,,,0,,425.0616313,4,4,2,2,0,0
5781,04/06/2019 00:00,DB07569,CIS-4-METHYL-N-[(1S)-3-(METHYLSULFANYL)-1-(PYRIDIN-4-YLCARBAMOYL)PROPYL]CYCLOHEXANECARBOXAMIDE,,,,,,solid,,,0.00798,12.4,5.63,[H][C@@](CCSC)(NC(=O)[C@]1([H])CC[C@]([H])(C)CC1)C(=O)NC1=CC=NC=C1,,,,,0,,349.1823981,2,1,1,1,0,0
5782,04/06/2019 00:00,DB07570,3-CYCLOHEXYL-1-(2-MORPHOLIN-4-YL-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID,,,,,,solid,,,0.00133,3.9,-4,OC(=O)C1=CC=C2C(=C1)N(CC(=O)N1CCOCC1)C(=C2C1CCCCC1)C1=CC=CC=C1,,,,,0,,446.2205574,5,3,2,1,1,1
5783,04/06/2019 00:00,DB07571,"N~2~-[(BENZYLOXY)CARBONYL]-N-[(1S,2S)-2-HYDROXY-1-(4-HYDROXYBENZYL)PROPYL]-L-LEUCINAMIDE",,,,,,solid,,,0.00846,9.5,-2.8,[H][C@@](C)(O)[C@]([H])(CC1=CC=C(O)C=C1)NC(=O)[C@]([H])(CC(C)C)NC(=O)OCC1=CC=CC=C1,,,,,0,,428.2311221,2,2,0,0,0,0
5784,04/06/2019 00:00,DB07572,3-{[(4-methylphenyl)sulfonyl]amino}propyl pyridin-4-ylcarbamate,,,,,,solid,,,0.0308,10.4,4.88,CC1=CC=C(C=C1)S(=O)(=O)NCCCOC(=O)NC1=CC=NC=C1,,,,,0,,349.1096271,2,2,1,1,0,0
5785,04/06/2019 00:00,DB07573,"(2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol",,,,,,solid,,,6.75,14.08,6.66,[H][C@@](O)(COC1=C(C)C=CC(C)=C1)CN1CCOCC1,,,,,0,,265.1677936,2,1,1,0,1,1
5786,04/06/2019 00:00,DB07574,"2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE",,,,,,solid,,,0.00629,9.45,-2.8,[H][C@@]1(CCC2=C(C(OC)=C(OC)C(OC)=C2)C2=CC=C(OC)C(=O)C=C12)NC(=O)CS,,,,,0,,431.1402585,3,2,0,0,0,0
5787,04/06/2019 00:00,DB07575,"2,4-DIAMINO-1,5-DIPHENYL-3-HYDROXYPENTANE",,,,,,solid,,,0.232,14,9.71,[H][C@](N)(CC1=CC=CC=C1)C(O)[C@@]([H])(N)CC1=CC=CC=C1,,,,,0,,270.1732133,2,2,0,0,0,0
5788,04/06/2019 00:00,DB07577,"6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE",,,,,,solid,,,0.771,17.22,7.77,CCC1=NC(N)=NC(N)=C1C1=CC=CC=C1,,,,,0,,214.1218464,2,2,1,1,0,0
5789,04/06/2019 00:00,DB07578,"3-[4-(2-METHYL-IMIDAZO[4,5-C]PYRIDIN-1-YL)BENZYL]-3H-BENZOTHIAZOL-2-ONE",,,,,,solid,,,0.0336,,5.33,CC1=NC2=C(C=CN=C2)N1C1=CC=C(CN2C(=O)SC3=C2C=CC=C3)C=C1,,,,,0,,372.1044821,5,5,3,3,0,0
5790,04/06/2019 00:00,DB07579,"BIS-1,2-{[(Z)-2-CARBOXY-2-METHYL-1,3-DIOXANE]-5-YLOXYCARBAMOYL}-ETHANE",,,,,,solid,,,0.815,2.63,1.73,[H][C@@]1(CO[C@](C)(OC1)C(O)=O)OC(O)=NCCN=C(O)O[C@@]1([H])CO[C@](C)(OC1)C(O)=O,,,,,0,,436.1329242,2,0,2,0,2,2
5791,04/06/2019 00:00,DB07580,"BIS-1,2-{[(Z)-2CARBOXY-2-METHYL-1,3-DIOXANE]-5-YLOXYCARBONYL}-PIPERAZINE",,,,,,solid,,,18.3,2.62,-3.8,[H][C@@]1(CO[C@](C)(OC1)C(O)=O)OC(=O)N1CCN(CC1)C(=O)O[C@@]1([H])CO[C@](C)(OC1)C(O)=O,,,,,0,,462.1485743,3,0,3,0,3,3
5792,04/06/2019 00:00,DB07581,5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOPROPYL-HEXANOIC ACID,,,,,,solid,,,0.389,4.52,9.87,[H][C@](N)(CC1CCCCC1)[C@@]([H])(O)C[C@@]([H])(C(C)C)C(O)=O,,,,,0,,271.2147438,1,0,0,0,0,0
5793,04/06/2019 00:00,DB07582,"N-[(2R,3S)-1-((2S)-2-{[(CYCLOPENTYLAMINO)CARBONYL]AMINO}-3-METHYLBUTANOYL)-2-(1-FORMYL-1-CYCLOBUTYL)PYRROLIDINYL]CYCLOPROPANECARBOXAMIDE",,,,,,solid,,,0.352,14.66,0.035,[H][C@](NC(=O)NC1CCCC1)(C(C)C)C(=O)N1CC[C@]([H])(NC(=O)C2CC2)[C@@]1([H])C1(CCC1)C=O,,,,,0,,446.2893057,4,0,1,0,1,1
5794,04/06/2019 00:00,DB07583,"(4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE",,,,,,solid,,,0.00441,10.1,9.17,[H][C@@]1(CNS(=O)(=O)C2=CC=CC3=CN=CC=C23)C[C@]([H])(CN1)OCC1=CC=C(Cl)C=C1,,,,,0,,431.1070402,4,3,2,1,1,1
5795,04/06/2019 00:00,DB07584,"N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine",,,,,,solid,,,0.0442,10.46,6.38,CC1=NN=C(N1)C1=CC=CC=C1NC1=NC=NC2=C1C=CN2,,,,,0,,291.1232434,4,4,3,3,0,0
5796,04/06/2019 00:00,DB07585,"5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine",,,,,,solid,,,0.117,12.01,6.83,ClC1=CNC2=C1C(=NC=N2)N1CCC2=C(C1)N=CN2,,,,,0,,274.073372,4,3,4,3,0,1
5797,04/06/2019 00:00,DB07586,"5-(4-METHYL-BENZOYLAMINO)-BIPHENYL-3,4'-DICARBOXYLIC ACID 3-DIMETHYLAMIDE-4'-HYDROXYAMIDE",,,,,,solid,,,0.00215,9.61,-0.86,CN(C)C(=O)C1=CC(=CC(NC(=O)C2=CC=C(C)C=C2)=C1)C1=CC=C(C=C1)C(=O)NO,,,,,0,,417.1688562,3,3,0,0,0,0
5798,04/06/2019 00:00,DB07587,"N-(1-CYANOCYCLOPROPYL)-3-({[(2S)-5-OXOPYRROLIDIN-2-YL]METHYL}SULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE",,,,,,solid,,,0.21,6.11,2.03,[H][C@@](CS(=O)(=O)C[C@]1([H])CCC(=O)N1)(N[C@@]([H])(C1=CC=C(F)C=C1)C(F)(F)F)C(=O)NC1(CC1)C#N,,,,,0,,490.1297891,3,1,1,0,1,1
5799,04/06/2019 00:00,DB07588,"3,4-DI-1H-INDOL-3-YL-1H-PYRROLE-2,5-DICARBOXYLIC ACID",,,,,,solid,,,0.00252,3.21,,OC(=O)C1=C(C2=CNC3=CC=CC=C23)C(=C(N1)C(O)=O)C1=CNC2=C1C=CC=C2,,,,,0,,385.106256,5,5,3,3,0,0
5800,04/06/2019 00:00,DB07589,"N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(BENZYLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-HYDROXYPHENYL)ETHYL]-L-ALANINAMIDE",,,,,,solid,,,0.0944,9.56,8.73,[H][C@@](CS(=O)(=O)CC1=CC=CC=C1)(N[C@@]([H])(C1=CC=C(O)C=C1)C(F)(F)F)C(=O)NC1(CN)CC1,,,,,0,,485.159612,3,2,0,0,0,0
5801,04/06/2019 00:00,DB07590,"S-[3-(3,4-DICHLOROPHENYL)-3-OXOPROPYL]-L-CYSTEINE",,,,,,solid,,,0.0308,1.62,8.94,[H][C@](N)(CSCCC(=O)C1=CC=C(Cl)C(Cl)=C1)C(O)=O,,,,,0,,320.9993196,1,1,0,0,0,0
5802,04/06/2019 00:00,DB07591,N1-CYCLOPENTYL-N2-(THIAZOL-2-YL)OXALAMIDE,,,,,,solid,,,0.288,9.93,-0.16,O=C(NC1CCCC1)C(=O)NC1=NC=CS1,,,,,0,,239.0728477,2,1,1,1,0,0
5803,04/06/2019 00:00,DB07592,(2R)-3-Methyl-1-phenyl-2-butanyl [(2S)-1-oxo-2-hexanyl]carbamate,,,,,,solid,,,0.00958,14.01,-7.3,[H][C@@](CCCC)(NC(=O)O[C@]([H])(CC1=CC=CC=C1)C(C)C)C=O,,,,,0,,305.1990937,1,1,0,0,0,0
5804,04/06/2019 00:00,DB07593,1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE,,,,,,solid,,,0.00534,13.95,-7.3,[H][C@@](CCCC)(NC(=O)OC1(CC2=CC=CC=C2)CCCC1)C=O,,,,,0,,317.1990937,2,1,0,0,0,0
5805,04/06/2019 00:00,DB07594,"4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL",,,,,,solid,,,0.104,9.21,2.57,CCC1=C(O)C=C(O)C(=C1)C1=C(C(C)=NN1)C1=CC=C2OCCOC2=C1,,,,,0,,352.1423071,4,3,2,1,0,1
5806,04/06/2019 00:00,DB07595,"(5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE",,,,,,solid,,,0.00151,11.65,5.02,BrC1=CC=CC(=C1)C1=NC2=[N+](NC=C2)C(NCC2=CC=NC=C2)=C1,,,,,1,,380.050534,4,4,3,3,0,0
5807,04/06/2019 00:00,DB07596,"(17beta)-17-(cyanomethyl)-2-methoxyestra-1(10),2,4-trien-3-yl sulfamate",,,,,,solid,,,0.00659,10.5,-4.9,[H][C@]1(CC#N)CC[C@@]2([H])[C@]3([H])CCC4=CC(OS(N)(=O)=O)=C(OC)C=C4[C@@]3([H])CC[C@]12C,,,,,0,,404.1769784,4,1,0,0,0,0
5808,04/06/2019 00:00,DB07597,"CIS-(1R,2S)-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL",,,,,,solid,,,10.8,13.89,9.42,[H][C@]1(N)CCC2=CC=CC=C2[C@@]1([H])O,,,,,0,,163.099714,2,1,0,0,0,0
5809,04/06/2019 00:00,DB07598,"2,3,6A,7,8,9-HEXAHYDRO-11H-[1,4]DIOXINO[2,3-G]PYRROLO[2,1-B][1,3]BENZOXAZIN-11-ONE",,,,,,solid,,,9.7,,-2,[H][C@@]12CCCN1C(=O)C1=C(O2)C=C2OCCOC2=C1,,,,,0,,247.0844579,4,1,3,0,1,3
5810,04/06/2019 00:00,DB07599,[(2-AMINO-ALPHA-METHOXYIMINO-4-THIAZOLYLACETYL)AMINO]METHYLBORONIC ACID,,,,,,solid,,,0.207,11.93,3.95,CO\N=C(/C(=O)NCB(O)O)C1=CSC(N)=N1,,,,,0,,258.0594062,1,1,1,1,0,0
5811,04/06/2019 00:00,DB07601,"4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol",,,,,,solid,,,0.227,7.47,6.67,OC1=CC(O)=C(Cl)C=C1C1=NOC2=C1C=C(NCCN1CCOCC1)C=C2,,,,,0,,389.1142338,4,3,2,1,1,1
5812,04/06/2019 00:00,DB07602,S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE,,,,,,solid,,,0.0157,1.76,9.14,[H][C@](N)(CSCCC(=O)NC1=CC2=C(C=C1)N=CN=C2NC1=CC=CC=C1)C(O)=O,,,,,0,,411.1365105,3,3,1,1,0,0
5813,04/06/2019 00:00,DB07603,N-hexanoyl-L-homocysteine,,,,,,solid,,,1.15,4.25,-0.47,[H][C@@](CCS)(NC(=O)CCCCC)C(O)=O,,,,,0,,233.1085645,0,0,0,0,0,0
5814,04/06/2019 00:00,DB07604,"(6AR,11AS,11BR)-10-ACETYL-9-HYDROXY-7,7-DIMETHYL-2,6,6A,7,11A,11B-HEXAHYDRO-11H-PYRROLO[1',2':2,3]ISOINDOLO[4,5,6-CD]INDOL-11-ONE",,,,,,solid,,,0.169,3.56,2,[H][C@@]12CC3=C4C(NC=C4[C@]1([H])[C@]1([H])N(C(O)=C(C(C)=O)C1=O)C2(C)C)=CC=C3,,,,,0,,336.1473925,5,2,3,1,1,2
5815,04/06/2019 00:00,DB07605,"2-({4-[(5-CHLORO-1H-INDOL-2-YL)SULFONYL]PIPERAZIN-1-YL}CARBONYL)THIENO[3,2-B]PYRIDINE 4-OXIDE",,,,,,solid,,,0.00897,9.63,-0.32,[O-][N+]1=CC=CC2=C1C=C(S2)C(=O)N1CCN(CC1)S(=O)(=O)C1=CC2=CC(Cl)=CC=C2N1,,,,,0,,476.0379747,5,4,4,3,1,1
5816,04/06/2019 00:00,DB07606,"6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE",,,,,,solid,,,0.0173,8.87,-1.3,CCC1=NN(C2=C1C(=O)NC(CC1=CC(O)=C(O)C=C1)=N2)C1=C(Cl)C=C(Cl)C=C1Cl,,,,,0,,464.0209734,4,4,2,2,0,0
5817,04/06/2019 00:00,DB07607,4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE,,,,,,solid,,,0.0208,11.8,4.89,C[S@@](=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC(I)=CC=C1)C1=CC=NC=C1,,,,,0,,485.0058811,4,4,2,2,0,0
5818,04/06/2019 00:00,DB07608,N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamide,,,,,,solid,,,0.00199,10.47,9.71,[H][C@@](CCN)(C(=O)NC1=CC=C2NN=C(NC(=O)C3=CC=CC=C3)C2=C1)C1=CC(Cl)=CC=C1,,,,,0,,447.1462026,4,4,1,1,0,0
5819,04/06/2019 00:00,DB07609,"N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE",,,,,,solid,,,0.675,,8.52,CN(C)CC1=CC=C(O1)C1=CC=CN=C1,,,,,0,,202.1106131,2,2,2,2,0,0
5820,04/06/2019 00:00,DB07610,"NAPHTHALENE-1,2-DIOL",,,,,,solid,,,0.71,9.04,-6.3,OC1=CC=C2C=CC=CC2=C1O,,,,,0,,160.0524295,2,2,0,0,0,0
5821,04/06/2019 00:00,DB07611,DECANE-1-THIOL,,,,,,solid,,,0.00308,10.2,-9.6,CCCCCCCCCCS,,,,,0,,174.1442217,0,0,0,0,0,0
5822,04/06/2019 00:00,DB07612,6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE,,,,,,solid,,,0.00292,18.54,3.95,CC(C)(C)NC1=NC(=NC2=C1C=C(C=C2)C1=CC=CC(N)=C1)C(F)(F)F,,,,,0,,360.1561813,3,3,1,1,0,0
5823,04/06/2019 00:00,DB07613,3-phenyl-5-(1H-pyrazol-3-yl)isoxazole,,,,,,solid,,,0.364,13.64,0.63,N1C=CC(=N1)C1=CC(=NO1)C1=CC=CC=C1,,,,,0,,211.0745619,3,3,2,2,0,0
5824,04/06/2019 00:00,DB07614,"PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-THIAZOLE",,,,,,solid,,,0.0522,14.17,1.88,N1C=CC(=N1)C1=CN=C(S1)C1=CC=CC=C1,,,,,0,,227.0517183,3,3,2,2,0,0
5825,04/06/2019 00:00,DB07615,Tranilast,,,,,,solid,,,0.0084,3.55,-2,COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC,,,,,0,,327.1106726,2,2,0,0,0,0
5826,04/06/2019 00:00,DB07616,"4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid",,,,,,solid,,,0.00591,3.39,2.38,CC1=CC(=CC=C1F)C1=CSC(NC2=CC=C(C(O)=O)C(O)=C2)=N1,,,,,0,,344.0630915,3,3,1,1,0,0
5827,04/06/2019 00:00,DB07617,N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE,,,,,,solid,,,0.331,,8.61,CNCC1=CC=C(O1)C1=CC=CN=C1,,,,,0,,188.094963,2,2,2,2,0,0
5828,04/06/2019 00:00,DB07618,"2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE",,,,,,solid,,,0.0795,11.88,10.21,NCC1CCN(CC(=O)NC2=CC=CC3=C2C(=O)C2=C(NN=C32)C2CCCCC2)CC1,,,,,0,,421.2477752,5,2,2,1,1,1
5829,04/06/2019 00:00,DB07619,"N-cyclopropyl-N-(trans-4-pyridin-3-ylcyclohexyl)-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide",,,,,,solid,,,0.00521,10.69,5.49,[H][C@@]1(CC[C@@]([H])(CC1)C1=CC=CN=C1)N(C1CC1)C(=O)C1=CC=C(C=C1)[C@](C)(O)C(F)(F)F,,,,,0,,432.2024628,4,2,1,1,0,0
5830,04/06/2019 00:00,DB07620,"2-[(2,4-DICHLORO-5-METHYLPHENYL)SULFONYL]-1,3-DINITRO-5-(TRIFLUOROMETHYL)BENZENE",,,,,,solid,,,0.000266,18.1,,CC1=CC(=C(Cl)C=C1Cl)S(=O)(=O)C1=C(C=C(C=C1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O,,,,,0,,457.935397,2,2,0,0,0,0
5831,04/06/2019 00:00,DB07621,(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE,,,,,,solid,,,1.76,,8.06,NCC1=CC=C(O1)C1=CC=CN=C1,,,,,0,,174.0793129,2,2,2,2,0,0
5832,04/06/2019 00:00,DB07622,"1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA",,,,,,solid,,,0.0303,8.74,6.63,CN1CCN(CC1)NC(=O)NC1=CC=CC2=C1C(=O)C1=C(NN=C21)C1=C(C)N=C(C)S1,,,,,0,,437.163394,5,3,3,2,1,1
5833,04/06/2019 00:00,DB07623,"4,4'-DIPYRIDYL DISULFIDE",,,,,,solid,,,0.192,,4.6,S(SC1=CC=NC=C1)C1=CC=NC=C1,,,,,0,,220.0128903,2,2,2,2,0,0
5834,04/06/2019 00:00,DB07624,"1-{[(3R)-3-methyl-4-({4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]phenyl}sulfonyl)piperazin-1-yl]methyl}cyclopropanecarboxamide",,,,,,solid,,,0.194,10.63,7.15,[H][C@@]1(C)CN(CC2(CC2)C(N)=O)CCN1S(=O)(=O)C1=CC=C(C=C1)[C@](C)(O)C(F)(F)F,,,,,0,,449.159612,3,1,1,0,1,1
5835,04/06/2019 00:00,DB07625,"4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide",,,,,,solid,,,0.00427,11.06,9.27,CCOC1=CC=C(OCC)C(NC(=O)C2=CC(C)=C(OCCN)C(C)=C2)=C1,,,,,0,,372.2049074,2,2,0,0,0,0
5836,04/06/2019 00:00,DB07626,"4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide",,,,,,solid,,,0.00314,11.55,9.28,CCOC1=C(NC(=O)C2=CC(C)=C(OCCN)C(C)=C2)C=C(C=C1Cl)N1CCCCC1,,,,,0,,445.2132196,3,2,1,0,1,1
5837,04/06/2019 00:00,DB07627,(2S)-4-METHYL-2-(3-PHENYLTHIOUREIDO)-N-((3S)-TETRAHYDRO-2-HYDROXY-3-FURANYL)PENTANAMIDE,,,,,,solid,,,0.0375,9.43,-2.7,[H][C@@](CC(C)C)(NC(=S)NC1=CC=CC=C1)C(=O)N[C@]1([H])CO[C@]([H])(O)C1,,,,,0,,351.1616627,2,1,1,0,1,1
5838,04/06/2019 00:00,DB07628,"6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one",,,,,,solid,,,0.0528,,-2.5,CN1C2=C(SC(C)=C2)C2=C1C(=O)N(CC1=CC=CC=C1F)N=C2,,,,,0,,327.0841613,4,4,3,3,0,0
5839,04/06/2019 00:00,DB07629,"N-((1R,2S)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE",,,,,,solid,,,0.00445,11.98,6.61,[H][C@@]1(CCCC[C@@]1([H])NC(=O)C1=NC2=C(CN(C)CC2)S1)NC(=O)C1=CC2=C(N1)C=CC(Cl)=C2,,,,,0,,471.1495738,5,3,3,2,0,1
5840,04/06/2019 00:00,DB07630,"N-((1R,2R)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE",,,,,,solid,,,0.00445,11.98,6.61,[H][C@]1(CCCC[C@@]1([H])NC(=O)C1=NC2=C(CN(C)CC2)S1)NC(=O)C1=CC2=C(N1)C=CC(Cl)=C2,,,,,0,,471.1495738,5,3,3,2,0,1
5841,04/06/2019 00:00,DB07631,"N-DODECYL-N,N-DIMETHYLGLYCINATE",,,,,,solid,,,4.03E-05,2.62,,CCCCCCCCCCCC[N+](C)(C)CC([O-])=O,,,,,0,,271.2511293,0,0,0,0,0,0
5842,04/06/2019 00:00,DB07632,"5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide",,,,,,solid,,,0.161,7.07,-2.1,NS(=O)(=O)C1=NN=C(S1)C1=CC=CC=C1Cl,,,,,0,,274.9589961,2,2,1,1,0,0
5843,04/06/2019 00:00,DB07633,octyl 3-deoxy-2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-xylo-hexopyranoside,,,,,,solid,,,5.72,12.22,-3,[H][C@@]1(O)C[C@@]([H])(O[C@]2([H])O[C@@]([H])(C)[C@@]([H])(O)[C@@]([H])(O)[C@]2([H])O)[C@]([H])(OCCCCCCCC)O[C@]1([H])CO,,,,,0,,422.2515828,2,0,2,0,2,2
5844,04/06/2019 00:00,DB07634,"(2,6-Dimethylphenoxy)acetic acid",,,,,,solid,,,1.17,4.04,-4.9,CC1=CC=CC(C)=C1OCC(O)=O,,,,,0,,180.0786442,1,1,0,0,0,0
5845,04/06/2019 00:00,DB07635,bis(4-hydroxyphenyl)methanone,,,,,,solid,,,0.19,7.55,-6.9,OC1=CC=C(C=C1)C(=O)C1=CC=C(O)C=C1,,,,,0,,214.0629942,2,2,0,0,0,0
5846,04/06/2019 00:00,DB07636,"5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE",,,,,,solid,,,0.0148,6.93,-0.81,CCCCCCCC1=C(O)C(=O)C2=C(N=CS2)C1=O,,,,,0,,279.0929144,2,1,1,1,0,0
5847,04/06/2019 00:00,DB07637,Dibromotyrosine,,,,,,solid,,,0.121,0.36,9.44,[H][C@](N)(CC1=CC(Br)=C(O)C(Br)=C1)C(O)=O,,,,,0,,336.8949173,1,1,0,0,0,0
5848,04/06/2019 00:00,DB07638,"(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL",,,,,,solid,,,0.0532,9.35,-4.9,[H][C@@]12CC(F)(F)C[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1)C1=CC=C(O)C=C1,,,,,0,,318.1067508,4,2,1,0,0,1
5849,04/06/2019 00:00,DB07639,3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER,,,,,,solid,,,0.000764,,10.31,CCOC(=O)C(CC1=CC2=C(C=C1)C=CC(=C2)C(N)N)C1=CC=C(OC2CCNC2)C=C1,,,,,0,,433.2365419,4,3,1,0,1,1
5850,04/06/2019 00:00,DB07640,"2-decyl-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione",,,,,,solid,,,0.0044,,-4.7,CCCCCCCCCCC1=C(C)C(=O)C(OC)=C(OC)C1=O,,,,,0,,322.2144094,1,0,0,0,0,0
5851,04/06/2019 00:00,DB07641,Decyl(dimethyl)phosphine oxide,,,,,,solid,,,0.00174,,-7.4,CCCCCCCCCCP(C)(C)=O,,,,,0,,218.1799521,0,0,0,0,0,0
5852,04/06/2019 00:00,DB07642,"5-{[1-(2-fluorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine",,,,,,solid,,,0.0488,16.54,8.31,NC1=NC2=CC=CC(OCC3CCN(CC4=CC=CC=C4F)CC3)=C2C(N)=N1,,,,,0,,381.1964886,4,3,2,1,1,1
5853,04/06/2019 00:00,DB07643,"5-{[1-(2,3-dichlorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine",,,,,,solid,,,0.00381,16.54,7.83,NC1=NC2=C(C(N)=N1)C(OCC1CCN(CC3=C(Cl)C(Cl)=CC=C3)CC1)=CC=C2,,,,,0,,431.1279657,4,3,2,1,1,1
5854,04/06/2019 00:00,DB07644,"5-[(1S)-1-(3-chlorophenyl)ethoxy]quinazoline-2,4-diamine",,,,,,solid,,,0.0182,16.54,7.59,[H][C@@](C)(OC1=C2C(N)=NC(N)=NC2=CC=C1)C1=CC(Cl)=CC=C1,,,,,0,,314.0934388,3,3,1,1,0,0
5855,04/06/2019 00:00,DB07645,SEBACIC ACID,,,,,,solid,,,0.912,4.72,,OC(=O)CCCCCCCCC(O)=O,,,,,0,,202.1205091,0,0,0,0,0,0
5856,04/06/2019 00:00,DB07646,"UNDECYLAMINE-N,N-DIMETHYL-N-OXIDE",,,,,,solid,,,0.000284,,4.17,CCCCCCCCCCC[N+](C)(C)[O-],,,,,0,,215.2249145,0,0,0,0,0,0
5857,04/06/2019 00:00,DB07647,"(2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL",,,,,,solid,,,0.00744,12.28,7.07,[H][C@](C)(O)CNC1=C2C(NC(=C2C2=CC=CC=C2)C2=CC=CC=C2)=NC=N1,,,,,0,,344.1637113,4,4,2,2,0,0
5858,04/06/2019 00:00,DB07648,"(2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL",,,,,,solid,,,0.0275,12.27,7.07,[H][C@](O)(CO)CNC1=C2C(NC(=C2C2=CC=CC=C2)C2=CC=CC=C2)=NC=N1,,,,,0,,360.1586259,4,4,2,2,0,0
5859,04/06/2019 00:00,DB07649,"(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(benzylsulfanyl)methyl]pyrrolidin-3-ol",,,,,,solid,,,0.0551,13.47,8.67,[H][C@]1(O)CN(CC2=CNC3=C2N=CN=C3N)C[C@]1([H])CSCC1=CC=CC=C1,,,,,0,,369.1623314,4,3,3,2,1,1
5860,04/06/2019 00:00,DB07650,DECYL FORMATE,,,,,,solid,,,0.00957,,-6.8,CCCCCCCCCCOC=O,,,,,0,,186.1619799,0,0,0,0,0,0
5861,04/06/2019 00:00,DB07651,N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE,,,,,,solid,,,0.00364,0.5,-1.4,[H][C@@](CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(C)=O)C(N)=O,,,,,0,,483.1370786,2,2,0,0,0,0
5862,04/06/2019 00:00,DB07652,"1-[2-DEOXYRIBOFURANOSYL]-2,4-DIFLUORO-5-METHYL-BENZENE-5'MONOPHOSPHATE",,,,,,solid,,,2.1,1.24,-3.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)C1=CC(C)=C(F)C=C1F,,,,,0,,324.0574313,2,1,1,0,1,1
5863,04/06/2019 00:00,DB07653,"N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE",,,,,,solid,,,0.055,4.68,2.09,OC(=O)CNC1=NC=NC2=C1C(=C(O2)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,345.1113413,4,4,2,2,0,0
5864,04/06/2019 00:00,DB07654,"(5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC",,,,,,solid,,,0.0735,15.58,2.03,CN(CCO)C1=NC=NC2=C1C(=C(O2)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,345.1477268,4,4,2,2,0,0
5865,04/06/2019 00:00,DB07655,"3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE",,,,,,solid,,,0.00947,12.28,7.07,OCCNC1=NC=NC2=C1C(=C(N2)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,330.1480612,4,4,2,2,0,0
5866,04/06/2019 00:00,DB07657,PHOSPHONIC ACID 2-DODECANOYLAMINO-HEXYL ESTER PROPYL ESTER,,,,,,solid,,,0.0023,1.91,0.13,[H][C@@](CCCC)(CO[P@](O)(=O)OCCO)NC(=O)CCCCCCCCCCC,,,,,0,,423.2749747,0,0,0,0,0,0
5867,04/06/2019 00:00,DB07658,AC-(D)PHE-PRO-BOROLYS-OH,,,,,,solid,,,0.453,12.51,10.2,[H][C@@](CCCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O,,,,,0,,432.2544006,2,1,1,0,1,1
5868,04/06/2019 00:00,DB07659,AC-(D)PHE-PRO-BOROHOMOLYS-OH,,,,,,solid,,,0.211,12.51,10.2,[H][C@@](CCCCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O,,,,,0,,446.2700506,2,1,1,0,1,1
5869,04/06/2019 00:00,DB07660,AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH,,,,,,solid,,,0.592,12.5,9.9,[H][C@@](CCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O,,,,,0,,418.2387505,2,1,1,0,1,1
5870,04/06/2019 00:00,DB07661,"1,6-DIHYDROXY NAPHTHALENE",,,,,,solid,,,0.664,9.44,-5.5,OC1=CC=C2C(O)=CC=CC2=C1,,,,,0,,160.0524295,2,2,0,0,0,0
5871,04/06/2019 00:00,DB07662,N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE,,,,,,solid,,,0.00807,14.42,3.97,BrC1=CC=CC(NC2=C3C=C(NC(=O)C=C)C=CC3=NC=N2)=C1,,,,,0,,368.0272731,3,3,1,1,0,0
5872,04/06/2019 00:00,DB07663,"2-[(1R)-1-CARBOXY-2-(4-HYDROXYPHENYL)ETHYL]-1,3-DIOXOISOINDOLINE-5-CARBOXYLIC ACID",,,,,,solid,,,0.0521,2.79,-6,[H][C@](CC1=CC=C(O)C=C1)(N1C(=O)C2=C(C=C(C=C2)C(O)=O)C1=O)C(O)=O,,,,,0,,355.0692018,3,2,1,0,0,1
5873,04/06/2019 00:00,DB07664,"5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE",,,,,,solid,,,0.00875,8.99,-0.5,NC1=NC(NC2=CC=C(C=C2)S(N)(=O)=O)=NN1C(=S)NC1=C(F)C=CC=C1F,,,,,0,,425.0540211,3,3,1,1,0,0
5874,04/06/2019 00:00,DB07665,"N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide",,,,,,solid,,,0.047,11.28,9.88,NC(=N)NOCCNC(=O)CC1=C(C=CC(NCC(F)(F)C2=NC=CC=C2)=C1F)C#N,,,,,0,,435.1630575,2,2,1,1,0,0
5875,04/06/2019 00:00,DB07666,"(3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE",,,,,,solid,,,0.0151,19.69,9.44,[H][C@]1(N)CN(C[C@]1([H])C1=CC(F)=C(F)C=C1F)C1=CC(=NC=N1)C1=CC(=CC=C1)S(C)(=O)=O,,,,,0,,448.1180815,4,3,2,1,1,1
5876,04/06/2019 00:00,DB07667,"2-((3',5'-DIMETHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID",,,,,,solid,,,0.0386,3.36,0.42,CC1=CC(=CC(C)=C1O)\N=N\C1=CC=CC=C1C(O)=O,,,,,0,,270.1004423,2,2,0,0,0,0
5877,04/06/2019 00:00,DB07668,3-(4-DIETHYLAMINO-2-HYDROXY-PHENYL)-2-METHYL-PROPIONIC ACID,,,,,,solid,,,0.752,3.82,4.85,CCN(CC)C1=CC(O)=C(\C=C(/C)C(O)=O)C=C1,,,,,0,,249.1364935,1,1,0,0,0,0
5878,04/06/2019 00:00,DB07669,"2,3-DIMETHYL-1,4-NAPHTHOQUINONE",,,,,,solid,,,0.312,,-7.2,CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O,,,,,0,,186.0680796,2,1,0,0,0,0
5879,04/06/2019 00:00,DB07670,4-METHYL-N-METHYL-N-(2-PHENYL-2H-PYRAZOL-3-YL)BENZENESULFONAMIDE,,,,,,solid,,,0.187,,2.06,CN(C1=CC=NN1C1=CC=CC=C1)S(=O)(=O)C1=CC=C(C)C=C1,,,,,0,,327.1041478,3,3,1,1,0,0
5880,04/06/2019 00:00,DB07671,"2-[1-METHYLHEXYL]-4,6-DINITROPHENOL",,,,,,solid,,,0.0122,4.57,-7.5,CCCCCC(C)C1=C(O)C(=CC(=C1)N(=O)=O)N(=O)=O,,,,,0,,282.1215717,1,1,0,0,0,0
5881,04/06/2019 00:00,DB07672,TRANS-2-(DIMETHYLPHENYLSILYL)-PIPERIDINE-N-OXIDE,,,,,,solid,,,0.000713,,3.69,[H][C@@]1(CC[N@@+](C)([O-])CC1)[Si](C)(C)C1=CC=CC=C1,,,,,0,,249.1548909,2,1,1,0,1,1
5882,04/06/2019 00:00,DB07673,DEAMINO-METHYL-PHENYLALANINE,,,,,,solid,,,0.863,4.76,,[H][C@](C)(CC1=CC=CC=C1)C(O)=O,,,,,0,,164.0837296,1,1,0,0,0,0
5883,04/06/2019 00:00,DB07674,"O,O-DIETHYL HYDROGEN THIOPHOSPHATE",,,,,,solid,,,6.06,2.86,,CCOP(O)(=S)OCC,,,,,0,,170.0166518,0,0,0,0,0,0
5884,04/06/2019 00:00,DB07675,(2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID,,,,,,solid,,,0.00985,3.73,-4.1,[H][C@@](CC1=CC=C(OCCN2C3=C(OC4=C2C=CC=C4)C=CC=C3)C=C1)(OCC)C(O)=O,,,,,0,,419.1732729,4,3,1,0,0,1
5885,04/06/2019 00:00,DB07676,"3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one",,,,,,solid,,,0.076,14.18,0.097,[H][C@@](O)(CO)CCONC1=C(NC2=CC=CC=C12)C1=C2C=CC=CC2=NC1=O,,,,,0,,365.1375561,4,3,2,1,0,1
5886,04/06/2019 00:00,DB07677,"2-methyl-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one",,,,,,solid,,,2.39,11.51,1.07,CC1=NC2=C(CSCC2)C(=O)N1,,,,,0,,182.0513839,2,1,2,1,0,1
5887,04/06/2019 00:00,DB07678,"(9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL",,,,,,solid,,,0.00126,9.67,-0.88,[H]\C(CC)=C(/[H])C1=C(O)C=C2CC[C@@]3([H])[C@]4([H])CC[C@]([H])(O)[C@@]4(C)CC[C@]3([H])C2=C1,,,,,0,,326.2245802,4,1,0,0,0,0
5888,04/06/2019 00:00,DB07679,"(9S,12S)-9-(1-methylethyl)-7,10-dioxo-2-oxa-8,11-diazabicyclo[12.2.2]octadeca-1(16),14,17-triene-12-carboxylic acid",,,,,,solid,,,0.23,3.79,-0.14,[H][C@]1(CC2=CC=C(OCCCCC(=O)N[C@@]([H])(C(C)C)C(=O)N1)C=C2)C(O)=O,,,,,0,,362.1841719,3,1,2,0,0,2
5889,04/06/2019 00:00,DB07680,[(1S)-1-(5-CHLORO-1-BENZOTHIEN-3-YL)-2-(2-NAPHTHYLAMINO)-2-OXOETHYL]PHOSPHONIC ACID,,,,,,solid,,,0.00715,1.52,-8.4,[H][C@@](C(=O)NC1=CC=C2C=CC=CC2=C1)(C1=CSC2=C1C=C(Cl)C=C2)P(O)(O)=O,,,,,0,,431.0147933,4,4,1,1,0,0
5890,04/06/2019 00:00,DB07681,DODECANESULFONATE ION,,,,,,solid,,,0.0145,-0.59,,CCCCCCCCCCCCS([O-])(=O)=O,,,,,-1,,249.1529892,0,0,0,0,0,0
5891,04/06/2019 00:00,DB07683,"N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine",,,,,,solid,,,0.00859,3.97,-9.2,[H][C@](NS(=O)(=O)C1=CC2=C(C=C1)C1=CC=CC=C1S2)(C(C)C)C(O)=O,,,,,0,,363.0599,3,3,1,1,0,0
5892,04/06/2019 00:00,DB07684,5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID,,,,,,solid,,,0.27,-2,4.85,CN(C)C1=C2C=CC(=CC2=CC=C1)S(O)(=O)=O,,,,,0,,251.0616143,2,2,0,0,0,0
5893,04/06/2019 00:00,DB07685,"4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE",,,,,,solid,,,0.0131,10.76,-0.21,NS(=O)(=O)C1=CC=C(NC2=CC(OCC3CCCCC3)=NC3=NC=NN23)C=C1,,,,,0,,402.1474096,4,3,2,2,0,0
5894,04/06/2019 00:00,DB07686,"4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE",,,,,,solid,,,0.024,10.76,1.52,NS(=O)(=O)C1=CC=C(NC2=CC(NC3CCCCC3)=NC3=NC=NN23)C=C1,,,,,0,,387.1477439,4,3,2,2,0,0
5895,04/06/2019 00:00,DB07687,"4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE",,,,,,solid,,,0.0655,10.93,10.28,[H][C@]1(N)CC[C@@]([H])(CC1)NC1=NC2=NC=NN2C(NC2=CC=C(C=C2)S(N)(=O)=O)=C1,,,,,0,,402.1586429,4,3,2,2,0,0
5896,04/06/2019 00:00,DB07688,"4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE",,,,,,solid,,,0.0311,10.76,-0.22,NS(=O)(=O)C1=CC=C(NC2=CC(OC3CCCCC3)=NC3=NC=NN23)C=C1,,,,,0,,388.1317595,4,3,2,2,0,0
5897,04/06/2019 00:00,DB07689,"METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE",,,,,,solid,,,0.169,15.87,3.06,COC(=O)C1CCN(CC1)C(=O)C1=CC=C(NCC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1,,,,,0,,436.1971366,4,3,3,2,1,1
5898,04/06/2019 00:00,DB07691,"2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid",,,,,,solid,,,0.00691,3.55,-4.1,OC(=O)C1=C(NC(=O)C2=CC=CC(=C2)S(=O)(=O)N2CCC3=CC=CC=C3C2)C=CC=C1,,,,,0,,436.1092927,4,3,1,0,0,1
5899,04/06/2019 00:00,DB07692,"1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine",,,,,,solid,,,0.189,,-4.6,FC1=CC=CC(F)=C1S(=O)(=O)N1CCN(CC1)S(=O)(=O)C1=CC=C2OCCOC2=C1,,,,,0,,460.0574347,4,2,2,0,1,2
5900,04/06/2019 00:00,DB07693,"N-(3,5-dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamide",,,,,,solid,,,0.00213,6.72,-3.2,CC1=CC=CC(C)=C1C(=O)NC1=CC(Br)=C(O)C(Br)=C1,,,,,0,,396.9313029,2,2,0,0,0,0
5901,04/06/2019 00:00,DB07694,"2,5-dichloro-N-(3,5-dibromo-4-hydroxyphenyl)benzamide",,,,,,solid,,,0.000962,6.72,-4.3,OC1=C(Br)C=C(NC(=O)C2=CC(Cl)=CC=C2Cl)C=C1Br,,,,,0,,436.822058,2,2,0,0,0,0
5902,04/06/2019 00:00,DB07695,"N-(3,5-dibromo-4-hydroxyphenyl)-4-hydroxy-3,5-dimethylbenzamide",,,,,,solid,,,0.00882,6.72,-3.2,CC1=CC(=CC(C)=C1O)C(=O)NC1=CC(Br)=C(O)C(Br)=C1,,,,,0,,412.9262175,2,2,0,0,0,0
5903,04/06/2019 00:00,DB07696,methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate,,,,,,solid,,,2.18,13.48,-7,[H][C@@](CC(=O)OC)(NC(=O)OC(C)(C)C)C(C)=O,,,,,0,,245.1263227,0,0,0,0,0,0
5904,04/06/2019 00:00,DB07697,"1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine",,,,,,solid,,,0.16,,-4.4,COC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)S(=O)(=O)C1=CC=C2OCCOC2=C1,,,,,0,,454.086843,4,2,2,0,1,2
5905,04/06/2019 00:00,DB07698,"3-(3-aminophenyl)-N-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amine",,,,,,solid,,,0.00512,14.72,3.7,NC1=CC=CC(=C1)C1=C2N=C(NC3=CC=CC(Cl)=C3)C=CN2N=C1,,,,,0,,335.0937731,4,4,2,2,0,0
5906,04/06/2019 00:00,DB07700,"3-CARBOXAMIDO-1,3,5(10)-ESTRATRIEN-17(R)-SPIRO-2'(5',5'-DIMETHYL-6'OXO)TETRAHYDROPYRAN",,,,,,solid,,,0.000163,14.77,-0.88,[H][C@@]12CC[C@@]3(CCC(C)(C)C(=O)O3)[C@@]1(C)CC[C@]1([H])C3=CC=C(C=C3CC[C@@]21[H])C(N)=O,,,,,0,,395.2460439,5,1,1,0,1,1
5907,04/06/2019 00:00,DB07701,"1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE",,,,,,solid,,,0.0045,17.02,8.62,[H][C@@]1(CC2CCN(CC3=CC=CC=C3)CC2)CC2=CC(OC)=C(OC)C=C2C1=O,,,,,0,,379.2147438,4,2,1,0,1,1
5908,04/06/2019 00:00,DB07702,17alpha-Estriol,,,,,,solid,,,0.119,10.33,-3.2,[H][C@@]12C[C@@H](O)[C@@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,,,,,0,,288.1725446,4,1,0,0,0,0
5909,04/06/2019 00:00,DB07703,"(3R,4S,5S,7R,9E,11R,12R)-12-ETHYL-4-HYDROXY-3,5,7,11-TETRAMETHYLOXACYCLODODEC-9-ENE-2,8-DIONE",,,,,,solid,,,0.245,14.45,-3,[H][C@@]1(C)C[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)O[C@]([H])(CC)[C@]([H])(C)\C=C\C1=O,,,,,0,,296.1987594,1,0,1,0,0,1
5910,04/06/2019 00:00,DB07704,"6-AMINO-4-[2-(4-METHOXYPHENYL)ETHYL]-1,7-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE",,,,,,solid,,,0.0289,11.09,4.05,COC1=CC=C(CCC2=C3N=CNC3=CC3=C2N=C(N)NC3=O)C=C1,,,,,0,,335.1382248,4,4,2,2,0,0
5911,04/06/2019 00:00,DB07705,"1-[(2S)-2-[(4-CHLOROBENZYL)OXY]-2-(2,4-DICHLOROPHENYL)ETHYL]-1H-IMIDAZOLE",,,,,,solid,,,0.00148,,6.77,[H][C@](CN1C=CN=C1)(OCC1=CC=C(Cl)C=C1)C1=C(Cl)C=C(Cl)C=C1,,,,,0,,380.0249961,3,3,1,1,0,0
5912,04/06/2019 00:00,DB07706,2-Hydroxyestradiol,,,,,,solid,,,0.0511,9.67,-0.88,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=C(C=C(O)C(O)=C4)[C@@]3([H])CC[C@]12C,,,,,0,,288.1725446,4,1,0,0,0,0
5913,04/06/2019 00:00,DB07707,"(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL",,,,,,solid,,,0.00706,10.31,-0.89,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])[C@@]([H])(COC)C[C@]12C,,,,,0,,316.2038448,4,1,0,0,0,0
5914,04/06/2019 00:00,DB07708,3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,,,,,,solid,,,0.222,9.31,0.54,OC1=CC=C(C=C1)N1N=C2C=CC(O)=CC2=C1Cl,,,,,0,,260.0352552,3,3,1,1,0,0
5915,04/06/2019 00:00,DB07710,PHENYLALANYLAMINODI(ETHYLOXY)ETHYL BENZENESULFONAMIDEAMINOCARBONYLBENZENESULFONAMIDE,,,,,,solid,,,0.0319,9.96,8,[H][C@](N)(CC1=CC=CC=C1)C(=O)NCCOCCOCCNC(=O)C1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,478.1886057,2,2,0,0,0,0
5916,04/06/2019 00:00,DB07711,"(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol",,,,,,solid,,,0.44,14.81,5.11,[H][C@@](C)(O)[C@@]([H])(CCCCCC)N1C=NC2=C(N)N=CN=C12,,,,,0,,277.1902604,2,2,2,2,0,0
5917,04/06/2019 00:00,DB07712,3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,,,,,,solid,,,0.244,9.41,1.39,CCC1=C2C=C(O)C=CC2=NN1C1=CC=C(O)C=C1,,,,,0,,254.1055277,3,3,1,1,0,0
5918,04/06/2019 00:00,DB07713,"(1S)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid",,,,,,solid,,,0.461,1.48,-4.8,COC1=CC=C(C=C1)C1=CC=C(C=C1)S(=O)(=O)N[C@H](C(C)C)P(O)(O)=O,,,,,0,,399.0905451,2,2,0,0,0,0
5919,04/06/2019 00:00,DB07714,"6-(3-METHYL-1,4-DIOXO-1,4-DIHYDRONAPHTHALEN-2-YL)HEXANOIC ACID",,,,,,solid,,,0.0237,3.99,-7.2,CC1=C(CCCCCC(O)=O)C(=O)C2=CC=CC=C2C1=O,,,,,0,,286.1205091,2,1,0,0,0,0
5920,04/06/2019 00:00,DB07715,Emodin,,,,,,solid,,,0.222,7.29,-5.4,CC1=CC(O)=C2C(=O)C3=C(C=C(O)C=C3O)C(=O)C2=C1,,,,,0,,270.0528234,3,2,0,0,0,0
5921,04/06/2019 00:00,DB07716,"(4Z)-2,8:7,12:11,15:14,18:17,22-PENTAANHYDRO-4,5,6,9,10,13,19,20,21-NONADEOXY-D-ARABINO-D-ALLO-D-ALLO-DOCOSA-4,9,20-TRIENITOL",,,,,,solid,,,2.19,12.96,-3,[H][C@@]12C[C@]3([H])O[C@]4([H])C\C=C/[C@]([H])(O)[C@@]([H])(CO)O[C@@]4([H])C=C[C@@]3([H])O[C@@]1([H])[C@]([H])(O)[C@@]1([H])OCC=CC[C@]1([H])O2,,,,,0,,422.1940679,5,0,5,0,2,5
5922,04/06/2019 00:00,DB07717,"(5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE",,,,,,solid,,,0.00155,14.69,-2.9,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12CCOCC1=CC(F)=CC(F)=C1,,,,,0,,446.2632515,5,1,0,0,0,0
5923,04/06/2019 00:00,DB07718,3-(4-HYDROXY-PHENYL)PYRUVIC ACID,,,,,,solid,,,1.49,2.91,-6,OC(=O)C(=O)CC1=CC=C(O)C=C1,,,,,0,,180.0422587,1,1,0,0,0,0
5924,04/06/2019 00:00,DB07719,"[(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid",,,,,,solid,,,0.11,-3.4,12.08,[H]N(C)C(=O)[C@H]1CC2=C(CN1C(=O)OC(C)(C)C)C=C(C=C2)N([H])S(O)(=O)=O,,,,,0,,385.1307565,2,1,1,0,0,1
5925,04/06/2019 00:00,DB07720,Epibatidine,,,,,,solid,,,0.467,,10.54,[H][C@@]12CC[C@@]([H])(N1)[C@]([H])(C2)C1=CC=C(Cl)N=C1,,,,,0,,208.0767261,3,1,3,1,2,2
5926,04/06/2019 00:00,DB07721,DIETHYL 4-METHOXYPHENYL PHOSPHATE,,,,,,solid,,,4.59,,-4.8,CCOP(=O)(OCC)OC1=CC=C(OC)C=C1,,,,,0,,260.0813603,1,1,0,0,0,0
5927,04/06/2019 00:00,DB07722,3-(4-NITRO-PHENOXY)-PROPAN-1-OL,,,,,,solid,,,1.93,15.9,-2.4,OCCCOC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,197.0688078,1,1,0,0,0,0
5928,04/06/2019 00:00,DB07723,3-(5-methoxy-1H-indol-3-yl)propanoic acid,,,,,,solid,,,0.336,4.45,-4.8,COC1=CC=C2NC=C(CCC(O)=O)C2=C1,,,,,0,,219.0895433,2,2,1,1,0,0
5929,04/06/2019 00:00,DB07724,Indeglitazar,,,,,,solid,,,0.0244,3.53,-4.5,COC1=CC=C(C=C1)S(=O)(=O)N1C=C(CCC(O)=O)C2=CC(OC)=CC=C12,,,,,0,,389.0933083,3,3,1,1,0,0
5930,04/06/2019 00:00,DB07726,"2-tert-butylbenzene-1,4-diol",,,,,,solid,,,2.75,9.94,-5.4,CC(C)(C)C1=CC(O)=CC=C1O,,,,,0,,166.0993797,1,1,0,0,0,0
5931,04/06/2019 00:00,DB07728,"2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE",,,,,,solid,,,0.0324,11.95,3.56,FC1=C(C=CC=C1)C1=CC(=CC=N1)C1=CC2=C(CCNC2=O)N1,,,,,0,,307.1120903,4,3,3,2,0,1
5932,04/06/2019 00:00,DB07729,3-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzamide,,,,,,solid,,,0.0844,4.28,-1,FC1=CC(=CC=C1)C(=O)NC1=CC=CC(=C1)C1=NN=NN1,,,,,0,,283.0869382,3,3,1,1,0,0
5933,04/06/2019 00:00,DB07730,"5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE",,,,,,solid,,,4.73,4.21,-6,OC1=CC(=CC=C1)C1=CC(=O)NS1(=O)=O,,,,,0,,225.0095787,2,1,1,0,0,1
5934,04/06/2019 00:00,DB07731,"4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL",,,,,,solid,,,0.424,8.4,4.09,NC1=C(\N=N\C2=CC=C(O)C=C2)C(N)=NN1,,,,,0,,218.0916089,2,2,1,1,0,0
5935,04/06/2019 00:00,DB07732,2-[(2-NAPHTHYLSULFONYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE,,,,,,solid,,,1.35,1.5,,OP(O)(=O)OCCNS(=O)(=O)C1=CC2=C(C=CC=C2)C=C1,,,,,0,,331.0279448,2,2,0,0,0,0
5936,04/06/2019 00:00,DB07733,"1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE",,,,,,solid,,,0.0421,10.07,-1.3,CN1N=C(C2=C1SC(=C2)C(=O)NCCS)C(F)(F)F,,,,,0,,309.0217386,2,2,2,2,0,0
5937,04/06/2019 00:00,DB07734,N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide,,,,,,solid,,,0.0539,10.21,8.62,SCCCC(=O)NC1CCN(CC2=CC=CC=C2)CC1,,,,,0,,292.1609344,2,1,1,0,1,1
5938,04/06/2019 00:00,DB07735,"N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide",,,,,,solid,,,0.0137,10.2,7.55,COC1=CC=CC(OC)=C1CN1CCC(CC1)NC(=O)CCCS,,,,,0,,352.1820638,2,1,1,0,1,1
5939,04/06/2019 00:00,DB07736,(2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide,,,,,,solid,,,0.0712,10.08,8.06,[H][C@]1(CN(CC2=CC=C(F)C=C2)CCN1)C(=O)NCCS,,,,,0,,297.1311115,2,1,1,0,1,1
5940,04/06/2019 00:00,DB07737,(2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide,,,,,,solid,,,0.0441,10.19,8.06,[H][C@]1(CN(CC2=CC=C(F)C=C2)CCN1)C(=O)NCCCS,,,,,0,,311.1467615,2,1,1,0,1,1
5941,04/06/2019 00:00,DB07738,"N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide",,,,,,solid,,,0.00578,10.2,6.72,COC1=C(OC)C(CN2CCC(CC2)NC(=O)CCCS)=CC(Br)=C1,,,,,0,,430.0925758,2,1,1,0,1,1
5942,04/06/2019 00:00,DB07739,"(3R)-3-(FLUOROMETHYL)-7-(THIOMORPHOLIN-4-YLSULFONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE",,,,,,solid,,,0.361,,7.21,[H][C@]1(CF)CC2=CC=C(C=C2CN1)S(=O)(=O)N1CCSCC1,,,,,0,,330.0871981,3,1,2,0,1,2
5943,04/06/2019 00:00,DB07740,"(7R,12R,13R)-13-formyl-12,14-dihydroxy-3,5,7-trimethyltetradeca-2,4-dienoic acid",,,,,,solid,,,0.048,5.09,-2.7,[H]C(C(O)=O)=C(C)C(\[H])=C(/C)C[C@]([H])(C)CCCC[C@@]([H])(O)[C@@]([H])(CO)C=O,,,,,0,,326.2093241,0,0,0,0,0,0
5944,04/06/2019 00:00,DB07741,"4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE",,,,,,solid,,,0.046,,9.83,[H][C@@]12CCC[N@@]1[C@@]([H])(C1=CC=C(C=C1)C(N)N)[C@@]1([H])C(=O)N(CC3=CC=C(F)C=C3)[C@]([H])(C(F)F)[C@@]21[H],,,,,0,,444.2136961,5,2,3,0,3,3
5945,04/06/2019 00:00,DB07742,"N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE",,,,,,solid,,,0.0181,9.95,-1.3,NS(=O)(=O)C1=CC=C(C=C1)C(=O)NCC1=CC=CC(F)=C1F,,,,,0,,326.0536697,2,2,0,0,0,0
5946,04/06/2019 00:00,DB07743,"S-[5-(TRIFLUOROMETHYL)-4H-1,2,4-TRIAZOL-3-YL] 5-(PHENYLETHYNYL)FURAN-2-CARBOTHIOATE",,,,,,solid,,,0.0248,4.84,-0.46,FC(F)(F)C1=NN=C(N1)SC(=O)C1=CC=C(O1)C#CC1=CC=CC=C1,,,,,0,,363.0289322,3,3,2,2,0,0
5947,04/06/2019 00:00,DB07744,Z-Val-Ala-Asp fluoromethyl ketone,,,,,,solid,,,0.0358,4.13,-4,CC(C)[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)CF,,,,,0,,453.1911285,1,1,0,0,0,0
5948,04/06/2019 00:00,DB07745,2-{[4-(TRIFLUOROMETHOXY)BENZOYL]AMINO}ETHYL DIHYDROGEN PHOSPHATE,,,,,,solid,,,0.152,1.54,-0.85,OP(O)(=O)OCCNC(=O)C1=CC=C(OC(F)(F)F)C=C1,,,,,0,,329.0276084,1,1,0,0,0,0
5949,04/06/2019 00:00,DB07746,3-ETHYL-6-{[(4-FLUOROPHENYL)SULFONYL]AMINO}-2-METHYLBENZOIC ACID,,,,,,solid,,,0.0233,3.91,,CCC1=CC=C(NS(=O)(=O)C2=CC=C(F)C=C2)C(C(O)=O)=C1C,,,,,0,,337.0784072,2,2,0,0,0,0
5950,04/06/2019 00:00,DB07747,"(3R)-N-(4-CHLOROPHENYL)-3-(HYDROXYMETHYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE",,,,,,solid,,,0.0683,7.64,8.44,[H][C@]1(CO)CC2=CC=C(C=C2CN1)S(=O)(=O)NC1=CC=C(Cl)C=C1,,,,,0,,352.0648411,3,2,1,0,0,1
5951,04/06/2019 00:00,DB07748,2-({[4-(TRIFLUOROMETHOXY)PHENYL]SULFONYL}AMINO)ETHYL DIHYDROGEN PHOSPHATE,,,,,,solid,,,3.45,1.5,-5.3,OP(O)(=O)OCCNS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1,,,,,0,,364.994594,1,1,0,0,0,0
5952,04/06/2019 00:00,DB07749,2-ACETYLAMINO-4-METHYL-PENTANOIC ACID (1-FORMYL-2-PHENYL-ETHYL)-AMIDE,,,,,,solid,,,0.0417,12.68,-1.1,[H][C@@](CC1=CC=CC=C1)(NC(=O)[C@]([H])(CC(C)C)NC(C)=O)C=O,,,,,0,,304.1786926,1,1,0,0,0,0
5953,04/06/2019 00:00,DB07750,"(2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol",,,,,,solid,,,0.02,13.76,8.7,[H]N(C1=CC=C(OC[C@H](O)CN(C)C)C=C1)C1=NC=CC(=N1)N([H])C1=C(Cl)C=CC(Cl)=C1,,,,,0,,447.1228803,3,3,1,1,0,0
5954,04/06/2019 00:00,DB07751,"(2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol",,,,,,solid,,,0.036,12.42,8.7,[H]N(C1=CC=C(OC[C@@H](O)CN(C)C)C=C1)C1=CC(=NC=N1)N([H])C1=C(F)C=CC=C1F,,,,,0,,415.1819814,3,3,1,1,0,0
5955,04/06/2019 00:00,DB07753,"3',5'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID",,,,,,solid,,,0.0215,4.05,,OC(=O)C1=CC=C(C=C1)C1=CC(F)=CC(F)=C1,,,,,0,,234.0492359,2,2,0,0,0,0
5956,04/06/2019 00:00,DB07754,N-({(1R)-1-carboxy-2-[(4-fluorobenzyl)sulfanyl]ethyl}carbamoyl)-L-glutamic acid,,,,,,solid,,,0.09,3.11,-2.5,[H][C@@](CCC(O)=O)(NC(=O)N[C@@]([H])(CSCC1=CC=C(F)C=C1)C(O)=O)C(O)=O,,,,,0,,402.0897002,1,1,0,0,0,0
5957,04/06/2019 00:00,DB07755,"(2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol",,,,,,solid,,,0.02,10.3,8.75,[H]N(C1=CC=C(OC[C@@H](O)CN(C)C)C=C1)C1=NC=CC(=N1)N([H])C1=C(Cl)C=CC(Cl)=C1,,,,,0,,447.1228803,3,3,1,1,0,0
5958,04/06/2019 00:00,DB07756,"1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL",,,,,,solid,,,0.00422,7.59,8.42,CC1=C(CSCC2=CC(=CC=C2)C(O)(O)C(F)(F)F)C(N)=C2C(F)=CC=CC2=N1,,,,,0,,426.1025117,3,3,1,1,0,0
5959,04/06/2019 00:00,DB07757,"(9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one",,,,,,solid,,,0.00706,8.93,-6.1,CCCC[C@]12CC3=CC(O)=CC=C3C1=C(Br)C(=O)CC2,,,,,0,,334.0568419,3,1,0,0,0,0
5960,04/06/2019 00:00,DB07758,"5-(2,5-DICHLOROPHENYL)-2-FUROIC ACID",,,,,,solid,,,0.0312,3.13,-4.7,OC(=O)C1=CC=C(O1)C1=CC(Cl)=CC=C1Cl,,,,,0,,255.9693994,2,2,1,1,0,0
5961,04/06/2019 00:00,DB07759,5-[2-(TRIFLUOROMETHYL)PHENYL]-2-FUROIC ACID,,,,,,solid,,,0.0504,3.13,-4.7,OC(=O)C1=CC=C(O1)C1=CC=CC=C1C(F)(F)F,,,,,0,,256.0347287,2,2,1,1,0,0
5962,04/06/2019 00:00,DB07760,"3-[(1E,7E)-8-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-3,6-dioxa-2,7-diazaocta-1,7-dien-1-yl]benzoic acid",,,,,,solid,,,0.104,4.01,2.98,OC(=O)C1=CC=CC(\C=N\OCCO\N=C\C2=CC(=O)NC(=O)N2)=C1,,,,,0,,346.0913342,2,2,1,1,0,0
5963,04/06/2019 00:00,DB07761,"(2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol",,,,,,solid,,,0.036,12.42,8.7,[H]N(C1=CC=C(OC[C@H](O)CN(C)C)C=C1)C1=CC(=NC=N1)N([H])C1=C(F)C=CC=C1F,,,,,0,,415.1819814,3,3,1,1,0,0
5964,04/06/2019 00:00,DB07762,4-(N-ACETYLAMINO)-3-[N-(2-ETHYLBUTANOYLAMINO)]BENZOIC ACID,,,,,,solid,,,0.108,4.02,-3.3,CCC(CC)C(=O)NC1=CC(=CC=C1NC(C)=O)C(O)=O,,,,,0,,292.1423071,1,1,0,0,0,0
5965,04/06/2019 00:00,DB07763,"(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE",,,,,,solid,,,0.0145,14.26,-9.4,C[C@]1(OC(=O)N(NC2=CC=CC=C2)C1=O)C1=CC=C(F)C=C1F,,,,,0,,318.0815987,3,2,1,0,1,1
5966,04/06/2019 00:00,DB07764,FLUORESCIN,,,,,,solid,,,0.0159,3.89,-6,OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=C1C=CC(O)=C2,,,,,0,,334.0841235,4,3,1,0,0,1
5967,04/06/2019 00:00,DB07765,"METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE",,,,,,solid,,,0.242,15.87,3,COC(=O)C1CCN(CC1)C(=O)C1=CC=C(C=C1)N(C)CC1=NC2=C(N)N=C(N)N=C2N=C1,,,,,0,,450.2127867,4,3,3,2,1,1
5968,04/06/2019 00:00,DB07766,"(2Z,3E)-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE 3-{O-[(3R)-3,4-DIHYDROXYBUTYL]OXIME}",,,,,,solid,,,0.144,10.69,6.85,[H][C@](O)(CO)CCO\N=C1\C(\NC2=CC=CC=C\12)=C1\C(=O)NC2=C1C=CC=C2,,,,,0,,365.1375561,4,2,2,0,0,2
5969,04/06/2019 00:00,DB07767,Ferulic acid,,,,,,solid,,,0.906,3.77,-4.9,COC1=CC(\C=C\C(O)=O)=CC=C1O,,,,,0,,194.0579088,1,1,0,0,0,0
5970,04/06/2019 00:00,DB07768,Epitestosterone,,,,,,solid,,,0.0333,19.09,-0.88,[H][C@@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C,,,,,0,,288.2089301,4,0,0,0,0,0
5971,04/06/2019 00:00,DB07769,S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE,,,,,,solid,,,0.00121,11.77,-4,C[C@](O)(COC1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,,,,,0,,402.0838844,2,2,0,0,0,0
5972,04/06/2019 00:00,DB07770,5-(4-FLUOROPHENYL)-3-{[(4-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID,,,,,,solid,,,0.00217,3.82,-9,CC1=CC=C(C=C1)S(=O)(=O)NC1=C(SC(=C1)C1=CC=C(F)C=C1)C(O)=O,,,,,0,,391.0348281,3,3,1,1,0,0
5973,04/06/2019 00:00,DB07771,"[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID",,,,,,solid,,,0.0044,1.66,-4.6,CC(C)=CCC\C(C)=C\CC\C(C)=C\CONC(=O)CP(O)(O)=O,,,,,0,,359.1861597,0,0,0,0,0,0
5974,04/06/2019 00:00,DB07772,"(1R)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid",,,,,,solid,,,0.461,1.48,-4.8,COC1=CC=C(C=C1)C1=CC=C(C=C1)S(=O)(=O)N[C@@H](C(C)C)P(O)(O)=O,,,,,0,,399.0905451,2,2,0,0,0,0
5975,04/06/2019 00:00,DB07773,5-FLUOROINDOLE PROPANOL PHOSPHATE,,,,,,solid,,,0.611,1.8,,OP(O)(=O)OCCCC1=CNC2=C1C=C(F)C=C2,,,,,0,,273.0566227,2,2,1,1,0,0
5976,04/06/2019 00:00,DB07775,"3',5'-DIBROMO-2',4,4',6'-TETRAHYDROXY AURONE",,,,,,solid,,,0.0527,6.18,-5.2,OC1=CC(O)=C2C(=O)\C(OC2=C1)=C\C1=C(O)C(Br)=C(O)C(Br)=C1,,,,,0,,441.8687622,3,2,1,0,0,1
5977,04/06/2019 00:00,DB07776,Flavone,,,,,Oral,solid,,,0.00819,15.63,-5.4,O=C1C=C(OC2=CC=CC=C12)C1=CC=CC=C1,,,,,0,,222.0680796,3,3,1,1,0,0
5978,04/06/2019 00:00,DB07778,FAMOXADONE,,,,,,solid,,,0.00215,14.26,-8.7,C[C@]1(OC(=O)N(NC2=CC=CC=C2)C1=O)C1=CC=C(OC2=CC=CC=C2)C=C1,,,,,0,,374.1266571,4,3,1,0,1,1
5979,04/06/2019 00:00,DB07779,N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE,,,,,,solid,,,0.0241,14.99,8.81,[H][C@](N)(CC(=O)N1CCC[C@@]1([H])CNC(=O)C1=CC=CC=C1)CC1=C(F)C=CC=C1,,,,,0,,383.2009053,3,2,1,0,1,1
5980,04/06/2019 00:00,DB07780,Farnesyl diphosphate,,,,,,solid,,,0.0807,1.77,,CC(C)=CCC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O,,,,,0,,382.1310265,0,0,0,0,0,0
5981,04/06/2019 00:00,DB07781,N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-NITRILOMETHYL-PYRIDYL]-THIOUREA,,,,,,solid,,,0.00967,10.86,3.67,CCOC1=C(F)C(CCNC(=S)NC2=NC=C(C=C2)C#N)=NC=C1,,,,,0,,345.1059594,2,2,2,2,0,0
5982,04/06/2019 00:00,DB07782,4-AMINO-2-TRIFLUOROMETHYL-5-HYDROXYMETHYLPYRIMIDINE PYROPHOSPHATE,,,,,,solid,,,1.63,1.9,1.21,NC1=NC(=NC=C1CO[P@@](O)(=O)OP(O)(O)=O)C(F)(F)F,,,,,0,,352.9789575,1,1,1,1,0,0
5983,04/06/2019 00:00,DB07783,1-((1R)-1-(HYDROXYMETHYL)-3-{6-[(3-PHENYLPROPANOYL)AMINO]-1H-INDOL-1-YL}PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE,,,,,,solid,,,0.032,13.54,3.53,[H][C@](CO)(CCN1C=CC2=C1C=C(NC(=O)CCC1=CC=CC=C1)C=C2)N1C=NC(=C1)C(N)=O,,,,,0,,445.2113897,4,4,2,2,0,0
5984,04/06/2019 00:00,DB07784,"[4-(4-ACETYLAMINO-PHENYL)-3,5-DIOXO-4-AZA-TRICYCLO[5.2.2.0 2,6]UNDEC-1-YLCARBAMOYLOXY]-ACETIC ACID",,,,,,solid,,,0.604,3.47,-1.1,[H][C@]12C(=O)N(C(=O)[C@@]1([H])[C@@]1(CC[C@@]2([H])CC1)NC(=O)OCC(O)=O)C1=CC=C(NC(C)=O)C=C1,,,,,0,,429.1536001,5,1,1,0,1,1
5985,04/06/2019 00:00,DB07785,"1-{(1R,2S)-2-HYDROXY-1-[2-(2-NAPHTHYLOXY)ETHYL]PROPYL}-1H-IMIDAZONE-4-CARBOXAMIDE",,,,,,solid,,,0.0369,13.88,3.53,[H][C@@](C)(O)[C@@]([H])(CCOC1=CC2=C(C=CC=C2)C=C1)N1C=NC(=C1)C(N)=O,,,,,0,,339.1582915,3,3,1,1,0,0
5986,04/06/2019 00:00,DB07786,"1-((1R,2S)-1-{2-[2-(4-CHLOROPHENYL)-1,3-BENZOXAZOL-7-YL]ETHYL}-2-HYDROXYPROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE",,,,,,solid,,,0.0436,13.88,3.53,[H][C@@](C)(O)[C@]([H])(CCC1=CC=CC2=C1OC(=N2)C1=CC=C(Cl)C=C1)N1C=NC(=C1)C(N)=O,,,,,0,,424.1302182,4,4,2,2,0,0
5987,04/06/2019 00:00,DB07787,"5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE",,,,,,solid,,,0.0249,9.36,8.75,FC1=C2C(=O)NC(=O)N(CCCCN3CCC(=CC3)C3=CC=CC=C3)C2=CC=C1,,,,,0,,393.1852552,4,3,2,1,0,1
5988,04/06/2019 00:00,DB07788,"(3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE",,,,,,solid,,,0.33,9.59,-3.3,[H]\C1=C([H])/C2=CC(OC)=CC(O)=C2C(=O)O[C@]([H])(C)C\C([H])=C([H])/C(=O)[C@@]([H])(O)[C@@]([H])(O)C1,,,,,0,,362.136553,2,1,1,0,0,1
5989,04/06/2019 00:00,DB07789,"1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea",,,,,,solid,,,0.201,8.4,5.57,CC1=CC(NC(=O)\N=C2\NC=C(CCNC3=NC=NC(NC4=NNC=N4)=C3)S2)=C(O1)C(F)(F)F,,,,,0,,494.1208754,4,4,4,4,0,0
5990,04/06/2019 00:00,DB07790,N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE,,,,,,solid,,,0.137,10.61,6.25,COCCNS(=O)(=O)C1=CC=C(NC2=NC(=CC=N2)C2=CN=C(C)N2C(C)C)C=C1,,,,,0,,430.1787097,3,3,2,2,0,0
5991,04/06/2019 00:00,DB07791,4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE,,,,,,solid,,,0.251,10.63,6.25,CNS(=O)(=O)C1=CC=C(NC2=NC(=CC=N2)C2=CN=C(C)N2C2CC2)C=C1,,,,,0,,384.1368449,4,3,2,2,0,0
5992,04/06/2019 00:00,DB07792,"(S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE",,,,,,solid,,,0.00712,9.29,-2,[H][C@@]1(CC2=C(C=CC=C2)N(CC(=O)NCCO)C1=O)NC(=O)C1=CC2=C(N1)SC(Cl)=C2,,,,,0,,446.0815538,4,3,3,2,0,1
5993,04/06/2019 00:00,DB07793,"(2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE",,,,,,solid,,,0.128,11.4,1.45,[H][C@@]1(Cl)SC2=NC(=CC2=C1)C(=O)N[C@@]1([H])CC2=C(C=CC=C2)N(CC(N)=O)C1=O,,,,,0,,402.055339,4,1,3,0,0,3
5994,04/06/2019 00:00,DB07794,"5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE",,,,,,solid,,,0.0431,13.47,2.61,NC1=NNC2=C1C=C(N=N2)C1=C2C=CC=CN2N=C1C1=CC=CC=C1,,,,,0,,327.1232434,5,5,4,4,0,0
5995,04/06/2019 00:00,DB07795,Fisetin,,,,,,solid,,,0.151,6.32,-3.9,OC1=CC2=C(C=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1,,,,,0,,286.047738,3,3,1,1,0,0
5996,04/06/2019 00:00,DB07796,"(3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE",,,,,,solid,,,0.101,16.93,11.49,[H][C@@]12CCC[N@@]1[C@@]([H])(C1=CC=C(C=C1)C(N)=[NH2+])[C@@]1([H])C(=O)N(CC3=CC=C(F)C=C3)C(=O)[C@@]21[H],,,,,1,,407.1877806,5,2,3,0,3,3
5997,04/06/2019 00:00,DB07797,N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-CHLORO-PYRIDYL]-THIOUREA,,,,,,solid,,,0.00278,10.88,3.68,CCOC1=C(F)C(CCNC(=S)NC2=NC=C(Cl)C=C2)=NC=C1,,,,,0,,354.071738,2,2,2,2,0,0
5998,04/06/2019 00:00,DB07798,"(3R)-3-(FLUOROMETHYL)-N-(3,3,3-TRIFLUOROPROPYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE",,,,,,solid,,,0.203,9.69,7.21,[H][C@]1(CF)CC2=CC=C(C=C2CN1)S(=O)(=O)NCCC(F)(F)F,,,,,0,,340.0868616,2,1,1,0,0,1
5999,04/06/2019 00:00,DB07800,N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE,,,,,,solid,,,0.00349,6.22,0.48,ClC1=CN=C(NS(=O)(=O)C2=C(NC(=O)C3=CC=C(C=C3)N3C=CC=CC3=O)C=CC=C2)C=C1,,,,,0,,480.0659037,4,4,2,2,0,0
6000,04/06/2019 00:00,DB07801,N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide,,,,,,solid,,,0.0148,9.87,5.08,CCCCNC(=O)C1=CC=CC(NC(=O)CCCCCNC2=C3N=CNC3=NC=N2)=C1,,,,,0,,423.2382732,3,3,2,2,0,0
6001,04/06/2019 00:00,DB07802,"3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE",,,,,,solid,,,0.0847,6.34,-7.3,CC1=C(Br)C(=O)OC2=C(Br)C(O)=CC=C12,,,,,0,,331.8683683,2,2,1,1,0,0
6002,04/06/2019 00:00,DB07803,2-phenyl-1H-imidazole-4-carboxylic acid,,,,,,solid,,,3.17,1.27,5.47,OC(=O)C1=CNC(=N1)C1=CC=CC=C1,,,,,0,,188.0585775,2,2,1,1,0,0
6003,04/06/2019 00:00,DB07804,"5-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1H-1,2,4-TRIAZOLE-3-SULFONAMIDE",,,,,,solid,,,0.329,7.1,-2.5,[H][C@@](C)(N1CC[C@]([H])(NS(=O)(=O)C2=NNC(=N2)C2=CC=C(Cl)S2)C1=O)C(=O)N1CCOCC1,,,,,0,,488.0703375,4,2,4,2,2,2
6004,04/06/2019 00:00,DB07805,"3-CHLORO-2,2-DIMETHYL-N-[4-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE",,,,,,solid,,,0.00685,13.81,-3.8,CC(C)(CCl)C(=O)NC1=CC=C(C=C1)C(F)(F)F,,,,,0,,279.0637764,1,1,0,0,0,0
6005,04/06/2019 00:00,DB07806,"(2R,4S)-2-[(R)-BENZYLCARBAMOYL-PHENYLACETYL-METHYL]-5,5-DIMETHYL-THIAZOLIDINE-4-CARBOXYLIC ACID",,,,,,solid,,,0.00532,2.89,6.19,[H][C@@](NC(=O)CC1=CC=CC=C1)(C(=O)NCC1=CC=CC=C1)[C@]1([H])N[C@@]([H])(C(O)=O)C(C)(C)S1,,,,,0,,441.1722273,3,2,1,0,1,1
6006,04/06/2019 00:00,DB07807,"(3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL",,,,,,solid,,,10.3,13.51,8.69,[H][C@@]1(O)CN(CCCC2=CC=CC=C2)C[C@]([H])(CO)[C@@]1([H])O,,,,,0,,265.1677936,2,1,1,0,1,1
6007,04/06/2019 00:00,DB07808,"(1S,2R)-2-[(2,5-difluorophenyl)carbamoyl]cyclopropanecarboxylic acid",,,,,,solid,,,0.728,3.52,-4.5,[H][C@@]1(C[C@@]1([H])C(=O)NC1=CC(F)=CC=C1F)C(O)=O,,,,,0,,241.0550496,2,1,0,0,0,0
6008,04/06/2019 00:00,DB07809,4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE,,,,,,solid,,,0.00561,19.32,11.48,CC1=CC=CC(=C1)C(=O)C1=CC=NC(NCC2=CC=C(C=C2)C(N)=N)=C1,,,,,0,,344.1637113,3,3,1,1,0,0
6009,04/06/2019 00:00,DB07810,"3-(4-HYDROXYPHENYL)-1-(2,4,6-TRIHYDROXYPHENYL)PROPAN-1-ONE",,,,,,solid,,,0.132,8,-3.6,OC1=CC=C(CCC(=O)C2=C(O)C=C(O)C=C2O)C=C1,,,,,0,,274.0841235,2,2,0,0,0,0
6010,04/06/2019 00:00,DB07811,"N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide",,,,,,solid,,,0.0333,15.4,-0.42,CC1=NN=C(O1)C1=CC=C(C(C)=C1)C1=CC(=CC=C1C)C(=O)NC1CC1,,,,,0,,347.1633769,4,3,1,1,0,0
6011,04/06/2019 00:00,DB07812,"N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide",,,,,,solid,,,0.00325,13.79,8.74,[H][C@](CN)(NC(=O)C1=CC=C(S1)C1=C2C=CNC2=NC=C1)C1=CC=CC=C1,,,,,0,,362.1201322,4,4,3,3,0,0
6012,04/06/2019 00:00,DB07813,GLYCYLALANYL-N-2-NAPHTHYL-L-PROLINEAMIDE,,,,,,solid,,,0.0942,12.49,7.84,[H][C@@](C)(NC(=O)CN)C(=O)N1CCC[C@@]1([H])C(=O)NC1=CC=C2C=CC=CC2=C1,,,,,0,,368.1848406,3,2,1,0,1,1
6013,04/06/2019 00:00,DB07814,Gibberellic acid,,,,,,solid,,,1.95,4.16,-0.9,[H][C@@]12CC[C@]3(O)C[C@]1(CC3=C)[C@@H](C(O)=O)[C@]1([H])[C@@]3(C)[C@@H](O)C=C[C@@]21OC3=O,,,,,0,,346.1416384,5,0,1,0,1,1
6014,04/06/2019 00:00,DB07815,GIBBERELLIN A4,,,,,,solid,,,1.19,4.29,-3,[H][C@@]12C[C@@]3(CC1=C)[C@@]([H])(CC2)[C@@]12CC[C@]([H])(O)[C@@](C)(C(=O)O1)[C@@]2([H])[C@]3([H])C(O)=O,,,,,0,,332.1623739,5,0,1,0,1,1
6015,04/06/2019 00:00,DB07816,N-(P-CYANOPHENYL)-N'-DIPHENYLMETHYL-GUANIDINE-ACETIC ACID,,,,,,solid,,,0.00728,2.97,9.49,OC(=O)C\N=C(\NC(C1=CC=CC=C1)C1=CC=CC=C1)NC1=CC=C(C=C1)C#N,,,,,0,,384.1586259,3,3,0,0,0,0
6016,04/06/2019 00:00,DB07817,"1-{3-[(4-pyridin-2-ylpiperazin-1-yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea",,,,,,solid,,,0.17,10.1,6.42,O=C(NC1=NC=CS1)NC1=CC(=CC=C1)S(=O)(=O)N1CCN(CC1)C1=CC=CC=N1,,,,,0,,444.1038305,4,3,3,2,1,1
6017,04/06/2019 00:00,DB07818,"(2E)-3-(2,4-DICHLOROPHENYL)-N-HYDROXYACRYLAMIDE",,,,,,solid,,,0.0533,9.55,-5.1,ONC(=O)\C=C\C1=CC=C(Cl)C=C1Cl,,,,,0,,230.9853838,1,1,0,0,0,0
6018,04/06/2019 00:00,DB07819,(2E)-3-(4-CHLOROPHENYL)-N-HYDROXYACRYLAMIDE,,,,,,solid,,,0.195,9.56,-5.1,ONC(=O)\C=C\C1=CC=C(Cl)C=C1,,,,,0,,197.0243562,1,1,0,0,0,0
6019,04/06/2019 00:00,DB07820,"6-(3',5'-DIMETHYLBENZYL)-1-ETHOXYMETHYL-5-ISOPROPYLURACIL",,,,,,solid,,,0.0463,10.23,-3.9,CCOCN1C(=O)NC(=O)C(C(C)C)=C1CC1=CC(C)=CC(C)=C1,,,,,0,,330.1943427,2,2,1,1,0,0
6020,04/06/2019 00:00,DB07821,"(1R)-1,2,2-trimethylpropyl (R)-methylphosphinate",,,,,,solid,,,1.87,,-6.6,[H][C@](C)(O[P@]([H])(C)=O)C(C)(C)C,,,,,0,,164.0966164,0,0,0,0,0,0
6021,04/06/2019 00:00,DB07823,"(2S)-2-[(3aR,4R,7S,7aS)-1,3-dioxooctahydro-2H-4,7-methanoisoindol-2-yl]propanoic acid",,,,,,solid,,,13.4,3.72,-6.1,[H][C@@](C)(N1C(=O)[C@@]2([H])[C@@]3([H])CC[C@]([H])(C3)[C@@]2([H])C1=O)C(O)=O,,,,,0,,237.100108,3,0,1,0,1,1
6022,04/06/2019 00:00,DB07824,"4-ethyl-5-methyl-2-(1H-tetrazol-5-yl)-1,2-dihydro-3H-pyrazol-3-one",,,,,,solid,,,1.81,4.65,0.65,CCC1=C(C)NN(C1=O)C1=NN=NN1,,,,,0,,194.0916089,2,2,2,2,0,0
6023,04/06/2019 00:00,DB07825,(3S)-1-(4-acetylphenyl)-5-oxopyrrolidine-3-carboxylic acid,,,,,,solid,,,1.43,3.63,-4.1,[H][C@]1(CN(C(=O)C1)C1=CC=C(C=C1)C(C)=O)C(O)=O,,,,,0,,247.0844579,2,1,1,0,1,1
6024,04/06/2019 00:00,DB07826,2-[4-chloro-2-(phenylcarbonyl)phenoxy]-N-phenylacetamide,,,,,,solid,,,0.000475,12.58,-4.9,ClC1=CC=C(OCC(=O)NC2=CC=CC=C2)C(=C1)C(=O)C1=CC=CC=C1,,,,,0,,365.0818711,3,3,0,0,0,0
6025,04/06/2019 00:00,DB07827,"4-{[1-METHYL-2,4-DIOXO-6-(3-PHENYLPROP-1-YN-1-YL)-1,4-DIHYDROQUINAZOLIN-3(2H)-YL]METHYL}BENZOIC ACID",,,,,,solid,,,0.00413,4.07,-7.4,CN1C(=O)N(CC2=CC=C(C=C2)C(O)=O)C(=O)C2=C1C=CC(=C2)C#CCC1=CC=CC=C1,,,,,0,,424.1423071,4,4,1,1,0,0
6026,04/06/2019 00:00,DB07829,4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE,,,,,,solid,,,0.0889,14.96,4.28,FC1=CC=C(C=C1)C1=NNC=C1C1=CC=NC=C1,,,,,0,,239.0858755,3,3,2,2,0,0
6027,04/06/2019 00:00,DB07830,"(4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE",,,,,,solid,,,0.113,,8.86,[H][C@]1(N)CN(CCC2=CC=C3OCOC3=C2)C(=O)C[C@]1([H])C1=CC(F)=C(F)C=C1F,,,,,0,,392.1347771,4,2,2,0,1,2
6028,04/06/2019 00:00,DB07831,"2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE",,,,,,solid,,,0.00137,11.12,2.12,CCCC1=CC=C(NC(=O)C2=CC=CC=C2NCC2=CNC(=O)C=C2)C=C1C(F)(F)F,,,,,0,,429.1664116,3,3,1,1,0,0
6029,04/06/2019 00:00,DB07832,"4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde",,,,,,solid,,,0.00173,10.04,6.99,CC1=C(NC2=CC=NC3=CC(=CC=C23)C2=CSC(C=O)=N2)C=C(O)C=C1,,,,,0,,361.0884977,4,4,2,2,0,0
6030,04/06/2019 00:00,DB07833,"N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide",,,,,,solid,,,0.0551,11.04,-0.89,CC1=NN=C(O1)C1=CC=C(C)C(=C1)C1=CC=C(C=C1)C(=O)NC1=CC(=CC=C1)C#N,,,,,0,,394.1429758,4,4,1,1,0,0
6031,04/06/2019 00:00,DB07834,"N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide",,,,,,solid,,,0.0288,14.91,-0.15,CC1=NN=C(O1)C1=CC=C(C)C(=C1)C1=CC=C(C=C1)C(=O)NCC1CC1,,,,,0,,347.1633769,4,3,1,1,0,0
6032,04/06/2019 00:00,DB07835,"N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide",,,,,,solid,,,0.000615,14.78,-0.084,CC1=CC=C(C=C1C1=CC=C(C=C1)C(=O)NCC1CC1)C(=O)NC1CC1,,,,,0,,348.183778,4,2,0,0,0,0
6033,04/06/2019 00:00,DB07836,1-DECYL-3-TRIFLUORO ETHYL-SN-GLYCERO-2-PHOSPHOMETHANOL,,,,,,solid,,,0.00663,1.9,-3.9,[H][C@](COCCCCCCCCCC)(COCC(F)(F)F)O[P@](O)(=O)OC,,,,,0,,408.18886,0,0,0,0,0,0
6034,04/06/2019 00:00,DB07837,"[4-(5-naphthalen-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]acetic acid",,,,,,solid,,,0.000232,4.84,3.79,OC(=O)CC1=CC=C(C=C1)C1=CNC2=NC=C(C=C12)C1=CC=C2C=CC=CC2=C1,,,,,0,,378.1368278,5,5,2,2,0,0
6035,04/06/2019 00:00,DB07838,(Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE,,,,,,solid,,,0.00303,6.1,-4.2,OC1=C(\C=C2/SC(=S)N(CC3=CC=CC=C3)C2=O)C=CC=C1[N+]([O-])=O,,,,,0,,372.0238489,3,2,1,0,1,1
6036,04/06/2019 00:00,DB07839,"N~2~-1,3-BENZOXAZOL-2-YL-3-CYCLOHEXYL-N-{2-[(4-METHOXYPHENYL)AMINO]ETHYL}-L-ALANINAMIDE",,,,,,solid,,,0.0334,8.8,5.46,[H][C@@](CC1CCCCC1)(NC1=NC2=CC=CC=C2O1)C(=O)NCCNC1=CC=C(OC)C=C1,,,,,0,,436.2474409,4,3,1,1,0,0
6037,04/06/2019 00:00,DB07840,"(E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol",,,,,,solid,,,0.00452,7.06,0.92,COC1=CC(=CC=C1)C(\O)=C1/C=NC2=NC=CC(=C12)C1=CC(F)=CC(F)=C1,,,,,0,,364.1023341,4,3,2,1,0,1
6038,04/06/2019 00:00,DB07841,Geranylgeranyl diphosphate,,,,,,solid,,,0.00463,1.77,,CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O,,,,,0,,450.1936268,0,0,0,0,0,0
6039,04/06/2019 00:00,DB07842,(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid,,,,,,solid,,,0.0133,4.06,-4.9,[H][C@@](CC1=CC=CC=C1)(OC1=CC=C(CC)C=C1)C(O)=O,,,,,0,,270.1255944,2,2,0,0,0,0
6040,04/06/2019 00:00,DB07843,5-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE,,,,,,solid,,,0.0341,8.61,-3.1,[H][C@@](C)(N1CC[C@]([H])(NS(=O)(=O)C2=CC3=C(S2)C=CC(Cl)=C3)C1=O)C(=O)N1CCOCC1,,,,,0,,471.0689405,4,2,3,1,2,2
6041,04/06/2019 00:00,DB07844,6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE,,,,,,solid,,,0.0322,8.61,-3.1,[H][C@@](C)(N1CC[C@]([H])(NS(=O)(=O)C2=CC3=C(S2)C=C(Cl)C=C3)C1=O)C(=O)N1CCOCC1,,,,,0,,471.0689405,4,2,3,1,2,2
6042,04/06/2019 00:00,DB07845,"2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide",,,,,,solid,,,0.0122,12.1,5.92,COC1=C(NC2=NC3=C(C=CN3)C(NC3=CC=CC(F)=C3C(N)=O)=N2)C=CC(CS(C)(=O)=O)=C1,,,,,0,,484.1329024,4,4,2,2,0,0
6043,04/06/2019 00:00,DB07846,"1S,3AS,8AS-TRIMETHYL-1-OXIDO-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL 2-ETHYLPHENYLCARBAMATE",,,,,,solid,,,0.00577,7.48,0.42,CCC1=CC=CC=C1N=C(O)OC1=CC2=C(C=C1)N(C)C1C2(C)CCN1(C)=O,,,,,0,,381.2052417,4,2,2,0,1,2
6044,04/06/2019 00:00,DB07847,6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-(4-MORPHOLINYL)-2-OXO ETHYL]-2-OXO-3-PYRROLIDINYL}-2-NAPHTHALENESULFONAMIDE,,,,,,solid,,,0.0978,10.04,-3.1,[H][C@@](C)(N1CC[C@]([H])(NS(=O)(=O)C2=CC3=CC=C(Cl)C=C3C=C2)C1=O)C(=O)N1CCOCC1,,,,,0,,465.1125195,4,2,2,0,2,2
6045,04/06/2019 00:00,DB07848,5-Chloro-N-{(3S)-1-[(2S)-1-(4-morpholinyl)-1-oxo-2-propanyl]-2-oxo-3-pyrrolidinyl}-1H-indole-2-sulfonamide,,,,,,solid,,,0.277,9.62,-3.1,C[C@H](N1CC[C@H](NS(=O)(=O)C2=CC3=C(N2)C=CC(Cl)=C3)C1=O)C(=O)N1CCOCC1,,,,,0,,454.1077685,4,2,3,1,2,2
6046,04/06/2019 00:00,DB07849,S-NONYL-CYSTEINE,,,,,,solid,,,0.0263,2.51,9.14,[H][C@](N)(CSCCCCCCCCC)C(O)=O,,,,,0,,247.1606,0,0,0,0,0,0
6047,04/06/2019 00:00,DB07850,"(1R,2S)-2-(5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)cyclohexanecarboxylic acid",,,,,,solid,,,0.332,4.51,-2.4,[H][C@]1(CCCC[C@]1([H])C1=NNC(=S)N1)C(O)=O,,,,,0,,227.0728477,2,1,1,1,0,0
6048,04/06/2019 00:00,DB07851,"(3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE",,,,,,solid,,,0.0567,,9.64,[H][C@]1(N)CCN(C[C@@]1([H])C1=CC(C)=CC=C1)C1=CC(OC)=C(OC)C=C1,,,,,0,,326.1994281,3,2,1,0,1,1
6049,04/06/2019 00:00,DB07852,"1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID",,,,,,solid,,,0.197,2.78,-0.18,CC1=NC(=NN1C1=CC(Cl)=CC(Cl)=C1)C(O)=O,,,,,0,,270.9915318,2,2,1,1,0,0
6050,04/06/2019 00:00,DB07853,"[4-({4-[(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO]QUINAZOLIN-2-YL}IMINO)CYCLOHEXA-2,5-DIEN-1-YL]ACETONITRILE",,,,,,solid,,,0.0435,9.03,5.04,[H]C1(CC#N)C=CC(C=C1)=NC1=NC2=CC=CC=C2C(N=C2NNC(=C2)C2CC2)=N1,,,,,0,,381.1701936,5,3,2,2,0,0
6051,04/06/2019 00:00,DB07854,N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE,,,,,,solid,,,0.0299,10.3,9.44,CNCC1=CC=C(C=C1)C1=NC=NC2=C1N=CN2,,,,,0,,239.1170954,3,3,2,2,0,0
6052,04/06/2019 00:00,DB07855,(S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE,,,,,,solid,,,0.0388,10.25,8.94,[H][C@](N)(C1=CC=CC=C1)C1=CC=C(C=C1)C1=C2N=CNC2=NC=N1,,,,,0,,301.1327455,4,4,2,2,0,0
6053,04/06/2019 00:00,DB07856,6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE,,,,,,solid,,,0.00243,10.43,9.8,ClC1=CC=C(C=C1)C1(CCNCC1)C1=CC=C(C=C1)C1=C2N=CNC2=NC=N1,,,,,0,,389.1407233,5,4,3,2,1,1
6054,04/06/2019 00:00,DB07857,(2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine,,,,,,solid,,,0.00314,14.63,9.68,NC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=C(C=C1)C1=CNN=C1,,,,,0,,297.1032752,3,3,1,1,0,0
6055,04/06/2019 00:00,DB07858,(2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine,,,,,,solid,,,0.00314,14.63,9.68,NC[C@H](C1=CC=C(Cl)C=C1)C1=CC=C(C=C1)C1=CNN=C1,,,,,0,,297.1032752,3,3,1,1,0,0
6056,04/06/2019 00:00,DB07859,4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE,,,,,,solid,,,0.000843,14.63,10.02,ClC1=CC=C(C=C1)C1(CCNCC1)C1=CC=C(C=C1)C1=CNN=C1,,,,,0,,337.1345753,4,3,2,1,1,1
6057,04/06/2019 00:00,DB07860,(2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE,,,,,,solid,,,0.0163,,9.7,[H][C@@](CN)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,,,,,0,,231.0814771,2,2,0,0,0,0
6058,04/06/2019 00:00,DB07861,(2R)-N-hydroxy-3-naphthalen-2-yl-2-[(naphthalen-2-ylsulfonyl)amino]propanamide,,,,,,solid,,,0.000431,8.69,-5.5,[H][C@](CC1=CC2=C(C=CC=C2)C=C1)(NS(=O)(=O)C1=CC2=C(C=CC=C2)C=C1)C(=O)NO,,,,,0,,420.1143781,4,4,0,0,0,0
6059,04/06/2019 00:00,DB07862,"7-(1-ETHYL-PROPYL)-7H-PYRROLO-[3,2-F]QUINAZOLINE-1,3-DIAMINE",,,,,,solid,,,0.167,16.77,5.98,CCC(CC)N1C=CC2=C1C=CC1=C2C(N)=NC(N)=N1,,,,,0,,269.1640456,3,3,2,2,0,0
6060,04/06/2019 00:00,DB07863,2-chloro-5-nitro-N-phenylbenzamide,,,,,,solid,,,0.00501,11.31,-4.3,[O-][N+](=O)C1=CC=C(Cl)C(=C1)C(=O)NC1=CC=CC=C1,,,,,0,,276.0301698,2,2,0,0,0,0
6061,04/06/2019 00:00,DB07864,4-[(CYCLOPROPYLETHYNYL)OXY]-6-FLUORO-3-ISOPROPYLQUINOLIN-2(1H)-ONE,,,,,,solid,,,0.00862,12.88,-1.6,CC(C)C1=C(OC#CC2CC2)C2=CC(F)=CC=C2NC1=O,,,,,0,,285.116507,3,2,1,1,0,0
6062,04/06/2019 00:00,DB07865,3-(1H-tetrazol-5-ylamino)cyclohex-2-en-1-one,,,,,,solid,,,1.05,4.58,-0.73,O=C1CCCC(NC2=NN=NN2)=C1,,,,,0,,179.0807099,2,1,1,1,0,0
6063,04/06/2019 00:00,DB07866,"(5S)-2-(cyclooctylamino)-5-methyl-5-propyl-1,3-thiazol-4(5H)-one",,,,,,solid,,,0.0272,,0.3,CCC[C@]1(C)SC(NC2CCCCCCC2)=NC1=O,,,,,0,,282.1765845,2,0,1,0,0,1
6064,04/06/2019 00:00,DB07867,6-CHLORO-4-(CYCLOHEXYLOXY)-3-PROPYLQUINOLIN-2(1H)-ONE,,,,,,solid,,,0.00559,12.8,-1.2,CCCC1=C(OC2CCCCC2)C2=CC(Cl)=CC=C2NC1=O,,,,,0,,319.1339066,3,2,1,1,0,0
6065,04/06/2019 00:00,DB07868,6-CHLORO-4-(CYCLOHEXYLSULFANYL)-3-PROPYLQUINOLIN-2(1H)-ONE,,,,,,solid,,,0.00281,13.22,-0.97,CCCC1=C(SC2CCCCC2)C2=CC(Cl)=CC=C2NC1=O,,,,,0,,335.111063,3,2,1,1,0,0
6066,04/06/2019 00:00,DB07869,6-CHLORO-4-(CYCLOHEXYLSULFINYL)-3-PROPYLQUINOLIN-2(1H)-ONE,,,,,,solid,,,0.0376,11.22,-0.18,CCCC1=C(C2=C(C=CC(Cl)=C2)N=C1O)[S@](=O)C1CCCCC1,,,,,0,,351.1059776,3,2,1,1,0,0
6067,04/06/2019 00:00,DB07870,(2S)-2-(4-{[3-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-2-YL]OXY}PHENOXY)PROPANOIC ACID,,,,,,solid,,,0.0104,2.78,-0.8,[H][C@](C)(OC1=CC=C(OC2=NC=C(C=C2Cl)C(F)(F)F)C=C1)C(O)=O,,,,,0,,361.0328702,2,2,1,1,0,0
6068,04/06/2019 00:00,DB07871,6-CHLORO-4-(CYCLOHEXYLOXY)-3-ISOPROPYLQUINOLIN-2(1H)-ONE,,,,,,solid,,,0.00693,12.78,-1.2,CC(C)C1=C(OC2CCCCC2)C2=CC(Cl)=CC=C2NC1=O,,,,,0,,319.1339066,3,2,1,1,0,0
6069,04/06/2019 00:00,DB07872,5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide,,,,,,solid,,,0.00195,11.57,5.25,[H][C@]1(CCN(CC(=O)NC2=C(F)C=C(C=C2)N2C=CC=CC2=O)C1)NC(=O)C1=CC=C(Cl)S1,,,,,0,,474.0928674,4,3,3,2,1,1
6070,04/06/2019 00:00,DB07873,Lauryl alcohol diphosphonic acid,,,,,,solid,,,3.11,0.69,-5.2,CCCCCCCCCCCC(O)(P(O)(O)=O)P(O)(O)=O,,,,,0,,346.1310265,0,0,0,0,0,0
6071,04/06/2019 00:00,DB07874,"(6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one",,,,,,solid,,,0.0167,18.23,6.58,COC1=CC(=CC=C1)C1=CC(=CC=C1)[C@]1(C)CC(=O)N(C)C(N)=N1,,,,,0,,323.1633769,3,2,1,0,0,1
6072,04/06/2019 00:00,DB07875,"5-Chloro-thiophene-2-carboxylic acid ((3S,4S)-1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-4-hydroxy-pyrrolidin-3-yl)-amide",,,,,,solid,,,0.00312,11.57,4.78,[H][C@]1(O)CN(CC(=O)NC2=C(F)C=C(C=C2)N2C=CC=CC2=O)C[C@]1([H])NC(=O)C1=CC=C(Cl)S1,,,,,0,,490.087782,4,3,3,2,1,1
6073,04/06/2019 00:00,DB07876,(S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE,,,,,,solid,,,0.232,,8.2,[H][C@]1(C)CNCCCN1S(=O)(=O)C1=C2C(C)=CN=CC2=CC=C1,,,,,0,,319.1354479,3,2,2,1,1,1
6074,04/06/2019 00:00,DB07877,"8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE",,,,,,solid,,,0.0443,18.4,10.55,CC(C)NCCCN1C(SC2=C(Br)C=C3OCOC3=C2)=NC2=C1N=CN=C2N,,,,,0,,464.063007,4,3,3,2,0,1
6075,04/06/2019 00:00,DB07878,"N-[(1S)-1-{1-[(1R,3E)-1-ACETYLPENT-3-EN-1-YL]-1H-1,2,3-TRIAZOL-4-YL}-1,2-DIMETHYLPROPYL]BENZAMIDE",,,,,,solid,,,0.0125,13.99,0.17,C\C=C\C[C@]([H])(C(C)=O)N1N=NC(=C1)[C@](C)(C(C)C)NC(=O)C1=CC=CC=C1,,,,,0,,368.2212261,2,2,1,1,0,0
6076,04/06/2019 00:00,DB07879,"N-hydroxy-5-[(3-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)carbonyl]thiophene-2-carboxamide",,,,,,solid,,,0.346,8.93,5.69,ONC(=O)C1=CC=C(S1)C(=O)N1CCN2C(C1)=NC=C2C1=CC=CC=C1,,,,,0,,368.0943114,4,3,3,2,0,1
6077,04/06/2019 00:00,DB07880,2-((4'-HYDROXYPHENYL)-AZO)BENZOIC ACID,,,,,,solid,,,0.0841,3.36,0.25,OC(=O)C1=CC=CC=C1\N=N\C1=CC=C(O)C=C1,,,,,0,,242.0691422,2,2,0,0,0,0
6078,04/06/2019 00:00,DB07881,N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE,,,,,,solid,,,0.0025,1.24,-1.2,[H][C@](CC1=CC=CC=C1)(NC(=O)CCCC(O)=O)[P@](O)(=O)OCC(=O)NCCC1=CC=CC=C1,,,,,0,,476.1712379,2,2,0,0,0,0
6079,04/06/2019 00:00,DB07882,"4-{4-[2-(1A,7A-DIMETHYL-4-OXY-OCTAHYDRO-1-OXA-4-AZA-CYCLOPROPA[A]NAPHTHALEN-4-YL) -ACETYLAMINO]-PHENYLCARBAMOYL}-BUTYRIC ACID",,,,,,solid,,,0.00989,4.11,-0.42,[H][C@@]12O[C@]1(C)CC[C@]1([H])[C@]2(C)CCC[N@+]1([O-])CC(=O)NC1=CC=C(NC(=O)CCCC(O)=O)C=C1,,,,,0,,459.2369358,4,1,2,0,2,2
6080,04/06/2019 00:00,DB07883,(2-AMINO-3-PHENYL-BICYCLO[2.2.1]HEPT-2-YL)-PHENYL-METHANONE,,,,,,solid,,,0.00323,,7.94,[H][C@]12CC[C@]([H])(C1)[C@](N)(C(=O)C1=CC=CC=C1)[C@]2([H])C1=CC=CC=C1,,,,,0,,291.1623143,4,2,0,0,0,0
6081,04/06/2019 00:00,DB07884,"ISOPROPYL (2S)-2-ETHYL-7-FLUORO-3-OXO-3,4-DIHYDROQUINOXALINE-1(2H)-CARBOXYLATE",,,,,,solid,,,1.62,12.28,-3.3,[H][C@@]1(CC)N(C(=O)OC(C)C)C2=CC(F)=CC=C2NC1=O,,,,,0,,280.1223206,2,1,1,0,0,1
6082,04/06/2019 00:00,DB07885,Talviraline,,,,,,solid,,,0.0101,8.16,-2.6,[H][C@@]1(CSC)N(C(=O)OC(C)C)C2=C(NC1=S)C=CC(OC)=C2,,,,,0,,340.0915345,2,1,1,0,0,1
6083,04/06/2019 00:00,DB07887,"(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)BENZYL)GUANIDINE",,,,,,solid,,,0.534,14.65,11.83,[H][C@@]1(CO)COB(O1)C1=CC=C(CNC(N)=N)C=C1,,,,,0,,249.1284718,2,1,1,0,1,1
6084,04/06/2019 00:00,DB07888,"3-(4-HYDROXYPHENYL)-4,5-DIHYDRO-5-ISOXAZOLE-ACETIC ACID METHYL ESTER",,,,,,solid,,,0.389,8.96,3.89,[H][C@]1(CC(=O)OC)CC(=NO1)C1=CC=C(O)C=C1,,,,,0,,235.0844579,2,1,1,0,0,1
6085,04/06/2019 00:00,DB07889,"(2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol",,,,,,solid,,,0.033,13.8,8.7,[H]N(C1=CC=C(OC[C@@H](O)CN(C)C)C=C1)C1=NC=CC(=N1)C1=C(C)N=C2C=CC=CN12,,,,,0,,418.2117241,4,4,3,3,0,0
6086,04/06/2019 00:00,DB07890,4-(2-HYDROXYPHENYLTHIO)-1-BUTENYLPHOSPHONIC ACID,,,,,,solid,,,1.44,3.62,-5.8,OC1=C(SCC\C=C\P(O)(O)=O)C=CC=C1,,,,,0,,260.0272165,1,1,0,0,0,0
6087,04/06/2019 00:00,DB07891,"4-{[(14beta,17alpha)-3-hydroxyestra-1,3,5(10)-trien-17-yl]oxy}-4-oxobutanoic acid",,,,,,solid,,,0.0048,4.31,-5.4,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=C(C=CC(O)=C4)[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O,,,,,0,,372.193674,4,1,0,0,0,0
6088,04/06/2019 00:00,DB07892,1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE,,,,,,solid,,,0.487,9.89,-2.7,CC1=C(SC2=CC=CC=C2)N(COCCO)C(=O)NC1=O,,,,,0,,308.083078,2,2,1,1,0,0
6089,04/06/2019 00:00,DB07893,PHENYL[1-(N-SUCCINYLAMINO)PENTYL]PHOSPHONATE,,,,,,solid,,,0.671,1.52,-1.6,[H][C@@](CCCC)(NC(=O)CCC(O)=O)[P@](O)(=O)OC1=CC=CC=C1,,,,,0,,343.1184741,1,1,0,0,0,0
6090,04/06/2019 00:00,DB07894,4-(2-HYDROXY-4-FLUOROPHENYLTHIO)-BUTYLPHOSPHONIC ACID,,,,,,solid,,,0.406,3.62,-6.1,OC1=CC=C(F)C=C1SCC\C=C\P(O)(O)=O,,,,,0,,278.0177947,1,1,0,0,0,0
6091,04/06/2019 00:00,DB07895,ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID,,,,,,solid,,,0.109,1.3,-3.9,[H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)C[C@@]([H])(O)P(O)(O)=O,,,,,0,,308.2116462,0,0,0,0,0,0
6092,04/06/2019 00:00,DB07896,(2S)-hydroxy(4-hydroxyphenyl)ethanoic acid,,,,,,solid,,,7.69,3.3,-4.1,[H][C@@](O)(C(O)=O)C1=CC=C(O)C=C1,,,,,0,,168.0422587,1,1,0,0,0,0
6093,04/06/2019 00:00,DB07897,1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE,,,,,,solid,,,6.03,14.6,9.5,OCCCCCCCCNCO,,,,,0,,175.1572289,0,0,0,0,0,0
6094,04/06/2019 00:00,DB07898,2-(BUTYRYLOXY)-1-{[(TETRAHYDROXYPHOSPHORANYL)OXY]METHYL}ETHYL BUTYRATE,,,,,,solid,,,0.165,8.8,-5.2,[H][C@@](COC(=O)CCC)(COP(O)(O)(O)O)OC(=O)CCC,,,,,0,,330.1079689,0,0,0,0,0,0
6095,04/06/2019 00:00,DB07899,(2S) N-acetyl-L-alanyl-Î±L-phenylalanyl-chloroethylketone,,,,,,solid,,,0.0374,12,-1.4,[H][C@@](C)(NC(C)=O)C(=O)N[C@@]([H])(CC1=CC=CC=C1)C(=O)CCCl,,,,,0,,324.1240702,1,1,0,0,0,0
6096,04/06/2019 00:00,DB07900,3-FORMYL-2-HYDROXY-5-METHYL-HEXANOIC ACID HYDROXYAMIDE,,,,,,solid,,,41.9,8.61,-3.8,[H][C@@](O)(C(=O)NO)[C@@]([H])(CC(C)C)C=O,,,,,0,,189.100108,0,0,0,0,0,0
6097,04/06/2019 00:00,DB07901,5-CHLORO-6-METHYL-N-(2-PHENYLETHYL)-2-PYRIDIN-2-YLPYRIMIDIN-4-AMINE,,,,,,solid,,,0.00831,17.94,4.1,CC1=C(Cl)C(NCCC2=CC=CC=C2)=NC(=N1)C1=NC=CC=C1,,,,,0,,324.1141742,3,3,2,2,0,0
6098,04/06/2019 00:00,DB07902,"TERT-BUTYL {2-[(1,3-THIAZOL-2-YLAMINO)CARBONYL]PYRIDIN-3-YL}CARBAMATE",,,,,,solid,,,0.0242,8.21,0.16,CC(C)(C)OC(=O)NC1=C(N=CC=C1)C(=O)NC1=NC=CS1,,,,,0,,320.0943114,2,2,2,2,0,0
6099,04/06/2019 00:00,DB07903,"3-[(2,2-DIMETHYLPROPANOYL)AMINO]-N-1,3-THIAZOL-2-YLPYRIDINE-2-CARBOXAMIDE",,,,,,solid,,,0.0192,8.25,0.2,CC(C)(C)C(=O)NC1=C(N=CC=C1)C(=O)NC1=NC=CS1,,,,,0,,304.0993968,2,2,2,2,0,0
6100,04/06/2019 00:00,DB07905,"(1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione",,,,,,solid,,,1.86,9.47,-3.3,[H][C@@]12C[C@]([H])(O)[C@]([H])(O)C(=O)C=CC[C@]([H])(C)OC(=O)C3=C(C=C(OC)C=C3O)[C@@]1([H])O2,,,,,0,,378.1314677,3,1,2,0,1,2
6101,04/06/2019 00:00,DB07906,"[(3R)-7-NITRO-1,2,3,4-TETRAHYDROISOQUINOLIN-3-YL]METHANOL",,,,,,solid,,,1.97,15.11,8.38,[H][C@]1(CO)CC2=CC=C(C=C2CN1)[N+]([O-])=O,,,,,0,,208.0847922,2,1,1,0,0,1
6102,04/06/2019 00:00,DB07907,(2S)-2-HYDROXYOCTANOIC ACID,,,,,,solid,,,11.2,4.42,-3.8,[H][C@](O)(CCCCCC)C(O)=O,,,,,0,,160.1099444,0,0,0,0,0,0
6103,04/06/2019 00:00,DB07908,7-HYDROXY-4-METHYL-3-(2-HYDROXY-ETHYL)COUMARIN,,,,,,solid,,,0.652,7.77,-2.4,CC1=C(CCO)C(=O)OC2=CC(O)=CC=C12,,,,,0,,220.0735589,2,2,1,1,0,0
6104,04/06/2019 00:00,DB07909,"(1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL",,,,,,solid,,,0.00298,4.14,-0.49,[H][C@]1(O)C[C@]([H])(CC[C@]1([H])C1=CC=C(C=C1)C(=O)NCCCC(O)=O)C1=CC=CC=C1,,,,,0,,381.1940083,3,2,0,0,0,0
6105,04/06/2019 00:00,DB07910,"(2S)-2-amino-3-phenylpropane-1,1-diol",,,,,,solid,,,13,11.85,8.8,[H][C@](N)(CC1=CC=CC=C1)C(O)O,,,,,0,,167.0946287,1,1,0,0,0,0
6106,04/06/2019 00:00,DB07911,"(3E)-2,6-DIOXO-6-PHENYLHEX-3-ENOATE",,,,,,solid,,,0.195,2.92,-7.5,[O-]C(=O)C(=O)\C=C\CC(=O)C1=CC=CC=C1,,,,,-1,,217.0506323,1,1,0,0,0,0
6107,04/06/2019 00:00,DB07912,2-OXOHEPTYLPHOSPHONIC ACID,,,,,,solid,,,11.6,1.68,-7.6,CCCCCC(=O)CP(O)(O)=O,,,,,0,,194.0707956,0,0,0,0,0,0
6108,04/06/2019 00:00,DB07913,HOMOPHENYLALANINYLMETHANE,,,,,,solid,,,0.392,17.62,7.98,[H][C@](N)(CCC1=CC=CC=C1)C(C)=O,,,,,0,,177.1153641,1,1,0,0,0,0
6109,04/06/2019 00:00,DB07914,"2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid",,,,,,solid,,,0.359,3.25,-6.1,OC(=O)C(\O)=C\C=C\C(=O)C1=CC=CC=C1,,,,,0,,218.0579088,1,1,0,0,0,0
6110,04/06/2019 00:00,DB07915,"(2E,4E)-2-Hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid",,,,,,solid,,,0.359,3.25,-6.1,OC(=O)C(\O)=C/C=C/C(=O)C1=CC=CC=C1,,,,,0,,218.0579088,1,1,0,0,0,0
6111,04/06/2019 00:00,DB07916,3-{6-[(8-HYDROXY-QUINOLINE-2-CARBONYL)-AMINO]-2-THIOPHEN-2-YL-HEXANOYLAMINO}-4-OXO-BUTYRI ACID,,,,,,solid,,,0.00418,4.65,0.86,[H][C@@](CC(O)=O)(NC(=O)[C@@]([H])(CCCCNC(=O)C1=NC2=C(C=CC=C2O)C=C1)C1=CC=CS1)C=O,,,,,0,,483.1464065,3,3,2,2,0,0
6112,04/06/2019 00:00,DB07917,4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE,,,,,,solid,,,0.0422,4.87,8.97,C(CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1)CC1=NN=NN1,,,,,0,,377.2215605,4,3,2,1,1,1
6113,04/06/2019 00:00,DB07918,2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,,,,,solid,,,0.01,7.88,1.22,CCCCCCCC1=[N+]([O-])C2=CC=CC=C2C(O)=C1,,,,,0,,259.1572289,2,2,1,1,0,0
6114,04/06/2019 00:00,DB07919,7-METHOXY-1-METHYL-9H-BETA-CARBOLINE,,,,,,solid,,,0.0613,13.54,6.15,COC1=CC=C2C(NC3=C2C=CN=C3C)=C1,,,,,0,,212.094963,3,3,2,2,0,0
6115,04/06/2019 00:00,DB07920,N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide,,,,,,solid,,,0.0121,10.16,,O=NC(=O)CNS(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,304.0517779,2,2,0,0,0,0
6116,04/06/2019 00:00,DB07921,2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide,,,,,,solid,,,0.31,9.73,,FC1=CC=C(C=C1)S(=O)(=O)NCC(=O)N=O,,,,,0,,246.0110559,1,1,0,0,0,0
6117,04/06/2019 00:00,DB07922,N-oxo-2-(phenylsulfonylamino)ethanamide,,,,,,solid,,,0.905,10.15,,O=NC(=O)CNS(=O)(=O)C1=CC=CC=C1,,,,,0,,228.0204777,1,1,0,0,0,0
6118,04/06/2019 00:00,DB07923,octyl alpha-L-altropyranoside,,,,,,solid,,,16,12.21,-3,[H][C@]1(O)[C@@]([H])(O)[C@]([H])(CO)O[C@@]([H])(OCCCCCCCC)[C@]1([H])O,,,,,0,,292.1885886,1,0,1,0,1,1
6119,04/06/2019 00:00,DB07924,octyl beta-D-galactopyranoside,,,,,,solid,,,16,12.21,-3,[H][C@]1(O)[C@@]([H])(O)[C@@]([H])(CO)O[C@@]([H])(OCCCCCCCC)[C@]1([H])O,,,,,0,,292.1885886,1,0,1,0,1,1
6120,04/06/2019 00:00,DB07925,4-(2-HYDROXYPHENYLSULFINYL)-BUTYLPHOSPHONIC ACID,,,,,,solid,,,15.4,1.81,-6.2,OC1=CC=CC=C1[S@](=O)CCCCP(O)(O)=O,,,,,0,,278.0377812,1,1,0,0,0,0
6121,04/06/2019 00:00,DB07926,N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE,,,,,,solid,,,0.0717,8.9,-0.71,[H][C@@](CC(C)C)(CC(=O)NO)C(=O)N[C@@]([H])(CC1=CC=C(OC)C=C1)C(=O)NC,,,,,0,,379.210721,1,1,0,0,0,0
6122,04/06/2019 00:00,DB07927,3-[(4-Carboxy-2-hydroxyphenyl)sulfamoyl]-2-thiophenecarboxylic acid,,,,,,solid,,,0.187,3.04,-6.2,OC(=O)C1=C(C=CS1)S(=O)(=O)NC1=C(O)C=C(C=C1)C(O)=O,,,,,0,,342.9820436,2,2,1,1,0,0
6123,04/06/2019 00:00,DB07928,N-(2-OXOTETRAHYDROFURAN-3-YL)OCTANAMIDE,,,,,,solid,,,0.833,12.71,-0.47,[H][C@@]1(CCOC1=O)NC(=O)CCCCCCC,,,,,0,,227.1521435,1,0,1,0,1,1
6124,04/06/2019 00:00,DB07929,"N-(TERT-BUTYL)-3,5-DIMETHYL-N'-[(5-METHYL-2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)CARBONYL]BENZOHYDRAZIDE",,,,,,solid,,,0.0102,14,-3,CC1=CC(=CC(C)=C1)C(=O)N(NC(=O)C1=C(C)C2=C(OCCO2)C=C1)C(C)(C)C,,,,,0,,396.2049074,3,2,1,0,0,1
6125,04/06/2019 00:00,DB07930,(3R)-3-HYDROXYDODECANOIC ACID,,,,,,solid,,,0.345,4.67,-2.8,[H][C@@](O)(CCCCCCCCC)CC(O)=O,,,,,0,,216.1725446,0,0,0,0,0,0
6126,04/06/2019 00:00,DB07931,Hexestrol,,,,,,solid,,,0.0139,9.93,-5.4,[H][C@](CC)(C1=CC=C(O)C=C1)[C@]([H])(CC)C1=CC=C(O)C=C1,,,,,0,,270.1619799,2,2,0,0,0,0
6127,04/06/2019 00:00,DB07932,"dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate",,,,,,solid,,,0.00942,8.91,-4.3,[H][C@]12O[C@]([H])(C(C(=O)OC)=C1C(=O)OC)C(=C2C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,,,,,0,,394.1052529,4,2,2,0,0,2
6128,04/06/2019 00:00,DB07933,Erteberel,,,,,,solid,,,0.0162,9.35,-4.9,[H][C@@]12CCC[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1)C1=CC=C(O)C=C1,,,,,0,,282.1255944,4,2,1,0,0,1
6129,04/06/2019 00:00,DB07934,[[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE,,,,,,solid,,,0.0923,9.73,8.78,[H][C@](CCNC1=CC=[NH+]C=C1)(NC(=O)CNS(=O)(=O)C1CCCCC1)C(=O)N1CCCCC1,,,,,1,,466.2482521,3,1,2,1,1,1
6130,04/06/2019 00:00,DB07935,"5-[(5-fluoro-3-methyl-1H-indazol-4-yl)oxy]benzene-1,3-dicarbonitrile",,,,,,solid,,,0.0158,14.33,2.41,CC1=NNC2=C1C(OC1=CC(=CC(=C1)C#N)C#N)=C(F)C=C2,,,,,0,,292.0760391,3,3,1,1,0,0
6131,04/06/2019 00:00,DB07936,N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine,,,,,,solid,,,0.0962,12.76,8.81,[H][C@@]1(CCN(C1)C(=O)C1=CC=C(NC2=NC(C3=CN=C(C)N3C(C)C)=C(F)C=N2)C=C1)N(C)C,,,,,0,,451.2495868,4,3,3,2,1,1
6132,04/06/2019 00:00,DB07937,"2-butoxy-9-(2,6-difluorobenzyl)-N-(2-morpholin-4-ylethyl)-9H-purin-6-amine",,,,,,solid,,,0.0616,16.53,6.39,CCCCOC1=NC(NCCN2CCOCC2)=C2N=CN(CC3=C(F)C=CC=C3F)C2=N1,,,,,0,,446.2241806,4,3,3,2,1,1
6133,04/06/2019 00:00,DB07938,"5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-chroman-5-yl]methyl]pyrimidine-2,4-diamine",,,,,,solid,,,0.0719,11.65,9.88,[H][C@]1(OC2=C(C=C1)C(CC1=CNC(=N)NC1=N)=CC(OC)=C2OC)C1CC1,,,,,0,,354.1691906,4,2,2,1,0,1
6134,04/06/2019 00:00,DB07939,N-(3-MERCAPTOPROPANOYL)-D-ALANINE,,,,,,solid,,,3.75,3.95,-1.8,[H][C@](C)(NC(=O)CCS)C(O)=O,,,,,0,,177.0459642,0,0,0,0,0,0
6135,04/06/2019 00:00,DB07940,"9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE",,,,,,solid,,,0.000587,,8.87,IC1=CC=CC(CNC2=C3CCCCC3=NC3=C2C=CC=C3)=C1,,,,,0,,414.0592966,4,3,1,1,0,0
6136,04/06/2019 00:00,DB07941,PH-797804,,,,,,solid,,,0.00321,14.79,-0.94,CNC(=O)C1=CC=C(C)C(=C1)N1C(C)=CC(OCC2=C(F)C=C(F)C=C2)=C(Br)C1=O,,,,,0,,476.054711,3,3,1,1,0,0
6137,04/06/2019 00:00,DB07942,2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine,,,,,,solid,,,0.026,14.98,1.69,FC1=CC=C(C=C1)C1=CNN=C1C1=CC(F)=NC=C1,,,,,0,,257.0764537,3,3,2,2,0,0
6138,04/06/2019 00:00,DB07943,2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol,,,,,,solid,,,0.0668,12.44,1.54,OCC(=O)N1CCC(CC1)C1=NNC(=C1C1=NC=NC=C1)C1=CC=C(Cl)C=C1,,,,,0,,397.1305526,4,3,3,2,1,1
6139,04/06/2019 00:00,DB07944,N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE,,,,,,solid,,,0.000572,7.68,8.85,CC1=CC(OCCNC2=CC=[NH+]C=C2)=CC(NS(=O)(=O)C2=CC=CC=C2)=C1,,,,,1,,384.137639,3,3,1,1,0,0
6140,04/06/2019 00:00,DB07945,"5-(3-carbamoylbenzyl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole-4-carboxylic acid",,,,,,solid,,,0.00325,3.09,-0.96,NC(=O)C1=CC=CC(CN2C3=C(CCCCC3)C3=CC=CC(C(O)=O)=C23)=C1,,,,,0,,362.1630426,4,3,1,1,0,0
6141,04/06/2019 00:00,DB07946,"N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide",,,,,,solid,,,0.0158,12.46,9.81,NC(=N)NOCCNC(=O)CC1=C(Cl)C=CC(NCC(F)(F)C2=CC=CC=C2)=C1F,,,,,0,,443.1335873,2,2,0,0,0,0
6142,04/06/2019 00:00,DB07947,ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE,,,,,,solid,,,0.00372,10.05,8.42,ClC1=CC=C(COCCNCCNS(=O)(=O)C2=CC=CC3=CN=CC=C23)C=C1,,,,,0,,419.1070402,3,3,1,1,0,0
6143,04/06/2019 00:00,DB07949,"({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID",,,,,,solid,,,0.0442,3.47,1.97,OC(=O)CO\N=C1/C2=CC=CCC2=N/C/1=C1\C(=O)N=C2CC=CC=C12,,,,,0,,335.0906059,4,0,2,0,0,2
6144,04/06/2019 00:00,DB07950,Indoleacetic acid,,,,,,solid,,,1.38,4.66,,OC(=O)CC1=CNC2=CC=CC=C12,,,,,0,,175.0633285,2,2,1,1,0,0
6145,04/06/2019 00:00,DB07951,N-[1H-INDOL-3-YL-ACETYL]ASPARTIC ACID,,,,,,solid,,,0.228,3.74,-2.7,[H][C@@](CC(O)=O)(NC(=O)CC1=CNC2=CC=CC=C12)C(O)=O,,,,,0,,290.0902715,2,2,1,1,0,0
6146,04/06/2019 00:00,DB07952,N-[1H-INDOL-3-YL-ACETYL]GLYCINE ACID,,,,,,solid,,,0.364,4.04,-2.8,OC(=O)CNC(=O)CC1=CNC2=C1C=CC=C2,,,,,0,,232.0847922,2,2,1,1,0,0
6147,04/06/2019 00:00,DB07953,N-[1H-INDOL-3-YL-ACETYL]VALINE ACID,,,,,,solid,,,0.249,4.15,-2.1,[H][C@](NC(=O)CC1=CNC2=CC=CC=C12)(C(C)C)C(O)=O,,,,,0,,274.1317424,2,2,1,1,0,0
6148,04/06/2019 00:00,DB07954,3-isobutyl-1-methyl-7H-xanthine,,,,,,solid,,,5.44,11.41,2.42,CC(C)CN1C2=C(N=CN2)C(=O)N(C)C1=O,,,,,0,,222.1116757,2,2,2,2,0,0
6149,04/06/2019 00:00,DB07955,(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE,,,,,,solid,,,0.119,,3.14,NC1=CC(C=O)=C(CC(=O)OCCBr)C=C1,,,,,0,,285.0000553,1,1,0,0,0,0
6150,04/06/2019 00:00,DB07956,[1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER,,,,,,solid,,,0.0134,11.96,-6.2,[H][C@](NC(=O)OC(C)(C)C)(C(C)C)C(=O)NC1=CC=CC(Cl)=C1C=O,,,,,0,,354.1346349,1,1,0,0,0,0
6151,04/06/2019 00:00,DB07957,METHYL(2-ACETOXY-2-(2-CARBOXY-4-AMINO-PHENYL))ACETATE,,,,,,solid,,,0.812,4.39,3.05,[H][C@](OC(C)=O)(C(=O)OC)C1=CC=C(N)C=C1C(O)=O,,,,,0,,267.0742871,1,1,0,0,0,0
6152,04/06/2019 00:00,DB07958,(2-CARBAMOYLMETHYL-5-PROPYL-OCTAHYDRO-INDOL-7-YL)ACETIC ACID,,,,,,solid,,,0.0502,4.6,-3.2,CCCC1=CC2=C(NC(CC(N)=O)=C2)C(CC(O)=O)=C1,,,,,0,,274.1317424,2,2,1,1,0,0
6153,04/06/2019 00:00,DB07959,3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE,,,,,,solid,,,0.137,10.11,3.94,N1N=C(C2=NC3=CC=CC=C3N2)C2=C1C=CC=C2,,,,,0,,234.0905463,4,4,2,2,0,0
6154,04/06/2019 00:00,DB07960,"5-ACETAMIDO-5,6-DIHYDRO-4-HYDROXY-6-ISOBUTOXY-4H-PYRAN-2-CARBOXYLIC ACID",,,,,,solid,,,23.2,3.76,-0.8,[H][C@]1(O)C=C(O[C@@]([H])(OCC(C)C)[C@]1([H])NC(C)=O)C(O)=O,,,,,0,,273.1212373,1,0,1,0,0,1
6155,04/06/2019 00:00,DB07961,"1-(4-CYANO-PHENYL)-3-[2-(2,6-DICHLORO-PHENYL)-1-IMINO-ETHYL]-THIOUREA",,,,,,solid,,,0.00534,9.33,5.64,ClC1=CC=CC(Cl)=C1CC(=N)NC(=S)NC1=CC=C(C=C1)C#N,,,,,0,,362.0159727,2,2,0,0,0,0
6156,04/06/2019 00:00,DB07962,"METHYL N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINATE",,,,,,solid,,,0.011,6.83,-1.5,COC(=O)CCNC(=O)C1=C(O)C(I)=CC(=C1)C1=C(F)C=C(F)C=C1,,,,,0,,460.9935624,2,2,0,0,0,0
6157,04/06/2019 00:00,DB07963,"N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINE",,,,,,solid,,,0.0331,3.04,-1.5,OC(=O)CCNC(=O)C1=C(O)C(I)=CC(=C1)C1=C(F)C=C(F)C=C1,,,,,0,,446.9779123,2,2,0,0,0,0
6158,04/06/2019 00:00,DB07964,"(3S)-4-{[4-(BUT-2-YNYLOXY)PHENYL]SULFONYL}-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE",,,,,,solid,,,0.0168,8.7,-4.9,[H][C@]1(N(CCSC1(C)C)S(=O)(=O)C1=CC=C(OCC#CC)C=C1)C(=O)NO,,,,,0,,398.0970138,2,1,1,0,1,1
6159,04/06/2019 00:00,DB07965,6-(cyclohexylamino)-9-[2-(4-methylpiperazin-1-yl)-ethyl]-9H-purine-2-carbonitrile,,,,,,solid,,,0.494,16.53,8.33,CN1CCN(CCN2C=NC3=C(NC4CCCCC4)N=C(N=C23)C#N)CC1,,,,,0,,368.2436929,4,2,3,2,1,1
6160,04/06/2019 00:00,DB07966,[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile,,,,,,solid,,,0.0211,12,4.32,N#CCC1=CC=C(NC2=NC3=CC=CC=C3C(NC3=NNC(=C3)C3CC3)=N2)C=C1,,,,,0,,381.1701936,5,4,2,2,0,0
6161,04/06/2019 00:00,DB07967,9-CYCLOPENTYL-6-[2-(3-IMIDAZOL-1-YL-PROPOXY)-PHENYLAMINO]-9H-PURINE-2-CARBONITRILE,,,,,,solid,,,0.208,12.69,6.79,N#CC1=NC2=C(N=CN2C2CCCC2)C(NC2=CC=CC=C2OCCCN2C=CN=C2)=N1,,,,,0,,428.2073074,5,4,3,3,0,0
6162,04/06/2019 00:00,DB07968,N-(2-CHLORO-4-FLUOROBENZOYL)-N'-(5-HYDROXY-2-METHOXYPHENYL)UREA,,,,,,solid,,,0.0113,7.19,-4.9,COC1=CC=C(O)C=C1NC(=O)NC(=O)C1=CC=C(F)C=C1Cl,,,,,0,,338.0469628,2,2,0,0,0,0
6163,04/06/2019 00:00,DB07969,3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol,,,,,,solid,,,0.113,9.75,7.48,CN1CCN(CC1)C1=NC2=C(C=C(C=C2N=C1)C(F)(F)F)C1=CC(O)=CC=C1,,,,,0,,388.1510959,4,3,2,1,1,1
6164,04/06/2019 00:00,DB07970,5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide,,,,,,solid,,,0.00228,11.55,3.87,CC1=C(NC2=CC(=CN=C2)C(N)=O)C=C(C=C1)C(=O)NC1=CC=CC(=C1)C(F)(F)F,,,,,0,,414.1303604,3,3,1,1,0,0
6165,04/06/2019 00:00,DB07971,"5-AMINO-2-{4-[(4-AMINOPHENYL)SULFANYL]PHENYL}-1H-ISOINDOLE-1,3(2H)-DIONE",,,,,,solid,,,0.00408,,3.83,NC1=CC=C(SC2=CC=C(C=C2)N2C(=O)C3=C(C=C(N)C=C3)C2=O)C=C1,,,,,0,,361.0884977,4,3,1,0,0,1
6166,04/06/2019 00:00,DB07972,1-(3-METHYLPHENYL)-1H-BENZIMIDAZOL-5-AMINE,,,,,,solid,,,0.208,,6.77,CC1=CC=CC(=C1)N1C=NC2=CC(N)=CC=C12,,,,,0,,223.1109474,3,3,1,1,0,0
6167,04/06/2019 00:00,DB07973,N-(1-ISOPROPYLPIPERIDIN-4-YL)-1-(3-METHOXYBENZYL)-1H-INDOLE-2-CARBOXAMIDE,,,,,,solid,,,0.00417,15.96,9.15,COC1=CC(CN2C(=CC3=C2C=CC=C3)C(=O)NC2CCN(CC2)C(C)C)=CC=C1,,,,,0,,405.2416272,4,3,2,1,1,1
6168,04/06/2019 00:00,DB07974,1-{2-[(4-CHLOROPHENYL)AMINO]-2-OXOETHYL}-N-(1-ISOPROPYLPIPERIDIN-4-YL)-1H-INDOLE-2-CARBOXAMIDE,,,,,,solid,,,0.00697,13.29,9.15,CC(C)N1CCC(CC1)NC(=O)C1=CC2=C(C=CC=C2)N1CC(=O)NC1=CC=C(Cl)C=C1,,,,,0,,452.1979038,4,3,2,1,1,1
6169,04/06/2019 00:00,DB07975,"2-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID",,,,,,solid,,,0.0044,3.05,-1.5,OC(=O)C1=C(CCC1)C(=O)NC1=C(F)C=C(C=C1F)C1=CC=CC(OC(F)(F)F)=C1,,,,,0,,427.084299,3,2,0,0,0,0
6170,04/06/2019 00:00,DB07976,3-{[(3-FLUORO-3'-METHOXYBIPHENYL-4-YL)AMINO]CARBONYL}THIOPHENE-2-CARBOXYLIC ACID,,,,,,solid,,,0.00185,3.17,-4.5,COC1=CC=CC(=C1)C1=CC=C(NC(=O)C2=C(SC=C2)C(O)=O)C(F)=C1,,,,,0,,371.0627571,3,3,1,1,0,0
6171,04/06/2019 00:00,DB07977,"3-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)THIOPHENE-2-CARBOXYLIC ACID",,,,,,solid,,,0.00158,3.17,-4.8,OC(=O)C1=C(C=CS1)C(=O)NC1=C(F)C=C(C=C1F)C1=CC(OC(F)(F)F)=CC=C1,,,,,0,,443.0250699,3,3,1,1,0,0
6172,04/06/2019 00:00,DB07978,"2-({[2,3,5,6-TETRAFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENTA-1,3-DIENE-1-CARBOXYLIC ACID",,,,,,solid,,,0.0143,2.56,-1.6,OC(=O)C1=C(C=CC1)C(=O)NC1=C(F)C(F)=C(C(F)=C1F)C1=CC(OC(F)(F)F)=CC=C1,,,,,0,,461.0498053,3,2,0,0,0,0
6173,04/06/2019 00:00,DB07979,"(2E)-3-(3,4-DIHYDROXYPHENYL)-2-IMINOPROPANOIC ACID",,,,,,solid,,,0.533,3.62,2.6,[H]N=C(CC1=CC(O)=C(O)C=C1)C(O)=O,,,,,0,,195.0531578,1,1,0,0,0,0
6174,04/06/2019 00:00,DB07981,2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-n-[(1R)-1-(hydroxymethyl)propyl]acetamide,,,,,,solid,,,0.00371,14.85,-1.8,CC[C@H](CO)NC(=O)CC1=C(C)N(C(=O)C2=CC=C(Cl)C=C2)C2=CC=C(OC)C=C12,,,,,0,,428.150285,3,3,1,1,0,0
6175,04/06/2019 00:00,DB07982,2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol,,,,,,solid,,,0.401,13.58,6.26,CC(C)N1C(C)=NC=C1C1=NC(NC2=CC=C(C=C2)N2CCN(CC2)C(=O)CO)=NC=C1,,,,,0,,435.2382732,4,3,3,2,1,1
6176,04/06/2019 00:00,DB07983,1-(4-IODOBENZOYL)-5-METHOXY-2-METHYL INDOLE-3-ACETIC ACID,,,,,,solid,,,0.00512,3.84,-2.3,COC1=CC=C2N(C(=O)C3=CC=C(I)C=C3)C(C)=C(CC(O)=O)C2=C1,,,,,0,,449.012406,3,3,1,1,0,0
6177,04/06/2019 00:00,DB07984,2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-n-[(1S)-1-(hydroxymethyl)propyl]acetamide,,,,,,solid,,,0.00371,5.23,3.08,CC[C@@H](CO)NC(=O)CC1=C(C)N(C(=O)C2=CC=C(Cl)C=C2)C2=C1C=C(OC)C=C2,,,,,0,,428.150285,3,3,1,1,0,0
6178,04/06/2019 00:00,DB07985,+/-METHYL 4-(AMINOIMINOMETHYL)-BETA-[3- INH (AMINOIMINO)PHENYL]BENZENE PENTANOATE,,,,,,solid,,,0.0197,,11.95,[H][C@](CCC1=CC=C(C=C1)C(N)=N)(CC(=O)OC)C1=CC=CC(=C1)C(N)=N,,,,,0,,352.189926,2,2,0,0,0,0
6179,04/06/2019 00:00,DB07986,[4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID,,,,,,solid,,,0.0127,2.61,3.24,OC(=O)CNS(=O)(=O)C1=CC=C(C=C1)N1CCC(CC1)C1=CC=CC=C1,,,,,0,,374.1300282,3,2,1,0,1,1
6180,04/06/2019 00:00,DB07987,"[2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER",,,,,,solid,,,0.00306,6.8,-1.4,[H][C@](CC(=O)NC1=NN=C(S)S1)(NC(=O)OCC1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,414.0820324,3,3,1,1,0,0
6181,04/06/2019 00:00,DB07988,"2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE",,,,,,solid,,,0.0126,6.45,-1.4,[H][C@@](CC1=C(F)C(F)=C(F)C(F)=C1F)(NC(=O)NC1=NN=C(S)S1)C(=O)NC,,,,,0,,427.0196077,2,2,1,1,0,0
6182,04/06/2019 00:00,DB07989,2-(ACETYL-HYDROXY-AMINO)-4-METHYL-PENTANOIC ACID METHYL ESTER,,,,,,solid,,,17,7.68,-6,[H][C@](CC(C)C)(N(O)C(C)=O)C(=O)OC,,,,,0,,203.115758,0,0,0,0,0,0
6183,04/06/2019 00:00,DB07990,"(RP,SP)-O-(2R)-(1-PHENOXYBUT-2-YL)-METHYLPHOSPHONIC ACID CHLORIDE",,,,,,solid,,,0.822,,-4.9,[H][C@@](CC)(COC1=CC=CC=C1)O[P@](C)(Cl)=O,,,,,0,,262.0525587,1,1,0,0,0,0
6184,04/06/2019 00:00,DB07991,N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE,,,,,,solid,,,0.000322,9.51,-1.7,[H][C@@](C)(CCC1=CC=C(O)C=C1)NC(=O)CC1=C(NC2=C1C=CC=C2)C1=CC=CC=C1,,,,,0,,398.1994281,4,4,1,1,0,0
6185,04/06/2019 00:00,DB07992,3-SULFOOXY-1H-INDOLE,,,,,,solid,,,0.787,-1.8,,OS(=O)(=O)OC1=CNC2=CC=CC=C12,,,,,0,,213.0095787,2,2,1,1,0,0
6186,04/06/2019 00:00,DB07993,"N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE",,,,,,solid,,,0.00197,16.29,7.12,NC1=NC=CC=C1NCC1=CC=CC(=C1)C1=CC2=C(C=CN2)C=C1,,,,,0,,314.1531466,4,4,2,2,0,0
6187,04/06/2019 00:00,DB07994,"N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE",,,,,,solid,,,0.000865,16.3,7.1,NC1=NC=CC=C1NCC1=C(OCC2=NC=CC=C2)C=CC(=C1)C1=CC2=C(C=CN2)C=C1,,,,,0,,421.1902604,5,5,3,3,0,0
6188,04/06/2019 00:00,DB07995,N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE,,,,,,solid,,,0.00118,10.04,8.1,BrC1=CC=C(\C=C\CNCCNS(=O)(=O)C2=CC=CC3=C2C=CN=C3)C=C1,,,,,0,,445.04596,3,3,1,1,0,0
6189,04/06/2019 00:00,DB07996,5-(2-methylpiperazine-1-sulfonyl)isoquinoline,,,,,,solid,,,0.709,,7.33,CC1CNCCN1S(=O)(=O)C1=C2C=CN=CC2=CC=C1,,,,,0,,291.1041478,3,2,2,1,1,1
6190,04/06/2019 00:00,DB07997,N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE,,,,,,solid,,,0.614,10.07,8.92,CNCCNS(=O)(=O)C1=CC=CC2=C1C=CN=C2,,,,,0,,265.0884977,2,2,1,1,0,0
6191,04/06/2019 00:00,DB07999,"{4-[(CARBOXYMETHOXY)CARBONYL]-3,3-DIOXIDO-1-OXONAPHTHO[1,2-D]ISOTHIAZOL-2(1H)-YL}ACETIC ACID",,,,,,solid,,,0.0925,2.5,-7,OC(=O)COC(=O)C1=C2C(C(=O)N(CC(O)=O)S2(=O)=O)=C2C=CC=CC2=C1,,,,,0,,393.0154519,3,2,1,0,0,1
6192,04/06/2019 00:00,DB08000,"2-(CARBOXYMETHYL)-1-OXO-1,2-DIHYDRONAPHTHO[1,2-D]ISOTHIAZOLE-4-CARBOXYLIC ACID 3,3-DIOXIDE",,,,,,solid,,,0.162,1.8,,OC(=O)CN1C(=O)C2=C(C(=CC3=CC=CC=C23)C(O)=O)S1(=O)=O,,,,,0,,335.0099726,3,2,1,0,0,1
6193,04/06/2019 00:00,DB08001,5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID,,,,,,solid,,,0.0662,3.86,-3.2,COC(=O)C1=C(O)C=CC=C1OC\C=C\C1=CC(=CC=C1)C1=C(CO)C(=NO1)C(O)=O,,,,,0,,425.1110666,3,3,1,1,0,0
6194,04/06/2019 00:00,DB08003,ISOTHIAZOLIDINONE ANALOG,,,,,,solid,,,0.0431,3.96,-1.4,[H][C@@](CC1=CC=C(C=C1)[C@]1([H])CC(=O)NS1(=O)=O)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(C)=O)C(N)=O,,,,,0,,486.1573056,3,2,1,0,1,1
6195,04/06/2019 00:00,DB08004,"(2S)-2-{[3-(3-aminophenyl)imidazo[1,2-b]pyridazin-6-yl]amino}-3-methylbutan-1-ol",,,,,,solid,,,0.089,15.1,4.38,[H][C@](CO)(NC1=NN2C(C=C1)=NC=C2C1=CC(N)=CC=C1)C(C)C,,,,,0,,311.1746103,3,3,2,2,0,0
6196,04/06/2019 00:00,DB08005,4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide,,,,,,solid,,,0.0185,14.16,2.68,CCNC(=O)N1CCC(CC1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1,,,,,0,,398.162187,4,3,3,2,1,1
6197,04/06/2019 00:00,DB08006,"N-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",,,,,,solid,,,0.00296,18.44,0.33,CC1=NC2=NC=NN2C(NC2=CC3=CC4=CC=CC=C4C=C3C=C2)=C1,,,,,0,,325.1327455,5,5,2,2,0,0
6198,04/06/2019 00:00,DB08007,(2R)-3-{[(BENZYLAMINO)CARBONYL]AMINO}-2-HYDROXYPROPANOIC ACID,,,,,,solid,,,1.08,3.67,-2.1,[H][C@@](O)(CNC(=O)NCC1=CC=CC=C1)C(O)=O,,,,,0,,238.0953569,1,1,0,0,0,0
6199,04/06/2019 00:00,DB08008,"5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine",,,,,,solid,,,0.0843,18.54,0.33,CC1=NC2=NC=NN2C(NC2=CC=C(C=C2)C(F)(F)F)=C1,,,,,0,,293.08883,3,3,2,2,0,0
6200,04/06/2019 00:00,DB08009,"5-[(E)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[2-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE",,,,,,solid,,,0.022,11.27,9.04,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(Cl)C=C3)=C1C,,,,,0,,414.1822538,3,2,2,1,0,1
6201,04/06/2019 00:00,DB08010,"(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime",,,,,,solid,,,0.00388,5.66,-3.7,O\N=C1/C(=O)N(CC2=C3OCOCC3=CC(F)=C2)C2=CC=CC(\C=C\C3=CC=CC=C3)=C12,,,,,0,,430.1328853,5,3,2,0,0,2
6202,04/06/2019 00:00,DB08011,"(3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime",,,,,,solid,,,0.0446,5.64,-3.8,O\N=C1\C(=O)N(CC2=C3OCOCC3=CC(F)=C2)C2=CC=C(F)C=C12,,,,,0,,346.0765133,4,2,2,0,0,2
6203,04/06/2019 00:00,DB08012,(METHYLPYRIDAZINE PIPERIDINE ETHYLOXYPHENYL)ETHYLACETATE,,,,,,solid,,,0.0682,,4.41,CCOC(=O)C1=CC=C(OCCC2CCN(CC2)C2=NN=C(C)C=C2)C=C1,,,,,0,,369.2052417,3,2,2,1,1,1
6204,04/06/2019 00:00,DB08013,(METHYLPYRIDAZINE PIPERIDINE PROPYLOXYPHENYL)ETHYLACETATE,,,,,,solid,,,0.038,,4.41,CCOC(=O)C1=CC=C(OCCCC2CCN(CC2)C2=NN=C(C)C=C2)C=C1,,,,,0,,383.2208918,3,2,2,1,1,1
6205,04/06/2019 00:00,DB08014,(METHYLPYRIDAZINE PIPERIDINE BUTYLOXYPHENYL)ETHYLACETATE,,,,,,solid,,,0.0203,,4.41,CCOC(=O)C1=CC=C(OCCCCC2CCN(CC2)C2=NN=C(C)C=C2)C=C1,,,,,0,,397.2365419,3,2,2,1,1,1
6206,04/06/2019 00:00,DB08015,"(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime",,,,,,solid,,,0.0146,5.65,-3.9,O\N=C1/C(=O)N(CC2=CC(F)=CC3=C2OCOC3)C2=CC=CC(=C12)C1=CC=CC=C1,,,,,0,,404.1172352,5,3,2,0,0,2
6207,04/06/2019 00:00,DB08016,"4-(6-CHLORO-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL) BUTYL PHOSPHATE",,,,,,solid,,,1.39,1.81,-5,OP(O)(=O)OCCCCC1=C(Cl)NC(=O)NC1=O,,,,,0,,298.0121504,1,1,1,1,0,0
6208,04/06/2019 00:00,DB08017,3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE,,,,,,solid,,,0.488,,3.44,COC1=NN=C(C=C1)N1CCN(CC1)C1=CC(C)=CC=C1,,,,,0,,284.1637113,3,2,2,1,1,1
6209,04/06/2019 00:00,DB08018,"N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE",,,,,,solid,,,0.00739,,10.19,[H][C@]1(CC2=NC(N)=CC(C)=C2)CNC[C@@]1([H])NCCNCC1=CC=C(Cl)C=C1,,,,,0,,373.2033236,3,2,2,1,1,1
6210,04/06/2019 00:00,DB08019,"N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine",,,,,,solid,,,0.00759,,10.19,[H][C@]1(CC2=NC(N)=CC(C)=C2)CNC[C@]1([H])NCCNCC1=CC(Cl)=CC=C1,,,,,0,,373.2033236,3,2,2,1,1,1
6211,04/06/2019 00:00,DB08020,"(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL",,,,,,solid,,,0.0128,9.31,-4.1,[H][C@@]12CCC[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1COC)C1=CC=C(O)C=C1,,,,,0,,326.1518092,4,2,1,0,0,1
6212,04/06/2019 00:00,DB08021,5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide,,,,,,solid,,,0.0688,9.56,5.95,ClC1=C(N2CCN(CC#C)CC2)C(NC(=O)C2=CC=C(Br)O2)=CC=C1,,,,,0,,421.0192666,3,2,2,1,1,1
6213,04/06/2019 00:00,DB08022,"(2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile",,,,,,solid,,,0.0134,8.14,5.5,[H][C@](C#N)(C1=NC2=C(S1)C=CC=C2)C1=NC(NCCC2=CC=CN=C2)=NC=C1,,,,,0,,372.1157155,4,4,3,3,0,0
6214,04/06/2019 00:00,DB08023,"N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine",,,,,,solid,,,0.056,,5.54,CN(C1CCCCC1)C1=NC(=CC=N1)C1=CN=C2C=CC=CN12,,,,,0,,307.1796957,4,3,3,3,0,0
6215,04/06/2019 00:00,DB08024,1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE,,,,,,solid,,,0.0666,,9.2,[H][C@](N)(CC1=CC=C(C=C1)C1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])CN,,,,,0,,323.1997624,3,2,1,0,1,1
6216,04/06/2019 00:00,DB08025,"N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE",,,,,,solid,,,0.00334,12,5.21,[H][C@@]1(CC[C@@]([H])(CC1)C(=O)NC1=CC(=CC=N1)C1=CC(NC2=CC=C(F)C=C2)=NC=C1)OC,,,,,0,,420.1961543,4,3,2,2,0,0
6217,04/06/2019 00:00,DB08026,"2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide",,,,,,solid,,,0.0206,14.82,7.08,CNC(=O)CN1CCC(CC1)NC1=NC(=CC=N1)C1=CN=C2C=CC=CN12,,,,,0,,365.1964084,4,3,4,3,1,1
6218,04/06/2019 00:00,DB08027,1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea,,,,,,solid,,,0.0223,13.65,8.08,CN(C)CC1=CC=C(CSCCNC(=O)NC2=CC=C(C)C(Cl)=C2)O1,,,,,0,,381.1277757,2,2,1,1,0,0
6219,04/06/2019 00:00,DB08028,"BUT-3-ENYL-[5-(4-CHLORO-PHENYL)-3,6-DIHYDRO-[1,3,4]THIADIAZIN-2-YLIDENE]-AMINE",,,,,,solid,,,0.0163,19.16,4.16,ClC1=CC=C(C=C1)C1=NN\C(SC1)=N\CCC=C,,,,,0,,279.0596961,2,1,1,0,0,1
6220,04/06/2019 00:00,DB08029,N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide,,,,,,solid,,,0.0727,8.74,-2.6,OCCN(CC(=O)NO)S(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,350.0936427,2,2,0,0,0,0
6221,04/06/2019 00:00,DB08030,3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide,,,,,,solid,,,0.012,8.88,-4.8,ONC(=O)CCOC1=CC=C(C=C1)C1=CC=C(C=C1)C#N,,,,,0,,282.1004423,2,2,0,0,0,0
6222,04/06/2019 00:00,DB08031,"N-[(13-CYCLOHEXYL-6,7-DIHYDROINDOLO[1,2-D][1,4]BENZOXAZEPIN-10-YL)CARBONYL]-2-METHYL-L-ALANINE",,,,,,solid,,,0.000943,3.79,-1.2,CC(C)(NC(=O)C1=CC=C2C(=C1)N1CCOC3=C(C=CC=C3)C1=C2C1CCCCC1)C(O)=O,,,,,0,,446.2205574,5,3,2,1,0,1
6223,04/06/2019 00:00,DB08032,"N,N-DIETHYL-2-[(2-THIENYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE",,,,,,solid,,,0.0496,7.9,-0.44,CCN(CC)C(=O)C1=C(NC(=O)C2=CC=CS2)SC2=C1CCCC2,,,,,0,,362.1122699,3,2,2,2,0,0
6224,04/06/2019 00:00,DB08033,"(5R)-N,N-DIETHYL-5-METHYL-2-[(THIOPHEN-2-YLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE",,,,,,solid,,,0.0268,7.9,-0.44,[H][C@@]1(C)CCC2=C(C1)C(C(=O)N(CC)CC)=C(NC(=O)C1=CC=CS1)S2,,,,,0,,376.12792,3,2,2,2,0,0
6225,04/06/2019 00:00,DB08034,"(E)-3,4-DIHYDROXY-N'-[(2-METHOXYNAPHTHALEN-1-YL)METHYLENE]BENZOHYDRAZIDE",,,,,,solid,,,0.0136,8.33,0.89,COC1=C(\C=N\NC(=O)C2=CC(O)=C(O)C=C2)C2=CC=CC=C2C=C1,,,,,0,,336.111007,3,3,0,0,0,0
6226,04/06/2019 00:00,DB08035,"1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE",,,,,,solid,,,0.031,19.98,6.39,CC1=CC=C(C)C(CC2=NN(C3=C2C(N)=NC=N3)C(C)(C)C)=C1,,,,,0,,309.1953457,3,3,2,2,0,0
6227,04/06/2019 00:00,DB08036,"6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one",,,,,,solid,,,0.00528,13.29,-1.5,O=C1NCC2=C3C(NC4=CC=CC=C34)=C3NC4=C(C=CC=C4)C3=C12,,,,,0,,311.105862,6,5,3,2,0,1
6228,04/06/2019 00:00,DB08037,"(2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide",,,,,,solid,,,0.0802,14.61,6.98,[H][C@@]1(F)CN(C)CC[C@]1([H])N(C)C(=O)N1CC(=C[C@@]1(CO)C1=CC=CC=C1)C1=CC(F)=CC=C1F,,,,,0,,459.2133618,4,2,2,0,1,2
6229,04/06/2019 00:00,DB08038,"L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide",,,,,,solid,,,1.34,12.78,8.09,[H][C@@](C)(N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CC=CC=C1)[C@@]([H])(C)O,,,,,0,,307.1895917,1,1,0,0,0,0
6230,04/06/2019 00:00,DB08039,"(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE",,,,,,solid,,,0.107,10.72,-2.1,CN(C)S(=O)(=O)C1=CC=C2NC(=O)\C(=C/C3=CC4=C(CCCC4)N3)C2=C1,,,,,0,,371.1303625,4,2,2,1,0,1
6231,04/06/2019 00:00,DB08040,N-[(2R)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]-L-alanine,,,,,,solid,,,0.433,3.8,-1.6,[H][C@@](C)(NC(=O)[C@@]([H])(CC(=O)NO)CC1=CC=CC=C1)C(O)=O,,,,,0,,294.1215717,1,1,0,0,0,0
6232,04/06/2019 00:00,DB08041,3-BENZYLOXYCARBONYLAMINO-2-HYDROXY-4-PHENYL-BUTYRIC ACID,,,,,,solid,,,0.178,3.75,-4.1,[H][C@@](CC1=CC=CC=C1)(NC(=O)OCC1=CC=CC=C1)[C@@]([H])(O)C(O)=O,,,,,0,,329.1263227,2,2,0,0,0,0
6233,04/06/2019 00:00,DB08042,"N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine",,,,,,solid,,,0.034,13.15,5.06,COC1=CC(NC2=NC(=CC=N2)N(C)C2=CC3=C(C=C2)C(C)=NN3)=CC(OC)=C1OC,,,,,0,,420.1909886,4,4,2,2,0,0
6234,04/06/2019 00:00,DB08043,1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA,,,,,,solid,,,0.00311,11.54,5.95,FC(F)(F)C1=CC(NC(=O)NC2=CC=C(OC3=CC=NC=C3)C=C2)=CC=C1,,,,,0,,373.1038113,3,3,1,1,0,0
6235,04/06/2019 00:00,DB08044,ABT-341,,,,,,solid,,,0.0141,,9.64,[H][C@]1(N)CC(=CC[C@]1([H])C1=CC(F)=C(F)C=C1F)C(=O)N1CCN2C(C1)=NN=C2C(F)(F)F,,,,,0,,445.1337295,4,2,2,1,0,1
6236,04/06/2019 00:00,DB08045,"4-{4-[4-(3-AMINOPROPOXY)PHENYL]-1H-PYRAZOL-5-YL}-6-CHLOROBENZENE-1,3-DIOL",,,,,,solid,,,0.0453,7.86,10.02,NCCCOC1=CC=C(C=C1)C1=C(NN=C1)C1=CC(Cl)=C(O)C=C1O,,,,,0,,359.1036691,3,3,1,1,0,0
6237,04/06/2019 00:00,DB08046,2-chloro-5-[(1S)-1-hydroxy-3-oxo-2H-isoindol-1-yl]benzenesulfonamide,,,,,,solid,,,0.0528,8.58,-2.6,NS(=O)(=O)C1=CC(=CC=C1Cl)[C@@]1(O)NC(=O)C2=CC=CC=C12,,,,,0,,338.0128055,3,2,1,0,0,1
6238,04/06/2019 00:00,DB08047,"4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol",,,,,,solid,,,0.00829,8.41,0.71,OC1=CC(O)=C(C=C1)C1=NN(CC=C)C2=C1C=CC=C2C(F)(F)F,,,,,0,,334.0929123,3,3,1,1,0,0
6239,04/06/2019 00:00,DB08048,"4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL",,,,,,solid,,,0.693,8.38,1.06,OC1=CC=C2C(NN=C2C2=CC=C(O)C=C2O)=C1,,,,,0,,242.0691422,3,3,1,1,0,0
6240,04/06/2019 00:00,DB08049,"7,8-dihydroxy-4-phenyl-2H-chromen-2-one",,,,,,solid,,,0.0829,7.93,-4.7,OC1=CC=C2C(OC(=O)C=C2C2=CC=CC=C2)=C1O,,,,,0,,254.0579088,3,3,1,1,0,0
6241,04/06/2019 00:00,DB08050,5-phenyl-2-keto-valeric acid,,,,,,solid,,,0.18,3.56,-9.7,OC(=O)C(=O)CCCC1=CC=CC=C1,,,,,0,,192.0786442,1,1,0,0,0,0
6242,04/06/2019 00:00,DB08051,"(2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE",,,,,,solid,,,0.0236,,8.48,[H][C@](N)(CC(=O)N1CCCCCN1C(=O)C1=CC=CC=C1)CC1=C(F)C=C(F)C(F)=C1,,,,,0,,419.1820617,3,2,1,0,1,1
6243,04/06/2019 00:00,DB08052,"1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,,,,,solid,,,0.0814,14.95,6.57,NC1=C2C(=NC=N1)N(N=C2C1=CC2=C(NC=C2)N=C1)C1CCCC1,,,,,0,,319.1545435,5,4,4,4,0,0
6244,04/06/2019 00:00,DB08053,"1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,,,,,solid,,,0.161,19.7,6.58,COC1=C(OC)C=C(C=C1)C1=NN(C2CCC2)C2=NC=NC(N)=C12,,,,,0,,325.1538748,4,3,2,2,0,0
6245,04/06/2019 00:00,DB08054,"1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,,,,,solid,,,0.0616,19.7,6.59,CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC2=CC=CN=C2C=C1,,,,,0,,304.1436445,4,4,3,3,0,0
6246,04/06/2019 00:00,DB08056,"N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine",,,,,,solid,,,0.00403,15.9,6.74,CC1=CC=CC(C)=C1NC1=NC=C(N2C=NC=C12)C1=CC=CC=C1,,,,,0,,314.1531466,4,4,2,2,0,0
6247,04/06/2019 00:00,DB08057,"N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine",,,,,,solid,,,0.00657,14.82,8.96,[H][C@]1(C)CN(CCN1)C1=CC=C2N=C(NC3=C(C)C=CC=C3Cl)C3=CN=CN3C2=C1,,,,,0,,406.1672724,5,4,3,2,1,1
6248,04/06/2019 00:00,DB08058,"4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one",,,,,,solid,,,0.0585,11.06,8.62,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCCNCC1,,,,,0,,380.1648541,4,3,2,1,1,1
6249,04/06/2019 00:00,DB08059,Wortmannin,,,,,,solid,,,0.121,,-3.2,[H][C@@]12CCC(=O)[C@@]1(C)C[C@@H](OC(C)=O)C1=C2C(=O)C2=C3C(=CO2)C(=O)O[C@H](COC)[C@]13C,,,,,0,,428.1471177,5,1,2,1,0,1
6250,04/06/2019 00:00,DB08060,4-(2-AMINOPHENYL)-4-OXOBUTANOIC ACID,,,,,,solid,,,0.949,4.27,2.4,NC1=CC=CC=C1C(=O)CCC(O)=O,,,,,0,,193.0738932,1,1,0,0,0,0
6251,04/06/2019 00:00,DB08061,4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE,,,,,,solid,,,0.0416,14.67,10.09,ClC1=CC=C(C=C1)C1=NNC(=C1)C1CCNCC1,,,,,0,,261.1032752,3,2,2,1,1,1
6252,04/06/2019 00:00,DB08062,"3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE",,,,,,solid,,,0.258,8.42,1.74,CSC1=NN=C(N1)C1=CC=C(Cl)C=C1,,,,,0,,225.0127459,2,2,1,1,0,0
6253,04/06/2019 00:00,DB08063,"1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE",,,,,,solid,,,0.00138,11.72,-4.1,COC1=CC=C(NC2=C(C(=O)N(CC3=CC=CC=C3)C2=O)C2=CC=CC=C2)C=C1,,,,,0,,384.1473925,4,3,1,0,0,1
6254,04/06/2019 00:00,DB08064,N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA,,,,,,solid,,,0.00741,11.57,4.78,CC(C)(C)C1=NNC(NC(=O)NC2=CC=C(Cl)C(COC3=CC=CN=C3)=C2)=C1,,,,,0,,399.1462026,3,3,2,2,0,0
6255,04/06/2019 00:00,DB08065,2-(1H-pyrazol-3-yl)-1H-benzimidazole,,,,,,solid,,,10.2,10.24,4.03,N1C=CC(=N1)C1=NC2=CC=CC=C2N1,,,,,0,,184.0748963,3,3,2,2,0,0
6256,04/06/2019 00:00,DB08066,N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE,,,,,,solid,,,0.0386,9.92,3.82,O=C(NC1=CNN=C1C1=NC2=C(N1)C=CC=C2)C1=CC=CC=C1,,,,,0,,303.11201,4,4,2,2,0,0
6257,04/06/2019 00:00,DB08067,4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM,,,,,,solid,,,0.0111,9.82,6.91,O=C(NC1CC1)NC1=CNN=C1C1=NC2=CC=C(C[NH+]3CCOCC3)C=C2N1,,,,,1,,382.1985994,5,3,3,2,1,1
6258,04/06/2019 00:00,DB08068,N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-,,,,,,solid,,,0.0519,14.17,7.43,[H][C@@]1(F)C[C@]([H])(CC(=C1)C(=O)NC1=CC=C(Cl)C(COC2=CN=CC=C2)=C1)N1CCOCC1,,,,,0,,445.1568476,4,2,2,1,1,1
6259,04/06/2019 00:00,DB08069,"4-AMINO-5-(2-METHYLPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOLE-3-THIONE",,,,,,solid,,,0.296,7.5,3.33,CC1=CC=CC=C1C1=NNC(=S)N1N,,,,,0,,206.0626173,2,2,1,1,0,0
6260,04/06/2019 00:00,DB08070,2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE,,,,,,solid,,,1.66,15.44,9.77,CC1=NNC=C1C1=CC=C(CCN)C=C1,,,,,0,,201.1265975,2,2,1,1,0,0
6261,04/06/2019 00:00,DB08071,"(2S)-1-methyl-2-[(2S,4R)-2-methyl-4-phenylpentyl]piperidine",,,,,,solid,,,0.000371,,10.02,[H][C@](C)(C[C@@]([H])(C)C1=CC=CC=C1)C[C@]1([H])CCCCN1C,,,,,0,,259.2299999,2,1,1,0,1,1
6262,04/06/2019 00:00,DB08072,"4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE",,,,,,solid,,,0.00138,11.63,9.28,CC(C)OC1=CC(NC(=O)C2=CC(Cl)=C(OCCN)C(Cl)=C2)=CC=C1,,,,,0,,382.0850979,2,2,0,0,0,0
6263,04/06/2019 00:00,DB08073,(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE,,,,,,solid,,,0.00172,14.17,9.24,[H][C@@](N)(COC1=CN=CC(=C1)C1=CC=C2NN=C(C)C2=C1)CC1=CNC2=CC=CC=C12,,,,,0,,397.1902604,5,5,3,3,0,0
6264,04/06/2019 00:00,DB08074,3-(3-methylbut-2-en-1-yl)-3H-purin-6-amine,,,,,,solid,,,0.424,18.18,3.93,CC(C)=CCN1C=NC(N)=C2N=CN=C12,,,,,0,,203.1170954,2,0,2,0,0,2
6265,04/06/2019 00:00,DB08075,"4-(2-amino-1,3-thiazol-4-yl)pyrimidin-2-amine",,,,,,solid,,,1.24,16.08,2.94,NC1=NC(=CS1)C1=NC(N)=NC=C1,,,,,0,,193.0422162,2,2,2,2,0,0
6266,04/06/2019 00:00,DB08076,"4-[1-(2,6-dichlorobenzyl)-2-methyl-1H-imidazol-4-yl]pyrimidin-2-amine",,,,,,solid,,,0.0327,16.29,3.85,CC1=NC(=CN1CC1=C(Cl)C=CC=C1Cl)C1=NC(N)=NC=C1,,,,,0,,333.0548008,3,3,2,2,0,0
6267,04/06/2019 00:00,DB08077,"2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID",,,,,,solid,,,0.00321,3.38,-4.4,CC(C)(OC1=CC=C(NC(=O)NC2=CC(Cl)=CC(Cl)=C2)C=C1)C(O)=O,,,,,0,,382.0487124,2,2,0,0,0,0
6268,04/06/2019 00:00,DB08078,{4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid,,,,,,solid,,,0.00786,3.28,-3.9,CCCC1=C(OCCCOC2=CC=C(OCC(O)=O)C=C2)C=CC(C(C)=O)=C1O,,,,,0,,402.1678532,2,2,0,0,0,0
6269,04/06/2019 00:00,DB08079,AMG-208,,,,,,solid,,,0.0115,,6.17,COC1=CC2=NC=CC(OCC3=NN=C4C=CC(=NN34)C3=CC=CC=C3)=C2C=C1,,,,,0,,383.1382248,5,5,3,3,0,0
6270,04/06/2019 00:00,DB08080,LATRUNCULIN B,,,,,,solid,,,0.0713,11.36,-4.4,[H][C@]1(CSC(=O)N1)[C@@]1(O)C[C@@]2([H])C[C@@]([H])(CC[C@]([H])(C)\C=C/CC\C(C)=C/C(=O)O2)O1,,,,,0,,395.176644,3,0,3,0,2,3
6271,04/06/2019 00:00,DB08081,3-OXO-OCTANOIC ACID (2-OXO-TETRAHYDRO-FURAN-3-YL)-AMIDE,,,,,,solid,,,4.28,10.31,-3.9,[H][C@@]1(CCOC1=O)NC(=O)CC(=O)CCCCC,,,,,0,,241.1314081,1,0,1,0,1,1
6272,04/06/2019 00:00,DB08082,N-(2-AMINOETHYL)-P-CHLOROBENZAMIDE,,,,,,solid,,,1.4,14.66,-0.92,OCCNC(=O)C1=CC=C(Cl)C=C1,,,,,0,,199.0400062,1,1,0,0,0,0
6273,04/06/2019 00:00,DB08083,"2-(1,3-thiazol-4-yl)-1H-benzimidazole-5-sulfonamide",,,,,,solid,,,0.346,9.29,2.67,NS(=O)(=O)C1=CC=C2NC(=NC2=C1)C1=CSC=N1,,,,,0,,280.0088675,3,3,2,2,0,0
6274,04/06/2019 00:00,DB08084,IDD594,,,,,,solid,,,0.00068,3.3,-3,OC(=O)COC1=CC(F)=CC=C1C(=S)NCC1=CC=C(Br)C=C1F,,,,,0,,414.9689328,2,2,0,0,0,0
6275,04/06/2019 00:00,DB08085,1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE,,,,,,solid,,,0.000471,17.15,-7.3,CCCCCCC1=CC=C(C=C1)C(=O)C=C,,,,,0,,216.1514153,1,1,0,0,0,0
6276,04/06/2019 00:00,DB08086,N-[12-(1H-imidazol-1-yl)dodecanoyl]-L-leucine,,,,,,solid,,,0.00654,4.26,6.79,[H][C@@](CC(C)C)(NC(=O)CCCCCCCCCCCN1C=CN=C1)C(O)=O,,,,,0,,379.283492,1,1,1,1,0,0
6277,04/06/2019 00:00,DB08087,"4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE",,,,,,solid,,,0.831,12.26,-3.1,[H][C@@]1(O)CCN2C(=O)N(C(=O)[C@]12[H])C1=CC=C(C#N)C2=CC=CC=C12,,,,,0,,307.0956913,4,2,2,0,2,2
6278,04/06/2019 00:00,DB08088,"2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile",,,,,,solid,,,0.0826,14.43,4.56,N#CC1=CC=C(\N=C2/O[C@@]([H])(C(F)(F)F)[C@]3([H])[C@](O)([H])CCN23)C(C)=C1Cl,,,,,0,,359.064839,3,1,2,0,2,2
6279,04/06/2019 00:00,DB08089,LGD-2226,,,,,,solid,,,0.00607,14.43,-2.2,FC(F)(F)CN(CC(F)(F)F)C1=CC2=C(NC(=O)C=C2C(F)(F)F)C=C1,,,,,0,,392.0571169,2,2,1,1,0,0
6280,04/06/2019 00:00,DB08090,"(3Z,5S,6R,7S,8R,8aR)-3-(octylimino)hexahydro[1,3]oxazolo[3,4-a]pyridine-5,6,7,8-tetrol",,,,,,solid,,,3.71,12.16,2.52,[H][C@]12CO\C(=N/CCCCCCCC)N1[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)[C@]2([H])O,,,,,0,,316.199822,2,0,2,0,2,2
6281,04/06/2019 00:00,DB08091,3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE,,,,,,solid,,,0.00506,11.25,5.67,FC1=CC(=CC(=C1)C(=O)NC1=CC=C2NC=C(CCC3=CC=NC=C3)C2=C1)N1CCOCC1,,,,,0,,444.1961543,5,4,3,2,1,1
6282,04/06/2019 00:00,DB08092,3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide,,,,,,solid,,,0.0648,11.28,-1.7,FC1=CC(=CC(=C1)C(=O)NC1=CC=C2NC=CC2=C1)N1CCOCC1,,,,,0,,339.138305,4,3,2,1,1,1
6283,04/06/2019 00:00,DB08093,3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE,,,,,,solid,,,0.0337,,6.53,NC1=C(OCC2=CC=CC3=CC=CC=C23)C=CC=N1,,,,,0,,250.1106131,3,3,1,1,0,0
6284,04/06/2019 00:00,DB08094,"(4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE",,,,,,solid,,,0.172,14.54,6,COC1=C(C(=O)C2=CN=C(NC3CCN(CC3)S(C)(=O)=O)N=C2N)C(F)=C(F)C=C1,,,,,0,,441.1282316,3,2,2,1,1,1
6285,04/06/2019 00:00,DB08095,"3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA",,,,,,solid,,,0.0184,10.61,2.54,[H][C@@](C)(NC1=NC=CC(=N1)N(C(=O)NC1=CC=CC=C1Cl)C1=CC=C(OC)C=C1)C(C)(C)O,,,,,0,,455.1724174,3,3,1,1,0,0
6286,04/06/2019 00:00,DB08096,"8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM",,,,,,solid,,,0.0106,8.59,2.1,CCN1C(NC2=CC=CC=C2Cl)=NC2=C1N=C(NC1=C(F)C=CC=C1F)N=C2,,,,,0,,400.1014786,4,4,2,2,0,0
6287,04/06/2019 00:00,DB08097,"2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE",,,,,,solid,,,0.00666,15.13,1.42,CC(C)N1C(NC2=CC=CC=C2F)=NC2=CN=C(OC3=C(F)C=CC=C3F)N=C12,,,,,0,,399.1306948,4,4,2,2,0,0
6288,04/06/2019 00:00,DB08098,"{[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-yl]thio}acetic acid",,,,,,solid,,,0.171,3.08,-2.8,OC(=O)CSC1=NN=C(O1)C1=CC=C(O1)[N+]([O-])=O,,,,,0,,270.9899059,2,2,2,2,0,0
6289,04/06/2019 00:00,DB08099,"6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine",,,,,,solid,,,0.0189,17.24,7.77,[H][C@]1(CCC2=CC=C(C=C2N1CCCOC)C1=C(N)N=C(N)N=C1CC)C1=CC=CC=C1,,,,,0,,417.2528606,4,3,2,1,0,1
6290,04/06/2019 00:00,DB08100,"2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol",,,,,,solid,,,0.00429,10.22,-5.9,CC1=CC(\C=C\C2=CC=CC=C2)=CC(C)=C1O,,,,,0,,224.1201151,2,2,0,0,0,0
6291,04/06/2019 00:00,DB08101,"2,6-dibromo-4-[(E)-2-phenylethenyl]phenol",,,,,,solid,,,0.00059,6.78,-7.4,OC1=C(Br)C=C(\C=C\C2=CC=CC=C2)C=C1Br,,,,,0,,351.9098391,2,2,0,0,0,0
6292,04/06/2019 00:00,DB08102,"3,5-dibromobiphenyl-4-ol",,,,,,solid,,,0.00303,6.7,-7.4,OC1=C(Br)C=C(C=C1Br)C1=CC=CC=C1,,,,,0,,325.8941891,2,2,0,0,0,0
6293,04/06/2019 00:00,DB08103,"2,6-dibromo-4-phenoxyphenol",,,,,,solid,,,0.00817,6.96,-7.3,OC1=C(Br)C=C(OC2=CC=CC=C2)C=C1Br,,,,,0,,341.8891037,2,2,0,0,0,0
6294,04/06/2019 00:00,DB08104,"N-(3,5-dibromo-4-hydroxyphenyl)benzamide",,,,,,solid,,,0.00795,6.72,-3.9,OC1=C(Br)C=C(NC(=O)C2=CC=CC=C2)C=C1Br,,,,,0,,368.9000027,2,2,0,0,0,0
6295,04/06/2019 00:00,DB08105,N-[(6-butoxynaphthalen-2-yl)sulfonyl]-L-glutamic acid,,,,,,solid,,,0.0157,2.97,-4.8,CCCCOC1=CC2=CC=C(C=C2C=C1)S(=O)(=O)N[C@@H](CCC(O)=O)C(O)=O,,,,,0,,409.1195231,2,2,0,0,0,0
6296,04/06/2019 00:00,DB08106,N-[(6-butoxynaphthalen-2-yl)sulfonyl]-D-glutamic acid,,,,,,solid,,,0.0157,2.97,-4.8,CCCCOC1=CC2=CC=C(C=C2C=C1)S(=O)(=O)N[C@H](CCC(O)=O)C(O)=O,,,,,0,,409.1195231,2,2,0,0,0,0
6297,04/06/2019 00:00,DB08107,N-{[6-(PENTYLOXY)NAPHTHALEN-2-YL]SULFONYL}-D-GLUTAMIC ACID,,,,,,solid,,,0.00847,2.97,-4.8,[H][C@](CCC(O)=O)(NS(=O)(=O)C1=CC2=C(C=C1)C=C(OCCCCC)C=C2)C(O)=O,,,,,0,,423.1351731,2,2,0,0,0,0
6298,04/06/2019 00:00,DB08108,N-({6-[(4-CYANOBENZYL)OXY]NAPHTHALEN-2-YL}SULFONYL)-D-GLUTAMIC ACID,,,,,,solid,,,0.00825,2.97,-4.9,[H][C@](CCC(O)=O)(NS(=O)(=O)C1=CC2=C(C=C1)C=C(OCC1=CC=C(C=C1)C#N)C=C2)C(O)=O,,,,,0,,468.099122,3,3,0,0,0,0
6299,04/06/2019 00:00,DB08109,"(1S,4R,7AR)-4-BUTOXY-1-[(1R)-1-FORMYLPROPYL]-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID",,,,,,solid,,,0.206,4.47,1.8,[H][C@](CC)(C=O)[C@@]1([H])NC(C(O)=O)=C2[C@@]1([H])CCC[C@@]2([H])OCCCC,,,,,0,,309.1940083,2,0,1,0,0,1
6300,04/06/2019 00:00,DB08110,"(1R,4S,7AS)-1-(1-FORMYLPROP-1-EN-1-YL)-4-METHOXY-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID",,,,,,solid,,,1.34,4.27,0.9,[H][C@]1(NC(C(O)=O)=C2[C@]1([H])CCC[C@]2([H])OC)C(=C/C)\C=O,,,,,0,,265.1314081,2,0,1,0,0,1
6301,04/06/2019 00:00,DB08111,"4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol",,,,,,solid,,,0.0383,9.85,1.82,OC1=CC=C(CC2=NN=C3C=CC(=NN23)C2=CC=CC=C2)C=C1,,,,,0,,302.1167611,4,4,2,2,0,0
6302,04/06/2019 00:00,DB08112,N-({6-[(4-CYANO-2-FLUOROBENZYL)OXY]NAPHTHALEN-2-YL}SULFONYL)-D-GLUTAMIC ACID,,,,,,solid,,,0.00453,2.97,-4.9,[H][C@](CCC(O)=O)(NS(=O)(=O)C1=CC2=C(C=C1)C=C(OCC1=C(F)C=C(C=C1)C#N)C=C2)C(O)=O,,,,,0,,486.0897002,3,3,0,0,0,0
6303,04/06/2019 00:00,DB08113,3-pyridin-4-yl-1H-indazole,,,,,,solid,,,0.248,13.84,3.77,N1N=C(C2=C1C=CC=C2)C1=CC=NC=C1,,,,,0,,195.0796473,3,3,2,2,0,0
6304,04/06/2019 00:00,DB08114,"5-benzyl-1,3-thiazol-2-amine",,,,,,solid,,,0.316,17.44,5.32,NC1=NC=C(CC2=CC=CC=C2)S1,,,,,0,,190.0564693,2,2,1,1,0,0
6305,04/06/2019 00:00,DB08115,2-aminoethyl naphthalen-1-ylacetate,,,,,,solid,,,0.0243,,9.23,NCCOC(=O)CC1=C2C=CC=CC2=CC=C1,,,,,0,,229.1102787,2,2,0,0,0,0
6306,04/06/2019 00:00,DB08116,"(3R)-4-{[(3,4-dihydroxyphenyl)acetyl]oxy}-N-(2-formylindolizin-3-yl)-3-sulfino-D-valine",,,,,,solid,,,1.71,-0.37,-4.9,[H][C@](NC1=C(C=O)C=C2C=CC=CN12)(C(O)=O)[C@](C)(COC(=O)CC1=CC(O)=C(O)C=C1)[S@](O)=O,,,,,0,,490.1046013,3,3,2,2,0,0
6307,04/06/2019 00:00,DB08118,"2-(methylamino)-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide",,,,,,solid,,,0.0908,9.55,2.2,CNC1=C(C=C(SC2=NN=CN2C)C=C1)C(=O)NC1=NC(C)=CS1,,,,,0,,360.0827011,3,3,2,2,0,0
6308,04/06/2019 00:00,DB08119,"1,1,1-TRIFLUORO-3-((N-ACETYL)-L-LEUCYLAMIDO)-4-PHENYL-BUTAN-2-ONE(N-ACETYL-L-LEUCYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)",,,,,,solid,,,0.00346,11,-1.1,[H][C@@](CC(C)C)(NC(C)=O)C(=O)N[C@@]([H])(CC1=CC=CC=C1)C(=O)C(F)(F)F,,,,,0,,372.1660773,1,1,0,0,0,0
6309,04/06/2019 00:00,DB08120,"6,8-DIMERCAPTO-OCTANOIC ACID AMIDE",,,,,,solid,,,0.0753,9.82,-0.58,[H][C@](S)(CCS)CCCCC(N)=O,,,,,0,,207.0751562,0,0,0,0,0,0
6310,04/06/2019 00:00,DB08121,(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid,,,,,,solid,,,0.00112,4,-4.9,[H][C@@](CC1=CC=CC=C1)(OC1=CC=C(C=C1)C1=CC=CC=C1)C(O)=O,,,,,0,,318.1255944,3,3,0,0,0,0
6311,04/06/2019 00:00,DB08122,"N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE",,,,,,solid,,,0.118,10.64,-2.3,CNS(=O)(=O)C1=CC=C(N\C=C2/C(=O)NC3=C2C=CC=C3)C=C1,,,,,0,,329.0834123,3,2,1,0,0,1
6312,04/06/2019 00:00,DB08123,"N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE",,,,,,solid,,,0.0336,9.81,1.62,CNS(=O)(=O)CC1=CC=C(N\N=C2/C(=O)NC3=C2C2=C(C=C3)N=CS2)C=C1,,,,,0,,401.0616313,4,3,2,1,0,1
6313,04/06/2019 00:00,DB08124,"3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE",,,,,,solid,,,0.123,10.93,0.78,O=C1NC2=CC=C(C=C2\C1=C\NC1=CC2=C(CS(=O)(=O)C2)C=C1)C1=CN=CO1,,,,,0,,393.078327,5,3,3,1,0,2
6314,04/06/2019 00:00,DB08125,"4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE",,,,,,solid,,,0.0108,6.9,0.59,O=C1NC2=CC=CC=C2\C1=C\NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1,,,,,0,,398.0507323,4,3,2,1,0,1
6315,04/06/2019 00:00,DB08126,"3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE",,,,,,solid,,,0.0376,10.3,4.01,NC(=N)NS(=O)(=O)C1=CC=C(N\C=C2/C(=O)NC3=C2C=CC=C3)C=C1,,,,,0,,357.0895603,3,2,1,0,0,1
6316,04/06/2019 00:00,DB08127,"1,3,3-trimethyl-2-[(1E,3E)-3-methylpenta-1,3-dien-1-yl]cyclohexene",,,,,,solid,,,0.0267,,,C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C,,,,,0,,204.1878008,1,0,0,0,0,0
6317,04/06/2019 00:00,DB08128,"(1S,4R,9S)-5-(trifluoromethyl)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-9-amine",,,,,,solid,,,0.451,,9.94,[H][C@]12CC[C@]([H])(C3=C(C=CC=C13)C(F)(F)F)[C@@]2([H])N,,,,,0,,227.092184,3,1,0,0,0,0
6318,04/06/2019 00:00,DB08129,(1R)-2-amino-1-[3-(trifluoromethyl)phenyl]ethanol,,,,,,solid,,,7.8,14.05,9.11,[H][C@](O)(CN)C1=CC=CC(=C1)C(F)(F)F,,,,,0,,205.0714486,1,1,0,0,0,0
6319,04/06/2019 00:00,DB08130,"N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine",,,,,,solid,,,0.0636,9.21,11.75,NCCNC1=NN=C(O1)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1,,,,,0,,475.0116927,3,3,1,1,0,0
6320,04/06/2019 00:00,DB08131,"2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-3-METHYL-BUTYRIC ACID",,,,,,solid,,,0.0321,3.4,4.2,[H][C@](NC(=O)C1=CC=C(CCC2=CNC3=C2C(=O)NC(N)=N3)C=C1)(C(C)C)C(O)=O,,,,,0,,397.1750042,3,3,2,2,0,0
6321,04/06/2019 00:00,DB08132,5-hydroxynaphthalene-1-sulfonamide,,,,,,solid,,,1.55,9.33,-5.6,NS(=O)(=O)C1=C2C=CC=C(O)C2=CC=C1,,,,,0,,223.0303141,2,2,0,0,0,0
6322,04/06/2019 00:00,DB08133,N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide,,,,,,solid,,,0.0266,9.32,-1.1,NS(=O)(=O)C1=CC=C(NC(=O)C2=NNC3=C2C=CC=C3)C=C1,,,,,0,,316.0630112,3,3,1,1,0,0
6323,04/06/2019 00:00,DB08134,4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide,,,,,,solid,,,0.12,10.74,0.096,NS(=O)(=O)C1=CC=C(NC2=NC(Cl)=CN=C2)C=C1,,,,,0,,284.0134742,2,2,1,1,0,0
6324,04/06/2019 00:00,DB08135,N-phenyl-1H-pyrazole-3-carboxamide,,,,,,solid,,,1.07,10.51,-0.14,O=C(NC1=CC=CC=C1)C1=NNC=C1,,,,,0,,187.0745619,2,2,1,1,0,0
6325,04/06/2019 00:00,DB08136,4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide,,,,,,solid,,,0.118,9.95,-0.81,CC(=O)NC1=CNN=C1C(=O)NC1=CC=C(F)C=C1,,,,,0,,262.0866038,2,2,1,1,0,0
6326,04/06/2019 00:00,DB08137,(4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide,,,,,,solid,,,0.0242,9.91,-0.82,FC1=CC=C(NC(=O)C2=NNC=C2NC(=O)C2=CC=CC=C2)C=C1,,,,,0,,324.1022539,3,3,1,1,0,0
6327,04/06/2019 00:00,DB08138,"{[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide",,,,,,solid,,,0.00435,9.22,-0.82,FC1=CC=C(NC(=O)C2=NNC=C2NC(=O)C2=C(F)C=CC=C2F)C=C1,,,,,0,,360.0834103,3,3,1,1,0,0
6328,04/06/2019 00:00,DB08139,"5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile",,,,,,solid,,,0.118,,0.34,CC(C)NC1=CC(Cl)=NC2=C(C=NN12)C#N,,,,,0,,235.062473,2,2,2,2,0,0
6329,04/06/2019 00:00,DB08140,"5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE",,,,,,solid,,,0.103,18.29,10.45,[H][C@]1(N)CC[C@@]([H])(CC1)NC1=NC2=C(C=NN2C(NC(C)C)=C1)C#N,,,,,0,,313.2014937,3,2,2,2,0,0
6330,04/06/2019 00:00,DB08141,"4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide",,,,,,solid,,,0.0761,9.08,9.72,[H][C@@]1(CCCNC1)NC(=O)C1=NNC=C1NC(=O)C1=C(F)C=CC=C1F,,,,,0,,349.1350312,3,2,2,1,1,1
6331,04/06/2019 00:00,DB08142,AT-7519,,,,,,solid,,,0.0267,9.62,10.24,ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1,,,,,0,,381.0759301,3,2,2,1,1,1
6332,04/06/2019 00:00,DB08143,"5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDE",,,,,,solid,,,0.00139,11.57,3.72,[H][C@]1(F)CN(CC(=O)NC2=CC=C(C=C2F)N2C=CC=CC2=O)C[C@]1([H])NC(=O)C1=CC=C(Cl)S1,,,,,0,,492.0834456,4,3,3,2,1,1
6333,04/06/2019 00:00,DB08144,"6-(2,6-dibromophenyl)pyrido[2,3-d]pyrimidine-2,7-diamine",,,,,,solid,,,0.0318,15.82,4.49,NC1=NC2=NC(N)=C(C=C2C=N1)C1=C(Br)C=CC=C1Br,,,,,0,,392.9224695,3,3,2,2,0,0
6334,04/06/2019 00:00,DB08145,"6-(2,6-DIMETHOXYPHENYL)PYRIDO[2,3-D]PYRIMIDINE-2,7-DIAMINE",,,,,,solid,,,0.313,15.82,4.49,COC1=CC=CC(OC)=C1C1=CC2=CN=C(N)N=C2N=C1N,,,,,0,,297.1225747,3,3,2,2,0,0
6335,04/06/2019 00:00,DB08146,"7-(2,5-dihydropyrrol-1-yl)-6-phenyl-pyrido[6,5-d]pyrimidin-2-amine",,,,,,solid,,,0.222,15.82,4.48,NC1=NC2=C(C=N1)C=C(C1=CC=CC=C1)C(=N2)N1CC=CC1,,,,,0,,289.1327455,4,3,3,2,0,1
6336,04/06/2019 00:00,DB08147,"4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid",,,,,,solid,,,0.000881,3.1,1.75,OC(=O)C(=O)CC(=O)C1=CC=CC(=C1)N(CC1=CC=CC=C1)CC1=CC=CC=C1,,,,,0,,387.1470582,3,3,0,0,0,0
6337,04/06/2019 00:00,DB08148,"1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine",,,,,,solid,,,0.0518,13.57,9.45,NCC1(CCN(CC1)C1=C2C=CNC2=NC=N1)C1=CC=C(Cl)C=C1,,,,,0,,341.1407233,4,3,3,2,1,1
6338,04/06/2019 00:00,DB08149,"1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine",,,,,,solid,,,0.0263,13.58,9.72,NCC1(CC2=CC=C(Cl)C=C2)CCN(CC1)C1=C2C=CNC2=NC=N1,,,,,0,,355.1563734,4,3,3,2,1,1
6339,04/06/2019 00:00,DB08150,"4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium",,,,,,solid,,,0.00715,13.59,9.85,[NH3+]C1(CC2=CC=C(Cl)C=C2)CCN(CC1)C1=C2C=CNC2=NC=N1,,,,,1,,342.1479998,4,3,3,2,1,1
6340,04/06/2019 00:00,DB08151,"(5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol",,,,,,solid,,,9.04,12.05,3.43,[H][C@]1(CO)O[C@@]2(CC(=NO2)C2=CC=CC=C2)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,295.1055873,3,1,2,0,1,2
6341,04/06/2019 00:00,DB08152,{(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate,,,,,,solid,,,0.029,13.46,-4.1,[H][C@@]1(COC(=O)CC2=CC(Cl)=CC=C2)CCCN1C(=O)CNC(=O)OC(C)(C)C,,,,,0,,410.1608496,2,1,1,0,1,1
6342,04/06/2019 00:00,DB08153,"(5E)-14-CHLORO-15,17-DIHYDROXY-4,7,8,9,10,11-HEXAHYDRO-2-BENZOXACYCLOPENTADECINE-1,12(3H,13H)-DIONE",,,,,,solid,,,0.089,7.03,-4.3,OC1=CC(O)=C2C(CC(=O)CCCCC\C=C\CCOC2=O)=C1Cl,,,,,0,,352.1077515,2,1,1,0,0,1
6343,04/06/2019 00:00,DB08154,3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile,,,,,,solid,,,0.00165,13.31,0.44,ClC1=CC(=CC(OC2=C(Cl)C=CC(OCC3=NNC4=C3C=CC=C4)=C2)=C1)C#N,,,,,0,,409.038482,4,4,1,1,0,0
6344,04/06/2019 00:00,DB08155,N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE,,,,,,solid,,,1.29,10.22,-0.94,CC(=O)NCCC1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,242.0725133,1,1,0,0,0,0
6345,04/06/2019 00:00,DB08156,3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID,,,,,,solid,,,2.46,3.43,,NS(=O)(=O)C1=CC=C(CCC(O)=O)C=C1,,,,,0,,229.0408788,1,1,0,0,0,0
6346,04/06/2019 00:00,DB08157,ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE,,,,,,solid,,,0.349,10.22,-7,CCOC(=O)CCC1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,257.072179,1,1,0,0,0,0
6347,04/06/2019 00:00,DB08158,"2,4-DINITROPHENYL 2-DEOXY-2-FLUORO-BETA-D-MANNOPYRANOSIDE",,,,,,solid,,,1.48,12.53,-3,[H][C@]1(CO)O[C@@]([H])(OC2=C(C=C(C=C2)[N+]([O-])=O)[N+]([O-])=O)[C@@]([H])(F)[C@@]([H])(O)[C@]1([H])O,,,,,0,,348.0605082,2,1,1,0,1,1
6348,04/06/2019 00:00,DB08159,"4-(5,11-DIOXO-5H-INDENO[1,2-C]ISOQUINOLIN-6(11H)-YL)BUTANOATE",,,,,,solid,,,0.0192,3.73,-5.2,OC(=O)CCCN1C2=C(C(=O)C3=CC=CC=C23)C2=CC=CC=C2C1=O,,,,,0,,333.100108,4,3,1,1,0,0
6349,04/06/2019 00:00,DB08160,"(2S)-2-AMINO-4-(METHYLSULFANYL)-1-(1,3-THIAZOL-2-YL)BUTANE-1,1-DIOL",,,,,,solid,,,4.12,8.06,9.84,[H][C@](N)(CCSC)C(O)(O)C1=NC=CS1,,,,,0,,234.0496697,1,1,1,1,0,0
6350,04/06/2019 00:00,DB08161,(S)-2-(MERCAPTOMETHYL)-5-PHENYLPENTANOIC ACID,,,,,,solid,,,0.0444,4.81,-9.6,[H][C@](CS)(CCCC1=CC=CC=C1)C(O)=O,,,,,0,,224.0871008,1,1,0,0,0,0
6351,04/06/2019 00:00,DB08162,Fasudil,,,,,,solid,,,0.531,,8.04,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2,,,,,0,,291.1041478,3,2,2,1,1,1
6352,04/06/2019 00:00,DB08163,5'-{[4-(aminooxy)butyl](methyl)amino}-5'-deoxy-8-ethenyladenosine,,,,,,solid,,,2.68,12.47,8.54,[H][C@]1(CN(C)CCCCON)O[C@@]([H])(N2C(C=C)=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,393.2124523,3,2,3,2,1,1
6353,04/06/2019 00:00,DB08164,"(3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE",,,,,,solid,,,0.0119,19.69,9.48,[H][C@]1(N)CN(CC[C@]1([H])C1=CC(F)=C(F)C=C1F)C1=NC=NC(=C1)C1=CC=CC(=C1)S(C)(=O)=O,,,,,0,,462.1337316,4,3,2,1,1,1
6354,04/06/2019 00:00,DB08165,indane-5-sulfonamide,,,,,,solid,,,0.77,10.46,,NS(=O)(=O)C1=CC=C2CCCC2=C1,,,,,0,,197.0510496,2,1,0,0,0,0
6355,04/06/2019 00:00,DB08166,"(4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile",,,,,,solid,,,0.141,11.84,9.93,[H][C@@]1(C#N)C2=C(N(C)C3=CC(Cl)=CC=C23)C(=O)NC11CCNCC1,,,,,0,,328.1090888,4,2,3,1,1,2
6356,04/06/2019 00:00,DB08167,Methylthioninium,,,,,,solid,,,0.376,,2.44,CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C,,,,,1,,284.121595,3,3,1,1,0,0
6357,04/06/2019 00:00,DB08168,7-AMINO-4-METHYL-CHROMEN-2-ONE,,,,,,solid,,,1.3,,3.37,CC1=CC(=O)OC2=C1C=CC(N)=C2,,,,,0,,175.0633285,2,2,1,1,0,0
6358,04/06/2019 00:00,DB08169,(2Z)-N-biphenyl-4-yl-2-cyano-3-cyclopropyl-3-hydroxyprop-2-enamide,,,,,,solid,,,0.00832,6.01,-2.6,O\C(C1CC1)=C(\C#N)C(=O)NC1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,304.1211778,3,2,0,0,0,0
6359,04/06/2019 00:00,DB08170,"(1R)-N,6-DIHYDROXY-7-METHOXY-2-[(4-METHOXYPHENYL)SULFONYL]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE",,,,,,solid,,,0.602,8.64,-4.6,[H][C@]1(N(CCC2=CC(O)=C(OC)C=C12)S(=O)(=O)C1=CC=C(OC)C=C1)C(=O)NO,,,,,0,,408.099122,3,2,1,0,0,1
6360,04/06/2019 00:00,DB08171,11-MERCAPTOUNDECANOIC ACID,,,,,,solid,,,0.0111,4.95,-9.6,OC(=O)CCCCCCCCCCS,,,,,0,,218.1340509,0,0,0,0,0,0
6361,04/06/2019 00:00,DB08172,(2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide,,,,,,solid,,,0.00411,5.84,-3.3,COC1=CC=CC=C1C1=CC(Cl)=C(NC(=O)C(\C#N)=C(\C)O)C=C1,,,,,0,,342.07712,2,2,0,0,0,0
6362,04/06/2019 00:00,DB08173,5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE,,,,,,solid,,,0.00177,13.59,-0.77,ClC1=CC=C(S1)C(=O)NCCNC(=O)C1=CC=C(C=C1)N1C=CC=CC1=O,,,,,0,,401.0600901,3,3,2,2,0,0
6363,04/06/2019 00:00,DB08174,"5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL)THIOPHENE-2-CARBOXAMIDE",,,,,,solid,,,0.000969,13.7,-0.072,[H][C@]1(CCC[C@]1([H])NC(=O)C1=CC=C(C=C1)N1C=CC=CC1=O)NC(=O)C1=CC=C(Cl)S1,,,,,0,,441.0913902,4,3,2,2,0,0
6364,04/06/2019 00:00,DB08175,"(2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID",,,,,,solid,,,0.00868,5.05,-4.1,COC(C)(C)CCC[C@@](C)([H])C\C=C\C(\C)=C\C(O)=O,,,,,0,,268.2038448,0,0,0,0,0,0
6365,04/06/2019 00:00,DB08176,(1Z)-4-(4-FLUOROPHENYL)-2-METHYLIDENEBUTAN-1-IMINE,,,,,,solid,,,0.0226,,8.52,[H]N=C([H])C(=C)CCC1=CC=C(F)C=C1,,,,,0,,177.0953776,1,1,0,0,0,0
6366,04/06/2019 00:00,DB08177,(E)-3-(5((5-(4-CHLOROPHENYL)FURAN-2-YL)METHYLENE)-4-OXO-2-THIOXOTHIAZOLIDIN-3-YL)PROPANOIC ACID,,,,,,solid,,,0.0126,4.4,-3.2,[H]\C(C1=CC=C(O1)C1=CC=C(Cl)C=C1)=C1/SC(=S)N(CCC(O)=O)C1=O,,,,,0,,392.9896275,3,2,2,1,1,1
6367,04/06/2019 00:00,DB08178,"4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine",,,,,,solid,,,0.823,12.66,5.38,COC1=C2C(NC=C2C2=NC(N)=NC=C2)=NC=C1,,,,,0,,241.09636,3,3,3,3,0,0
6368,04/06/2019 00:00,DB08179,"methyl 4-(2,3-dihydroxy-5-methylphenoxy)-2-hydroxy-6-methylbenzoate",,,,,,solid,,,0.0515,8.79,-4.4,COC(=O)C1=C(C)C=C(OC2=C(O)C(O)=CC(C)=C2)C=C1O,,,,,0,,304.0946882,2,2,0,0,0,0
6369,04/06/2019 00:00,DB08180,2-[METHYL-(5-GERANYL-4-METHYL-PENT-3-ENYL)-AMINO]-ETHYL-DIPHOSPHATE,,,,,,solid,,,0.0198,1.76,9.6,CN(CCO[P@@](O)(=O)OP(O)(O)=O)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C,,,,,0,,453.2045258,0,0,0,0,0,0
6370,04/06/2019 00:00,DB08181,2-((3'-METHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID,,,,,,solid,,,0.0592,3.36,0.34,CC1=CC(=CC=C1O)\N=N\C1=CC=CC=C1C(O)=O,,,,,0,,256.0847922,2,2,0,0,0,0
6371,04/06/2019 00:00,DB08182,"4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine",,,,,,solid,,,0.295,12.65,5.36,CCCOC1=C2C(NC=C2C2=NC(N)=NC=C2)=NC=C1,,,,,0,,269.1276601,3,3,3,3,0,0
6372,04/06/2019 00:00,DB08184,2-(2-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE,,,,,,solid,,,0.00587,14.96,11.21,CC1=C(C=CC=C1)C1=CC2=C(N1)C=CC(=C2)C(N)=N,,,,,0,,249.1265975,3,3,1,1,0,0
6373,04/06/2019 00:00,DB08185,2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE,,,,,,solid,,,1.71,1.23,3.99,[H][C@]1(COP(O)(O)=O)O[C@@]([H])(N2C=NC3=C2N=C(SC)N=C3NCCC(C)C)[C@]([H])(O)[C@]1([H])O,,,,,0,,463.1290558,3,2,3,2,1,1
6374,04/06/2019 00:00,DB08186,(3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE,,,,,,solid,,,0.142,19.67,-5.1,CN1C=C(\C=C\C(C)=O)C2=CC=CC=C12,,,,,0,,199.099714,2,2,1,1,0,0
6375,04/06/2019 00:00,DB08187,METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE,,,,,,solid,,,0.093,6.71,10.46,[H][C@](CC1=CC=CC=C1)(NC)C(=O)N1CCC[C@@]1([H])C(O)=NC[C@@]1([H])CC[C@]([H])(N)CC1,,,,,0,,386.2681763,3,1,1,0,1,1
6376,04/06/2019 00:00,DB08188,Emivirine,,,,,,solid,,,0.116,10.23,-3.9,CCOCN1C(=O)NC(=O)C(C(C)C)=C1CC1=CC=CC=C1,,,,,0,,302.1630426,2,2,1,1,0,0
6377,04/06/2019 00:00,DB08190,N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide,,,,,,solid,,,0.0223,14.23,-0.94,COC1=CC=C2NC(I)=C(CCNC(C)=O)C2=C1,,,,,0,,358.0178257,2,2,1,1,0,0
6378,04/06/2019 00:00,DB08191,"4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid",,,,,,solid,,,0.00225,4.25,3.63,OC(=O)C1=CC=C(C=C1)C1=CNC2=C1C=C(C=N2)C1=CC=CC=C1,,,,,0,,314.1055277,4,4,2,2,0,0
6379,04/06/2019 00:00,DB08192,2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE,,,,,,solid,,,0.00974,2.52,7.18,[H][C@]1(CC2=C(CN1)C=CC=C2)C1=NC(C(O)=O)=C(S1)C(C)C,,,,,0,,302.1088988,3,2,2,1,0,1
6380,04/06/2019 00:00,DB08193,2-(3-NITROPHENYL)ACETIC ACID,,,,,,solid,,,0.796,3.07,-9.7,OC(=O)CC1=CC(=CC=C1)[N+]([O-])=O,,,,,0,,181.0375077,1,1,0,0,0,0
6381,04/06/2019 00:00,DB08194,"4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine",,,,,,solid,,,4.41,16.92,4.9,CC1=NC(N)=NC2=C1CSCC2,,,,,0,,181.0673684,2,1,2,1,0,1
6382,04/06/2019 00:00,DB08195,(1R)-2-[(CYANOMETHYL)AMINO]-1-({[2-(DIFLUOROMETHOXY)BENZYL]SULFONYL}METHYL)-2-OXOETHYL MORPHOLINE-4-CARBOXYLATE,,,,,,solid,,,0.32,6.95,-4.1,[H][C@@](CS(=O)(=O)CC1=C(OC(F)F)C=CC=C1)(OC(=O)N1CCOCC1)C(=O)NCC#N,,,,,0,,461.1068275,2,1,1,0,1,1
6383,04/06/2019 00:00,DB08196,"2-((3',5'-DIMETHOXY-4'-HYDROXYPHENYL)AZO)BENZOIC ACID",,,,,,solid,,,0.0805,3.36,-0.48,COC1=CC(=CC(OC)=C1O)\N=N\C1=CC=CC=C1C(O)=O,,,,,0,,302.0902715,2,2,0,0,0,0
6384,04/06/2019 00:00,DB08197,"(5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime",,,,,,solid,,,0.0177,10,4.91,[H][C@]1(C\C(=N/O)C2=C(C1)N=C(N)N=C2C)C1=CC=C(F)C=C1C1=CC=CN=C1,,,,,0,,363.1495384,4,3,2,2,0,0
6385,04/06/2019 00:00,DB08198,"[(4R)-4-(3-HYDROXYPHENYL)-1,6-DIMETHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL](PHENYL)METHANONE",,,,,,solid,,,0.0149,9.39,-3,[H][C@@]1(NC(=S)N(C)C(C)=C1C(=O)C1=CC=CC=C1)C1=CC(O)=CC=C1,,,,,0,,338.1088988,3,2,1,0,0,1
6386,04/06/2019 00:00,DB08199,N-[(BENZYLOXY)CARBONYL]-L-CYSTEINYLGLYCINE,,,,,,solid,,,0.194,3.54,-5.5,[H][C@@](CS)(NC(=O)OCC1=CC=CC=C1)C(=O)NCC(O)=O,,,,,0,,312.0779926,1,1,0,0,0,0
6387,04/06/2019 00:00,DB08200,(1R)-menthyl hexyl phosphonate group,,,,,,solid,,,0.0384,1.93,,CCCCCCP(O)(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C,,,,,0,,304.2167315,1,0,0,0,0,0
6388,04/06/2019 00:00,DB08201,(1S)-menthyl hexyl phosphonate group,,,,,,solid,,,0.0384,1.93,,CCCCCCP(O)(=O)O[C@H]1C[C@@H](C)CC[C@@H]1C(C)C,,,,,0,,304.2167315,1,0,0,0,0,0
6389,04/06/2019 00:00,DB08202,4-({[(4-METHYLPIPERAZIN-1-YL)AMINO]CARBONOTHIOYL}AMINO)BENZENESULFONAMIDE,,,,,,solid,,,0.282,9.24,7.19,CN1CCN(CC1)NC(=S)NC1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,329.0980168,2,1,1,0,1,1
6390,04/06/2019 00:00,DB08203,"7-[2-METHOXY-1-(METHOXYMETHYL)ETHYL]-7H-PYRROLO[3,2-F] QUINAZOLINE-1,3-DIAMINE",,,,,,solid,,,0.546,16.77,5.98,COCC(COC)N1C=CC2=C1C=CC1=NC(N)=NC(N)=C21,,,,,0,,301.1538748,3,3,2,2,0,0
6391,04/06/2019 00:00,DB08204,3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE,,,,,,solid,,,0.00373,9.16,-6,OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC3=C(C=CC1=C23)[N+]([O-])=O)C1=CC=C(O)C=C1,,,,,0,,413.0899372,5,4,1,0,0,1
6392,04/06/2019 00:00,DB08205,"4-(1,3-BENZOXAZOL-2-YL)-2,6-DIMETHYLPHENOL",,,,,,solid,,,0.0771,9.78,0.2,CC1=CC(=CC(C)=C1O)C1=NC2=CC=CC=C2O1,,,,,0,,239.0946287,3,3,1,1,0,0
6393,04/06/2019 00:00,DB08206,"4-(1,3-BENZOXAZOL-2-YL)-2,6-DIBROMOPHENOL",,,,,,solid,,,0.0518,5.89,0.15,OC1=C(Br)C=C(C=C1Br)C1=NC2=C(O1)C=CC=C2,,,,,0,,366.8843527,3,3,1,1,0,0
6394,04/06/2019 00:00,DB08207,"2-(3,5-DIMETHYLPHENYL)-1,3-BENZOXAZOLE",,,,,,solid,,,0.0295,,0.15,CC1=CC(=CC(C)=C1)C1=NC2=C(O1)C=CC=C2,,,,,0,,223.099714,3,3,1,1,0,0
6395,04/06/2019 00:00,DB08208,"2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE",,,,,,solid,,,0.00659,11.94,-2.8,OCCONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(C=C1F)C#C,,,,,0,,350.0878269,2,2,0,0,0,0
6396,04/06/2019 00:00,DB08209,2-(4-DIMETHYLAMINOPHENYL)DIAZENYLBENZOIC ACID,,,,,,solid,,,0.0869,3.15,3.79,CN(C)C1=CC=C(C=C1)\N=N\C1=CC=CC=C1C(O)=O,,,,,0,,269.1164267,2,2,0,0,0,0
6397,04/06/2019 00:00,DB08210,"2-AMINO-4-FLUORO-5-[(1-METHYL-1H-IMIDAZOL-2-YL)SULFANYL]-N-(1,3-THIAZOL-2-YL)BENZAMIDE",,,,,,solid,,,0.0998,9.59,4.94,CN1C=CN=C1SC1=CC(C(=O)NC2=NC=CS2)=C(N)C=C1F,,,,,0,,349.0467302,3,3,2,2,0,0
6398,04/06/2019 00:00,DB08211,5-bromo-3-(pyrrolidin-1-ylsulfonyl)-1H-indole-2-carboxamide,,,,,,solid,,,0.0628,9.72,-2.7,NC(=O)C1=C(C2=CC(Br)=CC=C2N1)S(=O)(=O)N1CCCC1,,,,,0,,370.9939244,3,2,2,1,1,1
6399,04/06/2019 00:00,DB08212,1-[2-(3-ACETYL-2-HYDROXY-6-METHOXY-PHENYL)-CYCLOPROPYL]-3-(5-CYANO-PYRIDIN-2-YL)-THIOUREA,,,,,,solid,,,0.0132,9.81,-0.85,[H][C@]1(C[C@]1([H])C1=C(OC)C=CC(C(C)=O)=C1O)NC(=S)NC1=NC=C(C=C1)C#N,,,,,0,,382.1099614,3,2,1,1,0,0
6400,04/06/2019 00:00,DB08213,"1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE",,,,,,solid,,,0.0535,,-4.7,[H][C@@]1(COC2=CC=CC=C2)CCCN1S(=O)(=O)C1=CC2=C(C=C1)N(C)C(=O)C2=O,,,,,0,,400.1092927,4,2,2,0,1,2
6401,04/06/2019 00:00,DB08214,4-(1H-IMIDAZOL-1-YL)PHENOL,,,,,,solid,,,2.41,10.96,6.43,OC1=CC=C(C=C1)N1C=CN=C1,,,,,0,,160.0636629,2,2,1,1,0,0
6402,04/06/2019 00:00,DB08215,2-T-BUTYLAMINO-4-ETHYLAMINO-6-METHYLTHIO-S-TRIAZINE,,,,,,solid,,,0.034,14.31,5.72,CCNC1=NC(NC(C)(C)C)=NC(SC)=N1,,,,,0,,241.1361166,1,1,1,1,0,0
6403,04/06/2019 00:00,DB08216,2-((3'-TERTBUTYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID,,,,,,solid,,,0.00827,3.36,0.29,CC(C)(C)C1=CC(=CC=C1O)\N=N\C1=CC=CC=C1C(O)=O,,,,,0,,298.1317424,2,2,0,0,0,0
6404,04/06/2019 00:00,DB08217,"S-[(1-Hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate",,,,,,solid,,,0.754,14.76,0.37,CC1(C)C=C(CSS(C)(=O)=O)C(C)(C)N1O,,,,,0,,265.0806355,1,0,1,0,0,1
6405,04/06/2019 00:00,DB08218,"HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM",,,,,,solid,,,0.0619,13.51,2.25,O=N(=O)C1=CC=CC(=C1)\N=C1\N=CCC(=N1)C1=CC=CC(CN2C=NC=N2)=C1,,,,,0,,373.1287227,4,3,2,1,0,1
6406,04/06/2019 00:00,DB08219,"4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE",,,,,,solid,,,0.062,10.28,7.61,CC1=C(SC(=N)N1)C1=N\C(=N/C2=CC=C(C=C2)N2CCOCC2)N=CC1,,,,,0,,368.1419303,4,2,3,1,1,2
6407,04/06/2019 00:00,DB08220,"(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid",,,,,,solid,,,0.00264,4.58,-6.9,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C=C(CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(O)=O)C(=O)C1=CC=C(O)C=C1,,,,,0,,420.2300595,5,1,0,0,0,0
6408,04/06/2019 00:00,DB08221,N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE,,,,,,solid,,,0.00188,12.52,4.67,CC1=CC=C(NC(=O)C2=CC=CC(=C2)C(F)(F)F)C=C1NC1=NC=CC=C1C1=CC=NC=N1,,,,,0,,449.1463449,4,4,2,2,0,0
6409,04/06/2019 00:00,DB08222,METHOXYUNDECYLPHOSPHINIC ACID,,,,,,solid,,,0.149,1.96,,CCCCCCCCCCC[P@@](O)(=O)OC,,,,,0,,250.1697814,0,0,0,0,0,0
6410,04/06/2019 00:00,DB08223,"N-{(1S,2R)-1-BENZYL-3-[(CYCLOPROPYLMETHYL)(2-FURYLSULFONYL)AMINO]-2-HYDROXYPROPYL}-N'-METHYLSUCCINAMIDE",,,,,,solid,,,0.108,14.06,-0.73,[H][C@@](O)(CN(CC1CC1)S(=O)(=O)C1=CC=CO1)[C@]([H])(CC1=CC=CC=C1)NC(=O)CCC(=O)NC,,,,,0,,477.1933567,3,2,1,1,0,0
6411,04/06/2019 00:00,DB08224,"(1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL]ETHYL]-1-NAPHTHALENOL",,,,,,solid,,,0.26,14.91,-0.85,[H][C@]1(O)CC(=O)O[C@@]([H])(CC[C@@]2([H])[C@@]([H])(C)C=CC3=CCC[C@]([H])(O)[C@]23[H])C1,,,,,0,,306.1831093,3,0,1,0,1,1
6412,04/06/2019 00:00,DB08226,Myxopyronin B,,,,,,solid,,,0.00245,6.85,-6.4,CCCC\C(C)=C\C=C(/C)C(=O)C1=C(O)C=C(CCC\C=C\NC(=O)OC)OC1=O,,,,,0,,417.2151377,1,1,1,1,0,0
6413,04/06/2019 00:00,DB08227,"1-(1-HYDROXY-2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)PYRROLIDINE-2,5-DIONE",,,,,,solid,,,25.8,14.74,2.39,CC1(C)CC(CC(C)(C)N1O)N1C(=O)CCC1=O,,,,,0,,254.1630426,2,0,2,0,2,2
6414,04/06/2019 00:00,DB08228,"5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one",,,,,,solid,,,2.29,,-1.5,COC1=C2N(C)C(=O)C=C(C)C2=C(OC)C=C1,,,,,0,,233.1051933,2,2,1,1,0,0
6415,04/06/2019 00:00,DB08229,[N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID,,,,,,solid,,,0.0291,3.75,3,[H][C@](O)(CC(=O)N(N)CC(O)=O)C(=O)N(CC1=CC=CC=C1)CC1=CC=CC=C1,,,,,0,,385.1637708,2,2,0,0,0,0
6416,04/06/2019 00:00,DB08230,"5,7-DIHYDROXY-2-(3,4,5-TRIHYDROXYPHENYL)-4H-CHROMEN-4-ONE",,,,,,solid,,,0.184,6.63,-5.2,OC1=CC2=C(C(O)=C1)C(=O)C=C(O2)C1=CC(O)=C(O)C(O)=C1,,,,,0,,302.0426527,3,3,1,1,0,0
6417,04/06/2019 00:00,DB08231,Myristic acid,,,,,Topical,solid,,,0.00172,4.95,,CCCCCCCCCCCCCC(O)=O,,,,,0,,228.2089301,0,0,0,0,0,0
6418,04/06/2019 00:00,DB08232,"[5-(5-Amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid",,,,,,solid,,,0.0185,3.88,5.98,NC1=CC=C2NC(=CC2=N1)C1=CC(CC(O)=O)=CC(=C1O)C1=CC=CC(=C1)[N+]([O-])=O,,,,,0,,404.1120696,4,4,2,2,0,0
6419,04/06/2019 00:00,DB08233,6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE,,,,,,solid,,,0.0426,8.93,2.39,OC1=CC=C(NC2=NC(OCC3CCCCC3)=C3N=CNC3=N2)C=C1,,,,,0,,339.1695249,4,3,2,2,0,0
6420,04/06/2019 00:00,DB08234,"5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine",,,,,,solid,,,0.018,17.6,7.12,CCC1=NC(N)=NC(N)=C1C#CCC1=CC(OC)=CC=C1OC,,,,,0,,312.1586259,2,2,1,1,0,0
6421,04/06/2019 00:00,DB08235,N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide,,,,,,solid,,,0.00483,14.15,-2.4,CC1=C(CCNC(=O)C2=CC=CS2)C2=CC=CC=C2N1,,,,,0,,284.0983341,3,3,2,2,0,0
6422,04/06/2019 00:00,DB08236,"(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one",,,,,,solid,,,0.00561,8.11,-6.2,[H][C@]1(SCC(=O)N1C1=CC(Cl)=CC=C1O)C1=CC=CC(Br)=C1,,,,,0,,382.9382394,3,2,1,0,1,1
6423,04/06/2019 00:00,DB08237,2'-deoxy-N-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen phosphate),,,,,,solid,,,0.478,1.12,1.9,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=NC2=C1N=C(NCC1=CC=CC3=C1C=CC=C3)NC2=O,,,,,0,,487.1256847,5,4,3,2,1,1
6424,04/06/2019 00:00,DB08238,5-AMINO-NAPHTALENE-2-MONOSULFONATE,,,,,,solid,,,0.644,-2.2,3.58,NC1=CC=CC2=CC(=CC=C12)S(O)(=O)=O,,,,,0,,223.0303141,2,2,0,0,0,0
6425,04/06/2019 00:00,DB08239,"(2S)-4-(2,5-DIFLUOROPHENYL)-N-METHYL-2-PHENYL-N-PIPERIDIN-4-YL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE",,,,,,solid,,,0.0223,,10.03,[H][C@]1(C=C(CN1C(=O)N(C)C1CCNCC1)C1=CC(F)=CC=C1F)C1=CC=CC=C1,,,,,0,,397.1965689,4,2,2,0,1,2
6426,04/06/2019 00:00,DB08240,N-(4-CHLOROPHENYL)-3-(PHOSPHONOOXY)NAPHTHALENE-2-CARBOXAMIDE,,,,,,solid,,,0.00204,1.74,-4.4,OP(O)(=O)OC1=C(C=C2C=CC=CC2=C1)C(=O)NC1=CC=C(Cl)C=C1,,,,,0,,377.0219868,3,3,0,0,0,0
6427,04/06/2019 00:00,DB08241,4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE,,,,,,solid,,,0.0314,8.95,2.38,NC(=O)C1=CC=C(NC2=NC(OCC3CCCCC3)=C3N=CNC3=N2)C=C1,,,,,0,,366.1804239,4,3,2,2,0,0
6428,04/06/2019 00:00,DB08242,"N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide",,,,,,solid,,,0.0295,14.74,5.49,CNC(=O)C1=CC(NC2=C3C=NN(C3=NC=N2)C2=CC=CC=C2)=C(C)C=C1,,,,,0,,358.1542092,4,4,2,2,0,0
6429,04/06/2019 00:00,DB08244,"(1S)-1-CYCLOPROPYL-2-[(2S)-4-(2,5-DIFLUOROPHENYL)-2-PHENYL-2,5-DIHYDRO-1H-PYRROL-1-YL]-2-OXOETHANAMINE",,,,,,solid,,,0.00884,,8.49,[H][C@](N)(C1CC1)C(=O)N1CC(=C[C@@]1([H])C1=CC=CC=C1)C1=CC(F)=CC=C1F,,,,,0,,354.1543697,4,2,1,0,0,1
6430,04/06/2019 00:00,DB08245,1-(2-DEOXY-5-O-PHOSPHONO-BETA-D-ERYTHRO-PENTOFURANOSYL)-5-NITRO-1H-INDOLE,,,,,,solid,,,1.04,1.23,-3.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=CC2=CC(=CC=C12)[N+]([O-])=O,,,,,0,,358.0566021,3,2,2,1,1,1
6431,04/06/2019 00:00,DB08246,"(2S)-4-(2,5-DIFLUOROPHENYL)-N,N-DIMETHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE",,,,,,solid,,,0.0513,,-1.8,[H][C@]1(C=C(CN1C(=O)N(C)C)C1=CC(F)=CC=C1F)C1=CC=CC=C1,,,,,0,,328.1387196,3,2,1,0,0,1
6432,04/06/2019 00:00,DB08247,6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE,,,,,,solid,,,0.1,9.33,3.65,CC(C)C1=NC2=C(OCC3CCCCC3)N=C(N)N=C2N1,,,,,0,,289.1902604,3,2,2,2,0,0
6433,04/06/2019 00:00,DB08248,3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE,,,,,,solid,,,0.0197,8.93,2.38,NS(=O)(=O)C1=CC=CC(NC2=NC(OCC3CCCCC3)=C3N=CNC3=N2)=C1,,,,,0,,402.1474096,4,3,2,2,0,0
6434,04/06/2019 00:00,DB08249,"3,6,9,12,15-PENTAOXATRICOSAN-1-OL",,,,,,solid,,,0.00858,15.12,-2.7,CCCCCCCCOCCOCCOCCOCCOCCO,,,,,0,,350.2668389,0,0,0,0,0,0
6435,04/06/2019 00:00,DB08250,"(5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE",,,,,,solid,,,0.00996,13.46,9.9,CCNC(=O)N1N=C(C[C@@]1(CCCN)C1=CC=CC=C1)C1=C(F)C=CC(F)=C1,,,,,0,,386.1918178,3,2,1,0,0,1
6436,04/06/2019 00:00,DB08251,4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID,,,,,,solid,,,0.026,3.7,2.92,[H][C@@](CC(O)=O)(NC(=O)C1=CN=CC(=C1)C1=CC=C(C=C1)C(O)=O)C=O,,,,,0,,342.0851862,2,2,1,1,0,0
6437,04/06/2019 00:00,DB08252,2-((4'-HYDROXYNAPHTHYL)-AZO)BENZOIC ACID,,,,,,solid,,,0.0125,3.36,-0.18,OC(=O)C1=CC=CC=C1\N=N\C1=C2C=CC=CC2=C(O)C=C1,,,,,0,,292.0847922,3,3,0,0,0,0
6438,04/06/2019 00:00,DB08253,NAM NAPTHYLAMINOALANINE,,,,,,solid,,,0.126,16.45,7.99,[H][C@](N)(CC1=CC=CC2=C1C=CC=C2)C(N)=O,,,,,0,,214.1106131,2,2,0,0,0,0
6439,04/06/2019 00:00,DB08254,2-NAPHTHALENESULFONIC ACID,,,,,,solid,,,0.328,-1.8,,OS(=O)(=O)C1=CC2=C(C=CC=C2)C=C1,,,,,0,,208.0194151,2,2,0,0,0,0
6440,04/06/2019 00:00,DB08255,"(3AR,5R,6S,7R,7AR)-5-(HYDROXYMETHYL)-2-PROPYL-5,6,7,7A-TETRAHYDRO-3AH-PYRANO[3,2-D][1,3]THIAZOLE-6,7-DIOL",,,,,,solid,,,6.23,12.81,2.38,[H][C@]12O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])N=C(CCC)S2,,,,,0,,247.087829,2,0,2,0,1,2
6441,04/06/2019 00:00,DB08256,N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE,,,,,,solid,,,1.86,4.14,-1.6,OC(=O)CNC(=O)NC1CCCCC1,,,,,0,,200.1160924,1,0,0,0,0,0
6442,04/06/2019 00:00,DB08257,4-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}BUTANOIC ACID,,,,,,solid,,,0.809,4.32,-0.62,OC(=O)CCCNC(=O)NC1CCCCC1,,,,,0,,228.1473925,1,0,0,0,0,0
6443,04/06/2019 00:00,DB08258,6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID,,,,,,solid,,,0.574,4.39,-0.62,OC(=O)CCCCCNC(=O)NC1CCCCC1,,,,,0,,256.1786926,1,0,0,0,0,0
6444,04/06/2019 00:00,DB08259,7-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEPTANOIC ACID,,,,,,solid,,,0.231,4.49,-0.62,OC(=O)CCCCCCNC(=O)NC1CCCCC1,,,,,0,,270.1943427,1,0,0,0,0,0
6445,04/06/2019 00:00,DB08260,"(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide",,,,,,solid,,,0.805,12.49,-3,[H][C@@]12CO[C@@]([H])(N1C(=S)NCCCCCCCC)[C@]([H])(O)[C@@]([H])(O)[C@]2([H])O,,,,,0,,332.1769784,2,0,2,0,2,2
6446,04/06/2019 00:00,DB08261,"2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester",,,,,,solid,,,0.337,9.5,-3.4,[H][C@]1(O)C=C[C@@]([H])(O)[C@]1([H])OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12,,,,,0,,330.1103383,3,2,0,0,0,0
6447,04/06/2019 00:00,DB08262,"2,6-dicarboxynaphthalene",,,,,,solid,,,0.096,3.69,,OC(=O)C1=CC2=CC=C(C=C2C=C1)C(O)=O,,,,,0,,216.0422587,2,2,0,0,0,0
6448,04/06/2019 00:00,DB08263,N-(carboxycarbonyl)-D-phenylalanine,,,,,,solid,,,1.16,2.79,-6.3,[H][C@](CC1=CC=CC=C1)(NC(=O)C(O)=O)C(O)=O,,,,,0,,237.0637225,1,1,0,0,0,0
6449,04/06/2019 00:00,DB08264,"(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene",,,,,,solid,,,22.5,13.2,-3.4,[H][C@]1(O)C=CC2=C(C=CC=C2)[C@@]1([H])O,,,,,0,,162.0680796,2,1,0,0,0,0
6450,04/06/2019 00:00,DB08265,"2-(TOLUENE-4-SULFONYL)-2H-BENZO[D][1,2,3]DIAZABORININ-1-OL",,,,,,solid,,,0.038,6.76,2.08,CC1=CC=C(C=C1)S(=O)(=O)N1N=CC2=C(C=CC=C2)B1O,,,,,0,,300.0739937,3,2,1,0,0,1
6451,04/06/2019 00:00,DB08266,"Methyl [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethyl-2,4-octadienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate",,,,,,solid,,,0.00173,8.7,-2.5,[H]\C(CCC[C@@]([H])(C)C1=CC(=O)C([H])(C(=O)C(\C)=C(/[H])\C(\[H])=C(/C)CCC)C(=O)O1)=N/C(=O)OC,,,,,0,,417.2151377,1,0,1,0,0,1
6452,04/06/2019 00:00,DB08267,"6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,,,,,solid,,,0.0325,11.09,4.19,NC1=NC2=C(C=C3NC=NC3=C2CCC2=CC=CC=C2)C(=O)N1,,,,,0,,305.1276601,4,4,2,2,0,0
6453,04/06/2019 00:00,DB08268,"6-AMINO-4-[2-(4-METHYLPHENYL)ETHYL]-1,7-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE",,,,,,solid,,,0.0173,11.09,4.07,CC1=CC=C(CCC2=C3N=CNC3=CC3=C2N=C(N)NC3=O)C=C1,,,,,0,,319.1433102,4,4,2,2,0,0
6454,04/06/2019 00:00,DB08270,"N-(2-AMINOETHYL)-N~2~-{(1S)-1-[4'-(AMINOSULFONYL)BIPHENYL-4-YL]-2,2,2-TRIFLUOROETHYL}-L-LEUCINAMIDE",,,,,,solid,,,0.00694,10.28,9.13,[H][C@@](CC(C)C)(N[C@@]([H])(C1=CC=C(C=C1)C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F)C(=O)NCCN,,,,,0,,486.1912464,2,2,0,0,0,0
6455,04/06/2019 00:00,DB08271,N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID,,,,,,solid,,,0.569,8.74,-4.8,COC1=CC=C(C=C1)S(=O)(=O)N(CC(C)C)CC(=O)NO,,,,,0,,316.1092927,1,1,0,0,0,0
6456,04/06/2019 00:00,DB08272,(4S)-4-(2-NAPHTHYLMETHYL)-D-GLUTAMIC ACID,,,,,,solid,,,0.0901,2.19,9.53,[H][C@@](N)(C[C@]([H])(CC1=CC2=CC=CC=C2C=C1)C(O)=O)C(O)=O,,,,,0,,287.115758,2,2,0,0,0,0
6457,04/06/2019 00:00,DB08273,4-HYDROXY-5-IODO-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION,,,,,,solid,,,0.0395,4.42,-1.8,OC1=C(C=C(CC(=O)NCCCCCC([O-])=O)C=C1I)[N+]([O-])=O,,,,,-1,,435.0058578,1,1,0,0,0,0
6458,04/06/2019 00:00,DB08274,"6,7,8,9-TETRAHYDRO-4-HYDROXY-3-(1-PHENYLPROPYL)CYCLOHEPTA[B]PYRAN-2-ONE",,,,,,solid,,,0.0285,7.56,-6.1,[H][C@](CC)(C1=CC=CC=C1)C1=C(O)C2=C(CCCCC2)OC1=O,,,,,0,,298.1568946,3,2,1,1,0,0
6459,04/06/2019 00:00,DB08275,N-DODECANOYL-L-TYROSINE,,,,,,solid,,,0.00427,3.85,-0.78,[H][C@@](CC1=CC=C(O)C=C1)(NC(=O)CCCCCCCCCCC)C(O)=O,,,,,0,,363.2409585,1,1,0,0,0,0
6460,04/06/2019 00:00,DB08276,trifluoro-[hydroxy-[hydroxy-[2-(N-methyl-2-nitro-anilino)ethoxy]phosphoryl]oxy-phosphoryl]oxy-beryllium(1-),,,,,,solid,,,0.0132,2.08,-0.2,CN(CCO[P@](O)(=O)O[P@@](O)(=O)O[Be-](F)(F)F)C1=CC=CC=C1[N+]([O-])=O,,,,,,,,,,,,,
6461,04/06/2019 00:00,DB08277,"2-(2-CHLORO-4-FLUOROPHENOXY)-2-METHYL-N-[(1R,2S,3S,5S,7S)-5-(METHYLSULFONYL)-2-ADAMANTYL]PROPANAMIDE",,,,,,solid,,,0.00144,13.5,-4.6,[H][C@@]12C[C@@]3([H])C[C@@](C1)(C[C@@]([H])(C2)[C@@]3([H])NC(=O)C(C)(C)OC1=C(Cl)C=C(F)C=C1)S(C)(=O)=O,,,,,0,,443.1333352,5,1,0,0,0,0
6462,04/06/2019 00:00,DB08278,"1-(2-CYCLOPROPYLETHYL)-3-(1,1-DIOXIDO-2H-1,2,4-BENZOTHIADIAZIN-3-YL)-6-FLUORO-4-HYDROXYQUINOLIN-2(1H)-ONE",,,,,,solid,,,0.0205,5.74,-2.2,OC1=C(C(=O)N(CCC2CC2)C2=C1C=C(F)C=C2)C1=NC2=CC=CC=C2S(=O)(=O)N1,,,,,0,,427.1002053,5,3,2,1,0,1
6463,04/06/2019 00:00,DB08279,3-{ISOPROPYL[(TRANS-4-METHYLCYCLOHEXYL)CARBONYL]AMINO}-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID,,,,,,solid,,,0.00121,3.56,-2.1,[H][C@]1(C)CC[C@@]([H])(CC1)C(=O)N(C(C)C)C1=C(SC(=C1)C1=CC=CC=C1)C(O)=O,,,,,0,,385.1711647,3,2,1,1,0,0
6464,04/06/2019 00:00,DB08280,"(1S,3R,4S,5S,7S)-4-{[2-(4-METHOXYPHENOXY)-2-METHYLPROPANOYL]AMINO}ADAMANTANE-1-CARBOXAMIDE",,,,,,solid,,,0.0117,14.84,0.8,[H][C@@]12C[C@@]3([H])C[C@@](C1)(C[C@@]([H])(C2)[C@@]3([H])NC(=O)C(C)(C)OC1=CC=C(OC)C=C1)C(N)=O,,,,,0,,386.2205574,5,1,0,0,0,0
6465,04/06/2019 00:00,DB08281,"O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-bromophenyl)thiocarbamate",,,,,,solid,,,0.00327,10.87,-1.8,BrC1=CC=C(NC(=S)OCCN2C(=O)C3=C(C=CC=C3)C2=O)C=C1,,,,,0,,403.9830254,3,2,1,0,0,1
6466,04/06/2019 00:00,DB08282,"O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-chlorophenyl)thiocarbamate",,,,,,solid,,,0.00321,10.86,-1.8,ClC1=CC=C(NC(=S)OCCN2C(=O)C3=C(C=CC=C3)C2=O)C=C1,,,,,0,,360.033541,3,2,1,0,0,1
6467,04/06/2019 00:00,DB08283,"(2R,3R,4R,5S)-2-(HYDROXYMETHYL)-1-NONYLPIPERIDINE-3,4,5-TRIOL",,,,,,solid,,,9.58,12.9,8.37,[H][C@]1(O)CN(CCCCCCCCC)[C@]([H])(CO)[C@@]([H])(O)[C@]1([H])O,,,,,0,,289.2253085,1,0,1,0,1,1
6468,04/06/2019 00:00,DB08284,"O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-iodophenyl)thiocarbamate",,,,,,solid,,,0.00254,10.88,-1.8,IC1=CC=C(NC(=S)OCCN2C(=O)C3=C(C=CC=C3)C2=O)C=C1,,,,,0,,451.9691613,3,2,1,0,0,1
6469,04/06/2019 00:00,DB08285,"(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol",,,,,,solid,,,0.0132,13.05,4.62,[H][C@@](CC)(CO)NC1=NC2=C(C=NN2C(NCC2=CC=CC=C2)=N1)C(C)C,,,,,0,,354.2168095,3,3,2,2,0,0
6470,04/06/2019 00:00,DB08286,NAPHTHYLOXYACETIC ACID,,,,,,solid,,,0.237,4.05,-4.9,OC(=O)COC1=CC=CC2=CC=CC=C12,,,,,0,,202.0629942,2,2,0,0,0,0
6471,04/06/2019 00:00,DB08287,"(1R,2R)-N-(2-Aminoethyl)-2-{[(4-methoxyphenyl)sulfonyl]methyl}cyclohexanecarboxamide",,,,,,solid,,,0.315,14.96,8.76,[H][C@@]1(CS(=O)(=O)C2=CC=C(OC)C=C2)CCCC[C@@]1([H])C(=O)NCCN,,,,,0,,354.1613283,2,1,0,0,0,0
6472,04/06/2019 00:00,DB08288,CYCLOHEXYL-NORSTATINE,,,,,,solid,,,1.44,12.14,8.93,[H][C@](N)(CC1CCCCC1)[C@@]([H])(O)C(=O)OC(C)C,,,,,0,,243.1834437,1,0,0,0,0,0
6473,04/06/2019 00:00,DB08289,N-(PARA-GLUTARAMIDOPHENYL-ETHYL)-PIPERIDINIUM-N-OXIDE,,,,,,solid,,,0.0109,4.27,3.02,OC(=O)CCCC(=O)NC1=CC=C(CC[N+]2([O-])CCCCC2)C=C1,,,,,0,,334.1892573,2,1,1,0,1,1
6474,04/06/2019 00:00,DB08291,N-(3-AMINOPROPYL)-2-NITROBENZENAMINE,,,,,,solid,,,0.678,13.35,9.82,NCCCNC1=CC=CC=C1[N+]([O-])=O,,,,,0,,195.1007767,1,1,0,0,0,0
6475,04/06/2019 00:00,DB08292,"(5Z)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE",,,,,,solid,,,0.122,7.03,-4.3,OC1=CC(O)=C2C(CC(=O)CCC\C=C/CCOC2=O)=C1Cl,,,,,0,,324.0764513,2,1,1,0,0,1
6476,04/06/2019 00:00,DB08293,"(5E)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE",,,,,,solid,,,0.122,7.03,-4.3,OC1=CC(O)=C2C(CC(=O)CCC\C=C\CCOC2=O)=C1Cl,,,,,0,,324.0764513,2,1,1,0,0,1
6477,04/06/2019 00:00,DB08294,2-(4-HYDROXY-3-NITROPHENYL)ACETIC ACID,,,,,,solid,,,1.86,2.86,-6.7,OC(=O)CC1=CC(=C(O)C=C1)[N+]([O-])=O,,,,,0,,197.0324223,1,1,0,0,0,0
6478,04/06/2019 00:00,DB08295,4-HYDROXY-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION,,,,,,solid,,,0.0908,4.48,-1.8,OC1=C(C=C(CC(=O)NCCCCCC([O-])=O)C=C1)[N+]([O-])=O,,,,,-1,,309.1092098,1,1,0,0,0,0
6479,04/06/2019 00:00,DB08296,5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID,,,,,,solid,,,0.987,1.81,,OC(=O)CCCC[P@]([O-])(=O)OC1=CC=C(C=C1)[N+]([O-])=O,,,,,-1,,302.043512,1,1,0,0,0,0
6480,04/06/2019 00:00,DB08297,ORTHONITROPHENYL-BETA-D-FUCOPYRANOSIDE,,,,,,solid,,,15.7,12.21,-3.6,[H][C@]1(C)O[C@@]([H])(OC2=CC=CC=C2[N+]([O-])=O)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,285.0848518,2,1,1,0,1,1
6481,04/06/2019 00:00,DB08299,"4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid",,,,,,solid,,,0.00248,3.84,4.73,OC(=O)C1=CC=C(C=C1)C1=NC(C2=CC=CC(=C2)[N+]([O-])=O)=C2N=CC=CC2=C1,,,,,0,,371.0906059,4,4,2,2,0,0
6482,04/06/2019 00:00,DB08300,"1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,,,,,solid,,,0.0494,19.71,6.61,CN1N=C(C2=C(N)N=CN=C12)C1=CC2=CC=CC=C2C=C1,,,,,0,,275.1170954,4,4,2,2,0,0
6483,04/06/2019 00:00,DB08301,N-({[4-(AMINOSULFONYL)PHENYL]AMINO}CARBONYL)-4-METHYLBENZENESULFONAMIDE,,,,,,solid,,,0.0955,3.6,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,369.0453126,2,2,0,0,0,0
6484,04/06/2019 00:00,DB08302,3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid,,,,,,solid,,,0.0195,3.95,-3.3,CCC\C(=C\C1=CC=C(O1)C1=CC(=CC=C1)C(O)=O)[N+]([O-])=O,,,,,0,,301.0950226,2,2,1,1,0,0
6485,04/06/2019 00:00,DB08303,"(3S)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide",,,,,,solid,,,0.3,10.02,5.97,[H][C@@]1(NC2=CC(C)=C(C=C2S(=O)(=O)N1)S(=O)(=O)N1CCN(C)CC1)C1CCCC1,,,,,0,,428.1551974,4,1,2,0,1,2
6486,04/06/2019 00:00,DB08304,"(3R)-3-cyclopentyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide",,,,,,solid,,,0.241,9.57,5.91,[H][C@@]1(CC2=C(C=C(C=C2)S(=O)(=O)N2CCN(C)CC2)S(=O)(=O)N1)C1CCCC1,,,,,0,,413.1442983,4,1,2,0,1,2
6487,04/06/2019 00:00,DB08305,"(3R)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide",,,,,,solid,,,0.174,9.84,5.92,[H][C@@]1(CC2=CC(C)=C(C=C2S(=O)(=O)N1)S(=O)(=O)N1CCN(C)CC1)C1CCCC1,,,,,0,,427.1599484,4,1,2,0,1,2
6488,04/06/2019 00:00,DB08306,3-[(3-Nitrophenyl)sulfamoyl]-2-thiophenecarboxylic acid,,,,,,solid,,,0.00698,3.06,,[H]N(C1=CC(=CC=C1)[N+]([O-])=O)S(=O)(=O)C1=C(SC=C1)C(O)=O,,,,,0,,327.982378,2,2,1,1,0,0
6489,04/06/2019 00:00,DB08307,"2-{HYDROXY[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]METHYLENE}CYCLOHEXANE-1,3-DIONE",,,,,,solid,,,0.00755,4.13,-7.6,OC(C1=CC=C(C=C1[N+]([O-])=O)C(F)(F)F)=C1C(=O)CCCC1=O,,,,,0,,329.0511071,2,1,0,0,0,0
6490,04/06/2019 00:00,DB08308,"SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER",,,,,,solid,,,0.0108,4.31,-4.7,[H][C@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O,,,,,0,,374.2093241,4,0,0,0,0,0
6491,04/06/2019 00:00,DB08309,3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL,,,,,,solid,,,0.0305,9.01,8.04,OCCCNCCS(=O)(=O)C1=CC=C(NC2=NC(OCC3CCCCC3)=C3N=CNC3=N2)C=C1,,,,,0,,488.2205745,4,3,2,2,0,0
6492,04/06/2019 00:00,DB08310,"N-[(2R)-2-{[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl}hexyl]-N-hydroxyformamide",,,,,,solid,,,0.16,8.39,-0.37,[H][C@@](CCCC)(CN(O)C=O)C(=O)N1CCC[C@@]1([H])C1=NC2=C(O1)C=CC=C2,,,,,0,,359.1845063,3,2,2,1,1,1
6493,04/06/2019 00:00,DB08312,"6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE",,,,,,solid,,,0.471,15.25,5.11,NC1=NC(N)=C(N=O)C(OCC2CCCCC2)=N1,,,,,0,,251.1382248,2,1,1,1,0,0
6494,04/06/2019 00:00,DB08313,nocodazole,,,,,,solid,,,0.0185,8.34,3.9,COC(=O)NC1=NC2=CC=C(C=C2N1)C(=O)C1=CC=CS1,,,,,0,,301.0521122,3,3,2,2,0,0
6495,04/06/2019 00:00,DB08314,"(2-AMINO-1,3-OXAZOL-5-YL)-(3-BROMOPHENYL)METHANONE",,,,,,solid,,,0.303,13.58,1.32,NC1=NC=C(O1)C(=O)C1=CC(Br)=CC=C1,,,,,0,,265.9690896,2,2,1,1,0,0
6496,04/06/2019 00:00,DB08315,"2-AMINO-N,N-BIS(PHENYLMETHYL)-1,3-OXAZOLE-5-CARBOXAMIDE",,,,,,solid,,,0.0717,13.6,1.22,NC1=NC=C(O1)C(=O)N(CC1=CC=CC=C1)CC1=CC=CC=C1,,,,,0,,307.1320768,3,3,1,1,0,0
6497,04/06/2019 00:00,DB08316,"4-amino-7,7-dimethyl-7,8-dihydroquinazolin-5(6H)-one",,,,,,solid,,,4.4,16.65,3.87,CC1(C)CC(=O)C2=C(N)N=CN=C2C1,,,,,0,,191.105862,2,1,1,1,0,0
6498,04/06/2019 00:00,DB08317,"5-methyl-6-phenylquinazoline-2,4-diamine",,,,,,solid,,,0.0455,17.01,7.54,CC1=C(C=CC2=NC(N)=NC(N)=C12)C1=CC=CC=C1,,,,,0,,250.1218464,3,3,1,1,0,0
6499,04/06/2019 00:00,DB08318,"6-(2-phenoxyethoxy)-1,3,5-triazine-2,4-diamine",,,,,,solid,,,3.86,15.21,5.3,NC1=NC(OCCOC2=CC=CC=C2)=NC(N)=N1,,,,,0,,247.1069247,2,2,1,1,0,0
6500,04/06/2019 00:00,DB08319,"2'-HYDROXY-1,1'-BIPHENYL-2-SULFINIC ACID",,,,,,solid,,,3.02,0.88,-5.6,OC1=CC=CC=C1C1=CC=CC=C1[S@@](O)=O,,,,,0,,234.0350652,2,2,0,0,0,0
6501,04/06/2019 00:00,DB08320,"DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE",,,,,,solid,,,0.0165,9,-4.2,[H][C@]12O[C@]([H])(C(=C1C1=CC=C(O)C=C1)C1=CC=C(O)C=C1)[C@]([H])(C(=O)OCC)[C@]2([H])C(=O)OCC,,,,,0,,424.1522031,4,2,2,0,1,2
6502,04/06/2019 00:00,DB08321,"(1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol",,,,,,solid,,,11.3,12.83,8.47,[H][C@@]1(O)C(CO)=C[C@@]([H])(NCCCCCCCC)[C@]([H])(O)[C@@]1([H])O,,,,,0,,287.2096584,1,0,0,0,0,0
6503,04/06/2019 00:00,DB08322,"2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID",,,,,,solid,,,0.0287,3.17,-6,[H][C@@](CC(O)=O)(OC(=O)\C=C\C1=CC=C(O)C=C1)[C@@]([H])(OC(=O)\C=C\C1=CC=C(O)C=C1)C(O)=O,,,,,0,,456.1056468,2,2,0,0,0,0
6504,04/06/2019 00:00,DB08323,3-OXO-N-[(3S)-2-OXOPYRROLIDIN-3-YL]DODECANAMIDE,,,,,,solid,,,0.0621,10.31,-3.7,[H][C@@]1(CCNC1=O)NC(=O)CC(=O)CCCCCCCCC,,,,,0,,296.2099928,1,0,1,0,1,1
6505,04/06/2019 00:00,DB08324,N-3-OXO-DODECANOYL-L-HOMOSERINE LACTONE,,,,,,solid,,,0.0475,10.31,-3.9,[H][C@@]1(CCOC1=O)NC(=O)CC(=O)CCCCCCCCC,,,,,0,,297.1940083,1,0,1,0,1,1
6506,04/06/2019 00:00,DB08325,2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9-ISOPROPYLPURINE,,,,,,solid,,,0.307,10.32,6.11,CC(C)N1C=NC2=C1NC(NCCO)=N\C2=N/C1=CC=CC(Cl)=C1,,,,,0,,346.1308869,3,3,2,2,0,0
6507,04/06/2019 00:00,DB08326,"2-(6-HYDROXY-1,3-BENZOTHIAZOL-2-YL)-1,3-THIAZOL-4(5H)-ONE",,,,,,solid,,,0.0913,9.22,1,OC1=CC2=C(C=C1)N=C(S2)C1=NC(=O)CS1,,,,,0,,249.9870694,3,2,2,1,0,1
6508,04/06/2019 00:00,DB08327,"2-(3,6-DIHYDROXYPHENYL)ACETIC ACID",,,,,,solid,,,8.1,3.57,-5.9,OC(=O)CC1=CC(O)=CC=C1O,,,,,0,,168.0422587,1,1,0,0,0,0
6509,04/06/2019 00:00,DB08328,PANTOTHENYL-AMINOETHANOL-11-PIVALIC ACID,,,,,,solid,,,3.01,12.68,-1.5,[H][C@](O)(C(=O)NCCC(=O)NCCO)C(C)(C)COC(=O)C(C)(C)C,,,,,0,,346.2103867,0,0,0,0,0,0
6510,04/06/2019 00:00,DB08329,Sulthiame,,,,,,solid,,,1.96,10.55,,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O,,,,,0,,290.0394989,2,1,1,0,1,1
6511,04/06/2019 00:00,DB08330,METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,,,,,solid,,,0.000931,,-4.8,CO\C=C(\C(=O)OC)C1=C(\C=C\C2=CC=CC=C2)C=CC=C1,,,,,0,,294.1255944,2,2,0,0,0,0
6512,04/06/2019 00:00,DB08331,"N-1H-imidazol-2-yl-N'-[4-(1H-imidazol-2-ylamino)phenyl]benzene-1,4-diamine",,,,,,solid,,,0.0135,12.89,7.9,N(C1=NC=CN1)C1=CC=C(NC2=CC=C(NC3=NC=CN3)C=C2)C=C1,,,,,0,,331.1545435,4,4,2,2,0,0
6513,04/06/2019 00:00,DB08332,9-(2-carboxyethyl)-10-methylanthracene endoperoxide,,,,,,solid,,,0.0144,4.12,-4.9,C[C@@]12OO[C@@](CCC(O)=O)(C3=C1C=CC=C3)C1=C2C=CC=C1,,,,,0,,296.104859,5,2,2,0,0,2
6514,04/06/2019 00:00,DB08333,4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME,,,,,,solid,,,0.0475,9,2.26,OC1=CC=C(\C=N\OC(=O)C2CCCCC2)C=C1,,,,,0,,247.1208434,2,1,0,0,0,0
6515,04/06/2019 00:00,DB08334,3-FLUORO-4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME,,,,,,solid,,,0.0476,7.97,1.57,OC1=CC=C(\C=N\OC(=O)C2CCCCC2)C=C1F,,,,,0,,265.1114216,2,1,0,0,0,0
6516,04/06/2019 00:00,DB08335,"4-HYDROXYBENZALDEHYDE O-(3,3-DIMETHYLBUTANOYL)OXIME",,,,,,solid,,,0.0506,9,2.32,CC(C)(C)CC(=O)O\N=C\C1=CC=C(O)C=C1,,,,,0,,235.1208434,1,1,0,0,0,0
6517,04/06/2019 00:00,DB08336,"2-Methyl-2-propanyl [(1R)-2-methyl-1-(1,3,4-oxadiazol-2-yl)propyl]carbamate",,,,,,solid,,,0.49,12.85,-2.4,[H]N(C(=O)OC(C)(C)C)[C@]([H])(C(C)C)C1=NN=CO1,,,,,0,,241.1426415,1,1,1,1,0,0
6518,04/06/2019 00:00,DB08337,"2-Methyl-2-propanyl [(1S)-2-methyl-1-(1,3,4-oxadiazol-2-yl)propyl]carbamate",,,,,,solid,,,0.49,3.57,0.8,[H]N(C(=O)OC(C)(C)C)[C@@]([H])(C(C)C)C1=NN=CO1,,,,,0,,241.1426415,1,1,1,1,0,0
6519,04/06/2019 00:00,DB08338,"19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one",,,,,,solid,,,0.0208,11.67,3.4,O=C1CCCCC2=C3N=C(NC4=CC(N1)=CC=C4)N=C(NC1CC1)N3N=C2,,,,,0,,363.1807583,5,3,3,2,0,1
6520,04/06/2019 00:00,DB08339,"6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE",,,,,,solid,,,0.0135,13.12,1.51,CN1C(=O)C(=CC2=CN=C(NC3=CC(CO)=CC=C3)N=C12)C1=C(Cl)C=CC=C1Cl,,,,,0,,426.0650311,4,4,2,2,0,0
6521,04/06/2019 00:00,DB08340,"N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE",,,,,,solid,,,0.0147,11.99,2.37,N(C1=CC=CC=C1)C1=NC2=CC=NN2C(NC2=CC=CC=C2)=N1,,,,,0,,302.1279944,4,4,2,2,0,0
6522,04/06/2019 00:00,DB08341,"4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide",,,,,,solid,,,0.0262,10.66,9.29,[H][C@]1(CCC[C@@]1([H])N(C)C)NC1=NC(NC2=CC=C(C=C2)S(=O)(=O)NC)=NC=C1C(F)(F)F,,,,,0,,458.1711797,3,2,1,1,0,0
6523,04/06/2019 00:00,DB08342,S-PALMITOYL-L-CYSTEINE,,,,,,solid,,,0.000385,2.05,8.28,[H][C@](N)(CSC(=O)CCCCCCCCCCCCCCC)C(O)=O,,,,,0,,359.249415,0,0,0,0,0,0
6524,04/06/2019 00:00,DB08344,4-chloro-N-(3-methoxypropyl)-N-[(3S)-1-(2-phenylethyl)piperidin-3-yl]benzamide,,,,,,solid,,,0.00589,,8.5,[H][C@@]1(CCCN(CCC2=CC=CC=C2)C1)N(CCCOC)C(=O)C1=CC=C(Cl)C=C1,,,,,0,,414.2074059,3,2,1,0,1,1
6525,04/06/2019 00:00,DB08345,"4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,,,,,solid,,,0.0591,11.85,7.29,N#CC1=C2N=C(NC3=CC=CC=C3)N=C(NCCC3=CN=CN3)N2N=C1,,,,,0,,345.1450415,4,4,3,3,0,0
6526,04/06/2019 00:00,DB08346,"(5Z)-13-CHLORO-14,16-DIHYDROXY-3,4,7,8,9,10-HEXAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,11(12H)-DIONE",,,,,,solid,,,0.144,7.03,-4.3,OC1=CC(O)=C2C(CC(=O)CCCC\C=C\CCOC2=O)=C1Cl,,,,,0,,338.0921014,2,1,1,0,0,1
6527,04/06/2019 00:00,DB08347,4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile,,,,,,solid,,,0.156,11.54,9.75,CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CC(=N2)C#N,,,,,0,,287.1633769,2,1,1,0,0,1
6528,04/06/2019 00:00,DB08348,"N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE",,,,,,solid,,,0.0834,11.07,7.16,CN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C1,,,,,0,,295.1320768,3,3,1,1,0,0
6529,04/06/2019 00:00,DB08349,"N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide",,,,,,solid,,,0.0128,13.38,-0.55,CN1C2=C(C=NN2C2=C(F)C=C(F)C=C2)C(NC2=C(C)C=CC(=C2)C(=O)NC2CC2)=CC1=O,,,,,0,,449.1663314,5,4,2,2,0,0
6530,04/06/2019 00:00,DB08350,"5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE",,,,,,solid,,,0.00841,14.58,3.84,COC1=CC=CC=C1C1=CNC2=C1C=C(C=N2)C1=CC(=CN=C1)C(=O)N(C)C,,,,,0,,372.1586259,4,4,3,3,0,0
6531,04/06/2019 00:00,DB08351,N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide,,,,,,solid,,,0.0146,15.1,6.41,CC1=CC=C(C=C1C1=CC2=C(C=C1)N=C(NCCN1CCOCC1)N=C2)C(=O)NC1CC1,,,,,0,,431.2321252,5,3,2,1,1,1
6532,04/06/2019 00:00,DB08352,"6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine",,,,,,solid,,,0.0164,15.34,2.99,CC(C)NC1=NC2=C(S1)C=C(C=C2)C1=C(N=CO1)C1=CC=CC=C1F,,,,,0,,353.0998114,4,4,2,2,0,0
6533,04/06/2019 00:00,DB08353,"2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,,,,,solid,,,0.024,14.03,1.73,N#CC1=C2N=C(NCC3CCCCC3)N=C(NC3=CC=CC=C3)N2N=C1,,,,,0,,347.1858437,4,3,2,2,0,0
6534,04/06/2019 00:00,DB08354,"2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,,,,,solid,,,0.0156,13.26,1.68,ClC1=CC=C(CNC2=NC3=C(C=NN3C(NC3=CC=CC=C3)=N2)C#N)C=C1,,,,,0,,375.0999211,4,4,2,2,0,0
6535,04/06/2019 00:00,DB08355,"1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid",,,,,,solid,,,0.244,3.19,2.18,CN1N=C(C(O)=O)C2=C1C1=NC(NC3=CC=CC=C3)=NC=C1CC2,,,,,0,,321.1225747,4,3,2,2,0,0
6536,04/06/2019 00:00,DB08356,"4-[4-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl]benzene-1,3-diol",,,,,,solid,,,0.127,8.42,2.06,COC1=CC=C(C=C1)C1=C(C)NN=C1C1=C(O)C=C(O)C=C1,,,,,0,,296.1160924,3,3,1,1,0,0
6537,04/06/2019 00:00,DB08357,1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE,,,,,,solid,,,11.4,,-3.7,CCOCCOCCOCC,,,,,0,,162.1255944,0,0,0,0,0,0
6538,04/06/2019 00:00,DB08358,"2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE",,,,,,solid,,,0.00792,11.95,4.27,O=C1NCCC2=C1C=C(N2)C1=CC(=NC=C1)C1=CC2=C(C=CC=C2)N=C1,,,,,0,,340.1324111,5,4,4,3,0,1
6539,04/06/2019 00:00,DB08359,2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE,,,,,,solid,,,0.0369,12.65,1.77,CC(=O)C1=C(C)N=C(NC2=CC=CC=C2)S1,,,,,0,,232.067034,2,2,1,1,0,0
6540,04/06/2019 00:00,DB08360,"2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,,,,,solid,,,0.159,15.46,7.6,CCN1CCN(CC1)C1=NC2=C(C=NN2C(NC2=CC=CC=C2)=N1)C#N,,,,,0,,348.1810926,4,3,3,2,1,1
6541,04/06/2019 00:00,DB08361,"2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide",,,,,,solid,,,0.041,13.32,9.91,[H][C@]1(N)CCCC[C@@]1([H])NC1=NC(NC2=CC=CC(C)=C2)=C(C=N1)C(N)=O,,,,,0,,340.2011594,3,2,1,1,0,0
6542,04/06/2019 00:00,DB08362,"N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE",,,,,,solid,,,0.035,11.45,0.62,CC(=O)NC1=CC=CC(NC2=NC3=C(C=NN3C(NC3=CC=CC=C3)=N2)C#N)=C1,,,,,0,,384.1447071,4,4,2,2,0,0
6543,04/06/2019 00:00,DB08363,1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine,,,,,,solid,,,0.0246,,9.7,CCN1C2=CC=C(CNC)C=C2C2=C1C=CC=C2,,,,,0,,238.1469986,3,3,1,1,0,0
6544,04/06/2019 00:00,DB08364,1-{[(1E)-(3-HYDROXY-2-METHYL-5-{[(TRIHYDROXY-LAMBDA^5^-PHOSPHANYL)OXY]METHYL}PYRIDIN-4-YL)METHYLIDENE]AMINO}UNDECAN-2-ONE,,,,,,solid,,,0.0144,8.4,5.57,CCCCCCCCCC(=O)C\N=C\C1=C(COP(O)(O)O)C=NC(C)=C1O,,,,,0,,416.2076234,1,1,1,1,0,0
6545,04/06/2019 00:00,DB08365,"8-bromo-4-(2-chlorophenyl)-N-(2-hydroxyethyl)-6-methyl-1,3-dioxo-1,2,3,6-tetrahydropyrrolo[3,4-e]indole-7-carboxamide",,,,,,solid,,,0.00731,8.01,-1.8,CN1C2=C(C(Br)=C1C(=O)NCCO)C1=C(C(=O)NC1=O)C(=C2)C1=C(Cl)C=CC=C1,,,,,0,,474.9934457,4,3,2,1,0,1
6546,04/06/2019 00:00,DB08366,"3-({3-[(1S,4aS,6S,7S,9S,9aR)-1,6-dimethyl-2-oxodecahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid",,,,,,solid,,,0.0144,2.96,-3.4,[H][C@]12C[C@]3([H])O[C@@]1(C)C[C@@]1(C2)CCC(=O)[C@@](C)(CCC(=O)NC2=C(O)C=CC(C(O)=O)=C2O)[C@]31[H],,,,,0,,443.1944023,6,1,2,0,2,2
6547,04/06/2019 00:00,DB08367,(R)-2-(FORMYLOXY)-3-(PHOSPHONOOXY)PROPYL PENTANOATE,,,,,,solid,,,5.58,1.32,-6.6,[H][C@@](COC(=O)CCCC)(COP(O)(O)=O)OC=O,,,,,0,,284.0661041,0,0,0,0,0,0
6548,04/06/2019 00:00,DB08368,"OCTANE-1,3,5,7-TETRACARBOXYLIC ACID",,,,,,solid,,,2.89,3.33,,[H][C@](C)(C[C@]([H])(C[C@@]([H])(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O,,,,,0,,290.1001675,0,0,0,0,0,0
6549,04/06/2019 00:00,DB08369,1-(biphenyl-4-ylmethyl)-1H-imidazole,,,,,,solid,,,0.0431,,6.75,C(N1C=CN=C1)C1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,234.1156984,3,3,1,1,0,0
6550,04/06/2019 00:00,DB08370,S-(4-BROMOBENZYL)CYSTEINE,,,,,,solid,,,0.0533,1.46,9.14,[H][C@](N)(CSCC1=CC=C(Br)C=C1)C(O)=O,,,,,0,,288.9772117,1,1,0,0,0,0
6551,04/06/2019 00:00,DB08371,PARA-(BENZOYL)-PHENYLALANINE,,,,,,solid,,,0.044,1.59,9.21,[H][C@](N)(CC1=CC=C(C=C1)C(=O)C1=CC=CC=C1)C(O)=O,,,,,0,,269.1051933,2,2,0,0,0,0
6552,04/06/2019 00:00,DB08372,1-[2-(4-ETHOXY-3-FLUOROPYRIDIN-2-YL)ETHYL]-3-(5-METHYLPYRIDIN-2-YL)THIOUREA,,,,,,solid,,,0.0042,10.93,3.86,CCOC1=C(F)C(CCNC(=S)NC2=CC=C(C)C=N2)=NC=C1,,,,,0,,334.1263604,2,2,2,2,0,0
6553,04/06/2019 00:00,DB08373,"4,4'-BIS([H]METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL",,,,,,solid,,,0.000466,19.3,,CS(=O)(=O)C1=CC(Cl)=C(C=C1Cl)C1=C(Cl)C=C(C(Cl)=C1)S(C)(=O)=O,,,,,0,,445.8774615,2,2,0,0,0,0
6554,04/06/2019 00:00,DB08374,Phenylalanylmethylchloride,,,,,,solid,,,0.606,15.48,7.66,[H][C@](N)(CC1=CC=CC=C1)C(=O)CCl,,,,,0,,197.0607417,1,1,0,0,0,0
6555,04/06/2019 00:00,DB08375,PCNOTAXIME Group,,,,,,solid,,,0.0999,3.27,6.85,[H][C@](C=O)(N=C(O)C(=N/OC)\C1=CSC(=N)N1)[C@@]1([H])SCC(=C)C(=N1)C(O)=O,,,,,0,,397.0514606,2,1,2,1,0,1
6556,04/06/2019 00:00,DB08376,"(2R)-3-(phosphonooxy)propane-1,2-diyl diheptanoate",,,,,,solid,,,0.2,1.32,-6.7,[H][C@@](COC(=O)CCCCCC)(COP(O)(O)=O)OC(=O)CCCCCC,,,,,0,,396.1913046,0,0,0,0,0,0
6557,04/06/2019 00:00,DB08377,N-[4-(4-nitrophenylphospho)butanoyl]-D-alanine,,,,,,solid,,,0.1,1.86,0.84,[H][C@](C)(N=C(O)CCCP(O)(=O)OC1=CC=C(C=C1)N(=O)=O)C(O)=O,,,,,0,,360.0722521,1,1,0,0,0,0
6558,04/06/2019 00:00,DB08378,"4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID",,,,,,solid,,,2.03,4.21,0.91,[H][C@](O)(CCC(O)=O)NC1=CC=C(C=C1)N1C(=O)CCC1=O,,,,,0,,292.1059216,2,1,1,0,1,1
6559,04/06/2019 00:00,DB08379,6-(4-chloro-2-fluoro-3-phenoxybenzyl)pyridazin-3(2H)-one,,,,,,solid,,,0.00289,10.39,-2.7,FC1=C(CC2=NNC(=O)C=C2)C=CC(Cl)=C1OC1=CC=CC=C1,,,,,0,,330.0571335,3,3,1,1,0,0
6560,04/06/2019 00:00,DB08382,Gosogliptin,,,,,,solid,,,1.33,,9.38,[H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCC(F)(F)C1)N1CCN(CC1)C1=NC=CC=N1,,,,,0,,366.1979658,4,1,4,1,3,3
6561,04/06/2019 00:00,DB08383,"4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazole",,,,,,solid,,,0.00102,11.4,4.33,COC1=CC=C(C=C1)C1=C(N=C(N1)C1=CC=CS1)C1=CC=C(OC)C=C1,,,,,0,,362.1088988,4,4,2,2,0,0
6562,04/06/2019 00:00,DB08384,2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline,,,,,,solid,,,0.00182,15.62,5.2,C(OC1=CC=C(C=C1)C1=NNC=C1CC1=CC=NC=C1)C1=NC2=CC=CC=C2C=C1,,,,,0,,392.1637113,5,5,3,3,0,0
6563,04/06/2019 00:00,DB08385,4-(quinolin-3-ylmethyl)piperidine-1-carboxylic acid,,,,,,solid,,,0.0886,4.06,4.92,OC(=O)N1CCC(CC2=CN=C3C=CC=CC3=C2)CC1,,,,,0,,270.1368278,3,2,2,1,1,1
6564,04/06/2019 00:00,DB08386,2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline,,,,,,solid,,,0.00258,14.98,4.32,C(OC1=CC=C(C=C1)C1=NNC=C1C1=CC=NC=C1)C1=CC=C2C=CC=CC2=N1,,,,,0,,378.1480612,5,5,3,3,0,0
6565,04/06/2019 00:00,DB08387,2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline,,,,,,solid,,,0.00149,,4.31,CN1C=C(C(=N1)C1=CC=C(OCC2=NC3=CC=CC=C3C=C2)C=C1)C1=CC=NC=C1,,,,,0,,392.1637113,5,5,3,3,0,0
6566,04/06/2019 00:00,DB08388,"5-(2-ETHOXYETHYL)-5-[4-(4-FLUOROPHENOXY)PHENOXY]PYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE",,,,,,solid,,,0.0061,7.59,-4.1,CCOCCC1(OC2=CC=C(OC3=CC=C(F)C=C3)C=C2)C(=O)NC(=O)NC1=O,,,,,0,,402.1227145,3,2,1,0,1,1
6567,04/06/2019 00:00,DB08389,"6,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINE",,,,,,solid,,,0.00789,,5.37,[H][C@]1(CCN(C1)C1=NC=NC2=CC(OC)=C(OC)C=C12)OC1=CC2=CC=CC=C2C=C1,,,,,0,,401.1739416,5,4,2,1,1,1
6568,04/06/2019 00:00,DB08390,"(6S)-6-CYCLOPENTYL-6-[2-(3-FLUORO-4-ISOPROPOXYPHENYL)ETHYL]-4-HYDROXY-5,6-DIHYDRO-2H-PYRAN-2-ONE",,,,,,solid,,,0.00406,7.02,-4.9,CC(C)OC1=CC=C(CC[C@]2(CC(O)=CC(=O)O2)C2CCCC2)C=C1F,,,,,0,,362.1893376,3,1,1,0,0,1
6569,04/06/2019 00:00,DB08391,"6,7-DIMETHOXY-4-[(3R)-3-(QUINOXALIN-2-YLOXY)PYRROLIDIN-1-YL]QUINAZOLINE",,,,,,solid,,,0.0608,,5.37,[H][C@]1(CCN(C1)C1=NC=NC2=CC(OC)=C(OC)C=C12)OC1=NC2=CC=CC=C2N=C1,,,,,0,,403.1644395,5,4,3,2,1,1
6570,04/06/2019 00:00,DB08392,"2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL",,,,,,solid,,,0.076,15.57,2.17,COC1=CC=C(C=C1)C1=C(C2=C(NCCO)N=CN=C2O1)C1=CC=C(OC)C=C1,,,,,0,,391.1532062,4,4,2,2,0,0
6571,04/06/2019 00:00,DB08393,"2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL",,,,,,solid,,,0.0619,15.57,2.17,OCCNC1=NC=NC2=C1C(=C(O2)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,331.1320768,4,4,2,2,0,0
6572,04/06/2019 00:00,DB08394,PARA-NITROPHENYLPHOSPHONOBUTANOYL-GLYCINE,,,,,,solid,,,0.174,1.81,-1.3,OC(=O)CNC(=O)CCC[P@](O)(=O)OC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,346.0566021,1,1,0,0,0,0
6573,04/06/2019 00:00,DB08395,2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE,,,,,,solid,,,0.0599,8.21,-1,CCOCN1OC(=O)C(=C1C1=CC=NC(OC2=CC=CC=C2O)=N1)C1=CC=C(F)C=C1,,,,,0,,423.1230489,4,4,2,2,0,0
6574,04/06/2019 00:00,DB08396,"4-{[(Z)-(5-OXO-2-PHENYL-1,3-OXAZOL-4(5H)-YLIDENE)METHYL]AMINO}BUTANOIC ACID",,,,,,solid,,,0.214,3.91,-0.61,OC(=O)CCCNC=C1N=C(OC1=O)C1=CC=CC=C1,,,,,0,,274.0953569,2,1,1,0,0,1
6575,04/06/2019 00:00,DB08397,6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID,,,,,,solid,,,0.294,0.49,,OC(=O)C1=CC2=C(C=C1)C=C(C=C2)C(F)(F)P(O)(O)=O,,,,,0,,302.0155665,2,2,0,0,0,0
6576,04/06/2019 00:00,DB08398,"2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine",,,,,,solid,,,0.416,,5.43,CN1C(N)=NC2=NC=C(C=C12)C1=CC=CC=C1,,,,,0,,224.1061964,3,3,2,2,0,0
6577,04/06/2019 00:00,DB08399,PICEATANNOL,,,,,,solid,,,0.097,8.41,-6.2,OC1=CC(\C=C\C2=CC=C(O)C(O)=C2)=CC(O)=C1,,,,,0,,244.0735589,2,2,0,0,0,0
6578,04/06/2019 00:00,DB08400,4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzyl)piperidine-1-carboxylic acid,,,,,,solid,,,0.0132,3.89,0.79,OC(=O)N1CCC(CC2=CC(OC3=NC=C(C=C3)C(F)(F)F)=CC=C2)CC1,,,,,0,,380.1347771,3,2,2,1,1,1
6579,04/06/2019 00:00,DB08401,(2E)-2-({(2S)-2-CARBOXY-2-[(PHENOXYACETYL)AMINO]ETHOXY}IMINO)PENTANEDIOIC ACID,,,,,,solid,,,0.0979,2.83,-2.1,[H][C@@](CO\N=C(/CCC(O)=O)C(O)=O)(NC(=O)COC1=CC=CC=C1)C(O)=O,,,,,0,,382.1012302,1,1,0,0,0,0
6580,04/06/2019 00:00,DB08402,"2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID",,,,,,solid,,,0.0128,3.27,-0.027,OC(=O)C1=C(NC(=O)C2=C(Cl)C=C(Cl)C=C2)C=CC(OC2=NC=CC=N2)=C1,,,,,0,,403.0126612,3,3,1,1,0,0
6581,04/06/2019 00:00,DB08403,METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID,,,,,,solid,,,0.0684,8.9,-0.71,[H][C@@](CC(C)C)(CC(=O)NO)C(=O)N[C@@]([H])(CC1=CC=CC=C1)C(=O)NC,,,,,0,,349.2001563,1,1,0,0,0,0
6582,04/06/2019 00:00,DB08404,"S-(2-{[N-(2-HYDROXY-4-{[HYDROXY(OXIDO)PHOSPHINO]OXY}-3,3-DIMETHYLBUTANOYL)-BETA-ALANYL]AMINO}ETHYL) HEXANETHIOATE",,,,,,solid,,,0.0686,2.18,-1.5,[H][C@](O)(C(=O)NCCC(=O)NCCSC(=O)CCCCC)C(C)(C)CO[P@]([H])(O)=O,,,,,0,,440.174609,0,0,0,0,0,0
6583,04/06/2019 00:00,DB08405,"S-(2-{[N-(2-HYDROXY-4-{[HYDROXY(OXIDO)PHOSPHINO]OXY}-3,3-DIMETHYLBUTANOYL)-BETA-ALANYL]AMINO}ETHYL) HEPTANETHIOATE",,,,,,solid,,,0.0584,2.18,-1.5,[H][C@](O)(C(=O)NCCC(=O)NCCSC(=O)CCCCCC)C(C)(C)CO[P@]([H])(O)=O,,,,,0,,454.1902591,0,0,0,0,0,0
6584,04/06/2019 00:00,DB08406,"[N-(2,4-DIAMINOPTERIDIN-6-YL)-METHYL]-DIBENZ[B,F]AZEPINE",,,,,,solid,,,0.0579,15.87,3,NC1=NC2=C(N=C(CN3C4=CC=CC=C4C=CC4=CC=CC=C34)C=N2)C(N)=N1,,,,,0,,367.1545435,5,4,3,2,0,1
6585,04/06/2019 00:00,DB08407,PLATENSIMYCIN,,,,,,solid,,,0.0139,2.96,-3.4,[H][C@]12C[C@]3([H])O[C@@]1(C)C[C@@]1(C2)C=CC(=O)[C@@](C)(CCC(=O)NC2=C(O)C(=CC=C2O)C(O)=O)[C@]31[H],,,,,0,,441.1787522,6,1,2,0,2,2
6586,04/06/2019 00:00,DB08408,"(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl 2,2-dimethylpropanoate",,,,,,solid,,,0.0754,10.07,-1.5,[H][C@](O)(C(=O)NCCC(=O)NCCS)C(C)(C)COC(=O)C(C)(C)C,,,,,0,,362.1875431,0,0,0,0,0,0
6587,04/06/2019 00:00,DB08409,4-NITRO-BENZYLPHOSPHONOBUTANOYL-GLYCINE,,,,,,solid,,,0.145,1.89,-1.3,OC(=O)CNC(=O)CCC[P@@](O)(=O)OCC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,360.0722521,1,1,0,0,0,0
6588,04/06/2019 00:00,DB08410,PARA-NITROBENZYL GLUTARYL GLYCINIC ACID,,,,,,solid,,,0.0818,3.65,-0.7,OC(=O)CNC(=O)CCCC(=O)NCC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,323.1117353,1,1,0,0,0,0
6589,04/06/2019 00:00,DB08411,N-[4-(4-nitrophenylphospho)butanoyl]-L-alanine,,,,,,solid,,,0.108,1.81,-1.1,[H][C@@](C)(NC(=O)CCC[P@](O)(=O)OC1=CC=C(C=C1)[N+]([O-])=O)C(O)=O,,,,,0,,360.0722521,1,1,0,0,0,0
6590,04/06/2019 00:00,DB08412,6-{4-[HYDROXY-(4-NITRO-PHENOXY)-PHOSPHORYL]-BUTYRYLAMINO}-HEXANOIC ACID,,,,,,solid,,,0.018,1.82,-0.27,OC(=O)CCCCCNC(=O)CCC[P@](O)(=O)OC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,402.1192023,1,1,0,0,0,0
6591,04/06/2019 00:00,DB08413,METHYL-PHOSPHONIC ACID MONO-(4-NITRO-PHENYL) ESTER,,,,,,solid,,,1.69,1.87,,C[P@](O)(=O)OC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,217.014009,1,1,0,0,0,0
6592,04/06/2019 00:00,DB08414,"6-CHLORO-2-(1-FURO[2,3-C]PYRIDIN-5-YL-ETHYLSULFANYL)-PYRIMIDIN-4-YLAMINE",,,,,,solid,,,0.0889,,3.63,[H][C@@](C)(SC1=NC(N)=CC(Cl)=N1)C1=NC=C2OC=CC2=C1,,,,,0,,306.0342097,3,3,3,3,0,0
6593,04/06/2019 00:00,DB08416,"(9BETA,13ALPHA,14BETA,17ALPHA)-2-METHOXYESTRA-1,3,5(10)-TRIENE-3,17-DIYL DISULFAMATE",,,,,,solid,,,0.0173,10.34,-4.8,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=C(C=C(OC)C(OS(N)(=O)=O)=C4)[C@@]3([H])CC[C@]12C)OS(N)(=O)=O,,,,,0,,460.1337932,4,1,0,0,0,0
6594,04/06/2019 00:00,DB08418,"(4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinolin-8-yl sulfamate",,,,,,solid,,,0.0287,10.85,4.81,[H][C@]12CC[C@]3(C)C(=O)N(CC4=CC=CN=C4)C(=O)C[C@@]3([H])[C@]1([H])CCC1=C2C=CC(OS(N)(=O)=O)=C1,,,,,0,,469.167142,5,2,2,1,1,1
6595,04/06/2019 00:00,DB08419,(1S)-1-(PHENOXYMETHYL)PROPYL METHYLPHOSPHONOCHLORIDOATE,,,,,,solid,,,0.822,,-4.9,[H][C@](CC)(COC1=CC=CC=C1)O[P@](C)(Cl)=O,,,,,0,,262.0525587,1,1,0,0,0,0
6596,04/06/2019 00:00,DB08420,1-{[1-(2-AMINO-3-PHENYL-PROPIONYL)-PYRROLIDINE-2-CARBONYL]-AMINO}-2-(3-CYANO-PHENYL)-ETHANEBORONIC ACID,,,,,,solid,,,0.0391,12.55,7.7,[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)N[C@@]([H])(CC1=CC(=CC=C1)C#N)B(O)O,,,,,0,,434.2125357,3,2,1,0,1,1
6597,04/06/2019 00:00,DB08421,PIPERIDINE-2-CARBOXYLIC ACID TERT-BUTYLAMIDE,,,,,,solid,,,7.41,15.86,8.88,[H][C@]1(CCCCN1)C(=O)NC(C)(C)C,,,,,0,,184.1575633,1,0,1,0,1,1
6598,04/06/2019 00:00,DB08422,[PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE,,,,,,solid,,,0.172,15.29,8.86,[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCCNC1=CC=NC=C1,,,,,0,,381.2164751,3,2,2,1,1,1
6599,04/06/2019 00:00,DB08423,[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE,,,,,,solid,,,0.0121,,9.72,NC1=C(C=NN1C1=CC=C(F)C=C1)C(=O)C1=CC(OC2CCNCC2)=CC=C1,,,,,0,,380.1648541,4,3,2,1,1,1
6600,04/06/2019 00:00,DB08424,"[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE",,,,,,solid,,,0.099,13.62,2.18,[H][C@](O)(CO)COC1=CC(=CC=C1)C(=O)C1=C(N)N(N=C1)C1=CC=C(F)C=C1,,,,,0,,371.1281343,3,3,1,1,0,0
6601,04/06/2019 00:00,DB08426,"THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [2-OXO-1-(1H-PYRROLO[2,3-C]PYRIDIN-2-YLMETHYL)-PYRROLIDIN-3-YL]-AMIDE",,,,,,solid,,,0.0457,8.63,5.5,[H][C@@]1(CCN(CC2=CC3=C(N2)C=NC=C3)C1=O)NS(=O)(=O)C1=CC2=C(S1)C=CC=N2,,,,,0,,427.0772814,5,4,5,4,1,1
6602,04/06/2019 00:00,DB08427,PREPHENIC ACID,,,,,,solid,,,36,2.89,-2.1,[H][C@]1(O)C=C[C@](CC(=O)C(O)=O)(C=C1)C(O)=O,,,,,0,,226.047738,1,0,0,0,0,0
6603,04/06/2019 00:00,DB08428,3(S)-AMINO-4-PHENYL-BUTAN-2(S)-OL,,,,,,solid,,,7.43,14.92,9.47,[H][C@@](C)(O)[C@@]([H])(N)CC1=CC=CC=C1,,,,,0,,165.1153641,1,1,0,0,0,0
6604,04/06/2019 00:00,DB08429,N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide,,,,,,solid,,,0.0105,14.03,8.92,[H][C@](N)(CC(=O)N1CCC[C@@]1([H])CNC(=O)C1=CC=CC(=C1)S(C)(=O)=O)CC1=CC(Cl)=CC=C1,,,,,0,,477.1489051,3,2,1,0,1,1
6605,04/06/2019 00:00,DB08430,PARA-NITROPHENYL 1-THIO-BETA-D-GLUCOPYRANOSIDE,,,,,,solid,,,13,12.46,-3,[H][C@]1(CO)O[C@@]([H])(SC2=CC=C(C=C2)[N+]([O-])=O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,317.0569228,2,1,1,0,1,1
6606,04/06/2019 00:00,DB08431,"[(3R,4S)-4-HYDROXY-3-METHYL-2-OXOHEXYL]PHOSPHONIC ACID",,,,,,solid,,,40.5,2.09,-2.9,[H][C@](C)(C(=O)C[P@]([H])(O)=O)[C@@]([H])(O)CC,,,,,0,,194.0707956,0,0,0,0,0,0
6607,04/06/2019 00:00,DB08432,THYMIDINE-5'-THIOPHOSPHATE,,,,,,solid,,,3.01,1.82,-3.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(O)=S)N1C=C(C)C(=O)NC1=O,,,,,0,,338.0337585,2,1,2,1,1,1
6608,04/06/2019 00:00,DB08433,phenyl ethenesulfonate,,,,,,solid,,,0.691,,-9.7,C=CS(=O)(=O)OC1=CC=CC=C1,,,,,0,,184.0194151,1,1,0,0,0,0
6609,04/06/2019 00:00,DB08434,2-METHYLCARBAMOYL-3-(4-PHOSPHONOOXY-PHENYL)-CYCLOPROPANECARBOXYLIC ACID,,,,,,solid,,,0.89,1.78,-1.6,[H][C@]1(C(O)=O)[C@]([H])(C(=O)NC)[C@]1([H])C1=CC=C(OP(O)(O)=O)C=C1,,,,,0,,315.0507884,2,1,0,0,0,0
6610,04/06/2019 00:00,DB08435,"(5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid",,,,,,solid,,,0.003,4.66,-5,[H][C@]1(C\C=C\CCCC(O)=O)C=CC(=O)\C1=C/C=C/CCCCC,,,,,0,,316.2038448,1,0,0,0,0,0
6611,04/06/2019 00:00,DB08436,"8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-",,,,,,solid,,,0.204,18.6,5.07,CCCCN1C(CC2=CC3=C(OCO3)C=C2)=NC2=C(N)N=CN=C12,,,,,0,,325.1538748,4,3,3,2,0,1
6612,04/06/2019 00:00,DB08437,Puromycin,,,,,,solid,50mg/ml,,1.01,12.35,8.03,[H][C@](N)(CC1=CC=C(OC)C=C1)C(=O)N[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(N2C=NC3=C(N=CN=C23)N(C)C)[C@]1([H])O,,,,,0,,471.223017,4,3,3,2,1,1
6613,04/06/2019 00:00,DB08438,"(2E,4R,5S)-2,3,4,5-TETRAHYDROXY-6-(PALMITOYLOXY)HEX-2-ENOIC ACID",,,,,,solid,,,0.0118,3.03,-3.6,[H][C@](O)(COC(=O)CCCCCCCCCCCCCCC)[C@@]([H])(O)C(\O)=C(\O)C(O)=O,,,,,0,,432.2723182,0,0,0,0,0,0
6614,04/06/2019 00:00,DB08439,Parecoxib,,0.98,22 minutes (parecoxib); 8 hours (valdecoxib),40 mg,Intramuscular; Intravenous,solid,,,0.0162,4.24,0.42,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1,0.98,0.98,,,0,,370.0987281,3,3,1,1,0,0
6615,04/06/2019 00:00,DB08440,"N-1,10-phenanthrolin-5-ylacetamide",,,,,,solid,,,0.063,13.53,4.64,CC(=O)NC1=C2C=CC=NC2=C2N=CC=CC2=C1,,,,,0,,237.090212,3,3,2,2,0,0
6616,04/06/2019 00:00,DB08441,"6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE",,,,,,solid,,,0.0773,10.18,5.09,BrC1=C2NCCCNS(=O)(=O)C3=CC=CC(NC(N=C1)=N2)=C3,,,,,0,,383.0051578,3,2,2,1,0,1
6617,04/06/2019 00:00,DB08442,"4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol",,,,,,solid,,,0.0769,8.02,-0.88,[H][C@@]1(CCCN1C(=O)C1=C(O)C=C(O)C=C1)C1=CC=CC=C1C,,,,,0,,297.1364935,3,2,1,0,1,1
6618,04/06/2019 00:00,DB08443,"2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol",,,,,,solid,,,3.24,7.66,-3.5,OC1=CC(O)=C(C(=O)N2C=CC=C2)C(O)=C1,,,,,0,,219.0531578,2,2,1,1,0,0
6619,04/06/2019 00:00,DB08444,"3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile",,,,,,solid,,,0.00666,10.27,1.91,CC1=CC(=CC(OC2=C(Br)C=C(CC3=NNC4=NN=CC=C34)C=C2)=C1)C#N,,,,,0,,419.0381722,4,4,2,2,0,0
6620,04/06/2019 00:00,DB08445,"(3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE",,,,,,solid,,,0.0815,,9.44,[H][C@]1(N)CN(C[C@]1([H])C1=C(F)C=C(F)C(F)=C1)C1=CC(=NC=N1)C1=CC=C(OC)N=C1,,,,,0,,401.1463449,4,3,3,2,1,1
6621,04/06/2019 00:00,DB08446,"3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile",,,,,,solid,,,0.0039,10.21,1.89,FC1=C(CC2=NNC3=NN=CC=C23)C=CC(Br)=C1OC1=CC(=CC(Cl)=C1)C#N,,,,,0,,456.9741279,4,4,2,2,0,0
6622,04/06/2019 00:00,DB08447,3-{3-[(DIMETHYLAMINO)METHYL]-1H-INDOL-7-YL}PROPAN-1-OL,,,,,,solid,,,0.879,15.78,9.33,CN(C)CC1=CNC2=C1C=CC=C2CCCO,,,,,0,,232.1575633,2,2,1,1,0,0
6623,04/06/2019 00:00,DB08448,"(4aS)-5-[(2,4-diaminopteridin-6-yl)methyl]-4a,5-dihydro-2H-dibenzo[b,f]azepin-8-ol",,,,,,solid,,,0.188,10.16,3,[H][C@]12C=CCC=C1C=CC1=CC(O)=CC=C1N2CC1=NC2=C(N)N=C(N)N=C2N=C1,,,,,0,,385.1651082,5,3,3,2,0,1
6624,04/06/2019 00:00,DB08449,"2-(3-((4,5,7-trifluorobenzo[d]thiazol-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)acetic acid",,,,,,solid,,,0.0173,3.66,4.37,OC(=O)CN1C=C(CC2=NC3=C(S2)C(F)=CC(F)=C3F)C2=CC=CN=C12,,,,,0,,377.0445822,4,4,3,3,0,0
6625,04/06/2019 00:00,DB08450,N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine,,,,,,solid,,,0.0069,14.1,2.94,CC1=CC=CC(=N1)C1=NC(NC2=CC=C3NN=CC3=C2)=C2C=CC=CC2=N1,,,,,0,,352.1436445,5,5,3,3,0,0
6626,04/06/2019 00:00,DB08451,N-(QUINOLIN-8-YL)METHANESULFONAMIDE,,,,,,solid,,,0.475,7.25,3.7,CS(=O)(=O)NC1=CC=CC2=C1N=CC=C2,,,,,0,,222.0462986,2,2,1,1,0,0
6627,04/06/2019 00:00,DB08453,2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,,,,,solid,,,0.00189,7.88,1.22,CCCCCCCCCC1=[N+]([O-])C2=CC=CC=C2C(O)=C1,,,,,0,,287.188529,2,2,1,1,0,0
6628,04/06/2019 00:00,DB08454,N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE,,,,,,solid,,,0.0157,11.96,4,CC1=CC(NC2=C3C=CC=CC3=NC(=N2)C2=CC=CC=C2)=NN1,,,,,0,,301.1327455,4,4,2,2,0,0
6629,04/06/2019 00:00,DB08455,Ro 12-7310,,,,,,solid,,,0.00119,5.01,-5.9,[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(\C)/C(/[H])=C(\[H])C1=C(C)C=C(O)C(C)=C1C,,,,,0,,312.1725446,1,1,0,0,0,0
6630,04/06/2019 00:00,DB08456,"S-[(1-Hydroxy-2,2,5,5-tetramethyl-4-phenyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate",,,,,,solid,,,0.0624,14.76,0.44,CC1(C)N(O)C(C)(C)C(=C1CSS(C)(=O)=O)C1=CC=CC=C1,,,,,0,,341.1119356,2,1,1,0,0,1
6631,04/06/2019 00:00,DB08457,"4-(3,5-DIMETHYLPHENOXY)-5-(FURAN-2-YLMETHYLSULFANYLMETHYL)-3-IODO-6-METHYLPYRIDIN-2(1H)-ONE",,,,,,solid,,,0.0174,9.97,-3.3,CC1=C(CSCC2=CC=CO2)C(OC2=CC(C)=CC(C)=C2)=C(I)C(=O)N1,,,,,0,,481.0208625,3,3,2,2,0,0
6632,04/06/2019 00:00,DB08458,(4-BROMOPHENYL)[4-({(2E)-4-[CYCLOPROPYL(METHYL)AMINO]BUT-2-ENYL}OXY)PHENYL]METHANONE,,,,,,solid,,,0.000896,,8.98,CN(C\C=C\COC1=CC=C(C=C1)C(=O)C1=CC=C(Br)C=C1)C1CC1,,,,,0,,399.083391,3,2,0,0,0,0
6633,04/06/2019 00:00,DB08459,"3-chloro-5-[2-chloro-5-(1H-pyrazolo[3,4-b]pyridin-3-ylmethoxy)phenoxy]benzonitrile",,,,,,solid,,,0.00527,10.67,2.86,ClC1=CC(OC2=C(Cl)C=CC(OCC3=NNC4=NC=CC=C34)=C2)=CC(=C1)C#N,,,,,0,,410.033731,4,4,2,2,0,0
6634,04/06/2019 00:00,DB08460,"3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridin-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile",,,,,,solid,,,0.00691,10.52,4.61,NC1=CC=C2C(COC3=CC(OC4=CC(=CC(Cl)=C4)C#N)=C(Cl)C=C3)=NNC2=N1,,,,,0,,425.04463,4,4,2,2,0,0
6635,04/06/2019 00:00,DB08461,"3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL",,,,,,solid,,,0.217,9.98,6.39,CC(C)(C)N1N=C(CC2=CC(O)=CC=C2)C2=C1N=CN=C2N,,,,,0,,297.1589602,3,3,2,2,0,0
6636,04/06/2019 00:00,DB08462,N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE,,,,,,solid,,,0.0199,14.44,3.97,C=CC(=O)NC1=CC=C2N=CN=C(NC3=CC=CC=C3)C2=C1,,,,,0,,290.1167611,3,3,1,1,0,0
6637,04/06/2019 00:00,DB08463,(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol,,,,,,solid,,,0.0177,14.34,5.58,[H][C@@](CC)(CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=C(C=C2)C2=CC=CC=N2)=N1,,,,,0,,431.2433585,4,4,3,3,0,0
6638,04/06/2019 00:00,DB08464,"METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE",,,,,,solid,,,0.0399,7.04,-4.1,COC(=O)C1=C(CCC(=O)NC2=C(O)C=C(OC)C(O)=C2)C(Cl)=C(O)C=C1O,,,,,0,,411.0720942,2,2,0,0,0,0
6639,04/06/2019 00:00,DB08465,"2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE",,,,,,solid,,,0.0412,7.08,4.35,COC1=CC(N)=C(OC)C(CCOC(=O)C2=C(O)C=C(O)C(Cl)=C2)=C1OC,,,,,0,,397.0928297,2,2,0,0,0,0
6640,04/06/2019 00:00,DB08466,"5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol",,,,,,solid,,,0.0812,9.3,-5.4,OC1=CC=C(CCC2=CC(O)=CC(O)=C2)C=C1,,,,,0,,230.0942943,2,2,0,0,0,0
6641,04/06/2019 00:00,DB08467,"6-(2,3,4,5,6,7-HEXAHYDRO-2,4,4-TRIMETHYL-1-METYLENEINDEN-2-YL)-3-METHYLHEXA-2,4-DIENOIC ACID",,,,,,solid,,,0.00892,4.78,,O=C(O)\C=C(/C)\C=C\C[C@]1(C)CC2=C(CCCC2(C)C)C1=C,,,,,0,,300.2089301,2,0,0,0,0,0
6642,04/06/2019 00:00,DB08469,"tert-butyl 4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate",,,,,,solid,,,0.0687,,-3.3,CC(C)(C)OC(=O)N1CCC(CC1)C1=NC(=NO1)C1=CC=CS1,,,,,0,,335.1303625,3,2,3,2,1,1
6643,04/06/2019 00:00,DB08470,"3-(4-fluorophenyl)-5-phenyl-4H-1,2,4-triazole",,,,,,solid,,,0.0992,9.48,2.25,FC1=CC=C(C=C1)C1=NN=C(N1)C1=CC=CC=C1,,,,,0,,239.0858755,3,3,1,1,0,0
6644,04/06/2019 00:00,DB08471,"1-(thiophen-2-ylacetyl)-4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine",,,,,,solid,,,0.0825,,-2,O=C(CC1=CC=CS1)N1CCC(CC1)C1=NC(=NO1)C1=CC=CS1,,,,,0,,359.0762188,4,3,4,3,1,1
6645,04/06/2019 00:00,DB08472,(R)-Fluoxetine,,,,,,solid,,,0.0017,,9.8,CNCC[C@@H](OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,,,,,0,,309.1340489,2,2,0,0,0,0
6646,04/06/2019 00:00,DB08473,"5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole",,,,,,solid,,,2.59,12.46,5.24,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=CC(Cl)=C(Cl)C=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,318.0174122,3,2,2,1,1,1
6647,04/06/2019 00:00,DB08474,3-(CARBOXYAMIDE(2-CARBOXYAMIDE-2-TERTBUTYLETHYL))PENTAN,,,,,,solid,,,0.236,16.05,0.64,[H][C@](CC(=O)NC(CC)CC)(C(N)=O)C(C)(C)C,,,,,0,,242.1994281,0,0,0,0,0,0
6648,04/06/2019 00:00,DB08475,"[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl hydrogen hex-5-enylphosphonate",,,,,,solid,,,9.5,1.36,-4.1,CC1(C)OC[C@@H](COP(O)(=O)CCCCC=C)O1,,,,,0,,278.1283105,1,0,1,0,1,1
6649,04/06/2019 00:00,DB08476,3-AMINO-AZACYCLOTRIDECAN-2-ONE,,,,,,solid,,,0.444,14.93,8.44,[H][C@]1(N)CCCCCCCCCCNC1=O,,,,,0,,212.1888634,1,0,1,0,1,1
6650,04/06/2019 00:00,DB08478,N-[2-chloro-5-(trifluoromethyl)phenyl]imidodicarbonimidic diamide,,,,,,solid,,,0.0246,,9.77,NC(=N)NC(=N)NC1=C(Cl)C=CC(=C1)C(F)(F)F,,,,,0,,279.0498576,1,1,0,0,0,0
6651,04/06/2019 00:00,DB08479,"N-(3,5-dimethoxyphenyl)imidodicarbonimidic diamide",,,,,,solid,,,0.137,,9.96,COC1=CC(OC)=CC(NC(=N)NC(N)=N)=C1,,,,,0,,237.1225747,1,1,0,0,0,0
6652,04/06/2019 00:00,DB08480,4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN,,,,,,solid,,,0.0827,9.68,6.39,[H][C@]1(CCC2=C1C=CC=C2O)\N=C\C=C,,,,,0,,187.099714,2,1,0,0,0,0
6653,04/06/2019 00:00,DB08481,"4-METHYL-N-{(5E)-5-[(5-METHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}BENZENESULFONAMIDE",,,,,,solid,,,0.0435,9.98,-2.7,CC1=CC=C(O1)\C=C1/SC(NS(=O)(=O)C2=CC=C(C)C=C2)=NC1=O,,,,,0,,362.0394989,3,2,2,1,0,1
6654,04/06/2019 00:00,DB08482,[[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER,,,,,,solid,,,0.302,8.9,-0.4,[H][C@@](C)(NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)CC(=O)NO)C(=O)OCC,,,,,0,,401.2525858,0,0,0,0,0,0
6655,04/06/2019 00:00,DB08484,4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE,,,,,,solid,,,0.356,4.35,2.11,NC1=CC=C(C=C1)S(=O)(=O)NC(=O)NCCS,,,,,0,,275.0398333,1,1,0,0,0,0
6656,04/06/2019 00:00,DB08485,"(1S,4S,5S)-1,4,5-TRIHYDROXY-3-[3-(PHENYLTHIO)PHENYL]CYCLOHEX-2-ENE-1-CARBOXYLIC ACID",,,,,,solid,,,0.0893,3.29,-3.2,[H][C@@]1(O)C[C@@](O)(C=C(C2=CC=CC(SC3=CC=CC=C3)=C2)[C@@]1([H])O)C(O)=O,,,,,0,,358.0874947,3,2,0,0,0,0
6657,04/06/2019 00:00,DB08486,Efaproxiral,,,,,,solid,,,0.0027,3.56,-4.7,CC1=CC(NC(=O)CC2=CC=C(OC(C)(C)C(O)=O)C=C2)=CC(C)=C1,,,,,0,,341.1627082,2,2,0,0,0,0
6658,04/06/2019 00:00,DB08487,3-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE,,,,,,solid,,,0.0106,17.01,11.41,NC(=N)C1=CC(CN2CCN(CC2=O)S(=O)(=O)C2=CC3=C(S2)C=C(Cl)C=C3)=CC=C1,,,,,0,,462.0587101,4,3,2,1,1,1
6659,04/06/2019 00:00,DB08488,"4-{[(E)-2-(5-CHLOROTHIEN-2-YL)VINYL]SULFONYL}-1-(1H-PYRROLO[3,2-C]PYRIDIN-2-YLMETHYL)PIPERAZIN-2-ONE",,,,,,solid,,,0.0267,13.9,8.33,ClC1=CC=C(S1)\C=C\S(=O)(=O)N1CCN(CC2=CC3=C(N2)C=CN=C3)C(=O)C1,,,,,0,,436.0430601,4,3,4,3,1,1
6660,04/06/2019 00:00,DB08489,"N4-HYDROXY-2-ISOBUTYL-N1-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YL)-SUCCINAMIDE",,,,,,solid,,,0.0139,8.9,-0.71,[H][C@@](CC(C)C)(CC(=O)NO)C(=O)N[C@@]1([H])CC2=CN(CCCCCCNC1=O)C1=C2C=CC=C1,,,,,0,,456.2736556,3,2,2,1,0,1
6661,04/06/2019 00:00,DB08490,CTS-1027,,,,,,solid,,,0.0115,8.82,-4.1,ONC(=O)C1(CS(=O)(=O)C2=CC=C(OC3=CC=C(Cl)C=C3)C=C2)CCOCC1,,,,,0,,425.069986,3,2,1,0,1,1
6662,04/06/2019 00:00,DB08491,N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE,,,,,,solid,,,0.041,8.89,-4.1,ONC(=O)CC1(CCOCC1)S(=O)(=O)C1=CC=C(OC2=CC=CC=C2)C=C1,,,,,0,,391.1089584,3,2,1,0,1,1
6663,04/06/2019 00:00,DB08492,(2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID,,,,,,solid,,,0.00187,4.07,,CCCCCCC#CC1=CC=CC=C1\C=C\C(O)=O,,,,,0,,256.1463299,1,1,0,0,0,0
6664,04/06/2019 00:00,DB08493,"5-METHYL-3-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YLCARBAMOYL)-HEXANOIC ACID",,,,,,solid,,,0.0113,4.44,-0.75,[H][C@@](CC(C)C)(CC(O)=O)C(=O)N[C@@]1([H])CC2=CN(CCCCCCNC1=O)C1=C2C=CC=C1,,,,,0,,441.2627566,3,2,2,1,0,1
6665,04/06/2019 00:00,DB08494,"S-{2-[(2-chloro-4-sulfamoylphenyl)amino]-2-oxoethyl} 6-methyl-3,4-dihydroquinoline-1(2H)-carbothioate",,,,,,solid,,,0.00693,9.6,-0.87,CC1=CC2=C(C=C1)N(CCC2)C(=O)SCC(=O)NC1=C(Cl)C=C(C=C1)S(N)(=O)=O,,,,,0,,453.0583758,3,2,1,0,0,1
6666,04/06/2019 00:00,DB08495,4-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE,,,,,,solid,,,0.0103,17.01,11.48,NC(=N)C1=CC=C(CN2CCN(CC2=O)S(=O)(=O)C2=CC3=C(S2)C=C(Cl)C=C3)C=C1,,,,,0,,462.0587101,4,3,2,1,1,1
6667,04/06/2019 00:00,DB08496,(R)-warfarin,,,,,,solid,,,0.0472,5.56,-6.9,[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,,,,,0,,308.104859,3,3,1,1,0,0
6668,04/06/2019 00:00,DB08497,"(1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate",,,,,,solid,,,0.0126,5.51,-7,[H][C@@](OC(C)=O)(C(=O)NC1=CC=CC2=C1C(=O)C(=O)NC2=O)C1=CC=CC=C1,,,,,0,,366.0851862,3,2,1,0,0,1
6669,04/06/2019 00:00,DB08498,"(1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate",,,,,,solid,,,0.0033,5.51,-7,[H][C@@](OC(C)=O)(C(=O)NC1=CC=CC2=C1C(=O)C(=O)NC2=O)C1=CC=CC(Cl)=C1,,,,,0,,400.0462138,3,2,1,0,0,1
6670,04/06/2019 00:00,DB08499,"N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide",,,,,,solid,,,0.0199,5.64,-4.1,FCCOC1=CC=CC(NC(=O)CCC(=O)NC2=CC=C3C(=O)NC(=O)C(=O)C3=C2)=C1,,,,,0,,427.1179635,3,2,1,0,0,1
6671,04/06/2019 00:00,DB08500,"(3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol",,,,,,solid,,,4.45,12.07,4.18,[H][C@]1(C[C@]2(ON1)O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C1=CC2=CC=CC=C2C=C1,,,,,0,,347.1368874,4,2,2,0,2,2
6672,04/06/2019 00:00,DB08501,"DIETHYL PROPANE-1,3-DIYLBISCARBAMATE",,,,,,solid,,,3.99,15.33,,CCOC(=O)NCCCNC(=O)OCC,,,,,0,,218.1266571,0,0,0,0,0,0
6673,04/06/2019 00:00,DB08502,Capravirine,,,,,,solid,,,0.00387,14.18,5.53,CC(C)C1=C(SC2=CC(Cl)=CC(Cl)=C2)N(CC2=CC=NC=C2)C(COC(N)=O)=N1,,,,,0,,450.0684022,3,3,2,2,0,0
6674,04/06/2019 00:00,DB08503,"(3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol",,,,,,solid,,,27.9,12.07,4.17,[H][C@]1(C[C@]2(ON1)O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C1=CC=C(C)C=C1,,,,,0,,311.1368874,3,1,2,0,2,2
6675,04/06/2019 00:00,DB08504,"6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM",,,,,,solid,,,0.109,18.09,6.94,[H][C@@](N)(C(=O)N1CC[C@]([H])(F)C1)[C@@]([H])(C(=O)N(C)C)C1=CC=C(C=C1)C1=CN2N=CN=C2C=C1,,,,,0,,424.2023023,4,3,3,2,1,1
6676,04/06/2019 00:00,DB08505,methyl 4-bromo-N-[8-(hydroxyamino)-8-oxooctanoyl]-L-phenylalaninate,,,,,,solid,,,0.00778,8.91,-0.78,[H][C@@](CC1=CC=C(Br)C=C1)(NC(=O)CCCCCCC(=O)NO)C(=O)OC,,,,,0,,428.094684,1,1,0,0,0,0
6677,04/06/2019 00:00,DB08506,N-{(2S)-3-[(1R)-1-aminoethyl](hydroxy)phosphoryl-2-benzylpropanoyl}-L-phenylalanine,,,,,,solid,,,0.0362,-0.037,9.56,[H][C@@](C)(N)[P@@](O)(=O)C[C@@]([H])(CC1=CC=CC=C1)C(=O)N[C@@]([H])(CC1=CC=CC=C1)C(O)=O,,,,,0,,418.1657586,2,2,0,0,0,0
6678,04/06/2019 00:00,DB08507,N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID,,,,,,solid,,,0.00715,8.72,4.55,[H][C@](CC(C)C)(N(CC1=CC=CC=C1)[P@](C)(=O)C1=CC=CC=C1)C(=O)NO,,,,,0,,374.1759294,2,2,0,0,0,0
6679,04/06/2019 00:00,DB08508,N-BENZOYL-D-ALANINE,,,,,,solid,,,2.07,3.66,-1.3,[H][C@](C)(NC(=O)C1=CC=CC=C1)C(O)=O,,,,,0,,193.0738932,1,1,0,0,0,0
6680,04/06/2019 00:00,DB08509,1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE,,,,,,solid,,,0.0166,,6.79,COC1=CC(Cl)=C(OCCCCCCN2C=CN=C2)C=C1,,,,,0,,308.1291556,2,2,1,1,0,0
6681,04/06/2019 00:00,DB08510,5-ALPHA-PREGNANE-3-BETA-OL-HEMISUCCINATE,,,,,,solid,,,0.00175,4.11,-6.9,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@]([H])(CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O)C(C)=O,,,,,0,,418.2719243,4,0,0,0,0,0
6682,04/06/2019 00:00,DB08511,"6-amino-2-methyl-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,,,,,solid,,,0.227,11.06,4.97,CC1=NC2=C(N1)C=C1C(=O)NC(N)=NC1=C2,,,,,0,,215.0807099,3,3,2,2,0,0
6683,04/06/2019 00:00,DB08512,"6-amino-2-[(1-naphthylmethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,,,,,solid,,,0.0119,11.13,4.84,NC1=NC2=CC3=C(C=C2C(=O)N1)N=C(NCC1=CC=CC2=CC=CC=C12)N3,,,,,0,,356.1385591,5,5,2,2,0,0
6684,04/06/2019 00:00,DB08513,[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID,,,,,,solid,,,0.0219,3.27,3.95,CC1=CC(NC2=NC(NC3=CC=C(CC(O)=O)C=C3)=NC=C2C(N)=O)=CC=C1,,,,,0,,377.1487895,3,3,1,1,0,0
6685,04/06/2019 00:00,DB08514,"6-amino-2-[(thiophen-2-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,,,,,solid,,,0.124,10.91,4.85,NC1=NC2=CC3=C(NC(NCC4=CC=CS4)=N3)C=C2C(=O)N1,,,,,0,,312.07933,4,4,3,3,0,0
6686,04/06/2019 00:00,DB08515,"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,,,,,solid,,,2.09,10.76,-2.1,[H][C@](O)([C@@]1([H])CCCC=C1)[C@]1(NC(=O)[C@]2([H])CCO[C@]12C)C=O,,,,,0,,279.1470582,3,0,2,0,2,2
6687,04/06/2019 00:00,DB08516,(S)-(+)-2-[4-(FLUOROBENZYLOXY-BENZYLAMINO)PROPIONAMIDE],,,,,,solid,,,0.00233,15.36,3.88,[H][C@@](C)(\N=C\C1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O,,,,,0,,300.127406,2,2,0,0,0,0
6688,04/06/2019 00:00,DB08517,"(2S)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydro-4H-chromen-4-one",,,,,,solid,,,0.0883,9.33,-3.9,[H][C@]1(CC(=O)C2=C(O1)C=C(OC)C=C2O)C1=CC=C(O)C=C1,,,,,0,,286.0841235,3,2,1,0,0,1
6689,04/06/2019 00:00,DB08519,"N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine",,,,,,solid,,,0.0184,13.16,5.15,COC1=CC(NC2=NC=CC(NC3=CC=C4C(C)=NNC4=C3)=N2)=CC(OC)=C1OC,,,,,0,,406.1753386,4,4,2,2,0,0
6690,04/06/2019 00:00,DB08520,"(21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE",,,,,,solid,,,0.00157,,-2.6,[H][C@@]12CCCCN1C(=O)C(=O)C(C)(C)COC(=O)CCCCCCCCCCCOC2=O,,,,,0,,437.277738,2,0,2,0,2,2
6691,04/06/2019 00:00,DB08521,4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE,,,,,,solid,,,0.0384,11.91,5.16,C[S@@](=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1,,,,,0,,377.0998114,4,4,2,2,0,0
6692,04/06/2019 00:00,DB08522,4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE,,,,,,solid,,,0.00743,,5.5,FC1=CC=C(C=C1)C1=C(N(CC2CC2)C=N1)C1=CC=NC=C1,,,,,0,,293.1328257,4,3,2,2,0,0
6693,04/06/2019 00:00,DB08523,[HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL,,,,,,solid,,,11.5,13.45,0.19,OCN(O)CCCC1=CC=CC=C1,,,,,0,,181.1102787,1,1,0,0,0,0
6694,04/06/2019 00:00,DB08524,2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE,,,,,,solid,,,0.0417,8.27,-4.9,ON(CCOC1=CC=CC(=C1)C(=O)C1=CC=CC=C1)C=O,,,,,0,,285.100108,2,2,0,0,0,0
6695,04/06/2019 00:00,DB08525,HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE,,,,,,solid,,,3.35,8.51,5.28,CC1=NC(CCCN(O)C=O)=CC=C1,,,,,0,,194.1055277,1,1,1,1,0,0
6696,04/06/2019 00:00,DB08526,CARBOBENZYLOXY-(L)-LEUCINYL-(L)LEUCINYL METHOXYMETHYLKETONE,,,,,,solid,,,0.0393,13.38,-2.8,[H][C@@](O)(COC)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)NC(=O)OCC1=CC=CC=C1,,,,,0,,408.2624223,1,1,0,0,0,0
6697,04/06/2019 00:00,DB08527,"1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE",,,,,,solid,,,0.261,10.67,0.9,NC(=O)C1=NN(C2=C1C=CC1=C2C=NN1)C1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,356.0691592,4,4,2,2,0,0
6698,04/06/2019 00:00,DB08528,"2-AMINO-6-(3,5-DIMETHYLPHENYL)SULFONYLBENZONITRILE",,,,,,solid,,,0.0297,18.65,0.96,CC1=CC(=CC(C)=C1)S(=O)(=O)C1=C(C#N)C(N)=CC=C1,,,,,0,,286.0775987,2,2,0,0,0,0
6699,04/06/2019 00:00,DB08529,"(6E,11E)-HEPTADECA-6,11-DIENE-9,9-DIYLBIS(PHOSPHONIC ACID)",,,,,,solid,,,1.57,1.15,,CCCCC\C=C\CC(C\C=C\CCCCC)(P(O)(O)=O)P(O)(O)=O,,,,,0,,396.1830621,0,0,0,0,0,0
6700,04/06/2019 00:00,DB08530,"7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE",,,,,,solid,,,1.06,,8.79,CN1C2=C(N(CC3=CC=CC=C3)C(=N2)N2CC[NH2+]CC2)C(=O)N(C)C1=O,,,,,1,,355.1877004,4,3,3,2,1,1
6701,04/06/2019 00:00,DB08531,"5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,,,,,solid,,,0.0034,,5.02,ClC1=CC=CC(=C1Cl)C1=NC2=CC=NN2C(NCC2=CC=NC=C2)=C1,,,,,0,,369.0548008,4,4,3,3,0,0
6702,04/06/2019 00:00,DB08532,"6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine",,,,,,solid,,,0.0178,15.74,4.89,FC1=CC=CC=C1C1=CN2C=CN=C2C(NCC2=CC=CN=C2)=N1,,,,,0,,319.1233237,4,4,3,3,0,0
6703,04/06/2019 00:00,DB08533,"3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine",,,,,,solid,,,0.0432,16.1,5.15,CC1=CN=C2N1C=CN=C2NCC1=CC=NC=C1,,,,,0,,239.1170954,3,3,3,3,0,0
6704,04/06/2019 00:00,DB08534,"5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,,,,,solid,,,0.0177,,5.02,FC1=CC=CC=C1C1=NC2=CC=NN2C(NCC2=CC=NC=C2)=C1,,,,,0,,319.1233237,4,4,3,3,0,0
6705,04/06/2019 00:00,DB08535,"3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,,,,,solid,,,0.00787,,4.82,BrC1=C2N=C(C=C(NCC3=CC=CN=C3)N2N=C1)C1=CC=CC=C1,,,,,0,,379.0432575,4,4,3,3,0,0
6706,04/06/2019 00:00,DB08536,"3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine",,,,,,solid,,,0.00577,,1.51,BrC1=C2C=C(C=C(NCC3=CN=CN=C3)N2N=C1)C1=CC=CC=C1,,,,,0,,379.0432575,4,4,3,3,0,0
6707,04/06/2019 00:00,DB08537,"3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine",,,,,,solid,,,0.00634,,5.81,BrC1=CN=C2N1C=C(C=C2NCC1=CN=CN=C1)C1=CC=CC=C1,,,,,0,,379.0432575,4,4,3,3,0,0
6708,04/06/2019 00:00,DB08538,"N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine",,,,,,solid,,,0.0218,16.58,3.27,CCC1=C2N=C(C=C(NCC3=CN=C(N)N=C3)N2N=C1)C1=C(F)C=CC=C1F,,,,,0,,381.15135,4,4,3,3,0,0
6709,04/06/2019 00:00,DB08539,"3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,,,,,solid,,,0.00794,,4.84,C(NC1=CC(=NC2=C(C=NN12)C1CC1)C1=CC=CC=C1)C1=CN=CC=C1,,,,,0,,341.1640456,5,4,3,3,0,0
6710,04/06/2019 00:00,DB08540,"2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER",,,,,,solid,,,0.118,,5.55,CCOC(=O)C1=CSC(=N1)N1CCN(CC1)C1=NC2=CC=CC=C2SC1,,,,,0,,388.1027679,4,2,3,1,1,2
6711,04/06/2019 00:00,DB08541,"[(3S)-9-hydroxy-1-methyl-10-oxo-4,10-dihydro-3H-benzo[g]isochromen-3-yl]acetic acid",,,,,,solid,,,0.13,3.73,-4.4,[H][C@@]1(CC(O)=O)CC2=CC3=C(C(O)=CC=C3)C(=O)C2=C(C)O1,,,,,0,,286.0841235,3,1,1,0,0,1
6712,04/06/2019 00:00,DB08542,"3,4-dihydroxy-9,10-secoandrosta-1(10),2,4-triene-9,17-dione",,,,,,solid,,,0.0306,9.44,-6.3,[H][C@@]12CCC(=O)[C@@]1(C)CCC(=O)[C@@]2([H])CCC1=C(O)C(O)=CC=C1C,,,,,0,,316.1674592,3,1,0,0,0,0
6713,04/06/2019 00:00,DB08543,1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE,,,,,,solid,,,0.19,14.08,7.25,[H][C@@](O)(COC1=CC=C(C=C1)C1CCCCC1)CN1CCN(CC1)C1=CC=CC=N1,,,,,0,,395.2572773,4,2,2,1,1,1
6714,04/06/2019 00:00,DB08544,(S)-Fluoxetine,,,,,,solid,,,0.0017,,9.8,CNCC[C@H](OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,,,,,0,,309.1340489,2,2,0,0,0,0
6715,04/06/2019 00:00,DB08545,(1R)-1-PHENYLETHYL 4-(ACETYLAMINO)BENZYLPHOSPHONATE,,,,,,solid,,,0.0199,1.96,1.09,[H][C@@](C)(OP(O)(=O)CC1=CC=C(C=C1)N=C(C)[O-])C1=CC=CC=C1,,,,,-1,,332.1057183,2,2,0,0,0,0
6716,04/06/2019 00:00,DB08546,"4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE",,,,,,solid,,,0.1,14.83,11.48,[H][C@]1(O)C[N@]2[C@@]([H])(C1)[C@]1([H])C(=O)N(CC3=CC=C4OCOC4=C3)C(=O)[C@]1([H])[C@]2([H])C1=CC=C(C=C1)C(N)=N,,,,,0,,448.1746699,6,2,4,0,3,4
6717,04/06/2019 00:00,DB08547,PROGESTERONE-11-ALPHA-OL-HEMISUCCINATE,,,,,,solid,,,0.0085,4.22,-4.8,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(C[C@]12C)OC(=O)CCC(O)=O)C(C)=O,,,,,0,,430.2355388,4,0,0,0,0,0
6718,04/06/2019 00:00,DB08548,"[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl hydrogen hex-5-enylphosphonate",,,,,,solid,,,9.5,1.36,-4.1,CC1(C)OC[C@H](COP(O)(=O)CCCCC=C)O1,,,,,0,,278.1283105,1,0,1,0,1,1
6719,04/06/2019 00:00,DB08549,"(3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER",,,,,,solid,,,0.0708,-1.4,-4.4,[H][C@]1(CC2=C(CN1C(=O)OCC1=CC=CC=C1)C=C(NS(O)(=O)=O)C=C2)C(=O)NC,,,,,0,,419.1151064,3,2,1,0,0,1
6720,04/06/2019 00:00,DB08550,"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline",,,,,,solid,,,0.139,,8.35,ClC1=CC=C2CCNCC2=C1Cl,,,,,0,,201.0112046,2,1,1,0,0,1
6721,04/06/2019 00:00,DB08551,3-{(R)-(Dihydroxyboryl)[(2-thienylacetyl)amino]methyl}benzoic acid,,,,,,solid,,,0.0297,4.03,-3,[H][C@@](NC(=O)CC1=CC=CS1)(B(O)O)C1=CC(=CC=C1)C(O)=O,,,,,0,,319.0685739,2,2,1,1,0,0
6722,04/06/2019 00:00,DB08552,(1R)-1-(2-thienylacetylamino)-1-phenylmethylboronic acid,,,,,,solid,,,0.0373,12.72,-3,[H][C@@](NC(=O)CC1=CC=CS1)(B(O)O)C1=CC=CC=C1,,,,,0,,275.0787447,2,2,1,1,0,0
6723,04/06/2019 00:00,DB08553,"(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime",,,,,,solid,,,0.0387,8.37,10.13,O\N=C1/CCC2=CC(=CC=C12)C1=CN(N=C1C1=CC=NC=C1)C1CCNCC1,,,,,0,,373.1902604,5,3,3,2,1,1
6724,04/06/2019 00:00,DB08554,N-(3-carboxypropanoyl)-L-norvaline,,,,,,solid,,,9.55,3.64,-1.5,[H][C@@](CCC)(NC(=O)CCC(O)=O)C(O)=O,,,,,0,,217.0950226,0,0,0,0,0,0
6725,04/06/2019 00:00,DB08555,"1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline",,,,,,solid,,,0.000539,,5.21,COC1=CC2=C(C=C1Cl)C(=NCC2)C1=CC=CC(Br)=C1,,,,,0,,348.9869038,3,2,1,0,0,1
6726,04/06/2019 00:00,DB08556,"5'-ACETYL-4-{[(2,4-DIMETHYLPHENYL)SULFONYL]AMINO}-2,2'-BITHIOPHENE-5-CARBOXYLIC ACID",,,,,,solid,,,0.0093,3.8,-7.8,CC(=O)C1=CC=C(S1)C1=CC(NS(=O)(=O)C2=CC=C(C)C=C2C)=C(S1)C(O)=O,,,,,0,,435.0268856,3,3,2,2,0,0
6727,04/06/2019 00:00,DB08557,"2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide",,,,,,solid,,,0.0136,15.32,2.28,COCCNC1=CC(=CC=C1C(N)=O)N1C2=C(C3=CC=CC=C13)C(=O)CCC2,,,,,0,,377.1739416,4,3,1,1,0,0
6728,04/06/2019 00:00,DB08558,"2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL",,,,,,solid,,,3.67,12.48,-3,[H][C@]1(CO)O[C@@]([H])(SCCCCCCCC)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,,,,,0,,308.165745,1,0,1,0,1,1
6729,04/06/2019 00:00,DB08559,"N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide",,,,,,solid,,,6.2,3.35,-2.6,[H][C@@]1(NC(=O)CC2=CC=CC=C2)C(=O)[N@]2[C@]1([H])[S@@]([H])(O)C(C)(C)[C@]2([H])C(O)=O,,,,,0,,352.1092927,3,1,2,0,2,2
6730,04/06/2019 00:00,DB08560,3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE,,,,,,solid,,,0.00728,6.31,1.42,FC1=CC=C(C=C1)N1N=C(C=C1NS(=O)(=O)C1=CC=CC(F)=C1)C1=CC=CS1,,,,,0,,417.0417251,4,4,2,2,0,0
6731,04/06/2019 00:00,DB08561,"BENZYL 6-BENZYL-5,7-DIOXO-6,7-DIHYDRO-5H-[1,3]THIAZOLO[3,2-C]PYRIMIDINE-2-CARBOXYLATE",,,,,,solid,,,0.0176,,-5.2,O=C(OCC1=CC=CC=C1)C1=CN2C(S1)=CC(=O)N(CC1=CC=CC=C1)C2=O,,,,,0,,392.083078,4,4,2,2,0,0
6732,04/06/2019 00:00,DB08562,4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID,,,,,,solid,,,0.00133,4.21,-3.8,OC(=O)CCCC(=O)NC1=CC=C(\C=C\C2=CC=CC=C2)C=C1,,,,,0,,309.1364935,2,2,0,0,0,0
6733,04/06/2019 00:00,DB08564,(2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide,,,,,,solid,,,0.0117,14.36,8.81,CN(C)C\C=C\C(=O)NC1=CC=C2N=CN=C(NC3=CC(Br)=CC=C3)C2=C1,,,,,0,,425.0851224,3,3,1,1,0,0
6734,04/06/2019 00:00,DB08565,L-1-naphthyl-2-acetamido-ethane boronic acid,,,,,,solid,,,0.0446,12.74,-1.2,[H]N([C@@H](CC1=CC=CC2=CC=CC=C12)[B-](O)(O)O)C(C)=O,,,,,-1,,274.125612,2,2,0,0,0,0
6735,04/06/2019 00:00,DB08566,D-1-naphthyl-2-acetamido-ethane boronic acid,,,,,,solid,,,0.0446,6.15,2.04,[H]N(C(C)=O)[C@]([H])(CC1=C2C=CC=CC2=CC=C1)[B-](O)(O)O,,,,,-1,,274.125612,2,2,0,0,0,0
6736,04/06/2019 00:00,DB08568,(2S)-1-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-PHENYLPROPAN-2-AMINE,,,,,,solid,,,0.00135,14.17,9.29,[H][C@@](N)(COC1=CC(=CN=C1)C1=CC=C2NN=C(C)C2=C1)CC1=CC=CC=C1,,,,,0,,358.1793613,4,4,2,2,0,0
6737,04/06/2019 00:00,DB08569,"3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE",,,,,,solid,,,0.00218,14.17,9.28,[H][C@@](N)(COC1=CN=CC(=C1)C1=CC2=C(NN=C2C)C=C1)CC1=CC=C(Br)C=C1,,,,,0,,436.0898734,4,4,2,2,0,0
6738,04/06/2019 00:00,DB08570,4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID,,,,,,solid,,,0.633,3.61,-4.7,CC(=O)NC1=C(O)C=C(C=C1[N+]([O-])=O)C(O)=O,,,,,0,,240.038236,1,1,0,0,0,0
6739,04/06/2019 00:00,DB08571,4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID,,,,,,solid,,,2.82,4.65,2.16,CC(=O)NC1=C(N)C=C(C=C1O)C(O)=O,,,,,0,,210.0640568,1,1,0,0,0,0
6740,04/06/2019 00:00,DB08572,4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE,,,,,,solid,,,0.0471,11.61,3.72,NC(=O)C1=CC=C(NC2=NC(OCC3CCCCC3)=C(N=O)C(N)=N2)C=C1,,,,,0,,370.1753386,3,2,1,1,0,0
6741,04/06/2019 00:00,DB08573,3-[(4-CHLOROANILINO)SULFONYL]THIOPHENE-2-CARBOXYLIC ACID,,,,,,solid,,,0.0199,3.06,,OC(=O)C1=C(C=CS1)S(=O)(=O)NC1=CC=C(Cl)C=C1,,,,,0,,316.9583274,2,2,1,1,0,0
6742,04/06/2019 00:00,DB08574,"(5R)-2-SULFANYL-5-[4-(TRIFLUOROMETHYL)BENZYL]-1,3-THIAZOL-4-ONE",,,,,,solid,,,0.0136,5.65,-5.1,[H][C@]1(CC2=CC=C(C=C2)C(F)(F)F)SC(S)=NC1=O,,,,,0,,290.9999405,2,1,1,0,0,1
6743,04/06/2019 00:00,DB08575,"2-[(1S)-1-BENZYL-2-SULFANYLETHYL]-1H-IMIDAZO[4,5-C]PYRIDIN-5-IUM",,,,,,solid,,,0.00135,10.07,5.64,[H][C@](CS)(CC1=CC=CC=C1)C1=NC2=C(N1)C=C[NH+]=C2,,,,,1,,270.1059449,3,3,2,2,0,0
6744,04/06/2019 00:00,DB08576,"1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-2-(METHYLAMINO)ETHANONE",,,,,,solid,,,1.14,14.72,7.35,CNCC(=O)C1=NN=C(O1)C(C)(C)C,,,,,0,,197.1164267,1,1,1,1,0,0
6745,04/06/2019 00:00,DB08577,3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE,,,,,,solid,,,0.214,4.15,-2.1,CC1=CNC(\C=C2/C(=O)NC3=CC=CC=C23)=C1CCC(O)=O,,,,,0,,296.1160924,3,2,2,1,0,1
6746,04/06/2019 00:00,DB08578,4-[(5-bromopyridin-2-yl)amino]-4-oxobutanoic acid,,,,,,solid,,,0.368,3.17,2.09,OC(=O)CCC(=O)NC1=CC=C(Br)C=N1,,,,,0,,271.9796542,1,1,1,1,0,0
6747,04/06/2019 00:00,DB08579,"4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}aniline",,,,,,solid,,,0.206,,2.44,[H][C@]1(C)CN(C[C@@]([H])(C)C1)C(=O)C1=CC(Br)=CC=C1N,,,,,0,,310.0680753,2,1,1,0,1,1
6748,04/06/2019 00:00,DB08580,4-bromo-2-{[(2R)-2-(2-chlorobenzyl)pyrrolidin-1-yl]carbonyl}aniline,,,,,,solid,,,0.00261,,2.3,[H][C@]1(CC2=C(Cl)C=CC=C2)CCCN1C(=O)C1=CC(Br)=CC=C1N,,,,,0,,392.029103,3,2,1,0,1,1
6749,04/06/2019 00:00,DB08581,"4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid",,,,,,solid,,,0.0232,3.04,0.05,[H][C@]1(C)CN(C[C@@]([H])(C)C1)C(=O)C1=CC(Br)=CC=C1NC(=O)CCC(O)=O,,,,,0,,410.0841193,2,1,1,0,1,1
6750,04/06/2019 00:00,DB08582,"N-(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)-4-morpholin-4-yl-4-oxobutanamide",,,,,,solid,,,0.108,12.6,0.085,[H][C@]1(C)CN(C[C@@]([H])(C)C1)C(=O)C1=C(NC(=O)CCC(=O)N2CCOCC2)C=CC(Br)=C1,,,,,0,,479.1419685,3,1,2,0,2,2
6751,04/06/2019 00:00,DB08583,"2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide",,,,,,solid,,,0.0381,14.71,3.8,CCN1N=CC=C1C1=CNC2=NC=C(C=C12)C1=CC(C(=O)N(C)C)=C(N)C=C1,,,,,0,,374.1855093,4,4,3,3,0,0
6752,02/08/2018 00:00,DB08584,"6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline",,,,,,solid,,,0.0177,,4.26,CN1C=C(C=N1)C1=NN2C(SC3=CC=C4N=CC=CC4=C3)=NN=C2C=C1,,,,,0,,359.0953144,5,5,4,4,0,0
6753,04/06/2019 00:00,DB08585,"S-[2-({N-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] hexanethioate",,,,,,solid,,,0.22,1.79,-1.5,[H][C@@](O)(C(=O)NCCC(=O)NCCSC(=O)CCCCC)C(C)(C)COP(O)(O)=O,,,,,0,,456.1695236,0,0,0,0,0,0
6754,04/06/2019 00:00,DB08586,"S-[2-({N-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] octanethioate",,,,,,solid,,,0.0396,1.79,-1.5,[H][C@@](O)(C(=O)NCCC(=O)NCCSC(=O)CCCCCCC)C(C)(C)COP(O)(O)=O,,,,,0,,484.2008238,0,0,0,0,0,0
6755,04/06/2019 00:00,DB08587,SINAPINATE,,,,,,solid,,,0.631,3.61,-4.6,COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O,,,,,0,,224.0684735,1,1,0,0,0,0
6756,04/06/2019 00:00,DB08588,2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE,,,,,,solid,,,0.0772,,8.32,[H][C@@]1(N)CCCN(C1)C1=NC2=C(C=CC=C2)C(=O)N1CC1=C(C=CC=C1)C#N,,,,,0,,359.1746103,4,3,2,1,1,1
6757,04/06/2019 00:00,DB08589,SYRINGATE,,,,,,solid,,,2.64,8.44,-4.6,COC(=O)C1=CC(OC)=C(O)C(OC)=C1,,,,,0,,212.0684735,1,1,0,0,0,0
6758,04/06/2019 00:00,DB08590,1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE,,,,,,solid,,,0.0152,10.62,2.39,CC(C)(C)C(=O)OC1=CC=C2N(CCCO)C(NC(=O)C3=CC(=CC=C3)[N+]([O-])=O)=NC2=C1,,,,,0,,440.1695845,3,3,1,1,0,0
6759,04/06/2019 00:00,DB08591,"5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE",,,,,,solid,,,0.0813,3.78,-4,COC1=CC=C(C=C1N1CC(=O)NS1(=O)=O)C1=CC=CC=C1,,,,,0,,318.0674279,3,2,1,0,1,1
6760,04/06/2019 00:00,DB08593,"1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE",,,,,,solid,,,6.34,3.78,,O=C1CN(C2=CC=CC=C2)S(=O)(=O)N1,,,,,0,,212.0255631,2,1,1,0,1,1
6761,04/06/2019 00:00,DB08594,TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE,,,,,,solid,,,8.91,9.76,,CN(NC(=O)OC(C)(C)C)C#N,,,,,0,,171.1007767,0,0,0,0,0,0
6762,04/06/2019 00:00,DB08595,"4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL",,,,,,solid,,,0.0355,9.47,-4.2,[H][C@]12CC=C(C)[C@]([H])(C1)[C@@]([H])(OC2(C)C)C1=CC=C(O)C=C1,,,,,0,,258.1619799,3,1,1,0,1,1
6763,04/06/2019 00:00,DB08596,5'-deoxy-5'-piperidin-1-ylthymidine,,,,,,solid,,,25.5,9.98,8.66,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CN1CCCCC1)N1C=C(C)C(=O)NC1=O,,,,,0,,309.1688562,3,1,3,1,2,2
6764,04/06/2019 00:00,DB08597,"6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine",,,,,,solid,,,0.0148,,8.81,C(CN1CCCCC1)OC1=CC=C(C=C1)C1=CN2N=CC(=C2N=C1)C1=CC=NC=C1,,,,,0,,399.2059104,5,4,4,3,1,1
6765,04/06/2019 00:00,DB08598,"4-CHLORO-8-METHYL-7-(3-METHYL-BUT-2-ENYL)-6,7,8,9-TETRAHYDRO-2H-2,7,9A-TRIAZA-BENZO[CD]AZULENE-1-THIONE",,,,,,solid,,,0.0313,8.11,6.56,[H][C@]1(C)CN2C(=S)NC3=C2C(CN1CC=C(C)C)=CC(Cl)=C3,,,,,0,,321.1066463,3,2,2,1,0,1
6766,04/06/2019 00:00,DB08599,N-[(4-methoxyphenyl)sulfonyl]-D-alanine,,,,,,solid,,,2.67,2.67,-4.8,[H][C@](C)(NS(=O)(=O)C1=CC=C(OC)C=C1)C(O)=O,,,,,0,,259.0514435,1,1,0,0,0,0
6767,04/06/2019 00:00,DB08600,"5-CHLORO-8-METHYL-7-(3-METHYL-BUT-2-ENYL)-6,7,8,9-TETRAHYDRO-2H-2,7,9A-TRIAZA-BENZO[CD]AZULENE-1-THIONE",,,,,,solid,,,0.031,8.23,6.53,[H][C@]1(C)CN2C(=S)NC3=C2C(CN1CC=C(C)C)=C(Cl)C=C3,,,,,0,,321.1066463,3,2,2,1,0,1
6768,04/06/2019 00:00,DB08601,tributylstannanyl,,,,,,solid,,,0.0882,,,CCCC[Sn](CCCC)CCCC,,,,,0,,291.1134706,0,0,0,0,0,0
6769,04/06/2019 00:00,DB08602,"3-(2,6-difluorophenyl)-2-(methylthio)quinazolin-4(3H)-one",,,,,,solid,,,0.0079,,-2.8,CSC1=NC2=CC=CC=C2C(=O)N1C1=C(F)C=CC=C1F,,,,,0,,304.0481904,3,3,1,1,0,0
6770,04/06/2019 00:00,DB08603,N-[(1S)-5-amino-1-(chloroacetyl)pentyl]-4-methylbenzenesulfonamide,,,,,,solid,,,0.055,10.4,9.78,[H][C@@](CCCCN)(NS(=O)(=O)C1=CC=C(C)C=C1)C(=O)CCl,,,,,0,,332.0961412,1,1,0,0,0,0
6771,02/07/2019 00:00,DB08604,Triclosan,"A study conducted in 2000 demonstrated that low amounts of triclosan can be absorbed through skin and can enter the bloodstream. [PMID: 10722890] Triclosan is rapidly absorbed and distributed in the human body (Sandborgh-Englund et al., 2006). Maximum concentrations are reached within three hours after oral intake. However, the metabolism and excretion of the compound is fast.",,"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).",0.01,Topical,solid,,,0.00605,7.68,-6.7,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,,,,,0,,287.9511625,2,2,0,0,0,0
6772,04/06/2019 00:00,DB08605,"6-METHYL-2(PROPANE-1-SULFONYL)-2H-THIENO[3,2-D][1,2,3]DIAZABORININ-1-OL",,,,,,solid,,,0.115,6.09,1.24,CCCS(=O)(=O)N1N=CC2=C(C=C(C)S2)B1O,,,,,0,,272.0460647,2,1,2,1,0,1
6773,04/06/2019 00:00,DB08606,"(3R,4S)-1-[(4-AMINO-5H-PYRROLO[3,2-D]PYRIMIDIN-7-YL)METHYL]-4-[(METHYLSULFANYL)METHYL]PYRROLIDIN-3-OL",,,,,,solid,,,0.996,13.47,8.71,[H][C@]1(O)CN(CC2=CNC3=C(N)N=CN=C23)C[C@]1([H])CSC,,,,,0,,293.1310312,3,2,3,2,1,1
6774,04/06/2019 00:00,DB08607,"(5R)-5-(4-{[(2R)-6-HYDROXY-2,5,7,8-TETRAMETHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL]METHOXY}BENZYL)-1,3-THIAZOLIDINE-2,4-DIONE",,,,,,solid,,,0.00121,6.61,-4.6,[H][C@]1(CC2=CC=C(OC[C@@]3(C)CCC4=C(C)C(O)=C(C)C(C)=C4O3)C=C2)SC(=O)NC1=O,,,,,0,,441.160994,4,2,2,0,1,2
6775,04/06/2019 00:00,DB08608,"4-({(2R,5S)-2,5-DIMETHYL-4-[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]PIPERAZIN-1-YL}CARBONYL)BENZONITRILE",,,,,,solid,,,0.0366,9.55,-0.088,[H][C@@]1(C)CN(C(=O)[C@@](C)(O)C(F)(F)F)[C@@]([H])(C)CN1C(=O)C1=CC=C(C=C1)C#N,,,,,0,,383.1456762,2,1,1,0,1,1
6776,04/06/2019 00:00,DB08609,"(2R)-N-{4-[Ethyl(phenyl)sulfamoyl]-2-methylphenyl}-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide",,,,,,solid,,,0.00734,9.45,-5.2,[H]N(C(=O)C(C)(O)C(F)(F)F)C1=C(C)C=C(C=C1)S(=O)(=O)N(CC)C1=CC=CC=C1,,,,,0,,430.1174128,2,2,0,0,0,0
6777,04/06/2019 00:00,DB08610,N-(2-AMINOETHYL)-2-{3-CHLORO-4-[(4-ISOPROPYLBENZYL)OXY]PHENYL} ACETAMIDE,,,,,,solid,,,0.000419,14.54,9.16,CC(C)C1=CC=C(COC2=C(Cl)C=C(CC(=O)NCCN)C=C2)C=C1,,,,,0,,360.1604557,2,2,0,0,0,0
6778,04/06/2019 00:00,DB08611,"2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL",,,,,,solid,,,0.0297,15.1,-2.8,OCCOC1=C(C=CC=C1)C1=C(F)C(F)=C(F)C=C1,,,,,0,,268.0711143,2,2,0,0,0,0
6779,04/06/2019 00:00,DB08612,"1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE",,,,,,solid,,,0.00116,12.48,-9.7,CCCCCCCCSCC(=O)C(F)(F)F,,,,,0,,256.1108709,0,0,0,0,0,0
6780,04/06/2019 00:00,DB08613,"2,2,2-TRIFLUORO-1-{5-[(3-PHENYL-5,6-DIHYDROIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL)CARBONYL]THIOPHEN-2-YL}ETHANE-1,1-DIOL",,,,,,solid,,,0.116,7.11,5.68,OC(O)(C1=CC=C(S1)C(=O)N1CCN2C(C1)=NC=C2C1=CC=CC=C1)C(F)(F)F,,,,,0,,423.086447,4,3,3,2,0,1
6781,04/06/2019 00:00,DB08614,"3-[[(METHYLAMINO)SULFONYL]AMINO]-2-OXO-6-PHENYL-N-[3,3,3-TRIFLUORO-1-(1-METHYLETHYL)-2-OXOPHENYL]-1(2H)-PYRIDINE ACETAMIDE",,,,,,solid,,,0.00659,8.17,0.23,[H][C@](NC(=O)CN1C(=O)C(NS(=O)(=O)NC)=CC=C1C1=CC=CC=C1)(C(C)C)C(=O)C(F)(F)F,,,,,0,,488.1341255,2,2,1,1,0,0
6782,04/06/2019 00:00,DB08615,"2-[4-(DIMETHYLAMINO)PHENYL]-6-HYDROXY-3-METHYL-1,3-BENZOTHIAZOL-3-IUM",,,,,,solid,,,0.0024,8.93,3.37,CN(C)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(O)C=C2S1,,,,,1,,285.1056106,3,3,1,1,0,0
6783,04/06/2019 00:00,DB08617,"4-(2,2,2-TRIFLUOROETHYL)-L-PHENYLALANINE",,,,,,solid,,,0.363,2.14,9.44,[H][C@](N)(CC1=CC=C(CC(F)(F)F)C=C1)C(O)=O,,,,,0,,247.0820133,1,1,0,0,0,0
6784,04/06/2019 00:00,DB08618,3-(HYDROXY-PHENYL-PHOSPHINOYLOXY)-8-METHYL-8-AZA-BICYCLO[3.2.1]OCTANE-2-CARBOXYLIC ACID METHYL ESTER,,,,,,solid,,,9.49,2.12,8.77,[H][C@@]12CC[C@@]([H])(N1C)[C@@]([H])(C(=O)OC)[C@]([H])(C2)O[P@](O)(=O)C1=CC=CC=C1,,,,,0,,339.1235594,3,1,2,0,2,2
6785,04/06/2019 00:00,DB08619,Testosterone succinate,,,,,,solid,,,0.00844,4.31,-4.8,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCC(O)=O,,,,,0,,388.2249741,4,0,0,0,0,0
6786,04/06/2019 00:00,DB08620,"{(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide",,,,,,solid,,,0.458,,1.62,ClC1=NC=C(CN2CCS\C2=N/C#N)C=C1,,,,,0,,252.023645,2,1,2,1,1,1
6787,04/06/2019 00:00,DB08621,Thiamphenicol,,,,,,solid,,,2.27,7.65,-2.8,[H][C@](CO)(NC(=O)C(Cl)Cl)[C@]([H])(O)C1=CC=C(C=C1)S(C)(=O)=O,,,,,0,,355.0047989,1,1,0,0,0,0
6788,04/06/2019 00:00,DB08622,"4-(4-CHLORO-PHENYL)-1-{3-[2-(4-FLUORO-PHENYL)-[1,3]DITHIOLAN-2-YL]-PROPYL}-PIPERIDIN-4-OL",,,,,,solid,,,0.000141,13.96,8.69,OC1(CCN(CCCC2(SCCS2)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,,,,,0,,451.1206624,4,2,2,0,2,2
6789,04/06/2019 00:00,DB08623,"2-[CARBOXY-(2-THIOPHEN-2-YL-ACETYLAMINO)-METHYL]-5-METHYLENE-5,6-DIHYDRO-2H-[1,3]THIAZINE-4-CARBOXYLIC ACID",,,,,,solid,,,0.0534,3.62,0.098,[H][C@@](NC(=O)CC1=CC=CS1)(C(O)=O)C1=N[C@]([H])(C(O)=O)C(=C)CS1,,,,,0,,354.0344135,2,1,2,1,0,1
6790,04/06/2019 00:00,DB08624,BENZOTHIAZOLE,,,,,,solid,,,0.13,16.52,12,[H][C@](N)(CCCNC(N)=N)C(=O)C1=NC2=CC=CC=C2S1,,,,,0,,291.1153812,2,2,1,1,0,0
6791,04/06/2019 00:00,DB08626,Thiorphan,,,,,,solid,,,0.445,4.02,-1.8,[H][C@](CS)(CC1=CC=CC=C1)C(=O)NCC(O)=O,,,,,0,,253.0772643,1,1,0,0,0,0
6792,04/06/2019 00:00,DB08627,"(5R)-4-HYDROXY-3,5-DIMETHYL-5-[(1E,3E)-2-METHYLPENTA-1,3-DIENYL]THIOPHEN-2(5H)-ONE",,,,,,solid,,,0.151,6.87,-6.1,C\C=C\C(\C)=C\[C@@]1(C)SC(=O)C(C)=C1O,,,,,0,,224.0871008,1,0,1,0,0,1
6793,04/06/2019 00:00,DB08628,"(5R)-5-[(1E)-BUTA-1,3-DIENYL]-4-HYDROXY-3,5-DIMETHYLTHIOPHEN-2(5H)-ONE",,,,,,solid,,,0.582,6.76,-6.1,CC1=C(O)[C@](C)(SC1=O)\C=C\C=C,,,,,0,,196.0558006,1,0,1,0,0,1
6794,04/06/2019 00:00,DB08629,"N1-(2-AMINO-4-METHYLPENTYL)OCTAHYDRO-PYRROLO[1,2-A] PYRIMIDINE",,,,,,solid,,,13.8,,9.65,[H][C@](N)(CC(C)C)CN1CCC[N@@]2CCC[C@@]12[H],,,,,0,,225.2204979,2,0,2,0,2,2
6795,04/06/2019 00:00,DB08631,"N-(4-CHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE",,,,,,solid,,,0.0137,7.74,8.83,ClC1=CC=C(NS(=O)(=O)C2=CC=C3CCNCC3=C2)C=C1,,,,,0,,322.0542764,3,2,1,0,0,1
6796,04/06/2019 00:00,DB08632,"1,3,5-BENZENETRICARBOXYLIC ACID",,,,,,solid,,,0.837,3.14,,OC(=O)C1=CC(=CC(=C1)C(O)=O)C(O)=O,,,,,0,,210.0164379,1,1,0,0,0,0
6797,04/06/2019 00:00,DB08633,TNP-470,,,,,,solid,,,0.0234,7.31,-3.7,[H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1([H])[C@]([H])(OC)[C@@]([H])(CC[C@]11CO1)OC(=O)NC(=O)CCl,,,,,0,,401.1605153,3,0,2,0,2,2
6798,04/06/2019 00:00,DB08634,6-BENZYL-1-BENZYLOXYMETHYL-5-ISOPROPYL URACIL,,,,,,solid,,,0.00788,10.23,-3.9,CC(C)C1=C(CC2=CC=CC=C2)N(COCC2=CC=CC=C2)C(=O)NC1=O,,,,,0,,364.1786926,3,3,1,1,0,0
6799,04/06/2019 00:00,DB08635,N-(TRANS-4'-NITRO-4-STILBENYL)-N-METHYL-5-AMINO-PENTANOIC ACID,,,,,,solid,,,0.00174,4.69,5.46,CN(CCCCC(O)=O)C1=CC=C(\C=C\C2=CC=C(C=C2)[N+]([O-])=O)C=C1,,,,,0,,354.1579572,2,2,0,0,0,0
6800,04/06/2019 00:00,DB08636,2-Hydroxybenzalpyruvate,,,,,,solid,,,0.623,2.93,-6.4,OC(=O)C(=O)\C=C\C1=CC=CC=C1O,,,,,0,,192.0422587,1,1,0,0,0,0
6801,04/06/2019 00:00,DB08637,4-(2-METHOXYPHENYL)-2-OXOBUT-3-ENOIC ACID,,,,,,solid,,,0.284,3.03,-4.8,[H]\C(=C(/[H])C1=CC=CC=C1OC)C(=O)C(O)=O,,,,,0,,206.0579088,1,1,0,0,0,0
6802,04/06/2019 00:00,DB08638,2-AMINO-3-(1-HYDROPEROXY-1H-INDOL-3-YL)PROPAN-1-OL,,,,,,solid,,,2.25,2.05,9.35,[H][C@](N)(CC1=CN(OO)C2=CC=CC=C12)C(O)=O,,,,,0,,236.0797069,2,2,1,1,0,0
6803,04/06/2019 00:00,DB08639,Dapivirine,,,,,,solid,,,0.017,12.93,5.16,CC1=CC(C)=C(NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2)C(C)=C1,,,,,0,,329.1640456,3,3,1,1,0,0
6804,04/06/2019 00:00,DB08640,"(2S,3S)-3-FORMYL-2-({[(4-METHYLPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID",,,,,,solid,,,1.2,3.58,-7,[H][C@@](CC)(C=O)[C@@]([H])(CNS(=O)(=O)C1=CC=C(C)C=C1)C(O)=O,,,,,0,,313.0983937,1,1,0,0,0,0
6805,04/06/2019 00:00,DB08641,"(2S,3S)-3-FORMYL-2-({[(4-NITROPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID",,,,,,solid,,,0.125,3.12,-7,[H][C@@](CC)(C=O)[C@@]([H])(CNS(=O)(=O)C1=CC=C(C=C1)[N+]([O-])=O)C(O)=O,,,,,0,,344.0678219,1,1,0,0,0,0
6806,04/06/2019 00:00,DB08642,"(2R,6S)-6-{[methyl(3,4,5-trimethoxyphenyl)amino]methyl}-1,2,5,6,7,8-hexahydroquinazoline-2,4-diamine",,,,,,solid,,,0.237,,7.43,[H][C@]1(CN(C)C2=CC(OC)=C(OC)C(OC)=C2)CCC2=C(C1)C(N)=N[C@]([H])(N)N2,,,,,0,,375.2270398,3,1,1,0,0,1
6807,04/06/2019 00:00,DB08643,2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER,,,,,,solid,,,0.00165,9.97,7.62,[H][C@@](CS)(NCC1=CC=C(C=C1)C1=CC=CC=C1)C(=O)NCC(=O)N[C@@]([H])(C(C)C)C(=O)OC,,,,,0,,457.2035275,2,2,0,0,0,0
6808,04/06/2019 00:00,DB08644,{1-[2-(1-FORMYL-PROPYL)-3-METHANESULFONYLAMINO-PYRROLIDINE-1-CARBONYL]-2-METHYL-PROPYL}-CARBAMIC ACID TERT-BUTYL ESTER,,,,,,solid,,,0.826,10.36,-3.1,[H][C@@](CC)(C=O)[C@@]1([H])N(CC[C@]1([H])NS(C)(=O)=O)C(=O)[C@@]([H])(NC(=O)OC(C)(C)C)C(C)C,,,,,0,,433.2246568,1,0,1,0,1,1
6809,04/06/2019 00:00,DB08645,"6-CHLORO-3-(DICHLOROMETHYL)-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE",,,,,,solid,,,0.415,8.32,-4.1,[H][C@]1(NC2=CC(Cl)=C(C=C2S(=O)(=O)N1)S(N)(=O)=O)C(Cl)Cl,,,,,0,,378.9021808,2,1,1,0,0,1
6810,04/06/2019 00:00,DB08646,TRW3-(2-AMINO-3-HYDROXY-PROPYL)-6-(N'-CYCLOHEXYL-HYDRAZINO)OCTAHYDRO-INDOL-7-OL,,,,,,solid,,,0.108,9.4,7.64,[H][C@](N)(CC1=CNC2=C1C=CC(NNC1=CC=CC=C1)=C2O)C=O,,,,,0,,310.1429758,3,3,1,1,0,0
6811,04/06/2019 00:00,DB08647,TRAZEOLIDE,,,,,,solid,,,0.000898,3.93,-7.5,[H][C@]1(C)[C@]([H])(C(C)C)C2=C(C=C(C)C(=C2)C(=O)CCC(O)=O)C1(C)C,,,,,0,,316.2038448,2,1,0,0,0,0
6812,04/06/2019 00:00,DB08648,"(1R,3S,5S,8R)-8-Hydroxy-2-oxabicyclo[3.3.1]non-6-ene-3,5-dicarboxylic acid",,,,,,solid,,,78.1,3.31,-3.3,[H][C@@]1(O)C=C[C@]2(C[C@]([H])(O[C@]1([H])C2)C(O)=O)C(O)=O,,,,,0,,228.0633881,2,0,1,0,1,1
6813,04/06/2019 00:00,DB08649,(1S)-1-AMINO-2-(1H-INDOL-3-YL)ETHANOL,,,,,,solid,,,5.89,14.15,8.92,[H][C@](N)(O)CC1=CNC2=CC=CC=C12,,,,,0,,176.094963,2,2,1,1,0,0
6814,04/06/2019 00:00,DB08651,3'-THIO-THYMIDINE-5'-PHOSPHATE,,,,,,solid,,,1.25,1.28,-4.2,[H][C@]1(S)C[C@@]([H])(O[C@]1([H])COP(O)(O)=O)N1C=C(C)C(=O)NC1=O,,,,,0,,338.0337585,2,1,2,1,1,1
6815,04/06/2019 00:00,DB08652,2-(1H-INDOL-3-YL)ACETAMIDE,,,,,,solid,,,1.67,15.94,-2.5,NC(=O)CC1=CNC2=CC=CC=C12,,,,,0,,174.0793129,2,2,1,1,0,0
6816,04/06/2019 00:00,DB08653,2-(1H-INDOL-3-YL)ETHANAMINE,,,,,,solid,,,1.34,17.17,9.73,NCCC1=CNC2=CC=CC=C12,,,,,0,,160.1000484,2,2,1,1,0,0
6817,04/06/2019 00:00,DB08654,"TRANS-(1S,2S)-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL",,,,,,solid,,,10.8,13.89,9.42,[H][C@]1(N)CCC2=CC=CC=C2[C@]1([H])O,,,,,0,,163.099714,2,1,0,0,0,0
6818,04/06/2019 00:00,DB08655,"9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE",,,,,,solid,,,0.188,15.91,-3.6,CC(=O)N1C2=CC=CC=C2C2=C1C(=O)CCC2,,,,,0,,227.0946287,3,2,1,1,0,0
6819,04/06/2019 00:00,DB08656,5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide,,,,,,solid,,,0.000572,15.62,3.77,[H][C@](C)(NC(=O)C1=C(C)C=CC(N)=C1)C1=CC=CC2=C1C=CC=C2,,,,,0,,304.1575633,3,3,0,0,0,0
6820,04/06/2019 00:00,DB08657,2-(4-(2-((3-(5-(PYRIDIN-2-YLTHIO)THIAZOL-2-YL)UREIDO)METHYL)-1H-IMIDAZOL-4-YL)PHENOXY)ACETIC ACID,,,,,,solid,,,0.00247,3.58,5.19,OC(=O)COC1=CC=C(C=C1)C1=CNC(CNC(=O)NC2=NC=C(SC3=NC=CC=C3)S2)=N1,,,,,0,,482.0830951,4,4,3,3,0,0
6821,04/06/2019 00:00,DB08658,ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE,,,,,,solid,,,46.4,3.02,,CCO[P@](O)(=O)N(CC)CC,,,,,0,,181.08678,0,0,0,0,0,0
6822,04/06/2019 00:00,DB08659,2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide,,,,,,solid,,,0.0487,10.09,2.87,NNC(=O)C1=C(C2=C(N1)C=CC(=C2)S(N)(=O)=O)C1=CC=CC=C1,,,,,0,,330.0786613,3,3,1,1,0,0
6823,04/06/2019 00:00,DB08660,"1,2,5,8-tetrahydroxyanthracene-9,10-dione",,,,,,solid,,,0.549,7.5,-4.4,OC1=C(O)C2=C(C=C1)C(=O)C1=C(O)C=CC(O)=C1C2=O,,,,,0,,272.032088,3,2,0,0,0,0
6824,04/06/2019 00:00,DB08661,"1-(2,5-dideoxy-5-pyrrolidin-1-yl-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione",,,,,,solid,,,39.9,9.99,8.78,[H][C@@]1(O)C[C@]([H])(O[C@@]1([H])CN1CCCC1)N1C=C(C)C(=O)NC1=O,,,,,0,,295.1532062,3,1,3,1,2,2
6825,04/06/2019 00:00,DB08662,3-[1-(4-BROMO-PHENYL)-2-METHYL-PROPYL]-4-HYDROXY-CHROMEN-2-ONE,,,,,,solid,,,0.00225,6,-6.7,[H][C@](C(C)C)(C1=CC=C(Br)C=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,,,,,0,,372.0361065,3,3,1,1,0,0
6826,04/06/2019 00:00,DB08663,4-HYDROXY-7-METHOXY-3-(1-PHENYL-PROPYL)-CHROMEN-2-ONE,,,,,,solid,,,0.0296,6.54,-4.8,[H][C@](CC)(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=C(OC)C=C2,,,,,0,,310.1205091,3,3,1,1,0,0
6827,04/06/2019 00:00,DB08664,({3-[1-(4-HYDROXY-2-OXO-2H-CHROMEN-3-YL)-PROPYL]-PHENYLCARBAMOYL}-METHYL)-CARBAMIC ACID TERT-BUTYL ESTER,,,,,,solid,,,0.00464,6.26,-6.6,[H][C@](CC)(C1=CC=CC(NC(=O)CNC(=O)OC(C)(C)C)=C1)C1=C(O)C2=CC=CC=C2OC1=O,,,,,0,,452.1947366,3,3,1,1,0,0
6828,04/06/2019 00:00,DB08665,"6,11-DIHYDRO-11-ETHYL-6-METHYL-9-NITRO-5H-PYRIDO[2,3-B][1,5]BENZODIAZEPIN-5-ONE",,,,,,solid,,,0.255,,3.73,CCN1C2=CC(=CC=C2N(C)C(=O)C2=C1N=CC=C2)[N+]([O-])=O,,,,,0,,298.1065903,3,2,2,1,0,1
6829,04/06/2019 00:00,DB08666,5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine,,,,,,solid,,,0.0134,,3.9,NC1=C(\N=N\C2=CC=CC(=C2)C(F)(F)F)C(=N)N=N1,,,,,0,,268.0684289,2,1,1,0,0,1
6830,04/06/2019 00:00,DB08667,4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine,,,,,,solid,,,0.0174,,4.19,[H]N=C1N=NC(N)=C1\N=N\C1=CC=C(F)C=C1,,,,,0,,218.0716224,2,1,1,0,0,1
6831,04/06/2019 00:00,DB08668,3-(5-amino-3-imino-3H-pyrazol-4-ylazo)-benzoic acid,,,,,,solid,,,0.0661,3.99,4.95,[H]N=C1N=NC(N)=C1\N=N\C1=CC=CC(=C1)C(O)=O,,,,,0,,244.0708735,2,1,1,0,0,1
6832,04/06/2019 00:00,DB08669,"METHYL N-[(2S,3R)-3-AMINO-2-HYDROXY-3-(4-METHYLPHENYL)PROPANOYL]-D-ALANYL-D-LEUCINATE",,,,,,solid,,,0.164,11.97,8.12,[H][C@@](C)(NC(=O)[C@@]([H])(O)[C@]([H])(N)C1=CC=C(C)C=C1)C(=O)N[C@]([H])(CC(C)C)C(=O)OC,,,,,0,,393.2263711,1,1,0,0,0,0
6833,04/06/2019 00:00,DB08670,"METHYL N-[(2S,3R)-3-AMINO-2-HYDROXY-3-(4-ISOPROPYLPHENYL)PROPANOYL]-D-ALANYL-D-LEUCINATE",,,,,,solid,,,0.0308,11.98,8.12,[H][C@@](C)(NC(=O)[C@@]([H])(O)[C@]([H])(N)C1=CC=C(C=C1)C(C)C)C(=O)N[C@]([H])(CC(C)C)C(=O)OC,,,,,0,,421.2576712,1,1,0,0,0,0
6834,04/06/2019 00:00,DB08671,5-IMINO-4-(2-TRIFLUOROMETHYL-PHENYLAZO)-5H-PYRAZOL-3-YLAMINE,,,,,,solid,,,0.0132,,3.91,[H]N=C1N=NC(N)=C1\N=N\C1=CC=CC=C1C(F)(F)F,,,,,0,,268.0684289,2,1,1,0,0,1
6835,04/06/2019 00:00,DB08672,4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE,,,,,,solid,,,0.00261,14.76,8.23,[H][C@@](C)(CCC1=CC=C(C=C1)C(N)=O)NCC(=O)C1=CC=C(F)C=C1,,,,,0,,328.1587061,2,2,0,0,0,0
6836,04/06/2019 00:00,DB08673,"4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE",,,,,,solid,,,0.108,10.71,3.86,CC(C)C1=CN=C(NC2=CC=C(C=C2)S(N)(=O)=O)S1,,,,,0,,297.0605687,2,2,1,1,0,0
6837,04/06/2019 00:00,DB08674,"(20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE",,,,,,solid,,,0.1,17.65,6.68,[H][C@@]12CCN(C1=O)C1=C3C=C(OC4=C(C=CC(CN5C=NC=C5CN2)=C4)C#N)C=CC3=CC=C1,,,,,0,,435.1695249,6,4,3,1,1,2
6838,04/06/2019 00:00,DB08675,"(5Z)-7-{(1R,4S,5R,6R)-6-[(1E)-1-Octen-1-yl]-2,3-diazabicyclo[2.2.1]hept-2-en-5-yl}-5-heptenoic acid",,,,,,solid,,,0.000272,4.39,1.13,[H]\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@]2([H])C[C@@]([H])(N=N2)[C@]1([H])C(\[H])=C(/[H])CCCCCC,,,,,0,,332.2463783,2,0,1,0,0,1
6839,04/06/2019 00:00,DB08676,"(20S)-19,20,22,23-TETRAHYDRO-19-OXO-5H,21H-18,20-ETHANO-12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9-CARBONITRILE",,,,,,solid,,,0.116,17.66,7.61,[H][C@]12CCN(C1=O)C1=CC=CC3=C1C=C(OC1([H])CC(CN4C=NC=C4CCN2)=CC[C@]1([H])C#N)C=C3,,,,,0,,453.2164751,6,3,3,1,1,2
6840,04/06/2019 00:00,DB08677,N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE,,,,,,solid,,,0.367,10.07,4.87,CC(C)C1=CN\C(S1)=N\C(=O)CC1=CC=CN=C1,,,,,0,,261.0935831,2,2,2,2,0,0
6841,04/06/2019 00:00,DB08678,(4-ETHYLPHENYL)SULFAMIC ACID,,,,,,solid,,,1.3,-0.95,-9.8,CCC1=CC=C(NS(O)(=O)=O)C=C1,,,,,0,,201.0459642,1,1,0,0,0,0
6842,04/06/2019 00:00,DB08680,N-{3-[(E)-(tert-butoxyimino)methyl]-4-chlorophenyl}-2-methylfuran-3-carbimidothioic acid,,,,,,solid,,,0.00843,10.87,2.52,CC1=C(C=CO1)C(=S)NC1=CC(\C=N\OC(C)(C)C)=C(Cl)C=C1,,,,,0,,350.0855765,2,2,1,1,0,0
6843,04/06/2019 00:00,DB08681,1-METHYL ETHYL 2-CHLORO-5-[[[(1-METHYLETHOXY)THIOOXO]METHYL]AMINO]-BENZOATE,,,,,,solid,,,0.00268,10.65,-2.1,CC(C)OC(=S)NC1=CC(C(=O)OC(C)C)=C(Cl)C=C1,,,,,0,,315.0695921,1,1,0,0,0,0
6844,04/06/2019 00:00,DB08682,"1-METHYL ETHYL 1-CHLORO-5-[[(5,6DIHYDRO-2-METHYL-1,4-OXATHIIN-3-YL)CARBONYL]AMINO]BENZOATE",,,,,,solid,,,0.0213,12.89,-2.1,CC(C)OC(=O)C1=C(Cl)C=CC(NC(=O)C2=C(C)OCCS2)=C1,,,,,0,,355.0645067,2,1,1,0,0,1
6845,04/06/2019 00:00,DB08683,"REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE",,,,,,solid,,,0.0622,8.03,-4.4,[H][C@]12CC[C@]([H])(O1)N1C3=C(C=CC=C3)C3=C4C(=O)NC(=O)C4=C4C5=C(C=CC=C5)N2C4=C13,,,,,0,,393.1113413,8,5,5,2,1,3
6846,04/06/2019 00:00,DB08684,O-Decyl Hydrogen Thiocarbonate,,,,,,solid,,,0.00471,3,,CCCCCCCCCCOC(S)=O,,,,,0,,218.1340509,0,0,0,0,0,0
6847,04/06/2019 00:00,DB08685,"1-(1,4-dimethyl-1,2,3,4-tetrahydroquinoxalin-6-yl)methanamine",,,,,,solid,,,13.7,,9.72,CN1CCN(C)C2=CC(CN)=CC=C12,,,,,0,,191.1422475,2,1,1,0,0,1
6848,04/06/2019 00:00,DB08686,"5,6,7,8,9,10-HEXAHYDRO-4-HYDROXY-3-(1-PHENYLPROPYL)CYCLOOCTA[B]PYRAN-2-ONE",,,,,,solid,,,0.0194,7.59,-6,[H][C@](CC)(C1=CC=CC=C1)C1=C(O)C2=C(CCCCCC2)OC1=O,,,,,0,,312.1725446,3,2,1,1,0,0
6849,04/06/2019 00:00,DB08687,FG-2216,,,,,,solid,,,0.167,3.18,-0.13,OC(=O)CNC(=O)C1=C(O)C2=CC=CC=C2C(Cl)=N1,,,,,0,,280.0250844,2,2,1,1,0,0
6850,04/06/2019 00:00,DB08688,undecan-2-one,,,,,,solid,,,0.0118,19.64,-7.3,CCCCCCCCCC(C)=O,,,,,0,,170.1670653,0,0,0,0,0,0
6851,04/06/2019 00:00,DB08689,UBIQUINONE-1,,,,,,solid,,,0.239,,-4.7,COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O,,,,,0,,250.1205091,1,0,0,0,0,0
6852,04/06/2019 00:00,DB08690,UBIQUINONE-2,,,,,,solid,,,0.01,,-4.7,COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O,,,,,0,,318.1831093,1,0,0,0,0,0
6853,04/06/2019 00:00,DB08691,"ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate",,,,,,solid,,,0.0359,,2.04,CCOC(=O)C1=C(\C(=C/N)C#N)C2=C(N1C)C(Cl)=C(Cl)C=C2,,,,,0,,337.038482,2,2,1,1,0,0
6854,04/06/2019 00:00,DB08692,D-1-(4-chlorophenyl)-2-(acetamido)ethane boronic acid,,,,,,solid,,,0.215,12,-1.2,[H]N(C(C)=O)[C@]([H])(CC1=CC=C(Cl)C=C1)[B-](O)(O)O,,,,,-1,,258.0709896,1,1,0,0,0,0
6855,04/06/2019 00:00,DB08693,L-1-(4-chlorophenyl)-2-(acetamido)ethane boronic acid,,,,,,solid,,,0.215,5.42,1.17,[H]N([C@@H](CC1=CC=C(Cl)C=C1)[B-](O)(O)O)C(C)=O,,,,,-1,,258.0709896,1,1,0,0,0,0
6856,04/06/2019 00:00,DB08694,"9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol",,,,,,solid,,,0.373,9.81,4.7,NC1=NC=CC(=N1)C1=C2C=CN=C(N)N2C2=NC=CC(O)=C12,,,,,0,,293.102508,4,4,4,4,0,0
6857,04/06/2019 00:00,DB08695,3-(4-nitrophenyl)-1H-pyrazole,,,,,,solid,,,1.75,14.74,2.01,[O-][N+](=O)C1=CC=C(C=C1)C1=NNC=C1,,,,,0,,189.0538265,2,2,1,1,0,0
6858,04/06/2019 00:00,DB08697,"4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide",,,,,,solid,,,0.00318,12.31,9.28,CC1=CC(=CC(C)=C1OCCN)C(=O)NC1=CC(Cl)=CC(=C1)N1CCCCC1,,,,,0,,401.1870048,3,2,1,0,1,1
6859,04/06/2019 00:00,DB08698,"1-[(3S)-5-PHENYL-3-THIOPHEN-2-YL-3H-1,4-BENZODIAZEPIN-2-YL]AZETIDIN-3-OL",,,,,,solid,,,0.0063,14.76,3.82,[H][C@@]1(N=C(C2=CC=CC=C2)C2=CC=CC=C2N=C1N1CC(O)C1)C1=CC=CS1,,,,,0,,373.1248832,5,3,3,1,1,2
6860,04/06/2019 00:00,DB08699,"1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,,,,,solid,,,0.0509,19.98,6.39,CC1=CC(CC2=NN(C3=C2C(N)=NC=N3)C(C)(C)C)=CC=C1,,,,,0,,295.1796957,3,3,2,2,0,0
6861,04/06/2019 00:00,DB08701,"2-(3-BROMOPHENYL)-6-[(2-HYDROXYETHYL)AMINO]-1H-BENZO[DE]ISOQUINOLINE-1,3(2H)-DIONE",,,,,,solid,,,0.0114,15.59,2.24,OCCNC1=CC=C2C(=O)N(C(=O)C3=CC=CC1=C23)C1=CC(Br)=CC=C1,,,,,0,,410.0266044,4,3,1,0,0,1
6862,04/06/2019 00:00,DB08702,"2,5-DIPHENYLFURAN-3,4-DICARBOXYLIC ACID",,,,,,solid,,,0.0321,4.36,-5.2,OC(=O)C1=C(OC(=C1C(O)=O)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,308.0684735,3,3,1,1,0,0
6863,04/06/2019 00:00,DB08703,"12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one",,,,,,solid,,,0.00579,15.46,0.48,CC(C)OC1=CC=C2C(CCC3=C2C2=C(C=NC2=O)C2=C3N(CCO)C3=CC=CC=C23)=C1,,,,,0,,424.1786926,6,4,2,1,0,1
6864,04/06/2019 00:00,DB08704,"[[(3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(pentanoylamino)oxan-2-ylidene]amino] N-phenylcarbamate",,,,,,solid,,,0.883,11.81,-0.41,[H][C@]1(CO)O\C(=N/OC(=O)NC2=CC=CC=C2)[C@]([H])(NC(=O)CCCC)[C@@]([H])(O)[C@]1([H])O,,,,,0,,395.1692501,2,1,1,0,1,1
6865,04/06/2019 00:00,DB08705,"6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE",,,,,,solid,,,0.00567,6.87,-5.4,OC1=C(C=C(Br)C=C1)C1=CC(C2=CC=CC=C2)=C(C#N)C(=O)N1,,,,,0,,366.0003897,3,3,1,1,0,0
6866,04/06/2019 00:00,DB08706,"(2S)-({(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}AMINO)(4-FLUOROPHENYL)ACETIC ACID",,,,,,solid,,,0.0349,3.88,-0.59,[H][C@@](NC1=NC(=O)\C(S1)=C\C1=CC=C(CC)O1)(C(O)=O)C1=CC=C(F)C=C1,,,,,0,,374.0736562,3,2,2,1,0,1
6867,04/06/2019 00:00,DB08707,"4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine",,,,,,solid,,,0.0621,16.54,4.08,NC1=NC=CC(=N1)C1=CC2=C(ON=C2C=C1)C1=CC=C(Cl)C=C1,,,,,0,,322.0621387,4,4,2,2,0,0
6868,04/06/2019 00:00,DB08708,"N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine",,,,,,solid,,,0.0119,18.45,1.84,FC(F)(F)C1=CC=CC(=C1)C1=NN=C2C=CC(NC3CCCCC3)=NN12,,,,,0,,361.1514302,4,3,2,2,0,0
6869,04/06/2019 00:00,DB08709,"2,3-diphenyl-1H-indole-7-carboxylic acid",,,,,,solid,,,0.000692,3.1,,OC(=O)C1=CC=CC2=C1NC(=C2C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,313.1102787,4,4,1,1,0,0
6870,04/06/2019 00:00,DB08710,"(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-2-{[(S)-(4-FLUOROPHENYL)(1H-TETRAZOL-5-YL)METHYL]AMINO}-1,3-THIAZOL-4(5H)-ONE",,,,,,solid,,,0.114,3.94,-0.63,[H][C@@](NC1=NC(=O)\C(S1)=C\C1=CC=C(CC)O1)(C1=NN=NN1)C1=CC=C(F)C=C1,,,,,0,,398.0961229,4,3,3,2,0,1
6871,04/06/2019 00:00,DB08711,Methyl vanillate,,,,,,solid,,,3.57,9,-4.9,COC(=O)C1=CC(OC)=C(O)C=C1,,,,,0,,182.0579088,1,1,0,0,0,0
6872,04/06/2019 00:00,DB08712,11-[(MERCAPTOCARBONYL)OXY]UNDECANOIC ACID,,,,,,solid,,,0.0151,2.99,,OC(=O)CCCCCCCCCCOC(S)=O,,,,,0,,262.1238802,0,0,0,0,0,0
6873,04/06/2019 00:00,DB08713,"2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2N-METHYL-2H-TETRAZOL-5-YL]-PHENOL",,,,,,solid,,,0.105,,1.64,CN1N=NC(=N1)C1=CC(C)=C(OCCCC2=CC(C)=NO2)C(C)=C1,,,,,0,,327.1695249,3,3,2,2,0,0
6874,04/06/2019 00:00,DB08714,"2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL",,,,,,solid,,,0.106,,1.64,CC1=NOC(CCCOC2=C(C)C=C(C=C2C)N2N=NC(C)=N2)=C1,,,,,0,,327.1695249,3,3,2,2,0,0
6875,04/06/2019 00:00,DB08715,"2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL",,,,,,solid,,,0.0259,,1.66,CC1=NC(=CO1)C1=CC(C)=C(OCCCC2=CC(C)=NO2)C(C)=C1,,,,,0,,326.1630426,3,3,2,2,0,0
6876,04/06/2019 00:00,DB08717,"[(2S)-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-yl]acetic acid",,,,,,solid,,,3.67,4.42,1.34,[H][C@@]1(CC(O)=O)NC2=CC=CC=C2CN(C)C1=O,,,,,0,,234.1004423,2,1,1,0,0,1
6877,04/06/2019 00:00,DB08718,"4-(3-ethylthiophen-2-yl)benzene-1,2-diol",,,,,,solid,,,0.0443,8.99,-6.3,CCC1=C(SC=C1)C1=CC(O)=C(O)C=C1,,,,,0,,220.0558006,2,2,1,1,0,0
6878,04/06/2019 00:00,DB08719,"5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE",,,,,,solid,,,0.0172,,3.29,CC1=NOC(CCCCCOC2=CC=C(C=C2Cl)C2=NCCO2)=C1,,,,,0,,348.1240702,3,2,2,1,0,1
6879,04/06/2019 00:00,DB08720,"5-(5-(4-(4,5-dihydro-2-oxazoly)phenoxy)pentyl)-3-methyl osoxazole",,,,,,solid,,,0.0273,,3.99,CC1=NOC(CCCCCOC2=CC=C(C=C2)C2=NCCO2)=C1,,,,,0,,314.1630426,3,2,2,1,0,1
6880,04/06/2019 00:00,DB08721,"5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole",,,,,,solid,,,0.0297,15.12,2.73,OCCOCOCC1=NOC(CCCCCOC2=C(Cl)C=C(C=C2Cl)C2=NCCO2)=C1,,,,,0,,472.1167919,3,2,2,1,0,1
6881,04/06/2019 00:00,DB08722,5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole,,,,,,solid,,,0.00716,,3.06,[H][C@]1(C)COC(=N1)C1=CC=C(OCCCCCCCC2=CC(C)=NO2)C(Cl)=C1,,,,,0,,390.1710204,3,2,2,1,0,1
6882,04/06/2019 00:00,DB08723,"5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE",,,,,,solid,,,0.0112,,2.77,CC1=NOC(CCCCCOC2=C(Cl)C=C(C=C2Cl)C2=NCCO2)=C1,,,,,0,,382.0850979,3,2,2,1,0,1
6883,04/06/2019 00:00,DB08724,5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole,,,,,,solid,,,0.0219,,3.73,[H][C@]1(C)COC(=N1)C1=CC=C(OCCCCCC2=CC(C)=NO2)C=C1,,,,,0,,328.1786926,3,2,2,1,0,1
6884,04/06/2019 00:00,DB08725,"(S)-5-(7-(4-(4-Ethyl-4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole",,,,,,solid,,,0.00771,,3.72,CC[C@H]1COC(=N1)C1=CC=C(OCCCCCCCC2=CC(C)=NO2)C=C1,,,,,0,,370.2256428,3,2,2,1,0,1
6885,04/06/2019 00:00,DB08726,"5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole",,,,,,solid,,,0.0129,,3.99,CC1=NOC(CCCCCCCOC2=CC=C(C=C2)C2=NCCO2)=C1,,,,,0,,342.1943427,3,2,2,1,0,1
6886,04/06/2019 00:00,DB08727,"3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole",,,,,,solid,,,0.00985,,3.73,C[C@@H]1COC(=N1)C1=CC=C(OCCCCCCCC2=CC(C)=NO2)C=C1,,,,,0,,356.2099928,3,2,2,1,0,1
6887,04/06/2019 00:00,DB08728,"5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole",,,,,,solid,,,0.0212,,2.66,CC1=NOC(CCCOC2=C(Cl)C=C(C=C2Cl)C2=NCCO2)=C1,,,,,0,,354.0537977,3,2,2,1,0,1
6888,04/06/2019 00:00,DB08729,"5-ethoxy-4-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)thiophene-2-sulfonamide",,,,,,solid,,,0.331,8.83,-1.6,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=C(OCC)SC(=C1)S(N)(=O)=O,,,,,0,,397.0878461,3,3,3,3,0,0
6889,04/06/2019 00:00,DB08730,3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE,,,,,,solid,,,0.00351,11.35,5.53,FC1=CC(=CC(=C1)C(=O)NC1=CC=C2C=CN(CCC3=CC=NC=C3)C2=C1)N1CCOCC1,,,,,0,,444.1961543,5,4,3,2,1,1
6890,04/06/2019 00:00,DB08731,"2-[(1R)-2-carboxy-1-(naphthalen-1-ylmethyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid",,,,,,solid,,,0.00646,3.33,-6.5,[H][C@](CC(O)=O)(CC1=CC=CC2=CC=CC=C12)N1C(=O)C2=CC=C(C=C2C1=O)C(O)=O,,,,,0,,403.1055873,4,3,1,0,0,1
6891,04/06/2019 00:00,DB08732,NALPHA-[(BENZYLOXY)CARBONYL]-N-[(1R)-4-HYDROXY-1-METHYL-2-OXOBUTYL]-L-PHENYLALANINAMIDE,,,,,,solid,,,0.0146,12.7,-2.4,[H][C@](C)(NC(=O)[C@]([H])(CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)C(=O)CCO,,,,,0,,398.1841719,2,2,0,0,0,0
6892,04/06/2019 00:00,DB08733,"(2R,3R)-N^1^-[(1S)-2,2-DIMETHYL-1-(METHYLCARBAMOYL)PROPYL]-N^4^-HYDROXY-2-(2-METHYLPROPYL)-3-{[(1,3-THIAZOL-2-YLCARBONYL)AMINO]METHYL}BUTANEDIAMIDE",,,,,,solid,,,0.0201,8.85,0.38,[H][C@@](CNC(=O)C1=NC=CS1)(C(=O)NO)[C@@]([H])(CC(C)C)C(=O)N[C@]([H])(C(=O)NC)C(C)(C)C,,,,,0,,455.2202402,1,1,1,1,0,0
6893,04/06/2019 00:00,DB08734,"6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE",,,,,,solid,,,0.032,20,7.27,CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl,,,,,0,,393.0526079,2,1,1,0,0,1
6894,04/06/2019 00:00,DB08735,"R,S-Warfarin alcohol",,,,,,solid,,,0.0806,5.63,-2.5,[H][C@@](C)(O)C[C@]([H])(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,,,,,0,,310.1205091,3,3,1,1,0,0
6895,04/06/2019 00:00,DB08736,"S,R-Warfarin alcohol",,,,,,solid,,,0.0806,5.63,-2.5,[H][C@](C)(O)C[C@@]([H])(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,,,,,0,,310.1205091,3,3,1,1,0,0
6896,04/06/2019 00:00,DB08737,"(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL",,,,,,solid,,,0.0226,9.35,-4.9,[H][C@@]12CCC[C@]1([H])[C@@]([H])(OC1=CC=CC(O)=C21)C1=CC=C(O)C=C1,,,,,0,,282.1255944,4,2,1,0,0,1
6897,04/06/2019 00:00,DB08738,1-{3-oxo-3-[(2S)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]propyl}-3-phenylquinoxalin-2(1H)-one,,,,,,solid,,,0.066,,-1.4,[H][C@]1(CCCN1C(=O)CCN1C(=O)C(=NC2=CC=CC=C12)C1=CC=CC=C1)C(=O)N1CCCC1,,,,,0,,444.2161408,5,3,3,1,2,2
6898,04/06/2019 00:00,DB08739,"2-{3-[(2S)-4,4-difluoro-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]-3-oxopropyl}-isoindole-1,3(2H)-dione",,,,,,solid,,,0.4,17.5,-1.8,[H][C@]1(CC(F)(F)CN1C(=O)CCN1C(=O)C2=C(C=CC=C2)C1=O)C(=O)N1CCCC1,,,,,0,,405.1500126,4,1,3,0,2,3
6899,04/06/2019 00:00,DB08740,"CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE",,,,,,solid,,,0.771,13.52,9.49,[H][C@](N)(CC1CCCCC1)[C@@]([H])(O)[C@@]([H])(O)CC(C)C,,,,,0,,243.2198292,1,0,0,0,0,0
6900,04/06/2019 00:00,DB08741,"5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine",,,,,,solid,,,0.142,17.32,7.15,[H][C@@]1(OC2=C(OC)C(OC)=CC(CC3=C(N)N=C(N)N=C3)=C2C=C1)C1CC1,,,,,0,,354.1691906,4,2,2,1,0,1
6901,04/06/2019 00:00,DB08742,"1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)",,,,,,solid,,,0.00898,14.06,-2.8,C=C1\C(=C/C=C2\CCC[C@]3(C)[C@]([H])(CC[C@@]23[H])C#CC#CC(C)(O)C)C[C@](O)([H])C[C@@]1(O)[H],,,,,0,,394.2507949,3,0,0,0,0,0
6902,04/06/2019 00:00,DB08743,"2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE",,,,,,solid,,,0.861,,9.86,[H][C@@]1(N)CCCN(C1)C1=NC2=C(N1CC1=CC=CC=C1C#N)C(=O)N(C)C(=O)N2C,,,,,0,,393.191323,4,3,3,2,1,1
6903,04/06/2019 00:00,DB08744,"6-methoxy-9-methyl[1,3]dioxolo[4,5-h]quinolin-8(9H)-one",,,,,,solid,,,5.5,,-1.9,COC1=CC(=O)N(C)C2=C1C=CC1=C2OCO1,,,,,0,,233.0688078,3,2,2,1,0,1
6904,04/06/2019 00:00,DB08745,4-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINONE,,,,,,solid,,,0.051,17.05,8.72,ClC1=CC=C(\C=C\S(=O)(=O)N2CCN(CC3CCN(CC3)C3=CC=NC=C3)C(=O)C2)C=C1,,,,,0,,474.1492394,4,2,3,1,2,2
6905,04/06/2019 00:00,DB08746,1-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-4-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINE,,,,,,solid,,,0.0698,,8.75,ClC1=CC=C(\C=C\S(=O)(=O)N2CCN(CC3CCN(CC3)C3=CC=NC=C3)CC2)C=C1,,,,,0,,460.1699748,4,2,3,1,2,2
6906,04/06/2019 00:00,DB08747,"(11R)-10-acetyl-11-(2,4-dichlorophenyl)-6-hydroxy-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one",,,,,,solid,,,0.00333,9.58,-2,[H][C@]1(N(C(C)=O)C2=CC=CC(O)=C2NC2=C1C(=O)CC(C)(C)C2)C1=C(Cl)C=C(Cl)C=C1,,,,,0,,444.1007479,4,2,1,0,0,1
6907,04/06/2019 00:00,DB08748,4-(DIMETHYLAMINO)BENZOIC ACID,,,,,,solid,,,8.46,4.76,2.89,CN(C)C1=CC=C(C=C1)C(O)=O,,,,,0,,165.0789786,1,1,0,0,0,0
6908,04/06/2019 00:00,DB08749,3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE,,,,,,solid,,,0.0242,,9.03,CN(C1CCCCC1)C(=O)CCN1CC2=CC(=CC=C2N=C1N)C(=O)C1=CC=CC=C1,,,,,0,,418.2368762,4,2,1,0,0,1
6909,04/06/2019 00:00,DB08750,"1-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINE",,,,,,solid,,,0.0787,11.7,9.37,NCC1=CC=C(C=C1)C(=O)N1CCC2(CC1)NC1=CC=CC(F)=C1C(N)=N2,,,,,0,,367.1808385,4,2,2,0,1,2
6910,04/06/2019 00:00,DB08751,"N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE",,,,,,solid,,,0.503,,-0.79,CN(CCN(C)C1=CC=C(C2=NON=C12)[N+]([O-])=O)C(C)=O,,,,,0,,293.112404,2,2,1,1,0,0
6911,04/06/2019 00:00,DB08752,N-[(1S)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide,,,,,,solid,,,0.678,8.49,7.37,[H][C@@](CC1CCCCC1)(NC(=O)N1CCOCC1)C(=O)NC1(CCN(C)CC1)C#N,,,,,0,,405.27399,3,0,2,0,2,2
6912,04/06/2019 00:00,DB08753,"4-{(1E)-3-OXO-3-[(2-PHENYLETHYL)AMINO]PROP-1-EN-1-YL}-1,2-PHENYLENE DIACETATE",,,,,,solid,,,0.000717,15.17,1.21,CC(=O)OC1=CC=C(\C=C\C(=O)NCCC2=CC=CC=C2)C=C1OC(C)=O,,,,,0,,367.1419728,2,2,0,0,0,0
6913,04/06/2019 00:00,DB08754,"(2E)-3-(3,4-DIHYDROXYPHENYL)-N-[2-(4-HYDROXYPHENYL)ETHYL]ACRYLAMIDE",,,,,,solid,,,0.038,9.04,1.21,OC1=CC=C(CCNC(=O)\C=C\C2=CC=C(O)C(O)=C2)C=C1,,,,,0,,299.115758,2,2,0,0,0,0
6914,04/06/2019 00:00,DB08755,N-[(1S)-2-{[(1R)-2-(benzyloxy)-1-cyano-1-methylethyl]amino}-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide,,,,,,solid,,,0.03,8.2,-1.7,[H][C@@](CC1CCCCC1)(NC(=O)N1CCOCC1)C(=O)N[C@@](C)(COCC1=CC=CC=C1)C#N,,,,,0,,456.2736556,3,1,1,0,1,1
6915,04/06/2019 00:00,DB08756,(R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE,,,,,,solid,,,0.552,13.44,10.45,[H][C@](C)(N)[C@@]1([H])CC[C@@]([H])(CC1)C(=O)NC1=CC=NC=C1,,,,,0,,247.1684623,2,1,1,1,0,0
6916,04/06/2019 00:00,DB08757,5-(2-chlorophenyl)furan-2-carbohydrazide,,,,,,solid,,,0.0769,12.51,2.57,NNC(=O)C1=CC=C(O1)C1=CC=CC=C1Cl,,,,,0,,236.0352552,2,2,1,1,0,0
6917,04/06/2019 00:00,DB08758,"IMIDAZO[2,1-A]ISOQUINOLINE-2-CARBOHYDRAZIDE",,,,,,solid,,,0.313,13.99,3.45,NNC(=O)C1=CN2C=CC3=C(C=CC=C3)C2=N1,,,,,0,,226.0854609,3,3,2,2,0,0
6918,04/06/2019 00:00,DB08759,"[(3R,4S,5S,7R)-4,8-DIHYDROXY-3,5,7-TRIMETHYL-2-OXOOCTYL]PHOSPHONIC ACID",,,,,,solid,,,4.31,2.09,-1.8,[H][C@](C)(CO)C[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)C[P@@]([H])(O)=O,,,,,0,,266.1283105,0,0,0,0,0,0
6919,04/06/2019 00:00,DB08760,(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid,,,,,,solid,,,0.0299,3.66,-4.9,[H][C@@](CC1=CC=CC=C1)(OC1=CC=C(Cl)C=C1)C(O)=O,,,,,0,,276.055322,2,2,0,0,0,0
6920,04/06/2019 00:00,DB08761,"(3S,6S)-3,6-bis(4-hydroxybenzyl)piperazine-2,5-dione",,,,,,solid,,,0.147,9.19,-4.5,[H][C@@]1(CC2=CC=C(O)C=C2)NC(=O)[C@]([H])(CC2=CC=C(O)C=C2)NC1=O,,,,,0,,326.1266571,3,2,1,0,1,1
6921,04/06/2019 00:00,DB08762,O-(((1R)-((N-PHENYLMETHOXYCARBONYL-L-ALANYL)AMINO)ETHYL)HYDROXYPHOSPHONO)-L-BENZYLACETIC ACID,,,,,,solid,,,0.0187,0.84,-4.9,[H][C@@](C)(NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@]([H])(C)[P@](O)(=O)O[C@@]([H])(CC1=CC=CC=C1)C(O)=O,,,,,0,,478.1505025,2,2,0,0,0,0
6922,04/06/2019 00:00,DB08763,[N-(BENZYLOXYCARBONYL)AMINO](4-AMIDINOPHENYL)METHANE-PHOSPHONATE,,,,,,solid,,,0.0262,1.41,11.48,[H][C@](NC(=O)OCC1=CC=CC=C1)(C1=CC=C(C=C1)C(N)=N)P(O)(O)=O,,,,,0,,363.0984073,2,2,0,0,0,0
6923,04/06/2019 00:00,DB08765,"6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE",,,,,,solid,,,1.18,7.5,-1.9,NS(=O)(=O)C1=NC2=C(S1)C=C(O)C=C2,,,,,0,,229.9819841,2,2,1,1,0,0
6924,04/06/2019 00:00,DB08766,Zofenoprilat,,,,,,solid,,,0.0519,3.91,-1.3,C[C@H](CS)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1,,,,,0,,325.0806355,2,1,1,0,1,1
6925,04/06/2019 00:00,DB08767,2-(4-METHOXYPHENYL)ACETAMIDE,,,,,,solid,,,1.82,16.04,-2.4,COC1=CC=C(CC(N)=O)C=C1,,,,,0,,165.0789786,1,1,0,0,0,0
6926,04/06/2019 00:00,DB08768,N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE,,,,,,solid,,,0.0869,9.87,5.06,CC(C)=CCNC1=C2N=CNC2=NC=N1,,,,,0,,203.1170954,2,2,2,2,0,0
6927,04/06/2019 00:00,DB08770,"4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol",,,,,,solid,,,0.248,10.25,3.32,NC1=NC(NCCC2=CC=C(O)C=C2)=NC2=NC(=NN12)C1=CC=CO1,,,,,0,,337.1287227,4,4,3,3,0,0
6928,04/06/2019 00:00,DB08771,"(5R)-2-[(2-fluorophenyl)amino]-5-(1-methylethyl)-1,3-thiazol-4(5H)-one",,,,,,solid,,,0.0891,5.72,-1.6,[H][C@@]1(SC(NC2=C(F)C=CC=C2)=NC1=O)C(C)C,,,,,0,,252.0732623,2,1,1,0,0,1
6929,04/06/2019 00:00,DB08772,"3,4-DIHYDRO-4-OXO-3-((5-TRIFLUOROMETHYL-2-BENZOTHIAZOLYL)METHYL)-1-PHTHALAZINE ACETIC ACID",,,,,,solid,,,0.00117,3.97,2.31,OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C2=C1C=CC=C2,,,,,0,,419.0551469,4,4,2,2,0,0
6930,04/06/2019 00:00,DB08773,RALOXIFENE CORE,,,,,,solid,,,0.0104,9.18,-5.5,OC1=CC=C(C=C1)C1=CC2=C(S1)C=C(O)C=C2,,,,,0,,242.0401506,3,3,1,1,0,0
6931,04/06/2019 00:00,DB08774,"1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine",,,,,,solid,,,0.581,10.35,9.07,[H][C@]1(CN)CN(CCO1)C1=C(C=NC2=C1C=NN2)C1=CC=CC=C1,,,,,0,,309.1589602,4,3,3,2,1,1
6932,04/06/2019 00:00,DB08775,NÎ±-[(Benzyloxy)carbonyl]-N-[(2S)-4-fluoro-3-oxo-2-butanyl]-L-tyrosinamide,,,,,,solid,,,0.0215,5.21,1.3,[H][C@@](C)(N=C(O)[C@]([H])(CC1=CC=C(O)C=C1)N=C(O)OCC1=CC=CC=C1)C(=O)CF,,,,,0,,402.1591001,2,2,0,0,0,0
6933,04/06/2019 00:00,DB08776,"N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE",,,,,,solid,,,0.241,10.69,-1.9,CC(=O)NC1=NC2=C(S1)C(=O)NCCC2,,,,,0,,225.0571976,2,1,2,1,0,1
6934,04/06/2019 00:00,DB08777,"5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE",,,,,,solid,,,0.057,9.84,2.47,O=C1NC=NC2=C1C1=C(CCCC1)S2,,,,,0,,206.0513839,3,2,2,2,0,0
6935,04/06/2019 00:00,DB08778,"[4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone",,,,,,solid,,,0.0245,14.37,2.4,CC(C)(C)NC1=NC(N)=C(S1)C(=O)C1=CC=CC=C1,,,,,0,,275.1092332,2,2,1,1,0,0
6936,04/06/2019 00:00,DB08779,2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol,,,,,,solid,,,0.384,11.02,2.06,CSC1=NC(O)=C(CC2=CC=CS2)N1,,,,,0,,226.0234549,2,2,2,2,0,0
6937,04/06/2019 00:00,DB08780,6-MORPHOLIN-4-YL-9H-PURINE,,,,,,solid,,,3.57,9.84,4.94,C1CN(CCO1)C1=C2N=CNC2=NC=N1,,,,,0,,205.09636,3,2,3,2,1,1
6938,04/06/2019 00:00,DB08781,"1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE",,,,,,solid,,,0.576,9.98,9.03,[H][C@]1(CN)CN(CCO1)C1=C(Br)C=NC2=C1C=NN2,,,,,0,,311.0381722,3,2,3,2,1,1
6939,04/06/2019 00:00,DB08782,4-(2-AMINOETHYL)BENZENESULFONAMIDE,,,,,,solid,,,2.13,10.5,9.62,NCCC1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,200.0619486,1,1,0,0,0,0
6940,04/06/2019 00:00,DB08783,(4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid,,,,,,solid,,,0.0356,12.59,-7.2,[H][C@@](CC1=CC=C(C[Se](O)=O)C=C1)(NC(=O)OC(C)(C)C)C(=O)OC,,,,,0,,405.0690588,1,1,0,0,0,0
6941,04/06/2019 00:00,DB08784,2-(4-CHLORO-PHENYLAMINO)-NICOTINIC ACID,,,,,,solid,,,0.0588,1.88,5.52,OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1,,,,,0,,248.0352552,2,2,1,1,0,0
6942,04/06/2019 00:00,DB08785,4-METHYL-2H-CHROMEN-2-ONE,,,,,,solid,,,0.311,,-7,CC1=CC(=O)OC2=CC=CC=C12,,,,,0,,160.0524295,2,2,1,1,0,0
6943,04/06/2019 00:00,DB08786,4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine,,,,,,solid,,,10.8,16.34,5.68,COCCOC1=NC(N)=NC(C)=C1,,,,,0,,183.1007767,1,1,1,1,0,0
6944,04/06/2019 00:00,DB08787,"4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine",,,,,,solid,,,0.00279,16.1,2.35,NC1=NC(=C(C=N1)\N=N\C1=CC=CC=C1)C1=C(Cl)C=C(Cl)C=C1,,,,,0,,343.0391507,3,3,1,1,0,0
6945,04/06/2019 00:00,DB08788,"3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE",,,,,,solid,,,0.0353,15.04,-1.2,CCOC1=CC=C(C=C1)C1=C(C#N)C(N)=NC2=C1C(N)=C(S2)C(N)=O,,,,,0,,353.0946457,3,3,2,2,0,0
6946,04/06/2019 00:00,DB08789,"2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE",,,,,,solid,,,0.00275,13.9,1.84,CCNC(=O)C1=CC2=C(N=C(N)N=C2S1)C1=C(Cl)C=C(Cl)C=C1,,,,,0,,366.0108874,3,3,2,2,0,0
6947,04/06/2019 00:00,DB08790,1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID,,,,,,solid,,,1.63,3.42,0.4,OC(=O)C1=CN(N=C1)C1=CC=CC=C1,,,,,0,,188.0585775,2,2,1,1,0,0
6948,04/06/2019 00:00,DB08791,"1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE",,,,,,solid,,,0.103,13.78,2.88,NC(=O)C1=CN=C2C=CN(C2=C1)S(=O)(=O)C1=CC=CC=C1[N+]([O-])=O,,,,,0,,346.0371904,3,3,2,2,0,0
6949,04/06/2019 00:00,DB08792,Diloxanide,"Bioavailability is 90% (in diloxanide parental form), however diloxanide furoate is slowly absorbed from the gastrointestinal tract.",,3 hours,,,solid,,2.24,2.31,9.39,-5.9,CN(C(=O)C(Cl)Cl)C1=CC=C(O)C=C1,,,3,3,0,,233.0010339,1,1,0,0,0,0
6950,04/06/2019 00:00,DB08794,Ethyl biscoumacetate,,,,,,solid,153 mg/L (at 20 Â°C),,0.0677,4.82,-6.7,CCOC(=O)C(C1=C(O)C2=CC=CC=C2OC1=O)C1=C(O)C2=CC=CC=C2OC1=O,,,,,0,,408.0845175,4,4,2,2,0,0
6951,04/06/2019 00:00,DB08795,Azidocillin,,,,,,solid,,,0.611,3.32,-6.4,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O,,,,,0,,375.100125,3,1,2,0,2,2
6952,04/06/2019 00:00,DB08796,Pipazethate,,,,,,solid,,,0.0415,,8.96,O=C(OCCOCCN1CCCCC1)N1C2=CC=CC=C2SC2=C1N=CC=C2,,,,,0,,399.1616627,4,2,3,1,1,2
6953,04/06/2019 00:00,DB08797,Salicylamide,,,,,Oral,solid,2060 mg/L (at 25 Â°C),1.28,7.82,8.21,-1.8,NC(=O)C1=CC=CC=C1O,,,,,0,,137.0476785,1,1,0,0,0,0
6954,04/06/2019 00:00,DB08798,Sulfamoxole,,,,,,solid,1680 mg/L (at 20 Â°C),,0.267,6.81,1.94,CC1=C(C)N=C(NS(=O)(=O)C2=CC=C(N)C=C2)O1,,,,,0,,267.0677623,2,2,1,1,0,0
6955,04/06/2019 00:00,DB08799,Antazoline,,,,,Ophthalmic,solid,663 mg/L (at 30 Â°C),,0.114,,9.24,C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1,,,,,0,,265.1578976,3,2,1,0,0,1
6956,04/06/2019 00:00,DB08800,Chloropyramine,,,,,,solid,Insoluble,,0.441,,8.76,CN(C)CCN(CC1=CC=C(Cl)C=C1)C1=CC=CC=N1,,,,,0,,289.1345753,2,2,1,1,0,0
6957,04/06/2019 00:00,DB08801,Dimetindene,,,,,,solid,239 mg/L (at 37 Â°C),,0.0384,18.93,9.7,CC(C1=C(CCN(C)C)CC2=CC=CC=C12)C1=CC=CC=N1,,,,,0,,292.1939488,3,2,1,1,0,0
6958,04/06/2019 00:00,DB08802,Isothipendyl,,,,,,solid,,,0.14,,8.91,CC(CN1C2=CC=CC=C2SC2=C1N=CC=C2)N(C)C,,,,,0,,285.1299686,3,2,2,1,0,1
6959,04/06/2019 00:00,DB08803,Tymazoline,,,,,,solid,,,0.118,,7.66,CC(C)C1=C(OCC2=NCCN2)C=C(C)C=C1,,,,,0,,232.1575633,2,1,1,0,0,1
6960,04/06/2019 00:00,DB08804,Nandrolone decanoate,,0.58,,100 mg,Intramuscular,solid,3.09 mg/mL at 25 Â°C,2.62,0.000157,19.28,-4.7,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,0.58,0.58,,,0,,428.3290453,4,0,0,0,0,0
6961,04/06/2019 00:00,DB08805,Metiamide,,,,,,solid,,0.5,0.0287,12.48,6.91,CNC(=S)NCCSCC1=C(C)NC=N1,,,,,0,,244.0816385,1,1,1,1,0,0
6962,04/06/2019 00:00,DB08806,Roxatidine acetate,Well absorbed orally (80â€“90% bioavailability).,5-7%,5-6 hours,,,solid,,,0.0612,14.88,8.83,CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1,0.05,0.07,5,6,0,,348.2049074,2,1,1,0,1,1
6963,04/06/2019 00:00,DB08807,Bopindolol,,,,,,solid,3.3 mg/ml (malonate salt),,0.0016,16.8,9.29,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1,,,,,0,,380.2099928,3,3,1,1,0,0
6964,04/06/2019 00:00,DB08808,Bupranolol,Quickly and completely absorbed from the gut with less than 10% oral bioavailability.,0.76,2-4 hours,,,solid,,,0.143,14.09,9.76,CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1,0.76,0.76,2,4,0,,271.1339066,1,1,0,0,0,0
6965,04/06/2019 00:00,DB08809,Dichloroacetic acid,,,,1,Topical,liquid,1E+006 mg/L (at 20 Â°C),0.92,72.3,2.3,,OC(=O)C(Cl)Cl,,,,,0,,127.9431847,0,0,0,0,0,0
6966,04/06/2019 00:00,DB08810,Cinitapride,"The absorption of cinitapride (12mg) following oral administration was rapid, with peak levels being achieved 2 h after dosing; absorption following intramuscular administration (4mg) was even more rapid, with peak levels (50% more that oral levels) being achieved 1 h after dosing.",,3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.,,,solid,,,0.0141,13.62,9.74,CCOC1=CC(N)=C(C=C1C(=O)NC1CCN(CC2CCC=CC2)CC1)[N+]([O-])=O,,,,,0,,402.2267054,3,1,1,0,1,1
6967,04/06/2019 00:00,DB08811,Tofisopam,,,6-8 hours,,,solid,,,0.00239,,-2.2,CCC1C2=CC(OC)=C(OC)C=C2C(=NN=C1C)C1=CC(OC)=C(OC)C=C1,,,6,8,0,,382.1892573,3,2,1,0,0,1
6968,04/06/2019 00:00,DB08814,Triflusal,"Absorbed in the small intestine with a bioavailability range from 83% to 100%. There is no significant difference between the absorption of the oral solution and capsule formulation.[A7337] Triflusal displays a Cmax of 11.6 mcg/ml and a tmax of 0.88 h. The major metabolite of triflusal presents different pharmacokinetic properties by showing a Cmax and tmax of 92.7 mcg/ml and 4.96 h, respectively.[A31677]",0.99,"In the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.[L1186]",,,solid,<1 mg/ml,2.231,0.696,3.39,-7.1,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O,0.99,0.99,,,0,,248.0296434,1,1,0,0,0,0
6969,02/07/2019 00:00,DB08815,Lurasidone,"Lurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and  time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content.  
Bioavailability = 9-19%. ",~99%,"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours ",120 mg,Oral,solid,,,0.00789,,8.5,[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O,0.99,0.99,,,0,120,492.2558974,7,2,3,1,2,2
6970,02/07/2019 00:00,DB08816,Ticagrelor,"Absorbed quickly from the gut, the bioavailability being 36%.",>99.7%,"Ticagrelor has a half life of 7 hours, while its active metabolite has a half life of 9 hours. ",60 mg,Oral,solid,10 Î¼g/mL,,0.063,12.94,2.93,CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1,0.99,1,,,0,60,522.1860808,5,3,2,2,0,0
6971,04/06/2019 00:00,DB08818,Hyaluronic acid,Hyaluronic acid is absorbed and diffuses slowly out of the injection site.,,,20 mg/500mL,Topical,solid,Easily soluble in cold water. Insoluble in organic solvents.,,46.6,2.87,-3.9,CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O,,,,,0,,776.2334857,4,0,4,0,4,4
6972,02/07/2019 00:00,DB08819,Tafluprost,"Following instillation, tafluprost is absorbed through the cornea and is hydrolyzed to the biologically active acid metabolite, tafluprost acid. Tafluprost is an ester which makes the drug lipophillic enough to be quickly absorbed through. When administered to the eye, the peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax) of tafluprost acid in healthy subjects was 26 pg/mL and 10 minutes respectively. a
AUC, tafluprost acid = 394 pg*min/mL - 432 pg*min/mL. ",,,4.5 mcg,Ophthalmic,liquid,Insoluble ,4.05,0.00528,14.51,-2.9,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1,,,,,0,,452.2374306,2,1,0,0,0,0
6973,02/07/2019 00:00,DB08820,Ivacaftor,"Ivacaftor is well absorbed in the gastrointestinal tract.[A179674] Following administration of ivacaftor with fat-containing foods, peak plasma concentrations were reached at 4 hours (Tmax) with a maximum concentration (Cmax) of 768 ng/mL and AUC of 10600 ng * hr/mL. It is recommended that ivacaftor is taken with fat-containing foods as they increase absorption by approximately 2.5- to 4-fold.[L6838]",0.99,"In a clinical study, the apparent terminal half-life was approximately 12 hours following a single dose of ivacaftor.[L6838] One source mentions the half-life ranges from 12 to 14 hours.[A179674]",25 mg/1,Oral,solid,low (<0.05 Âµg/mL),3.13,0.002,6.57,-0.95,CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C,0.99,0.99,,,0,25,392.2099928,3,3,1,1,0,0
6974,02/07/2019 00:00,DB08822,Azilsartan medoxomil,"Azilsartan medoxomil is hydrolyzed to the active metabolite azilsartan in the GI tract. The presence of food does not affect oral absorption of azilsartan medoxomil, and the bioavailability is 60% for azilsartan. Maximum plasma concentrations are reached in 1.5 to 3 hours.",0.99,"The half-life is 11 hours, and it takes about 5 days to reach steady state concentrations.",40 mg/1,Oral,solid,practically insoluble,,0.00703,9.21,1.75,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1,0.99,0.99,,,0,40,568.1594137,6,6,3,3,0,0
6975,04/06/2019 00:00,DB08824,Ioflupane I-123,Absorption is 100% because administered I.V.,,Half life is 13.2 hours.,2 mCi/1mL,Intravenous,liquid,Soluble in water,,0.00566,,9.46,[H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C([123I])C=C1)C(=O)OC)N2CCCF,,,,,0,,427.0768712,3,1,2,0,2,2
6976,02/07/2019 00:00,DB08826,Deferiprone,Deferiprone is absorbed in the upper gastrointestinal tract. Absorption is rapid with maximum plasma concentrations occurring after 1 hour in the fasted state and after 2 hours in the fed state.,,The half-life is 1.9 hours.,500 mg/1,Oral,solid,Maximum water solubility of 16â€“18 g/L at 24Â°,,273,11.82,0.52,CN1C=CC(=O)C(O)=C1C,,,,,0,500,139.0633285,1,1,1,1,0,0
6977,02/07/2019 00:00,DB08828,Vismodegib,The absolute bioavailability of a single dose is 31.8%. Absorption is saturable and is not affected by food. ,,"The half-life after a single dose is 12 days, and after continuous daily dosing is 4 days.",150 mg/1,Oral,solid,0.1 Î¼g/mL and is pH dependent ,2.7,0.00173,10.27,3.7,CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1,,,,,0,150,420.0102187,3,3,1,1,0,0
6978,04/06/2019 00:00,DB08830,Dehydroascorbic acid,,,,,,solid,Soluble in water at 60Â°C,,190,1.56,-3,[H][C@](O)(CO)[C@@]1([H])OC(=O)C(=O)C1=O,,,,,0,,174.0164379,1,0,1,0,1,1
6979,04/06/2019 00:00,DB08831,2-deoxyglucose,,,,,,solid,,,379,12.84,-3,[H]C([H])(C=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)CO,,,,,0,,164.0684735,0,0,0,0,0,0
6980,04/06/2019 00:00,DB08833,Taurochenodeoxycholic acid,,,,,,solid,,,0.00748,-0.99,0.18,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(=O)NCCS(O)(=O)=O,,,,,0,,499.2967592,4,0,0,0,0,0
6981,04/06/2019 00:00,DB08834,Tauroursodeoxycholic acid,,,,,,solid,,,0.00748,-0.8,-0.32,[H][C@@]12CC[C@H]([C@H](C)CCC(=O)NCCS(O)(=O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C[C@]2([H])C[C@H](O)CC[C@]12C,,,,,0,,499.2967592,4,0,0,0,0,0
6982,04/06/2019 00:00,DB08835,Spaglumic Acid,,,,,,solid,,,3.22,3.01,-2,CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O,,,,,0,,304.0906655,0,0,0,0,0,0
6983,04/06/2019 00:00,DB08836,Temocapril,"Temocapril is rapidly absorbed in the gastrointestinal tract and converted into the 
diacid (active) metabolite, which inhibits ACE in plasma.  ",,13.1 hours in patients with normal liver function. ,,,solid,<1 mg/mL,,0.00342,3.88,5.14,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)C1=CC=CS1,,,,,0,,476.143964,3,2,2,1,1,1
6984,04/06/2019 00:00,DB08837,Tetraethylammonium,,,,,,solid,Soluble in water.,,0.00277,,,CC[N+](CC)(CC)CC,,,,,1,,130.1590261,0,0,0,0,0,0
6985,04/06/2019 00:00,DB08838,Agmatine,,,,,,solid,,,3.61,,12.61,NCCCCNC(N)=N,,,,,0,,130.1218464,0,0,0,0,0,0
6986,04/06/2019 00:00,DB08839,Serotonin,,,,,,solid,,,2.5,9.31,10,NCCC1=CNC2=CC=C(O)C=C12,,,,,0,,176.094963,2,2,1,1,0,0
6987,04/06/2019 00:00,DB08840,N-methylnicotinamide,,,,,,solid,,,18.6,13.75,3.62,CNC(=O)C1=CC=CN=C1,,,,,0,,136.0636629,1,1,1,1,0,0
6988,04/06/2019 00:00,DB08841,Tyramine,,,,,,solid,,,5.72,10.41,9.66,NCCC1=CC=C(O)C=C1,,,,,0,,137.084064,1,1,0,0,0,0
6989,04/06/2019 00:00,DB08842,Acetylcarnitine,Acetylcarnitine supplements are absorbed in a similar manner to L-carnitine.,,,,,solid,Very soluble in water and alcohol.,,0.355,4.09,-7,CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C,,,,,0,,203.115758,0,0,0,0,0,0
6990,04/06/2019 00:00,DB08843,GS 0573,,,,,,solid,,,1.94,1.36,6.02,NC1=NC(N)=C2N=CN(CCOCP(O)(O)=O)C2=N1,,,,,0,,288.0735895,2,2,2,2,0,0
6991,04/06/2019 00:00,DB08844,Uric acid,,,,,,solid,60 mg/L (at 20 Â°C),-2.17,1.76,7.61,-6.5,O=C1NC2=C(N1)C(=O)NC(=O)N2,,,,,0,,168.02834,2,2,2,2,0,0
6992,04/06/2019 00:00,DB08845,Oxogluric acid,,,,,,solid,100 g/l at 20 Â°C (68 Â°F),,53.1,2.66,-9.7,OC(=O)CCC(=O)C(O)=O,,,,,0,,146.0215233,0,0,0,0,0,0
6993,04/06/2019 00:00,DB08846,Ellagic Acid,"After oral consumption, ellagic acid reaches maximum concentrations in about 1 hour. ",,,,,solid,Slightly soluble in alcohol or water,,0.823,5.54,-4.8,OC1=C(O)C2=C3C(=C1)C(=O)OC1=C3C(=CC(O)=C1O)C(=O)O2,,,,,0,,302.0062672,4,4,2,2,0,0
6994,04/06/2019 00:00,DB08847,Hydroxyproline,,,,0.5 mL/100mL,Topical,solid,"Soluble in water at 0, 25, 50, and 60 Â°C",,492,1.64,10.62,O[C@H]1CN[C@@H](C1)C(O)=O,,,,,0,,131.0582431,1,0,1,0,1,1
6995,04/06/2019 00:00,DB08848,Guvacine,,,,,,solid,"Soluble in water, and almost insoluble in 100% alcohol, ether, chloroform, and benzene.",,30.8,3.76,9.77,OC(=O)C1=CCCNC1,,,,,0,,127.0633285,1,0,1,0,0,1
6996,04/06/2019 00:00,DB08855,Leukotriene C4,,,,,,solid,,,0.00254,1.8,9.31,CCCCC\C=C/C\C=C/C=C/C=C/[C@@H](SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)[C@@H](O)CCCC(O)=O,,,,,0,,625.3033011,0,0,0,0,0,0
6997,04/06/2019 00:00,DB08856,DADLE,,,,,,solid,,,0.00963,3.7,7.73,CC(C)C[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O,,,,,0,,569.2849486,2,2,0,0,0,0
6998,04/06/2019 00:00,DB08858,cis-Diamminechlorocholylglycinateplatinum(II),,,,,,solid,,,0.155,3.83,1.83,N.N.Cl.[Pt++].CC(CCC([O-])=NCC([O-])=O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,,,,,0,,728.287955,4,0,0,0,0,0
6999,04/06/2019 00:00,DB08860,Pitavastatin,"Bioavailability = 51%;
Time to peak, plasma = 1 hour;
Pitavastatin was absorbed in the small intestine but very little in the colon. Cmax decreases by 43% if pitavastatin is taken with a fatty meal but there are no significant changes to AUC or baseline LDL levels compared to fasting state. The Cmax and AUC of pitavastatin did not differ following evening or morning drug administration. ",>99%,Plasma elimination half-lfie = 12 hours ,1 mg/1,Oral,solid,Very slightly soluble ,,0.00394,4.13,4.86,O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O,0.99,1,,,0,1,421.1689365,4,3,1,1,0,0
7000,04/06/2019 00:00,DB08861,DPDPE,,,,,,solid,,,0.00632,3.39,7.73,CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)CC2=CC=C(O)C=C2)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H]1C(O)=O,,,,,0,,645.2290906,3,2,1,0,1,1
7001,02/07/2019 00:00,DB08864,Rilpivirine,"Absorption of rilpivirine is characterized by a lag time followed by a linear increase in plasma concentration. Under fasting conditions, the Cmax of rilpivirine can be decreased even by 46% while its AUC can be reduced by 43%. When given with a protein-rich drink the Cmax and AUC of rilpivirine is decreased by 50%. Therefore, it is recommended to consume rilpiviridine with a non-protein-rich meal. The average Tmax of various rilpivirine concentrations is 3-4 h.[A31331] The reported AUC in patients from clinical studies is 2235 ng h/ml.[FDA label]",>99%,"Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331] ",25 mg,Oral,solid,<0.1mg/ml,4.86,0.0116,12.93,5.16,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1,0.99,1,,,0,25,366.1592946,3,3,1,1,0,0
7002,02/07/2019 00:00,DB08865,Crizotinib,"The peak serum concentration was reached in 4 to 6 hours following an oral single-dose administration. Steady state was reached within 15 days when a dose of 250 mg twice daily was administered. The mean absolute bioavailability was 43% (range of 32% to 66%) following a single 250 mg oral dose. When taken with high-fat meal, AUC and Cmax were reduced. ",0.91,"Plasma terminal half-life, patients = 42 hours ",200 mg/1,Oral,solid,,1.83,0.00611,,10.12,C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl,0.91,0.91,,,0,200,449.1185439,4,3,3,2,1,1
7003,02/07/2019 00:00,DB08867,Ulipristal,"Tmax, healthy subjects, single oral dose = 60-90 minutes;
Cmax, healthy subjects, single oral dose = 176 Â± 89  ng/mL;
AUC(0-âˆž), healthy subjects, single oral dose = 556 Â± 260 ngÂ·h/mL;
",>94%,"Mean elimination half-life, single oral dose, healthy subject = 32.4 Â± 6.3 hours ",30 mg/1,Oral,solid,,,0.00943,12.7,4.89,CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12,0.94,1,,,0,30,433.261694,5,1,0,0,0,0
7004,02/07/2019 00:00,DB08868,Fingolimod,"The Tmax of fingolimod is 12-16 hours. 
Bioavailability: 93% ",>99.7%,6-9 days,0.25 mg,Oral,solid,Soluble,4.178,0.0069,14.41,9.38,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,0.99,1,144,216,0,0.25,307.2511293,1,1,0,0,0,0
7005,02/07/2019 00:00,DB08871,Eribulin,,,about 40 hours,0.5 mg/1mL,Intravenous,liquid,,,0.0798,14.81,9.39,[H][C@@]12O[C@@]3([H])CCC4CC(=O)C[C@H]5[C@H](C[C@H]6O[C@H](C[C@@H](C)C6=C)CC[C@@H]6O[C@H](CC6=C)CC[C@@]67C[C@@H](O[C@H]1[C@@H](O6)[C@@]3([H])O4)[C@@H]2O7)O[C@H](C[C@H](O)CN)[C@@H]5OC,,,,,0,,729.4088117,10,0,10,0,10,10
7006,04/06/2019 00:00,DB08872,Gabapentin enacarbil,"Gabapentin enacarbil is absorbed in the intestines by active transport through the proton-linked monocarboxylate transporter, MCT-1. ",,The elimination half-life of gabapentin is 5.1 to 6.0 hours.,300 mg/1,Oral,solid,Solubility of 0.5 mg/mL in water ,,0.325,4.35,-7.1,CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1,,,,,0,300,329.1838376,1,0,0,0,0,0
7007,04/06/2019 00:00,DB08873,Boceprevir,"Boceprevir reaches peak plasma concentration 2 hours after administration [FDA Label]. Absolute bioavailability has not been determined. When taken with food exposure increases up to 65%. In capsule, Boceprevir consists of two diaseromers in a 1:1 ratio. In plasma this ratio changes to 2:1 favoring the active diastereomer.",0.75,Boceprevir has a mean half-life of elimination of 3.4 hours [FDA Label].,200 mg/1,Oral,solid,,,0.0234,12.44,-0.91,[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C,0.75,0.75,,,0,200,519.3420695,3,0,1,0,1,1
7008,02/07/2019 00:00,DB08874,Fidaxomicin,"Fidaxomicin is not systemically absorbed as shown by a plasma concentrations below the lower limit of quantification after single-dose or multiple-dose. In contrast, fecal concentrations of fidaxomicin are much higher and are concentration-dependent.
Cmax = 2 hours;
Tmax = 5.2 ng/mL; 
AUC = 14 ngâ€¢hr/mL ",,"200 mg, healthy subjects = 11.7 hours ",200 mg,Oral,solid,,,0.0125,5.87,-1.4,CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\C(=O)OC(C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O,,,,,0,200,1056.425221,4,1,3,0,2,3
7009,02/07/2019 00:00,DB08875,Cabozantinib,"After oral administration, peak plasma concentration was achieved in 2-5 hours.",,Cabozantinib has a long half-life of 55 hours.,20 mg,Oral,solid,COMETRIQ is practically insoluble in water.,,0.00199,13.46,5.9,COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2,,,,,0,20,501.1699991,5,4,1,1,0,0
7010,02/07/2019 00:00,DB08877,Ruxolitinib,"Absorption is rapid and is not affected by food. 
Cmax, 15 mg, healthy subject = 649 nmol/L; 
Tmax, 15 mg, healthy subject = 1.5 hours;
Ruxolitinib does not accumulate significantly.  
",0.97,"Mean elimination half-life, 15 mg, healthy subject = 2.8 hours. ",10.0 mg/1,Oral,solid,Soluble in aqueous buffers across a pH of 1-8,,0.116,13.89,5.51,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,0.97,0.97,,,0,10,306.1592946,4,3,3,3,0,0
7011,04/06/2019 00:00,DB08878,Aminopterin,,,,,,solid,3.0X103 mg/L,-1.8,0.106,3.38,2.25,NC1=NC2=C(N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=N2)C(N)=N1,,,,,0,,440.1556657,3,3,2,2,0,0
7012,02/07/2019 00:00,DB08880,Teriflunomide,"After oral administration of teriflunomide, maximum plasma concentrations are reached, on average, in 1-4 hours.

",,The median half-life is 18 to 19 days.,14 mg,Oral,solid,Soluble in DMSO (practically insoluble in water).,,0.0124,5.48,-3.2,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,,,,,0,14,270.0616122,1,1,0,0,0,0
7013,02/07/2019 00:00,DB08881,Vemurafenib,"Vemurafenib is well absorbed after oral administration.[A31273] Peak concentrations are reached in 3 hours when an oral dose of 960 mg twice daily for 15 days has been given to patients. In the same conditions, Vemurafenib presents a Cmax of 62 mcg/ml and AUC of 601 mcg h/ml.[FDA label] It is unknown how food affects the absorption of vemurafenib. It presents an accumulation ratio of 7.36 after repeating doses of 960 mg [L1014]",>99%,The elimination half-life of Vemurafenib is estimated to be 57 hours (range of 30-120 hours).[A31274],240 mg,Oral,solid,<1 mg/mL ,5.1,0.000362,7.17,3.2,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,0.99,1,,,0,240,489.0725466,4,4,2,2,0,0
7014,02/07/2019 00:00,DB08882,Linagliptin,Oral bioavailability of linagliptin is 30%[A37050].,0.99,The terminal half life of linagliptin is 155 hours[A176948].,5 mg/1,Oral,solid,<1 mg/mL ,,0.0502,,9.86,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1,0.99,0.99,,,0,5,472.2335221,5,4,4,3,1,1
7015,02/07/2019 00:00,DB08883,Perampanel,"After oral adminitration, perampanel is absorbed rapidly and completely.",95-96%,Perampanel has a long elmination half-life of about 105 hours.,0.5 mg,Oral,solid,Practically insoluble in water.,,0.0056,,4.01,O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1,0.95,0.96,,,0,0.5,349.1215121,4,4,2,2,0,0
7016,02/07/2019 00:00,DB08884,Gadoxetic acid,,<10%,"Terminal elimination half-life, healthy subjects, adults = 0.91 - 0.95 hours ",181.43 mg/1mL,Intravenous,solid,,,0.497,1.98,9.99,[Gd+3].[H][C@@](CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)(CC1=CC=C(OCC)C=C1)N(CC(O)=O)CC(O)=O,0,0.1,,,0,,682.1121377,1,1,0,0,0,0
7017,04/06/2019 00:00,DB08887,Icosapent ethyl,"Icosapent ethyl is de-esterfied, converted into active EPA, and then absorbed in the small intestine. It reaches peak plasma concentration in 5 hours post-oral administration. Very little (<1%) is left circulating in the plasma as EPA incorporates into phospholipids, TG's, and cholesteryl esters. ",,The half life of EPA is 89 hours. ,1000 mg/1,Oral,solid,,,9.83E-05,,-7,CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC,,,,,0,1000,330.2558803,0,0,0,0,0,0
7018,02/07/2019 00:00,DB08889,Carfilzomib,"Cmax, single IV dose of 27 mg/m^2 = 4232 ng/mL; 
AUC, single IV dose of 27 mg/m^2 = 379 ngâ€¢hr/mL;
Carfilzomib does not accumulation in the systemic. At doses between 20 and 36 mg/m2, there was a dose-dependent increase in exposure.",0.97,"Following intravenous administration of doses â‰¥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of â‰¤ 1 hour on Day 1 of Cycle 1.",10 mg/5mL,Intravenous,solid,Insoluble ,,0.00484,11.91,4.96,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,0.97,0.97,,,0,,719.4257992,4,2,2,0,2,2
7019,02/07/2019 00:00,DB08890,Linaclotide,"When taken orally, linaclotide is not absorbed into the systemic. No detectable levels of linaclotide or its active metabolite were noted after doses of 125 mcg or 290 mcg were administered. ",,"Because linaclotide is not systemically absorbed, half life cannot be calculated. ",145 mcg,Oral,solid,Slightly soluble ,,0.701,3.06,7.65,[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,,,,,0,0.145,1525.389921,6,2,4,0,4,4
7020,04/06/2019 00:00,DB08891,Arbaclofen,"Unlike baclofen, absorption of arbaclofen is not limited to the upper small intestine. Arbaclofen can also be absorbed in the lower small intestine and the colon, allowing for the development of sustained release formulations.   ",,,,,solid, 2090 mg/L,1.3,0.712,3.89,9.79,[H][C@@](CN)(CC(O)=O)C1=CC=C(Cl)C=C1,,,,,0,,213.0556563,1,1,0,0,0,0
7021,04/06/2019 00:00,DB08892,Arbaclofen Placarbil,"Unlike baclofen, absorption of R-baclofen(arbaclofen) is not limited to the upper small intestine. The ability of arbaclofen to be absorbed throughout the gastrointestinal tract allowed for the development of the sustained release formulation, arbaclofen placarbil (AP). 

In one study of AP absorption in 10 healthy volunteers, one 20mg oral dose of AP, in the presence of food, resulted in a Tmax of 5.05h. 

The oral bioavailability of R-baclofen in rats when AP was dosed at 10mg/kg was 44  Â± 12%, and when dosed at 1mg/kg, oral bioavailability was 68 Â± 6%. 

In monkeys and dogs, the oral bioavailability of R-baclofen when AP was orally dosed was high: 94 Â± 16%, and 92 Â± 7%, respectively.  In comparison, when oral R-balofen was dosed oral bioavailability was 39 Â± 21% in monkeys and 49 Â± 20% in dogs.

Colonic absorption studies measuring R-baclofen bioavailability post intracolonic dosing in rats and monkeys, have revealed low bioavailability with the administration of R-baclofen (7 Â± 3% and 3 Â± 2%, respectively), and significantly higher R-baclofen bioavailability with intracolonic dosing of AP suspension ( 37 Â± 9% and 37 Â± 15%, in rats and monkeys respectively). 
Intracolonic dosing of AP suspension also resulted in high biolavailability of R-baclofen in dogs (77 Â± 23%).   

Absorption throughout the intestine is both passive and active and occurs via the monocarboxylate type 1 transporter.",,IV bolus administration of AP to rats showed that AP was converted to R-baclofen with a half life of 6 minutes. ,,,solid,,,0.0111,3.96,-7.1,CC(C)[C@H](OC(=O)NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1)OC(=O)C(C)C,,,,,0,,399.1448652,1,1,0,0,0,0
7022,02/07/2019 00:00,DB08893,Mirabegron,"The absolute bioavailability increases from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax and AUC increase more than dose proportionally. This relationship is more apparent at doses above 50 mg. Females generally have a lower magnitude of increase of Cmax and AUCtau compared to males when doses of mirabegron doubles or quadruples. Steady state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady state is approximately double that seen after a single dose.
Tmax, oral dose, healthy subjects= 3.5 hours;",0.71,Terminal elimination half-life = 50 hours ,25 mg,Oral,solid,Insoluble ,,0.00412,13.84,9.62,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,0.71,0.71,,,0,25,396.161997,3,3,1,1,0,0
7023,02/07/2019 00:00,DB08895,Tofacitinib,"74% oral absorption (absolute bioavailability), with peak plasma concentrations (T <sub> max</sub>) achieved in 0.5-1 hour.  

Administration with fatty meals does not alter AUC but reduces Cmax by 32%. ",,~3 hours,10 mg,Oral,solid,,1.808,0.299,8.46,7.13,[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,,,3,3,0,10,312.1698593,3,2,3,2,1,1
7024,02/07/2019 00:00,DB08896,Regorafenib,"Cmax = 2.5 Î¼g/mL;
Tmax = 4 hours; 
AUC = 70.4 Î¼g*h/mL; 
Cmax, steady-state = 3.9 Î¼g/mL;
AUC, steady-state = 58.3 Î¼g*h/mL;
The mean relative bioavailability of tablets compared to an oral solution is 69% to 83%.",,"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);  ",40 mg,Oral,solid,Insoluble ,,0.00102,10.52,2.02,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,,,,,0,40,482.0768809,3,3,1,1,0,0
7025,02/07/2019 00:00,DB08897,Aclidinium,"Bioavailability, healthy subjects = 6%;
T max, healthy subjects = 10 minutes;
Time to steady state, healthy subjects = 2 days; ",,"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours. ",322 Î¼g,Respiratory (inhalation),solid,Very slightly soluble ,,0.00152,10.35,-4.8,OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1,,,,,1,,484.1610769,6,3,5,2,3,3
7026,02/07/2019 00:00,DB08899,Enzalutamide,"The pharmacokinetic profile of enzalutamide and N-desmethyl enzalutamide (its major active metabolite) is described by a linear two-compartment model with first-order absorption. Enzalutamide also accumulates. Food does not affect its absorption. 
Tmax, prostate cancer patients = 1 hour (range of 0.5-3 hours);
Cmax, steady state, enzalutamide = 16.6 Î¼g/mL;
Cmax, steady state, N-desmethyl enzalutamide = 12.7 Î¼g/mL;
Time to steady state, daily dosing = 28 days; ",0.97,"The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.",40 mg/1,Oral,solid,Insoluble ,,0.00136,13.05,-1.7,CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F,0.97,0.97,,,0,40,464.0930096,3,2,1,0,1,1
7027,02/07/2019 00:00,DB08901,Ponatinib,"The absolute bioavailability of ponatinib is unknown. Peak concentrations of ponatinib are observed within 6 hours after Iclusig oral administration. Food does not affect absorption of food. The aqueous solubility of ponatinib is pH dependent, with higher pH resulting in lower solubility.
When 45 mg of ponatinib is given to cancer patients, the pharmacokinetic parameters are as follows: 
Cmax = 73 ng/mL;
AUC = 1253 ngâ€¢hr/mL; ",0.99,"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours). ",15 mg,Oral,solid,,,0.00295,11.36,8.03,CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1,0.99,0.99,,,0,15,532.2198441,5,4,3,2,1,1
7028,04/06/2019 00:00,DB08903,Bedaquiline,"Tmax, oral dose = 5 hours;
Food increases the oral bioavailability. AUC increases proportionally up to the highest dose studied in healthy volunteers. When 400 mg of bedaquiline is administered once daily for a week, the peak plasma concentration (Cmax) is 5.5 Î¼g/ml and an AUC of 64.75 Î¼gh/ml. ",,"Terminal elimination half-life, bedaquiline and M2 = 5.5 months. This long half-life suggests slow release of bedaquiline and M2 from peripheral tissues. ",100 mg/1,Oral,solid,Insoluble ,,0.000193,13.61,8.91,COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2,,,,,0,100,554.1568903,5,5,1,1,0,0
7029,04/06/2019 00:00,DB08905,Formestane,"Formestane has poor oral bioavailability, but is fully bioavailable when administered via the established intramuscular route. The AUC after an intravenous pulse dose does not vary considerably from that of an intramuscular dose. 

Within 24-48 h of the first dose of intramuscular formestane, a C(max) of 48.0 +/- 20.9 nmol/l was achieved in one study. [2]  ",,"Terminal plasma elimination half life of 18 minutes, when delivered intravenously. [2] ",,Intramuscular,solid,Insoluble ,2.66,0.0578,9.21,-3.7,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C,,,,,0,,302.1881947,4,0,0,0,0,0
7030,02/07/2019 00:00,DB08906,Fluticasone furoate,"Intranasal exposure of fluticasone furoate results in patients swallowing a larger portion of the dose[FDA Label][A177118]. However, absorption is poor and metabolism is high, therefore there is negligible systemic exposure with a nasal bioavailability of 0.50% and oral bioavialability of 1.26%[FDA Label][A7490]. Inhaled bioavailability is 13.9%[F4364]. A study of 24 healthy Caucasian males showed an inhaled bioavailability of 6.3-18.4%[A7490].",,15.1 hours for intranasal fluticasone furoate[FDA Label] and 24 hours for the inhaled formulation[F4364]. A study of 24 healthy Caucasian males showed a half life of 13.6 hours following intravenous administration and 17.3-23.9 hours followed inhalation[A7490].,27.5 micrograms/spray,Intrasinal,solid,Insoluble ,,0.0434,13.56,-3.4,[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,538.1636943,5,1,1,1,0,0
7031,02/07/2019 00:00,DB08907,Canagliflozin,"**Bioavailability and steady-state**

The absolute oral bioavailability of canagliflozin, on average, is approximately 65% [FDA label]. Steady-state concentrations are achieved after  4 to 5 days of daily dose administration between the range of 100mg to 300mg [FDA label].

**Effect of food on absorption** 

Co-administration of a high-fat meal with canagliflozin exerted no appreciable effect on the pharmacokinetic parameters of canagliflozin. This drug may be administered without regard to food. Despite this, because of the potential of canagliflozin to decrease postprandial plasma glucose excretion due to prolonged intestinal glucose absorption, it is advisable to take this drug before the first meal of the day [FDA label]. ",0.99,"In a clinical study, the terminal half-life of canagliflozin was 10.6 hours for the 100mg dose and 13.1 hours for the 300 mg dose [FDA label]. ",100 mg,Oral,solid,almost insoluble,3.44,0.0045,12.57,-3,[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1,0.99,0.99,,,0,100,444.1406731,4,3,2,1,1,1
7032,02/07/2019 00:00,DB08908,Dimethyl fumarate,"Once ingested, dimethyl fumarate is rapidly hydroylyzed by esterases to MMF. Thus there is negligible amount of dimethyl fumarate in the body, and all pharmacokinetic information is quantified with MMF. In multiple sclerosis patients, the time to maximum concentration of MMF is 2 to 2.5 hours and the maximum concentration is 1.87 mg/L.  
",,"MMF has a short half life of about 1 hour, and MMF does not accumulate after repeated doses of dimethyl fumarate.
",120 mg/1,Oral,solid,Highly soluble in water.,,12.9,,-6.5,[H]\C(=C(\[H])C(=O)OC)C(=O)OC,,,,,0,120,144.0422587,0,0,0,0,0,0
7033,04/06/2019 00:00,DB08909,Glycerol phenylbutyrate,"Glycerol phenylbutyrate is a prodrug in which phenylbutyrate (PBA) is released from the glycerol backbone by lipases in the gastrointestinal tract. PBA then undergoes beta-oxidtion to form PAA. When a single oral dose of 2.9 mL/m2 of Glycerol phenylbutyrate is given to fasting adult subjects, the pharmacokinetic parameters are as follows: 
Tmax: PBA = 2 hours; PAA = 4 hours; PAGN = 4 hours. 
Cmax: PBA = 37.0 Âµg/mL; PAA = 14.9 Âµg/mL; PAGN = 30.2 Âµg/mL. 
In healthy subjects, the hydrolysis of glycerol phenylbutyrate is incomplete, but to what extent is unknown. 
When glycerol phenylbutyrate is given to adult UCD patients, maximum plasma concentrations at steady state (Cmaxss) of PBA, PAA, and PAGN occurred at 8 h, 12 h, and 10 h, respectively, after the first dose in the day. Intact glycerol phenylbutyrate was not detectable in plasma in UCD patients.
",0.806,,1.1 g/1mL,Oral,solid,Insoluble ,,5.09E-05,,-6.6,O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1,0.806,0.806,,,0,,530.2668389,3,3,0,0,0,0
7034,02/07/2019 00:00,DB08910,Pomalidomide,"Pomalidomide is generally well absorbed. The major circulating component is the parent compound. 
Tmax, single oral dose = 2 -3 hours. 
When 4 mg of promalidomide is given to patients with multiple myeloma, the steady-state pharmacokinetic parameters are as follows:
AUC(T) = 400 ng.hr/mL;
Cmax = 75 ng/mL. 
Promalidomide accumulates following multiple doses. ",12-44%,"Healthy subjects = 9.4 hours;
Multiple myeloma patients = 7.5 hours. ",1 mg/1,Oral,solid,,,2.57,11.59,1.56,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,0.12,0.44,,,0,1,273.0749558,3,1,2,0,1,2
7035,02/07/2019 00:00,DB08911,Trametinib,"Trametinib is readily absorbed. When an oral administration of trametinib was given to patients with BRAF V600 mutation-positive melanoma, peak plasma concentration occurred 1.5 hours post-dose (Tmax). A single 2 mg oral dose has a bioavailability of 72%. When a dose of 2mg/day is given, the peak plasma concentration (Cmax) is 22.2 ng/mL [FDA label].",0.974,Elimination half-life = 3.9-4.8 days [FDA label].,0.5 mg,Oral,solid,,,0.0307,12.6,-3.7,CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,0.974,0.974,93.6,115.2,0,0.5,615.0778804,5,4,2,2,0,0
7036,02/07/2019 00:00,DB08912,Dabrafenib,"After oral administration, median time to achieve peak plasma concentration (Tmax) is 2 hours. Mean absolute bioavailability of oral dabrafenib is 95% [L2711].",0.997,The average terminal half-life of dabrafenib is 8 hours after oral dosing [FDA label].,50 mg/1,Oral,solid,very slightly soluble at pH 1,2.9,0.00327,7.16,2.91,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1,0.997,0.997,,,0,50,519.1010515,4,4,2,2,0,0
7037,04/06/2019 00:00,DB08913,Radium Ra 223 Dichloride,"Since Radium Ra 223 Dichloride is administered I.V., the bioavailability should be 100%. ",,"The half-life is relatively long at 11.4 days for radium-223.
",90 uCi/1mL,Intravenous,liquid,,,74.7,,,Cl[223Ra]Cl,,,,,0,,292.9562076,0,0,0,0,0,0
7038,04/06/2019 00:00,DB08915,Aleglitazar,,,,,,solid,,,0.00797,4.3,0.93,CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=O,,,,,0,,437.1296938,4,4,2,2,0,0
7039,02/07/2019 00:00,DB08916,Afatinib,"Following oral administration, time to peak plasma concentration (Tmax) is 2 to 5 hours [FDA Label]. Maximum concentration (Cmax) and area under the concentration-time curve from time zero to infinity (AUC0-âˆž) values increased slightly more than dose proportional in the range of 20 to 50 mg [FDA Label]. The geometric mean relative bioavailability of 20 mg tablets was 92% as compared to an oral solution [FDA Label].

Additionally, systemic exposure to afatinib is decreased by 50% (Cmax) and 39% (AUC0-âˆž), when administered with a high-fat meal compared to administration in the fasted state [L2937]. Based on population pharmacokinetic data derived from clinical trials in various tumor types, an average decrease of 26% in AUCss was observed when food was consumed within 3 hours before or 1 hour after taking afatinib [L2937].  ",0.95,"Afatinib is eliminated with an effective half-life of approximately 37 hours [L2937]. Thus, steady-state plasma concentrations of afatinib were achieved within 8 days of multiple dosing of afatinib resulting in an accumulation of 2.77-fold (AUC0-âˆž) and 2.11-fold (Cmax) [L2937]. In patients treated with afatinib for more than 6 months, a terminal half-life of 344 h was estimated [L2937].",20 mg/1,Oral,solid,,,0.0128,12.49,8.81,CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1,0.95,0.95,,,0,20,485.1629956,4,3,2,1,1,1
7040,04/06/2019 00:00,DB08921,(4R)-limonene,,,,,,solid,,,0.457,,,CC(=C)[C@@H]1CCC(C)=CC1,,,,,0,,136.1252005,1,0,0,0,0,0
7041,04/06/2019 00:00,DB08922,Perospirone,Perospirone is rapidly absorbed following oral administration with the time to reach peak plasma concentration of 0.8 to 1.5 hours. A single oral dose of 8mg perospirone results in peak plasma concentration of 5.7 ug/L [A19677]. Perospirone is not reported to be accumulated after repeated dosing. ,0.92,The elimination half life is approximately 1.9 hours following oral ingestion of 8mg perospirone [A19677]. ,,,solid,,,0.0317,,7.73,[H][C@@]12CCCC[C@]1([H])C(=O)N(CCCCN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O,0.92,0.92,,,0,,426.2089472,5,2,3,1,2,2
7042,02/07/2019 00:00,DB08930,Dolutegravir,"When 50 mg of dolutegravir once daily was orally administered to HIV-1 infected adults, the AUC, Cmax, and Cmin is 53.6 mcg h/mL, 3.67 mcg/mL, and 1.11 mcg/mL, respectively. The peak plasma concentration was observed 2 to 3 hours post-dose. Steady state is achieved within approximately 5 days with average accumulation ratios for AUC, Cmax, and C24h ranging from 1.2 to 1.5. When 50 mg once daily is given to pediatric patients (12 to < 18 years and weighing â‰¥40 kg) the Cmax, AUC, and C24 is 3.49 mcg/mL, 46 mcg.h/mL, and 0.90 mcg/mL respectively.[A7514]",0.989,The half-life of dolutegravir is 14 hours.[A7514],10 mg,Oral,solid,Slightly soluble,2.2,0.0922,10.1,-0.51,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2,0.989,0.989,,,0,10,419.1292771,4,2,3,1,1,2
7043,02/07/2019 00:00,DB08931,Riociguat,"The pharmacokinetics of riociguant are dose proportional from 0.5 mg to 2.5 mg. The absolute bioavailability is approximately 94%. After oral administration, peak plasma concentrations were achieved within 1.5 hours. Food does not affect the bioavailability of riociguat.",0.95,About 12 hours in patients and 7 hours in healthy subjects. ,0.5 mg,Oral,solid,4 mg/L at 25Â°C,,0.0682,18.9,3.5,COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2,0.95,0.95,,,0,0.5,422.1615001,4,4,3,3,0,0
7044,02/07/2019 00:00,DB08932,Macitentan,"Macitentan is administered orally, and it take about 8 hours for maximum plasma concentrations to be reached.",>99%,"The half life of macitentan is 16 hours, and the half life of it's active metabolite is 48 hours.",10 mg,Oral,solid,Not water soluble,,0.00668,7.76,2.26,CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1,0.99,1,,,0,10,585.9633483,3,3,2,2,0,0
7045,04/06/2019 00:00,DB08933,Luliconazole,"Although luliconazole is administered topically, clinical studies have shown that after the first dose in patients with tina pedis, a maximum plasma concentration of 0.40 Â± 0.76 ng/mL (mean Â± SD) occurred in 16.9 Â± 9.39 hours (mean Â± SD).",,The half life of luliconazole has yet to be determined.,10 mg/1g,Topical,solid,,,0.0659,,6.34,ClC1=CC(Cl)=C(C=C1)[C@@H]1CS\C(S1)=C(\C#N)N1C=CN=C1,,,,,0,,352.9614946,3,2,2,1,1,1
7046,02/07/2019 00:00,DB08934,Sofosbuvir,"When given orally, sofosbuvir reaches its maximum plasma concentration in about 0.5 to 2 hours with a maximal concentration (Cmax) of 567 ng/mL [FDA Label].",61-65%,Sofosbuvir has a terminal half life of 0.4 hours [FDA Label].,400 mg,Oral,solid,,1.62,0.824,9.7,-3.9,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1,0.61,0.65,,,0,400,529.1625444,3,2,2,1,1,1
7047,04/06/2019 00:00,DB08936,Chlorcyclizine,Readily absorbed after oral administration and widely distributed throughout the body. Metabolised by N-demethylation to form norchlorcyclizine and by N-oxidation.,,about 12 h. ,25 mg/1,Oral,solid,,,0.0424,,7.63,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,,,,,0,25,300.1393264,3,2,1,0,1,1
7048,04/06/2019 00:00,DB08939,Letosteine,,,,,,solid,,,3.55,2.74,7.41,CCOC(=O)CSCCC1NC(CS1)C(O)=O,,,,,0,,279.0599,1,0,1,0,1,1
7049,04/06/2019 00:00,DB08940,Kebuzone,,,,,,solid,,,0.113,4.17,-7.3,CC(=O)CCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,322.1317424,3,2,1,0,1,1
7050,04/06/2019 00:00,DB08941,Isoxsuprine,,,,10 mg/1,Oral,solid,,,0.0507,9.65,9,C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1,,,,,0,10,301.1677936,2,2,0,0,0,0
7051,04/06/2019 00:00,DB08942,Isoxicam,,,,,,solid,,,0.336,4.46,-0.97,CN1C(C(=O)N=C2NOC(C)=C2)=C(O)C2=CC=CC=C2S1(=O)=O,,,,,0,,335.0575915,3,2,2,1,0,1
7052,04/06/2019 00:00,DB08943,Isoconazole,,,,,,solid,,,0.000825,,6.77,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=C(Cl)C=CC=C1Cl,,,,,0,,413.9860238,3,3,1,1,0,0
7053,04/06/2019 00:00,DB08944,Isoaminile,,,,,,solid,,,0.0672,,8.73,CC(C)[C@@](C[C@H](C)N(C)C)(C#N)C1=CC=CC=C1,,,,,0,,244.1939488,1,1,0,0,0,0
7054,04/06/2019 00:00,DB08945,Iotroxic acid,,,,,,solid,,,0.00693,2.66,-1.3,OC(COCCOCCOCC(O)=NC1=C(I)C=C(I)C(C(O)=O)=C1I)=NC1=C(I)C=C(I)C(C(O)=O)=C1I,,,,,0,,1215.528068,2,2,0,0,0,0
7055,04/06/2019 00:00,DB08946,Iopanoic acid,,,,500 mg,Oral,solid,,,0.0138,2.85,1.76,CCC(CC1=C(I)C(N)=C(I)C=C1I)C(O)=O,,,,,0,500,570.8002226,1,1,0,0,0,0
7056,02/07/2019 00:00,DB08947,Iopamidol,,,,0.61,Intravascular,solid,,,0.117,4.15,1.42,[H][C@@](C)(O)C(O)=NC1=C(I)C(C(O)=NC(CO)CO)=C(I)C(C(O)=NC(CO)CO)=C1I,,,,,0,,776.8541087,1,1,0,0,0,0
7057,04/06/2019 00:00,DB08948,Iodamide,,,,,,solid,,,0.0182,3.06,2.17,CC(O)=NCC1=C(I)C(C(O)=O)=C(I)C(N=C(C)O)=C1I,,,,,0,,627.7853008,1,1,0,0,0,0
7058,02/07/2019 00:00,DB08949,Inositol nicotinate,"Gastrointestinal absorption of inositol hexanicotinate varies widely, with an average of 70% of an orally ingested dose absorbed from stomach and upper small intestines into the bloodstream as intact form. The maximum serum levels of nicotinic acid is reached approximately 6-10 hours after oral ingestion. At low concentrations, the absorption of nicotinic acid and nicotinamide is mediated by sodium ion-dependent facilitated diffusion. At higher concentrations, passive diffusion predominates with doses of 3 to 4 g of niacin being almost completely absorbed [L810]. ",,Mean elimination half life in healthy human adults is approximately one hour [A19550]. ,,Oral,solid,Insoluble,,0.0174,,4.02,O=C(O[C@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@@H]1OC(=O)C1=CC=CN=C1)C1=CC=CN=C1,,,,,0,,810.1921704,7,6,6,6,0,0
7059,04/06/2019 00:00,DB08950,Indoramin,,,,,,solid,,,0.00498,8.47,9.59,OC(=NC1CCN(CCC2=CNC3=CC=CC=C23)CC1)C1=CC=CC=C1,,,,,0,,347.1997624,4,3,2,1,1,1
7060,04/06/2019 00:00,DB08951,Indoprofen,,,2.3 hours.,,,solid,,,0.128,3.74,-3.5,CC(C(O)=O)C1=CC=C(C=C1)N1CC2=CC=CC=C2C1=O,,,2.3,2.3,0,,281.1051933,3,2,1,0,0,1
7061,04/06/2019 00:00,DB08952,Indenolol,,,,,,solid,,,0.277,14.09,9.67,CC(C)NCC(O)COC1=CC=CC2=C1C=CC2,,,,,0,,247.1572289,2,1,0,0,0,0
7062,04/06/2019 00:00,DB08953,Indalpine,,,,,,solid,,,0.0125,17.32,10.36,C(CC1=CNC2=CC=CC=C12)C1CCNCC1,,,,,0,,228.1626486,3,2,2,1,1,1
7063,04/06/2019 00:00,DB08954,Ifenprodil,,,,,,solid,,,0.105,9.67,9.03,CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1,,,,,0,,325.2041791,3,2,1,0,1,1
7064,04/06/2019 00:00,DB08955,Ibuproxam,,,,,,solid,,,0.0682,6.67,1.07,CC(C)CC1=CC=C(C=C1)C(C)C(O)=NO,,,,,0,,221.1415788,1,1,0,0,0,0
7065,04/06/2019 00:00,DB08956,Hydroxydione,,,,,,solid,,,0.0156,13.86,-3.3,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)CO,,,,,0,,332.2351449,4,0,0,0,0,0
7066,04/06/2019 00:00,DB08957,Hexoprenaline,,,,,,solid,,,0.199,8.69,10.18,OC(CNCCCCCCNCC(O)C1=CC(O)=C(O)C=C1)C1=CC(O)=C(O)C=C1,,,,,0,,420.2260367,2,2,0,0,0,0
7067,04/06/2019 00:00,DB08958,Hexetidine,,,,0.001,Buccal,solid,,,0.00594,,9.12,CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1,,,,,0,,339.3613484,1,0,1,0,1,1
7068,04/06/2019 00:00,DB08960,Hexamethonium,,,,,,solid,,,2.24E-05,,,C[N+](C)(C)CCCCCC[N+](C)(C)C,,,,,2,,202.2398018,0,0,0,0,0,0
7069,04/06/2019 00:00,DB08961,Azosemide,"Peak plasma concentrations are achieved in 3-4 hours when azosemide is administered to healthy humans in a fasting state.
There is an absorption lag time of approximately 1 hour. Oral bioavailability estimated to be 20.4%",0.95,Terminal half life 2-3 hours.,,,solid,,,0.0929,7.38,-0.77,NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CS2)C(=C1)C1=NNN=N1,0.95,0.95,,,0,,370.0073433,3,3,2,2,0,0
7070,04/06/2019 00:00,DB08962,Glibornuride,,,,,,solid,,,0.0635,4.32,-3.2,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N[C@@H]1[C@H](O)[C@]2(C)CC[C@H]1C2(C)C,,,,,0,,366.1613283,3,1,0,0,0,0
7071,04/06/2019 00:00,DB08964,Gemeprost,"Systemic absorption of gemeprost is limited with about 12-28% of administered dose of gemeprost reaching the systemic circulation [L878]. Following vaginal administration, peak plasma concentration is reached after 2-3 hours [A19726].  ",,,,,liquid,,,0.0176,14.68,-1.1,CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC,,,,,0,,394.2719243,1,0,0,0,0,0
7072,04/06/2019 00:00,DB08965,Fusafungine,,,,,,solid,,,0.0184,18.8,-5.4,[H]C1(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C1=O)C(C)C)C(C)C)C(C)C,,,,,0,,639.4094804,1,0,1,0,1,1
7073,04/06/2019 00:00,DB08966,Fursultiamine,,,,,Oral,solid,,,0.156,3.45,12.41,C\C(N(CC1=CN=C(C)NC1=N)C=O)=C(\CCO)SSCC1CCCO1,,,,,0,,398.1446327,2,1,2,1,1,1
7074,04/06/2019 00:00,DB08967,Dimetotiazine,,,,,,solid,,,0.0647,,8.99,CC(CN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(=O)(=O)N(C)C)N(C)C,,,,,0,,391.138819,3,2,1,0,0,1
7075,04/06/2019 00:00,DB08968,Fominoben,,,,,,solid,,,0.0303,15.49,5.55,CN(CC(=O)N1CCOCC1)CC1=C(Cl)C=CC=C1NC(=O)C1=CC=CC=C1,,,,,0,,401.1506193,3,2,1,0,1,1
7076,04/06/2019 00:00,DB08969,Flurothyl,,,,,,solid,,,2.14,,-4.2,FC(F)(F)COCC(F)(F)F,,,,,0,,182.0166341,0,0,0,0,0,0
7077,04/06/2019 00:00,DB08970,Fluprednidene,,,,,,solid,,,0.117,12.11,-3.3,[H][C@@]12CC(=C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,390.1842522,4,0,0,0,0,0
7078,04/06/2019 00:00,DB08971,Fluocortolone,,,,,,solid,,,0.0339,13.84,-0.23,[H][C@@]1(C)C[C@@]2([H])[C@]3([H])C[C@]([H])(F)C4=CC(=O)C=C[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]2(C)[C@@]1([H])C(=O)CO,,,,,0,,376.2049876,4,0,0,0,0,0
7079,04/06/2019 00:00,DB08972,Flumequine,,,,,,solid,,,1.24,6,-4.3,CC1CCC2=CC(F)=CC3=C2N1C=C(C(O)=O)C3=O,,,,,0,,261.0801215,3,2,2,1,0,1
7080,04/06/2019 00:00,DB08973,Fluclorolone acetonide,,,,,,solid,,,0.00175,13.73,-3.3,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,,,,,0,,486.1376076,5,0,1,0,1,1
7081,04/06/2019 00:00,DB08974,Flubendazole,,,,500 mg/1,Oral,solid,,,0.0334,7.08,1.92,COC(O)=NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=C(F)C=C1,,,,,0,500,313.0862695,3,3,1,1,0,0
7082,04/06/2019 00:00,DB08975,Florantyrone,,,,,,solid,,,0.000729,4.61,-7.5,OC(=O)CCC(=O)C1=CC2=C(C=C1)C1=C3C2=CC=CC3=CC=C1,,,,,0,,302.0942943,4,3,0,0,0,0
7083,02/07/2019 00:00,DB08976,Floctafenine,,,,200 mg,Oral,solid,,,0.0346,13.62,5.84,OC[C@@H](O)COC(=O)C1=C(NC2=C3C=CC=C(C3=NC=C2)C(F)(F)F)C=CC=C1,,,,,0,200,406.1140417,3,3,1,1,0,0
7084,04/06/2019 00:00,DB08978,Fentonium,,,,,,solid,,,5.82E-05,15.15,-2.7,[H][C@](CO)(C(=O)O[C@]1([H])C[C@]2([H])CC[C@]([H])(C1)[N+]2(C)CC(=O)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,484.248235,5,3,2,0,2,2
7085,04/06/2019 00:00,DB08979,Fenspiride,,,,,,solid,,,0.42,7.99,9.37,OC1=NCC2(CCN(CCC3=CC=CC=C3)CC2)O1,,,,,0,,260.1524779,3,1,2,0,1,2
7086,04/06/2019 00:00,DB08980,Fendiline,,,,,,solid,,,6.22E-05,,10.07,CC(NCCC(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,315.1986998,3,3,0,0,0,0
7087,04/06/2019 00:00,DB08981,Fenbufen,,,,,,solid,,,0.0121,4.22,-7.5,OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,254.0942943,2,2,0,0,0,0
7088,04/06/2019 00:00,DB08982,Etozoline,,,,,,solid,,,5.63,,5.35,[H]\C(C(=O)OCC)=C1\SC(N2CCCCC2)C(=O)N1C,,,,,0,,284.1194635,2,0,2,0,2,2
7089,04/06/2019 00:00,DB08983,Etofibrate,,,,,,solid,,,0.0357,,3.24,CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCOC(=O)C1=CN=CC=C1,,,,,0,,363.0873504,2,2,1,1,0,0
7090,04/06/2019 00:00,DB08984,Etofenamate,,,,,,solid,,,0.00936,15.12,-2.2,OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(=C1)C(F)(F)F,,,,,0,,369.1187927,2,2,0,0,0,0
7091,04/06/2019 00:00,DB08985,Etilefrine,,,,,,solid,,,13.8,9.1,9.73,CCNCC(O)C1=CC(O)=CC=C1,,,,,0,,181.1102787,1,1,0,0,0,0
7092,04/06/2019 00:00,DB08986,Etifoxine,,,,,,solid,,,0.00216,,5.18,CCNC1=NC2=CC=C(Cl)C=C2C(C)(O1)C1=CC=CC=C1,,,,,0,,300.1029408,3,2,1,0,0,1
7093,04/06/2019 00:00,DB08987,Etidocaine,,,,,,solid,,,0.0457,4.97,9.4,CCCN(CC)C(CC)C(O)=NC1=C(C)C=CC=C1C,,,,,0,,276.2201635,1,1,0,0,0,0
7094,04/06/2019 00:00,DB08988,Ethoheptazine,,,,,Oral,solid,,,0.575,,8.69,CCOC(=O)C1(CCCN(C)CC1)C1=CC=CC=C1,,,,,0,,261.172879,2,1,1,0,1,1
7095,04/06/2019 00:00,DB08989,Etamivan,,,,,,solid,,,12.4,8.95,-0.35,CCN(CC)C(=O)C1=CC(OC)=C(O)C=C1,,,,,0,,223.1208434,1,1,0,0,0,0
7096,04/06/2019 00:00,DB08990,Eprazinone,,,,,,solid,,,0.0484,16.21,7.32,CCOC(CN1CCN(CC(C)C(=O)C2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,380.2463783,3,2,1,0,1,1
7097,04/06/2019 00:00,DB08991,Epirizole,,,,,,solid,,,1.13,,2.25,COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1,,,,,0,,234.1116757,2,2,2,2,0,0
7098,04/06/2019 00:00,DB08992,Eperisone,,,,,,solid,,,0.0617,16.34,8.77,CCC1=CC=C(C=C1)C(=O)C(C)CN1CCCCC1,,,,,0,,259.1936144,2,1,1,0,1,1
7099,04/06/2019 00:00,DB08993,Enviomycin,,,,,,solid,,,0.155,2.5,11.74,[H]\C(NC(O)=N)=C1\N=C(O)[C@]([H])(CO)N=C(O)[C@]([H])(CO)N=C(O)[C@]([H])(CN=C(O)[C@@]([H])(N=C1O)[C@@]1([H])CCNC(=N)N1)N=C(O)C[C@@]([H])(N)[C@]([H])(O)CCN,,,,,0,,685.3255846,2,0,2,0,1,2
7100,04/06/2019 00:00,DB08994,Ditazole,,,,,,solid,,,0.146,15.27,-0.12,OCCN(CCO)C1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,324.1473925,3,3,1,1,0,0
7101,04/06/2019 00:00,DB08995,Diosmin,,,,,Oral,solid,,,1.54,8.48,-3.6,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)C=C2O1,,,,,0,,608.1741203,5,3,3,1,2,2
7102,04/06/2019 00:00,DB08996,Dimetacrine,,,Approximately 10 hours. (PMID 5312397),,,solid,,,0.0343,,9.2,CN(C)CCCN1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12,,,,,0,,294.2095988,3,2,1,0,0,1
7103,04/06/2019 00:00,DB08997,Dexetimide,,,,,,solid,,,0.00505,7.67,8.43,OC1=NC(=O)[C@@](CC1)(C1CCN(CC2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,362.1994281,4,2,2,0,1,2
7104,04/06/2019 00:00,DB08998,Demexiptiline,,,,,,solid,,,0.00281,,9.09,CNCCON=C1C2=CC=CC=C2C=CC2=CC=CC=C12,,,,,0,,278.1419132,3,3,0,0,0,0
7105,04/06/2019 00:00,DB08999,Cyclopentamine,,,,,,solid,,,0.476,,10.61,CNC(C)CC1CCCC1,,,,,0,,141.1517496,1,0,0,0,0,0
7106,04/06/2019 00:00,DB09000,Cyamemazine,,,,,,solid,,,0.029,,9.42,CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N,,,,,0,,323.1456187,3,2,1,0,0,1
7107,04/06/2019 00:00,DB09001,Barbexaclone,"After oral administration of barbexaclone in mice the maximum plasma levels of 
prophylhexedrine appeared after 4 minutes, and propylhexedrine was seen to penetrate the blood brain barrier rapidly. 
Bioavailability (AUC oral / AUC iv) = 0.37. [3]
Phenobarbital was observed to reach the blood more slowly, and brain uptake was a slow process. 
Equilibrium concentrations with plasma reached after 30 minutes after i.v injection. [3]",,"After IV administration in mice, levels of phenobarbital declined exponentially with a half life of 7.5h. [3]
For propylhexedrine t0.5a = 0.31h and t0.5b = 2.5h. ",,,solid,,,0.272,0.97,-4.5,[H][C@](C)(CC1CCCCC1)NC.CCC1(C(O)=NC(=O)N=C1O)C1=CC=CC=C1,,,,,0,,387.2521919,3,1,1,0,0,1
7108,04/06/2019 00:00,DB09002,Cloperastine,,,,,Oral,solid,,,0.000765,,8.82,ClC1=CC=C(C=C1)C(OCCN1CCCCC1)C1=CC=CC=C1,,,,,0,,329.1546421,3,2,1,0,1,1
7109,04/06/2019 00:00,DB09003,Clocapramine,,,,,,solid,,,0.0055,3.06,9.47,OC(=N)C1(CCN(CCCN2C3=CC=CC=C3CCC3=C2C=C(Cl)C=C3)CC1)N1CCCCC1,,,,,0,,480.2655895,5,2,3,0,2,3
7110,04/06/2019 00:00,DB09004,Clobutinol,,,,,,solid,,,0.535,14.64,9.41,CC(CN(C)C)C(C)(O)CC1=CC=C(Cl)C=C1,,,,,0,,255.138992,1,1,0,0,0,0
7111,04/06/2019 00:00,DB09006,Clinofibrate,,,,,,solid,,,0.000227,3.4,-4.6,CCC(C)(OC1=CC=C(C=C1)C1(CCCCC1)C1=CC=C(OC(C)(CC)C(O)=O)C=C1)C(O)=O,,,,,0,,468.2511889,3,2,0,0,0,0
7112,04/06/2019 00:00,DB09007,Chlorphenoxamine,,,,,,solid,,,0.00582,,8.87,CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,,,,,0,,303.138992,2,2,0,0,0,0
7113,04/06/2019 00:00,DB09008,Cefaloridine,,,,,,solid,,,0.00719,3.27,-0.017,[H][C@]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[C@@]2([H])N=C(O)CC1=CC=CS1)C([O-])=O,,,,,0,,415.066048,4,2,4,2,1,2
7114,04/06/2019 00:00,DB09009,Articaine,,,,,Submucosal,solid,,,0.0366,4.42,8.91,CCCNC(C)C(O)=NC1=C(SC=C1C)C(=O)OC,,,,,0,,284.1194635,1,1,1,1,0,0
7115,04/06/2019 00:00,DB09010,Carmofur,,,,,,solid,,,0.0273,5.55,-4.9,CCCCCCN=C(O)N1C=C(F)C(O)=NC1=O,,,,,0,,257.1175696,1,1,1,1,0,0
7116,04/06/2019 00:00,DB09011,Beclamide,,,,,,solid,,,0.436,14.13,-1.7,ClCCC(=O)NCC1=CC=CC=C1,,,,,0,,197.0607417,1,1,0,0,0,0
7117,04/06/2019 00:00,DB09012,Carbazochrome,,,,,Oral,solid,,,2.91,11.64,1.98,CN1CC(O)C2=C\C(=N\NC(N)=O)C(=O)C=C12,,,,,0,,236.0909402,2,0,1,0,1,1
7118,04/06/2019 00:00,DB09013,Befunolol,,,,,,solid,,,0.108,13.92,9.57,CC(C)NCC(O)COC1=CC=CC2=C1OC(=C2)C(C)=O,,,,,0,,291.1470582,2,2,1,1,0,0
7119,04/06/2019 00:00,DB09014,Captodiame,,,,,,solid,,,5.96E-05,,8.94,CCCCSC1=CC=C(C=C1)C(SCCN(C)C)C1=CC=CC=C1,,,,,0,,359.1741419,2,2,0,0,0,0
7120,04/06/2019 00:00,DB09015,Canrenoic acid,,,,,,solid,,,0.0442,4.48,-3.1,[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C,,,,,0,,358.2144094,4,0,0,0,0,0
7121,04/06/2019 00:00,DB09017,Brotizolam,The plasma concentration profile of brotizolam can be described as a one compartmental open model with first-order absorption.,,4.4 hours.,,,solid,,,0.058,18.49,3.9,CC1=NN=C2CN=C(C3=C(SC(Br)=C3)N12)C1=CC=CC=C1Cl,,,4.4,4.4,0,,391.9498071,4,3,3,2,0,1
7122,04/06/2019 00:00,DB09018,Bromopride,,,,,,solid,,,0.133,7.55,9.56,CCN(CC)CCN=C(O)C1=C(OC)C=C(N)C(Br)=C1,,,,,0,,343.089539,1,1,0,0,0,0
7123,04/06/2019 00:00,DB09019,Bromhexine,,,,1000 g/1000g,Not applicable,solid,,,0.00362,19.89,9.32,CN(CC1=CC(Br)=CC(Br)=C1N)C1CCCCC1,,,,,0,,373.9993228,2,1,0,0,0,0
7124,02/07/2019 00:00,DB09020,Bisacodyl,0.15,,16 hours,5 mg/1,Topical,solid,,,0.00127,,4.08,CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1,,,16,16,0,,361.1314081,3,3,1,1,0,0
7125,04/06/2019 00:00,DB09021,Benzoctamine,,,,,,solid,,,0.000844,,10.04,CNCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21,,,,,0,,249.1517496,5,2,0,0,0,0
7126,04/06/2019 00:00,DB09022,Benfluorex,,,,,,solid,,,0.00128,,9.14,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C1=CC=CC=C1,,,,,0,,351.1446135,2,2,0,0,0,0
7127,04/06/2019 00:00,DB09023,Benactyzine,,,,,,solid,,,0.188,11.05,8.96,CCN(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,327.1834437,2,2,0,0,0,0
7128,02/07/2019 00:00,DB09026,Aliskiren,"Poor, with a bioavailability of about 2.5%.",47-51%,Approximate accumulation halfâ€life of 24 hours.,150 mg,Oral,solid,Highly soluble in water (as hemifumarate salt),3.3,0.0021,14.56,9.57,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1,0.47,0.51,,,0,150,551.3934364,1,1,0,0,0,0
7129,04/06/2019 00:00,DB09027,Ledipasvir,"When given orally, ledipasvir reaches its maximum plasma concentration in about 4 to 4.5 hours with a maximum concentration (Cmax) of 323 ng/mL [FDA Label].",>99.8%,The median terminal half-life of ledipasvir is 47 hours [FDA Label].,,Oral,solid,,3.8,0.00182,3.76,5.85,[H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F,0.99,1,,,0,,888.4134379,10,5,4,2,2,2
7130,04/06/2019 00:00,DB09028,Cytisine,,,4.8 hours. ,,,solid,,,8.14,,9.82,O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12,,,4.8,4.8,0,,190.1106131,3,1,3,1,1,2
7131,02/07/2019 00:00,DB09030,Vorapaxar,"After oral administration, vorapaxar is rapidly absorbed and peak concentrations occur at a median tmax of 1 hour under faster conditions. Vorapaxar may be taken with or without food as ingestion with a high-fat meal did not result in meaningful changes in AUC. The mean absolute bioavailability is 100%.",,Vorapaxar has an effective half life of 3-4 days and an apparent terminal half life of 8 days.,2.5 mg,Oral,solid,,5.39,0.000654,14.78,4.32,[H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\C=C\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCC,,,,,0,2.5,492.2424358,5,2,2,1,1,1
7132,04/06/2019 00:00,DB09031,Miltefosine,"After oral administration, miltefosine is slowly absorbed from the gastrointestinal tract with an absolute bioavailability of 82% in rats and 94% in dogs. Absolute bioavailability has not been assessed in humans, however GI absorption rate in a two-compartment model is estimated to be 0.416 hr-1. ",0.96,The primary elimination half life is 7.05 days (range: 5.45-9.10 days) and the terminal half-life is 30.9 days (range: 30.8-31.2 days). ,50 mg/1,Oral,solid,,,0.00022,1.88,,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C,0.96,0.96,,,0,50,407.3164456,0,0,0,0,0,0
7133,02/07/2019 00:00,DB09034,Suvorexant,"Peak concentrations occur at a median Tmax of 2 hours under fasted conditions. Ingestion of suvorexant with a high-fat meal has no effect on AUC or Cmax, but may delay Tmax by approximately 1.5 hours. Mean absolute bioavailability of 10 mg is 82%. ",,Mean half life is approximately 12 hours. ,10 mg,Oral,solid,,,0.117,,0.25,[H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2,,,,,0,10,450.1571017,5,4,3,2,1,1
7134,02/07/2019 00:00,DB09038,Empagliflozin,"Following oral administration, peak plasma concentrations were reached at 1.5 hours post-dose and then declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. Administration following a high-fat and high-calorie meal results in a slightly lower exposure with AUC decreasing by approximately 16% and Cmax decreasing by approximately 37% compared to fasted condition. ",0.862,Terminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis. ,10 mg,Oral,solid,,,0.111,12.57,-3,[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1,0.862,0.862,,,0,10,450.1445309,4,2,2,0,2,2
7135,02/07/2019 00:00,DB09039,Eliglustat,"In CYP2D6 EMs (extensive metabolizers), median time to reach maximum plasma concentrations (tmax) occurs at 1.5 to 2 hours following multiple doses of eliglustat 84 mg twice daily. ",,6.5 hours in EM (extensive metabolizers) and 8.9 hours in PM (poor metabolizers). ,84 mg/1,Oral,solid,,,0.038,5.21,8.87,[H][C@](CN1CCCC1)(N=C(O)CCCCCCC)[C@]([H])(O)C1=CC2=C(OCCO2)C=C1,,,,,0,84,404.2675076,3,1,2,0,1,2
7136,02/07/2019 00:00,DB09040,Efinaconazole,,,29.9 hours in healthy patients. ,0.1,Topical,solid,,,0.61,12.7,7.45,C[C@@H](N1CCC(=C)CC1)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,,,,,0,,348.1761678,3,2,2,1,1,1
7137,04/06/2019 00:00,DB09041,Tavaborole,"7.5%. Subungual onychomycosis is difficult to treat due to the poorly perfused location of the infection in the nailbed. To be effective, a topical treatment must penetrate the nail plate and reach the site of infection at a concentration sufficient to exert anti-fungal activity. Tavaborole was shown to produce anti-fungal effects after 5 days of topical administration. ",,28.5 hr,43.5 mg/1mL,Topical,solid,,,11.3,8.91,-4.8,OB1OCC2=CC(F)=CC=C12,,,28.5,28.5,0,,152.0444881,2,1,1,0,0,1
7138,02/07/2019 00:00,DB09042,Tedizolid phosphate,Peak plasma tedizolid concentrations are achieved within approximately 3 hours following oral administration under fasting conditions or at the end of the 1 hour intravenous infusion of tedizolid phosphate. The absolute bioavailability is approximately 91% and no dosage adjustment is necessary between intravenous and oral administration. Oral tedizolid phosphate may be administered with or without food as total systemic exposure is unchanged between fasted and fed conditions.,70-90%,12 hours,200 mg,Intravenous,solid,,4.89,0.608,1.35,-1.6,CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O,0.7,0.9,12,12,0,,450.0852971,4,3,3,2,1,1
7139,02/07/2019 00:00,DB09047,Finafloxacin,,,,0.003,Auricular (otic),liquid,,,0.208,4.52,7.54,[H][C@]12CN(C[C@]1([H])OCCN2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1C#N)C(O)=O,,,,,0,,398.1390333,5,2,3,1,2,2
7140,04/06/2019 00:00,DB09048,Netupitant,"Upon oral administration of a single dose of netupitant, netupitant started to be measurable in plasma between 15 minutes and 3 hours after dosing. Plasma concentrations reached Cmax in approximately 5 hours. There was a greater than dose-proportional increase in the systemic exposure with the dose increase from 10 mg to 300 mg and a dose-proportional increase in systemic exposure with a dose increase from 300 mg to 450 mg.",0.995,96 hours with CV% of 61. ,,Oral,solid,,,0.00285,,7.6,CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CCN(C)CC1,0.995,0.995,,,0,,578.248031,4,3,2,1,1,1
7141,02/07/2019 00:00,DB09049,Naloxegol,"Following oral administration, naloxegol is absorbed with peak concentrations (Cmax) achieved in less than 2 hours.",~4.2%,6-11 hours.,12.5 mg,Oral,solid,,,0.0566,10.14,8.54,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5,0.04,0.02,6,11,0,12.5,651.3618615,5,1,2,0,1,2
7142,14/06/2019 00:00,DB09050,Ceftolozane,"The area under the curve (AUC) of ceftolozane-tazobactam after an injected dose of 1 g/0.5 g every 8 hours for 1 day was 172 mcgâ€¢h/mL[FDA label].
The Cmax (peak concentration) and AUC are dose-dependent. The Cmax on day one of the above dose of ceftolozane-tazobactam was 69.1 mcg/mL.[FDA label]",0.16,"2.77 hours on day 1 of treatment on a dose of 1 g/0.5 g every 8 hours.[FDA label,A179431]
3.12 hours on day 10 of treatment on a dose of 1 g/0.5 g every 8 hours.[FDA label]",,Intravenous,solid,,-6.17,0.0884,2.49,9.11,CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=NSC(N)=N1)C2=O)C([O-])=O,0.16,0.16,,,0,,666.1750979,4,2,4,2,1,2
7143,02/07/2019 00:00,DB09053,Ibrutinib,"Ibrutinib is rapidly absorbed after oral administration and it presents a Cmax, tmax and AUC of approximately 35 ng/ml, 1-2 hour and 953 mg.h/ml respectively.[T148]",0.25,The elimination half-life of ibrutinib is of approximately 4-6 hours.[T148],140 mg/1,Oral,solid,0.003 mg/ml,3.97,0.0203,19.7,6.58,NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1,0.25,0.25,,,0,140,440.196074,5,4,3,2,1,1
7144,02/07/2019 00:00,DB09054,Idelalisib,"Following oral administration, the median Tmax was observed at 1.5 hours.",0.84,The terminal elimination half-life is 8.2 hours.,100 mg,Oral,solid,,,0.0255,9.86,4.27,[H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,0.84,0.84,,,0,100,415.1556864,5,5,3,3,0,0
7145,04/06/2019 00:00,DB09055,Acipimox,,,,,,solid,,,12,-0.1,3.71,CC1=[N+]([O-])C=C(N=C1)C(O)=O,,,,,0,,154.0378421,1,1,1,1,0,0
7146,04/06/2019 00:00,DB09056,Amorolfine,,,,,,solid,,,0.000785,,8.49,[H]C(C)(CN1C[C@]([H])(C)O[C@]([H])(C)C1)CC1=CC=C(C=C1)C(C)(C)CC,,,,,0,,317.2718647,2,1,1,0,1,1
7147,04/06/2019 00:00,DB09059,Atosiban,"In women receiving 300 Î¼g/min by infusion for 6-12 h, average steady state concentrations of 442 ng/mL were reached within 1 h [L2469]. Steady state concentrations increase proportionally to dosage.",46-48%,Atosiban does not conform to either 1-compartment or 2-compartment kinetics. It has been determined to have an initial half life (tÎ±) of 0.21 h and a terminal half life (tÎ²) of 1.7 h [L2469].,6.75 mg/0.9ml,Intravenous,solid,,,0.0517,11.28,9.59,[H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](CC2=CC=C(OCC)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O,0.46,0.48,,,0,,993.4412086,3,1,2,0,2,2
7148,04/06/2019 00:00,DB09060,Avibactam,,5.7%-8.2%,Ceftazidime-avibactam has a half life of ~2.7-3.0 hours.,,Intravenous,solid,,,15,-2,-3.9,[H]OS(=O)(=O)ON1C(=O)N2C([H])([H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2([H])C(=O)N([H])[H],0.057,0.082,,,0,,265.0368561,2,0,2,0,2,2
7149,14/06/2019 00:00,DB09061,Cannabidiol,"Following a single buccal administration, maximum plasma concentrations of both CBD and THC typically occur within two to four hours. When administered buccally,
blood levels of THC and other cannabinoids are lower compared with inhalation of smoked cannabis. The resultant concentrations in the blood are lower than those obtained by inhaling the same dose because absorption is slower, redistribution into fatty tissues is rapid and additionally some of the THC undergoes hepatic first pass metabolism to 11-OH-THC, a psycho-active metabolite. 

The CBD component of sublingual Sativex was found to have a Tmax of 1.63hr and a Cmax of 2.50ng/mL, while buccal Sativex was found to have a Tmax of 2.80hr and a Cmax of 3.02ng/mL.",,"The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr. ",33.33 mg/1mL,Sublingual,solid,,,0.0126,9.13,-5.7,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1,,,,,0,1.66,314.2245802,2,1,0,0,0,0
7150,02/07/2019 00:00,DB09062,Cefminox,,,,,,solid,,,1.09,1.56,8.82,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSC[C@@H](N)C(O)=O)OC)C(O)=O,,,,,0,,519.066459,3,1,3,1,1,2
7151,02/07/2019 00:00,DB09063,Ceritinib,"After oral administration of ceritinib, peak concentrations were achieved after approximately 4 to 6 hours.",0.97,The terminal half life is 41 hours.,150 mg/1,Oral,solid,,,0.00222,11.58,10.07,CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1,0.97,0.97,,,0,150,557.2227387,4,3,2,1,1,1
7152,04/06/2019 00:00,DB09064,Ciprofibrate,,,,,,solid,,,0.00779,3.69,-4.9,CC(C)(OC1=CC=C(C=C1)C1CC1(Cl)Cl)C(O)=O,,,,,0,,288.0319997,2,1,0,0,0,0
7153,02/07/2019 00:00,DB09065,Cobicistat,Median peak plasma concentrations were observed at 3.5 hours post-dose.,97-98%,The terminal plasma half-life of cobicistat is approximately 3 to 4 hours.,150 mg,Oral,solid,0.1 mg/mL,,0.00125,14.18,6.69,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,0.97,0.98,,,0,150,775.3549598,5,4,3,2,1,1
7154,02/07/2019 00:00,DB09068,Vortioxetine,The maximal plasma vortioxetine concentration (Cmax) after dosing is reached within 7 to 11 hours postdose. Absolute bioavailability is 75%. No effect of food on the pharmacokinetics was observed.,,Mean terminal halfÂ­life is approximately 66 hours,10 mg/1,Oral,solid,,,0.00362,,8.85,CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1,,,,,0,10,298.1503697,3,2,1,0,1,1
7155,04/06/2019 00:00,DB09069,Trimetazidine,,,Half life of the modified release (MR) formulation was reported to be âˆ¼8 h in young volunteers (25 Â± 8) and âˆ¼12 h in elderly (72 Â± 4) (BarrÃ© et al. 2003).,,,solid,,1.04,0.754,,9.21,COC1=C(OC)C(OC)=C(CN2CCNCC2)C=C1,,,,,0,,266.1630426,2,1,1,0,1,1
7156,04/06/2019 00:00,DB09070,Tibolone,"Tibolone is extensively and rapidly absorbed after oral administration [L1879]. The parent drug undergoes extensive metabolism, with. Greater than 80% of a radioactive dose excreted from the body as metabolites, which suggests very low plasma concentrations of tibolone. Plasma concentrations of the metabolites appear within 30 minutes and peak within 1â€“1.5 hours.2,7 The plasma concentrations of the hydroxymetabolites are higher than those of the âˆ†4-isomer. Food does not appear to have an effect on the absorption of this drug [L1879].

",,The elimination half-life is approximately 45 h [L1720].,2.5 mg,Oral,solid,<0.1 g/L,,0.00722,16.27,-1.7,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC(=O)CC3)C[C@@]([H])(C)[C@@]21[H],,,,,0,2.5,312.2089301,4,0,0,0,0,0
7157,04/06/2019 00:00,DB09071,Tasimelteon,,0.9,The observed mean elimination half-life for tasimelteon is 1.3 Â± 0.4 hours.,20 mg/1,Oral,solid,1.1 mg/mL,2.43,0.0216,4.41,6.46,[H][C@@]1(CN=C(O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1,0.9,0.9,,,0,20,245.1415788,3,1,1,0,0,1
7158,02/07/2019 00:00,DB09072,Sodium oxybate,Absolute bioavailability is approximately 88%. Tmax of 30.7-51.9min [A19403].,0.01,0.5 to 1 hour.,0.5 g/1mL,Oral,solid,,,660,4.44,-2.4,[Na+].OCCCC([O-])=O,0.01,0.01,,,0,,126.0292884,0,0,0,0,0,0
7159,02/07/2019 00:00,DB09073,Palbociclib,"Palbociclib presents a linear pharmacokinetic profile and its peak plasma concentration was observed 6-12 hours after oral administration. The oral bioavailability is reported to be of 46% with a steady-state reached after 8 days and a median accumulation ratio of 2.4.[A176792]

The absorption of palbociclib is significantly reduced under fasting conditions and hence, food intake is recommended when this drug is administered.[A176792]",0.85,The mean plasma elimination half-life of palbociclib is 29 hours.[A176792],100 mg,Oral,solid,10 mg/ml (isethionate form),0.99,0.0174,11.34,8.86,CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O,0.85,0.85,,,0,100,447.2382732,5,3,4,3,1,1
7160,02/07/2019 00:00,DB09074,Olaparib,"Following oral administration, the absorption of olaparib is very rapid and can reach a peak concentration ranging between 4.7 and 9.1 mcg/ml after 1-3 hours. The reported AUC of olaparib after a dose of 200 mg is of 25.8 mcg.h/L and this AUC can be increased by 26% with constant administration. The consumption of a high-fat diet with olaparib can only decrease the tmax but do not have an effect in the peak concentration.[A35290]",,The reported elimination half-life ranges between 5 to 11 hours.[A35290],50 mg/1,Oral,solid,,,0.119,8.75,2.24,OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12,,,,,0,50,434.1754188,5,3,2,1,1,1
7161,02/07/2019 00:00,DB09075,Edoxaban,"Following oral administration, peak plasma edoxaban concentrations are observed within 1-2 hours. Absolute bioavailability is 62%. ",,The terminal elimination half-life of edoxaban following oral administration is 10 to 14 hours.,15 mg,Oral,solid,,,0.0114,10.74,6.33,CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1,,,,,0,15,547.1768511,4,2,3,2,0,1
7162,02/07/2019 00:00,DB09076,Umeclidinium,"Cmax occurred at 5 to 15 minutes, with steady state concentrations arriving in 14 days with 1.8-fold accumulation. ",0.89,The effective half-life after once daily dosing is 11 hours. ,55 Î¼g,Respiratory (inhalation),solid,,,1.94E-05,13.04,-3.7,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2,0.89,0.89,,,1,,428.2584057,6,3,3,0,3,3
7163,02/07/2019 00:00,DB09078,Lenvatinib,"Time to peak plasma concentration occurred from 1 to 4 hours postÂ­dose. Administration with food did not affect the extent of absorption, but decreased the rate of absorption and delayed the median Tmax from 2 hours to 4 hours.",0.98,The terminal elimination halfÂ­life of lenvatinib is approximately 28 hours.,10 mg,Oral,solid,,3.3,0.0177,3.56,6.1,COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N,0.98,0.98,,,0,10,426.1094828,4,3,1,1,0,0
7164,02/07/2019 00:00,DB09079,Nintedanib,"Nintedanib reaches maximum plasma concentrations approximately 2 to 4 hours after administration, and absolute bioavailability is 4.7%. ",,9.5 hours,100 mg/1,Oral,solid,,,0.0309,10.86,7.23,COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1,,,9.5,9.5,0,100,539.2532545,5,3,2,0,1,2
7165,02/07/2019 00:00,DB09080,Olodaterol,"Olodaterol reaches maximum plasma concentrations generally within 10 to 20 minutes following drug inhalation. In healthy volunteers, the absolute bioavailability of olodaterol following inhalation was estimated to be approximately 30%, whereas the absolute bioavailability was below 1% when given as an oral solution. Thus, the systemic availability of olodaterol after inhalation is mainly determined by lung absorption, while any swallowed portion of the dose only negligibly contributes to systemic exposure.",,"The terminal half-life following intravenous administration is 22 hours. The terminal half-life following inhalation in contrast is about 45 hours, indicating that the latter is determined by absorption rather than by elimination processes.",2.5 mcg,Respiratory (inhalation),solid,,,0.0703,9.22,9.84,COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1,,,,,0,,386.1841719,3,2,1,0,0,1
7166,04/06/2019 00:00,DB09081,Idebenone,"After oral administration, idebenone is rapidly absorbed. On repeat dosing, maximum plasma concentrations of idebenone are reached on average within 1 hour (median 0.67 h range: 0.33-2.00 h). Food increases the bioavailability of idebenone by approximately 5-7-fold and i therefore should always be administered with food [L885]. ",,,150 mg,Oral,solid,,,0.00747,16.84,-2,COC1=C(OC)C(=O)C(CCCCCCCCCCCCO)=C(C)C1=O,,,,,0,150,366.2406242,1,0,0,0,0,0
7167,04/06/2019 00:00,DB09082,Vilanterol,"Peak plasma concentrations are achieved within 10 minutes of inhalation. Absolute bioavailability was found to be 27.3% when administered by inhalation, whereas oral bioavailability was found to be less than 2% due to extensive first-pass metabolism. Systemic exposure is 24% higher in patients with COPD as compared to healthy subjects.",,21.3 hr,,Respiratory (inhalation),solid,,,0.00118,10.12,9.4,OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl,,,21.3,21.3,0,,485.1735785,2,2,0,0,0,0
7168,02/07/2019 00:00,DB09083,Ivabradine,"It is recommended to take ivabradine with food to reduce variability in systemic exposure. Administration with food slows absorption by 1 hour, but increases systemic absorption by 20-30%. Ivabradine's oral bioavailability is about 40%. ",0.7,2 hours. ,5 mg/5mL,Oral,solid,,,0.0202,,9.37,COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1,0.7,0.7,2,2,0,,468.2624223,4,2,1,0,0,1
7169,02/07/2019 00:00,DB09084,Benzydamine,"Oral doses of benzydamine are well absorbed and plasma drug concentrations reach a peak fairly rapidly and then decline with a half-life of approximately 13 hours. When applied topically, although the local drug concentrations are relatively large, the systemic absorption of topically applied benzydamine is relatively low compared to oral doses. This low topical absorption contributes to a decreased potential for any systemic drug side-effects when benzydamine is administered in this way. [L1121]",0.2,"Approximately 13 h after oral administration [L1121], with a terminal half life of about 7.7 h [A31528].",0.0015,Buccal,solid,Miscible,,0.0491,,9.26,CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12,0.2,0.2,,,0,,309.1841124,3,3,1,1,0,0
7170,02/07/2019 00:00,DB09085,Tetracaine,"Systemic absorption of anaesthetic from the combination cream is directly related to the duration and surface area of application.  Although peak plasma concentrations for lidocaine were measured, plasma levels for tetracaine could not be determined due to low levels (<0.9 ng/mL)",,"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.",40 mg,Topical,solid,,,0.555,,8.42,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,,,,,0,,264.183778,1,1,0,0,0,0
7171,04/06/2019 00:00,DB09086,Eugenol,,,,12 mg/1g,Topical,solid,,,1.44,9.94,-4.9,COC1=C(O)C=CC(CC=C)=C1,,,,,0,,164.0837296,1,1,0,0,0,0
7172,04/06/2019 00:00,DB09088,Amylocaine,A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s [T146].,,A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s [T146].,180 mg,Dental,solid,,,1.06,,8.91,CCC(C)(CN(C)C)OC(=O)C1=CC=CC=C1,,,,,0,,235.1572289,1,1,0,0,0,0
7173,02/07/2019 00:00,DB09089,Trimebutine,"The free base form or salt form of trimebutine are rapidly absorbed after oral administration, with the peak plasma concentration reached after 1 hour of ingestion [A19692]. The time to reach peak plasma concentration following a single oral dose of 200mg trimebutine is 0.80 hours [L872].",0.05,"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].",200 mg,Oral,solid,Insoluble,,0.019,,8.48,CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1,0.05,0.05,,,0,200,387.204573,2,2,0,0,0,0
7174,02/07/2019 00:00,DB09090,Pinaverium,"After oral administration, pinaverium is poorly absorbed (5-10%) followed by uptake by liver. Poor absorption is due to its highly polar quaternary ammonium group and high molecular weight [L873], which limits extensive diffusion across all cell membranes and promotes its selectivity towards the gastrointestinal tracts []. Peak plasma concentration is reached within one hour after administration and the absolute oral bioavailability is reported to be less than 1%. ",0.97,The mean elimination half life is approximately 1.5 hours [L873]. ,100 mg,Oral,solid,Slightly soluble,,3.42E-06,17.16,-3.8,COC1=C(OC)C=C(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)C(Br)=C1,0.97,0.97,,,1,100,510.2213473,5,1,1,0,1,1
7175,04/06/2019 00:00,DB09091,Tixocortol,"The absorption of tixocortol is the same as in other steroids including hydrocortisone.[L1078] Oral administration of tixocortol presents a 10-20% bioavailability with a significantly lower plasma Cmax than cortisol. The fast metabolism, larger volume of distribution and low bioavailability donates tixocortol with the absence of systemic activity.[A31439] ",,Tixocortol presents a shorter half-life than cortisol.[A31447],250 mg,Rectal,solid,Insoluble,4.48,0.0428,9.57,-2.8,[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,378.1864804,4,0,0,0,0,0
7176,04/06/2019 00:00,DB09092,Xanthinol,"Xanthinol is readily absorbed in the body with an absorption half life of 0.4 h.[T53] After absorption, xanthinol nicotinate rapidly degardes into the negatively charged nicotinic acid and the positively charged xanthinol ion.[A31450]",1,The reported elimination half-life of xanthinol is 1.67h.,150 mg,Oral,solid,<1 mg/mL ,,17.3,14.38,8.86,CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C,1,1,,,0,150,311.1593542,2,2,2,2,0,0
7177,04/06/2019 00:00,DB09093,Chlortetracycline,Chortetracycline reaches peak plasma concentation in about 3 hours [A1424]. Its oral bioavailability is 25-30%.,50-55%,The half-life of Chlortetracycline is 5.6 hours [A1424].,0.03,Topical,solid,,,0.288,3.58,7.97,[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O,0.5,0.55,,,0,,478.1142934,4,1,0,0,0,0
7178,02/07/2019 00:00,DB09094,Podophyllin,"Oral absorption: Podophyllum is very well and rapidly absorbed after ingestion.
Dermal absorption: systemic poisoning was reported after topical application in some cases. Symptoms were delayed between 2-24 hr.",,No data available. ,1 mg/4mL,Topical,solid,,,0.427,3.56,-2.6,COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O,,,,,0,,1692.547,18,8,6,0,2,6
7179,04/06/2019 00:00,DB09095,Difluocortolone,"The absorption of diflucortolone is made mainly percutaneously but it may be absorbed systemically. The absorption and bioavailability of diflucortolone will be related to the type of formulation found in the medication.[A31458] The percutaneous absorption depends on the vehicle, dose, treatment area, duration of treatment, the condition of treatment, the status of penetration barrier and localization of treated area in the body.[L1085] Thus, rectal administration of diflucortolone produces a slow and low absorption with an AUC, Cmax and Tmax of 10.8 ng h/ml, 0.75 ng/ml and 4.7 h, respectively.[L1084]",0.01,The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[A31459],0.001,Topical,solid,2.030 mg/L,3.86,0.0446,13.39,-3.3,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,0.01,0.01,,,0,,394.1955658,4,0,0,0,0,0
7180,02/07/2019 00:00,DB09096,Benzoyl peroxide,Benzoyl peroxide is absorbed percutaneously into the dermal layer of the epithelium. It is then metabolized to benzoic acid which can be absorbed systemically. There is no systemic absorption of benzoyl peroxide itself.,,Benzoyl peroxide is not absorbed into systemic circulation after topical application. Further studies are needed on its half life within the epithelium.,28.3 g/100g,Topical,solid,<1%,,0.0294,,-7.2,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,242.0579088,2,2,0,0,0,0
7181,02/07/2019 00:00,DB09097,Quinagolide,"The absorption of quinagolide is rapid and extensive with 95% of the dose absorbed after oral ingestion, however the absolute bioavailability is low (4 %) due to pre-systemic metabolism. The time to reach peak plasma concentration is 30-60 minutes. Prolactin-lowering effect of quinagolide at recommended therapeutic doses occurs within 2 hours after ingestion reaches a maximum within 4 to 6 hours and is maintained for at least 24 hours [L871].",,The terminal half-life for parent drug is 11.5 hours following single dose and 17 hours at steady state.,0.025 mg,Oral,solid,Sparingly soluble in water (0.2%) ,,0.154,10.2,8.22,[H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC,,,,,0,0.025,395.2242629,3,1,1,0,1,1
7182,04/06/2019 00:00,DB09099,Somatostatin,This pharmacokinetic data is irrelevant.,,The half-life of endogenous somatostatin is 1-3 minutes due to rapid degradation by peptidase enzymes present in the plasma and tissues [A20384].,3 mg,Intravenous,solid,,,0.0205,2.88,10.47,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O,,,,,0,,1636.716655,6,5,2,1,1,1
7183,02/07/2019 00:00,DB09101,Elvitegravir,"Following oral administration of elvitegravir and ritonavir with food, in HIV-1 infected subjects, peak elvitegravir plasma concentrations were observed approximately 4 hours post-dose.",98â€“99%,The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.,150 mg,Oral,solid,<0.3 mcg/mL,,0.00652,6.16,-0.53,[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2,0.98,0.99,,,0,150,447.1248787,3,3,1,1,0,0
7184,02/07/2019 00:00,DB09102,Daclatasvir,Studies demonstrated that peak plasma concentrations typically occurred within 2 hours after administration of multiple oral doses ranging from 1 - 100 mg once daily. Steady state is reached after approximately 4 days of once-daily daclatasvir administration. The absolute bioavailability of the tablet formulation is 67%. ,,"Following multiple dose administration of daclatasvir in HCV-infected subjects, with doses ranging from 1 mg to 100 mg once daily, the terminal elimination half-life of daclatasvir ranged from approximately 12 to 15 hours. ",30 mg/1,Oral,solid,Freely soluble (>700 mg/mL),,0.00852,11.15,6.09,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,,,,,0,30,738.3853313,6,4,4,2,2,2
7185,02/07/2019 00:00,DB09110,Coenzyme M,"Peak plasma concentrations were reached within 1.5-4 hours for free mesna, and 3-7 hours for total mesna following oral administration.  The average oral bioavailability is 58% for free mesna and 89% for total mesna.  Food has no effect on the urinary availability of mesna.",0.28,The elimination half-life is 0.36 hours for mesna and 1.17 hours for dimesna.,100 mg/1mL,Intravenous,solid,,,12.7,-1.2,-9.6,OS(=O)(=O)CCS,0.28,0.28,,,0,,141.9758361,0,0,0,0,0,0
7186,04/06/2019 00:00,DB09114,Colfosceril palmitate,"The absorption is done directly in the alveolus into the lung tissue.[L1110] As the lung surfactant is distributed in the bronchi, bronchioles and alveoli, its highest concentration is at the alveolar air-fluid interface where it remains as a monolayer.[A31515]",,The half-life of colfosceril palmitate is registered to be in the range of 20-36 hours.[L1112],108 mg,Endotracheal,solid,Very poor solubility,1.97,2.40E-05,1.86,-6.7,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,,,,,0,,733.5621551,0,0,0,0,0,0
7187,04/06/2019 00:00,DB09115,Diiodohydroxyquinoline,,,,210 mg,Topical,solid,,,0.0815,7.39,3.34,OC1=C2N=CC=CC2=C(I)C=C1I,,,,,0,,396.8460598,2,2,1,1,0,0
7188,04/06/2019 00:00,DB09116,Calcium carbimide,"It presents a very rapid absorption which has caused the presence of side effects as nausea, headache and vomiting.[L1114] The oral bioavailability of calcium carbimide depends on the administered dose which can vary from 50-81% on a dose of 0.3-1.5 mg/kg respectively.[T74] In preclinical trials, peak plasma concentration occurred at 60 minutes after administration.[L1114] The values of Cmax, AUC and T max of calcium carbimide of a dose of 1.5 mg/kg were 1.65 mcg/ml, 77.86 mcg/mg min and 12 minutes respectively.[A31522]",,Calcium carbimide is metabolized and eliminated very rapidly so the apparent half-life is of 92.4 minutes.[L1114],50 mg,Oral,solid,Soluble ,,8.71,,3.56,[Ca++].[N-]=C=[N-],,,,,0,50,79.96873898,0,0,0,0,0,0
7189,04/06/2019 00:00,DB09117,Paraldehyde,93% of orally administered paraldehyde is absorbed from the gastrointestinal tract.,,The mean half life is 7.5 hours in a range if 3.5-9.5 hours [A19738].,1,Intramuscular; Intravenous,liquid,125g/L,0.73,177,,-4,CC1OC(C)OC(C)O1,,,,,0,,132.0786442,1,0,1,0,1,1
7190,02/07/2019 00:00,DB09118,Stiripentol,Absorption of stiripentol is quick with the peak plasma concentration reached within 1.5 hours following oral administration. The systemic exposure increases in a dose-proportional relationship [L880]. It is rapidly taken up into the brain and enters the cerebellum and medulla. It displays low bioavailability due to water insolubility and metabolism [A19740].,,"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880]. ",250 mg/1,Oral,solid,Insoluble,3.53,0.405,14.34,-3.1,CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1,,,,,0,250,234.1255944,2,1,1,0,0,1
7191,02/07/2019 00:00,DB09119,Eslicarbazepine acetate,Eslicarbazepine active metabolite has a high bioavailability and reaches peak serum concentration 1-4 hours after a given dose. Eslicarbazepine acetate absorption is not affected by food.,,The apparent plasma half-life of eslicarbazepine is 10-20 hours in healthy subjects and 13-20 hours in epilepsy patients. Steady-state plasma concentrations are attained after 4 to 5 days of once daily dosing.,200 mg/1,Oral,solid,Water solubility of eslicarbazepine acetate is low at less than 1 mg/mL including at different pH values. Its main metabolite eslicarbazepine has a greater water solubility of 4.2 mg/mL.,8.8,0.11,15.96,-3.8,CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12,,,,,0,200,296.1160924,3,2,1,0,0,1
7192,02/07/2019 00:00,DB09120,Zucapsaicin,"Zucapsaicin displays low systemic absorption and localizes at the area of application. In animal studies, systemic absorption is 0.075% [L877]. ",,"In rats, the elimination half life of zucapsaicin and its metabolites is approximately 7 to 11 hours [L877].",0.00075,Topical,solid,Insoluble,,0.00841,9.93,-0.52,COC1=C(O)C=CC(CNC(=O)CCCC\C=C/C(C)C)=C1,,,,,0,,305.1990937,1,1,0,0,0,0
7193,04/06/2019 00:00,DB09121,Aurothioglucose,"In general, aurothioglucose is administered via intramuscular injection - preferably intragluteally [L1947] - after which the resultant absorption is typically slow and erratic [T149].

Gold is absorbed from injection sites, reaching peak concentration in blood in about 4 to 6 hours [L1937]. After a single intramuscular injection of 50 mg of aurothioglucose suspension in two subjects, peak serum levels were observed at approximately  235 g/dL and 450 g/dL [L1937].

Storage of gold in human tissues depends upon organ mass as well as the concentration of gold [L1937].Subsequently, tissues having the highest gold levels (w/w) may not necessarily have the largest total amounts of gold [L1937]. The highest concentrations of gold are generally found in the lymph nodes, adrenal glands, liver, kidneys, bone marrow, and spleen [L1937]. Relatively small concentrations are actually found in the articular structures [L1937]. In particular, following the administration of aurothioglucose doses, about 85% of the resultant plasma gold will be stored in the major bodily gold depots, which in decreasing order of total gold content are, the lymph nodes, bone marrow, liver, skin, and bone [L1937, L1947].",95-99%,"The biological half-life of gold salts (like aurothioglucose) following a single 50 mg dose demonstrates a biological half-life of about 3-27 days, where the half-life seemingly increases with increased number of doses [T147]. Following successive weekly doses, the half-life increases and may become 14-40 days after the third dose and up to 168 days after the eleventh weekly dose [L1925].",50 mg,Intramuscular,liquid,,,96.4,12.51,-3,OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O,0.95,0.99,,,0,,391.9992882,1,0,1,0,1,1
7194,02/07/2019 00:00,DB09123,Dienogest,"Dienogest is rapidly absorbed following oral administration, with 91% bioavailability. The peak plasma concentration of 47 ng/mL is reached at about 1.5 hours after single ingestion of 2 mg [L931]. The stable concentrations of the drug are reached after two days of initial treatment [A20331].",0.9,Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].,2.00 mg,Oral,solid,Practically insoluble,,0.0761,13.78,-3.3,[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H],0.9,0.9,,,0,2,311.188529,4,0,0,0,0,0
7195,04/06/2019 00:00,DB09124,Medrogestone,"When administered, medrogestone presents a very rapid gastrointestinal absorption with a bioavailability of 100%. The maximum serum concentration of medrogestone is 10-15 ng/ml.[T79]",,The half-life of medrogestone is reported to be of 4 hours.[T79],5 mg,Oral,solid,5.34e-06 mol/L,4.45,0.00404,19.18,-4.9,[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,,,,,0,5,340.2402303,4,0,0,0,0,0
7196,02/07/2019 00:00,DB09125,Potassium Citrate,,,,10 meq/1,Oral,solid,,,39.4,3.05,-4.2,[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,,,,0,,305.8946475,0,0,0,0,0,0
7197,02/07/2019 00:00,DB09128,Brexpiprazole,"Brexpiprazole reaches peak plasma concentration within 4 hours of administration, and steady state occurs within 10-12 days of dosing. Oral bioavailability is 95%, and can be administered with or without food. ",>99%,"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively. ",0.25 mg/1,Oral,solid,,,0.00227,13.56,8.4,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1,0.99,1,,,0,0.25,433.1823981,5,4,3,2,1,1
7198,02/07/2019 00:00,DB09129,Chromic chloride,Chromium absorption can increase with exercise.,,31- 41 hours,200 mcg,Oral,solid,,,5.83,-7,,[Cl-].[Cl-].[Cl-].[Cr+3],,,,,0,0.2,156.8470655,0,0,0,0,0,0
7199,02/07/2019 00:00,DB09132,Gadoteric acid,,,"Gadoteric acid demonstrates a mean elimination half-life of about 1.4 hr and 2.0 hr in female and male subjects, respectively.",376.9 mg/1mL,Intravenous,solid,,,12.8,0.47,10.08,[Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,,,,,0,,559.0913427,1,0,1,0,1,1
7200,02/07/2019 00:00,DB09133,Iothalamic acid,"Renal accumulation is sufficiently rapid that maximum radiographic density in the calyces and pelves occurs, in most instances, about 3 to 8 minutes after injection. In patients with impaired renal function, diagnostic opacification frequently is achieved only after prolonged periods.",,"In patients with normal renal function, the alpha and beta half-lives of Conray were approximately 10 and 90 minutes, respectively.",600 mg/1mL,Intravascular,solid,,,0.123,2.13,-1.7,CNC(=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,,,,,0,,613.7696508,1,1,0,0,0,0
7201,02/07/2019 00:00,DB09134,Ioversol,"Ioversol may be visualized in the renal parenchyma within 30 to 60 seconds following rapid intravenous injection. Opacification of the calyces and pelves in patients with normal renal function becomes apparent within 1 to 3 minutes, with optimum contrast occurring within 5 to 15 minutes.",,1.5 hr,339 mg/1mL,Intravascular,solid,,,1.04,11.72,-2.6,OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,,,1.5,1.5,0,,806.8646733,1,1,0,0,0,0
7202,04/06/2019 00:00,DB09135,Ioxilan,Peak iodine plasma levels occur immediately following rapid intravenous injection. Iodine plasma levels fall rapidly within 5 to 10 minutes. This can be accounted for by the dilution in the vascular and extravascular fluid compartments.,,An initial fast distribution phase with a half-life of 13.1 Â± 4.2 minutes (women) or 23.5 Â± 15.3 minutes (men) was followed by an elimination phase with a half-life of 102.0 Â± 16.9 minutes (women) and 137 Â± 35.4 minutes (men).,300 mg/1mL,Intravascular,solid,,,0.559,11.74,-1.7,CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I,,,,,0,,790.8697587,1,1,0,0,0,0
7203,04/06/2019 00:00,DB09136,Isosulfan blue,"Intradermal and parenchymal injections of vital blue dyes, such as isosulfan blue, can lead to systemic absorption through lymphatic channels and vascular beds near tumor sites.",0.01,Slow release of the dye from the subcutaneous tissue or the lymphatic tissue and the half-life of the dye in the body of several hours. ,50 mg/5mL,Subcutaneous,solid,,,0.00094,-2.5,5.33,CCN(CC)C1=CC=C(C=C1)C(=C1C=CC(C=C1)=[N+](CC)CC)C1=CC(=CC=C1S(O)(=O)=O)S(O)(=O)=O,0.01,0.01,,,1,,545.1774552,3,2,0,0,0,0
7204,04/06/2019 00:00,DB09137,Technetium Tc-99m mebrofenin,Visualisation in the liver could be detected by 5 minutes and maximum liver uptake occurred at 11 minutes post-injection. Hepatic duct and gallbladder visualization occurred by 10 to 15 minutes and intestinal activity was visualized by 30 to 60 minutes in subjects with normal hepatobiliary function The mean percent injected dose remaining in the blood at 10 minutes was 17%. ,,Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours.,45 mg/1,Intravenous,solid,,,0.0568,2.81,2.13,[99Tc].[H]OC(=O)C([H])([H])N(C([H])([H])C(=O)O[H])C([H])([H])C(=O)N([H])C1=C(C(Br)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H],,,,,0,,484.9539885,1,1,0,0,0,0
7205,04/06/2019 00:00,DB09138,Technetium Tc-99m medronate,"When injected intravenously, Technetium Tc 99m Medronate is rapidly cleared from the blood; about 50% of the dose is accumulated and retained by the skeleton, while the remaining 50% is excreted in the urine within 24 hours. About 10% of the injected dose remains in the blood at 1 hour post-injection, 5% at 2 hours, and less than 1% remains at 24 hours. Following intravenous administration of Technetium Tc 99m Medronate, skeletal uptake occurs as a function of blood flow to bone and bone efficiency in extracting the complex. ",,Technetium Tc-99m decays by isomeric transition with a physical half-life of 6.02 hours.,20 mg/10mL,Intravenous,solid,,,13.5,1.27,,O.O.[98Tc+4].[O-]P([O-])(=O)CP([O-])([O-])=O,,,,,0,,305.8610064,0,0,0,0,0,0
7206,04/06/2019 00:00,DB09139,Technetium Tc-99m oxidronate,"Technetium Tc-99m oxidronate is rapidly absorbed and cleared from blood plasma to reach the skeleton.[L1142] After 27 min of intravenous administration, a range of 45-50% of the technetium Tc-99m oxidronate is accumulated in the skeleton, reaching maximum accumulation at 1-hour post injection and remaining constant until 72 hours postinjection.[L1143]",20-30%,"The elimination of technetium Tc-99m oxidronate is marked by the presence of three different half-times which are: 1) rapid phase of 3.5 min, 2) intermediate phase of 27 min and 3) slow phase of 144 min.[L1143]",,,solid,Soluble,,13.5,0.75,-5,[99Tc].OC(P(O)(O)=O)P(O)(O)=O,0.2,0.3,,,0,,290.8651305,0,0,0,0,0,0
7207,02/07/2019 00:00,DB09142,Sincalide,"The intravenous (bolus) administration of sincalide causes a prompt contraction of the gallbladder that becomes maximal in 5 to 15 minutes, as compared with the stimulus of a fatty meal which causes a progressive contraction that becomes maximal after approximately 40 minutes.",,,5 ug/5mL,Intravenous,solid,,,0.00441,-2,8.23,CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,,,,,0,,1142.350739,4,4,1,1,0,0
7208,04/06/2019 00:00,DB09143,Sonidegib,"Sonidegib is rapidly absorbed in the fasted state with peak concentrations occurring 2-4 hours after administration. (2)  However, the total absorption of Sonidegib is low (roughly 6-7%). (1)",0.97,Half-life ~ 28 days (2),200 mg/1,Oral,solid,,,0.00155,14.21,5.45,[H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1,0.97,0.97,,,0,200,485.1926264,4,3,2,1,1,1
7209,04/06/2019 00:00,DB09144,Uridine triacetate,Maximum concentrations of uridine in plasma following oral administration are generally achieved within 2 to 3 hours.,,2 to 2.5 hours,951 mg/1g,Oral,solid,,,14.6,9.7,-4.3,CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N1C=CC(=O)NC1=O,,,,,0,,370.1012302,2,1,2,1,1,1
7210,02/07/2019 00:00,DB09146,Iron saccharate,The intravensously administered iron sacchrate injection would result rapidly in high serum iron levels. Maximum measured levels occured after 10 min of injection with an average of 30.00 mg/l.,,6 hours.,150 mg/1,Oral,solid,,,9.52,11.84,-3,O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,,,6,6,0,150,866.7641882,2,0,2,0,2,2
7211,04/06/2019 00:00,DB09148,Florbetaben (18F),"Ten minutes after intravenous bolus injection of 300 MBq of Neuraceq in human volunteers, approximately 6% of the injected radioactivity was distributed to the brain. Florbetaben F 18 plasma concentrations declined by approximately 75% at 20 minutes post-injection, and by approximately 90% at 50 minutes.",0.985,1 hr,135 mCi/1mL,Intravenous,solid,,,0.00103,,4.62,CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1,0.985,0.985,1,1,0,,358.1922067,2,2,0,0,0,0
7212,04/06/2019 00:00,DB09149,Florbetapir (18F)," The time-activity curves for florbetapir F 18 in the brain of subjects with positive scans show continual signal increases from time zero through 30 minutes post-administration, with stable values thereafter up to at least 90 minutes post-injection. Following the intravenous administration of 370 MBq (10 mCi) of florbetapir F 18 to healthy volunteers, the drug was distributed throughout the body with less than 5% of the injected F 18 radioactivity present in the blood by 20 minutes following administration, and less than 2% present by 45 minutes after administration.",,,1900 MBq/ml,Intravenous,solid,,,0.0058,,4.62,[H]N(C1=C([H])C([H])=C(\C([H])=C(/[H])C2=C([H])N=C(OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])[18F])C([H])=C2[H])C([H])=C1[H])C([H])([H])[H],,,,,0,,359.1874557,2,2,1,1,0,0
7213,04/06/2019 00:00,DB09151,Flutemetamol (18F),"The time-activity curves for flutemetamol F 18 in the brain of subjects with positive scans shows continual signal increases from time zero through 30 minutes post administration, with stable values thereafter up to at least 120 minutes post-injection. Following intravenous injection of 185 MBq (5 mCi) of Vizamyl in humans, flutemetamol F 18 plasma concentrations declined by approximately 75% in the first 20 minutes post-injection, and by approximately 90% in the first 180 minutes.",,,4.05 mCi/1mL,Intravenous,solid,,,0.0135,9.23,2.89,CNC1=C([18F])C=C(C=C1)C1=NC2=CC=C(O)C=C2S1,,,,,0,,273.060147,3,3,1,1,0,0
7214,02/07/2019 00:00,DB09153,Sodium chloride,"Absorption of sodium in the small intestine plays an important role in the absorption of chloride, amino acids, glucose, and water. Chloride, in the form of hydrochloric acid (HCl), is also an important component of gastric juice, which aids the digestion and absorption of many nutrients.",,17 minutes.,4.5 mg,Intravenous,solid,,,108,3.09,,[Na+].[Cl-],,,0.283333333,0.283333333,0,,57.95862196,0,0,0,0,0,0
7215,02/07/2019 00:00,DB09154,Sodium citrate,Tmax of 98-130min [A19414].,,18-54 min [A19414],4 g,Intravenous,solid,29.4g/L,,73.7,3.05,-4.2,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,,,,0,,257.9728353,0,0,0,0,0,0
7216,02/07/2019 00:00,DB09156,Iopromide,"Following administration, the degree of contrast enhancement is directly related to the iodine content in the administered dose; peak iodine plasma levels occur immediately following rapid intravenous injection. Iodine plasma levels fall rapidly within 5 to 10 minutes, which can be accounted for by the dilution in the vascular and extravascular fluid compartments. Contrast enhancement appears to be greatest immediately after bolus injections (15 seconds to 120 seconds). Thus, greatest enhancement may be detected by a series of consecutive two-to-three second scans performed within 30 to 90 seconds after injection (that is, dynamic computed tomographic imaging).
Injection may be visualized in the renal parenchyma within 30â€“60 seconds following rapid intravenous injection. Opacification of the calyces and pelves in patients with normal renal function becomes apparent within 1â€“3 minutes, with optimum contrast occurring within 5â€“15 minutes.

",,"After intravenous administration to healthy young volunteers, plasma iopromide concentration time profile shows an initial distribution phase with a half-life of 0.24 hour; a main elimination phase with a half-life of 2 hours; and a terminal elimination phase with a half-life of 6.2 hours. ",300 mg/1mL,Intra-arterial,solid,,,0.0915,4.23,2.19,COCC(O)=NC1=C(I)C(C(O)=NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I,,,,,0,,790.8697587,1,1,0,0,0,0
7217,02/07/2019 00:00,DB09157,Carbon dioxide,Data not found. ,,Data not found. ,100 mL/1L,Respiratory (inhalation),solid,,,186,,,O=C=O,,,,,0,,43.98982924,0,0,0,0,0,0
7218,02/07/2019 00:00,DB09158,Trypan blue free acid,,,,0.0006,Intraocular,solid,,,0.0121,-4.2,2.38,CC1=CC(=CC=C1\N=N\C1=C(C=C2C=C(C=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C=C(C=C2C=C1S(O)(=O)=O)S(O)(=O)=O,,,,,0,,872.0546336,6,6,0,0,0,0
7219,04/06/2019 00:00,DB09160,Technetium Tc-99m tetrofosmin,"After intravenous admministration, technetium 99m tetrofosmin is taken up in the heart where the uptake is done by potential-driven diffusion of the lipophilic cationic complex accross the sarcolemmal and mitochondrial membranes.[L1146] The uptake in myocardium represents approximately 1.2% of the administered activity after 5 minutes of injection and this activity reduces to 1% at 2 hours. Once taken by the myocardium, there is a minimal redistribution in the following 3-4 hours.[L1147]",,Technetium-99m tetrofosmin presents a very short half-life of 6.03 hours which is an advantage over other labeled radiopharmaceuticals.[A31592],,,solid,Soluble,,0.000664,,8.3,O.O.[98Tc].CCOCCP(CCOCC)CCP(CCOCC)CCOCC.CCOCCP(CCOCC)CCP(CCOCC)CCOCC,,,,,0,,898.4087114,0,0,0,0,0,0
7220,04/06/2019 00:00,DB09161,Technetium Tc-99m sestamibi,At five minutes post injection about 8% of the injected dose remains in circulation. Myocardial uptake which is coronary flow dependent is 1.2% of the injected dose at rest and 1.5% of the injected dose at exercise.,0.01,"Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours. Blood clearance studies indicate that the fast clearing component clears with a tÂ½ of 4.3 minutes at rest, and clears with a tÂ½ of 1.6 minutes under exercise conditions. The myocardial biological half-life is approximately six hours after a rest or exercise injection. The biological half-life for the liver is approximately 30 minutes after a rest or exercise injection. ",1 mg/5mL,Parenteral,solid,,,0.00465,16.14,-4.2,[Tc+].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-],0.01,0.01,,,1,,775.4102003,0,0,0,0,0,0
7221,04/06/2019 00:00,DB09164,Technetium Tc-99m disofenin,"In fasting normal individuals, peak liver uptake occurs by 10 minutes post-injection and peak gallbladder accumulation by 30-40 minutes post-injection [L794]. Hepatic uptake is about 88%.",,Technetium Tc99m decays by isomeric transition with a physical half-life of 6.02 hours [L794] but the Technetium Tc99M disofenin complex displays a hepatic elimination half life of 19 minutes [A18523].,20 mg/10mL,Intravenous,solid,,,0.0463,3.11,2.41,[99Tc].CC(C)C1=CC=CC(C(C)C)=C1NC(=O)CN(CC(O)=O)CC(O)=O,,,,,0,,449.0904266,1,1,0,0,0,0
7222,04/06/2019 00:00,DB09165,Technetium Tc-99m pyrophosphate,1-2h after injection approximately 40-50% is localized to the skeleton and 0.01-0.02% per gram to acutely infarcted myocardium [FDA Label].,,,12 mg/10mL,Intravenous,solid,Soluble,,10.8,1.7,,[99Tc+4].[O-]P([O-])(=O)OP([O-])([O-])=O,,,,,0,,272.8181803,0,0,0,0,0,0
7223,04/06/2019 00:00,DB09166,Etizolam,"Etizolam is well absorbed from the intestines with a biological bioavailability of 93% following oral administration. After a single oral dosing of 0.5mg etizolam, it takes approximately 0.9 hours to reach the peak plasma concentration of 8.3 ng/mL [L884]. ",,The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite Î±-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].,,,solid,Practically insoluble,,0.0425,18.28,4.64,CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl,,,,,0,,342.0705952,4,3,3,2,0,1
7224,04/06/2019 00:00,DB09167,Dosulepin,Dosulepin is well absorbed from the intestines to reach the peak plasma concentration of 37.6ng/mL at 2.18 hours (Tmax) following oral administration of 25mg [L881]. The steady state concentrations are variable among individuals due to dynamic relationship between the drug dose and plasma concentration [L882]. ,0.84,The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881]. ,,,solid,Partly miscible,,0.000572,,9.76,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12,0.84,0.84,,,0,,295.1394707,3,2,1,0,0,1
7225,04/06/2019 00:00,DB09168,4-Phenylfentanyl,,,,,,solid,,,0.000954,,9.05,CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,412.2514636,4,3,1,0,1,1
7226,04/06/2019 00:00,DB09169,3-Allylfentanyl,,,,,,solid,,,0.00179,,9.38,CCC(=O)N([C@@H]1CCN(CCC2=CC=CC=C2)C[C@@H]1CC=C)C1=CC=CC=C1,,,,,0,,376.2514636,3,2,1,0,1,1
7227,04/06/2019 00:00,DB09170,Î²-Hydroxythiofentanyl,,,,,,solid,,,0.0326,13.69,8.16,CCC(=O)N(C1CCN(CC(O)C2=CC=CS2)CC1)C1=CC=CC=C1,,,,,0,,358.1714991,3,2,2,1,1,1
7228,04/06/2019 00:00,DB09171,Î²-Methylfentanyl,,,,,,solid,,,0.0134,,9.07,CCC(=O)N(C1CCN(CC(C)C2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,350.2358136,3,2,1,0,1,1
7229,04/06/2019 00:00,DB09172,Brifentanil,,,,,,solid,,,0.117,15.81,7.54,CCN1N=NN(CCN2CC[C@@H]([C@H](C)C2)N(C(=O)COC)C2=CC=CC=C2F)C1=O,,,,,0,,420.228517,3,2,2,1,1,1
7230,04/06/2019 00:00,DB09173,Butyrfentanyl,,,,,,solid,,,0.0137,,8.77,CCCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,350.2358136,3,2,1,0,1,1
7231,04/06/2019 00:00,DB09174,Lofentanil,,,,,,solid,,,0.0166,,8.36,CCC(=O)N(C1=CC=CC=C1)[C@]1(CCN(CCC2=CC=CC=C2)C[C@H]1C)C(=O)OC,,,,,0,,408.2412929,3,2,1,0,1,1
7232,04/06/2019 00:00,DB09175,Mirfentanil,,,,,,solid,,,0.105,,8.41,O=C(N(C1CCN(CCC2=CC=CC=C2)CC1)C1=NC=CN=C1)C1=CC=CO1,,,,,0,,376.189926,4,3,3,2,1,1
7233,04/06/2019 00:00,DB09177,p-Fluorofentanyl,,,,,,solid,,,0.0167,,8.74,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=C(F)C=C1,,,,,0,,354.2107417,3,2,1,0,1,1
7234,04/06/2019 00:00,DB09178,Phenaridine,,,,,,solid,,,0.00866,,9.32,CCC(=O)N(C1CC(C)N(CCC2=CC=CC=C2)CC1C)C1=CC=CC=C1,,,,,0,,364.2514636,3,2,1,0,1,1
7235,04/06/2019 00:00,DB09179,R-30490,,,,,,solid,,,0.018,,8.85,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CC=C2)CC1,,,,,0,,380.2463783,3,2,1,0,1,1
7236,04/06/2019 00:00,DB09180,Thienylfentanyl,,,,,,solid,,,0.0341,,8.76,CCC(=O)N(C1CCN(CCC2=CC=CS2)CC1)C1=CC=CC=C1,,,,,0,,342.1765845,3,2,2,1,1,1
7237,04/06/2019 00:00,DB09181,Trefentanil,,,,,,solid,,,0.0261,,7.59,CCN1N=NN(CCN2CCC(CC2)(N(C(=O)CC)C2=CC=CC=C2F)C2=CC=CC=C2)C1=O,,,,,0,,466.2492525,4,3,2,1,1,1
7238,04/06/2019 00:00,DB09182,Benzylfentanyl,,,,,,solid,,,0.0534,,8.18,CCC(=O)N(C1CCN(CC2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,322.2045135,3,2,1,0,1,1
7239,02/07/2019 00:00,DB09183,Dasabuvir,Dasabuvir reaches peak plasma concentration 4 hours after administration [FDA Label]. The absolute bioavailability of Dasabuvir is 70%.,0.995,The half-life of elimination of dasabuvir is 5.5 to 6 hours [FDA Label]. ,250 mg,Oral,solid,,,0.000799,9.09,-4.8,COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C,0.995,0.995,,,0,250,493.167142,4,4,1,1,0,0
7240,04/06/2019 00:00,DB09184,Edivoxetine,,,,,,solid,,,0.247,13.4,8.14,[H][C@]1(CNCCO1)[C@@](O)(CC1=C(OC)C=CC(F)=C1)C1CCOCC1,,,,,0,,339.1845865,3,1,2,0,2,2
7241,04/06/2019 00:00,DB09185,Viloxazine,"Viloxazine is rapidly and almost completely absorbed following oral administration. The peak plasma concentration (Cmax) ranges between 540 and 1,600 ng/mL and the mean time to reach Cmax is approximately 86 minutes [A19786]. Increase in plasma drug concentration is dose-proportional [A19781].",,Elimination half life is approximately 3-4 hours [A19786].,,,solid,,,1.24,,8.19,CCOC1=CC=CC=C1OCC1CNCCO1,,,,,0,,237.1364935,2,1,1,0,1,1
7242,04/06/2019 00:00,DB09186,Nisoxetine,,,,,,solid,,,0.012,,9.8,CNCCC(OC1=CC=CC=C1OC)C1=CC=CC=C1,,,,,0,,271.1572289,2,2,0,0,0,0
7243,04/06/2019 00:00,DB09187,Lortalamine,,,,,,solid,,,0.654,10.2,8.28,CN1CCC23NC(=O)CC(C2C1)C1=CC(Cl)=CC=C1O3,,,,,0,,292.0978555,4,1,3,0,2,3
7244,04/06/2019 00:00,DB09188,Amedalin,,,,,,solid,,,0.0214,,10.24,CNCCC[C@]1(C)C(=O)N(C2=CC=CC=C12)C1=CC=CC=C1,,,,,0,,294.1732133,3,2,1,0,0,1
7245,04/06/2019 00:00,DB09189,Daledalin,,,,,,solid,,,0.0236,,10.54,[H]N(C)CCCC1(C)CN(C2=CC=CC=C12)C1=CC=CC=C1,,,,,0,,280.1939488,3,2,1,0,0,1
7246,04/06/2019 00:00,DB09190,Talopram,,,,,,solid,,,0.000693,,10.54,[H]N(C)CCCC1(OC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1,,,,,0,,295.1936144,3,2,1,0,0,1
7247,04/06/2019 00:00,DB09191,Talsupram,,,,,,solid,,,0.000338,,10.54,[H]N(C)CCCC1(SC(C)(C)C2=CC=CC=C12)C1=CC=CC=C1,,,,,0,,311.1707708,3,2,1,0,0,1
7248,04/06/2019 00:00,DB09192,Tandamine,,,,,,solid,,,0.0173,,9.27,CCN1C2=CC=CC=C2C2=C1C(C)(CCN(C)C)SCC2,,,,,0,,302.1816698,3,2,2,1,0,1
7249,04/06/2019 00:00,DB09193,"CP-39,332",,,,,,solid,,,0.000872,,10.28,CNC1CC(C2=CC=CC=C2)C2=CC=CC=C2C1,,,,,0,,237.1517496,3,2,0,0,0,0
7250,04/06/2019 00:00,DB09194,Etoperidone,The absorption and bioavailability is highly variable between individuals and can be as low as 12%. The lower bioavailability is explained due to its high metabolism.[A31351] The mean time to peak plasma concentration is ranged from 1.4-4.8 hours.[T49],,After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350],,,solid,,,0.425,,7.09,CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC,,,,,0,,377.1982382,3,2,2,1,1,1
7251,04/06/2019 00:00,DB09195,Lorpiprazole,"After oral administration, the serotonin antagonist and reuptake inhibitors are rapidly absorbed in the gastrointestinal tract. This absorption can be slow down depending on the type of diet. The maximum plasma concentration of this kind of drugs occurs approximately 1 hour after administration.[T86]",89-99%,"The estimated half-life for drugs like lorpiprazole, a serotonin antagonist and reuptake inhibitor, is in the range of 11-23 hours.[T86]",,,solid,,3.02,0.095,,7.57,[H][C@@]12CCC[C@]1([H])C1=NN=C(CCN3CCN(CC3)C3=CC=CC(=C3)C(F)(F)F)N1C2,0.89,0.99,,,0,,405.2140305,5,2,3,1,1,2
7252,04/06/2019 00:00,DB09196,Lubazodone,,,,,,solid,,,0.45,,8.19,[H]N1CCO[C@H](COC2=C3CCCC3=C(F)C=C2)C1,,,,,0,,251.132157,3,1,1,0,1,1
7253,04/06/2019 00:00,DB09197,Mepiprazole,,,,,,solid,,,0.409,15.24,7.7,[H]N1N=C(CCN2CCN(CC2)C2=CC(Cl)=CC=C2)C=C1C,,,,,0,,304.1454744,3,2,2,1,1,1
7254,04/06/2019 00:00,DB09198,Lobeglitazone,"In rat studies, the AUC for the doses 0.5, 1, and 2 mg/kg, AUC values were determined to be 459, 514, and 481 ug min/mL respectively. Absoprtion occurs rapidly after administration, with Tmax of 67.5 and 48.8 min and a Cmax of 0.962 and 0.4.94 ug/mL following doses of 0.5 and 2 mg/kg, respectively. Absolute bioavailability after oral administration was nearly complete and apparently not affected by the dosage; 92.1% following a 0.5 mg/kg dose and 99.0% following a 2 mg/kg dose. Furthermore, the extent of LB remaining in the GI tract at 24 h was found to be negligible, with values less than 0.2% of the oral dose, suggesting that the intestinal absorption is complete in rats at the dose range studied [A19749].",,"Following an intravenous dosage of 1 mg/kg, the half life was found to be 110 min [A19749].",,,solid,,,0.0181,7.61,3.96,COC1=CC=C(OC2=NC=NC(=C2)N(C)CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,,,,,0,,480.1467409,4,3,2,1,1,1
7255,04/06/2019 00:00,DB09199,Netoglitazone,,,,,,solid,,,0.00124,6.61,-4.9,FC1=C(COC2=CC=C3C=C(CC4SC(=O)NC4=O)C=CC3=C2)C=CC=C1,,,,,0,,381.0834926,4,3,1,0,1,1
7256,04/06/2019 00:00,DB09200,Rivoglitazone,,,,,,solid,,,0.0388,6.62,4.9,COC1=CC=C2N=C(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)N(C)C2=C1,,,,,0,,397.1096271,4,3,2,1,1,1
7257,04/06/2019 00:00,DB09201,Ciglitazone,,,,,,solid,,,0.00534,6.61,-4.8,CC1(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)CCCCC1,,,,,0,,333.1398646,3,1,1,0,1,1
7258,04/06/2019 00:00,DB09202,Cirazoline,,,,,,solid,,,0.389,,9.26,[H]N1CCN=C1COC1=CC=CC=C1C1CC1,,,,,0,,216.1262631,3,1,1,0,0,1
7259,04/06/2019 00:00,DB09203,Synephrine,,,,,,solid,,,18.6,9.76,9.15,CNCC(O)C1=CC=C(O)C=C1,,,,,0,,167.0946287,1,1,0,0,0,0
7260,04/06/2019 00:00,DB09204,Arotinolol,Arotinolol gets rapidly absorbed and distributed in the plasma. The plasma concentration peaks 2 hours after initial administration.[A31639],0.953,The reported half-life of arotinolol is 7.2 hours.[T87],,,solid,Slightly soluble,2.3,0.0225,13.51,9.84,CC(C)(C)NCC(O)CSC1=NC(=CS1)C1=CC=C(S1)C(N)=O,0.953,0.953,,,0,,371.0795899,2,2,2,2,0,0
7261,04/06/2019 00:00,DB09205,Moxisylyte,"Moxisylyte is rapidly absorbed after oral administration.[L1174] Its pharmacokinetic profile is linear in the dose range from 10 to 30 mg for the values of Cmax and AUC.[A31647] After intravenous administration, the maximal plasma concentration was of 352.8 ng/ml with an AUC of 152.6 mcg h/L.[A31650] In preclinical trials, the bioavailability was always presented in approximately 10%.[L1178]",,The half-life of moxisylyte was of 1-2 hours.[L1174],,,solid,>47.4 ug/ml,3.17,0.406,,8.79,CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1,,,,,0,,279.1834437,1,1,0,0,0,0
7262,04/06/2019 00:00,DB09206,Trimazosin,,,,,,solid,,,1.56,14.59,5.99,COC1=CC2=C(N=C(N=C2N)N2CCN(CC2)C(=O)OCC(C)(C)O)C(OC)=C1OC,,,,,0,,435.2117836,3,2,2,1,1,1
7263,04/06/2019 00:00,DB09207,AS-8112,,,,,,solid,,,0.114,14.64,8.32,[H]N(C)C1=C(Br)C=C(C(=O)N([H])[C@@H]2CN(C)CCN(CC)C2)C(OC)=C1,,,,,0,,398.1317382,2,1,1,0,1,1
7264,04/06/2019 00:00,DB09209,Pholcodine,"After oral administration of 60 mg of pholcodine, the Tmax and Cmax are reported to be 1.3 hours and 26.3 ng/ml. In the same administration, the AUC in plasma and saliva are reported to be 1.67 and 6.61 mg h/l respectively. The absorption of pholcodine is reported to represent approximately 88% of the administered dose.[A31738]",21-23%,"After oral administration of 60 mg of pholcodine, the half-life in plasma, saliva and urine are 45, 55 and 45 hours respectively.[A31738]",,,solid,Slightly soluble,1.08,0.489,13.78,9.19,[H][C@@]12OC3=C(OCCN4CCOCC4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,0.21,0.23,,,0,,398.2205574,6,1,3,0,2,3
7265,04/06/2019 00:00,DB09210,Piracetam,"Piracetam displays a linear and time-dependent pharmacokinetic properties with low intersubject variability over a large range of doses. Piracetam is rapidly and extensively absorbed following oral administration with the peak plasma concentration is reached within 1 hour after dosing in fasted subjects. Following a single oral dose of 3.2 g piracetam, the peak plasma concentration (Cmax) was 84 Âµg/mL. Intake of food may decrease the Cmax by 17% and increase the time to reach Cmax (Tmax) from 1 to 1.5 hours. Tmax in the cerebrospinal fluid is achieved approximately 5 hours post-administration [L1124]. 

The absolute bioavailability of piracetam oral formulations is close to 100% and the steady state plasma concentrations are achieved within 3 days of dosing [L1124]. ",,The plasma half life of piracetam is approximately 5 hours following oral or intravenous administration. The half life in the cerebrospinal fluid was 8.5 hours [L1124].,,,solid,,,4.76,-1.4,12.88,OC(=N)CN1CCCC1=O,,,,,0,,142.0742276,1,0,1,0,1,1
7266,04/06/2019 00:00,DB09211,Limaprost,Limaprost reaches peak plasma concentration in about 30 minutes [A19715].,,The mean half life of elimination is 1.64 hours [A19715].,,,solid,,,0.0248,4.44,-1.5,CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O,,,,,0,,380.2562743,1,0,0,0,0,0
7267,04/06/2019 00:00,DB09212,Loxoprofen,Loxoprofen is rapidly and completely absorbed from the GI tract with a bioavailability of 95% [L1268]. The absorption phase of the medication occurs in the first 4-6 hours after ingestion. Food ingestion with the medication causes a slight decrease in the rate of loxoprofen absorption.  [L1268].,0.99, The elimination half-life of Loxoprofen is approximately 15 hours [L1268].Steady concentration is achieved after 2-3 doses [L1268].  ,,,solid,47 mg/mL,,0.0663,4.19,-7.4,CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1,0.99,0.99,,,0,,246.1255944,2,1,0,0,0,0
7268,04/06/2019 00:00,DB09213,Dexibuprofen,"The time it take to reach peak plasma concentration is 2.25-5 hours post-administration of oral tablets containing 300mg of dexibuprofen.[A19254] For more information, refer to [ibuprofen].",,"Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254]. For more information, refer to [ibuprofen].",,,solid,Insoluble ,,0.0684,4.85,,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O,,,,,0,,206.1306798,1,1,0,0,0,0
7269,04/06/2019 00:00,DB09214,Dexketoprofen,"After oral ingestion, the Dexketoprofen onset of action is within 30 minutes. The plasma half-life of Dexketoprofen is about 4-6 hours. The Cmax is about 30 minutes [L1204]",,1.65 h [L1299],,,solid,,,0.0213,3.88,-7.5,[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,,,,,0,,254.0942943,2,2,0,0,0,0
7270,04/06/2019 00:00,DB09215,Droxicam,Tmax of 7 h. Bioavailability equivalent to [DB00554] which is thought to be completely absorbed in humans based on data from rabbits [A7026].,,Data not available for prodrug. See [DB00554] for information on the active compound.,,,solid,,,0.0319,,0.92,CN1C2=C(OC(=O)N(C2=O)C2=CC=CC=N2)C2=CC=CC=C2S1(=O)=O,,,,,0,,357.0419415,4,3,3,2,0,1
7271,04/06/2019 00:00,DB09216,Tolfenamic Acid,Tolfenamic acid pharmacokinetic is marked by a short tmax of 0.94-2.04 h.[A31842] It also presented a linear pharmacokinetic profile with an AUC from 13-50 mcg/ml.h if administered in a dose of 2-8 mg/kg respectively.[A31843] The oral absorption is delayed and it gives a mean lag-time to absorption of 32 min. The peak plasma concentration of 11.1 mcg/ml.[A31849] The bioavailability of tolfenamic acid is around 75%.[A31851],0.997,"The estimated half-life of tolfenamic acid is 8.01-13.50 hours.[A31842] When tested intravenously, the reported half-life was 6.1h.[A31849]",,,solid,1 mg/ml,5.17,0.0158,3.88,-2.1,CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O,0.997,0.997,,,0,,261.0556563,2,2,0,0,0,0
7272,04/06/2019 00:00,DB09217,Firocoxib,,,,,,solid,,,0.0105,19.69,-5,CC1(C)OC(=O)C(OCC2CC2)=C1C1=CC=C(C=C1)S(C)(=O)=O,,,,,0,,336.1031447,3,1,1,0,0,1
7273,04/06/2019 00:00,DB09218,Clonixin,,,,,,solid,,,0.0535,1.88,5.37,CC1=C(NC2=C(C=CC=N2)C(O)=O)C=CC=C1Cl,,,,,0,,262.0509053,2,2,1,1,0,0
7274,04/06/2019 00:00,DB09219,Bisoxatin,"Once dissociated from acetate, some bisoxatin is absorbed with a Tmax of 4 h [L926].",,,,,solid,,,0.0201,9.15,-5,OC1=CC=C(C=C1)C1(OC2=CC=CC=C2NC1=O)C1=CC=C(O)C=C1,,,,,0,,333.100108,4,3,1,0,0,1
7275,04/06/2019 00:00,DB09220,Nicorandil,"Following oral administration, nicorandil is well absorbed from the gastrointestinal tract with the oral bioavailability of 75% with the maximum peak plasma concentration (Cmax) reached within 30-60 minutes. The mean Cmax is Cmax then is approximately 300 ng/ml [A20328]. Steady-state plasma concentrations of nicorandil usually are reached within approximately 96-120 h after twice daily dosing (10 or 20mg) [L887]. ",0.25,The elimination half life is approximately 1 hour [A20328]. ,,,solid,Partly miscible,,1.19,13.81,3.62,[O-][N+](=O)OCCNC(=O)C1=CC=CN=C1,0.25,0.25,,,0,,211.0593058,1,1,1,1,0,0
7276,04/06/2019 00:00,DB09221,Polaprezinc,"Intestinal absorption of L-CAZ was studied in rats by Sano et al. [L1309] using 14C- and 65Zn-labeled compounds. They suggested that L-CAZ dissociates to its components, L-carnosine and zinc, during intestinal absorption [L1309]. 
",,The half-life of polaprezinc has been studied in rats and found to be approximately 2 hours [L1311].,,,solid,,,10.9,3.37,9.13,[Zn++].[H][C@@](CC1=CN=CN1)([N-]C(=O)CCN)C([O-])=O,,,,,0,,288.0200824,1,1,1,1,0,0
7277,04/06/2019 00:00,DB09223,Blonanserin,"Blonanserin has a Tmax of 1.5 h and a bioavailablity of 55% [A7841, A31487]. Tmax has been observed to be prolonged and relative bioavailability increased when administered with food [A7841].",0.997,Blonanserin has a half life of elimination of 10.7-16.2 h [A31487].,,,solid,,5.266,0.0359,,7.97,CCN1CCN(CC1)C1=NC2=C(CCCCCC2)C(=C1)C1=CC=C(F)C=C1,0.997,0.997,,,0,,367.2423762,4,2,2,1,1,1
7278,04/06/2019 00:00,DB09224,Melperone,Oral doses are rapidly absorbed (Tmax 1.5â€“3.0 hours post oral ingestion)[A3145].,50-70%,"Approximately 3-4 hours after oral administration [A31862]. After intramuscular injection, the half-life has been found to be approximately 6 hours [A31862].",,,solid,,,0.049,16.4,8.9,CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1,0.5,0.7,,,0,,263.1685425,2,1,1,0,1,1
7279,04/06/2019 00:00,DB09225,Zotepine,"Preclinical pharmacokinetic studies have shown a dose-dependent increase in plasma levels with a tmax between 2-4 hours and Cmax from 6.9-19.6 ng/ml when administered in a dose of 25-100 mg of zotepine. The maximum concentration peaks and slow declines thereafter.[A31864] When administered orally in preclinical studies, zotepine was proven to be absorbed rapidly and almost completely from the gastrointestinal tract.The unchanged drug and metabolites are rapidly distributed to the tissues.[A31892]",0.97,The half-life of zotepine is reported to be of 21 hours.[A31893],,,solid,Poorly soluble ,4.25,0.000777,,8.92,CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,0.97,0.97,,,0,,331.0797629,3,2,1,0,0,1
7280,04/06/2019 00:00,DB09226,RP-5063,,,,,,solid,,,0.0132,3.14,7.48,OC1=NC2=C(OC1)C=CC(OCCCCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl)=C2,,,,,0,,449.127297,4,2,2,0,1,2
7281,04/06/2019 00:00,DB09227,Barnidipine,"Following a single, modified-release dose of 10mg barnidipine, the peak plasma concentration was approximately 0.48 Âµg/L and the area under the curve (AUC) was 2.85 Âµg/Lxh [A7842]. The peak plasma concentrations are reached within 5 to 6 hours after oral administration of 20mg barnidipine. While the plasma concentrations of the drug may vary between individuals, the absolute bioavailability of the barnidipine is approximately 1.1% due to extensive first-pass hepatic metabolism [L1131]. After repeated administration of 20mg barnidipine to healthy individuals, the concomitant intake of food did not have a statistically significant effect on the AUC, Cmax or half-life of the drug [L1131].",26-32%,"In a two-compartment analytical model, the median terminal elimination half life of barnidipine was 20 hours after repeated administration [L1131].",,,solid,,,0.004,19.47,7.91,COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@H]1CCN(CC2=CC=CC=C2)C1,0.26,0.32,,,0,,491.2056356,4,2,2,0,1,2
7282,04/06/2019 00:00,DB09229,Aranidipine,"After administration, aranidipine is rapidly absorbed from the gastrointestinal tract. After absorption, the AUC and Cmax increased linearly in a dose-dependent manner, the Cmax was attained in approximate 3.8-4.8 hours for aranidipine and 4.8-6 hours for the metabolite M-1. The bioavailability of aranidipine in rat, dog, and monkey was about 48%, 41% and 3% respectively.[L1343]",,The elimination half-life of aranidipine and the M-1 metabolite are 1.1-1.2 hour and 2.7-3.5 hour respectively.[L1343],,,solid,Insoluble,,0.0112,16.8,-6.6,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)=O,,,,,0,,388.127051,2,1,1,0,0,1
7283,04/06/2019 00:00,DB09230,Azelnidipine,"Oral ingestion of azelnidipine demonstrates rapid and dose-dependent absorption [L1382].
",,16 â€“28 hours [L1383].,,,solid,Insoluble in water,,0.00082,19.88,6,CC(C)OC(=O)C1=C(C)NC(N)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC1CN(C1)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,582.2478348,5,3,2,0,1,2
7284,04/06/2019 00:00,DB09231,Benidipine,Benidipine is rapidly absorbed after oral administration reaching a maximum concentration within 2 hours. The short period of time needed for maximum concentration to get reached is a particular characteristic of benidipine when compared with other calcium channel blockers. The registered maximum concentration and AUC are dose-dependent and it can go from 0.55-3.89 ng/ml and 1.04-6.7 ng.h/ml respectively when administered in a dose of 2-8 mg.[A31950],0.98,The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950],,,solid,<1 mg/ml,3.79,0.00243,19.47,7.89,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1,0.98,0.98,,,0,,505.2212857,4,2,2,0,1,2
7285,04/06/2019 00:00,DB09232,Cilnidipine,"Cilnidipine presents a very rapid absorption with a maximum peaked concentration after 2 hours. Its distribution tends to be higher in the liver as well as in kidneys, plasma and other tissues. Cilnidipine does not present a high accumulation in the tissue after repeated oral administration.[L1444]

Cilnidipine is reported to present very low bioavailability determined to be approximately 13%. This low bioavailability is suggested to be due to its low aqueous solubility and high permeability. Hence, efforts have been made in order to find an innovative formulation that can significantly improve the bioavailability of this drug. One of these formulations corresponds to the generation of polymeric nanoparticles which enhance the bioavailability by 2.5-3-fold.[L6124]",0.98,The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004],,,solid,Insoluble,4.7,0.000566,19.46,-4.1,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1,0.98,0.98,,,0,,492.1896512,3,2,1,0,0,1
7286,04/06/2019 00:00,DB09233,Cronidipine,,,,,,solid,,,0.00397,19.47,3.69,[H]N1C(C)=C(C(C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCC2COC3(CCN(CC3)C3=CC=C(Cl)C=C3)O2)=C1C)C(=O)OC,,,,,0,,597.1877927,5,2,3,0,2,3
7287,04/06/2019 00:00,DB09234,Darodipine,,,,,,solid,,,0.258,19.45,-3.3,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OCC,,,,,0,,371.1481208,3,2,2,1,0,1
7288,04/06/2019 00:00,DB09235,Efonidipine,"The metabolism of efonidipine was studied in rats. The absorption ratio of radioactivity estimated from the sum of biliary and urinary excretions was found to be approximately 62% [L1457]. The radioactivity was high in the gastrointestinal tract and liver, followed by the adrenal glands [L1457], suggesting high rates of metabolism in these regions.  

The unchanged drug in the plasma accounted for 47.7% of radioactivity at 2hr after ingestion, demonstrating a lower first-pass effect in comparison with other drugs in the same class. In plasma, major metabolites of NZ-105 were: N-debenzylated compound (DBZ), N-dephenylated compound (DPH), oxidative deaminated compound (AL), AL-corresponding pyridine compound (ALP), unknown metabolite M-1 and M-25.  NZ-105 was metabolized by N-debenzylation, N-dephenylation, oxidative deamination, ester hydrolysis and oxidation of 1, 4-dihydropyridine ring to its corresponding pyridine [L1457].

",,The peak plasma concentration is attained at approximately 1.5 to 3.67 hours after ingestion. The half-life is measured to be about 4 hours [L1450].,,,solid,poorly soluble,,0.000248,19.49,2.33,CC1=C(C(C2=CC=CC(=C2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(CC1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,631.2447372,5,3,2,0,1,2
7289,04/06/2019 00:00,DB09236,Lacidipine,"Since it is a highly lipophilic compound, lacidpine is rapidly absorbed from the gastrointestinal tract following oral administration with the peak plasma concentrations reached between 30 and 150 minutes of dosing [L1126]. The peak plasma concentrations display large interindividual variability, with the values ranging from 1.6 to 5.7 Î¼g/L following single-dose oral administration of lacidipine 4mg in healthy young volunteers [A31537].

Absolute bioavailability is less than 10% due to extensive first-pass metabolism in the liver [L1126].",,The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [L1126].,,,solid,,,0.00224,19.47,-6.4,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC,,,,,0,,455.2307878,2,1,1,0,0,1
7290,04/06/2019 00:00,DB09237,Levamlodipine,"After oral administration of therapeutic doses,  absorption produces peak plasma concentrations between 6 and 12 hours. Absolute bioavailability has been estimated to be between 64 and 90%. The bioavailability of amlodipine besylate tablets is not altered by the presence of food [L1485].
",0.93,The plasma elimination half-life of this drug is 31 Â± 13 hrs [L1484]. ,,,solid,81 mg/mL,3.3,0.0074,19.12,9.45,CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC,0.93,0.93,,,0,,408.1451996,2,1,1,0,0,1
7291,04/06/2019 00:00,DB09238,Manidipine,The median Tmax is 1.5 h [A7845]. Administration with food produces an 1.3-1.6-fold increase in Cmax but no change in Tmax. Manidipine does not accumulate significantly with multiple doses.,0.99,"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.",,,solid,<1mg/mL,,0.000995,19.47,7.89,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,0.99,0.99,,,0,,610.2791349,5,3,2,0,1,2
7292,04/06/2019 00:00,DB09239,Niguldipine,,,,,,solid,,,0.000113,19.47,9.59,[H]N1C(C)=C([C@H](C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCCCN2CCC(CC2)(C2=CC=CC=C2)C2=CC=CC=C2)=C1C)C(=O)OC,,,,,0,,609.283886,5,3,2,0,1,2
7293,04/06/2019 00:00,DB09240,Niludipine,,,,,,solid,,,0.00375,19.46,-3.8,[H]N1C(C)=C(C(C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCCOCCC)=C1C)C(=O)OCCOCCC,,,,,0,,490.231516,2,1,1,0,0,1
7294,02/07/2019 00:00,DB09241,Methylene blue,,(71â€“77%,5â€“6.5 hours (after IV dose).,0.01,Ophthalmic,solid,,,0.0296,,2.44,[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1,0.71,0.77,,,0,,319.0909963,3,3,1,1,0,0
7295,04/06/2019 00:00,DB09242,Moxonidine,"90% of an oral dose is absorbed with negligible interference from food intake or first pass metabolism, resulting in a high bioavailability of 88%. [FDA label]",0.1,Plasma elimination half life is 2.2 - 2.3 hours while renal elimination half life is 2.6-2.8 hours. [FDA label],,,solid,<1 mg/mL,,0.114,,7.26,COC1=NC(C)=NC(Cl)=C1NC1=NCCN1,0.1,0.1,,,0,,241.0730377,2,1,2,1,0,1
7296,04/06/2019 00:00,DB09243,Hydracarbazine,,,,,,solid,,,9.3,13.88,6.03,[H]N([H])N([H])C1=NN=C(C=C1)C(=O)N([H])[H],,,,,0,,153.0650598,1,1,1,1,0,0
7297,04/06/2019 00:00,DB09244,Pirlindole,Well absorbed with a bioavailability of 90% [L1390].,0.97,0.7Â±0.3 in one study of healthy volunteers [L1390],,,solid,0.0168,2.8,0.107,,8.38,CC1=CC=C2N3CCNC4CCCC(=C34)C2=C1,0.97,0.97,,,0,,226.1469986,4,2,2,1,0,1
7298,04/06/2019 00:00,DB09245,Toloxatone,,,1-3 h [A31957],,,solid,0.0122,1.26,54.9,14.61,-1.7,CC1=CC(=CC=C1)N1CC(CO)OC1=O,,,,,0,,207.0895433,2,1,1,0,1,1
7299,04/06/2019 00:00,DB09246,Benmoxin,,,,,,solid,,,0.0289,14.47,3.32,CC(NNC(=O)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,240.1262631,2,2,0,0,0,0
7300,04/06/2019 00:00,DB09247,Iproclozide,,,,,,solid,,,0.2,11.58,3.97,CC(C)NNC(=O)COC1=CC=C(Cl)C=C1,,,,,0,,242.0822054,1,1,0,0,0,0
7301,04/06/2019 00:00,DB09248,Mebanazine,,,,,,solid,,,10.6,,5.33,CC(NN)C1=CC=CC=C1,,,,,0,,136.1000484,1,1,0,0,0,0
7302,04/06/2019 00:00,DB09249,Octamoxin,,,,,,solid,,,6.27,,5.92,CCCCCCC(C)NN,,,,,0,,144.1626486,0,0,0,0,0,0
7303,04/06/2019 00:00,DB09250,Pheniprazine,,,,,,solid,,,3.75,,5.65,CC(CC1=CC=CC=C1)NN,,,,,0,,150.1156984,1,1,0,0,0,0
7304,04/06/2019 00:00,DB09251,Phenoxypropazine,,,,,,solid,,,6.03,,5.45,[H]N([H])N([H])C(C)COC1=CC=CC=C1,,,,,0,,166.1106131,1,1,0,0,0,0
7305,04/06/2019 00:00,DB09252,Pivhydrazine,,,,,,solid,,,0.33,12.91,3.41,[H]N(CC1=CC=CC=C1)N([H])C(=O)C(C)(C)C,,,,,0,,206.1419132,1,1,0,0,0,0
7306,04/06/2019 00:00,DB09253,Safrazine,,,,,,solid,,,2.24,,5.8,CC(CCC1=CC2=C(OCO2)C=C1)NN,,,,,0,,208.1211778,2,1,1,0,0,1
7307,04/06/2019 00:00,DB09254,Caroxazone,,,,,,solid,,,11.9,15.42,-4.7,NC(=O)CN1CC2=CC=CC=C2OC1=O,,,,,0,,206.0691422,2,1,1,0,0,1
7308,04/06/2019 00:00,DB09256,Tegafur,"Tegafur displays a dose-proportional pharmacokinetic properties. Tegafur is rapidly and well absorbed into the systemic circulation, reaching the peak plasma concentration within 1 to 2 hours of administration [L934]. ",0.523,The elimination half life of tegafur is approximately 11 hours [L934].,,Oral,solid,Partly miscible,,14,8.08,-4.3,FC1=CN(C2CCCO2)C(=O)NC1=O,0.523,0.523,,,0,,200.0597204,2,1,2,1,1,1
7309,04/06/2019 00:00,DB09257,Gimeracil,"Mean 5-FU maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) values were approximately 3-fold higher after Teysuno administration than after administration of tegafur alone, despite a 16-fold lower Teysuno dose (50 mg of tegafur) compared to tegafur alone (800 mg), and are attributed to inhibition of DPD by gimeracil. Maximum plasma uracil concentration was observed at 4 hours, with a return to baseline levels within approximately 48 hours after dosing, indicating the reversibility of the DPD inhibition by gimeracil.

After administration of a single dose of 50 mg Teysuno (expressed as tegafur content), median Tmax for Teysuno components tegafur, gimeracil, and oteracil was 0.5, 1.0, and 2.0 hours, respectively [L933].",0.523,"Following a single dose of Teysuno, T1/2 values ranged from 6.7 to 11.3 hours for tegafur, from 3.1 to 4.1 hours for gimeracil, and from 1.8 to 9.5 hours for oteracil [L933].",,Oral,solid,,,14.2,8.66,-4.5,OC1=CC(=O)NC=C1Cl,0.523,0.523,,,0,,144.993056,1,1,1,1,0,0
7310,04/06/2019 00:00,DB09262,Imidafenacin,The absolute oral bioavailability is 57.8% [A19796]. Tmax is 1-3 h after administration.,0.88,The half life of elimination is 3 h [A19796].,,,solid,,,0.00951,16.11,7.35,CC1=NC=CN1CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1,0.88,0.88,,,0,,319.1684623,3,3,1,1,0,0
7311,04/06/2019 00:00,DB09267,Strontium ranelate,"The absolute bioavailability of strontium is about 25% (within a range of 19-27%) after an oral dose of 2 g strontium ranelate. Maximum plasma concentrations are reached approximately 3-5 hours after a single dose of 2 g. Steady state is reached after 2 weeks of treatement. The intake of strontium ranelate with calcium or food reduces the bioavailablity of strontium ranelate by about 60-70%, compared with administration 3 hours after a meal [L1127].

Due to the relatively slow absorption of strontium, food and calcium intake should be avoided both before and after administration of strontium ranelate. Conversely, oral supplementation with vitamin D has no effect on strontium exposure whatsoever. [L1127]",,The effective half-life of strontium is approximately 60 hours [L1127].,2 g,Oral,solid,,,2.17,1.63,,[Sr++].[Sr++].[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O,,,,,0,,513.7957104,1,1,1,1,0,0
7312,04/06/2019 00:00,DB09268,Picosulfuric acid,"In healthy volunteers receiving 2 packets of sodium picosulfate in combination with magnesium oxide and anhydrous citric acid every 6 hours, the mean peak plasma concentrations (Cmax) of sodium picosulfate was achieved within 7 hours (Tmax) [FDA Label]. The mean Cmax of its active metabolite, BHPM, was 0.05 ng/mL [FDA Label]. ",,The terminal half-life of sodium picosulfate was 7.4 hours [FDA Label].,,Oral,solid,,,0.0185,-2.5,4.08,OS(=O)(=O)OC1=CC=C(C=C1)C(C1=CC=C(OS(O)(=O)=O)C=C1)C1=CC=CC=N1,,,,,0,,437.0239084,3,3,1,1,0,0
7313,04/06/2019 00:00,DB09269,Phenylacetic acid,,,,,Intravenous,solid,,,3.61,4.55,,OC(=O)CC1=CC=CC=C1,,,,,0,,136.0524295,1,1,0,0,0,0
7314,02/07/2019 00:00,DB09270,Ubidecarenone,Ubidecarenone is absorbed from the small intestine into the lymphatics and then it can enter the blood. The hydrophobicity and large molecular weight limit its absorption making it very poor and variable depending on the food intake and the number of lipids presented in the food. The absorption is lower in the presence of an empty stomach and greater in presence of high lipid food diet. The daily dosage of ubidecarenone presents the reach of maximal serum concentration by reaching a plateau after three weeks.[L1065] The pharmacokinetic properties may vary between different brands but studies have reported an AUC of 11.51 mcg h/ml and a Cmax of 0.32 mcg/ml at a time of 7.9 h.[A31414],0.95,The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.[A31414],50 mg,Oral,solid,Sparingly soluble,10,0.000193,,-4.7,COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O,0.95,0.95,,,0,50,862.6839114,1,0,0,0,0,0
7315,04/06/2019 00:00,DB09271,Cimetropium,,,,,,solid,,,0.00244,15.15,-2.7,[H][C@](CO)(C(=O)O[C@@]1([H])C[C@@]2([H])[C@]3([H])O[C@]3([H])[C@@]([H])(C1)[N+]2(C)CC1CC1)C1=CC=CC=C1,,,,,1,,358.2012848,5,1,3,0,3,3
7316,02/07/2019 00:00,DB09272,Eluxadoline,"The oral absorption of eluxadoline is poor - estimated to be 1.02%, this could be attributed to poor in vitro GI permeability, and its zwitterionic nature leading to a negatively charged molecule across the GI pH range.",0.81,The mean plasma elimination half-life ranged from 3.7 hours to 6 hours. ,100 mg,Oral,solid,,,0.00268,3.66,7.99,COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O,0.81,0.81,,,0,100,569.2638192,4,4,1,1,0,0
7317,04/06/2019 00:00,DB09273,Doxofylline,"After repeated administrations doxofylline reaches the steady-state in about 4 days. Following oral administration of 400 mg doxofylline twice daily for 5 days in adults with chronic bronchitis, the peak plasma concentrations (Cmax) at steady state ranged from 5.78 to 20.76 mcg/mL. The time to reach maximum concentration (Tmax) was 1.19 Â± 0.19 hours [L1169]. The absolute bioavailability of doxofylline in healthy subjects was 63 Â± 25% [L1169]. ",0.48,"Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 Â± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 Â± 0.80 hours [L1169]. ",,,solid,Insoluble,,14.5,,-1.3,CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O,0.48,0.48,,,0,,266.1015049,3,2,3,2,1,1
7318,04/06/2019 00:00,DB09274,Artesunate,"After intravenous administration artesunate is rapidly metabolized to its active metabolite, dihydroartemisinin (DHA) [L891]. Tmax for DHA is 0.5-15 min. After intramuscular administration Tmax is 8-12 min. Cmax was observed to be 45-fold and 20-fold lower in children and adults respectively with intramuscular versus intravenous administration. Elimination was observed to be 32-fold and 13-fold slower in children and adults respectively with intramuscular versus intravenous administration.",0.93,Half life of elimination after intravenous bolus was observed to be less than 5 min for artesunate and 21-64 min for DHA [L891]. Half life after intramuscular administration is 48 min in children and 41 min in adults.,,,solid,,,0.678,3.77,-4.2,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4,0.93,0.93,,,0,,384.1784179,5,0,4,0,4,4
7319,04/06/2019 00:00,DB09275,Bismuth subcitrate potassium,"The mean peak whole-blood bismuth level after ingestion of colloidal bismuth subcitrate (214 mg bismuth) was more than 50 mg/liter and occurred at 30 minutes. After ingestion of bismuth subnitrate (205 mg bismuth), however, there was no evidence of bismuth absorption into blood, although in three of the volunteers who took bismuth subnitrate a week after colloidal bismuth subcitrate, baseline levels of blood bismuth were still elevated. Forty-five minutes after taking colloidal bismuth subcitrate, mean plasma levels for all five volunteers were also assessed and were 79.76 microg/liter as compared to blood levels of 47.6 microg/liter.",>90%,The elimination half-life of bismuth is approximately 5 days,,Oral,solid,,,13.8,3.05,-4.2,[K+].[K+].[K+].[K+].[K+].[Bi+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O,0.9,1,,,0,,779.790337,0,0,0,0,0,0
7320,02/07/2019 00:00,DB09276,Sodium aurothiomalate,"Gold sodium thiomalate solutions are rapidly absorbed following IM injection, with peak serum concentrations occurring in 3-6 hours.",85-90%,12.5 days,50 mg/1mL,Intramuscular,solid,,,35.2,3.18,,[Na+].OC(=O)CC(S[Au])C([O-])=O,0.85,0.9,300,300,0,,367.9393676,0,0,0,0,0,0
7321,04/06/2019 00:00,DB09277,Choline C 11,"The highest normal tissue uptake is seen in renal cortex, liver, pancreas and salivary glands. It presents a variable bowel, prostate and pituitary uptake and a low uptake in the cerebral cortex. The short half-life of choline C11 limits the availability and it is recommended to be delivered within 2-3 half-lives from producing cyclotron.[L1492] ",,The isotope half-life of choline C11 is 20.4 min.[A32037],,,solid,Soluble,,5.45,13.97,-3.2,[Cl-].C[N+](C)([11CH3])CCO,,,,,0,,138.0878253,0,0,0,0,0,0
7322,02/07/2019 00:00,DB09278,Activated charcoal,No evidence of systemic absorption of activated charcoal,,,225 mg,Oral,solid,Insoluble,,0,,,[C],,,,,0,225,12,0,0,0,0,0,0
7323,04/06/2019 00:00,DB09279,Fimasartan,Tmax is 0.5-1.3 h [A20319].,,The half life of elimination is 7-10 h [A20319].,,,solid,,,0.00469,4.23,1.34,CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1,,,,,0,,501.2310796,4,4,2,2,0,0
7324,04/06/2019 00:00,DB09280,Lumacaftor,"Following administration of Orkambi (lumacaftor/[DB08820]) with fat containing foods, peak plasma concentrations were reached at 4 hours (Tmax). It's recommended that Orkambi should be taken with fat-containing foods as they increase absorption of lumacaftor by approximately 2-fold, and[DB08820 by 3-fold [FDA Label].",,The half-life of lumacaftor is approximately 26 hours [FDA Label].,,Oral,solid,,,0.00376,4.17,3.5,CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O,,,,,0,,452.1183781,5,3,2,1,0,1
7325,04/06/2019 00:00,DB09282,Molsidomine,Peak plasma drug concentration (tmax) occurs from 1 to 2 hours after administration.,,,,,solid,4.65e-03 to 1.74,-1.61,13.3,7.99,-3.2,CCOC(=O)[N-]C1=C[N+](=NO1)N1CCOCC1,,,,,0,,242.1015049,2,1,2,1,1,1
7326,04/06/2019 00:00,DB09283,Trapidil,Trapidil has a Tmax of 1 h [A19770].,,The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].,,,solid,41  mg/mL,,1.93,,1.02,CCN(CC)C1=CC(C)=NC2=NC=NN12,,,,,0,,205.1327455,2,2,2,2,0,0
7327,04/06/2019 00:00,DB09284,Imolamine,,,,,,solid,,1.96,0.162,,8.17,CCN(CC)CCN1C(=N)ON=C1C1=CC=CC=C1,,,,,0,,260.1637113,2,2,1,1,0,0
7328,04/06/2019 00:00,DB09285,Morniflumate,,1, 2h [L1498],,,solid,soluble in DMSO,,0.0861,14.21,5.86,FC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OCCN2CCOCC2)=CC=C1,1,1,2,2,0,,395.1456762,3,2,2,1,1,1
7329,04/06/2019 00:00,DB09286,Pipamperone,,,17-26h [L1522],,,solid,soluble in methanol,2.02,0.182,15.94,8.69,NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1,,,17,26,0,,375.2322054,3,1,2,0,2,2
7330,04/06/2019 00:00,DB09288,Propacetamol,"The bioavailability of 2g of propacetamol is similar to the bioavailability found in 1 g of intravenous paracetamol. Peak plasma concentration is obtained as and from the end of infusion. Pharmacokinetic analysis with intravenous propacetamol showed a significantly higher and earlier maximum plasma concentration than orally administered paracetamol. The Cmax, Tmax and AUC are 12.72 mcg/ml, 0.25 h and 25.5 mcg.h/ml. After infusion with propacetamol, significant concentrations of paracetamol are observed in cerebrospinal fluid.[L1509]",,The half-life of propacetamol is of 3.6 h.[L1509],,,solid,Soluble,1.65,0.513,14.67,6.83,CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1,,,,,0,,264.1473925,1,1,0,0,0,0
7331,04/06/2019 00:00,DB09289,Tianeptine,"Well absorbed, approximately 99% bioavailability [A31998].",0.95,Approximately 2.5 h [A33320],,,solid,,,0.00413,4.22,8.1,CN1C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=C(C=C(Cl)C=C2)S1(=O)=O,0.95,0.95,,,0,,436.122356,3,2,1,0,0,1
7332,04/06/2019 00:00,DB09290,Ramosetron,,,,,,solid,,,0.0696,12.68,6.36,CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C2=C1C=CC=C2,,,,,0,,279.1371622,4,3,2,2,0,0
7333,02/07/2019 00:00,DB09291,Rolapitant,"Following administration of rolapitant, plasma concentrations reached peak levels in about 4 hours. ",0.998,Mean terminal half life ranged from 169 to 183 hours (~7 days). ,1.8 mg/1mL,Intravenous,solid,,,0.00166,14.15,8.3,C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,0.998,0.998,,,0,,500.1898474,4,2,2,0,2,2
7334,04/06/2019 00:00,DB09292,Sacubitril,"Peak plasma concentrations of sacubitril and it's metabolite, LBQ657 are reached in 0.5 hours and 2 hours respectively. Food does not clinically affect the systemic exposure of sacubitril or LBQ657. The oral bioavailability of sacubitril is >60%. It should be noted that the valsartan found in this combination is more bioavailable than other market available valsartan. ",,"The half life of sacubitril is 1.1 to 3.6 hours, and the half life of it's metabolite LBQ657 is 9.9 to 11.1 hours. ",,Oral,solid,,,0.000942,4.18,-1.6,[H][C@@](CC1=CC=C(C=C1)C1=CC=CC=C1)(C[C@@]([H])(C)C(=O)OCC)NC(=O)CCC(O)=O,,,,,0,,411.204573,2,2,0,0,0,0
7335,04/06/2019 00:00,DB09295,Talniflumate,,1,Approximately 2h in 12 subjects [A31964],,,solid,5 mg/mL clear,4.47,0.00417,13.33,3.5,FC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OC2OC(=O)C3=CC=CC=C23)=CC=C1,1,1,,,0,,414.0827416,4,3,2,1,0,1
7336,04/06/2019 00:00,DB09296,Ombitasvir,Ombitasvir reaches peak plasma concentration 5 hours after administration [FDA Label]. It has an absolute bioavailability of 48%. Taking ombitasvir with high or normal fat meals increases exposure by 1.76 or 1.82 fold respectively. ,0.999,Ombitasvir has a half life of elimination of 21-25 hours [FDA Label],,Oral,solid,,,0.00193,12.77,2.16,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1,0.999,0.999,,,0,,893.5051121,6,3,3,0,3,3
7337,04/06/2019 00:00,DB09297,Paritaprevir,"Tmax of approximately 4 to 5 hours with a maximum concentration (Cmax) of 194 ng/mL [FDA Label].
",0.986,5.5 hr [FDA Label],,Oral,solid,,,0.00778,3.8,2.64,[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1,0.986,0.986,,,0,,765.2944677,8,4,4,2,1,2
7338,04/06/2019 00:00,DB09298,Silibinin,,,,,,solid,,,0.0926,7.75,-3,[H][C@@]1(OC2=C(O[C@@H]1CO)C=CC(=C2)[C@@]1([H])OC2=C(C(O)=CC(O)=C2)C(=O)[C@@H]1O)C1=CC(OC)=C(O)C=C1,,,,,0,,482.1212969,5,3,2,0,0,2
7339,02/07/2019 00:00,DB09299,Tenofovir alafenamide,"As compared to the parent molecule, [tenofovir], tenofovir alafenamide presents a lipophilic group that masks the negative charge of the parent moiety which in order improves its oral bioavailability.[A178060]

Due to the molecular properties of tenofovir alafenamide, this molecule is highly stable in the plasma and, after administration of this prodrug, there is a low concentration of tenofovir in plasma. After oral administration, tenofovir alafenamide is rapidly absorbed by the gut. When a single dose is administered, a peak concentration of 16 ng/ml of the parent compound, corresponding to about 73% of the dose, is observed after 2 hours with an AUC of 270 ng.h/ml.[A178060, A18473] Once inside the body, tenofovir alafenamide enters hepatocytes by passive diffusion regulated by the organic anion transporters 1B1 and 1B3 for its activation.[A178249]

Administration of tenofovir alafenamide concomitantly with a high-fat meal results in an increase of about 65% in its internal exposure.[L6286]",0.8,The reported half-life for tenofovir alafenamide is of 0.51 hours.[A178231],25 mg/1,Oral,solid,4.86 mg/ml at 20 ÂºC,1.6,0.236,11.36,5.12,CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1,0.8,0.8,,,0,25,476.1937047,3,3,2,2,0,0
7340,02/07/2019 00:00,DB09300,Butylscopolamine,Scopolamine butylbromide has extremely low oral bioavailability with only 0.25-0.82% reaching systemic circulation [A7905]. Peak plasma concentration is reached 0.25-2 hours. Scopolamine butylbromide does not cross the blood brain barrier.,,The half life of elimination is 1-5 hours [A7905].,20 mg,Intramuscular; Intravenous; Subcutaneous,solid,,,0.00201,15.15,-2.7,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,,,,,1,,360.2169349,4,1,3,0,3,3
7341,04/06/2019 00:00,DB09304,Setiptiline,,,,,,solid,,,0.0338,,7.44,CN1CCC2=C(C1)C1=CC=CC=C1CC1=CC=CC=C21,,,,,0,,261.1517496,4,2,1,0,0,1
7342,04/06/2019 00:00,DB09305,Aptazapine,,,,,,solid,,,2.7,,6.92,CN1CCN2C(C1)C1=CC=CN1CC1=C2C=CC=C1,,,,,0,,253.1578976,4,2,3,1,1,2
7343,04/06/2019 00:00,DB09306,Metralindole,,,,,,solid,,,0.367,,8.95,COC1=CC2=C(C=C1)N1CCN(C)C3=NCCC2=C13,,,,,0,,255.1371622,4,2,3,1,0,2
7344,04/06/2019 00:00,DB09308,Solithromycin,,,,,,solid,,,0.0167,12.8,7.68,[H][C@]12N(CCCCN3C=C(N=N3)C3=CC(N)=CC=C3)C(=O)O[C@]1(C)[C@@]([H])(CC)OC(=O)[C@@](C)(F)C(=O)[C@]([H])(C)[C@@]([H])(O[C@]1([H])O[C@]([H])(C)C[C@]([H])(N(C)C)[C@@]1([H])O)[C@@](C)(C[C@@]([H])(C)C(=O)[C@]2([H])C)OC,,,,,0,,844.4746205,5,2,4,1,3,3
7345,04/06/2019 00:00,DB09309,Kitasamycin,,,,,,solid,,,0.131,12.68,7.9,CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C,,,,,0,,785.4561558,3,0,3,0,2,3
7346,04/06/2019 00:00,DB09313,Ioxaglic acid,"Following the intravascular route of injection, Ioxaglic acid is rapidly transported through the circulatory system to the kidneys.

 The pharmacokinetics of radiopaque contrast media given by the IV route are described by a two-compartment model with a rapid alpha phase for drug distribution and a slow beta phase for the elimination of the drug[L1883]. Following the intravenous administration of 50 mL of ioxaglic acid in 10 healthy volunteers, the mean peak plasma concentration occurred at two (1-3) minutes, reaching a concentration of 2.1 (1.8-2.8) mg/mL. 

Approximately 50 percent of the intravenously administered dose was recovered in the urine at two hours, and 90% percent was recovered at the 24 hour time point [L1883].",,Hexabrix 320 is rapidly eliminated by the kidneys with a half-life of about 90 minutes [L1884],,Intravascular,solid,soluble ,,0.0152,2.13,-1.7,CNC(=O)C1=C(I)C(C(=O)NCC(=O)NC2=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C2I)=C(I)C(N(C)C(C)=O)=C1I,,,,,0,,1268.565851,2,2,0,0,0,0
7347,04/06/2019 00:00,DB09314,Technetium Tc-99m pertechnetate,,,,108 mCi/1mL,Intravenous; Intravesical; Ophthalmic,solid,,,137,15.7,-1.8,O.O.O.O.[98Tc-],,,,,-1,,169.9500233,0,0,0,0,0,0
7348,04/06/2019 00:00,DB09316,Thallous Chloride,"After IV administration, thallous chloride clears rapidly from the blood, with maximum concentration in the myocardium after about 10 min.
Only 5-8% of injected activity remained in the blood, following 5 minutes of intravenous administration.",,"91% of the blood radioactivity has a t1/2 of 5 min.
9% has t1/2 of 40 hours.",1 mCi/1mL,Intravenous,solid,,,123,,,[Cl-].[Tl+],,,,,0,,239.9432802,0,0,0,0,0,0
7349,04/06/2019 00:00,DB09319,Carindacillin,,,,382 mg/1,Oral,solid,,,0.00491,3.29,-6.3,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(=O)OC1=CC2=C(CCC2)C=C1)C1=CC=CC=C1)C(O)=O,,,,,0,382,494.1511576,5,2,2,0,2,2
7350,04/06/2019 00:00,DB09320,Procaine benzylpenicillin,"After intramuscular injection, it dissolves slowly at the site of injection, giving a plateau type of blood level at about 4 hours which falls slowly over a period of the next 15 to 20 hours. ",0.6,Intramuscular injection of benzylpenicillin has a plasma half-life of 30 minutes [L783]. ,300000 unit,Intramuscular,solid,Slightly soluble,,0.285,3.53,-2.8,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,0.6,0.6,,,0,,570.2512059,4,2,2,0,2,2
7351,04/06/2019 00:00,DB09324,Sulbactam,"Peak serum concentrations are reached almost immediately following a 15-minute intravenous infusion of sulbactam + ampicillin. Mean peak serum levels for sulbactam range from 48 to 88 mcg/mL following intravenous administration of 2000 mg of ampicillin plus 1000 mg sulbactam. After an intramuscular injection of 1000 mg ampicillin plus 500 mg sulbactam, peak sulbactam serum levels ranging from 6 to 24 mcg/mL are attained.",0.38,~1 hr,,Intramuscular; Intravenous,solid,,,48.5,3.09,-3.8,[H][C@@]12CC(=O)N1[C@@]([H])(C(O)=O)C(C)(C)S2(=O)=O,0.38,0.38,1,1,0,,233.0357935,2,0,2,0,2,2
7352,04/06/2019 00:00,DB09327,Tegafur-uracil,"The absorption into systemic circulation is very rapid and the peak concentration is reached within 1-2 hours. After a single dose of tegafur/uracil of 300 mg/m2/day in three divided doses, tegafur plasma concentration of >1000 ng/ml are maintained throughout the 8-hour dosing interval, whereas uracil concentrations decline rapidly following the peak concentration. The plasma concentration of 5-fluorouracil peaks at 30-60 min after administration with 200 ng/ml and remain detectable for 8-hour dosing interval. There is no significant long-term accumulation of either uracil, tegafur or 5-fluorouracil.[L934]",0.52,The presence of uracil generates an increase in the half-life of tegafur and it is registered to be of 11 hours.[A1821] The elimination half-life of uracil is of 20-40 minutes.[L934],,,solid,,,14,8.08,-4.3,O=C1NC=CC(=O)N1.FC1=CN(C2CCCO2)C(=O)NC1=O,0.52,0.52,,,0,,312.0869977,3,2,3,2,1,1
7353,02/07/2019 00:00,DB09330,Osimertinib,The median time to Cmax was found to be 6 hours. ,,The population estimated mean half-life is 48 hours. ,40 mg,Oral,solid,,,0.0224,13.64,8.87,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,,,,,0,40,499.2695733,4,4,2,2,0,0
7354,04/06/2019 00:00,DB09332,Kappadione,"Menadiol sodium phosphate (vitamin K3), the synthetic analog of vitamin K, being water soluble, is advised in intestinal malabsorption or in states in which bile flow is deficient. The primary disadvantage is that it takes 24 h to initiate therapeutic effects, however, this effect lasts for several days. The dose is 5â€“40 mg orally, daily. Menadiol sodium phosphate, even in moderate doses, may lead to hemolytic anemia and, for this reason, neonates should not receive this medication. This precautionary measure is valid especially those that are deficient in glucose 6-phosphate dehydrogenase (G6PD); their immature livers are unable to compensate for the heavy bilirubin load and there is an increased risk of kernicterus [L1563].

",,"Mean elimination half-life of menadione was 27.17 min in the plasma of rabbits, in one study [L1574].",,,solid,,,8.03,1.47,,[Na+].[Na+].[Na+].[Na+].CC1=C(OP([O-])([O-])=O)C2=CC=CC=C2C(OP([O-])([O-])=O)=C1,,,,,0,,421.9285176,2,2,0,0,0,0
7355,04/06/2019 00:00,DB09333,Iopodic acid,"The lipophilicity of ipodate is sufficient for passage through the gastrointestinal mucosa.[A32080] After ingestion, iopodic acid is promptly absorbed by passive diffusion in the small intestinal mucosa. The presence of bile salts in the duodenum is essential for its diffusion through the intestine wall and a high-fat diet is important in order to increase the absorption effectivity. The maximum effect is showed to be attained 5 hours after the initial dosage and the effect were retained for more than 60 hours.[A32087]",,,500 mg,Oral,solid,Insoluble,3.73,0.00819,1.99,4.16,CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I,,,,,0,500,597.8111217,1,1,0,0,0,0
7356,04/06/2019 00:00,DB09335,Alatrofloxacin,,,,5 mg,Intravenous,solid,,,0.0388,5.41,8.09,[H][C@@]12CN(C[C@]1([H])[C@H]2NC(=O)[C@H](C)NC(=O)[C@H](C)N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=CC=C(F)C=C1F)C(O)=O,,,,,0,,558.1838526,5,3,3,2,1,1
7357,04/06/2019 00:00,DB09338,Mersalyl,,,,,,solid,partially miscible in water,,9.9,3.24,-1.3,COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O,,,,,0,,485.0762303,1,1,0,0,0,0
7358,04/06/2019 00:00,DB09340,Tyropanoic acid,"This triiodide is well absorbed by the small intestine and it is excreted in the bile within 2 h  after oral administration [L1608].  It has been found to be readily absorbed and show maximal radiographic definition at 10-12 h post ingestion, but this can occur as early as 4-6h [L1611].

",%,,,,solid,slightly water soluble ,,0.00318,2.52,-3.9,CCCC(=O)NC1=C(I)C=C(I)C(CC(CC)C(O)=O)=C1I,,,,,0,,640.8420874,1,1,0,0,0,0
7359,04/06/2019 00:00,DB09342,Propoxycaine,,,,,,solid,10 Âµg/mL in water,,1.79,,8.96,CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC,,,,,0,,294.1943427,1,1,0,0,0,0
7360,04/06/2019 00:00,DB09343,Tipiracil,"Absorption of tipiracil is suggested to be done by the gastrointestinal tract. [A31261] Administration of a single 35 mg/m2 dose of TAS-102 containing tipiracil and trifluridine, generates the absoprtion rates of tipiracil of AUC 301 ng h/ml, maximum observed plasma concentration (Cmax) 69 ng/ml and time for maximum observed plasma concentration (Tmax) 3 h. [A31259] The consumption of a high-fat and high-calorie meal can decrease Cmax and AUC by 40%.[A31260]  ",,Tipiracil mean elmination half-life is 2.1 hours.[A31259],,Oral,solid,5 mg/ml (warmed),,0.731,7.28,11.55,ClC1=C(CN2CCCC2=N)NC(=O)NC1=O,,,,,0,,242.0570533,2,1,2,1,1,1
7361,02/07/2019 00:00,DB09345,Pramocaine,There is minimal absorption after topical administration and it is not given orally.,,,0.005,Topical,solid,,,0.221,,7.06,CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1,,,,,0,,293.1990937,2,1,1,0,1,1
7362,04/06/2019 00:00,DB09346,Metrizoic acid,,,,,,solid,,,0.0877,2.16,-3.9,CN(C(C)=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,,,,,0,,627.7853008,1,1,0,0,0,0
7363,04/06/2019 00:00,DB09347,Acetrizoic acid,"After intravenous administration, acetrizoic acid gets largely distributed in the extracellular fluid space.[T131] Radiographic agents like acetrizoic agents present variations in the plasma concentration depending on the dose and injection rate. After 5 minutes of administration, about 80% of the administered dose will stay outside of the intravascular compartment. There are some exceptions to the diffusion, such as the brain, neural tissue and testes where the tight junctions do not allow extravascularization.[L1707]",0.05,"When water-soluble contrast agents, such as acetrizoic acid, are administered, it is reported a half-life of approximate 4 hours.[L1708]",,,solid,Soluble,1.04,0.0559,2.33,-4.5,CC(=O)NC1=C(I)C(C(O)=O)=C(I)C=C1I,0.05,0.05,,,0,,556.7481871,1,1,0,0,0,0
7364,04/06/2019 00:00,DB09348,Propiolactone,,,The half-life of propiolactone in water is of 225 minutes.[A32148],,,liquid,370 g/L at 25ÂºC,-0.564,436,,-7.1,O=C1CCO1,,,,,0,,72.02112937,1,0,1,0,1,1
7365,04/06/2019 00:00,DB09350,Piperonyl butoxide,"Piperonyl butoxide is applied topically. In a study evaluating the 7-day urinary accumulation of piperonyl butoxide after topical application, it was found that approximately 2% of the dose was absorbed through the skin. The percutaneous absorption when applied to the scalp was found to be 8.3%. ",, 32 hours.,,Topical,solid,,,0.00611,,-3.6,CCCCOCCOCCOCC1=CC2=C(OCO2)C=C1CCC,,,32,32,0,,338.2093241,2,1,1,0,0,1
7366,04/06/2019 00:00,DB09351,Levobetaxolol,Levobetaxolol is applied topically to the eye but some does reach systemic circulaton with a Tmax of 3 h [FDA Label]. ,,The mean half life of levobetaxolol is 20 h [FDA Label].,,,solid,,,0.0298,14.09,9.67,CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1,,,,,0,,307.2147438,2,1,0,0,0,0
7367,04/06/2019 00:00,DB09352,Hydroxyamphetamine,Intended for local use only (ophthalmic use).,,,,Ophthalmic,,,,3.13,10.48,9.8,CC(N)CC1=CC=C(O)C=C1,,,,,0,,151.099714,1,1,0,0,0,0
7368,04/06/2019 00:00,DB09355,Sulfabenzamide,,,,,Vaginal,,,,0.134,4.32,2.09,NC1=CC=C(C=C1)S(=O)(=O)NC(=O)C1=CC=CC=C1,,,,,0,,276.0568632,2,2,0,0,0,0
7369,14/12/2018 00:00,DB09357,Dexpanthenol,"Dexpanthenol is soluble in water and alcohol, although insoluble in fats and oil based substances. With the appropriate vehicle, Dexpanthenol is easily penetrated into the skin. Rate of penetration and absorption is reduced when Dexpanthenol is administered as an oil/water formula.",,Half life have not been reported,250 mg/1mL,Oral,,,,121,12.69,-2.4,CC(C)(CO)[C@@H](O)C(=O)NCCCO,,,,,0,,205.1314081,0,0,0,0,0,0
7370,04/06/2019 00:00,DB09364,Procaine merethoxylline,,,,,,,,,3.43,2.99,3.71,O.[Hg+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[CH2]C(CN=C(O)C1=CC=CC=C1OCC([O-])=O)OCCOC,,,,,0,,765.2549229,2,2,0,0,0,0
7371,04/06/2019 00:00,DB09366,Propyliodone,,,,,,,,,0.238,,-7.2,CCCOC(=O)CN1C=C(I)C(=O)C(I)=C1,,,,,0,,446.8828392,1,1,1,1,0,0
7372,04/06/2019 00:00,DB09371,Norethynodrel,,,,,,,,,0.00982,16.21,-1.7,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3,,,,,0,,298.1932801,4,0,0,0,0,0
7373,04/06/2019 00:00,DB09372,Tannic acid,"After ingestion it has poor bioavailability, due to large size, high affinity to bound to plasma proteins and low lipid solubility. Its main actions are due to local effects.
",,,0.07,Topical,,,,0.407,7.61,-4.8,OC1=CC(=CC(O)=C1O)C(=O)OC1=C(O)C(O)=CC(=C1)C(=O)OC[C@H]1OC(OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H]1OC(=O)C1=CC(OC(=O)C2=CC(O)=C(O)C(O)=C2)=C(O)C(O)=C1,,,,,0,,1700.172974,11,10,1,0,1,1
7374,02/07/2019 00:00,DB09374,Indocyanine green acid form,It has a peak spectral absorption at about 800 nm.,0.98,ICG has a half-life of 150 to 180 seconds.,25 mg/1,Intravenous,,,,3.82E-05,-0.94,2.66,CC1(C)\C(=C\C=C\C=C\C=C\C2=[N+](CCCCS(O)(=O)=O)C3=C(C4=CC=CC=C4C=C3)C2(C)C)N(CCCCS(O)(=O)=O)C2=C1C1=CC=CC=C1C=C2,0.98,0.98,,,1,,753.3026557,6,4,2,0,0,2
7375,04/06/2019 00:00,DB09376,Lapyrium,,,,,,solid,Partly soluble,,9.66E-05,12.73,-6.5,CCCCCCCCCCCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1,,,,,1,,363.2642194,1,1,1,1,0,0
7376,04/06/2019 00:00,DB09378,Fluprednisolone,,,,,,,,,0.261,12.58,-2.9,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,378.1842522,4,0,0,0,0,0
7377,04/06/2019 00:00,DB09380,Sodium chromate Cr-51,,,,.2 mCi/1mL,Intravenous,,,,262,-2.3,,[Na+].[Na+].[O-][51Cr]([O-])(=O)=O,,,,,0,,160.9039644,0,0,0,0,0,0
7378,04/06/2019 00:00,DB09383,Meprednisone,,,,,,,,,0.0711,12.44,-3.3,[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO,,,,,0,,372.193674,4,0,0,0,0,0
7379,02/07/2019 00:00,DB09389,Norgestrel,,,,0.075 mg,Oral,,,,0.00583,17.91,-1.5,CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C,,,,,0,0.075,312.2089301,4,0,0,0,0,0
7380,02/07/2019 00:00,DB09395,Sodium acetate,It is readily available in the circulation after IV administration. ,,,0.164,Intravenous,,,,429,4.54,,[Na+].CC([O-])=O,,,,,0,,82.00307362,0,0,0,0,0,0
7381,04/06/2019 00:00,DB09397,Technetium Tc-99m sulfur colloid,"When administered subcutaneously, Technetium Tc 99m Sulfur Colloid enters the lymphatic capillaries and is transported with lymph to lymph nodes where it can be used to detect drainage of primary tumours. 
When administered by intraperitoneal injection, Technetium Tc 99m Sulfur Colloid mixes with the peritoneal fluid where the rate of clearance from the cavity allows assessment of shunt patency.
When administered by intravenous injection, Technetium Tc 99m Sulfur Colloid is taken up by the reticuloendothelial system (RES), allowing RES rich structures to be imaged. Uptake of the radioactive colloid by organs of the RES is dependent upon both their relative blood flow rates and the functional capacity of the phagocytic cells.
When administered orally, Technetium Tc 99m sulfur colloid can be used in esophageal transit studies, gastroesophageal reflux scintigraphy, and for the detection of pulmonary aspiration of gastric contents. This is possible as the active substance is not absorbed from the GI tract. ",,"Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours. Following intravenous administration, Technetium Tc 99m Sulfur Colloid Injection is rapidly cleared from the blood by the reticuloendothelial system with a nominal half-life of approximately 2 1/2 minutes.",18.1 mg/10mL,,,,,0.608,,,[99Tc].S1SSSSSSS1,,,,,0,,354.6828227,1,0,1,0,1,1
7382,04/06/2019 00:00,DB09400,Selenomethionine Se-75,,,,,Oral,,,,109,1.56,9.5,C[75Se]CC[C@H](N)C(O)=O,,,,,0,,192.001502,0,0,0,0,0,0
7383,19/06/2019 00:00,DB09401,Isosorbide,,,,450 mg/1mL,Oral,,,,1210,13.03,-3.5,[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H],,,,,0,,146.0579088,2,0,2,0,2,2
7384,04/06/2019 00:00,DB09403,Iocetamic acid,,,,,,,,,0.0537,2.74,1.58,CC(CN(C(C)=O)C1=C(I)C=C(I)C(N)=C1I)C(O)=O,,,,,0,,613.8060363,1,1,0,0,0,0
7385,04/06/2019 00:00,DB09409,Magnesium acetate tetrahydrate,Intestinal absorption is achieved mainly through passive diffusion.,0.3,Elimination half-life has been reported to be 27.7 hours following an overdose of 400mEq magnesium in an adult.,,Intravenous,solid,Soluble,,98.2,4.54,,O.O.O.O.[Mg++].CC([O-])=O.CC([O-])=O,0.3,0.3,,,0,,214.0539091,0,0,0,0,0,0
7386,04/06/2019 00:00,DB09418,Potassium perchlorate,"Perchlorate is rapidly absorbed from the gastrointestinal (GI) tract after ingestion [A32611]. The time to reach peak plasma levels of perchlorate is approximately 3 hours following oral administration [L2364]. As potassium perchlorate is an organic compound with complete ionization in water, dermal absorption through intact skin is unlikely [L2370]. ",,Perchlorate has a half-life in humans of approximately 6 to 8 hours [A32611].,200 mg,Oral,solid,17 g/L at 20 Â°C,,102,-7.1,,[K+].[O-][Cl](=O)(=O)=O,,,,,0,200,137.9122178,0,0,0,0,0,0
7387,04/06/2019 00:00,DB09419,Xylose,"When 12 normal healthy subjects were given an intravenous D-xylose dosing of 10 grams and then an oral dose of 25 grams a week later, the observed absorption percentage was about 69.4% (p < 0.002) and the observed absorption rate was approximately 1.03/hr (p< 0.05) [A32672].

The maximum concentration observed in the subjects was 0.53 mg/L with 71 minutes being the time to reach the maximum concentration [T171]. The absolute bioavailability recorded was 69% [T171].",,The elimination half-life observed in healthy individuals is 75 minutes [T171].,25 g,Oral,solid,,,380,12.34,-3,OC[C@@H](O)[C@H](O)[C@@H](O)C=O,,,,,0,,150.0528234,0,0,0,0,0,0
7388,02/07/2019 00:00,DB09421,Protirelin,,,,.2 mg,Intravenous,,,,4.18,11.15,6.74,[H][C@@](CC1=CN=CN1)(NC(=O)[C@]1([H])CCC(=O)N1)C(=O)N1CCC[C@@]1([H])C(N)=O,,,,,0,,362.1702532,3,1,3,1,2,2
7389,04/06/2019 00:00,DB09425,Indium In-111 pentetate,"After intrathecal administration, the radiopharmaceutical is absorbed from the subarachnoid space as described below, and the remainder flows superiorly to the basal cisterns within 2 to 4 hours and subsequently will be apparent in the Sylvian cisterns, the interhemispheric cisterns, and over the cerebral convexities. In normal individuals, the radiopharmaceutical will have ascended to the parasagittal region within 24 hours with simultaneous partial or complete clearance of activity from the basal cisterns and Sylvian regions. In contrast to air, the radiopharmaceutical does not normally enter the cerebral ventricles.
Although the primary absorption of cerebrospinal fluid (CSF) into the blood stream occurs at the arachnoid villi, there is some evidence that a significant fraction of CSF is also absorbed across both the cerebral and spinal leptomeninges. Lesser quantities may also be absorbed across the ventricular ependyma. It is also generally held that these alternate routes of CSF absorption may assume primary importance when the major routes of the flow are pathologically obstructed",,Indium 111 decays by electron capture with a physical half-life of 67.9 hours.,3.75 mCi/1.5mL,Intrathecal,,,,5.71,1.95,8.82,[111In+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)CC(O)=O,,,,,0,,501.0199718,0,0,0,0,0,0
7390,04/06/2019 00:00,DB09459,L-tartaric acid,Oral or parenteral doses of monosodium 14C-L(+)-tartrate (400 mg/kg) are rapidly excreted by rats and a proportion completely metabolized to CO2. The oral dose was well-absorbed.,,,,Oral,,,,161,2.72,-4.3,O[C@H]([C@@H](O)C(O)=O)C(O)=O,,,,,0,,150.0164379,0,0,0,0,0,0
7391,04/06/2019 00:00,DB09460,Sodium carbonate,"The uptake of sodium, via exposure to sodium carbonate, is much less than the uptake of sodium via food. Therefore, sodium carbonate is not expected to be systemically available in the body. Furthermore,  an oral uptake of sodium carbonate will result in a neutralization in the stomach due to the gastric acid.",,,,Intravenous,,,,607,6.05,,[Na+].[Na+].[O-]C([O-])=O,,,,,0,,105.9642824,0,0,0,0,0,0
7392,02/07/2019 00:00,DB09462,Glycerin,"Well absorbed orally, poorly absorbed rectally.  Studies in humans and animals indicate glycerol is rapidly absorbed in the intestine and the stomach",,30 - 45 minutes,4.0 g/200mL,Topical,,,,1170,13.61,-3,OCC(O)CO,,,,,0,,92.04734412,0,0,0,0,0,0
7393,04/06/2019 00:00,DB09473,Indium In-111 oxyquinoline,"After injection of labeled leukocytes into normal volunteers, about 30% of the dose is taken up by spleen and 30% by liver, reaching a plateau at 2-48 hours after injection.",,Indium In 111 decays by electron capture with a physical half-life of 67.2 hours (2.8 days). Between 9.5 to 24.4% of the injected dose remains in whole blood and clears with a biological half-time of 2.8 to 5.5 hours. The remainder (13-18%) clears from blood with a biological half-time of 64 to 116 hours.,2 mCi/1mL,Intravenous,,,,0.00128,9.36,4.83,[111In+3].[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2,,,,,0,,543.0399194,6,6,3,3,0,0
7394,02/07/2019 00:00,DB09477,Enalaprilat,"Enalaprilat is poorly absorbed following oral administration, and is therefore only available as an intravenous injection.",0.5,11 hr,1.25 mg/1mL,Intravenous,,,,0.876,3.13,7.83,[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O,0.5,0.5,11,11,0,,348.1685219,2,1,1,0,1,1
7395,04/06/2019 00:00,DB09480,Iofetamine I-123,,,,,,,,,0.00511,,10.35,CC(C)NC(C)CC1=CC=C([123I])C=C1,,,,,0,,299.0495136,1,1,0,0,0,0
7396,04/06/2019 00:00,DB09481,Magnesium carbonate,About 40-60% of magnesium is absorbed following oral administration [L593]. Percent absorption decreases as dose increases.,0.3,Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].,100 mg,Oral,solid,0.1g/L,,226,6.05,,[Mg++].[O-]C([O-])=O,0.3,0.3,,,0,100,83.96978556,0,0,0,0,0,0
7397,04/06/2019 00:00,DB09483,Potassium lactate,,,,,Intravenous,,,,786,3.78,-3.7,[K+].CC(O)C([O-])=O,,,,,0,,127.9875757,0,0,0,0,0,0
7398,04/06/2019 00:00,DB09487,Iotrolan,,,,240 mg,Intrathecal,,,,0.539,11.5,-3.3,CN(C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I,,,,,0,,1625.729347,2,2,0,0,0,0
7399,04/06/2019 00:00,DB09488,Acrivastine,"Acrivastine was absorbed rapidly from the combination capsule following oral administration and was as bioavailable as a solution of acrivastine. After administration of SEMPREX-D Capsules, maximum plasma acrivastine concentrations were achieved at 1.14 Â± 0.23 hour.",,The mean terminal half-life for acrivastine was 1.9 Â± 0.3 hours following single oral doses and increased to 3.5 Â± 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 Â± 1.4 hours.,,Oral,,,,0.00994,3.68,8.63,[H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O,,,,,0,,348.183778,3,2,2,1,1,1
7400,19/06/2019 00:00,DB09490,Indium In-111 chloride,"Indium In-111 Chloride is a radioactive tracer for labeling monoclonal antibodies in certain preparations such as OncoScint, ProstaScint and Zevalin. Its absoption is related to the final product and not specific to Indium In-111 Chloride alone",,2.8 days,5 mCi/0.5mL,Intravenous,,,,27.4,,,Cl[111In](Cl)Cl,,,67.2,67.2,0,,215.811661,0,0,0,0,0,0
7401,04/06/2019 00:00,DB09494,Cetyl alcohol,"Following ingestion at a dose level of 2.0 g/kg in rats, cetyl alcohol was partly absorbed [L1810]. Administration of 0.2 mg cetyl alcohol in rat by stomach tube indicated good absorption as 63-96 % of radiolabeled cetyl alcohol was detected in the lymph [A32209]. About 15% of total cetyl alcohol was unchanged during its passage through the mucosal cells of the small intestine but mostly underwent oxidation to palmitic acid [A32209]. The extent of absorption was reported to be 26% in poultry [A32209].",,,80 mg/100mL,Topical,solid,Insoluble,,0.000181,16.84,-2,CCCCCCCCCCCCCCCCO,,,,,0,,242.2609657,0,0,0,0,0,0
7402,04/06/2019 00:00,DB09495,Avobenzone,,,,1 kg/1kg,Cutaneous,,,,0.000622,9.88,-4.8,COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C,,,,,0,,310.1568946,2,2,0,0,0,0
7403,02/07/2019 00:00,DB09496,Octinoxate,"Can be systemically absorbed after skin application, being found in the deeper layers of the stratum corneum as well as urine, plasma, and breast milk [A19207]. The mean maximum plasma concentration detected after application of 2mg/cm2 sunscreen was 7ng/mL in women and 16ng/mL in men [A19212]. ",,,50 mg,Topical,liquid,<0.1 g/100 mL at 27Â°C,5.8,0.000452,,-4.8,[H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC,,,,,0,,290.1881947,1,1,0,0,0,0
7404,04/06/2019 00:00,DB09498,Strontium chloride Sr-89,"Following intravenous injection, strontium chloride 89 behaves like its calcium analog. It clears rapidly from the blood stream and selectively gets localized on the bone mineral, preferentially in zones of osteogenesis, where it can stay retained for about 14 days.[FDA label]",45-60%,Strontium chloride 89 presents a half-life of 50.5 days.[A31266],1 mCi/1mL,Intravenous,liquid,10.9-22.6 mg/ml,,51.8,-7,,[Cl-].[Cl-].[89Sr++],0.45,0.6,,,0,,158.8451561,0,0,0,0,0,0
7405,04/06/2019 00:00,DB09501,Ferric ammonium citrate,,,,,Oral,,,,106,3.05,-4.2,N.[Fe+3].OC(=O)CC(O)(CC(O)=O)C(O)=O,,,,,3,,264.9868435,0,0,0,0,0,0
7406,04/06/2019 00:00,DB09502,Fludeoxyglucose F-18,Fludeoxyglucose F 18 Injection is rapidly distributed to all organs of the body after intravenous administration.,,10-13 minutes,0.5 Ci/1mL,Intravenous,,,,139,10.32,-3,[H]C(=O)[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)CO,,,0.166666667,0.216666667,0,,181.0615865,0,0,0,0,0,0
7407,04/06/2019 00:00,DB09510,Urea C-13,,,,75 mg,Oral,,,,11.8,0.55,15,N[13C](O)=N,,,,,0,75,61.03571759,0,0,0,0,0,0
7408,02/07/2019 00:00,DB09512,Simethicone,Not absorbed following oral administration.,,The drug is not absorbed. ,166.0 mg,Oral,,,,1.71,,-3.7,O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C,,,,,0,166,238.0512886,0,0,0,0,0,0
7409,04/06/2019 00:00,DB09513,Urea C-14,,,14C-urea that is not hydrolyzed by H. pylori is excreted in the urine with a half-life of approximately 12 hours. About 10% of the 14C remains in the body at 72 hours and is gradually excreted with a biological half-life of 40 days.,1 uCi/1,Oral,,,,412,15.73,-2.4,N[14C](N)=O,,,,,0,,62.03560474,0,0,0,0,0,0
7410,04/06/2019 00:00,DB09516,Mequinol,The systemic exposure to mequinol was assessed in eight healthy subjects following two weeks of twice-daily topical treatment of a tretinoin and mequinol combination product [FDA Label]. About dose of the product corresponding to about 37.3 ug/cm^2 of mequinol was applied to the subjects' backs [FDA Label]. The mean Cmax for mequinol was 9.92 ng/mL (range between 4.22 and 23.62 ng/mL) and the Tmax was 2 hours (range between 1 to 2 hours) [FDA Label]. The safety of mequinol in this combination formulation is supported by the low systemic exposures of the agent in the subjects [L993].,,Mequinol demonstrated an elimination half-life of 30 to 90 minutes following intravenous infusion of 5 or 10 grams/m^2 over 3 to 5 hours in melanoma patients; similar values were reported after intra-arterial infusion [L2532].,,Topical,,,,36.1,9.94,-4.8,COC1=CC=C(O)C=C1,,,,,0,,124.0524295,1,1,0,0,0,0
7411,02/07/2019 00:00,DB09517,Sodium ferric gluconate complex,Peak drug levels (Cmax) varied significantly by dosage and by rate of administration. Highest Cmax value is observed in the regimen in which 125 mg was administered in 7 minutes (19.0 mg/L).,," The terminal elimination half-life for drug bound iron was approximately 1 hour, with the value varying by dose but not by rate of administration. In adults, the shortest terminal elimination half-life of 0.825h occurs with the 62.5 mg/4 min dosing regimen and the longest value of 1.45h is achieved with 125 mg/7 min regimen. In pediatric patients, the half-life was 2 hours following administration of 1.5 mg/kg dose and 2.5 hours following administration of 3.0mg/kg dose.",12.5 mg,Intravenous,liquid,,,824,11.84,-3,[O--].[O--].[O--].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,,,,,0,,2088.475923,10,0,10,0,10,10
7412,02/07/2019 00:00,DB09526,Hydroquinone,,,,0.04,Topical,,6.72g/L at 20 deg C,0.59,95.5,9.68,-5.9,OC1=CC=C(O)C=C1,,,,,0,,110.0367794,1,1,0,0,0,0
7413,04/06/2019 00:00,DB09534,Ecamsule,"Ecamsule is a topical preparation, it should not be absorbed. Research done by L'Oreal on human subjects revealed that the systemically absorbed dose of [(14)C]-Ecamsule is less than 0.1% and under realistic exposure conditions, the human systemic exposure to this UVA filter is negligible and poses no risk to human health.",,Ecamsule is not absorbed and has no reported half life data.,,Topical,,,,0.00571,-1,-5,CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC1=CC=C(C=C2C3CCC(CS(O)(=O)=O)(C2=O)C3(C)C)C=C1,,,,,0,,562.16951,5,1,0,0,0,0
7414,02/07/2019 00:00,DB09543,Methyl salicylate,"Approximately 12-20% of topically applied methyl salicylate may be systemically absorbed through intact skin within 10 hours of application, and absorption varies with different conditions such as surface area and pH. Dermal bioavailability is in the range of 11.8 â€“ 30.7%. For the assessment of potential oral exposure to salicylates, bioavailability is assumed to be 100% [L777].",,The plasma half-life for  salicylate is 2 to 3 hr in low doses and about 12 hr at usual anti-inflammatory doses. The half-life of salicylate may be as long as 15 to 30 hr at high therapeutic doses or when there is intoxication. ,23 g/100g,Percutaneous; Topical; Transdermal,liquid,Slightly soluble,2.5,5.73,9.72,-4.3,COC(=O)C1=CC=CC=C1O,,,,,0,,152.0473441,1,1,0,0,0,0
7415,04/06/2019 00:00,DB09546,Iobenguane sulfate I-123,,,,25 mCi/1,Intravenous,liquid,Soluble,,0.1,,11.75,OS(O)(=O)=O.NC(=N)NCC1=CC([123I])=CC=C1.NC(=N)NCC1=CC([123I])=CC=C1,,,,,0,,639.9535022,2,2,0,0,0,0
7416,04/06/2019 00:00,DB09552,Thonzonium,,,,,Auricular (otic),solid,Soluble ,,1.82E-05,,3.12,CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C1=NC=CC=N1,,,,,1,,511.4370388,2,2,1,1,0,0
7417,04/06/2019 00:00,DB09555,Dexchlorpheniramine maleate,Oral bioavailability in rats  40.5%,0.2,20-30 h,2 mg/5mL,Oral,,,,0.0519,,9.47,OC(=O)\C=C/C(O)=O.CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1,0.2,0.2,20,30,0,,390.1346349,2,2,1,1,0,0
7418,04/06/2019 00:00,DB09561,Sodium glycerophosphate,Peak serum phosphate concentration is reached in 4h [A32667].,,Inorganic phosphate has a half-life of elimination of 2.06h [A32667].,216 mg/1mL,Intravenous,solid,Soluble,,81.5,1.51,-3,[Na+].[Na+].OCC(O)COP([O-])([O-])=O,,,,,0,,215.9775631,0,0,0,0,0,0
7419,04/06/2019 00:00,DB09563,Choline C-11,,,,100 mCi/1mL,Intravenous,,,,3.61,13.97,-3.2,C[N+](C)([11CH3])CCO,,,,,1,,103.1184241,0,0,0,0,0,0
7420,02/07/2019 00:00,DB09570,Ixazomib,"After oral administration, the time to reach maximum concentration in plasma was 1 hour. The mean absolute oral bioavailability is 58%. ",0.99,Terminal half-life is 9.5 days. ,2.3 mg,Oral,solid,,,0.0179,3.47,1.63,[H][C@@](CC(C)C)(N=C(O)CN=C(O)C1=C(Cl)C=CC(Cl)=C1)B(O)O,0.99,0.99,,,0,2.3,360.0814928,1,1,0,0,0,0
7421,04/06/2019 00:00,DB09571,Levmetamfetamine,,, The elimination half-life of levomethamphetamine is between 13.3 and 15 hours.,50 mg/1,Nasal,solid,,,0.928,,10.21,CN[C@H](C)CC1=CC=CC=C1,,,,,0,,149.1204495,1,1,0,0,0,0
7422,04/06/2019 00:00,DB11056,Stannous chloride,,,,0.05 mg/9.5mg,Oral,solid,Freely soluble,,65.4,-7,,[Cl-].[Cl-].[Sn++],,,,,0,,189.8399001,0,0,0,0,0,0
7423,04/06/2019 00:00,DB11071,Phenyl salicylate,Rapidly absorbed. Refer to [DB00945] for detailed salicylate absorption information.,,Mean half-life of 1.1 h  [L2478].,,Oral,solid,insoluble ,,0.216,9.67,-4.3,OC1=CC=CC=C1C(=O)OC1=CC=CC=C1,,,,,0,,214.0629942,2,2,0,0,0,0
7424,02/07/2019 00:00,DB11073,Cetylpyridinium,"Most available formulations consisting of cetylpyridinium chloride as an active ingredient are either mouthwashes, tootpastes, lozenges, or mouth sprays. The oral retention of cetylpyridinium chloride given as 1 min mouth rinse of 10 mL of 2.2 MMOL solution was recorded as 65% of the administered dose [L2758].

Additionally, it has been recorded that quaternary ammonium compounds like Cetylpyridinium chloride are generally poorly absorbed by the oral route [L2757]. Furthermore, although systemic absorption from the parenteral route of administration is possible, systemic effects from percutaneous absorption through intact skin is considered rare [L2757]. ",,No readily available data regarding the half-life of cetylpyridinium chloride is available [L2757] and various products that actually contain cetylpyridinium chloride as an active ingredient suggest that no pharmacokinetic data are available for the agent [L2760].,0.07 mL/100L,Topical,,,,6.53E-06,,,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1,,,,,1,,304.2998766,1,1,1,1,0,0
7425,02/07/2019 00:00,DB11079,Trolamine salicylate,"Following topical administration of 10% trolamine salicylate in healthy volunteers, salicylic acid could not be detected in serum indicating low systemic absorption [A32190].",,,10 g/100mL,Topical,,Soluble,,11.3,2.79,-6.3,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,,,,,0,,287.1368874,1,1,0,0,0,0
7426,04/06/2019 00:00,DB11085,Resorcinol,The dermal absorption of resorcinol seems to be low (< 1%) when applied on healthy and intact skin [F62]. The agent absorbed very slightly under normal conditions & the absorption was lower when applied to the scalp than to clean shaven skin due to a strong fixation by the hair [L2744].,,"Specific data regarding the half-life of resorcinol is not readily available, although, in one case of dermal exposure, an adult male with a 90% phenol exposure had an elimination half-life of about 14 hours [L2744].",,Topical,,,,82.3,9.26,-5.7,OC1=CC(O)=CC=C1,,,,,0,,110.0367794,1,1,0,0,0,0
7427,02/07/2019 00:00,DB11089,Docusate,"Docusate is not absorbed systemically[L1801,L5912]. As the actions of docusate are local and it is not absorbed, the pharmacokinetic parameters are not available[L5912]. ",,,50 mg/1,Oral,solid,Soluble,3.95,0.00402,-0.75,-6.9,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(O)(=O)=O,,,,,0,50,422.2338246,0,0,0,0,0,0
7428,04/06/2019 00:00,DB11093,Calcium Citrate,The percentage of calcium absorbed varies inversely with intake [A19538]. Tmax of about 3.5-5h varying with formulation [A19541].,0.464,,350 mg,Oral,solid,,,4.12,3.05,-4.2,[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,0.464,0.464,,,0,350,497.8948279,0,0,0,0,0,0
7429,04/06/2019 00:00,DB11096,Meradimate,Meradimate is not absorbed through the skin.[L2749],,"As meradimate is not absorbed, this pharmacokinetic property is not relevant.",,Topical,solid,Insoluble,,0.00587,19.39,2.28,CC(C)C1CCC(C)CC1OC(=O)C1=CC=CC=C1N,,,,,0,,275.188529,2,1,0,0,0,0
7430,04/06/2019 00:00,DB11098,Potassium bicarbonate,Potassium bicarbonate intake is done mainly in the small intestine in which approximately 90% of the potassium will be absorbed by passive diffusion.[A32222],,"Some reports have shown that after absorption, most body potassium exchanges rapidly with a half-life of less than 7 hours.[A32222]",391 mg/1,Oral,solid,Soluble,,681,6.05,,[K+].OC([O-])=O,,,,,0,391,99.95627557,0,0,0,0,0,0
7431,02/07/2019 00:00,DB11100,Allantoin,"In studies on human subjects, a recovery of 19% and 34% of allantoin in the urine was observed but only in two individuals and only after the administration of massive doses of allantoin [L1834]. After intravenous administration, recovery in the urine was practically quantitative with doses of 75 to 600 mgm in the human model [L1834]. After 240 mgm, excretion continued for 72 hours in human subjects and the results were similar in regards to subcutaneous injection [L1834].",,"When studied in cattle, sheep, and horses, the half-life of allantoin is in the range of 1 to 2.5 hours [FDA Label].",0.5 g/100g,Topical,,,,4.73,7.95,-3.4,NC(=O)NC1NC(=O)NC1=O,,,,,0,,158.0439901,1,0,1,0,1,1
7432,04/06/2019 00:00,DB11102,N-acetyltyrosine,,,,,Intravenous,solid,,,2.51,3.67,-2,CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,,,,,0,,223.0844579,1,1,0,0,0,0
7433,04/06/2019 00:00,DB11107,Potassium bitartrate,There is little systemic absorption expected following rectal administration of potassium bitartrate. ,,No pharmacokinetic data available. ,,Rectal,solid,Partially soluble,,566,2.72,-4.3,[K+].O[C@H]([C@@H](O)C([O-])=O)C(O)=O,,,,,0,,187.9723196,0,0,0,0,0,0
7434,04/06/2019 00:00,DB11110,Magnesium citrate,"Mean plasma concentration of magnesium after administration of oral doses of magnesium citrate are reported to be of around 0.7 mmol/L and the concentration in saliva rested in 0.28 mmol/L. In reports, it has also been proven that the absorption and bioavailability of magnesium are greater when administered in the form of magnesium citrate when compared with other forms such as magnesium ocude.[A33128]",0.9,The study of the half-life of magnesium citrate is very difficult due to the half-life of the available isotopes for magnesium.[A19349],1.745 g/1mL,Oral,solid,Partially soluble in cold water,,6.34,3.05,-4.2,[Mg++].[Mg++].[Mg++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,0.9,0.9,,,0,,449.9621801,0,0,0,0,0,0
7435,02/07/2019 00:00,DB11115,Ensulizole,,,,0.03 mg/1mL,Topical,solid,Soluble,,0.317,-2.2,4.93,OS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C1=CC=CC=C1,,,,,0,,274.0412132,3,3,1,1,0,0
7436,04/06/2019 00:00,DB11117,Undecylenic acid,Undecylenic acid may be absorbed through the skin [MSDS]. ,,No information regarding half-life.,4.8 mg/36.97mL,Topical,solid,Insoluble,,0.0189,5.02,,OC(=O)CCCCCCCCC=C,,,,,0,,184.1463299,0,0,0,0,0,0
7437,02/07/2019 00:00,DB11121,Chloroxylenol,"No chloroxylenol was detected in the blood following the dermal administration of 2 g of p-chloroxylenol in an ethanol/olive oil vehicle in human subjects [A32349]. After a dose of 5 g, only traces were found, after 8 g, 1 mg % (1 mg/dL) was found in the blood after 3 hours, and 4 mg % (4 mg/dL) after 24 hours [A32349]. After a dose of 20 g, 4 mg % (4 mg/dL) was measured after half an hour, and 1 mg % (1 mg/dL) was present at 72 hours [A32349].

For antiseptic purposes, chloroxylenol is considered to be well-absorbed when applied to the skin [L1999]. ",0.852,"One study estimated the mean terminal half-life and mean residence time after a 200 mg intravenous single dose of chloroxylenol in healthy mongrel dog subjects to be 1.7 and 1.69 hours, respectively [L1989, L1993]. Alternatively, some product monographs liken chloroxylenol to a similar liquid antiseptic, triclosan, whose calculated urinary excretion half-life in man is approximately 10 hours [L1992]. ",1 g/100mL,Topical,liquid,"0.03 g/100ml at 15 degrees Celsius, 0.5 g/100ml at 100 degrees Celsius",,0.855,9.21,-6.3,CC1=CC(O)=CC(C)=C1Cl,0.852,0.852,,,0,,156.0341926,1,1,0,0,0,0
7438,02/07/2019 00:00,DB11125,Benzethonium,It is reported that percutaneous absorption of benzethonium is clinically insignificant [L1923]. Benzethonium chloride belongs to the family of ,,Pharmacokinetic studies on benzethonium have not been conducted. ,1.3 mg/1g,Topical,solid,Soluble,,7.49E-06,17.31,-4.1,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1,,,,,1,,412.321006,2,2,0,0,0,0
7439,02/07/2019 00:00,DB11126,Calcium gluconate,"Approximately one-fifth to one-third of orally administered calcium is absorbed in the small intestine, depending on presence of vitamin D metabolites, pH in lumen, and on dietary factors, such as calcium binding to fiber or phytates. Calcium absorption is increased when a calcium deficiency is present or when a patient is on a low-calcium diet. In patients with achlorhydria or hypochlorhydria, calcium absorption, especially with the carbonate salt, may be reduced. ",0.45,,0.465 meq/1mL,Intravenous,,,,44.2,3.39,-3,[Ca++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,0.45,0.45,,,0,,430.0635464,0,0,0,0,0,0
7440,04/06/2019 00:00,DB11129,Carbamide peroxide,"Upon treatment into the external auditory canal or the dental cavity, exposure to carbamide peroxide is limited to the intimate contact with the treated area without any systemic absorption.",,No established pharmacokinetic data.,7.8 mg/12mL,Topical,solid,500 g/L at Â°C,,11.8,0.55,15,OO.NC(O)=N,,,,,0,,94.03784205,0,0,0,0,0,0
7441,04/06/2019 00:00,DB11134,Cupric oxide,"Following oral administration, copper is mainly absorbed through the gastrointestinal tract from the stomach, duodenum, and jejunum. All other intakes of copper (inhalation and dermal) are insignificant in comparison to the oral route. The bioavailability of copper from cupric oxide depends on the solubilization of the oxide in the gastrointestinal tract [L2437]. According to studies on cattle and swine, copper oxide displays low absorption rate and high excretion rate [L2422]. In rats exposed to aerosols containing 50-80 mg/m^3, pulmonary uptake of copper oxide occurred [L2422]. ",,No pharmacokinetic data available. ,100 mg/1,Topical,solid,Insoluble,,270,15.7,-1.8,[O--].[Cu++],,,,,0,,78.92451212,0,0,0,0,0,0
7442,04/06/2019 00:00,DB11140,Chromium Cr-51,,,,1 mCi/5mL,Oral,,,,0,,,[51Cr],,,,,0,,50.9447674,0,0,0,0,0,0
7443,04/06/2019 00:00,DB11141,Manganese gluconate,,,,,Oral,,,,36.3,3.39,-3,[Mn++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,,,,,0,,445.0390005,0,0,0,0,0,0
7444,04/06/2019 00:00,DB11142,Selenomethionine,,,,,Oral,,,,109,1.56,9.5,C[Se]CC[C@H](N)C(O)=O,,,,,0,,196.9954999,0,0,0,0,0,0
7445,04/06/2019 00:00,DB11145,Oxyquinoline,,,,,Oral,solid,Insoluble,,4.18,9.36,4.83,OC1=CC=CC2=C1N=CC=C2,,,,,0,,145.0527638,2,2,1,1,0,0
7446,04/06/2019 00:00,DB11148,Butamben,"When butamben is administered epidurally in a suspension form, the physical characteristics of butamben allow a very slow release.[L2445] When administered topically, butamben is also reported to have a very low systemic absorption which allows for a longer duration of action.[T173]",,"The effective half-life of unencapsulated butamben is registered to be of 90 minutes. Some efforts were made to prepare D, L-lactic acid capsules which increased the half-life of butamben to even 400 hours.[T176]",,Topical,solid,140 mg/L,2.87,0.336,,2.76,CCCCOC(=O)C1=CC=C(N)C=C1,,,,,0,,193.1102787,1,1,0,0,0,0
7447,04/06/2019 00:00,DB11154,Zinc citrate,,,,,Oral,,,,6.11,3.05,-4.2,[Zn++].[Zn++].[Zn++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,,,,0,,569.7944816,0,0,0,0,0,0
7448,02/07/2019 00:00,DB11155,Triclocarban,"A human exposure study in a small group of subjects demonstrated that a portion of the TCC present in bar soaps is absorbed through the skin and is excreted in urine as N-glucuronides [A32932].

Because they are produced and used in large quantities in various products, they are absorbed into the human body of the general population [L2679].

The absorption of triclocarban during a human pharmacokinetic study was estimated at 0.6% of the 70 + or - 15 mg of triclocarban in the soap used. The triclocarban-N-glucuronide urine concentration varied considerably among the study subjects, and continuous daily use of the soap led to steady-state levels of excretion [L2685].
",,10 hours [L2680],459 mg/150mL,Topical,solid,Insoluble ,,0.0029,11.42,-4.6,ClC1=CC=C(NC(=O)NC2=CC(Cl)=C(Cl)C=C2)C=C1,,,,,0,,313.9780459,2,2,0,0,0,0
7449,02/07/2019 00:00,DB11156,Pyrantel,"Pyrantel is poorly absorbed from the GI tract of humans [L1893], [L1908].

Peak serum concentrations occur 1â€“3 hours after a single dose [L1904].

",,"In pigs, following intravenous administration, pyrantel exhibited a half-life of 1.75 +/- 0.19 h [A32291]. ",125 mg,Oral,solid,insoluble in water,,0.118,,10.71,[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1,,,,,0,125,206.0877694,2,1,2,1,0,1
7450,04/06/2019 00:00,DB11157,Anthralin,"Anthralin penetrates damaged skin and psoriatic lesions faster and to a greater extent than normal skin, likely due to increased vascularity of psoriatic lesions [L1932].



",,,0.01,Topical,solid,not soluble in water,,0.184,8.47,-5.6,OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2,,,,,0,,226.0629942,3,2,0,0,0,0
7451,04/06/2019 00:00,DB11160,Phenyltoloxamine,"Readily accessible data regarding the absorption of phenyltoloxamine is not available. In fact, many first-generation H1 antihistamines have never had their pharmacokinetics (ie. absorption, distribution, metabolism, and elimination) optimally investigated [A32705].",,"Readily accessible data regarding the half-life of phenyltoloxamine is not available. In fact, many first-generation H1 antihistamines have never had their pharmacokinetics (ie. absorption, distribution, metabolism, and elimination) optimally investigated [A32705].",,Oral,,,,0.0423,,8.78,CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1,,,,,0,,255.1623143,2,2,0,0,0,0
7452,04/06/2019 00:00,DB11164,Bicisate,"After intravenous administration, bicisate presents a very large brain extraction.[A32374] About 5% of the administered dose remains in the blood one hour after administration. The highest concentration of radioactivity in blood was attained 0.5 minutes after intravenous injection and it represented 13.9% of the injected dose.[L2034] After intravenous administration of bicisate, the permeability surface area was 0.48 ml.g/min.[A32395]",,"The stability of bicisate is superior when compared to other brain radiopharmaceuticals.[T152] Thus, the reported half-life of bicisate is of 6.02 hours.[L2032] When broadly studied in clinical trials, the pharmacokinetic profile fits a three-compartment model with half-lives of 43 seconds, 49.5 minutes and 533 minutes.[A32390]",1.35 mg/1,Intravenous,solid,Insoluble,,0.0867,9.65,5.76,CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC,,,,,0,,324.1177492,0,0,0,0,0,0
7453,04/06/2019 00:00,DB11168,Calcium threonate,"Human studies demonstrate that calcium from calcium L-threonate is absorbed [L2463]. In an open-label, single- and multiple-dose study of healthy adult Chinese subjects receiving a single oral dose of 2025 mg calcium theronate, the peak plasma concentration (Cmax) was 32.3 mg/L [A27266]. The time to reach peak plasma concentration (Tmax) was approximately 2 hours [A27266]. ",,The terminal-phase elimination half-life following a single oral dose of 2025 mg calcium theronate in healthy adult Chinese subjects was approximately 2.7 hours [A27266]. ,,Oral,solid,Soluble,,86.1,3.4,-3,[Ca++].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O,,,,,0,,310.0212876,0,0,0,0,0,0
7454,04/06/2019 00:00,DB11174,2-(l-menthoxy)ethanol,,,,,Topical,,,,0.144,15.12,-2.7,[H][C@@]1(C)CC[C@@]([H])(C(C)C)[C@@]([H])(C1)OCCO,,,,,0,,200.17763,1,0,0,0,0,0
7455,04/06/2019 00:00,DB11175,Zinc picolinate,,,,,Oral,,,,12.2,1,5.52,[Zn++].[O-]C(=O)C1=CC=CC=N1.[O-]C(=O)C1=CC=CC=N1,,,,,0,,307.9775489,2,2,2,2,0,0
7456,04/06/2019 00:00,DB11176,Zeaxanthin,,,,,Oral,,,,0.000649,18.91,-0.79,C\C(\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,,,,,0,,568.428031,2,0,0,0,0,0
7457,04/06/2019 00:00,DB11180,Tetrofosmin,"After intravenous administration, tetrofosmin is rapidly cleared from the blood and taken up by the heart, skeletal muscle, liver, spleen and kidneys.[A32342]",,Refer to [DB09160],0.23 mg/1,Intravenous,liquid,Soluble ,,0.000664,,8.3,CCOCCP(CCOCC)CCP(CCOCC)CCOCC,,,,,0,,382.240183,0,0,0,0,0,0
7458,04/06/2019 00:00,DB11181,Homatropine,No pharmacokinetic data available.,,No pharmacokinetic data available.,50 mg/5mL,Ophthalmic,solid,Soluble as hydrobromide,,5.57,11.99,9.38,[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)C1=CC=CC=C1)N2C,,,,,0,,275.1521435,3,1,2,0,2,2
7459,02/07/2019 00:00,DB11182,Rose bengal free acid,No information available. ,,Doses between 0.01 and 10 mg/kg in rat resulted in an initial biological half-life of 2 min and a terminal half-life of 100 min. The biological half-life for excretion is around 30 minutes in rats and rabbits [A32403].,1.3 mg/1,Ophthalmic,solid,,,0.000681,2.55,1.89,OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12,,,,,0,,971.4991759,4,2,1,0,0,1
7460,04/06/2019 00:00,DB11183,Light green SF yellowish,,,,1.5 mg/1.5mg,Ophthalmic,,,,7.65E-05,-2.3,3.52,[Na+].[Na+].CCN(CC1=CC(=CC=C1)S([O-])(=O)=O)C1=CC=C(C=C1)C(C1=CC=C(C=C1)S([O-])(=O)=O)=C1C=CC(C=C1)=[N+](CC)CC1=CC(=CC=C1)S([O-])(=O)=O,,,,,0,,792.1221822,5,4,0,0,0,0
7461,04/06/2019 00:00,DB11184,Oftasceine,,,,0.5 mg/0.5mg,Ophthalmic,,,,0.0413,1.51,7.22,OC(=O)CN(CC(O)=O)CC1=CC2=C(OC3=CC(O)=C(CN(CC(O)=O)CC(O)=O)C=C3C22OC(=O)C3=CC=CC=C23)C=C1O,,,,,0,,622.1434889,5,3,2,0,0,2
7462,04/06/2019 00:00,DB11185,Sulisobenzone,"Does not penetrate the skin to a large degree, but enhances the ability of other chemicals to penetrate [L2665].",,,2 g/100g,Topical,,10 microgram/mL,,0.214,-2.4,-5,COC1=C(C=C(C(=O)C2=CC=CC=C2)C(O)=C1)S(O)(=O)=O,,,,,0,,308.0354591,2,2,0,0,0,0
7463,04/06/2019 00:00,DB11186,Pentoxyverine,"In humans, maximum plasma concentrations are achieved 1.2 hours after oral dosing [A32160]. ",,The half-life is 2.3 hours following oral dosing [A32160]. ,,Oral,solid,1 g/10 ml,,0.0231,,9.41,CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1,,,,,0,,333.2303939,2,1,0,0,0,0
7464,04/06/2019 00:00,DB11189,Magnesium glycinate,,,,,Oral,,,,136,2.31,9.24,[Mg++].NCC([O-])=O.NCC([O-])=O,,,,,0,,172.0334484,0,0,0,0,0,0
7465,04/06/2019 00:00,DB11190,Pantethine,,,,,Oral,,,,0.117,12.38,-2.8,CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO,,,,,0,,554.2444063,0,0,0,0,0,0
7466,04/06/2019 00:00,DB11192,L-threonic acid,,,,,Oral,,,,488,3.4,-3,[H][C@](O)(CO)[C@@]([H])(O)C(O)=O,,,,,0,,136.0371734,0,0,0,0,0,0
7467,04/06/2019 00:00,DB11195,Xylitol,Xylitol is absorbed in the small intestine via passive diffusion with a slow absorption rate [A22081].,,No pharmacokinetic data available.,0.07 g/100g,Dental,solid,,,664,12.76,-3,OC[C@H](O)[C@@H](O)[C@H](O)CO,,,,,0,,152.0684735,0,0,0,0,0,0
7468,04/06/2019 00:00,DB11197,Ferrous cysteine glycinate,,,,,Oral,,,,23.1,2.35,9.05,[Fe++].NCC(O)=O.[H][C@](N)(CS)C(O)=O.[H][C@](N)(C[S-])C([O-])=O,,,,,0,,370.9908148,0,0,0,0,0,0
7469,04/06/2019 00:00,DB11200,Aluminum zirconium octachlorohydrex gly,"A preliminary study of the dermal absorption of aluminium from antiperspirants using aluminum-26 was performed. After repeated exposure for 6 days to aluminum chlorohydrate 21 % (about 13 mg of aluminium) to each axilla under occlusive dressing in two volunteers (one man and a woman), on skin previously tape stripped twice, blood and urine samples were obtained. Aluminium was detected in the blood 6 hours after the primary application and remained detectable for 15 days therafter. The results of this study estimate that the proportion of aluminium is absorbed averaged 0.012%. The shortcomings of this study are that it was not done in accordance with good practice (GCP) and it was performed using only 2 volunteers [L2703].",,,18.6 mL/100mL,Topical,,,,11.9,2.31,9.24,O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O,,,,,5,,261.8976855,0,0,0,0,0,0
7470,04/06/2019 00:00,DB11201,Menthyl salicylate,"May be absorbed through intact skin. The absorption of topical salicylates is proportional to the surface area exposed, the duration of exposure, concentration and skin integrity. Absorption characteristics of salicylates vary with the dose, formulation,  and route of administration. Percutaneous absorption is enhanced by exercise, heat, occlusion, or disruption of the integrity of the skin or application to large areas of skin. Both the rate and extent of absorption increases after continuous application, increasing its bioavailability [F91].",,,,Oral,liquid,,4.01,0.0275,9.72,-4.3,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1O,,,,,0,,276.1725446,2,1,0,0,0,0
7471,04/06/2019 00:00,DB11205,Alcloxa,,,,,Oral,,,,2.35,7.95,-3.4,[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].NC(=O)NC1NC(=O)[N-]C1=O,,,,,0,,313.9790536,1,0,1,0,1,1
7472,04/06/2019 00:00,DB11206,Bemotrizinol,No pharmacokinetic data available.,,No pharmacokinetic data available.,,Topical,solid,Insoluble,,0.000339,6.37,0.35,CCCCC(CC)COC1=CC(O)=C(C=C1)C1=NC(=NC(=N1)C1=CC=C(OC)C=C1)C1=C(O)C=C(OCC(CC)CCCC)C=C1,,,,,0,,627.3672217,4,4,1,1,0,0
7473,04/06/2019 00:00,DB11207,Amiloxate,"According to _in vitro_ studies of amiloxate-containing tape strips on porcine ear, there was no detection of amiloxate undergoing skin penetration [F35].",,No pharmacokinetic data available. ,,Topical,liquid,Insoluble ,,0.00738,,-4.8,COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1,,,,,0,,248.1412445,1,1,0,0,0,0
7474,04/06/2019 00:00,DB11210,Ferrous bisglycinate,,,,,Oral,,,,211,2.31,9.24,[Fe++].NCC([O-])=O.NCC([O-])=O,,,,,0,,203.9833442,0,0,0,0,0,0
7475,04/06/2019 00:00,DB11217,Arbutin,Arbutin was found to be extensively absorbed from the gastrointestinal tract where it is primarily converted to hydroquinone [F43]. ,,No pharmacokinetic data available. ,0.6 g/30mL,Topical,solid,â‰¥ 10g/100g,1.35,39.1,9.82,-3,OC[C@H]1O[C@@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,272.0896029,2,1,1,0,1,1
7476,02/07/2019 00:00,DB11219,Enzacamene,"The maximum plasma concentration of enzacamene was 16ng/mL in healthy female volunteers following daily whole-body topical application of 2mg/cm^2 of sunscreen formulation at 10% (weight/weight) for four days [A19212]. Blood concentration of enzacamene (4-MBC) and its main metabolite, 3-(4-carboxybenzylidene)camphor, peaked within 10 h after oral administration of enzacamene [A32925]. ",,"The half life of enzacamene (4-MBC) and its main metabolite, 3-(4-carboxybenzylidene)camphor, displayed half-lives of approximately 15 h after reaching peak plasma concentrations after oral administration in rats [A32925].",0.06,Topical,solid,Poorly soluble,5.14,0.0051,,-5.2,CC1=CC=C(\C=C2/C3CCC(C)(C2=O)C3(C)C)C=C1,,,,,0,,254.1670653,3,1,0,0,0,0
7477,04/06/2019 00:00,DB11220,Octacosanol,,,,,Oral,,,,1.25E-05,16.84,-2,CCCCCCCCCCCCCCCCCCCCCCCCCCCCO,,,,,0,,410.4487665,0,0,0,0,0,0
7478,04/06/2019 00:00,DB11221,Dioxybenzone,"Dioxybenzone is a derivative of benzophenone. In monkeys, percutaneous absorption of benzophenone was observed [L2525]. Other derivatives of benzophenone are capable of crossing the skin via direct penetration through the intercellular laminae of the stratum corneum (SC) or by passive diffusion by high-concentration gradient into the systemic circulation, where they are transported to different tissues including liver and brain [A32726]. ",,No pharmacokinetic data available. ,,Topical,solid,,,0.148,6.78,-4.8,COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1O,,,,,0,,244.0735589,2,2,0,0,0,0
7479,04/06/2019 00:00,DB11226,Ethylhexyl methoxycrylene,"Ethylhexyl methoxycrylene is reported as having little to no absorption through the skin [F101]. At this time, however, studies demonstrate that the components of most commonly used sunscreens are likely absorbed into the skin at least to some extent - although penetration to deeper tissues and the cutaneous circulation remains limited [A33070]. Despite the extensive use of sunscreen products around the world, there have been few reports of adverse effects related to their use [A33070].",,Ethylhexyl methoxycrylene is reported as having little to no absorption through the skin [F101]. The systemic presence of the compound is consequently expected to be minimal.,,Topical,,,,0.00109,,-4.8,CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C1=CC=C(OC)C=C1,,,,,0,,391.2147438,2,2,0,0,0,0
7480,04/06/2019 00:00,DB11231,Lycopene,,,,,Oral,,,,0.000397,,,CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C,,,,,0,,536.4382018,0,0,0,0,0,0
7481,04/06/2019 00:00,DB11233,Silver citrate,,,,,Topical,,,,60.1,3.05,-4.2,[Ag+].[Ag+].[Ag+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,,,,0,,509.7188185,0,0,0,0,0,0
7482,04/06/2019 00:00,DB11235,Thonzylamine,,,,,Oral,solid,Highly Soluble,,0.733,,8.62,COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1,,,,,0,,286.1793613,2,2,1,1,0,0
7483,04/06/2019 00:00,DB11244,Cyclomethicone 5,,,,0.16 g/0.6g,Topical,,,,0.00803,,-3.3,C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1,,,,,0,,370.0939567,1,0,1,0,1,1
7484,04/06/2019 00:00,DB11246,Copper gluconate,,,,,Oral,,,,37.9,3.39,-3,[Cu++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,,,,,0,,453.0305529,0,0,0,0,0,0
7485,04/06/2019 00:00,DB11248,Zinc gluconate,Please refer to DrugBank entry [DB01593],,280 days [L2091],50 mg/1,Oral,solid,moderately soluble ,,40,3.39,-3,[Zn++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,,,,,0,50,454.0300976,0,0,0,0,0,0
7486,04/06/2019 00:00,DB11250,Glyceryl monostearate,,,,,Topical,,,,0.00108,13.62,-3,CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO,,,,,0,,358.3083098,0,0,0,0,0,0
7487,02/07/2019 00:00,DB11254,Hexylresorcinol,"Owing to the poor absorption of hexylresorcinol, systemic exposure and symptoms are unusual [L2739].",,"Readily accessible data regarding the half-life of hexylresorcinol is not available. Nevertheless, when hexylresorcinol is employed in its primary indication as a topical antiseptic or an oral anesthetic, it is generally accepted that pharmacokinetic considerations do not arise since the pharmacological action is local to the topically applied or oro-pharyngeal cavity area [L2735, F57, F58].",1 mg/1mL,Oral,,,,0.454,9.55,-5.6,CCCCCCC1=C(O)C=C(O)C=C1,,,,,0,,194.1306798,1,1,0,0,0,0
7488,04/06/2019 00:00,DB11255,Chromium picolinate,,,,,Oral,,,,0.0312,,2.85,O=C(O[Cr](OC(=O)C1=CC=CC=N1)OC(=O)C1=CC=CC=N1)C1=CC=CC=N1,,,,,0,,418.0131176,3,3,3,3,0,0
7489,04/06/2019 00:00,DB11256,Levomefolic acid,Absorbed in the proximal small intestines via the active proton-coupled folate transporter (PCFT) that transports both oxidized and reduced folic acids. Passive diffusion also occurs at the proximal and distal portions of the small intestines [A19277]. A single oral dose of 906nmol of levomefolic acid in healthy females resulted in the mean peak plasma concentration of 39.4nmol/L [A19276].,0.56,"The mean elimination half-life is approximately 3 hours after 5mg of oral L-methylfolate, administered daily for 7 days [775].",15 mg/1,Oral,solid,Approximately 0.3 mg/ml,,0.332,3.5,3.54,CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2,0.56,0.56,,,0,15,459.1866315,3,2,2,1,0,1
7490,04/06/2019 00:00,DB11259,Diosmetin,Diosmin is hydrolyzed to its aglycone diosmetin by intestinal microflora enzymes before its absorption into the body [A27231].,,,0.1 mL/100mL,Topical,,,,0.0754,6.64,-4.8,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O1)C=C(O)C=C2O,,,,,0,,300.0633881,3,3,1,1,0,0
7491,04/06/2019 00:00,DB11260,Diacetyl benzoyl lathyrol,,,,0.1 mL/100mL,Topical,,,,0.000363,,-5.5,C[C@H]1C[C@@]2(OC(C)=O)[C@H]([C@H]1OC(=O)C1=CC=CC=C1)[C@@H](OC(C)=O)C(=C)CC[C@H]1[C@@H](\C=C(C)\C2=O)C1(C)C,,,,,0,,522.2617536,4,1,0,0,0,0
7492,04/06/2019 00:00,DB11262,Bisoctrizole,"A rat and human dermal penetration study _in vitro_ indicates that bisoctrizole displays minimal absorption through the skin, with only about 0.01% and 0.06 % of the applied dose penetration through the human and rat skin membrane, respectively [F90]. Despite low dermal uptake, potential bioaccumulation after repeated skin applications cannot be excluded [F90]. ",,No pharmacokinetic data available. ,,Topical,solid,< 5 ng/L at 25 Â°C,12.7,0.000458,7.56,-0.54,CC(C)(C)CC(C)(C)C1=CC(CC2=C(O)C(=CC(=C2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)=C(O)C(=C1)N1N=C2C=CC=CC2=N1,,,,,0,,658.3995248,6,6,2,2,0,0
7493,04/06/2019 00:00,DB11263,Polydatin,,,,0.21 mL/100mL,Topical,,,,0.766,8.6,-3,OC[C@H]1O[C@@H](OC2=CC(O)=CC(\C=C\C3=CC=C(O)C=C3)=C2)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,390.1314677,3,2,1,0,1,1
7494,04/06/2019 00:00,DB11264,Calcium glycerophosphate,,,,,Oral,solid,Soluble,,50.9,1.13,-3,[Ca++].OCC(CO)OP([O-])([O-])=O,,,,,0,,209.9606156,0,0,0,0,0,0
7495,04/06/2019 00:00,DB11267,Triethoxycaprylylsilane,,,,,Topical,,,,0.000822,,-3.8,CCCCCCCC[Si](OCC)(OCC)OCC,,,,,0,,276.2120714,0,0,0,0,0,0
7496,04/06/2019 00:00,DB11268,Protocatechualdehyde,,,,0.032 mL/100mL,Topical,,,,14.3,7.46,-6.3,OC1=CC=C(C=O)C=C1O,,,,,0,,138.0316941,1,1,0,0,0,0
7497,04/06/2019 00:00,DB11269,Diethylamino hydroxybenzoyl hexyl benzoate,"Based on the findings of a rat study assessing dermal or percutaneous absorption, only a minor amount of diethylamino hydroxybenzoyl hexyl benzoate will undergo percutaneous absorption and most of the compounds will remain in the upper layers of the stratum corneum [F107]. In rat and porcine skin, the percutaneous absorption was 0.10 Â± 0.12 Î¼g/cm^2 or 0.04 Â± 0.05% [F107]. ",,No pharmacokinetic data. ,,Topical,solid,< 0.01 mg/L,6.2,0.00702,7.29,3.38,CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(C=C1O)N(CC)CC,,,,,0,,397.2253085,2,2,0,0,0,0
7498,04/06/2019 00:00,DB11272,Methyl undecenoyl leucinate,,,,0.1 mL/100mL,Topical,,,,0.00165,12.94,-1.3,COC(=O)[C@H](CC(C)C)NC(=O)CCCCCCCCC=C,,,,,0,,311.2460439,0,0,0,0,0,0
7499,04/06/2019 00:00,DB11273,Dihydroergocornine,Dihydroergocornine absorption in man after oral administration is very rapid when compared to the mixture or most of the components. The time to reach maximum plasma concentration or 0.57 ng-eq/ml is 1.4 hours. It presents an absorption half-life of 0.32 hours. The absorption percentage is of about 25% which corresponds to the registered absorption presented in the ergoloid mixture.[T191] To know more about the pharmacokinetics please visit [DB01049].,,To know more about the pharmacokinetics please visit [DB01049].,,Oral,solid,,2.33,0.402,9.71,8.39,[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,,,,,0,,563.3107694,7,2,5,1,4,4
7500,04/06/2019 00:00,DB11274,Dihydro-alpha-ergocryptine,Alpha-dihydroergocryptine is rapidly absorbed but it presents a very low bioavailability as it is part of a first-pass hepatic metabolism and thus less of 5% of the administered dose reaches blood circulation. The peak plasma concentration is attained after 30-120 minutes. The absorption of alpha-dihydroergocryptine is not affected by the co-administration with food.[A32987] When administered in repeated oral doses the Cmax after 1 hour was registered to be 2157 pg/ml.[A32994] To know more about the ergoloid mesylate mixture please visit [DB01049].,,Alpha-dihydroergocryptine has been studied in Parkinson disease models and it has shown a half-life of 12-16 hours.[A32986] To know more about the ergoloid mesylate mixture please visit [DB01049].,,Oral,solid,,5.9,0.264,9.71,8.39,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,,,,,0,,577.3264195,7,2,5,1,4,4
7501,04/06/2019 00:00,DB11275,Epicriptine,Please refer to [DB01049] and to know more about the isomer please refer to [DB11274].,,Please refer to [DB01049] and to know more about the isomer please refer to [DB11274].,,Oral,solid,,,0.276,9.71,8.39,[H][C@@]12CCCN1C(=O)[C@]([H])([C@H](C)CC)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,,,,,0,,577.3264195,7,2,5,1,4,4
7502,04/06/2019 00:00,DB11278,DL-Methylephedrine,"Methylephedrine is rapidly absorbed following oral administration [L2836].  Peak plasma concentrations of ephedrine (from which methylephedrine is derived) occur 2-3h after administration [T217].  Due to the fact that methylephedrine is a derivative of ephedrine [L2844], peak plasma concentrations are likely similar.",,3-6 hours (Ephedrine) [F100].,,Oral,solid,,2.47,15.4,13.88,8.86,C[C@@H]([C@H](O)C1=CC=CC=C1)N(C)C,,,,,0,,179.1310142,1,1,0,0,0,0
7503,04/06/2019 00:00,DB11279,Brilliant green cation,,,,,Topical,,,,0.0003,,5.36,CCN(CC)C1=CC=C(C=C1)C(C1=CC=CC=C1)=C1C=CC(C=C1)=[N+](CC)CC,,,,,1,,385.2638255,3,2,0,0,0,0
7504,04/06/2019 00:00,DB11281,Bismuth subcarbonate,,,,,Oral,,,,90.4,6.05,,[O--].[O--].[Bi+3].[Bi+3].[O-]C([O-])=O,,,,,0,,509.9353705,0,0,0,0,0,0
7505,04/06/2019 00:00,DB11282,Diethyltoluamide,"Most diethyltoluamide (DEET) formulations employ the agent as a liquid to be applied onto human skin in an effort to repel mosquitoes from feeding on the skin. Topical application and absorption is consequently the most common route of absorption. When used appropriately, DEET formulations are generally not indicated for too many other routes of absorption or administration, like parenterally or orally.

DEET is absorbed quickly through intact skin; 48% of the applied dose is totally absorbed within 6 hours [L2775]. Topical absorption is the usual route of entry as DEET is normally applied to the skin as a mosquito repellent [L2775]. DEET applied to the skin has also been shown to accumulate in the dermis [L2775]. DEET is rapidly absorbed after oral ingestion [L2775]. Additionally, animal experiments demonstrate that DEET can cross the placenta [L2775].

DEET is efficiently absorbed across the skin and by the gut [L2779]. Blood concentrations of about 3 mg/L have been reported several hours after dermal application in the prescribed fashion [L2779].

Between 9% and 56% of dermally applied DEET is absorbed through the skin with peak blood levels being attained within 1 hour [L2775]. Absorption through the skin varies according to the site exposed to the DEET [L2775]. In animal model surfaces corresponding to the human palmar surface (an area that is typically heavily exposed during the application of liquid DEET), 68% of administered topical DEET was absorbed [L2775]. As a consequence, small children are at increased risk of excessive absorption of DEET applied to the skin because of their relatively higher surface to volume ratio compared to adults [L2775].",,The elimination half-life of diethyltoluamide (DEET) is observed to be about 2.5 hours [A33060].,10 g/100mL,Topical,,,,1.68,,-0.95,CCN(CC)C(=O)C1=CC(C)=CC=C1,,,,,0,,191.1310142,1,1,0,0,0,0
7506,04/06/2019 00:00,DB11283,DL-dimyristoylphosphatidylcholine,,,,,Intravenous,,,,4.03E-05,1.86,-6.7,CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC,,,,,0,,677.4995549,0,0,0,0,0,0
7507,04/06/2019 00:00,DB11284,DL-dimyristoylphosphatidylglycerol,,,,,Intravenous,solid,,,0.000281,1.89,-3,CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC,,,,,0,,666.447185,0,0,0,0,0,0
7508,04/06/2019 00:00,DB11285,Ethyl ferulate,,,,,Topical,,,,0.328,9.87,-4.9,[H]\C(=C(\[H])C1=CC(OC)=C(O)C=C1)C(=O)OCC,,,,,0,,222.0892089,1,1,0,0,0,0
7509,04/06/2019 00:00,DB11288,Borneol,,,,,Transdermal,,,,0.805,19.6,-0.78,CC1(C)C2CCC1(C)C(O)C2,,,,,0,,154.1357652,2,0,0,0,0,0
7510,04/06/2019 00:00,DB11290,Aluminium tristearate,,,,,Topical,,,,1.02E-05,4.95,,[Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O,,,,,0,,876.7726547,0,0,0,0,0,0
7511,04/06/2019 00:00,DB11291,2-ethylhexyl benzoate,,,,,Topical,,,,0.00206,,-6.9,CCCCC(CC)COC(=O)C1=CC=CC=C1,,,,,0,,234.1619799,1,1,0,0,0,0
7512,04/06/2019 00:00,DB11296,Prezatide,Prezatide both free and in complex with copper can pass through the stratum corneum [A19504]. Its absorption is pH dependent with the highest absorption occurring at physiological pH. ,,Prezatide is rapidly eliminated within minutes [A19502].,,,solid,,,3.14,3.46,10.2,NCCCC[C@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)CN)C(O)=O,,,,,0,,340.1859032,1,1,1,1,0,0
7513,04/06/2019 00:00,DB11297,Palmitoyl oligopeptide,,,,,Topical,,,,0.00146,3.49,10.2,CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(O)=O,,,,,0,,578.4155688,1,1,1,1,0,0
7514,04/06/2019 00:00,DB11299,Vanillyl butyl ether,,,,1.53 g/153g,Topical,,,,0.425,9.91,-4.1,CCCCOCC1=CC(OC)=C(O)C=C1,,,,,0,,210.1255944,1,1,0,0,0,0
7515,01/05/2019 00:00,DB11315,Methscopolamine,,,,,Oral,,,,0.0145,15.15,-2.7,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,,,,,1,,318.1699847,4,1,3,0,3,3
7516,04/06/2019 00:00,DB11318,"1,2-Docosahexanoyl-sn-glycero-3-phosphoserine",,,,,Oral,,,,0.000121,1.47,9.38,[H]C(CC)=C([H])C\C([H])=C(\[H])C\C([H])=C(\[H])C\C([H])=C(\[H])C\C([H])=C(\[H])C\C([H])=C(\[H])CCC(=O)OC[C@]([H])(COP(O)(=O)OC[C@]([H])(N)C(O)=O)OC(=O)CC\C([H])=C(\[H])C\C([H])=C(\[H])C\C([H])=C(\[H])CC([H])=C([H])C\C([H])=C(\[H])C\C([H])=C(\[H])CC,,,,,0,,879.5050342,0,0,0,0,0,0
7517,04/06/2019 00:00,DB11323,Glycol salicylate,Salicylate absorption follows first-order kinetics with an absorption half-life ranging from 5 to 16 minutes [L2700].,,"The serum half-life of [DB00945], a similar salicylate, is 20 min [L2700].",,Topical,liquid,13.1 g/L,,3.8,9.72,-2.8,OCCOC(=O)C1=CC=CC=C1O,,,,,0,,182.0579088,1,1,0,0,0,0
7518,04/06/2019 00:00,DB11324,Nonivamide,,,About 7 minutes [F31].,,Topical,,Soluble in water (slightly),,0.0233,9.93,-0.52,CCCCCCCCC(=O)NCC1=CC(OC)=C(O)C=C1,,,,,0,,293.1990937,1,1,0,0,0,0
7519,04/06/2019 00:00,DB11327,Dipyrithione,,,,,Topical,,,2.32,0.0511,,0.55,[O-][N+]1=CC=CC=C1SSC1=CC=CC=[N+]1[O-],,,,,0,,252.0027195,2,2,2,2,0,0
7520,04/06/2019 00:00,DB11328,Tetradecyl hydrogen sulfate (ester),,,,10 mg/1mL,Intravenous,,,,0.0104,-1.1,,CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O,,,,,0,,294.1864804,0,0,0,0,0,0
7521,04/06/2019 00:00,DB11331,1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)),,,,,Endotracheal,,,,0.000102,1.89,-3,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC,,,,,0,,748.5254353,0,0,0,0,0,0
7522,04/06/2019 00:00,DB11332,Sinapultide," Administered directly to the lung, where biophysical effects occur at the terminal airways and alveolar surface. No human pharmacokinetic studies have been done to characterize the absorption, distribution, metabolism, or elimination of this drug [L2507].",,,,Endotracheal,,,,0.00967,3.08,,[H][C@](N)(CCCCN)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCCN)C(O)=O,,,,,0,,2467.830403,0,0,0,0,0,0
7523,04/06/2019 00:00,DB11335,Ascorbyl glucoside,,,,,Topical,,,,168,4.14,-3,OC[C@H](O)[C@H]1OC(=O)C(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)=C1O,,,,,0,,338.0849114,2,0,2,0,1,2
7524,04/06/2019 00:00,DB11336,Kinetin,,,,,Topical,,,,0.94,10.2,5.16,C(NC1=NC=NC2=C1NC=N2)C1=CC=CO1,,,,,0,,215.0807099,3,3,3,3,0,0
7525,04/06/2019 00:00,DB11337,Zeatin,,,,,Topical,,,,0.283,10.21,3.46,C\C(CO)=C/CNC1=C2N=CNC2=NC=N1,,,,,0,,219.11201,2,2,2,2,0,0
7526,04/06/2019 00:00,DB11340,Ubiquinol,,,,,Oral,,,,0.000233,10.27,-4.7,COC1=C(OC)C(O)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(C)=C1O,,,,,0,,864.6995614,1,1,0,0,0,0
7527,04/06/2019 00:00,DB11344,(+)-menthol,,,,,Topical,,,,0.558,19.55,-0.81,CC(C)[C@H]1CC[C@H](C)C[C@@H]1O,,,,,0,,156.1514153,1,0,0,0,0,0
7528,04/06/2019 00:00,DB11345,(S)-camphor,"Absorption of camphor in the mucous membranes and the gastrointestinal tract is rapid, and peak concentration following oral ingestion occurs within 5 to 90 minutes [L2805]. ",,"Following oral ingestion of 200 mg camphor, the half life was 167 minutes [L2805]. ",,Topical,solid,,,0.88,,-7.5,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2,,,,,0,,152.1201151,2,0,0,0,0,0
7529,04/06/2019 00:00,DB11359,Guaiacol,"In rats, guaiacol is rapidly absorbed, being present in the blood 5 minutes after oral administration, and reaching its peak plasma concentration in about 10 minutes. Its elimination from the blood is usually as rapid.",,,,Rectal,,,,67.4,9.98,-4.9,COC1=C(O)C=CC=C1,,,,,0,,124.0524295,1,1,0,0,0,0
7530,02/07/2019 00:00,DB11362,Selexipag,"After oral administration, maximum concentrations of selexipag and its metabolite were observed to be reached at 1-3 and 3-4 hours, respectively. Absorption was impaired in the presence of food, resulting in delayed time to maximum concentration as well as ~30% lower peak plasma concentration. However, exposure was not found to be significantly affected by food.",,Selexipag's terminal half life is 0.8-2.5 hours. The active metabolite's terminal half life is 6.2-13.5 hours. ,1000 mcg,Oral,solid,,,0.00434,3.77,1.41,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1,,,,,0,1,496.2144265,3,3,1,1,0,0
7531,02/07/2019 00:00,DB11363,Alectinib,"Alectinib reached maximal concentrations at 4 hours following administration of 600 mg twice daily under fed conditions in patients with ALK-positive NSCLC. The absolute bioavailability was 37% in the fed state. A high-fat, high-calorie meal increased the combined exposure of alectinib and its major metabolite M4 by 3.1-fold following oral administration of a single 600 mg dose. ",>99%,The mean elimination half life is 33 hr for alectinib and 31 hr for M4. ,150 mg/1,Oral,solid,,,0.0105,12.18,6.97,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=C(N1)C=C(C=C3)C#N)C2=O,0.99,1,,,0,150,482.2681763,6,3,3,1,2,2
7532,04/06/2019 00:00,DB11364,Pidotimod,Bioavailability of 45% [L929].,,Half life of 4 h [L929].,,,solid,,,19.5,3.57,-2.2,OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1,,,,,0,,244.0517779,2,0,2,0,2,2
7533,04/06/2019 00:00,DB11366,Roquinimex,,,,,,solid,,,0.123,6.03,-2.4,CN(C(=O)C1=C(O)C2=C(C=CC=C2)N(C)C1=O)C1=CC=CC=C1,,,,,0,,308.1160924,3,3,1,1,0,0
7534,04/06/2019 00:00,DB11367,Cefroxadine,Oral bioavailability of 90% [A20320].,0.1,The serum half life is 0.9-1.1 h [A20320]. ,,,solid,,,0.987,3.28,7.6,[H][C@]12SCC(OC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CCC=CC1)C(O)=O,0.1,0.1,,,0,,365.1045417,3,0,2,0,1,2
7535,04/06/2019 00:00,DB11368,Chlorophetanol,,,,,,solid,,,5.2,15.1,-2.8,OCCOC1=CC=C(Cl)C=C1,,,,,0,,172.0291072,1,1,0,0,0,0
7536,04/06/2019 00:00,DB11371,Alfaxalone,,,,,,,,,0.0242,18.3,-1.4,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C(=O)C[C@]12C)C(C)=O,,,,,0,,332.2351449,4,0,0,0,0,0
7537,04/06/2019 00:00,DB11372,Altrenogest,,,,,,,,,0.0301,18.4,-0.18,[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H],,,,,0,,310.1932801,4,0,0,0,0,0
7538,04/06/2019 00:00,DB11373,Amitraz,,,,,,,,,0.000647,,8.83,CN(\C=N\C1=C(C)C=C(C)C=C1)\C=N\C1=C(C)C=C(C)C=C1,,,,,0,,293.1891977,2,2,0,0,0,0
7539,04/06/2019 00:00,DB11376,Azaperone,,,,,,,,,0.23,16.4,7.16,FC1=CC=C(C=C1)C(=O)CCCN1CCN(CC1)C1=CC=CC=N1,,,,,0,,327.1746905,3,2,2,1,1,1
7540,04/06/2019 00:00,DB11377,Bambermycins,,,,,,,,,0.12,-3.5,11.07,[H]\C(CC\C(C)=C(/[H])CCOC(=O)[C@]([H])(O)COP(O)(=O)O[C@@]1([H])O[C@]([H])(C(O)=O)[C@@](C)(O)[C@]([H])(OC(O)=N)[C@@]1([H])O[C@]1([H])O[C@]([H])(CO[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)[C@@]([H])(O[C@]2([H])O[C@]([H])(C)[C@@]([H])(O[C@]3([H])O[C@]([H])(C(O)=NC4=C(O)CCC4=O)[C@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])N=C(C)O)[C@]([H])(O)[C@@]1([H])N=C(C)O)=C(\[H])C(C)(C)CCC(=C)C\C([H])=C(/C)CCC=C(C)C,,,,,0,,1596.660998,6,0,5,0,5,5
7541,04/06/2019 00:00,DB11378,Buquinolate,,,,,,,,,0.0136,5.95,-1.6,CCOC(=O)C1=CNC2=CC(OCC(C)C)=C(OCC(C)C)C=C2C1=O,,,,,0,,361.188923,2,2,1,1,0,0
7542,04/06/2019 00:00,DB11379,Butonate,,,,,,,,,2.79,,-7.1,CCCC(=O)OC(C(Cl)(Cl)Cl)P(=O)(OC)OC,,,,,0,,325.9644432,0,0,0,0,0,0
7543,04/06/2019 00:00,DB11380,Cambendazole,,,,,,,,,0.0211,10.21,3.93,CC(C)OC(=O)NC1=CC2=C(NC(=N2)C2=CSC=N2)C=C1,,,,,0,,302.0837467,3,3,2,2,0,0
7544,04/06/2019 00:00,DB11383,Carbomycin,,,,,,,,,0.115,12.66,7.2,[H]\C1=C([H])/[C@]2([H])O[C@@]2([H])C[C@@]([H])(C)OC(=O)C[C@@]([H])(OC(C)=O)[C@]([H])(OC)[C@@]([H])(O[C@]2([H])O[C@]([H])(C)[C@@]([H])(O[C@@]3([H])C[C@@](C)(O)[C@@]([H])(OC(=O)CC(C)C)[C@]([H])(C)O3)[C@]([H])(N(C)C)[C@@]2([H])O)[C@@]([H])(CC=O)C[C@@]([H])(C)C1=O,,,,,0,,841.4459851,4,0,4,0,3,4
7545,04/06/2019 00:00,DB11385,Cefalonium,,,,,,,,,0.00345,2.89,-0.85,[H][C@]12SCC(C[N+]3=CC=C(C=C3)C(N)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C([O-])=O,,,,,0,,458.0718617,4,2,4,2,1,2
7546,04/06/2019 00:00,DB11386,Chlorobutanol,"Following oral administration in healthy subjects, the plasma concentration fell by 50% in 24 hours post-administration [A32743].",0.03,"Following oral administration, the terminal elimination half life in healthy subjects was 10.3 Â± 1.3 days [A32743]. ",,Auricular (otic),solid,,,1.65,12.59,-3.9,CC(C)(O)C(Cl)(Cl)Cl,0.03,0.03,,,0,,175.9562479,0,0,0,0,0,0
7547,04/06/2019 00:00,DB11387,Chloroform,,,,,,,,,6.95,,,ClC(Cl)Cl,,,,,0,,117.9143831,0,0,0,0,0,0
7548,04/06/2019 00:00,DB11389,Clorsulon,,,,,,,,,0.086,9.61,-0.86,NC1=C(C=C(C(=C1)C(Cl)=C(Cl)Cl)S(N)(=O)=O)S(N)(=O)=O,,,,,0,,378.9021808,1,1,0,0,0,0
7549,04/06/2019 00:00,DB11390,Coumaphos,,,,,,,,,0.00148,,-7.3,CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(C)=C(Cl)C(=O)O2,,,,,0,,362.0144589,2,2,1,1,0,0
7550,04/06/2019 00:00,DB11392,Cythioate,,,,,,,,,0.488,10.27,,COP(=S)(OC)OC1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,296.9894511,1,1,0,0,0,0
7551,04/06/2019 00:00,DB11393,Danofloxacin,,,,,,,,,0.738,5.65,6.73,[H][C@]12CN(C3=C(F)C=C4C(=O)C(=CN(C5CC5)C4=C3)C(O)=O)[C@]([H])(CN1C)C2,,,,,0,,357.1488697,5,2,3,1,2,2
7552,04/06/2019 00:00,DB11394,Decoquinate,,,,,,,,,0.000679,5.95,-1.5,CCCCCCCCCCOC1=C(OCC)C=C2NC=C(C(=O)OCC)C(=O)C2=C1,,,,,0,,417.2515232,2,2,1,1,0,0
7553,04/06/2019 00:00,DB11395,Deracoxib,,,,,,,,,0.0104,10.7,0.68,COC1=C(F)C=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)F,,,,,0,,397.070797,3,3,1,1,0,0
7554,04/06/2019 00:00,DB11396,Dichlorophen,,,,,,,,,0.0309,7.22,-6.3,OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O,,,,,0,,268.0057849,2,2,0,0,0,0
7555,04/06/2019 00:00,DB11397,Dichlorvos,,,,,,,,,9.77,,-9.1,COP(=O)(OC)OC=C(Cl)Cl,,,,,0,,219.9459007,0,0,0,0,0,0
7556,04/06/2019 00:00,DB11398,Diclazuril,,,,,,,,,0.0035,3.24,-9.1,OC1=NC(=O)N(N=C1)C1=CC(Cl)=C(C(C#N)C2=CC=C(Cl)C=C2)C(Cl)=C1,,,,,0,,405.9791086,3,3,1,1,0,0
7557,04/06/2019 00:00,DB11399,Dirlotapide,,,,,,,,,9.05E-05,8.92,0.85,CN(CC1=CC=CC=C1)C(=O)[C@@H](NC(=O)C1=CC2=C(C=CC(NC(=O)C3=CC=CC=C3C3=CC=C(C=C3)C(F)(F)F)=C2)N1C)C1=CC=CC=C1,,,,,0,,674.2504756,6,6,1,1,0,0
7558,04/06/2019 00:00,DB11400,Doramectin,,,,,,,,,0.00599,12.47,-3.4,[H]\C1=C(C)/[C@@]([H])(O[C@@]2([H])C[C@]([H])(OC)[C@@]([H])(O[C@@]3([H])C[C@]([H])(OC)[C@@]([H])(O)[C@]([H])(C)O3)[C@]([H])(C)O2)[C@@]([H])(C)\C([H])=C(/[H])\C(\[H])=C2/CO[C@]3([H])[C@]([H])(O)C(C)=C[C@@]([H])(C(=O)O[C@@]4([H])C[C@@]([H])(C1)O[C@@]1(C4)O[C@]([H])(C4CCCCC4)[C@@]([H])(C)C=C1)[C@]23O,,,,,0,,898.507857,8,0,6,0,4,6
7559,04/06/2019 00:00,DB11401,Efrotomycin,,,,,,,,,0.0166,4.97,2.96,[H]\C(C)=C(\[H])/C(/[H])=C(\[H])C1OC(O)(C(CC)C(O)=NC\C([H])=C(/[H])\C(\[H])=C(/C)C(OC)C(C)C2OC(\C([H])=C(/[H])\C(\[H])=C(/[H])C([H])=C(C)C(\O)=C3\C(=O)C=CN(C)C3=O)C(O)C2O)C(O)C(OC2OC(C)C(OC3OC(C)C(OC)C(O)C3OC)C(OC)C2O)C1(C)C,,,,,0,,1144.593043,5,0,5,0,4,5
7560,04/06/2019 00:00,DB11403,Emodepside,,,,,,,,,0.00277,18.28,1.63,[H][C@]1(C)OC(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@]([H])(CC2=CC=C(C=C2)N2CCOCC2)OC(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@]([H])(C)OC(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@]([H])(CC2=CC=C(C=C2)N2CCOCC2)OC(=O)[C@]([H])(CC(C)C)N(C)C1=O,,,,,0,,1118.651502,5,2,3,0,3,3
7561,04/06/2019 00:00,DB11405,Eprinomectin,,,,,,,,,0.00462,5.74,2.64,[H]\C1=C(C)/[C@@]([H])(O[C@@]2([H])C[C@]([H])(OC)[C@@]([H])(O[C@@]3([H])C[C@]([H])(OC)[C@]([H])(N=C(C)O)[C@]([H])(C)O3)[C@]([H])(C)O2)[C@@]([H])(C)\C([H])=C(/[H])\C(\[H])=C2/CO[C@]3([H])[C@]([H])(O)C(C)=C[C@@]([H])(C(=O)O[C@@]4([H])C[C@@]([H])(C1)O[C@@]1(C4)O[C@]([H])(C(C)C)[C@@]([H])(C)C=C1)[C@]23O.[H]\C1=C(C)/[C@@]([H])(O[C@@]2([H])C[C@]([H])(OC)[C@@]([H])(O[C@@]3([H])C[C@]([H])(OC)[C@]([H])(N=C(C)O)[C@]([H])(C)O3)[C@]([H])(C)O2)[C@@]([H])(C)\C([H])=C(/[H])\C(\[H])=C2/CO[C@]3([H])[C@]([H])(O)C(C)=C[C@@]([H])(C(=O)O[C@@]4([H])C[C@@]([H])(C1)O[C@@]1(C4)O[C@]([H])([C@@]([H])(C)CC)[C@@]([H])(C)C=C1)[C@]23O,,,,,0,,1813.021862,14,0,12,0,8,12
7562,04/06/2019 00:00,DB11408,Famphur,,,,,,,,,0.229,,,COP(=S)(OC)OC1=CC=C(C=C1)S(=O)(=O)N(C)C,,,,,0,,325.0207512,1,1,0,0,0,0
7563,04/06/2019 00:00,DB11409,Febantel,,,,,,,,,0.0052,9.48,-2.6,COCC(=O)NC1=C(C=CC(SC2=CC=CC=C2)=C1)N=C(NC(=O)OC)NC(=O)OC,,,,,0,,446.1260054,2,2,0,0,0,0
7564,04/06/2019 00:00,DB11410,Fenbendazole,,,,,,,,,0.00609,9.59,4.06,COC(=O)NC1=NC2=C(N1)C=CC(SC1=CC=CC=C1)=C2,,,,,0,,299.0728477,3,3,1,1,0,0
7565,04/06/2019 00:00,DB11411,Fenprostalene,,,,,,,,,0.0164,13.95,-2.9,COC(=O)CCC=C=CC[C@@H]1[C@H](O)C[C@H](O)[C@H]1\C=C\[C@H](O)COC1=CC=CC=C1,,,,,0,,402.2042387,2,1,0,0,0,0
7566,04/06/2019 00:00,DB11412,Fenthion,,,,,,,,,0.0042,,,COP(=S)(OC)OC1=CC=C(SC)C(C)=C1,,,,,0,,278.020023,1,1,0,0,0,0
7567,04/06/2019 00:00,DB11413,Florfenicol,,,,,,,,,0.219,8.49,-3.4,CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl,,,,,0,,357.0004625,1,1,0,0,0,0
7568,04/06/2019 00:00,DB11416,Gamithromycin,,,,,,,,,0.294,12.46,9.95,[H][C@@]1(C)C[C@]([H])(N(C)C)[C@@]([H])(O)[C@]([H])(O[C@]2([H])[C@@]([H])(C)[C@]([H])(O[C@@]3([H])C[C@@](C)(OC)[C@@]([H])(O)[C@]([H])(C)O3)[C@@]([H])(C)C(=O)O[C@]([H])(CC)[C@@](C)(O)[C@]([H])(O)[C@@]([H])(C)CN(CCC)[C@]([H])(C)C[C@@]2(C)O)O1,,,,,0,,776.5398259,3,0,3,0,3,3
7569,04/06/2019 00:00,DB11417,Gleptoferron,,,,,,,,,351,3.23,-3.6,[Fe+].OO.[H]C(O)(CO[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O)C([H])(O)C([H])(O)C([H])(O)C([H])(O)C([O-])=O,,,,,0,,477.0542826,1,0,1,0,1,1
7570,04/06/2019 00:00,DB11419,Haloxon,,,,,,,,,0.0206,,-7.3,CC1=C(Cl)C(=O)OC2=C1C=CC(OP(=O)(OCCCl)OCCCl)=C2,,,,,0,,413.9593578,2,2,1,1,0,0
7571,04/06/2019 00:00,DB11420,Squalane,,,,,Topical,,,,3.74E-06,,,CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C,,,,,0,,422.485152,0,0,0,0,0,0
7572,04/06/2019 00:00,DB11421,Imidacloprid,,,,,,,,,0.346,9.39,5.28,[O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1,,,,,0,,255.0523022,2,1,2,1,1,1
7573,04/06/2019 00:00,DB11423,Lasalocid,,,,,,,,,0.00432,2.64,-3,[H][C@@](C)(CCC1=C(C(O)=O)C(O)=C(C)C=C1)[C@]([H])(O)[C@]([H])(C)C(=O)[C@]([H])(CC)[C@@]1([H])O[C@@](CC)(C[C@]1([H])C)[C@@]1([H])CC[C@](O)(CC)[C@]([H])(C)O1,,,,,0,,590.3818687,3,1,2,0,2,2
7574,04/06/2019 00:00,DB11424,Lufenuron,,,,,,,,,0.00139,9.02,-5.2,FC(C(F)(F)F)C(F)(F)OC1=C(Cl)C=C(NC(=O)NC(=O)C2=C(F)C=CC=C2F)C(Cl)=C1,,,,,0,,509.9784232,2,2,0,0,0,0
7575,04/06/2019 00:00,DB11425,Luprostiol,,,,,,,,,0.0229,4.31,-2.9,O[C@H](COC1=CC(Cl)=CC=C1)CS[C@@H]1[C@@H](O)C[C@@H](O)[C@H]1C\C=C/CCCC(O)=O,,,,,0,,444.1373373,2,1,0,0,0,0
7576,04/06/2019 00:00,DB11426,Marbofloxacin,,,,,,,,,2.6,5.38,6.16,CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN3N(C)COC1=C23)C(O)=O,,,,,0,,362.1390333,4,2,3,1,1,2
7577,04/06/2019 00:00,DB11427,Maropitant,,,,,,,,,6.27E-05,,9.43,[H][C@]1(NCC2=CC(=CC=C2OC)C(C)(C)C)C2CCN(CC2)[C@@]1([H])C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,468.3140639,6,3,3,0,3,3
7578,04/06/2019 00:00,DB11428,Medetomidine,,,,,,,,,0.185,13.13,7.07,CC(C1=CN=CN1)C1=CC=CC(C)=C1C,,,,,0,,200.1313485,2,2,1,1,0,0
7579,04/06/2019 00:00,DB11429,Mibolerone,,,,,,,,,0.0194,18.34,-0.53,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H],,,,,0,,302.2245802,4,0,0,0,0,0
7580,04/06/2019 00:00,DB11430,Monensin,,,,,,,,,0.00633,4.24,-2.9,[H][C@@]1(C[C@H](C)[C@@]([H])(O1)[C@]1(CC)CC[C@@]([H])(O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@]([H])(O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)[C@@]1([H])O[C@@](O)(CO)[C@H](C)C[C@@H]1C,,,,,0,,670.4292128,5,0,5,0,5,5
7581,04/06/2019 00:00,DB11431,Moxidectin,"The penetration of moxidectin in the parasite is not restricted as this compound is a very poor substrate of p-glycoprotein, which is vital for the reduction of the uptake of lipophilic compounds from the GI tract and for the increase in biliary, intestinal and renal secretion. After oral administration of moxidectin, the plasma maximal concentration of 70.4 mg/kg was reached after 0.37 day with a reported AUC of 363.6 mcg/day/ml.[A33385] It is also important to mention that oral bioavailability is enhanced with the co-administration with lipids.[T237]",,Moxidectin reporter terminal half-life is 20.2 days.[A33398],,,solid,Insoluble,6,0.0052,12.55,2.81,[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O,,,,,0,,639.3771177,5,0,4,0,3,4
7582,04/06/2019 00:00,DB11432,Narasin,,,,,,,,,0.00241,4.5,-3,[H][C@@]1(CC[C@](O)(CC)[C@H](C)O1)[C@]1(C)CC[C@]2(O1)O[C@@]1(O[C@]([H])([C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@]3([H])O[C@@]([H])([C@@H](CC)C(O)=O)[C@@H](C)C[C@@H]3C)[C@@H](C)C[C@H]1C)C=C[C@H]2O,,,,,0,,764.5074631,5,0,5,0,4,5
7583,04/06/2019 00:00,DB11433,Nequinate,,,,,,,,,0.000763,6.15,-1.8,CCCCC1=CC2=C(NC=C(C(=O)OC)C2=O)C=C1OCC1=CC=CC=C1,,,,,0,,365.1627082,3,3,1,1,0,0
7584,04/06/2019 00:00,DB11436,Nifurpirinol,,,,,,,,,0.0919,14.22,4.16,[H]\C(=C(\[H])C1=NC(CO)=CC=C1)C1=CC=C(O1)[N+]([O-])=O,,,,,0,,246.0640568,2,2,2,2,0,0
7585,04/06/2019 00:00,DB11437,Nitarsone,,,,,,,,,3.83,3.2,,O[As](O)(=O)C1=CC=C(C=C1)N(=O)=O,,,,,0,,246.9461938,1,1,0,0,0,0
7586,04/06/2019 00:00,DB11438,Nitenpyram,,,,,,,,,0.317,,3.5,[H]C(=C(NC)N(CC)CC1=CN=C(Cl)C=C1)N(=O)=O,,,,,0,,270.0883534,1,1,1,1,0,0
7587,04/06/2019 00:00,DB11440,Norgestomet,,,,,,,,,0.00489,17.68,-4.7,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)C[C@H](C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],,,,,0,,372.2300595,4,0,0,0,0,0
7588,04/06/2019 00:00,DB11442,Oleandomycin,,,,,,,,,0.407,12.67,9,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1O,,,,,0,,687.4193764,4,0,4,0,4,4
7589,04/06/2019 00:00,DB11443,Orbifloxacin,,,,,,,,,0.0254,5.49,8.77,[H][C@]1(C)CN(C[C@@]([H])(C)N1)C1=C(F)C(F)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O,,,,,0,,395.1456762,4,2,2,1,1,1
7590,04/06/2019 00:00,DB11446,Oxfendazole,,,,,,,,,0.387,9.26,3.57,COC(=O)NC1=NC2=CC(=CC=C2N1)S(=O)C1=CC=CC=C1,,,,,0,,315.0677623,3,3,1,1,0,0
7591,04/06/2019 00:00,DB11447,Phenothiazine,,,,,,,,,0.39,17.91,-0.95,N1C2=CC=CC=C2SC2=CC=CC=C12,,,,,0,,199.0455703,3,2,1,0,0,1
7592,04/06/2019 00:00,DB11448,Phosmet,,,,,,,,,0.0443,,-7.1,COP(=S)(OC)SCN1C(=O)C2=CC=CC=C2C1=O,,,,,0,,316.9945365,2,1,1,0,0,1
7593,04/06/2019 00:00,DB11449,Phthalofyne,,,,,,,,,0.0232,3.08,-7,CCC(C)(OC(=O)C1=CC=CC=C1C(O)=O)C#C,,,,,0,,246.0892089,1,1,0,0,0,0
7594,04/06/2019 00:00,DB11450,Pimobendan,,,,1 g/1g,Not applicable,,,,0.0113,5.23,4.51,COC1=CC=C(C=C1)C1=NC2=C(N1)C=CC(=C2)C1=NN=C(O)CC1C,,,,,0,,334.1429758,4,3,2,1,0,1
7595,04/06/2019 00:00,DB11454,Prostalene,,,,,,,,,0.0288,14.51,-1.3,CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=C=CCCC(=O)OC,,,,,0,,380.2562743,1,0,0,0,0,0
7596,04/06/2019 00:00,DB11455,Robenacoxib,,,,,,,,,0.00411,3.65,-2.5,CCC1=CC(CC(O)=O)=C(NC2=C(F)C(F)=CC(F)=C2F)C=C1,,,,,0,,327.0882415,2,2,0,0,0,0
7597,04/06/2019 00:00,DB11456,Ronnel,,,,,,,,,0.000927,,,COP(=S)(OC)OC1=CC(Cl)=C(Cl)C=C1Cl,,,,,0,,319.8997348,1,1,0,0,0,0
7598,04/06/2019 00:00,DB11457,Rotenone,,,,,,,,,0.0129,11.8,-4.2,[H][C@@]12COC3=C(C=C(OC)C(OC)=C3)[C@]1([H])C(=O)C1=CC=C3O[C@H](CC3=C1O2)C(C)=C,,,,,0,,394.1416384,5,2,3,0,0,3
7599,04/06/2019 00:00,DB11458,Roxarsone,,,,,,,,,3.86,3.43,-6.8,OC1=C(C=C(C=C1)[As](O)(O)=O)N(=O)=O,,,,,0,,262.9411084,1,1,0,0,0,0
7600,04/06/2019 00:00,DB11459,Selamectin,,,,,,,,,0.00425,9.58,-3.6,[H]\C1=C(C)/[C@@]([H])(O[C@@]2([H])C[C@]([H])(OC)[C@@]([H])(O)[C@]([H])(C)O2)[C@@]([H])(C)\C([H])=C(/[H])\C(\[H])=C2/CO[C@]3([H])\C(=N/O)C(C)=C[C@@]([H])(C(=O)O[C@@]4([H])C[C@@]([H])(C1)O[C@@]1(CC[C@]([H])(C)[C@]([H])(O1)C1CCCCC1)C4)[C@]23O,,,,,0,,769.4401118,7,0,5,0,4,5
7601,04/06/2019 00:00,DB11460,Squalene,,,,,,,,,0.000502,,,CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C,,,,,0,,410.3912516,0,0,0,0,0,0
7602,04/06/2019 00:00,DB11461,Sulfachlorpyridazine,,,,,,,,,0.133,6.6,2.02,NC1=CC=C(C=C1)S(=O)(=O)NC1=NN=C(Cl)C=C1,,,,,0,,284.0134742,2,2,1,1,0,0
7603,04/06/2019 00:00,DB11462,Sulfaethoxypyridazine,,,,,,,,,0.221,6.84,2.02,CCOC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1,,,,,0,,294.0786613,2,2,1,1,0,0
7604,04/06/2019 00:00,DB11463,Sulfanitran,,,,,,,,,0.0343,7.44,-4.4,CC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,335.0575915,2,2,0,0,0,0
7605,04/06/2019 00:00,DB11464,Sulfaquinoxaline,,,,,,,,,0.0761,6.79,2.13,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC2=C(C=CC=C2)N=C1,,,,,0,,300.0680966,3,3,1,1,0,0
7606,04/06/2019 00:00,DB11466,Tepoxalin,,,,,,,,,0.00375,8.53,1.31,COC1=CC=C(C=C1)N1N=C(CCC(=O)N(C)O)C=C1C1=CC=C(Cl)C=C1,,,,,0,,385.1193192,3,3,1,1,0,0
7607,04/06/2019 00:00,DB11467,Thiostrepton,,,,,,,,,0.032,2.28,,[H]\C(C)=C1/N=C(O)C(N=C(O)C2=CSC(=N2)C23CCC(=NC2C2=CSC(=N2)C(N=C(O)C2=CSC(=N2)C(N=C(O)C2CSC1=N2)C(C)(O)C(C)O)C(C)OC(=O)C1=NC2=C(C=CC(NC(C(C)CC)C(O)=NC(C)C(O)=NC(=C)C(O)=NC(C)C(O)=N3)C2O)C(=C1)C(C)O)C1=NC(=CS1)C(O)=NC(=C)C(O)=NC(=C)C(O)=N)C(C)O,,,,,0,,1663.492352,10,5,9,5,0,4
7608,04/06/2019 00:00,DB11468,Tiamulin,,,,,,,,,0.000524,14.43,9.51,[H][C@@]12C(=O)CC[C@]11CC[C@@]([H])(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CSCCN(CC)CC,,,,,0,,493.32258,3,0,0,0,0,0
7609,04/06/2019 00:00,DB11470,Tildipirosin,,,,,,,,,0.0548,12.68,9.46,[H]\C1=C([H])/C(=O)[C@]([H])(C)C[C@]([H])(CCN2CCCCC2)[C@]([H])(O[C@]2([H])O[C@]([H])(C)[C@@]([H])(O)[C@]([H])(N(C)C)[C@@]2([H])O)[C@@]([H])(C)[C@]([H])(O)CC(=O)O[C@]([H])(CC)[C@@]([H])(CN2CCCCC2)C([H])=C1C,,,,,0,,733.5241162,4,0,4,0,3,4
7610,04/06/2019 00:00,DB11471,Tilmicosin,,,,,,,,,0.0484,12.55,10.16,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC,,,,,0,,868.5660406,4,0,4,0,3,4
7611,04/06/2019 00:00,DB11472,Tioxidazole,,,,,,,,,0.0403,12.11,1.36,CCCOC1=CC=C2N=C(NC(=O)OC)SC2=C1,,,,,0,,266.0725133,2,2,1,1,0,0
7612,04/06/2019 00:00,DB11473,Metrifonate,,,,,,,,,7.17,10.12,-4.9,COP(=O)(OC)C(O)C(Cl)(Cl)Cl,,,,,0,,255.9225784,0,0,0,0,0,0
7613,04/06/2019 00:00,DB11475,Tylosin,,,,,,,,,0.211,12.45,7.2,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC,,,,,0,,915.51915,4,0,4,0,3,4
7614,04/06/2019 00:00,DB11476,Virginiamycin,,,,100 kg/100kg,Not applicable,,,,0.0436,3.16,2.21,[H]\C1=C(/[H])\C(\C)=C([H])/C(O)CC(=O)CC2=NC(=CO2)C(=O)N2CCC=C2C(=O)OC(C(C)C)C(C)\C([H])=C([H])/C(O)=NC1.CCC1N=C(O)C(N=C(O)C2=C(O)C=CC=N2)C(C)OC(=O)C(N=C(O)C2CC(=O)CCN2C(=O)C(CC2=CC=CC=C2)N(C)C(=O)C2CCCN2C1=O)C1=CC=CC=C1,,,,,0,,1348.601591,9,4,7,2,2,5
7615,04/06/2019 00:00,DB11477,Xylazine,,,,,,,,,0.261,,6.94,CC1=CC=CC(C)=C1NC1=NCCCS1,,,,,0,,220.1034195,2,1,1,0,0,1
7616,04/06/2019 00:00,DB11478,Zeranol,,,,,,,,,0.164,8.68,-1.3,C[C@H]1CCC[C@H](O)CCCCCC2=CC(O)=CC(O)=C2C(=O)O1,,,,,0,,322.1780239,2,1,1,0,0,1
7617,04/06/2019 00:00,DB11479,Zilpaterol,,,,,,,,,2.01,12.8,9.14,CC(C)N[C@@H]1CCN2C(=O)NC3=CC=CC([C@H]1O)=C23,,,,,0,,261.1477268,3,2,2,1,0,1
7618,04/06/2019 00:00,DB11480,Zoalene,,,,,,,,,0.109,12.37,-0.85,CC1=C(C=C(C=C1C(N)=O)[N+]([O-])=O)[N+]([O-])=O,,,,,0,,225.0385703,1,1,0,0,0,0
7619,04/06/2019 00:00,DB11481,Atipamezole,,,,,,solid,,,0.0706,13.33,7.2,CCC1(CC2=CC=CC=C2C1)C1=CN=CN1,,,,,0,,212.1313485,3,2,1,1,0,0
7620,04/06/2019 00:00,DB11485,Ceftiofur,,,,,,solid,,,0.105,2.83,4.19,[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,,,,,0,,523.0290109,4,2,4,2,1,2
7621,04/06/2019 00:00,DB11487,Dexamethasone isonicotinate,,,,,,solid,,,0.0254,12.44,3.41,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=NC=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,497.221366,5,1,1,1,0,0
7622,04/06/2019 00:00,DB11490,Nalorphine,,,,,,solid,,,1.36,10.2,8.81,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC=C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,,,,,0,,311.1521435,5,1,2,0,1,2
7623,04/06/2019 00:00,DB11491,Sarafloxacin,,,,,,solid,,,0.105,5.74,8.68,OC(=O)C1=CN(C2=CC=C(F)C=C2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O,,,,,0,,385.1237978,4,3,2,1,1,1
7624,04/06/2019 00:00,DB11495,(S)-methoprene,,,,,,,,,0.00307,,-4.1,[H]\C(C[C@@]([H])(C)CCCC(C)(C)OC)=C(\[H])/C(/C)=C(\[H])C(=O)OC(C)C,,,,,0,,310.2507949,0,0,0,0,0,0
7625,04/06/2019 00:00,DB11496,2-mercaptobenzothiazole,,,,,,,,,0.118,10.9,-2.2,S=C1NC2=C(S1)C=CC=C2,,,,,0,,166.9863412,2,2,1,1,0,0
7626,04/06/2019 00:00,DB11502,Butacaine,,,,,,,,,0.0424,,10.55,CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1,,,,,0,,306.2307282,1,1,0,0,0,0
7627,04/06/2019 00:00,DB11507,Cloprostenol,,,,,,,,,0.0337,4.36,-2.9,[H]\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@@]([H])(O)C[C@@]([H])(O)[C@]1([H])C(\[H])=C(/[H])[C@@]([H])(O)COC1=CC=CC(Cl)=C1,,,,,0,,424.1652663,2,1,0,0,0,0
7628,04/06/2019 00:00,DB11510,Deslorelin,,,,,,,,,0.0238,2.8,11.9,[H][C@@](CO)(N=C(O)[C@]([H])(CC1=CNC2=CC=CC=C12)N=C(O)[C@]([H])(CC1=CN=CN1)N=C(O)[C@]1([H])CCC(O)=N1)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(O)=N[C@]([H])(CC1=CNC2=CC=CC=C12)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCNC(N)=N)C(=O)N1CCC[C@@]1([H])C(O)=NCC,,,,,0,,1281.640711,8,6,5,3,1,2
7629,04/06/2019 00:00,DB11511,Difloxacin,,,,,,,,,0.126,5.64,6.45,CN1CCN(CC1)C1=C(F)C=C2C(=C1)N(C=C(C(O)=O)C2=O)C1=CC=C(F)C=C1,,,,,0,,399.1394479,4,3,2,1,1,1
7630,04/06/2019 00:00,DB11512,Dihydrostreptomycin,,,,,,,,,16,12.11,11.31,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO,,,,,0,,583.2813198,3,0,2,0,2,2
7631,04/06/2019 00:00,DB11518,Flunixin,,,,,,,,,0.0402,1.88,5.38,CC1=C(C=CC=C1NC1=C(C=CC=N1)C(O)=O)C(F)(F)F,,,,,0,,296.0772623,2,2,1,1,0,0
7632,04/06/2019 00:00,DB11519,Fluprostenol,,,,,,,,,0.0164,4.36,-2.9,[H]\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@@]([H])(O)C[C@@]([H])(O)[C@]1([H])C(\[H])=C(/[H])[C@@]([H])(O)COC1=CC=CC(=C1)C(F)(F)F,,,,,0,,458.1916233,2,1,0,0,0,0
7633,04/06/2019 00:00,DB11520,Hygromycin B,,,,,,,,,213,11.41,9.55,CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3OC4(O[C@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O,,,,,0,,527.2326382,4,0,3,0,3,3
7634,04/06/2019 00:00,DB11521,Imidocarb,,,,,,,,,0.169,11.38,9.54,O=C(NC1=CC=CC(=C1)C1=NCCN1)NC1=CC=CC(=C1)C1=NCCN1,,,,,0,,348.1698593,4,2,2,0,0,2
7635,04/06/2019 00:00,DB11522,Isoflupredone,,,,,,,,,0.0811,12.55,-3.3,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@]([H])(O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,378.1842522,4,0,0,0,0,0
7636,04/06/2019 00:00,DB11525,Maduramicin,,,,,,,,,0.0157,4.01,-2.9,N.[H][C@@](C)([C@@]1([H])O[C@@]2(CC[C@](C)(O2)[C@@]2([H])CC[C@](C)(O2)[C@]2([H])O[C@]([H])(C[C@]2([H])O[C@]2([H])C[C@]([H])(OC)[C@@]([H])(OC)[C@]([H])(C)O2)[C@@]2([H])O[C@](C)(O)[C@]([H])(C)C[C@]2([H])C)C[C@]([H])(O)[C@@]1([H])C)[C@]1([H])O[C@](O)(CC(O)=O)[C@@]([H])(C)[C@]([H])(OC)[C@@]1([H])OC,,,,,0,,933.5661002,7,0,7,0,7,7
7637,04/06/2019 00:00,DB11526,Masitinib,,,,,,,,,0.012,9.52,8.17,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(N=C3NC(=CS3)C3=CN=CC=C3)=C(C)C=C2)CC1,,,,,0,,498.2201806,5,4,3,2,1,1
7638,04/06/2019 00:00,DB11529,Melengestrol,,,,,,,,,0.00748,12.21,-4,[H][C@@]12CC(=C)[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,,,,,0,,354.2194948,4,0,0,0,0,0
7639,04/06/2019 00:00,DB11537,Pirlimycin,,,,,,,,,0.466,3.26,8.81,[H][C@@](C)(Cl)[C@@]([H])(N=C(O)[C@]1([H])C[C@]([H])(CC)CCN1)[C@@]1([H])O[C@]([H])(SC)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O,,,,,0,,410.1642208,2,0,2,0,2,2
7640,04/06/2019 00:00,DB11540,Propiopromazine,,,,,,,,,0.00538,16.64,8.5,CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN(C)C)C=C1,,,,,0,,340.1609344,3,2,1,0,0,1
7641,04/06/2019 00:00,DB11541,Ractopamine,,,,,,,,,0.0266,9.19,9.89,CC(CCC1=CC=C(O)C=C1)NCC(O)C1=CC=C(O)C=C1,,,,,0,,301.1677936,2,2,0,0,0,0
7642,04/06/2019 00:00,DB11543,Romifidine,,,,,,,,,0.0859,,8.06,FC1=CC=CC(Br)=C1NC1=NCCN1,,,,,0,,256.9963876,2,1,1,0,0,1
7643,04/06/2019 00:00,DB11544,Salinomycin,,,,,,,,,0.00297,4.45,-3,[H][C@@](C)(C(=O)[C@]([H])(CC)[C@@]1([H])O[C@@]2(O[C@@]3(CC[C@](C)(O3)[C@@]3([H])CC[C@](O)(CC)[C@]([H])(C)O3)[C@]([H])(O)C=C2)[C@]([H])(C)C[C@]1([H])C)[C@@]([H])(O)[C@]([H])(C)[C@]1([H])O[C@]([H])(CC[C@]1([H])C)[C@@]([H])(CC)C(O)=O,,,,,0,,750.4918131,5,0,5,0,4,5
7644,11/06/2019 00:00,DB11545,Semduramicin,,,,100 kg/100kg,Not applicable,,,,0.0289,3.95,-2.9,[H][C@@]1(C[C@H](O[C@@]2([H])CC[C@H](OC)[C@@H](C)O2)[C@@]([H])(O1)[C@]1(C)CC[C@@]([H])(O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@]([H])(O2)[C@@H](C)[C@]2([H])O[C@](O)(CC(O)=O)[C@@H](C)[C@H](O)[C@H]2OC)O1)[C@@]1([H])O[C@](C)(O)[C@H](C)C[C@@H]1C,,,,,0,,872.5133364,7,0,7,0,7,7
7645,04/06/2019 00:00,DB11549,Tiletamine,,,,,,,,,0.0965,18.69,7.56,CCNC1(CCCCC1=O)C1=CC=CS1,,,,,0,,223.1030852,2,1,1,1,0,0
7646,04/06/2019 00:00,DB11551,Trenbolone,,,,,,,,,0.0586,18.4,-0.89,[H][C@@]12CC[C@H](O)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H],,,,,0,,270.1619799,4,0,0,0,0,0
7647,04/06/2019 00:00,DB11552,Tricaine,,,,,,,,,2.5,,2.89,CCOC(=O)C1=CC(N)=CC=C1,,,,,0,,165.0789786,1,1,0,0,0,0
7648,04/06/2019 00:00,DB11554,Tylvalosin,,,,,,,,,0.0361,12.57,7.2,[H]\C1=C([H])/C(=O)[C@]([H])(C)C[C@]([H])(CC=O)[C@]([H])(O[C@]2([H])O[C@]([H])(C)[C@@]([H])(O[C@@]3([H])C[C@@](C)(O)[C@@]([H])(OC(=O)CC(C)C)[C@]([H])(C)O3)[C@]([H])(N(C)C)[C@@]2([H])O)[C@@]([H])(C)[C@@]([H])(CC(=O)O[C@]([H])(CC)[C@@]([H])(CO[C@]2([H])O[C@]([H])(C)[C@@]([H])(O)[C@@]([H])(OC)[C@@]2([H])OC)C([H])=C1C)OC(C)=O,,,,,0,,1041.58723,4,0,4,0,3,4
7649,04/06/2019 00:00,DB11555,Zolazepam,,,,,,,,,0.269,,2.79,CN1N=C(C)C2=C1N(C)C(=O)CN=C2C1=CC=CC=C1F,,,,,0,,286.1229893,3,2,2,1,0,1
7650,04/06/2019 00:00,DB11556,Detomidine,,,,,,solid,,,0.655,13.26,7.15,CC1=C(C)C(CC2=CN=CN2)=CC=C1,,,,,0,,186.1156984,2,2,1,1,0,0
7651,04/06/2019 00:00,DB11558,Toluene,,,,,,solid,526 mg/L (at 25 Â°C),2.73,0.508,,,CC1=CC=CC=C1,,,,,0,,92.06260026,1,1,0,0,0,0
7652,04/06/2019 00:00,DB11560,Lesinurad,"Oral lesinurad is rapidly absorbed, reaching maximum plasma concentrations (Cmax) within 1â€“4 h following the administration a single 200 mg dose (in either the fed or fasted state).",,,200 mg/1,Oral,solid,,,0.00779,3.13,-0.05,OC(=O)CSC1=NN=C(Br)N1C1=CC=C(C2CC2)C2=C1C=CC=C2,,,,,0,200,402.9990098,4,3,1,1,0,0
7653,04/06/2019 00:00,DB11561,Aminacrine,,,,,,solid,,,0.0755,,9.29,NC1=C2C=CC=CC2=NC2=C1C=CC=C2,,,,,0,,194.0843983,3,3,1,1,0,0
7654,04/06/2019 00:00,DB11562,Bicuculline,,,,,,solid,,,0.361,14.72,7.43,[H][C@]1(OC(=O)C2=C1C=CC1=C2OCO1)[C@@]1([H])N(C)CCC2=CC3=C(OCO3)C=C12,,,,,0,,367.1055873,6,2,4,0,0,4
7655,02/07/2019 00:00,DB11570,Padimate O,Padimate O is capable of human skin penetration [A32458].,,No pharmacokinetic data available. ,0.027,Topical,liquid,Insoluble,,0.0355,,2.9,CCCCC(CC)COC(=O)C1=CC=C(C=C1)N(C)C,,,,,0,,277.2041791,1,1,0,0,0,0
7656,02/07/2019 00:00,DB11573,Aluminum chlorohydrate,"Penetration of aluminum chlorohydrate following dermal application is minimal, with the rate being around 0.01% and up to 0.06% in pre-damaged skin [A32407]. In a preliminary study, dermally applied aluminium chlorohydrate displayed 0.012% of the applied aluminium being absorbed through the skin, which accounts for 4 mcg of aluminum following a single dermal application [A32406]. This is about 2.5% of the aluminium typically absorbed by the gut from food over the same time period [A32406].",,No pharmacokinetic information available. ,0.25 g/1,Topical,liquid,Soluble,,451,15.7,-1.8,O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-],,,,,0,,191.9561929,0,0,0,0,0,0
7657,04/06/2019 00:00,DB11574,Elbasvir, Elbasvir reaches peak plasma concentration 3-6 hours after administration [FDA Label]. Elbasvir has an absolute bioavailability of 32%. When taken with food the peak concentration of Elbasvir increases 1.5 fold but this increase in exposure has not been deemed clinically relevant.,0.999,The geometric mean apparent terminal half-life for Grazoprevir is 24 hours in HCV-infected subjects [FDA Label].,,Oral,solid,,,0.0044,12.42,5.39,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1,0.999,0.999,,,0,,881.4224451,9,6,6,3,2,3
7658,04/06/2019 00:00,DB11575,Grazoprevir,Grazoprevir reaches peak plasma concentration 0.5-3 hours after administration [FDA Label]. Grazoprevir has an absolute bioavailability of 27%. When taken with food the peak concentration of Grazoprevir increases 2.8 fold but this increase in exposure has not been deemed clinically relevant.,0.988,The geometric mean apparent terminal half-life for Grazoprevir is 31 hours in HCV-infected subjects [FDA Label].,,Oral,solid,,,0.0097,5.31,1.81,[H][C@@]12C[C@@]1([H])OC(O)=N[C@]([H])(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=NS(=O)(=O)C1CC1)OC1=C(CCCCC2)N=C2C=CC(OC)=CC2=N1)C(C)(C)C,0.988,0.988,,,0,,766.3359982,7,2,3,1,1,2
7659,02/07/2019 00:00,DB11577,Indigotindisulfonic Acid,Biologically inert [L2223].,,4-5 minutes post-injection [L2215],8 mg/1mL,Intramuscular; Intravenous,liquid,1g/100ml ,,0.0996,-2.8,-7.7,OS(=O)(=O)C1=CC2=C(N\C(C2=O)=C2\NC3=C(C=C(C=C3)S(O)(=O)=O)C2=O)C=C1,,,,,0,,421.9878573,4,2,2,0,0,2
7660,02/07/2019 00:00,DB11581,Venetoclax,"Following several oral administrations after a meal, the maximum plasma concentration of venetoclax was reached 5-8 hours after the dose [A18567]. Venetoclax steady state AUC (area under the curve) increased proportionally over the dose range of 150-800 mg. After a low-fat meal, venetoclax mean (Â± standard deviation) steady-state Cmax was 2.1 Â± 1.1 Î¼g/mL and AUC0-24 was 32.8 Â± 16.9 Î¼gâ€¢h/mL at the 400 mg once daily dose [FDA label]. 

When compared with the fasted state, venetoclax exposure increased by 3.4 times when ingested with a low-fat meal and 5.2 times with a high-fat meal. When comparing low versus high fat, the Cmax and AUC were both increased by 50% when ingested with a high-fat meal. The FDA label indicataes that venetoclax should be taken with food [A40022], [FDA label].",,"The half-life of venetoclax is reported to be 19-26 hours, after administration of a single 50-mg dose [A40022], [FDA label].",10 mg,Oral,solid,,99,0.000933,4.19,7.96,CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1,,,,,0,10,867.3180956,8,5,4,2,2,2
7661,04/06/2019 00:00,DB11582,Thiocolchicoside,"Oral bioavailability is ~25%
After intramuscular administration, thiocolchicoside Cmax occur in 30 min and .reach values of 113 ng/mL after a 4 mg dose and 175 ng/mL after a 8 mg dose. The corresponding values of AUC are respectively 283 and 417 ng.h/mL. The pharmacologically active metabolite SL18.0740 is found at lower concentrations with a Cmax of 11.7 ng/mL occurring 5 h post administration and an AUC of 83 ng.h/mL [L1658].

After oral administration, no thiocolchicoside is detected in plasma. Only two metabolites are observed: The pharmacologically active metabolite SL18.0740 and an inactive metabolite SL59.0955. For both metabolites, maximum plasma concentrations occur 1hour after thiocolchicoside administration. After a single oral dose of 8 mg of thiocolchicoside the Cmax and AUC of SL18.0740 are about 60 ng/mL and 130 ng.h/mL respectively. For SL59.0955 these values are much lower: Cmax around 13 ng/mL and AUC ranging from 15.5 ng.h/mL (until 3h) to 39.7 ng.h/mL (until 24h) [L1658].

",,Approximately 7.7h [L1670].,,,solid,10 mg/mL,0.34,0.348,12.2,-1.2,COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC,,,,,0,,563.1825173,4,2,1,0,1,1
7662,04/06/2019 00:00,DB11583,Cetalkonium,"Cetalkonium is used mainly topically and it is not absorbed.[T53] When administered orally and parenterally, cetalkonium absorption may happen but it is very insignificant.[L2815]",,"As cetalkonium is not absorbed, this pharmacokinetic property is not relevant.",,Oral,solid,8.5 g/L,2.5,3.37E-06,18.11,,CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,,,,,1,,360.3624769,1,1,0,0,0,0
7663,04/06/2019 00:00,DB11584,Pipradrol,Rapidly absorbed [T179].,,,,Oral,solid,,,0.0306,12.88,9.53,[H]N1CCCCC1C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,267.1623143,3,2,1,0,1,1
7664,04/06/2019 00:00,DB11585,Drometrizole trisiloxane,"Drometrizole trisiloxane is reported as having little to no absorption through the skin [L2780, L2783]. At this time, however, studies demonstrate that the components of most commonly used sunscreens are likely absorbed into the skin at least to some extent - although penetration to deeper tissues and the cutaneous circulation remains limited [A33070]. Despite the extensive use of sunscreen products around the world, there have been few reports of adverse effects related to their use [A33070].",,"Drometrizole trisiloxane is reported as having little to no absorption through the skin [L2780, L2783]. The systemic presence of the compound is consequently expected to be minimal.",,Topical,solid,,,0.000703,9.96,-0.38,CC(CC1=C(O)C(=CC(C)=C1)N1N=C2C=CC=CC2=N1)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C,,,,,0,,501.2299217,3,3,1,1,0,0
7665,02/07/2019 00:00,DB11586,Asunaprevir,"In preclinical studies, asunaprevir showed a high liver-to-plasma AUC ratio. It is rapidly absorbed within 30 minutes of administration.[L2278] Clinical pharmacokinetic studies showed a tmax of 2-4 hours.[A18434] The pharmacokinetic profile act in a dose-proportional manner and in a dose of 100 mg the steady-state Cmax and AUC was 572 ng/ml and 1887 ng.h/ml. The absolute bioavailability is reported to be 9.3%. The absorption of asunaprevir is increased if it is accompanied by a high-fat diet.[L2287]",0.99,Clinical pharmacokinetic studies showed a mean terminal half-life of 15-20 hours.[A18434],100 mg/1,Not applicable,solid,<50 mg/L,,0.00299,3.77,1.85,COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2,0.99,0.99,,,0,,747.2704767,5,2,2,1,1,1
7666,04/06/2019 00:00,DB11587,Etafedrine,"Similar to its parent drug, ephedrine, it is readily and completely absorbed from the gastrointestinal tract; plasma peak concentrations are reached an hour after ingestion [L2566].
            
A single oral dose of 24 mg produced an average peak plasma concentration of 0.10 mg/L [L2566].",,It has a plasma half-life ranging from 3 to 6 hours depending on urinary pH [L2566].,,Oral,solid,,,9.44,13.88,9.14,CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1,,,,,0,,193.1466642,1,1,0,0,0,0
7667,04/06/2019 00:00,DB11590,Thimerosal,Less than 0.01% of an ingested dose is absorbed from the GI tract (rat study) [L1687].,0.99,"A study was done to study the pharmacokinetics of Thimerosal in mice. Estimated half-lives (in days) were 8.8 for blood, 10.7 for brain, 7.8 for heart, 7.7 for liver and 45.2 for kidney [L1685].

The the long half-life of ethylmercury (~50 days on average in humans) results in accumulation that may be harmful to the developing fetal brain, as it is more susceptible to organomercurial compounds than the adult brain [L1687].
",,,solid,1 g/mL,,6.17,,-6.6,CC[Hg]SC1=CC=CC=C1C(=O)O[Na],0.99,0.99,,,0,,405.9927378,1,1,0,0,0,0
7668,02/07/2019 00:00,DB11591,Bilastine,Bilastine has a Tmax of 1.13 h [FDA Label]. The absolute bioavailability is 61%. No accumulation observed with daily dosing of 20-100 mg after 14 days. Cmax decreased by 25 % and 33% when taken with a low fat and high fat meal compared to fasted state. Administration with grapefruit juice decreased Cmax by 30%.,84-90%,The mean half life of elimination is 14.5h [FDA Label].,20 mg,Oral,solid,,,0.00203,4.06,9.43,CCOCCN1C(=NC2=CC=CC=C12)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1,0.84,0.9,,,0,20,463.283492,4,3,2,1,1,1
7669,04/06/2019 00:00,DB11592,Nitrocefin,,,,,,solid,,,0.0022,3.07,-3.2,[H][C@]12SCC(\C=C\C3=CC=C(C=C3[N+]([O-])=O)[N+]([O-])=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O,,,,,0,,516.0409555,4,2,3,1,1,2
7670,04/06/2019 00:00,DB11593,Isatoic anhydride,,,,,,solid,,,4.15,9.4,-2.4,O=C1NC2=CC=CC=C2C(=O)O1,,,,,0,,163.026943,2,2,1,1,0,0
7671,02/07/2019 00:00,DB11594,Domiphen,,,,1.5 mg,Oral,solid,,,4.80E-06,,-4.9,CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1,,,,,1,1.5,334.3104413,1,1,0,0,0,0
7672,02/07/2019 00:00,DB11596,Levoleucovorin,"After rapid intravenous administration, serum total tetrahydrofolate (total-THF) concentrations reached a mean peak of 1722 ng/mL. Serum (6S)-5-methyl-5,6,7,8-tetrahydrofolate concentrations reached a mean peak of 275 ng/mL and the mean time to peak was 0.9 hours. ",,"The mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8-tetrahydrofolate was 5.1 and 6.8 hours, respectively.",50 mg/5mL,Intravenous,solid,,,0.3,3.27,2.69,NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1,,,,,0,,473.1658961,3,2,2,1,0,1
7673,04/06/2019 00:00,DB11602,Hydroxyethyl cellulose,,,,6 mg/1mL,Topical,solid,Soluble,,2.85,13.95,-2.9,CC(O)COCC1OC(OC2C(COCC(C)O)OC(OCC(C)O)C(OCC(C)O)C2OCC(C)O)C(OCC(C)O)C(OCC(C)O)C1OCC(C)O,,,,,0,,806.45113,2,0,2,0,2,2
7674,04/06/2019 00:00,DB11609,Normethadone,,,,,Oral,solid,,,0.00737,18.8,8.83,CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,295.1936144,2,2,0,0,0,0
7675,04/06/2019 00:00,DB11610,Oxilofrine,,,,,Oral,solid,Partly miscible,,12.2,9.19,9.8,[H][C@@](C)(NC)[C@]([H])(O)C1=CC=C(O)C=C1,,,,,0,,181.1102787,1,1,0,0,0,0
7676,02/07/2019 00:00,DB11611,Lifitegrast,The mean peak plasma concentration (Cmax) of 1.70ng/mL was reached within 15 minutes of application. Quantifiable trough plasma concentrations ranged from 0.55 ng/mL to 3.74 ng/mL [L769]. Observations show limited systemic exposure that produces significant clinical outcomes.,0.95,"Not possible to calculate plasma elimination half-life based on plasma concentrations of lifitegrast, but reported to be relatively short in rat I.V. pharmacokinetics study [A19223].",0.05,Ophthalmic,solid,Soluble,,0.00571,3.27,-1.3,CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1,0.95,0.95,,,0,,614.0681275,5,4,2,1,0,1
7677,04/06/2019 00:00,DB11613,Velpatasvir,Oral bioavailability of 25-30% [A19175]. ,>99.5%,15h [FDA Label].,,Oral,solid,,,0.00153,3.74,5.98,[H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1,0.99,1,,,0,,882.4064607,9,6,5,2,2,3
7678,02/07/2019 00:00,DB11614,Rupatadine,Rupatidine is rapidly absorbed with a Tmax of 1 h [FDA Label]. Administration with a high fat meal increases exposure by 23% and increases Tmax to 2 h.,98.5-99.0%,"The half life of elimination is 15.9 h in children 2-5 years old, 12.3 h in children 6-11 years old, 5.9 h in adults, and 8.7 h in geriatric patients [FDA Label].",1 mg,Oral,solid,,0.8,0.00544,,7.19,CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1,0.985,0.99,,,0,1,415.1815255,5,3,3,2,1,1
7679,04/06/2019 00:00,DB11616,Pirarubicin,,,,,,solid,,,0.301,7.99,9.09,[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(C=CC=C2OC)C4=O)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O[C@]1([H])CCCCO1,,,,,0,,627.2315756,6,2,2,0,2,2
7680,04/06/2019 00:00,DB11617,Aclarubicin,,,,,,solid,,,0.218,7.47,8.64,CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C2=C(O)C3=C(C=C2[C@H]1C(=O)OC)C(=O)C1=C(C(O)=CC=C1)C3=O,,,,,0,,811.34152,7,2,3,0,3,3
7681,04/06/2019 00:00,DB11618,Zorubicin,,,,,,solid,,,0.0525,7.22,9.39,[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(C=CC=C2OC)C4=O)C(C)=NN=C(O)C2=CC=CC=C2)O[C@@]([H])(C)[C@@]1([H])O,,,,,0,,645.2322443,6,3,1,0,1,1
7682,04/06/2019 00:00,DB11619,Gestrinone,The oral absorption of gestrinone is 30% Â±30 [L1700].,,Plasma half-life is 24 hr [L1695].,,,solid,,,0.00969,17.88,-1.5,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H],,,,,0,,308.17763,4,0,0,0,0,0
7683,04/06/2019 00:00,DB11620,Neridronic Acid,,,,,,solid,,,13.5,0.69,10.21,NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O,,,,,0,,277.0480251,0,0,0,0,0,0
7684,04/06/2019 00:00,DB11622,Dehydrocholic acid,The duodenal experiment indicates that dehydrocholic acid is absorbed from the proximal small intestine [A33022].,,No pharmacokinetic data available. ,300 mg,Oral,solid,Insoluble,,0.00705,4.35,-6.9,[H][C@@]1(CC[C@@]2([H])[C@]3([H])C(=O)C[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC(=O)[C@]12C)[C@H](C)CCC(O)=O,,,,,0,300,402.2406242,4,0,0,0,0,0
7685,04/06/2019 00:00,DB11623,Candoxatrilat,,,,,,solid,,,0.766,4.08,0.48,COCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(O)=O,,,,,0,,399.2257024,2,0,0,0,0,0
7686,04/06/2019 00:00,DB11625,Perflenapent,,,,,,,,,0.0383,,,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,,,,,0,,287.9808386,0,0,0,0,0,0
7687,04/06/2019 00:00,DB11628,Depreotide,,,,,,,,,0.00502,9.67,10.63,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC2=CC=CC=C2)N(C)C(=O)[C@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O,,,,,0,,1356.683505,5,4,2,1,1,1
7688,04/06/2019 00:00,DB11629,Laropiprant,,,,,,,,,0.00428,3.98,,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1,,,,,0,,435.070735,4,3,1,1,0,0
7689,04/06/2019 00:00,DB11632,Opicapone,"Oral opicapone demonstrates linear, dose-dependent absorption. However, following simultaneous ingestion of a high-fat, high-calorie meal, the maximal plasma concentration is decreased [L2337].

tmax of 1.0 h to 2.5 h after once-daily multiple-dose administration of up to 50 mg opicapone [L2343].
",>99.7%,"1.58-4.50h [L2339]

Despite the short half-life, the observed half-life of opicapone-induced COMT inhibition in human red blood cells was 61.6 h (standard deviation [SD] = 37.6 h) [A32590].",25 mg,Oral,solid,minimal,,0.044,5.97,-0.47,CC1=C(C2=NOC(=N2)C2=CC(=C(O)C(O)=C2)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl,0.99,1,,,0,25,411.9977394,3,3,2,2,0,0
7690,04/06/2019 00:00,DB11633,Isavuconazole,"Following oral administration of 200 mg isavuconazole, the mean peak plasma concentration (Cmax) at steady state was 7499 ng/mL. Cmax following oral administration of 600 mg isavuconazole was 20028 ng/mL [FDA Label]. It is proposed that the Cmax at steady state is reached approximately 2â€“3 hours after single and multiple dosing of isavuconazole [FDA Label]. Administration of 400 mg of oral and intravenous isavuconazole resulted in mean AUC of 189462.8 h*ng/mL and 193906.8 h*ng/mL, respectively [L1482]. While isavuconazole can be administered with or without food, concurrent consumption of a high-fat meal reduced oral isavuconazole Cmax by 9% and increased AUC by 9% [FDA Label]. The absolute bioavailability of isavuconazole following oral administration of a single dose of isavuconazole is 98% [FDA Label]. ",,"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482]. ",,,,,,0.0162,12.59,2.32,C[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1,,,,,0,,437.1121876,4,4,2,2,0,0
7691,04/06/2019 00:00,DB11636,Nomegestrol,,,,,,,,,0.0122,12.7,-3.8,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,,,,,0,,328.2038448,4,0,0,0,0,0
7692,04/06/2019 00:00,DB11637,Delamanid,"Following a single oral dose administration of 100 mg delamanid, the peak plasma concentration was 135 ng/mL [A31968]. Steady-state concentration is reached after 10-14 days [A31978]. Delamanid plasma exposure increases less than proportionally with increasing dose. In animal models (dog, rat, mouse), the oral bioavailability of delamanid was reported to be 35%â€“60% [A31966]. The absolute oral bioavailability in humans is estimated to range from 25 to 47% [A31967]. Oral bioavailability in humans is enhanced when administered with a standard meal, by about 2.7 fold compared to fasting conditions [L1407] because delamanid exhibits poor water solubility [A31967].",â‰¥99.5%,The half life ranges from 30 to 38 hours [L1407].,50 mg,Oral,solid,,,0.00222,,5.51,C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)[N+]([O-])=O,0.99,0.05,,,0,50,534.1726192,5,3,3,1,1,2
7693,04/06/2019 00:00,DB11638,Artenimol,The reported oral bioavailability of Artenimol was reported to be 45% in healthy adults [L1149]. The observed Tmax was 1-2 h This is known to increase in malaria infected patients which could be attributed to reduced metabolism by the liver or the drug's collection in infected erythrocytes. Artenimol was obeserved to have flip-flop kinetics with an overall absorption half-life of 1.04 h. When administered with food the AUC for Artenimol increases by 144%. Cmax was observed to increase by 129% but was not found to be statistically significant. Food was observed to delay Tmax by 1 h.,44-93%,Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].,,,solid,,,3.16,12.11,-4.1,[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4,0.44,0.93,,,0,,284.1623739,5,0,4,0,4,4
7694,04/06/2019 00:00,DB11640,Amifampridine,"Orally-administered amifampridine is rapidly absorbed in humans to reach the peak plasma concentrations within by 0.6 to 1.3 hours [F272]. A single oral dose of 20 mg amifampridine in fasted individuals resulted in mean peak plasma concentrations (Cmax) ranging from 16 to 137 ng/mL [F272]. Bioavailability is approximately 93-100% based on recoveries of unmetabolised amifampridine and a major 3-N-acetylated amifampridine metabolite in urine [F272]. Food consumption decreases amifampridine absorption and exposure with a decrease in the time to reach maximum concentrations (Tmax) [A33865]. It is approximated that food consumption lowers the Cmax on average by ~44% and lowers AUC by ~20%. based on geometric mean ratios [F272]. 

Systemic exposure to amifampridine is affected by the overall metabolic acetylation activity of NAT enzymes and NAT2 genotype [A33881]. The NAT enzymes are highly polymorphic that results in variable slow acetylator (SA) and rapid acetylator (RA) phenotypes. Slow acetylators are more prone to increased systemic exposure to amifampridine, and may require higher doses for therapeutic efficacy [A33881, F272]. ",,The plasma elimination half-life is approximately 2.5 hours for amifampridine and 4 hours for 3-N-acetylamifampridine [F272].,10 mg/1,Oral,solid,Soluble,,5.8,15.5,11.81,NC1=CNC=CC1=N,,,,,0,10,109.0639972,1,1,1,1,0,0
7695,04/06/2019 00:00,DB11641,Vinflunine,Vinflunine displays a linear pharmacokinetic profile in the range of administered doses (from 30 mg/m^2 to 400 mg/m^2) in cancer patients [L2381]. ,0.011,"The mean terminal half-life is approximately 40 h [L2381]. The half life of the main metabolite, DVFL, is approximately 120 hours [L2381]. ",25 mg/ml,Intravenous,solid,,,0.00564,10.87,8.66,CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC,0.011,0.011,,,0,,816.3909711,9,3,6,1,2,5
7696,04/06/2019 00:00,DB11642,Pitolisant,"Pitolisant is rapidly and well absorbed. Following oral administration of 20 mg in healthy individuals, the peak plasma concentration (Cmax) was approximately 30 ng/mL [A32025]. The Cmax is typically reached approximately 3 hours following administration [L1471]. Food intake significantly reduces the systemic exposure of pitolisant with a decrease in both AUC and Cmax [L1476]. Following repeated dosing, the steady-state plasma concentration is achieved after 5-6 days of administration leading to an increased serum level around 100% [L1471]. Inter individual variability is reported to be high [L1471]. The absolute bioavailability of pitolisant has not been determined [L1476].",,Pitolisant has a plasma half-life of 10-12 hours [L1471].,18 mg,Oral,,,,0.00142,,9.67,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1,,,,,0,18,295.1702921,2,1,1,0,1,1
7697,04/06/2019 00:00,DB11644,Tafamidis,"After oral administration of tafamidis soft capsule, the maximum plasma concentration (Cmax) is achieved at a median time (tmax) of 2 hours after dosing in the fasted state [FDA Label]. Concomitant administration of food decreased the rate of absorption, but not the extent of absorption [FDA Label]. These results support the administration of tafamidis with or without food [FDA Label].",0.999,"After daily administration of a 20mg tafamidis dose for fourteen days in healthy subjects, the mean steady-state half-life observed was 59 hours [FDA Label].",61 mg/1,Oral,solid,,,0.0323,3.73,-0.41,OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1,0.999,0.999,,,0,61,306.9802984,3,3,1,1,0,0
7698,04/06/2019 00:00,DB11645,PF-4191834,,,,,,,,,0.00307,15.93,2.45,CN1N=CC=C1C1=CC=C(SC2=CC=CC(=C2)C2(CCOCC2)C(N)=O)C=C1,,,,,0,,393.151098,4,3,2,1,1,1
7699,04/06/2019 00:00,DB11647,Incyclinide,,,,,,,,,0.819,5.55,-1.2,NC(=O)C1=C(O)C[C@@H]2C[C@@H]3CC4=C(C(O)=CC=C4)C(=O)C3=C(O)[C@]2(O)C1=O,,,,,0,,371.1005019,4,1,0,0,0,0
7700,04/06/2019 00:00,DB11648,Afuresertib,,,,,,,,,0.00781,13.79,9.02,CN1N=CC(Cl)=C1C1=C(Cl)SC(=C1)C(=O)N[C@H](CN)CC1=CC=CC(F)=C1,,,,,0,,426.0484157,3,3,2,2,0,0
7701,04/06/2019 00:00,DB11649,Lersivirine,,,,,,,,,0.15,15.4,2.09,CCC1=NN(CCO)C(CC)=C1OC1=CC(=CC(=C1)C#N)C#N,,,,,0,,310.1429758,2,2,1,1,0,0
7702,04/06/2019 00:00,DB11650,HT-0712,,,,,,,,,0.000252,14.48,-1.5,COC1=CC=C(C=C1OC1CCCC1)[C@H]1CNC(=O)[C@H](CC2=CC(C)=CC=C2)C1,,,,,0,,393.2303939,4,2,1,0,1,1
7703,04/06/2019 00:00,DB11651,Dactolisib,,,,,,,,,0.00563,,4.07,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CN=C2C=CC=CC2=C1)C1=CC=C(C=C1)C(C)(C)C#N,,,,,0,,469.1902604,6,6,3,3,0,0
7704,04/06/2019 00:00,DB11652,Tucatinib,,,,,,,,,0.004,17.08,4.57,CC1=CC(NC2=NC=NC3=CC=C(NC4=NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1,,,,,0,,480.202222,6,5,4,3,0,1
7705,26/06/2019 00:00,DB11653,Bremelanotide,Bremelanotide has a T<sub>max</sub> or 1.0 hour (0.5-1.0 hours) and is 100% bioavailable.[L4894] The C<sub>max</sub> is 72.8ng/mL and the AUC is 276hr\*ng/mL.[L4894],0.21,The half life of bremelanotide is 2.7 hours (1.9-4.0 hours).[L4894],,,solid,,,0.0251,3.45,11.96,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O,0.21,0.21,,,0,,1024.524284,5,4,3,2,1,1
7706,04/06/2019 00:00,DB11654,T-2000,,,,,,,,,0.0409,,-3.9,COCN1C(=O)N(COC)C(=O)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,368.1372217,3,2,1,0,1,1
7707,04/06/2019 00:00,DB11655,Evacetrapib,,,,,,,,,0.00324,4.34,6.11,CN1N=NC(=N1)N(CC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)[C@H]1CCCN(C[C@H]2CC[C@@H](CC2)C(O)=O)C2=C1C=C(C)C=C2C,,,,,0,,638.2803937,5,3,2,1,0,1
7708,04/06/2019 00:00,DB11656,Rebamipide,,,,,,,,,0.00766,3.52,1.74,OC(=O)C(CC1=CC(O)=NC2=CC=CC=C12)NC(=O)C1=CC=C(Cl)C=C1,,,,,0,,370.0720346,3,3,1,1,0,0
7709,04/06/2019 00:00,DB11658,QAV-680,,,,,,,,,0.0498,4.37,3.72,CC1=C(CC(O)=O)C2=CC=CN=C2N1CC1=CC=C(C=C1)S(C)(=O)=O,,,,,0,,358.0987281,3,3,2,2,0,0
7710,04/06/2019 00:00,DB11660,Latanoprostene Bunod,"In a study with 22 healthy subjects monitored for 28 days, there were no quantifiable plasma concentrations of latanoprostene bunod (Lower Limit Of Quantitation, LLOQ, of 10.0 pg/mL) or butanediol mononitrate (LLOQ of 200 pg/mL) post daily dose of one drop bilaterally in the morning on Day 1 and 28 [FDA Label].

The mean time of maximum plasma concentration (Tmax) for latanoprost acid was about 5 minutes post dosage on both Day 1 and 28 of therapy [FDA Label].

The mean maximum plasma concentrations (Cmax) of latanoprost acid (LLOQ of 30 pg/mL) were 59.1 pg/mL on Day 1 and 28, respectively [FDA Label]. ",,"The half-life after application of latanoprostene bunod in rabbits was 1.8 hours in cornea, 2.1 hours in aqueous humor, and 4.6 hours in the iris/ciliary body [A31285].",0.00024,Ophthalmic,liquid,,,0.0032,14.47,-2.7,O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1,,,,,0,,507.2832173,2,1,0,0,0,0
7711,04/06/2019 00:00,DB11662,Rabusertib,,,,,,,,,0.0236,10.47,8.19,CC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(Br)=C2)N=C1,,,,,0,,435.0906017,3,2,2,1,1,1
7712,04/06/2019 00:00,DB11663,Pictilisib,,,,,,,,,0.0661,13.19,6.26,CS(=O)(=O)N1CCN(CC2=CC3=C(S2)C(=NC(=N3)C2=C3C=NNC3=CC=C2)N2CCOCC2)CC1,,,,,0,,513.1616797,6,4,5,3,2,2
7713,04/06/2019 00:00,DB11664,Psilocybine,,,,,,,,,2.7,1.74,9.54,CN(C)CCC1=CNC2=CC=CC(OP(O)(O)=O)=C12,,,,,0,,284.0925937,2,2,1,1,0,0
7714,04/06/2019 00:00,DB11665,BMS-690514,,,,,,,,,0.306,14.09,9.51,COC1=CC=CC(NC2=NC=NN3C=CC(CN4CC[C@@H](N)[C@H](O)C4)=C23)=C1,,,,,0,,368.196074,4,3,3,2,1,1
7715,04/06/2019 00:00,DB11666,Buparlisib,,,,,,,,,0.0916,12.28,9.3,FC(F)(F)C1=CC(=N)NC=C1C1=CC(=NC(=N1)N1CCOCC1)N1CCOCC1,,,,,0,,410.1678086,4,2,4,2,2,2
7716,04/06/2019 00:00,DB11667,2'-cyano-2'-deoxy-1-(beta-D-arabinofuranosyl)cytosine,,,,,,,,,25.1,13.12,-0.23,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1C#N,,,,,0,,252.0858549,2,1,2,1,1,1
7717,04/06/2019 00:00,DB11669,Ortataxel,,,,,,,,,0.0218,11.03,-3,CC(C)C[C@H](NC(=O)OC(C)(C)C)[C@@H](O)C(=O)O[C@H]1[C@@H]2OC(=O)O[C@@]22[C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O,,,,,0,,871.3626494,6,1,2,0,2,2
7718,04/06/2019 00:00,DB11670,SP-8203,,,,,,,,,0.0671,11.16,10.13,CC(=O)N(CCCCNCCCN1C(=O)NC2=CC=CC=C2C1=O)CCCN1C(=O)NC2=CC=CC=C2C1=O,,,,,0,,534.2590682,4,4,2,2,0,0
7719,04/06/2019 00:00,DB11671,AZD-4877,,,,,,,,,0.00292,,9.77,CC(C)C(N(CCCN)C(=O)C1=CC=C(C)C=C1)C1=NC2=C(C(C)=NS2)C(=O)N1CC1=CC=CC=C1,,,,,0,,503.2354963,4,4,2,2,0,0
7720,04/06/2019 00:00,DB11672,Curcumin,"Curcumin displays poor absorption into the gastrointestinal tract. In a rat study, oral administration of a single dose of 2 g of curcumin resulted in a plasma concentration of less than 5 Î¼g/mL, indicating poor absorption from the gut [F114].",,No pharmacokinetic data available. ,,,solid,Insoluble in cold water,,0.00575,9.06,-4.4,COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O,,,,,0,,368.1259884,2,2,0,0,0,0
7721,04/06/2019 00:00,DB11673,Pyridoxamine,,,,,,,,,29,7.82,9.82,CC1=C(O)C(CN)=C(CO)C=N1,,,,,0,,168.0898776,1,1,1,1,0,0
7722,04/06/2019 00:00,DB11674,Equol,,,,,,,,,0.0445,9.63,-4.9,OC1=CC=C(C=C1)[C@H]1COC2=C(C1)C=CC(O)=C2,,,,,0,,242.0942943,3,2,1,0,0,1
7723,04/06/2019 00:00,DB11675,Mosapride,,,,,,,,,0.0218,14.46,5.98,CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1,,,,,0,,421.1568476,3,2,1,0,1,1
7724,04/06/2019 00:00,DB11676,Galidesivir,,,,,,,,,1.19,7.19,12.21,[H][C@]1(CO)N[C@@]([H])(C2=CNC3=C2N=CNC3=N)[C@]([H])(O)[C@]1([H])O,,,,,0,,265.1174893,3,2,3,2,1,1
7725,04/06/2019 00:00,DB11677,Triheptanoin,,,,,,,,,0.000415,,-6.6,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC,,,,,0,,428.3137891,0,0,0,0,0,0
7726,04/06/2019 00:00,DB11678,Treosulfan,,,,,,,,,17,12.99,-3.5,CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O,,,,,0,,278.0130094,0,0,0,0,0,0
7727,04/06/2019 00:00,DB11679,Fruquintinib,,,,,,,,,0.0803,14.99,2.57,CNC(=O)C1=C(C)OC2=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=CC=C12,,,,,0,,393.1324707,4,4,2,2,0,0
7728,04/06/2019 00:00,DB11681,Tofimilast,,,,,,,,,0.179,,2.48,CCC1=NN(C2CCCC2)C2=C1CCN1C(=NN=C21)C1=CC=CS1,,,,,0,,339.1517667,5,3,4,3,0,1
7729,04/06/2019 00:00,DB11682,Daprodustat,,,,,,,,,0.345,0.35,-9.1,OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,,,,,0,,393.1899856,3,0,1,0,1,1
7730,04/06/2019 00:00,DB11683,PF-06282999,,,,,,,,,0.0182,8.01,-3.2,COC1=CC=C(Cl)C=C1C1=CC(=O)NC(=S)N1CC(N)=O,,,,,0,,325.0287899,2,2,1,1,0,0
7731,04/06/2019 00:00,DB11684,APR-246,,,,,,,,,499,14.54,6.9,COCC1(CO)N2CCC(CC2)C1=O,,,,,0,,199.1208434,3,0,3,0,3,3
7732,04/06/2019 00:00,DB11686,Iferanserin,,,,,,,,,0.000939,14.66,9.49,CN1CCCC[C@H]1CCC1=CC=CC=C1NC(=O)\C=C\C1=CC=CC=C1,,,,,0,,348.2201635,3,2,1,0,1,1
7733,04/06/2019 00:00,DB11687,E-6201,,,,,,,,,0.43,9.86,2.98,CCNC1=CC2=C(C(O)=C1)C(=O)O[C@@H](C)[C@H](C)\C=C/C(=O)[C@@H](O)[C@@H](O)C\C=C\2,,,,,0,,389.1838376,2,1,1,0,0,1
7734,04/06/2019 00:00,DB11688,2-chloroethyl-3-sarcosinamide-1-nitrosourea,,,,,,,,,3.81,15.31,-4.5,CN(CC(N)=O)C(=O)N(CCCl)N=O,,,,,0,,222.0519679,0,0,0,0,0,0
7735,04/06/2019 00:00,DB11689,Selumetinib,,,,,,,,,0.0424,6.49,5.43,CN1C=NC2=C1C=C(C(O)=NOCCO)C(NC1=C(Cl)C=C(Br)C=C1)=C2F,,,,,0,,456.0000083,3,3,1,1,0,0
7736,04/06/2019 00:00,DB11691,Naldemedine,Tmax is 0.75 h [FDA Label]. Administration with a high-fat meal reduces Cmax by 35% and increases Tmax to 2.5 h.,93-94%,The terminal elimination half life is 11 h [FDA Label].,.2 mg/1,Oral,,Slightly soluble,,0.227,9.86,9.05,[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CC6)CC[C@@]14[C@@]5(O)CC(C(=O)NC(C)(C)C1=NC(=NO1)C1=CC=CC=C1)=C2O)=CC=C3O,0.93,0.94,,,0,0.2,570.2478348,8,3,3,1,1,2
7737,04/06/2019 00:00,DB11692,Pavinetant,,,,,,,,,0.000433,5.36,0.43,CC[C@H](NC(=O)C1=C(NS(C)(=O)=O)C(=NC2=CC=CC=C12)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,459.1616627,4,4,1,1,0,0
7738,04/06/2019 00:00,DB11693,Voclosporin,,,,,,,,,0.00401,11.83,-2.4,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,,,,,0,,1213.841368,1,0,1,0,1,1
7739,04/06/2019 00:00,DB11694,Ilorasertib,,,,,,,,,0.00695,11.28,4.96,NC1=C2C(SC=C2C2=CC=C(NC(=O)NC3=CC(F)=CC=C3)C=C2)=C(C=N1)C1=CN(CCO)N=C1,,,,,0,,488.1430731,5,5,3,3,0,0
7740,04/06/2019 00:00,DB11695,Carnosine,,,,,,,,,11.1,3.37,9.13,NCCC(=O)N[C@@H](CC1=CN=CN1)C(O)=O,,,,,0,,226.1065903,1,1,1,1,0,0
7741,04/06/2019 00:00,DB11696,Racecadotril,,,,,,,,,0.00176,12.6,-2.1,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1,,,,,0,,385.1347792,2,2,0,0,0,0
7742,04/06/2019 00:00,DB11697,Pacritinib,,,,,,,,,0.0023,18.58,8.68,C(CN1CCCC1)OC1=CC=C2C=C1COC\C=C\COCC1=CC(=CC=C1)C1=CC=N\C(N1)=N\2,,,,,0,,472.2474409,5,2,3,0,1,3
7743,04/06/2019 00:00,DB11698,Ipragliflozin,,,,,,,,,0.0299,12.57,-3,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1,,,,,0,,404.109373,4,3,2,1,1,1
7744,04/06/2019 00:00,DB11699,Tropisetron,"The absorption of tropisetron from the gastrointestinal tract is rapid (mean half-life of about 20 minutes) and nearly complete (more than 95%). Due to first-pass metabolism in the liver, the absolute bioavailability of a 5 mg oral dose is 60%. The peak plasma concentration is attained within three hours. ",0.71,5.7 h. ,,,,,,1.33,12.18,9.34,[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C1=CNC3=CC=CC=C13)N2C,0.71,0.71,5.7,5.7,0,,284.1524779,4,2,3,1,2,2
7745,04/06/2019 00:00,DB11700,Setmelanotide,,,,,,,,,0.0259,11.98,11.68,C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O,,,,,0,,1116.485808,5,4,3,2,1,1
7746,04/06/2019 00:00,DB11701,Amenamevir,,,,,,,,,0.123,12.19,-2,CC1=CC=CC(C)=C1N(CC(=O)NC1=CC=C(C=C1)C1=NOC=N1)C(=O)C1CCS(=O)(=O)CC1,,,,,0,,482.1623909,4,3,2,1,1,1
7747,04/06/2019 00:00,DB11702,Antineoplaston A10,,,,,,,,,0.304,11.56,-2.4,O=C(CC1=CC=CC=C1)N[C@H]1CCC(=O)NC1=O,,,,,0,,246.1004423,2,1,1,0,1,1
7748,04/06/2019 00:00,DB11703,Acalabrutinib,The geometric mean absolute bioavailability of acalabrutinib is 25% with a median time to peak plasma concentrations (Tmax) of 0.75 hours [FDA Label].,,"After administering a single oral dose of 100 mg acalabrutinib, the median terminal elimination half-life of the drug was found to be 0.9 (with a range of 0.6 to 2.8) hours [FDA Label].

The half-life of the active metabolite, ACP-5862, is about 6.9 hours [FDA Label].",100 mg/1,Oral,solid,Freely soluble in water at pH values below 3 but is practically insoluble in water at pH values above 6,,0.0109,12.34,5,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1,,,,,0,100,465.191323,5,4,4,3,1,1
7749,04/06/2019 00:00,DB11704,Adomeglivant,,,,,,,,,6.76E-05,3.89,-0.85,CC1=CC(O[C@@H](CCC(F)(F)F)C2=CC=C(C=C2)C(=O)NCCC(O)=O)=CC(C)=C1C1=CC=C(C=C1)C(C)(C)C,,,,,0,,555.2596433,3,3,0,0,0,0
7750,04/06/2019 00:00,DB11705,Iomeprol,,,,,,,,,0.155,5.65,2.53,CN(C(=O)CO)C1=C(I)C(C(O)=NCC(O)CO)=C(I)C(C(O)=NCC(O)CO)=C1I,,,,,0,,776.8541087,1,1,0,0,0,0
7751,04/06/2019 00:00,DB11706,Raxatrigine,,,,,,,,,0.0142,15.69,8.84,NC(=O)[C@@H]1CC[C@@H](N1)C1=CC=C(OCC2=CC=CC=C2F)C=C1,,,,,0,,314.1430561,3,2,1,0,1,1
7752,04/06/2019 00:00,DB11708,Peficitinib,,,,,,,,,0.159,13.85,5.7,NC(=O)C1=CN=C2NC=CC2=C1N[C@H]1[C@H]2CC3C[C@@H]1C[C@@](O)(C3)C2,,,,,0,,326.1742759,6,2,2,2,0,0
7753,04/06/2019 00:00,DB11709,Acetyl hexapeptide-8,,,,,Topical,,,,0.0981,3.55,12.09,CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=C)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O,,,,,0,,886.4443198,0,0,0,0,0,0
7754,04/06/2019 00:00,DB11710,Trigonellamide,,,,,,,,,0.725,12.24,-2.2,C[N+]1=CC=CC(=C1)C(N)=O,,,,,1,,137.0709393,1,1,1,1,0,0
7755,04/06/2019 00:00,DB11711,Navarixin,,,,,,,,,0.0386,7.98,-1.4,CCC[C@@H](NC1=C(CC2=CC=CC(C(=O)N(C)C)=C2O)C(=O)C1=O)C1=CC=C(C)O1,,,,,0,,410.1841719,3,3,1,1,0,0
7756,26/06/2019 00:00,DB11712,Tezacaftor,"The Cmax, Tmax and AUC of tezacaftor, when administered with ivacaftor, are 5.95 mcg/ml, 2-6 h, and 84.5 mcg.h/ml respectively.[L6814] Exposure of tezacaftor/ivacaftor increases 3-fold when it is administered with a high-fat meal.[L6814]",0.99,"The apparent half-life of tezacaftor is approximately 57.2 hours.[A179665,L6829]",,Oral,solid,Insoluble in water,99,0.0124,11.54,-2.8,CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO,0.99,0.99,,,0,,520.1821212,5,3,2,1,0,1
7757,04/06/2019 00:00,DB11713,Ruzasvir,,,,,,,,,0.00425,11.07,6.04,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C2N3[C@@H](OC4=C(C3=CC2=C1)C(F)=CC(=C4)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=CN=C(S1)C1CC1,,,,,0,,946.3959933,10,6,7,4,2,3
7758,04/06/2019 00:00,DB11716,Misonidazole,,,,,,,,,6.8,13.97,-1.9,COCC(O)CN1C=CN=C1[N+]([O-])=O,,,,,0,,201.0749558,1,1,1,1,0,0
7759,04/06/2019 00:00,DB11717,Epacadostat,,,,,,,,,0.419,5.45,-1.4,NS(=O)(=O)NCCNC1=NON=C1\C(NC1=CC(Br)=C(F)C=C1)=N\O,,,,,0,,436.9917132,2,2,1,1,0,0
7760,04/06/2019 00:00,DB11718,Encorafenib,"After oral administration, the median Tmax of encorafenib is 2 hours. At least 86% of the dose is absorbed.
Administration of a single dose of BRAFTOVI 100 mg (0.2 times the recommended dose) with a high-fat, high-calorie meal (comprised of approximately 150 calories from protein, 350 calories from carbohydrates, and 500 calories from fat) decreased the mean maximum encorafenib concentration (Cmax) by 36% with no effect on AUC (area under the curve) [FDA label].",0.86,The mean (CV%) terminal half-life (t1/2) of encorafenib is 3.5 hours (17%) [FDA label],50 mg/1,Oral,solid,,,0.0112,8.45,3.08,COC(=O)N[C@@H](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=CC(Cl)=CC(NS(C)(=O)=O)=C1F)C(C)C,0.86,0.86,,,0,50,539.1517792,3,3,2,2,0,0
7761,04/06/2019 00:00,DB11719,UK-390957,,,,,,,,,0.0275,10.35,7.27,CSC1=CC=C(OC2=CC=C(C=C2CN(C)C)S(N)(=O)=O)C=C1,,,,,0,,352.0915345,2,2,0,0,0,0
7762,04/06/2019 00:00,DB11720,Angiotensin 1-7,,,,,,,,,0.0403,2.95,11.74,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(O)=O,,,,,0,,898.4661008,3,2,2,1,1,1
7763,04/06/2019 00:00,DB11721,Mitoglitazone,,,,,,,,,0.0139,6.61,2.78,CCC1=CN=C(C=C1)C(=O)COC1=CC=C(CC2SC(=O)NC2=O)C=C1,,,,,0,,370.0987281,3,2,2,1,1,1
7764,04/06/2019 00:00,DB11723,Dutogliptin,,,10-13 hours,,,,,,6.93,8.63,10.1,OB(O)[C@@H]1CCCN1C(=O)CN[C@@H]1CCNC1,,,10,13,0,,241.1597719,2,0,2,0,2,2
7765,04/06/2019 00:00,DB11724,Bombesin,,,,,,,,,0.0283,10.99,11.87,[H]N=C(N([H])[H])N([H])CCC[C@H](N([H])C(=O)[C@H](CCC(=O)N([H])[H])N([H])C(=O)[C@@H]1CCC(=O)N1[H])C(=O)N([H])[C@@H](CC(C)C)C(=O)N([H])CC(=O)N([H])[C@@H](CC(=O)N([H])[H])C(=O)N([H])[C@@H](CCC(=O)N([H])[H])C(=O)N([H])[C@@H](CC1=CN([H])C2=CC=CC=C12)C(=O)N([H])[C@@H](C)C(=O)N([H])[C@@H](C(C)C)C(=O)N([H])CC(=O)N([H])[C@@H](CC1=CN([H])C=N1)C(=O)N([H])[C@@H](CC(C)C)C(=O)N([H])[C@@H](CCSC)C(=O)N([H])[H],,,,,0,,1618.815064,4,3,3,2,1,1
7766,04/06/2019 00:00,DB11725,Latrepirdine,,,,,,,,,0.0171,,7.17,CN1CCC2=C(C1)C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1,,,,,0,,319.2048478,4,3,3,2,0,1
7767,04/06/2019 00:00,DB11726,Encenicline,,,,,,,,,0.00872,14.42,7.28,ClC1=C2SC(=CC2=CC=C1)C(=O)N[C@H]1CN2CCC1CC2,,,,,0,,320.0750118,5,2,4,1,3,3
7768,04/06/2019 00:00,DB11729,GSK-2330672,,,,,,,,,0.00735,2.02,8.41,CCCC[C@]1(CC)CS(=O)(=O)C2=CC(CNC(CC(O)=O)CC(O)=O)=C(OC)C=C2[C@H](N1)C1=CC=CC=C1,,,,,0,,546.2399726,3,2,1,0,0,1
7769,02/07/2019 00:00,DB11730,Ribociclib,"Ribociclib is orally bioavailable, highly selective inhibitor of CDK4/6 kinases with inhibitory IC50 concentrations in the low nanomolar range. 
Following oral dosing, ribociclib was rapidly absorbed with median Tmax ranging from 1 to 5 hours. Plasma concentrations increased approximately 2- to 3-fold from Cycle 1 Day 1 to Cycle 1 Day 18/21 due to accumulation, with steady state reached by approximately Day 8 on the basis of trough concentrations after repeated daily dosing. Dose-proportionality analyses demonstrated that exposure to ribociclib increased with dose, with both Cmax and area under the curve (AUC) increasing slightly more than proportional to dose, over the dose range 50â€“1,200 mg/day",,32.6 hours,200 mg,Oral,,,,0.231,11.59,8.87,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1,,,32.6,32.6,0,200,434.2542576,5,3,4,3,1,1
7770,04/06/2019 00:00,DB11731,Depatuxizumab mafodotin,,,,,,,,,0.00598,3.89,1.6,[H][C@](C)(CC)[C@]([H])(N(C)C(=O)[C@@]([H])(N=C(O)[C@]([H])(C(C)C)N(C)C(=O)CCCCCN1C(=O)C=CC1=O)C(C)C)[C@@]([H])(CC(=O)N1CCC[C@@]1([H])C([H])(OC)[C@@]([H])(C)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=O)OC,,,,,0,,924.5572073,3,1,2,0,1,2
7771,04/06/2019 00:00,DB11732,Lasmiditan,,,,,,,,,0.0175,9.35,7.97,CN1CCC(CC1)C(=O)C1=CC=CC(NC(=O)C2=C(F)C=C(F)C=C2F)=N1,,,,,0,,377.1351115,3,2,2,1,1,1
7772,04/06/2019 00:00,DB11734,Fedovapagon,,,,,,,,,0.0762,14.79,-1.8,CN(C)C(=O)[C@@H]1CCCN1C(=O)NCC1=CC=C(C=C1C)C(=O)N1CCCCC2=C1C=CC=C2,,,,,0,,462.2630909,4,2,2,0,1,2
7773,04/06/2019 00:00,DB11735,Galactose,The absorption of galactose from the human jejunum was calculated to be 1.0 g per minute per 30 cm of the gut [A32869].,,Readily accessible data regarding the half-life of galactose is not available.,,Intrauterine,,,,261,12.26,-3,[H]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO,,,,,0,,180.0633881,0,0,0,0,0,0
7774,04/06/2019 00:00,DB11736,PF-00489791,,,,,,,,,0.132,3.57,4.89,CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC,,,,,0,,476.1954224,3,3,3,3,0,0
7775,04/06/2019 00:00,DB11737,Icotinib,Bioavailability = 52%,,5.5 hrs,,,,,,0.0126,16.14,4.62,C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1,,,5.5,5.5,0,,391.1532062,4,3,2,1,0,1
7776,04/06/2019 00:00,DB11738,Rilmenidine,,,,,,,,,1.34,,7.11,C1CC1C(NC1=NCCO1)C1CC1,,,,,0,,180.1262631,3,0,1,0,0,1
7777,04/06/2019 00:00,DB11739,Vonoprazan,,,,,,,,,0.049,,9.01,CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1,,,,,0,,345.094726,3,3,2,2,0,0
7778,04/06/2019 00:00,DB11740,MK-1775,,,,,,,,,0.0625,13.69,7.96,CN1CCN(CC1)C1=CC=C(NC2=NC=C3C(=O)N(CC=C)N(C3=N2)C2=NC(=CC=C2)C(C)(C)O)C=C1,,,,,0,,500.2648223,5,4,4,3,1,1
7779,04/06/2019 00:00,DB11741,Famitinib,,,,,,,,,0.0708,11.46,9.01,CCN(CC)CCN1CCC2=C(C(C)=C(N2)\C=C2/C(=O)NC3=CC=C(F)C=C23)C1=O,,,,,0,,410.2118043,4,2,3,1,0,2
7780,04/06/2019 00:00,DB11742,Ebastine,,,,,,,,,6.47E-05,16.45,8.43,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,469.2980795,4,3,1,0,1,1
7781,04/06/2019 00:00,DB11743,Ipatasertib,,,,,,,,,0.0516,13.68,9.49,[H][C@](CNC(C)C)(C(=O)N1CCN(CC1)C1=NC=NC2=C1[C@]([H])(C)C[C@@]2([H])O)C1=CC=C(Cl)C=C1,,,,,0,,457.2244529,4,2,2,1,1,1
7782,04/06/2019 00:00,DB11744,Epetraborole,,,,,,,,,1.04,7.92,9.28,NC[C@H]1OB(O)C2=C1C=CC=C2OCCCO,,,,,0,,237.1172384,2,1,1,0,0,1
7783,04/06/2019 00:00,DB11745,Otenabant,,,,,,,,,0.0107,15.89,8.97,CCNC1(CCN(CC1)C1=C2N=C(N(C2=NC=N1)C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl)C(N)=O,,,,,0,,509.1497638,5,4,3,2,1,1
7784,04/06/2019 00:00,DB11747,Barasertib,,,,,,,,,0.0468,1.5,9.5,CCN(CCCOC1=CC=C2C(NC3=CC(CC(=O)NC4=CC=CC(F)=C4)=NN3)=NC=NC2=C1)CCOP(O)(O)=O,,,,,0,,587.2057466,4,4,2,2,0,0
7785,04/06/2019 00:00,DB11748,Benfotiamine,,,,,,,,,0.039,1.66,2.91,CC(N(CC1=CN=C(C)NC1=N)C=O)=C(CCOP(O)(O)=O)SC(=O)C1=CC=CC=C1,,,,,0,,466.1075921,2,2,1,1,0,0
7786,04/06/2019 00:00,DB11749,(R)-Praziquantel,,,,,,,,,0.381,19.38,-0.22,[H][C@@]12CN(CC(=O)N1CCC1=CC=CC=C21)C(=O)C1CCCCC1,,,,,0,,312.183778,4,1,2,0,1,2
7787,04/06/2019 00:00,DB11750,Clobetasol,,,,,,,,,0.0142,12.47,-3.4,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,410.1660153,4,0,0,0,0,0
7788,04/06/2019 00:00,DB11751,Cabotegravir,,,,,,,,,0.113,10.04,-0.7,C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N12,,,,,0,,405.1136271,4,2,3,1,1,2
7789,04/06/2019 00:00,DB11753,Rifamycin,"Rifamycin has a very poor absorption[A39996] and thus, the generation of an oral modified-release formulation using the technology of the multi-matrix structure was required for the generation of the FDA approved product. This preparation allows the delivery of the active ingredient in the distal small bowel and colon without interfering with the flora in the upper gastrointestinal tract.[A39997]

The multi-matrix is made by a lipophiic matrix surrounded in a hydrophilic matrix which allows for the protection of the active ingredient from dissolution in the intestinal aqueous fluids before it arrives in the cecum. All this matrix is surrounded by a gastro-resistant polymer that only desintegrate in a pH lower than 7.[A39998]

All this administration-customed formulation allows for a bioavailability of <0.1% and the plasma concentrations are reported to be of <2 ng/ml in patients receiving a dose of 400 mg. This confirms that the site of action of rifamycin stays in the small intestine and colon which prevents the need for dose adjustments in special populations as well as systemic drug interactions.[A39998]

The reported Cmax, tmax, AUC and mean residence time after a dosage of 250 mg of rifamycin is 36 mg/L, 5 min, 11.84 mg.h/L and 0.49 h respectively.[A39998]",,The reported half-life when a dose of 250 mg of rifamycin was administered is 3 h.[A39998],194 mg/1,Oral,solid,Insoluble,5,0.0147,7.09,-1.1,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C2O,,,,,0,194,697.3098259,5,2,3,0,0,3
7790,04/06/2019 00:00,DB11755,Tetrahydrocannabivarin,,,,,,,,,0.0089,9.34,-4.9,CCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1,,,,,0,,286.1932801,3,1,1,0,0,1
7791,04/06/2019 00:00,DB11757,Istradefylline,,,,,,,,,0.182,,-1.4,[H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC,,,,,0,,384.1797552,3,3,2,2,0,0
7792,04/06/2019 00:00,DB11758,Cenicriviroc,,,,,,,,,0.000769,13.83,6.59,CCCCOCCOC1=CC=C(C=C1)C1=CC=C2N(CC(C)C)CCC\C(=C/C2=C1)C(=O)NC1=CC=C(C=C1)[S@@+]([O-])CC1=CN=CN1CCC,,,,,0,,696.3709271,5,4,2,1,0,1
7793,04/06/2019 00:00,DB11759,Pevonedistat,,,,,,,,,0.136,11.4,7.15,[H][C@]1(O)C[C@@]([H])(C[C@@]1([H])COS(N)(=O)=O)N1C=CC2=C(N[C@@]3([H])CCC4=CC=CC=C34)N=CN=C12,,,,,0,,443.1627253,5,3,2,2,0,0
7794,04/06/2019 00:00,DB11760,Talazoparib,"Talzenna capsules have a reach peak plasma concentration in 1-2 h [FDA Label]. If taken with a high fat meal, Cmax decreases by 43%, Tmax increases by 1-4 h, and no change occurs in AUC.",0.74,The mean terminal plasma half life of Talzenna capsules is 90 h with a standard deviation of 58 h [FDA Label].,0.25 mg/1,Oral,solid,,,0.101,9.48,1.66,CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1,0.74,0.74,,,0,0.25,380.1197155,5,4,3,2,0,1
7795,04/06/2019 00:00,DB11761,Tenapanor,,,,,,,,,0.00292,9.86,6.84,CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2,,,,,0,,1142.309743,6,4,2,0,0,2
7796,04/06/2019 00:00,DB11762,Marizomib,,,,,,,,,1.29,10.32,-2.2,C[C@@]12OC(=O)[C@@]1(NC(=O)[C@@H]2CCCl)[C@@H](O)[C@H]1CCCC=C1,,,,,0,,313.1080858,3,0,2,0,2,2
7797,04/06/2019 00:00,DB11763,Momelotinib,,,,,,,,,0.0325,14.02,2.62,O=C(NCC#N)C1=CC=C(C=C1)C1=CC=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1,,,,,0,,414.1804239,4,3,2,1,1,1
7798,04/06/2019 00:00,DB11764,Spebrutinib,,,,,,,,,0.0102,13.88,2.98,COCCOC1=CC=C(NC2=NC=C(F)C(NC3=CC=CC(NC(=O)C=C)=C3)=N2)C=C1,,,,,0,,423.1706678,3,3,1,1,0,0
7799,04/06/2019 00:00,DB11765,PF-04991532,,,,,,,,,0.00949,3.49,4.1,[H][C@@](CC1CCCC1)(N1C=NC(=C1)C(F)(F)F)C(O)=NC1=NC=C(C=C1)C(O)=O,,,,,0,,396.1409251,3,2,2,2,0,0
7800,04/06/2019 00:00,DB11766,AZD-1305,,,,,,,,,0.0833,15.11,6.5,CC(C)(C)OC(=O)NCCN1C[C@H]2CN(CCOC3=CC=C(C=C3F)C#N)C[C@@H](C1)O2,,,,,0,,434.2329337,3,1,2,0,2,2
7801,04/06/2019 00:00,DB11768,Zytron,,,,,,,,,0.00172,9.85,,COP(=S)(NC(C)C)OC1=CC=C(Cl)C=C1Cl,,,,,0,,312.9859917,1,1,0,0,0,0
7802,04/06/2019 00:00,DB11769,Funapide,,,,,,,,,0.0341,,-3.1,FC(F)(F)C1=CC=C(CN2C(=O)[C@@]3(COC4=C3C=C3OCOC3=C4)C3=CC=CC=C23)O1,,,,,0,,429.0824072,6,3,4,1,0,3
7803,04/06/2019 00:00,DB11770,Talinolol,,,,,,,,,0.0593,8.62,9.79,CC(C)(C)NCC(O)COC1=CC=C(NC(O)=NC2CCCCC2)C=C1,,,,,0,,363.2521919,2,1,0,0,0,0
7804,04/06/2019 00:00,DB11772,Pilaralisib,Orally available,,,,,,,,0.0048,5.99,8.48,COC1=CC=C(Cl)C(NC2=C(NS(=O)(=O)C3=CC(NC(=O)C(C)(C)N)=CC=C3)N=C3C=CC=CC3=N2)=C1,,,,,0,,540.134652,4,4,1,1,0,0
7805,04/06/2019 00:00,DB11773,BMS-903452,,,,,,,,,0.0185,19.68,2,CS(=O)(=O)C1=CC=C(N2C=C(Cl)C(OC3CCN(CC3)C3=NC=C(Cl)C=N3)=CC2=O)C(F)=C1,,,,,0,,512.0488097,4,3,3,2,1,1
7806,04/06/2019 00:00,DB11774,Pazufloxacin,,,,,,,,,2.41,5.59,8.16,[H][C@]1(C)COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C1(N)CC1,,,,,0,,318.1015852,4,2,2,1,0,1
7807,04/06/2019 00:00,DB11775,PF-03758309,,,,,,,,,0.00732,10.36,8.1,CN(C)C[C@@H](NC(=O)N1CC2=C(NN=C2NC2=C3SC=CC3=NC(C)=N2)C1(C)C)C1=CC=CC=C1,,,,,0,,490.2263286,5,4,4,3,0,1
7808,04/06/2019 00:00,DB11778,Danusertib,,,,,,,,,0.0323,12.16,7.74,CO[C@@H](C(=O)N1CC2=C(C1)C(NC(=O)C1=CC=C(C=C1)N1CCN(C)CC1)=NN2)C1=CC=CC=C1,,,,,0,,474.2379388,5,3,3,1,1,2
7809,04/06/2019 00:00,DB11779,Danoprevir,,,,,,,,,0.0413,3.77,-3.5,CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2=CC=CC(F)=C2C1)C(=O)NS(=O)(=O)C1CC1,,,,,0,,731.3000273,6,1,3,0,1,3
7810,04/06/2019 00:00,DB11780,Allicin,,,,,,,,,6.13,,-5.7,C=CCSS(=O)CC=C,,,,,0,,162.0173069,0,0,0,0,0,0
7811,04/06/2019 00:00,DB11781,Tosedostat,,,,,,,,,0.092,8.61,-2.2,CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)C1=CC=CC=C1,,,,,0,,406.2103867,2,1,0,0,0,0
7812,04/06/2019 00:00,DB11782,Birinapant,,,,,,,,,0.0352,12.28,8.9,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(NC2=CC(F)=CC=C12)C1=C(C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C2=CC=C(F)C=C2N1,,,,,0,,806.429088,6,4,4,2,2,2
7813,04/06/2019 00:00,DB11783,Imidapril,,,,,,,,,0.447,3.49,5.22,[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(=O)OCC)C(=O)N1C(=O)N(C)C[C@@]1([H])C(O)=O,,,,,0,,405.1899856,2,1,1,0,1,1
7814,04/06/2019 00:00,DB11784,NRX-1074,,,,,,,,,2.35,12.01,7.61,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O,,,,,0,,503.2743839,3,1,2,0,2,2
7815,04/06/2019 00:00,DB11785,Anisodamine,,,,,,,,,17.4,14.44,8.84,CN1[C@@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1,,,,,0,,305.1627082,3,1,2,0,2,2
7816,04/06/2019 00:00,DB11786,Pefcalcitol,,,,,,,,,0.00253,11.52,-2.8,C[C@H](OCC(=O)NCC(F)(F)C(F)(F)F)C1=CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,,,,,0,,519.2407997,3,0,0,0,0,0
7817,04/06/2019 00:00,DB11787,Ralimetinib,,,,,,,,,0.00371,11.83,4.41,CC(C)(C)CN1C(N)=NC2=CC=C(N=C12)C1=C(NC(=N1)C(C)(C)C)C1=CC=C(F)C=C1,,,,,0,,420.2437731,4,4,3,3,0,0
7818,04/06/2019 00:00,DB11789,Hyodeoxycholic Acid,,,,,,,,,0.015,4.79,-2.7,[H][C@@]1(CC[C@@]2([H])[C@]3([H])C[C@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,,,,,0,,392.2926598,4,0,0,0,0,0
7819,04/06/2019 00:00,DB11790,Radafaxine,,,,,,,,,1.54,10.75,7.61,C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1,,,,,0,,255.1026065,2,1,1,0,1,1
7820,04/06/2019 00:00,DB11791,Capmatinib,,,,,,,,,0.00529,12.77,4.55,CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1,,,,,0,,412.1447874,5,5,3,3,0,0
7821,04/06/2019 00:00,DB11792,Mirodenafil,,,,,,,,,0.181,7.69,5.83,CCCOC1=CC=C(C=C1C1=NC2=C(N(CC)C=C2CCC)C(=O)N1)S(=O)(=O)N1CCN(CCO)CC1,,,,,0,,531.2515403,4,3,3,2,1,1
7822,02/07/2019 00:00,DB11793,Niraparib,"The absolute bioavailability of niraparib is approximately 73%. Following oral administration of niraparib, peak plasma concentration, Cmax, is reached within 3 hours. Concomitant administration of a high fat meal (800-1,000 calories with approximately 50% of total caloric content of the meal from fat) did not significantly affect the pharmacokinetics of niraparib.  
Following a single-dose administration of 300 mg niraparib, the mean (Â±SD) peak plasma concentration (Cmax) was 804 (Â± 403) ng/mL. The systemic exposures (Cmax and AUC) of niraparib increased in a dose proportional manner with daily doses ranging 30 mg (0.1 times the approved recommended dosage) to 400 mg (1.3 times the approved recommended dosage). The accumulation ratio of niraparib exposure following 21 days of repeated daily doses was approximately 2 fold for doses ranging from 30 mg to 400 mg.  ",0.83,"Following multiple daily doses of 300 mg niraparib, the mean half-life (t1/2) is 36 hours.",100 mg/1,Oral,,,,0.0149,14.03,10.1,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1,0.83,0.83,,,0,100,320.1637113,4,3,2,1,1,1
7823,04/06/2019 00:00,DB11794,Berzosertib,,,,,,,,,0.0401,16.52,9.22,CNCC1=CC=C(C=C1)C1=NOC(=C1)C1=NC(=CN=C1N)C1=CC=C(C=C1)S(=O)(=O)C(C)C,,,,,0,,463.1678107,4,4,2,2,0,0
7824,04/06/2019 00:00,DB11795,GSK-2636771,,,,,,,,,0.0114,2.79,6.9,CC1=NC2=C(C=C(C=C2N1CC1=C(C)C(=CC=C1)C(F)(F)F)N1CCOCC1)C(O)=O,,,,,0,,433.1613262,4,3,2,1,1,1
7825,04/06/2019 00:00,DB11796,Fostemsavir,,,,,,,,,0.431,1.25,1.87,COC1=C2C(=CN(COP(O)(O)=O)C2=C(N=C1)N1C=NC(C)=N1)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1,,,,,0,,583.1580474,5,4,4,3,1,1
7826,04/06/2019 00:00,DB11797,Aceneuramic acid,,,,,,,,,18.2,2.98,2.11,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(N=C(C)O)[C@@]([H])(O)CC(=O)C(O)=O,,,,,0,,309.1059812,0,0,0,0,0,0
7827,04/06/2019 00:00,DB11798,Tanzisertib,,,,,,,,,0.0557,12.99,4.58,[H][C@@]1(CCOC1)N1C(NC2=C(F)C=C(F)C=C2F)=NC2=CN=C(N[C@@]3([H])CC[C@]([H])(O)CC3)N=C12,,,,,0,,448.1834586,5,3,3,2,1,1
7828,04/06/2019 00:00,DB11799,Bictegravir,"Bictegravir is rapidly absorbed within the body. Tmax= 2.0-4.0h [FDA LABEL, 1219]
",%,"17. 3h [FDA LABEL, L1219]",,Oral,solid,,,0.0537,9.81,-0.3,OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O,,,,,0,,449.1198553,5,2,3,1,1,2
7829,04/06/2019 00:00,DB11800,Tivozanib,,,,,,,,,0.00792,6.61,5.74,COC1=C(OC)C=C2C(OC3=CC(Cl)=C(C=C3)N=C(O)N=C3NOC(C)=C3)=CC=NC2=C1,,,,,0,,454.1043974,4,4,2,2,0,0
7830,04/06/2019 00:00,DB11801,Rapastinel,,,,,,,,,37.4,11.92,7.61,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O,,,,,0,,413.2274337,2,0,2,0,2,2
7831,04/06/2019 00:00,DB11804,AZD-5672,,,,,,,,,0.00182,19.4,7.43,CCN(C1CCN(CC[C@H](C2=CC=C(C=C2)S(C)(=O)=O)C2=CC(F)=CC(F)=C2)CC1)C(=O)CC1=CC=C(C=C1)S(C)(=O)=O,,,,,0,,632.2190208,4,3,1,0,1,1
7832,04/06/2019 00:00,DB11805,Saracatinib,,,,,,,,,0.0942,11.81,8.19,CN1CCN(CCOC2=CC3=C(C(NC4=C(Cl)C=CC5=C4OCO5)=NC=N3)C(OC3CCOCC3)=C2)CC1,,,,,0,,541.2091968,6,3,4,1,2,3
7833,04/06/2019 00:00,DB11806,VTP-194204,,,,,,,,,0.000104,4.83,,C\C(\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(=C1)C(C)(C)CCC2(C)C)=C/C(O)=O,,,,,0,,352.2402303,3,1,0,0,0,0
7834,04/06/2019 00:00,DB11807,Dexmecamylamine,,,,,,,,,0.124,,10.88,CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C,,,,,0,,167.1673997,2,0,0,0,0,0
7835,04/06/2019 00:00,DB11808,Faldaprevir,,,,,,,,,0.00295,3.38,1.11,[H][C@@](N=C(O)OC1CCCC1)(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=O)OC1=C2C=CC(OC)=C(Br)C2=NC(=C1)C1=CSC(N=C(O)C(C)C)=N1)C(C)(C)C,,,,,0,,868.2465102,6,3,3,2,1,1
7836,04/06/2019 00:00,DB11809,Artefenomel,,,,,,,,,0.000467,,6.71,C(CN1CCOCC1)OC1=CC=C(C=C1)[C@H]1CC[C@]2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3,,,,,0,,469.2828233,8,1,2,0,2,2
7837,04/06/2019 00:00,DB11810,Etarfolatide,,,,,,,,,0.0697,2.87,7.1,N[C@@H](CNC(=O)CC[C@@H](NC(=O)C1=CC=C(NCC2=CNC3=NC=NC(=O)C3=N2)C=C1)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O,,,,,0,,730.2129229,3,1,2,0,0,2
7838,04/06/2019 00:00,DB11811,Arhalofenate,,,,,,,,,0.00166,14.75,-1.6,CC(=O)NCCOC(=O)[C@H](OC1=CC=CC(=C1)C(F)(F)F)C1=CC=C(Cl)C=C1,,,,,0,,415.0798204,2,2,0,0,0,0
7839,04/06/2019 00:00,DB11812,Talaporfin,,,,,,,,,0.00797,2.79,5.45,CCC1=C(C)\C2=C\C3=C(C=C)C(C)=C(N3)\C=C3/N=C([C@@H](CCC(O)=O)[C@@H]3C)/C(/CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C3\N\C(=C/C1=N2)C(C)=C3C(O)=O,,,,,0,,711.2904279,5,3,5,3,0,2
7840,04/06/2019 00:00,DB11813,Mipsagargin,,,,,,,,,0.00891,2.52,7.35,CCCCCCCC(=O)O[C@@H]1[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]3OC(=O)[C@@](C)(O)[C@@]3(O)[C@H](C[C@](C)(OC(C)=O)[C@@H]12)OC(=O)CCCCCCCCCCCNC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C(O)=O,,,,,0,,1408.663642,3,0,1,0,1,1
7841,04/06/2019 00:00,DB11814,PF-03882845,,,,,,,,,0.00499,4.09,3.39,OC(=O)C1=CC2=C(C=C1)C1=NN([C@@H](C3CCCC3)[C@H]1CC2)C1=CC=C(C#N)C(Cl)=C1,,,,,0,,419.1400546,5,2,1,0,0,1
7842,04/06/2019 00:00,DB11815,Tilarginine,,,,,,,,,1.45,2.48,12.64,CNC(=N)NCCC[C@H](N)C(O)=O,,,,,0,,188.1273258,0,0,0,0,0,0
7843,04/06/2019 00:00,DB11816,Omecamtiv Mecarbil,,,,,,,,,0.142,10.31,5.58,COC(=O)N1CCN(CC2=C(F)C(NC(=O)NC3=CC=C(C)N=C3)=CC=C2)CC1,,,,,0,,401.1863178,3,2,2,1,1,1
7844,02/07/2019 00:00,DB11817,Baricitinib,"Baricitinib diaplays a dose-proportional increase in systemic exposure in the therapeutic dose range with linear pharmacokinetics. When orally administered, baricitinb is rapidly absorbed with an oral bioavailability of approximately 79 % (CV = 3.94 %). It has a median time to reach peak plasma concentration (Tmax) of 1hour (range: 0.5-3hours). Food consumption affects the exposure by decreasing it by up to 14 %, and decreasing the peak plasma concentration (Cmax) by up to 18 % and Tmax by 0.5 hours [FDA Label]. ",%,Mean half-life in patients with rheumatoid arthritis is approximately 12.5 hrs (CV = 27.4 %) [FDA Label]. ,2 mg,Oral,solid,,,0.357,13.89,3.91,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,,,,,0,2,371.1164438,4,3,4,3,1,1
7845,04/06/2019 00:00,DB11818,Retosiban,,,,,,,,,0.156,10.88,0.44,CC[C@H](C)[C@H]1N([C@@H](C(=O)N2CCOCC2)C2=COC(C)=N2)C(=O)[C@H](NC1=O)C1CC2=CC=CC=C2C1,,,,,0,,494.2529202,5,2,3,1,2,2
7846,04/06/2019 00:00,DB11819,ASP-4058,,,,,,,,,0.0335,11.51,5.48,C[C@H](OC1=CC=C(C=C1C(F)(F)F)C1=NC(=NO1)C1=CC=C2NC=NC2=C1)C(F)(F)F,,,,,0,,442.0864449,4,4,2,2,0,0
7847,04/06/2019 00:00,DB11820,Nifurtimox,,,,,,,,,0.285,,0.34,CC1CS(=O)(=O)CCN1\N=C\C1=CC=C(O1)[N+]([O-])=O,,,,,0,,287.0575915,2,1,2,1,1,1
7848,04/06/2019 00:00,DB11821,Danegaptide,,,,,,,,,1.91,3.32,8.13,NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)C1=CC=CC=C1,,,,,0,,291.121906,2,1,1,0,1,1
7849,04/06/2019 00:00,DB11822,TMC-647055,,,,,,,,,0.00371,4.16,-0.39,COC1=CC=C2C3=C(C4CCCCC4)C4=CC=C5C=C4N3CC(=CC2=C1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O,,,,,0,,606.2512059,6,3,3,1,0,2
7850,04/06/2019 00:00,DB11823,Esketamine,"Due to the fact that this drug is administered via nasal spray, absorption is rapid. The mean absolute bioavailability is approximately 48% after esketamine nasal spray administration. The time to achieve peak esketamine plasma concentration is 20 to 40 minutes after the last nasal spray of esketamine. Inter-subject variability of esketamine ranges from 27% to 66% for Cmax (maximum concentration) and 18% to 45% for AUC (area under the curve). The intra-subject variability of esketamine is about 15% for Cmax and 10% for AUC [FDA label]. ",0.43,The mean terminal half-life (t1/2) ranges from 7 to 12 hours [FDA label]. ,28 mg/0.2mL,Nasal,solid,feely soluble in water,3.2887,0.0464,19.77,7.16,CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl,0.43,0.43,,,0,,237.0920418,2,1,0,0,0,0
7851,04/06/2019 00:00,DB11824,Tofogliflozin,,,,,,,,,0.327,12,-3,CCC1=CC=C(CC2=CC=C3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=C2)C=C1,,,,,0,,386.1729386,4,2,2,0,1,2
7852,04/06/2019 00:00,DB11825,Mirogabalin,,,,,,,,,1.53,4.54,9.9,CCC1=C[C@@H]2[C@@H](C[C@]2(CN)CC(O)=O)C1,,,,,0,,209.1415788,2,0,0,0,0,0
7853,02/07/2019 00:00,DB11827,Ertugliflozin,"Preclinical studies showed that ertugliflozin is well absorbed and had an oral bioavailability of 70-90%. The reported Tmax occurred at 0.5-1.5 hours after dosage.[A31583] Following oral administration, the Cmax and AUC appeared to be dose proportional.Administration of 15 mg reported values of Cmax and AUC of 268 ng/ml and 1193 ng h/ml respectively.[L1136]",94-96%,The terminal elimination half-life of ertugliflozin is 11-17 hours.[A31583],15 mg,Oral,solid,Very slightly soluble,,0.119,11.98,-3.1,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1,0.94,0.96,,,0,15,436.1288808,4,2,2,0,2,2
7854,04/06/2019 00:00,DB11828,Neratinib,"Neratinib and its major active metabolites M3. M6, and M7 have a Tmax of 2-8 h [FDA Label]. Administration with a high fat meal increases Cmax by 1.7-fold and total exposure by 2.2-fold. Administration with a standard meal increases Cmax by 1.2-fold and total exposure by 1.1-fold. Administration with gastric acid reducing agents such as proton pump inhibitors reduces Cmax by 71% and total exposure by 65%.",0.99,"The mean half life of elimination ranges from 7-17 h following a single dose [FDA Label]. The mean plasma half life during multiple doses is 14.6 h for neratinib, 21.6 h for M3, 13.8 h for M6, and 10.4 h for M7.",40 mg/1,Oral,solid,,,0.00674,12.55,8.81,CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N,0.99,0.99,,,0,40,556.1989665,4,4,2,2,0,0
7855,04/06/2019 00:00,DB11829,Ruboxistaurin,,,,,,,,,0.0337,7.03,8.8,[H][C@@]1(CN(C)C)CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)N=C2O)C2=CN(CCO1)C1=CC=CC=C21,,,,,0,,468.2161408,6,4,4,2,0,2
7856,04/06/2019 00:00,DB11830,Mocetinostat,,,,,,,,,0.00854,13.98,4.37,NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1,,,,,0,,396.1698593,4,4,2,2,0,0
7857,04/06/2019 00:00,DB11831,Dinitrochlorobenzene,,,,,,,,,0.0366,19.94,,ClC1=C(C=C(C=C1)N(=O)=O)N(=O)=O,,,,,0,,201.9781343,1,1,0,0,0,0
7858,04/06/2019 00:00,DB11832,Crenolanib,,,,,,,,,0.0129,,10.03,CC1(COC2=CC=C3N(C=NC3=C2)C2=CC=C3C=CC=C(N4CCC(N)CC4)C3=N2)COC1,,,,,0,,443.2321252,6,4,4,2,2,2
7859,04/06/2019 00:00,DB11833,Basimglurant,,,,,,,,,0.00504,,5.46,CC1=NC(C#CC2=CC=NC(Cl)=C2)=C(C)N1C1=CC=C(F)C=C1,,,,,0,,325.0782033,3,3,2,2,0,0
7860,04/06/2019 00:00,DB11835,Indium In-111 pentetreotide,,,,,,,,,0.0217,2.08,,[111In+3].CC(O)C(CO)N=C(O)C1CSSCC(N=C(O)C(CC2=CC=CC=C2)N=C([O-])CN(CCN(CCC(C(O)=O)C(O)=O)CC([O-])=O)CC([O-])=O)C(O)=NC(CC2=CC=CC=C2)C(O)=NC(CC2=CNC3=CC=CC=C23)C(O)=NC(CCCCN)C([O-])=NC(C(C)O)C(O)=N1,,,,,-1,,1471.416062,5,4,2,1,0,1
7861,04/06/2019 00:00,DB11836,Sapanisertib,,,,,,,,,0.23,13.86,4.07,CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1,,,,,0,,309.1338081,4,4,3,3,0,0
7862,04/06/2019 00:00,DB11837,Osilodrostat,,,,,,,,,0.356,,7.15,FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12,,,,,0,,227.0858755,3,2,2,1,0,1
7863,04/06/2019 00:00,DB11838,Revamilast,,,,,,,,,0.0209,9.51,4,[O-][N+]1=CC(Cl)=C(NC(=O)C2=CC=C(OC(F)F)C3=C2C2=C(O3)C=CN=C2)C(Cl)=C1,,,,,0,,438.9938176,4,4,3,3,0,0
7864,04/06/2019 00:00,DB11839,PZ-128,,,,,,,,,0.00282,11.51,11.9,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,,,,,0,,1085.768872,1,1,0,0,0,0
7865,04/06/2019 00:00,DB11841,Entinostat,,,,,,,,,0.00574,13.54,4.74,NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1,,,,,0,,376.1535405,3,3,1,1,0,0
7866,04/06/2019 00:00,DB11842,Angiotensin II,"Following the intravenous infusion of angiotensin II in adult patients with septic or other distributive shock, the serum levels of angiotensin II observed were similar at baseline and hour 3 after the intravenous infusion. After 3 hours of treatment, the serum level of angiotensin I (the angiotensin II precursos peptide) is however, reduced by about 40% [FDA Label].",,The plasma half-life of intravenously administered angiotensin II is less than one minute [FDA Label].,2.5 mg/1mL,Intravenous,liquid,,,0.0156,3.15,10.83,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O,,,,,0,,1045.534515,4,3,2,1,1,1
7867,04/06/2019 00:00,DB11843,PF-04958242,,,,,,,,,0.0176,9.07,-4.1,CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC1=CC=C(C=C1)C1=CC=C(S1)C#N,,,,,0,,392.0864491,3,2,2,1,1,1
7868,04/06/2019 00:00,DB11844,Pritelivir,,,,,,,,,0.0115,8.58,4.42,CN(C(=O)CC1=CC=C(C=C1)C1=CC=CC=N1)C1=NC(C)=C(S1)S(N)(=O)=O,,,,,0,,402.0820324,3,3,2,2,0,0
7869,04/06/2019 00:00,DB11845,Lucitanib,,,,,,,,,0.00128,15.34,9.39,CNC(=O)C1=C2C=CC(OC3=C4C=C(OC)C(OCC5(N)CC5)=CC4=NC=C3)=CC2=CC=C1,,,,,0,,443.1845063,5,4,1,1,0,0
7870,04/06/2019 00:00,DB11846,Creatinine,,,,,,,,,9.92,13.19,2.96,CN1CC(=O)NC1=N,,,,,0,,113.0589118,1,0,1,0,1,1
7871,04/06/2019 00:00,DB11847,Cadazolid,,,,,,,,,0.264,6.06,0.31,OC[C@H]1CN(C(=O)O1)C1=CC(F)=C(OCC2(O)CCN(CC2)C2=C(F)C=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O)C=C1,,,,,0,,585.1922713,6,3,3,1,2,2
7872,04/06/2019 00:00,DB11848,Mannose 6-phosphate,,,,,,,,,21.7,1.49,-3.5,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)C=O,,,,,0,,260.0297186,0,0,0,0,0,0
7873,04/06/2019 00:00,DB11851,Bafetinib,,,,,,,,,0.00691,7.23,9.49,[H][C@@]1(CCN(CC2=C(C=C(C=C2)C(O)=NC2=CC(NC3=NC=CC(=N3)C3=CN=CN=C3)=C(C)C=C2)C(F)(F)F)C1)N(C)C,,,,,0,,576.2572923,5,4,3,2,1,1
7874,04/06/2019 00:00,DB11852,Tegobuvir,,,,,,,,,0.00222,,1.96,FC1=CC=CC=C1C1=NC2=CN(CC3=CC=C(N=N3)C3=CC=C(C=C3C(F)(F)F)C(F)(F)F)C=CC2=N1,,,,,0,,517.113743,5,3,3,1,0,2
7875,04/06/2019 00:00,DB11853,Relugolix,,,,,,,,,0.00198,9.07,7.69,CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1,,,,,0,,623.1762444,5,5,3,3,0,0
7876,04/06/2019 00:00,DB11855,Revefenacin,"In pharmacokinetic studies, revefenacin was absorbed very rapidly and presented a linear increase in plasma exposure with Cmax, tmax and AUC that ranged between 0.02-0.15 ng/ml, 0.48-0.51 hours and 0.03-0.36 ng.h/ml, respectively.[A40025] The bioaccumulation of revefenacin was very limited and the steady-state was achieved by day 7.[L4822]",0.71,The apparent terminal half-life of a dose of 350 mcg of revefenacin was 22.3-70 hours.[A40025],175 ug/3mL,Respiratory (inhalation),solid,< 1 mg/ml,3.22,0.00721,12.74,8.65,CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1,0.71,0.71,,,0,,597.3315049,5,3,2,0,2,2
7877,04/06/2019 00:00,DB11858,Leukotriene D4,,,,,,,,,0.00258,3.29,8.05,CCCCC\C=C/C\C=C/C=C/C=C/[C@@H](SC[C@H](N)C(=O)NCC(O)=O)[C@@H](O)CCCC(O)=O,,,,,0,,496.260708,0,0,0,0,0,0
7878,04/06/2019 00:00,DB11859,Brexanolone,"It has been determined that brexanolone has a low oral bioavailability of approximately <5% in adults, which suggests infant exposure would also be expected to be low [FDA Label].",0.99,The terminal half-life observed for brexanolone is approximately 9 hours [FDA Label].,5 mg/1mL,Intravenous,solid,,,0.00136,18.3,-1.4,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O,0.99,0.99,,,0,,318.2558803,4,0,0,0,0,0
7879,04/06/2019 00:00,DB11860,Aramchol,,,,,,,,,7.83E-05,4.48,-0.088,CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1,,,,,0,,701.5958246,4,0,0,0,0,0
7880,04/06/2019 00:00,DB11861,Litronesib,,,,,,,,,0.0162,8.35,9.2,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)C1=CC=CC=C1,,,,,0,,511.2286967,2,1,1,0,0,1
7881,04/06/2019 00:00,DB11863,Alvelestat,,,,,,,,,0.00275,12.17,2,CN1N=CC=C1C1=C(C)N(C2=CC=CC(=C2)C(F)(F)F)C(=O)C(=C1)C(=O)NCC1=NC=C(C=C1)S(C)(=O)=O,,,,,0,,545.1344598,4,4,3,3,0,0
7882,04/06/2019 00:00,DB11864,Preladenant,,,,,,,,,0.218,,7.95,COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1,,,,,0,,503.2393358,6,5,5,4,1,1
7883,04/06/2019 00:00,DB11865,Brivanib alaninate,,,,,,,,,0.0127,16.59,7.34,C[C@H](COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C)OC(=O)[C@H](C)N,,,,,0,,441.1812325,4,4,3,3,0,0
7884,04/06/2019 00:00,DB11867,JNJ-39393406,,,,,,,,,0.0956,11.4,3.84,CN(C)C(=O)CCN1N=C(NC2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC=NC=C1,,,,,0,,416.1408449,4,3,3,2,0,1
7885,04/06/2019 00:00,DB11868,Etiracetam,,,,,,,,,2.74,-2.2,13.02,CCC(N1CCCC1=O)C(O)=N,,,,,0,,170.1055277,1,0,1,0,1,1
7886,04/06/2019 00:00,DB11869,Valspodar,,,,,,,,,0.0052,11.78,-2.3,C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C,,,,,0,,1213.841368,1,0,1,0,1,1
7887,04/06/2019 00:00,DB11870,RG-4733,,,,,,,,,0.00228,10.85,-4.5,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C2=CC=CC=C2NC1=O,,,,,0,,469.1424826,3,2,1,0,0,1
7888,04/06/2019 00:00,DB11871,PF-00610355,,,,,,,,,0.00121,7.85,9.58,CC(C)(CC1=CC=CC(CC(=O)NCC2=CC=CC(=C2)C2=CC=C(O)C=C2)=C1)NC[C@H](O)C1=CC=C(O)C(NS(C)(=O)=O)=C1,,,,,0,,617.255957,4,4,0,0,0,0
7889,04/06/2019 00:00,DB11872,ZD-6126,,,,,,,,,0.0165,1.79,-1.5,COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=C2C=CC(OP(O)(O)=O)=C3)=C1,,,,,0,,437.1239534,3,2,0,0,0,0
7890,04/06/2019 00:00,DB11873,Verinurad,,,,,,,,,0.00471,3.59,4.8,CC(C)(SC1=CC=NC=C1C1=C2C=CC=CC2=C(C=C1)C#N)C(O)=O,,,,,0,,348.0932488,3,3,1,1,0,0
7891,04/06/2019 00:00,DB11874,Crocin,,,,,,,,,0.567,11.67,-3.7,C\C(\C=C\C=C(/C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,976.3787529,4,0,4,0,4,4
7892,04/06/2019 00:00,DB11875,"3,3'-diindolylmethane",,,,,,,,,0.00163,16.52,,C(C1=CNC2=CC=CC=C12)C1=CNC2=CC=CC=C12,,,,,0,,246.1156984,4,4,2,2,0,0
7893,04/06/2019 00:00,DB11876,Alanyl Glutamine,,,,,,,,,1,-0.56,13.02,[H][C@@](C)(N)C(O)=N[C@@]([H])(CCC(O)=N)C(O)=O,,,,,0,,217.106256,0,0,0,0,0,0
7894,04/06/2019 00:00,DB11877,Basmisanil,,,,,,,,,0.223,,1.34,CC1=C(COC2=CC=C(C=N2)C(=O)N2CCS(=O)(=O)CC2)C(=NO1)C1=CC=C(F)C=C1,,,,,0,,445.11077,4,3,3,2,1,1
7895,04/06/2019 00:00,DB11878,Filibuvir,,,,,,,,,0.0104,7.03,6.04,CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C2CCCC2)=CC(CC)=N1,,,,,0,,503.28964,5,3,4,3,0,1
7896,04/06/2019 00:00,DB11879,Dusquetide,,,,,,,,,0.0992,12.21,11.74,CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(N)=O,,,,,0,,553.3700156,1,0,1,0,1,1
7897,04/06/2019 00:00,DB11880,Acridine Carboxamide,,,,,,,,,0.0376,14.76,8.51,CN(C)CCNC(=O)C1=C2N=C3C=CC=CC3=CC2=CC=C1,,,,,0,,293.1528122,3,3,1,1,0,0
7898,04/06/2019 00:00,DB11881,AUY922,,,,,,,,,0.0658,8.5,7.05,CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=CC(=C(O)C=C1O)C(C)(C)C,,,,,0,,479.2420212,4,3,2,1,1,1
7899,04/06/2019 00:00,DB11882,BPC-157,,,,,,,,,0.508,2.96,10.2,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)CN)C(=O)N[C@@H](C(C)C)C(O)=O,,,,,0,,1418.704159,4,0,4,0,4,4
7900,04/06/2019 00:00,DB11883,SB-705498,,,,,,,,,0.0188,12.38,5.26,FC(F)(F)C1=CC=C(N=C1)N1CC[C@H](C1)NC(=O)NC1=CC=CC=C1Br,,,,,0,,428.0459579,3,2,2,1,1,1
7901,04/06/2019 00:00,DB11885,Anlotinib,,,,,,,,,0.00238,16.65,9.39,COC1=CC2=C(OC3=CC=C4NC(C)=CC4=C3F)C=CN=C2C=C1OCC1(N)CC1,,,,,0,,407.1645198,5,4,2,2,0,0
7902,04/06/2019 00:00,DB11886,Infigratinib,,,,,,,,,0.0183,7.2,8.28,CCN1CCN(CC1)C1=CC=C(NC2=CC(=NC=N2)N(C)C(O)=NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1,,,,,0,,559.1865432,4,3,2,1,1,1
7903,04/06/2019 00:00,DB11888,Laninamivir octanoate,,,,,,,,,0.171,3.45,11.89,[H][C@@](O)(COC(=O)CCCCCCC)[C@@]([H])(OC)[C@]1([H])OC(=C[C@]([H])(NC(N)=N)[C@@]1([H])N=C(C)O)C(O)=O,,,,,0,,472.2533141,1,0,1,0,0,1
7904,04/06/2019 00:00,DB11889,Lanicemine,,,,,,,,,1.85,,9.31,N[C@@H](CC1=CC=CC=N1)C1=CC=CC=C1,,,,,0,,198.1156984,2,2,1,1,0,0
7905,04/06/2019 00:00,DB11890,Cilengitide,,,,,,,,,0.144,3.59,12.02,CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O,,,,,0,,588.3019956,2,1,1,0,1,1
7906,04/06/2019 00:00,DB11891,CUDC-907,,,,,,,,,0.0153,9.24,3.36,COC1=CC=C(C=N1)C1=NC(N2CCOCC2)=C2SC(CN(C)C3=NC=C(C=N3)C(=O)NO)=CC2=N1,,,,,0,,508.1641222,5,4,5,4,1,1
7907,04/06/2019 00:00,DB11892,Prulifloxacin,,,,,,,,,0.593,6.03,5.16,CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N1CCN(CC2=C(C)OC(=O)O2)CC1,,,,,0,,461.1056846,5,3,4,2,1,2
7908,04/06/2019 00:00,DB11893,Avagacestat,,,,,,,,,0.0269,14.02,-2.4,NC(=O)[C@@H](CCC(F)(F)F)N(CC1=CC=C(C=C1F)C1=NOC=N1)S(=O)(=O)C1=CC=C(Cl)C=C1,,,,,0,,520.0595166,3,3,1,1,0,0
7909,04/06/2019 00:00,DB11894,Efatutazone,,,,,,,,,0.00599,7.61,4.86,CN1C(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)=NC2=CC=C(OC3=CC(C)=C(N)C(C)=C3)C=C12,,,,,0,,502.1674763,5,4,2,1,1,1
7910,04/06/2019 00:00,DB11896,Gedatolisib,,,,,,,,,0.0382,11.17,9.67,CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1,,,,,0,,615.3281508,6,3,4,1,3,3
7911,04/06/2019 00:00,DB11898,"2,4-thiazolidinedione",,,,,,,,,77.9,7.36,,O=C1CSC(=O)N1,,,,,0,,116.9884493,1,0,1,0,1,1
7912,04/06/2019 00:00,DB11899,MK-8776,,,,,,,,,0.0971,,9.57,CN1C=C(C=N1)C1=C2N=C([C@@H]3CCCNC3)C(Br)=C(N)N2N=C1,,,,,0,,375.0807057,4,3,4,3,1,1
7913,04/06/2019 00:00,DB11900,OC-459,,,,,,,,,0.00211,4.45,3.84,CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O,,,,,0,,348.127406,4,4,2,2,0,0
7914,02/07/2019 00:00,DB11901,Apalutamide,"Mean absolute oral bioavailability was approximately 100%. Median time to achieve peak plasma concentration (tmax) was 2 hours (range: 1 to 5 hours). Median tmax may be increased with a high-fat meal. Administration of oral apalutamide at recommended dosages resulted in a steady state within 4 weeks with a maximum peak concentration (Cmax) and AUC of 6.0 mcg/mL and 100 mcgÂ·h/mL, respectively [FDA Label]. Cmax and AUC of apalutamide is expected to increase in a dose-proportional manner. The mean mean peak-to-trough ratio was 1.63 indicating low daily fluctuations in the plasma concentrations of the drug. 

The major active metabolite N-desmethyl apalutamide Cmax was 5.9 mcg/mL (1.0) and AUC was 124 mcgÂ·h/mL (23) at steady-state after the recommended dosage. ",0.96,The mean effective half-life for apalutamide in patients with NM-CRPC was approximately 3 days at steady-state [FDA Label].,60 mg,Oral,solid,,,0.00178,13.05,-0.75,CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F,0.96,0.96,,,0,60,477.0882586,4,2,2,1,1,1
7915,04/06/2019 00:00,DB11902,Gisadenafil,,,,,,,,,0.54,8.02,6.11,CCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1,,,,,0,,519.2263882,4,3,4,3,1,1
7916,04/06/2019 00:00,DB11903,GW842166,,,,,,,,,0.0044,10.78,-1.2,FC(F)(F)C1=NC(NC2=C(Cl)C=C(Cl)C=C2)=NC=C1C(=O)NCC1CCOCC1,,,,,0,,448.0680658,3,2,2,1,1,1
7917,04/06/2019 00:00,DB11904,Flumatinib,,,,,,,,,0.0102,11.21,7.57,CN1CCN(CC2=CC=C(C=C2C(F)(F)F)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)N=C2)CC1,,,,,0,,562.2416422,5,4,4,3,1,1
7918,04/06/2019 00:00,DB11905,Sutezolid,,,,,,,,,0.237,14.85,-0.14,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(N2CCSCC2)C(F)=C1,,,,,0,,353.1209407,3,1,2,0,2,2
7919,04/06/2019 00:00,DB11906,Acyline,,,,,,,,,0.00321,10.61,11.36,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(C)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(C)=O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,,,,,0,,1531.741921,7,6,2,1,1,1
7920,04/06/2019 00:00,DB11907,Rociletinib,,,,,,,,,0.0162,13.63,3.62,COC1=CC(=CC=C1NC1=NC=C(C(NC2=CC=CC(NC(=O)C=C)=C2)=N1)C(F)(F)F)N1CCN(CC1)C(C)=O,,,,,0,,555.2205724,4,3,2,1,1,1
7921,04/06/2019 00:00,DB11909,Varespladib,,,,,,,,,0.00699,3.63,-3.7,CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=CC=C2N1CC1=CC=CC=C1,,,,,0,,380.1372217,3,3,1,1,0,0
7922,04/06/2019 00:00,DB11910,MK-0249,,,,,,,,,0.00312,,9.37,CC1=NC2=CC=CC(=C2C(=O)N1C1=CC=C(OCCCN2CCCC2)C=C1)C(F)(F)F,,,,,0,,431.1820617,4,3,2,1,1,1
7923,04/06/2019 00:00,DB11911,Galunisertib,,,,,,,,,0.0112,14.58,3.36,CC1=CC=CC(=N1)C1=NN2CCCC2=C1C1=C2C=C(C=CC2=NC=C1)C(N)=O,,,,,0,,369.1589602,5,4,4,3,0,1
7924,04/06/2019 00:00,DB11912,Lanopepden,,,,,,,,,0.304,8.42,7.09,CC1=NC(NNC(=O)[C@H](CC2CCCC2)CN(O)C=O)=C(F)C(=N1)N1CCN2CCOC[C@@H]2C1,,,,,0,,479.2656308,4,1,3,1,2,2
7925,04/06/2019 00:00,DB11913,LY-2090314,,,,,,,,,0.0323,9.82,5.56,FC1=CC2=C3N(CCN(C2)C(=O)N2CCCCC2)C=C(C3=C1)C1=C(C(=O)NC1=O)C1=CN=C2C=CC=CN12,,,,,0,,512.1972169,7,4,6,3,1,3
7926,04/06/2019 00:00,DB11915,Valbenazine,Oral bioavailability of 49% [FDA Label]. Tmax of 0.5-1h. ,>99%,Both valbenazine and its active metabolite [+]-Î±-HTBZ have a half life of 15-22 hours [FDA Label].,40 mg/1,Oral,solid,,,0.0383,,8.41,COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1,0.99,1,,,0,40,418.2831577,3,1,2,0,1,2
7927,04/06/2019 00:00,DB11917,Vatiquinone,,,,,,,,,0.00125,19.53,-0.82,CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O,,,,,0,,440.3290453,1,0,0,0,0,0
7928,04/06/2019 00:00,DB11918,Guadecitabine,,,,,,,,,2.89,1.79,2.67,NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)O[C@H]2C[C@@H](O[C@@H]2CO)N2C=NC(N)=NC2=O)O1,,,,,0,,557.1383746,5,3,5,3,2,2
7929,04/06/2019 00:00,DB11919,6-O-benzylguanine,,,,,,,,,0.12,12.86,5.21,N=C1NC2=C(N=CN2)C(OCC2=CC=CC=C2)=N1,,,,,0,,241.09636,3,3,2,2,0,0
7930,04/06/2019 00:00,DB11920,Lesogaberan,,,,,,,,,132,2.16,8.92,NC[C@@H](F)CP(O)=O,,,,,0,,141.0354934,0,0,0,0,0,0
7931,19/06/2019 00:00,DB11921,Deflazacort,"Deflazacort is rapidly absorbed after oral administration with peak concentration occurring within 1-2 hours.[A179464,FDA label] One pharmacokinetic study determined an AUC (area under the curve) of 280 ng/ml Â· h.[A18725]

The bioavailability of both the oral suspension and tablet are similar.[FDA label] In clinical studies, coadministration of deflazacort crushed with food or applesauce did not affect absorption or bioavailability.[FDA label]
",,"The half-life of deflazacort ranges from 1.1 to 1.9 h [A18725,L6703] ",22.75 mg/1mL,Oral,solid,108 Î¼g/mL,2.4,0.0175,14.74,0.48,[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@]([H])(O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O,,,,,0,,441.2151377,5,0,1,0,0,1
7932,04/06/2019 00:00,DB11922,Danirixin,,,,,,,,,0.0662,5.34,8.22,CC1=C(NC(=O)NC2=CC=C(Cl)C(=C2O)S(=O)(=O)[C@H]2CCCNC2)C=CC=C1F,,,,,0,,441.0925331,3,2,1,0,1,1
7933,04/06/2019 00:00,DB11923,Decoglurant,,,,,,,,,0.0023,,4.54,NC1=CC=C(C=N1)C#CC1=C2N=C(C=C(N2N=C1)C(F)(F)F)C1=CC=C(C=C1)C(F)(F)F,,,,,0,,447.0918647,4,4,3,3,0,0
7934,04/06/2019 00:00,DB11924,Safingol,,,,,,,,,0.00453,14.42,9.29,CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO,,,,,0,,301.2980795,0,0,0,0,0,0
7935,04/06/2019 00:00,DB11925,Vistusertib,,,,,,,,,0.0692,14.84,2,CNC(=O)C1=CC(=CC=C1)C1=CC=C2C(N=C(N=C2N2CCOC[C@@H]2C)N2CCOC[C@@H]2C)=N1,,,,,0,,462.2379388,5,3,4,2,2,2
7936,04/06/2019 00:00,DB11927,Lodenafil carbonate,,,,,,,,,0.0928,7.6,5.47,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CCOC(=O)OCCN2CCN(CC2)S(=O)(=O)C2=CC=C(OCC)C(=C2)C2=NC3=C(N(C)N=C3CCC)C(=O)N2)CC1,,,,,0,,1034.410243,8,6,6,4,2,2
7937,04/06/2019 00:00,DB11929,Vaniprevir,,,,,,,,,0.0108,5.44,0.68,[H][C@@]1(CC)C[C@]1(N=C(O)[C@]1([H])C[C@]2([H])CN1C(=O)[C@@]([H])(N=C(O)OCC(C)(C)CCCCC1=C3CN(CC3=CC=C1)C(=O)O2)C(C)(C)C)C(O)=NS(=O)(=O)C1CC1,,,,,0,,757.3720493,6,1,3,0,1,3
7938,04/06/2019 00:00,DB11932,Abametapir,,,,,,,,,0.98,,3.8,CC1=CC=C(N=C1)C1=CC=C(C)C=N1,,,,,0,,184.1000484,2,2,2,2,0,0
7939,04/06/2019 00:00,DB11933,Riboprine,,,,,Oral,,,,4.23,12.45,4.85,[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(NCC=C(C)C)N=CN=C23)[C@]([H])(O)[C@]1([H])O,,,,,0,,335.1593542,3,2,3,2,1,1
7940,04/06/2019 00:00,DB11934,Epelsiban,,,,,,,,,0.0985,11.19,6.21,CC[C@H](C)[C@H]1N([C@@H](C(=O)N2CCOCC2)C2=CC=C(C)N=C2C)C(=O)[C@H](NC1=O)C1CC2=CC=CC=C2C1,,,,,0,,518.2893057,5,2,3,1,2,2
7941,04/06/2019 00:00,DB11935,Flomoxef,,,,,,,,,1.22,3.28,-1.5,CO[C@]1(NC(=O)CSC(F)F)[C@H]2OCC(CSC3=NN=NN3CCO)=C(N2C1=O)C(O)=O,,,,,0,,496.0646454,3,1,3,1,1,2
7942,04/06/2019 00:00,DB11936,Bempedoic acid,,,,,,,,,0.0211,4.44,-1.3,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,,,,,0,,344.2562743,0,0,0,0,0,0
7943,04/06/2019 00:00,DB11937,Kynurenic Acid,,,,,,,,,0.954,3.17,-4.4,OC(=O)C1=CC(=O)C2=CC=CC=C2N1,,,,,0,,189.0425931,2,2,1,1,0,0
7944,04/06/2019 00:00,DB11938,Difelikefalin,,,,,,,,,0.0103,1.92,10.26,CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O,,,,,0,,679.4057324,3,2,1,0,1,1
7945,04/06/2019 00:00,DB11939,Henagliflozin,,,,,,,,,0.182,11.98,-3.1,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@]23OC[C@@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1F,,,,,0,,454.119459,4,2,2,0,2,2
7946,04/06/2019 00:00,DB11940,Triapine,,,,,,,,,0.323,11.67,4.95,NC(=S)N\N=C\C1=C(N)C=CC=N1,,,,,0,,195.0578663,1,1,1,1,0,0
7947,04/06/2019 00:00,DB11941,Tasisulam,,,,,,,,,0.00269,4.03,,ClC1=CC(Cl)=C(C=C1)C(=O)NS(=O)(=O)C1=CC=C(Br)S1,,,,,0,,412.8349525,2,2,1,1,0,0
7948,04/06/2019 00:00,DB11942,Selinexor,,,,,,,,,0.00555,12.18,1.34,FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F,,,,,0,,443.0929273,3,3,2,2,0,0
7949,04/06/2019 00:00,DB11943,Delafloxacin,The median time to peak plasma concentration for orally administered Delafloxacin is 0.75 (0.5-4.0) hours after a single dose and 1.00 (0.5-6.0) hours for steady state dosing [FDA Label]. The median time to peak plasma concentration for intravenously administered Delafloxacin is 1.00 (1.0-1.2) hours for a single dose and 1.0 (1.0-1.0) hour for steady state dosing. The absolute bioavailability for orally administed Delafloxacin is 58.8%.,0.84,The mean half life of elimination of Delafloxacin is 3.7 hours after a single intravenous administration [FDA Label]. The mean half life of elimination for multple oral administrations is 4.2-8.5 hours.,300 mg/10.5mL,Intravenous,solid,,,0.0699,5.62,-1.3,NC1=NC(N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23)=C(F)C=C1F,0.84,0.84,,,0,,440.0499172,4,3,3,2,1,1
7950,04/06/2019 00:00,DB11944,Ingavirin,,,,,,,,,1.87,4.15,6.55,OC(=O)CCCC(=O)NCCC1=CNC=N1,,,,,0,,225.1113413,1,1,1,1,0,0
7951,04/06/2019 00:00,DB11946,AZD-1981,,,,,,,,,0.00637,3.85,-4.4,CC(=O)NC1=C2C(=CC=C1)N(CC(O)=O)C(C)=C2SC1=CC=C(Cl)C=C1,,,,,0,,388.0648411,3,3,1,1,0,0
7952,04/06/2019 00:00,DB11947,Pridopidine,,,,,,,,,0.045,19.7,8.03,CCCN1CCC(CC1)C1=CC=CC(=C1)S(C)(=O)=O,,,,,0,,281.14495,2,1,1,0,1,1
7953,04/06/2019 00:00,DB11948,Lapachone,,,,,,,,,0.0563,,-4.9,CC1(C)CCC2=C(O1)C1=CC=CC=C1C(=O)C2=O,,,,,0,,242.0942943,3,1,1,0,0,1
7954,04/06/2019 00:00,DB11949,Vestipitant,,,,,,,,,0.00434,,7.45,C[C@@H](N(C)C(=O)N1CCNC[C@@H]1C1=CC=C(F)C=C1C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,,,,,0,,491.1807599,3,2,1,0,1,1
7955,04/06/2019 00:00,DB11950,Teneligliptin,,,,,,,,,1.4,,9.38,[H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1,,,,,0,,426.2201806,5,2,4,1,3,3
7956,04/06/2019 00:00,DB11951,Lemborexant,,,,,,,,,0.0111,12.12,3.15,CC1=NC(C)=C(OC[C@]2(C[C@H]2C(=O)NC2=CC=C(F)C=N2)C2=CC=CC(F)=C2)C=N1,,,,,0,,410.1554323,4,3,2,2,0,0
7957,04/06/2019 00:00,DB11952,Duvelisib,Duvelisib is rapidly absorbed and its peak plasma concentration is reached 1-2 hours after initial administration with a bioavailability of 42% and with a minimal accumulation whose rate ranges between 1.5 and 2.9.[A39034] The maximal plasma concentration is reported to range in between 471 to 3294 ng/ml with a systemic exposure ranging from 2001 to 19059 ng.h/ml. Changes in the administered dose produce correspondent changes in all absorption parameters indicating a dose-response profile.[A39035],0.98,The reported half-life of duvelisib is in the range of 5.2 to 10.9 hours.[A39035],15 mg/1,Oral,solid,<1 mg/ml,4.55,0.0195,9.86,3.99,C[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1,0.98,0.98,,,0,15,416.1152368,5,5,3,3,0,0
7958,04/06/2019 00:00,DB11953,PF-04447943,,,,,,,,,0.629,12.31,6.53,[H][C@@]1(C)CN(CC2=NC=CC=N2)C[C@@]1([H])C1=NC2=C(C=NN2C2CCOCC2)C(O)=N1,,,,,0,,395.206973,5,3,5,3,2,2
7959,04/06/2019 00:00,DB11954,Lomibuvir,,,,,,,,,0.00443,4.08,-1.5,C[C@H]1CC[C@@H](CC1)C(=O)N([C@H]1CC[C@H](O)CC1)C1=C(SC(=C1)C#CC(C)(C)C)C(O)=O,,,,,0,,445.2286796,3,1,1,1,0,0
7960,04/06/2019 00:00,DB11956,Delanzomib,,,,,,,,,0.0587,8.64,0.46,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)C1=CC=CC(=N1)C1=CC=CC=C1)[C@@H](C)O)B(O)O,,,,,0,,413.2122014,2,2,1,1,0,0
7961,04/06/2019 00:00,DB11957,Idalopirdine,,,,,,,,,0.00356,16.75,9.59,FC(F)C(F)(F)COC1=CC=CC(CNCCC2=CNC3=CC(F)=CC=C23)=C1,,,,,0,,398.1417543,3,3,1,1,0,0
7962,04/06/2019 00:00,DB11958,Brivanib,,,,,,,,,0.049,14.83,2.04,C[C@@H](O)COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C,,,,,0,,370.1441187,4,4,3,3,0,0
7963,04/06/2019 00:00,DB11960,Carboxyamidotriazole,,,,,,,,,0.00318,13.13,0.69,NC(=O)C1=C(N)N(CC2=CC(Cl)=C(C(=O)C3=CC=C(Cl)C=C3)C(Cl)=C2)N=N1,,,,,0,,423.0056577,3,3,1,1,0,0
7964,04/06/2019 00:00,DB11961,AZD-1236,,,,,,,,,0.237,8.88,0.88,C[C@]1(CS(=O)(=O)N2CCC(CC2)OC2=CC=C(Cl)C=N2)NC(=O)NC1=O,,,,,0,,402.0764684,3,1,3,1,2,2
7965,04/06/2019 00:00,DB11962,GSK-1059615,,,,,,,,,0.00404,7.9,4.97,O=C1NC(=O)\C(S1)=C\C1=CC=C2N=CC=C(C3=CC=NC=C3)C2=C1,,,,,0,,333.0571976,4,3,3,2,1,1
7966,04/06/2019 00:00,DB11963,Dacomitinib,"Dacomitinib has shown a linear kinetics after single and multiple dose range studies. The absorption and distribution do not seem to be affected by food or the consumption of antacids. The peak plasma concentration after a dosage of 45 mg for 4 days is of 104 ng/ml.[A40012] The reported AUC0-24h and tmax are of 2213 ng.h/mL and 6 hours, respectively. As well, following oral administration, the absolute oral bioavailability is 80% [FDA Label].",,Dacomitinib is reported to have a very large half-life of 70 hours.[T367],15 mg,Oral,solid,<1 mg/mL ,3.92,0.00874,12.5,8.55,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,,,,,0,15,469.1680809,4,3,2,1,1,1
7967,04/06/2019 00:00,DB11964,Ilaprazole,,,,,,,,,0.0934,10.27,4.27,COC1=C(C)C(C[S+]([O-])C2=NC3=CC(=CC=C3N2)N2C=CC=C2)=NC=C1,,,,,0,,366.1150468,4,4,3,3,0,0
7968,04/06/2019 00:00,DB11965,SJG-136,,,,,,,,,0.0162,,4.4,COC1=CC2=C(C=C1OCCCOC1=CC3=C(C=C1OC)C(=O)N1CC(=C)C[C@H]1C=N3)N=C[C@@H]1CC(=C)CN1C2=O,,,,,0,,556.2321847,6,2,4,0,2,4
7969,04/06/2019 00:00,DB11966,BMS-986094,,,,,,,,,0.213,10.23,3.47,COC1=C2N=CN([C@@H]3O[C@H](COP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)OC4=C5C=CC=CC5=CC=C4)[C@@H](O)[C@@]3(C)O)C2=NC(N)=N1,,,,,0,,658.2516135,5,4,3,2,1,1
7970,04/06/2019 00:00,DB11967,Binimetinib,"Following oral administration in a pharmacokinetic study, at least 50% of the binimetinib dose was absorbed with a median time to maximum concentration (Tmax) of 1.6 hours [FDA label].

The administration of a single dose of MEKTOVI 45 mg with a high-fat, high-calorie meal (consisting of approximately 150 calories from protein, 350 calories from carbohydrate, and 500 calories from fat) in healthy subjects had no effect on binimetinib exposure [FDA label].",0.97,The mean (CV%) terminal half-life (t1/2) of binimetinib is 3.5 hours (28.5%) [FDA label].,15 mg/1,Oral,solid,,,0.0499,10.26,5.3,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO,0.97,0.97,,,0,15,440.0295589,3,3,1,1,0,0
7971,04/06/2019 00:00,DB11968,MK-7145,,,,,,,,,0.327,13.3,7.27,CC1=C2COC(=O)C2=CC=C1[C@@H](O)CN1CCN(C[C@H](O)C2=C(C)C3=C(C=C2)C(=O)OC3)CC1,,,,,0,,466.2103867,5,2,3,0,1,3
7972,04/06/2019 00:00,DB11969,Uprosertib,,,,,,,,,0.0351,14.04,9.02,CN1N=CC(Cl)=C1C1=C(Cl)OC(=C1)C(=O)N[C@H](CN)CC1=CC=C(F)C(F)=C1,,,,,0,,428.0618376,3,3,2,2,0,0
7973,04/06/2019 00:00,DB11970,Burixafor,,,,,,,,,0.0624,1.28,10.86,NC1=NC(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)=NC(=C1)N1CCN(CCP(O)(O)=O)CC1,,,,,0,,566.3821741,4,1,2,1,1,1
7974,04/06/2019 00:00,DB11971,Vilaprisan,,,,,,,,,0.0175,11.81,-4.2,C[C@]12C[C@H](C3=CC=C(C=C3)S(C)(=O)=O)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F,,,,,0,,544.1706715,5,1,0,0,0,0
7975,04/06/2019 00:00,DB11973,Tesevatinib,,,50-70 hours,,,,,,0.00276,14.01,9.84,COC1=C(OC[C@H]2C[C@H]3CN(C)C[C@H]3C2)C=C2N=CN=C(NC3=CC=C(Cl)C(Cl)=C3F)C2=C1,,,50,70,0,,490.1338596,5,3,2,1,1,1
7976,04/06/2019 00:00,DB11974,PF-04691502,,,,,,,,,0.14,7.58,14.62,[H][C@@]1(CC[C@@]([H])(CC1)N1C(=O)C(=CC2=C(C)NC(=N)N=C12)C1=CN=C(OC)C=C1)OCCO,,,,,0,,425.2063043,4,3,3,3,0,0
7977,04/06/2019 00:00,DB11975,TAK-448,,,,,,,,,0.0182,9.4,12.08,CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(N)=O,,,,,0,,1224.603991,5,4,2,1,1,1
7978,04/06/2019 00:00,DB11977,Golvatinib,,,,,,,,,0.0403,11.38,8.26,CN1CCN(CC1)C1CCN(CC1)C(=O)NC1=CC(OC2=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C(F)=C2)=CC=N1,,,,,0,,633.2875091,6,3,3,1,2,2
7979,04/06/2019 00:00,DB11978,Glasdegib,"Glasdegib presents a dose-proportional pharmacokinetic profile which is observed by the presence of a broad dose-proportional maximum plasma concentration. In this study and on a dose of 50 mg, the median time to reach a maximum concentration of 321 ng/ml was of 4 hours with an AUC of 9587 ng.h/ml.[A173857] The oral bioavailability of glasdegib is reported to be of 55%.[A40310]

In a multiple dose study of 50 mg, the Cmax, tmax and AUC was reported to be 542 ng/ml, 4 h and 9310 ng.h/ml respectively. In this same study, the average concentration at a steady state was of 388 ng/ml.[A173857]

The absorption rates of glasdegib can be modified by the concomitant consumption of a high-fat, high-calorie meal.[FDA label]",0.91,The reported half-life of glasdegib is of 17.4 hours.[T367],100 mg/1,Oral,solid,0.02 mg/ml (in the form of di-HCl monohydrate salt),2.28,0.0469,11.39,6.67,CN1CC[C@H](C[C@@H]1C1=NC2=CC=CC=C2N1)NC(=O)NC1=CC=C(C=C1)C#N,0.91,0.91,,,0,100,374.1855093,4,3,2,1,1,1
7980,02/07/2019 00:00,DB11979,Elagolix,"The Tmax of elagolix is reported as being 1.0 hours [FDA Label]. The effect of a high-fat meal (relative to fasting) can result in a reduction of the AUC and Cmax by as much as 24% and 36%, respectively [FDA Label].",0.8,The terminal phase elimination half-life of elagolix is recorded as being 4 to 6 hours [FDA Label].,150 mg,Oral,solid,<1 mg/mL,,0.00243,3.86,9.04,COC1=C(F)C(=CC=C1)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O,0.8,0.8,,,0,150,631.2105622,4,4,1,1,0,0
7981,04/06/2019 00:00,DB11981,Elamipretide,,,,,,,,,0.0155,9.62,11.84,CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,,,,,0,,639.3856657,2,2,0,0,0,0
7982,04/06/2019 00:00,DB11982,GDC-0623,,,,,,,,,0.0427,12.05,7.84,OCCONC(=O)C1=C(NC2=C(F)C=C(I)C=C2)N2C=NC=C2C=C1,,,,,0,,456.0094665,3,3,2,2,0,0
7983,04/06/2019 00:00,DB11984,Letaxaban,,,,,,,,,0.102,8.92,7.23,[H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O,,,,,0,,479.1281696,4,2,2,0,1,2
7984,04/06/2019 00:00,DB11985,Dapaconazole,,,,,,,,,0.000534,,6.77,FC(F)(F)C1=CC=C(COC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1,,,,,0,,414.0513531,3,3,1,1,0,0
7985,04/06/2019 00:00,DB11986,Entrectinib,,,,,,,,,0.0089,12.39,7.78,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)C(NC2CCOCC2)=C1,,,,,0,,560.2711308,6,4,3,1,2,2
7986,04/06/2019 00:00,DB11987,GSK-2018682,,,,,,,,,0.0424,4.62,-0.35,CC(C)OC1=C(Cl)C=C(C=N1)C1=NC(=NO1)C1=C2C=CN(CCCC(O)=O)C2=CC=C1,,,,,0,,440.1251328,4,4,3,3,0,0
7987,04/06/2019 00:00,DB11989,Benznidazole,"Benznidazole has a bioavailability of 91.7% and a Tmax of 2.93 h [A20368, A20369].",,The half life of elimination is 13.27 h [A20369].,100 mg/1,Oral,,,,0.306,2.28,4.37,OC(CN1C=CN=C1N(=O)=O)=NCC1=CC=CC=C1,,,,,0,100,260.0909402,2,2,1,1,0,0
7988,04/06/2019 00:00,DB11990,MK-0812,,,,,,,,,0.0243,,10.16,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](CN2CCC3=C(C2)C=C(C=N3)C(F)(F)F)(C1)C(C)C,,,,,0,,455.2759621,4,1,3,1,1,2
7989,04/06/2019 00:00,DB11991,Oprozomib,,,,,,,,,0.0121,11.5,2,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)[C@@]1(C)CO1,,,,,0,,532.1991704,3,2,2,1,1,1
7990,04/06/2019 00:00,DB11992,Omarigliptin,,,,,,,,,0.543,,8.81,CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=CC(F)=CC=C1F,,,,,0,,398.1224179,4,2,3,1,1,2
7991,04/06/2019 00:00,DB11993,PF-03463275,,,,,,,,,0.352,,9.04,CN1C[C@H]2[C@H](CN(CC3=CC=C(F)C(Cl)=C3)C(=O)C3=CN(C)C=N3)[C@H]2C1,,,,,0,,376.1466172,4,2,2,1,1,1
7992,04/06/2019 00:00,DB11994,Diacerein,Bioavailability of 50-60% [A19300]. Entirely converted to the active metabolite rhein [DB13174] before reaching systemic circulation.,0.99,4-10h [A19300].,,,,,,0.0407,3.37,-6.8,CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O,0.99,0.99,4,10,0,,368.0532173,3,2,0,0,0,0
7993,04/06/2019 00:00,DB11995,Avatrombopag,"Following single dosing under fasted and fed conditions, mean peak concentrations occurred at 5-8 hours and declined with a half-life of 16-18 hours in Japanese and white subjects. Administration with food did not have an effect on the rate or extent of avatrombopag absorption, however, significantly reduced pharmacokinetic variability relative to the fasting state [A33097].

Avatrombopag showed dose-proportional pharmacokinetics after single doses from 10 mg (0.25-times the lowest approved dosage) to 80 mg (1.3-times the highest recommended dosage). Healthy subjects administered 40 mg of avatrombopag showed a geometric mean (%CV) maximal concentration (Cmax) of 166 (84%) ng/mL and area under the time-concentration curve, extrapolated to infinity (AUC0-inf) of 4198 (83%) ng.hr/mL. The pharmacokinetics of avatrombopag are similar in both healthy subjects and the chronic liver disease population [FDA label].",0.96,The mean plasma elimination half-life (%CV) of avatrombopag is approximately 19 hours (19%) [FDA label].,20 mg/1,Oral,solid,Insoluble ,,0.00465,3.5,8.4,OC(=O)C1CCN(CC1)C1=C(Cl)C=C(C=N1)C(=O)NC1=NC(C2=CC(Cl)=CS2)=C(S1)N1CCN(CC1)C1CCCCC1,0.96,0.96,,,0,20,648.1510863,6,3,5,3,2,2
7994,04/06/2019 00:00,DB11996,Thymopentin,,,,,,,,,0.0758,2.87,12.08,[H][C@](N)(CCCNC(N)=N)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CC(O)=O)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(O)=O,,,,,0,,679.3653241,1,1,0,0,0,0
7995,04/06/2019 00:00,DB11998,Sorivudine,,,,,,,,,14.8,9.74,-3,OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O,,,,,0,,347.9956982,2,1,2,1,1,1
7996,04/06/2019 00:00,DB11999,Vosaroxin,,,,,,,,,0.128,5.06,8.8,CN[C@H]1CN(C[C@@H]1OC)C1=CC=C2C(=O)C(=CN(C3=NC=CS3)C2=N1)C(O)=O,,,,,0,,401.1157751,4,3,4,3,1,1
7997,04/06/2019 00:00,DB12000,Apabetalone,,,,,,,,,0.0432,8.63,-1.7,COC1=CC2=C(C(=O)N=C(N2)C2=CC(C)=C(OCCO)C(C)=C2)C(OC)=C1,,,,,0,,370.1528718,3,3,1,1,0,0
7998,04/06/2019 00:00,DB12001,Abemaciclib,"The plasma concentration of the drug increases in a dose-proportional manner. Following a single oral dose administration of 200 mg abemaciclib, the mean peak plasma concentration (Cmax) of 158 ng/mL is reached after 6 hours. The median time to reach maximum plasma concentration (Tmax) ranges from 4-6 hours following an oral administration of abemaciclib over a range of 50â€“275 mg [A27282], but may range up to 24 hours [FDA Label]. The absolute bioavailability of the drug is reported to be 45% [FDA Label]. ",95-98%,The mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV) [FDA Label].,100 mg,Oral,,,,0.0159,10.27,7.94,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1,0.95,0.98,,,0,100,506.2717995,5,4,4,3,1,1
7999,04/06/2019 00:00,DB12002,AZD-4818,,,,,,,,,0.00582,2.72,8.22,CNC(=O)C1=C(OC[C@@H](O)CN2CCC3(CC4=CC(Cl)=CC=C4O3)CC2)C=C(OC(C)(C)C(O)=O)C(Cl)=C1,,,,,0,,566.1586567,4,2,2,0,1,2
8000,04/06/2019 00:00,DB12004,Briciclib,,,,,,,,,0.0788,1.62,-4.3,COC1=CC(OC)=C(\C=C\S(=O)(=O)CC2=CC=C(OC)C(OP(O)(O)=O)=C2)C(OC)=C1,,,,,0,,474.0749546,2,2,0,0,0,0
8001,04/06/2019 00:00,DB12005,Nirogacestat,,,,,,,,,0.0104,11.48,10.45,CCC[C@H](N[C@H]1CCC2=CC(F)=CC(F)=C2C1)C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C,,,,,0,,489.3279174,3,2,1,1,0,0
8002,04/06/2019 00:00,DB12006,BMS-906024,,,,,,,,,0.00812,10.04,0.096,CN1C2=CC=CC=C2C(=N[C@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)C1=O)C1=CC=CC=C1,,,,,0,,556.19091,3,2,1,0,0,1
8003,04/06/2019 00:00,DB12007,Isoflavone,"Following oral ingestion, serum isoflavone concentrations increase in a dose-dependent manner [A33098]. Isoflavones are metabolized by gut microflora, where they need to undergo deglycosylation in order to be absorbed in the intestine [A33103]. After oral ingestion, glycosylated isoflavones are rapidly deglycosylated, absorbed and metabolized in intestinal enterocytes and liver, entering the systemic circulation predominantly as conjugates with limited bioavailability [A33103]. In humans, the mean time to reach peak plasma concentrations (Tmax) for conjugated and unconjugated genistein and daidzein are approximately 5-6 and 6-8 hours, respectively [A33103]. ",,"The half-life of isoflavones is between 4 and 8 h [A33098]. Daidzein has a longer intestinal half-life than genistein due to more rapid degradation of genistein [A33100]. Individual half-life of daidzein and genistein in a human pharmacokinetic study were 7.75 h and 7.77 h, respectively [A33103]. ",,,solid,,,0.00843,,-5.3,O=C1C(=COC2=CC=CC=C12)C1=CC=CC=C1,,,,,0,,222.0680796,3,3,1,1,0,0
8004,04/06/2019 00:00,DB12008,Prexasertib,,,,,,,,,0.0496,10.02,9.85,COC1=CC=CC(OCCCN)=C1C1=CC(NC2=CN=C(C=N2)C#N)=NN1,,,,,0,,365.1600228,3,3,2,2,0,0
8005,04/06/2019 00:00,DB12009,GW-406381,,,,,,,,,0.00249,19.69,0.98,CCOC1=CC=C(C=C1)C1=NN2N=CC=CC2=C1C1=CC=C(C=C1)S(C)(=O)=O,,,,,0,,393.1147125,4,4,2,2,0,0
8006,04/06/2019 00:00,DB12010,Fostamatinib,"Fostmatinib is the methylene phosphate prodrug of R406, the active metabolite [FDA Label]. It is extensively hydrolyzed by intestinal alkaline phosphatase. Only negligible amounts of fostamatinib enter systemic circulation [A32934,FDA Label].

R406 has an absolute bioavailability of 55% and reaches peak plasma concentrations in approximately 1.5 h [A32934,FDA Label]. Administration with a high calorie, high fat meal increases exposure by 23% and the maximum plasma concentration by 15%. This may lengthen time to peak plasma concentration to approximately 3 h [A32934]. Exposure to R406 is known to be dose proportional up to 200 mg twice daily [FDA Label]. R406 accumulates 2-3 fold with twice daily dosing at 100-160 mg.",0.983,"R406 has a half-life of elimination of approximately 15 h [A32934,FDA Label].",100 mg/1,Oral,,,,0.052,1.46,2.71,COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC,0.983,0.983,,,0,100,580.1482913,4,3,3,2,0,1
8007,04/06/2019 00:00,DB12011,Fevipiprant,,,,,,,,,0.00857,4.39,3.73,CC1=C(CC(O)=O)C2=CC=CN=C2N1CC1=CC=C(C=C1C(F)(F)F)S(C)(=O)=O,,,,,0,,426.0861127,3,3,2,2,0,0
8008,04/06/2019 00:00,DB12012,PF-04457845,,,,,,,,,0.0186,11.23,1.38,FC(F)(F)C1=CC=C(OC2=CC=CC(C=C3CCN(CC3)C(=O)NC3=CC=CN=N3)=C2)N=C1,,,,,0,,455.1569095,4,3,3,2,1,1
8009,04/06/2019 00:00,DB12013,Axelopran,,,,,,,,,0.0719,12.4,8.75,NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO,,,,,0,,457.2940567,4,1,2,0,2,2
8010,04/06/2019 00:00,DB12015,Alpelisib,"Alpelisib reached a peak concentration in plasma of 1320Â±912ng/mL after 2 hours.[A179254] Alpelisib has an AUC<sub>last</sub> of 11,100Â±3760h ng/mL and an AUC<sub>INF</sub> of 11,100Â±3770h ng/mL.[A179254] A large, high fat meal increases the AUC by 73% and C<sub>max</sub> by 84% while a small, low fat meal increases the AUC by 77% and C<sub>max</sub> by 145%.[Label]",0.89,The mean half life of alprelisib is 8 to 9 hours.[Label],150 mg/1,Oral,solid,,,0.00528,7.79,2.81,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F,0.89,0.89,,,0,150,441.1446306,3,2,3,2,1,1
8011,04/06/2019 00:00,DB12016,Ponesimod,,,,,,,,,0.00626,13.62,0.91,CCC\N=C1/S\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C,,,,,0,,460.122356,3,2,1,0,1,1
8012,04/06/2019 00:00,DB12017,Ozagrel,,,,,,,,,0.424,4.21,6.75,OC(=O)\C=C\C1=CC=C(CN2C=CN=C2)C=C1,,,,,0,,228.0898776,2,2,1,1,0,0
8013,04/06/2019 00:00,DB12019,Tesetaxel,,,,,,,,,0.0157,11.75,7.55,CN(C)C[C@@H]1O[C@H]2[C@@H](O1)[C@]1(C)CC[C@H]3OC[C@@]3(OC(C)=O)[C@H]1[C@H](OC(=O)C1=CC=CC=C1)[C@]1(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=C(F)C=CC=N3)C(C)=C2C1(C)C,,,,,0,,881.4110172,7,2,3,1,2,2
8014,04/06/2019 00:00,DB12020,Tecovirimat,"Readily absorbed following oral administration, with mean times to maximum concentration from 3 to 4 h [A35133].
A study was conducted to determine the safety, tolerability, and pharmacokinetics of ST-246 administered as a single daily oral dose. Steady state was reached by day 6 (within 3 to 5 half-lives)[A35134].",0.8,Approximately 20h [F619].,200 mg/1,Oral,solid,insoluble ,2.7321,0.021,9.15,-6.2,FC(F)(F)C1=CC=C(C=C1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O,0.8,0.8,,,0,200,376.103477,6,1,1,0,1,1
8015,04/06/2019 00:00,DB12021,Dinaciclib,,,,,,,,,0.0524,15.92,4.63,CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N1CCCC[C@H]1CCO,,,,,0,,396.2273741,4,3,4,3,1,1
8016,04/06/2019 00:00,DB12022,Evatanepag,,,,,,,,,0.00144,3.05,1.07,CC(C)(C)C1=CC=C(CN(CC2=CC=CC(OCC(O)=O)=C2)S(=O)(=O)C2=CC=CN=C2)C=C1,,,,,0,,468.171893,3,3,1,1,0,0
8017,04/06/2019 00:00,DB12024,PF-04418948,,,,,,,,,0.00455,3.91,-1.1,COC1=CC=C2C=C(OCC3(CN(C3)C(=O)C3=CC=C(F)C=C3)C(O)=O)C=CC2=C1,,,,,0,,409.132551,4,3,1,0,1,1
8018,04/06/2019 00:00,DB12025,Triptolide,,,,,,,,,0.886,12.54,-3.8,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O,,,,,0,,360.1572885,7,0,4,0,3,4
8019,04/06/2019 00:00,DB12026,Voxilaprevir,"When provided as the fixed dose combination product Vosevi with [DB08934] and [DB11613], voxilaprevir reaches a maximum concentration (Cmax) of 192 ng/mL at a maximum time (Tmax) of 4 hours post-dose [FDA Label].",0.99,33 hr [FDA Label],,Oral,,,,0.0506,3.74,-0.84,CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=C(O2)N=C2C=C(OC)C=CC2=N1)C(C)(C)C,0.99,0.99,,,0,,868.3452611,7,2,3,1,1,2
8020,04/06/2019 00:00,DB12027,Serdemetan,,,,,,,,,0.00292,17.16,8,C(CC1=CNC2=CC=CC=C12)NC1=CC=C(NC2=CC=NC=C2)C=C1,,,,,0,,328.1687966,4,4,2,2,0,0
8021,04/06/2019 00:00,DB12028,Broxuridine,,,,,,,,,6.48,6.5,-3,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO)N1C=C(Br)C(O)=NC1=O,,,,,0,,305.9851336,2,1,2,1,1,1
8022,04/06/2019 00:00,DB12029,Chlorogenic Acid,,,,,,,,,3.44,3.33,-3.2,O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\C2=CC(O)=C(O)C=C2)[C@@H]1O)C(O)=O,,,,,0,,354.0950822,2,1,0,0,0,0
8023,04/06/2019 00:00,DB12030,Fluorescein lisicol,,,,,,,,,0.000627,3.52,-0.4,C[C@H](CCC(=O)N[C@@H](CCCCNC(=S)NC1=CC=C(C2C3=CC=C(O)C=C3OC3=C2C=CC(O)=C3)C(=C1)C(O)=O)C(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,,,,,0,,927.4339809,8,3,1,0,0,1
8024,04/06/2019 00:00,DB12032,Atagabalin,,,,,,,,,5.46,4.68,9.91,C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C,,,,,0,,185.1415788,1,0,0,0,0,0
8025,04/06/2019 00:00,DB12035,Sarecycline,"The median time to peak plasma concentration (Tmax) of sarecycline is 1.5 to 2.0 hours [FDA Label]. When the medication is taken with a meal consisting of high fat (about 50% of total caloric content of the meal), high caloric (about 800 to 1000 Kcal), and milk content the Tmax can be delayed by approximately 0.53 hours and the Cmax and AUC can be decreased by 31% and 27%, respectively [FDA Label].",0.625,The mean elimination half-life of sarecycline is 21 to 22 hours [FDA Label].,100 mg/1,Oral,solid,,,2.01,2.95,8.26,[H][C@@]12CC3=C(C(O)=CC=C3CN(C)OC)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@]([H])(N(C)C)[C@]1([H])C2,0.625,0.625,,,0,100,487.1954649,4,1,0,0,0,0
8026,04/06/2019 00:00,DB12036,Naquotinib,,,,,,,,,0.0688,13.69,8.57,CCC1=C(O[C@@H]2CCN(C2)C(=O)C=C)N=C(NC2=CC=C(C=C2)N2CCC(CC2)N2CCN(C)CC2)C(=N1)C(N)=O,,,,,0,,562.3379872,5,2,4,1,3,3
8027,04/06/2019 00:00,DB12037,Vedroprevir,,,,,,,,,0.00189,3.12,5.74,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@@H]2C[C@@H]2C1)C(C)(C)C)OC1=C2C=CC(OCCN3CCOCC3)=C(Cl)C2=NC(=C1)C1=CSC(NC(C)C)=N1)C(O)=O,,,,,0,,909.3861752,8,3,4,2,2,2
8028,04/06/2019 00:00,DB12039,Epicatechin,,,,,,,,,0.645,9,-3.3,O[C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1,,,,,0,,290.0790382,3,2,1,0,0,1
8029,04/06/2019 00:00,DB12040,2-octyl cyanoacrylate,,,,,,,,,0.0244,,-7.2,CCCCCCC(C)OC(=O)C(=C)C#N,,,,,0,,209.1415788,0,0,0,0,0,0
8030,04/06/2019 00:00,DB12041,Mapracorat,,,,,,,,,0.00337,10.86,5.81,CC1=CC=C2C(NC[C@](O)(CC(C)(C)C3=CC(F)=CC4=C3OCC4)C(F)(F)F)=CC=CC2=N1,,,,,0,,462.193041,4,3,2,1,0,1
8031,04/06/2019 00:00,DB12042,Ibodutant,,,,,,,,,0.000314,12.37,10.03,CC1=CC=C2C=C(SC2=C1)C(=O)NC1(CCCC1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)NCC1CCN(CC2CCOCC2)CC1,,,,,0,,644.339627,6,3,3,1,2,2
8032,04/06/2019 00:00,DB12043,Sepetaprost,,,,,,,,,0.00652,14.01,-2.9,CC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@@H](O)[C@@H]2\C=C\[C@@H](O)COC2=CC(F)=CC=C2F)OC1,,,,,0,,482.2479953,3,1,1,0,1,1
8033,04/06/2019 00:00,DB12044,MK-0893,,,,,,,,,0.000203,3.94,2.22,COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1,,,,,0,,587.1378617,5,5,1,1,0,0
8034,04/06/2019 00:00,DB12045,Mericitabine,,,,,,,,,0.133,19.22,-0.28,CC(C)C(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,,,,,0,,399.1805638,2,1,2,1,1,1
8035,04/06/2019 00:00,DB12046,Atopaxar,,,,,,,,,0.00591,13.29,6.61,CCOC1=CC2=C(C(=N)N(CC(=O)C3=CC(=C(OC)C(=C3)N3CCOCC3)C(C)(C)C)C2)C(F)=C1OCC,,,,,0,,527.2795495,4,2,2,0,1,2
8036,04/06/2019 00:00,DB12047,Ganetespib,,,,,,,,,0.221,8.13,1.02,CC(C)C1=CC(C2=NN=C(O)N2C2=CC=C3N(C)C=CC3=C2)=C(O)C=C1O,,,,,0,,364.1535405,4,4,2,2,0,0
8037,04/06/2019 00:00,DB12048,Savolitinib,,,,,,,,,0.337,,6.67,C[C@H](N1N=NC2=NC=C(N=C12)C1=CN(C)N=C1)C1=CN2C=CN=C2C=C1,,,,,0,,345.1450415,5,5,5,5,0,0
8038,04/06/2019 00:00,DB12049,Dasolampanel etibutil,,,,,,,,,0.00895,3.93,6.73,CCC(CC)COC(=O)[C@@H]1C[C@H]2C[C@H](CC[C@H]2CN1)OC1=CC=CC(Cl)=C1C1=NN=NN1,,,,,0,,461.2193676,4,2,2,1,1,1
8039,04/06/2019 00:00,DB12050,LY-3039478,,,,,,,,,0.0994,11.41,2.24,C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C2=CC=CN=C2N(CCO)C1=O,,,,,0,,464.1671399,3,2,2,1,0,1
8040,04/06/2019 00:00,DB12051,Setrobuvir,,,,,,,,,0.0281,5.5,0.69,CS(=O)(=O)NC1=CC=C2NC(=NS(=O)(=O)C2=C1)C1=C(O)[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2N(CC2=CC=C(F)C=C2)C1=O,,,,,0,,560.1199547,6,2,2,0,0,2
8041,04/06/2019 00:00,DB12052,Icariin,,,,,,,,,0.612,7.07,-3,COC1=CC=C(C=C1)C1=C(O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)C(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(CC=C(C)C)=C2O1,,,,,0,,676.2367206,5,3,3,1,2,2
8042,04/06/2019 00:00,DB12054,BQ-123,,,,,,,,,0.13,4.04,,CC(C)C[C@@H]1NC(=O)[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(O)=O)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC1=O)C(C)C,,,,,0,,610.3114977,4,2,3,1,2,2
8043,04/06/2019 00:00,DB12055,MK-0767,,,,,,,,,0.00458,6.63,-1.4,COC1=CC=C(CC2OC(=O)NC2=O)C=C1C(=O)NCC1=CC=C(C=C1)C(F)(F)F,,,,,0,,422.1089563,3,2,1,0,1,1
8044,04/06/2019 00:00,DB12057,ORM-12741,,,,,,,,,0.0307,,7.41,COC[C@@]1(C)CCCN2CCC3=C(OC4=CC=CC=C34)[C@H]12,,,,,0,,285.172879,4,2,3,1,1,2
8045,04/06/2019 00:00,DB12058,Recoflavone,,,,,,,,,0.0158,2.79,-4.3,COC1=CC=C(C=C1OC)C1=CC(=O)C2=C(OC)C=C(OCC(O)=O)C=C2O1,,,,,0,,386.1001675,3,3,1,1,0,0
8046,04/06/2019 00:00,DB12059,JNJ-40411813,,,,,,,,,0.0429,,-1.4,CCCCN1C=CC(N2CCC(CC2)C2=CC=CC=C2)=C(Cl)C1=O,,,,,0,,344.1655411,3,2,2,1,1,1
8047,04/06/2019 00:00,DB12060,RRx-001,,,,,,,,,0.473,,-5,[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O,,,,,0,,266.9490824,1,0,1,0,1,1
8048,04/06/2019 00:00,DB12061,Pardoprunox,,,,,,,,,7.88,9.46,7.37,CN1CCN(CC1)C1=C2OC(=O)NC2=CC=C1,,,,,0,,233.1164267,3,2,2,1,1,1
8049,04/06/2019 00:00,DB12062,Volasertib,,,,,,,,,0.0576,8.29,9.29,[H][C@@]1(CC[C@@]([H])(CC1)N1CCN(CC2CC2)CC1)N=C(O)C1=CC(OC)=C(NC2=NC=C3N(C)C(=O)[C@@]([H])(CC)N(C(C)C)C3=N2)C=C1,,,,,0,,618.4005875,6,2,3,1,1,2
8050,04/06/2019 00:00,DB12063,CERC-301,,,,,,,,,0.134,15.63,3.42,CC1=CC=C(COC(=O)N2CC[C@H](CNC3=NC=CC=N3)[C@H](F)C2)C=C1,,,,,0,,358.1805042,3,2,2,1,1,1
8051,04/06/2019 00:00,DB12064,BMS-777607,,,,,,,,,0.00109,4.36,6.74,CCOC1=C(C(O)=NC2=CC(F)=C(OC3=C(Cl)C(=N)NC=C3)C=C2)C(=O)N(C=C1)C1=CC=C(F)C=C1,,,,,0,,512.1062892,4,4,2,2,0,0
8052,04/06/2019 00:00,DB12065,Radalbuvir,,,,,,,,,0.00556,4.08,-1.6,CC1=CC[C@@H](CC1)C(=O)N([C@H]1CC[C@](O)(CO[C@H]2CCOC2)CC1)C1=C(SC(=C1)C#CC(C)(C)C)C(O)=O,,,,,0,,543.265459,4,1,2,1,1,1
8053,04/06/2019 00:00,DB12066,Orteronel,,,,,,,,,0.107,12.85,6.2,CNC(=O)C1=CC=C2C=C(C=CC2=C1)[C@@]1(O)CCN2C=NC=C12,,,,,0,,307.1320768,4,3,2,1,0,1
8054,04/06/2019 00:00,DB12067,BMS-394136,,,,,,,,,0.00355,15.23,3.45,CC1=C([C@H](N2N=CC=C2N1)C1=CC=C(Cl)C(Cl)=C1)C(=O)N1CCC[C@H]1C1=CC=C(F)C=C1,,,,,0,,470.1076449,5,3,3,1,1,2
8055,04/06/2019 00:00,DB12068,T-900607,,,,,,,,,0.0511,5.84,-4,COC1=CC=C(NS(=O)(=O)C2=C(F)C(F)=C(F)C(F)=C2F)C=C1NC(N)=O,,,,,0,,411.0312179,2,2,0,0,0,0
8056,04/06/2019 00:00,DB12069,Sovaprevir,,,,,,,,,0.003,3.76,5.6,COC1=CC2=NC(=CC(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](CC(=O)N3CCCCC3)C(C)(C)C)C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)=C2C=C1)C1=CC=CC=C1,,,,,0,,799.3614847,7,3,3,1,2,2
8057,02/07/2019 00:00,DB12070,Letermovir,"Letermovir has a bioavailability of 94% in healthy subjects when administered without cyclosporin, 35% in HSCT recipients when administered without cyclosporin, and 85% in HSCT recipients when administered with cyclosporin [FDA Label].

Letermovir's Tmax is 45 min to 2.25 h [FDA Label]. Time to steady state has been observed to be 9-10 days. 

Taking Letermovir with food increases Cmax by an average of 129.82% (range of 104.35%-161.50%) [FDA Label]. No significant effect on AUC has been observed .",0.99,The mean terminal half-life was observed to be 12 hours following administration of Letemovir 480 mg IV once daily [FDA Label].,20 mg/1mL,Intravenous,solid,,,0.01,3.75,7.15,COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=CC(=CC=C1OC)C(F)(F)F,0.99,0.99,,,0,,572.2046683,5,3,2,0,1,2
8058,04/06/2019 00:00,DB12071,Vabicaserin,,,,,,,,,0.252,,8.9,C1C[C@H]2CN3CCNCC4=C3C(=CC=C4)[C@H]2C1,,,,,0,,228.1626486,4,1,2,0,0,2
8059,04/06/2019 00:00,DB12072,Orantinib,,,,,,,,,0.0372,-0.53,15,[H]\C(C1=C(C)C(CCC(O)=O)=C(C)N1)=C1\C(O)=NC2=CC=CC=C12,,,,,0,,310.1317424,3,2,2,1,0,1
8060,04/06/2019 00:00,DB12073,Albaconazole,,,,,,,,,0.0245,12.6,2.38,C[C@@H](N1C=NC2=CC(Cl)=CC=C2C1=O)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,,,,,0,,431.0960589,4,4,2,2,0,0
8061,04/06/2019 00:00,DB12074,Censavudine,,,,,,,,,0.278,9.95,-3.2,CC1=CN([C@@H]2O[C@](CO)(C=C2)C#C)C(=O)NC1=O,,,,,0,,248.0797069,2,1,2,1,0,1
8062,04/06/2019 00:00,DB12078,Enobosarm,,,,,,,,,0.00432,3.53,0.36,C[C@](O)(COC1=CC=C(C=C1)C#N)C(O)=NC1=CC(=C(C=C1)C#N)C(F)(F)F,,,,,0,,389.098726,2,2,0,0,0,0
8063,04/06/2019 00:00,DB12079,Gefarnate,,,,,,,,,0.00102,,-7,[H]\C(CC\C(C)=C(/[H])CCC(=O)OC\C([H])=C(/C)CCC=C(C)C)=C(\C)CCC=C(C)C,,,,,0,,400.3341306,0,0,0,0,0,0
8064,04/06/2019 00:00,DB12080,Ritobegron,,,,,,,,,0.0103,3.73,10.01,C[C@H](NCCC1=C(C)C=C(OCC(O)=O)C(C)=C1)[C@H](O)C1=CC=C(O)C=C1,,,,,0,,373.188923,2,2,0,0,0,0
8065,04/06/2019 00:00,DB12081,Anecortave,,,,,,,,,0.0334,12.58,-3.3,C[C@]12CC=C3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,,,,,0,,344.1987594,4,0,0,0,0,0
8066,04/06/2019 00:00,DB12082,Vesnarinone,,,,,,,,,0.0968,15.28,2.94,COC1=C(OC)C=C(C=C1)C(=O)N1CCN(CC1)C1=CC=C2NC(=O)CCC2=C1,,,,,0,,395.1845063,4,2,2,0,1,2
8067,04/06/2019 00:00,DB12083,Mafosfamide,,,,,,,,,5.54,-0.9,0.057,OS(=O)(=O)CCS[C@H]1CCO[P@@](=O)(N1)N(CCCl)CCCl,,,,,0,,399.9850057,1,0,1,0,1,1
8068,04/06/2019 00:00,DB12084,ADP-597,,,,,,,,,0.059,12.12,3.58,COC1=C(NC2=C(C)N=C(C=C2)S(C)(=O)=O)N=CN=C1OC1CCN(CC1)C(=O)OC(C)C,,,,,0,,479.1838546,3,2,3,2,1,1
8069,04/06/2019 00:00,DB12085,LCL-161,,,,,,,,,0.00313,11.87,8.6,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C1=NC(=CS1)C(=O)C1=CC=C(F)C=C1,,,,,0,,500.2257401,4,2,2,1,1,1
8070,04/06/2019 00:00,DB12086,Oxitropium,,,,,,,,,0.00635,15.15,-2.7,CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,,,,,1,,332.1856347,4,1,3,0,3,3
8071,04/06/2019 00:00,DB12087,Vanillyl alcohol,,,,,,,,,29.4,9.92,-2.8,COC1=C(O)C=CC(CO)=C1,,,,,0,,154.0629942,1,1,0,0,0,0
8072,04/06/2019 00:00,DB12088,TT-232,,,,,,,,,0.00927,7.7,10.61,C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=CC=CC=C23)C(=O)N[C@@H](CCCCN)C(=O)N1)C(N)=O,,,,,0,,946.3829654,5,4,2,1,1,1
8073,04/06/2019 00:00,DB12092,Naftopidil,,,,,,,,,0.0699,14.08,7.35,COC1=CC=CC=C1N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1,,,,,0,,392.2099928,4,3,1,0,1,1
8074,04/06/2019 00:00,DB12093,Tetrahydropalmatine,,,,,,,,,0.0246,,5.34,COC1=CC=C2C[C@@H]3N(CCC4=CC(OC)=C(OC)C=C34)CC2=C1OC,,,,,0,,355.1783583,4,2,2,0,0,2
8075,04/06/2019 00:00,DB12094,Semapimod,,,,,,,,,0.0377,13.48,7.88,C\C(=N/NC(N)=N)C1=CC(=CC(NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)C(\C)=N\NC(N)=N)C(\C)=N\NC(N)=N)=C1)C(\C)=N\NC(N)=N,,,,,0,,744.4520629,2,2,0,0,0,0
8076,02/07/2019 00:00,DB12095,Telotristat ethyl,"Low systemic absorption. Tmax of 2â€“4 h, supporting the 8-hourly administration",,4â€“12 h,250 mg,Oral,solid,,,0.00294,16.06,6.94,CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C1=NC(N)=NC(O[C@H](C2=CC=C(Cl)C=C2N2C=CC(C)=N2)C(F)(F)F)=C1,,,4,12,0,250,574.170701,4,4,2,2,0,0
8077,04/06/2019 00:00,DB12096,PF-05175157,,,,,,,,,0.0529,11.36,6.01,CC(C)N1N=CC2=C1C(=O)CC1(CCN(CC1)C(=O)C1=CC=C3N=C(C)NC3=C1)C2,,,,,0,,405.2164751,5,3,3,2,1,1
8078,04/06/2019 00:00,DB12097,Mannitol busulfan,,,,,,,,,18.7,12.56,-3.6,CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(C)(=O)=O,,,,,0,,338.0341388,0,0,0,0,0,0
8079,04/06/2019 00:00,DB12098,L-Baclofen,,,,,,,,,0.712,3.89,9.79,NC[C@@H](CC(O)=O)C1=CC=C(Cl)C=C1,,,,,0,,213.0556563,1,1,0,0,0,0
8080,04/06/2019 00:00,DB12099,"UK-396,082",,,,,,,,,1.58,4.24,10.21,[H][C@](CCCN)(CC1=CN(CCC)C=N1)C(O)=O,,,,,0,,239.1633769,1,1,1,1,0,0
8081,04/06/2019 00:00,DB12100,Abediterol,,,,,,,,,0.00458,8.51,9.74,O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1,,,,,0,,460.2173639,3,3,1,1,0,0
8082,04/06/2019 00:00,DB12101,CC-220,,,,,,,,,0.0702,11.61,6.91,O=C1N(CC2=C1C=CC=C2OCC1=CC=C(CN2CCOCC2)C=C1)[C@H]1CCC(=O)NC1=O,,,,,0,,449.195071,5,2,3,0,2,3
8083,04/06/2019 00:00,DB12105,Imagabalin,,,,,,,,,3.01,4.53,10.54,CCC[C@@H](C)C[C@H](N)CC(O)=O,,,,,0,,173.1415788,0,0,0,0,0,0
8084,04/06/2019 00:00,DB12106,PF-06305591,,,,,,,,,0.0632,11.52,7.17,C[C@H]([C@H](N)C1=NC2=CC=C(C=C2N1)C(C)(C)C)C(N)=O,,,,,0,,274.1793613,2,2,1,1,0,0
8085,04/06/2019 00:00,DB12107,Vaborbactam,"The peak plasma concentrations (Cmax) and AUC of vaborbactam increase in a dose-proportional manner. In healthy adult subjects, the Cmax following administration of multiple 2 g dose as a 3-hour infusion was 55.6 mg/L and AUC was 588 mgâ€¢h/L. In patients with the same dosing regimen, the Cmax was 71.3 mg/L and AUC was 835 mgâ€¢h/L at steady state [FDA Label]. The exposure of vaborbactam in terms of Cmax and AUC are not expected to change with repeated dosing, and there was no evidence of accumulation of vaborbactam in plasma in a repeated dosing study [A32054].",0.33,The half life of vaborbactam in healthy subjects following multiple 2 g dose administration as a 3-hour infusion was 1.68 hours. The half life of vaborbactam following administration of 2 g by 3 hour infusion was 2.25 hours [FDA Label]. ,,Intravenous,solid,,,0.155,3.75,-2.6,OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1,0.33,0.33,,,0,,297.084224,2,1,2,1,1,1
8086,04/06/2019 00:00,DB12108,Taselisib,,,,,,,,,0.267,15.69,3.89,CC(C)N1N=C(C)N=C1C1=CN2CCOC3=CC(=CC=C3C2=N1)C1=CN(N=C1)C(C)(C)C(N)=O,,,,,0,,460.2335221,5,4,4,3,0,1
8087,04/06/2019 00:00,DB12109,CPI-613,,,,,,,,,6.99E-05,4.47,,OC(=O)CCCCC(CCSCC1=CC=CC=C1)SCC1=CC=CC=C1,,,,,0,,388.1530721,2,2,0,0,0,0
8088,04/06/2019 00:00,DB12110,m-Chlorophenylpiperazine,,,,,,,,,3.12,,8.87,ClC1=CC(=CC=C1)N1CCNCC1,,,,,0,,196.0767261,2,1,1,0,1,1
8089,04/06/2019 00:00,DB12111,MK-212,,,,,,,,,1.03,,8.73,ClC1=NC(=CN=C1)N1CCNCC1,,,,,0,,198.067224,2,1,2,1,1,1
8090,04/06/2019 00:00,DB12112,Zuretinol acetate,,,,,,,,,0.00238,,-7,CC(=O)OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C,,,,,0,,328.2402303,1,0,0,0,0,0
8091,04/06/2019 00:00,DB12113,CE-224535,,,,,,,,,0.0785,13.02,-1.3,COC[C@H](O)CN1C(=O)C=NN(C1=O)C1=CC=C(Cl)C(=C1)C(=O)NCC1(O)CCCCCC1,,,,,0,,480.1775623,3,2,1,1,0,0
8092,04/06/2019 00:00,DB12114,Poziotinib,,,,,,,,,0.0117,13.99,4.49,COC1=C(OC2CCN(CC2)C(=O)C=C)C=C2C(NC3=CC=C(Cl)C(Cl)=C3F)=NC=NC2=C1,,,,,0,,490.0974741,4,3,2,1,1,1
8093,04/06/2019 00:00,DB12115,AZD-9164,,,,,,,,,4.23E-05,,6.71,C[C@@](N1CCCCC1)(C(=O)O[C@H]1C[N+]2(CCC3=CC=C(F)C=C3)CCC1CC2)C1=CC=CC=C1,,,,,1,,465.2911831,6,2,4,0,4,4
8094,04/06/2019 00:00,DB12116,Epigallocatechin gallate,,,,,Topical,,,,0.0728,7.99,-5.4,OC1=CC(O)=C2C[C@@H](OC(=O)C3=CC(O)=C(O)C(O)=C3)[C@H](OC2=C1)C1=CC(O)=C(O)C(O)=C1,,,,,0,,458.0849114,4,3,1,0,0,1
8095,04/06/2019 00:00,DB12117,Mitometh,,,,,,,,,5.18E-06,,,CC(Cl)(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl,,,,,0,,331.9693111,2,2,0,0,0,0
8096,04/06/2019 00:00,DB12120,Avoralstat,,,,,,,,,0.00687,0.55,11.49,COC1=CC(=C(C=C1C=C)C(=O)NC1=CC=C(C=C1)C(N)=N)C1=CC=C(N=C1C(O)=O)C(=O)NCC1CC1,,,,,0,,513.201219,4,3,1,1,0,0
8097,04/06/2019 00:00,DB12121,Entospletinib,,,,,,,,,0.132,9.81,6.66,C1CN(CCO1)C1=CC=C(C=C1)N=C1NC(=CN2C=CN=C12)C1=CC2=NNC=C2C=C1,,,,,0,,411.1807583,6,5,4,3,1,1
8098,04/06/2019 00:00,DB12122,Figopitant,,,,,,,,,0.00397,,7.78,CN(CCC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C(=O)[C@@H](N1CCN(CC2CC2)CC1)C1=CC=CC=C1,,,,,0,,527.2371319,4,2,1,0,1,1
8099,04/06/2019 00:00,DB12123,Cinepazide,,,,,,,,,0.502,,5.91,COC1=CC(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)=CC(OC)=C1OC,,,,,0,,417.2263711,3,1,2,0,2,2
8100,04/06/2019 00:00,DB12124,Namitecan,,,,,,,,,0.106,11.71,8.86,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=CC1=C3\C=N\OCCN)C2=O,,,,,0,,434.1590198,5,3,4,2,0,2
8101,04/06/2019 00:00,DB12125,Dianicline,,,,,,,,,38.6,,9.29,C1C[C@@]23C[N@@]1CC[C@@H]2OC1=C(C3)N=CC=C1,,,,,0,,216.1262631,4,1,4,1,2,3
8102,04/06/2019 00:00,DB12126,Bradykinin,,,,,,,,,0.0566,3.39,12.44,N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,,,,,0,,1059.561398,5,2,3,0,3,3
8103,04/06/2019 00:00,DB12127,Sultamicillin,,,,,,,,,0.283,11.71,7.23,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C,,,,,0,,594.1454205,5,1,4,0,4,4
8104,04/06/2019 00:00,DB12128,Ulimorelin,,,,,,,,,0.00834,11.14,6.27,C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](CC2=CC=C(F)C=C2)C(=O)NCCCC2=CC=CC=C2O1,,,,,0,,538.2955339,4,2,1,0,0,1
8105,04/06/2019 00:00,DB12129,Tideglusib,,,,,,solid,Sparingly soluble,3.28,0.00704,,,O=C1SN(C(=O)N1CC1=CC=CC=C1)C1=C2C=CC=CC2=CC=C1,,,,,0,,334.0775987,4,4,1,1,0,0
8106,04/06/2019 00:00,DB12130,Lorlatinib,"The median lorlatinib Tmax was 1.2 hours (0.5 to 4 hours) following a single oral 100 mg dose and 2 hours (0.5 to 23 hours) following 100 mg orally once daily at steady state [FDA Label].

The mean absolute bioavailability is 81% (90% CI 75.7%, 86.2%) after oral administration compared to intravenous administration [FDA Label].

Administration of lorlatinib with a high fat, high-calorie meal (approximately 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat) had no clinically meaningful effect on lorlatinib pharmacokinetics [FDA Label].  ",0.66,The mean plasma half-life (tÂ½) of lorlatinib was 24 hours (40%) after a single oral 100 mg dose of lorlatinib [FDA Label].,100 mg,Oral,solid,,,0.108,19.7,5.71,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2,0.66,0.66,,,0,100,406.1553521,4,3,3,2,0,1
8107,04/06/2019 00:00,DB12131,Vinpocetine,,,,,,,,,0.0254,,6.94,[H][C@]12N3CCC[C@@]1(CC)C=C(N1C4=CC=CC=C4C(CC3)=C21)C(=O)OCC,,,,,0,,350.1994281,5,2,4,1,1,3
8108,04/06/2019 00:00,DB12133,BLXA4,,,,,,,,,0.0259,4.26,-2.9,CCCCC[C@@H](O)\C=C\C1=CC=CC=C1\C=C\[C@@H](O)[C@@H](O)CCCC(O)=O,,,,,0,,376.2249741,1,1,0,0,0,0
8109,04/06/2019 00:00,DB12134,Gepotidacin,,,,,,,,,0.311,,8.62,O=C1C=CC2=C3N1C[C@@H](CN1CCC(CC1)NCC1=CC4=C(OCCC4)C=N1)N3C(=O)C=N2,,,,,0,,448.2222888,6,3,6,3,1,3
8110,04/06/2019 00:00,DB12135,Elubrixin,,,,,,,,,0.0989,5.78,7.18,OC1=C(C(Cl)=CC=C1NC(=O)NC1=C(Cl)C(F)=CC=C1)S(=O)(=O)N1CCNCC1,,,,,0,,462.0331596,3,2,1,0,1,1
8111,04/06/2019 00:00,DB12137,GSK-256066,,,,,,,,,0.0156,5,6.79,COC1=CC=CC(=C1)N=C1C(=CNC2=C1C=C(C=C2C)S(=O)(=O)C1=CC=CC(=C1)C(=O)N(C)C)C(O)=N,,,,,0,,518.1623909,4,4,1,1,0,0
8112,04/06/2019 00:00,DB12138,PF-03715455,,,,,,,,,0.000891,8.02,4.19,CC(C)(C)C1=NN(C(NC(O)=NCC2=CC=CC=C2SC2=CN3C(C=C2)=NN=C3C2=CC=CC=C2SCCO)=C1)C1=CC(Cl)=C(O)C=C1,,,,,0,,699.1853076,6,6,3,3,0,0
8113,04/06/2019 00:00,DB12139,Alisporivir,,,,,,,,,0.00917,11.85,-2.4,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O)C(C)C,,,,,0,,1215.857018,1,0,1,0,1,1
8114,04/06/2019 00:00,DB12140,Dilmapimod,,,,,,,,,0.0118,13.38,1.74,CC1=CC(F)=CC=C1C1=C2C=CC(=O)N(C2=NC(NC(CO)CO)=N1)C1=C(F)C=CC=C1F,,,,,0,,456.1409251,4,4,2,2,0,0
8115,04/06/2019 00:00,DB12141,Gilteritinib,"In preclinical trials, the maximal plasma concentration of gilteritinib was observed 2 hours after oral administration and followed by a maximal intratumor concentration after 4-8 hours. The maximum concentration, as well as the AUC, were modified correspondingly with the dose and were reported to be 374 ng/ml and 6943 ng.h/ml, respectively.[A40048] The steady-state plasma level is reached within 15 days of dosing with an approximate 10-fold bioaccumulation.[L4833]

In a fasted state in humans, the tmax is reported to be of 4-6 hours. The Cmax and AUC were decreased by 26% and 10% respectively by the co-ingestion of a high-fat meal with a tmax delay of 2 hours.[L4834]",0.94,The reported median half-life of gilteritinib was of approximate 45-159 hours.[L4833],40 mg/1,Oral,solid,<1 mg/mL ,99,0.0223,14.21,8.47,CCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O,0.94,0.94,,,0,40,552.3536373,5,2,4,1,3,3
8116,04/06/2019 00:00,DB12143,Rezatomidine,,,,,,,,,0.0111,9.98,,C[C@H](C1=CNC(=S)N1)C1=C(C)C(C)=CC=C1,,,,,0,,232.1034195,2,2,1,1,0,0
8117,04/06/2019 00:00,DB12144,BMS-275183,,,,,,,,,0.0139,10.48,-3,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(C)=C([C@@H](OC(C)=O)C1=O)C2(C)C,,,,,0,,845.3833848,5,1,1,0,1,1
8118,04/06/2019 00:00,DB12145,AZD-0328,,,,,,,,,45.3,,8.28,C1C2=C(O[C@]11CN3CCC1CC3)N=CC=C2,,,,,0,,216.1262631,5,1,5,1,3,4
8119,04/06/2019 00:00,DB12146,Rigosertib,,,,,,,,,0.0226,2.27,5.24,COC1=CC(OC)=C(\C=C\S(=O)(=O)CC2=CC=C(OC)C(NCC(O)=O)=C2)C(OC)=C1,,,,,0,,451.1300878,2,2,0,0,0,0
8120,04/06/2019 00:00,DB12147,Erdafitinib,"Following administration of erdafitinib 8 mg once daily, the mean (coefficient of variation [CV%]) steady-state maximum observed plasma concentration (Cmax), area under the curve (AUCtau), and minimum observed plasma concentration (Cmin) were 1,399 ng/mL (51%), 29,268 ngÂ·h/mL (60%), and 936 ng/mL (65%), respectively [FDA Label].

Following single and repeat once daily dosing, erdafitinib exposure (maximum observed plasma concentration [Cmax] and area under the plasma concentration time curve [AUC]) increased proportionally across the dose range of 0.5 to 12 mg (0.06 to 1.3 times the maximum approved recommended dose) [FDA Label]. Steady state was achieved after 2 weeks with once daily dosing and the mean accumulation ratio was 4-fold [FDA Label].

The median time to achieve peak plasma concentration (tmax) was 2.5 hours (range: 2 to 6 hours) [FDA Label]. And finally, no clinically meaningful differences with erdafitinib pharmacokinetics were observed following administration of a high-fat and high-calorie meal (800 calories to 1,000 calories with approximately 50% of total caloric content of the meal from fat) in healthy subjects [FDA Label].  ",,"The mean effective half-life documented for erdafitinib is 59 hours [FDA Label], although it has also been observed between 50 to 60 hours [A177115]. ",3 mg/1,Oral,solid,<1 mg/mL,,0.013,,9.72,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1,,,,,0,3,446.2430242,4,4,2,2,0,0
8121,04/06/2019 00:00,DB12148,Menatetrenone,,,,,,,,,0.000489,,-7.2,[H]\C(CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC1=C(C)C(=O)C2=CC=CC=C2C1=O)=C(\C)CCC=C(C)C,,,,,0,,444.3028305,2,1,0,0,0,0
8122,04/06/2019 00:00,DB12149,S-3304,,,,,,,,,0.00163,3.37,,CC1=CC=C(C=C1)C#CC1=CC=C(S1)S(=O)(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(O)=O,,,,,0,,464.0864491,4,4,2,2,0,0
8123,04/06/2019 00:00,DB12150,Pelubiprofen,,,,,,,,,0.0147,4.11,-4.9,[H]\C(C1=CC=C(C=C1)C(C)C(O)=O)=C1\CCCCC1=O,,,,,0,,258.1255944,2,1,0,0,0,0
8124,04/06/2019 00:00,DB12151,Brincidofovir,,,,,,,,,0.00124,1.07,1.75,CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O,,,,,0,,561.3542876,1,1,1,1,0,0
8125,04/06/2019 00:00,DB12153,Citicoline,,,,,,,,,7.99,1.84,-2.6,C[N+](C)(C)CCOP([O-])(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(N)=NC1=O,,,,,0,,488.1073309,2,1,2,1,1,1
8126,04/06/2019 00:00,DB12154,Itacitinib,,,,,,,,,0.0232,13.89,6.68,FC1=C(N=CC=C1C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1)C(F)(F)F,,,,,0,,553.1961692,6,4,6,4,2,2
8127,04/06/2019 00:00,DB12155,Napabucasin,,,,,,,,,0.115,13.98,-3.3,CC(=O)C1=CC2=C(O1)C(=O)C1=CC=CC=C1C2=O,,,,,0,,240.0422587,3,2,1,1,0,0
8128,04/06/2019 00:00,DB12156,Cordycepin,,,,,,,,,11.3,13.53,4.99,[H][C@@]1(CO)C[C@@]([H])(O)[C@@]([H])(O1)N1C=NC2=C(N)N=CN=C12,,,,,0,,251.1018393,3,2,3,2,1,1
8129,04/06/2019 00:00,DB12158,Filorexant,,,,,,,,,0.0203,,1.2,C[C@@H]1CC[C@@H](COC2=CC=C(F)C=N2)CN1C(=O)C1=CC(C)=CC=C1C1=NC=CC=N1,,,,,0,,420.1961543,4,3,3,2,1,1
8130,04/06/2019 00:00,DB12160,Bucillamine,,,,,,,,,0.401,3.94,0.68,[H][C@@](CS)(N=C(O)C(C)(C)S)C(O)=O,,,,,0,,223.0336853,0,0,0,0,0,0
8131,04/06/2019 00:00,DB12161,Deutetrabenazine,"The extent of absorption is 80% with oral deutetrabenazine. As deutetrabenazine is extensively metabolized to its main active metabolites following administration, linear dose dependence of peak plasma concentrations (Cmax) and AUC was observed for the metabolites after single or multiple doses of deutetrabenazine (6 mg to 24 mg and 7.5 mg twice daily to 22.5 mg twice daily) [FDA Label]. Cmax of deuterated Î±-HTBZ and Î²-HTBZ are reached within 3-4 hours post-dosing [FDA Label]. Food may increase the Cmax of Î±-HTBZ or Î²-HTBZ by approximately 50%, but is unlikely to have an effect on the AUC [FDA Label].",0.82,The half-life of total (Î±+Î²)-HTBZ from deutetrabenazine is approximately 9 to 10 hours [FDA Label].,12 mg/1,Oral,solid,,,0.361,18.26,7.33,[2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,0.82,0.82,,,0,12,323.2367542,3,1,2,0,1,2
8132,04/06/2019 00:00,DB12162,HX-1171,,,,,,,,,0.0445,10.75,-4.8,CCCCCCOC1=CC(C)=C(O)C(C)=C1C,,,,,0,,236.17763,1,1,0,0,0,0
8133,04/06/2019 00:00,DB12163,Sarpogrelate,,,,,,,,,0.0109,3.78,8.15,COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1,,,,,0,,429.2151377,2,2,0,0,0,0
8134,04/06/2019 00:00,DB12165,Presatovir,,,,,,,,,0.0415,5.05,9.83,CC1=CN2N=C(C=C2N=C1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)C1=CC(Cl)=CC=C1NS(C)(=O)=O,,,,,0,,531.1819365,5,3,4,2,2,2
8135,04/06/2019 00:00,DB12167,LY-3023414,,,,,,,,,0.0883,14.34,4.31,CO[C@@H](C)CN1C(=O)N(C)C2=C1C1=CC(=CC=C1N=C2)C1=CC(=CN=C1)C(C)(C)O,,,,,0,,406.2004907,4,4,3,3,0,0
8136,04/06/2019 00:00,DB12168,MK-0557,,,,,,,,,0.013,11.55,3.03,FC1=C(C=CC=C1)N1C=CC(NC(=O)[C@H]2CC[C@@]3(CC2)OC(=O)C2=C3C=NC=C2)=N1,,,,,0,,406.1441187,5,3,3,2,0,1
8137,04/06/2019 00:00,DB12170,Veledimex,,,,,,,,,0.000501,9.87,-2.4,CCC[C@@H](N(NC(=O)C1=CC=CC(OC)=C1CC)C(=O)C1=CC(C)=CC(C)=C1)C(C)(C)C,,,,,0,,438.2882431,2,2,0,0,0,0
8138,04/06/2019 00:00,DB12172,Nimorazole,,,,,,,,,9.58,,5.99,O=N(=O)C1=CN=CN1CCN1CCOCC1,,,,,0,,226.1065903,2,1,2,1,1,1
8139,04/06/2019 00:00,DB12173,Diphencyprone,,,,,,,,,0.00987,,-8.3,O=C1C(=C1C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,206.0731649,3,3,0,0,0,0
8140,04/06/2019 00:00,DB12174,CUDC-101,,,,,,,,,0.00476,8.91,4.66,COC1=C(OCCCCCCC(=O)NO)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1,,,,,0,,434.1954053,3,3,1,1,0,0
8141,04/06/2019 00:00,DB12176,Tricaprylin,,,,,,,,,6.36E-05,,-6.6,[H]C(COC(=O)CCCCCCC)(COC(=O)CCCCCCC)OC(=O)CCCCCCC,,,,,0,,470.3607393,0,0,0,0,0,0
8142,04/06/2019 00:00,DB12177,Eplivanserin,,,,,,,,,0.00672,9.47,7.81,CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)/C1=CC=CC=C1F,,,,,0,,328.1587061,2,2,0,0,0,0
8143,04/06/2019 00:00,DB12178,Telinavir,,,,,,,,,0.00427,13.59,0.59,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C2C=CC=CC2=N1)C(=O)NC(C)(C)C,,,,,0,,604.3373185,3,3,1,1,0,0
8144,04/06/2019 00:00,DB12179,Secoisolariciresinol,,,,,,,,,0.012,9.96,-2.6,COC1=C(O)C=CC(C[C@@H](CO)[C@H](CO)CC2=CC(OC)=C(O)C=C2)=C1,,,,,0,,362.1729386,2,2,0,0,0,0
8145,04/06/2019 00:00,DB12180,Apitolisib,,,,,,,,,0.101,4.42,15.01,[H][C@@](C)(O)C(=O)N1CCN(CC2=C(C)C3=C(S2)C(=NC(=N3)C2=CNC(=N)N=C2)N2CCOCC2)CC1,,,,,0,,498.2161578,5,3,5,3,2,2
8146,04/06/2019 00:00,DB12181,Dalcetrapib,,,,,,,,,0.000392,12.65,-1.9,CCC(CC)CC1(CCCCC1)C(=O)NC1=CC=CC=C1SC(=O)C(C)C,,,,,0,,389.2388504,2,1,0,0,0,0
8147,04/06/2019 00:00,DB12183,Sapitinib,,,,,,,,,0.0218,14.05,6.98,CNC(=O)CN1CCC(CC1)OC1=C(OC)C=C2N=CN=C(NC3=CC=CC(Cl)=C3F)C2=C1,,,,,0,,473.1629956,4,3,2,1,1,1
8148,04/06/2019 00:00,DB12184,Gepirone,,,,,,,,,1.09,,7.62,CC1(C)CC(=O)N(CCCCN2CCN(CC2)C2=NC=CC=N2)C(=O)C1,,,,,0,,359.2321252,3,1,3,1,2,2
8149,04/06/2019 00:00,DB12185,Exatecan,,,,,,,,,0.221,11.71,9.52,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C(F)C(C)=C4CC[C@H](N)C3=C14)C2=O,,,,,0,,435.1594344,6,3,4,2,0,2
8150,04/06/2019 00:00,DB12186,SRT-2104,,,,,,,,,0.0264,11.2,5.89,CC1=C(SC(=N1)C1=CC=CN=C1)C(=O)NC1=CC=CC=C1C1=CN2C(CN3CCOCC3)=CSC2=N1,,,,,0,,516.140216,6,5,5,4,1,1
8151,04/06/2019 00:00,DB12187,Abacavir hydroxyacetate,,,,,,,,,0.917,13.13,5.77,NC1=NC(NC2CC2)=C2N=CN([C@@H]3C[C@H](COC(=O)CO)C=C3)C2=N1,,,,,0,,344.1596885,4,2,2,2,0,0
8152,04/06/2019 00:00,DB12188,Zicronapine,,,,,,,,,0.00512,,8.34,CN1CCN(CC1(C)C)[C@@H]1C[C@H](C2=C1C=C(Cl)C=C2)C1=CC=CC=C1,,,,,0,,354.1862765,4,2,1,0,1,1
8153,04/06/2019 00:00,DB12190,Faropenem,,,,,,,,,14.7,4.16,-2.8,[H][C@]12SC([C@H]3CCCO3)=C(N1C(=O)[C@@H]2[C@@H](C)O)C(O)=O,,,,,0,,285.0670936,3,0,3,0,2,3
8154,04/06/2019 00:00,DB12191,Obatoclax,,,,,,,,,0.00402,13.97,4.68,COC1=CC(=N\C1=C/C1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1,,,,,0,,317.1528122,4,3,3,2,0,1
8155,04/06/2019 00:00,DB12192,Emeramide,,,,,,,,,0.0564,9.77,-0.64,SCCNC(=O)C1=CC(=CC=C1)C(=O)NCCS,,,,,0,,284.0653198,1,1,0,0,0,0
8156,04/06/2019 00:00,DB12193,Ajulemic acid,,,,,,,,,0.00125,4.07,-4.9,[H][C@@]12CC(=CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC)C(O)=O,,,,,0,,400.2613596,3,1,1,0,0,1
8157,04/06/2019 00:00,DB12194,Atamestane,,,,,,,,,0.0156,18.79,-4.9,CC1=CC(=O)C=C2CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]3[C@@]12C,,,,,0,,298.1932801,4,0,0,0,0,0
8158,04/06/2019 00:00,DB12195,VP-14637,,,,,,,,,0.0649,8.83,-0.96,CC1=NN=NN1N=CC1=CC=C(O)C(=C1)C(C1=CC=C(O)C=C1)C1=CC(C=NN2N=NN=C2C)=CC=C1O,,,,,0,,510.1876346,5,5,2,2,0,0
8159,04/06/2019 00:00,DB12196,CP-866087,,,,,,,,,0.00299,9.73,10.4,CC[C@]1([C@H]2CN(CC3(O)CC4=CC=CC=C4C3)C[C@@H]12)C1=CC=CC(NS(C)(=O)=O)=C1,,,,,0,,426.1977138,5,2,1,0,1,1
8160,04/06/2019 00:00,DB12197,Auriclosene,,,,,,,,,2.14,-1.8,-8.4,CC(C)(CS(O)(=O)=O)N(Cl)Cl,,,,,0,,220.9680195,0,0,0,0,0,0
8161,04/06/2019 00:00,DB12198,Fosdagrocorat,,,,,,,,,0.000737,0.44,5.02,[H][C@]12CCC3=C(C=CC(=C3)C(=O)NC3=C(C)N=CC=C3)[C@]1(CC1=CC=CC=C1)CC[C@](C2)(OP(O)(O)=O)C(F)(F)F,,,,,0,,574.1844433,5,3,1,1,0,0
8162,04/06/2019 00:00,DB12199,TRV-120027,,,,,,,,,0.055,3.4,11.75,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(O)=O,,,,,0,,925.5133853,3,2,2,1,1,1
8163,04/06/2019 00:00,DB12200,Tivantinib,,,,,,,,,0.00745,9.72,-8.6,O=C1NC(=O)[C@H]([C@@H]1C1=CNC2=CC=CC=C12)C1=CN2CCCC3=C2C1=CC=C3,,,,,0,,369.1477268,6,4,4,2,1,2
8164,04/06/2019 00:00,DB12201,PF-03654746,,,,,,,,,0.0436,15.08,8.15,CCNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1,,,,,0,,322.1856698,3,1,1,0,1,1
8165,04/06/2019 00:00,DB12203,Tozadenant,,,,,,,,,0.111,10.76,0.13,COC1=C2N=C(NC(=O)N3CCC(C)(O)CC3)SC2=C(C=C1)N1CCOCC1,,,,,0,,406.1674763,4,2,3,1,2,2
8166,04/06/2019 00:00,DB12204,Terbogrel,,,,,,,,,0.00754,3.52,6.82,CC(C)(C)N\C(NC#N)=N\C1=CC=CC(=C1)C(=C/CCCC(O)=O)\C1=CC=CN=C1,,,,,0,,405.2164751,2,2,1,1,0,0
8167,04/06/2019 00:00,DB12206,N-6022,,,,,,,,,0.0183,4.73,6.44,CC1=CC(=CC=C1N1C(CCC(O)=O)=CC=C1C1=CC=C(C=C1)N1C=CN=C1)C(N)=O,,,,,0,,414.1691906,4,4,2,2,0,0
8168,04/06/2019 00:00,DB12207,Verdinexor,,,,,,,,,0.0044,11.44,5.59,FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=CC=CC=N2)C=N1)C(F)(F)F,,,,,0,,442.0976783,3,3,2,2,0,0
8169,04/06/2019 00:00,DB12209,Tirasemtiv,,,,,,,,,0.142,10.42,-2,CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C,,,,,0,,230.1167611,2,2,2,2,0,0
8170,04/06/2019 00:00,DB12210,AZD-6280,,,,,,,,,0.0142,14.38,3.78,CCCNC(=O)C1=NN=C2C(=CC=CC2=C1N)C1=CC(OC)=CC=C1OC,,,,,0,,366.1691906,3,3,1,1,0,0
8171,04/06/2019 00:00,DB12211,PSI-697,,,,,,,,,0.0022,3.46,2.07,OC(=O)C1=C2C=CC3=C(CCCC3)C2=NC(CC2=CC=C(Cl)C=C2)=C1O,,,,,0,,367.0975211,4,3,1,1,0,0
8172,04/06/2019 00:00,DB12212,Landiolol,,,,,,,,,0.334,14.04,8.79,CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1,,,,,0,,509.2737152,3,1,2,0,2,2
8173,04/06/2019 00:00,DB12214,Luseogliflozin,,,,,,,,,0.0513,12.85,-2.8,CCOC1=CC=C(CC2=CC([C@@H]3S[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=C(OC)C=C2C)C=C1,,,,,0,,434.1763097,3,2,1,0,1,1
8174,04/06/2019 00:00,DB12216,Bergapten,,,,,,,,,0.148,,-2.8,COC1=C2C=CC(=O)OC2=CC2=C1C=CO2,,,,,0,,216.0422587,3,3,2,2,0,0
8175,04/06/2019 00:00,DB12218,AZD-5363,,,,,,,,,0.0819,4.66,9.47,[H][C@@](CCO)(N=C(O)C1(N)CCN(CC1)C1=NC=NC2=C1C=CN2)C1=CC=C(Cl)C=C1,,,,,0,,428.1727517,4,3,3,2,1,1
8176,04/06/2019 00:00,DB12219,GSK-424887,,,,,,,,,0.000331,,8.54,C[C@H](N(C)C(=O)CC1(CCN(C)CC1)C1=CC=C(F)C=C1)C1=C2C=CC=CC2=CC(Cl)=C1,,,,,0,,452.2030695,4,3,1,0,1,1
8177,04/06/2019 00:00,DB12220,ORG-25935,,,,,,,,,0.00924,1.68,10.59,COC1=CC=C2[C@H]([C@@H](CN(C)CC(O)=O)CCC2=C1)C1=CC=CC=C1,,,,,0,,339.1834437,3,2,0,0,0,0
8178,04/06/2019 00:00,DB12221,Canrenone,,,,,,,,,0.0042,19.94,-4.8,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C,,,,,0,,340.2038448,5,0,1,0,1,1
8179,04/06/2019 00:00,DB12222,Lurtotecan,,,,,,,,,0.713,11.71,7.86,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C4OCCOC4=CC1=C3CN1CCN(C)CC1)C2=O,,,,,0,,518.2165347,7,3,6,2,1,4
8180,04/06/2019 00:00,DB12223,Squaric Acid Dibutyl Ester,,,,,,,,,0.285,,-4.8,CCCCOC1=C(OCCCC)C(=O)C1=O,,,,,0,,226.1205091,1,1,0,0,0,0
8181,04/06/2019 00:00,DB12224,Oxothiazolidinecarboxylic acid,,,,,,,,,44.3,3.19,,OC(=O)[C@@H]1CSC(=O)N1,,,,,0,,146.999014,1,0,1,0,1,1
8182,04/06/2019 00:00,DB12225,Beclabuvir,,,,,,,,,0.00525,5.29,7.3,[H][C@@]12C[C@@]1(CN1C3=C(C=CC(=C3)C(O)=NS(=O)(=O)N(C)C)C(C3CCCCC3)=C1C1=C2C=C(OC)C=C1)C(=O)N1[C@@]2([H])CC[C@]1([H])CN(C)C2,,,,,0,,659.3141405,8,3,4,1,2,3
8183,04/06/2019 00:00,DB12226,Terameprocol,,,,,,,,,0.000192,,-4.3,COC1=CC=C(C[C@H](C)[C@H](C)CC2=CC=C(OC)C(OC)=C2)C=C1OC,,,,,0,,358.2144094,2,2,0,0,0,0
8184,04/06/2019 00:00,DB12227,Tetulomab tetraxetan Lu-177,,,,,,,,,0.14,1.07,9.97,N[C@@H](CCCCNC(=S)NC1=CC=C(CC2CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN2CC(O)=O)C=C1)C(O)=O,,,,,0,,697.3105117,2,1,1,0,1,1
8185,04/06/2019 00:00,DB12228,Telcagepant,,,,,,,,,0.0191,8.08,5.52,[H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1,,,,,0,,566.2064798,5,3,4,2,2,2
8186,04/06/2019 00:00,DB12229,Cerlapirdine,,,,,,,,,0.00476,9.13,7.83,CN(C)CCCOC1=CC=C2NN=C(C2=C1)S(=O)(=O)C1=C2C=CC=CC2=CC=C1,,,,,0,,409.1460126,4,4,1,1,0,0
8187,04/06/2019 00:00,DB12230,Bunazosin,,,,,,,,,0.112,12.72,5.83,CCCC(=O)N1CCCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(=N)N1,,,,,0,,373.2113897,3,2,2,1,1,1
8188,04/06/2019 00:00,DB12231,Temefos,,,,,,,,,0.000145,,,COP(=S)(OC)OC1=CC=C(SC2=CC=C(OP(=S)(OC)OC)C=C2)C=C1,,,,,0,,465.9897246,2,2,0,0,0,0
8189,04/06/2019 00:00,DB12232,KRN-7000,,,,,,,,,0.00054,7.42,2.73,[H][C@@](O)(CCCCCCCCCCCCCC)[C@@]([H])(O)[C@]([H])(CO[C@@]1([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]1([H])O)N=C(O)CCCCCCCCCCCCCCCCCCCCCCCCC,,,,,0,,857.7319837,1,0,1,0,1,1
8190,04/06/2019 00:00,DB12233,Iguratimod,,,,,,,,,0.0556,2.96,-0.034,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C2C(=O)C(=COC2=C1)N=CO,,,,,0,,374.0572572,3,3,1,1,0,0
8191,04/06/2019 00:00,DB12234,BMS-214662,,,,,,,,,0.0163,12.61,6.61,[H][C@@]1(CC2=CC=CC=C2)CN(CC2=CN=CN2)C2=C(CN1S(=O)(=O)C1=CC=CS1)C=C(C=C2)C#N,,,,,0,,489.129317,5,4,3,2,0,1
8192,04/06/2019 00:00,DB12235,Estetrol,,,,,,,,,1.38,10.33,-3.3,[H][C@@]1(O)[C@]([H])(O)[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]2(C)[C@@]1([H])O,,,,,0,,304.1674592,4,1,0,0,0,0
8193,04/06/2019 00:00,DB12236,Bexagliflozin,,,,,,,,,0.0565,12.57,-3,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(OCCOC3CC3)C=C2)=C1,,,,,0,,464.1601809,4,2,1,0,1,1
8194,04/06/2019 00:00,DB12237,GW-274150,,,,,,,,,1.55,2.15,12.6,CC(=N)NCCSCC[C@H](N)C(O)=O,,,,,0,,219.1041478,0,0,0,0,0,0
8195,04/06/2019 00:00,DB12238,MK-0777,,,,,,,,,0.0155,,1.51,CCN1N=CN=C1COC1=NN2C(C=C1C(C)(C)C)=NN=C2C1=CC=CC=C1F,,,,,0,,395.1869865,4,4,3,3,0,0
8196,04/06/2019 00:00,DB12239,Balicatib,,,,,,,,,0.142,11.76,8.34,CCCN1CCN(CC1)C1=CC=C(C=C1)C(=O)NC1(CCCCC1)C(=O)NCC#N,,,,,0,,411.2634253,3,1,1,0,1,1
8197,04/06/2019 00:00,DB12241,TAK-733,,,,,,,,,0.0705,10.5,0.08,[H][C@](O)(CO)CN1C=NC2=C(C1=O)C(NC1=C(F)C=C(I)C=C1)=C(F)C(=O)N2C,,,,,0,,504.0106094,3,3,2,2,0,0
8198,04/06/2019 00:00,DB12242,AZD-7762,,,,,,,,,0.0129,8.32,9.55,[H][C@@]1(CCCNC1)NC(=O)C1=C(NC(O)=N)C=C(S1)C1=CC(F)=CC=C1,,,,,0,,362.1212751,3,2,2,1,1,1
8199,04/06/2019 00:00,DB12243,Edaravone,"The peak plasma concentration of the parent drug is reached at the end of infusion, without accumulation of the drug with multiple dosing regimen. The mean Cmax value in healthy male adults is 888ng/mL for intravenous infusion. The values of AUC and Cmax are increased in a dose-proportional relationship. The oral bioavailability in mouse studies is 38% of the I.V. delivery [A19138].",0.92,The mean terminal elimination half-life of edaravone is 4.5 to 6 hours and the half-lives of its metabolites are 2 to 2.8 hours.,30 mg/100mL,Intravenous,solid,<1 mg/mL,,0.939,13.45,-1.5,CC1=NN(C(=O)C1)C1=CC=CC=C1,0.92,0.92,,,0,,174.0793129,2,1,1,0,0,1
8200,04/06/2019 00:00,DB12244,CP-601927,,,,,,,,,0.0548,,9.86,FC(F)(F)C1=CC2=C(C=C1)[C@H]1C[C@@H]2CNC1,,,,,0,,227.092184,3,1,1,0,1,1
8201,04/06/2019 00:00,DB12245,Triclabendazole,"After a single oral dose of 10 mg/kg triclabendazole with a 560-kcal meal to patients diagnosed with fascioliasis, mean peak plasma concentrations (Cmax) for triclabendazole, the sulfoxide, and sulfone metabolites were 1.16, 38.6, and 2.29 Î¼mol/L, respectively. The area under the curve (AUC) for triclabendazole, the sulfoxide and sulfone metabolites were 5.72, 386, and 30.5 Î¼molâˆ™h/L, respectively.[FDA label]

After the oral administration of a single dose of triclabendazole at 10 mg/kg with a 560 calorie meal to patients with fascioliasis, the median Tmax for the parent compound as well as the active sulfoxide metabolite was 3 to 4 hours.[FDA label]

**Effect of Food**
Cmax and AUC of triclabendazole and sulfoxide metabolite increased about 2-3 times when triclabendazole was administered as a single dose at 10 mg/kg with a meal containing approximately 560 calories. Additionally, the sulfoxide metabolite Tmax increased from 2 hours in fasting subjects to 4 hours in fed subjects [FDA label]. ",0.984,"The plasma elimination half-life (t1/2) of triclabendazole, the sulfoxide and sulfone metabolites in human is about 8, 14, and 11 hours, respectively.[FDA label]",250 mg/1,Oral,solid,1.0 mg/dL,3.48,0.000508,10.46,4.54,CSC1=NC2=C(N1)C=C(Cl)C(OC1=CC=CC(Cl)=C1Cl)=C2,0.984,0.984,,,0,250,357.9501169,3,3,1,1,0,0
8202,04/06/2019 00:00,DB12247,AZD-4547,,,,,,,,,0.0217,13.74,9.02,COC1=CC(OC)=CC(CCC2=CC(NC(=O)C3=CC=C(C=C3)N3C[C@H](C)N[C@H](C)C3)=NN2)=C1,,,,,0,,463.2583399,4,3,2,1,1,1
8203,04/06/2019 00:00,DB12248,Tulobuterol,,,,,,,,,0.366,13.9,9.55,CC(C)(C)NCC(O)C1=CC=CC=C1Cl,,,,,0,,227.1076919,1,1,0,0,0,0
8204,04/06/2019 00:00,DB12251,Moxaverine,,,,,,,,,0.00102,,6.49,CCC1=NC(CC2=CC=CC=C2)=C2C=C(OC)C(OC)=CC2=C1,,,,,0,,307.1572289,3,3,1,1,0,0
8205,04/06/2019 00:00,DB12252,PG-701,,,,,,,,,3.04,12.07,-3.4,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@@]3(O)C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O,,,,,0,,376.1522031,7,0,4,0,3,4
8206,04/06/2019 00:00,DB12253,GDC-0810,,,,,,,,,0.000198,3.87,1.63,CC\C(=C(\C1=CC=C(\C=C\C(O)=O)C=C1)C1=CC=C2NN=CC2=C1)C1=CC=C(F)C=C1Cl,,,,,0,,446.1197338,4,4,1,1,0,0
8207,04/06/2019 00:00,DB12254,ABT-751,,,,,,,,,0.0323,7.21,3.58,COC1=CC=C(C=C1)S(=O)(=O)NC1=C(NC2=CC=C(O)C=C2)N=CC=C1,,,,,0,,371.093977,3,3,1,1,0,0
8208,04/06/2019 00:00,DB12255,Vadadustat,,,,,,,,,0.0436,3.12,1.15,OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1,,,,,0,,306.0407345,2,2,1,1,0,0
8209,04/06/2019 00:00,DB12259,CG-200745,,,,,,,,,0.00493,8.76,9.45,CN(C)CCCNC(=O)C(\COC1=C2C=CC=CC2=CC=C1)=C\CCCCC(=O)NO,,,,,0,,427.2471065,2,2,0,0,0,0
8210,04/06/2019 00:00,DB12260,Radiprodil,,,,,,,,,0.00973,9.51,-2,FC1=CC=C(CC2CCN(CC2)C(=O)C(=O)NC2=CC=C3NC(=O)OC3=C2)C=C1,,,,,0,,397.1437843,4,3,2,1,1,1
8211,04/06/2019 00:00,DB12262,CRS-3123,,,,,,,,,0.00154,10.3,8.42,BrC1=CC2=C(OCC[C@H]2NCCCNC2=CC(=O)C3=C(N2)C=CS3)C(Br)=C1,,,,,0,,510.956472,4,3,3,2,0,1
8212,04/06/2019 00:00,DB12263,Begacestat,,,,,,,,,0.23,6.99,-2.8,OC[C@@H](NS(=O)(=O)C1=CC=C(Cl)S1)C(C(F)(F)F)C(F)(F)F,,,,,0,,390.9538321,1,1,1,1,0,0
8213,04/06/2019 00:00,DB12264,Atevirdine,,,,,,,,,0.0382,14.5,6.88,CCNC1=CC=CN=C1N1CCN(CC1)C(=O)C1=CC2=CC(OC)=CC=C2N1,,,,,0,,379.200825,4,3,3,2,1,1
8214,04/06/2019 00:00,DB12265,Fexinidazole,,,,,,,,,0.0927,,1.03,CSC1=CC=C(OCC2=NC=C(N2C)[N+]([O-])=O)C=C1,,,,,0,,279.0677623,2,2,1,1,0,0
8215,02/07/2019 00:00,DB12267,Brigatinib,"Administration of brigatinib at a concentration of 90 mg generates a Cmax of 552 ng/ml and AUC of 8165 ng h/ml while the administration of 180 mg presents a Cmax of 1452 ng/ml and AUC of 20276 ng h/ml. It has a dose proportional exposure with an accumulation ratio on the range of 1.9 to 2.4. Following oral administration of brigatinib, the Tmax is presented in a range from 1 to 4 hours. Consumption of a high-fat meal compared to overnight fasting reduces Cmax by 13% without presenting an effect on AUC.[A31320]",0.66,The half-life of brigatinib at steady-state was 25 hours.[L1028],180 mg,Oral,solid,Insoluble,5.17,0.022,12.88,8.54,COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1,0.66,0.66,,,0,180,583.2591378,5,3,3,1,2,2
8216,04/06/2019 00:00,DB12268,Carmegliptin,,,,,,,,,1.05,,9.22,[H][C@@]1(CF)CN(C(=O)C1)[C@@]1([H])CN2CCC3=CC(OC)=C(OC)C=C3[C@]2([H])C[C@]1([H])N,,,,,0,,377.21147,4,1,3,0,2,3
8217,04/06/2019 00:00,DB12269,PF-06273340,,,,,,,,,0.0154,12.34,6.05,CC(C)(CO)N1C=C(C(=O)C2=CC(NC(=O)CC3=CC=C(Cl)C=N3)=CN=C2)C2=CN=C(N)N=C12,,,,,0,,479.1472652,4,4,4,4,0,0
8218,04/06/2019 00:00,DB12270,Losmapimod,,,,,,,,,0.00393,13.86,2.6,CC1=C(C=C(C=C1F)C(=O)NC1CC1)C1=CC=C(C=N1)C(=O)NCC(C)(C)C,,,,,0,,383.2009053,3,2,1,1,0,0
8219,04/06/2019 00:00,DB12271,ORE-1001,,,,,,,,,0.018,2.66,8.33,[H][C@@](CC(C)C)(N[C@@]([H])(CC1=CN=CN1CC1=CC(Cl)=CC(Cl)=C1)C(O)=O)C(O)=O,,,,,0,,427.1065616,2,2,1,1,0,0
8220,04/06/2019 00:00,DB12272,Vidupiprant,,,,,,,,,0.000145,3.11,-0.83,CC(C)(C)NC(=O)C1=CC=C(OC2=CC(F)=C(CC(O)=O)C=C2Cl)C(NS(=O)(=O)C2=CC=C(C=C2Cl)C2CC2)=C1,,,,,0,,608.0950912,4,3,0,0,0,0
8221,04/06/2019 00:00,DB12273,Ecopipam,,,,,,,,,0.0236,7.5,8.52,[H][C@]12CCC3=CC=CC=C3[C@]1([H])C1=CC(O)=C(Cl)C=C1CCN2C,,,,,0,,313.1233419,4,2,1,0,0,1
8222,04/06/2019 00:00,DB12275,Seviteronel,,,,,,,,,0.0463,8,0.4,CC(C)[C@@](O)(C1=CN=NN1)C1=CC=C2C=C(OC(F)F)C(OC(F)F)=CC2=C1,,,,,0,,399.1206043,3,3,1,1,0,0
8223,04/06/2019 00:00,DB12276,Apomine,,,,,,,,,0.024,10.75,-5.1,CC(C)OP(=O)(OC(C)C)C(CC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)P(=O)(OC(C)C)OC(C)C,,,,,0,,562.3188273,1,1,0,0,0,0
8224,02/07/2019 00:00,DB12278,Propiverine,"Propiverine is rapidly absorbed from the gastrointestinal tract with maximum plasma concentrations attained after 2.3 hours. the
mean absolute bioavailability of mictonorm 15 mg tablets (propiverine)  is 40.5 %.  It undergoes heavy first-pass metabolism in the liver [L2315].
",90-95%,"In three studies including a total of 37 healthy volunteers mean elimination half-life was 14.1, 20.1 and
22.1 hours, respectively [L2315]. ",30 mg,Oral,solid,5mg/mL,,0.00635,,8.72,CCCOC(C(=O)OC1CCN(C)CC1)(C1=CC=CC=C1)C1=CC=CC=C1,0.9,0.95,,,0,30,367.2147438,3,2,1,0,1,1
8225,04/06/2019 00:00,DB12279,OBP-801,,,,,,,,,0.637,10.84,-2.2,CC(C)[C@H]1NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C)C(=O)N2)OC(=O)C[C@@H]1O,,,,,0,,473.1654277,2,0,2,0,1,2
8226,04/06/2019 00:00,DB12280,AZD-5423,,,,,,,,,0.00082,7.37,1.37,COC1=CC(=CC=C1)[C@@H](OC1=CC=C2N(N=CC2=C1)C1=CC=C(F)C=C1)[C@H](C)NC(=O)C(F)(F)F,,,,,0,,487.1519044,4,4,1,1,0,0
8227,04/06/2019 00:00,DB12282,Defactinib,,,,,,,,,0.0184,12.63,4.03,CNC(=O)C1=CC=C(NC2=NC=C(C(NCC3=C(N=CC=N3)N(C)S(C)(=O)=O)=N2)C(F)(F)F)C=C1,,,,,0,,510.1409422,3,3,2,2,0,0
8228,04/06/2019 00:00,DB12283,Balapiravir,,,,,,,,,0.0875,19.22,-0.23,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-],,,,,0,,494.2125119,2,1,2,1,1,1
8229,04/06/2019 00:00,DB12284,LY-2608204,,,,,,,,,0.000932,10.67,8,O=C(NC1=NC=C(SCCN2CCCC2)S1)[C@@]1(C[C@H]1C1CCCCC1)C1=CC=C(C=C1)S(=O)(=O)C1CC1,,,,,0,,559.199705,6,2,2,1,1,1
8230,04/06/2019 00:00,DB12285,Verubecestat,,,,,,,,,0.0367,11.55,5.68,CN1C(N)=N[C@@](C)(CS1(=O)=O)C1=CC(NC(=O)C2=CC=C(F)C=N2)=CC=C1F,,,,,0,,409.1020168,3,2,2,1,0,1
8231,04/06/2019 00:00,DB12286,Simendan,,,,,,,,,0.126,4.76,0.48,CC1CC(O)=NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1,,,,,0,,280.107259,2,1,1,0,0,1
8232,04/06/2019 00:00,DB12287,Talsaclidine,,,,,,,,,0.666,,8.76,C#CCO[C@H]1CN2CCC1CC2,,,,,0,,165.1153641,3,0,3,0,3,3
8233,04/06/2019 00:00,DB12288,Piromelatine,,,,,,,,,0.0154,14.72,-1.4,COC1=CC=C2NC=C(CCNC(=O)C3=CC(=O)C=CO3)C2=C1,,,,,0,,312.111007,3,3,2,2,0,0
8234,04/06/2019 00:00,DB12289,Darexaban,,,,,,,,,0.0291,8.32,8.95,COC1=CC=C(C=C1)C(=O)NC1=C(NC(=O)C2=CC=C(C=C2)N2CCCN(C)CC2)C(O)=CC=C1,,,,,0,,474.2267054,4,3,1,0,1,1
8235,04/06/2019 00:00,DB12290,Puerarin,,,,,,,,,1.08,6.03,-3,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=C(O)C=CC2=C1OC=C(C2=O)C1=CC=C(O)C=C1,,,,,0,,416.1107322,4,3,2,1,1,1
8236,04/06/2019 00:00,DB12291,Tacedinaline,,,,,,,,,0.0351,13.48,3.24,CC(=O)NC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1N,,,,,0,,269.1164267,2,2,0,0,0,0
8237,04/06/2019 00:00,DB12292,Barusiban,,,,,,,,,0.0157,11.74,9.9,CC[C@H](C)[C@@H]1NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)CCSCC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC1=O)[C@H](C)CC)C(=O)N(C)[C@H](CO)CCCN,,,,,0,,829.452031,3,2,2,1,1,1
8238,04/06/2019 00:00,DB12293,Nefopam,,,,,,,,,0.0803,,7.72,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1,,,,,0,,253.1466642,3,2,1,0,0,1
8239,04/06/2019 00:00,DB12295,Evodenoson,,,,,,,,,0.318,12.39,2.97,COC(=O)N1CCC(CC#CC2=NC(N)=C3N=CN([C@@H]4O[C@@H]([C@@H](O)[C@H]4O)C(=O)NC4CC4)C3=N2)CC1,,,,,0,,499.2179316,5,2,4,2,2,2
8240,04/06/2019 00:00,DB12297,GLPG-0187,,,,,,,,,0.0165,1.65,8.01,COC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CNC1=C(C)C(=NC(C)=N1)N1CCC(CC1)C1=CC=C2CCCNC2=N1)C(O)=O,,,,,0,,595.2576883,5,3,4,2,1,2
8241,04/06/2019 00:00,DB12298,5-(hydroxymethyl)-2-furaldehyde,,,,,,,,,31.1,13.65,-3.4,OCC1=CC=C(O1)C=O,,,,,0,,126.0316941,1,1,1,1,0,0
8242,04/06/2019 00:00,DB12299,Bavisant,,,,,,,,,2.46,,7.11,O=C(N1CCN(CC1)C1CC1)C1=CC=C(CN2CCOCC2)C=C1,,,,,0,,329.2103271,4,1,2,0,2,2
8243,04/06/2019 00:00,DB12300,P-nitrobiphenyl,,,,,,,,,0.013,,,O=N(=O)C1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,199.0633285,2,2,0,0,0,0
8244,02/07/2019 00:00,DB12301,Doravirine,"The absolute bioavailability of doravirine is reported to be 64% with a Tmax of 2 hours [FDA Label]. Following oral [14â€‰C]doravirine administration, all of the administered dose was recovered [A38823] and the agent is considered to be well absorbed [A38824]. Moreover, the co-administration with food did not greatly alter doravirine's pharmacokinetic profile during clinical studies [A38824].",0.76,The elimination half-life t1/2 determined for doravirine is recorded as 15 hours [FDA Label].,100 mg,Oral,,,,0.0115,7.34,1.12,CN1C(O)=NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F,0.76,0.76,,,0,100,425.0502516,3,3,2,2,0,0
8245,04/06/2019 00:00,DB12302,CP-724714,,,,,,,,,0.00223,14.71,5.19,COCC(=O)NC\C=C\C1=CC=C2N=CN=C(NC3=CC=C(OC4=CC=C(C)N=C4)C(C)=C3)C2=C1,,,,,0,,469.2113897,4,4,2,2,0,0
8246,04/06/2019 00:00,DB12303,Motolimod,,,,,,,,,0.00485,,7.93,CCCN(CCC)C(=O)C1=CC2=CC=C(C=C2N=C(N)C1)C1=CC=C(C=C1)C(=O)N1CCCC1,,,,,0,,458.2681763,4,2,2,0,1,2
8247,04/06/2019 00:00,DB12305,Dasotraline,,,,,,,,,9.79E-05,,9.52,N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C12,,,,,0,,291.0581548,3,2,0,0,0,0
8248,04/06/2019 00:00,DB12306,Cipargamin,,,,,,,,,0.00483,12.26,6.58,C[C@H]1CC2=C(NC3=CC(Cl)=C(F)C=C23)[C@@]2(N1)C(=O)NC1=CC=C(Cl)C=C21,,,,,0,,389.0497956,5,3,3,1,0,2
8249,04/06/2019 00:00,DB12307,Foretinib,,,,,,,,,0.00193,4.59,6.88,COC1=C(OCCCN2CCOCC2)C=C2N=CC=C(OC3=C(F)C=C(C=C3)N=C(O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C2=C1,,,,,0,,632.2446412,6,4,2,1,1,1
8250,04/06/2019 00:00,DB12308,Eltanolone,,,,,,,,,0.00136,18.3,-1.4,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C,,,,,0,,318.2558803,4,0,0,0,0,0
8251,04/06/2019 00:00,DB12309,GI-181771X,,,,,,,,,0.00228,2.77,-4.4,CC(C)N(C(=O)CN1C2=CC=CC=C2N(C2=CC=CC=C2)C(=O)[C@@H](NC(=O)NC2=CC=CC(=C2)C(O)=O)C1=O)C1=CC=CC=C1,,,,,0,,605.2274337,5,4,1,0,0,1
8252,04/06/2019 00:00,DB12310,Trehalose,,,,,,,,,592,11.91,-3,OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,342.1162115,2,0,2,0,2,2
8253,04/06/2019 00:00,DB12311,CP1-1189,,,,,,,,,0.177,13.74,-0.84,CC(=O)NC1=CC=C(C=C1)C(=O)NC(C)(C)C,,,,,0,,234.1368278,1,1,0,0,0,0
8254,04/06/2019 00:00,DB12312,ORG-25435,,,,,,,,,0.104,,6.27,CC[C@@H](N(CCOC)CCOC)C(=O)OC1=C(OC)C=C(C)C=C1OC,,,,,0,,369.2151377,1,1,0,0,0,0
8255,04/06/2019 00:00,DB12313,Dopexamine,,,,,,,,,0.00243,10.71,10.14,OC1=C(O)C=C(CCNCCCCCCNCCC2=CC=CC=C2)C=C1,,,,,0,,356.2463783,2,2,0,0,0,0
8256,04/06/2019 00:00,DB12314,Chlorproguanil,,,,,,,,,0.0808,,10,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C(Cl)=C1,,,,,0,,287.0704508,1,1,0,0,0,0
8257,04/06/2019 00:00,DB12316,9CUAB30,,,,,,,,,0.00157,4.78,,[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(/C)\C(\[H])=C1/CCCC2=CC=CC=C12,,,,,0,,294.1619799,2,1,0,0,0,0
8258,04/06/2019 00:00,DB12318,BMS-599626,,,,,,,,,0.0129,12.24,7.49,CC1=C2N(C=C1NC(=O)OC[C@@H]1COCCN1)N=CN=C2NC1=CC=C2N(CC3=CC=CC(F)=C3)N=CC2=C1,,,,,0,,530.2190149,6,5,4,3,1,1
8259,04/06/2019 00:00,DB12319,Benzbromarone,,,,,,,,,0.0131,5.11,-3.8,CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=CC=CC=C2O1,,,,,0,,421.9153184,3,3,1,1,0,0
8260,04/06/2019 00:00,DB12320,Palovarotene,,,,,,,,,0.000344,4.13,2.44,CC1(C)CCC(C)(C)C2=C1C=C(CN1C=CC=N1)C(\C=C\C1=CC=C(C=C1)C(O)=O)=C2,,,,,0,,414.2307282,4,3,1,1,0,0
8261,04/06/2019 00:00,DB12321,Ifetroban,,,,,,,,,0.0146,4.65,-2.2,CCCCCNC(=O)C1=COC(=N1)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1CC1=CC=CC=C1CCC(O)=O,,,,,0,,440.2311221,4,2,3,1,2,2
8262,04/06/2019 00:00,DB12322,GW-870086,,,,,,,,,0.0084,13.56,-3.4,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1C(C)(C)C1(C)C)C(=O)OCC#N,,,,,0,,559.2745444,5,0,0,0,0,0
8263,04/06/2019 00:00,DB12323,Radotinib,,,,,,,,,0.00234,12.22,6.29,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=N3)=C2)=CC(=C1)C(F)(F)F,,,,,0,,530.179042,5,5,3,3,0,0
8264,04/06/2019 00:00,DB12325,Idasanutlin,,,,,,,,,0.001,3.91,7.1,COC1=CC(=CC=C1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1C1=CC=CC(Cl)=C1F)C1=CC=C(Cl)C=C1F)C(O)=O,,,,,0,,615.1503182,4,3,1,0,1,1
8265,04/06/2019 00:00,DB12326,Antroquinonol,,,,,,,,,0.00399,13.51,-3.4,COC1=C(OC)C(=O)[C@H](C)[C@@H](C\C=C(/C)CC\C=C(/C)CCC=C(C)C)[C@H]1O,,,,,0,,390.2770097,1,0,0,0,0,0
8266,04/06/2019 00:00,DB12327,Salvinorin A,,,,,,,,,0.08,16.45,-2.9,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)C1=COC=C1,,,,,0,,432.1784179,4,1,2,1,1,1
8267,04/06/2019 00:00,DB12328,Cantharidin,"Cantharidin is absorbed from the gastrointestinal tract, and, to a limited extent from the skin as well [L2648].

Little pharmacodynamic and pharmacokinetic data regarding cantharidin in the human body currently exists; recruitment for First-Time-In-Human clinical trials regarding such information have been ongoing in 2018 [L2647]. There are however some studies regarding such data in animal models like beagle dogs [A32901].",,Little pharmacodynamic and pharmacokinetic data regarding cantharidin in the human body currently exists; recruitment for First-Time-In-Human clinical trials regarding such information have been ongoing in 2018 [L2647]. There are however some studies regarding such data in animal models like beagle dogs [A32901].,0.7 g/100g,Topical,,,,16.6,,-4.2,[H][C@]12CC[C@]([H])(O1)[C@]1(C)C(=O)OC(=O)[C@]21C,,,,,0,,196.0735589,3,0,3,0,3,3
8268,04/06/2019 00:00,DB12329,Eravacycline,"Following single-dose intravenous administration, eravacycline AUC (area under the curve) and Cmax (maximum concentration) increase dose-proportionally for doses from 1 mg/kg - 3 mg/kg (3 times the approved dose). There is approximately 45% accumulation following intravenous dosing of 1 mg/kg every 12 hours [FDA label].",0.79,The mean elimination half-life is 20 hours [FDA label].,50 mg/1,Intravenous,solid,,,0.838,2.62,8.53,[H][C@@]12CC3=C(C(O)=C(NC(=O)CN4CCCC4)C=C3F)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@]([H])(N(C)C)[C@]1([H])C2,0.79,0.79,,,0,,558.2125922,5,1,1,0,1,1
8269,04/06/2019 00:00,DB12332,Rucaparib,"Rucaparib demonstrates a linear pharmacokinetic properties over a dose range from 240 to 840 mg twice daily with time-independence and dose-proportionality. The mean steady-state rucaparib Cmax was 1940 ng/mL (54% coefficient of variation [CV]) and AUC0-12h was 16900 hâ‹…ng/mL (54% CV) at the approved recommended dosage. The time to reach the steady-state peak plasma concentration (Tmax) was 1.9 hours at the recommended dosage. 
The mean absolute bioavailability of rucaparib immediate-release tablet was 36% with a range from 30% to 45%. Following a high-fat meal, the Cmax was increased by 20% and AUC 0-24h was increased by 38%, and T max was delayed by 2.5 hours, as compared to dosing under fasted conditions [FDA Label]. ",0.7,"Following a single oral dose of 600mg rucaparib, the mean terminal half life (t1/2) was 17-19 hours [FDA Label].",200 mg/1,Oral,solid,1 mg/mL,,0.0114,13.16,9.32,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3,0.7,0.7,,,0,200,323.1433904,4,3,2,1,0,1
8270,04/06/2019 00:00,DB12334,Milataxel,,,,,,,,,0.0672,11.42,-2.9,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CO4)C(C)=C([C@@H](O)C(=O)[C@]12C)C3(C)C,,,,,0,,853.3520847,6,2,2,1,1,1
8271,04/06/2019 00:00,DB12336,GDC-0917,,,,,,,,,0.0281,9.92,8.58,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)NC1=C(N=C(S1)C1=NC=CO1)C1=CC=CC=C1,,,,,0,,564.2518746,5,3,3,2,1,1
8272,04/06/2019 00:00,DB12337,N-acetylsulfanilyl chloride,,,,,,,,,0.223,4.21,0.49,CC(O)=NC1=CC=C(C=C1)S(Cl)(=O)=O,,,,,0,,232.9913418,1,1,0,0,0,0
8273,04/06/2019 00:00,DB12338,Carisbamate,,,,,,,,,2.15,13.43,-3.5,NC(=O)OC[C@@H](O)C1=CC=CC=C1Cl,,,,,0,,215.0349209,1,1,0,0,0,0
8274,04/06/2019 00:00,DB12339,Radezolid,,,,,,,,,0.043,8.56,7.46,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C(F)=C1)C1=CC=C(CNCC2=CN=NN2)C=C1,,,,,0,,438.1815668,4,3,2,1,1,1
8275,04/06/2019 00:00,DB12340,Navitoclax,,,,,,,,,0.000212,4.23,8.29,[H][C@@](CCN1CCOCC1)(CSC1=CC=CC=C1)NC1=C(C=C(C=C1)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC2=C(CCC(C)(C)C2)C2=CC=C(Cl)C=C2)CC1)S(=O)(=O)C(F)(F)F,,,,,0,,973.2955098,7,4,2,0,2,2
8276,04/06/2019 00:00,DB12341,LY-2456302,,,,,,,,,0.000673,13.87,8.97,CC1=CC(=CC(C)=C1)[C@@H]1CCCN1CC1=CC=C(OC2=CC=C(C=C2F)C(N)=O)C=C1,,,,,0,,418.2056563,4,3,1,0,1,1
8277,04/06/2019 00:00,DB12343,Temocillin,,,,,,,,,0.102,3.1,-4.3,CO[C@]1(NC(=O)C(C(O)=O)C2=CSC=C2)[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O,,,,,0,,414.0555429,3,1,3,1,2,2
8278,04/06/2019 00:00,DB12345,MBX-2982,,,,,,,,,0.0375,,3.09,CCC1=CN=C(N=C1)N1CCC(CC1)C1=NC(COC2=CC=C(C=C2)N2C=NN=N2)=CS1,,,,,0,,448.1793784,5,4,4,3,1,1
8279,04/06/2019 00:00,DB12347,CG-400549,,,,,,,,,0.00718,,4.01,CC1=C(CN2C=CC(OCCC3=CC=CS3)=CC2=O)C=CC=C1N,,,,,0,,340.1245489,3,3,2,2,0,0
8280,04/06/2019 00:00,DB12348,"5-amino-1,3,4-thiadiazole-2-thiol",,,,,,,,,1.88,6.49,0.21,NC1=NN=C(S)S1,,,,,0,,132.9768391,1,1,1,1,0,0
8281,04/06/2019 00:00,DB12350,Rostafuroxin,,,,,,,,,0.0347,13.22,-1.3,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1=COC=C1,,,,,0,,374.2457096,5,1,1,1,0,0
8282,04/06/2019 00:00,DB12352,Bizelesin,,,,,,,,,0.00398,8.44,-6.3,CC1=CNC2=C(O)C=C3N(C[C@@H](CCl)C3=C12)C(=O)C1=CC2=CC(NC(=O)NC3=CC=C4NC(=CC4=C3)C(=O)N3C[C@@H](CCl)C4=C5C(C)=CNC5=C(O)C=C34)=CC=C2N1,,,,,0,,814.2185716,10,8,6,4,0,2
8283,04/06/2019 00:00,DB12353,Ulodesine,,,,,,,,,1.72,10.03,7.47,OC[C@H]1CN(CC2=CNC3=C2N=CNC3=O)C[C@@H]1O,,,,,0,,264.1222404,3,2,3,2,1,1
8284,04/06/2019 00:00,DB12354,Imrecoxib,,,,,,,,,0.00535,13.51,-0.36,CCCN1CC(=C(C1=O)C1=CC=C(C)C=C1)C1=CC=C(C=C1)S(C)(=O)=O,,,,,0,,369.1398646,3,2,1,0,0,1
8285,04/06/2019 00:00,DB12355,Netazepide,,,,,,,,,0.00452,13.24,4.31,CNC1=CC(NC(=O)N[C@@H]2N=C(C3=CC=CC=N3)C3=CC=CC=C3N(CC(=O)C(C)(C)C)C2=O)=CC=C1,,,,,0,,498.2379388,4,3,2,1,0,1
8286,04/06/2019 00:00,DB12357,BMS-863233,,,,,,,,,0.176,10.25,7.98,[H][C@]1(CCCN1)C1=NC2=C(OC3=C2C=C(Cl)C=C3)C(O)=N1,,,,,0,,289.0618043,4,3,3,2,1,1
8287,04/06/2019 00:00,DB12358,Enbucrilate,,,,,,,,,1.27,,-7.2,CCCCOC(=O)C(=C)C#N,,,,,0,,153.0789786,0,0,0,0,0,0
8288,04/06/2019 00:00,DB12359,BIIB021,,,,,,,,,0.099,6.14,10.72,COC1=C(C)C=NC(CN2C=NC3=C(Cl)NC(=N)N=C23)=C1C,,,,,0,,318.0995868,3,3,3,3,0,0
8289,04/06/2019 00:00,DB12360,PF-03654764,,,,,,,,,0.00908,15.23,8.15,CC(C)CNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1,,,,,0,,350.21697,3,1,1,0,1,1
8290,04/06/2019 00:00,DB12361,Piclozotan,,,,,,,,,0.0685,,8.48,ClC1=COC2=CC=CC=C2C(=O)N1CCCCN1CCC(=CC1)C1=CC=CC=N1,,,,,0,,409.1557047,4,2,3,1,0,2
8291,04/06/2019 00:00,DB12362,Diaminopropanol tetraacetic acid,,,,,,,,,9.18,1.79,7.77,OC(CN(CC(O)=O)CC(O)=O)CN(CC(O)=O)CC(O)=O,,,,,0,,322.1012302,0,0,0,0,0,0
8292,04/06/2019 00:00,DB12364,Betrixaban,Betrixaban presents a rapid absorption at a dose of 80 mg. Its peak plasma concentration is registered within 3-4 hours after oral administration in healthy humans. The oral bioavailability is 34% and it can be reduced with consumption of high fat food [A27287].,0.6,Betrixaban presents a long half-life of between 19-27 hours [A7708].,40 mg/1,Oral,solid,2.5-2.7 mg/ml,,0.0163,11.63,10.91,COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1,0.6,0.6,,,0,40,451.1411172,3,3,1,1,0,0
8293,04/06/2019 00:00,DB12365,Perzinfotel,,,,,,,,,11.2,1.79,-5.7,OP(O)(=O)CCN1CCCNC2=C1C(=O)C2=O,,,,,0,,260.0562081,2,1,1,0,0,1
8294,04/06/2019 00:00,DB12367,Selurampanel,,,,,,,,,0.207,8.3,2.43,CC(C)C1=C(C=C2C(NC(=O)N(NS(C)(=O)=O)C2=O)=C1)C1=CC=NN1C,,,,,0,,377.1157751,3,3,2,2,0,0
8295,04/06/2019 00:00,DB12368,AZD-3839,,,,,,,,,0.00374,,5.27,NC1=N[C@@](C2=CC=CC(F)=C12)(C1=CC=CC(=C1)C1=CN=CN=C1)C1=CC=NC(=C1)C(F)F,,,,,0,,431.1357802,5,4,3,2,0,1
8296,04/06/2019 00:00,DB12369,Sotrastaurin,,,,,,,,,0.0643,6.4,7,CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12,,,,,0,,438.1804239,6,4,4,2,1,2
8297,04/06/2019 00:00,DB12370,Ipamorelin,,,,,,,,,0.0032,11.79,10.2,CC(C)(N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H](CC1=CC=C2C=CC=CC2=C1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(N)=O,,,,,0,,711.3856657,4,4,1,1,0,0
8298,04/06/2019 00:00,DB12371,Siponimod,"The time (Tmax) to attain maximum plasma concentrations (Cmax) after oral administration of immediate-release oral doses of siponimod was found to be approximately 4 hours ( with a range 3 - 8 hours). Siponimod is heavily absorbed (at a rate greater than or equal to 70%). The absolute oral bioavailability of siponimod is about 84%. Steady-state concentrations were attained after approximately 6 days of daily administration of a single dose of siponimod [FDA label]. 

**Effects of food on absorption**

Food ingestion leads to delayed siponimod absorption (the median Tmax increased by approximately 2-3 hours). Food intake has no effect on the systemic exposure of siponimod (Cmax and AUC). Therefore, siponimod may be taken without regard to food [FDA label].
",0.999,The apparent elimination half-life is approximately 30 hours [FDA label]. ,0.25 mg/1,Oral,solid,"100 mg/mL , warm water ",6.77,0.00032,3.33,8.5,CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F,0.999,0.999,,,0,0.25,516.2599776,4,2,1,0,1,1
8299,04/06/2019 00:00,DB12375,Oglemilast,,,,,,,,,0.0242,9.31,2.4,CS(=O)(=O)NC1=CC2=C(OC3=C2C(=CC=C3OC(F)F)C(=O)NC2=C(Cl)C=NC=C2Cl)C=C1,,,,,0,,514.9921033,4,4,2,2,0,0
8300,04/06/2019 00:00,DB12376,Ricolinostat,,,,,,,,,0.014,8.91,-1.4,ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,433.2113897,3,3,1,1,0,0
8301,04/06/2019 00:00,DB12377,Relebactam,,,,,,,,,2.91,-2,10.03,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O,,,,,0,,348.1103554,3,0,3,0,3,3
8302,04/06/2019 00:00,DB12378,Apricoxib,,,,,,,,,0.0191,10.87,-4.8,CCOC1=CC=C(C=C1)C1=CC(C)=CN1C1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,356.1194635,3,3,1,1,0,0
8303,04/06/2019 00:00,DB12379,Indirubin,,,,,,,,,0.0347,7.42,-2.6,O=C1NC2=CC=CC=C2\C1=C1/NC2=CC=CC=C2C1=O,,,,,0,,262.0742276,4,2,2,0,0,2
8304,04/06/2019 00:00,DB12380,GDC-0152,,,,,,,,,0.00823,9.51,8.55,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)NC1=C(N=NS1)C1=CC=CC=C1,,,,,0,,498.2413099,4,2,2,1,1,1
8305,04/06/2019 00:00,DB12381,Merestinib,,,,,,,,,0.00246,13.09,1.85,CN1N=CC2=CC(OC3=C(F)C=C(NC(=O)C4=CC=C(C)N(C4=O)C4=CC=C(F)C=C4)C=C3)=C(C=C12)C1=CNN=C1,,,,,0,,552.172145,6,6,3,3,0,0
8306,04/06/2019 00:00,DB12382,R-306465,,,,,,,,,0.174,9.23,1.49,ONC(=O)C1=CN=C(N=C1)N1CCN(CC1)S(=O)(=O)C1=CC2=CC=CC=C2C=C1,,,,,0,,413.1157751,4,3,2,1,1,1
8307,04/06/2019 00:00,DB12383,Cytochlor,,,,,,,,,5.08,13.89,-2.3,NC1=NC(=O)N(C=C1Cl)[C@H]1C[C@H](O)[C@@H](CO)O1,,,,,0,,261.0516335,2,1,2,1,1,1
8308,04/06/2019 00:00,DB12384,AR-67,,,,,,,,,0.0278,9.65,3.18,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=CC1=C3[Si](C)(C)C(C)(C)C)C2=O,,,,,0,,478.1923986,5,3,4,2,0,2
8309,04/06/2019 00:00,DB12385,10-hydroxycamptothecin,,,,,,,,,0.331,9.65,3.17,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=CC1=C3)C2=O,,,,,0,,364.1059216,5,3,4,2,0,2
8310,04/06/2019 00:00,DB12387,OSI-027,,,,,,,,,0.0326,3.82,2.62,COC1=C2NC(=CC2=CC=C1)C1=C2N(N=CN=C2N)C(=N1)[C@H]1CC[C@@H](CC1)C(O)=O,,,,,0,,406.1753386,5,4,3,3,0,0
8311,04/06/2019 00:00,DB12388,Evocalcet,,,,,,,,,0.00224,4.23,9.48,C[C@@H](N[C@H]1CCN(C1)C1=CC=C(CC(O)=O)C=C1)C1=C2C=CC=CC2=CC=C1,,,,,0,,374.1994281,4,3,1,0,1,1
8312,04/06/2019 00:00,DB12389,Zamicastat,,,,,,,,,0.00542,10.35,8.98,FC1=CC(F)=C2OC[C@@H](CC2=C1)N1C(=S)NC=C1CCNCC1=CC=CC=C1,,,,,0,,401.1373397,4,3,2,1,0,1
8313,04/06/2019 00:00,DB12390,MBX-8025,,,,,,,,,0.00102,3.58,-4,CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC1=CC=C(OCC(O)=O)C(C)=C1,,,,,0,,444.1218295,2,2,0,0,0,0
8314,04/06/2019 00:00,DB12391,Sagopilone,,,,,,,,,0.0024,14.08,2.88,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1,,,,,0,,543.265459,4,2,3,1,2,2
8315,04/06/2019 00:00,DB12392,Resminostat,,,,,,,,,0.18,9.57,8.24,CN(C)CC1=CC=C(C=C1)S(=O)(=O)N1C=CC(\C=C\C(=O)NO)=C1,,,,,0,,349.1096271,2,2,1,1,0,0
8316,04/06/2019 00:00,DB12393,Fanapanel,,,,,,,,,2.89,1.54,-3,OP(O)(=O)CN1C(=O)C(=O)NC2=C1C=C(N1CCOCC1)C(=C2)C(F)(F)F,,,,,0,,409.0650565,3,2,2,1,1,1
8317,04/06/2019 00:00,DB12394,Eleclazine,,,,,,,,,0.019,,0.6,FC(F)(F)OC1=CC=C(C=C1)C1=CC=C2OCCN(CC3=NC=CC=N3)C(=O)C2=C1,,,,,0,,415.114376,4,3,2,1,0,1
8318,04/06/2019 00:00,DB12395,Esreboxetine,,,,,,,,,0.0223,,7.91,[H][C@]1(CNCCO1)[C@@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1,,,,,0,,313.1677936,3,2,1,0,1,1
8319,04/06/2019 00:00,DB12397,DSM-265,,,,,,,,,0.000979,15.73,-1.3,CC1=NC2=NC(=NN2C(NC2=CC=C(C=C2)S(F)(F)(F)(F)F)=C1)C(C)(F)F,,,,,0,,415.0701639,3,3,2,2,0,0
8320,04/06/2019 00:00,DB12398,Naproxen etemesil,,,,,,,,,0.00214,,-4.8,COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(=O)OCCS(C)(=O)=O,,,,,0,,336.1031447,2,2,0,0,0,0
8321,04/06/2019 00:00,DB12399,Polmacoxib,,,,,,,,,0.00269,10.09,-4.9,CC1(C)OC(=C(C1=O)C1=CC=CC(F)=C1)C1=CC=C(C=C1)S(N)(=O)=O,,,,,0,,361.0784072,3,2,1,0,0,1
8322,04/06/2019 00:00,DB12400,Voxtalisib,,,,,,,,,0.369,7.32,3.67,CCN1C(=O)C(=CC2=C(C)N=C(N)N=C12)C1=CC=NN1,,,,,0,,270.1229091,3,3,3,3,0,0
8323,04/06/2019 00:00,DB12401,Bromperidol,,,,,,,,,0.00723,13.97,8.07,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1,,,,,0,,419.0896193,3,2,1,0,1,1
8324,04/06/2019 00:00,DB12402,Pumosetrag,,,,,,,,,0.0902,6.64,7.45,O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O,,,,,0,,303.1041478,5,2,5,2,3,3
8325,04/06/2019 00:00,DB12404,Remimazolam,,,,,,,,,0.0213,,5.99,COC(=O)CC[C@@H]1N=C(C2=CC=CC=N2)C2=CC(Br)=CC=C2N2C(C)=CN=C12,,,,,0,,438.0691379,4,3,3,2,0,1
8326,04/06/2019 00:00,DB12405,Triciribine,,,,,,,,,9.02,12.46,8.35,[H][C@]1(CO)O[C@@]([H])(N2C=C3C4=C(N=CN=C24)N(C)NC3=N)[C@]([H])(O)[C@]1([H])O,,,,,0,,320.123303,4,2,4,2,1,2
8327,04/06/2019 00:00,DB12406,Lisofylline,,,,,,,,,7.76,17.68,-0.85,C[C@@H](O)CCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O,,,,,0,,280.1535405,2,2,2,2,0,0
8328,04/06/2019 00:00,DB12407,Iobitridol,,,,,,,,,0.309,3.41,-0.77,CN(CC(O)CO)C(=O)C1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(N=C(O)C(CO)CO)=C1I,,,,,0,,834.8959735,1,1,0,0,0,0
8329,04/06/2019 00:00,DB12408,PF-03635659,,,,,,,,,0.00165,9.48,7.27,CC(C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)N1CC(C1)OC1=CC=CC(O)=C1,,,,,0,,444.2412929,4,3,1,0,1,1
8330,04/06/2019 00:00,DB12410,Sabarubicin,,,,,,,,,1.25,9.1,11.05,[H][C@]1(N)C[C@]([H])(O[C@]2([H])[C@]([H])(C)O[C@]([H])(C[C@]2([H])O)O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=CC=CC=C2C4=O)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O,,,,,0,,643.2264902,6,2,2,0,2,2
8331,04/06/2019 00:00,DB12411,R-428,,,,,,,,,0.0081,11.76,10.55,NC1=NC(NC2=CC=C3CC[C@@H](CCC3=C2)N2CCCC2)=NN1C1=CC2=C(N=N1)C1=CC=CC=C1CCC2,,,,,0,,506.2906431,7,4,3,2,1,1
8332,04/06/2019 00:00,DB12412,Gemigliptin,,,,,,,,,0.084,,8.33,N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(C1)N=C(N=C2C(F)(F)F)C(F)(F)F,,,,,0,,489.1411006,3,1,3,1,1,2
8333,04/06/2019 00:00,DB12414,Usistapide,,,,,,,,,6.97E-05,14.09,7.03,COC(=O)[C@H](N1CCC(CC1)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=C(C=C2)C(F)(F)F)C=C1)C1=CC=CC=C1,,,,,0,,572.2286775,5,4,1,0,1,1
8334,04/06/2019 00:00,DB12415,Galeterone,,,,,,,,,0.00219,18.2,5.31,[H][C@@]12CC=C(N3C=NC4=CC=CC=C34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C,,,,,0,,388.2514636,6,2,1,1,0,0
8335,04/06/2019 00:00,DB12416,VTP-27999,,,,,,,,,0.00854,7.6,9.45,[H][C@@](CN=C(O)N1CCC[C@]([H])(C1)[C@@]([H])(OCCN=C(O)OC)C1=CC(Cl)=CC=C1)(C[C@@]1([H])CCCOC1)NC,,,,,0,,524.2765481,3,1,2,0,2,2
8336,04/06/2019 00:00,DB12417,Anagliptin,,,,,,,,,0.179,13.3,8.29,CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N,,,,,0,,383.206973,3,2,3,2,1,1
8337,04/06/2019 00:00,DB12418,Saccharin,,,,,,,,,6.51,1.94,,O=C1NS(=O)(=O)C2=C1C=CC=C2,,,,,0,,182.999014,2,1,1,0,0,1
8338,04/06/2019 00:00,DB12419,HSD-016,,,,,,,,,0.0381,10.58,-1,C[C@@H]1CN(CCN1S(=O)(=O)C1=CC=CC(=C1)[C@@](C)(O)C(F)(F)F)C1=CC=C(F)C=C1C(F)(F)F,,,,,0,,514.1161111,3,2,1,0,1,1
8339,04/06/2019 00:00,DB12420,Diazepinomicin,,,,,,,,,0.004,8.88,0.73,CC(C)=CCC\C(C)=C\CC\C(C)=C\CN1C2=CC(O)=CC(O)=C2NC2=C(C=CC=C2O)C1=O,,,,,0,,462.2518576,3,2,1,0,0,1
8340,04/06/2019 00:00,DB12422,Sulforaphane,,,,,,,,,2.55,,-3.6,C[S@@+]([O-])CCCCN=C=S,,,,,0,,177.028206,0,0,0,0,0,0
8341,04/06/2019 00:00,DB12423,Fozivudine Tidoxil,,,,,,,,,0.00252,1.89,-3.9,CCCCCCCCCCCCSCC(COP(O)(=O)OC[C@H]1O[C@H](C[C@@H]1N=[N+]=[N-])N1C=C(C)C(=O)NC1=O)OCCCCCCCCCC,,,,,0,,745.4213216,2,1,2,1,1,1
8342,04/06/2019 00:00,DB12424,MK-3207,,,,,,,,,0.0141,11.74,6.68,FC1=CC(=CC(F)=C1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)NC1=CC=C2C[C@]3(CC2=C1)C(=O)NC1=C3C=CC=N1,,,,,0,,557.2238462,7,3,3,1,1,2
8343,04/06/2019 00:00,DB12425,Liothyronine I-131,,,,,,,,,0.0195,0.3,9.48,N[C@@H](CC1=CC([131I])=C(OC2=CC([131I])=C(O)C=C2)C([131I])=C1)C(O)=O,,,,,0,,662.7950067,2,2,0,0,0,0
8344,04/06/2019 00:00,DB12426,Bitopertin,,,,,,,,,0.0508,19.71,2.88,C[C@H](OC1=CC=C(C=C1C(=O)N1CCN(CC1)C1=C(F)C=C(C=N1)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,,,,,0,,543.1062747,3,2,2,1,1,1
8345,04/06/2019 00:00,DB12427,Orvepitant,,,,,,,,,0.00439,,7.7,C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN2[C@@H](CCC2=O)C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,,,,,0,,628.2648239,5,2,3,0,3,3
8346,04/06/2019 00:00,DB12428,PAC-14028,,,,,,,,,0.00151,9.24,1.74,CCCC1=C(\C=C\C(=O)N[C@H](C)C2=CC(F)=C(NS(C)(=O)=O)C(F)=C2)C=CC(=N1)C(F)(F)F,,,,,0,,491.1302037,2,2,1,1,0,0
8347,04/06/2019 00:00,DB12429,CI-1040,,,,,,,,,0.00134,6.58,4.64,OC(=NOCC1CC1)C1=C(NC2=C(Cl)C=C(I)C=C2)C(F)=C(F)C=C1,,,,,0,,477.9756598,3,2,0,0,0,0
8348,04/06/2019 00:00,DB12430,BC-3781,,,,,,,,,0.00494,14.19,10.08,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CSC1CCC(N)CC1O,,,,,0,,507.3018445,4,0,0,0,0,0
8349,04/06/2019 00:00,DB12432,CC-401,,,,,,,,,0.0295,10.58,8.82,C(CN1CCCCC1)OC1=CC=CC(=C1)C1=NNC2=CC=C(C=C12)C1=NNC=N1,,,,,0,,388.2011594,5,4,3,2,1,1
8350,04/06/2019 00:00,DB12433,SCH-900271,,,,,,,,,0.218,7.51,-5,CC1(CCCC2=CC(=O)OC3=C2C(=O)NC(=O)N3)CC1,,,,,0,,276.111007,3,2,2,2,0,0
8351,04/06/2019 00:00,DB12434,Steviolbioside,,,,,,,,,1.37,4.59,-3,C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(O)=O,,,,,0,,642.3251417,6,0,2,0,2,2
8352,04/06/2019 00:00,DB12435,Tipelukast,,,,,,,,,0.000419,3.77,-4.6,CCCC1=C(O)C(=CC=C1SCCCOC1=C(CCC)C(OCCCC(O)=O)=C(C=C1)C(C)=O)C(C)=O,,,,,0,,530.2338246,2,2,0,0,0,0
8353,04/06/2019 00:00,DB12436,Vofopitant,,,,,,,,,0.00468,,8.83,COC1=CC=C(C=C1CN[C@H]1CCCN[C@H]1C1=CC=CC=C1)N1N=NN=C1C(F)(F)F,,,,,0,,432.188544,4,3,2,1,1,1
8354,04/06/2019 00:00,DB12438,Filociclovir,,,,,,,,,6.62,10.15,0.42,NC1=NC2=C(N=CN2\C=C2\CC2(CO)CO)C(=O)N1,,,,,0,,263.1018393,3,2,2,2,0,0
8355,04/06/2019 00:00,DB12439,Ioforminol,,,,,,,,,0.286,11.44,-3.2,OCC(O)CNC(=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(N(CC(O)CN(C=O)C2=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C2I)C=O)=C1I,,,,,0,,1521.682003,2,2,0,0,0,0
8356,04/06/2019 00:00,DB12440,Verdiperstat,,,,,,,,,0.283,11.39,-4.1,CC(C)OCCN1C2=C(NC=C2)C(=O)NC1=S,,,,,0,,253.0884977,2,2,2,2,0,0
8357,04/06/2019 00:00,DB12441,Tavilermide,,,,,,,,,0.228,2.7,9.89,NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)C2=C(OCC[C@H](NC1=O)C(=O)NCC(O)=O)C=CC(=C2)[N+]([O-])=O,,,,,0,,580.2129058,2,1,1,0,0,1
8358,04/06/2019 00:00,DB12442,Alvespimycin,"Increasing concentration of the drug results in dose-proportional increase in the plasma concentration. At the maximum tolerated dose of 80mg/m^2, the plasma concentration exceeded 63nM (mean IC50 for 17-DMAG in the NCI 60 human tumor cell line panel) for less than 24 hours in all patients. The mean peak concentration (Cmax) reached 2680 nmol/L at this dose. ",,"The half-life across all dose levels ranged from 9.9 to 54.1 h (median, 18.2 h) [A19251]. ",,,solid,Soluble,,0.0124,7.55,7,[H]/C1=C([H])/[C@]([H])(OC)[C@@]([H])(OC(O)=N)\C(C)=C([H])\[C@]([H])(C)[C@@]([H])(O)[C@]([H])(C[C@]([H])(C)CC2=C(NCCN(C)C)C(=O)C=C(N=C(O)\C(C)=C\1/[H])C2=O)OC,,,,,0,,616.3472145,2,0,1,0,0,1
8359,04/06/2019 00:00,DB12443,Sonedenoson,,,,,,,,,0.944,12.45,3.22,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC(OCCC2=CC=C(Cl)C=C2)=N1,,,,,0,,421.1152964,4,3,3,2,1,1
8360,04/06/2019 00:00,DB12444,Theanine,,,,,Oral,,,,4.25,2.16,10.01,[H][C@](N)(CCC(O)=NCC)C(O)=O,,,,,0,,174.1004423,0,0,0,0,0,0
8361,04/06/2019 00:00,DB12445,Nitroaspirin,,,,,,,,,0.00402,,-6,CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1,,,,,0,,331.0692018,2,2,0,0,0,0
8362,04/06/2019 00:00,DB12446,Derenofylline,,,,,,,,,0.0509,13.5,6.82,O[C@H]1CC[C@@H](CC1)NC1=C2C=CNC2=NC(=N1)C1=CC=CC=C1,,,,,0,,308.1637113,4,3,2,2,0,0
8363,04/06/2019 00:00,DB12447,Nadifloxacin,,,,,,,,,0.632,6.13,0.44,CC1CCC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCC(O)CC1,,,,,0,,360.1485354,4,2,3,1,1,2
8364,04/06/2019 00:00,DB12448,Lifibrol,,,,,,,,,0.00586,4.36,-3,CC(C)(C)C1=CC=C(CCC(O)COC2=CC=C(C=C2)C(O)=O)C=C1,,,,,0,,342.1831093,2,2,0,0,0,0
8365,04/06/2019 00:00,DB12449,Tempol,,,,,,,,,125,15.14,-2.7,CC1(C)CC(O)CC(C)(C)N1[O],,,,,0,,172.1337538,1,0,1,0,1,1
8366,04/06/2019 00:00,DB12450,Propyl Gallate,,,,,,,,,1.71,8.11,-5.5,CCCOC(=O)C1=CC(O)=C(O)C(O)=C1,,,,,0,,212.0684735,1,1,0,0,0,0
8367,04/06/2019 00:00,DB12451,SCY-635,,,,,,,,,0.00597,11.8,8.32,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O)C(C)C,,,,,0,,1320.881853,1,0,1,0,1,1
8368,04/06/2019 00:00,DB12452,Caprylic alcohol,,,,,,,,,0.532,16.84,-2,CCCCCCCCO,,,,,0,,130.1357652,0,0,0,0,0,0
8369,04/06/2019 00:00,DB12453,Chlorine Dioxide,,,,,,,,,672,,,O=[Cl]=O,,,,,,,,,,,,,
8370,04/06/2019 00:00,DB12454,Zalypsis,,,,,,,,,0.0252,9.35,7.15,COC1=C(O)C2=C(C[C@H]3[C@H](O)N4[C@@H](CC5=C([C@@H]4CNC(=O)\C=C\C4=CC=CC(=C4)C(F)(F)F)C4=C(OCO4)C(C)=C5OC(C)=O)[C@@H]2N3C)C=C1C,,,,,0,,709.2610998,7,3,4,0,1,4
8371,04/06/2019 00:00,DB12455,Omadacycline,"Omadacycline has an mean absolute oral bioavailability of 34.5% and a mean Tmax of2.5 h with oral dosing. With multiple dosing, Omadacycline displays an accumulation factor of 1.5. [FDA Label] Official labeling states that food does not significantly impact rate or extent of absorption, however, conflicting data exists suggesting food may lower the bioavailability of omadacycline taken after eating. [FDA Label,A39785] The exposure in alveolar cells and epithelial lining fluid is 25.8 and 1.5 fold higher than plasma exposure after IV administration, suggesting Omadacycline penetrates the lungs to a significant degree.[FDA Label]",0.2,Omadacycline has a mean half life of elimination of 16.2 h. [FDA Label],100 mg/5mL,Intravenous,solid,,,0.213,2.87,10.54,[H][C@@]12CC3=C(C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C,0.2,0.2,,,0,,556.2896996,4,1,0,0,0,0
8372,04/06/2019 00:00,DB12457,Rimegepant,,,,,,,,,0.0755,10.7,8.95,N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N2C(=O)NC3=NC=CC=C23)C2=C1C=CC=N2)C1=C(F)C(F)=CC=C1,,,,,0,,534.2190952,6,4,4,3,1,1
8373,04/06/2019 00:00,DB12458,Muscimol,,,,,,,,,57.9,5.78,7.46,NCC1=CC(O)=NO1,,,,,0,,114.0429274,1,1,1,1,0,0
8374,04/06/2019 00:00,DB12459,Belotecan,,,,,,,,,0.0779,11.73,10.24,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=CC1=C3CCNC(C)C)C2=O,,,,,0,,433.2001563,5,3,4,2,0,2
8375,04/06/2019 00:00,DB12461,GLPG-0492,,,,,,,,,0.00522,14.44,-3,CN1C(=O)N(C(=O)[C@@]1(CO)C1=CC=CC=C1)C1=CC=C(C#N)C(=C1)C(F)(F)F,,,,,0,,389.098726,3,2,1,0,1,1
8376,04/06/2019 00:00,DB12462,Ralinepag,,,,,,,,,0.00165,4.1,-1.1,OC(=O)COC[C@H]1CC[C@H](COC(=O)N(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)CC1,,,,,0,,431.1499506,3,2,0,0,0,0
8377,04/06/2019 00:00,DB12463,Semagacestat,,,,,,,,,1.16,11.91,-3.7,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1C2=CC=CC=C2CCN(C)C1=O,,,,,0,,361.2001563,2,1,1,0,0,1
8378,04/06/2019 00:00,DB12464,Bevenopran,,,,,,,,,0.0267,13.24,9.37,COC1=CC(CNCCC2CCOCC2)=CC=C1OC1=CN=C(C=N1)C(N)=O,,,,,0,,386.1954053,3,2,2,1,1,1
8379,04/06/2019 00:00,DB12465,Ketanserin,,,,,,,,,0.156,11.42,7.29,FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1,,,,,0,,395.1645198,4,3,2,1,1,1
8380,04/06/2019 00:00,DB12466,Favipiravir,,,,,,,,,8.7,9.39,-3.9,NC(=O)C1=NC(F)=CN=C1O,,,,,0,,157.0287546,1,1,1,1,0,0
8381,04/06/2019 00:00,DB12467,TU-100,,,,,,,,,0.131,11.8,3.87,CN1C2C3=C(C1C1=CC=CC=C1C2=O)C(=O)C1=CC=CC=C1C3=O,,,,,0,,315.0895433,5,2,2,0,0,2
8382,04/06/2019 00:00,DB12468,Pf-04531083,,,,,,,,,0.0401,13,3.99,COC1=CC=C(Cl)C(=C1)C1=CC=C(NC(=O)C2=CC=NN2C)N=C1N,,,,,0,,357.0992524,3,3,2,2,0,0
8383,04/06/2019 00:00,DB12470,Dexelvucitabine,,,,,,,,,1.04,14.63,-3,NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](CO)C=C1,,,,,0,,227.0706194,2,1,2,1,0,1
8384,04/06/2019 00:00,DB12471,MK-3118,,,,,,,,,0.000346,4.4,9.75,CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)N4N=CN=C4C4=CC=NC=C4)C3=CC[C@@]2(C)[C@@H]1C(O)=O,,,,,0,,729.5193056,7,2,3,2,1,1
8385,04/06/2019 00:00,DB12472,Levodropropizine,,,,,,,,,97.1,14,7.65,[H][C@@](O)(CO)CN1CCN(CC1)C1=CC=CC=C1,,,,,0,,236.1524779,2,1,1,0,1,1
8386,04/06/2019 00:00,DB12473,Taurolidine,,,,,,,,,16.2,10.53,1.97,O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1,,,,,0,,284.061297,2,0,2,0,2,2
8387,04/06/2019 00:00,DB12474,Lynestrenol,,,,,,,,,0.00366,17.59,-1.7,C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,,,,,0,,284.2140155,4,0,0,0,0,0
8388,04/06/2019 00:00,DB12475,Biphenyl dimethyl dicarboxylate,,,,,,,,,0.00577,,-6.6,COC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)OC,,,,,0,,270.0892089,2,2,0,0,0,0
8389,04/06/2019 00:00,DB12476,CPG-52852,,,,,,,,,0.181,12.07,5.33,CCC1=NC2=C(N1CCCCNS(C)(=O)=O)C1=CC=CC=C1N=C2N,,,,,0,,361.157246,3,3,2,2,0,0
8390,04/06/2019 00:00,DB12477,Perfluoro tert-butylcyclohexane,,,,,,,,,0.0475,,,FC(F)(F)C(C(F)(F)F)(C(F)(F)F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F,,,,,0,,499.9680644,1,0,0,0,0,0
8391,04/06/2019 00:00,DB12478,Piribedil,,,,,,,,,1.57,,6.53,C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1,,,,,0,,298.1429758,4,2,3,1,1,2
8392,04/06/2019 00:00,DB12479,Zabofloxacin,,,,,,,,,0.196,5.53,9.41,CON=C1CN(CC11CNC1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=N1)C(O)=O,,,,,0,,401.1499323,5,2,4,2,2,2
8393,04/06/2019 00:00,DB12480,Betulinic Acid,,,,,,,,,0.000204,4.75,-0.84,[H]OC(=O)[C@]12CC[C@@]([H])(C(C)=C)[C@]1([H])[C@@]1([H])CC[C@]3([H])[C@@]4(C)CC[C@]([H])(O[H])C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC2,,,,,0,,456.3603454,5,0,0,0,0,0
8394,04/06/2019 00:00,DB12482,Acotiamide,,,,,,,,,0.0191,8.24,9.62,COC1=C(OC)C=C(C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C)C(O)=C1,,,,,0,,450.1936911,2,2,1,1,0,0
8395,04/06/2019 00:00,DB12483,Copanlisib,"The plasma levels of copanlisib increases in a dose-proportional manner with linear pharmacokinetic properties and no time dependency. Following a steady state exposure at 0.8 mg/kg, the mean peak plasma concentration (Cmax) of copanlisib is 463 ng/mL with the range of 105 to 1670 ng/mL [FDA Label]. ",,The geometric mean terminal elimination half-life of copanlisib is 39.1 (range: 14.6 to 82.4; SD: 15.0) hours [FDA Label]. ,15 mg/1mL,Intravenous,solid,,,0.231,10.15,6.88,COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21,,,,,0,,480.2233514,5,2,4,1,1,3
8396,04/06/2019 00:00,DB12484,Tetrahydrouridine,,,,,,,,,209,11.47,-3,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,,,,,0,,248.1008362,2,0,2,0,2,2
8397,04/06/2019 00:00,DB12485,Pimonidazole,,,,,,,,,4.92,14.39,8.76,OC(CN1C=CN=C1[N+]([O-])=O)CN1CCCCC1,,,,,0,,254.1378904,2,1,2,1,1,1
8398,04/06/2019 00:00,DB12486,Elobixibat,,,,,,,,,0.000294,3.58,-2.7,CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=CC(SC)=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C3=CC=CC=C3)C=C2S(=O)(=O)C1,,,,,0,,695.2698928,4,3,1,0,0,1
8399,04/06/2019 00:00,DB12489,Mirvetuximab Soravtansine,,,,,,,,,0.00238,-0.63,-1.3,CO[C@@H]1C=CC=C(C)CC2=CC(N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)[C@]3(C)O[C@H]3[C@H](C)[C@@H]3C[C@@]1(O)NC(=O)O3)=C(Cl)C(OC)=C2,,,,,0,,976.3034933,4,1,3,0,2,3
8400,04/06/2019 00:00,DB12491,Fasiglifam,,,,,,,,,0.000185,3.76,-4.4,CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C1=CC=CC(COC2=CC=C3[C@H](CC(O)=O)COC3=C2)=C1,,,,,0,,524.1868744,4,3,1,0,0,1
8401,04/06/2019 00:00,DB12492,Piritramide,,,,,,,,,0.0185,2.71,9.44,OC(=N)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)N1CCCCC1,,,,,0,,430.2732617,4,2,2,0,2,2
8402,04/06/2019 00:00,DB12493,PD-217014,,,,,,,,,1.04,,9.89,COC(=O)C[C@@]1(CN)C[C@@H]2CC[C@@H]2C1,,,,,0,,197.1415788,2,0,0,0,0,0
8403,04/06/2019 00:00,DB12494,SGI-1776,,,,,,,,,0.0141,,9.29,CN1CCC(CNC2=NN3C(C=C2)=NC=C3C2=CC=CC(OC(F)(F)F)=C2)CC1,,,,,0,,405.177645,4,3,3,2,1,1
8404,04/06/2019 00:00,DB12495,Selepressin,,,,,,,,,0.0249,11.4,10.08,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O,,,,,0,,1047.499392,3,1,2,0,2,2
8405,04/06/2019 00:00,DB12497,Alagebrium,,,,,,,,,0.00424,14.69,-8.5,CC1=C(C)[N+](CC(=O)C2=CC=CC=C2)=CS1,,,,,1,,232.0790615,2,2,1,1,0,0
8406,04/06/2019 00:00,DB12499,Clascoterone,,,,,,,,,0.00753,13.78,-3.3,[H][C@@]12CC[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,402.2406242,4,0,0,0,0,0
8407,04/06/2019 00:00,DB12500,Fedratinib,,,,,,,,,0.0189,9.92,8.98,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)NC1=NC1=CC(=CC=C1)S(=O)(=O)NC(C)(C)C,,,,,0,,524.25696,4,3,2,1,1,1
8408,04/06/2019 00:00,DB12501,ABT-384,,,,,,,,,0.0482,15.1,6.46,CC(C)(N1CCN(CC1)C1=NC=C(C=C1)C(F)(F)F)C(=O)N[C@H]1C2CC3CC1C[C@@](C3)(C2)C(N)=O,,,,,0,,493.26646,6,1,2,1,1,1
8409,04/06/2019 00:00,DB12504,JNJ-40346527,,,,,,,,,0.00687,5.81,4.19,CC1(C)CCC(=CC1)C1=C(NC(=O)C2=NC=C(N2)C#N)C=CC(=N1)C1CC(C)(C)OC(C)(C)C1,,,,,0,,461.2790754,4,2,3,2,1,1
8410,04/06/2019 00:00,DB12505,E-7820,,,,,,,,,0.0285,7.12,,CC1=C2C(=CNC2=C(NS(=O)(=O)C2=CC=CC(=C2)C#N)C=C1)C#N,,,,,0,,336.0680966,3,3,1,1,0,0
8411,04/06/2019 00:00,DB12506,Fenamole,,,,,,,,,0.623,2.15,0.042,N=C1N=NNN1C1=CC=CC=C1,,,,,0,,161.0701452,2,2,1,1,0,0
8412,04/06/2019 00:00,DB12507,Atecegatran metoxil,,,,,,,,,0.0369,12.27,6.49,CO\N=C(/N)C1=CC=C(CNC(=O)[C@@H]2CCN2C(=O)[C@H](O)C2=CC(OC(F)F)=CC(Cl)=C2)C=C1,,,,,0,,496.132504,3,2,1,0,1,1
8413,04/06/2019 00:00,DB12508,E7107,,,,,,,,,0.0275,13.8,8.29,CC[C@H](O)[C@@H](C)[C@H]1O[C@@H]1C[C@@](C)(O)\C=C\C=C(/C)[C@H]1OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N2CCN(CC2)C2CCCCCC2)\C=C\[C@@H]1C,,,,,0,,718.4768317,4,0,3,0,2,3
8414,04/06/2019 00:00,DB12509,Imeglimin,,,,,,,,,4.63,19.01,10.22,C[C@@H]1NC(N)=NC(=N1)N(C)C,,,,,0,,155.1170954,1,0,1,0,0,1
8415,04/06/2019 00:00,DB12511,Imiglitazar,,,,,,,,,0.0101,4.15,2.73,CC1=C(COC2=CC=C(CO\N=C(/CCC(O)=O)C3=CC=CC=C3)C=C2)N=C(O1)C1=CC=CC=C1,,,,,0,,470.1841719,4,4,1,1,0,0
8416,04/06/2019 00:00,DB12512,Verucerfont,,,,,,,,,0.0614,,2.84,CC[C@H](NC1=CC(C)=NC2=C(C(C)=NN12)C1=CC=C(OC)C=C1C)C1=NC(C)=NO1,,,,,0,,406.2117241,4,4,3,3,0,0
8417,04/06/2019 00:00,DB12513,Omaveloxolone,,,,,,,,,0.00119,10.11,-5.3,CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,,,,,0,,554.3319997,5,0,0,0,0,0
8418,04/06/2019 00:00,DB12514,Iofolastat I-123,,,,,,,,,0.0925,2.83,9.54,OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNCC1=CC=C([123I])C=C1)C(O)=O)C(O)=O,,,,,0,,531.0826642,1,1,0,0,0,0
8419,04/06/2019 00:00,DB12515,9-aminocamptothecin,,,,,,,,,0.633,11.71,3.91,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=C(N)C1=C3)C2=O,,,,,0,,363.121906,5,3,4,2,0,2
8420,04/06/2019 00:00,DB12517,PF-00446687,,,,,,,,,0.00863,13.64,9.05,C[C@H]1CN(C[C@@H](C)[C@]1(O)C1=CC=CC=C1)C(=O)[C@@H]1CN(C[C@H]1C1=CC=C(F)C=C1F)C(C)(C)C,,,,,0,,470.2744848,4,2,2,0,2,2
8421,04/06/2019 00:00,DB12518,Raclopride,,,,,,,,,0.133,5.31,9.32,[H][C@@]1(CN=C(O)C2=C(O)C(Cl)=CC(Cl)=C2OC)CCCN1CC,,,,,0,,346.0850979,2,1,1,0,1,1
8422,04/06/2019 00:00,DB12519,Sarcosine,,,,,,,,,308,2.06,10.35,CNCC(O)=O,,,,,0,,89.04767846,0,0,0,0,0,0
8423,04/06/2019 00:00,DB12521,Methyl pyrrolidone,,,,,,,,,853,,-1,CN1CCCC1=O,,,,,0,,99.06841391,1,0,1,0,1,1
8424,04/06/2019 00:00,DB12522,Toreforant,,,,,,,,,0.00517,11.9,9.41,CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1,,,,,0,,392.268845,4,3,3,2,1,1
8425,04/06/2019 00:00,DB12523,Mizolastine,,,,,,,,,0.104,12.24,5.93,CN(C1CCN(CC1)C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1)C1=NC=CC(O)=N1,,,,,0,,432.2073876,5,4,3,2,1,1
8426,04/06/2019 00:00,DB12524,BI-671800,,,,,,,,,0.0196,3.86,7.09,CN(C)C1=NC(CC2=CC=C(NC(=O)C3=CC=C(C=C3)C(F)(F)F)C=C2)=NC(N(C)C)=C1CC(O)=O,,,,,0,,501.1987744,3,3,1,1,0,0
8427,04/06/2019 00:00,DB12526,Batefenterol,,,,,,,,,0.00363,8.49,9.02,COC1=CC(NC(=O)CCN2CCC(CC2)OC(=O)NC2=CC=CC=C2C2=CC=CC=C2)=C(Cl)C=C1CNC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1,,,,,0,,739.2772764,6,5,2,1,1,1
8428,04/06/2019 00:00,DB12527,Sofinicline,,,,,,,,,0.266,,9.68,ClC1=C(Cl)N=CC(=C1)N1C[C@@H]2CN[C@@H]2C1,,,,,0,,243.0330027,3,1,3,1,2,2
8429,04/06/2019 00:00,DB12528,Glyceryl Trierucate,,,,,,,,,6.67E-06,,-6.6,CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC\C=C/CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC,,,,,0,,1052.971092,0,0,0,0,0,0
8430,04/06/2019 00:00,DB12531,Lobucavir,,,,,,,,,7.54,10.17,0.67,NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)[C@H]2CO)C(=O)N1,,,,,0,,265.1174893,3,2,2,2,0,0
8431,04/06/2019 00:00,DB12532,Oxetacaine,A peak plasma concentration of oxetacaine of approximately 20 ng/ml is attained about one hour after oral administration.[T213] LEss than 1/3 of the administered dose is absorbed as it undergoes extensive metabolism.[T214],,Oxetacaine presents a very short half-life of approximately one hour.[T213],,Oral,solid,<0.1 g/100 ml at 23 ÂºC,,0.0102,15.59,5.78,CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1)C(C)(C)CC1=CC=CC=C1,,,,,0,,467.3147922,2,2,0,0,0,0
8432,04/06/2019 00:00,DB12533,Cevipabulin,,,,,,,,,0.0275,15.68,10.1,CNCCCOC1=CC(F)=C(C(F)=C1)C1=C(N[C@@H](C)C(F)(F)F)N2N=CN=C2N=C1Cl,,,,,0,,464.115078,3,3,2,2,0,0
8433,04/06/2019 00:00,DB12535,AC-430,,,,,,,,,0.0259,12.23,3.36,CC1=CC(NC2=NC(=NC3=CC=CC=C23)C(O)C2=CC=C(F)C=C2)=NN1,,,,,0,,349.1338884,4,4,2,2,0,0
8434,04/06/2019 00:00,DB12536,N-acetylmannosamine,,,,,,,,,148,11.56,-1.2,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(NC(C)=O)C=O,,,,,0,,221.0899372,0,0,0,0,0,0
8435,04/06/2019 00:00,DB12537,Benzodiazepine,,,,,,,,,1.02,5.55,16.87,N1N=CC=CC2=CC=CC=C12,,,,,0,,144.0687483,2,1,1,0,0,1
8436,04/06/2019 00:00,DB12538,Nepadutant,,,,,,,,,0.432,10.13,,CC(C)C[C@@H]1NC(=O)[C@@H]2CNC(=O)C[C@H](NC(=O)[C@H](CC(=O)N[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3NC(C)=O)NC1=O)C(=O)N[C@@H](CC1=CNC3=CC=CC=C13)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2,,,,,0,,946.4184819,6,3,4,1,3,3
8437,04/06/2019 00:00,DB12539,Oltipraz,,,,,,,,,0.138,,0.23,CC1=C(SSC1=S)C1=CN=CC=N1,,,,,0,,225.9693112,2,2,2,2,0,0
8438,04/06/2019 00:00,DB12540,Lecozotan,,,,,,,,,0.0402,,6.75,C[C@H](CN(C(=O)C1=CC=C(C=C1)C#N)C1=CC=CC=N1)N1CCN(CC1)C1=CC=CC2=C1OCCO2,,,,,0,,483.2270398,5,3,3,1,1,2
8439,04/06/2019 00:00,DB12541,SAR-405838,,,,,,,,,0.00208,12.88,8.99,CC(C)(C)C[C@@H]1N[C@H]([C@H](C2=C(F)C(Cl)=CC=C2)[C@]11C(=O)NC2=C1C=CC(Cl)=C2)C(=O)N[C@H]1CC[C@H](O)CC1,,,,,0,,561.1961255,5,2,2,0,1,2
8440,04/06/2019 00:00,DB12542,GSK-356278,,,,,,,,,0.0701,,3.32,CCN1N=CC2=C(NC3CCOCC3)C(=CN=C12)C1=NN=C(CC2=C(C)N=C(C)S2)O1,,,,,0,,439.179044,5,4,5,4,1,1
8441,04/06/2019 00:00,DB12543,Samidorphan,,,,,,,,,0.629,7.88,8.94,NC(=O)C1=C(O)C2=C(C[C@H]3N(CC4CC4)CC[C@@]22CC(=O)CC[C@@]32O)C=C1,,,,,0,,370.1892573,5,1,1,0,1,1
8442,04/06/2019 00:00,DB12545,Indobufen,,,,,,,,,0.0781,3.83,-3.5,CCC(C(O)=O)C1=CC=C(C=C1)N1CC2=CC=CC=C2C1=O,,,,,0,,295.1208434,3,2,1,0,0,1
8443,04/06/2019 00:00,DB12547,LY-2886721,,,,,,,,,0.0267,11.55,7.48,NC1=N[C@]2(COC[C@H]2CS1)C1=C(F)C=CC(NC(=O)C2=CC=C(F)C=N2)=C1,,,,,0,,390.0962032,4,2,3,1,1,2
8444,04/06/2019 00:00,DB12548,Sparsentan,,,,,,,,,0.0122,5.69,3.52,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C,,,,,0,,592.2719414,5,3,2,1,0,1
8445,04/06/2019 00:00,DB12549,Pyrazoloacridine,,,,,,,,,0.159,4.9,9.66,COC1=CC=C2NC3=C4C(=CC=C3[N+]([O-])=O)N(CCCN(C)C)N=C4C2=C1,,,,,0,,367.1644395,4,3,2,1,0,1
8446,04/06/2019 00:00,DB12550,Taladegib,,,,,,,,,0.0033,,3.69,CN(C1CCN(CC1)C1=NN=C(C2=CC=NN2C)C2=CC=CC=C12)C(=O)C1=C(C=C(F)C=C1)C(F)(F)F,,,,,0,,512.1947723,5,4,3,2,1,1
8447,04/06/2019 00:00,DB12551,Idazoxan,,,,,,,,,1.37,,8.62,C1CN=C(N1)C1COC2=CC=CC=C2O1,,,,,0,,204.0898776,3,1,2,0,0,2
8448,04/06/2019 00:00,DB12553,Fluocinolone,,,,,,,,,0.342,11.75,-3.3,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,,,,,0,,412.169745,4,0,0,0,0,0
8449,04/06/2019 00:00,DB12554,Mebeverine,,,,,,,,,0.0029,,10.31,CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC1=CC=C(OC)C=C1,,,,,0,,429.2515232,2,2,0,0,0,0
8450,04/06/2019 00:00,DB12555,Nelotanserin,,,,,,,,,0.0102,10.49,1.59,COC1=CC=C(NC(=O)NC2=CC=C(F)C=C2F)C=C1C1=C(Br)C=NN1C,,,,,0,,436.0346443,3,3,1,1,0,0
8451,04/06/2019 00:00,DB12556,MK-5108,,,,,,,,,0.00168,4.29,2.79,OC(=O)[C@@]1(CC2=CC=CC(NC3=NC=CS3)=N2)CC[C@@H](CC1)OC1=C(F)C(Cl)=CC=C1,,,,,0,,461.0976184,4,3,2,2,0,0
8452,04/06/2019 00:00,DB12557,FK-614,,,,,,,,,0.00396,3.94,5.91,CCCCCS(=O)(=O)NC(=O)C1=CC=C2N=C(C)N(CC3=CC=C(Cl)C=C3Cl)C2=C1,,,,,0,,467.083718,3,3,1,1,0,0
8453,04/06/2019 00:00,DB12558,AEE-788,,,,,,,,,0.00749,10.79,8.69,[H][C@](C)(N=C1N=CNC2=C1C=C(N2)C1=CC=C(CN2CCN(CC)CC2)C=C1)C1=CC=CC=C1,,,,,0,,440.268845,5,4,3,2,1,1
8454,04/06/2019 00:00,DB12559,EC-17,,,,,,,,,0.0345,3.63,2.12,NC(=O)CC[C@H](N(CCNC(=S)NC1=CC=C2C(=C1)C(=O)OC21C2=CC=C(O)C=C2OC2=C1C=CC(O)=C2)C(=O)C1=CC=C(NCC2=CN=C3N=C(N)NC(=O)C3=N2)C=C1)C(O)=O,,,,,0,,872.2336584,8,6,4,2,0,2
8455,04/06/2019 00:00,DB12561,WNT-974,,,,,,,,,0.0108,11.94,5.09,CC1=CC(=CC=N1)C1=NC=C(CC(=O)NC2=CC=C(C=N2)C2=CN=CC=N2)C=C1C,,,,,0,,396.1698593,4,4,4,4,0,0
8456,04/06/2019 00:00,DB12562,Setipiprant,,,,,,,,,0.00289,3.93,-1.3,OC(=O)CN1C2=C(CN(CC2)C(=O)C2=CC=CC3=CC=CC=C23)C2=CC(F)=CC=C12,,,,,0,,402.1379707,5,4,2,1,0,1
8457,04/06/2019 00:00,DB12563,MK-0686,,,,,,,,,0.000165,6.44,-4.3,COC(=O)C1=C(Cl)C=CC=C1C1=CC=C([C@@H](C)NC(=O)C2(CC2)NC(=O)C(F)(F)F)C(F)=C1,,,,,0,,486.0969476,3,2,0,0,0,0
8458,04/06/2019 00:00,DB12564,Gemcitabine elaidate,,,,,,,,,0.00035,11.52,-0.96,CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O,,,,,0,,527.3170779,2,1,2,1,1,1
8459,04/06/2019 00:00,DB12565,Abexinostat,,,,,,,,,0.0767,9.83,8.23,CN(C)CC1=C(OC2=CC=CC=C12)C(=O)NCCOC1=CC=C(C=C1)C(=O)NO,,,,,0,,397.1637708,3,3,1,1,0,0
8460,04/06/2019 00:00,DB12566,Decernotinib,,,,,,,,,0.0321,11.76,5,CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F,,,,,0,,392.1572439,3,3,3,3,0,0
8461,04/06/2019 00:00,DB12567,Camicinal,,,,,,,,,0.0226,,9.35,C[C@H]1CN(CC2=CC=C(CC(=O)N3CCC(CC3)NC3=CC=CC(F)=C3)C=C2)CCN1,,,,,0,,424.2638399,4,2,2,0,2,2
8462,04/06/2019 00:00,DB12569,Tonapofylline,,,,,,,,,0.118,4.13,-0.69,CCCN1C2=C(NC(=N2)C23CCC(CCC(O)=O)(CC2)CC3)C(=O)N(CCC)C1=O,,,,,0,,416.2423555,5,2,2,2,0,0
8463,04/06/2019 00:00,DB12570,CC-223,,,,,,,,,0.109,13.62,3.61,CO[C@H]1CC[C@@H](CC1)N1C(=O)CNC2=C1N=C(C=N2)C1=CN=C(C=C1)C(C)(C)O,,,,,0,,397.2113897,4,2,3,2,0,1
8464,04/06/2019 00:00,DB12571,Rimacalib,,,,,,,,,0.0462,,5.49,C[C@H](C1=NOC(NC(=N)N2CCOCC2)=C1)C1=CC=C(C(F)=C1)C1=CC=CC=C1,,,,,0,,394.1805042,4,3,2,1,1,1
8465,04/06/2019 00:00,DB12572,Pexacerfont,,,,,,,,,0.0136,18.85,3.12,CC[C@@H](C)NC1=NC(C)=NC2=C(C(C)=NN12)C1=CC=C(OC)N=C1C,,,,,0,,340.2011594,3,3,3,3,0,0
8466,04/06/2019 00:00,DB12573,LY-2452473,,,,,,,,,0.0565,14.24,4.99,CC(C)OC(=O)N[C@@H]1CC2=C(C1)C1=CC(=CC=C1N2CC1=CC=CC=N1)C#N,,,,,0,,374.1742759,4,3,2,2,0,0
8467,04/06/2019 00:00,DB12574,LY-295501,,,,,,,,,0.00833,3.6,-4.9,ClC1=C(Cl)C=C(NC(=O)NS(=O)(=O)C2=CC=C3OCCC3=C2)C=C1,,,,,0,,385.9894832,3,2,1,0,0,1
8468,04/06/2019 00:00,DB12575,Ronopterin,,,,,,,,,1.98,13.51,10.04,[H][C@@](C)(O)[C@]([H])(O)[C@@]1([H])CN=C2NC(=N)NC(N)=C2N1,,,,,0,,240.1334738,2,0,2,0,0,2
8469,04/06/2019 00:00,DB12576,AZD-3043,,,,,,,,,0.128,16.59,-4.6,CCCOC(=O)CC1=CC=C(OCC(=O)N(CC)CC)C(OCC)=C1,,,,,0,,351.204573,1,1,0,0,0,0
8470,04/06/2019 00:00,DB12577,Fosbretabulin,,,,,,,,,0.00239,1.62,-4.3,COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1OP(O)(O)=O,,,,,0,,396.0974043,2,2,0,0,0,0
8471,04/06/2019 00:00,DB12579,JNJ-37822681,,,,,,,,,0.0446,17.74,7.11,FC1=C(F)C=C(CN2CCC(CC2)NC2=CC=C(N=N2)C(F)(F)F)C=C1,,,,,0,,372.1373376,3,2,2,1,1,1
8472,04/06/2019 00:00,DB12580,Tradipitant,,,,,,,,,0.000824,,4.21,FC(F)(F)C1=CC(=CC(CN2N=NC(=C2C2=CC=NC=C2)C2=NC=CC=C2C(=O)C2=CC=CC=C2Cl)=C1)C(F)(F)F,,,,,0,,587.0947571,5,5,3,3,0,0
8473,04/06/2019 00:00,DB12581,Ozarelix,,,,,,,,,0.00636,9.5,11.86,CCCC[C@H](NC(=O)[C@@H](CCCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,,,,,0,,1457.701118,6,5,2,1,1,1
8474,04/06/2019 00:00,DB12582,Piperine,,,,,,,,,0.149,,-0.13,O=C(\C=C\C=C\C1=CC2=C(OCO2)C=C1)N1CCCCC1,,,,,0,,285.1364935,3,1,2,0,1,2
8475,04/06/2019 00:00,DB12585,Ondelopran,,,,,,,,,0.00461,13.46,9.27,NC(=O)C1=CC=C(OC2=C(F)C=C(CNCCC3CCOCC3)C=C2)N=C1,,,,,0,,373.1801698,3,2,2,1,1,1
8476,04/06/2019 00:00,DB12586,Anhydrovinblastine,,,,,,,,,0.00781,10.87,8.78,CCC1=C[C@@H]2C[N@](C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=CC2=C(C=C1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC,,,,,0,,792.4098148,9,3,6,1,1,5
8477,04/06/2019 00:00,DB12587,Razupenem,,,,,,,,,0.0412,3.08,9.81,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3=NC(=CS3)C3=C[C@H](C)NC3)=C(N2C1=O)C(O)=O,,,,,0,,407.0973482,4,1,4,1,1,3
8478,04/06/2019 00:00,DB12588,AZD-1480,,,,,,,,,0.045,9.26,5.68,[H][C@@](C)(NC1=NC=C(Cl)C(N=C2NNC(C)=C2)=N1)C1=NC=C(F)C=N1,,,,,0,,348.1013983,3,3,3,3,0,0
8479,04/06/2019 00:00,DB12590,Indiplon,,,,,,,,,0.00449,,0.96,CN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C(=O)C1=CC=CS1,,,,,0,,376.0993968,4,4,3,3,0,0
8480,04/06/2019 00:00,DB12591,BMS-911543,,,,,,,,,0.748,11,4.18,CCN1C(=CC2=C3N(C)C=NC3=C(NC3=NN(C)C(C)=C3)N=C12)C(=O)N(C1CC1)C1CC1,,,,,0,,432.2386075,6,4,4,4,0,0
8481,04/06/2019 00:00,DB12592,EC-18,,,,,,,,,8.03E-06,,-6.6,CCCCCCCCCCCCCCCC(=O)OCC(COC(C)=O)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC,,,,,0,,634.51724,0,0,0,0,0,0
8482,04/06/2019 00:00,DB12593,Apaziquone,,,,,,,,,4.8,13.48,-2.5,CN1C(\C=C\CO)=C(CO)C2=C1C(=O)C=C(N1CC1)C2=O,,,,,0,,288.111007,3,1,2,1,1,1
8483,04/06/2019 00:00,DB12594,AZD-9056,,,,,,,,,0.00034,13.64,9.94,OCCCNCCCC1=CC(C(=O)NCC23CC4CC(CC(C4)C2)C3)=C(Cl)C=C1,,,,,0,,418.238706,5,1,0,0,0,0
8484,04/06/2019 00:00,DB12596,Combretastatin,,,,,,,,,0.0545,9.99,-3.1,COC1=CC=C(C[C@@H](O)C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,,,,,0,,334.1416384,2,2,0,0,0,0
8485,04/06/2019 00:00,DB12597,ABL-001,,,,,,,,,0.0545,11.06,4.19,O[C@@H]1CCN(C1)C1=C(C=C(C=N1)C(=O)NC1=CC=C(OC(F)(F)Cl)C=C1)C1=CC=NN1,,,,,0,,449.1066236,4,3,3,2,1,1
8486,04/06/2019 00:00,DB12598,Nafamostat,,,Approximately 8 minutes [A19227],,,solid,,,0.0341,,11.32,NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N,,,,,0,,347.1382248,3,3,0,0,0,0
8487,04/06/2019 00:00,DB12601,Sonolisib,,,,,,,,,0.0267,8.49,-2.8,COC[C@H]1OC(=O)\C(=C\N(CC=C)CC=C)C2=C(O)C(=O)C3=C([C@@H](C[C@@]4(C)[C@H]3CCC4=O)OC(C)=O)[C@@]12C,,,,,0,,525.2362671,4,0,1,0,1,1
8488,04/06/2019 00:00,DB12602,Pentetreotide,,,,,,,,,0.0382,1.09,10.2,C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN(CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC2=CNC3=CC=CC=C23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1,,,,,0,,1393.56826,5,4,2,1,1,1
8489,04/06/2019 00:00,DB12604,Sisomicin,,,,,,,,,15.6,12.55,9.88,[H][C@@]1(N)CC=C(CN)O[C@]1([H])O[C@]1([H])[C@@]([H])(N)C[C@@]([H])(N)[C@]([H])(O[C@@]2([H])OC[C@](C)(O)[C@]([H])(NC)[C@@]2([H])O)[C@@]1([H])O,,,,,0,,447.2692985,3,0,2,0,1,2
8490,04/06/2019 00:00,DB12605,Etripamil,,,,,,,,,0.00305,,9.52,COC(=O)C1=CC(CCN(C)CCC[C@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)=CC=C1,,,,,0,,452.2675076,2,2,0,0,0,0
8491,04/06/2019 00:00,DB12606,Netivudine,,,,,,,,,2,9.44,-3,CC#CC1=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C(=O)NC1=O,,,,,0,,282.0851862,2,1,2,1,1,1
8492,04/06/2019 00:00,DB12608,Emixustat,,,,,,,,,0.0311,14.38,9.67,NCC[C@@H](O)C1=CC(OCC2CCCCC2)=CC=C1,,,,,0,,263.188529,2,1,0,0,0,0
8493,04/06/2019 00:00,DB12610,Ebselen,,,,,,,,,4.35,,-5.1,O=C1N([Se]C2=CC=CC=C12)C1=CC=CC=C1,,,,,0,,274.9849352,3,3,1,1,0,0
8494,04/06/2019 00:00,DB12611,PF-477736,,,,,,,,,0.0684,10.56,8.33,CN1C=C(C=N1)C1=C2C=NNC(=O)C3=C2C(N1)=CC(NC(=O)[C@H](N)C1CCCCC1)=C3,,,,,0,,419.206973,5,3,3,2,0,1
8495,04/06/2019 00:00,DB12612,Ozanimod,,,,,,,,,0.161,15.6,8.96,CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=CC=CC2=C1CC[C@@H]2NCCO,,,,,0,,404.1848406,4,3,1,1,0,0
8496,04/06/2019 00:00,DB12613,Davunetide,,,,,,,,,0.343,3.33,7.05,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O,,,,,0,,824.4392174,2,0,2,0,2,2
8497,04/06/2019 00:00,DB12614,Reparixin,,,,,,,,,0.0143,7.17,-2.4,[H][C@](C)(C(O)=NS(C)(=O)=O)C1=CC=C(CC(C)C)C=C1,,,,,0,,283.1242145,1,1,0,0,0,0
8498,04/06/2019 00:00,DB12615,Plazomicin,Administration of 15 mg/kg plazomicin by 30-minute IV infusion resulted in peak plasma concentrations of 73.7 Â± 19.7 Î¼g/mL in healthy adult subjects and 51.0 Â± 26.7 Î¼g/mL in patients with complicated urinary tract infections (cUTI) [FDA Label]. The area under the curve (AUC) were 257 Â± 67.0 Î¼g.h/mL in healthy adults and 226 Â± 113 Î¼g.h/mL in cUTI patients [FDA Label]. ,0.2,The mean (Â±SD) half-life of plazomicin was 3.5 h (Â±0.5) in healthy adults with normal renal function receiving 15 mg/kg plazomicin via intravenous infusion [FDA Label].,500 mg/10mL,Intravenous,,,,12.3,12.48,9.89,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H]2O)NC(=O)[C@@H](O)CCN)OC[C@]1(C)O,0.2,0.2,,,0,,592.3431917,3,0,2,0,1,2
8499,04/06/2019 00:00,DB12617,Mizoribine,,,,,,,,,36.1,8.19,2.77,NC(=O)C1=C(O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,,,,,0,,259.0804351,2,1,2,1,1,1
8500,04/06/2019 00:00,DB12618,Apocynin,,,,,,,,,3.04,8.27,-4.9,COC1=C(O)C=CC(=C1)C(C)=O,,,,,0,,166.0629942,1,1,0,0,0,0
8501,04/06/2019 00:00,DB12619,BMS-188797,,,,,,,,,0.00675,10.47,-1.2,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C3=CC=CC=C3)C3=CC=CC=C3)C(C)=C([C@@H](OC(C)=O)C1=O)C2(C)C,,,,,0,,869.3258699,7,3,1,0,1,1
8502,04/06/2019 00:00,DB12621,ST-101,,,,,,,,,0.171,,0.23,O=C1N=C2C=CC=CN2C11CC2=CC=CC=C2C1,,,,,0,,236.094963,4,1,2,0,0,2
8503,04/06/2019 00:00,DB12622,Lupeol,,,,,,,,,0.000195,19.49,-0.84,[H][C@]12[C@@H](CC[C@]1(C)CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(C)=C,,,,,0,,426.3861662,5,0,0,0,0,0
8504,04/06/2019 00:00,DB12623,Taprenepag,,,,,,,,,0.0219,3.11,2.11,OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1,,,,,0,,478.1310908,4,4,2,2,0,0
8505,04/06/2019 00:00,DB12624,Octenidine,,,,,,,,,2.60E-05,,10.89,CCCCCCCCN=C1C=CN(CCCCCCCCCCN2C=CC(C=C2)=NCCCCCCCC)C=C1,,,,,0,,550.497448,2,2,2,2,0,0
8506,04/06/2019 00:00,DB12625,Evogliptin,,,,,,,,,0.11,13.69,8.78,CC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F,,,,,0,,401.1926264,2,1,1,0,1,1
8507,04/06/2019 00:00,DB12627,GSK-1292263,,,,,,,,,0.0679,19.69,3.71,CC(C)C1=NOC(=N1)N1CCC(COC2=CC=C(N=C2)C2=CC=C(C=C2)S(C)(=O)=O)CC1,,,,,0,,456.1831264,4,3,3,2,1,1
8508,04/06/2019 00:00,DB12628,Methyl-D9-choline,,,,,,,,,3.61,13.97,-3.2,[2H]C([2H])([2H])[N+](CCO)(C([2H])([2H])[2H])C([2H])([2H])[2H],,,,,1,,113.1634812,0,0,0,0,0,0
8509,04/06/2019 00:00,DB12629,"3,5-diiodothyropropionic acid",,,,,,,,,0.00692,2.5,-3.7,OC(=O)CCC1=CC(I)=C(OC2=CC=C(O)C=C2)C(I)=C1,,,,,0,,509.8825049,2,2,0,0,0,0
8510,04/06/2019 00:00,DB12630,Isopentyl 2-cyanoacrylate,,,,,,,,,0.339,,-7.2,CC(C)CCOC(=O)C(=C)C#N,,,,,0,,167.0946287,0,0,0,0,0,0
8511,04/06/2019 00:00,DB12631,Aclerastide,,,,,,,,,0.0359,2.95,11.77,CCCC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(O)=O,,,,,0,,912.4817509,3,2,2,1,1,1
8512,04/06/2019 00:00,DB12632,JNJ-41443532,,,,,,,,,0.00374,12.93,6.7,O[C@]1(CC[C@@H](CC1)N1CC(C1)NC(=O)CNC(=O)C1=CC=CC(=C1)C(F)(F)F)C1=CN=CS1,,,,,0,,482.1599463,4,2,2,1,1,1
8513,04/06/2019 00:00,DB12633,BMS-184476,,,,,,,,,0.00214,11.13,-1.2,CSCO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]12C)C3(C)C,,,,,0,,913.3343264,7,3,1,0,1,1
8514,04/06/2019 00:00,DB12635,Aleplasinin,,,,,,,,,0.000461,3.41,-9.7,CC1=CC=CC(=C1)C1=CC=C2N(CC3=CC=C(C=C3)C(C)(C)C)C=C(C(=O)C(O)=O)C2=C1,,,,,0,,425.1990937,4,4,1,1,0,0
8515,04/06/2019 00:00,DB12637,Onapristone,,,,,,,,,0.00759,14.34,4.89,CN(C)C1=CC=C(C=C1)[C@H]1C[C@]2(C)[C@@H](CC[C@]2(O)CCCO)[C@@H]2CCC3=CC(=O)CCC3=C12,,,,,0,,449.2929941,5,1,0,0,0,0
8516,04/06/2019 00:00,DB12638,PU-H71,,,,,,,,,0.0691,18.4,10.55,CC(C)NCCCN1C(SC2=C(I)C=C3OCOC3=C2)=NC2=C(N)N=CN=C12,,,,,0,,512.0491429,4,3,3,2,0,1
8517,04/06/2019 00:00,DB12640,CP-609754,,,,,,,,,0.00207,12.22,6.19,CN1C=NC=C1[C@@](O)(C1=CC=C(Cl)C=C1)C1=CC=C2N(C)C(=O)C=C(C3=CC=CC(=C3)C#C)C2=C1,,,,,0,,479.1400546,5,5,2,2,0,0
8518,04/06/2019 00:00,DB12641,Tedatioxetine,,,,,,,,,0.000695,,10.03,CC1=CC=C(SC2=CC=CC=C2C2CCNCC2)C=C1,,,,,0,,283.1394707,3,2,1,0,1,1
8519,04/06/2019 00:00,DB12642,Olumacostat glasaretil,,,,,,,,,0.00331,18.4,-3.2,CCCCCCCCCCCCCCOC1=CC=C(O1)C(=O)OCC(=O)N(C)CC(=O)OCC,,,,,0,,481.3039527,1,1,1,1,0,0
8520,04/06/2019 00:00,DB12643,Nelivaptan,,,,,,,,,0.0114,14.81,3.46,[H][C@]1(O)CN([C@@]([H])(C1)C(=O)N(C)C)[C@@]1(C(=O)N(C2=C1C=C(Cl)C=C2)S(=O)(=O)C1=C(OC)C=C(OC)C=C1)C1=CC=CC=C1OC,,,,,0,,629.1598637,5,3,2,0,1,2
8521,04/06/2019 00:00,DB12644,AZD-2066,,,,,,,,,0.0743,,3.93,C[C@@H](OC1=NN=C(N1C)C1=CC=NC=C1)C1=NOC(=C1)C1=CC=CC(Cl)=C1,,,,,0,,381.0992524,4,4,3,3,0,0
8522,04/06/2019 00:00,DB12645,Givinostat,,,,,,,,,0.0052,9.99,9.35,CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C=C3)C(=O)NO)C=CC2=C1,,,,,0,,421.2001563,3,3,0,0,0,0
8523,04/06/2019 00:00,DB12647,Tocotrienol,,,,,,,,,0.000793,10.01,-4.9,CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC1(C)CCC2=CC(O)=CC=C2O1,,,,,0,,382.2871805,2,1,1,0,0,1
8524,04/06/2019 00:00,DB12648,Nona-arginine,,,,,,,,,0.317,,12.85,N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,,,,,0,,1422.920564,0,0,0,0,0,0
8525,04/06/2019 00:00,DB12649,Ibipinabant,,,,,,,,,0.00176,19.11,1.28,CN\C(=N/S(=O)(=O)C1=CC=C(Cl)C=C1)N1C[C@@H](C(=N1)C1=CC=C(Cl)C=C1)C1=CC=CC=C1,,,,,0,,486.0684022,4,3,1,0,0,1
8526,04/06/2019 00:00,DB12650,L-deprenyl-D2 C-11,,,,,,,,,0.0254,,8.67,[2H]C([2H])(C#C)N([11CH3])[C@H](C)CC1=CC=CC=C1,,,,,0,,188.1600866,1,1,0,0,0,0
8527,04/06/2019 00:00,DB12651,Bardoxolone,,,,,,,,,0.00401,4.6,-5.3,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,,,,,0,,491.3035588,5,0,0,0,0,0
8528,04/06/2019 00:00,DB12654,GSK-376501,,,,,,,,,0.000129,4.69,-3.7,COCCOC1=CC(OCCOC)=CC(CN2C3=CC=CC=C3C(=C2C(O)=O)C2=CC=C(C=C2)C(C)(C)C)=C1,,,,,0,,531.2620879,4,4,1,1,0,0
8529,04/06/2019 00:00,DB12655,Patidegib,,,,,,,,,0.000464,11.58,9.99,C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC[C@@H]4C[C@@H](CC[C@]4(C)[C@H]3CC2=C(C)C1)NS(C)(=O)=O,,,,,0,,504.3385644,6,0,2,0,2,2
8530,04/06/2019 00:00,DB12657,JNJ-42396302,,,,,,,,,0.112,,4.5,COCCC1=CC=C(C=N1)C1=C(C)N=C2N1N=CC=C2N1CCOCC1,,,,,0,,353.185175,4,3,4,3,1,1
8531,04/06/2019 00:00,DB12658,AFN-1252,,,,,,,,,0.0427,12.03,3.57,CN(CC1=C(C)C2=CC=CC=C2O1)C(=O)\C=C\C1=CC2=C(NC(=O)CC2)N=C1,,,,,0,,375.1582915,4,3,3,2,0,1
8532,04/06/2019 00:00,DB12659,SJ-733,,,,,,,,,0.00532,13.64,4.78,FC1=CC=C(NC(=O)[C@@H]2[C@H](N(CC(F)(F)F)C(=O)C3=CC=CC=C23)C2=CC=CN=C2)C=C1C#N,,,,,0,,468.1209386,4,3,2,1,0,1
8533,04/06/2019 00:00,DB12660,Samatasvir,,,,,,,,,0.000691,11,5.82,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC2=CC=C(C=C2N1)C1=CSC2=C1SC=C2C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1,,,,,0,,884.3138233,9,7,6,4,2,2
8534,04/06/2019 00:00,DB12661,Urapidil,,,,,,,,,0.541,,8.11,COC1=CC=CC=C1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1,,,,,0,,387.2270398,3,2,2,1,1,1
8535,04/06/2019 00:00,DB12662,Naveglitazar,,,,,,,,,0.00107,3.64,-3.5,CO[C@@H](CC1=CC=C(OCCCOC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1)C(O)=O,,,,,0,,422.1729386,3,3,0,0,0,0
8536,04/06/2019 00:00,DB12663,Letrazuril,,,,,,,,,0.00276,6.5,-9.3,FC1=CC=C(C=C1)C(C#N)C1=C(Cl)C=C(C=C1Cl)N1N=CC(=O)NC1=O,,,,,0,,390.0086591,3,3,1,1,0,0
8537,04/06/2019 00:00,DB12664,Indantadol,,,,,,,,,0.485,16.4,8.61,NC(=O)CNC1CC2=CC=CC=C2C1,,,,,0,,190.1106131,2,1,0,0,0,0
8538,04/06/2019 00:00,DB12665,Isoquercetin,,,,,,,,,1.95,6.43,-3,OC[C@H]1O[C@@H](OC2=C(OC3=C(C(O)=CC(O)=C3)C2=O)C2=CC=C(O)C(O)=C2)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,464.0954761,4,3,2,1,1,1
8539,04/06/2019 00:00,DB12666,Emapunil,,,,,,,,,0.0418,15.13,0.42,CCN(CC1=CC=CC=C1)C(=O)CN1C(=O)N(C)C2=CN=C(N=C12)C1=CC=CC=C1,,,,,0,,401.185175,4,4,2,2,0,0
8540,04/06/2019 00:00,DB12667,Protionamide,,,,,,,,,0.0983,,7.31,CCCC1=NC=CC(=C1)C(S)=N,,,,,0,,180.0721194,1,1,1,1,0,0
8541,04/06/2019 00:00,DB12668,Metenkefalin,,,,,,,,,0.0196,3.61,7.73,CSCC[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O,,,,,0,,573.2257195,2,2,0,0,0,0
8542,04/06/2019 00:00,DB12669,4SC-203,,,,,,,,,0.00204,10,8.02,COC1=CC=C(C)C=C1NC(=O)NC1=NC2=CC=C(NC3=NC=NC4=CC(OCCCN5CCN(C)CC5)=C(OC)C=C34)C=C2S1,,,,,0,,642.2736727,6,5,3,2,1,1
8543,04/06/2019 00:00,DB12670,Rolofylline,,,,,,,,,0.125,7.83,-0.72,CCCN1C2=C(NC(=N2)C23C[C@@H]4CC2C[C@H](C3)C4)C(=O)N(CCC)C1=O,,,,,0,,356.2212261,6,2,2,2,0,0
8544,04/06/2019 00:00,DB12671,Beloranib,,,,,,,,,0.00264,,8.77,CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1,,,,,0,,499.293388,4,1,2,0,2,2
8545,04/06/2019 00:00,DB12672,Icaritin,,,,,,,,,0.00821,6.22,-3.8,COC1=CC=C(C=C1)C1=C(O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1,,,,,0,,368.1259884,3,3,1,1,0,0
8546,04/06/2019 00:00,DB12673,ATX-914,,,,,,,,,0.00287,,0.28,CC(C)C1=CC=C(C=C1)C1=NC(=O)N(CC2=CC=C3N=C(Br)C=NC3=C2)C2=CC=C(OCC#C)C=C12,,,,,0,,538.1004381,5,5,2,2,0,0
8547,04/06/2019 00:00,DB12674,Lurbinectedin,,,,,,,,,0.0646,9.35,7.2,COC1=CC=C2NC3=C(CCN[C@]33CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=C6C(O)=C(OC)C(C)=C7)[C@H](O)N5[C@@H](COC3=O)C3=C4C(OC(C)=O)=C(C)C4=C3OCO4)C2=C1,,,,,0,,784.2778146,11,4,8,1,2,7
8548,04/06/2019 00:00,DB12675,PF-04995274,,,,,,,,,0.205,14.26,9.59,OC1(CN2CCC(COC3=NOC4=CC=CC(O[C@@H]5CCOC5)=C34)CC2)CCOCC1,,,,,0,,432.2260367,5,2,4,1,3,3
8549,04/06/2019 00:00,DB12676,Modufolin,,,,,,,,,0.823,2.93,4.6,[H][C@@]12CN(CN1C1=C(NC2)N=C(N)NC1=O)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,,,,,0,,457.1709815,4,2,3,1,1,2
8550,04/06/2019 00:00,DB12677,Soblidotin,,,,,,,,,0.00826,12.7,8.03,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,,,,,0,,701.5091349,2,1,1,0,1,1
8551,04/06/2019 00:00,DB12678,Relamorelin,,,,,,,,,0.00126,11.85,10.31,NC(=O)C1(CCNCC1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@@H](CC1=CSC2=CC=CC=C12)NC(=O)C1CCNCC1,,,,,0,,790.3624877,7,5,4,2,2,2
8552,04/06/2019 00:00,DB12679,WP 1066,,,,,,,,,0.00537,12.15,0.42,C[C@H](NC(=O)C(=C\C1=CC=CC(Br)=N1)\C#N)C1=CC=CC=C1,,,,,0,,355.0320242,2,2,1,1,0,0
8553,04/06/2019 00:00,DB12680,Intepirdine,,,,,,,,,0.057,,8.61,O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1,,,,,0,,353.1197978,4,3,2,1,1,1
8554,04/06/2019 00:00,DB12681,Salirasib,,,,,,,,,0.000659,3.41,,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O,,,,,0,,358.1966512,1,1,0,0,0,0
8555,04/06/2019 00:00,DB12682,Mubritinib,,,,,,,,,0.0124,,0.8,FC(F)(F)C1=CC=C(\C=C\C2=NC(COC3=CC=C(CCCCN4C=CN=N4)C=C3)=CO2)C=C1,,,,,0,,468.1773106,4,4,2,2,0,0
8556,04/06/2019 00:00,DB12685,K-134,,,,,,,,,0.141,14.19,-0.2,O[C@@H]1CCCC[C@H]1N(C1CC1)C(=O)NCCCOC1=CC=C2NC(=O)C=CC2=C1,,,,,0,,399.2158064,4,2,1,1,0,0
8557,04/06/2019 00:00,DB12686,PHA-793887,,,,,,,,,0.426,6.86,8.8,CC(C)CC(O)=NC1=NNC2=C1CN(C(=O)C1CCN(C)CC1)C2(C)C,,,,,0,,361.2477752,3,1,3,1,1,2
8558,04/06/2019 00:00,DB12687,Vesatolimod,,,,,,,,,0.0637,11.32,9.19,CCCCOC1=NC(N)=C2NC(=O)CN(CC3=CC=CC(CN4CCCC4)=C3)C2=N1,,,,,0,,410.2430242,4,2,3,1,1,2
8559,04/06/2019 00:00,DB12689,Azeliragon,,,,,,,,,8.86E-05,,9.8,CCCCC1=NC(=CN1C1=CC=C(OC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(OCCCN(CC)CC)C=C1,,,,,0,,531.2652551,4,4,1,1,0,0
8560,04/06/2019 00:00,DB12690,LY-2584702,,,,,,,,,0.01,9.16,5.92,CN1C=C(N=C1C1CCN(CC1)C1=C2C=NNC2=NC=N1)C1=CC=C(F)C(=C1)C(F)(F)F,,,,,0,,445.1638065,5,4,4,3,1,1
8561,04/06/2019 00:00,DB12691,UK-432097,,,,,,,,,0.0473,2.83,7.3,[H][C@@]1(O)[C@]([H])(O)[C@]([H])(O[C@@]1([H])N1C=NC2=C(NCC(C3=CC=CC=C3)C3=CC=CC=C3)N=C(N=C12)C(=O)NCCN=C(O)NC1CCN(CC1)C1=CC=CC=N1)C(O)=NCC,,,,,0,,777.3710782,7,5,5,3,2,2
8562,04/06/2019 00:00,DB12692,Gusperimus,,,,,,,,,0.129,11.37,12.28,NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCNC(N)=N,,,,,0,,387.295788,0,0,0,0,0,0
8563,04/06/2019 00:00,DB12693,Ritanserin,,,,,,,,,0.00981,,8,CC1=C(CCN2CCC(CC2)=C(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)C(=O)N2C=CSC2=N1,,,,,0,,477.1686399,5,4,3,2,1,1
8564,04/06/2019 00:00,DB12694,CE-326597,,,,,,,,,0.00105,15.88,1.57,CC(C)N(CC1=CC=CC=C1)C(=O)CN1C2=CC=CC=C2N2C(=NN=C2C2=CC=CC=C2)[C@H](CC2=CNC3=CC=CC=C23)C1=O,,,,,0,,594.2743243,7,6,3,2,0,1
8565,04/06/2019 00:00,DB12695,Phenethyl Isothiocyanate,,,,,,,,,0.0277,,-3.1,S=C=NCCC1=CC=CC=C1,,,,,0,,163.0455703,1,1,0,0,0,0
8566,04/06/2019 00:00,DB12696,BMS-582949,,,,,,,,,0.0923,7.44,5.1,CCCN=C(O)C1=CN2NC=NC(=NC3=C(C)C=CC(=C3)C(O)=NC3CC3)C2=C1C,,,,,0,,406.2117241,4,3,2,2,0,0
8567,04/06/2019 00:00,DB12697,Methylselenocysteine,,,,,,,,,156,1.46,8.4,C[Se]C[C@H](N)C(O)=O,,,,,0,,182.9798498,0,0,0,0,0,0
8568,04/06/2019 00:00,DB12700,Solamargine,,,,,,,,,0.198,11.89,9.54,C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CN1,,,,,0,,867.4980206,9,0,5,0,5,5
8569,04/06/2019 00:00,DB12702,Velusetrag,,,,,,,,,0.116,14.32,8.19,CC(C)N1C(=O)C(=CC2=CC=CC=C12)C(=O)N[C@@H]1C[C@@H]2CC[C@H](C1)N2C[C@@H](O)CN(C)S(C)(=O)=O,,,,,0,,504.2406413,4,2,3,1,2,2
8570,04/06/2019 00:00,DB12703,Omipalisib,,,,,,,,,0.00193,6.58,4,COC1=C(NS(=O)(=O)C2=C(F)C=C(F)C=C2)C=C(C=N1)C1=CC2=C(C=CN=C2C=C1)C1=CN=NC=C1,,,,,0,,505.1020168,5,5,3,3,0,0
8571,04/06/2019 00:00,DB12704,Spiradoline,,,,,,,,,0.0147,,9.76,[H][C@@]1(CC[C@@]2(CCCO2)C[C@]1([H])N1CCCC1)N(C)C(=O)CC1=CC(Cl)=C(Cl)C=C1,,,,,0,,424.1684336,4,1,2,0,2,2
8572,04/06/2019 00:00,DB12705,Cenerimod,,,,,,,,,0.0744,13.62,0.62,CCC1=CC(=CC(C)=C1OC[C@@H](O)CO)C1=NOC(=N1)C1=CC(=NC(OC)=C1)C1CCCC1,,,,,0,,453.2263711,4,3,2,2,0,0
8573,04/06/2019 00:00,DB12706,Seletalisib,,,,,,,,,0.00623,10.71,5.09,[O-][N+]1=CC(=CC=C1)C1=NC2=C(Cl)C=CC=C2C=C1[C@@H](NC1=NC=NC2=CC=CN=C12)C(F)(F)F,,,,,0,,482.0869714,5,5,4,4,0,0
8574,04/06/2019 00:00,DB12707,AR-42,,,,,,,,,0.00992,9.8,-4.2,CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1,,,,,0,,312.1473925,2,2,0,0,0,0
8575,04/06/2019 00:00,DB12708,Sulprostone,,,,,,,,,0.0296,4.08,-2.9,CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O,,,,,0,,465.1821233,2,1,0,0,0,0
8576,04/06/2019 00:00,DB12709,Tributyrin,,,,,,,,,0.317,,-6.6,CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC,,,,,0,,302.1729386,0,0,0,0,0,0
8577,04/06/2019 00:00,DB12710,Perazine,,,,,,,,,0.0601,,8.41,CN1CCN(CCCN2C3=CC=CC=C3SC3=CC=CC=C23)CC1,,,,,0,,339.1769188,4,2,2,0,1,2
8578,04/06/2019 00:00,DB12711,LTX-109,,,,,,,,,0.00105,12.68,12.17,CC(C)(C)C1=C(C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCCC2=CC=CC=C2)C2=CC(=CC(=C2N1)C(C)(C)C)C(C)(C)C,,,,,0,,787.5584851,3,3,1,1,0,0
8579,04/06/2019 00:00,DB12712,Pilsicainide,,,,,,,,,0.0902,5,10.83,CC1=CC=CC(C)=C1N=C(O)CC12CCCN1CCC2,,,,,0,,272.1888634,3,1,2,0,2,2
8580,04/06/2019 00:00,DB12713,Sotagliflozin,,,,,,,,,0.042,12.47,-3.7,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1,,,,,0,,424.1111226,3,2,1,0,1,1
8581,04/06/2019 00:00,DB12714,Nerispirdine,,,,,,,,,0.054,,7.49,CCCN(N1C=C(C)C2=CC=CC=C12)C1=CC=NC=C1F,,,,,0,,283.1484758,3,3,2,2,0,0
8582,04/06/2019 00:00,DB12715,MSX-122,,,,,,,,,0.0106,14.36,3.68,C(NC1=NC=CC=N1)C1=CC=C(CNC2=NC=CC=N2)C=C1,,,,,0,,292.1436445,3,3,2,2,0,0
8583,04/06/2019 00:00,DB12716,NB-001,,,,,,,,,1.13,16.84,10.26,NC1=C2N=CN(CCNCCCCCO)C2=NC=N1,,,,,0,,264.1698593,2,2,2,2,0,0
8584,04/06/2019 00:00,DB12717,Mibampator,,,,,,,,,0.00187,11.2,,CC(C)S(=O)(=O)NC[C@H](C)C1=CC=C(C=C1)C1=CC=C(CCNS(C)(=O)=O)C=C1,,,,,0,,438.1646994,2,2,0,0,0,0
8585,04/06/2019 00:00,DB12719,Turofexorate isopropyl,,,,,,,,,0.00135,13.58,-4.5,CC(C)OC(=O)C1=CN(CC(C)(C)C2=C1NC1=CC=CC=C21)C(=O)C1=CC(F)=C(F)C=C1,,,,,0,,438.1754991,4,3,2,1,0,1
8586,04/06/2019 00:00,DB12720,Nivocasan,,,,,,,,,0.0728,10.29,2.96,CC(C)[C@]1(CC(=NO1)C1=NC=CC2=CC=CC=C12)C(=O)N[C@H]1CC(=O)O[C@]1(O)CF,,,,,0,,415.154349,4,2,3,1,1,2
8587,04/06/2019 00:00,DB12721,RO-5028442,,,,,,,,,0.00667,,9.15,CN(C)CCN1C=C(C(=O)N2CCC3(CC2)OCC2=CC=CC=C32)C2=CC=C(Cl)C=C12,,,,,0,,437.1870048,5,3,3,1,1,2
8588,04/06/2019 00:00,DB12724,AZD-7295,,,,,,,,,0.002,13.71,6.05,CCCS(=O)(=O)N1CCN(CC2=CC=C(NC(=O)C3=CC=C(C=C3)C3=CC(NC(=O)C4CC4)=CC=C3OC(F)(F)F)C=C2)CC1,,,,,0,,644.2280259,5,3,1,0,1,1
8589,04/06/2019 00:00,DB12725,TD-8954,,,,,,,,,0.0518,10.75,9.77,COC(=O)N1CCC(CN2CCC(CNC(=O)C3=C4NC(=NC4=CC=C3)C(C)C)CC2)CC1,,,,,0,,455.28964,4,2,3,1,2,2
8590,04/06/2019 00:00,DB12727,Perfosfamide,,,,,,,,,13.3,11.36,0.0046,OO[C@@H]1CCO[P@](=O)(N1)N(CCCl)CCCl,,,,,0,,292.014649,1,0,1,0,1,1
8591,04/06/2019 00:00,DB12728,Fenpropidin,,,,,,,,,0.000461,,10.08,CC(CN1CCCCC1)CC1=CC=C(C=C1)C(C)(C)C,,,,,0,,273.24565,2,1,1,0,1,1
8592,04/06/2019 00:00,DB12729,ASP-3026,,,,,,,,,0.0167,9.54,8.49,COC1=CC(=CC=C1NC1=NC(NC2=CC=CC=C2S(=O)(=O)C(C)C)=NC=N1)N1CCC(CC1)N1CCN(C)CC1,,,,,0,,580.2944081,5,3,3,1,2,2
8593,04/06/2019 00:00,DB12730,Dolastatin 10,,,,,,,,,0.00127,12.3,8.03,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C1=NC=CS1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,,,,,0,,784.4921049,3,2,2,1,1,1
8594,04/06/2019 00:00,DB12731,Daporinad,,,,,,,,,0.00342,15.59,4.84,O=C(NCCCCC1CCN(CC1)C(=O)C1=CC=CC=C1)\C=C\C1=CC=CN=C1,,,,,0,,391.2259772,3,2,2,1,1,1
8595,04/06/2019 00:00,DB12732,Firategrast,,,,,,,,,0.000824,3.42,-2.9,CCOCC1=CC(OC)=C(C(OC)=C1)C1=CC=C(C[C@H](NC(=O)C2=C(F)C=CC=C2F)C(O)=O)C=C1,,,,,0,,499.180644,3,3,0,0,0,0
8596,04/06/2019 00:00,DB12733,Dipraglurant,,,,,,,,,0.00458,17.86,6.58,FC1=CN2C=C(CCC#CC3=CC=CC=N3)N=C2C=C1,,,,,0,,265.1015256,3,3,3,3,0,0
8597,04/06/2019 00:00,DB12736,Etanidazole,,,,,,,,,4.63,2.09,4.11,OCCN=C(O)CN1C=CN=C1N(=O)=O,,,,,0,,214.0702048,1,1,1,1,0,0
8598,04/06/2019 00:00,DB12739,Bindarit,,,,,,,,,0.0144,3.76,0.73,CC(C)(OCC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12)C(O)=O,,,,,0,,324.1473925,3,3,1,1,0,0
8599,04/06/2019 00:00,DB12740,CC-115,,,,,,,,,0.0229,8.91,2.05,CCN1C(=O)CNC2=C1N=C(C=N2)C1=CC=C(N=C1C)C1=NN=CN1,,,,,0,,336.1447071,4,3,4,3,0,1
8600,04/06/2019 00:00,DB12741,DTP-348,,,,,,,,,3.83,11.48,3.09,CC1=NC=C(N1CCNS(N)(=O)=O)N(=O)=O,,,,,0,,249.0531748,1,1,1,1,0,0
8601,04/06/2019 00:00,DB12742,Amuvatinib,Orally available,,,,,,,,0.0741,14.11,1.37,S=C(NCC1=CC=C2OCOC2=C1)N1CCN(CC1)C1=NC=NC2=C1OC1=C2C=CC=C1,,,,,0,,447.1365105,6,4,4,2,1,2
8602,04/06/2019 00:00,DB12743,Z-160,,,,,,,,,0.000237,,7.3,O=C(CC(C1=CC=CC=C1)C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,460.2514636,5,4,1,0,1,1
8603,04/06/2019 00:00,DB12744,CGI-1842,,,,,,,,,0.00493,10.56,7.31,COC1=CC=C(Br)C=C1NC(=O)NC1=C2C=CN(CC3=CC=NC(N)=C3)C2=CC=C1,,,,,0,,465.080037,4,4,2,2,0,0
8604,04/06/2019 00:00,DB12745,GSK-690693,,,,,,,,,0.0664,13.27,10.07,[H][C@]1(COC2=C3N(CC)C(=NC3=C(N=C2)C#CC(C)(C)O)C2=NON=C2N)CCCNC1,,,,,0,,425.2175377,4,3,4,3,1,1
8605,04/06/2019 00:00,DB12746,AKN-028,,,,,,,,,0.042,14.26,4.14,NC1=C(NC2=CC=C3NC=CC3=C2)N=C(C=N1)C1=CC=NC=C1,,,,,0,,302.1279944,4,4,3,3,0,0
8606,04/06/2019 00:00,DB12748,LTX-315,,,,,,,,,0.00289,12.16,10.89,NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](C(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(N)=O,,,,,0,,1438.839017,8,8,3,3,0,0
8607,04/06/2019 00:00,DB12749,Butylphthalide,,,,,,,,,0.0654,15.7,-6.9,CCCCC1OC(=O)C2=C1C=CC=C2,,,,,0,,190.0993797,2,1,1,0,0,1
8608,04/06/2019 00:00,DB12750,N-omega-nitro-L-arginine methyl ester,,,,,,,,,0.698,10.05,8.15,[H][C@](N)(CCCNC(=N)NN(=O)=O)C(=O)OC,,,,,0,,233.112404,0,0,0,0,0,0
8609,04/06/2019 00:00,DB12751,Malic Acid,,,,,,,,,218,3.2,-3.9,OC(CC(O)=O)C(O)=O,,,,,0,,134.0215233,0,0,0,0,0,0
8610,04/06/2019 00:00,DB12752,Bucindolol,,,,,,,,,0.00744,14.09,9.69,CC(C)(CC1=CNC2=CC=CC=C12)NCC(O)COC1=CC=CC=C1C#N,,,,,0,,363.194677,3,3,1,1,0,0
8611,04/06/2019 00:00,DB12756,TAK-901,,,,,,,,,0.00415,13.72,8.54,CCS(=O)(=O)C1=CC=CC(=C1)C1=CC(C(=O)NC2CCN(C)CC2)=C(C)C2=C1C1=C(N2)N=CC(C)=C1,,,,,0,,504.2195119,5,4,3,2,1,1
8612,04/06/2019 00:00,DB12757,Pelitrexol,,,,,,,,,0.0375,3.77,0.96,CC1=C(CC[C@@H]2CNC3=C(C2)C(=O)NC(N)=N3)SC(=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,,,,,0,,463.1525545,3,2,3,2,0,1
8613,04/06/2019 00:00,DB12758,Atreleuton,,,,,,,,,0.00611,8.46,-5.7,C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O,,,,,0,,318.0838269,2,2,1,1,0,0
8614,04/06/2019 00:00,DB12760,GW-493838,,,,,,,,,0.207,12.01,1.02,CC(C)(C)C1=NN=C(O1)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(NC3=CC=C(Cl)C=C3F)N=CN=C12,,,,,0,,489.1327581,5,4,4,3,1,1
8615,04/06/2019 00:00,DB12761,Timcodar,,,,,,,,,0.00018,17.9,5.35,COC1=CC(=CC(OC)=C1OC)C(=O)C(=O)N(C)[C@@H](CC1=CC=C(Cl)C=C1)C(=O)N(CC1=CC=CC=C1)C(CCC1=CC=NC=C1)CCC1=CC=NC=C1,,,,,0,,748.3027628,5,5,2,2,0,0
8616,04/06/2019 00:00,DB12762,Rabacfosadine,,,,,,,,,0.336,12.41,5.81,CCOC(=O)[C@H](C)NP(=O)(COCCN1C=NC2=C(NC3CC3)N=C(N)N=C12)N[C@@H](C)C(=O)OCC,,,,,0,,526.2417175,3,2,2,2,0,0
8617,04/06/2019 00:00,DB12763,MK-1496,,,,,,,,,0.461,14.11,9.91,C[C@H](N)C1=CC=C(C=C1)[C@H](O)CNC(C)(C)C,,,,,0,,236.1888634,1,1,0,0,0,0
8618,04/06/2019 00:00,DB12764,ABC-294640,,,,,,,,,0.000215,15.12,5.02,ClC1=CC=C(C=C1)C12CC3CC(CC(C3)(C1)C(=O)NCC1=CC=NC=C1)C2,,,,,0,,380.1655411,6,2,1,1,0,0
8619,04/06/2019 00:00,DB12765,Methyl isocyanate,,,,,,,,,37.3,,-5.1,CN=C=O,,,,,0,,57.02146372,0,0,0,0,0,0
8620,04/06/2019 00:00,DB12766,Cicletanine,,,,,,,,,0.727,8.57,5.51,CC1=C(O)C2=C(C=N1)C(OC2)C1=CC=C(Cl)C=C1,,,,,0,,261.0556563,3,2,2,1,0,1
8621,04/06/2019 00:00,DB12767,Gaxilose,,,,,,,,,284,11.98,-3,OC[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C=O,,,,,0,,312.1056468,1,0,1,0,1,1
8622,04/06/2019 00:00,DB12769,Lometrexol,,,,,,,,,0.131,-2.6,14.85,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CC[C@@]2([H])CNC3=C(C2)C(O)=NC(=N)N3)C=C1)C(O)=O,,,,,0,,443.1804835,3,2,2,1,0,1
8623,04/06/2019 00:00,DB12770,Lafutidine,,,,,,,,,0.243,8.87,7.94,[H]\C(COC1=NC=CC(CN2CCCCC2)=C1)=C(/[H])CN=C(O)CS(=O)CC1=CC=CO1,,,,,0,,431.1878774,3,2,3,2,1,1
8624,04/06/2019 00:00,DB12771,Hydroxytyrosol,,,,,,,,,17.4,9.45,-2.4,OCCC1=CC=C(O)C(O)=C1,,,,,0,,154.0629942,1,1,0,0,0,0
8625,04/06/2019 00:00,DB12774,AZD-8055,,,,,,,,,0.241,14.59,2,COC1=CC=C(C=C1CO)C1=CC=C2C(=N1)N=C(N=C2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,,,,,0,,465.2376045,5,3,4,2,2,2
8626,04/06/2019 00:00,DB12776,E-6005,,,,,,,,,0.00449,12.54,4.56,CNC1=NC(C2=CC=CC(NC(=O)C3=CC=C(C=C3)C(=O)OC)=C2)=C2C=C(OC)C(OC)=CC2=N1,,,,,0,,472.1746699,4,4,1,1,0,0
8627,04/06/2019 00:00,DB12777,Somatoprim,,,,,,,,,0.00501,11.61,10.18,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CCCNC(=O)CCCN(CC(N)=O)C(=O)[C@H](CC2=CC=CC=C2)NC1=O,,,,,0,,1122.565087,7,6,3,2,1,1
8628,04/06/2019 00:00,DB12779,Higenamine,,,,,,,,,0.236,8.75,9.55,OC1=CC=C(CC2NCCC3=C2C=C(O)C(O)=C3)C=C1,,,,,0,,271.1208434,3,2,1,0,0,1
8629,04/06/2019 00:00,DB12780,Quinfamide,,,,,,,,,0.0315,13.07,-3.1,ClC(Cl)C(=O)N1CCCC2=CC(OC(=O)C3=CC=CO3)=CC=C12,,,,,0,,353.0221633,3,2,2,1,0,1
8630,04/06/2019 00:00,DB12781,Balaglitazone,,,,,,,,,0.0434,7.61,2.05,CN1C(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)=NC2=CC=CC=C2C1=O,,,,,0,,395.093977,4,3,2,1,1,1
8631,04/06/2019 00:00,DB12782,SCH-486757,,,,,,,,,0.00687,12.78,7.45,O[C@]1(C[C@@H]2CC[C@H](C1)N2C(C1=CC=CC=C1Cl)C1=CC=CC=C1Cl)C1=NC=CC=N1,,,,,0,,439.1218177,5,3,3,1,2,2
8632,04/06/2019 00:00,DB12783,Benserazide,"In a study, three patients were administered 50 mg of radiolabelled 14C-benserazide by both intravenous and oral routes [F2, L2553]. Three additional patients received oral doses of 50 mg 14C-benserazide alone [F2, L2553]. Comparison of the time-plasma concentration curves of total radioactivity in the patients receiving oral and intravenous 14C-benserazide indicated that between 66% and 74% of the administered dose was absorbed from the gastrointestinal tract [F2, L2553]. Peak plasma concentrations of radioactivity were detected one hour after oral administration in five of the six patients [F2, L2553].",0,The half-life of benserazide is documented as 1.5 hours [T181].,,Oral,,,,5.15,8.66,7.48,NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1,0,0,,,0,,257.1011706,1,1,0,0,0,0
8633,04/06/2019 00:00,DB12784,NS-018,,,,,,,,,0.0227,11.89,4.93,C[C@H](NC1=CC(=CC(NC2=CN=CC=N2)=N1)C1=CN(C)N=C1)C1=CC=C(F)C=C1,,,,,0,,389.1764219,4,4,3,3,0,0
8634,04/06/2019 00:00,DB12785,Furaprevir,,,,,,,,,0.0122,3.74,-0.38,CC(C)OC1=CC=C(C=C1)C1=NC2=C(OC3=C2C=CC=C3)C(O[C@@H]2C[C@@H]3N(C2)C(=O)[C@H](CCCCC\C=C/[C@@H]2C[C@]2(NC3=O)C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)OC2CCCC2)=N1,,,,,0,,896.377863,9,4,4,2,1,2
8635,04/06/2019 00:00,DB12787,Norethandrolone,,,,,,,,,0.0174,19.28,-0.27,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,,,,,0,,302.2245802,4,0,0,0,0,0
8636,02/07/2019 00:00,DB12789,Dinoprost,,,,5 mg,Intra-amniotic,,,,0.117,4.36,-1.6,[H]\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@@]([H])(O)C[C@@]([H])(O)[C@]1([H])C(\[H])=C(/[H])[C@@]([H])(O)CCCCC,,,,,0,,354.2406242,1,0,0,0,0,0
8637,04/06/2019 00:00,DB12791,Laninamivir,,,,,,,,,0.745,3.61,12,[H][C@@](O)(CO)[C@@]([H])(OC)[C@]1([H])OC(=C[C@]([H])(NC(N)=N)[C@@]1([H])N=C(C)O)C(O)=O,,,,,0,,346.148849,1,0,1,0,0,1
8638,04/06/2019 00:00,DB12792,Boscalid,,,,,,,,,0.000747,10.7,-0.11,ClC1=CC=C(C=C1)C1=C(NC(=O)C2=C(Cl)N=CC=C2)C=CC=C1,,,,,0,,342.0326684,3,3,1,1,0,0
8639,04/06/2019 00:00,DB12794,p-Quaterphenyl,,,,,,,,,4.70E-06,,,C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,306.1408506,4,4,0,0,0,0
8640,04/06/2019 00:00,DB12795,CMX-2043,,,,,,,,,0.0852,3.5,-1.3,C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CCCC[C@@H]1CCSS1)C(O)=O,,,,,0,,406.1232286,1,0,1,0,1,1
8641,04/06/2019 00:00,DB12796,MRX-I,,,,,,,,,0.237,17.59,1.23,FC1=C(N2CCC(=O)C=C2)C(F)=C(F)C(=C1)N1C[C@H](CNC2=NOC=C2)OC1=O,,,,,0,,408.1045396,4,2,3,1,1,2
8642,04/06/2019 00:00,DB12798,Relenopride,,,,,,,,,0.00713,14.42,8.72,COC1=CC(N)=C(Cl)C=C1C(=O)NCC1CCN(CC[C@H](OC(N)=O)C2=CC=C(F)C=C2)CC1,,,,,0,,492.1939613,3,2,1,0,1,1
8643,04/06/2019 00:00,DB12799,Laniquidar,,,,,,,,,0.000453,,8.11,COC(=O)C1=CN=C2N1CCC1=CC=CC=C1C2=C1CCN(CCC2=CC=C(OCC3=CC=C4C=CC=CC4=N3)C=C2)CC1,,,,,0,,584.278741,7,5,4,2,1,2
8644,04/06/2019 00:00,DB12800,CHF-6001,,,,,,,,,0.000157,7.06,0.1,CS(=O)(=O)NC1=CC=C(C=C1OCC1CC1)C(=O)O[C@@H](CC1=C(Cl)C=[N+]([O-])C=C1Cl)C1=CC=C(OC(F)F)C(OCC2CC2)=C1,,,,,0,,686.1067987,5,3,1,1,0,0
8645,04/06/2019 00:00,DB12802,Picropodophyllin,,,,,,,,,0.114,14.02,-3.2,COC1=CC(=CC(OC)=C1OC)[C@H]1[C@H]2[C@H](COC2=O)[C@@H](O)C2=CC3=C(OCO3)C=C12,,,,,0,,414.1314677,5,2,2,0,1,2
8646,04/06/2019 00:00,DB12803,Dichloroisoproterenol,,,,,,,,,0.127,14.01,9.51,CC(C)NCC(O)C1=CC=C(Cl)C(Cl)=C1,,,,,0,,247.0530695,1,1,0,0,0,0
8647,04/06/2019 00:00,DB12804,Daniquidone,,,,,,,,,0.15,13.45,5.76,NC1=CC=C2N=C3N(CC2=C1)C(=O)C1=CC=CC=C31,,,,,0,,249.090212,4,2,2,0,0,2
8648,04/06/2019 00:00,DB12805,Ataciguat,,,,,,,,,0.00263,5.84,-3.8,ClC1=CC=C(S1)S(=O)(=O)NC1=C(C=C(Cl)C=C1)C(=O)NC1=CC=C(C=C1)S(=O)(=O)N1CCOCC1,,,,,0,,574.9813037,4,3,2,1,1,1
8649,04/06/2019 00:00,DB12806,GSK-1004723,,,,,,,,,0.000106,,9.79,ClC1=CC=C(CC2=NN(C[C@H]3CCCN3CCCCC3=CC=C(OCCCN4CCCCCC4)C=C3)C(=O)C3=CC=CC=C23)C=C1,,,,,0,,640.3544045,6,4,3,1,2,2
8650,04/06/2019 00:00,DB12808,Trifarotene,,,,,,,,,0.000945,3.97,4.75,CC(C)(C)C1=CC(=CC=C1N1CCCC1)C1=CC(=CC=C1OCCO)C1=CC=C(C=C1)C(O)=O,,,,,0,,459.2409585,4,3,1,0,1,1
8651,04/06/2019 00:00,DB12809,BK-MDA,,,,,,,,,8.98,18.65,7.55,CC(N)C(=O)C1=CC=C2OCOC2=C1,,,,,0,,193.0738932,2,1,1,0,0,1
8652,04/06/2019 00:00,DB12810,AN-2718,,,,,,,,,2.58,8.86,-4.8,OB1OCC2=CC(Cl)=CC=C12,,,,,0,,168.0149375,2,1,1,0,0,1
8653,04/06/2019 00:00,DB12812,Palomid 529,,,,,,,,,0.00343,14.59,-3,COC1=CC=C(COC2=C(OC)C=C3C(OC(=O)C4=CC(=CC=C34)C(C)O)=C2)C=C1,,,,,0,,406.1416384,4,4,1,1,0,0
8654,04/06/2019 00:00,DB12816,Terpinen-4-ol,,,,,,,,,2.5,20,-0.61,CC(C)C1(O)CCC(C)=CC1,,,,,0,,154.1357652,1,0,0,0,0,0
8655,04/06/2019 00:00,DB12817,Zoliflodacin,,,,,,,,,0.631,7.31,-1.9,[H][C@]12[C@H](C)O[C@H](C)CN1C1=C(CC22C(=O)NC(=O)NC2=O)C=C2C(ON=C2N2[C@@H](C)COC2=O)=C1F,,,,,0,,487.1503263,6,2,5,1,3,4
8656,04/06/2019 00:00,DB12818,NM-3,,,,,,,,,0.914,3.32,-4.1,COC1=CC(O)=C2C(=O)OC(=CC2=C1)C(C)C(O)=O,,,,,0,,264.0633881,2,2,1,1,0,0
8657,04/06/2019 00:00,DB12819,GSI-136,,,,,,,,,0.0765,8.19,-2.8,CCC(CC)[C@@H](CO)NS(=O)(=O)C1=CC=C(Cl)S1,,,,,0,,311.0416631,1,1,1,1,0,0
8658,04/06/2019 00:00,DB12821,Perflubutane,,,,,,,,,0.0485,,,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F,,,,,0,,237.9840322,0,0,0,0,0,0
8659,04/06/2019 00:00,DB12823,Tecarfarin,,,,,,,,,0.0026,5.13,-6.7,CC(OC(=O)C1=CC=C(CC2=C(O)C3=CC=CC=C3OC2=O)C=C1)(C(F)(F)F)C(F)(F)F,,,,,0,,460.0745429,3,3,1,1,0,0
8660,04/06/2019 00:00,DB12825,Lefamulin,,,,,,,,,0.00494,14.19,10.08,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O,,,,,0,,507.3018445,4,0,0,0,0,0
8661,04/06/2019 00:00,DB12827,Indoximod,,,,,,,,,0.721,2.58,9.39,CN1C=C(C[C@@H](N)C(O)=O)C2=CC=CC=C12,,,,,0,,218.1055277,2,2,1,1,0,0
8662,04/06/2019 00:00,DB12829,Amithiozone,,,,,,,,,0.0512,5.72,5.11,[H]\C(=N/NC(S)=N)C1=CC=C(C=C1)N=C(C)O,,,,,0,,236.073182,1,1,0,0,0,0
8663,04/06/2019 00:00,DB12830,Cebranopadol,,,,,,,,,0.00106,15.95,9.92,CN(C)[C@]1(CC[C@@]2(CC1)OCCC1=C2NC2=CC=C(F)C=C12)C1=CC=CC=C1,,,,,0,,378.2107417,5,3,2,1,0,1
8664,04/06/2019 00:00,DB12831,Gabexate,,,,,,solid,,,0.109,,12.13,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1,,,,,0,,321.1688562,1,1,0,0,0,0
8665,04/06/2019 00:00,DB12832,Prednimustine,,,,,,,,,0.000642,12.61,1.72,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCC3=CC=C(C=C3)N(CCCl)CCCl)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,645.2623935,5,1,0,0,0,0
8666,04/06/2019 00:00,DB12833,Tandospirone,,,,,,,,,1.1,,7.62,[H][C@]12CC[C@]([H])(C1)[C@]1([H])C(=O)N(CCCCN3CCN(CC3)C3=NC=CC=N3)C(=O)[C@]21[H],,,,,0,,383.2321252,5,1,3,1,2,2
8667,04/06/2019 00:00,DB12834,Secnidazole,"Secnidazole is rapidly and completely absorbed after oral administration [A27210]. Following a single oral dose of 2 g in healthy adult female subjects, the mean (SD) secnidazole peak plasma concentration (Cmax) of 45.4 (7.64) mcg/mL and mean (SD) systemic exposure (AUC0-inf) of 1331.6 (230.16) mcg x hr/mL was reached. Median (range) time to peak concentration (Tmax) was 4.0 (3.0-4.0) hours [FDA Label]. ",5-15%,The plasma elimination half-life for secnidazole is approximately 17 hours [FDA Label]. ,2 g/4.8g,Oral,,,,4.88,15.16,3.08,CC(O)CN1C(C)=NC=C1N(=O)=O,0.05,0.15,,,0,,185.0800412,1,1,1,1,0,0
8668,04/06/2019 00:00,DB12836,Grapiprant,"Studies in animals (horse) have shown the presence of a concentration >0.005 ng/ml in serum 72 hours after initial administration of a dose of 2 mg/kg. It is rapidly absorbed and the reported Cmax in this reports was 31.9 ng/ml in a Tmax of 1.5 hours and AUC of 2000 ng.hr/ml.[A39836] In the case of bioavailability, grapiprant presents a mean bioavailability of 39%.[A39837] The bioavailability, time for peak concentration and maximal concentration has been reported to be significantly reduced after food.[A49842]",,The reported elimination half-life in animal studies (horse) is of 5.86 hours.[A39836],,,solid,Insoluble,4.56,0.00595,4.33,6.86,CCC1=NC2=C(C)N=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1,,,,,0,,491.1991108,4,4,2,2,0,0
8669,04/06/2019 00:00,DB12837,UK-500001,,,,,,,,,0.00285,8.55,-0.94,CC1=CC(C(=O)N[C@H]2CC[C@H](CC2)NC(=O)C2=C(OC3=CC(F)=C(F)C=C3)N=CC(F)=C2)=C(O)C=C1,,,,,0,,499.1718909,4,3,1,1,0,0
8670,04/06/2019 00:00,DB12838,Tetrasul,,,,,,,,,1.17E-05,,,ClC1=CC=C(SC2=C(Cl)C=C(Cl)C(Cl)=C2)C=C1,,,,,0,,321.8944319,2,2,0,0,0,0
8671,04/06/2019 00:00,DB12839,Pegvaliase,"At steady state during maintenance treatment with pegvaliase 20 mg and 40 mg subcutaneously once daily, the mean Â± SD (range) peak plasma concentration (Cmax) was 14.0 Â± 16.3 (0.26 to 68.5) mg/L and 16.7 Â± 19.5 (0.24 to 63.8) mg/L, respectively [FDA Label]. The time to reach Cmax (Tmax) was approximately 8 hours [FDA Label].",,"Following once-daily subcutaneous administration of 20 mg and 40 mg pegvaliase, the mean Â± SD (range) half-life at steady state was 47 Â± 42 (14 to 132) hours and 60 Â± 45 (14 to 127) hours, respectively [FDA Label].",10 mg/0.5mL,Subcutaneous,solid,,,0.63,2.24,9.53,COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O,,,,,0,,318.2154721,0,0,0,0,0,0
8672,04/06/2019 00:00,DB12840,Pirnabine,,,,,,,,,0.0191,,-4.9,CC1CCC2=C(C1)C1=C(OC2(C)C)C=C(C)C=C1OC(C)=O,,,,,0,,300.1725446,3,1,1,0,0,1
8673,04/06/2019 00:00,DB12843,Oleandrin,,,,,,,,,0.00299,6.82,-3.2,CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O,,,,,0,,576.3298331,6,0,2,0,1,2
8674,04/06/2019 00:00,DB12846,Reproterol,,,,,,,,,2.88,8.84,9.66,CN1C2=C(N(CCCNCC(O)C3=CC(O)=CC(O)=C3)C=N2)C(=O)N(C)C1=O,,,,,0,,389.1699188,3,3,2,2,0,0
8675,04/06/2019 00:00,DB12847,Pyroxamide,,,,,,,,,0.24,8.91,4.38,ONC(=O)CCCCCCC(=O)NC1=CN=CC=C1,,,,,0,,265.1426415,1,1,1,1,0,0
8676,04/06/2019 00:00,DB12848,PF-04217903,,,,,,,,,0.224,15.39,4.5,OCCN1C=C(C=N1)C1=CN=C2N=NN(CC3=CC4=CC=CN=C4C=C3)C2=N1,,,,,0,,372.1447071,5,5,4,4,0,0
8677,04/06/2019 00:00,DB12850,Etalocib,,,,,,,,,0.000267,3.6,-3.7,CCCC1=C(OCCCOC2=CC(O)=C(C=C2CC)C2=CC=C(F)C=C2)C=CC=C1OC1=CC=CC=C1C(O)=O,,,,,0,,544.226117,4,4,0,0,0,0
8678,04/06/2019 00:00,DB12852,MK-0752,,,,,,,,,0.0038,3.53,,OC(=O)CC[C@H]1CC[C@@](CC1)(C1=C(F)C=CC(F)=C1)S(=O)(=O)C1=CC=C(Cl)C=C1,,,,,0,,442.0817143,3,2,0,0,0,0
8679,04/06/2019 00:00,DB12853,DA-6886,,,,,,,,,0.209,14.5,9.22,COC1=CC(N)=C(Cl)C=C1C(=O)NCC1CCN(CCCN2C=CN=N2)CC1,,,,,0,,406.1884018,3,2,2,1,1,1
8680,04/06/2019 00:00,DB12854,BMS-908662,,,,,,,,,0.0136,9.64,4.15,COC(=O)NC1=NC2=CC(=CC=C2N1)C1(O)N(C(=O)C2=CC=CC=C12)C1=CC(Cl)=CC=C1C,,,,,0,,462.1094828,5,4,2,1,0,1
8681,04/06/2019 00:00,DB12855,Apricitabine,,,,,,,,,3.41,14.28,0.72,NC1=NC(=O)N(C=C1)[C@H]1CO[C@@H](CO)S1,,,,,0,,229.0521122,2,1,2,1,1,1
8682,04/06/2019 00:00,DB12856,Timonacic,,,,,,,,,84,2.59,7.7,OC(=O)C1CSCN1,,,,,0,,133.0197495,1,0,1,0,1,1
8683,04/06/2019 00:00,DB12857,NVP-LEQ-506,,,,,,,,,0.0331,13.84,5.02,C[C@@H]1CN(CCN1C1=CN=C(C=N1)C(C)(C)O)C1=NN=C(CC2=CC=CC=C2)C(C)=C1C,,,,,0,,432.2637596,4,3,3,2,1,1
8684,04/06/2019 00:00,DB12858,LY-377604,,,,,,,,,0.000366,13.37,9.5,CC(C)(CC1=CC=C(OC2=CC=C(C=N2)C(N)=O)C=C1)NC[C@H](O)COC1=CC=CC2=C1C1=C(N2)C=CC=C1,,,,,0,,524.2423555,5,5,2,2,0,0
8685,04/06/2019 00:00,DB12860,Actinium,,,,,,,,,0,,,[Ac],,,,,0,,227.0277521,0,0,0,0,0,0
8686,04/06/2019 00:00,DB12861,Rimeporide,,,,,,,,,0.157,10.08,6.98,CC1=CC(=C(C=C1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O,,,,,0,,333.0453126,1,1,0,0,0,0
8687,04/06/2019 00:00,DB12863,Sivelestat,,,,,,,,,0.0152,2.77,-1.6,CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O,,,,,0,,434.114772,2,2,0,0,0,0
8688,04/06/2019 00:00,DB12864,Melarsoprol,,,,,,,,,0.804,12.77,7.17,NC1=NC(NC2=CC=C(C=C2)[As]2SCC(CO)S2)=NC(N)=N1,,,,,0,,397.9964726,3,2,2,1,1,1
8689,04/06/2019 00:00,DB12865,Etelcalcetide,"The pharmacokinetics of etelcalcetide is linear and does not change over time following single (5 to 60 mg) and multiple intravenous doses (2.5 to 20 mg) in chronic kidney disease patients with secondary hyperparathyroidism requiring hemodialysis. Etelcalcetide exhibited tri-exponential decay following intravenous administration. Based on population pharmacokinetic analysis, following three times a week intravenous dosing at the end of each 3- to 6-hour hemodialysis session in chronic kidney disease patients, etelcalcetide plasma levels reached steady state in 7-8 weeks after dosing with a predicted accumulation ratio of 3- to 4-fold",,3 to 4 days,10 mg/2mL,Intravenous,,,,0.132,-1.3,12.57,C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O,,,,,0,,1047.52907,0,0,0,0,0,0
8690,04/06/2019 00:00,DB12866,Pradigastat,,,,,,,,,0.000507,5.03,4.31,OC(=O)C[C@H]1CC[C@@H](CC1)C1=CC=C(C=C1)C1=NC=C(NC2=CN=C(C=C2)C(F)(F)F)C=C1,,,,,0,,455.1820617,4,3,2,2,0,0
8691,04/06/2019 00:00,DB12867,Benperidol,,,,,,,,,0.0306,11.67,8.55,OC1=NC2=CC=CC=C2N1C1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1,,,,,0,,381.1852552,4,3,2,1,1,1
8692,04/06/2019 00:00,DB12868,Intoplicine,,,,,,,,,0.0113,8.85,10.63,CN(C)CCCNC1=NC=C(C)C2=C1C1=C(N2)C=CC2=CC(O)=CC=C12,,,,,0,,348.1950114,4,4,2,2,0,0
8693,04/06/2019 00:00,DB12869,Eliprodil,,,,,,,,,0.00558,14.07,8.88,OC(CN1CCC(CC2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,,,,,0,,347.1452203,3,2,1,0,1,1
8694,04/06/2019 00:00,DB12870,Buthionine Sulfoximine,,,,,,,,,2.2,2.18,9.09,CCCCS(=N)(=O)CCC(N)C(O)=O,,,,,0,,222.1038134,0,0,0,0,0,0
8695,04/06/2019 00:00,DB12873,Dianhydrogalactitol,,,,,,,,,1000,12.77,-3.6,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,,,,,0,,146.0579088,2,0,2,0,2,2
8696,04/06/2019 00:00,DB12874,Quizartinib,,,,,,,,,0.0509,10.43,6.62,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1,,,,,0,,560.2205745,6,5,4,3,1,1
8697,04/06/2019 00:00,DB12875,Mavatrep,,,,,,,,,0.000351,11.49,5.3,CC(C)(O)C1=CC=CC=C1C1=CC=C2N=C(NC2=C1)\C=C\C1=CC=C(C=C1)C(F)(F)F,,,,,0,,422.160598,4,4,1,1,0,0
8698,04/06/2019 00:00,DB12876,GS-9256,,,,,,,,,0.00136,1.55,0.88,COC1=C(Cl)C2=NC(=CC(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCCCC[C@@H]3C[C@]3(NC4=O)P(O)(=O)CC3=C(F)C=CC=C3F)NC(=O)OC3CCCC3)=C2C=C1)C1=CSC(NC(C)C)=N1,,,,,0,,956.3274545,8,4,4,2,2,2
8699,04/06/2019 00:00,DB12877,Oxatomide,,,,,,,,,0.0393,12.92,8.01,OC1=NC2=CC=CC=C2N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,426.2419616,5,4,2,1,1,1
8700,04/06/2019 00:00,DB12878,AV-101,,,,,,,,,0.634,0.92,8.96,N[C@@H](CC(=O)C1=C(N)C=C(Cl)C=C1)C(O)=O,,,,,0,,242.0458199,1,1,0,0,0,0
8701,04/06/2019 00:00,DB12879,Omigapil,,,,,,,,,0.0122,,7.31,CN(CC#C)CC1=CC2=CC=CC=C2OC2=CC=CC=C12,,,,,0,,275.1310142,3,2,1,0,0,1
8702,04/06/2019 00:00,DB12881,Indole-3-carbinol,,,,,,,,,3.75,15.1,-2.7,OCC1=CNC2=CC=CC=C12,,,,,0,,147.0684139,2,2,1,1,0,0
8703,04/06/2019 00:00,DB12882,Ombrabulin,,,,,,,,,0.0214,11.8,7.69,COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1NC(=O)[C@@H](N)CO,,,,,0,,402.1790866,2,2,0,0,0,0
8704,04/06/2019 00:00,DB12883,Eltoprazine,,,,,,,,,11.6,,8.83,C1CN(CCN1)C1=C2OCCOC2=CC=C1,,,,,0,,220.1211778,3,1,2,0,1,2
8705,04/06/2019 00:00,DB12884,Lavoltidine,,,,,,,,,0.291,13.45,8.74,CN1N=C(CO)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1,,,,,0,,359.2321252,3,2,2,1,1,1
8706,04/06/2019 00:00,DB12885,CF-102,,,,,,,,,0.0793,12.39,1.13,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(NCC3=CC=CC(I)=C3)N=C(Cl)N=C12,,,,,0,,544.0122787,4,3,3,2,1,1
8707,04/06/2019 00:00,DB12886,GSK-1521498,,,,,,,,,0.00111,10.58,8.11,FC1=CC(=CC(F)=C1CNC1CC2=CC=CC=C2C1)C1=CC=CC(=C1)C1=NNC=N1,,,,,0,,402.1656031,5,4,1,1,0,0
8708,04/06/2019 00:00,DB12887,Tazemetostat,,,,,,,,,0.00932,11.64,7.19,CCN(C1CCOCC1)C1=CC(=CC(C(=O)NCC2=C(C)C=C(C)NC2=O)=C1C)C1=CC=C(CN2CCOCC2)C=C1,,,,,0,,572.3362559,5,3,3,1,2,2
8709,04/06/2019 00:00,DB12888,Ezutromid,,,,,,,,,0.0138,,-1.4,CCS(=O)(=O)C1=CC=C2OC(=NC2=C1)C1=CC=C2C=CC=CC2=C1,,,,,0,,337.0772643,4,4,1,1,0,0
8710,04/06/2019 00:00,DB12889,Velneperit,,,,,,,,,0.0466,11.66,2.94,CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)NC1=NC=C(C=C1)C(F)(F)F,,,,,0,,407.1490473,2,1,1,1,0,0
8711,04/06/2019 00:00,DB12890,Dihydrexidine,,,,,,,,,0.0445,9.74,9.01,OC1=C(O)C=C2[C@H]3[C@H](CCC2=C1)NCC1=CC=CC=C31,,,,,0,,267.1259288,4,2,1,0,0,1
8712,04/06/2019 00:00,DB12892,MGB-BP-3,,,,,,,,,0.00445,14.23,5.99,CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC=C(\C=C\C4=CN=C5C=CC=CC5=C4)C=C3)=CN2C)C=C1C(=O)NCCN1CCOCC1,,,,,0,,631.2907027,6,5,4,3,1,1
8713,04/06/2019 00:00,DB12894,Raluridine,,,,,,,,,30.3,8.42,-3,OC[C@H]1O[C@H](C[C@@H]1F)N1C=C(Cl)C(=O)NC1=O,,,,,0,,264.0313127,2,1,2,1,1,1
8714,04/06/2019 00:00,DB12895,TD-139,,,,,,,,,0.774,12.54,0.021,OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)N2C=C(N=N2)C2=CC=CC(F)=C2)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CC(F)=CC=C1,,,,,0,,648.1813894,6,4,4,2,2,2
8715,04/06/2019 00:00,DB12896,PSI-352938,,,,,,,,,2.77,16.21,3.43,CCOC1=C2N=CN([C@@H]3O[C@@H]4CO[P@@](=O)(OC(C)C)O[C@H]4[C@@]3(C)F)C2=NC(N)=N1,,,,,0,,431.1369983,4,2,4,2,2,2
8716,04/06/2019 00:00,DB12897,MK-7622,,,,,,,,,0.0029,14.56,6.03,CC1=CC=C(CC2=CC3=C(N=CN([C@H]4CCCC[C@@H]4O)C3=O)C3=CC=CC=C23)C=N1,,,,,0,,399.194677,5,4,2,2,0,0
8717,04/06/2019 00:00,DB12899,TT-301,,,,,,,,,0.0726,,4.56,C1CN(CCN1C1=NC=CC=N1)C1=C(C=C(N=N1)C1=CC=CC=C1)C1=CC=NC=C1,,,,,0,,395.1858437,5,4,4,3,1,1
8718,04/06/2019 00:00,DB12900,Irdabisant,,,,,,,,,0.0675,10.43,9.57,C[C@@H]1CCCN1CCCOC1=CC=C(C=C1)C1=NNC(=O)C=C1,,,,,0,,313.179027,3,2,2,1,1,1
8719,04/06/2019 00:00,DB12901,Fiacitabine,,,,,,,,,0.468,5.22,0.89,[H][C@]1(CO)O[C@@]([H])(N2C=C(I)C(=N)N=C2O)[C@@]([H])(F)[C@]1([H])O,,,,,0,,370.9778321,2,1,2,1,1,1
8720,04/06/2019 00:00,DB12902,Trofosfamide,,,,,,,,,12,,0.15,ClCCN(CCCl)P1(=O)OCCCN1CCCl,,,,,0,,322.0171475,1,0,1,0,1,1
8721,04/06/2019 00:00,DB12903,DEBIO-1347,,,,,,,,,0.0172,12.18,6.83,CC1=NC2=CC=C(C=C2N1)N1N=CC(C(=O)C2=CC3=CC=CC=C3N2)=C1N,,,,,0,,356.1385591,5,5,3,3,0,0
8722,04/06/2019 00:00,DB12904,ZSTK-474,,,,,,,,,0.53,,5.74,FC(F)C1=NC2=CC=CC=C2N1C1=NC(=NC(=N1)N1CCOCC1)N1CCOCC1,,,,,0,,417.1724794,5,3,4,2,2,2
8723,04/06/2019 00:00,DB12906,LY-2334737,,,,,,,,,0.549,11.12,-2.4,CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,,,,,0,,389.1762273,2,1,2,1,1,1
8724,04/06/2019 00:00,DB12907,Mannose,,,,,,,,,261,11.8,-3,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)C=O,,,,,0,,180.0633881,0,0,0,0,0,0
8725,04/06/2019 00:00,DB12910,Emicerfont,,,,,,,,,0.296,15.54,9.34,COC1=CC=C(N2CCC3=C2N=C(C)C=C3N2C=CC(=N2)N2CCNC2=O)C(C)=C1,,,,,0,,404.196074,5,3,4,2,1,2
8726,04/06/2019 00:00,DB12911,Nicoboxil,"Specific investigations on absorption of dermally applied nicoboxil in laboratory animals or target species were not available [F12]. Published data for nicotinate esters related to nicoboxil indicated however, that members of this class of compounds are in principle able to penetrate skin [12].

Regardless, there is interest in the studies that demonstrate nicoboxil and nonivamide combination topical applications as effective and safe analgesic products precisely because such topical formulations are expected to have much lower systemic absorption - and thus less exposure to systemic side effects (ie. like gastrointestinal upset, drowsiness, etc.) - than the oral non-steroidal anti-inflammatory drugs, opioids, muscle relaxants, and steroids that may be more commonly prescribed over a rubefacient like nicoboxil [A32785, A32786].  

Nevertheless, despite the fact that topical nicoboxil and nonivamide products been available to use in some parts of Europe since the 1950s to treat discomfort of the muscuoskeletal system, the effects of nicoboxil and nonivamide have not been investigated in detail and a lack of detailed studies on nicoboxil pharmacodynamics and pharmacokinetics remains ongoing [A32785].",,"The half-life of ester hydrolysis was found to be very short in the presence of human serum albumin - less than 15 minutes, 50uM [F12].",,Topical,,,,6.1,,3.24,CCCCOCCOC(=O)C1=CN=CC=C1,,,,,0,,223.1208434,1,1,1,1,0,0
8727,04/06/2019 00:00,DB12912,Nolatrexed,,,,,,,,,0.0486,11.23,4.66,CC1=CC=C2N=C(N)NC(=O)C2=C1SC1=CC=NC=C1,,,,,0,,284.073182,3,3,2,2,0,0
8728,04/06/2019 00:00,DB12914,MGL-3196,,,,,,,,,0.0126,5.65,-5.2,CC(C)C1=CC(OC2=C(Cl)C=C(C=C2Cl)N2N=C(C#N)C(=O)NC2=O)=NNC1=O,,,,,0,,434.0297082,3,3,2,2,0,0
8729,04/06/2019 00:00,DB12916,Mitolactol,,,,,,,,,39.7,12.63,-3.5,O[C@@H](CBr)[C@@H](O)[C@@H](O)[C@H](O)CBr,,,,,0,,305.9102331,0,0,0,0,0,0
8730,04/06/2019 00:00,DB12919,T-62,,,,,,,,,0.00376,,-5.8,NC1=C(C(=O)C2=CC=C(Cl)C=C2)C2=C(CCCC2)S1,,,,,0,,291.0484627,3,2,1,1,0,0
8731,04/06/2019 00:00,DB12920,Pinometostat,,,,,,,,,0.0181,12.26,9.05,[H][C@]1(CCC2=NC3=C(N2)C=C(C=C3)C(C)(C)C)C[C@]([H])(C1)N(C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C(C)C,,,,,0,,562.3379872,6,4,4,3,1,1
8732,04/06/2019 00:00,DB12921,Chlorsulfaquinoxaline,,,,,,,,,0.0166,6.64,2.12,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC2=CC=CC(Cl)=C2N=C1,,,,,0,,334.0291243,3,3,1,1,0,0
8733,04/06/2019 00:00,DB12923,Gallopamil,,,,,,,,,0.00548,,9.68,COC1=CC(=CC(OC)=C1OC)C(CCCN(C)CCC1=CC(OC)=C(OC)C=C1)(C#N)C(C)C,,,,,0,,484.2937224,2,2,0,0,0,0
8734,02/07/2019 00:00,DB12924,Ozenoxacin,"Four studies were performed in which varying strengths of ozenoxacin cream, up to 2% (twice the concentration of the marketed formulation), were administered to 110 patients. Three of the studies examined systemic absorption in healthy subjects and in subjects having impetigo. The studies were performed with either single or repeated application of up to 1 g ozenoxacin cream to intact or abraded skin (up to 200 cm squared surface area). No systemic absorption was seen in 84 of 86 subjects, and negligible systemic absorption was seen at the level of detection (0.489 ng/mL) in 2 subjects [FDA Label, A31451].",~80-85%,,0.01,Topical,solid,,,0.103,6.1,6.77,CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O,0.8,0.85,,,0,,363.1582915,4,3,2,2,0,0
8735,04/06/2019 00:00,DB12925,Crolibulin,,,,,,,,,0.0177,,3.51,COC1=CC(=CC(Br)=C1OC)[C@@H]1C2=CC=C(N)C(N)=C2OC(N)=C1C#N,,,,,0,,416.0484025,3,2,1,0,0,1
8736,04/06/2019 00:00,DB12926,Cafedrine,,,,,,,,,1.56,13.89,9.43,C[C@H](NCCN1C=NC2=C1C(=O)N(C)C(=O)N2C)[C@H](O)C1=CC=CC=C1,,,,,0,,357.1800896,3,3,2,2,0,0
8737,04/06/2019 00:00,DB12927,Theodrenaline,,,,,,,,,3.71,9.36,8.66,CN1C2=C(N(CCNCC(O)C3=CC(O)=C(O)C=C3)C=N2)C(=O)N(C)C1=O,,,,,0,,375.1542688,3,3,2,2,0,0
8738,04/06/2019 00:00,DB12928,GET-73,,,,,,,,,0.0268,14.72,-1.7,COCCCC(=O)NCC1=CC=C(C=C1)C(F)(F)F,,,,,0,,275.1133134,1,1,0,0,0,0
8739,04/06/2019 00:00,DB12929,JNJ-39220675,,,,,,,,,0.205,,8.27,FC1=CC=C(OC2=CC=C(C=N2)C(=O)N2CCCN(CC2)C2CCC2)C=C1,,,,,0,,369.1852552,4,2,2,1,1,1
8740,04/06/2019 00:00,DB12930,Opipramol,,,,,,,,,0.105,15.59,7.86,OCCN1CCN(CCCN2C3=CC=CC=C3C=CC3=CC=CC=C23)CC1,,,,,0,,363.2310625,4,2,2,0,1,2
8741,04/06/2019 00:00,DB12931,Fenobam,,,,,,,,,0.552,11.44,-0.65,CN1CC(=O)N=C1NC(=O)NC1=CC(Cl)=CC=C1,,,,,0,,266.0570533,2,1,1,0,0,1
8742,04/06/2019 00:00,DB12932,Merotocin,,,,,,,,,0.0174,9.5,-6,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N(CC(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)CC1=CC=C(F)C=C1,,,,,0,,1041.475366,3,2,1,0,1,1
8743,04/06/2019 00:00,DB12933,RO-4987655,,,,,,,,,0.0164,6.65,4.73,OCCON=C(O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C(CN2OCCCC2=O)=C1,,,,,0,,565.0321534,3,2,1,0,1,1
8744,04/06/2019 00:00,DB12934,Granotapide,,,,,,,,,0.000104,13.44,-1.3,CCOC(=O)C(COC(=O)CC1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=C(C=C2)C(F)(F)F)C(=C1)C(=O)N(C)C)(C(=O)OCC)C1=CC=CC=C1,,,,,0,,718.2502008,4,4,0,0,0,0
8745,04/06/2019 00:00,DB12935,Remogliflozin etabonate,,,,,,,,,0.189,12.2,1.49,CCOC(=O)OC[C@H]1O[C@@H](OC2=NN(C(C)C)C(C)=C2CC2=CC=C(OC(C)C)C=C2)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,522.2577308,3,2,2,1,1,1
8746,04/06/2019 00:00,DB12937,Quercetin-3'-O-phosphate,,,,,,,,,0.105,1.87,-4,OC1=CC(O)=C2C(=O)C(O)=C(OC2=C1)C1=CC(OP(O)(O)=O)=C(O)C=C1,,,,,0,,382.0089832,3,3,1,1,0,0
8747,04/06/2019 00:00,DB12938,Isoxaflutole,,,,,,,,,0.0472,19.6,-0.48,[H]C1=NOC(=C1C(=O)C1=C(C([H])=C(C([H])=C1[H])C(F)(F)F)S(=O)(=O)C([H])([H])[H])C1([H])C([H])([H])C1([H])[H],,,,,0,,359.0439135,3,2,1,1,0,0
8748,04/06/2019 00:00,DB12939,Nikkomycin Z,,,,,,,,,4.47,2.61,7.77,C[C@@H]([C@H](N)C(=O)N[C@@H]([C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O)C(O)=O)[C@H](O)C1=CC=C(O)C=N1,,,,,0,,495.160142,3,2,3,2,1,1
8749,04/06/2019 00:00,DB12941,ODM-201,,,,,,,,,0.0727,9.81,2.37,C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O,,,,,0,,398.1258015,3,3,2,2,0,0
8750,04/06/2019 00:00,DB12942,Lactitol,,,,,,,,,377,12.1,-3,[H][C@](O)(CO)[C@@]([H])(O)[C@]([H])(O[C@]1([H])O[C@]([H])(CO)[C@]([H])(O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)CO,,,,,0,,344.1318616,1,0,1,0,1,1
8751,04/06/2019 00:00,DB12944,Phloroglucinol,,,,,,,,,35.8,9.13,-5.4,OC1=CC(O)=CC(O)=C1,,,,,0,,126.0316941,1,1,0,0,0,0
8752,04/06/2019 00:00,DB12945,Dihydralazine,,,,,,,,,0.961,10.38,-1.2,NN=C1NNC(=NN)C2=CC=CC=C12,,,,,0,,190.0966943,2,2,1,1,0,0
8753,04/06/2019 00:00,DB12946,"8-cyclopentyl-1,3-dipropylxanthine",,,,,,,,,0.594,11.57,2.62,CCCN1C2=C(N=C(N2)C2CCCC2)C(=O)N(CCC)C1=O,,,,,0,,304.189926,3,2,2,2,0,0
8754,04/06/2019 00:00,DB12947,Doxifluridine,,,,,,,,,5.36,6.2,-3.6,C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=C(F)C(O)=NC1=O,,,,,0,,246.0651997,2,1,2,1,1,1
8755,04/06/2019 00:00,DB12948,Didox,,,,,,,,,5.54,8.32,-5.1,ONC(=O)C1=CC(O)=C(O)C=C1,,,,,0,,169.0375077,1,1,0,0,0,0
8756,04/06/2019 00:00,DB12949,PF-03382792,,,,,,,,,0.0618,14.23,9.62,CC1(C)C(=O)N(C(=O)NCC2CCN(CC3(O)CCOCC3)CC2)C2=CC(F)=CC=C12,,,,,0,,433.2376847,4,1,3,0,2,3
8757,04/06/2019 00:00,DB12951,Pivagabine,,,,,,,,,1.18,4.13,6.6,CC(C)(C)C(O)=NCCCC(O)=O,,,,,0,,187.1208434,0,0,0,0,0,0
8758,04/06/2019 00:00,DB12952,Methylprednisone,,,,,,,,,0.0587,12.58,-3.3,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,,,,,0,,372.193674,4,0,0,0,0,0
8759,04/06/2019 00:00,DB12954,Terizidone,,,,,,,,,0.252,3.54,2.75,O=C1NOCC1\N=C\C1=CC=C(\C=N\C2CONC2=O)C=C1,,,,,0,,302.1015049,3,1,2,0,2,2
8760,04/06/2019 00:00,DB12955,Delparantag,,,,,,,,,0.00453,12.96,10.81,COC1=CC=C(NC(=O)[C@H](CCCCN)NC(=O)C2=CC(NC(=O)[C@H](CCCCN)NC(=O)C3=CC(NC(=O)[C@H](CCCCN)NC(=O)C4=CC(NC(=O)[C@@H](N)CCCCN)=CC=C4OC)=CC=C3OC)=CC=C2OC)C=C1C(N)=O,,,,,0,,1125.597115,4,4,0,0,0,0
8761,04/06/2019 00:00,DB12957,5-fluoro-2'-deoxycytidine,,,,,,,,,0.556,8.81,0.2,[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO)N1C=C(F)C(=N)N=C1O,,,,,0,,245.0811841,2,1,2,1,1,1
8762,04/06/2019 00:00,DB12958,Prothipendyl,,,,,,,,,0.128,,9.2,CN(C)CCCN1C2=CC=CC=C2SC2=C1N=CC=C2,,,,,0,,285.1299686,3,2,2,1,0,1
8763,04/06/2019 00:00,DB12959,IOWH-032,,,,,,,,,0.0342,5.81,-2.6,OC1=C(Br)C=C(C=C1Br)C1=NOC(=N1)C(=O)NCC1=CC=C(OC2=CC=CC=C2)C=C1,,,,,0,,542.9429302,4,4,1,1,0,0
8764,04/06/2019 00:00,DB12960,INCB-9471,,,,,,,,,0.0287,,8.42,CCO[C@@H]1CC2=CC(=CC=C2[C@H]1N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1=C(C)N=CN=C1C)C(F)(F)F,,,,,0,,559.3134102,5,2,3,1,2,2
8765,04/06/2019 00:00,DB12961,Leukotriene B4,,,,,,,,,0.0152,4.65,-1.3,CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O,,,,,0,,336.2300595,0,0,0,0,0,0
8766,04/06/2019 00:00,DB12962,CP-547632,,,,,,,,,0.00366,7.55,10.07,NC(=O)C1=C(NC(O)=NCCCCN2CCCC2)SN=C1OCC1=C(F)C=C(Br)C=C1F,,,,,0,,531.0751292,3,2,2,1,1,1
8767,04/06/2019 00:00,DB12963,CCX-354,,,,,,,,,0.114,11.15,5.05,COC1=CC(=CC=C1Cl)N1CCN(CC1)C(=O)CN1N=C(C2=NC=CN2)C2=CC=CN=C12,,,,,0,,451.1523506,5,4,4,3,1,1
8768,04/06/2019 00:00,DB12964,Lerisetron,,,,,,,,,0.435,,8.84,C(N1C2=CC=CC=C2N=C1N1CCNCC1)C1=CC=CC=C1,,,,,0,,292.1687966,4,3,2,1,1,1
8769,04/06/2019 00:00,DB12966,Falnidamol,,,,,,,,,0.0468,13.6,8.45,CN1CCC(CC1)NC1=NC=C2N=CN=C(NC3=CC=C(F)C(Cl)=C3)C2=N1,,,,,0,,387.1374495,4,3,3,2,1,1
8770,04/06/2019 00:00,DB12967,Mitoguazone,,,,,,,,,0.313,17.98,9.06,CC(\C=N\NC(N)=N)=NNC(N)=N,,,,,0,,184.1184924,0,0,0,0,0,0
8771,04/06/2019 00:00,DB12968,DONU,,,,,,,,,4.15,12.37,-3,O[C@H]1CCC[C@@H](O)[C@@H]1NC(=O)N(CCCl)N=O,,,,,0,,265.0829337,1,0,0,0,0,0
8772,04/06/2019 00:00,DB12969,Methylinositol,,,,,,,,,544,12.36,-3.6,CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O,,,,,0,,194.0790382,1,0,0,0,0,0
8773,04/06/2019 00:00,DB12970,Levoglucose,,,,,,,,,261,12.26,-3,OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C=O,,,,,0,,180.0633881,0,0,0,0,0,0
8774,04/06/2019 00:00,DB12971,Pactimibe,,,,,,,,,0.00222,4.74,3.6,CCCCCCCCN1CCC2=C1C(NC(=O)C(C)(C)C)=C(C)C(CC(O)=O)=C2C,,,,,0,,416.3038931,2,1,1,0,0,1
8775,04/06/2019 00:00,DB12972,Sepranolone,,,,,,,,,0.00136,18.3,-1.4,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C,,,,,0,,318.2558803,4,0,0,0,0,0
8776,04/06/2019 00:00,DB12973,Serlopitant,,,,,,,,,0.00496,17.12,2.07,C[C@@H](O[C@H]1CC[C@@H]2CN(C[C@H]2[C@@H]1C1=CC=C(F)C=C1)C1=CC(=O)CC1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,,,,,0,,555.2008267,5,2,1,0,1,1
8777,04/06/2019 00:00,DB12974,Roniciclib,,,,,,,,,0.0496,11.8,2.5,C[C@@H](O)[C@@H](C)OC1=C(C=NC(NC2=CC=C(C=C2)[S@](=N)(=O)C2CC2)=N1)C(F)(F)F,,,,,0,,430.1286462,3,2,1,1,0,0
8778,04/06/2019 00:00,DB12975,Pyronaridine,,,,,,,,,0.0132,7.96,10.08,COC1=NC2=C(NC3=CC(CN4CCCC4)=C(O)C(CN4CCCC4)=C3)C3=CC=C(Cl)C=C3N=C2C=C1,,,,,0,,517.2244529,6,4,4,2,2,2
8779,04/06/2019 00:00,DB12977,Simenepag isopropyl,,,,,,,,,0.00115,14.46,-3,CCCCC[C@H](O)C1=CC=C(C=C1)N1[C@@H](COCC2=CC=C(S2)C(=O)OC(C)C)CCC1=O,,,,,0,,473.2235942,3,2,2,1,1,1
8780,04/06/2019 00:00,DB12978,Pexidartinib,,,,,,,,,0.00315,15.68,6.76,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,,,,,0,,417.0968078,4,4,4,4,0,0
8781,04/06/2019 00:00,DB12979,Nepicastat,,,,,,,,,0.062,10.3,8.28,NCC1=CNC(=S)N1[C@H]1CCC2=C(C1)C=C(F)C=C2F,,,,,0,,295.0954749,3,2,1,1,0,0
8782,04/06/2019 00:00,DB12980,CHS-828,,,,,,,,,0.00815,19.11,5.61,ClC1=CC=C(OCCCCCCNC(NC2=CC=NC=C2)=NC#N)C=C1,,,,,0,,371.151288,2,2,1,1,0,0
8783,04/06/2019 00:00,DB12981,XL-888,,,,,,,,,0.0289,8.17,6.73,[H][C@@](C)(CC)NC1=C(C=C(C)C(=C1)C(O)=N[C@]1([H])C[C@]2([H])CC[C@]([H])(C1)N2C1=NC=C(C=C1)C(=O)C1CC1)C(O)=N,,,,,0,,503.28964,5,2,3,1,2,2
8784,04/06/2019 00:00,DB12983,Phthalocyanine,,,,,,,,,0.0105,5.52,2.52,N1C2=C3C=CC=CC3=C1\N=C1/N=C(/N=C3\N=C(NC4=N\C(=N/2)C2=CC=CC=C42)C2=CC=CC=C32)C2=CC=CC=C12,,,,,0,,514.1654426,9,6,5,2,0,3
8785,04/06/2019 00:00,DB12984,Larotaxel,,,,,,,,,0.00567,11.26,-3.6,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@H]3[C@]4(C[C@H]4C[C@H]4OC[C@@]34OC(C)=O)C1=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,,,,,0,,831.3466054,7,2,1,0,1,1
8786,04/06/2019 00:00,DB12985,Quisinostat,,,,,,,,,0.0716,9.17,10.06,CN1C=C(CNCC2CCN(CC2)C2=NC=C(C=N2)C(=O)NO)C2=CC=CC=C12,,,,,0,,394.2117241,4,3,3,2,1,1
8787,04/06/2019 00:00,DB12986,VS-5584,,,,,,,,,0.557,16,3.14,CC(C)N1C(C)=NC2=C(N=C(N=C12)N1CCOCC1)C1=CN=C(N)N=C1,,,,,0,,354.1916573,4,3,4,3,1,1
8788,04/06/2019 00:00,DB12987,Penclomedine,,,,,,,,,0.0217,,-0.92,COC1=C(Cl)C(OC)=C(Cl)C(=N1)C(Cl)(Cl)Cl,,,,,0,,322.8841168,1,1,1,1,0,0
8789,04/06/2019 00:00,DB12988,LY-518674,,,,,,,,,0.00751,3.87,-4,CC1=CC=C(CN2N=C(CCCC3=CC=C(OC(C)(C)C(O)=O)C=C3)NC2=O)C=C1,,,,,0,,409.2001563,3,3,1,1,0,0
8790,04/06/2019 00:00,DB12989,Neosaxitoxin,,,,,,,,,4.19,10.6,9.14,NC(=O)OC[C@H]1[C@@H]2NC(N)=N[C@]22N(CCC2(O)O)C(=N)N1O,,,,,0,,315.1291166,3,0,3,0,2,3
8791,04/06/2019 00:00,DB12990,Icosabutate,,,,,,,,,0.000116,4.26,-4.2,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(O)=O,,,,,0,,374.2820951,0,0,0,0,0,0
8792,04/06/2019 00:00,DB12991,Deoxyspergualin,,,,,,,,,0.129,11.37,12.28,NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N,,,,,0,,387.295788,0,0,0,0,0,0
8793,04/06/2019 00:00,DB12994,MIP-1095 I-123,,,,,,,,,0.101,3.09,,OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)NC1=CC=C([123I])C=C1)C(O)=O)C(O)=O,,,,,0,,560.0728278,1,1,0,0,0,0
8794,04/06/2019 00:00,DB12996,Acteoside,,,,,,,,,0.966,9.01,-3.6,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCC3=CC(O)=C(O)C=C3)O[C@H](CO)[C@H]2OC(=O)\C=C\C2=CC(O)=C(O)C=C2)[C@H](O)[C@H](O)[C@H]1O,,,,,0,,624.2054205,4,2,2,0,2,2
8795,04/06/2019 00:00,DB12997,Brilacidin,,,,,,,,,0.0158,10.05,12.36,NC(=N)NCCCCC(=O)NC1=C(O[C@@H]2CCNC2)C(NC(=O)C2=CC(=NC=N2)C(=O)NC2=CC(=CC(NC(=O)CCCCNC(N)=N)=C2O[C@@H]2CCNC2)C(F)(F)F)=CC(=C1)C(F)(F)F,,,,,0,,936.3941946,5,3,3,1,2,2
8796,04/06/2019 00:00,DB12998,PF-00217830,,,,,,,,,0.0336,11.89,8.43,O=C1CCC2=CC=C(OCCCCN3CCN(CC3)C3=CC=CC4=CC=CC=C34)N=C2N1,,,,,0,,430.2368762,5,3,3,1,1,2
8797,04/06/2019 00:00,DB12999,MK-6186,,,,,,,,,0.0225,9.99,2.13,ClC1=CC(OC2=C3C=NN(CC4=NNC5=NC=CC=C45)C3=CC=C2Cl)=CC(=C1)C#N,,,,,0,,434.0449644,5,5,3,3,0,0
8798,04/06/2019 00:00,DB13000,PCI-27483,,,,,,,,,0.0417,2.96,11.66,NC(=N)C1=CC=C2N=C(NC2=C1)C1=CC(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=CC(=C1O)C1=CC(=CC=C1O)S(N)(=O)=O,,,,,0,,596.1325473,4,4,1,1,0,0
8799,04/06/2019 00:00,DB13001,Tinoridine,,,,,,,,,0.021,17.65,7.31,CCOC(=O)C1=C(N)SC2=C1CCN(CC1=CC=CC=C1)C2,,,,,0,,316.1245489,3,2,2,1,0,1
8800,04/06/2019 00:00,DB13002,HKI-357,,,,,,,,,0.00395,12.55,8.81,CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)=C(C=NC2=C1)C#N,,,,,0,,573.1942957,4,4,1,1,0,0
8801,04/06/2019 00:00,DB13003,Cortivazol,,,,,,,,,0.0033,12.47,2.05,C[C@@H]1C[C@H]2[C@@H]3C=C(C)C4=CC5=C(C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O)C=NN5C1=CC=CC=C1,,,,,0,,530.2780723,6,2,1,1,0,0
8802,04/06/2019 00:00,DB13004,Mavoglurant,,,,,,,,,0.0246,12.87,-3.7,COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#CC1=CC(C)=CC=C1,,,,,0,,313.1677936,3,1,1,0,1,1
8803,04/06/2019 00:00,DB13005,Rebastinib,,,,,,,,,0.00469,7.67,4.73,CNC(=O)C1=NC=CC(OC2=CC(F)=C(C=C2)N=C(O)NC2=CC(=NN2C2=CC=C3N=CC=CC3=C2)C(C)(C)C)=C1,,,,,0,,553.223766,5,5,3,3,0,0
8804,04/06/2019 00:00,DB13006,Cibinetide,,,,,,,,,0.232,2.91,11.67,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O,,,,,0,,1256.599694,1,0,1,0,1,1
8805,04/06/2019 00:00,DB13008,"2,2-bis(4-hydroxy-3-tert-butylphenyl)propane",,,,,,,,,0.000672,10.4,-5,CC(C)(C)C1=CC(=CC=C1O)C(C)(C)C1=CC=C(O)C(=C1)C(C)(C)C,,,,,0,,340.2402303,2,2,0,0,0,0
8806,04/06/2019 00:00,DB13009,Carbendazim,,,,,,,,,0.825,9.7,4.28,COC(=O)NC1=NC2=CC=CC=C2N1,,,,,0,,191.0694765,2,2,1,1,0,0
8807,04/06/2019 00:00,DB13010,4-isothioureidobutyronitrile,,,,,,,,,5.69,,10.59,NC(=N)SCCCC#N,,,,,0,,143.0517183,0,0,0,0,0,0
8808,04/06/2019 00:00,DB13011,Diethylhomospermine,,,,,,,,,0.0826,,11.29,CCNCCCCNCCCCNCCCCNCC,,,,,0,,286.3096472,0,0,0,0,0,0
8809,04/06/2019 00:00,DB13012,AQX-1125,,,,,,,,,0.0202,15.04,10.2,C[C@]12CC[C@@H]([C@@H](CN)[C@@H]1CCC2=C)[C@@]1(C)CC[C@H](O)C[C@@H]1CO,,,,,0,,321.2667794,3,0,0,0,0,0
8810,04/06/2019 00:00,DB13013,LFF-571,,,,,,,,,0.0057,3.54,0.3,CNC(=O)C[C@@H]1NC(=O)C2=CSC(=N2)C2=CC=C(N=C2C2=CSC(=N2)C2=CSC(=N2)[C@@H](NC(=O)CNC(=O)C2=C(COC)SC(=N2)[C@@H](NC(=O)C2=C(C)SC1=N2)C(C)C)[C@@H](O)C1=CC=CC=C1)C1=NC(=CS1)N(CCCCC(O)=O)C(=O)O[C@H]1CC[C@@H](CC1)C(O)=O,,,,,0,,1365.299255,10,8,8,7,0,1
8811,04/06/2019 00:00,DB13014,Hypericin,,,,,,,,,0.00732,1.39,16.11,CC1=CC(O)=C2C(=O)C3=C(O)C=C(O)C4=C3C3=C2C1=C1C(C)=CC(O)=C2C(=O)C5=C(O)C=C(O)C4=C5C3=C12,,,,,0,,504.0845175,8,8,0,0,0,0
8812,04/06/2019 00:00,DB13016,LY-2300559,,,,,,,,,0.00275,4.01,-3.4,CCCC1=C(OCC2=CC=C(C=C2)[C@H](O)C2=CC=CC(=C2)C(O)=O)C=CC(C(C)=O)=C1O,,,,,0,,434.1729386,3,3,0,0,0,0
8813,04/06/2019 00:00,DB13018,Dimiracetam,,,,,,,,,169,11.16,-2.4,O=C1CN2C(CCC2=O)N1,,,,,0,,140.0585775,2,0,2,0,2,2
8814,04/06/2019 00:00,DB13019,Henatinib,,,,,,,,,0.202,11.46,6.46,CC1=C(NC2=C1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2)\C=C1/C(=O)NC2=CC=C(F)C=C12,,,,,0,,468.2172836,5,2,4,1,1,3
8815,04/06/2019 00:00,DB13020,Apratastat,,,,,,,,,0.0416,8.7,-3.1,CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)C1=CC=C(OCC#CCO)C=C1,,,,,0,,414.0919284,2,1,1,0,1,1
8816,04/06/2019 00:00,DB13021,123I-iodometomidate,,,,,,,,,0.0459,,4.55,COC(=O)C1=CN=CN1[C@H](C)C1=CC=C(I)C=C1,,,,,0,,356.0021757,2,2,1,1,0,0
8817,04/06/2019 00:00,DB13022,LY-2874455,,,,,,,,,0.00392,14.13,2.46,C[C@@H](OC1=CC=C2NN=C(\C=C\C3=CN(CCO)N=C3)C2=C1)C1=C(Cl)C=NC=C1Cl,,,,,0,,443.0915802,4,4,3,3,0,0
8818,04/06/2019 00:00,DB13023,IPI-493,,,,,,,,,0.0124,12.78,-3.3,CO[C@H]1C[C@H](C)CC2=C(N)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O,,,,,0,,545.2737152,2,0,1,0,0,1
8819,04/06/2019 00:00,DB13024,MK-8245,,,,,,,,,0.475,3.47,0.08,OC(=O)CN1N=NC(=N1)C1=CC(=NO1)N1CCC(CC1)OC1=C(Br)C=CC(F)=C1,,,,,0,,466.0400433,4,3,3,2,1,1
8820,04/06/2019 00:00,DB13025,Tiapride,"The bioavailability of tiapride is approximately 75 percent. It has a Tmax is 0.4-1.5 hours and Tss is 24-48 hours with 3 time daily dosing.  Benzamide and its derivatives are highly water-soluble but known to cross the blood-brain barrier, necessitating carrier-mediated transport. ",,2.9â€“3.6 hours,,,,,,0.139,6.46,8.17,CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O,,,2.9,3.6,0,,328.1456782,1,1,0,0,0,0
8821,04/06/2019 00:00,DB13026,Ornidazole,,,,,,,,,3.34,13.89,3.08,CC1=NC=C(N1CC(O)CCl)N(=O)=O,,,,,0,,219.0410689,1,1,1,1,0,0
8822,04/06/2019 00:00,DB13027,Tucaresol,,,,,,,,,0.0362,4.06,-4.9,OC(=O)C1=CC=C(COC2=CC=CC(O)=C2C=O)C=C1,,,,,0,,272.0684735,2,2,0,0,0,0
8823,04/06/2019 00:00,DB13028,Biapenem,,,,,,,,,2.75,3.51,-1.6,[H][C@](C)(O)[C@@]1([H])C(=O)N2C(C([O-])=O)=C(SC3CN4C=NC=[N+]4C3)[C@]([H])(C)[C@]12[H],,,,,0,,350.1048761,4,1,4,1,1,3
8824,04/06/2019 00:00,DB13029,MK-0873,,,,,,,,,0.00503,14.29,1.9,[O-][N+]1=CC(=CC=C1)C#CC1=CC(=CC=C1)N1C=C(C(=O)NC2CC2)C(=O)C2=CC=CN=C12,,,,,0,,422.1378904,5,4,3,3,0,0
8825,04/06/2019 00:00,DB13030,2'-fluoro-5-ethylarabinosyluracil,,,,,,,,,120,9.85,-3,OC[C@H]1O[C@H]([C@@H](F)[C@@H]1O)N1C=CC(=O)NC1=O,,,,,0,,246.0651997,2,1,2,1,1,1
8826,04/06/2019 00:00,DB13032,Enecadin,,,,,,,,,0.0141,,9.82,CC1=NC(=CC(OCCCCCN2CCCCC2)=N1)C1=CC=C(F)C=C1,,,,,0,,357.2216407,3,2,2,1,1,1
8827,04/06/2019 00:00,DB13034,Foxy-5,,,,,,,,,0.033,3.39,,CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O,,,,,0,,694.2302128,0,0,0,0,0,0
8828,04/06/2019 00:00,DB13035,AG-24322,,,,,,,,,0.00401,9.69,9.03,CCNCC1=CN=CC(=C1C)C1=CC=C2NN=C(C3=NC4=C(F)C=C(F)C=C4N3)C2=C1,,,,,0,,418.1717511,5,5,3,3,0,0
8829,04/06/2019 00:00,DB13036,Ramatroban,,,,,,,,,0.0227,4.39,,[H][C@]1(CCC2=C(C1)C1=CC=CC=C1N2CCC(O)=O)NS(=O)(=O)C1=CC=C(F)C=C1,,,,,0,,416.1206064,4,3,1,1,0,0
8830,04/06/2019 00:00,DB13038,Glyceryl Trioleate,,,,,,,,,6.14E-06,,-6.6,CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COC(=O)CCCCCCC\C=C/CCCCCCCC)OC(=O)CCCCCCC\C=C/CCCCCCCC,,,,,0,,884.783291,0,0,0,0,0,0
8831,04/06/2019 00:00,DB13039,Aminaphthone,,,,,,,,,0.0147,9.55,2.54,CC1=C(OC(=O)C2=CC=C(N)C=C2)C(O)=C2C=CC=CC2=C1O,,,,,0,,309.100108,3,3,0,0,0,0
8832,04/06/2019 00:00,DB13040,Gandotinib,,,,,,,,,0.0144,12.56,5.74,CC1=CC(NC2=NN3C(CC4=CC=C(Cl)C=C4F)=C(C)N=C3C(CN3CCOCC3)=C2)=NN1,,,,,0,,469.1793143,5,4,4,3,1,1
8833,04/06/2019 00:00,DB13041,Odalasvir,,,,,,,,,0.000969,10.94,5.25,COC(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](C[C@@H]2CCCC[C@H]12)C1=NC2=CC=C(C=C2N1)C1=CC2=CC=C1CCC1=CC=C(CC2)C(=C1)C1=CC=C2N=C(NC2=C1)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@@H](NC(=O)OC)C(C)C,,,,,0,,1000.557482,14,6,4,2,2,2
8834,04/06/2019 00:00,DB13042,Fenoverine,,,,,,,,,0.0259,16.18,6.64,O=C(CN1CCN(CC2=CC3=C(OCO3)C=C2)CC1)N1C2=CC=CC=C2SC2=CC=CC=C12,,,,,0,,459.1616627,6,3,3,0,1,3
8835,04/06/2019 00:00,DB13044,Gossypol,,,,,,,,,0.00385,7.8,-6.1,CC(C)C1=C2C=C(C)C(=C(O)C2=C(C=O)C(O)=C1O)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C,,,,,0,,518.1940679,4,4,0,0,0,0
8836,04/06/2019 00:00,DB13046,Tocladesine,,,,,,,,,3.04,1.78,2.77,NC1=C2N=C(Cl)N([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)C2=NC=N1,,,,,0,,363.0135474,4,2,4,2,2,2
8837,04/06/2019 00:00,DB13048,PAC-1,,,,,,,,,0.0859,8.58,7.17,OC1=C(\C=N\NC(=O)CN2CCN(CC3=CC=CC=C3)CC2)C=CC=C1CC=C,,,,,0,,392.2212261,3,2,1,0,1,1
8838,04/06/2019 00:00,DB13050,Tirilazad,,,,,,,,,0.0773,18.26,6.59,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(CC1)C1=CC(=NC(=N1)N1CCCC1)N1CCCC1,,,,,0,,624.4151749,8,1,4,1,3,3
8839,04/06/2019 00:00,DB13051,CH-5132799,,,,,,,,,0.25,6.77,14.21,CS(=O)(=O)N1CCC2=C(N=C(N=C12)N1CCOCC1)C1=CNC(=N)N=C1,,,,,0,,377.1270085,4,2,4,2,1,2
8840,04/06/2019 00:00,DB13052,Upamostat,,,,,,,,,0.00497,9.16,4.98,CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC1=CC=CC(=C1)C(\N)=N/O)NS(=O)(=O)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C,,,,,0,,629.3247052,3,2,1,0,1,1
8841,04/06/2019 00:00,DB13053,CP-195543,,,,,,,,,0.00161,3.65,-3.3,O[C@@H]1[C@@H](CC2=CC=CC=C2)COC2=CC(=CC=C12)C1=CC(=CC=C1C(O)=O)C(F)(F)F,,,,,0,,428.1235437,4,3,1,0,0,1
8842,04/06/2019 00:00,DB13054,ACT-451840,,,,,,,,,0.00419,17.93,6.35,CC(=O)N1CCN(CC1)C1=CC=C(CN([C@@H](CC2=CC=CC=C2)C(=O)N2CCN(CC3=CC=C(C=C3)C#N)CC2)C(=O)\C=C\C2=CC=C(C=C2)C(C)(C)C)C=C1,,,,,0,,750.4257396,6,4,2,0,2,2
8843,04/06/2019 00:00,DB13055,Oteseconazole,,,,,,,,,0.00458,10.67,2.01,O[C@@](CN1C=NN=N1)(C1=CC=C(F)C=C1F)C(F)(F)C1=CC=C(C=N1)C1=CC=C(OCC(F)(F)F)C=C1,,,,,0,,527.1192223,4,4,2,2,0,0
8844,04/06/2019 00:00,DB13056,Irsogladine,,,,,,,,,0.52,15.57,5.32,NC1=NC(=NC(N)=N1)C1=C(Cl)C=CC(Cl)=C1,,,,,0,,255.0078506,2,2,1,1,0,0
8845,04/06/2019 00:00,DB13058,Methanesulfonyl Fluoride,,,,,,,,,5.16,,,CS(F)(=O)=O,,,,,0,,97.98377856,0,0,0,0,0,0
8846,04/06/2019 00:00,DB13059,PF-03814735,,,,,,,,,0.0377,12.57,4.24,CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C1=C2C=CC(NC2=NC=C(C(NC3CCC3)=N2)C(F)(F)F)=C1,,,,,0,,474.1991087,5,2,3,1,1,2
8847,04/06/2019 00:00,DB13060,CEP-37440,,,,,,,,,0.0226,12.72,8.32,CNC(=O)C1=CC=CC=C1NC1=C(Cl)C=NC(NC2=CC=C3C[C@H](CCCC3=C2OC)N2CCN(CCO)CC2)=N1,,,,,0,,579.2724658,5,3,2,1,1,1
8848,04/06/2019 00:00,DB13061,MLN8054,,,,,,,,,0.00087,4.59,2.81,OC(=O)C1=CC=C(NC2=NC=C3CN=C(C4=C(C=CC(Cl)=C4)C3=N2)C2=C(F)C=CC=C2F)C=C1,,,,,0,,476.0851598,5,4,2,1,0,1
8849,04/06/2019 00:00,DB13062,ME-344,,,,,,,,,0.00747,9.58,-4.9,CC1=C(O)C=CC2=C1OC[C@H]([C@H]2C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,,,,,0,,348.1361591,4,3,1,0,0,1
8850,04/06/2019 00:00,DB13063,Parthenolide,,,,,,,,,0.196,,-4.2,C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,,,,,0,,248.1412445,3,0,2,0,2,2
8851,04/06/2019 00:00,DB13064,Tramazoline,,,,,,,,,0.408,,9.89,C1CN=C(NC2=CC=CC3=C2CCCC3)N1,,,,,0,,215.1422475,3,1,1,0,0,1
8852,04/06/2019 00:00,DB13065,LY-2811376,,,,,,,,,0.0279,,8.23,C[C@]1(CCSC(N)=N1)C1=CC(=C(F)C=C1F)C1=CN=CN=C1,,,,,0,,320.0907239,3,2,2,1,0,1
8853,04/06/2019 00:00,DB13066,Liarozole,,,,,,,,,0.0179,12.2,6.74,ClC1=CC=CC(=C1)C(N1C=CN=C1)C1=CC=C2N=CNC2=C1,,,,,0,,308.0828741,4,4,2,2,0,0
8854,04/06/2019 00:00,DB13067,Rotigaptide,,,,,,,,,1.56,9.5,-1.9,C[C@@H](NC(=O)CNC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H]1CCCN1C(=O)[C@@H](CC1=CC=C(O)C=C1)NC(C)=O)C(=O)NCC(N)=O,,,,,0,,617.2809258,3,1,2,0,2,2
8855,04/06/2019 00:00,DB13068,9-(N-methyl-L-isoleucine)-cyclosporin A,,,,,,,,,0.00967,11.83,-2.4,CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC1=O)C(C)C,,,,,0,,1201.841368,1,0,1,0,1,1
8856,04/06/2019 00:00,DB13069,Nimustine,,,,,,,,,0.093,4.25,2.75,CC1=NC=C(CN=C(O)N(CCCl)N=O)C(=N)N1,,,,,0,,272.0788513,1,1,1,1,0,0
8857,04/06/2019 00:00,DB13070,Surinabant,,,,,,,,,0.00176,5.86,1.26,CCC1=C(N(N=C1C(O)=NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Br)C=C1,,,,,0,,520.0432288,4,3,2,1,1,1
8858,04/06/2019 00:00,DB13071,Creatinolfosfate,,,,,,,,,9.81,1.48,12.3,CN(CCOP(O)(O)=O)C(N)=N,,,,,0,,197.0565425,0,0,0,0,0,0
8859,04/06/2019 00:00,DB13072,GDC-0349,,,,,,,,,0.0367,13.05,5.73,CCNC(=O)NC1=CC=C(C=C1)C1=NC2=C(CCN(C2)C2COC2)C(=N1)N1CCOC[C@@H]1C,,,,,0,,452.2535889,5,2,4,1,2,3
8860,04/06/2019 00:00,DB13074,Macimorelin,"Macimorelin is a novel, synthetic ghrelin agonist, which is readily absorbed from the gastrointestinal tract [A31482]. The maximum plasma concentration (Cmax) was observed between 0.5 and 1.5 hours following oral administration of 0.5mg/kg macimorelin to patients with AGHD under fasting for at least 8 hours. Higher doses of drug demonstrate a dose-proportional increase in plasma concentrations [A31482]. A liquid meal decreased the macimorelin Cmax and AUC by 55% and 49%, respectively [FDA Label].",,The mean terminal half-life (T1/2) is 4.1 hours following administration of a single oral dose of 0.5 mg macimorelin/kg body weight in healthy subjects [FDA Label].,60 mg/1mg,Oral,,,,0.00616,12.4,8.34,CC(C)(N)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)NC=O,,,,,0,,474.2379388,4,4,2,2,0,0
8861,04/06/2019 00:00,DB13075,Menaquinone 7,,,,,Oral,,,,0.000229,,-7.2,[H]\C(CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC1=C(C)C(=O)C2=CC=CC=C2C1=O)=C(\C)CCC=C(C)C,,,,,0,,648.4906313,2,1,0,0,0,0
8862,04/06/2019 00:00,DB13077,LCB01-0371,,,,,,,,,0.948,14.61,3.35,CN1CCN(C=N1)C1=CC=C(C=C1F)N1C[C@H](CO)OC1=O,,,,,0,,308.1284686,3,1,2,0,1,2
8863,04/06/2019 00:00,DB13078,KOSN-1724,,,,,,,,,0.0286,14.06,0.8,C[C@H]1\C=C/C\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1=NOC(C)=C1,,,,,0,,473.277738,2,1,2,1,0,1
8864,04/06/2019 00:00,DB13080,Roluperidone,,,,,,,,,0.0826,14.19,6.45,FC1=CC=C(C=C1)C(=O)CN1CCC(CN2CC3=CC=CC=C3C2=O)CC1,,,,,0,,366.1743562,4,2,2,0,1,2
8865,04/06/2019 00:00,DB13082,Nefiracetam,,,,,,,,,0.349,4.72,1.2,CC1=CC=CC(C)=C1N=C(O)CN1CCCC1=O,,,,,0,,246.1368278,2,1,1,0,1,1
8866,04/06/2019 00:00,DB13083,Talarozole,,,,,,,,,0.0145,13.11,2.76,CCC(CC)C(N1C=NC=N1)C1=CC=C(NC2=NC3=CC=CC=C3S2)C=C1,,,,,0,,377.1674167,4,4,2,2,0,0
8867,04/06/2019 00:00,DB13084,Pyritinol,,,,,,,,,0.232,9.14,6.02,CC1=C(O)C(CO)=C(CSSCC2=C(CO)C(O)=C(C)N=C2)C=N1,,,,,0,,368.0864491,2,2,2,2,0,0
8868,04/06/2019 00:00,DB13086,SCYX-7158,,,,,,,,,0.00372,8.78,-4.1,CC1(C)OB(O)C2=CC(NC(=O)C3=CC=C(F)C=C3C(F)(F)F)=CC=C12,,,,,0,,367.1002866,3,2,1,0,0,1
8869,04/06/2019 00:00,DB13087,Miridesap,,,,,,,,,9.95,3.5,-0.77,OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O,,,,,0,,340.1634365,2,0,2,0,2,2
8870,04/06/2019 00:00,DB13088,AZD-0424,,,,,,,,,0.128,11.82,6.61,CC(C)OC1=C2C(NC3=C(Cl)C=NC4=C3OCO4)=NC=NC2=CC(OCCN2CCN(CC2)C(C)=O)=C1,,,,,0,,528.1887957,5,3,4,2,1,2
8871,04/06/2019 00:00,DB13089,Enoxolone,,,,,,,,,0.00172,4.44,-0.84,[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O,,,,,0,,470.33961,5,0,0,0,0,0
8872,04/06/2019 00:00,DB13090,Zidebactam,,,,,,,,,2.13,-2,9.16,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NNC(=O)[C@@H]2CCCNC2)C1=O,,,,,0,,391.116169,3,0,3,0,3,3
8873,04/06/2019 00:00,DB13091,Tiropramide,,,,,,,,,0.00395,8.41,9.38,CCCN(CCC)C(=O)C(CC1=CC=C(OCCN(CC)CC)C=C1)N=C(O)C1=CC=CC=C1,,,,,0,,467.3147922,2,2,0,0,0,0
8874,04/06/2019 00:00,DB13092,Meclocycline,Estimated oral bioavailability of ~66% and tmax of 4h based on that of demeclocycline due to structural similarity [A1424].,~75-91%,Half life estimated to be ~5.6h based on that of chlortetracycline due to structural similarity [A1424].,,,solid,Soluble,,0.542,2.61,7.76,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)C4=C(Cl)C=CC(O)=C4C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O,0.75,0.91,,,0,,476.0986433,4,1,0,0,0,0
8875,04/06/2019 00:00,DB13093,TAK-593,,,,,,,,,0.0232,11.53,2.24,CN1N=C(C)C=C1C(=O)NC1=CC(OC2=NN3C=C(NC(=O)C4CC4)N=C3C=C2)=CC=C1C,,,,,0,,445.1862376,5,4,3,3,0,0
8876,04/06/2019 00:00,DB13094,Pruvanserin,,,,,,,,,0.0188,13.2,7.05,FC1=CC=C(CCN2CCN(CC2)C(=O)C2=C3NC=C(C#N)C3=CC=C2)C=C1,,,,,0,,376.1699395,4,3,2,1,1,1
8877,04/06/2019 00:00,DB13095,JTK-853,,,,,,,,,0.00286,4.53,3.59,[H][C@@]1(CN(CCN1S(=O)(=O)C1=CC=C(C=C1)C(F)(F)F)C1=NC2=NC(=NC=C2S1)C1CC1)C(O)=NCC1=CC(F)=C(OC(F)(F)F)C=C1,,,,,0,,704.1110428,6,4,3,2,1,1
8878,04/06/2019 00:00,DB13096,Gacyclidine,,,,,,,,,0.0173,,10.45,C[C@H]1CCCC[C@]1(N1CCCCC1)C1=CC=CS1,,,,,0,,263.1707708,3,1,2,1,1,1
8879,04/06/2019 00:00,DB13097,1alpha-Hydroxyvitamin D5,,,,,,,,,0.000923,14.39,-2.8,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C(C)C,,,,,0,,428.3654308,3,0,0,0,0,0
8880,04/06/2019 00:00,DB13098,CT-2584,,,,,,,,,0.000453,14.9,10.17,CCCCCCCCCCCCNCC(O)CCCCCCCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O,,,,,0,,533.4304906,2,2,2,2,0,0
8881,04/06/2019 00:00,DB13099,Valnoctamide,,,,,,,,,4.42,17.09,-1.1,CCC(C)C(CC)C(N)=O,,,,,0,,143.1310142,0,0,0,0,0,0
8882,04/06/2019 00:00,DB13100,Biguanide,,,,,,,,,1.81,,12.06,NC(=N)NC(N)=N,,,,,0,,101.0701452,0,0,0,0,0,0
8883,04/06/2019 00:00,DB13101,4SC-202,,,,,,,,,0.0279,14.37,3.28,CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\C=C\C(=O)NC2=CC=CC=C2N)=C1,,,,,0,,447.1365105,4,4,2,2,0,0
8884,04/06/2019 00:00,DB13102,AZD-8418,,,,,,,,,0.109,13.26,-1.5,C[C@@H](C1CC1)N1CC2=CC(=CC(Cl)=C2C1=O)C1=CC(=NO1)C(=O)N(C)C,,,,,0,,373.1193192,4,2,2,1,0,1
8885,04/06/2019 00:00,DB13103,GPX-150,,,,,,,,,0.331,8.1,9.36,COC1=C2C(=N)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(=O)CO)C(O)=C3C(=O)C2=CC=C1,,,,,0,,542.1900452,5,2,1,0,1,1
8886,04/06/2019 00:00,DB13104,X-396,,,,,,,,,0.0181,11.48,6.85,C[C@@H](OC1=CC(=NN=C1N)C(=O)NC1=CC=C(C=C1)C(=O)N1CCN(C)CC1)C1=C(Cl)C=CC(F)=C1Cl,,,,,0,,546.1349222,4,3,2,1,1,1
8887,04/06/2019 00:00,DB13105,Resolvin E1,,,,,,,,,0.045,4.65,-1.1,CC[C@@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O,,,,,0,,350.2093241,0,0,0,0,0,0
8888,04/06/2019 00:00,DB13106,Glycovir,,,,,,,,,0.0224,,7.01,CCCCN1C[C@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](OC(=O)CCC)[C@H]1COC(=O)CCC,,,,,0,,499.3145174,1,0,1,0,1,1
8889,04/06/2019 00:00,DB13107,QGC-001,,,,,,,,,1.62,-1.3,10.19,N[C@@H](CCS(O)(=O)=O)CSSC[C@@H](N)CCS(O)(=O)=O,,,,,0,,368.0204204,0,0,0,0,0,0
8890,04/06/2019 00:00,DB13108,Mephedrone,,,,,,,,,0.715,18.66,8.05,CNC(C)C(=O)C1=CC=C(C)C=C1,,,,,0,,177.1153641,1,1,0,0,0,0
8891,04/06/2019 00:00,DB13109,PKI-179,,,,,,,,,0.056,11.15,5.69,O=C(NC1=CC=NC=C1)NC1=CC=C(C=C1)C1=NC(=NC(=N1)N1[C@H]2CC[C@@H]1COC2)N1CCOCC1,,,,,0,,488.2284368,6,3,5,2,3,3
8892,04/06/2019 00:00,DB13111,Chromanol,,,,,,,,,0.359,10.8,-4.9,CC1=C(O)C(C)=C2CCC(C)(C)OC2=C1C,,,,,0,,220.1463299,2,1,1,0,0,1
8893,04/06/2019 00:00,DB13113,JNJ-38877605,,,,,,,,,0.0115,,4.41,CN1C=C(C=N1)C1=NN2C(C=C1)=NN=C2C(F)(F)C1=CC=C2N=CC=CC2=C1,,,,,0,,377.1200499,5,5,4,4,0,0
8894,04/06/2019 00:00,DB13114,Amitriptylinoxide,,,,,,,,,0.000277,,4.04,CN(C)(=O)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,,,,,0,,293.1779644,3,2,0,0,0,0
8895,04/06/2019 00:00,DB13115,Saroglitazar,,,,,,,,,0.00149,3.73,-4.1,CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C2=CC=C(SC)C=C2)C=C1)C(O)=O,,,,,0,,439.1817294,3,3,1,1,0,0
8896,04/06/2019 00:00,DB13116,Norflurane,,,,,,,,,18.6,,,FCC(F)(F)F,,,,,0,,102.0092629,0,0,0,0,0,0
8897,04/06/2019 00:00,DB13117,Pentafluoropropane,,,,,,,,,13.4,,,FC(F)CC(F)(F)F,,,,,0,,134.0154912,0,0,0,0,0,0
8898,04/06/2019 00:00,DB13118,Paquinimod,,,,,,,,,0.0653,6.28,-2.2,CCN(C(=O)C1=C(O)C2=C(CC)C=CC=C2N(C)C1=O)C1=CC=CC=C1,,,,,0,,350.1630426,3,3,1,1,0,0
8899,04/06/2019 00:00,DB13119,GSK-364735,,,,,,,,,0.104,4.83,2.24,CN1C(=O)C(C(=O)NCCO)=C(O)C2=NC=C(CC3=CC=C(F)C=C3)C=C12,,,,,0,,371.1281343,3,3,2,2,0,0
8900,04/06/2019 00:00,DB13120,Deferitazole,,,,,,,,,0.0852,3.2,0.46,COCCOCCOCCOC1=C(O)C(=CC=C1)C1=N[C@](C)(CS1)C(O)=O,,,,,0,,399.1351731,2,1,1,0,0,1
8901,04/06/2019 00:00,DB13121,Hydroxypropyl tetrahydropyrantriol,,,,,,,,,572,12.7,-2.5,CC(O)C[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,192.0997736,1,0,1,0,1,1
8902,04/06/2019 00:00,DB13122,Trabodenoson,,,,,,,,,1.46,12.45,3.71,O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)N1C=NC2=C(NC3CCCC3)N=CN=C12,,,,,0,,380.1444324,4,2,3,2,1,1
8903,04/06/2019 00:00,DB13123,OTX-008,,,,,,,,,0.0209,14.19,9.11,CN(C)CCNC(=O)COC1=C2CC3=CC=CC(CC4=CC=CC(CC5=C(OCC(=O)NCCN(C)C)C(CC1=CC=C2)=CC=C5)=C4OCC(=O)NCCN(C)C)=C3OCC(=O)NCCN(C)C,,,,,0,,936.5473113,5,4,0,0,0,0
8904,04/06/2019 00:00,DB13124,Troxerutin,,,,,Topical,,,,1.43,8.34,-2.8,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(OCCO)=CC(O)=C4C3=O)C3=CC(OCCO)=C(OCCO)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,,,,,0,,742.2320291,5,3,3,1,2,2
8905,04/06/2019 00:00,DB13125,Lusutrombopag,"Lusutrombopag is rapidly absorbed following oral administration [A36730]. It exhibited a doseâ€proportional pharmacokinetic profile over the single dose range of 1 mg to 50 mg, which was similar in both healthy subjects and those with chronic liver disease. A geometric mean (%CV) maximal concentration (Cmax) and area under the curve (AUC) in healthy subjects receiving 3 mg of lusutrombopag were 111 (20.4) ng/mL and 2931 (23.4) ng.hr/mL [FDA Label]. The accumulation ratios of Cmax and AUC were approximately 2 with onceâ€daily multipleâ€dose administration, and steadyâ€state plasma lusutrombopag concentrations were achieved after Day 5. The time to reach peak plasma concentrations (Tmax) were approximately 6 to 8 hours after oral administration in patients with chronic liver disease [FDA Label]. Food consumption is not reported to affect the absorption and bioavailability of lusutrombopag [FDA Label]. ",0.999,"In healthy adult subjects, the terminal elimination halfâ€life (t1/2) was approximately 27 hours [FDA Label].",3 mg/1,Oral,solid,Practically insoluble,,0.000145,3.02,-1.2,CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C1=CSC(NC(=O)C2=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C2)=N1,0.999,0.999,,,0,3,590.1408985,3,3,1,1,0,0
8906,04/06/2019 00:00,DB13126,BMS-986115,,,,,,,,,0.0111,9.36,-0.19,CC1=CC=CC2=C1NC(=O)[C@@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)N=C2C1=CC=CC(F)=C1,,,,,0,,574.1814882,3,2,1,0,0,1
8907,04/06/2019 00:00,DB13129,Trimegestone,,,,,,,,,0.0188,13.7,-3.4,C[C@H](O)C(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C,,,,,0,,342.2194948,4,0,0,0,0,0
8908,04/06/2019 00:00,DB13132,Artemisinin,,,,,,,,,1.27,,-4.4,[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C(=O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4,,,,,0,,282.1467238,5,0,4,0,4,4
8909,04/06/2019 00:00,DB13135,AGN-201904,,,,,,,,,0.0385,2.54,4.78,COC1=CC=C2N(C(=NC2=C1)[S+]([O-])CC1=NC=C(C)C(OC)=C1C)S(=O)(=O)C1=CC=C(OCC(O)=O)C=C1,,,,,0,,559.1083068,4,4,2,2,0,0
8910,04/06/2019 00:00,DB13136,Fluindione,,,,,,,,,0.0549,4.19,-7.5,FC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O,,,,,0,,240.0586577,3,2,0,0,0,0
8911,04/06/2019 00:00,DB13137,PM-060184,,,,,,,,,0.000527,13.17,-0.23,COC1=CC[C@H](OC1=O)[C@@H](C)\C=C(/C)\C=C/C=C\C(=O)N[C@H](C(=O)N\C=C/C[C@H](C\C=C/C)OC(N)=O)C(C)(C)C,,,,,0,,571.3257508,1,0,1,0,0,1
8912,04/06/2019 00:00,DB13138,Neladenoson bialanate,,,,,,,,,0.00945,12.2,8.39,C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1,,,,,0,,715.1802222,5,4,3,2,1,1
8913,04/06/2019 00:00,DB13139,Levosalbutamol,"Inhalation delivers the medication directly into the airways and lungs, thereby minimizing side effects because of reduced systemic absorption of the inhaled medications. ",,3.3 - 4 hours,1.25 mg/0.5mL,Respiratory (inhalation),solid,,,2.15,10.12,9.4,CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1,,,,,0,,239.1521435,1,1,0,0,0,0
8914,04/06/2019 00:00,DB13141,Ambroxol acefyllinate,,,,,,solid,,,14.7,15.26,9.01,CN1C2=C(N(CC(O)=O)C=N2)C(=O)N(C)C1=O.NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@H](O)CC1,,,,,0,,614.0487922,4,3,2,2,0,0
8915,04/06/2019 00:00,DB13142,Calcium glubionate,"Minimal unless chronic, high doses; absorption predominantly in the duodenum and dependent on calcitriol and vitamin D; mean absorption of calcium intake varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, adults 25%); during pregnancy, calcium absorption doubles; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acid environment (IOM 2011); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia",,,,,solid,,,47.2,11.32,-3.6,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O)[C@H](O)CO,,,,,0,,592.1163698,1,0,1,0,1,1
8916,04/06/2019 00:00,DB13143,Methallenestril,,,,,,solid,,,0.00102,4.53,-4.8,CC[C@H](C1=CC=C2C=C(OC)C=CC2=C1)C(C)(C)C(O)=O,,,,,0,,286.1568946,2,2,0,0,0,0
8917,04/06/2019 00:00,DB13145,Nedaplatin,,0.5,,,,solid,10 mg/mL,,138,,,[H][N]([H])([H])[Pt]1(OCC(=O)O1)[N]([H])([H])[H],0.5,0.5,,,,,,,,,,,
8918,04/06/2019 00:00,DB13146,Fluciclovine (18F),"After intravenous administration of fluciclovine, the major distribution happens in liver (14%), red bone marrow (12%), lung (7%), myocardium (4%) and pancreas (3%). With increasing time, the dose gets distributed into skeletal muscle.[L1051]",,"Fluciclovine is a cyclotron produced radionuclide that decays by positron emission (ÃŸ+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen 18 with a physical half-life of 109.7 minutes.[A31383]",221 mCi/1mL,Intravenous,liquid,Soluble,,173,2.07,9.42,N[C@]1(C[C@H]([18F])C1)C(O)=O,,,,,0,,132.0564415,1,0,0,0,0,0
8919,04/06/2019 00:00,DB13153,Levomenol,"The purpose of the present investigations was to study the cutaneous absorption of sesquiterpenic alcohol, the major active principle of chamomile. For these investigations 14C-labelled levomenol ((-)-6-methyl-2-(4-methyl-3-cyclohexen-1-yl)-5-hepten-2-ol; (-)-alpha-bisabolol) was prepared by biochemical incorporation of [14C]-acetate into the molecule. 5 h after topical application of the radiolabelled substance onto nude mice half of the radioactivity was found in the skin. The other part was measured in tissue and organes. 90% of this radioactivity was analysed as intact levomenol.",,,0.02 g/1mL,Topical,solid,,,0.0729,,-0.47,[H][C@@]1(CCC(C)=CC1)[C@@](C)(O)CCC=C(C)C,,,,,0,,222.1983655,1,0,0,0,0,0
8920,04/06/2019 00:00,DB13154,Parachlorophenol,absorbed from gastrointestinal tract.,,,,Dental,solid,,,14,8.96,-6.3,OC1=CC=C(Cl)C=C1,,,,,0,,128.0028925,1,1,0,0,0,0
8921,04/06/2019 00:00,DB13155,Esculin,"Rarely, absorbed into the blood stream if used as a combination with other ingredients in suppository form. But, Applying cream or ointment form to open wound or skin may lead this drug to absorb and circulate into blood stream.",,Absorption half life about 1 hour and elimination half life about 20 hours,,Rectal,solid,,,10.3,8.12,-3,OC[C@H]1O[C@@H](OC2=C(O)C=C3OC(=O)C=CC3=C2)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,340.0794321,3,2,2,1,1,1
8922,02/07/2019 00:00,DB13156,Inosine pranobex,Rapidly absorbed from GIT,,50 min,500 mg,Oral,solid,,,13.8,8.93,0.58,C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O,,,0.833333333,0.833333333,0,500,1114.554641,6,5,3,2,1,1
8923,07/09/2018 00:00,DB13157,Sodium lauryl sulfoacetate,,,,,Rectal,solid,,,0.00576,-1.1,-7.3,[Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O,,,,,0,,330.1476892,0,0,0,0,0,0
8924,02/07/2019 00:00,DB13158,Clobetasone,"Absorption is dependent on many drug-related factors including: intrinsic properties of the steroid itself; concentration of the drug (increased concentration generally leads to more drug being absorbed but may plateau at higher concentrations); vehicle used (optimized or augmented vehicles > ointments or gels > creams or lotions); duration of exposure; frequency of application; combination with other products that break down the skin barrier and increase absorption (e.g., salicylic acid, urea). Patient-related factors that influence absorption include: patient age (infants and children absorb topical medications more quickly and to a greater degree than adults, and have a greater total skin surface to body weight ratio; the elderly have thinner skin and absorb drug more readily); disruption of the skin due to inflammation or disease (e.g., absorption increased in atopic dermatitis); total skin area treated; skin site treated (absorption is much greater from thin-skinned areas such as scalp, face, eyelid, axilla, and scrotum than from areas with thicker skin such as forearm, knee, elbow, palm and sole); absorption is increased with increased temperature or humidity of the skin or the environment; occlusion of the treated skin (via plastic wrap, oily vehicles, dressings, tape, diapers, tight-fitting clothing, etc.) can increase absorption up to 10-fold.
",,,0.0005,Topical,solid,,,0.00691,12.49,-3.9,[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]2(C)[C@@]1(O)C(=O)CCl,,,,,0,,408.1503652,4,0,0,0,0,0
8925,04/06/2019 00:00,DB13160,Alphaprodine,,,,,,solid,,,0.475,,8.9,CCC(=O)O[C@]1(CCN(C)C[C@H]1C)C1=CC=CC=C1,,,,,0,,261.172879,2,1,1,0,1,1
8926,04/06/2019 00:00,DB13163,Terpin hydrate,,,,,Oral,solid,Partially soluble in cold water,2.32,8.31,18.93,-0.69,O.CC(C)(O)[C@H]1CC[C@@](C)(O)CC1,,,,,0,,190.1568946,1,0,0,0,0,0
8927,04/06/2019 00:00,DB13164,Olmutinib,tmax of 3-4h with oral administration [L766].,,8-11h [L766].,,,solid,,,0.00792,13.85,7.96,CN1CCN(CC1)C1=CC=C(NC2=NC(OC3=CC=CC(NC(=O)C=C)=C3)=C3SC=CC3=N2)C=C1,,,8,11,0,,486.1837951,5,4,3,2,1,1
8928,04/06/2019 00:00,DB13165,Ripasudil,,55.4-59.8%,"The half life of Ripasudil is 0.455 hrs.
",,,solid,,,0.3,,8.2,C[C@H]1CNCCCN1S(=O)(=O)C1=C2C(F)=CN=CC2=CC=C1,0.554,0.598,,,0,,323.110376,3,2,2,1,1,1
8929,04/06/2019 00:00,DB13166,Zofenopril,,,,,,solid,,,0.00311,3.5,-1.3,C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1,,,,,0,,429.1068502,3,2,1,0,1,1
8930,04/06/2019 00:00,DB13167,Alclofenac,The absorption of alclofenac from the gastrointestinal tract is irregular. After oral or rectal administration maximum plasma concentrations are reached within 1-4 hours. ,,The plasma half-life varies between 1.5 and 5.5 hours. ,,,solid,,,0.288,3.71,-4.9,OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1,,,,,0,,226.0396719,1,1,0,0,0,0
8931,04/06/2019 00:00,DB13169,Nandrolone,,,,,,solid,,,0.0561,19.28,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],,,,,0,,274.1932801,4,0,0,0,0,0
8932,04/06/2019 00:00,DB13170,Plecanatide,"Plecanatide is minimally absorbed with negligible systemic availability following oral administration.
Concentrations of plecanatide and its active metabolite in plasma are below the limit of quantitation after an oral dose of 3 mg. Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (Cmax), and half-life (tÂ½) cannot be calculated. ",, half-life (tÂ½) cannot be calculated due to negligible systemic absorbance,3 mg/1,Oral,solid,,,0.165,2.43,,[H][C@](C)(O)[C@]1([H])N=C(O)[C@]2([H])CSSC[C@]([H])(N=C(O)[C@]([H])(CCC(O)=O)N=C(O)[C@]([H])(CC(O)=O)N=C(O)[C@@]([H])(N)CC(O)=N)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CSSC[C@]([H])(N=C(O)CN=C1O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(C)C(O)=N2,,,,,0,3,1680.625199,3,0,3,0,0,3
8933,04/06/2019 00:00,DB13171,Glyceryl 1-oleate,,,,,,solid,,,0.00151,13.62,-3,[H]\C(CCCCCCCC)=C(/[H])CCCCCCCC(=O)OCC(O)CO,,,,,0,,356.2926598,0,0,0,0,0,0
8934,04/06/2019 00:00,DB13174,Rhein,Tmax of 1.6-2.6 hours [A19300].,0.99,4-10h [A19300].,,,solid,,,0.214,3.4,-4.4,OC(=O)C1=CC2=C(C(O)=C1)C(=O)C1=C(C=CC=C1O)C2=O,0.99,0.99,4,10,0,,284.032088,3,2,0,0,0,0
8935,04/06/2019 00:00,DB13175,Rheinanthrone,About 10% of rheinanthrone is absorbed from the gut [A19250].,,,,,solid,,,0.122,3.54,-4.4,OC(=O)C1=CC(O)=C2C(CC3=C(C(O)=CC=C3)C2=O)=C1,,,,,0,,270.0528234,3,2,0,0,0,0
8936,04/06/2019 00:00,DB13177,4-methylumbelliferyl beta-D-glucoside,,,,,,solid,,,5.11,12.2,-3,CC1=CC(=O)OC2=CC(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=CC=C12,,,,,0,,338.1001675,3,2,2,1,1,1
8937,02/07/2019 00:00,DB13178,Inositol,"Inositol is absorbed from the small intestine.[T184] In patients with inositol deficiency, the maximal plasma concentration after oral administration of inositol is registered to be of 4 hours.[A32803] Inositol is taken up by the tissues via sodium-dependent inositol co-transporter which also mediates glucose uptake.[A32804] Oral ingestion of inositol is registered to generate a maximal plasma concentration of 36-45 mcg.[A32805]",,The pharmacokinetic profile of inositol was studied in preterm infants and the estimated elimination half-life was reported to be of 5.22 hours.[A32802],250 mg,Oral,solid,0.17 mg/ml,-2.08,485,12.29,-3.6,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,,,,,0,250,180.0633881,1,0,0,0,0,0
8938,04/06/2019 00:00,DB13179,Troleandomycin,,,,,,solid,,,0.0192,19.62,7.87,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,,,,,0,,813.4510704,4,0,4,0,4,4
8939,04/06/2019 00:00,DB13180,Gluconic Acid,,,,,Intravenous,liquid,,,159,3.39,-3,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O,,,,,0,,196.0583027,0,0,0,0,0,0
8940,04/06/2019 00:00,DB13181,Methylbenactyzium,,,,,,solid,,,0.00057,11.05,-4.5,CC[N+](C)(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,342.2063702,2,2,0,0,0,0
8941,04/06/2019 00:00,DB13182,Daidzein,,,,,,solid,,,0.0849,6.48,-5.3,OC1=CC=C(C=C1)C1=COC2=C(C=CC(O)=C2)C1=O,,,,,0,,254.0579088,3,3,1,1,0,0
8942,04/06/2019 00:00,DB13183,Technetium Tc-99m etifenin,,,,,,solid,,,0.182,3.26,2.15,[98Tc].CCC1=CC=CC(CC)=C1N=C(O)CN(CC(O)=O)CC(O)=O.CCC1=CC=CC(CC)=C1N=C([O-])CN(CC([O-])=O)CC([O-])=O,,,,,-3,,739.1911303,2,2,0,0,0,0
8943,04/06/2019 00:00,DB13185,Oxabolone cipionate,,,,,,solid,,,0.00377,9.23,-3.7,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=C(O)C(=O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,,,,,0,,414.2770097,5,0,0,0,0,0
8944,04/06/2019 00:00,DB13191,Phosphocreatine,,,,,,solid,3.52 mg/mL,,3.52,-1.1,11.57,CN(CC(O)=O)C(=N)NP(O)(O)=O,,,,,0,,211.0358071,0,0,0,0,0,0
8945,04/06/2019 00:00,DB13202,Piprozolin,,,,,,,,,4.12,,5.38,[H]\C(C(=O)OCC)=C1\SC(N2CCCCC2)C(=O)N1CC,,,,,0,,298.1351136,2,0,2,0,2,2
8946,04/06/2019 00:00,DB13203,Bamifylline,,,,,,,,,1.79,15.59,8.7,CCN(CCO)CCN1C(CC2=CC=CC=C2)=NC2=C1C(=O)N(C)C(=O)N2C,,,,,0,,385.2113897,3,3,2,2,0,0
8947,04/06/2019 00:00,DB13204,Dimethyl carbate,,,,,,,,,4.92,,-6.8,COC(=O)[C@H]1[C@@H]2C[C@@H](C=C2)[C@H]1C(=O)OC,,,,,0,,210.0892089,2,0,0,0,0,0
8948,04/06/2019 00:00,DB13205,Teclozan,,,,,,,,,0.00142,16.38,-3.8,CCOCCN(CC1=CC=C(CN(CCOCC)C(=O)C(Cl)Cl)C=C1)C(=O)C(Cl)Cl,,,,,0,,500.0803181,1,1,0,0,0,0
8949,04/06/2019 00:00,DB13206,Bamethan,,,,,,,,,1.85,9.2,9.96,CCCCNCC(O)C1=CC=C(O)C=C1,,,,,0,,209.1415788,1,1,0,0,0,0
8950,04/06/2019 00:00,DB13207,Arginine glutamate,,,,,,,,,2.28,2.41,12.41,N[C@@H](CCC(O)=O)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O,,,,,0,,321.1648335,0,0,0,0,0,0
8951,04/06/2019 00:00,DB13208,Prednylidene,,,,,,,,,0.359,12.12,-2.9,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC(=C)[C@]2(O)C(=O)CO,,,,,0,,372.193674,4,0,0,0,0,0
8952,04/06/2019 00:00,DB13211,Guanoxan,,,,,,,,,1.33,,11.99,NC(=N)NCC1COC2=CC=CC=C2O1,,,,,0,,207.1007767,2,1,1,0,0,1
8953,04/06/2019 00:00,DB13212,Phenolsulfonphthalein,,,,,,,,,0.018,9.16,-6,OC1=CC=C(C=C1)C1(OS(=O)(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1,,,,,0,,354.0561945,4,3,1,0,0,1
8954,04/06/2019 00:00,DB13213,Butaperazine,,,,,,,,,0.0103,17.29,7.86,CCCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1,,,,,0,,409.2187836,4,2,2,0,1,2
8955,04/06/2019 00:00,DB13214,Sulfadicramide,,,,,,,,,1.23,4.41,2.11,CC(C)=CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1,,,,,0,,254.0725133,1,1,0,0,0,0
8956,04/06/2019 00:00,DB13215,Sulfobromophthalein,,,,,,,,,0.00799,-3.4,-6.5,OC1=CC=C(C=C1S(O)(=O)=O)C1(OC(=O)C2=C1C(Br)=C(Br)C(Br)=C2Br)C1=CC(=C(O)C=C1)S(O)(=O)=O,,,,,0,,789.6448869,4,3,1,0,0,1
8957,04/06/2019 00:00,DB13216,Oxolamine,,,,,,,,,0.277,,8.96,CCN(CC)CCC1=NC(=NO1)C1=CC=CC=C1,,,,,0,,245.1528122,2,2,1,1,0,0
8958,04/06/2019 00:00,DB13217,Fentiazac,,,,,,,,,0.00136,4.82,1.3,OC(=O)CC1=C(N=C(S1)C1=CC=CC=C1)C1=CC=C(Cl)C=C1,,,,,0,,329.0277273,3,3,1,1,0,0
8959,04/06/2019 00:00,DB13218,Mandelic acid,,,,,,,,,16.8,3.75,-4.1,OC(C(O)=O)C1=CC=CC=C1,,,,,0,,152.0473441,1,1,0,0,0,0
8960,04/06/2019 00:00,DB13219,Medifoxamine,,,,,,,,,0.327,,8.18,CN(C)CC(OC1=CC=CC=C1)OC1=CC=CC=C1,,,,,0,,257.1415788,2,2,0,0,0,0
8961,04/06/2019 00:00,DB13220,Ferrous aspartate,,,,,,,,,35.1,1.7,9.61,[Fe++].N[C@@H](CC([O-])=O)C([O-])=O,,,,,0,,186.9567951,0,0,0,0,0,0
8962,04/06/2019 00:00,DB13221,Apronalide,,,,,,,,,7.52,11.75,-6.3,CC(C)C(CC=C)C(=O)NC(N)=O,,,,,0,,184.1211778,0,0,0,0,0,0
8963,04/06/2019 00:00,DB13222,Tilbroquinol,,,,,,,,,0.299,7.84,4.46,CC1=C2C=CC=NC2=C(O)C(Br)=C1,,,,,0,,236.978926,2,2,1,1,0,0
8964,04/06/2019 00:00,DB13223,Fluocortin,,,,,,,,,0.0302,3.73,-0.23,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@H]1C(=O)C(O)=O,,,,,0,,390.1842522,4,0,0,0,0,0
8965,04/06/2019 00:00,DB13224,Piperidione,,,,,,,,,29,14.47,-3.4,CCC1(CC)C(=O)CCNC1=O,,,,,0,,169.1102787,1,0,1,0,1,1
8966,04/06/2019 00:00,DB13225,Dibenzepin,,,,,,,,,1.08,,8.23,CN(C)CCN1C2=CC=CC=C2N(C)C2=CC=CC=C2C1=O,,,,,0,,295.1684623,3,2,1,0,0,1
8967,04/06/2019 00:00,DB13226,Acetylleucine,,,,,,,,,10.9,4.2,-1.8,CC(C)CC(NC(C)=O)C(O)=O,,,,,0,,173.1051933,0,0,0,0,0,0
8968,04/06/2019 00:00,DB13227,Tribenoside,,,,,,,,,0.00325,12.36,-3.6,CCOC1O[C@H]([C@@H](COCC2=CC=CC=C2)OCC2=CC=CC=C2)[C@H](OCC2=CC=CC=C2)[C@H]1O,,,,,0,,478.2355388,4,3,1,0,1,1
8969,04/06/2019 00:00,DB13228,Flosequinan,,,,,,,,,7.25,,-1.4,CN1C=C(C(=O)C2=C1C=C(F)C=C2)S(C)=O,,,,,0,,239.0416278,2,2,1,1,0,0
8970,04/06/2019 00:00,DB13229,Enibomal,,,,,,,,,0.661,7.89,,CC(C)C1(CC(Br)=C)C(=O)NC(=O)N(C)C1=O,,,,,0,,302.0266044,1,0,1,0,1,1
8971,04/06/2019 00:00,DB13230,Gestonorone,,,,,,,,,0.0213,12.7,-3.8,[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],,,,,0,,316.2038448,4,0,0,0,0,0
8972,04/06/2019 00:00,DB13231,Calcium lactate,"In order to be absorbed, calcium must be in its freely soluble form (Ca2+) or bound to a soluble organic molecule. Calcium absorption mainly occurs at the duodenum and proximal jejunum due to more acidic pH and the abundance of the calcium binding proteins [F59]. The mean calcium absorption is about 25% of calcium intake (range is 10 â€“ 40%) in the small intestine, and is mediated by both passive diffusion and active transport [F59]. ",,No pharmacokinetic data available. ,324 mg,Oral,solid,48 g/L,,191,3.78,-3.7,[Ca++].CC(O)C([O-])=O.CC(O)C([O-])=O,,,,,0,324,218.010329,0,0,0,0,0,0
8973,04/06/2019 00:00,DB13232,Suxibuzone,,,,,,,,,0.033,3.67,-7,CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,438.1790866,3,2,1,0,1,1
8974,04/06/2019 00:00,DB13233,Alaproclate,,,,,,,,,0.0377,,7.34,CC(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1,,,,,0,,255.1026065,1,1,0,0,0,0
8975,04/06/2019 00:00,DB13234,Propanidid,,,,,,,,,0.229,16.59,-4.6,CCCOC(=O)CC1=CC(OC)=C(OCC(=O)N(CC)CC)C=C1,,,,,0,,337.188923,1,1,0,0,0,0
8976,04/06/2019 00:00,DB13236,Stibophen,,,,,,,,,0.919,-3.5,-6.5,O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Sb+3].[O-]C1=C([O-])C(=CC(=C1)S([O-])(=O)=O)S([O-])(=O)=O.[O-]C1=C([O-])C(=CC(=C1)S([O-])(=O)=O)S([O-])(=O)=O,,,,,0,,893.7648329,2,2,0,0,0,0
8977,04/06/2019 00:00,DB13237,Clofoctol,,,,,,,,,3.62E-05,10.28,-5.5,CC(C)(C)CC(C)(C)C1=CC=C(O)C(CC2=C(Cl)C=C(Cl)C=C2)=C1,,,,,0,,364.1360708,2,2,0,0,0,0
8978,04/06/2019 00:00,DB13238,Tuaminoheptane,,,,,,,,,3.29,,10.43,CCCCCC(C)N,,,,,0,,115.1360995,0,0,0,0,0,0
8979,04/06/2019 00:00,DB13239,Neltenexine,,,,,,,,,0.00115,11.23,8.84,O[C@H]1CC[C@@H](CC1)NCC1=CC(Br)=CC(Br)=C1NC(=O)C1=CC=CS1,,,,,0,,485.9612231,3,2,1,1,0,0
8980,04/06/2019 00:00,DB13240,Cymarin,,,,,,,,,0.0804,7.18,0.27,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4(O)C[C@H](CC[C@]4(C=O)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](OC)[C@H](O)[C@@H](C)O1)C1=CC(=O)OC1,,,,,0,,548.298533,6,0,2,0,1,2
8981,04/06/2019 00:00,DB13242,Bucladesine,,,,,,,,,1.62,1.72,2.46,CCCC(=O)NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC,,,,,0,,469.1362494,4,2,4,2,2,2
8982,04/06/2019 00:00,DB13243,Tiazofurine,,,,,,,,,0.858,7.6,4.32,[H][C@]1(CO)O[C@@]([H])(C2=NC(=CS2)C(O)=N)[C@]([H])(O)[C@]1([H])O,,,,,0,,260.0466925,2,1,2,1,1,1
8983,04/06/2019 00:00,DB13244,Aminomethylbenzoic acid,,,,,,,,,3.65,3.87,9.53,NCC1=CC=C(C=C1)C(O)=O,,,,,0,,151.0633285,1,1,0,0,0,0
8984,04/06/2019 00:00,DB13245,Thiram,,,,,,,,,0.0437,,,CN(C)C(=S)SSC(=S)N(C)C,,,,,0,,239.9883324,0,0,0,0,0,0
8985,04/06/2019 00:00,DB13246,Quinupramine,,,,,,,,,0.0173,,8.71,C1CN2CCC1C(C2)N1C2=CC=CC=C2CCC2=CC=CC=C12,,,,,0,,304.1939488,6,2,4,0,3,4
8986,04/06/2019 00:00,DB13247,Pramiracetam,,,,,,,,,5.31,15.85,9.61,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,,,,,0,,269.2103271,1,0,1,0,1,1
8987,04/06/2019 00:00,DB13248,Phthalylsulfathiazole,,,,,,,,,0.0171,2.91,0.59,OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1,,,,,0,,403.0296625,3,3,1,1,0,0
8988,04/06/2019 00:00,DB13250,Methylmethionine chloride,,,,,,,,,9.2,2.24,9.41,[Cl-].C[S+](C)CC[C@H](N)C(O)=O,,,,,0,,199.0433774,0,0,0,0,0,0
8989,04/06/2019 00:00,DB13251,Octopamine,,,,,,,,,17.2,9.64,8.98,NCC(O)C1=CC=C(O)C=C1,,,,,0,,153.0789786,1,1,0,0,0,0
8990,04/06/2019 00:00,DB13252,Tropatepine,,,,,,,,,0.000866,,9.37,CN1[C@H]2CC[C@@H]1CC(C2)=C1C2=CC=CC=C2CSC2=C1C=CC=C2,,,,,0,,333.1551207,5,2,3,0,2,3
8991,04/06/2019 00:00,DB13253,Proxibarbal,,,,,,,,,23.5,7.18,-2.5,CC(O)CC1(CC=C)C(=O)NC(=O)NC1=O,,,,,0,,226.0953569,1,0,1,0,1,1
8992,04/06/2019 00:00,DB13254,Prifinium,,,,,,,,,0.00015,,,CC[N+]1(CC)CCC(C1C)=C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,306.2216263,3,2,1,0,1,1
8993,04/06/2019 00:00,DB13255,Propatyl nitrate,,,,,,,,,0.257,,-5.6,CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O,,,,,0,,269.0495289,0,0,0,0,0,0
8994,04/06/2019 00:00,DB13256,Clothiapine,,,,,,,,,0.0142,,7.23,CN1CCN(CC1)C1=NC2=CC=CC=C2SC2=C1C=C(Cl)C=C2,,,,,0,,343.0909963,4,2,2,0,1,2
8995,04/06/2019 00:00,DB13258,Etofamide,,,,,,,,,0.000915,16.68,-3.6,CCOCCN(CC1=CC=C(OC2=CC=C(C=C2)[N+]([O-])=O)C=C1)C(=O)C(Cl)Cl,,,,,0,,426.0749271,2,2,0,0,0,0
8996,04/06/2019 00:00,DB13259,Ethyl chloride,,,,,Topical,,,,14.1,,,CCCl,,,,,0,,64.00797784,0,0,0,0,0,0
8997,04/06/2019 00:00,DB13261,Sitafloxacin,,,,,,,,,0.055,5.7,9.37,O.O.O.N[C@@H]1CN(CC11CC1)C1=C(F)C=C2C(=O)C(=CN([C@@H]3C[C@@H]3F)C2=C1Cl)C(O)=O.N[C@@H]1CN(CC11CC1)C1=C(F)C=C2C(=O)C(=CN([C@@H]3C[C@@H]3F)C2=C1Cl)C(O)=O,,,,,0,,872.2326452,10,4,4,2,2,2
8998,04/06/2019 00:00,DB13262,Aceclidine,,,,,,,,,226,,9.17,CC(=O)OC1CN2CCC1CC2,,,,,0,,169.1102787,3,0,3,0,3,3
8999,04/06/2019 00:00,DB13264,Penimepicycline,,,,,,,,,8.04,3,8.2,CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O.CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(=O)NCN2CCN(CCO)CC2)=C1O,,,,,0,,936.3575215,8,2,3,0,3,3
9000,04/06/2019 00:00,DB13265,Hexobendine,,,,,,,,,0.0599,,9.26,COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN(C)CCN(C)CCCOC(=O)C1=CC(OC)=C(OC)C(OC)=C1,,,,,0,,592.2995956,2,2,0,0,0,0
9001,04/06/2019 00:00,DB13266,Cefatrizine,,,,,,,,,0.149,2.92,7.22,[H][C@@]1(NC(=O)[C@H](N)C2=CC=C(O)C=C2)C(=O)N2C(C(O)=O)=C(CSC3=CNN=N3)CS[C@]12[H],,,,,0,,462.0780097,4,2,3,1,1,2
9002,04/06/2019 00:00,DB13267,Ritiometan,,,,,,,,,1.44,3.15,,OC(=O)CSC(SCC(O)=O)SCC(O)=O,,,,,0,,285.963951,0,0,0,0,0,0
9003,04/06/2019 00:00,DB13268,Acetarsol,The absorption seems to be very minimal but there are reports of allergic reactions after vaginal administration of acetarsol.[A32839],,This pharmacokinetic property was not addressed.,,Vaginal,solid,Slightly soluble ,,2.8,3.55,-4.5,CC(=O)NC1=CC(=CC=C1O)[As](O)(O)=O,,,,,0,,274.9774939,1,1,0,0,0,0
9004,04/06/2019 00:00,DB13269,Dichlorobenzyl alcohol,Dichlorobenzyl alcohol is released almost immediately from its formulation and reaches peak concentration after 3-4 minutes.[F72] The concentration in saliva after 120 minutes represents about 50% of the administered dose.[F73],,This pharmacokinetic property has not been fully studied.,,Oral,solid,Slightly Soluble,2.36,1.38,14.68,-2.9,OCC1=C(Cl)C=C(Cl)C=C1,,,,,0,,175.9795702,1,1,0,0,0,0
9005,04/06/2019 00:00,DB13270,Dibekacin,,,,,,,,,33.9,12.54,9.96,[H][C@@]1(N)CC[C@@]([H])(CN)O[C@]1([H])O[C@]1([H])[C@@]([H])(N)C[C@@]([H])(N)[C@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(N)[C@@]2([H])O)[C@@]1([H])O,,,,,0,,451.2642131,3,0,2,0,2,2
9006,04/06/2019 00:00,DB13272,Meladrazine,,,,,,,,,0.527,12.95,7.24,CCN(CC)C1=NC(=NN)N=C(N1)N(CC)CC,,,,,0,,253.2014937,1,1,1,1,0,0
9007,04/06/2019 00:00,DB13273,Sultopride,,,,,,,,,0.0995,6.19,7.9,CCN1CCCC1CN=C(O)C1=C(OC)C=CC(=C1)S(=O)(=O)CC,,,,,0,,354.1613283,2,1,1,0,1,1
9008,04/06/2019 00:00,DB13274,Micronomicin,,,,,,,,,17.5,12.55,10.06,CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1,,,,,0,,463.3005987,3,0,2,0,2,2
9009,04/06/2019 00:00,DB13275,Clorindione,,,,,,,,,0.00531,4.4,-7.5,ClC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O,,,,,0,,256.0291072,3,2,0,0,0,0
9010,04/06/2019 00:00,DB13276,Idanpramine,,,,,,,,,0.0357,10.61,8.31,COC1=CC=C(C=C1)C1(NC(=O)N(CCN2CCCCC2)C1=O)C1=CC=C(OC)C=C1,,,,,0,,423.2158064,4,2,2,0,2,2
9011,04/06/2019 00:00,DB13277,Benziodarone,,,,,,,,,0.0139,5.61,-3,CCC1=C(C(=O)C2=CC(I)=C(O)C(I)=C2)C2=CC=CC=C2O1,,,,,0,,517.8875902,3,3,1,1,0,0
9012,04/06/2019 00:00,DB13278,Bucetin,,,,,,,,,2.17,14.58,-2.6,CCOC1=CC=C(NC(=O)CC(C)O)C=C1,,,,,0,,223.1208434,1,1,0,0,0,0
9013,04/06/2019 00:00,DB13279,Carbocromen,,,,,,,,,0.0443,,9.1,CCOC(=O)COC1=CC2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2,,,,,0,,361.188923,2,2,1,1,0,0
9014,04/06/2019 00:00,DB13280,Aluminium acetoacetate,,,,,,,,,0.083,4.02,-7.5,[Al+3].CC(=O)CC([O-])=O.CC(=O)CC([O-])=O.CC(=O)CC([O-])=O,,,,,0,,330.0531457,0,0,0,0,0,0
9015,04/06/2019 00:00,DB13282,Benzododecinium,,,,,,,,,4.79E-06,18.11,,CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,,,,,1,,304.2998766,1,1,0,0,0,0
9016,04/06/2019 00:00,DB13283,Sulfaisodimidine,,,,,,,,,0.229,6.12,5,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(C)=N1,,,,,0,,278.0837467,2,2,1,1,0,0
9017,04/06/2019 00:00,DB13284,Meticrane,,,,,,,,,0.679,9.96,,CC1=CC2=C(C=C1S(N)(=O)=O)S(=O)(=O)CCC2,,,,,0,,275.0285999,2,1,1,0,0,1
9018,04/06/2019 00:00,DB13285,Etilamfetamine,,,,,,,,,0.277,,10.29,CCNC(C)CC1=CC=CC=C1,,,,,0,,163.1360995,1,1,0,0,0,0
9019,04/06/2019 00:00,DB13286,Bumadizone,,,,,,,,,0.0541,4.35,-7,CCCCC(C(O)=O)C(=O)N(NC1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,326.1630426,2,2,0,0,0,0
9020,04/06/2019 00:00,DB13288,Tromantadine,,,,,,,,,0.0806,2.95,8.87,CN(C)CCOCC(O)=NC12CC3CC(CC(C3)C1)C2,,,,,0,,280.2150781,4,0,0,0,0,0
9021,04/06/2019 00:00,DB13289,Rimazolium,,,,,,,,,0.554,,-7.3,CCOC(=O)C1=C[N+](C)=C2CCCC(C)N2C1=O,,,,,1,,251.1390189,2,1,2,1,0,1
9022,04/06/2019 00:00,DB13290,Olaflur,,,,,,,,,0.0017,15.12,9.72,F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO,,,,,0,,498.4572002,0,0,0,0,0,0
9023,04/06/2019 00:00,DB13291,Cloridarol,,,,,,,,,0.0188,12.63,-3,OC(C1=CC2=CC=CC=C2O1)C1=CC=C(Cl)C=C1,,,,,0,,258.0447573,3,3,1,1,0,0
9024,04/06/2019 00:00,DB13292,Pimethixene,,,,,,,,,0.00433,,7.96,CN1CCC(CC1)=C1C2=CC=CC=C2SC2=CC=CC=C12,,,,,0,,293.1238206,4,2,2,0,1,2
9025,04/06/2019 00:00,DB13294,Azidamfenicol,,,,,,,,,0.55,2.91,0.86,[H][C@](CO)(N=C(O)CN=[N+]=[N-])[C@]([H])(O)C1=CC=C(C=C1)N(=O)=O,,,,,0,,295.0916685,1,1,0,0,0,0
9026,04/06/2019 00:00,DB13296,Propamidine,,,,,,,,,0.0586,,12.13,NC(=N)C1=CC=C(OCCCOC2=CC=C(C=C2)C(N)=N)C=C1,,,,,0,,312.1586259,2,2,0,0,0,0
9027,04/06/2019 00:00,DB13297,Idrocilamide,,,,,,,,,0.498,15.38,-0.43,OCCNC(=O)\C=C\C1=CC=CC=C1,,,,,0,,191.0946287,1,1,0,0,0,0
9028,04/06/2019 00:00,DB13300,Epicillin,,,,,,,,,0.792,3.25,7.6,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C(=O)N2[C@H]1C(O)=O,,,,,0,,351.1252772,3,0,2,0,2,2
9029,04/06/2019 00:00,DB13303,Febarbamate,,,,,,,,,0.0616,-2.7,11.57,CCCCOCC(CN1C(=O)N=C(O)C(CC)(C2=CC=CC=C2)C1=O)OC(O)=N,,,,,0,,405.1899856,2,1,1,0,0,1
9030,04/06/2019 00:00,DB13304,Triaziquone,,,,,,,,,75.2,,-6.6,O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1,,,,,0,,231.1007767,4,0,3,0,3,3
9031,04/06/2019 00:00,DB13305,Tolpropamine,,,,,,,,,0.00602,,9.65,CN(C)CCC(C1=CC=CC=C1)C1=CC=C(C)C=C1,,,,,0,,253.1830497,2,2,0,0,0,0
9032,04/06/2019 00:00,DB13306,Chlorquinaldol,There is a high degree of variability in the extent of absorption of topically applied chorquinaldol preparations.[A177766] It is reported to be between 4.2 and 23.5% of the applied dose. This is quite low compared to orally administered preparations which displayed 67.6% absorption in the same study.,,,,,solid,,,0.0538,6.99,4,CC1=NC2=C(C=C1)C(Cl)=CC(Cl)=C2O,,,,,0,,226.9904692,2,2,1,1,0,0
9033,04/06/2019 00:00,DB13307,Proscillaridin,,,,,,,,,0.0427,12.22,0.3,[H][C@@]1(CC[C@]2(O)[C@]3([H])CCC4=C[C@]([H])(CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O)C1=COC(=O)C=C1,,,,,0,,530.2879683,6,1,2,1,1,1
9034,04/06/2019 00:00,DB13308,Oxametacin,,,,,,,,,0.00569,8.86,-2.3,COC1=CC=C2N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C(CC(=O)NO)C2=C1,,,,,0,,372.0876847,3,3,1,1,0,0
9035,04/06/2019 00:00,DB13309,Benproperine,,,,,,,,,0.00143,,9.05,CC(COC1=CC=CC=C1CC1=CC=CC=C1)N1CCCCC1,,,,,0,,309.2092645,3,2,1,0,1,1
9036,04/06/2019 00:00,DB13310,Ormeloxifene,,,,,,,,,0.000102,,9,[H][C@@]1(C2=CC=C(OCCN3CCCC3)C=C2)C2=C(OC(C)(C)[C@@]1([H])C1=CC=CC=C1)C=C(OC)C=C2,,,,,0,,457.261694,5,3,2,0,1,2
9037,04/06/2019 00:00,DB13311,Trepibutone,,,,,,,,,0.103,3.45,-4.4,CCOC1=CC(OCC)=C(OCC)C=C1C(=O)CCC(O)=O,,,,,0,,310.1416384,1,1,0,0,0,0
9038,04/06/2019 00:00,DB13312,Delapril,,,,,,,,,0.00537,3.82,5.21,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=C(C1)C=CC=C2,,,,,0,,452.2311221,3,2,0,0,0,0
9039,04/06/2019 00:00,DB13313,Melevodopa,,,,,,,,,2.15,9.29,6.97,COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1,,,,,0,,211.0844579,1,1,0,0,0,0
9040,04/06/2019 00:00,DB13314,Alminoprofen,,,,,,,,,0.676,4.15,4.77,CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1,,,,,0,,219.1259288,1,1,0,0,0,0
9041,04/06/2019 00:00,DB13315,Sobrerol,,,,,,,,,26,14.48,-2.8,CC1=CC[C@H](C[C@@H]1O)C(C)(C)O,,,,,0,,170.1306798,1,0,0,0,0,0
9042,04/06/2019 00:00,DB13316,Ibopamine,,,,,,,,,0.05,,10.01,CNCCC1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C=C1,,,,,0,,307.1783583,1,1,0,0,0,0
9043,04/06/2019 00:00,DB13317,Flunoxaprofen,,,,,,,,,0.0499,4.59,0.12,C[C@H](C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(F)C=C1,,,,,0,,285.0801215,3,3,1,1,0,0
9044,04/06/2019 00:00,DB13318,Demecolcine,,,,,,,,,0.032,16.96,9.7,[H][C@@]1(CCC2=CC(OC)=C(OC)C(OC)=C2C2=CC=C(OC)C(=O)C=C12)NC,,,,,0,,371.1732729,3,2,0,0,0,0
9045,04/06/2019 00:00,DB13319,Propenidazole,,,,,,,,,0.344,18.17,1.38,CCOC(=O)C(=C\C1=NC=C(N1C)[N+]([O-])=O)\C(C)=O,,,,,0,,267.0855205,1,1,1,1,0,0
9046,04/06/2019 00:00,DB13320,Sulfaperin,,,,,,,,,0.312,7.03,2.02,CC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1,,,,,0,,264.0680966,2,2,1,1,0,0
9047,04/06/2019 00:00,DB13321,Methiodal,,,,,,,,,9.39,-1.8,,OS(=O)(=O)CI,,,,,0,,221.884763,0,0,0,0,0,0
9048,04/06/2019 00:00,DB13322,Hydrotalcite,,,,,,,,,51.2,6.05,,O.O.O.O.O.O.O.O.O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[O-]C([O-])=O,,,,,-2,,617.9401763,0,0,0,0,0,0
9049,04/06/2019 00:00,DB13323,Trichloroethylene,,,,,,,,,1.96,,,ClC=C(Cl)Cl,,,,,0,,129.9143831,0,0,0,0,0,0
9050,04/06/2019 00:00,DB13324,Tetrazepam,,,,,,,,,0.0423,,3.24,CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CCCCC1,,,,,0,,288.1029408,3,1,1,0,0,1
9051,04/06/2019 00:00,DB13325,Nifurzide,,,,,,,,,0.0188,8.87,0.27,[O-][N+](=O)C1=CC=C(O1)\C=C\C=N\NC(=O)C1=CC=C(S1)[N+]([O-])=O,,,,,0,,336.016455,2,2,2,2,0,0
9052,04/06/2019 00:00,DB13326,Euflavine,,,,,,,,,0.00207,,2.35,[Cl-].C[N+]1=C2C=C(N)C=CC2=CC2=C1C=C(N)C=C2,,,,,0,,259.0876251,3,3,1,1,0,0
9053,04/06/2019 00:00,DB13327,Picotamide,,,,,,,,,0.0168,13.44,5.12,COC1=CC=C(C=C1C(=O)NCC1=CC=CN=C1)C(=O)NCC1=CC=CN=C1,,,,,0,,376.1535405,3,3,2,2,0,0
9054,04/06/2019 00:00,DB13328,Butanilicaine,,,,,,,,,0.0535,3.01,8.92,CCCCNCC(O)=NC1=C(C)C=CC=C1Cl,,,,,0,,254.1185909,1,1,0,0,0,0
9055,04/06/2019 00:00,DB13329,Guaiazulen,,,,,,,,,0.14,,,CC(C)C1=CC2=C(C)C=CC2=C(C)C=C1,,,,,0,,198.1408506,2,0,0,0,0,0
9056,04/06/2019 00:00,DB13330,Amezinium metilsulfate,,,,,,,,,0.117,,-1.9,COS([O-])(=O)=O.COC1=CC(N)=CN=[N+]1C1=CC=CC=C1,,,,,0,,313.0732416,2,2,1,1,0,0
9057,04/06/2019 00:00,DB13331,Pyrithyldione,,,,,,,,,1.61,3.27,5.16,CCC1(CC)C(O)=NC=CC1=O,,,,,0,,167.0946287,1,0,1,0,0,1
9058,04/06/2019 00:00,DB13332,Dibutylsuccinate,,,,,,,,,0.339,,-6.7,CCCCOC(=O)CCC(=O)OCCCC,,,,,0,,230.1518092,0,0,0,0,0,0
9059,04/06/2019 00:00,DB13333,Efloxate,,,,,,,,,0.00781,15.8,-4.8,CCOC(=O)COC1=CC2=C(C=C1)C(=O)C=C(O2)C1=CC=CC=C1,,,,,0,,324.0997736,3,3,1,1,0,0
9060,04/06/2019 00:00,DB13334,Mannosulfan,,,,,,,,,3.62,12.7,-3.7,CS(=O)(=O)OC[C@@H](OS(C)(=O)=O)[C@@H](O)[C@H](O)[C@@H](COS(C)(=O)=O)OS(C)(=O)=O,,,,,0,,493.9892394,0,0,0,0,0,0
9061,04/06/2019 00:00,DB13335,Pinazepam,,,,,,,,,0.00918,,2.89,ClC1=CC2=C(C=C1)N(CC#C)C(=O)CN=C2C1=CC=CC=C1,,,,,0,,308.0716407,3,2,1,0,0,1
9062,04/06/2019 00:00,DB13336,Dimethylphthalate,,,,,,,,,1.09,,-6.6,COC(=O)C1=CC=CC=C1C(=O)OC,,,,,0,,194.0579088,1,1,0,0,0,0
9063,04/06/2019 00:00,DB13337,Pheneticillin,,,,,,,,,0.356,3.47,-4.9,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C)OC1=CC=CC=C1)C(O)=O,,,,,0,,364.1092927,3,1,2,0,2,2
9064,04/06/2019 00:00,DB13338,Flurithromycin,,,,,,,,,0.355,11.82,8.38,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,,,,,0,,751.4518194,3,0,3,0,3,3
9065,04/06/2019 00:00,DB13339,Etoglucid,,,,,,,,,2.79,,-3.4,C(COCCOCC1CO1)OCCOCC1CO1,,,,,0,,262.1416384,2,0,2,0,2,2
9066,04/06/2019 00:00,DB13340,Suloctidil,,,,,,,,,0.000974,13.87,9.76,CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1,,,,,0,,337.2439357,1,1,0,0,0,0
9067,04/06/2019 00:00,DB13341,Fenozolone,,,,,,,,,0.257,3.48,1.4,CCN=C1OC(C(O)=N1)C1=CC=CC=C1,,,,,0,,204.0898776,2,1,1,0,0,1
9068,04/06/2019 00:00,DB13342,Cinepazet,,,,,,,,,0.325,,4.86,CCOC(=O)CN1CCN(CC1)C(=O)\C=C\C1=CC(OC)=C(OC)C(OC)=C1,,,,,0,,392.1947366,2,1,1,0,1,1
9069,04/06/2019 00:00,DB13343,Tioxolone,,,,,,,,,3.71,7.35,-5.8,OC1=CC2=C(SC(=O)O2)C=C1,,,,,0,,167.988115,2,2,1,1,0,0
9070,04/06/2019 00:00,DB13344,Mercuric amidochloride,,,,,,,,,132,,8.86,[NH2-].[Cl-].[Hg++],,,,,0,,252.9582197,0,0,0,0,0,0
9071,04/06/2019 00:00,DB13345,Dihydroergocristine,"Dihydroergocristine presents an absorption in the digestive tract of about 25% of the administered dose. When dihydroergocristine was orally administered in humans and the peak plasma concentration of 0.28 mcg/l was achieved after 0.46 hours. In the same report, the AUC was reported to be 0.39 mcg/l.h.[A32881] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].",0.68,"The half-life of dihydroergocristine has only been studied as part of the therapeutic mixture, please refer to [DB01049].",,Oral,solid,10 mg/ml,5.86,0.0492,4.75,8.68,[H][C@@]12CCCN1C(=O)[C@]([H])(CC1=CC=CC=C1)N1C(=O)[C@@](O[C@@]21O)(N=C(O)[C@@]1([H])CN(C)[C@]2([H])CC3=CNC4=CC=CC(=C34)[C@@]2([H])C1)C(C)C,0.68,0.68,,,0,,611.3107694,8,3,5,1,4,4
9072,04/06/2019 00:00,DB13346,Bufexamac,"Method of application affects the extent of cutaneous absorption [A27192]. Following rectal administration as suppositories, the systemic absorption was reported to be low [A32823]. ",,No data available. ,0.05,Topical,solid,Immiscible,,0.233,8.86,-4.8,CCCCOC1=CC=C(CC(=O)NO)C=C1,,,,,0,,223.1208434,1,1,0,0,0,0
9073,04/06/2019 00:00,DB13347,Diphenadione,,,,,,,,,0.000755,4.18,-7.4,O=C(C(C1=CC=CC=C1)C1=CC=CC=C1)C1C(=O)C2=CC=CC=C2C1=O,,,,,0,,340.1099444,4,3,0,0,0,0
9074,04/06/2019 00:00,DB13348,Tiadenol,,,,,,,,,0.0021,15.25,-2.6,OCCSCCCCCCCCCCSCCO,,,,,0,,294.1687222,0,0,0,0,0,0
9075,04/06/2019 00:00,DB13349,Talastine,,,,,,,,,0.0692,,8.05,CN(C)CCN1N=C(CC2=CC=CC=C2)C2=CC=CC=C2C1=O,,,,,0,,307.1684623,3,3,1,1,0,0
9076,04/06/2019 00:00,DB13350,Azanidazole,,,,,,,,,0.806,16.59,4.06,CN1C(\C=C\C2=CC=NC(N)=N2)=NC=C1[N+]([O-])=O,,,,,0,,246.0865236,2,2,2,2,0,0
9077,04/06/2019 00:00,DB13351,Piperidolate,,,,,,,,,0.0111,,8.31,CCN1CCCC(C1)OC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,323.188529,3,2,1,0,1,1
9078,04/06/2019 00:00,DB13352,Deanol,,,,,,,,,1400,15.59,9.03,CN(C)CCO,,,,,0,,89.08406397,0,0,0,0,0,0
9079,04/06/2019 00:00,DB13353,Viminol,,,,,,,,,0.00865,13.86,10.14,CCC(C)N(CC(O)C1=CC=CN1CC1=CC=CC=C1Cl)C(C)CC,,,,,0,,362.2124913,2,2,1,1,0,0
9080,04/06/2019 00:00,DB13354,Phenprobamate,,,,,,,,,0.514,15.69,,NC(=O)OCCCC1=CC=CC=C1,,,,,0,,179.0946287,1,1,0,0,0,0
9081,04/06/2019 00:00,DB13355,Visnadine,,,,,,,,,0.0257,,-4.9,[H][C@@](C)(CC)C(=O)O[C@]1([H])[C@]([H])(OC(C)=O)C2=C(OC1(C)C)C=CC1=C2OC(=O)C=C1,,,,,0,,388.1522031,3,2,2,1,0,1
9082,04/06/2019 00:00,DB13356,Mesulfen,,,,,,,,,0.00192,,,CC1=CC=C2SC3=CC(C)=CC=C3SC2=C1,,,,,0,,244.0380424,3,2,1,0,0,1
9083,04/06/2019 00:00,DB13357,Styramate,,,,,,,,,5.83,13.66,-3.4,NC(=O)OCC(O)C1=CC=CC=C1,,,,,0,,181.0738932,1,1,0,0,0,0
9084,04/06/2019 00:00,DB13358,Cibenzoline,,,,,,,,,0.00485,,10.41,C1C(C2=NCCN2)C1(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,262.1469986,4,2,1,0,0,1
9085,04/06/2019 00:00,DB13360,Tolciclate,,,,,,,,,0.000373,,0.076,CN(C(=S)OC1=CC=C2[C@H]3CC[C@H](C3)C2=C1)C1=CC(C)=CC=C1,,,,,0,,323.1343853,4,2,0,0,0,0
9086,04/06/2019 00:00,DB13361,Trimethyldiphenylpropylamine,,,,,,,,,0.00539,,9.91,CC(CC(C1=CC=CC=C1)C1=CC=CC=C1)N(C)C,,,,,0,,253.1830497,2,2,0,0,0,0
9087,04/06/2019 00:00,DB13362,Pheneturide,,,,,,,,,0.118,3.39,4.63,CCC(C(O)=NC(O)=N)C1=CC=CC=C1,,,,,0,,206.1055277,1,1,0,0,0,0
9088,04/06/2019 00:00,DB13363,Oxaceprol,,,,,,,,,640,3.69,-1.8,[H][C@]1(O)CN(C(C)=O)[C@@]([H])(C1)C(O)=O,,,,,0,,173.0688078,1,0,1,0,1,1
9089,04/06/2019 00:00,DB13364,Feprazone,,,,,,,,,0.106,5.17,,CC(C)=CCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,320.1524779,3,2,1,0,1,1
9090,04/06/2019 00:00,DB13367,Cloricromen,,,,,,,,,0.0624,,9.1,CCOC(=O)COC1=CC=C2C(C)=C(CCN(CC)CC)C(=O)OC2=C1Cl,,,,,0,,395.1499506,2,2,1,1,0,0
9091,04/06/2019 00:00,DB13368,Motretinide,,,,,,,,,0.000767,16.33,-0.22,CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C,,,,,0,,353.2354792,1,1,0,0,0,0
9092,04/06/2019 00:00,DB13369,Benzilone,,,,,,,,,0.000375,11.05,-4.5,CC[N+]1(CC)CCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,354.2063702,3,2,1,0,1,1
9093,04/06/2019 00:00,DB13370,Bromisoval,,,,,,,,,0.45,2.67,3.56,CC(C)C(Br)C(O)=NC(O)=N,,,,,0,,222.0003897,0,0,0,0,0,0
9094,04/06/2019 00:00,DB13371,Difenpiramide,,,,,,,,,0.00557,12.02,4.04,O=C(CC1=CC=C(C=C1)C1=CC=CC=C1)NC1=CC=CC=N1,,,,,0,,288.1262631,3,3,1,1,0,0
9095,04/06/2019 00:00,DB13374,Vincamine,,,,,,,,,0.216,10.52,6.7,[H][C@]12N3CCC[C@@]1(CC)C[C@@](O)(N1C4=CC=CC=C4C(CC3)=C21)C(=O)OC,,,,,0,,354.1943427,5,2,4,1,1,3
9096,04/06/2019 00:00,DB13376,Succinimide,,,,,,,,,228,9.9,-7.2,O=C1CCC(=O)N1,,,,,0,,99.0320284,1,0,1,0,1,1
9097,04/06/2019 00:00,DB13377,Vinbarbital,,,,,,,,,0.512,1.23,-4.3,[H]\C(CC)=C(\C)C1(CC)C(O)=NC(=O)N=C1O,,,,,0,,224.1160924,1,0,1,0,0,1
9098,04/06/2019 00:00,DB13378,Norfenefrine,,,,,,,,,18.6,9.56,8.91,NCC(O)C1=CC(O)=CC=C1,,,,,0,,153.0789786,1,1,0,0,0,0
9099,04/06/2019 00:00,DB13379,Chiniofon,,,,,,,,,0.496,-4.4,2.82,[Na+].OC([O-])=O.OC1=C(I)C=C(C2=CC=CN=C12)S(O)(=O)=O,,,,,0,,434.8885648,2,2,1,1,0,0
9100,04/06/2019 00:00,DB13380,Difemerine,,,,,,,,,0.125,11.05,8.99,CN(C)C(C)(C)COC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,327.1834437,2,2,0,0,0,0
9101,04/06/2019 00:00,DB13381,Sodium feredetate,,,,,Oral,,,,0.0541,1.12,-7,[Na+].[O-]C(=O)C[N+]12CC[N+]34CC(=O)O[Fe--]13(OC(=O)C2)OC(=O)C4,,,,,0,,366.9840721,4,0,4,0,4,4
9102,04/06/2019 00:00,DB13382,Chlorproethazine,,,,,,,,,0.00107,,9.74,CCN(CC)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,,,,,0,,346.1270474,3,2,1,0,0,1
9103,04/06/2019 00:00,DB13383,Diiodohydroxypropane,,,,,,,,,0.564,14.16,-3.2,OC(CI)CI,,,,,0,,311.8508108,0,0,0,0,0,0
9104,04/06/2019 00:00,DB13384,Melitracen,,,,,,,,,0.00318,,9.76,CN(C)CCC=C1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12,,,,,0,,291.1986998,3,2,0,0,0,0
9105,04/06/2019 00:00,DB13386,Epimestrol,,,,,,,,,0.0143,13.62,-3.2,COC1=CC=C2[C@H]3CC[C@]4(C)[C@H](O)[C@H](O)C[C@H]4[C@@H]3CCC2=C1,,,,,0,,302.1881947,4,1,0,0,0,0
9106,04/06/2019 00:00,DB13387,Hematin,,,,,,,,,0.0583,3.68,4.96,[OH-].[Fe+3].CC1=C2[N-]C(\C=C3/N=C(/C=C4\[N-]\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O,,,,,0,,633.1800327,5,3,5,3,0,2
9107,04/06/2019 00:00,DB13388,Phenylmercuric nitrate,,,,,,,,,13.4,,-3.5,[O-][N+](=O)O[Hg]C1=CC=CC=C1,,,,,0,,340.997586,1,1,0,0,0,0
9108,04/06/2019 00:00,DB13389,Iopydol,,,,,,,,,4.82,13.98,-3,OCC(O)CN1C=C(I)C(=O)C(I)=C1,,,,,0,,420.8671891,1,1,1,1,0,0
9109,04/06/2019 00:00,DB13391,Levoverbenone,,,,,,,,,3.84,19.84,-4.7,[H][C@]12C[C@]([H])(C(=O)C=C1C)C2(C)C,,,,,0,,150.1044651,3,0,0,0,0,0
9110,04/06/2019 00:00,DB13392,Mercurochrome,,,,,,,,,0.0844,15.6,2.47,O[Hg]C1=C2OC3=CC(=O)C(Br)=CC3=C(C2=CC(Br)=C1O[Na])C1=CC=CC=C1C(=O)O[Na],,,,,0,,749.8189437,4,2,1,0,0,1
9111,04/06/2019 00:00,DB13393,Emetine,,,,,,,,,0.00282,,9.11,[H][C@]1(C[C@@]2([H])C[C@]3([H])N(CCC4=CC(OC)=C(OC)C=C34)C[C@]2([H])CC)NCCC2=CC(OC)=C(OC)C=C12,,,,,0,,480.2988078,5,2,3,0,1,3
9112,04/06/2019 00:00,DB13394,Adrenalone,,,,,,,,,8.68,7.5,8.24,CNCC(=O)C1=CC(O)=C(O)C=C1,,,,,0,,181.0738932,1,1,0,0,0,0
9113,04/06/2019 00:00,DB13395,Eprozinol,,,,,,,,,0.174,14.44,7.89,COC(CN1CCN(CCC(O)C2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,354.2307282,3,2,1,0,1,1
9114,04/06/2019 00:00,DB13396,Neocitrullamon,,,,,,,,,0.0177,1.68,9.2,NC(CCCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(O)=O,,,,,0,,367.1532062,3,2,1,0,1,1
9115,04/06/2019 00:00,DB13397,Prenoxdiazine,,,,,,,,,0.02,,8.49,C(CC1=NC(CC(C2=CC=CC=C2)C2=CC=CC=C2)=NO1)N1CCCCC1,,,,,0,,361.2154125,4,3,2,1,1,1
9116,04/06/2019 00:00,DB13398,Oxyfedrine,,,,,,,,,0.0217,13.88,9.06,COC1=CC(=CC=C1)C(=O)CCN[C@@H](C)[C@H](O)C1=CC=CC=C1,,,,,0,,313.1677936,2,2,0,0,0,0
9117,04/06/2019 00:00,DB13399,Terguride,,,,,,,,,0.131,-2.3,15,[H][C@]1(CN(C)[C@]2([H])CC3=CNC4=CC=CC(=C34)[C@@]2([H])C1)N=C(O)N(CC)CC,,,,,0,,340.2263115,4,2,2,1,1,1
9118,04/06/2019 00:00,DB13400,Linsidomine,,,,,,,,,31.2,10.02,-2.9,[NH-]C1=C[N+](=NO1)N1CCOCC1,,,,,0,,170.0803756,2,1,2,1,1,1
9119,04/06/2019 00:00,DB13401,Metildigoxin,,,,,,,,,0.0608,7.15,-3,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@]([H])(CC[C@]4(C)[C@@]3([H])C[C@@]([H])(O)[C@]12C)O[C@@]1([H])C[C@]([H])(O)[C@]([H])(O[C@@]2([H])C[C@]([H])(O)[C@]([H])(O[C@@]3([H])C[C@]([H])(O)[C@]([H])(OC)[C@@]([H])(C)O3)[C@@]([H])(C)O2)[C@@]([H])(C)O1)C1=CC(=O)OC1,,,,,0,,794.4452568,8,0,4,0,3,4
9120,04/06/2019 00:00,DB13402,Acetylglycinamide chloral hydrate,,,,,,,,,43.4,3.77,-2,OC(O)C(Cl)(Cl)Cl.CC(=O)NCC(O)=O,,,,,0,,280.9624555,0,0,0,0,0,0
9121,04/06/2019 00:00,DB13403,Oxypertine,,,,,,,,,0.0349,17.51,8.51,COC1=C(OC)C=C2C(NC(C)=C2CCN2CCN(CC2)C2=CC=CC=C2)=C1,,,,,0,,379.2259772,4,3,2,1,1,1
9122,04/06/2019 00:00,DB13404,Edetate sodium,,,,,,,,,97.1,1.49,8.13,[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,,,,,0,,380.0184425,0,0,0,0,0,0
9123,04/06/2019 00:00,DB13405,Mefruside,,,,,,,,,0.221,8.68,-4.2,CN(CC1(C)CCCO1)S(=O)(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O,,,,,0,,382.0423914,2,1,1,0,1,1
9124,04/06/2019 00:00,DB13406,Carbutamide,,,,,,,,,0.348,1.72,2.83,CCCCN=C(O)NS(=O)(=O)C1=CC=C(N)C=C1,,,,,0,,271.0990624,1,1,0,0,0,0
9125,04/06/2019 00:00,DB13407,Nifenazone,,,,,,,,,0.393,7.23,3.85,CN1N(C(=O)C(N=C(O)C2=CN=CC=C2)=C1C)C1=CC=CC=C1,,,,,0,,308.1273258,3,3,2,2,0,0
9126,04/06/2019 00:00,DB13408,Methylpropylpropanediol dinitrate,,,,,,,,,0.153,,-5.8,CCCC(C)(CO[N+]([O-])=O)CO[N+]([O-])=O,,,,,0,,222.0851862,0,0,0,0,0,0
9127,04/06/2019 00:00,DB13409,Rokitamycin,,,,,,,,,0.061,12.71,7.9,CCCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(=O)CC)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C,,,,,0,,827.4667205,3,0,3,0,2,3
9128,04/06/2019 00:00,DB13410,Guanoxabenz,,,,,,,,,0.0951,14.79,6.25,ONC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl,,,,,0,,246.0075162,1,1,0,0,0,0
9129,04/06/2019 00:00,DB13411,Lofepramine,,,,,,,,,0.000838,17.02,6.53,CN(CCCN1C2=CC=CC=C2CCC2=CC=CC=C12)CC(=O)C1=CC=C(Cl)C=C1,,,,,0,,418.1811912,4,3,1,0,0,1
9130,04/06/2019 00:00,DB13412,Pirisudanol,,,,,,,,,1.64,9.44,8.38,CN(C)CCOC(=O)CCC(=O)OCC1=C(CO)C(O)=C(C)N=C1,,,,,0,,340.1634365,1,1,1,1,0,0
9131,04/06/2019 00:00,DB13413,Phenglutarimide,,,,,,,,,0.187,11.7,9.96,CCN(CC)CCC1(CCC(=O)NC1=O)C1=CC=CC=C1,,,,,0,,288.183778,2,1,1,0,1,1
9132,04/06/2019 00:00,DB13414,Fenyramidol,,,,,,,,,0.94,14.1,6.61,OC(CNC1=CC=CC=N1)C1=CC=CC=C1,,,,,0,,214.1106131,2,2,1,1,0,0
9133,04/06/2019 00:00,DB13415,Pentetrazol,,,,,,,,,4.51,,-0.45,C1CCN2N=NN=C2CC1,,,,,0,,138.0905463,2,1,2,1,0,1
9134,04/06/2019 00:00,DB13416,Sulbutiamine,,,,,,,,,0.0467,,6.56,CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(CC1=C(N)N=C(C)N=C1)C=O)=C(\C)N(CC1=C(N)N=C(C)N=C1)C=O,,,,,0,,702.2981732,2,2,2,2,0,0
9135,04/06/2019 00:00,DB13417,Morinamide,,,,,,,,,3.67,7.88,1.89,OC(=NCN1CCOCC1)C1=CN=CC=N1,,,,,0,,222.1116757,2,1,2,1,1,1
9136,04/06/2019 00:00,DB13418,Moxestrol,,,,,,,,,0.00928,10.21,-3.7,CO[C@H]1C[C@@]2(C)[C@@H](CC[C@@]2(O)C#C)[C@@H]2CCC3=CC(O)=CC=C3[C@@H]12,,,,,0,,326.1881947,4,1,0,0,0,0
9137,04/06/2019 00:00,DB13419,Troxipide,,,,,,,,,0.327,7.58,9.79,COC1=CC(=CC(OC)=C1OC)C(O)=NC1CCCNC1,,,,,0,,294.1579572,2,1,1,0,1,1
9138,04/06/2019 00:00,DB13420,Thiazinam,,,,,,,,,0.000171,,-4.7,CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)[N+](C)(C)C,,,,,1,,299.1576462,3,2,1,0,0,1
9139,04/06/2019 00:00,DB13421,Edoxudine,"Edoxudine cream is able to penetrate the skin in a very rapid manner. This easy penetration allows edoxudine to have a greater activity when compared with other topical antivirals that have better antiviral activity in vitro.[A32643] In preclinical trials in mice, after intravenous administration of edoxudine, the mean residence time was 25 min. Edoxudine presented a bioavailability of 49% with a Cmax and tmax of 2.4 mcg/g and 31.1 min respectively. The AUC in plasma of edoxudine is significantly higher when administered orally when compared with intravenous administration.[A27185]",,"In preclinical trials on mice, after intravenous administration, edoxudine presented a very short distribution half-life of 1.4 min. In the same trials, the elimination half-life was reported to be of 24.1 min.[A27185]",0.03,Topical,solid,>38.4 mcg/ml,-1.09,61.4,9.95,-3,CCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O,,,,,0,,256.1059216,2,1,2,1,1,1
9140,04/06/2019 00:00,DB13422,Nicofuranose,,,,,,,,,0.0593,10.22,3.84,[H][C@]1(COC(=O)C2=CN=CC=C2)O[C@](O)(COC(=O)C2=CN=CC=C2)[C@@]([H])(OC(=O)C2=CN=CC=C2)[C@]1([H])OC(=O)C1=CN=CC=C1,,,,,0,,600.149243,5,4,5,4,1,1
9141,04/06/2019 00:00,DB13424,Clofenotane,,,,,,,,,3.52E-06,,,ClC1=CC=C(C=C1)C(C1=CC=C(Cl)C=C1)C(Cl)(Cl)Cl,,,,,0,,351.9146887,2,2,0,0,0,0
9142,04/06/2019 00:00,DB13425,Flutrimazole,,,,,,,,,0.000894,,6.62,FC1=CC=C(C=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1F,,,,,0,,346.128155,4,4,1,1,0,0
9143,04/06/2019 00:00,DB13428,Iobenzamic acid,,,,,,,,,0.00929,2.7,0.93,NC1=C(I)C=C(I)C(C(=O)N(CCC(O)=O)C2=CC=CC=C2)=C1I,,,,,0,,661.8060363,2,2,0,0,0,0
9144,04/06/2019 00:00,DB13429,Tolonidine,,,,,,,,,0.764,,9.01,CC1=CC=C(NC2=NCCN2)C(Cl)=C1,,,,,0,,209.0719751,2,1,1,0,0,1
9145,04/06/2019 00:00,DB13430,Mebutizide,,,,,,,,,0.324,9.06,-2.6,CCC(C)C(C)C1NC2=CC(Cl)=C(C=C2S(=O)(=O)N1)S(N)(=O)=O,,,,,0,,381.0583758,2,1,1,0,0,1
9146,04/06/2019 00:00,DB13431,Proglumide,,,,,,,,,0.141,4.42,2.24,CCCN(CCC)C(=O)C(CCC(O)=O)N=C(O)C1=CC=CC=C1,,,,,0,,334.1892573,1,1,0,0,0,0
9147,04/06/2019 00:00,DB13432,Lonazolac,,,,,,,,,0.00937,4.31,1.89,OC(=O)CC1=CN(N=C1C1=CC=C(Cl)C=C1)C1=CC=CC=C1,,,,,0,,312.0665553,3,3,1,1,0,0
9148,04/06/2019 00:00,DB13433,Simfibrate,,,,,,,,,0.000181,,-4.6,CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,,,,,0,,468.1106439,2,2,0,0,0,0
9149,04/06/2019 00:00,DB13434,Fenticonazole,,,,,,,,,0.000304,,6.77,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CC=C(SC2=CC=CC=C2)C=C1,,,,,0,,454.0673396,4,4,1,1,0,0
9150,04/06/2019 00:00,DB13435,Endralazine,,,,,,,,,0.257,10.32,-1,N\N=C1/NN=C2CCN(CC2=C1)C(=O)C1=CC=CC=C1,,,,,0,,269.1276601,3,2,2,1,0,1
9151,04/06/2019 00:00,DB13436,Droxypropine,,,,,,,,,0.567,15.12,8.06,CCC(=O)C1(CCN(CCOCCO)CC1)C1=CC=CC=C1,,,,,0,,305.1990937,2,1,1,0,1,1
9152,04/06/2019 00:00,DB13437,Medazepam,,,,,,,,,0.0126,,9.57,CN1CCN=C(C2=CC=CC=C2)C2=C1C=CC(Cl)=C2,,,,,0,,270.0923762,3,2,1,0,0,1
9153,04/06/2019 00:00,DB13438,Prolintane,,,,,,,,,0.0233,,10.46,CCCC(CC1=CC=CC=C1)N1CCCC1,,,,,0,,217.1830497,2,1,1,0,1,1
9154,04/06/2019 00:00,DB13439,Fenpiprane,,,,,,,,,0.00108,,9.85,C(CN1CCCCC1)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,279.1986998,3,2,1,0,1,1
9155,04/06/2019 00:00,DB13441,Niceritrol,,,,,,,,,0.0115,,3.84,O=C(OCC(COC(=O)C1=CN=CC=C1)(COC(=O)C1=CN=CC=C1)COC(=O)C1=CN=CC=C1)C1=CN=CC=C1,,,,,0,,556.1594137,4,4,4,4,0,0
9156,04/06/2019 00:00,DB13442,Citiolone,,,,,,,,,8.12,5.78,1.79,CC(O)=NC1CCSC1=O,,,,,0,,159.0353995,1,0,1,0,1,1
9157,04/06/2019 00:00,DB13443,Esatenolol,,,,,,,,,0.429,14.08,9.67,CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1,,,,,0,,266.1630426,1,1,0,0,0,0
9158,04/06/2019 00:00,DB13444,Ioxitalamic acid,"When administered ioxitalamate is not absorbed in the GI tract. In the case of presence of an intestinal perforation, ioxitalamate is completely absorbed.[F55] When administered intravascularly, ioxitalamate is rapidly distributed in the interstitial space and intravascular compartment.[F56]",0.27,The elimination half-life of ioxitalamate is 1.1 hours.[T56],,Oral,solid,Soluble,,0.0525,2.87,1.91,CC(O)=NC1=C(I)C(C(O)=NCCO)=C(I)C(C(O)=O)=C1I,0.27,0.27,,,0,,643.7802155,1,1,0,0,0,0
9159,04/06/2019 00:00,DB13445,Nepinalone,,,,,,,,,0.0429,19.18,8.98,CC1(CCN2CCCCC2)C(=O)CCC2=CC=CC=C12,,,,,0,,271.1936144,3,1,1,0,1,1
9160,04/06/2019 00:00,DB13448,Mazaticol,,,,,,,,,0.0457,10.4,9.36,CN1[C@@H]2CCC(C)(C)[C@@H]1C[C@@H](C2)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1,,,,,0,,405.1432357,4,2,4,2,2,2
9161,04/06/2019 00:00,DB13449,Proxyphylline,,,,,,,,,14.6,15.17,-0.97,CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C,,,,,0,,238.1065903,2,2,2,2,0,0
9162,04/06/2019 00:00,DB13451,Tioclomarol,,,,,,,,,0.000581,4.83,-3.1,OC(CC(C1=CC=C(Cl)S1)C1=C(O)C2=CC=CC=C2OC1=O)C1=CC=C(Cl)C=C1,,,,,0,,446.0146354,4,4,2,2,0,0
9163,04/06/2019 00:00,DB13452,Cadralazine,,,,,,,,,1.05,5.5,2.08,CCOC(O)=NNC1=NN=C(C=C1)N(CC)CC(C)O,,,,,0,,283.1644395,1,1,1,1,0,0
9164,04/06/2019 00:00,DB13454,Nicomorphine,,,,,,,,,0.0709,,9.1,[H][C@@]12OC3=C(OC(=O)C4=CN=CC=C4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@]2([H])OC(=O)C1=CN=CC=C1,,,,,0,,495.1794209,7,3,4,2,1,2
9165,04/06/2019 00:00,DB13455,Phenibut,,,,,,,,,1.56,4.44,9.8,NCC(CC(O)=O)C1=CC=CC=C1,,,,,0,,179.0946287,1,1,0,0,0,0
9166,04/06/2019 00:00,DB13456,Midecamycin,"Midecamycin is rapidly and almost completely absorbed when orally administered.[A33075] It is mainly absorbed in the alkaline intestinal environment. This rapid absorption is due to its liposoluble property which allows for good penetration in the tissues, especially bronchial secretion, prostatic tissue, middle ear exudates and bone tissue. The tissue/serum ratio concentration is greater than 1 which indicates that this product does not stay long in the plasma. After oral administration of 600 mg of midecamycin, the peak serum concentration is 0.8 mg/L and it is attained 1 hour after oral administration. This concentration dereased significantly after 4-6 hours.[A33081] ",0.15,"The half-life of midecamycin is longer than the first macrolide antibiotics.[A33081] after intravenous administration, the half-life reported is of 54 minutes.[A33082]",,,solid,Insoluble,2.22,0.0935,12.71,7.9,[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C,0.15,0.15,,,0,,813.4510704,3,0,3,0,2,3
9167,04/06/2019 00:00,DB13457,Oxaflozane,,,,,,,,,0.302,,7.2,CC(C)N1CCOC(C1)C1=CC=CC(=C1)C(F)(F)F,,,,,0,,273.1340489,2,1,1,0,1,1
9168,04/06/2019 00:00,DB13458,Thebacon,,,,,,,,,0.179,,9.36,COC1=CC=C2C[C@@H]3[C@@H]4CC=C(OC(C)=O)[C@@H]5OC1=C2[C@]45CCN3C,,,,,0,,341.1627082,5,1,2,0,1,2
9169,04/06/2019 00:00,DB13459,Pecilocin,,,,,,,,,0.181,18.09,-1.4,CCCC[C@@H](O)\C=C(/C)\C=C\C=C\C(=O)N1CCCC1=O,,,,,0,,291.1834437,1,0,1,0,1,1
9170,04/06/2019 00:00,DB13460,Ronifibrate,,,,,,,,,0.0153,,3.24,CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCCOC(=O)C1=CN=CC=C1,,,,,0,,377.1030004,2,2,1,1,0,0
9171,04/06/2019 00:00,DB13461,Cefcapene,,,,,,,,,0.0382,3.11,4.13,CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)C1=CSC(N)=N1,,,,,0,,453.0776753,3,1,3,1,1,2
9172,04/06/2019 00:00,DB13462,Bephenium,,,,,,,,,4.35E-05,18.33,-4.9,C[N+](C)(CCOC1=CC=CC=C1)CC1=CC=CC=C1,,,,,1,,256.1695907,2,2,0,0,0,0
9173,04/06/2019 00:00,DB13463,Oxetorone,,,,,,,,,0.0166,,9.76,CN(C)CCC=C1C2=C(COC3=CC=CC=C13)C1=CC=CC=C1O2,,,,,0,,319.1572289,4,3,2,1,0,1
9174,04/06/2019 00:00,DB13464,Ornipressin,,,,,,,,,0.064,9.25,9.85,NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,,,,,0,,1041.416056,4,2,2,0,2,2
9175,04/06/2019 00:00,DB13465,Ciclobendazole,,,,,,,,,0.129,3.29,1.86,COC(O)=NC1=NC2=C(N1)C=C(C=C2)C(=O)C1CC1,,,,,0,,259.0956913,3,2,1,1,0,0
9176,04/06/2019 00:00,DB13466,Deptropine,,,,,,,,,0.000588,,9.55,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1C2=CC=CC=C2CCC2=C1C=CC=C2,,,,,0,,333.2092645,5,2,2,0,2,2
9177,04/06/2019 00:00,DB13467,Lanatoside C,,,,,,,,,0.3,7.15,-3,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@]([H])(CC[C@]4(C)[C@@]3([H])C[C@@]([H])(O)[C@]12C)O[C@@]1([H])C[C@]([H])(O)[C@]([H])(O[C@@]2([H])C[C@]([H])(O)[C@]([H])(O[C@@]3([H])C[C@]([H])(OC(C)=O)[C@]([H])(O[C@]4([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]4([H])O)[C@@]([H])(C)O3)[C@@]([H])(C)O2)[C@@]([H])(C)O1)C1=CC(=O)OC1,,,,,0,,984.4929948,9,0,5,0,4,5
9178,04/06/2019 00:00,DB13468,Etybenzatropine,,,,,,,,,0.00115,,9.82,CCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,321.2092645,4,2,2,0,2,2
9179,04/06/2019 00:00,DB13469,Phanquinone,,,,,,,,,1.72,,1.69,O=C1C(=O)C2=C(C=CC=N2)C2=C1N=CC=C2,,,,,0,,210.0429274,3,2,2,2,0,0
9180,04/06/2019 00:00,DB13470,Cefodizime,,,,,,,,,0.0931,3.22,6.84,[H][C@]12SCC(CSC3=NC(C)=C(CC(O)=O)S3)=C(N1C(=O)[C@@]2([H])N=C(O)C(=N/OC)\C1=CSC(=N)N1)C(O)=O,,,,,0,,584.027631,4,2,4,2,1,2
9181,04/06/2019 00:00,DB13471,Nalfurafine,,,,,,,,,0.162,10.29,9.51,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CC2)[C@H]1O5)C(=O)\C=C\C1=COC=C1,,,,,0,,476.2311221,7,2,3,1,1,2
9182,04/06/2019 00:00,DB13472,Cyclofenil,,,,,,,,,0.000792,,-6.8,CC(=O)OC1=CC=C(C=C1)C(=C1CCCCC1)C1=CC=C(OC(C)=O)C=C1,,,,,0,,364.1674592,3,2,0,0,0,0
9183,04/06/2019 00:00,DB13474,Tipepidine,,,,,,,,,0.122,,7.84,CN1CCCC(C1)=C(C1=CC=CS1)C1=CC=CS1,,,,,0,,275.0802415,3,2,3,2,1,1
9184,04/06/2019 00:00,DB13475,Furazidin,,,,,,,,,0.14,8.23,0.48,[O-][N+](=O)C1=CC=C(O1)\C=C\C=N\N1CC(=O)NC1=O,,,,,0,,264.0494694,2,1,2,1,1,1
9185,04/06/2019 00:00,DB13476,Diisopromine,,,,,,,,,0.000617,,10.74,CC(C)N(CCC(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C,,,,,0,,295.2299999,2,2,0,0,0,0
9186,04/06/2019 00:00,DB13478,Meptazinol,,,,,,,,,0.354,10.23,9.16,CCC1(CCCCN(C)C1)C1=CC(O)=CC=C1,,,,,0,,233.1779644,2,1,1,0,1,1
9187,04/06/2019 00:00,DB13479,Histapyrrodine,,,,,,,,,0.0597,,9.27,C(CN1CCCC1)N(CC1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,280.1939488,3,2,1,0,1,1
9188,04/06/2019 00:00,DB13481,Tenidap,,,,,,,,,0.00947,4.83,-0.69,NC(=O)N1C(=O)\C(=C(/O)C2=CC=CS2)C2=CC(Cl)=CC=C12,,,,,0,,320.0022408,3,2,2,1,0,1
9189,04/06/2019 00:00,DB13482,Dimefline,,,,,,,,,0.0373,,6.24,COC1=CC=C2C(=O)C(C)=C(OC2=C1CN(C)C)C1=CC=CC=C1,,,,,0,,323.1521435,3,3,1,1,0,0
9190,04/06/2019 00:00,DB13483,Etamsylate,,,,,,,,,17.4,-2.8,-6,CCNCC.OC1=CC(=C(O)C=C1)S(O)(=O)=O,,,,,0,,263.0827436,1,1,0,0,0,0
9191,04/06/2019 00:00,DB13484,Quinbolone,,,,,,,,,0.001,18.86,-4.6,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2OC1=CCCC1,,,,,0,,352.2402303,5,0,0,0,0,0
9192,04/06/2019 00:00,DB13485,Sulfametomidine,,,,,,,,,0.26,7.18,3.66,COC1=NC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1,,,,,0,,294.0786613,2,2,1,1,0,0
9193,04/06/2019 00:00,DB13487,Iodine (131I) norcholesterol,,,,,,,,,0.000117,18.19,-1.4,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](C[131I])C4=C(CC[C@H](O)C4)[C@H]3CC[C@]12C,,,,,0,,516.2531657,4,0,0,0,0,0
9194,04/06/2019 00:00,DB13488,Bencyclane,,,,,,,,,0.000361,,9.46,CN(C)CCCOC1(CC2=CC=CC=C2)CCCCCC1,,,,,0,,289.2405646,2,1,0,0,0,0
9195,04/06/2019 00:00,DB13489,Bamipine,,,,,,,,,0.0434,,8.76,CN1CCC(CC1)N(CC1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,280.1939488,3,2,1,0,1,1
9196,04/06/2019 00:00,DB13490,Hidrosmin,,,,,,,,,1.08,9.55,-2.8,COC1=CC=C(C=C1O)C1=CC(=O)C2=C(OCCO)C=C(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)C=C2O1,,,,,0,,652.2003351,5,3,3,1,2,2
9197,04/06/2019 00:00,DB13491,Fluperolone,,,,,,,,,0.0579,12.53,-3.4,C[C@H](O)C(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,,,,,0,,392.1999022,4,0,0,0,0,0
9198,04/06/2019 00:00,DB13493,Cyclobutyrol,,,,,,,,,11.8,4.71,-3.1,CCC(C(O)=O)C1(O)CCCCC1,,,,,0,,186.1255944,1,0,0,0,0,0
9199,04/06/2019 00:00,DB13494,Dimetofrine,,,,,,,,,10.7,8.97,9.68,CNCC(O)C1=CC(OC)=C(O)C(OC)=C1,,,,,0,,227.115758,1,1,0,0,0,0
9200,04/06/2019 00:00,DB13495,Paraoxon,,,,,,,,,1.44,,-9.2,CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,275.0558738,1,1,0,0,0,0
9201,04/06/2019 00:00,DB13496,Iprindole,,,,,,,,,0.0148,,9.66,CN(C)CCCN1C2=C(CCCCCC2)C2=CC=CC=C12,,,,,0,,284.2252489,3,2,1,1,0,0
9202,04/06/2019 00:00,DB13497,Valethamate,,,,,,,,,6.57E-05,,-7.1,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)C1=CC=CC=C1,,,,,1,,306.2427557,1,1,0,0,0,0
9203,04/06/2019 00:00,DB13499,Cefsulodin,,,,,,,,,0.0186,-1.4,-0.7,NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](C2=CC=CC=C2)S(O)(=O)=O)C3=O)C([O-])=O)C=C1,,,,,0,,532.0722556,4,2,3,1,1,2
9204,04/06/2019 00:00,DB13500,Otilonium,,,,,,,,,2.42E-05,12.75,-3.9,CCCCCCCCOC1=CC=CC=C1C(=O)NC1=CC=C(C=C1)C(=O)OCC[N+](C)(CC)CC,,,,,1,,483.3217343,2,2,0,0,0,0
9205,04/06/2019 00:00,DB13501,Bendazac,"Administered as its lysine salt, a 500 mg oral tablet of bendazac is well absorbed into the human body with maximum plasma concentrations Cmax ranging from 35 to 55 mg/L being attained within 0.5 to 1 hour in healthy volunteers after oral administration of a single 500 mg dose [A39863, A39869].",>99%,"The plasma elimination half-life recorded for bendazac is given as 1.7 to 5.2 hours, with a mean of 3.5 hours [A39863, A39869].",,,,,,0.103,3.66,0.35,OC(=O)COC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12,0.99,1,,,0,,282.1004423,3,3,1,1,0,0
9206,04/06/2019 00:00,DB13502,Budipine,,,,,,,,,0.00129,,9.99,CC(C)(C)N1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,293.2143499,3,2,1,0,1,1
9207,04/06/2019 00:00,DB13504,Cefetamet,,,,,,,,,0.18,3.36,0.72,[H][C@]12SCC(C)=C(N1C(=O)[C@@]2([H])N=C(O)C(=N/OC)\C1=CSC(=N)N1)C(O)=O,,,,,0,,397.0514606,3,1,3,1,1,2
9208,04/06/2019 00:00,DB13505,Emepronium,,,,,,,,,6.80E-06,,,CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,282.2216263,2,2,0,0,0,0
9209,04/06/2019 00:00,DB13506,Carfecillin,,,,,,,,,0.018,3.29,-6.3,CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)OC3=CC=CC=C3)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O,,,,,0,,454.1198574,4,2,2,0,2,2
9210,04/06/2019 00:00,DB13507,Poldine,,,,,,,,,0.000537,11.05,-4.5,C[N+]1(C)CCCC1COC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,340.1907201,3,2,1,0,1,1
9211,04/06/2019 00:00,DB13508,Cloranolol,,,,,,,,,0.0879,14.09,9.76,CC(C)(C)NCC(O)COC1=CC(Cl)=CC=C1Cl,,,,,0,,291.0792842,1,1,0,0,0,0
9212,04/06/2019 00:00,DB13509,Aloxiprin,,,,,,,,,36.2,3.41,-7.1,[O--].[O--].[O--].[Al+3].[Al+3].CC(=O)OC1=CC=CC=C1C(O)=O,,,,,0,,281.9900799,1,1,0,0,0,0
9213,04/06/2019 00:00,DB13510,Buflomedil,,,,,,,,,0.486,15.61,8.69,COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1,,,,,0,,307.1783583,2,1,1,0,1,1
9214,04/06/2019 00:00,DB13511,Clebopride,,,,,,,,,0.0198,14.61,8.52,COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC2=CC=CC=C2)CC1,,,,,0,,373.1557047,3,2,1,0,1,1
9215,04/06/2019 00:00,DB13512,Clefamide,,,,,,,,,0.00872,15.54,-2.5,OCCN(CC1=CC=C(OC2=CC=C(C=C2)N(=O)=O)C=C1)C(=O)C(Cl)Cl,,,,,0,,398.043627,2,2,0,0,0,0
9216,04/06/2019 00:00,DB13513,Tribromometacresol,,,,,,,,,0.0149,6.51,-7.7,CC1=C(Br)C=C(Br)C(O)=C1Br,,,,,0,,341.7890511,1,1,0,0,0,0
9217,04/06/2019 00:00,DB13514,Pranoprofen,,,,,,,,,1.03,3.63,2.24,CC(C(O)=O)C1=CC2=C(OC3=C(C2)C=CC=N3)C=C1,,,,,0,,255.0895433,3,2,2,1,0,1
9218,04/06/2019 00:00,DB13515,Levomethadone,,,,,,,,,0.0059,18.78,9.12,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,309.2092645,2,2,0,0,0,0
9219,04/06/2019 00:00,DB13516,Clodantoin,,,,,,,,,0.00216,10.05,,CCCCC(CC)C1NC(=O)N(SC(Cl)(Cl)Cl)C1=O,,,,,0,,346.0076318,1,0,1,0,1,1
9220,04/06/2019 00:00,DB13517,Angiotensinamide,,,,,,,,,0.0169,3.42,11.7,CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O,,,,,0,,1030.534849,4,3,2,1,1,1
9221,04/06/2019 00:00,DB13519,Cerium oxalate,,,,,,,,,3.6,1.36,,[Ce+3].[Ce+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O,,,,,0,,543.7498528,0,0,0,0,0,0
9222,04/06/2019 00:00,DB13520,Metergoline,,,,,,,,,0.0109,4.35,8.69,[H][C@]1(CN=C(O)OCC2=CC=CC=C2)CN(C)[C@]2([H])CC3=CN(C)C4=CC=CC(=C34)[C@@]2([H])C1,,,,,0,,403.2259772,5,3,2,1,1,1
9223,04/06/2019 00:00,DB13522,Mebicar,,,,,,,,,244,,-2.7,CN1[C@H]2[C@@H](N(C)C1=O)N(C)C(=O)N2C,,,,,0,,198.1116757,2,0,2,0,2,2
9224,04/06/2019 00:00,DB13523,Veralipride,,,,,,,,,0.185,5.93,8.61,COC1=CC(=CC(C(O)=NCC2CCCN2CC=C)=C1OC)S(N)(=O)=O,,,,,0,,383.1514919,2,1,1,0,1,1
9225,04/06/2019 00:00,DB13524,Propyphenazone,,,,,Oral,,,,9.26,,0.47,CC(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1,,,,,0,,230.1419132,2,2,1,1,0,0
9226,04/06/2019 00:00,DB13526,Pentaerithrityl,,,,,,,,,479,14.3,-2.8,OCC(CO)(CO)CO,,,,,0,,136.0735589,0,0,0,0,0,0
9227,04/06/2019 00:00,DB13527,Proglumetacin,,,,,,,,,0.00114,8.69,8.03,CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CCOC(=O)CC2=C(C)N(C(=O)C3=CC=C(Cl)C=C3)C3=C2C=C(OC)C=C3)CC1)N=C(O)C1=CC=CC=C1,,,,,0,,843.3973915,5,4,2,1,1,1
9228,04/06/2019 00:00,DB13528,Chlormadinone,,,,,,,,,0.00677,12.7,-3.8,[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)CC[C@]12C,,,,,0,,362.1648724,4,0,0,0,0,0
9229,04/06/2019 00:00,DB13529,Dobesilic acid,,,,,,,,,17.4,-2.8,-6,OC1=CC(=C(O)C=C1)S(O)(=O)=O,,,,,0,,189.9935943,1,1,0,0,0,0
9230,04/06/2019 00:00,DB13530,Mepindolol,,,,,,,,,0.354,14.09,9.67,CC(C)NCC(O)COC1=CC=CC2=C1C=C(C)N2,,,,,0,,262.1681279,2,2,1,1,0,0
9231,04/06/2019 00:00,DB13531,Nicofetamide,,,,,,,,,0.00398,15.01,3.62,O=C(NC(CC1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CN=C1,,,,,0,,302.1419132,3,3,1,1,0,0
9232,04/06/2019 00:00,DB13532,Cyclopenthiazide,,,,,,,,,0.279,9.07,-2.6,NS(=O)(=O)C1=CC2=C(NC(CC3CCCC3)NS2(=O)=O)C=C1Cl,,,,,0,,379.0427257,3,1,1,0,0,1
9233,04/06/2019 00:00,DB13533,Methylestrenolone,,,,,,,,,0.0302,19.28,-0.53,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,,,,,0,,288.2089301,4,0,0,0,0,0
9234,04/06/2019 00:00,DB13534,Gedocarnil,,,,,,,,,0.00156,11.58,2.43,COCC1=C(N=CC2=C1C1=C(N2)C=CC=C1OC1=CC=C(Cl)C=C1)C(=O)OC(C)C,,,,,0,,424.1189848,4,4,2,2,0,0
9235,04/06/2019 00:00,DB13536,Broxyquinoline,,,,,,,,,0.105,7.14,3.31,OC1=C2N=CC=CC2=C(Br)C=C1Br,,,,,0,,300.873788,2,2,1,1,0,0
9236,04/06/2019 00:00,DB13537,Gitoformate,,,,,,,,,0.0169,6.82,-3.2,C[C@H]1O[C@H](C[C@H](OC=O)[C@@H]1OC=O)O[C@@H]1[C@@H](C)O[C@H](C[C@@H]1OC=O)O[C@@H]1[C@@H](C)O[C@H](C[C@@H]1OC=O)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@H]([C@H](C[C@]32O)OC=O)C2=CC(=O)OC2)C1,,,,,0,,920.4041798,8,0,4,0,3,4
9237,04/06/2019 00:00,DB13538,Guacetisal,,,,,,,,,0.0169,,-4.9,COC1=CC=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O,,,,,0,,286.0841235,2,2,0,0,0,0
9238,04/06/2019 00:00,DB13539,Iodoxamic acid,,,,,,,,,0.00307,2.64,-0.44,OC(CCOCCOCCOCCOCCC(O)=NC1=C(I)C=C(I)C(C(O)=O)=C1I)=NC1=C(I)C=C(I)C(C(O)=O)=C1I,,,,,0,,1287.585583,2,2,0,0,0,0
9239,04/06/2019 00:00,DB13540,Isepamicin,,,,,,,,,89,4.68,9.97,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](N)C[C@H]2N=C(O)[C@@H](O)CN)OC[C@]1(C)O,,,,,0,,569.2908218,3,0,2,0,2,2
9240,04/06/2019 00:00,DB13541,Iprazochrome,,,,,,,,,0.397,3.75,5.18,CC(C)N1CC(O)C2=C\C(=N\NC(O)=N)C(=O)C=C12,,,,,0,,264.1222404,2,0,1,0,1,1
9241,04/06/2019 00:00,DB13542,Bevonium,,,,,,,,,0.000297,11.05,-4.5,C[N+]1(C)CCCCC1COC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,354.2063702,3,2,1,0,1,1
9242,04/06/2019 00:00,DB13543,Mitobronitol,,,,,,,,,39.7,12.63,-3.5,[H][C@@](O)(CBr)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)CBr,,,,,0,,305.9102331,0,0,0,0,0,0
9243,04/06/2019 00:00,DB13544,Ethenzamide,,,,,Oral,,,,0.841,7.9,6.2,CCOC1=CC=CC=C1C(O)=N,,,,,0,,165.0789786,1,1,0,0,0,0
9244,04/06/2019 00:00,DB13545,Isobromindione,,,,,,,,,0.00722,4.55,-7.5,BrC1=CC=C2C(=O)C(C(=O)C2=C1)C1=CC=CC=C1,,,,,0,,299.9785916,3,2,0,0,0,0
9245,04/06/2019 00:00,DB13546,Nizofenone,,,,,,,,,0.00733,,6.73,CCN(CC)CC1=NC=CN1C1=C(C=C(C=C1)N(=O)=O)C(=O)C1=CC=CC=C1Cl,,,,,0,,412.1302182,3,3,1,1,0,0
9246,04/06/2019 00:00,DB13547,Sulfatolamide,,,,,,,,,0.344,6.13,2.25,NCC1=CC=C(C=C1)S(N)(=O)=O.NC(=S)NS(=O)(=O)C1=CC=C(N)C=C1,,,,,0,,417.0599171,2,2,0,0,0,0
9247,04/06/2019 00:00,DB13548,Dibrompropamidine,,,,,,,,,0.0133,,11.81,NC(=N)C1=CC=C(OCCCOC2=CC=C(C=C2Br)C(N)=N)C(Br)=C1,,,,,0,,467.97965,2,2,0,0,0,0
9248,04/06/2019 00:00,DB13549,4-dimethylaminophenol,,,,,,,,,187,10.33,5.92,CN(C)C1=CC=C(O)C=C1,,,,,0,,137.084064,1,1,0,0,0,0
9249,04/06/2019 00:00,DB13550,Bifemelane,,,,,,,,,0.00162,,10.54,CNCCCCOC1=CC=CC=C1CC1=CC=CC=C1,,,,,0,,269.1779644,2,2,0,0,0,0
9250,04/06/2019 00:00,DB13551,Cinchophen,,,,,,,,,0.0355,3.57,1.26,OC(=O)C1=CC(=NC2=CC=CC=C12)C1=CC=CC=C1,,,,,0,,249.0789786,3,3,1,1,0,0
9251,04/06/2019 00:00,DB13552,Trifluperidol,,,,,,,,,0.0178,13.93,8.02,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC(=CC=C1)C(F)(F)F,,,,,0,,409.1664919,3,2,1,0,1,1
9252,04/06/2019 00:00,DB13553,Carumonam,,,,,,,,,0.318,-1.9,3.09,NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O,,,,,0,,466.0212826,2,1,2,1,1,1
9253,04/06/2019 00:00,DB13554,Moperone,,,,,,,,,0.0102,14.02,8.17,CC1=CC=C(C=C1)C1(O)CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1,,,,,0,,355.1947573,3,2,1,0,1,1
9254,04/06/2019 00:00,DB13555,Prajmaline,,,,,,,,,0.0299,12.01,-0.54,CCC[N@@+]12[C@H]3C[C@]45[C@H](O)[C@H]3[C@@H](C[C@H]1[C@@H]4N(C)C1=C5C=CC=C1)[C@H](CC)[C@H]2O,,,,,1,,369.2536547,7,1,5,0,4,5
9255,04/06/2019 00:00,DB13556,Sulfamazone,,,,,,,,,0.0389,-1.6,-0.6,COC1=CC=C(NS(=O)(=O)C2=CC=C(NC(C3=C(C)N(C)N(C3=O)C3=CC=CC=C3)S(O)(=O)=O)C=C2)N=N1,,,,,0,,560.1147891,4,4,2,2,0,0
9256,04/06/2019 00:00,DB13557,Thiopropazate,,,,,,,,,0.00639,,7.5,CC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,,,,,0,,445.1590758,4,2,2,0,1,2
9257,04/06/2019 00:00,DB13558,Morclofone,,,,,,,,,0.0135,,5.17,COC1=CC(=CC(OC)=C1OCCN1CCOCC1)C(=O)C1=CC=C(Cl)C=C1,,,,,0,,405.1343005,3,2,1,0,1,1
9258,04/06/2019 00:00,DB13559,Rimiterol,,,,,,,,,6.83,9.74,8.93,O[C@@H]([C@@H]1CCCCN1)C1=CC(O)=C(O)C=C1,,,,,0,,223.1208434,2,1,1,0,1,1
9259,04/06/2019 00:00,DB13561,Clobenzorex,,,,,,,,,0.00105,,8.88,C[C@@H](CC1=CC=CC=C1)NCC1=CC=CC=C1Cl,,,,,0,,259.1127773,2,2,0,0,0,0
9260,04/06/2019 00:00,DB13563,Norgestrienone,,,,,,,,,0.0113,17.57,-1.7,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H],,,,,0,,294.1619799,4,0,0,0,0,0
9261,04/06/2019 00:00,DB13564,Zipeprol,,,,,,,,,0.198,13.72,7.79,COC(CN1CCN(CC(O)C(OC)C2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,384.2412929,3,2,1,0,1,1
9262,04/06/2019 00:00,DB13565,Benzoxonium,,,,,,,,,0.000139,13.67,-3.3,CCCCCCCCCCCC[N+](CCO)(CCO)CC1=CC=CC=C1,,,,,1,,364.321006,1,1,0,0,0,0
9263,04/06/2019 00:00,DB13566,Sequifenadine,,,,,,,,,0.0106,13.19,8.95,CC1=CC=CC=C1C(O)(C1CN2CCC1CC2)C1=CC=CC=C1C,,,,,0,,321.2092645,5,2,3,0,3,3
9264,04/06/2019 00:00,DB13567,Desaspidin,,,,,,,,,0.0678,3.2,-4.7,CCCC(=O)C1=C(O)C=C(OC)C(CC2=C(O)C(C)(C)C(O)=C(C(=O)CCC)C2=O)=C1O,,,,,0,,446.1940679,2,1,0,0,0,0
9265,04/06/2019 00:00,DB13568,Diodone,,,,,,,,,1.92,2.53,-8.2,OCCNCCO.OC(=O)CN1C=C(I)C(=O)C(I)=C1,,,,,0,,509.9148676,1,1,1,1,0,0
9266,04/06/2019 00:00,DB13569,Ferrous chloride,,,,,,,,,33.1,-7,,[Cl-].[Cl-].[Fe++],,,,,0,,125.8726429,0,0,0,0,0,0
9267,04/06/2019 00:00,DB13571,Pentamycin,,,,,,,,,0.209,12.89,-2.8,CCCCC[C@@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)[C@@H](O)[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O,,,,,0,,670.3928273,1,0,1,0,0,1
9268,04/06/2019 00:00,DB13572,Emylcamate,,,,,,,,,8.38,15.93,,CCC(C)(CC)OC(N)=O,,,,,0,,145.1102787,0,0,0,0,0,0
9269,04/06/2019 00:00,DB13573,Acefylline,,,,,,,,,14.7,3.26,-1,CN1C2=C(N(CC(O)=O)C=N2)C(=O)N(C)C1=O,,,,,0,,238.0702048,2,2,2,2,0,0
9270,04/06/2019 00:00,DB13574,Heptaminol,,,,,,,,,16.2,18.53,10.43,CC(N)CCCC(C)(C)O,,,,,0,,145.1466642,0,0,0,0,0,0
9271,04/06/2019 00:00,DB13575,Bietaserpine,,,,,,,,,0.00677,,9.81,CCN(CC)CCN1C2=CC(OC)=CC=C2C2=C1[C@H]1C[C@H]3[C@H](C[C@@H](OC(=O)C4=CC(OC)=C(OC)C(OC)=C4)[C@H](OC)[C@H]3C(=O)OC)CN1CC2,,,,,0,,707.3781803,6,3,3,1,1,2
9272,04/06/2019 00:00,DB13576,Aluminium nicotinate,,,,,,,,,0.0189,2.79,4.19,[Al+3].[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1,,,,,0,,393.0541487,3,3,3,3,0,0
9273,04/06/2019 00:00,DB13577,Allobarbital,,,,,,,,,0.493,1.36,-4.2,OC1=NC(=O)N=C(O)C1(CC=C)CC=C,,,,,0,,208.0847922,1,0,1,0,0,1
9274,04/06/2019 00:00,DB13578,Metabutethamine,,,,,,,,,0.207,,9.67,CC(C)CNCCOC(=O)C1=CC=CC(N)=C1,,,,,0,,236.1524779,1,1,0,0,0,0
9275,04/06/2019 00:00,DB13579,Mepixanox,,,,,,,,,0.0796,,7.25,COC1=CC=C2C(=O)C3=CC=CC=C3OC2=C1CN1CCCCC1,,,,,0,,323.1521435,4,3,2,1,1,1
9276,04/06/2019 00:00,DB13580,Succinylsulfathiazole,,,,,,,,,0.185,3.36,0.59,OC(=O)CCC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1,,,,,0,,355.0296625,2,2,1,1,0,0
9277,04/06/2019 00:00,DB13581,Rociverine,,,,,,,,,0.0582,14.09,9.2,CCN(CC)CC(C)OC(=O)[C@H]1CCCC[C@]1(O)C1CCCCC1,,,,,0,,339.277344,2,0,0,0,0,0
9278,04/06/2019 00:00,DB13582,Ferric (59Fe) citrate,,,,,,,,,2.25,3.05,-4.2,[59Fe+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,,,,0,,247.938403,0,0,0,0,0,0
9279,04/06/2019 00:00,DB13583,Mephenesin,,,,,Topical,solid,Sparingly soluble,,20.8,13.62,-3,CC1=CC=CC=C1OCC(O)CO,,,,,0,,182.0942943,1,1,0,0,0,0
9280,04/06/2019 00:00,DB13584,Gallamine,,,,,,,,,0.134,,9.71,CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC,,,,,0,,423.3460923,1,1,0,0,0,0
9281,04/06/2019 00:00,DB13585,Aminoethyl nitrate,,,,,,,,,6.37,,9.29,NCCO[N+]([O-])=O,,,,,0,,106.0378421,0,0,0,0,0,0
9282,04/06/2019 00:00,DB13586,Metandienone,,,,,,,,,0.0161,18.86,-0.53,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,300.2089301,4,0,0,0,0,0
9283,04/06/2019 00:00,DB13587,Mesterolone,,,,,,,,,0.00641,19.38,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C[C@H](C)[C@]12C,,,,,0,,304.2402303,4,0,0,0,0,0
9284,04/06/2019 00:00,DB13588,Naftidrofuryl,,,,,,,,,0.000636,,8.96,CCN(CC)CCOC(=O)C(CC1CCCO1)CC1=C2C=CC=CC2=CC=C1,,,,,0,,383.2460439,3,2,1,0,1,1
9285,04/06/2019 00:00,DB13590,Calcium pangamate,,,,,,,,,16.3,2.98,6.58,[Ca++].CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,,,,,0,,600.1690741,0,0,0,0,0,0
9286,04/06/2019 00:00,DB13591,Metopimazine,,,,,,,,,0.0135,-0.66,13.04,CS(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CC2)C(O)=N)C=C1,,,,,0,,445.1493837,4,2,2,0,1,2
9287,04/06/2019 00:00,DB13592,Etamiphylline,,,,,,,,,7.22,,9.26,CCN(CC)CCN1C=NC2=C1C(=O)N(C)C(=O)N2C,,,,,0,,279.1695249,2,2,2,2,0,0
9288,04/06/2019 00:00,DB13593,Zolimidine,,,,,,,,,0.0187,19.68,5.64,CS(=O)(=O)C1=CC=C(C=C1)C1=CN2C=CC=CC2=N1,,,,,0,,272.0619486,3,3,2,2,0,0
9289,04/06/2019 00:00,DB13596,Oxycinchophen,,,,,,,,,0.0849,3.36,1.72,OC(=O)C1=C(O)C(=NC2=CC=CC=C12)C1=CC=CC=C1,,,,,0,,265.0738932,3,3,1,1,0,0
9290,04/06/2019 00:00,DB13597,Moroxydine,,,,,,,,,1.41,,11.85,NC(=N)NC(=N)N1CCOCC1,,,,,0,,171.11201,1,0,1,0,1,1
9291,04/06/2019 00:00,DB13598,Diethyl ether,,,,,,,,,39,,-4.1,CCOCC,,,,,0,,74.07316494,0,0,0,0,0,0
9292,04/06/2019 00:00,DB13599,Difetarsone,,,,,,,,,0.167,3.16,4.51,O[As](O)(=O)C1=CC=C(NCCNC2=CC=C(C=C2)[As](O)(O)=O)C=C1,,,,,0,,459.9596793,2,2,0,0,0,0
9293,04/06/2019 00:00,DB13600,Deltamethrin,,,,,,,,,0.00125,10.62,-3.7,[H][C@@](OC(=O)[C@]1([H])[C@]([H])(C=C(Br)Br)C1(C)C)(C#N)C1=CC(OC2=CC=CC=C2)=CC=C1,,,,,0,,502.9731677,3,2,0,0,0,0
9294,04/06/2019 00:00,DB13601,Oxiracetam,,,,,,,,,7.14,-1.7,12.63,OC1CN(CC(O)=N)C(=O)C1,,,,,0,,158.0691422,1,0,1,0,1,1
9295,04/06/2019 00:00,DB13602,Promegestone,,,,,,,,,0.00772,19,-4.7,CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@]12C,,,,,0,,326.2245802,4,0,0,0,0,0
9296,04/06/2019 00:00,DB13603,Pyrrolnitrin,,,,,,,,,0.0724,15.06,,[O-][N+](=O)C1=C(Cl)C=CC=C1C1=CNC=C1Cl,,,,,0,,255.9806328,2,2,1,1,0,0
9297,04/06/2019 00:00,DB13604,Guanazodine,,,,,,,,,0.961,,12.4,NC(=N)NCC1CCCCCCN1,,,,,0,,184.1687966,1,0,1,0,1,1
9298,04/06/2019 00:00,DB13605,Phenoperidine,,,,,,,,,0.0384,14.44,8.62,CCOC(=O)C1(CCN(CCC(O)C2=CC=CC=C2)CC1)C1=CC=CC=C1,,,,,0,,367.2147438,3,2,1,0,1,1
9299,04/06/2019 00:00,DB13606,Phenazocine,,,,,,,,,0.00743,9.96,10.86,C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CCC1=CC=CC=C1,,,,,0,,321.2092645,4,2,1,0,1,1
9300,04/06/2019 00:00,DB13607,Picloxydine,,,,,,,,,0.0577,,10.07,ClC1=CC=C(NC(=N)NC(=N)N2CCN(CC2)C(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1,,,,,0,,474.1562461,3,2,1,0,1,1
9301,04/06/2019 00:00,DB13608,Tiocarlide,,,,,,,,,0.000298,12.62,-4.5,CC(C)CCOC1=CC=C(NC(=S)NC2=CC=C(OCCC(C)C)C=C2)C=C1,,,,,0,,400.2184493,2,2,0,0,0,0
9302,04/06/2019 00:00,DB13609,Umifenovir,,,,,,,,,0.00678,6.01,9.87,CCOC(=O)C1=C(CSC2=CC=CC=C2)N(C)C2=CC(Br)=C(O)C(CN(C)C)=C12,,,,,0,,476.0769258,3,3,1,1,0,0
9303,04/06/2019 00:00,DB13610,Flumedroxone,,,,,,,,,0.00796,12.38,-3.8,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@@H](C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(F)(F)F,,,,,0,,398.2068794,4,0,0,0,0,0
9304,04/06/2019 00:00,DB13611,Chlormidazole,,,,,,,,,0.0173,,6.13,CC1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C=C1,,,,,0,,256.0767261,3,3,1,1,0,0
9305,04/06/2019 00:00,DB13612,Carbaspirin calcium,,,,,,,,,0.00848,3.41,-7.1,[Ca++].NC(N)=O.CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O,,,,,0,,458.0638211,2,2,0,0,0,0
9306,04/06/2019 00:00,DB13613,Ticlatone,,,,,,,,,0.568,4.77,-0.14,OC1=NSC2=C1C=CC(Cl)=C2,,,,,0,,184.9702124,2,2,1,1,0,0
9307,04/06/2019 00:00,DB13614,Metizoline,,,,,,,,,0.0233,,10.09,CC1=C(CC2=NCCN2)C2=CC=CC=C2S1,,,,,0,,230.0877694,3,2,2,1,0,1
9308,04/06/2019 00:00,DB13615,Mifamurtide,"Due to rapid clearance from plasma, administration of mifamurtide is associated with a very low serum concentration of total (liposomal and free) drug. The mean AUC was 17.0 Â± 4.86 h x nM and peak plasma concentration (Cmax) was 15.7 Â± 3.72 nM following intravenous administration of 4 mg mifamurtide in healthy adult subjects [L1203]. Variability in AUC and Cmax is reported to be low [A31748].",,"Following intravenous administration of 4 mg mifamurtide in healthy adult subjects, the half life was 2.05 Â± 0.40 hours. In pediatric and adult patients with psteosarcoma, the half life was 2.04 Â± 0.456 hours after intravenous infusion of 2 mg/m^2 [L1203].",4 mg,Intravenous,solid,,,0.00132,1.9,-3.5,O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC,,,,,0,,1276.741021,0,0,0,0,0,0
9309,04/06/2019 00:00,DB13616,Melagatran,,,,,,,,,0.116,3.01,11.49,[H][C@@](NCC(O)=O)(C1CCCCC1)C(=O)N1CC[C@@]1([H])C(O)=NCC1=CC=C(C=C1)C(N)=N,,,,,0,,429.2376045,3,1,1,0,1,1
9310,04/06/2019 00:00,DB13617,Clorexolone,,,,,,,,,0.0803,8.85,-1.2,NS(=O)(=O)C1=C(Cl)C=C2CN(C3CCCCC3)C(=O)C2=C1,,,,,0,,328.0648411,3,1,1,0,0,1
9311,04/06/2019 00:00,DB13618,Ipriflavone,,,,,,,,,0.0044,,-4.7,CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C1=CC=CC=C1,,,,,0,,280.1099444,3,3,1,1,0,0
9312,04/06/2019 00:00,DB13619,Bornaprine,,,,,,,,,0.00256,,10,CCN(CC)CCCOC(=O)C1(C[C@@H]2CC[C@H]1C2)C1=CC=CC=C1,,,,,0,,329.2354792,3,1,0,0,0,0
9313,04/06/2019 00:00,DB13620,Potassium gluconate,"Potassium is rapidly and well absorbed.  A 2016 dose-response trial found that humans absorb about 94% of potassium gluconate in supplements, and this absorption rate is similar to that of potassium from potatoes [A32902].

     ",,,4.68 g,Oral,solid,,,833,3.39,-3,[K+].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,,,,,0,,234.0141844,0,0,0,0,0,0
9314,04/06/2019 00:00,DB13621,Tetragalacturonic acid hydroxymethylester,,,,,,,,,122,11.18,-3.7,OCOC(=O)[C@H]1O[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@@H](O[C@@H]3[C@H](O)[C@@H](O)[C@@H](O[C@@H]4[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]4C(=O)OCO)O[C@@H]3C(=O)OCO)O[C@@H]2C(=O)OCO)[C@H](O)[C@@H](O)[C@H]1O,,,,,0,,842.1811753,4,0,4,0,4,4
9315,04/06/2019 00:00,DB13622,Selenium (75Se) norcholesterol,,,,,,,,,0.000337,18.19,-1.4,C[75Se]C[C@@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCC(C)C)[C@@]3(C)CC[C@@H]2C2=C1C[C@@H](O)CC2,,,,,0,,475.2930396,4,0,0,0,0,0
9316,04/06/2019 00:00,DB13623,Fabomotizole,,,,,,,,,0.178,10.79,6.67,CCOC1=CC=C2NC(SCCN3CCOCC3)=NC2=C1,,,,,0,,307.1354479,3,2,2,1,1,1
9317,04/06/2019 00:00,DB13624,Methoxyphenamine,,,,,,,,,0.783,,10.04,CNC(C)CC1=CC=CC=C1OC,,,,,0,,179.1310142,1,1,0,0,0,0
9318,04/06/2019 00:00,DB13625,Carbuterol,,,,,,,,,0.299,-4.5,15.19,CC(C)(C)NCC(O)C1=CC(NC(O)=N)=C(O)C=C1,,,,,0,,267.1582915,1,1,0,0,0,0
9319,04/06/2019 00:00,DB13626,Aluminium glycinate,,,,,,,,,30.6,2.31,9.24,O.[OH-].[OH-].[Al+3].NCC([O-])=O,,,,,0,,153.021786,0,0,0,0,0,0
9320,04/06/2019 00:00,DB13627,Oxolinic acid,,,,,,,,,1.91,5.58,-4.3,CCN1C=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12,,,,,0,,261.0637225,3,2,2,1,0,1
9321,04/06/2019 00:00,DB13628,Ethyl hydroxybenzoate,,,,,,,,,2.49,8.5,-6.1,CCOC(=O)C1=CC=C(O)C=C1,,,,,0,,166.0629942,1,1,0,0,0,0
9322,04/06/2019 00:00,DB13629,Mofebutazone,,,,,,,,,0.428,3.83,-3.1,CCCCC1C(O)=NN(C1=O)C1=CC=CC=C1,,,,,0,,232.1211778,2,1,1,0,0,1
9323,04/06/2019 00:00,DB13630,Bibenzonium,,,,,,,,,1.91E-05,,-4.2,C[N+](C)(C)CCOC(CC1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,284.2008909,2,2,0,0,0,0
9324,04/06/2019 00:00,DB13631,Methoserpidine,,,,,,,,,0.0113,16.65,7.03,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=CC=C(OC)C=C45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1,,,,,0,,608.2733809,6,3,3,1,1,2
9325,04/06/2019 00:00,DB13632,Protiofate,,,,,,,,,0.27,6.29,-4.5,CCCOC(=O)C1=C(O)C(O)=C(S1)C(=O)OCCC,,,,,0,,288.0667592,1,1,1,1,0,0
9326,04/06/2019 00:00,DB13634,Pentifylline,,,,,,,,,3.23,,-0.93,CCCCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O,,,,,0,,264.1586259,2,2,2,2,0,0
9327,01/05/2019 00:00,DB13635,Tiracizine,,,,,,,,,0.0741,3.61,7.13,CCOC(O)=NC1=CC2=C(CCC3=CC=CC=C3N2C(=O)CN(C)C)C=C1,,,,,0,,367.1895917,3,2,1,0,0,1
9328,01/05/2019 00:00,DB13636,Etanautine,,,,,,,,,14.7,,8.87,CN1C2=C(N(CC(O)=O)C=N2)C(=O)N(C)C1=O.CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,493.2325191,4,4,2,2,0,0
9329,01/05/2019 00:00,DB13637,Tenitramine,,,,,,,,,0.444,,7.6,[O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O,,,,,0,,416.1139201,0,0,0,0,0,0
9330,01/05/2019 00:00,DB13638,Cefbuperazone,,,,,,,,,1.11,3.37,-1.5,CCN1CCN(C(=O)N[C@H]([C@H](C)O)C(=O)N[C@@]2(OC)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C(=O)C1=O,,,,,0,,627.1529655,4,1,4,1,2,3
9331,01/05/2019 00:00,DB13639,Ferrous tartrate,,,,,,,,,94.8,2.72,-4.3,[Fe++].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O,,,,,0,,203.9357253,0,0,0,0,0,0
9332,01/05/2019 00:00,DB13640,Acetoxolone,,,,,,,,,0.000555,4.44,-5.1,CC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C,,,,,0,,512.3501746,5,0,0,0,0,0
9333,01/05/2019 00:00,DB13641,Metisazone,,,,,,,,,0.113,6.67,5.14,CN1C(=O)\C(=N\NC(S)=N)C2=CC=CC=C12,,,,,0,,234.0575319,2,1,1,0,0,1
9334,01/05/2019 00:00,DB13642,Pridinol,,,,,,,,,0.0192,13.36,9.34,OC(CCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,295.1936144,3,2,1,0,1,1
9335,01/05/2019 00:00,DB13643,Loprazolam,,,,,,,,,0.0917,19.13,8.06,[H]\C(N1CCN(C)CC1)=C1\N=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(=C3)N(=O)=O)N2C1=O,,,,,0,,464.1363662,5,2,3,0,1,3
9336,01/05/2019 00:00,DB13644,Methylthiouracil,,,,,,,,,1.87,8.57,-0.087,CC1=CC(O)=NC(S)=N1,,,,,0,,142.0200838,1,1,1,1,0,0
9337,01/05/2019 00:00,DB13645,Ethacizine,,,,,,,,,0.00945,12.9,9.7,CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN(CC)CC)C=C1,,,,,0,,413.1773127,3,2,1,0,0,1
9338,01/05/2019 00:00,DB13648,Alcuronium,,,,,,,,,0.000244,15.3,1.52,[H][C@@]12C[C@@]3([H])\C(C[N@+]1(CC=C)CC[C@@]21C2=C(C=CC=C2)N2\C=C4/[C@]5([H])N(\C=C3/[C@@]12[H])C1=C(C=CC=C1)[C@@]51CC[N@@+]2(CC=C)C\C(=C\CO)[C@]4([H])C[C@@]12[H])=C/CO,,,,,2,,666.3922797,11,2,7,0,4,7
9339,01/05/2019 00:00,DB13649,Proquazone,,,,,,,,,0.00927,,-3.3,CC(C)N1C(=O)N=C(C2=CC=CC=C2)C2=CC=C(C)C=C12,,,,,0,,278.1419132,3,3,1,1,0,0
9340,01/05/2019 00:00,DB13651,Lorajmine,,,,,,,,,0.438,13.33,7.27,CC[C@@H]1[C@@H](O)N2[C@H]3C[C@]45[C@H](OC(=O)CCl)[C@H]3[C@H]1C[C@H]2[C@@H]4N(C)C1=CC=CC=C51,,,,,0,,402.1710204,7,1,5,0,4,5
9341,01/05/2019 00:00,DB13652,Bunaftine,,,,,,,,,0.0147,,9.01,CCCCN(CCN(CC)CC)C(=O)C1=C2C=CC=CC2=CC=C1,,,,,0,,326.2358136,2,2,0,0,0,0
9342,01/05/2019 00:00,DB13653,Lorcainide,,,,,,,,,0.00749,,8.83,CC(C)N1CCC(CC1)N(C(=O)CC1=CC=CC=C1)C1=CC=C(Cl)C=C1,,,,,0,,370.1811912,3,2,1,0,1,1
9343,01/05/2019 00:00,DB13655,Nikethamide,,,,,,,,,109,,3.61,CCN(CC)C(=O)C1=CN=CC=C1,,,,,0,,178.1106131,1,1,1,1,0,0
9344,01/05/2019 00:00,DB13656,Eberconazole,,,,,,,,,0.00215,,6.68,ClC1=CC(Cl)=C2C(N3C=CN=C3)C3=CC=CC=C3CCC2=C1,,,,,0,,328.0534038,4,3,1,1,0,0
9345,01/05/2019 00:00,DB13657,Benorilate,,,,,,,,,0.0141,14.66,-4.4,CC(=O)NC1=CC=C(OC(=O)C2=CC=CC=C2OC(C)=O)C=C1,,,,,0,,313.0950226,2,2,0,0,0,0
9346,01/05/2019 00:00,DB13659,Tenonitrozole,,,,,,,,,0.21,10.08,-4.2,O=C(NC1=NC=C(S1)N(=O)=O)C1=CC=CS1,,,,,0,,254.977233,2,2,2,2,0,0
9347,01/05/2019 00:00,DB13660,Propicillin,,,,,,,,,0.22,3.39,-4.9,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(CC)OC1=CC=CC=C1)C(O)=O,,,,,0,,378.1249428,3,1,2,0,2,2
9348,01/05/2019 00:00,DB13661,Niridazole,,,,,,,,,1.16,3.47,-1.3,OC1=NCCN1C1=NC=C(S1)N(=O)=O,,,,,0,,214.0160611,2,1,2,1,0,1
9349,01/05/2019 00:00,DB13662,Hexapropymate,,,,,,,,,0.0594,15.57,,NC(=O)OC1(CC#C)CCCCC1,,,,,0,,181.1102787,1,0,0,0,0,0
9350,01/05/2019 00:00,DB13663,Clofenamide,,,,,,,,,0.905,8.59,,NS(=O)(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O,,,,,0,,269.9535764,1,1,0,0,0,0
9351,01/05/2019 00:00,DB13664,Formocortal,,,,,,,,,0.00875,13.64,-3.4,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C=O)=C4C=C(CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C)OCCCl,,,,,0,,568.2239241,5,0,1,0,1,1
9352,01/05/2019 00:00,DB13665,Fluanisone,,,,,,,,,0.091,16.4,7.18,COC1=CC=CC=C1N1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1,,,,,0,,356.1900063,3,2,1,0,1,1
9353,01/05/2019 00:00,DB13666,Tiemonium iodide,,,,,,,,,0.00124,12.82,-3.8,[I-].C[N+]1(CCC(O)(C2=CC=CS2)C2=CC=CC=C2)CCOCC1,,,,,0,,445.057248,3,2,2,1,1,1
9354,01/05/2019 00:00,DB13667,Cefozopran,,,,,,,,,0.024,2.74,0.074,[H][C@]12SCC(C[N+]3=C4C=CC=NN4C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=NSC(N)=N1)C([O-])=O,,,,,0,,515.0794066,5,3,5,3,1,2
9355,01/05/2019 00:00,DB13668,Ipidacrine,,,,,,,,,1.58,,9.72,NC1=C2CCCC2=NC2=C1CCCC2,,,,,0,,188.1313485,3,1,1,1,0,0
9356,01/05/2019 00:00,DB13669,Morpholine,,,,,,,,,691,,8.51,C1COCCN1,,,,,0,,87.06841391,1,0,1,0,1,1
9357,01/05/2019 00:00,DB13670,Oxantel,,,,,,,,,0.659,9.39,10.9,CN1CCCN=C1\C=C\C1=CC=CC(O)=C1,,,,,0,,216.1262631,2,1,1,0,0,1
9358,01/05/2019 00:00,DB13671,Sulbentine,,,,,,,,,0.00736,,3.95,S=C1SCN(CC2=CC=CC=C2)CN1CC1=CC=CC=C1,,,,,0,,314.0911406,3,2,1,0,1,1
9359,01/05/2019 00:00,DB13672,Dimethylaminopropionylphenothiazine,,,,,,,,,0.0303,17.21,7.31,CC(N(C)C)C(=O)N1C2=CC=CC=C2SC2=CC=CC=C12,,,,,0,,298.1139842,3,2,1,0,0,1
9360,01/05/2019 00:00,DB13673,Bekanamycin,,,,,,,,,75.9,12.49,9.76,[H][C@]1(N)C[C@@]([H])(N)[C@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(N)[C@@]2([H])O)[C@@]([H])(O)[C@]1([H])O[C@@]1([H])O[C@]([H])(CN)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])N,,,,,0,,483.2540424,3,0,2,0,2,2
9361,01/05/2019 00:00,DB13674,Cridanimod,,,,,,,,,0.197,3.68,-3.2,OC(=O)CN1C2=CC=CC=C2C(=O)C2=CC=CC=C12,,,,,0,,253.0738932,3,3,1,1,0,0
9362,01/05/2019 00:00,DB13675,Metahexamide,,,,,,,,,0.228,4.32,2.21,CC1=CC=C(C=C1N)S(=O)(=O)NC(=O)NC1CCCCC1,,,,,0,,311.1303625,2,1,0,0,0,0
9363,01/05/2019 00:00,DB13676,Mosapramine,,,,,,,,,0.0111,4.46,9.31,OC1=NC2CCCCN2C11CCN(CCCN2C3=CC=CC=C3CCC3=C2C=C(Cl)C=C3)CC1,,,,,0,,478.2499394,6,2,4,0,2,4
9364,01/05/2019 00:00,DB13677,Carboquone,,,,,,,,,1.18,-3,11.56,COC(COC(O)=N)C1=C(N2CC2)C(=O)C(C)=C(N2CC2)C1=O,,,,,0,,321.1324707,3,0,2,0,2,2
9365,01/05/2019 00:00,DB13678,Dihexyverine,,,,,,,,,0.00172,,8.18,O=C(OCCN1CCCCC1)C1(CCCCC1)C1CCCCC1,,,,,0,,321.2667794,3,0,1,0,1,1
9366,01/05/2019 00:00,DB13679,Dexchlorpheniramine,,,,,Oral,,,,0.0519,,9.47,CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1,,,,,0,,274.1236763,2,2,1,1,0,0
9367,01/05/2019 00:00,DB13680,Naftazone,,,,,,,,,0.31,11.64,-1.2,NC(=O)N\N=C1/C=CC2=CC=CC=C2C1=O,,,,,0,,215.0694765,2,1,0,0,0,0
9368,01/05/2019 00:00,DB13681,Butalamine,,,,,,,,,0.0532,6.87,8.79,CCCCN(CCCC)CCN=C1ONC(=N1)C1=CC=CC=C1,,,,,0,,316.2263115,2,2,1,1,0,0
9369,01/05/2019 00:00,DB13682,Cefpirome,,,,,,,,,0.00721,2.67,3.54,[H][C@]12SCC(C[N+]3=C4CCCC4=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C([O-])=O,,,,,0,,514.1093098,5,2,4,2,1,2
9370,01/05/2019 00:00,DB13683,Quinisocaine,,,,,,,,,0.0655,,8.64,CCCCC1=CC2=CC=CC=C2C(OCCN(C)C)=N1,,,,,0,,272.1888634,2,2,1,1,0,0
9371,01/05/2019 00:00,DB13684,Omoconazole,,,,,,,,,0.000918,,6.45,C\C(N1C=CN=C1)=C(\OCCOC1=CC=C(Cl)C=C1)C1=C(Cl)C=C(Cl)C=C1,,,,,0,,422.0355608,3,3,1,1,0,0
9372,01/05/2019 00:00,DB13685,Quingestanol,,,,,,,,,0.00211,17.59,-1.7,C[C@]12CC[C@H]3[C@@H](CC=C4C=C(CC[C@H]34)OC3CCCC3)[C@@H]1CC[C@@]2(O)C#C,,,,,0,,366.2558803,5,0,0,0,0,0
9373,01/05/2019 00:00,DB13686,Clometocillin,,,,,,,,,0.0282,3.26,-4.2,COC(C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)C1=CC=C(Cl)C(Cl)=C1,,,,,0,,432.031348,3,1,2,0,2,2
9374,01/05/2019 00:00,DB13687,Niaprazine,,,,,,,,,0.0522,7.45,8.47,CC(CCN1CCN(CC1)C1=CC=C(F)C=C1)N=C(O)C1=CN=CC=C1,,,,,0,,356.2012396,3,2,2,1,1,1
9375,01/05/2019 00:00,DB13689,Tacalcitol,,,,,,,,,0.0105,14.39,-1.1,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,,,,,0,,416.3290453,3,0,0,0,0,0
9376,01/05/2019 00:00,DB13690,Vinyl ether,,,,,,,,,2.8,,-5.1,C=COC=C,,,,,0,,70.04186481,0,0,0,0,0,0
9377,01/05/2019 00:00,DB13691,Acetyldigoxin,,,,,,,,,0.0674,7.15,-3,C[C@H]1O[C@H](C[C@H](OC(C)=O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,,,,,0,,822.4401714,8,0,4,0,3,4
9378,01/05/2019 00:00,DB13692,Tretoquinol,,,,,,,,,0.0986,9.53,8.52,COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC,,,,,0,,345.1576228,3,2,1,0,0,1
9379,01/05/2019 00:00,DB13693,Sulbenicillin,,,,,,,,,0.741,-1.1,-6.4,CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C3=CC=CC=C3)S(O)(=O)=O)C(=O)N2[C@H]1C(O)=O,,,,,0,,414.0555429,3,1,2,0,2,2
9380,01/05/2019 00:00,DB13694,Distigmine,,,,,,,,,0.000462,19.23,,CN(CCCCCCN(C)C(=O)OC1=C[N+](C)=CC=C1)C(=O)OC1=C[N+](C)=CC=C1,,,,,2,,416.2412583,2,2,2,2,0,0
9381,01/05/2019 00:00,DB13695,Penthienate,,,,,,,,,0.00162,11.18,-4.5,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCC1)C1=CC=CS1,,,,,1,,340.1940912,2,1,1,1,0,0
9382,01/05/2019 00:00,DB13696,Bromochlorosalicylanilide,,,,,,,,,0.0168,7.49,-4.3,OC1=CC=C(Br)C=C1C(=O)NC1=CC=C(Cl)C=C1,,,,,0,,324.9505183,2,2,0,0,0,0
9383,01/05/2019 00:00,DB13697,Ambazone,,,,,,,,,0.0529,6.8,8.09,NC(=N)NN=C1C=CC(C=C1)=NNC(S)=N,,,,,0,,237.0796644,1,0,0,0,0,0
9384,01/05/2019 00:00,DB13698,Ferrous carbonate,,,,,,,,,75.1,6.05,,[Fe++].[O-]C([O-])=O,,,,,0,,115.9196814,0,0,0,0,0,0
9385,01/05/2019 00:00,DB13699,Sulfathiourea,,,,,,,,,0.159,6.31,2.27,NC1=CC=C(C=C1)S(=O)(=O)NC(S)=N,,,,,0,,231.0136185,1,1,0,0,0,0
9386,01/05/2019 00:00,DB13701,Ioglicic acid,,,,,,,,,0.102,2.13,-2.2,CNC(=O)CNC(=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,,,,,0,,670.7911145,1,1,0,0,0,0
9387,01/05/2019 00:00,DB13702,Tibezonium iodide,,,,,,,,,1.28E-05,9.79,2.1,[I-].CC[N+](C)(CC)CCSC1=NC2=CC=CC=C2N=C(C1)C1=CC=C(SC2=CC=CC=C2)C=C1,,,,,0,,601.108238,4,3,1,0,0,1
9388,01/05/2019 00:00,DB13703,Gepefrine,,,,,,,,,3.44,10.36,9.71,[H][C@@](C)(N)CC1=CC(O)=CC=C1,,,,,0,,151.099714,1,1,0,0,0,0
9389,01/05/2019 00:00,DB13705,Decamethoxine,,,,,,,,,3.10E-06,,-7.5,[Cl-].[Cl-].CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C,,,,,0,,692.5025642,2,0,0,0,0,0
9390,01/05/2019 00:00,DB13706,Eosin,,,,,,,,,0.00126,3.39,1.98,[Na+].[Na+].[O-]C(=O)C1=C(C=CC=C1)C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C1C=C(Br)C([O-])=C2Br,,,,,0,,687.6744103,4,2,1,0,0,1
9391,01/05/2019 00:00,DB13707,Sodium tartrate,,,,5.6 g,Oral,solid,Soluble in cold water,,779,2.72,-4.3,[Na+].[Na+].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O,,,,,0,,193.9803264,0,0,0,0,0,0
9392,01/05/2019 00:00,DB13708,Fenquizone,,,,,,,,,0.102,9.53,-1.9,NS(=O)(=O)C1=C(Cl)C=C2NC(NC(=O)C2=C1)C1=CC=CC=C1,,,,,0,,337.0287899,3,2,1,0,0,1
9393,01/05/2019 00:00,DB13709,Ciclonicate,,,,,,,,,0.156,,3.24,C[C@@H]1C[C@H](CC(C)(C)C1)OC(=O)C1=CC=CN=C1,,,,,0,,247.1572289,2,1,1,1,0,0
9394,01/05/2019 00:00,DB13710,Metenolone,,,,,,,,,0.022,19.38,-0.88,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])CC(=O)C=C(C)[C@]4(C)[C@@]3([H])CC[C@]12C,,,,,0,,302.2245802,4,0,0,0,0,0
9395,01/05/2019 00:00,DB13711,Tritoqualine,,,,,,,,,0.204,13.29,7.06,CCOC1=C(OCC)C(OCC)=C(N)C2=C1C(OC2=O)C1N(C)CCC2=CC3=C(OCO3)C(OC)=C12,,,,,0,,500.215866,5,2,3,0,0,3
9396,01/05/2019 00:00,DB13712,Dixanthogen,,,,,,,,,0.0108,,-4.8,CCOC(=S)SSC(=S)OCC,,,,,0,,241.9563636,0,0,0,0,0,0
9397,01/05/2019 00:00,DB13713,Quifenadine,,,,,,,,,0.0553,13.17,9,OC(C1CN2CCC1CC2)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,293.1779644,5,2,3,0,3,3
9398,01/05/2019 00:00,DB13714,Xibornol,,,,,,,,,0.00348,10.86,-5.2,CC1=CC(O)=C(C=C1C)[C@H]1C[C@@H]2CC[C@@]1(C)C2(C)C,,,,,0,,258.1983655,3,1,0,0,0,0
9399,01/05/2019 00:00,DB13715,Dilazep,,,,,,,,,0.0502,,9.54,COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN1CCCN(CCCOC(=O)C2=CC(OC)=C(OC)C(OC)=C2)CC1,,,,,0,,604.2995956,3,2,1,0,1,1
9400,01/05/2019 00:00,DB13716,Dibutylphthalate,,,,,,,,,0.00596,,-6.7,CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC,,,,,0,,278.1518092,1,1,0,0,0,0
9401,01/05/2019 00:00,DB13717,Phenothrin,,,,,,,,,0.00201,,-7.1,CC(C)=CC1C(C(=O)OCC2=CC=CC(OC3=CC=CC=C3)=C2)C1(C)C,,,,,0,,350.1881947,3,2,0,0,0,0
9402,01/05/2019 00:00,DB13718,Hydroquinine,,,,,,,,,0.312,13.89,9.18,CC[C@H]1C[N@@]2CC[C@H]1C[C@H]2[C@H](O)C1=C2C=C(OC)C=CC2=NC=C1,,,,,0,,326.1994281,5,2,4,1,3,3
9403,01/05/2019 00:00,DB13719,Trolnitrate,,,,,,,,,1.18,,7.3,O=N(=O)OCCN(CCON(=O)=O)CCON(=O)=O,,,,,0,,284.060428,0,0,0,0,0,0
9404,01/05/2019 00:00,DB13720,Diphemanil,Poorly absorbed from the gastrointestinal tract with an absolute bioavailability of 15 to 25%.,,,,,,,,0.000372,,,C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,278.1903262,3,2,1,0,1,1
9405,01/05/2019 00:00,DB13721,Cypermethrin,,,,,,,,,0.000864,10.62,-7.1,CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC2=CC=CC=C2)=C1,,,,,0,,415.0741988,3,2,0,0,0,0
9406,01/05/2019 00:00,DB13722,Pirprofen,,,,,,,,,1.21,4.25,-1.2,CC(C(O)=O)C1=CC(Cl)=C(C=C1)N1CC=CC1,,,,,0,,251.0713064,2,1,1,0,0,1
9407,01/05/2019 00:00,DB13723,Meldonium,,,,,,,,,20.2,4.14,,C[N+](C)(C)NCCC([O-])=O,,,,,0,,146.1055277,0,0,0,0,0,0
9408,01/05/2019 00:00,DB13724,Nifuratel,,,,,,,,,0.109,,-2.1,CSCC1CN(\N=C\C2=CC=C(O2)[N+]([O-])=O)C(=O)O1,,,,,0,,285.0419415,2,1,2,1,1,1
9409,01/05/2019 00:00,DB13725,Terodiline,,,,,,,,,0.000317,,10.62,CC(CC(C1=CC=CC=C1)C1=CC=CC=C1)NC(C)(C)C,,,,,0,,281.2143499,2,2,0,0,0,0
9410,01/05/2019 00:00,DB13726,Sulfaguanidine,,,,,,,,,0.805,10.53,7.72,NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1,,,,,0,,214.0524466,1,1,0,0,0,0
9411,01/05/2019 00:00,DB13727,Azapetine,,,,,,,,,0.0159,,7.34,C=CCN1CC2=CC=CC=C2C2=CC=CC=C2C1,,,,,0,,235.1360995,3,2,1,0,0,1
9412,01/05/2019 00:00,DB13728,Halometasone,,,,,,,,,0.0356,12.42,-3.3,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C(Cl)=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,,,,,0,,444.1515081,4,0,0,0,0,0
9413,01/05/2019 00:00,DB13729,Camostat,,,,,,,,,0.0626,19.54,8.54,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1,,,,,0,,398.1590198,2,2,0,0,0,0
9414,01/05/2019 00:00,DB13730,Nifurtoinol,,,,,,,,,0.544,11.84,-2.2,OCN1C(=O)CN(\N=C\C2=CC=C(O2)[N+]([O-])=O)C1=O,,,,,0,,268.044384,2,1,2,1,1,1
9415,01/05/2019 00:00,DB13731,Butamirate,,,,,,,,,0.107,,9.41,CCC(C(=O)OCCOCCN(CC)CC)C1=CC=CC=C1,,,,,0,,307.2147438,1,1,0,0,0,0
9416,01/05/2019 00:00,DB13732,Meglumine antimoniate,,,,,,,,,240,12.65,9.11,O[Sb](=O)=O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,,,,,0,,365.0070572,0,0,0,0,0,0
9417,01/05/2019 00:00,DB13733,Methylpentynol,,,,,,,,,0.632,15.82,-2.4,CCC(C)(O)C#C,,,,,0,,98.07316494,0,0,0,0,0,0
9418,01/05/2019 00:00,DB13736,Fenoxazoline,,,,,,,,,0.316,,9.26,CC(C)C1=CC=CC=C1OCC1=NCCN1,,,,,0,,218.1419132,2,1,1,0,0,1
9419,01/05/2019 00:00,DB13737,Cyclobarbital,,,,,,,,,0.696,7.14,,CCC1(C(=O)NC(=O)NC1=O)C1=CCCCC1,,,,,0,,236.1160924,2,0,1,0,1,1
9420,01/05/2019 00:00,DB13738,Camylofin,,,,,,,,,0.067,,9.19,CCN(CC)CCNC(C(=O)OCCC(C)C)C1=CC=CC=C1,,,,,0,,320.2463783,1,1,0,0,0,0
9421,01/05/2019 00:00,DB13739,Penamecillin,,,,,,,,,0.0867,11.85,-2.8,[H][C@]12SC(C)(C)[C@@]([H])(N1C(=O)[C@@]2([H])NC(=O)CC1=CC=CC=C1)C(=O)OCOC(C)=O,,,,,0,,406.1198574,3,1,2,0,2,2
9422,01/05/2019 00:00,DB13740,Bemegride,,,,,,,,,2.35,3.64,-3.3,CCC1(C)CC(O)=NC(=O)C1,,,,,0,,155.0946287,1,0,1,0,0,1
9423,01/05/2019 00:00,DB13741,Ioglycamic acid,,,,,,,,,0.00591,2.02,-4.2,OC(=O)C1=C(I)C(NC(=O)COCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C(I)C=C1I,,,,,0,,1127.475639,2,2,0,0,0,0
9424,01/05/2019 00:00,DB13744,Piromidic acid,,,,,,,,,1.21,5.61,3.03,CCN1C=C(C(O)=O)C(=O)C2=CN=C(N=C12)N1CCCC1,,,,,0,,288.1222404,3,2,3,2,1,1
9425,01/05/2019 00:00,DB13745,Fazadinium bromide,,,,,,,,,0.00575,,-0.091,[Br-].[Br-].CC1=C(N(\N=N\N2C3=CC=CC=[N+]3C(C)=C2C2=CC=CC=C2)C2=CC=CC=[N+]12)C1=CC=CC=C1,,,,,0,,602.042919,6,6,4,4,0,0
9426,01/05/2019 00:00,DB13747,Trolamine,Dermal absorption of trolamine increases with the dose [A27174]. This has been found to range from 19-28% in rats with doses of 68-276 mg/kg in 190 Î¼L of acetone without occlusion and from 60-80% in mice with doses of 79-1120 mg/kg in the same volume of acetone.,,,0.036 mg/3mL,Topical,liquid,Miscible,-1.59,497,15.12,8.44,OCCN(CCO)CCO,,,,,0,,149.1051933,0,0,0,0,0,0
9427,01/05/2019 00:00,DB13748,Tidiacic arginine,,,,,,,,,20.6,2.41,12.41,OC(=O)C1CSC(N1)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O,,,,,0,,351.1212544,1,0,1,0,1,1
9428,01/05/2019 00:00,DB13749,Magnesium gluconate,"A high-fat diet may decrease the amount of magnesium absorbed in the diet. Over-cooking food also may decrease the amount of magnesium absorbed from dietary sources [L2602].

About 1/3 of magnesium is absorbed from the small intestine. The fraction of magnesium absorbed is inversely proportional to amount ingested [L2606].

Oral absorption is estimated to be 15% to 30% [L2604].",25-30%,,,Oral,solid,Soluble in cold water,-3.175,43.2,3.39,-3,O.O.[Mg++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,0.25,0.3,,,0,,450.1071265,0,0,0,0,0,0
9429,01/05/2019 00:00,DB13750,Obidoxime,,,,,,,,,0.114,,4.61,O=[NH+]C=C1C=CN(COCN2C=CC(=C[NH+]=O)C=C2)C=C1,,,,,2,,288.1211432,2,0,2,0,0,2
9430,01/05/2019 00:00,DB13751,Glycyrrhizic acid,"Glycyrrhizic acid is mainly absorbed after presystemic hydrolysis and formation of glycyrrhetinic acid.[A33064] Therefore, after oral administration of a dose of 100 mg of glycyrrhizic acid, this major metabolite appears in plasma in a concentration of 200 ng/ml while glycyrrhizic acid cannot be found. The finding of a minimal amount of glycyrrhizic acid in urine suggests the existence of a partial absorption in the gastrointestinal tract.[A33067]",,"Depending on the dose, the second elimination phase in humans has a half-life of 3.5 hours.[A33066]",,Dental,solid,Easily soluble in hot water,2.8,0.0545,2.96,-3.7,[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O,,,,,0,,822.4037859,7,0,2,0,2,2
9431,01/05/2019 00:00,DB13752,Tetramethrin,,,,,,,,,0.0754,,-4.1,CC(C)=CC1C(C(=O)OCN2C(=O)C3=C(CCCC3)C2=O)C1(C)C,,,,,0,,331.1783583,3,0,1,0,0,1
9432,01/05/2019 00:00,DB13753,Cetiedil,,,,,,,,,0.00741,,8.73,O=C(OCCN1CCCCCC1)C(C1CCCCC1)C1=CSC=C1,,,,,0,,349.2075502,3,1,2,1,1,1
9433,01/05/2019 00:00,DB13754,Mephenoxalone,,,,,,,,,0.745,3.73,1.29,COC1=CC=CC=C1OCC1CN=C(O)O1,,,,,0,,223.0844579,2,1,1,0,0,1
9434,01/05/2019 00:00,DB13755,Iocarmic acid,,,,,,,,,0.00511,2.18,3.69,CN=C(O)C1=C(I)C(C(O)=O)=C(I)C(N=C(O)CCCCC(O)=NC2=C(I)C(C(O)=NC)=C(I)C(C(O)=O)=C2I)=C1I,,,,,0,,1253.554952,2,2,0,0,0,0
9435,01/05/2019 00:00,DB13756,Peruvoside,,,,,,,,,0.0791,7.18,0.27,CO[C@@H]1[C@@H](O)[C@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@H]1O,,,,,0,,548.298533,6,0,2,0,1,2
9436,01/05/2019 00:00,DB13757,Epanolol,,,,,,,,,0.0613,9.58,8.71,OC(CNCCNC(=O)CC1=CC=C(O)C=C1)COC1=CC=CC=C1C#N,,,,,0,,369.1688562,2,2,0,0,0,0
9437,01/05/2019 00:00,DB13758,Meclofenoxate,,,,,,,,,2.9,,8.42,CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1,,,,,0,,257.0818711,1,1,0,0,0,0
9438,01/05/2019 00:00,DB13759,Fenpiverinium,,,,,,,,,2.66E-05,16.19,-3.3,C[N+]1(CCC(C(N)=O)(C2=CC=CC=C2)C2=CC=CC=C2)CCCCC1,,,,,1,,337.22744,3,2,1,0,1,1
9439,01/05/2019 00:00,DB13760,Niperotidine,,,,,,,,,0.0439,,7.8,CN(C)CC1=CC=C(CSCCNC(NCC2=CC=C3OCOC3=C2)=C[N+]([O-])=O)O1,,,,,0,,434.1623909,3,2,2,1,0,1
9440,01/05/2019 00:00,DB13762,Dexrabeprazole,,,,,,,,,0.336,9.35,4.24,COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=CC=CC=C3N2)=C1C,,,,,0,,359.1303625,3,3,2,2,0,0
9441,01/05/2019 00:00,DB13763,Aurotioprol,,,,,,,,,21.3,-1.1,-3.2,[Na+].[Au+].OC(C[S-])CS([O-])(=O)=O,,,,,0,,389.9270887,0,0,0,0,0,0
9442,01/05/2019 00:00,DB13764,Monoxerutin,,,,,,,,,2.68,7.13,-3.6,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(OCCO)=CC(O)=C4C3=O)C3=CC=C(O)C(O)=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,,,,,0,,654.1795996,5,3,3,1,2,2
9443,01/05/2019 00:00,DB13766,Lidoflazine,,,,,,,,,0.000536,4.92,8.55,CC1=CC=CC(C)=C1N=C(O)CN1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1,,,,,0,,491.2748192,4,3,1,0,1,1
9444,01/05/2019 00:00,DB13767,Vorozole,,,,,,,,,0.204,,2.18,CN1N=NC2=CC=C(C=C12)[C@@H](N1C=NC=N1)C1=CC=C(Cl)C=C1,,,,,0,,324.0890221,4,4,2,2,0,0
9445,01/05/2019 00:00,DB13768,Domiodol,,,,,,,,,17.3,14.6,-3,OCC1COC(CI)O1,,,,,0,,243.9596421,1,0,1,0,1,1
9446,01/05/2019 00:00,DB13769,Emetonium iodide,,,,,,,,,2.63E-05,,-4.3,[I-].CC[N+](C)(CC)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,425.1215625,2,2,0,0,0,0
9447,01/05/2019 00:00,DB13770,Vinylbital,,,,,,,,,0.149,1.23,-4.3,CCCC(C)C1(C=C)C(O)=NC(=O)N=C1O,,,,,0,,224.1160924,1,0,1,0,0,1
9448,01/05/2019 00:00,DB13771,Ferric sodium citrate,,,,,,,,,1.48,3.05,-4.2,[Na+].[Fe+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O,,,,,0,,266.9204092,0,0,0,0,0,0
9449,01/05/2019 00:00,DB13772,Rufloxacin,,,,,,,,,0.96,5.4,6.09,CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN3CCSC1=C23)C(O)=O,,,,,0,,363.1052907,4,2,3,1,1,2
9450,01/05/2019 00:00,DB13773,Sulfamethoxypyridazine,,,,,,,,,0.325,6.84,2.02,COC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1,,,,,0,,280.0630112,2,2,1,1,0,0
9451,01/05/2019 00:00,DB13774,Myristalkonium,,,,,,,,,3.57E-06,18.11,,CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,,,,,1,,332.3311768,1,1,0,0,0,0
9452,01/05/2019 00:00,DB13775,Tertatolol,,,,,,,,,0.0221,14.09,9.76,CC(C)(C)NCC(O)COC1=CC=CC2=C1SCCC2,,,,,0,,295.1606,2,1,1,0,0,1
9453,01/05/2019 00:00,DB13776,Ibacitabine,,,,,,,,,3.31,13.89,-2,NC1=NC(=O)N(C=C1I)[C@H]1C[C@H](O)[C@@H](CO)O1,,,,,0,,352.9872539,2,1,2,1,1,1
9454,01/05/2019 00:00,DB13777,Prenalterol,,,,,,,,,2.61,10.11,9.47,CC(C)NC[C@H](O)COC1=CC=C(O)C=C1,,,,,0,,225.1364935,1,1,0,0,0,0
9455,01/05/2019 00:00,DB13778,Cefazedone,,,,,,,,,0.0078,3.19,0.24,CC1=NN=C(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)CN2C=C(Cl)C(=O)C(Cl)=C2)C3=O)C(O)=O)S1,,,,,0,,546.9612369,4,2,4,2,1,2
9456,01/05/2019 00:00,DB13779,Guanoclor,,,,,,,,,0.392,,11.22,NC(=N)NNCCOC1=C(Cl)C=CC=C1Cl,,,,,0,,262.0388164,1,1,0,0,0,0
9457,01/05/2019 00:00,DB13780,Aluminium clofibrate,,,,,,,,,0.000616,3.37,-4.9,[OH-].[Al+3].CC(C)(OC1=CC=C(Cl)C=C1)C([O-])=O.CC(C)(OC1=CC=C(Cl)C=C1)C([O-])=O,,,,,0,,470.047972,2,2,0,0,0,0
9458,01/05/2019 00:00,DB13781,Xamoterol,,,,,,,,,1.01,-3.4,15.05,OC(CNCCN=C(O)N1CCOCC1)COC1=CC=C(O)C=C1,,,,,0,,339.1794209,2,1,1,0,1,1
9459,01/05/2019 00:00,DB13782,Imipramine oxide,,,,,,,,,0.00428,,4.46,CN(C)(=O)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,,,,,0,,296.1888634,3,2,1,0,0,1
9460,01/05/2019 00:00,DB13783,Acemetacin,After 8 days of oral administration twice daily of acemetacin there was an age-dependant Cmax of 276.8 ng/ml in elderly compared to 187 ng/ml for younger individuals. There was also a Tmax of 2.5 h and AUC in a range of 483-712 ng h/ml.[A31355] The bioavailability of acemetacin after repeated doses is aproximately 66% in plasma and 64% in urine.[A31356],0.9,The elimination half-life of acemetacin after steady-state is 4.5 hours.[A31356],,,solid,Slightly soluble,4.49,0.00229,3.26,-2.3,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O,0.9,0.9,,,0,,415.082265,3,3,1,1,0,0
9461,01/05/2019 00:00,DB13784,Dixyrazine,,,,,,,,,0.0327,15.12,7.87,CC(CN1CCN(CCOCCO)CC1)CN1C2=CC=CC=C2SC2=CC=CC=C12,,,,,0,,427.2293483,4,2,2,0,1,2
9462,01/05/2019 00:00,DB13785,Dropropizine,,,,,,,,,97.1,14,7.65,OCC(O)CN1CCN(CC1)C1=CC=CC=C1,,,,,0,,236.1524779,2,1,1,0,1,1
9463,01/05/2019 00:00,DB13786,Magnesium orotate,,,,,,,,,0.0526,2.83,-6,[Mg++].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1,,,,,0,,334.0036049,2,2,2,2,0,0
9464,01/05/2019 00:00,DB13787,Tilidine,,,,,,,,,0.181,,8.6,[H][C@]1(C=CCC[C@]1(C(=O)OCC)C1=CC=CC=C1)N(C)C,,,,,0,,273.172879,2,1,0,0,0,0
9465,01/05/2019 00:00,DB13788,Chlorbenzoxamine,,,,,,,,,0.000652,,7.93,CC1=CC=CC=C1CN1CCN(CCOC(C2=CC=CC=C2)C2=CC=CC=C2Cl)CC1,,,,,0,,434.2124913,4,3,1,0,1,1
9466,01/05/2019 00:00,DB13789,Aluminium acetotartrate,,,,,,,,,90.8,2.72,-4.3,[Al+3].CC([O-])=O.O[C@H]([C@@H](O)C([O-])=O)C([O-])=O,,,,,0,,233.9956308,0,0,0,0,0,0
9467,01/05/2019 00:00,DB13790,Fipexide,,,,,,,,,0.167,16.56,6.09,ClC1=CC=C(OCC(=O)N2CCN(CC3=CC4=C(OCO4)C=C3)CC2)C=C1,,,,,0,,388.1189848,4,2,2,0,1,2
9468,01/05/2019 00:00,DB13791,Penfluridol,,,,,,,,,0.000747,13.9,8.96,OC1(CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1)C1=CC(=C(Cl)C=C1)C(F)(F)F,,,,,0,,523.1701333,4,3,1,0,1,1
9469,01/05/2019 00:00,DB13792,Clopamide,,,,,,,,,0.139,8.85,1.32,C[C@H]1CCC[C@@H](C)N1NC(=O)C1=CC=C(Cl)C(=C1)S(N)(=O)=O,,,,,0,,345.0913902,2,1,1,0,1,1
9470,01/05/2019 00:00,DB13793,Vinburnine,,,,,,,,,0.175,19.25,6.3,[H][C@]12N3CCC[C@@]1(CC)CC(=O)N1C4=CC=CC=C4C(CC3)=C21,,,,,0,,294.1732133,5,2,4,1,1,3
9471,01/05/2019 00:00,DB13794,Dimethoxanate,,,,,,,,,0.0218,,8.87,CN(C)CCOCCOC(=O)N1C2=CC=CC=C2SC2=CC=CC=C12,,,,,0,,358.1351136,3,2,1,0,0,1
9472,01/05/2019 00:00,DB13795,Brodimoprim,,,,,,,,,0.338,17.33,7.16,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1Br,,,,,0,,338.0378378,2,2,1,1,0,0
9473,01/05/2019 00:00,DB13796,Dibunate,,,,,,,,,0.00106,-1.2,,CC(C)(C)C1=CC=C2C(C=CC(=C2S(O)(=O)=O)C(C)(C)C)=C1,,,,,0,,320.1446156,2,2,0,0,0,0
9474,01/05/2019 00:00,DB13797,Iodocholesterol (131I),,,,,,,,,3.97E-05,18.2,-1.4,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C[131I])[C@H]3CC[C@]12C,,,,,0,,516.2531657,4,0,0,0,0,0
9475,01/05/2019 00:00,DB13798,Demoxytocin,,,,,,,,,0.0427,9.5,-6,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,,,,,0,,991.4255585,3,1,2,0,2,2
9476,01/05/2019 00:00,DB13799,Ethadione,,,,,,,,,160,,,CCN1C(=O)OC(C)(C)C1=O,,,,,0,,157.0738932,1,0,1,0,1,1
9477,01/05/2019 00:00,DB13800,Calcium levulinate,"General calcium absorption occurs primarily in the duodenum by an active transcellular and saturable system, which is stimulated and regulated by 1,25(OH)2D,25 and through a passive and vitamin D-independent paracellular transport in the jejunum and ileum, and even in the colon - where absorption is only about 4% even when the intake is high [A33038]. Ultimately, calcium absorption depends mainly on the amount of intake - in general, absorption increases at lower intakes and decreases at high intakes [A33038].

Readily accessible data regarding the specific absorption of calcium levulinate is not available although the formulation is considered a low molecular weight organic calcium ion type that is easily absorbed through the intestinal wall [L2765].",,Readily accessible data regarding the half-life of calcium levulinate is not available.,,Intramuscular; Intravenous; Subcutaneous,,,,1.82,4.32,-7.3,[Ca++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O,,,,,0,,270.0416291,0,0,0,0,0,0
9478,01/05/2019 00:00,DB13801,Muzolimine,,,,,,,,,0.218,13.71,8.15,CC(N1NC(=N)CC1=O)C1=CC(Cl)=C(Cl)C=C1,,,,,0,,271.0279173,2,1,1,0,1,1
9479,01/05/2019 00:00,DB13802,Epomediol,,,,,,,,,79.2,13.61,-3.3,CC1(C)O[C@@]2(C)[C@@H](O)C[C@@H]1C[C@H]2O,,,,,0,,186.1255944,3,0,2,0,2,2
9480,01/05/2019 00:00,DB13803,Xipamide,,,,,,,,,0.0339,3.66,0.87,CC1=CC=CC(C)=C1N=C(O)C1=CC(=C(Cl)C=C1O)S(N)(=O)=O,,,,,0,,354.0441056,2,2,0,0,0,0
9481,01/05/2019 00:00,DB13804,Benzylthiouracil,,,,,,,,,0.0504,8.09,-3.2,O=C1NC(=S)NC(CC2=CC=CC=C2)=C1,,,,,0,,218.0513839,2,2,1,1,0,0
9482,09/05/2019 00:00,DB13805,Reposal,,,,,,,,,0.182,7.14,,CCC1(C(=O)NC(=O)NC1=O)C1=CC2CCC(C2)C1,,,,,0,,262.1317424,3,0,1,0,1,1
9483,01/05/2019 00:00,DB13806,Linopirdine,,,,,,,,,0.00188,,5.35,O=C1N(C2=CC=CC=C2C1(CC1=CC=NC=C1)CC1=CC=NC=C1)C1=CC=CC=C1,,,,,0,,391.1684623,5,4,3,2,0,1
9484,01/05/2019 00:00,DB13807,Tisopurine,,,,,,,,,0.677,8.47,-0.17,S=C1N=CNC2=C1C=NN2,,,,,0,,152.0156671,2,2,2,2,0,0
9485,01/05/2019 00:00,DB13808,Mebhydrolin,,,,,,,,,0.0367,,7.2,CN1CCC2=C(C1)C1=CC=CC=C1N2CC1=CC=CC=C1,,,,,0,,276.1626486,4,3,2,1,0,1
9486,01/05/2019 00:00,DB13810,Dimemorfan,,,,,,,,,0.00154,,10.04,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC1=CC=C(C)C=C31,,,,,0,,255.1986998,4,1,1,0,1,1
9487,01/05/2019 00:00,DB13812,Bufylline,,,,,,,,,28.9,11.44,2.44,CC(C)(N)CO.CN1C2=C(N=CN2)C(=O)N(C)C1=O,,,,,0,,269.1487895,2,2,2,2,0,0
9488,02/07/2019 00:00,DB13813,Iodoform,"Iodoform is reported to be absorbed through denuded skin, wounds or mucous membranes [L2646]. ",,No pharmacokinetic data available. ,0.03,Topical,solid,Slightly soluble,,0.143,,,[H]C(I)(I)I,,,,,0,,393.721244,0,0,0,0,0,0
9489,01/05/2019 00:00,DB13814,Talampicillin,,,,,,,,,0.0433,11.52,7.23,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(=O)OC1OC(=O)C2=CC=CC=C12,,,,,0,,481.1307565,5,2,3,0,2,3
9490,01/05/2019 00:00,DB13815,Xenysalate,,,,,,,,,0.244,9.58,8.84,CCN(CC)CCOC(=O)C1=CC=CC(=C1O)C1=CC=CC=C1,,,,,0,,313.1677936,2,2,0,0,0,0
9491,01/05/2019 00:00,DB13816,Aspoxicillin,,,,,,,,,0.101,2.53,9.91,[H][C@@](N)(CC(O)=NC)C(O)=N[C@@]([H])(C(O)=N[C@]1([H])C(=O)N2[C@]1([H])SC(C)(C)[C@]2([H])C(O)=O)C1=CC=C(O)C=C1,,,,,0,,493.1631192,3,1,2,0,2,2
9492,01/05/2019 00:00,DB13817,Carbromal,,,,,,,,,0.257,2.73,4.6,CCC(Br)(CC)C(O)=NC(O)=N,,,,,0,,236.0160398,0,0,0,0,0,0
9493,01/05/2019 00:00,DB13818,Bibrocathol,,,,,,,,,0.375,6.26,-8,[OH-].[Bi+3].[O-]C1=C([O-])C(Br)=C(Br)C(Br)=C1Br,,,,,0,,645.646316,1,1,0,0,0,0
9494,01/05/2019 00:00,DB13819,Proxazole,,,,,,,,,0.0882,,8.97,CCC(C1=NOC(CCN(CC)CC)=N1)C1=CC=CC=C1,,,,,0,,287.1997624,2,2,1,1,0,0
9495,01/05/2019 00:00,DB13820,Oxomemazine,,,,,,,,,0.0856,,8.02,CC(CN(C)C)CN1C2=CC=CC=C2S(=O)(=O)C2=CC=CC=C12,,,,,0,,330.1401989,3,2,1,0,0,1
9496,01/05/2019 00:00,DB13821,Ceftezole,,,,,,,,,0.867,2.88,-0.36,OC(=O)C1=C(CSC2=NN=CS2)CS[C@@H]2[C@H](NC(=O)CN3C=NN=N3)C(=O)N12,,,,,0,,440.0143639,4,2,4,2,1,2
9497,01/05/2019 00:00,DB13822,Meprotixol,,,,,,,,,0.00681,13.08,9.48,COC1=CC2=C(SC3=CC=CC=C3C2(O)CCCN(C)C)C=C1,,,,,0,,329.14495,3,2,1,0,0,1
9498,01/05/2019 00:00,DB13823,Pipemidic acid,,,,,,,,,0.746,5.31,8.57,CCN1C=C(C(O)=O)C(=O)C2=CN=C(N=C12)N1CCNCC1,,,,,0,,303.1331394,3,2,3,2,1,1
9499,01/05/2019 00:00,DB13824,Enprostil,,,,,,,,,0.0149,13.99,-2.9,COC(=O)CCC=C=CC[C@H]1[C@H](\C=C\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O,,,,,0,,400.1885886,2,1,0,0,0,0
9500,01/05/2019 00:00,DB13825,Fedrilate,,,,,,,,,0.237,,7.36,CC(CCN1CCOCC1)OC(=O)C1(CCOCC1)C1=CC=CC=C1,,,,,0,,347.2096584,3,1,2,0,2,2
9501,01/05/2019 00:00,DB13826,Etohexadiol,,,,,,,,,48.3,14.76,-2.6,CCCC(O)C(CC)CO,,,,,0,,146.1306798,0,0,0,0,0,0
9502,01/05/2019 00:00,DB13827,Indanazoline,,,,,,,,,0.563,,9.93,C1CC2=C(C1)C(NC1=NCCN1)=CC=C2,,,,,0,,201.1265975,3,1,1,0,0,1
9503,01/05/2019 00:00,DB13828,Cyfluthrin,,,,,,,,,0.000657,10.31,-7.1,CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=C(F)C(OC2=CC=CC=C2)=C1,,,,,0,,433.064777,3,2,0,0,0,0
9504,01/05/2019 00:00,DB13829,Calcium silicate,,,,,,,,,0.784,9.82,-4.8,[Ca++].O[Si](O)(O)[O-].O[Si](O)(O)[O-],,,,,0,,229.9227112,0,0,0,0,0,0
9505,01/05/2019 00:00,DB13830,Copper usnate,,,,,,,,,0.0277,7.47,-5,[Cu++].CC(=O)C1C(=O)C=C2OC3=C(C(C)=O)C([O-])=C(C)C([O-])=C3C2(C)C1=O,,,,,0,,405.0035503,3,1,1,0,0,1
9506,01/05/2019 00:00,DB13832,Ranimustine,,,,,,,,,15.5,12.2,-3.6,CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,327.0833276,1,0,1,0,1,1
9507,01/05/2019 00:00,DB13833,Methylatropine,,,,,,,,,0.00561,15.15,-2.7,C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1,,,,,1,,304.1907201,3,1,2,0,2,2
9508,01/05/2019 00:00,DB13834,Phenylmercuric borate,,,,,,,,,54.1,,,[OH-].OB(O)[O-].[Hg+]C1=CC=CC=C1.[Hg+]C1=CC=CC=C1,,,,,0,,636.0319753,2,2,0,0,0,0
9509,01/05/2019 00:00,DB13835,Caroverine,,,,,,,,,0.03,,8.68,CCN(CC)CCN1C(=O)C(CC2=CC=C(OC)C=C2)=NC2=CC=CC=C12,,,,,0,,365.2103271,3,3,1,1,0,0
9510,09/05/2019 00:00,DB13836,Metampicillin,,,,,,,,,0.109,3.24,4.14,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=C)C1=CC=CC=C1)C(O)=O,,,,,0,,361.1096271,3,1,2,0,2,2
9511,01/05/2019 00:00,DB13837,Doxefazepam,,,,,,,,,0.0626,10.67,-2.3,OCCN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1F,,,,,0,,348.0676982,3,2,1,0,0,1
9512,01/05/2019 00:00,DB13838,Noxytiolin,,,,,,,,,6.4,13.86,-3,CNC(=S)NCO,,,,,0,,120.0357339,0,0,0,0,0,0
9513,01/05/2019 00:00,DB13839,Dipyrocetyl,,,,,,,,,1.41,3.16,-6.9,CC(=O)OC1=CC=CC(C(O)=O)=C1OC(C)=O,,,,,0,,238.047738,1,1,0,0,0,0
9514,01/05/2019 00:00,DB13840,Hydroxyethylpromethazine,,,,,,,,,0.000583,13.97,-3.3,CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)[N+](C)(C)CCO,,,,,1,,329.1682108,3,2,1,0,0,1
9515,01/05/2019 00:00,DB13841,Clopenthixol,,,,,,,,,0.0026,15.59,8.03,[H]C(CCN1CCN(CCO)CC1)=C1C2=C(SC3=C1C=C(Cl)C=C3)C=CC=C2,,,,,0,,400.1376121,4,2,2,0,1,2
9516,09/05/2019 00:00,DB13842,Etofylline nicotinate,,,,,,,,,3.18,,3.24,CN1C2=C(N(CCOC(=O)C3=CC=CN=C3)C=N2)C(=O)N(C)C1=O,,,,,0,,329.112404,3,3,3,3,0,0
9517,01/05/2019 00:00,DB13843,Cloprednol,,,,,,,,,0.099,12.58,-2.9,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)C=C[C@]12C,,,,,0,,392.1390516,4,0,0,0,0,0
9518,01/05/2019 00:00,DB13844,Pipenzolate,,,,,,,,,0.000371,11.05,-4.5,CC[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,354.2063702,3,2,1,0,1,1
9519,01/05/2019 00:00,DB13845,Etafenone,,,,,,,,,0.0111,16.33,8.53,CCN(CC)CCOC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,,,,,0,,325.2041791,2,2,0,0,0,0
9520,01/05/2019 00:00,DB13846,Pyrrobutamine,,,,,,,,,0.00171,,8.91,ClC1=CC=C(CC(=CCN2CCCC2)C2=CC=CC=C2)C=C1,,,,,0,,311.1440774,3,2,1,0,1,1
9521,01/05/2019 00:00,DB13848,Fluorodopa (18F),,,,,,,,,2.39,1.32,9.4,N[C@@H](CC1=CC(O)=C(O)C=C1[18F])C(O)=O,,,,,0,,214.0619208,1,1,0,0,0,0
9522,01/05/2019 00:00,DB13849,Clofibride,,,,,,,,,0.0998,,-1.4,CN(C)C(=O)CCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,,,,,0,,327.1237359,1,1,0,0,0,0
9523,01/05/2019 00:00,DB13850,Timepidium,,,,,,,,,0.00842,,-4.2,COC1CC(C[N+](C)(C)C1)=C(C1=CC=CS1)C1=CC=CS1,,,,,1,,320.1137327,3,2,3,2,1,1
9524,09/05/2019 00:00,DB13851,Artemotil,,,,,,,,,0.276,,-3.9,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OCC)[C@@H]2C)O4,,,,,0,,312.193674,5,0,4,0,4,4
9525,01/05/2019 00:00,DB13852,Mefenorex,,,,,,,,,0.0176,,9.83,CC(CC1=CC=CC=C1)NCCCCl,,,,,0,,211.1127773,1,1,0,0,0,0
9526,02/07/2019 00:00,DB13853,Anethole trithione,"Although anethole trithione (ATT) has a high lipophilicity (log P = 3.8) and a high intestinal permeability, it has an extremely low water solubility (0.38 ug/ml). This low solubility limits ATT dissolution and bioavailability [A32614, A32616].

Regardless, after ATT was administered to twenty-two healthy Chinese volunteers, the Cmax observed was about 0.98 +/- 0.49 ng/mL and the recorded Tmax was 2.2 +/- 1.9 h [A32615].",,"Despite the medication being studied and discussed as early as the 1980s, detailed pharmacokinetic information about it is not readily accessible and limited new pharmacokinetic data has only been determined for the drug for the first time only very recently (as recently as 2007) [A32615].

Consequently, after anethole trithione was administered to twenty-two healthy Chinese volunteers, the half-life observed was about 3.78 +/- 2.12 hours [A32615].",25.0 mg,Oral,,,,0.00879,,-4.8,COC1=CC=C(C=C1)C1=CC(=S)SS1,,,,,0,25,239.9737279,2,2,1,1,0,0
9527,01/05/2019 00:00,DB13854,Gamolenic acid,"The findings from a pharmacokinetic study suggest that therapeutic levels of GLA can be achieved within a week. The fasting plasma GLA levels plateaued within seven days of beginning treatment, regardless of dose [F27]. ",,No pharmacokinetic data available.,,Oral,liquid,,,0.000254,4.92,,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O,,,,,0,,278.2245802,0,0,0,0,0,0
9528,01/05/2019 00:00,DB13855,Nifuroxazide,,,,,,,,,0.105,8.33,-1.7,OC1=CC=C(C=C1)C(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O,,,,,0,,275.0542204,2,2,1,1,0,0
9529,01/05/2019 00:00,DB13856,Fluclorolone,,,,,,,,,0.0202,11.76,-3.3,C[C@]12C[C@H](Cl)[C@@]3(Cl)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,,,,,0,,446.1063075,4,0,0,0,0,0
9530,01/05/2019 00:00,DB13857,Demegestone,,,,,,,,,0.0111,18.42,-4.7,[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H],,,,,0,,312.2089301,4,0,0,0,0,0
9531,01/05/2019 00:00,DB13858,Dimazole,,,,,,,,,0.139,,9.28,CCN(CC)CCOC1=CC2=C(C=C1)N=C(S2)N(C)C,,,,,0,,293.1561834,2,2,1,1,0,0
9532,01/05/2019 00:00,DB13860,Imidazole salicylate,,,,,,solid,,,11.3,2.79,-6.3,N1C=CN=C1.OC(=O)C1=CC=CC=C1O,,,,,0,,206.0691422,2,2,1,1,0,0
9533,01/05/2019 00:00,DB13861,Iopentol,,,,,,solid,,,0.445,11.73,-1.7,COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,,,,,0,,834.8959735,1,1,0,0,0,0
9534,01/05/2019 00:00,DB13863,Fosfructose,,,,,,solid,,,13.6,1.01,-3.5,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)C(=O)COP(O)(O)=O,,,,,0,,339.9960491,0,0,0,0,0,0
9535,01/05/2019 00:00,DB13865,Dehydroemetine,,,,,,solid,,,0.0078,,9.04,[H][C@@]12CC(C[C@H]3NCCC4=C3C=C(OC)C(OC)=C4)=C(CC)CN1CCC1=C2C=C(OC)C(OC)=C1,,,,,0,,478.2831577,5,2,3,0,0,3
9536,09/05/2019 00:00,DB13866,Etynodiol,,,,,,solid,,,0.00785,17.52,-1.4,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](O)C=C3CC[C@@]21[H],,,,,0,,300.2089301,4,0,0,0,0,0
9537,01/05/2019 00:00,DB13867,Fluticasone,"Intranasal exposure of [DB08906] results in patients swallowing a larger portion of the dose[F4361,A177118]. However, absorption is poor and metabolism is high, therefore there is negligible systemic exposure with a nasal bioavailability of 0.50% and oral bioavialability of 1.26%[F4361,A7490]. Inhaled bioavailability is 13.9%[F4364]. A study of 24 healthy Caucasian males showed an inhaled bioavailability of 6.3-18.4%[A7490].

Intranasal bioavailability of [DB00588] is <2%, and oral bioavailability is <1%[F4358][FDA Label]. Intranasal exposure results in the majority of the dose being swallowed[A177118]. Topical absorption of [DB00588] is very low but can change depending on a number of factors including integrity of the skin and the presence of inflammation or disease[F4355]. A study of 24 healthy Caucasian males showed an inhaled bioavailability of 9.0%[A7490].",0.99,"15.1 hours for intranasal [DB08906][F4361] and 24 hours for the inhaled formulation[F4364]. A study of 24 healthy Caucasian males showed a half life of 13.6 hours following intravenous administration and 17.3-23.9 hours followed inhalation[A7490].

7.8 hours for intravenous [DB00588][F4358][FDA Label]. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation[A7490].",,,solid,,,0.0344,12.19,-3.4,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,0.99,0.99,,,0,,444.158215,4,0,0,0,0,0
9538,05/01/2018 00:00,DB13868,Adefovir,,,,,,solid,,,2.02,1.35,5.12,NC1=C2N=CN(CCOCP(O)(O)=O)C2=NC=N1,,,,,0,,273.0626905,2,2,2,2,0,0
9539,01/05/2019 00:00,DB13869,2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol,,,,,,solid,,,0.0101,9.34,2.14,COC1=C(O)C(\C=N\C2=CC=C(C)C=C2)=CC=C1,,,,,0,,241.1102787,2,2,0,0,0,0
9540,01/05/2019 00:00,DB13871,Albendazole oxide,,,,,,solid,,,4.45,7.07,1.99,CCCS(=O)C1=CC2=C(C=C1)N=C(N2)N=C(O)OC,,,,,0,,281.0834123,2,2,1,1,0,0
9541,01/05/2019 00:00,DB13872,Lormetazepam,,,The terminal phase half life is 11 h [L927].,,,solid,,,0.0164,10.68,-2.2,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl,,,,,0,,334.027583,3,2,1,0,0,1
9542,01/05/2019 00:00,DB13873,Fenofibric acid,"Some studies have demonstrated that the bioavailability of fenofibric acid (a sample administration of 130 mg oral suspension to healthy volunteers about 4 hours after a light breakfast) is approximately 81% in the stomach, 88% in the proximal small bowel, 84% in the distal small bowel, and 78% in the colon [A32038]. Nevertheless, following the oral administration of fenofibric acid in healthy volunteers, median peak plasma levels for the drug occurred about 2.5 hours after administration [FDA Label]. Moreover, exposure after administration of three 35 mg fenofibric acid tablets is largely comparable to that of one 105 mg tablet [FDA Label].",0.99,"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].",45 mg/1,Oral,solid,,,0.0051,3.1,-4.9,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O,0.99,0.99,,,0,45,318.0658866,2,2,0,0,0,0
9543,02/07/2019 00:00,DB13874,Enasidenib,"Following a single oral dose of 100mg enasidenib, the peak plasma concentration of 1.3 mcg/mL is reached at 4 hours after ingestion. The absolute bioavailability is aproximately 57% and the steady-state plasma levels are reached within 29 days of once-daily dosing [FDA Label].",0.985,Enasidenib has a terminal half-life of 137 hours [FDA Label].,100 mg,Oral,solid,,,0.0366,11.37,3.82,CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=NC(=CC=C1)C(F)(F)F,0.985,0.985,,,0,100,473.1398775,3,3,3,3,0,0
9544,02/07/2019 00:00,DB13875,Harmaline,,,,,,solid,,,0.0576,14.95,6.46,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NCC1,,,,,0,,214.1106131,3,2,2,1,0,1
9545,01/05/2019 00:00,DB13876,Brofaromine,,,,,,solid,,,0.0321,,9.9,COC1=CC2=C(OC(=C2)C2CCNCC2)C(Br)=C1,,,,,0,,309.0364409,3,2,2,1,1,1
9546,01/05/2019 00:00,DB13877,Iniparib,,,,,,solid,,,0.129,13,-0.68,NC(=O)C1=CC(=C(I)C=C1)[N+]([O-])=O,,,,,0,,291.93449,1,1,0,0,0,0
9547,01/05/2019 00:00,DB13878,Pibrentasvir,"In healthy subjects, the time it takes to reach the peak plasma concentration (Tmax) is approximately 5 hours. The mean peak plasma concentration (Cmax) is 110ng/mL in non-cirrhotic HCV-infected subjects. Relative to fasting conditions, the consumption of meals increases the absorption of pibrentasvir by 40-53% [FDA Label]. ",>99.9%,The elimination half life (t1/2) is approximately 13 hours [FDA Label]. ,,Oral,solid,<0.1 mg/mL,,0.00538,3.58,5.34,CO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1=NC2=C(N1)C=C(F)C(=C2)[C@H]1CC[C@@H](N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C=C1F,0.99,1,,,0,,1112.4907,10,6,6,2,4,4
9548,01/05/2019 00:00,DB13879,Glecaprevir,"In healthy subjects, the time it takes to reach the peak plasma concentration (Tmax) is approximately 5 hours. The mean peak plasma concentration (Cmax) is 597ng/mL in non-cirrhotic HCV-infected subjects. Relative to fasting conditions, the consumption of meals increases the absorption of glecaprevir by 83-163% [FDA Label]. ",0.975,The elimination half life (t1/2) is approximately 6 hours [FDA Label]. ,,Oral,solid,<0.1 to 0.3 mg/mL,,0.0463,3.74,-1.2,CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC\C=C\C(F)(F)C2=NC3=C(C=CC=C3)N=C2O[C@@H]2C[C@H](N(C2)C1=O)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1,0.975,0.975,,,0,,838.2983109,7,2,3,1,1,2
9549,01/05/2019 00:00,DB13882,Methyl nicotinate,"The presence of methyl group facilitates the penetration of methyl nicotinate through the skin with good lipophilicity, allowing rapid absorption following topical administration [F64]. _In vitro_, about 80-90% of the polar compounds methyl nicotinate rapidly penetrated the skin [F64]. It was demonstrated in excised skin of hairless mice that methyl nicotinate can effectively bypass the stratum corneum layer of the skin [F64]. In humans, nicotinic acid and nicotinamide were shown to be rapidly absorbed from the stomach and intestine via a sodium carrier-mediated mechanism at low concentrations [F64]. ",,"_In vitro_, the half-life of methyl nicotinate in the dermis was 3 to 10 minutes [A33028]. ",,Topical,solid,Soluble,0.8,193,,3.24,COC(=O)C1=CN=CC=C1,,,,,0,,137.0476785,1,1,1,1,0,0
9550,02/07/2019 00:00,DB13908,Amylmetacresol,Rapidly absorbed and eliminated [L2574].,,,0.6 mg,Oral,solid,not soluble,,0.068,10.39,-5.5,CCCCCC1=CC=C(C)C=C1O,,,,,0,0.6,178.1357652,1,1,0,0,0,0
9551,02/07/2019 00:00,DB13909,Bismuth subgallate,"Bismuth subgallate is only slightly, if at all, absorbed after oral ingestion [L2314]. The general human oral bioavailability of bismuth subgallate has been reported as low as 0.04% [L2314]. Any absorption that does occur is likely to happen from the upper small intestine [A32571].

The gastrointestinal absorption of bismuth from bismuth compounds demonstrates a large interindividual variation [L2314]. Factors affecting the absorption involve the formulation of the bismuth subgallate compound as well as the dietary factors of the individuals themselves [A32571]. Nevertheless, absorption can be enhanced with the concomitant intake of citrate and sulfhydryl-group-containing compounds [L2314]. Conversely, the simultaneous administration of antacids or a diet that is high in thiol content can lower absorption of bismuth subgallate [A32571].",>90%,The bismuth component of bismuth subgallate is known to have a terminal half-life of 21-72 days [L2330].,200 mg/1,Oral,solid,Insoluble in cold water and hot water.,,44.8,3.93,-2.3,O[Bi]1OC2=CC(=CC(O)=C2O1)C(O)=O,0.9,1,,,0,200,393.9890116,2,1,1,0,0,1
9552,02/07/2019 00:00,DB13910,Valproate bismuth,,,,67.5 mg,Rectal,solid,,,0.0716,5.14,,[Bi+3].CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O,,,,,0,,638.3020129,0,0,0,0,0,0
9553,02/07/2019 00:00,DB13911,Phloxine B,,,,0.015,Dental,solid,,,7.49E-05,2.52,1.84,[Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C1C=C(Br)C([O-])=C2Br,,,,,0,,823.5185208,4,2,1,0,0,1
9554,01/05/2019 00:00,DB13912,Coumermycin A1,,,,,,solid,,,0.0111,5.21,-4,CO[C@H]1[C@H](OC(=O)C2=CC=C(C)N2)[C@H](O)[C@@H](OC2=C(C)C3=C(C=C2)C(O)=C(NC(=O)C2=C(C)C(=CN2)C(=O)NC2=C(O)C4=C(OC2=O)C(C)=C(O[C@H]2OC(C)(C)[C@@H](OC)[C@H](OC(=O)C5=CC=C(C)N5)[C@@H]2O)C=C4)C(=O)O3)OC1(C)C,,,,,0,,1109.375339,9,7,7,5,2,2
9555,01/05/2019 00:00,DB13914,Volixibat,,,,,,solid,,,0.115,-1.9,2.23,[H][C@@]1([C@@H](O)[C@](CC)(CCCC)CS(=O)(=O)C2=CC=C(C=C12)N(C)C)C1=CC=CC(NC(=O)N[C@@H]2O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](OCC3=CC=CC=C3)[C@H]2O)=C1,,,,,0,,805.2914161,5,3,2,0,1,2
9556,01/05/2019 00:00,DB13916,Toyocamycin,,,,,,solid,,,2.42,12.46,4.71,NC1=C2C(=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1)C#N,,,,,0,,291.0967539,3,2,3,2,1,1
9557,01/05/2019 00:00,DB13917,Deoxyepinephrine,,,,,,solid,,,6.28,9.27,10.29,CNCCC1=CC(O)=C(O)C=C1,,,,,0,,167.0946287,1,1,0,0,0,0
9558,01/05/2019 00:00,DB13918,Diclofop-methyl,,,,,,solid,,,0.00138,,-3.7,COC(=O)C(C)OC1=CC=C(OC2=C(Cl)C=C(Cl)C=C2)C=C1,,,,,0,,340.0269143,2,2,0,0,0,0
9559,01/05/2019 00:00,DB13919,Candesartan,,,,,,solid,,,0.00745,3.44,1.5,CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,,,,,0,,440.1596885,5,5,2,2,0,0
9560,01/05/2019 00:00,DB13920,Valopicitabine,,,,,,solid,,,0.723,5.79,7.49,[H][C@](N)(C(C)C)C(=O)O[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(N2C=CC(=N)N=C2O)[C@]1(C)O,,,,,0,,356.1695845,2,1,2,1,1,1
9561,01/05/2019 00:00,DB13921,2'-C-methylcytidine,,,,,,solid,,,2.19,5.9,3.18,[H][C@]1(CO)O[C@@]([H])(N2C=CC(=N)N=C2O)[C@](C)(O)[C@]1([H])O,,,,,0,,257.1011706,2,1,2,1,1,1
9562,01/05/2019 00:00,DB13925,Dotatate gallium Ga-68,"Dotatate gallium 68 presents a higher affinity for the somatostatin receptor subtype 2 when compared with the other gallium 68 analogues. Intravenous administration of dotatate gallium 68 is absorbed and distributed to all the somatostatin subtype 2 receptor-containing organs like pituitary, thyroid, spleen, adrenals, kidney, pancreas, prostate, liver and salivary glands. There is no uptake in cerebral cortex or in the heart and the uptake presented in thymus and lung are very low.[A31365]",,The half-life of gallium 68 is estimated to be of 68 min.[A31362],,,solid,At pH above 7 can be soluble,-3.69,0.068,1.32,10.29,[Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,,,,,0,,1500.496907,6,4,3,1,2,2
9563,01/05/2019 00:00,DB13927,anle138b,,,,,,solid,,,0.0278,13.51,2.51,BrC1=CC=CC(=C1)C1=NNC(=C1)C1=CC2=C(OCO2)C=C1,,,,,0,,342.0003897,4,3,2,1,0,1
9564,01/05/2019 00:00,DB13929,Relcovaptan,,,,,,solid,,,0.00767,7.72,-3.8,COC1=CC=C(C=C1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(C2=CC(Cl)=CC=C12)C1=CC=CC=C1Cl,,,,,0,,619.0946766,5,3,2,0,1,2
9565,01/05/2019 00:00,DB13930,Ulixertinib,,,,,,solid,,,0.00447,12.78,4.65,[H]N([C@H](CO)C1=CC(Cl)=CC=C1)C(=O)C1=CC(=CN1[H])C1=CC(=NC=C1Cl)N([H])C(C)C,,,,,0,,432.1119813,3,3,2,2,0,0
9566,01/05/2019 00:00,DB13931,Netarsudil,"The systemic exposure of netarsudil and its active metabolite, AR-13503, after topical ocular administration of netarsudil opthalmic solution 0.02% once daily (one drop bilaterally in the morning) for eight days in 18 healthy subjects demonstrated no quantifiable plasma concentrations of netarsudil (lower limit of quantitation [LLOQ] 0.100 ng/mL) post dose on Day 1 and Day 8. Only one plasma concentration at 0.11 ng/mL for the active metabolite was observed for one subject on Day 8 at 8 hours post dose [FDA Label].",0.6,The half-life of netarsudil incubated *in vitro* with human corneal tissue is 175 minutes [A31475].,0.200 mg/1mL,Ophthalmic; Topical,liquid,,,0.000277,13.49,8.69,CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1,0.6,0.6,,,0,,453.2052417,4,4,1,1,0,0
9567,01/05/2019 00:00,DB13934,Ligandrol,,,,,,solid,,,0.053,10.91,-2,O[C@H]([C@H]1CCCN1C1=CC=C(C#N)C(=C1)C(F)(F)F)C(F)(F)F,,,,,0,,338.0853823,2,1,1,0,1,1
9568,01/05/2019 00:00,DB13935,AC-262536,,,,,,solid,,,0.084,15.16,2.03,[H][C@]12CC[C@]([H])(C[C@H](O)C1)N2C1=CC=C(C#N)C2=CC=CC=C12,,,,,0,,278.1419132,4,2,2,0,2,2
9569,01/05/2019 00:00,DB13936,JNJ-28330835,,,,,,solid,,,0.0124,2.66,0.78,C[C@]1(CC(=NN1)C(F)(F)F)C(O)=NC1=CC(=C(C=C1)C#N)C(F)(F)F,,,,,0,,364.0758803,2,1,1,0,0,1
9570,01/05/2019 00:00,DB13937,LGD-3303,,,,,,solid,,,0.00474,10.46,-0.64,CCC1=C(C)C2=C(C=CC3=C2C(Cl)=CC(O)=N3)N1CC(F)(F)F,,,,,0,,342.0746754,3,3,2,2,0,0
9571,09/05/2019 00:00,DB13938,S-40503,,,,,,solid,,,0.552,14.5,8.3,[H][C@]1(C[C@]([H])(N(C)C)C2=C(N1)C=CC(=C2)N(=O)=O)C(C)(C)CO,,,,,0,,293.1739416,2,1,1,0,0,1
9572,01/05/2019 00:00,DB13939,RAD-140,,,,,,solid,,,0.153,12.17,-1.1,[H][C@@](C)(O)[C@@]([H])(NC1=C(C)C(Cl)=C(C=C1)C#N)C1=NN=C(O1)C1=CC=C(C=C1)C#N,,,,,0,,393.0992524,3,3,1,1,0,0
9573,01/05/2019 00:00,DB13940,"2,5-Dimethoxy-4-ethylthioamphetamine",,,,,,solid,,,0.267,,9.91,CCSC1=CC(OC)=C(CC(C)N)C=C1OC,,,,,0,,255.1292999,1,1,0,0,0,0
9574,01/05/2019 00:00,DB13941,Piperaquine,"Piperaquine is slowly absorbed and exhibits multiple peaks in its plasma concentration curve suggestive of enterohepatic recycling occurring alongside the absorption process [L1149]. Due to this complication there is no discreet value for bioavailability but piperaquine is highly absorbed into systemic circulation. When taken with food, Cmax increases by 217% and mean exposure increases by 177%. Tmax is not affected by food and remains around 5 h [FDA Label]. Piperaquine has been observed to accumulate more in females to a degree of 30-50% more than males [FDA Label]. It also collects in red blood cells similar to [DB11638].",>99%,The terminal elimination half-life was observed to be 576h or 24 days [L1149]. This is thought to be due to the extensive distribution of piperaquine.,,,solid,,,0.0167,,8.47,ClC1=CC2=C(C=C1)C(=CC=N2)N1CCN(CCCN2CCN(CC2)C2=CC=NC3=C2C=CC(Cl)=C3)CC1,0.99,1,,,0,,534.2065504,6,4,4,2,2,2
9575,02/07/2019 00:00,DB13943,Testosterone cypionate,"Testosterone cypionate is an esterified anabolic which allows it to present a greater degree of solubility in fats and thus, the release and absorption occur in a slow rate compare to homologous molecules.[L1152] Intramuscular administration of 200 mg of testosterone cypionate produced a mean supratherapeutic Cmax of 1122 ng/dl which occurred 4-5 days post-injection. After the fifth day, the levels of testosterone cypionate in plasma went down reaching an average of 400 ng/dl.[A31613]",0.4,"The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.[L1151]",200 mg/1mL,Intramuscular,solid,Insoluble,,0.000437,18.52,-4.8,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,0.4,0.4,,,0,,412.2977451,5,0,0,0,0,0
9576,02/07/2019 00:00,DB13944,Testosterone enanthate,"The pharmacokinetic profile of testosterone enanthate was studied in a regime of multiple dosing and the testosterone level was reported to present a Cmax above 1200 ng/dl after 24 hours of the last dose. The concentration decreased sequentially until it reached 600 ng/dl after one week. The pharmacokinetic profile of testosterone enanthate presented differences depending on the administered dose in which the tmax was shifted to a range of 36-48 hours. The plasma testosterone level plateaued below the therapeutic range after 3-4 weeks. This reports showed that the different formulation of testosterone enanthate and testosterone cypionate generates a different profile and thus, they are not therapeutically equivalent.[A31613] ",0.4,Testosterone enanthate presents a long half-life in the range of 7-9 days.[A31616],200 mg,Intramuscular,solid,Insoluble,3.58,0.000463,18.52,-4.8,[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.4,0.4,,,0,,400.2977451,4,0,0,0,0,0
9577,02/07/2019 00:00,DB13946,Testosterone undecanoate,"The absorption of testosterone undecanoate varies based on the formulation.  The intramuscular formulation of testosterone esters is suspended in oil and is absorbed from the lipid phase.  Testosterone is released when tissue esterases cleave the undecanoic acid side chain. [F4247]  
The oral formulation of testosterone undecanoate is also formulated as a prodrug, is best absorbed with food and ideal absorption occurs when taken with a meal containing at least 30 g of fat. [FDA Label]",0.4,"Based on one source, Testosterone undecanoate in castor oil (for intramuscular injection) has a half life of 33.9 days, allowing it to maintain serum levels in the normal range for over 6 weeks. [A176954]  It should be noted that the half life of testosterone reported in the literature is inconsistent. [F4247]",250 mg/1mL,Intramuscular,solid,Insoluble,,7.40E-05,18.52,-4.8,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,0.4,0.4,,,0,,456.3603454,4,0,0,0,0,0
9578,01/05/2019 00:00,DB13947,Testosterone enantate benzilic acid hydrazone,,,,,Intramuscular,,,,0.000122,11.09,2.14,[H]N(N=C1CC[C@@]2(C)C(CC[C@@]3([H])[C@]4([H])CC[C@H](OC(=O)CCCCCC)[C@@]4(C)CC[C@]23[H])=C1)C(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,624.3927081,6,2,0,0,0,0
9579,09/05/2019 00:00,DB13948,"N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine",,,,,,solid,,,0.0197,8.32,10.2,COC1=CC(C#N)=C(OC)C=C1CCNCC1=C(O)C=CC=C1,,,,,0,,312.1473925,2,2,0,0,0,0
9580,01/05/2019 00:00,DB13950,WIN 55212-2,,,,,,solid,,,0.00444,,6.35,CC1=C(C(=O)C2=CC=CC3=CC=CC=C23)C2=C3N1[C@H](CN1CCOCC1)COC3=CC=C2,,,,,0,,426.1943427,6,4,3,1,1,2
9581,01/05/2019 00:00,DB13951,Stanolone acetate,,,,,,,,,0.00115,,-6.8,[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C,,,,,0,,332.2351449,4,0,0,0,0,0
9582,01/05/2019 00:00,DB13952,Estradiol acetate,"Drug delivery from Femring is rapid for the first hour and then declines to a relatively constant rate for the remainder of the 3-month dosing interval. Estradiol acetate is rapidly hydrolyzed to estradiol which is absorbed through the vaginal mucosa as evidenced by the mean time to maximum concentration (tmax) for estradiol of about 1 hour (range 0.25 to 1.5 hrs). Following the maximum concentration (Cmax=1129pg/mL), serum estradiol decreases rapidly such that by 24 to 48 hours postdose, serum estradiol concentrations are relatively constant through the end of the 3-month dosing interval [FDA Label].",,,0.05 mg/1d,Vaginal,,,,0.00183,19.38,-0.88,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H],,,,,0,,314.1881947,4,1,0,0,0,0
9583,01/05/2019 00:00,DB13953,Estradiol benzoate,,,,,Intramuscular,,,,0.000189,19.38,-0.88,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)C5=CC=CC=C5)=CC=C4[C@@]3([H])CC[C@]12C,,,,,0,,376.2038448,5,2,0,0,0,0
9584,01/05/2019 00:00,DB13954,Estradiol cypionate,"When conjugated with aryl and alkyl groups for parenteral administration, the rate of absorption of oily preparations is slowed with a prolonged duration of action, such that a single intramuscular injection of estradiol valerate or estradiol cypionate is absorbed over several weeks [FDA Label].",,,5 mg/1mL,Intramuscular,,,,0.000118,10.33,-5.4,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,,,,,0,,396.266445,5,1,0,0,0,0
9585,01/05/2019 00:00,DB13955,Estradiol dienanthate,,,,,Intramuscular,,,,1.16E-05,,-6.8,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(OC(=O)CCCCCC)=CC=C4[C@H]3CC[C@]12C,,,,,0,,496.35526,4,1,0,0,0,0
9586,02/07/2019 00:00,DB13956,Estradiol valerate,"IM Injection: When conjugated with aryl and alkyl groups for parenteral administration, the rate of absorption of oily preparations is slowed with a prolonged duration of action, such that a single intramuscular injection of estradiol valerate or estradiol cypionate is absorbed over several weeks [FDA Label].

Natazia: After oral administration of estradiol valerate, cleavage to 17Î²-estradiol and valeric acid takes place during absorption by the intestinal mucosa or in the course of the first liver passage. This gives rise to estradiol and its metabolites, estrone and other metabolites. Maximum serum estradiol concentrations of 73.3 pg/mL are reached at a median of approximately 6 hours (range: 1.5â€“12 hours) and the area under the estradiol concentration curve [AUC(0â€“24h)] was 1301 pgÂ·h/mL after single ingestion of a tablet containing 3 mg estradiol valerate under fasted condition on Day 1 of the 28-day sequential regimen.",,,10 mg/1mL,Intramuscular,,,,0.000617,10.33,-5.4,[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,,,,,0,,356.2351449,4,1,0,0,0,0
9587,01/05/2019 00:00,DB13957,J147,,,,,,solid,,,0.000115,,-1.9,COC1=CC(\C=N\N(C(=O)C(F)(F)F)C2=C(C)C=C(C)C=C2)=CC=C1,,,,,0,,350.1242124,2,2,0,0,0,0
9588,01/05/2019 00:00,DB13958,Trestolone acetate,,,,,,solid,,,0.00582,18.34,-4.7,[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H],,,,,0,,330.2194948,4,0,0,0,0,0
9589,01/05/2019 00:00,DB13960,Bronopol,"Bronopol was rapidly absorbed in animal studies. It may be absorbed via aerosol inhalation, dermal contact, and ingestion [L2578]. In rats, approximately 40% of the topically applied dose of bronopol was absorbed through the skin within 24 hr [L2578]. Following oral administration of 1 mg/kg in rats, the peak plasma concentrations of bronopol were reached up to 2 hours post-dosing [A32797].",,"The half-life of bronopol in the biological systems is not reported in the literature. The half-life value reported for bronopol reflects the environment fate of the compound. When released into the air as vapours, bronopol is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals where the half life for this reaction is approximately 11 days [L2578]. The photolysis half-life is 24 hours in water but may be up to 2 days under natural sunlight [L2578]. ",,Topical,solid,25-25g/100mL at 22Â°C,-0.6,12.8,12.55,-3.7,OCC(Br)(CO)[N+]([O-])=O,,,,,0,,198.9480198,0,0,0,0,0,0
9590,02/07/2019 00:00,DB13962,Calcium saccharate,,,,,Intravenous,solid,,,90.1,2.83,-3.7,[Ca++].[H][C@](O)(C([O-])=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)C([O-])=O,,,,,0,,247.9845082,0,0,0,0,0,0
9591,09/05/2019 00:00,DB13963,"1,2-dichlorobenzene",,,,,,solid,,,0.13,,,ClC1=C(Cl)C=CC=C1,,,,,0,,145.9690055,1,1,0,0,0,0
9592,02/07/2019 00:00,DB13966,Isopropyl myristate,"Dermal absorption of isopropyl myristate is predicated to be 0.00020 mg/cm2/event, which is considered a very low absorption rate [L1969]. In a study, topically applied isopropyl myristate was largely retained in the stratum corneum [A32332]. It was not detected in the receptor fluid of flow-through diffusion cells in in-vitro skin permeation experiments using human epidermis (stratum corneum and viable epidermis) and dermis of varying thickness [A32332]. ",,"Readily available information regarding the pharmacokinetics of isopropyl myristate is not available [L1978, T151].",0.5,Topical,solid,,,0.00011,,-7,CCCCCCCCCCCCCC(=O)OC(C)C,,,,,0,,270.2558803,0,0,0,0,0,0
9593,02/07/2019 00:00,DB13967,Patent Blue,"Patent blue is selectively absorbed in the lymphatics.[A32574] When administered orally, patent blue has a very low absorption and limited systemic availability.[L2331]",,The elimination half-life is of about 24-48 hours.[L2326],50 mg,Intravenous; Subcutaneous,solid,Soluble,-1.82,0.00268,-2.6,5.33,CCN(CC)C1=CC=C(C=C1)C(=C1C=CC(C=C1)=[N+](CC)CC)C1=C(C=C(C(O)=C1)S(O)(=O)=O)S(O)(=O)=O,,,,,1,,561.1723698,3,2,0,0,0,0
9594,01/05/2019 00:00,DB13969,Quaternium-24,,,,,,solid,,,5.77E-06,,,[Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCC,,,,,0,,333.3162281,0,0,0,0,0,0
9595,01/05/2019 00:00,DB13970,Dioctyldimonium,,,,,,solid,,,6.00E-06,,,CCCCCCCC[N+](C)(C)CCCCCCCC,,,,,1,,270.3155267,0,0,0,0,0,0
9596,01/05/2019 00:00,DB13972,Racemethionine,,,,,Intravenous,solid,,,23.9,2.53,9.5,CSCCC(N)C(O)=O,,,,,0,,149.0510496,0,0,0,0,0,0
9597,09/05/2019 00:00,DB13977,Potassium carbonate,,,,0.1 g/100mL,Topical,solid,,,303,6.05,,[K+].[K+].[O-]C([O-])=O,,,,,0,,137.9121572,0,0,0,0,0,0
9598,01/05/2019 00:00,DB13978,Selisistat,,,,,,solid,,,0.041,15.73,-2.6,NC(=O)C1CCCC2=C1NC1=C2C=C(Cl)C=C1,,,,,0,,248.0716407,3,2,1,1,0,0
9599,09/05/2019 00:00,DB13981,Nomegestrol acetate,,,,,,solid,,,0.00415,17.72,-4.8,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H],,,,,0,,370.2144094,4,0,0,0,0,0
9600,01/05/2019 00:00,DB13983,"5,7,2â€²-trihydroxy-6,8-dimethoxyflavone",,,,,,solid,,,0.0901,6.61,-4.6,COC1=C(O)C(OC)=C2OC(=CC(=O)C2=C1O)C1=CC=CC=C1O,,,,,0,,330.0739528,3,3,1,1,0,0
9601,01/05/2019 00:00,DB13984,Cyclopropane,,,,,,solid,,,10.1,,,C1CC1,,,,,0,,42.04695019,1,0,0,0,0,0
9602,01/05/2019 00:00,DB13985,Lutetium Lu 177 dotatate,"At the recommended intravenous dose, the mean blood exposure (AUC) of lutetium Lu 177 dotatate was 41 ng.h/mL (coefficient of variation, or CV, 36 %). The mean maximum plasma concentration (Cmax) was 10 ng/mL (CV 50%) and was observed at the end of the intravenous infusion of lutetium Lu 177 dotatate [FDA Label].",0.43,The mean (Â± standard deviation) effective blood elimination half-life is 3.5 (Â±1.4) hours and the mean terminal blood half-life is 71 (Â± 28) hours [FDA Label]. ,10 mCi/1mL,Intravenous,solid,,,0.0491,2.48,,[177Lu+3].[H][C@](C)(O)[C@]([H])(N=C(O)[C@]1([H])CSSC[C@]([H])(N=C(O)[C@@]([H])(CC2=CC=CC=C2)N=C([O-])CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC([O-])=O)CC2)C(O)=N[C@@]([H])(CC2=CC=C([O-])C=C2)C(O)=N[C@]([H])(CC2=CNC3=CC=CC=C23)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@]([H])(C(O)=N1)[C@@]([H])(C)O)C(O)=O,0.43,0.43,,,0,,1608.515092,6,4,3,1,1,2
9603,01/05/2019 00:00,DB13987,Strontium chloride,"About 30 percent of ingested strontium is absorbed into the blood through the gut [L2886]. The amount of strontium absorbed tends to decrease with age and is higher (about 60 percent) in children in their first year of life [L2886]. Once it is absorbed into the blood, most of it ends up in bone; with the remainder going to soft tissues or being excreted in urine, feces, and sweat [L2886]. About 8 percent of ingested strontium remains in the body after 30 days, and this decreases to about 4 percent after 1 year [L2886].",30-40%,Readily accessible information about the half-life of strontium calcium used in toothpastes is not available.,,Dental,solid,,,51.8,3.09,,[Cl-].[Cl-].[Sr++],0.3,0.4,,,0,,157.8433175,0,0,0,0,0,0
9604,09/05/2019 00:00,DB13988,SB-269970,,,,,,solid,,,0.263,8.21,8.95,CC1CCN(CC[C@H]2CCCN2S(=O)(=O)C2=CC=CC(O)=C2)CC1,,,,,0,,352.1820638,3,1,2,0,2,2
9605,09/05/2019 00:00,DB13989,Epitizide,,,,,,solid,,,0.346,9.05,-3.2,NS(=O)(=O)C1=CC2=C(NC(CSCC(F)(F)F)NS2(=O)=O)C=C1Cl,,,,,0,,424.9552312,2,1,1,0,0,1
9606,09/05/2019 00:00,DB13990,Dipropyl-4-hydroxytryptamine,,,,,,solid,,,0.367,9.1,10.66,CCCN(CCC)CCC1=CNC2=C1C(O)=CC=C2,,,,,0,,260.1888634,2,2,1,1,0,0
9607,09/05/2019 00:00,DB13991,Pipequaline,,,,,,solid,,,0.000135,,10.36,C(CC1=C2C=CC=CC2=NC(=C1)C1=CC=CC=C1)C1CCNCC1,,,,,0,,316.1939488,4,3,2,1,1,1
9608,01/05/2019 00:00,DB13992,Azintamide,,,,,,solid,,,0.705,18.8,-0.022,CCN(CC)C(=O)CSC1=CC=C(Cl)N=N1,,,,,0,,259.0546107,1,1,1,1,0,0
9609,01/05/2019 00:00,DB13993,MRK-409,,,,,,solid,,,0.0249,,1.2,CN1N=CN=C1COC1=NN2C(C=C1C1CCC1)=NN=C2C1=C(F)C=CC=C1F,,,,,0,,397.1462646,5,4,3,3,0,0
9610,01/05/2019 00:00,DB13994,AZD-7325,,,,,,solid,,,0.0172,14.38,2.92,CCCNC(=O)C1=C(N)C2=CC=CC(=C2N=N1)C1=C(F)C=CC=C1OC,,,,,0,,354.1492041,3,3,1,1,0,0
9611,01/05/2019 00:00,DB13995,Ferric pyrophosphate citrate,"The results of the present studies show that ferric pyrophosphate is as well absorbed in adults. The absorption of iron depends upon the route of entry. Ferric pyrophosphate has a very high bioavailability of 83-94%.[A31991] The AUC and Cmax have a dose-dependent pharmacokinetic response, being of 675-1840 mcg.h/dL and 113-261 mcg/dL respectively when given in a dose from 2.5 to 10 mg. The time to reach maximum dose is approximate 4.5 hours.[A31994]",,The half-life of ferric pyrophosphate is 1.48 hours.[A31994],272 mg/1,Intravenous,solid,Soluble ,,7.6,3.05,-4.2,[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O.OP([O-])(=O)OP([O-])([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,,,,0,,1321.556535,0,0,0,0,0,0
9612,01/05/2019 00:00,DB13996,Magnesium acetate,,,,,Intravenous,,,,98.2,4.54,,[Mg++].CC([O-])=O.CC([O-])=O,,,,,0,,142.0116504,0,0,0,0,0,0
9613,01/05/2019 00:00,DB13997,Baloxavir marboxil,Tmax: 4h [FDA label],%,Terminal elimination half-life: 79.1 h [FDA label].,20 mg/1,Oral,solid,Soluble in water ,2.24,0.0412,,-0.6,[H][C@@]12COCCN1C(=O)C1=C(OCOC(=O)OC)C(=O)C=CN1N2[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C12,,,,,0,20,571.1224775,6,3,4,1,1,3
9614,01/05/2019 00:00,DB14000,Tetraglyme,,,,,,solid,,,3.88,,-3.4,COCCOCCOCCOCCOC,,,,,0,,222.1467238,0,0,0,0,0,0
9615,02/07/2019 00:00,DB14001,alpha-Tocopherol succinate,"_In addition to any following information, owing to alpha-Tocopherol succinate's closely related chemical nature with alpha-Tocopherol acetate, please also refer to the drug information page for alpha-Tocopherol acetate for further data._

It is generally believed that alpha-tocopherol succinate is ultimately de-esterified or cleaved to provide alpha-tocopherol once administered to the human body [F47]. It is consequently expected that pharmacodynamics and pharmacokinetics similar to that of alpha-tocopherol to be followed [F47]. 

50 to 80% absorbed from gastrointestinal tract.",,"_In addition to any following information, owing to alpha-Tocopherol succinate's closely related chemical nature with alpha-Tocopherol acetate, please also refer to the drug information page for alpha-Tocopherol acetate for further data._

It is generally believed that alpha-tocopherol succinate is ultimately de-esterified or cleaved to provide alpha-tocopherol once administered to the human body [F47]. It is consequently expected that pharmacodynamics and pharmacokinetics similar to that of alpha-tocopherol to be followed [F47].",400 unit,Oral,,,,1.18E-05,4,-4.9,[H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@]1(C)CCC2=C(C)C(OC(=O)CCC(O)=O)=C(C)C(C)=C2O1,,,,,0,,530.3971248,2,1,1,0,0,1
9616,01/05/2019 00:00,DB14002,D-alpha-Tocopherol acetate,"_In addition to any following information, owing to d-alpha-Tocopherol acetate's closely related chemical nature with alpha-Tocopherol acetate, please also refer to the drug information page for alpha-Tocopherol acetate for further data._

50 to 80% absorbed from gastrointestinal tract.",,"_In addition to any following information, owing to d-alpha-Tocopherol acetate's closely related chemical nature with alpha-Tocopherol acetate, please also refer to the drug information page for alpha-Tocopherol acetate for further data._",800 unit,Oral,,,,2.93E-06,,-4.9,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(C)C(OC(C)=O)=C(C)C(C)=C2O1,,,,,0,,472.3916455,2,1,1,0,0,1
9617,01/05/2019 00:00,DB14006,Choline salicylate,"Onset: 1-2 hr after ingestion [L2133]

In the oral form, choline salicylate is absorbed across the buccal mucosa. There is a need for caution not to exceed the stated dose and monitor for any signs of suggested salicylism, especially when this drug is used for infants [L2135].

In one study, it was found that this drug was more rapidly absorbed than ASA (absorption t1/2 = 0.1 vs 0.36 h) [L2138].",,"The plasma half-life of salicylic acid is 2-4 hours [L2139].
Up to 15 â€“ 30 h with larger doses due to saturation of liver metabolism capacity [L2142].",,Oral,solid,,,0.396,2.79,-6.3,C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O,,,,,0,,241.1314081,1,1,0,0,0,0
9618,01/05/2019 00:00,DB14007,Pentetic acid,"DTPA and its trisodium salts present a very poor bioavailability after oral administration. Therefore, the normal administration of DTPA is done by slow intravenous infusion or inhalation with a nebulizer.[A32501] When inhaled, the absorption is of about 20% of the administered dose.[A32511]",,"In preclinical studies, DTPA has been shown to present a very short half-life of 18.5-31.8 min after intravenous administration.",20 mg/1,Intravenous; Respiratory (inhalation),solid,Highly soluble,-4.9,4.18,1.95,8.82,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O,,,,,0,,393.1383439,0,0,0,0,0,0
9619,01/05/2019 00:00,DB14008,Hispidulin,,,,,,solid,,,0.0791,7.09,-4.8,COC1=C(O)C2=C(OC(=CC2=O)C2=CC=C(O)C=C2)C=C1O,,,,,0,,300.0633881,3,3,1,1,0,0
9620,09/05/2019 00:00,DB14010,"5-methoxy-N,N-dimethyltryptamine",,,,,,solid,,,0.723,17.44,9.58,COC1=CC=C2NC=C(CCN(C)C)C2=C1,,,,,0,,218.1419132,2,2,1,1,0,0
9621,01/05/2019 00:00,DB14011,Nabiximols,"Individual subject plasma concentration data and pharmacokinetic parameters show a high degree of inter-subject variability.

Following a single buccal administration, maximum plasma concentrations of both CBD and THC typically occur within two to four hours. When administered buccally, blood levels of THC and other cannabinoids are lower compared with inhalation of smoked cannabis. The resultant concentrations in the blood are lower than those obtained by inhaling the same dose because absorption is slower, redistribution into fatty tissues is rapid and additionally some of the THC undergoes hepatic first-pass metabolism to 11-OH-THC, a psycho-active metabolite. ",,Elimination from plasma is bi-exponential with an initial half-life of one to two hours. The terminal elimination half-lives are of the order of 24 to 36 hours or longer. ,,,solid,,,0.0126,9.34,-4.9,[H][C@]1(CCC(C)=C[C@@]1([H])C1=C(O)C=C(CCCCC)C=C1O)C(C)=C.[H][C@@]12CCC(C)=C[C@@]1([H])C1=C(O)C=C(CCCCC)C=C1OC2(C)C,,,,,0,,628.4491604,5,2,1,0,0,1
9622,01/05/2019 00:00,DB14013,SR-9009,,,,,,solid,,,0.00162,,7.13,CCOC(=O)N1CCC(CN(CC2=CC=C(S2)[N+]([O-])=O)CC2=CC=C(Cl)C=C2)C1,,,,,0,,437.1176049,3,2,2,1,1,1
9623,01/05/2019 00:00,DB14014,SR-9011,,,,,,solid,,,0.000833,14.75,7.13,CCCCCNC(=O)N1CCC(CN(CC2=CC=C(S2)[N+]([O-])=O)CC2=CC=C(Cl)C=C2)C1,,,,,0,,478.1805395,3,2,2,1,1,1
9624,01/05/2019 00:00,DB14017,H3B-8800,,,,,,solid,,,0.153,13.92,6.89,C[C@H](\C=C\C=C(/C)[C@H]1OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N2CCN(C)CC2)\C=C\[C@@H]1C)C1=CC=CC=N1,,,,,0,,555.3308362,3,1,3,1,1,2
9625,02/07/2019 00:00,DB14018,Bromotheophylline,"When administered after one single oral dosage, bromotheophylline is rapidly absorbed and it reaches a maximal plasma concentration of 2.5 mg/L in 0.78 hours. The mean residence time is registered to be of 12 hours with an AUC in the first 8 hours of 27 mg.h/L.[L2742]",,The apparent elimination half-life is registered to be 21.35 hours.[L2743],50 mg/1,Oral,solid,Soluble,,3.92,5.58,-3,CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O,,,,,0,50,257.9752376,2,2,2,2,0,0
9626,01/05/2019 00:00,DB14019,Fosnetupitant,"Following single intravenous doses of Akynzeo for injection in patients (235 mg fosnetupitant and 0.25 mg palonosetron infused in 30 minutes) or fosnetupitant in healthy subjects (235 mg fosnetupitant infused in 30 minutes), maximum concentration of fosnetupitant was achieved at the end of the 30-minute infusion [FDA label].

Oral bioavailability in each species varied substantially between animals, with 42-105%, 34-83% and 37-62% in rats, dogs, and monkeys. The large variation is most likely due to the low numbers of animals used in the studies [F29].
",,"Netupitant is eliminated from the body in a multi-exponential fashion, with an apparent elimination half-life in cancer patients of 80 Â± 29 hours (mean Â± SD) [FDA label].",,Intravenous,solid,1.4 mg/mL at acidic PH (2) and ,,0.000216,-0.11,6.74,CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CC[N+](C)(COP(O)([O-])=O)CC1,,,,,0,,688.2249262,4,3,2,1,1,1
9627,01/05/2019 00:00,DB14020,Benzoin,No pharmacokinetic data available. ,,No pharmacokinetic data available. ,0.25,Topical,solid,,,0.561,12.62,-3.8,OC(C(=O)C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,212.0837296,2,2,0,0,0,0
9628,09/05/2019 00:00,DB14025,Clinafloxacin,,,,,,solid,,,0.445,5.45,9.63,NC1CCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O,,,,,0,,365.0942473,4,2,2,1,1,1
9629,01/05/2019 00:00,DB14026,Thiosalicylic acid,,,,,,solid,,,1.7,3.34,,OC(=O)C1=C(S)C=CC=C1,,,,,0,,154.0088504,1,1,0,0,0,0
9630,01/05/2019 00:00,DB14027,Taspoglutide,,,,,,solid,,,0.0408,2.96,12.07,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O,,,,,0,,3337.709525,6,6,2,2,0,0
9631,01/05/2019 00:00,DB14028,Nordazepam,,,,,,solid,,,0.0219,12.3,2.85,ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1,,,,,0,,270.0559907,3,2,1,0,0,1
9632,09/05/2019 00:00,DB14029,Furafylline,,,,,,solid,,,0.00961,,10.52,FC1=C(C=C(C=N1)C1CC2CCC1N2)C1=CC=C(C=C1)C#N,,,,,0,,293.1328257,4,2,3,1,2,2
9633,01/05/2019 00:00,DB14030,PZM21,,,,,,solid,,,0.00964,9.56,8.39,C[C@@H](CC1=CSC=C1)NC(=O)NC[C@H](CC1=CC=C(O)C=C1)N(C)C,,,,,0,,361.1823981,2,2,1,1,0,0
9634,01/05/2019 00:00,DB14031,Tretamine,,,,,,solid,,,10.1,,8.48,C1CN1C1=NC(=NC(=N1)N1CC1)N1CC1,,,,,0,,204.1123444,4,1,4,1,3,3
9635,01/05/2019 00:00,DB14033,Acetyl sulfisoxazole," Readily absorbed from the gastrointestinal tract [L2793].

In a pharmacokinetic study, the adjustments for variable renal clearances between oral and intravenous administration and using the unbound plasma concentrations, the bioavailability for an oral dose of sulfisoxazole was found to be 0.95 +/- 0.04 [L2800].",0.85,The serum half-life is 10 -12 hours [L2793].,0.5 g/5mL,Oral,solid,,,0.136,18.1,1.61,CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1,0.85,0.85,,,0,,309.078327,2,2,1,1,0,0
9636,01/05/2019 00:00,DB14034,Darglitazone,,,,,,solid,,,0.0137,6.61,0.85,CC1=C(CCC(=O)C2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C(O1)C1=CC=CC=C1,,,,,0,,420.1143781,4,3,2,1,1,1
9637,01/05/2019 00:00,DB14035,Englitazone,,,,,,solid,,,0.00121,6.61,-4.9,O=C1NC(=O)C(CC2=CC=C3O[C@@H](CC4=CC=CC=C4)CCC3=C2)S1,,,,,0,,353.1085645,4,2,2,0,1,2
9638,01/05/2019 00:00,DB14037,Madecassic acid,,,,,Topical,solid,,,0.0356,4.64,-2.8,[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(O)=O,,,,,0,,504.3450893,5,0,0,0,0,0
9639,01/05/2019 00:00,DB14038,beta-Sitosterol,,,,35 mg/1,Oral,solid,,,1.84E-05,18.2,-1.4,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC[C@@H](CC)C(C)C,,,,,0,35,414.3861662,4,0,0,0,0,0
9640,01/05/2019 00:00,DB14043,Palmidrol,,,,,,solid,,,0.00136,15.46,-1.3,CCCCCCCCCCCCCCCC(=O)NCCO,,,,,0,,299.2824294,0,0,0,0,0,0
9641,01/05/2019 00:00,DB14044,Hopantenic acid,,,,,,solid,,,40.1,4.37,-2.8,CC(C)(CO)[C@@H](O)C(=O)NCCCC(O)=O,,,,,0,,233.1263227,0,0,0,0,0,0
9642,09/05/2019 00:00,DB14045,Cholesteryl chloride,,,,,,,,,7.39E-06,,,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](Cl)CC[C@]4(C)[C@H]3CC[C@]12C,,,,,0,,404.3209791,4,0,0,0,0,0
9643,01/05/2019 00:00,DB14050,Cannabidivarin,"Like Î”9-THC, CBDV has low water solubility and poor oral bioavailability (~6% in humans), making oral administration an unfavourable method of delivery. Despite this, CBDV has relatively rapid absorption with peak concentrations seen around 2 h after oral administration in animal pharmacokinetic studies [A33348].

Orally administered CBDV in mice was found to have a plasma Cmax of 0.47ug/mL and Tmax of 30 minutes, and a brain Cmax of 0.94ug/mL and Tmax of 60 minutes [A33348].",,"Orally administered CBDV in mice was found to have a plasma elimination half life of 222 minutes, and a brain elimination half life of 204 minutes [A33348].",,,solid,,,0.033,9.13,-5.7,[H][C@]1(CCC(C)=C[C@H]1C1=C(O)C=C(CCC)C=C1O)C(C)=C,,,,,0,,286.1932801,2,1,0,0,0,0
9644,01/05/2019 00:00,DB14051,Malacidin A,,,,,,solid,,,0.0197,2.8,10.18,CC(C)CC\C=C/C=C/C(=O)N[C@@H](C(C)C(O)=O)C(=O)N[C@H]1C(C)NC(=O)[C@@H]2C[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](NC1=O)C(C)C)C(O)C(O)=O)C(C)C(O)=O)C(C)C,,,,,0,,1248.623783,2,0,2,0,2,2
9645,01/05/2019 00:00,DB14052,Malacidin B,,,,,,solid,,,0.0167,2.8,10.18,CCC(C)CC\C=C/C=C/C(=O)N[C@@H](C(C)C(O)=O)C(=O)N[C@H]1C(C)NC(=O)[C@@H]2C[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](NC1=O)C(C)C)C(O)C(O)=O)C(C)C(O)=O)C(C)C,,,,,0,,1262.639433,2,0,2,0,2,2
9646,01/05/2019 00:00,DB14054,Asiatic acid,,,,,Topical,solid,,,0.0114,4.74,-2.8,[H][C@@]12CC[C@]3(C)[C@]([H])(CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@]5(CC[C@@]34C)C(O)=O)[C@@]1(C)C[C@@H](O)[C@H](O)[C@@]2(C)CO,,,,,0,,488.3501746,5,0,0,0,0,0
9647,10/04/2019 00:00,DB14055,(S)-Warfarin,,,,,,solid,,,0.0472,5.56,-6.9,CC(=O)C[C@@H](C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,,,,,0,,308.104859,3,3,1,1,0,0
9648,01/05/2019 00:00,DB14056,Nigericin,,,,,,solid,,,0.00137,4.07,-3.4,[H][C@@]1(C[C@H](C)[C@@]([H])(O1)[C@]1(C)CC[C@@]([H])(O1)[C@]1(C)C[C@@H](C)[C@]2(O1)O[C@]([H])(C[C@@]1([H])CC[C@H](C)[C@@]([H])(O1)[C@@H](C)C(O)=O)C[C@@H](OC)[C@H]2C)[C@@]1([H])O[C@@](O)(CO)[C@H](C)C[C@@H]1C,,,,,0,,724.476163,6,0,6,0,6,6
9649,01/05/2019 00:00,DB14057,Valinomycin,,,,,,solid,,,0.0108,11.19,,CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC(=O)[C@@H](NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC(=O)[C@@H](NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC1=O)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C,,,,,0,,1110.63116,1,0,1,0,1,1
9650,01/05/2019 00:00,DB14058,Basifungin,,,,,,solid,,,0.00395,11.76,-2.3,CC[C@@H](C)[C@@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC2=CC=CC=C2)N(C)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)C(NC1=O)C(C)C)[C@H](C)C(C)C,,,,,0,,1084.693641,4,2,2,0,2,2
9651,01/05/2019 00:00,DB14059,SC-236,,,Long plasma half-life [A28366].,,,solid,insoluble ,,0.004,10.6,-0.44,NS(=O)(=O)C1=CC=C(C=C1)N1N=C(C=C1C1=CC=C(Cl)C=C1)C(F)(F)F,,,,,0,,401.0212599,3,3,1,1,0,0
9652,09/05/2019 00:00,DB14060,NS-398,,,,,,solid,,,0.0277,6.81,-4.9,CS(=O)(=O)NC1=CC=C(C=C1OC1CCCCC1)[N+]([O-])=O,,,,,0,,314.0936427,2,1,0,0,0,0
9653,01/05/2019 00:00,DB14061,Hycanthone,,,,,,solid,,,0.0168,14.79,8.67,CCN(CC)CCNC1=C2C(=O)C3=CC=CC=C3SC2=C(CO)C=C1,,,,,0,,356.155849,3,3,1,1,0,0
9654,01/05/2019 00:00,DB14062,Concanamycin A,,,,,,solid,,,0.0128,11.68,-3,[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](CC)[C@@H](O)[C@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@@H](O)[C@H](OC(N)=O)[C@@H](C)O2)[C@H](C)[C@H](O1)\C=C\C,,,,,0,,865.5187561,3,0,3,0,2,3
9655,01/05/2019 00:00,DB14063,Dexverapamil,,,,,,solid,,,0.00394,,9.68,COC1=CC=C(CCN(C)CCC[C@@](C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1OC,,,,,0,,454.2831577,2,2,0,0,0,0
9656,01/05/2019 00:00,DB14064,Emopamil,,,,,,solid,,,0.00416,,9.76,CC(C)C(CCCN(C)CCC1=CC=CC=C1)(C#N)C1=CC=CC=C1,,,,,0,,334.240899,2,2,0,0,0,0
9657,01/05/2019 00:00,DB14065,Lomerizine,,,,,,solid,,,0.00673,,6.73,COC1=CC=C(CN2CCN(CC2)C(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)C(OC)=C1OC,,,,,0,,468.2224493,4,3,1,0,1,1
9658,01/05/2019 00:00,DB14066,Tetrandrine,,,,,,solid,,,0.00296,,8.28,COC1=CC=C2C[C@@H]3N(C)CCC4=C3C(OC3=CC5=C(CCN(C)[C@H]5CC5=CC=C(OC1=C2)C=C5)C=C3OC)=C(OC)C(OC)=C4,,,,,0,,622.3042871,8,4,4,0,0,4
9659,01/05/2019 00:00,DB14067,Dofequidar,,,,,,solid,,,0.0199,14.08,6.73,OC(COC1=CC=CC2=C1C=CC=N2)CN1CCN(CC1)C(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,481.2365419,5,4,2,1,1,1
9660,01/05/2019 00:00,DB14068,Dexniguldipine,,,,,,solid,,,0.000113,19.47,9.59,[H]N1C(C)=C([C@@H](C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCCCN2CCC(CC2)(C2=CC=CC=C2)C2=CC=CC=C2)=C1C)C(=O)OC,,,,,0,,609.283886,5,3,2,0,1,2
9661,01/05/2019 00:00,DB14069,ONT-093,,,,,,solid,,,0.000423,12.39,5.26,[H]\C(COCC)=C(\[H])C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=C(NC(C)C)C=C1)C1=CC=C(NC(C)C)C=C1,,,,,0,,494.3045618,4,4,1,1,0,0
9662,01/05/2019 00:00,DB14070,HM-30181,,,,,,solid,,,0.00472,11.44,8.46,[H]N(C(=O)C1=CC(=O)C2=CC=CC=C2O1)C1=CC(OC)=C(OC)C=C1C1=NN(N=N1)C1=CC=C(CCN2CCC3=CC(OC)=C(OC)C=C3C2)C=C1,,,,,0,,688.2645475,7,6,3,2,0,1
9663,01/05/2019 00:00,DB14071,Desmethylsertraline,,,,,,solid,,,9.79E-05,,9.52,[H][C@]1(N)CC[C@@]([H])(C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12,,,,,0,,291.0581548,3,2,0,0,0,0
9664,01/05/2019 00:00,DB14072,Reversin 121,,,,,,solid,,,0.000514,12.16,-5,CC(C)(C)OC(=O)N[C@@H](CC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CCCCNC(=O)OCC1=CC=CC=C1)C(=O)OC(C)(C)C,,,,,0,,641.3312301,2,2,0,0,0,0
9665,01/05/2019 00:00,DB14073,Gondoic acid,,,,,,solid,,,4.95E-05,4.95,,CCCCCCCC\C=C/CCCCCCCCCC(O)=O,,,,,0,,310.2871805,0,0,0,0,0,0
9666,01/05/2019 00:00,DB14074,Icaridin,"In a dermal metabolism rat study, dermal application of 20 mg/kg of radio-labeled icaridin resulted in 61-66% of the dose absorbed through the skin [L4595]. Following topical application of 20 mg/kg on rats, the peak plasma concentrations were measured to be 0.5 Î¼g/mL in male rats and 0.8-1.6 Î¼g/mL in female rats [L4595]. In a study of human volunteers, less than 6% of the applied doses were absorbed after topical application of 14.7 or 15.0 mg of technical grade icaridin and covering the application site with a protective wrap for eight hours [L4595]. ",,"The first elimination half-lives of icaridin were determined in a study of five male and female rats treated with a single dose of 20 mg/kg icaridin dermally. The half-lives were 35.7 hours for male and 23.9 hours in female rats [L6103]. In another study of rats treated daily for 2 weeks with 20 mg/kg of unlabeled icaridin, followed by exposure to a single dose of 20 mg/kg of the radiolabeled icaridin for 7 days, the 1st elimination half-lives were 10.9 and 9.1 hours for the males and females, respectively [L6103]. The 2nd half-lives were 144 and 105 hours, respectively [L6103].",2.1 g/30mL,Topical,liquid,Insoluble,,25.1,15.92,-2.4,CCC(C)OC(=O)N1CCCCC1CCO,,,,,0,,229.1677936,1,0,1,0,1,1
9667,01/05/2019 00:00,DB14075,Imidurea,,,,,,solid,,,0.758,7.55,-3.3,OCN1C(NC(=O)NCNC(=O)NC2N(CO)C(=O)NC2=O)C(=O)NC1=O,,,,,0,,388.1091095,2,0,2,0,2,2
9668,01/05/2019 00:00,DB14077,Magnesium stearate,,,,5 mg/1,Vaginal,solid,,,1.13E-05,4.95,,[Mg++].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O,,,,,0,,590.5124524,0,0,0,0,0,0
9669,01/05/2019 00:00,DB14078,Medronic acid,,,,10 mg/1,Intravenous,solid,,,16,1.27,,OP(O)(=O)CP(O)(O)=O,,,,,0,,175.9639612,0,0,0,0,0,0
9670,01/05/2019 00:00,DB14079,Hydroxybutyloxide,,,,5 g/50mL,Oral,solid,,,112,15.29,-2.5,CC(O)CCOCCC(C)O,,,,,0,,162.1255944,0,0,0,0,0,0
9671,01/05/2019 00:00,DB14080,Acetylcysteine magnesium,,,,,Oral,solid,,,0.136,3.82,-2,[Mg++].[H]N([C@@H](CS)C([O-])=O)C(C)=O.[H]N([C@@H](CS)C([O-])=O)C(C)=O,,,,,0,,348.0300199,0,0,0,0,0,0
9672,01/05/2019 00:00,DB14081,Asiaticoside,,,,,Topical,solid,,,0.798,11.75,-3.6,[H][C@@]12CC[C@]3(C)[C@]([H])(CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@]5(CC[C@@]34C)C(=O)O[C@@H]3O[C@H](CO[C@@H]4O[C@H](CO)[C@@H](O[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)[C@@]1(C)C[C@@H](O)[C@H](O)[C@@]2(C)CO,,,,,0,,958.5137303,8,0,3,0,3,3
9673,01/05/2019 00:00,DB14082,Betiatide,,,,1 mg/1,Intravenous,solid,,,0.107,3.64,-4.5,OC(=O)CNC(=O)CNC(=O)CNC(=O)CSC(=O)C1=CC=CC=C1,,,,,0,,367.0838063,1,1,0,0,0,0
9674,01/05/2019 00:00,DB14083,Bisphenol A diglycidyl ether,,,,,,solid,,,0.000822,,-3.8,CC(C)(C1=CC=C(OCC2CO2)C=C1)C1=CC=C(OCC2CO2)C=C1,,,,,0,,340.1674592,4,2,2,0,2,2
9675,01/05/2019 00:00,DB14084,Butylparaben,,,,,,solid,,,0.466,8.5,-6.1,CCCCOC(=O)C1=CC=C(O)C=C1,,,,,0,,194.0942943,1,1,0,0,0,0
9676,01/05/2019 00:00,DB14085,Cadmium,,,,,,solid,,,0,,,[Cd],,,,,0,,113.9033585,0,0,0,0,0,0
9677,01/05/2019 00:00,DB14086,Cianidanol,,,,0.45 g/100g,Oral,solid,,,0.645,9,-3.3,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C(O)=C1,,,,,0,,290.0790382,3,2,1,0,0,1
9678,01/05/2019 00:00,DB14088,Osbond acid,,,,,,solid,,,0.000104,4.89,,CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O,,,,,0,,330.2558803,0,0,0,0,0,0
9679,01/05/2019 00:00,DB14089,Dimercaptosuccinic acid,,,,1.1 mg/1,Intravenous,solid,,,2.43,3.37,,OC(=O)C(S)C(S)C(O)=O,,,,,0,,181.9707507,0,0,0,0,0,0
9680,01/05/2019 00:00,DB14090,Dimethyl sulfone,,,,0.51 g/0.51g,Oral,solid,,,55.8,,,CS(C)(=O)=O,,,,,0,,94.00885043,0,0,0,0,0,0
9681,01/05/2019 00:00,DB14092,8-epi-Cyanocobalamin,,,,1 mg/1mL,Intramuscular,solid,,,0.117,1.81,,[Co+3].[C-]#N.[H][C@@](C)(CN=C(O)CC[C@@]1(C)C2=NC([H])([C@]1([H])CC(O)=N)[C@]1(C)NC(=C(C)C3=NC(=CC4=NC(=C2C)[C@@]([H])(CCC([O-])=N)C4(C)C)[C@]([H])(CCC([O-])=N)[C@]3(C)CC(O)=N)[C@@]([H])(CCC([O-])=N)[C@]1(C)CC(O)=N)OP(O)(=O)O[C@]1([H])[C@@]([H])(CO)O[C@]([H])([N+]2=CNC3=C2C=C(C)C(C)=C3)[C@]1([H])O,,,,,0,,1354.5674,8,2,7,1,2,6
9682,01/05/2019 00:00,DB14093,"(1,2,6,7-3H)Testosterone",,,,,,solid,,,0.0333,18.52,-0.88,[3H]C1C([3H])C2=CC(=O)C([3H])C([3H])[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,,,,,0,,296.2418271,4,0,0,0,0,0
9683,01/05/2019 00:00,DB14094,Tocopherylquinone,,,,,,solid,,,0.000414,19.44,-0.86,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O,,,,,0,,446.3759955,1,0,0,0,0,0
9684,01/05/2019 00:00,DB14096,"1,2-icosapentoyl-sn-glycero-3-phosphoserine",,,,,Oral,solid,,,0.000104,1.47,9.38,[H]C(N)(COP(O)(=O)OCC([H])(COC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(=O)CCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(O)=O,,,,,0,,841.4893841,0,0,0,0,0,0
9685,01/05/2019 00:00,DB14097,13-cis-12-(3'-Carboxyphenyl)retinoic acid,,,,,Topical,solid,,,0.000946,3.74,,[H]\C(=C(\[H])C1=C(C)CCCC1(C)C)\C(\C)=C(/[H])C([H])=C(\C(C)=C(\[H])C(O)=O)C1=CC(=CC=C1)C(O)=O,,,,,0,,420.2300595,2,1,0,0,0,0
9686,01/05/2019 00:00,DB14098,Cobalamin,,,,,Oral,solid,,,0.0127,1.82,8.97,[Co++].[H]N([H])C(=O)CC[C@@H]1C2=N\C(=C(C)/C3=N[C@@](C)([C@]4([H])[N-]\C(=C(C)/C5=N/C(=C\2)/C(C)(C)[C@@H]5CCC(=O)N([H])[H])[C@](C)(CCC(=O)N([H])C[C@H](C)OP([O-])(=O)O[C@@H]2[C@@H](CO)O[C@@H]([C@@H]2O)N2C=NC5=C2C=C(C)C(C)=C5)[C@H]4CC(=O)N([H])[H])[C@@](C)(CC(=O)N([H])[H])[C@@H]3CCC(=O)N([H])[H])\[C@@]1(C)CC(=O)N([H])[H],,,,,0,,1328.564326,8,2,7,1,2,6
9687,01/05/2019 00:00,DB14099,"1,2-Distearoyllecithin",,,,,,solid,,,2.16E-05,1.86,-6.7,CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,,,,,0,,789.6247554,0,0,0,0,0,0
9688,01/05/2019 00:00,DB14103,Methionine sulfoximine,,,,,Intramuscular,,,,7.39,1.89,9.09,CS(=N)(=O)CC[C@H](N)C(O)=O,,,,,0,,180.0568632,0,0,0,0,0,0
9689,01/05/2019 00:00,DB14104,Linoleic acid,,,,,Oral,,,,0.000154,4.99,,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O,,,,,0,,280.2402303,0,0,0,0,0,0
9690,01/05/2019 00:00,DB14105,"Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)",,,,,,,,,0.000119,1.89,-3,[Na+].[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC,,,,,0,,744.4917295,0,0,0,0,0,0
9691,01/05/2019 00:00,DB14106,Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate,,,,1 mg/1mL,Intravenous,,,,0.0366,16.14,-4.2,[Cu+].F[B-](F)(F)F.COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-],,,,,0,,602.2687717,0,0,0,0,0,0
9692,01/05/2019 00:00,DB14107,7-Aminodesacetoxycephalosporanic acid,,,,,Topical,,,,15.8,3.42,7.39,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2N)C(O)=O,,,,,0,,214.0412132,2,0,2,0,1,2
9693,01/05/2019 00:00,DB14108,"1,2-Hexanediol",,,,1 g/100mL,Topical,,,,178,14.27,-2.9,CCCCC(O)CO,,,,,0,,118.0993797,0,0,0,0,0,0
9694,01/05/2019 00:00,DB14109,alpha-Arbutin,,,,,Topical,,,,39.1,9.82,-3,OC[C@H]1O[C@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O,,,,,0,,272.0896029,2,1,1,0,1,1
9695,01/05/2019 00:00,DB14110,Butylene glycol,,,,0.04 g/0.9mL,Topical,,,,742,15.41,-2.4,CC(O)CCO,,,,,0,,90.06807956,0,0,0,0,0,0
9696,01/05/2019 00:00,DB14111,Ceramide NP,,,,0.05 1/200mL,Topical,,,,9.71E-05,13.27,-1,CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC,,,,,0,,581.5383098,0,0,0,0,0,0
9697,01/05/2019 00:00,DB14119,Phytosphingosine,,,,,Topical,,,,0.0446,13.45,8.91,CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO,,,,,0,,317.2929941,0,0,0,0,0,0
9698,01/05/2019 00:00,DB14120,Phenylethyl resorcinol,,,,,Topical,solid,,,0.159,9.46,-5.4,CC(C1=CC=CC=C1)C1=CC=C(O)C=C1O,,,,,0,,214.0993797,2,2,0,0,0,0
9699,01/05/2019 00:00,DB14121,Parasorbic acid,,,,0.086 g/100g,Oral,,,,26.6,,-6.8,C[C@H]1CC=CC(=O)O1,,,,,0,,112.0524295,1,0,1,0,0,1
9700,01/05/2019 00:00,DB14122,Dihydroxymethoxychalcone,,,,0.05 mL/100mL,Topical,,,,0.0777,7.2,-4.9,COC1=C(C(=O)\C=C\C2=CC=CC=C2)C(O)=CC(O)=C1,,,,,0,,270.0892089,2,2,0,0,0,0
9701,01/05/2019 00:00,DB14125,Benazeprilat,,,,,,,,,0.0285,3.08,7.96,[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(O)=O,,,,,0,,396.1685219,3,2,1,0,0,1
9702,24/05/2019 00:00,DB14126,Tenofovir,"Tenofovir as the active moiety presents a very low bioavailability when orally administered. Hence, the administration of this active agent is required to be under its two prodrug forms, [tenofovir disoproxil] and [tenofovir alafenamide]. This reduced absorption is suggested to be related to the presence of two negative charges among its structure. This negative charge limits its cellular penetration, and its passive diffusion across cellular membranes and intestinal mucosa hindering its availability for oral administration.[A178060]

Intravenous tenofovir has been shown to produce a maximum plasma concentration of 2500 ng/ml with an AUC of 4800 ng.h/ml.[A18473]",0.072,The reported half-life of tenofovir is of 32 hours.[A178231],,,solid,13.4 mg/ml,-1.6,1.87,1.35,3.74,C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O,0.072,0.072,,,0,,287.0783406,2,2,2,2,0,0
9703,01/05/2019 00:00,DB14127,Sacubitrilat,,,,,,,,,0.00358,3.98,-1.6,C[C@H](C[C@@H](CC1=CC=C(C=C1)C1=CC=CC=C1)NC(=O)CCC(O)=O)C(O)=O,,,,,0,,383.1732729,2,2,0,0,0,0
9704,01/05/2019 00:00,DB14128,Nadide,,,,,Topical,,,,2.14,1.86,6.4,NC(=O)C1=C[N+](=CC=C1)[C@@H]1O[C@H](COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C2N=CN=C3N)[C@@H](O)[C@H]1O,,,,,0,,663.1091218,5,3,5,3,2,2
9705,01/05/2019 00:00,DB14129,Macelignan,,,,0.15 mL/100mL,Topical,,,,0.00285,10.28,-4.5,COC1=CC(C[C@H](C)[C@H](C)CC2=CC3=C(OCO3)C=C2)=CC=C1O,,,,,0,,328.1674592,3,2,1,0,0,1
9706,01/05/2019 00:00,DB14130,Methyl salicylate 2-ethylbutyrate,,,,,Topical,,,,0.0547,,-6.8,CCC(CC)C(=O)OC1=CC=CC=C1C(=O)OC,,,,,0,,250.1205091,1,1,0,0,0,0
9707,01/05/2019 00:00,DB14132,8-chlorotheophylline,,,,,,,,,9.41,5.14,-3.3,CN1C2=C(NC(Cl)=N2)C(=O)N(C)C1=O,,,,,0,,214.0257531,2,2,2,2,0,0
9708,01/05/2019 00:00,DB14134,Octyldodecanol,,,,0.28 g/3.5g,Topical,,,,3.06E-05,17.68,-1.6,CCCCCCCCCCC(CO)CCCCCCCC,,,,,0,,298.323566,0,0,0,0,0,0
9709,01/05/2019 00:00,DB14135,Hypochlorous acid,,,,1 g/100mL,Oral,,,,512,7.93,-5.9,OCl,,,,,0,,51.97159233,0,0,0,0,0,0
9710,01/05/2019 00:00,DB14136,(-)-menthol 1-propylene glycol carbonate,,,,,Topical,,,,0.194,14.82,-2.9,[H]C(C)(O)COC(=O)O[C@]1([H])C[C@]([H])(C)CC[C@@]1([H])C(C)C,,,,,0,,258.1831093,1,0,0,0,0,0
9711,01/05/2019 00:00,DB14137,Palmitoyl tetrapeptide-7,,,,,Topical,,,,0.00556,3.54,11.23,[H]N([H])C(=O)CC[C@H](N([H])C(=O)CN([H])C(=O)CCCCCCCCCCCCCCC)C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCCN=C(N([H])[H])N([H])[H])C(O)=O,,,,,0,,694.4741463,1,0,1,0,1,1
9712,01/05/2019 00:00,DB14141,p-Phenylenediamine,,,,0.01 mg/1mL,Topical,,,,75.8,,6.46,NC1=CC=C(N)C=C1,,,,,0,,108.0687483,1,1,0,0,0,0
9713,01/05/2019 00:00,DB14143,Distearyldimonium,,,,,Topical,,,,3.19E-06,,,CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC,,,,,1,,550.628528,0,0,0,0,0,0
9714,01/05/2019 00:00,DB14144,p-Aminophenol,,,,0.01 mg/1mL,Topical,,,,121,10.4,5.43,NC1=CC=C(O)C=C1,,,,,0,,109.0527638,1,1,0,0,0,0
9715,01/05/2019 00:00,DB14146,Loxicodegol,Loxicodegol has a Tmax of 1.8h and a bioavailability of 34% with oral administration [A34016]. It enters the brain about 17-70 times more slowly than oxycodone [A33997]. Loxicodegol is also a p-glycoprotein substrate further reducing its transport into the brain.,,Loxicodegol has a half-life of 4.53 h allowing for a longer duration of action [A34016].,,,solid,,,0.0487,13.58,8.92,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CC[C@]2([H])OCCOCCOCCOCCOCCOCCOC,,,,,0,,595.3356468,5,1,2,0,1,2
9716,01/05/2019 00:00,DB14149,Glyceryl stearate SE,,,,0.45 mg/1mL,Topical,,,,0.00108,13.62,-3,[Na+].[K+].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO.[H][C@](O)(CO)COC(=O)CCCCCCCCCCCCCCCCC.[H][C@@](O)(CO)COC(=O)CCCCCCCCCCCCCCCCC,,,,,0,,1703.405816,0,0,0,0,0,0
9717,01/05/2019 00:00,DB14150,Chloric acid,,,,,Oral,,,,137,4.62,,[H]O[Cl](=O)=O,,,,,0,,83.96142157,0,0,0,0,0,0
9718,01/05/2019 00:00,DB14152,Ginsenosides,,,,0.7 g/100g,Topical,,,,0.000182,19.49,-0.26,[H][C@@]1(CC[C@]2(C)C1([H])CC[C@]1([H])[C@@]3(C)CC[C@]([H])(O)C(C)(C)[C@]3([H])CC[C@@]21C)C(C)(O)CCC=C(C)C,,,,,0,,444.3967309,4,0,0,0,0,0
9719,22/06/2019 00:00,DB14156,Synthetic camphor,,,,5 mg/100g,Topical,,,,0.88,,-7.5,CC1(C)C2CCC1(C)C(=O)C2,,,,,0,,152.1201151,2,0,0,0,0,0
9720,01/05/2019 00:00,DB14159,Oxidronic acid,,,,3.15 mg/1,Intravenous,,,,13.5,0.75,-5,OC(P(O)(O)=O)P(O)(O)=O,,,,,0,,191.9588758,0,0,0,0,0,0
9721,01/05/2019 00:00,DB14173,Diazolidinylurea,,,,,Topical,,,,29.1,12.58,-3,OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O,,,,,0,,278.0862488,1,0,1,0,1,1
9722,01/05/2019 00:00,DB14174,Dipentamethylenethiuram disulfide,,,,,,,,,0.00677,,,S=C(SSC(=S)N1CCCCC1)N1CCCCC1,,,,,0,,320.0509326,2,0,2,0,2,2
9723,01/05/2019 00:00,DB14175,alpha-Amyl cinnamaldehyde,,,,,,,,,0.0069,,-4.5,CCCCC\C(C=O)=C\C1=CC=CC=C1,,,,,0,,202.1357652,1,1,0,0,0,0
9724,01/05/2019 00:00,DB14176,Benzylparaben,,,,,,,,,0.135,8.5,-6.1,OC1=CC=C(C=C1)C(=O)OCC1=CC=CC=C1,,,,,0,,228.0786442,2,2,0,0,0,0
9725,01/05/2019 00:00,DB14177,Propylparaben,,,,,,,,,0.96,8.5,-6.1,CCCOC(=O)C1=CC=C(O)C=C1,,,,,0,,180.0786442,1,1,0,0,0,0
9726,01/05/2019 00:00,DB14178,Tetramethylthiuram monosulfide,,,,,,,,,0.0683,,,CN(C)C(=S)SC(=S)N(C)C,,,,,0,,208.0162614,0,0,0,0,0,0
9727,01/05/2019 00:00,DB14182,Dichromate,,,,,,,,,4.68,-2.3,,[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O,,,,,-2,,215.8465145,0,0,0,0,0,0
9728,01/05/2019 00:00,DB14183,Geraniol,"The profile of the geraniol concentrations in rat blood following oral administration of the emulsified formulation was characterized by a peak concentration at 30 min of about 270 Î¼g/mL and an area under concentration (AUC) similar to that obtained by the intravenous administration of the same geraniol dose, indicating an absolute bioavailability of 92% [A34260]. Geraniol appears able to permeate directly from the bloodstream to the central nervous system following its oral administration to rats, reaching detectable amounts in the CSF; peak concentration in the CSF was found to be about 2.5 Î¼g/mL and was observed 30 min after oral administration [A34260].",,"In vitro measurements indicated that geraniol is highly stable in human and rat whole blood, whereas following intravenous administration geraniol is eliminated from the bloodstream with a relatively short half-life (about 12 min), starting from a concentration of about 300 Î¼g/mL [A34260].",,,,,,1.37,16.33,-2.2,CC(C)=CCC\C(C)=C\CO,,,,,0,,154.1357652,0,0,0,0,0,0
9729,01/05/2019 00:00,DB14184,Cinnamaldehyde,Cinnamaldehyde is 52% absorbed through the skin and shown to be rapidly absorbed from the gut [A34266].,,,,,,,,0.409,,-4.4,O=C\C=C\C1=CC=CC=C1,,,,,0,,132.0575149,1,1,0,0,0,0
9730,01/05/2019 00:00,DB14185,Aripiprazole lauroxil,"Following a single extended-release intramuscular injection of aripiprazole lauroxil, aripiprazole can be detected in the systemic circulation from 5 to 6 days and is continued to be released for an additional 36 days. The concentrations of aripiprazole increases with consecutive doses of aripiprazole lauroxil and the steady state is reached following the fourth monthly injection [FDA Label]. The systemic exposure to aripiprazole was similar when comparing deltoid and gluteal intramuscular injections [FDA Label]. ",>99%,"The mean aripiprazole terminal elimination half-life ranged from 29.2 days to 34.9 days after every 4-week injection of aripiprazole lauroxil 441, 662 and 882 mg [FDA Label]. ",1064 mg/3.9mL,Intramuscular,solid,<0.01 mg/mL,5.3,0.000237,,7.46,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12,0.99,1,,,0,,659.3256625,4,2,2,0,1,2
9731,01/05/2019 00:00,DB14186,Cinnamyl alcohol,Cinnamyl alcohol is 66% absorbed through the skin and shown to be rapidly absorbed from the gut [A34266].,,,,,,,,2.34,15.62,-2.5,OC\C=C\C1=CC=CC=C1,,,,,0,,134.0731649,1,1,0,0,0,0
9732,01/05/2019 00:00,DB14187,Hydroxycitronellal,,,The mean elimination half-life has been found to be 3.3 h [A34269].,,,,,,0.639,18.21,-1.3,[H]C(=O)CC(C)CCCC(C)(C)O,,,,,0,,172.1463299,0,0,0,0,0,0
9733,09/05/2019 00:00,DB14188,Isoeugenol,,,,,,,,,1.36,10.01,-4.9,COC1=CC(C=CC)=CC=C1O,,,,,0,,164.0837296,1,1,0,0,0,0
9734,01/05/2019 00:00,DB14189,Ethylenediamine,"After oral administration its bioavailability is about 0.34, due to a substantial first-pass effect[A34285].",,Ethylenediamine has a short half life of ~0.55 hours [A34285].,,,,,,560,,9.69,NCCN,,,,,0,,60.06874826,0,0,0,0,0,0
9735,01/05/2019 00:00,DB14191,Diphenylguanidine,,,,,,,,,0.377,,9.38,N=C(NC1=CC=CC=C1)NC1=CC=CC=C1,,,,,0,,211.1109474,2,2,0,0,0,0
9736,01/05/2019 00:00,DB14193,Ditiocarb Zinc,,,,,,,,,19.2,-1.3,17,CCN(CC)C1=S[Zn++]2([SH-]1)[SH-]C(=S2)N(CC)CC,,,,,0,,364.011375,2,0,2,0,0,2
9737,01/05/2019 00:00,DB14194,Zinc Dibutyldithiocarbamate,,,,,,,,,0.596,-0.98,17,CCCCN(CCCC)C1=S[Zn++]2([SH-]1)[SH-]C(=S2)N(CCCC)CCCC,,,,,0,,476.1365755,2,0,2,0,0,2
9738,01/05/2019 00:00,DB14195,4-(Isopropylamino)diphenylamine,,,,,,,,,0.048,,6.42,CC(C)NC1=CC=C(NC2=CC=CC=C2)C=C1,,,,,0,,226.1469986,2,2,0,0,0,0
9739,01/05/2019 00:00,DB14196,"N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine",,,,,,,,,0.00542,,6.42,C1CCC(CC1)NC1=CC=C(NC2=CC=CC=C2)C=C1,,,,,0,,266.1782987,3,2,0,0,0,0
9740,09/05/2019 00:00,DB14197,Methylchloroisothiazolinone,,,,,,,,,50,,-6.9,CN1SC(Cl)=CC1=O,,,,,0,,148.9702124,1,1,1,1,0,0
9741,09/05/2019 00:00,DB14198,Quaternium-15,,,,,,,,,334,,3.7,[ClH-].Cl\C=C\C[N+]12CN3CN(CN(C3)C1)C2,,,,,,,,,,,,,
9742,01/05/2019 00:00,DB14199,Bromothalonil,,,,,,,,,0.0807,,,BrCC(Br)(CCC#N)C#N,,,,,0,,263.8897724,0,0,0,0,0,0
9743,01/05/2019 00:00,DB14200,Thiohexam,,,,,,,,,0.0135,,6.08,C1CCC(CC1)NSC1=NC2=CC=CC=C2S1,,,,,0,,264.0754905,3,2,1,1,0,0
9744,01/05/2019 00:00,DB14201,"2,2'-Dibenzothiazyl disulfide",,,,,,,,,0.0117,,0.77,S(SC1=NC2=CC=CC=C2S1)C1=NC2=CC=CC=C2S1,,,,,0,,331.9570323,4,4,2,2,0,0
9745,01/05/2019 00:00,DB14202,Morpholinylmercaptobenzothiazole,,,,,,,,,0.393,,1.32,C1CN(CCO1)SC1=NC2=CC=CC=C2S1,,,,,0,,252.039105,3,2,2,1,1,1
9746,01/05/2019 00:00,DB14203,Disperse Blue 106,,,,,,,,,0.0403,15.58,2.55,CCN(CCO)C1=CC=C(\N=N\C2=NC=C(S2)N(=O)=O)C(C)=C1,,,,,0,,335.1052104,2,2,1,1,0,0
9747,01/05/2019 00:00,DB14206,Cobalt chloride,,,,,,,,,35.3,-7,,[Cl-].[Cl-].[Co++],,,,,0,,128.8709004,0,0,0,0,0,0
9748,01/05/2019 00:00,DB14207,Fosinoprilat,,,,,,,,,0.00447,1.76,-4.7,[H][C@]1(C[C@H](N(C1)C(=O)CP(O)(=O)CCCCC1=CC=CC=C1)C(O)=O)C1CCCCC1,,,,,0,,435.2174598,3,1,1,0,1,1
9749,01/05/2019 00:00,DB14208,Ramiprilat,,,,,,,,,0.214,3.13,8.05,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O,,,,,0,,388.199822,3,1,1,0,1,1
9750,01/05/2019 00:00,DB14209,Trandolaprilat,,,,,,,,,0.0834,3.13,8.04,[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1[C@@]([H])(C[C@@]2([H])CCCC[C@]12[H])C(O)=O,,,,,0,,402.2154721,3,1,1,0,1,1
9751,01/05/2019 00:00,DB14210,Moexiprilat,,,,,,,,,0.0303,2.91,7.8,COC1=C(OC)C=C2CN([C@@H](CC2=C1)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O,,,,,0,,470.2053013,3,2,1,0,0,1
9752,01/05/2019 00:00,DB14212,Methylparaben,,,,0.3 g/100g,Topical,,,,3.69,8.5,-6.1,COC(=O)C1=CC=C(O)C=C1,,,,,0,,152.0473441,1,1,0,0,0,0
9753,01/05/2019 00:00,DB14213,Perindoprilat,,,,,,,,,7.2,3.08,8.06,[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(O)=O)[C@@]1([H])CCCC2)C(O)=O,,,,,0,,340.199822,2,0,1,0,1,1
9754,01/05/2019 00:00,DB14214,Rose bengal lactone,,,,,,,,,0.000519,6.5,-3.8,OC1=C(I)C2=C(C=C1I)C1(OC(=O)C3=C1C(Cl)=C(Cl)C(Cl)=C3Cl)C1=CC(I)=C(O)C(I)=C1O2,,,,,0,,971.4991759,5,3,2,0,0,2
9755,01/05/2019 00:00,DB14215,Rose Bengal AT,,,,,,,,,0.000628,6.5,-3.8,[Na+].[Na+].[O-]C1=C(I)C=C2C(OC3=C(I)C([O-])=C(I)C=C3C22OC(=O)C3=C(Cl)C=CC(Cl)=C23)=C1I,,,,,0,,947.5410091,5,3,2,0,0,2
9756,01/05/2019 00:00,DB14217,Quinaprilat,,,,,,,,,0.0359,3.07,7.8,C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CC2=C(C[C@H]1C(O)=O)C=CC=C2,,,,,0,,410.1841719,3,2,1,0,0,1
9757,01/05/2019 00:00,DB14218,Telotristat,,,,,,,,,0.00348,1.69,9.42,CC1=NN(C=C1)C1=CC(Cl)=CC=C1[C@@H](OC1=NC(N)=NC(=C1)C1=CC=C(C[C@H](N)C(O)=O)C=C1)C(F)(F)F,,,,,0,,546.1394009,4,4,2,2,0,0
9758,01/05/2019 00:00,DB14219,Monomethyl fumarate,,,,,,,,,40.1,3.12,-6.8,COC(=O)\C=C\C(O)=O,,,,,0,,130.0266087,0,0,0,0,0,0
9759,01/05/2019 00:00,DB14221,Beclomethasone 17-monopropionate,,,,,,,,,0.00787,13.52,-3.3,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,464.1965665,4,0,0,0,0,0
9760,09/05/2019 00:00,DB14227,Technetium Tc-99m,,,,,,,,,0,,,[99Tc],,,,,0,,98.9062547,0,0,0,0,0,0
9761,01/05/2019 00:00,DB14232,Deacetylbisacodyl,,,,,,,,,0.0657,9.57,4.09,OC1=CC=C(C=C1)C(C1=CC=C(O)C=C1)C1=CC=CC=N1,,,,,0,,277.1102787,3,3,1,1,0,0
9762,01/05/2019 00:00,DB14471,2-Ethylhexyl 4-phenylbenzophenone-2'-carboxylate,,,,,,,,,3.90E-05,,-6.8,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)C1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,414.2194948,3,3,0,0,0,0
9763,01/05/2019 00:00,DB14474,Sorbitan,,,,,,,,,1060,12.75,-3,[H][C@@](O)(CO)[C@@]1([H])OC[C@]([H])(O)[C@@]1([H])O,,,,,0,,164.0684735,1,0,1,0,1,1
9764,01/05/2019 00:00,DB14475,L-Lactic acid,,,,,,,,,562,3.78,-3.7,C[C@H](O)C(O)=O,,,,,0,,90.03169405,0,0,0,0,0,0
9765,02/07/2019 00:00,DB14476,DL-alpha-Tocopherol,,,,400 unit,Oral,,,,7.04E-06,10.8,-4.9,CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2=C(C)C(O)=C(C)C(C)=C2O1,,,,,0,,430.3810808,2,1,1,0,0,1
9766,01/05/2019 00:00,DB14479,Acetylcysteine zinc,,,,,Oral,,,,0.626,3.82,-2,[Zn++].CC(=O)N[C@@H](CS)C([O-])=O.CC(=O)N[C@@H](CS)C([O-])=O,,,,,0,,387.9741204,0,0,0,0,0,0
9767,01/05/2019 00:00,DB14480,Acetylcysteine amide,,,,,Oral,,,,5.27,9.96,-2,[H]N([H])C(=O)[C@H](CS)N([H])C(C)=O,,,,,0,,162.0462986,0,0,0,0,0,0
9768,01/05/2019 00:00,DB14481,Calcium phosphate dihydrate,,,,18.6 g/100g,Oral,,,,38.9,1.8,,O.O.[Ca++].OP([O-])([O-])=O,,,,,0,,171.9449655,0,0,0,0,0,0
9769,02/07/2019 00:00,DB14482,Sodium ascorbate,,,,500 mg,Oral,,,,625,4.36,-3,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,,,,,0,500,198.0140322,1,0,1,0,0,1
9770,02/07/2019 00:00,DB14483,Calcium ascorbate,,,,166.7 mg,Oral,,,,16,4.36,-3,[Ca++].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-],,,,,0,166.7,390.0111169,2,0,2,0,0,2
9771,01/05/2019 00:00,DB14484,Magnesium ascorbate,,,,,Oral,,,,9.07,4.36,-3,[Mg++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,,,,,0,,374.0335676,2,0,2,0,0,2
9772,01/05/2019 00:00,DB14485,Zinc ascorbate,,,,,Oral,,,,43.4,4.36,-3,[Zn++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,,,,,0,,413.9776681,2,0,2,0,0,2
9773,01/05/2019 00:00,DB14486,Niacinamide ascorbate,,,,,Oral,,,,245,4.36,-3,NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O,,,,,0,,298.0801008,2,1,2,1,0,1
9774,01/05/2019 00:00,DB14487,Zinc acetate,"Zinc is absorbed in the small intestine by a carrier-mediated mechanism [L2092]. Under regular physiologic conditions, transport processes of uptake do not saturate. The exact amount of zinc absorbed is difficult to determine because zinc is secreted into the gut. Zinc administered in aqueous solutions to fasting subjects is absorbed quite efficiently (at a rate of 60-70%), however, absorption from solid diets is less efficient and varies greatly, dependent on zinc content and diet composition [L2092].  

Generally, 33% is considered to be the average zinc absorption in humans [L2092]. More recent studies have determined different absorption rates for various populations based on their type of diet and phytate to zinc molar ratio. Zinc absorption is concentration dependent and increases  linearly with  dietary zinc up to a maximum rate [L20902].

Additionally zinc status may influence zinc absorption. Zinc-deprived humans absorb this element with increased efficiency, whereas humans on a high-zinc diet show a reduced efficiency of absorption [L2092].",60-70%,The half-life of zinc in humans is approximately 280 days [L2091].,0.001 mg/1mL,Topical,,,,49.9,4.54,,[Zn++].CC([O-])=O.CC([O-])=O,0.6,0.7,,,0,,181.9557509,0,0,0,0,0,0
9775,02/07/2019 00:00,DB14488,Ferrous gluconate,"The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.",,,38 mg/1,Oral,,,,36.6,3.39,-3,[Fe++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,,,,,0,38,446.0358929,0,0,0,0,0,0
9776,01/05/2019 00:00,DB14489,Ferrous succinate,"The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.",,,,,,,,31.8,3.55,,[Fe++].[O-]C(=O)CCC([O-])=O,,,,,0,,171.9458961,0,0,0,0,0,0
9777,01/05/2019 00:00,DB14490,Ferrous ascorbate,"The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.",,,33 mg,Oral,,,,125,4.36,-3,[Fe++].[H][C@](O)(CO)[C@@]1([H])OC(=O)C(O)=C1O.[H][C@](O)(CO)[C@@]1([H])OC(=O)C([O-])=C1[O-],,,,,0,33,405.9834634,2,0,2,0,0,2
9778,02/07/2019 00:00,DB14491,Ferrous fumarate,"The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.",,,65 mg,Oral,,,,13.1,3.35,,[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O,,,,,0,65,169.930246,0,0,0,0,0,0
9779,01/05/2019 00:00,DB14493,Zinc glycinate,,,,,Oral,,,,194,2.31,9.24,[Zn++].[H]N([H])CC([O-])=O.[H]N([H])CC([O-])=O,,,,,0,,211.9775489,0,0,0,0,0,0
9780,01/05/2019 00:00,DB14494,Zinc carbonate,,,,,Topical,,,,109,6.05,,[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Zn++].[Zn++].[Zn++].[Zn++].[Zn++].[O-]C([O-])=O.[O-]C([O-])=O,,,,,0,,541.6316366,0,0,0,0,0,0
9781,01/05/2019 00:00,DB14495,Manganese citrate,,,,,Oral,,,,5.03,3.05,-4.2,[Mn++].[Mn++].[Mn++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,,,,0,,542.8211903,0,0,0,0,0,0
9782,01/05/2019 00:00,DB14497,Calcium magnesium potassium carbonate chloride hydroxide,,,,,Oral,,,,15.7,6.05,,[OH-].[OH-].[OH-].[Mg++].[Cl-].[K++].[K++].[Ca++].[O-]C([O-])=O,,,,,,,,,,,,,
9783,02/07/2019 00:00,DB14498,Potassium acetate,,,,196 mg/1mL,Intravenous,,,,342,4.54,,[K+].CC([O-])=O,,,,,0,,97.97701102,0,0,0,0,0,0
9784,01/05/2019 00:00,DB14501,Ferrous glycine sulfate,"The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.",,,,,,,,211,2.31,9.24,[Fe++].NCC([O-])=O.NCC([O-])=O.OS(O)(=O)=O,,,,,0,,301.9507238,0,0,0,0,0,0
9785,02/07/2019 00:00,DB14507,Lithium citrate,,,,8 meq/5mL,Oral,,,,194,3.05,-4.2,[Li+].[Li+].[Li+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,,,,0,,210.0515412,0,0,0,0,0,0
9786,01/05/2019 00:00,DB14508,Lithium succinate,,,,,,,,,448,3.55,,[Li+].[Li+].[O-]C(=O)CCC([O-])=O,,,,,0,,130.0429677,0,0,0,0,0,0
9787,02/07/2019 00:00,DB14509,Lithium carbonate,Lithium absorption is rapid and oral bioavailability is close to 100%[A176639].,,The half life of lithium carbonate is 18 to 36 hours[FDA Label]. Other sources say it may be 7 to 20 hours[L5858].,300 mg,Oral,,100mM,,644,6.05,,[Li+].[Li+].[O-]C([O-])=O,,,,,0,300,74.01675296,0,0,0,0,0,0
9788,01/05/2019 00:00,DB14511,Acetate,,,,,Oral,,,,490,4.54,,CC([O-])=O,,,,,-1,,59.01385292,0,0,0,0,0,0
9789,02/07/2019 00:00,DB14512,Mometasone furoate,The mean time to peak concentration is 1.0 to 2.5 hours[FDA Label]. Bioavailability has been reported as <1%[FDA Label] but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%[A176918]. The 0.1% ointment may have a bioavailability of 0.7%[F4295].,0.98,"The terminal half life of an inhaled dose is approximately 5 hours[FDA Label] though it has been reported as 5.8 hours by other sources[F4292,A176906].",110 ug/1,Respiratory (inhalation),solid,Insoluble,4.115,0.0108,13.84,-3.1,[H][C@@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@]([H])(O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)CCl,0.98,0.98,,,0,,520.141944,5,1,1,1,0,0
9790,01/05/2019 00:00,DB14514,Magnesium levulinate,,,,,,,,,1.22,4.32,-7.3,[Mg++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O,,,,,0,,254.0640799,0,0,0,0,0,0
9791,01/05/2019 00:00,DB14515,Magnesium lactate,,,,,,,,,15.7,3.78,-3.7,[Mg+4].CC([O-])C([O-])=O.CC([O-])C([O-])=O,,,,,,,,,,,,,
9792,01/05/2019 00:00,DB14518,Aluminum acetate,,,,0.008 mg/4mL,Topical,,,,4.81,4.54,,[Al+3].CC([O-])=O.CC([O-])=O.CC([O-])=O,,,,,0,,204.0214516,0,0,0,0,0,0
9793,01/05/2019 00:00,DB14520,Tetraferric tricitrate decahydrate,"Iron absorption and systemic iron homeostasis are regulated by hepcidin, which is a peptide hormone that also regulates the activity of the iron-efflux protein, ferroportin-1 [A32514]. Iron is mostly absorbed in the duodenum and upper jejunum [L2258]. Fe3+ displays low solubility at the neutral pH of the intestine and is mainly be converted to ferrous iron (Fe2+) by ferric reductases [T28], as ferric salts are only half as well absorbed as ferrous salts [L2258]. Once converted in the intestinal lumen, Fe+2 is transported across the apical membrane of enterocytes [A32514]. The absorption rate of non-haem iron is 2-20% [A32514]. Stored iron may be liberated via ferroportin-mediated efflux, which is coupled by reoxidation of Fe2+ to Fe3+ by ceruloplasmin in the serum or hephaestin in the enterocyte membrane [A32524]. Fe3+ subsequently binds to transferrin, which keeps ferric cation in a redox-inert state and delivers it into tissues [A32514].

It is proposed that there may be separate cellular uptake pathways for ferrous iron and ferric iron. While ferrous iron is primarily carried by divalent metal transporter-1 (DMAT-1), cellular uptake of ferric iron is predominantly mediated by beta-3 integrin and mobilferrin, which is also referred to as calreticulin in some sources as a homologue [A32507]. However, the most dominant pathway in humans is unclear [A32507]. ",,The pharmacokinetic properties of ferric compounds vary.,210 mg/1,Oral,,,,0.503,3.05,-4.2,O.O.O.O.O.O.O.O.O.O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O,,,,,0,210,967.8325042,0,0,0,0,0,0
9794,01/05/2019 00:00,DB14526,Chromic citrate,"Chromium compounds are both absorbed by the lung and the gastrointestinal tract. Oral absorption of chromium compounds in humans can range between 0.5% and 10%, with the hexavalent (VI) chromium more easily absorbed than the trivalent (III) form [L1982]. Absorption of chromium from the intestinal tract is low, ranging from less than 0.4% to 2.5% of the amount consumed [L1986]. Vitamin C and the vitamin B niacin is reported to enhance chromium absorption [L1986].

Most hexavalent Cr (VI) undergoes partial intragastric reduction to Cr (III) upon absorption, which is an action mainly mediated by sulfhydryl groups of amino acids [L1982]. Cr (VI) readily penetrates cell membranes and chromium can be found in both erythrocytes and plasma after gastrointestinal absorption of Cr (IV). In comparison, the presence of chromium is limited to the plasma as Cr (III) displays poor cell membrane penetration [L1982]. Once transported through the cell membrane, Cr (VI) is rapidly reduced to Cr (III), which subsequently binds to macromolecules or conjugate with proteins. Cr (III) may be bound to transferrin or other plasma proteins, or as complexes, such as glucose tolerance factor (GTF). ",0.95,The elimination half-life of hexavalent chromium is 15 to 41 hours [L1982].,,,,,,2.01,3.05,-4.2,[Cr+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,0.95,0.95,,,0,,240.944035,0,0,0,0,0,0
9795,01/05/2019 00:00,DB14527,Chromic nitrate,"Chromium compounds are both absorbed by the lung and the gastrointestinal tract. Oral absorption of chromium compounds in humans can range between 0.5% and 10%, with the hexavalent (VI) chromium more easily absorbed than the trivalent (III) form [L1982]. Absorption of chromium from the intestinal tract is low, ranging from less than 0.4% to 2.5% of the amount consumed [L1986]. Vitamin C and the vitamin B niacin is reported to enhance chromium absorption [L1986].

Most hexavalent Cr (VI) undergoes partial intragastric reduction to Cr (III) upon absorption, which is an action mainly mediated by sulfhydryl groups of amino acids [L1982]. Cr (VI) readily penetrates cell membranes and chromium can be found in both erythrocytes and plasma after gastrointestinal absorption of Cr (IV). In comparison, the presence of chromium is limited to the plasma as Cr (III) displays poor cell membrane penetration [L1982]. Once transported through the cell membrane, Cr (VI) is rapidly reduced to Cr (III), which subsequently binds to macromolecules or conjugate with proteins. Cr (III) may be bound to transferrin or other plasma proteins, or as complexes, such as glucose tolerance factor (GTF). ",0.95,The elimination half-life of hexavalent chromium is 15 to 41 hours [L1982].,,,,,,0.0893,,-9.9,[Cr+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O,0.95,0.95,,,0,,237.9039611,0,0,0,0,0,0
9796,01/05/2019 00:00,DB14528,Chromium gluconate,"Chromium compounds are both absorbed by the lung and the gastrointestinal tract. Oral absorption of chromium compounds in humans can range between 0.5% and 10%, with the hexavalent (VI) chromium more easily absorbed than the trivalent (III) form [L1982]. Absorption of chromium from the intestinal tract is low, ranging from less than 0.4% to 2.5% of the amount consumed [L1986]. Vitamin C and the vitamin B niacin is reported to enhance chromium absorption [L1986].

Most hexavalent Cr (VI) undergoes partial intragastric reduction to Cr (III) upon absorption, which is an action mainly mediated by sulfhydryl groups of amino acids [L1982]. Cr (VI) readily penetrates cell membranes and chromium can be found in both erythrocytes and plasma after gastrointestinal absorption of Cr (IV). In comparison, the presence of chromium is limited to the plasma as Cr (III) displays poor cell membrane penetration [L1982]. Once transported through the cell membrane, Cr (VI) is rapidly reduced to Cr (III), which subsequently binds to macromolecules or conjugate with proteins. Cr (III) may be bound to transferrin or other plasma proteins, or as complexes, such as glucose tolerance factor (GTF). ",0.95,The elimination half-life of hexavalent chromium is 15 to 41 hours [L1982].,,,,,,22.8,3.39,-3,[Cr+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,0.95,0.95,,,0,,637.0919406,0,0,0,0,0,0
9797,01/05/2019 00:00,DB14529,Chromium nicotinate,"Chromium compounds are both absorbed by the lung and the gastrointestinal tract. Oral absorption of chromium compounds in humans can range between 0.5% and 10%, with the hexavalent (VI) chromium more easily absorbed than the trivalent (III) form [L1982]. Absorption of chromium from the intestinal tract is low, ranging from less than 0.4% to 2.5% of the amount consumed [L1986]. Vitamin C and the vitamin B niacin is reported to enhance chromium absorption [L1986].

Most hexavalent Cr (VI) undergoes partial intragastric reduction to Cr (III) upon absorption, which is an action mainly mediated by sulfhydryl groups of amino acids [L1982]. Cr (VI) readily penetrates cell membranes and chromium can be found in both erythrocytes and plasma after gastrointestinal absorption of Cr (IV). In comparison, the presence of chromium is limited to the plasma as Cr (III) displays poor cell membrane penetration [L1982]. Once transported through the cell membrane, Cr (VI) is rapidly reduced to Cr (III), which subsequently binds to macromolecules or conjugate with proteins. Cr (III) may be bound to transferrin or other plasma proteins, or as complexes, such as glucose tolerance factor (GTF). ",0.95,The elimination half-life of hexavalent chromium is 15 to 41 hours [L1982].,,Oral,,,,0.0286,2.79,4.19,[Cr+3].[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1,0.95,0.95,,,0,,418.0131176,3,3,3,3,0,0
9798,01/05/2019 00:00,DB14530,Chromous sulfate,"Chromium compounds are both absorbed by the lung and the gastrointestinal tract. Oral absorption of chromium compounds in humans can range between 0.5% and 10%, with the hexavalent (VI) chromium more easily absorbed than the trivalent (III) form [L1982]. Absorption of chromium from the intestinal tract is low, ranging from less than 0.4% to 2.5% of the amount consumed [L1986]. Vitamin C and the vitamin B niacin is reported to enhance chromium absorption [L1986].

Most hexavalent Cr (VI) undergoes partial intragastric reduction to Cr (III) upon absorption, which is an action mainly mediated by sulfhydryl groups of amino acids [L1982]. Cr (VI) readily penetrates cell membranes and chromium can be found in both erythrocytes and plasma after gastrointestinal absorption of Cr (IV). In comparison, the presence of chromium is limited to the plasma as Cr (III) displays poor cell membrane penetration [L1982]. Once transported through the cell membrane, Cr (VI) is rapidly reduced to Cr (III), which subsequently binds to macromolecules or conjugate with proteins. Cr (III) may be bound to transferrin or other plasma proteins, or as complexes, such as glucose tolerance factor (GTF). ",0.95,The elimination half-life of hexavalent chromium is 15 to 41 hours [L1982].,,,,,,53.5,-3,,[Cr++].[O-]S([O-])(=O)=O,0.95,0.95,,,0,,147.892237,0,0,0,0,0,0
9799,01/05/2019 00:00,DB14531,Carbonate ion,,,,,,,,,756,6.05,,[O-]C([O-])=O,,,,,-2,,59.98584102,0,0,0,0,0,0
9800,02/07/2019 00:00,DB14533,Zinc chloride,"Zinc is absorbed in the small intestine by a carrier-mediated mechanism [L2092]. Under regular physiologic conditions, transport processes of uptake do not saturate. The exact amount of zinc absorbed is difficult to determine because zinc is secreted into the gut. Zinc administered in aqueous solutions to fasting subjects is absorbed quite efficiently (at a rate of 60-70%), however, absorption from solid diets is less efficient and varies greatly, dependent on zinc content and diet composition [L2092].  

Generally, 33% is considered to be the average zinc absorption in humans [L2092]. More recent studies have determined different absorption rates for various populations based on their type of diet and phytate to zinc molar ratio. Zinc absorption is concentration dependent and increases  linearly with  dietary zinc up to a maximum rate [L20902].

Additionally zinc status may influence zinc absorption. Zinc-deprived humans absorb this element with increased efficiency, whereas humans on a high-zinc diet show a reduced efficiency of absorption [L2092].",60-70%,The half-life of zinc in humans is approximately 280 days [L2091].,1 mg,Oral,,,,46.1,-7,,[Cl-].[Cl-].[Zn++],0.6,0.7,,,0,1,133.8668476,0,0,0,0,0,0
9801,01/05/2019 00:00,DB14537,Chromate ion Cr-51,,,,,,,,,283,-2.3,,[O-][51Cr]([O-])(=O)=O,,,,,-2,,114.925523,0,0,0,0,0,0
9802,01/05/2019 00:00,DB14538,Hydrocortisone aceponate,Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.,0.95,6-8 hours,,,,,,0.00526,14.81,-2.8,[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.95,0.95,6,8,0,,460.2461035,4,0,0,0,0,0
9803,02/07/2019 00:00,DB14539,Hydrocortisone acetate,Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.,0.95,6-8 hours,1 g/100g,Topical,,,,0.0582,12.61,-2.8,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.95,0.95,6,8,0,,404.2198887,4,0,0,0,0,0
9804,01/05/2019 00:00,DB14540,Hydrocortisone butyrate,Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.,0.95,6-8 hours,1.0 mg/1g,Topical,,,,0.0136,13.75,-2.8,[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.95,0.95,6,8,0,,432.2511889,4,0,0,0,0,0
9805,01/05/2019 00:00,DB14541,Hydrocortisone cypionate,Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.,0.95,6-8 hours,10 mg/5mL,Oral,,,,0.00326,12.61,-2.8,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC3CCCC3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.95,0.95,6,8,0,,486.2981391,5,0,0,0,0,0
9806,01/05/2019 00:00,DB14542,Hydrocortisone phosphate,Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.,0.95,6-8 hours,,,,,,0.73,1.18,-2.8,[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.95,0.95,6,8,0,,442.1756546,4,0,0,0,0,0
9807,01/05/2019 00:00,DB14543,Hydrocortisone probutate,Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.,0.95,6-8 hours,1 mg/1g,Topical,,,,0.00283,14.81,-2.8,[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.95,0.95,6,8,0,,488.2774036,4,0,0,0,0,0
9808,02/07/2019 00:00,DB14544,Hydrocortisone valerate,Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.,0.95,6-8 hours,2 mg/1g,Topical,,,,0.00763,13.75,-2.8,[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,0.95,0.95,6,8,0,,446.2668389,4,0,0,0,0,0
9809,01/05/2019 00:00,DB14545,Hydrocortisone succinate,,,,100 mg/2mL,Intramuscular; Intravenous,,,,0.0653,3.66,-2.8,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,462.225368,4,0,0,0,0,0
9810,01/05/2019 00:00,DB14550,Gallium chloride Ga-67,,,,2 mCi/1mL,Intravenous,,,,11.2,2.68,,[Cl-].[Cl-].[Cl-].[67Ga+3],,,,,0,,171.8347597,0,0,0,0,0,0
9811,11/06/2019 00:00,DB14554,Dotatate,,,,40 ug/1,Intravenous,,,,0.0758,2.48,,[H][C@](C)(O)[C@]([H])(N=C(O)[C@]1([H])CSSC[C@]([H])(N=C(O)[C@@]([H])(CC2=CC=CC=C2)N=C(O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)C(O)=N[C@]([H])(CC2=CC=C(O)C=C2)C(O)=N[C@]([H])(CC2=CNC3=CC=CC=C23)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@]([H])(C(O)=N1)[C@@]([H])(C)O)C(O)=O,,,,,0,,1434.594809,6,4,3,1,1,2
9812,01/05/2019 00:00,DB14555,Ursadiol,,,,300 mg/1,Oral,,,,0.00253,19.49,-0.3,[H][C@@]12CC[C@]3(C)[C@]([H])(CCC4=C5CC(C)(C)CC[C@]5(C)[C@@H](O)C[C@@]34C)[C@@]1(C)CC[C@H](O)C2(C)C,,,,,0,300,442.3810808,5,0,0,0,0,0
9813,01/05/2019 00:00,DB14556,Peracetic acid,,,,8.0 g/4000mL,Topical,,,,366,7.69,-6,CC(=O)OO,,,,,0,,76.01604399,0,0,0,0,0,0
9814,01/05/2019 00:00,DB14557,Ethylhexylglycerin,,,,5 mg/500mL,Topical,,,,2.73,13.64,-3,CCCCC(CC)COCC(O)CO,,,,,0,,204.1725446,0,0,0,0,0,0
9815,01/05/2019 00:00,DB14568,Ivosidenib,"Ivosidenib has a Tmax of 3  hours following oral administration of a 2 250 mg tablets (total 500 mg) [FDA Label]. When given with a high-fat meal, Cmax increases by 98% and AUC by 25%.

The AUC and Cmax increase in a less than dose-proportional manner in the range of 200-1200 mg daily [FDA Label]. Accumulation ratios have been determined to be 1.9 for AUC and 1.5 for Cmax over the course of one month. Steady state is known to be reached within 14 days of daily administration.",92-96%,Ivosidenib has a terminal half-life of 93 h [FDA Label].,250 mg/1,Oral,solid,,,0.0208,12.14,1.81,[H][C@@](N(C(=O)[C@]1([H])CCC(=O)N1C1=NC=CC(=C1)C#N)C1=CC(F)=CN=C1)(C(=O)NC1CC(F)(F)C1)C1=C(Cl)C=CC=C1,0.92,0.96,,,0,250,582.1394009,5,3,3,2,1,1
9816,01/05/2019 00:00,DB14569,Tedizolid,,,,,,,,,0.382,14.61,-1.7,CN1N=NC(=N1)C1=NC=C(C=C1)C1=C(F)C=C(C=C1)N1C[C@H](CO)OC1=O,,,,,0,,370.1189666,4,3,3,2,1,1
9817,01/05/2019 00:00,DB14570,Hydroxyprogesterone,,,,,,,,,0.0293,12.7,-3.8,[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,330.2194948,4,0,0,0,0,0
9818,01/05/2019 00:00,DB14575,Eslicarbazepine,,,,,,,,,0.554,14.1,-3.2,NC(=O)N1C2=C(C[C@H](O)C3=C1C=CC=C3)C=CC=C2,,,,,0,,254.1055277,3,2,1,0,0,1
9819,01/05/2019 00:00,DB14581,CPI-1205,,,,,,,,,0.00741,11.15,3.46,COC1=C(CNC(=O)C2=C(C)N([C@H](C)C3CCN(CC(F)(F)F)CC3)C3=CC=CC=C23)C(=O)NC(C)=C1,,,,,0,,518.2504756,4,3,3,2,1,1
9820,01/05/2019 00:00,DB14583,Segesterone acetate,"Contraceptive vaginal rings provided sustained release of contraceptive levels of segesterone acetate over 90 days in a pharmacokinetic study of healthy women [A37083]. Following vaginal administration for up to 13 cycles, segesterone acetate was absorbed into systemic administration and reached the peak plasma concentration in 2 hours in Cycle 1, Cycle 3, and Cycle 13. Concentrations declined after time to reach plasma concentration (Tmax) and became more constant after 96 hours post-dose.Over subsequent cycles of use, the peak serum concentrations of segesterone acetate decreased. In Cycle 1, 3 and 13, the peak plasma concentrations were 1147, 363, and 294 pg/mL [FDA Label]. ",0.95,The mean (SD) half life of segesterone acetate is 4.5 (3.4) hours [FDA Label].,,,solid,Insoluble,,0.00231,17.46,-4.7,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],0.95,0.95,,,0,,370.2144094,4,0,0,0,0,0
9821,01/05/2019 00:00,DB14584,Segesterone,,,,,,,,,0.0241,12.21,-4,[H][C@@]12CC(=C)[C@](O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],,,,,0,,328.2038448,4,0,0,0,0,0
9822,01/05/2019 00:00,DB14589,Caprylyl glycol,,,,,Topical,,,,18.2,14.27,-2.9,CCCCCCC(O)CO,,,,,0,,146.1306798,0,0,0,0,0,0
9823,14/12/2018 00:00,DB00873,Loteprednol,,,,,,,,,0.0336,12.01,-2.9,[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,394.1547016,4,0,0,0,0,0
9824,01/05/2019 00:00,DB14598,Edetate calcium disodium anhydrous,,,,200 mg/1mL,Intramuscular,,,,23.1,2.35,7.73,[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,,,,,0,,374.0014949,0,0,0,0,0,0
9825,01/05/2019 00:00,DB14599,Edetate copper disodium,,,,,,,,,23.7,2.35,7.73,[Na+].[Na+].[Cu++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,,,,,0,,396.9685014,0,0,0,0,0,0
9826,01/05/2019 00:00,DB14600,Edetate disodium anhydrous,Poorly absorbed from the gastrointestinal tract. Well absorbed following intramuscular injection.,,The half life of edetate calcium disodium is 20 to 60 minutes.,24 g/100g,Dental,,,,72,2.35,7.73,[Na+].[Na+].OC(=O)CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O,,,,,0,,336.054554,0,0,0,0,0,0
9827,01/05/2019 00:00,DB14623,Acetyl chloride,,,,,,,,,91.1,19.33,-9.1,CC(Cl)=O,,,,,0,,77.9872424,0,0,0,0,0,0
9828,01/05/2019 00:00,DB14624,Nandrolone hydrogen sulfate,,,,,,,,,0.018,-1.3,-4.7,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2OS(O)(=O)=O,,,,,0,,354.1500949,4,0,0,0,0,0
9829,01/05/2019 00:00,DB14625,Meprednisone acetate,,,,,,,,,0.0168,12.46,-3.9,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,,,,,0,,414.2042387,4,0,0,0,0,0
9830,01/05/2019 00:00,DB14626,Pregnenolone acetate,,,,,,,,,0.00188,19.4,-6.8,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(C)=O,,,,,0,,358.2507949,4,0,0,0,0,0
9831,01/05/2019 00:00,DB14627,Oxyphenisatin acetate,,,,,,,,,0.000493,12.8,-6.5,CC(=O)OC1=CC=C(C=C1)C1(C(=O)NC2=CC=CC=C12)C1=CC=C(OC(C)=O)C=C1,,,,,0,,401.1263227,4,3,1,0,0,1
9832,01/05/2019 00:00,DB14628,Pseudosaccharin chloride,,,,,,,,,0.282,,-3.5,ClC1=NS(=O)(=O)C2=CC=CC=C12,,,,,0,,200.965127,2,1,1,0,0,1
9833,01/05/2019 00:00,DB14629,Trifluoroethyl acetate,,,,,,,,,15.7,,-7,CC(=O)OCC(F)(F)F,,,,,0,,142.0241641,0,0,0,0,0,0
9834,01/05/2019 00:00,DB14630,Tyramine O-sulfate,,,,,,,,,1.63,-1.9,9.8,NCCC1=CC=C(OS(O)(=O)=O)C=C1,,,,,0,,217.0408788,1,1,0,0,0,0
9835,02/07/2019 00:00,DB14631,Prednisolone phosphate,,,,10 mg,Ophthalmic,,,,0.432,1.18,-2.9,[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,440.1600045,4,0,0,0,0,0
9836,01/05/2019 00:00,DB14632,Prednisolone tebutate,,,,,,,,,0.00929,12.61,-2.9,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,458.2668389,4,0,0,0,0,0
9837,01/05/2019 00:00,DB14633,Prednisolone hemisuccinate,,,,,,,,,0.0483,3.66,-2.9,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,460.209718,4,0,0,0,0,0
9838,01/05/2019 00:00,DB14634,Fluprednidene acetate,,,,,,,,,0.0292,12.12,-3.4,[H][C@@]12CC(=C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,432.1948169,4,0,0,0,0,0
9839,01/05/2019 00:00,DB14635,Curcumin sulfate,"Curcumin displays poor absorption into the gastrointestinal tract. In a rat study, oral administration of a single dose of 2 g of curcumin resulted in a plasma concentration of less than 5 Î¼g/mL, indicating poor absorption from the gut [F114].",,No pharmacokinetic data available. ,,,,,,0.00831,-2.2,-4.4,COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC=C(OS(O)(=O)=O)C(OC)=C2)=CC=C1O,,,,,0,,448.0828032,2,2,0,0,0,0
9840,01/05/2019 00:00,DB14636,Triciribine phosphate,,,,,,,,,3.11,1.23,8.33,CN1N=C(N)C2=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C3=C2C1=NC=N3,,,,,0,,400.0896335,4,2,4,2,1,2
9841,01/05/2019 00:00,DB14637,Fluprednisolone acetate,,,,,,,,,0.0414,12.61,-2.9,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,,,,,0,,420.1948169,4,0,0,0,0,0
9842,01/05/2019 00:00,DB14638,Diloxanide furoate,"Bioavailability is 90% (in diloxanide parental form), however diloxanide furoate is slowly absorbed from the gastrointestinal tract.",,3 hours,,,,,,0.0382,13.09,-3.1,CN(C(=O)C(Cl)Cl)C1=CC=C(OC(=O)C2=CC=CO2)C=C1,,,3,3,0,,327.0065132,2,2,1,1,0,0
9843,01/05/2019 00:00,DB14639,Boldenone undecylenate,,,14 days,,,,,,5.54E-05,18.39,-5,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCCCCCCCC=C,,,336,336,0,,452.3290453,4,0,0,0,0,0
9844,01/05/2019 00:00,DB14640,Isoflupredone acetate,,,,,,,,,0.025,12.58,-3.4,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,420.1948169,4,0,0,0,0,0
9845,01/05/2019 00:00,DB14641,Estriol tripropionate,,,,,,,,,0.000438,,-6.6,[H][C@]1(C[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)CC)=CC=C4[C@@]3([H])CC[C@]2(C)[C@@]1([H])OC(=O)CC)OC(=O)CC,,,,,0,,456.2511889,4,1,0,0,0,0
9846,23/05/2019 00:00,DB14642,Lypressin,,,,,,,,,0.0497,2.86,,[H]N([H])C(=O)C[C@]1([H])NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC1=O)C(=O)N1CCC[C@H]1C(=O)NC([H])(CCCCN)C(=O)NCC(N)=O,,,,,0,,1055.431707,4,2,2,0,2,2
9847,01/05/2019 00:00,DB14643,Methylprednisolone aceponate,,,,,,,,,0.00637,14.8,-2.9,[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,,,,,0,,472.2461035,4,0,0,0,0,0
9848,01/05/2019 00:00,DB14644,Methylprednisolone hemisuccinate,,,,125 mg/2mL,Intramuscular; Intravenous,,,,0.0264,3.66,-2.9,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,,,,,0,,474.225368,4,0,0,0,0,0
9849,01/05/2019 00:00,DB14645,Nitrogen trichloride,,,,,,,,,11.3,,,ClN(Cl)Cl,,,,,0,,118.909632,0,0,0,0,0,0
9850,01/05/2019 00:00,DB14646,Prednisone acetate,,,,,,,,,0.0235,12.6,-3.8,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,400.1885886,4,0,0,0,0,0
9851,01/05/2019 00:00,DB14647,Sulfur chloride,,,,,,,,,7.32,,,ClSSCl,,,,,0,,133.8818474,0,0,0,0,0,0
9852,01/05/2019 00:00,DB14648,Acetyl simvastatin,,,,,,,,,0.0021,,-6.6,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@H](CC(=O)O3)OC(C)=O)[C@@H]12,,,,,0,,460.282489,3,0,1,0,1,1
9853,01/05/2019 00:00,DB14649,Dexamethasone acetate,,,,1 g/1g,Not applicable,,,,0.0164,12.44,-3.4,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,434.2104669,4,0,0,0,0,0
9854,01/05/2019 00:00,DB14650,Menadiol diphosphate,,,,,,,,,0.854,1.47,,CC1=C(OP(O)(O)=O)C2=CC=CC=C2C(OP(O)(O)=O)=C1,,,,,0,,334.0007406,2,2,0,0,0,0
9855,01/05/2019 00:00,DB14651,Perphenazine enanthate,,,,,,,,,0.000557,,7.48,CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,,,,,0,,515.2373261,4,2,2,0,1,2
9856,01/05/2019 00:00,DB14652,Clocortolone acetate,,,,,,,,,0.00394,13.83,-3.3,[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,452.17658,4,0,0,0,0,0
9857,01/05/2019 00:00,DB14653,Clocortolone caproate,,,,,,,,,0.00103,13.83,-3.3,CCCCCC(=O)OCC(=O)[C@H]1[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C,,,,,0,,508.2391802,4,0,0,0,0,0
9858,01/05/2019 00:00,DB14654,Bisoxatin acetate,,,,,,,,,0.00211,1.91,-1.8,CC(=O)OC1=CC=C(C=C1)C1(OC2=CC=CC=C2N=C1O)C1=CC=C(OC(C)=O)C=C1,,,,,0,,417.1212373,4,3,1,0,0,1
9859,01/05/2019 00:00,DB14655,Drostanolone propionate,Well absorbed following parenteral administration.,,,,,,,,0.000631,,-6.9,[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C,,,,,0,,360.266445,4,0,0,0,0,0
9860,01/05/2019 00:00,DB14656,Chlorphenesin carbamate,,,,,,,,,0.391,-3.3,11.23,OC(COC(O)=N)COC1=CC=C(Cl)C=C1,,,,,0,,245.0454855,1,1,0,0,0,0
9861,01/05/2019 00:00,DB14657,Paramethasone acetate,,,,,,,,,0.0244,12.47,-2.9,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,434.2104669,4,0,0,0,0,0
9862,01/05/2019 00:00,DB14658,Chloramphenicol palmitate,,,,1 g/1g,Not applicable,,,,9.51E-05,9.07,-3.4,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,,,,,0,,560.2419924,1,1,0,0,0,0
9863,01/05/2019 00:00,DB14659,Melengestrol acetate,,,,,,,,,0.00147,17.54,-4.9,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,,,,,0,,396.2300595,4,0,0,0,0,0
9864,01/05/2019 00:00,DB14660,Trenbolone acetate,,,,,,,,,0.00758,18.4,-4.8,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CCC4=C3C=C[C@]12C)OC(C)=O,,,,,0,,312.1725446,4,0,0,0,0,0
9865,01/05/2019 00:00,DB14661,Loperamide oxide,,,,,,,,,0.000221,13.66,4.01,CN(C)C(=O)C(CC[N+]1([O-])CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,0,,492.2179706,4,3,1,0,1,1
9866,01/05/2019 00:00,DB14662,Flunisolide acetate,,,,,,,,,0.0113,14.62,-2.9,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,476.2210316,5,0,1,0,1,1
9867,01/05/2019 00:00,DB14663,Ribavirin monophosphate,,,,,,,,,3.34,1.23,-1.2,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,,,,,0,,324.0471,2,1,2,1,1,1
9868,01/05/2019 00:00,DB14664,Difluocortolone pivalate,,,,,,,,,0.00492,13.61,-3.4,[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,,,,0,,478.2530807,4,0,0,0,0,0
9869,01/05/2019 00:00,DB14665,Bornyl acetate,,,,,,,,,0.0601,,-7,CC(=O)O[C@@H]1C[C@@H]2CC[C@@]1(C)C2(C)C,,,,,0,,196.1463299,2,0,0,0,0,0
9870,01/05/2019 00:00,DB14666,Oleoyl chloride,,,,,,,,,1.14E-05,,-9.1,CCCCCCCC\C=C/CCCCCCCC(Cl)=O,,,,,0,,300.2219934,0,0,0,0,0,0
9871,01/05/2019 00:00,DB14667,Phenyl hydrogen sulfate,,,,,,,,,3.57,-2.2,,OS(=O)(=O)OC1=CC=CC=C1,,,,,0,,173.9986797,1,1,0,0,0,0
9872,01/05/2019 00:00,DB14668,Dienestrol diacetate,,,,,,,,,0.000534,,-6.8,C\C=C(\C(=C\C)\C1=CC=C(OC(C)=O)C=C1)/C1=CC=C(OC(C)=O)C=C1,,,,,0,,350.1518092,2,2,0,0,0,0
9873,01/05/2019 00:00,DB14669,Betamethasone phosphate,,,,,,,,,2.9,1.18,-3.4,[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,472.1662328,4,0,0,0,0,0
9874,01/05/2019 00:00,DB14670,Lauroyl chloride,,,,,,,,,0.0003,,-9.1,CCCCCCCCCCCC(Cl)=O,,,,,0,,218.143743,0,0,0,0,0,0
9875,01/05/2019 00:00,DB14671,Temazepam acetate,,,,,,,,,0.00921,,-1.7,CN1C2=CC=C(Cl)C=C2C(=NC(OC(C)=O)C1=O)C1=CC=CC=C1,,,,,0,,342.07712,3,2,1,0,0,1
9876,01/05/2019 00:00,DB14672,Oxazepam acetate,,,,,,,,,0.0125,11.38,-1.8,CC(=O)OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O,,,,,0,,328.06147,3,2,1,0,0,1
9877,01/05/2019 00:00,DB14673,Flurandrenolide acetate,,,,,,,,,0.0162,14.67,-2.8,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,,,,,0,,478.2366817,5,0,1,0,1,1
9878,01/05/2019 00:00,DB14674,Estramustine phosphate,,,,,,,,,0.000468,1.86,,[H][C@@]12CC[C@H](OP(O)(O)=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC(=O)N(CCCl)CCCl)C=C3,,,,,0,,519.1344297,4,1,0,0,0,0
9879,01/05/2019 00:00,DB14675,Temsavir,,,,,,,,,0.147,9.07,1.25,COC1=CN=C(N2C=NC(C)=N2)C2=C1C(=CN2)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1,,,,,0,,473.1811522,5,4,4,3,1,1
9880,01/05/2019 00:00,DB14676,Fagrocorat,,,,,,,,,0.000701,11.24,5.2,[H][C@]12CCC3=C(C=CC(=C3)C(=O)NC3=C(C)N=CC=C3)[C@]1(CC1=CC=CC=C1)CC[C@@](O)(C2)C(F)(F)F,,,,,0,,494.2181128,5,3,1,1,0,0
9881,01/05/2019 00:00,DB14677,Gestonorone caproate,,,,,,,,,0.00141,17.69,-4.7,[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],,,,,0,,414.2770097,4,0,0,0,0,0
9882,01/05/2019 00:00,DB14678,Norethindrone enanthate,,,,,,,,,0.00148,18.25,-4.7,[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],,,,,0,,410.2820951,4,0,0,0,0,0
9883,01/05/2019 00:00,DB14679,Quingestanol acetate,,,,,,,,,0.00175,,-4.8,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(OC4CCCC4)=CC3=CC[C@@]21[H],,,,,0,,408.266445,5,0,0,0,0,0
9884,01/05/2019 00:00,DB14680,Combretastatin A4,,,,,,,,,0.00977,9.84,-4.3,COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1O,,,,,0,,316.1310737,2,2,0,0,0,0
9885,01/05/2019 00:00,DB14681,Cortisone,,,,,,,,,0.136,12.58,-3.3,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,,,,0,,360.193674,4,0,0,0,0,0
9886,01/05/2019 00:00,DB14682,Dextrorphan,,,,,,,,,0.173,10.46,9.66,[H][C@]12CC3=C(C=C(O)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C,,,,,0,,257.1779644,4,1,1,0,1,1
9887,01/05/2019 00:00,DB14683,Prezatide copper,Prezatide both free and in complex with copper can pass through the stratum corneum [A19504]. Its absorption is pH dependent with the highest absorption occurring at physiological pH. ,,Prezatide is rapidly eliminated within minutes [A19502].,0.22 mg/22g,Topical,,,,2.08,3.46,10.2,[Cu++].NCCCC[C@H](NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN)C([O-])=O,,,,,1,,402.1071271,1,1,1,1,0,0
9888,01/05/2019 00:00,DB14701,Ethyl 8-hydroxy-alpha-(2-propynylamino)-5-quinolinepropanoate,,,,,,,,,0.0166,8.85,5.34,CCOC(=O)C(CC1=C2C=CC=NC2=C(O)C=C1)NCC#C,,,,,0,,298.1317424,2,2,1,1,0,0
9889,01/05/2019 00:00,DB14703,Dexamethasone metasulfobenzoate,,,,,Auricular (otic); Ophthalmic,,,,0.0457,-2.5,-3.4,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,,,,0,,576.1829319,5,1,0,0,0,0
9890,01/05/2019 00:00,DB14704,Ribitol,,,,,,,,,664,12.76,-3,OC[C@H](O)[C@H](O)[C@H](O)CO,,,,,0,,152.0684735,0,0,0,0,0,0
9891,01/05/2019 00:00,DB14705,Ceramide AP,,,,,,,,,0.000253,12.7,-2.8,CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC,,,,,0,,599.5488744,0,0,0,0,0,0
9892,01/05/2019 00:00,DB14706,Ceramide NG,,,,,,,,,3.66E-05,13.83,-1,CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC,,,,,0,,567.5590452,0,0,0,0,0,0
9893,02/07/2019 00:00,DB14708,Tosylchloramide,,,,,,,,,0.388,4.89,,CC1=CC=C(C=C1)S(=O)(=O)NCl,,,,,0,,204.9964272,1,1,0,0,0,0
9894,01/05/2019 00:00,DB14714,Tenivastatin,,,,,,,,,0.0402,4.21,-2.7,[H][C@@](O)(CC[C@@]1([H])[C@@H](C)C=CC2=C[C@H](C)C[C@H](OC(=O)C(C)(C)CC)[C@]12[H])C[C@@H](O)CC(O)=O,,,,,0,,436.282489,2,0,0,0,0,0
9895,01/05/2019 00:00,DB14715,Cinazepam,,,,,,,,,0.00593,3.33,-2.5,OC(=O)CCC(=O)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Br)=CC=C2NC1=O,,,,,0,,463.9774613,3,2,1,0,0,1
9896,01/05/2019 00:00,DB14716,Clonazolam,,,,,,,,,0.0426,17.54,4.09,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(=C3)N(=O)=O)N12,,,,,0,,353.0679523,4,3,2,1,0,1
9897,01/05/2019 00:00,DB14717,Nitrazolam,,,,,,,,,0.0725,17.76,4.84,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(=C3)[N+]([O-])=O)N12,,,,,0,,319.1069247,4,3,2,1,0,1
9898,01/05/2019 00:00,DB14718,Pyrazolam,,,,,,,,,0.0759,18.38,2.75,CC1=NN=C2CN=C(C3=CC=CC=N3)C3=C(C=CC(Br)=C3)N12,,,,,0,,353.0276075,4,3,3,2,0,1
9899,01/05/2019 00:00,DB14719,Bentazepam,,,,,,,,,0.00557,10.36,3.25,O=C1CN=C(C2=C(N1)SC1=C2CCCC1)C1=CC=CC=C1,,,,,0,,296.0983341,4,2,2,1,0,1
9900,01/05/2019 00:00,DB14720,Brovanexine,,,,,,,,,0.000345,14.07,8.8,COC1=C(OC(C)=O)C=CC(=C1)C(=O)NC1=C(CN(C)C2CCCCC2)C=C(Br)C=C1Br,,,,,0,,566.0415816,3,2,0,0,0,0
9901,01/05/2019 00:00,DB14723,Larotrectinib,"The mean absolute bioavailability of larotrectinib capsules has been recorded as 34%, from a range spanning 32% to 37% [FDA Label]. In adult patients who received larotrectinib capsules 100 mg twice daily, peak plasma levels Cmax were achieved at about one hour after dosing and steady-state was reached within the time span of three days [FDA Label]. The mean steady-state of these administered larotrectinib capsules was Cmax 788 ng/mL and the AUC(0-24hr) was 4351 ng*h/mL [FDA Label]. Concurrently, in healthy subjects, the AUC of the administered larotrectinib oral solution formulation was similar to that of the capsules and the particular Cmax was 36% greater with the oral solution [FDA Label].

The AUC of larotrectinib was similar but the Cmax was reduced by 35% after oral administration of a single 100 mg capsule of larotrectinib to healthy subjects taken with a high-fat meal (approximately 900 calories, 58 grams carbohydrate, 56 grams fat and 43 grams protein) compared to the Cmax and AUC in the fasted state [FDA Label]. ",0.7,The half-life of larotrectinib has been determined to be 2.9 hours [FDA Label].,100 mg/1,Oral,solid,,,0.238,10.94,0.7,O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1,0.7,0.7,,,0,100,428.1772304,5,3,4,2,2,2
9902,01/05/2019 00:00,DB14725,Cefamandole nafate,,,,1 g,Intramuscular; Intravenous,,,,0.227,3.1,-1.7,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](OC=O)C1=CC=CC=C1)C(O)=O,,,,,0,,490.0729243,4,2,3,1,1,2
9903,01/05/2019 00:00,DB14726,Dabigatran,,,,,,,,,0.0975,3.18,12.52,CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(=C2)C(=O)N(CCC(O)=O)C1=NC=CC=C1,,,,,0,,471.2018877,4,4,2,2,0,0
9904,01/05/2019 00:00,DB14727,Riboflavin tetrabutyrate,,,,,Oral,,,,0.0092,6.04,-3.5,CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](CN1C2=C(C=C(C)C(C)=C2)N=C2C(=O)NC(=O)N=C12)OC(=O)CCC,,,,,0,,656.3057436,3,1,2,0,0,2
9905,01/05/2019 00:00,DB14729,Rebeccamycin,,,,,,,,,0.0196,8.05,-3,CO[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]1CO)N1C2=C(C3=C1C(Cl)=CC=C3)C1=C(C(=O)NC1=O)C1=C2NC2=C1C=CC=C2Cl,,,,,0,,569.0756554,7,5,4,2,1,2
9906,01/05/2019 00:00,DB14732,Queuine,"Humans recover queuine from either ingested food or the gut flora [A173830, A173833, A173851]. The proportion of queuine salvaged and absorbed from the normal turnover process of human microbiota has not yet been determined, but it may be significant given the number of microorganisms in the human gastrointestinal tract [A173830]. Furthermore, it is believed that there may exist a dedicated transporter for queuine, considering various purines, purine-derivatives and base analogs are incapable of affecting queuine transport in competitive uptake experiments [A173830, A173833].   ",,Data regarding the half-life of queuine is not readily available or accessible.,,,solid,,,0.59,1.95,21.26,NC1=NC2=C(C(CN[C@H]3C=C[C@H](O)[C@@H]3O)=CN2)C(=O)N1,,,,,0,,277.1174893,3,2,2,2,0,0
9907,01/05/2019 00:00,DB14734,Cannabigerol,,,,,,,,,0.00512,9.16,-5.7,CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1,,,,,0,,316.2402303,1,1,0,0,0,0
9908,01/05/2019 00:00,DB14735,Cannabichromene,,,,,,,,,0.00152,9.47,-4.9,CCCCCC1=CC2=C(C=CC(C)(CCC=C(C)C)O2)C(O)=C1,,,,,0,,314.2245802,2,1,1,0,0,1
9909,01/05/2019 00:00,DB14736,Cannabivarin,,,,,,,,,0.00367,9.32,-4.9,CCCC1=CC(O)=C2C(OC(C)(C)C3=C2C=C(C)C=C3)=C1,,,,,0,,282.1619799,3,2,1,0,0,1
9910,01/05/2019 00:00,DB14737,Cannabinol,,,,,,,,,0.000339,9.32,-4.9,CCCCCC1=CC2=C(C(O)=C1)C1=C(C=CC(C)=C1)C(C)(C)O2,,,,,0,,310.1932801,3,2,1,0,0,1
9911,01/05/2019 00:00,DB14739,Phenolsulfonic acid,,,,,Topical,,,,14.4,-2.6,-6.1,OC1=CC=C(C=C1)S(O)(=O)=O,,,,,0,,173.9986797,1,1,0,0,0,0
9912,02/07/2019 00:00,DB00781,Polymyxin B,Administration by the oral route does not lead to absorption[A176426].,0.79,"In one study the half life was 9 to 11.5 hours[A176390]. However, a Canadian monograph states the half life to be 6 hours, and 48-72 hours in patients with renal insufficiency[F4151].",500000 unit,Oral; Topical,solid,Soluble,,0.0744,11.57,10.23,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,0.79,0.79,,,0,,1202.749927,2,1,1,0,1,1
9913,01/05/2019 00:00,DB14746,Lauryl glucoside,,,,16.5 g/100mL,Topical,,,,0.72,12.21,-3,CCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,348.2511889,1,0,1,0,1,1
9914,15/05/2019 00:00,DB14750,Cidoxepin,,,,,,,,,0.0319,,9.76,CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=CC=C2,,,,,0,,279.1623143,3,2,1,0,0,1
9915,01/05/2019 00:00,DB14753,Hydroxystilbamidine,,,,,,,,,0.0644,8.22,12.14,NC(=N)C1=CC=C(\C=C\C2=C(O)C=C(C=C2)C(N)=N)C=C1,,,,,0,,280.1324111,2,2,0,0,0,0
9916,01/05/2019 00:00,DB14754,Solriamfetol,"Oral bioavailability of solriamfetol is approximately 95%[FDA Label]. Peak plasma concentration is reached in 2 hours (with a range of 1.25 to 3 hours) in fasted patients[FDA Label]. When solriamfetol is taken with a high fat meal, the time to peak plasma concentration increases to 3 hours[FDA Label].",0.133,7.1 hours[FDA Label]. Other studies have found the mean half life to be 6.1 Â± 1.2 hours in fasted subjects and 5.9 Â± 1.2 hours in fed subjects[A176744].,150 mg/1,Oral,,,,1.95,15.68,9.08,N[C@@H](COC(N)=O)CC1=CC=CC=C1,0.133,0.133,,,0,150,194.1055277,1,1,0,0,0,0
9917,01/05/2019 00:00,DB14755,beta-Isosparteine,,,,,,,,,0.931,,9.16,[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2CCCC[C@@]12[H],,,,,0,,234.2095988,4,0,4,0,4,4
9918,03/04/2019 00:00,DB14756,meso-Tartaric acid,,,,,,,,,161,2.72,-4.3,O[C@@H]([C@@H](O)C(O)=O)C(O)=O,,,,,0,,150.0164379,0,0,0,0,0,0
9919,01/05/2019 00:00,DB14761,Remdesivir,,,,,,,,,0.339,10.23,0.65,CCC(CC)COC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1,,,,,0,,602.2253987,4,3,3,2,1,1
9920,01/05/2019 00:00,DB14763,Cycloguanil,,,,,,,,,0.246,16.13,8.18,CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1,,,,,0,,251.0937731,2,1,1,0,0,1
9921,21/05/2019 00:00,DB14768,PF-06459988,,,,,,,,,0.177,10.26,3.63,CO[C@H]1CN(C[C@@H]1COC1=C2C(Cl)=CNC2=NC(NC2=CN(C)N=C2)=N1)C(=O)C=C,,,,,0,,431.1472652,4,3,4,3,1,1
9922,21/05/2019 00:00,DB14772,DCFBC F-18,,,,,,,,,0.09,3.11,-2.5,OC(=O)CC[C@H](NC(=O)N[C@@H](CSCC1=CC=C([18F])C=C1)C(O)=O)C(O)=O,,,,,0,,401.0922349,1,1,0,0,0,0
9923,21/05/2019 00:00,DB14787,BMS-830216,,,,,,,,,0.0125,1.21,-3.8,COC1=CC(=CC=C1OC[C@H](OP(O)(O)=O)C1CC1)N1C=NC2=C(SC(=C2)C2=CC=C(Cl)C=C2)C1=O,,,,,0,,548.0573864,5,4,2,2,0,0
9924,21/05/2019 00:00,DB14793,RO-5045337,,,,,,,,,5.24E-05,,5.34,CCOC1=C(C=CC(=C1)C(C)(C)C)C1=N[C@@](C)(C2=CC=C(Cl)C=C2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)C1=CC=C(Cl)C=C1,,,,,0,,726.2773324,5,3,2,0,1,2
9925,21/05/2019 00:00,DB14799,PF-06821497,,,,,,,,,0.0132,11.14,-1.4,CO[C@H](C1COC1)C1=C(Cl)C2=C(CCN(CC3=C(OC)C=C(C)NC3=O)C2=O)C(Cl)=C1,,,,,0,,466.1062272,4,2,3,1,1,2
9926,21/05/2019 00:00,DB14805,DCFPyL F-18,,,,,,,,,0.191,2.99,,OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O,,,,,0,,441.1525267,1,1,1,1,0,0
9927,21/05/2019 00:00,DB14815,Ginsenoside B2,,,,,,,,,0.812,11.85,-3.6,[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)C(C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,946.5501158,7,0,3,0,3,3
9928,21/05/2019 00:00,DB14830,Fluoromisonidazole F-18,,,,,,,,,5.39,13.64,0.001,OC(C[18F])CN1C=CN=C1[N+]([O-])=O,,,,,0,,188.0575041,1,1,1,1,0,0
9929,21/05/2019 00:00,DB14835,SUVN-G3031,,,,,,,,,0.373,13.97,9.11,O=C(CN1CCOCC1)NC1=CC=C(OC2CCN(CC2)C2CCC2)C=C1,,,,,0,,373.2365419,4,1,2,0,2,2
9930,21/05/2019 00:00,DB14855,2-(aminomethyl)phenol,,,,,,,,,41.2,8.32,10.18,NCC1=CC=CC=C1O,,,,,0,,123.0684139,1,1,0,0,0,0
9931,21/05/2019 00:00,DB14856,PF-05089771,,,,,,,,,0.00358,5.63,3.67,NC1=C(C=NN1)C1=CC(Cl)=CC=C1OC1=CC(F)=C(C=C1Cl)S(=O)(=O)NC1=CSC=N1,,,,,0,,498.9742648,4,4,2,2,0,0
9932,21/05/2019 00:00,DB14862,PF-06815345,,,,,,,,,0.0219,,9.06,CCOC(=O)O[C@@H](C)N1N=NN=C1C1=C(C=NN1C)C1=CC=C(C=C1F)C(=O)N([C@@H]1CCCNC1)C1=NC=CC=C1Cl,,,,,0,,597.2015063,5,4,4,3,1,1
9933,21/05/2019 00:00,DB14870,PF-5190457,,,,,,,,,0.011,,8.67,CC1=CN2C=C(CC(=O)N3CCC4(CN(C4)[C@@H]4CCC5=C4C=CC(=C5)C4=CC(C)=NC=N4)CC3)N=C2S1,,,,,0,,512.2358306,7,4,5,3,2,2
9934,21/05/2019 00:00,DB14885,PF-05180999,,,,,,,,,0.0178,,2.89,CN1N=CC(C2=C3N(N=CN=C3N3CCC3)C(C)=N2)=C1C1=NC=C(C=C1)C(F)(F)F,,,,,0,,414.1528272,5,4,5,4,1,1
9935,21/05/2019 00:00,DB14887,PF-04620110,,,,,,,,,0.159,5.03,4.41,NC1=NC=NC2=C1C(=O)N(CCO2)C1=CC=C(C=C1)[C@H]1CC[C@H](CC(O)=O)CC1,,,,,0,,396.1797552,4,2,2,1,0,1
9936,21/05/2019 00:00,DB14900,ISO-1 F-18,,,,,,,,,0.00691,14.2,8,COC1=C(OC)C=C2CN(CCCCNC(=O)C3=C(OCC[18F])C=CC(C)=C3)CCC2=C1,,,,,0,,443.2449705,3,2,1,0,0,1
9937,21/05/2019 00:00,DB14902,JHU-75528 C-11,,,,,,,,,0.0161,9.73,1.14,[11CH3]OC1=CC=C(C=C1)C1=C(C#N)C(=NN1C1=CC=C(Cl)C=C1Cl)C(=O)NN1CCCCC1,,,,,0,,468.1186639,4,3,2,1,1,1
9938,21/05/2019 00:00,DB14914,Flortaucipir F-18,,,,,,,,,0.0111,13.03,8.13,[18F]C1=CC=C(C=N1)C1=CC=C2C(NC3=C2C=NC=C3)=C1,,,,,0,,262.0884103,4,4,3,3,0,0
9939,21/05/2019 00:00,DB14924,PF-06651600,,,,,,,,,0.457,13.59,6.6,C[C@H]1CC[C@H](CN1C(=O)C=C)NC1=NC=NC2=C1C=CN2,,,,,0,,285.1589602,3,2,3,2,1,1
9940,21/05/2019 00:00,DB14930,Alovudine F-18,,,,,,,,,79.2,10.11,-3,CC1=CN([C@H]2C[C@H]([18F])[C@@H](CO)O2)C(=O)NC1=O,,,,,0,,243.0884699,2,1,2,1,1,1
9941,21/05/2019 00:00,DB14936,Menaquinone 6,,,,,,,,,0.000266,,-7.2,CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O,,,,,0,,580.428031,2,1,0,0,0,0
9942,21/05/2019 00:00,DB14940,Aspartyl-alanyl-diketopiperazine,,,,,,,,,9.14,4.02,-4.5,C[C@@H]1NC(=O)[C@H](CC(O)=O)NC1=O,,,,,0,,186.0640568,1,0,1,0,1,1
9943,21/05/2019 00:00,DB14941,BMS-817399,,,,,,,,,0.128,13.57,-1.1,CC(C)[C@@H](NC(=O)NCC(C)(C)O)C(=O)N1CC[C@](O)(C2=CC=C(Cl)C=C2)C(C)(C)C1,,,,,0,,453.2394343,2,1,1,0,1,1
9944,21/05/2019 00:00,DB14942,BMS-986141,,,,,,,,,0.03,,2.11,COC1=NN2C=C(N=C2S1)C1=CC2=C(O1)C=C(OC)C=C2OCC1=CSC(=N1)C1=CC=C(C=C1)C(=O)N(C)C,,,,,0,,561.1140608,6,6,4,4,0,0
9945,21/05/2019 00:00,DB14948,BMS-986020,,,,,,,,,0.00669,4.53,0.67,C[C@@H](OC(=O)NC1=C(ON=C1C)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(O)=O)C1=CC=CC=C1,,,,,0,,482.1841719,5,4,1,1,0,0
9946,21/05/2019 00:00,DB14950,BMS-929075,,,,,,,,,0.0132,14.8,0.43,CNC(=O)C1=C(OC2=C1C(F)=C(C=C2)C1=C(C)C=CC(=C1)C(=O)NC1(CC1)C1=NC=CC=N1)C1=CC=C(F)C=C1,,,,,0,,538.1816471,6,5,2,2,0,0
9947,21/05/2019 00:00,DB14955,PF-04634817,,,,,,,,,0.0706,,9.98,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1C[C@@H]2C[C@H]1CN2C1=NC=NC(=C1)C(F)(F)F,,,,,0,,511.2770247,5,1,4,1,3,3
9948,21/05/2019 00:00,DB14978,MIP-1095 I-131,,,,,,,,,0.101,3.09,,OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)NC1=CC=C([131I])C=C1)C(O)=O)C(O)=O,,,,,0,,568.0733634,1,1,0,0,0,0
9949,21/05/2019 00:00,DB15003,PF-06700841,,,,,,,,,1.5,10.91,4.45,CN1C=C(NC2=NC=CC(=N2)N2C[C@@H]3CC[C@H](C2)N3C(=O)[C@@H]2CC2(F)F)C=N1,,,,,0,,389.1775647,5,2,4,2,2,2
9950,21/05/2019 00:00,DB15009,PF-04937319,,,,,,,,,0.112,13.15,0.62,CN(C)C(=O)C1=NC=C(OC2=CC(=CC3=C2C=C(C)O3)C(=O)NC2=NC=C(C)N=C2)C=N1,,,,,0,,432.1546031,4,4,3,3,0,0
9951,21/05/2019 00:00,DB15023,BMS-791826,,,,,,,,,0.00103,6.83,0.88,CCN(C)C(=O)C1=CC=C(C=C1F)C1=NC2=C(C=C1)[C@H](C1=CC=CC=C1O2)C(C)(C)C(=O)NC1=NN=CS1,,,,,0,,531.1740389,5,4,3,2,0,1
9952,21/05/2019 00:00,DB15046,LY-2881835,,,,,,,,,0.000605,3.8,9.27,CC#C[C@@H](CC(O)=O)C1=CC=C(OCC2=CC=C(CN3CCC4(CC3)C=CC3=C4C=CC=C3)C=C2)C=C1,,,,,0,,491.2460439,5,3,1,0,1,1
9953,21/05/2019 00:00,DB15047,BMS-919373,,,,,,,,,0.00219,9.29,4.42,NS(=O)(=O)C1=CN=CC(=C1)C1=NC(NCC2=NC=CC=C2)=C2C(C=CC=C2C2=CC=CC=C2)=N1,,,,,0,,468.1368449,5,5,3,3,0,0
9954,21/05/2019 00:00,DB15057,NUC-1031,,,,,,,,,0.0664,10.22,3.64,C[C@H](NP(=O)(OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1,,,,,0,,580.1534569,4,3,2,1,1,1
9955,21/05/2019 00:00,DB15065,PF-06291874,,,,,,,,,0.00204,3.89,0.68,CCC[C@H](OC1=CC(C)=C(N2C=C(C=N2)C(F)(F)F)C(C)=C1)C1=CC=C(C=C1)C(=O)NCCC(O)=O,,,,,0,,503.203191,3,3,1,1,0,0
9956,21/05/2019 00:00,DB15073,Ribose,,,,,,,,,380,12.34,-3,OC[C@@H](O)[C@@H](O)[C@@H](O)C=O,,,,,0,,150.0528234,0,0,0,0,0,0
9957,21/05/2019 00:00,DB15087,Psicose,,,,,,,,,399,12.16,-3,OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO,,,,,0,,180.0633881,0,0,0,0,0,0
9958,21/05/2019 00:00,DB15092,LY-2624803,,,,,,,,,0.146,3.13,8.36,CC(C)(CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=CC=CC=C12)C(O)=O,,,,,0,,379.1895917,4,2,2,0,1,2
9959,21/05/2019 00:00,DB15105,PF-06751979,,,,,,,,,0.0123,10.11,6.95,C[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)C1=NC(NC(=O)C2=NC=C(OC(F)F)C=C2)=CS1,,,,,0,,455.0897379,4,2,4,2,1,2
9960,21/05/2019 00:00,DB15111,Acetic acid C-11,,,,,,,,,323,4.54,,C[11C](O)=O,,,,,0,,59.03256297,0,0,0,0,0,0
9961,21/05/2019 00:00,DB15120,GSK-239512,,,,,,,,,0.236,,9.4,O=C1CCCN1C1=CC=C(OC2=CC3=C(CCN(CC3)C3CCC3)C=C2)N=C1,,,,,0,,377.2103271,5,2,3,1,1,2
9962,21/05/2019 00:00,DB15124,PF-05241328,,,,,,,,,0.0104,4.13,1.34,CC(C)COC1=NC=C(C=C1Cl)N1N=C(C)C2=C1C=CC(=C2)C(=O)NS(C)(=O)=O,,,,,0,,436.0972038,3,3,2,2,0,0
9963,21/05/2019 00:00,DB15134,Fluoroazomycin arabinoside F-18,,,,,,,,,13,12.45,-0.016,O[C@H]1[C@H](O)[C@H](O[C@@H]1C[18F])N1C=CN=C1[N+]([O-])=O,,,,,0,,246.0629834,2,1,2,1,1,1
9964,21/05/2019 00:00,DB15136,Rebaudioside A,,,,,,,,,14.4,11.75,-3.6,C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,,,,,0,,966.4307885,8,0,4,0,4,4
9965,21/05/2019 00:00,DB15143,PF-06650833,,,,,,,,,0.0936,10.59,2.52,CC[C@H]1[C@@H](COC2=C3C=C(OC)C(=CC3=CC=N2)C(N)=O)NC(=O)[C@H]1F,,,,,0,,361.1437843,3,2,2,1,1,1
9966,21/05/2019 00:00,DB15144,Altropane I-123,,,,,,,,,0.0081,,7.59,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1)N2C\C=C\[123I],,,,,0,,425.0612211,3,1,2,0,2,2
9967,21/05/2019 00:00,DB15151,RO-6870810,,,,,,,,,0.0262,15.47,8.1,CN1CCN(CCCNC(=O)C[C@@H]2N=C(C3=C(SC(C)=C3C)N3C(C)=NN=C23)C2=CC=C(Cl)C=C2)CC1,,,,,0,,539.2234074,5,3,4,2,1,2
9968,21/05/2019 00:00,DB15152,TMC-649128,,,,,,,,,0.239,19.22,4.08,CC(C)C(=O)OC[C@]1(O[C@H]([C@@H](C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-],,,,,0,,422.1913826,2,1,2,1,1,1
9969,21/05/2019 00:00,DB15161,Pittsburgh Compound B,,,,,,,,,0.0162,9.23,3.65,[11CH3]NC1=CC=C(C=C1)C1=NC2=C(S1)C=C(O)C=C2,,,,,0,,255.0784676,3,3,1,1,0,0
9970,21/05/2019 00:00,DB15169,H3B-6527,,,,,,,,,0.0162,9.98,8.14,CCN1CCN(CC1)C1=CC=C(NC2=CC(=NC=N2)N(C)C(=O)NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C(NC(=O)C=C)=C1,,,,,0,,628.2080069,4,3,2,1,1,1
9971,21/05/2019 00:00,DB15173,JNJ-42165279,,,,,,,,,0.141,11.98,6.01,FC1(F)OC2=CC=C(CN3CCN(CC3)C(=O)NC3=C(Cl)C=CN=C3)C=C2O1,,,,,0,,410.0957245,4,2,3,1,1,2
9972,21/05/2019 00:00,DB15193,BMS-955176,,,,,,,,,8.57E-05,4.1,10.72,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC=C(C6=CC=C(C=C6)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)NCCN1CCS(=O)(=O)CC1,,,,,0,,690.4430295,7,1,1,0,1,1
9973,21/05/2019 00:00,DB15202,Fluoroacetic acid F-18,,,,,,,,,87.8,3.13,,OC(=O)C[18F],,,,,0,,77.01424234,0,0,0,0,0,0
9974,21/05/2019 00:00,DB15203,JNJ-26489112,,,,,,,,,1.9,10.21,0.23,NS(=O)(=O)NC[C@H]1COC2=C(O1)C=CC(Cl)=C2,,,,,0,,278.0128055,2,1,1,0,0,1
9975,21/05/2019 00:00,DB15208,NOP-1A,,,,,,,,,0.00134,15.21,8.71,CNC(=O)[C@H](CN1CCC2(CC1)OCCC1=C2SC(F)=C1)CC1=CC=CC=C1F,,,,,0,,420.1683055,4,2,3,1,1,2
9976,21/05/2019 00:00,DB15214,BMS-986104,,,,,,,,,0.000108,14.78,9.96,CCCCCC[C@@H]1CCC2=C(C1)C=CC(=C2)[C@H]1CC[C@](N)(CO)C1,,,,,0,,329.2718647,3,1,0,0,0,0
9977,21/05/2019 00:00,DB15221,PF-06260414,,,,,,,,,0.195,10.51,2.18,C[C@@H]1CNS(=O)(=O)N(C1)C1=CC2=CC=NC(C#N)=C2C=C1,,,,,0,,302.0837467,3,2,2,1,1,1
9978,21/05/2019 00:00,DB15229,CNV-2197944,,,,,,,,,0.119,,4.55,C[C@H]1CN(CCN1C(=O)C1=CC=CN=C1C)S(=O)(=O)C1=CC=C(C=C1)C(F)(F)F,,,,,0,,427.1177472,3,2,2,1,1,1
9979,21/05/2019 00:00,DB15243,2-(1-hexyloxyethyl)-2-devinylpyropheophorbide a,,,,,,,,,0.0139,3.81,5.09,CCCCCCOC(C)C1=C(C)/C2=C/C3=N/C(/[C@@H](CCC(O)=O)[C@@H]3C)=C3\CC(=O)C4=C3NC(/C=C3\N=C(\C=C\1/N\2)C(C)=C3CC)=C4C,,,,,0,,636.367556,6,3,5,3,0,2
9980,21/05/2019 00:00,DB15244,NM-404 I-131,,,,,,,,,1.06E-05,1.88,,C[N+](C)(C)CCOP([O-])(=O)OCCCCCCCCCCCCCCCCCCC1=CC=C([131I])C=C1,,,,,0,,641.2773454,1,1,0,0,0,0
9981,21/05/2019 00:00,DB15246,Salvianolic acid A,,,,,,,,,0.00867,3.14,-6.3,OC(=O)[C@@H](CC1=CC(O)=C(O)C=C1)OC(=O)\C=C\C1=C(/C=C/C2=CC(O)=C(O)C=C2)C(O)=C(O)C=C1,,,,,0,,494.1212969,3,3,0,0,0,0
9982,28/05/2019 00:00,DB15250,Vercirnon,,,,,,,,,5.61E-05,7.3,0.5,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC1=C(C=C(Cl)C=C1)C(=O)C1=CC=[N+]([O-])C=C1,,,,,0,,444.0910558,3,3,1,1,0,0
9983,21/05/2019 00:00,DB15254,RO-5126766 free base,,,,,,,,,0.0177,9,0.97,CNS(=O)(=O)NC1=C(F)C(CC2=C(C)C3=C(OC2=O)C=C(OC2=NC=CC=N2)C=C3)=CC=N1,,,,,0,,471.1012679,4,4,3,3,0,0
9984,21/05/2019 00:00,DB15264,PD-0299685,,,,,,,,,1.22,4.87,10.23,CCC[C@@H](C)C[C@H](CN)CC(O)=O,,,,,0,,187.1572289,0,0,0,0,0,0
9985,21/05/2019 00:00,DB15282,Fluorofuranylnorprogesterone F-18,,,,,,,,,0.0251,14.61,-2.9,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C[C@H]1O[C@H](O[C@@]21C(=O)C[18F])C1=CC=CO1,,,,,0,,427.202437,6,1,2,1,1,1
9986,21/05/2019 00:00,DB15291,BMS-986142,,,,,,,,,0.00094,14.11,-0.95,CN1C(=O)N(C(=O)C2=C1C(F)=CC=C2)C1=C(C)C(=CC=C1)C1=C2C3=C(C[C@H](CC3)C(C)(C)O)NC2=C(C=C1F)C(N)=O,,,,,0,,572.2235119,6,5,2,2,0,0
9987,21/05/2019 00:00,DB15296,D-fluoromethyltyrosine F-18,,,,,,,,,2.63,2.06,9.47,N[C@H](CC1=CC=C(OC[18F])C=C1)C(O)=O,,,,,0,,212.0826562,1,1,0,0,0,0
9988,21/05/2019 00:00,DB15317,Posiphen,,,,,,,,,0.0509,12.86,6.58,CN1CC[C@@]2(C)[C@@H]1N(C)C1=CC=C(OC(=O)NC3=CC=CC=C3)C=C21,,,,,0,,337.179027,4,2,2,0,1,2
9989,21/05/2019 00:00,DB15319,VM4-037,,,,,,,,,0.017,3.42,-0.083,CC(C)[C@H](N1C=C(COC2=CC3=C(C=C2)N=C(S3)S(N)(=O)=O)N=N1)C(=O)N[C@@H](CC1=CC=C(OCCF)C=C1)C(O)=O,,,,,0,,620.1523175,4,4,2,2,0,0
9990,21/05/2019 00:00,DB15324,ORM-13070 C-11,,,,,,,,,0.791,,6.98,[11CH3]OCC1=CC=CN=C1N1CCN(C[C@H]2COC3=CC=CC=C3O2)CC1,,,,,0,,354.2010253,4,2,3,1,1,2
9991,21/05/2019 00:00,DB15344,beta-Hydroxyisovaleric acid,,,,,,,,,384,4.55,-2.7,CC(C)(O)CC(O)=O,,,,,0,,118.0629942,0,0,0,0,0,0
9992,21/05/2019 00:00,DB15345,GSK-945237,,,,,,,,,0.12,,8.39,FC1=C2[C@H](CN3CCC(CC3)NCC3=NN=C4OCCOC4=C3)CN3C2=C(C=C1)C=CC3=O,,,,,0,,451.2019679,6,3,5,2,1,3
9993,21/05/2019 00:00,DB15350,D-chiro-Inositol,,,,,,,,,485,12.29,-3.6,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O,,,,,0,,180.0633881,1,0,0,0,0,0
9994,21/05/2019 00:00,DB15358,JNJ-54175446,,,,,,,,,0.0112,,-0.63,C[C@H]1N(CCC2=C1N=NN2C1=NC=C(F)C=N1)C(=O)C1=C(Cl)C(=CC=C1)C(F)(F)F,,,,,0,,440.0775496,4,3,3,2,0,1
9995,21/05/2019 00:00,DB15360,"Carfentanil, C-11",,,,,,,,,0.0259,,8.05,CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC2=CC=CC=C2)CC1)C(=O)O[11CH3],,,,,0,,393.2370764,3,2,1,0,1,1
9996,21/05/2019 00:00,DB15367,LY-2623091,,,,,,,,,0.00666,8.72,6.91,C[C@H](CN1CCOCC1)N1C(NC(N)=O)=NC2=C1C=CC(\C=C1/C3=CC=CC=C3COC3=CC(F)=CC=C13)=C2,,,,,0,,527.233268,6,4,3,1,1,2
9997,21/05/2019 00:00,DB15372,JNJ-27548547,,,,,,,,,2.56E-05,14.79,-4.3,CCCCCCCCCCCCCCCCCC(=O)OCC(CSSC1=CC=C(COC(=O)N2[C@H]3CN4C5=C([C@@H](COC(N)=O)[C@@]4(OC)[C@@H]23)C(=O)C(N)=C(C)C5=O)C=C1)OC(=O)CCCCCCCCCCCCCCCCC,,,,,0,,1138.667352,5,1,3,0,2,3
9998,21/05/2019 00:00,DB15374,Cobalt Co-60,,,,,,,,,0,,,[60Co],,,,,0,,59.9338171,0,0,0,0,0,0
9999,21/05/2019 00:00,DB15380,Flutriciclamide F-18,,,,,,,,,0.0494,,-1.1,CCN(CC)C(=O)[C@H]1CCCC2=C1C1=C(OC)C=CC=C1N2CC[18F],,,,,0,,345.2081911,3,2,1,1,0,0
10000,21/05/2019 00:00,DB15382,SAR-125844,,,,,,,,,0.00157,7.8,6.02,FC1=CC=C(C=C1)C1=NN2C(SC3=CC=C4N=C(NC(=O)NCCN5CCOCC5)SC4=C3)=NN=C2C=C1,,,,,0,,550.1369422,6,5,4,3,1,1
10001,21/05/2019 00:00,DB15394,gamma-Tocopherol,,,,,,,,,7.37E-06,10.47,-4.9,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2,,,,,0,,416.3654308,2,1,1,0,0,1
10002,21/05/2019 00:00,DB15399,BMS-754807,,,,,,,,,0.0356,12.01,2.89,C[C@]1(CCCN1C1=NN2C=CC=C2C(NC2=NNC(=C2)C2CC2)=N1)C(=O)NC1=CN=C(F)C=C1,,,,,0,,461.2087846,6,4,5,4,1,1
10003,21/05/2019 00:00,DB15410,(S)-Propafenone,,,,,,,,,0.00758,14.09,9.72,CCCNC[C@H](O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,,,,,0,,341.1990937,2,2,0,0,0,0
10004,21/05/2019 00:00,DB15424,Bfpet F-18,,,,,,,,,8.74E-06,,,[18F]C1=CC=C(C=C1)[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,1,,356.1228267,4,4,0,0,0,0
10005,21/05/2019 00:00,DB15435,BMS-986158,,,,,,,,,0.00819,14.53,1.96,CN1N=NC(C)=C1C1=CC2=C(N=C1)C1=C(C=C(C=C1)C(C)(C)O)N2[C@@H](C1CCOCC1)C1=CC=CC=C1,,,,,0,,495.2634253,6,5,4,3,1,1
10006,21/05/2019 00:00,DB15440,GSK-3117391,,,,,,,,,0.0234,8.9,5.71,ONC(=O)CCC1=NC=C(CN[C@@H](C2CCCCC2)C(=O)OC2CCCC2)C=C1,,,,,0,,403.2471065,3,1,1,1,0,0
10007,21/05/2019 00:00,DB15450,PF-05105679,,,,,,,,,0.00099,4.07,2.97,C[C@@H](N(CC1=CC(=CC=C1)C(O)=O)C(=O)C1=CC2=C(C=CC=C2)N=C1)C1=CC=C(F)C=C1,,,,,0,,428.1536208,4,4,1,1,0,0
10008,21/05/2019 00:00,DB15457,Snubh-nm-333 F-18,,,,,,,,,0.00721,,3.64,CNC1=CC=C(C=C1)C1=NC2=C(S1)C=C([18F])C=C2,,,,,0,,257.0652324,3,3,1,1,0,0
10009,23/05/2019 00:00,DB15460,AGG-523,,,,,,,,,0.000355,4.25,-1.2,CC(C)(CC1=CC=C(F)C=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)C1=CC=C(C=C1)C1=CC=CC=C1,,,,,0,,476.2111356,3,3,0,0,0,0
10010,19/06/2019 00:00,DB15464,Urolithin A,,,,,,,,,0.263,7.21,-7.1,OC1=CC2=C(C=C1)C1=C(C=C(O)C=C1)C(=O)O2,,,,,0,,228.0422587,3,3,1,1,0,0
